<SEC-DOCUMENT>0000950170-25-027982.txt : 20250227
<SEC-HEADER>0000950170-25-027982.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250226173342
ACCESSION NUMBER:		0000950170-25-027982
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		25671633

	BUSINESS ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		919 EAST HILLSDALE BOULEVARD
		STREET 2:		SUITE 250
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gern-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-26T17:17:13.5729+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:gern="http://www.geron.com/20241231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_26d73443-b530-404b-a728-97e8ba301d05" name="dei:AmendmentFlag" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7">false</ix:nonNumeric><ix:nonNumeric id="F_b8a40b0d-57b8-4eb8-bb53-891b5f563592" name="dei:EntityCentralIndexKey" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7">0000886744</ix:nonNumeric><ix:nonNumeric id="F_cabef66c-bc33-408a-9fb3-4eae52d00f42" name="dei:DocumentFiscalPeriodFocus" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7">FY</ix:nonNumeric><ix:nonFraction id="F_1e7bd566-1752-45f9-87e1-a254ef8b2f87" name="us-gaap:CommitmentsAndContingencies" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_43d919e9-8f34-4532-901b-4bc0e74ccfa9" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_57e68bf4-b075-47ff-94cb-4fffa7fbe456" name="us-gaap:PreferredStockValue" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a7f284af-766e-40ff-94ba-04d6489d905a" name="us-gaap:PreferredStockValue" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_075bab03-7a15-4dd6-87b2-88c5d830351e" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe" name="us-gaap:NumberOfOperatingSegments" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_22c29184-2380-4a26-aec3-6f112ba2f86e" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" contextRef="C_e4b1ab6e-2114-4b83-8ccc-b3e864bf5c71">P3M</ix:nonNumeric><ix:nonNumeric id="F_bdc4642e-5d95-4614-922b-411dcd56cbf5" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" contextRef="C_e4b1ab6e-2114-4b83-8ccc-b3e864bf5c71" format="ixt-sec:durweek">6</ix:nonNumeric><ix:nonNumeric id="F_63389fc4-357d-477a-9d6b-0ecf16309618" name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" contextRef="C_13a5e7dc-1814-4249-b841-344c76f1b61e">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric id="F_48950aed-512d-4e10-b713-0562fb188089" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="gern-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_81b5227f-c6cc-4463-87df-b07ef92efeea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_833a88bd-1656-4796-b8aa-0fb692b42fdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8348b52f-8813-4f32-97db-ccc55a82dd58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85175ee7-1c57-4e09-a0fa-9cca0710633c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_867aa2fc-a030-470c-984d-778ea052f5b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87979f69-8b59-4913-a42e-83306a925036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87998687-0289-453c-ace1-aaa39dc47de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a986e2f-1a04-4888-9532-0bcd96b69f07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b21a8eb-d5f2-4432-a5df-39b506f65c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8eb77d4c-4335-48c8-9562-05e492af76dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90739fa8-e72e-4147-a181-ff8aba129f93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_912929c3-b7b6-4d47-ab01-1fc308ac8161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91c5c5f0-c7f2-42ce-8dcb-ed6118918880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:SinaDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92e38419-310b-4d37-89de-c52fbe362d53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9378206f-1b63-4c2e-84ae-c7c453b28fb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9553826f-3f43-4285-8839-dca64833f51a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95741265-2348-4239-94c8-9bc131f6f43a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95b33fbb-e8c1-4fd0-a15d-92e7aa65e86a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9660272a-a38b-4587-990c-81de73711c8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9706dd18-9926-47e0-b3e8-d29b8905bbab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97cc69ce-fec1-4d91-ac38-fcc58be903e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9814d90e-77b9-4d3a-907e-2bf9844e66cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:SalesReturnsAndAllowanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9979f2e9-baa0-488c-bfc3-27175ab0bfd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9accca2e-98a7-4feb-90e0-dd4c4473e5a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bd8d342-06ae-415c-868d-cf0b5f73cacf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d292321-d77a-49f3-8195-59f85dac9752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:LicenseFeesAndRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e25d180-78c3-41f5-b9e4-3eedf3398835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f924c06-9556-4a79-8ba5-be2f6840286d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9feb8ba3-51fd-46c5-a45b-f7d80b5c6b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0f038aa-10fb-4ef4-a320-6fa3bd5a6a6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a177d587-0918-4df7-8a99-cd04f1e5d2b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4269ae4-d56a-4edf-a592-a2ea8119922f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-21</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a450a2dc-f974-4416-9511-c7302a719fa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a57a8238-5f15-4041-aa47-381c050af69a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:RevenuesBeforeAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5c5ddc7-dfaa-4256-a811-8005fe000d01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8af3954-eaf3-42b5-9e3a-4922b0dd6706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a91cce50-3f56-4202-8cbb-e2061a4afe4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aebd100b-45b2-4709-8a8b-13cb1b274d38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af40aa95-e806-4f0d-9a2b-c4155550c1c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_afd8ecd1-ed86-4a5a-81e0-ee569ecd5bc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b09d7f2d-153d-4916-ae66-f66dee60587b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1066105-def2-48bc-a08b-a1be59df1fe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3d1f256-a05e-41ae-82ba-3a0ca866b306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b494d8bd-5ad3-4784-83cb-b49455558821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b54b04e2-e7b3-40e7-b38b-61e399b5089e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChargebackAndDistributorServiceFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b715e801-fcfb-431f-8bab-f2e143bebd19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b78714b6-f9c0-495e-8c29-1ef95e3bcf60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:HerculesLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba48a767-b0d9-4ebe-9ba8-df6962a5903f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd2577b2-9506-4398-a405-ba1b3a537279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd7cb667-7647-4a87-b629-ce1a51b824be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdeda059-8b87-497a-b9cd-e4cf9530f303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_becb8b88-64b7-49ab-8230-4c474b6aaf48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_beffeaec-493f-452e-bd41-2df765eaa06a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf2a2f52-c8bd-498e-90a9-db80650a3434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c155be43-9cca-497f-9c0d-dff7e4f971aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2ddaf0c-c480-4121-89b7-e270b06ea351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c38d97f7-08a0-4702-99f8-8f86ab3205f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3e030b6-7508-4442-bbe2-6485ef87fd91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:SubsequentDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c553e0ac-d5c1-4b9f-adf7-7df417d4ceff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c57b8848-5a92-444a-b366-673e8854e689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c65b60ba-872b-41db-a6e2-d82180268abc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c72d7d41-863d-4713-921b-5709d77691bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca99313c-81e1-4fdc-aa00-501a9a8750eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cba66e27-c320-4315-b06d-66eeb091ebf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc4a2b91-0d00-4a37-ad88-ee5bbfe05947"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccbb9418-68cc-4fe4-a4a4-5c49b6f5042f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf181ee0-e9ee-474a-9747-6fe8c5a5fe77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0c523ca-eeda-4f55-8129-78a974c61e15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d17eed81-8c6b-456e-9079-f7df0f14e619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1fd165f-236b-4ae7-b110-10c3c05b8919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3392540-02f2-4e5b-8f42-37beb9ba9e45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6e09048-ab65-4a10-a9a5-9d240f0d04d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d755aa78-f964-4edb-8019-908621c662cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8b9e1c3-d9eb-45ec-948d-6b383d0103b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:McKessonFinancialCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d99633b0-a319-42ee-a07d-8348a36501df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dba11232-95dc-4b7a-a0b2-f0bc6076e0cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbe4854e-8234-4b3f-bb3b-8c19d5981bf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0278ce3-6fc4-403a-a17d-ddee1151eca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e03f65aa-0f08-4125-91e7-89e207442e89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0933482-a77f-4d10-a7bc-f05210a15513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e0d5fa89-8410-4f47-ab1c-e5b7ef68f3cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gern:EmployeesAboveTheVicePresidentLevelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e14d38b0-ffbb-44d6-87e8-09d3acf16873"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1976851-cb4c-4762-8274-5ea9e52c9f8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3a7796a-70fb-4745-ac2a-15cfb3d6b8c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3b2e318-43ca-4428-8f97-24dd7e3a155c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3cb3a12-8449-4080-9d04-c09977c81469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3f5c2dc-7c9d-424d-9590-a69e1018f7df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4021ad0-3e5e-48de-9cd9-3300958d415f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e43f9ac5-e990-42e5-a162-14377ebe69a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4b1ab6e-2114-4b83-8ccc-b3e864bf5c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6cc2f93-1577-4be8-9efd-57f44ff9b16c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e92973db-cfa0-4226-992e-ba00f3710cd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb68352e-6df9-4716-b022-e07659784349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebc02be3-4e6f-4b78-bff8-d2cfc26bed45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebd06010-cba9-4fe3-8531-00bccfe44019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ece3b919-9c68-4419-b2c9-c5d7c4dcca3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f086f31f-ebe6-4d2c-8914-9edaca62d90f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0e977cf-938a-4204-9bd8-6c42bf0b34b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f15e23b8-0e8e-4dda-a5e3-a439fd53eafa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f18cad10-57aa-4265-bcc3-f8c0b2fe427f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f38cb9df-eb50-49af-95e3-99de5b6c1109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f41156cc-9535-49b9-8050-64099a0eb8b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5b3d0b0-b24e-4a9c-9342-027dfaa89069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:TotalGrossToNetAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f748ab50-900a-4fdc-8839-e5051a63beb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f784b962-1d18-4a7e-8f25-c81f2229ede3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f79ee241-9a76-41d9-93df-733bd1f3b85d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyFourPreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f836de54-c5fa-4e2c-bc3b-676b8b48b141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8d8f292-1d56-4204-b316-2a9290be7c09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faf26aae-a2ff-481b-b390-795807f43711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb2e1524-ef21-4d37-878b-0564d9d43f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc579693-1a73-41bc-8a82-5c04df25f0f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffad885e-eeb0-4c57-b284-7102190be086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03b38bc3-3391-4183-82aa-61b99babb682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04908c45-edaa-4013-80e1-3425b2d3f4a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04ccb33e-9db2-4428-ab1f-e86203e71f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05b9bc29-068c-441c-b91d-5eaab4b6ab0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-30</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06fd0fff-364c-40d2-aea0-8957283902a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08593508-3737-4150-83da-4b9da613a6e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08984eb3-5203-4824-90b9-9a8e53b3fb49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b8accab-dfee-4fdd-a488-21c280ad6a1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10d09233-7a55-4348-a7b7-3be6db7ca118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13450eff-f3fb-4504-9420-67b321adf1b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13a5e7dc-1814-4249-b841-344c76f1b61e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15852a6c-ac98-4815-b64c-948a1a3c90a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17031fc2-3062-43d6-85c0-79a5d605b251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17d0f4ad-e466-499f-a3c7-32b9663b6681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18c60a52-303b-412b-986a-7e6145b28956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1be1e923-b173-4348-90d9-a245cf7eecd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d985ed6-a26a-4250-9a37-ac2116b89df0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-10</xbrli:startDate><xbrli:endDate>2020-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d9cd387-5d68-43ac-8286-4091e49b513a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e35341b-2d2c-4a8f-916a-1bacddb10f79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:PrepaidPriorToThirdAnniversaryOfFundingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e3660ee-c4ab-4b1a-a885-f4768cde0fc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e5e1688-ab30-4578-81a0-c6560b774866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21447006-602d-46aa-a917-f6697b7e69d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23479e27-d886-45ff-8c25-d7ca04bd3cee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoPreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24fe1187-bbca-4f70-b50e-1470d3032743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_275fb7a4-efea-4c31-83c8-55c94f697b31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d097eb2-6e57-4299-a3e5-9151a4df0198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f02a42c-f14d-4389-a9d0-40ae1afee99a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f48563d-cfb2-405d-b3c5-32ab5e666ff0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fc64b5e-3892-4a81-a7e8-b127182a99ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3111e83f-2076-4782-b9bc-ed01f0ea1874"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_335cdb98-b657-42f3-973a-6dc964cba271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3360e8d8-eaad-4e88-a960-8e7053699623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_344637f9-35dd-4606-aaa8-39e3e4eed402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3462f4ba-71e7-4d47-bf58-841e2d8028a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyFourPreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3776fecd-f521-4873-82e1-b99ba90cc41d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38766db5-3955-4239-979e-89377c2bc7bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38ee5de3-7306-4f4b-8d58-eb882cf9590d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39107341-c344-46be-aec9-e2e8aba0d53f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b922920-9a03-448f-bb58-c0e801fa437e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:HerculesLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c58eba1-098b-4137-bffd-fc83f6d66c00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ca647dc-16b1-48f8-b741-24db5011baac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_407442e0-3cce-4289-80e2-39b67a1f061b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4318e20a-42cf-473e-af78-4bb847a7d856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_432034fc-3319-4587-adae-2e7c9b692266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_442d47d2-f480-4e09-a7ea-6656c80440a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4599e5dd-ea25-4616-91b6-01afed02aaca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46ea59e0-e969-4c87-9aa0-1688daa1c9f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_478aad18-c78e-45d2-87ec-89af59700049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48142c5b-ce3f-4966-921e-0b74263697ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoStockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49f4818c-2720-4101-a534-f0f765371106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c42d843-dd04-4e25-a34a-b1f703d11e39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4cbc89b0-e52f-4d52-bc4b-5e66f232255a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d32eb3b-1b07-4090-88b7-029d9a631b5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dcad59e-1e3b-43e6-a526-804130f682d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f241416-b409-4908-b332-b7b4d33cd845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_501b1eb2-a39a-4305-ada7-ee277b99376c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50c8ecec-b2ba-4651-95b8-c5c262b21836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50fa79d0-89b9-452b-b91e-8b9da8f97576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_522fafdb-07e4-4339-b103-c323ad02c3e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53975bd8-a789-4655-ac7f-6b97e0b87f47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53d31f32-ae1d-49da-94b2-102d0fe79050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54df7d29-aa46-434f-bb2e-e36ffb0cf1c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:LicenseFeesAndRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54e7473e-71f1-4f3c-b458-f1ccbff39749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_552c454b-a9ab-449e-b749-65c139a3cf3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57c67b07-3a75-4f83-a90b-a0845eba9d49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_59108335-739f-4e5e-b267-22b8c789f159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cdbb065-c4af-42c3-8862-71fcb82d98f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d81f491-dae6-42b2-9a9d-49bae561bc54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60b6c4c4-4c33-4d69-a53f-c3b0700c6a65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61e2613d-481e-46a9-a123-9bcad10f9439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_634d30a6-a512-472f-83d8-6f6a44496fa1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyLeaseAndFosterCityLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63aba9ed-ce8e-4616-9977-5edb1c01930b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6535ff7f-99fc-4830-9136-f45d3598ba88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66ae5200-0971-4718-bfb2-d5a1adbf70ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6787832d-92fa-4613-99b8-8a61345db4cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68fdfe38-0960-431a-a3e9-7b0ac25ccc4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a2d0968-c085-4357-bd45-6a8affcd8162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6da2f1f4-f5f1-49c8-b49b-064df08d4b0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dee5fa2-b2df-4b03-9654-001c5bf49a8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ec90163-a65e-40c3-a187-132ae7c4e62a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fcf6750-e138-4d4c-96d6-c8e04e8003f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7040d2ec-efa9-4e10-8449-1b261c220739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70ca9604-7e05-4828-abc7-17e9195e5429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_710a5831-6f23-4a2b-a4c5-44b55c5ee9c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_710c0d17-5aa1-473a-867a-7efd92be1f08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71d1f837-aa40-49d4-bd3f-4a76ced03892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_747285d8-621a-48db-811f-49f35ea38d3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78978391-737a-40c3-9d68-851dcc4702f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_799b9a49-462d-486f-9022-ce4831f01775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b831c0a-b680-4a42-bf82-33530e797307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c4b014b-4b49-4de5-99e6-77cd32c236fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d3dad2f-bb11-4150-964c-bc94e9c01233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d57e1e2-e7e9-4439-be29-506043e9a42a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e54cf5e-d7b0-4905-96d8-e3ba1772cfd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ec87361-5500-473b-846d-d51e7d5b6cdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f38441e-2b05-4d47-8fbc-1af5f0430674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:LicenseFeesAndRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f4d8a67-ca97-43b2-8f25-f36157f4f6b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f8c13fe-b7c8-47a4-9aa3-5c471dd1c446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ff95c91-1f33-4631-89e1-565d8329dc34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886744</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Item"><xbrli:measure>gern:Item</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Plan"><xbrli:measure>gern:Plan</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>gern:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b594768e-a825-40e0-997a-23655ecd9aeb" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_ee50eca2-e555-49bc-b703-3ff5ac445b1d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746; </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Fiscal Year Ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9a5138a-1aa5-46d8-9bef-8bcad6f7a41c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b03b6ade-16e8-4476-aa1a-3add5f3d7d50" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_709161c1-8393-4d9f-b956-78388f2c01be" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b86f3797-610b-4ab0-b668-66c38f626e87" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">          </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">         </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> .</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58f1f8ec-1836-4cff-8011-d350045ed197" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">000-20859</span></ix:nonNumeric></span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:15pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1074c17-9cd7-4be3-b535-38a8620fd97e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:35.187%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:35.185%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_19065c60-8f59-4880-bbac-ee0d02ce7f0e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_4aaeaf82-59b5-4f4b-a6c9-8cde5dfcf2a4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">75-2287752</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:7pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_41800749-02e8-4e93-be69-d8bf5adfe6ef" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">919 East Hillsdale Blvd.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_cb024a79-2b93-4cda-85d7-ad7c9ae1ba3e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_540cc183-e155-4851-92eb-e11337ba0a27" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:7.5pt;"><ix:nonNumeric id="F_a0c8dfc5-010a-4543-98e5-06a64532cf72" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_3a62eb84-6bd2-4419-8e3e-7179f34f8b7c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94404</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_963b9701-d5b2-47eb-9354-e0972ef3191d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eec82bd0-7d10-493d-b809-b2451a192840" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">473-7700</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.26%;box-sizing:content-box;"/>
    <td style="width:23.12%;box-sizing:content-box;"/>
    <td style="width:43.62%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class:</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading symbol(s):</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered:</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_63064263-b6e5-4dbe-b94f-1e39cad8bc79" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_13a61ed6-a9e8-4913-ad82-2d1f27649817" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GERN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_da62c10f-b7e7-4389-b377-b2a33cf1517c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well&#8209;known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45850bd9-591c-40a4-abd2-39dd6ce899fd" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  &#9744;    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de1aa834-6bfd-4826-9c61-6ce1ad59e026" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3843e50e-1c34-47f4-b58b-7a5a71b501aa" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S&#8209;T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df7a2e15-9c02-4edb-a8a2-04ad1f457cc2" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;   No &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non&#8209;accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b&#8209;2 of the Exchange Act.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.571%;box-sizing:content-box;"/>
    <td style="width:2.857%;box-sizing:content-box;"/>
    <td style="width:21.429%;box-sizing:content-box;"/>
    <td style="width:4.286%;box-sizing:content-box;"/>
    <td style="width:25.714%;box-sizing:content-box;"/>
    <td style="width:1.429%;box-sizing:content-box;"/>
    <td style="width:15.714%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_45b8d0d9-99e0-4c9a-ab88-2d7f2c8402dd" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_dbd02901-7902-4e12-bdb5-e010f59abfe7" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_a4f07cfb-9465-4e79-8f28-4e841cd48dd1" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c986f20-ba1c-48e6-8dd4-342cf9b3004d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_484bc8b2-4fea-4c80-b319-effb5d805d61" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b&#8209;2 of the Act).  Yes    &#9744;  No  </span><span style="font-size:8.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e187259e-e97b-46a8-80da-962ad03f320c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of voting and non&#8209;voting common equity held by non&#8209;affiliates of the registrant was approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:8.5pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_6e48d79b-7fbc-4163-93ef-5b96a37913ef" contextRef="C_ccbb9418-68cc-4fe4-a4a4-5c49b6f5042f" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">2,430,700,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based upon the closing price of the registrant&#8217;s common stock on June 30, 2024 on the Nasdaq Global Select Market. The calculation of the aggregate market value of voting and non&#8209;voting common equity held by non&#8209;affiliates of the registrant excludes shares of common stock held by each officer, director and stockholder that the registrant concluded were affiliates on that date. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 21, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there were </span><span style="font-size:8.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2d33bc8-3035-4f4b-afe9-b9608f7901a6" contextRef="C_8a986e2f-1a04-4888-9532-0bcd96b69f07" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">636,904,470</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ares of common stock outstanding.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4082e6c0-b996-4b92-9263-677c9ec7fc20" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:90%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:9%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Document</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form 10&#8209;K<br/>Parts</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2024.</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">III</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc_page">&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.34%;box-sizing:content-box;"/>
    <td style="width:83.48%;box-sizing:content-box;"/>
    <td style="width:6.18%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="#item_5_market_for_registrants_common_equ"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases <br/>of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_or_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;text-indent:12.25pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder <br/>Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10.1pt;padding-left:10.1pt;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10&#8209;K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and other trademarks or service marks of Geron Corporation appearing in this Annual Report on Form 10-K (this "Report") are the property of Geron Corporation. This Report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In this Report, unless otherwise indicated or the context otherwise requires, &#8220;Geron,&#8221; &#8220;the registrant,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Geron Corporation, a Delaware corporation, and its wholly owned subsidiaries, Geron UK Limited, a United Kingdom company, and Geron Netherlands, B.V., a Dutch company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward&#8209;Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Report, including &#8220;Business&#8221; in Part I, Item 1 of this Report and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of this Report, contains forward&#8209;looking statements that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Geron Corporation, or Geron or the Company, to differ materially from those expressed or implied by such forward&#8209;looking statements. All statements other than statements of historical fact are statements that could be deemed forward&#8209;looking statements. In some cases, forward&#8209;looking statements can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;projects,&#8221; &#8220;believes,&#8221; &#8220;predicts,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; or &#8220;continue&#8221; or the negative thereof or other comparable terminology. The risks and uncertainties referred to above include, without limitation, risks and uncertainties related to: (a) whether we are successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with lower-risk myelodysplastic syndromes, or lower-risk MDS, with transfusion dependent anemia; (b) whether the European Commission, or EC, approves RYTELO for the treatment of patients with lower-risk MDS with transfusion dependent anemia and whether the FDA and EC will approve imetelstat for other indications on the timelines expected, or at all; (c) our plans to commercialize RYTELO in the European Union, or EU; (d) whether we overcome potential delays and other adverse impacts caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones; (e) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (f) whether RYTELO (imetelstat) may cause, or have attributed to it, adverse events that could delay or prevent the commencement and/or completion of clinical trials, impact its regulatory approval, or limit its commercial potential; (g) whether the IMpactMF Phase 3 trial for relapsed/refractory myelofibrosis, or R/R MF, has a positive outcome and demonstrates safety and effectiveness to the satisfaction of the FDA and international regulatory authorities, and whether our projected rates for enrollment and death events differ from actual rates, which may cause the interim and final analyses to occur later than anticipated; (h) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable; (i) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease; (j) whether we meet our post-marketing requirements and commitments for RYTELO; (k) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that impact commercialization of RYTELO or the continuation of the IMpactMF trial and other clinical trials; (l) whether we are able to establish and maintain effective sales, marketing and distribution capabilities, obtain adequate coverage and third-party payor reimbursement, and achieve adequate acceptance in the marketplace; (m) whether we are able to obtain and maintain the exclusivity terms and scopes provided by patent and patent term extensions, regulatory exclusivity, and have freedom to operate; (n) that we may be unable to successfully commercialize RYTELO due to competitive products, or otherwise; (o) that we may decide to partner and not to commercialize RYTELO independently in the United States, or U.S., or in Europe and other international markets; (p) whether we stay in compliance with and satisfy our obligations under our debt and synthetic royalty agreements; and (q) the impact of general economic, industry or political climate in the U.S. or internationally and the effects of macroeconomic conditions on our business and business prospects, financial condition and results of operations; as well as other risks that are described herein and that are otherwise described from time to time in our Securities and Exchange Commission reports including, but not limited to, the factors described in &#8220;Risk Factors,&#8221; in Part I, Item 1A of this Report. Geron assumes no obligation for and except as required by law, disclaims any obligation to update these forward&#8209;looking statements to reflect future information, events or circumstances.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Factor Summary</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this summary to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report. The summary below is qualified in its entirety by that more complete discussion of such risks and uncertainties. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report as part of your evaluation of an investment in our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to the Commercialization of RYTELO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Imetelstat)</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our near-term prospects are wholly dependent on RYTELO. We have limited experience with the commercialization of RYTELO, and if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indication of use, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience as a commercial company and our sales, marketing, and distribution of RYTELO may be unsuccessful or less successful than anticipated. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to continue to execute on our sales, marketing and distribution plans to commercialize RYTELO, we may be unable to generate meaningful product revenue.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not obtain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To be commercially successful, RYTELO must be accepted by the healthcare community, which can be slow to adopt or unreceptive to new technologies and products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the market opportunities for RYTELO are smaller than we believe, our revenue may be adversely affected and our business may suffer.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If competitors develop products, product candidates or technologies that are superior to or more cost-effective than RYTELO, it would significantly impact the development and commercial viability of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on a select network of third party distributors, specialty pharmacies and other vendors to distribute RYTELO, and any failure by such distributors, specialty pharmacies and vendors could adversely affect our revenues, financial condition, or results of operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are seeking regulatory approval to commercialize RYTELO in the EU, and any such approval, if received, will be subject to pricing, drug marketing and reimbursement regulations in the EU, which may materially affect our ability to commercialize and receive reimbursement coverage for RYTELO in the EU.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Approval of RYTELO</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to maintain regulatory approval for RYTELO in the U.S. for lower-risk MDS, which would severely and adversely affect our business and business prospects, and might cause us to cease operations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our regulatory approval for RYTELO in the U.S. for lower-risk MDS is subject to certain post-marketing requirements and commitments, and we may be subject to penalties or product withdrawal if we fail to comply with such regulatory requirements or commitments, or if we experience unanticipated problems with RYTELO.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to obtain regulatory approval to commercialize RYTELO in any other jurisdictions or for any new indications, or may experience significant delays in doing so, any of which could severely and adversely affect our business and business prospects, and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Compliance with Healthcare Laws</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA, the Department of Justice, or DOJ, and other regulatory authorities actively enforce regulations related to the promotion and advertisement of pharmaceutical products, and if we were found to have violated the Food, Drug and Cosmetic Act, we could be subject to significant penalties, including civil, criminal and administrative penalties.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to the Further Development of RYTELO (Imetelstat)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that we will be able to continue to develop RYTELO or advance it in clinical trials, or that we will be able to receive regulatory approval for RYTELO in any other indications in the U.S., the EU, or any other region, on a timely basis or at all.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could halt or limit its further commercialization, delay or prevent its regulatory approval in any other jurisdiction or indication, or cause us to delay or terminate our clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results and data we disclosed from prior non-clinical studies and clinical trials may not predict success in later clinical trials, and we cannot assure you that any ongoing or future clinical trials of imetelstat, including IMpactMF, will lead to similar results and data that could potentially enable us to obtain any further regulatory approvals.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing RYTELO (Imetelstat)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure by us to maintain a manufacturing supply chain to appropriately and adequately supply RYTELO for commercial and future clinical uses would adversely affect our ability to commercialize RYTELO and result in a further delay in or cessation of clinical trials, and our business and business prospects could be severely harmed.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If third parties that manufacture RYTELO fail to perform as needed, the commercial and clinical supply of RYTELO could be interrupted or limited, and we may be unable to successfully commercialize RYTELO or conduct or complete current or potential future clinical trials.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Operating Results, Financial Position and Need for Additional Capital</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have a history of net losses and may not achieve consistent future profitability for some time, if ever.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our common stock could decline. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to obtain additional capital if and when needed would force us to further delay, reduce or eliminate the further development of imetelstat, or to halt the commercialization of RYTELO, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Indebtedness and Liabilities</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our level of indebtedness and debt service obligations could adversely affect our financial condition, and may make it more difficult for us to fund our operations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Protecting Our Intellectual Property</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection and relevant regulatory exclusivities for RYTELO, our competitors could develop and commercialize products similar or identical to RYTELO, and our ability to successfully commercialize RYTELO may be adversely affected.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on RYTELO for an adequate amount of time.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The validity, scope and enforceability of any patents listed in the Orange Book that cover RYTELO or its methods of use can be challenged by third parties and may not protect us from generic or innovator competition.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock and Financial Reporting</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, our stock price has been extremely volatile, and your investment may suffer a decline in value.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calculation of Aggregate Market Value of Non&#8209;Affiliate Shares</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of calculating the aggregate market value of shares of our common stock held by non&#8209;affiliates as set forth on the cover page of this Report, we have assumed that all outstanding shares are held by non&#8209;affiliates, except for shares held directly or indirectly by each of our executive officers and directors. In the case of 5% or greater stockholders, we have not deemed any such stockholders to be affiliates given the lack of facts and circumstances that would indicate that any such stockholders exercise, or have the ability to exercise, any control over Geron. These assumptions should not be deemed to constitute an admission that all executive officers and directors are, in fact, affiliates of Geron, or that there are no other persons who may be deemed to be affiliates of Geron. Further information concerning shareholdings of our executive officers, directors and principal stockholders is incorporated by reference in Part III, Item 12 of this Report.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">M 1.     BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor, RYTELO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imetelstat), harnesses Nobel Prize winning science in a treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the disease of these hematologic malignancies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We commercially launched RYTELO in the U.S. in June 2024 following its approval by the U.S. Food and Drug Administration, or FDA, on June 6, 2024 for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, with transfusion-dependent, or TD, anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents, or ESAs. Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life. We believe that the uptake of RYTELO since launch is supported by the high unmet need in lower-risk MDS and significant product differentiation, including observed benefit of RYTELO in difficult-to-treat sub-populations such as patients with high transfusion burden and ring sideroblast negative, or RS- patients. We believe that the favorable FDA label and National Comprehensive Cancer Network, or NCCN&#174;, Clinical Practice Guidelines in Oncology, or NCCN Guidelines&#174;, position RYTELO as a potential blockbuster treatment that can compete for significant market segments in lower-risk MDS, including first-line ESA ineligible patients and second-line patients regardless of prior treatment or RS status.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we submitted a marketing authorization application, or MAA, in the European Union, or EU, that was validated for review by the European Medicines Agency, or EMA, for RYTELO for the same proposed indication as in the U.S., and in December 2024, the Committee for Medicinal Products for Human Use, or CHMP, of the EMA adopted a positive opinion recommending the approval of RYTELO for the treatment of adult patients with TD anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic, or non-del 5q, abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission, or EC, is reviewing the CHMP's recommendation, and we expect a potential approval decision by the EC in the first half of 2025.  We are preparing for the potential commercialization of RYTELO in select EU countries in 2026, subject to regulatory approval, which could include working with experienced third parties who can provide contracted services, including essential critical path activities such as reimbursement, Health Technology Assessment, or HTA, submissions, market access and distribution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to lower-risk MDS, we are developing imetelstat for the treatment of other myeloid hematologic malignancies. Our Phase 3 IMpactMF clinical trial is evaluating imetelstat in patients with intermediate-2 or high-risk myelofibrosis, or MF, who have relapsed after or are refractory to treatment with a janus associate kinase inhibitor, or JAK inhibitor, or relapsed/refractory MF, or R/R MF, with overall survival, or OS, as the primary endpoint. As of February 2025, the trial reached approximately 80% enrollment. Based on our current planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that telomerase inhibition with imetelstat represents a novel mechanism of action with unique benefits in hematologic malignancies and potentially in other tumor types.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy is to maximize the value of our first-in-class telomerase inhibitor, RYTELO (imetelstat). This includes maximizing the commercial opportunity for RYTELO in lower-risk MDS by investing in and executing on our U.S. commercial launch. We expect to deliver steady growth by executing across several key imperatives, including driving new patient starts across all eligible lower-risk MDS population segments, particularly in second-line lower-risk MDS; reinforcing with health care providers, or HCPs, the value of duration of treatment we have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">observed with RYTELO; educating HCPs on appropriate management of patient safety with RYTELO; and leveraging strong payor access for RYTELO.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also plan to progress our development programs that could help identify potential additional indications for imetelstat. This includes continuing to enroll the Phase 3 IMpactMF trial, which, if positive and approved in label expansion, could significantly increase the RYTELO commercial opportunity. Additionally, we plan to execute on our pipeline programs and assess the data to understand the potential to develop imetelstat in additional hematologic malignancies and as a potential combination therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Commercialization of RYTELO</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO is the first and only FDA approved telomerase inhibitor. The FDA label indicates that RYTELO is approved for certain ESA ineligible or ESA relapsed/refractory lower-risk MDS patients, regardless of RS status. In August 2024, the MDS NCCN Guidelines</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were updated to include imetelstat as a Category 1 treatment in second-line RS+/RS- patients regardless of prior treatment and as a Category 2A treatment for first-line ESA-ineligible RS+/RS- patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that lower-risk MDS represents a significant market opportunity with blockbuster potential for RYTELO in this indication. We estimate there are approximately 15,400 treatment-eligible lower-risk MDS patients consistent with the FDA label in 2025, based on IQVIA projected claims and Clarivate/Decision Resources Group, or DRG, incidence data. This is comprised of approximately 3,400 first-line ESA ineligible patients, approximately 7,600 second-line ESA relapsed/refractory patients (approximately 5,700 RS- and 1,900 RS+, respectively), and approximately 4,400 third-line plus ESA relapsed/refractory patients (approximately 3,300 RS- and 1,100 RS+, respectively). We estimate that approximately 45% of first-line patients will progress to second-line treatment and approximately 59% of second-line patients will progress to third-line treatment in 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support this significant market opportunity, our commercial team includes 50 key account managers, oncology clinical educators, and field reimbursement and national account teams, along with our medical affairs field team. We offer a wide range of resources to support access and affordability for eligible RYTELO patients, including our Reach for RYTELO&#153; patient support program, which provides a range of resources which are designed to support access and affordability to eligible patients prescribed RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization Plans for RYTELO in the EU</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to receiving regulatory approval, our goal in the EU is to optimize patient access and revenues for RYTELO in prioritized countries. We are preparing to commercialize RYTELO in select EU countries in 2026, which could include working with experienced third parties who can provide contracted services, including essential critical path activities such as reimbursement, HTA submissions, market access and distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Background of Telomerase Inhibition in Hematologic Malignancies and Imetelstat Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the human body, normal growth and maintenance of tissues occurs by cell division. However, most cells are only able to divide a limited number of times, and this number of divisions is regulated by telomere length. Telomeres are repetitions of a deoxyribonucleic acid, or DNA, sequence located at the ends of chromosomes. They act as protective caps to maintain stability and integrity of the chromosomes, which contain the cell&#8217;s genetic material. Normally, every time a cell divides, the telomeres shorten. Eventually, they shrink to a critically short length, and as a result, the cell either dies by apoptosis or stops dividing and senesces.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Telomerase is a naturally occurring enzyme that maintains telomeres and prevents them from shortening during cell division, such as stem cells that must remain immortalized to support normal health. Telomerase consists of at least two essential components: a ribonucleic acid, or RNA, template, which binds to the telomere, and a catalytic subunit with reverse transcriptase activity, which adds a specific DNA sequence to the chromosome ends. The 2009 Nobel Prize for Physiology or Medicine was awarded to Drs. Elizabeth H. Blackburn, Carol W. Greider and Jack Szostak, former Geron collaborators, for the discovery of how chromosomes are protected by both telomeres and telomerase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Telomerase is upregulated in many tumor cells and malignant stem and progenitor cells, enabling the continued and uncontrolled proliferation of the malignant cells that drive tumor growth and progression. We believe that inhibiting telomerase may be an attractive approach to treating cancer because it may limit the proliferative capacity of malignant stem and progenitor cells, which are believed to be important drivers of tumor growth and progression. We and others have observed in various in vitro, ex vivo and rodent tumor models that inhibiting telomerase: (a) results in telomere shortening and (b) arrests uncontrolled malignant cell proliferation and tumor growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many myeloid hematologic malignancies, such as essential thrombocythemia, or ET, MF and MDS, have been shown to arise from malignant stem and progenitor cells that express higher telomerase activity and have shorter telomeres when compared to normal healthy cells. In vitro studies have suggested that tumor cells with short telomeres may be especially sensitive to the anti&#8209;proliferative effects of inhibiting telomerase.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Imetelstat, our proprietary telomerase inhibitor which was discovered and developed at Geron, was designed to inhibit telomerase in malignant cells with continuously upregulated telomerase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Imetelstat is a lipid conjugated 13&#8209;mer oligonucleotide that we designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity. Imetelstat does not act as an antisense inhibitor of protein translation. The compound has a proprietary thio&#8209;phosphoramidate backbone, which is designed to provide resistance to the effect of cellular nucleases, thus conferring improved stability in plasma and tissues, as well as improved binding affinity to its target. To improve the ability of imetelstat to penetrate cellular membranes, we conjugated the oligonucleotide to a lipid group. Imetelstat&#8217;s IC50, or half maximal inhibitory concentration, is 3 &#8211; 9 nM in cell free assays.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that imetelstat may have the potential to suppress the proliferation of malignant stem and progenitor cells while transiently affecting normal cells. Early clinical data from a Phase 2 trial of imetelstat in patients with ET, or the ET Trial, and a pilot study of imetelstat in patients with MF conducted at Mayo Clinic, or the Pilot Study, suggested that imetelstat inhibits the progenitor cells of the malignant clones believed to be responsible for the underlying diseases in a relatively select manner, indicating potential disease-modifying activity. These data were published in two separate articles in a September 2015 issue of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the Phase 2 IMbark study, an association of survival improvement and reduction in variant allele frequency, or VAF, was observed for high-risk imetelstat-treated MF patients, results which were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of Clinical Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 2021. Additionally, in the Phase 2/3 IMerge study, SF3B1 VAF reduction was associated with longest transfusion independence, or TI, and with 8-week, 24-week and 1-year TI duration in imetelstat-treated lower-risk MDS patients. These results were published in The Lancet and at the European Hematology Association, or EHA, annual meeting in 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pipeline Chart</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44536338_0.jpg" alt="img44536338_0.jpg" style="width:624px;height:261px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lower-Risk Myelodysplastic Syndromes (MDS)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MDS is a group of blood disorders in which the proliferation of malignant progenitor cells produces multiple malignant cell clones in the bone marrow resulting in disordered and ineffective production of the myeloid lineage, which includes red blood cells, white blood cells and platelets. In MDS, bone marrow and peripheral blood cells may have abnormal, or dysplastic, cell morphology. MDS is frequently characterized clinically by severe anemia, or low red blood cell counts, and low hemoglobin. In addition, other peripheral cytopenias, or low numbers of white blood cells and platelets, may cause life&#8209;threatening infections and bleeding. Transformation to acute myeloid leukemia, or AML, is reported to occur in up to 30% of MDS cases and results in poorer overall survival.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MDS is the most common of the myeloid malignancies. There are approximately 60,000 people in the U.S. living with the disease and approximately 16,000 reported new cases of MDS in the U.S. every year, according to Clarivate/DRG MDS Syndicated Report 2020, 2021, 2022. We believe that there are approximately 15,400 lower-risk MDS patients in the U.S. in 2025 that are eligible for treatment with RYTELO based on its approved FDA label, based on IQVIA projected claims and Clarivate/DRG incidence data. MDS is primarily a disease of the elderly, with median age at diagnosis around 70 years. The majority of patients, approximately 70%, fall into what are considered to be the lower-risk groups at diagnosis, according to the International Prognostic Scoring System, or IPSS, which assigns relative risk of progression to AML and overall survival by taking into account the presence of a number of disease factors, such as cytopenias and cytogenetics.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chronic anemia is the predominant clinical problem in patients who have lower-risk MDS. Typically, these patients are treated with ESAs, such as erythropoietin, or EPO. Although ESAs provide an improvement in anemia in approximately 50% of patients, the effect is transient with a median duration of response of approximately two years. Once ESAs fail for patients, HMAs and lenalidomide have been used to improve anemia, but with limited success, such as reported &#8805; 8-week red blood cell, or RBC, transfusion independence, or RBC-TI, rates of 17% for azacitidine, an HMA, and 27% for lenalidomide in non-del 5q lower-risk MDS patients. In August 2023, Reblozyl, or luspatercept, was approved for the treatment of anemia in adult patients with very low-to-intermediate-risk MDS without previous erythropoiesis stimulating agent use, or ESA-naive, who may require regular RBC transfusions. In April 2020, luspatercept was approved for use in ESA-failed lower-risk MDS patients with ringed sideroblasts. Such patients comprise approximately 15% to 30% of all lower-risk MDS patients. The majority of patients who do not have ringed sideroblasts or who no longer respond to ESAs or other available drug therapies become dependent on red blood cell transfusions due to low hemoglobin. Serial red blood cell transfusions can lead to elevated levels of iron in the blood and other tissues, which the body has no normal way to eliminate. Iron overload is a potentially dangerous condition. Published studies in patients with MDS have shown that iron overload resulting from regular red blood cell transfusions is associated with a poorer overall survival and a higher risk of developing AML.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 IMerge Trial in Lower-Risk MDS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our regulatory approval in the U.S. for certain patients with lower-risk MDS and our EMA submission are each based on positive data from the IMerge Phase 3 clinical trial. The trial met its primary endpoint of &#8805; 8-week red blood cell transfusion independence rate and a key secondary endpoint of &#8805; 24-week red blood cell transfusion independence rate, demonstrating highly statistically significant (i.e., p&lt;0.001 for both) and clinically meaningful benefits with imetelstat treatment versus placebo. Furthermore, statistically significant and clinically meaningful efficacy results were observed in the trial across key MDS patient subtypes, including patients who were ringed sideroblast positive, or RS positive, and ringed sideroblast negative, or RS negative; patients with high (4-6 RBC units/8 weeks) and very high baseline transfusion burden (&gt;6 RBC units/8 weeks); and patients classified as Low or Intermediate-1 risk according to the IPSS. The most common Grade 3/4 adverse reactions were neutropenia (72%) and thrombocytopenia (65%), which lasted a median duration of less than two weeks, and in more than 80% of patients were resolved to Grade &lt;2 in under four weeks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Myelofibrosis (MF)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MF, a type of myeloproliferative neoplasm, is a chronic blood cancer in which abnormal or malignant precursor cells in the bone marrow proliferate rapidly, causing scar tissue, or fibrosis, to form. As a result, normal blood production in the bone marrow is impaired and may shift to other organs, such as the spleen and liver, which can cause them to enlarge substantially. People with MF may have abnormally low or high numbers of circulating RBCs, white blood cells or platelets, and abnormally high numbers of immature cells in the blood or bone marrow. MF patients can also suffer from debilitating constitutional symptoms, such as drenching night sweats, fatigue, severe itching, or pruritus, abdominal pain, fever and bone pain. There are estimated to be approximately 12,000 patients living with MF in the U.S., of which an estimated approximately 10,000 patients are expected to be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relapsed/refractory to JAK inhibitors in 2028 and potentially eligible for treatment with imetelstat if it is approved in that indication, according to IQVIA claims data and a DRG 2022 report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approximately 70% of MF patients are classified as having Intermediate&#8209;2 or High-risk disease, as defined by the Dynamic International Prognostic Scoring System Plus described in a 2011 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Journal of Clinical Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> article. Drug therapies currently approved by the FDA and other regulatory authorities for treating these MF patients include JAK inhibitors, ruxolitinib, fedratinib and momelotinib, as well as pacritinib, a kinase inhibitor. Currently, no drug therapy is approved for those patients who fail or no longer respond to JAK inhibitor treatment, and median survival for MF patients after discontinuation from ruxolitinib is only approximately 14&#8211;16 months, representing a significant unmet medical need.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ongoing Phase 3 IMpactMF Trial in Relapsed/Refractory MF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trial Design</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMpactMF, our Phase 3 clinical trial in relapsed/refractory MF, is an open label, 2:1 randomized, controlled clinical trial designed to evaluate imetelstat (9.4 mg/kg administered by intravenous infusion over two hours every three weeks) in approximately 320 patients. Patients relapsed after or refractory to a JAK inhibitor are defined as having an inadequate spleen response or symptom response after treatment with a JAK inhibitor for at least six months, including an optimal dose of a JAK inhibitor for at least two months. The best available therapy, or BAT, control arm of IMpactMF excludes the use of JAK inhibitors. With respect to the trial design for IMpactMF, the FDA urged us to consider adding a third dosing arm to assess a lower dose and/or a more frequent dosing schedule that might improve the planned trial&#8217;s chance of success by identifying a less toxic regimen and/or more effective spleen response, one of the trial&#8217;s secondary endpoints. Based on data from IMbark, we believe that testing a lower dose regimen would likely result in a lower median OS, which is the trial&#8217;s primary endpoint, in the imetelstat treatment arm. We believe existing data also suggest that lowering the dose would not result in a clinically meaningful reduction in toxicity. For these reasons, we therefore determined not to add a third dosing arm to the trial design, and the FDA did not object to our proposed imetelstat dose and schedule of 9.4 mg/kg every three weeks. Our belief may ultimately be incorrect. Therefore, our failure to add a third dosing arm could result in a failure to maintain regulatory clearance from the FDA and similar international regulatory authorities, could result in the trial&#8217;s failure, or could otherwise delay, limit or prevent marketing approval of imetelstat for relapsed/refractory MF by the FDA or similar international regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary efficacy endpoint for IMpactMF is OS. Key secondary endpoints include symptom response; spleen response; progression free survival; complete remission, partial remission or clinical improvement, as defined by the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria; duration of response; safety; pharmacokinetics; and patient reported outcomes. There are IMpactMF sites across North America, South America, Europe, Australia and Asia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMpactMF is designed with &gt;85% power to detect a 40% reduction in the risk of death (hazard ratio=0.60; one-sided alpha=0.025). The final analysis for OS is planned to be conducted after more than 50% of the patients planned to be enrolled in the trial have died (referred to as an event). An interim analysis of OS, in which the alpha spend is expected to be approximately 0.01, is planned to be conducted after approximately 70% of the total projected number of events (deaths) for the final analysis have occurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Current Status of IMpactMF</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMpactMF opened for patient screening and enrollment in December 2020. As of February 2025, the trial was approximately 80% enrolled.  Based on our planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028. Because these analyses are event-driven and it is uncertain whether actual rates for enrollment and events will reflect current planning assumptions, the results may be available at different times than currently expected. At the interim analysis, if the pre-specified statistical OS criterion is met, then we expect such data may potentially support the registration of imetelstat in relapsed/refractory MF. Subject to protocol-specified stopping rules for futility, if the pre-specified OS criterion is not met at the interim analysis, the trial will continue to the final analysis, which is expected to occur approximately one year later.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing and achievement of either or both of the planned analyses depend on numerous factors, including enrollment rates and blinded death rates, which have in the past been, and may continue to be, lower than our projections. In addition, our ability to enroll, conduct and complete IMpactMF depends on whether we can obtain and maintain the relevant clearances from regulatory authorities and other institutions to enroll, conduct and complete the trial.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvement in Overall Survival and Potential Disease-Modifying Activity Observed in IMbark Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IMbark Phase 2 clinical trial was designed to evaluate two dosing regimens of imetelstat (either 4.7 mg/kg or 9.4 mg/kg administered by intravenous infusion every three weeks) in patients with relapsed/refractory MF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously reported efficacy and safety results from the IMbark Phase 2 clinical trial, including median OS of 28.1 months for patients on the high dose arm of the study, which is almost twice the reported median OS of 14&#8211;16 months in medical literature. To evaluate this potential benefit, we conducted a post-hoc analysis of OS for patients treated with imetelstat 9.4 mg/kg in IMbark compared to OS calculated from real world data, or RWD, collected at the Moffitt Cancer Center for patients who had discontinued treatment with ruxolitinib, a JAK inhibitor, and who were subsequently treated with BAT. To make a comparison between the IMbark data and RWD, a cohort from the real-world dataset was identified that closely matched the IMbark patients, using guidelines for inclusion and exclusion criteria as defined in the IMbark clinical protocol, such as platelet count and spleen size. Calculations from two propensity score analysis approaches resulted in a median OS of 30.7 months for the imetelstat-treated patients from IMbark, which is more than double the median OS of 12.0 months using RWD for patients treated with BAT. These analyses also showed a 65% &#8211; 67% lower risk of death for the imetelstat-treated patients vs. BAT-treated patients. We believe these analyses suggest potentially longer OS for imetelstat-treated relapsed/refractory MF patients in IMbark, compared to BAT in closely-matched patients from RWD. However, comparative analyses between RWD and our clinical trial data have several limitations. For instance, the analyses create a balance between treatment groups with respect to commonly available covariates, but do not take into account the unmeasured and unknown covariates that may affect the outcomes of the analyses. Potential biases are introduced by factors which include, for example, the selection of the patients included in the analyses, misclassification in the matching process, the small sample size, and estimates that may not represent the outcomes for the true treated patient population. For these and other reasons, such comparative analyses and any conclusions from such analyses should be considered carefully and with caution, and should not be relied upon as demonstrative or otherwise predictive or indicative of any current or potential future clinical trial results of imetelstat in relapsed/refractory MF, including IMpactMF.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In IMbark, patients also experienced other positive clinical outcomes, including symptom improvement, spleen reduction and bone marrow fibrosis improvement. In June 2020, we reported correlation analyses from IMbark that showed a trend of longer OS in patients who achieved symptom response, spleen volume reductions and improved bone marrow fibrosis, in a dose-dependent manner. Furthermore, the reductions in the variant allele frequency of key driver mutations in MF and the improvement in bone marrow fibrosis observed in IMbark have also been correlated to the improvement in OS. We believe the improvement in bone marrow fibrosis, potential survival benefit, molecular data and correlations from IMbark provide strong evidence of the potential for disease modification with imetelstat, which we believe would differentiate imetelstat from currently approved treatments for MF, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The safety results observed in IMbark were consistent with prior clinical trials of imetelstat in hematologic malignancies, and no new safety signals were identified. In the 9.4 mg/kg arm, reversible and manageable Grade 3/4 thrombocytopenia and neutropenia were reported in 24/59 patients (41%) and 19/59 patients (32%), respectively, without significant clinical consequences. 1/59 patients (2%) had Grade 3 febrile neutropenia. 3/59 patients (5%) had Grade 3/4 bleeding. 6/59 patients (10%) had Grade 3/4 infections. Furthermore, more than 70% of the observed Grade 3/4 cytopenias resolved to Grade 2 or lower by laboratory assessment within four weeks.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Fast Track Designation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review. Fast Track designation is intended to facilitate and expedite development and review of an NDA to address unmet medical needs in the treatment of serious or life-threatening conditions. However, Fast Track designation does not accelerate conduct of clinical trials or mean that the regulatory requirements are less stringent, nor does it ensure that imetelstat will receive marketing approval or that approval will be granted within any particular timeframe. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data emerging from the imetelstat clinical development program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2017, the FDA granted Fast Track designation to imetelstat for the treatment of adult patients with TD anemia due to lower-risk MDS who do not have a non-del 5q abnormality and who are refractory or resistant to treatment with an ESA (i.e., the treatment population in IMerge Phase 3).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2019, the FDA granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-Risk MF whose disease has relapsed after or is refractory to JAK inhibitor treatment (i.e., the treatment population in IMpactMF).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Potential Additional Indications</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMproveMF: Phase 1 Combination Clinical Trial in Frontline Myelofibrosis (Frontline MF)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also evaluating imetelstat as a combination therapy in the Phase 1 IMproveMF clinical trial as a first-line treatment for patients with Intermediate-1, Intermediate-2 or High-Risk myelofibrosis. Based on the dose escalation findings in Part 1 of the study, presented at the American Society of Hematology, or ASH, annual meeting in December 2024, imetelstat 9.4 mg/kg dosed every four weeks with ruxolitinib was the selected dose for the dose expansion Part 2 of the study, which is currently enrolling patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMpress: Investigator-Led Phase 2 Clinical Trial in Higher Risk Myelodysplastic Syndromes (Higher Risk MDS) and Acute Myeloid Leukemia (AML)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Imetelstat is also being studied in an investigator-led IMpress Phase 2 clinical trial in Intermediate-2 or High-Risk myelodysplastic syndromes, or higher-risk MDS, and acute myeloid leukemia, or AML, patients that are relapsed or refractory to hypomethylating agent, or HMA, treatment. Based on observations from an interim analysis from the first cohort, presented at ASH in December 2024, the protocol was amended to a more frequent dosing schedule for a second cohort of patients being enrolled and treated with this modified schedule as of August 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, pending the results of IMpress, we plan to support a Phase 1/2 investigator-led study, called TELOMERE, in relapsed/refractory AML, using a combination approach of imetelstat and venetoclax or azacitidine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research Programs</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Next Generation Telomerase Inhibitor Discovery</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initiated a discovery program to identify lead compounds as a potential next generation oral telomerase inhibitor. If the leads we have identified are optimized, we may conduct preclinical experiments that may serve as a basis for potential future clinical testing. Discovery research is an uncertain and unpredictable process. As such, the timing and nature of any results from this discovery effort are difficult to forecast. If we optimize lead compounds from this discovery program, we expect to provide an update on our efforts at that time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Lymphoid Hematologic Malignancies</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Academic research data suggests that certain lymphoid hematologic malignancies have higher telomerase activity and shorter telomeres when compared to normal healthy cells. Based on this scientific hypothesis, we conducted a preclinical research project with MD Anderson Cancer Center to determine the potential application of imetelstat in lymphoid hematologic malignancies.  The project was completed, and preliminary results of the research project were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Blood</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in November 2022.  Exploring the utility of imetelstat in lymphoid hematologic malignancies remains an area of interest for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property and Regulatory Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual property, including patent protection, is very important to our business. We file patent applications in the U.S. and other jurisdictions, and we also rely on trade secret protection and contractual arrangements to protect aspects of our business. An enforceable patent with appropriate claim coverage can provide an advantage over competitors who may seek to employ similar approaches to develop therapeutics, and so the future commercial success of RYTELO (imetelstat), and therefore our future success, will be in part dependent on our intellectual property strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our intellectual property strategy includes the early development of a technology, such as imetelstat, followed by rounds of increasingly focused innovation around a product opportunity, including identification and definition of a specific product candidate and uses thereof, manufacturing processes, product formulation and methods of treatment and administration. The result of this process is that products in development are often protected by several families of patent filings that are filed at different times during the development process and cover different aspects of the product. Consequently, earlier filed, broad technology patents will usually expire ahead of patents covering later developments, such as product formulations and methods of treatment and administration, so that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patent expirations on a product may span several years. Patent coverage may also vary from country to country based on the scope of available patent protection. There are also opportunities to obtain an extension of patent coverage for a product in certain countries, which adds further complexity to the determination of patent life.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may endeavor to monitor worldwide patent filings by third parties that are relevant to our business. Based on this monitoring, we may determine that an action is appropriate to protect our business interests. Such actions may include negotiating patent licenses where appropriate, filing oppositions against a patent, filing a request for post grant review against a patent or filing a request for the declaration of an interference with a patent application or issued patent.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information provided in this section should be reviewed in the context of the section entitled &#8220;Risks Related to Protecting Our Intellectual Property&#8221; described in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RYTELO (imetelstat)</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO was developed internally by us, and we hold global commercial rights to it. We own issued patents related to RYTELO in the U.S., Europe and other countries. Although composition of matter patents generally provide the most comprehensive coverage of a therapeutic product such as RYTELO, subsequent patent filings directed to other aspects of RYTELO may also provide additional patent coverage with later expiration dates. In addition, it may be possible to obtain patent term extensions of some patents in some countries for claims covering RYTELO or relating to RYTELO, such as methods of treatment with RYTELO, which could further extend the patent term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have issued patents in the U.S., Europe and other countries that provide patent coverage into 2033 (not including any patent term extension) pertaining to the treatment of MDS and MF with RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., our method of treatment patent rights for MDS and MF expire in March 2033 (not including any patent term extension). We also hold an issued patent in the U.S. covering the composition of matter of RYTELO (imetelstat) that expires in December 2025. Now that we have received approval for RYTELO in the U.S., we have applied for patent term extensions under the provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (as amended), or the Hatch-Waxman Act, which, if granted, would  extend the patent term of either our method of treatment patent for MDS and MF or our composition of matter patent by up to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe and other countries, our patent rights for use in MDS and MF expire in November 2033 (not including any patent term extension). Our composition of matter patent coverage expired in September 2024. Subject to receiving approval for RYTELO from the EC, we plan to seek patent term extension under a Supplementary Protection Certificate, or SPC, as permitted under European Council (EC) Regulation No. 469/2009, or the European SPC Regulation, of one of our use patents, such as our patent for use in MDS, in the European Economic Area, or the EEA, which could extend the patent term by up to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., Europe, and other countries, we are also pursuing other patent rights relating to RYTELO (imetelstat), such as methods of treatment of MDS in specific patient subpopulations, reagents useful in the manufacturing processes for the drug, and other methods of treatment and kit claims, certain of which are co&#8209;owned with other entities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Extension</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we are in the process of seeking patent term extension for some of our issued patents covering RYTELO, it is not possible to obtain patent term extension of any patents that expired prior to or are issued following regulatory approval. For the patents for which we are seeking a patent term extension, we may not be granted any such patent term extension and/or the applicable time period of such patent term extension could be less than we have projected. Moreover, in some countries, including the U.S., such patent term extensions, if any, are limited to those claims which encompass the product composition and treatment indications as approved by the relevant healthcare regulatory authority.  During the life of the patent term extension, however, its scope of protection will expand to include any additional indications subsequently approved for the product and claimed by the patent.  Furthermore, some jurisdictions, including the U.S., allow the filing of patent term extension applications on multiple patents, but ultimately the patent owner must select one patent to which the extension is applied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., now that we have received approval for RYTELO in certain patients with lower-risk MDS, we may potentially extend the term of our composition of matter patent in the U.S. for a maximum of five years until December 2030, subject to U.S. Patent and Trademark Office, or USPTO, approval. Alternatively, we may potentially extend the term of our method of treatment for MDS claims in the U.S. until August 2037, subject to USPTO approval. As we have previously disclosed, we expect to apply patent term extension, if granted, to our method of treatment patent, since doing so provides a longer patent term. However, if we do not receive a patent term extension for our U.S. method of treatment patent for MDS, it will expire in March 2033. Once our composition of matter patent expires in the U.S., we must rely on our method of treatment patent and other patents and regulatory exclusivity for RYTELO in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, in Europe, subject to receiving approval from the EC for RYTELO in certain patients with lower-risk MDS, we plan to seek to potentially extend the term of our patents in the EEA for the use of RYTELO in MDS for a maximum of five years, from November 2033 until November 2038, subject to European Patent Office approval. Since our European composition of matter patents expired in September 2024, we must rely on our use and other patents and, subject to receiving approval from the EC, regulatory exclusivity for RYTELO in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not have sufficient patent life and regulatory exclusivity to protect RYTELO in the U.S. and EU, our financial results, business and business prospects, and future development of imetelstat could be materially and adversely affected, which might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Market Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a drug to qualify for orphan drug designation by the FDA, both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act, or ODA, and FDA&#8217;s implementing regulations. Orphan drug designation is granted by the FDA&#8217;s Office of Orphan Drug Products in order to support development of medicines for rare diseases or conditions, which generally are those that affect fewer than 200,000 people in the U.S. or, if the disease or condition affects more than 200,000 individuals annually in the U.S., if there is no reasonable expectation that the cost of developing and making the drug would be recovered from sales in the U.S. Orphan drug designation qualifies the sponsor of the drug for various development incentives under the ODA, including certain tax credits for qualified clinical testing</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and exemption from user fees. A drug granted approval for an orphan designated indication generally receives seven years of market exclusivity, during which time the FDA generally may not approve any other application for the same product for the same use, with certain limited exceptions, most notably when the later product is shown to be clinically superior to the product with exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.  The FDA can revoke a product&#8217;s orphan drug exclusivity under certain circumstances, including when the product sponsor is unable to assure the availability of sufficient quantities of the product to meet patient needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A marketing application for a prescription drug product that has received orphan drug designation is not subject to a prescription drug user fee unless the application includes an indication for a disease or condition other than the rare disease or condition for which the drug was granted orphan drug designation. The granting of orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. The safety and effectiveness of a drug product must be established through adequate and well&#8209;controlled studies. Orphan drug exclusivity does not prevent the FDA from approving a drug product containing a different active moiety for the same disease or condition, or a drug product containing the same active moiety for a different disease or condition , and also imposes certain requirements on manufacturers, such as the availability of drug supply, in order to maintain orphan drug exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2015 and December 2015, the FDA granted orphan drug designation to imetelstat for the treatment of MF and MDS, respectively, and following approval of RYTELO in June 2024, the FDA listed in its Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, that RYTELO has orphan drug exclusivity, which is expected to provide orphan drug exclusivity until June 2031, subject to our continuing compliance with the requirements to maintain such orphan drug exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to orphan drug exclusivity, under the Hatch-Waxman Act, if a product is a &#8220;new chemical entity&#8221; or NCE, generally meaning that the active moiety has never before been approved in any drug, there is a period of five years from approval of the first indication during which the FDA may not accept for filing any abbreviated new drug application, or ANDA, under section 505(j) of the Federal Food, Drug, and Cosmetic Act, or an application under section 505(b)(2) of the statute for a drug with the same active moiety.  An ANDA or 505(b)(2) application may be submitted after four years, however, if the sponsor of the application makes a Paragraph IV certification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our request for NCE exclusivity for RYTELO is pending review by the FDA.  If the FDA were to grant NCE exclusivity for RYTELO, NCE exclusivity would continue until June 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product that is not an NCE may qualify for a three-year period of exclusivity if the NDA contains new clinical data, (other than bioavailability studies) derived from studies conducted by or for the sponsor, that were necessary for approval. In that instance, the exclusivity period does not preclude filing or review of an ANDA or 505(b)(2) application; rather, the FDA is precluded from granting final approval to the ANDA or 505(b)(2) application until three years after approval of the RLD. Additionally, the exclusivity applies only to the conditions of approval that required submission of the clinical data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the US, the exclusivity periods and patent-related protections described above also may be eligible for a six-month extension of regulatory exclusivity, or pediatric exclusivity, pursuant to section 505A of the Federal Food, Drug, and Cosmetic Act, if the sponsor submits pediatric data that &#8220;fairly respond&#8221; to a written request from FDA for such data; however, we do not expect to receive pediatric exclusivity for RYTELO in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Europe</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EEA, pursuant to the European Union Data Exclusivity Directive 2004/27/EC, upon drug product approval a new medicinal product is entitled to New Active Substance, or NAS, exclusivity in the form of eight years of data exclusivity and two years of market exclusivity, conferring a total of ten years of exclusivity for the first-approved indication. Thus, subject to receiving approval from the EC for RYTELO for the treatment of certain patients with lower-risk MDS, we expect to have a total of ten years of NAS exclusivity for this indication from the time of approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to NAS exclusivity, orphan drug designation by the EC provides regulatory and financial incentives for companies to develop and market therapies that treat a life&#8209;threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU, and where no satisfactory treatment is available. Orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers, as well as protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure. In addition, ten years of market exclusivity is granted following receipt of drug product approval, meaning that another application for marketing authorization of a later similar medicinal product for the same therapeutic indication will generally not be approved by the EC. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable to not justify maintenance of market exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2015 and July 2020, the EC granted orphan drug designation to imetelstat for the treatment of MF and MDS, respectively. As part of its review of our MAA for RYTELO, the EMA reviewed the grant of orphan drug designation for the treatment of certain patients with MDS. If RYTELO is approved by the EC and we continue to maintain orphan drug designation for RYTELO for MDS, we anticipate that we will have the potential to retain market exclusivity in the EEA for RYTELO in the approved indication for ten years post-approval. However, if in the future the EC chooses not to maintain its grant of orphan designation for RYTELO for MDS, we will not be eligible for 10 years of orphan drug exclusivity, although we would still be eligible for up to 10 years of NAS exclusivity, as described above.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, subject to RYTELO's approval by the EC, under the European Pediatric Regulation, if we fulfill our pediatric investigation plan agreed upon with the EMA, we would be eligible to receive an additional two years of exclusivity, which may enable us to maintain orphan drug exclusivity in the EEA for RYTELO in certain patients with lower-risk MDS for an additional two years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Collaboration with Janssen Biotech, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the effective date of termination of the license and collaboration agreement, or the Prior Collaboration Agreement, with Janssen Biotech, Inc., or Janssen, on September 28, 2018, we regained global rights to imetelstat and are continuing the development, commercialization and marketing of imetelstat on our own. In accordance with the termination provisions of the Prior Collaboration Agreement, we have an exclusive worldwide license for intellectual property developed under the Prior Collaboration Agreement for the further development, commercialization and marketing of imetelstat, without any economic obligations to Janssen with respect to such license. Janssen has assigned to us certain intellectual property developed by it under the Prior Collaboration Agreement. We now are responsible for the costs of maintaining, prosecuting and litigating all imetelstat intellectual property that we own.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no material license agreements.  We have global rights to imetelstat, which was discovered and developed at Geron.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A typical sequence of steps in the manufacture of imetelstat drug product includes the following key components:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">starting materials, which are well&#8209;defined raw materials that are used to make bulk drug substance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bulk drug substance, which is the active pharmaceutical ingredient in a drug product that provides pharmacological activity or other direct effect in the treatment of disease; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">final drug product, which is the finished dosage form that contains the drug substance that is shipped to the clinic for patient treatment.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since September 2018, we have engaged third&#8209;party contract manufacturers and have established our own manufacturing supply chain to manufacture and supply additional quantities of imetelstat that meet applicable regulatory standards for current and potential commercial uses and current and potential future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have direct control over third&#8209;party personnel or operations. These third&#8209;party contract manufacturers, and/or any other third parties that we may rely upon for the manufacture and/or supply of imetelstat, typically complete their services on a proposal by proposal basis under master supply agreements and may need to make substantial investments to enable sufficient capacity increases and cost reductions, and to implement those regulatory and compliance standards necessary for commercial production and successful Phase 3 clinical trials. These third&#8209;party contract manufacturers, and/or any other third parties that we may rely upon for the manufacture and/or supply of imetelstat, may not be able to achieve such capacity increases, cost reductions, or regulatory and compliance standards, and even if they do, such achievements may not be at a commercially reasonable cost. We are responsible for establishing any long&#8209;term commitments or commercial supply agreements with any of the third&#8209;party contract manufacturers for imetelstat. The information provided in this section should be reviewed in the context of the section entitled &#8220;Risks Related to Manufacturing RYTELO (Imetelstat)&#8221; under Part I, Item 1A, &#8220;Risk Factors&#8221; of this Report.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by intense and dynamic competition with rapidly advancing technologies and a strong emphasis on proprietary products. While we believe our proprietary oligonucleotide chemistry; experience with the biological mechanisms related to RYTELO, telomeres and telomerase; clinical data to date indicating potential disease-modifying activity with RYTELO treatment; and knowledge and expertise around the development of potential treatments for myeloid hematologic malignancies provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. RYTELO is competing with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware of.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competition in Lower-Risk MDS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current standard of care for the treatment of lower-risk MDS is the use of ESAs to address the patient&#8217;s chronic anemia. Once ESAs are no longer effective, serial blood transfusions are often administered that can cause damaging effects to other organs due to iron overload, resulting in shorter survival. In addition, other best available therapies are used without durable effect for the patient.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In lower-risk MDS, data from IMerge Phase 3 resulted in FDA approval of RYTELO in June 2024 for the treatment of certain patients with lower-risk MDS.  IMerge showed meaningful and durable transfusion independence, activity across MDS patient subtypes, and potential disease-modifying activity achievable with  RYTELO treatment. We believe that these key features are differentiators compared to currently approved products as well as investigational drugs currently in clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In lower-risk MDS, RYTELO competes against a number of currently existing therapies, including ESAs and other hematopoietic growth factors that are indicated for anemia; immunomodulators, such as Revlimid (lenalidomide) by Celgene Corporation, or Celgene, a Bristol Myers Squibb Company, or BMS, company;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hypomethylating agents, such as Vidaza (azacitidine) by Celgene and manufacturers of generic azacitidine; Dacogen (decitabine) by Otsuka America Pharmaceutical, Inc. and other manufacturers in the U.S. and Janssen in the EU; Inqovi (oral combination of decitabine and cedazuridine) by Astex Pharmaceuticals, Inc., or Astex; Tibsovo (ivosidenib), an IDH1 inhibitor, by Servier Pharmaceuticals, LLC; and Reblozyl (luspatercept), a TGF-beta inhibitor, by BMS. In August 2023, luspatercept was also approved for the treatment of anemia in ESA-naive adult patients with very low-to intermediate-risk MDS who may require regular RBC transfusions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other therapies currently in Phase 3 development in lower-risk MDS include elritercept (KER-050), a TGF-beta inhibitor, by Keros Therapeutics, Inc.; and Reblozyl (luspatercept) in non-transfusion-dependent lower-risk MDS patients, by BMS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there are multiple Phase 1 and Phase 2 clinical trials of other agents being developed for lower-risk MDS, including but not limited to: LB&#8208;100, a PP2A inhibitor, by Lixte Biotechnology Holdings, Inc.; bemcentinib, an AXL inhibitor, by BerGenBio ASA; H3B&#8208;8800, a spliceosome inhibitor, by H3 Biomedicine, Inc.; TP-0184, an inhibitor of ALK2 or ACVR1 kinase, by Sumitomo Dainippon Pharma Oncology, Inc; ilginatinib (NS-018), a JAK2 inhibitor, by NS Pharma, Inc., a U.S. subsidiary of Nippon Shinyaku Co., Ltd., or NS Pharma; a lower dose of ASTX727, an oral formulation of decitabine and cedazuridine, referred to as ASTX727 LD, by Astex; ASTX030, an oral formulation of azacitidine and cedazuridine, by Astex; JSP191, or briquilimab, an anti-C-kit antibody, by Jasper Therapeutics, Inc.; R289, an oral inhibitor of interleukin receptor-associated kinases 1 and 4, or IRAK1/4, by Rigel Pharmaceuticals, Inc.; a combination treatment regimen of luspatercept and lenalidomide by BMS; and HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, by BMS and etavopivat, an oral, small molecule activator of erythrocyte pyruvate kinase (PKR) by Forma Therapeutics, Inc., a Novo Nordisk Company; canakinumab, an interleukin antagonist, by Novartis AG; and AG946, a next-generation pyruvate kinase-R (PKR) activator, by Agios Pharmaceuticals, Inc.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competition in Relapsed/Refractory MF</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current standard of care for the treatment of Intermediate-2 or High-risk MF is the use of JAK inhibitors, to address the patient&#8217;s symptoms. Once JAK inhibitors fail or are no longer effective, a variety of best available therapies are used since there are no approved treatments for this patient population and median OS is 14 to 16 months after discontinuation from the predominant JAK inhibitor being used today.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Intermediate-2 or High-risk relapsed/refractory MF, data from IMbark suggest potential disease-modifying activity with RYTELO treatment and a potential meaningful improvement in OS, which is supported in a comparison to real-world data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved for commercial sale for the treatment of relapsed/refractory MF, RYTELO would compete against currently approved JAK inhibitors: Jakafi (ruxolitinib) by Incyte Corporation, or Incyte, Inrebic (fedratinib) by Celgene, and OJJAARA (momelotinib), which was approved in September 2023 for the treatment of intermediate or high-risk MF, including primary MF or secondary MF (postpolycythemia vera and post-essential thrombocytopenia), in adults with anemia, by GlaxoSmithKline plc, or GSK, as well as a kinase inhibitor, Vonjo (pacritinib), by CTI Biopharma Corp., which was approved in February 2022 for the treatment of adults with Intermediate or High-Risk primary or secondary myelofibrosis with a platelet count below 50 &#215; 109/L. Other treatment modalities for MF include hydroxyurea for the management of splenomegaly, leukocytosis, thrombocytosis and constitutional symptoms; splenectomy and splenic irradiation for the management of splenomegaly and co-existing cytopenias; chemotherapy; and pegylated interferon. Drugs for the treatment of MF-associated anemia include ESAs, androgens, danazol, corticosteroids, thalidomide and lenalidomide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other therapies currently in Phase 3 development in MF, some of which may obtain regulatory approval earlier than RYTELO for MF, include momelotinib plus AZD5153, a BET inhibitor by GSK; pelabresib (CPI-0610), a BET inhibitor, by MorphoSys AG (acquired by Novartis in 2024); and navtemadlin, an MDM2-inhibitor, by Kartos Therapeutics, Inc. Other approaches for MF currently under investigation that could compete with RYTELO in the future include luspatercept; zinpentraxin alfa (RG6354, formerly PRM-151), an anti-fibrosis antibody, by F. Hoffmann-La Roche, Ltd.; INCB160058, a JAK2 inhibitor, by Incyte; AJ1-11095, a JAK2 inhibitor, by Ajax Therapeutics, Inc.; SLT-5505, a pan-LOX inhibitor, by Syntara Limited; tasquinimod, an S100A9 inhibitor, by Active Biotech AB; XPOVIO (selinexor), a nuclear export inhibitor, by Karyopharm Therapeutics, Inc.; TL-895, an oral tyrosine kinase inhibitor, by Telios Pharma, Inc.; pelcitoclax (APG-1252), a dual BCL-2/BCL-XL inhibitor, by Ascentage Pharma; DISC-0974, a monoclonal antibody against hemojuvelin (HJV) by DISC Management Inc.; KER-050 in combination with ruxolitinib, by Keros Therapeutics; CK0804, an allogeneic T-regulatory cell agent, by Cellenkos, Inc. in collaboration with Incyte; TP-3654, PIM kinase inhibitor by Sumitomo Pharma Co., Ltd.; and a mutated-CALR vaccine, a peptide-based vaccine, from the Icahn School of Medicine at Mount Sinai.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation by governmental authorities in the U.S. and other countries is a significant factor in the development, manufacture and marketing of RYTELO (imetelstat). Imetelstat will require regulatory approval by regulatory authorities prior to commercialization in any jurisdictions where it is not yet approved. In particular, potential human therapeutic products, such as imetelstat, are subject to rigorous preclinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in European and other countries. Various governmental statutes and regulations at both the federal and state level also govern or influence testing, manufacturing, safety, labeling, storage, import, export, distribution, sale and recordkeeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with appropriate statutes and regulations require the expenditure of substantial time and money, and there can be no guarantee that approvals will be granted. Moreover, compliance with government regulations governing personal data and information security requires the expenditure of substantial time and financial resources. The information provided in this section should be reviewed in the context of the sections entitled &#8220;Risks Related to the Further Development of RYTELO (Imetelstat)&#8221; and &#8220;Risks Related to Regulatory Approval of RYTELO&#8221; under Part I, Item 1A, &#8220;Risk Factors&#8221; of this Report.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">United States Food and Drug Administration Regulatory Approval Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to commencement of clinical trials involving humans, preclinical testing of new pharmaceutical products is generally conducted on animals in the laboratory to evaluate the potential efficacy and safety of a product candidate. The results of these trials are submitted to the FDA as part of an Investigational New Drug, or IND, application, which must become effective before clinical testing in humans can begin. The FDA can place an IND on clinical hold at any time, which prevents the conduct of clinical trials under the IND until safety concerns or questions are addressed by the IND sponsor to the FDA&#8217;s satisfaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Typically, clinical evaluation involves a time consuming and costly three phase trial process. In Phase 1, clinical trials are conducted with a small number of healthy volunteers or patients afflicted with a specific disease to assess safety and to evaluate the pattern of drug distribution and metabolism within the body. In Phase 2, clinical trials are conducted with groups of patients afflicted with a specific disease in order to determine preliminary efficacy, optimal dosages and expanded evidence of safety. The Phase 2 trials can be conducted comparing the investigational treatment to a comparator arm, or not. If used, a comparator usually includes standard of care therapy. Safety and efficacy data from Phase 2 clinical trials, even if favorable, may not provide sufficient rationale for proceeding to a Phase 3 clinical trial. In Phase 3, large scale, multi&#8209;center, comparative trials are conducted with patients afflicted with a target disease to provide sufficient data to demonstrate the efficacy and safety required by the FDA. The FDA closely monitors the progress of each of the three phases of clinical testing and may, at its discretion, re&#8209;evaluate, alter, suspend, or terminate the trials. Human clinical trials must be conducted in compliance with Good Clinical Practice, or GCP, regulations and applicable laws, with the oversight of Institutional Review Boards for the protection of human subjects. The manufacture of drug product candidates is subject to requirements that drugs be manufactured, packaged and labeled in conformity with current Good Manufacturing Practices, or cGMP, and applicable laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of the preclinical and clinical testing of drugs and complete manufacturing information are submitted to the FDA in the form of an NDA for review and approval prior to commencement of commercial sales. Submission of an NDA requires the payment of a substantial user fee to the FDA, which may be waived in certain cases. In responding to an NDA submission, the FDA may approve the drug for commercialization, impose limitations on its indications for use and labeling, including in the form of Risk Evaluation and Mitigation Strategies or may issue a complete response letter. Even if an NDA is approved, its sponsor is subject to ongoing and pervasive regulatory compliance requirements.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">European Union and Other Regulatory Approval Process</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to initiating clinical trials in a region outside of the U.S., a clinical trial application must be submitted and reviewed by the appropriate regulatory authority governing clinical trials in the country in which the trial will be conducted. Whether or not FDA clearance or approval has been obtained, approval of a product by comparable regulatory authorities in the EU and other countries is necessary prior to marketing the product in such countries. The competent regulatory authorities may impose their own requirements and may refuse to grant an approval, or may require additional data before granting it, even though the relevant product has been cleared or approved by the FDA or another authority. As with the FDA, the regulatory authorities in the EU and other developed countries have lengthy approval processes for pharmaceutical products. The process for gaining approval in particular countries varies, but generally follows a similar sequence to that described for FDA approval. In Europe, the EMA and the CHMP provide a mechanism for EU member states to exchange information on all aspects of product licensing. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EU has established the EMA for the evaluation of medical products, with a centralized procedure which is mandatory for orphan and oncology products and which grants a single marketing authorization valid in all EU member states.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fraud and Abuse, and Transparency Laws and Regulations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to additional regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. These additional regulations could affect our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third&#8209;party payors. Such laws include, without limitation, state and federal bribery/anti&#8209;kickback, the False Claims Act, privacy and data security laws, and healthcare professionals payment transparency laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti&#8209;Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully, directly or indirectly, solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare, Medicaid TRICARE, and the Veterans Health Administration. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals, the Anti&#8209;Kickback Statute has been violated. The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act or ACA, among other things, amended the intent requirement of the federal Anti&#8209;Kickback Statute such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate, in order to commit a violation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal civil and criminal false claims and false statement laws, including the federal civil False Claims Act and its whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provisions that permit private individuals to bring an action on behalf of the government to enforce the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed. Entities can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product off&#8209;label, or for providing medically unnecessary services or items. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Criminal prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third&#8209;party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, transmission and breach reporting of individually identifiable health information, upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers and their respective business associates and their subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, and information related to ownership and investment interests held by physicians and their immediate family members.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state anti&#8209;kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non&#8209;governmental third-party payors, including private insurers. Additionally, we may be subject to state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and certain industry compliance guidance documents. Further, we may be subject to state and foreign laws that require drug manufacturers or other pharmaceutical companies to report information related to payments and other transfers of value to physicians, other healthcare providers and healthcare entities, or marketing expenditures, as well as state, foreign and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws that require the reporting of information related to drug pricing; and state, federal and foreign laws governing the privacy and security of personal data (including key-coded data and health information), including the European Union&#8217;s General Data Protection Regulation, or EU GDPR, many of which differ from each other in significant ways, thus complicating compliance efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our operations are found to be in violation of any of these or any other healthcare regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Privacy and Security</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we process personal or sensitive data. Accordingly, we are, or may become, subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy and security. Efforts to ensure that our current and future business arrangements will comply with applicable data privacy and data security laws and regulations will involve substantial costs. For example, foreign data privacy and security laws (including but not limited to the EU GDPR and UK GDPR) impose strict significant and complex compliance obligations on entities that are subject to those laws. As one example, the EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. These obligations may include limiting personal data processing to only what is necessary for specified, explicit, and legitimate purposes; requiring a legal basis for personal data processing; requiring the appointment of a data protection officer in certain circumstances; increasing transparency obligations to data subjects; requiring data protection impact assessments in certain circumstances; limiting the collection and retention of personal data; increasing rights for data subjects formalizing a heightened and codified standard for data subject consent, requiring the implementation and maintenance of technical and organizational safeguards for personal data, mandating data breach notifications to relevant supervisory authority(ies), and mandating the appointment of representatives in the UK and/or the EU in certain circumstances. Moreover, we expect that there will continue to be new proposed data privacy and security laws, regulations and industry standards in the U.S. As one example, the California Consumer Privacy Act of 2018, or CCPA, imposes numerous obligations on covered business. Although the CCPA exempts certain data (such as some data processed in the context of clinical trials), the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal data we maintain about California residents.</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CCPA provides for civil penalties and a private right of action for data breaches which may include an award of statutory damages. Failure, or perceived failure, to comply with all applicable obligations could result in enforcement actions, fines, litigation, and other consequences. See the section titled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;We are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, industry standards,  policies and other obligations related to data privacy and security. Our (or third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration; fines and penalties; disruptions for our business operations; reputational harm; loss of revenue and profits; and other adverse business impacts,&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> under &#8220;Risk Factors&#8221; in Part I, Item 1A of this Report for additional information about the laws and regulations to which we may become subject and about the risks to our business associated with such laws and regulations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate that receives regulatory approval. In the U.S. and markets in other countries, sales of RYTELO will depend, in part, on the extent to which third&#8209;party payors provide coverage and establish adequate reimbursement levels.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., third&#8209;party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that a product is safe, effective and medically necessary; appropriate for the specific patient; cost-effective; supported by peer-reviewed medical journals; included in clinical practice guidelines; and neither cosmetic, experimental, nor investigational. A third-party payor could also require that certain lines of therapy be completed or failed prior to reimbursing our therapy. The principal decisions about reimbursement for new medicines are typically made by CMS. CMS decides whether and to what extent products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Third-party payors determine which products and procedures they will cover and establish reimbursement levels. Third&#8209;party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost&#8209;effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA&#8209;approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost&#8209;effectiveness of RYTELO, in addition to the costs required to obtain the FDA approvals. Nonetheless, RYTELO may not be considered medically necessary or cost&#8209;effective. Moreover, the process for determining whether a third&#8209;party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product, as there is no uniform coverage and reimbursement policy among third-party payors in the U.S. Adequate third&#8209;party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in RYTELO. Even if a third-party payor covers a particular product or procedure, the resulting reimbursement payment rates may not be adequate. Coverage policies and third-party payor reimbursement rates may change. Thus, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce demand for the product and also have a material adverse effect on future sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries, Presidential executive orders, and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. For example, on August 16, 2022, the Inflation Reduction Act of 2022 was signed into law, which, among other things, (i) directs the Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare that have been on the market for at least seven years (the &#8220;Medicare Drug Price Negotiation Program&#8221;), and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively in fiscal year 2023.  On August 15, 2024, HHS announced the agreed upon prices of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Additionally, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. and some foreign jurisdictions are considering or have enacted legislative and regulatory proposals to contain healthcare costs, as well as to improve quality and expand access. For example, in March 2010, the ACA was signed into law, which included a number of provisions of importance to the biopharmaceutical industry. There have been judicial and Congressional challenges and amendments to certain aspects of the ACA. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. We expect that other healthcare reform measures that may be adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections, may result in more rigorous coverage criteria and lower reimbursement, and additional downward pressure on the price that may be charged for RYTELO. It is unclear how any such healthcare reform measures will impact the pharmaceutical industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011 was enacted, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and, due to subsequent legislative amendments to the statute will stay in effect through 2032 unless additional Congressional action is taken. More recently, there has been heightened governmental scrutiny in the U.S. to control the rising cost of healthcare.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information About Our Executive Officers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth certain information with respect to our executive officers and other members of management as of January 31, 2025:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:5.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.46%;box-sizing:content-box;"/>
    <td style="width:65.7%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Position</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Officers</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John A. Scarlett, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michelle Robertson</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Finance, Chief Financial Officer and Treasurer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joseph Eid, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Research and Development</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Faye Feller, M.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Medical Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Andrew J. Grethlein, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Operating Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Scott A. Samuels, Esq.</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Legal Officer and Secretary</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Ziegler</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Commercial Officer</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="7" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Members of Management</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Melissa A. Kelly Behrs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Business Operations and Chief Alliance Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Edward E. Koval</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Business Officer</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shannon T. Odam</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Senior Vice President, Chief People Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">John A. Scarlett, M.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Chief Executive Officer and a director since September 2011 and President since January 2012 and was appointed to Chairman of the Board in December 2018. Dr. Scarlett served as a director of CytomX Therapeutics, Inc., a biopharmaceutical company focused on developing antibody therapeutics for the treatment of cancer, from June 2016 to June 2022. He was also a director for Chiasma, Inc., a biopharmaceutical company focused on transforming injectable drugs into oral medications, from February 2015 until its acquisition by Amyrt Pharma plc, a biopharmaceutical company, in August 2021. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc., a privately held, oncology oriented biopharmaceutical company, from February 2009 until its acquisition by Onyx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceuticals, Inc., an oncology oriented biopharmaceutical company, in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc., an endocrinology oriented biopharmaceutical company, and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., a contract biopharmaceutical manufacturing operation, and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk A/S. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michelle Robertson</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Vice President, Chief Financial Officer and Treasurer since September 2023. Prior to joining Geron, she served as the Chief Financial Officer and Treasurer of Editas Medicine, Inc., a CRISPR genome editing company, from January 2020 to May 2023. Before that, she served as Chief Financial Officer of Momenta Pharmaceuticals, Inc. from 2018 until 2020, when Momenta was acquired by Johnson &amp; Johnson. Prior to joining Momenta, Ms. Robertson held multiple commercial finance roles of increasing responsibility, including Vice President, Oncology Finance for Baxalta Incorporated following its spin-off from Baxter International Inc., from 2015 to 2016; Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, Inc. from 2012 to 2015; and various finance and commercial operations roles at Genzyme Corporation (acquired by Sanofi). She also currently serves as a member of the board of directors and as the chair of the audit committee for Verastem, Inc., a publicly-traded biopharmaceutical company. Ms. Robertson received her B.S. in Finance and A.S. in Accounting and Management from Bentley University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joseph Eid, M.D., </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President Research and Development since November 2024. Prior to joining Geron, Dr. Eid served as President, Research and Development for Dragonfly Therapeutics, Inc., a clinical stage biopharmaceutical company, with overall responsibilities for Dragonfly's discovery and clinical research strategy and execution, from February 2023 to March 2024. Before joining Dragonfly Dr. Eid served as Executive Vice President, Chief Medical Officer at Luzsana Biotechnology, Inc., a pharmaceutical company and a subsidiary of Hengrui Pharmaceuticals, from October 2021 to September 2022.  Prior to his biotechnology leadership roles, Dr. Eid served as Senior Vice President and Head, Global Medical Affairs for Bristol Myers Squibb, or BMS, from 2017 to 2021, where he led global medical affairs across four therapeutic franchises. Prior to BMS, Dr. Eid spent nine years at Merck, first at Merck Research Labs, where he led the first-in-human strategy of their global KEYTRUDA&#174; program, and then at Merck Global Human Health, where he built Merck's global oncology medical affairs team. Dr. Eid started his pharmaceutical career at Hoffmann La Roche, where he was responsible for both early- and late-stage assets and led several clinical teams. Prior to entering the biopharmaceutical industry, Dr. Eid was an Assistant Professor in the hematology department of Robert Wood Johnson Medical School in New Jersey from 1999 to 2004 and as a volunteer, through 2019. Dr. Eid received his M.D. from Saint Joseph University, Faculty of Medicine, and serves on ALSAC/St Jude Children&#8217;s Research Hospital board, and on the board of Angle PLC, a liquid biopsy company.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Faye Feller, M.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Vice President, Chief Medical Officer since July 2022. Previously, she served as our Vice President of Clinical Development since she joined Geron in April 2019. In this role, Dr. Feller played a strategic role in designing and driving execution of Geron&#8217;s Phase 3 clinical trials, served as the primary medical point of contact between Geron and our clinical investigators and led the preparation of data for assessment by the data monitoring committees. Prior to joining Geron, Dr. Feller was Senior Director at Janssen Research and Development, LLC (Janssen), a global pharmaceutical company, and both a Compound Lead and Study Responsible Physician for multiple clinical trials of early and late-stage development assets at Janssen from February 2015 to March 2019. Prior to Janssen, Dr. Feller was an instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York from July 2013 to February 2015. She received a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Andrew J. Grethlein, Ph.D.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Vice President, Chief Operating Officer since January 2019. Previously, he served as our Executive Vice President, Development and Technical Operations, from July 2014 to January 2019. He joined Geron in September 2012 as our Executive Vice President, Technical Operations. Prior to joining Geron, Dr. Grethlein was Executive Vice President and Chief Operating Officer for Inspiration Biopharmaceuticals, a biopharmaceutical company, from January 2010 to September 2012. From October 2008 until January 2010, Dr. Grethlein was Senior Vice President of Biotechnology and Portfolio Management Team Leader for Hematology at Ipsen S.A., a global specialty pharmaceutical company. His responsibilities at Ipsen included planning and execution of worldwide strategy for product and portfolio development in the hematologic therapeutic area. From 2003 to 2008, Dr. Grethlein served as Senior Vice President of Pharmaceutical Operations at Tercica, Inc., an endocrinology&#8209;oriented biopharmaceutical company, where he was</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a member of the senior executive team that governed corporate strategy, business planning and company operations, and had responsibility for all manufacturing and quality functions. Before joining Tercica, Dr. Grethlein served in various positions at Elan Corporation, a biotechnology company, from 1997 to 2003, including as Senior Director, South San Francisco Pharmaceutical Operations. From 1995 to 1997, Dr. Grethlein served as Manager, Biologics Development and Manufacturing, for Athena Neurosciences, Inc., a pharmaceutical company. Prior to this, he served in various engineering positions for the Michigan Biotechnology Institute, a non-profit technology research and business development corporation. Dr. Grethlein received his A.A. degree in liberal arts from Simon&#8217;s Rock Early College, his B.S. in biology from Bates College, and his M.S. and Ph.D. in chemical engineering from Michigan State University.</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scott A. Samuels, Esq.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Vice President, Chief Legal Officer and Secretary since August 2023. Prior to joining Geron, Mr. Samuels served as Chief Legal Officer and Chief Compliance Officer of Prilenia Therapeutics, Inc., a clinical-stage biotechnology company, from March to May 2023. Before that, he served as Senior Vice President, General Counsel of BeiGene, Ltd., a global oncology company, from May 2017 to July 2022, where he built a large, global legal and compliance team, oversaw launches of three internally developed drug products in the U.S., Europe and China and development of a global healthcare compliance program, and led key strategic transactions with Amgen, Inc., Novartis AG and Celgene (now Bristol Myers Squibb). Prior to BeiGene, Mr. Samuels was assistant general counsel and then acting general counsel at ARIAD Pharmaceuticals, Inc., where he managed the company&#8217;s legal affairs, including SEC compliance and corporate governance and key licensing and distribution agreements prior to ARIAD&#8217;s acquisition by Takeda. Mr. Samuels also practiced law for 17 years in the corporate and life sciences practices at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., a national law firm. Mr. Samuels received his B.A. in philosophy from Cornell University and his J.D. from George Mason University School of Law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.587%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">James Ziegler </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President, Chief Commercial Officer since September 2024. Prior to joining Geron, Mr. Ziegler served as the Executive Vice President, Commercial for Iovance Biotherapeutics, Inc., a biopharmaceutical company, from February 2020 to September 2024, with global responsibilities for Iovance's novel tumor infiltrating lymphocyte cell therapy program, where he led the U.S. commercial launch of Amtagvi&#153; for patients with previously treated advanced melanoma. Previously, Mr. Ziegler served in numerous commercial roles at Gilead Sciences, Inc., from 2011 to 2020, most recently as Vice President of the Cardiopulmonary and Inflammation Business Unit. Mr. Ziegler's  earlier experience included commercial roles of increasing responsibility at Biogen, Inc., Amgen and Pfizer, Inc. Prior to his roles in the biopharmaceutical industry, Mr. Ziegler served as an armor officer in the U.S. Army. Mr. Ziegler received a B.S. from the United States Military Academy at West Point and an M.B.A. from the University of Chicago.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Melissa A. Kelly Behrs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has served as our Executive Vice President, Business Operations and Chief Alliance Officer since December 2021. Previously, she was our Executive Vice President, Chief Business Officer from January 2019 to December 2021, Executive Vice President, Business Development and Portfolio &amp; Alliance Management, from February 2014 to January 2019, and our Senior Vice President, Portfolio and Alliance Management from September 2012 to February 2014. Ms. Behrs joined Geron in November 1998 as Director of Corporate Development. Since then, she has also served in various managerial positions, including General Manager, R&amp;D Technologies; Vice President, Corporate Development; Senior Vice President, Therapeutic Development, Oncology; and Senior Vice President, Strategic Portfolio Management. From 1990 to 1998, Ms. Behrs worked at Genetics Institute, Inc., a biotechnology research and development company, serving initially as Assistant Treasurer and then as Associate Director of Preclinical Operations where she was responsible for all business development, regulatory, and project management activities for the Preclinical Development function. Ms. Behrs received a B.S. from Boston College and an M.B.A. from Babson College.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Edward E. Koval </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Executive Vice President, Chief Business Officer since December 2021. From 2020 to 2021, he was Chief Business Officer at ZebiAI Therapeutics, a company spun out of X-Chem, Inc. in order to discover and develop advanced drug discovery programs based on novel machine learning technologies, until its acquisition by Relay Therapeutics, Inc., a clinical-stage precision medicine company, in April 2021. Prior to the spin-out of ZebiAI, from 2013 to 2020, he was Senior Vice President, Corporate Development, at X-Chem, Inc., a drug discovery company, where he closed multiple transactions with multinational pharmaceutical companies for programs in oncology, hematology/oncology, inflammation, infectious disease and rare diseases. From 2012 to 2015, Mr. Koval served as an independent corporate and business development consultant, advising multiple private and public biotech companies on partnering and fundraising. Mr. Koval&#8217;s prior pharmaceutical experience from 1992 to 2012 includes serving roles in business and corporate development, strategic planning, alliance management and financial evaluation and analysis at Novartis Pharmaceuticals Corporation, a pharmaceutical company, Merck &amp; Co., Inc., a pharmaceutical company, and Chiron Corporation, a pharmaceutical company, where he finalized negotiations and executed and managed multiple strategic corporate partnerships and alliances. Mr. Koval holds an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">M.Sc. in Engineering from Rensselaer Polytechnic Institute and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shannon T. Odam </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has served as our Senior Vice President, Chief People Officer since January 2024. Previously, she served as our Vice President, Human Resources since joining Geron in June 2019. Prior to joining Geron, Ms. Odam served as Vice President, Human Resources at BioElectron Technology Corp., a clinical-stage biotechnology company, where she created and executed upon a unified vision by streamlining organizational design structure, designed leadership development programs to drive skills needed for future growth and led and executed human resources operations, from May 2017 to July 2018, before its acquisition by PTC Therapeutics Inc. in 2019. Before that, Ms. Odam served in various human capital roles at PricewaterhouseCoopers, or PWC, a multinational professional services firm, from 2007 to 2017. While at PWC, Ms. Odam served as the Silicon Valley Diversity and Inclusion Leader, the Audit Human Resources Leader, as well as an executive coach for PWC&#8217;s Coaching Center of Excellence. Ms. Odam received a B.S. in criminology from California State University, Fresno, an M.S. in Organizational Development from University of San Francisco and an Executive Coaching Credential from the Hudson Institute of Coaching.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Values</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fostering and maintaining a strong, healthy culture is a key strategic focus. We recognize and value the unique strengths of each of our team members, and the impact and contributions of every employee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our core values are the foundational principles of our organization. These values reflect who we are, how we work and the way our employees interact with one another, our partners, our communities, and our shareholders.  They are the essential tenets that guide our business decisions, govern our relationships, both internally and externally, and articulate what we stand for and who we are. These values dictate the ways in which we interact, work and communicate, how we resolve conflicts and ultimately, how we strive to make Geron successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44536338_1.jpg" alt="img44536338_1.jpg" style="width:624px;height:315px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our team of talented professionals is the foundation of our company and fuels our historical and prospective achievements for patients. We consider the intellectual capital of our employees to be an essential driver of our business and key to our future opportunities. As of December 31, 2024, we had 229 full&#8209;time employees, of which 142 were women and 87 were men. Twenty-two of our employees hold Ph.D. degrees and 90 hold other advanced degrees. Of this current total workforce, 96 employees were engaged in, or directly supported, our commercial, marketing, market access, and business insight and analytics activities; 82 were engaged in, or directly supported, our medical affairs, quality, regulatory, pharmacovigilance, biometrics, clinical science, and research and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development activities; and 51 were engaged in, or directly supported, general and administrative activities, such as business development, legal, finance, human resources, information technology and administration. Every employee plays a vital role in furthering our business goals and advancing the development and delivery of our novel medicine to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our employee base, we have established, and expect to continue to establish, consulting agreements with drug development professionals, clinicians, attorneys and regulatory experts with experience in numerous fields, including clinical science, biostatistics, clinical operations, pharmacovigilance, quality, manufacturing and regulatory affairs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To succeed in our mission, we must attract, recruit, retain, develop and motivate qualified clinical, nonclinical, commercial, scientific, manufacturing, regulatory, management and other personnel needed to support our business and operations. As a biotechnology company with office locations in the San Francisco Bay Area and northern New Jersey, and with remote employees throughout the U.S., we operate in a highly competitive industry and geographies for employee talent. In 2024, we engaged in extensive recruiting efforts to source and interview a talented and diverse pipeline of candidates, and enhanced our capabilities by significantly expanding our employee base. We grew our workforce by 103 employees, 74 of whom are part of our commercial team, who play a critical role in commercializing RYTELO. We maintain a comprehensive dashboard of measurements, including recruitment productivity, diversity, equity and inclusion metrics, employee engagement scores, total rewards benchmarking, participation rates and satisfaction scores for internal training, turnover rates and exit interview results, to guide our human capital management efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our ability to attract highly skilled and talented employees in a competitive labor market is enhanced by nurturing our workplace culture, providing competitive compensation and benefits programs and supporting employee career development and related management training. To that end, we continue to invest resources and energy into being an employer of choice &#8211; attracting and engaging individuals who are innovative, curious, driven, diligent, collaborative and of the highest integrity and ethics. Some of our key efforts in this area and management of our human capital assets generally are described here.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation and Benefits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our compensation philosophy is to provide pay and benefits that are competitive in the biotechnology and pharmaceutical industry where we compete for talent. We monitor our compensation programs closely and review them annually to provide what we consider a competitive mix of compensation and health, welfare and retirement benefits for all our employees. Our compensation package for all employees includes market-competitive base salaries, eligibility for annual performance bonuses and equity grants. Annual cash bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Any actual bonus payout is based on a combination of individual performance and corporate performance. All regular-status, full-time employees are eligible to participate in our comprehensive benefit program, pursuant to plan terms and conditions. Plan choices include medical, dental, vision, life insurance, flexible spending accounts, short and long-term disability insurance, a 401(k) retirement savings plan with a discretionary matching employer contribution, and an employee stock purchase plan. We also provide regular-status, full-time employees with a generous time off program that includes vacation, sick, holiday, and paid leave for certain life events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Every year, we undertake a detailed review of our compensation by position and level and make adjustments necessary to ensure that we continue to provide competitive compensation. We publish pay ranges in all job postings for jobs as required by various states&#8217; pay disclosure requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Culture</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We value an inclusive and diverse workplace because we believe that having a team of people with wide-ranging backgrounds, experiences, perspectives and skillsets enhances our corporate culture and is key to our long-term success. As of December 31, 2024, approximately 62% of our global workforce was women.  In addition, 15% of our employees in managerial roles were women, and approximately 7% of our executive management, vice president and above, were women.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Code of Business Conduct and Ethics prohibits conduct that creates an intimidating, hostile or offensive work environment, and we are committed against workplace discrimination on any grounds, including disability, nationality, race and religion. As of December 31, 2024, approximately 31% of our employees were self-identified as non-white.  In addition, during 2024, we furthered the development of our hybrid workforce program that provides a variety of virtual and in-person collaboration opportunities, such as leadership training and coaching</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">resources.  Since 2021, we have utilized a peer-centric employee recognition program to empower employees to champion our workplace culture and values, and promote direct praise to peers. In addition, we have implemented a reward program that enables managers to recognize employees who have demonstrated exceptional performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we pride ourselves on an open culture that respects co-workers, values employees&#8217; health and well-being and fosters professional development. We support employee growth and development in a variety of ways, including with group training, individual mentoring and coaching, conference attendance and tuition reimbursement. Our management conducts annual employee engagement surveys and reports to our board of directors on human capital management topics, including corporate culture, employee development and retention, and compensation and benefits. Similarly, our board of directors regularly provides input on important decisions relating to these matters, including with respect to employee compensation and benefits, talent retention and development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Environmental, Social and Governance (ESG) Efforts</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commitment to corporate responsibility is integrated throughout our business and informed by our values and ambition to change lives by changing the course of blood cancer. To support blood cancer patients and to address the availability of medical treatment for lower income patients, we have established a patient support program intended to support lower income patients eligible to receive RYTELO</span><span style="color:#505154;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Our ESG initiatives reflect our commitment to making a difference for blood cancer patients and health care providers who care for them through RYTELO and our pipeline of investigational therapies to treat hematologic malignancies.  Our ESG priorities also reflect our commitment to fostering a strong culture for employees and governing with integrity to advance our mission and create value for stockholders. We review our ESG practices and disclosures on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Communication and Engagement</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that part of what sets us apart from other companies is our culture and, in particular, our focus on providing timely and transparent communications and creating a strong sense of belonging and inclusiveness. We engage in periodic in-office and in-person meetings and interactions, as well as in-office and in-person training and development opportunities, to encourage cross-functional team-building and collaboration, in conjunction with which many of our teams engage in group lunches and dinners. We held a summer contest that encouraged our employees to share summer travel experiences and special events, building rapport and strengthening employee relationships, and we conduct organizational and team-specific holiday events to promote connectivity among our employees. We share information and news with employees through quarterly all-hands meetings, monthly newsletters to employees, social media posts on our intranet and outward facing social media sites, such as LinkedIn, and regular employee chats with our Chief Executive Officer and other members of senior management. We survey our employees each year to measure their level of engagement at the Company. Our employee engagement scores have remained relatively steady over the past three years. These surveys provide rich feedback each year that helps us to continue to grow our culture and make Geron a great place to work.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health, Wellness and Safety</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer benefits that promote our employees&#8217; whole health and wellness, including reimbursement for certain wellness costs, external support from our employee assistance programs and mental wellness services, which covers therapy and/or coaching for our employees and their dependents, including high school and college-aged children.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relations with our employees to be good.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate and Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation was incorporated in the State of Delaware on November 28, 1990. Geron UK Limited was incorporated in the United Kingdom on September 29, 2021. Geron Netherlands B.V. was incorporated in the Netherlands on February 17, 2023. Our principal executive offices are located at 919 E. Hillsdale Blvd., Suite 250, Foster City, CA 94404, and our telephone number is 650-473-7700. Our website address is http://www.geron.com.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file or furnish electronically with the U.S. Securities and Exchange Commission, or the SEC, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We make copies of these reports available free of charge through the &#8220;SEC Filings&#8221; tab on the &#8220;Investors &amp; Media&#8221; page of our website as soon as reasonably practicable after we file or furnish them with the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information contained on or accessible through our website is not incorporated into, and does not form a part of, this Report or any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1A.           R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ISK FACTORS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We operate in a dynamic and rapidly changing environment involving numerous risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described below, together with all of the other information included in this Report. Our business faces significant risks and uncertainties, and those described below may not be the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also significantly impair our business, financial condition or results of operations. If any of these risks or uncertainties occur, our business, financial condition or results of operations could suffer, the market price of our common stock could decline and you could lose all or part of your investment in our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to THE Commercialization of RYTELO</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our near-term prospects are wholly dependent on RYTELO. We have limited experience with the commercialization of RYTELO, and if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indication of use, our ability to generate meaningful revenue or achieve profitability will be materially and adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we received FDA approval to commercialize RYTELO in the U.S. for certain patients with lower-risk MDS, and we initiated a commercial launch of RYTELO in the U.S. in that indication. RYTELO is our only product approved for marketing by the FDA, and our ability to generate revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO in the U.S. for lower-risk MDS or to expand its indications of use. We may not be able to successfully commercialize RYTELO for a number of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to establish or demonstrate in the medical community the safety and efficacy of RYTELO and its potential advantages over and side effects compared to existing treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">physicians may be reluctant to prescribe RYTELO until longer-term efficacy and safety data exists;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our limited historical experience in marketing, selling and distributing RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reimbursement and coverage policies of government and private payors such as Medicare, Medicaid, insurance companies, health maintenance organizations and other plan administrators;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relative price of RYTELO as compared to alternative treatment options;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relatively low incidence and prevalence of patients in RYTELO&#8217;s approved indication, including the reliability of our market and sales estimates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.528%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.743198935713313%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future competitive or other market factors may adversely affect the commercial potential of RYTELO;  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to obtain and maintain regulatory approvals for RYTELO in any other jurisdictions or for any other indications, including in the EU for lower-risk MDS or in any other jurisdiction for relapsed/refractory MF;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changed or increased regulatory restrictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to the label for RYTELO that further restrict how we market and sell RYTELO, including adverse events observed in ongoing and future studies of imetelstat such as our Phase 3 IMpactMF clinical trial;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.528%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.743198935713313%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the capabilities of third party manufacturers may adversely affect the success of our commercialization of RYTELO; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may need additional financial or other resources to successfully commercialize RYTELO; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to maintain adequate commercial supplies of RYTELO to meet demand or at an acceptable cost or at all.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, successful commercialization of RYTELO may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all.  In any event, if we are unable to successfully commercialize RYTELO in the U.S. for lower-risk MDS, or to expand its indications of use, our ability to generate meaningful revenue from product sales and achieve profitability will be materially and adversely affected, which in turn would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience as a commercial company and our sales, marketing, and distribution of RYTELO may be unsuccessful or less successful than anticipated.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company, we have limited prior experience in selling and marketing or commercializing an approved drug product in the U.S., and we have no experience marketing or commercializing an approved drug outside of the U.S. The success of our commercialization efforts is subject to, among other things, managing our internal sales, marketing, and distribution capabilities and our ability to navigate the significant expenses and risks involved with the management of such capabilities. For example, our commercial launch of RYTELO in the U.S. may not continue as planned or anticipated, which may require us to, among others, adjust or amend our commercialization plan and incur significant expenses. Further, given our limited historical experience commercializing drug products, we do not have a track record of successfully executing a commercial launch. If we are unsuccessful in accomplishing our objectives or if our commercialization efforts do not continue as planned, we may not be able to successfully commercialize RYTELO in lower-risk MDS, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to continue to execute on our sales, marketing and distribution plans to commercialize RYTELO, we may be unable to generate meaningful product revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To successfully commercialize RYTELO in the U.S., we need to continue to execute on our sales, marketing and distribution plans. The ongoing execution of our sales, marketing and distribution plans requires investment of capital and time, and we cannot be certain that we will be able to continue to execute on our plans successfully. In addition, we compete with many companies that currently have extensive, experienced and well-funded sales, distribution and marketing operations to recruit, hire, train and retain marketing and sales personnel. If we are unable to recruit as needed, and to retain and effectively train marketing and sales personnel and equip them with compliant and effective materials, our efforts to successfully commercialize RYTELO could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no marketing or sales organization outside of the U.S., and as a company, we have no experience selling and marketing approved drugs outside of the U.S. To successfully commercialize RYTELO outside of the U.S, we will need to develop these capabilities, either on our own or with others, including third party contractors. Doing so will require additional investment of capital and time. We may seek strategic partnerships, collaborations, alliances or licensing arrangements, at an appropriate time, to assist us in the potential development and commercialization of RYTELO in the EU, or we may seek to self-commercialize and need to establish business operations in such regions.  If we receive regulatory approval to commercialize RYTELO in any other regions, such as the EU, we may be unsuccessful in our efforts to recruit, hire, train and retain personnel to support such business operations; or we may be unable to enter into and conduct successful strategic partnerships, collaborations, alliances or licensing arrangements with third parties to commercialize RYTELO in such regions, should we seek to do so. Any failure or delay in the execution of our sales, marketing and distribution plans would adversely impact the commercialization of RYTELO outside the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, given our limited experience in marketing and selling RYTELO, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually required to effectively commercialize RYTELO. As such, we may be required to hire substantially more sales representatives and medical support liaisons to adequately support the commercialization of RYTELO, or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets where RYTELO</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may be approved for marketing in the future, such as the EU, or any other regions where we might seek drug product approval for RYTELO, we may enter into arrangements with other entities to utilize their local marketing and distribution capabilities, but we may be unable to enter into such arrangements on favorable terms, if at all. If potential future partners do not commit sufficient resources to commercialize RYTELO and any future products, and we are unable to develop the necessary marketing capabilities on our own, we may be unable to generate sufficient product revenue to sustain our business. In any event, if we are unable to establish and maintain adequate sales and marketing capabilities for RYTELO, whether on our own or through collaborations, our results of operations may be negatively impacted. Any of the foregoing would negatively impact our business and business prospects, severely and adversely affect our financial results, and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain acceptable prices or adequate reimbursement for RYTELO, the use of RYTELO could be severely limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to successfully commercialize RYTELO will depend significantly on obtaining acceptable prices and the availability of coverage and adequate reimbursement to patients from third-party payors. Government payors, such as the Medicare and Medicaid programs, and other third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and the reimbursement levels. Although CMS assigned a permanent and product specific J-Code (J0870) for RYTELO, which became effective on January 1, 2025, until CMS and commercial payor systems are updated, physicians may continue to use the non-specific miscellaneous J-Code to bill third-party payors for RYTELO. Because miscellaneous J-Codes may be used for a wide variety of products, health plans may have more difficulty determining the actual product used and billed for the patient. These claims increase the provider administrative burden and must often be submitted with additional information and manually processed, which can delay claims processing times as well as increase the likelihood for claim denials and claim errors. Further, the resulting reimbursement payment rates may not be adequate or may require significant restrictions on use or increased co-payments from commercially insured patients that patients may find unacceptably high. Patients are unlikely to use RYTELO unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of its cost. Therefore, coverage and adequate reimbursement will be critical to market acceptance of RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, government authorities and other third-party payors in the U.S. and other jurisdictions are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, which may ultimately have a negative effect on the pricing for RYTELO. However, the Medicare Drug Pricing Negotiation Program provisions of the law are currently subject to legal challenges. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the U.S. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of RYTELO to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure that coverage and reimbursement will be available for RYTELO, and, if reimbursement is available, what the level of reimbursement will be. Although we have received a permanent and product-specific J-Code (J0870) for RYTELO which became effective on January 1, 2025, there may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar international regulatory authorities. Coverage and reimbursement may impact the demand for, or the price of RYTELO, and reimbursement policies in the U.S. and other jurisdictions may evolve which may adversely impact our ability to successfully commercialize RYTELO. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize RYTELO, which would negatively impact our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">To be commercially successful, RYTELO must be accepted by the healthcare community, which can be slow to adopt or unreceptive to new technologies and products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO may not achieve market acceptance in the U.S. for lower-risk MDS or any other indication that might be approved by the FDA in the future, or achieve the potential international revenue we believe may be possible if RYTELO is approved outside the U.S., since hospitals, physicians, patients or the medical community in general may decide not to accept and utilize RYTELO. RYTELO competes with a number of conventional and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">widely accepted drugs and therapies manufactured and marketed by major pharmaceutical companies. The degree of market acceptance of RYTELO depends on a number of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the clinical indications for which RYTELO is or may in the future be approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the establishment and demonstration to the medical community of the clinical efficacy and safety of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to demonstrate that RYTELO is superior to alternatives on the market at the time, including with respect to efficacy, safety, cost or route of administration;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of medical professionals to prescribe, and patients to use, RYTELO, or to continue to use RYTELO; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the publication of unfavorable safety or efficacy data concerning RYTELO by third parties or us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on use of RYTELO alone or in combination with other products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the label and promotional claims allowed by the FDA for RYTELO, as well as any such claims allowed by similar international regulatory authorities for RYTELO, if any, including usage for only certain indications and any limitations or warnings about the prevalence or severity of any side effects;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of RYTELO as well as competitive products, including sequencing of available products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of sales, marketing and distribution support for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of the third party distributors and specialty pharmacies we contract with to process prescriptions and dispense RYTELO and the processes required to place orders with such distributors and specialty pharmacies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which RYTELO is approved for inclusion on formularies in hospitals and managed care organizations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing of RYTELO, both in absolute terms and relative to alternative treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement by government and third-party payors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors, including governmental authorities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be unable to demonstrate any therapeutic or economic advantage for RYTELO compared to established or standard-of-care therapies, or newly developed therapies, for myeloid hematologic malignancies. National health insurance and/or third-party payors may decide that any potential benefit that RYTELO may provide to clinical outcomes in myeloid hematologic malignancies is not adequate to justify the potential adverse effects or the costs of treatment with RYTELO. If the healthcare community does not accept RYTELO for any of the foregoing reasons, or for any other reasons, our ability to commercialize RYTELO in the U.S. for lower-risk MDS or for any other indications for which RYTELO may be approved, may be negatively impacted or precluded altogether, which would seriously and adversely affect our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for RYTELO are smaller than we believe, our revenue may be adversely affected, and our business may suffer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are commercializing RYTELO in lower-risk MDS, and the addressable patient population in lower-risk MDS is based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new information from us or others may change the estimated incidence or prevalence of patients with lower-risk MDS in the U.S. or the EU. Additionally, the potentially addressable patient population for RYTELO may not ultimately be amenable to treatment with RYTELO, or we may be unable to successfully identify patients and achieve a significant market share in RYTELO&#8217;s approved indication, or initial sales of RYTELO may deplete the prevalence pool of patients in the RYTELO&#8217;s approved indication more quickly than expected, which would have a negative impact on sales of RYTELO in the future.  Our commercialization of RYTELO in the U.S. is limited to certain patients with lower-risk MDS, and any future potential commercialization will be limited to the therapeutic indications examined in our clinical trials and as determined by the FDA and similar international regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorities, which would not permit us to market RYTELO for any other indications not expressly approved by those regulatory authorities. Future regulatory approvals for RYTELO, if any, could be conditioned upon label restrictions that materially limit the addressable patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our market opportunity may also be limited by the pricing, reimbursement and access we are able to achieve for RYTELO, the quality and expiration of our intellectual property rights and regulatory exclusivity, duration of RYTELO treatment in lower-risk MDS and future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunities for RYTELO that we or any potential future collaborative partners develop could be significantly diminished, which would have a material adverse impact on our business and business prospects, and would adversely affect our ability to achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If competitors develop products, product candidates or technologies that are superior to or more cost-effective than RYTELO, it would significantly impact the development and commercial viability of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by intense and dynamic competition with rapidly advancing technologies and a strong emphasis on proprietary products. While we believe our proprietary oligonucleotide chemistry; experience with the biological mechanisms related to RYTELO, telomeres and telomerase; clinical data to date indicating potential disease-modifying activity with RYTELO treatment; and knowledge and expertise around the development of potential treatments for myeloid hematologic malignancies provide us with competitive advantages, we face competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. RYTELO competes with other products and therapies that currently exist, are being developed or will in the future be developed, some of which we may not currently be aware of.  A discussion of current and potential future competitors of RYTELO can be found in the sub&#8209;section entitled &#8220;Competition&#8221; in Part I, Item 1, entitled &#8220;Business&#8221; and elsewhere in this Report. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#65279;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their strategic partners, could have substantially greater financial, technical and human resources than we do and significantly greater experience in obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. We believe that the commercial success of RYTELO is subject to a number of factors, including: product efficacy and safety; method of product administration; cost of manufacturing; the timing and scope of regulatory consents; status of coverage and reimbursement; price; the level of generic competition; and our patent and regulatory exclusivity position.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. We anticipate increased competition in the future as new companies explore treatments for myeloid hematologic malignancies, which may significantly impact the commercial viability of RYTELO. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for research, clinical development and marketing of products similar to RYTELO. These companies and institutions compete with us in recruiting and retaining qualified development and management personnel as well as in acquiring technologies complementary to the RYTELO program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the foregoing, competitors may develop more commercially desirable or affordable products than RYTELO or achieve earlier patent protection or product commercialization than we may be able to achieve with RYTELO. Competitors have developed, or are in the process of developing, technologies that are, or in the future may be, competitive to RYTELO. Some of these products may have an entirely different approach or means of accomplishing therapeutic effects similar or superior to those that may be demonstrated by RYTELO. Competitors may develop products that are safer, more effective, or less costly than RYTELO, or more convenient to administer to patients and, therefore, present a serious competitive threat to RYTELO. In addition, competitors may price their products below what we may determine to be an acceptable price for RYTELO, may receive better third-party payor coverage and/or reimbursement, or may be more cost-effective than RYTELO. Such competitive products or activities by competitors may render RYTELO obsolete, which may cause us to cease any further development or future commercialization of RYTELO, which would severely and adversely affect our financial results, business and business prospects, and the future of RYTELO, and might cause us to cease operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on a select network of third party distributors, specialty pharmacies and other vendors to distribute RYTELO in the U.S., and any failure by such distributors, specialty pharmacies and vendors could adversely affect our revenues, financial condition, or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on a select network of third party distributors, specialty pharmacies and other vendors to distribute RYTELO in the U.S., and the financial failure of any of these parties could adversely affect our revenues, financial condition or results of operations. We rely on such distributors and specialty pharmacies to effectively distribute RYTELO in a timely manner, provide certain patient support services, manage prescription intake, collect accurate patient and inventory data and collect payments from payors. While we have entered into agreements with each of these parties, they may not perform as agreed, our strategic priorities may change or they may terminate their agreements with us. Further, an inability by our distributors or specialty pharmacies to meet our patients&#8217; needs may lead to reputational harm or patient loss. In the event that such network fails to properly meet our or our patients&#8217; needs, we may need to partner with other distributors, specialty pharmacies or vendors to replace or supplement our current network and there is no guarantee that we will be able to do so on commercially reasonable terms or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are seeking regulatory approval to commercialize RYTELO in the EU, and any such approval, if received, will be subject to pricing, drug marketing, post-market and reimbursement regulations in the EU, which may materially affect our ability to commercialize and receive reimbursement coverage for RYTELO in the EU.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are seeking approval to market RYTELO in the EU for lower-risk MDS. Even if we obtain approval for RYTELO in the EU, the competent regulatory authorities may still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions. We will also be subject to rules and regulations in the EU applicable to the manufacturing, marketing, promotion and sale of medicinal products. If we or a regulatory authority discovers previously unknown problems with RYTELO, such as adverse events of unanticipated severity or frequency, or problems with a facility where RYTELO is manufactured, a regulatory authority may impose restrictions relative to RYTELO or the manufacturing facility, including requiring recall or withdrawal of RYTELO from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for RYTELO will be subject to regulatory requirements and continuing regulatory review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the marketing authorization, or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the pricing of RYTELO will be subject to governmental control and other market regulations which could put pressure on the pricing and usage of RYTELO. In the EU, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, if approved, market acceptance and sales of  RYTELO will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for RYTELO and may be affected by existing and future healthcare reform measures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. If RYTELO is approved for commercialization in the EU, in some countries we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of RYTELO to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for RYTELO, if it is approved for marketing in the EU. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of RYTELO is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of RYTELO in those countries would be negatively affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Much like the federal Anti-Kickback Statute prohibition in the U.S., the provision of benefits or advantages to physicians and other healthcare professionals to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. Interactions between</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pharmaceutical companies and health care professionals are governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Infringement of related laws could result in substantial fines and imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments made to physicians and other healthcare professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians may require prior notification or approval by the physician&#8217;s or healthcare professional&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO REGULATORY APPROVAL OF RYTELO</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to maintain regulatory approval for RYTELO in the U.S. for lower-risk MDS, which would severely and adversely affect our business and business prospects, and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we received regulatory approval from the FDA to commercialize RYTELO in the U.S. in certain patients with lower-risk MDS. Federal, state and local governments in the U.S. have significant regulations in place that may limit or prevent us from successfully commercializing RYTELO for lower-risk MDS. We do not currently have regulatory approval for RYTELO in any other jurisdiction or for any other indication, and governments in other jurisdictions have significant regulations that may limit or prevent us from successfully commercializing RYTELO in other jurisdictions. Failure to maintain regulatory approval for RYTELO for lower-risk MDS, or delays in obtaining, failure to obtain, or limitations in the scope of such approvals in any other jurisdictions or for any other indications, could:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">result in a withdrawal of RYTELO from the market or could otherwise delay, limit or preclude any revenue we may receive from the commercialization of RYTELO for lower-risk MDS;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly harm the commercial potential of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impede, halt or increase the costs of our activities and plans for clinical development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminish any competitive advantages that may have been available to us; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or preclude any revenue we may receive from the future commercialization of RYTELO in any other jurisdictions or for any other indications, if any.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, approved products and their manufacturers, together with other vendors involved in the commercialization process, are subject to continual review, and discovery of previously unknown problems with a product or its manufacturer may result in restrictions on the product or manufacturer, including import restrictions, seizure and withdrawal of the product from the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization and sales of RYTELO are subject to government regulations related to numerous matters, including the processes of:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advertising and promoting;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">selling and marketing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">medical information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">labeling; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distribution.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, and to the extent that, we are unable to comply with these regulations, our ability to earn revenue  from the commercialization of RYTELO will be materially and adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if RYTELO causes serious or unexpected side effects, or if other safety risks are observed as a result of our commercialization efforts for RYTELO in lower-risk MDS or in current or potential future clinical trials, a number of potential significant negative consequences could result, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw approval of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall RYTELO, seek to change the way it is administered, conduct additional clinical trials or change the labeling of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require revisions to the labeling of RYTELO, including limitations on approved uses or the addition of further warnings, contraindications or other safety information, or may impose restrictions on distribution in the form of additional requirements in a risk evaluation and management plan or risk management plan;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience manufacturing delays and supply disruptions if regulatory inspectors identify regulatory noncompliance by third-party manufacturers requiring remediation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO may be rendered less competitive and sales, if any, may decrease;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer generally both among clinicians and patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be exposed to potential lawsuits and associated legal expenses, including costs of resolving claims;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may refuse to approve pending applications or supplements to approved applications filed by us, or may suspend or revoke license approvals; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change or stop ongoing clinical trials of RYTELO (imetelstat), which would negatively impact the development of RYTELO (imetelstat) for other potential indications.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance for RYTELO, could substantially increase the costs and expenses of commercializing RYTELO, or could limit its commercial potential, which in turn could delay or prevent us from generating any meaningful revenues from the sale of the RYTELO.  If RYTELO is approved outside the U.S., we will be subject to similar requirements, considerations and risks in other regions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our regulatory approval for RYTELO in the U.S. for lower-risk MDS is subject to post-marketing requirements and commitments, and we may be subject to penalties or product withdrawal if we fail to comply with these regulatory requirements and commitments or if we experience unanticipated problems with RYTELO.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our regulatory approval for RYTELO in lower-risk MDS is subject to non-clinical, clinical and manufacturing post-marketing requirements and commitments, including the requirement of continuing to assess long-term safety of RYTELO (imetelstat) in the IMerge trial and a clinical trial to evaluate alternative dosing regimens in lower-risk MDS, with timelines for completion and reporting established by the FDA. In addition, RYTELO and the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities related to RYTELO will be subject to continual requirements of, and review by, the FDA and comparable regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, compliance with good pharmacovigilance practices, registration requirements, current Good Manufacturing Practice, or cGMP, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding promotional interactions with healthcare professionals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with these post-marketing requirements and commitments or any other regulatory requirements, or later discovery of previously unknown problems with RYTELO, or our manufacturers, or manufacturing processes for RYTELO, may result in actions such as:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on RYTELO manufacturing, distribution or use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on labeling or marketing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional post-marketing requirements or commitments; warning letters, withdrawal of RYTELO from the market;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or termination of ongoing clinical trials of imetelstat in other indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant civil, criminal and administrative penalties, including fines, restitutions or disgorgement of profits or revenues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of RYTELO; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detentions; injunctions or the imposition of civil or criminal penalties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity. </span></div></div>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. In addition, the regulations, policies or guidance of the FDA or any other regulatory authority may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. We also cannot predict the likelihood, nature, or extent of adverse government regulation that may arise from pending or future legislation or administrative action, either in the United States or abroad.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to fulfill the post-marketing requirements and commitments established by the FDA for RYTELO in lower-risk MDS, or that may be applied to the approval and commercialization of RYTELO by any regulatory authority, or are unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, there may be a negative impact to our business and continued regulatory approval of RYTELO. Under such circumstances, we or our respective service providers may be subject to the actions listed above, including losing marketing approval for RYTELO, which would severely and adversely affect our business and business prospects, and might cause us to cease operations. If RYTELO is approved outside the U.S., we will be subject to similar requirements, considerations and risks in other regions.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to obtain regulatory approval to commercialize RYTELO in any other jurisdictions or for any new indications, or may experience significant delays in doing so, any of which could severely and adversely affect our business and business prospects, and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may never receive regulatory approval for RYTELO in any other jurisdictions or for any new indications. It can take many years to obtain approval, if approval is obtained at all. Of the large number of drugs in development, only a small percentage complete the development and regulatory approval process and are successfully commercialized. In addition, the lengthy review process and the unpredictability of future or ongoing clinical trials may result in a delay in obtaining, or our failure to obtain, regulatory approval for RYTELO in lower-risk MDS in any jurisdiction other than the U.S., or our inability to obtain  regulatory approval for RYTELO for relapsed/refractory MF or for any other indications, which could significantly harm our business and business prospects, and might cause us to cease operations.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securing marketing approval requires the submission of extensive non-clinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish to the satisfaction of such regulatory authorities the product candidate&#8217;s safety and efficacy, as well as information about the product manufacturing process and any inspections of manufacturing facilities conducted by regulatory authorities through the filing of an NDA in the U.S. and an MAA in the EU. Although RYTELO is approved in the U.S. in lower-risk MDS and the EMA is reviewing our MAA for RYTELO for lower-risk MDS, there can be no assurance that we will receive regulatory approval from the EC for the commercialization of RYTELO for lower-risk MDS or in any other jurisdiction or for any new indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any marketing approval that we may receive for RYTELO in the EU for lower-risk MDS, or in any other jurisdiction or for any other indication may also be limited or subject to restrictions or post-approval commitments that increase our costs or render RYTELO not commercially viable, which would harm our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities may also not approve the labeling claims that are necessary or desirable for the successful commercialization of a drug, such as RYTELO. For example, although we received regulatory approval from the FDA in June 2024 to commercialize RYTELO in lower-risk MDS, any future regulatory clearances that we might obtain for RYTELO may be limited to fewer or narrower indications than we might request, or may be granted subject to the performance of post-marketing studies, which may impose further requirements or restrictions on the distribution or use of RYTELO, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO and affect reimbursement by third-party payors. Future regulatory clearances, if any, may be limited to a smaller patient population, or may require a different drug formulation or a different manufacturing process, than we might in the future decide to seek.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delay in obtaining or failure to obtain required approvals of RYTELO in any other jurisdictions or for any other indications, or limitations on any regulatory approval that we might receive in the future, if any, could reduce the potential commercial use of RYTELO, and potential market demand for RYTELO and therefore result in decreased revenue for us from any commercialization of RYTELO in any other jurisdictions or for any other indications, any of which could severely and adversely affect our financial results and ability to raise additional capital, if needed, the price of our common stock, our business and business prospects, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may experience additional risks related to operating outside of the U.S. that could materially adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have employees located outside of the U.S., conduct clinical trials outside of the U.S., and are seeking to obtain regulatory approval to market RYTELO in the EU, which may subject us to additional risks related to operating outside of the U.S., such as:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the EC and other foreign regulatory approvals, if any, may take longer and be more costly to obtain than approvals in the U.S., due to differing regulatory requirements in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval policies or regulations in the EU or of regulatory authorities outside of the U.S. may significantly change in a manner rendering our clinical data insufficient for potential approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the EMA and other regulatory authorities outside of the U.S. may disagree with the design, implementation or results of our clinical trials or our interpretation of data from nonclinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may experience unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks of potential noncompliance with legal requirements applicable to privacy, data protection, information security and other matters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks of potential noncompliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased taxes outside of the U.S., including withholding and payroll taxes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties staffing and managing operations outside of the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable regulations outside of the U.S.; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the new Trump administration has called for substantial changes to foreign trade policy and has raised the possibility of imposing significant increases in tariffs on international trade. We cannot predict what effects these and potential additional tariffs will have on our business, including in the context of escalating global trade and political tensions. However, such tariffs and other trade restrictions could increase our cost of doing business, reduce our gross margins or otherwise negatively impact our financial results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other risks associated with international operations may materially adversely affect our ability to attain or maintain profitable operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Uncertainty in the regulatory framework and future legislation could lead to disruption in the execution of international multi-center clinical trials, the monitoring of adverse events through pharmacovigilance programs, the evaluation of the benefit-risk profiles of new medicinal products, and determination of marketing authorization across different jurisdictions. Changes to existing regulations may add considerably to the time from clinical development to marketing authorization and commercialization of products in foreign jurisdictions and increase our costs. We cannot predict the impact of such changes and future regulation on our business or the results of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although orphan drug designation has been granted to RYTELO for the treatment of MDS and MF in the U.S. and in the EU, these designations may not be maintained, which would eliminate the benefits associated with orphan drug designation, including market exclusivity, which could limit the period of exclusivity we are able to maintain for the commercialization of RYTELO, and would likely harm our business and business prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA granted orphan drug designation to RYTELO in June 2015 for the treatment of MF and for the treatment of MDS in December 2015, and the EC granted orphan drug designation in December 2015 to RYTELO for the treatment of MF and in July 2020 for the treatment of MDS. Orphan drug exclusivity confers seven and 10 years of exclusivity in the U.S. and EU, respectively, following approval, subject to satisfying regulatory requirements. The FDA has confirmed seven years of orphan drug exclusivity for RYTELO following its approval on June 6, 2024 for its approved indication in lower-risk MDS.  As part of its review of our MAA for RYTELO, the EMA reviewed the grant of orphan drug designation for the treatment of certain patients with MDS. Designation as an orphan drug does not guarantee that any regulatory authority will accelerate regulatory review of, or ultimately approve, RYTELO for any indication, or at all, in the U.S., EU or any other country, nor does it limit the ability of any regulatory authority to grant orphan drug designation to product candidates of other companies that treat the same indications as RYTELO prior to RYTELO receiving any exclusive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may lose orphan drug exclusivity for certain reasons, including if the FDA or the EMA determines that the request for orphan drug designation was materially defective or if we cannot ensure sufficient quantities of RYTELO to meet the needs of patients with lower-risk MDS or MF. Failure to maintain orphan designation status, or failure to agree to and complete any agreed upon pediatric plan, would lead to the inability to obtain or the loss of such regulatory exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we maintain orphan drug exclusivity for RYTELO, the exclusivity may not effectively protect RYTELO from all competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug product is approved, the FDA or other regulatory authorities can subsequently approve a different drug with the same active moiety for the same condition, if the FDA or other regulatory authorities conclude that the later drug is safer, more effective, or makes a major contribution to patient care. The occurrence of any of these events could limit the period of exclusivity we are able to maintain for RYTELO, and may harm our business and business prospects. In addition, for any other indication that we are currently or may in the future seek to develop or obtain regulatory approval for RYTELO, orphan drug designation will neither shorten the development time nor regulatory review time for RYTELO, and it does not give RYTELO any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in the U.S. for lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO&#8217;s activity in other indications, such as from IMpactMF.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even though we reported positive top-line results from IMerge Phase 3 in January 2023 and received regulatory approval from the FDA in June 2024 to commercialize RYTELO in lower-risk MDS, the top-line results from IMerge Phase 3 are not necessarily predictive of RYTELO&#8217;s activity in other indications and for other pivotal trials that may be needed to support any application to the FDA or similar international regulatory authorities for such other indications, such as from IMpactMF.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, with respect to the trial design for IMpactMF, the FDA urged us to consider adding a third dosing arm to the trial to assess a lower dose and/or a more frequent dosing schedule that might improve the trial&#8217;s chance of success by identifying a less toxic regimen and/or more effective spleen response, one of the trial&#8217;s secondary endpoints. Based on data from IMbark, we believe that testing a lower dose regimen would likely result in a lower median OS, which is the trial&#8217;s primary endpoint, in the imetelstat treatment arm. Existing data also suggest that lowering the dose would not result in a clinically meaningful reduction in toxicity, and for these reasons we determined not to add a third dosing arm to the trial design and the FDA did not object to our proposed imetelstat sodium dose and schedule of 9.4 mg/kg every three weeks. Our belief may ultimately be incorrect. Therefore, our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to add a third dosing arm could result in a failure to maintain regulatory clearance from the FDA and similar international regulatory authorities for relapsed/refractory MF, could result in the trial&#8217;s failure, or could otherwise delay, limit or prevent marketing approval of imetelstat for relapsed/refractory MF by the FDA or similar international regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities have substantial discretion in the approval process and can delay, limit or deny approval of RYTELO in other jurisdictions or indications, or require us to conduct additional non-clinical or clinical testing or abandon a program for many reasons, including:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreement with the design or implementation of our clinical trials, including our statistical analysis of trial results;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to demonstrate that RYTELO&#8217;s efficacy results provide sufficient evidence of overall clinical benefit;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable benefit-to-risk assessment, in the case of marginal efficacy and/or clinically relevant safety concerns, for any proposed indication;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using RYTELO or drugs similar to RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreement with our interpretation of data from non-clinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rejection by the FDA of foreign data included in any future supplemental NDA, or sNDA, submissions for any future indications and the non-applicability of this data to the U.S. population and U.S. medical practice; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identification of critical issues as a result of a pre-approval health authority inspection that could negatively impact the integrity of data in the MAA and any future sNDA and lead to a rejection by the FDA, EMA, or similar international regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by international regulatory authorities that regulatory approval for RYTELO should be narrowed or made more restrictive than our current approval in the U.S. for lower-risk MDS or any future indication for which approval is sought, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreement regarding the formulation, labeling and/or the specifications for RYTELO; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of the quality or stability of RYTELO to meet acceptable regulatory standards;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the EMA or the competent authorities of the individual EU Member States or similar international regulatory authorities may lack resources or be delayed in conducting pre-approval inspections due to lack of resources or other reasons;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we or any third-party service providers may be unable to demonstrate compliance with GMP, GCP, or other applicable regulatory and other requirements to the satisfaction of the FDA, the EMA, the competent authorities of the individual EU Member States or similar international regulatory authorities; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in regulatory policies or approval processes, or potential reduction of unmet medical need with the entry of competitive therapies to the market, could render our clinical efficacy or safety data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events may result in a failure to further develop, obtain regulatory approval for or commercialize RYTELO in any jurisdiction or in any indication other than lower-risk MDS in the U.S., which could severely and adversely affect our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, in recent years, there has been increased public and political scrutiny on the FDA and similar international regulatory authorities with respect to the approval process for new drugs, and as a result regulatory authorities may apply more stringent regulatory standards, especially regarding drug safety, when reviewing regulatory submissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO COMPLIANCE WITH HEALTHCARE LAWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA, DOJ and other regulatory authorities actively enforce regulations related to the promotion and advertisement of pharmaceutical products, and if we were found to have violated the Food, Drug and Cosmetic Act, we could be subject to significant civil, criminal and administrative penalties.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA, DOJ and other agencies actively enforce regulations related to the promotion and advertisement of pharmaceutical products. If we were found to have violated the Food, Drug, and Cosmetic Act, we could be subject to significant civil, criminal and administrative penalties, which could inhibit our ability to commercialize RYTELO and generate revenue, require us to expend significant time and resources in response, and generate negative publicity. Enforcement actions include, among others:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory inspection findings;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters, or untitled letters;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on, or prohibitions against, marketing RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on, or prohibitions against, importation or exportation of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension of review or refusal to approve pending applications or supplements to approved applications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusion from participation in government-funded healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusion from eligibility for the award of government contracts for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of regulatory approval for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">civil and criminal penalties and fines.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The imposition of any of these penalties or other commercial limitations, including equivalent penalties or commercial limitations imposed by foreign regulatory authorities, could severely and adversely affect our financial results, business and business prospects, including the commercialization of RYTELO, and might cause us to cease operations. Similar requirements and related consequences apply outside the U.S.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients in affording pharmaceuticals have become the subject of scrutiny. In recent years, some pharmaceutical manufacturers were named in class action lawsuits challenging the legality of their patient assistance programs and support of independent charitable patient support foundations under a variety of federal and state laws. At least one insurer also has directed its network pharmacies to no longer accept manufacturer co-payment coupons for certain specialty drugs the insurer identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patient assistance program and support of independent charitable  foundations could become the target of similar litigation. In addition, there has been regulatory review and enhanced government scrutiny of donations by pharmaceutical companies to patient assistance programs operated by charitable foundations. For example, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Office of Inspector General of the U.S. Department of Health &amp; Human Services, or OIG, has established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a donor&#8217;s product. If we or our vendors or donation recipients are deemed to fail to comply with laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. A government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our business activities become subject to challenge under supranational, national, federal, state or international healthcare laws, including fraud and abuse, transparency, and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including federal and state fraud and abuse laws, including anti-kickback and false claims laws; data privacy and security laws, including the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH; and transparency laws related to payments and/or other transfers of value made to physicians, other healthcare professionals and teaching hospitals. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we market, sell and distribute RYTELO. For details regarding the restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate, see Item 1 &#8220;Business-Government Regulation- Fraud and Abuse, and Transparency Laws and Regulations&#8221; of this Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal and state enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. If our operations are found to be in violation of any of these or any other healthcare and privacy-related regulatory laws that may apply to us, our ability to operate our business and our results of operations could be adversely affected by:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement and imprisonment;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or comparable foreign programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reputational harm;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished profits and future earnings;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">curtailment of our operations. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The adoption of health policy changes and healthcare reform both in the U.S. and outside the U.S. may adversely affect our business and financial results.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S. and some jurisdictions outside the U.S., there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could impact our business. Generally, there has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing, including specialty drug</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing practices, in light of the rising cost of prescription drugs and biologics. Specifically, there have been U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the price of drugs under Medicare, and reform government program reimbursement methodologies for drugs and biologics. For details regarding these legislative and regulatory changes and proposed changes regarding the healthcare system that may affect our ability to operate, see Item 1 &#8220;Business - Healthcare Reform&#8221; in this Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business and financial results. Managed care organizations, as well as Medicaid and other government authorities, continue to seek price discounts. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on future sales of RYTELO in the U.S., and outside the U.S. if approved in other jurisdictions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO THE FURTHER DEVELOPMENT OF RYTELO (IMETELSTAT)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot be certain that we will be able to continue to develop RYTELO  or advance it in clinical trials, or that we will be able to receive regulatory approval for RYTELO in any other indications in the U.S., the EU or any other region, on a timely basis or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are wholly dependent on the success of RYTELO (imetelstat), which is our only approved product, and our ability to generate revenue from product sales and achieve profitability is wholly dependent on our ability to successfully commercialize RYTELO for lower-risk MDS or to expand its indications of use. In this regard, in addition to lower-risk MDS, which is the only indication for which RYTELO has received marketing approval in the U.S., we are developing imetelstat for the treatment of several myeloid hematologic malignancies. Our ability to further develop imetelstat and to expand its indications of use to other myeloid hematologic malignancies is subject to significant risks and uncertainties, including, among other things, our ability to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receive regulatory approval to commercialize RYTELO in lower-risk MDS from the EC without the requirement for the conduct and completion of additional pre-approval clinical trials or further analyses, testing or development commitments, if at all, any of which could result in increased costs to us, and delay, limit or preclude our ability to generate revenue in the EU; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">generate sufficient safety and efficacy data from the IMpactMF clinical trial to support any application for regulatory approval in relapsed/refractory MF, without clinically meaningful safety issues, side effects or dose-limiting toxicities related to imetelstat that may negatively impact its benefit-risk profile;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ascertain that the use of imetelstat does not result in significant systemic or organ toxicities, including hepatotoxicity, or other safety issues resulting in an unacceptable benefit-risk profile;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain additional capital if and when needed in order to enable us to further advance imetelstat clinical trials in other myeloid hematologic malignancies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain and maintain required regulatory clearances and approvals to enable continued clinical development of imetelstat; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enter into and maintain commercially reasonable arrangements with third parties to provide services needed to further research, develop and commercialize RYTELO, including maintaining the agreements with our contract research organizations, or CROs, and third-party manufacturers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recruit and retain sufficient qualified and experienced personnel to support the development and commercialization of RYTELO in potential other approved indications and jurisdictions outside the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enter into and maintain arrangements with third parties to provide services needed to support the commercialization of RYTELO for territories outside of the U.S. in compliance with applicable laws;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieve acceptance of RYTELO treatment by patients and the relevant medical communities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compete effectively with other approved treatments in lower-risk MDS, and relapsed/refractory MF if imetelstat is approved in relapsed/refractory MF, and potentially other myeloid hematologic malignancies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain appropriate coverage and reimbursement levels for the cost of RYTELO from governmental authorities, private health insurers and other third-party payors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain, maintain and enforce adequate intellectual property and regulatory exclusivity for RYTELO in the U.S. and globally.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If we are not able to successfully achieve these goals and overcome other challenges that we may encounter in the research, development, manufacturing and commercialization of RYTELO in indications other than lower-risk MDS, we may be forced to abandon our development and/or commercialization of RYTELO in indications other than lower-risk MDS, which could severely harm our business and business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our clinical trials of imetelstat could be interrupted, delayed, terminated or abandoned for a variety of reasons which could severely and adversely affect our financial results, business and business prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The conduct and completion of our clinical trials could be interrupted, delayed or abandoned for a variety of reasons, including as a result of clinical trial failures, suspensions, terminations or delays related to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient recruitment, enrollment and retention challenges and operational delays, including in connection with opening new clinical trial sites, while also competing with clinical trials for other investigational drugs in the same patient population; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">use of trial endpoints such as overall survival, that inherently require prolonged periods of clinical observation or analysis of the resulting data to determine trial outcomes, including the need for a certain number of events, or deaths, to occur in IMpactMF prior to the interim or final analysis in that trial of overall survival; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and/or maintaining regulatory clearances in the U.S. or other jurisdictions to commence, conduct or modify current or potential future clinical trials of imetelstat, in a timely manner, or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigational new drug applications, or INDs, and equivalent submissions in other countries for imetelstat being placed on full or partial clinical hold, suspended or subject to other requirements by the FDA or other similar international regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contracting with a sufficient number of clinical trial sites to conduct current and potential future clinical trials, and ensuring that such contracts contain all necessary terms and conditions required by applicable laws, including providing for valid mechanisms to engage in cross-border data transfers, as well as identifying, recruiting and training suitable clinical investigators;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining or accessing necessary clinical data in accordance with appropriate clinical or quality practices and regulatory requirements, in a timely and accurate manner to ensure complete data sets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responding to safety findings, recommendations or conclusions by the data safety review committees, independent data monitoring committees and/or expert committees of current and potential future clinical trials of imetelstat based on emerging data occurring during such clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing sufficient quantities that meet our specifications, cost and quality requirements, and timelines for imetelstat, or for other clinical trial materials, in a manner that meets the quality standards of the FDA and other similar international regulatory authorities, and responding to any disruptions to drug supply, clinical trial materials or quality issues that may arise;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effects of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, changes in tariffs or other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with current and future regulatory requirements, policies or guidelines, including domestic and international laws and regulations pertaining to fraud and abuse, transparency, and the privacy and security of health information;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reaching agreement on acceptable terms and on a timely basis, if at all, with collaborators, physician investigators, vendors and other third parties located in the U.S. or other countries, including our CROs, laboratory service providers and clinical trial sites, on all aspects of clinical development and collaborating with them successfully; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party clinical contractors, including investigators or our CROs not performing our clinical trials according to our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements, or not performing data collection or analyses in a timely or accurate manner.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failures or delays with respect to any of these events could adversely affect our ability to conduct or complete the clinical trials being conducted by us or our investigators, or to commence, conduct and complete potential future clinical trials of imetelstat, which could increase development costs, or interrupt, further delay or halt our development, of imetelstat, any of which could severely and adversely affect our financial results, business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RYTELO may cause, or have attributed to it, undesirable or unintended side effects or other adverse events that could halt or limit its further commercialization, delay or prevent its regulatory approval in any other jurisdiction or indication, or cause us to delay or terminate our clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO (imetelstat) has been administered only to a limited number of patients in clinical trials. While the FDA granted approval of RYTELO based on the data included in our NDA, including data from the Phase 3 IMerge trial, we do not know whether the results when a larger number of patients receive RYTELO from commercial use, including results related to safety, will be consistent with the results from earlier clinical trials that served as the basis for its approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, because remaining patients in ongoing clinical trials continue to receive imetelstat, additional or more severe toxicities or safety issues may be observed, and the benefit-risk profile of imetelstat will continue to be assessed, including the risk of hepatotoxicity, severe cytopenias, fatal bleeding with or without any associated thrombocytopenia, patient injury or death. New data relating to imetelstat, including from adverse event reports and our post-marketing requirements in the United States, and from ongoing clinical trials of imetelstat, may result in changes to the product label and may adversely affect sales, or result in withdrawal of imetelstat from the market. The FDA and regulatory authorities in other jurisdictions may also consider the new data in reviewing our marketing applications for additional indications and/or in other jurisdictions, or impose post-approval requirements. If any of these actions were to occur, it could result in significant expense and delay or limit our ability to generate sales revenues.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, as a result of commercialization of RYTELO, or in current or potential future clinical trials, RYTELO may cause, or have attributed to it, undesirable or unintended side effects or other adverse events affecting its safety or efficacy that could interrupt, further delay or halt its commercialization or current or potential future clinical trials. In this regard, adverse events and dose-limiting toxicities observed in previous and ongoing clinical trials include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hematologic toxicities, such as profound and/or prolonged thrombocytopenia or neutropenia;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bleeding events, with or without thrombocytopenia, including Grade 3/4 bleeding events;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">febrile neutropenia;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hepatotoxicity and liver function test abnormalities, as well as hepatic failure;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gastrointestinal events;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infection events, with or without neutropenia, including Grade 3/4 infection events;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">muscular and joint pain;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fatigue;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">headache; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infusion-related reactions.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If patients who receive RYTELO as a result of commercialization or in any clinical trials experience similar or more severe adverse events, or new or unusual adverse events, or if the FDA or other similar international regulatory authorities determine that efficacy and safety data from our commercialization efforts or in clinical trials do not support an adequate benefit-risk profile to justify continued treatment of patients, then the FDA or other similar international regulatory authorities may halt or restrict the commercialization of RYTELO or place one or more of our INDs on clinical hold, as occurred in March 2014. If this were to occur, there could be a significant delay in, or possible termination of, one or more of our clinical trials, and our commercialization efforts could be halted, which might cause us to cease operations. If such toxicities or other safety issues identified as a result of our commercialization of RYTELO or in any clinical trial are determined by us, the FDA or similar international regulatory authorities to result in an unacceptable benefit-risk profile, then:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA could withdraw or restrict regulatory approval for RYTELO in the U.S. for lower-risk MDS;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional information supporting the benefit-risk profile of RYTELO may be requested by the FDA or similar international regulatory authorities and if any such information is not available or, if available, not deemed acceptable, regulatory approval could be withdrawn by the FDA in the U.S., and/or current clinical trials could be suspended, terminated, or placed on clinical hold by the FDA or similar international regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to retain enrolled patients in our current clinical trials may be negatively affected, resulting in incomplete data sets and the inability to adequately assess the benefit-risk profile of RYTELO in a specific patient population; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additional, unexpected clinical trials or non-clinical studies may be required to be conducted; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO may not receive or maintain regulatory clearances and approvals required to enable its continued development.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The occurrence of any of these events could interrupt, further delay, or halt, our commercialization or RYTELO or its further development, and as a result, could preclude the commercialization of RYTELO in any additional indications, as well as increase costs for continued development in additional indications, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, business and business prospects, any of which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Results and data we disclosed from prior non-clinical studies and clinical trials may not predict success in later clinical trials, and we cannot assure you that any ongoing or future clinical trials of imetelstat, including IMpactMF, will lead to similar results and data that could potentially enable us to obtain any further regulatory approvals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The design of a clinical trial can determine whether its results will support regulatory approval of a product, and flaws in the trial design may not become apparent until the clinical trial is well advanced or during the approval process after the trial is completed. A clinical trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of imetelstat clinical trials with smaller sample sizes can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, making the trial results of clinical trials with smaller sample sizes less reliable than trials with a larger number of patients. As a result, there may be less certainty that imetelstat will achieve a statistically significant effect in any future clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, success in non-clinical testing and early clinical trials, including Phase 2 clinical trials, such as IMbark, does not ensure that later clinical trials will be successful, nor does it predict final clinical trial results. In addition, even though we reported positive top-line results from IMerge Phase 3 in January 2023, this does not ensure that any other clinical trials of imetelstat will be successful. Later stage clinical trials of imetelstat may fail to show an acceptable benefit-risk profile despite having progressed through non-clinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have frequently suffered significant setbacks in later clinical trials, even after achieving promising results in earlier non-clinical studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, Phase 3 clinical trials with larger numbers of patients or longer durations of therapy may fail to replicate efficacy and safety results observed in earlier clinical trials, such as IMbark, and if this were to occur with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMpactMF, this would adversely affect future development prospects of imetelstat, and as a result, impact the potential commercialization of imetelstat in relapsed/refractory MF, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, if needed, business and business prospects, any of which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, non-clinical and clinical data are often susceptible to varying interpretations and analyses. In some instances, there can be significant variability between different clinical trials of imetelstat due to numerous factors, including changes in trial procedures set forth in trial protocols, differences in the size and type of patient populations, and changes in and adherence to the dosing regimens. For example, although the statistical analyses comparing IMbark data to closely matched real world data, or RWD, published in the September 2021 issue of the Annals of Hematology, suggest potentially favorable overall survival in relapsed/refractory MF patients treated with imetelstat, compared to BAT using closely matched patients&#8217; RWD, such comparative analyses between RWD and our clinical trial data have several limitations. For instance, the analyses create a balance between treatment groups with respect to commonly available covariates, but do not take into account the unmeasured and unknown covariates that may affect the outcomes of the analyses. Potential biases are introduced by factors which include, for example, the selection of the patients included in the analyses, misclassification in the matching process, the small sample size, and estimates that may not represent the outcomes for the true treated patient population. Failure to achieve results supporting a positive benefit-risk profile in current or potential future imetelstat clinical trials would interrupt, further delay, or halt, any development of imetelstat, which would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, if needed, business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, preliminary data are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Additional or updated safety and efficacy data from current or potential future clinical trials of imetelstat may result in a benefit-risk profile that does not justify the continued development and/or potential regulatory approval of imetelstat in a particular patient population, or at all. Any data reported from IMpactMF may materially differ from and be less positive than data previously reported from IMbark. Thus, reported data should be considered carefully and with caution, and not relied upon as indicative of future clinical results. Such additional data could result in a lower benefit-risk profile than initially expected, which could halt the commercialization of RYTELO, hinder the potential success of IMpactMF, IMproveMF or IMpress, or cause us to abandon further development of imetelstat entirely.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Top-line results and data may differ from future results of the same study, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Moreover, as remaining patients in IMerge Phase 3 continue to be treated and followed under the extension phase of the trial and longer-term outcomes are assessed, these additional and more mature data may alter the benefit-risk profile of imetelstat in an adverse manner, including with respect to overall survival. Material adverse differences in future results, compared to preliminary, interim or top-line data, could severely and adversely affect our financial results, business and business prospects, including the commercialization of RYTELO, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our current and potential future clinical trials of imetelstat. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to continue the development of imetelstat.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have the ability to independently conduct clinical trials. Therefore, we rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, service providers, vendors, suppliers and consultants, to conduct clinical trials of imetelstat. The third parties we contract with for execution of our current and potential future clinical or investigator-sponsored trials of imetelstat play a critical role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control their performance, or the amount or timing of resources that they devote to imetelstat. For example, we have retained CROs to support our clinical development activities, and any failure by our CROs to perform their contractual obligations, or disputes with our CROs about the quality of their performance or other matters, could further delay or halt our clinical development activities. These third parties may also have relationships with other commercial entities, some of which may compete with us. Under certain circumstances, these third parties may terminate their agreements with us without cause and upon immediate written notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we rely on third parties to conduct our clinical trials, we remain responsible for ensuring that each clinical trial is conducted in accordance with its investigational plan and protocol, and applicable laws. Moreover, the FDA and similar international regulatory authorities require us to comply with GCP regulations and standards for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the rights, integrity and confidentiality of patients participating in clinical trials are protected, including being adequately informed of the potential risks. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, or similar international regulatory authorities, may require us to perform additional clinical trials. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP or other applicable regulations. In addition, our clinical trials must be conducted with imetelstat produced under applicable GMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials. Our ability to comply with these regulations and standards may be contingent upon activities conducted by third parties, and if they fail to perform in accordance with contractual obligations and legal requirements, our development of imetelstat may be interrupted, further delayed or halted. Any failures by us or third parties noted above would have a severe adverse effect on our results of operations, financial condition and ability to raise additional capital, if needed, business and business prospects, including the commercialization of RYTELO, any of which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the execution of clinical trials and the subsequent compilation and analysis of the data produced, including the interim and final analyses for IMpactMF, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. If the quality or accuracy of the clinical data obtained, compiled or analyzed by third parties is compromised due to their failure to adhere to our clinical trial protocols, GCP or GMP requirements, or for any other reason, we may need to enter into new arrangements with alternative third parties, which would cause delay, and could be difficult, costly or impossible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Switching or adding clinical research organizations, or CROs, investigators, vendors and other third parties involves additional costs and delays because of the time it takes to finalize a contract with a new CRO and for their commencement of work. Although we carefully manage our relationships with our CROs, investigators, vendors and other third parties, we and any of these third parties may nonetheless encounter challenges or delays in the future, which could have a material and adverse impact on our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain principal investigators for our clinical trials serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected conduct of the trial. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of any future applications for regulatory approval of imetelstat, including in any additional indications by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not control the conduct of current or any potential future investigator-led clinical trials, and data from such trials could show marginal efficacy and/or clinically relevant safety concerns related to imetelstat resulting in an unfavorable benefit-risk assessment that could materially and adversely impact our ongoing clinical trials, or our development program as a whole.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not control the design or administration of investigator-led clinical trials, nor the submission, approval or maintenance of any IND or international equivalent filings required to conduct these clinical trials. In addition, we do not have control over the timing and reporting of the data from any such investigator-led clinical trials. A delay in the timely completion of or reporting of data from any current or potential future investigator-led clinical trial could have a material adverse effect on our ability to maintain regulatory approval for RYTELO in lower-risk MDS, or to further develop or advance it in clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investigator-led clinical trials may be conducted under less rigorous clinical standards than those used in company-sponsored clinical trials. Accordingly, regulatory authorities may closely scrutinize the data collected from these investigator-led clinical trials. In addition, any investigator-led clinical trials could show marginal efficacy and/or clinically relevant safety concerns that could delay, limit or preclude the further clinical development or marketing approval of RYTELO in any indication. To the extent that the results of any investigator-led clinical trials raise safety or other concerns, regulatory authorities may withdraw or restrict approval for RYTELO, question the results of such investigator-led clinical trials, or question the results of any of our clinical trials. Safety concerns</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arising from future investigator-led clinical trials could result in withdrawal of approval of RYTELO, partial or full clinical holds being placed on our INDs by the FDA or other similar international regulatory authorities, as occurred in March 2014, which would further delay or prevent us from commercializing RYTELO or advancing it into further clinical development. Any of the foregoing would delay or preclude any future marketing approvals for RYTELO and could cause us to discontinue our development of it, which would severely harm our business and prospects and could potentially cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Manufacturing RYTELO (IMETELSTAT)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure by us to maintain a manufacturing supply chain to appropriately and adequately supply RYTELO for commercial and future clinical uses would adversely affect our ability to commercialize RYTELO and result in a further delay in or cessation of clinical trials, and our business and business prospects could be severely harmed, and we could cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of RYTELO (imetelstat) must comply with applicable regulatory standards for commercial uses and current and potential future clinical trials. The process of manufacturing RYTELO is complex and subject to several risks, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to consistently manufacture and attain sufficient production yields with acceptable quality control and quality assurance to meet market demand for our commercialization of RYTELO, as well as the needs for continuing clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain existing commercial supply agreements and to establish additional or alternative supply agreements if necessary, including our ability to successfully transfer manufacturing technology and attain regulatory approval at any such additional or alternative suppliers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on third-party manufacturers and suppliers, whose efforts we do not control;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supply chain issues, including the timely availability of product and management of shelf-life, including raw materials, drug substance, and drug product and other supplies, any of which may be impacted by a number of factors, including the effects of macroeconomic or other global conditions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shortage of qualified personnel at any of our third party suppliers; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory acceptance and compliance with regulatory requirements, which are less well-defined for oligonucleotide products than for small molecule drugs and vary in each country.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of these and other risks, we may be unable to maintain a manufacturing infrastructure and supply chain capable of providing RYTELO for clinical and commercial use, which would delay or adversely affect our RYTELO commercialization efforts; result in lost sales; delay or result in a cessation of our current or potential future clinical trials; delay or preclude potential future regulatory approvals of RYTELO in other jurisdictions or indications; and could cause financial and reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If third parties that manufacture RYTELO fail to perform as needed, the commercial and clinical supply of RYTELO could be interrupted or limited, and we may be unable to successfully commercialize RYTELO or conduct or complete current or potential future clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our RYTELO manufacturing supply chain relies, and will continue to rely, solely upon third-party manufacturers to perform certain manufacturing, quality control, and other technical and scientific work with respect to RYTELO, as well as to supply starting materials and manufacture drug substance and drug product for our commercialization of RYTELO, as well as current and potential future clinical trials. While we have established arrangements with third parties for the manufacture of RYTELO, our manufacturing supply chain is highly specialized, and as such we are reliant upon a small group of third-party manufacturers to supply starting materials, drug substance and drug product. Failure by such third-party manufacturers to perform in a timely manner and in compliance with all regulatory requirements, or at all, could further delay, perhaps substantially, or preclude our ability to commercialize RYTELO and/or pursue further development of RYTELO on our own, increase our costs, result in lost sales, and otherwise negatively affect our financial results, business and business prospects. In this regard, recent FDA inspections of one of our third-party drug product manufacturers identified certain deficiencies in the manufacturer&#8217;s processes and facilities which, while not directly related to the FDA approval or ongoing production of RYTELO, could impact the manufacturer&#8217;s ability to produce and deliver products, including RYTELO, if not remediated by the manufacturer, and could lead to delays or shortages in drug supply, or the inability to manufacture or ship drug supply necessary for non-clinical and clinical activities and commercialization. We expect to rely on third-party manufacturers to produce and deliver sufficient quantities of RYTELO and other materials to support commercialization and clinical trials on a timely basis and to comply with applicable regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements. We do not have direct control over these third-party personnel or operations. Reliance on these third-party manufacturers is subject to numerous risks, including:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to execute timely contracts or production orders with any additional third-party manufacturers and suppliers that we may identify on acceptable terms, or at all;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays and disruptions experienced by third-party manufacturers that adversely impact the ability of such parties to fulfill their contractual obligations to us, including to provide the quantities of RYTELO required to meet commercial and clinical needs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">capacity limitations and scheduling constraints experienced by third-party manufacturers due to scheduling, maintenance and other commitments, and queued manufacturing activities in contracted facilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements by regulatory authorities to validate and qualify significant activities for any current or additional manufacturer, which could involve technology transfer, new testing, compliance inspections, and would likely require FDA or comparable foreign regulatory authority approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability of third-party manufacturers to timely formulate and manufacture RYTELO or to produce or ship RYTELO in the quantities or of the quality required to meet commercial and clinical needs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible mislabeling by third-party manufacturers of finished drug product for both commercial and clinical use, potentially resulting in product recall and harm to our business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decisions by third-party manufacturers to exit the contract manufacturing business during the time required to supply clinical trials or to successfully produce, store and distribute RYTELO to meet commercial needs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance by third-party manufacturers with GMP standards mandated by the FDA and state agencies and other government regulations, including foreign governing regulations, corresponding to similar international regulatory authorities, including any deficiencies identified during regulatory inspections, such as those identified in a recent FDA inspection of one of our third-party manufacturers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">breach or termination of manufacturing or supply contracts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inadequate storage or maintenance at contracted facilities resulting in theft or spoilage; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters that affect contracted facilities, including manufacturing, warehousing, and distribution facilities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of these risks could lead to delays or shortages in drug supply, or the inability to manufacture or ship drug supply necessary for commercialization, and non-clinical and clinical activities, which could severely and adversely affect our financial results, business and business prospects.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, third-party manufacturers and/or any other manufacturers may need to make substantial investments to enable sufficient capacity increases and cost reductions, and to implement those regulatory and compliance standards necessary for successful commercialization of RYTELO. These third-party manufacturers may not be willing or able to achieve such capacity increases, cost reductions, or regulatory and compliance standards, and even if they do, such achievements may not be at commercially reasonable costs. Changing manufacturers may be prolonged and difficult due to inherent technical complexities, regulatory risks, and because the number of potential manufacturers for oligonucleotide products is limited. It may be difficult or impossible for us to find a replacement manufacturer on acceptable terms, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our OPERATING RESULTS AND Financial Position</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> have a history of net losses and may not achieve consistent future profitability for some time, if ever.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are incurring and have incurred net losses every year since our operations began in 1990, except for one. As of December 31, 2024, our accumulated deficit was approximately $1.8 billion. Losses have resulted principally from costs incurred in connection with our research and development activities and from general and administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with our operations. Although we have recently begun to commercialize RYTELO, our revenue and profit potential is unproven and our very limited operating history as a commercial company makes our future operating results difficult to predict. If we do not generate sufficient revenue from commercial sales of RYTELO, or if we experience unforeseen events or choose to make other investments in our business, we may continue to experience negative cash flow as we fund our operations and imetelstat clinical development activities and research programs, and continue with the commercialization of RYTELO, including as a result of our obligation to pay royalty payments under the Royalty Pharma Agreement and service our debt obligations. We will need to generate significant revenues to achieve consistent future profitability, and we may never achieve consistent future profitability. Even if we do become profitable in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to achieve consistent future profitability could negatively impact the market price of our common stock and our ability to sustain operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">operating results are unpredictable and may fluctuate. If our operating results are below the expectations of securities analysts or investors, the trading price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating results are difficult to predict and will likely fluctuate from quarter to quarter and year to year. Due to the limited historical sales data of RYTELO in lower-risk MDS since its approval by the FDA in June 2024, RYTELO sales will be difficult to predict from period to period and as a result, you should not rely on RYTELO sales results in any period as being indicative of future performance. Sales of RYTELO may be below our own guidance or the expectations of securities analysts or investors in the future. To the extent that we do not meet our guidance, our financial projections or estimates, or the expectations of analysts or investors, our stock price may be adversely impacted, perhaps significantly. We believe that our quarterly and annual results of operations may be affected by a variety of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which coverage and reimbursement for RYTELO is available from government and health administration authorities, private health insurers, managed care programs and other third-party payors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the amount of deductions from gross sales, including government-mandated rebates, chargebacks and discounts that can vary because of changes to the government discount percentage, including increases in the government discount percentage resulting from price increases we may take in the future, or due to different levels of utilization by entities entitled to government rebates and discounts and changes in patient demographics;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increases in the scope of eligibility for customers to purchase RYTELO at the discounted government price or to obtain government-mandated rebates on purchases of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in our cost of sales;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and level of royalty payments under the Royalty Pharma Agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, cost and level of investment in our sales and marketing efforts to support RYTELO sales;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, cost and level of investment in our research and development activities involving imetelstat and potential future product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures we may incur to develop and/or commercialize any additional products, product candidates, or technologies that we may develop, in-license, or acquire.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, changes in our operations, such as increased development, manufacturing and clinical trial expenses, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses may also cause significant fluctuations in our expenses. In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price, the magnitude of the expense that we must recognize may vary significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For these and other reasons, it is difficult for us to accurately forecast future sales of RYTELO, operating expenses or future profits or losses. As a result, our operating results in future periods could be below our guidance or the expectations of securities analysts or investors, which could cause the trading price of our common stock to decline, perhaps significantly.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our financial projections and estimates are subject to significant risks, assumptions, and uncertainties, and our actual results may differ materially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial projections and estimates are subject to significant risks, assumptions, and uncertainties, and our actual results may differ materially. These projections and estimates include estimates of the total addressable market for RYTELO, assumptions regarding patient market share and duration of therapy, as well as assumptions regarding our ability to meet demand. These projections and estimates are subject to various factors beyond our control, including, for example, the level of demand for RYTELO, the extent to which coverage and reimbursement for RYTELO is available from government and health administration authorities, private health insurers, managed care programs and other third-party payors, increased costs in the supply chain, increased labor costs, changes in the regulatory environment, the impact of global health crises and changes in our senior management team. Our financial projections and estimates constitute forward-looking statements, are for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial projections and estimates are inherently uncertain and are subject to a wide variety of significant business,  economic, competitive and other risks and uncertainties. Actual results may differ materially from the results contemplated by the financial projections. Our independent auditors have not studied,  reviewed, compiled or performed any procedures with respect to the projections, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto. While all financial projections, estimates and targets are necessarily speculative, we believe that the preparation of financial projections involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of our future performance or that actual results will not differ materially from those presented in the financial projections or estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to obtain additional capital, if and when needed, would force us to further delay, reduce or eliminate the further development of RYTELO, or to halt the commercialization of RYTELO, any of which would severely and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful drug development and commercialization requires significant amounts of capital. As of December 31, 2024, we had approximately $502.9 million in cash, cash equivalents, restricted cash and marketable securities. While we believe that, based on our current operating plans and assumptions, our existing cash, cash equivalents, and marketable securities, together with anticipated net revenues from sales of RYTELO, will be sufficient to fund our projected operating requirements for the foreseeable future, if we do not generate net revenues from commercial sales of RYTELO at the levels we anticipate, if we experience unforeseen events or choose to make other investments in our business, or our assumptions regarding our projected operating expenses are otherwise incorrect, we may require additional funding, which could include a combination of public or private equity offerings, debt financings (including additional tranches under the Pharmakon Loan Agreement, if available), collaborations, strategic alliances, licensing arrangements or marketing and distribution arrangements, which may not be possible. For example, changes in our operations, such as increased development, manufacturing and clinical trial expenses, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses, may cause our operating expenses to increase, perhaps significantly, which could require us to raise additional funding. If adequate funds are not available to us when we need them, our RYTELO commercialization efforts may be adversely affected and we may be unable to pursue further development of imetelstat, which would severely harm our business and we might cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite FDA approval of RYTELO in June 2024, the outcome of any clinical activities and/or regulatory approval process is highly uncertain, and we cannot reasonably estimate whether our future development activities may succeed, whether we will obtain regulatory approval for RYTELO in the EU in lower-risk MDS, or in any other jurisdictions or indications we are pursuing or may in the future pursue, or whether we will be able to effectively commercialize RYTELO in the U.S. for lower-risk MDS or other potential jurisdictions or indications, if at all. We may never recoup our investment in any RYTELO development which would adversely affect our financial condition and our business and business prospects, and might cause us to cease operations. In addition, our plans and timing expectations could be further delayed or interrupted by the effects of macroeconomic or other global conditions, including those resulting from inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues. Further, our future capital requirements are difficult to forecast and will depend on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of the assumptions underlying our estimates for our capital needs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of sales and market acceptance of RYTELO;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, timing, magnitude and costs of non-clinical and clinical development, manufacturing and commercialization of RYTELO, including potential commercialization in the EU for lower-risk MDS, if approved, or in any other jurisdictions or other indication we may pursue, subject to clearances and approvals by the FDA and similar international regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or disruptions in opening sites, screening and enrolling patients or treating and following patients, in our current or any potential future clinical trials of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcomes of regulatory reviews or other regulatory actions related to RYTELO, including with respect to our MAA submission for RYTELO in the EU for lower-risk MDS;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing, developing, commercializing and marketing RYTELO, including with respect to third-party vendors and service providers and our ability to achieve any meaningful reduction in manufacturing costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sales price for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate third-party reimbursement for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other drugs and technologies, or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions, or to which we out-license RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are able to enter into and conduct successful arrangements with third parties, including for the commercialization and marketing of RYTELO in any regions outside of the U.S.; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent and scope of our selling, general and administrative expenses, including expenses associated with potential future litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our level of indebtedness and associated debt service obligations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of maintaining and operating facilities in California and New Jersey, as well as higher expenses for travel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">macroeconomic or other global conditions that may reduce our ability to access equity or debt capital or other financing on preferable terms, which may adversely affect future capital requirements and forecasts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of enabling our personnel to work remotely, including providing supplies, equipment and technology necessary for them to perform their responsibilities.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event we need to raise additional capital to fund our business, including pursuant to the 2023 Sales Agreement with B. Riley Securities, Inc., the Tranche B Loan and the Tranche C Loan under the Pharmakon Loan Agreement, which are subject to certain funding conditions; capital lease transactions or other financing sources, such additional capital may not be available on acceptable terms, or at all. We may be unable to raise equity capital, or may be forced to do so at a stock price or on other terms that could result in substantial dilution of ownership for our stockholders. The receptivity of the public and private debt and equity markets to proposed financings has been substantially affected by uncertainty in the general economic, market and political climate due to the effects of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, and may in the future be affected by other factors which are unpredictable and over which we have no control. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, which could reduce or eliminate our ability to raise additional funds through financings, and could negatively impact the terms upon which we may raise those funds. Similarly, these macroeconomic conditions have created extreme volatility and disruption in the capital markets and is expected to have further global economic consequences. If the equity and credit markets deteriorate, including as a result of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, it may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. If we are unable to effectively commercialize RYTELO, or raise additional capital, if needed, or establish alternative collaborative arrangements with third-party collaborative partners for RYTELO when needed, the development and commercialization of RYTELO may be further delayed, altered or abandoned, which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may seek additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Due to uncertainty in the general economic, market and political climate, we may determine that it is necessary or appropriate to raise additional funds proactively to meet longer-term anticipated operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the 2023 Sales Agreement, your ownership interest as a stockholder may be diluted, and the terms may include liquidation or other preferences that materially and adversely affect your rights as a stockholder. In addition, we have borrowed, and in the future may borrow, additional capital from institutional and commercial banking sources to fund development and our future growth, including pursuant to our Pharmakon Loan Agreement or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms under agreements, such as our Pharmakon Loan Agreement, that include restrictive covenants, including covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Moreover, if we raise additional funds through alliance, collaborative or licensing arrangements with third parties, we may have to relinquish valuable rights to RYTELO or our technologies or grant licenses on terms that are not favorable to us.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Indebtedness and ROYALTY PAYMENT OBLIGATIONS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our level of indebtedness and debt service obligations could adversely affect our financial condition and may make it more difficult for us to fund our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into the Pharmakon Loan Agreement. We drew the Tranche A Loan of $125.0 million on November 1, 2024 and as of November 1, 2024, the total outstanding principal amount under the Pharmakon Loan Agreement was $125.0 million. The tranches for the remaining $125.0 million available to us under the Pharmakon Loan Agreement are as follows: (a) a Tranche B Loan of $75.0 million, which is available until December 31, 2025 and is available at our option, subject to certain customary and limited conditions; and (b) a Tranche C Loan of $50.0 million, which is available until December 31, 2025, subject to certain conditions including achieving a certain revenue milestone on or prior to November 30, 2025. If we do not achieve such revenue milestone within the required timeline, we will not be eligible to draw down the Tranche C Loan. In addition, before we would consider drawing down any of the remaining tranches under the Pharmakon Loan Agreement, if available, we must first satisfy ourselves that we will have access to future alternate sources of capital, such as from commercial revenues or the equity capital markets or debt capital markets, in order to repay any additional principal borrowed, which we may be unable to do, in which case, our liquidity and ability to fund our operations may be substantially impaired.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Further, the terms of the Pharmakon Loan Agreement place restrictions on our operating and financial flexibility, and limit or prohibit our ability to dispose of certain assets, change our line of business, and engage in other significant transactions. This indebtedness may create additional financing risk for us, particularly if our business or prevailing financial market conditions are not conducive to paying off or refinancing the outstanding debt obligations at maturity. If we draw down any of the remaining tranches under the Pharmakon Loan Agreement, our indebtedness will increase, which would further increase our risk of being unable to pay off or refinance our outstanding debt obligations at maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our indebtedness could also have important negative consequences, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will need to repay the indebtedness by making payments of interest and principal, which will reduce the amount of cash available to finance our operations, our research and development efforts and other general corporate activities; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to comply with the obligations of our affirmative and restrictive covenants in the Pharmakon Loan Agreement could result in an event of default that, if not cured or waived, would permit the Lenders to accelerate our obligation to repay this indebtedness, and the Lenders could seek to enforce their security interest in the assets securing such indebtedness.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may borrow additional capital in the future to fund clinical development and our future growth, including pursuant to the Pharmakon Loan Agreement or potentially pursuant to new arrangements with different lenders. To the extent additional debt is added to our current debt levels, the risks described above could increase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The terms of the Pharmakon Loan Agreement place restrictions on our operating and financial flexibility.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pharmakon Loan Agreement imposes operating and other restrictions on us. Such restrictions will affect, and in many respects limit or prohibit, our ability and the ability of our subsidiaries to, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dispose of certain assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">change our line of business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in mergers, acquisitions or consolidations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incur additional indebtedness;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">create liens on assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pay dividends and make contributions or repurchase our capital stock; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in certain transactions with affiliates.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not have cash available in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to make scheduled interest payments on or to refinance our indebtedness depends on our future performance and ability to raise additional sources of cash, which is subject to economic, financial, competitive and other factors beyond our control. If we are unable to generate sufficient cash to service our debt, we may be required to adopt one or more alternatives, such as selling assets, restructuring our debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. If we desire to refinance our indebtedness, our ability to do so will depend on the state of the capital and lending markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to satisfy our current and future debt obligations under the Pharmakon Loan Agreement or to comply with certain covenants in the Pharmakon Loan Agreement could result in an event of default, the occurrence and continuance of which provides the lenders with the right to demand immediate repayment of all outstanding obligations under the Pharmakon Loan Agreement (and in the case of certain insolvency, liquidation, bankruptcy or similar events, automatically requires immediate repayment of all outstanding obligations under the Pharmakon Loan Agreement), and to exercise remedies against us and the collateral securing the Pharmakon Loan Agreement. These events of default include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">insolvency, liquidation, bankruptcy or similar events; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to observe covenants under the Pharmakon Loan Agreement and ancillary collateral documents, which failure, in certain limited cases, is not cured within 10 or 20 days; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of a withdrawal event in respect to RYTELO; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of a material adverse change;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material misrepresentations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain cross-default of third-party indebtedness or certain default or termination events of hedging assessments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">certain money judgments being entered against us which are not timely paid, discharged or stayed; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our assets are attached or seized.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the event of default, the lenders could accelerate all of the amounts due under the Pharmakon Loan Agreement. Under such circumstances, we may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time of such acceleration. In that case, we may be required to delay, limit, reduce or terminate our RYTELO development or commercialization efforts or grant to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others rights to develop and market RYTELO. The lenders could also exercise their rights to take possession and dispose of the collateral securing the Pharmakon Loan Agreement, which collateral includes substantially all of our property including, without limitation, our intellectual property, subject to certain exceptions. Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Royalty Pharma Agreement places certain restrictions on our operational flexibility.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Agreement contains covenants that impose on us certain obligations with respect to royalty payments, diligence, reporting, indemnification and includes restriction on intellectual property transfers and out-licenses, and certain other actions. The Royalty Pharma Agreement also limits our ability to create or incur liens or dispose of certain assets related to imetelstat. We have no rights to repurchase the revenue interests in RYTELO sold to Royalty Pharma (other than in connection with a change of control event), thereby limiting our ability to eliminate future applicability of the covenants contained in the Royalty Pharma Agreement. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might otherwise be advantageous to us and our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Protecting Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain sufficient intellectual property protection and relevant regulatory exclusivities for RYTELO, both in the U.S. and in other countries, our competitors could develop and commercialize products similar or identical to RYTELO, and our ability to successfully commercialize RYTELO may be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Protection of our proprietary technology is critically important to our business. Our success and the success of our commercialization and planned future development of RYTELO will depend on our ability to protect our technologies and RYTELO through patents, regulatory exclusivity, and other intellectual property rights. Our success will depend in part on our ability to obtain, maintain, enforce, and extend our patents and maintain trade secrets, both in the U.S. and in other countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and in other countries. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing RYTELO or our technology and/or limit the duration of the patent protection for RYTELO and our technology. In the event that we are unsuccessful in obtaining, maintaining, enforcing and extending our patents and other intellectual property rights or having our licensors maintain the intellectual property rights we have licensed, the value of RYTELO and/or our technologies will be adversely affected, and we may not be able to further develop or commercialize RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have method-of-use patents that protect the use of RYTELO for the treatment of certain diseases, this type of patent does not prevent a generic competitor from making and marketing a product that is identical to RYTELO for an indication that is outside the scope of our approved use after our composition-of-matter patents or their patent term extensions, and any regulatory exclusivities have expired. Moreover, even if competitors do not actively promote their product for our approved indications, physicians may prescribe or use these generic products &#8220;off-label,&#8221; which would result in decreased sales for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our patents covering RYTELO, we also expect to rely on regulatory exclusivity, including orphan drug exclusivity of up to 7 years in the U.S. and 10 years in the EU following approval, to protect our rights to commercialize RYTELO for its approved uses, but such regulatory exclusivity may be limited or withdrawn. See &#8220;Risks Related to Regulatory Approval of RYTELO -- </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although orphan drug designation has been granted to RYTELO for the treatment of MDS and MF in the U.S. and in the EU, these designations may not be maintained, which would eliminate the benefits associated with orphan drug designation, including market exclusivity, which could limit the period of exclusivity we are able to maintain for the commercialization of RYTELO, and would likely harm our business and business prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to orphan drug exclusivity, we expect to rely on other forms of regulatory exclusivity to protect our ability to commercialize RYTELO.  In the U.S., New Chemical Entity, or NCE, exclusivity would entitle us to four years of data exclusivity and one year of market exclusivity, for a total of five years of NCE exclusivity from the date of approval of the first-approved indication. Our request for NCE exclusivity is still pending with FDA, and might not be awarded or could be awarded and then later withdrawn. In Europe, New Active Substance, or NAS, exclusivity is expected to entitle us to eight years of data exclusivity and two years of market exclusivity, for a total of ten years of NAS exclusivity for the first-approved indication, but as with other forms of regulatory exclusivity, NAS exclusivity could be limited or withdrawn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss or impairment of our intellectual property rights related to RYTELO might further delay or halt ongoing or potential future clinical trials of RYTELO and any applications for regulatory approval, and might further delay or preclude any future development or commercialization of RYTELO by us. Furthermore, such loss of intellectual property rights could impair our ability to exclude others from commercializing products similar or identical to RYTELO and therefore result in decreased sales for us. Occurrence of any of these events would materially and adversely affect our financial results, business and business prospects, and might cause us to cease operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The USPTO and various governmental patent agencies in other countries require compliance with a number of procedural, documentary, fee payment, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications. Failure to respond to official actions within prescribed time limits, and nonpayment of fees, for example, maintenance fees, renewal fees, and annuity fees could result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the jurisdiction. In such an event, potential competitors might be able to enter the market with the same or similar products to RYTELO, and this circumstance could harm our financial condition, business and business prospects. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us or jointly owned with us, any of the foregoing could expose us to liability to the applicable patent owner or patent co-owner.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on RYTELO for an adequate amount of time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the U.S., the natural expiration of a patent is generally 20 years after its first effective nonprovisional filing date. As a result, our intellectual property may not provide us with sufficient patent rights to exclude others from commercializing products similar or identical to RYTELO.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the Hatch-Waxman Act permits one patent per approved product to receive a patent term extension of up to five years beyond its normal expiration. The length of the patent term extension is typically calculated as one half of the clinical trial period plus the entire period of time during the review of the NDA by the FDA, minus any time of delay by us during these periods. There is also a limit on the patent term extension to a term that is no greater than fourteen years from drug approval. Only one U.S. patent may receive patent term extension under the Hatch-Waxman Act. We have applied to the USPTO for patent term extension of some of our patents. Once the USPTO and the FDA determine the extension period for each proposed eligible patent, we will select the one patent to be extended. We expect to apply any patent term extension that is granted in the U.S. to our method of treatment patent for MDS and MF that expires on March 15, 2033. If such patent term extension is granted, we expect the term of the patent to extend through August 2037, although such timing is subject to approval by the USPTO as part of its review of our application for patent term extension and could differ from our calculation. Currently, communication of patent term extension approval and the length of the granted extension period by the USPTO may occur up to several years from filing of an application for patent term extension. Accordingly, we will decide on the specific patent to be extended only after such communication from the USPTO.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar extensions are also available in certain countries and territories outside the U.S., such as in Japan, and in Europe as Supplementary Protection Certificates, or SPCs. However, we might not be granted a patent term extension at all because of failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the U.S., and any equivalent regulatory authorities and patent offices in other countries, may not agree with our assessment of whether such extensions are available, may refuse to grant extensions to our patents, or may grant more limited extensions than we request and could be less than five years. If we select and are granted a patent term extension on a recently filed and issued patent, we may not receive the full benefit of a possible patent term extension, if at all. Moreover, in some countries, the scope of protection for claims under patent term extension, if any, is limited to the product composition as approved and, for a method of treatment patent, to the approved indications. If we do not have sufficient patent life and regulatory exclusivity to protect RYTELO, our financial results, business and business prospects would be materially and adversely affected, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe and other countries, our composition of matter patent coverage expired in September 2024, and our method of treatment patent rights for MDS and MF expire in November 2033. Our method of treatment patents may be eligible for patent term extension of up to five years under an SPC, permitted under European Council (EC) Regulation No. 469/2009, or the European SPC Regulation, upon receipt of drug product approval, such as, for example, our method of treatment patent for MDS. In Europe, we have separate method of treatment patents</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">covering MDS and MF, and a SPC may only be applied to one patent. Accordingly, in countries of the EEA, we must rely on regulatory exclusivity and our method of treatment patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of RYTELO occurs after a patent has expired in a country that does not allow interim patent term extensions, as is the case in many countries and territories including Europe, we will be unable to obtain any patent term extension of that expired patent, and the duration of our patent rights may be limited. Accordingly, in Europe and such other similar countries and territories, we will not be able to seek patent term extension of our composition of matter patent, as it expired in September 2024.  If we do not have sufficient patent life and regulatory exclusivity to protect RYTELO, our financial results, business and business prospects would be materially and adversely affected, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, there are regulations for the listing of patents in the Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Some of our patents have been listed in the Orange Book. Manufacturers of generic drugs may challenge the listing. If an appropriate patent covering RYTELO is not listed in the Orange Book or is subsequently removed from the Orange Book, a manufacturer of generic drugs would not be required to provide advance notice to us of any abbreviated NDA filed with the FDA to obtain permission to sell a generic version of RYTELO. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The validity, scope and enforceability of any patents listed in the Orange Book that cover RYTELO or its methods of use can be challenged by third parties and may not protect us from generic or innovator competition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a third party files an application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act or an abbreviated new drug application, or ANDA, under Section 505(j) to obtain permission to sell a generic or follow-on version of RYTELO, and relies in whole or in part on studies conducted by or for us, the third-party will be required to certify to the FDA that either: (1) there is no patent information listed in the Orange Book with respect to our NDA for RYTELO; (2) the patents listed in the Orange Book have expired; (3) the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third-party&#8217;s generic product. A certification that the new product will not infringe the Orange Book-listed patents for RYTELO, or that such patents are invalid, is called a paragraph IV certification. If the third-party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us within 20 days after the third-party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third-party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third-party. If the product has NCE exclusivity and the notice is given and the suit filed in the fifth year of exclusivity, the regulatory stay extends until 7.5 years after approval of the reference product.  If we do not file a patent infringement lawsuit within the required 45-day period, the third-party&#8217;s ANDA will not be subject to the 30-month stay of FDA approval.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our issued U.S. patents covering RYTELO or its methods of use may not provide adequate protection from competitive products if competitors receive approval of an ANDA application or are able to design around the patents. One or more competitors may circumvent these patents by filing a marketing application with the FDA for a competitive product containing the active moiety in RYTELO and successfully challenging the validity of the patents or successfully designing around the patents. Any successful challenge and/or designing around one or more of the patents could result in a generic version of RYTELO being commercialized before the expiration of the patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patents covering RYTELO or its methods of use are successfully challenged or designed around, or if we are unsuccessful in enforcing our patents against generics, we could face competition prior to the expiration of these patents, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property rights, which could be expensive, time consuming and unsuccessful, and which could result in the invalidity or unenforceability of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">our patents covering RYTELO or its methods of use.</span><span style="color:#0000ff;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#0000ff;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe, misappropriate or otherwise violate our patents or other intellectual property rights. To counter infringement or unauthorized use, we may be required to file and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The initiation of a claim against a third party by us may also cause the third-party to bring counter claims against us, such as claims asserting that our patents are invalid or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of written description or non-statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, IPR or post-grant review, or oppositions or similar proceedings outside the U.S., in parallel with litigation or even outside the context of litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court and if any such lawsuits will ultimately be resolved successfully. Further, even if we prevail, the infringer may file an appeal and the court judgment may be overturned and/or that an adverse decision may be issued by an appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly in a manner insufficient to achieve our business objectives. Even if we establish infringement, we may not seek, or the court may decide not to grant, an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection for RYTELO, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Additionally, any adverse outcome could allow third parties to commercialize RYTELO and compete directly with us, without payment to us.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, if</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are engaged in intellectual property litigation, there would be public announcements of filings, briefings, hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these events to be negative, it could have an adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in jurisdictions outside the U.S. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many countries outside the U.S. have compulsory licensing laws under which a patent owner must grant licenses to third parties. Proceedings to enforce our patent rights in jurisdictions outside the U.S. could result in substantial costs and divert our efforts and attention from other aspects of our business, and could put our patents at risk of being invalidated or interpreted narrowly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. or international patent law or interpretations of such patent laws could diminish the value of our patents in general, thereby impairing our ability to protect our technologies and RYTELO.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of pharmaceutical and biopharmaceutical companies, including ours, are highly uncertain and involve complex legal and technical questions. In particular, legal principles for biotechnology and pharmaceutical patents in the U.S. and in other countries are evolving, and the extent to which we will be able to obtain patent coverage to protect our technologies and RYTELO, or enforce or defend issued patents, is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. has enacted and implemented wide-ranging patent reform legislation, including the Leahy-Smith America Invents Act, or the AIA, signed into law on September 16, 2011. The U.S. Supreme Court has ruled on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Depending on actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents or patents that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce our existing patents or patents that we may obtain in the future. Occurrence of these events and/or significant impairment of our RYTELO patent rights could severely and adversely affect our financial results, business and business prospects, which might cause us to cease operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the AIA, in March 2013, the U.S. transitioned to a first-inventor-to-file system under which, assuming the other requirements for patentability are met, the first inventor to file a patent application is entitled to the patent. However, since the publication of discoveries in scientific or patent literature tends to lag behind actual discoveries by at least several months and sometimes several years, we are not able to be certain upon filing a patent application that the persons or entities that we name as inventors or applicants in our patent applications were the first to invent the inventions disclosed therein, or the first to file patent applications for these inventions. Thus, our ability to protect our patentable intellectual property depends, in part, on our ability to be the first to file patent applications with respect to our inventions, or inventions that were developed by our former collaboration partner and assigned to us, for the future development, commercialization and manufacture of RYTELO. As a result, if we are not the first inventor-to-file, we may not be able to obtain patents for discoveries that we otherwise would consider patentable and that we consider to be significant to the future success of RYTELO. Delay in the filing of a patent application for any purpose, including further development or refinement of an invention, may result in the risk of loss of patent rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2012, the European Patent Package, or EU Patent Package, was approved and included regulations with the goal of providing for a single pan-European Unitary Patent, and a new European Unified Patent Court, or UPC, for litigation of European patents. The EU Patent Package was ratified in February 2023 and currently covers certain EU states. As of June 1, 2023, all European patents, including those issued prior to ratification, by default automatically fall under the jurisdiction of the UPC and allow for the possibility of obtaining pan-European injunctions and are at risk of central revocation at the UPC in participating UPC states. Under the EU Patent Package, patent holders are permitted to &#8220;opt out&#8221; of the UPC on a patent-by-patent basis during an initial seven year transitional period after June 1, 2023. Owners of European patent applications who receive notice of grant after the EU Patent Package came into effect could, for the UPC contracting states, either obtain a Unitary Patent or validate the patent nationally and file an opt-out demand. The EU Patent Package may increase the uncertainties and costs surrounding the enforcement or defense of our issued European patents and pending applications. The full impact on future European patent filing strategy and the enforcement or defense of our issued European patents in member states and/or the UPC is not known.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting, maintaining, defending and enforcing patents for RYTELO and our technologies in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. are less extensive than those in the U.S. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover RYTELO and our technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights in the U.S or worldwide and challenges to our owned or licensed patent rights would result in costly and time-consuming legal proceedings that could prevent or limit development or commercialization of RYTELO.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our patents or those patent rights we have licensed, including patent rights that we may seek with respect to inventions made by past or future collaborators, may be challenged through administrative or judicial proceedings, which could result in the loss of important patent rights. For example, where more than one party seeks U.S. patent protection for the same technology in patent applications that are subject to the law before the implementation of the AIA, the USPTO may declare an interference proceeding in order to ascertain the party to which the patent should be issued. Patent interferences are typically complex, highly contested legal proceedings, subject to appeal. They are usually expensive and prolonged and can cause significant delay in the issuance of patents. Our pending patent applications or our issued patents, or those we have licensed and may license from others, may be drawn into interference proceedings or be challenged through post-grant review procedures or litigation, any of which could delay or prevent the issuance of patents, or result in the loss of issued patent rights. We may not be able to obtain from our past or future collaborators the information needed to support our patent rights which could result in the loss of important patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the AIA, interference proceedings between patent applications filed on or after March 16, 2013, have been replaced with other types of proceedings, including derivation proceedings. The AIA also includes post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions, such as inter partes review, or IPR, covered business method post-grant reviews and other post-grant reviews. This applies to all our U.S. patents and those we have licensed and may license from others, even those issued before March 16, 2013. A third party could attempt to use the USPTO procedures to invalidate patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. U.S. patents owned or licensed by us may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. In addition, the IPR process under the AIA permits any person, whether they are accused of infringing the patent at issue or not, such as entities associated with hedge funds, to challenge the validity of certain patents. Significant impairment of our RYTELO patent rights could severely and adversely affect our financial results, business and business prospects, which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain jurisdictions, such as Europe, China, Japan, New Zealand and Australia, permit third parties to file oppositions or invalidation trials against granted patents or patents proposed to be granted. Because we seek to enable potential global commercialization of RYTELO, securing both proprietary protection and freedom to operate outside of the U.S. is important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third party proceedings such as oppositions and invalidation trials require significant time and costs, and if we are unsuccessful or are unable to commit these types of resources to protect our RYTELO patent rights, we could lose our patent rights and we could be prevented or limited in the development and commercialization of RYTELO.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As more groups become engaged in scientific research and product development in the areas of telomerase biology and hematologic malignancies, the risk of our patents, or patents that we have in-licensed, being challenged through patent interferences, derivation proceedings, IPRs, post-grant proceedings, oppositions, invalidation trials, re-examinations, litigation or other means will likely increase. Challenges to our patents through these procedures would be extremely expensive and time-consuming, even if the outcome was favorable to us. An adverse outcome in a patent dispute could severely harm our ability to further develop or commercialize RYTELO, or could otherwise have a material adverse effect on our business, and might cause us to cease operations, by:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">causing us to lose patent rights in the relevant jurisdiction(s);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjecting us to litigation, or otherwise preventing us from commercializing RYTELO in the relevant jurisdiction(s);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring us to obtain licenses to the disputed patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">forcing us to cease using the disputed technology; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring us to develop or obtain alternative technologies. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to infringement claims that are costly to defend, and such claims may limit our ability to use disputed technologies and prevent us from pursuing research, development, manufacturing or commercialization of RYTELO.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of RYTELO will depend upon our ability to research, develop, manufacture, market and sell RYTELO without infringing or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and many pharmaceutical companies, including potential competitors, have substantial patent portfolios. Since we cannot be aware of all intellectual property rights potentially relating to RYTELO and its uses, we do not know with certainty that RYTELO, or the commercialization thereof, does not and will not infringe or otherwise violate any third party&#8217;s intellectual property. For example, we are aware that certain third parties have or may be prosecuting patents and patent estates that may relate to RYTELO, and while these patents have expired, or we believe that a reasonable court should find they are invalid and/or would not be infringed by the manufacture, use or sale of RYTELO, it is possible that the owner(s) of these patents will assert claims against us in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event our technologies infringe the rights of others or require the use of discoveries and technologies controlled by third parties, we may be prevented from pursuing research, development, manufacturing or commercialization of RYTELO, or may be required to obtain unblocking licenses from such third parties, develop alternative non-infringing technologies, which we may not be able to do at an acceptable cost or on acceptable terms, or at all, or cease the commercialization and continued development of RYTELO. If we are unable to resolve an infringement claim successfully, we could be subject to an injunction that would prevent us from commercializing RYTELO and could also require us to pay substantial damages.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while our past collaboration agreements have terminated, we are still subject to indemnification obligations to certain collaborators, including with respect to claims of third-party patent infringement. In addition to infringement claims, in the future we may also be subject to other claims relating to intellectual property, such as claims that we have misappropriated the trade secrets of third parties. Our success therefore depends significantly on our ability to operate without infringing patents and the proprietary rights of others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may become aware of discoveries and technologies controlled by third parties that are advantageous or necessary to further develop or manufacture RYTELO. Under such circumstances, we may initiate negotiations for licenses to other technologies as the need or opportunity arises. We may not be able to obtain a license to a technology required to pursue the research, development, manufacturing or commercialization of RYTELO on commercially favorable terms, or at all, or such licenses may be terminated on certain grounds, including as a result of our failure to comply with any material obligations under such licenses. If we do not obtain a necessary license or if such a license is terminated, we may need to redesign such technologies or obtain rights to alternative technologies, which may not be possible, and even if possible, could cause further delays in the development efforts for RYTELO and could increase the development and/or production costs of RYTELO. In cases where we are unable to license necessary technologies, we could be subject to litigation and prevented from pursuing research, development, manufacturing or commercialization of RYTELO, which would materially and adversely impact our business. Failure by us to obtain rights to alternative technologies or a license to any technology that may be required to pursue research, development, manufacturing or commercialization of RYTELO would further delay current and potential future clinical trials of RYTELO and any applications for regulatory approval, impair our ability to sell RYTELO, and therefore result in decreased sales of RYTELO for us. Occurrence of any of these events could materially and adversely affect our business and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a registered trademark, RYTELO, for our product and failure to maintain such trademark could adversely affect our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a registered trademark, RYTELO, which is the commercial trade name for imetelstat, in a number of countries and regions, including in the U.S. and Europe. Opposition or cancellation proceedings, however, may be filed against our trademarks, and our trademarks may not survive such proceedings. If our United States trademark application which forms the basis for our international registration, or IR, for our commercial trade name is withdrawn or abandoned within the first 5 years of our IR, we will lose our IR registrations which could adversely affect our business. We may be unable to maintain or enforce our current and future trademarks, and if we fail to satisfy the applicable regulatory requirements, we may not have enforceable trademark rights or registrations in such jurisdictions. Our product trademark, RYTELO, is approved by the FDA and the EMA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in disputes with past or future collaborator(s) over intellectual property inventorship, ownership or use, and publications by us, or by investigators, scientific consultants, research collaborators or others. Such disputes could impair our ability to obtain patent protection or protect our proprietary information, which, in either case, could have a significant impact on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventions discovered under research, material transfer or other collaboration agreements may become jointly owned by us and the other party to such agreements in some cases and may be the exclusive property of either party in other cases. Under some circumstances, it may be difficult to determine who invents and owns a particular invention, or whether it is jointly owned, and disputes can arise regarding inventorship, ownership and use of those inventions. These disputes could be costly and time-consuming, and an unfavorable outcome could have a significant adverse effect on our business if we are not able to protect or license rights to these inventions. In addition, clinical trial investigators, scientific consultants and research collaborators generally have contractual rights to publish data and other proprietary information, subject to review by the trial sponsor. Publications by us, or by investigators, scientific consultants, previous employees, research collaborators or others, either with permission or in contravention of the terms of their agreements with us or with our past or future collaborators, may impair our ability to obtain patent protection or protect proprietary information which could have a material adverse effect on our business, and might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Much of the information and know-how that is critical to our business is not patentable, and we may not be able to prevent others from obtaining this information and establishing competitive enterprises.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on trade secrets to protect our proprietary technology, especially in circumstances in which we believe patent protection is not appropriate or available. We attempt to protect our proprietary technology in part by confidentiality agreements with our employees, consultants, collaborators and contractors. However, we cannot provide assurance that these agreements will not be breached, that we would have adequate remedies for any breach,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or that our trade secrets will not otherwise become known or be independently discovered by competitors, any of which would harm our business significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2016, the Defend Trade Secrets Act of 2016, or the DTSA, was enacted, providing a federal cause of action for misappropriation of trade secrets. Under the DTSA, an employer may not collect enhanced damages or attorney fees from an employee or contractor in a trade secret dispute brought under the DTSA, unless certain advanced provisions are observed. We cannot provide assurance that our existing agreements with employees and contractors contain notice provisions that would enable us to seek enhanced damages or attorneys&#8217; fees in the event of any dispute for misappropriation of trade secrets brought under the DTSA.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Managing Our Growth and Other Business Operations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to successfully retain or recruit key personnel to support the commercialization and further development of RYTELO or to otherwise successfully manage our growth.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to successfully commercialize RYTELO in the U.S. for lower-risk MDS  and in any other jurisdiction or indication for which it is approved, and to continue to develop RYTELO in other myeloid hematologic malignancies depends to a significant extent on the skills, experience and efforts of our executive officers and key members of our staff. In addition, we need to recruit, maintain, motivate and integrate additional personnel with expertise and experience in sales, marketing, market access, commercial operations, pricing, clinical science, biostatistics, clinical operations, pharmacovigilance, quality, manufacturing, regulatory affairs, medical affairs, legal affairs, and compliance to enable us to further commercialize and further develop RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face intense competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions, and competition in our geographic regions is particularly intense. The substantial risks and uncertainties related to our commercialization and further development of RYTELO, and the risks and uncertainties regarding our future business viability could have an adverse impact on our ability to retain and recruit qualified personnel. We may also face higher than expected personnel costs in order to attract new personnel due to shortages in qualified applicants, or to maintain our current management and personnel due to the increased number of opportunities in the biotechnology sector. If we are unable to successfully retain, motivate and incentivize our existing personnel, or to attract, assimilate and retain other highly qualified personnel in the future on acceptable terms, our ability to commercialize and further develop RYTELO will be impaired, and our business and the price of our common stock would be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our personnel are currently performing their duties in multiple jurisdictions, and if we are unable or fail to comply with employment, tax, benefits and other laws in such jurisdictions, we may face penalties, fines or litigation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to develop, manufacture and commercialize RYTELO depends, in part, on our ability to effectively manage any future growth. Our management may have to divert financial and other resources, as well as devote a substantial amount of time, to managing growth activities, such as enhancing operational, financial and management processes and systems. If we do not effectively manage the expansion of our operations, we could experience weaknesses in our infrastructure and ability to comply with applicable legal and regulatory requirements and regulations, operational mistakes or shortcomings, loss of business opportunities, loss of employees and reduced productivity among remaining employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we seek to establish potential future collaborative arrangements for RYTELO, we may be unable to establish such collaborative arrangements on acceptable terms, or at all, and may have to delay, alter or abandon commercialization or further development of RYTELO.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to develop RYTELO broadly for hematologic malignancies, and to commercialize, market and sell RYTELO in the U.S. for certain patients with lower-risk MDS and potentially in the EU for certain patients with lower-risk MDS. We may seek to self-commercialize or seek a collaborative partner or partners, at an appropriate time, to assist us in the potential development and commercialization of RYTELO outside the U.S., and to provide funding for such activities. We face significant competition in seeking appropriate collaborative partners, and these potential collaborative arrangements are complex and time consuming to negotiate, document and implement. Our ability to seek and establish potential collaborative arrangements may be impacted by delays in marketing approvals of RYTELO in lower-risk MDS in the EU and in reporting results from IMpactMF, as well as the period of the patent protection and market exclusivity for RYTELO. In addition, the terms of our Pharmakon Loan Agreement may limit our ability to enter into certain collaborative arrangements and any future debt agreements may continue or further limit our ability to enter into such agreements. We may not be able to establish collaborative arrangements on acceptable terms, or at all. In this regard, collaborative arrangements with third parties may require us to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relinquish material rights, including revenue from commercialization, or assume material ongoing development obligations that we would have to fund or otherwise support.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If we are unable to negotiate collaborative arrangements, we may have to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, curtail or abandon the additional development of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay, curtail or abandon the commercialization of RYTELO in jurisdictions where it is approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduce the scope of potential future sales or marketing activities; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increase our expenditures and undertake development or commercialization activities at our own expense, which will require additional capital than our current resources.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have established subsidiaries in the United Kingdom and the Netherlands, which exposes us to additional costs and risks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The wholly-owned subsidiaries we have established in the U.K. and the Netherlands subject us to certain additional costs and risks associated with doing business outside the U.S., including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the increased complexity and costs inherent in managing international operations in geographically disparate locations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges and costs of complying with diverse regulatory, financial and legal requirements, which are subject to change at any time;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially adverse tax consequences, including changes in applicable tax laws and regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potentially costly trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them, including in connection with new Trump administration changes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">natural disasters, political and economic instability, including terrorism and civil and political unrest, outbreak of health epidemics, and the resulting global economic and social impacts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the U.S.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain or maintain sufficient insurance on commercially reasonable terms or with adequate coverage against potential liabilities in order to protect ourselves against claims such as product liability or personal injury claims arising from our commercialization of RYTELO, claims related to clinical trial conduct, or claims related to data protection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business exposes us to potential product liability and other risks that are inherent in the testing, manufacturing and marketing of human therapeutic products. We may become subject to product liability or personal injury claims related to the commercialization of RYTELO, or claims related to clinical trial conduct, including if the use of RYTELO is alleged to have injured patients, such as injuries alleged to arise from any hepatotoxicity or hemorrhagic event associated with the use of RYTELO. We currently have product liability and clinical trial liability insurance that we believe is adequate, but we may experience losses in excess of our coverage or that are not covered by our insurance, and we may not be able to maintain this type of insurance for the commercialization of RYTELO, or any of our current or potential future clinical trials of RYTELO. In addition, this type of insurance may become too expensive for us to afford because of the highly risky and uncertain nature of commercialization of RYTELO, clinical trials generally and the high cost of insurance for our business activities. We may be unable to obtain or maintain clinical trial insurance in all of the jurisdictions where we conduct current or potential future clinical trials. In addition, business liability, product liability and cybersecurity insurance are becoming increasingly expensive, particularly for biotechnology and pharmaceutical companies, and the pool of insurers offering insurance coverage to biotechnology and pharmaceutical companies generally is becoming smaller, making it more difficult to obtain insurance for our business activities at a reasonable price, or at all. Being unable to obtain or maintain product liability, clinical trial liability, cybersecurity or other insurance for our business activities in the future on acceptable terms or with adequate coverage against potential liabilities would have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on our business, and could cause us to limit or cease our commercialization and further development of RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In the past, we and certain of our officers have been named as defendants in securities class action lawsuits and shareholder derivative lawsuits. Potential similar or related lawsuits that may be filed in the future, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations. Any such lawsuits, or other lawsuits to which we are subject, will be costly to defend or pursue and are uncertain in their outcome.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not currently a party to any material pending legal proceedings. However, securities class action lawsuits and/or derivative lawsuits have often been brought against companies, including biotechnology and biopharmaceutical companies, that experience volatility in the market price of their securities. This risk is especially relevant for us because we often experience significant stock price volatility in connection with our activities.  In 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed, and final judgment with respect to the other two lawsuits was entered in October 2023.  In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  All seven of the shareholder derivative actions were dismissed with prejudice.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. We could be forced to expend significant resources in the defense of any additional lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A decision adverse to our interests in any legal proceedings, could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our business, our stock price, cash flow, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to third-party litigation, and such litigation would be costly to defend or pursue and uncertain in its outcome.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business may bring us into conflict with our licensees, licensors, or others with whom we have contractual or other business relationships, or with our competitors or others whose interests differ from ours. Our commercial launch of RYTELO may result in product or personal injury disputes, or other disputes with health care providers, patients or other third parties as a result of our commercialization efforts. We may experience employment-related disputes. We may become involved in performance or other disputes with the CROs we have retained to support our clinical development activities, or with other third parties such as service providers, vendors, manufacturers, suppliers or consultants. If we are unable to resolve those conflicts on terms that are satisfactory to all parties, we may become involved in litigation brought by or against us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lawsuits are subject to inherent uncertainties, and defense and disposition costs depend upon many unknown factors. Despite the availability of insurance, we may incur substantial legal fees and costs in connection with litigation. Lawsuits could result in judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise negatively affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of such litigation could lead to increased volatility in our stock price and a decrease in the value of our stockholders&#8217; investment in our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to export control and import laws and regulations, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISKS RELATED TO INFORMATION TECHNOLOGY SYSTEMS, DATA SECURITY AND DATA PRIVACY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or data, or those of third parties with whom we work, are or were compromised, we could experience adverse consequences resulting from such compromise, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations, including our clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we (and third parties with whom we work) collect, receive, store, use, transfer, make accessible, protect, secure, dispose of, transmit, disclose, or otherwise process (commonly known as processing) proprietary, confidential, and sensitive data, including personal data (such as health-related data and participant study related data), intellectual property, and trade secrets (collectively, sensitive information). In addition, we rely on third-party service providers to establish and maintain appropriate information technology and data security protections, including disaster recovery and business continuity procedures, over the information technology systems they provide us to operate our critical business systems, including cloud-based infrastructure and systems, employee email, and data storage and management systems. However, except for contractual duties and obligations, we have limited ability to control or monitor third parties&#8217; safeguards and actions related to such matters, and these third parties may not have adequate information security measures in place. Furthermore, while we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. Most of our employees work remotely, resulting in increased risks of loss or theft of company devices as well as increased risks to our information technology systems and data, as employees utilize network connections, computers, and devices outside our premises and networks, including working at home and while in transit and in public locations. Additionally, the prevalent use of mobile devices that access our sensitive information increases the risk of security incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information technology systems, including in our remote work environment, and those of the third parties with whom we work, have been in the past and may continue to be vulnerable to evolving threats. These threats are prevalent, continue to increase, and come from a variety of sources such as traditional &#8220;hackers,&#8221; threat actors, &#8220;hacktivist,&#8221; organized criminal threats actors, or internal bad actors, personnel (such as through theft, error or misuse), sophisticated nation states and nation-state-supported actors. These threats include, but are not limited to, social-engineering attacks, targeted phishing campaigns, malicious code or malware, unauthorized intrusions, denial-of-service attacks, personnel misconduct or errors, ransomware attacks, supply-chain attacks, software bugs, computer viruses, server malfunctions, software, hardware or data center failures, loss of data or other information technology assets, natural disasters, terrorism, war, telecommunication and electrical failures and attacks enhanced or facilitated by artificial intelligence, or AI, and other similar threats. In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant interruptions in operations, loss of sensitive data and income, reputational harm, and diversion of funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we were to experience such an attack, extortion payments might alleviate the negative impact of a ransomware attack, but we might be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. Similarly, supply-chain attacks and attacks on clinical trial sites as well as regulatory and health authorities have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains, or of clinical trial sites and regulatory and health authorities, have not been compromised or that they do not contain exploitable defects or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bugs that could result in a breach of or disruption to our information technology systems or the third-party information technology systems that support us and the services provided to us, or remediate and recover compromised systems in a timely manner. For example, in February 2024, one of our service providers that processes clinical trial data experienced a security incident that resulted in certain of the service provider&#8217;s information systems being unavailable for a limited period of time. Based on the service provider&#8217;s forensic investigation findings that were shared with us, we believe that this incident did not have a material impact on us, our clinical trials or clinical trial participants. As another example, in March 2024, we learned about another security incident, involving another service provider, that processes personnel data for our limited number of UK personnel and directors of Geron UK Ltd. Following the service provider&#8217;s forensic investigation, the service provider informed us that it did not determine the specific data involved or the incident&#8217;s impact. While we believe that this incident did not have a material impact on us, out of an abundance of caution, we submitted a notification to the UK Information Commissioner&#8217;s Office and notified potentially affected personnel and directors of the incident.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these or similar incidents or threats may result in unauthorized, unlawful or accidental loss, corruption, access, modification, destruction, alteration, acquisition or disclosure of sensitive information, such as clinical trial data or information, intellectual property, proprietary business data and personal data. The costs to us to attempt to protect against such security incidents could be significant, including potentially requiring us to modify our business, and while we have implemented security measures, policies and procedures designed to protect our information technology systems from cybersecurity threats and to identify and remediate vulnerabilities, such measures may not be fully implemented, complied with or successful in protecting our systems and information. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. We may be unable in the future to detect cybersecurity threats or vulnerabilities in our information technology systems because such threats and techniques change frequently, are sophisticated in nature, and may not be detected until after a security incident has occurred. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. Unremediated high risk or critical vulnerabilities pose material risks to our business, particularly due to the reliance on software vendors to adequately patch and implement fixes to address critical or high-risk vulnerabilities in a timely manner. Further, we may be materially impacted by software updates applied by our software vendors if such updates cause significant downtime to our systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or third parties with whom we work experience or are perceived to have experienced a breach, we may experience material adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections), interruptions in our operations, including disruption of our commercialization and development efforts, interruptions or restrictions on processing sensitive data (which could result in delays in obtaining, or our inability to obtain, regulatory approvals and significantly increase our costs to recover or reproduce the data), reputational harm, litigation (including class action claims), indemnification obligations, negative publicity, financial loss, and other harms. In addition, such a breach may require public notification of the breach, or we may choose to voluntarily notify relevant stakeholders, or take other actions, such as providing credit monitoring and identity theft protection services, and we have done so in the past. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative AI technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our contracts with relevant stakeholders include obligations relating to the safeguard of sensitive information, and a breach could lead to claims against us by such stakeholders. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities, damages, or claims relating to our data privacy and security obligations. In addition, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to successfully implement or upgrade our enterprise resource planning and other information systems, our business and results of operation could be adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We periodically implement or upgrade new or enhanced enterprise resource planning, or ERP, and other business systems in order to better manage our business operations. Implementation or upgrade of new business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">processes and information systems requires the commitment of significant personnel, training and financial resources, and entails risks to our business operations. If we do not successfully implement ERP and other information systems improvements, or if there are delays or difficulties in implementing these systems, we may not realize anticipated productivity improvements or cost efficiencies, and we may experience operational difficulties and challenges in effectively managing our business, all of which could result in quality issues, reputational harm, lost market and revenue opportunities, and otherwise adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, in 2024 we implemented a new ERP and other information systems to help us manage our operations and financial reporting.  This project required, and may continue to require, investment of capital and human resources, the re-engineering of processes of our business, and the attention of many employees who would otherwise be focused on other aspects of our business. Costs and risks inherent in implementing new systems, such as the ERP that we implemented in 2024, may include disruptions to business continuity, administrative and technical problems, interruptions or delays in sales, expenditure overruns, delays in paying our suppliers and employees, and data migration issues. If we do not properly address or mitigate these issues, this could result in increased costs and diversion of resources, negatively impacting our operating results and ability to effectively manage our business. Additionally, if the ERP system that we implemented in 2024 does not operate as intended, the effectiveness of our internal control over financial reporting could be negatively affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and third parties with whom we work are subject to stringent and changing U.S. and foreign laws, regulations, rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue and profits; and other adverse business impacts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we process personal data and other sensitive data, including proprietary and confidential business data, trade secrets, intellectual property, clinical trial participant data, and other sensitive third-party data. We are therefore subject to or affected by numerous data privacy and security obligations, such as federal, state, local and foreign laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations governing the processing of personal data. These obligations may change, are subject to differing interpretations and may be inconsistent among jurisdictions or conflict. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business; affect us or our collaborators&#8217;, service providers&#8217; and contractors&#8217; ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal data; necessitate the acceptance of more onerous obligations in our contracts; result in liability; or impose additional costs on us. These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the U.S., an increasing number of laws, regulations, and industry standards apply to data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation, or the EU GDPR, and the United Kingdom&#8217;s GDPR, or the UK GDPR (collectively, the &#8220;GDPR&#8221;), impose strict requirements on the processing of personal data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, under GDPR, government regulators may impose temporary or definitive bans on data processing, fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to transfer personal data from the EEA, the UK and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. The EEA and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the EEA and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups, and some EEA regulators have prevented companies from transferring personal data out of the EEA for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to data privacy and security in the U.S. For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health data. Additionally, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA, collectively CCPA, imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for statutory fines for noncompliance. While the CCPA contains limited exceptions for clinical trial data, the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. In addition, the CPRA establishes a California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of an enforcement action, and applies to personal data of business representatives and employees. Other states have also enacted data privacy and security laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act, both of which differ from the CPRA and became effective in 2023. If we become subject to new data privacy and security laws, at the state level or otherwise, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and we are, and may become in the future, subject to such obligations. We are also be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We may publish privacy policies, marketing materials, white papers, and other statements, such as statements relating to compliance with certain certifications or self-regulatory principles concerning data privacy and security. Regulators in the United States are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that, in the future, we may fail or be perceived to have failed to comply with applicable data privacy and security obligations. Moreover, despite our best compliance efforts, we may not be successful in achieving compliance if our personnel or third parties with whom we work fail to comply with such obligations, which could negatively impact our business operations and compliance posture. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions; litigation; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including: interruptions or stoppages in our business operations including, as relevant, clinical trials; inability to process personal data or to operate in certain jurisdictions; limited ability to continue to develop or commercialize RYTELO; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations. Moreover, clinical trial participants or research subjects about whom we or our vendors obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information.</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock and Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Historically, our stock price has been extremely volatile and your investment may suffer a decline in value.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, our stock price has been extremely volatile. Between January 1, 2014 and December 31, 2024, our stock has traded as high as $6.38 per share and as low as $0.89 per share. Between January 1, 2024 and December 31, 2024, the price has ranged between a high of $5.34 per share and a low of $1.64 per share. The significant market price fluctuations of our common stock have been due to and may in the future be influenced by a variety of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of RYTELO sales in the U.S.;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements regarding regulatory approval or non-approval of RYTELO in any other jurisdictions or indications, or specific label indications for RYTELO; or restrictions, warnings or limitations in its use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements regarding the further research and development of RYTELO, or adverse efficacy or safety results of, further delays in the commencement, enrollment or conduct of, discontinuation of, or further modifications or refinements to any current or potential future clinical trials, for any reason, or our inability, for any reason, to successfully continue the development of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain additional capital if and when needed to further advance our development program;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations applicable to RYTELO, including laws or regulations concerning the commercialization of RYTELO or clinical trial requirements for approval or other regulatory developments related to RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of technological innovations, new commercial products, or clinical progress or lack thereof by us, potential future collaborative partners or our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse developments concerning our manufacturers, including our inability to obtain adequate product supply for RYTELO or inability to do so at acceptable prices;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth of the market opportunity for RYTELO in its currently approved and any potential future approved indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disputes or other developments relating to RYTELO proprietary rights, including patents, litigation matters and our ability to obtain, enforce and defend patent protection and maintain regulatory exclusivity for RYTELO and our technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms and timing of any future collaboration agreements for the further development and commercialization of RYTELO that we may establish;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, collaborations, joint ventures or capital commitments by us or our competitors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the demand in the market for our common stock;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased or continuing operating losses;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general domestic and international market conditions or market conditions relating to the biopharmaceutical and pharmaceutical industries, especially given the volatility caused by macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">perceptions of the biotechnology and pharmaceutical industry by the public, legislature, regulators and the investment community;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of commentary, articles or research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage, by securities analysts, bloggers, news media or other third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">large stockholders increasing or exiting their position in our common stock or an increase in the short interest in our common stock;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of stock by our officers and directors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements of or developments concerning any litigation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions instituted by activist shareholders or others;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of common stock to partners, vendors or investors to raise additional capital or as a result of option or warrant exercises; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other events or factors that are beyond our control; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the occurrence of any other risks and uncertainties discussed under the heading &#8220;Risk Factors.&#8221;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our charter, bylaws and Delaware law may inhibit potential acquisition bids for us, which may adversely affect the market price of our common stock and/or prevent holders of our common stock from benefiting from what they believe may be the positive aspects of acquisitions and takeovers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of our charter documents and bylaws may make it substantially more difficult for a third party to acquire control of us and may prevent changes in our management, including provisions that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prevent stockholders from taking actions by written consent;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">divide the board of directors into separate classes with terms of office that are structured to prevent all of the directors from being elected in any one year; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">set forth procedures for nominating directors and submitting proposals for consideration at stockholders&#8217; meetings.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, our certificate of incorporation provides our board of directors with the authority to issue up to 3,000,000 shares of undesignated preferred stock and to determine or alter the rights, preferences, privileges and restrictions granted to or imported upon these shares without further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction without further action by our stockholders. As a result, the market price of our common stock may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If in the future, we issue preferred stock that has preference over our common stock with respect to the payment of dividends or upon our liquidation, dissolution or winding up, or if we issue preferred stock with voting rights that dilute the voting power of our common stock, the rights of holders of our common stock or the market price of our common stock could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of Delaware law may also inhibit potential acquisition bids for us or prevent us from engaging in business combinations. In addition, we have individual severance agreements with our executive officers and a company-wide severance plan, either of which could require a potential acquirer to pay a higher price. Either collectively or individually, these provisions may prevent holders of our common stock from benefiting from what they may believe are the positive aspects of acquisitions and takeovers, including the potential realization of a higher rate of return on their investment from these types of transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The exclusive forum provisions in our amended and restated bylaws could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or any of our directors, officers, or employees, or the underwriters of any offering giving rise to such claim, which may discourage lawsuits with respect to such claims.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any derivative claim or cause of action or proceeding brought on our behalf;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees, or our stockholders, to us or to our stockholders;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, arising pursuant to any provision of the General Corporation Law of the State of Delaware, our certificate of incorporation, or our bylaws;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any claim or cause of action against us or any of our current or former directors, officers or other employees, or our stockholders, governed by the internal affairs doctrine or otherwise related to our internal affairs.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act of 1933, as amended, or the Securities Act, or the rules and regulations thereunder. Our amended and restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or the Federal Forum Provision, including for all causes of action asserted against any defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. The application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court, and our stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions, and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such an instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions, which costs could be borne by stockholders, and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to the exclusive forum provisions in our amended and restated bylaws, including the Federal Forum Provision. These provisions could limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, or our stockholders or the underwriters of any offering giving rise to such claims, which may discourage lawsuits with respect to such claims. Furthermore, if a court were to find the exclusive forum provisions contained in our bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material and adverse impact on our business and our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not intend to pay cash dividends on our common stock in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend upon our financial condition, results of operations, capital requirements and other factors, and will be at the discretion of our board of directors. In addition, the terms of our Pharmakon Loan Agreement restrict our ability to pay dividends and any future debt agreements may continue to or further restrict our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, independent contractors, principal investigators, clinical trial sites, contract research organizations, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees, independent contractors, principal investigators, clinical trial sites, CROs, consultants or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the FDA&#8217;s or similar international regulatory authorities&#8217; regulations, including those laws requiring the reporting of true, complete and accurate information; manufacturing standards; healthcare fraud and abuse laws and regulations; or laws that require the true, complete and accurate reporting of financial information or data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our non-clinical studies or clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could adversely affect our business, financial condition, results of operations or prospects through:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the imposition of civil, criminal and administrative penalties, damages and monetary fines;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contractual damages;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reputational harm;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">diminished potential profits and future earnings; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">curtailment of our operations.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business could be negatively impacted by environmental, social and corporate governance, or ESG, matters or our reporting of such matters.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is an increasing focus from certain investors, employees, partners, and other stakeholders concerning ESG matters. We may be, or be perceived to be, not acting responsibly in connection with these matters, which could negatively impact us. Moreover, the SEC has proposed, and may continue to propose, certain mandated ESG reporting requirements, such as the SEC&#8217;s final rules designed to enhance and standardize climate-related disclosures, which, if such climate-related disclosure rules ultimately go into effect, would significantly increase our compliance and reporting costs and may also result in disclosures that certain investors or other stakeholders deem to impact our reputation negatively and/or that harm our stock price. We currently do not report our environmental emissions and absent a legal requirement to do so we currently do not plan to report our environmental emissions, and lack of reporting could result in certain investors declining to invest in our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, the criteria by which our ESG practices, including our initiatives and public goals, are assessed may change due to the evolution of the sustainability landscape, which could result in greater expectations of us and may cause us to undertake costly initiatives to satisfy new criteria. If we are unable to respond effectively to these changes to the sustainability landscape, governments, customers, and investors may conclude that our policies and/or actions with respect to ESG matters are inadequate. If we fail or are perceived to have failed to achieve previously announced public goals or to accurately disclose our progress on such goals or initiatives, our reputation, business, financial condition and results of operations could be adversely impacted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, requires that we establish and maintain an adequate internal control structure and procedures for financial reporting. Our Annual Reports on Form 10-K must contain an annual assessment by management of the effectiveness of our internal control over financial reporting and must include disclosure of any material weaknesses in internal control over financial reporting that we have identified. In addition, our independent registered public accounting firm must provide an opinion annually on the effectiveness of our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The requirements of Section 404 are ongoing and also apply to future years. We expect that our internal control over financial reporting will continue to evolve as our business develops, including in connection with our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commercialization of RYTELO. Although we are committed to continue to improve our internal control processes and we will continue to diligently and vigorously review our internal control over financial reporting in order to ensure compliance with Section 404 requirements, any control system, regardless of how well designed, operated and evaluated, can provide only reasonable, not absolute, assurance that its objectives will be met. Moreover, in 2024 we implemented a new ERP and other information systems to help us manage our operations and financial reporting. However, there is an increased risk that changing controls may be ineffective in connection with the implementation of the new ERP and this ERP system may place additional burdens on employees to learn and adapt our processes to effectively operate under the ERP system. If the ERP system that we implemented in 2024 does not operate as intended, the effectiveness of our internal control over financial reporting could be negatively impacted. Therefore, we cannot assure you that material weaknesses or significant deficiencies will not exist or otherwise be discovered in the future, particularly in light of our increased reliance on personnel working remotely. If material weaknesses or other significant deficiencies occur, such weaknesses or deficiencies could result in misstatements of our results of operations, restatements of our financial statements, a decline in our stock price, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use, excise or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of our domestic and foreign sales and earnings. Any new taxes could adversely affect our domestic and international business operations and our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. Future guidance from the U.S. Internal Revenue Service and other tax authorities with respect to such legislation may adversely affect us, and certain aspects of such legislation could be repealed or modified in the future, which could have an adverse effect on us. For example, the Inflation Reduction Act of 2022 included provisions that impacted the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that is imposed on the corporation repurchasing such stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of earnings from other countries, and the deductibility of expenses or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. For example, under the Tax Cuts and Jobs Act of 2017, effective January 1, 2022, research and experimental expenses must be capitalized for tax purposes and amortized over five years for research activities conducted in the United States and over fifteen years for research activities conducted outside the United States, instead of being deducted in the year incurred. Unless this provision is modified or repealed by Congress, or the U.S. Department of the Treasury issues regulations narrowing its application, our future tax obligations could be increased, which could harm our operating results. The impact of this provision will depend on multiple factors, including the amount of research and experimental expenses we incur, whether we achieve sufficient income to fully utilize such deductions and whether we conduct our research and experimental activities inside or outside the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net operating loss carryforwards attributable to tax years beginning before January 1, 2018 could expire unused and be unavailable to offset future income tax liabilities. In addition, under current U.S. federal income tax law, federal net operating losses incurred in taxable years beginning after December 31, 2017, can be carried forward indefinitely, but the deductibility of such federal net operating losses in a taxable year is limited to 80% of taxable income in such year. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point cumulative change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change taxable income or taxes may be limited. Changes in our stock ownership  have occurred in the past, and future ownership changes, some of which may be outside our control, could occur in the future, as a result of shifts in our stock ownership. If a limitation were to apply, utilization of a portion of our domestic net operating loss and tax credit carryforwards could be limited in future periods, and a portion of the carryforwards may expire before being available to reduce future income tax liabilities, which could adversely impact our financial position. At the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, in June 2024, California enacted legislation that, with certain exceptions, suspends the use of California net operating losses to offset California income and limits the use of California business tax credits to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">offset California taxes, for taxable years beginning after 2023 and before 2027. It is also uncertain if and to what extent various states will conform to current U.S. federal income tax law.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1B. UNRESOLVE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D STAFF COMMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_9d4db841-4040-49af-8130-b75213b7c7ed" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_9d4db841-4040-49af-8130-b75213b7c7ed_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in the biopharmaceutical sector, which is a highly regulated sector subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; disruption of our clinical trials, manufacturing or supply chain; violation of privacy laws and other litigation and legal risk; and reputational risk. We rely primarily on industry-leading third parties and a cloud-based infrastructure for our information technology systems, and accordingly are dependent on these third parties&#8217; own cybersecurity risk management practices and strategy. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including clinical trial data, intellectual property, confidential information that is proprietary, strategic, financial or competitive in nature, and personal data (&#8220;Information Systems and Data&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9365d51-f92d-462d-a65a-e9d7fd331738" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We take a risk-based approach to identify and assess the cybersecurity threats and risks that could affect our business and Information Systems and Data.  Our Information Technology personnel help identify, assess and manage our cybersecurity threats and risks, and support our efforts to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use various methods and tools to identify, assess and manage cybersecurity threats and risks, including, for example, automated tools, industry reports, third party threat assessments and penetration testing. In addition, we encrypt data at rest and maintain network security controls, such as firewalls and virtual private networks. We also conduct computerized system monitoring and access control, including asset management, tracking and disposal associated with onboarding and offboarding of personnel. We maintain cybersecurity insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90bdaef6-ceec-4029-8744-390a20f65019" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. For example, we have implemented and maintain an incident response plan, and we utilize automated tools designed to maintain email security. We have also implemented a computerized system security and password policy that defines security for access to computer systems managed and controlled by us, and a procedure for computerized system incident management to address any unplanned issues in regulated computerized systems that could impact subject safety, product quality, and data integrity. We periodically conduct cybersecurity incident tabletop training exercises involving our personnel and plan to conduct similar training in 2025.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0246080b-20b7-4edb-8206-ae894cec5ae2" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9fb0844-88b1-449c-ad94-e91dcaa4a750" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management processes.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eaee845d-97b4-4832-8a26-c62d1f8aed4e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, our head of Information Technology evaluates material risks from cybersecurity threats and reports periodically to the Audit Committee of our Board, which evaluates our overall enterprise risk. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, cybersecurity software providers such as Crowdstrike, cybersecurity service providers such as Mimecast, penetration testing firms, auditors, and professional services firms, including legal counsel. These relationships enable us to leverage specialized knowledge and insights, enabling our cybersecurity strategies and processes to remain consistent with industry best practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party service providers to perform a variety of functions throughout our business, such as contract manufacturing organizations, contract research organizations, suppliers and consultants, and third party logistics organizations and distributors to distribute RYTELO. We conduct quality audits of regulated vendors, which typically include an assessment of such vendor&#8217;s information technology systems, and we impose appropriate contractual obligations on vendors pertaining to information security. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our efforts may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9d4db841-4040-49af-8130-b75213b7c7ed_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b1c2ed4-86f8-431c-9b0b-b9a08941c47d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2abeb59a-11a9-4d53-9a85-b262a95612bb" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity threats that may materially affect us </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Report, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Information Technology Systems, Data Security and Data Privacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9d60646-4433-4ac2-a640-6088b0475c9f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be3bb9df-7855-44d7-88e4-2d91afd5cb40" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_234925f5-d938-4907-96c3-8700f5a65e39" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9da2177-def8-4aa4-a687-7dc441e57773" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc874063-203b-421b-ab90-3c115a2c5bdd" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2729f3c0-08e3-4ecc-93fc-ee69873ccf5c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33dd99d3-c213-4a5e-844a-0a84e199b3ae" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to hire information technology personnel with skills appropriate to help us prepare for cybersecurity incidents, approve cybersecurity processes, and review security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including executive management. When appropriate given the nature of any potential cybersecurity incident, our executive management works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, and to make any legally required notifications to individuals or regulatory agencies, including making any required disclosures under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 2. P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ROPERTIES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is 11 years with an option to extend for an additional five years and a one-time option to terminate the New Jersey Lease without cause as of the 103</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month anniversary of the commencement date of the lease. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is 87 months with an option to extend for an additional five years. The Foster City Lease commenced on March 10, 2020, upon our control of the office space on that date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 3. LEGAL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> PROCEEDINGS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may be involved in legal proceedings relating to claims arising out of our operations. We are not currently involved in any material legal proceedings, and our management believes there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our operations, financial condition, or cash flows. We may, however, be involved in material legal proceedings in the future. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 4. MINE SAF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ETY DISCLOSURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> II</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market under the symbol GERN. As of February 21, 2025, there were approximately 439 stockholders of record of our common stock. This number does not include &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following graph shows a comparison from December 31, 2019 through December 31, 2024, of the cumulative total return on an assumed investment of $100.00 in our common stock as compared to the same investment in the Nasdaq Composite Index and the Nasdaq Biotechnology Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the Nasdaq Composite Index and Nasdaq Biotechnology Index assume reinvestment of dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img44536338_2.jpg" alt="img44536338_2.jpg" style="width:607px;height:290px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any filing of Geron Corporation under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such filing.</span></p>
  <p style="text-indent:5.2%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never paid cash dividends on our capital stock and do not anticipate paying cash dividends in the foreseeable future, but intend to retain our capital resources for reinvestment in our business. In addition, the terms of our Pharmakon Loan Agreement restrict our ability to pay dividends and any future debt agreements may continue to or further restrict our ability to pay dividends. Any future determination to pay cash dividends will be at the discretion of the board of directors and will be dependent upon our financial condition, results of operations, capital requirements, compliance with the terms of our Pharmakon Loan Agreement or other future debt agreements, and other factors our board of directors deems relevant.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, there were no unregistered sales of equity securities by us.</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 6. [RESERVED]</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-9.091%;padding-left:8.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion should be read in conjunction with the section entitled &#8220;Business&#8221; in Part I, Item 1 and the audited financial statements and notes thereto included in Part II, Item 8 of this Report. The information provided should be reviewed in the context of the sections entitled  &#8220;Risks Related to the Further Development of RYTELO (Imetelstat),&#8221; &#8220;Risks Related to the Commercialization of RYTELO&#8221; and &#8220;Risks Related to Regulatory Approval of RYTELO&#8221; in Part II, Item 1A entitled &#8220;Risk Factors&#8221; and elsewhere in this Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor, RYTELO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imetelstat), harnesses Nobel Prize winning science in a treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the disease of these hematologic malignancies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We commercially launched RYTELO in the U.S. in June 2024 following its approval by the U.S. Food and Drug Administration, or FDA on June 6, 2024 for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, with transfusion-dependent, or TD, anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents, or ESAs. Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life. We believe that the uptake of RYTELO since launch is supported by the high unmet need in lower-risk MDS and significant product differentiation, including observed benefit of RYTELO in difficult-to-treat sub-populations such as patients with high transfusion burden and ring sideroblast negative, or RS- patients. We believe that the favorable FDA label and the National Comprehensive Cancer Network, or NCCN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Clinical Practice Guidelines in Oncology, or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NCCN Guidelines</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, position RYTELO as a potential blockbuster treatment that can compete for significant market segments in lower-risk MDS, including first-line ESA ineligible patients and second-line patients regardless of prior treatment or RS status.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we submitted a marketing authorization application, or MAA, in the European Union, or EU, that was validated for review by the European Medicines Agency, or EMA, for RYTELO for the same proposed indication as in the U.S., and in December 2024, the Committee for Medicinal Products for Human Use, or CHMP, of the EMA adopted a positive opinion recommending the approval of RYTELO for the treatment of adult patients with TD anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic, or non-del 5q, abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. The European Commission, or EC, is reviewing the CHMP's recommendation, and we expect a potential approval decision by the EC in the first half of 2025. We are preparing for the potential commercialization of RYTELO in select EU countries in 2026, subject to regulatory approval, which could include working with experienced third parties who can provide contracted services, including essential critical path activities such as reimbursement, Health Technology Assessment, or HTA, submissions, market access and distribution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to lower-risk MDS, we are developing imetelstat for the treatment of other myeloid hematologic malignancies. Our Phase 3 IMpactMF clinical trial is evaluating imetelstat in patients with intermediate-2 or high-risk myelofibrosis, or MF, who have relapsed after or are refractory to treatment with a janus associate kinase inhibitor, or JAK inhibitor, or relapsed/refractory MF, or R/R MF, with overall survival, or OS, as the primary endpoint. As of February 2025, the trial reached approximately 80% enrollment. Based on our current planning assumptions for enrollment and event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that telomerase inhibition with imetelstat represents a novel mechanism of action with unique benefits in hematologic malignancies and potentially in other tumor types.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have financed our operations primarily through the sale of equity securities, draw downs on our debt facilities, interest income on our marketable securities and payments we received under the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Pharma Agreement and our prior collaborative and licensing arrangements. As of  December 31, 2024, we had approximately $502.9 million in cash, cash equivalents, restricted cash and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, we completed an underwritten offering of 41,999,998 shares of our common stock and a pre-funded warrant to purchase 8,002,668 shares of our common stock, or the 2024 pre-funded warrant. All of the securities were issued separately. The offering price of the common stock was $3.00 per share. The offering price of the 2024 pre-funded warrant was $2.99 per share. The 2024 pre-funded warrant has an exercise price of $0.001 per share and may be exercised at any time until it is exercised in full. As of  December 31, 2024, the 2024 pre-funded warrant had not been exercised. The net cash proceeds from the March 2024 public offering were approximately $141.0 million, after deducting the underwriting discount and other offering expenses paid by us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We</span><span style="color:#008080;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">began commercializing RYTELO in June 2024, and the commercial potential of and our ability to successfully commercialize RYTELO is unproven. Our success in commercializing RYTELO will require, among other things, effective sales, marketing, manufacturing, distribution, information systems and pricing strategies, as well as compliance with applicable laws and regulations. In addition, although we recently began commercializing RYTELO, substantially all of our revenues to date have been payments under prior collaboration agreements, and milestones, royalties and other revenues from our licensing arrangements. We reported a small profit for the year ended December 31, 2015, and we have not reported any profit since. We have incurred significant net losses since our inception in 1990, resulting principally from costs incurred in connection with our research and development activities and from general and administrative costs associated with our operations. As of December 31, 2024, we had an accumulated deficit of approximately $1.8 billion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a 5-year senior secured term loan facility of up to $250.0 million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $125.0 million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $75.0 million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $50.0 million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, may be requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed ($86.5 million) under the Hercules Loan Agreement, which was terminated effective November 1, 2024. The Term Loans mature on November 1, 2029. The Term Loans bear interest at a variable rate per annum equal to 5.75% plus the three-month Secured Overnight Financing Rate, or SOFR, with a SOFR floor of 3.00%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received an upfront payment of $125.0 million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right to receive tiered royalty payments with respect to annual U.S. net sales, or Annual Net Sales, of RYTELO beginning on July 1, 2024, ranging from: (i) 7.75% of Annual Net Sales up to $500.0 million; (ii) 3.0% of Annual Net Sales in excess of $500.0 million but less than or equal to $1.0 billion; and (iii) 1.0% in respect of Annual Net Sales in excess of $1.0 billion, or the Royalty Payments. The Royalty Payments to Royalty Pharma are capped, such that they will cease upon reaching a multiple of 1.65 times the Purchase Price if Royalty Pharma receives Royalty Payments in that amount in respect of net sales occurring on or before June 30, 2031, or upon reaching a multiple of 2.0 times the Purchase Price thereafter. Our Royalty Payment obligations under the Royalty Pharma Agreement may be discharged in connection with a change of control of Geron in an amount equal to 1.65 times the Purchase Price minus the aggregate Royalty Payments received by Royalty Pharma as of the date of the closing of the change of control, if the closing of the change of control occurs on or prior to December 31, 2027, or in an amount equal to 2.0 times the Purchase Price minus the aggregate Royalty Payments received by Royalty Pharma as of the date of the closing of the change of control, if the closing of the change of control occurs after December 31, 2027. There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The significance of future losses, future revenues and any potential future profitability will depend primarily on the clinical and commercial success of RYTELO, our sole product. In addition, we are developing RYTELO for the treatment of several myeloid hematologic malignancies that will continue to require additional time and significant investment in clinical trials to complete. We also expect to continue to seek regulatory approvals of RYTELO in jurisdictions outside of the United States, such as our MAA submission for RYTELO in the EU. As a result, we expect research and development expenses and selling, general and administrative expenses to increase in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future periods as we continue to support the commercialization of RYTELO in the U.S. and further development of RYTELO, including the conduct and completion of IMpactMF, IMproveMF and IMpress, as well as the potential commercialization of RYTELO in the EU, if approved, in lower-risk MDS. In addition, we expect our interest expense to increase due to the draw down of the Tranche A Loan and potential future draw downs of the other Term Loans under the Pharmakon Loan Agreement, if available, as well as the non-cash interest expense related to the Royalty Pharma Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operations and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. While Note 1 of Notes to Consolidated Financial Statements of this Report describes the significant accounting policies used in the preparation of our consolidated financial statements, we believe the following accounting estimates and policies to be critical.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial Accruals</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current imetelstat clinical trials are being supported by CROs and other vendors. Invoicing from CROs for services rendered can be delayed. We accrue the cost of services rendered in connection with CRO activities, which include, management, monitoring costs, project management costs, and investigator fees. We accrue expenses for clinical trial activities performed by CROs based upon the amount of work completed on each trial. We maintain regular communications with our CROs to assess the reasonableness of our accrual. To date, differences between actual clinical trial expenses and accrued clinical trial expenses recorded have not been material and are adjusted for in the period in which they become known. However, if we incorrectly accrue activity levels associated with the CRO services at a given point in time, we could be required to record material adjustments in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Sales, Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Items Deducted from Gross Product Sales</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. The most significant items deducted from gross product sales where we exercise judgment are rebates, sales returns and chargebacks. Actual results may differ from these estimates under different assumptions and conditions. We estimate these potential price adjustments (chargebacks and co-payment assistance) as a reduction (i.e., constraint) to transaction price and recognize a corresponding reserve liability. Variable consideration will be re-evaluated at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">least on a quarterly basis, and we will continue to re-evaluate variable consideration on an ongoing basis. The amount of variable consideration can vary from period to period because of fluctuations in discounts, rebates, refunds, credits, price concessions, incentives, performance bonuses, penalties, or other similar items. </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability related to the Royalty Payments under the Royalty Pharma Agreement and the related revenue interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assess the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#8217;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations have fluctuated from period to period and may continue to fluctuate in the future. Results of operations for any period may be unrelated to results of operations for any other period. Thus, historical results should not be viewed as indicative of future operating results. In this regard, although we have begun to recognize revenue from RYTELO product sales in the U.S., we are early in the product launch. We expect that our sales revenue may vary significantly from period to period as the launch progresses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO is our only product approved for marketing  and is approved solely in the U.S. for certain patients with lower-risk MDS. Revenue based on sales of RYTELO is dependent on our ability to successfully commercialize  RYTELO in the U.S. and to obtain regulatory approvals to commercialize RYTELO in other jurisdictions and in other indications. We are subject to risks common to companies in our industry and at our stage of development, including, but not limited to, risks inherent in research and development efforts, including the development, manufacture, regulatory approval for and commercialization of RYTELO; uncertainty of non-clinical and clinical trial results or regulatory approvals or clearances; the future development of imetelstat by us and its use by patients generally, including any future efficacy or safety results from clinical or commercial use that may cause the benefit-risk profile of imetelstat to become unacceptable; the uncertain and unpredictable drug research and discovery process; overcoming disruptions and/or delays due to macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues; our need for substantial additional capital; enforcement of our patent and proprietary rights; reliance upon our CROs, contract manufacturing organizations, or CMOs, consultants, licensees, investigators and other third parties; and potential competition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the Years Ended December 31, 2024, 2023, and 2022</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth our results of operations for the years ended December 31:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:28.531%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.083%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:8.083%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.16%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.763%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.103%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.061999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.06%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.763%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.103%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change $</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change %</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change $</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change %</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="26" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands, except for percentage data)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenues, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,495</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,495</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">499</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">262</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(359</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,994</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,757</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(359</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,256</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,256</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,738</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,046</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,308</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,518</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,528</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and<br/>&#160;&#160;&#160;administrative expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,732</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,135</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,597</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,628</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,507</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,726</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,181</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,545</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,146</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,035</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,607</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,152</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,455</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,529</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,623</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">618</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,504</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,312</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,192</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,882</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,430</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income and (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(236</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(213</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,002</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,025</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(102</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,707</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,707</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(174,572</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(184,127</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,555</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(141,901</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42,226</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Not meaningful</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Revenues, net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On June 6, 2024, the FDA approved RYTELO for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, with transfusion-dependent, or TD, anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents, or ESA. To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. We did not generate any revenue from product sales prior to June 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total product revenue, net for the twelve months ended December 31, 2024 was approximately $76.5 million. We expect product revenues, net to increase in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. Total gross-to-net adjustments for the twelve months ended December 31, 2024 was 14.4% of gross product revenue. The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as set forth below for the twelve months ended December 31, 2024. We expect gross-to-net adjustments to be in the range of mid- to high-teen percentages of gross product revenue in 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:71.434%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:26.564999999999998%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross product revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,418</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross-to-net adjustments:</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chargebacks and distributor service fees</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,772</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government rebates</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(926</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales returns and allowances</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(225</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross-to-net adjustments</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,923</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net product revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,495</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.), or Lineage, in 2013, we are entitled to receive royalties on sales from certain research or commercial products utilizing our divested intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized royalty revenues of $499,000, $237,000 and $596,000 during the years ended December 31, 2024, 2023 and 2022, respectively. Royalty revenues reflect estimated royalties from sales of cell-based research products from our divested stem cell assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future license fee and royalty revenues are dependent on additional agreements being signed, if any, our current license agreement with Lineage being maintained, and the underlying patent rights for the license remaining active. We expect royalty revenues in 2025 to be lower than 2024 as a result of reduced royalties from sales of cell-based research products from our divested stem cell assets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our operating expenses, including as a percentage of expenses, for the years ended December 31:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.705%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.461%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.461%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.021000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.941000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.461%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.922000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.920999999999999%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change $</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change %</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change $</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change %</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="20" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Cost of goods sold</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,256</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,256</span></p></td>
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">**</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,738</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,046</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,308</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,518</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,528</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Selling, general and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,732</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,135</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,597</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,628</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,507</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total operating cost and expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,726</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,181</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,545</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,146</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,035</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Not meaningful</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold was approximately $1.3 million for the year ended December 31, 2024, respectively, which consisted of costs to manufacture and distribute our marketed product, RYTELO. We began capitalizing inventory upon FDA approval of RYTELO. All product costs incurred prior to FDA approval of RYTELO in June 2024 were expensed as research and development expenses. As a result, the manufacturing costs related to the inventory  manufactured prior to receiving FDA approval were expensed in a prior period and are therefore excluded from the cost of goods sold for the year ended December 31, 2024. We estimate our cost of sales related to product revenue as a percentage of net product revenue will continue to be positively affected for the next 18 to 24 months as we sell through certain inventory that was previously expensed prior to FDA approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cost of goods sold consist of raw materials, third-party manufacturing costs to manufacture the raw materials into finished product, freight, and indirect overhead costs associated with the sale of RYTELO in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, our RYTELO (imetelstat) program and our research discovery program related to potential next generation telomerase inhibitors were the only research and development programs we supported. For these research and development programs, we incur direct external, personnel-related and other research and development costs. For the years ended December 31, 2024, 2023 and 2022, research and development expenses consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial supply, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the years ended December 31, 2024, 2023 and 2022 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.44%;box-sizing:content-box;"/>
    <td style="width:1.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.92%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.92%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.92%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Direct external research and development expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Clinical program: Imetelstat</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,424</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,914</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,699</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel related expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,411</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,595</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,042</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All other research and development expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,903</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,537</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,777</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,738</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,046</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,518</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease in research and development expenses in 2024 as compared to 2023, was primarily due to manufacturing and quality costs that were capitalized in the current period, beginning with the third quarter of 2024, due to FDA approval of RYTELO in June 2024, versus being expensed in 2023. The decrease is partially offset by an increase in labor costs due to higher headcount and incentive and stock-based compensation expense recognized due to the vesting of performance-based stock options upon FDA approval. We expect research and development expenses to increase in the future as we support IMpactMF, IMproveMF and IMpress, and continue the long-term treatment and follow-up of remaining patients in IMerge Phase 3.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in research and development expenses in 2023 as compared to 2022 primarily reflects the net result of increased personnel-related expenses for additional headcount and higher consulting costs related to compilation and analysis of data for top-line results and preparations for regulatory submissions in lower-risk MDS, partially offset by decreased manufacturing costs due to the timing of imetelstat manufacturing batches and reduced clinical trial expenses due to declining number of patients in IMerge Phase 3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A discussion of the risks and uncertainties associated with the development of imetelstat can be found in the sub&#8209;sections entitled &#8220;Risks Related to the Further Development of RYTELO (Imetelstat),&#8221; &#8220;Risks Related to the Commercialization of RYTELO&#8221; and &#8220;Risks Related to Regulatory Approval of RYTELO&#8221; in Part II, Item 1A entitled &#8220;Risk Factors&#8221; and elsewhere in this Report. As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of ongoing and potential future imetelstat research and development projects, anticipated completion dates, or when and to what extent we will receive cash inflows from the commercialization and sale of RYTELO in any other jurisdictions or indications we are pursuing or may in the future pursue, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses were $145.7 million, $69.1 million, and $43.6 million for the years ended December 31, 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in selling, general and administrative expenses in 2024 as compared to 2023 primarily reflects the net result of higher personnel-related expenses of approximately $40.0 million related to increased headcount to support commercial launch of RYTELO in the U.S. and stock-based compensation recognized upon FDA approval of RYTELO due to the vesting of performance-based stock options, as well as increased costs for commercial preparatory activities and launch support of approximately $33.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in selling, general and administrative expenses in 2023 as compared to 2022 primarily reflects the net result of higher personnel-related expenses of approximately $19.0 million for additional headcount and expenses related to commercial launch readiness, as well as increased costs for commercial preparatory activities of approximately $9.7 million; partially offset by lower legal expenses in 2023 primarily related to $7.0 million that was recorded in the third quarter of 2022 for our portion of the settlement in connection with a class action lawsuit. We expect selling, general and administrative expenses to increase in 2025 as our commercialization activities continue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Income</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest income was $19.6 million, $18.2 million, and $2.5 million for the years ended December 31, 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in interest income in 2024 compared to 2023 primarily reflects a larger marketable securities portfolio due to the receipt of net cash proceeds from the underwritten offering completed in March 2024, as well as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">higher yields from marketable securities purchases. Interest earned in future periods will depend on the size of our marketable securities portfolio and prevailing interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in interest income in 2023 compared to 2022 primarily reflects a larger marketable securities portfolio, with the receipt of net cash proceeds from the underwritten public offering completed in January 2023 and cash proceeds from warrant exercises in 2023, as well as higher yields from marketable securities purchases. Interest earned in future periods will depend on the size of our marketable securities portfolio and prevailing interest rates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense was $18.5 million, $8.3 million, and $6.9 million for the years ended December 31, 2024, 2023 and 2022, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in interest expense in 2024 as compared to 2023 primarily reflects $5.3 million in non-cash interest expense related to the Royalty Pharma Agreement, $2.3 million in Pharmakon Loan Agreement and $2.6 million increase related to the Hercules agreement in comparison to the prior year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase in interest expense in 2023 compared to 2022 primarily reflects rising interest rates and an increased principal debt balance under the Pharmakon Loan and the Royalty Pharma agreements. Interest expense reflects interest owed under the Loan Agreement, interest expense recognized under the Royalty Pharma Agreement, as well as amortization of associated debt issuance costs and debt discounts using the effective interest method and accrual for an end of term charge.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into the Pharmakon Loan Agreement, and in connection with this transaction, all obligations outstanding under the Hercules Loan Agreement were repaid in full on November 1, 2024, upon which the Hercules Loan Agreement was terminated. We expect our interest expense to increase in future periods due to the draw down of the Tranche A Loan and potential future draw downs of the other Term Loans under the Pharmakon Loan Agreement. See Note 9 on Debt in Notes to Consolidated Financial Statements of this Report for additional information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the Royalty Pharma Agreement as a liability financing, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related non-cash interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assess the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#8217;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. See Note 9 on Debt </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in Notes to Consolidated Financial Statements of this Report for additional information</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other (Loss) Income, Net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other (loss) income, net was a loss of $236,000 for the year ended December 31, 2024, and loss of $23,000 and income of $1.0 million for the years ended December 31, 2023 and 2022, respectively. Net other (loss) income and expense primarily reflects bank charges related to our cash operating accounts and marketable securities portfolio, foreign currency transaction adjustments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the second quarter of 2022, we recognized other income of approximately $1.3 million related to the reimbursement of certain legal expenses under our insurance policies. See Note 4 on Fair Value Measurements &#8211; Equity Investment in Notes to Consolidated Financial Statements of this Report for additional information about the sales of our equity investment. Net other income also includes bank charges related to our cash operating accounts and marketable securities portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gain (Loss) on extinguishment of debt</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded a loss on the extinguishment of debt of $1.7 million for the twelve months ended December 31, 2024. This loss is related to the settlement of debt outstanding under the Hercules Loan Agreement. See Note 9 on Debt in Notes to Consolidated Financial Statements of this Report for additional information.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash, restricted cash, cash equivalents and marketable securities of $502.9 million, compared to $378.1 million at December 31, 2023. The increase in cash, restricted cash, cash equivalents, and current and noncurrent marketable securities from  December 31, 2024 was primarily the result of the receipt of net cash proceeds of $141.0 million from our underwritten public offering in March 2024, after deducting the underwriting discount and other offering expenses paid by us, and $246.1 million net cash proceeds received under the Pharmakon Loan Agreement and Royalty Pharma Agreement in November 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, we completed an underwritten public offering consisting of 41,999,998 shares of our common stock and a pre-funded warrant to purchase 8,002,668 shares of our common stock. All of the securities were issued separately. The offering price of the common stock was $3.00 per share. The offering price of the 2024 pre-funded warrant was $2.99 per share. The 2024 pre-funded warrant has an exercise price of $0.001 per share and may be exercised at any time until it is exercised in full. As of  December 31, 2024, the 2024 pre-funded warrant had not been exercised. The net cash proceeds from this offering were approximately $141.0 million, after deducting the underwriting discount and other offering expenses paid by us, and excluding any future proceeds from the exercise of the 2024 pre-funded warrant. See Note 10 on Stockholders&#8217; Equity in Notes to Condensed Consolidated Financial Statements of this Report for additional information about the underwritten offering completed in March 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into the Pharmakon Loan Agreement. We drew the Tranche A Loan of $125.0 million on November 1, 2024, a portion of which was utilized to repay all outstanding indebtedness associated with the Hercules Loan Agreement. The Pharmakon Loan Agreement provides two additional committed term loan tranches, the Tranche B Loan and the Tranche C Loan, in principal amounts of $75.0 million and $50.0 million, respectively, subject to customary conditions to fund and, in the case of the Tranche C Loan, achieving certain minimum net sales milestone. The Tranche B Loan and the Tranche C Loan may be requested on or prior to December 31, 2025. The Term Loans mature on November 1, 2029. The Term Loans bear interest at a variable rate per annum equal to 5.75% plus three-month SOFR with a SOFR floor of 3.00%. See Note 9 on Debt in Notes to Consolidated Financial Statements of this Report for additional information on the Pharmakon Loan Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into the Royalty Pharma Agreement with Royalty Pharma. Pursuant to the Royalty Pharma Agreement, we received $125.0 million, or the Purchase Price, in exchange for which Royalty Pharma obtained the right to receive the Royalty Payments. The Royalty Payments to Royalty Pharma are capped, such that they will cease upon reaching a multiple of 1.65 times the Purchase Price if Royalty Pharma receives Royalty Payments in that amount in respect of net sales occurring on or before June 30, 2031, or upon reaching a multiple of 2.0 times the Purchase Price thereafter. There are no other royalties payable on RYTELO, which was developed internally and is exclusively owned by Geron. See Note 9 on Debt in Notes to Consolidated Financial Statements of this Report for additional information on the Royalty Pharma Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, warrants to purchase 1,071,981 shares of our common stock were exercised for net cash proceeds of approximately $1.4 million. The warrants were issued in connection with underwritten public offerings of our common stock in 2020 and 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 10, 2023, we completed an underwritten public offering of 68,007,741 shares of our common stock and a pre-funded warrant to purchase 25,000,000 shares of our common stock, or the 2023 pre-funded warrant. The net cash proceeds from this offering were approximately $213.3 million, after deducting the underwriting discount and other offering expenses paid by us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement, with B. Riley Securities, pursuant to which we may elect to issue and sell shares of our common stock having an aggregate offering price of up to $100.0 million in such quantities and on such minimum price terms as we set from time to time through B. Riley Securities as our sales agent. We have agreed to pay B. Riley Securities an aggregate commission equal to up to 3.0% of the gross proceeds of the sales under the agreement. To date, no sales of common stock have occurred under the 2023 Sales Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an investment policy to invest our cash in liquid, investment-grade securities, such as interest-bearing money market funds, certificates of deposit, U.S. Treasury securities, municipal securities, government and agency securities, corporate notes and commercial paper. Our investment portfolio does not contain securities with exposure to sub-prime mortgages, collateralized debt obligations, asset-backed securities or auction rate securities and, to date, we have not recognized any other-than-temporary impairment charges on our marketable securities or any significant changes in aggregate fair value that would impact our cash resources or liquidity. To date, we have not experienced lack of access to our invested cash and cash equivalents; however, access to our invested cash and cash equivalents may be impacted by adverse conditions in the financial and credit markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may, from time to time, consider additional funding through a combination of new collaborative arrangements, strategic alliances, and additional equity and debt financings or from other sources. We will continue to manage our capital structure and consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. Any such capital transactions may or may not be similar to transactions in which we have engaged in the past. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future Funding Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successful drug development and commercialization requires significant amounts of capital. As of December 31, 2024, we had approximately $502.9 million in cash, cash equivalents, restricted cash and marketable securities. Based on our current operating plans and assumptions, we believe that our existing cash, cash equivalents, and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund our projected operating requirements for the foreseeable future.  However, if we do not generate net revenues from commercial sales of RYTELO at the levels we anticipate, if we experience unforeseen events or choose to make other investments in our business, or our assumptions regarding our projected operating expenses are otherwise incorrect, we may require additional funding, which could include a combination of public or private equity offerings, debt financings (including additional tranches under the Pharmakon Loan Agreement, if available), collaborations, strategic alliances, licensing arrangements or marketing and distribution arrangements, which may not be possible. For example, changes in our operations, such as increased development, manufacturing and clinical trial expenses, or our undertaking of additional programs, business activities, or entry into strategic transactions, including potential future acquisitions of products, technologies or businesses, may cause our operating expenses to increase, perhaps significantly, which could require us to raise additional funding. If adequate funds are not available to us when we need them, our RYTELO commercialization efforts may be adversely affected and we may be unable to pursue further development of imetelstat, which would severely harm our business and we might cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Despite FDA approval of RYTELO in June 2024, the outcome of any clinical activities and/or regulatory approval process is highly uncertain, and we cannot reasonably estimate whether our future development activities may succeed, whether we will obtain regulatory approval for RYTELO in the EU for lower-risk MDS, or in any other jurisdictions or indications we are pursuing or may in the future pursue, or whether we will be able to effectively commercialize RYTELO in the U.S. for lower-risk MDS or in any other potential jurisdiction or indication, if at all. We may never recoup our investment in any RYTELO development, which would adversely affect our financial condition and our business and business prospects, and might cause us to cease operations. In addition, our plans and timing expectations could be further delayed or interrupted by the effects of macroeconomic or other global conditions, including those resulting from inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues. Further, our future capital requirements are difficult to forecast and will depend on many factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accuracy of the assumptions underlying our estimates for our capital needs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of sales and market acceptance of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, progress, timing, magnitude and costs of non-clinical and clinical development, manufacturing and commercialization of RYTELO, including potential commercialization in the EU for lower-risk MDS, if approved, or in any other jurisdictions or other indication we may pursue, subject to clearances and approvals by the FDA and similar international regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or disruptions in opening sites, screening and enrolling patients or treating and following patients, in our current or any potential future clinical trials of RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcomes of regulatory reviews or other regulatory actions related to RYTELO, including with respect to our MAA submission for RYTELO in the EU for lower-risk MDS;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of manufacturing, developing, commercializing and marketing RYTELO, including with respect to third-party vendors and service providers and our ability to achieve any meaningful reduction in manufacturing costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sales price for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate third-party reimbursement for RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we acquire or in-license other drugs and technologies, or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions, or to which we out-license RYTELO;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are able to enter into and conduct successful arrangements with third parties, including for the commercialization and marketing of RYTELO in any regions outside of the U.S., if approved for commercialization in such regions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent and scope of our selling, general and administrative expenses, including expenses associated with potential future litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our level of indebtedness and associated debt service obligations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of maintaining and operating facilities in California and New Jersey, as well as higher expenses for travel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">macroeconomic or other global conditions that may reduce our ability to access equity or debt capital or other financing on preferable terms, which may adversely affect future capital requirements and forecasts; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of enabling our personnel to work remotely, including providing supplies, equipment and technology necessary for them to perform their responsibilities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event we need to raise additional capital to fund our business, including pursuant to the 2023 Sales Agreement with B. Riley Securities, Inc., the Tranche B Loan and the Tranche C Loan under the Pharmakon Loan Agreement, which are subject to certain funding conditions, capital lease transactions or other financing sources, such additional capital may not be available on acceptable terms, or at all. We may be unable to raise equity capital, or may be forced to do so at a stock price or on other terms that could result in substantial dilution of ownership for our stockholders. The receptivity of the public and private debt and equity markets to proposed financings has been substantially affected by uncertainty in the general economic, market and political climate due to the effects of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, and may in the future be affected by other factors which are unpredictable and over which we have no control. These effects have increased market volatility and could result in a significant long-term disruption of global financial markets, which could reduce or eliminate our ability to raise additional funds through financings, and could negatively impact the terms upon which we may raise those funds. Similarly, these macroeconomic conditions have created extreme volatility and disruption in the capital markets and is expected to have further global economic consequences. If the equity and credit markets deteriorate, including as a result of macroeconomic or other global conditions, such as inflation, rising interest rates, prospects of a recession, government shutdowns, further changes in tariffs and other trade restrictions, bank failures and other disruptions to financial systems, civil or political unrest, military conflicts, pandemics or other health crises and supply chain and resource issues, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive. If we are unable to effectively commercialize RYTELO, or raise additional capital, if needed, or establish alternative collaborative arrangements with third-party collaborative partners for RYTELO, when needed, the development and commercialization of RYTELO may be further delayed, altered or abandoned, which might cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may seek additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Due to uncertainty in the general economic, market and political climate, we may determine that it is necessary or appropriate to raise additional funds proactively to meet longer-term anticipated operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, including pursuant to the 2023 Sales Agreement, your ownership interest as a stockholder may be diluted, and the terms may include liquidation or other preferences that materially and adversely affect your rights as a stockholder. In addition, we have borrowed, and in the future may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">borrow, additional capital from institutional and commercial banking sources to fund clinical development and our future growth, including pursuant to our Pharmakon Loan Agreement or potentially pursuant to new arrangements with different lenders. We may borrow funds on terms under agreements, such as our Pharmakon Loan Agreement, that include restrictive covenants, including covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Moreover, if we raise additional funds through alliance, collaborative or licensing arrangements with third parties, we may have to relinquish valuable rights to RYTELO or our technologies or grant licenses on terms that are not favorable to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows Used In Operating Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in operating activities was $218.6 million, $167.7 million and $127.4 million in 2024, 2023 and 2022, respectively. The increase in net cash used in operating activities in 2024 and 2023 primarily reflects an increase in net loss to $174.6 million , adjusted for non-cash items including stock based compensation expense related to employees and directors stock awards.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows Used In/Provided By Investing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities was $106.0 million in 2024, primarily reflects decreased purchases of marketable securities, as well as increased proceeds from maturities of marketable securities. Net cash used in investing activities was $180.3 million and net cash provided by investing activities was $62.1 million in 2023 and 2022, respectively, which primarily reflects a higher rate of purchases than maturities of marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities in 2024, 2023 and 2022 was $334.4 million, $362.0 million, and $87.3 million, respectively.  Financing activities in 2024 primarily reflect an underwriting offering of 41,999,998 shares of common stock and a pre-funded warrant to purchase 8,002,668 shares in March 2024. The net cash proceeds from the March 2024 offering were approximately $141.0 million, after deducting the underwriting discount and other offering expenses paid by us, and $246.1 million net cash proceeds received under the Pharmakon Loan Agreement and Royalty Pharma Agreement.</span></p>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our material cash requirements in the short- and long-term consist of the following operational and manufacturing expenditures, a portion of which contain contractual or other obligations. We currently plan to fund our material cash requirements with our current financial resources together with net revenues from sales of RYTELO; however, if we do not generate sufficient funds from commercial sales of RYTELO, if we experience unforeseen events or choose to make other investments in our business, or our assumptions regarding our projected operating expenses are otherwise incorrect, we may require additional funding to fund our material cash requirements, which could include a combination of additional equity and debt financings, new collaborative arrangements, strategic alliances, or from other sources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating expenditures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary uses of cash and operating expenses relate to paying employees and consultants, commercializing RYTELO, administering clinical trials, ensuring an adequate supply of RYTELO (imetelstat), and providing technology and facility infrastructure to support our operations. Our research and development expenses in 2024 were $103.7 million, and we expect our investment in research and development expenses to increase in 2025. Our selling, general and administrative expenses were $145.7 million in 2024, and we expect our selling, general, and administrative expenses to increase in 2025 to support our commercial growth. On a long-term basis, we plan to manage future cash requirements relative to our long-term business plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operating expenditures primarily consist of our obligations under commercial purchase commitments related to our manufacturing and supply agreements for RYTELO and operating leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO requires long lead times to manufacture. Therefore, we make substantial and often long-term investments in our supply chain in order to ensure we have enough drug product to meet potential future commercialization requirements, as well as clinical trial needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have engaged third&#8209;party contract manufacturers and have re-established our own manufacturing supply chain to manufacture and supply quantities of RYTELO that meet applicable regulatory standards for current and potential future clinical trials and commercial uses. Related to those contract manufacturing agreements, we have commercial purchase commitments for approximately $131.4 million in the aggregate as of December 31, 2024. These purchase commitments can vary based on the commercial demand of RYTELO and are binding based on future manufacturing needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The leases for our office facilities in New Jersey and California contain rate escalations and options for us to extend the leases. Our operating expenditures primarily consist of our obligations under operating leases. The aggregate amount of future operating lease payments over the term of our leases is $3.2 million as of December 31, 2024. Refer to Note 8 on Operating Leases in Notes to Consolidated Financial Statements of this Report for additional detail of our lease obligations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have a long-term principal debt balance of $125.0 million in principal debt outstanding related to the Pharmakon Loan Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into the Pharmakon Loan Agreement, and in connection with this transaction, all obligations outstanding under the Hercules Loan Agreement were repaid in full on November 1, 2024, upon which the Hercules Loan Agreement was terminated. We expect our interest expense to increase in future periods due to the draw down of the Tranche A Loan and potential future draw downs of the other Term Loans under the Pharmakon Loan Agreement. See Note 9 on Debt in Notes to Consolidated Financial Statements of this Report for additional information on the Pharmakon Loan Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into the Royalty Pharma Agreement, pursuant to which we received an upfront payment of $125.0 million, or the Purchase Price, and Royalty Pharma obtained the right to receive Royalty Payments on future U.S. net sales of RYTELO for each calendar quarter during the term of the agreement. We are obligated to make Royalty Payments each quarter based on U.S. net sales of RYTELO at the royalty rates set forth in the agreement, which Royalty Payments are not determinable at this time, until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031, or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price. See Note 9 on Debt in Notes to Consolidated Financial Statements of this Report for additional information on the Royalty Pharma Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, we enter into agreements with CROs for clinical trials and with other vendors for preclinical research studies, investigator-led trials and other services and products for operating purposes. We have not considered these commitments to be contractual obligations since the contracts are generally cancelable at any time by us upon less than 180 days&#8217; prior written notice. We also have certain in-license agreements that require us to pay milestones to such third parties upon achievement of certain development, regulatory or commercial milestones. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval and commercial milestones, which may not be achieved.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7A. Q</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following discussion about our market risk disclosures contains forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. We are exposed to credit risk and interest rate risk. We do not use derivative financial instruments for speculative or trading purposes.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit Risk. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple financial institutions in the United States. Deposits with banks may exceed the amount of insurance provided on such deposits. While we monitor the cash balances in our operating accounts and adjust the cash balances as appropriate, these cash balances could be impacted if the underlying financial institutions fail or could be subject to other adverse conditions in the financial markets. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, U.S. government-sponsored enterprise securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. We limit our credit and liquidity risks through our investment policy and through regular reviews of our portfolio against our policy. To date, we have not experienced any loss or lack of access to cash in our operating accounts or to our cash equivalents and marketable securities in our investment portfolio. The effect of a hypothetical decrease of 1% in the average yield earned on our cash equivalents and marketable securities would have resulted in an immaterial impact on our interest income for the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk.   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The primary objective of our investment activities is to manage our marketable securities portfolio to preserve principal and liquidity while maximizing the return on the investment portfolio through the full investment of available funds without significantly increasing risk. To achieve this objective, we primarily invest in widely diversified investments with fixed interest rates, which carry a degree of interest rate risk. Fixed rate securities may have their fair value adversely impacted due to a rise in interest rates. Due in part to these factors, our future interest income may fall short of expectations due to changes in market conditions and in interest rates or we may suffer losses in principal if forced to sell securities which may have declined in fair value due to changes in interest rates.  The fair value of our cash equivalents and marketable securities at December 31, 2024 was $502.9 million. These investments include $50.2 million of cash equivalents which are due in less than 90 days, $327.6 million of short-term investments which are due in less than one year and $94.5 million of long-term investments which are due in one to two years. We primarily invest our marketable securities portfolio in securities with at least an investment grade rating to minimize interest rate and credit risk as well as to provide for an immediate source of funds. Although changes in interest rates may affect the fair value of the marketable securities portfolio and cause unrealized gains or losses, such gains or losses would not be realized unless the investments are sold. Due to the nature of our investments, which are primarily money market funds, U.S. government-sponsored enterprise securities, commercial paper and corporate notes, we have concluded that there is no material interest rate risk exposure and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to risks associated with changes in interest rates in connection with our term loans. On November 1, 2024, we entered into a loan agreement (the &#8220;Loan Agreement&#8221;) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a &#8220;Lender&#8221;), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, which provides for a 5-year senior secured term loan facility of up to $250.0 million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $125.0 million (the &#8220;Tranche A Loan&#8221;) which was funded on November 1, 2024 (the &#8220;Tranche A Closing Date&#8221;); (ii) a Tranche B Loan in an aggregate principal amount of $75.0 million (the &#8220;Tranche B Loan&#8221;) which is available, subject to certain limited conditions, at the Company&#8217;s option; and (iii) a Tranche C Loan in an aggregate principal amount of $50.0 million (the &#8220;Tranche C Loan&#8221;, and together with the Tranche A Loan and the Tranche B Loan, collectively, the &#8220;Term Loans&#8221;) which is available to us upon reaching a specified trailing twelve-month RYTELO&#153; revenue milestone. The Term Loans mature on November 1, 2029 (the "Maturity Date"). The Term Loans bear interest at a variable rate per annum equal to 5.75% plus three-month Secured Overnight Financing Rate (&#8220;SOFR&#8221;) with a SOFR floor of 3.00%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was 10.32%. Interest is due and payable quarterly on the last day of each quarter with the first payment due on December 31, 2024. The Loan Agreement requires we pay an amount equal to 2.50% of the Lenders&#8217; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan. Based on our current indebtedness of $125.0 million under the Term Loans as of December 31, 2024,  a 1.0% change in the SOFR would increase net interest expense on our current indebtedness by approximately $6.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Currency Risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">   </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We may be exposed to fluctuations in foreign currencies with regard to certain agreements with service providers. Depending on the strengthening or weakening of the United States dollar, realized and unrealized currency may fluctuate. Management has determined that these fluctuations would not have a material impact on the financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_supplementar"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 8. FINANCIAL STATEME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following financial statements and the related notes thereto, of Geron Corporation and its consolidated subsidiaries, and the Report of Independent Registered Public Accounting Firm, Ernst &amp; Young LLP, are filed as a part of this Report.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.26%;box-sizing:content-box;"/>
    <td style="width:6.74%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span><ix:nonNumeric id="F_ddf7e96f-b19e-45f1-a8bc-1465a1489444" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#note_1_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Geron Corporation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe11bf57-e3d9-468d-a6a4-cfaab74c6da7" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Geron Corporation (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024 and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 26, 2025 expressed an unqualified opinion thereon.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.28%;box-sizing:content-box;"/>
    <td style="width:83.72%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;text-indent:72pt;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-left:72pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue recognition - net product revenue</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As described in Note 1 to the financial statements, the Company sells its sole product, RYTELO, through third party distributors and specialty pharmacies. The third party distributors subsequently resell the product through their related specialty pharmacy providers to patients and health care providers. Product revenue from RYTELO sales is recorded net of variable consideration related to government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:16.28%;box-sizing:content-box;"/>
    <td style="width:83.72%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">fees, upon delivery of the product to the customers. Variable consideration is recorded at the time the related product revenue is recognized or in the same period that the related product revenue is recognized. For the period ended December 31, 2024, the Company has recorded gross product revenue of $89.4 million and net product revenue of $76.5 million, net of total gross-to-net adjustments of $12.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Auditing the Company&#8217;s product revenue was challenging, specifically related to the effort required to audit third party distributors and specialty pharmacies sales activity to assess whether items deducted from gross product sales were complete and properly accounted for in the estimation of variable consideration. This involved assessing estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, expectations regarding future utilization rates and channel inventory data. <br/>
</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Our audit procedures over the Company&#8217;s product revenue from third party distributors and specialty pharmacies included, among others, performing analytical procedures to detect and investigate potential anomalies within the data. We also examined the terms and conditions for a sample of new or amended contracts with third party distributors to ensure appropriate revenue recognition treatment. We also confirmed the terms and conditions of contracts directly with a sample of third party distributors, to identify any potential side agreements and terms impacting the appropriateness of revenue recognized. In addition, we obtained written representations from the Company&#8217;s personnel that oversee the commercial operations regarding the completeness of the terms and conditions reported to the Company&#8217;s legal and accounting departments.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_589284f5-eb08-4dd6-aa87-69929f518824" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 1992.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_219e0fc2-6b5f-49ad-8878-abec1ab12e57" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Jose, California</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Geron Corporation</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited Geron Corporation&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Geron Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 26, 2025 expressed an unqualified opinion thereon.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> San Jose, California</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> February 26, 2025</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED BALANCE </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.472%;box-sizing:content-box;"/>
    <td style="width:1.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.603%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15.603%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ASSETS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_812b0185-8fe9-4bcf-bc23-f00e3c3fbd08" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,016</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de933eaa-9a97-4859-af60-73fb21ba3331" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,023</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa8f6022-ae17-41da-94fa-1a576589b19f" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,860</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb29fd94-a540-4516-b86f-0af37696a1d8" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8895f688-af1f-48fe-ab9d-b2a60d56129a" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75d9a0f4-3cf5-4742-8acd-334b8646849e" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,676</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e7b5015-af42-4a14-a716-e89307704c3b" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,946</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc0d0bea-e76c-45a4-977f-be294c6ad0b9" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:NontradeReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,853</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfa33b03-c3a0-4bfd-ba65-1d35d8f2832b" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:NontradeReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab8f4498-aea9-4464-ae32-a6936d3f6a3c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,714</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b7b1649-3bcd-41dc-b033-1ccb9f671514" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,053</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8d903fe-4e81-4fd5-9525-f192ab622ab8" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,879</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fce85f4c-45b2-4622-aa80-b562783a9bce" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490,992</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b96a95cd-34d3-42e1-b22c-3b2006e5b152" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341,348</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdf751b5-73e6-4e0a-9dd1-85d54fe8ac0a" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,519</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90593b22-8a5c-43bc-bf47-a8ce6a5bb150" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e80e749a-b907-4385-bf82-01ee21e481c0" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,310</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb64496-b934-4554-bd28-f027c74ab1ed" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,177</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ce29e59-263e-4d5a-b40f-0d52e270d9b0" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,881</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74caa8ce-2e83-41cd-b669-91ca36789789" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,556</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5a3aa4f-c0cf-4216-a6bb-d82054d9766d" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,079</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_464468e0-e1b0-4f5b-bcd1-28a8d60c87c6" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,697</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23342465-6ed0-4d10-a3c8-5a80aba55293" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,781</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29cfaaf7-0f4d-4e72-a71a-a964ee6dddfd" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,076</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b44b725-cc74-4bad-a332-d97e12a9c10d" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,595</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82139d85-d0d7-4c9b-a91a-b42c25f1a223" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,161</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e8d64d5-0445-49b3-b4d0-e38f9301a4dc" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,808</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7614c751-3166-40b4-8250-e6135319603c" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,759</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b9c8ef-0e47-46ad-95e1-0fe9c3064bd7" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">974</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bb8ddcd-56ff-45bf-a91e-583aea7b0db6" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3">949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liability related to sale of future royalties</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fa0683a-f6dc-43ce-87b8-409a704461f7" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:LiabilityRelatedToSaleOfFutureRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8f08164-d5d0-4ced-b125-0ea8af599246" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,549</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98063a31-9af4-4e77-98d0-0106e9e0693b" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,308</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef47f803-b47c-4204-a738-aaf6f9e67336" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,893</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed6264b6-d94b-4aac-8917-6f7ed7d3e766" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,298</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20685f1b-1db3-4e7b-9b2a-dc81a8c6f4e4" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b3d4a56-0b50-4283-850d-f93e0af18685" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,266</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fcee147-d483-44be-bec8-d6b22bb13a54" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,006</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent liability related to sale of future royalties</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7d04c25-d371-40fd-ad75-3b8486eccf68" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,421</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;">
    <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent debt</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93f4554c-3947-4128-8377-3c620117eddf" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,476</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81685c33-791b-4928-9e50-1fd3fc23b9c3" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,051</ix:nonFraction></span></p></td>
    <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca96dfc5-976f-412e-85ac-49e1e538c6f4" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">313,461</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7764ccde-1ec6-4742-8d73-c38e1fec2ea5" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">146,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_1e7bd566-1752-45f9-87e1-a254ef8b2f87;"><span style="-sec-ix-hidden:F_43d919e9-8f34-4532-901b-4bc0e74ccfa9;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d39d09d-5ce3-42ae-988d-a2935a761c22" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_aa2355f5-3f1c-4480-8842-2280d841a76c" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0050eff5-6556-4196-9f85-598b2bdf24b0" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_95c08f86-9a57-46b6-b64b-0418f1068397" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93191638-c4c6-463b-ae5c-0d95105f68a0" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d5c895ad-36a3-452d-8380-12e332271ba5" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0802e70a-29d6-4244-b1a4-721fc6874726" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5bfb4060-68aa-49ae-a91a-1fc6e9515b04" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>&#160;&#160;&#160;shares issued and outstanding at December 31, 2024 and 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_57e68bf4-b075-47ff-94cb-4fffa7fbe456;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_a7f284af-766e-40ff-94ba-04d6489d905a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61fcc0c9-e194-447b-86db-7c210b6cfeea" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_7e15d54e-808d-4382-b8f4-4f6f7d487568" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19ac7154-748c-4ff3-ab66-8a716e35cfa2" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4317bdf9-cd75-41c2-9a7f-2b6688377422" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,350,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized; <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba668ac2-8b92-4c32-a232-ac7c2cf1bb5e" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e8baf14d-58bf-4205-a249-32424a4844fc" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">606,387,666</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bc4669c-1d31-418d-93ec-ce138995f850" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fee11e69-affa-484d-af6f-f96d4a29c01f" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">544,912,215</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding<br/>&#160;&#160;&#160;at December 31, 2024 and 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cacec14-5ccf-4eb8-92ee-578277d8f219" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">606</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09334395-e678-4370-888f-ab0442de1754" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">545</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_508c9d71-e7be-4537-94d4-a8757f4eafb3" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,051,794</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca9fe6f5-224b-480f-847b-06c875cbe170" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,844,988</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44d3c4a0-b7f4-4460-a47d-89b3c37e1612" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,772,341</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74462f0c-a920-4b76-8df9-655db4797ada" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,597,769</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4c5879-b85d-4709-99b7-f6142c05470d" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1eed248-98fd-455d-8ab9-36ba79b809a3" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3">185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_154a0b6a-0f09-4f10-ae21-614d185cdd78" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280,320</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4308541-ae59-4dc3-b880-3e12eb6da142" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b72dfec3-705b-4da4-9633-9ab45260ff81" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,781</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e390f3b-9fed-4fb3-a504-f511bad79f21" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,076</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F OPERATIONS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.25%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.197000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.197000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.54%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.197000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Product revenue, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d932607-abae-4019-8138-51dcd5d27b7d" contextRef="C_522fafdb-07e4-4339-b103-c323ad02c3e7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,495</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a8a1545-6460-43d2-a0e5-fbcc88cecd16" contextRef="C_a91cce50-3f56-4202-8cbb-e2061a4afe4d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6618a07c-d4a5-4ca3-b1a3-12b2b692576e" contextRef="C_9979f2e9-baa0-488c-bfc3-27175ab0bfd6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License fees and royalties</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8deebb5-3316-44e5-9f7f-4b02ab8c5ade" contextRef="C_54df7d29-aa46-434f-bb2e-e36ffb0cf1c7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4bb3f01-c89e-43bb-af41-29b6a268572a" contextRef="C_7f38441e-2b05-4d47-8fbc-1af5f0430674" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_529d5db4-4474-47cf-99bb-362208fb28b8" contextRef="C_9d292321-d77a-49f3-8195-59f85dac9752" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4a95005-17f1-4afc-88e4-abb7a092a890" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,256</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9262e17d-8d35-474a-a820-adef83a29095" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3be454a-a8e5-4d6f-b0c3-8b32c7f611a0" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,046</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b237b2b2-4459-49eb-a75e-e6bf3904960b" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,518</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f55a90f-29f8-4ca3-84a3-f33be89653ef" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">145,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0221685-0357-42ec-904b-d9495254f9a3" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,135</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9755eaa-fa6c-4a86-82d7-337451b63a01" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,628</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cb6e45d-9de8-4e53-afad-9b909461957e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,726</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30157bdb-59fd-4569-bd83-5eaa8c456cd5" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,181</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73ac5f0c-14c4-4f49-a774-5c62de584bff" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,146</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a754ca-f0f2-4f1a-90c2-d26d34f4ca72" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">173,732</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a617df-25c3-4796-9a9a-a5f86fc50562" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">193,944</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0426b26-f0a1-4ad2-bc64-fb59750cf8b1" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">138,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c781a37-1588-4460-b608-6b263fb3077d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,607</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3350d50-c62a-4c46-8618-ce5ea9603945" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,152</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88198c9c-9cc6-4f1a-9317-c469cfeedf2a" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c54b32c-9aaf-4325-bb52-8976fcb31cde" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,504</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_844209a9-8fce-4b47-9205-8717ac6c1ee2" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,312</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed78a984-5a36-4262-bae9-2973c6b7e168" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,882</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52ff9f42-cf65-4103-be22-76ab6c0eb5d6" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef7bc292-d953-4e5d-905b-a6977fa5a752" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2c6db8c-473c-4eac-aab1-cd1dba052d07" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss on extinguishment of debt</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d397d94-1ba0-476a-9eea-b34ef503cc7a" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,707</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49539888-b6f2-424f-ad6d-d25b05566cc3" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b63e9a93-afce-48d5-8658-ee43495af3f5" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75d3689d-f154-48a1-9196-ce9adc4104ef" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3725e44-f40e-478f-bd27-00c8d6451a65" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8bb2ac66-d8b1-4e40-95c1-1e4ca1acd499" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.27</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9667dbdf-63a2-4c65-8e2a-d4040e122fdd" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_27849bee-dd81-4f9b-befd-e0f344c1fe7b" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.32</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03f4010-f907-4e85-aa29-a3964d7fb2ee" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0b09dd1a-b350-41a8-83ea-b84a52118770" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.37</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares used in computing basic and <br/>&#160;&#160;&#160;diluted net loss per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df748b26-0556-49f0-b56b-b1a12e4d6c2e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7f6de24c-185a-4708-ae03-205f7449a1a8" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">646,033,247</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afbf85e0-ec48-4ef6-9094-09e8dddf923d" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f3710073-b82e-43f2-8680-4247fe781f80" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">570,645,405</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d616b9c6-fb7a-4580-b934-5b4f32052295" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3e8dd9f3-7079-4856-ad9c-1c64c0a3dbf2" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">380,784,846</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STATEMENTS OF CO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MPREHENSIVE LOSS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.56%;box-sizing:content-box;"/>
    <td style="width:1.519%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.934000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.519%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.975%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.519%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.975%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fd6c14c-f553-4b6b-b7b3-ec5a46bf3962" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6376558b-e041-4b98-89be-2e5dec5aad8c" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc0d9307-ef26-4486-a18e-4d6dfc004d2a" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss (gain) on marketable securities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c57c6812-edf9-433a-95e6-8699d2194635" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4abdf747-d9fd-467b-9171-0e41b6556eb1" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3">431</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15a119db-ca60-4969-948e-d38b11a1d692" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">68</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_215039e0-856f-446f-a8d5-ce7cd9b1f0b7" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a20dc78-4e86-4019-ba64-c5d525c1bb94" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a345a3ea-a8f8-4136-9067-bcafed027c14" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67b6a06a-d158-420d-b9e6-3d12c500fbdb" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe6ac07e-00e1-4666-aec1-6c2212e6521a" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">183,723</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaeb4413-e060-431b-9c76-c7a56643dcb0" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,947</ix:nonFraction></span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.74%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.66%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.14%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders'</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2021</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44f16411-c14e-4d28-aab3-92ab7adf4814" contextRef="C_87979f69-8b59-4913-a42e-83306a925036" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">323,731,591</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_058e0fc5-d23b-4c2d-89f9-ab6b0e0b9b33" contextRef="C_87979f69-8b59-4913-a42e-83306a925036" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">324</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46d94c8e-3299-42f9-9ce4-0308e1db38aa" contextRef="C_08984eb3-5203-4824-90b9-9a8e53b3fb49" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,398,006</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7092ff20-fe67-4a5b-97cd-863eebfc9c41" contextRef="C_17d0f4ad-e466-499f-a3c7-32b9663b6681" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,271,741</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fee57700-bd22-46cb-8122-c105c65b469f" contextRef="C_e1976851-cb4c-4762-8274-5ea9e52c9f8b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">173</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ac52faa-b2ed-4a27-ba53-53c191887280" contextRef="C_0b8accab-dfee-4fdd-a488-21c280ad6a1b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,416</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1da30298-8fd4-4607-8107-7b1ffd4d9f84" contextRef="C_4c42d843-dd04-4e25-a34a-b1f703d11e39" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3672568f-3ad1-47a6-bc71-3bb0e17ba4ad" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ee37a67-124c-4df6-9067-860b4a519439" contextRef="C_39107341-c344-46be-aec9-e2e8aba0d53f" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef679a5e-a67b-46ce-b844-953d787086b3" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">68</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e8b0609-9fbf-4414-852b-79c5eaed3d80" contextRef="C_39107341-c344-46be-aec9-e2e8aba0d53f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c967d11-5302-41f5-89e9-b57321517b5b" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock, pre-funded<br/>&#160;&#160;&#160;warrant and warrants to purchase  <br/>&#160;&#160;&#160;common stock in public offering,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee24207-1c02-4ff7-9ed8-5ce391ab4c49" contextRef="C_f15e23b8-0e8e-4dda-a5e3-a439fd53eafa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,066</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd29d91d-d700-436b-8638-9b387d894745" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,333,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59133ce0-14ad-45b0-bca3-4641e90356f3" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3">53</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b062a03-f9a5-4b22-ad9c-73d72c578eb8" contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,863</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2dfc793-d5f7-4487-932f-da180a428216" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,916</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa2dee53-f6d2-4e53-86a2-697c7f89e42a" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,663,387</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad8483b-aaaf-4f6e-8a4c-e4a158876e9b" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca1f661-4878-491d-acb8-b988c417fc5e" contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,151</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e014323-f555-4522-a695-a4690b5f7985" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,163</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation related to<br/>&#160;&#160;&#160;issuance of common stock and <br/>&#160;&#160;&#160;options in exchange for services</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff17f34f-c4b9-44f4-8a77-d2d9e5eebca1" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3336420-770d-4a77-ae42-47ed19778082" contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">264</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f204a165-a6db-4daf-b6a3-19aab4898725" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">264</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuances of common stock <br/>&#160;&#160;&#160;under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36d674d9-5c75-498d-9a1b-5bab76daa907" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,518,250</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e9b1900-e7e4-470c-a1b8-f037cb8f495f" contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f34486-945a-4f35-a048-9b9a9a729577" contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,184</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5e06ffd-f33b-497e-93d8-acc58b7c45f6" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation for equity-<br/>&#160;&#160;&#160;based awards to employees<br/>&#160;&#160;&#160;and directors</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bee341ba-266c-4740-8f7c-b03353863d08" contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7abc6bc8-baca-459e-be5a-b792ef2f0f77" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93914976-3dcf-44c7-a223-30d4249efaa9" contextRef="C_57c67b07-3a75-4f83-a90b-a0845eba9d49" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">390,262,524</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_012feda0-cf77-423a-badd-f96f40d732ed" contextRef="C_57c67b07-3a75-4f83-a90b-a0845eba9d49" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">390</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84a3ee51-67d1-4d09-848e-335a63c77039" contextRef="C_f38cb9df-eb50-49af-95e3-99de5b6c1109" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,493,469</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7729e67-4a8b-4f3a-95e8-c2967502b46a" contextRef="C_7c4b014b-4b49-4de5-99e6-77cd32c236fc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,413,642</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f323869-3750-406d-a670-236dcf4e0deb" contextRef="C_442d47d2-f480-4e09-a7ea-6656c80440a8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-">219</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f0bf244-027b-4c54-866b-a3a949de1fa9" contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,998</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49f620e7-3754-4621-a87c-7d80515b04e0" contextRef="C_3360e8d8-eaad-4e88-a960-8e7053699623" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbb3b687-ab84-45bd-a535-8cbf64112aed" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d9c0f38-030e-4967-8c1c-049301d9b423" contextRef="C_2f02a42c-f14d-4389-a9d0-40ae1afee99a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3">431</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec8a574-4c0a-4419-a2b0-776de2f6ebe3" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3">431</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee082f77-cec7-44bb-9190-62359c6f2098" contextRef="C_2f02a42c-f14d-4389-a9d0-40ae1afee99a" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8658b480-bbad-47ed-a1fa-0f48b22360e9" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock, pre-funded<br/>&#160;&#160;&#160;warrant and warrants to purchase  <br/>&#160;&#160;&#160;common stock in public offering,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b038ee2-ba38-499f-b7a6-f239bbc071a1" contextRef="C_4dcad59e-1e3b-43e6-a526-804130f682d4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,507</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0439cd37-f048-4b67-894e-9708de23acf6" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,007,741</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f2683a-e099-4fe0-92fa-205882ec6fbf" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3">68</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9534fd71-818d-4623-be9c-36ec8ba561cf" contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,269</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7b00710-4f3d-48b6-a4a1-80193c9fead7" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,337</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f40225-b770-4f28-8350-c93b57f3a0db" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,349,858</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15a727a4-85b1-46e9-9116-795d2f459ef4" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1c030b3-b5f7-4cce-9038-093d5de17cc1" contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,834</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6a3da67-d0cd-42ee-b84b-340c3922d9d4" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,912</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation related to<br/>&#160;&#160;&#160;issuance of common stock and <br/>&#160;&#160;&#160;options in exchange for services</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6da2683-01e0-4b31-a1ca-18a80e4d6c15" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,864</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57c4b745-eb7f-4028-b82c-f4fb79292020" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13ae2b89-1db1-4ede-beaa-c8ef037b8402" contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adebf9f4-42db-4e5e-a8c7-02e816c4c97f" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">829</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuances of common stock <br/>&#160;&#160;&#160;under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5874e2cd-edf6-43f1-b71e-82896980ae07" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,255,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3cedfe3-67dc-49f5-90b3-49b8e8554517" contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_235db96b-22c2-4f21-9d8a-a6f28a1baf01" contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,062</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94de86a8-283f-4946-8c5f-89037b1f1902" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,070</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation for equity-<br/>&#160;&#160;&#160;based awards to employees<br/>&#160;&#160;&#160;and directors</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ba0b77-5680-4680-a27d-6c7e95f3b092" contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,526</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_242282de-69a5-4f98-a5f5-ddc61fadd6f0" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,526</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_760823e3-0973-4707-be49-5b9d6e90cd79" contextRef="C_8eb77d4c-4335-48c8-9562-05e492af76dc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">544,912,215</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c6096a7-5e0b-486d-9a2a-48a7a48459c1" contextRef="C_8eb77d4c-4335-48c8-9562-05e492af76dc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">545</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7535fb2c-4c36-407c-9160-82c769a0b62b" contextRef="C_cf181ee0-e9ee-474a-9747-6fe8c5a5fe77" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,844,988</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_823ce54e-9508-48e5-ba9c-081c44b6e0a0" contextRef="C_7f8c13fe-b7c8-47a4-9aa3-5c471dd1c446" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,597,769</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4c34e56-12ed-40bf-95f1-411546f31812" contextRef="C_71d1f837-aa40-49d4-bd3f-4a76ced03892" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec73b497-8141-43fc-9111-44c7f7004864" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aceb52a-8887-41a0-91b4-20c9970456e9" contextRef="C_9e25d180-78c3-41f5-b9e4-3eedf3398835" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77389319-7d1d-4e92-b706-f55854a90e0a" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78f1350c-2220-424f-974a-876e20d8b749" contextRef="C_ba48a767-b0d9-4ebe-9ba8-df6962a5903f" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">88</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8955b3fc-a4b2-45b8-95d6-f54a1d660ec0" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-">88</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b153788-4bf5-4c55-8ca4-c82059ac0733" contextRef="C_ba48a767-b0d9-4ebe-9ba8-df6962a5903f" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44090d8a-83df-4f30-8f56-c5450f82fe97" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">Issuance of common stock, pre-funded<br/>&#160;&#160;&#160;warrant and warrants to purchase  <br/>&#160;&#160;&#160;common stock in public offering,<br/>&#160;&#160;&#160;net of issuance costs of $</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_401433a8-11ea-4921-8a01-184e5cccc2d7" contextRef="C_90739fa8-e72e-4147-a181-ff8aba129f93" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7202d94-d3d4-4269-8aef-8ca3a04b5c92" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">41,999,998</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ad967b3-f657-4635-a84b-9d5a73ea111a" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3">42</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5db575f9-6ecf-42a5-8259-3a58a68562d6" contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,687</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8181308b-4980-43cd-bcef-2d1b6bf0f151" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,729</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock in<br/>&#160;&#160;&#160;connection with exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_036bce50-2d71-4f35-ba47-e199c4952029" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,071,981</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4af869-b193-4d73-becf-ad02ad9d3765" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e685269-82ce-47fd-b0f5-c53f19d89c97" contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,393</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2531462-1362-48a3-84e6-a16a1dd84738" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation related to<br/>&#160;&#160;&#160;issuance of common stock and <br/>&#160;&#160;&#160;options in exchange for services</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3799f6f4-9bb4-45d3-8434-2c46deece504" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,351</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a800cd0-ff04-48fd-b01e-2d0c2eec7264" contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">134</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cfb65eb-5e91-4b9e-b33e-8b7093ea6304" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3">134</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuances of common stock <br/>&#160;&#160;&#160;under equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a65ef10-38f0-473c-933d-d4261b14aea7" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,395,121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65b3137c-0fe0-44e0-b09e-f4e5e50e26a8" contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3">18</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61901433-caf9-48ef-aebc-4cff533674de" contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,665</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8af13dc-1eeb-4b5f-95f3-4800ba4e161f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,683</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation for equity-<br/>&#160;&#160;&#160;based awards to employees<br/>&#160;&#160;&#160;and directors</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d4ffdfd-f252-4260-9298-0a33f155002e" contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,927</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1026960b-2f20-4993-87b6-26eb2847831f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,927</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balances at December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_943c9266-ca8c-4423-802d-d2b2075e320e" contextRef="C_a5c5ddc7-dfaa-4256-a811-8005fe000d01" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">606,387,666</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b020498-8595-48da-b6f3-9ed94d57760b" contextRef="C_a5c5ddc7-dfaa-4256-a811-8005fe000d01" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">606</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00992095-1501-4327-ab87-db00a2133167" contextRef="C_9feb8ba3-51fd-46c5-a45b-f7d80b5c6b95" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,051,794</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c610e7d-4ead-4d36-a3b2-3ae291199975" contextRef="C_552c454b-a9ab-449e-b749-65c139a3cf3c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,772,341</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d5be308-44a4-4680-9d4d-ac9c845d0e41" contextRef="C_fc579693-1a73-41bc-8a82-5c04df25f0f9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">261</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d64ede8-20f1-4bcb-8a22-4eb9b3c8674c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280,320</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.438%;box-sizing:content-box;"/>
    <td style="width:1.299%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.115%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.299%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.275%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.299%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.275%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33ad62d5-ea09-4732-ad6f-0f8a0e909a51" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,572</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7216fbf0-adaf-4e99-a7a6-a1d8f568f674" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">184,127</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03e4e39a-a48a-4266-a5ea-7c011d47da0d" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,901</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in<br/>&#160;operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e9630b3-79d7-4774-9141-f10f250f418c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">546</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0693592-24d3-4713-bbab-bc52d419c5e2" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4f3fbc5-c6a1-4bfe-8496-2b981984cbe7" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion and amortization on investments, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5cbba39-ea0a-444e-a898-07b94bd55b0e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,683</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd55c20a-4de7-429c-b561-c4aa0bf1681f" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0028ac57-9adf-4d70-a27a-27762bd9b15d" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">965</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs/debt discount</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72282d4a-4d9f-4708-89c7-efc922867b03" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,108</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbc7e26f-b020-4a53-8d2d-34a8374326db" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99bfa767-63c7-4151-a26c-22f5c2809f9f" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment on royalty agreement</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc2943f-79a2-433f-803c-33f1d825fd09" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:PaymentOnRoyaltyAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,186</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash interest expense on liabilities for sales of future royalties</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e583434-6b76-49c5-97b7-1315a66211d2" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,345</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss of extinguishment of debt</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d02b4cd-6715-4d68-a627-68300efbb573" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,707</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation for services by non-employees</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a11231d-984e-4250-81db-d518dd6f65e3" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28b1b870-c659-4d05-8a62-dc93dc55b28a" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">828</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c94e1de-2a35-453d-a77f-aa50d2e1c777" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">264</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation for employees and directors</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8cb0b5c-5ee1-4da1-b583-75616385c1f6" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60ceb1f1-b8d3-42fa-a879-a1c4d757635d" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,526</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38bff75c-3708-4dc8-9eef-c73c7093ee95" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dadd2c38-9732-4ed9-927f-5bfaf972d974" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">675</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_313f52a4-9b3a-4963-bd7e-bf3966aeee54" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf2f194f-091b-4b17-a276-2d0d875b528c" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">580</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase in allowance for doubtful accounts</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e5299bb-bd9c-4515-b2ba-a3027808b486" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:IncreaseInAllowanceForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09b04647-5ab8-4760-949d-6d5e13e67aa9" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,971</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50a8168c-e47f-4e7f-a1d4-dfb87f4b02dd" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,695</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cae4ef4c-e596-49df-aa2f-a9c0aa781f6f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,198</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41bbf653-5179-4a4b-8ff3-f71d95416bbe" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,490</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af2ead2e-2197-4773-bec0-c7317ad72481" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,381</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce3a1b4-32a5-4273-95a6-f470c055870a" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ba6774-e019-482e-9a00-24e5073181ed" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">886</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479416f7-9abd-4274-b0ca-80a8b22f5f1a" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,630</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposit and other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd7518de-ab14-4851-920a-381258e326bd" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">618</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef2a6a20-e271-48ce-9e8f-028eb0f6c86f" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79f1ea9e-0e45-4531-935c-7c710bdfdd44" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">594</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e339ac2-b7a8-46e8-85d1-595492a4d593" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3b7133-8b09-40fb-a66e-1137485b84c5" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,029</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d8d0b61-6838-43a7-8e53-46113400d119" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,503</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued compensation and benefits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_987748f9-c3d3-40e4-a622-81efb148e8d4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,049</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_805bf7bc-2e1a-468f-864c-037808970d83" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,224</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6355c41-d560-405a-9ed2-83f97671fc54" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,435</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71b1f931-d045-4fa2-bf34-9cef89c12e9c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,759</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_470203fe-914d-4953-b794-de1e9c7e9f3f" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,208</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_224ed1bf-75c5-462b-88b9-911813b1da00" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,266</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:25pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a2354b2-a439-4b58-a8d3-f5711bfd7f1e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9e007ad-0937-4b49-ba15-a62f087ef704" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">640</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08ff0e10-0635-4dcd-9824-76f85c69a539" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c46a5f0-b293-4ae6-8a11-40df2fb93fb3" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">218,618</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87cee3df-a3e1-436f-a366-d01705a38b70" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">167,743</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d2e02b1-cb10-48b9-8e5d-9f9d5813bb01" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">127,379</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bee8173-ec7d-4fc5-9edd-052687c88330" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">680</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a70e0bab-61da-4651-8913-04dc66562c92" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d6ced3-ef75-4374-96e1-34fe8b6ba893" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b8c816-601a-4e97-b558-debded9422ab" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">476,932</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_213f5548-0c50-421f-aacc-10fb250d11dc" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475,594</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b1a7d4b-4b2d-4ff6-808c-ce1180b083c2" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,007</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a20f6298-21fe-4fbb-8725-956cba29e774" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">371,608</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d8d8ae5-5748-4ec4-b52e-7cd3d035fd18" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,102</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7861066c-abef-4bc5-8e21-8b1638fd4d91" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,505</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4aa65fb-9e34-470a-8cea-6171d927f1c1" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">106,004</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27c6f550-90ed-4b19-96ad-1e7568df8813" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">180,322</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0a9ed18-e1e1-463c-806d-2cb3c88e9af4" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,067</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuances of common stock from equity plans</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f751bab-0500-4380-8e17-f2da22e28009" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,683</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_606aa39a-17aa-429b-a411-1ed1c9af79f2" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,072</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1815b45-1e31-4d32-b149-39b5a6134534" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,185</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and warrants <br/>&#160;&#160;&#160;in public offering, net of paid issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cecac0ea-0b30-4462-acdb-52d904afe22b" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,729</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a35237a-3f2c-4338-87ad-00bf300b0e27" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213,337</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96498626-4554-4322-80ea-c40ea503e877" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,916</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce4b1264-8307-408c-a595-d5c12548a975" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,394</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cb3a636-8629-4a3c-84dc-a51c53dc74bf" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,912</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc62a797-405d-45bf-a72e-6677aded5b3d" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,163</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of future royalties</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a71a93d-e8bb-4421-8485-e7b4d57eadd8" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:ProceedsFromSaleOfFutureRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from debt financing, net of paid debt issuance costs and debt discounts</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18eb4811-6e58-4e40-bc2d-87978ef41703" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,120</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc9ce04e-5c13-4b75-80f3-c79fe355591b" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,700</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repayment of debt</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cccca09-5de4-4297-9946-946fff452329" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,554</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:30pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22ca60d5-1113-49b6-9c45-069a7f1d5417" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334,372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffe8764f-6cdb-4c71-90af-2216de8cb956" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362,021</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c232f9d-9f49-43b8-91ab-adb8f297db2e" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,264</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net effect of exchange rates on cash, cash<br/>&#160;&#160;&#160;equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d014a4c1-8d85-47d1-b348-1516076fde1c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c12ce3d-87a3-4499-a943-885540c4006d" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca35dc36-bc26-4f77-80b0-b93139d77bf4" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in cash, cash equivalents <br/>&#160;&#160;&#160;and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b49b890c-ece8-4140-b507-1e9b14158fa2" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,738</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae7a8236-2312-456f-83c4-580970e57fd9" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,929</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_922ab298-8e9d-44d9-81f6-3b3bcbd5fb42" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,974</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;at the beginning of the period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61262f9b-0935-472e-8bc3-0dd41fc341b8" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,138</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a819b22a-398a-4aac-b502-c9501d519fd2" contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,209</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44519b0a-c7da-48e7-8781-76f120333ab8" contextRef="C_0b8accab-dfee-4fdd-a488-21c280ad6a1b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,235</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash <br/>&#160;&#160;&#160;at the end of the period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50c03b10-980c-493d-b546-63aef5381ea8" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,876</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_932dd683-db53-4ebc-9956-fa4d837b9cd3" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,138</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51982665-5e06-4534-a684-c1b857fe7833" contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,209</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:nonNumeric id="F_f9cf17f0-f995-4bd5-beb4-097010dee656" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="note_1_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms &#8220;Geron&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; and &#8220;us&#8221; as used in this report refer to Geron Corporation, which was incorporated in the State of Delaware on November 28, 1990, and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. Geron UK was incorporated in September 2021, and its operations commenced in January 2022. Geron Netherlands was incorporated in February 2023, and its operations commenced in June 2023.  The Company's first-in-class telomerase inhibitor, RYTELO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imetelstat), was approved by the U.S. Food and Drug Administration, or FDA, on June 6, 2024 for the treatment of certain adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, and is under development for the treatment of other hematologic malignancies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc0ffe87-e45e-40ad-80b8-f49754cafa20" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. Foreign currency translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#8217; equity, on our consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1b3f941-46c6-45e4-8eca-b983befdea85" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_d1b3f941-46c6-45e4-8eca-b983befdea85_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d46f569-08f1-409f-81ae-c291ef0ab720" contextRef="C_59108335-739f-4e5e-b267-22b8c789f159" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,095,238</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_486c75f4-9676-4940-aa52-f81d30bbfb22" contextRef="C_6dee5fa2-b2df-4b03-9654-001c5bf49a8a" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,335,239</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7459775d-24b0-4b26-bc9d-ccae4841845a" contextRef="C_59108335-739f-4e5e-b267-22b8c789f159" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b90234e5-c34a-4511-9d5d-4e5a53630092" contextRef="C_6dee5fa2-b2df-4b03-9654-001c5bf49a8a" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. In January 2023, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56b6f06a-bbb9-4ccd-bf37-8243c5d4351c" contextRef="C_08593508-3737-4150-83da-4b9da613a6e2" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,007,741</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e57488d-cea9-4432-acb8-7f9bdbaf5017" contextRef="C_9accca2e-98a7-4feb-90e0-dd4c4473e5a3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2023 pre-funded warrant. In March 2024, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_574ffa5e-2190-4e7d-9f7b-f0297aec328d" contextRef="C_38ee5de3-7306-4f4b-8d58-eb882cf9590d" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">41,999,998</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd45bb7f-2ee8-4718-8e5c-4dc7bd475262" contextRef="C_3462f4ba-71e7-4d47-bf58-841e2d8028a7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,002,668</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2024 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 10 on Stockholders' Equity for further discussion of our public offerings.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d1b3f941-46c6-45e4-8eca-b983befdea85_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2024, 2023, and 2022, the diluted net loss per share calculation excludes potential dilutive securities of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca45a7e-e715-4520-8b3b-00a7178e6188" contextRef="C_f8d8f292-1d56-4204-b316-2a9290be7c09" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,369,889</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83e2c7f0-161a-462d-bea2-c1233ce05952" contextRef="C_7d57e1e2-e7e9-4439-be29-506043e9a42a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,458,854</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6c38662-c430-4bd8-b1be-8ca85ac133e3" contextRef="C_7ec87361-5500-473b-846d-d51e7d5b6cdc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">145,726,765</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_1" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20b39356-7994-4094-9c5b-42646cdaff10" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_20b39356-7994-4094-9c5b-42646cdaff10_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_20b39356-7994-4094-9c5b-42646cdaff10_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_1410e17b-8fcf-47c3-a460-0076a1321bfd" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true" continuedAt="F_1410e17b-8fcf-47c3-a460-0076a1321bfd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. We recognize shipping and handling costs as an expense in cost of goods sold when we transfer control to a customer. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We distribute RYTELO in the U.S. through third party distributors and specialty pharmacies who are our customers. The third party distributors subsequently resell our product through their related specialty pharmacy providers to patients and health care providers. Separately, we have or may enter into payment arrangements with various third-party payors including pharmacy benefit managers, private healthcare insurers and government healthcare programs who provide coverage and reimbursement for our product that have been prescribed to a patient.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies. To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. See Note 2 on Revenue Recognition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Sales, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_2" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_3"><div><ix:continuation id="F_1410e17b-8fcf-47c3-a460-0076a1321bfd_1" continuedAt="F_1410e17b-8fcf-47c3-a460-0076a1321bfd_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Items Deducted from Gross Product Sales</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. The most significant items deducted from gross product sales where we exercise judgment are rebates, sales returns and chargebacks.</span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Product Revenues</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net product revenues are recognized, net of variable consideration related to certain allowances and accruals, at the time our customers obtain control of our product, which is generally upon delivery to our customers. We use the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts to estimate variable consideration and consideration payable to parties other than our customers related to our product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record reserves, based on contractual terms, for components related to product sold during the reporting period, as well as our estimate of product that remains in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare providers. On a quarterly basis, we update our estimates and record any needed adjustments in the period we identify the adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell RYTELO to our customers at wholesale acquisition cost, and calculate product revenue from RYTELO sales, net of variable consideration and consideration payable to parties other than our customers. Variable consideration and consideration payable to parties other than our customers consists of estimates related to the following categories:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Allowances</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We pay fees for distribution services, such as fees for certain data that customers provide to us. We estimate our customers will earn these fees and deduct these fees from gross product revenues and accounts receivable at the time we recognize the related revenues.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discounts for Prompt Payment</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We provide for prompt payment discounts to our customers, which are recorded as a reduction in gross product revenue in the same period that the related product revenue is recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Returns</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer customers the right to return products if they are damaged, defective, or expired, as defined in customer agreements. We estimate product returns considering experience from similar products in the market, historical return patterns, sales data, and inventory levels in the distribution channel. These estimates are recorded as a reduction in gross product revenue at the time of sale. Once products are returned, they are destroyed; we do not record a right of return asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chargebacks</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks occur when our contracted customers, mainly federal agencies that can purchase off the Federal Supply Schedule and Public Health Service 340B covered entities, buy directly from our distributors and wholesalers at discounted prices. The distributors and wholesalers then charge us the difference between their purchase price and the discounted price. We estimate chargebacks considering the terms of the applicable arrangement and our visibility regarding utilization. These chargebacks are recorded in the same period as the related revenue, reducing our net product revenue and receivables. We typically issue credits for these amounts within a few weeks of notification.</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_3" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_4"><div><ix:continuation id="F_1410e17b-8fcf-47c3-a460-0076a1321bfd_2" continuedAt="F_1410e17b-8fcf-47c3-a460-0076a1321bfd_3"><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Rebates</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to discount obligations under government programs. Reserves for rebates payable under these government programs are recorded in the same period as gross product revenue, reducing our gross product revenue and creating a liability in accrued liabilities. Major rebates include those from the Medicare and Medicaid programs. Estimates for rebates are made considering statutory discount rates and expected utilization. These estimates are updated each period with actual claims and other current information, taking into account historical data, comparable products and other considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-payment Assistance</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer co-payment assistance to patients with commercial insurance that have coverage and reside in states that allow co-payment assistance. We estimate the average co-payment assistance amounts for our products based on expected customer demographics and record any such amounts within accrued expenses and a reduction to product revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of Intellectual Property</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_4" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1410e17b-8fcf-47c3-a460-0076a1321bfd_3"><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df2b125d-9e59-4f32-b324-35107e108566" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:InterestExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability related to the Royalty Pharma Agreement and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assessed the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#8217;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c0482ae-369c-4445-80f5-da8b5a641f29" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations.  If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 4 on Fair Value Measurements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbc50aa9-041d-4d51-a735-7bb3f1844223" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_10a84c55-8bb9-4b06-81cd-1f8e34e9b470" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true" continuedAt="F_10a84c55-8bb9-4b06-81cd-1f8e34e9b470_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Accounts receivable are stated net of an allowance that reflects our current estimate of credit losses expected to occur over the life of the receivable. In developing our allowance for expected credit losses, we use assumptions to capture the risk of loss, even if remote, based on a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The payment terms on our trade receivables are relatively short. As a result, our collection risk is mitigated to a certain extent by the fact that sales are collected in a relatively short period of time, allowing for the ability to reduce exposure on defaults if collection issues are identified</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We update our allowance as necessary to reflect expected credit losses over the remaining lives of the accounts receivable for outstanding trade receivables that are past due, have known disputes or have experienced any negative credit events that may result in future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_5" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_10a84c55-8bb9-4b06-81cd-1f8e34e9b470_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collectability issues. We do not currently expect our current or future exposures to credit losses to have a significant impact on us. The estimated allowance for expected credit losses was not material as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, nor were the changes to the allowance during any of the periods presented.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79b81e55-2e26-491a-9bf9-d165a0ef2eda" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory is recorded at the lower of cost or net realized value, with cost determined under the weighted average method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, salaries, wages and stock-based compensation for personnel involved in the manufacturing process, and indirect overhead costs. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. Prior to regulatory approval, we expensed costs associated with the manufacture of a product candidate to research and development expense unless we are reasonably certain such costs have future commercial use and net realizable value. Since we consider attaining regulatory approval of a product candidate to be highly uncertain and difficult to predict, we expect only in rare instances that pre-launch inventory will be capitalized, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We began capitalizing inventory related to RYTELO in the quarter ended June 30, 2024, as we received approval of RYTELO on June 6, 2024, and the related costs were expected to be recoverable through the commercialization of RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d104f9ee-c443-4ec8-afa1-97a1308474b3" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:CostOfSalesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs. Cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. For the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, other than packaging costs, substantially all of our RYTELO inventory sold had a zero-cost basis as it was recorded as research and development expenses prior to the FDA&#8217;s approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8cab4cd-ac97-4e21-984c-b3dfc45a67b5" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current RYTELO (imetelstat) clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_6" continuedAt="F_f9cf17f0-f995-4bd5-beb4-097010dee656_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59c9641c-9e90-4791-a7dd-0511951124d8" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and Amortization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record property and equipment at cost and calculate depreciation using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1616b450-2530-4369-a96a-0edc2d31e843" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2387a91b-b859-4a73-8b32-8fa2b0349569" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock or restricted stock unit awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 10 on Stockholders&#8217; Equity.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dffff53e-92bc-4e23-bf16-cb29b70842ff" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45ec2dd9-4817-4a92-a372-a3f6fa7f62de" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:DebtPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_f9cf17f0-f995-4bd5-beb4-097010dee656_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70682e9b-1a2b-4d09-bdb3-c3767c43277f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#8217; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2599758c-9551-4025-bd53-e89ba766228d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51f66d73-2bbc-42d1-94e8-7765ecca9758" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_075bab03-7a15-4dd6-87b2-88c5d830351e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> represents our chief operating decision maker. We view our operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. For additional information, see Note 13 on Segment Reporting.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f20747ad-193b-4a35-a27d-3579319404c2" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued and Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1a01b63-fcbf-464f-8b0d-6e1beebe8bde" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment.</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods.  We adopted the guidance in the annual period ended December 31, 2024. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13. We view our operations as a single segment. See Note 13 on Segment Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_7aaa359a-617d-45fc-903c-9207360b3e82" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. REVENUE RECOGNITON</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Product Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9db2a7fc-5cae-4a44-ad2b-5f8dfc2d7478" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" escape="true" continuedAt="F_9db2a7fc-5cae-4a44-ad2b-5f8dfc2d7478_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9db2a7fc-5cae-4a44-ad2b-5f8dfc2d7478_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.434%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:26.564999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross product revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a39aaa23-fbe9-42eb-8b37-6600025f017a" contextRef="C_a57a8238-5f15-4041-aa47-381c050af69a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,418</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross-to-net adjustments:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chargebacks and distributor service fees</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b10dadee-7dfb-40fe-ab84-7d6c5d3cec75" contextRef="C_b54b04e2-e7b3-40e7-b38b-61e399b5089e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,772</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government rebates</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b8b8e74-d377-4c68-8035-119ce9be76b6" contextRef="C_d755aa78-f964-4edb-8019-908621c662cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">926</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales returns and allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f1113d2-379f-4375-a0bf-30f8bb1c33fd" contextRef="C_9814d90e-77b9-4d3a-907e-2bf9844e66cc" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross-to-net adjustments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2d6fd0d-15ca-473f-b7a9-6a1011e8a8c4" contextRef="C_f5b3d0b0-b24e-4a9c-9342-027dfaa89069" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,923</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net product revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2ad3dbc-9b7e-4f9d-9c72-e40468f4ad69" contextRef="C_522fafdb-07e4-4339-b103-c323ad02c3e7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_909d6628-6d94-4b4e-afe9-6b6b75ff1057" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:InventoryDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVENTORY</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our inventories are related to the manufacturing of RYTELO. </span><span><ix:nonNumeric id="F_d2e4ffa4-aec9-471a-a748-7e165e11b342" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true" continuedAt="F_d2e4ffa4-aec9-471a-a748-7e165e11b342_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our inventory as of December 31, 2024: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d2e4ffa4-aec9-471a-a748-7e165e11b342_1" continuedAt="F_d2e4ffa4-aec9-471a-a748-7e165e11b342_2">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.88%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:43.120000000000005%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6977c68f-b1c9-420d-a855-5f91b5cbbd04" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:InventoryRawMaterialsAndSupplies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,904</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e259f9c-c9d3-4ff4-9291-af3ef4aedf7a" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:InventoryWorkInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,093</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b91560b2-625e-41d6-98da-04454c6c0d61" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:InventoryFinishedGoods" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37809950-8f9f-42e7-9cb3-51213db9efc4" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,714</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_d2e4ffa4-aec9-471a-a748-7e165e11b342_2"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:nonNumeric id="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents, Restricted Cash and Marketable Securities</span></p><div><ix:nonNumeric id="F_63559f1a-ab9d-4fb5-b402-9e0677c28f1c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" escape="true" continuedAt="F_63559f1a-ab9d-4fb5-b402-9e0677c28f1c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.337%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87eb4618-09f1-4490-8002-eac06986d926" contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,215</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_095e5a54-0125-4e53-908f-efd68b1b52a0" contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,215</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bb4d2f3-d74c-41e4-8a2e-4380c3c35a4a" contextRef="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,978</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d40cbb7c-55cf-41c0-87f7-28e55e8a17c1" contextRef="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b" name="gern:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35eae2f3-3f62-4c7b-911f-d1d3724a703b" contextRef="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,977</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac75c302-82ca-4059-9ef3-c879d44097ae" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,193</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_635d1a08-aa59-4b71-8f04-f9b9d628cd48" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:CashAndCashEquivalentsUnrealizedLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2128ca22-a5a3-4903-be91-379223cd2f32" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,192</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6aa2671-3819-4590-8372-0e2ed5b4f6fe" contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16a2187c-a521-4e52-99bd-2e06314d22bb" contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a1bae39-b0cf-406f-9dfb-bb6dfc9d5fe7" contextRef="C_50fa79d0-89b9-452b-b91e-8b9da8f97576" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd214dc0-b4d5-4f71-8ab0-84324c2227c9" contextRef="C_50fa79d0-89b9-452b-b91e-8b9da8f97576" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68198153-2144-4fdb-b4a5-23eb0ec339d6" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41975bca-23be-404c-b82f-511796a9c77b" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,860</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377efc67-17d1-4c2f-b1ba-a630aaf4fd5d" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,937</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cd99a46-d251-4b33-8a11-7920a582bed8" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e61c79-3b46-4e84-9a4e-74a2e8c51c0a" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,959</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a44fcce1-eac9-4f32-9edb-7616db92a24b" contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,620</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1731833a-b386-4c28-ab55-05dcce98ba55" contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_972827ce-0805-4c9e-a703-df0927303f31" contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4acd2c-d598-4cfa-9dfa-0cd9d43a4f99" contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,610</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa2b59cd-a306-4b0c-b39f-3fbb9c65917a" contextRef="C_4599e5dd-ea25-4616-91b6-01afed02aaca" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,741</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f294e7-88d2-4abf-87bc-f70469c6570d" contextRef="C_4599e5dd-ea25-4616-91b6-01afed02aaca" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbf659f4-5d3c-477c-ae30-059c3c007731" contextRef="C_4599e5dd-ea25-4616-91b6-01afed02aaca" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17721376-21ba-4213-97cc-ba4ef44f9a96" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,131</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97ade9ee-9557-42ab-9bd1-2a2247bb67b7" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f64e876-0e91-4289-b37f-feb63351cc59" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f1ca466-351f-4950-9e1b-3a2401a0a5dd" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180,225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb9db193-29c6-4666-a1f5-d02bc41aea4d" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,361</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a9ed543-b391-42ce-9c72-380a2f1a9fd5" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">284</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6efa5a8c-a1d8-4c2f-a0f3-a668c7cb07b6" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d9a235d-d6fc-4bd2-a2b3-3a81592c936a" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,618</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cf480bb-1dcf-4e9f-aa02-e451b160c9c7" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55a269c6-ac7b-441a-b63a-4efd1717c521" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66f85f91-032e-4748-a293-9f363f51b5b2" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6a79685-cc70-4176-b41a-a2f013f7ec0f" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,909</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77f3c088-03ee-4870-a9ac-b4224034ed80" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">421,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_948e21f4-1130-4524-b988-88dac7c0ea9b" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">470</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9ea9fbd-2410-4aa8-8b94-5f267dec4f3a" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23f4137e-3709-4331-9957-e2f5f30a89c5" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">422,069</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_1" continuedAt="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_63559f1a-ab9d-4fb5-b402-9e0677c28f1c_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.337%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.301%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.864%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dfb5297-aa2e-4dab-8162-1a462b2cfed4" contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ae60958-702c-4719-b6b2-666e334e8b82" contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eb74d6c-8ea5-496b-8701-0ce1a3018d42" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f21598e3-406f-494a-acbb-2e2536e6dc76" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,815</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd3458ac-9f43-4cb4-b8ff-9c64fcfb1a97" contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3">843</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c956c86-c7b3-4089-99a6-7c2e39f28034" contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3">843</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a71e67-e375-4201-89ee-9d831c2eb728" contextRef="C_78978391-737a-40c3-9d68-851dcc4702f4" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3">272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb6cc6d4-0edd-4ee5-8ba0-dad85f2e7a8c" contextRef="C_78978391-737a-40c3-9d68-851dcc4702f4" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3">272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44aa6ca8-be52-4bd8-a809-bc93222a617d" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_352e9f33-9d20-4fe7-ac6a-d36ecfafc936" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:RestrictedInvestmentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,115</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e7bae57-cc56-4bf8-a363-d050bc1c651c" contextRef="C_634d30a6-a512-472f-83d8-6f6a44496fa1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,752</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479eff1c-dbaf-4d81-a7a0-39e2c76636fa" contextRef="C_634d30a6-a512-472f-83d8-6f6a44496fa1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d69e8bb-f716-4378-b3d7-8207c67bddae" contextRef="C_634d30a6-a512-472f-83d8-6f6a44496fa1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11173291-3cd5-457f-a3d2-e63e409ba587" contextRef="C_335cdb98-b657-42f3-973a-6dc964cba271" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,877</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3385a966-e8b9-4427-8121-cd7cb472e1ae" contextRef="C_335cdb98-b657-42f3-973a-6dc964cba271" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ad8be0-33da-4097-bc3a-6382c05eb6ed" contextRef="C_335cdb98-b657-42f3-973a-6dc964cba271" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,894</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1cd7a98-7152-4e22-8e7b-af32002f79d8" contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,250</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84eb8233-7fa6-4f0f-8793-c4afd2dabae4" contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2813aed-5592-47c8-936e-9062054681a1" contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_264ab2f4-0d45-4427-bd57-bcce025e7135" contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,201</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7de1cf12-836c-479e-8e65-dbbb0f9feece" contextRef="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,598</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_399aeb7e-b6d2-4a57-a399-cc0eff26a10c" contextRef="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afa96b49-6ff8-4a77-8d2d-1fdef64e948d" contextRef="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cb2efea-c085-4dab-9ff4-0f7da922a5b2" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,270</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_330f22a3-f74f-4307-8c4e-1b8a536c7ea7" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d2eb039-ae94-4778-9f73-c8715c46f459" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">33</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b3b1f9e-ed16-4f2f-9871-98ec950a70bd" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,268</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82ad382c-84e1-4bea-9874-b9953081885a" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,409</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_413033af-303a-4ef8-adb1-d9dbf2e286ea" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_936b1d2a-3d39-4ce7-a01f-b6459df48f95" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">63</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_869c0f9a-7085-4036-94b4-d8dfe7735a4e" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,360</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de2275a5-dc71-4d42-8b9c-4d34a4c061fa" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,628</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a28f7e79-8c5f-4f10-80c6-070e58caf924" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1aeb9f8-50fe-4193-8e2a-857c579df7c8" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">24</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c109d090-e2f3-4739-ab7c-1b80450b82e5" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,734</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f7698d1-6893-49d5-bd91-654b185a45b9" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,784</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8723f6bb-1266-489a-a92f-64166f5d012e" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0411d34-1128-4e0f-a6d8-848f473cba10" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">212</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a096ba0-c7e2-4b46-92da-0da07f076845" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_2" continuedAt="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ffdbdb7-56a7-455f-9fb7-b55426252eca" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.76%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_882ff649-1c77-4675-88fa-641eeaf95ec4" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,593</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b894488-7927-4fee-aa0c-3ef8fd45bb26" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4373d2a3-4606-4897-bbc2-47a335e751e7" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,593</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_864bf9d3-c69b-40c2-936f-71cd686f31d2" contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_990c2e50-4517-412e-980e-3de56cbeb0a5" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,076</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1209979-03eb-47ad-9be0-07bb77904e34" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">56</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3635a0f3-f358-454d-aeab-21b8b958afda" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,076</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b15e1ff-6c3c-44f2-94bd-89b6a14e3a1f" contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">56</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2aa6b2fd-8237-44b0-b66b-a225ee27ed71" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e256966-0030-4dad-b098-b7ace84078b2" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f8c7a8-f4b9-4b76-b6c4-028492eb283a" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee3f06f0-407d-4fc2-9ec3-813add0cab9b" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a17255e1-9685-499b-9f1b-46fc954357d5" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,542</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a1f1333-29e3-4b02-a775-a01a51a41a55" contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c368dae-dfb6-43ec-bc72-238024dfd874" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,506</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0522581f-1a66-49ab-89fa-0e26de76a06d" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4105b1a-754b-4d8e-a698-592433c78509" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,506</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe42b2c-efc6-4a1e-8a80-0c55b7bf699e" contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">98</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fd99e7d-a96b-4223-b077-f2233786a742" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169,724</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0aaa168-2a47-400a-b787-5b381f3d0695" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_756fcd5f-98a1-45e0-8adb-829775d65408" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_412398bc-07ee-4cac-8628-b6f6ddb40567" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4608c58-c01c-4629-9d94-120f998398d3" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,717</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_161ac69d-cf6a-452d-b7d5-1b2c8cbdfc74" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c61db07-f6b7-467f-8b68-f74e8b5b1f03" contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28af4b16-452f-4925-aa46-1cacd9ea10d7" contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_997cb6ad-b529-4e8a-941e-677dc458e595" contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce0fbfc3-1756-43da-a2f9-be23744f5a0a" contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2702367b-64a3-4129-870e-651ea9cdf529" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,622</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0e2f7d3-2946-4e59-a9e1-5e7f790b70fd" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">33</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a5d31b-fae5-434f-97dc-7123cdaa389b" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,622</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31ba9081-d6b8-4a3b-bbf8-fc3c6d07149f" contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3">33</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8c4e810-0caf-40ea-9de4-01da3fe165db" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,567</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4b000df-8477-437e-bac1-ab6d0903f2ba" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc4806e-60a0-46ed-8e08-066959546f79" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,567</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4181f318-a687-414e-aebd-5be179250cf1" contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33890984-6907-4fe6-81fd-b47fa89854ff" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_052c0e4f-3eea-40a1-981c-fd7f8ba074b4" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90e33335-9926-4889-b2e2-29c3a16a59f0" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,952</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2be9d355-d8d3-43cd-a2da-55fd564f044b" contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a0d8d13-9e78-42f7-8317-bf5545a1d9ea" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac5b4032-b346-40e1-95d5-c00f09ddcdf0" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3a559f0-0ed3-4da2-be63-6b7fe65b240e" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,518</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea88ad00-53fb-43ec-a3aa-0ffdf5cee9d4" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gross unrealized losses related to U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of December 31, 2024 and 2023 were due to changes in interest rates and not credit risk. If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors.  Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflict between Ukraine and Russia, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We do not intend to sell the investments and it is not more likely that not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value on a Recurring Basis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We categorize financial instruments recorded at fair value on our consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:1.84%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:90.16%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></p></td>
     </tr>
    </table></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_3" continuedAt="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_4">
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:1.84%;box-sizing:content-box;"/>
      <td style="width:7%;box-sizing:content-box;"/>
      <td style="width:1%;box-sizing:content-box;"/>
      <td style="width:90.16%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The embedded derivatives are classified within Level 3 of the fair value hierarchy. See Note 9 on Debt.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liability Related to the Sale of Future Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined the fair value of the liability related to the sale of future royalties based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3. See Note 9 on Debt.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#212529;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73c85e3e-f761-4436-ba68-cd5bcf9ae86b" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:FairValueMeasurementsInterTransfersBetweenLevels" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Level 1, Level 2, and Level 3 during the periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20cdfba5-408e-40bc-8d91-e813ab6c49aa" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_20cdfba5-408e-40bc-8d91-e813ab6c49aa_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 and indicates the fair value category assigned.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.008%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.482000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.142000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.922%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6ea2a23-5def-408f-84ec-747b99c40dbf" contextRef="C_95741265-2348-4239-94c8-9bc131f6f43a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,802</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fef454f8-459d-43ee-b094-c0e87ec6599f" contextRef="C_92e38419-310b-4d37-89de-c52fbe362d53" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,802</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_306acfdc-5676-42ee-b6c3-9d4baca724b7" contextRef="C_9378206f-1b63-4c2e-84ae-c7c453b28fb4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8dfb500-4183-4913-9094-59b265b02bf9" contextRef="C_e3b2e318-43ca-4428-8f97-24dd7e3a155c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">273</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf743e7c-7177-4e01-b454-5a5af6c87369" contextRef="C_81b5227f-c6cc-4463-87df-b07ef92efeea" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_111727e5-94ba-4c3a-a9bc-4dc4f4c2b0eb" contextRef="C_8b21a8eb-d5f2-4432-a5df-39b506f65c7b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,570</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6fb5385-2316-4738-8ee4-e00579d6767a" contextRef="C_e0933482-a77f-4d10-a7bc-f05210a15513" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0333e75-0041-4d72-bafa-6fc4ab2d2059" contextRef="C_747285d8-621a-48db-811f-49f35ea38d3d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,748</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec31dbbf-4c9d-40de-85c1-614b62ecec0a" contextRef="C_68fdfe38-0960-431a-a3e9-7b0ac25ccc4d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,201</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3f3d8cc-f4cc-4c90-85ce-92af072b748a" contextRef="C_17031fc2-3062-43d6-85c0-79a5d605b251" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185,201</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdcd57f8-acf3-4aae-be07-dce10cb41ba1" contextRef="C_f748ab50-900a-4fdc-8839-e5051a63beb9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_851d45fe-9605-4bea-90ae-2c02036168c9" contextRef="C_24fe1187-bbca-4f70-b50e-1470d3032743" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,527</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b38db7d-66a9-4c3c-b4d1-b0b4102ee9b5" contextRef="C_53d31f32-ae1d-49da-94b2-102d0fe79050" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,075</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50345e39-644e-4768-b278-259ef4b3852c" contextRef="C_5cdbb065-c4af-42c3-8862-71fcb82d98f6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427,046</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21c6a09a-14da-448f-88ad-f737bba0b25a" contextRef="C_b715e801-fcfb-431f-8bab-f2e143bebd19" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474,121</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b46f28-0233-4605-ada3-485e6a0e7078" contextRef="C_7ff95c91-1f33-4631-89e1-565d8329dc34" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,658</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a77a563-308b-443d-8390-be317e36f3f1" contextRef="C_4cbc89b0-e52f-4d52-bc4b-5e66f232255a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,658</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72086aca-081a-4802-af4e-9988250c785e" contextRef="C_4f241416-b409-4908-b332-b7b4d33cd845" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5df5fb7b-520f-4bca-b8cc-7dded2c26cb6" contextRef="C_7d3dad2f-bb11-4150-964c-bc94e9c01233" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7655c78-8c5e-4d0f-bb85-a2c2544b6b6c" contextRef="C_9706dd18-9926-47e0-b3e8-d29b8905bbab" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67c13420-9b2f-41b7-94ea-07c2c3e6c21f" contextRef="C_66ae5200-0971-4718-bfb2-d5a1adbf70ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dffeeb5b-6cc4-4d24-ab3f-d0d77fe4fe08" contextRef="C_becb8b88-64b7-49ab-8230-4c474b6aaf48" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e174155c-7ea1-4687-b092-be11f9255495" contextRef="C_d1fd165f-236b-4ae7-b110-10c3c05b8919" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b59f29ab-95a3-4136-b49e-e86a726edc10" contextRef="C_ebd06010-cba9-4fe3-8531-00bccfe44019" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,268</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70ba9f94-8c71-49b4-8e01-8870155c6787" contextRef="C_b494d8bd-5ad3-4784-83cb-b49455558821" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,268</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1bca93b-a2a6-4f01-81e8-1e04357040f4" contextRef="C_867aa2fc-a030-470c-984d-778ea052f5b5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,092</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50411d2f-5cda-42e9-aec2-883661a22180" contextRef="C_6da2f1f4-f5f1-49c8-b49b-064df08d4b0b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,092</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a82e7f93-1887-41aa-bf18-ac9b10e9f160" contextRef="C_4318e20a-42cf-473e-af78-4bb847a7d856" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8d169f3-f212-48c1-b495-1b5d89c1451c" contextRef="C_49f4818c-2720-4101-a534-f0f765371106" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306,974</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fa895d9-2077-44b5-b10a-7fbbbb385d6e" contextRef="C_6787832d-92fa-4613-99b8-8a61345db4cc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324,904</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.074%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:continuation id="F_20cdfba5-408e-40bc-8d91-e813ab6c49aa_1" continuedAt="F_20cdfba5-408e-40bc-8d91-e813ab6c49aa_2"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in restricted cash on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in current portion of marketable securities on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in noncurrent portion of marketable securities on our consolidated balance sheets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a_4"><div><ix:continuation id="F_20cdfba5-408e-40bc-8d91-e813ab6c49aa_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Risk</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple institutions in the United States. Generally, these deposits may be redeemed upon demand and therefore, bear minimal risk. Deposits with banks may exceed the amount of insurance provided on such deposits. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, government-sponsored enterprise securities, U.S. Treasury securities, municipal securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. However, we are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents to the extent recorded in our consolidated balance sheets. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk of our financial position at the depository institutions in which those deposits are held. As of  December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a870bced-a433-42b6-b64b-75400fd81ddb" contextRef="C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408" name="us-gaap:ConcentrationRiskCustomer"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_819efcbc-dd4c-462a-93d6-29dcda955d22" contextRef="C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable: McKesson Financial Center, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d26a8431-3a1e-49aa-bd71-2ce4558749f0" contextRef="C_d8b9e1c3-d9eb-45ec-948d-6b383d0103b4" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable; ASD Specialty Healthcare LLC, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eed7789-5d88-4a9e-9dd5-fb3128c90add" contextRef="C_38766db5-3955-4239-979e-89377c2bc7bf" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">38</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable; Cardinal Health Inc., which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2a7a3a7-3000-42ed-bcaf-ff9276a34660" contextRef="C_1d9cd387-5d68-43ac-8286-4091e49b513a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">17</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable; and Sina Drug, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c5fd900-e6f4-497a-99d3-0724b0a21aab" contextRef="C_91c5c5f0-c7f2-42ce-8dcb-ed6118918880" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_0e3c3b3e-4c18-4424-a32c-b546efffe3e8" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. PROPERTY AND EQUIPMENT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b71d06dd-d1ae-43db-b5df-d1ff62bea2d7" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true" continuedAt="F_b71d06dd-d1ae-43db-b5df-d1ff62bea2d7_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, stated at cost, is comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.6%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and computer equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f07cc260-1650-4829-b6be-bc42e539eccf" contextRef="C_bd2577b2-9506-4398-a405-ba1b3a537279" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,878</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdf31f3e-dff2-464b-b8b0-3a5244234256" contextRef="C_d99633b0-a319-42ee-a07d-8348a36501df" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,273</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef8f1d1a-8414-420f-ab50-c80d78cea1eb" contextRef="C_9553826f-3f43-4285-8839-dca64833f51a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c05e058-3283-4103-8ebb-404b880ccd68" contextRef="C_f836de54-c5fa-4e2c-bc3b-676b8b48b141" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d39855fe-545e-4f33-9e69-2fcf17094331" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,007</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be4a5fb1-3c3c-4697-91d5-445cc8ded2b4" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,408</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9969a23e-c2d9-478b-bdc8-cac843b011e9" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,697</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a7778bf-ec06-444b-b069-faf86e0a62ba" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,231</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0cfb7eb-a287-4922-a7b7-7e7308396244" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,310</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5bed175-feec-4c33-814e-2bca4ef18f6f" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,177</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_b71d06dd-d1ae-43db-b5df-d1ff62bea2d7_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_60ac4847-6287-40c7-945a-4cb3f415bbfb" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. ACCRUED LIABILITIES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0256451a-c37d-48d0-b987-41307602a675" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_0256451a-c37d-48d0-b987-41307602a675_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.6%;box-sizing:content-box;"/>
        <td style="width:1.86%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.86%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.34%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CRO and clinical trial costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_473fd94b-51f5-4346-9c04-adf249175cb1" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,968</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16e7c4db-2fbc-4996-b36b-16d6b206e4b3" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,541</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing activities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6994dda4-d96f-4bcd-ac16-dcc14b924354" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:AccruedManufacturingActivitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,839</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec26ef3-ef4c-4b30-afe4-81fc077489b1" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:AccruedManufacturingActivitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,629</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional legal and accounting fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01082603-f118-4982-a863-38cccd6fcb7e" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb50d859-0551-4f83-b8d2-33438be75398" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">556</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest payable</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de6969f0-d95a-4de6-90b2-7f547ec99a0e" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b155b438-76ed-4793-a9c1-9b2df9eeb2d1" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_389e57bb-5332-40f2-8505-b15ed6fd88cb" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05f54997-e48f-43be-9e27-7b341ed91c56" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">814</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a274347-bc80-4ef1-8d94-b094a7a5711c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f77764f5-f525-414c-85da-fe8a70245d7c" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,308</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_0256451a-c37d-48d0-b987-41307602a675_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_03891902-74cf-43cf-9a0c-41d83383144d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_03891902-74cf-43cf-9a0c-41d83383144d_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purported Securities Lawsuits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are not currently a party to any material pending legal proceedings. However, in 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed, and final judgment with respect to the other two lawsuits was entered in October 2023. In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  All seven of the shareholder derivative actions were dismissed with prejudice. There is no liability outstanding with respect to these lawsuits as of December 31, 2024, because they were fully settled during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. We could be forced to expend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_03891902-74cf-43cf-9a0c-41d83383144d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant resources in the defense of any additional lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Expenses associated with any potential future lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. We have not established any reserve for any potential liability relating to any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifications to Officers and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21859aa3-b9e2-4f46-a51a-33ec743a5434" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:NumberOfSeverancePlan" unitRef="U_Plan" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> severance plans that apply to all of our employees who are not subject to performance improvement plans, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a69d4d-c45a-4228-88de-8766de6822b6" contextRef="C_e0d5fa89-8410-4f47-ab1c-e5b7ef68f3cf" name="gern:NumberOfSeverancePlan" unitRef="U_Plan" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plan covering employees above the Senior Vice President level, i.e., executives, and all other employees hired before January 1, 2022, and the other plan covering all non-executive employees hired on or after January 1, 2022.  The severance plans provide for, among other benefits: (i) a severance payment upon a Change of Control Triggering Event and Separation from Service and (ii) a severance payment for each non&#8209;executive employee upon a Non&#8209;Change of Control Triggering Event and Separation from Service. As defined in the severance plans, a Change of Control Triggering Event and Separation from Service requires a &#8220;double trigger&#8221; where: (i) an employee is terminated by us without cause in connection with a change of control or within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90f4246b-5d49-4a91-b146-a3f5449b7568" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months following a change of control provided, however, that if an employee is terminated by us in connection with a change of control but immediately accepts employment with our successor or acquirer, the employee will not be eligible for the benefits outlined in the plans, (ii) an employee resigns because in connection with a change of control, the offered terms of employment (new or continuing) by us or our successor or acquirer within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_109e94c4-7c72-4c91-8b44-d2c22870826c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days after the change of control results in a material change in the terms of employment, or (iii) after accepting (or continuing) employment with us after a change of control, an employee resigns within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20ebaed1-ecd8-445b-bce1-ff0885690c95" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months following a change of control due to a material change in the terms of employment. Under the severance plans, a Non&#8209;Change of Control Triggering Event and Separation from Service is defined as an event where an employee is terminated by us without cause. Severance payments range from</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_22c29184-2380-4a26-aec3-6f112ba2f86e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c474040-3f74-4eec-a7b2-a36944b8967d" contextRef="C_e14d38b0-ffbb-44d6-87e8-09d3acf16873" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months of base salary in connection with a Change of Control Triggering Event or from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bdc4642e-5d95-4614-922b-411dcd56cbf5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six weeks</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c692317-06b4-4fed-bc45-6581386b35bd" contextRef="C_e14d38b0-ffbb-44d6-87e8-09d3acf16873" name="gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months of base salary in connection with a Non-Change of Control Triggering Event, as well as a pro-rata portion of the employee&#8217;s annual target bonus, depending on the employee&#8217;s position with us, payable in a lump sum payment, and monthly COBRA payments for the severance period. The severance plans also provide that they shall not supersede the provisions of any individual employment agreements entered into between us and our employees, and that the employees with such agreements will be entitled to whichever benefits are greater under the severance plan or their employment agreement. A copy of the severance plan covering our executive officers is filed as an exhibit to this Report. As of December 31, 2024, all our executive officers have employment agreements with severance provisions and will receive the greater severance benefits of their agreements or those in the severance plan applicable to them.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_114ae0c2-e091-4840-913f-479caf2a793f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_114ae0c2-e091-4840-913f-479caf2a793f_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. OPERATING LEASES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Jersey Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91da9249-33ec-4a08-b47a-9e822ac3a70a" contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><ix:nonNumeric id="F_5b6735f4-22cb-4f45-99cc-2416017a6d75" contextRef="C_7b831c0a-b680-4a42-bf82-33530e797307" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_114ae0c2-e091-4840-913f-479caf2a793f_1" continuedAt="F_114ae0c2-e091-4840-913f-479caf2a793f_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44f26f98-f7cf-4131-ad99-b445e966b869" contextRef="C_7b831c0a-b680-4a42-bf82-33530e797307" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aca00b71-f6bf-4352-b860-21d9b1462d65" contextRef="C_05b9bc29-068c-441c-b91d-5eaab4b6ab0c" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-time option to terminate the New Jersey Lease without cause as of the 103</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month anniversary of the commencement date of the lease</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date. Based on the initial term of the New Jersey Lease of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c47a5cd-6650-4581-83f2-dbfea2a1fb8e" contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, the right-of-use asset and corresponding operating lease liability was approxima</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tely</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79ff40fe-137f-4d8f-821f-822606ade7fe" contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ed770cd4-990e-452e-a6b9-d7cf0885d37d" contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represented the present value of lease pay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments over the initial lease term, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dd61fde-97ef-4a30-a1b9-883d710338d2" contextRef="C_c553e0ac-d5c1-4b9f-adf7-7df417d4ceff" name="gern:OperatingLeaseRentAbatementPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rent abatement period, using an incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9984cdf9-c65a-4901-9e5b-06eff40a9683" contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n information available as of October 1, 2019. As of December 31, 2024, the New Jersey Lease makes up $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74b1eb36-c3fb-48d7-910d-3c2e9b8cfdac" contextRef="C_87998687-0289-453c-ace1-aaa39dc47de9" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of our total right-of-use asset balance. Under the New Jersey Lease, we are also obligated to pay certain variable expenses separately from the base rent, including electricity and common area maintenance. Such costs are being expensed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the period they are incurred. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining lease term for the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1989ce0d-2947-4a57-9dad-1c2350516d55" contextRef="C_aebd100b-45b2-4709-8a8b-13cb1b274d38" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ye</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ars.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d691dd1-2782-46ed-a5ce-f1eb993bd83c" contextRef="C_63aba9ed-ce8e-4616-9977-5edb1c01930b" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_842cabde-297f-4ee3-895c-090d126f3b67" contextRef="C_63aba9ed-ce8e-4616-9977-5edb1c01930b" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Foster City Lease commenced on March 10, 2020, upon the substantial completion of all tenant improvements. As of the lease commencement date, the right-of-use asset and corresponding operating lease liability was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d1c8e00-cf9a-44cc-8a1d-ac6a8b4467f4" contextRef="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, which represented the present value of remaining lease payments using an incremental borro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">wing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a859a870-e267-46d8-8c3e-f2d9ad023d95" contextRef="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="INF">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% over the initial lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_baef92d4-b523-450e-9f60-5d63e5b0cc7b" contextRef="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbc037db-28d3-4039-acd2-8b40ae896f50" contextRef="C_1d985ed6-a26a-4250-9a37-ac2116b89df0" name="gern:OperatingLeaseRentAbatementPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rent abatement period. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Foster City Lease makes up $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_735c1ed7-fa79-458d-8767-1ec0b2a43ac4" contextRef="C_a8af3954-eaf3-42b5-9e3a-4922b0dd6706" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of our total right-of-use asset balance. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Foster City Lease, we are also obligated to pay certain variable expenses separately from the base rent, including taxes and common area maintenance. Such costs are considered non-lease components and have been excluded from the calculation of the right-of-use asset and corresponding operating lease liability and are being expensed in the period they are incurred. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining lease term for the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ded8bb3a-433e-4116-b0a9-d65f52ad7027" contextRef="C_6fcf6750-e138-4d4c-96d6-c8e04e8003f1" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_822e9d8f-c5f5-4142-954c-dde729234e78" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_822e9d8f-c5f5-4142-954c-dde729234e78_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, and the Foster City Lease were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:19.516%;box-sizing:content-box;"/>
        <td style="width:22.555%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.296999999999997%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:2.639%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.077%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3.259%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.657%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0423a5c3-b82b-4d35-b664-f0a44e92202d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">987</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10315d1f-a3db-41ad-8088-20c6293d7a84" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">962</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7b7cd93-6d60-46ca-b6e7-ccc1260f0eb3" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9516251-5ca6-4b3f-b958-e291a6b82a73" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa5f16e-5495-4595-a689-0897f84e6e7a" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">344</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73d7647e-0cd1-4569-835e-b7d8342bf7cf" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ce2de9b-5fa9-4725-901b-a0bfca313e9b" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,248</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40397594-a2ec-4303-86cb-b06ad35ff3e8" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,306</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffe1ddd6-225b-40d6-9594-3f0895f77657" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,254</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:10%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:60%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:continuation id="F_822e9d8f-c5f5-4142-954c-dde729234e78_1"><div class="item-list-element-wrapper" style="margin-left:5.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.3875491341761395%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs represent non-lease components, such as common area maintenance charges.</span></div></div></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_114ae0c2-e091-4840-913f-479caf2a793f_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb9759c0-efb8-43d2-862b-5c9b8f83af5e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:35.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.686%;box-sizing:content-box;"/>
        <td style="width:2.857%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:26.457%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eea94f30-4c31-48b6-92ec-d02c18d8e95f" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e6b2328-54d1-4a44-bb45-b9d65deb4809" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,040</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c143c1f8-a9e9-45b5-a020-9fb0737123ae" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">716</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd6ebd5f-0bc3-4aa9-ad49-6156b306290e" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">376</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ba97847-b1e4-4a52-95da-72b0673721f5" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aed5141e-c549-4b3d-bd4c-a8b24d1c6b69" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1387fa7-c968-40e6-baf0-1a058b3a5a2d" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,821</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bff9db2-c8ee-4428-91b5-ed7a77228313" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">581</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77e53283-f654-42b5-b051-e6139c1806eb" contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,240</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5c1fdfe9-ce4b-4173-ab4d-89d8cd31db6e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_5c1fdfe9-ce4b-4173-ab4d-89d8cd31db6e_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. DEBT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hercules Loan Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 30, 2020, we, Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, or SVB, entered into a term loan facility, or the Term Loan, for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76bdfd09-72a3-4b8a-a8dd-ae37425a78a8" contextRef="C_afd8ecd1-ed86-4a5a-81e0-ee569ecd5bc3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was amended in August 2021, or the Original Loan Agreement. On June 30, 2022, we entered into a second amendment to the Original Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c68839c2-660d-4ec4-9c15-a52a50030c39" contextRef="C_afd8ecd1-ed86-4a5a-81e0-ee569ecd5bc3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27e4423f-43f9-42b6-a9bd-871f050a20b1" contextRef="C_c65b60ba-872b-41db-a6e2-d82180268abc" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with such principal being available in a series of tranches, subject to certain terms and conditions. Over the course of the Term Loan, we had drawn down a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99bbfef3-95e4-4570-bcf6-3761decb9cfa" contextRef="C_7040d2ec-efa9-4e10-8449-1b261c220739" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All obligations outstanding under the Hercules Loan Agreement, amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4177ba3e-bae2-4733-b75d-6bb8b6efe8c7" contextRef="C_b78714b6-f9c0-495e-8c29-1ef95e3bcf60" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">86.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were repaid in full on November 1, 2024, upon which the Hercules Loan Agreement was terminated and all liens on our assets granted in connection with the Hercules Loan Agreement were released.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmakon Loan Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa5247f9-a31f-48af-a89a-6490d26c9658" contextRef="C_bf2a2f52-c8bd-498e-90a9-db80650a3434" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year senior secured term loan facility of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02696b3b-77ae-4b19-9800-c2b821af7d6f" contextRef="C_60b6c4c4-4c33-4d69-a53f-c3b0700c6a65" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">250.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe7d4bee-d856-4a67-8ac5-2134785c6fbf" contextRef="C_70ca9604-7e05-4828-abc7-17e9195e5429" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15cec262-b985-4dcd-8d75-1bd6d849eca9" contextRef="C_6535ff7f-99fc-4830-9136-f45d3598ba88" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80d1e5ed-b1f7-4f26-8136-770692d5d2f6" contextRef="C_e6cc2f93-1577-4be8-9efd-57f44ff9b16c" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, may be requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed under the Hercules Loan Agreement, which was terminated effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bc719cf-ae64-4464-89b7-d4b439007b06" contextRef="C_3b922920-9a03-448f-bb58-c0e801fa437e" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The remaining proceeds will be used to fund our general corporate and working capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loans mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da29e78c-1a5c-4d97-8dc8-2bbbccf33c35" contextRef="C_13a5e7dc-1814-4249-b841-344c76f1b61e" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 1, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Term Loans bear interest at a variable rate per annum equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae93062-8c1b-4c0e-bac9-6118c294bfdb" contextRef="C_13a5e7dc-1814-4249-b841-344c76f1b61e" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% plus the three-month Secured Overnight Financing Rate, or SOFR, with a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_63389fc4-357d-477a-9d6b-0ecf16309618;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOFR</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> floor of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33446183-d741-40b1-911e-c1c10c460dce" contextRef="C_61e2613d-481e-46a9-a123-9bcad10f9439" name="gern:DebtInstrumentFloorRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3dd16ee-6910-48c9-8f8d-8df2db843929" contextRef="C_70ca9604-7e05-4828-abc7-17e9195e5429" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Interest is due and payable quarterly on the last day of each quarter with the first payment due on December 31, 2024. The Pharmakon Loan Agreement requires we pay an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f062065-1237-4e1e-a24d-ed769cf0051f" contextRef="C_61e2613d-481e-46a9-a123-9bcad10f9439" name="gern:PercentageOfCommitmentAmountToFundLoan" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Lenders&#8217; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d8a2103-3fa5-429c-a86e-2c61ef692960" contextRef="C_1e35341b-2d2c-4a8f-916a-1bacddb10f79" name="gern:PrepaymentPremiumOnPercentageOfTermLoan" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fddd206a-84bd-4ec7-9ae8-c2c5d208f6d5" contextRef="C_10d09233-7a55-4348-a7b7-3be6db7ca118" name="gern:PrepaymentPremiumOnPercentageOfTermLoan" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26aaaa2e-5ddc-4015-ae69-bae3e5c1ab0b" contextRef="C_1e5e1688-ab30-4578-81a0-c6560b774866" name="gern:PrepaymentPremiumOnPercentageOfTermLoan" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a make-whole amount equal to the sum of all interest that would have accrued through such 2nd anniversary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_5c1fdfe9-ce4b-4173-ab4d-89d8cd31db6e_1" continuedAt="F_5c1fdfe9-ce4b-4173-ab4d-89d8cd31db6e_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Pharmakon Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pharmakon Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We and our subsidiaries are bound by certain affirmative covenants setting forth actions that are required during the term of the Pharmakon Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we and our subsidiaries are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Pharmakon Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#8217; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified exceptions. The Pharmakon Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or the occurrence of a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgements, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Pharmakon Loan Agreement. Upon the occurrence and during the continuance of an event of default, the Lenders may, among other things, accelerate our obligations under the Pharmakon Loan Agreement (including all obligations for principal, interest and any applicable make-whole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Minimum Payments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_794f4bb0-37a3-4057-9438-cfa7407db859" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.96%;box-sizing:content-box;"/>
        <td style="width:46.1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:22.939999999999998%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38a7ff6-e913-466f-922b-48ac43ea3d9e" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4ea4e9e-0c35-4743-a354-7cd678305911" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_010012e2-13d3-47a7-a8a5-fc58def85351" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11ad6189-586b-45fa-8dcb-af1c1b0a7e75" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,081</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d7be102-e675-4943-b388-e6e258d0a9bd" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,116</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_341f750b-37ad-46f3-88c1-1f7d5e54f69d" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">135,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba5929f-7f13-4571-b274-771c8dabb74a" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:LongTermDebtGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190,475</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:  amount representing interest</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f931d163-2940-4404-a5ac-f1486b1e6c8d" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:AccumulatedCapitalizedInterestCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,474</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:  unamortized debt discount and issuance costs</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ac48523-4275-421f-bc46-2e264ff39033" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent portion of debt</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e7870e8-e27d-480b-9a49-661f9debf37d" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,476</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities Related to Sale of Future Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, </span><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#2b333d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be2c395-bacf-4bd3-9574-dc5ded19e6d0" contextRef="C_9bd8d342-06ae-415c-868d-cf0b5f73cacf" name="gern:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Purchase Price, in exchange</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for which Royalty Pharma obtained the right, or the Revenue Participation Right, to receive certain amounts calculated as a percentage of future U.S. net sales of RYTELO for each calendar quarter, or Royalty Payments, during the term contemplated by the Royalty Pharma Agreement. Specifically, </span><span><ix:nonNumeric id="F_7b048f02-cf35-40a7-a192-f0d4971bc451" contextRef="C_54e7473e-71f1-4f3c-b458-f1ccbff39749" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" continuedAt="F_7b048f02-cf35-40a7-a192-f0d4971bc451_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue participation rate commences at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35e97a9d-8a7b-46ec-9232-24b02fdce884" contextRef="C_cba66e27-c320-4315-b06d-66eeb091ebf4" name="gern:PercentageOfAnnualNetSales" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">7.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for annual U.S. net sales of up to and equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ebbb937-cf7e-4183-ad96-7afcd2e250e2" contextRef="C_4d32eb3b-1b07-4090-88b7-029d9a631b5c" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">500.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million declining to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56f555b1-6250-471c-897f-62b4912ba4c0" contextRef="C_04908c45-edaa-4013-80e1-3425b2d3f4a4" name="gern:PercentageOfAnnualNetSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for annual U.S. net sales exceeding $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a29ca48e-8e17-4d49-8bc3-a2ba16b01e9c" contextRef="C_97cc69ce-fec1-4d91-ac38-fcc58be903e6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="9" decimals="INF" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031 or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.</span></ix:nonNumeric></span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5c1fdfe9-ce4b-4173-ab4d-89d8cd31db6e_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7b048f02-cf35-40a7-a192-f0d4971bc451_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we had the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Buy-Out Payment&#8221; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the Royalty Pharma Agreement as a financing liability, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over the estimated term of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined the fair value of the liability related to the sale of future royalties is based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying value of the liabilities related to sale of future revenues as of December 31, 2024 is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec063344-2353-4416-8a35-96fb1fdf6f11" contextRef="C_85175ee7-1c57-4e09-a0fa-9cca0710633c" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">124.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ab0878c-a6c2-4d06-ba96-2b0352d6ebe3" contextRef="C_54e7473e-71f1-4f3c-b458-f1ccbff39749" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in non-cash interest expense in the twelve months ended December 31, 2024 related to the Royalty Pharma Agreement.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eefd9704-a69d-4515-882e-b0edcc67eaae" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the activity within the liability related to sale of future royalties during the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.8%;box-sizing:content-box;"/>
        <td style="width:1.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:33.24%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liability Related to Sale of Future Royalties</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrying value of liability related to sale of future royalties at November 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d72dd40a-3c2a-45a0-8519-16ba9a624278" contextRef="C_6a2d0968-c085-4357-bd45-6a8affcd8162" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,634</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5a18c7c-ebfe-43c4-b2c9-383da735613b" contextRef="C_e03f65aa-0f08-4125-91e7-89e207442e89" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,345</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f26d212-9661-4e91-9132-f1e710408d4c" contextRef="C_e03f65aa-0f08-4125-91e7-89e207442e89" name="us-gaap:PaymentsForRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,186</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrying value of liability related to sale of future royalties at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc3f064f-6e69-4be3-bea3-46da67435b2e" contextRef="C_85175ee7-1c57-4e09-a0fa-9cca0710633c" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">124,793</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Embedded Derivatives and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.  The embedded derivatives are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023 our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c014d901-a55e-49db-9583-80e3ebec9445" contextRef="C_2f48563d-cfb2-405d-b3c5-32ab5e666ff0" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">675,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c70bce0-764e-4a57-81fa-7b6c188c756f" contextRef="C_ffad885e-eeb0-4c57-b284-7102190be086" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,350,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 1, 2022, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a104fbc-561d-46e9-8891-f4d3c4eb77ec" contextRef="C_5d81f491-dae6-42b2-9a9d-49bae561bc54" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,333,334</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b232a02-f42f-4cbb-80bb-8c65dc4fed9d" contextRef="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,095,238</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2022 pre-funded warrant, together with accompanying warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c61191f2-3d3f-4fe4-9123-56d1d0118067" contextRef="C_48142c5b-ce3f-4966-921e-0b74263697ba" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,714,286</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our common stock, also known as the 2022 stock purchase warrants. The shares of common stock and the 2022 pre-funded warrant were immediately separable from the 2022 stock purchase warrants. All of the securities were issued separately. The combined public offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_1" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the common stock and accompanying 2022 stock purchase warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c4b6126-4b64-4ddf-9bbc-7e74de0486e8" contextRef="C_bd7cb667-7647-4a87-b629-ce1a51b824be" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2022 stock purchase warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62127ad7-9e6b-471a-8187-707249fb6119" contextRef="C_48142c5b-ce3f-4966-921e-0b74263697ba" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and are exercisable immediately. The term of the 2022 stock purchase warrants expired in the third quarter of 2023, pursuant to the terms of the warrant agreement. The combined public offering price of the 2022 pre-funded warrant and accompanying 2022 stock purchase warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f725df0a-fd87-4784-86d6-ca87f3e98e95" contextRef="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">1.049</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2022 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3baf58cf-5353-41c2-a510-43cb3f391888" contextRef="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until the 2022 pre-funded warrant is exercised in full. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of the 2022 pre-funded warrant and all of the 2022 stock purchase warrants have been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_458d86c8-2ddc-4375-ba7b-e10fc8cfdde8" contextRef="C_5d81f491-dae6-42b2-9a9d-49bae561bc54" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2022 pre-funded warrant and 2022 stock purchase warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the issuance of the 2022 pre-funded warrant and 2022 stock purchase warrants, we evaluated the terms of each warrant to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and FASB Accounting Standards Codification Topic 815,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2022 pre-funded warrant and the 2022 stock purchase warrants include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2022 pre-funded warrant and the 2022 stock purchase warrants should be classified as equity with no subsequent remeasurement as long as such warrants continue to be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 10, 2023 we completed an underwritten public offering consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_723049e2-3322-41b2-a2aa-32f55d5fc666" contextRef="C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">68,007,741</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and the 2023 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c07e95e5-4d91-4418-8749-39c7b5292ff2" contextRef="C_e3f5c2dc-7c9d-424d-9590-a69e1018f7df" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.45</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The public offering price of the 2023 pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8e78a05-2c34-48b2-b012-233768dd2d38" contextRef="C_432034fc-3319-4587-adae-2e7c9b692266" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">2.449</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2023 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b55bbbf-bc04-4cf5-8efd-cb3133feada7" contextRef="C_432034fc-3319-4587-adae-2e7c9b692266" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until the 2023 pre-funded warrant is exercised in full. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, none of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 pre-funded warrant has been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe68040-bd73-49a7-998c-9ed2e9d09091" contextRef="C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">213.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2023 pre-funded warrant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the issuance of the 2023 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and FASB Accounting Standards Codification Topic 815, Derivatives and Hedging. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2023 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2023 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29552e16-556c-45c9-a94f-642d4261c2a7" contextRef="C_a4269ae4-d56a-4edf-a592-a2ea8119922f" name="gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">41,999,998</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_764c762f-bb68-49e8-9f30-a1794d07cdc8" contextRef="C_f79ee241-9a76-41d9-93df-733bd1f3b85d" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,002,668</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2024 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8f6e1f1-41d6-446a-8ec3-494a94483a86" contextRef="C_faf26aae-a2ff-481b-b390-795807f43711" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The public offering price of the 2024 pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7209635b-1585-437a-b031-0b2266fce8af" contextRef="C_f79ee241-9a76-41d9-93df-733bd1f3b85d" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2024 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_371673e8-9a3a-431a-9fb2-0c5990fb6c36" contextRef="C_f79ee241-9a76-41d9-93df-733bd1f3b85d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until the 2024 pre-funded warrant is exercised in full. As of December 31, 2024, none of the 2024 pre-funded warrant has been exercised. The net cash proceeds from the March 2024 offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e96fcd6-0c3d-4f9c-aeda-8d95e3a0f1df" contextRef="C_a4269ae4-d56a-4edf-a592-a2ea8119922f" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">141.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting the underwriting discount and other offering expenses paid by us, and excluding any future proceeds from the exercise of the pre-funded warrant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the issuance of the 2024 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and FASB Accounting Standards Codification Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2024 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2024 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_2" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_3"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Exercises</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, warrants to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c12ab290-2ddb-48be-bd7d-99e354b62529" contextRef="C_9660272a-a38b-4587-990c-81de73711c8d" name="gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,071,981</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_819b3bbc-e42f-4342-b85f-86afa1e992f5" contextRef="C_e92973db-cfa0-4226-992e-ba00f3710cd8" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants were issued in connection with underwritten public offerings of common stock and pre-funded warrants, together with accompanying stock purchase warrants in May 2020, April 2022, and January 2023. As of December 31, 2024, the following warrants remained outstanding:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-funded warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85f6c159-24f2-4011-a39b-6566570193d4" contextRef="C_04ccb33e-9db2-4428-ab1f-e86203e71f68" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to purchas</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d3ea270-02c7-401f-8ad8-8ff51e2f023d" contextRef="C_04ccb33e-9db2-4428-ab1f-e86203e71f68" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,433,145</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, which have no expiration date; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock purchase warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7d76a28-4b0e-4d40-818b-53c4be01d05f" contextRef="C_f784b962-1d18-4a7e-8f25-c81f2229ede3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98c99134-80a6-4434-937c-7111edefc0da" contextRef="C_f784b962-1d18-4a7e-8f25-c81f2229ede3" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,402,522</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hares of our common stock related to the public offering of our common stock in May 2020, which expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13efd343-b34e-48fc-8bc5-3964de0a143d" contextRef="C_f784b962-1d18-4a7e-8f25-c81f2229ede3" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dfa8a73-0946-40b2-8186-ccab75d428d3" contextRef="C_8348b52f-8813-4f32-97db-ccc55a82dd58" name="gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,349,859</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae767d76-9962-4f25-85f2-0f08cef5e160" contextRef="C_7e54cf5e-d7b0-4905-96d8-e3ba1772cfd6" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">105.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million The warrants were issued in connection with an underwritten public offering of common stock and a pre-funded warrant, together with accompanying stock purchase warrants in May 2020. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32799005-a514-4411-922b-5d10baa833cb" contextRef="C_ebc02be3-4e6f-4b78-bff8-d2cfc26bed45" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">51,430,477</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock was outstanding and stock purchase warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2c898d6-bd2e-4d6b-955a-601ee94459a6" contextRef="C_f086f31f-ebe6-4d2c-8914-9edaca62d90f" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,474,503</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock associated with the May 2020 public offering remained outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement with B. Riley, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b723e34-8b5d-4f83-b8bb-52d2804ea4fe" contextRef="C_f0e977cf-938a-4204-9bd8-6c42bf0b34b1" name="gern:CommonStockAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from time to time through B. Riley as the sales agent. We have agreed to pay B. Riley an aggregate commission rate equal to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50ab5eb7-a0dd-4d72-876a-d8d1ef6232d8" contextRef="C_f0e977cf-938a-4204-9bd8-6c42bf0b34b1" name="gern:MaximumCommissionRate" unitRef="U_pure" scale="-2" decimals="INF">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2023 Sales Agreement.  The 2023 Sales Agreement will automatically terminate upon the earlier of (i) the sale of all common stock subject to the 2023 Sales Agreement, or (ii) termination of the 2023 Sales Agreement in accordance with its terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e47e178-0cf9-4fb0-a6bb-bdfe86d8efe5" contextRef="C_ece3b919-9c68-4419-b2c9-c5d7c4dcca3d" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f8cf00b7-24b3-49c3-b920-8caafa98a730" contextRef="C_2d097eb2-6e57-4299-a3e5-9151a4df0198" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock were sold pursuant to the 2023 Sales Agreement during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2011 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2011, our stockholders approved the adoption of the 2011 Incentive Award Plan, or 2011 Plan. The 2011 Plan provided for grants of either incentive stock options or nonstatutory stock options and stock purchase rights to employees (including officers and employee directors) and consultants (including non&#8209;employee directors). Upon the adoption of the 2018 Equity Incentive Plan in May 2018 (see below), no further grants of stock options or stock purchase rights were made under the 2011 Plan. Stock options granted under the 2011 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97147fad-d359-41d4-9a40-cefffd973ca1" contextRef="C_a450a2dc-f974-4416-9511-c7302a719fa4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. Stock option exercise prices were equal to the fair market value of the underlying common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service&#8209;based stock options under the 2011 Plan generally vested over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9c90039-2003-4b2d-b191-180e4bf4abb2" contextRef="C_eb68352e-6df9-4716-b022-e07659784349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. Other stock awards (restricted stock awards and restricted stock units) had variable vesting schedules which were determined by our board of directors on the date of grant. All outstanding awards granted under the 2011 Plan remain subject to the terms of the 2011 Plan and the individual award agreements thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2018, our stockholders approved the adoption of the 2018 Equity Incentive Plan, or 2018 Plan, as the successor to the 2011 Plan. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. Eligible participants under the 2018 Plan include our employees, consultants and non-employee directors. The number of shares reserved for issuance under the 2018 Plan (subject to adjustment for certain changes in capitalization) is equal to the sum of (i) the unallocated shares of common stock remaining available for future grants under the 2011 Plan as of May 15, 2018, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b71a2b-6c6f-440c-969f-22aa98de0b76" contextRef="C_2fc64b5e-3892-4a81-a7e8-b127182a99ad" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> newly </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reserved shares of common stock and (iii) the number of shares subject to awards granted under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_3" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_4"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2002 Equity Incentive Plan, and the 2011 Plan as such shares become available from time to time, referred to as the Prior Plans&#8217; Returning Shares. Such Prior Plans&#8217; Returning Shares become available for issuance under the 2018 Plan if outstanding stock awards granted under the 2002 Equity Incentive Plan and the 2011 Plan, after May 15, 2018, expire or terminate for any reason prior to exercise or settlement or are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or, subject to certain exceptions, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award. In May 2023, May 2022 and May 2021, our stockholders approved amendments to our 2018 Equity Incentive Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4dcb7a-9778-4d04-a91c-956e73dd4b19" contextRef="C_46ea59e0-e969-4c87-9aa0-1688daa1c9f0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,360,000</ix:nonFraction></span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ae08904-49ee-4657-b765-c6649be071f3" contextRef="C_21447006-602d-46aa-a917-f6697b7e69d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58a2ad36-2004-4426-975b-94e5231d839b" contextRef="C_e3a7796a-70fb-4745-ac2a-15cfb3d6b8c8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an aggregate total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5352b55e-34dc-4626-afd9-73910cf7df24" contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,447,090</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock have been reserved under the 2018 Equity Incentive Plan, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a65134a1-110f-4148-8467-f36ef5536ed6" contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">32,587,928</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> available for future grants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2018 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75a9de43-de59-4e19-94c9-2883b71681c0" contextRef="C_18c60a52-303b-412b-986a-7e6145b28956" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. Stock option exercise prices shall be equal to the fair market value of the underlying common stock on the date of grant. If, at the time we grant a stock option, the optionee directly or by attribution owns stock possessing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31b10bbd-f5ca-453d-b895-df6fa8097c59" contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" unitRef="U_pure" scale="-2" decimals="INF">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total combined voting power of all classes of our stock, the stock option exercise price shall be at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7030c30d-afd9-44f7-aa79-739aaedea49b" contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" unitRef="U_pure" scale="-2" decimals="INF">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the underlying common stock and shall not be exercisable more than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c1071ac-0239-400a-9aa3-4d1bcf5e035b" contextRef="C_d3392540-02f2-4e5b-8f42-37beb9ba9e45" name="gern:ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We grant service-based and performance-based stock options to employees under the 2018 Plan. Service-based stock options generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8c096ae-3637-4c50-8712-b6054189a795" contextRef="C_d3392540-02f2-4e5b-8f42-37beb9ba9e45" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of the stock option grant. Performance-based stock options vest upon the achievement of specified milestones. Other stock awards (restricted stock awards and restricted stock units) have variable vesting schedules as determined by our board of directors on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain circumstances, stock options may be exercised prior to vesting, subject to our right to repurchase the shares underlying such stock option at the exercise price paid per share. Our repurchase rights would generally terminate on a vesting schedule identical to the vesting schedule of the exercised stock option. During 2024 and 2023, we did not repurchase any shares under the 2018 Plan. As of December 31, 2024, we have no shares outstanding subject to repurchase under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our Non&#8209;Employee Director Compensation Policy adopted by our board of directors in March 2014, as amended and restated in February 2024 and February and March 2022, provides for the automatic grant to non&#8209;employee directors of the following types of equity awards under the 2018 Plan:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each person who becomes a non&#8209;employee director, whether by election by our stockholders or by appointment by our board of directors to fill a vacancy, will automatically be granted a stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38a9c6ba-04b2-46f6-9a25-7dff361929c1" contextRef="C_dba11232-95dc-4b7a-a0b2-f0bc6076e0cb" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">270,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, or First Director Option, on the date such person first becomes a non&#8209;employee director. The First Director Option vests annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d679e5ae-55e5-4d01-8549-f749fa07c0f1" contextRef="C_f18cad10-57aa-4265-bcc3-f8c0b2fe427f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon each anniversary date of appointment to our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsequent Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each non&#8209;employee director (other than any director receiving a First Director Option on the date of the annual meeting) will automatically be granted a subsequent stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89510334-1c74-4a57-bf71-39b3b1e811e0" contextRef="C_c3e030b6-7508-4442-bbe2-6485ef87fd91" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">180,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, a Subsequent Director Option, on the date of the annual meeting of stockholders in each year during such director&#8217;s service on our board of directors. The Subsequent Director Option vests in full on the earlier of: (i) the date of the next annual meeting of our stockholders or (ii) the first anniversary of the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, our board of directors approved the adoption of the 2018 Inducement Award Plan, or the Inducement Plan, pursuant to which we reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2c440e3-9337-48c6-b6e8-4b970922545c" contextRef="C_c155be43-9cca-497f-9c0d-dff7e4f971aa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock to be used exclusively for grants of inducement awards to individuals who were not previously Geron employees or non-employee directors, other than following a bona fide period of non-employment.  Since adoption of the Inducement Plan, t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he compensation committee of our board of directors, or the compensation committee, has approved amendments to our Inducement Plan to increase the aggregate total number of shares issuable under such plan to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d2759f6-840f-47f7-9a39-989d04e516f7" contextRef="C_c2ddaf0c-c480-4121-89b7-e270b06ea351" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock.  The most recent amendment, approved by the compensation committee in December 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b69b6421-0aa8-43f1-a94a-12eb2f6a3c28" contextRef="C_e3cb3a12-8449-4080-9d04-c09977c81469" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, effective as of January 1, 2025, to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc7492b1-5495-4fff-bd63-ec595ebefb31" contextRef="C_833a88bd-1656-4796-b8aa-0fb692b42fdd" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, an aggregate total of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_4" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_5"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c42239d-43f6-4787-90e3-8357bd7e538a" contextRef="C_1e3660ee-c4ab-4b1a-a885-f4768cde0fc5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,959,342</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock have been reserved under the Inducement Plan, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_111bf922-474d-4e2d-a6d4-1e43d8910483" contextRef="C_1e3660ee-c4ab-4b1a-a885-f4768cde0fc5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">851,137</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> available for future grants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards, and all awards under the Inducement Plan are intended to meet the standards under Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved 2018 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#8217; Market Value Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018, our board of directors adopted a Directors&#8217; Market Value Stock Purchase Plan, or the Directors Market Plan. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7206442e-75c5-4a3b-a767-d2e6b89689e7" contextRef="C_06fd0fff-364c-40d2-aea0-8957283902a3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock have been reserved for the Directors Market Plan. Under the Directors Market Plan, non-employee directors may purchase shares of our common stock at the prevailing market price on the purchase date with cash compensation payable to them for their services as a board member. As stated in Geron&#8217;s Non-Employee Director Compensation Policy, each non-employee director receives annual cash compensation, payable quarterly in arrears, for their services on the board and various committees of the board. As provided in the Non-Employee Director Compensation Policy, a non-employee director may elect to receive fully vested shares of common stock in lieu of cash and such shares shall be issuable from the Directors Market Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, we issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7095e372-1834-4031-b0c0-0be25fc01c15" contextRef="C_13450eff-f3fb-4504-9420-67b321adf1b9" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,351</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38bd2ffb-039e-45de-a882-f139de827b8a" contextRef="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,864</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec65d2d9-076b-46fd-a4f0-d99e39ec7fc4" contextRef="C_3111e83f-2076-4782-b9bc-ed01f0ea1874" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,962</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, under the Directors Market Plan. The weighted average grant date fair value of stock granted during the years ended December 31, 2024 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_228f093b-1ee9-4d9f-9461-4333ca16ab07" contextRef="C_13450eff-f3fb-4504-9420-67b321adf1b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.84</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_102bacf3-07da-4286-99ae-17a1cfb47d20" contextRef="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa3261cb-7824-4138-a1cb-a634eaf542a4" contextRef="C_3111e83f-2076-4782-b9bc-ed01f0ea1874" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. The total fair value of vested stock grants during 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78aa6370-2a7c-4d5a-b52b-5496668656ec" contextRef="C_13450eff-f3fb-4504-9420-67b321adf1b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">32,079</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4e9eb29-fbe4-4823-9e52-e9686a8ef5e4" contextRef="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">85,400</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8414026b-c487-426c-be46-c5cc5f26b268" contextRef="C_3111e83f-2076-4782-b9bc-ed01f0ea1874" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">29,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a032cf3-eca9-4ee7-9e1d-2fd152932be4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, Inducement Plan and Directors Market Plan is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.72%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Available</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For Grant</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87aa576e-a59b-42a6-a9bb-2686c5775867" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,750,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a10bac-9ff2-4312-9835-4deb56f4b110" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">72,984,351</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8239f2-a012-4f43-9792-81b252dbd5aa" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbad5f20-1212-499f-8f24-7d439ecbcd9d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,603,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7456b955-062c-4d2e-a23c-f00fcc322aff" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,603,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_334d4b75-2dc8-4c40-a2cb-084e12730670" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.86</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c3d9541-ca88-4bb7-a00a-b12f0c4e5f73" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,351</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_010e80d9-6bc7-4dab-9ec0-d5e23da2061b" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,907,649</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44963a4e-4959-4bba-935e-31e9798732e6" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.77</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options cancelled/forfeited/expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33613232-dc0d-4f0b-874b-66035d6c778b" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,171,390</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3edaafd9-b963-4db1-93e4-f949b95372e5" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,713,075</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ff0094a-4eb4-4407-ad9c-76d117b9c72e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.24</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e81efcfd-c962-4e21-8c2a-b19bde45c996" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,309,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d36a7fb7-46ca-4bee-b979-c294b906104c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,967,367</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b38a9d76-ef8e-4a4b-b9fc-4ce8d426cf86" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_4ffef491-959a-494e-85f7-cbd45140615c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.35</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fc12cc9-9a06-4754-b2ec-acf3f252f0f6" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">94,204,849</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercisable at <br/>&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1faf68a5-0fac-4e45-9b19-dbb9cd66cc08" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,943,520</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_112bf966-7183-4397-a8f1-7a236f24ca3c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.06</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_8775a655-6d98-463d-a52a-a61fb69fe49d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d911dea9-c35e-4747-9cbc-d44cf72120ea" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">57,488,305</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options fully vested and expected<br/>&#160;&#160;&#160;&#160;to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9ede76c-7c8e-415f-b3d1-8dcf5c535246" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">74,159,549</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb241461-5069-4082-b526-e458f5874866" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.39</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e94da6c0-333e-48d3-a3ba-2c39bd04e50e" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.30</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec5b6b1-8480-42ec-8c31-79df5efde3d8" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">92,613,420</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8a3c649-8e36-40e2-9457-22bc2071526a" contextRef="C_bdeda059-8b87-497a-b9cd-e4cf9530f303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based stock options granted that have not achieved the specified performance milestone.</span></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on Geron&#8217;s closing stock price of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d533cca2-4a6c-440b-9d27-2566338393fc" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.54</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of December 31, 2024, which would have been received by the option holders had all the option holders exercised their stock options as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, 2023 and 2022, there were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1ab4fcc-8673-4362-abb7-3877cae0ff40" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,943,520</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b36ba45-d79b-4541-b50f-0dfa5acd8a8e" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,995,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02f94de1-0a5d-4e4f-891b-357e42db3ea2" contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,085,389</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercisable stock options outstanding at weighted average exercise prices per share of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4642928b-cd89-4245-95cc-14c331376fe7" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cad2f14e-fec9-40d0-89fd-6af3a9b28350" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6520349b-0b78-4c21-a3d6-9e28174d4884" contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.17</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, all of which were granted at an exercise price equal to the fair market value of our common stock.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_5" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_6"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total pretax intrinsic value of stock options exercised during 2024, 2023, and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f3b4513-5f10-4c19-b7d4-6d8e1d131cb4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2248f6a-0017-41cc-a998-56a9b892ad24" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million  and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b87916bb-5607-42cb-8758-21fb898043a8" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Cash received from the exercise of stock options in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 totaled approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_851138b4-0dcb-4e30-9993-3fa01bad9d97" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="0" decimals="1" format="ixt:num-dot-decimal">31.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a575bfb0-ad62-4ba2-9fc1-383b4377b688" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="0" decimals="1" format="ixt:num-dot-decimal">12.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6ecad68-ffe4-4478-a6e0-d8a2a480554a" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="0" decimals="1" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2014, our board of directors adopted the 2014 Employee Stock Purchase Plan, or 2014 Purchase Plan. The 2014 Purchase Plan was approved by our stockholders in May 2014. The 2014 Purchase Plan replaced the 1996 Employee Stock Purchase Plan, or 1996 Purchase Plan, which was terminated effective as of the date the 2014 Purchase Plan was approved by our stockholders. In May 2022, our stockholders approved an amendment to our 2014 Purchase Plan to increase the total num</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b72fa4ad-1ae3-466b-be20-8bc5e4e9384a" contextRef="C_6ec90163-a65e-40c3-a187-132ae7c4e62a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, for an aggregate total reserve of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ab1d658-7b60-42a9-ab4b-b593757ce91f" contextRef="C_15852a6c-ac98-4815-b64c-948a1a3c90a1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ares. As of December 31, 2024, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46941953-ee56-4cf8-9ac5-8db0a31ca8f3" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,741,634</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock have been issued under the 2014 Purchase Plan since its adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2014 Purchase Plan is comprised of a series of offering periods, each with a maximum duration (not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca20c405-9648-4791-8abe-035c43e229b3" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months) with new offering periods commencing on January 1st and July 1st of each year. The date an employee enters the offering period will be designated as the entry date for purposes of that offering period. An employee may participate only in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff264806-ec98-43b8-8aab-3a3a7c5f3fcb" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" unitRef="U_Item" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> offering period at a time. Each offering period consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb17c524-23b1-4c2b-8fb8-b79af58c71d8" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" unitRef="U_Item" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive purchase periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3185bc27-2c8d-4b34-8366-84cba140bd65" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; duration, with the last day of such period designated a purchase date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the 2014 Purchase Plan, employees can choose to have up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2d13071-25b2-48fa-bfee-6a6e271f37ef" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" unitRef="U_pure" scale="-2" decimals="INF">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their annual salary withheld to purchase our common stock, up to a limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4f96dd0-c53a-47a4-bd4c-45b6bd27bd39" contextRef="C_275fb7a4-efea-4c31-83c8-55c94f697b31" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" unitRef="U_USD" decimals="INF" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per year. An employee may not make additional payments into such account or increase the withholding percentage during the offering period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purchase price per share at which common stock is purchased by the employee on each purchase date within the offering period is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9af08305-b4cd-4ef1-bb39-cd7cd6cff14b" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of (i) the fair market value per share of our common stock on the employee&#8217;s entry date into that offering period or (ii) the fair market value per share of our common stock on the purchase date. If the fair market value per share of our common stock on the purchase date is less than the fair market value at the beginning of the offering period, a new </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb1da935-4dec-4539-beb8-73e563b2c2cb" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month offering period will automatically begin on the first business day following the purchase date with a new fair market value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation for Employees and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure and recognize compensation expense for all share&#8209;based payment awards made to employees and directors, including employee stock options, restricted stock awards, restricted stock unit awards, and employee stock purchases, based on grant&#8209;date fair values for these instruments. We use the Black-Scholes option&#8209;pricing model to estimate the grant&#8209;date fair value of our service-based and performance-based stock options and employee stock purchases. The fair value for service&#8209;based restricted stock awards and restricted stock unit awards is determined using the fair value of our common stock on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As stock&#8209;based compensation expense recognized on the consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures, but at a minimum, reflects the grant&#8209;date fair value of those awards that actually vested in the period. Forfeitures have been estimated at the time of grant based on historical data and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, 2023, and 2022, our board of directors awarded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daa27c9d-c749-442c-bea1-c3ac9a63a794" contextRef="C_407442e0-3cce-4289-80e2-39b67a1f061b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">208,100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c848d2b-e871-4b46-aab6-f0e78c844f19" contextRef="C_53975bd8-a789-4655-ac7f-6b97e0b87f47" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">832,790</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a84183dc-c704-494e-87c9-d28f05e5fed6" contextRef="C_a177d587-0918-4df7-8a99-cd04f1e5d2b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,741,750</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> perfo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rmance-based stock options, respectively, to certain employees. These performance-based stock options are included in the outstanding stock options table above. Performance-based stock options vest only upon achievement of discrete milestones. Stock-based compensation expense for performance-based stock options is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being achieved, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize stock&#8209;based compensation expense for service-based stock options on a straight&#8209;line basis over the requisite service period, which is generally the vesting period. We reco</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gnized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_292cd253-dee7-4712-80b5-59cdcf07a91d" contextRef="C_407442e0-3cce-4289-80e2-39b67a1f061b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_6" continuedAt="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_7"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a796f5be-ab58-4f7c-9615-1d06dbf2d25b" contextRef="C_53975bd8-a789-4655-ac7f-6b97e0b87f47" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2023. We did not recognize any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended December 31, 2022 ,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as the achievement of the specified milestones was not considered probable during that time. </span><span><ix:nonNumeric id="F_e29fa5db-e1d1-4bd8-aa10-7d236dff595f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_e29fa5db-e1d1-4bd8-aa10-7d236dff595f_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock&#8209;based compensation expense related to service-based stock options and employee stock purchases for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, which was allocated as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e29fa5db-e1d1-4bd8-aa10-7d236dff595f_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.281%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.764000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8bcecef-21f2-443f-b2ab-fe5ec729cc42" contextRef="C_e43f9ac5-e990-42e5-a162-14377ebe69a7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,280</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4619605e-2e8d-4be1-aeeb-ed9deff1404a" contextRef="C_c38d97f7-08a0-4702-99f8-8f86ab3205f8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,426</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74fbd64f-f763-4eb0-936f-c336cb290b66" contextRef="C_501b1eb2-a39a-4305-ada7-ee277b99376c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,720</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f96d4a38-d64c-4133-b318-c8d745bdc462" contextRef="C_799b9a49-462d-486f-9022-ce4831f01775" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,647</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42746394-4723-4fb8-943c-1a8976a05ecc" contextRef="C_03b38bc3-3391-4183-82aa-61b99babb682" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,099</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e64e89e-a90a-4a58-82f7-3bebbea4ddcd" contextRef="C_23479e27-d886-45ff-8c25-d7ca04bd3cee" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,281</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a0bd475-5871-4827-9198-173eb6d4fc22" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,927</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b797ce7-4ed7-4067-89c9-6078bf9340ef" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea5c42ca-8066-41c0-b396-f639244c316b" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,001</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67d1e2d2-6d9b-4b5d-8de2-cf18dd54cc07" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was capitalized to inventory for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0072c981-b561-4dbb-b0c9-515bf89feccc" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 has been estimated at the date of grant using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.36%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89b3d1fa-d931-44a3-8c53-e4cfaa867e16" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6da028b-5e51-4dc1-abc4-f96dacd4d008" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b055a5a-b312-493d-836d-6841ba40ebe0" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9273b2b1-d2c2-4086-b8f7-5ea9170716e3" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f67b0d0-0d01-44c2-94b5-9255eaeb2935" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.87</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1fbdab7-0291-456f-baec-a70b61acad9a" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8738b1f7-c9bd-4ab4-9134-4c1bfb024ca8" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.83</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_803a4958-6f9f-4733-9aa2-426ca744445d" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.77</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b6809a3-4874-4fe4-a04c-37986c066c05" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.82</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3fa08fa-242f-4363-b449-58b32103e748" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_149272c7-93ca-4072-8596-79ffe399a50b" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb89a32a-af04-4f1e-9db4-d85d54101049" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71cdf7ea-1198-44a0-9721-b51c46aaffb0" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0efacec-e537-4a54-9639-8e67f86993ba" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ec4b954-3250-46af-9ab8-1e711e1ff135" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_04bc8b7a-d51b-45f0-828f-46c8920d56c3" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_71730464-1137-4c60-b926-c18ff90479dc" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ec7ab7b5-48ac-4594-9ca6-247731a994d2" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2ac6b6c-0e25-424f-8a13-22a7ca5eb0d4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of employee stock purchases in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 has been estimated using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:18.36%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8990397-5472-4ee6-b7c6-330ce5f8eb54" contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2823e92-db1f-46b7-bc9c-d78682c6cced" contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc1535ea-b119-4729-a581-7cb2fa09aece" contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e0adbd-b511-41bd-9060-9900c00733c4" contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">. to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e0cfa73-a7d1-40fa-b79b-153404379f2a" contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">1.19</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6de2ef5f-2ae7-47fe-aded-6714858136c1" contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4f2e8d8-e9f4-4f9b-ada4-b92147472d90" contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.83</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8133eb3-edce-4ce0-b470-75a1f0d56af3" contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.61</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21873e23-e898-474a-8058-90dceb51873f" contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">0.87</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd2c1918-bbdb-4d07-9bb9-262d291602c7" contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85b0299f-2495-4102-a33c-19a51c94136e" contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_505d1d20-406f-45f5-bbb9-7833032be38c" contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c1ab24a-5f41-4ff8-b1e9-9c1aa04b4e11" contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1615bc-702e-4334-be9b-9702530e06ea" contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fda18233-3858-496d-b1bd-643610f443d6" contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_dd861fee-bb87-4d8b-9fe3-b3ce158ed8c2" contextRef="C_478aad18-c78e-45d2-87ec-89af59700049" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_097a7de3-966d-4305-ae9e-ef69cbf2e4b9" contextRef="C_d6e09048-ab65-4a10-a9a5-9d240f0d04d7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_67498a68-c59d-4f03-a575-60029250bbc9" contextRef="C_ca99313c-81e1-4fdc-aa00-501a9a8750eb" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_99d2815d-eb8d-44d1-8f64-53ebbf21dfc0" contextRef="C_a0f038aa-10fb-4ef4-a320-6fa3bd5a6a6a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_fc5037f4-5f80-4ac4-9749-6833eee3da5a" contextRef="C_af40aa95-e806-4f0d-9a2b-c4155550c1c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><ix:nonNumeric id="F_eeeca4ad-e554-4806-9d91-3854743cd511" contextRef="C_710a5831-6f23-4a2b-a4c5-44b55c5ee9c6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend yield is based on historical cash dividend payments and we have paid no cash dividends to date. The expected volatility range is based on historical volatilities of our stock, since traded options on our common stock do not correspond to option terms and the trading volume of options is limited. The risk&#8209;free interest rate range is based on the U.S. Zero Coupon Treasury Strip Yields for the expected term in effect on the date of grant for an award. The expected term of stock options is derived from actual historical exercise and post&#8209;vesting cancellation data and represents the period of time that stock options granted are expected to be outstanding. The expected term of employees&#8217; purchase rights is equal to the purchase period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Black-Scholes option&#8209;pricing model, the weighted-average estimated fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6be0cd7-8b1c-4efb-b3ba-93189571f53e" contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dff05cb-9693-47ef-a6bd-be4584139e68" contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5cedbd5-ff2b-40e0-92cc-be4ca7c3c6db" contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. The weighted average estimated fair value of employees&#8217; purchase rights for the years ended December 31, 2024, 2023 and 2022 w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_538d214a-2df7-47e3-a52e-b39a81f166ce" contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.82</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd58051f-3eee-4ce1-9144-8cde0be35c78" contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9a14e17-177e-4b4c-b171-25f19ae35cd4" contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. As of December 31, 2024, total compensation cost related to unvested share&#8209;based payment awards not yet recognized, net of estimated forfeitures and assuming no probability of achievement for outstanding performance-based stock options, was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87188bbd-57b4-4bc0-a1f2-452859f8a3ab" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">65.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f658223-c795-4118-898d-363b73e0b4a7" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months on a weighted&#8209;average basis.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81_7"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation to Service Providers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We grant stock options to consultants from time to time in exchange for services performed for us. In general, the stock options vest over the contractual period of the consulting arrangement. The fair value of stock options held by consultants is recorded as operating expenses over the vesting term of the respective equity awards. With the adoption of Accounting Standards Update 2018-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASU 2018-07, in the first quarter of 2019, the measurement date of stock options granted to consultants was fixed at the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded stock&#8209;based compensation expe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nse of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a8bb30f-56c5-44a7-8bbe-dd0a21b0f65f" contextRef="C_dbe4854e-8234-4b3f-bb3b-8c19d5981bf6" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">103,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b9eef0c-cb7d-45c9-b11b-c2789438a21a" contextRef="C_7f4d8a67-ca97-43b2-8f25-f36157f4f6b9" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">742,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8b1cfb8-3b21-4e1f-b48e-9dc7afb6a654" contextRef="C_e0278ce3-6fc4-403a-a17d-ddee1151eca7" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">235,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the vested portion of the fair value of stock options held by consultants in 2024, 2023, and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0832cbd-a429-4d47-99aa-429b7b39acd0" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" escape="true" continuedAt="F_b0832cbd-a429-4d47-99aa-429b7b39acd0_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.133%;box-sizing:content-box;"/>
        <td style="width:1.667%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:23.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c9f6487-eeaa-48fd-9d0e-c7887bfc9bae" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,967,367</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and awards available for grant</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c39a25e6-f2f4-4f89-b509-63c85050427e" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,309,969</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9428bc9c-3cf6-4a9f-be79-488adc1b84d1" contextRef="C_b1066105-def2-48bc-a08b-a1be59df1fe9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">258,366</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ebc2ed8-9262-4a56-9588-7fb891241405" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,835,667</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16c03763-1d49-4890-b54b-378e8f588eaa" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">171,371,369</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_b0832cbd-a429-4d47-99aa-429b7b39acd0_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_c278426e-2e11-405d-a84e-14e8a6db247c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_c278426e-2e11-405d-a84e-14e8a6db247c_1"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. INCOME TAXES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b017453-31f6-4092-8682-5f5e8785e6e9" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of Income/(Loss) before income taxes are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.9%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.78%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3.4%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:20.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50557ddf-515b-44fd-b2c9-c3c745cc5d35" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,737</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b01fd18-9a23-43e2-8344-044121307003" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,884</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dc00069-39ac-4c39-acff-9b56318f3ab7" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,930</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b9b339a-15ba-4880-8bc0-0fcbd023e2a8" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bff284d-e457-4128-96d5-592306a07fce" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be5187eb-1c39-45a9-93ee-d24ae555bfbc" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4238943b-6083-4ee6-bbcc-aaba7f21907d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">174,521</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71eaeb9e-cbd6-49b1-8ac0-6ca3b8ccf3a1" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,734</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4df10418-d3b9-4262-a6ce-95e51685640d" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">141,902</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_344d87d8-665c-4e55-a78b-8551ac42f5e5" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provision for (benefit from) income taxes:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.224%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.164%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:4.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.104%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:4.201%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:21.104%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9feeb256-25c3-40df-98b1-8388fc7cbd51" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb5fbd20-acbf-4532-b80f-f7e6f7651752" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b6df448-453b-4e2c-9723-af8a606d4d0f" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_593b3d9a-6977-4a33-8bba-eb621befddd5" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">449</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2b18bde-16f2-42c4-ab42-e5b77eddd447" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div><ix:nonNumeric id="F_be0ae519-3c8f-4723-90fb-09b7a7ae4298" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_be0ae519-3c8f-4723-90fb-09b7a7ae4298_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.889%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.122%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3.281%;box-sizing:content-box;"/>
        <td style="width:5.181%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.122%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3.101%;box-sizing:content-box;"/>
        <td style="width:4.081%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.942%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:3.281%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c96094f-ae99-42ef-a0fb-4b83f622a016" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32b54690-9a4c-4dd9-bb92-3c792ad2f8d5" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f05cb2b-1a3b-41ea-b3ea-5c55c3e8798f" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79a49445-54df-4828-8330-8b63cf43941d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b90fb593-7b42-424a-a83a-cd700d682dd4" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f56a4d52-f9e4-47c3-9964-09d60fe69390" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db5554d7-ef1f-4348-815c-f5fab04c6552" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a2baacf-bda6-4ec0-9914-b1e1936cc496" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f43bc94c-617c-48dc-bad4-528024dd8a0f" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb9543c5-901b-4946-abeb-e87148cf2ef4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a42e3bc4-3511-49e4-8bf9-1342263af187" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1ef9afe-5764-46ac-92e8-8412a72ec72e" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss not benefitted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc40da67-4412-4b49-814a-e0f4265aaf22" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ba00e22-ff1c-4a40-ac88-f681ab18dd6a" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_412daa98-93d4-40cf-bcb2-097614cb028b" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21b85213-5ab0-4763-8ab3-7846173583cc" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5de68629-d8a5-4e96-b3dc-f916341ca694" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85385ef7-7e55-4759-8727-e9c9706d538f" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba23980a-21b4-4a02-b264-672665d98509" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">20.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9bee23b7-a7f9-4ed9-9d8a-97d28afcfb52" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24aa90ec-eff7-4079-9ea1-2a0f21e5d31d" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">27.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f95e797-d979-48a1-b23c-6e70ab0f2d2c" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f71be06-5b0b-4ec9-93e9-697f84c794bb" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6d8a9df-33b3-44b3-a3b7-e05578a164f7" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_c278426e-2e11-405d-a84e-14e8a6db247c_1" continuedAt="F_c278426e-2e11-405d-a84e-14e8a6db247c_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_be0ae519-3c8f-4723-90fb-09b7a7ae4298_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><ix:nonNumeric id="F_a6a2d675-1b16-4197-a27c-33ef09e6ce02" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_a6a2d675-1b16-4197-a27c-33ef09e6ce02_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of our deferred tax assets are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a6a2d675-1b16-4197-a27c-33ef09e6ce02_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.413%;box-sizing:content-box;"/>
        <td style="width:1.5%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.863000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.36%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.863000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22aa7ab5-9fec-48f5-bcec-d565a3d6150b" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e28bb15-4a68-4ce5-840d-3fe50872a4ff" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">272,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_248ba70e-362b-46f2-aadd-75edd00f086c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:DeferredTaxAssetsFederalAndStateCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,492</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f39763d-9b3d-4aad-9cff-53954b6aa769" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:DeferredTaxAssetsFederalAndStateCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,700</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f288367a-06e8-4214-8c70-d94933c49dfa" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,503</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_802c8d41-0e29-4ef5-a7b0-5fad9b76d3df" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,300</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2695cbf0-8ab0-4c4e-8e76-6c2d9c803214" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,353</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a28e1244-9c75-4ba5-9bce-ac8518918ebb" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue Participation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aedc9b3-e0a7-492e-b745-7a058591441c" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:DeferredTaxAssetsRevenueParticipation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c14c18c5-8484-4d9e-80f0-9e9a571244e8" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">767</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fa433c2-01fe-41d0-93f9-4b9c0d31c8e4" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,100</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2d76017-d274-4f52-896a-85f7f95bd070" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,963</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3a5aed4-8521-444d-8bee-d8e9c9a18b98" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,600</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629e99ba-e0c2-406a-acf4-b7a32234a2ee" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430,595</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4262e037-1cd2-4bbd-8213-3bb977975746" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">396,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1b2557-c0f8-4736-ae53-3c1c3092131b" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">429,913</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b5e4b13-af52-4eee-9b8a-9cc5588354c5" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">395,200</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b05030f-9a9b-41ec-a943-50e5eb38c4c2" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3bc2a6e-76db-4595-bfbc-171a5fb792cd" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71bf048c-27fb-4708-8474-1cec6421ed78" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a449bea5-ca91-47b3-8594-cec2084d151e" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8c7bb82-392c-43e3-b7dd-39d480340b71" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18aa806-f5a8-48cf-a18c-f9a3a1bb584b" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial performance. Forming a conclusion that a valuation allowance is not required is difficult when there is negative evidence such as cumulative losses in recent years. Because of our history of losses, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6e827f8-f06e-4ce6-ad5e-b3725cc9def1" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08a57297-c357-4716-ab25-a9020d01e1da" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">45.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had domestic federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec6b6fb-9e7b-4f04-9d7a-39e56b5d48bc" contextRef="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Of this, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fa734ba-3117-4c53-bbb5-1cf3012df2b5" contextRef="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d" name="gern:OperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">631.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will expire at various dates beginning in 2025 through 2037 and the remaining will carryforward indefinitely under the new tax laws, but is subject to an 80% taxable income limitation for tax years beginning after 2020. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdbec5e8-472a-4532-a9c4-5c2fe5abbaee" contextRef="C_f41156cc-9535-49b9-8050-64099a0eb8b5" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">844.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion expiring at various dates beginning in 2028 through 2044. We also had federal tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99e318da-e0ea-4967-855c-ba48a1ec32d9" contextRef="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million expiring at various dates beginning in 2025 through 2044, if not utilized. Our state tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92fb4ff2-2ece-4f06-a9c4-c622dfba21bb" contextRef="C_f41156cc-9535-49b9-8050-64099a0eb8b5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million carry forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We adopted the provision of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, we recognized no material adjustment in the liability for unrecognized tax benefits. At December 31, 2024, we had approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce50be07-a955-4cbd-8530-c4d0de68bf17" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on of unrecognized tax benefits, none of which would currently affect our effective tax rate if recognized due to our net deferred tax assets being fully offset by a valuation allowance.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a95789f9-59f9-436a-9d7a-45d513a8ca3f" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.757%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6685758f-99ae-4cfb-9628-fcc87fcdc6d5" contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,331</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37b54052-83f0-4681-aca9-7b605183f8d4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">494</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d00eab1-8f17-4f73-995d-d1a9aced1933" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cd695da-01b0-4d56-be0e-259b0bbfff44" contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,310</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If applicable, we would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2024, there has been no interest expense or penalties related to unrecognized tax benefits.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p></div>
  <div><ix:continuation id="F_c278426e-2e11-405d-a84e-14e8a6db247c_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently expect any significant changes to unrecognized tax benefits during the fiscal year ended December 31, 2025. In certain cases, our uncertain tax positions are related to tax years that remain subject to examination by the relevant tax authorities. Tax years for which we have carryforward net operating loss and credit attributes remain subject to examination by federal and most state tax authorities.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_bf6f0552-13cb-47d4-a6e4-f08885463ba8" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c511785-4766-47db-9e01-ed22138694e6" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true" continuedAt="F_6c511785-4766-47db-9e01-ed22138694e6_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.291%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.437000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.437000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.8%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.437000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental operating and investing activities:</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fb1ea8c-fa06-4264-bcd7-3bde3026dd6d" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1c2e20c-7283-40bc-a828-d0523acbcb6c" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">431</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e7267bc-dfe8-48d8-9916-557a0a6163ad" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Reclassification between prepaid and other<br/>&#160;&#160;&#160;current assets and deposits and other assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb843d14-0cdf-43ed-a8f3-59b1eef7fc7e" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="gern:ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest paid</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3bec6d6-5986-4bb0-b5d9-4f95d7d66c60" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,364</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b15287d-064c-4318-a7c8-dc82ce255e13" contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,017</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad87b9e7-319d-4e7d-80a4-e79b0afba167" contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,154</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_6c511785-4766-47db-9e01-ed22138694e6_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div><ix:nonNumeric id="F_f54e0200-00ca-49c0-8a9f-55169136964a" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. SEGMENT REPORTING</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently developing therapies for the treatment of hematologic malignancies. To date, our only source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, we have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a053beb-ea5a-4e72-8ea4-a985727ae767" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8351dcaf-de65-4b9f-9b6a-7412ad73e8d9" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment. We define our operating segments based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker or CODM to analyze financial performance, make decisions, and allocate resources. Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_48950aed-512d-4e10-b713-0562fb188089;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the CODM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_def9db1e-67ba-44fc-aa0f-849a8e72ba4b" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Further, the CODM reviews the segment's assets based on total assets reported on the consolidated balance sheet. All long-lived assets are held in the United States.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e943352-4435-4b34-963b-bad0d8f6f45a" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00ab337d-b01d-4a36-a8d7-35a482bf0fd4" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" escape="true" continuedAt="F_00ab337d-b01d-4a36-a8d7-35a482bf0fd4_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_00ab337d-b01d-4a36-a8d7-35a482bf0fd4_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.22%;box-sizing:content-box;"/>
        <td style="width:1.34%;box-sizing:content-box;"/>
        <td style="width:23.7%;box-sizing:content-box;"/>
        <td style="width:1.54%;box-sizing:content-box;"/>
        <td style="width:21.2%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="5" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Product revenue, net</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d715795b-7e05-4c20-9fca-ae92364b4f58" contextRef="C_50c8ecec-b2ba-4651-95b8-c5c262b21836" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">76.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Royalties</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a977d92-ae9d-4035-96c4-0bfa2a4cf478" contextRef="C_3776fecd-f521-4873-82e1-b99ba90cc41d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3305e6e-3f6e-4d3f-ad57-593dfc8e2deb" contextRef="C_b3d1f256-a05e-41ae-82ba-3a0ca866b306" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3e2d800-b451-4d0c-8217-ba0d27aaed1d" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">77.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdb86014-38a9-4fc6-bf91-a172e06a05e5" contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5cb804e-7489-4b5f-9a04-f554a87ae28c" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Research and clinical expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc1f27a8-1c04-485d-a974-bd48244341d8" contextRef="C_d0c523ca-eeda-4f55-8129-78a974c61e15" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">67.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2fd225c-13af-41b1-9091-4102a6c2a4fa" contextRef="C_912929c3-b7b6-4d47-ab01-1fc308ac8161" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">74.9</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Chemistry, manufacturing, and control expenses</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5d040de-6c94-4952-9f93-9d109862f597" contextRef="C_95b33fbb-e8c1-4fd0-a15d-92e7aa65e86a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.2</ix:nonFraction></span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5809ec53-7970-4c08-9e63-d7458efe52f7" contextRef="C_c57b8848-5a92-444a-b366-673e8854e689" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.5</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Commercial expenses</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7296b9c6-cef8-4e0d-b856-a9d3100166b3" contextRef="C_c72d7d41-863d-4713-921b-5709d77691bf" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">72.0</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cb10ff5-acab-44cd-add0-6b99610d2aad" contextRef="C_cc4a2b91-0d00-4a37-ad88-ee5bbfe05947" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.4</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses*</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_138d24fe-66d4-4838-b1b9-1328b58dd5f8" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">83.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8c82fbe-7476-4389-bb62-b894d69b33f0" contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.4</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7a1efd1-0d89-452d-8c6c-9f5e60f78697" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">250.7</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03acafaf-5499-407c-896c-4136828ece59" contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">194.2</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_062446a5-8ff8-4498-8226-e0f5935ad5cf" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">173.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_957d2082-ca36-4e85-9e62-c0b18e111bb2" contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">193.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and other income (expense)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bda81fa-1057-4c6e-a578-25ac4686f50c" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="gern:TotalInterestAndOtherIncomeExpense" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bc262d0-219f-4701-b573-997b210af84d" contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3" name="gern:TotalInterestAndOtherIncomeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61c4e5cc-237f-4de1-914d-950e4be1ec24" contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">174.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52c4579d-dded-4600-ac3f-a45b9075dc1e" contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">184.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.</span></p></ix:continuation></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, the Company consists of a single operating and reportable segment and the consolidated financial statements and notes thereto are presented as a single reportable segment.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9A. CONTROLS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AND PROCEDURES</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(I)  Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have carried out an evaluation under the supervision and with the participation of management, including our Chief Executive Officer and our Chief Financial Officer, of our disclosure controls and procedures (as defined in Rule 13a&#8209;15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In designing and evaluating disclosure controls and procedures, our management recognizes that any system of controls, however well designed and operated, can provide only reasonable assurance, and not absolute assurance, that the desired control objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals in all future circumstances. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our Chief Executive Officer and our Chief Financial Officer have concluded, based on their evaluation as of the end of the period covered by this Report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(II)  Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(III)  Management&#8217;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management is responsible for establishing and maintaining an adequate internal control over financial reporting for us. Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial reporting based on the framework set forth in &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on our evaluation under the framework set forth in &#8220;Internal Control&#8212;Integrated Framework,&#8221; our management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(IV)  Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Report includes an attestation report of our independent registered public accounting firm. It is set forth in Item 8 above.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_or_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9B. OTHE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8c55ddab-a213-4ac5-81f9-ef36eba0666c" contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f9cf7e9c-fb0f-43e9-90ce-0b4bff0c3bf1" contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a8a6e871-8d3f-4945-84f8-bde2c7635390" contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_aae82a06-82fd-4efc-9df8-a54d7784ffc1" contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9C.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> III</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain information required by Part III is omitted from this Report because we will file with the U.S. Securities and Exchange Commission a definitive proxy statement pursuant to Regulation 14A in connection with the solicitation of proxies for Geron&#8217;s Annual Meeting of Stockholders expected to be held in May 2025, or the Proxy Statement, not later than 120 days after the end of the fiscal year covered by this Report, and certain information included therein is incorporated herein by reference, or an amendment to this Report under cover of Form 10-K/A containing the information required by this Part III.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identification of Directors and Nominees for Director</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item concerning our directors and nominees for director is incorporated by reference from the section captioned &#8220;Proposal 1: Election of Directors&#8221; contained in our Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identification of Executive Officers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item concerning our executive officers is set forth in Part I, Item 1 of this Report.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Ethics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Conduct with which every person who works for Geron, including our board of directors, is expected to comply. The Code of Conduct is publicly available on our website under the Investors &amp; Media section at www.geron.com. This website address is intended to be an inactive, textual reference only; none of the material on this website is part of this Report. If any substantive amendments are made to the Code of Conduct or any waiver granted, including any implicit waiver, from a provision of the Code of Conduct to our Chief Executive Officer, Chief Financial Officer or Corporate Controller, we will disclose the nature of such amendment or waiver on that website or in a report on Form 8&#8209;K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copies of the Code of Conduct will be furnished without charge to any person who submits a written request directed to the attention of our Corporate Secretary, at our offices located at 919 East Hillsdale Boulevard, Suite 250, Foster City, California, 94404.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted an </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_082c05ad-5a5b-4b79-998a-30deffc0b416" contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> governing the purchase, sale and/or other dispositions of our securities by our directors, officers and employees. A copy of the Insider Trading Policy is filed as an exhibit to this Report. In addition, it is the Company&#8217;s practice to comply with applicable laws and regulations relating to insider trading.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Corporate Governance Matters</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item concerning our audit committee, audit committee financial expert and procedures by which stockholders may recommend nominees to our board of directors, may be found under the sections captioned &#8220;Board Leadership and Governance&#8221; and &#8220;Other Matters&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 11. EXECUTI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VE COMPENSATION</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference from the sections captioned &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Compensation Committee Report,&#8221; &#8220;Executive Compensation Tables and Related Narrative Disclosure,&#8221; &#8220;Compensation of Directors&#8221; and &#8220;Compensation Committee Interlocks and Insider Participation&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OW</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference from the sections captioned &#8220;Equity Compensation Plan Information&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference from the sections captioned &#8220;Proposal 1: Election of Directors&#8221; and &#8220;Certain Transactions&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOU</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NTANT FEES AND SERVICES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference from the section captioned &#8220;Principal Accountant Fees and Services&#8221; contained in the Proxy Statement.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 15. EXHIBITS AND FINAN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CIAL STATEMENT SCHEDULES</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) (1) Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in Part II, Item 8 of this Report:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.8%;box-sizing:content-box;"/>
    <td style="width:6.2%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets&#8212;December 31, 2024 and 2023</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><a href="#statements_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations&#8212;Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><a href="#statements_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Comprehensive Loss&#8212;Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><a href="#statements_stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity&#8212;Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><a href="#statements_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows&#8212;Years Ended December 31, 2024, 2023 and 2022</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#note_1_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial statement schedules are omitted because they are not required or the information is disclosed in the financial statements listed in Item 15(a)(1) above.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:18pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:45.84%;box-sizing:content-box;"/>
    <td style="width:9.6%;box-sizing:content-box;"/>
    <td style="width:6.72%;box-sizing:content-box;"/>
    <td style="width:18.24%;box-sizing:content-box;"/>
    <td style="width:11.6%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporation by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit<br/>Number</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing Date</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677412002137/exhibit3-3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 18, 2012</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677412002137/exhibit3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 18, 2012</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677419001851/geron3600721-ex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0000886744/000120677421001453/geron3909221-ex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 13, 2021</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023026166/gern-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of the Restated Certificate of Incorporation</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 2, 2023</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023070765/gern-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws of Registrant</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 15, 2023</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017024022056/gern-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Capital Stock</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2024</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000104746913002849/a2213377zex-4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Common Stock Certificate</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 15, 2013</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677420001694/geron3763911-ex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 26, 2020</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677420001694/geron3763911-ex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Warrant to Purchase Common Stock</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 26, 2020</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459022012684/gern-ex41_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 30, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023000349/gern-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 6, 2023</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017024033921/gern-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 20, 2024</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677412000967/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2012</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677411001222/exhibit10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2011 Incentive Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 16, 2011</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000104746913002849/a2213377zex-10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement under 2011 Incentive Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 15, 2013</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000104746913002849/a2213377zex-10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Award Agreement under 2011 Incentive Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 15, 2013</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000110465915035645/a15-6935_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non&#8209;Employee Director Stock Option Agreement under 2011 Incentive Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 7, 2015</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023026166/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan, as amended*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">June 2, 2023</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">UK Sub-Plan to 2018 Equity Incentive Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of 2018 Equity Incentive Plan Option Agreement (Time Based)*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of 2018 Equity Incentive Plan Option Agreement (Performance Based)*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1013_107.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Non-Employee Director Stock Option Agreement under 2018 Equity Incentive Plan, as amended*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1015_105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance-Vesting Stock Option Agreement under 2018 Equity Incentive Plan, as amended*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="gern-ex10_12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Agreement under 2018 Equity Incentive Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="gern-ex10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2018 Inducement Award Plan, as amended January 1, 2025*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">UK Sub-Plan to 2018 Inducement Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1019_103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Stock Option Agreement under 2018 Inducement Award Plan, as amended*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1020_102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance-Vesting Stock Option Agreement under 2018 Inducement Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex10_17.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Restricted Stock Unit Agreement under 2018 Inducement Award Plan*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677422001399/geron4061651-ex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2014 Employee Stock Purchase Plan, as amended*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 13, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:45.84%;box-sizing:content-box;"/>
    <td style="width:9.6%;box-sizing:content-box;"/>
    <td style="width:6.72%;box-sizing:content-box;"/>
    <td style="width:18.24%;box-sizing:content-box;"/>
    <td style="width:11.6%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_6.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of 2018 Inducement Award Plan Option Agreement (Time Based)*</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017022022712/gern-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of 2018 Inducement Award Plan Option Agreement (Performance Based)*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017024022056/gern-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Policy, as amended February 16, 2022, March 7, 2022 and February 14, 2024*</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2024</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459018026208/gern-ex101_99.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors&#8217; Market Value Stock Purchase Plan, effective October 1, 2018*</span></a><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 1, 2018</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459022009627/gern-ex1022_125.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Severance Plan, effective as of January 1, 2022*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 10, 2022</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1029_99.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement between the Registrant and John A. Scarlett, M.D., effective as of January 31, 2019*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019006759/gern-ex1031_97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Employment Agreement between the Registrant and Andrew J. Grethlein, effective as of January 31, 2019*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 7, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023057760/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Scott A. Samuels, effective as of August 1, 2023*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 2, 2023</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023057760/gern-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Michelle Robertson, effective as of September 25, 2023*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 2, 2023</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017024123282/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and James Ziegler, effective as of September 9, 2024*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 7, 2024</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="gern-ex10_29.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement by and between the Registrant and Joseph Eid, effective as of November 11, 2024</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000156459019015326/gern-ex1018_162.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease Agreement by and between Registrant and 3 Sylvan Realty LLC, effective as of April 30, 2019</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">May 2, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000120677419003542/geron3657421-ex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease Agreement by and between Registrant and Hudson Metro Center LLC, effective as of October 9, 2019</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">October 15, 2019</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000&#8209;20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.06875in;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017023057772/gern-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">At Market Issuance Sales Agreement, dated November 1, 2023, by and between Registrant and B. Riley Securities, Inc.</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 2, 2023</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex10_33.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Loan Agreement, dated November 1, 2024, among Registrant,  BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership&#x5E;</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Revenue Participation Right Purchase and Sale Agreement, dated November 1, 2024, by and between Registrant and Royalty Pharma Development Funding, LLC&#x5E;</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (see signature page)</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Form of Rule 13a&#8209;14(a), as adopted pursuant to Section 302(a) of the Sarbanes&#8209;Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Form of Rule 13a&#8209;14(a), as adopted pursuant to Section 302(a) of the Sarbanes&#8209;Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002**</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:45.84%;box-sizing:content-box;"/>
    <td style="width:9.6%;box-sizing:content-box;"/>
    <td style="width:6.72%;box-sizing:content-box;"/>
    <td style="width:18.24%;box-sizing:content-box;"/>
    <td style="width:11.6%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="gern-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#8209;Oxley Act of 2002**</span></a></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/886744/000095017024022056/gern-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Incentive Compensation Recoupment Policy, effective October 2, 2023*</span></a></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 28, 2024</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">000-20859</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The following materials from the Registrant&#8217;s annual report on Form 10&#8209;K for the year ended December 31, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL) include: (i) Consolidated Balance Sheets as of December 31, 2024 and 2023, (ii) Consolidated Statements of Operations, Consolidated Comprehensive Loss, Stockholders&#8217; Equity and Cash Flows for each of the three years in the period ended December 31, 2024, and (iii) Notes to Consolidated Financial Statements</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;text-indent:8.1pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-8.1pt;padding-left:8.1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x5E;    Certain portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted information is of the type that the Registrant customarily and actually treats as private or confidential.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*     Management contract or compensation plan or arrangement.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**   The certifications attached as Exhibits 32.1 and 32.2 that accompany this Report, are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Report), irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 16. FORM</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 10&#8209;K SUMMARY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GERON CORPORATION</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michelle Robertson</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MICHELLE ROBERTSON</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Vice President, Finance,</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW BY ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, John A. Scarlett, M.D. and Michelle Robertson, and each one of them, attorneys&#8209;in&#8209;fact for the undersigned, each with the power of substitution, for the undersigned in any and all capacities, to sign any and all amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys&#8209;in&#8209;fact, or his or her substitutes, may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his/her name.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:17.82%;box-sizing:content-box;"/>
    <td style="width:8.88%;box-sizing:content-box;"/>
    <td style="width:15.02%;box-sizing:content-box;"/>
    <td style="width:17.98%;box-sizing:content-box;"/>
    <td style="width:5.32%;box-sizing:content-box;"/>
    <td style="width:18.36%;box-sizing:content-box;"/>
    <td style="width:6.34%;box-sizing:content-box;"/>
    <td style="width:4.9%;box-sizing:content-box;"/>
    <td style="width:5.38%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;text-indent:10pt;vertical-align:middle;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John A. Scarlett</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board (Principal Executive Officer)</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">JOHN A. SCARLETT</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michelle Robertson</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Finance, Chief</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Officer and Treasurer (Principal</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial and Accounting Officer)</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MICHELLE ROBERTSON</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ GAURAV AGGARWAL</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GAURAV AGGARWAL</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dawn C. Bir</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DAWN C. BIR</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">V. Bryan Lawlis</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">V. BRYAN LAWLIS</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;text-indent:10pt;vertical-align:middle;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;text-indent:10pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John McDonald</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">JOHN F. McDONALD</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;text-indent:10pt;vertical-align:middle;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;text-indent:10pt;vertical-align:middle;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Susan Molineaux</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" rowspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SUSAN M. MOLINEAUX</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Elizabeth G. O&#8217;Farrell</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ELIZABETH G. O&#8217;FARRELL</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Robert J. Spiegel</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 26, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ROBERT J. SPIEGEL</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>gern-ex10_12.htm
<DESCRIPTION>EX-10.12
<TEXT>
<html>
 <head>
  <title>EX-10.12</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Sell to Cover</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Grant Notice<br>(2018 Equity Incentive Plan</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to its 2018 Equity Incentive Plan, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) hereby awards to Participant (as defined below), the number of restricted stock units specified and on the terms set forth below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The RSU Award is subject to all of the terms and conditions set forth herein and in the Plan and the Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></p>
  <table style="border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.58%;box-sizing:content-box;"></td>
    <td style="width:40.42%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Participant:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of Grant:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of Restricted Stock Units:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.14%;box-sizing:content-box;"></td>
    <td style="width:68.86%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vesting Schedule:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25% of the restricted stock units shall vest on the first anniversary of the date of grant and 25% annually thereafter, subject to the terms of the Plan, this Grant Notice and the Agreement.</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, vesting shall terminate upon Participant&#x2019;s termination of Continuous Service.</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issuance Schedule:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section  6 of the Agreement.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant Acknowledgements:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award is governed by this RSU Award Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the prospectus containing information required by Section 10(a) of the Securities Act (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the fullest extent permitted under the Plan and applicable law, any Withholding Taxes (as defined in the RSU Award Agreement) applicable to the RSU Award will be satisfied through the sale of a number of the shares issuable in settlement of the RSU Award as determined in accordance with Section 5 of the Agreement and the remittance of the cash proceeds to the Company. Under the Agreement, the Company or, if different, your employer shall make payment from the cash proceeds of this sale directly to the appropriate tax or social security authorities in an amount equal to the taxes required to be remitted. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The mandatory sale of shares to cover Withholding Taxes is imposed by the Company on you in connection with your receipt of this RSU Award.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acceptance of this Grant Notice and related RSU Award Agreement and Plan can be evidenced through original signature on the relevant document or acknowledgment through an online or electronic system established and maintained by the Company or another third party designated by the Company.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:  RSU Award Agreement, 2018 Equity Incentive Plan, as amended</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Sell to Cover</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation <br>2018 Equity Incentive Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement (RSU Award)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As reflected by your Restricted Stock Unit Grant Notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Geron Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has granted you a RSU Award under its 2018 Equity Incentive Plan, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for the number of restricted stock units as indicated in your Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The terms of the RSU Award as specified in this Award Agreement for the RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Grant Notice constitute your &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general terms applicable to the RSU Award are as follows:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Plan Document</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9 of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on the RSU Award; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8(d) of the Plan regarding the Company&#x2019;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant of the RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This RSU Award represents your right to be issued on a future date the number of shares of the Company&#x2019;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 4 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by the RSU Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Restricted Stock Units shall vest as set forth in the Grant Notice. In the event of either a Change in Control or a Corporate Transaction that is not a license, and you have not terminated your Continuous Service prior to the effective date of the Change in Control or Corporate Transaction, then the vesting of your Restricted Stock Units will be accelerated in full upon the effective date of such Change in Control or Corporate Transaction.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">280G Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then any such 280G Payment (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be equal to the Reduced Amount. The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pro Rata Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless you and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of a Change in Control triggering the Payment shall perform the aforementioned calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or the Company.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 3(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 3(a) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in Section 3(a), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You shall receive no benefit or adjustment to the RSU Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with the RSU Award after such shares have been delivered to you.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that, regardless of any action taken by the Company, or if different, the Affiliate employing or engaging you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the ultimate liability for all income tax (including U.S. federal, state, and local taxes and/or non-U.S. taxes), social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax-Related Items</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award, including, but not limited to, the grant of the RSU Award, the vesting of the RSU Award, the issuance of shares in settlement of vesting of the RSU Award, the subsequent sale of any shares of Common Stock acquired pursuant to the RSU Award and the receipt of any dividends or dividend equivalent; and (ii) do not commit to and are under no obligation to reduce or eliminate your liability for Tax-Related Items.  Further, if you become subject to taxation in more than one country, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one country.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each vesting date, and on or before the time you receive a distribution of the shares underlying your Restricted Stock Units, and at any other time as reasonably requested by the Company in accordance with applicable law, you agree to make adequate provision for any sums required to satisfy the withholding obligations of the Company, the Employer or any Affiliate in connection with any Tax-Related Items that arise in connection with the RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Withholding Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company shall arrange a mandatory sale (on your behalf pursuant to your authorization under this section and without further consent) of the shares of Common Stock issued in settlement upon the vesting of your Restricted Stock Units in an amount necessary to satisfy the Withholding Taxes and shall satisfy the Withholding Taxes by withholding from the proceeds of such sale (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mandatory Sell to Cover</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  You hereby acknowledge and agree that the Company shall have the authority to administer the Mandatory Sell to Cover arrangement in its sole discretion with a registered broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FINRA Dealer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as the Company may select as the agent (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">who will sell on the open market at the then prevailing market price(s), as soon as practicable on or after each date on which your Restricted Stock Units vest, the number (rounded up to the next whole number) of the shares of Common Stock to be delivered to you in connection with the vesting of the Restricted Stock Units sufficient to generate proceeds to cover (i) the Withholding Taxes that you are required to pay pursuant to the Plan and this Agreement as a result of the vesting of the Restricted Stock Units (or shares being issued thereunder, as applicable) and (ii) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto any remaining funds shall be remitted to you.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, for any reason, such Mandatory Sell to Cover does not result in sufficient proceeds to satisfy the Withholding Taxes, or if such Mandatory Sell to Cover is not permitted by applicable law, the Company or an Affiliate may, in its sole discretion, satisfy all or any portion of the Withholding Taxes relating to the RSU Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company or the Employer; (ii) causing you to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with your Restricted Stock Units with a fair market value (measured as of the date shares of Common Stock are issued to you) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld will not exceed the amount necessary to satisfy the Company&#x2019;s required tax withholding obligations using the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Compensation Committee of the Board.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the tax withholding obligations of the Company and/or any Affiliate with respect to the Tax-Related Items are satisfied, the Company shall have no obligation to deliver to you any Common Stock.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event the Company&#x2019;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Tax-Related Items withholding obligation was greater than the amount withheld by the Company or your Employer, you agree to indemnify and hold the Company and your Employer harmless from any failure by the Company or your Employer to withhold the proper amount.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that the Mandatory Sell to Cover is imposed by the Company on you pursuant to the terms of the RSU Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts, or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s).  If the maximum rate is used, any over-withheld amount may be refunded to you in cash by the Company or Employer (with no entitlement to the equivalent in shares of Common Stock), or if not refunded, you may seek a </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refund from the local tax authorities.  You must pay to the Company and/or the Employer any amount of Tax-Related Items that the Company and/or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Issuance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 4 above, and subject to any different provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Original Issuance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if (i) selling shares of the Company&#x2019;s Common Stock in the public market on the Original Issuance Date to satisfy your tax withholding obligation in accordance with Section 5 of this Agreement is prohibited for any reason, and (ii) the Company elects not to instead satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original Issuance Date and shall instead be delivered to you on the earliest of: (1) the first date that you are not prohibited from selling shares of the Company&#x2019;s Common Stock in the open market, or (2) such earlier date that the Company elects to satisfy its tax withholding obligation by withholding shares from your distribution; provided, however, that notwithstanding the foregoing, in no event will the shares be delivered to you any later than: (A) December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of the taxable year in which the Original Issuance Date occurs), or (B) if and only if permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock are no longer subject to a &#x201c;substantial risk of forfeiture&#x201d; within the meaning of Treasury Regulations Section 1.409A-1(d). Delivery of the shares is intended to comply with the requirements for the short-term deferral exemption available under Treasury Regulations Section 1.409A-1(b)(4) and shall be construed and administered in such manner.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition and notwithstanding the foregoing, no shares of Common Stock issuable to you under this Section 6 as a result of the vesting of one or more Restricted Stock Units will be delivered to you until any filings that may be required pursuant to the Hart-Scott-Rodino (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HSR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) Act in connection with the issuance of such shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HSR Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  If the HSR Requirements apply to the issuance of any shares of Common Stock issuable to you under this Section 6 upon vesting of one or more Restricted Stock Units, such shares of Common Stock will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when you are permitted to sell shares of Common Stock on an established stock exchange or stock market, as determined by the Company </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in accordance with the Company&#x2019;s then-effective policy on trading in Company securities.  Notwithstanding the foregoing, the issuance date for any shares of Common Stock delayed under this Section 6(c) shall</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in no event </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> later than </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31 of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the calendar year in which the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Original Issuance Date occurs (that is, the last day of your taxable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> year in which the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Original Issuance Date occurs), unless a later issuance date is</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> permitted without incurring adverse tax consequences </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under Section 409A of the Code (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or other applicable law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as otherwise provided in the Plan, the RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Liability for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation, (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so, and (c) agree that the Company has no duty or obligation to minimize the tax consequences to you of the RSU Award and shall not be liable to you for any adverse tax consequences to you arising in connection with the RSU Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company&#x2019;s policy permitting certain individuals to sell shares of the Company only during certain &#x201c;window&#x201d; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber shares of the Company, as in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Not a Service Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Your RSU Award is not an employment or service contract, and nothing in your RSU Award will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your RSU Award will obligate the Company or an Affiliate, their respective shareholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notices provided for in your RSU Award or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this RSU Award by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this RSU Award, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">14.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect on Other Employee Benefit Plans</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he value of this RSU Award (or shares received upon settlement) will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#x2019;s or any Affiliate&#x2019;s employee benefit plans.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting Rights</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will not have voting or any other rights as a shareholder of the Company with respect to the shares to be issued pursuant to this RSU Award until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a shareholder of the Company. Nothing contained in this RSU Award, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">16.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The rights and obligations of the Company under your RSU Award will be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by, the Company&#x2019;s successors and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your RSU Award.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	You acknowledge and agree that you have reviewed your RSU Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your RSU Award, and fully understand all provisions of your RSU Award.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RSU Award Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	All obligations of the Company under the Plan and this RSU Award Agreement will be binding on any successor to the Company, whether the existence of such successor is the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">17.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If you have questions regarding these or any other terms and conditions applicable to the RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment II</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>gern-ex10_13.htm
<DESCRIPTION>EX-10.13
<TEXT>
<html>
 <head>
  <title>EX-10.13</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.13</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended 2018 Inducement Award Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2018 Inducement Award Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adopted by the Board of Directors:  December 14, 2018</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(with 3,000,000 share reserve)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  January 29, 2019 (added 5,000,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  February 11, 2020 (added 1,300,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  February 1, 2021 (added 800,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  May 91, 2021 (added 5,000,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  February 2, 2022 (added 1,000,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  July 15, 2022 (added 5,000,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  June 21, 2023 (added 13,900,000 shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amended and Restated:  January 1, 2025 (Added 5,300,000 Shares)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> General.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligible Award Recipients.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Awards may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules.  A person who previously served as an Employee or Director will not be eligible to receive Awards, other than following a bona fide period of non-employment.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Stock Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Plan provides for the grant of the following types of Stock Awards: (i) Nonstatutory Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards and (v) Other Stock Awards.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Plan, through the granting of Stock Awards, is intended to 1) help the Company and any Affiliate secure and retain the services of eligible Stock Award recipients, 2) provide an inducement material for such persons to enter into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules, 3) provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and 4) provide a means by which the eligible recipients may benefit from increases in value of the Common Stock. The Plan is also intended to provide long-term incentives that align the interests of our eligible Stock Award recipients with the interests of our stockholders.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration by Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).  However, notwithstanding the foregoing or anything in the Plan to the contrary, the grant of Stock Awards will be approved by the Company&#x2019;s independent compensation committee or a majority of the Company&#x2019;s independent directors (as defined in Rule 5605(a)(2) of the Nasdaq Listing Rules) in order to comply with the exemption from the stockholder approval requirement for &#x201c;inducement grants&#x201d; provided under Rule 5635(c)(4) of the Nasdaq Listing Rules.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Powers of Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To determine (A) who will be granted Stock Awards; (B) when and how each Stock Award will be granted; (C) what type of Stock Award will be granted; (D) the provisions of each Stock Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Stock Award; (E) the number of shares of Common Stock subject to, or the cash value of, a Stock Award; and (F) the Fair Market Value applicable to a Stock Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To construe and interpret the Plan and Stock Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Stock Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Stock Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Stock Award fully effective.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To settle all controversies regarding the Plan and Stock Awards granted under it.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To accelerate, in whole or in part, the time at which a Stock Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or a Stock Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#x2019;s rights under his or her then-outstanding Stock Award without his or her written consent except as provided in subsection (viii) below.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Stock Awards granted under the Plan exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  Except as provided in the Plan (including Section 2(b)(viii)) or a Stock Award Agreement, no amendment of the Plan will materially impair a Participant&#x2019;s rights under an outstanding Stock Award without the Participant&#x2019;s written consent. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(vii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To submit any amendment to the Plan for stockholder approval (to the extent the Board determines advisable or to the extent required pursuant to applicable laws or listing requirements), including, but not limited to, amendments to the Plan to comply with other applicable laws or listing requirements, provided, however, that any amendment provided in Section 9(a) relating to Capitalization Adjustments shall not require stockholder approval.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(viii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To approve forms of Stock Award Agreements for use under the Plan and to amend the terms of any one or more Stock Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Stock Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion and applicable laws or listing requirements, including Rule 5635(c) of the Nasdaq Listing Rules; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that a Participant&#x2019;s rights under any Stock Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#x2019;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#x2019;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Stock Awards without the affected Participant&#x2019;s consent (A) to clarify the manner of exemption from, or to bring the Stock Award into compliance with, Section 409A of the Code; or (B) to comply with other applicable laws or listing requirements.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ix)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Stock Awards.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Stock Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delegation to Committee.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.  However, notwithstanding the foregoing or anything in the Plan to the contrary, the grant of Stock Awards will be approved by the Company&#x2019;s independent compensation committee or a majority of the Company&#x2019;s independent directors (as defined in Rule 5605(a)(2) of the Nasdaq Listing Rules) in order to comply with the exemption from the stockholder approval requirement for &#x201c;inducement grants&#x201d; provided under Rule 5635(c)(4) of the Nasdaq Listing Rules.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect of Board&#x2019;s Decision.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Repricing; Cancellation and Re-Grant of Stock Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends and Dividend Equivalents.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Stock Award, as determined by the Board and contained in the applicable Stock Award Agreement; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Stock Award Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Stock Award Agreement (including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Stock Award Agreement. </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares Subject to the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Reserve.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed 40,300,000 shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reversion of Shares to the Share Reserve. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of the shares covered by such Stock Award having been issued, or (ii) is settled in cash (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Participant receives cash rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased or reacquired by the Company for any reason, including because of the failure to meet a contingency or condition required to vest such shares in the Participant, then the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Plan. Any shares reacquired or withheld by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration for the exercise or purchase price of a Stock Award (including any shares subject to a Stock Award that are not delivered to a Participant because such Stock Award is exercised through a reduction of shares subject to such Stock Award (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., &#x201c;net exercised&#x201d;))  will again become available for issuance under the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Source of Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligibility.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eligibility for Stock Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Stock Awards may be granted only to persons who are Employees described in Section 1(a), where the Stock Award is an inducement material to the individual&#x2019;s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.  For clarity, Stock Awards may not be granted to (1) Directors, for service in such capacity, or (2) any individual who was previously an Employee or Director, other than following a bona fide period of non-employment.  Notwithstanding the foregoing, Stock Awards may not be granted to Employees who are providing Continuous Service only to any &#x201c;parent&#x201d; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A of the Code.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval Requirements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All Stock Awards must be granted either by a majority of the Company&#x2019;s independent directors or by the Company&#x2019;s compensation committee comprised of independent directors within the meaning of Rule 5605(a)(2) of the Nasdaq Listing Rules.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions Relating to Options and Stock Appreciation Rights.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be Nonstatutory Stock Options.  The provisions of separate Options or SARs need not be identical; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that each Stock Award Agreement will conform to</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(through incorporation of provisions hereof by reference in the applicable Stock Award Agreement or otherwise) the substance of each of the following provisions:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No Option or SAR will be exercisable after the expiration of ten (10) years from the date of its grant or such shorter period specified in the Stock Award Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Stock Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Stock Award if such Stock Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Price for Options.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by cash, check, bank draft or money order payable to the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#x201c;net exercise,&#x201d; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Stock Award Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise and Payment of a SAR.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Stock Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consideration, as determined by the Board and contained in the Stock Award Agreement evidencing such SAR.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability of Options and SARs.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board may determine.  In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section 5(e) on the transferability of Options and SARs will apply.  Notwithstanding the foregoing or anything in the Plan or a Stock Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.   </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on Transfer.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws.  Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Domestic Relations Orders.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2).  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beneficiary Designation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#x2019;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Generally.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Continuous Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates (other than for Cause and other than upon the Participant&#x2019;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Extension of Termination Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercise of an Option or SAR following the termination of the Participant&#x2019;s Continuous Service (other than for Cause and other than upon the Participant&#x2019;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#x2019;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.  In addition, unless otherwise provided in a Participant&#x2019;s Stock Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#x2019;s Continuous Service (other than for Cause) would violate the Company&#x2019;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#x2019;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#x2019;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Stock Award Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability of Participant.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates as a result of the Participant&#x2019;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 24 months following such termination of Continuous Service (or such longer or shorter period specified in the Stock Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Stock Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Death of Participant.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the applicable Stock Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#x2019;s Continuous Service terminates as a result of the Participant&#x2019;s death, or (ii) the Participant dies within the period (if any) specified in the Stock Award Agreement for exercisability after the termination of the Participant&#x2019;s Continuous Service (for a reason other than death), then the Participant&#x2019;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#x2019;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#x2019;s death, but only within such period of time ending on the earlier of (i) the date 24 months following the date of death (or such longer or shorter period specified in the Stock Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Stock Award Agreement.  If, after the Participant&#x2019;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination for Cause.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as explicitly provided otherwise in a Participant&#x2019;s Stock Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service is terminated for Cause, the Participant&#x2019;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Exempt Employees.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Stock Award may vest prior to such date).  Consistent with the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#x2019;s retirement (as such term may be defined in the Participant&#x2019;s Stock Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#x2019;s or Affiliate&#x2019;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#x2019;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of Stock Awards Other than Options and SARs.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  To the extent consistent with the Company&#x2019;s bylaws, at the Board&#x2019;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#x2019;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company or (B) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Participant&#x2019;s Continuous Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  If a Participant&#x2019;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.  Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Awards.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consideration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Restrictions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Participant&#x2019;s Continuous Service.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#x2019;s termination of Continuous Service.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Stock Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan (including, but not limited to, Section 2(f)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Covenants of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Availability of Shares.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Law Compliance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of a Stock Award or the subsequent issuance of cash or Common Stock pursuant to the Stock Award if such grant or issuance would be in violation of any applicable securities law.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Obligation to Notify or Minimize Taxes.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of a Stock Award or a possible period in which the Stock Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of a Stock Award to the holder of such Stock Award.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Proceeds from Sales of Common Stock.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Action Constituting Grant of Stock Awards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Corporate action constituting a grant by the Company of a Stock Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Stock Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Stock Award Agreement or related grant documents as a result of a clerical error in the preparation of the Stock Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Stock Award Agreement or related grant documents.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholder Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to a Stock Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Stock Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Stock Award has been entered into the books and records of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Employment or Other Service Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Nothing in the Plan, any Stock Award Agreement or any other instrument executed thereunder or in connection with any Stock Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Stock Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause or (ii) as may be applicable after the grant of a Stock Award should the Employee recipient&#x2019;s service capacity change to that of a Consultant or Director, (1) the service of a Consultant pursuant to the terms of such Consultant&#x2019;s agreement with the Company or an Affiliate, or (2) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Time Commitment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  In the event a Participant&#x2019;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Stock Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Stock Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Stock Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Stock Award that is so reduced or extended.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Assurances.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Stock Award, (i) to give written assurances satisfactory </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Company as to the Participant&#x2019;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Stock Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Stock Award for the Participant&#x2019;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Obligations.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Unless prohibited by the terms of a Stock Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to a Stock Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)  withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from a Stock Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Stock Award Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Electronic Delivery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Any reference herein to a &#x201c;written&#x201d; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#x2019;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferrals.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Stock Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Stock Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#x2019;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Section 409A of the Code.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise expressly provided for in a Stock Award Agreement, the Plan and Stock Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Stock Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code.  To the extent that the Board determines that any Stock Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Stock Award Agreement evidencing such Stock Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and, to the extent applicable, the Plan and Stock Award Agreements will be interpreted in accordance with the requirements of Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Stock Award Agreement specifically provides otherwise), if the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shares of Common Stock are publicly traded and a Participant holding a Stock Award that constitutes &#x201c;deferred compensation&#x201d; under Section 409A of the Code is a &#x201c;specified employee&#x201d; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#x201c;separation from service&#x201d; before a date that is six months following the date of such Participant&#x2019;s &#x201c;separation from service&#x201d; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#x2019;s death.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clawback/Recovery.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  All Stock Awards granted under the Plan will be subject to recoupment in accordance with any clawback provisions in a Participant&#x2019;s employment agreement or other agreement with the Company or any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#x2019;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in a Stock Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#x201c;good reason&#x201d; or &#x201c;constructive termination&#x201d; (or similar term) under any agreement with the Company or an Affiliate.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments upon Changes in Common Stock; Other Corporate Events.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalization Adjustments.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a) and (ii) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dissolution or Liquidation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#x2019;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#x2019;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The following provisions will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the Stock Award Agreement or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.  In the event of a Corporate Transaction, then, notwithstanding any other provision of the Plan, the Board may take one or more of the following actions with respect to Stock Awards, contingent upon the closing or completion of the Corporate Transaction:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrange for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#x2019;s parent company) to assume or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction);</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrange for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#x2019;s parent company);</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accelerate the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to a date prior to the effective time of such Corporate Transaction as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective date of the Corporate Transaction), with such Stock Award terminating if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the Board may require Participants to complete and deliver to the Company a notice of exercise before the effective date of a Corporate Transaction, which exercise is contingent upon the effectiveness of such Corporate Transaction;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cancel or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the Corporate Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(vi)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction, over (B) any exercise price payable by such holder in connection with such exercise.</font><font style="color:#0000ff;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, this payment may be zero ($0) if the value of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#x2019;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board need not take the same action or actions with respect to all Stock Awards or  portions thereof or with respect to all Participants.  The Board may take different actions with respect to the vested and unvested portions of a Stock Award.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   Change in Control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.  </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination or Suspension of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board may suspend or terminate the Plan at any time.  No Stock Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Impairment of Rights.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suspension or termination of the Plan will not materially impair rights and obligations under any Stock Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date of Plan.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Plan will become effective on the Effective Date.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Choice of Law.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#x2019;s conflict of laws rules.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalization Adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant and for purposes of the application of this Plan, the occurrence of any of the following events: (i) such Participant&#x2019;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#x2019;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#x2019;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#x2019;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate. The determination that a termination of the Participant&#x2019;s Continuous Service is either for Cause or without Cause will be made by the Company, in its sole discretion.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Stock Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will be deemed to have occurred upon the first to occur of an event set forth in any one of the following paragraphs:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of any merger or consolidation, the voting securities of the Company outstanding immediately prior thereto represent (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less than 49% of the combined voting power of the voting securities of the Company or such surviving or acquiring entity outstanding immediately after such merger or consolidation; </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during any period of twenty-four consecutive calendar months, the individuals who at the beginning of such period constitute the Board, and any new directors whose election by such Board or nomination for election by stockholders was approved by a vote of at least two-thirds of the members of such Board who were either directors on such Board at the beginning of the period or whose election or nomination for election as directors was previously so approved, for any reason cease to constitute at least a majority of the members thereof; </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) shall become the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 20% of the then outstanding shares of Common Stock of the Company; </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any sale of all or substantially all of the assets of the Company; or </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the complete liquidation or dissolution of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any Stock Award which provides for the deferral of compensation and is subject to Section 409A of the Code, the transaction or event with respect to such Stock Award must also constitute a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation &#167;1.409A-3(i)(5) to the extent required by Section 409A.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee shall have full and final authority, which shall be exercised in its discretion, to determine conclusively whether a Change in Control of the Company has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters relating thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a Change in Control shall not be deemed to occur solely because the threshold voting power of the Company&#x2019;s then outstanding securities in Section 13(e)(i) or (iii) is acquired by (A) a trustee or other fiduciary holding securities under one or more employee benefit plans maintained by the Company or any of its subsidiaries or (B) any corporation which, immediately prior to such acquisition, is owned directly or indirectly by the stockholders of the Company in the same proportion as their ownership of stock in the Company immediately prior to such acquisition.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing or any other provision of this Plan, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Stock Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Geron Corporation, a Delaware corporation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#x201c;Consultant&#x201d; for purposes of the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#x2019;s securities to such person.  Consultants are not eligible to be granted Stock Awards under this Plan with respect to their service in such capacity.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continuous Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that the Participant&#x2019;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#x2019;s service with the Company or an Affiliate, will not terminate a Participant&#x2019;s Continuous Service; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#x2019;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#x2019;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#x2019;s or Affiliate&#x2019;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a sale or other disposition of at least ninety percent (90%) of the outstanding securities of the Company; </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iv)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Corporate Transaction will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a member of the Board. Directors are not eligible to be granted Stock Awards with respect to their service in such capacity under this Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a Participant,  the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(o)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the effective date of this Plan document, which is December 14, 2018, the date the Plan was approved by the Board.  </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(p)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#x201c;Employee&#x201d; for purposes of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(q)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a corporation, partnership, limited liability company or other domestic or foreign entity.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(r)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(s)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date, the value of the Common Stock determined as follows:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:15.067%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:15.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.069%;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(t)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation S-K</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a &#x201c;non-employee director&#x201d; for purposes of Rule 16b-3.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(u)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nonstatutory Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any option granted pursuant to Section 5 that does not qualify as an &#x201c;incentive stock option&#x201d; within the meaning of Section 422 of the Code.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(v)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(w)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(x)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(y)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Optionholder</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(z)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Stock Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(aa)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Own,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Owned,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Owner,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a person or Entity will be deemed to &#x201c;Own,&#x201d; to have &#x201c;Owned,&#x201d; to be the &#x201c;Owner&#x201d; of, or to have acquired &#x201c;Ownership&#x201d; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(bb)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a person to whom a Stock Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(cc)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this Geron Corporation 2018 Inducement Award Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(dd)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ee)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ff)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(gg)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(hh)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 405</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Rule 405 promulgated under the Securities Act.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(jj)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(kk)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SAR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ll)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any right to receive Common Stock granted under the Plan, including a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award or any Other Stock Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(mm)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(nn)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>gern-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10.17</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Sell to Cover</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Grant Notice<br>(2018 Inducement Award Plan</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), pursuant to its 2018 Inducement Award Plan, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), hereby awards to Participant (as defined below), the number of restricted stock units specified and on the terms set forth below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The RSU Award is subject to all of the terms and conditions set forth herein and in the Plan and the Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), both of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></p>
  <table style="border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:59.58%;box-sizing:content-box;"></td>
    <td style="width:40.42%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Participant:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date of Grant:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of Restricted Stock Units:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:97.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:31.14%;box-sizing:content-box;"></td>
    <td style="width:68.86%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vesting Schedule:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25% of the restricted stock units shall vest on the first anniversary of the date of grant and 25% annually thereafter, subject to the terms of the Plan, this Grant Notice and the Agreement. Notwithstanding the foregoing, vesting shall terminate upon Participant&#x2019;s termination of Continuous Service.</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Issuance Schedule:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in Section 6 of the Agreement.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant Acknowledgements:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award is governed by this RSU Award Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the prospectus containing information required by Section 10(a) of the Securities Act (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prospectus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). In the event of any conflict between the provisions in the RSU Award Agreement or the Prospectus and the terms of the Plan, the terms of the Plan shall control.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the fullest extent permitted under the Plan and applicable law, any Withholding Taxes (as defined in the RSU Award Agreement) applicable to the RSU Award will be satisfied through the sale of a number of the shares issuable in settlement of the RSU Award as determined in accordance with Section 5 of the Agreement and the remittance of the cash proceeds to the Company. Under the Agreement, the Company or, if different, your employer shall make payment from the cash proceeds of this sale directly to the appropriate tax or social security authorities in an amount equal to the taxes required to be remitted. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The mandatory sale of shares to cover Withholding Taxes is imposed by the Company on you in connection with your receipt of this RSU Award.</font></div></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acceptance of this Grant Notice and related RSU Award Agreement and Plan can be evidenced through original signature on the relevant document or acknowledgment through an online or electronic system established and maintained by the Company or another third party designated by the Company.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:  RSU Award Agreement, 2018 Inducement Award Plan, as amended</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Sell to Cover</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation <br>2018 Inducement Award Plan</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award Agreement (RSU Award)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As reflected by your Restricted Stock Unit Grant Notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Geron Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has granted you a RSU Award under its 2018 Inducement Award Plan, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) for the number of restricted stock units as indicated in your Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The terms of the RSU Award as specified in this Award Agreement for the RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the Grant Notice constitute your &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;. Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The general terms applicable to the RSU Award are as follows:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Plan Document</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9 of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on the RSU Award; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8(d) of the Plan regarding the Company&#x2019;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant of the RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This RSU Award represents your right to be issued on a future date the number of shares of the Company&#x2019;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 4 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by the RSU Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Restricted Stock Units shall vest as set forth in the Grant Notice. In the event of either a Change in Control or a Corporate Transaction that is not a license, and you have not terminated your Continuous Service prior to the effective date of the Change in Control or Corporate Transaction, then the vesting of your Restricted Stock Units will be accelerated in full upon the effective date of such Change in Control or Corporate Transaction.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">280G Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then any such 280G Payment (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be equal to the Reduced Amount. The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pro Rata Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless you and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of a Change in Control triggering the Payment shall perform the aforementioned calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or the Company.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 3(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 3(a) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) in Section 3(a), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You shall receive no benefit or adjustment to the RSU Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with the RSU Award after such shares have been delivered to you.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that, regardless of any action taken by the Company, or if different, the Affiliate employing or engaging you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the ultimate liability for all income tax (including U.S. federal, state, and local taxes and/or non-U.S. taxes), social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable to you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax-Related Items</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award, including, but not limited to, the grant of the RSU Award, the vesting of the RSU Award, the issuance of shares in settlement of vesting of the RSU Award, the subsequent sale of any shares of Common Stock acquired pursuant to the RSU Award and the receipt of any dividends or dividend equivalent; and (ii) do not commit to and are under no obligation to reduce or eliminate your liability for Tax-Related Items.  Further, if you become subject to taxation in more than one country, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one country.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each vesting date, and on or before the time you receive a distribution of the shares underlying your Restricted Stock Units, and at any other time as reasonably requested by the Company in accordance with applicable law, you agree to make adequate provision for any sums required to satisfy the withholding obligations of the Company, the Employer or any Affiliate in connection with any Tax-Related Items that arise in connection with the RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Withholding Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company shall arrange a mandatory sale (on your behalf pursuant to your authorization under this section and without further consent) of the shares of Common Stock issued in settlement upon the vesting of your Restricted Stock Units in an amount necessary to satisfy the Withholding Taxes and shall satisfy the Withholding Taxes by withholding from the proceeds of such sale (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mandatory Sell to Cover</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  You hereby acknowledge and agree that the Company shall have the authority to administer the Mandatory Sell to Cover arrangement in its sole discretion with a registered broker-dealer that is a member of the Financial Industry Regulatory Authority (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FINRA Dealer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as the Company may select as the agent (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">who will sell on the open market at the then prevailing market price(s), as soon as practicable on or after each date on which your Restricted Stock Units vest, the number (rounded up to the next whole number) of the shares of Common Stock to be delivered to you in connection with the vesting of the Restricted Stock Units sufficient to generate proceeds to cover (i) the Withholding Taxes that you are required to pay pursuant to the Plan and this Agreement as a result of the vesting of the Restricted Stock Units (or shares being issued thereunder, as applicable) and (ii) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto any remaining funds shall be remitted to you.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, for any reason, such Mandatory Sell to Cover does not result in sufficient proceeds to satisfy the Withholding Taxes, or if such Mandatory Sell to Cover is not permitted by applicable law, the Company or an Affiliate may, in its sole discretion, satisfy all or any portion of the Withholding Taxes relating to the RSU Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company or the Employer; (ii) causing you to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted by the Company); or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with your Restricted Stock Units with a fair market value (measured as of the date shares of Common Stock are issued to you) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld will not exceed the amount necessary to satisfy the Company&#x2019;s required tax withholding obligations using the maximum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income; and to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable, such share withholding procedure will be subject to the express prior approval of the Board or the Compensation Committee of the Board.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless the tax withholding obligations of the Company and/or any Affiliate with respect to the Tax-Related Items are satisfied, the Company shall have no obligation to deliver to you any Common Stock.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event the Company&#x2019;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Tax-Related Items withholding obligation was greater than the amount withheld by the Company or your Employer, you agree to indemnify and hold the Company and your Employer harmless from any failure by the Company or your Employer to withhold the proper amount.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You acknowledge that the Mandatory Sell to Cover is imposed by the Company on you pursuant to the terms of the RSU Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts, or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s).  If the maximum rate is used, any over-withheld amount may be refunded to you in cash by the Company or Employer (with no entitlement to the equivalent in shares of Common Stock), or if not refunded, you may seek a </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refund from the local tax authorities.  You must pay to the Company and/or the Employer any amount of Tax-Related Items that the Company and/or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Issuance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 4 above, and subject to any different provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Original Issuance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if (i) selling shares of the Company&#x2019;s Common Stock in the public market on the Original Issuance Date to satisfy your tax withholding obligation in accordance with Section 5 of this Agreement is prohibited for any reason, and (ii) the Company elects not to instead satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original Issuance Date and shall instead be delivered to you on the earliest of: (1) the first date that you are not prohibited from selling shares of the Company&#x2019;s Common Stock in the open market  or (2) such earlier date that the Company elects to satisfy its tax withholding obligation by withholding shares from your distribution; provided, however, that notwithstanding the foregoing, in no event will the shares be delivered to you any later than: (A) December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of the taxable year in which the Original Issuance Date occurs), or (B) if and only if permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock are no longer subject to a &#x201c;substantial risk of forfeiture&#x201d; within the meaning of Treasury Regulations Section 1.409A-1(d). Delivery of the shares is intended to comply with the requirements for the short-term deferral exemption available under Treasury Regulations Section 1.409A-1(b)(4) and shall be construed and administered in such manner.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition and notwithstanding the foregoing, no shares of Common Stock issuable to you under this Section 6 as a result of the vesting of one or more Restricted Stock Units will be delivered to you until any filings that may be required pursuant to the Hart-Scott-Rodino (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HSR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) Act in connection with the issuance of such shares have been filed and any required waiting period under the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HSR Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  If the HSR Requirements apply to the issuance of any shares of Common Stock issuable to you under this Section 6 upon vesting of one or more Restricted Stock Units, such shares of Common Stock will not be issued on the Original Issuance Date and will instead be issued on the first business day on or following the date when all such HSR Requirements are satisfied and when you are permitted to sell shares of Common Stock on an established stock exchange or stock market, as determined by the Company </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in accordance with the Company&#x2019;s then-effective policy on trading in Company securities.  Notwithstanding the foregoing, the issuance date for any shares of Common Stock delayed under this Section 6(c) shall</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in no event </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> later than </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31 of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the calendar year in which the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Original Issuance Date occurs (that is, the last day of your taxable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> year in which the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Original Issuance Date occurs), unless a later issuance date is</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> permitted without incurring adverse tax consequences </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under Section 409A of the Code (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or other applicable law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as otherwise provided in the Plan, the RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Liability for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation, (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so, and (c) agree that the Company has no duty or obligation to minimize the tax consequences to you of the RSU Award and shall not be liable to you for any adverse tax consequences to you arising in connection with the RSU Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company&#x2019;s policy permitting certain individuals to sell shares of the Company only during certain &#x201c;window&#x201d; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber shares of the Company, as in effect from time to time.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSU Award Not a Service Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Your RSU Award is not an employment or service contract, and nothing in your RSU Award will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your RSU Award will obligate the Company or an Affiliate, their respective shareholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any notices provided for in your RSU Award or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this RSU Award by electronic means or to request your consent to participate in the Plan by electronic means. By accepting this RSU Award, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">14.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect on Other Employee Benefit Plans</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he value of this RSU Award (or shares received upon settlement) will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#x2019;s or any Affiliate&#x2019;s employee benefit plans.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Voting Rights</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You will not have voting or any other rights as a shareholder of the Company with respect to the shares to be issued pursuant to this RSU Award until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a shareholder of the Company. Nothing contained in this RSU Award, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">16.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	The rights and obligations of the Company under your RSU Award will be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by, the Company&#x2019;s successors and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your RSU Award.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	You acknowledge and agree that you have reviewed your RSU Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your RSU Award, and fully understand all provisions of your RSU Award.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This RSU Award Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	All obligations of the Company under the Plan and this RSU Award Agreement will be binding on any successor to the Company, whether the existence of such successor is the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">17.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Questions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If you have questions regarding these or any other terms and conditions applicable to the RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attachment II</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2018 Inducement Award Plan</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>5
<FILENAME>gern-ex10_29.htm
<DESCRIPTION>EX-10.29
<TEXT>
<html>
 <head>
  <title>EX-10.29</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.29</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">November 1, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">This Employment Agreement (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) is made effective as of November 11, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Joseph Eid, M.D. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) and Geron Corporation, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, the Company desires to employ Executive to provide personal services to the Company, and wishes to provide Executive with certain compensation and benefits in return for Executive&#x2019;s services;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Whereas</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, Executive wishes to be employed by the Company and provide personal services to the Company in return for certain compensation and benefits; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Now, Therefore</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, in consideration of the mutual promises and covenants contained herein, it is hereby agreed by and between the parties hereto as follows:</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE I</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>definitions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For purposes of the Agreement, the following terms are defined as follows:</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means any of the following:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">any willful act or omission by Executive constituting dishonesty, fraud or other malfeasance against the Company; </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive&#x2019;s conviction of a felony under the laws of the United States or any state thereof or any other jurisdiction in which the Company conducts business; </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive&#x2019;s debarment by the U.S. Food and Drug Administration (FDA) from working in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992, or other ineligibility under any law or regulation to perform Executive&#x2019;s duties to the Company; or </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive&#x2019;s breach of any of the material policies of the Company. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning set forth in the Equity Incentive Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means Geron Corporation, any wholly-owned subsidiaries, and its successors in interest.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Comparable Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means employment on terms which provide (a) the same or greater rate of base pay or salary as in effect immediately prior to Executive&#x2019;s termination, (b) the same, equivalent or higher job title and level of responsibility as Executive had prior to Executive&#x2019;s termination, (c) equivalent or higher bonus opportunity as the bonus opportunity for the year preceding the year in which the termination occurs, and (d) a principal work location that is both (i) no more than forty-five (45) miles from Executive&#x2019;s principal work location immediately prior to Executive&#x2019;s termination and (ii) no more than thirty (30) miles farther from Executive&#x2019;s principal weekday residence than was Executive&#x2019;s principal work location immediately prior to the termination.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means an Involuntary Termination Without Cause that occurs at any time, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> that such termination constitutes a &#x201c;separation from service&#x201d; within the meaning of Section 409A of the Code and the regulations promulgated thereunder, including Treasury Regulation Section 1.409A-1(h) (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Involuntary Termination Without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means Executive&#x2019;s dismissal or discharge other than (i) for Cause, or (ii) after an involuntary or voluntary filing of a petition under chapter 7 or 11 of 11 USC Section 101 et. seq., an assignment for the benefit of creditors, a liquidation of the company&#x2019;s assets in formal proceeding or otherwise or any other event of insolvency by the Company, in any case, without an offer of Comparable Employment by the Company or a successor, acquirer, or affiliate of the Company. For purposes of this Agreement, the termination of Executive&#x2019;s employment due to Executive&#x2019;s death or disability will not constitute a termination for Cause.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;Inducement Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Company&#x2019;s 2018 Inducement Award Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">1.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Equity Incentive Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d; means the Company&#x2019;s 2018 Equity Incentive Award Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE II</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Employment by the Company</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Position and Duties. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> Subject to the terms set forth herein, the Company agrees to employ Executive in the position of Executive Vice President, Research &amp; Development.  During the Executive&#x2019;s employment in this position, Executive will report to the Chief Executive Officer.  Executive shall serve in an employee capacity and shall perform such duties as are assigned to Executive by the Chief Executive Officer and, except as otherwise instructed by the Chief Executive Officer, such other duties as are customarily associated with the position of Executive Vice President, Research &amp; Development.  During Executive&#x2019;s employment with the Company, Executive will devote Executive&#x2019;s best efforts and substantially all of Executive&#x2019;s business time and attention (except for vacation periods as set forth herein and reasonable periods of illness or other incapacities permitted by the Company&#x2019;s general employment policies or as otherwise set forth in this Agreement) to the business of the Company.   </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employment at Will.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Both the Company and Executive acknowledge and agree that Executive&#x2019;s employment with the Company is &#x201c;at-will&#x201d; and not for any specified period of time, and may be terminated at any time by Executive or the Company, with or without Cause, and with or without prior notice; provided, however, that if Executive&#x2019;s employment with the Company is terminated under circumstances that constitute a Covered Termination, Executive will be eligible to receive certain severance payments and benefits as set forth in Article IV below.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Employment Policies.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  The employment relationship between the parties shall also be governed by the general employment policies and practices of the Company, including but not limited to </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">those policies relating to protection of confidential information and assignment of inventions.  In the event of a conflict between the terms of this Agreement and the Company&#x2019;s general employment policies or practices, this Agreement shall control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">2.4	Indemnification.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company shall provide for indemnification of the Executive as set forth in the Indemnification Agreement attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">    </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE III</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Compensation</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  Executive shall receive for services to be rendered hereunder such annual base salary as is approved by the Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) or the Compensation Committee of the Board, payable on the regular payroll dates of the Company, subject to increase in the sole discretion of the Board or Compensation Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;).  As of the Effective Date of this Agreement, Executive&#x2019;s Base Salary is $650,000.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  As of the Effective Date of this Agreement, Executive shall be eligible to earn, for each fiscal year of the Company ending December 31, during Executive&#x2019;s employment with the Company, an annual discretionary cash bonus (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) targeted at fifty-five percent (55%) of Executive&#x2019;s Base Salary.  Executive&#x2019;s discretionary Annual Bonus will be paid during the standard timing for year-end performance bonuses, with the eligibility cutoff date for participation being October 1st in the performance year for which any bonus may be paid. It is tied to the achievement of certain performance goals established for the Company and each individual and prorated for the individual&#x2019;s performance period.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> The total bonus pool generated for distribution, if any, is determined at the discretion of the Board and then distributed based on individual performance.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">If the Company determines, in its reasonable discretion, that Executive has engaged in any misconduct intended to affect the payment of Executive&#x2019;s Annual Bonus or has otherwise engaged in any act or omission that would constitute Cause for termination of employment, as defined by Section 1.2 of the Agreement, Executive will automatically and immediately forfeit Executive&#x2019;s entire Annual Bonus.  If the Annual Bonus has already been paid to Executive, such Annual Bonus will be deemed unearned, and the Company shall have the right to recover the entire amount of the Annual Bonus paid to Executive for the calendar year(s) in which such misconduct or other act or omission constituting Cause occurred.  Without limiting the foregoing, any such misconduct or other act or omission constituting Cause will subject Executive to disciplinary action up to and including termination of employment.  In addition, any Annual Bonus paid to Executive for the calendar year(s) in which such misconduct or other Cause occurred is subject to recoupment in accordance with The Dodd&#x2013;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations, any other clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable laws, regulations, or statutes.  Recovery by the Company of an Annual Bonus in accordance with this Section shall not constitute an event giving rise to a right by Executive to voluntarily terminate Executive&#x2019;s employment for Cause based on such recovery by the Company, nor shall it constitute &#x201c;constructive termination&#x201d;, or any similar term or circumstance under the Agreement or any other plan or agreement with the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Inducement Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In accordance with the terms approved by Board or the Company&#x2019;s Compensation Committee of the Board, the Executive shall receive a time-based option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Inducement Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) to purchase two-and-one-half million shares (2,500,000) of Company common stock having an exercise price equal to the fair market value of Company common stock, as reported by the Nasdaq Global Select Market, on the first date of Executive&#x2019;s employment, and vesting with respect </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">to 12.5% of the shares on the six-month anniversary of the Executive&#x2019;s first date of employment and with respect to remaining shares on each monthly anniversary of the Executive&#x2019;s first date of employment in equal installments over 42 months thereafter.  The Inducement Option serves as an inducement material to Executive entering into employment with the Company and will be granted under the Company&#x2019;s Inducement Plan as non-statutory stock options.  The vesting of the Inducement Option shall be subject to Executive&#x2019;s continued service to the Company through the applicable vesting dates, provided, that upon the occurrence of a Change of Control, subject to Executive&#x2019;s continued service to the Company through the date of such Change of Control, the Inducement Option shall vest and become exercisable with respect to one hundred percent (100%) of the unvested shares subject thereto. The Inducement Option otherwise shall be subject to and governed in all respects by the terms of the Inducement Plan and the stock option agreement for the option grant to be entered into between the Company and Executive.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">3.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Standard Company Benefits; Vacation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Executive shall be entitled to all rights and benefits for which Executive is eligible under the terms and conditions of the Company&#x2019;s benefit and compensation plans, practices, policies, and programs, as in effect from time to time, that are provided by the Company to its executive employees generally.  Except as specifically provided herein, nothing in this Agreement is construed or interpreted to provide greater rights, participation, coverage, or benefits under such benefit plans or programs provided to executive employees pursuant to the terms and conditions of such benefit plans and programs.  Executive will be eligible for vacation accruals in accordance with the Company&#x2019;s current time off policy, starting with twenty (20) days per year.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">3.5	Sign-On Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">. Executive shall be paid a cash sign-on bonus in the amount of $200,000. The Sign-On Bonus will be paid on the first scheduled payroll following the Effective Date; provided however, if Executive has voluntarily left the Company and is no longer employed by the Company on the first anniversary of the Effective Date, such Sign-On Bonus will be deemed unearned, and the Company shall have the right to recover the entire $200,000, which shall be reimbursed by Executive to the Company within thirty (30) days after such voluntary departure by Executive. The Sign-On Bonus will be subject to applicable taxes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">If the Company determines, in its reasonable discretion, that Executive has engaged in any misconduct or has otherwise engaged in any act or omission that would constitute Cause for termination of employment, as defined by Section 1.2 of this Agreement, the Sign-On Bonus will be deemed unearned, and the Company shall have the right to recover the entire amount of the Sign-On Bonus. Without limiting the foregoing, any such misconduct or other act or omission constituting Cause will subject Executive to disciplinary action up to and including termination of employment. The Sign-On Bonus is subject to recoupment in accordance with The Dodd&#x2013;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations, any other clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable laws, regulations or statutes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Recovery by the Company of the Sign-On Bonus in accordance with this Section shall not constitute an event giving rise to a right by Executive to voluntarily terminate her employment for cause based on such recovery by Company, nor shall it constitute &#x201c;constructive termination,&#x201d; or any similar term or circumstance under the Agreement or any other plan or agreement with the Company. If the Executive&#x2019;s employment terminates for any reason other than a Covered Termination, the amounts paid under this Section will be repayable to the Company within one year following the Grant Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE IV</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>SEVERANCE BENEFITS AND RELEASE</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Severance Benefits.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  If Executive&#x2019;s employment terminates due to a Covered Termination after the date of execution of this Agreement, Executive shall receive:</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:4.8%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Payment of Accrued Obligations Upon Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  Upon a termination of Executive&#x2019;s employment for any reason at any time following the Effective Date, the Company shall pay to Executive in a single lump-sum cash payment as soon as administratively practicable following the date of termination, the aggregate amount of Executive&#x2019;s (A) earned but unpaid Base Salary, and (B) accrued but unpaid vacation pay.  In addition, Executive shall be promptly paid for incurred but unreimbursed business expenses upon Executive&#x2019;s submission of such expenses in accordance with the Company&#x2019;s expense reimbursement policies.  The amounts set forth in this Section 4.1(i) are collectively referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:4.8%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Severance Upon a Covered Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  If Executive&#x2019;s employment terminates due to a Covered Termination at any time after the Effective Date, then, in addition to the Accrued Obligations: </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.667%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive shall be paid target Annual Bonus for the fiscal year in which the termination occurs, prorated for the length of service provided during the calendar year through the termination date, payable in a single lump-sum payment within thirty (30) days following the date of termination; </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.667%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive shall be paid an aggregate amount equal to twelve (12) months of Executive&#x2019;s Base Salary in effect on the date of termination, payable to Executive in a single lump-sum amount on the sixtieth (60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) day following the date of termination;</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.667%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive and Executive&#x2019;s covered dependents will be eligible to continue their health care benefit coverage as permitted by COBRA (Internal Revenue Code Section 4980B) at the Company&#x2019;s expense for the lesser of (i) twelve (12) months following the Covered Termination, or (ii) until the Executive and/or Executive&#x2019;s covered dependents are no longer eligible for COBRA (for clarification and as an example, in the event Executive is covered by another health plan, etc.).  Thereafter, Executive and Executive&#x2019;s covered dependents shall be entitled to maintain coverage for Executive and Executive&#x2019;s eligible dependents at Executive&#x2019;s own expense for the balance of the period that Executive is entitled to coverage under COBRA; and</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.667%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">the Inducement Option, along with any subsequent options or other exercisable equity interest in the Company held by Executive as of the date of termination shall remain outstanding and exercisable through the earlier of (i) the second (2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">) anniversary of the date of termination or (ii) the original expiration date of the option or other equity interest.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, if Executive&#x2019;s employment terminates due to a Covered Termination at any time after the Effective Date, Executive will receive the greater of (i) the severance benefits above, or (ii) the severance benefits provided for in the Amended and Restated Severance Plan attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, which may be amended from time-to-time by the Company at the Company&#x2019;s sole discretion, that is in effect at the time of termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, all amounts payable under this Agreement shall be subject to applicable federal, state, local or foreign tax withholding requirements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Parachute Payments.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  If any payment or benefit Executive would receive in connection with a Change in Control from the Company or otherwise (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;), then such Payment shall be reduced to the Reduced Amount. The &#x201c;Reduced Amount&#x201d; shall be either (x) the largest portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive&#x2019;s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in payments or benefits constituting &#x201c;parachute payments&#x201d; is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order unless Executive elects in writing a different order (provided, however, that such election shall be subject to Company approval): reduction of cash payments; cancellation of accelerated vesting of stock awards; reduction of employee benefits.  In the event that acceleration of vesting of stock award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant of Executive&#x2019;s stock awards unless Executive elects in writing a different order for cancellation.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">The Company for general audit purposes shall engage a nationally recognized public accounting firm (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) to perform the foregoing calculations. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.  The Accounting Firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15) calendar days after the date on which Executive&#x2019;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the Accounting Firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding, and conclusive upon the Company and Executive.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Release.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Notwithstanding the foregoing, Executive&#x2019;s right to receive the amounts provided for in Sections 4.1(ii) and 4.2, and the Change of Control acceleration in any stock option agreement shall be subject to and conditioned upon Executive&#x2019;s execution and non-revocation of a release of claims in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) (as such form may be modified to take into account changes in the law) within fifty (50) days following the termination date.  Such Release shall specifically relate to all of Executive&#x2019;s rights and claims in existence at the time of such execution and shall confirm Executive&#x2019;s obligations under the Proprietary Information and Inventions Agreement (as defined below).  It is understood that Executive has a certain period to consider whether to execute such Release, as set forth in the Release, and Executive may revoke such Release within seven (7) business days after execution. In the event Executive does not execute such Release within the applicable period, or if Executive revokes such Release within the subsequent seven (7) business day period, none of the aforesaid benefits set forth in Sections 4.1(ii), 4.2, and the Change of Control acceleration in any stock option agreement shall be payable to Executive under this Agreement and this Agreement shall be null and void.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Section 409A.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of the Separation from Service to be a &#x201c;specified </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">employee&#x201d; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (a) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service or (b) the date of Executive&#x2019;s death.  Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 4.4 shall be paid in a lump sum to Executive (or Executive&#x2019;s estate or beneficiaries), and any remaining payments due under the Agreement shall be paid as otherwise provided herein.  For purposes of Section 409A of the Code, Executive&#x2019;s right to receive the payments of compensation pursuant to the Agreement shall be treated as a right to receive a series of separate payments and accordingly, each payment shall at all times be considered a separate and distinct payment.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">4.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Mitigation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of the Covered Termination, or otherwise.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE V</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Proprietary Information Obligations</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Executive agrees to abide by the Proprietary Information and Inventions Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Proprietary Information and Inventions Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;) attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Remedies.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Executive&#x2019;s duties under the Proprietary Information and Inventions Agreement shall survive termination of Executive&#x2019;s employment with the Company and the termination of this Agreement.  Executive acknowledges that a remedy at law for any breach or threatened breach by Executive of the provisions of the Proprietary Information and Inventions Agreement would be inadequate, and Executive therefore agrees that the Company shall be entitled to injunctive relief in case of any such breach or threatened breach.</font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE VI</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Outside Activities</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">No Other Employment.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Except with the prior written consent of the Board, Executive shall not during the term of Executive&#x2019;s employment with the Company, undertake or engage in any other employment, occupation, or business enterprise.  Notwithstanding the foregoing, during the term of Executive&#x2019;s employment with the Company, Executive may (a) undertake or engage in any other employment, occupation or business enterprise in which Executive is a passive investor, and/or (b) engage in civic and not-for-profit activities, in each case, so long as such activities do not materially interfere with the performance of Executive&#x2019;s duties hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">No Conflicting Business Interests.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">During the term of Executive&#x2019;s employment by the Company, except on behalf of the Company, Executive shall not directly or indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by, or have any business connection with any other person, corporation, firm, partnership, or other entity whatsoever which were known by Executive to compete directly with the Company, throughout the world, in any line of business engaged </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">in (or planned to be engaged in) by the Company; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, that anything above to the contrary notwithstanding, Executive may own, as a passive investor, securities of any competitor corporation, so long as Executive&#x2019;s direct holdings in any one such corporation shall not in the aggregate constitute more than 1% of the voting stock of such corporation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:12pt;justify-content:center;align-items:baseline;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE VII</font><div style="width:100%;display:inline;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"><br>Noninterference</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">While employed by the Company, and for one (1) year immediately following the date on which Executive terminates employment or otherwise ceases providing services to the Company, Executive agrees not to interfere with the business of the Company by soliciting or attempting to solicit any employee of the Company to terminate such employee&#x2019;s employment in order to become an employee, consultant, or independent contractor to or for any pharmaceutical or biotechnology competitor of the Company.  Executive&#x2019;s duties under this Article VII shall survive termination of Executive&#x2019;s employment with the Company and the termination of this Agreement.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE VIII</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">DEBARMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;" id="ole_link3"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Executive certifies that Executive has never been: (a) debarred </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">by any relevant authorities, pursuant to any applicable law, including, but not limited to, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Section 306(a) and (b) of the US Federal Food, Drug, and Cosmetic Act; (b) convicted of any of the felonies identified among the Exclusion Authorities listed on the U.S. Department of Health and Human Services (HHS) Office of Inspector General website; or (c) listed as being suspended, debarred, or excluded, or otherwise ineligible to participate in Federal procurement or non-procurement programs, including, but not limited to, being listed on the List of Excluded Individuals/Entities (LEIE) database on the HHS Office of Inspector General website. If Executive becomes suspended, debarred, or excluded pursuant to any of the foregoing, Executive must notify the Company immediately in writing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Calibri;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">ARTICLE IX</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">General Provisions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Notices.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Any notices provided hereunder must be in writing and shall be deemed effective upon the earlier of personal delivery (including personal delivery by telex) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#x2019;s address as listed on the Company payroll.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  To the extend applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulations or other such guidance that may be issued after the Effective Date (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;).  Notwithstanding any provision of this Agreement to the contrary, in the event that following the Effective Date, the Company determines in good faith that any compensation or benefits payable under this Agreement may not be either exempt from or compliant with Section 409A, the Company may adopt such amendments to this Agreement or adopt other policies or procedures (including amendments, policies and procedures with retroactive effect), or take any other commercially reasonable actions necessary or appropriate to preserve the intended tax treatment of the compensation and benefits payable hereunder, including without limitation actions intended to (i) exempt the compensation and benefits payable under this Agreement from Section </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">409A, and/or (ii) comply with the requirements of Section 409A, provided, that this Section 8.2 does not, and shall not be construed so as to, create any obligation on the part of the Company to adopt any such amendments, policies or procedures or to take any other such actions or to create any liability on the part of the Company for any failure to do so.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Severability.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal, or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed, and enforced in such jurisdiction as if such invalid, illegal, or unenforceable provisions had never been contained herein.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Waiver.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">If either party should waive any breach of any provisions of this Agreement, they shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Complete Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  This Agreement and Exhibits A, B, C and D hereto constitute the entire agreement between Executive and the Company and are the complete, final, and exclusive embodiment of their agreement with regard to this subject matter (except for the Equity Incentive Plan and the Inducement Plan and award agreements thereunder, the Amended and Restated Severance Plan, and any successors thereto).  As of the Effective Date, this Agreement supersedes any prior agreement between Executive and the Company or any predecessor employer in its entirety. Executive and the Company acknowledge and agree that this Agreement is entered into without reliance on any promise or representation other than those expressly contained herein or therein and cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9.6	Counterparts and Electronic Signatures.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.  The parties agree that execution of this Agreement by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this Agreement, each party hereby waives any right to raise any defense or waiver based upon execution of this Agreement by means of such electronic signatures or maintenance of the executed agreement electronically.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> 	Headings.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Successors and Assigns.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors, and administrators, except that Executive may not assign any of Executive&#x2019;s duties hereunder and Executive may not assign any of Executive&#x2019;s rights hereunder, without the written consent of the Company, which shall not be withheld unreasonably.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Arbitration.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  In the event of any contractual, statutory or tort dispute or claim relating to or arising out of Executive&#x2019;s employment relationship with the Company (including but not limited to any claims of wrongful termination or age, sex, race, or other discrimination, but not including workers&#x2019; compensation claims), Executive and the Company agree that all such disputes will be finally resolved by </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">binding arbitration conducted by a single neutral arbitrator associated with the American Arbitration Association in Foster City, California.  Executive and the Company hereby waive their respective rights to have any such disputes or claims tried to a judge or jury. However, the Company agrees that this arbitration provision will not apply to any claim, by either Executive or the Company, for injunctive relief. The administrative costs of any arbitration proceeding between Executive and the Company and the fees and costs of the arbitrator shall be borne by the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Attorneys&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  If either party hereto brings any action to enforce rights hereunder, each party in any such action shall be responsible for its own attorneys&#x2019; fees and costs incurred in connection with such action.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  Executive acknowledges that Executive (a) has had the opportunity to discuss this matter with and obtain advice from independent counsel of Executive&#x2019;s own choice and has been advised to do so by the Company, (b) has carefully read and fully understands all the provisions of this Agreement, and (c) is knowingly and voluntarily entering into this Agreement.  Executive represents that Executive (i) is familiar with the restrictive covenants set forth in the Proprietary Information and Inventions Agreement and (ii) is fully aware of Executive&#x2019;s obligations thereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Choice of Law.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  All questions concerning the construction, validity and interpretation of this Agreement will be governed by the law of the State of California.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Personal Information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  Executive understands that the Company may hold certain personal information about him or her, including, but not limited to, your name, home address, telephone number, date of birth, social security number, salary, nationality, and job title (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#x201d;).  Certain Personal Data may also constitute &#x201c;Sensitive Personal Data&#x201d; within the meaning of applicable local law.  Such data include, but are not limited to, Personal Data and any changes thereto, and other appropriate personal and financial data about you.  The Company&#x2019;s lawful basis for processing Personal Data and Sensitive Personal Data include fulfilling its role as an employer, compliance with law, and legitimate business interest.  Executive hereby provides express consent to the Company to process such Personal Data and Sensitive Personal Data and to transfer any such Personal Data and Sensitive Personal Data to any third parties outside the country in which you are employed or retained, for purposes of administrating and managing your employment relationship with the Company.  Executive may, at any time, review his or her Personal Data, request any necessary corrections to it, or withdraw his or her consent in writing by contacting the Company; however, withdrawal of your consent may affect your employment with the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Eligibility to Work</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.  In accordance with federal law, all new employees are required to present evidence of their eligibility to be employed in the United States and this Agreement is subject to proof of Executive&#x2019;s ability to lawfully work in the United States.  Accordingly, the Company requests that Executive provide the Company with appropriate documentation for this purpose within 72 hours of the first day of employment.  Acceptable documents include, but are not limited to, a birth certificate, a passport, a visa, permanent residence card, or driver&#x2019;s license and social security card.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:11pt;font-family:Calibri;justify-content:flex-start;min-width:2.4%;">9.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Pre-Employment Screenings as a Condition of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Source Sans Pro',sans-serif;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">As a condition of employment, Executive will be required to submit to a background check which must yield results considered acceptable to the Company.  Standard screenings include verification of prior employment and education, a drug test, and a criminal history check.  Additional screenings, such as a credit check or Department of Motor Vehicles record check, may be applicable based on job function.  Further, the </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Company will require the receipt of professional references that are predominately positive in content and character.  If the results of any of these screenings are determined by the Company to be noncompliant with its policies, procedures, or general business requirements, the Company reserves the right to unilaterally revoke this Agreement, with no obligation or liability to you.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">, the parties have executed this Agreement on the respective dates set forth below:</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">By:   </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  /s/ John A. Scarlett	</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">   	John A. Scarlett, MD</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  	Chairman of the Board, President &amp; CEO</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Date:	 </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  01-Nov-2024	</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Accepted and agreed this [  1</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">    ] day of _</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">November</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">______, 2024,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">  /s/ Joseph Eid	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Joseph Eid, M.D.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>6
<FILENAME>gern-ex10_33.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html>
 <head>
  <title>EX-10.33</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.33</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#x201c;[***]&#x201d;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LOAN AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated as of November 1, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">among</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit Party</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as additional </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BIOPHARMA CREDIT PLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collateral Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">),</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BPCR LIMITED PARTNERSHIP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(as a </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">)</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.94%;box-sizing:content-box;"></td>
    <td style="width:82.16%;box-sizing:content-box;"></td>
    <td style="width:2.9%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ACCOUNTING AND OTHER TERMS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounting</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Defined Terms.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SOFR</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LOANS AND TERMS OF PAYMENT</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Promise to Pay</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of Interest on the</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Requirements of Law; Increased Costs</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxes; Withholding, Etc.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional Consideration</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Evidence of Debt; Note Register; Term Loan Notes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CONDITIONS TO TERM LOANS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conditions Precedent to Tranche A Loan</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conditions Precedent to Tranche B Loan</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conditions Precedent to Tranche C Loan</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional Conditions Precedent to Term Loans</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Covenant to Deliver</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Procedures for Borrowing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Due Organization, Existence, Power and Authority</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity Interests</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization; No Conflict</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government Consents; Third-Party Consents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Binding Obligation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collateral</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adverse Proceedings, Compliance with Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exchange Act Documents; Financial Statements; Financial Condition; No Material Adverse Change; Books and Records</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Solvency</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of Taxes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Environmental Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material Contracts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory Compliance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.14</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Margin Stock</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.15</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subsidiaries; Capitalization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.16</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.17</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Full Disclosure</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.18</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws; Anti-Money Laundering Laws; Sanctions; Export and Import Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Health Care Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.20</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory Approvals or Licensures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Supply and Manufacturing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.22</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cybersecurity and Data Protection</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional Representations and Warranties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty Revenue Documents.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">AFFIRMATIVE COVENANTS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maintenance of Existence</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.94%;box-sizing:content-box;"></td>
    <td style="width:82.16%;box-sizing:content-box;"></td>
    <td style="width:2.9%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Statements, Notices</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxes</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insurance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating Accounts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance with Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Protection of Intellectual Property Rights</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Books and Records</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Access to Collateral; Audits</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Use of Proceeds</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Further Assurances</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional Collateral; Guarantors</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Formation or Acquisition of Subsidiaries; Designated Guarantors</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.14</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Post-Closing Requirements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.15</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Environmental</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.16</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory; Returns; Maintenance of Properties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.17</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Regulatory Obligations; Maintenance of Regulatory Approval or Licensure; Licensure and Designation; Manufacturing, Marketing and Distribution</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.18</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material Contracts; Collateral Documents; Royalty Revenue Contract</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NEGATIVE COVENANTS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dispositions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fundamental Changes; Location of Collateral</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mergers, Acquisitions, Liquidations or Dissolutions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Encumbrances</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Further Negative Pledges; Negative Pledge</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maintenance of Collateral Accounts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Distributions; Investments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Restrictions on Subsidiary Distributions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subordinated Debt; Permitted Convertible Indebtedness; Royalty Revenue Contract</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendments or Waivers of Organizational Documents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance with Sanctions and Anti-Money Laundering Laws</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.14</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Material Contracts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">EVENTS OF DEFAULT</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Covenant Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Withdrawal Event; Material Adverse Change;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attachment; Levy; Restraint on Business</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Insolvency</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other Agreements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Judgments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Misrepresentations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loan Documents; Collateral</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ERISA Event</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intercreditor Agreement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RIGHTS AND REMEDIES UPON AN EVENT OF DEFAULT</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rights and Remedies</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Power of Attorney</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Application of Payments and Proceeds Upon Default</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collateral Agent&#x2019;s Liability for Collateral</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Waiver; Remedies Cumulative</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Demand Waiver; Makewhole Amount; Prepayment Premium</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NOTICES</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.94%;box-sizing:content-box;"></td>
    <td style="width:82.16%;box-sizing:content-box;"></td>
    <td style="width:2.9%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CHOICE OF LAW, VENUE, AND JURY TRIAL WAIVER</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GENERAL PROVISIONS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Successors and Assigns</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indemnification</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severability of Provisions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Correction of Loan Documents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendments in Writing; Integration</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Counterparts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Survival</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Confidentiality</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attorneys&#x2019; Fees, Costs and Expenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of Set-Off</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marshalling; Payments Set Aside</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Electronic Execution of Documents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Captions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.14</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Construction of Agreement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.15</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third Parties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.16</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Advisory or Fiduciary Duty</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.17</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Credit Parties&#x2019; Agent</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">COLLATERAL AGENT</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Appointment and Authority</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rights as a Lender</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exculpatory Provisions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reliance by Collateral Agent</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delegation of Duties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Resignation of Collateral Agent</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-Reliance on Collateral Agent and Other Lenders</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collateral and Guaranty Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reimbursement by Lenders</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notices and Items to Lenders</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:36pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEFINITIONS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:72pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Definitions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Loan Advance Request Form</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Form of Tranche A Term Loan Note</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Form of Tranche B Term Loan Note</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Form of Tranche C Term Loan Note</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Form of Security Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Commitments; Notice Addresses</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:		Form of Compliance Certificate</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LOAN AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS LOAN AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated as of November 1, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) by and among GERON CORPORATION, a Delaware corporation (as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and a Credit Party), the Guarantors signatory hereto or otherwise party hereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), provides the terms on which each Lender shall make, and Borrower shall repay, the Credit Extensions (as hereinafter defined).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACCOUNTING AND OTHER TERMS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.1	Accounting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as otherwise expressly provided herein, all accounting terms not otherwise defined in this Agreement shall have the meanings assigned to them in conformity with GAAP.  Calculations and determinations must be made following GAAP.  If at any time any change in GAAP would affect the computation of any financial requirement set forth in any Loan Document (including for purposes of measuring compliance with any provision of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), and either Borrower or the Collateral Agent shall so request, the Collateral Agent and Borrower shall negotiate in good faith to amend such requirement to preserve the original intent thereof in light of such change in GAAP; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, until so amended, (x) such requirement shall continue to be computed in accordance with GAAP prior to such change therein and (y) all financial statements, Compliance Certificates and similar documents provided, delivered or submitted hereunder shall be provided, delivered or submitted together with a reconciliation between the calculations and amounts set forth therein before and after giving effect to such change in GAAP.  Notwithstanding any other provision contained herein, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts referred to herein, including in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be made, without giving effect to any election under ASC 825-10 (or any other Financial Accounting Standards Board Accounting Standards Codification (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or Financial Accounting Standard or Applicable Accounting Standard (including IFRS 9) having a similar result or effect) to value any Indebtedness or other liabilities of any Credit Party or any Subsidiary of any Credit Party at &#x201c;fair value&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.2	Defined Terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein.  All references to &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; are United States Dollars, unless otherwise noted.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.3	Currency</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof and solely with respect to the amount of any Indebtedness, Investment or other transaction made or consummated in a currency other than Dollars, no Default or Event of Default shall be deemed to have occurred after the time such Indebtedness, Investment or other transaction is incurred, made or consummated (so long as such Indebtedness, Investment or other transaction, at the time incurred, made or consummated, was permitted hereunder) solely as a result of changes in rates of currency exchange occurring over time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.4	SOFR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR Reference Rate or Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR Reference Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes.  The Collateral Agent and its affiliates or other related entities may engage in transactions that affect the calculation of the Term SOFR Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to Borrower.  The Collateral Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and shall have no liability to Borrower, any Lender or any other Person for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LOANS AND TERMS OF PAYMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1	Promise to Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower hereby unconditionally promises to pay each Lender the outstanding principal amount of the Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2	Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Availability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to the terms and conditions of this Agreement (including </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">):</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower agrees to request in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and each Lender severally agrees to make a term loan to Borrower on the Tranche A Closing Date in an original principal amount equal to such Lender&#x2019;s Applicable Percentage of the Tranche A Loan Amount requested by Borrower, but, for the avoidance of doubt, not greater than such Lender&#x2019;s Tranche A Commitment (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At Borrower&#x2019;s election pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each Lender severally agrees to make a term loan to Borrower on the Tranche B Closing Date in an original principal amount equal to such Lender&#x2019;s Applicable Percentage of the Tranche B Loan Amount requested by Borrower, but, for the avoidance of doubt, not greater than such Lender&#x2019;s Tranche B Commitment (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At Borrower&#x2019;s election pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> each Lender severally agrees to make a term loan to Borrower on the Tranche C Closing Date in an original principal amount equal to such Lender&#x2019;s Applicable Percentage of the Tranche C Loan Amount requested by Borrower, but, for the avoidance of doubt, not greater than such Lender&#x2019;s Tranche C Commitment (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After repayment or prepayment (in whole or in part), no Term Loan (or any portion thereof) may be re-borrowed.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Repayment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loans, including all unpaid principal thereunder (and, for the avoidance of doubt, all accrued and unpaid interest, all due and unpaid Lender Expenses and any and all other outstanding amounts payable under the Loan Documents), are due and payable in full on the Term Loan Maturity Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loans may be prepaid only in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, except as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayment of Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower shall have the option, at any time after the Tranche A Closing Date, to prepay, in part (in multiples of not less than [***]) or in whole, outstanding principal amounts under the Term Loans advanced by Lenders under this Agreement; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (A) Borrower provides written notice to the Collateral Agent of its election to prepay, in part (in multiples of not less than [***]) or in whole, the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loans at least five (5) Business Days prior to such prepayment (which notice shall include the amount of the outstanding principal amount of the Term Loans to be prepaid), and (B) the prepayment of such principal amount shall be accompanied by any and all accrued and unpaid interest thereon through the date of prepayment, any and all amounts payable in connection with such prepayment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as applicable) and, in the case of a prepayment in whole and not in part, any and all other amounts payable or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  The Collateral Agent will promptly notify each Lender of its receipt of such notice, and the amount of such Lender&#x2019;s Applicable Percentage of such prepayment.  Borrower may rescind any notice of prepayment under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if such prepayment would have resulted from a refinancing of the Term Loans or other contingent transaction, which refinancing or transaction shall not be consummated or shall otherwise be delayed (in which case, the date of prepayment may be extended with the consent of the Collateral Agent (not to be unreasonably withheld, conditioned, or delayed) or a new notice shall be required to be sent in connection with any subsequent prepayment).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower shall promptly, and in any event no later than ten (10) Business Days prior (or immediately if known fewer than ten (10) Business Days prior) to the consummation of such Change in Control, notify the Collateral Agent in writing of the occurrence (or anticipated occurrence) of a Change in Control, which notice shall include reasonable detail as to the nature, timing and other circumstances of such Change in Control (such notice, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Borrower shall prepay in full all of the Term Loans advanced by Lenders under this Agreement, immediately upon (and concurrent with) the consummation of such Change in Control, in an amount equal to the sum of (A) all unpaid principal and any and all accrued and unpaid interest thereon through the date of prepayment (such interest to be calculated based on Term SOFR for the Interest Period during which such Change in Control is consummated), and (B) any and all amounts payable with respect to the prepayment under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as applicable), together with any and all other amounts payable or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  The Collateral Agent will promptly notify each Lender of its receipt of the Change in Control Notice, and the amount of such Lender&#x2019;s Applicable Percentage of such prepayment.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to any prepayment, repurchase, redemption or similar action, of the Permitted Convertible Indebtedness in accordance with its terms (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Indebtedness Redemption</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that occurs prior to the Term Loan Maturity Date, Borrower shall promptly, and in any event no later than five (5) days prior to the consummation of such Convertible Indebtedness Redemption, notify the Collateral Agent in writing of the expected occurrence of such Convertible Indebtedness Redemption, which notice shall include reasonable detail as to the nature, timing and other circumstances of such Convertible Indebtedness Redemption (such notice, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Convertible Indebtedness Redemption Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Borrower shall prepay in full all of the Term Loans advanced by Lenders under this Agreement no later than concurrently with such Convertible Indebtedness Redemption, in an amount equal to the sum of (A) all unpaid and outstanding principal and any and all accrued and unpaid interest with respect to the Term Loans, and (B) any applicable amounts payable with respect to the prepayment under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (as applicable) and all other amounts payable or accrued and not yet paid under this Agreement and the other Loan Documents (including pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  The Collateral Agent will promptly notify each Lender of its receipt of the Convertible Indebtedness Redemption Notice, and the amount of such Lender&#x2019;s Applicable Percentage of such prepayment.  Notwithstanding the foregoing, none of the following shall be deemed to be a Convertible Indebtedness Redemption: (w) the conversion to Equity Interests (and payment of cash in lieu of fractional shares) by holders of Permitted Convertible Indebtedness (including any cash payment upon conversion) or required payment of any interest with respect to any Permitted Convertible Indebtedness, in each case, in accordance with the terms of the indenture or other documentation governing such Permitted Convertible Indebtedness; (x) delivery of Equity Interests and cash in lieu of fractional shares or in respect of accrued and unpaid interest to any holder of Permitted Convertible Indebtedness to induce such holder to convert Permitted Convertible Indebtedness in accordance with the terms of the indenture governing such Permitted Convertible Indebtedness; (y) any prepayment, repurchase, redemption or similar action of the Permitted Convertible Indebtedness using cash proceeds of any issuance of Permitted Convertible Indebtedness (and any cash proceeds received pursuant to the exercise, early unwind or termination of any Permitted Equity Derivatives in connection with such prepayment, repurchase, redemption or action); or (z) the exchange of existing Permitted Convertible Indebtedness for (1)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness constituting new Permitted Convertible Indebtedness (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refinancing Convertible Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (or the cash proceeds from the issuance of such Refinancing Convertible Debt) to the extent such Refinancing Convertible Debt is permitted to be issued under the terms of this Agreement, (2) Equity Interests, (3) the cash proceeds, if any, received pursuant to the exercise, early unwind or termination of any Permitted Equity Derivatives entered into in connection with such existing Permitted Convertible Indebtedness, or (4) cash in respect of accrued and unpaid interest on such exchanged existing Permitted Convertible Indebtedness (any such transaction described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (w)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(z)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayment Application</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any prepayment of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (together with the accompanying Makewhole Amount and Prepayment Premium that is payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable) shall be paid to Lenders in accordance with their respective Applicable Percentages for application to the Obligations in the following order:  (i) first, to due and unpaid Lender Expenses; (ii) second, to accrued and unpaid interest at the Default Rate incurred pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if any; (iii) third, without duplication of amounts paid pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, to accrued and unpaid interest at the Term Loan Rate; (iv) fourth, to accrued and unpaid Additional Consideration, if any; (v) fifth, to the Prepayment Premium; (vi) sixth, to the Makewhole Amount, if applicable; (vii) seventh, to the outstanding principal amount of the Term Loans being prepaid (in such order as the Collateral Agent or the Required Lenders may direct); and (viii) eighth, to any remaining amounts then due and payable under this Agreement and the other Loan Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Makewhole Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any prepayment of the Tranche A Loan by Borrower (A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or (B) as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case occurring prior to the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date shall, in any such case, be accompanied by payment of an amount equal to the Tranche A Makewhole Amount.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any prepayment of the Tranche B Loan by Borrower (A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (B) as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case occurring prior to the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date shall, in any such case, be accompanied by payment of an amount equal to the Tranche B Makewhole Amount.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any prepayment of the Tranche C Loan by Borrower (A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (B) as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case occurring prior to the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date shall, in any such case, be accompanied by payment of an amount equal to the Tranche C Makewhole Amount.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayment Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any prepayment of the Tranche A Loan by Borrower (A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (B) as a result of the occurrence of the maturity of the Term Loans pursuant to the proviso in the definition of Term Loan Maturity Date, or (C) as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall, in any such case, be accompanied by payment of an amount equal to the Tranche A Prepayment Premium.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any prepayment of the Tranche B Loan by Borrower (A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (B) as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall, in any such case, be accompanied by payment of an amount equal to the Tranche B Prepayment Premium.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any prepayment of the Tranche C Loan by Borrower (A) pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or (B) as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall, in any such case, be accompanied by payment of an amount equal to the Tranche C Prepayment Premium.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Makewhole Amount or Prepayment Premium payable as a result of any prepayment of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be presumed to be the liquidated damages sustained by each applicable Lender as the result of the early redemption and repayment of such Term Loan Notes and Borrower agrees that it is reasonable under the circumstances currently existing.  BORROWER EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT MAY LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT OR FUTURE REQUIREMENTS OF LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF ANY MAKEWHOLE AMOUNT OR PREPAYMENT PREMIUM IN CONNECTION WITH ANY SUCH PREPAYMENT OR ACCELERATION OR OTHERWISE.  Borrower expressly agrees that (to the fullest extent it may lawfully do so) that: (i) each Makewhole Amount and Prepayment Premium is reasonable and is the product of an arm&#x2019;s-length transaction among sophisticated business people, ably represented by counsel; (ii) each Makewhole Amount and Prepayment Premium shall be payable notwithstanding the then-prevailing market rates at the time payment thereof is made; (iii) there has been a course of conduct among Lenders and Borrower giving specific consideration in this transaction for such agreement to pay each Makewhole Amount and Prepayment Premium; and (iv) Borrower shall be estopped hereafter from claiming differently than as agreed to in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower expressly acknowledges that its agreement to pay the Makewhole Amount and Prepayment Premium, as the case may be, to applicable Lenders as herein described is a material inducement to such Lenders to make any Credit Extension.  Without affecting any of any Lender&#x2019;s rights or remedies hereunder or in respect hereof, if Borrower fails to pay the applicable Makewhole Amount or Prepayment Premium when due, then the amount thereof shall thereafter bear interest until paid in full at the Default Rate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3	Payment of Interest on the Credit Extensions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, the principal amount outstanding under each Term Loan shall accrue interest at a </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">per annum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rate equal to Term SOFR for the Interest Period therefor </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">plus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Applicable Margin (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which interest shall be payable quarterly in arrears in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest shall accrue on each Term Loan commencing on, and including, the day on which such Term Loan is made, and shall accrue on such Term Loan, or any portion thereof, through and including the day on which such Term Loan or such portion is paid.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest is due and payable quarterly on each Interest Date, as calculated by the Collateral Agent (which calculations shall be deemed correct absent manifest error, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Collateral Agent shall provide evidence of such calculation upon Borrower&#x2019;s written request), commencing on December 31, 2024; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if any such date is not a Business Day, the applicable interest shall be due and payable on the immediately preceding Business Day.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Default Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event Borrower fails to pay any of the Obligations when due (after giving effect to any applicable grace or cure period), or upon the commencement and during the continuance of an Insolvency Proceeding of Borrower, or upon the occurrence and during the continuance of any other Event of Default, immediately (and without notice or demand by any Lender or the Collateral Agent for payment thereof to Borrower), such past due Obligations shall accrue interest at a rate </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">per annum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which is three percentage points (3.00%) above the rate that is otherwise applicable thereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Default Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and, notwithstanding anything to the contrary in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, such interest shall be payable entirely in cash on demand of the Collateral Agent; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, with respect to any Event of Default of the type described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, other than </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 7.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Collateral Agent shall notify Borrower in writing regarding the accrual of interest at the Default Rate in respect of any such Obligations as promptly as practicable following the occurrence of such Event of Default; provided, further, that the failure of the Collateral Agent to deliver such notice to Borrower shall not constitute a waiver of any such Event of Default or affect the right of any Lender or the Collateral Agent to collect or demand such accrued interest with respect to any time prior to the giving of such notice or otherwise prejudice or limit any rights or remedies of the Collateral Agent or any Lender.  Payment or acceptance of the increased interest rate provided in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is not a permitted alternative to timely payment of any Obligations and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of the Collateral Agent or any Lender.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">360-Day Year</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Interest payable under each Term Loan shall be computed on the basis of a year of 360 days, and in each case shall be payable for the actual number of days elapsed.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as otherwise expressly provided herein, all Term Loan payments and any other payments hereunder by (or on behalf of) Borrower shall be made on the date specified herein to such bank account of each applicable Lender as such Lender (or the Collateral Agent) shall have designated in a written notice to Borrower delivered on or before the Tranche A Closing Date (which such notice may be updated by such Lender (or the Collateral Agent) by written notice to Borrower from time to time after the Tranche A Closing Date on two (2) Business Days&#x2019; notice).  Except as otherwise expressly provided herein, interest is payable quarterly on each Interest Date</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if any such date is not a Business Day, the applicable interest shall be due and payable on the immediately preceding Business Day.  Payments of principal or interest received after 11:00 a.m. New York City time on such date are considered received at the opening of business on the next Business Day.  When any payment is due on a day that is not a Business Day, such payment is due on the immediately preceding Business Day.  All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In connection with the use or administration of Term SOFR, the Collateral Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.  The Collateral Agent will promptly notify Borrower and the Lenders of the effectiveness of any Conforming Changes in connection with the use or administration of Term SOFR.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement Setting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary herein or in any other Loan Document:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Benchmark Replacement for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Benchmark Replacement for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) Business Day after the date notice of such Benchmark Replacement is provided to Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Collateral Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders.  For the avoidance of doubt, if the Benchmark Replacement is Daily Simple SOFR, all interest payments will be payable on a quarterly basis.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In connection with the implementation and administration of a Benchmark Replacement, the Collateral Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices; Standards for Decisions and Determinations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent will promptly notify Borrower and the Lenders of (A) the implementation of any Benchmark Replacement and (B) the effectiveness of any Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in connection with the use, administration, adoption or implementation of a Benchmark Replacement.  The Collateral Agent will notify Borrower of (x) the removal or reinstatement of any tenor of a Benchmark pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below and (y) the commencement of any Benchmark Unavailability Period.  Any determination, decision or election that may be made by the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Agent or, if applicable, any Lender (or group of Lenders) pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unavailability of Tenor of Benchmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (A) if the then-current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (1) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Collateral Agent in its reasonable discretion or (2) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Collateral Agent may modify the definition of &#x201c;Interest Period&#x201d; (or any similar or analogous definition) for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (B) if a tenor that was removed pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (A)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above either (1) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (2) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Collateral Agent may modify the definition of &#x201c;Interest Period&#x201d; (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4	Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower shall pay to or reimburse (or pay directly on behalf of) each Lender and the Collateral Agent, as applicable, all of such Person&#x2019;s reasonable and documented Lender Expenses incurred through and after the Effective Date, promptly after receipt of a written demand therefor by such Lender or the Collateral Agent (with, in the case of any Lender, a copy of such demand to the Collateral Agent), setting forth in reasonable detail such Person&#x2019;s Lender Expenses; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Borrower&#x2019;s obligation to pay or reimburse Lender Expenses incurred through (and including) the Effective Date shall be subject to the terms of the Letter Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5	Requirements of Law; Increased Costs</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the event that any applicable Change in Law:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	does or shall subject any Lender to any Tax of any kind whatsoever with respect to this Agreement or any other Loan Documents or the Term Loans made hereunder (except, in each case, Indemnified Taxes, Taxes described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Excluded Taxes, and Connection Income Taxes);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	does or shall impose, modify or hold applicable any reserve, capital requirement, special deposit, compulsory loan, insurance charge or similar requirements against assets held by, or deposits or other liabilities in or for the account of, advances or loans by, or other credit extended by, or any other acquisition of funds by, any Lender; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	does or shall impose on any Lender any other condition (other than Taxes, which are addressed in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above); and the result of any of the foregoing is to increase the cost to such Lender (as determined by such Lender in good faith using calculation methods customary in the industry) of making, renewing or maintaining the Term Loans or to reduce any amount receivable in respect thereof or to reduce the rate of return on the capital of such Lender or any Person controlling such Lender, then, in any such case, Borrower shall promptly pay to the applicable Lender, within thirty (30) days of its receipt of the certificate described below, any additional amounts necessary to compensate such Lender for such additional cost or reduced amounts receivable or rate of return as reasonably determined by such Lender with respect to this Agreement or the Term Loans made hereunder.  If any Lender becomes entitled to claim any additional amounts pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, it shall notify Borrower in writing of the event by reason of which it has become so entitled (with a copy of such notice to the Collateral Agent), and a certificate as to any additional amounts payable pursuant to the foregoing sentence containing the calculation thereof in reasonable detail submitted by such Lender to Borrower (with a copy of such certificate to the Collateral Agent) shall be conclusive in the absence of manifest error.  The provisions hereof shall survive the termination of this Agreement and the payment of the outstanding Term Loans and all other Obligations.  Failure or delay on the part of any Lender to demand compensation for any increased costs or reduction in amounts received or receivable or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduction in return on capital under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not constitute a waiver of such Lender&#x2019;s right to demand such compensation; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that Borrower shall not be under any obligation to compensate such Lender under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to increased costs or reductions with respect to any period prior to the date that is 180 days prior to the date of the delivery of the notice required pursuant to the foregoing provisions of this paragraph; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6	Taxes; Withholding, Etc.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All sums payable by any Credit Party hereunder and under the other Loan Documents shall (except to the extent required by Requirements of Law) be paid free and clear of, and without any deduction or withholding on account of, any Tax imposed, levied, collected, withheld or assessed by any Governmental Authority.  In addition, the Credit Parties shall pay, in a timely manner, to the relevant Governmental Authority in accordance with Requirements of Law, Other Taxes, and Borrower shall furnish, in a timely manner, to each Lender (as applicable, with a copy to the Collateral Agent) the original or a certified copy of a receipt evidencing payment thereof or other evidence reasonably satisfactory to the Collateral Agent of such payment and of the remittance thereof to the relevant taxing or other Governmental Authority.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any Credit Party or any other Person (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is required by Requirements of Law to make any deduction or withholding on account of any Tax (as determined in the good faith discretion of such Withholding Agent) from any sum paid or payable by any Credit Party to any Lender under any of the Loan Documents:  (i) such Withholding Agent shall make any such withholding or deduction; (ii) such Withholding Agent shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with Requirements of Law; (iii) if the Tax is an Indemnified Tax, the sum payable by such Withholding Agent in respect of which the relevant deduction, withholding or payment of Indemnified Tax is required shall be increased to the extent necessary to ensure that, after the making of that deduction, withholding or payment (including any deductions for Indemnified Taxes applicable to additional sums payable under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), such Lender receives on the due date a net sum equal to what it would have received had no such deduction, withholding or payment of Indemnified Tax been required or made; and (iv) Borrower shall (or shall cause such Withholding Agent, if not Borrower, to) deliver to such Lender (with a copy to the Collateral Agent) the original or a certified copy of a receipt evidencing payment thereof or other evidence reasonably satisfactory to such Lender of such deduction, withholding or payment and of the remittance thereof to the relevant taxing or other Governmental Authority.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Parties shall jointly and severally indemnify each Lender for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) paid by such Lender and any liability (including any reasonable expenses) arising therefrom or with respect thereto whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  Any indemnification payment pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be made to the applicable Lender within thirty (30) days from written demand therefor.  A certificate as to the amount of such payment or liability delivered to the Credit Parties by a Lender (with a copy to the Withholding Agent, if not a Credit Party), or by the Withholding Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver, as soon as practicable, to Borrower, at the times reasonably requested in writing by Borrower, such properly completed and executed documentation as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, such Lender, if reasonably requested in writing by Borrower, shall deliver, as soon as practicable, such other documentation prescribed by Requirements of Law or otherwise reasonably requested by Borrower to enable Borrower to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6(d)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below) shall not be required if in such Lender&#x2019;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.  For the avoidance of doubt, for the purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the term &#x201c;Lender&#x201d; shall include each applicable assignee thereof.  Without limiting the generality of the foregoing:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any Lender is organized under the laws of the United States, such Lender shall deliver and shall cause each applicable assignee thereof to deliver, to Borrower, on or prior to the Tranche A Closing Date or on or prior to the applicable date of assignment, as applicable, and at such other times as may be necessary in the determination of Borrower, upon reasonable request in writing by Borrower, two (2) executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any Lender is a Foreign Lender, such Lender shall deliver, and shall cause each applicable assignee thereof to deliver, to Borrower, on or prior to, the Tranche A Closing Date and, the date on which a Lender Transfer involving such Lender occurs, as applicable, and at such other times as may be necessary in the determination of Borrower, upon reasonable request in writing by Borrower:</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, a properly completed and duly executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;interest&#x201d; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, a properly completed and duly executed copy of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#x201c;business profits&#x201d; or &#x201c;other income&#x201d; article of such tax treaty;</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a completed and duly executed copy of IRS Form W-8ECI;</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the extent that such Foreign Lender is not the beneficial owner, a properly completed and duly executed copy of IRS W-8IMY and a withholding statement, along with IRS Form W-9, W-8BEN-E, W-8BEN, W-8ECI or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a certificate referenced in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(d)(ii)(4)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below on behalf of each such direct and indirect partner; or</font></p>
  <p style="margin-left:26.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(4)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of a Foreign Lender claiming the benefits of the exemption for &#x201c;portfolio interest&#x201d; under Section 881(c) of the IRC, it shall provide Borrower with a properly completed and duly executed copy of IRS Form W-8BEN-E or IRS Form W-8BEN, as applicable, and a certificate reasonably satisfactory to Borrower to the effect that such Foreign Lender is not a &#x201c;bank&#x201d; within the meaning of 881(c)(3)(A) of the IRC, a &#x201c;10 percent shareholder&#x201d; of Borrower within the meaning of Section 871(h)(3)(B) of the IRC, or a &#x201c;controlled foreign corporation&#x201d; related to Borrower as described in Section 881(c)(3)(C) of the IRC.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any Lender is a Foreign Lender it shall, to the extent it is legally entitled to do so, deliver to Borrower (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a party to this Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed copies of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit Borrower to determine the withholding or deduction required to be made.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a payment made to any Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the IRC, as applicable), such Lender shall deliver to Borrower at the time or times prescribed by law and at such time or times reasonably requested by Borrower such documentation prescribed by applicable law (including as</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prescribed by Section 1471(b)(3)(C)(i) of the IRC) and such additional documentation reasonably requested by Borrower as may be necessary for Borrower to comply with their obligations under FATCA and to determine that Lender has complied with its obligations under FATCA or to determine the amount to deduct and withhold from such payment.  Solely for purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, &#x201c;FATCA&#x201d; shall include any amendments made to FATCA after the date of this Agreement.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Lender agrees that if any form or certification it previously delivered pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify Borrower and Collateral Agent in writing of its legal inability to do so.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any party hereto determines, in its discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including by the payment of additional amounts pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority and the requirement to repay such refund to such Governmental Authority is not due to the indemnified party&#x2019;s failure to timely provide complete and accurate IRS forms and other documentation required pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the payment of such amount would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the indemnification payments or additional amounts giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower is currently treated as a corporation for U.S. federal income tax purposes.  Borrower shall provide the Required Lenders with a prior written notice before taking any affirmative action (including making any election under Section 301.7701-3(c) of the Treasury Regulations (or any successor provision) by way of filing an IRS Form 8832) to change its U.S. entity tax classification.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower shall use commercially reasonable efforts to furnish upon request any information to assist any Lender (i) in the computation of accruals with respect to any &#x201c;original issue discount&#x201d; or &#x201c;market discount&#x201d; arising with respect to the Term Loans for U.S. federal income tax purposes and GAAP, and (ii) with its compliance with any associated tax reporting or filing requirements of such Lender or its partners, members or beneficial owners.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party&#x2019;s obligations under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall survive any assignment of rights by, or the replacement of, a Lender, the termination of the Term Loan Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7	Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As additional consideration for the obligation of each Lender to fund its Applicable Percentage of the Term Loans and the funding of its Applicable Percentage of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	on the Tranche A Closing Date, Borrower shall pay to each Lender an amount equal to the product of (i) the sum of such Lender&#x2019;s Tranche A Commitment, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ii) 0.0250 (each such product, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	on the Tranche B Closing Date, Borrower shall pay to each Lender an amount equal to the product of (i) the sum of such Lender&#x2019;s Tranche B Commitment, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ii) 0.0250 (each such product, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	on the Tranche C Closing Date, Borrower shall pay to each Lender an amount equal to the product of (i) the sum of such Lender&#x2019;s Tranche C Commitment, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ii) 0.025 (each such product, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any and all Additional Consideration shall be fully earned when paid and shall not be refundable for any reason whatsoever and such Additional Consideration shall be treated as original issue discount with respect to the applicable Term Loan for U.S. federal income tax purposes, unless otherwise required by Requirements of Law.  The Additional Consideration payable hereunder shall be deducted, as applicable, from the proceeds of the Tranche A Loan (with respect to the Tranche A Additional Consideration), the Tranche B Loan (with respect to the Tranche B Additional Consideration) and the Tranche C Loan (with respect to the Tranche C Additional Consideration) to be advanced to Borrower pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8	Evidence of Debt; Note Register; Term Loan Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evidence of Debt; Register</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower will maintain at all times at its principal executive office, a register that identifies each beneficial owner that is entitled to a payment of principal and stated interest on each Term Loan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and provides for the registration and transfer of Term Loan Notes so that each Term Loan is at all times in &#x201c;registered form&#x201d; within the meaning of Section 5f.103-1(c) of the United States Treasury Regulations (or any amended or successor version) and Section 163(f), 871(h)(2) and 881(c)(2) of the IRC and any related regulations (and any other relevant or successor provisions of the IRC or such regulations).  Each Term Loan:  (i) shall, pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, be registered as to both principal and any stated interest with Borrower or its agent, and (ii) shall be transferred or exchanged by any Lender only through a book entry system maintained by Borrower.  Any Term Loan Note issued in exchange for any other Term Loan Note or upon transfer thereof shall carry the rights to unpaid interest and interest to accrue that were carried by the Term Loan Note so exchanged or transferred, and neither gain nor loss of interest shall result from any such transfer or exchange.  Any stamp, documentary, transfer or similar tax or governmental charge or fee relating to such transaction shall be paid by the party requesting the exchange.  The entries in the Note Register shall be conclusive and binding for all purposes, including as to the outstanding principal amount of the Term Loan Note and the payment of interest, principal and other sums due hereunder absent manifest error and Borrower, Lenders and any of their respective agents shall treat the Person recorded in the Note Register as the sole and exclusive record and beneficial holder and owner of such Term Loan Note or any other Loan Document (including this Agreement), and a Lender hereunder, for all purposes whatsoever.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower shall execute and deliver to each Lender to evidence such Lender&#x2019;s Term Loan, (i) on the Tranche A Closing Date, a Tranche A Note, (ii) on the Tranche B Closing Date (if any), a Tranche B Note, and (iii) on the Tranche C Closing Date (if any), a Tranche C Note.  All amounts due under the Term Loan Notes shall be repayable as set forth in this Agreement and interest shall accrue on the principal amount of the Term Loans represented by the Term Loan Notes, in each case, in accordance with the terms of this Agreement.  All Term Loan Notes shall rank for all purposes </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pari passu</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with each other.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONDITIONS TO TERM LOANS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.1	Conditions Precedent to Tranche A Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Lender&#x2019;s obligation to advance its Applicable Percentage of the Tranche A Loan Amount is subject to the satisfaction (or waiver in Lenders&#x2019; sole discretion in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof) of the following conditions:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s and each Lender&#x2019;s receipt of:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on the Effective Date, (i) copies of the Loan Agreement, the Disclosure Letter, the Perfection Certificate for Borrower and its Subsidiaries and the Advance Request Form for the Tranche A Loan, in each case (x) dated as of the Effective Date, (y) executed (where applicable) and delivered by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on the Tranche A Closing Date, copies of the other Loan Documents (including the schedules thereto), including the Tranche A Notes executed by Borrower, the Collateral Documents (but excluding any Control Agreements, Collateral Access Agreements and any other Loan Document described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter to be delivered after the Tranche A Closing Date), the Intercreditor Agreement, in each case (x) dated as of the Tranche A Closing Date, (y) executed (where applicable) and delivered by each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt of (i) true, correct, complete and up-to-date copies of the Operating Documents of each of the Credit Parties and (ii) a Secretary&#x2019;s Certificate, dated the Tranche A Closing Date, certifying that the foregoing copies are true, correct and complete (such Secretary&#x2019;s Certificate (as applicable) to be in form and substance reasonably satisfactory to the Collateral Agent);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt of a good standing certificate for each Credit Party (where applicable in the subject jurisdiction), certified (where available) by the Secretary of State (or the equivalent thereof) of the jurisdiction of incorporation, formation or organization of such Person as of a date no earlier than thirty (30) days prior to the Tranche A Closing Date;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt of a Secretary&#x2019;s Certificate in relation to each Credit Party, dated the Tranche A Closing Date, certifying that:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attached to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Credit Party of the Loan Documents to which it is a party;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the name(s) and title(s) of the officers or other signatories of such Credit Party authorized to execute the Loan Documents to which such Credit Party is a party on behalf of such Credit Party, together with a sample of the true signature(s) of each such signatory; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each Credit Party shall have obtained all Governmental Approvals, if any, and all consents of other Persons, if any, in each case that are necessary in connection with the transactions contemplated by the Loan Documents and each of the foregoing shall be in full force and effect and in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt on the Tranche A Closing Date an opinion of Cooley LLP, counsel to Borrower, in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Collateral Agent&#x2019;s receipt of (i) evidence that any products liability and general liability insurance policies maintained regarding any Collateral are in full force and effect and (ii) appropriate evidence showing the Collateral Agent, for the benefit of Lenders and the other Secured Parties, having been named as additional insured or loss payee, as applicable (such evidence to be in form and substance reasonably satisfactory to the Collateral Agent) with respect to any products liability and general liability insurance policies maintained in the United States regarding any Collateral;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt prior to the Tranche A Closing Date of Borrower&#x2019;s U.S. tax forms and all documentation and other information required by bank regulatory authorities under applicable &#x201c;know-your-customer&#x201d; and anti-money laundering rules and regulations, including the U.S.A. Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patriot Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">concurrent with the funding of the Tranche A Loan, payment of (i) Lender Expenses then due as specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof for which Borrower has received an invoice at least one (1) Business Day prior, and (ii) payment of the Tranche A Additional Consideration, which such payments shall be deducted from the proceeds of the Tranche A Loan;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt on or before the Effective Date of a true, correct and complete copy of the Royalty Revenue Contract and other Royalty Revenue Documents duly executed by all parties thereto;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt on the Tranche A Closing Date of: (i) a payoff letter in respect of all Indebtedness and any and all other amounts outstanding under the Existing Credit Agreement and the termination of all extensions of credit thereunder, executed and delivered by all parties thereto, and evidence of the repayment in full of all such Indebtedness and other amounts pursuant to such payoff letter prior to or concurrent with the funding of the Tranche A Loan on the Tranche A Closing Date (which evidence shall be in the form of a funds flow showing payment in full of any and all amounts described or otherwise referred to in the payoff letter); and (ii) evidence that all Liens on or security interests in any and all collateral securing the payment of any such Indebtedness and any guaranty or other obligations of Borrower or any of its Subsidiaries under the Existing Credit Agreement in favor of any Person have been effectively terminated as of the Tranche A Closing Date following such repayment in full of all such Indebtedness and other amounts pursuant to such payoff letter; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Collateral Agent&#x2019;s receipt of a certificate, dated the Tranche A Closing Date and signed by a Responsible Officer of Borrower, confirming: (i) there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter; (ii) satisfaction of the conditions precedent set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (such certificate to be in form and substance reasonably satisfactory to the Collateral Agent); and (iii) that the organizational structure and capital structure of Borrower and each of its Subsidiaries is as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.15</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter as at the Tranche A Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.2	Conditions Precedent to Tranche B Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Lender&#x2019;s obligation to advance its Applicable Percentage of the Tranche B Loan Amount is subject to the satisfaction (or waiver in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof) of the following conditions:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Collateral Agent&#x2019;s and each Lender&#x2019;s receipt, on the Tranche B Closing Date, of the Tranche B Note executed by Borrower, and, if and to the extent any update thereto is necessary between the Tranche A Closing Date and the Tranche B Closing Date, an updated Disclosure Letter or Perfection Certificate (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in no event may the Disclosure Letter or the Perfection Certificate be updated in a manner that would reflect or evidence a Default or an Event of Default (with or without such update)), in each case (x) dated as of the Tranche B Closing Date, (y) executed (where applicable) and delivered by each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the Collateral Agent&#x2019;s receipt of a Secretary&#x2019;s Certificate in relation to each Credit Party, dated the Tranche B Closing Date, certifying that:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	(A) the Borrowing Resolutions (and, if applicable, resolutions of the holders of all of its issued shares) adopted as of the Tranche A Closing Date authorizing the Term Loans and previously delivered to the Collateral Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have not been modified and remain in full force and effect or, alternatively, (B) attached to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing the Tranche B Loan; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	the Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	the Tranche A Loan has been funded on the Tranche A Closing Date;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	concurrent with the funding of the Tranche B Loan, payment of Lender Expenses then due as specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof for which Borrower has received an invoice at least one (1) Business Day prior, and payment of the Tranche B Additional Consideration in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which such payments shall be deducted from the proceeds of the Tranche B Loan; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	the Collateral Agent&#x2019;s receipt of a certificate, dated the Tranche B Closing Date and signed by a Responsible Officer of Borrower, confirming: (i) there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter delivered in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2(a)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable and (ii) the satisfaction of the conditions precedent set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (such certificate to be in form and substance reasonably satisfactory to the Collateral Agent).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.3	Conditions Precedent to Tranche C Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Lender&#x2019;s obligation to advance its Applicable Percentage of the Tranche C Loan Amount is subject to the satisfaction (or waiver in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof) of the following conditions:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the Collateral Agent&#x2019;s and each Lender&#x2019;s receipt, on the Tranche C Closing Date, of the Tranche C Note executed by Borrower, and, if and to the extent any update thereto is necessary between the prior Closing Date and the Tranche C Closing Date, an updated Disclosure Letter or Perfection Certificate (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in no event may the Disclosure Letter or the Perfection Certificate be updated in a manner that would reflect or evidence a Default or an Event of Default (with or without such update)), in each case (x) dated as of the Tranche C Closing Date, (y) executed (where applicable) and delivered by each applicable Credit Party, and (z) in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the Collateral Agent&#x2019;s receipt of a Secretary&#x2019;s Certificate in relation to each Credit Party, dated the Tranche C Closing Date, certifying that:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	(A) the Borrowing Resolutions (and, if applicable, resolutions of the holders of all of its issued shares) adopted as of the Tranche A Closing Date authorizing the Term Loans and previously delivered to the Collateral Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have not been modified and remain in full force and effect or, alternatively, (B) attached to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing the Tranche B Loan; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	the Collateral Agent and each Lender may conclusively rely on such certificate with respect to the authority of such officers unless and until such Credit Party shall have delivered to the Collateral Agent a further certificate canceling or amending such prior certificate;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	concurrent with the funding of the Tranche C Loan, payment of Lender Expenses then due as specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof for which Borrower has received an invoice at least one (1) Business Day prior, and payment of the Tranche C Additional Consideration in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which such payments shall be deducted from the proceeds of the Tranche C Loan;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	the Tranche A Loan has been funded on the Tranche A Closing Date;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	the Collateral Agent&#x2019;s receipt of a certificate, dated the Tranche C Closing Date and signed by a Responsible Officer of Borrower, confirming: (i) the Tranche C Net Sales Trigger has occurred; (ii) there is no Adverse Proceeding pending or, to the Knowledge of Borrower, threatened, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter delivered in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable; and (iii) satisfaction of the conditions precedent set forth in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (such certificate to be in form and substance reasonably satisfactory to the Collateral Agent).  For the avoidance of doubt, Borrower shall not be permitted to deliver an Advance Request Form with respect to, and no Lender shall have any obligation to fund, the Tranche C Loan (or any portion thereof), unless and until the Tranche C Net Sales Trigger has occurred; and</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	concurrent with the funding of the Tranche C Loan, payment of Lender Expenses then due as specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof for which Borrower has received an invoice at least one (1) Business Day prior, and payment of the Tranche C Additional Consideration in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which such payments shall be deducted from the proceeds of the Tranche C Loan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.4	Additional Conditions Precedent to Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The obligation of each Lender to advance its Applicable Percentage of each Term Loan is subject to the following additional conditions precedent:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the representations and warranties made by the Credit Parties in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement and in the other Loan Documents are true and correct in all material respects on the applicable Closing Date, unless any such representation or warranty is stated to relate to a specific earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date (it being understood that any representation or warranty that is qualified as to &#x201c;materiality,&#x201d; &#x201c;Material Adverse Change,&#x201d; or similar language shall be true and correct in all respects, in each case, on the applicable Closing Date (both with and without giving effect to the Term Loans) or as of such earlier date, as applicable); and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there shall not have occurred any Default, that is then continuing, or any Event of Default (including, for the avoidance of doubt, any Material Adverse Change or Withdrawal Event).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.5	Covenant to Deliver</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Credit Parties agree to deliver to the Collateral Agent or each Lender, as applicable, each item required to be delivered to Collateral Agent or each Lender, as applicable, under this Agreement as a condition precedent to any Credit Extension; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any such items set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter shall be delivered to the Collateral Agent within the time period prescribed therefor on such schedule.  The Credit Parties expressly agree that a Credit Extension made prior to the receipt by the Collateral Agent or any Lender, as applicable, of any such item shall not constitute a waiver by the Collateral Agent or any Lender of the Credit Parties&#x2019; obligation to deliver such item, and the making of any Credit Extension in the absence of any such item required to have been delivered by the date of such Credit Extension shall be in the applicable Lender&#x2019;s sole discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.6	Procedures for Borrowing</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to the prior satisfaction of all other applicable conditions to the making of each Term Loan set forth in this Agreement, to obtain any Term Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile a completed Advance Request Form (but for the funds flow to be attached thereto) for such Term Loan executed by a Responsible Officer of Borrower (which notice shall be irrevocable on and after the date on which such notice is given and Borrower shall be bound to make a borrowing in accordance therewith), in which case each Lender agrees to advance its Applicable Percentage of such Term Loan to Borrower on the Tranche A Closing Date, Tranche B Closing Date or Tranche C Closing Date, as applicable, by wire transfer of same day funds in Dollars, to such account(s) in the United States as may be designated in writing to the Collateral Agent by Borrower at least two (2) Business Days prior to the Tranche A Closing Date, Tranche B Closing Date or Tranche C Closing Date, as applicable; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, with respect to the Tranche B Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile, at its option should it wish to obtain the Tranche B Loan, such completed Advance Request Form no later than December 31, 2025; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, with respect to the Tranche C Loan, Borrower shall deliver to the Collateral Agent and Lenders by electronic mail or facsimile, at its option should it wish to obtain the Tranche C Loan, such completed Advance Request Form no earlier than the date on which the Tranche C Net Sales Trigger has occurred and no later than December 31, 2025.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPRESENTATIONS AND WARRANTIES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to induce each Lender and the Collateral Agent to enter into this Agreement and for each Lender to make the Credit Extensions to be made on the Effective Date and each applicable Closing Date, each Credit Party, jointly and severally with each other Credit Party, represents and warrants to each Lender and the Collateral Agent that the following statements are true and correct as of the Effective Date and each applicable Closing Date on which a Term Loan is made (both with and without giving effect to the Term Loans) except as otherwise specified below:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.1	Due Organization, Existence, Power and Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower and each of its Subsidiaries (a) is duly incorporated, organized or formed, and validly existing and, to the extent the concept is applicable in such</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdiction, in good standing, under the laws of its jurisdiction of incorporation, organization or formation identified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.15</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, (b) has all requisite power and authority to (i) own, lease, license and operate its assets and properties and to carry on its business as currently conducted and (ii) execute and deliver the Loan Documents to which it is a party and to perform its obligations thereunder and otherwise carry out the transactions contemplated thereby, (c) is duly qualified and, to the extent the concept is applicable in such jurisdiction, in good standing, under the laws of each jurisdiction where its ownership, lease, license or operation of assets or properties or the conduct of its business requires such qualification, and (d) has all requisite Governmental Approvals to operate its business as currently conducted; except in each case referred to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (other than with respect to Borrower and any other Credit Party), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, to the extent that failure to do so could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2	Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All of the outstanding Equity Interests in each Subsidiary of Borrower which are required to be pledged pursuant to the Collateral Documents have been duly authorized and validly issued, are (where required by Requirements of Law to be) fully paid and, in the case of Equity Interests representing corporate interests, are non-assessable, and all such Equity Interests owned directly by Borrower or any other Credit Party are owned free and clear of all Liens except for Permitted Liens.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter identifies each Person, the Equity Interests in which as of the applicable Closing Date are required to be pledged on the applicable Closing Date pursuant to the Collateral Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.3	Authorization; No Conflict</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, the execution, delivery and performance by each Credit Party of the Loan Documents to which it is a party, and the consummation of the transactions contemplated thereby, (a) have been duly authorized by all necessary corporate or other organizational action and (b) do not and will not (i) contravene the terms of any of such Credit Party&#x2019;s Operating Documents, (ii) conflict with or result in any breach or contravention of, or require any payment to be made under (A) after giving effect to the payoff and termination of the Existing Credit Agreement, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Credit Party is a party or affecting such Credit Party or the assets or properties of such Credit Party or any of its Subsidiaries or (B) any order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which such Credit Party or any of its properties or assets are subject, (iii) result in the creation of any Lien (other than under or otherwise permitted under the Loan Documents) or (iv) violate any Requirements of Law, except, in the cases of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (b)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, to the extent that such conflict, breach, contravention, payment or violation could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.4	Government Consents; Third-Party Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, no Governmental Approval or other approval, consent, exemption or authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person (including any counterparty to any Company IP Agreement or other Material Contract) is necessary or required in connection with (a) the execution, delivery or performance by, or enforcement against, any Credit Party of this Agreement or any other Loan Document, or for the consummation of the transactions contemplated hereby or thereby, (b) the grant by any Credit Party of the Liens granted by it pursuant to the Collateral Documents, (c) the perfection or maintenance of the Liens created under the Collateral Documents (including the priority thereof) or (d) the exercise by the Collateral Agent or any Lender of its rights under the Loan Documents or the remedies in respect of the Collateral pursuant to the Collateral Documents, except in each case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, for (i) filings or registrations necessary to perfect the Liens on the Collateral granted by the Credit Parties to the Collateral Agent for the benefit of Lenders and the other Secured Parties, (ii) the approvals, consents, exemptions, authorizations, actions, notices and filings which have been duly obtained, taken, given or made and are in full force and effect, (iii) filings under state or federal securities laws, (iv) notices required to be delivered by the Collateral Agent or any Lender in connection with, or the cooperation of any third Person (that is not an Affiliate of any Credit Party) that is required for, any exercise of any of the rights or remedies by the Collateral Agent or any Lender, and (v) those approvals, consents, exemptions, authorizations or other actions, notices or filings, the failure of which to obtain or make could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.5	Binding Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement has been duly executed and delivered by Borrower and each other Credit Party that is a party hereto and each other Loan Document has been duly executed and delivered by each Credit Party that is a party thereto, constitutes a legal, valid and binding obligation of Borrower or such Credit Party (as applicable), enforceable against Borrower or such Credit Party (as applicable) in accordance with its respective</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&#x2019; rights generally, by general principles of equity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.6	Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In connection with this Agreement, Borrower has delivered to the Collateral Agent a completed certificate signed by a Responsible Officer of Borrower (as may be updated from time to time in accordance with the terms herein, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Perfection Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Each Credit Party, jointly and severally, represents and warrants to the Collateral Agent and each Lender that:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) its exact legal name is that indicated on the Perfection Certificate and on the signature page thereof; (ii) it is an organization or company of the type and is organized or incorporated in the jurisdiction set forth in the Perfection Certificate; (iii) the Perfection Certificate accurately sets forth its organizational identification or registration number or accurately states that it has none; (iv) the Perfection Certificate accurately sets forth its place of business or registered office address, or, if more than one, its chief executive office or registered office address, as well as its mailing address (if different than its chief executive office or registered office address); (v) except as set forth in the Perfection Certificate, it (and each of its predecessors) has not, in the five (5) years prior to the applicable Closing Date, changed its jurisdiction of formation, organizational structure or type, or any organizational number assigned by its jurisdiction; and (vi) all other information set forth on the Perfection Certificate pertaining to it and each of its Subsidiaries is accurate and complete in all material respects.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) it has good and valid title to, has the rights it purports to have in, and subject to Permitted Subsidiary Distribution Restrictions, Permitted Negative Pledges and the occurrence of the applicable Closing Date, the power to transfer, each item of the Collateral (including each item of Current Company IP) upon which it purports to grant a Lien under any Collateral Document, free and clear of any and all Liens except Permitted Liens and except for such irregularities or defects in title as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, and (ii) it has no deposit accounts maintained at a bank or other depository or financial institution which are not Excluded Accounts other than the deposit accounts described in the Perfection Certificate delivered to the Collateral Agent in connection herewith.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a true, correct and complete list of each pending, registered, issued or exclusively in-licensed Patent (including any Patents that are or are intended to be listed in the FDA&#x2019;s so-called &#x201c;Orange Book&#x201d; as covering Product), Copyright and Trademark that relates to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, and regulatory exclusivities that are listed in the FDA&#x2019;s so called &#x201c;Orange Book&#x201d; as covering Product, and any other pending, registered, issued or in-licensed Patent (including any Patents that are or are intended to be listed in the FDA&#x2019;s so-called &#x201c;Orange Book&#x201d; as covering Product), Copyright and Trademark that, individually or taken together with any other such Patents, Copyrights or Trademarks or regulatory exclusivities, is material to the business of Borrower and its Subsidiaries, taken as a whole, and in each case, is owned or co-owned by or exclusively or non-exclusively licensed to any Credit Party or any of its Subsidiaries, (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Company IP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including its name/title, current owner or co-owners (including ownership interest), registration, patent or application number, and registration or application date, in each jurisdiction where issued or filed in the Territory, is set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) (x) to the Credit Party&#x2019;s Knowledge, each item of Current Company IP owned or co-owned by a Credit Party or any of its Subsidiaries is valid, subsisting and enforceable (or will be enforceable upon issuance), (y) no such item of Current Company IP has in any respect lapsed, expired, been cancelled, held unpatentable, held unenforceable or held or become abandoned or unenforceable except in the exercise of normal prosecution practices and reasonable business judgment, and (z) to the Credit Party&#x2019;s Knowledge, no circumstance or grounds exist that would invalidate or reduce, in whole or in part, the validity, enforceability, subsistence or scope of any such Current Company IP, or reduce the ownership or use of such Current Company IP, by any Credit Party or any of its Subsidiaries, and (B) no written notice has been received by the Credit Party or any of its Subsidiaries challenging the validity, patentability, enforceability, inventorship or ownership (other than from patent and trade-mark offices through the normal prosecution practices), or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability (other than from patent and trademark offices through the normal prosecution practices), of any such item of Current Company IP owned or co-owned by a Credit Party or any of its Subsidiaries;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Knowledge of any Credit Party, (A) each item of Current Company IP that is exclusively or nonexclusively in-licensed from another Person is valid, subsisting and enforceable and no item of Current Company IP that is exclusively or nonexclusively in-licensed by a Credit Party or any of its Subsidiaries has in any respect lapsed, expired, has been cancelled, held unpatentable, held unenforceable or held invalidated, or has become abandoned (other than through the lapse, expiration or abandonment of such Current Company IP in the exercise of normal prosecution practices and reasonable business judgment of licensor), and (B) no written notice has been received challenging the validity, patentability, enforceability, inventorship or ownership, or relating to any lapse, expiration, invalidation, cancellation, abandonment or unenforceability, of any item of Current Company IP that is exclusively or nonexclusively in-licensed by a Credit Party or any of its Subsidiaries (other than from patent and trademark offices through the licensor&#x2019;s normal prosecution practices);</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Knowledge of each Credit Party, all published patents, patent applications, articles and prior art references known to the Credit Party and reasonably believed to be material to patentability of one or more claims of Current Company IP owned or co-owned by a Credit Party were disclosed to the U.S. Patent and Trademark Office and, to the Knowledge of each Credit Party, the Product as currently approved by FDA</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">does not infringe the claims of an issued U.S. patent or the currently pending claims of a published U.S. patent application as of the applicable Closing Date if the currently pending claims were to issue and were valid, except as would not be reasonably expected to materially adversely affect the exploitation of any Product; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, (A) each Person who has or has had any rights in or to exclusively owned Current Company IP or any trade secrets owned by any Credit Party or any of its Subsidiaries, including each inventor named on the Patents within such owned Current Company IP, has executed an agreement assigning his, her or its entire right, title and interest in and to such owned Current Company IP and such trade secrets, and the inventions, ideas, discoveries, writings, works of authorship, information and other intellectual property embodied, described or claimed therein, to the stated owner thereof, and (B) to the Knowledge of each Credit Party, no such Person has any contractual or other obligation that would preclude or conflict with such assignment or the exploitation of any Product in the Territory or entitle such Person to ongoing payments.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Each Credit Party or any of its Subsidiaries possesses valid title to the Current Company IP for which it is listed as the owner or co-owner, as applicable, on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter; and (ii) there are no Liens on any Current Company IP, other than Permitted Liens.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no maintenance, annuity or renewal fees that are currently overdue beyond their allotted grace period for any of the Current Company IP which is owned by or, to Credit Party&#x2019;s Knowledge, exclusively licensed to any Credit Party or any of its Subsidiaries, nor have any applications or registrations therefor lapsed or become abandoned, been cancelled or expired (other than through the lapse, expiration or abandonment of such Current Company IP in the exercise of normal prosecution practices and reasonable business judgment of the Credit Parties, their respective Subsidiaries or the licensor).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no unpaid fees, royalties or indemnification payments under any Company IP Agreement that have become due or are reasonably expected to become due or overdue.  Each Company IP Agreement is in full force and effect and, to the Knowledge of each Credit Party, is legal, valid, binding, and enforceable in accordance with its respective terms, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors&#x2019; rights generally or by equitable principles relating to enforceability.  No Credit Party or any of its Subsidiaries, is in material breach of or default under any Company IP Agreement to which it is a party or may otherwise be bound, and to the Knowledge of each Credit Party, no circumstances or grounds exist that could give rise to a claim of material breach or right of rescission, termination, non-renewal, revision, or amendment of any of the Company IP Agreements, including the execution, delivery and performance of this Agreement and the other Loan Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No payments by any Credit Party or any of its Subsidiaries are due to any other Person in respect of the Current Company IP, other than pursuant to the Company IP Agreements, the Royalty Revenue</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract, and those fees payable to patent offices in connection with the prosecution and maintenance of the Current Company IP and associated attorney fees.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) (i) No Credit Party or any of its Subsidiaries has undertaken any acts, and, (ii) to the Knowledge of such Credit Party in the case of Current Company IP owned or co-owned by or exclusively or non-exclusively licensed to any Credit Party or any of its Subsidiaries, no circumstance or grounds exist, that would invalidate or reduce, in whole or in part, the enforceability or scope of any Credit Party&#x2019;s or any of its Subsidiary&#x2019;s  right or entitlement to the Current Company IP in any manner that could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(h)(A)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter; and (B) (i) no Credit Party or any of its Subsidiaries has omitted to undertake any acts necessary to maintain, or (ii) to the Knowledge of such Credit Party in the case of Current Company IP owned or co-owned by or exclusively or non-exclusively licensed to any Credit Party or any of its Subsidiaries, no circumstances or grounds exist that would impair, the validity or, in whole or in part, the enforceability or scope of any Credit Party&#x2019;s or any of its Subsidiary&#x2019;s right or entitlement to the Current Company IP in any manner that could reasonably be expected to materially adversely affect any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory, , except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(h)(B)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as noted on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the Knowledge of any Credit Party, there is no commercially available product or other technology of any third-party that infringes a Patent within the Current Company IP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of each applicable Closing Date, (i) except as noted on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(j)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, no Credit Party is a party to, nor is it bound by, any Restricted License, and (ii) except as noted on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(j)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, no Credit Party nor any of its Subsidiaries is a party to, nor is it bound by, any Excluded License.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In each case where an issued Patent within the Current Company IP where such Patent is owned or co-owned by any Credit Party or its Subsidiaries by assignment, the assignment has been duly recorded with the U.S. Patent and Trademark Office.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no pending or, to the Knowledge of each Credit Party, threatened (in writing) claims against Borrower or any of its Subsidiaries alleging (i) that any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory infringes or violates (or in the past infringed or violated), or form a reasonable basis for a claim of infringement or violation of, any of the rights of any third parties in or to any Intellectual Property (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-Party IP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or constitutes a misappropriation of (or in the past constituted a misappropriation of) any Third-Party IP, or (ii) that any Current Company IP is invalid, unpatentable or unenforceable (other than from patent and trademark offices through the normal prosecution practices).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Knowledge of each Credit Party, the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory does not (i) infringe or violate (or in the past infringed or violated) or form a reasonable basis for a claim of infringement or violation of any of the rights of third parties in or to any Third-Party IP (including any issued or registered Third-Party IP), or (ii) or constitute (or constituted) a misappropriation of any Third-Party IP.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(n)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, there are no settlements, covenants not to sue, consents, judgments, orders or similar obligations which:  (i) restrict the rights of any Credit Party or any of its Subsidiaries to use any Intellectual Property relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory (in order to accommodate any Third-Party IP or otherwise), or (ii) permit any third parties to use any Company IP.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(o)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of each Credit Party, (i) there is no, nor has there been any, infringement or violation by any Person of any of the Company IP or the rights therein and (ii) there is no, nor has there been any, misappropriation by any Person of any of the Company IP or the subject matter thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party and each of its Subsidiaries has taken commercially reasonable measures customary in the health and life sciences sector to protect the confidentiality and value of trade secrets owned or licensed by such Credit Party or any of its Subsidiaries in each case relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product in the Territory.  Any use or disclosure by a Credit Party or any of its Subsidiaries of any such trade secrets to any third-party has been pursuant to the terms of a written agreement including appropriate confidentiality, access, use and non-disclosure provisions with such third-party, and, to the Knowledge of the Credit Party, no Credit Party or any of its Subsidiaries has suffered any material data breach or other incident that has resulted in any loss, unauthorized access, use, disclosure or modification of any such trade secrets.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Product made, used or sold under the Patents within the Current Company IP has been marked with the proper patent notice.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Knowledge of each Credit Party, at the time of any shipment of any Product occurring prior to the applicable Closing Date, the units thereof so shipped complied with their relevant specifications and were developed and manufactured in accordance with then applicable FDA Good Manufacturing Practices, FDA Good Clinical Practices, FDA Good Laboratory Practices, and other Requirements of Law.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the Current Company IP consisting of Patents, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.6(s)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Knowledge of such Credit Party, all prior art material to such Patents was adequately disclosed, to the extent such disclosure is required, to the relevant patent office or considered by the respective patent offices during prosecution of such Patents;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsequent to the issuance of such Patents, no Credit Party nor any Subsidiary nor any of their respective predecessors-in-interest, has filed any disclaimer or made or permitted any other voluntary reduction in the scope of the inventions claimed in such Patents;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Knowledge of such Credit Party, no subject matter designated allowable or allowed by the U.S. Patent and Trademark Office of such Patents is subject to any competing conception claims of allowable or allowed subject matter of any patent applications or patents of any third-party and have not been the subject of any interference, and such Patents are not and have not been the subject of any re-examination, opposition or any other post-grant proceedings;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if any of such Patents is terminally disclaimed to another patent or patent application, all patents and patent applications subject to such terminal disclaimer are included in the Collateral; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neither any Credit Party nor any Subsidiaries has received advice from legal counsel expressing an opinion, including a preliminary or qualified opinion, which concludes that a challenge to the validity or enforceability, subsistence or scope of any such Patents is more likely than not to succeed.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) Neither any Credit Party nor any Subsidiary, nor, to the Knowledge of such Credit Party, any of their respective agents or representatives, have (i) engaged in any conduct, the result of which would invalidate or render unpatentable or unenforceable or materially reduce, in whole or in part, the validity, enforceability, subsistence or scope of any Patent included within Current Company IP, or (ii) omitted to perform any necessary act to maintain the validity, patentability, enforceability, subsistence or scope of any such Patent, and (B) to the Knowledge of such Credit Party, no prior owner of any such Patent of any Credit Party or any of its Subsidiaries, nor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of such prior owner&#x2019;s agents or representatives, have (i) engaged in any conduct, the result of which would invalidate or render unpatentable or unenforceable or materially reduce, in whole or in part, the validity, enforceability, subsistence or scope of any such Patent, or (ii) omitted to perform any necessary act to maintain the validity, patentability, enforceability, subsistence or scope of any such Patent.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Collateral Documents create in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a valid and continuing and, upon the making of the filings and the taking of the actions required under the terms of the Loan Documents, perfected Lien on and security interest in the Collateral (in each case, solely to the extent perfection is available under Requirements of Law through the making of such filings and taking of such actions and except to the extent expressly not required to be perfected pursuant to the terms of the Loan Documents), securing the payment of the Obligations, and having priority over all other Liens on and security interests in the Collateral (except Permitted Liens).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.7	Adverse Proceedings, Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective date and the Tranche A Closing Date, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, (i) there are no Adverse Proceedings pending or, to the Knowledge of such Credit Party, threatened in writing, at law, in equity, in arbitration or before any Governmental Authority, by or against Borrower or any of Borrower&#x2019;s Subsidiaries; and (ii) neither Borrower nor any of Borrower&#x2019;s Subsidiaries (A) is in material violation of any Requirements of Law, excluding any Requirement of Law which is being contested in good faith by appropriate proceedings, or (B) is subject to or in default with respect to any final judgments, orders, writs, injunctions, settlement agreements, decrees, rules or regulations of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency, instrumentality, or other Governmental Authority, domestic or foreign.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of each Closing Date other than the Tranche A Closing Date, (i) except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, there are no Adverse Proceedings pending or, to the Knowledge of any Credit Party, threatened in writing, at law, in equity, in arbitration or before any Governmental Authority, by or against Borrower or any of Borrower&#x2019;s Subsidiaries, which, if adversely determined, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change; and (ii) neither Borrower nor any of Borrower&#x2019;s Subsidiaries (A) is in violation of any Requirements of Law, excluding any Requirement of Law which is being contested in good faith by appropriate proceedings, where such violation could reasonably be expected to result in uninsured damages, penalties or costs to Borrower or any of Borrower&#x2019;s Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting or (B) is subject to or in default with respect to any final judgment, order, writ, injunction, settlement agreement, decree, rule or regulation of any court or any federal, state, municipal or other governmental department, commission, board, bureau, agency, instrumentality, or other Governmental Authority, domestic or foreign</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that could reasonably be expected to result in uninsured damages, penalties or costs to Borrower or any of its Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of Borrower and its Subsidiaries, to the Knowledge of each such Credit Party, is in compliance in all material respects with the terms of all settlement agreements relating to any Adverse Proceeding to which Borrower or any Subsidiary is a party.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.8	Exchange Act Documents; Financial Statements; Financial Condition; No Material Adverse Change; Books and Records</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Exchange Act Documents filed by Borrower with the SEC since December 31, 2023, when they were filed with the SEC, conformed in all material respects to the requirements of the Exchange Act, and as of the time they were filed with the SEC, none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein (excluding any projections and forward-looking statements, estimates, budgets and general economic or industry data of a general nature), in the light of the circumstances under which they were made, not misleading; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to projected financial information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being understood that such projections are not a guarantee of financial</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance and are subject to uncertainties and contingencies, many of which are beyond the control of Borrower or any Subsidiary, and neither Borrower nor any Subsidiary can give any assurance that such projections will be attained, that actual results may differ in a material manner from such projections and any failure to meet such projections shall not be deemed to be a breach of any representation or covenant herein).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower&#x2019;s audited annual financial statements as of December 31, 2023 and unaudited quarterly financial statements as of March 31, 2024 and June 30, 2024 (in each case, including the related notes thereto) of Borrower and its Subsidiaries included in the Exchange Act Documents present fairly in all material respects the consolidated financial condition of Borrower and such Subsidiaries and their consolidated results of operations as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified.  Such financial statements have been prepared in conformity with GAAP applied on a consistent basis throughout the periods covered thereby, except as otherwise disclosed therein and, in the case of unaudited, interim financial statements, subject to normal year-end audit adjustments and the exclusion of certain footnotes.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower acknowledges that its management is responsible for the preparation and fair presentation of the financial statements of Borrower and each of its Subsidiaries delivered to the Collateral Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case, in conformance, in all material respects, with GAAP.  Borrower has, suitable for a company of its size and stage of development, designed, implemented and maintained internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since December 31, 2023, there has not occurred any change or event that has had or could reasonably be expected to have, either alone or in conjunction with any other change(s), event(s) or failure(s), a Material Adverse Change.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since December 31, 2023, there has not occurred any Transfer by Borrower or any Subsidiary, voluntary or involuntary, of any material part of the business, assets or property of Borrower or any Subsidiary, and no purchase or other acquisition by any of them of any business, assets or property (including any Equity Interests of any other Person) material to Borrower or any Subsidiary, in each case, which is not reflected in the financial statements of Borrower and its Subsidiaries included in the Exchange Act Documents (or in the notes thereto) and has not otherwise been disclosed in writing to the Collateral Agent or Lenders on or prior to the applicable Closing Date.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Books of Borrower and each of its Subsidiaries in existence immediately prior to the Effective Date and each applicable Closing Date contain full, true and correct entries of all dealings and transactions in relation to its business and activities in conformity with GAAP and Requirements of Law in all material respects.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.9	Solvency</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Credit Parties and their Subsidiaries, on a consolidated basis, are Solvent.  Without limiting the generality of the foregoing, there has been no proposal made or resolution adopted by any competent corporate body for the dissolution or liquidation of any Credit Party, nor do any circumstances exist which may result in the dissolution or liquidation of any Credit Party (other than in respect of a dissolution or liquidation expressly permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3(a)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.10	Payment of Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All U.S. federal, state, local and non-U.S. income and other material Tax returns and reports (or extensions thereof) of each Credit Party and each of its Subsidiaries required to be filed by any of them have been timely filed and are correct in all material respects, and all other Taxes which are due and payable by any Credit Party or any of its Subsidiaries and all assessments, fees and other governmental charges upon any Credit Party or any of its Subsidiaries and upon their respective properties, assets, income, businesses and franchises which are due and payable in each case have been paid when due and payable, unless and only to the extent that the validity or amount thereof is being contested in good faith by appropriate proceedings; provided that no such Tax or any claim for Taxes that have become due and payable shall be required to be paid if, (i) the applicable Credit Party has set aside on its books adequate reserves therefor in conformity with GAAP or (ii) the failure to pay such Taxes, individually or in the aggregate, does not result or could not reasonably be expected to result in a Material Adverse Change.  There</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is no proposed Tax assessment against any Credit Party or any of its Subsidiaries that, if made, results or could reasonably be likely to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link2"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.11	Environmental Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither Borrower nor any of its Subsidiaries nor any of their respective Facilities or operations is subject to any outstanding written order, consent decree or settlement agreement with any Person relating to any Environmental Law, any Environmental Claim, or any Hazardous Materials Activity that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change.  There are and, to the Knowledge of such Credit Party, have been, no conditions, occurrences, or Hazardous Materials Activities that could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change.  To the Knowledge of such Credit Party, no predecessor of Borrower or any of its Subsidiaries has filed any notice under any Environmental Law indicating past or present treatment of Hazardous Materials at any Facility, which could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change (but, for the avoidance of doubt, neither Borrower nor any of its Subsidiaries has, directly or indirectly, undertaken any investigation of or made any inquiries to, or relating to, any of its or its Subsidiaries&#x2019; predecessors), and neither Borrower&#x2019;s nor any of its Subsidiaries&#x2019; operations involves the generation, transportation, treatment, storage or disposal of hazardous waste, as defined under </font><font id="ole_link1"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40 C.F.R. Parts 260&#x2013;270</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any foreign or United States state equivalents, which could reasonably be expected to form the basis of an Environmental Claim against Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change.  No event or condition has occurred or is occurring with respect to any Credit Party relating to any Environmental Law, any Release of Hazardous Materials, or any Hazardous Materials Activity that, individually or in the aggregate, has resulted in, or could reasonably be expected to result in, a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.12	Material Contracts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As of each applicable Closing Date after giving effect to the consummation of the transactions contemplated by this Agreement, except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, each Material Contract is a valid and binding obligation of the applicable Credit Party and, to the Knowledge of such Credit Party, each other party thereto, and is in full force and effect, and neither the applicable Credit Party nor, to the Knowledge of such Credit Party, any other party thereto is in material breach thereof or default thereunder, except where such breach or default (which default has not been cured or waived) could not reasonably be expected to give rise to any cancellation, termination or acceleration right of the applicable counterparty thereto.  As of each applicable Closing Date, except as described on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, no Credit Party or any of its Subsidiaries has received any written notice from any party to any Material Contract asserting or to the Knowledge of such Credit Party, threatening in writing to assert, circumstances that could reasonably be expected to result in the cancellation, termination or invalidation of any Material Contract (or any provision thereof) or the acceleration of such Credit Party&#x2019;s or Subsidiary&#x2019;s obligations thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.13	Regulatory Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No Credit Party is or is required to be registered as, or is a company &#x201c;controlled&#x201d; by, an &#x201c;investment company&#x201d; as defined in, or is subject to regulation under, the Investment Company Act of 1940, as amended.  Except as could not reasonably be expected to result in a Material Adverse Change, each Credit Party has complied with the Federal Fair Labor Standards Act (and any foreign or United States state equivalent, as applicable).  Except as could not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, each Plan is in compliance with the applicable provisions of ERISA, the IRC and other U.S. federal or state or foreign Requirements of Law, respectively.  (i) No ERISA Event has occurred or is reasonably expected to occur; (ii) neither any Credit Party nor any ERISA Affiliate has incurred, or reasonably expects to incur, any liability (and no event has occurred which, with the giving of notice under Section 4219 of ERISA, would result in such liability) under Section 4201 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">et seq</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. of ERISA with respect to a Multiemployer Plan; and (iii) neither any Credit Party (to the extent applicable) nor any ERISA Affiliate has engaged in a transaction that would be subject to Section 4069 or 4212(c) of ERISA, except, with respect to each of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, as could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.14	Margin Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No Credit Party is engaged principally, or as one of its important activities, in extending credit for the purpose of, whether immediate or ultimate, purchasing or carrying Margin Stock.  No Credit</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Party owns any Margin Stock.  No Credit Party or any of its Subsidiaries has taken or permitted to be taken any action that might cause any Loan Document to violate Regulation T, U or X of the Federal Reserve Board.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.15	Subsidiaries; Capitalization</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Schedule 4.15 of the Disclosure Letter includes a complete and accurate list, as of each applicable Closing Date, of Borrower and each of its Subsidiaries, setting forth (a) its name and jurisdiction of incorporation, organization or formation, (b) in the case of each Credit Party (other than Borrower), the number of authorized and issued shares (or equivalent) of each class (where applicable) of its Equity Interests outstanding, and (c) the percentage of its outstanding shares of each class owned (directly or indirectly) by Borrower or any of its Subsidiaries and the certificate numbers(s) for the same (if any), and (d) the number and effect, if exercised, of all of its outstanding options, warrants, rights of conversion or purchase and all other similar rights with respect thereto.  Except as set forth on Schedule 4.15 of the Disclosure Letter, each Credit Party is a Registered Organization.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.16	Employee Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither Borrower nor any of its Subsidiaries is engaged in any unfair labor practice that could reasonably be expected to result in a Material Adverse Change.  There is (a) no unfair labor practice complaint pending against Borrower or any of its Subsidiaries or, to the Knowledge of such Credit Party, threatened in writing against any of them in each case before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement that is pending against Borrower or any of its Subsidiaries or, to the Knowledge of such Credit Party, threatened in writing against any of them, (b) no strike or work stoppage in existence or, to the Knowledge of such Credit Party, threatened in writing involving Borrower or any of its Subsidiaries, and (c) to the Knowledge of such Credit Party, no union representation question existing with respect to the employees of Borrower or any of its Subsidiaries and, to the Knowledge of such Credit Party, no union organization activity that is taking place that in each case specified in any of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, individually or taken together with any other matter specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, could reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.17	Full Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  None of the documents, certificates or written statements (excluding any projections and forward-looking statements, estimates, budgets and general economic or industry data of a general nature) furnished or otherwise made available to the Collateral Agent or any Lender by or on behalf of any Credit Party for use in connection with the transactions contemplated hereby (in each case, taken as a whole and as modified or supplemented by other information so furnished promptly after the same becomes available) contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein, as of the time when made or delivered, not misleading in light of the circumstances in which the same were made; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to projected financial information, Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being understood that such projections are not a guarantee of financial performance and are subject to uncertainties and contingencies, many of which are beyond the control of Borrower or any Subsidiary, and neither Borrower nor any Subsidiary can give any assurance that such projections will be attained, that actual results may differ in a material manner from such projections and any failure to meet such projections shall not be deemed to be a breach of any representation or covenant herein).  To the Knowledge of such Credit Party, there are no facts (other than matters of a general economic or industry nature) that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change and that have not been disclosed herein or in such other documents, certificates and written statements furnished or made available to the Collateral Agent or any Lender for use in connection with the transactions contemplated hereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.18	Anti-Corruption Laws; Anti-Money Laundering Laws; Sanctions; Export and Import Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Borrower or any of its Subsidiaries, or any of their respective directors, officers, or, to the Knowledge of such Credit Party, any employee or any agent of Borrower or any of its Subsidiaries, has (i) used any corporate funds of Borrower or any of its Subsidiaries for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity, (ii) made any direct or, to the Knowledge of such Credit Party, indirect unlawful payment to any foreign or domestic government official or employee or any Person from corporate funds of Borrower or any of its Subsidiaries, (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the U.K. Bribery Act of 2010, or any other applicable anti-corruption laws (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or (iv) made any bribe, improper rebate, payoff, influence payment, kickback or other unlawful payment, and no part of the proceeds of any Credit Extension will be used, directly or, to</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Knowledge of such Credit Party, indirectly, for any payments to any governmental official or employee, political party, official of a political party, candidate for political office or anyone else acting in an official capacity, in order to obtain, retain or direct business, or to obtain any improper advantage, in violation of Anti-Corruption Laws.  No action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or any of its Subsidiaries, with respect to Anti-Corruption Laws is pending or to the Knowledge of such Credit Party, threatened in writing nor is there a basis for such action, suit, or proceeding.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) The operations of Borrower and each of its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Bank Secrecy Act of 1970 (as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT) Act of 2001) and the anti-money laundering laws and counterterrorist financing, rules and regulations of each jurisdiction (foreign or domestic) in which Borrower and its Subsidiaries, is subject to such jurisdiction&#x2019;s Requirements of Law (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (ii) no action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or its Subsidiaries, with respect to the Anti-Money Laundering Laws is pending or to the Knowledge of such Credit Party, threatened in writing.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of Borrower or any of its Subsidiaries, or any of their respective directors, officers, or, to the Knowledge of such Credit Party, any employee or agent of Borrower or any of its Subsidiaries, is, or is 50% or more owned or otherwise controlled by individuals or entities that are, the target or subject of any economic, trade or financial sanctions or restrictive measures administered and enforced by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the U.S. Department of State, the United Nations Security Council, the European Union and each member state thereof or His Majesty&#x2019;s Treasury of the United Kingdom (collectively &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Neither Borrower nor its Subsidiaries: (i) has assets located in, or otherwise directly or indirectly derives revenues from or engages in, investments, dealings, activities, or transactions in or with, any Sanctioned Country; or (ii) directly or indirectly derives revenues from, conducts any business or engages in investments, dealings, activities, or transactions with, any Blocked Person, including the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person.  Borrower will not, directly or indirectly (including through an agent or any other Person), use the proceeds of any Term Loans, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other Person, for (x) the purpose of financing the activities of any Person that is the target or subject of Sanctions or in any Sanctioned Country, (y) use in any Sanctioned Country, or (z) any purpose that could cause any Person to be in violation of Sanctions.  No action, suit or proceeding by or before any Governmental Authority or any arbitrator involving Borrower or any of its Subsidiaries, with respect to Sanctions is pending or to the Knowledge of such Credit Party, threatened in writing, nor is there a basis for such action, suit or proceeding.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower will not, directly or, to the Knowledge of such Credit Party, indirectly (including through an agent or any other Person), use the proceeds of any Credit Extension, or lend, contribute or otherwise make available the proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person, for (i) any payments to any government official or employee, political party, official of a political party, candidate for political office or anyone else, in order to obtain, retain or direct business, or to obtain any improper advantage in violation of Anti-Corruption Laws, (ii) in violation of any Anti-Money Laundering Laws, or (iii) in violation of Sanctions.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower and each of its Subsidiaries, and their respective officers, directors, employees and, to the Knowledge of such Credit Party, any agent or Borrower or any of its Subsidiaries, are in compliance in all respects with Sanctions.  Borrower and each of its Subsidiaries have instituted and maintain policies and procedures reasonably designed to ensure compliance with Sanctions, Anti-Money Laundering Laws, and all applicable Export and Import Laws and Anti-Corruption Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower and each of its Subsidiaries are in compliance in all material respects with applicable Export and Import Laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.19	Health Care Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries and each</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">officer, Affiliate, and employee acting on behalf of such Credit Party or any of its Subsidiaries, is in compliance in all material respects with all applicable Health Care Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compliance with Regulatory Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries that are subject thereto, is in compliance in all material respects with applicable FDA Laws; and any and all laws relating to designations (including any Orphan Drug, Fast Track, Breakthrough Therapy, Priority Review and Rare Pediatric Disease designations), research, development, testing, approval, licensure, clearance, authorization, exclusivity, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and requirements, reporting, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of any Product in the Territory.  Any Product distributed, including for investigational use, or sold in the Territory at all times during the past six (6) years has been (i) manufactured and developed in all material respects in accordance with current FDA Good Manufacturing Practices, FDA Good Clinical Practices and FDA Good Laboratory Practices (as applicable), and (ii) if and to the extent such Product is required to be approved or cleared by the relevant Governmental Authority pursuant to FDA Laws in order to be legally marketed in the Territory for such Product&#x2019;s intended uses, such Product has been approved or cleared for such intended uses, meets in all material respects any additional conditions of approval, clearance, authorization, or licensure by the competent Governmental Authority, and except as has been set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no inquiries regarding material issues have been initiated by any competent Governmental Authority.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Applicability of Controlled Substances Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Product does not contain a controlled substance (as that term is defined under the Controlled Substances Act (21 U.S.C. &#167; 801 et seq.)).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Within the past six (6) years, neither any Credit Party, nor, to the Knowledge of such Credit Party, any Subsidiary or any officer or employee or Affiliate of any Credit Party or Subsidiary in its capacity as a Subsidiary or as an officer, employee or Affiliate of a Credit Party or Subsidiary (as applicable), nor, to the Knowledge of such Credit Party, any agent of any Credit Party or Subsidiary, (i) has made an untrue statement of a material fact or a fraudulent statement to any Governmental Authority under any Health Care Law, (ii) has failed to disclose a material fact to any Governmental Authority under any Health Care Law, or (iii) has otherwise committed an act, made a statement or failed to make a statement that, at the time such statement or disclosure was made (or, in the case of such failure, should have been made) or such act was committed, could reasonably be expected to constitute a material violation of any Health Care Law. Each Credit Party has implemented reasonable and appropriate policies and procedures designed to ensure compliance with all Health Care Laws concerning the types of statements, disclosures, acts, and omissions described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proceedings; Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as has been set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter:  (i) there is no Adverse Proceeding pending or, to the Knowledge of such Credit Party, threatened in writing, against any Credit Party or any of its Subsidiaries relating to any allegations of non-compliance with any Health Care Laws, Data Protection Laws or FDA Laws; and (ii) to the Knowledge of such Credit Party, there are no facts, circumstances or conditions that, individually or in the aggregate, could reasonably be expected to form the basis for any such Adverse Proceeding.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recalls, Safety Notices, Etc</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as has been set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, neither any Credit Party nor any of its Subsidiaries has initiated or otherwise engaged in any recalls, field notifications, safety warnings, &#x201c;dear doctor&#x201d; letters, investigator notices, safety alerts or other notices of action, including as a result of any Risk Evaluation and Mitigation Strategy (or foreign equivalent) proposed or enforced by the FDA, or any other equivalent foreign Governmental Authority relating to an alleged lack of safety or regulatory compliance of any Product.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, neither any Credit Party nor any of its Subsidiaries has a reasonable expectation that there are grounds for imposition of a clinical hold or a withdrawal of applicable designations of Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies / Clinical Trials</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All pre-clinical and clinical studies (including trials) relating to Product conducted by or on behalf of any Credit Party or any of its Subsidiaries have been, or are being, conducted in compliance with all applicable Requirements of Law, including the applicable requirements of FDA Laws, FDA Good Laboratory Practices, FDA Good Clinical Practices, applicable human subject protections (including 21 C.F.R. parts 50 and 56), and the Animal Welfare Act and applicable experimental protocols, procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and controls, United States state equivalents and equivalent foreign laws and applicable regulations.  No research involving human subjects (including clinical trials) relating to Product conducted by or sponsored by any Credit Party or any of its Subsidiaries has been conducted by or supported by any U.S. federal department or agency, and none are subject to regulation under 45 C.F.R. Part 46.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, during the past six (6) years, no clinical study involving Product conducted by or on behalf of any Credit Party or any of its Subsidiaries has been terminated or suspended by any Regulatory Agency and neither any Credit Party nor any of its Subsidiaries has received any notice that the FDA (or foreign equivalent), any other Governmental Authority or any institutional review board, ethics committee or safety monitoring committee (or foreign equivalent) has recommended, initiated or, to the Knowledge of such Credit Party threatened to initiate any action to suspend or terminate any clinical trial conducted by or on behalf of any Credit Party or any of its Subsidiaries or to otherwise restrict the preclinical research on or clinical study of Product.  None of the safety or efficacy issues raised by a Governmental Authority in the context of a clinical hold (or foreign equivalent) placed on products under development by any Credit Party or any of its Subsidiaries could reasonably be expected to adversely impact the research, development, testing, manufacture, approval, clearance, authorization, exclusivity, licensure, designation, post-approval (or post-licensure, post-authorization or post-clearance, as applicable) monitoring and commitments, reporting, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of Product in the Territory.  Any clinical hold (or foreign equivalent) placed on products under development by any Credit Party or any of its Subsidiaries, or terminations of clinical trials by any Credit Party or any of its Subsidiaries, could not reasonably be expected to adversely impact the financial condition of any Credit Party and its Subsidiaries (taken as a whole), or the ability of any Credit Party and its Subsidiaries (taken as a whole) to fulfill the payment obligations under the Loan Agreement or the Royalty Revenue Contract.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advertising / Promotion</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For the past six (6) years, each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, officers, employees and agents has advertised, promoted, marketed and distributed (including for investigational use) Product in the Territory in compliance in all material respects with the applicable requirements of FDA Laws, and other Requirements of Law.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, for the past six (6) years, neither any Credit Party nor, to the Knowledge of such Credit Party, any of its Subsidiaries, officers, employees or agents has received any written notice of or is subject to any civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, untitled letter, proceeding or request for information from the FDA (or foreign equivalents) or any other Governmental Authority concerning noncompliance with any applicable FDA Laws, or other Requirements of Law with regard to advertising, promoting, marketing or distributing Product in the Territory.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recordkeeping / Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, has maintained records relating to the research, development, testing, manufacture, recall, production, handling, labeling, packaging, storage, supply, promotion, distribution, marketing, commercialization, import, export and sale of Product in the Territory in compliance in all material respects with FDA Laws, Health Care Laws, and other applicable Requirements of Law, and each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, has submitted to the FDA (or foreign equivalents) and other Governmental Authorities (including Regulatory Agencies) in a timely manner all material notices and annual or other reports required to be made, including adverse experience reports, annual reports specific to holders of Orphan Drug designations and safety reports for Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Prohibited Transactions; No Whistleblowers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, within the past six (6) years, to the Knowledge of such Credit Party, neither any Credit Party, any Subsidiary, any officer, Affiliate or employee of a Credit Party or Subsidiary, nor any other Person acting on behalf of any Credit Party or any Subsidiary, directly or indirectly:  (i) has offered or paid any remuneration, in cash or in kind, to, or made any financial arrangements with, any past, present or potential patient, supplier, physician or contractor, in order to illegally obtain business or payments from such Person in material violation of any Health Care Law; (ii) has given or made, or is party to any illegal agreement to give or make, any illegal gift or gratuitous payment of any kind, nature or description (whether in money, property or services) to any past, present or potential patient, supplier, physician or contractor, or any other Person in material violation of any Health Care Law; (iii) has presented, or caused to be presented, a claim for any designated health service pursuant to a referral to an entity from a physician who has (or whose immediate family member has) a financial relationship with that entity, in material violation of any Health Care Law; (iv) has given or made, or is party to any agreement to give or make on behalf of any Credit Party or any of its Subsidiaries, any contribution, payment or gift of funds or property to, or for the private use of, any</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">governmental official, employee or agent where either the contribution, payment or gift or the purpose of such contribution, payment or gift is or was a material violation of the laws of any Governmental Authority having jurisdiction over such payment, contribution or gift; (v) has established or maintained any unrecorded fund or asset for any purpose or made any materially misleading, false or artificial entries on any of its books or records for any reason; or (vi) has made, or is party to any agreement to make, any payment to any Person with the intention or understanding that any part of such payment would be in material violation of any Health Care Law.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(j)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of such Credit Party, there are no actions pending or threatened (in writing) against any Credit Party or any of its Subsidiaries or any of their respective Affiliates under any foreign, federal or United States state healthcare whistleblower statute, including under the False Claims Act of 1863 (31 U.S.C. &#167; 3729 et seq.).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusion</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.19(k)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, neither any Credit Party nor, to the Knowledge of such Credit Party, any Subsidiary or any officer, employee or Affiliate of a Credit Party or Subsidiary having authority to act on behalf of any Credit Party or any Subsidiary, is or, to the Knowledge of such Credit Party, has been threatened in writing to be:  (i) excluded from any Governmental Payor Program pursuant to 42 U.S.C. &#167; 1320a-7b and related regulations; (ii) &#x201c;suspended&#x201d; or &#x201c;debarred&#x201d; from selling any products to the U.S. government or its agencies pursuant to the Federal Acquisition Regulation relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), or other U.S. Requirements of Law; (iii) debarred, disqualified, suspended or excluded from participation in Medicare, Medicaid or any other Governmental Payor Program or is listed on the General Services Administration list of excluded parties; (iv) debarred by FDA (or foreign equivalent) or (v) a party to any other action or proceeding by any Governmental Authority that would prohibit the applicable Credit Party or Subsidiary from distributing or selling any Product in the Territory or providing any services to any governmental or other purchaser pursuant to any Health Care Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party and, to the Knowledge of such Credit Party, each of its Subsidiaries, to the extent applicable, is in material compliance with all applicable foreign, federal, state, and local laws and regulations regarding the privacy, data protection, access, exchange, use, security, and notification of breaches of health information and regarding standards, implementation specifications, and requirements for electronic transactions.  Each Credit Party and each of its Subsidiaries, to the extent applicable, has implemented written policies and procedures as well as training as are reasonable and customary in the pharmaceutical industry, that are designed to satisfy the requirements of all applicable Requirements of Law, and that are otherwise designed to assure continued compliance and to detect non-compliance.  Neither any Credit Party, nor, to the Knowledge of such Credit Party, any Subsidiary that is not a Credit Party, is a &#x201c;covered entity&#x201d; or &#x201c;business associate&#x201d; as defined in HIPAA (45 C.F.R. &#167; 160.103).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Corporate Integrity Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither any Credit Party or Subsidiary, nor any of their respective Affiliates, nor, to the Knowledge of such Credit Party, any of their respective officers, directors, managing employees or agents, is, or in the reasonable business judgment of Borrower probably (as defined in ASC 450-20-20) will become within ninety (90) days of the applicable Closing Date, a party to, or has any ongoing reporting or disclosure obligations under, or is otherwise subject to, any order, individual integrity agreement, corporate integrity agreement, monitoring agreement, deferred prosecution agreement, consent decree, corrective action plan, settlement agreement or order or other similar agreements, or any order, in each case imposed by any Governmental Authority concerning compliance with any laws, rules or regulations, issued under or in connection with a Governmental Payor Program.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.20	Regulatory Approvals or Licensures</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.20(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, each Credit Party, Subsidiary involved in research, development, testing, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and requirements, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of Product in the Territory has all Regulatory Approvals or Licensures material to the conduct of its business and operations.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.20(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of any Credit Party, no event or circumstance (or series of related events or circumstances) has occurred or, in the reasonable business judgment of such Credit Party, is reasonably likely to occur, that would cause or could reasonably be expected to cause Product to no longer meet requirements or criteria of any applicable Regulatory Approvals or Licensures or designations.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party, each Subsidiary and, to the Knowledge of such Credit Party, each licensee of a Credit Party or a Subsidiary of any Intellectual Property relating to Product, is in compliance with, and at all times during the past six (6) years, has complied with, all applicable foreign, federal, state and local laws, rules and regulations governing any aspect of the research, development, testing, approval, licensure, clearance, authorization, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and requirements, reporting, manufacture, production, packaging, labeling, use, commercialization, designation, exclusivity, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of Product in the Territory, including all such regulations promulgated by each applicable Regulatory Agency (including the FDA, the European Commission, the EMA, the competent authorities of the EU Member States or any other applicable foreign equivalents), except where any instance of failure to comply with any such laws, rules or regulations could not, whether individually or taken together with any other such failures, reasonably be expected to result in a Material Adverse Change.  No Credit Party or its Subsidiaries has received any written notice from any Regulatory Agency citing action or inaction by any Credit Party or any of its Subsidiaries that would constitute a violation of any applicable foreign, federal, state or local laws, rules, or regulations, including a Warning Letter or Untitled Letter from FDA (or equivalent communication from any other Regulatory Agency).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.21	Supply and Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of any Credit Party, Product at all times has been manufactured in sufficient quantities and of a sufficient quality to satisfy demand of Product in the Territory, without the occurrence of any event or series of related events causing inventory of Product to have become exhausted prior to satisfying such demand.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of such Credit Party, no event or circumstances (or series of related events or circumstances) has occurred that has caused or could reasonably be expected to cause (i) Product to be manufactured in a quantity or of a quality insufficient to satisfy current or future demand of such Product in the Territory or (ii) inventory of Product in the Territory to have become exhausted prior to satisfying such demand of such Product in the Territory.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of such Credit Party, no event or circumstance (or series of related events or circumstances) has occurred or, in the reasonable business judgment of Borrower, is reasonably likely to occur, that would cause or could reasonably be expected to cause Product for the Territory not to be manufactured in any calendar year in sufficient quantities to satisfy the expected needs of patients with the disease or condition for which RYTELO&#153;, or any other Product, was designated as an Orphan Drug for such calendar year, as reasonably determined by Responsible Officers of the Borrowers in good faith (provided such calendar year occurs during the full 7-year term of orphan drug exclusive approval granted for RYTELO&#153; under 21 C.F.R. &#167; 316.34, ending June 6, 2031, or such other relevant period).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of any Credit Party, (i) no manufacturer (including a contract manufacturer), licensing partner, or producer of Product has been during the last five (5) years or is currently subject to a material Regulatory Agency shutdown or voluntary shutdown, restriction or import or export prohibition, (ii) no manufacturer (including a contract manufacturer), licensing partner, or producer of Product has received in the last five (5) years a Form 483 or is currently subject to (1) a Form 483 or (2) other written Regulatory Agency notice of inspectional observations, Warning Letter, Untitled Letter or request to make changes to Product that could impact any Product, in either case of sub-clause (1) or (2) above with respect to any facility manufacturing or producing Product for import, export, distribution or sale in the Territory, and (iii) with respect to each such Form 483 received (if any) or other written Regulatory Agency notice (if any), all scientific and technical violations or other issues relating to FDA Good Manufacturing Practice requirements, or foreign equivalents, documented therein, and any disputes regarding any such violations or issues, have been corrected or otherwise resolved.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as disclosed in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.21(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, no Credit Party or any of its Subsidiaries has received any written notice or, to the Knowledge of such Credit party, other notice, from any party to any Manufacturing Agreement containing any indication by or intent or threat of, such party to reduce or cease, in any material respect, the supply of Product in the Territory or the materials (including raw materials), components (including component raw materials and other component materials), equipment, technology (including software, systems, and solutions), or any other element needed to fulfill its contractual obligations related to Product for the Territory in any Manufacturing Agreement through calendar year 2029 (or such earlier date in accordance with the terms and conditions of such Manufacturing Agreement, as applicable).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.22	Cybersecurity and Data Protection</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of any Credit Party, the information technology systems (including software and hardware) used in the business of each of Borrower and its Subsidiaries, including any technology systems made available by Borrower or any of its Subsidiaries to any medical partners, physicians, patients, payors, patient assistance programs, or other third parties in connection with Product, (altogether, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) operate and perform in all material respects as required to permit each of Borrower and its Subsidiaries to conduct their respective businesses as presently conducted in the Territory.  Borrower and each of its Subsidiaries has implemented and shall maintain reasonable security controls and safeguards designed to protect the confidentiality, integrity, and availability of Sensitive Information and designed to protect the Systems.  To the Knowledge of such Credit Party, no System contains any material ransomware, disabling codes or instructions, spyware, Trojan horses, worms, viruses or other software routines that are designed or intended to delete, destroy, disable, disrupt, impair, interfere with, perform unauthorized modifications to, or provide unauthorized access to any Sensitive Information or Systems.  Borrower and its Subsidiaries have and maintain back-up systems, consistent with the industry in which Borrower and each of its Subsidiaries operate and the size and condition of Borrower and each of its Subsidiaries, designed to provide continuing availability of the material functionality provided by the Systems in the event of any malfunction of, or other event interrupting access to or the functionality of, such Systems.  Borrower and each of its Subsidiaries use commercially reasonable efforts to promptly identify and implement material security patches that are generally available for the Systems.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, Borrower and each of its Subsidiaries has implemented and maintains a commercially reasonable, enterprise-wide privacy and information security program (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Program</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), with plans, policies and procedures for privacy and physical and cyber security, (including for disaster recovery, business continuity, encryption, data back-up, Systems access controls, workstation use and security, incident detection, and incident response), that includes commercially reasonable and appropriate administrative, technical and physical safeguards designed to protect the integrity and availability of the Systems, consistent with the industry in which Borrower and each of its Subsidiaries operate and the size and condition of Borrower and its Subsidiaries, and designed to protect against (i) any unauthorized, accidental, or unlawful access to or acquisition, use, disclosure, transmission, retention, processing, loss, destruction, corruption, or modification of Personal Data that would require notification to any affected individuals or any Governmental Authority under any applicable Data Protection Laws (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Data Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) any unauthorized, accidental, or unlawful access to or acquisition, use, disclosure, transmission, loss, destruction, corruption, or modification of Sensitive Information that is not Personal Data, and (iii) any security incidents that would result in unauthorized, accidental, or unlawful access to or acquisition, use, control, disruption, destruction, or modification of any of the Systems (including cyber-attacks) that could reasonably be expected to result in a material and adverse effect on the operation of Borrower&#x2019;s or any of its Subsidiaries&#x2019; business operations as currently conducted (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Incidents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower and each of its Subsidiaries has conducted commercially reasonable privacy and security audits and penetration tests at reasonable intervals on all Systems that maintain, store, access, or process Sensitive Information, in each case consistent with the industry in which Borrower and each of its Subsidiaries operate and the size and condition of Borrower and its Subsidiaries.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, Borrower and each of its Subsidiaries has addressed and remediated all material privacy or data security issues identified as &#x201c;critical,&#x201d; &#x201c;high risk,&#x201d; or similar level of risk rating raised in any such audits or penetration tests (including any third-party audits of the Systems).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower and each of its Subsidiaries have conducted commercially reasonable privacy and data security diligence, consistent with generally accepted practices within the industry in which Borrower and each of its Subsidiaries operate and in material compliance with any applicable Data Protection Laws, on applicable service providers (including clinical trial investigators, contract research organizations, contract laboratories, contract manufacturers, suppliers, clinical data management organizations, back-office service providers, vendors, and contractors) that (i) collect, create, receive, access, maintain, store, or otherwise process Sensitive Information for or on behalf of Borrower or any of its Subsidiaries, or (ii) access or maintain the Systems.  Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, neither Borrower nor any of its Subsidiaries have, in the past five (5) years, received written notice from any such service provider that the service provider experienced a Security Incident materially impacting Borrower&#x2019;s or any of its Subsidiaries&#x2019; Sensitive Information.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, to the Knowledge of Borrower, neither Borrower nor any of its Subsidiaries, have in the past five (5) years suffered any (i) Personal Data Breaches, or (ii) any other Security Incidents which, individually or together with any other such breaches or incidents, could reasonably be expected to have a material and adverse effect on Borrower&#x2019;s or any of its Subsidiaries&#x2019; business operations, such as a material disruption of development, manufacturing, or commercialization programs relating to Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, Borrower and each of its Subsidiaries is in material compliance with the requirements of (i) their respective Security Programs, (ii) their respective contractual obligations regarding privacy, security, or notification of breaches of Personal Data, (iii) their respective contractual non-disclosure obligations, (iv) their respective publicly available privacy notices and policies, and (v)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all applicable Data Protection Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.22(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, in the past five (5) years: (i) neither Borrower nor any of its Subsidiaries has received any written third-party claims or,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the Knowledge of such Credit Party, any threat (in writing) of a third-party claim, related to any Personal Data Breaches or other Security Incidents; and (ii) neither Borrower nor any of its Subsidiaries has received any written notice of any claims or investigations (including investigations by any Governmental Authority) relating to any Personal Data Breaches or other Security Incidents, except, in each case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above as could not reasonably be expected to be material to Borrower and its Subsidiaries, taken as a whole.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.23	Additional Representations and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date and the Tranche A Closing Date, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.24(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, after giving effect to consummation of the transactions contemplated by this Agreement, (i) there is no Indebtedness for borrowed money owed to Borrower or any of its Subsidiaries other than Permitted Indebtedness or Permitted Investments, or owed by Borrower or any of its Subsidiaries, other than Permitted Indebtedness, and (ii) all Indebtedness and any and all other amounts outstanding under the Existing Credit Agreement are paid or repaid in full, no further extension of credit is available thereunder and all Liens on or security interests in any and all collateral securing the payment of any such Indebtedness and any guaranty and other obligation of Borrower or any of its Subsidiaries thereunder in favor of any Person have been terminated.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of each Closing Date other than the Tranche A Closing Date, there is no Indebtedness for borrowed money (x) owed to Borrower or any of its Subsidiaries other than Permitted Indebtedness or Permitted Investments, or (y) owed by Borrower or any of its Subsidiaries other than Permitted Indebtedness.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date and Tranche A Closing Date, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.23(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, neither Borrower nor any of its Subsidiaries are party to, or otherwise bound by, any Hedging Agreements.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of any Closing Date other than the Tranche A Closing Date, neither Borrower nor any of its Subsidiaries are party to, or otherwise bound by, any Hedging Agreements, except for Hedging Agreements expressly permitted by this Agreement.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as has been disclosed in the Exchange Act Documents, as of each Closing Date, there is no registration rights agreement, investors&#x2019; rights agreement or other similar agreement relating to, governing or otherwise affecting the ownership of any Equity Interest that is required to be pledged pursuant to the Collateral Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.24	Royalty Revenue Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date and the applicable Closing Date, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.24(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, neither Borrower nor any of its Subsidiaries is obligated to pay any royalty, revenue participation, milestone payment, deferred payment or any other contingent payment in respect of Product except pursuant to the Royalty Revenue Contract.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the Effective Date and the applicable Closing Date, except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.24(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, there are no disputes between Borrower or any of its Subsidiaries, on the one hand, and Royalty Pharma, on the other hand, under any Royalty Revenue Document that has not been completely resolved.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AFFIRMATIVE COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party covenants and agrees that, until payment in full of all Obligations (other than inchoate indemnity obligations), each Credit Party shall, and shall cause each of its Subsidiaries:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.1	Maintenance of Existence</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  (a) Preserve, renew and maintain in full force and effect its and all its Subsidiaries&#x2019; legal existence under the Requirements of Law in their respective jurisdictions of organization, incorporation or formation (other than as otherwise expressly permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); (b) take all commercially reasonable action to maintain all rights, privileges (including its good standing (to the extent the concept is applicable in such jurisdiction)), permits, licenses and franchises necessary or desirable for it and all of its Subsidiaries in the ordinary course of its business, except in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (other than with respect to Borrower) and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, (i) to the extent that failure to do so could not reasonably be expected to result in a Material Adverse Change or (ii) pursuant to a transaction permitted by this Agreement; and (c) comply with all Requirements of Law of any Governmental Authority to which it is subject, except where the failure to do so could not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.2	Financial Statements, Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Deliver to the Collateral Agent:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Within [***] days after the end of each fiscal year of Borrower, beginning with the fiscal year ending December 31, 2024, a consolidated balance sheet of Borrower and its Subsidiaries, as of the end of such fiscal year, and the related consolidated statements of income, cash flows and stockholders&#x2019; equity for such fiscal year, setting forth in each case, certified by a Responsible Officer of Borrower, in comparative form the figures for the previous fiscal year, all prepared in accordance with GAAP, with such consolidated financial statements to be audited and accompanied by (x) a report and opinion of Borrower&#x2019;s independent certified public accounting firm of recognized national standing (which report and opinion shall be prepared in accordance with GAAP and shall not be subject to any qualification as to &#x201c;going concern&#x201d; or &#x201c;scope of audit&#x201d; (other than any qualification resulting from the Term Loan Maturity Date occurring within twelve (12) months of the relevant audit)), stating that such financial statements fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows of Borrower and its Subsidiaries as of the dates and for the periods specified in accordance with GAAP, and (y) if and only if Borrower is required to comply with the internal control provisions pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 requiring an attestation report of such independent certified public accounting firm, an attestation report of such independent certified public accounting firm as to Borrower&#x2019;s internal controls pursuant to Section 404 of the Sarbanes-Oxley Act of</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2002 attesting to management&#x2019;s assessment that such internal controls meet the requirements of the Sarbanes-Oxley Act of 2002;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Financial Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Within [***] days after the end of each of the first three (3) fiscal quarters of each fiscal year of Borrower, beginning with respect to the fiscal quarter ending September 30, 2024, a consolidated balance sheet of Borrower and its Subsidiaries, as of the end of such fiscal quarter, and the related consolidated statements of income and cash flows and for such fiscal quarter and (in respect of the second and third fiscal quarters of such fiscal year) for the then-elapsed portion of Borrower&#x2019;s fiscal year, setting forth in each case in comparative form the figures for the comparable period or periods in the previous fiscal year, all prepared in accordance with GAAP;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon delivery (or within [***] following any deemed delivery) of financial statements pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2(a)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a duly completed Compliance Certificate signed by a Responsible Officer of Borrower, certifying, among other things, that (A) such financial statements fairly present, in all material respects, the consolidated financial condition, results of operations and cash flows of Borrower and its Subsidiaries as of the applicable dates and for the applicable periods in accordance with GAAP consistently applied, and are not subject to any qualification or statement as to &#x201c;going concern&#x201d; or scope of audit other than as expressly permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (B) no Event of Default or Default has occurred or, if such an Event of Default or Default has occurred, specifying the nature and extent thereof and any corrective action taken or proposed to be taken with respect thereto; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Within [***] after the reasonable request of the Collateral Agent therefor, such additional information regarding the operations, properties, business, liabilities or condition (financial or otherwise) of Borrower and its Subsidiaries (including with respect to the Collateral), or compliance with the terms of this Agreement or any other Loan Documents,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in each case in a form reasonably acceptable to the Collateral Agent; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Borrower shall not be obligated to disclose any information that is restricted by Requirements of Law or contractual agreement with a third-party (so long as such contractual restriction was not agreed to for the specific purpose of preventing disclosure under this Agreement) or that is subject to the attorney-client privilege or constitutes attorney work product.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Defaults or Events of Default, ERISA Events, Withdrawal Events and Material Adverse Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Written notice as promptly as practicable (and in any event within [***]) after a Responsible Officer of any Credit Party shall have obtained knowledge thereof, of (i) the receipt by Borrower or any of its Subsidiaries of any written notice from the FDA or any other Regulatory Agency of a pending recommendation or a final decision to withdraw marketing authorization for such Product in the U.S., or (ii) the occurrence of, or the occurrence of any event which could reasonably be expected to result in, any (x) Default or Event of Default (including, for the avoidance of doubt, any Withdrawal Event or Material Adverse Change) or (y) ERISA Event.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Action Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Promptly (and in any event within [***]) upon any Credit Party&#x2019;s receipt or otherwise obtaining Knowledge thereof, written notice (which shall be deemed given to the extent timely reported in a Form 8-K under the Exchange Act and available on the SEC&#x2019;s EDGAR system (or any successor system adopted by the SEC), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such notice shall be deemed to have been so given with respect to additional information the Collateral Agent may reasonably request only if it includes such additional information) of: (i) correspondence received from the SEC (or comparable agency in any applicable foreign.  jurisdiction) concerning any investigation or possible investigation or other material inquiry by such agency regarding financial or other operational results of Borrower or any Subsidiary of Borrower; or (ii) any legal action, litigation, investigation or proceeding pending or threatened in writing against Borrower or any of its Subsidiaries or any material out-licensing partners (A) that could reasonably be expected to result in uninsured damages or costs to Borrower or any of its Subsidiaries in an amount in excess of the materiality thresholds applied by Borrower in accordance with the Exchange Act and related regulations and standards for purposes of its Exchange Act reporting or (B) that alleges violations of any Health Care Laws, FDA Laws, EU Laws, U.K. Laws, Data Protection Laws or any other applicable statutes, rules, regulations, standards, guidelines, policies and orders, or applicable foreign equivalents, administered or issued by any U.S. or foreign Governmental Authority which, individually or together with any other such allegations, could reasonably be expected to result in a Material Adverse Change; and in each case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, provide such additional information (including a description in reasonable detail regarding any material development) as the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Agent may reasonably request in relation thereto; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that neither Borrower nor any other Credit Party shall be obligated to disclose any information that is reasonably subject to the assertion of attorney-client privilege or attorney work-product.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Written notice within [***] after any material change in accounting policies or financial reporting practices by Borrower or any Subsidiary.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Prompt written notice of any Credit Party&#x2019;s obtaining Knowledge of (i) any assignment of any of Borrower&#x2019;s or Royalty Pharma&#x2019;s obligations, rights, interests or benefits under the Royalty Revenue Contract or any other Royalty Revenue Document to which Borrower or any of its Subsidiaries is a party, or (ii) any acquisition of any interest in any of Royalty Pharma&#x2019;s rights, interests or benefits under the Royalty Revenue Contract or any other Royalty Revenue Document to which Borrower or any of its Subsidiaries is a party, together with a copy of any joinder or other agreement pursuant to which such assignee or acquirer agrees to be bound by the terms and obligations set forth in the Royalty Revenue Contract.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Statements and Reports</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within [***] after entering into the same, copies of any amendments, restatements, amendment and restatements, supplements, modifications, consents, approvals or waivers to or otherwise in respect of the Royalty Revenue Contract or any other Royalty Revenue Document, in each case that would (A) change the calculation or time of any payment to Royalty Pharma, including any change to the basis or manner for calculating any late or overdue payments (including any fees or interest payments thereon), (B) change any of the terms of the RPI Obligations (as such term is defined in the Intercreditor Agreement as in effect on the Tranche A Closing Date), including any change to obligate Borrower or any of its Subsidiaries to make any payment to Royalty Pharma with respect to such RPI Obligations, (C) contravene in any respect any of the terms or conditions set forth in this Agreement, (D) adversely affect the payment or priority subordination set forth in the Intercreditor Agreement to the Obligations owed to Lenders or (E) obligate any Credit Party or any of its Subsidiaries to make (or exercise any option with respect thereto), directly or indirectly, any payment or reimbursement of any kind to Royalty Pharma pursuant to the Royalty Revenue Contract or other Royalty Revenue Document other than the payments described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10(g)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within [***] of the making thereof, notice specifying in reasonable detail any (A) fees or payments made to Royalty Pharma in connection with any amendment, restatement, amendment and restatement, supplement, modification, consent, approval or waiver to or otherwise in respect of the Royalty Revenue Contract or any other Royalty Revenue Document or (B) any fees, payments or reimbursement made to Royalty Pharma, including underpayments made by Borrower following an audit conducted pursuant to Section 7.4 of the Royalty Revenue Contract, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">than</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (1) reimbursements or payments to accounting firms pursuant to Sections 2.3 and 7.4(c) of the Royalty Revenue Contract and (2) regularly scheduled Revenue Payments (as defined in the Royalty Revenue Contract);</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within [***] after the furnishing thereof, copies each report furnished to Royalty Pharma pursuant to Sections 7.2 and 7.3 of the Royalty Revenue Contract and any other material correspondence furnished to Royalty Pharma or Borrower in connection with any such reports;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Within [***] thereof, notice of any accrual or payment of interest pursuant to Section 7.12 of the Royalty Revenue Contract (including a description in reasonable detail regarding the underlying payment(s) in respect of which such interest has accrued or been paid); and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within [***] after the request therefor by the Collateral Agent, copies of any material statement or report furnished to any holder of debt securities of Borrower or any Subsidiary pursuant to the terms of any indenture, loan or credit or similar agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, any documents, materials, notices or other information, that Borrower, any Credit Party or any Subsidiary of Borrower is required to deliver under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 5.2(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above shall be deemed to have been made if such item shall have been made available within the time period specified above on the SEC&#x2019;s EDGAR system (or any successor system adopted by the SEC), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in the case of any notice required to be delivered under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, such notice shall be deemed to have been so made with respect to additional information the Collateral Agent may reasonably request only if it includes such additional information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.3	Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Timely file all required income and other material Tax returns and reports or extensions therefor and timely pay all Taxes, assessments, deposits and contributions imposed upon it or any of its properties or assets or in respect of any of its income, businesses or franchises before any penalty or fine accrue thereon; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no such Tax or any claim for Taxes that has become due and payable and has or may become a Lien on any Collateral shall be required to be paid if (a) it is being contested in good faith by appropriate proceedings promptly instituted and diligently conducted, so long as adequate reserves therefor have been set aside on its books and maintained in conformity with GAAP or IFRS, as applicable and (b) solely in the case of a Tax or claim that has or may become a Lien against any Collateral, such contest proceedings conclusively operate to stay the sale or forfeiture of any portion of any Collateral to satisfy such Tax or claim.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.4	Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Maintain with financially sound and reputable independent insurance companies or underwriters, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons of comparable size engaged in the same or similar business, of such types and in such amounts (after giving effect to any self-insurance reasonable and customary for similarly situated Persons of comparable size engaged in the same or similar businesses as Borrower and its Subsidiaries) as are customarily carried under similar circumstances by such other Persons.  Subject to the timing requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (solely with respect to any such policies in effect as of the Tranche A Closing Date), any products liability or general liability insurance maintained in the United States regarding Collateral shall name the Collateral Agent, on behalf of the Lenders and the other Secured Parties, as additional insured or loss payee, as applicable (the additional insured clauses or endorsements for which, in form and substance reasonably satisfactory to the Collateral Agent).  So long as no Event of Default shall have occurred and be continuing, with respect to the Borrower&#x2019;s and its Subsidiaries&#x2019; property and general liability policies, and at all times with respect to any other policies (including any product liability policies) the Borrower and its Subsidiaries may retain all or any portion of the proceeds of any such insurance of the Borrower and its Subsidiaries (and the Collateral Agent and each Lender shall promptly remit to Borrower any proceeds received by it with respect to any such insurance).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5	Operating Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In the case of any Credit Party, following the establishment of any new Collateral Account at or with any bank or other depository or financial institution located in (a) the United States, subject such account to a Control Agreement or other appropriate instrument that is reasonably acceptable to the Collateral Agent, and (b) any jurisdiction other than the United States, comply with requirements set forth in the applicable Collateral Document in relation to Collateral Accounts in such jurisdiction.  For each Collateral Account that each Credit Party at any time maintains in the United States, such Credit Party shall, within thirty (30) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) of establishing such Collateral Account, cause the applicable bank or other depository or financial institution located in the United States, at or with which any Collateral Account is maintained to execute and deliver, and such Credit Party shall execute and deliver, to the Collateral Agent, a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect the Collateral Agent&#x2019;s Lien, for the benefit of Lenders and the other Secured Parties, in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be terminated without the prior written consent of the Collateral Agent.  The provisions of the previous three (3) sentences shall not apply to (1) accounts exclusively used for payroll, payroll Taxes and other employee wage and benefit payments to or for the benefit of any Credit Party&#x2019;s employees, (2) zero balance accounts, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, within two (2) Business Days of any deposit made into any such zero balance account, such deposit is swept in full to an account subject to a Control Agreement, (3) accounts (including trust accounts) used exclusively for escrow, customs, insurance or fiduciary purposes, (4) merchant accounts, (5) accounts used exclusively for compliance with any Requirements of Law to the extent such Requirements of Law prohibit the granting of a Lien thereon, (6) accounts which constitute cash collateral in respect of a Permitted Lien, (7) any other account established and maintained in the ordinary course of business or in furtherance of a </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> general corporate purpose and designated as an Excluded Account by a Responsible Officer of Borrower in writing delivered to the Collateral Agent, the cash balance of which, individually or together with all other such accounts excluded pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (7)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, does not exceed [***] at any time, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if the cash balance of such account, individually or together</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with all other such accounts excluded pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (7)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, exceeds [***] at any time, (x) such account shall no longer be deemed to be an Excluded Account hereunder as of such time, with the effect that the accounts which remain as Excluded Accounts pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (7)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are in compliance with the requirements for exclusion under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (7)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (y) such account shall be deemed to be a Collateral Account on such date and Borrower shall comply with the requirements of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to such account, and (8) accounts not otherwise described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (1)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(7)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above constituting Excluded Property (all such accounts in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (1)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(8)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Notwithstanding the foregoing, the Credit Parties shall have until the date that is thirty (30) days (or such longer period as the Collateral Agent may agree in writing (such agreement not to be unreasonably withheld, conditioned or delayed so long as such Credit Party is using reasonable good faith efforts)) following (i) the Tranche A Closing Date to comply with the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with regards to Collateral Accounts (other than Excluded Accounts) of the Credit Parties in existence on the Tranche A Closing Date (or opened during such 30-day period) and (ii) the closing date of any Acquisition or other Investment to comply with the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with regards to Collateral Accounts (other than Excluded Accounts) of the Credit Parties acquired in connection with such Acquisition or other Investment.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6	Compliance with Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comply in all respects with the Requirements of Law and all orders, writs, injunctions, decrees and judgments applicable to it or to its business or its assets or properties (including Environmental Laws, ERISA, Anti-Money Laundering Laws, Anti-Corruption Laws, Export and Import Laws, Health Care Laws, FDA Laws, Data Protection Laws, the Federal Fair Labor Standards Act, EU Laws, U.K. Laws, and any foreign equivalents thereof), including in connection with governing any aspect of the research, development, testing, approval, licensure, clearance, authorization, exclusivity, licensure, designation, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring or commitments, reporting, (including post-marketing safety reports, if any), manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, offer for sale, distribution or sale of Product in the Territory, except, in each case, if the failure to comply therewith individually or taken together with any other such failures, could not reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Institute and maintain policies and procedures reasonably designed to ensure compliance with applicable Sanctions, Anti-Money Laundering Laws, Export and Import Laws, Anti-Corruption Laws and Data Protection Laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7	Protection of Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as expressly permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below to use commercially reasonable efforts to (i) protect, defend and maintain the validity and enforceability of Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, import, storage, transport, offer for sale, distribution or sale of any Product in the Territory, including defending any future or current oppositions, interference proceedings, reissue proceedings, reexamination proceedings, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review proceedings, derivative proceedings, post-grant review proceedings, cancellation proceedings, injunctions, lawsuits, paragraph IV patent certifications or lawsuits under the Hatch-Waxman Act, hearings, investigations, complaints, arbitrations, mediations, demands, International Trade Commission investigations, decrees, or any other disputes, disagreements, or claims, challenging the legality, validity, patentability, enforceability, inventorship or ownership of any such Company IP; (ii) maintain the confidential nature of any material trade secrets and trade secret rights used in any research, development, manufacture, production use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory; (iii) not allow any Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory, to be abandoned, disclaimed, forfeited or dedicated to the public (other than through the abandonment of Current Company IP in the exercise of the Credit Parties&#x2019; normal prosecution practices and reasonable business judgment, e.g., the abandonment of a continuation application that is no longer needed to maintain the pendency of another patent application) or any Company IP Agreement to be terminated by any Credit Party or any of its Subsidiaries, as applicable, without the Collateral Agent&#x2019;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that with respect to any such Company IP that is not owned by a Credit Party or any of its Subsidiaries, the obligations in sub-</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above shall apply only to the extent a Credit Party or any of its Subsidiaries have the right to take such</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actions or to cause any licensee or other third-party to take such actions pursuant to applicable agreements or contractual rights.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Except as a Credit Party may otherwise determine in its reasonable business judgment, use commercially reasonable efforts, at its (or its Subsidiary&#x2019;s) sole expense, either directly or indirectly, with respect to any licensee or licensor under the terms of any Credit Party&#x2019;s (or any Subsidiary&#x2019;s) agreement with the respective licensee or licensor, as applicable, to take any and all actions (including taking legal action to specifically enforce the applicable terms of any license agreement) and prepare, execute, deliver and file agreements, documents or instruments which are necessary to (A) prosecute and maintain the Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory and (B) diligently defend or assert the Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory against material infringement, misappropriation, violation or interference by any other Persons and, in the case of Copyrights, Trademarks and Patents within the Company IP, against any claims of invalidity, unpatentability or unenforceability (including by bringing any legal action for infringement, dilution, violation, derivation or defending any counterclaim of invalidity or action of a non-Affiliate third-party for declaratory judgment of non-infringement or non-interference); and (ii) use commercially reasonable efforts to cause any licensee or licensor of any Company IP not to, and such Credit Party shall not, disclaim, forfeit, dedicated to the public or abandon, or fail to take any action necessary to prevent the disclaimer, forfeiture or abandonment of Company IP material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory.  Each Credit Party agrees to (1) notify the Collateral Agent in writing, promptly (and in any event within ten (10) Business Days) after a Credit Party or any of its Subsidiaries first becomes aware of, and thereafter (2) keep the Collateral Agent reasonably informed regarding, (x) of any infringement or violation of any of the rights of any Credit Party or its Subsidiary in or to any Company IP, or any misappropriation by any Person of any Company IP or any of the subject matter thereof, and (y) any Product that infringes or violates any Third-Party IP or constitutes a misappropriation of any Third-Party IP.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Save as contemplated by any Permitted License, use commercially reasonable efforts to protect, defend and maintain market and data exclusivity for the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product through the Term Loan Maturity Date, and use commercially reasonable efforts to not allow for the manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of an equivalent or bioequivalent version of Product before the Term Loan Maturity Date, without the Collateral Agent&#x2019;s prior written consent.  Borrower agrees to (i) promptly notify the Collateral Agent in writing of (provided that no Credit Party or third-party confidential information will be shared that violates trade secret protection or a court order), and (ii) keep the Collateral Agent reasonably informed regarding the commencement of any material filings or submissions in any opposition, interference proceeding, reissue proceeding, reexamination proceeding, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter partes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> review proceeding, post-grant review proceeding, derivation proceeding, cancellation proceeding, injunction, lawsuit, hearing, investigation, complaint, arbitration, mediation, demand, International Trade Commission investigation, decree, or any other dispute, disagreement, or claim, in each case challenging the legality, validity, patentability, enforceability, inventorship ownership of any material Company IP (including any claim in any Patent within the Company IP that is material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of Product).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.8	Books and Records</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Maintain proper Books, in which entries that are full, true and correct in all material respects and are in conformity with GAAP consistently applied shall be made of all material financial transactions and matters involving the assets, properties and business of such Credit Party (or such Subsidiary).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.9	Access to Collateral; Audits</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Allow the Collateral Agent, or its agents or representatives, at any time after the occurrence and during the continuance of an Event of Default, during normal business hours and upon reasonable advance notice, to visit and inspect any of the Collateral or to inspect and copy and (at the sole discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the Collateral Agent) audit any Credit Party&#x2019;s Books.  The foregoing inspections and audits, if any, shall be at the relevant Credit Party&#x2019;s expense.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.10	Use of Proceeds</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  (a) Use the proceeds of the Term Loans solely to repay all Indebtedness and any and all other amounts outstanding under the Existing Credit Agreement and any and all costs and expenses associated therewith, and to fund its general corporate and working capital requirements; and (b) not use the proceeds of the Term Loans or any other Credit Extensions, directly or indirectly, for the purpose of purchasing or carrying any Margin Stock, for the purpose of reducing or retiring any Indebtedness that was originally incurred to purchase or carry any Margin Stock, for the purpose of extending credit to any other Person for the purpose of purchasing or carrying any Margin Stock or for any other purpose that might cause any Term Loan or other Credit Extension to be considered a &#x201c;purpose credit&#x201d; within the meaning of Regulation T, U or X of the Federal Reserve Board.  If requested by the Collateral Agent, Borrower shall complete and sign Part I of a copy of Federal Reserve Form G-3 referred to in Regulation U and deliver such copy to the Collateral Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.11	Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Promptly upon the reasonable written request of the Collateral Agent, execute, acknowledge and deliver such further documents and do such other acts and things in order to effectuate or carry out more effectively the purposes of this Agreement and the other Loan Documents at its expense, including after the Tranche A Closing Date taking such steps as are reasonably deemed necessary or desirable by the Collateral Agent to maintain, protect and enforce its Lien, for the benefit of Lenders and the other Secured Parties, on Collateral securing the Obligations created under the Collateral Documents and the other Loan Documents in accordance with the terms of the Collateral Documents and the other Loan Documents, subject to Permitted Liens.  Notwithstanding the foregoing, no perfection steps shall be required outside of the United States or the jurisdiction of organization of a Credit Party (and, if different, the jurisdiction of the principal place of business of such Credit Party).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.12	Additional Collateral; Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party (other than Borrower) shall, and Borrower and each other Credit Party shall cause each of its Subsidiaries (other than Excluded Subsidiaries) to: (i) guarantee the Obligations; (ii) grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations expressly set forth herein and the limitations expressly set forth in the other Loan Documents), and pledge to the Collateral Agent for the benefit of Lenders and the other Secured Parties, all of such Credit Party&#x2019;s or Subsidiary&#x2019;s properties and assets constituting Collateral (including the certificated and uncertificated Equity Interests (other than Excluded Equity Interests) in such Subsidiary), whether now existing or hereafter acquired or existing (including in connection with an Asset Acquisition), to secure such guaranty; and (iii) subject to the timing requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if and only to the extent applicable, execute and deliver to the Collateral Agent, a joinder or pledge amendment to the Security Agreement (in the form(s) attached thereto),</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a joinder to the Intercreditor Agreement (if applicable) and such other Collateral Documents or other documents required under the terms of the Loan Documents or as the Collateral Agent may reasonably request, including (x) in connection with each pledge of certificated Equity Interests, such certificate(s) together with stock powers, stock transfer forms or assignments, as applicable, properly endorsed for transfer to the Collateral Agent or duly executed in blank, in each case reasonably satisfactory to the Collateral Agent, and (y) in connection with each pledge of uncertificated Equity Interests of a Person organized in the U.S., an executed uncertificated stock control agreement among the issuer, the registered owner and the Collateral Agent, substantially in the form attached to the Security Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower and each other Credit Party shall, and shall cause each of its Subsidiaries (other than Excluded Subsidiaries) to: (i) grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations set forth herein and the limitations set forth in the other Loan Documents), and pledge to the Collateral Agent for the benefit of Lenders and the other Secured Parties, all of such Credit Party&#x2019;s or Subsidiary&#x2019;s properties and assets constituting Collateral (including the certificated and uncertificated Equity Interests (other than Excluded Equity Interests) in such Subsidiary), whether now existing or hereafter acquired or existing (including in connection with an Asset Acquisition), to secure the payment and performance in full of all of the Obligations; and (ii) subject to the timing requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 5.13 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if and only to the extent applicable, execute and deliver to the Collateral Agent a joinder or pledge amendment to the Security Agreement (in the form(s) attached thereto),</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a joinder to the Intercreditor Agreement (if applicable) and such other Collateral Documents or other documents required under the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terms of the Loan Documents or as the Collateral Agent may reasonably request, including (x) in connection with each pledge of certificated Equity Interests, such certificate(s) together with stock powers, stock transfer forms or assignments, as applicable, properly endorsed for transfer to the Collateral Agent or duly executed in blank, in each case reasonably satisfactory to the Collateral Agent, and (y) in connection with each pledge of uncertificated Equity Interests of a Person organized in the U.S. that is a Credit Party, an executed uncertificated stock control agreement among the issuer, the registered owner and the Collateral Agent, substantially in the form attached to the Security Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing, each Credit Party&#x2019;s obligations to take the actions set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above with respect to any assets acquired as part of an Asset Acquisition or in connection with the Stock Acquisition of a Subsidiary after the Tranche A Closing Date or any Subsidiary incorporated, organized, formed or acquired (including by a Stock Acquisition) after the Tranche A Closing Date, shall in each case be subject to the timing requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any document, agreement or instrument executed or issued pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be a Loan Document for all purposes under this Agreement and the other Loan Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event after the Effective Date any Credit Party acquires any fee title to real estate in the U.S. with a fair market value (reasonably determined in good faith by a Responsible Officer of such Credit Party) in excess of [***], unless otherwise agreed by the Collateral Agent, such Person shall execute or deliver, or cause to be executed or delivered, to the Collateral Agent, (i) within sixty (60) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, an appraisal complying with the Financial Institutions Reform, Recovery and Enforcement Act of 1989, (ii) within forty-five (45) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after receipt of notice from the Collateral Agent that such real estate is located in a Special Flood Hazard Area, Federal Flood Insurance, (iii) within sixty (60) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, a fully executed Mortgage, in form and substance reasonably satisfactory to the Collateral Agent, together with an A.L.T.A. lender&#x2019;s title insurance policy issued by a title insurer reasonably satisfactory to the Collateral Agent, in form and substance (including any endorsements) and in an amount reasonably satisfactory to the Collateral Agent insuring that the Mortgage is a valid and enforceable first priority Lien on the respective property, free and clear of all defects, encumbrances and Liens (other than Permitted Liens), (iv) simultaneously with such acquisition, then-current A.L.T.A. surveys, certified to the Collateral Agent by a licensed surveyor sufficient to allow the issuer of the lender&#x2019;s title insurance policy to issue such policy without a survey exception and (v) within sixty (60) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) after such acquisition, an environmental site assessment prepared by a qualified firm reasonably acceptable to the Collateral Agent, in form and substance reasonably satisfactory to the Collateral Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.13	Formation or Acquisition of Subsidiaries; Designated Guarantors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If (i) any Credit Party or any of its Subsidiaries at any time after the Tranche A Closing Date incorporates, organizes, forms or acquires (including by a Stock Acquisition or an Asset Acquisition) a Subsidiary (including by division), other than an Excluded Subsidiary (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) Borrower elects, in its sole discretion, to designate an Excluded Subsidiary as a Credit Party (such designated Subsidiary, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designated Guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), such Credit Party shall (x) notify the Collateral Agent in writing promptly, and in no event later than [***] after such incorporation, organization, formation or acquisition, or designation, as applicable, and (y) within thirty (30) days (or such longer period as the Collateral Agent may agree in writing (such agreement, with respect to any Designated Guarantor that is a Foreign Subsidiary, not to be unreasonably withheld, conditioned or delayed so long as such Credit Party is using reasonable good faith efforts)) after such incorporation, organization, formation or acquisition, or designation, as applicable: (a) without limiting the generality of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, such Credit Party will cause such New Subsidiary or Designated Guarantor, as applicable, to the extent required or applicable to execute and deliver to the Collateral Agent a joinder to the Security Agreement (in the form attached thereto), any relevant IP Agreement or other Collateral Documents, and such other Collateral Documents or other documents as the Collateral Agent may reasonably request; (b) such New Subsidiary or Designated Guarantor, as applicable, will deliver (or cause to be delivered) to the Collateral Agent (i) true, correct and complete copies of the Operating Documents of such New Subsidiary or Designated Guarantor, as applicable, (ii) a Secretary&#x2019;s Certificate, certifying that the copies of the Operating Documents of such New Subsidiary or Designated Guarantor, as applicable, are true, correct and complete (such Secretary&#x2019;s Certificate to be in form and substance reasonably satisfactory to the Collateral Agent) and (iii) a good standing certificate for such New Subsidiary or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designated Guarantor, as applicable, certified by the Secretary of State (or the equivalent thereof) of its jurisdiction of organization, incorporation or formation (where applicable in the subject jurisdiction); and (c) such Credit Party will cause such New Subsidiary or Designated Guarantor, as applicable, to satisfy all requirements contained in this Agreement (including </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and each other Loan Document if and to the extent applicable to such New Subsidiary or Designated Guarantor.  The parties hereto agree that any New Subsidiary or Designated Guarantor, as applicable, shall constitute a Credit Party for all purposes hereunder as of the date of the execution and delivery of any joinder contemplated by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above or the date such New Subsidiary or Designated Guarantor, as applicable, provides any guarantee of the Obligations as contemplated by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any document, agreement or instrument executed or issued pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be a Loan Document for all purposes under this Agreement and the other Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.14	Post-Closing Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower will, and will cause each of its Subsidiaries, as applicable, to take each of the actions set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter within the time period prescribed therefor on such schedule, which shall include, among other things, that, notwithstanding anything to the contrary in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Credit Parties shall have until the date that is thirty (30) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) following the Tranche A Closing Date to comply with the provisions of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with regards to naming the Collateral Agent, on behalf of the Lenders and the other Secured Parties, as additional insured or loss payee, on any products liability or general liability insurance policies maintained in the United States regarding any Collateral in effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All representations and warranties and covenants contained in this Agreement and the other Loan Documents shall be deemed modified to the extent necessary to take the actions set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter within the time periods set forth therein, rather than elsewhere provided in the Loan Documents, such that to the extent any such action set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter is not overdue, the applicable Credit Party shall not be in breach of any representation or warranty or covenant contained in this Agreement or any other Loan Document applicable to such action for the period from the Tranche A Closing Date until the date on which such action is required to be fulfilled as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.15	Environmental</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deliver to the Collateral Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as soon as practicable following receipt thereof, copies of all environmental audits, investigations, analyses and reports of any kind or character, whether prepared by personnel of Borrower or any of its Subsidiaries or by independent consultants, governmental authorities or any other Persons, with respect to any significant environmental matter at any Facility or with respect to any Environmental Claim that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promptly upon a Responsible Officer of any Credit Party or any of its Subsidiaries obtaining knowledge of the occurrence thereof, written notice describing in reasonable detail (A) any Release required to be reported to any federal, state, local or foreign governmental or regulatory agency under any applicable Environmental Laws, (B) any remedial action taken by (or on behalf of) any Credit Party or any other Person in response to (x) any Hazardous Materials Activities, the existence of which, individually or in the aggregate, could reasonably be expected to result in one or more Environmental Claims resulting in a Material Adverse Change, or (y) any Environmental Claims that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, and (C) any Credit Party&#x2019;s discovery of any occurrence or condition on any real property adjoining or in the vicinity of any Facility that could cause such Facility or any part thereof to be subject to any material restrictions on the ownership, occupancy, transferability or use thereof under any Environmental Laws, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to real property adjoining or in the vicinity of any Facility, Borrower shall have no duty to affirmatively investigate or make any efforts to become or stay informed regarding any such adjoining or nearby properties;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as soon as practicable following the sending or receipt thereof by any Credit Party, a copy of any and all written communications with respect to (A) any Environmental Claims that, individually</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or in the aggregate, could reasonably be expected to result in a Material Adverse Change, (B) any Release required to be reported to any federal, state, local or foreign governmental or regulatory agency, and (C) any request for information from any Governmental Authority that suggests such Governmental Authority is investigating whether any Credit Party or any of its Subsidiaries may be potentially responsible for any Hazardous Materials Activity that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prompt written notice describing in reasonable detail of (A) any proposed acquisition of stock, assets, or property by Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to (x) expose Borrower or any of its Subsidiaries to, or result in, Environmental Claims which could reasonably be expected to result in a Material Adverse Change or (y) affect the ability of Borrower or any of its Subsidiaries to maintain in full force and effect all material Governmental Approvals required under any Environmental Laws for their respective operations, and (B) any proposed action to be taken by Borrower or any of its Subsidiaries to modify current operations, in each case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (A)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, that, individually or taken together with any other such proposed acquisitions or actions, could reasonably be expected to result in a Material Adverse Change; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with reasonable promptness, such other documents and information as from time to time may be reasonably requested by the Collateral Agent in relation to any matters disclosed pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.15(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party shall, and shall cause each of its Subsidiaries to, promptly take any and all actions reasonably necessary to (i) cure any violation of applicable Environmental Laws by Borrower or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change, and (ii) make an appropriate response to any Environmental Claim against Borrower or any of its Subsidiaries and discharge any obligations it may have to any Person thereunder where failure to do so, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.16	Inventory; Returns; Maintenance of Properties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Keep all Inventory which constitutes Product in good and marketable condition, free from material defects and otherwise keep all Inventory which constitutes Product in compliance with all applicable FDA Laws, EU Laws, U.K. Laws and all other foreign equivalents, as applicable, except where the failure to do so could not reasonably be expected to result in a Material Adverse Change.  Returns and allowances between a Credit Party and its Account Debtors shall follow such Credit Party&#x2019;s customary practices.  Each Credit Party will, and will cause each of its Subsidiaries to, maintain or cause to be maintained in good repair, working order and condition, ordinary wear and tear, casualty and condemnation excepted, all material tangible properties used or useful in its respective business, and from time to time will make or cause to be made all commercially reasonable repairs, renewals and replacements thereof except where failure to do so could not reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.17	Regulatory Obligations; Maintenance of Regulatory Approval or Licensure; Licensure and Designation; Manufacturing, Marketing and Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Comply in all material respects with Governmental Authority research, development, testing, post-marketing approval, authorization, clearance, or licensure requirements for Product in the Territory, as applicable, (ii) maintain all Regulatory Approvals or Licensures required or otherwise material to manufacture, market, and distribute Product in the Territory (including meeting the supplier standards of Medicare, Medicaid, and other federal healthcare programs), and (iii) with respect to each calendar year commencing with calendar year 2024, maintain manufacturing capacity to sell Product which has been designated as an Orphan Drug in the Territory in sufficient quantities to satisfy or exceed the expected needs of patients with the disease or condition for which Product was designated as an Orphan Drug for such calendar year, as reasonably determined by Responsible Officers of the Credit Parties in good faith.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deliver to the Collateral Agent, as promptly as practicable after a Responsible Officer of Borrower shall have obtained Knowledge thereof, written notice describing in reasonable detail any instance where any Credit Party or any of its Subsidiaries or licensing partners: (i) has a reasonable expectation that there are grounds for imposition of a clinical hold, as described in 21 C.F.R. &#167; 312.42  or foreign equivalent, withdrawal of an</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investigational New Drug Application, as defined in 21 C.F.R. &#167; 312.380 or foreign equivalent, withdrawal or suspension of a Product approval or licensure, as described in 21 C.F.R. Part 314 or foreign equivalent, or a recall, as defined in 21 C.F.R. &#167; 7.3 or foreign equivalent, in each case with respect to Product; (ii) has been issued a Warning Letter or Untitled Letter or Form FDA-483 from FDA (or equivalent communication from any other Regulatory Agency) with respect to Product; (iii) has received notice from a Regulatory Agency (including the European Medicines Authority) that an application for Product will not be approved in its present form;  or (iv) has a reasonable expectation that Product will lose exclusivity under 21 C.F.R. &#167; 316 or foreign equivalent or face a supply shortage materially impacting Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.18	Material Contracts; Collateral Documents; Royalty Revenue Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Comply with all of its covenants, agreements, undertakings and obligations arising under, and fulfill all of its obligations under, (a) subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, each Material Contract to which it is a party, except as could not reasonably be expected to have a Material Adverse Change, (b) the Royalty Revenue Contract and each other Royalty Revenue Document to which it is a party, except in each case to the extent prohibited by or as would contravene in any respect any of the terms or conditions set forth in this Agreement (including </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), or (c) each Collateral Document to which it is a party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NEGATIVE COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party covenants and agrees that, until payment in full of all Obligations (other than inchoate indemnity obligations), such Credit Party shall not, and shall cause each of its Subsidiaries not to:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.1	Dispositions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Convey, sell, lease, transfer, exchange, assign, covenant not to sue, enter into a coexistence agreement, exclusively or nonexclusively license out, or otherwise dispose of (including any sale-leaseback or any transfer of assets pursuant to a plan of division), directly or indirectly and whether in one or a series of transactions (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), all or any part of its properties or assets constituting Collateral (including, for the avoidance of doubt, any Equity Interests constituting Collateral issued by any Subsidiary which are owned or otherwise held by such Credit Party) or any Company IP that does not constitute Collateral under the Loan Documents but is related to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the Territory; except, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for Permitted Transfers (unless otherwise expressly prohibited in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.6(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.2	Fundamental Changes; Location of Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Without at least ten (10) days prior written notice to the Collateral Agent, solely in the case of a Credit Party: (i) change its jurisdiction of organization, incorporation or formation, (ii) change its organizational structure or type, (iii) change its legal name, or (iv) change any organizational number (if any) assigned by its jurisdiction of organization, incorporation or formation.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintain its primary Books at or deliver any Collateral with a fair market value (reasonably determined in good faith by a Responsible Officer of Borrower), individually or together with any other Collateral, in excess of [***] to, one or more mortgaged or leased locations or one or more warehouses, processors or bailees, as applicable, unless, subject to the timing requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if and only to the extent applicable (solely with respect to such locations, warehouses, processors or bailees where such Books or Collateral is located on the Closing Date or during the 30-day period following the Closing Date), such Credit Party uses commercially reasonable efforts to obtain, within thirty (30) days after such Books or Collateral are maintained (or such longer period as the Collateral Agent may agree in writing in its sole discretion, taking into account reasonable good faith efforts) a Collateral Access Agreement for such mortgaged or leased location or such warehouse, processor or bailee governing such Books or such Collateral (as applicable), in form and substance reasonably satisfactory to the Collateral Agent, to the extent such Collateral is located in the United States or the jurisdiction of organization of such Credit Party (or, if different, the jurisdiction of the principal place of business of such Credit Party).  Notwithstanding anything to the contrary herein, such obligation to deliver Collateral Access Agreements will not apply to any inventory or assets while in transit (including such assets stored at any temporary location pending transit).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Establish or maintain any bank account of any Credit party other than the bank accounts set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 6.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter (which bank accounts constitute all of the deposit accounts,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities accounts or other similar accounts maintained by any Credit Party on the Tranche A Closing Date), unless, in the case of any bank account that is not an Excluded Account, (i) the Collateral Agent is provided at least ten (10) Business Days&#x2019; written notice from such Credit Party prior to the establishment or maintenance of such account and (ii) such account is or is made subject to a Control Agreement or an applicable Collateral Document to the extent required by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintain cash in any bank account located in other than the United States, the United Kingdom, the Netherlands or the jurisdiction of organization of such Credit Party (or, if different, the jurisdiction of the principal place of business of such Credit Party) that would be in excess of the amount of cash that would be appropriate for (i) the continued operations in the ordinary course of business of such Credit Party or Subsidiary and (ii) such other business needs of such Person, as reasonably determined by a Responsible Officer of Borrower in good faith, consistent with prudent cash management practices and not with an intent to hinder the security interests available under the Loan Documents.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Take any action or engage in any transaction (or series of actions or transactions), whether by reorganization, sale of assets, merger, dissolution, amendment of Operating Documents or otherwise, the primary purpose of which is to evade, avoid or seek to avoid the performance or observance of any of the covenants, agreements or obligations of any Credit Party under the Loan Documents (including under the Collateral Documents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.3	Mergers, Acquisitions, Liquidations or Dissolutions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Merge, divide itself into two (2) or more entities, consolidate, liquidate or dissolve, or permit any of its Subsidiaries to merge, divide itself into two (2) or more entities, consolidate, liquidate or dissolve with or into any other Person, except that:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x) any Subsidiary of Borrower may merge or consolidate with or into a Credit Party, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Credit Party is the surviving entity and (y) any Subsidiary of Borrower may liquidate or dissolve, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, prior to or concurrent with such liquidation or dissolution, the remaining assets of such Subsidiary shall be distributed to another Subsidiary, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the liquidating or dissolving Subsidiary is a Credit Party, all of the assets and business of such Subsidiary shall be distributed to an existing or newly-formed Credit Party, and if the liquidating or dissolving Subsidiary is not a Credit Party, all of the assets and business of such Subsidiary are transferred to a Credit Party or another Subsidiary; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">finally</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that neither such dissolution or liquidation nor such transfer could reasonably be expected to result in a Material Adverse Change;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Subsidiary of Borrower may merge or consolidate with any other Subsidiary of Borrower, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if any party to such merger or consolidation is a Credit Party then either (x) such Credit Party is the surviving entity or (y) the surviving or resulting entity executes and delivers to the Collateral Agent a joinder to the Security Agreement in the form attached thereto, a joinder to any relevant IP Agreement, a joinder to the Intercreditor Agreement and such other Collateral Documents or other documents required under the terms of the Loan Documents or as the Collateral Agent may reasonably request, as applicable, and otherwise satisfies the requirements of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as promptly as practicable but in no event later than thirty (30) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts) following the completion of such merger or consolidation;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Subsidiary of Borrower may divide itself into two (2) or more entities or be dissolved or liquidated, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if such Subsidiary is a Credit Party, the properties and assets of such Subsidiary are allocated or distributed to an existing or newly formed or newly joined Credit Party;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[reserved]; and</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Permitted Acquisition or Permitted Investment may be structured as a merger or consolidation.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Make, or permit any of its Subsidiaries to make, Acquisitions outside the ordinary course of business, including any purchase of all or substantially all of the assets of, or any division or line of business of, any other Person, other than Permitted Acquisitions or Permitted Investments.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit any Credit Party or its Subsidiaries from entering into in-licensing agreements; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in each case no Indebtedness that is not Permitted Indebtedness hereunder is incurred or assumed in connection therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.4	Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Directly or indirectly, create, incur, assume or guaranty or otherwise become or remain liable with respect to, any Indebtedness that is not Permitted Indebtedness hereunder; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the accrual of interest, the accretion of accreted value and the payment of interest in the form of additional Indebtedness shall not be deemed to be an incurrence of Indebtedness for purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5	Encumbrances</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for Permitted Liens, (i) create, incur, allow, or suffer to exist any Lien on any Collateral, or (ii) permit (other than pursuant to the terms of the Loan Documents) any material portion of the Collateral (including, for the avoidance of doubt, any Equity Interests constituting Collateral issued by any Subsidiary which are owned or otherwise held by such Credit Party) not to be subject to the first priority security interest (subject to Permitted Liens, the limitations expressly set forth herein and the limitations expressly set forth in the other Loan Documents) granted in the Loan Documents or otherwise pursuant to the Collateral Documents, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, other than as a direct result of any action by the Collateral Agent or any Lender or failure of the Collateral Agent or any Lender to perform an obligation thereof under the Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.6	No Further Negative Pledges; Negative Pledge</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enter into any agreement, document or instrument directly or indirectly prohibiting (or having the effect of prohibiting) or limiting the ability of such Credit Party or Subsidiary to create, incur, assume or suffer to exist any Lien upon any Collateral, whether now owned or hereafter acquired, in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, with respect to the Obligations or under the Loan Documents, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, other than Permitted Negative Pledges.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 6.1 and 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no Credit Party will Transfer, or create, incur, allow or suffer to exist any Lien on, any Equity Interests constituting Collateral issued by any Subsidiary which are owned or otherwise held by such Credit Party, except for:  (i) Permitted Liens; (ii) Permitted Transfers between or among Credit Parties, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any and all steps as may be required to be taken in order to create and maintain a first priority security interest in and Lien upon (subject to Permitted Liens, the limitations expressly set forth herein and the limitations expressly set forth in the other Loan Documents) such Equity Interests in favor of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, are taken promptly, and in no event later than thirty (30) days (or such longer period as the Collateral Agent may agree in writing and in its sole discretion, taking into account reasonable good faith efforts), following the completion of any such Permitted Transfer; and (iii) sales, assignments, transfers, exchanges or other dispositions to qualify directors if required by Requirements of Law or otherwise permitted under this Agreement, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such sale, assignment, transfer, exchange or other disposition shall be for the minimum number of Equity Interests as are necessary for such qualification under Requirements of Law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link13"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.7	Maintenance of Collateral Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Maintain any Collateral Account </font><font id="ole_link14"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">except in accordance with the terms of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.8	Distributions; Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pay any dividends or make any distribution or payment on, or redeem, retire or repurchase any of its Equity Interests (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), except, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for Permitted Distributions, Permitted Transactions and Permitted Equity Derivatives.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directly or indirectly, make any Investment other than Permitted Acquisitions and Permitted Investments.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit any Credit Party or its Subsidiaries from entering into in-licensing agreements; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in each case no Indebtedness that is not Permitted Indebtedness is incurred or assumed in connection therewith.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.9	No Restrictions on Subsidiary Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Enter into any agreement, document or instrument directly or indirectly prohibiting (or having the effect of prohibiting) or limiting the ability of any Subsidiary of Borrower to (a) pay dividends or make any other distributions on any of such Subsidiary&#x2019;s Equity Interests owned by Borrower or any of its other Subsidiaries, (b) repay or prepay any Indebtedness owed by such Subsidiary to Borrower or any of its other Subsidiaries, (c) make loans or advances to Borrower or any of its other Subsidiaries, or (d) transfer, lease or license any Collateral to Borrower or any of its other Subsidiaries, except, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for Permitted Subsidiary Distribution Restrictions.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.10	Subordinated Debt; Permitted Convertible Indebtedness; Royalty Revenue Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in this Agreement:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Make or permit any voluntary or optional prepayment or repayment of the outstanding principal amount of any Subordinated Debt other than in accordance with the express terms of a subordination, intercreditor or other similar agreement relating to such Subordinated Debt, if any, that is in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Make or permit any payment of interest (including accrued and unpaid interest) in cash on or in respect of any Subordinated Debt at any time that a Default or Event of Default shall have occurred and be continuing other than in accordance with the express terms of a subordination, intercreditor or other similar agreement relating to such Subordinated Debt, if any, that is in form and substance reasonably satisfactory to the Collateral Agent;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of any Subsidiary of Borrower, create, incur or assume or otherwise become directly liable for any Subordinated Debt, or guaranty or otherwise become directly or indirectly liable for any Subordinated Debt of Borrower or any other Subsidiary of Borrower, unless such Subsidiary of Borrower is a Credit Party;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amend, restate, supplement or otherwise modify any terms, conditions or other provisions of any Subordinated Debt, or any agreement, instrument or other document relating thereto, in any manner which would contravene in any respect any of the foregoing clauses of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or adversely affect the payment or priority subordination thereof (as applicable) to Obligations owed to Lenders, in each case except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt, if any, is subject, without the prior written consent of the Collateral Agent (in its sole discretion).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Make or permit (or exercise any option with respect thereto), directly or indirectly, any payment, prepayment, repurchase or redemption for cash of any Permitted Convertible Indebtedness, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that nothing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall prohibit or otherwise restrict (i) any Permitted Transaction, (ii) scheduled cash interest payments, (iii) required cash payments of accrued but unpaid interest upon repurchase, redemption or conversion thereof, (iv) cash payments in lieu of any fractional share issuable upon conversion thereof, or (v) any ordinary course fees or other expenses in connection therewith.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amend, restate, supplement, modify or replace, or renew or alter, including pursuant to any waiver, consent or approval, any terms, conditions or other provisions of the Royalty Revenue Contract or any other Royalty Revenue Document as in effect on the Tranche A Closing Date in any manner which would: (i) change the calculation or time of any payment to Royalty Pharma pursuant thereto, including any change to the basis or manner for calculating any late or overdue payments (including any fees or interest payments thereon), (ii) change any of the terms of the RPI Obligations (as such term is defined in the Intercreditor Agreement as in effect on the Tranche A Closing Date), in each case other than in a manner consistent with such RPI Obligations set forth in the Royalty Revenue Contract as in effect as of the Tranche A Closing Date, including any change to obligate Borrower or any of its Subsidiaries to make any payment to Royalty Pharma with respect to such RPI Obligations: (x) relating to the occurrence of a change of control of Borrower or the termination of the Royalty Revenue Contract or any other Royalty Revenue Document, (y) in advance of the time when any such payments are due and payable under the Royalty Revenue Contract as in effect as of the Tranche A Closing Date, including any advance payment or</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prepayment, or (z) in a minimum amount to be paid upon the occurrence (or non-occurrence) of certain events or conditions, including a &#x201c;true up&#x201d; payment that is payable if a specified amount of royalty payments are not received by Royalty Pharma, as applicable, by a specified date (it being understood and agreed that the royalty payments under the Royalty Revenue Contract as in effect as of the Tranche A Closing Date do not include the payment features described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (x)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(z)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above), (iii) contravene in any respect any of the terms or conditions set forth in this Agreement (including </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (g)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below) or any other Loan Document (including the Intercreditor Agreement) or (iv) adversely affect the payment or priority subordination set forth in the Intercreditor Agreement to the Obligations owed to Lenders, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> other than to the extent not prohibited by the Intercreditor Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Make or cause any of its Subsidiaries to make (or exercise any option with respect thereto), directly or indirectly, any payment or reimbursement of any kind to Royalty Pharma pursuant to the Royalty Revenue Contract or other Royalty Revenue Document, in each case except for: (i) any payments due and payable to Royalty Pharma pursuant to the Royalty Revenue Contract or other Royalty Revenue Document as in effect as of the Tranche A Closing Date and taking into account any restatement, amendment and restatement, supplement or modification thereto or any approval, consent or waiver in respect thereof, permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, but excluding in all cases: (w) any advance payment before such payment is due and payable, including any payment based on a change of control of Borrower or to purchase or repurchase any interests, rights or benefits of Royalty Pharma under the Royalty Revenue Contract, (x) any prepayment of any of the royalty payments or similar payments owed under the Royalty Revenue Contract or any other Royalty Revenue Document, (y) any minimum amount to be paid upon the occurrence (or non-occurrence) of certain events or conditions, including any payment resulting from or otherwise in connection with the termination of the Royalty Revenue Contract or any &#x201c;true up&#x201d; payment that is payable if a specified amount of royalty payments are not received by Royalty Pharma by a specified date (it being understood and agreed that the royalty payments due and payable under the Royalty Revenue Contract as in effect as of the Tranche A Closing Date do not include the payment features described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (w)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above), in each case only so long as paid when due and payable under the Royalty Revenue Contract as in effect as of the Tranche A Closing Date, or (z) any other payment that Borrower has the right, but not the obligation, to make pursuant to the Royalty Revenue Contract or other Royalty Revenue Document (if any) or that Borrower agrees to make pursuant to any amendment, restatement, amendment and restatement, supplement or modification thereto or any approval, consent or waiver in respect thereof; (ii) any indemnity payment due and payable to Royalty Pharma pursuant to the Royalty Revenue Contract or other Royalty Revenue Document as in effect as of the Tranche A Closing Date, or (iii) any expenses, late fees or interest payments due and payable to Royalty Pharma pursuant to (and calculated in accordance with) the Royalty Revenue Contract or other Royalty Revenue Document as in effect as of the Tranche A Closing Date relating directly to any underpayment of any of the foregoing in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.11	Amendments or Waivers of Organizational Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Amend, restate, supplement or otherwise modify, or waive, any provision of its Operating Documents in a manner that would reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.12	Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Become an &#x201c;investment company&#x201d; under the Investment Company Act of 1940, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to any ERISA Affiliate, cause or suffer to exist (i) any event that would result in the imposition of a Lien under ERISA on any assets or properties of any Credit Party or a Subsidiary of a Credit Party with respect to any Plan or (ii) any other ERISA Event that, in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, could reasonably be expected to, individually or in the aggregate, result in a Material Adverse Change; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permit the occurrence of any other event with respect to any present pension, profit sharing or deferred compensation plan which could reasonably be expected to result in a Material Adverse Change.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.13	Compliance with Sanctions and Anti-Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Collateral Agent and each Lender hereby notifies each Credit Party that pursuant to the requirements of Sanctions and Anti-Money Laundering Laws, and such Person&#x2019;s policies and practices, the Collateral Agent and each Lender is required to obtain, verify and record certain information and documentation that identifies each Credit Party and its principals, which information includes the name and address of each Credit Party and its principals and such other information that will allow the Collateral Agent and each Lender to identify such party in accordance with Sanctions and Anti-Money Laundering Laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Credit Party will, nor will any Credit Party permit any of its Subsidiaries or controlled Affiliates to, directly or indirectly, enter into any documents or contracts with any Blocked Person.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each Credit Party shall notify the Collateral Agent and each Lender in writing promptly (but in any event within three (3) Business Days) upon any Responsible Officer of any Credit Party becoming aware that any Credit Party or any Subsidiary or Affiliate of any Credit Party is a Blocked Person or Credit Party or any Subsidiary or Affiliate of any Credit Party or any of their respective directors, officers or employees is (i) is convicted on, (ii) pleads nolo contendere to, (iii) is indicted on, or (iv) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Credit Party will, nor will any Credit Party permit any of its Subsidiaries or controlled Affiliates to, directly or indirectly, (i) conduct any prohibited business or engage in any prohibited investment, activity, transaction or dealing with any Blocked Person, including the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any investment, activity, transaction or dealing relating to, any property or interests in property blocked pursuant to Sanctions, or (iii) engage in or conspire to engage in any investment, activity, transaction or dealing that evades or avoids or violates, or has the purpose of evading or avoiding, or attempts to violate, any prohibitions under Sanctions or applicable Anti-Money Laundering Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower will not, directly or, to the Knowledge of Borrower, indirectly (including through an agent or any other Person), use any of the proceeds of any Credit Extension, or lend, contribute or otherwise make available such proceeds of any Credit Extension to any Subsidiary, joint venture partner or other Person, (i) for any payments to any government official or employee, political party, official of a political party, candidate for political office or anyone else, in order to obtain, retain or direct business, or to obtain any improper advantage, in violation in any respect of Anti-Corruption Laws, (ii) in violation in any respect of any Anti-Money Laundering Laws, (iii) in violation of Sanctions or (iv) in violation of Export or Import Laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower shall not, and shall not permit any of its Subsidiaries to, directly or, to the Knowledge of Borrower, indirectly, fund all or part of any repayment of the Credit Extensions or other payments under this Agreement out of proceeds derived from criminal activity or activity or transactions in violation in any respect of Anti- Corruption Laws, Export or Import Laws, Anti-Money Laundering Laws or Sanctions, or that would otherwise cause any Person (including any Person participating in the Credit Extensions, whether as agent, lender, sponsor, underwriter, advisor, investor, or otherwise) to be in violation in any respect of Anti-Corruption Laws, Export or Import Laws, Anti-Money Laundering Laws or Sanctions.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.14	Material Contracts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Waive, amend, cancel or terminate, exercise or fail to exercise, any rights constituting or relating to any of the Material Contracts or (ii) breach, default under, or take any action or fail to take any action that, with the passage of time or the giving of notice or both, would constitute a default or event of default under any of the Material Contracts, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which, individually or taken together with any other such waivers, amendments, cancellations, terminations, exercises or failures, could reasonably be expected to have a Material Adverse Change.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From and after the Tranche A Closing Date, enter into any Manufacturing Agreement (excluding, for the avoidance of doubt, any Manufacturing Agreement listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and all amendments, restatements, amendment and restatements, extensions, supplements or other modifications thereto) relating to active pharmaceutical ingredients or finished products relating to RYTELO&#153; (i) that cannot be collaterally assigned to secure the Obligations, (ii) that cannot be assigned to a purchaser in a foreclosure sale of all or any portion of the Collateral (subject to assumption by the purchaser of all obligations under such Material Contract) in the event of any exercise of rights or remedies under the Loan Documents, or (iii) that contains provisions that restrict or penalize the granting of a security interest in or Lien on such Material Contract or the assignment of such Material Contract upon the sale or other disposition of all or a portion of a product to which such Material Contract relates, in each case without using its commercially reasonable efforts to ensure such Manufacturing Agreement does not contain the terms listed in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EVENTS OF DEFAULT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any one of the following shall constitute an event of default (an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) under this Agreement:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.1	Payment Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any Credit Party fails to (a) make any payment of any principal of the Term Loans when and as the same shall become due and payable, whether at the due date thereof (including pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or at a date fixed for prepayment (whether voluntary or mandatory) thereof or by acceleration thereof or otherwise, or (b) within [***] after the same becomes due and payable, any payment of interest or premium pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including any applicable Additional Consideration, Makewhole Amount or Prepayment Premium, (which such five (5) Business Day cure period shall not apply to any such payments due on the Term Loan Maturity Date or such earlier date pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(i),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof or the date of acceleration pursuant to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof).  A failure to pay any such interest, premium or Obligations pursuant to the foregoing </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> prior to the end of such five (5) Business Day-period shall not constitute an Event of Default (unless such payment is due on the Term Loan Maturity Date or such earlier date pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(i),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof or the date of acceleration pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.2	Covenant Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Parties: (i) fail or neglect to perform any obligation in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.14,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or (ii) violate or breach any covenant or agreement in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Parties fail or neglect to perform any obligation in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.17</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, in the case where such failure or neglect is capable of being cured such failure or neglect continues for ten (10) days after the earlier of the date on which (i) a Responsible Officer of any Credit Party becomes aware of such failure or neglect and (ii) written notice thereof shall have been delivered to Borrower by the Collateral Agent or any Lender.  Cure periods provided under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply, among other things, to any of the covenants referenced in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Credit Parties fail or neglect to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents on its part to be performed, kept or observed and, where such failure or neglect is capable of being cured such failure or neglect continues for twenty (20) days after the earlier of the date on which (i) a Responsible Officer of any Credit Party becomes aware of such failure or neglect and (ii) written notice thereof shall have been delivered to Borrower by the Collateral Agent or any Lender.  Cure periods provided under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply, among other things, to any of the covenants referenced in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.3	Withdrawal Event; Material Adverse Change; </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  A (a) Withdrawal Event occurs with respect to RYTELO&#153;, or (b) a Material Adverse Change occurs.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.4	Attachment; Levy; Restraint on Business</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) The service of process seeking to attach, by trustee or similar process, any funds of any Credit Party or of any entity under the control of any Credit Party (including a Subsidiary) in excess of [***] on deposit or otherwise maintained with the Collateral Agent, or (ii) a notice of Lien or levy is filed against any material portion of Collateral by any Governmental Authority, and the same under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof are not, within</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thirty (30) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no Credit Extensions shall be made during any thirty (30) day cure period; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i) Any material portion of Collateral is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower and its Subsidiaries from conducting any material part of their business, taken as a whole.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.5	Insolvency</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking:  (i) relief in respect of any Credit Party, or of a substantial part of the property of any Credit Party, under Title 11 of the United States Code, as now constituted or hereafter amended, or any other federal, state or foreign bankruptcy, insolvency, receivership or other similar law; (ii) the voluntary or involuntary appointment of a receiver, interim receiver, receiver and manager, administrative receiver, administrator, trustee, custodian, sequestrator, conservator or other similar official for or in respect of any Credit Party or for all or a substantial part of the property or assets or undertakings of any Credit Party; (iii) issuance of a warrant of attachment, execution, distraint or similar process against all or a substantial part of the property or assets or undertakings of any Credit Party; or (iv) the winding-up or liquidation of any Credit Party; and in each case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, such proceeding or petition shall continue undismissed or unstayed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall be entered;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Credit Party shall:  (i) voluntarily commence any proceeding or file any petition seeking relief under Title 11 of the United States Code, as now constituted or hereafter amended, or any other existing or future federal, state or foreign bankruptcy, insolvency, receivership, relief of debtors or similar law; (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or the filing of any petition described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above; (iii) apply for or consent to the appointment of a receiver, interim receiver, receiver and manager, administrative receiver, administrator, trustee, custodian, sequestrator, conservator or other similar official for or in respect of any Credit Party or for any portion of the property or assets or undertakings of any Credit Party; (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding; (v) make a general assignment for the benefit of creditors, or enter into a composition, compromise, assignment or arrangement with any of its creditors (whether by way of a voluntary arrangement, schedule of arrangement, deed of compromise or otherwise); (vi) become unable to, admit in writing its inability to or fail to, generally pay its debts as they become due; (vii) take any action for the purpose of effecting any of the foregoing; or (viii) wind up or liquidate (except as otherwise expressly permitted hereunder);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Credit Party shall be insolvent as defined in any statute of the Bankruptcy Code or in the fraudulent conveyance or fraudulent transfer statutes of the State of Delaware or other applicable jurisdiction of organization; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An affirmative vote by the applicable Board of Directors to commence any case, proceeding or other action described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above or any other action by any Credit Party to otherwise cause, consent to, approve or acquiesce in any of the acts described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.6	Other Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any Credit Party or any of its Subsidiaries fails to pay any Indebtedness (other than the Indebtedness represented by this Agreement and the other Loan Documents) within any applicable grace period after such payment is due and payable (including at final maturity) or after the acceleration of any such Indebtedness by the holder(s) thereof because of a default, in each case, if the total amount of such Indebtedness unpaid or accelerated exceeds [***] (except, in each case, to the extent such failure is in compliance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Without limiting the generality of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, an event of default occurs under any Hedging Agreement as to which any Credit Party or any of its Subsidiaries is the defaulting party or any termination event occurs under any Hedging Agreement as to which any Credit Party or any of its Subsidiaries is a party, in either</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">case if, in respect of such Hedging Agreement and as a result of such occurrence, the Hedge Termination Value owed by any such Credit Party or Subsidiary is greater than [***];</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower fails to timely pay, in accordance with the terms and conditions of the Royalty Revenue Contract, after the same becomes due, any amount owing under the Royalty Revenue Contract or any other Royalty Revenue Document, unless: (x) such payment is not subject to an Adverse Proceeding that has been commenced or brought by Royalty Pharma against the Borrower; or (y) the amount of such payment, individually or when aggregated with any other amounts due under the Royalty Revenue Contract or any other Royalty Revenue Document and unpaid, is less than [***]; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower makes, directly or indirectly, any payment, prepayment, repurchase, redemption, conversion, exchange or similar action of any Permitted Convertible Indebtedness that is neither a Permitted Transaction nor otherwise expressly permitted under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.7	Judgments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  One or more final, non-appealable judgments, orders, or decrees for the payment of money in an amount in excess of [***] (but excluding any final judgments, orders, or decrees for the payment of money, in each case that is covered by a policy from an independent third-party insurance carrier as to which such insurance carrier has not excluded or denied liability or by an indemnification claim against a solvent and unaffiliated Person that is not a Credit Party or a Subsidiary of a Credit Party as to which such Person has not denied liability for such claim), shall be rendered against one or more Credit Parties and the same are not, within thirty (30) days after the entry thereof, discharged or execution thereof stayed or bonded pending appeal, or such judgments are not discharged prior to the expiration of any such stay.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.8	Misrepresentations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any Credit Party or any Person acting for any Credit Party makes or is deemed to make any representation, warranty, or other statement now or later in this Agreement, any other Loan Document or in any writing delivered to the Collateral Agent or any Lender or to induce the Collateral Agent or any Lender to enter this Agreement or any other Loan Document, and such representation, warranty, or other statement is incorrect in any material respect (or, to the extent any such representation, warranty or other statement is qualified by materiality or Material Adverse Change, in any respect) when made or deemed to be made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.9	Loan Documents; Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any material provision of any Loan Document shall for any reason cease to be valid and binding on or enforceable against any Credit Party, or any Credit Party shall so state in writing or bring an action to limit its obligations or liabilities thereunder; or any Collateral Document shall for any reason (other than pursuant to or as expressly permitted by the terms thereof) cease to create a valid security interest in any material portion of the Collateral purported to be covered thereby or such security interest shall for any reason (other than pursuant to the terms of the Loan Documents) cease to be a perfected and first priority security interest in any material portion of the Collateral subject thereto, subject only to Permitted Liens, in each case, other than as a direct result of any action by the Collateral Agent or any Lender or failure of the Collateral Agent or any Lender to perform an obligation thereof under the Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.10	ERISA Event</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  An ERISA Event occurs that, individually or taken together with any other ERISA Events, results or could reasonably be expected to result in a Material Adverse Change or the imposition of a Lien under Section 303(k) of ERISA on any Collateral that, individually or taken together with any other such Liens, could reasonably be expected to result in a Material Adverse Change.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.11	Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  (i) A default or breach occurs under the Intercreditor Agreement, or any other subordination, intercreditor or other similar agreement with respect to any Permitted Indebtedness that constitutes Subordinated Debt or Permitted Convertible Indebtedness or (ii) any creditor party to such an agreement with the Collateral Agent (or Lenders) and any Credit Party breaches any of the terms of such agreement, in each case of clauses (i) and (ii) to the extent such breach or default results or could reasonably be expected to result in a Material</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse Change.  For the avoidance of doubt, default or breaches by any Secured Party shall not constitute an Event of Default hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RIGHTS AND REMEDIES UPON AN EVENT OF DEFAULT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.1	Rights and Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  While an Event of Default occurs and continues, the Collateral Agent may, or at the request of the Required Lenders, will, without notice or demand:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">declare all Obligations (including, for the avoidance of doubt, any and all amounts payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable) immediately due and payable (but if an Event of Default described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> occurs, all Obligations, including any and all amounts payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable, are automatically and immediately due and payable without any notice, demand or other action by the Collateral Agent or any Lender), whereupon all Obligations for principal, interest, premium or otherwise (including, for the avoidance of doubt, any and all amounts payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable) shall become due and payable by Borrower without presentment for payment, demand, notice of protest or other demand or notice of any kind, which are all expressly waived by the Credit Parties hereby;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stop advancing money or extending credit for Borrower&#x2019;s benefit under this Agreement;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that the Collateral Agent considers advisable, notify any Person owing Borrower money of the Collateral Agent&#x2019;s security interest, for the benefit of the Lenders and the other Secured Parties, in such funds, and verify the amount of the Collateral Accounts;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">make any payments and do any acts it considers necessary or reasonable to protect the Collateral or the Collateral Agent&#x2019;s security interest, for the benefit of Lenders and the other Secured Parties, in the Collateral.  Borrower shall assemble the Collateral if the Collateral Agent or the Required Lenders requests and make it available as the Collateral Agent designates or the Required Lenders designate.  The Collateral Agent or its agents or representatives may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien that appears to be prior or superior to its security interest, for the benefit of Lenders and the other Secured Parties, and pay all expenses incurred.  Borrower grants the Collateral Agent an irrevocable, royalty-free license or other right to enter, use, operate and occupy (and for its agents or representatives to enter, use, operate and occupy), without charge, any such premises to exercise any of the Collateral Agent&#x2019;s or any Lender&#x2019;s rights or remedies under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, advertise for sale, sell, assign, license out, convey, transfer or grant options to purchase any Collateral);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">apply to the Obligations (i) any balances and deposits of Borrower it holds, (ii) any amount held by the Collateral Agent owing to or for the credit or the account of Borrower or (iii) any balance from any Collateral Account of any Credit Party or instruct the bank at which any such Collateral Account is maintained to pay the balance of any such Collateral Account to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, or to any Lender on behalf of itself and the other Secured Parties, as the Collateral Agent shall direct;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral.  With respect to any and all Intellectual Property owned or held by any Credit Party and included in Collateral, each Credit Party hereby grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, to the maximum extent permitted: an irrevocable, non-exclusive, assignable, royalty-free license or other right to use (and for its agents or representatives to use), without charge, including the right to sublicense, use and practice, any and all of such Credit Party&#x2019;s rights to such Intellectual Property in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, advertise for sale, sell, assign, license out, convey, transfer or grant options to purchase any Collateral, and access to all media in which any of the licensed items may be recorded or stored and to all Software and programs used for the compilation or printout thereof; and in connection with the Collateral Agent&#x2019;s exercise of its rights or remedies under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (including in order to take possession of, collect, receive, assemble, process, appropriate, remove, realize upon, sell, assign, license out, convey, transfer or grant options to purchase any Collateral), each Credit Party&#x2019;s rights under all licenses and all franchise contracts inure to the benefit of all Secured Parties;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">place a &#x201c;hold&#x201d; on any account maintained with the Collateral Agent or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demand and receive possession of the Books of any Credit Party regarding Collateral; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exercise all rights and remedies available to the Collateral Agent or any Lender under the Collateral Documents or any other Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the Collateral Agent and Lender agrees that in connection with any foreclosure or other exercise of rights under this Agreement or any other Loan Document with respect to any Intellectual Property included in the Collateral, the rights of the licensees under any license of such Intellectual Property will not be terminated, limited or otherwise adversely affected so long as no default exists thereunder in a way that would permit the licensor to terminate such license (commonly termed a non-disturbance).  Without limitation to any other provision herein or in any other Loan Document, while an Event of Default occurs and continues, at the Collateral Agent&#x2019;s or the Required Lenders&#x2019; request, representatives from Borrower and the Collateral Agent shall promptly meet (in person or telephonically) to discuss in good faith how to collect, receive, appropriate and realize upon Borrower&#x2019;s rights and interests in, to and under any Company IP Agreement, including in connection with any foreclosure or other exercise of the Collateral Agent&#x2019;s or any Lender&#x2019;s rights with respect thereto.  If Borrower and the Collateral Agent do not mutually agree with respect thereto within ten (10) Business Days after such request by the Collateral Agent, then the Collateral Agent may request Borrower to, and Borrower (promptly following the receipt of such request) shall, use reasonable best efforts to obtain the written consent of any counterparty to the exercise by the Collateral Agent or any Lender of any and all rights and remedies under this Agreement or any other Loan Document with respect to any Company IP Agreement, in form and substance reasonably satisfactory to the Collateral Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.2	Power of Attorney</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower hereby irrevocably appoints the Collateral Agent and any Related Party thereof as its lawful attorney-in-fact, exercisable solely upon the occurrence and during the continuance of an Event of Default, to:  (a) endorse Borrower&#x2019;s name on any checks or other forms of payment or security; (b) sign Borrower&#x2019;s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Collateral Accounts directly with depository banks where the Collateral Accounts are maintained, for amounts and on terms the Collateral Agent determines reasonable; (d) make, settle, and adjust all claims under Borrower&#x2019;s products liability or general liability insurance policies maintained in any jurisdiction regarding Collateral; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of the Collateral Agent or a third-party as the Code permits.  Borrower hereby appoints the Collateral Agent and any Related Party thereof as its lawful attorney-in-fact solely to file or record any documents necessary to perfect or continue the perfection of the Collateral Agent&#x2019;s security interest, for the benefit of Lenders and the other Secured Parties, in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted) have been satisfied in full and no Lender is under any further obligation to make Credit Extensions hereunder.  The foregoing appointment of the Collateral Agent and any Related Party thereof as Borrower&#x2019;s attorney in fact, and all of the Collateral Agent&#x2019;s (or such Related Party&#x2019;s) rights and powers, coupled with an interest, are irrevocable until all Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted) have been fully repaid and performed and each Lender&#x2019;s obligation to provide Credit Extensions terminates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.3	Application of Payments and Proceeds Upon Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If an Event of Default has occurred and is continuing, the Collateral Agent shall apply any funds in its possession, whether from Borrower account balances, payments, proceeds realized as the result of any collection of Collateral Accounts or disposition of any other Collateral, or otherwise, to the Obligations in such order as the Collateral Agent shall determine in its sole discretion.  Any surplus shall be paid to Borrower or other Persons legally entitled thereto; Borrower shall remain liable to Lenders for any deficiency.  If the Collateral Agent or any Lender directly or indirectly enters into a deferred payment or other credit transaction with any purchaser at any sale of Collateral, the Collateral Agent or such Lender, as applicable, shall have</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the option, exercisable at any time, of either reducing the Obligations by the principal amount of the purchase price or deferring the reduction of the Obligations until the actual receipt by the applicable Lender(s) of cash therefor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.4	Collateral Agent&#x2019;s Liability for Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  So long as the Collateral Agent complies with Requirements of Law regarding the safekeeping of the Collateral in the possession or under the control of the Collateral Agent and absent bad faith, gross negligence or willful misconduct of the Collateral Agent (as determined by a court of competent jurisdiction by final and nonappealable judgment), the Collateral Agent shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; or (c) any act or default of any other Person.  In no event shall the Collateral Agent or any Lender have any liability for any diminution in the value of the Collateral for any reason except as a result of the Collateral Agent&#x2019;s bad faith, gross negligence or willful misconduct (as determined by a court of competent jurisdiction by final and nonappealable judgment).  Subject to the forgoing, Borrower bears all risk of loss, damage or destruction of the Collateral.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.5	No Waiver; Remedies Cumulative</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent&#x2019;s or any Lender&#x2019;s failure, at any time or times, to require strict performance by Borrower or any other Person of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of the Collateral Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith.  No waiver hereunder shall be effective unless signed by the party granting the waiver and then is only effective for the specific instance and purpose for which it is given.  Each of the Collateral Agent&#x2019;s and Lender&#x2019;s rights and remedies under this Agreement and the other Loan Documents are cumulative.  Each of the Collateral Agent and Lenders has all rights and remedies provided under the Code, by law, or in equity.  The exercise by the Collateral Agent or any Lender of one right or remedy is not an election and shall not preclude the Collateral Agent or any Lender from exercising any other remedy under this Agreement or other remedy available at law or in equity, and the waiver by the Collateral Agent or any Lender of any Event of Default is not a continuing waiver.  The Collateral Agent&#x2019;s or any Lender&#x2019;s delay in exercising any remedy is not a waiver, election, or acquiescence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.6	Demand Waiver; Makewhole Amount; Prepayment Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by the Collateral Agent on which Borrower is liable.  Borrower acknowledges and agrees that if the Obligations shall be or are prepaid pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or the maturity of all Obligations shall be accelerated pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by reason of the occurrence of an Event of Default, the applicable Makewhole Amount and Prepayment Premium that is payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable, as well as any accrued Additional Consideration that is payable pursuant to the ultimate paragraph of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall become due and payable by Borrower upon such prepayment, whether such prepayment is voluntary or mandatory, as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or acceleration, whether in the case of acceleration such acceleration is automatic or is effected by the Collateral Agent&#x2019;s or any Lender&#x2019;s declaration thereof, as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and shall also become due and payable in the event the Obligations are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other similar means, and Borrower shall pay the applicable Makewhole Amount and Prepayment Premium that is payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(e)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as applicable, as well as any accrued Additional Consideration that is payable pursuant to the ultimate paragraph of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as compensation to Lenders for the loss of its investment opportunity and not as a penalty, and Borrower waives any right to object thereto in any voluntary or involuntary bankruptcy, insolvency or similar proceeding or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTICES</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All notices, consents, requests, approvals, demands, or other communication by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, or email address (if any) indicated below.  Any party to this Agreement may change its mailing or electronic mail address by giving all other parties hereto written notice thereof in accordance with the terms of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Borrower or any other Credit Party:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation<br>919 East Hillsdale Boulevard</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 250</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foster City, CA 94404<br>Attn:	Chief Executive Officer</font></p>
  <p style="margin-left:33.333%;text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Financial Officer<br>Email:	[***]</font></p>
  <p style="margin-left:33.333%;text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="margin-left:33.333%;text-indent:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with copies to (which shall not constitute notice) to:</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation<br>919 East Hillsdale Boulevard</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Suite 250</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foster City, CA 94404</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn:  Chief Legal Officer<br>Email:  [***]</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley LLP</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3 Embarcadero Center</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20th Floor</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Francisco, CA 94111-4004</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attn:  Mischi a Marca <br>Email: [***]</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-30%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to Collateral Agent:	BioPharma Credit PLC<br>c/o Company Matters Ltd.</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Central Square</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29 Wellington Street</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leeds</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LS1 4DL</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom<br>Attn:  Company Secretary<br>Tel:  [***]<br>Email:  [***]</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy to (which shall not constitute notice) to:</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmakon Advisors, LP<br>110 East 59th Street, #2800<br>New York, NY 10022<br>Attn:  Pedro Gonzalez de Cosio<br>Phone: [***]<br>Email:  [***]</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Akin Gump Strauss Hauer &amp; Feld LLP<br>One Bryant Park<br>New York, NY 10036-6745<br>Attn:  Geoffrey E. Secol<br>Phone:  [***]<br>Email:  [***]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;text-indent:-30%;padding-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to any Lender:	To the address of such Lender set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with a copy to (which shall not constitute notice) to:</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmakon Advisors, LP<br>110 East 59th Street, #2800</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, NY 10022<br>Attn:  Pedro Gonzalez de Cosio<br>Phone: [***]<br>Email:  [***]</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="margin-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Akin Gump Strauss Hauer &amp; Feld LLP<br>One Bryant Park<br>New York, NY 10036-6745<br>Attn:  Geoffrey E. Secol<br>Phone:  [***]<br>Email:  [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CHOICE OF LAW, VENUE, AND JURY TRIAL WAIVER</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (EXCLUDING THOSE LOAN DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION) SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING THE ENFORCEMENT OF ANY LIENS IN COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.  Each party hereto submits to the exclusive jurisdiction of the courts of the State of New York sitting in New York County, and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, and agrees that all claims in respect of any such action, litigation or proceeding may be heard and determined in such New York State court or, to the fullest extent permitted by Requirements of Law, in such Federal court; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that nothing in this Agreement shall be deemed to operate to preclude the Collateral Agent or any Lender from bringing suit or taking other legal action in any other jurisdiction to realize on the Collateral or any other security for the Obligations, or to enforce a judgment or other court order in favor of the Collateral Agent or any Lender.  Each Credit Party expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and each Credit Party hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">forum non conveniens</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and hereby consents to the granting of such legal or equitable relief as is deemed appropriate by such court.  Each Credit Party hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to such party at the address set forth in (or otherwise provided in accordance with the terms of) </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of this Agreement and that service so made shall be deemed completed upon the earlier to occur of such party&#x2019;s actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TO THE FULLEST EXTENT PERMITTED BY REQUIREMENTS OF LAW, EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ITS RIGHT TO A JURY TRIAL IN ANY CLAIM, SUIT, ACTION OR PROCEEDING WITH RESPECT TO, OR DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH, THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREIN AND THEREIN OR RELATED HERETO OR THERETO (WHETHER FOUNDED IN CONTRACT, TORT OR ANY OTHER THEORY).  EACH PARTY HERETO (A) CERTIFIES THAT NO OTHER PARTY AND NO RELATED PARTY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 10</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AND (C) HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GENERAL PROVISIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.1	Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement binds and is for the benefit of the parties hereto and their respective successors and permitted assigns.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Credit Party may transfer, pledge or assign this Agreement or any other Loan Document or any rights or obligations hereunder or thereunder without the prior written consent of each Lender.  Subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any Lender may at any time sell, transfer, assign or pledge this Agreement or any other Loan Document or any of its rights or obligations hereunder or thereunder, or grant a participation in all or any part of, or any interest in, such Lender&#x2019;s obligations, rights or benefits under this Agreement and the other Loan Documents, including with respect to any Term Loan (or any portion thereof), to any other Lender, any Affiliate of any Lender or any third Person without Borrower&#x2019;s consent(any such sale, transfer, assignment, pledge or grant of a participation, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including, for the avoidance of doubt, in furtherance of, as contemplated under or otherwise in connection with any Lender&#x2019;s credit facility (including any exercise of rights or remedies thereunder or any actions as a result of any such exercise); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no Lender may make a Lender Transfer to a Disqualified Assignee without Borrower&#x2019;s prior written consent except after the occurrence and during the continuance of an Event of Default (in which case such consent is not required).</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the case of a Lender Transfer in the form of a participation granted by any Lender to any third Person, (i) such Lender&#x2019;s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of its obligations hereunder, (iii) Borrower shall continue to deal solely and directly with such Lender in connection with such Lender&#x2019;s rights and obligations under this Agreement and (iv) any agreement or instrument pursuant to which such Lender sells such participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, restatement, amendment and restatement, supplement or other modification hereto, in each case subject to the terms and conditions of this Agreement.  Borrower agrees that each participant shall be entitled to the benefits of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 2.5 and 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (subject to the requirements and limitations therein, including the requirements under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (it being understood that the documentation required under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be delivered to the applicable Lender)) to the same extent as if it were a Person that had acquired its interest by assignment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, with respect to any participation, such participant shall not be entitled to receive any greater payment under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sections 2.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> than the applicable Lender (i.e., the party that participated the interest) would have been entitled to receive, except to the extent of any entitlement to receive a greater payment resulting from a Change in Law that occurs after such participant acquired the applicable participation.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower shall record any Lender Transfer in the Note Register.  Each Lender shall provide Borrower and the Collateral Agent with written notice of a Lender Transfer delivered no later than [***] (or immediately if known fewer than [***]) prior to the date on which such Lender Transfer is proposed to be consummated.  If any Lender sells a participation, such Lender shall, acting solely for this purpose as a non-fiduciary agent of Borrower, maintain a register on which it enters the name and address of each participant and principal amounts (and stated interest) of each participant&#x2019;s interest in the Term Loans or other obligations under the Loan Documents (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such Lender shall have no obligation to disclose all or any portion of the Participant Register (including the identity of any participant or any information relating to a participant&#x2019;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in &#x201c;registered form&#x201d; within the meaning of Section 5f.103-1(c) of the United States Treasury regulations (or any amended or successor version) or Section 163(f), 871(h)(2) and 881(c)(2) of the IRC and any related regulations (and any other relevant or successor provisions of the IRC or such regulations).  The entries in the Participant Register shall be conclusive absent manifest error, and the Collateral Agent and each Lender shall treat</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any attempted transfer, pledge or assignment of this Agreement or any other Loan Document or any rights or obligations hereunder or thereunder in violation of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be null and void.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.2	Indemnification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower agrees to indemnify and hold harmless each of the Collateral Agent, Lenders and its and their respective Affiliates (and its or their respective successors and assigns) and each manager, member, partner, controlling Person, director, officer, employee, agent or sub-agent, advisor and affiliate thereof (each such Person, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from and against any and all Indemnified Liabilities; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Borrower shall have no obligation to any Indemnified Person hereunder with respect to any Indemnified Liabilities to the extent such Indemnified Liabilities (i) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the bad faith, gross negligence or willful misconduct of such Indemnified Person (or the bad faith, gross negligence or willful misconduct of such Indemnified Person&#x2019;s affiliates or controlling Persons or any of their respective managers, members, partners, controlling Persons, directors, officers, employees, agents or sub-agents, advisors or affiliates), (ii) result from a claim brought by Borrower against an Indemnified Person for material breach in bad faith of any of such Indemnified Person&#x2019;s obligations hereunder or under any other Loan Document, if Borrower has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction, or (iii) result from a claim not involving an act or omission of Borrower or any of its Subsidiaries that is brought by an Indemnified Person against another Indemnified Person (other than against the Collateral Agent or the Intercreditor Agent in their capacities as such).  This </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply with respect to Taxes other than any Taxes that represent liabilities, obligations, losses, damages, penalties, claims, costs, expenses and disbursements arising from any non-Tax claim.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent permitted by Requirements of Law, no party to this Agreement shall assert, and each party to this Agreement hereby waives, any claim against any other party hereto (and its or their successors and assigns), and each manager, member, partner, controlling Person, director, officer, employee, agent or sub-agent, advisor and affiliate thereof, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) (whether or not the claim therefor is based on contract, tort or duty imposed by any applicable legal requirement) arising out of, in connection with, arising out of, as a result of, or in any way related to, this Agreement or any Loan Document or any agreement or instrument contemplated hereby or thereby or referred to herein or therein, the transactions contemplated hereby or thereby, any Credit Extension or the use of the proceeds thereof or any act or omission or event occurring in connection therewith, and each party to this Agreement hereby waives, releases and agrees not to sue upon any such claim or any such damages, whether or not accrued and whether or not known or suspected to exist in its favor.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any action taken by any Credit Party under or with respect to any Loan Document (including, for the avoidance of doubt, the Intercreditor Agreement), even if required under any Loan Document (including, for the avoidance of doubt, the Intercreditor Agreement), or at the request of the Collateral Agent (including in its capacity as Intercreditor Agent under the Intercreditor Agreement) or any Lender, shall be at the expense of such Credit Party, and neither the Collateral Agent (including in its capacity as Intercreditor Agent under the Intercreditor Agreement) nor any Secured Party shall be required under any Loan Document (including, for the avoidance of doubt, the Intercreditor Agreement) to reimburse any Credit Party or any Subsidiary of any Credit Party therefor except as expressly provided therein.  In addition, and without limiting the generality of Section 2.4, Borrower agrees to pay or reimburse upon demand each of the Collateral Agent (including in its capacity as Intercreditor Agent under the Intercreditor Agreement) and Lenders (and their respective successors and assigns) and each of their respective Related Parties, if applicable, for any and all fees, expenses and disbursements of the kind or nature described in clause (b) of the definition of &#x201c;Lender Expenses&#x201d; or in the definition of &#x201c;Indemnified Liabilities&#x201d; incurred by it.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.3	Severability of Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In case any provision in or obligation hereunder or under any other Loan Document shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.4	Correction of Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent or Required Lenders may correct patent errors and fill in any blanks in the Loan Documents consistent with the agreement of the parties hereto so long as the Collateral Agent or Required Lenders, as applicable, provides the Credit Parties and the other parties hereto with written notice of such correction and allows the Credit Parties at least ten (10) days to object to such correction in writing delivered to the Collateral Agent and each Lender.  In the event of such objection, such correction shall not be made except by an amendment to this Agreement in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.5	Amendments in Writing; Integration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No amendment, restatement, amendment and restatement or other modification of or supplement to any provision of this Agreement or any other Loan Document, or waiver, discharge or termination of any obligation hereunder or thereunder, no approval or consent hereunder or thereunder (including any consent to any departure by Borrower or any other Credit Party herefrom or therefrom), shall in any event be effective unless the same shall be in writing and signed by Borrower (on its own behalf and on behalf of each other Credit Party) and the Required Lenders; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no such amendment, restatement, amendment and restatement, modification, supplement, waiver, discharge, termination, approval or consent shall, unless in writing and signed by the Collateral Agent and the Required Lenders, affect the rights or duties of, or any amounts payable to, the Collateral Agent under this Agreement or any other Loan Document.  Any such waiver, approval or consent granted shall be limited to the specific circumstance expressly described in it, and shall not apply to any subsequent or other circumstance, whether similar or dissimilar, or give rise to, or evidence, any obligation or commitment to grant any further waiver, approval or consent.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations among the parties hereto about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.6	Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.7	Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination Prior to Term Loan Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and all Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted and any other obligations which, by their terms, are to survive the termination of this Agreement) have been paid in full and satisfied in accordance with the terms of this Agreement.  The obligation of Borrower or any other the Credit Parties in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to indemnify Indemnified Persons shall survive until the statute of limitations with respect to such claim or cause of action shall have run.  So long as all Obligations (other than contingent indemnification obligations to the extent no claim giving rise thereto has been asserted and any other obligations which, by their terms, are to survive the termination of this Agreement and for which no claim has been made) have been paid in full and satisfied in accordance with the terms of this Agreement, this Agreement shall be terminated (a) prior to the Term Loan Maturity Date by Borrower, effective [***] (or such shorter period as the Collateral Agent may agree in its sole discretion) after all Obligations have been paid in full and written notice of termination is delivered to the Collateral Agent and the Lenders or (b) if no such notice is delivered, automatically on the Term Loan Maturity Date once all Obligations have been paid in full.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.8	Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any information regarding the Credit Parties and their Subsidiaries and their businesses provided to the Collateral Agent or any Lender by or on behalf of any Credit Party pursuant to the Loan Documents shall be deemed &#x201c;Confidential Information&#x201d;; provided, however, that Confidential Information does not include information that is either:  (i) in the public domain or in the possession of the Collateral Agent, any Lender or any of their respective Affiliates or when disclosed to the Collateral Agent, any Lender or any of their respective Affiliates, or becomes part of the public domain after disclosure to the Collateral Agent, any Lender or any of their respective Affiliates, in each case, other than as a result of a breach by the Collateral Agent, any Lender or any of their</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">respective Affiliates of the obligations under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; or (ii) disclosed to the Collateral Agent, any Lender or any of their respective Affiliates by a third-party if the Collateral Agent, such Lender or such Affiliate, as applicable, does not know (following reasonable inquiry) that the third-party is prohibited from disclosing the information.  Neither the Collateral Agent nor any Lender shall disclose any Confidential Information to a third-party or use Confidential Information for any purpose other than the administration of the Loan Documents, the exercise of its rights or remedies under the Loan Documents or the performance of its duties or obligations under the Loan Documents.  The foregoing in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> notwithstanding, the Collateral Agent and each Lender may disclose Confidential Information:  (a) to any of its Subsidiaries or Affiliates; (b) to prospective transferees, purchasers or participants of any interest in the Term Loans (including, for the avoidance of doubt, in connection with any proposed Lender Transfer), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no such disclosure to any Disqualified Assignees shall be permitted hereunder without Borrower&#x2019;s prior written consent (which consent shall not be required after the occurrence and during the continuance of an Event of Default); (c) as required by law, regulation, subpoena, or other order, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (x) prior to any disclosure under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Collateral Agent or such Lender, as applicable, agrees to endeavor to provide Borrower with prior written notice thereof, and with respect to any law, regulation, subpoena or other order, to the extent that the Collateral Agent or such Lender is permitted to provide such prior notice to Borrower pursuant to the terms hereof, and (y) any disclosure under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be limited solely to that portion of the Confidential Information as may be specifically compelled by such law, regulation, subpoena or other order; (d) as the Collateral Agent or any Lender otherwise deems necessary or prudent under Sanctions, Anti-Money Laundering Laws, the Anti-Corruption Laws, or Export and Import Laws, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, prior to any disclosure under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Collateral Agent or such Lender, as applicable, agrees to endeavor to provide Borrower with prior written notice thereof to the extent practicable, and with respect to any law, regulation, subpoena or other order, to the extent that the Collateral Agent or such Lender is permitted to provide such prior notice to Borrower; (e)  to the extent requested by regulators having jurisdiction over the Collateral Agent or such Lender or as otherwise required in connection with the Collateral Agent&#x2019;s or such Lender&#x2019;s examination or audit by such regulators (including any self-regulatory authority, such as the National Association of Insurance Commissioners); (f), as the Collateral Agent or such Lender considers reasonably necessary in exercising any rights or remedies under the Loan Documents or in connection with any proceeding relating to the Agreement or any other Loan Documents; (g) as to any party hereto; (h) to third-party service providers of the Collateral Agent or such Lender;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (i) to any of the Collateral Agent&#x2019;s or such Lender&#x2019;s Related Parties; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the third parties to which Confidential Information is disclosed pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">h</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above are bound by obligations of confidentiality and non-use that are no less restrictive than those contained herein.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall survive the termination of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.9	Attorneys&#x2019; Fees, Costs and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In any action or proceeding between, on the one hand, any Credit Party and, on the other hand, the Collateral Agent or any Lender, arising out of or relating to the Loan Documents other than in connection with the enforcement against any Credit Party of this Agreement or any other Loan Document, the prevailing party shall be entitled to recover its reasonable attorneys&#x2019; fees and other costs and expenses incurred, in addition to any other relief to which it may be entitled.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.10	Right of Set-Off</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In addition to any rights now or hereafter granted under Requirements of Law and not by way of limitation of any such rights, upon the occurrence of an Event of Default and at any time thereafter during the continuance of any Event of Default, each Lender is hereby authorized by each Credit Party at any time or from time to time, without prior notice to any Credit Party, any such notice being hereby expressly waived by Borrower (on its own behalf and on behalf of each other Credit Party), to set off and to appropriate and to apply any and all deposits (general or special, including Indebtedness evidenced by certificates of deposit, whether matured or unmatured, but not including trust accounts) and any other Indebtedness at any time held or owing by such Lender to or for the credit or the account of any Credit Party against and on account of the obligations and liabilities of any Credit Party to such Lender hereunder and under the other Loan Documents, including all claims of any nature or description arising out of or connected hereto or with any other Loan Document, irrespective of whether or not (a) the Collateral Agent or such Lender shall have made any demand hereunder or (b) the principal of or the interest on the Term Loans or any other amounts due hereunder shall have become due and payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and although such obligations and liabilities, or any of them, may be contingent or unmatured.  Each Lender agrees</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">promptly to notify Borrower and the Collateral Agent after any such set off and application made by such Lender; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the failure to give such notice shall not affect the validity of such set off and application.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.11	Marshalling; Payments Set Aside</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Neither the Collateral Agent nor any Lender shall be under any obligation to marshal any assets in favor of any Credit Party or any other Person or against or in payment of any or all of the Obligations.  To the extent that any Credit Party makes a payment or payments to any Lender, or the Collateral Agent or any Lender enforces any Liens or exercises its rights of setoff, and such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other party under any bankruptcy law, any other state or federal law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in full force and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.12	Electronic Execution of Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The words &#x201c;execution,&#x201d; &#x201c;signed,&#x201d; &#x201c;signature,&#x201d; and words of like import in this Agreement and the other Loan Documents shall be deemed to include electronic signatures or electronic records, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any Requirements of Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.13	Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Section headings herein are included herein for convenience of reference only and shall not constitute a part hereof for any other purpose or be given any substantive effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.14	Construction of Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The parties hereto mutually acknowledge that they and their respective attorneys have participated in the preparation and negotiation of this Agreement.  In cases of uncertainty, this Agreement shall be construed without regard to which of the parties hereto caused the uncertainty to exist.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.15	Third Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Nothing in this Agreement, whether express or implied, is intended to:  (a) except as expressly provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, confer any benefits, rights or remedies under or by reason of this Agreement on any Persons other than the express parties to it and their respective successors and permitted assigns; (b) relieve or discharge the obligation or liability of any Person not an express party to this Agreement; or (c) give any Person not an express party to this Agreement any right of subrogation or action against any party to this Agreement.  Unless expressly provided to the contrary in this Agreement, a Person who is not a party to this Agreement has no rights under the Contracts (Rights of Third Parties) Act 1999 to enforce or enjoy the benefit of any term of this Agreement.  Notwithstanding any term of any Loan Document, the consent of any Person who is not a party to this Agreement is not required to rescind or vary this Agreement at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.16	No Advisory or Fiduciary Duty</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent and each Lender may have economic interests that conflict with those of the Credit Parties.  Each Credit Party agrees that nothing in the Loan Documents or otherwise will be deemed to create an advisory, fiduciary or agency relationship or fiduciary or other implied duty between any Lender or the Collateral Agent, on the one hand, and such Credit Party, its Subsidiaries, and any of their respective stockholders or affiliates, on the other hand.  Each Credit Party acknowledges and agrees that (i) the transactions contemplated by the Loan Documents are arm&#x2019;s-length commercial transactions between each Lender and the Collateral Agent, on the one hand, and such Credit Party, its Subsidiaries and their respective affiliates, on the other hand, (ii) in connection therewith and with the process leading to such transaction, the Collateral Agent and each Lender is acting solely as a principal and not the advisor, agent or fiduciary of such Credit Party, its Subsidiaries or their respective affiliates, management, stockholders, creditors or any other Person, (iii) neither the Collateral Agent nor any Lender has assumed an advisory or fiduciary responsibility in favor of any Credit Party, its Subsidiaries or their respective affiliates with respect to the transactions contemplated hereby or the process leading thereto (irrespective of whether the Collateral Agent or any Lender or any of their respective affiliates has advised or is currently advising such Credit Party, its Subsidiaries or their respective affiliates on other matters) or any other obligation to such Credit Party, its Subsidiaries or their respective affiliates except the obligations expressly set forth in the Loan Documents, and (iv) each Credit Party, its Subsidiaries and their respective affiliates have consulted their own legal and financial advisors to the extent each deemed appropriate.  Each Credit Party further acknowledges and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">agrees that it is responsible for making its own independent judgment with respect to such transactions and the process leading thereto.  Each Credit Party agrees that it will not claim that the Collateral Agent or any Lender has rendered advisory services of any nature or respect or owes a fiduciary or similar duty to such Credit Party, its Subsidiaries or their respective affiliates in connection with such transaction or the process leading thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.17	Credit Parties&#x2019; Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the Credit Parties hereby irrevocably appoints Borrower, as its agent, attorney-in-fact and legal representative for all purposes, including requesting disbursement of the Term Loans and receiving account statements and other notices and communications to Credit Parties (or any of them) from the Collateral Agent or the Lenders, executing amendments, waivers or other modifications of or supplements to Loan Documents and executing or designating new Loan Documents.  The Collateral Agent or the Lenders may rely, and shall be fully protected in relying, on any request for the Term Loans, disbursement instruction, report, information or any other notice or communication made or given by Borrower and any amendment, restatement, amendment and restatement, waiver or other modification of or supplement to a Loan Document or the execution or designation of new Loan Documents executed or made by Borrower, whether in its own name or on behalf of one or more of the other Credit Parties, and the Collateral Agent or the Lenders shall not have any obligation to make any inquiry or request any confirmation from or on behalf of any other Credit Party as to the binding effect on it of any such request, instruction, report, information, other notice, communication, amendment, restatement, amendment and restatement, supplement, waiver, other modification, execution or designation, nor shall the joint and several character of the Credit Parties&#x2019; obligations hereunder be affected thereby.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COLLATERAL AGENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.1	Appointment and Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each of the Lenders hereby irrevocably appoints BioPharma Credit PLC to act on its behalf as the Collateral Agent hereunder and under the other Loan Documents and authorizes the Collateral Agent to take such actions on its behalf and to exercise such powers as are delegated to the Collateral Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.  Except for the first two (2) sentences of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the penultimate paragraph of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are solely for the benefit of the Collateral Agent and Lenders, and neither Borrower nor any other Credit Party shall have rights as a third-party beneficiary of any of such provisions.  Subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any action required or permitted to be taken by the Collateral Agent hereunder shall be taken with the prior approval of the Required Lenders.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.2	Rights as a Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Person serving as the Collateral Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Collateral Agent and the term &#x201c;Lender&#x201d; or &#x201c;Lenders&#x201d; shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Collateral Agent hereunder in its individual capacity.  Such Person and its Affiliates may lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Collateral Agent hereunder and without any duty to account therefor to any Lender.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.3	Exculpatory Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Collateral Agent shall not have any duties or obligations to the Lenders except those expressly set forth herein and in the other Loan Documents to which it is a party.  Without limiting the generality of the foregoing, with respect to the Lenders, the Collateral Agent:</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or Event of Default has occurred and is continuing;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents to which it is a party that the Collateral Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in such other Loan Documents), </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the Collateral Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Collateral Agent to liability or that is contrary to any Loan Document or Requirements of Law; and</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">shall not, except as expressly set forth herein and in the other Loan Documents to which it is a party, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Credit Party or any of its Affiliates that is communicated to or obtained by the Person serving as the Collateral Agent or any of its Affiliates in any capacity.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Collateral Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Collateral Agent shall believe in good faith shall be necessary, under the circumstances as provided in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment.  The Collateral Agent shall be deemed not to have knowledge of any Default or Event of Default unless and until notice describing such Default or Event of Default is given to the Collateral Agent in writing by Borrower or a Lender.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Collateral Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default or Event of Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Collateral Agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.4	Reliance by Collateral Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.  The Collateral Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person and shall not incur any liability for relying thereon.  The Collateral Agent may consult with legal counsel (who may be counsel for Borrower), independent accountants, manufacturing consultants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants, consultants or experts.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.5	Delegation of Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Collateral Agent.  The Collateral Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties.  The exculpatory provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall apply to any such sub-agent and to the Related Parties of the Collateral Agent and any such sub-agent.  The Collateral Agent shall not be responsible for the negligence or misconduct of any sub-agent except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Collateral Agent acted with gross negligence or willful misconduct in the selection of such sub-agent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.6	Resignation of Collateral Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent may at any time give notice of its resignation to the Lenders and Borrower.  Upon the receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with Borrower so long as no Default or Event of Default has occurred and is continuing, to appoint a successor (which shall not be a Disqualified Assignee except after the occurrence and during the continuation of an Event of Default).  If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within thirty (30) days after the retiring Collateral Agent gives notice of its resignation, then the retiring Collateral Agent may, on behalf of the Lenders, appoint a successor Collateral Agent that is a Related Party of the Collateral Agent or any Lender; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, whether or not a successor has been appointed or has accepted such appointment, such resignation shall become effective upon delivery of the notice thereof.  Upon the acceptance of a successor&#x2019;s appointment as Collateral Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Collateral Agent, and the retiring Collateral Agent shall be discharged from all of its duties and obligations under the Loan Documents (if not already discharged therefrom as provided above in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).  After the retiring Collateral Agent&#x2019;s resignation, the provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall continue in effect for the benefit of such retiring Collateral Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of them while the retiring Collateral Agent was acting as Collateral Agent.  Upon any resignation by the Collateral Agent, all payments, communications and determinations provided to be made by, to or through the Collateral Agent shall instead be made by, to or through each Lender directly, until such time as a Person accepts an appointment as Collateral Agent in accordance with this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.7	Non-Reliance on Collateral Agent and Other Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Lender acknowledges that it has, independently and without reliance upon the Collateral Agent or any other Lender or any of their respective Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement and make Credit Extensions hereunder.  Each Lender also acknowledges that it will, independently and without reliance upon the Collateral Agent or any other Lender or any of their respective Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.8	Collateral and Guaranty Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each Lender agrees that any action taken by the Collateral Agent or the Required Lenders in accordance with the provisions of this Agreement or of the other Loan Documents, and the exercise by the Collateral Agent or Required Lenders of the powers set forth herein or therein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Lenders.  Without limiting the generality of the foregoing, the Lenders irrevocably authorize and instruct the Collateral Agent, at its option and in its discretion, and the Collateral Agent agrees:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to release any Lien on any property granted to or held by the Collateral Agent under any Collateral Document (i) upon payment and satisfaction in full of the Obligations (other than inchoate indemnity obligations), (ii) that is sold, transferred, disposed or to be sold, transferred, disposed as part of or in connection with any sale, transfer or other disposition (other than any sale to a Credit Party) permitted hereunder, (iii) subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if approved, authorized or ratified in writing by the Required Lenders, or (iv) to the extent such property is owned by a Guarantor upon the release of such Guarantor from its obligations under the Loan Documents pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to subordinate any Lien on any property granted to or held by the Collateral Agent under any Loan Document to the holder of any Lien on such property that is permitted by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Permitted Liens&#x201d; (solely with respect to modifications, replacements, extensions or renewals of Liens permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Permitted Liens&#x201d;);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to release any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents) if such Person ceases to be a Subsidiary (or becomes an Excluded Subsidiary (to the extent not designated by Borrower to be a Designated Guarantor)) as a result of a transaction permitted hereunder or upon payment and satisfaction in full of the Obligations (other than inchoate indemnity obligations);</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to enter into non-disturbance and similar agreements in connection with the licensing of Intellectual Property permitted pursuant to the terms of this Agreement; and</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to enter into a subordination, intercreditor, or other similar agreement with respect to (i) any Indebtedness that constitutes Subordinated Debt that in each case is permitted under the definition of Permitted Indebtedness, or (ii) any Indebtedness under the Royalty Revenue Contract and other Royalty Revenue Documents.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon request by the Collateral Agent at any time the Required Lenders will confirm in writing the Collateral Agent&#x2019;s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents) pursuant to this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In each case as specified in this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Collateral Agent will (and each Lender irrevocably authorizes and instructs the Collateral Agent to), at Borrower&#x2019;s expense, (A) deliver to Borrower any Collateral that is in the Collateral Agent&#x2019;s possession (if any) in connection with the release of the Collateral Agent&#x2019;s Lien thereon, and (B) execute and deliver to the applicable Credit Party such documents as such Credit Party may reasonably request (i) to evidence the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">release or subordination of such item of Collateral from the Liens and security interests granted under the Collateral Documents, (ii) to enter into non-disturbance or similar agreements in connection with the licensing of Intellectual Property, (iii) to enter into a subordination, intercreditor, or other similar agreement with respect to any Indebtedness that constitutes Subordinated Debt to the extent such Subordinated Debt is permitted under the definition of Permitted Indebtedness or (iv) to evidence the release of any Guarantor from its obligations under the Security Agreement (and other applicable Collateral Documents), in each case in accordance with the terms of the Loan Documents and this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and in form and substance reasonably acceptable to the Collateral Agent.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Without limiting the generality of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.10</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, the Collateral Agent shall deliver to the Lenders notice of any action taken by it under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> promptly after the taking thereof; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, delivery of or failure to deliver any such notice shall not affect the Collateral Agent&#x2019;s rights, powers, privileges and protections under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.9	Reimbursement by Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  To the extent that Borrower for any reason fails to indefeasibly pay any amount required under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to be paid by it to the Collateral Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Collateral Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender&#x2019;s </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">pro rata</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> share (based upon the percentages as used in determining the Required Lenders as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that the unreimbursed expense or indemnified loss, damage, liability or related expense, as the case may be, was incurred by or asserted against the Collateral Agent (or any such sub-agent) in its capacity as such or against any Related Party of any of the foregoing acting for the Collateral Agent (or any sub-agent) in connection with such capacity.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12.10	Notices and Items to Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Collateral Agent shall deliver to the Lenders each notice, report, statement, approval, direction, consent, exemption, authorization, waiver, certificate, filing or other item received by it pursuant to this Agreement or any other Loan Document (including any item received by it pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any delivery of or failure to deliver any such notice, report, statement, approval, direction, consent, exemption, authorization, waiver, certificate, filing or item shall not otherwise alter or effect the rights of the Lenders or the Collateral Agent under this Agreement or any other Loan Document or the validity of such item.  In addition, to the extent the Collateral Agent or the Required Lenders deliver any notices, approvals, authorizations, directions, consents or waivers to Borrower pursuant to this Agreement or any other Loan Document, the Collateral Agent or the Required Lenders, as applicable, will also deliver such notice, approval, authorization, direction, consent or waiver to the other Lenders on or about the same time such notice, approval, authorization, direction, consent or waiver is provided to Borrower; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the delivery of or failure to deliver such notice, approval, authorization, direction, consent or waiver to the other Lenders shall not in any way effect the obligations of Borrower, or the rights of the Collateral Agent or the Required Lenders, in respect of such notice, approval, authorization, direction, consent or waiver or the validity thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#010000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DEFINITIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13.1	Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For the purposes of and as used in the Loan Documents:  (a) references to any Person include its successors and assigns and, in the case of any Governmental Authority, any Person succeeding to its functions and capacities; (b) except as the context otherwise requires (including to the extent otherwise expressly provided in any Loan Document), (i) references to any law, statute, treaty, order, policy, rule or regulation include any amendments, supplements and successors thereto and (ii) references to any contract, agreement, consent, waiver, instrument or other document include any amendments, restatements, amendments and restatements, supplements or other modifications thereto or thereof from time to time to the extent permitted by the provisions thereof and to the extent permitted by or otherwise not in contravention of this Agreement or any other Loan Documents; (c) the words &#x201c;shall&#x201d; and &#x201c;will&#x201d; are interchangeable and will be understood to be imperative or mandatory in nature; (d) the word &#x201c;may&#x201d; is permissive; (e) the word &#x201c;or&#x201d; has the inclusive meaning represented by the phrase &#x201c;and/or&#x201d;; (f) the words &#x201c;include&#x201d;, &#x201c;includes&#x201d; and &#x201c;including&#x201d; are not limiting; (g) the singular includes the plural and the plural includes the singular; (h) numbers denoting amounts that are set off in parentheses are negative unless the context dictates otherwise; (i) each authorization herein shall be deemed irrevocable and coupled with an interest; (j) all accounting terms shall be interpreted, and all determinations relating thereto shall be made, in accordance with GAAP; (k) references to any time of day shall be to New York time; (l) the words &#x201c;herein&#x201d;, &#x201c;hereof&#x201d;, &#x201c;hereby&#x201d;, &#x201c;hereto&#x201d; and &#x201c;hereunder&#x201d; refer to this Agreement as a whole; and (m) unless otherwise expressly provided, references to specific</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sections, articles, clauses, sub-clauses, annexes and exhibits are to this Agreement and references to specific schedules are to the Disclosure Letter.  The provisions of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall survive the termination of this Agreement.  As used in this Agreement, the following capitalized terms have the following meanings:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Account</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;account&#x201d; as defined in the Code with such additions to such term as may hereafter be made, and includes all accounts receivable, book debts, and other sums owing to Credit Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Account Debtor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;account debtor&#x201d; as defined in the Code with such additions to such term as may hereafter be made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any Stock Acquisition, or (b) any Asset Acquisition.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, individually or collectively, as the context dictates, the Tranche A Additional Consideration, the Tranche B Additional Consideration and the Tranche C Additional Consideration.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance Request Form</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Loan Advance Request Form in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any action, suit, proceeding, hearing (whether administrative, judicial or otherwise), governmental investigation or arbitration (whether or not purportedly on behalf of any Credit Party or any of its Subsidiaries) at law or in equity, or before or by any Governmental Authority, domestic or foreign (including any Environmental Claims), whether pending or, to the Knowledge of such Credit Party, threatened against or adversely affecting any Credit Party or any of its Subsidiaries or any property of Borrower or any of its Subsidiaries.  For the avoidance of doubt, an action, suit, proceeding, hearing, or arbitration that follows or precedes an investigation shall be treated as a new and separate Adverse Proceeding from the investigation, whether or not such action, suit, proceeding, hearing, or arbitration is brought by any Governmental Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, each other Person that owns or controls, directly or indirectly, such Person, any other Person that controls or is controlled by or is under common control with such Person, and each of that Person&#x2019;s senior executive officers, directors, partners and, for any Person that is a limited liability company or limited liability partnership, that Person&#x2019;s managers and members.  As used in this definition, &#x201c;control&#x201d; means (a) direct or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in a Person or (b) the power to direct or cause the direction of the management of such Person by contract or otherwise.  In no event shall the Collateral Agent or any Lender be deemed to be an Affiliate of Borrower or any of its Subsidiaries.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Corruption Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is defined in Section </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.18(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anti-Money Laundering Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.18(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Margin</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any day, as to any Term Loan, a rate </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">per annum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equal to five and three-quarters percent (5.75%).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means at any time: (a) with respect to the Tranche A Loan or the Tranche A Loan Amount, the percentage equal to a fraction, the numerator of which is (i) on or prior to the Tranche A Closing Date, the amount of such Lender&#x2019;s Tranche A Commitment at such time and the denominator of which is the Tranche A Loan Amount at such time or (ii) thereafter, the outstanding principal amount of such Lender&#x2019;s portion of the Tranche A Loan at such time, and the denominator of which is the aggregate outstanding principal amount of the Tranche A Loan at such time; (b) with respect to the Tranche B Loan or the Tranche B Loan Amount, the percentage equal to a fraction, the numerator of which is (i) on or prior to the Tranche B Closing Date, the amount of such Lender&#x2019;s Tranche B Commitment at such time and the denominator of which is the Tranche B Loan Amount at such time or (ii) thereafter, the outstanding principal amount of such Lender&#x2019;s portion of the Tranche B Loan at such time, and the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">denominator of which is the aggregate outstanding principal amount of the Tranche B Loan at such time; (c) with respect to the Tranche C Loan or the Tranche C Loan Amount, the percentage equal to a fraction, the numerator of which is (i) on or prior to the Tranche C Closing Date, the amount of such Lender&#x2019;s Tranche C Commitment at such time and the denominator of which is the Tranche C Loan Amount at such time or (ii) thereafter, the outstanding principal amount of such Lender&#x2019;s portion of the Tranche C Loan at such time, and the denominator of which is the aggregate outstanding principal amount of the Tranche C Loan at such time; and (d) with respect to the Term Loans and the Term Loan Commitments, the percentage equal to a fraction, the numerator of which is, the sum of the amount of such Lender&#x2019;s outstanding Term Loan Commitments and the amount of such Lender&#x2019;s portion of the outstanding principal amount of the Term Loans at such time, and the denominator of which is the sum of the amount of all outstanding Term Loan Commitments and the aggregate outstanding principal amount of the Term Loans at such time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Asset Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to Borrower or any of its Subsidiaries, any purchase, exclusive or nonexclusive in-license or other acquisition of any of the properties or assets (other than properties or assets from third parties used in the ordinary course of business, including inventory, raw materials, vehicles, equipment, office supplies, software and other similar assets) of any other Person (including any purchase or other acquisition of any entire business unit, line of business or division of such Person).  Notwithstanding the foregoing, &#x201c;Asset Acquisition&#x201d; does not include any in-license or any collaboration, co-promotion or co-marketing arrangement pursuant to which Borrower or any Subsidiary acquires rights to research, develop, use, make, promote, sell, lease or market the products of another Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Tenor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (a) if the then-current Benchmark is a term rate, any tenor for such Benchmark or that is or may be used for determining the length of an Interest Period or (b) otherwise, any payment period for interest calculated with reference to such Benchmark, as applicable, pursuant to this Agreement as of such date.  means, as of any date of determination and with respect to the then-current Benchmark, as applicable, (a) if such Benchmark is a term rate, any tenor for such Benchmark (or component thereof) that is or may be used for determining the length of an interest period pursuant to this Agreement or (b) otherwise, any payment period for interest calculated with reference to such Benchmark (or component thereof) that is or may be used for determining any frequency of making payments of interest calculated with reference to such Benchmark pursuant to this Agreement, in each case, as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of &#x201c;Interest Period&#x201d; pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy Code</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Title 11 of the United States Code entitled &#x201c;Bankruptcy,&#x201d; as now and hereafter in effect, or any successor statute (and any foreign equivalent).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means, initially, the Term SOFR Reference Rate; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that if a Benchmark Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then &#x201c;Benchmark&#x201d; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Benchmark Transition Event, the first alternative set forth in the order below that can be determined by the Collateral Agent for the applicable Benchmark Replacement Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	the sum of (i) Daily Simple SOFR and (ii) 0.26161% (26.161 basis points); and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the sum of: (i) the alternate benchmark rate that has been selected by the Collateral Agent and Borrower giving due consideration to (A) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii) the related Benchmark Replacement Adjustment;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, if the Benchmark Replacement as determined pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement Adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement (other than Daily Simple SOFR), the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Collateral Agent and Borrower giving due consideration to (a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for Dollar-denominated syndicated credit facilities at such time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Replacement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a date and time determined by the Collateral Agent in its reasonable discretion, which date shall be no later than the earliest to occur of the following events with respect to the then-current Benchmark:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Benchmark Transition Event,&#x201d; the later of (i) the date of the public statement or publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof); and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Benchmark Transition Event,&#x201d; the first date on which such Benchmark (or the published component used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non-representative; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such non-representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, the &#x201c;Benchmark Replacement Date&#x201d; will be deemed to have occurred in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Transition Event</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence of one or more of the following events with respect to the then-current Benchmark:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, a &#x201c;Benchmark Transition Event&#x201d; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benchmark Unavailability Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and (b) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Blocked Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an individual or entity that is, or is 50% or more owned or controlled by individuals or entities that are: (i) the subject or target of blocking or asset-freezing Sanctions or (ii) located, organized or resident in a Sanctioned Country.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, (i) in the case of any corporation, the board of directors of such Person, (ii) in the case of any limited liability company, the board of managers of such Person, or if there is none, the Board of Directors of the managing member of such Person, (iii) in the case of any partnership, the Board of Directors of the general partner of such Person and (iv) in any other case, the functional equivalent of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Governors</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Governors of the United States Federal Reserve System, or any successor thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Books</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all books and records including ledgers, records regarding a Credit Party&#x2019;s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrower</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowing Resolutions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, those resolutions adopted by such Person&#x2019;s Board of Directors or other competent corporate body, as required pursuant to Requirements of Law and delivered by such Person to the Collateral Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> approving the Loan Documents to which such Person is a party and the transactions contemplated thereby (including the Term Loan).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day that is not a Saturday or a Sunday or a day on which banks are authorized or required to be closed in New York, New York or London, England.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Lease</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as applied to any Person, any lease of, or other arrangement conveying the right to use, any property by that Person as lessee which, in accordance with GAAP, is required to be accounted for as a finance lease (and not an operating lease) on a balance sheet of that Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Lease Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, with respect to any Capital Lease, any lease entered into as part of any sale leaseback transaction of any Person or any synthetic lease, the amount of all obligations of such Person that is (or that would be, if such synthetic lease or other lease were accounted for as a Capital Lease) capitalized on a balance sheet of such Person prepared in accordance with GAAP.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	securities issued or directly and fully guaranteed or insured by the United States government or any agency or instrumentality of the United States government or by the government of any other member country of the Organisation for Economic Co-operation and Development</font><font style="color:#000000;white-space:pre-wrap;font-size:10.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OECD</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (provided that the full faith and credit of the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United States or such other member country of OECD, as applicable, is pledged in support of those securities) or any agency or instrumentality of the OECD, in each case, having maturities of not more than two (2) years from the date of acquisition;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	certificates of deposit, time deposits with maturities of one year or less from the date of acquisition, bankers&#x2019; acceptances with maturities not exceeding one year and overnight bank deposits and demand deposits, in each case, with any commercial bank having (i) capital and surplus in excess of $500,000,000 in the case of U.S. banks or (ii) capital and surplus in excess of $100,000,000 (or the U.S. dollar equivalent as of the date of determination) in the case of non-U.S. banks or a rating for its long-term unsecured and noncredit enhanced debt obligations of &#x201c;A&#x201d; or higher by Standard &amp; Poor&#x2019;s Rating Services or Fitch Ratings Ltd or &#x201c;A2&#x201d; or higher by Moody&#x2019;s Investors Service Limited;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	commercial paper or marketable short-term money market or readily marketable direct obligations and similar securities having a credit rating of either A-1 or higher by Standard &amp; Poor&#x2019;s Rating Service or F1 or higher by Fitch Ratings Ltd or P-1 or higher Moody&#x2019;s Investors Service Limited, and, in each case, maturing within two (2) years after the date of acquisition;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	repurchase obligations with a term of not more than seven (7) days for underlying securities of the types described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above entered into with any financial institution meeting the qualifications specified in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	investment funds investing ninety-five percent (95.0%) of their assets in securities of the types described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	investments in money market funds which have a credit rating of either A-1 or higher by Standard &amp; Poor&#x2019;s Rating Service or F1 or higher by Fitch Ratings Ltd or P-1 or higher by Moody&#x2019;s Investors Service Limited (or, if at any time none of Fitch Ratings Ltd, Moody&#x2019;s Investors Service Limited or Standard &amp; Poor&#x2019;s Rating Service shall be rating such obligations, an equivalent rating from another rating agency) and that have portfolio assets of at least $1,000,000,000; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	other investments in accordance with Borrower&#x2019;s investment policy as of the Effective Date or otherwise approved in writing by the Collateral Agent (such approval not to be unreasonably withheld, conditioned or delayed).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the provisions of the California Consumer Privacy Act, as amended by the California Privacy Rights Act and codified at Cal. Civ. Code &#167; 1798.100 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">et seq</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., together with any effective implementing regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means: (a) a transaction or series of transactions (including any merger or consolidation involving Borrower) whereby any &#x201c;person&#x201d; or &#x201c;group&#x201d; (within the meaning of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 13(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Exchange Act, but excluding any employee benefit plan of such Person or its Subsidiaries, and any Person acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) (i) is or becomes the &#x201c;beneficial owner&#x201d; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a more than fifty percent (50.0%) of any class of outstanding Equity Interests of Borrower ordinarily entitled to vote in the election of directors (or compatible voting Equity Interests), or (ii) obtains the power (whether or not exercised) to elect a majority of directors of Borrower; (b) a sale, directly or indirectly, of all or substantially all of the consolidated assets of Borrower and its Subsidiaries in one transaction or a series of transactions (whether by way of merger, stock purchase, asset purchase or otherwise); or (c) a merger or consolidation involving Borrower in which Borrower is not the surviving Person or in which Persons holding more than fifty percent (50.0%) of the power to elect a majority of directors of Borrower immediately prior to such merger or consolidation do not continue to hold at least fifty percent (50.0%) of such power immediately after such merger or consolidation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the occurrence, after the date of this Agreement, of any of the following:  (a) the adoption or taking into effect of any law, treaty, order, policy, rule or regulation, (b) any change in any law, treaty,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">order, policy, rule or regulation or in the administration, interpretation or application thereof by any Governmental Authority or (c) the making or issuance of any request, guideline or directive (whether or not having the force of law) by any Governmental Authority; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that notwithstanding anything herein to the contrary, (x) the regulations promulgated under the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall be deemed to be a &#x201c;Change in Law&#x201d;, regardless of the date enacted, adopted or issued.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A Closing Date, the Tranche B Closing Date or the Tranche C Closing Date, as applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CMIA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the California Confidentiality of Medical Information Act, codified at Cal. Civ. Code pt. 2.6 &#167; 56 </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">et seq</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles of the Code, the definition of such term contained in Article 9 of the Code shall govern; provided, further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, the Collateral Agent&#x2019;s Lien, for the benefit of Lenders and the other Secured Parties, on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &#x201c;Code&#x201d; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, &#x201c;Collateral&#x201d;, as such term is defined in the Security Agreement and any and all other assets and properties of whatever kind and nature subject or purported to be subject from time to time to a Lien under any Collateral Document, but in any event excluding all Excluded Property.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Access Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an agreement, in form and substance reasonably satisfactory to the Collateral Agent and to which the Collateral Agent is a party, pursuant to which a mortgagee or lessor of real property on which Collateral is stored or otherwise located, or a warehouseman, processor or other bailee of Inventory or other property owned by any Credit Party, acknowledges the Liens and security interests of the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and waives (or, if approved by the Collateral Agent in its sole discretion, subordinates) any Liens or security interests held by such Person on any such Collateral, and, in the case of any such agreement with a mortgagee or lessor, permits the Collateral Agent and any Lender (and its representatives and designees) reasonable access to any Collateral stored or otherwise located thereon.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Account</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Deposit Account of a Credit Party maintained with a bank or other depository or financial institution located in the United States, and any Securities Account of a Credit Party maintained with a securities intermediary located in the United States or any Commodity Account of a Credit Party maintained with a commodity intermediary located in the United States, in each case, other than an Excluded Account.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Security Agreement, the Control Agreements, the IP Agreements, any Mortgages and all other instruments, documents and agreements delivered by any Credit Party pursuant to or incidental to this Agreement or any of the other Loan Documents, in each case, in order to grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, or perfect a Lien on any Collateral as security for the Obligations, and all amendments, restatements, amendments and restatements, modifications or supplements thereof or thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commodity Account</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;commodity account&#x201d; as defined in the Code with such additions to such term as may hereafter be made.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company IP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all of the following, as they exist in and throughout the Territory:  (a) Current Company IP; (b) improvements, continuations, continuations-in-part, divisions, provisionals or any substitute applications with respect to any of the Current Company IP, any patent issued with respect to any of the Current Company IP, including any patent right claiming the apparatus, system, component or composition of matter of, or the method of making or using, any Product in the Territory, any reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent and all foreign and international counterparts of any of the foregoing, and any confirmation patent or registration patent or patent of addition based on any such patent; (c) trade secrets or trade secret rights, including any rights to unpatented inventions, know-how, show-how, operating manuals, confidential or proprietary information, research in progress, algorithms, data, databases, data collections, designs, processes, procedures, methods, protocols, materials, formulae, drawings, schematics, blueprints, flow charts, models, strategies, prototypes, techniques, and the results of experimentation and testing, including samples, in each case, as specifically related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) to the extent not described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, any and all IP Ancillary Rights specifically relating to any of the foregoing (other than all income, royalties, proceeds and liabilities at any time due and payable or asserted under or with respect to any of the foregoing), including, for the avoidance of doubt, all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights, and (e) regulatory filings, submissions and approvals related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of any Product in the Territory and all data provided in any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company IP Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each contract or agreement, pursuant to which Borrower or any of its Subsidiaries has the legal right to exploit Current Company IP or other Intellectual Property that is owned by another Person and is material to the business of Borrower and its Subsidiaries, or to any aspect of the research, development, manufacture, production, use, supply, commercialization, marketing, importing, storage, transport, offer for sale, distribution, lease or sale of Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time of determination, any Person (and each other Person that owns or controls, directly or indirectly, such Person, or that controls or is controlled by or is under common control with such Person) that is directly and primarily engaged in the same, substantially the same, or similar line of business as Borrower and its Subsidiaries, taken as a whole, as of such time.  As used in this definition, &#x201c;control&#x201d; means (a) direct or indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in a Person or (b) the power to direct or cause the direction of the management of such Person by contract or otherwise.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain certificate in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit E</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Conforming Changes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#x201c;Business Day,&#x201d; the definition of &#x201c;U.S. Government Securities Business Day,&#x201d; the definition of &#x201c;Interest Period&#x201d; or any similar or analogous definition (or the addition of a concept of &#x201c;interest period&#x201d;), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, the applicability and length of lookback periods and other technical, administrative or operational matters) that the Collateral Agent decides (after consultation with Borrower) may be appropriate to reflect the adoption and implementation of any such rate or to permit the use and administration thereof by the Collateral Agent in a manner substantially consistent with market practice (or, if the Collateral Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Collateral Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Collateral Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Connection Income Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contingent Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any Person, (a) any direct or indirect liability, contingent or not, of that Person for any indebtedness, lease, dividend, letter of credit or other obligation of another Person directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable (other than by endorsements of instruments in the course of collection) and (b) any obligation of that Person to pay an earn-out payment, milestone payment or similar contingent payment or contingent compensation (including purchase price adjustments but excluding license fees, royalties payable and milestones based on net sales) to a counterparty incurred or created in connection with an Acquisition, Transfer, or Investment or otherwise in connection with any collaboration, development or similar agreement, in each instance where such contingent payment or compensation becomes due and payable upon the occurrence of an event or the performance of an act (and not solely with the passage of time).  The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable by a Responsible Officer of such Person, the amount required to be shown as a liability on the balance sheet of such Person in accordance with GAAP (or, if not required to be so shown, the maximum reasonably anticipated amount reasonably determined by a Responsible Officer of such Person in good faith); but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.  Notwithstanding anything to the contrary in the foregoing, Permitted Equity Derivatives shall not constitute a Contingent Obligation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Control Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Credit Party, any control agreement entered into among such Credit Party, the Collateral Agent and, in the case of a Deposit Account, the bank or other depository or financial institution located in the United States, at which such Credit Party maintains such Deposit Account, or, in the case of a Securities Account or a Commodity Account, the securities intermediary or commodity intermediary located in the United States, at which such Credit Party maintain such Securities Account or Commodities Account, in either case, pursuant to which the Collateral Agent obtains control (within the meaning of the Code), or otherwise has a perfected first priority security interest (subject to any Permitted Liens), over such Collateral Account.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copyrights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret (and all related IP Ancillary Rights).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Extension</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Term Loan or any other extension of credit by any Lender for Borrower&#x2019;s benefit pursuant to this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Party</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Borrower and each Guarantor (including any Designated Guarantor).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Company IP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Daily Simple SOFR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means, for any day, SOFR, with the conventions for this rate (which will include a lookback) being established by the Collateral Agent in accordance with the conventions for this rate recommended by the Relevant Governmental Body for determining &#x201c;Daily Simple SOFR&#x201d; for bilateral business loans; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if the Collateral Agent decides that any such convention is not administratively feasible for the Collateral Agent, then the Collateral Agent may establish another convention in its reasonable discretion.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Protection Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all applicable foreign or domestic (including U.S. federal, state and local), statutes, ordinances, orders, rules, regulations, judgments, Governmental Approvals, or any other requirements of Governmental Authorities relating to privacy, security, notification of breaches, transfers, or confidentiality of Personal Data or other Sensitive Information or to any database registration or data localization requirements, in each case, in any manner applicable to Borrower or any of its Subsidiaries, including, to the extent applicable, Section 5 of the FTC Act and other consumer protection laws, HIPAA, GDPR, CCPA and other comprehensive state privacy laws (including the New Jersey Privacy Act and Consumer Data Protection Act, once effective and as applicable), CMIA and other U.S. state medical information privacy laws and genetic testing laws.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any breach of or default under any term, provision, condition, covenant or agreement contained in this Agreement or any other Loan Document or any other event, in each case that, with the giving of notice or the lapse of time or both, would constitute an Event of Default.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Default Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deposit Account</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;deposit account&#x201d; as defined in the Code with such additions to such term as may hereafter be made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designated Guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the disclosure letter to this Loan Agreement, dated the Effective Date and delivered by the Credit Parties to the Collateral Agent pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, as updated on each subsequent Closing Date (if required and as expressly permitted hereunder).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disqualified Assignee</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any Competitor, or (b) any Person listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 13.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter as of the Effective Date delivered pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disqualified Equity Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Equity Interest that, by its terms (or by the terms of any security or other Equity Interests into which it is convertible or for which it is exchangeable) or upon the happening of any event or condition: (a) matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise (except if redeemable or convertible into other Equity Interest that would not constitute a Disqualified Equity Interest or as a result of a change of control, asset sale or similar event so long as any and all rights of the holders thereof upon the occurrence of a change of control, asset sale or similar event shall be subject to the prior repayment in full in cash of the Term Loans and the satisfaction in full of all other Obligations (other than inchoate indemnity obligations) in accordance with the terms of this Agreement); (b) is redeemable at the option of the holder thereof, in whole or in part (except if redeemable or convertible into other Equity Interest that would not constitute a Disqualified Equity Interest or as a result of a change of control, asset sale or similar event so long as any rights of the holders thereof upon the occurrence of a change of control, asset sale or similar event shall be subject to the prior repayment in full in cash of the Term Loans and the satisfaction in full of all other Obligations (other than inchoate indemnity obligations) in accordance with this Agreement); (c) provides for the scheduled payments of dividends or distributions in cash; or (d) is convertible into or exchangeable for (i) Indebtedness which is not Permitted Indebtedness or (ii) any other Equity Interest that would constitute a Disqualified Equity Interest; in each case described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, prior to the date that is 180 days after the Term Loan Maturity Date; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, if any such Equity Interest is issued pursuant to any plan for the benefit of any employee, director, manager or consultant of Borrower or its Subsidiaries or by any such plan to such employee, director, manager or consultant, such Equity Interest shall not constitute a &#x201c;Disqualified Equity Interest&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">solely because it may be required to be repurchased by Borrower or its Subsidiaries in order to satisfy applicable statutory or regulatory obligations or as a result of the termination, death or disability of such employee, director, manager or consultant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dollars</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or use of the sign &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means only lawful money of the United States and not any other currency, regardless of whether that currency uses the &#x201c;$&#x201d; sign to denote its currency or may be readily converted into lawful money of the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Domestic Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Credit Party, a Subsidiary of such Credit Party that is incorporated or organized under the laws of the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any investigation, notice, notice of violation, claim, action, suit, proceeding, demand, abatement order or other order or directive (conditional or otherwise), by any Governmental Authority or any other Person, arising (i) pursuant to or in connection with any actual or alleged violation of any Environmental Law; (ii) in connection with any Hazardous Material or any actual or alleged Hazardous Materials Activity; or (iii) in connection with any actual or alleged damage, injury, threat or harm to health, safety, natural resources or the environment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Environmental Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all current or future, foreign or domestic, statutes, ordinances, orders, rules, regulations, judgments, Governmental Approvals, or any other requirements of Governmental Authorities relating to (i) environmental matters, including those relating to any Hazardous Materials Activity; (ii) the generation,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">use, storage, transportation or disposal of Hazardous Materials; or (iii) occupational safety and health, industrial hygiene, land use or the protection of human, plant or animal health or welfare, in each case, in any manner applicable to any Credit Party or any of its Subsidiaries or any Facility.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means collectively, with respect to any Person, any and all shares, interests, participations or other equivalents (however designated) of capital stock of a corporation, any and all equivalent ownership interests in such Person (other than a corporation), including partnership interests and membership interests, and any and all warrants, rights or options to purchase or other arrangements or rights to acquire (by purchase, conversion, dividend, distribution or otherwise) any of the foregoing (and all other rights, powers, privileges, interests, claims and other property in any manner arising therefrom or relating thereto); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any Permitted Convertible Indebtedness or other </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness convertible into Equity Interests (or into any combination of cash and Equity Interests based on the value of such Equity Interests) shall not constitute Equity Interests unless and until (and solely to the extent) so converted into Equity Interests.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Employee Retirement Income Security Act of 1974, and the regulations promulgated thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any trade or business (whether or not incorporated) that, together with such Person, is treated as a single employer under Section 414(b) or (c) of the IRC or, solely for purposes of Section 302 of ERISA or Section 412 of the IRC, Section 414(m) or (o) of the IRC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ERISA Event</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any &#x201c;reportable event,&#x201d; as defined in Section 4043 of ERISA or the regulations issued thereunder, with respect to a Plan (other than an event for which the 30-day notice period is waived by regulation); (b) with respect to a Plan, the failure by Borrower or its Subsidiaries or their ERISA Affiliates to satisfy the minimum funding standard of Section 412 of the IRC and Section 302 of ERISA, whether or not waived; (c) the failure by Borrower or its Subsidiaries or their ERISA Affiliates to make by its due date a required installment under Section 430(j) of the IRC with respect to any Plan or to make any required contribution to a Multiemployer Plan; (d) the filing pursuant to Section 412(c) of the IRC or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan; (e) the incurrence by Borrower or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination of any Plan; (f) the receipt by Borrower or its Subsidiaries or any of their respective ERISA Affiliates from the Pension Benefit Guaranty Corporation (referred to and defined in ERISA) or a plan administrator of any notice relating to the intention to terminate any Plan under Section 4041 or any Multiemployer Plan under 4041A of ERISA or to appoint a trustee to administer any Plan under Section 4042 of ERISA, or the occurrence of any event or condition which could reasonably be expected to constitute grounds under ERISA for the termination of, or the appointment of a trustee to administer, any Plan under Section 4041 Section or 4042 of ERISA; (g) the incurrence by Borrower or its Subsidiaries or any of their respective ERISA Affiliates of any liability with respect to the withdrawal from any Plan pursuant to Section 4063 of ERISA or Multiemployer Plan; (h) the receipt by Borrower or its Subsidiaries or any of their respective ERISA Affiliates of any notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent, within the meaning of Section 4245 of ERISA; (i) the &#x201c;substantial cessation of operations&#x201d; by Borrower or its Subsidiaries or their ERISA Affiliates within the meaning of Section 4062(e) of ERISA with respect to a Plan; or (j) the occurrence of a nonexempt prohibited transaction (within the meaning of Section 4975 of the IRC or Section 406 of ERISA) with respect to a Plan which could reasonably be expected to result in a material liability to Borrower or its Subsidiaries.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EU Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all applicable statutes, rules and regulations implemented administered or enforced by the European Commission, the European Medicines Agency (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the competent authorities of the EU Member States including, but not limited to, the EU Community Code on medicinal products (Directive 2001/83/EC), the EMA Regulation (Regulation (EC) No 726/2004), the Manufacturing Directive (Commission Directive 2003/94/EC), the Clinical Trials Regulation (Regulation (EU) No 536/2014), and related implementing legislation of individual EU Member States and related guidance at EU level and national level in individual EU Member States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EU Member State</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a country that is (a) included in the Territory and (b) a member state of the European Union.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European Union</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the individual Member States of the European Union.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event of Default</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exchange Act Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all documents filed by Borrower with the SEC pursuant to the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Accounts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Equity Interests</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively:  (i) any Equity Interests in any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) are validly prohibited by Requirements of Law; (ii) any Equity Interests in any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other third-party and such consent, approval or waiver has not been obtained by Borrower following Borrower&#x2019;s commercially reasonable efforts to obtain the same; (iii) any Equity Interests in any Subsidiary that is a non-Wholly-Owned Subsidiary that the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Equity Interests, to secure the Obligations (and any guaranty thereof) are validly prohibited by, or would give any third-party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, the Operating Documents or the joint venture agreement or shareholder agreement with respect to, or any other contract with such third-party relating to such non-Wholly-Owned Subsidiary, including any contract evidencing Indebtedness of such non-Wholly-Owned Subsidiary (other than customary non-assignment provisions which are ineffective under Article 9 of the Code or other Requirements of Law), but only, in each case, to the extent, and for so long as such Operating Document, joint venture agreement, shareholder agreement or other contract is in effect; (iv) all or a portion of the Equity Interests in a Foreign Subsidiary, the pledge of which would, in the reasonable determination of a Responsible Officer of Borrower in good faith, reasonably be expected to result in a tax liability for Borrower or its Subsidiaries under Section 956 of the IRC (or a successor or similar provision) or Treasury Regulations promulgated thereunder as a result of a change in Requirements of Law occurring after the date hereof that causes a material adverse tax consequence to Borrower or its Subsidiaries; and (v) any Equity Interests in any other Subsidiary with respect to which, Borrower and the Collateral Agent reasonably determine by mutual agreement that the cost of granting the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a security interest in and Lien upon, and pledging to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Equity Interests, to secure the Obligations (and any guaranty thereof) are excessive, relative to the value to be afforded to the Secured Parties thereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded License</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an exclusive or non-exclusive license or exclusive or non-exclusive sublicense, by a Credit Party to a Person other than Borrower or any Subsidiary of Borrower, of any Intellectual Property within the Territory covering Product that conveys to the licensee or sublicensee exclusive rights to practice all or substantially all rights to such Intellectual Property in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Property</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning set forth for such term in the Security Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Subsidiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively: (i) any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Subsidiary&#x2019;s properties and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests in such Subsidiary to secure the Obligations (and any guaranty thereof) are validly prohibited by Requirements of Law; (ii) any Subsidiary with respect to which the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, such Subsidiary&#x2019;s properties and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests in such Subsidiary to secure the Obligations (and any guaranty thereof) require the consent, approval or waiver of any Governmental</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authority or other third-party (other than Borrower or an Affiliate of Borrower) and any such consent, approval or waiver has not been obtained, directly or indirectly, by Borrower following Borrower&#x2019;s direct and indirect commercially reasonable efforts to obtain the same; (iii) any Subsidiary that is a non-Wholly Owned Subsidiary, with respect to which, the grant to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of a security interest in and Lien upon, and the pledge to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, of, the properties and assets of such non-Wholly Owned Subsidiary, to secure the Obligations (and any guaranty thereof) are validly prohibited by, or would give any third-party (other than Borrower or an Affiliate of Borrower) the right to terminate its obligations under, such non-Wholly Owned Subsidiary&#x2019;s Operating Documents or the joint venture agreement or shareholder agreement with respect thereto or any other contract with such third-party relating to such non-Wholly Owned Subsidiary, including any contract evidencing Indebtedness of such non-Wholly Owned Subsidiary (other than customary non-assignment provisions which are ineffective under Article 9 of the Code or other Requirements of Law), but only, in each case, to the extent, and for so long as such Operating Document, joint venture agreement, shareholder agreement or other contract is in effect; (iv) with respect to any Foreign Subsidiary, the properties and assets owned by such Subsidiary have an aggregate fair market value (as reasonably determined in good faith by a Responsible Officer of Borrower), individually and when aggregated together with all other Subsidiaries excluded under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, of less than [***] and (v) any other Subsidiary with respect to which, Borrower and the Collateral Agent reasonably determine by mutual agreement that the cost of granting the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a security interest in and Lien upon, and pledging to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, such Subsidiary&#x2019;s properties and assets subject or purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests of such Subsidiary to secure the Obligations (and any guaranty thereof) are excessive relative to the value to be afforded to the Secured Parties thereby.  Notwithstanding the foregoing or any other provision of this Agreement, the parties hereto agree that without the prior written consent of the Collateral Agent or the Required Lenders, no Subsidiary existing as of the Effective Date or organized, formed or acquired, directly or indirectly, by any Credit Party from and after the Effective Date, that at any time (A) owns, co-owns or otherwise maintains any material Company IP, (B) holds a Material Marketing Authorization, (C) licenses any Company IP from any third-party, (D) enters into any Material Contract or otherwise becomes a party thereto or bound thereby or (E) otherwise engages in any business operations material to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer or sale, distribution or sale of Product in the Territory and owns properties and assets with an aggregate fair market value (as reasonably determined in good faith by a Responsible Officer of Borrower) equal to or greater than [***], individually and when aggregated together with all other Subsidiaries excluded under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, shall, in any such case, be (or be deemed to be) an Excluded Subsidiary for any purpose under the Loan Documents and, therefore, such Subsidiary shall constitute a Credit Party for all purposes under the Loan Documents, as of the date of such ownership, co-ownership, maintenance, license, entry or becoming so bound or engagement, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additionally</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case, Borrower shall cause such entity, within the time periods required by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.14</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as and to the extent applicable, to become a Guarantor in accordance therewith.  For the avoidance of doubt, Geron UK Limited and Geron Netherlands B.V. shall be deemed to be an Excluded Subsidiary hereunder as of the Tranche A Closing Date, and each such Subsidiary shall be subject to the immediately preceding sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excluded Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any of the following Taxes imposed on or with respect to Lender or required to be withheld or deducted from a payment to Lender, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed by the United States or as a result of Lender being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) U.S. federal withholding Taxes imposed on amounts payable to or for the account of Lender with respect to any Obligation pursuant to a law in effect on the date on which (i) Lender acquires such interest in any Obligation or (ii) Lender changes its lending office, except in each case to the extent that, pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, amounts with respect to such Taxes were payable either to Lender&#x2019;s assignor immediately before Lender became a party hereto or to Lender immediately before it changed its lending office, (c) Taxes attributable to Lender&#x2019;s failure to comply with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and (d) any U.S. federal withholding Taxes imposed under FATCA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing Credit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, that certain Loan and Security Agreement, dated September 30, 2020, by and among Borrower, Hercules Capital, Inc. and Silicon Valley Bank, as amended by that certain Amendment to Loan and Security Agreement, dated August 12, 2021, by and among Borrower, Hercules Capital, Inc. and Silicon Valley Bank, that certain Second Amendment to Loan and Security Agreement, dated June</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30, 2022, by and among Borrower, Hercules Capital, Inc. and Silicon Valley Bank, and that certain Third Amendment to Loan and Security Agreement, dated December 14, 2023, by and among Borrower, Hercules Capital, Inc. and Silicon Valley Bank, together with all other instruments, documents and agreements delivered by Borrower, in each case, in order to grant or perfect a Lien on any collateral as security for the obligations under the Existing Credit Agreement, and all amendments, restatements, modifications or supplements thereof or thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Export and Import Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any applicable law, regulation, order or directive that applies to the import, export, re-export, transfer, disclosure or provision of goods, software, technology or technical assistance including restrictions or controls administered pursuant to the U.S. Export Administration Regulations, 15 C.F.R. Parts 730-774, administered by the U.S. Department of Commerce, Bureau of Industry and Security; U.S. Customs regulations; and similar import and export laws, regulations, orders and directives of other jurisdictions to the extent applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facility</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Credit Party, any real property (including all buildings, fixtures or other improvements located thereon) now, hereafter or heretofore owned, leased, operated or used by such Credit Party or any of its Subsidiaries or any of their respective predecessors or Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FATCA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Sections 1471 through 1474 of the IRC, as of the date of this Agreement (including, for the avoidance of doubt, any agreements between the governments of the United States and the jurisdiction in which the applicable Lender is resident implementing such provisions), or any amended or successor version that is substantively comparable and not materially more onerous to comply with, and any current or future regulations promulgated thereunder or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the IRC, any intergovernmental agreement entered into in connection with the implementation of the foregoing sections of the IRC and any fiscal or regulatory legislation, regulations, rules or practices adopted pursuant to, or official interpretations implementing such Sections of the IRC or intergovernmental agreements.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FCPA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.18(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Food and Drug Administration (and any United States state and foreign equivalents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA Good Clinical Practices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the standards set forth in 21 C.F.R. Parts 50, 56, 312 and 314 (and any foreign equivalents), and as interpreted through FDA&#x2019;s applicable guidance documents (and foreign equivalents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA Good Laboratory Practices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the standards set forth in 21 C.F.R. Part 58 (and any foreign equivalent), and as interpreted through applicable guidance documents by FDA (and foreign equivalents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA Good Manufacturing Practices</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the standards set forth in 21 C.F.R. Parts 210 and 211 (and any foreign equivalents), and as interpreted through applicable guidance documents by FDA (and foreign equivalents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all applicable statutes (including the Food, Drug, and Cosmetic Act (21 U.S.C &#167; 301 et seq.) and the Public Health Service Act (42 U.S.C. &#167; 262 through &#167; 263)), rules and regulations implemented, administered, or enforced by the FDA and any United States state and foreign equivalents, and as interpreted through applicable guidance documents by the FDA (and United States state and foreign equivalents).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal Reserve Board</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Governors of the Federal Reserve System.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Floor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a rate of interest equal to three percent (3.00%) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">per annum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Lender that is not a &#x201c;United States person&#x201d; as defined in Section 7701(a)(30) of the IRC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Credit Party, any Subsidiary of such Credit Party that is not a Domestic Subsidiary.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means with respect to Borrower and its Subsidiaries, generally accepted accounting principles in the United States as set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination, consistently applied.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as amended and restated from time to time, collectively, (i) Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EU GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and (ii) the UK Data Protection Act 2018 and the EU GDPR as it forms part of the laws of the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018 and as amended by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UK GDPR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any consent, authorization, approval, licensure, clearance, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any nation or government, any state or other political subdivision thereof, any agency (including Regulatory Agencies, data protection authorities, and agencies acting as supervisory governmental organizations on issues of privacy protection), government department (including the U.S. Department of Justice), authority (including state attorneys general), instrumentality, regulatory body, ministry, board, commission, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Payor Programs</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all governmental third-party payor programs in which any Credit Party or its Subsidiaries participates, including Medicare, Medicaid, TRICARE or any other U.S. federal or state health care programs.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Guarantor</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, any Person that is, pursuant to the terms of any Loan Document, a guarantor of any of the Obligations at that time, including any Designated Guarantor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hazardous Materials</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any Governmental Authority or which may or could pose a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hazardous Materials Activity</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any past, current, proposed or threatened activity, event or occurrence involving any Hazardous Materials, including the use, manufacture, possession, storage, holding, presence, existence, location, Release, threatened Release, discharge, placement, generation, transportation, processing, construction, treatment, abatement, removal, remediation, disposal, disposition or handling of any Hazardous Materials, and any corrective action or response action with respect to any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Health Care Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively: (a) applicable federal, state or local laws, rules, regulations, orders, ordinances, codes, statutes, standards, and requirements issued under or in connection with Medicare, Medicaid or any other Governmental Payor Program or</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Private third-party Payor Programs; (b) applicable federal and state laws and regulations governing health information, including HIPAA; (c) applicable federal, state and local fraud and abuse laws of any Governmental Authority, including the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7(b)), the Stark law (42 U.S.C. &#167; 1395nn and 1396b(s)), the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes, and also any other U.S. or foreign laws or regulations that are applicable to health care fraud, abuse, corruption, waste, bribery, inducements, false statements, or false claims; (d) the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Pub. L. No. 108-173) and the regulations promulgated thereunder and any other federal, state or local laws or regulations (or foreign equivalents thereof) governing the disclosure of payments or providing other items of value or remuneration or drug product samples to health care professionals, to the extent applicable; (e) the Physician Payment Sunshine Act (42 U.S.C. &#167; 1320a-7h); (f) all applicable reporting and disclosure requirements, including any arising under the Medicaid Drug Rebate Program (e.g., Monthly and Quarterly Average Manufacturer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Price, Baseline Average Manufacturer Price, and Rebate Per Unit, as applicable), Medicare Part B (Quarterly Average Sales Price), Section 602 of the Veteran&#x2019;s Health Care Act (Public Health Service 340B Quarterly Ceiling Price), Section 603 of the Veteran&#x2019;s Health Care Act  (Quarterly and Annual Non-Federal Average Manufacturer Price and Federal Ceiling Price), Best Price, Federal Supply Schedule Contract Prices and Tricare Retail Pharmacy Refunds, and Medicare Part D; (g) applicable federal, state or local laws, rules, regulations, ordinances, statutes and requirements relating to (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) the regulation of managed care, third-party payors and Persons bearing the financial risk for the provision or arrangement of health care services, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billings to insurance companies, health maintenance organizations and other Managed Care Plans or otherwise relating to insurance fraud and (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">iii</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) any insurance, health maintenance organization or managed care Requirements of Law; (h) regulations for the protection of human research subjects (including 45 C.F.R. part 46, and any foreign or United States state equivalents); (i) requirements for licensure or permitting of personnel who are engaged in marketing, sales, or medical activities under federal, state, or local laws (or foreign equivalents); (j) requirements concerning disclosure of pricing information and other company information to the public, customers, prescribers or to state and local agencies under federal, state, or local laws (or foreign equivalents); (k) laws and regulations requiring the adoption of compliance codes or policies; (l) the interoperability, information blocking, and health information technology certification program regulations promulgated under the 21st Century Cures Act, the underlying provisions of the 21st Century Cures Act (42 U.S.C. &#167; 300jj et seq.) and regulations implementing information blocking penalties promulgated under the 21</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Century Cures Act, as applicable, and (m) any other applicable Requirements of Law relating to research, development, testing, approval, exclusivity, licensure, clearance, authorization, designation, post-approval (or post-licensure, post-clearance, or post-approval, as applicable) monitoring or commitments, reporting, manufacture, production, packaging, labeling, use, commercialization, marketing, promotion, advertising, importing, exporting, storage, transport, distribution, sale or offer for sale, or payment of or for Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedge Termination Value</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Hedging Agreement, after taking into account the effect of any legally enforceable netting agreement relating to such Hedging Agreement (if any), (a) for any date occurring on or after the date such Hedging Agreement has been closed out and termination value determined in accordance therewith, such termination value, and (b) for any date occurring prior to the date referenced in cause (a) above, the amount determine as the mark-to-market value for such Hedging Agreement, as determined based upon one or more mid-market or other readily available quotation(s) provided by any recognized dealer in such Hedging Agreement (which may include a Lender or any Affiliate of a Lender).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any interest rate, currency, commodity or equity swap, collar, cap, floor or forward rate agreement, or other agreement or arrangement designed to protect a Person against fluctuations in interest rates, currency exchange rates or commodity or equity prices or values (including any option with respect to any of the foregoing and any combination of the foregoing agreements or arrangements), and any confirmation execution in connection with any such agreement or arrangement.  Notwithstanding anything to the contrary in the foregoing, any Permitted Equity Derivative shall not constitute a Hedging Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Health Insurance Portability and Accountability Act of 1996, as amended and supplemented by the Health Information Technology for Economic and Clinical Health (HITECH) Act of 2009, any and all rules or regulations promulgated from time to time thereunder (including the regulations codified in 45 C.F.R. Parts 160, 162, and 164), and any U.S. state or federal laws with regard to the security, privacy, or notification of breaches of the confidentiality of health information which are not preempted pursuant to 45 C.F.R. Part 160, Subpart B.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IFRS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means international accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the relevant financial statements.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, without duplication:  (a) all indebtedness for advanced or borrowed money of, or credit extended to, such Person; (b) all obligations issued, undertaken or assumed by such Person as the deferred purchase price of assets, properties, services or rights (other than (i) accrued expenses and trade payables entered into in the ordinary course of business consistent with past practice which are not more than one hundred and eighty (180) days past due or subject to a bona fide dispute, (ii) obligations to pay for services provided by employees and individual independent contractors in the ordinary course of business consistent with past practice which are not more than one hundred twenty (120) days past due or subject to a bona fide dispute, (iii) liabilities associated with customer prepayments and deposits and (iv) prepaid or deferred revenue arising in the ordinary course</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of business), including (A) any obligation or liability to pay deferred purchase price or other similar deferred consideration for such assets, properties, services or rights where such deferred purchase price or consideration becomes due and payable solely upon the passage of time, and (B) any obligation described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Contingent Obligation that becomes due and payable (or that becomes due and payable) solely with the passage of time (and not the occurrence of an event or the performance of an act); (c) the face amount of all letters of credit issued for the account of such Person and, without duplication, all drafts drawn thereunder and all reimbursement or payment obligations with respect to letters of credit, surety bonds, performance bonds and other similar instruments issued by such Person; (d) all obligations of such Person evidenced by notes, bonds, debentures or other debt securities or similar instruments (including debt securities convertible into Equity Interests (including Permitted Convertible Indebtedness)), including obligations so evidenced incurred in connection with the acquisition of properties, assets or businesses; (e) all indebtedness of such Person created or arising under any conditional sale or other title retention agreement or incurred as financing, in either case with respect to property acquired by such Person (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property); (f) all Capital Lease Obligations of such Person; (g) the principal balance outstanding under any synthetic lease, off-balance sheet loan or similar off balance sheet financing product by such Person; (h) Disqualified Equity Interests; (i) all indebtedness referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above of other Persons secured by (or for which the holder of such indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in assets or properties (including accounts and contracts rights) owned by such Person, even though such Person has not assumed or become liable for the payment of such indebtedness of such other Persons; and (j) all Contingent Obligations of such Person.  For the avoidance of doubt, &#x201c;Indebtedness&#x201d; shall include Permitted Convertible Indebtedness but shall not include any Permitted Equity Derivatives.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Liabilities</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, any and all liabilities, obligations, losses, damages (including natural resource damages), penalties, claims, actions, judgments, suits, costs, reasonable and documented out-of-pocket fees, expenses and disbursements of any kind or nature whatsoever (including the reasonable and documented fees and disbursements of one primary legal counsel for Indemnified Persons plus, as applicable, one local legal counsel in each relevant material jurisdiction and one intellectual property legal counsel, and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Persons), incurred by any Indemnified Person or asserted against any Indemnified Person by any Person (including Borrower or any other Credit Party) relating to or arising out of or in connection with, or as a result of, this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby (including any Lender&#x2019;s agreement to make Credit Extensions or the use or intended use of the proceeds thereof, or any enforcement of any of the Loan Documents (including any sale of, collection from, or other realization upon any of the Collateral or the enforcement of any guaranty of the Obligations)), including (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) any Term Loan or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by Borrower or any of its Subsidiaries, or any liability relating to any Environmental Law, any Release of Hazardous Materials or any Hazardous Materials Activity, (iv) any actual or prospective claim, suit, litigation, investigation, hearing or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by, commenced or threatened in writing by any Person (including Borrower or any of its affiliates), and regardless of whether any Indemnified Person is or is designated as a party or a potential party thereto, and (v) the enforcement of the indemnity hereunder, in each case whether direct, indirect or consequential and whether based on any federal, state or foreign laws, statutes, rules or regulations, on common law or equitable cause or on contract or otherwise, that may be imposed on, incurred by, or asserted against any such Indemnified Person, in any manner.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Credit Party under any Loan Document and (b) to the extent not otherwise described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, Other Taxes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insolvency Proceeding</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, any proceeding by or against such Person under the Bankruptcy Code, or any other domestic or foreign bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">arrangement, rescue process or other relief; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, solely with respect to any Person incorporated, organized or formed in any jurisdiction other than the United States, &#x201c;Insolvency Proceeding&#x201d; shall not include any winding-up petition against such Credit Party which is frivolous or vexatious and is discharged or dismissed within thirty (30) days of the commencement thereof or any step or procedure in connection with any transaction otherwise permitted under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Copyrights, Trademarks, and Patents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	trade secrets and trade secret rights, including any rights to unpatented inventions, know-how, show-how and operating manuals;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	(i) all computer programs, including source code and object code versions, (ii) all data, databases and compilations of data, whether machine readable or otherwise, and (iii) all documentation, training materials and configurations related to any of the foregoing (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	all right, title and interest arising under any contract or Requirements of Law in or relating to Internet Domain Names;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	design rights;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	IP Ancillary Rights (including all IP Ancillary Rights related to any of the foregoing); and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	any similar or equivalent rights to any of the foregoing anywhere in the world.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain New York law-governed intercreditor agreement, dated as of the Tranche A Closing Date, between the Collateral Agent (for the benefit of Lenders and the other Secured Parties) and Royalty Pharma, and acknowledged and agreed by Borrower and the other Credit Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the last day of each calendar quarter, commencing with the last Business Day occurring in the calendar quarter during which the Tranche A Closing Date occurs.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to each Term Loan: (a)(i) with respect to the Tranche A Loan, the period commencing on (and including) the Tranche A Closing Date and ending on (and including) December 31, 2024, (ii) with respect to the Tranche B Loan, the period commencing on (and including) the Tranche B Closing Date and ending on (and including) the first Interest Date following the Tranche B Closing Date, and (iii) with respect to the Tranche C Loan, the period commencing on (and including) the Tranche C Closing Date and ending on (and including) the first Interest Date following the Tranche C Closing Date; and (b) thereafter, with respect to each Term Loan, each period beginning on (and including) the first day following the end of the preceding Interest Period and ending on the earlier of (and including) (x) the next Interest Date and (y) the Term Loan Maturity Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Internet Domain Name</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all right, title and interest (and all related IP Ancillary Rights) arising under any contract or Requirements of Law in or relating to Internet domain names.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all &#x201c;inventory&#x201d; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes all merchandise (including Product), materials (including raw materials), parts, components (including component materials and component raw materials), supplies, packing and shipping materials, work in process and finished products, technology (including software, systems, and solutions), and all elements needed to fulfill obligations related to Product under any Manufacturing Agreements including such inventory as is temporarily out of a Credit Party&#x2019;s or Subsidiary&#x2019;s custody or possession or in transit (prior to title having transferred) and including any returned goods and any documents of title representing any of the above.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any beneficial ownership interest in any Person (including Equity Interests), (b) any Acquisition or (c) the making of any advance, loan, extension of credit or capital contribution in or to, any Person.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amount of an Investment shall be the amount actually invested (which, in the case of any Investment by a Credit Party or any of its Subsidiaries constituting the contribution of an asset or property, shall be based on the good faith estimate of the fair market value of such asset or property at the time such Investment is made as reasonably determined in good faith by a Responsible Officer of such Credit Party), less the amount of cash received or returned for such Investment, without adjustment for subsequent increases or decreases in the value of such Investment or write-ups, write-downs or write-offs with respect thereto; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that in no event shall such amount be less than zero.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, (a) those certain IP Security Agreement(s) entered into by and between Borrower and the Collateral Agent, dated as of the Tranche A Closing Date, and (b) any IP Security Agreement entered into by and between any relevant Credit Party and the Collateral Agent after the Tranche A Closing Date in accordance with the Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP Ancillary Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights, including any rights to unpatented inventions, know-how, show-how and operating manuals, all income, royalties, proceeds and liabilities at any time due or payable or asserted under or with respect to any of the foregoing or otherwise with respect thereto, including all rights to sue or recover at law or in equity for any past, present or future infringement, misappropriation, dilution, violation or other impairment thereof, and, in each case, all rights to obtain any other intellectual property right ancillary to any Copyright, Trademark, Patent, Software, trade secrets or trade secret rights.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IP Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means &#x201c;IP Security Agreement&#x201d;, as such term is defined in the Security Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IRC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, or any successor statute.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States Internal Revenue Service or any successor agency.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Knowledge</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, the actual knowledge, after reasonable investigation, of the Responsible Officers of such Person; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with respect to Borrower, reasonable investigation means that Borrower has also affirmatively sought out information from its Subsidiaries.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each Person signatory hereto as a &#x201c;Lender&#x201d; and its successors and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	all reasonable and documented out-of-pocket fees and expenses of the Collateral Agent and, as applicable, each Lender (and their respective successors and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any legal counsel or other professional advisors (it being agreed that such legal counsel fees, expenses and disbursements shall be limited to one primary legal counsel, one local legal counsel in each applicable jurisdiction and one intellectual property legal counsel (as and to the extent applicable) for the Collateral Agent, Lenders and Related Parties, taken as a whole</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person)), manufacturing consultants, safety consultants or intellectual property experts (it being agreed that such consultant or expert fees, expenses and disbursements shall be limited to one of each such consultant and one such expert for the Collateral Agent, Lenders and such Related Parties, taken as a whole) therefor, (i) incurred in connection with developing, preparing, negotiating, syndicating, executing and delivering, and interpreting, investigating and administering, the Loan Documents (or any term or provision thereof), any commitment, proposal letter, letter of intent or term sheet therefor or any other document prepared in connection therewith, (ii) incurred in connection with the consummation and administration of any transaction contemplated therein, (iii) incurred in connection with the performance of any obligation or agreement contemplated therein, (iv) incurred in connection with any modification or amendment or restatement of any term or provision of, or any supplement to, or the termination (in whole or in part) of, any Loan Document, (v) incurred in connection with internal audit reviews and Collateral audits, or (vi) otherwise incurred with respect to the Credit Parties in connection with the Loan Documents, including any filing or recording fees and expenses; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the payment by Borrower of the Lender Expenses incurred for</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">legal counsel which are due and payable on the Tranche A Closing Date shall be calculated in accordance with the provisions of the Letter Agreement providing therefor; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	all reasonable and documented out-of-pocket costs and expenses incurred by the Collateral Agent and each Lender (and their respective successors and assigns) and their respective Related Parties (including the reasonable and documented out-of-pocket fees, expenses and disbursements of any legal counsel therefor for the Collateral Agent, Lenders and such Related Parties taken as a whole and in the case of an actual or perceived conflict of interest, one additional legal counsel for such affected Indemnified Person) in connection with (i) any refinancing or restructuring of the credit arrangements provided hereunder in the nature of a &#x201c;work-out,&#x201d; (ii) the enforcement or protection or preservation of any right or remedy under any Loan Document, any Obligation, with respect to any of the Collateral or any other related right or remedy, or (iii) the commencement, defense, conduct of, intervention in, or the taking of any other action with respect to, any proceeding (including any Insolvency Proceeding) related to any Credit Party or any Subsidiary of any Credit Party in respect of any Loan Document or Obligation, or otherwise in connection with any Loan Document or Obligation (or the response to and preparation for any subpoena or request for document production relating thereto).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lender Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Letter Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain agreement by and among Pharmakon Advisors, LP and Borrower dated September 12, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind or assignment for security purposes, whether voluntarily incurred or arising by operation of law or otherwise against any property or assets.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation Acts</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Limitation Act 1980 and the Foreign Limitation Periods Act 1984.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, this Agreement, the Disclosure Letter, the Term Loan Notes, the Security Agreement, the IP Agreements, the Perfection Certificate, any Control Agreement, any Collateral Access Agreement, the Intercreditor Agreement, any other Collateral Document, any guaranties executed by a Guarantor in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties in connection with this Agreement, and any other present or future agreement between or among a Credit Party, the Collateral Agent and any Lender in connection with this Agreement, including in each case, for the avoidance of doubt, any annexes, exhibits or schedules thereto, and any related ancillary documents, accessions, agreements, waivers or consents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Logistics Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any agreement between the Borrower or its Subsidiaries, on the one hand, and a Person acting solely as a Logistics Provider, on the other hand, including agreements with specialty pharmacies and specialty distributors, in each case (x) entered into in the ordinary course of business and (y) that does not substantively constitute an out-licensing or sale transaction with respect to Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Logistics Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Person that has the right, option or obligation to distribute, transport, warehouse, package, import, or provide similar logistics services with respect to Product pursuant to a Logistics Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Makewhole Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A Makewhole Amount, the Tranche B Makewhole Amount or the Tranche C Makewhole Amount (as applicable) or any combination thereof, as the context dictates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Managed Care Plans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all health maintenance organizations, preferred provider organizations, individual practice associations, competitive medical plans and similar arrangements.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any manufacturing or supply contract or agreement entered into by any Credit Party or any of its Subsidiaries with third parties for (i) the commercial supply in the Territory of any Product for any indication or (ii) the commercial manufacture or in-bound supply of any raw materials or component(s) (including component raw materials and other component materials) incorporated into any Product (with the Manufacturing Agreements in effect as of the Effective Date being set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter),</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (b) any future contract or agreement entered into after the Effective Date by any Credit Party or any of its Subsidiaries with third parties for (i) the clinical or commercial manufacture or in-bound supply in the Territory of Product for any indication or (ii) the commercial manufacture or in-bound supply of any raw materials or component(s) (including component raw materials and other component materials) incorporated into any Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means &#x201c;margin stock&#x201d; within the meaning of Regulations U and X of the Federal Reserve Board as now and from time-to-time hereafter in effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Change</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any material adverse change in or material adverse effect on: (a) the business, financial condition, properties or assets (including all or any material portion of the Collateral), liabilities (actual or contingent), operations or performance of the Credit Parties, taken as a whole, since December 31, 2023; (b) without limiting the generality of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, (i) any of the rights or remedies of the Credit Parties, taken as a whole, in or related to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the U.S., or (ii) the period of regulatory exclusivity granted by the applicable Regulatory Agency for Product in the U.S. (including Orphan Drug exclusivity); (c) any ability of the Credit Parties, taken as a whole, to fulfill the payment or performance obligations under the Loan Agreement or any other Loan Document; (d) the binding nature or validity of, or the ability of the Collateral Agent, the Intercreditor Agent or any Lender to enforce, any of the Loan Documents or any of its material rights or remedies under any of the Loan Documents; or (e) the validity, perfection (except to the extent expressly permitted under the Loan Documents) or priority of Liens in favor of the Collateral Agent, for the benefit of the Lenders and the other Secured Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any contract or other arrangement to which any Credit Party or any of its Subsidiaries is a party (other than the Loan Documents) or by which any of its assets or properties are bound, in each case, relating to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the Territory, for which the breach of, default or nonperformance under, cancellation or termination of or the failure to renew could reasonably be expected to result in a Material Adverse Change.  For the avoidance of doubt, (x) each Manufacturing Agreement and each Company IP Agreement is deemed to be a Material Contract for all purposes hereunder and (y) the Royalty Revenue Contract and each other Royalty Revenue Document is deemed to be a Material Contract for all purposes hereunder.  For the avoidance of doubt, the following agreements are not Material Contracts: (a) any customer contracts, (b) any purchase orders or statements of work entered into from time to time in the ordinary course of business pursuant to Manufacturing Agreements, except, in each case if any such order or statement is in the form of an amendment to or otherwise amends any material terms of any Manufacturing Agreement, (c) agreements or other contractual arrangements in connection with capital expenditures in the ordinary course of business, (d) agreements or other contractual arrangements entered into in the ordinary course of business in connection with the purchase of materials or the sale of third-party products for further distribution and (e) distribution agreements entered into in the ordinary course of business with third parties for the sale of Product in a specific territory outside of the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Marketing Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a marketing authorization with respect to RYTELO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United Kingdom or the European Union (and as to the European Union, excluding, for the avoidance of doubt, authorizations granted in its individual member states).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicaid</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the health care assistance program established by Title XIX of the SSA (42 U.S.C. &#167; 1396 et seq.).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicare</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the health insurance program for the aged and disabled established by Title XVIII of the SSA (42 U.S.C. 1395 et seq.).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MHRA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Medicines and Healthcare products Regulatory Agency that regulates medicinal products, medical devices and blood components for transfusion in the U.K.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mortgage</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any deed of trust, leasehold deed of trust, mortgage, leasehold mortgage, deed to secure debt, leasehold deed to secure debt or other document creating a Lien on real estate or any interest in real estate.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Multiemployer Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a multiemployer plan within the meaning of Section 4001(a)(3) or Section 3(37) of ERISA (a) to which Borrower or its Subsidiaries or their respective ERISA Affiliates is then making or accruing an obligation to make contributions; (b) to which Borrower or its Subsidiaries or their respective ERISA Affiliates has within the preceding five (5) plan years made contributions; or (c) with respect to which Borrower or its Subsidiaries could incur material liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a new drug application, submitted to the FDA pursuant to 21 U.S.C. &#167; 355 seeking authorization to market a new drug in the United States, or any foreign equivalent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any period, net sales of RYTELO&#153; in the U.S. occurring during such period, determined by a Responsible Officer of Borrower in good faith in accordance with GAAP and as presented in Borrower&#x2019;s financial statements (including, with respect of any portion of such period covered by financial statements filed with the SEC (if any), such filed financial statements); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that &#x201c;Net Sales&#x201d; shall exclude any milestone payments, any non-recurring payments and any non-sales-based revenues or proceeds.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Register</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the Credit Parties&#x2019; obligations to pay when due any and all debts, principal, interest, Lender Expenses, the Additional Consideration, the Makewhole Amount, the Prepayment Premium and any other fees, expenses, indemnities and amounts any Credit Party owes any Lender or the Collateral Agent now or later, under this Agreement or any other Loan Document, including interest accruing after Insolvency Proceedings begin (whether or not allowed), and to perform Borrower&#x2019;s duties under the Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OFAC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.18(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively with respect to any Person, such Person&#x2019;s formation and constitutional documents and, (a) if such Person is a corporation, its bylaws (or similar organizational regulations), (b) if such Person is an exempted company or a company limited by shares, its memorandum and articles of association (or similar organizational regulations), (c) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (d) if such Person is a partnership, its partnership agreement (or similar agreement), in each case including all amendments, restatements, amendment and restatements, supplements and other modifications thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ordinary course of business</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in respect of any transaction involving any Person, the ordinary course of such Person&#x2019;s business, undertaken by such Person in good faith and not for purposes of evading any covenant, prepayment obligation or restriction in any Loan Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan Drug</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a drug or biologic that meets the definition for &#x201c;orphan drug&#x201d; provided in 21 C.F.R. &#167; 316.3(b)(10) that has been granted an orphan drug designation by the Secretary of U.S. Department of Health and Human Services under 21 U.S.C. &#167; 360bb, and any foreign equivalents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Connection Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Lender, Taxes imposed as a result of a present or former connection (including present or former connection of its agents) between such Lender and the jurisdiction imposing such Tax (other than connections arising solely from such Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Term Loan or Loan Document).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all present or future stamp, court or documentary, intangible, recording, excise, filing, value added Taxes, mortgage or property Taxes, charges or similar levies or similar Taxes that arise from any payment made hereunder, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to a Lender Transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1(d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all patents and patent applications (including any improvements, continuations, continuations-in-part, divisions, provisionals or any substitute applications), any patent issued with respect to any of the foregoing patent applications, any reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign and international counterparts of any of the foregoing.  For the avoidance of doubt, patents and patent applications under this definition include individual patent claims and include all those filed with the U.S. Patent and Trademark Office or which could be nationalized in the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patriot Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1(h).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PCI Cap</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as of the date of the pricing of any Permitted Convertible Indebtedness or other date of determination, as applicable, an amount not to exceed the greater of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the product of (i) TTM Net Revenue for the trailing twelve-month period ended as of day immediately prior to such date, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ii) 2.0; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in any case no Default or Event of Default has occurred and is continuing as of such date (including, for the avoidance of doubt, any Material Adverse Change or Withdrawal Event).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Perfection Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic Term SOFR Determination Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; has the meaning specified in the definition of &#x201c;Term SOFR&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Acquisition, so long as:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	no Default or Event of Default shall have occurred and be continuing as of, or could reasonably be expected to result from, the consummation of such Acquisition;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	the properties or assets being acquired or licensed, or the Person whose Equity Interests are being acquired, are useful in or engaged in, as applicable, (i) the same or a related line of business as that then-conducted by Borrower or its Subsidiaries, or (ii) a line of business that is ancillary to and in furtherance of a line of business as that then-conducted by Borrower or its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	in the case of an Asset Acquisition, the subject assets are being acquired or licensed by a Credit Party, and within the timeframes expressly set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to all assets constituting Collateral, such Credit Party shall have executed and delivered or authorized, as applicable, any and all security agreements, financing statements and any other documentation required by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or reasonably requested by the Collateral Agent, in order to include the newly acquired or licensed assets within the Collateral, as applicable, to the extent required by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	in the case of a Stock Acquisition, the subject Equity Interests are being acquired in such Acquisition directly or indirectly by a Credit Party, and such Credit Party shall have complied with its obligations under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.13</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	any Indebtedness or Liens assumed in connection with such Acquisition are otherwise permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Convertible Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Indebtedness of Borrower or any Subsidiary of Borrower that is a Credit Party having a feature which entitles the holder thereof in certain circumstances to convert or exchange all or a portion of such Indebtedness into Equity Interests in Borrower or such Subsidiary (or other securities or property following a merger event or other change of the common stock of Borrower or such Subsidiary), cash or any combination of cash and such Equity Interests (or such other securities or property) based on the market price of such Equity Interests (or such other securities or property); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that (a) such Indebtedness shall be unsecured, (b) such Indebtedness shall not be guaranteed by any Subsidiary of Borrower, (c) such Indebtedness shall bear interest at a rate </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">per annum</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> not to exceed the greater of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***] </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and such rate as is customary in the market at such time, as determined in the reasonable commercial judgement of a Responsible Officer of Borrower in good faith, (d) such Indebtedness shall not include covenants and defaults (other than covenants and defaults customary for</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">convertible indebtedness but not customary for loans, as determined by Borrower in its good faith judgment) that are, taken as a whole, more restrictive on the Credit Parties than the provisions of this Agreement (as determined by Borrower in its good faith judgment), (e) immediately prior to and after giving effect to the incurrence of such Indebtedness, no Default or Event of Default shall have occurred and be continuing or could reasonably be expected to occur as a result therefrom (after giving effect to this Agreement), (f) such Indebtedness shall not (i) mature or be mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, (ii) be redeemable at the option of the holder thereof, in whole or in part or (iii) provide for the scheduled payment of dividends or distributions (other than scheduled cash interest payments) in cash, in each case of the foregoing </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clauses (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, earlier than six (6) months after the Term Loan Maturity Date (it being understood, for the avoidance of doubt, that (w) a redemption right of Borrower or such Subsidiary in respect of such Indebtedness, (x) conversion rights of holders in respect of such Indebtedness, (y) acceleration rights of holders of such Indebtedness upon the occurrence of an event of default specified in the agreement governing such Indebtedness and (z) the obligation to pay customary amounts to holders of such Indebtedness in connection with a &#x201c;change of control&#x201d; or &#x201c;fundamental change&#x201d;, in each case, shall not be considered in connection with the determination of scheduled maturity date for purposes of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">); (g) immediately after giving effect to the incurrence of any such Indebtedness (and any prepayment, repurchase or redemption of any existing Permitted Convertible Indebtedness using cash proceeds of the issuance of such Indebtedness (and any cash proceeds received pursuant to the exercise, early unwind or termination of any Permitted Equity Derivatives in connection with such prepayment, repurchase or redemption)), the amount of all Permitted Convertible Indebtedness permitted hereunder (together with any Indebtedness incurred to refinance Permitted Convertible Indebtedness pursuant to clause (u) of the definition of Permitted Indebtedness) and then outstanding shall not exceed the PCI Cap; and (h) Borrower shall have delivered to the Collateral Agent a certificate of a Responsible Officer of Borrower certifying as to the foregoing clauses </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with respect to any such Indebtedness.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in each case subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if applicable:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	dividends, distributions or other payments by any Wholly Owned Subsidiary of Borrower on its Equity Interests to, or the redemption, retirement or purchase by any Wholly Owned Subsidiary of Borrower of its Equity Interests from, Borrower or any other Wholly Owned Subsidiary of Borrower;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	dividends, distributions or other payments by any non-Wholly Owned Subsidiary on its Equity Interests to, or the redemption, retirement or purchase by any non-Wholly Owned Subsidiary of its Equity Interests from, Borrower or any other Subsidiary or each other owner of such non-Wholly Owned Subsidiary&#x2019;s Equity Interests based on their relative ownership interests of the relevant class of such Equity Interests;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	exchanges, redemptions or conversions by Borrower in whole or in part any of its Equity Interests for or into another class of its Equity Interests or rights to acquire its Equity Interests or with proceeds from substantially concurrent equity contributions or issuances of new Equity Interests;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	any such payments arising from (i) a Permitted Acquisition or (ii) other Permitted Investment, in each case of this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by Borrower or any of its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	the payment of dividends by Borrower solely in non-cash pay and non-redeemable capital stock (including, for the avoidance of doubt, dividends and distributions payable solely in Equity Interests);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	cash payments in lieu of the issuance of fractional shares arising out of stock dividends, splits or combinations or in connection with the exercise of warrants, options or other securities convertible into or exchangeable for Equity Interests, including Permitted Convertible Indebtedness;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	in connection with any Acquisition or other Investment by Borrower or any of its Subsidiaries, (i) the receipt or acceptance of the return to Borrower or any of its Subsidiaries of Equity Interests of Borrower constituting a portion of the purchase price consideration in settlement of indemnification claims, or as a result of a purchase price adjustment (including earn-outs or similar obligations) and (ii) payments or distributions to equity holders pursuant to appraisal rights required under Requirements of Law;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	the distribution of rights pursuant to any shareholder rights plan or the redemption of such rights for nominal consideration in accordance with the terms of any shareholder rights plan;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	dividends, distributions or payments on its Equity Interests by any Subsidiary to any Credit Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	dividends, distributions or payments on its Equity Interests by any Subsidiary that is not a Credit Party to any other Subsidiary that is not a Credit Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	purchases of Equity Interests of Borrower or its Subsidiaries in connection with net settlements, the exercise of stock options by way of cashless exercise, or in connection with the satisfaction of withholding tax obligations;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	issuance to directors, officers, employees or contractors of Borrower or its Subsidiaries of awards or common stock of Borrower pursuant to awards, of restricted stock, restricted stock units, or other rights to acquire common stock of Borrower, in each case pursuant to plans or agreements approved by Borrower&#x2019;s Board of Directors (or committee thereof) or stockholders;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	the repurchase, retirement or other acquisition or retirement for value of Equity Interests of Borrower or any of its Subsidiaries held by any future, present or former employee, consultant, officer or director (or spouse, ex-spouse or estate of any of the foregoing or trust for the benefit of any of the foregoing or any lineal descendants thereof) of Borrower or any of its Subsidiaries pursuant to any management equity plan or stock option plan or any other management or employee benefit plan or agreement, or any stock subscription or shareholder agreement or employment agreement; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the aggregate payments made under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (m)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> do not exceed in any calendar year the sum of (i) [***] </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">plus</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ii) the amount of any payments received in such calendar year under key-man life insurance policies;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	dividends or distributions on its Equity Interests by Borrower or any of its Subsidiaries payable solely in additional shares of its common stock;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	additional Restricted Payments in an aggregate amount not to exceed [***] in the aggregate; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	solely in connection with Permitted Convertible Indebtedness, the Credit Parties or its Subsidiaries may enter into Permitted Equity Derivatives (and may settle, terminate or unwind any such Permitted Equity Derivatives in connection with any refinancing, repurchase, redemption, early conversion or maturity of such Permitted Convertible Indebtedness).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Equity Derivative</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any call or capped call option (or substantively equivalent equity derivative transaction) or &#x201c;call spread&#x201d; transaction (which consists of separate call option and warrant transactions) relating to the Equity Interests of Borrower or any other Credit Party purchased by Borrower or such Credit Party in connection with the issuance of Permitted Convertible Indebtedness by Borrower or such other Credit Party, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the purchase price for such call or capped call option or such other transaction (net of any proceeds received from the issuance of any related warrant transactions) does not exceed the net cash proceeds received by Borrower or such other Credit Party from the issuance of such Permitted Convertible Indebtedness.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Indebtedness of the Credit Parties to Secured Parties under this Agreement and the other Loan Documents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Indebtedness existing on the Effective Date and shown on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no Indebtedness of any Credit Party or any Subsidiary under the Existing Credit Agreement existing on the Tranche A Closing Date or any time thereafter, which shall be repaid in full pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be &#x201c;Permitted Indebtedness&#x201d; for purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other purposes under this Agreement (other than for purposes of the representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or the other Loan Documents;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Permitted Convertible Indebtedness (for the avoidance of doubt, in an aggregate principal amount not to exceed the PCI Cap at the time of any incurrence thereof);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	(i) Indebtedness incurred to finance the purchase, construction, repair, or improvement of fixed assets and (ii) Capital Lease Obligations; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that all such Indebtedness and Capital Lease Obligations do not exceed [***] in the aggregate at any time outstanding;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Indebtedness in connection with trade credit, corporate credit cards, purchasing cards or bank card products, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any such Indebtedness that is secured shall not exceed [***] in the aggregate at any time outstanding;</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	guarantees of Permitted Indebtedness;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Indebtedness assumed in connection with any Permitted Acquisition or Permitted Investment, so long as (i) such Indebtedness was not incurred in connection with, or in anticipation of, such Acquisition or Investment and (ii) such Indebtedness is at all times Subordinated Debt or Capital Lease Obligations;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	Indebtedness of Borrower or any of its Subsidiaries with respect to letters of credit, bank guarantees, bankers&#x2019; acceptances, warehouse receipts or similar instruments outstanding and to the extent secured, secured solely by cash or Cash Equivalents, in each case entered into in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Indebtedness owed: (i) by a Credit Party to another Credit Party; (ii) by a Subsidiary of Borrower that is not a Credit Party to another Subsidiary of Borrower that is not a Credit Party; (iii) by a Credit Party to a Subsidiary of Borrower that is not a Credit Party; or (iv) by a Subsidiary of Borrower that is not a Credit Party to a Credit Party, not to exceed [***] in the aggregate at any time outstanding;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Indebtedness consisting of Contingent Obligations described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition thereof: (i) of a Credit Party of Permitted Indebtedness of another Credit Party (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder); (ii) of a Subsidiary of Borrower which is not a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder) of another Subsidiary of Borrower which is not a Credit Party; (iii) of a Subsidiary of Borrower which is not a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder) of a Credit Party; or </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of a Credit Party of Permitted Indebtedness (or obligations that do not constitute Indebtedness hereunder and are not prohibited hereunder) of a Subsidiary of Borrower which is not a Credit Party not to exceed [***] in the aggregate at any time outstanding;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Indebtedness consisting of Contingent Obligations described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition thereof, incurred in connection with any Permitted Acquisition, Permitted Transfer, Permitted Investment or any in-licensing or any collaboration, co-promotion or co-marketing arrangement; provided such Indebtedness is due and payable upon the occurrence of an event or the performance of an act (and not solely with the passage of time);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Indebtedness of any Person that becomes a (direct or indirect) Subsidiary of Borrower (or of any Person not previously a Subsidiary that is merged or consolidated with or into a Subsidiary of Borrower in a transaction permitted hereunder after the Effective Date); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all such Indebtedness was not made in contemplation of or in connection with such Person becoming a (direct or indirect) Subsidiary of Borrower (or merging or consolidating with or into a Subsidiary of Borrower) or the Permitted Acquisition of any related assets;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	(i) Indebtedness with respect to workers&#x2019; compensation claims, payment obligations in connection with health, disability or other types of social security benefits, unemployment or other insurance obligations, reclamation and statutory obligations or (ii) Indebtedness related to employee benefit plans, including annual employee bonuses, accrued wage increases and 401(k) plan matching obligations; in each case, incurred in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	Indebtedness in respect of performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and similar obligations arising in the ordinary course of business;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Indebtedness in respect of netting services, overdraft protection and other cash management services, in each case in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Indebtedness consisting of the financing of insurance premiums in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	Indebtedness consisting of guarantees resulting from endorsement of negotiable instruments for collection by any Credit Party in the ordinary course of business;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	unsecured Indebtedness incurred in connection with any items of Permitted Distributions in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (m)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Distributions;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	to the extent constituting Indebtedness, Permitted Equity Derivatives;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	Indebtedness under any (i) unsecured Hedging Agreements entered into for hedging and not speculative purposes, and (ii) Hedging Agreements with respect to interest rates that are secured only by cash or Cash Equivalents and entered into for hedging and not speculative purposes;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	subject to the proviso immediately below, extensions, refinancings, renewals, modifications, amendments, restatements and, in the case of any items of Permitted Indebtedness in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition thereof or Permitted Indebtedness constituting notes governed by an indenture (including Permitted Convertible Indebtedness), exchanges, of any items of Permitted Indebtedness in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in the case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, the principal amount thereof is not increased (other than by any reasonable amount of premium (if any), interest (including post-petition interest), fees, expenses, charges or additional or contingent interest reasonably incurred in connection with the same and the terms thereof); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in the case of any Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, (w) the maturity thereof is not shortened to a date that is less than six (6) months after the Term Loan Maturity Date, (x) the amount of all Permitted Convertible Indebtedness permitted hereunder and then outstanding does not exceed the PCI Cap, (y) there is no change to or addition of any direct or indirect obligor with respect thereto unless such new obligor thereto is or shall become a Guarantor hereunder, and (z) such extension, refinancing, renewal, modification, amendment, restatement or exchange is expressly permitted under this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) 	other Indebtedness, not to exceed [***] in the aggregate at any time outstanding.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the foregoing or anything in this Agreement to the contrary, except with respect to the Royalty Revenue Contract and the other Royalty Revenue Documents, (x) no direct or indirect synthetic royalty or similar financing transaction involving the sale of revenues or royalties entered into after the Tranche A Closing Date, and (y) except to the extent incurred in connection with any Permitted Acquisitions, Permitted Investments, in-licensing agreements or any collaboration, co-promotion or co-marketing arrangements, no Indebtedness constituting royalty payments or milestone payments based on net sales or similar payments that is, directly or indirectly, created, incurred, assumed or guaranteed after the Tranche A Closing Date, in each case of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sub-clause (x)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(y)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, by a Credit Party or any of its Subsidiaries, shall in any instance be permitted under this Agreement without the prior written consent of the Collateral Agent or the Required Lenders.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Investments (including Investments in Borrower and Subsidiaries) existing on the Effective Date and shown on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, and any extensions, renewals or reinvestments thereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Investments consisting of cash and Cash Equivalents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Investments consisting of deposit accounts or securities accounts;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Investments in connection with Permitted Transfers;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Investments consisting of (i) travel advances and employee relocation loans and other employee advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower pursuant to employee stock purchase plans or agreements approved by Borrower&#x2019;s Board of Directors (or committee thereof);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	Investments consisting of accounts or notes receivable of, or prepaid royalties and other credit extensions, to customers, suppliers and manufacturers who are not Affiliates, in the ordinary course of business; provided that this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (h)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall not apply to Investments of any Credit Party in any of its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	joint ventures or strategic alliances consisting of the licensing of technology, the development of technology or the providing of technical support;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Investments (i) required in connection with a Permitted Acquisition (including the formation of any Subsidiary for the purpose of effectuating such Permitted Acquisition, the capitalization of such Subsidiary whether by capital contribution or intercompany loans, in each case, to the extent otherwise permitted by the terms of this Agreement, related Investments in Subsidiaries necessary to consummate such Permitted Acquisition, and the receipt of any non-cash consideration in a Permitted Acquisition), and (ii) consisting of earnest money deposits required in connection with a Permitted Acquisition or other acquisition of properties or assets not otherwise prohibited hereunder;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	Investments constituting the formation of any Subsidiary for the purpose of consummating a merger or acquisition transaction permitted by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.3(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, which such transaction is otherwise a Permitted Investment;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	Investments of any Person that (i) becomes a Subsidiary of Borrower (or of any Person not previously a Subsidiary of Borrower that is merged or consolidated with or into a Subsidiary of Borrower in a transaction permitted hereunder) after the Effective Date, or (ii) are assumed after the Effective Date by any Subsidiary of Borrower in connection with an acquisition of assets from such Person by such Subsidiary, in either case, in a Permitted Acquisition; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in each case any such Investment (w) does not constitute Indebtedness of such Person, (x) exists at the time such Person becomes a Subsidiary of Borrower (or is merged or consolidated with or into a Subsidiary of Borrower) or such assets are acquired, (y) was not made in contemplation of or in connection with such Person becoming a Subsidiary of Borrower (or merging or consolidating with or into a Subsidiary of Borrower) or such acquisition of assets, and (z) could not reasonably be expected to result in a Default or an Event of Default;	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	Investments arising as a result of the licensing of Intellectual Property in the ordinary course of business and not prohibited hereunder;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	to the extent constituting an Investment, any Permitted Equity Derivative, including the payment of premiums in connection therewith;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Investments by: (i) any Credit Party in any other Credit Party; (ii) any Subsidiary of Borrower which is not a Credit Party in another Subsidiary of Borrower which is not a Credit Party; (iii) any Subsidiary of Borrower which is not a Credit Party in any Credit Party; and (iv)(A) any Credit Party or a Subsidiary of Borrower which is not a Credit Party as of the Effective Date and shown on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter, and (B) any Credit Party or a Subsidiary of Borrower which is not a Credit Party as of any time after the Effective Date not to exceed [***] in the aggregate among all such Credit Parties at any time outstanding in addition to the amount specified in sub-clause (iv)(A) above;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Repurchases of capital stock of Borrower or any of its Subsidiaries deemed to occur upon the exercise of options, warrants or other rights to acquire capital stock of Borrower or such Subsidiary solely to the extent that shares of such capital stock represent a portion of the exercise price of such options, warrants or such rights;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	Investments consisting of non-cash consideration received for any Permitted Transfer;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	Investments consisting of acquisitions of assets from third parties used in the ordinary course of business, including inventory, raw materials, vehicles, equipment, office supplies, software and other similar assets;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	Investments consisting of in-licensing agreements, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, no Indebtedness that is not Permitted Indebtedness is incurred or assumed in connection therewith;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t)	to the extent constituting an Investment, any Permitted License;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	(i) unsecured Hedging Agreements entered into for hedging and not speculative purposes, and (ii) Hedging Agreements with respect to interest rates that are secured only by cash or Cash Equivalents and entered into for hedging and not speculative purposes; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v) other Investments, not to exceed [***] in the aggregate;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, none of the foregoing Investments shall be a &#x201c;Permitted Investment&#x201d; if any Indebtedness or Liens assumed in connection with such Investment are not otherwise permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively: (a) any exclusive or non-exclusive license or covenant not to sue with respect to Product in any geography outside of the Territory, (b) any exclusive or non-exclusive license or covenant not to sue with respect to any Intellectual Property (including, for clarity, any Company IP) that is not related to the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product, whether within or outside the Territory; (c) licenses pursuant to any Logistics Agreements, Manufacturing Agreements or otherwise with a logistics provider or contract manufacturer, in each case solely with respect to the services provided under such agreement, whether within or outside the Territory; (d) any non-exclusive licenses with respect to any research and development, whether within or outside the Territory; (e) any intercompany license or other similar arrangement described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (k)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Transfers among Credit Parties and Subsidiaries, whether within or outside the Territory; and (f) any intercompany license or other similar arrangement among Credit Parties, whether within or outside of the Territory.  Notwithstanding the foregoing or any other provision of this Agreement, no Excluded License with respect to Product entered into after the Tranche A Closing Date shall be a &#x201c;Permitted License&#x201d; hereunder without the prior written consent of the Collateral Agent or the Required Lenders.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Liens in favor and for the benefit of any Lender and the other Secured Parties securing the Obligations pursuant to any Loan Document;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Liens existing on the Effective Date and set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no Liens on any of the collateral securing the payment of any Indebtedness of any Credit Party or any Subsidiary under the Existing Credit Agreement existing on the Tranche A Closing Date or any time thereafter, which such Indebtedness shall be repaid in full pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be a &#x201c;Permitted Lien&#x201d; for purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other purposes under this Agreement (other than for purposes of the representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or the other Loan Documents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Liens for Taxes, assessments or governmental charges which (i) are not yet due and payable or (ii) if due and payable, are being contested in good faith and by appropriate proceedings; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, in each case, adequate reserves therefor have been set aside on the books of the applicable Person and maintained in conformity with GAAP;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	(i) pledges or deposits made in the ordinary course of business (other than Liens imposed by ERISA) in connection with workers&#x2019; compensation, payroll taxes, unemployment insurance, old-age pensions, or other similar social security legislation, (ii) pledges or deposits made in the ordinary course of business securing liability for reimbursement or indemnification obligations of (including obligations in respect of letters of credit or bank guarantees for the benefit of) insurance carriers providing property, casualty or liability insurance to Borrower or any of its Subsidiaries, (iii) subject to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.2(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, statutory or common law Liens of landlords, (iv) pledges or deposits to secure performance of tenders, bids, leases, statutory or regulatory obligations, surety and appeal bonds, government contracts, performance and return-of-money bonds and other obligations of like nature, in each case other than for borrowed money and entered into in the ordinary course of business, (v) Liens otherwise arising by operation of law in favor of the owner or sublessor of leased premises and confined to the property rented, (vi) Liens that are restrictions on transfer of securities imposed by applicable securities laws, and (vii)  Liens resulting from a filing by a lessor as a precautionary filing for a true lease;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Liens arising from attachments or judgments, orders, or decrees in circumstances not constituting an Event of Default under either </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.7</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Liens (including the right of set-off) in favor of banks or other financial institutions incurred on deposits made in accounts held at such institutions in the ordinary course of business; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such Liens (i) are not given in connection with the incurrence of any Indebtedness, (ii) relate solely to obligations for administrative and other banking fees and expenses incurred in the ordinary course of business in connection with the establishment or maintenance of such accounts and (iii) are within the general parameters customary in the banking industry;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	Liens that are contractual rights of set-off (i) relating to pooled deposit or sweep accounts of Borrower or any of its Subsidiaries to permit satisfaction of overdraft or similar obligations incurred in the ordinary course of business or (ii) relating to purchase orders and other agreements entered into with customers of Borrower or any of its Subsidiaries in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	Liens solely on any cash earnest money deposits made by Borrower or any of its Subsidiaries in connection with any Permitted Acquisition, Permitted Investment or other acquisition of assets or properties not otherwise prohibited under this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	Liens existing on assets or properties at the time of its acquisition or existing on the assets or properties of any Person at the time such Person becomes a Subsidiary of Borrower, in each case after the Effective Date; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that (i) neither such Lien was created nor the Indebtedness secured thereby was incurred in contemplation of such acquisition or such Person becoming a Subsidiary of Borrower, (ii) such Lien does not extend to or cover any other assets or properties (other than the proceeds or products thereof and other than after-acquired assets or properties subject to a Lien securing Indebtedness and other obligations incurred prior to such time and which Indebtedness and other obligations are permitted hereunder that requires, pursuant to its terms and conditions in effect at such time, a pledge of after-acquired assets or properties, it being understood that such requirement shall not be permitted to apply to any assets or properties to which such requirement would not have applied but for such acquisition), (iii) the Indebtedness and other obligations secured thereby is permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof and (iv) such Liens are of the type otherwise permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	Liens securing Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of &#x201c;Permitted Indebtedness&#x201d; (including any extensions, refinancings, modifications, amendments or restatements of such Indebtedness permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (v)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Indebtedness); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such Lien does not extend to or cover any assets or properties other than those described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Indebtedness;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	servitudes, easements, rights-of-way, restrictions and other similar encumbrances on real property imposed by Requirements of Law and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor defects or other irregularities in title which, in the aggregate, are not material, and which do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of the business of any Credit Party or any Subsidiary of any Credit Party;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	to the extent constituting a Lien, escrow arrangements securing indemnification obligations associated with any Permitted Acquisition or Permitted Investment;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	(i) leases or subleases of real property granted in the ordinary course of business (including, if referring to a Person other than a Credit Party or a Subsidiary, in the ordinary course of such Person&#x2019;s business), (ii) licenses, sublicenses, leases or subleases of personal property (other than Intellectual Property) granted to third parties in the ordinary course of business, in each case which do not interfere in any material respect with the operations of the business of any Credit Party or any of its Subsidiaries and do not prohibit granting the Collateral Agent a security interest in any Credit Party&#x2019;s personal property held at such location for the benefit of the Lenders and other Secured Parties, (iii) Permitted Licenses, and (iv) retained interests of lessors or licensors or similar parties under any in-licenses;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	Liens on cash or other current assets pledged to secure: (i) Indebtedness in respect of corporate credit cards, purchasing cards or bank card products, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the portion of such Indebtedness secured pursuant to this clause (n) shall not exceed [***] in the aggregate at any time outstanding; or (ii) Indebtedness in the form of letters of credit or bank guarantees entered into in the ordinary course of business, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any such Indebtedness is secured solely by cash or Cash Equivalents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	Liens on any properties or assets of Borrower or any of its Subsidiaries which do not constitute Collateral under the Loan Documents, other than (i) any Company IP that does not constitute Collateral under the Loan Documents but is related to any research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the Territory and (ii) Equity Interests of any Subsidiary;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	Liens on any properties or assets of Borrower or any of its Subsidiaries imposed by law or regulation which were incurred in the ordinary course of business, including landlords&#x2019;, carriers&#x2019;, warehousemen&#x2019;s, mechanics&#x2019;, materialmen&#x2019;s, contractors&#x2019;, suppliers of materials&#x2019;, architects&#x2019; and repairmen&#x2019;s Liens, and other similar Liens arising in the ordinary course of business; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such Liens (i) do not materially detract from the value of such properties or assets subject thereto or materially impair the use of such properties or assets subject thereto in the operations of the business of Borrower or such Subsidiary or (ii) are being contested in good faith by appropriate proceedings, which conclusively operate to stay the sale or forfeiture of any portion of such properties or assets subject thereto and for which adequate reserves have been set aside on the books of the applicable Person and maintained in conformity with GAAP, if required;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	Liens in favor of customs and revenue authorities arising as a Requirement of Law which were incurred in the ordinary course of business, to secure payment of customs duties in connection with the importation of goods in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	Liens on any goods sold to Borrower or any of its Subsidiaries in the ordinary course of business in favor of the seller thereof, but only to the extent securing the unpaid purchase price for such goods and any related expenses;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	Liens securing Permitted Indebtedness of a Credit Party in favor of any other Credit Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(t) 	Liens securing Indebtedness owed by a Subsidiary of Borrower that is not a Credit Party permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Indebtedness, in favor of a Credit Party or another Subsidiary of Borrower that is not a Credit Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(u)	Liens on insurance policies and the proceeds thereof; provided, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, such Liens are not given in connection with the incurrence of any Indebtedness, secure only the financing of the insurance premiums with respect thereto, and are within the general parameters customary in the insurance industry;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	Liens solely on cash and Cash Equivalents in each case securing Hedging Agreements with respect to interest rates that are entered into for hedging and not speculative purposes; and</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)	customary backup security interests securing Indebtedness under the Royalty Revenue Contract and other Royalty Revenue Documents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)	additional Liens on assets or properties, in each case so long as neither (i) the aggregate principal amount of the Indebtedness and other obligations secured thereby nor (ii) the aggregate fair market value of the assets or properties subject thereto (as reasonably determined in good faith by a Responsible Officer of Borrower) exceeds [***] in the aggregate for all such Liens at any time outstanding; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(x)	subject to the provisos immediately below, the modification, replacement, extension or renewal of the Liens described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that any such modification, replacement, extension or renewal must (i) be limited to the assets or properties encumbered by the existing Lien (and any additions, accessions, parts, improvements and attachments thereto and the proceeds thereof) and (ii) not increase the principal amount of any Indebtedness secured by the existing Lien (other than by any reasonable premium or other reasonable amount paid and fees and expenses reasonably incurred in connection therewith); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that to the extent any of the Liens described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(w)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above secure Indebtedness of a Credit Party, such Liens, and any such modification, replacement, extension or renewal thereof, shall constitute Permitted Liens if and only to the extent that such Indebtedness is permitted under </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Negative Pledges</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	prohibitions or limitations with regard to specific properties or assets encumbered by Permitted Liens, if and only to the extent each such prohibition or limitation applies only to such properties or assets;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	prohibitions or limitations set forth in any lease, license or other similar agreement entered into in the ordinary course of business and not prohibited hereunder;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	prohibitions or limitations relating to Permitted Indebtedness, in each case if and only to the extent such prohibitions or limitations, taken as a whole, are not materially more restrictive than the prohibitions and limitations set forth in this Agreement and the other Loan Documents, taken as a whole (as reasonably determined by a Responsible Officer of Borrower in good faith); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no prohibition or limitation relating to Indebtedness of any Credit Party or any Subsidiary under the Existing Credit Agreement existing on the Tranche A Closing Date or any time thereafter, which such Indebtedness shall be repaid in full pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be a &#x201c;Permitted Negative Pledge&#x201d; for purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other purpose under this Agreement (other than for purposes of the representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or the other Loan Documents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	customary provisions restricting assignments, subletting, sublicensing or other transfer of properties or assets subject thereto set forth in leases, subleases, licenses and other similar agreements that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such restriction applies only to the properties or assets subject to such leases, subleases, licenses or agreements, and customary provisions restricting assignment, pledges or transfer of any agreement entered into in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	prohibitions or limitations imposed by Requirements of Law;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	prohibitions or limitations that exist as of the Effective Date under Indebtedness existing on the Effective Date;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	customary prohibitions or limitations arising in connection with any Permitted Transfer or contained in any agreement relating to any Permitted Transfer pending the consummation of such Permitted Transfer;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	customary provisions in shareholders&#x2019; agreements, joint venture agreements, organizational documents or similar binding agreements relating to, or any agreement evidencing Indebtedness of, any joint venture entity or non-Wholly Owned Subsidiary and applicable solely to such joint venture entity or non-Wholly Owned Subsidiary and the Equity Interests issued thereby;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	customary net worth provisions set forth in real property leases entered into by Subsidiaries of Borrower, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	customary net worth provisions set forth in customer agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	restrictions on cash or other deposits (including escrowed funds) imposed by agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	prohibitions or limitations set forth in any agreement in effect at the time any Person becomes a Subsidiary (but not any amendment, modification, restatement, renewal, extension, supplement or replacement expanding the scope of any such restriction or condition); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that such agreement was not entered into in contemplation of such Person becoming a Subsidiary and each such prohibition or limitation does not apply to Borrower or any other Subsidiary (other than such Person and any other Person that is a Subsidiary of such first Person at the time such first Person becomes a Subsidiary);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	prohibitions or limitations imposed by any Loan Document;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	customary provisions set forth in joint venture agreements or agreements governing minority investments that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to the joint venture entity or minority investment that is the subject of such agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	limitations imposed with respect to any license acquired in a Permitted Acquisition;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	customary provisions restricting assignments or other transfer of properties or assets subject thereto set forth in any agreement entered into in the ordinary course of business, if and only to the extent each such restriction applies only to the properties or assets subject to such agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	prohibitions or limitations imposed by any agreement evidencing any Permitted Indebtedness of the type described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Indebtedness;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	prohibitions or limitations imposed by any Royalty Revenue Document; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s) 	prohibitions or limitations imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the agreements referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, except to the extent that any such amendment, modification, restatement, renewal, extension, supplement or replacement expands the scope of any such prohibition or limitation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Subsidiary Distribution Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, in each case notwithstanding </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	prohibitions or limitations with regard to specific properties or assets encumbered by Permitted Liens, if and only to the extent each such prohibition or limitation applies only to such properties or assets;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	prohibitions or limitations set forth in any lease, license or other similar agreement entered into in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	prohibitions or limitations relating to Permitted Indebtedness, in each case if and only to the extent such prohibitions or limitations, taken as a whole, are not materially more restrictive than the prohibitions and limitations set forth in this Agreement and the other Loan Documents, taken as a whole (as reasonably determined by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a Responsible Officer of Borrower in good faith); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that no prohibition or limitation relating to Indebtedness of any Credit Party or any Subsidiary under the Existing Credit Agreement existing on the Tranche A Closing Date or any time thereafter, which such Indebtedness shall be repaid in full pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.10(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be a &#x201c;Permitted Negative Pledge&#x201d; for purposes of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.9</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or any other purpose under this Agreement (other than for purposes of the representations and warranties set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) or the other Loan Documents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	customary provisions restricting assignments, subletting, sublicensing or other transfer of properties or assets subject thereto set forth in leases, subleases, licenses and other similar agreements that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such restriction applies only to the properties or assets subject to such leases, subleases, licenses or agreements, and customary provisions restricting assignment, pledges or transfer of any agreement entered into in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	prohibitions or limitations on the transfer or assignment of any properties, assets or Equity Interests set forth in any agreement entered into in the ordinary course of business that is not otherwise prohibited under this Agreement or any other Loan Document, if and only to the extent each such prohibition or limitation applies only to such properties, assets or Equity Interests;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	prohibitions or limitations imposed by Requirements of Law;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	prohibitions or limitations that exist as of the Effective Date under Indebtedness existing on the Effective Date;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	customary prohibitions or limitations arising in connection with any Permitted Transfer or contained in any agreement relating to any Permitted Transfer pending the consummation of such Permitted Transfer;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	customary provisions in shareholders&#x2019; agreements, joint venture agreements, organizational documents or similar binding agreements relating to, or any agreement evidencing Indebtedness of, any joint venture entity or non-Wholly Owned Subsidiary and applicable solely to such joint venture entity or non-Wholly Owned Subsidiary and the Equity Interests issued thereby;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	customary net worth provisions set forth in real property leases entered into by Subsidiaries of Borrower, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	customary net worth provisions set forth in customer agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document, so long as such net worth provisions could not reasonably be expected to impair the ability of Borrower or its Subsidiaries to meet their ongoing obligations (as reasonably determined by a Responsible Officer of Borrower in good faith);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	restrictions on cash or other deposits (including escrowed funds) imposed by agreements entered into in the ordinary course of business that are not otherwise prohibited under this Agreement or any other Loan Document;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	prohibitions or limitations set forth in any agreement in effect at the time any Person becomes a Subsidiary (but not any amendment, modification, restatement, renewal, extension, supplement or replacement expanding the scope of any such restriction or condition); provided that such agreement was not entered into in contemplation of such Person becoming a Subsidiary and each such prohibition or limitation does not apply to Borrower or any other Subsidiary (other than such Person and any other Person that is a Subsidiary of such first Person at the time such first Person becomes a Subsidiary);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	prohibitions or limitations imposed by any Loan Document or by any Royalty Revenue Document;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	customary provisions set forth in joint venture agreements or agreements governing minority investments that are not otherwise prohibited under this Agreement or any other Loan Document, if and only to the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">extent each such prohibition or limitation applies only to the joint venture entity or minority investment that is the subject of such agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	customary provisions restricting assignments or other transfer of properties or assets subject thereto set forth in any agreement entered into in the ordinary course of business, if and only to the extent each such restriction applies only to the properties or assets subject to such agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	prohibitions or limitations imposed by any agreement evidencing any Permitted Indebtedness of the type described in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the definition of Permitted Indebtedness; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	prohibitions or limitations imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the agreements referred to in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clauses (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> through </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, except to the extent that any such amendment, modification, restatement, renewal, extension, supplement or replacement expands the scope of any such prohibition or limitation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Transfers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Transfers of any properties or assets which do not constitute Collateral under the Loan Documents, other than any Company IP that does not constitute Collateral under the Loan Documents but is related to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the Territory;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Transfers of Inventory in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Transfers of surplus, damaged, worn out or obsolete equipment or immaterial property or assets that is, in the reasonable judgment of a Responsible Officer of Borrower exercised in good faith, no longer economically practicable to maintain or useful in the ordinary course of business, and Transfers of other properties or assets in lieu of any pending or threatened institution of any proceedings for the condemnation or seizure of such properties or assets or for the exercise of any right of eminent domain;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Transfers made in connection with Permitted Liens, Permitted Acquisitions or Permitted Investments;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Transfers of cash and Cash Equivalents in the ordinary course of business for equivalent value and in a manner that is not prohibited under this Agreement or the other Loan Documents;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	Transfers (i) between or among Credit Parties, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that, with respect to any properties or assets constituting Collateral under the Loan Documents, any and all steps as may be required to be taken in order to create and maintain a first priority security interest in and Lien upon such properties and assets in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties, including as required pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.12</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are taken contemporaneously with the completion of any such Transfer, and (ii) between or among non-Credit Parties;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	the sale or issuance of Equity Interests of any Subsidiary of Borrower to any Credit Party or Subsidiary, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, any such sale or issuance by a Credit Party shall be to another Credit Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	the discount without recourse or sale or other disposition of unpaid and overdue accounts receivable arising in the ordinary course of business in connection with the compromise, collection or settlement thereof and not part of a financing transaction;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	any abandonment, disclaimer, forfeiture, dedication to the public, cancellation, non-renewal or discontinuance of use or maintenance of Company IP that a Responsible Officer of Borrower reasonably determines in good faith (i) is no longer economically practicable to maintain or useful in the ordinary course of business and that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii) could not reasonably be expected to be adverse to the rights, remedies and benefits available to, or conferred upon, the Collateral Agent or any Lender under any Loan Document in any material respect;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	without limiting </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> above, Transfers by Borrower or any of its Subsidiaries pursuant to any Permitted License;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(k)	intercompany licenses or grants of rights of distribution, co-promotion or similar commercial rights: (i) between or among the Credit Parties; (ii) between or among the Credit Parties and Subsidiaries that are not Credit Parties and, in the case of any such licenses or grant of rights that relates to any aspect of the research, development, manufacture, production, use, commercialization, marketing, importing, storage, transport, packaging, labeling, promotion, advertising, offer for sale, distribution or sale of any Product within the Territory entered into prior to the Effective Date, listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 12.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Letter; and (iii) between or among Subsidiaries that are not Credit Parties, together, in each case, with renewals, replacements and extensions thereof (including additional licenses or grants in relation to new territories) on comparable terms in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(l)	any involuntary loss, damage or destruction of property or any involuntary condemnation, seizure or taking, by exercise of the power of eminent domain or otherwise, or confiscation or requisition of use of property;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(m)	licenses, sublicenses, leases or subleases, in each case other than relating to any Company IP, granted to third parties in the ordinary course of business;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(n)	the abandonment disclaimer, forfeiture, dedication to the public, or other disposition of any Company IP that is (i) not material to any aspect of the research, development, manufacture, production, use (by any Credit Party or its Subsidiaries), commercialization, marketing, importing, storage, transport, packaging, labelling, promotion, advertising, offer for sale, distribution or sale of Product in the Territory or (ii) no longer used or useful in any material respect in any Product line of business of Borrower and its Subsidiaries;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(o)	any involuntary disposition or any sale, lease, license or other disposition of property (other than, for the avoidance of doubt, any Company IP) in settlement of, or to make payment in satisfaction of, any property or casualty insurance;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p)	sales, leases, licenses, transfers or other dispositions of property to the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such sale, lease, license, transfer or other disposition are promptly applied to the purchase price of similar replacement property;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(q)	any early unwind, settlement or termination of any Permitted Equity Derivative;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(r)	other Transfers made in the ordinary course of business on commercially reasonable arm&#x2019;s length terms; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(s)	other Transfers of properties or assets, in each case so long as (i) the fair market value of such properties or assets (as reasonably determined in good faith by a Responsible Officer of Borrower) does not exceed, individually or together with any other such Transfers under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (s)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, [***] at any time and (ii) such Transfer is not otherwise prohibited hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, exempted company, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Data</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means information protected under applicable Data Protection Laws as &#x201c;personal data,&#x201d; &#x201c;personal information,&#x201d; &#x201c;personally identifiable information,&#x201d; &#x201c;protected health information,&#x201d; &#x201c;medical information,&#x201d; &#x201c;individually identifiable health information,&#x201d; &#x201c;identifiable private information,&#x201d; &#x201c;bulk sensitive personal data,&#x201d; &#x201c;United States government-related data,&#x201d; or any similar terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personal Data Breach</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.22(b).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the IRC or Section 302 of ERISA which is maintained or contributed to by Borrower or its Subsidiaries or their respective ERISA Affiliates or with respect to which Borrower or its Subsidiaries have any liability (including under Section 4069 of ERISA).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepayment Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A Prepayment Premium, the Tranche B Prepayment Premium or the Tranche C Prepayment Premium (as applicable) or any combination thereof, as the context dictates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively: (a) the pharmaceutical product known as RYTELO&#153; (imetelstat, which includes imetelstat sodium) (and foreign-named equivalents), approved by the FDA under NDA N217779, and any successor product thereto, and any other product used for the treatment of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">myelodysplastic syndromes (MDS) with transfusion-dependent (TD) anemia, owned or controlled by Borrower or any of its Subsidiaries, in any dosage form, dosing regimen, strength or route of administration (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RYTELO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (b) any proposed or approved pharmaceutical product owned or controlled by Borrower or any of its Subsidiaries that contains imetelstat or imetelstat sodium in any form, and any successors thereto, for any indication, in any dosage form, dosing regimen, strength or route of administration; and (c) any successor product(s) of RYTELO&#153; (imetelstat, which includes imetelstat sodium) (and foreign-named equivalents) under development or hereinafter developed, including in conjunction with out-licensing partners, owned or controlled by Borrower or its Subsidiaries, in any dosage form, dosing regimen, strength or route of administration.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registered Organization</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;registered organization&#x201d; as defined in the Code with such additions to such term as may hereafter be made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a U.S. or foreign Governmental Authority with responsibility for the approval of the marketing and sale of drug products or other regulation of drug products, or otherwise having authority to regulate Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Approvals or Licensures</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all approvals, authorizations, designations, licensures or clearances and any product or establishment licenses, registrations or authorizations of any Regulatory Agency necessary for the manufacture, use, storage, import, export, transport, offer for sale, or distribution or sale of Product.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Submission Material</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all regulatory filings, submissions, approvals, licensures, and authorizations related to any research, development, manufacture, production, use, commercialization, post-approval (or post-licensure, post-authorization, or post-clearance, as applicable) monitoring and reporting (including post-marketing safety reports), marketing, importing, storage, transport, offer for sale, distribution or sale of Product in the Territory, including all data and information provided in, and used to develop, any of the foregoing, and any other material that is exempt from disclosure under 5 U.S.C. &#167; 552.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, such Person&#x2019;s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person&#x2019;s Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any release, spill, emission, leaking, pumping, pouring, injection, escaping, deposit, disposal, discharge, dispersal, dumping, leaching or migration of any Hazardous Material into the indoor or outdoor environment (including the abandonment or disposal of any barrels, containers or other closed receptacles containing any Hazardous Material), including the movement of any Hazardous Material through the air, soil, surface water or groundwater.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relevant Governmental Body</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Board of Governors of the Federal Reserve System or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Board of Governors of the Federal Reserve System or the Federal Reserve Bank of New York, or any successor thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Required Lenders</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Lenders representing greater than fifty percent (50%) of the principal amount of the Term Loans outstanding as of such date.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Requirements of Law</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as to any Person, the organizational or governing documents of such Person, and any law (statutory or common, foreign or domestic), treaty, order, policy, rule or regulation or determination of an arbitrator or a court or other Governmental Authority (including Environmental Laws, Health Care Laws, Data Protection Laws, FDA Laws, EU Laws, U.K. Laws, and all other applicable statutes, rules, regulations, standards, guidelines, policies and orders administered or issued by any foreign Governmental Authority), in each case, applicable to and binding upon such Person or any of its assets or properties or to which such Person or any of its assets or properties are subject, including, with respect to Borrower, the rules or requirements of any applicable U.S. national securities exchange applicable to Borrower or any of its Equity Interests.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Responsible Officers</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Credit Party, collectively, each of the 	Chairman of the Board, President, Chief Executive Officer, Executive Vice Presidents, Chief Financial Officer, Chief Alliance Officer, Chief Medical Officer, Chief Operating Officer, Chief Business Officer, Chief Commercial Officer, Data Protection Officer, Chief Legal Officer, and head of information technology of such Credit Party or, in each case, if none, of Borrower.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted License</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any material license or other material agreement of the kind or nature subject or purported to be subject from time to time to a Lien under any Collateral Document, with respect to which a Credit Party is the licensee and pursuant to which such Credit Party controls any of the Company IP, (a) that prohibits or otherwise restricts such Credit Party from granting a security interest in its interest therein to the Collateral Agent, for the benefit of Lenders and the other Secured Parties (other than as a result of customary anti-assignment provisions) in a manner enforceable under Requirements of Law, or (b) for which a breach of or default under could reasonably be expected to interfere with the Collateral Agent&#x2019;s or any Lender&#x2019;s right to sell or otherwise dispose of any Collateral.  For the avoidance of doubt, software, open source code, application programming interfaces or trademarks, copyrights or patents of others that are commercially available to the public under the shrinkwrap licenses, clickwrap licenses, online terms of service or other terms of use or similar agreements and intellectual property rights of customers used by Borrower in the course of providing service to third parties in the ordinary course of business shall not constitute a Restricted License.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.8(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Pharma</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Royalty Pharma Development Funding, LLC and its successors and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Revenue Contract</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Revenue Participation Right Purchase and Sale Agreement, dated as November 1, 2024, by and between Borrower and Royalty Pharma, as in effect on the Tranche A Closing Date, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Revenue Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively: (a) the Royalty Revenue Contract; and (b) each other document entered into from time to time in connection therewith, in each case as in effect on the Tranche A Closing Date, as may be amended, restated, supplemented, modified or replaced, or renewed or altered (including pursuant to any waiver, consent or approval) from time to time in accordance with </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.10(f)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereof, including all documents delivered or filed pursuant to the Royalty Revenue Contract.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctioned Country</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, at any time, a country or territory which is itself the subject or target of comprehensive Sanctions (currently, those portions of the Donetsk People&#x2019;s Republic, the Luhansk People&#x2019;s Republic, Kherson and Zaporizhzhia regions (and such other regions) of Ukraine over which any Sanctions authority of the United States or the United Kingdom imposes comprehensive Sanctions, Crimea, Cuba, Iran, Syria and North Korea).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sanctions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.18(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Securities and Exchange Commission and any analogous Governmental Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secretary&#x2019;s Certificate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, a certificate of such Person executed by its Secretary, authorized signatory or director certifying as to the various matters set forth therein.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5 of the FTC Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Section 5(a) of the U.S. Federal Trade Commission Act (15 U.S.C. &#167; 45), which prohibits unfair and deceptive acts or practices in or affecting commerce and serves as the primary basis for U.S. Federal Trade Commission authority on privacy and security.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secured Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each Lender, each other Indemnified Person and each other holder of any Obligation of a Credit Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Account</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any &#x201c;securities account&#x201d; as defined in the Code with such additions to such term as may hereafter be made.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Guaranty and Security Agreement, dated as of the Tranche A Closing Date, by and among the Credit Parties and the Collateral Agent, in form and substance substantially similar to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto or in such form or substance as the Credit Parties and the Collateral Agent may otherwise agree.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Incidents</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.22(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Security Program</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.22(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sensitive Information</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, (a) any Personal Data that is subject to any Data Protection Law(s), (b) any information in which Borrower or any of its Subsidiaries have IP Ancillary Rights or any other Intellectual Property rights (including Company IP), (c) any information with respect to which Borrower or any of its Subsidiaries have contractual non-disclosure obligations, and (d) Regulatory Submission Materials.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOFR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOFR Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Software</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means &#x201c;Software&#x201d;, as such term is defined in the Security Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solvent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means as of any date of determination, that, as of such date, (a) the value of the assets (including goodwill minus disposition costs) of such Person (both at fair value and present fair saleable value), on a going concern basis, is greater than the total amount of liabilities (including contingent and unliquidated liabilities) of such Person, (b) such Person is able to generally pay all liabilities (including trade debt) of such Person as such liabilities become absolute and mature in the ordinary course of business consistent with past practice and (c) such Person does not have unreasonably small capital after giving due consideration to the prevailing practice in the industry in which it is engaged or will be engaged.  In computing the amount of contingent or unliquidated liabilities at any time, such liabilities shall be computed at the amount that, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SSA</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Social Security Act of 1935, codified at Title 42, Chapter 7, of the United States Code.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Acquisition</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the purchase or other acquisition by Borrower or any of its Subsidiaries of a of the Equity Interests (by merger, stock purchase or otherwise) in any other Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subordinated Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Indebtedness in the form of or otherwise constituting term debt incurred by any Credit Party or any Subsidiary thereof (including any Indebtedness incurred in connection with any Acquisition or other Investment) that:  (a) is subordinated in right of payment to the Obligations at all times until all of the Obligations have been paid, performed or discharged in full and Borrower has no further right to obtain any Credit Extension hereunder, pursuant to a subordination, intercreditor or other similar agreement that is in form and substance reasonably satisfactory to the Collateral Agent (which agreement shall include turnover provisions that are reasonably satisfactory to the Collateral Agent); (b) except as permitted by </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clause (d)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> below, is not subject to scheduled amortization, redemption (mandatory), sinking fund or similar payment and does not have a final maturity, in each case, before a date that is at least 120 days following the Term Loan Maturity Date; (c) does not include covenants</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(including financial covenants) and agreements (excluding agreements with respect to maturity, amortization, pricing and other economic terms) that, taken as a whole, are more restrictive or onerous on the Credit Parties in any material respect than the comparable covenants and agreements, taken as a whole, in the Loan Documents (as reasonably determined by a Responsible Officer of such Credit Party in good faith); (d) is not subject to repayment or prepayment, including pursuant to a put option exercisable by the holder of any such Indebtedness, prior to a date that is at least 120 days following the final maturity thereof except in the case of an event of default or change of control (or, in each case, the equivalent thereof, however described); and (e) does not provide or otherwise include provisions having the effect of providing that a default or event of default (or the equivalent thereof, however described) under or in respect of such Indebtedness shall exist, or such Indebtedness shall otherwise become due prior to its scheduled maturity or the holder or holders thereof or any trustee or agent on its or their behalf shall be permitted (with or without the giving of notice, the lapse of time or both) to cause any such Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity, in any such case upon the occurrence of a Default or Event of Default hereunder unless and until the Obligations have been declared, or have otherwise automatically become, immediately due and payable pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding the foregoing, Indebtedness under Permitted Convertible Indebtedness and Indebtedness under the Royalty Revenue Contract and other Royalty Revenue Documents shall not constitute Subordinated Debt.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, (a) with respect to any Person not incorporated in England and Wales, a corporation, partnership, limited liability company or other entity of which more than fifty percent (50.0%) of whose shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the Board of Directors (or similar body) of such corporation, partnership or other entity are at the time owned, directly or indirectly through one or more intermediaries, or both, by such Person, and (b) with respect to any Person incorporated in England and Wales, any subsidiary incorporated in England and Wales within the meaning of section 1159 of the Companies Act 2006.  Unless the context otherwise requires, each reference to a Subsidiary herein shall be a reference to a Subsidiary of a Credit Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systems</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.22(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of the Tranche A Loan, the Tranche B Loan or the Tranche C Note, as applicable, and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the Tranche A Loan, and, to the extent funded, each of the Tranche B Loan and the Tranche C Loan or any combination thereof, as the context dictates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an original principal amount equal to up to Two Hundred and Fifty Million Dollars ($250,000,000.00).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, each of the Tranche A Commitment, the Tranche B Commitment or the Tranche C Commitment, as applicable, and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Commitments</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, the Tranche A Commitment, the Tranche B Commitment and the Tranche C Commitment or any combination thereof, as the context dictates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Note</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Tranche A Note, the Tranche B Note, or the Tranche C Note, as applicable, and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Notes</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means collectively, the Tranche A Note, the Tranche B Note, and the Tranche C Note or any combination thereof, as the context dictates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term Loan Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term SOFR</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any day in any calendar month, the Term SOFR Reference Rate for a tenor of three (3) months</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to the applicable Interest Period on the day (such day, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic Term SOFR Determination</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that is two (2) U.S. Government Securities Business Days&#x2019; prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government Securities Business Days prior to such Periodic Term SOFR Determination Day; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if Term SOFR determined as provided above (including pursuant to the proviso above) shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term SOFR Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference Rate selected by the Collateral Agent in its reasonable discretion).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term SOFR Reference Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the forward-looking term rate based on SOFR.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to Product, the United States.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-Party IP</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6(l)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trademarks</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, service marks, elements of package or trade dress of goods or services, logos and other source or business identifiers, together with the goodwill associated therewith, including all registrations and recordings thereof, and all applications in connection therewith, in the United States Patent and Trademark Office or in any similar office or agency of the United States or any state thereof or in any similar office or agency anywhere in the world in which foreign counterparts are registered or issued, and (b) all renewals thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the date on which the Tranche A Loan is advanced by Lenders, which, as indicated in the completed Advance Request Form in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto for the Tranche A Loan delivered by Borrower to the Collateral Agent and subject to the satisfaction of the conditions precedent to the Tranche A Loan set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche A Loan on the Tranche A Closing Date in the aggregate principal amount set forth opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(a)(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Loan Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an original principal amount equal to One Hundred and Twenty-Five Million Dollars ($125,000,000.00).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Makewhole Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of the date of any prepayment of the Tranche A Loan occurring prior to the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date, pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an amount equal to the sum of all interest that would have accrued and been payable from such date of prepayment through the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date on the amount of principal prepaid.  For purposes of calculating the Tranche A Makewhole Amount: (a) the date of determination shall be such date of prepayment, using the interest rate as in effect on such date, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for purposes of any such prepayment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the date of determination shall be the date on which the Change in Control is consummated; and (b) the Default Rate shall not apply to any interest that would have accrued and been payable from and after such date of determination.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Note</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a promissory note in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as it may be amended, restated, supplemented or otherwise modified from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche A Prepayment Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any prepayment of the Tranche A Loan by Borrower pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an amount equal to the product of the amount of any principal so prepaid, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link8"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font id="ole_link9"></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if such prepayment occurs prior to the 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date, 0.03;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	if such prepayment occurs on or after the 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date but prior to the 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date, 0.02; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	if such prepayment occurs on or after the 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche A Closing Date but prior to the Term Loan Maturity Date, 0.01.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, no Tranche A Prepayment Premium shall be due and owing for any payment of principal of the Tranche A Loan made on the Term Loan Maturity Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the date on which the Tranche B Loan is advanced by Lenders, which, as indicated in the Advance Request Form in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto for the Tranche B Loan and subject to the satisfaction of the conditions precedent to the Tranche B Loan set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be sixty (60) days (or such shorter period as may be agreed to by Lenders) following the delivery by Borrower to the Collateral Agent of the completed Advance Request Form for the Tranche B Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and, in no event, later than February 27, 2026.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche B Loan on the Tranche B Closing Date in the aggregate principal amount set forth opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the parties hereto agree that such commitment, and any obligations of such Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect if the Tranche B Closing Date does not occur on or before February 27, 2026 (at such time in either case, for purposes of this Agreement, such Lender&#x2019;s Tranche B Commitment equals zero).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(a)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Loan Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an original principal amount equal to Seventy-Five Million Dollars ($75,000,000.00); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the Tranche B Closing Date does not occur on or before February 27, 2026, then the Tranche B Loan Amount, from and after such time for purposes of this Agreement, equals zero.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Makewhole Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of the date of any prepayment of the Tranche B Loan occurring prior to the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an amount equal to the sum of all interest that would have accrued and been payable from such date of prepayment through the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date on the amount of principal prepaid.  For purposes of calculating the Tranche B Makewhole Amount: (a) the date of determination shall be such date of prepayment, using the interest rate as in effect on such date, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for purposes of any such prepayment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the date of determination shall be the date on which the Change in Control is consummated; and (b) the Default Rate shall not apply to any interest that would have accrued and been payable from and after such date of determination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Note</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a promissory note in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-2</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as it may be amended, restated, supplemented or otherwise modified from time to time.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche B Prepayment Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any prepayment of the Tranche B Loan by Borrower pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an amount equal to the product of the amount of any principal so prepaid</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	if such prepayment occurs prior to the 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date, 0.03;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	if such prepayment occurs on or after the 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date but prior to the 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date, 0.02; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	if such prepayment occurs on or after the 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche B Closing Date but prior to the Term Loan Maturity Date, 0.01.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, no Tranche B Prepayment Premium shall be due and owing for any payment of principal of the Tranche B Loan made on the Term Loan Maturity Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Additional Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.7(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Closing Date</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the date on which the Tranche C Loan is advanced by Lenders, which, as indicated in the Advance Request Form in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto for the Tranche C Loan and subject to the satisfaction of the conditions precedent to the Tranche C Loan set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, shall be sixty (60) days (or such shorter period as may be agreed to by Lenders) following the delivery by Borrower to the Collateral Agent of a completed Advance Request Form for the Tranche C Loan and, in no event, earlier than the date that is sixty (60) days (or such shorter period as may be agreed to by Lenders) after the occurrence of the Tranche C Net Sales Trigger or later than February 27, 2026.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Commitment</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Lender, the commitment of such Lender to make the Credit Extensions relating to the Tranche C Loan on the Tranche C Closing Date in the aggregate principal amount set forth opposite such Lender&#x2019;s name on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the parties hereto agree that such commitment, and any obligations of such Lender hereunder with respect thereto, shall terminate automatically without any further action by any party hereto and be of no further force and effect if the Tranche C Net Sales Trigger does not occur on or before November 30, 2025 or the Tranche C Closing Date does not occur on or before February 27, 2026 (at such time in either of which case, for purposes of this Agreement, such Lender&#x2019;s Tranche C Commitment equals zero).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Loan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(a)(iii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Loan Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an original principal amount requested by Borrower of Fifty Million Dollars ($50,000,000.00); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if the Tranche C Net Sales Trigger does not occur on or before November 30, 2025 or the Tranche C Closing Date does not occur on or before February 27, 2026, then in either such case the Tranche C Loan Amount, from and after such time for purposes of this Agreement, equals zero.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Makewhole Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of the date of any prepayment of the Tranche C Loan occurring prior to the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an amount equal to the sum of all interest that would have accrued and been payable from such date of prepayment through the 2</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date on the amount of principal prepaid.  For purposes of calculating the Tranche C Makewhole Amount: (a) the date of determination shall be such date of prepayment, using the interest rate as in effect on such date, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, for purposes of any such prepayment pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)(ii)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the date of determination shall be the date on which the Change in Control is consummated; and (b) the Default Rate shall not apply to any interest that would have accrued and been payable from and after such date of determination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Net Sales Trigger</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the delivery of a completed Advance Request Form in the form of </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto for the Tranche C Loan, TTM Net Revenue having exceeded $110,000,000 for the trailing twelve-month period ended as of the last day of the calendar month ended immediately prior to the date of such Advance Request Form, as reasonably determined by a Responsible Officer of Borrower in good faith in</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accordance with GAAP and supported by Borrower&#x2019;s financial statements (including, with respect of any portion of such trailing twelve-month period covered by financial statements filed with the SEC (if any), such filed financial statements).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Note</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a promissory note in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B-3</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as it may be amended, restated, supplemented or otherwise modified from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tranche C Prepayment Premium</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any prepayment of the Tranche C Loan by Borrower pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2(c)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or as a result of the acceleration of the maturity of the Term Loans pursuant to </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an amount equal to the product of the amount of any principal so prepaid, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">multiplied by</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	if such prepayment occurs prior to the 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date, 0.03;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	if such prepayment occurs on or after the 3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date but prior to the 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date, 0.02; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	if such prepayment occurs on or after the 4</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year anniversary of the Tranche C Closing Date but prior to the Term Loan Maturity Date, 0.01.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the avoidance of doubt, no Tranche C Prepayment Premium shall be due and owing for any payment of principal of the Tranche C Loan made on the Term Loan Maturity Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 6.1</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Treasury Regulations</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; mean those regulations promulgated pursuant to the IRC.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TRICARE</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, a program of medical benefits covering former and active members of the uniformed services and certain of their dependents, financed and administered by the United States Departments of Defense, Health and Human Services and Transportation, and all laws applicable to such programs.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TTM Net Revenue</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, as of any date of determination, the sum of trailing twelve-month Net Sales and royalty revenue as of such date, as determined by a Responsible Officer of Borrower in good faith in accordance with GAAP and as presented in Borrower&#x2019;s financial statements (including, with respect of any portion of such trailing twelve-month period covered by financial statements filed with the SEC (if any), such filed financial statements).  For the avoidance of doubt, TTM Net Revenue shall not include any milestone payments, non-recurring payments or non-sales-based revenues or proceeds.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.K. Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all applicable statutes, rules and regulations implemented administered or enforced by the MHRA, the National Health Services (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NHS</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), or the competent authorities of the United Kingdom&#x2019;s constituent countries, including, but not limited to, the Human Medicines Regulations 2012 (SI 2012/1916), and related implementing legislation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unadjusted Benchmark Replacement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.K</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; means the United Kingdom of Great Britain and Northern Ireland, including, as the context requires, England and Wales.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United States</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America, its fifty (50) states, the District of Columbia, Puerto Rico and any other jurisdiction within the United States of America.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Government Securities Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Wholly Owned Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, a Subsidiary of such Person, all of the Equity Interests of which (other than directors&#x2019; qualifying shares or nominee or other similar shares required pursuant to Requirements of Law) are owned by such Person or another Wholly Owned Subsidiary of such Person.  Unless the context otherwise requires, each reference to a Wholly Owned Subsidiary herein shall be a reference to a Wholly Owned Subsidiary of a Credit Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withdrawal Event</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any voluntary withdrawal or removal of RYTELO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Territory by any Credit Party or any of its Subsidiaries, (b) the loss of marketing authorization for RYTELO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Territory, (c) the receipt by any Credit Party or any of its Subsidiaries of any written notice from the FDA or any other Regulatory Agency of pending recommendation to withdraw marketing authorization for RYTELO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Territory that has not been rescinded or otherwise withdrawn within sixty (60) days of the receipt thereof, or (d) the receipt by any Credit Party or any of its Subsidiaries of any written notice from the FDA or any other Regulatory Agency of final decision</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to withdraw marketing authorization for RYTELO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withdrawal Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding Agent</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.6(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature page follows]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the parties hereto have caused this Agreement to be executed as of the Tranche A Closing Date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GERON CORPORATION,<br>as Borrower and a Credit Party</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By_________________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:______________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:_______________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page to Loan Agreement</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BIOPHARMA CREDIT PLC,<br>as Collateral Agent</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  Pharmakon Advisors, LP,<br>its Investment Manager</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  Pharmakon Management I, LLC,<br>its General Partner</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By_________________________________________<br>Name:  Pedro Gonzalez de Cosio<br>Title:  Managing Member</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BPCR LIMITED PARTNERSHIP,<br>as a Lender</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: Pharmakon Advisors, LP,<br>its Investment Manager</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By: Pharmakon Management I, LLC,<br>its General Partner</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By_________________________________________<br>Name:  Pedro Gonzalez de Cosio<br>Title:  Managing Member</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP,<br>as Lender</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	BioPharma Credit Investments V GP LLC,<br>its General Partner</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:  Pharmakon Advisors, LP,<br>its Investment Manager</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By______________________________________<br>Name:  Pedro Gonzalez de Cosio<br>Title:  Managing Member</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page to Loan Agreement</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>7
<FILENAME>gern-ex10_34.htm
<DESCRIPTION>EX-10.34
<TEXT>
<html>
 <head>
  <title>EX-10.34</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 10.34</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH &#x201c;[***]&#x201d;. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="zzmpfixed_titlepage">&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Participation Right</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase and Sale Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By and Between</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Pharma Development Funding, LLC</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Dated as of November 1, 2024	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.333%;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Page</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.9%;box-sizing:content-box;"></td>
    <td style="width:81.8%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 1 DEFINITIONS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Definitions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certain Interpretations</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 1.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Headings</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 2 PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase, Sale and Assignment</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Assumed Obligations, Etc</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 2.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">True Sale</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 3 CLOSING; PAYMENT OF PURCHASE PRICE</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Closing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of Purchase Price</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bill of Sale</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Legal Opinion</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loan Agreements.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Seller Form W-9</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 3.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Buyer Form W-9</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Existence; Good Standing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enforceability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Conflicts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Litigation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compliance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intellectual Property</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title to Revenue Participation Right; No Liens</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lien Related Representation and Warranties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.9%;box-sizing:content-box;"></td>
    <td style="width:81.8%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 4.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brokers&#x2019; Fees</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF THE BUYER</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Existence; Good Standing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorization</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enforceability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Conflicts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consents</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Litigation</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brokers&#x2019; Fees</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 5.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Access to Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 6 NO OTHER REPRESENTATIONS AND WARRANTIES</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 7 COVENANTS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Seller Diligence Requirements</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reporting</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue Payments; Revenue Payment Details; Buy-Out Payment; Change of Control.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inspections and Audits of the Seller</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intellectual Property Matters</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-Licenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Out-Licenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Disclosures</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">[***]</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Efforts to Consummate Transactions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Further Assurances</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Late Payments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Negative Pledge; No Impairment and Liens</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 7.14</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restriction on Indebtedness</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 8 INDEMNIFICATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Indemnity</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notice of Claims</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Limitations on Liability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.9%;box-sizing:content-box;"></td>
    <td style="width:81.8%;box-sizing:content-box;"></td>
    <td style="width:3.3%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Third Party Claims</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exclusive Remedy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 8.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Treatment for Indemnification Payments.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 9 CONFIDENTIALITY</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Confidentiality</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 9.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorized Disclosure.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 10 TERMINATION</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 10.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Survival</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ARTICLE 11 MISCELLANEOUS</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.1</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notices</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.2</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expenses</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.3</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Assignment; Transfer Restrictions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.4</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amendment and Waiver</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.5</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entire Agreement</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.6</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No Third Party Beneficiaries</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.7</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Governing</font><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Law</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.8</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jurisdiction;</font><font style="text-transform:uppercase;color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Venue</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.9</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Severability</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.10</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Specific Performance</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.11</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Counterparts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.12</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Relationship of the Parties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</font></p></td>
   </tr>
   <tr style="height:12pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 11.13</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intercreditor Agreement.</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Index of Exhibits</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Payment Instructions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Form of Bill of Sale</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Form of Legal Opinion</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:	Form of Intercreditor Agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iii</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REVENUE PARTICIPATION RIGHT </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchase and sale</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This REVENUE PARTICIPATION RIGHT </font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchase and sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AGREEMENT (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated as of November 1, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), is made and entered into by and between Royalty Pharma Development Funding, LLC, a Delaware limited liability company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and Geron Corporation, a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">W I T N E S S E T H</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Seller is in the business of, among other things, developing and commercializing pharmaceutical products, including the Product, in or for the Territory; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS, the Buyer desires to purchase the Revenue Participation Right and receive the Revenue Payments from the Seller, and the Seller desires to sell the Revenue Participation Right and pay the Revenue Payments to the Buyer, in each case on the terms and conditions set forth in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Seller and the Buyer hereby agree as follows:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>DEFINITIONS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.1	Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The following terms, as used herein, shall have the following meanings:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any particular Person, any other Person directly or indirectly controlling, controlled by or under common control with such particular Person.  For purposes of the foregoing sentence, the term &#x201c;control&#x201d; means direct or indirect ownership of (a) fifty percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting and equity rights of such Person, firm, trust, corporation, partnership or other entity or combination thereof, or (b) the power to direct the management of such person, firm, trust, corporation, partnership or other entity or combination thereof, by contract or otherwise. For purposes hereof, any Person shall be deemed to control a partnership, limited liability company, association or other business entity if such Person, directly or indirectly through one or more intermediaries, shall be allocated a majority of partnership, limited liability company, association or other business entity gains or losses or shall be or control the managing director or general partner of such partnership, limited liability company, association or other business entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for a given Calendar Year, aggregate Net Sales for each Calendar Quarter occurring during such Calendar Year.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Back-Up Security Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 2.3.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bankruptcy Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#x2019; rights generally.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BioPharma</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means BioPharma Credit plc.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bill of Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 3.3.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in New York are permitted or required by applicable law or regulation to remain closed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-Out Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.3(d).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-Out Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Revenue Payments received by the Buyer as of the Change of Control Closing, if the Change of Control Closing occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Revenue Payments received by the Buyer as of the Change of Control Closing, if the Change of Control Closing occurs after December 31, 2027.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.1(a).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Quarter</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a period of three (3) consecutive months ending at midnight, New York City time on the last day of March, June, September, or December respectively.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calendar Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a period of twelve (12) consecutive months commencing on January 1 of any year.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) a transaction or series of related transactions that results in the sale or other disposition of all or substantially all of the Seller&#x2019;s and its Affiliates&#x2019; assets, on a consolidated basis; (b) a merger or consolidation with a Third Party in which the Seller is not the surviving corporation or in which, if the Seller is the surviving corporation, the stockholders of the Seller immediately prior to the consummation of such merger or consolidation do not, immediately after consummation of such merger or consolidation, possess, directly or indirectly through one or more intermediaries, a majority of the voting power of all of the surviving entity&#x2019;s outstanding stock and other securities and the power to elect a majority of the members of Seller&#x2019;s board of directors; or (c) a transaction or series of related transactions with one or more Third Parties (which may include a tender offer for the Seller&#x2019;s stock or the issuance, sale or exchange of stock of the Seller) if the stockholders of the Seller immediately prior to such transaction(s) do not, immediately after consummation of such transaction(s), possess, directly or indirectly through one or more intermediaries, a majority of the voting power of all of the Seller&#x2019;s or its successor&#x2019;s outstanding stock and other securities and the power to elect a majority of the members of the Seller&#x2019;s or its successor&#x2019;s board of directors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the closing, occurrence or other consummation of a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change of Control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Registrational Clinical Trial (including the MF Trial) and any other material clinical trial (including the Post-Marketing Commitment Dosing Trial) conducted by or on behalf of a Related Party and intended to support the Marketing Approval or Commercialization of a Product in or for the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a summary of any material updates with respect to the Clinical Trials, including (a) the progress of the Clinical Trials (including any material modifications to the Clinical Trials, any changes to the expected timing of the Clinical Trials, any event that requires an update to the data and safety monitoring board or the investigator&#x2019;s brochure and any notice of a clinical hold of a Clinical Trial) and (b) plans to start any Clinical Trials.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 2.3.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Combination Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the definition of &#x201c;Net Sales&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all activities and plans directed to the marketing, detailing, promotion, selling and securing of reimbursement of the Product in or for the Territory (including using, importing, selling and offering for sale of the Product in or for the Territory), and shall include post-Marketing Approval studies to the extent required by the FDA, post-launch marketing, promoting, detailing, marketing research, or customer service, and regulatory compliance.  When used as a verb, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialize</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean to engage in Commercialization. For clarity, &#x201c;Commercialization&#x201d; excludes Manufacturing activities and research and development activities, including pre-clinical and clinical development activities.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercially Reasonable Efforts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a summary of material updates with respect to the Related Parties&#x2019; sales and marketing activities and plans and, if material, commercial manufacturing matters with respect to each Product in or for the Territory. Copies of internal presentations or reports of summaries of such material information or developments, and copies of presentations or reports received by the Seller or its Affiliate from any Third Party, may be used (but are not obligated to be provided) in the Commercial Updates.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 9.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract Manufacturing Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any agreement or arrangement (including any memorandum of understanding regarding a future agreement) between the Seller or any of its Affiliates and any Third Party for the Manufacture of a Product (including bulk drug product, bulk drug substance and finished product) for Commercialization of such Product in the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Controlling Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 11.13.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Core Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Revenue Participation Right, the Revenue Payments and all &#x201c;proceeds&#x201d; (as defined in the UCC) of each of the foregoing.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Product NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the definition of &#x201c;Product&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Customary Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) an intercreditor agreement with substantially the same terms as the Intercreditor Agreement, subject to such customary changes to reflect the exclusion (if any) of any collateral provided to an applicable Third Party secured debt provider compared to the collateral provided to BioPharma under the Intercreditor Agreement and (b) such other intercreditor agreement in form and substance that is reasonably satisfactory to the Buyer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Sharing Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.9.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Room</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.9.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 9.1.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Disclosure Schedule, dated as of the Effective Date, delivered to the Buyer by the Seller concurrently with the execution of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all activities directed to the research, development, importation, exportation, use, registration, modification, enhancement, improvement, optimization, seeking and obtaining Marketing Approvals for, Manufacturing or Commercialization of the Product in or for the Territory.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean to engage in Exploitation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the U.S. Food and Drug Administration.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GAAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means generally accepted accounting principles in the United States in effect from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governmental Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any: (a) nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal); (d) multi-national organization or body; or (e) individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gross Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the definition of &#x201c;Net Sales&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hercules Loan and Security Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Loan and Security Agreement, dated as of September 30, 2020, as amended, by and among the Seller, Hercules Capital, Inc. and Silicon Valley Bank, a division of First Citizens Bank &amp; Trust Company.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hercules Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means all Indebtedness or other obligations of the Seller outstanding under the Hercules Loan Documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hercules Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Hercules Loan and Security Agreement and all other agreements and documents entered in connection therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Imetelstat</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means imetelstat, including imetelstat sodium.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any improvement, optimization, enhancement or modification of, or invention or discovery related to the Exploitation of, a Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any indebtedness for borrowed money, obligation evidenced by a note, bond, debenture or similar instrument, or guarantee of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.2.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifying Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.2.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any license, settlement agreement or other agreement or arrangement between the Seller or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which the Seller or any of its Affiliates obtains a license or a covenant not to sue or similar grant of rights to any Patents or other intellectual property rights that are necessary to Exploit a Product. In-Licenses exclude (a) Logistics Agreements, (b) any non-exclusive license under shrink-wrap, click wrap or other off-the-shelf contracts for commercially available, unmodified software, (c) non-exclusive licenses for generally available laboratory, research or development tools and (d) any agreement with a clinical trial site, vendor or services provider containing a non-exclusive license that is incidental to the primary purpose of such agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all of the following as they exist at any time: (a) the Patent Rights; (b) rights in registered and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and registrations and applications for registration of any of the foregoing, in each case, as related to a Product in or for the Territory; (c) copyrights in both published and unpublished works, including all compilations, databases and computer programs, manuals and other documentation and all copyright registrations and applications, and all derivatives, translations, adaptations and combinations of the above, in each case, as related to a Product in or for the Territory; (d) rights in all Know-How related to a Product or necessary to Exploit a Product in or for the Territory; (e) any and all other intellectual property rights and/or proprietary rights, whether or not patentable, specifically relating to any of the foregoing; (f) claims of infringement and misappropriation against Third Parties relating to any of the foregoing; and (g) intellectual property rights in regulatory filings, submissions, applications, registrations and approvals, including Marketing Approvals, related to a Product in or for the Territory.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an updated list of the Patent Rights, including any new Patents issued or filed, amended or supplemented, or any abandonments or other termination of prosecution with respect to any of the Patent Rights, and any other material information or developments with respect to the Intellectual Property Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Intercreditor Agreement by and among BioPharma and the Buyer, and acknowledged and agreed to by the Seller and any future Guarantor (as defined therein), in substantially the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit D</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Janssen License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Collaboration and License Agreement between Seller and Janssen Biotech, Inc. dated November 13, 2014.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Janssen License Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 4.8(b).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Judgment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any judgment, order, writ, injunction, citation, award or decree of any nature.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Know-How</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all proprietary or confidential information, know-how and trade secrets, including processes, formulae, models and techniques, rights in research in progress, algorithms, data, databases, data collections, chemical and biological materials (including any compounds, DNA, RNA, clones, vectors, cells and any expression product, progeny, derivatives or improvements thereto), and the results of experimentation and testing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Knowledge of the Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the actual knowledge of [***], after reasonable due inquiry.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind or assignment for security purposes, whether voluntarily incurred or arising by operation of law or otherwise against any property or assets.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licensee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party licensee  (other than a Logistics Provider) party to any Out-License.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Logistics Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any agreement between the Seller or any of its Affiliates, on the one hand, and a Third Party acting solely as a Logistics Provider, on the other hand, including such agreements with specialty pharmacies and specialty distributors.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Logistics Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a Third Party that has the right, option or obligation to distribute, transport, warehouse, package, import, or provide similar logistics services with respect to Product in one or more regions in the Territory on behalf of a Related Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means manufacturing, production, formulating, processing, filling, finishing, quality control, quality assurance, stability testing, packaging, labeling, shipping, importing, storage and similar activities with respect to a Product (and components thereof or therefor) in or for the Territory, and regulatory compliance with respect to the foregoing.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacture</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean to engage in Manufacturing.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Capitalization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means an amount equal to the product of (a) the total number of issued and outstanding shares of equity interests of the Seller (or any successor entity) or any direct</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or indirect parent of the Seller on the date of determination and (b) the arithmetic mean of the closing prices per share of such equity interests for the [***] consecutive trading days immediately preceding the date of determination.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to the Product, any and all approvals (including drug and/or device approval applications), licenses, registrations or authorizations from the applicable Regulatory Authority sufficient to Manufacture or Commercialize such product in or for the Territory in accordance with applicable laws, including, if required, pricing or reimbursement approvals.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Adverse Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MF Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the clinical trial entitled &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; (NCT04576156).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Sales</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Combination Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a product that includes the Product and at least one additional active pharmaceutical ingredient  that is not the Product, whether co-formulated, co-administered or sold at a single price point or otherwise sold to be administered together, sequentially or as part of a course of treatment. Pharmaceutical dosage form vehicles, buffers, diluents, adjuvants, excipients and similar inert materials shall not be deemed to be &#x201c;active ingredients&#x201d;, except in the case where such vehicle, buffer, diluent, adjuvant, excipient or similar inert material is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. &#167; 210.3(b)(7), and imaging agents shall not be considered &#x201c;active ingredients&#x201d; for purposes of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Indication</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the treatment of patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus associated kinase (JAK) inhibitor treatment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Out-License</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any license between the Seller or any of its Affiliates, on the one hand, and any Third Party, on the other hand, pursuant to which the Seller or any of its Affiliates grants a license or sublicense of any Intellectual Property Right to Commercialize the Product in the Territory. For clarity, &#x201c;Out-License&#x201d; specifically excludes any research licenses that do not include a Commercialization license, Logistics Agreement or Contract Manufacturing Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participation Start Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means July 1, 2024.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patent Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any existing or future Patent owned or in-licensed by the Seller or any other Related Party or under which the Seller or any other Related Party is empowered to grant a license or sublicense and the subject matter of which is necessary in the Exploitation of a Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all patents and patent applications existing as of the date of this Agreement and all patent applications filed hereafter, in each case, in or for the Territory, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any of the foregoing patent applications, any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent or other governmental actions which extend any of the subject matter of a patent, and any substitution patent, confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Convertible Debt</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means Indebtedness in the form of convertible notes issued after the Effective Date having a feature which entitles the holder thereof to convert or exchange all or a portion of such Indebtedness into (i) common stock of the Seller (or any direct or indirect parent Person thereof, including following a Change of Control) or (ii) cash or any combination of cash and common stock; provided, that:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) such Indebtedness shall not be issued in an aggregate principal amount in excess of the greater of (i) [***]% of the Market Capitalization of the Seller (determined in the case of an underwritten transaction as of the date of pricing for such transaction) and (ii) the then-outstanding principal amount of Permitted Convertible Debt previously issued in compliance with this Agreement (such an issuance a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refinancing Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in each case determined at the time of each such new issuance of such Indebtedness;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) such Indebtedness shall be unsecured;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) such Indebtedness shall not be guaranteed by or otherwise owing by any subsidiary of the Seller;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) such Indebtedness shall not have a scheduled maturity date, amortization or principal payments or require any mandatory repurchase or redemption, in each case prior to the date that is five (5) Calendar Years after its issuance date (such date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturity Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e) in the case of a Refinancing Transaction, the net proceeds therefrom must first be used to purchase and cancel previously issued Permitted Convertible Debt (with such net proceeds being applied so that the Permitted Convertible Debt that matures the earliest is paid first and the Permitted Convertible Debt that matures the latest is paid last) and the remainder of the net proceeds, if any, may be used for any purpose not prohibited by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f) such Indebtedness shall not require the Seller (or any of its Affiliates) to settle, repurchase, redeem, exchange or otherwise make payments on such Indebtedness using cash or cash equivalents prior to the applicable Maturity Date (other than (i) fair value payments in cash</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in lieu of issuing fractional shares in connection with conversions of such Indebtedness by holders thereof, (ii) following a merger, consolidation, binding share exchange or event pursuant to which the common stock of the Seller was exchanged in full or in part for cash or cash equivalents  or (iii) cash to make payments of interest on such Indebtedness).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For clarity, (x) customary conversion rights consistent with the foregoing in this definition of the holders of such Permitted Convertible Debt, (y) customary acceleration rights of the holders of such Permitted Convertible Debt upon the occurrence and continuance of an event of default, and (z) the customary obligation to repurchase such Permitted Convertible Debt upon a customary &#x201c;fundamental change&#x201d; or similar event shall be permitted under clause (d) or (f) above of this definition.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Lien</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permitted Secured Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any individual, firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity or other entity, enterprise, association or organization.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmakon Credit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means that certain Loan Agreement, dated as of the date hereof, by and among the Seller, BioPharma, BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP and the guarantors signatory thereto or otherwise party thereto from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmakon Loan Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the &#x201c;Loan Documents&#x201d; as defined in the Pharmakon Credit Agreement which are in effect on the date hereof and have been delivered to the Buyer prior to the date hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-Marketing Commitment Dosing Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a randomized post-Marketing Approval Clinical Trial comparing at least 2 dosages of Imetelstat in patients with low or intermediate-1 risk myelodysplastic syndromes (LR-MDS) to evaluate alternative dosing regimens such as different dose levels, dosing frequencies, and duration of treatment, as required to be conducted by the Current Product NDA.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prime Rate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the prime rate published by The Wall Street Journal, from time to time, as the prime rate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (a) any product that contains Imetelstat as an active ingredient or as an active moiety, alone or in combination with one or more other active ingredients or active moieties, in any preparation, strength, form, or formulation; (b) any Improvement of (a), and (c) any metabolite, salt, ester, hydrate, anhydrate, solvate, isomer, enantiomer, crystalline form, co-crystalline form, amorphous form, free acid form, deuterated form, free base form, pro-drug (including any ester pro-drug) form, racemate, polymorph, chelate, stereoisomer, or tautomer of (a) or (b), or any optically active form thereof.  Product includes RYTELO (for which the FDA has approved Seller&#x2019;s NDA 217779 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current Product NDA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;)).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any and all of the following: (a) Intellectual Property Rights, (b) regulatory filings, submissions and approvals, including Marketing Approvals, with or from any Regulatory Authorities related to a Product in and for the Territory, (c) In-Licenses, (d) Out-Licenses, (e) Logistics Agreements, and (f) Contract Manufacturing Agreements.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means one hundred and twenty-five million dollars ($125,000,000).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.2(a).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.2(a).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Receiving Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 9.1.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refinancing Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the definition of &#x201c;Permitted Convertible Debt&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrational Clinical Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any human clinical study of a Product that is designed (as of the time of initiation of such Clinical Trial) to obtain the results and data to support the filing of an application for Marketing Approval of such Product (including label expansion but excluding the data that may be necessary to support the pricing and/or reimbursement approval), including so called Phase 2/3 trials and any human clinical study that would satisfy the requirements of 21 &#167; CFR 312.21(c) or corresponding foreign regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Governmental Entity, including the FDA, that has responsibility in granting a Marketing Approval.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Updates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means a summary of any and all material information and developments that impact a Product in or for the Territory (including the Manufacturing of Product) with respect to compliance with applicable rules and regulations of a Regulatory Authority or any regulatory filings or submissions made to, or responses from, any Regulatory Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means each of the Seller, its Affiliates, and their respective Licensees, as applicable; provided that a Logistics Provider (in its capacity as such) shall not be a Related Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representative</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to any Person, (a) any direct or indirect member or partner of such Person and (b) any manager, director, trustee, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, contractors, actual and potential lenders, investors, co-investors and assignees, bankers and financial advisers) of such Person.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Participation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the right to receive payment in full of all Revenue Payments, and an undivided ownership interest in all accounts (as defined in the UCC), general intangibles (as defined in the UCC), payment intangibles (as defined in the UCC) and all other rights to payment on account of, in connection with or arising from all Net Sales occurring on and after the Participation Start Date, and all proceeds thereof, in an amount equal to the Revenue Percentage.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means for each Calendar Quarter occurring (in whole or in part) during the Revenue Payment Term, an amount payable to the Buyer equal to the product of (a) Net Sales during such Calendar Quarter (or, for any Calendar Quarter occurring in part during the Revenue Payment Term, Net Sales for the calendar days falling within the Revenue Payment Term during such Calendar Quarter) and (b) the applicable Revenue Percentage; provided, for the avoidance of doubt, that if the Revenue Payment Term ends in accordance with clause (a) thereof, the aggregate Revenue Payments payable to the Buyer under this Agreement shall not exceed 1.65 times the Purchase Price and (b) if the Revenue Payment Term ends in accordance with clause (b) thereof, the aggregate Revenue Payments payable to the Buyer under this Agreement shall not exceed 2.0 times the Purchase Price.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Payment Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the period commencing on the Participation Start Date and ending on the earlier to occur of (a) the date (if any) on which the aggregate Revenue Payments paid to the Buyer in respect of Net Sales occurring between the Participation Start Date and June 30, 2031 equals or exceeds 1.65 times the Purchase Price or (b) the date on which the aggregate Revenue Payments paid to the Buyer equals or exceeds 2.0 times the Purchase Price.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Percentage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means (i) 7.75% in respect of Annual Net Sales of up to $500,000,000, (ii) 3.0% in respect of Annual Net Sales in excess of $500,000,000 but less than or equal to $1,000,000,000 and (iii) 1.0% in respect of Annual Net Sales in excess of $1,000,000,000.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 7.3(c).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any recalls, field notifications, market withdrawals, warnings, &#x201c;dear doctor&#x201d; letters, investigator notices, safety alerts or other notices of action issued or instigated by or on behalf of any Related Party or any Regulatory Authority relating to an alleged lack of safety or regulatory compliance of or with respect to a Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in the preamble.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.1(b).</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any federal, state, local or foreign income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Territory</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the United States of America (including its territories and possessions).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any Person that is not the Seller or Buyer or their respective Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; is defined in Section 8.2.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transaction Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means this Agreement and the Bill of Sale.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UCC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the Uniform Commercial Code in the State of New York; provided, that, if with respect to any financing statement or by reason of any provisions of law, the perfection, priority or the effect of perfection, priority or non-perfection of the security interests granted to the Buyer pursuant to this Agreement or any related document is governed by the Uniform Commercial Code in a jurisdiction of the United States other than New York, then &#x201c;UCC&#x201d; means the Uniform Commercial Code in such other jurisdiction for purposes of the provisions of this Agreement, any related document and any financing statement relating to such perfection, priority or effect of perfection, priority or non-perfection.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.2	Certain Interpretations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	&#x201c;either&#x201d; and &#x201c;or&#x201d; are not exclusive and &#x201c;include,&#x201d; &#x201c;includes&#x201d; and &#x201c;including&#x201d; are not limiting and shall be deemed to be followed by the words &#x201c;without limitation&#x201d;;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	&#x201c;extent&#x201d; in the phrase &#x201c;to the extent&#x201d; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#x201c;if&#x201d;;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	&#x201c;hereof,&#x201d; &#x201c;hereto,&#x201d; &#x201c;herein&#x201d; and &#x201c;hereunder&#x201d; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	references to a Person are also to its permitted successors and assigns, and references to a Governmental Entity are also to its succeeding governing entity in the relevant jurisdiction;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	definitions are applicable to the singular as well as the plural forms of such terms;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	unless otherwise indicated, references to an &#x201c;Article&#x201d;, &#x201c;Section&#x201d; or &#x201c;Exhibit&#x201d; refer to an Article or Section of, or an Exhibit to, this Agreement, and references to a &#x201c;Schedule&#x201d; refer to the corresponding part of the Disclosure Schedule;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	provisions referring to matters that would or could have, or would or could reasonably be expected to have, or similar phrases, shall be deemed to have such result or expectation with or without the giving of notice or the passage of time, or both;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(h)	accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement or any related document shall be prepared in conformity with GAAP;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement, and references to a contract include the exhibits, schedules, appendices and similar attachments thereto and also include any amendment or modification to such contract after the date hereof, to the extent not prohibited by this Agreement; and</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(j)	references to &#x201c;$&#x201d; or otherwise to dollar amounts refer to the lawful currency of the United States, and all payments under this Agreement shall be made in immediately available funds.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1.3	Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.1	Purchase, Sale and Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date and upon the terms and subject to the conditions of this Agreement, in exchange for the Buyer&#x2019;s payment of the Purchase Price, the Seller hereby sells, transfers, assigns and conveys to the Buyer, and the Buyer hereby purchases, acquires and accepts from the Seller, the Revenue Participation Right free and clear of all Liens (other than Liens created by the Buyer). From and after the Effective Date, upon receipt of the Purchase Price in accordance with Section 3.2, the Seller relinquishes all of the Seller&#x2019;s and its Affiliates&#x2019; right, title and interest in and to the Revenue Participation Right, and all such right, title and interest shall vest in the Buyer. In addition, the Seller hereby agrees to pay to the Buyer the Revenue Payments on the terms and conditions set forth herein.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.2	No Assumed Obligations, Etc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding any provision in this Agreement to the contrary, the Buyer is only agreeing, on the terms and conditions set forth in this Agreement, to purchase, acquire and accept the Revenue Participation Right and is not assuming any liability or obligation of the Seller or its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2.3	True Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. It is the intention of the parties hereto that the sale, transfer, assignment and conveyance of the Revenue Participation Right contemplated by this Agreement be, and is, a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller  to the Buyer of all of the Seller&#x2019;s rights, title and interests in and to the Revenue Participation Right. Neither the Seller nor the Buyer intends the transactions contemplated by this Agreement to be, or for any purpose characterized as, a loan from the Buyer to the Seller, a financing transaction or a borrowing.  It is the intention of the parties hereto that the beneficial interest in and title to the Revenue Participation Right and any &#x201c;proceeds&#x201d; (as such term is defined in the UCC) thereof shall not be part of the Seller&#x2019;s estate in the event of the filing of a petition by or against the Seller under any Bankruptcy Laws. The Seller  hereby waives, to the maximum extent permitted by applicable law, any right to contest or otherwise assert that the sale contemplated by this Agreement does not constitute a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller to the Buyer of all of the Seller&#x2019;s right, title and interest in and to the Revenue Participation Right under applicable laws, which waiver shall, to the maximum extent permitted by applicable laws, be enforceable against the Seller in any bankruptcy or insolvency proceeding relating to the Seller. Accordingly, the Seller shall treat the sale, transfer, assignment and conveyance of the Revenue Participation Right as a sale of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;accounts,&#x201d; &#x201c;payment intangibles&#x201d; or &#x201c;general intangibles&#x201d; (as appropriate) in accordance with the UCC, and the Seller hereby authorizes the Buyer and its authorized representatives at any time to file one or more financing statements or any amendments to financing statements previously filed by the Buyer (and continuation statements with respect to such financing statements when applicable) naming the Seller as the seller and the Buyer as the buyer in respect of the Revenue Participation Right.  Not in derogation of the foregoing statement of the intent of the parties hereto, and for the purposes of providing additional assurances to the Buyer, including in the event that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, the Seller hereby unconditionally and irrevocably grants to the Buyer a continuing security interest and Lien in, and a right to set off against, any and all right, title and interest of the Seller, in, to and under the Revenue Participation Right, Revenue Payments, Product Rights, Product and any &#x201c;proceeds&#x201d; (as defined in the UCC) of the foregoing (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collateral</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as security for the payment of amounts to the Buyer equal to 2.0 times the Purchase Price less all Revenue Payments received by the Buyer pursuant to this Agreement, and for all of the Seller&#x2019;s obligations under the Transaction Documents, including the obligations to pay the Revenue Payments (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Back-Up Security Interest</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and the Seller does hereby authorize the Buyer and its representatives, from and after the Effective Date, to file one or more financing statements (and continuation statements and any amendments with respect to such financing statements when applicable) in such manner and such jurisdictions as are necessary or appropriate to perfect (or provide priority of) such Back-Up Security Interest; provided that [***] such Back-Up Security Interest shall be automatically terminated upon the termination of this Agreement as provided in Section 10.1 [***]. Following the termination of the Back-Up Security Interest in accordance with the proviso in the immediately preceding sentence, upon the Seller&#x2019;s request, the Buyer shall, at the expense of the Seller, file a UCC-3 termination statement terminating the Back-Up Security Interest.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>CLOSING; PAYMENT OF PURCHASE PRICE</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.1	Closing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The purchase and sale of the Revenue Participation Right shall take place remotely via the exchange of documents and signatures on the date hereof or such other place, time and date as the parties hereto may mutually agree.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.2	Payment of Purchase Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date, the Buyer shall pay to the Seller the Purchase Price by wire transfer of immediately available funds to the account specified on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.3	Bill of Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date, upon confirmation of the receipt of the Purchase Price, the Seller shall deliver to the Buyer a duly executed bill of sale evidencing the sale, transfer, assignment and conveyance of the Revenue Participation Right in form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bill of Sale</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.4	Legal Opinion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date, the Seller shall deliver to the Buyer the legal opinion of Cooley LLP, as corporate counsel to the Seller in the form attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.5	Loan Agreements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	On or prior to the Effective Date, the Seller shall deliver to the Buyer a fully executed copy of the Pharmakon Credit Agreement, the other Pharmakon Loan Documents and related security filings.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	On the Effective Date, the Seller shall deliver to the Buyer the Intercreditor Agreement, duly executed by the Seller and Pharmakon.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	On or prior to the Effective Date, (i) all Hercules Indebtedness and related Liens shall have been paid off and released, as applicable and (ii) the Seller shall deliver to the Buyer an executed payoff letter with respect thereto and Lien release documents and termination filings, each in form and substance reasonably satisfactory to the Buyer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.6	Seller Form W-9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On or prior to the Effective Date, the Seller shall deliver to the Buyer a valid, properly executed IRS Form W-9 certifying that the Seller is exempt from U.S. federal withholding tax and &#x201c;backup&#x201d; withholding tax.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3.7	Buyer Form W-9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On or prior to the Effective Date, the Buyer shall deliver to the Seller a valid, properly executed IRS Form W-9 certifying that the Buyer is exempt from U.S. federal withholding tax with respect to the Revenue Payments.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>REPRESENTATIONS AND WARRANTIES OF THE SELLER</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except as set forth on the Disclosure Schedule attached hereto, the Seller represents and warrants to the Buyer that as of the Effective Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.1	Existence; Good Standing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Seller is a corporation, duly organized, validly existing and in good standing under the laws of Delaware. The Seller is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.2	Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Seller.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.3	Enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement has been duly executed and delivered by an authorized officer of the Seller and constitutes the valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.4	No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) contravene or conflict with the organizational documents of the Seller or (ii) contravene or conflict with or constitute a default under any law, Judgment or agreement binding upon or applicable to the Seller except for such contraventions, conflicts or defaults that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.5	Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Seller or any of its Affiliates in connection with (i) the execution and delivery by the Seller of this Agreement, (ii) the performance by the Seller of its obligations under this Agreement or (iii) the consummation by the Seller of any of the transactions contemplated by this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.6	No Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller is not a party to, and has not received any written notice of, any action, claim, suit, investigation or proceeding pending before any Governmental Entity and, to the Knowledge of the Seller, no such action, claim, suit, investigation or proceeding has been threatened against the Seller, that, either individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.7	Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	All applications, submissions, information and data related to a Product in or for the Territory submitted or utilized as the basis for any request to any Regulatory Authority  by or on behalf of the Seller were true and correct in all material respects as of the date of such submission or request, and any material updates, changes, corrections or modification to such applications, submissions, information or data required under applicable laws or regulations have been submitted to the applicable Regulatory Authority.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller has provided to the Buyer prior to the Effective Date in the Data Rooms true, correct and complete copies of all material written communications sent or received since [***] by the Seller and any of its Affiliates to or from any Regulatory Authorities that relate to its or their Exploitation of Product. All material Safety Notices are reflected in the investigator&#x2019;s brochure dated August 14, 2024 disclosed in the Data Room named &#x201c;Geron-BD-2024&#x201d; prior to the Effective Date.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Neither the Seller nor any of its Affiliates has committed any act, made any statement or failed to make any statement in respect of a Product that would reasonably be expected to provide a basis for the FDA to invoke its policy with respect to &#x201c;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#x201d;, or any other Governmental Entity to invoke similar policies, set forth in any applicable laws or regulations.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Since [***] (A) there have been no Safety Notices, (B) to the Knowledge of the Seller, there are no unresolved material product complaints with respect to a Product, which would reasonably be expected to result in a Material Adverse Effect, and (C) to the Knowledge of the Seller, there are no facts currently in existence that would, individually or in the aggregate, reasonably be expected to result in (1) a material Safety Notice with respect to a Product, or (2) a</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material change in the labeling of a Product. The Seller has not experienced any significant failures in the Manufacturing of a Product for clinical use or commercial use that have not been resolved, or that would, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Seller has been in compliance with all applicable laws administered or issued by the FDA or any similar Regulatory Authority, including the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, applicable requirements in FDA regulations, and any orders issued by FDA or similar Regulatory Authorities, and all other laws regarding ownership, developing, testing, disposal, Commercializing, and complaint handling or adverse event reporting for the products of the Seller, except to the extent that such failure to comply with such applicable laws would not reasonably be expected to result in a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.8	Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There are no In-Licenses currently in effect or contemplated.  [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Out-Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There are no Out-Licenses currently in effect or contemplated. The Janssen License was terminated with an effective termination date of September 28, 2018. The Seller has an exclusive, worldwide, royalty-free, fully paid-up, perpetual license to the Intellectual Property Rights developed by or on behalf of Janssen Biotech, Inc. or its Affiliates under the Janssen License and necessary to Exploit the Product  (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Janssen License Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.9	Intellectual Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.9(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule lists all of the currently existing Patents included within the Patent Rights. Except as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.9(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule, the Seller is the sole and exclusive registered owner of all of the existing Patent Rights. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.9(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule specifies the respective patent or patent application numbers as to each listed Patent or patent application within the existing Patent Rights.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.9(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule specifies any Person other than the Seller owning or having an interest in any existing Patent Right, including the nature of such interest.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	None of the Seller nor any of its Affiliates is a party to any pending, and, to the Knowledge of the Seller, there is no threatened litigation, interference, reexamination, opposition or like procedure or proceeding involving any of the existing Patent Rights or other Intellectual Property Rights.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	All of the issued Patents within the existing Patent Rights owned by the Seller are enforceable, in full force and effect, and have not lapsed, expired or otherwise terminated, except in the ordinary course of business, and to the Knowledge of the Seller, are valid.  None of the Seller nor any of its Affiliates has received any written notice relating to the lapse, expiration or other termination of any of the issued patents within the existing Patent Rights, except in the ordinary course of business.  None of the Seller nor any of its Affiliates has received any written notice or written legal opinion that alleges that any issued Patent within any of the existing Patent Rights or any other existing Intellectual Property Rights are invalid or unenforceable.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	None of the Seller nor any of its Affiliates has received any written notice that there is any, and, to the Knowledge of the Seller, there is no, Person who is or claims to be an inventor under any of the existing Patent Rights who is not a named inventor thereof or claims to be an owner of any other Intellectual Property Rights.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Seller or its Affiliate has paid all maintenance fees, annuities and like payments required with respect to all of the existing Patent Rights, except non-material ordinary course of business abandonments.  The Seller is prosecuting and maintaining all existing Patent Rights, except such non-material Patent Rights as may be abandoned or allowed to expire in the ordinary course of business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	[***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	No Product Rights are owned or in-licensed by any Affiliate of the Seller, and none of Seller or any of its Affiliates intend for any Affiliate to own or in-license any Product Rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.10	Title to Revenue Participation Right; No Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  On the Effective Date, subject to receipt of the Purchase Price by Seller in accordance with Section 3.2, the Buyer will have acquired, subject to the terms and conditions set forth in this Agreement, good and marketable title to the Core Collateral, in each case free and clear of all Liens (other than the Back-Up Security Interest, which shall be a first priority Lien). After giving effect to the repayment in full of the Hercules Indebtedness, which shall occur on or prior to the date hereof, none of the Product Rights or Product is subject to, or encumbered by, any Lien (other than the Buyer&#x2019;s Back-Up Security Interest and other than any Permitted Liens). The Buyer has a Lien in the Product Rights and the Product that is superior to any Lien of any other Person other than any Lien expressly permitted by clause (c) of the definition of &#x201c;Permitted Liens&#x201d; and solely to the extent contemplated by and subject to the Intercreditor Agreement. The Seller holds all rights, interests, and title in the Collateral and has all authority and received all consents necessary to fully grant the Back-Up Security Interest.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.11	Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedule 4.12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Disclosure Schedule sets forth a complete list of the outstanding Indebtedness of, or incurred or assumed by, the Seller and its Affiliates, and of any Liens that secures any such Indebtedness.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.12	Lien Related Representation and Warranties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller&#x2019;s exact legal name (as defined in Section 9-503(a) of the UCC) is, and for the immediately preceding ten (10) years has been, &#x201c;Geron Corporation&#x201d;. The Seller is, and for the prior ten (10) years has been, a corporation and incorporated in Delaware. The Seller&#x2019;s chief executive office is (and has been since [***]) located at 919 E. Hillsdale Blvd., Suite 250, Foster City, CA 94404. The Seller does not own any real property.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4.13	Brokers&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except Cowen and Company, LLC, there is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Seller or any of its Affiliate who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>REPRESENTATIONS AND WARRANTIES OF THE BUYER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Buyer hereby represents and warrants to the Seller that as of the Effective Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.1	Existence; Good Standing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer is a Delaware limited liability company, duly organized, validly existing and in good standing under the laws of the state of Delaware. The Buyer is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a material adverse effect on the business of the Buyer or the ability of the Buyer to enter into and to perform its obligations under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.2	Authorization</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer has the requisite right, power and authority to execute, deliver and perform its obligations under this Agreement.  The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Buyer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.3	Enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement has been duly executed and delivered by an authorized person of the Buyer and constitutes the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.4	No Conflicts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The execution, delivery and performance by the Buyer of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) contravene or conflict with the organizational documents of the Buyer or (ii) contravene or conflict with or constitute a default under any law, Judgment or agreement binding upon or applicable to the Buyer except for such contraventions, conflicts or defaults that, individually or in the aggregate, would not reasonably be expected to have a material adverse effect on the ability of the Buyer to enter into and perform its material obligations under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.5	Consents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer in connection with (i) the execution and delivery by the Buyer of this Agreement, (ii) the performance by the Buyer of its obligations under this Agreement or (iii) the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.6	No Litigation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There is no action, claim, suit, investigation or proceeding pending or, to the knowledge of the Buyer, threatened before any Governmental Entity to which the Buyer is a party that would reasonably be expected to prevent or materially and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.7	Financing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer has sufficient cash on hand or other sources of immediately available funds to pay the Purchase Price on the Effective Date. The Buyer acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.8	Brokers&#x2019; Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5.9	Access to Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Buyer acknowledges that it has (a) reviewed Seller&#x2019;s documents and information relating to the Product contained in the Data Rooms and (b) had the opportunity to ask such questions of, and to receive answers from, representatives of the Seller concerning the Product, in each case, as it deemed necessary to make an informed decision to enter into this Agreement.  The Buyer has such knowledge, sophistication and experience in financial and business matters that it is capable of evaluating the risks and merits of entering into the transaction contemplated by this Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>NO OTHER REPRESENTATIONS AND WARRANTIES.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN ANY TRANSACTION DOCUMENT, NONE OF THE PARTIES HERETO MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENT RIGHTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.1	Seller Diligence Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Seller shall, directly or indirectly through its Affiliates or any Licensees, use Commercially Reasonable Efforts to (a) complete the MF Trial and the Post-Marketing Commitment Dosing Trial and obtain Marketing Approval for the Product in the New Indication and (b) Commercialize the Product in the Territory for all approved indications. In furtherance of the foregoing, (i) the Seller shall use Commercially Reasonable Efforts to prepare, execute, deliver and file any and all agreements, documents or instruments, or amendments or modifications to any existing agreements, documents or instruments, that are necessary or desirable to maintain any Marketing Approval that is necessary to Commercialize the Product in the Territory for all approved indications, and (ii) the Seller shall not withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or abandonment of, any obtained Marketing Approval for the Product in the Territory, except (x) in connection with a permanent withdrawal or abandonment of the Product in the Territory consistent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the Seller&#x2019;s obligation in the first sentence of this Section 7.1 or (y) as required by applicable law or otherwise directed or required by a Regulatory Authority.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2	Reporting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	From and after the Effective Date, the Seller shall provide the Buyer promptly following the end of each Calendar Quarter, but in any event no later than (x) [***] calendar days after the end of each of the first three Calendar Quarters in a Calendar Year and (y) [***] calendar days after the end of the last Calendar Quarter in a Calendar Year (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Deadline</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), a reasonably detailed report (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) setting forth, with respect to such same period, (i) the Commercial Updates, (ii) the Intellectual Property Updates, (iii) the Clinical Updates, and (iv) the Regulatory Updates, each subject to Section 7.2(c);  provided that Seller shall not be required to provide Clinical Updates following completion of the final study report for the MF Trial and the Post-Marketing Commitment Dosing Trial. Upon reasonable request by Buyer (which request shall not be made more than once per Calendar Quarter), Seller shall in good faith discuss with Buyer in a teleconference such additional information related to the Product as the Buyer may reasonably request; provided that Seller shall not be obligated to provide or prepare any written material or response in connection with such teleconference.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	To the extent commercially practical and permitted by applicable laws, the Seller shall in good faith endeavor to (x) notify the Buyer if the Seller intends to issue any press release or other public disclosure containing top-line data from a Registrational Clinical Trial or information that would reasonably reflect the occurrence (or expected occurrence) of a Material Adverse Effect and (y)  provide a draft of such release or disclosure, in each case, prior to the issuance thereof.  The Seller shall have the sole discretion to make alterations to such draft copy in the final press release or public disclosure and to determine whether to issue such press release or public disclosure.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Notwithstanding the foregoing, Seller shall not be required to include in the Quarterly Report (i) any information that is prohibited to be so disclosed under applicable laws (including those related to patient information and privacy laws) and (ii) any information that does not relate to the Revenue Participation Right, the Product Rights or the Product.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Seller shall prepare and maintain, and shall require each Related Party to prepare and maintain, reasonably complete and accurate records of the information to be disclosed in each Quarterly Report.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	Each Quarterly Report, the information contained therein and any other information provided under this </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shall be the Confidential Information of Seller and subject to the obligations of confidentiality set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Article 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.3	Revenue Payments; Revenue Payment Details; Buy-Out Payment; Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	For each Calendar Quarter occurring (in whole or in part) during the Revenue Payment Term, the Seller shall pay to the Buyer the Revenue Payment for each such Calendar Quarter promptly, but in any event no later than the Quarterly Deadline.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Provided that the Buyer has provided to the Seller a valid, properly executed Internal Revenue Service Form W-9 or other appropriate form certifying that the Buyer is exempt from U.S. federal withholding Tax, the Seller shall make all payments required to be made by it to the Buyer pursuant to this Agreement in U.S. dollars by wire transfer of immediately available funds, without set-off, reduction or deduction, or withholding for or on account of any Taxes, to the bank account designated in writing from time to time by the Buyer.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	For each Calendar Quarter occurring (in whole or in part) during the Revenue Payment Term, the Seller shall provide the Buyer promptly following the end of such Calendar Quarter, but in any event no later than the Quarterly Deadline, a report (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Report</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) setting forth in reasonable detail (i) Gross Sales and Net Sales for such Calendar Quarter and Calendar Year to date (including a detailed break-down of all permitted deductions from Gross Sales used to determine Net Sales and any Net Sales described in Section 7.5(e)), and (ii) the calculation of the Revenue Payment payable to the Buyer for the applicable Calendar Quarter, identifying  the number of units of the Product sold by the Seller, its Affiliates and each Licensee in the Territory.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	If, at any time during the term of this Agreement, the Seller or one or more of its Affiliates enters into a definitive agreement for or otherwise obtains knowledge of a Change of Control, the Seller shall have the option (but not the obligation), by written notice to Buyer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-Out Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) no later than [***] Business Days following the entry into such definitive agreement for or such awareness of a Change of Control (which notice shall be irrevocable), to elect to pay (or cause to be paid) to the Buyer the applicable Buy-Out Payment at such Change of Control Closing. If the Seller exercises its option to make the Buy-Out Payment, the Seller shall, concurrently with the Change of Control Closing, pay (or cause to be paid) to the Buyer the applicable Buy-Out Payment amount by wire transfer of immediately available funds to one or more accounts specified by the Buyer. For the avoidance of doubt, the Seller shall have no obligation to pay any additional Revenue Payments following payment in full of the Buy-Out Payment to the Buyer and this Agreement shall terminate in accordance with Section 10.1. If such Change of Control Closing with respect to the Change of Control for which a Buy-Out Notice has been delivered does not occur, the Seller shall have no obligation to pay the Buy-Out Payment and this Agreement shall continue in full force and effect in accordance with its terms, including this Section 7.3, which shall apply to any subsequent Change of Control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.4	Inspections and Audits of the Seller</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Upon no less than [***] Business Days&#x2019; prior written notice and during normal business hours, the Buyer may cause an inspection and/or audit, by an independent public accounting firm reasonably acceptable to the Seller and subject to a confidentiality agreement between the Seller and such public accounting firm reasonably acceptable to the Seller, the Buyer and such independent public accounting firm, of the Seller&#x2019;s and its Affiliates&#x2019; books of account for up to [***] prior to the audit, for the sole purpose of determining the correctness of the Revenue Payments made under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Any such inspection and/or audit shall be permitted with respect to the Revenue Payments no more frequently than [***]. In connection with any such inspection and/or audit,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the Buyer&#x2019;s reasonable request, the Seller and its Affiliates shall exercise any rights it may have under any Out-License relating to Net Sales of a Product in the Territory to cause an inspection and/or audit by such independent public accounting firm to be made of the books of account of any counterparty thereto for the purpose of determining the correctness of the Revenue Payments made under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="docxtextref11"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	All of the expenses of any inspection or audit requested by the Buyer hereunder (including the fees and expenses of such independent public accounting firm designated for such purpose) shall be borne by </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the Buyer, if such independent public accounting firm determines that the Revenue Payments previously paid were incorrect by an amount less than or equal to [***] of the Revenue Payments actually paid for the period reviewed by such independent public accounting firm or (ii) the Seller, if such independent public accounting firm determines that the Revenue Payments previously paid were incorrect by an amount greater than </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Revenue Payments actually paid for the period reviewed by such independent public accounting firm.  The terms on which such independent public accounting firm is engaged shall provide that such independent public accounting firm shall not disclose to the Buyer the confidential information of the Seller or any counterparty to any Out-License relating to a Product, except to the extent such disclosure is either necessary to determine the correctness of a Revenue Payment or otherwise would be included in a Quarterly Report or Revenue Report. All information obtained by the Buyer as a result of any such inspection or audit shall be Confidential Information subject to ARTICLE 9 and such independent public accounting firm shall be considered a representative of the Buyer for purpose of ARTICLE 9. The Seller shall pay any underpayments discovered during the course of an audit conducted pursuant to this Section 7.4, with interest in accordance with Section 7.12, within </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Business Days of receipt of the audit report.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.5	Intellectual Property Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller shall provide to the Buyer a copy of any written notice received from any Third Party alleging or claiming that any Exploitation of a Product infringes or misappropriates any Patents or other intellectual property rights of such or any other Third Party, together with copies of material correspondence sent or received by any Related Party related thereto, as soon as practicable and in any event not more than [***] Business Days following such delivery or receipt.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller shall promptly inform the Buyer of any infringement, misappropriation, or violation by a Third Party of any Patent Right or other Intellectual Property Right, or of any allegation by a Third Party that any Patent Right or other Intellectual Property Right is invalid or unenforceable, of which any Related Party becomes aware.  Without limiting the foregoing, the Seller shall provide to the Buyer a copy of any written notice of any infringement, misappropriation, violation, invalidity, or unenforceability of any Patent Rights or other Intellectual Property Rights delivered or received by any Related Party, as well as copies of material correspondence related thereto, as soon as practicable and in any event not more than [***] Business Days following such delivery or receipt.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller shall, or shall cause another Related Party to, take all commercially reasonable steps to enforce and defend all Patent Rights and other Intellectual Property Rights that</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are necessary to the use, commercialization, and manufacture of the Product for the indication for which it is approved by the FDA; provided that Seller shall not be required to enforce or defend any Patent Right or other Intellectual Property Right if, in Seller&#x2019;s good faith judgment, such enforcement or defense would have an adverse effect on the scope, enforceability or validity of such Patent Right or Intellectual Property Right.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Reasonably prior to the Seller&#x2019;s or any of its Affiliate&#x2019;s initiating, or permitting a Licensee to initiate, an enforcement action regarding any suspected infringement, misappropriation, or violation by a Third Party of any Patent Right or other Intellectual Property Right, the Seller shall provide the Buyer with written notice of such enforcement action and thereafter shall provide the Buyer with such additional information as the Buyer may reasonably request, provided that the Buyer shall make such requests no more than [***] per Calendar Quarter.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	If the Seller or any of its Affiliates or Licensees recovers monetary damages from a Third Party, where such damages, whether in the form of judgment or settlement, result from the misappropriation, infringement, or other violation of any of the Patent Rights or other Intellectual Property Rights, such recovery will be allocated first to the reimbursement of any expenses incurred by the Seller and its Affiliates or Licensees in bringing such action (including all reasonable attorneys&#x2019; fees, and any remaining amounts allocable to the infringement of any Patent Rights will be treated as Net Sales of the Product (provided that treble or punitive damages shall be treated as Net Sales of the Product solely to the extent received by the Seller).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	The Seller shall, or shall cause another Related Party to, prosecute, and maintain all Patent Rights, except such non-material Patent Rights as may be abandoned or allowed to expire in the ordinary course of business.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.6	In-Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller shall promptly (and in any event within [***] Business Days) provide the Buyer with (i) executed copies of any In-License, (ii) executed copies of each amendment, supplement, modification or written waiver of any provision of any In-License, and (iii) copies of all material reports provided to the counterparty to any In-License or provided in writing by the counterparty to any In-License ; provided that Seller may redact such In-Licenses, amendments, supplements, modifications, written waivers and material reports to remove information that is not relevant to the Revenue Participation Right, the Product Rights or the Product. [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller shall or shall cause its Affiliates (as applicable) to, comply in all material respects with its and their obligations under each In-License and shall not take any action or forego any action that would reasonably be expected to result in a material breach thereof.  Promptly, and in any event within [***] Business Days, after receipt of any (written or oral) notice from a counterparty to any In-License of an alleged material breach under any In-License , the Seller shall provide the Buyer with a copy thereof. The Seller shall, or shall cause its Affiliates (as applicable) to, use its or their commercially reasonable efforts to cure any material breaches by it under such In-License and shall give written notice to the Buyer upon curing any such breach.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller shall provide the Buyer with written notice following the Seller or any of its Affiliate&#x2019;s becoming aware of a counterparty&#x2019;s breach of its material obligations under any</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-License. Promptly, and in any event within [***] Business Days following the Seller&#x2019;s or its Affiliate&#x2019;s notice to a counterparty to any In-License of an alleged material breach by such counterparty under any such In-License, the Seller shall provide the Buyer with a copy thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Seller shall not, and shall cause its Affiliates not to, amend or modify in any material respect, terminate or assign (other than assignments pursuant to Section 11.3) any In-License with respect to a Product without obtaining the Buyer&#x2019;s prior written consent (not to be unreasonably conditioned, withheld or delayed) if such amendment, modification, termination or assignment could reasonably be expected to have a Material Adverse Effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	 The Seller shall provide the Buyer with written notice promptly (and in any event within [***] Business Days) following the termination of any In-License.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.7	Out-Licenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller shall not, and shall not permit any of its Affiliates to, enter into an Out-License without the Buyer&#x2019;s prior written consent, which consent shall not be unreasonably withheld or delayed.  The Seller shall not take or fail to take any action that would result in the termination or revocation of the Janssen License Grant without the Buyer&#x2019;s prior written consent.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Seller shall promptly (and in any event within [***] Business Days) provide the Buyer with (i) executed copies of each Out-License, (ii) executed copies of each amendment, supplement, modification or written waiver of any provision of any Out-License and (iii) copies of all material reports provided by the Seller or any of its Affiliates to the counterparty to any Out-License or provided to the Seller or any of its Affiliates in writing by the counterparty to any Out-License.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller shall not, and shall cause its Affiliates not to, amend or modify in any material respect, terminate or assign (other than assignments pursuant to Section 11.3) any Out-License without obtaining the Buyer&#x2019;s prior written consent (not to be unreasonably conditioned, withheld or delayed).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Seller shall use [***] to ensure that all Out-Licenses contain provisions permitting the Seller or its Affiliate to audit such Licensee on terms and conditions consistent in all material respects with the Buyer&#x2019;s rights to audit the Seller and its Affiliates set forth in Section 7.4.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Seller shall, or shall cause its Affiliates (as applicable) to, comply in all material respects with its and their obligations under each Out-License and shall not take any action or forego any action that would reasonably be expected to result in a material breach thereof.  Promptly, and in any event within [***] Business Days, after receipt of any (written or oral) notice from a counterparty to any Out-License or any of its Affiliates of an alleged material breach under any Out-License by Seller or its Affiliates, the Seller shall provide the Buyer with a copy thereof. The Seller shall, or shall cause its Affiliates (as applicable) to, use its or their commercially reasonable efforts to cure any material breaches by it under such Out-License and shall give written notice to the Buyer upon curing any such breach.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(f)	The Seller shall provide the Buyer with written notice following becoming aware of a counterparty&#x2019;s material breach of its obligations under any Out-License. Promptly, and in any event within [***] Business Days following the Seller&#x2019;s or its Affiliate&#x2019;s notice to a counterparty to any Out-License of an alleged material breach by such counterparty under any such Out-License, the Seller shall provide the Buyer with a copy thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(g)	The Seller shall provide the Buyer with written notice promptly (and in any event within [***] Business Days) following the termination of any Out-License.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.8	Disclosures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except for a press release previously approved in form and substance by the Seller and the Buyer, the Seller&#x2019;s Current Report on Form 8-K describing the material terms of this Agreement and the transactions contemplated by this Agreement (so long as the Seller provides a reasonable opportunity to Buyer to comment on such Form 8-K and considers such comments in good faith) or any other public announcement using substantially the same text as such press release or Form 8-K or other public announcement made in accordance with this Agreement, neither the Buyer nor the Seller shall, and each party shall cause its respective Representatives, Affiliates and Affiliates&#x2019; Representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party (which consent shall not be unreasonably withheld or delayed) except as may be required by applicable law, regulation or stock exchange rule (in which case either party required to make the press release or other public announcement or disclosure shall allow the other party reasonable time to comment on, and, if applicable, reasonably request the disclosing party to seek confidential treatment in respect of portions of, such press release or other public announcement or disclosure in advance of such issuance); provided that (a) no review or consent shall be required with respect to disclosures by either party hereto otherwise previously approved pursuant to this Section 7.8 and (b) notwithstanding anything herein to the contrary, each party hereto may, without the review or consent of the other party hereto, disclose (and nothing herein shall be construed to restrict either party hereto from disclosing) the Purchase Price and the amount and nature of the Revenue Participation Right (and related accounting disclosures of the transactions contemplated hereby) if required by accounting or securities laws (as reasonably determined by the disclosing party) or is required by such party&#x2019;s independent auditors in such party&#x2019;s periodic reports and financial statements.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.9	Post-Closing Obligation.  [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.10	Efforts to Consummate Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the terms and conditions of this Agreement, each of the Seller and the Buyer will use, and will cause its respective Affiliates to use, its and their [***] to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate the transactions contemplated by this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.11	Further Assurances</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Seller and the Buyer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to and carry on the transactions contemplated by this Agreement.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="docxtextref12"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.12	Late Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If any amounts payable by the Seller shall be overdue for [***] Business Days (other than payments overdue as a result of underreporting by a Licensee to the Seller discovered through an audit of the applicable Out-License or as a result of underreporting by a customer, distributor or Logistic Provider), the Seller shall additionally pay to the Buyer a late fee of the lesser of </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> [***] over the Prime Rate, and </font><font id="docxtextref13"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the highest rate permitted under applicable law shall accrue on all unpaid amounts with respect to any payment owed to either party hereunder, including the Purchase Price or any Revenue Payment or Buy-Out Payment, from the date such obligation was due until the date payment is made. The imposition and payment of a late fee shall not constitute a waiver of the rights of either party with respect to such payment default.  In no event shall any late fee interest owed or paid under this Section 7.12 be counted, in the case of the Buyer, towards its obligations to pay the Purchase Price or, in the case of the Seller, towards its obligation to pay the Revenue Payments or the Buy-Out Payment.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.13	Negative Pledge; No Impairment and Liens</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller (and any Third Party assuming the Seller&#x2019;s obligations under this Agreement pursuant to Section 11.3) shall not, and shall not permit any of its Affiliates to, create, incur, assume or suffer to exist any Lien on [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Notwithstanding anything herein to the contrary, none of the Seller nor any of its Affiliates shall enter into any contracts or arrangements, or amend, restate, supplement, waive any rights under or otherwise modify any contracts or arrangements with the intent to circumvent the provisions of this Agreement. For the avoidance of doubt, this Section 7.13(b) shall not restrict (x) the granting of any Permitted Liens on the specific asset expressly mentioned in the applicable clause of the definition of &#x201c;Permitted Liens&#x201d; to be permitted, (y) the incurrence of any Permitted Secured Indebtedness or any unsecured Indebtedness not explicitly prohibited under this Agreement or (z) any licenses (including any In-Licenses or Out-Licenses) not explicitly prohibited under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Seller agrees that (A) it will not without giving the Buyer prior written notice as promptly as practical, and in any event at least five (5) Business Days prior thereto, change (i) its legal name (as defined in Section 9-503(a) of the Uniform Commercial Code in effect in Delaware), (ii) its jurisdiction of organization or (iii) its legal entity structure or identity, (B) it will notify Buyer within 30 days after changing the address of its chief executive office, and (C) it shall otherwise cooperate and act as reasonably requested by the Buyer so that the Buyer can (1) create, maintain, continue and protect the Buyer&#x2019;s enforceable perfected security interest and Lien (with the priority (and, as applicable, for the duration) provided for in this Agreement) on the Collateral and (2) maintain, continue and protect the purchase and sale of the Revenue Participation Right contemplated by this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 7.14	 Restriction on Indebtedness</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***], the Seller shall not (and shall not permit any of its subsidiaries to) incur, purchase, assume or acquire (a) any Indebtedness that is secured by the assets or property of the Seller or any of its subsidiaries other than Permitted Secured Indebtedness and (b) any Indebtedness that may (or is allowed or required to) be converted into one or more types of equity interests of the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller or any of its subsidiaries other than Permitted Convertible Debt.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>INDEMNIFICATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.1	General Indemnity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to Section 8.3, from and after the Effective Date:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link2"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller hereby agrees to indemnify, defend and hold harmless the Buyer and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buyer Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from, against and in respect of all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising out of or resulting from (i) </font><font id="ole_link14"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any inaccuracy in or breach of any of the representations or warranties (in each case, when made) of the Seller in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any Transaction Document and (ii) any breach of any of the covenants or agreements of the Seller in any Transaction Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Buyer hereby agrees to indemnify, defend and hold harmless the Seller and its Affiliates and its and their directors, officers, agents and employees (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Seller Indemnified Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from, against and in respect of all Losses suffered or incurred by the Seller  Indemnified Parties to the extent arising out of or resulting from (i) any inaccuracy in or breach of any of the representations or warranties (in each case, when made) of the Buyer in any Transaction Document or (ii) any breach of any of the covenants or agreements of the Buyer in any Transaction Document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.2	Notice of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If either a Buyer Indemnified Party, on the one hand, or a Seller Indemnified Party, on the other hand (such Buyer Indemnified Party on the one hand and such Seller Indemnified Party on the other hand being hereinafter referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnified Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), has suffered or incurred any Losses for which indemnification may be sought under this ARTICLE 8, the Indemnified Party shall so notify the other party from whom indemnification is sought under this ARTICLE 8 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifying Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of the relevant Transaction Document in respect of which such Loss shall have occurred.  If any claim, action, suit or proceeding is asserted or instituted by or against a Third Party (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third Party Claim</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) with respect to which an Indemnified Party intends to claim any Loss under this Section 8.2, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding.  A failure by an Indemnified Party to give timely notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this Section 8.2 shall not limit the obligation of the Indemnifying Party under this ARTICLE 8, except to the extent such Indemnifying Party is actually prejudiced thereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.3	Limitations on Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	As of any date of determination, the Seller&#x2019;s maximum liability for breaches of representations or warranties pursuant to Section 8.1(a)(i) shall not exceed, an amount equal to [***].</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	As of any date of determination, the Buyer&#x2019;s maximum liability pursuant to Section 8.1(b) shall not exceed [***].</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	Except for  Losses arising from (x) a breach of confidentiality obligations under ARTICLE 9, (y) a breach of the Data Sharing Addendum or (z) a party&#x2019;s fraud, gross negligence or willful misconduct, no party hereto shall be liable to the other for any lost profits, lost revenue, lost opportunity, indirect, consequential, punitive, special or incidental damages (and no claim for indemnification hereunder shall be asserted) under this ARTICLE 8 with respect to the other party as a result of any breach or violation of any representation, warranty, covenant or agreement of such party or its Affiliates (including under this ARTICLE 8) in or pursuant to any Transaction Document. Notwithstanding the foregoing, (i) the Buyer shall be entitled to make indemnification claims, in accordance with the procedures set forth in this ARTICLE 8, for Losses that include any portion of the Revenue Payments or the Buy-Out Payment that the Buyer was entitled to receive but did not receive timely or at all due to any indemnifiable events under any Transaction Document, and such portion of the Revenue Payments or the Buy-Out Payment shall not be deemed lost profits, lost revenue, lost opportunity, indirect, consequential, punitive, special or incidental damages for any purpose of this ARTICLE 8 and (ii) any lost profits, lost revenue, lost opportunity, indirect, consequential, punitive, special, incidental damages or similar damages awarded to a Third Party in connection with a Third Party Claim pursuant to Section 8.4 shall be considered Losses for purposes of this ARTICLE 8.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link6"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.4	Third Party Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon providing notice to an Indemnifying Party by an Indemnified Party pursuant to Section 8.2 of the commencement of any Third Party Claim with respect to which such Indemnified Party intends to claim any Loss under this ARTICLE 8, such Indemnifying Party shall, unless waived in writing by the Indemnified Party, defend such claim, at such Indemnifying Party&#x2019;s expense and with counsel of its choice reasonably satisfactory to the Indemnified Party.  The Indemnified Party shall, at the request of the Indemnifying Party, use commercially reasonable efforts to cooperate in such defense; provided, that the Indemnifying Party shall bear the Indemnified Party&#x2019;s reasonable out-of-pocket costs and expenses incurred in connection with such cooperation.  </font><font id="ole_link7"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Indemnified Party may, without the request of the Indemnifying Party, retain separate co-counsel at the Indemnified Party&#x2019;s expense and may participate in the defense of such claim; provided, that, if the Indemnifying Party and the Indemnified Party have conflicting interests or different defenses available with respect to such Third Party Claim, the Indemnified Party may hire its own separate counsel (provided that such counsel is not reasonably objected to by the Indemnifying Party) with respect to such Third Party Claim and the related action or suit, and the reasonable fees and expenses of such counsel shall be considered the Indemnified Party&#x2019;s Losses for purposes of this Agreement.  Neither the Indemnifying Party nor the Indemnified Party shall consent to the entry of any Judgment or enter into any settlement with respect to such claim without the prior written consent of the other party; provided that consent of the Indemnified Party shall not be required if such Judgment or settlement (A) provides for the payment by the Indemnifying Party of money as the sole relief (if any) for the claimant (other than customary and reasonable confidentiality obligations relating to such claim, Judgment or settlement), (B) results in the full and general release of the Indemnified Party from all liabilities arising out of, relating to or in connection with such claim and (C) does not involve a finding or admission of any violation of any law, rule, regulation or Judgment, or the rights of any Person, and has no effect on any other claims that may be made against the Indemnified Party.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event the Indemnifying Party does not or ceases to conduct the defense of such claim, including as a result of the Indemnified Party&#x2019;s waiver of defense conduct, in compliance with this Section 8.4, (i) the Indemnified Party may defend against, and consent to the entry of any Judgment or enter into any settlement with respect to, such claim in any manner such Indemnified Party reasonably deems appropriate, (ii) the Indemnifying Party shall reimburse the Indemnified Party promptly and periodically for the reasonable out-of-pocket costs of defending against such claim, including reasonable attorneys&#x2019; fees and expenses against reasonably detailed invoices, and (iii) the Indemnifying Party shall remain responsible for any Losses the Indemnified Party may suffer as a result of such claim to the full extent provided in this ARTICLE 8. Any party&#x2019;s assumption of the defense of any Third Party Claim can be made with a reservation of the right to contest the right of Indemnified Party to be indemnified with respect to such claim under this Agreement, and a party&#x2019;s consent to any settlement of a Third Party Claim shall not be used as evidence of the truth of the allegations in any Third Party Claim or the merits of such Third Party Claim.  Furthermore, the existence of any Third Party Claim shall not create a presumption of any breach by a party to this Agreement of any of its representations, warranties or covenants set forth in this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.5	Exclusive Remedy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as set forth in Section 11.10, from and after the Effective Date, the rights of the parties hereto pursuant to (and subject to the conditions of) this ARTICLE 8 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any claims (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties, covenants and agreements made under any Transaction Document, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert any other claim or action in respect of any such breach.  Notwithstanding the foregoing, claims for fraud shall not be waived or limited in any way by this ARTICLE 8.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 8.6	Tax Treatment for Indemnification Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any indemnification payments made pursuant to this ARTICLE 8 will be treated as an adjustment to the Purchase Price for tax purposes to the fullest extent permitted by applicable law, except to the extent otherwise required pursuant to a &#x201c;determination,&#x201d; within the meaning of Section 1313(a) of the U.S. internal Revenue Code of 1986, as amended, or a comparable provision of non-U.S. law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>CONFIDENTIALITY</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.1	Confidentiality</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as provided in this ARTICLE 9 or otherwise agreed in writing by the parties, the parties agree that, during the term of this Agreement and for [***] thereafter, each party (the &#x201c;Receiving Party&#x201d;) shall (a) keep confidential and shall not publish or otherwise disclose, except as permitted pursuant to Section 9.2, any information furnished to it by or on behalf of the other party (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosing Party</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and its Affiliates in connection with the negotiation of, entry into and performance under this Agreement (such information, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confidential Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; of the Disclosing Party), and (b) shall not use the Confidential Information of the Disclosing Party for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder), except in each case ((a)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and (b)) for that portion of such information that the Receiving Party can demonstrate by competent proof:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party or its Representatives in breach of this Agreement;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	is independently developed by the Receiving Party or any of its Affiliates without the use or reference of the Confidential Information of the Disclosing Party; or</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party who did not receive such Confidential Information from the Disclosing Party and without obligations of confidentiality with respect thereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 9.2	Authorized Disclosure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	Either party may disclose Confidential Information to the extent such disclosure is reasonably necessary in the following situations:</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(i)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prosecuting or defending litigation;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with applicable laws and regulations, including regulations promulgated by securities exchanges;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with a valid order of a court or administrative body of competent jurisdiction or other Governmental Entity;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iv)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for regulatory, Tax or customs purposes;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(v)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for audit purposes, provided that each recipient of Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as those set forth in this Agreement prior to any such disclosure;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vi)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure to its Affiliates and its and its Affiliates&#x2019; Representatives on a need-to-know basis; provided, that each recipient of Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as those set forth in this Agreement prior to any such disclosure;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclosure to its actual or potential licensees, investors, lenders, acquirers financiers or other sources of funding (including underwriters, debt financiers, royalty financing partners and co-investors), and their respective accountants, financial advisors and other</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment, financing transaction or acquisition and that each recipient of Confidential Information must be bound by obligations of confidentiality and non-use at least as stringent as those set forth in this Agreement prior to any such disclosure; or</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#010000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(viii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the prior written consent of the Disclosing Party.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#x2019;s Confidential Information pursuant to Section 9.2(a)(i), (ii), (iii) or (iv), it will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential treatment of such information.  Without limiting the foregoing, a party may disclose the other party&#x2019;s Confidential Information, without the other party&#x2019;s prior written permission, to the extent it is required to do so under applicable law, regulation, or a court or administrative order or an order of another Governmental Entity that has compelling jurisdiction over such party; however, prior to such disclosure, the compelled party shall notify the other party (which notice shall include a copy of the relevant portion of any applicable subpoena or order) as promptly as possible after it learns of such requirement to disclose, except to the extent such notification would be impractical or legally impermissible (in which event notification shall be made as soon as reasonably practicable and permissible), provide the other party with reasonable opportunity to pursue legal action to prevent or limit the required disclosure, and, if requested, provide reasonable assistance at the other party&#x2019;s expense in undertaking reasonable legal action to prevent or limit the required disclosure. In the event of any such required disclosure, the party required to disclose the other party&#x2019;s Confidential Information shall disclose only that portion of the other party&#x2019;s Confidential Information that it is legally required to disclose based on the advice of its counsel. The Receiving Party shall continue to hold in confidence hereunder any such disclosed Confidential Information of the Disclosing Party unless and until such information is no longer required to be held in confidence under the terms of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	The Buyer shall not seek and shall not assist any Third Party in seeking, because of, or based upon, any Confidential Information of the Seller, Patent or any other form of intellectual property protection with respect to, or related to, any such Confidential Information or use the Confidential Information of the Seller to obtain, or seek to obtain, a commercial advantage over the Seller.  Without limiting the foregoing, the Buyer shall not file and shall not assist any Third Party in filing any Patent application based upon, disclosing or using any of the Confidential Information of the Seller provided hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	The Receiving Party shall be liable to the Disclosing Party for any breach by its Affiliates or Representatives in the case of any disclosure made by a Receiving Party under Section 9.2(a)(vi), if any such Person violates the terms of its confidentiality obligation or any of the terms set forth in this Agreement as if such Person was a party hereto.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	The Buyer hereby acknowledges that the Seller may from time to time provide the Buyer with information that may constitute material non-public information with respect to itself and Licensees.  Seller makes no representation or warranty and assumes no duty to inform Buyer whether any information delivered to Buyer pursuant to this Agreement constitutes material</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">non-public information.  The Buyer hereby agrees that it shall not, and shall instruct its Affiliates or Representatives to not, trade any securities of the Seller or any Licensee while in possession of any information received by it from the Seller pursuant to this Agreement, in violation of securities laws.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>TERMINATION</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.1	Term and Expiration; Surviving Payments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be effective as of the Effective Date and, unless otherwise early terminated by mutual agreement of Seller and Buyer, shall continue until such time as the Seller has made all Revenue Payments or the Buy-Out Payment, as applicable, in full under this Agreement, at which time this Agreement shall automatically terminate.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 10.2	Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary in this ARTICLE 10, the following provisions shall survive termination of this Agreement: ARTICLE 1 (Definitions);  Section 7.4 (Inspections and Audits of the Seller); Section 7.12 (Late Payments); ARTICLE 8 (Indemnification); ARTICLE 9 (Confidentiality); Section 10.1 (Term and Expiration; Surviving Payments); Section 10.2 (Survival); ARTICLE 11 (Miscellaneous).  Termination of this Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ARTICLE 11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>MISCELLANEOUS</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.1	Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this Section 11.1:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to the Seller, to it at</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">919 E. Hillsdale Blvd., Suite 250</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foster City, CA 94404</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention:  Michelle Robertson</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email:  [***]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">919 E. Hillsdale Blvd., Suite 250</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foster City, CA 94404</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention:  Legal Department</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email:  [***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a copy to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cooley LLP</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3 Embarcadero Center<br>20th Floor<br>San Francisco, CA 94111</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Gian-Michele a Marca</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Telephone: [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If to the Buyer, to it at</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Pharma Development Funding, LLC</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110 E. 59th Street, Suite 3300</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New York, New York 10022</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: General Counsel</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: [***]</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With a copy to</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">:</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwin Procter LLP</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100 Northern Avenue</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Boston, Massachusetts 02210</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attention: Robert M. Crawford and Jacqueline Mercier</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Email: [***]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All notices and communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by email, with an acknowledgement of receipt being produced by the recipient&#x2019;s email account, or (iii) one (1) Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.2	Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Except as otherwise provided herein, all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring such fees, costs and expenses.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.3	Assignment; Transfer Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	The Seller shall not sell, assign or otherwise transfer, including by asset sale, merger, change of control, operation of law, or otherwise, this Agreement or any portion of the Seller&#x2019;s rights, title or interest in or to any Product Rights to any Person without the prior written consent of the Buyer except (i) to an Affiliate or (ii) to a Third Party in connection with a Change of Control; provided, in the case of each of clause (i) and (ii), that such Affiliate or Third Party (A) agrees in a writing reasonably acceptable to the Buyer that (1) such Affiliate or Third Party (as applicable) assumes all of the obligations of the Seller to the Buyer under this Agreement and (2) the Seller, in the case of a transfer to an Affiliate, guarantees the performance thereof by such Affiliate and (B) prior to or concurrent with any such sale, assignment or transfer, takes all actions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required (or reasonably requested by the Buyer after being given a reasonable time to make such a request after written notice of such prospective sale, assignment or transfer) to (1) create, continue, maintain and protect the Buyer&#x2019;s perfected Back-Up Security Interest and Lien (with the priority (and, as applicable, for the duration) contemplated by this Agreement) in the Collateral and (2) maintain, continue and protect the purchase and sale of the Revenue Participation Right contemplated by this Agreement. For the avoidance of doubt, nothing in this Section 11.3 shall prohibit (A) any Lien (x) permitted in accordance with Section 7.13(a) or (y) incurred pursuant to an Out-License consented to by the Buyer in accordance with Section 7.7 or (B) any abandonment of Patent Rights not prohibited under any other sections of this Agreement. In connection with any Out-License permitted under Section 7.7 or other licenses not otherwise prohibited by this Agreement, upon request of the Seller or the applicable licensee, Buyer shall enter into a customary non-disturbance agreement with the relevant licensee.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	The Buyer may assign this Agreement without the prior written consent of the Seller (it being understood that Buyer shall remain liable for its or its assignee&#x2019;s obligations under this Agreement, [***]; [***].</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	A party assigning this Agreement as set forth in this Section 11.3 will promptly notify the other party of such assignment.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d)	Any purported sale, assignment or transfer in violation of this Section 11.3 shall be null and void.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(e)	This Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.4	Amendment and Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	This Agreement may be amended, restated, modified or supplemented only in a writing signed by each of the Seller and the Buyer.  Any provision of this Agreement may be waived only in a writing signed by the party hereto granting such waiver.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	No failure or delay on the part of either party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy.  No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.5	Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement, the Exhibits annexed hereto and the Disclosure Schedule constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.6	No Third Party Beneficiaries</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement is for the sole benefit of the Seller and the Buyer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successors and assigns, any legal or equitable rights hereunder, except that the Indemnified Parties shall be third party beneficiaries of the benefits provided for in ARTICLE 8.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.7	Governing</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Law</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.8	Jurisdiction;</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Venue</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)	EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER AND THE SELLER EACH HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT.  THE BUYER AND THE SELLER EACH HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW.  EACH OF THE BUYER AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS.  NOTHING IN THIS AGREEMENT OR IN ANY OTHER DOCUMENT SHALL AFFECT ANY RIGHT THAT THE BUYER AND THE SELLER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER DOCUMENT AGAINST THE OTHER PARTY OR ITS AFFILIATES OR ITS OR THEIR PROPERTIES IN THE COURTS OF ANY JURISDICTION.  THE BUYER AND THE SELLER EACH AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE BUYER OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO Section 11.1 HEREOF.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)	EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT.  EACH OF THE BUYER AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c)	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each party hereto irrevocably and unconditionally waives any right to trial by jury with respect to any proceeding arising out of, relating to or in connection with this Agreement or any transaction contemplated hereby.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.9	Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.10	Specific Performance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Each party acknowledges and agrees that the other party may be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated.  Accordingly, notwithstanding Section 8.5, each party agrees that, without posting bond or other undertaking, the other party shall be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity.  Each party further agrees that, in the event of any action for specific performance in respect of such breach or violation, it shall not assert that the defense that a remedy at law would be adequate.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.11	Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &#x201c;PDF,&#x201d; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.12	Relationship of the Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The relationship between the Buyer, on the one hand, and the Seller, on the other hand, is solely that of purchaser and seller/guarantor, and no party hereto has any fiduciary or other special relationship with any other party or any of its Affiliates.  This Agreement is not a partnership or similar agreement, and nothing contained herein shall be deemed to constitute the Buyer and the Seller as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes.  The Buyer and the Seller acknowledge and agree that the Buyer&#x2019;s interests hereunder are not equity interests and that the Buyer shall have the rights of a secured party (as defined in the UCC) with respect to the Revenue Participation Right.  The Buyer and the Seller agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Entity.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 11.13	Intercreditor Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything to the contrary herein, the Liens and Back-Up Security Interest granted to the Buyer and its successors and assigns pursuant to this Agreement and the exercise of any right or remedy by the Buyer and its successors and assigns hereunder are subject to the provisions of the Intercreditor Agreement and the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provisions of any Customary Intercreditor Agreement.  If there is a conflict between the terms of the Intercreditor Agreement or a Customary Intercreditor Agreement (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Controlling Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), on the one hand, and the terms of this Agreement, on the other hand, with respect to the Liens, the Back-Up Security Interest or the exercise of any right or remedy of the Buyer or any holder of any Indebtedness that is a party to a Controlling Agreement, then the terms of such Controlling Agreement will control.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page Follows</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.92%;box-sizing:content-box;"></td>
    <td style="width:84.08%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SELLER</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GERON CORPORATION</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michelle Robertson</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Michelle Robertson</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Executive Vice President, Chief</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financial Officer and Treasurer</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">BUYER</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td colspan="2" style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ROYALTY PHARMA DEVELOPMENT FUNDING, LLC</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty Pharma Holdings, Ltd., its Manager</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ George W. Lloyd</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: George W. Lloyd</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: Director</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[Signature Page to Revenue Participation Right Purchase and Sale Agreement]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>8
<FILENAME>gern-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">(Revised August 15, 2024)</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#365f91;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Table of Contents</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.86%;box-sizing:content-box;"></td>
    <td style="width:3.14%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Introduction</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Statement of Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Transactions Subject to this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Persons Subject to this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Material Nonpublic Information</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Quarterly Trading Blackouts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Event-Specific Trading Blackouts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Exceptions to this Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Special and Prohibited Transactions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Pre-Clearance and Advance Notice of Transactions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Short-Swing Trading, Control Stock and Section 16 Reports</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Prohibition of Trading During Pension Plan Blackouts</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Policy&#x2019;s Duration</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Individual Responsibility</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Penalties</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Amendments</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Frequently Asked Questions</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:justify;"><font style="color:#0000ff;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plan Guidelines</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:5pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">16</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Introduction</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">During the course of your relationship with Geron Corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Geron</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), you may receive material information that is not yet publicly available (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">material nonpublic information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) about Geron or other publicly traded companies. Material nonpublic information may give you, or someone you pass that information on to, a leg up over others when deciding whether to buy, sell or otherwise transact in Geron&#x2019;s securities or the securities of another publicly traded company. This policy sets forth guidelines with respect to transactions in Geron securities and in the securities of other applicable publicly traded companies, in each case by our employees, directors and consultants who may become aware of material non-public information (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">designated consultants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) and the other persons or entities subject to this policy as described below.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Company has appointed the Chief Legal Officer as the Company&#x2019;s Insider Trading Compliance Officer and the Chief Financial Officer and any other person designated by the Chief Legal Officer as an alternate in the event the Chief Legal Officer is unavailable (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;).  The Audit Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Audit Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) of the Board of Directors of the Company is responsible for oversight of this Policy. Questions regarding this Policy should be directed to the Insider Trading Compliance Officer.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Statement of Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">It is the policy of Geron that an employee, director or designated consultant of Geron (or any other person or entity subject to this policy) who is aware of material nonpublic information relating to Geron </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">may not</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">, directly or indirectly:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:7.507%;text-indent:-3.739%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1.	engage in any transactions in Geron&#x2019;s securities, except as otherwise specified under the heading &#x201c;Exceptions to this Policy&#x201d; below;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:7.507%;text-indent:-3.739%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2.	recommend the purchase or sale of any of Geron&#x2019;s securities;</font></p>
  <p style="margin-left:7.507%;text-indent:-3.739%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3.	disclose material nonpublic information to persons within Geron whose jobs do not require them to have that information, or outside of Geron to other persons, such as family, friends, business associates and investors, unless the disclosure is made in accordance with Geron&#x2019;s policies regarding the protection or authorized external disclosure of information regarding Geron; or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:7.507%;text-indent:-3.739%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.	assist anyone engaged in the above activities.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The prohibition against insider trading is absolute. It applies </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">even if</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> the decision to trade is not based on such material nonpublic information.  It also applies to transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) and also to very small transactions.  All that matters is whether you are aware of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">any</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> material nonpublic information relating to Geron at the time of the transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The U.S. federal securities laws do not recognize any mitigating circumstances to insider trading. In addition, even the appearance of an improper transaction must be avoided to preserve Geron&#x2019;s reputation for adhering to the highest standards of conduct. In some circumstances, you may need to forgo a planned transaction even if you planned it before becoming aware of the material nonpublic information. So, even if you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting to trade, you must wait.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">It is also important to note that the laws prohibiting insider trading are not limited to trading by the insider alone; advising others to trade on the basis of material nonpublic information is illegal and squarely prohibited by this policy. Liability in such cases can extend both to the &#x201c;tippee&#x201d;&#x2014;the person to whom the insider disclosed material nonpublic information&#x2014;and to the &#x201c;tipper,&#x201d; the insider himself or herself.  In such cases, you can be held liable for your own transactions, as well as the transactions by a tippee and even the transactions of a tippee&#x2019;s tippee. For these and other reasons, it is the policy of Geron that no employee, director or designated consultant of Geron (or any other person or entity subject to this policy) may either (a) recommend to another person or entity that they buy, hold or sell Geron&#x2019;s securities </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">at any time</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> or (b) disclose material nonpublic information to persons within Geron whose jobs do not require them to have that information, or outside of Geron to other persons (unless the disclosure is made in accordance with Geron&#x2019;s policies regarding the protection or authorized external disclosure of information regarding Geron).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In addition, it is the policy of Geron that no person subject to this policy who, in the course of his or her relationship with Geron, learns of any confidential information that is material to another publicly traded company, including but not limited to a customer, supplier, partner or collaborator of Geron or an economically-linked company such as a competitor of Geron, may trade in that other company&#x2019;s securities until the information becomes public or is no longer material to that other company.</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">There are no exceptions to this policy, except as specifically noted above or below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">    </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Transactions Subject to this Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This policy applies to all transactions in securities issued by Geron, as well as derivative securities that are not issued by Geron, such as exchange-traded put or call options or swaps relating to Geron&#x2019;s securities. Accordingly, for purposes of this policy, the terms &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">trade</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">trading</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; include not only purchases and sales of Geron&#x2019;s common stock in the public market but also any other purchases, sales, transfers, gifts or other acquisitions and dispositions of common or preferred equity, options, warrants and other securities (including debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Persons Subject to this Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This policy applies to you and all other employees, directors and designated consultants of Geron and its subsidiaries. This policy also applies to members of your family who reside with you, any other persons with whom you share a household, any family members who do not live in your household but whose transactions in Geron&#x2019;s securities are directed by you or are subject to your influence or control and any other individuals or entities whose transactions in securities you influence, direct or control (including, e.g., a venture or other investment fund, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">if</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> you influence, direct or control transactions by the fund). </font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:9pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">However, this policy does not apply to any entity that invests in securities in the ordinary course of its business (e.g., a venture or other investment fund) if (and only if) such entity has established its own insider trading controls and procedures in compliance with applicable securities laws with respect to trading in Geron&#x2019;s securities. The foregoing persons who are deemed subject to this policy are referred to in this policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Related Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.&#x201d; You are responsible for making sure that your Related Persons comply with this policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Material Nonpublic Information</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Material information</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">It is not always easy to figure out whether you are aware of material nonpublic information. But there is one important factor to determine whether nonpublic information you know about a public company is material:  whether the information could be expected to affect the market price of that company&#x2019;s securities or to be considered important by investors who are considering trading that company&#x2019;s securities. If the information makes you want to trade, it would probably have the same effect on others. Keep in mind that both positive and negative information can be material.  A good general rule of thumb: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">when in doubt, do not trade</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by relevant enforcement authorities with the benefit of hindsight. Depending on the specific details, the following items may be considered material nonpublic information until publicly disclosed within the meaning of this policy. There may be other types of information that would qualify as material information as well; use this list merely as a non-exhaustive guide:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">financial or sales results or forecasts;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">changes in previously provided guidance;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">status of product or product candidate development or regulatory approvals;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">clinical data relating to products or product candidates;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">timelines for pre-clinical studies or clinical trials;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">acquisitions or dispositions of assets, divisions or companies;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">public or private sales of debt or equity securities;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">stock splits, dividends or changes in dividend policy;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the establishment of a repurchase program for Geron&#x2019;s securities;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">gain or loss of a significant licensor, licensee or supplier;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">changes or new corporate partner relationships or collaborations</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">notice of issuance or denial of patents;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">regulatory developments;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">management, Board or control changes;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">employee layoffs;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">a disruption in Geron&#x2019;s operations or breach or unauthorized access of its property or assets, including its facilities and information technology infrastructure;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">tender offers or proxy fights;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">accounting restatements;</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">litigation or settlements; and</font></p>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">impending bankruptcy.</font></p>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">When information is considered public</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The prohibition on trading when you have material nonpublic information lifts once that information becomes publicly disseminated. But for information to be considered publicly disseminated, it must be widely disseminated through a press release, a filing with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), or other widely disseminated announcement. Once information is publicly disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. Generally speaking, information will be considered publicly disseminated for purposes of this policy only after one full trading day has elapsed since the information was publicly disclosed. For example, if we announce material nonpublic information before trading begins on Wednesday, then during an open trading window you may execute a transaction in our securities on Thursday; if we announce material nonpublic information after trading ends on Wednesday, then during an open trading window you may execute a transaction in our securities on Friday. Depending on the particular circumstances, Geron may determine that a longer waiting period should apply to the release of specific material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Quarterly Trading Blackouts</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The following persons are designated </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Covered Insiders</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">under this Policy:</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1.	members of the Board of Directors;</font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2.	employees with the title of &#x201c;Vice President&#x201d; or above;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3.	members of the Finance and Accounting department who prepare the Company&#x2019;s financial statements and/or quarterly securities filings, as determined jointly by the Insider Trading Compliance Officer and the Chief Financial Officer;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.	members of the Commercial department who have access to, or receive, national or global sales information, as determined jointly by the Insider Trading Compliance Officer and the Chief Commercial Officer;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.	all members of the following functional departments: Legal, Business Development, and Investor Relations and Corporate Communications, unless specifically excluded by the Insider Trading Compliance Officer;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6.	consultants of Geron who have been notified of their designation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">anyone else designated from time to time by the Insider Trading Compliance Officer.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Because these Covered Insiders are most likely to have regular access to material nonpublic information about Geron, we require them to do more than refrain from insider trading. To minimize even the appearance of insider trading among our Covered Insiders, we have established &#x201c;quarterly trading blackout periods&#x201d; during which our Covered Insiders and their Related Persons&#x2014;regardless of whether they are aware of material nonpublic information or not&#x2014;may not conduct any trades in Geron securities. That means that, except as described in this policy, Covered Insiders and their Related Persons will be able to trade in Geron securities </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">only</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> during limited open trading window periods that generally will begin after one full trading day has elapsed since the public dissemination of Geron&#x2019;s financial results covering the immediately preceding quarterly or annual period, as applicable, and will end at the beginning of the next quarterly trading blackout period, as described in the next paragraph.  Of course, even during an open trading window period, and even if you are not a Covered Insider, you may not (unless an exception applies) conduct any trades in Geron securities if you are otherwise in possession of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">For purposes of this policy, each &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">quarterly trading blackout period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d; will generally begin at the end of the day that is two weeks before the end of each fiscal quarter and will end after one full trading day has elapsed since the public dissemination of Geron&#x2019;s financial results for that quarter. Please note that the quarterly trading blackout period may commence early or may be extended if, in the judgment of Geron&#x2019;s Insider Trading Compliance Officer, there exists undisclosed information that would make trades by Covered Insiders inappropriate. It is important to note that the fact that the quarterly trading blackout period has commenced early or has been extended should be considered material nonpublic information that should not be communicated to any other person.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A Covered Insider who believes that special circumstances require him or her to trade during a quarterly trading blackout period (or an event-specific trading blackout as described in the next paragraph) should consult the Insider Trading Compliance Officer. Permission to trade during a quarterly trading blackout period will be granted only where the circumstances are extenuating, the Insider Trading Compliance Officer concludes that the person is not in fact aware of any material nonpublic information relating to Geron or its securities, and there appears to be no significant risk that the trade may subsequently be questioned.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Event-Specific Trading Blackouts</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">From time to time, an event may occur that is material to Geron and is known by only a few directors, officers, employees and/or designated consultants. So long as the event remains material and nonpublic, the persons designated by the Insider Trading Compliance Officer may not trade in Geron&#x2019;s securities.  In that situation, Geron will notify the designated individuals that neither they nor their Related Persons may trade in Geron&#x2019;s securities. The existence of an event-specific trading blackout should also be considered material nonpublic information and should not be communicated to any other person.  Even if you have not been designated as a person who should not trade due to an event-specific trading blackout, you should not trade while aware of material nonpublic information.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The quarterly and event-specific trading blackouts do not apply to those transactions to which this policy does not apply, as described under the heading &#x201c;Exceptions to this Policy&#x201d; below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exceptions to this Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This policy does not apply in the case of the following transactions, except as specifically noted:</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Option Exercises.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> This policy does not apply to the exercise of options granted under Geron&#x2019;s equity compensation plans for which payment is made in cash or, where permitted under the option, by a net exercise transaction with the Company.  This policy does, however, apply to any sale of stock underlying the exercised options, whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes.  For this reason, you may </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> effect a broker-assisted cashless exercise or same-day sale (these broker-assisted cashless exercise and same-day sale transactions always include a market sale of stock underlying the options) during a trading blackout period or any time that you are aware of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Withholding Transactions.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> This policy does not apply to the surrender of shares directly to Geron to satisfy tax withholding obligations as a result of the issuance of shares upon vesting or exercise of restricted stock units, options or other equity awards granted under Geron&#x2019;s equity compensation plans.  Of course, any market sale of the stock received upon exercise or vesting of any such equity awards remains subject to all provisions of this policy whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">ESPP. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This policy does not apply to the purchase of stock by employees under Geron&#x2019;s Employee Stock Purchase Plan (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">ESPP</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) on periodic designated dates in accordance with the ESPP.  This policy does however apply to an employee&#x2019;s initial election to participate in the ESPP, changes (other than complete withdrawals) to an employee&#x2019;s election to participate in the ESPP for any enrollment period, or to the subsequent sale of the stock acquired pursuant to the ESPP.  Accordingly, such elections or changes (other than complete withdrawals) thereto may not be effected during a trading blackout period or when an employee is otherwise in possession of material non-public information relating to Geron or any of its securities.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12.3pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#x2019; Market Value Stock Purchase Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  This policy does not apply to purchases of stock from the Company under Geron&#x2019;s Directors&#x2019; Market Value Stock Purchase Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#x2019; Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) on periodic designated dates in accordance with the Directors&#x2019; Plan and Geron&#x2019;s Non-Employee Directors&#x2019; Compensation Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#x2019; Compensation Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). This policy does apply, however, to a director&#x2019;s election to receive stock in lieu of cash compensation under the Directors&#x2019; Plan and the Directors&#x2019; Compensation Policy, and to a director&#x2019;s sale of stock purchased under the Directors&#x2019; Plan. Accordingly, such elections may not be effected during a trading blackout period or when a director is otherwise in possession of material non-public information relating to Geron or any of its securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Automatic Trading Programs.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), and as permitted by Geron, employees and directors may establish a trading plan under which a broker is instructed to buy or sell Geron securities based on pre-determined criteria (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Trading Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). So long as a Trading Plan is properly established, purchases and sales of Geron securities pursuant to that Trading Plan are not subject to this policy. To be properly established, an employee&#x2019;s or director&#x2019;s Trading Plan must be established in compliance with the requirements of Rule 10b5-1 of the Exchange Act and Geron&#x2019;s 10b5-1 Trading Plan Guidelines (which are attached as Exhibit B to this policy) at a time when such employee or director was not subject to a trading blackout period and such employee or director was not otherwise aware of any material nonpublic information relating to Geron or its securities. Moreover, and pursuant to Geron&#x2019;s 10b5-1 Trading Plan Guidelines, all 10b5-1 Trading Plans must be reviewed and pre-approved by Geron&#x2019; Insider Trading Compliance Officer before being established to confirm that the 10b5-1 Trading Plan complies with all pertinent company policies and applicable securities laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Special and Prohibited Transactions</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Inherently Speculative Transactions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No Geron employee, director or designated consultant may engage in short sales, transactions in put options, call options or other derivative securities on an exchange or in any other organized market, or in any other inherently speculative transactions with respect to Geron&#x2019;s stock.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Hedging Transactions.</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Geron employees, directors and designated consultants are prohibited from engaging in any hedging and other transactions described in this paragraph. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit a Geron employee, director or designated consultant to continue to own Geron&#x2019;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the Geron employee, director or designated consultant may no longer have the same objectives as Geron&#x2019;s other stockholders.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Margin Accounts and Pledged Securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#x2019;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in Geron&#x2019;s securities, Geron employees, directors and designated consultants are prohibited from holding Geron&#x2019;s securities in a margin account or otherwise pledging Geron&#x2019;s securities as collateral for a loan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Standing and Limit Orders.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Standing and limit orders (except standing and limit orders under approved Trading Plans, as discussed above) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a Geron employee, director or designated consultant is in possession of material nonpublic information. Geron therefore discourages placing standing or limit orders on Geron&#x2019;s securities. If a person subject to this policy determines that they must use a standing order or limit order (other than under an approved Trading Plan as discussed above), the order should be limited to short duration and the person using such standing order or limit order is required to cancel such instructions immediately in the event restrictions are imposed on their ability to trade pursuant to the &#x201c;Quarterly Trading Blackouts&#x201d; and &#x201c;Event-Specific Trading Blackouts&#x201d; provisions above.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">401(k) Plan Transactions (applicable only to Geron employees who hold shares of Geron stock in their 401(k) Plan under Geron&#x2019;s now-discontinued practice of 401(k) matching utilizing Geron stock)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. This policy applies to certain elections you may make under the 401(k) plan, including: an election to make an intra-plan transfer of an existing account balance out of the Geron stock fund; and an election to borrow money against your 401(k) plan account if the loan will result in a liquidation of some or all of your Geron stock fund balance.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Pre-Clearance and Advance Notice of Transactions</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In addition to the requirements above, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">all</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Geron officers, directors, employees and designated consultants face a further restriction: Even during an open trading window, they may not engage in any transaction in, or enter into, modify or terminate any contract, instruction or written plan or arrangement in, Geron&#x2019;s securities (including acquisitions and dispositions of Geron&#x2019;s stock, the exercise of stock options, the sale of Geron stock issued upon the exercise of stock options, and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link1"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">the sale of Geron&#x2019;s stock purchased under the ESPP or the Directors&#x2019; Plan) without first obtaining pre-clearance in writing from </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Geron&#x2019;s  Insider Trading Compliance Officer </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">or his or her designee. The Insider Trading Compliance Officer or his or her designee will then determine whether the Covered Insider may proceed. If after consulting with the Insider Trading Compliance Officer, it is determined that such officer, director, employee or designated consultant is in possession of material, non-public information, there can be no transactions involving such security except as otherwise provided under &#x201c;Exceptions to this Policy,&#x201d; above. Pre-cleared transactions not completed within five trading days will require new pre-clearance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The requirement for pre-clearance as set forth in the above paragraph does not apply to transactions covered in &#x201c;Exceptions to this Policy,&#x201d; above.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> Once any transaction takes place, each officer or director who is a Section 16 reporting person pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, must immediately notify Geron&#x2019;s Insider Trading Compliance Officer or his or her designee so that Geron may assist in any Section 16 reporting obligations.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Short-Swing Trading, Control Stock and Section 16 Reports</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Officers and directors subject to the reporting obligations under Section 16 of the Exchange Act should take care to avoid short-swing transactions (within the meaning of Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule 144 under the Securities Act of 1933, as amended), and should file all appropriate Section 16(a) reports (Forms 3, 4 and 5), and any notices of sale required by Rule 144.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Prohibition of Trading During Pension Plan Blackouts</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No director or Section 16 officer of Geron may, directly or indirectly, purchase, sell or otherwise transfer any equity security of Geron (other than an exempt security) during any &#x201c;blackout period&#x2019;&#x2019; (as defined in Regulation BTR under the Exchange Act) if a director or Section 16 officer acquires or previously acquired such equity security in connection with his or her service or employment as a director or Section 16 officer, such as Geron stock held in the Geron 401K Plan. This prohibition does not apply to any transactions that are specifically exempted, including but not limited to, purchases or sales of Geron&#x2019;s securities made pursuant to, and in compliance with, a Trading Plan; compensatory grants or awards of equity securities pursuant to a plan that, by its terms, permits Section 16 officers and directors to receive automatic grants or awards and specifies the terms of the grants and awards; or acquisitions or dispositions of equity securities involving a </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">bona fide</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> gift or by will or the laws of descent or pursuant to a domestic relations order. Geron will notify each director and Section 16 officer of any blackout periods in accordance with the provisions of Regulation BTR.  Because Regulation BTR is very complex, no director or Section 16 officer of Geron should engage in any transactions in Geron&#x2019;s securities, even if believed to be exempt from Regulation BTR, without first consulting with Geron&#x2019;s Insider Trading Compliance Officer.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Policy&#x2019;s Duration</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This policy continues to apply to your transactions in Geron&#x2019;s securities and the securities of other applicable public companies as more specifically set forth in this policy until your relationship with Geron has ended. However, if you are aware of material nonpublic information when your relationship with Geron ends, you are reminded that the federal securities laws prohibit you from trading in Geron&#x2019;s securities or the securities of other applicable publicly traded companies until the material nonpublic information has been publicly disseminated or is no longer material.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Individual Responsibility</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Persons subject to this policy have ethical and legal obligations to maintain the confidentiality of information about Geron and to not engage in transactions in Geron&#x2019;s securities or the securities of other applicable public companies while aware of material nonpublic information, as more specifically set forth in this policy. Each individual is responsible for making sure that he or she complies with this policy, and that any family member, household member or other person or entity whose transactions are subject to this policy, as discussed under the heading &#x201c;Persons Subject to this Policy&#x201d; above, also comply with this policy. In all cases, the responsibility for determining whether an individual is aware of material nonpublic information rests with that individual, and any action on the part of Geron or any employee or director of Geron pursuant to this policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary action by Geron for any conduct prohibited by this policy or applicable securities laws. See &#x201c;Penalties&#x201d; below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Penalties</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Anyone who engages in insider trading or otherwise violates this policy may be subject to both civil liability and criminal penalties. Violators also risk disciplinary action by Geron, up to and including termination of employment. Anyone who has questions about this policy should contact their own attorney or Geron&#x2019;s Insider Trading Compliance Officer, at TradingCompliance@geron.com. Please also see Frequently Asked Questions, which are attached as </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:6.667%;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Amendments</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Geron is committed to continuously reviewing and updating its policies and procedures. Geron therefore reserves the right to amend, alter or terminate this policy at any time and for any reason. A current copy of Geron&#x2019;s policies regarding insider trading may be obtained by.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Frequently Asked Questions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What is insider trading?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Generally speaking, insider trading is the buying or selling of stocks, bonds, futures or other securities by someone who possesses or is otherwise aware of material nonpublic information about the securities or the issuer of the securities. Insider trading also includes trading in derivatives (such as put or call options) where the price is linked to the underlying price of a company&#x2019;s stock. It does not matter whether the decision to buy or sell was influenced by the material nonpublic information, how many shares you buy or sell, or whether it has an effect on the stock price. Bottom line: If, during the course of your relationship with Geron, you become aware of material nonpublic information about Geron and you trade in Geron&#x2019;s securities, you have broken the law and violated our insider trading policy.  In addition, our insider trading policy provides that if in the course of your relationship with Geron, you learn of any confidential information that is material to another publicly traded company, including but not limited to a customer, supplier, partner or collaborator of Geron or an economically-linked company such as a competitor of Geron, you may not trade in that other company&#x2019;s securities until the information becomes public or is no longer material to that other company.  For example, if you learn of nonpublic information during the course of your relationship with Geron that could affect the stock price of a Geron competitor, you may not trade in that competitor&#x2019;s stock until the information becomes public or is no longer material.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Why is insider trading illegal?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If company insiders are able to use their confidential knowledge to their financial advantage, other investors would not have confidence in the fairness and integrity of the market. This ensures that there is an even playing field by requiring those who are aware of material nonpublic information to refrain from trading.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What is material nonpublic information?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Information is material if it would influence a reasonable investor to buy or sell a stock, bond future or other security. This could mean many things: financial or sales results, clinical or regulatory results, potential acquisitions or major contracts to name just a few. Information is nonpublic if it has not yet been publicly disseminated within the meaning of our insider trading policy.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Who can be guilty of insider trading?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Anyone who buys or sells a security while aware of material nonpublic information, or provides material nonpublic information that someone else uses to buy or sell a security, may be guilty of insider trading. This applies to all individuals, including officers, directors and others who don&#x2019;t even work at Geron. Regardless of who you are, if you know something material about the value of a security that not everyone knows and you trade (or convince someone else to trade) in that security, you may be found guilty of insider trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Does Geron have an insider trading policy?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Yes, the insider trading policy is available to read on our website on our Corporate Governance webpage.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What if I work in a foreign office?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The same rules apply to U.S. and foreign employees and consultants. The Securities and Exchange Commission (the U.S. government agency in charge of investor protection) and the Financial Industry Regulatory Authority (a private regulator that oversees U.S. securities exchanges) routinely investigate trading in a company&#x2019;s securities conducted by individuals and firms based abroad. In addition, as a Geron director, employee or consultant, our policies apply to you no matter where you work.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What if I don&#x2019;t buy or sell anything, but I tell someone else material nonpublic information and they buy or sell?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">That is called &#x201c;tipping.&#x201d; You are the &#x201c;tipper&#x201d; and the other person is called the &#x201c;tippee.&#x201d; If the tippee buys or sells based on that material nonpublic information, both you and the &#x201c;tippee&#x201d; could be found guilty of insider trading. In fact, if you tell family members who tell others and those people then trade on the information, those family members and the &#x201c;tippee&#x201d; might be found guilty of insider trading too. To prevent this, you may not discuss material nonpublic information about the company with anyone outside Geron, including spouses, family members, friends or business associates (unless the disclosure is made in accordance with Geron&#x2019;s policies regarding the protection or authorized external disclosure of information regarding Geron). This includes anonymous discussions on the internet about Geron or companies with which Geron does business.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">8.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What if I don&#x2019;t tell them the information itself; I just tell them whether they should buy or sell?</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">That is still tipping, and you can still be responsible for insider trading. You may never recommend to another person that they buy, hold or sell Geron&#x2019;s common stock or any derivative security related to Geron&#x2019;s common stock, since that could be a form of tipping.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">9.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What are the sanctions if I trade on material nonpublic information or tip off someone else?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">In addition to disciplinary action by Geron&#x2014;which may include termination of employment&#x2014;you may be liable for civil sanctions for trading on material nonpublic information. The sanctions may include return of any profit made or loss avoided as well as penalties of up to three times any profit made or any loss avoided. Persons found liable for tipping material nonpublic information, even if they did not trade themselves, may be liable for the amount of any profit gained or loss avoided by everyone in the chain of tippees as well as a penalty of up to three times that amount. In addition, anyone convicted of criminal insider trading could face prison and additional fines.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">10.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What is &#x201c;loss avoided&#x201d;?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If you sell common stock or a related derivative security before negative news is publicly announced, and as a result of the announcement the stock price declines, you have avoided the loss caused by the negative news.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">11.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Am I restricted from trading securities of any companies other than Geron, for example a customer, partner or competitor of Geron?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Yes, you may be restricted from doing so due to your awareness of material nonpublic information. U.S. insider trading laws generally restrict everyone aware of material nonpublic information about a company from trading in that company&#x2019;s securities, regardless of whether the person is directly connected with that company, except in limited circumstances. You should be particularly conscious of this restriction if, through your position at Geron, you sometimes obtain sensitive, material information about other companies and their business dealings with Geron. Please also refer to Question 1 above and our insider trading policy with respect to restrictions on trading in the securities of other public companies.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">So if I do not trade Geron securities when I have material nonpublic information, and I don&#x2019;t &#x201c;tip&#x201d; other people, I am in the clear, right?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Not necessarily. Even if you do not violate U.S. law, you may still violate our policies. For example, employees and consultants may violate our policies by breaching their confidentiality obligations or by recommending Geron stock as an investment, even if these actions do not violate securities laws. Our policies are stricter than the law requires so that we and our employees and consultants can avoid even the appearance of wrongdoing. Therefore, please review the entire policy carefully.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">So when can I buy or sell my Geron securities?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If you are aware of material nonpublic information, you may not buy or sell our common stock until one full trading day has elapsed since the information was publicly disclosed. At that point, the information is considered publicly disseminated for purposes of our insider trading policy. For example, if we announce material nonpublic information before trading begins on Wednesday, then during an open trading window you may execute a transaction in our securities on Thursday; if we announce material nonpublic information after trading ends on Wednesday, then during an open trading window you may execute a transaction in our securities on Friday. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Even if you are not aware of any material nonpublic information, you may not trade our common stock during any trading &#x201c;blackout&#x201d; period to which you are subject</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Our insider trading policy describes the quarterly trading blackout period and the Geron personnel who are subject to the quarterly trading blackout period, and additional event-driven trading blackout periods that may be applicable to you and announced by email.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">14.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">If I have an open order to buy or sell Geron securities on the date a blackout period commences, can I leave it to my broker to cancel the open order and avoid executing the trade?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No, unless it is in connection with a 10b5-1 trading plan (see Question 26 below). If you have any open orders when a blackout period commences other than in connection with a 10b5-1 trading plan, it is your responsibility to cancel these orders with your broker. If you have an open order and it executes after a blackout period commences not in connection with a</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">10b5-1 trading plan, you will have violated our insider trading policy and may also have violated insider trading laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">15.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Am I allowed to trade derivative securities of Geron&#x2019;s common stock?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No. Under our policies, you may not trade in derivative securities related to our common stock, which include publicly traded call and put options. In addition, under our policies, you may not engage in short selling of our common stock at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Derivative securities&#x201d; are securities other than common stock that are speculative in nature because they permit a person to leverage their investment using a relatively small amount of money. Examples of derivative securities include &#x201c;put options&#x201d; and &#x201c;call options.&#x201d; These are different from employee options and other equity awards granted under our equity compensation plans, which are not derivative securities for purposes of our policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Short selling&#x201d; is profiting when you expect the price of the stock to decline, and includes transactions in which you borrow stock from a broker, sell it, and eventually buy it back on the market to return the borrowed shares to the broker. Profit is realized if the stock price decreases during the period of borrowing.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">16.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Why does Geron prohibit trading in derivative securities and short selling?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Many companies with volatile stock prices have adopted similar policies because of the temptation it represents to try to benefit from a relatively low-cost method of trading on short-term swings in stock prices, without actually holding the underlying common stock, and encourages speculative trading. We are dedicated to building stockholder</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> value, short selling our common stock conflicts with our values and would not be well-received by our stockholders.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">17.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Can I purchase Geron securities on margin or hold them in a margin account?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Under our policies, you may not purchase our common stock on margin or hold it in a margin account at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;Purchasing on margin&#x201d; is the use of borrowed money from a brokerage firm to purchase our securities. Holding our securities in a margin account includes holding the securities in an account in which the shares can be sold to pay a loan to the brokerage firm.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">18.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Why does Geron prohibit me from purchasing Geron securities on margin or holding them in a margin account?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Margin loans are subject to a margin call whether or not you possess material nonpublic information at the time of the call. If a margin call were to be made at a time when you were aware of material nonpublic information and you could not or did not supply other collateral, you may be liable under insider trading laws because of the sale of the securities (through the margin call). The sale would be attributed to you even though the lender made the ultimate determination to sell. The U.S. Securities and Exchange Commission takes the view that you</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">made the determination to not supply the additional collateral and you are therefore responsible for the sale.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">19.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Can I pledge my Geron shares as collateral for a personal loan?</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> No. Pledging your shares as collateral for a personal loan could cause the pledgee to transfer your shares during a trading blackout period or when you are otherwise aware of material nonpublic information. As a result, you may not pledge your shares as collateral for a loan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">20.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Can I hedge my ownership position in Geron?</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">  Hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds are prohibited by our insider trading policy. Since such hedging transactions allow you to continue to own Geron&#x2019;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership, you may no longer have the same objectives as Geron&#x2019;s other shareholders. Therefore, our insider trading policy prohibits you from engaging in any such transactions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">21.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Can I exercise options granted to me under Geron&#x2019;s equity compensation plans during a trading blackout period or when I possess material nonpublic information?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Yes, if you are not selling shares to pay for the exercise price. You may exercise the options for which payment is made in cash (or via net exercise transaction with Geron) and receive shares, but you may not sell the shares underlying the options (even to pay the exercise price or any taxes due) during a trading blackout period or any time that you are aware of material nonpublic information.  To be clear, you may </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> effect a broker-assisted cashless exercise or a same-day sale (because these broker-assisted cashless exercise and same-day sale transactions always include a market sale) during a trading blackout period or any time that you are aware of material nonpublic information</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">22.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Am I subject to trading blackout periods if I am no longer an employee or consultant of Geron?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No. However, even if you are not subject to our trading blackout period after you leave Geron, you should not trade in Geron securities if you are aware of material nonpublic information. That restriction under the federal securities laws stays with you as long as the information you possess is material and not publicly disseminated within the meaning of our insider trading policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">23.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What if I purchased publicly traded options or other derivative securities before I became a Geron employee or consultant?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The same rules apply as for employee stock options. You may exercise the publicly traded options at any time, but you may not sell the securities during a trading blackout period or at any time that you are aware of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">24.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">May I own shares of a mutual fund that invests in Geron?</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Yes.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">25.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Are mutual fund shares holding Geron common stock subject to the trading blackout periods?</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">No. You may trade in mutual funds holding Geron common stock  at any time.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">26.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">May I use a &#x201c;routine trading program&#x201d; or &#x201c;10b5-1 plan&#x201d;?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Yes, subject to the requirements discussed in our insider trading policy and Geron&#x2019;s 10b5-1 Trading Plan Guidelines. A routine trading program, also known as a 10b5-1 plan, allows you to set up a highly structured program with your stock broker where you specify ahead of time the date, price, and amount of securities to be traded. If you wish to create a 10b5-1 plan, please contact our Insider Trading Compliance Officer to obtain pre-approval at TradingCompliance@geron.com. A copy of Geron&#x2019;s 10b5-1 Trading Plan Guidelines is attached hereto as Exhibit B.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">27.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">What happens if I violate our insider trading policy?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Violating our policies may result in disciplinary action, which may include termination of your employment or other relationship with Geron. In addition, you may be subject to criminal and civil sanctions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline double;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">28.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Who should I contact if I have questions about our insider trading policy or specific trades?</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">You should contact our Insider Trading Compliance Officer at TradingCompliance@geron.com.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">15</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Geron Corporation</font></p>
  <p style="margin-left:25.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:24.231%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plan Guidelines (</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Revised August 15, 2024)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:10.4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.96%;text-indent:6.958%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">This document lays out guidelines for any Rule 10b5-1 trading plan covering publicly traded stock of Geron Corporation (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">the </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;). In addition to honoring these guidelines, all 10b5-1 trading plans, along with any amendments or modifications to those plans, must comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="margin-left:2.96%;text-indent:6.958%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Participants. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Company&#x2019;s directors and executive officers (i.e., Section 16 officers) are required to adopt a 10b5-1 trading plan to govern all trades they make involving the Company securities, other than Qualified Sell-to-Cover Transactions, and may not make other trades in Company securities in the open market absent special circumstances approved by the Insider Trading Compliance Officer (or the Chief Financial Officer in the event of trades by the Insider Trading Compliance Officer). Other Company employees are permitted to adopt a 10b5-1 trading plan.</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.686%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Plan Adoption and Approval. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan must be in writing and signed by the participant establishing the plan. The Company may keep a copy of each 10b5-1 trading plan. The Insider Trading Compliance Officer or an individual designated by the Insider Trading Compliance Officer must pre-approve, in writing, each 10b5-1 trading plan, including any amendment, modification or termination. Participants must enter into a plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 of the Exchange Act. In addition, all participants that enter into a 10b5-1 trading plan must act in good faith with respect to such plan. Compliance with the terms of the 10b5-1 trading plan and the execution of transactions pursuant to the 10b5-1 trading plan are the sole responsibility of the participant establishing the 10b5-1 trading plan, not the Company or the Insider Trading Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.613%;text-indent:-3.685%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Designated Brokers. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">All 10b5-1 trading plans must be established using the broker designated by the Company and listed below:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:12.96%;text-indent:-3.966%;padding-left:3.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">o	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">E*TRADE / Morgan Stanley</font></p>
  <p style="margin-left:16.28%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Representation/Certification. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan must include a representation certifying that, at the time of adoption, the participant: (i) is not aware of any material nonpublic information about the Company or its securities and (ii) is adopting the 10b5-1 trading plan in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.613%;text-indent:-3.686%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Timing and Term of a Plan. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">There are limits on when a 10b5-1 trading plan can be adopted, so plan ahead. In short, a participant can only set up a 10b5-1 trading plan when the participant does not possess material nonpublic information about the Company. In addition, participants that are subject to trading windows under the Company&#x2019;s Insider Trading Policy may only adopt a trading plan during an open trading window. Each 10b5-1 trading plan must have a term of at least 6 months but no longer than 24 months. That said, a 10b5-1 trading plan may provide for early termination at any time after 90 days following the termination of the participant&#x2019;s employment or directorship.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.67%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Timing of a Plan Amendment or Modification. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">All participants must pre-clear any modification of a 10b5-1 trading plan with the Insider Trading Compliance Officer or an individual designated by the Insider Trading Compliance Officer. In addition, all participants must promptly notify the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">16</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Officer or an individual designated by the Insider Trading Compliance Officer following any pre-approved modification of a 10b5-1 trading plan and provide a copy of such modified plan. Each 10b5-1 trading plan may be amended or modified to change the amount, price or timing of the purchase or sale of the securities underlying a 10b5-1 trading plan (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Material Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) only when the participant does not possess material nonpublic information about the Company. In addition, participants that are subject to trading windows under the Company&#x2019;s Insider Trading Policy may only enter into a Material Modification during an open trading window. Any Material Modification must include the representation set forth under &#x201c;Representation/Certification&#x201d; above. A Material Modification of a 10b5-1 trading plan may not be entered into more than once in any 6-month period. If a participant enters into separate contracts at the same time with different agents to execute trades that are collectively compliant with Rule 10b5- 1, such contracts may be treated as a single plan and a Material Modification of any such contract will be considered a Material Modification of the other such contracts.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. All participants must obtain pre-approval of any termination of a 10b5-1 trading plan from the Insider Trading Compliance Officer. Participants are discouraged from terminating a 10b5-1 trading plan while in possession of material nonpublic information. In addition, participants that are subject to trading windows under the Company&#x2019;s Insider Trading Policy are discouraged from terminating a 10b5-1 trading plan during a closed trading window. If a participant terminates their 10b5-1 trading plan early, they must wait at least 30 days before trading outside of the 10b5-1 trading plan. (Note for clarity: before the expiration of the 30 days waiting period, a participant may exercise the options that were subject to their terminated 10b5-1 trading plan for which payment is made in cash (or via net exercise transactions with the Company), but may not sell the stock underlying those options, </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">including</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> in a broker-assisted cashless exercise or same-day sale transaction).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Delayed Effectiveness of First Trade. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The first trade under a 10b5-1 trading plan cannot occur until the expiration of the applicable waiting period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Waiting Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;) as follows: (i) if the participant is a director or Section 16 officer of the Company, the later of (A) 90 days following the adoption of the 10b5-1 trading plan or (B) two business days following the disclosure of the Company&#x2019;s financial results in a Form 10-Q or Form 10-K for the fiscal quarter in which the plan was adopted (subject to a maximum of 120 days after adoption of the plan), and (ii) for all other participants, at least 30 days. Following a Material Modification of a 10b5-1 trading plan, a participant may not trade under the plan until the expiration of the applicable Waiting Period measured from the date of the Material Modification.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.622%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Relationships with Plan Broker; No Subsequent Influence. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">If the 10b5-1 trading plan</font></p>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">allows a broker discretion regarding the details of trading (e.g., timing, share amounts), the participant cannot communicate any material nonpublic information about the Company to the broker, or attempt to influence how the broker exercises its discretion. In addition, any individual who is authorized to exercise discretion in executing the participant&#x2019;s 10b5-1 trading plan must be a different individual from the person who executes trades for the participant in other securities.</font></p>
  <p style="margin-left:7.96%;text-indent:7.343%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.613%;text-indent:-3.685%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Plan Specifications; Discretion Regarding Trades. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan must specify the amount of stock to be purchased or sold, or specify or set an objective formula for determining the amount of stock to be sold. Other than plans providing for nondiscretionary sell-to-cover transactions to satisfy tax withholding obligations arising exclusively from the vesting of restricted stock or restricted stock units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;font-kerning:none;min-width:fit-content;">Qualified Sell-to-Cover Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#x201d;), 10b5-1 trading plans that are designed to effect the open-market purchase or sale of Company securities as a single trade may only be entered into once per 12-month period. Transaction types such as market, limit, and VWAP orders are allowed. Each 10b5-1 trading plan should specify the timing of trading or allow for the broker to exercise its discretion regarding the timing of trading. While the Company generally will not comment on the specific trading instructions</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">17</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:7.96%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">proposed to be included in a 10b5-1 trading plan, the Insider Trading Compliance Officer may, in the exercise of their discretion, refrain from approving a proposed 10b5-1 trading plan on the basis of the proposed trading instructions. For example, the Insider Trading Compliance Officer likely will not approve a 10b5-1 trading plan if the trading instructions provide for trades on a frequent (e.g., weekly) basis for an extended time period.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.231%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Other Trades. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Trading the Company&#x2019;s securities outside of a participant&#x2019;s 10b5-1 trading plan could, in certain circumstances, jeopardize the validity of a participant&#x2019;s plan. Accordingly, no participant who has a 10b5-1 trading plan may make open-market sales of the Company&#x2019;s securities outside of the plan while their 10b5-1 trading plan is in effect if such sales would cause or potentially cause the participant to not be able to make all of the trades under his or her 10b5-1 trading plan because the Rule 144(e) volume limitations (if applicable to the participant) would otherwise be exceeded.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.613%;text-indent:-3.686%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Only One Plan in Effect at Any Time. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">A participant may have only one 10b5-1 trading plan in effect at any time. However, a participant may, during the term of an existing plan, adopt one new 10b5-1 trading plan to replace the existing plan, but only if the first scheduled trade under the new 10b5-1 trading plan does not occur before all trades under the existing 10b5-1 trading plan are completed or expire without execution; provided, however, that if a participant terminates the existing plan after adoption of the replacement plan but prior to the existing plan&#x2019;s scheduled expiration, the participant&#x2019;s trades may not commence under the replacement plan until the expiration of the applicable Waiting Period, measured from the date of termination of the existing plan. This restriction on overlapping plans does not apply to plans providing for Qualified Sell-to-Cover Transactions.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.686%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Mandatory Suspension or Termination. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Each 10b5-1 trading plan must suspend trades or terminate if legal, regulatory, or contractual restrictions are imposed on the participant, or other events occur that would prohibit sales under such a plan. For example, trading would need to be suspended or the plan terminated if these guidelines were amended to preclude the particular sort of trade contemplated by the plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Compliance with Rule 144. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">For directors and Section 16 officers, each 10b5-1 trading plan must provide for specific procedures to comply with Rule 144 under the Securities Act of 1933, as amended, including the filing of Forms 144, when applicable. If you need additional information on Rule 144 and Form 144, please contact the Insider Trading Compliance Officer. If requested by the Company, participants must footnote trades disclosed on Forms 144 to indicate that the trades were made pursuant to a 10b5-1 trading plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.613%;text-indent:-3.686%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Broker Obligation to Provide Notice of Trades. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Each 10b5-1 trading plan must provide that the broker will promptly notify the participant and the Company of any trades under the plan so that, where required, the participant can make timely filings under the Exchange Act (i.e., no later than the close of business on the day of the trade).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.67%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.222%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Required Exchange Act Filings. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The Company is required to disclose certain information on a quarterly basis on Form 10-Q and 10-K with respect to the adoption, Material Modification or termination of 10b5-1 trading plans by any director or Section 16 officer. Directors and Section 16 officers must, in any Section 16 filing reporting a transaction effected pursuant to a 10b5-1 trading plan, check the appropriate box to indicate that the transaction is pursuant to a 10b5-1 trading plan and provide the date of adoption of the plan. By entering into a 10b5-1 trading plan, the Company&#x2019;s directors and Section 16 officers are deemed to understand, and agree to cooperate with the Company with respect to, such disclosure obligations, including by notifying the Insider Trading Compliance Officer of information relevant to the preparation of such disclosure.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">18</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:4.613%;text-indent:-3.686%;padding-left:3.347%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.241%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. Exercises of stock options for which payment is made in cash (or via net exercise transactions with the Company) currently can be executed at any time. Same day sale exercises or broker-assisted cashless exercises of stock options are subject to the restrictions set forth in this document and the Company&#x2019;s Insider Trading Policy. However, the Company will permit same day sales and broker-assisted cashless exercises under a 10b5-1 trading plan. Once a broker in a same day sale or broker-assisted cashless exercise disposes of the applicable shares in accordance with the 10b5-1 trading plan, the broker will notify the Company in writing and the administrator of the Company&#x2019;s stock plans will process the transaction. The participant should not be involved with this type of same day sale exercise.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.622%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Pledging the Company&#x2019;s Stock to Secure Margin of Other Loans</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. The Company does not permit officers or directors to pledge the Company&#x2019;s stock or securities as collateral to secure loans. Such pledges also cannot be carried out through a 10b5-1 trading plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Company Not Party to the Plan. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan may not have the Company as party to the plan, although it can have a representation by the participant to the effect that the Company has reviewed the plan.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.627%;text-indent:-3.671%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Guidelines Takes Precedence</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. In any event of any conflict between the guidelines in this document and any 10b5-1 trading plan, this document shall control, to the extent the 10b5-1 trading plan would permit activities otherwise prohibited by this document.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:5%;text-indent:-3.636%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">&#xf0b7;	</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exceptions; Waivers. </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">All requests for exceptions to or waivers of these guidelines must be reviewed and approved by the Insider Trading Compliance Officer or an individual designated by the Insider Trading Compliance Officer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>9
<FILENAME>gern-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">List of Subsidiaries</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron UK Limited, incorporated September 29, 2021</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Geron Netherlands B.V., incorporated February 17, 2023</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>gern-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-225184, 333-238595, 333-248637 and 333-269111) and in the related prospectuses and prospectus supplements,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-8 Nos. 333-239324, 333-258864, 333-273669, and 333-284209) pertaining to the 2018 Inducement Award Plan and the 2018 Equity Incentive Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-230171) pertaining to the 2018 Inducement Award Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-228147) pertaining to the Directors&#x2019; Market Value Stock Purchase Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-225190) pertaining to the 2018 Equity Incentive Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-196677) pertaining to the 2014 Employee Stock Purchase Plan,</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-174350) pertaining to the 2011 Incentive Award Plan, the 2002 Equity Incentive Plan, the 1996 Directors&#x2019; Stock Option Plan and the 1992 Stock Option Plan, </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-266795) pertaining to the 2018 Equity Incentive Plan, the 2018 Inducement Award Plan and the 2014 Employee Stock Purchase Plan.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our reports dated February 26, 2025, with respect to the consolidated financial statements of Geron Corporation and the effectiveness of internal control over financial reporting of Geron Corporation included in this Annual Report (Form 10-K) of Geron Corporation for the year ended December 31, 2024.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Jose, California</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 26, 2025</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>gern-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 31.1</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM OF RULE 13A&#x2011;14(A)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302(A) OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, John A. Scarlett, M.D., certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10&#x2011;K of Geron Corporation;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John A. Scarlett</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">JOHN A. SCARLETT, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>gern-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.75in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 31.2</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM OF RULE 13A&#x2011;14(A)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302(A) OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Michelle Robertson, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this annual report on Form 10&#x2011;K of Geron Corporation;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15d&#x2011;15(f)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: February 26, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michelle Robertson</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MICHELLE ROBERTSON</font></p><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Vice President, Finance,</font></p><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.75in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>gern-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 32.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, the undersigned officer of Geron Corporation (the &#x201c;Company&#x201d;) hereby certifies, to such officer&#x2019;s knowledge, that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accompanying annual report on Form 10&#x2011;K of the Company for the year ended December 31, 2024 (the &#x201c;Report&#x201d;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55%;box-sizing:content-box;"></td>
    <td style="width:45%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: February 26, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John A. Scarlett</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">JOHN A. SCARLETT, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Chairman of the Board</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Form 10&#x2011;K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10&#x2011;K), irrespective of any general incorporation language contained in such filing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>gern-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT 32.2</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, the undersigned officer of Geron Corporation (the &#x201c;Company&#x201d;) hereby certifies, to such officer&#x2019;s knowledge, that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the accompanying annual report on Form 10&#x2011;K of the Company for the year ended December 31, 2024 (the &#x201c;Report&#x201d;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55%;box-sizing:content-box;"></td>
    <td style="width:45%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:bottom;padding-bottom:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: February 26, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michelle Robertson</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">MICHELLE ROBERTSON</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Executive Vice President, Finance,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer and Treasurer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Form 10&#x2011;K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10&#x2011;K), irrespective of any general incorporation language contained in such filing.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img44536338_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44536338_0.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" <W$3 # 2(  A$! Q$!_\0
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M]$!P3_XBN1?_ #!Y+[C_ !^_XB#Q[_T6_%__ (DN<_\ S:?IS_P^6_X*9?\
M1UWBW_PDOAC_ /,/1_P^6_X*9?\ 1UWBW_PDOAC_ /,/7YC44?\ $-?#G_H@
M."?_ !%<B_\ F#R7W!_Q$'CW_HM^+_\ Q)<Y_P#FT_3G_A\M_P %,O\ HZ[Q
M;_X27PQ_^8>C_A\M_P %,O\ HZ[Q;_X27PQ_^8>OS&HH_P"(:^'/_1 <$_\
MB*Y%_P#,'DON#_B(/'O_ $6_%_\ XDN<_P#S:?IS_P /EO\ @IE_T==XM_\
M"2^&/_S#T?\ #Y;_ (*9?]'7>+?_  DOAC_\P]?F-11_Q#7PY_Z(#@G_ ,17
M(O\ Y@\E]P?\1!X]_P"BWXO_ /$ESG_YM/TY_P"'RW_!3+_HZ[Q;_P"$E\,?
M_F'H_P"'RW_!3+_HZ[Q;_P"$E\,?_F'K\QJ*/^(:^'/_ $0'!/\ XBN1?_,'
MDON#_B(/'O\ T6_%_P#XDN<__-I^G/\ P^6_X*9?]'7>+?\ PDOAC_\ ,/1_
MP^6_X*9?]'7>+?\ PDOAC_\ ,/7YC44?\0U\.?\ H@."?_$5R+_Y@\E]P?\
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MG_H@."?_ !%<B_\ F#R7W!_Q$'CW_HM^+_\ Q)<Y_P#FT_3G_A\M_P %,O\
MHZ[Q;_X27PQ_^8>C_A\M_P %,O\ HZ[Q;_X27PQ_^8>OS&HH_P"(:^'/_1 <
M$_\ B*Y%_P#,'DON#_B(/'O_ $6_%_\ XDN<_P#S:?IS_P /EO\ @IE_T==X
MM_\ "2^&/_S#T?\ #Y;_ (*9?]'7>+?_  DOAC_\P]?F-11_Q#7PY_Z(#@G_
M ,17(O\ Y@\E]P?\1!X]_P"BWXO_ /$ESG_YM/TY_P"'RW_!3+_HZ[Q;_P"$
ME\,?_F'H_P"'RW_!3+_HZ[Q;_P"$E\,?_F'K\QJ*/^(:^'/_ $0'!/\ XBN1
M?_,'DON#_B(/'O\ T6_%_P#XDN<__-I^G/\ P^6_X*9?]'7>+?\ PDOAC_\
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M6_X*9?\ 1UWBW_PDOAC_ /,/1_P^6_X*9?\ 1UWBW_PDOAC_ /,/7YC44?\
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M_P"$E\,?_F'H_P"'RW_!3+_HZ[Q;_P"$E\,?_F'K\QJ*/^(:^'/_ $0'!/\
MXBN1?_,'DON#_B(/'O\ T6_%_P#XDN<__-I^G/\ P^6_X*9?]'7>+?\ PDOA
MC_\ ,/1_P^6_X*9?]'7>+?\ PDOAC_\ ,/7YC44?\0U\.?\ H@."?_$5R+_Y
M@\E]P?\ $0>/?^BWXO\ _$ESG_YM/TY_X?+?\%,O^CKO%O\ X27PQ_\ F'H_
MX?+?\%,O^CKO%O\ X27PQ_\ F'K\QJ*/^(:^'/\ T0'!/_B*Y%_\P>2^X/\
MB(/'O_1;\7_^)+G/_P VGZ<_\/EO^"F7_1UWBW_PDOAC_P#,/1_P^6_X*9?]
M'7>+?_"2^&/_ ,P]?F-11_Q#7PY_Z(#@G_Q%<B_^8/)?<'_$0>/?^BWXO_\
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M:^'/_1 <$_\ B*Y%_P#,'DON#_B(/'O_ $6_%_\ XDN<_P#S:?IS_P /EO\
M@IE_T==XM_\ "2^&/_S#T?\ #Y;_ (*9?]'7>+?_  DOAC_\P]?F-11_Q#7P
MY_Z(#@G_ ,17(O\ Y@\E]P?\1!X]_P"BWXO_ /$ESG_YM/TY_P"'RW_!3+_H
MZ[Q;_P"$E\,?_F'H_P"'RW_!3+_HZ[Q;_P"$E\,?_F'K\QJ*/^(:^'/_ $0'
M!/\ XBN1?_,'DON#_B(/'O\ T6_%_P#XDN<__-I^G/\ P^6_X*9?]'7>+?\
MPDOAC_\ ,/1_P^6_X*9?]'7>+?\ PDOAC_\ ,/7YC44?\0U\.?\ H@."?_$5
MR+_Y@\E]P?\ $0>/?^BWXO\ _$ESG_YM/TY_X?+?\%,O^CKO%O\ X27PQ_\
MF'H_X?+?\%,O^CKO%O\ X27PQ_\ F'K\QJ*/^(:^'/\ T0'!/_B*Y%_\P>2^
MX/\ B(/'O_1;\7_^)+G/_P VGZ<_\/EO^"F7_1UWBW_PDOAC_P#,/1_P^6_X
M*9?]'7>+?_"2^&/_ ,P]?F-11_Q#7PY_Z(#@G_Q%<B_^8/)?<'_$0>/?^BWX
MO_\ $ESG_P";3].?^'RW_!3+_HZ[Q;_X27PQ_P#F'H_X?+?\%,O^CKO%O_A)
M?#'_ .8>OS&HH_XAKX<_]$!P3_XBN1?_ #!Y+[@_XB#Q[_T6_%__ (DN<_\
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M]'7>+?\ PDOAC_\ ,/1_P^6_X*9?]'7>+?\ PDOAC_\ ,/7YC44?\0U\.?\
MH@."?_$5R+_Y@\E]P?\ $0>/?^BWXO\ _$ESG_YM/TY_X?+?\%,O^CKO%O\
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MW_PDOAC_ /,/7YC44?\ $-?#G_H@."?_ !%<B_\ F#R7W!_Q$'CW_HM^+_\
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M\QJ*/^(:^'/_ $0'!/\ XBN1?_,'DON#_B(/'O\ T6_%_P#XDN<__-I^G/\
MP^6_X*9?]'7>+?\ PDOAC_\ ,/1_P^6_X*9?]'7>+?\ PDOAC_\ ,/7YC44?
M\0U\.?\ H@."?_$5R+_Y@\E]P?\ $0>/?^BWXO\ _$ESG_YM/TY_X?+?\%,O
M^CKO%O\ X27PQ_\ F'H_X?+?\%,O^CKO%O\ X27PQ_\ F'K\QJ*/^(:^'/\
MT0'!/_B*Y%_\P>2^X/\ B(/'O_1;\7_^)+G/_P VGZ<_\/EO^"F7_1UWBW_P
MDOAC_P#,/1_P^6_X*9?]'7>+?_"2^&/_ ,P]?F-11_Q#7PY_Z(#@G_Q%<B_^
M8/)?<'_$0>/?^BWXO_\ $ESG_P";3].?^'RW_!3+_HZ[Q;_X27PQ_P#F'H_X
M?+?\%,O^CKO%O_A)?#'_ .8>OS&HH_XAKX<_]$!P3_XBN1?_ #!Y+[@_XB#Q
M[_T6_%__ (DN<_\ S:?IS_P^6_X*9?\ 1UWBW_PDOAC_ /,/1_P^6_X*9?\
M1UWBW_PDOAC_ /,/7YC44?\ $-?#G_H@."?_ !%<B_\ F#R7W!_Q$'CW_HM^
M+_\ Q)<Y_P#FT_3G_A\M_P %,O\ HZ[Q;_X27PQ_^8>C_A\M_P %,O\ HZ[Q
M;_X27PQ_^8>OS&HH_P"(:^'/_1 <$_\ B*Y%_P#,'DON#_B(/'O_ $6_%_\
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M_HM^+_\ Q)<Y_P#FT_3G_A\M_P %,O\ HZ[Q;_X27PQ_^8>C_A\M_P %,O\
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M_-I^G/\ P^6_X*9?]'7>+?\ PDOAC_\ ,/1_P^6_X*9?]'7>+?\ PDOAC_\
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M_P#XDN<__-I^G/\ P^6_X*9?]'7>+?\ PDOAC_\ ,/1_P^6_X*9?]'7>+?\
MPDOAC_\ ,/7YC44?\0U\.?\ H@."?_$5R+_Y@\E]P?\ $0>/?^BWXO\ _$ES
MG_YM/TY_X?+?\%,O^CKO%O\ X27PQ_\ F'H_X?+?\%,O^CKO%O\ X27PQ_\
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M /,/1_P^6_X*9?\ 1UWBW_PDOAC_ /,/7YC44?\ $-?#G_H@."?_ !%<B_\
MF#R7W!_Q$'CW_HM^+_\ Q)<Y_P#FT_3G_A\M_P %,O\ HZ[Q;_X27PQ_^8>C
M_A\M_P %,O\ HZ[Q;_X27PQ_^8>OS&HH_P"(:^'/_1 <$_\ B*Y%_P#,'DON
M#_B(/'O_ $6_%_\ XDN<_P#S:?IS_P /EO\ @IE_T==XM_\ "2^&/_S#T?\
M#Y;_ (*9?]'7>+?_  DOAC_\P]?F-11_Q#7PY_Z(#@G_ ,17(O\ Y@\E]P?\
M1!X]_P"BWXO_ /$ESG_YM/TY_P"'RW_!3+_HZ[Q;_P"$E\,?_F'H_P"'RW_!
M3+_HZ[Q;_P"$E\,?_F'K\QJ*/^(:^'/_ $0'!/\ XBN1?_,'DON#_B(/'O\
MT6_%_P#XDN<__-I^G/\ P^6_X*9?]'7>+?\ PDOAC_\ ,/1_P^6_X*9?]'7>
M+?\ PDOAC_\ ,/7YC44?\0U\.?\ H@."?_$5R+_Y@\E]P?\ $0>/?^BWXO\
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MXO\ _$ESG_YM/TY_X?+?\%,O^CKO%O\ X27PQ_\ F'H_X?+?\%,O^CKO%O\
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M $0'!/\ XBN1?_,'DON,I>(G'ST7&_%Z\_\ 67.;_P#J;H?IO_P^3_X*8_\
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MO_F#R7W!_P 1#X__ .BYXP_\2;.O_FT_3?\ X?)_\%,?^CK?%O\ X27PQ_\
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M>2^XSEXC<?\ V>.>,/7_ %ESK\/]M_,_37_A\C_P4O\ ^CK/%O\ X2?PR_\
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MEO\ [!Y?@@_XB)X@?]%UQC_XD^=__-Q^FG_#X_\ X*6_]'5^+/\ PDOAE_\
M,11_P^/_ ."EO_1U?BS_ ,)+X9?_ #$5^9=%#\./#A;< <$M_P#9*Y%;_P!0
M/)?TB)>(_B MN.N,6_\ LI\[M_ZG'Z:?\/C_ /@I;_T=7XL_\)+X9?\ S$4?
M\/C_ /@I;_T=7XL_\)+X9?\ S$5^9=%9_P#$-O#K_H@>"O\ Q%LB_P#F#R7W
M(S_XB-X@_P#1=\9?^)/G?_S<?II_P^/_ ."EO_1U?BS_ ,)+X9?_ #$4?\/C
M_P#@I;_T=7XL_P#"2^&7_P Q%?F711_Q#;PZ_P"B!X*_\1;(_P#Y@\E]P?\
M$1?$'_HN^,O_ !)\[_\ FX_33_A\?_P4M_Z.K\6?^$E\,O\ YB*4?\%CO^"E
MQZ?M5>+/_"2^&7Z_\417YFA">O _6I  .E'_ !#;PZ_Z('@K_P 1;(__ )@\
ME]P?\1%\0?\ HN^,O_$GSO\ ^;C],A_P6,_X*6=_VJ_%A/\ V*7PR_\ F(I?
M^'QO_!2S_HZKQ9_X2?PR_P#F(K\S:*/^(;>'7_1 \%?^(MD?_P P>2^X/^(B
M^(/_ $7?&7_B3YW_ /-Q^F7_  ^-_P""EG_1U7BS_P )/X9?_,11_P /C?\
M@I9_T=5XL_\ "3^&7_S$5^9M%'_$-O#K_H@>"O\ Q%LC_P#F#R7W!_Q$7Q!_
MZ+OC+_Q)\[_^;C],O^'QO_!2S_HZKQ9_X2?PR_\ F(H_X?&_\%+/^CJO%G_A
M)_#+_P"8BOS-HH_XAMX=?]$#P5_XBV1__,'DON#_ (B+X@_]%WQE_P")/G?_
M ,W'Z9?\/C?^"EG_ $=5XL_\)/X9?_,11_P^-_X*6?\ 1U7BS_PD_AG_ /,1
M7YG!2?IW-2A0/KW-'_$-O#K_ *('@K_Q%LC_ /F#R7W!_P 1%\0?^B[XR_\
M$GSO_P";C],!_P %BO\ @I9W_:J\6?3_ (1/X9?S_P"$)IW_  ^*_P""E7_1
MU/BS_P )/X9__,37YGT4?\0V\.O^B!X*_P#$6R/_ .8/)?<'_$1?$'_HN^,O
M_$GSO_YN/TP_X?%?\%*O^CJ?%G_A)_#/_P"8FC_A\5_P4J_Z.I\6?^$G\,__
M )B:_,^BC_B&WAU_T0/!7_B+9'_\P>2^XF7B/X@K_FN^,F^W^M&=_C_MVA^F
M'_#XK_@I5_T=3XL_\)/X9_\ S$TO_#XO_@I5_P!'4^*__"2^&7_S$5^9U%'_
M !#;PZ_Z('@K_P 1;(__ )@\E]QD_$?Q";O_ *]\9?+B?.__ )N/TQ_X?%_\
M%*O^CJ?%?_A)?#+_ .8BC_A\7_P4J_Z.I\5_^$E\,O\ YB*_,ZBC_B&WAU_T
M0/!7_B+9'_\ ,'DON%_Q$;Q"_P"B[XS_ /$HSO\ ^;O)?<?IC_P^+_X*5?\
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MG\5G_N4_AI_\Q-?FH !P*6C_ (AQX>?]$%P7_P"(MD?_ ,P^2^X/^(C^(?\
MT7O&G_B4YY_\W>2^X_2O_A\)_P %)?\ HZ;Q7_X2GPT_^8JC_A\)_P %)?\
MHZ;Q7_X2GPT_^8JOS4HH_P"(<>'G_1!<%_\ B+9'_P#,/DON#_B(_B'_ -%[
MQI_XE.>?_-WDON/TK_X?"?\ !27_ *.F\5_^$I\-/_F*H_X?"?\ !27_ *.F
M\5_^$I\-/_F*K\U*4*3T_/M1_P 0X\//^B"X+_\ $6R/_P"8?)?<'_$2/$-?
M\U[QFO\ NZ<\\O\ J.\E]R/TJ_X?"?\ !27_ *.F\5_^$I\-/_F*J1?^"P/_
M  4EZG]J;Q7]/^$4^&GZ_P#%$U^:P4#W/K_AZ4ZC_B''AY_T07!?_B+9'_\
M,/DON,WXE>(FRX\XT]?]:<\OTV_V[3;\MK'Z4_\ #X'_ (*1_P#1TOBO_P )
M3X:__,51_P /@?\ @I'_ -'2^*__  E/AK_\Q5?FM11_Q#CP\_Z(+@O_ ,1;
M(_\ YA\E]Q'_ !$GQ%_Z+[C7_P 2G//_ )O\E]Q^E/\ P^!_X*1_]'2^*_\
MPE/AK_\ ,51_P^!_X*1_]'2^*_\ PE/AK_\ ,57YK44?\0X\//\ H@N"_P#Q
M%LC_ /F'R7W!_P 1)\1?^B^XU_\ $ISS_P";_)?<?I3_ ,/@?^"D?_1TOBO_
M ,)3X:__ #%4?\/@?^"D?_1TOBO_ ,)3X:__ #%5^:U%'_$./#S_ *(+@O\
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M?I/_ ,/?_P#@I#_T=)XK_P#"5^&W_P Q='_#W_\ X*0_]'2>*_\ PE?AM_\
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MZ'Q5_P"$K\-__F+K\W:*/^(<>'G_ $0?!G_B+Y'_ /,(O^(F>)'_ $<'C?\
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M[?\ !1K_ *.@\5?^$M\./_F,K\WZ*R?AWX>O_F@^#%Z<+Y)^?U$R?B?XDO\
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MN!>#?3_5C)/Q_P!AU]%^(GXG>)*W\0N./_$LS[_YX'Z.#_@KG_P49/ _:?\
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ME_P47_Z.>\4_^$M\./\ YC*_.*BC_B'7A]_T0G!O_B,9)_\ ,(?\1/\ $O\
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M<[XI_P#"6^''_P QM'_#V_\ X**_]'.^*?\ PEOAQ_\ ,;7YR44?\0Z\/O\
MHA>#?_$8R3_YA\E]P?\ $4/$O_HXG'7_ (EN?_\ SP\E]Q^C?_#V_P#X**_]
M'.^*?_"6^''_ ,QM*/\ @K=_P46/3]IWQ3_X2_PX_P#F-K\YE3N>/;U_P_G4
MH&.!4/P]\/EMP+P:W_V3&26_]0O)?T@_XBAXE_\ 1Q..O_$MS_\ ^>'DON/T
M9'_!6W_@HH/^;G?%)/OX6^''\O\ A#:7_A[=_P %%/\ HYSQ1_X2WPX_^8RO
MSEHK+_B'?A__ -$+P=_XC&2?_,(?\10\2_\ HXG'7_B6Y_\ _/#R7W'Z-?\
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M+P=_XC&2?_,(?\11\3/^CB\=_P#B7<0?_/#R7W'Z+#_@K7_P42/ _:;\4?\
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M_P#,(GXJ>)BW\1N._3_6[B#_ .>!^B:_\%9O^"B)_P";FO% '_8K_#KGZ?\
M%&U*/^"L_P#P4/'_ #<SXG_'PM\.?_F-K\ZJ*/\ B'?A_P#]$+P=_P"(QDG_
M ,PF3\5/$Y_\W&X[7E_K?Q!_\\#]%?\ A[/_ ,%#_P#HYGQ/_P"$M\.?_F-H
M_P"'L_\ P4/_ .CF?$__ (2WPY_^8VOSJHH_XAWX?_\ 1"\'?^(QDG_S"3_Q
M%/Q._P"CC<>?^)?Q!_\ /#R7W'Z*_P##V?\ X*'_ /1S/B?_ ,);X<__ #&T
M?\/9_P#@H?\ ]',^)_\ PEOAS_\ ,;7YU44?\0[\/_\ HA>#O_$8R3_YA#_B
M*?B=_P!'&X\_\2_B#_YX>2^X_17_ (>S_P#!0_\ Z.9\3_\ A+?#G_YC:/\
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M<0__ #Q\E]Q^B/\ P]B_X*%_]'+^)_\ PE_AU_\ ,=1_P]B_X*%_]'+^)_\
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M^"KO_!0H_P#-RWB<#U_X1CX=_P#S'U^>:IW//MZ?X_RI]'_$/. /^B&X/_\
M$9R7_P"8@_XBKXH?]'(X^_\ $PXA_P#GCY+[C]#?^'KO_!0C_HY;Q/\ ^$Q\
M//\ YCZ/^'KO_!0?_HY7Q/\ ^$Q\//\ YCZ_/*BC_B'G '_1#<'_ /B,Y+_\
MQ!_Q%7Q0_P"CD<??^)AQ#_\ /'R7W'Z&_P##UW_@H/\ ]'*^)_\ PF/AY_\
M,?1_P]=_X*#_ /1ROB?_ ,)CX>?_ #'U^>5%'_$/. /^B&X/_P#$9R7_ .8@
M_P"(J^*'_1R./O\ Q,.(?_GCY+[C]#?^'KO_  4'_P"CE?$__A,?#S_YCZ/^
M'KO_  4'_P"CE?$__A,?#S_YCZ_/*BC_ (AYP!_T0W!__B,Y+_\ ,1#\6/%!
M:+Q(X^]?]<.(?+;_ (4==OP1^AO_  ]=_P""@_\ T<KXG_\ "8^'G_S'T?\
M#UW_ (*#_P#1ROB?_P )CX>?_,?7YY44?\0\X _Z(;@__P 1G)?_ )B,_P#B
M*_BE_P!'*X__ /$QXB_^>/DON/T-_P"'KO\ P4'_ .CE?$__ (3'P\_^8^C_
M (>N_P#!0?\ Z.5\3_\ A,?#S_YCZ_/*BC_B'G '_1#<'_\ B,Y+_P#,0?\
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MZ7_AZS_P4$_Z.3\3?^$Q\//_ )CZ_/6BLO\ B'W 7_1$<(?^(UDO_P Q&?\
MQ%CQ3_Z.5Q__ .)CQ%_\\3]"O^'K/_!03_HY/Q-_X3'P\_\ F/H_X>L_\%!/
M^CD_$W_A,?#S_P"8^OSUHH_XA]P%_P!$1PA_XC63?_,0?\17\4O^CE<?_P#B
M9<1?_/$_0K_AZS_P4$_Z.3\3?^$Q\//_ )CZ/^'K/_!03_HY/Q-_X3'P\_\
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M_@H#_P!'(^)?_"8^'G_S(4?\/5?^"@/_ $<CXE_\)CX>?_,A7Y\44?\ $/>
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MM?)$?\1;\5O^CF^(7_B:<2?_ #R\E]Q^@?\ P]0_;]_Z./\ $O\ X3/P^_\
MF1H_X>H?M^_]''^)?_"9^'W_ ,R-?GY2@$]/\_6G_P 0]X!7_-#\'K_NVLE\
MO^H+R7W(7_$6_%;_ *.;XA?^)IQ)_P#/+R7W'Z!?\/4/V_?^CC_$O_A,_#[_
M .9&GC_@J;^W\>O[1_B4#_L6?A]G_P!1"OS_ %4#W/\ +Z4ZLWP!P#]G@?@_
MU_U9R7RV_P!B\E_2#_B+?BM_T<WQ"_\ $TXD_P#GEY+[C] ?^'IO[?G_ $<?
MXE_\)KX?_P#S(T?\/3?V_/\ HX_Q+_X37P__ /F1K\_J*G_B'W 7_1$<(?\
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M/^CC_$O_ (37P_\ _F1K\_J*/^(?<!?]$1PA_P"(UDW_ ,Q>2^X7_$7/%?\
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MY/\ *GU$I]OO_P" :*'?[O\ @B  <"EHHK,<I):+?\$%%%%!FVWJPHHHH$%
M!/2G*I/L/Y_2I0 .G^?K0 U4 Y/)_E3Z** "BBB@ HI0I/3\^U2A0/<^O^'I
M03*27F^W^?8:J=S^7^-2444&3;>X4444""BBB@ HHHH **** "BBI%3N?R_Q
MI-I;B;2W&A2?8>O^'K4H4#I^?>EHK*4F_)=O\^YE*3?DNW^?<****<8/=[=N
MO_ _,D***D">OY?_ %ZT;45V_7^N[ 8%)^G<U*% ^O<TZBLI2;\EV ****D
MHHHH **** "BBB@ HHIP4GV'K0)M+<:!G@5*$ Z\G]*< !TI:#.4V]M%^(44
M44$!1110 4444 %%%% !112@$]/\_6@!*>$)Z\#]:>J@>Y_E]*=09RG_ "_?
M_E_P1  .E+1109A112@$\"@!*>J$\G@?SIRH!R>3_*GT ( !P*6BB@ HHHH
M****B4[:+7SZ?\$B4[:+7SZ?\$****R;OJS)N^K"BBB@ I0">E.5.YX]O7_#
M^=2@8X% #0H'N?6G444 %%%%4HM^2[_Y=P"BG!2?8>O^'K4H4#I^?>KO&&B5
MW_6[_0F4DO-_UN-5.YY]O3_'^5/HHK-MO<R;;W"BBBD(**** "BBB@ HHHH
M**4 G@5(J <GD_RH :J$\G@?SJ0 #@4M% -VU84444&4IWT6GGU_X 4444$!
M1110 4444 %%%/5.YX]O7_#^=)M+<!H!/2I0H'N?6G 8X%%92DWY+\_4 HHH
MJ0"BBGA">O _6@3:6[&@$]/\_6I54#W/\OI2@ =*6KC%O?1?GZ?YF4IMZ+1?
MC\PHHHK1))61(4444V[:L HHHK*4[Z+3SZO_ " ****@ HIP4GV'K_AZU*%
MZ?GWH 8J=S^7^-2444 %%%% !110 3TH *<JD^P_G]*>$ Z\G]*?09RG_+]_
M^7_!$  Z?Y^M+1109A1110 4444 %%%% !1110 4H!/3_/UIP0GKP/UJ0 #I
M42FEMJ_P(E-+;5_@(J@>Y_E]*=116;;>K,VV]6%%%%5&'5Z>7?\ R_,04H!/
M IRH3R>!_.I  .!5.2CHNGX?Y@-5 .3R?Y4^BBLVV]6 4444@"BBB@ HHHH
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M3N:>$]?R_P#KU)0 T*!]>YIU%% FTMPHHHH,Y3;VT7XA0 3TIRJ3[#^?TJ4
M#I_GZT$#0@'7D_I3Z** "BBB@ HHHJ922\W^7J 4445DVWN 4444@"BE )Z?
MY^M2JH'N?Y?2@ER2]>W];#%0GD\#T[__ %JE QP***N,&]7HOS,G)O?[N@44
M45HDEHA!12@$\"I%0#D\G^5#DEZ]$ U4)Y/ _G4@ ' I:*R<F_3H@"BBBI *
M***!-I;A111092DWY+L%%%%!(445(J=S^7^- # I/3\^U2A0/<^O^'I3J* "
MBBB@ HHIP4GV'K0 T#/ J54[GGV]/\?Y4X #I2T %%%% !1110W;5@W;5GYW
MT445^@']8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !113@I/L/7_  ]: ;MJQM2*G<_E_C3PH'3\^]+092G?1:>?7_@!11100%%%
M% !1110 4444 %%% !/2@ IRJ3[#^?TIX0#KR?TI]9RG_+]_^7_!,Y3_ )?O
M_P O^"( !T_S]:6BBLS,*** ,\"@ IP4GV'K3U3N>?;T_P ?Y4^@!  .E+11
M0 4445I&'5_=_F 4444W-+16?Y+^O(B4TMM7^ 4445FVWJS-MO5A1112$%*
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M:>$]?R_^O4E*4^BU\^W^?Y -"@?7N:=1163=]6 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3@I/L/6@3:6XT#/ J54[GGV]/\?Y4X #I2T&<IM[:+\0HHHH("BBB@ HHHH
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M'N?6@ER2\WV_S[#%3N>/;U_P_G4H&.!1109.3>_W= HHHH$%%%2*G<_E_C0
MT*3[#U_P]:E"@=/S[TM% !1110 4444";2W"BBB@RE)OR78****"0HHIZH3R
M>!_.AM+<!H!/ J14 Y/)_E3@ .!2TM7OHNW?U?Z+YM[ %%%%, HHIRJ3[#^?
MTI-I:L3:6K&@$]*E" =>3^E.  Z?Y^M+6<IM[:+\3.4V]M%^(4445! 4444
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M% FTMPHHHH,I2;\E_6X4444$A113U3N>/;U_P_G0 T GI4H4#W/K3@,<"B@
MHHHH ***<%)]AZT - SP*E5.YY]O3_'^5.  Z4M !1110 4444-VU8-VU844
M45E*=]%IY]?^ 92G?1:>?7_@!1114$!112A2>GY]JM0ZRT7];]OS _.ZBBBO
MT4_K@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^F?A5^
MQC^UC\<O"B>.O@]^SO\ %WXD^#9-0O-*B\3^$/!&MZUHDVHZ<8A?V<.HVEJ]
MM--9M-&EPL4C^5(3$Y$BNJ_,U?WL?\&]O_*.7PW_ -E:^*?_ *=+"OQ[QO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Z9^%7[&/[6/QR\*)XZ^#W[._Q=^)/@V34
M+S2HO$_A#P1K>M:)-J.G&(7]G#J-I:O;336;31I<+%(_E2$Q.1(KJOI!_P""
M:'_!0, D_L<_M"X )./AEXD)XYX LB2?0 $GH 37]>__  ;V_P#*.7PW_P!E
M:^*?_ITL*_9SQ1XS\'^![&VU/QIXK\->$--O=0@TFSU#Q1KNE^'[&[U6YBN+
MBVTRVN]6NK2"?4+B"TNIH+.*1[F6*VN)(XV2&1E_A3C?Z5O%W#/&W$O"N7\)
MY%CZ62YWC\JPM6I/,Y8K$PP=>=*-2=.A7474G&#E*-."2;T5EK_:'!WT9>%N
M(N#^'N)<=Q/G6"J9OD^!S/$4Z<,NCAL//%T8590A.M1<E3@Y\L74DV]+N[/\
MQ/QY^R'^U;\+M/GU?XD?LS_'SP)HUL&,^M^+?A#X_P! T2-4!9V.L:EH%MIA
M15!+.MT5 !). :^=Z_UBM.U/3=8LXM0TG4+'5+"X&Z"^TZ[M[ZSF7^]%<VTD
ML,@]T=A7Y#_\%!_^".7[.7[9'A;Q!XE\">&/#/P7_:*CM+J]\/\ Q#\+Z5#H
MFA>*M7!:==.^*.@Z-;QVFO6FJ2?Z--XJBLG\7Z0SV]W%=ZM864GA_4.[@WZ9
M.7X[,J&7<<<,?V%AZ]6-&6<Y5BZN,P^#E*2ASXW+:]"&*AAZ;]ZM6P^(Q-:$
M;\N$J-:\?%OT3<=@\OK8_@[B+^VJ]&E*K'*<RPM+"5L7&,>;EP>/H5YX>5>:
MTI4J]##TIRLI8J%S_/MK^R#_ ()F?\$0/V2O'/[+GPM^.'[37AK7?BSXW^,W
MA+2_B!9:$?&7BSP=X4\(>&/$ENVH>%[+3X? VL>&]8U/5+K0KJPU+6+[5]6N
MK5;RX6ST_3[:*SDN=0_D2^(OP]\8_";QYXO^&?Q"T*\\,^-_ GB#5/"_BC0K
M] MSINL:1=26EY 60M%<0&2/S;2\MI);2^M)(+RSFGM9X9G_ *%O^"?O_!?F
M7]F3X%>$/@%\=?@_K7Q(T?X;:?'X?\!^-? ^N:;IFO0^$;4'^R?#OB'0M;B2
MPU"70T;^S].UFQU?3BVC0V%E=:5->6<VIW_['X]8'Q+S[@K+GX38[%K%5,QP
M^+Q\\CS2EEV8XW**F%K2HSR_,?K&&O0=>="M5AA<53JXBDX.#J4E4A+\G\$\
M9X>Y+Q?CUXGX+"O#4\!7PV!AG.6U<?@,)FM/$TE5ACL![#$6K*C"M2I2Q.&G
M2H5%-3]G5=.<?-/^"UW_  2V^$W[#UM\,/C!^S_<>(=/^&GQ$U_4?!&N^"?$
M6IS^(/\ A%/%=II<NN:1<Z'X@OYI-8O-*U[2K+6%FT_5VO;K3+S1FG35KJ#5
M8[+3/P!K]=?^"I?_  56\1?\%$]3\#>&]&\ M\,/A!\-KS4M8T3P_?ZO#KWB
M3Q%XFU6UAL9O$/B*_M[*RLK(6%@DUAH^C:<D\=HE]J=S>:GJ,EY;Q:=^15?7
M>$&#XYP'A_D>%\1:]7$<4TXXOZW/$XFEC,;'#2Q=:6 I8_%T)U*6)QE/".E&
MK556K-I1C7JU,1&K.7RWBIBN#<;QQG.)X"H4Z'#4WA?JL*&'JX3"2Q$<+1CC
M:F"PM:-.KA\+4Q2JRITY4Z44^:5&G"A*G%%%36]O<7<T=O:P37-Q*VV*"WB>
M::5L$[8XHU9W; )PJDX!..*9)')#(\4T;Q2QL5>.1&21&'571@&5AW! ([BO
MTNZO:ZO:]KZVVO;>UTU<_/;.U[.U[7MI?>U]KV:=AE%%%,045+!!/<S1V]M#
M+<3RL$BA@C>6:1ST6..,,[L>RJI/M1-!-;2O!<0RP3Q,5EAFC>*6-AU5XW"N
MC#N& /M2NKVNKVO:^MMKVWM?2X[.U[.U[7MI?>U]KVUL14444Q!15E+.\EMI
MKR.UN9+2W94GND@E>V@=\;$FG5#%&SY&U792V1@'-5J2:=[-.SL[.]G9.S[.
MS3L^C3ZC::M=-75U=;J[5UW5TU?NF%%%%,04444 %%%% !115NXL+ZTBMY[J
MRN[:&[0R6LUQ;30Q7*#&7MY)$5)D&X9:,L!D<\BDY132;2<KJ*;2;:U:2ZV6
MKL-)M-I-I;M+17=E=]+O37J5****8@HHI\<<DTB111O++*ZQQQ1JSR22.0J(
MB*"SN[$*JJ"S$@ $FC;<-]AE%37%M<VDKV]W;SVLZ'#PW$4D,J'T>.15=3]5
M%0T)II----736J:>S3ZI@TTVFK-:-/=/LPHHHH **** "BBB@ HHHH ****
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M>Z=J%O'=V5W _P!B&Z&YMIHIHFP-R.IP,U?_ .';_P"WM_T:'\?O_#;>(_\
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MFK]'T8E/5.YX]O7_  _G3PH'N?6G4S.4^B^__( ,<"BE )( !))   R23P
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M?Y_U;U)<DO7M_6PP(3UX'ZU( !TI:*ER;].B6QDY-[_<%%%%(04444 %%%%
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MP* &A0/<^M.HHH **** "BG!2?8>O^'K4H4#I^?>@!BIW/Y?XU)110 4444
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M4:2^5+)'OV.RG]<?^#DS_DPWX>_]G2> ?_59?&:ORY_X-FO^3K?CY_V;V_\
MZLCP37Y9P-5JT/H?\95:-2I1JPQF;.%2E.5.I!_VKE2O&<&I1=FU=-.S:/TG
MC.E3K?2JX3I5J<*M.>%RM3IU(1G"2_LW,G:4))QDKI.S3U5S^D[]K7_@F]^S
MG^U3\'+SX1-X+\&?"87_ (J\%:]-XU^'?P]\':5XLM-.\.>)-/U/7-*TN^M]
M-M/LLWB+P_'JN@17MQ]MM=-GU&'5+C2M62Q.FW7NG[._[(W[./[*GA:R\)_
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MXAV[7MS::/9V5O/=FW@@@-Q+&TQAABB+[(T4?V!_LD?\FI?LR?\ 9O?P7_\
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MW.B>)='T_7=(N);7X<^(;BVDGTW5+>ZLYI+>>..>!Y(6:&9$DC*NH8?VK?M
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M17ZJ?F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?TY?\&Q_P#R7;]IW_LDOA#_ -3&2OYC:_IR_P"#8_\
MY+M^T[_V27PA_P"IC)7XI](O_DRW'?\ V 9?_P"KO+#]>\!?^3N<%?\ 8=C?
M_51F)_4%^W)_R93^V#_V:W^T#_ZJ;Q;7^8?#--;S17%O+)!<02)-!/#(T4T,
MT3!XI8I4*O')&ZJZ2(P9& 92" :_U7?B;\/]!^+/PV^(/PK\5-?KX8^)?@?Q
M9\/_ !&VEW"6>IKH/C+0;_PYK#:==RP7,=K?C3]2N#:7$EM<)!<".5X)54QM
M^1?@#_@@'_P3H\#:_8:]?^#/B+\1#IUW#>P:-X_^(=[>:!-+;L)(H[_3?#=A
MX774K3S%5Y[#4);FRNU4V]Y;W%K)+!)_&?T=_&O@_P *<AXIPG$E#.<3BLTS
M#"8S!4,KP>'Q*JT\/A*E&<*E3$8S"TZ4I3DDN9N/+=MZ6?\ 6OCQX0<5^)F=
M\-8KA^ME.'PV78'%87%ULRQ=?#NE.OBH58SA3H87$U*D8PBV^5)\UDEK=?5/
M_!*[QU\3/B5_P3Z_9?\ &GQ?O]4U7QYK'@.\2_UC6WEFU?6M$TKQ7XBT;P5K
M6HW4\<=Q?W>L>"-.\.ZG-J=R9KG5&NCJ%Q=7DUR]W-^*O_!S_IVDOX5_8YU:
M1@NNP>(/C9IUF@4 S:3=Z;\,KG4F=LAB+:\LM*$2D$*;N4@J7;?_ %+6=GH?
MA70K6PL+;2O#GAKPWI,%G96=K%::3HFA:'H]FL-O;6\$2P6.F:5I=A;)%#%&
ML-I9VD"HBQPQ@+_ _P#\%OOVY_"G[9/[3VDZ!\*]8CU_X.? /1=3\&^%/$5I
M,TVE^+_%>M7UM>>/?%NBL51'T6ZGTS0O#NE7<8EAU:T\+IKMG<S6&JV@CYOH
M[9?C^+_'F7%^4Y6\MR7+\?Q-G^.IX>-L'E6%SK#9KA<!E-.K&$*7,ZN84\/0
MH14)5,+AL35ITU"A/DZ/'G'8+A;P3CPMF>8K,,WQV"X=R/!5*\KXO,\3D^)R
MS$X[,YTW.=7E5/ 3Q%:M)RC#$U\/2J5'.O#G_<;_ (-]O@]\)/'7[!^J:WXV
M^%OPY\8ZROQZ^(5BNK^*O!'AGQ#J:V4'A[P))!9K?ZOIEY="UA>>9XK<2B*-
MYI61%,CD_77[4'_!(WX!?M._M*_L_?$?Q!X1\(^%O@[\+O"GC>/Q[\/O ^C6
M'@V;XD>))=<\+7W@72M7?P[8:?\ \4TL+>+)_$=W!=0:Q+%:Z;H]E+#!JES?
M6'A?_!N9_P H_-6_[.$^(_\ ZC?P_K]#O^"AG[8VE?L+_LN>-OCM<Z5;^(?$
ML%SIWA+X<^&;QKF*PU_X@>)#<)HMMJ<UKMEBTC3+2SU/Q'K*I/:3W6E:)>V%
ME=P:A=V;5X?&V<\;T/'WB[ <&YEF-+/,SXHS;(<KI4,54ARRSF%3+&J+G45+
M"RA3Q,IT\6G3^HSC'%QJ4I454C[7"&4<'5O!'A;&\6Y?E]3)\NX<RK.\QJU\
M-"7-'*94\Q3K*$'5Q,9U,/&%3"M5/KD92PTJ=157"7U9X1\%> OA;X4L_"_@
M7PKX5^'W@KP]9,ECH'A?1=*\,^'-(L;>,O)Y&FZ7;V>GVD$<:M)*ZQ(,!I)&
M)+-7^?I^S9^R;XT_X*P?MX?&.[\*3#P7\-/$'Q+\<_%KXD^-K;3(3:>!? WB
MKQEJ^I:+I&D:;FVMI_$6LI.FB>%])8JJ"VO=5NXY-.T74B/&O'O_  5$_P""
M@'Q'U_Q%KWB#]JGXMVT?B>WU*QU+PUX<\2W'ACP.FEZK;RV=SI=GX)T(6/AF
MVLQ93/:HPTQKPI^^ENI;MI+E_P"L/_@WB^#NC> ?V!K7XF06D)\0?';XE>-_
M$VJ:F8$2[DT;P3K%U\-]"T9K@#?-I^F7OAGQ%J=I&Y(@O/$.JE<>:U?L4>%>
M)_HP\"<:\88_.<MS;B[B^>1</9)B<*L5B89;CJ_]J8W,L5B)YA0IO&U84*4\
M1A9U*3A4Q&$@\32E3G.G+\G?$O#OTC.->$.%<%E.897PMPK3SG/LWPV)>&P\
M\PP='^S,'E^&H0P5:HL)2E6J1P^)A3J<\,/B9K#U8U(1G'])?V8OV%OV6?V0
M?#>G:%\#_A'X8T#4[2V2&_\ 'NIZ?:Z[\2O$,_EJMQ>:YXXU&"76YC=2*]Q_
M9EE<6&@6$DTL6D:/IUJ5MU^B?&_P]\!?$O0KOPO\1O!/A+Q]X:OXG@O?#_C/
MPYI'B?1;N*0 21W&EZU9WME,K87(>%N54]5!'Q-_P4A^ 7[6/[3/P-M?@_\
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M+#X:>"[.^L+ZS^&WB6XM+VRN[?18[BUN[6XCCGM[B"2.:":-)8G5U5A_,_\
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MPV99?.K%TJDX4JE6G&5&=6A.IAL30CS2B_\ /+_X)G_\I _V.?\ LX3X9_\
MJ265?Z6U?YI/_!,__E('^QS_ -G"?#/_ -22RK_2VK]G^FE_R6?"'_9,5O\
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M3^//B#3?$OC+2_C?XL\$V6H:7X>T;PU;IX>TGP=\/-8LK5M/T*TLK.2:._\
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MK02Y)>;[?Y]ABIW/'MZ_X?SJ4#' HHH,G)O?[N@4444""BBB@ HHHH ****
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MEMJ_P"BBBLVV]S)MO<****0!2@$]/\_6G!">O _6I  .E "*H'N?Y?2G444
M%%%%4HN7IW **4*3].YJ8*!]?6KO&&F[_KKT]/\ AR922\WV&*G<_E_C4E%%
M9MM[F3;>X4444A!1110 4444 %%%% '[,?\ !!W_ )2 ^'O^R6_$O_TVV5?W
M 5_#_P#\$'?^4@/A[_LEOQ+_ /3;95_<!7^:?TL_^3IT/^R5RC_U+S0_U5^A
ME_R:'%?]ECG7_J#DQ_E[:BI.HW_8?;;K\?W\G2O[@?\ @AGXZ^)7CK]A/29?
MB-J6KZQ!X7^)GC+P?\/=3UJ:>[N[CX?Z18>&I[&WBO;E//N[#1_$E_XHT+3]
M\UREC::7%I5O+%;:?#9VM#1O^"$'[ ^FZN-4U/2/BOXJB^T?:)=)U[XCSP:;
M<,9?->.5O#6D^'=3$4G*.(M2B?82$=&PX_6OP+X$\&_#'PAH'@'X?>&M(\(>
M#/"VGQZ7X?\ #>A6<=CI6E6,;/)Y-M;Q #=+-)+<W,\A>XN[N:>[NI9KF>65
M_?\ 'CQUX,\0^$\#PWP]EN9UL72S/#8^IF6:8/#X6&"IX>A7IRIX/EQ.(Q$Z
M^)=50JMQHTHT5).524HJ'SGT=?H\\=>&/&./XHXFS7*J&#JY1BLMIY5E&-Q6
M,GCJN)KX>K"ICG/"X;#PP^%5%U**4J]65>47RTHQDY_C%_P<#V&EW7[#OAJ[
MOF"7NF?M >!+G12 -TE]/X1^(EC<0;L@B-M*N=0G91D,]M$2N45EO?\ ! +_
M ),4U/\ [+O\0?\ U'_ U?F!_P %X/VVO"'QF\:>#?V8OA=KMKXC\,_"#7-1
M\2_$C7=+NEN]&O?B:]I<:#8>';&>+-M=S>!])NM;@U6\MY;B :MXCN](S#>:
M'?(_Z?\ _! +_DQ34_\ LN_Q!_\ 4?\  U3GO#^:</?15RJEFU&KA<1F?&&&
MSBAA:\90K4,%C?K2PGM*<DG#ZQ2HK&PB_>5/$P<E&3E&+X=XFRCB;Z8F<U<E
MKT<7ALJX'Q625\9AYQJ4,3C\ L$\;[.I%N-3ZK6KRP$YKW74PDU!R@HRE^DW
M[3O[*7PI_:Z\-^ O!7QFMM7U;P5X'^)>E?$Z3PQINI/I5CXJU/1?#GBKP[8Z
M-XBNK6-=4;02GBJYOKJVTJ^TRZN9[.VA>\%LT\4GLW@CX?> _AIH-IX6^'7@
MOPKX#\-6$:Q6>@>#_#^E>&](MD48 BT_2+6SM5)ZLXBWNQ+.S,23^?/_  5H
M_:H^)_[(W[)=U\0OA!+I5AXW\3^/= ^'%CK^J6*:FWABV\0Z+XGU.[U_2;"<
MFPN-;M$T!8--_M2"]TV"6Z-U<V%YY"0/^&7_  1E_;8_:6\:_MMZ5\,?BA\:
MOB1\3_"7Q8\+^.Q?Z-\0?%^N^+K/3->\.>']0\9Z?K7A^+6[V]7P_<I%HE[I
MDL&D?8M/N=/OC!<VDS66EM9?FW#_ (8\:\6>%F<<6T\^H4N%N%%FV,P>0U\3
MBI?6)X&G'&YQB:.%I0>$H5?9.\*]9RKXF5)47[*C"E,_4^)?%O@'@SQ@R3@J
MKP[B*W&'&3R; XWB+#X3!Q^K4\PJRP&1X6OBZTUC,11]LK3H4%##X6-9UX^V
MKU*T#]I?^"H/_!/?X8_M1_ GXA>-/#'@/1M/_:)\$^'=3\6^"?%V@:=::;X@
M\6W&A6\FI7G@GQ'/:01MXDM?$5C!=:?HPU5WGTC7KBPO;.\M;5M3MK_^%O2H
M]-FU338=9N[JPT>6_LX]5OK&TCO[ZSTV2XC6^N[.PEN;**]NK>U,LUO:27EI
M'<S(D+W,"N94_P!0!E5E*L RL"K*P!5E(P00>""."#P1P:_S&/'&D0>'O&OB
M_0+4DVNA^*/$&D6Q/4P:;JUW90DYR<F.!<Y)YK^COHA\49KFF3<6\,X_&XC$
M83)*F4XO*'6J2K5,'2S.&84<5AJ$JSJ*GAJ=3 T*]##J/LH5J^(FH?O)7_EO
MZ;7".3Y1GO!?%F78#"X;&\04LYP>=*C2A0IXZME$\LK8/%8B-%4Y5<54I9CB
M,/B,0Y>VG1H86#G^[BU_=+^R#_P3%_8.^$/@CP=XV\#^ /#WQNU#Q'X>T?Q)
MI7Q:^*%M8^.KK7=/UFQM]4TS6M T?4;0^$_#=O<6MTD^G2Z'H-GJD=G,D-]J
M=]*K3O\ IS96-EIMK!8Z=9VMA96T:Q6UG96\5K:V\2 *D<%O D<44:* JI&B
MJH    K^+W]C/XJ?\%;OCA^SUH'[-G[*%OJNB_";P?>ZUIH^,4=K:>%;[2],
MU.\?49_"<7Q8\37IBBM] N[R6?3[#P#:IXVTFUO8[3[2VD16%K;?HC^SW_P2
M1_;[\$?$?PO\7_'/[?EWX=\9:)J^FZO>QZ+??$SXNPZW;6MS'<W6@>)'\7^(
MO =MK>EZE$);#4[&^MK^QGAGF&R<;6;\;\0?#J=#-L^K>(?C;D<\TP^+QRRK
M XROFW$>;5L/"<W@?[1P66TJSR!XFDJ3^K4<-7IX:,K4Z7)!17[IX:>*$,1D
MW#M#PR\ N((93B<'EW]L9A@,/DO"^2T,3.G368/+,?FE6@N)%A:OM5]:Q&*P
M]7%SA>K652;F?JC^U_\ \$\OV;_VP_!VN:9XR\#Z#X;^(MQ9W+^&OB]X8T;3
M]-\;Z#K10M9W6H7]I%;2>*=&^T!1J/A_7I;JTN;66Y-C)IFIM;:K:_P.?%OX
M8>*O@K\3_'WPE\;VJ6GBSX=>*]:\(Z['"9&M9;W1;Z:S:]L)98X7N-,U&../
M4-+NS$@O-.N;:Z10DRU_IFU_#%_P6_\ #-EH7_!0[XGWMG"D'_"5^$_AEXDO
M%CX62]/@G2M!FGV#Y4>9=!CDEP 9)C).X,DKNWW'T2>.<ZJ9]F_!./Q^)QF3
MRR6KF^6T<36G7678K!8O!X>K1PGM)2='#8JAC95*M&#]E&KAJ<X4XRJ5IS_/
MOII^'V04>',EX_R_+L+@<[AGU')<UKX2A3P[S3!X_!8[$T:^-5.,57Q6#Q&!
MC3HUYKVTJ.*J4ZE2<*5"%/\ 5[_@DE_P2B^#4GP<\"?M/?M%^#K#XD>-?B):
M6WC'X>^"_$\+7O@SPCX/N2TGAO5M1\.RG^S?%.M^);$Q>((SKT.I:/I^EWVD
M)::;%JD-U>O_ $1:9IGAGPI:VFD:/I^A>&[*:3R;'3-,M-/T>UEE"Y\JTLK6
M.VB>0(,^7#$6"CI@5\G?\$\?B?X3^+7[%'[-?B/PA>VEU;:/\(O W@36[2UD
MC+:)XK\ >&]-\)>)=%N8$=Y+1[/5-)G>TBN!'+/I<^GWZI]GO('?XZ_X*8_\
M$I[[]N?Q1X>^*G@KXP7/@?XA^%?"D7A.S\->+;:^U?X=ZG8VNHZCJEM/;2:=
M(=5\':I+=:G,NJZE8Z=K]OJ4%KIZG2+>YMY;RX_&.)LVQ/'WB?G6"\2>,,=P
MO@*.;9O@J5;$8#&9M@\B6$Q-6C@\NI930Q&&^K4$Z<*57$0LW-2Q6*<YU*M8
M_=^$LFPOAOX1Y#F'A5P/E_%^95\ER/'UL/A<RP.2X_B+Z[A:%?'YI6SK$87%
M?6L1:I.M1PL[KV?+A,'&G"E1PY]3?M??L8_L4?&3X>^.O%G[0?P[\#^&+;2-
M!U37_$'QGT:PTSP?X[\,66EVTM[<ZZWC+3K$7NH#3TB>X33M=BUW2KN3,$^D
M7OGF"3^!G5?#^F:U\1=2\+?"E?$?BO1M6\:7?A_X;IJ.FPP>+?$FFW^N2:=X
M02^T?3I;J"'Q%K%M+IZW.FV,UQ%'J5P]M;22H$9OT;_:T^'W_!3;]E?X/W'[
M/'Q_U_XB7W[-M_X@TI]/OK+6U\<_##5+S2I);C0]*L?&;6\^O>']*-U&^I6'
M@#7+CPY;7=_80:R?"TEWIMK>0=1_P1 ^$^D?%#]O;PAJ6MVT5]9_"/P3XP^+
M$%G<0)/;RZOI1TGPGH%RZN"(Y='UWQEIVO6$ZX>'4]*LI%(*U_6_AGE=?PH\
M.^,>*L3QU2X\R3"X/$X_(:&6XZIB<FIX;+\+*5"G2565=X',,PQ4X87%X6A6
MGA\)&G1YI5:KFZ?\2^+6<8;QG\3^!>#L+X=UO#C/\;CL)EO$>)S;+J6$SVKB
MLSQD(5ZE;V4,.LQRS+,'3GB\#C,10ABL;*I6Y(4:*IJK^\'_  3\_P"".?P4
M_9[\(^'_ !U^T#X2\/?%WX]ZE9VNIZC:>)[2U\0>!?AQ<7,*3'P_X>\/W7VK
M0];U?2Y&$=[XNU2VOYFU"W\WPTNDVJM+??M+!I]A;64>FVUE:6^G10"UBT^"
MVABLH[4)Y8MH[6-%@2 1_((5C$83Y0NWBH-:_MC^Q]6_X1X:<VO_ -FW_P#8
M:ZP]S'I+:Q]EE_LP:I)9Q37D>G&]\@7SVL,MRMMYK0122A4/\NGC'_@C1_P4
M>\>_%BZ^.'B7]KCX977Q3GUE]=MO&5MXT^+ECJ^C7GVH7=K!X=GL_ T)\/:9
MIKK%#I.E:1]DT[2[2WMK2RMH;>"*-?X_P==^+6<9SG/B)XG8+AJK12J8!9GA
ML=CZ52K7=24<%E>7X:K2H9=EV&C3C&K4A/F@ZE*4:&*JSK5(_P!Q8[#KP5R/
M(<A\+_"3'\64:SE2S*648K+LMK4J.'C1C/,,XS/%4:N(S3-,9*I*5&G.GR35
M&K&>)P=&&'IR_3W]O7_@E'\!OVK/!'B+7? /@[PO\+/V@+.RN]1\+^-O"^EV
MGA_3?%.KQHTZ:)\1--TN*VL=:L]:=%LCXEGMI/$6A2/;WL%W>:?;76B:C_#G
MKWA[6/"FO:UX8\1Z=<Z1XA\.:OJ6@ZYI-ZGEWFEZSH]Y-I^IZ==QY.RYLKVW
MGMITR=DL3+GC-?Z77PYLO&NF_#WP)IWQ)U/2-;^(EAX.\,V7CW6= CGBT+5_
M&=KHME!XHU318KJWM+F+2K_6X[Z[T^.XM;:=+2:%9;>%PT:_PJ?\%=/!4'@7
M_@H;^T;86=O%;V6NZ[X8\:P"&-(DGG\:^!?#'B76+@H@ \V77]1U8W$C#?-<
M"6=RS2%C_0_T4^.\[QV:Y]P#FN:5,VP&7Y=4S;)J]:O5Q#PL,'CL-@,7A\'7
MKKVLL#B5C</B,/0GRQH>RJ3I4X>WJH_E_P"F7X<9!@,FX;\2<FRBEDF89EFE
M/)<_PV'P]'"_6YX[+L5F6"Q6-H8>]&.881Y?BL+B<1#FGB%6I0K5:BP]%GYN
M5[C^SK^T3\4OV6?BMX>^,?P@UM-'\6:#Y]O+;WD4MWH7B+1;T(NI^&_$VF17
M%K_:NA:FD<1N;47%O<07,%IJ6G75CJMA87UMX=17]J8W 8+,<%BLNQ^%H8S
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MO"7'.'I6HYWEM?(,RG!6BL?D]3ZS@JM9VUJXO XZI1A9O]UE=FH\J<O[//\
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MBBBIE)+S?];@%%%%9-M[@%%%%( HI0">!4BH!R>3_*@ER2]>B&A">O _6I
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MHHH **** "BBB@ K^]C_ (-[?^4<OAO_ +*U\4__ $Z6%?P3U_>Q_P &]O\
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M?YA_A_\ Y#VB?]A?3?\ TMAKZ#Z%W_),\?\ _8URS_U7XL\3Z7'_ "47 _\
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MYO=[RDWN_4_RB?%__(V^*/\ L8M;_P#3G=5_IM?L3?\ )F?[(_\ V;'\!/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH _O8_X-[?^4<OAO\ [*U\4_\
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M"7C+0-'\4^%]>TZ0RZ?K?A[Q!I]OJNC:M92,J,]IJ.G7=M=V[,BLT4R%E4Y
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M\:/:FSOX3;NB-%L*@C,^/7[0GP=_9D^'&M?%;XW^.M%\">#-$A=GO-3G!O\
M5KT(SP:+X<T>'S-3\1:]>E=EEH^D6MW?3G=)Y2P132Q_!^+?CIF/C5DO"7">
M X9Q&%Q^'Q]'&XVGAJLLPJYKGCPE3+Z%+*\+0P\:T*+^M8R<*4O;5IRKTJ27
M[AU*WVOA?X,8#PAS?BCB?&\14,3@J^"JX/!U,12C@:66Y,L53QU:IF.)K5Y4
MI5D\-A82J1]E2C&A4J-_OE3H_P Z/_!SGX_TNV^&_P"RS\+5ND?6M9\;^//'
M\MDF&DM]+\-:#I?AVWNKC!W0I>7?BNYBL\KBX:QOMIS:L*_(_P#X(3_M$?\
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M>'7$G#M.DJF83P;Q^3:)SCG&6OZW@80;^#ZW.G+ 5)ZM4,76LG<_F?PHXO?
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M^<\,87AG/\;D]#'95CJV*IX1T4JU6GBZ=.$Y2J4IR4HP;BG&4;)GZ(?M2_\
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M/B+;PW<:$O%))8^/+:>(2@,UO)$RY3;7\"%?LS_P1J_X*0Z;^PG\9-=\*?%
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M[6[@Z=6E*M2<&HRC*BI)R4VH?U_5_E<:;_R6JP_[*C:_^I9'7^J/7^5QIO\
MR6JP_P"RHVO_ *ED=?8_0O\ @\4O^P'AC\N)CY;Z6_\ $\-?^PWB+_TKAT_U
M1Z_S[_\ @O-_RDX^.7_8N_!W_P!5%X,K_00K_/O_ ."\W_*3CXY?]B[\'?\
MU47@ROBOH;_\G3S7_LB,V_\ 5SPZ?7?2Q_Y-MEG_ &6.6?\ JHSX_H._X-NO
M^3"?&_\ V<Y\0?\ U7GPCKKO^#B'_E'A<_\ 9;OAE_Z(\35R/_!MU_R83XW_
M .SG/B#_ .J\^$===_P<0_\ */"Y_P"RW?#+_P!$>)JY<7_REQ#_ +.;@O\
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MV'I9;2H8.G2EA,)0Y8TZ5.:U^L1^LNM=55G9412S,0JJH+,S,<!5 R222
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MOL/K/L</[?V?-R^T]A2YK7]G'8_RTXVX=_U.XMXBX6>,_M%Y!FV-ROZZL/\
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M5::C:7(*365[KIN]4\:7.GS0,]M<Z;-XH?3[VWDDBOK:Y5S7YMZE_P A&_\
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MP^\3>)=2ECLM/TC2_$MO;V.J:1J6LW[I!INGZ]H<%C]HN;;38_$%]?2PB?\
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M2]"EFA9PKF*1[!GC+J&*,I8 Y%);_!OX06OCJ7XH6OPJ^&]M\2Y_,$_Q$M_
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M*SC&5%3P]#/*^8T<QPF*Q]:2Y*5#%5EBL+4KU'"E1K8RE6KU*5"%6I']T_\
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M^]C_ "W"BBB@ HI0">!4BH!R>3_*KLHZRU?1?Y_UTZDN27KT0U4)Y/ _G4@
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M\?CL9CITDXTYXS%5\3*G%N[C"5:<W!-I-J+2;5WJ?60_;W_;I  '[:7[60
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M_-L?C,-'E:<>6AB,14I+E:35HZ-)K4****^A/#"BBB@ HHHH **** "BBB@
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M_&O]N7]K_P#:+TV30OC1^T5\4_'?AR=HWN/"E]XGN].\'W4D+;X9KOPAH?\
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MN)J2C2C3H4:M4HHHK^KS^9 HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)!1117><04444 %%%% !12A2>GY]JE"@>Y]?\/2@F4DO-]O\^PU4[G\O\?\
M#_\ 54E%%!DVWN%%%% @HHHH **** "BBB@ HH SP*E5.YY]O3_'^5)R2W^[
MJ)R2W^[J,"D^P]:E  Z4M%9.3?DNW^?<R<F_)=O\^X4445)(445(J=S^7^-
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M@\QP>%Q^$K)*KA<;AZ.*PU5)W2J4*\*E*:3U2E%V>IYV$S'&Y=B:>+RW&8K
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M[]J$J000?C_\5R"",$$'Q;@@C@@\$5\O45YF+R7)\PJJOC\IRS&UU!4U6Q>
MPN)JJ$6W&"J5J4YJ$6VU&]DVVE=L]+!9]GF6T7A\NSG-<!AW.51T,%F.,PM%
MU)*,95'2H5J<'.48Q4IN/,U&*;:2LI))))))))).22>223R23R2>M)117IGE
M!7M7P_\ VD_VBOA-H4GA?X5_'SXU?#/PS+J%QJTOAWX?_%/QSX,T*35;N*W@
MNM3DTCPYKNFZ>^H7,%I:0W%XUN;F:*UMXY)&2&,+XK17-B\%@\?2^KX["8;&
MT.:,_8XNA2Q-+GC?EG[.M"<.:-WRRY;J[LU<Z\%C\=EU;ZSE^-Q> Q')*G[?
M!8FMA:W).W-#VM"=.?)*RYH\UG973LCV?XA?M'_M#_%S1(/#/Q7^//QG^)WA
MNUU*#6;;P_\ $+XH^./&FB6^KVMO=VEMJL&E>)-=U*PAU*WM+^^M8+Z.W6ZB
MM[V[ACE6.XF5^!\%^.?&WPV\2:=XR^'?C'Q3X!\8:0+L:3XK\%^(-6\+>)-,
M%_97&FWPT[7=#N['5+(7NG7=W878MKJ+[3975Q:S;X)Y8VY:GA">O _6LZ67
M9;AL+4P-# 8*A@JL:D:N#HX6A3PM2-:/)5C/#PIQI3C5B^6HI0:G'25T:5\U
MS/$XRGF.)S''XC,*,J4J..KXS$5<92E0DIT)4\34J2K0E1DE*DXS3IR2E!IZ
MGU /VX/VU#T_:^_:B_\ #_\ Q8_7_BK:^:)YI[NXGN[N>:ZN[J:6XN;FYE>>
MXN+B9VEFGFFE9I)9I9&:2661FDD=F=F+,28@ .E+6&$RW+,N=7^SLNP&7^V4
M55>"P>'PKJJ'-R*JZ%.'.H<TN52OR\TK;N]8_.,VS54EF>:9CF*H.;HK'X[$
MXQ474Y54=)8BK45-S4(<[A;FY(\U^56^C?@C^UW^TS^SA!=V7P1^-7COX?:5
M?W#7EYH&E:L;KPQ<WSK&CZA+X7U:+4?#S:B\<,44FH'3/MCPQI \[1*$J_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY+\_4RE)OR7Y^H4445)(444]4)Y/ _G0 T G@5*J@>Y_E]*4 #@4M !1110
M444H4GZ=S6BA;673I_G_ ) W;5B5($]?R_\ KTX*!]>YIU)SZ1T7?^MOZV,I
M3Z+3S[_Y?F%%%%00%%%% !1110 4444 %%% &>!0 4X*3[#UIZIW//MZ?X_R
MI] "  =*6BB@F4DO-]O\^P4444&3;>X4444""BBB@ HHHH *4 GI_GZTY4)Y
M/ _G4@ ' J)32T6K_(!%4#W/\OI3J**S;;U8!1112 * ">E.52?8?S^E2@ =
M/\_6FDWL1*:6BU?];C50#D\G^5/HHK2,$M7J^W3_ ()FVWJPHHHJQ!1114RD
MEYOM_GV ****R;;W ***4*3].YI )4@3U_+_ .O3@H'U[FG4 %%%% !1110
M445(J=S^7^- FTMQH4GV'K_AZU*% Z?GWI:*#*4F_)=O\^X4444$A1110 44
M44 %%%% !113E4GV'\_I2;2U8FTM6( 3P*D5 .3R?Y4X #I_GZTM9RFWHM%^
M+,Y3;T6B_%A1114I-[?UZD!113@I/L/6M%%1U>_];?U<!H&>!4JH!R>3Z=O_
M *].  Z4M3*;>VB_$ HHHJ "BBB@ HHHH **** "BBE )Z?Y^M "4\(3UX'Z
MT]5 ]S_+Z4Z@SE/^7[_\O^"( !TI:**#,**** "E"D_3N:>$]?R_^O4E #0H
M'U[FG444 %%%% !11101*=M%KY]/^"%%%%!DW?5A1110 4 9X%."D^P]:E
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MJ3[#^?TIX0#KR?TI]9RG_+]_^7_! 0 #I_GZTM%%9@%%%% !11101*:6VK_
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MAEH_XB#?@7_TBS^$W_ATO!__ -#+1_K[XN_]&&Q__BQ^"/\ YH#_ %)\+?\
MH]>!_P#$ XQ_^4>O]/3^8RBOZ<_^(@WX%_\ 2+/X3?\ ATO!_P#]#+1_Q$&_
M O\ Z19_";_PZ7@__P"AEH_U]\7?^C#8_P#\6/P1_P#- ?ZD^%O_ $>O _\
MB <8_P#RCU_IZ?S&45_3G_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P"(@WX%_P#2
M+/X3?^'2\'__ $,M'^OOB[_T8;'_ /BQ^"/_ )H#_4GPM_Z/7@?_ ! .,?\
MY1Z_T]/YC**_IS_XB#?@7_TBS^$W_ATO!_\ ]#+1_P 1!OP+_P"D6?PF_P##
MI>#_ /Z&6C_7WQ=_Z,-C_P#Q8_!'_P T!_J3X6_]'KP/_B <8_\ RCU_IZ?S
M&45_3G_Q$&_ O_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\ _0RT
M?Z^^+O\ T8;'_P#BQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F,HK^G/\
MXB#?@7_TBS^$W_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P!??%W_
M *,-C_\ Q8_!'_S0'^I/A;_T>O _^(!QC_\ */7^GI_,917].?\ Q$&_ O\
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M_P#$ XQ_^4>O]/3^8RBOZ<_^(@WX%_\ 2+/X3?\ ATO!_P#]#+1_Q$&_ O\
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M^: _U)\+?^CUX'_Q .,?_E'K_3T_F,HK^G/_ (B#?@7_ -(L_A-_X=+P?_\
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M$&_ O_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\ _0RT?Z^^+O\
MT8;'_P#BQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F,HK^G/\ XB#?@7_T
MBS^$W_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P!??%W_ *,-C_\
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MWQ=_Z,-C_P#Q8_!'_P T!_J3X6_]'KP/_B <8_\ RCU_IZ?S&45_3G_Q$&_
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MI&E2ASU*,(1YIS4>:<HP5[RE%7:_DRHK^G/_ (B#?@7_ -(L_A-_X=+P?_\
M0RT?\1!OP+_Z19_";_PZ7@__ .AEK?\ U]\7?^C#8_\ \6/P1_\ -!A_J3X6
M_P#1Z\#_ .(!QC_\H]?Z>G\QE%?TY_\ $0;\"_\ I%G\)O\ PZ7@_P#^AEH_
MXB#?@7_TBS^$W_ATO!__ -#+1_K[XN_]&&Q__BQ^"/\ YH#_ %)\+?\ H]>!
M_P#$ XQ_^4>O]/3^8RBOZ<_^(@WX%_\ 2+/X3?\ ATO!_P#]#+1_Q$&_ O\
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M^: _U)\+?^CUX'_Q .,?_E'K_3T_F,HK^G/_ (B#?@7_ -(L_A-_X=+P?_\
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M$&_ O_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\ _0RT?Z^^+O\
MT8;'_P#BQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F,HK^G/\ XB#?@7_T
MBS^$W_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P!??%W_ *,-C_\
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MWQ=_Z,-C_P#Q8_!'_P T!_J3X6_]'KP/_B <8_\ RCU_IZ?S&45_3G_Q$&_
MO_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\ _0RT?Z^^+O\ T8;'
M_P#BQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F,HK^G/\ XB#?@7_TBS^$
MW_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P!??%W_ *,-C_\ Q8_!
M'_S0'^I/A;_T>O _^(!QC_\ */7^GI_,917].?\ Q$&_ O\ Z19_";_PZ7@_
M_P"AEH_XB#?@7_TBS^$W_ATO!_\ ]#+1_K[XN_\ 1AL?_P"+'X(_^: _U)\+
M?^CUX'_Q .,?_E'K_3T_F,HK^G/_ (B#?@7_ -(L_A-_X=+P?_\ 0RT?\1!O
MP+_Z19_";_PZ7@__ .AEH_U]\7?^C#8__P 6/P1_\T!_J3X6_P#1Z\#_ .(!
MQC_\H]?Z>G\QE%?TY_\ $0;\"_\ I%G\)O\ PZ7@_P#^AEH_XB#?@7_TBS^$
MW_ATO!__ -#+1_K[XN_]&&Q__BQ^"/\ YH#_ %)\+?\ H]>!_P#$ XQ_^4>O
M]/3^8RBOZ<_^(@WX%_\ 2+/X3?\ ATO!_P#]#+1_Q$&_ O\ Z19_";_PZ7@_
M_P"AEH_U]\7?^C#8_P#\6/P1_P#- ?ZD^%O_ $>O _\ B <8_P#RCU_IZ?S&
M45_3G_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P"(@WX%_P#2+/X3?^'2\'__ $,M
M'^OOB[_T8;'_ /BQ^"/_ )H#_4GPM_Z/7@?_ ! .,?\ Y1Z_T]/YC**_IS_X
MB#?@7_TBS^$W_ATO!_\ ]#+1_P 1!OP+_P"D6?PF_P##I>#_ /Z&6C_7WQ=_
MZ,-C_P#Q8_!'_P T!_J3X6_]'KP/_B <8_\ RCU_IZ?S&45_3G_Q$&_ O_I%
MG\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\ _0RT?Z^^+O\ T8;'_P#B
MQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F,HK^G/\ XB#?@7_TBS^$W_AT
MO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P!??%W_ *,-C_\ Q8_!'_S0
M'^I/A;_T>O _^(!QC_\ */7^GI_,917].?\ Q$&_ O\ Z19_";_PZ7@__P"A
MEH_XB#?@7_TBS^$W_ATO!_\ ]#+1_K[XN_\ 1AL?_P"+'X(_^: _U)\+?^CU
MX'_Q .,?_E'K_3T_F,HK^G/_ (B#?@7_ -(L_A-_X=+P?_\ 0RT?\1!OP+_Z
M19_";_PZ7@__ .AEH_U]\7?^C#8__P 6/P1_\T!_J3X6_P#1Z\#_ .(!QC_\
MH]?Z>G\QE%?V$>#_ /@L/\"_%G[,?Q?_ &CO^'<7PFL/^%4^,O!7A+_A#?\
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M_P#]#+7H_P"OOB[_ -&&Q_\ XL?@C_YH//\ ]2?"W_H]>!_\0#C'_P"4>O\
M3T_F,HK^G/\ XB#?@7_TBS^$W_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\
M^AEH_P!??%W_ *,-C_\ Q8_!'_S0'^I/A;_T>O _^(!QC_\ */7^GI_,917]
M.?\ Q$&_ O\ Z19_";_PZ7@__P"AEH_XB#?@7_TBS^$W_ATO!_\ ]#+1_K[X
MN_\ 1AL?_P"+'X(_^: _U)\+?^CUX'_Q .,?_E'K_3T_F,HK^G/_ (B#?@7_
M -(L_A-_X=+P?_\ 0RT?\1!OP+_Z19_";_PZ7@__ .AEH_U]\7?^C#8__P 6
M/P1_\T!_J3X6_P#1Z\#_ .(!QC_\H]?Z>G\QE%?TY_\ $0;\"_\ I%G\)O\
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M6?PF_P##I>#_ /Z&6C_7WQ=_Z,-C_P#Q8_!'_P T!_J3X6_]'KP/_B <8_\
MRCU_IZ?S&45_3G_Q$&_ O_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+
MP?\ _0RT?Z^^+O\ T8;'_P#BQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F
M,HK^G/\ XB#?@7_TBS^$W_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH
M_P!??%W_ *,-C_\ Q8_!'_S0'^I/A;_T>O _^(!QC_\ */7^GI_,917].?\
MQ$&_ O\ Z19_";_PZ7@__P"AEH_XB#?@7_TBS^$W_ATO!_\ ]#+1_K[XN_\
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MIZ?S&45_3G_Q$&_ O_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\
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MAEH_XB#?@7_TBS^$W_ATO!__ -#+1_K[XN_]&&Q__BQ^"/\ YH#_ %)\+?\
MH]>!_P#$ XQ_^4>O]/3^8RBOZ<_^(@WX%_\ 2+/X3?\ ATO!_P#]#+1_Q$&_
M O\ Z19_";_PZ7@__P"AEH_U]\7?^C#8_P#\6/P1_P#- ?ZD^%O_ $>O _\
MB <8_P#RCU_IZ?S&45_3G_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P"(@WX%_P#2
M+/X3?^'2\'__ $,M'^OOB[_T8;'_ /BQ^"/_ )H#_4GPM_Z/7@?_ ! .,?\
MY1Z_T]/YC**_IS_XB#?@7_TBS^$W_ATO!_\ ]#+1_P 1!OP+_P"D6?PF_P##
MI>#_ /Z&6C_7WQ=_Z,-C_P#Q8_!'_P T!_J3X6_]'KP/_B <8_\ RCU_IZ?S
M&45_3G_Q$&_ O_I%G\)O_#I>#_\ Z&6C_B(-^!?_ $BS^$W_ (=+P?\ _0RT
M?Z^^+O\ T8;'_P#BQ^"/_F@/]2?"W_H]>!_\0#C'_P"4>O\ 3T_F,HK^G/\
MXB#?@7_TBS^$W_ATO!__ -#+1_Q$&_ O_I%G\)O_  Z7@_\ ^AEH_P!??%W_
M *,-C_\ Q8_!'_S0'^I/A;_T>O _^(!QC_\ */7^GI_,917].@_X.#/@8>G_
M  2R^$WU_P"%I>#\?^LRT_\ XB"O@7_TBT^$W_ATO!__ -#-1_K[XN_]&&Q_
M_BQ^"/\ YH$^"_"Q;^-F!_\ $ XQ?;_J']?ZV_F,5.Y_+_&I*_IO_P"(@KX%
M_P#2+3X3?^'2\'__ $,U'_$05\"_^D6GPF_\.EX/_P#H9J/]??%W_HPV/_\
M%C\$?_-!#X*\+'OXVX'_ ,5_QEY?]./7\/E_,A17]-__ !$%? O_ *1:?";_
M ,.EX/\ _H9J/^(@KX%_](M/A-_X=+P?_P#0S4?Z^^+O_1AL?_XL?@C_ .:"
M?]2/"O\ Z/;@?_%?\8__ "CU_IZ?S(45_3?_ ,1!7P+_ .D6GPF_\.EX/_\
MH9J/^(@KX%_](M/A-_X=+P?_ /0S4?Z^^+O_ $8;'_\ BQ^"/_F@/]2/"O\
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M_P##H^$/_H::/^(@+X&_](NOA1_X='PA_P#0TT?Z^>+?_1B,?_XL;@G_ .:
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M_P#1B,?_ .+&X)_^:"'P3X3]/'+ +_O'G&G_ ,S^I_,[17],7_#_ /\ @?\
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M[ ?ZB^$__1\\!_XKSC3_ .9_7^GI_,^% ^O<TZOZ7O\ A_Y\#_\ I%]\*?\
MPZ'A#_Z&JC_A_P"? _\ Z1??"G_PZ'A#_P"AJK-\=^+3U?@7C_\ Q8G!7_S0
M'^HOA/\ ]'SP'_BO.-/_ )G]?Z>G\T-%?TO?\/\ SX'_ /2+[X4_^'0\(?\
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M_'P/_P"D7_PI_P##G^$/_H:Z3X^\6NG@5CU_WD7@I_\ NP4N O";KXYX%_\
M>.^-%V_ZA_7MTVZ?S2  =*6OZ6O^'_'P/_Z1?_"G_P .?X0_^AKH_P"'_'P/
M_P"D7_PI_P##G^$/_H:ZS_U[\6O^C%X__P 6)P5_\T#_ -1_"5:?\1SP"M_U
M;OC73[L/Z_T]/YI:*_I:_P"'_'P/_P"D7_PI_P##G^$/_H:Z/^'_ !\#_P#I
M%_\ "G_PY_A#_P"AKH_U[\6?^C%X_P#\6)P5_P#-!#X%\)GOXZX'_P 5UQKY
M?]0_]:=]/YI:*_I:_P"'_'P/_P"D7_PI_P##G^$/_H:Z/^'_ !\#_P#I%_\
M"G_PY_A#_P"AKH_U[\6?^C%X_P#\6)P5_P#- O\ 43PE_P"CZX#_ ,5UQK_\
MS^O]/3^:6@#/ K^EP?\ !?;X'G_G%_\ "D#U_P"%G^$/_H:Z?_P_U^!XZ?\
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M/_A_E\$/^D8?PJ_\.=X1_P#H;:^FOV2?^"L_P0_:E^,-G\)_^'>GPJ\"_:]
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MBOZ3/^']GP1_Z1C?"O\ \.;X1_\ H;Z/^']GP1_Z1C?"O_PYOA'_ .AOJ?\
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MHK^C?_A^W\%?^D:7PN_\.5X3_P#H=*/^'[?P5_Z1I?"[_P .5X3_ /H=*/\
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MV\5WK_Q _'6_[.#P8OSQ!#\/_!I[?2%R]?\ >,>//+K]6]?Z>G\Y]%?T8?\
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M]'^O'BK_ -&0QW_BP>#/_F@/^(=^#'_20V7?^*PX]_\ F8_G6H )Z5_16/\
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MF]\,O_#D>%?_ *'FG_\ #\?X-?\ 2-_X9?\ AR/"O_T/5'^N_BI_T9+'?^+
MX._^7^O]/1/P\\%5O](G+?\ Q5_'_P#\R^OW?=_.V$)Z\#]:D  Z5_1!_P /
MQ_@U_P!(W_AE_P"''\*__0]4?\/Q_@U_TC?^&7_AQ_"O_P!#U1_KOXJ?]&2Q
MW_BP.#O_ )?Z_P!/2'X=^"KW^D7EOI_Q"[C_ ,O^H;U_IZ?SP45_0_\ \/Q_
M@U_TC?\ AE_X<?PK_P#0]4?\/Q_@U_TC?^&7_AQ_"O\ ]#U1_KOXI_\ 1DL=
M_P")_P &_P#S03_Q#GP4_P"DBLM_\5=Q_P#_ #+Z_P!/3^>"BOZ'_P#A^/\
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M]?Z>D?\ $./!/_I(W+?_ !5GB!_\S>O]/3^>2BOZ&_\ A^'\&O\ I'!\,O\
MPX_A7_Z'NG#_ (+@_!L_\XX/AD!Z_P#"QO"O_P!#W2_UW\5%OX)8W_Q8'!WX
M?O\ 7K_3T/\ B''@G_TD;EO_ (JSQ _^9O7^GI_/$!G@5*J=SS[>G^/\J_H;
M_P"'X/P;'3_@G%\,A_W4;PM_]#Y1_P /P?@Y_P!(X_AG_P"''\+?_0^4?Z[>
M*C_YLGCDO+Q X.3Z=?;^O9^>KL?\0X\$_P#I(S+?_%6^('_S*?SST5_0Q_P_
M!^#G_2./X9_^''\+?_0^4?\ #\'X.?\ 2./X9_\ AQ_"W_T/E'^N_BI_T9+&
M_P#BP.#?+_I_Z_AWT/\ B'/@G_TD9EO_ (JWQ _^93^>>BOZ&/\ A^#\'/\
MI''\,_\ PX_A;_Z'RG#_ (+?_!T_\XX_AF!Z_P#"QO"WZ?\ &/G-'^N_BHM7
MX)8W_P 6!P=Y?]/_ %_#OH/PY\$UJ_I&9;_XJWQ _P#F4_GEJ14[G\O\:_H8
M_P"'WWP<_P"D<GPS_P##C>%O_H?*/^'WWP<_Z1R?#/\ \.-X6_\ H?*A\<^*
M;V\%,<O^[_X.\O\ I^O/\.[(?AUX)/;Z1V6K_O%GB#_\RG\]=%?T*?\ #[[X
M.?\ 2.3X9_\ AQO"W_T/E'_#[[X.?](Y/AG_ .'&\+?_ $/E3_KMXI?]&4QW
M_B?\'?\ R_U_IZ1_Q#?P1_Z2.RW_ ,59X@__ #*?SUT5_0I_P^^^#G_2.3X9
M_P#AQO"W_P!#Y1_P^^^#G_2.3X9_^'&\+?\ T/E'^NWBE_T93'?^)_P=_P#+
M_7^GH?\ $-_!'_I([+?_ !5GB#_\RG\]=%?T*?\ #[[X.?\ 2.3X9_\ AQO"
MW_T/E+_P^_\ @[_TCE^&G_AQO"W_ -#[1_KMXI?]&4QW_B?\'?\ R_U_IZ'_
M !#?P1_Z2.RW_P 59X@__,I_/517]"O_  ^_^#O_ $CE^&G_ (<;PM_]#[1_
MP^_^#O\ TCE^&G_AQO"W_P!#[1_KMXI?]&4QW_B?\'?_ "_U_IZ'_$-_!'_I
M([+?_%6>(/\ \RG\]5%?T*_\/O\ X._](Y?AI_X<;PM_]#[2C_@M]\'CT_X)
MR_#3_P .-X6_^A]IKC3Q3>W@ICM-_P#C/^#OUQ'K^'?0_P"(<>"/_21V6_\
MBK/$'_YE/YZ:>J$\G@?SK^A;_A]W\'?^D<WPT_\ #C>%O_H?:/\ A]W\'?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@@**** "BBB@ HHHH **** "G!2?8>O\ AZTY4[G\O\:DJ)3Z+[_\N_\
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M444 %%%% !12A2?IW-2A0/KW-!,I)>;[#0GK^7_UZDHHH,FV]PHHHH$%%%%
M!1110 4444 %% !/2I0@'7D_I0)R2W^X8JD^P_G]*E  Z?Y^M+109.3?IV_K
M<****"0HH SP*E5.YY]O3_'^5 # I/L/6I0 .E+10 4444 %%%%)M+=B;2W8
M4445G*;>BT7X_,RE-O1:+\?F%%%%02%%%/5">3P/YT - )X%2*@')Y/\J< !
MP*6@ HHHH ***4*3T_/M6BAUE]W^; 2I%3N?R_QIP4#W/K_AZ4ZDY]%HN_\
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M3U_+_P"O4E #0H'U[FG444 %%%% !11101*=M%KY]/\ @A11109-WU84444
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M *!J'WU/_DA?\44_!K_H\/B=_P"$/"O_ ,[?7^EK]O\ _";^#_\ H9=&_P#
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M^= #0">!4BH!R>3_ "IP ' I: /S7HHHK](/[ "BBB@ HHHH **** "BBB@
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M "-3Q\#M?(!_M?1^?^OW_P"1J3SC+%OC*:^4_P#Y$:RO'O;"U/OA_P#)'O\
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M_P"@.K]\/+^_Y_U9GSI17T?_ ,,T^*_^@]X>_/4O_D&G_P##,OBS_H/^'?\
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M#_P&K_\ *_/\^S*_U=SI_P#,OK??3_\ DSY3HKZM'[)'C5LX\2>%N/5M6_\
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M ()^_$MAG_A-/ PYQ]_7_P#Y35]M_KOPIM_;6%_\!K__ "G^OD?&?ZF<4?\
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MOX"Y_P!OQ#_\I:C_ %ZX2_Z'>%_\!Q'_ ,I(_P!1^*_^A+BO_ \/_P#+O/\
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M?K7Z.+_P34^*N,_\)W\/3]7\1^O_ & J?_P[6^*W_0]_#W_OYXD_^45'^O\
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M4!_Q#WC/_H08S_P/#?\ R_S_ #[,_,^BOTS'_!+WXN$X_P"%@_#G_OKQ-_\
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M@M^'/&Z6G#N,\O?PJ73_ *?KO^?F?EY17ZC#_@E1\8B<?\+%^&G_ 'WXI_\
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M_K4_*>BOU;'_  22^-1 /_"R?A=S_P!-/%G_ ,SE/'_!(_XU$ _\+*^%W/\
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M.BOUL_X= ?&[_HIOPK_[^>+O_F;J1?\ @C[\;NI^)OPK^GF>+OU_XINON?\
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M\QKPB\2'MPGF'_@S!_\ S5YGX[T5^Q0_X(P_'8D#_A:?PEY_V_&/_P S-/\
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M_P"#<!_\V>?Y]F?B#2@$\"OW '_!"C]H8X/_  M_X,<\_P"L\<?_ #)U,O\
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M^'!_[1W_ $6/X)?]_?'?_P R%)^-GA6G9\9Y9_X+QW_S("\!?%Y_\T-FNO\
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M<95_X*Q__P QA_Q+GXV_]&]SG_P=EG_S=Y_GV9_/[17] 8_X-XOVFR<#XV_
MG_O[\0/_ )C:=_Q#O_M-_P#1;?@1_P!_/B!_\QM1+QX\)=;<;Y5;J_9X_P##
M_8_^"/\ XER\;?\ HWN<_P#@[+/+_J.\_P"K,_GZHK^@8?\ !N_^TT2!_P +
MN^!//_33X@?_ #'4_P#XAW/VG/\ HMWP(_[^?$#_ .8VLO\ B._A'_T7&5?^
M"LP_^8Q_\2X^-W_1O,Y_\'99_P#-Y_/M17]!/_$.Y^TY_P!%N^!'_?SX@?\
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MI0I/T[FOZ!1_P;P?M-]_C9\"#_VU^((_]TRG_P#$/'^TW_T6OX$?]_?B!_\
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M .O(_G_" =>3^E/K]_O^(>;]IK_HM?P)_P"_OQ _^8RC_B'F_::_Z+7\"?\
MO[\0/_F,K-^.OA*]^.,J_P#!>/\ _F,S?T;O')[^'6=?^#LL_P#F\_ &BOW_
M /\ B'F_::[_ !L^!/\ W]^(!_\ =-%'_$/-^TS_ -%L^!7_ '\\?_\ S'4+
MQT\).O'&5+_N'C[_ /J&+_B6WQQ_Z-UG7_@W+/\ YO/P H SP*_?_P#XAYOV
MF?\ HMGP*_[^>/\ _P"8ZGC_ (-Z?VF!T^-7P*_[^^/_ /YC:T_XCOX1I>[Q
MOE7_ (+Q_P"/^QA_Q+;XX_\ 1NLZ_P#!N6?_ #>?@$J=SS[>G^/\J?7[]_\
M$/5^TS_T6OX%?]_?'_\ \QM'_$/5^TS_ -%K^!7_ ']\?_\ S&UF_'7PE>_'
M&5?^"\?_ /,8?\2V^./_ $;K.O\ P;EG_P WGX"45^_?_$/5^TS_ -%K^!7_
M ']\?_\ S&T?\0]7[3/_ $6OX%?]_?'_ /\ ,;2_XCIX2_\ 1;Y5_P""\?\
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MO@7_ -_?'_\ \QU*/^#>W]I?O\:O@6?^VOC\?^Z;1_Q'7PD_Z+?*O_!6/_\
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M?\0^G[2W_1:/@9_W]\??_,=3_P"(Z^$G_1;Y5_X*Q_E_U!^?]68?\2T>.O\
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M_P"9//\ /LP_XEF\=O\ HV^=_P#@[*__ )X'X(T5^]W_ !#[_M*_]%H^!O\
MW]\??_,=1_Q#[_M*_P#1:/@;_P!_?'W_ ,QU'_$<O";_ *+;*O\ P7C_ /YD
M\_S[,/\ B6;QV_Z-OG?_ (.RO_YX'X(T5^]W_$/O^TK_ -%H^!O_ ']\??\
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M(?O]I3_HL_P._P"_GCW_ .8^C_B.7A-_T6V5?^"\?_\ ,GG^?9A_Q+)X\?\
M1ML\_P#!V5__ #P\_P ^S/P4HK]Z_P#B'[_:4_Z+/\#O^_GCW_YCZ/\ B'[_
M &E/^BS_  ._[^>/?_F/H_XCEX3?]%ME7_@O'_\ S)Y_GV8?\2R>/'_1ML\_
M\'97_P#/#S_/LS\%**_>O_B'[_:4_P"BS_ [_OYX]_\ F/H_XA^_VE/^BS_
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M^:]%%%?I!_8 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M93TZGZ?U%8S^)_+\D,G3[P_'^1J:H4^\/Q_D:FJ1QW7JOS"K%5ZL5G4Z?/\
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MH_'^9J=.A^O]!4"?='X_S-3IT/U_H*]"6[]7^9YX^I8P3G'/3^M,5<_2K,0
MSCV_KUJ9.R;&G9W'JN.>_P"E2)]X?C_(TVG)]X?C_(U*;<97\_R-8MM:]_\
M(FHHHK(HL5.O0?0?RJ(*3[#UJ8< #TI75[7U F3[H_'^9IU-3[H_'^9IU8RW
M?J_S+@VWZ+_(DC[_ (?UJ=.I^G]14$??\/ZU.G4_3^HK"?Q/Y?DC4G3[P_'^
M1J:H4^\/Q_D:FJ0%7J/J/YU/4*@DCV(J:@"Q4Z]!]!_*H*G7H/H/Y4'03I]T
M?C_,TZFI]T?C_,U,@'7N#Q6$MWZO\RHNS;\A4!&3ZXQ^M3)U/T_J*93TZGZ?
MU%83^)_+\D:IW2?>_P"9.GWA^/\ (U-4*?>'X_R-35(PJQ5>K%9U.GS_ $ <
M%)^G<U,!@ >@Q114RES&L9.3?16V^XF3[H_'^9J=.A^O]!4"?='X_P S4Z=#
M]?Z"I+'T].I^G]13*E12.3QQTK&?Q/Y?D@)4^\/Q_D:G7J/J/YU GWA^/\C4
MZ]1]1_.HM?\ KK_7]/2U1;T73F3_ ")Z***BIT^?Z&Q.O0?0?RJ=/NC\?YFH
M%Z#Z#^53I]T?C_,UF!.G0_7^@J=%!Y///2H$Z'Z_T%6$Z'Z_T%3/X7\OS1O'
M9>B_(?3TZGZ?U%,IZ=3]/ZBL1DZ?>'X_R-35"GWA^/\ (U.!D@>IQ64]UZ?J
MQK1KU0E6*0*!T_/O2U!JI<U]-K$Z]!]!_*EI%Z#Z#^5+042IT/U_H*GC[_A_
M6H$Z'Z_T%3Q]_P /ZUE).[?33] )*D0'KV(XI$'/T&?Y5+4%QE:RMN_^ .3[
MP_'^1J=>H^H_G4"?>'X_R-3KU'U'\ZRGNO3]6:D]%%%0:4^OR_4G7H/H/Y5.
MGW1^/\S4"]!]!_*IT^Z/Q_F:#0G3H?K_ $%3Q]_P_K4"=#]?Z"IX^_X?UK&?
MQ/Y?D@)*<GWA^/\ (TVG)]X?C_(U$MGZ/\C6&S]?T1-7;_#[Q>? WB*/7QIO
M]J>7:75K]E^V?80?M*JN_P"T?9;S&S;G9Y)W9^\N,UQ(Y(^HKTCX8^$]-\:>
M*8=#U2:]M[22RO+DR:?)!%<![=%9 'N+:ZB"$L=X,))'1EKR<T>$CEV-ECXR
MG@EAJKQ4(N:E*AR/VB3IRA.[C>W)*,NS3/2RM8N68X*. E&&->)HK"SDH.,:
M[FO9RDJD9PLI6;YHRCW3V//JL57JQ7>< 5,GW1^/\S4-3)]T?C_,T6O\M3>.
MR]%^1.G0_7^@I],3H?K_ $%/K&?Q/Y?DACTZGZ?U%3I]X?C_ "-0)U/T_J*G
M3[P_'^1KGG\3^7Y("=>H^H_G4]0+U'U'\ZGJ36&S]?T18HHHJ92Y36+Y6WOI
M_D3)]T?C_,U.G0_7^@J!/NC\?YFITZ'Z_P!!2EK"_=+\T:K5)]TA]21]_P /
MZU'4D??\/ZUA/X7\OS0R2G)]X?C_ "-(!DXJ8*!]>YJ%)*+75W_%;FD))*W5
MO\[:CEZCZC^=3U O4?4?SJ>H-"8*![GU_P /2G444 3)]T?C_,U.G0_7^@J!
M/NC\?YFITZ'Z_P!!6$MWZO\ ,W3T2ZV3)X^_X?UJ2HX^_P"']:DI#'IU/T_J
M*EJ).I^G]14M8S^)_+\D..Z]5^8J]1]1_.IZ@7J/J*GJ3<L4445G4Z?/]"X;
MOT_5$R?='X_S-3IT/U_H*@3[H_'^9J=.A^O]!69J/IZ=3]/ZBF4].I^G]14S
M^%_+\T!.GWA^/\C4Z]1]1_.H$^\/Q_D:G7J/J/YU,$K7ZWM^1K#9^OZ(GHHH
MK,LL5.O0?0?RJ"IUZ#Z#^5<X"U*G0_7^@J*I4Z'Z_P!!0;QV7HOR'T].I^G]
M13*>G4_3^HH&3I]X?C_(U.O4?4?SJ!/O#\?Y&IUZCZC^=93W7I^K-8.R^=OR
M)Z***PJ=/G^A9.O0?0?RJ=/NC\?YFH%Z#Z#^53I]T?C_ #-$O@C\OR9<-WZ?
MJAU2IT/U_H*BJ5.A^O\ 05F:CZE12.3W'3_&D3O^']:DJ9_"_E^:+C)Z+SW]
M6.3[P_'^1J:H4^\/Q_D:FK$U"K%5ZL4 3KT'T'\JG3[H_'^9J!>@^@_E4Z?=
M'X_S-1/9>OZ,WCLO1?D.J2/O^']:CJ2/O^']:R&3IU/T_J*EJ).I^G]14M8S
M^)_+\D..Z]5^9HB]SIZ:?Y7W;PW7G;^N86B\OR]G^UNW[^V-O>JU7191#2H[
M_=)YS7QMMN5\ORQ \F=NS=OW+C.\KM_ASS5*LJ?)[_(FOWDN:]]9Z7>K>FW9
M>1UU>>\/:--^RARVMI"WN+1+6W>[[NX58JO5BK,R=>@^@_E2TB]!]!_*EKG-
MX[+T7Y$J=#]?Z"IX^_X?UJ!.A^O]!4\??\/ZT%P^)?/\F24Y/O#\?Y&FTY/O
M#\?Y&E+9^C_(V)UZCZC^=3U O4?4?SJ>L "K%5ZL5G4Z?/\ 0Z J9/NC\?YF
MH:F3[H_'^9K,"=.A^O\ 05/'W_#^M0)T/U_H*GC[_A_6@WCLO1?D24Y/O#\?
MY&FTY/O#\?Y&L9_$_E^2&34445)K#9^OZ(L4444%DR?='X_S-6$^Z/Q_F:KI
M]T?C_,U83[H_'^9J)[+U_1EPW?I^J)TZ'Z_T%/IB=#]?Z"GUD:CTZGZ?U%2U
M$G4_3^HJ6E+9^C_(<=UZK\Q5ZCZC^=3U O4?4?SJ>L#<**** "BBB@ HHHH
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M.G3A1IT\+EN$HX/#PIT::5.E"-&C",:=-*%.*48I12"BBBI/4"BBB@ HHHH
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MG  =/\_6EH **** "BBB@3:6X4444&<IM[:+\3\UZ***_2#^Q0HHHH ****
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MJ5>H^H_G24J]1]1_.I GHHHKG-*?7Y?J3KT'T'\JG3[H_'^9J%02!CT'\JG
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MU(R8 #I1110!8J=>@^@_E4%3KT'T'\JSE/M]_P#P#H)T^Z/Q_F:G3H?K_05
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M^F=J_E#P\\+/]8?%;,?#+^W?J?\ 9N<<399_;?\ 9?UCVW^K<\9'V_\ 9O\
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M]@#X@_\ JX?B'7\A?3._Y-OPY_V6^"_]4/$!_4WT2?\ DX.??]D;C?\ U=Y
M?SC_ /!RQ_R?5\*/^S3/ O\ ZN'X[U_/-7]#/_!RQ_R?5\*/^S3/ O\ ZN'X
M[U_/-7[%X#_\F?\ #_\ [$%'_P!/5S\J\:_^3J\<?]CNK_Z9HG["_P#!!S_E
M)U\"?^P!\8__ %3WC>O[N?C[\+C\</@3\:O@JNN#PPWQ?^$OQ'^%P\2'33K(
M\/'X@>#M9\)C7#HXO]*.JC23JWV\Z:-4TTWPM_LOV^S\W[1'_"-_P0<_Y2=?
M G_L ?&/_P!4]XWK^ZS]H_XG:C\%/V>?CS\9='TVRUG5_A)\&/BC\3M+T?4I
M)XM.U74? 7@?7/%5CINH2VK)<QV5]<Z5%:W4ELZ3I!+(T++(%(_C3Z6"QS\:
M>%EEC4<R?#/#BR^4O9\L<<^(L]^J.7ME*C95_9M^UBZ=OC3C=']9?1A>#7A'
MQ,\Q3EEZXDSYXZ*]I>6#7#^2?64O9.-6[H\Z7LI*I?X&I69_/=\&O^#9SX3^
M$O&NA^(/C-^TIXE^+/A72=1MM0O/ WAOX:6GPSA\0):31SII6K^()_'GCN^7
M1[UHS;ZK%I5IIFISV4LL5AJ^F71CO8_Z0/&_C;P'\'/A]X@\=^-];T?P1\//
MA_X>N-6US6=0DCL=(T+0='MAG"J  $BCCM;"QMHWN+NX>VL+&":YF@A?\L?^
M"3W_  5,B_X*(:-\3]"\;>%/#7P[^+WPWOM/U4^%_#>H:A=Z9KWP^UB**UL_
M$>G?VO++?M<Z5X@AO-*\0PJ\MM9+J'AJ82*^K>3'Y)_P<#?LY_$[XR_L>6WQ
M$^'7B7Q7]A^ VLW?C/XA_#72M3OHO#OC/P)>164.J>)]5T2WD6UU;6/AG/8V
MWB#3KB]C>/2O#=UXSO(B+A8%?X+B.'B!QSXK</\  /C3Q16R[%8?,J&5RQ-3
M#9;'"9=#-:=#$4Y8&AE-'"9;*>;?[%AZ>.Y904YT)XJHZ6&E"/W&02X'X-\,
M\]XW\(N'*./PU?+Z^91P]/$9A+%8^>63K4*D<96S.KBLPC#+%];Q$\%S1FX0
MKQPT%5Q$92_C^^)=]\1OV\_VR/B=X@^%/@?6O$OCGX_?%3XA>,?!W@+3VMI]
M;_LRZN-;\46FCK)-/!:RW&A>$[!A=2>>D;IILSQ#!1#Z]_PZ5_X*/?\ 1H_Q
M2_[\Z#_\NZX#_@G;^T7X'_9+_;*^"W[0GQ(TWQ1J_@KX=7OC*YUS3O!=CI>I
M>)KF/Q#\.O%_A*R&EV.M:UX>TR=X]2U^RFN1=:Q9!+*.YEB::=(K>;^K/_B)
M0_80_P"B:?M5?^$%\*O_ )]M?V[XC\5^+'!&99-D/AEX=X;B?AS#<.X&+Q=:
MCCJTL)BJ&(QF"CEZGA\QPD>6C@<+@:JYZ<IWK.4JC32C_'? '#/ACQCE^;9W
MXB\>8CAS/\1GV-DL+2JX.C'%8:M1PF+>.<*^ Q+4JV-Q.,IOEG&"5%)07+)R
M_D'^/?[(/[3'[+UOX:O/C_\ !OQA\+K3QC-JEMX9N_$EM:+;:O<Z-'92ZG;V
MUQ8W=Y$L]I%J-G(\,SQ2/'-OB618Y2G]X/\ P19_Y1B_LJ_]@#X@_P#JX?B'
M7\RO_!9#_@I_^S]_P4&\)? O0?@KX7^+GAZ\^&?B/QOJ^OR?$OP]X1T2VNK;
MQ)IGAZSL$TE_#/COQA)<3Q2Z3<M=+=Q6*1QO"8I)V9UC_IJ_X(L_\HQ?V5?^
MP!\0?_5P_$.OQ+Z1><<59]X%\%YIQID5/AOB/$<=N..RBE"K3AAH4<OXIHX2
M<85Z^)JQ]OA*="NU*M.[J-KEBU&/Z]X"95PUDGC3Q;EO".<SS_(*'!7-@LTJ
M2I3GB)5L=PS6Q492HT</3?L,5.M17+2A94TI<TDY/[2^#?Q3C\<^)/CQX%N[
MA9/$?P1^,5[X'U>-R%N'TSQ/X-\'?%OP?=^1G<MF/"OQ%TS1K:<#R[B;0[PA
MC+',J_BE^Q#_ ,$_+3X0?\%A_P!MKXL-H(MO G@71=.\6?"1VM_)L8-8_:<%
MWKVJ2:%E %@\)6ND?$7P1]GA.RVL=1MU;Y98,[_PF_:/3X8?\%\/VM_@#J]]
M]G\._M'_  [^#EQI$,LN(3\2_AI\!_!>MZ*4\P^5 =1\%R>,[.4H4EOKZVT.
MUQ,Z6Z+^^MR=-TU;_6;O[%8K%9*^IZK/Y%MLT[3!=7*M>WK[,6=@MQ>W"^?)
MY-J)[J5=GFRLW\WYGB\[\,Z>9Y9EZG3R_P 5?#'A/%IQE*$7A\]P^49EF%:E
M3BK2<,7A^(,EIT[\L<-C:DK)V@?T#EV%R?Q#J9=F&.<9X[PT\1>)\*TU&<E7
MR:OFF P-*I4D[Q4\+7R/-ZDVG)XC"4XMO69X;IWQ9CU_]J#Q1\%M*N \7PR^
M"GA?QWXQ2)A)&-6^+'C'7]*\&V=P0<6][IVD_"[Q1?&!OWDEGXCLYV"QM$9/
MYZO^#GK_ ))O^R-_V._Q8_\ 3#X*KZ"_X(Q?M#3?M7?M8?\ !5+X^/---IGC
M3QY^S_;>#5N/,5[/X>>'(OCEX<\!V9A? MYE\*Z5I,NH1QI&LFI2W=PR>9*Y
M/S[_ ,'/7_)-_P!D;_L=_BQ_Z8?!5?H?AEPQ4X,^DEP3PQ7A[/%Y7@,!+'Q:
M]Z.99GX=3SG,J<GO+V&/S'$8>$GK[*E35HI**^$\1>(X<6_1^XPXCHSY\-F6
M.QBP,D_=EE^7<>T\IR^HEM'VV"P%"O.*_P"7E6;;DVY/XT_X-G_^3P?CA_V;
M7JW_ *M#X9U^_7_!<O\ Y1:?M0_]T3_]:)^$E?@+_P &S_\ R>#\</\ LVO5
MO_5H?#.OWZ_X+E_\HM/VH?\ NB?_ *T3\)*^H\6_^4L^"_\ LI/#'_U9Y8?-
M^%O_ "C#Q?\ ]B#Q%_\ 5;F!_GJVEW=6%U;7UE<36EY97$-W:75O(\-Q;75O
M(LT%Q!-&5>*:&5$DBD1@Z.JLI! -?ZKOPXUR^\3_  \\!^)=44)J7B'P9X7U
MS44"+&$OM6T.QO[M1&ORQA;BXD&Q?E7&T<"O\Y3_ ()_?L"_&+]N;XR^$_#/
MA;PEKT?PDT_Q/I2_%SXI-97%KX6\(>%X)X;W7+2/7)8A97?B_4-)66V\.>';
M22?4;J_NK6YN8;31H=0U2S_TDXH['2K".&);;3]-TVT2.-!Y=M:6-C9PA449
MV106UM!& ,E8XHD[*O'I_31SW)L;F'!.0X3$X?%9SE,,\Q694J%2%6K@*&8_
MV3#!T,1R.3I5<3+!UJRH3Y:D:5.E5<%"O3E+S_HBY-FV$P'&&=8K#U\/E.9S
MR;#9?4K0G3I8VM@/[3GBJU#G252GAUBZ-)UH<U.52I4I*7/1J1C_ )X7_!5_
M4[[X7?\ !5?]HOQ3X(O$TK7?"OQ6\"^/M"U&TCCSI_BI?!W@;QDM^L;*8WN;
M;Q%-)<S>8K"6Z21I Y9B?[0OV!/^"BWP+_;P^&6AZWX2\1Z)H'Q>L]'MC\2?
M@U?:G!#XK\+ZW;P0KJUWI&GW4D=]XB\%S73F;1O%&G0W%H]I/!::J=-UN*^T
MRU_@>_;L^,FF_M!?MC?M(_&#0[B&\\.^-/BUXLN?"M[ 6:/4/"&EW[Z#X1U
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M=7HUJ%%%%=IQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX[KU7YBKU'U'\ZGJ!>H^H_G4]8&X4444 %%%% !1110 4444 %%%% !1110
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MU?YH^"__ "E7Q+_V5GB;_P"G<[/Z^\0O^3)Y/_V)>#__ $UEQ^FU?RJ_M?\
M_)P7QM_[*1XL_P#3M<5_557\JO[7_P#R<%\;?^RD>+/_ $[7%?U9X_\ ^X\&
M_P#922_]0:Q^(^&/^\Y__P!BF'_J91/+?AU^Q+^T3^T1X2N?&WPK\):9K7AV
M#6;[0'N[WQ7X;T64ZE86]C=742VFJZE:W)C2*_M\3&(1NS,$+;":RM=_X)#?
MMU7Q/V;X:>'7^;//Q)\!IQD'^+71Z5]'?LY?\%&]9_90^&=U\.=.^%.F>-89
M_%&K>)FU6]\6W6B2B75+73+1K1;2#0-27RX4TU&$IN"SM*V44* >_P!5_P""
M\OBW32=O[-GAV7!Q\WQ,U-.X';P8WK7]*>"M;/L/@<MEPKA<-CL8\/0=6GC9
M1A35;ECS13GB<&N52T5IO_$S\@\0*>55<1BUG=>MAJ'M)J$L.I2DX)Z-J-'$
M.[6_NKT6A]L_\$E_V4_C;^RG\/\ XN^'/C7X9L?#FI>*O&.A:WH:V'B+0?$,
M-W8VFBSV-RS2Z'J%\+:6&<(&CN1"765&A,@$GE_S)?M\?\GH?M1?]EL\?_\
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MQ* @" 5_6'^WQ_R8K^VG_P!FF?M&_P#JGO&5?YC5%?JO'GT=/]=N+.$N*/\
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M/&VDJ)BD<U]X:^%/PRU8:=>%-Q-GJ,<!L=0MW5DGL;J>&6.2*5D;]%OVS/\
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MY3G)N4I2DVY2E)MN4I-MMMMMMMNX44451(4444 %%%% !1110 4444 %%%%
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M #I_GZTU.A^O]!3ZRFW=J^G;Y(8].I^G]15A.I^G]15=.I^G]15A.I^G]14
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MNC\?YFHFU:W6_P"A<-WZ?JBPGW1^/\S3J:GW1^/\S3JR-22/O^']:DJ./O\
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M;RV]EH?B/27M4CM2)%F>36XIE=OD"02*?F9:^3/@Q_P3\\8?"_XH>"O'U_\
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MV6K;]1MYY+-/[,O+*\M-1W3#[%<VES!<^5+!*B4[+QEX0U+6SX:T[Q5X;O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^L_V!_^3ZOV+/\ L[/]G+_U</@VODROK/\
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M21]_P_K5B/O^']:KQ]_P_K5B/O\ A_6D!)3D^\/Q_D:;3D^\/Q_D:4MGZ/\
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M?>'X_P C4U0I]X?C_(U-0;A5H*3].YJ$)Z_E_P#7JY7.  8 'H,5,GW1^/\
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M1J:@H*L57JQ7.:4^OR_4G7H/H/Y4M(O0?0?RIP!/2@T)$Z'Z_P!!5A.A^O\
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M[;1HM3T#4OB!/J>HS>-K[2KJTNO%<NH7LFNRW[W<YD]X_9PO8](_;@_X**^
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MM(3->W=I:S@&Q\0_AO\ #;]G;XU_\%,_@Y\$_ GAOX8?#?XB?\$L=$^.&J^
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M?$&UDTZ6&&QNY=$FT/X>QVFI3VZB\EFTS7O&ESJ$-A.UK;I+I@NC-=D1V/\
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M>7.DF_1 7FLH=06WFN[=#&]S;QR6ZS0M*)D_SS_^"9G_ "D&_8Y_[.#^&O\
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MAIX1T;2?$?P^E&  8Q8_$G4(E5?W:O'(T?R2"OD__@E-^U3_ ,+7_P""H?\
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M?I_H5IJFO0CQ9X^UB*;:?(N?#/A'0M*M;I\Y_L[QG.H5@S%>3Q5XOGP)X?\
M$W$M"45C\'E\J&41<(U7/.<PJ0P&5)4)1DJZAC<31K5*/+)3HTZG,N52:ZO#
M3A6/&G''#O#U:+>!Q>.C6S22G*GR93@83QN9MUHN+HN>#P]:E3J\RY:M2G9\
MSBG\)_\ !2+_ () >//^">7PY\ _%&]^+.E_%WPMXQ\97/@;5+G2_!-[X1;P
MOK4FC7.N: MQ]H\2>(EOXM<L])\0A7!LA9RZ2B'[2UZ@A_':O[6?!/Q+O_\
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MX*U?Q!;1%H=%O]8\(^+M5U#P>DLNV.XNGL_%=S9JWF'3)\;:^,Q'TBO!S#K
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MI;W7EB2?3+[S!:7BK&\FV*X\F0QA]KE5W;0K*3S%?5O[6G_(\^"?^R1>!/\
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M^H_G4]0+U'U'\ZGIU.GS_0 JQ5>K%<]3I\_T.@*F3[H_'^9J&ID^Z/Q_F:S
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M:!H'B*T\0VMS8ZU%K=EIEI;+JO\ :-C>7%C<27QGE-E)]D5UMTCC3M?^%;^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT/\ GVO_  *7_P EY?GW8>WJ_P [^Z/^7E^?=G7#Q9("#]B3C_INW_QJG_\
M"72?\^*?^!#?_&JXZBE]5H?\^_\ R:?_ ,EY?U=E+$UUM/\ \EA_\CY'8_\
M"72?\^*?^!#?_&J?_P )E+_SX1_]_P!O_C5<712^IX;_ )]+_P "G_\ )!]:
MK_\ /Q_^ Q_^1\OS[L[<>-90 /[/CX&/^/AO_C52#QQ* !_9T?'_ $\M_P#&
M:X2BCZGAO^?2_P# I_\ R7E^?=A]:K_\_'_X#'_Y'R_/NSOAX[F P--B_P#
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M*7]CY=_T#1_\&5O_ )9_6O=A_:>._P"@A_\ @%+_ .0/:U^,MRN?^)! <_\
M40D_^1*>/C3=+G'A^WY]=0D_^1*\1HI?V/EO_0,O_!E;_P"6>7]78?VICO\
MH(?_ (+I?_('N'_"Z[O_ *%^W_\ !A)_\B4H^-EV"#_PC]OQ_P!1"3_Y$KPZ
MBC^QLM_Z!E_X-K?_ "P:S7,%MB'_ ."Z/_RL]T'QONP0?^$>M^#G_D(R?_(E
M2?\ "\KO_H7;?_P92?\ R'7@]%+^Q<K_ .@6/_@VO_\ +/+\^['_ &MF'_00
M_P#P71_^5GO/_"\KG_H7(/\ P9R?_(5/'QUN@ /^$;M^/^HG)_\ (5>!T4GD
MF5O?"1?_ '%K_P#RWR&LWS%;8E_^"Z/_ ,K/V-^$WQ?N)_\ @G%^U9K1T*%6
MT_XM?!^V6W%^Y647.JZ2I<R?9 4*;^ $;..HK\]!\>[L# \-6W_@SE_^0J\B
ML]1\8V_AC6--T^_\2P>#-1O+*;7["SNM4C\,7VH6#H=.EUBU@==*NKRRDN8S
M9/>QO/;/<(8"C2KNYJOFL@X*R[*L7Q3B*CHXN.><23SFC"FZ\'@J4LER3+?J
M=5^WE[2I&KEE3$<_N^YB(0Y5RW?T&=\78W,\-PW0IJKAI9-P_#*:LYJC-8RI
M'-\WS#ZW33HQY(2IYA3H<GO6G0G)2?-9?0?_  OV[[^&;;_P:2C_ -L33A\?
MKL'(\,V__@TE_P#D&OGJBOI/["RK_H$C_P"#:_\ \M\OS[L\#^V<R7_,2_\
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M*6O_ (-I?_D"GK^TC>J,?\(G:GG/_(7E_P#D"OF>BE_J[DS_ .8*/_@[$?\
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M/^$-L_\ P=3?_*ZE_P"&I]0_Z$VS_P#!U/\ _*ZOD^BE_JQD7_0!'_P?BO\
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M_P"A9#_PIQG_ ,T>7Y]V/_6OB#_H8R_\)\)Y?]./+^KL^W!^VCJ8&!X L/\
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M3.&?^A7#_P *<;_\T^7Y]V/_ %PXD_Z&<_\ PFP?_P S^7Y]V?=0_;>U0?\
M-.]/)]?^$CN?_E13O^&X-5_Z)WI__A1W/_RHKX3HI?ZE\,O3^RX/_N9QO_S3
M_7S#_7#B3_H9S_\ ";!__,_E^?=GW<O[<6JJ,?\ "N]//.?^1CN?_E/4B_MR
MZJN?^+<Z><_]3)<__*>O@VBJCP/PP]7E4?3ZUC?+?_:?+;U^;7&/$BVS.?\
MX38/_P"9_P"OFS[T_P"&Y]5_Z)SI_P#X4MS_ /*:E'[=&J@Y_P"%<Z?_ .%)
M<_\ RFKX*HHEP3PJM/[)@W_V%8[RW_VKR_JXI<:\2Q_YFDV_^P;!V^?^S_@?
M? _;KU4')^&^G'_N9;D?^X8U)_PW=JO_ $3;3_\ PIKG_P"4M? =%9O@CA=[
MY5#_ ,*L=_\ -1G_ *Z\3_\ 0TG_ .$V"_\ F8^__P#AO+5O^B;:=_X4US_\
MI:>/V]=7  _X5KIO'_4S77_RFK\_:*7^I'"W_0IA_P"%6._^:0_UVXG_ .AK
M/_PEP/\ \S>7Y]V?H'_PWKJW_1-=._\ "GN?_E+3A^WQK P!\---/_<S76?7
M_H"U^?84GZ=S4H4#Z]S2? _"KWRF#_[FL=_\U?UKW97^N_%/_0UG_P"$N!_^
M9C]!5_;VU<<M\---)]!XGN<?C_Q)#_A4J_M]ZNO3X9Z;_P"%/<]O^X)7Y[T4
MO]1>%/\ H4P_\*L?_P#-0?Z[\4_]#:?_ (2X'_YF/T*_X;\UC_HF>F_^%/=?
M_*6E'[?NL @_\*RTWC_J:+K_ .4M?GI12? ?";WRB'_A5C__ )J#_7CBG_H:
MS_\ "7 __,O]?-GZ'?\ #P#5_P#HF.F_^%1=?_*2E_X> :M_T3'3O_"IN?\
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MYST5[_\ J!PC_P!">'_A9F'_ ,UG@KCOBM;9O/\ \)<#_P#,I^C8_P""ANM
M8'PNTO\ \*F[_P#E)2_\/#M:[_"[2_\ PJKL?^X,U^<=%'^H'"/_ $)X?^%F
M8?\ S6#X^XK6^<5/3ZK@/+_J%\NOGYGZ/+_P40UE3G_A5NF'C'_(UW7_ ,HJ
MD'_!1/600?\ A5FF<?\ 4UW7_P HJ_-VBD_#[@][Y-#_ ,*\P_\ FLS?'_%W
M_0XFO^Y3 ?\ S)K\_P!3])1_P46UD$'_ (57IG'_ %-EU_\ *&G_ /#QG6O^
MB5:7_P"%9=__ "BK\UZ*7_$/>#_^A-#_ ,+,Q_\ FL7^O_%W_0XJ?^$F _\
MF3R_/NS]*_\ AXYK?_1*M*_\*N[_ /E%2_\ #QS6O^B4Z7_X5EW_ /*&OS3I
MZIW/'MZ_X?SJ7X><&+?):?\ X69CKM_U&?UUW92\0.+UMG,__"/+_P#YD/TM
M7_@H]K>,#X4:6<=_^$MN_7_L 5*/^"CVM#_FE&E9]_%EW_\ **OS2 QP**R?
MA]P=TR6FE_V&9CY;_P"U^7Y[W8?\1!XP_P"AS4_\),O_ /F3R_/NS],5_P""
MD6MKG_BU&E'/_4VW?_RAIW_#R/6_^B3Z5_X5MW_\H:_,RBI?AYP<W=Y+3_\
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M>?\ S/5^7M%9/PYX+Z9'37_<[F3_ #QGE_5W?9>(W&D5KGE33O@LM_\ F/\
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M (*M^(%SCX+:-SZ^-KW_ .9NE_X>N>(._P %M&_\+:]'_NM&OR0HI?\ $+.
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M^%):-Q_U/%]_\S-?D+16:\*N 6].'J?_ (7YKY?]1W]?-D?\18\0/^BBJ?\
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M8.H?I_Q2?-2K_P %G_$RC'_"@="/.?\ DH.H?_,G7XDT4/P<\-G_ ,TS2_\
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M\?\ !=WQ6"#_ ,,W>'N/^JEZE_\ ,97X$44GX'>%CWX3H_\ ATSS_P">8_\
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M3GCBM^/,1_X9.&/_ )RG]'8_X.'_ !F>G[+7AGZ_\+5U7'_J"U)_Q$.^,?\
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M (97\,'C'_)5]5_^82G?\1%WC/\ Z-6\,?\ AV-5_P#F#K^;*BE_Q+SX._\
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MG])/_$17XS_Z-7\,?^'7U7_YA:/^(BOQG_T:OX8_\.OJO_S"U_-M0!G@4?\
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M[\0__/</^)J?'W_HX.)_\,/"G_SB\OS[L_I!_P"(B/QG_P!&M>&/_#JZK_\
M,-1_Q$1^,_\ HUKPQ_X=75?_ )AJ_F^HH_XEZ\'?^B+H?^'?B'_Y[DOZ5GCX
MMO$+$-_]B'A6W3_J1:_\/?K?^D'_ (B(_&?_ $:UX8_\.KJO_P PU'_$1'XS
M_P"C6O#'_AU=5_\ F&K^;ZBC_B7KP=_Z(NA_X=^(?_GN9_\ $UGC_P#]'"Q/
M_A@X4_\ G#Y?GW9_2?I?_!PQXRU'4].T]OV7?#,2WU]:69E'Q3U5S&+JXC@,
M@4^!U#% ^X*6 8C&1G->R?M)?\%Q/%7P%^-/C/X3VG[.WA_Q+;^%/^$=\O6[
MGXC:EIDU[_;OA/0O$C[[&+PA>I!]F?6&M%VW,OFI LQV&0QI_*?%+)!)'-#(
M\,T+I+%+$[1R121L'CDCD0AD=& 9'4AE8 @@@&MCQ%J7B/6-9O-1\6ZAK>J>
M(+C[/_:%]XBNK^]UF?R;6""T^V76IR2WLOE645M#;^>[;+6."./$*1@>55^C
MGX72SO!8JGPYA:>4T\JS/#XK*GF6>NIBLQKXO*:F S".(>:^UIPP&&P^98:=
M&,E3JRS*$ZD7*C3:]NC]+7QICP[F&#J<78RKGE;.LGQ."SM9/PQ&E@LIPV!S
MREF>5RPRR3V-6IF>,Q.4XN%><'5H1RBK3IR4<364OZ)O^(B/QG_T:UX8_P##
MJZK_ /,-1_Q$1^,_^C6?#'_AU=5_^8:OYOPI/T[FI0H'U[FO4?T>_!WIP70;
M_P"QQQ#;YO\ M;\-_(\3_B:SQ_\ ^CA8G_PP<*?_ #A\OS[L_H_'_!Q!XS[_
M ++7ACZ#XJZK_P#,-2_\1$'C+_HUKPS_ .'6U7_YA:_G!HI_\2]>#O\ T1E!
M_P#=7XA_^>W^?J'_ !-9X_?]'"Q/_AAX4_\ G$?T??\ $1!XR_Z-:\,_^'6U
M7_YA:/\ B(@\9?\ 1K7AG_PZVJ__ #"U_.#11_Q+UX._]$70_P##OQ#_ //<
M/^)J_'[_ *.%B?\ PP\*?_.(_H^_XB(/&7_1K7AG_P .MJO_ ,PM'_$1!XR_
MZ-:\,_\ AU=5_P#F%K^<(*3T_/M4H4#W/K_AZ5,OH^>#B_YHR@WV_MCB'\?^
M%?0F7TK?'Y?\W"Q+?;^P>%/Q_P"$+0_H['_!P[XR/7]EOPR/^ZJZK^O_ !0U
M+_Q$.^,O^C6_#/\ X=75?_F&K^<6BL_^)??!_P#Z(RA_X=^(?_GL9_\ $UWT
M@/\ HX>)_P##!PI_\XC^CK_B(=\9?]&M^&?_  ZNJ_\ S#4?\1#OC+_HUOPS
M_P"'5U7_ .8:OYQ:*/\ B7WP?_Z(RA_X=^(/_GL'_$UWT@/^CAXG_P ,'"G_
M ,X3^CK_ (B'?&7_ $:WX9_\.KJO_P PU'_$0[XR_P"C6_#/_AU=5_\ F&K^
M<6BC_B7WP?\ ^B,H?^'?B#_Y[!_Q-=](#_HX>)_\,'"G_P X3^CK_B(=\9?]
M&M^&?_#JZK_\PU'_ !$.^,O^C6_#/_AU=5_^8:OYQ:*/^)??!_\ Z(RA_P"'
M?B#_ .>P?\37?2 _Z.'B?_#!PI_\X3^CK_B(=\9?]&M^&?\ PZNJ_P#S#4?\
M1#OC+_HUOPS_ .'5U7_YAJ_G%HH_XE]\'_\ HC*'_AWX@_\ GL'_ !-=](#_
M *.'B?\ PP<*?_.$_HZ_XB'?&7_1K?AG_P .KJO_ ,PU'_$0[XR_Z-;\,_\
MAU=5_P#F&K^<6I%3N?R_QJ_^)>_!Y*\N#:'I_:_$%_\ U;?UWN)_2O\ I +?
MQ#Q/_A@X3_\ G"?T<#_@X;\9G_FUOPR!Z_\ "U=5_3_BAN:=_P 1#/C+_HUW
MPS_X=35?_F'K^<FBI?T??![IP907_=7XA?\ [UC-_2Q^D%T\1,2O^Z!PF_\
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MKJG_ ,PM?SD4]4)Y/ _G1_Q+YX/_ /1&T/\ P\<0_P#SV\OS[L/^)L?I!?\
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M$7$^O^K_  E^'_" ?T5_\1!WC#_HV#PU_P"'2U3_ .8BC_B(.\8?]&P>&O\
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MO_#I:I_\Q%?SL45/_$O_ (0_]$;0_P##OQ!_\]O+\^[#_B;7Z0O_ $<;%?\
MB/\ "7_S@\OS[L_HG_XB"_&'_1L/AK_PZ6J?_,11_P 1!?C#_HV'PU_X=+5/
M_F(K^=BBC_B7_P (?^B-H?\ AWX@_P#GMY?GW8?\3:_2%_Z.-BO_ !'^$O\
MYP>7Y]V?T3_\1!?C#_HV'PU_X=+5/_F(KS'QC_P7P_:0U198O!'PD^#WA&.2
M53'/K*^+?%]_!"LTLAC26+7O#5@TKQ?9X))9=,D7"74D<,;W$!LOPFHK?#^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\!0RBO2<\+0PN70I4\#3HWE[2D\)"C25"K3J1K4^2+C43U#!<5\1Y;G]3BG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^E/P?_P"48_[7
MO_98_@M_Z=M&K\UJ_2GX/_\ *,?]KW_LL?P6_P#3MHU?FM7YUP'_ ,C7Q/\
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M$IWT6GGU_P" 92G?1:>?7_@!1114$!112A2?IW- "5($]?R_^O3@H'U[FG4
M%%%% !1110 444 $]* "G*I/L/Y_2GA .O)_2GT ( !T_P _6OT?_P""G/\
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M2!/7\O\ Z] # I/T[FI0H'U[FG44 %%%%!G*?;[_ /@!11109A1110 4444
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M[:+7SZ?\$:% ]SZ_X>E.HHH,F[ZL**** "BBB@ HHHH **** "BG!2?8>O\
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M/Z*\&/ S-LRXDQ;\3?#WBC"\-5N".*,WRS%9ME_$&18*KFN!R[ZWEM2&.HO
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MH.@Z9&LNH:I?RJ[QVMI&S(KRNJ.0I=00IYKEZ^V?^"<'_)\_[,G_ &4_2O\
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M )$H_P"%#^(O^@QHOYWW_P B5]34H!/ JUD&7O5PJ)?]?9?TO4/^*LOTSO\
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M!PY_\S'R7_PS[XE_Z#6A_G?_ /R'1_PS[XE_Z#6A_G?_ /R'7UI11_867_\
M/NI_X-D1_P 5:_IH_P#18<'_ /B <.?_ #-_5_2WR7_PS[XE_P"@UH?YW_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OK/]@?_ )/J_8L_[.S_ &<O_5P^#:^3*^L_V!_^3ZOV+/\ L[/]G+_U</@V
MO!XJ_P"28XC_ .Q#G'_JOQ![?#/_ "4?#_\ V.\J_P#4_#GR91117O'B!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !113U3N>/;U_P /YT";2W&@$]*E"@>Y]:<!C@44&4I-^2_/U"BBB@D****
M"BBB@ HHHH ***<%)]AZ_P"'K0W;5@W;5C:D5.Y_+_&GA0.GY]Z6LI3OHM//
MK_P#*4[Z+3SZ_P# "BBBI2;T1 444H4GZ=S6BBHZOI^'^8"5($]?R_\ KTX*
M!]>YIU3*?1:>??\ R_, HHHJ "BBB@ HHHH **** "BB@#/ H *<%)]AZT]4
M[GGV]/\ '^5/H,Y3Z+[_ /(0 #I2T44&84444 %* 3T_S]:<$)Z\#]:D  Z4
M (J@>Y_E]*=110 4444 %%%%!$II:+5_D%%%%!FVWJPHHHH$%%*%)^G<U*%
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M/>%? 7V6W$L7AS6;[3$U+Q%K5W92ZGX@O]1%L)KVVN)(=!0;(K31;?;+)/\
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M_P"Q0^&W_IZ\65\F_M=?\%6_VQ?%GQO\;:9X'^(^H?!WP;X&\8Z]X;\/>%?
M7V6W$L7AS6;[3$U+Q%K5W92ZGX@O]1%L)KVVN)(=!0;(K31;?;+)/]9_\&]'
M_(^?M.?]BC\-?_3SXMK\0?VEO#'B/PC^T#\9M%\5:#K/AO5X_B9XWNWTS7=-
MO-*OQ9ZAXEU.]T^\%K?0P3-:7]E/!>6-TJ&"\M)H;FVDE@E21O?R;A_AW//'
MSQ/GG>599FN(P&2\(3RZGF6'H8R-!8C*,/#&5:.&Q"J4G-J&'IRK^RE.E&2A
M&<%6FI_*<0\6<7<,_17\%:7#6>9UD6$S/B/C^GFU;)L7B<OGB983/\55R^AB
M,;A)4J\8*57%U88;V\:5>5-U)TZDL/3E2_I[^%_Q)N?^"FG_  2G^,*_%RSL
M]1^)?@;3?'&B7VLV%A;V)O?B-\,O#FG^/O!'B^PLX1Y6GW.K6>HZ)8^(4TY;
M2TO9;CQ-96-O8:9?+80?(7_!O1_R/G[3G_8H_#7_ -//BVOJ']AGPGJ/[%7_
M  2D^,_Q-^+UM+X2U3QQ8?$CXH6&BZU#+INK0)XA\(Z-X#^&WA^ZM;I%>#4O
M%NJ:1IMYI4$D8<1>*M/6Z$3K-'#\O?\ !O1_R/G[3G_8H_#7_P!//BVORC,8
M87#>'7TCL!D2C'A/!\795')(8=WP%+%3S;+5F]# \MZ2H49T\'&$:+=.-'V'
M)[CBW^ZY35QV-\7/H?9IQ-*<^.\PX!SN?$E3%JV:U\##(LWED&*S3GM7EBL1
M3JYA.K/$)5I8CZS[3]XIJ/S]^V]_P58_:%N_CEXG\ _LY^-;SX+?!WX1ZW?>
M O"6C>$-*TC3;C6QX1N9-#N-:U1[C3998M.N9[&2/0O#<"66DZ7H4>GP3Z:V
MHB\N)/O'_@F-X4\%?LB?\$^_BI^W?XGTPZ_XZ\::'XT\2+/<LK7S>'/!FO:K
MX8\+>$+6[??-9#Q;XVL9M0UB^60&\6_T62\CD_L6U:OYM?CK_P EN^,?_95/
MB%_ZEVKU_3/^R-H[_M:?\$6O%GP+\%7,-]\0/#&A?$+P1)I(;R))/%>A>.;G
MXJ>#=*(RI1-=TF^\-V,-X_\ HKW5Q<B1R+:Z1/OO%'AO(N%O#;@S*LLP.'RC
MA[-^*N"\NXUQV%I0HXO&Y$X8K$XFOF^/IPA7Q-\9R5ZF(Q%63CB*B4.557$_
M*_!'C#B?C?QC\1,]SK,\5Q!Q7P_P+XCYOX;Y;CJ]3$X'+.)XU,#@\'AL@RNK
M4GA<&UEZJ86EA,)0C&6%I.4U*5",C\9H?^"LW[=:?%,?$\_&6_E4ZQ_:#?#I
M["S_ .%8-IOVHS'PV/"@0"/2OLQ_L\7Z7R^)Q;XN/^$A.IC[?7ZZ_P#!5+PC
MX#_:I_8*^$O[=GA?18=#\8>'M,\ :U=7RPJ=5_X0[Q]J-IX?U3P9J-] (WO#
MX6\>:S83:7=S-+!9O%KAL$C_ +<FD/\ ,?%X1\4R>*%\#Q>&M>?QF^MCPTOA
M)='U ^)F\1&\_L[^P?["^S_VI_;/]H?Z#_9GV7[:+O-MY F&ROZE/VU-/A_9
M2_X(W>"/V>_&MY9VWQ$\4Z!\,_!,6D+<)/,/$R^,M)^*/CB&W0EGNK+08-.U
M;39M0C5;:*YFTT[XVO+2&3T_$7)>'N&>,O!G%<'Y=EV4Y]B>+\'E;H9+A\/A
M)8[A.O"-/.'BJ>$A%8C"8;#3C:O5C45*G7KRC+637C^$7$G%G&?AW](G ^(&
M<9OG_"^"X S#/(XKB/&8O,(Y9QWAJLJW#RP5;'5)RPF.QF,ISOAJ$Z3K5<-A
MH2AI%/!_:\N%_;N_X)#_  \_:$M0-3^(GPEM-"\7^)I(@'OVU?PI+/\ #OXN
MQ2K@M:V5U')<^/6AD(9M-TK3)UDD1HVF^$?^"&GP._X6+^U?JOQ5U&S\_0O@
M3X.O=8MYGC\R!?&OC:.[\+^&X)58>7N716\8ZK;2,2\%[I%K+$@D598OHC_@
MAC\4M%\;>&_VC/V-/'3B^\.>-_#>H>-]&TJ>0!+O2];TV#P!\3]+C,NY2UYI
MM[X3N;>UB4X2'6+MHG F=?</A1X)UC_@F3_P3*_:9\7^) =*^,/C3QW\0O"6
M@73(;34I-4CUZ[^#GP^O+!21YUI91:;KGQ3TEA)(MQHVHRW4<DD4B(/A,RQV
M,X.R;Q*\&LN?L\PSOB[+,NX(I-M1>1>(51U,10HQCJ\+EF'P^/P^)K)1C3Q.
M*;D[6BOT[)\KR[Q#XA\&_I$9NE5RGAG@'.<W\2JZ2E*/$_A)3C3PF)Q,I^ZL
M;G6+Q658O!T)2G.M@\$E"-US/\Z_%ZZ?_P %)?\ @K4_A>_U&XG^&>J_$&_\
M*6<ME<%%E^%'P;T35+W4/[*N5;?9KXUM_#.KZE:W"EI+34/%9G6/<@A'Z7_\
M%-OB;^WEI/BOP[\ ?V+OA)\;/"GPG\&^%-#&J>.?@W\/O$N-9OY[1?[/\+^&
MO$WA_1Y%T7P]X3TB.PM9(?#U[:3S:I->6-ZZP:9#;G\2_P#@EC\2-&^%W[>'
MP"U[Q%>PZ=HFL:YKO@:[N[C"Q1W?CWPGKOA/0!)*WRV\3^)]6T5)KB0K%# T
MKS/'$'=?VD_X*H_M<?MZ?LB_%[2=4^&'B/3M/^ ?CC0],;PSJ4_P]\,:_:Z-
MXLT^V-KXB\-:IK>I:+<W,.HW4D">(=-@O;IA>6.H3QZ:TJ:3?P6/L\8Y+F&"
M\4_#S@_*<MX:S3+,A\/N7AC*^,*^*P^28C-,-BJV#QV(A'#83&+%YS3R_"86
MM&C5HSC&,'BU..(C3YOF_#SB/*<R\#/%SQ!S_.>,LCSGBCQ8OQKGGA[A<#B^
M)<+D>+P6%S#+<+4GC<=@)8#AVKFV88[#SQ-#$4ZDYS^H^SGA9UE'T?\ X)XO
M^U9^T!\&OCS^S1^WU\./BS+X6U/PS!8^&/&WQ5\(ZUH.O:OH_B:/4[#7-$.N
MZWI5I+K.L^&[V+2_$'AW5YY;W6M-N)7>2Z,-AI:V_P">/_!$G]EK1_%_[2GQ
M2^)7CJQBOY?V:!I^F:'I=S$CVJ?$3Q/?>)=)L]:EAE#K,_AS3O"^ORV4;(6M
M-7OM*U2*6*ZTZW+>"V/_  6(_P""B6II?2:;X]T;4(]+LI-2U.2Q^$G@J[33
MM.A>.*74+YH/#TBV=E%+-#')=7!C@1Y8T:0,Z@_<?_! KXH1ZE\0?VJ?"6O:
MG:R>*/'%IX(^)-M YA@NM0?2-7\7V/BR]@@0)YD4=YXPT%IDB79;&X3:JK*<
M<?$_#7''!G ?C3G-6APWDE'B3#\-3I9-PAC,=6P>73>,H9;Q%B*=#$X'!K"?
MVGEF)=3%.DFII3G:$:4.;T.">,_#+Q'\4?HX<.T,5QEQ)B.#L7QE2K\1>(.7
MY7A\PS>$<NQ.<\(X.KBL'F>8/'K)<ZP2I8%5VI4Y.E2O5G7J./RE^W'_ ,%6
M/VE?%_Q^\;:%\%/B9KOPM^%GP^\4:KX6\*V7A(V^G7_B0^'K^;3KOQ1XCU)H
MY[S43K=[;3W5CI3R0:59:.UA:RZ8^H#4+V]_6']F+]IGXH_M4?\ !*W]J+QU
M\7[W3-7\8>&/A[^T1\/I->T[38=)GU_3]%^"UOJ]KJVLV=HR::-:ED\0W%O=
MRZ79Z;8S16UO(MA%.;B6;^9#]K'X,>+?@%^T-\5OAKXOTN]TZZTGQEK]UHMU
M=6]Q#!K_ (5U'5KVZ\.>)-+EN$4WFFZOIC0SQ7$9<).+FSF9;NUN8H_Z'?V
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M_DH^'_\ L=Y5_P"I^'/DRBBBO>/$"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _2GX/_P#*,?\ :]_[+'\%O_3MHU?FM7O'A?X_^)O"
MWP"^*'[/5KHVA7/A;XI>)?"7BK4]9N%U :_IFH>$;RWNK:&PDCO5TY[.[%K%
M'/'<6#SIF1X[CYE1/!Z^/X5R;'93C^.*^,A"%//.,:F<Y>X5(U'4P,N&^&LM
M4ZBBVZ4_K>6XN#ISM+EA&=N6<6_J^)<VP69X+@ZCA)SE4R;A2GE..4Z<H*&-
MAG^?X]P@Y:5(?5LPPTU4A>/-.4/BA)(HHHK[ ^4"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HI0">!4BH!R>3_*@ER2]>B&JA/)X'\ZD  X%+109.3?
MIT04444""BBB@ HHHH **** "BBGJG<\>WK_ (?SI-I;B;2W&A2>GY]JE"@>
MY]?\/2G45E*3?DOZW,I2;\E_6X4445)(444\(3UX'ZT - )Z5*% ]SZTH '2
MEH ****:3>P!1116JBHZOIU_K_AP;MJPHHHJ)3OHM//K_P  RE.^BT\^O_ "
MBBBH("BBE"D_3N: $J0)Z_E_]>G!0/KW-.H **** "BBB@ HHH )Z4 %.52?
M8?S^E/" =>3^E/H 0 #I_GZTM%% !11109RGT7W_ .04444&85^CW_!3G_DL
MOPC_ .S8?@W_ .B->K\X:]S^/OQZ\2?M"^)O"WBKQ3H^AZ-J/A?X>>%?AW##
MH"W\=E=V'A1+U+34)8]1O;^>.\NA>N;A$N&A!1?+502*^/S;)L=B^,^#\ZHP
MA+ 9/E_%6&QTY5(QJ0JYM3R:.#4*3]ZHIO UU-QO[.T>;22/K<JS?!83@_BW
M)JTYK'9OC^%\1@H*G*5.=/*JF;RQCG47NTW%8R@X*7\2\N7X6>&4H!/2G!">
MO _6I0,<"OK932VU?X'R0T*![GUIU%%9MM[@%%%%( HHHJE%R].Y$II:+5_D
M%%%%:J*7KW,VV]6%*%)Z?GVIZIW/Y?XU)4RG;1:^?3_@E1@]WMVZ_P# _,:%
M ]SZ_P"'I3J**R;OJRG)1T6_;_-_TPHHHH,VV]PHHHH$%%*%)Z?GVJ4*![GU
M_P /2@!JIW/Y?XU)110 4444 %% &>!4JIW//MZ?X_RH$Y);_=U&!2?8>M2@
M =*6B@R<F_)=O\^X4444$A1110 4444 %%%% !113U0GD\#^=)M+5B;2U8T
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MY]_\OS"BBBM5%+;[^I 4444P"BBBLY3[??\ \ #[_P!7_P"49'A?_L\6X_\
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M#$4L%C,/2Q-.C[+$0J4ZE6,UA:6&2.>*22&:%TEAEB=HY8Y(V#I)'(A#QNC
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M1K_A#_\ A8OB$Z]_PC/]L_\ "0?V/FQL[+[)_;7]E:)_:'_'IYGG_P!DV/\
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M;:2FKWTMS!IZW;0V[7TMK T<5SJ#V]LU_<K->O;P-.8D\K5.YY]O3_'^5.
MZ4M?<83"8? 83"X'"4U1PN#P]'"8:DG*2I8?#TXT:--2FY3DH4X1BG*4I-*\
MFW=GY?F&/Q>:8_&YGCZSQ..S'%XG'XW$2C"$J^+QE:>(Q-:4*<84XNK6J3FX
MTX0A%RM",8I)%%%%=!R!112@$]/\_6@!*>J$\G@>G?\ ^M3U4#W/\OI3J  #
M' HHHH **** "BBBLY3[??\ \ SE/M]__ "BBBLS,*** ">E6HMZO1?U]WJ
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M QP*B4TMM7^!$II;:O\  :% ]SZTZBBLVV]S)MO<****0!2@$]/\_6G!">O
M_6I  .E "*H'N?Y?2G444 %%%%7&'5Z>7?\ R_, HHHJW)1T2^7^9,I)>;_K
M<****R;;W,FV]PHHHI""BE"D_3UJ4*!]>YH :$]?R_\ KU)110 4444 %%%%
M !10 3TJ4(!UY/Z4 ,52?8?S^E2@ =/\_6EHH ****!.26_W=0HHHH,G)OR7
M;_/N%%%%!(444\(3UX'ZTFTMV T GI_GZU]I?MP?!SP!\%?B7X!\/_#O2;C1
M](\1?!'X<^.-1M+C4]1U;/B#Q'%JCZK/!/JES=W45O*UK"8[;SFBAVD1@!CG
MXS  Z5^CG_!3;_DLGPD_[-B^#G_I/KM? YWC\92X]X'P-'%8BE@L;E?&=3%X
M6%:I'#XJ>$I\/O"SQ%&,E3JSP[K5G0E.+=+VU7D:]I*_W&38/"5N!.-\;5PU
M"IC,'F?!U/"8J=*$L1AH8NIGT<5"A6<74I0Q"HT57C"48U?94^=2Y(V_.2BB
MBOMSX<****!-I:L****TC#J_N_S,Y3;T6B_,***D5.Y_+_&K;27Z?Y$I-[#
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MDR^;*_EI(L4>V.-%7P+PW_R,6@?]AK2O_2Z"OKC_ (*&_P#)X7Q?_P"Y _\
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MJ@>Y_E]*=110VWN9MMZL****0@HI0I/T[FI0H'U[F@#\N:***_4#^V HHHH
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MK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\
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M_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\
MAGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'
M_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9
M_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_A
MOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW
M$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]
M/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=
M_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2
M-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__
M ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V
M-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_P
MWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^J
MO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>
MG^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>
M0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")
M&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[
M_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";
M&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<
M'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]N
MK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\
MT4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/
M_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#A
MUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/
M_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'
MUG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E
M%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W
M5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__
M $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG
M_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\
MAGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'
M_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9
M_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_A
MOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW
M$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]
M/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=
M_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2
M-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__
M ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V
M-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_P
MWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^J
MO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>
MG^UG_P")&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>
M0?\ AGR[_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")
M&_&'_P";&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[
M_P"9_)?<'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";
M&C_AOC]NK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<
M'^LW$?\ T4&=_P#AUQ__ ,T'UG_PWQ^W5_T>G^UG_P")&_&'_P";&C_AOC]N
MK_H]/]K/_P 2-^,/_P V-?)E%'^JO"__ $3>0?\ AGR[_P"9_)?<'^LW$?\
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M $4&=_\ AUQ__P T'UG_ ,-\?MU?]'I_M9_^)&_&'_YL:/\ AOC]NK_H]/\
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M $4&=_\ AUQ__P T'UG_ ,-\?MU?]'I_M9_^)&_&'_YL:/\ AOC]NK_H]/\
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M $4&=_\ AUQ__P T'UG_ ,-\?MU?]'I_M9_^)&_&'_YL:/\ AOC]NK_H]/\
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M_P##?'[=7_1Z?[6?_B1OQA_^;&C_ (;X_;J_Z/3_ &L__$C?C#_\V-?)H!/
MJ14 Y/)_E1_JKPO_ -$WD'_AGR[_ .9_)?<2^)^(U_S4&=WZ+^U<?_\ +SZQ
M7]O;]NL\G]M/]K,#_LXWXP\_^7E4G_#>_P"W1_T>C^UE_P")&?&'_P";&ODV
MBC_57A?_ *)O(/\ PSY=_P#,_DON,WQ1Q(_^:@SM>7]JX_\ ^7GUE_PWO^W3
M_P!'H_M9?^)&?&#_ .;&C_AO?]NG_H]']K+_ ,2,^,'_ ,V-?)M%'^JO"_\
MT3>0?^&?+O\ YG\E]Q/^LW$G_109Y_X=L?\ _-'DON/K+_AO?]NG_H]']K+_
M ,2,^,'_ ,V-'_#>_P"W3_T>C^UE_P")&?&#_P";&ODVBC_57A?_ *)O(/\
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MC_57AC_HG,A_\,^7_P#S.'^L_$O_ $4.>?\ AVQ__P T'UA_PWI^W-_T>?\
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M_$BOB_\ _-C7R?14?ZJ\,?\ 1.9#_P"&?+__ )G(_P!:.)?^BBSW_P .V/\
M_FCR7W'UA_PWI^W-_P!'G_M8?^)%?%__ .;&C_AO3]N;_H\_]K#_ ,2*^+__
M ,V-?)]*%)Z?GVH_U5X8_P"B<R'_ ,,^7_\ S.'^M'$O_119[_X=L?\ _-'D
MON/J_P#X;T_;F_Z//_:P_P#$BOB__P#-C4B_MX_MS=3^V?\ M8?3_AHKXO\
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MC_Z/-_:N_P#$B?B]_P#-A2C]O#]N0]/VS/VKO_$B?B]^O_%85\IA">O _6I
M .E1+ACA=;<.9"W_ -B?+[?^HX?ZT<3?]%%GO_AWS#_YH/JP?MW_ +<8Z_MF
M?M7$_P#9Q/Q>Q^'_ !6%._X;P_;B_P"CR_VK?_$B/B]_\V%?*5%9OA?AE_\
M-.9#_P"&C+__ )G\@_UHXF_Z*+/?_#OF'_S0?5O_  WA^W%_T>7^U;_XD1\7
MO_FPKWK]H;_@IW^T_P#%+Q;X:UKX:_M _M,_"[1=&^'GA/PKJ>C:5\>/B%IL
M6M>)-%ANAK/BJXM] \16-H]YK,MQ'YUQ<+/?SK;1R75R[%4C_-BOJG]KKX#>
M&_V>_'W@WPKX7U?7-9T_Q1\)? OQ$FFU]K"2\M+_ ,5Q:B]UI\4FG65A!)9V
MILD%N[VXF(=O,9B!7SF/X=X"AQ+P[0Q7#^5K.*V#SZ>40IY7AXX6="C'*_[4
M>)ITZ2PTZD(U,']6EB(3E"];V#@Y5.;Z' <1<>3X<XAKX7/\T>44,9D,<VG4
MS/$2Q4*]:69++%AJE2J\13ISE#%_6%AYPC.U+VZE&,.63_AO#]N+_H\O]JW_
M ,2(^+W_ ,V%'_#>'[<7_1Y?[5O_ (D1\7O_ )L*^4J*^DCPIPR_^:<R%+O_
M &1E_E_U#^2^Y>1\W+BOB5:+B+/6_P#L;YAI_P"7!]6_\-X?MQ?]'E_M6_\
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M_P")"?%O_P":ZC_ANG]MS_H\;]JC_P 2$^+?_P UU?*]%'^J_#/_ $3N1?\
MAHR__P"9P_UJXH_Z*3/_ /P\9C_\T>2^X^J/^&Z?VW/^CQOVJ/\ Q(3XM_\
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M_P#$@_BU_P#-=1_PW1^VU_T>)^U/_P")!_%K_P":ZOEBBC_5?AG_ *)W(O\
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MG ?_ #/Y+[@_ULXJ_P"BFX@_\/.8_P#S2?4G_#<G[:W_ $>#^U)_XD#\6?\
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M\E]Q]1_\-Q?MJ_\ 1X'[4?\ XD!\6/\ YK:/^&XOVU?^CP/VH_\ Q(#XL?\
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M -1R/];^+/\ HI^(O_#UF7_S3Y+[CZ@_X;>_;1_Z.\_:@_\ #_?%?_YK*/\
MAM[]M'_H[S]J#_P_WQ7_ /FLKY?HH_U8X:_Z)[(O_#3E_P#\S^2^X/\ 6_BS
M_HI^(O\ P]9E_P#-/DON/J#_ (;>_;1_Z.\_:@_\/]\5_P#YK*/^&WOVT?\
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MMO\ ;1/3]KO]I_\ \/[\5O\ YK*^8E3N>/;U_P /YU*!C@4?ZL<-?]$]D?\
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M3Y'TW_PVO^V7_P!';?M-_P#A^OBI_P#-71_PVO\ ME_]';?M-_\ A^OBI_\
M-77S)11_JSPW_P!$_D?_ (:<!_\ ,_DON%_KCQ=_T5/$?_A\S/\ ^:CZ;_X;
M7_;+_P"CMOVF_P#P_7Q4_P#FKH_X;7_;+_Z.V_:;_P##]?%3_P":NOF2GA">
MO _6C_5GAO\ Z)_(_P#PTX#_ .9_)?<'^N/%W_14\1_^'S,__FH^F1^VM^V6
M>G[6W[3?_A^OBI^O_%5U(/VU?VRAU_:V_:;)_P"R]?%3'X?\577S, !TI:/]
M6>&_^B?R/_PTX#_YG\E]P?ZX\7?]%3Q'_P"'S,__ )J/IK_AM;]LG_H[7]IK
M_P /S\4__FKH_P"&UOVR?^CM?VFO_#\_%/\ ^:NOF6BC_5GAO_HG\C_\-. _
M^9_)?<'^N/%W_14\1_\ A\S/_P":CZ:_X;6_;)_Z.U_::_\ #\_%/_YJZ/\
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MI?\ S54?\-I_MC_]'9_M,?\ A]_BE_\ -57S/11_JSPY_P!$_DG_ (:L!_\
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M&T_VQ_\ H[/]IC_P^_Q2_P#FJKYGHKZ#_5GAS_HG\D_\-6 _^9SY7_7+B_\
MZ*KB3_P^9I_\U'TQ_P -I_MC_P#1V?[3'_A]_BE_\U5'_#:?[8__ $=G^TQ_
MX??XI?\ S55\ST4UPQPZ]N'\D]?[*P-O_4</]<N+_P#HJN)/_#YFG_S4?3'_
M  VG^V/_ -'9_M,?^'W^*7_S54H_;1_;'/\ S=G^TQCN?^%[_%+_ .:JOFH)
MZ_E_]>I*K_5KAJ.BX?R1ON\IP&C\O]G_ *[LB7&O%^RXJXD?G_;F::?^76OY
M'TL/VT?VQ1_S=E^TP?K\=_BE_P#-52_\-I?MB_\ 1V7[2_\ X??XI?\ S55\
MT45'^K7#G_1/Y)_X:L!_\SF?^N?&'_15\2_^'W-/_FKR7W'TO_PVE^V+_P!'
M9?M+_P#A]_BE_P#-51_PVE^V+_T=E^TO_P"'W^*7_P U5?-%%'^K/#G_ $3^
M2?\ AJP'_P SB_USXP_Z*OB7_P /N:?_ #5Y+[CZ7_X;2_;%_P"CLOVE_P#P
M^_Q2_P#FJH_X;2_;%_Z.R_:7_P##[_%+_P":JOFBBC_5GAS_ *)_)/\ PU8#
M_P"9P_USXP_Z*OB7_P /N:?_ #5Y+[CZ7_X;2_;%_P"CLOVE_P#P^_Q2_P#F
MJH_X;2_;%_Z.R_:7_P##[_%+_P":JOFBBC_5GAS_ *)_)/\ PU8#_P"9P_US
MXP_Z*OB7_P /N:?_ #5Y+[CZ7_X;2_;%_P"CLOVE_P#P^_Q2_P#FJH_X;2_;
M%_Z.R_:7_P##[_%+_P":JOFBBC_5GAS_ *)_)/\ PU8#_P"9P_USXP_Z*OB7
M_P /N:?_ #5Y+[CZ7_X;2_;%_P"CLOVE_P#P^_Q2_P#FJH'[:/[8QZ?M8_M+
M_P#A]_BE_P#-57S4JD^P_G]*E  Z?Y^M'^K/#G_1/Y)_X:L!_P#,X?ZY\8?]
M%7Q+_P"'W-/_ )J\E]Q]*C]L_P#;%'7]K+]I<G_LN_Q2Q_ZE-._X;0_;$_Z.
MP_:6_P##[?%'_P":FOFFBC_5GAS_ *)_)/\ PU8#_P"9P_USXO7_ #5?$B_[
MKN:>7_45Y+[D?2W_  VA^V)_T=A^TM_X?;XH_P#S4T?\-H?MB?\ 1V'[2W_A
M]OBC_P#-37S311_JSPY_T3^2?^&K ?\ S.9OC;C#[/%?$GK_ &YFGEM_M7DO
MZ1]+?\-H?MB?]'8?M+?^'V^*/_S4T?\ #:'[8G_1V'[2W_A]OBC_ /-37S4
M3TJ4*![GUH_U9X<_Z)_)/_#5@/\ YG(_USXP_P"BLXE_\/N:?_-1])K^V;^V
M)U/[6'[2P]O^%[?%'G_RZN/YU)_PV?\ MA_]'7_M*_\ A]?BC_\ -37S511_
MJSPY_P!$_DG_ (:L!_\ ,X?ZY\8?]%9Q+_X?<T_^:CZ5_P"&S_VP_P#HZ_\
M:5_\/K\4?_FIH_X;/_;#_P"CK_VE?_#Z_%'_ .:FOFJBC_5GAS_HG\D_\-6
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M2?\ AJP/_P H\E]P/C7C!:OBWB5?]UW-/_FKR7W>1])_\-F?M@?]'6_M)_\
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MX?LU_P#FL^DO^&R_VO\ _HZS]I+_ ,/G\3__ )J*/^&R_P!K_P#Z.L_:2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6W2K*AB,/6]G-*7LJU*I;EJ1;****^[/BPHHHH **** "BB@ GI0 4]4)Y/
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M12UE\EU?]?KNC\X;2W&!2?IW-2A0/KW-.HI.3>FR[(RE)OR78****DD****
M"BBB@ HHHH ***<%)]AZT - SP*E5.YY]O3_ !_E3@ .E+0 4444$N27KT04
M44H!/2@R<F_3HA*>J=SQ[>O^'\Z>% ]SZTZ@0 8X%%%% !1110 4445G*?\
M+]_^7_! ****S **** "E"D_3N:>$]?R_P#KU)0E?1$2GT6OGV_S_(:% ^O<
MTZBBM8PZO[O\_P"K&3=]6%%%%6 4H4GI^?:GJG<_E_C4E1*=M%KY]/\ @@-"
M@>Y]?\/2G445DW?5@%%%% !11103*27F_P O4****#)MO<****!!13@I/L/7
M_#UJ4*!T_/O0 Q4[G\O\:DHHH **** "BE )Z?Y^M2JH'N?Y?2@!@0GKP/UJ
M0 #I2T4 %%%% !1112<DO7HB7)+UZ(****R<F_3HC)R;].B"BBBDDWHA!10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5]9_L#_\GU?L6?\ 9V?[.7_JX?!M?)E?6?[ _P#R?5^Q
M9_V=G^SE_P"KA\&UX/%7_),<1_\ 8ASC_P!5^(/;X9_Y*/A__L=Y5_ZGX<^3
M****]X\0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-VU84445$I]%IY]_\OS,I3Z+3S[_ .7YA1114$!112A2>GY]J $J14[G\O\
M&G!0/<^O^'I3J "BBB@ HHHH *** ,\"@ IP4GV'K3U3N>?;T_Q_E3Z $  Z
M4M%% !11109RGT7W_P"7?^MPHHHH,PHHHH *4 GI_GZTY4SR>!^M2  =*B4T
MM%J_R 15 ]S_ "^E.HHK-MO5@%%%%( HHHJE%OTZLB4TM%J_R"BBBM5%+UZL
MS;;U85[_ /M$? '5?V>?%?A3PIJ_B'3_ !)<^*?AQX4^(L=UIMG<V=O96GBO
M^T&MM,=;J1Y)KBUCL0T\ZB.-WE*1H5C\Q_ U3N>/;U_P_G7Z/?\ !3/_ )+%
M\(_^S8O@Y_Z(UZOC,WSK'X3C3@_)L/5C' 9MEW%>(Q])TJ<I5:N5T\E>"<:L
MHNI35)XW$.4:<HJIS153FY(I?8Y1DV!Q?!O%^<8BE*6/RG'\+8? U54J15*E
MF=3.(XU2I1DJ=1U%@\.HRJ1DZ?++DY7-M_G(% ]SZ_X>E.HHKZQN^K/DVU%6
M7W?YA11109-M[A1110(**4 GI4H4#W/K0 Q4[GCV]?\ #^=2@8X%%% !1110
M 445(J=S^7^- FTMQH4GV'K_ (>M2A0.GY]Z6B@RE)OR7;_/N%%%%!(4444
M%%%% !1110 444Y5)Z\#^?T_QI-I:L3:6K$ )X%2*@')Y/\ *G  <"EK.4V]
M%HOS,Y3;T6B_,****48M^2_K;_/8@***<%)]AZUK917;]?Z[(!H!/2I0@'7D
M_I3@ .G^?K2UG*;>VB_$ HHHJ "BBB@ HHHH **** "BBE )Z?Y^M "4\(3U
MX'ZT]5 ]S_+Z4Z@SE/\ E^__ "_X(@ '2EHHH,PHHHH **** "BBB@ HHHH
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M^"__ )A/$?[&U;_H&WW_ ("S?_$4?V-JW_0-OO\ P%F_^(KVZBE_Q4T\1/\
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MR\?^.\_RI_\ 9.I_] ^\_P# >7_XFO8**/\ BIIXB?\ 1M^"_P#POSS_ .:
M_P"+<#P!_P"DA_&'_P ,?!?_ ,P^O]+7Q_\ LG4_^@?>?^ \O_Q-']DZG_T#
M[S_P'E_^)KV"BC_BIIXB?]&VX+_\+\\_^:!?\6X'@#_TD1XP_P#ACX*\N^ ?
MG_2U\?\ [)U/_H'WG_@/+_\ $T?V3J?_ $#[S_P'E_\ B:]@HI_\5-/$/_HV
MW!?_ (7YY_\ +_7^EK/_ !;>^ '_ $D1XQ?^&3@K_P"8/7^EKY -)U+O87GT
M^S3<_P#CE2C2]1' L+S_ ,!IO_B*]:HI?\5-/$3_ *-OP7_X7YY_\T"_XMO/
M #_I(CQA_P##'P5_\PGDO]F:E_SX7G_@--_\11_9FI?\^%Y_X#3?_$5ZU11_
MQ4T\1/\ HV_!?_A?GG_S0'_%MYX ?])$>,/_ (8^"O\ YA/)?[,U+_GPO/\
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M_$G_ ,37J5%4OVF?B&MO#;@OU^OYY?\ ]2"?^+;GZ/\ _P!)$^,7_ACX*_\
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M7YY_\O)_XMMOH_?])%>,?_ACX*_^8/7^EKYG_9]__P ^5U_WXE_^)H_L^_\
M^?*Z_P"_$O\ \37IE%'_ !4Q\0_^C;\&?^%^>?\ R\/^+;;Z/W_217C'_P"&
M/@K_ .8/7^EKYG_9]_\ \^5U_P!^)?\ XFGKIM]U-G<_3R9/U^6O2:*/^*F/
MB'_T;?@S_P +\\_^7A_Q;;?1^_Z2*\8__#'P5_\ ,'K_ $M?.OL%]_SYW/\
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M\[_^7^O]+6/^+;+Z/W_21?C'_P"&/@G_ .8#@?L-Y_SZW'_?F3_XFC[#>?\
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M_/N%%%%22%%%% !1110 4444 %%%/5">3P/YTTODN_\ 6[\A-I:L: 3P*D5
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MK Y=C<QKX# 8=T(87"1Q-/"K'5,P5157BJRI4*:CS5(S<_S(HK_1Z_X=$_\
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MRM('\):=JUEX69(+9%9M':9WGFEDGE_)O_@OY^QC^S!^RUX+_9IUG]G[X/\
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M*_I<_GH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OK/]@?_ )/J
M_8L_[.S_ &<O_5P^#:^3*^L_V!_^3ZOV+/\ L[/]G+_U</@VO!XJ_P"28XC_
M .Q#G'_JOQ![?#/_ "4?#_\ V.\J_P#4_#GR91117O'B!1110 4444 %%%%
M!1110 4444 %%%% !1110 44H!8X ))[#FK<=G(V"Y" C/\ >;\@0!^?X4FT
MMV"3>Q3HK:73X!C<7<]\G )]@H!'TW'ZFIELK7</W7_C\GI_O5$JL8]WZ)?J
MT7R2\CGZ*ZA-/LSG,([?QR>_^W4G]GV8_P"6"_\ ?3G^;5/MX=I?<O\ ,:I2
M;LFOO?\ D<G178+IMD0";=?^^G]?]ZIQI=@0/]&7H/XY/_BZAXJ"=N66GI_G
MZ_AWTKV$^\?O?^1Q%%=TNE:?N'^C+W_CD]#_ +=2_P!DZ=_SZI_WU)_\72>+
MII7<9_='R_O>O]/2_JM3^:'WR_\ D3@**]"32--.<VJ=OXI/?_;J==%TLCFT
M3K_?E]O^FE3]>I?RU/NC_P#)>O\ 3T/JM3^:'WR_^1/-J*]070])VC_0H^_\
M<OJ?^FE/&A:22/\ 0H^H_BE_^.5+Q]*-KPJ:]E'R_O>O]/2U@JC2?-#7SEY?
MW?7^GIY917K*^']') -C'_WW-Z?]=*L)X=T4DYL(SQ_?F]1_TTI?VC1_DJ_=
M'_Y/U_IZ'U&K_-3^^7_R/K_3T\>HKVA/#>AG.=/B[?QS>_\ TUI__",Z%_T#
MHO\ ON?_ ..U#S.@G9PJ_=#R_O\ K_3TI8"JW;GI_?+R_N^O]/3Q2BO<!X7T
M$@?\2V+H/^6D_P#\=IP\+: 2/^);%U'_ "TG_P#CM+^U*'_/NK]T/_DQ_P!G
M5OYZ7WR_^0]?Z>GAM%>\+X3\/$@'3(O^_MQZ?]=JE_X1+P[_ - R+_O[<_\
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MO_;_ *>ZD_X5AX#_ .A=MO\ P)O_ /Y+I?ZTX'_GQB__  &C_P#+O7^GH_\
M5W&?\_L-_P"!5?\ Y4?$E%?;Z_"[P$0"?#EM_P"!.H>O_7W4X^%?@ @?\4W;
M=!_R]:C_ /)E2^*L#&UZ&+U[1H^7_3[U_IZ6N&L8TG[?#:_WJOE_TZ]?Z>GP
MS17W0/A7\/\ (_XINVZC_EZU'U_Z_*G7X4_#XD ^&K7_ ,"=0]/^ORI?%F 2
MO]7QFG]RC_\ +_7\.^A_JUC/^?\ A?\ P*K_ /*O7^GI\(45]Z?\*G^'G_0L
MVO\ X%:C_P#)E2+\)?AV1SX9M>O_ #]:C[?]/E+_ %NR^W-]7QEO\%"^]O\
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M_P"?S5?;_I_J7QQEB=GA<?\ ^ 8?_P": ?!^8VTQ."3_ ,=?_P"4?U^7YK
M=/\ /UI:_2]/@C\+#G/A"S[?\ONK>_\ T_U.OP.^%1 )\'V?_@;JWK_V$*7^
MO66?] N/_P# ,/\ _-'K_3TS_P!3<Q_Z"<%_X'7_ /E!^9-%?IQ_PHWX4_\
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M_P#L7]67=G\_M%?T#_\ #(?[./\ T2[2O_!IXD_^752)^R'^SB<Y^%VD]O\
MF*>(_?\ ZC-9_P#$8N'O^A=G/_@K _\ S<"\(>(&K_VAD_\ X-QOE_U ^O\
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MIT.M#4-(O+K2KJ[@MM4L#+$+RPF=+NU,D8GB0NN?U7'[%7[+Q(_XM)H_4?\
M,7\4_P#R]KK/$_\ P3Z_9V\'W]GIVN_!S08+F^TRTUBV6'Q!XEN$DL+[S3:R
MEXM?(1I!$S&)]LB# D56.!\SF'BOP?B>).'<YJT,^I8O*<'GV'PF#5'++8NG
MFD<LCBJCYLQ53_95@Z+7(FOWSY[>[?Z+ ^%?&&&X=X@R>C7R*IA,WQ>15\7C
M76S*^$GED\Q>&IKERYT_]J>,JI\[4OW*Y/M6_F&HK^EC_AB7]EO_ *)%H_\
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M_92_Z([HW_@Z\6__ #05/_$=^%_^A5G_ /X)R[_YX^O]/1Q\"^)WI_:F0_\
M@[,/+_J7'\Q%%?T^+^PQ^R@0"?@YHW_@[\6^O_8P4O\ PPO^RA_T1S1O_!WX
MN_\ F@H_XCMPO_T*L_\ _!.7?_/'U_K:O^($<4?]#7(/_!V8_P#SN]?Z>G\P
M5."D^P]?\/6OZA%_85_9.+#/P;T7_P '7BWT_P"Q@JPG["G[)Q.#\&]%QC_H
M->+?;_J8*E^//"R=GE6?_*CEW_SR]?P[Z#\".*>F:Y!_X.S'Y_\ ,M^X_EX"
M@=/S[TM?U%?\,)_LF_\ 1&M%_P#!WXN_^:&I%_81_9,(Y^#6B]?^@WXN]O\
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MU &>!7]:Z_\ !/?]C@GGX':%T_Z#WC/V_P"IEJQ'_P $]?V-^?\ BQVA=O\
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M^/ (3UX'ZU( !TK^Q-?^"</[$Y )^ N@?^%#XX]?^QHI?^'<'[$__1!= _\
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MR?\ !,_]AK:/^,??#O?_ )F'QUZG_J:J>/\ @F?^PT2/^,??#O4?\S%XZ_\
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MY('_ !C7X9Z#_F9_B'_\V%2_I:\!1M?(.+]>V%R;R_ZG?K_3T?\ Q)AXB_\
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M^'2'_!.K_HV+PM_X5/Q'_P#FRH_XG!\/O^B=XR_\)<D_^?GK_3T/^)(/$O\
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MTU_P3R_Z-G\,?^%1\1?_ )L:/^'37_!/+_HV?PQ_X5'Q%_\ FQJ/^)NN /\
MHG^,?_"7)?\ Y^>O]/3/_B1;Q/\ ^BHX"_\ "WB'_P"AWU_IZ?P545_>M_PZ
M;_X)Y#_FV?PO_P"%/\1#_/QC1_PZ<_X)Y_\ 1L_A?_PI_B)_\V--?2[\/EOP
M]QBW_P!@N26_]7FO]:!_Q(MXG_\ 14<!?^%O$/\ ]#OK_3T_@IIZIW/'MZ_X
M?SK^]/\ X=.?\$\_^C9_"_\ X4_Q$_\ FQI?^'3O_!/3_HVCPQ_X5'Q%_P#F
MQJG]+W@![</\8K_N5R6_R_X7/7^M0_XD6\3_ /HJ. O_  MXA_\ H=]?Z>G\
M& &.!17]Y_\ PZ=_X)Z?]&T>&/\ PJ/B+_\ -C1_PZ=_X)Z?]&T>&/\ PJ/B
M+_\ -C4?\3=< ?\ 1/\ &/\ X2Y+_P#/SU_IZ'_$BWB?_P!%1P%_X6\0_P#T
M.^O]/3^#"BO[S_\ AT[_ ,$]/^C:/#'_ (5'Q%_^;&C_ (=._P#!/3_HVCPQ
M_P"%1\1?_FQH_P")NN /^B?XQ_\ "7)?_GYZ_P!/0_XD6\3_ /HJ. O_  MX
MA_\ H=]?Z>G\&%%?WG_\.G?^">G_ $;1X8_\*CXB_P#S8T?\.G?^">G_ $;1
MX8_\*CXB_P#S8T?\3=< ?]$_QC_X2Y+_ //SU_IZ'_$BWB?_ -%1P%_X6\0_
M_0[Z_P!/3^#"BO[S_P#AT[_P3T_Z-H\,?^%1\1?_ )L:/^'3O_!/3_HVCPQ_
MX5'Q%_\ FQH_XFZX _Z)_C'_ ,)<E_\ GYZ_T]#_ (D6\3_^BHX"_P#"WB'_
M .AWU_IZ?P845_>?_P .G?\ @GI_T;1X8_\ "H^(O_S8T?\ #IW_ ()Z?]&T
M>&/_  J/B+_\V-'_ !-UP!_T3_&/_A+DO_S\]?Z>A_Q(MXG_ /14<!?^%O$/
M_P!#OK_3T_@PIP4GV'K_ (>M?WF_\.G?^">G_1M'AC_PJ/B)_P#-C3O^'3__
M  3U_P"C:?#'_A3_ !$_^;"E_P 3=< ?]$_QA_X2Y+_\^P?T%?%#IQ1P%_X6
M\0_/_FG/N/X-0H'3\^]+7]Y/_#J#_@GM_P!&T^&/_"G^(G_S84?\.H/^">W_
M $;3X8_\*?XB?_-A1_Q-UP!_T3_&'_A+DO\ \^S/_B1/Q1>_%/ 7_A;Q#Y?]
M4YZ_AWT_@VHK^\G_ (=0?\$]O^C:?#'_ (4_Q$_^;"C_ (=0?\$]O^C:?#'_
M (4_Q$_^;"C_ (FZX _Z)_C#_P )<E_^?8O^)$O%#_HJ> ?_  MXA_\ H<]?
MZ>G\&U* 3P*_O(_X=0?\$]O^C:?#'_A3_$3_ .;"E_X=0?\ !/8=/V:?#(_[
MFCXB?_-C1_Q-UP!_T3_&'_A+DO\ \^P_XD2\4/\ HJ> ?_"WB'_Z'/7^GI_!
MTJ <GD_RI]?WA?\ #J'_ ()[_P#1M7AG_P *CXB?_-C1_P .H?\ @GO_ -&U
M>&?_  J/B)_\V-'_ !-UP!_T3_&'_A+DO_S[#_B1+Q0_Z*G@'_PMXA_^ASU_
MIZ?P>T5_>%_PZA_X)[_]&U>&?_"H^(G_ ,V-'_#J'_@GO_T;5X9_\*CXB?\
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M_P /YU*!C@4446[ZO\%Z+]=_R ****8!12@$]/\ /UJY9VC75S;VR<R3RQQ
MXR%WL 6QZ("68]@">*XLQS'!93@,;F>88BGA<!EV$Q./QV)JNU+#8/!T9XC$
MXBK))\M.C1ISJ3=G:,6TGL>GD>39KQ)G>3\-Y#@:^:9[Q!FN7Y)DV686*GBL
MQS;-<71P&78'#P;2E7Q>,Q%&A1BVN:I4BKZG5^$_#ZW;?VE>INMHW(MH6'$\
MJ'YI'!&&BB;Y0O(>0$-\L95_4*AMX([6"&WA7;%#&L:#OM0 9)[L>K'J6))Y
M-35_S6_2#\;<_P#';Q$S7BS,Z^(I9)0K5\!PAD<ZC]ADG#].JUA:2I*3I_VA
MC8QAC,VQ*O+$8VI*,91PM#"4*'_H??00^ASP1]"CP!X8\,.'<'@,3QECL'@<
M[\5N,J-&/UWC+CJOA8O,L3/%2A&N\BR>I4JY3PME\N6G@,GHTZDX3S/&YIC,
M84445^'']GA1110 445]X6'_  3)_;FU.QLM2L?@'JTUEJ%I;7UG,?&/PWA,
MMK=PI<6\IBG\91S1&2*1&,<T<<J9VR(C@J/0P&4YIFCJK+,MS#,714'66 P>
M)QCHJHY*FZJP].HZ:FX24'.W,XR4;\KM\MQ/QSP3P5'!SXRXPX6X2AF,J\,O
MGQ/Q!E.0QQT\*J3Q,<'+-<7A%BI8=5Z#KQH.;HJM2=1152%_@^BKFHZ?>:3J
M%]I>H0FVO]-O+G3[ZW+QR&"\LYWM[F$O$\D3F*:-T+QN\;%<H[*033K@::;3
M333:::LTUHTT]4T]&GL?3PG"I"%2G.-2G4C&<)PDI0G"24HSA*+<91E%IQDF
MTTTTVF%%%%(H**][^"G[,'QY_:+B\1S?!?X=:GX[B\)2:5%XBDL-0T+3TTR3
M6UU%]+21M;U73!.UTNE7[ 6OGF(6^9_*\V'S.5^+OP6^)_P&\5IX'^+?A*\\
M%^*I-)L]<31[V\TN^F;2M0ENH+.\\[2+_4;0)/+972*AN!,IA)>-0R%NV66Y
MC#!4\RG@,;#+JLG"ECY86O'!5)J4X.%/%.FJ$Y*<)P<8U&^:$XVO%I?.4>,.
M$<1Q%B>$,/Q3PY7XLP5%8C&<+T<[RRKQ%A,.Z.'Q*KXG)(8J694*+P^*PM=5
M:N&A!T<3AZJER5J<I>74445Q'T84444 %%%% !17]%O[''_!)'X#?%;]G;P)
M\4?BQXE\>ZEXI^)GA^/Q+;0>$M<TK1=(\,:9J3R-I5M:I-HNK2W^KQV:Q3:E
M<:A++9QW<KV2:6GV1Y[G\9/VN_@)'^S)^T/\1O@M:ZY+XCTWPE>Z3-HVLW,4
M$%]=Z+XC\/Z5XFTE-2AMF,*:E9V.L0V-^\<=O%=75M+>6]K;6US!"GUN<\$Y
M_D.39;GN84*$,!FGL50=.O&I5I2Q.'EBJ$,1327LY5:$)S7*ZBBXN%1PFU%_
M@_AY])#PN\4/$'B_PRX3S',L1Q1P7',:F90Q>5U\'@<70RC-,/DN:5\KQDY2
M6)I8/,L5AL//VU/#5*RK1KX6GB,-&=:'S;1117R1^\!1110 4444 %%%% !1
M110 4444 %%%% !1110 45^W7[,/_!('2_VB?@/\.OC1/\>]0\)S>.],U#47
M\/0_#>VUJ/3#8Z[JNC")=4?QOI;78D&FBX+FPMMAF,6Q@GF/^7W[3OP7A_9W
M^._Q%^#$'B*3Q9#X#U2QTU/$,VEKHLFIB]T/2]8,SZ6E_JBVAC.HFW""_N=P
MA$N]2_EI])FG"/$&397@,ZS' K#Y;F?U?ZEB%BL'6=7ZUAI8NA>C1KU*]/GH
M0E/][3ARVY9<LVHO\>X*\>O"OQ#XVXG\.N$>):F:<7\'?VI_K%E4LDS_  $<
M!_8N;4<CS+EQ^8Y7A,NQ?U?-*]+#+ZGB\1[92]M0]I0C*JO!J***^;/V$***
M* "BBOL7]A3]F72OVLOVA-"^%7B'Q!>^&_#*:+K7BKQ)?:2;0:W<:1H:6ROI
MNB-?17%I%J-]>7MG#]IGM+R.RM#=WIL[HVP@?MR[+\5FN/P>6X*"J8O'8BEA
ML/"4HPC*K6FH1YIR:C"*;O*3=HQ3;V/G>+N*LEX'X8S[C#B/$SPF1<-95C<Y
MS7$4Z-7$U:6"P-&=>LZ6'HQG5KUI1AR4J-.+E4J2C!:NY\=45^_7[?O_  2P
M^"_P&_9]\2?&WX/>(/&MC?\ @&?PZVO^'_%>KZ;KFF:[I&MZ_I?AAYK&X73-
M*O--UBVOM9M+YB;F[LKNV@N+.WTZ"YE@E'X"UZG$O#&:\)YA'+<WA1C7J8>G
MBZ4\/55:C5H5)U*:G"?+&2M4HU:<HSA"2E!NSBXRE\5X.^,_ _CIPI6XQX#Q
M./K97A<WQ61XVCFF!EE^/P69X3#8/&5,/7H.I6IR4L'F&"Q-.MAZ]>C.%=0]
MHJU.M2IE%%%?/'ZN%%%% !1110 4444 %%%?3'P>_8Y_:6^/OA:Z\:_"'X4Z
MOXU\+V>M7?AVXU>RU3PU801ZS8VFGW]W9"+6=:TVYD:&UU2PE::.![<F?RUF
M:6.9(^K!X'&YA66'P&#Q6.Q#C*:H8/#U<36<(VYI*E1A.;C&ZYI<ME=7>IXN
M?\2<.\*9>\VXHS_)>&\JC6I8=YEG^:X')\O6(K\RHT'C,QKX;#*M6<9*E2=3
MGJ<LN2+LSYGHKL_B'\//&7PI\9Z[\/?B#H<_AKQCX9N(;37=#NKBRNI]/N+B
MSMM0ABDGTZYO+*0R6=W;3@P7,JA90K,'#*O&5A5I5*-2I1K4YTJU*<Z56E5A
M*G4I5*<G&=.I"24H3A).,X22E&2::331Z.#QF$S'"87,,OQ6&QV QV&H8S!8
M[!UZ6*PF,PF*I1KX;%87$T)3HXC#8BC.%:A7HSG2JTIQJ4Y2A)-E%%%0=(44
M^..2:2.**-Y9976.**-6>221V"I'&B@L[NQ"JJ@LS$  D@5]9^&?V#OVQ?%V
MD0ZYH?[.WQ,DTRX@%S;3:EH?]@2W-NWW)K:RU^;3+ZXCE7#PM#;.)XF66'?&
MZN>S!Y=F&82G# 8'&8Z5-*4XX/"U\3*$7LYQHPFXIV=FTD['S^?\6<*\*4:&
M(XIXEX?X:H8F;I8:OG^<Y=D]'$5(V<J="IF.)PT*LXJ46X4Y2DKJZU1\DT5W
MGQ"^%OQ(^$NN'PU\3O OBOP#KIC::+3/%FA:CH=S=6RN8_MEB+^WA2_L6=2L
M=]9/<6DI'[N9QS5?X=_#SQE\6/&F@?#SX?:'-XD\9>*+N2QT'1(+FQLY=0NH
MK6XO98ENM3NK*P@$=K:W$[R75W!$J1-E\X!R>%Q2Q*P;PU=8MU8T%A71J?67
M7G)0A15#E]JZLI248TU'GE)J*3;2.U9WDTLHGQ!'-\LED-/!5<RGG:Q^%>40
MRZA2G7KYA/,E5^IQP5&C3J5JN*=94*=*$ZDZD81DUQ=%?9'Q"_X)^_M?_"GP
M7X@^(?C_ .#.H^'?!WA:S74->UJ;Q5X"OH]/LWN(+19GM-+\57VH3@W%S#'L
MM;2>3+AB@0,P^-ZVQV6YCEE2%',L!C<OJU(>UITL=A:^$J3IN3BJD(8BG3E*
M#E&4>=)QYHM7NF<'#7&'"7&>$KYAP?Q1P[Q7@,+B7@\3C>&L[RS/<)A\6J5.
MN\+7Q.5XK%4:6)5&M1K.A4G&JJ56G4<>2<6RBOOB+_@F!^W;-%'-%\ -5:.6
M-)8V_P"$T^&8W)(H9&PWC0,,J0<$ C/(!KX+FADMYI8)EV30220RH2"4DB8H
MZDJ2IVLI&5)!QD$CFKQV49ME:I/,\LS'+E7Y_8/'8+$X15O9J#J>R>(I4_:<
MBJ4W/DORJ<.:W,K\W#/'G W&LL=#@WC/A3BV>6?5_P"TH\,\191GTLO^MNNL
M+]>CE6,Q;PGUEX;$K#^W5/VSP]=4^9TJG+'117IWPS^"WQ;^,VHSZ5\*?AQX
MR^(%[:!6OE\+:!J&JV^G*ZLT;ZI?6T#6.F1R;2(I-0N;9)7PD;,[*IY*%"OB
M:L*&&HU<17J.U.C0ISJU9O>T*=.,IR=M;139[V8YGEN3X+$9EF^88+*\NPD/
M:8K'YCBZ&!P6&IW4>?$8K$U*5"C#F:7-4J1C=I7NT>8T5]3^-_V(?VMOAUHM
MQXC\7_L__$C3M#LH&NK_ %.TT-]=M=.M4C:66[U-_#\FJ'3;2&-&:XN;X6\%
MOP)I(R0#\L5MB\!CLOJ1I8_!8O!591YHT\7AJV&J2C>W-&%:$).-]+I6N>?D
M/%'#/%6&J8WA?B+(N),'1J>QJXO(<WR_.,-2JM<RI5*^7XC$4H5''WN24U*V
MMK!14UM;7%Y<06EI!-=7=U-%;6MK;1//<7-Q.ZQ0P00Q*TDTTTC+'%%&K/([
M*B*6(!^N-*_8#_;-UG1H]>L?V<?B:-/EA6XC6^T0:5J;Q."R,NAZK/9:V2RC
M<J#3_,*E2%(92:P>6YCF#J+ 8#&XYTDI55@\+7Q+IQ=[2J*C3GR)V=G*R=GV
M,L_XOX3X4CAI\4\4<.\-0QDY4\)+/\[RW)XXJI'EYH8:68XG#*O./-'FC2<I
M+FC=:J_R#16_XG\*^)_!.N7_ (8\9>'-=\)^)-+D$.IZ!XDTF_T/6=/E9%D6
M.]TS4X+:]MF>-TD030H7C=77*,I.=INF:EK6H6>DZ/I]]JVJZA<1VEAINFVE
MQ?ZA?74S!(;:SL[6.6YN;B5R%CAAC>1V(55).*Y73J1J.E*G.-53=-TG&2J*
MHGRN#@US*:E[KBUS7TM<]JGB\+6PL,=2Q.'JX*I0CBJ>,IUJ<\+4PTJ?M8XB
M&(C)TI4)4FJD:T9NFZ;YU+EU*-%?8>G_ /!/W]M'4]+76+;]G'XEI9O$DRQW
MND1:9J1CD0.O_$EU*ZM-8#[2-T1L!*C?(Z*_RU\P>+?!OB[P#KMYX7\<^%_$
M/@[Q)IY07V@>*-&U'0=9M/,&Z-KC3=4M[6\B25/GB=X0DJ$/&S(03V8K*LTP
M-.%7'9;C\'2J.U.IBL'B,/3J.U[0G6IPC-VUM%O34^?R/C?@OB;%8G \-\7\
M+\08W!Q<L7@\CS_*<VQ6%BI*#EB</@,7B*M"*E*,6ZL(I2DDW=I'-T45ZC\,
M/@E\7OC3J-QI?PG^&WC+X@7=GL.H?\(OH-_J=IIBRAS"^K:C#"=.TI)MCB&3
M4;JU29QLC9G(4\M"A7Q-6%##4:N(KU':G1H4YU:LWO:%.G&4Y.VMHIL]K,LS
MRW)L%B,RS?,,#E6782"J8K,,RQ>'P."PT')14\1BL54I4*,'*48J52I%<S2O
M=I'EU%?47CW]BC]K'X9:/<>(/&GP#^(^E:'9PFYOM7MM"DUS3M.ME5G>YU.[
M\/R:I#IMO&JGS9[][>*([5D=&90?EVM<7@,=E]14L?@\7@JLH\T:>+P];#5)
M1VYE"M"$G&^ETK'#D/$_#?%.%GCN&.(<CXCP5.I[*IC,AS; 9OA85;<WLYXC
M+\1B*,:G+KR2FI6UM8****Y3W HHHH **** *.I?\>4W_;/_ -&QURM=5J7_
M !Y3?]L__1L=<K7^V?[-S_DQO%7_ &=?//\ UD.!3_BL_P!(Z:7TWO"QO_I%
M7@C_ ->YXXA1117^@I_S^2FWHM%^/S"BBB@D***4*3].YH 2I GK^7_UZ<%
M^O<TZ@ HHHH **** "BBB@RE/HOOZ_+M_6P4444$!110!G@4 %."D^P]:>J=
MSS[>G^/\J?4.3>D?F^B_K]-F @ '2EHHIJ*6N[[L HHHJ@"G!2?8>O\ AZTY
M4[G\O\:DJ)3Z+[_\N_\ 6YG*?1??_EW_ *W$"@=/S[TM%%9&84444 %%%% !
M1110 4444 %* 3P*55)]A_/Z5*  ,"GHM]7V[>O^2^],B4TM%J_R&J@')Y/\
MJ?110VWN9MMZL****0@HI0I/3\^U2A0/<^O^'I0 U4[G\O\ &I*** "BBB@
MHHHH **** "BBB@ER2]>W];!114BIW/Y?XT&3DWO]Q^6=%%%?J!_;X4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_HH_\$6?^48O[*O\
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MY0PSJ<L:;I.IPU?Z*/\ P19_Y1B_LJ_]@#X@_P#JX?B'7^==7^BC_P $6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'X_S-65Z#Z#^55D^Z/Q_F:LKT'T'\JSJ=/G^AO'9>B_(<O4?4?SJRGWA^/\
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M?\/ZUF:PV?K^B)*F3[H_'^9J&ID^Z/Q_F:#JCLO1?D/7J/J/YU849(!J-5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGX#,J,,1AJ7C/PEFZIU(J47B^'L5+/\ +IN,DT_99AEF%JJZ>L$SU"BBBO\
MFP/_ $2 HHHH **** "O]!?P-_R)/@__ +%;P_\ ^FFTK_/HK_07\#?\B3X/
M_P"Q6\/_ /IIM*_H?P!_C\4_]>LG_P#2\R/\F?VIO_(M\%/^P[C_ /\ 4?@\
M_A1/@#Q'\5?V@;_X;^$(;6X\4>-_BEK'AO08+VZCL;275-4\27EM:)<WDO[J
MVA:5U#S/\J+ECP*^E/BY_P $S/VMO@OX3B\8>*?!.EZII]QKVA^&[:P\&Z[;
M^*]>N]7\17JZ;I%K9Z)I4,M]=-=W\D-H@@CD;SIX4"DN*P_V7_\ E(5\)O\
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MVI7_ &O_ (,R?%N3P.OP^:/QAKGA7^P$\2'Q4"-&M=*N1?\ ]J-H/AT@W/\
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M%@\HRS,<7E<,ZEE>#Q.:9IEV2X6G@\LG0Q.+Q^/Q>,]O6Q4<KP6%^O4>:O\
MR[_M*?\ !//]IG]EK11XL\?^&=)UWP.MQ%:77C;P%JDOB'0-,N;A_+MDUF.Y
ML-*UW1H+F0I#;ZAJ>BVFF2W4L%DEZ;V>&W?Y4^''@#Q'\5?'OA'X;^$(;6X\
M4>-]>T[PWH,%[=1V-I+JFJ7"6UHEQ>2_NK:%I74/,_RHN6/ K^XSX,^*=?\
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M<_4I5JU2M3JUX1P+>)S!TJ\*,*<5/ 2I3P[E3E:HYR]^*Y5^R^%WTV.)\^\
MO'/C?C7!\/X+Q%\+*E&C@<NPN QF RZM4XDC3R?A6..RW$YA7QE6I0XHI8ZC
MFM.CBZ+>%A1IKZM4;JOX.^.?_!.+]IO]G;X<:O\ %7XFZ/X.T_PCHEUI-E>S
M:=XUTC4=0:YUK4K;2K&*TTZ-H[B]=KJZC:6.U$LL-JEQ=O&+:VGDCP/V<?V
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M&#2]"T.SDO+ZY*(9)IF5,1VUG:PJ]Q>WUU)!96-K'+=7EQ!;QR2+QU?U??\
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M.)*>"@Y3ITJD\$^&L1F%&E/DA5K4)I2G6J3?].W_  4@_P"3(/VB?^Q+M?\
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M/6G*G<_E_C4E!F(% Z?GWI:** /ROHHHK]0/[@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O]%'_ ((L_P#*,7]E7_L ?$'_ -7#\0Z_
MSKJ_L\_X)@_\%8_V /V>?V$_@!\&_C%\>SX.^)/@C2?&-IXG\-GX6?&CQ!_9
ML^J?$GQGKVGJ-8\*_#K7-!O1<Z1JNGW@;3]4NEB%QY%P8KJ*>"+^6OI:</9_
MQ)P!D.#X=R/.,^QE'C#"8FMA,ERW&YIB:6&CDN>4I8BI0P-&O5A0C5JTJ<JT
MH*G&I5IP<E*<4_Z1^C!GN2</\<YUB\^SC*LDPE7A/%X:EBLWS#"9;AZF(EG&
M258T*=;&5J-.=:5.E5J1I1DYN%*I-1<82:\D_P""VG[>O[4'[(7[>WP*M?@W
M\4_$V@^!-.^!_P -?B-K_P ,H;_RO!?C35(?C!\6K35[7Q'I_DR&>W\1:)X=
MTW0=3EC9)QI\$1MWBGACE7^EWX$_&;P5^T3\&_AQ\;?A[>"^\'?$WPIIGBC2
M"[1O<68OH=NH:+J2QL\<6KZ!J<=[H6M6H9OLNJZ=>VK$F(U_"I_P7"_:L^ ?
M[8'[5_P^^)?[.GCS_A8G@G0_V>?"?@;5-:_X1?QGX2^R^*=,^)/Q:U^^TO\
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MR\7/^R3Q'_J7A#^]_P!EU_RL$^BG_P!G3R__ -5N9GJ%%%%?\WI_Z&(4444
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MXHY/+#5,-B*N5Y3# Y'B:\YS7-#"+$X>5?$UX--T85(X15(<\*E>I^[G.?\
MGAX,^&N4YSQ%P!PEQ']"CQ!I9QA,XRG!<:<=XGB;Q)R;+:%&A4A3Q.?RRC-:
M66Y-EN(A.,<QQ."K9Y+"8A4<1ALNPJ^LX:AAOS _8?\ B+^UM\&=<\<_%O\
M9K\%Z[XZ\,^%-,TQ?BWX?BT?4->\*W^BW5Q<-IHUK3--N;;47U&R,5_>Z=J6
MBEM6T6T35+N8KH<FL17']%?[&/\ P4O^&'[7'B%?AP_A#Q-\._BM%HUYK,V@
M7FW7O#>H6VEB$:F^D>)K*"VFC>U,HDDM]>T?1?E9(;6XOK@E*_-7_@FM_P %
M(OV>O@%\+;#X'_%3PG=?#B2WUG4=6E^)OA[3;[Q#I'BJ\U:X+R:EXVL;(7?B
M2QU>SM4L=)MKC2['6]/FTNPM8Q!HT=HD4_ZM3?\ !0W]@'0Q/XL3XW?#^*]U
M"#9=W^D^&O$E[XCNX5;S!#>6ND^%[C7W4.H98;JW^^ 0N[!KQO#BK@\JRK*J
M^%\1<MIX1Q]MG7#^:K"QIT*M2;G5IX&>*Q6#Q> E335.551K87$5U/$J-2$H
MP/T#Z7N#XAXXXWXWRS.?HE<8XS/X55EOASXJ<$U,[KXK,\#A*%&A@\3Q)A\E
MR7/\BXGIXF4)8FC@9ULOSK*<MGA\FG4PN(I5,4?"7_!;#]G?X>?\*S\.?M':
M3I-CHOQ&M/&FB>"_$FHV:):_\)?H&KZ7K4MF=5A0HE[K6BW>F6RV.HE&O6TB
M6[L[N6>ULM.6Q^^/^"95W;WG["W[/<UM(LL:>'?$=HS+T%Q8^//%=E=1G_:A
MN;>:)O\ :0U^!_\ P4K_ ."AND_M</X;^&WPPTO5=+^$?@W6Y/$DFI>(+:"S
MUKQCXKBM+_2+'5%L(I[EM*T/3-+U'4DTNVN)DU"]?5KBYU2TLY;>TM;?VO\
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M.'$&-IUDJ>/S++Z%3*J7M*E)4J>&JXF%6%:M""G5KS4*DZ-14J:ITY5)5O\
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M^@#X/U\G\,.,*'BCX75<KSFKQY7K8"CQ]P3/!9G4RQ\/9#"-7!T^(LLI8J>
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M^RFS=1M?)_77XM?\%7_V-?A-X7O#X)\7K\5/$=E;B+1/!'P_T?5;6RN)&5A
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M-+1:O^MQH0#KR?TI]%%#;?\ 7Z&;;>["BBBD(**4 GI4H4#W/K0 Q4[G\O\
M'_.:EHHH **** "BBB@ HHHH ****"7)+U[?UL%%%2*G<_E_C09.3>_W#0I/
ML/7_  ]:E"@=/S[TM% @HHHH ***D">OY?\ UZ3:6X'Y5T445^HG]P!1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_,TZFI]T?C_ #-.J2RQ4L2DD]ACK^(Z>M1CJ/J/YU:3K^']17.4I632^_\
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M^1IM.3[P_'^1I2V?H_R.@FJ5.A^O]!452IT/U_H*P-8;/U_1$@!/3_/UJ8<
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M44 %%%% !1110 4444 %%%% !7^.O^TA_P G$?'K_LM'Q2_]3C7:_P!BBO\
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ME6R''QI5(MIJ%2C5Y*U*I:].K"$UK%']-O\ P6+\&6'B[_@G[\9;JYBB>_\
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MS#+<70QV"Q--2E!SP^+PM2K0K04XR@Y4ZDHJ491;NFD4445D=H4444 %%%*
M20 "22  !DDG@  <DD]!0 E%:9T360"3I&I@ $DFPN@ !R228L  <DGI693<
M91MS1E&^UTU?TN9PJTJM_95*=2UK\DXSM?:_*W:_2^X4444C0**** "BBB@
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MU8T GI4H0#KR?TIP '3_ #]:6B]MOOZ_\#Y?-F<IM[:+\0HHHI$!112@$]*
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MRB.*E35&6)CEN.KX-5W24ZBI.LJ/M'352HH.7*IRMS,HHHKWCQ HHK[_ /\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%?*O[;7[1^A_LG?LN_&#XX:O>_9;_P +^%+VS\%VL9LS>:O\0]?7^Q/
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M0?0?RJ);0]/T199IZ=3]/ZBF4].I^G]14&Z:>VI9C[_A_6K*=#]?Z"JT??\
M#^M64Z'Z_P!!6,_B?R_)#'U.O0?0?RJ"IUZ#Z#^58Q^.7S_-%PW?I^J+-/3J
M?I_44T#) ]:F  Z5F:DL??\ #^M25''W_#^M25,_A?R_-%PW?I^J)D^Z/Q_F
M:M553[H_'^9JU6#2;3?3;^OD;1W7JOS')]X?C_(U93J?I_4570'(/8?_ *N*
ML)U/T_J*SF_>3[6_-LW+,??\/ZU:3[H_'^9JK'W_  _K5I/NC\?YFI;N[OJ
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M\ZSJ=/G^AI3Z_+]2>BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH ****
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MUW(481O\9O J+(5(1GC\$73.BMC:619(RZ@DJ)$) #KGYA_X.ZO^2D_L0?\
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MTI*7L:=*$X0P\Y)VC5JJK.;A=3A&$'))5(W^V\'N&\PIU<PXBK4IX:E4P%3
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M3/#8:&6:%R_C+QAX:\(1QEX(I7,4KZXL4\3((9X7DAN98;>26:/^#NOZNO\
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MV;+S]ESX,:Y\6_@SX8\7?$'Q7X0MO&>O:UK:ZF-1DC\7W%QXCT6QGB@O[>*
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MQ]2BZ\<NK5ZRG&,5S3C.O"C*'-36E25.%2C&6GM>3WSZ'$?M(?"E9]B,'EO
M_B-G/#&%S"GEM7BS+\MR]T:E6M4]CAJV'RRMCZ5=T<7-.6%I8K$8/,*U*S6
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M5IM,T+6"/#F@^&K.074L!NK*6_%@B-K.J7CPB2/Y;AKPZS_B3'YG@8*AEO\
M8U5X?,ZV.E)1P^(4JD/81C2C4E5J7I5)-Q:I1A'GE52G34_V[QC^EMX7>#_"
MO!O$V(EF?%W_ !$/ PS3@W+N&:-&I7S7*I4<'7_M2O6QU;"4\!@^3'X6G&-6
M,\=4Q%7V%/!3='%RPW\=U='X.T"7Q7XN\+>%X QF\2>(]#T"$)]\RZQJ=KIT
M83K\V^Y&WWQ7]@OCK]CK_@G/\<_ WB+7+'P=\%--\/\ A_3M1N-4^(/P4U?P
MSX2B\)1VMG-=W6K7VI>!+B'PX7TZUAFO&3Q/8:GIZ1PO)<V<L2,*_/\ _P""
M4O[-?[,/Q!OOC9XQD\.1?$N/X9?&[3(O@[XX\6PW^D:XNB:5$-5T#5Y-"L]4
MCTZ*\FN;:TU/R[NTDD$FQ9;>VR]E%[M3PES3#Y[DV5O-LFQ-'./K-7#XBCB*
MMY4<#35;%<U#V,JFL+PI5*7M:+J.,:E2DY)'YC@_IW<%9MX:>(?&T>!?$/)L
M?P#_ &/@LURG'97@;4\PXFQ;R[)E0S*6.HX1NGB)1Q&,PN,C@<?'"0JU\+@\
M73A*2]I_:H_X)B?L=_"[]G#XV?$3P;X UW3_ !5X+^''B?Q%X?OI_'OC+4(;
M75=,TZ:XLYY;*]UF:TNDCE16:"XBDAD VNC D5_+=7^@[XO\*>&_'7A?7O!W
MC#2K37/"WB72[O1]?T>^W_8]2TJ]B:&\L[GRI(I/)FB9DDV2(VTG##K7\V__
M  6!_9J^ 7P*\)_!#4_@W\.?#O@6^\0>(O&EAKDV@2WY_M&TL]-T&XLXKJ*Y
MO[J%OL\TLS0R"-9$\V50^UV4_9>+/A_AZ&#?$.2X;*,KR_*\'3AC,'AL/]5K
M8FM6QL*4:L(8>@J,W&->"<JDXRY8M+I?^>?H)_2KS7,\^AX4>(F;<><;<5\;
M<0XJOP_Q!G.;/.L!D^ R_ANOCJV"Q&(S7,Y9A0A5J99B9PIX/#U:3JUX3E9R
MJ./X54445_.9_KJ7-/T^_P!6O['2M+LKK4=3U.\MM/T[3[&"6ZO;^_O9DMK.
MRL[6!7FN;JZN)8X+>"%'EFED2.-6=@#_ $/?LP?\$3]%O/#.F>*_VH_%'B"V
MU_4[:*\3X9^!;ZPL(M!CGB5X[3Q/XGGLM3DU#5(Q)MO+'0([*SL;J+RXM;U:
M(L:_G9AFEMY8KBWED@G@D2:&:%VBEAEB8/'+%(A5XY(W571T8,C ,I! -?IK
MK_\ P5C_ &J]9^!&@?!VU\1C0O$>F[['6OC-I5U<P?$7Q%X?MXXH]*TYKY=J
MZ1J\ $BZKXKTZ1-<UF..Q?S[&]75KW6ON>",=P9E]?,,7Q;@,5F4Z.'C/*\+
M3BJF%KUU)JI2KTN:FG5DG"5*5>;PL:<:[J0=7V"E_-'TD>'/I#\5Y;PMD?@1
MQ1DO".'S'-:V&XUSO%5'A<[R[+94HSPF,RW&2HXJ4,%2G#$0QU'+*$<[JXFI
MET<)7IX%YE.G^QWC?_@BQ^R3X@T6XM/"%[\2/ &N>0PL-:M/$R>([5+H1LL4
MFIZ/X@L[D7]IYA62XM;'4-&GEVA(;ZU!)/\ .%^U'^S/X^_91^+.J?"OQ[]F
MO)8K6#6O#7B33TD32O%GA>^FN8+#7+".4M-;%I[2\L;^PG+3:?J=E>6OFW,$
M<%Y<_O!_P1>^/7QW^+-O\:_#/Q.\9>*_B'X4\(Q^#]0T'Q#XSU;4?$.KZ1K.
MN3:_%>Z+#K^K3W6I7EG>V>FQ7BV%Q=W$6EM9AK5+5-0D6?S+_@O-:Z*)/V9;
MU3"OB)T^+%K($1/M$VBQ-\/I8#=.!Y@AM;Z:X%BCD(9+O43$"PFQ^D<79#PI
MGGA]#C?(LHCD->C.F_84X0H1KTWF2RRM1J4J3^KS:JR]M0KTHQJ24%"7Q.$/
MX^\!/$[QS\-?I65_HV^)O'M;Q/RW,,/BX_VGBZ]?,J^78J'!\^-,NS#"8[&P
M6;8=5,%1679CEF,K5L+1J8AXBA=4J>)K^:?\$JOV)_V<_P!ISX3?$GQ7\9_!
M5]XIUKP_\1(O#VDW%MXL\5^'H[72_P#A&M(U)H3;^'M9TN&=WN[V9VFN$EE"
M[$1E1<'Y]_X*K_LR_!G]F'XH?#'PU\%_"]SX7T?Q)X"O-<UBVN?$'B#Q"USJ
M</B&^L(YUN/$.IZG<6ZBUACC\FWECA)7>8RY+']+_P#@A9_R0/XQ_P#97X__
M %"_#M8O_!63]CK]H_\ :2^*7PM\1_!3X;R>-M&\/> +[1-8O(_%7@C0?L>I
MR^(KV_CM3;^*/$NB7<VZTGBE$UM!-;_,4,OF*Z+IB.%\)C/"'+L9E?#]#%Y[
M6IX2?UG Y7'$9K57]IRC6E[3#T)XN:5%.-1W:5--2M%&&5^-6>\/?3ZXOR#C
M3Q5S'(O#++ZV<T8Y1Q/QI6RO@C!5'P9AJV!I?4\TS&AD>'J2S"HJF%AR0E+&
M34Z2=:5W^7/_  2[_9[^%'[2O[1'B'P#\8O#MQXF\+6'PG\1^*;73[;6]<T"
M2/6]/\3^"M-M+HWN@:AIMZZQV>LZA$;9[AK9S,LCQ-)%$R?<'_!4+]A3]F7]
MFO\ 9VT+Q_\ ![P'?>&?%5[\5O#?ABYU"Y\8^,=?C?1=1\-^,M0N[466OZ[J
M5DC27>D6$@N$MUN(Q"4CE6.657[/_@E?^Q-^T]^SK^T;XC\=?&7X7R^#/"M]
M\(_$OAFUU5_%O@/71+KE_P"*?!&HVEC]C\,^*-:U!#-9Z1J,WVB2T2U3[.8Y
M)TEEA23Z)_X+<_\ )H?A?_LNO@W_ -0[XB495PMA<)X49YB\WX>HX;.Z$,RG
M3Q&8Y5&AF=*"E1]C.%3$T(XJ$4N;V4DTDG+D>K)XX\;<ZSSZ<_AGD7 /BQCL
MY\.,RQ/!^&QF5<(\;U<RX,QV(J4\<\QP^)PF3YE7R;$UIR5+ZY2J0G-M4_;1
M^$_E$K[;_8M_8:^)G[97BN]M?#]Q%X2^'?AF>V3QI\1-2M);NSTZ6X"RQ:+H
M>GI);MKOB6XMB;I-/%U9V=E:!;K5-0LQ<Z?%?_$E?6G[(G[8OQ0_8^\>R>*O
M!$B:WX:UE(K7QK\/M4O)[?0/%=G")/LTKR1).VEZYIK2/)I.NVUO+<6ADFMI
MX;W3;N]L+G\4X>EDD<YP#XBAB9Y-[9?78X1M5>3E?*WR_O'153D>(C1<:[H^
MT5!^UY$_]'/%FGXD5?#SBB'A'7R?#^(3R^7^KE3/*<*F"^LJI!UHT_;/ZG#,
M)X55XY74S&-3*X9B\-+,J;P7MVOZ(O#/_!%_]CK1M(ALM<7XF>+M3$ 2YUK4
MO&?]F2R7!Y>>VL= TW3+&WC#$K#!-%>&.(*LTUQ(&F?\_P#]N#_@D-:_"#P%
MXA^,/[/'B+Q%XD\.^$K&ZUOQAX \6/97^O:;H%FKW&IZYX;US3[/3(]2LM%M
M%>[OM'U&P_M&/3;:ZO8=6U&>,63_  AXM_X**_MC>./BQ%\2K+XQ>-/#M^NL
M0W&@^ _"&K:I8?#^Q@%POV/05\$17,NDZ_:.OEVMP=?M=7U'5OE:_NKF8HR_
MV;VK-JWA*V?Q=I]G:-J?AR%O$^EW11["U:]TQ3K6GW!F9XVLX3)<V\QE=D:%
M6\QF4DG^ALCR[P\\1,%G>7Y3PVLGEED:4,/F4:%/#U[XB.(6&Q*J4:DI3E&6
M'E*KA\7*HIP<6W*3E[/_ ";\2N+/I9?1*XC\-N+..O%^7']'C*KCL1FW!]7,
M<5FF6)934RJIG.32PN/PM&CAZ=6CFM&C@LVR*G@Y4,3"JH0I4HTOK?\ GRPP
MRW$L5O;Q23SSR)###"C2RS2RL$CBBC0,\DDCLJ(B*6=B%4$D"OZ./V6?^"*_
M@^Y\&Z/XN_:AUWQ1)XLUJS@U#_A6WA+4+71=/\+PW48DCT[Q)K?V2_U'5M<B
MC9#>PZ1-I-AIMWYUDMQK"1K=M^8/_!-GX::+\2OVY/A#H]S&-0\-^&/$&N^/
M&^T* T\?@72=4U_PU++"Z[7W^(K+0&N('7:8FF5E(!4_T??\%./COXM_9_\
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MZ]S3J*!!1110 445(J=S^7^-)M+<!@4GI^?:I0H'N?7_  ]*=164I-^2_K<
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M\DM_>7OC._F2SK^DOX&?\%(?V(OVB-.M+OX<?M%_#D:I<:?#J$WA'QEKEO\
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MKOBCX6^+-)\)27#A7N[VS\6>&-=U32K-3P]Y/H^DW6I\8<6>CWF#AF5OW?\
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M7-KX(\*:;86=O8V^CV&H:_8W^JZ@D=M;HL^H:;8^$YKJ4E[F.ZE#W5Q^-/\
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M:6^F_P!H^(=4T[1M(GDT[2+::[72=-CTW0-+A@L9-1U.998[BXEOYFN-L?\
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M@UB.&LXRS"8C%YWB<7P_CY957C*M7S1SH5<;ASN?^"9W_)C'[/7_ &+6O_\
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MC\-I>V^E0W%MH&E6>B)JNM_8+#2+>[OYLSZO?SW%_J>HW)FBMY+>SM?YX/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@;QGB*\*,JN44E.2BI?6L36E)MI*-.E0P<ZDYO[,6HIO1R1^JYM^TL^CYEV
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MEX0_OG]EO_RL&^BG_P!G3P'_ *K,T/2Z***_YO3_ -#<**** "BBB@ HHHH
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MU>$O"V@WD_\ H=Y<0^1<W$UM^\\SR?-2-U[7X9?\%$/VQ?@YX%\/?#3X<?&
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M\IR/A?(\IRW.(2HSPTH9K@,!@</A<PA+#U*E"4<72K)T:DZ33A*47^E6M?\
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MAIGB*?5H[VUT^/3K:&VOM$\2Z+'_ &?%%&TJVMS:7+K//<R13Q"9EIG[2O\
MP4:_::_:CT!O!WC;7]#\+>!IW274O!?P\TR]T#1-<D@N([JU_MZ?4-5UO6]7
M@M)X89X-/N]7?2UN88+PV#7D$,\?ZMP;QCP7P?D\LSAAL?C^,L5A<30Q4I1J
MJA*53%SKTJ;K5:OLJ=&2AAGB*M*%2O4E2;4>9M/^'/I"?1]^D5](#Q!H\&XG
M-^%^%OH]9-GF39CDE*A5P3S*A0P>1T,NQN*A@,'@7C<7F-.I7SF&4X+&XC"Y
M;A:>.C"554Z<:D?'OVM?CM=_M)?M"_$SXO3":+3?$>NO;>%K*<,CZ?X.T2"+
M1?"UK)"25ANCHUC:76I+&%235;F_N-NZ9B?//A9\8_BE\$O$B^+OA-X[\2>
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M;#2K&SL;>WMHOH_QY_P<?_MT^)]+N],\)>#?V?\ X;S75M-#%K^B^#?%6O\
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MZK44<L?Y8_<OZZ+[@YI=W][+7VZ]_P"?RZ_\")?_ (NC[=>_\_EU_P"!$O\
M\756BERQ_EC]R_R\E]P<TOYI?>_ZZ+[BU]NO?^?RZ_\  B;_ .+I?[0OQTO;
ML?\ ;S-_\752BCDA_+'_ ,!7^0<TOYI?>_ZZ+[BY_:.H?\_UY_X$S_\ Q=+_
M &EJ/_/_ 'O_ (%3_P#QRJ5%')#^6/\ X"O\A\TOYI?>_P#/R1=_M+4?^?\
MO?\ P*G_ /CE+_:>I?\ 01OO_ NX_P#CE4:*.2'\D?\ P%?Y>2^X.>?\TO\
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M\O)?</VD_P">?_@3_P _)&I_;FM?]!C5/_!A=_\ QZE_M[7/^@SJO_@QO/\
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M>QH_\^J7_@N/^7DON#VU7_G[4_\  Y?YFY_PD_B7_H8=<_\ !M?_ /R12_\
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M5HL'A6_^P>EI_P"2%1Q>->OUS%)?]A%6[_\ )^W_  QW(^)_Q,'7XB^.R?\
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M_P#"2A_\K\E]P?VIF?\ T,<?_P"%>(_^6>2^X]0_X7?\:?\ HKWQ0_\ "_\
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M!_W47Q?_ /+BC_A?7QS_ .BT?%C_ ,.+XP_^7%>3T4?V5E?_ $+<!_X1X?\
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MS3A\?_CR3Q\;/BYG_LI/C+_Y=5Y*J$\G@?SJ0 #@4?V3E7_0LR__ ,(L-_\
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M /0JRW_PAPO_ ,J#^W,[_P"AQFO_ (<,7_\ +O)?<>T_\-(_M$CI\>_C2/\
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M7_X083_Y5Y+[A_ZP9]_T.\W_ /#EC?\ Y<>X?\-.?M)CI^T)\<!_W5CQ[_\
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MZQ\0_P#0]SG_ ,.F._\ EY[Q_P -3_M._P#1QOQX_P##O?$'_P":&C_AJ?\
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M&?'?_P .]\0/_FAKPBBC^PLD_P"A-E7_ (;L)_\ *0_UCXA_Z'V=?^'3'?\
MR_R7W'N__#4O[3G_ $<9\=__  [WQ _^:&C_ (:E_:<_Z.,^._\ X=[X@?\
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MW83_ .4GY]_K)Q%_T/\ .O\ PZ8[_P"7GNO_  U%^TS_ -'%?'7_ ,.YX_\
M_F@H_P"&HOVF?^CBOCK_ .'<\?\ _P T%>%5(J=S^7^-']A9)_T)LJ_\-V$_
M^4B?$O$*WS_.O_#KCO\ Y>>Y#]J']IH]/VB?CK]?^%N?$#'_ *D%2C]J#]I@
M?\W$_'4_7XN>/_\ YH*\,HH_L+)/^A-E7_ANPG_RDR?$_$;_ .9_G27_ &-<
M=_\ +SW3_AJ']IC_ *.(^.G_ (=OQ_\ _-!1_P -0_M,?]'$?'3_ ,.WX_\
M_F@KPNBC^PLD_P"A-E7_ (;L)_\ *2?]9>(_^A_G?_AUQW_R_P E]Q[I_P -
M0_M,?]'$?'3_ ,.WX_\ _F@H_P"&H?VF/^CB/CI_X=OQ_P#_ #05X73@I/L/
M6G_8>2?]"?*O_#?A/_E/DON#_67B/_H?YW_X=<=_\O\ )?<>Y#]J#]I@\#]H
MCXZ?^';\?_\ S05*O[3W[2_4_M$?'0^W_"V_'_'_ )<'/\J\-  Z4M']AY)_
MT)\J_P##?A/_ )3Y+[@_UEXC_P"A_G?_ (=<=_\ +_)?<>Y_\-0?M+?]'#_'
M/_P[7C[_ .:"C_AJ#]I;_HX?XY_^':\??_-!7AE%']AY)_T)\J_\-^$_^4^2
M^X/]9>(_^A_G?_AUQW_R_P E]Q[G_P -0?M+?]'#_'/_ ,.UX^_^:"C_ (:@
M_:6_Z.'^.?\ X=KQ]_\ -!7AE%']AY)_T)\J_P##?A/_ )3Y+[@_UEXB6O\
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MJ^_3\_Z[]")32VU?X#0H'N?6G445+;>YDVWN%%%%( HHHH *ZWP;_P A2?\
MZ\)?_2BUKDJZWP;_ ,A2?_KPE_\ 2BUK^>?I8?\ *.7BY_V2>(_]2\(?WS^R
MW_Y6#?13_P"SIX#_ -5F:'I=%%%?\WI_Z&X4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]9_L#_\GU?L
M6?\ 9V?[.7_JX?!M?)E?6?[ _P#R?5^Q9_V=G^SE_P"KA\&UX/%7_),<1_\
M8ASC_P!5^(/;X9_Y*/A__L=Y5_ZGX<^3****]X\0**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY?2E  Z4M!E*;>BT7X_,****"0HHIZH3R>!_.@!H!/ J14 Y/)_E3@ .!2T
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MA&E0K\3PSS+I9#1Q+H+#U<U6(@\'3K/$U*.'5.5;E4G6JTZ23]^<8W:^8Z4
MG@4Y4)Y/ _G4@ ' KZH^0&J@')Y/\J?110)M+<****#*4F_)=O\ /N%%%%!(
M4444 %%%% !12@$]*E"@>Y]:ER2\WV_S[ ,5.Y_+_'_.:EHHK)MO< HHHI %
M%* 3T_S]:E50/<_R^E!+DEZ]OZV&!">O _6I0,<"BBM(PZO[O\S)R;W^X***
M*T$%%%%)M+< HHHK*4F_)=O\^X!110!G@5(!3@I/L/6GJG<\^WI_C_*GT (
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M)7TA\A*=M%KY]/\ @C0H'N?7_#TIU%%!DW?5A1110 4 9X%."D^P]:E  Z4
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M_P#Y][S_ +Y@_P#C]>=T $]*/^*?WT;_ /H1<2_^)7FG_P D9_\ %>/]H?\
M]%MX<_\ BKN&O_D#T3_A+]/_ .?>\_[Y@_\ C].'BVP/_+M>#ZK#_P#'J\^"
M =>3^E/H_P"*?WT;_P#H1<2_^)7FG_R0O^*\?[0__HMO#G_Q5W#7_P A_5WY
M6[__ (2RQ_Y][O\ [YA_^/4?\)98_P#/O=_]\P__ !ZN HH_XI_?1O\ ^A%Q
M+_XE>:?_ "0?\5X_VA__ $6WAS_XJ[AK_P"0_J[\K=__ ,)98_\ /O=_]\P_
M_'J/^$LL?^?>[_[YA_\ CU<!11_Q3^^C=_T(N)?_ !*\T_\ D@_XKQ_M#_\
MHMO#G_Q5W#7_ ,A_5WY6[_\ X2RQ_P"?>[_[YA_^/4?\)98_\^]W_P!\P_\
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M4V7_ #PNO^^8O_CM<+13_P"*?WT;_P#H1<2_^)7FG_R0?\5YOVB/_1;>'/\
MXJWAK_Y [K_A*;+_ )X77_?,7_QVE'BBS/2WNO\ OF+]?WM<.$)Z\#]:D  Z
M5$OH ?1N6V1<2M_]E7FEO_2@_P"*\W[1'_HMO#G_ ,5;PU_\@=M_PDMG_P \
M+G\HO_CM'_"2V?\ SPN?RB_^.UQ5%3_Q(#]'#_H1<2_^)7FG_P E_5WY6/\
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M_MB#_GE+_P".?_%4?VQ!_P \I?\ QS_XJN>HH_XD$^CE_P!"/B3_ ,2K-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$E%?F_Z_(^"$J0)Z_E_]>G!0/KW-.K.4^BT\^_\ E^8!1114 %%%% !1110
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MU>E7^KXS#X6M&OA*[I3G[+$T)-*M0J<M6E)I3BG8****^X/S<***<%)]AZT
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M ^O<T -">OY?_7J2BB@ HHHH,Y3Z+[_\@HH )Z5*$ Z\G]*#,8JD^P_G]*E
M Z?Y^M+10 4444 %%%%)R2W^[J 4445DY-^2[?Y]P"BBBI VO#?_ ",6@?\
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M_P")/EO_ -"'K_2U^X/^'<O[7W_1.O"?_A\_@#_\]&C_ (=R_M??]$Z\)_\
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MO[7W_1.O"?\ X?/X _\ ST:^'Z*/JG&7_0^X8_\ $2S7_P"C7U_I:GUGA/\
MZ$O$7_B3Y;_]"'K_ $M?N#_AW+^U]_T3KPG_ .'S^ /_ ,]&C_AW+^U]_P!$
MZ\)_^'S^ /\ \]&OA^BCZIQE_P!#[AC_ ,1+-?\ Z-?7^EJ?6>$_^A+Q%_XD
M^6__ $(>O]+7[@_X=R_M??\ 1.O"?_A\_@#_ //1H_X=R_M??]$Z\)_^'S^
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M_P#/1KX?HH^J<9?]#[AC_P 1+-?_ *-?7^EJ?6>$_P#H2\1?^)/EO_T(>O\
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M>%=3U.Y@TS2?B-?:KJ,T%E:SRQV.F65YJ%VZK;V5K<7,D<+_ )$5]9_L#_\
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M  ^?P!_^>C7P_11]4XR_Z'W#'_B)9K_]&OK_ $M3ZSPG_P!"7B+_ ,2?+?\
MZ$/7^EK]P?\ #N7]K[_HG7A/_P /G\ ?_GHT?\.Y?VOO^B=>$_\ P^?P!_\
MGHU\/T4?5.,O^A]PQ_XB6:__ $:^O]+4^L\)_P#0EXB_\2?+?_H0]?Z6OW!_
MP[E_:^_Z)UX3_P##Y_ '_P">C1_P[E_:^_Z)UX3_ /#Y_ '_ .>C7P_11]4X
MR_Z'W#'_ (B6:_\ T:^O]+4^L\)_]"7B+_Q)\M_^A#U_I:_<'_#N7]K[_HG7
MA/\ \/G\ ?\ YZ-'_#N7]K[_ *)UX3_\/G\ ?_GHU\/T4?5.,O\ H?<,?^(E
MFO\ ]&OK_2U/K/"?_0EXB_\ $GRW_P"A#U_I:_<'_#N7]K[_ *)UX3_\/G\
M?_GHT?\ #N7]K[_HG7A/_P /G\ ?_GHU\/T4?5.,O^A]PQ_XB6:__1KZ_P!+
M4^L\)_\ 0EXB_P#$GRW_ .A#U_I:_<'_  [E_:^_Z)UX3_\ #Y_ '_YZ-'_#
MN7]K[_HG7A/_ ,/G\ ?_ )Z-?#]%'U3C+_H?<,?^(EFO_P!&OK_2U/K/"?\
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M\MO^,0?G^&_7[='_  3F_:['3X=^$_K_ ,+S^ .?_5H4O_#N?]KS_HG?A/\
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M  O+X!<?^90Y_E3_ /AW5^UU_P!$\\)_^'R^ 7_SSZ^(Z*/JO&/_ $/N&?\
MQ$\T_P#HT]?Z6I]:X1_Z$?$?_B4Y9_\ 0<?;G_#NK]KK_HGGA/\ \/E\ O\
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M>O\ 2U/K7"'_ $(^)/\ Q*LK_P#H-/MG_AW7^UU_T3SPI_X?'X!__//IZ_\
M!.O]KCJ?AYX4/M_PO#X"<?\ F3N?Y5\4  =*6LW0XQ>G]N\->JX4S1/I_P!5
MF[=?P\[GUKA#_H1\2?\ B597_P#0:?;/_#NW]KC_ *)YX4_\/A\!/_GG4?\
M#NW]KC_HGGA3_P /A\!/_GG5\345/U7C#_H>\-?^(IFG_P!&?K_2U/K7"'_0
MCXD_\2K*_P#Z#3[9_P"'=O[7'_1//"G_ (?#X"?_ #SJ/^'=O[7'_1//"G_A
M\/@)_P#/.KXFHH^J\8?]#WAO_P 13-/+_JL_7\.VH\5P@M7D?$G_ (E65_\
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M (>_X"__ #SJ^***/JO&/_0^X9_\1/-/_HT]?Z6I]:X/_P"A%Q+_ .)7E?\
M]!GK_2U^U_\ AWA^UM_T3WPI_P"'O^ O_P \ZC_AWA^UM_T3[PI_X>_X"_\
MSS:^+%3N?R_QJ2CZKQC_ -#WAK_Q$\T_^C0EXW@];9%Q(_\ NZ\K\O\ JC'Y
M_AV9]IC_ ()X_M9C_FGWA0GU_P"%W_ ;]/\ BYO%._X=Y_M:?]$^\*?^'O\
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M6G;7[3_X=Z_M9_\ 1/\ PI_X>[X#_P#SS:7_ (=Z?M:?]$^\*_\ A[?@/_\
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MMRK_ .@H^TO^'>W[67_1/_"O_A[?@1_\\RC_ (=[?M9?]$_\*_\ A[?@1_\
M/,KXMHH^J\7_ /0\X;_\17-/_HR#ZWP;_P!"'B;_ ,2W*O\ Z"C[2_X=[?M9
M?]$_\*_^'M^!'_SS*/\ AWM^UE_T3_PK_P"'M^!'_P \ROBVBCZKQ?\ ]#SA
MO_Q%<T_^C(/K?!O_ $(>)O\ Q+<J_P#H*/M+_AWM^UE_T3_PK_X>WX$?_/,H
M_P"'>W[67_1/_"O_ (>WX$?_ #S*^+0,\"I53N>?;T_Q_E1]5XO_ .AYPW_X
MBN:?_1D)XS@Q;Y#Q-Z?ZVY5?_P!8H^SA_P $]?VLC_S3_P + >O_  NSX$G^
M7Q,J4?\ !/;]K$=/A]X6_P##V? G_P">77Q?11]5XO\ ^AYPW_XBN:?_ $9&
M;QO!K_YD/$_HN+LJ_P#H)/M'_AWO^UC_ -$_\+?^'K^!/_SRZ/\ AWO^UC_T
M3_PM_P"'K^!/_P \NOBZBCZKQ?\ ]#SAO_Q%<T_^C(GZWP9_T(.)_P#Q+LJ_
M^@D^T?\ AWO^UC_T3_PM_P"'K^!/_P \NC_AWO\ M8_]$_\ "W_AZ_@3_P#/
M+KXNHH^J\7_]#SAO_P 17-/_ *,@^M\&?]"#B?\ \2[*O_H)/M'_ (=[_M9'
M_FG_ (6_\/9\"1_/XETO_#O;]K+_ *)_X5_\/;\"/_GF5\6T4?5>+_\ H>\-
M_P#B*9I_]&0?6^#/^A!Q/_XEV5?_ $$GVE_P[V_:R_Z)_P"%?_#V_ C_ .>9
M1_P[V_:R_P"B?^%?_#V_ C_YYE?%M%'U7C#_ *'O#7_B*9I_]&?K_2U7UO@W
M_H0\3_\ B6Y5_P#05Z_TM?M+_AWM^UE_T3_PK_X>WX$?_/,H_P"'>W[67_1/
M_"O_ (>WX$?_ #S*^+:>$)Z\#]:/JO&'_0]X:_\ $4S3_P"C/U_I:CQG!BWR
M'B;_ ,2W*O+_ *HG^M.VOV?_ ,.]OVLO^B?^%?\ P]OP(_\ GF5(O_!/;]J\
M?\R!X5)_[+9\"./I_P 7+KXP  Z4M'U7C#_H>\-?^(IFG_T9^O\ 2UR>-X->
MG]@<3I?]E=E6O_FD_P!>9]H?\.^?VL/^A \*_P#A[/@3_P#/+H_X=\_M8?\
M0@>%?_#V? G_ .>77Q?11]5XP_Z'O#7_ (BF:?\ T9^O]+6?K?!G_0@XG_\
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M#PM_X>OX%?\ SRZ^,**CZKQ=_P!#SAO_ ,17,_\ Z,?7^EK'UO@O_H0<4?\
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M;]O]<<H\O^J%T_K>VOV*/V /VJN_@+PN/^ZT? W/_JR*D'[ 7[5(Z> O"_\
MX>CX&_\ SR*^.**M8+B[=YYPXO+_ %5S/\?^,Q1F\;P0]^'N*O3_ %RRCR_Z
MH3U^_P"_[(_X8#_:J_Z$+PO_ .'H^!O_ ,\BC_A@/]JK_H0O"_\ X>CX&_\
MSR*^-Z*T^J\7_P#0\X;_ /$5S/\ ^C(GZYP/_P!$]Q7_ .)EE'_T">O]+7[(
M_P"& _VJO^A"\+_^'H^!O_SR*/\ A@/]JK_H0O"__AZ/@;_\\BOC>BD\-Q<M
M\]X;_P#$5S3_ .C(/KG _P#T3W%?_B991_\ 0)Z_TM?LC_A@/]JK_H0O"_\
MX>CX&_\ SR*/^& _VJO^A"\+_P#AZ/@;_P#/(KXWHK-X?B]_\SSARWEPMF?_
M -&(?7."/^B>XJ_\3'*/_H%/LC_A@/\ :J_Z$+PO_P"'H^!O_P \BC_A@/\
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M#L?^K(KX[  Z?Y^M+1]5XN_Z'G#G_B+9G_\ 1B9O'<$/;A[BM+_LLLH3Z?\
M5".W7^M#[&_X8%_:H_Z$/PO_ .'G^!W_ ,\BC_A@7]JC_H0_"_\ X>?X'?\
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M\@4\(3UX'ZU2PG%BUEG?#J_[M?,KO;HN+[]_-?+5/&\!K?ASBW_Q-<G_ /H
M/KP?L'?M1'_F1/#7X_&+X)__ #Q*E7]@W]J ?\R+X9)_[+%\$^/I_P 7$KY"
M  Z4M)X?BVUEG7#J7EPOF6OK_P 9?_75LS>/X$>G^K?%UO\ LMLFU_\ - 9]
M??\ #!_[4/\ T(OAG_P\7P3_ /GBT?\ #!_[4/\ T(OAG_P\7P3_ /GBU\@T
M5/U;BS_H=\._^(OF7_T7D_7> _\ HF^+O_$VR;_Z7Y]??\,'_M0_]"+X9_\
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MOF7_ -%XGCN UOPWQ=Z?Z[9-?_U@/7^EK]>?\,)?M/\ _0C>&?\ P\7P4_\
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MSZ[_ .&$_P!I_P#Z$;PU_P"'@^"O_P \.C_AA/\ :?\ ^A&\-?\ AX/@K_\
M/#KY$HK/ZMQ9_P!#KA[_ ,1C,O\ Z+@^N\!_]$WQ=_XFV3?_ $OSZ[_X83_:
M?_Z$;PU_X>#X*_\ SPZ/^&$_VG_^A&\-?^'@^"O_ ,\.OD2BCZMQ7_T.N'O_
M !&,R_\ HN#Z[P'_ -$WQ=_XFV3?_2_/KO\ X83_ &G_ /H1O#7_ (>#X*__
M #PZ/^&$_P!I_P#Z$;PU_P"'@^"O_P \.OD<(3UX'ZU( !TH^K<6=,ZX>_\
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M_P!$UQ?_ .)ODW_TOCZU7]A;]IH<GP/X:)_[*_\ !?C_ ,R%3_\ AAC]IO\
MZ$?PU_X=_P""_P#\\*ODBBLWA^+'J\ZX>_\ $8S+_P"BX/KO 7_1-<7_ /B;
MY-_]+X^M_P#AAC]IO_H1_#7_ (=_X+__ #PJ/^&&/VF_^A'\-?\ AW_@O_\
M/"KY(HI?5N*_^AUP]_XC&9?_ $7!]=X"_P"B:XO_ /$WR;_Z7Q];_P###'[3
M?_0C^&O_  [_ ,%__GA4?\,,?M-_]"/X:_\ #O\ P7_^>%7R111]6XK_ .AU
MP]_XC&9?_1<3+'\ K_FFN+V^W^N^3?\ TOCZX_X87_:<_P"A&\-_^'>^"_\
M\\*C_AA?]IS_ *$;PW_X=[X+_P#SPJ^1Z*/JW%G_ $.N'?\ Q&,R_P#HO]?Z
M6N3QW 3WX:XP_P#$XR7_ .E[Z_AVU^N/^&%_VG/^A&\-_P#AWO@O_P#/"H_X
M87_:<_Z$;PW_ .'>^"__ ,\*OD>BCZMQ9_T.N'?_ !&,R_\ HO\ 7^EJOKO
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MAC]IH=/ _AO_ ,.]\&/_ )X5?)5%'U;BS_H=<._^(QF7_P!%_K_2U/KO /\
MT37&'_B<9+_]+WU_I:_6W_##7[37_0C^&_\ P[WP8_\ GA4?\,-?M-?]"/X;
M_P##O?!C_P">%7R311]6XL_Z'7#O_B,9E_\ 1?Z_TM3Z[P#_ -$UQA_XG&2_
M_2]]?Z6OUM_PPU^TU_T(_AO_ ,.]\&/_ )X5'_##7[37_0C^&_\ P[WP8_\
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M4[:+7SZ?\$B4[:+7SZ?\$:% ]SZ_X>E.HHK)N^K,F[ZL**** "BBB@ HHHH
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M  <"EHHIVL 444 $]* "G*I/L/Y_2GA .O)_2GUG*?\ +]_^7_!,Y3_E^_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%GAK_P!F^H?^M=Q>%%%%?HI^?!1110 445(J=S^7^- # I/3\^U2A0/<^O\
MAZ4ZB@ HHHH$VEN%%%%!E*3?DOS]0HHHH)"BBG!2?8>O^'K0W;5@- SP*E5.
MYY]O3_'^5.  Z4M92FWMHOQ ****@ HHHH!NVK"BBBM(PZO[O\_ZN92G?1:>
M?5_Y!113E4GV'\_I5Z179$)-[#0">E2J@')Y/\J< !T_S]:6LY3;T6B_%FJ@
MEJ]U]R_KN%%%%0*4^WW_ / "BBB@S"BB@ GI0 4Y5)]A_/Z4\(!UY/Z4^@!
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M_P *LYR7G&+CTO<]5HKP]]7U20DOJ-Z<]A<S*OX*KA1^ %,_M+4?^?\ O?\
MP*G_ /CE;_49]:D?N;_R/47#->VN*I)];0FU][:O]R/<Z ">E>&?VEJ/_/\
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M_P#@9<?_ !RC^S9_\_8_^ O_ ##_ %5K_P#071_\%S_S]?Z>GT(J9Y/ _6I
M .E?._\ :NJ?]!*__P# RX_^.4?VKJG_ $$K_P#\#+C_ ..4UETNM2+^37ZD
MOA/$/?&4;=O93\O[VO7_ (%]/HFBOG;^U=4_Z"5__P"!EQ_\<H_M75/^@E?_
M /@9<?\ QRK^HS_GC]S)_P!4:_\ T&4?_!4__DO7^GI]$T5\[?VKJG_02O\
M_P #+C_XY1_:NJ?]!*__ / RX_\ CE'U&?\ S\C]S#_5&O\ ]!E'_P %3_\
MDO7^GI]$T5\[_P!K:K_T$]0_\#;G_P".4?VMJO\ T$]0_P# VY_^.5,L!-_\
MO8I=N5_YA_JCB/\ H,H_^"Y_YGT117SO_:VJ_P#03U#_ ,#;G_XY1_:VJ_\
M03U#_P #;G_XY4_V;/\ Y^Q_\!?^8?ZHXC_H,H_^"Y_YGT13@I/L/7_#UKYU
M_M;5?^@GJ'_@;<__ !RC^UM5_P"@GJ'_ (&W/_QRC^S9_P#/V/\ X"_\P_U1
MQ'_091_\%S_S/H\*!T_/O2U\W_VMJO\ T$]0_P# VY_^.4?VMJO_ $$]0_\
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M_P"@ZC_X)G_\F?3U.52>O _G]/\ &OE_^V=8_P"@KJ7_ ('77_QVE_MK6?\
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MH_MK6?\ H+:G_P"!]U_\=H_LJ?\ S^A_X"_\_7^GHO\ 4?$_]!]#_P $U/\
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MU_IZ?7=%?(G]NZW_ -!G5?\ P8W?_P >H_MW6_\ H,ZK_P"#&[_^/4?V5/\
MY_0_\!?^?K_3T/\ 4/%?]###_P#@FI_\EZ_T]/KU5)^GK_A4H '3_/UKX^_M
M_7?^@UJW_@QO/_CU']OZ[_T&M6_\&-Y_\>J'E%5_\OX)=N67XZZDO@+%O_F8
MX=+M[&IY?W]?^ MKZ?85%?'O]OZ[_P!!K5O_  8WG_QZC^W]=_Z#6K?^#&\_
M^/5/]C5/^?\ #_P&7^9/^H&*_P"ACA__  14_P#D_7^GI]A45\>_V_KO_0:U
M;_P8WG_QZC^W]=_Z#6K?^#&\_P#CU']C5/\ G_#_ ,!E_F'^H&*_Z&.'_P#!
M%3_Y/U_IZ?85%?'O]OZ[_P!!K5O_  8WG_QZC^W]=_Z#6K?^#&\_^/4?V-4_
MY_P_\!E_F'^H&*_Z&.'_ /!%3_Y/U_IZ?85%?'O]OZ[_ -!K5O\ P8WG_P >
MH_M_7?\ H-:M_P"#&\_^/4?V-4_Y_P /_ 9?YA_J!BO^ACA__!%3_P"3]?Z>
MGV%17Q[_ &_KO_0:U;_P8WG_ ,>H_M_7?^@UJW_@QO/_ (]3633OK6A;_#+_
M #_K\0_U Q7_ $,</_X)J?\ R1]A@$]/\_6I54#W/\OI7QO_ &_KO_0:U;_P
M8WG_ ,>H_M_7?^@UJW_@QO/_ (]3>45+65>"7E!^6[YO7UZ[Z2_#_%O_ )F6
M'2_Z\5/SYS[*HKXU_M_7?^@UJW_@QO/_ (]1_;^N_P#0:U;_ ,&-Y_\ 'J7]
MC3_Y_P /_ '_ /)>O]/2?^(>8O\ Z&6'_P#!%3_Y,^RJ*^-?[?UW_H-:M_X,
M;S_X]1_;^N_]!K5O_!C>?_'J/[&G_P _X?\ @#_^2]?Z>A_Q#S%_]#+#_P#@
MBI_\F?95%?&O]OZZ.FM:L/\ N)7G_P >I?\ A(->_P"@WJ__ (,KW_X]2_L:
MI_S_ (?^ 2_S#_B'F+_Z&6'_ /!%3_Y,^R:*^-O^$@U[_H-ZO_X,KW_X]1_P
MD&O?]!O5_P#P97O_ ,>H_L:I_P _X?\ @,O\P_XAYB_^AEA__!%3_P"3/LFB
MOC;_ (2#7O\ H-ZO_P"#*]_^/4?\)!KW_0;U?_P97O\ \>H_L:I_S_A_X#+_
M ##_ (AYB_\ H98?_P $5/\ Y,^R:D5.Y_+_ !KXR_X2#7O^@WJ__@RO?_CU
M+_PD.O\ _0<UC_P9WO\ \?H_L:I_S_A_X#+_ ##_ (AYB_\ H98?_P $5/\
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MS[>I0">!7Q!_PDGB+_H/ZU_X-+[_ ./T?\))XB_Z#^M?^#2^_P#C]']C5/\
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M# I/3\^U2A0OU]:=14RDWY+^MP"BBBI ***<JD^P_G]* &@$]*E" =>3^E.
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MQJ2BBAN_Z+M_7_#F3;>X4444A!12@$\"I%0#D\G^5 #50GD\#^=2  <"EHH
M**** "BBB@ HHHH ****!.26_P!W4***>J=SQ[>O^'\Z#)R;\EV_S[C0">E2
MA0/<^O\ AZ4X#' HH)"BBB@ HHIX0GKP/UI-I;L!H!/3_/UJ55 YZG_/2E
MZ4M9RFWHM%^/S ****@ HHHH!NVK"BBB@RE.^BT\^O\ P HHHK2,.K^[_,@*
M**4*3].YK31+LD E2!/7\O\ Z]."@?7N:=64I]%IY]_\OS ****@ HHHH **
M**#.4_Y?O_R_X(4444&8444 9X% !3@I/L/6GJG<\^WI_C_*GT ( !TI:**
M"BBB@#\EZ***_6#^\ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?6?[ __)]7[%G_ &=G^SE_
MZN'P;7R97UG^P/\ \GU?L6?]G9_LY?\ JX?!M>#Q5_R3'$?_ &(<X_\ 5?B#
MV^&?^2CX?_['>5?^I^'/DRBBBO>/$"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHIZ1O(VV-&=O15+''J0 <#W/% #**THM)O9<$1J@(R#(ZC\PNY@?
M8J".^*MIX?NV.#-;@8SD-*?3L8E_G6;JTUO./R=_RO\ UZ%JG.6T6_E;\_4P
MJ*Z(>&[ILXN+?CU\S_XBIU\*7C9_TFV&/^NO_P ;J?K%#_GY'\?\O/\ JS*5
M"JW90E^'^?\ 6O9G+45UJ^$+UNEU:]<<^;_\;J=/!-^_2[M!SC_EMZ9_YYU/
MUO#_ //V/X_Y#^K5_P#GW+\/\_/\^S.+HKN1X$U G'VRS_\ (_\ \:IX\ :D
M3@7ME_Y'_P#C53]=PO\ S^C]TO\ (KZKB'_RZE^'^9P=%>@CX=ZF0#]NL.?>
MX_\ C-2K\-M489%_IXX!Y^T=_P#MC2^OX/\ Y_P^Z7_R/G_5F-8/$O:C+\/\
M_,\YHKTD?#+5FSC4-.X]?M/_ ,8JPOPJU=NFI:;UQS]J_P#C%3_:."_Z"(?=
M+_Y$KZCB_P#GQ/\ \E_S/+J*]6'PEUDG']I:9_Y-?_(]3)\']:;'_$STOG/&
M;OMZ_P"CU+S3 +?$T_NG_P#(_P!:]F/^S\:]L//_ ,E5_2\E_D>2!2?IW-2A
M0/KW->OCX.ZX0"-3TG'UO/\ Y%J5?@QKS=-4TCIGEKW_ .1*C^U\M_Z"Z?;:
M?3_MTAY;F$M/JT[/IS0_/F/':*]F7X)Z^V?^)KHXQ[WO_P B4\?!#Q V<:MH
MW'J;W_Y$I/.<L6^+I_\ @-3_ .0!91F+VPE3[X?_ "1XM17N"_ GQ$W_ #%]
M%_.^/_MIG]*E7X!^)&Q_Q.-$&?4W_P#\AFD\[RI;XVDOE4_^0'_8^9?] E3[
MX?\ R9X517OB_L^^)6QC6M#&<][_ +9_Z<ZD'[/'B8G UO0OSU#_ .0ZEY[E
M*WQM+_P&I_\ (#639F]L'4^^'_R?F?/]%?0Z_LY>*&Z:[H/3/74/_D.GC]F[
MQ2V<:[X?X]3J/_R%4O/\G6^/H_=4_P#D!K)<T>V#J_?#_P"3/G6BOI#_ (9H
M\5?]!_P__P"5'_Y"J5?V8O%C8_XJ#PZ,G')U+_Y!I/B')EOCZ/\ X#4_^0_K
MY%+(LW>V!J_?3_\ D_Z^3/FH#/ J54[GGV]/\?Y5]-+^R]XMQQX@\.?B=3S_
M .D-2#]ESQ>1G_A(?#?YZG_\@5C+B3)MEF%%?*JG_P"D:$O(LZ>BP%9?.G?_
M -.>?]:GS)17T^O[*_C%^GB'PU^+:IZX_P"@>:F'[*/C(\_\)'X8Y&?O:K_\
MKA6?^LF1_P#0QH?=4_\ E?\ 6O9D_P"KN=?]"^M]]/\ ^6'RU17U4O[)GC1A
MD>)/#';JVJ]_^X=4Z_LB^-FS_P 5+X6&/]K5O_E=4OB;(5OF5!6\JO\ \K'_
M *MYX_\ F75O_ J7_P L\_ZL?)U2*G<_E_C7UJO[(/C88 \2^%<GC)?5^_\
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MCQEX'X]7U[_Y3U/^NO"JU><X7_P&OY?].O/^K,I<&\3O59/B?_ J'_RT^$
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M_AM]2_BC_P"4%6(_^"5?Q@(X^(?PU!YZOXH]<=?^$?J'XE<#I?\ )18/_P
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MZ4^OUU7_ (([_'%O^:G?"GKC_6>+_P#YFJE'_!'+XY$X_P"%G_"C_OYXO_\
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M@?\ !N[^TZ0#_P +M^ _(S_K?B#_ /,93Q_P;L_M/$ _\+N^ W/_ $U^(/\
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M_?WXB?\ S$U['_$>_!__ *+K*?\ P5F'_P Q>?Y]F>/_ ,2_>,G_ $06;_\
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ME\\9O^B!SC_P;EW_ ,V^?Y]F?SP45_0__P 0XG[4?_1<O@%_W]^(G_S%4?\
M$.)^U'_T7+X!?]_?B)_\Q5'_ !'OP?\ ^BZRG_P5F'_S%Y_GV8?\2^>,W_1
MYQ_X-R[_ .;?/\^S/YX*4 G@5_0]_P 0XG[4?_1<O@%_W]^(G_S%4\?\&X_[
M48X'QQ^ 7_?[XB?_ #$T?\1[\'_^BZRG_P %9A_\Q>?Y]F)_1\\9^G &</\
M[BY<O_=WS_/L?SQ*@')Y/\J?7]#?_$.1^U'_ -%Q^ 7_ '^^(G_S$T?\0Y'[
M4?\ T7'X!?\ ?[XB?_,31_Q'OP?_ .BZRG_P5F'_ ,Q>?Y]F9OZ/7C0]7P!G
M'_@W+?\ YN\_S[,_GDHK^AO_ (AR/VH_^BX_ +_O]\1/_F)H_P"(<C]J/_HN
M/P"_[_?$3_YB:/\ B/?@_P#]%UE/_@K,/_F+S_/LQ?\ $O/C1_T0&<?^#<M_
M^;O/\^S/YY* ">E?T-C_ (-R/VH^_P <?@%CVF^(G_S$U(/^#<K]J$=/CA\
M_P#O[\0_U_XHJC_B/?@__P!%UE/_ (*S#_YB\_S[,/\ B7GQH_Z(#./_  ;E
MO_S=Y_GV9_/*$ Z\G]*?7]#'_$.7^U%_T7'X!_\ ?[XA_P#S%4?\0Y?[47_1
M<?@'_P!_OB'_ /,51_Q'OP?_ .BZRG_P5F'_ ,Q>?Y]F'_$O/C1_T0&<?^#<
MM_\ F[S_ #[,_GGHK^AC_B'+_:B_Z+C\ _\ O]\0_P#YBJ/^(<O]J+_HN/P#
M_P"_WQ#_ /F*H_XCWX/_ /1=93_X*S#_ .8O/\^S#_B7GQH_Z(#./_!N6_\
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M?G^?9A_Q+OXT_P#1O\X_\&Y;_P#-Q_/.$)Z\#]:D  Z5_0M_Q#G?M0_]%P^
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M(U&?/BHTW0CRR:C+FFN5M)V;/ :***](X HHHH **** "BBB@ HHHH ****
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MY?BL%2QM)1A)SPT\12IQK)0J4YOV;DU"I3FTHU(.5"BBBO>/%"BBB@ HHHH
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M^BT\^K_R"BBBD0%%%* 3P* $IZH3R>!_.G*@')Y/\J?0 @ ' I:** "BBB@
MHHHH **** "BBB@SE/HOO_R"E )Z4Y4[GCV]?\/YU*!C@4&8T*![GUIU%% !
M1110 4H!/3_/UIP0GKP/UJ0 #I42FEMJ_P  $50/<_R^E.HHK-MO5@%%%%(
MHHHH)E)+S?8****I1<O3N9-M[A1116JBEZ]Q!12A2>GY]JE"@>Y]?\/2E*27
MF^W^?8!H3U_+_P"O4E%%9-M[@%%%%( HHHH$Y);_ '!11109.3?IV_K<****
M"0HH SP*E5.YY]O3_'^5 # I/L/6I0 .E+10 4444 %%%/"$]>!^M FTMV-
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M1>*'EJKSXJR.&;.ES_V>L+C98-5;7]D\S5JFC]UU%ELHWU2<=3_,OHK]/O\
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M7]&=$=UZK\RPGW1^/\S3J:GW1^/\S3JR-PHHHH **** "BBB@ HHHH ****
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MG!H'@9X;47VJZ;=W0MH7FF>* 2^5&TLC(@+L3[-'Z35.IX=X_P 1*_ 6;87
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M&^'BZDOB:QUI/%VH&UU"UO-,VR:7;V; W%]J=U-;Z=864=Q=:E<0V,5Q(O\
MIKZ2]_8^&],D\4W=D=4L]$LG\1WZ%+?3C?V]A&VKW:%]D<%D;A+B92^Q(H,%
MMJJ<?E7'F'X\^CUG/!V:91XI9MQ,\ZIU<=B<CQ]?&0IJAA)8*4J&8Y96S3,Z
M&)P>/CBJE"ABW##UZ=2C7>&Y:M/VL/TO@FOP5X[91Q7EN:>&V6<.K**E+!X?
M.,%1PLYNMBHXM1K8#,:.79=7P^+P4L-"M7PJG7HSIU:"Q'-3J.E+_*"H ).
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M2X;P.(J85YECZ,<2ZE2A&E+$590JXS+L/A\)2]M"F\17QL.:MS4XTVHRDO\
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MFUGQ?<6C^(O$.N:O<0RW-GX<T2,6D4AGA\.^'[&RB%K#4\?_  9_81_X*G_
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M>N#Z5_I<?M'_ /!/7]F']I;P%I?PY\3_  S\&^%M MO'/A#Q?JT_@;PCX?\
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MU'PCXEEU#6=<\!^%=6U6^DC^(GC&".2\U"_TJXN[ET@BBA1YYG98HXXU(1%
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MNX5L(USQ=J;2F_\ +I^'?_)0/ O_ &./AC_T]V-?ZFGQ'X^'GCS/_0F>*/\
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MNG0ZJND:#J&A^#H-+?PSXN\2RW0(\1:]?:M::A!8P6=S;Z0]M+J,@:2T_GX
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MU!'8BBO])#Q_\&?V$?\ @J?\"KW5(X?A_P#%_P 'ZZU_I.B_%OP/%IUMX_\
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MU*-&5>I3S#"U:Z^JU^2*G2@L74HUZ<N:EB)2IUZ=+^O?]C7]FWP5^R=^S?\
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MPY\22%(88P$AB0L5CB0!(T"HH  %?VS?$C]G;]GX_#SQZ#\"_@[@^"_%(/\
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MEF683GBJ=*%2K#"XJA@:M>G3G[%2J\E&?\5E%%%?UB?S&%%%% !1110!]5_
MQ2?">HX_Z&*[Y[?\@S2*]K"@>Y]?\/2O&/@5_P BCJ/_ &,=Y_Z;-(KVFOAL
MS;^NXE=%4?ST6Y_-7%W_ "4N<?\ 87+_ -(@%%%%<!\X%%%."D^P]: &@9X%
M2JG<\^WI_C_*G  =*6@ HHHH **** ;MJPHHHH,I3OHM//K_ , ****" HHI
M0">G^?K0 E/"$]>!^M/50/<_R^E.H 0 #I2T44 %%%% !11109RGV^__ ( 4
M444&84444 %*%)Z?GVIZIW/Y?XU)4N6MHZOOT7]?UV :% ]SZ_X>E.HHH4;:
MO5_EZ %%%%4 4H!/2G*G<\>WK_A_.I0,<"HE-+;5_@1*:6VK_ :% ]SZTZBB
MLVV]S)MO<****0!1110 4444 %%%% !12A2?IW-2A0/KW-.UM_NZ_/M^?EU)
ME)+S?8:$]?R_^O4E%%#=_ELNW]?>9-M[A1112$%%* 3P*D5 .3R?Y4 -5">3
MP/YU( !P*6B@ HHHH **** "BBB@ HHHH$Y);_=U"BBGJG<\>WK_ (?SH,G)
MOR7;_/N- )Z5*% ]SZTX#' HH)"BBB@ HHIX0GKP/UI-I;L!H!/3_/UJ55 ]
MS_+Z4H '2EK.4V]%HOQ^8!1114 %%%% -VU84444&4I]%IY]_P#+\PHHHK10
M[_=_P2 HHI0I/3\^U::+R0"5(J=S^7^-."@>Y]?\/2G5G*?1??U^7;^M@"BB
MBLP"BBB@ HHHH,Y3_E^__+_@A11109A110!G@4 %."D^P]:>J=SS[>G^/\J?
M0 @ '2EHHH **** "E )Z?Y^M."$]>!^M2  =*"7+I'5_@A%4#W/\OI3J**
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MP]B<=PE[#-)8;$O*)588;!4)TOKB@\)#$*MA<0G1E45:U-SY.5J3_P!*:O\
M,F_9J_Y/Z^ /_9W_ ,*__5SZ#7^FS7^=0/V7OC-^R7_P4Y_9U^&_QN\+Q^&/
M$&L_M-?!WQOX;:WUC1-;L?$?@C5_CS#I>B>*-/NM$U'44@LM5N="U-8K'4OL
M.LVAMGCU'3;.7"'\:^B7C\#0POBUE];&8:ECL?PU@JV"P=2O3AB<72P.%XA>
M,J8:C*2J5XX58G#O$.G&2I*M3<^523/UGZ3V!QE;&>%V/I87$5<%@N(<92QF
M+IT:D\/A:F,Q60?5(8BM&+A1EB7AZZH*I*/M72FH7<6C_17K_,F_9J_Y/Z^
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MU)-,&M:%:^+_  ^\%G]G?5M7U+P_ [RR6]M"WH9AP%C,'EN(Q\,;1Q'L,/\
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MO^&U_P!LO_H[;]IO_P /U\5/_FKH_P"&U_VR_P#H[;]IO_P_7Q4_^:NOL_\
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M#UH :!G@5*$ Z\G]*< !TI: /._'W_,)_P"W_P#]LZ\[KT3Q]_S"?^W_ /\
M;.O.Z]C"_P"[T_\ M_\ ]+D?H61?\BK"_P#<?_U)K!11170>L%%%% !1110
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MUF2/7=:37_$%]/I>@QR7UI!HEE:C3[QH;&0:D$LOJ[]CNP^&_P 1_P#@GO\
M _P]\#/$USX+\$^*/V;M"\*>'_%/P\O].A\2^!M;U#P9_8?B'5--O_(OK.T^
M(OA+Q?+J]SJD^H6MW/;^.-/OI=6MY[I;J-_A#QW_ ,$D?VJ/B%HE[X8\0?\
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M=+$JZ@^F:XMK_95U_/;_ ,$N?VU)_P#@EA^UC\7_ (8_M">'=0L/!'BC5O\
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MJ;]N;_D]G]L/_LZ;]H/_ -6UXNKY9K_4CA?_ ))GAW_L191_ZK\.?YN<1_\
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M_P DZ\ _]B5X5_\ 3%84?3;_ -S\./\ L)XI_P#37#X?0]_WOC__ +!^&O\
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M0:A"XN;%;R2ZLWAO8K>XA_SLZ_O_ /\ @OG_ ,HT/BW_ -CG\(?_ %8^@5_
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MXO#'BKXK>!O#GBBW(4$O:ZMH6IWVB:BAPIT[4[LN0JDC^,+X/^.E_P"";?\
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M:9=:MI&O:5+'<Z5K.JZ9?6>I:/?VL]K?/)''#?6]E>VO\;G[1/@"P_X(L_\
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MA?\ M[?\F,?MH?\ 9IW[1?\ ZI_QC7]9?2K_ .3H>$WIA_\ UH<,?S%]&?\
MY-QXF_XL1_ZHJY_+S_P;*6&B2?M&?M'ZE<+"?$=G\%=$LM)9HU-PNBZAXYTR
M?7_*E/SI$;W3?#?GHORR.("W,:U_4#^UW\(?V//C#X3\*Z/^V3;?#F[\&Z3X
MBFU+PG!\2_'TO@/2/^$F?3;BUEFL;A?$_AF+4=2CTJ6[187FNI+>UEN7BCC6
M25F_@]_X)5?MI6'[#7[77A7XH^*C?-\+O%.C:I\-OBQ'IUJ;Z^M_!WB*>PO8
M=<L[-<RSS>&/$^C^'_$%Q#:I+?WFDZ?JFF6$;W.H(C?W>?'GX _LR?\ !13]
MGVR\)^-I=+^)?PI\5MI_B_P3XX\#:_:/>:3JD$-S!IWBSP3XHL5O[:VU*"VO
M+ZPF$L%[97-K=7^DZQIUU;375HWR?TE,FS'A_P :<MXMS#&Y]DW#V=87*XX;
MB/A]3>/RV>"PG]G8^A@:BQ&#BL=0C!8N6&^MT95L-C&X5+SG&'TWT>\UP&>>
M$68\+X#!Y)FV>Y1B<REB,@SQQ^I9A#&8I8_ U\;!T,6W@ZTIO"1Q'U:M&CB,
M*N>G[L'+S_\ 9[N/^";_ .RIX<USPE^S[\3/V;OAIX<\2:TOB+6]*TGXY^&M
M0M[_ %M;&VTP:A(VO^.=6FBF^PV=K;,MO+%$R01EHRXW5_'/_P %T_%7P\\;
M?\%#?'WBGX;>*?#7C+2-6\!?"YM2\0>$]<TOQ%HMWK5CX2M-,ECAU71[F[L9
MIK73++2K:XCCN)'AEB,4FQU*+_13\-_^#=C]@7P)>:KJ7C'5/C3\6(;BPU&U
MM-/\;>.=)T31]%%Q;RQ0ZO"/ 'AGP;J-QJVFA_M$,NIZK=:*TT4;W.B21J\;
M_P 6/Q_^%D'P0^-GQ2^$=IXM\.^/;+X>^-M>\,:?XS\*:KI^LZ#XFTS3KV2/
M3=8LK[2[J\LA)>V!MY;ZP2YEFTG43=Z5=E;RRG1?T/Z.&5<$8WQ#XDXCX=XY
MXMXKSC#9"L/F-;B3*%@O[0H9GBL*WB8XZIF6.QF)J8*IEN'I5:>,IT&_;T)4
M)5H4ING\'X_9GQC@^!.'\@S[@SA?AG*L3G3KX"EP_FCQ:P-;+L-B+8>6#IX#
M!X3#T\7#,*]6E/"5*R7L:T:T:4JD%4_TOOV5/^37OV;O^R"?![_U7GAVO\V/
M]K0$?M4_M, @@C]H+XS @\$$?$;Q)D$=B*_OZ_X)0?M&^#/VCOV%O@!J?AS6
M;6]\2_#?X<^$?A)\1M%:\MYM:T+Q?\.]#L_"<\VL6D4CRVD?BBTT>W\5Z.\J
MJMUI6KV[*?.BN8H?RY_X*B_\$6_V<U^%W[7W[97PXU+XIZ9\78](\2?&Z?P=
M'X@\.W/PRCU.UU:'Q9\3-1BT63P@WBA$U30X_%&K1VB^,!9:;JUR9K2"/3(8
M=+B_.O GC3*?"[Q5XZR#B^GCL!C,^SBCD.%E'#.I3HYC'/Z]&FL7><94<-5C
MC8XB.*4:E+V$'43DIT^?[WQHX1S3Q(\-."\\X5G@\;A,ERFKG6)C+$*G4JX"
M624*LWAO=E&KB*<L)*C+#.4*BK35-I.%3E^,/^#;;]J'_A#_ (T?%#]E'Q#J
M/EZ+\7]$/Q#\ 6T\N(H_B%X%LV7Q'I]C#D W7B3P*9-4O)"&Q;_#ZV12A8A_
MV9_;C_8G@^-7_!1C_@FY\>H=%%SI'@_Q/XOTSXF:D8/,ABM_A5I6H_&CX10W
M> 5DBN/%UAXET]TFRK_;X5(:)9%K^&']GWXS>)?V=_C?\*_CAX0=O[?^%_CC
MP_XPM+82M!'JEOI5_%+J>A74BAF&G^(-*-[H>I* 2]AJ%S'_ !5_J#?#SQWX
M:^*7@'P3\2_!M\NI^$OB#X3\/>-/#.H* /MF@^)])M-:TFX959PCRV-[ TD>
MXF*0M&QW*:]GZ2^7YEX;^).$\1<@BZ-+C3AS/,DQTHMPIPS6KDE?(<36ER+E
MC-Y?C<OS#"QDOWV/P%:LW)QFUY/T><=E_'_A_B> <\DJM3A'/\GSG!PG:4YY
M93S>CG6&I1Y]906.P>.P.)E%_NL%CJ5)**E%/\5/^#A#]HS_ (4_^Q#_ ,*J
MTF_^R^*OVD/&.G^"DBBE\J[3P)X6DMO%OCF^A(.6MY9[7PQX6U", B6R\63(
MQ"L<_P (=?NA_P ' _[1G_"Y/VY;KX9:3?\ VKPI^SCX1TWP!!'#+YEG)XWU
MY(O%GCN_BY.RZADO]"\):BF%VW7@\K@[2[_A?7](_1MX/_U1\)\@5:E[/,.(
M_:<3X^\;2OFL:7]GQE?WER911R]2A*W)5=72+;1_/_T@>*O]:?$[.W2J^TP.
M0<G#F"L[Q2RV53Z_)6]U\^:U<<XSC\=)4M6DF?TE?\&S7_)U7Q^_[-]/_JQO
M!E?H/_P<QW$\?[*7P%MTFE2"X_:!1IX4D=8IVA^'?C,PF:,,$D,1=S&75C&6
M8K@L<_GQ_P &S7_)U7Q^_P"S?3_ZL;P97]4?[7G[&7P)_;>^&UE\+_CSH>L:
MGHFCZ]#XG\.:GX=UZ\\/:_X=\006=WIW]I:9>6_G6<[S:;?7UA/9ZOIVJ:=)
M#<M*;,7<%K<V_P#,'BUQ/EO!GTI\NXGS>GB:F6Y/2R'$8N.#I4ZV)]E/))8?
MGI4JE6C";ISK1J.+J1ERQER<T^6+_HSPOX<S#B[Z-F/X<RJ>'IYAFM7.J&%E
MBZDZ.']I#.(5W&K4ITZTX*I&E*FFJ<ES27-:/-)?AA_P;&ZEXDF^"G[4>D74
MURWA&P^*/@;4-"@=G-I%XBU3PIJ-OXIDMT(\M;B;3=(\(+=%&+-'#:;U 5"W
MC/\ P=!6&E1ZU^Q?JD9 UN[TOX]V%X  2VE:==_""XTTN>&4)=ZIJOE#Y@^^
M;[A3Y_Z1_P!F+]ESX%?L2?!Q?A5\&M(/A3P)I=]JWBW7]7\0:N;[5-8UB[M[
M<:OXI\5Z]>_9XI;E=-TVRM7G\NRT_3]*TRTM;:WM;.T1%_AS_P""S_[;&B?M
MF?M<ZA+\/]2MM6^#_P %])D^&GP\UFQD,UEXKFAOI;_Q?XUM9,M'+9:YKLAL
M-&N;=S;ZAX:T'0M314EO9E'9X2XNIXF_2;S?Q%X?P.*PG#> CF..Q,\12C2:
MHXCAZ?#F!IXCV<JE&&-S'$S_ +1^K*I4GRTL3/FG["<SF\4,+3\._HZY7P%G
MF-PV*S_&O 8+#PH5)5$ZU#/89_C)T/:1IU983 8>'U'ZPZ<(\U3#Q<8^VA$_
MNC_9+_Y-5_9F_P"S??@S_P"JY\-U_G;?\%"_B_X^^-O[:/[1WB[XAZ[=:WJ>
MG?%OQYX+T2*::=K'P_X0\%^*M8\/>&/#>BVLLLJ6&E:7IEE$$MX2!<7LU]J=
MT9M0U"]N9_\ 1)_9+_Y-5_9F_P"S??@S_P"JY\-U_FT_M9?\G3_M+_\ 9P'Q
ME_\ 5B^(Z]'Z).&P\_$'Q0Q4Z-*>)P].-&A7E"+JT:6)SG'2Q$*<VN:$:SP]
M!U%%KG]E"]^5'G?2AQ%>' OAOAH5JD</7G*K6HQG)4JM3#Y3@HT)U()\LY45
M7K*FY)\OM)VMS,_M'_X-X+#1+3_@G=97&E+"+_5/C5\3KWQ(8HU21M9B7P]I
MMO\ :&7YI91X=L-!"N_S"#R8Q\D:U^'W_!R#K_B:_P#VZ?!>@:K/=#P[H'[/
MO@V?PK9.S"S5-9\6>.YM:U*WCP$-S>ZE9_8;NX&Z26/1[.!WV6L21^H_\&_?
M_!0GP'\"->\9_LG?&KQ-8^$O!OQ3\36WC+X6^+-=O;73O#>B_$273+;1=?\
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M,HI9A14'*=:6!QF#J_78JG%87"UGB9R=+G</O<SJ4>'?''*<XS6KA<-E_&'
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M;P3:63GP[X/'B*UCN8O$?AVR\+>&-/U34WT>]T=8=0N-4@:#U.%,-P#QCB>
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MQ;P7BSZ+;I'=QS+!)<0A)G_ESHK]0XN\+.#>,^%\MX-S3+YX7A[*,5A,7EV
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MBVU'0)]2T[5WLKC1_&N@^(]$,B:AI-C/;WZ:<NHVH2:&UNX;>\O8KB/]I/\
M:M_: _:]\;:5\1/VBOB'=?$;Q?HGANU\(Z3J<V@^%/#,&G^'K/4=3U:#3[;1
M_!FA>'=$0_VCK&HW,UY_9IO[IIU2ZNIHK>V2'YYHK[C_ %?R'^V'Q%_8F4?Z
MP.A]5>>?V;@O[8>&Y5#ZN\S]C]=]AR)0]C[?V?*E'ELK'QW]NYW_ &5_8/\
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M;OX;_P#! 3]KGP-+XB:+XF_!;7[SX$_#6,7.-4MO#7[4,\[^'+ZRG=A-'?\
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M6)O!J7/EM#>_$;Q 8?"WPWT^6.3(E@O?'.MZ!;W:JDK+9O<2^5(L;*?\K/\
M:6^#/B/]EK]I;XS_  -U*YOK;7_@G\6?%_@NTU96>TO+N+PIXBN[;P_XELYH
M?*DA76--M].U_3;F+RF\B]MIXQ&2H']+?_!<G_@I$W[2G_!,_P#X)M>%M'UN
M&?Q!^TEX7@^.7QJ@T^1(Q%KWPET__A6VJ:1<QQ%0VD7WQ@N_B!-:P>6JB]\
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MA111092DWY+^MSSOQ]_S"?\ M_\ _;.O.Z]$\??\PG_M_P#_ &SKSNO8PO\
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M?2S#'4L=5YW5QE/%UX8NJZC3J.IB(U%6GSM)SYIOF:3E>Q[<WQ!\5_'SXP^
M]4_:-^+?Q \;QZIXA\'^%?%'Q ^(/B_Q!XX\2Z-X&?7X8M1,.L>*-2U+4/L6
MBV&H:I?V=C]K6UAF>=HT0S2,W^D9\6_A7\0?#?[+'BCX3?L37W@7X)>/]&\$
M6V@_!&[N=#L9/!/A&:RN;.2.'^S&TK6K&-;S2X]0L[?4KK1M92VU2_BUN^L=
M4>*>*?\ S!:_6#]FO_@M/^WI^S'X0TCX>^'/B!X=^(O@7PYI]MI7AGPU\7?#
M*^*U\.Z;9@1VVGZ9XATV_P##OC%M.M;=([.QTV_\27NGZ9910VFEVME!$B+_
M #UX\^$'$O'U+@W$\&XC)**X/Q6(Q"X9SBE[/(\<JM3!5*,OJU/#5\'5]C]4
MEAZV#QE!8:O@\16IQJTE[2EB?W7P4\5.'^":O%F'XLH9Q5?%6&H4'Q%E-3VF
M<X)TZ>,IUH_6)XBCBZ:J_68XBEB\+6>(HXK#TINE5:IU,/\ T&_ 'P%_P<17
M/Q?\&P_&CXW?"72/A3IWB/2[KQK>:[X=^ &L6VM>%[348FUC3M*L?AO\/;'Q
MA+J>I:;'-'IV_4_#"K+-"UUK&GNLA3]2_P#@H[\=/A[^S_\ L6?M"^+OB%JF
MGVD&N_"[QMX!\+:/>2Q?:?%WC7QQX8U;P]X;\,Z=9LWG7TE[>WPGU);>.8V&
MA6FJZO<HMCIUU+'_ "9^)O\ @XT_X*!:];&#2M'_ &>O!<OEE/MOAKX<^);N
MY#$']Z%\8_$'Q79[U)^4&T,>%4,C_,6_([X_?M1?M!_M2>)X_%WQ_P#BSXP^
M)VL6S7)TN/7]1"Z'H"7K1M=P>&/"^GQV7AGPO:W+0PM<6OA_2--MYVBC>:-W
M16'Y;@OHY\;<7<59#G7&F7>&_!&3Y+6P]:MEGA]E-/+\3FGL<3#$RA6AAJ,<
M/[6LZ2HO&U\;6EA:<F\/A)-S3_2<7X^<'\+<-9UE'"..X_XQS7-Z5:E2S'CK
M-)X[#Y<ZN'EAXRI3Q%:5?V='VDJJPE'"4HXFI&U?%12@UH>#/VP?VMOAQX8T
MGP3\//VI/VB_ ?@W08IH-#\)>#/C=\2_"_AC1H+F[GO[B'2=!T/Q/8Z5IT5Q
M?75U>31V=I"DMW<SW#AIII';QKQEXU\9?$7Q-JWC7X@^+?$WCOQEKTT5SKOB
MWQEKVJ^)_$VM7$-M#9PW&K:]K=W?:KJ,T-G;6]K%+>7<TD=M;PP(PBBC5>9H
MK^U\/E65X/$UL9A,MP&%Q>)Y_K&*P^#P]#$U_:356I[:O2IQJU?:5(JI/GE+
MGFE.5Y),_D"OF>98K#T<)BLPQN)PN'Y/88:OBZ];#T/9P=.G[&C4J2IT^2FW
M3AR1CRP;A&T78^L5_;V_;H151/VT?VL41%"HB_M%_&!555&%55'C$!54
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M3+\'G6;83 5N?VN!PV8XRA@ZO/?G]IAJ5:%&?/=\_-!\UW>]V?OQ_P $L/\
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ME#!T<%@:>+5.D\4Z4U>/D_COQKXD^)/C;QA\1/&6I2ZQXN\=^)]>\8^*-6F
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ML1B:M2O7JSLES5*U64ZDY627-*3=DE<^LA^WO^W2H"K^VE^UD%   '[1GQ@
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MOK/]@?\ Y/J_8L_[.S_9R_\ 5P^#:\'BK_DF.(_^Q#G'_JOQ![?#/_)1\/\
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MF*NKT'T'\JYJG3Y_H:0?3Y_D7(NGX+_(U=JE%T_!?Y&KM<9T4^OR_4O1=O\
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MX?UK13H?K_05A4Z?/]#HAN_3]46H>H^I_E5]/NC\?YFJ$/4?4_RJ^GW1^/\
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M.U]7[K0]!]#_ #K\*?\ @XT_Y1H^*/\ LK_PF_\ 3M?5Z60?\CO*O^P_"_\
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M)_"K_P!030:_R$Z_U[/V:?\ DW+X ?\ 9$_A5_Z@F@U\_P"*O^[Y+_U^QO\
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MKGX;?M:_#+]JC0M,%MX;_:?^'UO8^*KBWB_<I\5?A59Z5H.HRW#Q@1V_]K^
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MS&%'<,R1&:4QJ0AED(WG^7G_ (*>?LL?#K]C/]L'QW\ OA7J?B_6/!GAG0/
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MG-N65K+/JO\ 9TL!&R2S#'^V]M]=O>]+V?LMI\_NE%%%?O!^*A1110 4444
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M%%%%!DY-^2[?Y]PHHHH)"BBI%3N?R_QH :%)]AZ_X>M2A0.GY]Z6B@ HHHH
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MX:\(95E^'S)8C%8[&8JE'&5JE:IAZ'LX8'+DL91IK,,57C1E6C6A9>QE(_D
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MI<VE^'?<XQ\9\/POQB^ L#PGGW$_$^(RG!YIE.!RCV'+F#Q5;$PJTJM:K[F
MH8*AA*N)Q.,K\U*,'%*#]^4/&X4\):_$G"BXUQG$^2\.\.X?-<5EN:8W-/;<
MV!6'HX:=*I2HT_>QU;%UL52P^'PE'EJ2FI-S7NQE_%+17[):?\8?V /VRO\
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MMO5O<****YSI"BBB@ HHHH *_@G_ ."\'[&?_#-/[7-Y\5/">E?8_A7^TO\
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MOA5X3N+.X\3 7=LPN-.N_$UQ<Z7X$T34HDF&G^(_%FC7<\36L4[+_?M^VO\
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M^">W[)OPZBO?B%\./A_\6M<TC3(KOQQ\6_VA;'0]=TB:>-(C>7T/ASQ3)=>
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M]X[K]9\,O^4M_$'_ +NO_P!2< ?F/B)_RB[P-Z<,?^H^-/VZ_P"">7_!$/\
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MUP7E&/\ "_,>(LVX4X:R?BCASV&91CD%6EB:,(X7,,/&OE];,%E665,31Q.
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M.;J?5[?Q$_B'0?AYJ":)JPEM=8MDBO=/32]-^RR10)M^RPL58Y+?@G_P;_\
M['O[,W[4/@O]IG4/C_\ !WPI\4;WP?XH^&=EX9N/$B:BTFCVNL:5XQGU.&T^
MPW]F EY+86;R^8)#NMX]I49!_,K_ (+(?\I,/VK_ /L<O#/_ *K?P77[D_\
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M1-I+;3QQQ>.];\-WKJDL0E>V$!_=RL*_?'_@I[_P2L_9!\*?L+?M!>._@/\
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M>GMJO]C0F+1]1OK,3)I0E,=P\C2&8+*O]"WQ'_Y)YX\_[$SQ1_Z8[ZOX./\
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MF?$&.R["5<!@,:\FHU\DGBZ.#P.)G@J+ITL+.:]DZ%'#14HJI"E3=DOY)O\
M@@C^S5\"OVG/VB?C+X4^/?PT\/?$_P .^'_@L?$.C:3XC6]:UT_6O^$Y\+:;
M_:, LKNSD\_[#>W5MEW=/+G?Y-V"/Z+/'?\ P0M_8+\;_&'X>_$&'X<P^#O
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M 444H!/2M-%Y(!*>J=SQ[>O^'\Z>% ]SZTZLY3Z+[_\ (  QP****S ****
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MR,6(4?\ "U;1<D@#<VBZPJC)[LQ"J.I8@#DBOO3_ (.2/^3]? ?_ &;!\/\
M_P!6/\8*_=LY_P"4G.#O^S79Q_ZM\8?BV4_\HZ\5_P#9R,J_]5>$/8O^#9*X
MF7]H3]I2U61A;S?!KP]<2Q _(\UMXWM(X)&'=HTN[A5/82OZU^1?[4?PM\9?
M&?\ X*9?M,_"+X;:/_;7C;X@_MJ_'7PEX5TA)H+.&XU35OC/XMM;99[J=H[6
MQL;?<UQ>WEP\=M8V4,]S,Z0PNP_6[_@V4_Y.,_:0_P"R*:)_ZG6F5\:>$_C9
MX(_9V_X+H_$/XP?$B:*T\"^%OVZOVC[7Q-JD\#7-OH.F>*_'OQ+\&R>);F&-
M))FMO#,GB&/Q!<-;137<<.FR2VD$]RD43^-AL9C\N\</'',,IPGU_-<%X;9'
MC<MP*A.?U[,<+E<*V"PKA3<:DWB,13I4.6$E.2GRQ:=F>K7PF!S#P=\&\#FF
M*^I9;C/$'.<'F&-YHP^IX#$YDZ6+Q*G-2A!4*$ZE;FG%PBX\TDU<_2'7/^"9
M'_!*[_@F_P"!_"WB#_@HC\7O$OQ@^*/B:U>_T[X<^%;GQ+H6FZPUH$%Y;^&/
M"'@:XM/&EQI%G>-)92>,/%WC#P_H.J2PQQ?9-'NY)--;]8_^"2GQ_P#V'?C9
MX>^-^F?L0?L^:W\!_"W@37/ \'BXZ_H>@:/J'C2[URP\2C0M2EDTGQ;XQO[U
MM-@T74XMVLZF;B*.]B:,;YKF.'YC_P""EG_!'S7_ /@HM\:_ _[2GP=_:#\$
M:1H>L_#SPWX7U*#7;:_\3:'-H>E7>K:EI/B;P%K7AB>[L]4L]4M=;9WTJ4V=
MD]S')JEOKDHU-[>U^F_^"5_[./[)G[&,GQ@_9L^#?QUMOC;^T#8VW@SQ9^T5
MJ5I+BRTRXC?Q!I/AG2['2M,DU+0/#$>ER3:TMSX>F\0ZUXOMY-0BN_$4\=K=
MZ+:VW\R\:\39'Q;X48K,LUX]XYXQ\1\7'!8W-,@BLSPO"W"G)G.%AC?K>387
M!X7)<%A:%)+!4,56J8B>(S"OA:E"G24E[#^B>$.'LXX7\3<-E^6<$\&\*< 8
M5XS!Y;GDO[.Q'$G$SGE.(GA/JN;8G%XG-\9B:U2^+K8>C3HPH8&CB:=>I4<7
M[;^*;]E2*.#]OS]FZ&%$BAA_;!^#T44<:A4CCC^-'AU$1%& J(H"JH    '
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M_8U_P7*EDO/^"27[&5[<MYUW/\2_V=YI9W ,KR7/[-7Q7EG8OUS+)AW .&8
MD$@8_CEK^Q;_ (+A?\HB/V+?^RC?LX?^LS_%>OW#Q@2_XB3X .VJXPSE)];/
M+\%=7[.RNNMEV/QOPJ_Y-]XXKI_JIE#MTNL?B[.W=7=NUS^.FBBBOZ'/P@_L
M?_X((?\ *,3]L+_LJ?QD_P#6?/AK7\<%?V.?\$$Y(T_X)A_MBL\B(L7Q0^,L
MDA=U41Q_\,^?#<^8Y) 1,(YWMA<(W/RG'\<=?SOX1?\ )T?I!?\ 94<-_P#J
MLS#_ #1^\^*?_)N? S_LFL^_]6&!/W%_X-Z?^4B^A?\ 9(/BE_Z1:57AG_!;
M/_E*!^U/_P!A3X7_ /JD/AG7N7_!O4RC_@HQH ) +?"'XI*H) +-]@TQL*#U
M.U6; YVJ3T!KPW_@MG_RE _:G_["GPO_ /5(?#.C _\ *4N=?]F9P_\ ZU67
MDXS_ )1NRG_L[>(_]9C&'[C?\&QTTDOP7_:HLI&\RUC^)G@.98' :,27?A35
MHKAMAR#YT=K;HX((98E!X%?G[_P;96VB2_MS_$V6_6)M6M/V9?&DN@+-&K>7
M,_Q*^$UMJ$]M(W,=XFGS2VZ[/G>RNK\$[ X/W]_P;%?\DA_:K_[*1\.__48U
MVOYO?V /VM]2_8D_:K^'/QZ@LK[6/#FCW5_X?^(7AW3GA2\\0_#_ ,2V[:?X
MBL;07$D-O)J5@#:^(=$AN+BUMI=>T72TNKF&U:9Q\#5X?S#BCB;Z7/#^4J^8
MYGEW U+ TE)4_K&*CP]FN(IX7F=H1>,G2^K<TW&"=:\Y1CS27W%//,#PYP_]
M%O/,S?+E^7X_C.IC*KBY^PPTL]RNA4Q+BKRDL)"H\1RP4IVI6A&4K1?])G[:
ML'_!!>]_:E^,D_[5&L_$N#]H'_A)+6'XF0VL7[2#6<>LVNA:1:V:V1T#2[C0
MS8C18=+^Q?V/,^F?9?*^P[;;RU'1?LC_ +;_ /P0G_8?NO'EY^SO\2O'?A>X
M^)$'ARV\6-J_A#]HKQ3'>P^%9-;ET80P:]X9O8+1[=_$&IEI8(EFD68(7" J
MV_\ ME?\$U/V<_\ @KPNB_M?_L?_ !^\%Z/X[UW1=&TGQA>I;#7/"OBL:;IX
MBTB/QQIFEO#XL\!_$;1M,-CHVHKJMC=W3Z/I>EZ?=^'[6:R6_F_-CXJ_\$%?
M#G[,W[/7Q6^+?[2W[9/PV\)>+-$\(ZO=?"[0--M3H_A3Q)XVTZR?4=.\.WNO
M>+);77]=N-?:!]'L]&\,>%4U6WN+N'5A->PVLVF3? 9#'PJXAX3R?A+B_P 4
MO&+ 9O5I91P_FWAWBLRQU>.%S7"5,+1C@</E'^J^*I?V=A<50I8C!*<I_5<-
M2HJMR8BC*G'[C.GXEY#Q/FO%'"OAMX48W*Z53-,\ROCS#9?@Z,L3EN*IXBK+
M&5\T_P!8\-5^OXG#5JE#%N,8_6<15K>QYZ%6,WYA_P $&[O1[_\ X*C7M]X>
MB,&@7G@3XVW>APE&C,.CW$UI-ID11U1T,=D\"%'1&4C#*I! ^>/^"X.K:GJ?
M_!3S]I6'4;^[O8='D^%NDZ3#<SR31:;IB?!OX?WZV%C&[%+6T^W7]]>F"$)&
MUY>W=RRF>YF=_8O^#>IE'_!1C0 2 6^$/Q2502 6;[!IC84'J=JLV!SM4GH#
M7AO_  6S_P"4H'[4_P#V%/A?_P"J0^&=?O.6THT_I19K#6?L?!;"QA.I[]3W
M>*,OI\SFU=SE&ZE)6<KROHVC\3Q]6<_HXY=._+[;Q=Q,IQA>,'?AO&3Y>5.W
M+&5G&+NE96U2/$O^"?W["7Q&_;_^.,7PE\$ZK9^$M T729/%'Q%^(&I69U*R
M\&^%H;B&R2YATA+S3YM=UK5-0N+?3M%T6"]M#=3R2W5W>6.F6.H7UM^X_P 1
M_@Y_P0:_X)RZY)\/?C'9?$C]K#XY^%H88O%/A^SO]5\2W.D:L\"RRV^K:3HN
MO_#CX4:5.[/C_A&M;UC6]>T> Q#4HFG9+JX\'_X-QOVA_A=\)_V@_C)\*OB#
MKNC^%]:^.?A/P;;_  ]UC7+BWL+/4O$G@C5M>EF\%VVI7+I%!JWB2R\4O?:7
M9RO%'JMSX>&GP22:K-I=G>?4'QJ_X-VM:\6?M _%7XN^(OVK_"'A#X&^*?''
MBCXEZQK&O^'KV?QUH>E^(M=O/$FN6&K76HZKI?A)6TY+VZME\77FMI#-Y::I
M>Z!#F6QKX_Q'XUH+Q4SGA;C_ (YXFX!X(RO(<KQO#^&X96/R_%<7XO&TZ<L?
M.MFV68+&9C5IX?$2K8".7X>5*%:5#]VZ=6&(=?ZO@'A"L_#3*>).".#.'>-^
M,,RSK,L'GF(XB>"QV'X5PN$J3C@8TLKS#%X7 4YXBA"EC98[$1JSHQK/G4Z<
MZ"H?9W[77Q#^#?QB_P"""_Q'^('P(^'#_"SX/:_X"\.2>!_AW=:=I&G2>&++
M0OVB/#VDRV[6&BWNHZ7 \FMZ3>:I$UK>W!<W*7$KK=/*J_FK_P &QO\ R6[]
MJ+_LE?@G_P!2Z]K]'OVL(OV:-$_X(4_&KP9^R9XT_P"$[^!_PZT'3/ 'A[Q5
M-J%WJ<NK:UHO[0'A9/%%W+J]Y8Z9#JTFH^*+S4K^'4-(LXO#U]%?02^&E&B2
M:>B_G#_P;&_\EN_:B_[)7X)_]2Z]K\RRF%&G]';Z0$,-0S/#85>(V9/"X?.H
MUXYO1PTL;PC+#T\TCB93Q"S&-!TUC'7G.L\1SNI.4FY/]$S6=6?CQX&SQ%;+
ML1B7P%EZQ-?*)49975Q$<)Q.J\\MEAXQH/ 2K*H\)[&,:2H<BIQC&R7X3?MN
M_P#)Z'[7?_9S_P ??_5K>+*_I-_X-?VUT^%OVRDG>4^&5\0? YM*C9Y# FNO
MIWQ3'B!X8R?)6633T\-+<.@$CI%:K(2J187]HK_@@OX)_:L^.'Q5^-W[,W[7
M/A%M"\9_%KX@7GQ*\.:YI4'C:;P/\2KCQ7JES\0M!L]=\):S:*TNF>)9]2@B
M\+Z[I6F:GH\4<5M=:SJ09+L_1OQ<^)?[.7_!"K]AC6/V?_A/X\L_%O[47C;3
M=5UO0+>[ALY?%?B'XA^*+.RT.Z^+'BG1+$W4'A3P5X4LK."3PKH^K7+IJL>@
M6?A^TOM;OY-?UQ/L/$+Q(X<\2O#/)_"O@EXW.^->)/\ 5?*ZF4RRK,\)6R'^
MR\5EV-Q^-S2IBL'3HX?#X:6!]C7K4JE6G##UJF*YWAJ<JC^5X$\/\_\ #[Q#
MS7Q*XP6$R?A#A_\ UCS*GFBS/+\32SO^T\-C\)@<)EL,-BJE6O6Q"QBK4:52
MG2G*M2IX;D6(G&FOY^OV%_VF=*_8^_X*IS>+[74A8_"CQ)\:/B+\'?&DK3+%
M9#X:^-_&]YI%AJM](K;!8>%M8M_"_C*X*!RT/AYHXU;S,'[\_P""O/\ P3_O
M_&7_  55_9_MO"MA-9^%_P!N+6/"%IK%_90E(]*\3^$K[2/#7Q8U&&-$:,#3
M? :^'O'%]* 9;J_U#5IWB9PTDO\ ,C)))-))--(\LLKO)++([/))([%GDD=B
M6=W8EG=B69B2222:_P!"[_@FI\7/A_\ MK_L@?LM?M$_$1;+4_BO^S')XI\)
M:UXGU"Y1;KP]X[\/^ =1^'?BG6M3O)3Y8'C/X;>(])\9:LK&&**ZUJTGS&MB
M%/U'C96S#PJSKAWQ5R:G5Q4ZG#&;>'F?^RBE+$8BOEN(QG"6/K1NU:CG>&B\
M76FIR]A3P^&IMRE3B_G/!ZC@/$O*,^\,\VG2P\*?$>6<=Y)[27NT,/1S"AA.
M*,%1E9.]7)\1)86C%QC[:I7Q$THQJ27XG?\ !R+\>--B\5_L\_L=>#&@L/#/
MPO\ "O\ PLSQ+HNGL!86>IZQ;S>#_AWH[0!L6UQX9\)Z5K]U!"03_9OC&R<-
MM8 _R_U]3_MN?M!W7[4_[6'QU^/$LT\VG>//'VJS^%4N ZS6G@31?*\.> K&
M5'P8YK/P=I&B6]R D:M=)-)Y:%RH^6*_;/";A)\$>'G"_#U6#CCL/EL,7FSE
M=U)9QF4I9AFGM)N\JCIXS$U:$)S?-[*E3CHHJ*_'_$_BA<8\=\29]2DI8*OC
MYX7+%&RA'*LOC' Y=R07NP53"8>E6G"/N^UJU'JVVRBBBOT4^""BBB@ HHHH
M **** "OK/\ 8'_Y/J_8L_[.S_9R_P#5P^#:^3*^L_V!_P#D^K]BS_L[/]G+
M_P!7#X-KP>*O^28XC_[$.<?^J_$'M\,_\E'P_P#]CO*O_4_#GR91117O'B!1
M110 4444 %%%% !1110 4444 %%%2*G<_E_C0)M+<:FX$%>,=^WT/^%;4#JX
M4J><C<.X/T]#CBLNG([(P93@C_/([BHJ0YUH[/\ !^3\OR[$>T=]M.J_K^OS
M.@3[P_'^1J]%_#^/]:Q;>\1B!*0C=,G[IX/.>B_B<>A[#:A(.T@Y'/(_&N.<
M7%--6T?H].CZG73DI<MFGMZZ6Z;FMIM_?:5?V>IZ9>W>G:EIUU;W^GZA87$U
MG?6%]9S1W%I>V5W;O'<6MW:W$<<]O<021S03(DL3JZJP_2#X)?\ !6?]OSX&
M:79>'_"_[0'B#Q'X;T^SL;&ST'XF:?HWQ(M[6QTZXDFM+*RU3Q;8:EXDT^TB
MAN)M.2WT[7+2%-,^R6,:)#I.C#3OS40<D]L8_E5^+M_NC^E?,YWPYD'$=!X;
MB#),JSK"QLX4<UR_"8^G"2LU*G'%4JBIS3O:<.62>JDF?091G^>\/UWB<BSC
M-,GQ#5I5LLQV)P4YQ>\:DL-5I^T@[).$^:+6C31^W%Q_P7V_X*!W>D?V9#JG
MPAL+U?-SXAM/AI$^KGS5N FZ&_UJ]T'_ $<S1M#MT0;FM(//\]6NEN?B/X^?
MM\?M@_M-)>67QC^/7CGQ#X>OHEM[KP3I%[!X,\ 7-M%.UQ;1WW@?P;;Z#X7U
M66U<A8=0UC3-0U4JB^=?RL"Q^-(NGX+_ %J[7S^4^&_A_D.*CCLFX-X;R_&0
MESTL90RC!+%4973O1Q$J,JM#5)I49P2LDDDD>YF?B%QSGF'^I9MQ;Q!CL'*/
M)4PE?-<9+#5DHN/[^@JL:5;1N[JPFW=W;;;+*]1]1_.KB=#]?Z"J:]1]1_.K
MB=#]?Z"OJY_"_E^:/E8[KU7YEN+^'\?ZU;3J?I_454B_A_'^M78E))[#'7\1
MT]:YY_"_E^:.A:->J+L7;_=']*MH,#/KC_/ZU5CX./0?X5<7H/H/Y5RSZ?/]
M#=/JOD78^_X?UK13H?K_ $%9T??\/ZUHIT/U_H*YZG3Y_H;0^%?/\V6H>H^I
M_E5M/O#\?Y&JD/4?4_RJY&I9AZ<\_@:YI[KT_5FL-WZ?JBPG7\/ZBKT8S@'L
M/\!5>)0I/KCD_B*M)U/T_J*YYN[MVN=$-WZ?JBXO0?0?RJ['W_#^M4EZ#Z#^
M578^_P"']:XI*Z:7E^:-2U%V_P!X?TK1AZCZG^59T7;_ 'A_2M&'J/J?Y5#A
M:+>[_#=?U^AT%M/O#\?Y&K<2DG/08_J.E5D4<'OS_A5V'H/H?YUS57;5=E^;
M-8R3LNR_R+4?!QZ#_"KB]!]!_*J:=3]/ZBKB]!]!_*N:6_R7Y(Z(;/U_1%V/
MO^']:M1=O]X?TJK'W_#^M6HNW^]_A6$_B?R_)&]/K\OU+B?>'X_R-7HOX?Q_
MK5-!W].!_G\:N1?P_C_6N:;UDUV_)&J;6W:Q>0?*/?K^=7(NW^Z/Z533[H_'
M^9JY%V_W1_2N2?PO^NJ-X?9^7Z%U>@^@_E5FJR]!]!_*K-8G5#XE\_R9=3H?
MK_05:A'Z$Y_*JT8Z CJ1^7%7XQA<#U_H*Y9_"_E^:-D]FO4LI]T?C_,U;AZ#
MZ'^=58QD*#[_ -:N1C!P/3^HKGFO=]'?]/U-8-M._?\ R+\7;_=']*M1]_P_
MK56+M_NC^E6H^_X?UKGG\+^7YHVAN_3]47*M*"6&/4?SJNJ[OH*N1=O]X?TK
M"3LF_P"MSJ@U:W;?[V6XQM('U/Z593[P_'^1JNGWA^/\C5A/O#\?Y&N6H[J[
M[_HS:&[]/U1?AZ#Z'^=6DZGZ?U%58>@^A_G5I.I^G]17/+>'K^J-H[KU7YFA
M%T_!?Y&K,??\/ZU6BZ?@O\C5P*!_6L)_"_E^:.F'Q+Y_DRU$F!D^O3\L5<3H
M?K_0573H?K_0583H?K_05S2VEZK]#>.Z]5^9[MX7\=Z!I?P.^(7@&Z:[_P"$
M@\3^)?#6I:8D=L7M/LFE3P37;W%R741,%A98T".SLRX 7<R^1)]T?C_,UWNA
M?#F;5_AAXL^)2:M'#%X2UK1]'FTAK-GDO/[8EABCN(KT7 6+R6FR\+VS[E7*
MR@MA>"3[H_'^9KP<OA@(5<X>"JSJ5:F;RGF49\UJ./\ [.R^#I0YJ<%R?4X8
M.HN5U(\U23]HW>,?<S*>/G1R=8VE"G3IY5&&7./+>K@/K^/FJL^6<WS_ %N>
M+@^94Y<L(^XE:4KD7;_=']*NKT'T'\JI1=O]T?TK0C4$#/8#]17;-;>5[_@<
M,=EZ+\BRJ@YSVJW%V_WA_2JL??\ #^M6HNW^\/Z5C-:-]O\ -&\/A7S_ #9<
M3[P_'^1JXGW1^/\ ,U40'.>P_P /_KU;3[H_'^9K"6S]'^1TQV7HOR+</0?0
M_P ZO+T'T'\JHP]!]#_.KR]!]!_*N2IT^?Z&T-GZ_P"1<BZ?@O\ (U<  Z53
MBZ?@O\C5VN>?3Y_H:P^)?UT997J/J/YU<3H?K_0537J/J/YU<3H?K_05SU.G
MS_0Z8;OT_5%N+^'\?ZU>3[H_'^9JC%_#^/\ 6M"( @9]"?UK">R]?\SJAM\_
M\BU%V_W1_2KB@ #W )JHG7\/ZBKB]!]!_*N2?Q/Y?DC6'Q+Y_D6:NIT/U_H*
MI5=3H?K_ $%8U.GS_0WCNO5?F6H>H^I_E5]/NC\?YFJ$/4?4_P JOI]T?C_,
MUSSV?G+]+?H=$=UZK\RW#T'T/\ZNJH ![D52AZ#Z'^=7EZ#Z#^5<]3I\_P!#
MHB]5YM+\46%Z#Z#^578^_P"']:I+T'T'\JNQ]_P_K7/4Z?/]#<M1=O\ >']*
MOIT/U_H*H1=O]X?TJ^G0_7^@KGJ=/G^ATK1KU1;B_A_'^M6D^\/Q_D:JQ?P_
MC_6K2?>'X_R-82W?^!_F;K5)]RXGW1^/\S5A/NC\?YFJZ?='X_S-6$^Z/Q_F
M:Y9[KT_5G1#[/_;OZ%R+M_NC^E:,73\%_D:SHNW^Z/Z5HQ=/P7^1K*?POY?F
MCH+,??\ #^M6XP1C/]X'^558NOXK_,U<7J/J/YUR2;NUTNG^".@LI]X?C_(U
M<3[H_'^9JFGWA^/\C5Q/NC\?YFL9[+U_1F\=EZ+\BW#T'T/\ZO+T'T'\JHP]
M!]#_ #J\O0?0?RKEFK6\VW]]CHIN]K]&E\E8N1=/P7^1JS'W_#^M5HNGX+_(
MU9C[_A_6L*G3Y_H=4=X^J+47;_>']*OIT/U_H*H1=O\ >']*OIT/U_H*QEU_
MPR_0W+<7\/X_UJVG4_3^HJI%_#^/]:MIU/T_J*Y9[O\ PK_TI&\=EZ+\BXO0
M?0?RJPO0?0?RJNO0?0?RJPO0?0?RK&?POY?FC:&S]?T1>BZ_BO\ ,U<7J/J/
MYU3BZ_BO\S5Q>H^H_G7-+:7JORB=D=UZK\RXG0_7^@JRGW1^/\S59.A^O]!5
ME/NC_/<USSV7K^C.B.Z]5^9;AZ#Z'^=6DZGZ?U%5H@1P?0_SJRG4_3^HK"?P
MOY?FC<T(NGX+_(U>7J/J/YU1BZ?@O\C5Y>H^H_G7+4Z?/]#HA]G_ +=_0L+U
M'U'\ZLI]X?C_ "-5EZCZC^=64^\/Q_D:QG\+^7YHZX;OT_5%Q/NC\?YFK</0
M?0_SJHGW1^/\S5N'H/H?YUS3V7K^C-H[KU7YEY>@^@_E5A>@^@_E5=>@^@_E
M5A>@^@_E7-4Z?/\ 0Z8?$OG^3+L??\/ZU:B[?[P_I56/O^']:M1=O]X?TK&?
MPOY?FC>.Z]5^9?3H?K_0593[H_'^9JLG0_7^@JRGW1^/\S7-/9>OZ,Z([KU7
MYEA/NC\?YFG4U/NC\?YFG5D;A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^0?_!4+_@D
MU\.?V_/#;>-?"ESI'PX_::\-Z2+'PIX_NHI8?#GC"SMG5[3PI\48]-T^_P!3
MN](B036^C^)--M+O7?"[W'FQ6>NZ7"_AZZ_A9_:"_9F^.W[+/CFZ^'?QZ^&G
MB?X=>(HIKQ=.?6M.F70_$]G8SK;SZQX-\21+)H7B[0_-=(_[7\/W^H623-]F
MFEBNXY8(_P#4BKQ7X[?LY_ []IKP5=_#WX\?#/PQ\2O"MW#-$EIKUI*FI:6;
MB2UEGNO#GB/39K'Q+X5U&1[*T+:IX:U?2=2Q;Q*+H(H6OZ9\&_I)9_X;T</P
M_GM"MQ'PA3G:CAU42S;)J<FW*.55ZTXTJV%3?.LMQ4H45+_=L3@U*I[3^=_%
MGZ/N2>(%:OGN2UZ60<55(7K5W3;RO-ZD;*,LSHTHRJT<39<CS##1G5<7?$8?
M%N-/D_RT:*_KY^/W_!LWX-U2ZU+6/V9_VA=7\)K/=W=S9>!_B_H$?B;3+>&X
MCMWM]/MO'7AA]*U:SM+"Z6]2![_PCXBOY].N;&&ZO9;[3;K4-:_,;Q3_ ,&]
MW_!1KP_=7-OI/AKX2^.88+L6T5]X6^*>EVEK>0F-W_M"V3QK8^#[U;0,HA*7
MEG:W_F2(19&$/*G]T9#](/P@X@H0K4.-<LRVHXQ=3"Y\ZF25Z,G;]W.680HX
M6K*-_>EA<3B*6]JC2=OXRSOP+\5,CKRI5N$,QS""DU3Q.2*GG%"M%?;C' SJ
MXBG%](XG#T*G>FM#\/Z*_:_P]_P;]_\ !2/6M26QU+P'\-O"-JT,LAUCQ#\6
M/"MSIJ/& 4MVB\*3>)]7,TY)6)DTIX 0?/GA7!/Z,? /_@V6O(M2TG5OVG/V
MC=.FTVVFCEUCP+\$_#][*^IH 6:WMOB3XUCTZ33X?,58Y6_X5I<SW$#R>3/I
MTRI+6V=^/WA!D.'G7Q''.38Z2@Y0P^259YYB*TK-QIPCE<,53ISFURJ6(J4:
M46TZM2G&\EED_@AXJ9U7C1P_!F;8-.2C.OG%*&34*46TI5)RS*>&G.,$^9QH
M4ZU6235.G.7NO^7#X<?#3X@_%_QEHGP]^%W@WQ%X]\;>([N*RT;PUX7TNZU;
M5;V:61(RX@M8W\BT@WB6]U"Z:"PT^V$EU?7-O;123)_;3_P2H_X(M^%_V0YM
M%^/?[0ITCQW^T@UI#=^'-"M_L^H^#?@NU]86K3Q:=*R2P^(?B'9327MC>>+H
M)GT;38V:W\*Q2E&\1ZG]PZ/H/_!/+_@D[\+KF+38O 'P%T+5O.O9VNK_ %3Q
M1\4?B%>1!=ZQ2ZA<^(?B-XR\J9!Y&GVK7.A:"9F%K;:/8LX7^?K]O?\ X+@_
M$/X[:?K?PK_9BL-9^$GPJU>POM&\1>,=6%I'\4/&5C=L8;BWL9+"YO+3P)HU
MU:;X)HM,O;[Q#>PS/YFLZ9#+/IC?SOQ!Q_XG?2$]IPWX<Y)C^$> ,5.>'S?B
MG-FZ%;,L'=1K4)UZ'/3A3<>:G6RG**^.KXARC3QN-I8*K6@OV/"Y#X6?1WA'
MB'Q%SW \5\?8:G#$91PCD[CB'@L7;FHUE0JN,T^:U2EFV;TL#AZ$8RJ8+!U\
M;2HN7VA_P6&_X*J^'_#WA77?V5OV8_&W]H>/-9NKO1/C)\1O"]ZWV/P5HEG-
M>:?K/P\\/:Q:2QM+XSU:\@%GXFU*QEEM/#FAI?:+')/K^L3R^%_Y.J**_HOP
MY\.LB\,^'J60Y)&=:4ZCQ.99GB(P6,S3&RBHRKUW!*,*=.*5+"X:+<,/12CS
M5*LZU:K_ !=XI>*'$7BQQ/5XCS^4*$(4UA<JRG#3J2P.48",G*.'PZJ-RJ5:
MLVZV,Q4U&IBJ\G+EI484,/1****^^/S<***4 G@4 )3U0GD\#^=.5 .3R?Y4
M^LY3[??_ , #S;X@@#^R /\ I_\ _;*O.*](^(/_ #"/^W__ -LJ\WKVL%_N
MU/\ [?\ _3DS](R#_D4X3_N/_P"I-8****ZCV HHHH **** "BBB@ HHHH *
M*** "K=A?7>EWUEJ=A.]K?:==VU]97,>/,M[NTF2XMITW KOBFC21<@C<HR"
M.*J44FE).,DG%IIII---6::>C36C3T:&FTTTVFFFFG9IK5--:IIZIK8_TT/V
M%/VO? 7[;O[-_@?XQ>%=1TV?7+K2+#1/BGX5@8?:?!?Q(M-.M1XJ\.WME*S3
MQ6#WDDE_X?N9U":MX=O--U! //DBB^!/@!_P0H_9S^ '[7L'[4.B>.?%>N:%
MX9\2:GXR^&GP=U'2-+@T3P5XEO7N)--FN/$D5S+?>(-*\)R7<D_A73VTO2KR
MRNK/2+G4M6U=["87W\3GP"_:6^._[+GC,^/_ ( _$[Q-\,O%$D"6E]=:%<02
MZ=K5E'(9H]/\1>']3M[_ ,/>)-/BF/GQ6&O:7J-I%< 7$4*3*L@_3#5/^"_/
M_!2C4="DT>#XF> ](O)8&@/B72_A1X*_MU"P(,\::AI^H:#'/@_*RZ&$0X9(
MU8!A_"V9_1L\3^%\UXGP_A3QAEF7<)\84:F"S' 9AB<3@\71RZK*LU@,0X99
MF,:U+"4\37H8;,,)5H8]X>K6IRIT_:U?:_V=EWT@O#GB/+>'*_B9PIF./XFX
M5JT\7@,;@</A\7A:N/I1HWQU!3S' 2I5,54P]"OB,#BJ=?!*O2I34Y^SI^R_
MI@_X+<?MG>#_ -FC]CSQ_P##&WURT?XQ_M%>%]9^&O@WPO;W*'5;;PCXCA?1
MO'_C.^A3=-8Z/IWANZU+2-/O7\MKOQ)J6G6]F9%MM2FL?P;_ .#:;_D^/XM_
M]FH^-/\ U;WP/K\'_B=\5/B1\:/&FK_$3XL^./$WQ#\<:](LFJ^)_%NKW>LZ
MM<K$-EO;+<7<DGV:PLHL6^GZ;:+!I^G6J1VEC;6]M''$OI'[-/[5OQ]_8_\
M'6K?$K]G7QZ?AWXUUSPI?>"-4UD>&/!GBP7?A?4=7T37;S2SIOCGP[XFTB(3
M:KX<T6[^V06$6H1&R$,-W';SW44_ZGDG@'5X9\%^*?#S*LRP6+XEXJH5*V89
MOC%B,+ELL?/ZM"E0A[&AB\52R_"4,/[.E+V%6M5JSK8B5*DJ_L*/YKG/C;3X
MC\7.&^.\SP&,PO#W#->E3P.5X1T,3F$<#!UYU:TO:UL+AJF.Q5:MSU(^VI4J
M=*%&@JE3V/MJO]??_!RM_P F*?"O_L['P)_ZJ'XZU_#]7W!^TM_P4?\ VS_V
MP/ FE?#3]HKXR_\ "P_!.B>++#QSI>B?\*\^%/A+[+XITS1]=T&QU3^TO W@
M;PSJ\WD:3XFUNT^Q7%_+ITGVWSYK22YMK2:W^'Z^W\#O#_.?#/@/#\+Y]B<L
MQ>84LSS+&RK916Q5?!NEC*D)THQJ8S!8"NZD5%^T3PZBG;EG+<^.\9..<I\0
M^-:_$F2X?,<+@:N79?A(TLTHX:ABU4PE.<*DG3PF+QM%0DY+D:KN35^:,=C[
MD_X)F_\ *07]CK_LX+X;?^I#:5_>=_P4T_Y1\_MB_P#9O_Q&_P#3#<U_G"_#
M3XD>-/@]\0?!OQ3^'.M'PYX\^'_B+2_%?A'7AI^E:J=)U_1KJ.\TV^_LS7+'
M4]'OQ;W$2.;34]/O;&< QW-M-$S(?O3XF_\ !8'_ (*+?&/X?>,?A7\1_P!H
M?_A(_ ?C_P /ZEX6\6Z%_P *E^!FD?VMH.K6[6NH6/\ :F@_#+2]9L/M$#LG
MVK3-1LKR+.Z"XB<!A\/XQ>#/%'B#X@<"\5Y+C\APN7\,?4/K]'-,5F%'&UOJ
MN=+,JGU.GA,KQM"IS4/<A[;$8>]7W9<L/?/L_"CQ;X<X%X'XSX9S?!9WB,?Q
M$\<\%6R[#8"MA*7UG*/[/A]:J8G,L'6ARUO>G[&A7M2]Y<T_</W1_P"#83_D
MG_[7O_8X_"#_ -,GCVO&_P#@Y[_Y*'^R'_V)GQ<_]/G@6OPD_9@_;T_:P_8S
ML/&&F?LV?%8_#BQ\?7>C7_BRW_X0?X;^,!JMWX?AU&WTB8/X]\'^*9+ VL.J
MWZ%=,>R2Y$X-VL[06YBQ_P!I_P#;5_::_;+U'PAJO[2?Q+_X6/?^ [+5]/\
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MR:;2LWN?![_E-GX9_P"TC>H_^K^U&O[7_P#@I)_R8#^V1_V;C\6?_4.U2O\
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MT:&+S">3JEB*$5/!5,'43J5L.L,L#3JN->M["E\!?MA_\$J/^"QW[56EQO\
M%S]KSX,_&'2]%9;W3/AK8:WXF^&WA>2]@$OV>XM/"NA?"O0O!-]KD*RRQ6NM
M>(W748H9I8?[7CA=D;\KO^";7[&OQ5\*_P#!63X&? [XX> M5\%>+/A%XON?
MBIXLT35DM[E+.W^'/A^_\;^%M8L[^PFO-+UC1M5\36'AF+2]9TF]O=+O!?0S
M6UU*JMC^R;]@GXH?MH?%OX2:EXL_;8^"7@CX&>.IO$!B\*>&_"%QJ4-QJ/A7
M[!;2?VIK_AS5/$_C.]\-7QU%[FW@LKWQ"=0GAB:6[T?2U6"2^YCPSX7\#>.?
M^"G/Q/\ B?HOV"_\3? O]D;X=_!OQ7?6YBE:PU_XM?$SQA\1;30KEE!*:SHW
MA3P=I>J7",?.MM'\=Z:N1'?,E<65^.?%^0Y-XA< YG@>#I9?@.%,[PN$QW!6
M#R_"X#+,QQJPV58;$X6MD<UE.*PM3%9G2I3E##QJK&RI<U9.%6E/KS+P:X6S
MK-N!.-\NQG%<<?C>)LGQ&*P?%^+QV)QV8X#!NOF6(H8FEG,7F>&Q-/"Y=5JP
MC.O*D\'&KRT7STZL?P:_X.<OBW]I\6_LN_ FTNMO]C^'?&_Q:U^S#Y\X^(]2
ML?!_A&Y>//RFU'A;QM%&Q!W_ &R4 CRSN_.S_@@=_P I,/A%_P!B=\7O_5;>
M(JY3_@N#\6O^%L?\%(/C@EM=?:M'^&,/A+X2Z,=^_P C_A$?#UG/XEM< E4\
MCQUJ_BM-BGC[S@2,X'Y\? /]H'XO?LP_$W1OC%\#?%Q\#_$?P_::Q8:3XB&A
M>&?$@M;37]+NM&U:$Z/XOT;7]!N1=Z;>7%ONN]+G>W,@GMFAN8XID_J?@;@/
M%U/HX8'@O O#87,^(^!,Q<*F-E5I8>EF'%F%Q>80>-G1HXBO"%"IF4*5:5.A
M6J4Z=+EA2GR1@?S7QGQKA8>/^,XNQBQ&(R[(.-<OYX82-.I7JX'AC$X7 R6$
MA5JT*,YUH9=.I24ZU*G.=3FE4@I.2_T(?^"J?[3WC_\ 9$_8E^*OQC^%L>GI
MX^MYO#7A'PUJNIPK=6_AR]\::]9>'W\30V$L<EMJ.HZ):WD][I-G?*^G-JD=
MI+J-O?6,-QI]WG_\$M?VVK#]NK]E#PMX[UJ[LI?BQX-$?P_^-FDQQV\/_%8Z
M99Q>7XECT^-8XX=(\=Z2]MXBM5AMX]/MK^YUG0;0RG0[@C^(;X__ /!47]NK
M]J+X::I\'_CK\<O^$Y^'6LW^D:GJ7AW_ (5G\'O#/VF^T*_BU/2I_P"UO!_P
M^\/Z[#]EOH(I_*M]3BAGV^7<QS0LT9\B_9B_;/\ VF?V-M8\5:[^S;\4KWX;
M:AXVTRPTCQ4$\.^#?%FG:U9Z5=2WFF&YT7QSX=\3:,M[IT]Q=BQU2"PAU.T@
MOM1M(+R.UU"]AN/QW#?1*Q\O"_&9#C<1PQ3\0J?$DLWRS/\ "5\RJ8"KE<L-
M@L(\HS#%U<IHXZG0M'&8J$*&7UHT\6L-44FJN(M^KXCZ4&"CXCX7.\)0XCJ<
M"SX?CE>8Y'BJ.7T\;3S&.(Q>)6:X'"TLSJX.=>\L)AI3K8ZE*IA7B(.*=.@W
M]V_\%G?^"?S_ +%G[2$_BKP%HS6O[/WQRNM5\4_#P6D!&G>#?$"S)<>+?AJS
M(H2VAT:ZNX]4\+0NJ+)X5U*RL();V[T'5YH_['/V,?A3X4\#_P#!/OX.>#?V
M8]3T/P2_B?\ 9ZT+Q!X-\>MH-IKUN?B)X[\!6NJK\3/$VBF:TC\3:@_BG48]
M<UG2KR[@%U';?V );*R@@AMOX<_B3_P4'_;/_;J7P'^SS^T?\>M,\2_#OQ3\
M3O!&Z35/A=\'/#D/AK5KG51H5OXI76_"'P]T#7[%=(L=;U%KO[)J<,=SI\UY
M:W4<]O-)$W]V7B7X8^+/V3/V,]7^&W[!_P ,?#.M>-/A;X)>U^#?P[\7ZI<_
MV/KFKOJT=]K$VN:I<ZQHT^I:SJ2WNNZ^YNM=TB/6O$4L=K-J.FVUVTL'SOC_
M  XMR[@GPBX(XTSK*\3Q='.<3">,PV+JU>&,RP&"C@\!@<UXAQF<X/+E3QN&
M^MT:6)=?"8G"SHRS+'8K$4E6C1G[W@=+A?'\8^*/&/".49E0X6EE.'E#"8C#
M4Z7$>7XW&2Q6.QF69'A,IQ6/E4PF)^JUJF']ABL/B858Y?@L-0J.DZL?SU\=
M_LW?\%UO%NB7OAZQ_;N_9H\.VMS9S6$NK>&/AO/X9\17L,J&-KC^UD^%>LWG
MA^_D4Y6\\-W-C<V;XDLIXI%5Q_-1^W'_ ,$E/V\/V8])\2_';XQ?V/\ &OPM
M-J+:GX\^+?@?QCKOCJ]L;W5+J.,:UXXC\7Z5H/C<+?7<ZQWGB&;2]1TNWNG1
M-2U>![FT-Q^__P  ?VV_^"Y7Q%^+_@WP7X^_8'^%?A?P3<^(]+MO''BC6O!W
MQ*^&]EH_A?\ M&*#7M6LO%?B7XP:]I,]W9V N;JSM]+T+Q'=WLB1"RTF]65%
M;]=/V]O&?@;P%^Q9^U)XB^(US80>%!\"_B5HMW!J+Q)%JVH>)O"FI^'-!\/V
MXE^674?$.NZIIVBZ9"!NDO[ZW5=I.X>#D/B/Q]X3\6Y!DL,L\*\PI<28S T,
M9@N!\#P]/$XNAB,;2PJIU<9PU["O0QLW5<LOAC(5J,IZPP]6G&<%[>=\ <$^
M)W"^=YO+,/$O U<@PF,KX3&<9XS/8X?#5J&$J8EU*6$X@]M1K82*I*..GA)4
MJRCI*O3G*,W_ )CU?TE?\&S7_)U7Q^_[-]/_ *L;P97\VM?2/[,W[7?[0_['
M?BS7_''[.7Q"/PZ\4>)_#I\*:[J?_"*>"/%POM ;4K'5S8FP\=>&O$^FVY_M
M'3;*X%W:6<%\HB,*W(MYIXI/[I\4>%<PXWX XFX5RJM@\/F&=8&GAL+6S"I7
MI8*G4AB\-B&\14PV'Q=>$'"C))T\/5ES.*Y;-M?QCX;\2X'@_CCAWB7,Z6+K
MX#*,;/$8FE@:=&KBYPEA:]%*A3Q%?"T93YZL6U4KTERJ3YKI)_U=_P#!S-_R
M:Q\ /^S@&_\ 5=>,:]D_X-SO^4?6I_\ 9P7Q(_\ 4>\ U_)%^TS_ ,%#OVP_
MVQ?"OA_P3^T=\7_^%B^&/"WB ^*="TS_ (0#X7>$?L.O'3KS2?MWVWP)X)\,
M:A=?\2_4+NW^RWEW<6?[[S?L_GQQ2)L?LY?\%+?VVOV2OA]-\+/V??C6? '@
M.X\1:EXKET$_#GX3>*PVOZO:Z=9ZA?#4_&_@3Q)K""XM]*L$^R1Z@MC$8#)!
M;1RS3O+_ #_B/H_\95O ? >%T<SX97$&%XFGG53&2QF:_P!CRPLL3C*RIPQ"
MR9XUXCDQ$$XRR^-/F4E[6R3E^Y8?QQX3I>->.\1Y9=Q$\CQ/#L,HAA8X3+?[
M5CB8X?!TG.=!YLL&J'-AYM26.E4Y7%^SNVE]]_\ !Q?_ ,I!M._[-_\ AO\
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M-+T#5],TLR3S3-9-.XE'V_B9X"\8\39APIQWPSQ1EV"\2LBRW*L+F^.J4JV
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M_)HOP+_[..L/_59?$2OT)_X(W?\ *,_]E#_L3O%'_JR?&M?PY?M,_P#!1/\
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M-PV IY;5_L?A[&93BOJE:AF6(Q53VF)Q$)T/;8.AS4%*53V51*G+R&OZG/\
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M*W@L+A\PJXK.WB(O#U'RN4)X^I+#QC.=6I6<HO\ 1[_@V:_Y.J^/W_9OI_\
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M*6LY3;T6B_'YF4IMZ+1?C\PHHHJ"0HHHH **** "BBB@ HHI0I/3\^U-*_\
MGT7J E2*G<_E_C3@H'N?7_#TIU%[;;]_\NWKOZ&4I]%]_7Y=OZV"BBBD0%%%
M &>!0 4Y5)YZ#_/2GJG<\^WI_C_*GT ( !T_S]:6BB@ HHHH **** "BBB@
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MJNA_[@C7YQT5/^H7"7_0GAKK_O>/\O\ J+\BO]?>+%K_ &Q-6ZO"8#]<*?T
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M05.O_!276U&/^%3Z4>G_ #-UWV_[@-?F53@I/L/7_#UK[=^'?!EG?):=NO\
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M[_+^KL_9T?\ !8?Q&  ?@1HAP /^1^OA_P"ZH:F'_!8WQ(N<? ?0^?7Q_?\
M_P RM?BY14OPB\.GOPW2_P##AF__ ,\!_P#$7_$;_HI*O_ANR?\ ^=_E^?=G
M[3K_ ,%D?$B]/@+H?7//C^__ /F4J=?^"S'B9>#\!-"/.?\ DH&H#_W5#7XH
MT5+\'_#A[\-4G_W4<X_^>)7_ !&'Q'_Z*6K_ .&[)_\ YW'[:+_P6=\2KC'P
M"T,XS_S4*_[Y_P"I2J0?\%H?$P(/_"@="X_ZJ%J'_P R=?B/14OP=\-WK_JS
M2[?\C+.=NW_(Q'_Q&/Q)7_-35?\ PW9/_P#.[R_JY^WH_P""TWB<#'_#/^@_
M^'"U#_YDZD'_  6J\3@ ?\,_:"?^ZAZAZ_\ 8I5^'X4GI^?:I0H'N?7_  ]*
MSEX.>&G7ABDWV_M+.?\ YXZ?UYC?C1XE1M;B>K=;+^S<FTV_ZES_ *]6?N(G
M_!:SQ0H'_&/N@=,<_$/4?_F2&.E64_X+9^*5&/\ AGS0#P!_R4341T_[E(U^
M&E%9/P;\-7I_JQ2UZ+,LZ_\ GC<G_B-?B=_T5-7_ ,-F2^7?+7V_/NS]SU_X
M+;^*5.1^SUX?/(//Q$U'M_W*53#_ (+>^*003^SQH!P<_P#)1M1'_NH&OPJH
MIKP5\,WK+A>EZ?VEG7EN_P"TO+;_ #:'_P 1M\4/^BJK?^&S)/\ YV>7Y]V?
MNT/^"X/BD'/_  SOH'_AQ]1_^8^I5_X+C>*@ #^SKX?./^JCZB/_ '3S7X0@
M$]*E"@>Y]:4O!;POV?"U%^7]IYW^/_"E_6O=E+QO\4EHN*ZVG_4KR/\ ^=GE
M_5V?O%'_ ,%R/%2_\VZ>'_Q^)&HYYY_Z$[BIQ_P7.\5CC_AG/P]P,?\ )2-2
M_P#F.-?@Q16+\%/#![\*T?\ PYYW^N9C7CCXIK;BRM_X:\C_ /G8?O8O_!=/
MQ8HP/V<O#W;K\2=2[?\ <GU*O_!=?Q6N?^,</#QS_P!5*U+_ .8VOP.HJ7X(
M^%SWX4HO_NIYW_\ //R+7CIXJK;BVMIM_P )>1?_ #K/WU7_ (+N>+%Z?LW^
M'>N?^2E:E_\ ,;5A?^"\7BQ1C_AFWPZ><_\ )2]2_P#F,K\ J*E^!_A8]^%*
M/_ATSS_YYE?\1V\5_P#HKJW_ (:LB_\ G7_7S9_0$O\ P7G\6KC'[-GATXS_
M ,U,U/OG_J3*F'_!>WQ:.G[-/ASZ_P#"S=3S_P"H77\^]%2_ SPJ>_"='_PZ
M9[_\]!_\1Y\65_S5];_PU9#_ /.KR_JY_0:/^"^/BX #_AFCPYP,?\E.U/\
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M6_\ F#K^:>G!2?8>M2_H\^#CWX+H?^'CB'_Y[C_XF0\:8Z_Z\5U;_J3<-_\
MSGUV_/NS^EQ?^#C[QJ#@?LH^%SG_ *JUJW_S!U83_@X_\;+C_C%'PMUSC_A;
M6K?S_P"$"K^:  #I2TG]'?P;>CX*H?\ AXXB_P#GN2_I*>-GV>.,0O/^Q>&[
M_P#JF\OZNS^F5?\ @Y&\;+Q_PR?X6(_[*WJW_P P52C_ (.2O&P '_#)WA;C
M_JKFK?\ S U_,K14/Z.G@R]'P30_\//$?_SX!?26\;U_S76(_P##+PU_\Y3^
MFT?\')OC<#'_  R;X5_\.YJ__P P-?1_[3G_  77\6?L^^,O"/A6S_9Q\.^)
MX_$WPP\&_$*2]N?B3J6EO9S>*8[]Y-+2"+P=?+-%9?8P$NC)&\WF'=!'M&?Y
M Z^VOVZ_B%X*^)?Q.^'FK>!/$5AXETS1_@1\,O#&I7NG&8P6NO:3;ZH=2TQG
MFBBWW%G]IA6<Q!XE=S'YA='5?D<T^C]X7TN+^$\'A."?^$;%Y?Q14S?DS#B*
MIA_K&%ADSRKV^)>9REAI<U?&>QA&M26(;J*4:OLDH?8Y5](SQ7J\&\7XW%\=
M_P#"U@\PX5IY-[3+>&Z>(^KXNIG*S58?"K*X1Q,>2A@_;SE1K/#I4W&5+VC<
M_P!E/^(D[QO_ -&F>%?_  [FK_\ S U(/^#DOQOW_9.\*C_NKFKG_P!T*OYE
M H'3\^]+7UO_ !+GX,?]$30_\//$?_SX/D/^)F/'#_HN\1_X9.&?_G*?TU?\
M1)?C?_HT[PK_ .';U?\ ^8*C_B)+\;_]&G>%?_#MZO\ _,%7\RM%'_$N?@Q_
MT1-#_P //$?_ ,^ _P")F/'#_HN\1_X9.&?_ )RG]-7_ !$E^-_^C3O"O_AV
M]7_^8*C_ (B2_&__ $:=X5_\.WJ__P P5?S*T4?\2Y^"_P#T1-#_ ,//$?\
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M* 3P*/\ B77P9_Z(JA_X>>(__GP'_$S?CE_T7F(_\,G#'_SE/Z:?^(DOQO\
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MZ-1\+?\ AVM6_P#F#K^:"BC_ (EU\&O^B*H?^'CB+_Y[F;^E!XZO;CW$)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA!1116L8=7KY=O\ /\@"BBBK **** "BE )Z?Y^M2JH'N?Y?2I<DO7M_6P#
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M]%IY]7_D92G?1:>?5_Y!1114$!112A2>GY]J $J14[G\O\:<% ]SZ_X>E.H
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M/7\O_KU)01*?1:^?;_/\AH4#Z]S3J**#)N^K"BBB@ HHHH **** "BBB@ H
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M5#S&VU)/_M_3[^5_T_+4_P!;W_T+U_X5/_YG/FKRY/\ GF__ 'RW^%'ER?\
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MV\&L=B(4'B%AG'#*NZ2ES*DZ]'GM;VD4[K\1O+D_YYO_ -\M_A1Y<G_/-_\
MOEO\*^I:*^E_M)_\^5_X,_\ M/7^EK\E_KF_^A<O_"M__,Q\M>7)_P \W_[Y
M;_"CRY/^>;_]\M_A7U+11_:3_P"?*_\ !G_VGK_2U/\ 7-_]"Y?^%;_^9CY:
M\N3_ )YO_P!\M_A1Y<G_ #S?_OEO\*^I:*/[2?\ SY7_ (,_^T]?Z6I_KF_^
MA<O_  K?_P S'RUY<G_/-_\ OEO\*/+D_P">;_\ ?+?X5]2T4?VD_P#GRO\
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MW_RX5NK]KZ?]._7\/F?Z[/\ Z%J_\+'_ /,Q\I>7)_SS?_OEO\*/+D_YYO\
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MU0GD\#^=']K/_GPO_!O_ -S]?Z6H^-VM7EL?_"M__,WK_2U^1_*D/2-S_P
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M[_[:U_[J>OX;GQ7Y,O\ SRD_[X;_  H\F7_GE)_WPW^%?:E%+^V7_P! R_\
M!O\ ]S]?Z6J_XB#+_H4Q_P#"Y_\ S)Z_TM?BOR9?^>4G_?#?X4>3+_SRD_[X
M;_"OM2BC^V7_ - R_P#!O_W/U_I:G_$09?\ 0IC_ .%S_P#F3U_I:_%?DR_\
M\I/^^&_PH\F7_GE)_P!\-_A7VI11_;+_ .@9?^#?_N?K_2U/^(@R_P"A3'_P
MN?\ \R>O]+7XK\F7_GE)_P!\-_A1Y,O_ #RD_P"^&_PK[4HH_ME_] R_\&__
M '/U_I:G_$09?]"F/_A<_P#YD]?Z6OQ7Y,O_ #RD_P"^&_PH\F7_ )Y2?]\-
M_A7VI10LX;=EAE_X-]/^G?K^'S/^(@R_Z%,?_"Y__,GK_2U^,/L=V(1<&UN1
M;F3RA/Y$ODF7:6\L2[=ADV@MLW;MH)Q@9J+R9?\ GE)_WPW^%?N'JBY_X)O^
M&AT_XRWG)_\ #8:__P#6_"OA< #I_GZUX&0<:/.XYRWERPSRGB#-<CLL6ZWM
MUEM6%/ZRV\-2]DZW.Y>QM4]G9+VL]SZCBO/_ /5F?#\%A5C7GG"V2<2N];ZO
M]5><49U7@_X5?VRP_(XK$?NW5O=T:=K/XD\F7_GE)_WPW^%'DR_\\I/^^&_P
MK[<HKW_[9?\ T#+_ ,&__<_7^EK\G_Q$67_0HC_X7/\ ^8_7^EK\1^3+_P \
MI/\ OAO\*/)E_P">4G_?#?X5]N44?VR_^@9?^#?_ +GZ_P!+4_XB++_H41_\
M+G_\Q^O]+7XC\F7_ )Y2?]\-_A1Y,O\ SRD_[X;_  K[<HH_ME_] R_\&_\
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M1%_]S[\O^H-^?X=F?#?DR_\ /*3_ +X;_"CR9?\ GE)_WPW^%?<E2!/7\O\
MZ]']LO\ Z!E_X-_^Y^O]+6?^(D2_Z$\?_"]__,?K_2U^%_)E_P">4G_?#?X4
M>3+_ ,\I/^^&_P *^[**/[9?_0,O_!O_ -S]?Z6I_P 1(E_T)X_^%[_^8_7^
MEK\)^3+_ ,\I/^^&_P */)E_YY2?]\-_A7W911_;+_Z!E_X-_P#N?K_2U/\
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M_P#H31_\.#_^8CX$\B?_ )XR_P#?M_\ "CR)_P#GC+_W[?\ PK[[HH_MU_\
M0,O_  <__E8?\1,G_P!":/\ X<'_ /,9\">1/_SQE_[]O_A1Y$__ #QE_P"_
M;_X5]]T4?VZ_^@9?^#G_ /*P_P"(F2_Z$T?_  X/_P"8SX$\B?\ YXR_]^W_
M ,*/(G_YXR_]^W_PK[[HH_MU_P#0,O\ P<__ )60_$^73)8O_NH-?^Z1\">1
M/_SQE_[]O_A1Y$__ #QE_P"_;_X5]]T4?VZ_^@9?^#G_ /*Q?\1/G_T)8_\
MAP?_ ,Q'P)Y$_P#SQE_[]O\ X4>1/_SQE_[]O_A7WW2@$\"C^W7_ - R_P#!
MS_\ E8?\1/G_ -"6/_AP?_S$? ?D3_\ /&7_ +]O_A1Y$_\ SQE_[]O_ (5^
M@"H!R>3_ "I]']NO_H%7_@[_ .Y!_P 1/G_T)8_^'!__ #$?GYY$_P#SQE_[
M]O\ X4>1/_SQE_[]O_A7Z!T4_P"W7_T"K_P=_P#<O7^EJ?\ $3Y_]"6/_AP?
M_P Q'Y^>1/\ \\9?^_;_ .%'D3_\\9?^_;_X5^@=%']NO_H%7_@[_P"Y>O\
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M^(+;85/_ +C^G7V7K_2U^3_XBG/_ *$<?_#B_P#YA/SM\B?_ )XR_P#?M_\
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M -"./_AQ?_S"?G+]GN/^>$W_ 'Z?_P")H^SW'_/";_OT_P#\37Z-44?ZP/\
MZ!%_X/?_ ,J#_B*<_P#H1Q_\.+_^83\Y?L]Q_P \)O\ OT__ ,31]GN/^>$W
M_?I__B:_1JBC_6!_] B_\'O_ .5$R\59+_F1Q;[?VB__ )A/SE^SW'_/";_O
MT_\ \31]GN/^>$W_ 'Z?_P")K]&J*/\ 6!_] B_\'O\ ^5$_\17G_P!"*/\
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MBD0%%% &>!0 4X*3[#UIZIW//MZ?X_RI] "  =*6BB@ HHHH **** "BBB@
MHHHH(E/HM?/M_G^04H!/ IRH3R>!_.I  .!09-WU8U4 Y/)_E3Z** "BBB@
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MI); %%%%, HHI0">G^?K0 E/"$]>!^M/50/<_P OI3JSE/\ E^__ "_X("
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M"M#!TI4</BJL9UW'DC*GAJ\HMW5*=N5\E1117U!\>%%%% !1110 444 9X%
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M66K[=%_77H%%%%!84 9X%."D^P]:E  Z5,I)>;_+U)E)+S?Y>HU4[GGV]/\
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MBC_YS^?Y]F']@8[_ )_Y)_XDO#G_ ,]?/\^S/DRBOK/_ (43^SY_T>[\)O\
MPTO[2_\ \Z"C_A1/[/G_ $>[\)O_  TO[2__ ,Z"C_63+O\ H'S_ /\ $5XH
M_P#G/Y_GV8?V!CO^?^2?^)+PY_\ /7S_ #[,^3**^L_^%$_L^?\ 1[OPF_\
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M_63+O^@?/_\ Q%>*/_G/Y_GV8?V!CO\ G_DG_B2\.?\ SU\_S[,^3**^L_\
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M]F']@8[_ )_Y)_XDO#G_ ,]?/\^S/DRBOK/_ (43^SY_T>[\)O\ PTO[2_\
M\Z"C_A1/[/G_ $>[\)O_  TO[2__ ,Z"C_63+O\ H'S_ /\ $5XH_P#G/Y_G
MV8?V!CO^?^2?^)+PY_\ /7S_ #[,^3**^L_^%$_L^?\ 1[OPF_\ #2_M+_\
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MRBOK/_A1/[/G_1[OPF_\-+^TO_\ .@H_X43^SY_T>[\)O_#2_M+_ /SH*/\
M63+O^@?/_P#Q%>*/_G/Y_GV8?V!CO^?^2?\ B2\.?_/7S_/LSY,HKZS_ .%$
M_L^?]'N_";_PTO[2_P#\Z"C_ (43^SY_T>[\)O\ PTO[2_\ \Z"C_63+O^@?
M/_\ Q%>*/_G/Y_GV8?V!CO\ G_DG_B2\.?\ SU\_S[,^3**^L_\ A1/[/G_1
M[OPF_P##2_M+_P#SH*/^%$_L^?\ 1[OPF_\ #2_M+_\ SH*/]9,N_P"@?/\
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MG[_[M3BBW_JF#_5['_\ 01D?_B3\-?\ SV/D^BOK#_A1?[/W_1[7PG_\-/\
MM*__ #H:/^%%_L_?]'M?"?\ \-/^TK_\Z&A\39=TP^?>O^JO$_X?\(_YD/(,
MPZ8C(O7_ %HX9_#_ (5_S/D^BOK#_A1?[/W_ $>U\)__  T_[2O_ ,Z&C_A1
M?[/W_1[7PG_\-/\ M*__ #H:S_UDR_\ Z!\^_P#$6XG_ /G.9_ZNYA_T$9%_
MXE'#/_SW/D^BOK#_ (47^S]_T>U\)_\ PT_[2O\ \Z&C_A1?[/W_ $>S\)__
M  T_[2O_ ,Z&C_6/+_\ H'S[_P 17B?_ .<X?ZNYA_T$9%_XE'#/_P ]SY/I
MP4GV'K_AZU]8CX$_L_#K^VS\*#[?\*G_ &E,?C_Q:*I/^%&?L_?]'L?"C_PT
M_P"TG_\ .BH_UCR__H'S[_Q%>)__ )SA_J[F'_01D7_B4<-?_/?S_JS/D\*!
MT_/O2U]7_P#"C/V?_P#H]CX4?^&G_:3_ /G14?\ "C/V?_\ H]CX4?\ AI_V
MD_\ YT5'^L>7_P#0/GW_ (BO$_\ \YQ?ZNX__H(R+_Q*.&O_ )[>?Y]F?*%%
M?5__  HS]G__ */8^%'_ (:?]I/_ .=%1_PHS]G_ /Z/8^%'_AI_VD__ )T5
M'^L>7_\ 0/GW_B*\3_\ SG#_ %=Q_P#T$9%_XE'#7_SV\_S[,^4**^L/^%%_
ML_?]'L_"<?\ =)_VE/Z?"$T?\*+_ &?O^CVOA/\ ^&G_ &E?_G0T?ZR9?_T#
MY]_XBO%'_P YP_U>Q_\ T$9'_P")/PU_\]CY/I0">!7UB/@3^S^>?^&V?A1C
MV^$_[2G]?A"*D'P+_9^' _;8^%'_ (:?]I3_ .=%1_K'E_\ T#Y]_P"(KQ/_
M /.</]7L?_T$9'_XD_#7_P ]CY.5 .3R?Y4^OJ__ (49^S__ -'L?"C_ ,-/
M^TG_ /.BH_X49^S_ /\ 1['PH_\ #3_M)_\ SHJ/]8\O_P"@?/O_ !%>)_\
MYSA_J]C_ /H(R/\ \2?AK_Y['RA17U?_ ,*,_9__ .CV/A1_X:?]I/\ ^=%1
M_P *,_9__P"CV/A1_P"&G_:3_P#G14?ZQY?_ - ^??\ B*\3_P#SG)>08];8
MC(F_^RHX95O_ #+GRA17U?\ \*,_9_\ ^CV/A1_X:?\ :3_^=%1_PHS]G_\
MZ/8^%'_AI_VD_P#YT5'^L>7_ /0/GW_B*\3_ /SG,WP]F#U>(R+_ ,2CAG_Y
M[GRA17U?_P *,_9__P"CV/A1_P"&G_:3_P#G14?\*,_9_P#^CV/A1_X:?]I/
M_P"=%1_K'E__ $#Y]_XBO$__ ,YQ?ZNYA_T$9%_XE'#/_P ]SY0HKZP'P+^
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M'_H)R#_Q*^%O_GP?*P '2EKZH_X4A\!/^CT/A7_X:O\ :._^=+1_PI#X"?\
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M_$W_ ,Z!?ZMYC_T$9!_XE7"__P ^//\ /LSY7HKZH_X4A\!/^CT/A7_X:O\
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MKZF_X4C\!O\ H\[X5_\ AK/VC?\ YTM'_"D?@-_T>=\*_P#PUG[1O_SI:/\
M6/+_ /H'S[_Q%N)__G1Y_GV8O]6LQ_Z">'__ !+.%O\ Y\^?Y]F?+-%?4X^"
M'P'/3]LWX5_^&L_:-_K\)14H^"/P%'3]LSX6?7_A5G[1F?\ U4U'^L>7_P#0
M/GW_ (BW$_\ \Z//\^S#_5K,?^@GA_\ \2SA;_Y\^?Y]F?*ZIW/Y?XU)7U+_
M ,*2^ W_ $>9\+/_  UO[1G_ ,Z:C_A27P&_Z/,^%G_AK?VC/_G34?ZQY?\
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MY/5KB'+HZO#Y[?I_QBW$R[=\H\^OX6$^&LQ6^)X?_P#$MX5_7.3Y: )Z5*%
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M_P#\-;^T1_\ .II?ZQ9?_P! ^>_^(OQ+_P#.CS_JS,WPQF;WQ7#W_B7\)_\
MSZ\_S[,^7:*^H_\ A2GP'_Z/)^%W_AK?VB?_ )U%'_"E/@/_ -'D_"[_ ,-;
M^T3_ /.HH_UBR_\ Z!\]_P#$7XF_^= O]6,R_P"@GAW_ ,2_A/\ ^?7G^?9G
MRY17U'_PI3X#_P#1Y/PN_P##6_M$_P#SJ*/^%*? ?_H\GX7?^&M_:)_^=11_
MK%E__0/GO_B+\3?_ #H#_5C,O^@GAW_Q+^$__GUY_GV9\N45]1_\*4^ _P#T
M>3\+O_#6_M$__.HH'P3^!!Z?MD_"[_PUO[1/_P ZBC_6++_^@?/?_$7XF_\
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M_P#AKOVAS_[RH4O_  I7X$?]'C_##_PUW[0__P ZNI?$F7],/GC?_9,<2_\
MSI#_ %7S+_H)X=_\2_A/_P"?9\O45]0_\*5^!'_1X_PP_P##7?M#_P#SJZ/^
M%*_ C_H\?X8?^&N_:'_^=76;XBP#U=#//_$8XE_^=(?ZKYE_T$\._P#B7\)_
M_/L^7J*^H?\ A2OP(_Z/'^&'_AKOVA__ )U=.'P3^!7_ $>+\,"/^R7?M##_
M -Y72_UAP'_0/GG_ (C'$O\ \Z0_U7S+_H)X=_\ $OX3_P#GV?+H!/2I0H'N
M?6OJ$?!;X%=/^&Q?A>,?]4O_ &A_Z?"HTO\ PI;X%?\ 1XWPO_\ #7_M#_\
MSJ:/]8<!_P! ^>?^(QQ+_P#.D7^K&9?]!/#W_B7<)_\ SZ/E^BOJ#_A2WP*_
MZ/&^%_\ X:_]H?\ ^=31_P *6^!7_1XWPO\ _#7_ +0__P ZFC_6' ?] ^>?
M^(QQ+_\ .D/]6,R_Z">'O_$NX4_^?1\OT5]0?\*6^!7_ $>-\+__  U_[0__
M ,ZFC_A2WP*_Z/&^%_\ X:_]H?\ ^=31_K#@/^@?//\ Q&.)?_G2'^K&9?\
M03P]_P")=PI_\^CY?HKZA'P4^!9Z?MB_"_\ \-?^T/\ _.JIX^"OP+'_ #>)
M\+\]S_PK#]H?_P"=31_K#@/^@?//_$8XE_\ G2)\-9BO^8GAUOM_K?PFOSSH
M^7PGK^7_ ->I*^GO^%+_  ,_Z/$^%_\ X;#]H;_YU-'_  I?X&?]'B?"_P#\
M-A^T-_\ .IH_UAP'_0/GG_B,<2__ #I,GPQF;WQ7#O\ XE_"7_S[/F&BOI[_
M (4O\#/^CQ/A?_X;#]H;_P"=31_PI?X&?]'B?"__ ,-A^T-_\ZFC_6' ?] ^
M>?\ B,<2_P#SI%_JOF7_ $$\._\ B7\)_P#S[/F&OT5_X);_ /)U^C_]B1XT
M_P#2*WKPC_A2_P #/^CQ/A?_ .&P_:&_^=37WI_P3@^%OPET3]IG2[_0/VFO
MA]XSOT\'>+8_[#TWP%\:])O98);2W62X@NO$/PYTS2S]G.UY(I[ZW=X3(83+
M*B02_GGBWGF"K^&7'=&%#-XSJ\,9O",JW#^?X:DG+"5$G4KXC+:5"C#^:I5J
M0A%:RDEJ?J'@IP[F&&\7/#BO4Q&12A1XPR.I.-#BCAK%5G&..I-JEAL-F];$
M5YM?#3HTJE2;TC!O0_&VBOI__A2WP*_Z/%^&'_AK_P!H;_YU5'_"EO@5_P!'
MB_##_P -?^T-_P#.JK]#_P!8<!_T#YY_XC'$O_SI/R__ %7S+_H)X=_\2_A/
M_P"?9\P45]/_ /"EO@5_T>+\,/\ PU_[0W_SJJ/^%+? K_H\7X8?^&O_ &AO
M_G54?ZPX#_H'SS_Q&.)?_G2'^J^9?]!/#O\ XE_"?_S[/F"BOI\?!;X%G@?M
MB?##_P -?^T-_P#.KIX^"GP+'7]L/X8'_NF'[0O_ ,ZND^(LO7_+C//3_5GB
M3]<I0GPQF2WQ7#OI_KAPE?\ ]79\OA2?8>M2@ =*^GO^%+_ S_H\+X8?^&Q_
M:%_^=51_PI?X&?\ 1X7PP_\ #8_M"_\ SJJS?$6!?_+C.TNW^K7$GX_\)6ID
M^&,T?_,5PXEV_P!<.$O+?_A;]/Z3/F*BOIW_ (4O\#/^CPOAA_X;']H7_P"=
M52_\*7^!?_1X?PQ_\-?^T+_\ZNDL_P "_P#F'SNW?_5GB1_EE)/^JV9_]!7#
MG_B8<)?_ #[\_P ^S/F&BOI[_A2_P+_Z/#^&/_AK_P!H7_YUE/'P5^!@Z_M@
M_#$_]TP_:$_7_BUE:+B#+XK_ '?/+_\ 9,<2)O[\I#_5;,_^@KAS_P 3#A+_
M .??G^?9GS %)]AZ_P"'K4H4#I^?>OIW_A3'P-_Z/!^&/_AL?VA/_G5T?\*8
M^!O_ $>#\,?_  V/[0G_ ,ZNHEQ%@7_RXSM+M_JUQ'^/_"5J'^JV9_\ 05PY
M_P")APE_\^_/\^S/F.BOIS_A3'P-_P"CP?AC_P"&Q_:$_P#G5T?\*8^!O_1X
M/PQ_\-C^T)_\ZNI_U@P'_0/G?_B,\1__ #J#_5;,_P#H*X<_\3#A+_Y]^?Y]
MF?,=%?3G_"F/@;_T>#\,?_#8_M"?_.KH_P"%,? W_H\'X8_^&Q_:$_\ G5T?
MZP8#_H'SO_Q&>(__ )U!_JMF?_05PY_XF'"7_P ^_/\ /LSYCHKZ<_X4Q\#?
M^CP?AC_X;']H3_YU='_"F/@;_P!'@_#'_P -C^T)_P#.KH_U@P'_ $#YW_XC
M/$?_ ,Z@_P!5LS_Z"N'/_$PX2_\ GWY_GV9\QT5].?\ "F/@;_T>#\,?_#8_
MM"?_ #JZ/^%,? W_ */!^&/_ (;']H3_ .=71_K!@/\ H'SO_P 1GB/_ .=0
M?ZK9G_T%<.?^)APE_P#/OS_/LSYCHKZ<_P"%,? W_H\'X8_^&Q_:$_\ G5TX
M?!;X''_F\#X98_[)C^T'^F?A8*/]8,!_T#YW_P"(SQ'_ /.H'POF2WQ7#B_[
MO#A+_P"??]:]F?,(!/2I0@'7D_I7TZ/@Q\#!T_:_^&7_ (;']H+]?^+6TO\
MPIGX&_\ 1X'PR_\ #8_M!_\ SK:/]8,!_P! ^>?^(SQ)_P#.GS_/LS.7#&:/
M;%<.)?\ 98\(W_\ 5X?,E%?3?_"F?@;_ -'@?#+_ ,-C^T'_ /.MH_X4S\#?
M^CP/AE_X;']H/_YUM'^L& _Z!\\_\1GB3_YT^?Y]F1_JMF?_ $%<.?\ B8\(
M_P#S\/F2BOIO_A3/P-_Z/ ^&7_AL?V@__G6TH^#'P./3]K_X9?\ AL?V@O\
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MYY_GV9\R4X*3[#U_P]:^G!\%_@<.O[7WPR/_ '3+]H+]?^+6T_\ X4U\#_\
MH[WX9?\ ALOV@O\ YUE+_6' O;#YW;O_ *L\2>6W_"3Y];6\[,/]5<S_ .@K
MAO\ \3'A'_Y^>?Y]F?,H4#I^?>EKZ9_X4U\#_P#H[WX9?^&S_:"_^=91_P *
M:^!__1WOPR_\-G^T%_\ .LH7$& 7_,/GGJ^&>)+OU_X2?/Y:]F'^JN9_]!7#
M?_B8\(__ #\\_P ^S/F:BOIG_A37P/\ ^CO?AE_X;/\ :"_^=91_PIKX'_\
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MM ?_ #KJ/^%-_!#_ *.\^&?_ (;/]H#_ .==1_;^!_Y\9W_XC7$?_P ZO/\
M/LP_U5S3_H*X;_\ $RX0_P#GX?,]%?3'_"F_@A_T=Y\,_P#PV?[0'_SKJ/\
MA3?P0_Z.\^&?_AL_V@/_ )UU"S_ O;#YV_\ NVN(_+_J5>?]68?ZJYI_T%<-
M_P#B9<(?_/P^9Z ,\"OIH?!GX('_ )N\^&8'K_PK/]H#_P"==4H^#7P/'3]K
MSX9_^&S_ &@?_G757^L&7Q_Y<9VY?]DSQ)9?^8K^O)DOA?,UMBN&F_\ LL^#
M]/7_ (73YE5.YY]O3_'^5/KZ8_X4W\$/^CO/AG_X;/\ : _^==1_PIOX(?\
M1WGPS_\ #9_M ?\ SKJE\0X%[T,[_P#$:XC_ /G49/A7-7OBN&__ !,^#]-O
M^I[_ %UV9\ST5],?\*;^"'_1WGPS_P##9_M ?_.NH_X4W\$/^CO/AG_X;/\
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M)?\ 1W'PT_\ #:?'[_YU]'_"G?@E_P!'<?#3_P -K\?O_G7T?V_@?^?&=_\
MB-<1_P#SJ\_S[,7^J>:?]!7#7_B9\'__ #]/FJBOI7_A3OP2_P"CN/AI_P"&
MU^/W_P Z^C_A3OP2_P"CN/AI_P"&U^/W_P Z^C^W\#_SXSO_ ,1KB/\ ^=7G
M^?9A_JGFG_05PU_XF?!__P _3YJHKZ5_X4[\$O\ H[CX:?\ AM?C]_\ .OH_
MX4[\$>_[7/PT_P##:?'X_P#O+Q2?$& 6]#.__$:XC_\ G5Y_U9A_JIFG_05P
MU_XF?!__ ,_3YJHKZ6_X4Y\$?^CN?AK_ .&S^/W_ ,["C_A3GP1_Z.Y^&O\
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MX9]?]=.#?P_X7OS/FRBOI/\ X4]\$_\ H[;X;?\ AM?CY_\ .QH_X4]\$_\
MH[;X;?\ AM?CY_\ .QH_M_ _\^,[_P#$:XC_ /G5Y_GV9G_JEFO_ $%\,_\
MB:\&_P#S^/FRBOI/_A3WP3_Z.V^&W_AM?CY_\[&@?![X*'I^UK\-O_#:_'S_
M .=C1_;^!_Y\9W_XC7$?_P ZO/\ /LP_U2S7_H+X9_\ $UX-_P#G\?-E/5">
M3P/YU]*K\'/@F.3^UM\-B?\ LFOQ\X_\QC3_ /A3WP3_ .CMOAM_X;7X^?\
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M-M\>@?U^&7]*D'P?^"HZ?M9?#?\ \-O\>O\ YV55_K!E\5[M#.F^[X;XB_\
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M7POZ_P"O'!7X?\9!I_P^UF?.@&.!17T7_P *D^#/_1UGPZ_\-S\=?_G:T?\
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M #]:6BLG)OT[?UN 4445(!10!G@5*J=SS[>G^/\ *@3DEO\ =U&!2?8>M2@
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M)_2@!BJ3[#^?TJ4 #I_GZTM% !1110 445(J=S^7^- # I/3\^U2A0/<^O\
MAZ4ZB@ HHHH ****3:6XFTMPHHHK*4F_)?GZF4I-^2_/U"BBBI)"BBGA">O
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M+5_D1*:6BU?Y#50#D\G^5/HHK-MO5F;;>K"BBBD(**** "BBB@ HHHH **4
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M% Z?GWH)&*G<_E_C4E%% !1110 4444 ?CO1117[ ?Z !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%/"$]>!^M FTMV- )Z?Y^M2JH'N?Y?2E  Z4M!E*;>BT7X_,*^L
MOV"/^3Z?V+O^SLOV<_\ U<'@ZODVOK+]@C_D^G]B[_L[+]G/_P!7!X.KP>*O
M^28XC_[$.<?^J_$'M<,?\E+P]_V/,I_]3\.?)M%%%>\>&%%%% !1110 444H
M4GI^?:@!*D">OY?_ %Z<% ^O<TZLI3Z+3S[_ .7YF4I]%IY]_P#+\PHHHJ"
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M *]:6C!>?XO^O\K@,"D_3N:F"@=/S[TM%9RDWY+M_GW ****D HHHH ****
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M]OO_ . %%%%!F%%% !/2@ IRJ3[#^?TIX0#KR?TI] "  =/\_6EHHH ****
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M )Z4Y5)]A_/Z5* !T_S]:#)N^K&JF.3R?TI]%% !1110 4 9X%."D^P]:E
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M5DOI@_2V6WTI/I%KT\;?$O\ ^B;R7W&O_$K'T8O^D<? ;_Q4'A]_]#WDON/
MO^&7O@/_ -$_M/\ P=>)O_EU1_PR]\!_^B?VG_@Z\3?_ "ZKWVBC_B<'Z6W_
M $E)](O_ ,7;XE__ $3"_P")5_HP_P#2./@-_P"*@\/?_H>/ O\ AE[X#_\
M1/[3_P '7B;_ .75'_#+WP'_ .B?VG_@Z\3?_+JO?:*/^)P?I;?])2?2+_\
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M75>^T4O^)P/I:_\ 24?TB_\ Q=OB7_\ 1-Y+[@_XE6^C!_TCAX"_^*?\/?\
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M2K?1@_Z1P\!?_%/^'O\ ]#ODON/ _P#AE_X$_P#0@6O_ (.O$W_RZH_X9?\
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M/@,L/4JTZU2@O"#P^5&=:C&K"E5G27#W)*K2A7K0IU)1<H1K58Q:52:?B/\
MPSC\%?\ H1K7_P &WB'_ .6]'_#./P5_Z$:U_P#!MXA_^6]>W457_$WOTLO^
MDH?I$_\ BZ_$K_Z)O)?<9?\ $J/T6_\ I&SP"_\ %.>'?_T.>2^X\1_X9Q^"
MO_0C6O\ X-O$/_RWH_X9Q^"O_0C6O_@V\0__ "WKVZBG_P 3??2S_P"DH?I$
M_P#B[/$K_P"B87_$J/T6_P#I&OP!_P#%.>'?_P!#AXC_ ,,X_!7_ *$:U_\
M!MXA_P#EO1_PSC\%?^A&M?\ P;>(?_EO7MU%'_$WWTL_^DH?I$_^+L\2O_HF
M#_B5#Z+7_2-?@#_XISP[_P#H</$O^&<O@L.G@>U'_<7\0_\ RWH_X9R^"_\
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M1YQE>;9MF%;-,R6"JTLP6#5*G3^I5L5ST_JV'HSY^>FH^])QY6]+V:SO#?\
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MZPV+K5IY@L,IT98;$8>C%4OJU&C%QE&LV^>+:<59V=C[<_X=9?\ !1'_ *-
M^-?_ (2S_P#Q^L?6/^"9_P#P4#T.W:YOOV._V@98D1I&_LGX;^(=?E"H"6/V
M?0K34K@G .%$19OX0217^EK7Q-I/_!1W]A[6?BSK_P #(?VD/ &F?%;PSXWU
M_P"&^L^$/%#ZSX-N8/''AC6+WP_K'ARUU'Q;I.B:+JE]#K6GW6FV;:5J5[;:
MM<I&FD3WPN+8R_SWEGTN/$W-OK,\M\/,HS6E@**Q.8/+,)Q!BOJ>&NU[?$U*
M&(Q$<+1;32K5XJG=/71G[MF/T7/#O+/JT,PX\S3+*N.J_5\"LQQ.1X;ZWB+)
M^QPU.O0H2Q-6S3]E1DYV:=M4?YL7BKP?XM\"ZU=>&_&_A?Q%X.\16.W[;H'B
MK1-3\/:U:;\[?M6E:O:V=];[MK;?-@3.TXS@USM?ZAO[2G[)_P  ?VN/ =[\
M/?CS\.M#\:Z5/;SQZ3J\UM':^+?"=Y,C+'J_@_Q3 BZOX?U*W=A*'L[@6EZJ
MM::K::AIT]S93_YY_P#P4"_8J\6_L(_M)>)_@EX@OIM?\.26EMXM^&?C&2".
MV;Q?\/M9N+R#2=2N;>(M%:ZOI][I^I>']?MD"Q)K6D7LUFK:9<6$\W]#>#/T
M@LB\6*V(R>MEU3A[B?"89XMY;4Q,<9A,PPE.4(5L1EV+]EAYRJ4)SA+$8.M0
MA5I4JD:E&IBJ=/$5*/X/XM^!N<^&%&AFU+'PSWAS$XA87^T(8:6%Q6!Q52,I
MTJ&/PJJXB$85HPE&ABZ5:=.I4A*G5IX:I.A"M\2(C2,J(I9F(554$DLQP  ,
MDDG@  DG@ FOT<^%?_!)#_@HK\8M L?%'@K]ESQLFAZE;PW=A?>--7\%?#)[
MRSN(Q-;7MII_Q)\3^$]4N;.YA*S6UU!920W$3QRPN\<B,W[S_P#!OA^P%\-I
M?A6_[;7Q-\,:3XM\:^)?$VMZ#\%8=<L;;4].\$Z#X/U%]&UGQEI5K=++!%XN
MU?Q59:MI%KJK0&^T+3- SI-U =>U('][/VEOVV?V6OV/K;P]<?M&_%_0_AO)
MXK:Z_P"$=TR;3/$OB;7]6ALGACO+VU\->#-$\1^(#IEI+<0PW&JOIB:;#/*D
M$ETLK!*_/?$SZ3.>Y3QGB^ _#/A.GQ-G668JM@,97Q.%S+-'B<PPT'+&X++<
MGR>KAL;6^H2A5I8C$3Q.M6C74<-[&E&O5^Y\//H\9+FO"6%XV\1.)ZG#N3YC
MAJ6-PE##8G+LM5# 8F45@\7F.;9K2Q&#HK&QG3J4,/"AI2JT7+$NK5=&E_G\
M?&__ ()K?MU?LZ:+>^)?BW^S3\0]#\,Z7#)<ZMXGT*+1OB#X:T:TAC:66]UO
MQ!\.M6\5Z/HUC&BDR7NJ7MI:HV(VE$C!3\.U_J ?!7]KK]F']I'PQKOBGX,?
M&SX>_$#0/#=E->^*VL=9ALKWPSIB0-/-?^*=!UQ--UOP_IGV=97-]K>FV5DZ
M0W $S?9YQ'_G[_\ !2WXK?LT_&']K?XA^*OV4?AMH?P\^%%O(FBQW?AZ&?3-
M)^(_B/3[N^.N?$G3_#)*:;X4TWQ#-/%;Z7I&DV>G0W>FZ;:^(=1L+/7-<U2U
MA^O\$?&KC#Q$SG.>&^+.!JN29ADF%AB<;F6#HXS X'!U*LE&A@<QR[-ZM3&X
M/%8F//4PD:>)Q52M"E6E+#TJ-&=<^2\8_!_A/@+*,IX@X7XSIYS@,XQ,\/@\
MOQ=;"8W&8NG2BY5L;@,PRJG#!XK#89\E/%.>'PT*,ZM*,:]6K5A1/@>BBBOZ
M7/YW"BBB@ KZR_8(_P"3Z?V+O^SLOV<__5P>#J^3:^LOV"/^3Z?V+O\ L[+]
MG/\ ]7!X.KP>*O\ DF.(_P#L0YQ_ZK\0>YPQ_P E+P]_V/,I_P#4_#GR;112
MA2>GY]J]X\,2I%3N?R_QIP4#W/K_ (>E.K.4^B^_K\NW];&4I]%]_7Y=OZV"
MBBBLR HHI0">E "4]4[GCV]?\/YT\*![GUIU  !C@4444TF]@"BBBM(P6[W[
M=/\ @_D 444=>E$I]%]_^7?^MS.4^B^__+O_ %N%'7I5Z"S+[6D.U21\H^\1
MGN>@_4_0UJQPQ1?<15XQG&6/U)Y/YU@YKU?]=?\ AQQI2EJW9/OJW\O\VC$2
MUN9,;(9"#T)7:#WR"V 1[]^U3C3+PGF(+[F2/'T^5F/Z8]ZZ*/JOT_I4]8.O
M+I%+UN_U1M'#P;2;E\FE^C.:_LB]/\"?]_%_QIRZ+?MR(T(S@GS$_J177(G
M)]!Q^'K5I.GX_P!!63Q4T]%!_*6__@1HL-2>SD^FZ\O[O]7]+<<-"U$?\L5S
MW/G1?_%T\:%J9Y$"_P#?Z'_XNNYJ9/NC\?YFLI8RJFU:&ENC[+^]_5_2Q]5I
M]Y_>O\OZN_*W!#0-4)P(%_[_ $/_ ,73QX<U8\B!/^_\/_Q==^G4_3^HJVGW
M1^/\S42QU9*Z5/?K&7_R7E^+\K;+!46TKU-6OM1\O[O]7]+>;CPUJYZ6Z?\
M?^'_ .+J0>%=:.,6\?./^7B'O_P.O38D)R3P./QZ_P"?\:M+U7ZBH_M"O_+2
M_P# 9?\ R?\ 5WY6OZAA[VYJK:W]Z/E_<_K7R/+!X1UP]+>+_P "8?\ XNGC
MP;KYQBVB.>G^DP?_ !=>MQ]_P_K5V/JOT_I6/]IXG^6E_P" R_\ DQ_V?0_F
MJ_\ @4?_ )#^KORMXV/!>OCK:1D_]?5MC_T94H\%>(2<"SC_ / NU_\ CM>S
M5:3[P_'^1J99KB8VM"CKWC/R_P"GG]7]+:K+,.TGS5=4OM0\O[G]7]+>)?\
M"$>(_P#GSB'_ &]VW])33AX%\2GI9Q?^!=K_ /':]S5<_2KH '3_ #]:S><8
ME67+1U=O@EY?]//,/[+P_P#-6_\  H?_ "']7?E;P,> /$YY%G#_ .!EK_\
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M/_\ !U#_ .9C\YA^SC\6#TT.R_\ !WI/_P ET\?LV_%HC/\ 8=C_ .#S2?\
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MX7U7]G'XJ?$*]L97\5^%/%WA'2]&OTO;N.*&QUBYLX;V":R6864^Y9)#'+)
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M /)U?K:GW1^/\S4T8);CT_J.M3+Q(S])OV&6?^$^([_]A9<?#;(&KNOFF_\
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M^U&?^9*T<X[?\)GX5Q^.=4J=?^">?[4QP!X)T?GI_P 5IX4]/^PK7]$4??\
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MOZZP*F7_ ()B?MA <?#_ $/GO_PGO@W_ .7/^?2OZB:G7H/H/Y5/_$?^-O\
MH#X=_P#"''__ #T-%]&_@)M+Z]Q/JU_S,,N\O^I1_5_2W\N0_P""8?[8AZ>
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M )HJ/^')'_!1#_HD_A?_ ,.K\.?_ )HJ_N2HJ/\ B;;Q-_Z%O!W_ (:\U_\
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M^'*'_!0O_HE/AC_PZ?PZ_P#FBH_X<H?\%"_^B4^&/_#I_#K_ .:*O[@:*/\
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MDO-]@/QOHHHK]B/]" HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]Y/HGPP\-MIK6UPH)Q:SZS\1-)O(PX'F7.E(T;'[/**_$G_@@Y_RDZ^!/_8
M^,?_ *I[QO7O/_!QI\6_^$V_;D\/?#6UNM^G_!7X/>%M'O+,/N%OXI\;W>H^
M.=3G(SB-KKPSJO@I"FT,5M4D+,LBA?!O^"#G_*3KX$_]@#XQ_P#JGO&]/@S(
M/]7_ *)6<4YT^3$9MP!QCG^(=K.I_:^ S+$X.HU_V+'@8)Z\R@I*R:2GB_._
M[<^D_E,X3YJ&6<<\)9)05[\G]EX_+L/BX7_[&*QLK:6<FGJFW_;M^VWH.N>*
M?V,?VN?#'AC1M6\1^)?$?[,/Q\T'P]X>T'3KS5]<U[7-8^%7BS3])T;1M)T^
M&XO]4U;5+^XM['3M.L;>>\O;R>&VMH99I41OX"_@U_P2O_;Z^-'C70_!^F_L
MO_&+P-;ZKJ-M:W_B_P"*W@'Q-\,_"'AZP>:-;[6-3U?QIINBI<6VFVSR7<EC
MI":EK-\L+6NE:;?WSQ6S_P"C;XQ\7^&_A]X0\5>/?&>KVV@>#_!'AO7/%_BO
M7KT2FST3PWX:TRZUG7=7NQ!'-.;;3=+LKJ\G$,,LIBA?RXW?"GSCX$_M&_ _
M]IOPG?\ CCX"_$GP[\3O"NE:Y<>&M3U?P[+=&+3]=M;*QU&?3+RWOK:SO+:Y
M6QU.PNT$MLB2P744D+NI)'\D^%'C)Q=X5\+\20X?X9P^98/,<PPTZ^>8ZAF%
M3 Y7CGA94,-1JRPWLL-*I47[VG1K8FE.HXV491N?U%XF^$_"WB5Q'P_+/>(:
M^7XK 8'$0HY-@JV!IXW,L&L3&MB*M-8A5,1&G3?[NI6HX>I"FI7;C*QZ;X5T
M:7PYX8\.>'I]0N-6FT'0='T:;5;O_CZU.72]/M[&34+GYF_TB]> W,WS-^\D
M;YCU/^:U_P %'O&>A?$#]O']K3Q7X:FLKK0K_P".?CVTTZ^TZ1)K'4H=$UF?
M06U6TGC+1W$&JRZ9)J,=S&S1W NO/C8I(I/]D'_!;G]L[X_?L=_LW:'=? [P
MIY+_ !<U;6OAYKGQI%ZQG^$=S<:9%=Z9'I.CI:MYGB7Q;IJ>(U\/^(;B]BM/
M#=QH$\XL[O4[O2WM_P" MF9F+,2S,2S,Q)9F)R22>22>23R3R:_HOZ'? ^/P
MV&S_ ,1<;7P_U?/J4LFRRA1K4JM:<<-CW7S/$XNE1;6#?UJAAZ6%H55"O.FJ
MU=TJ>&J86IB/P3Z5W&.!Q&(R3@+!T:_UC)*L<VS&O6I5:=*#Q&"C2R[#X6K5
M2>+7U:M6JXFO3<Z,)NE056>(IXFG02OZH/\ @V;^ ']H^,_VA/VG=5LLV_AG
M1-'^#'@R[DCWQ2:KXCN+;Q?XYD@9AMAO=*TO1_!=N)4)E-GXENH<QQ2NLW\K
M]?Z+W_!'CX ?\,\?\$^O@-H-[9?8O$_Q#T2;XS^+PT?DSRZK\36CUW1X[R$@
M/#>Z7X(/A/0;N*7]['-I+I(L; Q)^C_2NXL_U>\+,3E5&KR8WBW,<)DU-1E:
MI' T9?VCF55*^M*5+"4\#6T?NX]*ROS+X#Z,O#/]N^)6'S*M3Y\)PO@,5F\W
M)7IO&U4L!E]-OI4C5Q53&TMO>P3=]+/Y8_X+#?MC+^S9\<O^";FA0ZI]CLHO
MVDH/B]\01%/Y+VW@+P[;V_PUU,71!7_1]7\._%#QTMNK[[<W&CO),A,$=?K7
M^T_\%M-_:,_9W^-'P-U00+#\3_AQXI\)V=S<+NBTW7-0TN<>&]:P0P\W0O$"
M:9K$!*L!/8QDJP!4_G/_ ,%!O^"/?@K_ (*"_&3P]\7O&/QW\>> Y/#/P]TO
MX?Z9X7T/PYH&L:3;VNG:]XCU^;4H9KZXM)TNM1N?$3I=K(LS%;.W G,*0P6_
MZT^#-"O/"W@_PIX9U#6[KQ+?^'?#6A:%?>([Z&.VO=?O-(TNUT^YUN\MXGDB
M@NM5FMWOKB&*1XXIIW1'95#'^".(,XX4PO"7A36X5S*I+C'AR&;5N(KX'%X>
M6'QM7.8YUD]2EB:U&&'Q/U*=7$8=NA5FOW=*2TE)G]MY%E7$V)XH\3*7$N7P
MCPIG\\LI9#;&86NJ^$IY0\HS6%3#TJTZ^'6,C2H5TJU.#O.K%ZJ,5_E.:OI.
MI:#JVIZ%K-E/IVKZ+J-[I.JZ?=)Y=S8:EIUS+9WUE<)D[)[6ZAE@F3)VR1L,
M\5_H@_\ !%G_ )1B_LJ_]@#X@_\ JX?B'7\@_P#P6G^ '_"@/^"A?QIMK&R^
MQ>&?BW<6'QR\+XC\N.:#XB&ZN/%;Q( (TBA^(UAXTM((XCL2VMX0%C),:?U\
M?\$6?^48O[*O_8 ^(/\ ZN'XAU_6GTI,_P -Q3X)>'W$F$LL/GG$.1YI3@GS
M>R>,X8SRM.A)Z_O,/4G.A43UC4IRB]4S^7OHW9)B.&O&+CCA_%7=?)LASK+I
MR:M[587B/)*4*\5_)7IQA6IM:2A4C):-'Z&V>H^%OBAX?\8Z#>6EOJFDC4_%
M_P .O%^A7P65)!:RW6CZIINHP#&+?6='N+?4(HFP9M)U>TESB8&OXQ_^"9__
M  3\U#PS_P %C?'/PO\ %5G+?>%?V+_$GB_XB&\OHQMUB/3KRVM/@?J#MM A
MU#4V\3>%_B#:1A03%H=VH8;-U?T._LS_ ![M;'_@IC_P41_90U*[2-Y9_@G^
MT-X#M'ERTD>J_ GX0>"_B=!&)"-B0ZC:>!]3@MH-P>75=8NF1"LCR?=7A#X"
M^!/!/QN^,?Q[T2S\GQQ\<=!^&&A^-;AHXR)T^%5CXCTK0KB"4 2(UQI>NV]E
M>1GB1=&T]F=Q'$D'\TY#Q?FGA+EW'G#M-UX4?$+P^X>Q>4RC>U.MQ!@LMQM'
M$1J7]SZIDF=Y[A)5Z?OO'X6A!M2A>']#9WPKEOB?F'!.?3]A*MP)QUGN%S.+
MM>I2R/&8_"5:$J=O>^LYOD^2XI49^ZL%B:TTG&=I>@2^,-*C\<6/@!7\W7+O
MPIJOC":.-U;[!I6GZOH^BVSW: ;H_P"UKS4[M=.<D+-_8NJ!0Q@;;_,K_P '
M/7_)-_V1O^QW^+'_ *8?!5?I7^QA\?K;]HW_ (*&_P#!2C5=,NTO?"_P)T[]
MF_\ 9Y\(2QR[XF'A?4/CU?\ CZX0)F!OM/Q%DUZ"&[A9_MFFZ?ICF1DCA5/S
M4_X.>O\ DF_[(W_8[_%C_P!,/@JO<\%L@K\,^/WA_E&*C*&,C@</F.+A/25.
MKGO >)SZ%&47\$\-A\SH8:K#=5:,[^\V>-XO9W1XA\#^.,TPTHSPDL;6P&%G
M#6-2GDO&V&R6=:,OMPQ%?+ZV(IRV=*K"S<4F\?\ X-?_ /D5OVS/^P_\"_\
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M)C_$/I!\;9)P;X:YY3SC"5,QGQ1A<9PQE^74:JH3KXG,L%B8U*\\1R5?J]'
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M<Q<?[2K4*CFZ56-&7Y25_77_ ,&O_P#R*W[9G_8?^!?_ *;OBM7\BE?UU_\
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M^&O^P_H__IQMJ_T_?VK/^37?VDO^R!_&+_U7GB*O\P+PI_R-/AK_ +#^C_\
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M>LOE^J)H^_X?UJ5>H^H_G44??\/ZU*O4?4?SKGE*^W3\3JC&VKWMMV+<??\
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MH?K_ $%6ZYI_"_E^:+4FW%;)-+U]29/NC\?YFIH^_P"']:A3[H_'^9J:/O\
MA_6L34E7J/J/YU/4"]1]1_.K*J6_K0W;5E1=FF_/\F3Q]5^G]*MHH/)YYZ5"
MB@*,>@Y[U.G0_7^@KG-4[Z^=B5/O#\?Y&K:=#]?Z"JB?>'X_R-6TZ'Z_T%<Y
MM#9^OZ(MU,GW1^/\S4-3)]T?C_,U$]EZ_HSHAL_7]$6JG08V@^O]:C3J?I_4
M5,O4?4?SKGGLO7]&63U.O0?0?RJ"IUZ#Z#^59&T/A7S_ #9+'W_#^M78^J_3
M^E4H^_X?UJ['U7Z?TK&?Q/Y?DC6&[]/U1/5I/O#\?Y&JM6D^\/Q_D:R=GS77
MPK3YJ_X6-2VG0_7^@J9.I^G]14*=#]?Z"IDZGZ?U%9&\=EZ+\B9>H^H_G4]0
M+U'U'\ZL $]*PEN_5_F=$=EZ+\B:/HOU_K5V/O\ A_6J:#&T>_\ 6KD??\/Z
MUG-Z+S_X#-(/IW=_P_X!;4  >X%3)T/U_H*A7H/H/Y5,G0_7^@K"?POY?FC4
ME3[P_'^1JVG0_7^@JHGWA^/\C5M.A^O]!6)O'9>B_(F3J?I_45.%)]AZU G4
M_3^HJVGW1^/\S6,_B?R_)&D-WZ?JB5.I^G]15R/HOU_K5-.I^G]15R/HOU_K
M7*=$-WZ?JBS4Z]!]!_*H*G7H/H/Y4&T=UZK\R6/O^']:F3[P_P ]C42 C.>_
M_P!>K2]!]!_*N<W)DZ'Z_P!!5U/O#\?Y&J2=#]?Z"KJ?>'X_R-8S^)_+\C2'
M7Y?J35Z;\2_^0QI'_8L:-_Z#/7F5=AXLUZW\07UC=6\$T"VND6&G.LQ0LTMH
ML@D==C,/+8O\F<,0,LJYQ7F8FG.6.P-51;ITZ6,C.6EHNI]7Y$^OO<DK6734
M]7#5:<,!CZ,II5*M; 2IPUO-4I8AU&M+>ZIQO=K=6N<]'T7Z_P!:LU6C_A^O
M]:LUTG,3)]T?C_,U-'W_  _K4*?='X_S-31]_P /ZUA+=^K_ #-X[+T7Y%V/
MJOT_I5Q.A^O]!5./JOT_I5Q.A^O]!6,]UZ?JSHCLO1?D2I]X?C_(U-4*?>'X
M_P C4U93^%_+\T:0W?I^J+%3)]T?C_,U#4R?='X_S-8FI=3J?I_45,O4?4?S
MJ%.I^G]14R]1]1_.HGLO7]&=!;C[_A_6I5ZCZC^=11]_P_K4J]1]1_.LBX;O
MT_5$]68^J_3^E5JLQ]5^G]*YSHAN_3]43U;3J?I_454JVG4_3^HK&?Q/Y?DC
MII]?E^I:3H?K_05,G4_3^HJ%.A^O]!4R=3]/ZBLY_"_E^:-"9>H^H_G4]0+U
M'U'\ZGK$WCLO1?D3Q]%^O]:NQ]_P_K5*/HOU_K5V/O\ A_6L);OU?YFT-GZ_
MHB9/O#\?Y&IJA3[P_'^1JRB@\GL>G^-8SW7I^K-8M)MOM^J)4&=H]A_*IP !
M@5$GWA_GL:FJ#9:I/N6TZ_A_A4M1)U/T_J*EKG.@MIU/T_J*F7J/J/YU"G4_
M3^HJ9>H^H_G4+XY>G^1T$]3KT'T'\J@J=>@^@_E7-4Z?/]#:'PKY_FR6/O\
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M!GO#%YUY<6TMA=K-=^7"D,<Y*F.'=&@ DD+_ )%]#?P R3A[Z/6$\5\I\/\
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M_$6A:WI^MZ\D]W)>7MD/%5X!;R12W,EM%%_Q*M-R(+>(DVL9))9R_P!/>-_
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MP]:&TMP&@9X%2JG<\^WI_C_*G  =*6LI3;VT7X@%%%%0 4444 %%%%!G*?\
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M#+V+5;(W^IVL4UQ?W5J+34[U#9F5XIHOH?%#Z.O".<\#YEE_ G"F0Y1Q3"6
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MORO#_@&P9"6$UM?^+M6T6&ZV+*4LGN)_+=(F%?YSW[6/[3WC_P#;&^/'C/\
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M-3+JF69=A8RQ6'EAJOM<-3G&JG2DY-13DN65_>/]6_P-_P B3X/_ .Q6\/\
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MFIW2V%I8:98PE+>TLK'3].L;>"UL;.V$[7E^U[J-Y_*;_P '&W[3_@WXL?M
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MB:M_ZC7A*OLROC/]AO\ Y)-XA_[*)JW_ *C7A*OLRO\ @I_:5_\ *=_TG?\
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M;:;-)#/:30W5Q?2079L-MS(;@B/ZP_8$^(^F^)/A%_P@+2I'KOP^U"_1[9Y
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MGA">O _6GJH'N?Y?2G4]%MJ^_;T7ZOY)&<I_R_?_ )?\$0 #I2T44C,****
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MW_#^M01J#@GN?RYQ5H #I6#5U;^MR]RU&,%?IG]*GJ"/JOT_I4]8%0^)?/\
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M6=M#9:=HR_ K1-+T^UC2&TT_3M*_9M^#]G:VEG!&JQ6]M&L1,4$2K'$&*HH
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M'[=L&OC&H/\ M9_'N]CX8 Z5J7Q*\1:CH+(&^81MH5UIK1@EL1E1N<?,?@>
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MQ)K.E>']#LY-0UG6]0M-*TNQB:-)+N_OITMK6W1YGCA0RS2(F^62.),[I'1
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M*=M%KY]/^"%%%%!DW?5A1110 4H!/2G*G<\>WK_A_.I0,<"@!H4#W/K3J**
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M0O95BC>5H[:WE=8T=R JDCGJ_M6_8VTSX2?\$J?^"1]K^VR/AO;>./C#\2?
MOA/Q_K=^SVD.LZ_=_%+7=*TSX:^#8_$7V2>Y\.^!=%T[6=!U37+*W\]Y+Q-=
MU%+>[U:ZL;*/\T\3_$*7A_E>4RP.3U.(>(>)L\P?#?#>2PQ-/!0QF:8[F5*6
M)Q=2,XX?"TN5*I/E;E4J4:;E1ISGB*/Z'X<\"1XXS+-(XW-:>19%P]D^+S_B
M#-YX>>+GA<MP7*ZD</A:<HRKXFI=N$>9*-.G5J*-6<(4*O\ *]XD_8)_;;\'
M^&6\9>)_V3/VA]#\-1Q^?=:IJ'PC\;P)IT&&)N-6MSHQO-'MP%PT^J6]I"I9
M%9PTD8;Y-DCDBD>*5'BEB=HY(Y%9)(Y$8JZ.C ,CHP*LK ,K @@$5_2!X#_X
M.6_VJ]/\8Q7GQ)^"OP*\4> Y]2ADOM \(V?CCPAXFL]*\T":WT?Q)J?C+Q;I
MWVH6Y+++JOAV^26Y4$?9H6,:?"G_  5F_;"_9B_;,^-/A'XD?LX_!B;X=7'_
M  B:W'Q0\;ZQIMKX?\5_$;Q?K LKD6NOZ#HNIZCH$TW@J&"73!XL5Y=;\375
M_>Q7EY=:-HWAZ1O+X3XH\5JO$-#)>.?#W 9?@,;AL5B:/$O#F>4LPRW SPT(
MSC@\SPN)<<5"K6<XT:56C*3JUI)TL-/#PQ.(PWH\3\-^&=+(J^;\&\=X['8[
M!XC#8>KP]G^35<#F&,AB)RA+%Y?B<.I8:=.BHRJU:56*]G2BU4KPK3P]'$>/
M:[_P3._;%\-_LJV7[96L?#*"U^"-]HNC>*X]0'B;P_-XFC\%^(9K*#0_&=QX
M5@OY-6B\/ZD^HV,L,AB.HPV-S'JUWIUOI!-^/@BOV1^(7[=W_!2[7?\ @GIX
M?^ GC'X1Z[HW[*(\%>"_ EI\=W^"7Q!T>3Q'X T._P!-L_"'AV;XJW=Q_P *
M^N],N5TK2O#<=[I>EVFIZ]96@TZ[U._N;W49+W\I/A_\-/B/\6/$,?A'X6?#
M_P ;?$OQ9+:76H1>&/A_X5UWQEXADL+%5:]O8]%\.V&I:D]I9JZ-=7*VQAMU
M=3*Z!@3]'P;FO$]; \0XKC;$<*4E@N(,SH9=6X>QLZN$H9'AU1>&_M:OB:TX
MT<QIN55XF,I4>2FZ3J4:,FXG@<6Y9PY1QF18;@^AQ-5>,R++JV/HY[A(4\56
MSFNZOM_[,HX>E"5; 32IK#R4:O//VBIU:L4F<317N'@?]F;]HGXE?$#7?A5X
M#^!WQ6\4_$GPM=7%EXL\#Z3X#\2S^)?"5U:S2V]U#XMTHZ<EUX7>VN89;:?^
MWX].$-S&UO(5F'EUK_&O]DG]IO\ 9QM[*^^.GP)^)_POTK4KM=/TW7O%GA+5
M;#PWJ&HM!)<C3;'Q*()-!O-2^S12W!T^WU&2\6&*65H0D;L/I_[>R-8ZAECS
MG*O[2Q-*%;#9?_:.#^O8BC.'M(5:&$]M[>K2G!J<*E.G*,H/F3:U/G5DN<O!
MULQ64YF\OP]25+$8Y8#%?4Z%6$N2=.MBO9>PI5(3]R4)SC*,O=:3T/GBBBOJ
MOX2?L-?MA_';P_!XM^$?[-GQA\<>$KM)Y+#Q9I7@G6(_"^IK;2/%<+I/B*_M
M[/1M6D@F1X98=-O;J6.96B9!("M;9CFF691A_K>;9C@,KPO.J?UG,<9A\%A^
M>2;C#VV)J4J?/)1DU'FNTFTM&8X#+<QS6O\ 5LLP&-S'$\KG]7P&%KXROR)I
M.?LL/3J5.5-I.7+9-I-ZH^5*^NOV(_V/?&O[<OQWTWX#> _%'ACP?K=_X;\1
M^)Y-=\6C57TJWL/#=I'<7$0BT>QO[R:ZN99[>&%/+BB56EE>8>4L<L5[^P-^
MW-I]W<V-S^QM^U+Y]K-)!*;?X!?%.]MR\;%6,%Y9>%;BTNHB1F.XM9YH)4(>
M*1T8,?TN_P"""/A;Q/X)_P""G$/A+QGX<U[PCXJ\/_"WXKZ;KWAGQ/I&H:!X
M@T34;>STH3Z?J^C:K;VFI:;>P$@36MY;0SQD@/&IKX7CSC6AEO 7&.><+YSE
M.+S7)>',QS3!RPV)P68QHU:%"4Z->K0IU*L9TE-P_B1=.3:3NG9_9\%<(U\P
MXUX3R;B/*<SPV69OQ!E^6XN.(P^+P#K4J]>,:U&G7G3I2A4=/F_AR52*3DK-
M77Y5?M;?LV^)/V0_VAOB-^SKXN\0:)XJ\1?#>X\/6VI:_P"'([^+1=0;Q%X0
M\/\ C"W:QCU.WM;Y5M[/Q#;VD_GP1DW,$QC#1%';YQK]4O\ @MG_ ,I0/VI_
M^PI\+_\ U2'PSK\_?A-\$OC!\>/$A\'_  7^&/CGXI>)DM_MEQHW@7PSJWB2
M\L;'S%B.H:DNEVMPFEZ<LK)&^H:B]K91R.B/.K,H/L\'Y]/,. N%.)<]Q>&H
MULQX3X?SC-<;6E1P>$CB<?E.#Q>+K2<G3H8>E*O6G)1O&G3348V22/)XJR2&
M!XVXFX>R;"XBM2P'$^>95EN$I1JXO$RP^"S/%87#48J*G6KU51I03=I3FTY.
M[;9Y?17TW\8_V+OVL_V?M*?Q!\9_V=OBY\/?#41MDF\5:]X*UI/"-O+>RQP6
MEM<^*[6VN?#MM>7$\L<,5E/J<=V\SK$(?,(6OF2OH\OS++LVPT<9E688+,\)
M*3C'%9?BJ&,PTI12;C&OAJE2DY)2BVE*Z4DVK-'@X[+\?EE=X7,L#C,OQ48J
M4L-CL-6PE=1;:4G1Q$*=11;32;C9M.VS"M31-$UKQ+K&E^'O#FD:IX@U_7+^
MTTK1=#T2PN]5UC5]4OYTMK'3=+TRPBGO=0O[RYDCM[2SM()KBXGD2*&-Y&53
MEU^Z7_!OM^SM_P +B_;FMOB;JUC]I\*_LY>#]4\>RR31>99R>-O$"2^$? UC
M+P=EU"=1U_Q7ISDKLNO"*N"2H5O#XWXHPW!7"/$/%6+A&K2R/*\3C84)3]FL
M5BHQY,%@_:6?(\9C)T,+&?*^659.SM9^SP=PWB.+^*<BX:PLI4ZF<YEA\'.M
M&'M'AL-*7/C,7R77.L)A(5\3*-US1I-75[GXZ^/O@W\7OA2FER_%'X5?$CX;
M1:X]Y'HLGC[P-XG\')K#Z>+9K]-+?Q%I>G+J#V*WEFUXMH9C;"ZMC,$$\6_S
M>O[=_P#@J['X$_X*%_\ !,?Q[\>/A1!_:.H?LU?&7QWK&GO&\5U?3:-\+?'G
MB3X5^/I?/B0+!H^O>"'M?BQ#;MB1=)LM#6>0SQ/N_B(KY;PE\1,1XC<.XW,,
MRRJ.0Y[D^=X_(L[R95IUG@L9A/95:=I5(4ZCA5PU>D^9QY'6C7C3E.,+GT?B
MAP'0X!S["8'+\SEG>2YMD^!SK)\W=*-)8S"XI5*=2\:<YTU.EB*-5<JES*E*
MC*<8RG8**]*^%OP:^+?QO\1-X1^#?PS\>?%+Q,EL;V?0_ 'A36_%FI6E@LB1
M/J%];:)97LECIT4LD<<VH7@@LX6=!+.A89^C/$__  3?_;Z\(M:KK'['?[14
MWVQ"\+>'_A3XN\71J J,5N9?">F:W'928<8BO'@E8AU5"T<@7[G&\1</Y;BH
M8',<]R; 8V</:0P>-S/!87%3A:_/##UZ].M*%M>90:MK<^-PF0YYC\-+&8#)
MLVQN$A+DGBL)EV,Q.&C.]N25>C1G2C*[2Y7).[M8^*:*]>^)?[/OQZ^"]II5
M_P#&+X(_%[X36.NW%S::)>_$OX:^,_ EIK-W9QQS7=KI5QXIT72H=0N+6&:*
M6YAM'FD@CECDE55=2:/PF^"7Q@^/'B0^#_@O\,?'/Q2\3);_ &RXT;P+X9U;
MQ)>6-CYBQ'4-272[6X32].65DC?4-1>ULHY'1'G5F4'J6:Y6\#/,UF6 >6TX
MSG/,%C,.\#"%.3A4E/%JI]7C&$TXSDZB49)Q;35CF>6YBL9'+GE^-683E",,
M"\+76,G*I%3A&.%]G[>4IQ:E!*#<HM-)IW/+Z*^F_C'^Q=^UG^S]I3^(/C/^
MSM\7/A[X:B-LDWBK7O!6M)X1MY;V6."TMKGQ7:VUSX=MKRXGECABLI]3CNWF
M=8A#YA"U\WZ?I]_JU_9:7I=E=ZEJ>I7=MI^G:=I]M->7^H7]Y,EM9V5E9VR2
M7%U=W5Q)'!;6T$<DT\TB11([LJEX'-,LS3"_7LLS' YC@KR7US XO#XO"W@E
M*:^L8>I4I7C&2E)<_NIINR:#&Y;F.78CZGF& QN Q=HOZKC<+7PN(M)M1?L*
M].G5M)IJ+Y=6FE=HJ45[#XD_9X^/_@SQGX=^'/C#X&_&'PI\0O&$*7/A+P)X
MD^&?C70O&?BBWEGN;6.?P[X7U31+76];ADNK.[MDETRQND>>UN858R02JOL'
MCW_@GY^V[\,/"%UX^\>_LL?&_P -^#M.L)]4U?7[SP#KDMCH.F6J&2ZU'Q&;
M.UN9?#EC;1@O<7>NQ:?;PH"TLBKS7)5XCX>H2P4*V>Y-1GF7_(NA5S3 TY8_
MWW3_ -BC.NGBO?3A^X53WTX[JQTT\@SVM'&3I9+FU6&7_P"_RIY=C)QP/NJ?
M^V2C1:PWN-3_ 'SA[K4MG<^/JMQV%]+;/>165W):1%A+=1VTSVT94 L'G5#$
MA4,I;<PP",XR*LZ'H>M^)M8TSP[X;T?5/$/B#6[ZVTO1M"T/3[O5M8U?4[V5
M8+/3M,TRPAN+V_OKN=TAMK2T@EN)Y76.*-W8*?["OV5OV>_C'X8_X('_ +1'
MPRU'X1?$S3?BMXX7XNZKIOPSO? 7BFT^(6J37NK^']+TQ;'P9/I4?B2\DU&Q
MT-+BP2#39&N[4+/;B2$AZ^1\1_$3!^'N$R'$5Z&&QM;.^)\EX?6&K9E3R^>&
MP^:UJE*OFKYJ&)E4H8"-*4ZD'3ITYMJ,\31^(^IX X"Q7'>+SJA1KXC!TLGX
M=S?/'B*67U,=#$5\MI4ZE'+$HUL/&G6QDJJA"2G4J02<HX>KL?QPT5Z]\2_V
M?/CW\%[/2]0^,7P0^+WPGL-<N;BST6^^)?PU\9^!+/6+RTB2>ZM=+N?%.BZ5
M#J%S;0R1S7$%H\TL,4B22(J,I/D-??X7%X3'4(XG!8K#XS#3<E#$86M3Q%";
MA)QFHU:,ITY.,DXR2D^62:=FFCX?$X7$X.M+#XS#U\+7@HN=#$T:E"M%3BI1
M<J56,9Q4HM2BW%7BTU=-,****Z# **** "BBB@ HHHH ***>J$\G@?SH$VEJ
MQH!/ J14 Y/)_E3@ .!2T&<IMZ+1?F%%%%! 4444 %%%% !1110 444H!/2@
M!*>J=SQ[>O\ A_.GA0/<^M.K.4^B^_\ R,Y3Z+[_ /( ,<"BBBLS,***4 GI
M_GZT )3PA/7@?K3U4#W/\OI3J $  Z5]8_L%_P#)\W[&'_9V'[.O_JW_  =7
MR?7UA^P7_P GS?L8?]G8?LZ_^K?\'5X/%/\ R3'$?_8ASC_U7X@]SAC_ )*7
MA[_L>93_ .I^'/D^BBBOHXPZO7R[?Y_D>&%%%%$I]%KY]O\ /\B)3Z+7S[?Y
M_D%%%%9&04444 %*%)Z?GVIZIW/Y?XU)0 T*!]>YIU%% !3TZGZ?U%,IR'!^
MO%3)7B[?UJ!.O4?4?SJ< GI42*20>@R/Y]JN  =/\_6LY--179:_<C52245N
M]%^1+$@ 7/)S^'6OTU_X)1?L>_\ #8_[7W@GPKXATO\ M#X3_#G9\4/B[]HA
M\S3[_P ,>'+ZT_LSP=<^8JPW'_"=^))])\.7U@EQ!J!\,7/B?6-/+OHDVW\S
M8^B_7^M?W8?\$+_V4_\ AG[]D&Q^)NLQ[/&?[3']@_$>^^3;Y'@>VL;S_A7%
MK_I7AW1=5C\S2M:U'6_(FO\ 7M(?^W/[2T&^6VU.?S?P[Q^X^J< >'F:XS!U
MG1SK.6\BR22DXU*6)QL)K$XVDTFXSP&!CB,31FUR_6HX:,KJ;/VCP(X#CQ[X
MA99A,91]MDN3_P#"WG4914J=7#8*<'A\%43LI4\?C98?#5H74GA98B4=8H_:
MFBBBO\EC_5L**** /AC_ (*._LO0?M<?LB_%'X6V>EQ:EXXT^P'CSX5,SI%<
M6GQ'\(PW5WHL-E-+'+#!+XCT^?6/!5U++&572_%&H!);65H[RW_ST98)[666
MVN89;>YMY98+BWGC>&>">&1HY89HI LD4L4BLDD;JKHZE6 8$5_J*U_#]_P6
MT_9%_P"&=OVJ+OXF^%]+^R?#+]HK^T_'.F?9H=EEI'Q AN(?^%C:"NQ0D7VK
M4KZS\7VJ8CB$/B>:QM$,6E2;/[0^B5Q]'"X[-/#W'UK4\Q=7.LA]I-V6-HT8
M1S3 TTV]<1A*5/&TH1481^IXR;O.LK_QK]*_@.6)P>5^(& HWJ9=&&2Y]R15
MW@J]9RRO&S:2TH8NK4P56<G*<_KF"@K0HL_'-.I^G]14R]1]1_.H4ZGZ?U%3
M+U'U'\Z_NV>R]?T9_#D-WZ?JBW'W_#^M2KU'U'\ZBC[_ (?UJTB@%3U)(/TY
MK%R2_0UNMKZ]B4(3UX'ZU;4 *,>@_E4-3KT'T'\JP*3=XKHFOS)DZ'Z_T%6Z
MJ)T/U_H*MUC/XG\OR1L2IT/U_H*O)U/T_J*I1@D$#U_H*NIU/T_J*YY_$_E^
M2-(-:Z]OU+"J3@]NOUYJPG4_3^HJ)/NC\?YFI4ZGZ?U%926C;U[>6J_'S^ZQ
MH7(^B_7^M6:K1]%^O]:NIW_#^M8MV3?8WCLO1?D2Q]5^G]*GJ%/O#_/8U:5.
MY_+_ !K WBDDMKM?-Z:DL8/RGMC^E7$Z'Z_T%0K]T?05,G0_7^@K&3N[_)%W
M=K=-R9.I^G]15M/NC\?YFJB=3]/ZBK:?='X_S-<\_B?R_)&Y=3J?I_45,O4?
M4?SJ%.I^G]14R]1]1_.H;2W-8;?/_(MQ]_P_K5I5  /<\Y_PJK'W_#^M6UZ#
MZ#^58%DL??\ #^M6UZ#Z#^55(^_X?UJVO0?0?RKG-H?"OG^;)DZ'Z_T%2I]X
M?C_(U$G0_7^@J>-26'8<\_@:RFM;]]ODD:P:5[^7ZEE.A^O]!5U ">?3/ZBJ
M@  P*N)U/T_J*QF[*W??Y6-5JD^Y,O4?4?SJTG4_3^HJJO4?4?SJTG4_3^HK
M(UAL_7]$6T^Z/Q_F:FC[_A_6H4^Z/Q_F:F3O^']:PEN_5_F=$':+;[_HBVO0
M?0?RJU$G&3Z]/P'7_/YU7CZK]/Z5<3H?K_05S%[DJ?>'^>QJ:H4^\/Q_D:FK
M*>Z]/U9<-WZ?JBQ4R?='X_S-0U.@)  ]_P"9K&>R]?T9J7$ZGZ?U%3+U'U'\
MZA3J?I_45,O4?4?SK(Z#[$\ ?\F>?'7_ +'_ .'W_I;I]?*2?P_\!_I7TMX(
M\0:#:_LJ?&?P[=:WI%MX@U3QOX&N],T*?4K*'6-1M;2[L6N[FPTR29;V[M[9
M4=KB:W@DCA56,C*%./FE/X?^ _TKXWAJG4AC>,'4A."J\55*E-SC**J4WD&0
M0]I!R2YX<\)QYHWCS0E&]XM+Z[B*I3J8/@Y0J0FZ?"<*=51E&3IU/]8>()\E
M1)MPGR3A/EE:7+.,K6DF[%3KT'T'\J@J=1D*!Z#^5?2S6J??_@'S2W7JOS)D
MZ'Z_T%7 ,D"H(D '/)R?IT%6$^\/Q_D:S>B?HS923O;H2@ # JS5>K%8%1W7
MJOS)X^B_7^M7$ZGZ?U%4X^B_7^M7$ZGZ?U%82W?J_P S<MI]T?C_ #-31]_P
M_K4*?='X_P S4T??\/ZUG-V5N_Z&\=EZ+\BY$H!4]R,_I5BH(^J_3^E3UA/X
M7\OS1I#=^G^1.O0?0?RJ9.A^O]!4*]!]!_*IDZ'Z_P!!6)J3)U/T_J*MI]T?
MC_,U7B0D\\#!^O45: QP*SFTU9.^O]?F;IINR=_Z_P""6*GC_A^O]:C0<_09
M_E4R]1]1_.N::W?=V_#_ (!4=UZK\RW'W_#^M2KU'U'\ZBC[_A_6I5ZCZC^=
M0=$=UZK\RW'W_#^M3)]X?C_(U"G?\/ZU:4  >I'7ZUC/XG\OR1N2HH/)['I_
MC4Z?>'X_R-1)T/U_H*E3[P_'^1KGG\3_ *Z(T@V[^5OU+:=#]?Z"K=5$Z'Z_
MT%6ZSG\+^7YHT)X^B_7^M6:K1]%^O]:LUB;7M%/>R7Z?YD\?(7Z_UJS5:/HO
MU_K5FL);OU?YC6J3[I%F/JOT_I4]01]5^G]*GJ/M_P#;OZFT-GZ_HB=>@^@_
ME4R=#]?Z"HE&0H]A_*IP,#%8-737?_,Z(/2W6]_R+-3)]T?C_,U#4R?='X_S
M-8MW=RRZG4_3^HJVGW1^/\S51.I^G]15M/NC\?YFLY[+U_1G031]_P /ZU*O
M4?4?SJ*/O^']:LJHX)]B/:L6TMRH.S]=/O:)57=5A."!_GI4,??\/ZU,GWA^
M/\C6-]$NWZFQ-5I/O#\?Y&JM6D^\/Q_D:PG\3^7Y(WCLO1?D6TZ'Z_T%3)U/
MT_J*A3H?K_0585<<GK4-I6OUT1T1V7HOR+2#(4>IQ^M6  .E5X^B_7^M6:YZ
MFTO7]2X-W2Z:_D3)]T?C_,U-'W_#^M0I]T?C_,U-'W_#^M8&Q=CZK]/Z5/4$
M?5?I_2IZF?POY?FC>.R]%^184$@ >@_E4RC Q^-11]5^G]*GK$U@];=-_P B
MQ4R?='X_S-0U,GW1^/\ ,USFA*G4_3^HJY'T7Z_UJFG4_3^HJY'T7Z_UK&?Q
M/Y?DCK@[/Y6_%%V/O^']:E7J/J/YU%'W_#^M2KU'U'\ZDU)ZLQ]5^G]*K59C
MZK]/Z5S2V?H_R-H?"OG^;)ZM)]X?C_(U5JTGWA^/\C6!<=UZK\R:O4/B1_R&
M=)_[%?1O_09J\OKT?Q_>6E[JVF26=U;7<<?AS2H))+:>*=$FC67S(7:)G598
M\C?&Q#KD;@,BO,Q2;S#+VD[*CCTW9V3:PUDWLKV=K[V=MCVL-**RO,XMI2E6
MR]Q3:NTI8F[2W=KJ]MKJ^YQR?='X_P S4T??\/ZU"GW1^/\ ,U-'W_#^M=,_
MA?R_-'##9^OZ(E7J/J/YU/4"]1]1_.IZB224;=5_D=$'=?.WX(LQ]5^G]*N)
MT/U_H*IQ]5^G]*N)T/U_H*YU\$O7_(Z(;/U_1$J?>'X_R-6TZ'Z_T%5$^\/Q
M_D:MIT/U_H*@LF3J?I_45+42=3]/ZBI:YSH+:=3]/ZBIEZCZC^=0IU/T_J*F
M7J/J/YU$]EZ_HS6&S]?T1;C[_A_6I5ZCZC^=11]_P_K4J]1]1_.LC:&[]/U1
M;C[_ (?UJ9/O#\?Y&H8^_P"']:F3[P_'^1KG.B&[]/U1-5M.I^G]152K:=3]
M/ZBL9_$_E^2-H[KU7YEI.A^O]!4R=3]/ZBH4Z'Z_T%3)U/T_J*SG\+^7YHW)
MEZCZC^=3U O4?4?SJ>L3>.R]%^1/'T7Z_P!:NQ]_P_K5*/\ A^O]:NQ]_P /
MZUA+=^K_ #-8-;=6_P!/^ 3)]X?C_(U;3H?K_0543[P_'^1JVG0_7^@K&>Z]
M/U9H2I]X?C_(U-4*?>'X_P C4U0;QV7HOR+:=3]/ZBI:B3J?I_45+7.=);3J
M?I_45,O4?4?SJ%.I^G]14R]1]1_.H7QR]/\ (Z">IUZ#Z#^505.O0?0?RKFJ
M=/G^AM#X5\_S9+'W_#^M78^J_3^E4H^_X?UJ['U7Z?TK-JVYK#=^GZHGJQ5>
MK%8S^)_+\D;1W7JOS)4Z'Z_T%3)U/T_J*A3H?K_05,G4_3^HJ3<N1]%^O]:L
MU6CZ+]?ZU9K"6[]7^9O'9>B_(F3[H_'^9J:/O^']:A3[H_'^9J:/O^']:RJ=
M/G^AM#9^OZ(DHHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** /%?VD
M_P#DW3X^_P#9%?BG_P"H-KM?X[-?[+GQ(\'K\0OAWX]\ MJ!TE?''@OQ3X/;
M55M1?-IB^)M#OM%.H+9&XM!>&R%Z;D6INK87!C\HW$._S%_CK_XA!O\ K(7_
M .:F?_E+U^I^'7$F2Y#0S6&:XSZK+$U<)*BOJ^+K\\:<*ZF[X:A64>5SCI/E
M;O[M[.WXSXJ\)Y_Q)B,EJ9+@/KL<)1QT,0_K6"PWLY5IX9TU;%XF@Y\RISU@
MI)<OO6NK_LE_P;K_ /*(7]EO_L)?'G_UHGXK5^ ?_!VY_P G%_LC_P#9%?&W
M_J<QU_6S_P $[?V.4_8%_9"^%?[*B?$1OBM_PK2?QW</X\;PF/ _]N/XW^(O
MBSQ\P7PN/$GB_P#LM=-_X2<:2 ?$6I&\^PF_+6WVK[%;? '_  5N_P""*:_\
M%3/B)\(O'P_:6/P*;X5^"]=\'G2O^%.#XG+KRZSKD>M+J O?^%J?#PZ4;4JU
MLUJ;74A<!EE%Q!L,;^9DN>97A..\9G.(Q7L\MJX[.:U/$^QQ$^:GBWB7AY>Q
MA2EB%[3VD-'24H<WOJ-G;U^(.'<XQWAM@,@PN#]KF]#+L@H5<)]8PL.6K@EA
M%B8>WJ5X89^R]E4]Z-9QGR_NY3O&_P#-A_P:E?\ *1KXJ?\ 9G7Q(_\ 5P_
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MO_@F@G_!+SX&_$'X-#XTM\<9/'GQ7O?B<_B8_#H?#1-+2Z\(>$O"J:$NB?\
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M-T<3FF.EB*>(J1K5:='#I6P]"C6PD5B,/5AK[>:BH5VXN<^1*G'[?.^'^/\
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M[HNB:<7Q_?OT0G@,>,_&VO:!K?A?5K[0?$6E7^B:SILQ@OM,U.VEM+RVE #
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MJF;9S5S'.)U,*LRHYZLKR_V>&I4GF<,6Z#4,!>4<KJTOWM2^(33]G\[5Z/\
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M/I[]HSXX-\ O!&E^,5\,KXK.I>*K'PU_9S:R=#$(O-)UO5/MOVL:7J_F&/\
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MW$&<T,%[L*$X4ITZ$<#C,W=:I'#T_:8C&5,%2Q%2G0J0JU98:G3YJOXT^-O
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M[+<7FUXH &C3R+:4^8>-P"]6%?37_!.+_DIGCS_L14_]2#2J]W_X*.?\DO\
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M K\K/VD%)^-/C,]!_P 4[^/_ !2FA5^J=?E?^TA_R6CQG_W+O_J*:%7^WG[
M]V^F%XD/_K&OC#_UZ'@X?XN?MU&U]$CP[M_TD9PC_P"NS\73PX #@4M%%?\
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MM/;QCX)TJ7Q/X9:UGF\*2ZYI7B[[/ ?%-MIIBBT^XL+\ZM/X9.D17VD7-D=
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M.Q3Q>;!+)#)L==\4CQME'8'\H/C?^U[??MR?\%"_AI^T)J'@2S^'$_B#XA?
MG0E\*66OR>)XK.+POK'AO1UN&UJ71M!DO)+UH'NB'TR$VRR):AYEA65OM> ^
M$^+LCXVXKSJ/AO1\-."\YX%Q6&QV28/B;(\XR^MQ/@L1&6#S+#8+*IT_J4ZF
M65,1AITZ6$A0YHU:U2K[6M&+^0XTXGX6SGA#AC*9>(%;Q"XNRGC3#8C!YQB^
M'LYRG'4>'<90Y<7E^(Q>9PG];C#,:>'Q$:E3%2KVE3I0I^SHN1_6=_P5G_;I
M^'?_  3U/P]^*^@_!?PU\0_VK/B;X7\5^ OA9XO\3V+-I/@[P1X7O])U7Q0V
MKZG;7%OK9TZ75O%NE,OAGP[=:-/XEED>35==LK;1K2*?Y)_X(^?\%?\ XY_M
MF?'GQ5^SU^T9H_@2^GU7P-KGC+P/XD\(^'Y?#TL5UX?O-.36/"VM:;)J=_8Z
MAIUYHVI7%]I]['%!>VDFDSVM\=334HYM/^=_^#H/_D-?L5_]@O\ :!_]*_@U
M7YZ_\&_?_*23P%[_  W^+&?_  E)C_.ORSA?PSX,S#Z+V8\88_*(8WB>?#G$
MF94<YQ5:O7QF J9#FN;4<NP^73G4<<#@J=/ P53"X>,*5>56O*LJCJ>[^D\2
M>(G%N ^D?@.%<%FL\)P[#/\ A[+ZN4X:E1HX3&T\[RS*ZN/KX^,*:EC<7.IC
M9NGB:\IU**I48T7!0U\._;HTJ3]A/_@J?\6-0^"UAIFA3_!WXV^%/BY\.](O
MK&.\T#1[C7]*\+_%S1M&_LR-K97\.V$WB)--M-/CEADBT>&&U2Y26,7 _JT^
M%?[?GQU\9_\ !'/Q)^W5J]MX$7XVZ3X-^*FN6L%GX?OX?!+7W@[XI>(O"&D>
M=H,FN37KPG2-,M?M<::S&9KH23*T2OY8_EV_X+F?\I2OVGO]WX*?^L\?":OV
MP_9[5I?^#:KQRD0,C)\,_P!H%G5!N95C^.WC.:0L%R5"0@RN3C;&-YPO-?5^
M*&599Q!X7_1ZS_.L!A<PS?,\[\*LLQ^88JFJN)Q.6YQD=;%YG@:U:3<YX;&8
ME*M7IR;4ZBYF[W;^;\.,RS'(O$?QVR/*<;B,#E679/XE9C@<!AYNGAL/F&59
MS0PV78RC2C[L,1A,.W1HU(I.%-\JTLE_/_\ MI_\%0OVEOV\O!_@[P1\<;7X
M:V^B^!_$MSXJT5O _A;4M O6U2ZTN?2)1>SWWB/6DGM?LEQ(5B2&%A+M<RD
MH?SGHHK^NLBX?R3AC+J64</Y9A,HRRC.K4I8' TE1P].I7J2JUIQIQT4JE24
MIS?63;/Y8SK/,WXBS"IFN>9CBLTS&M"E3JXS&5'5KU(4*<:5*,IO5JG3C&$>
MT4D%%%%>P>4%%%% !1110 4H!/ I54GKP/Y_3_&I0 .!01*:6BU?Y#50#D\G
M^5/HHH,VV]6%%%% @HHHH **** "BBB@ HI0">E2A0/<^M2Y)>;[?Y]B7)+S
M?;_/L,5.YX]O7_#^=2@8X%%%9.3>_P!W0R<F]_NZ!1112$%%* 3T_P _6I54
M#W/\OI0 P(3UX'ZU( !TI:* "BBBJ46_)=P"OK#]@O\ Y/F_8P_[.P_9U_\
M5O\ @ZOD^OK#]@O_ )/F_8P_[.P_9U_]6_X.KQ>*N6'"_$?_ &(<X]7_ ,)V
M(_KL>WPRTN)>';]<\RE+_P +\.?)]%%%>U*3?DNQ\]*3?DNP4445)(445(J=
MS^7^- # I/3\^U2A0/<^O^'I3J* "BBB@ HHHH ***<%)]AZT 6X6W!?4'!^
MN?ZU;K/3Y"".Q'X_7_/TJ\K!AD'ZCN#Z&LI1MJMOR^8X[KU7YGW3_P $Z/V2
M[[]M#]J_X:_!N2WNSX(BNW\;?%K4;1IH6TOX7>%;FTN/$@%W;L+C3[OQ)<7.
ME^!]%U&))A8>(O%6CW4\36L4[+_HW6%A8Z58V6F:996FG:;IUI;V&GZ?86\-
MG8V%C9PI;VEE96END=O:VEK;QQP6]O!''#!#&D42*BJH_P N?P)\2OB-\,KV
MZU/X;^/_ !M\/M2U&U%AJ&H>"/%6N^$[Z^L1.EP+*\N]!O["XNK07$4<XMIY
M'A$T:2A-Z*P]5'[6'[5!_P";EOV@ /7_ (7)\1OT_P"*CYK^8_&SP/XE\6LZ
MRS&4^+,ORG)LFP,L/@,LK9?BL3..*Q-15,?CJE2GB*<'5Q*IX6@HQC:-'"4K
M>_.HW_2_@SXU\.>%.39EA:G"N/S7.,WQL<1CLRHX_#8:+PN&ING@<%3ISP]2
M:IX=U,37<I2O*MBJOV(TU'_3.HK_ #.U_:N_:E"C_C)7X_G@<GXR?$0G_P!2
M.I4_:N_:D.<_M*?'X].OQC^(GO\ ]3'7XE_Q)GGG_1<Y3_X9\9_\V>O];?LO
M_$XN2?\ 1$9K_P"'?"?_ #(?Z7]%?YI0_:L_:BP/^,DOCYT'_-8OB'_\T53)
M^U9^U%@_\9)?'SK_ -%A^(?H/^IBK-_0WSM)O_7C*M/^I/B__FPJ/TP\D:O_
M *DYKO;_ )&^$\O^H0_TKZ_/'_@J+^RM/^UK^Q[\1O!'A[28M4^)?A"*'XE?
M"M!;O/?W'BSPDLMS=>'M,6-HV>_\:>&9=>\'Z?'+*EDNK:WIM[>9CL59/X:/
M^&J_VH?^CD?CW_X>'XA__-%4R?M4_M0L!_QD?\>C[_\ "X/B%ZGK_P 5%7JY
M#]%3BKAG/,JS_+>.\IIX_)L?A<PPLGE&-Y)5<-5A55*JEC$YT*RBZ->FWRU:
M,YTY)QDT>7GOTI^%N),ES7(<RX&S6> S? 8G 8I+-\'SQIXFE*DZE*3P;4*U
M&4E5H5+7IUH4ZD;2BK>(IU/T_J*F7J/J/YTDD\]U<3W-S-+<7-Q))/<7$\CS
M3SSS.9)9II9"TDLLLC,\DCLSN[,S$L2:5>H^H_G7]L2;=DTDU9NSNKVV3LKK
M7=I7[(_BV]F[/R3:UM?M=I/YLMQ]_P /ZU<3^'_@/]*IQ]_P_K5Q/X?^ _TK
M"IT^?Z%0W?I^J+%3KT'T'\J@J=02 !Z#^59FRW7JOS)DZ'Z_T%7E0GD\#^=5
MHD &3R<_EP*O5A/66FVGY+\^YISJZ2ZM:_G_ %_3DC "D#U_H*G3J?I_45"G
M0_7^@J9.I^G^%93Z?/\ 0TCNO5%M/NC_ #W-68DYR?3I^(Z_Y_*J\?1?K_6K
MB=3]/ZBL9_"_E^:.J$4]7KKL3+U'U'\ZMQ]_P_K51>H^H_G5N/O^']:YY_"_
ME^:-?0N1* 5/<C/Z58J"/JOT_I4]8E1^)?UT)UZ#Z#^53)T/U_H*A7H/H/Y5
M,G0_7^@KG-B9.I^G]15M/NC\?YFJ\29.3QQT]>GY?S^E6@,<"L9_$_E^2-TT
M]M2VG4_3^HJ9>H^H_G4*=3]/ZBIEZCZC^=<\_B?R_(TAN_3]46X^_P"']:MK
MT'T'\JJ1]_P_K5Q?X?PJ34DC[_A_6K:C(4#T'\J@JS'U7Z?TK!JSL:1DDHKJ
M_P#,LQ)@9///3TZ?G_+ZU83[P_'^1J).A^O]!4J?>'X_R-83^)_UT1H35;3J
M?I_454JVG4_3^HK&IT^?Z&\=EZ+\B9>H^H_G5I.I^G]159020>P(S5E.I^G]
M163=DWV-H;/U_1%R/HOU_K5FJT?1?K_6K-8/5M]RRS'U7Z?TJXG0_7^@JG'U
M7Z?TJXG0_7^@KG-X[+T7Y$J?>'X_R-35"GWA^/\ (U:0#KW!XK*>Z]/U9<79
MM^1.J$\G@?SJT@ 4 >_\S453)]T?C_,UC/9>O^9I%W3?F2IU/T_J*L*I)![
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MH_R-8-62ZZ_F35:3[P_'^1JK5I/O#\?Y&L#2.Z]5^9-6YJ&DZAH\\5OJ-O\
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M5N6G_:U^SZ_Y0O\ H[?]F]P?_J?F 4445_#A_8P4444 %%%% !1110 4444
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M=;TK4Y$*[PR6%_;W3J5P=P98B"N#G.,'-?TT726^O:'<1V=U'):ZUI4R6M[
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M3P^-CCLRJX>KF.%PDZV+QLHQH8/+\/#$2PEZ<L36E25;$+:_X)T?\EJ\5?\
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M4GAG4J4,>L%B.2OAZBPM.CB,.ZGUE^P_=^.[OX$Z(WB\6S:1#=WEMX%FW/\
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MNZ1=:@9(6N(Q8V^H6\MV7@1)&G3[.DFZ%8Y&E7**CE@I_=0?MJ?LR@ #XE
M   >#/'X  X  'A3  '  Z5^#?0>\/\ P&XAXISCC3QQXZX-R/#<%XK**G#G
M"'&/$>0</Y?Q)F.*6,KO,<;'.LPPLLUR[)I8.C[3+*%*>&Q.)Q6'_M*I/"1E
M@<;^E?2)XG\2<KR; 9!X=<.9_F-;B"CCH9KGF0Y5F>9XK*<)1]A36%P[R_"U
MXX+%8^->HH8RI4C6HT:-7ZI"-=QQ.'WOVA/BUKWPO\*&P\ >#_$/B[QWK%I)
M!H%EH7AO5-9T[0H0#!_;6KG3[.>WB@M""-/TUB)=0N8Q'Y:V4-W-%^%_B[PA
M\4+:34?%?CGPGXXL6U+4);K4]?\ $OA[7+&.ZU/49GFDDN=0U&RAA:ZNYWD<
M!I-\CEMH.,5^V?\ PVK^S-_T4O\ \LWX@?\ S*U\X_M6_M,?!'XE?!7Q!X2\
M%>-O[:\0WVH^'I[73_\ A&_%VG>;%8ZS:7=T_P!KU;0;"Q3RK>*23;)<HS[=
MD:NY53_77TR<E\(/&;)>(.-9?2MX$QSX&X4SG,.!?"_A_BC@?%X3%9MA<NGB
M7AZ=/#\2U\QS3.L]Q6'I8/ZQ1PTJ\:/U;!X+")0DJ_X;X"YAQUP#C\LX>7@K
MQ)AUQ'G6 PW$?&.9Y/Q%0KT<%6Q<:2JRE5RBGA<'E^6T:M2O[*I65-U/:U\1
M7?,G3^B?V+/$MMXC_9W\%112H]WX<DUGPUJ4:')M[BQU6ZNK2-^X:31[[2[D
MCMYXQD8-?F/^T7\(_%K_ +3WB3PKIFCWEQ=_$3Q0-;\,O';R-!J-OXEE6\NK
MN*15*FVTR^FU"'4YB0EI]AN9IBD*"0U_V6OVD[GX"^(+^TUBUN]6\!^)7MVU
MNPLV5K[3+ZW#1V^MZ5%-)'!+.L+FWO[1Y(/MULL!\]9;*W5OU>LOVMOV=KZP
M344^)VC6\;1B0V][::Q::A$<8:-["?34NS(IRI$44@;DQLZ$,?*X<SCP0^EU
M]&[PG\/^._%?(_#'B_PGQ'#^&SJCG.-RG XS,,OX=RNIP_7E@(YSF654,3A>
M(,D^JXJ6:8.KB?[&S:'+BL%7ITO88GNS7 >(?@=XL<;<3\-\$YCQAD?&U+,Z
MN7U,OP^.Q%#"XK-,;#,Z:Q+R_"8VI1K99F'MJ*P=>%)8_!2YJ.(ISE[2CZMX
MKUBQ^'?P[U[6Y95BL?!WA&_O$:4@;DT;2I&MH@!]Z6=X(H8XU!:261(T!9E!
M_G;^&WPT\7_%?Q39>$?!FF/J&IW9\R>=]T6GZ58JRK/J>K7@1TL["V#+OD*O
M+-(T=K:0W%Y/!;R_9O[6G[7NF?%#1W^''PT^VCPC-<PW'B+Q#=V\UA-XB^R2
M)<6>G6%C.([NVTB.Y2.[NI;Z&WO+RY@MXA;6UM!*;^W^Q+\<_A'\(?#?CBT^
M(7B6/P[JFM:YIMS8D:!XAU66[L+6PDB.ZXT/1M26..&XEDV0W$L;!I7>-"'=
MJ^1^D1Q]X,?2>^DGX7>&F)\1,EX>\(N ,KS^&<\>3S7+,KR7&YCBZ%#'YEE>
M2YWFV(P^5QP^)HY!DN2X+.)3KT*F-K8FI@:&/I4L++%^YX6<,\?^#_A-QCQ;
M2X5Q^:<<\38S+)9?PU'!XS&9AA\)1J5,-A,9F&7X&E5QCJT:F9YAF&(P"C3J
M0P].C#$5,+4G65#]"O@=\$/"'[/O@J73]/*7FKS6XU#Q?XJEMR+S5KBUA>1Q
M'&@EFM]*L%,RZ;IL32>4C232&XOKFYGF_-W]JGQQ\9?CIK\>C^'/AE\3K3X:
M>'[IWT:U?P1XGBEU_4$62!_$>HP_V9E"T3R0Z39RYDL;.66258KN]NHH_O7_
M (;5_9F_Z*7_ .6;\0/_ )E:/^&U?V9O^BE_^6;\0/\ YE:_JGQ5P7T<N/?"
M[)?!GA'Z3WA1X5>'664:6'QN2\+\:<!8FKG.$PLX5<+@<;CL7Q13JO!O%*>8
M9E&4:N*SC,91Q>88NM)58U_QC@O$>*W#7&.8<?9[X/\ &O&G%6,G.KA\PSCA
M_B6C# 5JRE"MB,/AZ&33@J_L.7"X1IPHX#"IT<+0@G!T_@7]AS7?#GPS^*'C
MS_A9.J:3X#NX?"0TQ!XSN;;PY=0WKZSIMQ/8!=8:TFBN7AA6:6VPLC1Q+(Z%
M4!'Z8:M\8OV=-?MDL]=^)'PAUJTBG6YCM=6\2^$]1MH[E(Y(DN$@O+J:))TB
MFFC655$BQRR(&"R,#^(7[1?B[P]X\^-7CWQ;X4U#^U?#VM:C8SZ9J'V2^L?M
M,4.C:;:2/]DU*VL[Z';<6\T>VXMHF.S>JE&5F\4K_/W@'Z9^;?1RR+/?!3A7
MA3@SQ$X1X9XQXQPN6<49AC<34AQ-EU3B#&O"YDX9;6KY9B,+C<-3HXC#5,/4
MKT*E"=*5.K4I\DI?TYQ-X X+Q6S++O$'.LZS_A;/,WR+(:V+R;"X>C&648J&
M68?VV$4L73IXRE6P]652E5C5A3J0JJ:G"$N:)_3QX5O/"]_H&FW?@N?0[KPQ
M-'*=)G\-O8OHDD2W$R3&P;3?]",8NUG63[/\HG64-^\#U^:'[?\ K'PON?#V
MB:9X9OO!,_CFU\=7#^*+;0GT:3Q';K'I&HQW0UXV&;^)Q>S0+-'J#+(;G 93
M+&^SNOV</VIO@1X"^"?@/PCXL\='2?$.BV.I0:EIQ\,>,;_[-)/KVJWD*_:]
M,\/WMC,)+:Y@E!M[J4*)-CE95=%_,OXU>(]'\7_%KXB^)_#]V;[0]=\7:UJ6
ME7IM[FU-W8W5Y));7'V:\AM[N 31E9!%<P0SH&"RQ1N&0?TO]+KZ4'!W$?T8
MN$,JX:S#PVX@XB\2LFX>P_$_#V3<197FV:>'DL1DF"SS&PH97@,77QV65<!F
M%!Y$XYC1P\J"<Z%6*KQ=,_(_ [P>S[*O%_/<;FV&XMRO*N$L?F=7)\TQ^5XS
M!8/BE4LQQ&7X=U<9B:%/#XR&)PM3^T;X6I551J-6#]FU,\PHHHK_ !>/[^"B
MBB@ HHHH **** "BBB@ HHHH *_*_P#:0_Y+1XS_ .Y=_P#44T*OU0K\KOVC
MR#\9_&9!R,^'A^*^%=#4C\""#[BO]O/V!Z?_ !.#XD.SLOHU\8)OHF_%#P=L
MK]W9V[V?8_Q;_;JM?\2D^'2NKOZ1G"32ZM+PS\7;NW975^UUW/$***D5.Y_+
M_&O^N0_Y0Q@4GI^?:I0H'U[FG44 %%%% !1110 4444 %%%% FTMPHHIP4GV
M'K092DWY+\_4:!G@5*J=SS[>G^/\J< !TI:"0HHHH ***<%)]AZ_X>M#=M6
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M+7S[?Y_D1*?1:^?;_/\ (*^L/V"_^3YOV,/^SL/V=?\ U;_@ZOD^OK#]@O\
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M *]\(_\ 0\PG_@.(_P#E/G^?9GW_ %.O0?05^?Z_\%!OAJ?^9*\=?7;H&/\
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MJ*MI]T?C_,U^9B_\%./A*IS_ ,(#\13QC[GAK_Y?5*/^"GOPE  _X5_\1?\
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M=K_?POD_^@@TAXL>':6O%67K7^3%]E_U#'ZO1]5^G]*MHH/)YYQ[=J_)M?\
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MQ^*O_?'A'T_[&2LGX5>(33_XQ?'[/[>$_P#FD<?&+PS3=^+\M6EOX>-WNO\
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M3_Z"C7_B//A#_P!%SE7_ (*S#_YB/W&3[H_'^9J:/O\ A_6OPY'_  77_9X
M _X5#\9_^_?@?U_[&RID_P""Z_[/ R?^%0?&CG'6/P./7_J;#6,O!CQ/::7!
M^9?^#,%W_P"PLTAX]>$"5GQUE.]_X68=E_U!G[BKU'U'\ZMQ]_P_K7X9C_@N
MQ^SN,'_A4/QHX.?]5X'_ /FLJ=?^"[O[.RYS\(/C3SC_ )9^!O?_ *FRLO\
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ME1_Q$*_LS?\ 1%/CK_WZ\ ?_ #94?\0*\6_^B(S7_P &X#_YL\_S[,/^)DO
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M0I4:.&S6K5J3E91A3IPR^4YR;>D8IM]M&?N[17X%?\1!_P"S3_T17XY_]^_
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MQS_[]^ ?_FQH_P"(%>+?_1$9K_X-P'_S9Y_GV8O^)EO K_HX^2?^"LS_ /F
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MD_\ !.:?_,'G^?9G[XT5^" _X."/V:C_ ,T6^.8^L7@'_P";&E_XB"/V:O\
MHB_QR_[]> ?_ )L:G_B!GBS_ -$3FG_@W ?_ #8+_B9GP)_Z.1DG_@G-/_G>
M?O=17X(_\1!'[-7_ $1?XY?]^O /_P V-'_$01^S5_T1?XY?]^O /_S8T?\
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'IW_ /K5*!C@445DY-[_ '=#)R;W^[H%%%%(044H!/ J14 Y/)_E0 U4)Y/
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MHX?VKO\ LK7P>_\ 3KI%?G?7Y[P-_P C7Q,_[.%5_P#6-X-/T7CW_D5^&/\
MV;K#_P#K8<9!1117Z$?G04444 %%%/"$]>!^M FTMV- )Z?Y^M2JH'N?Y?2E
M  Z4M!E*;>BT7X_,****"0HHHH **** "BBB@ HHI0I/3\^U "5(J=S^7^-.
M"@>Y]?\ #TIU!E*?1??U^7;^M@HHHH("BBE )Z4 )3U3N>/;U_P_G3PH'N?6
MG4  &.!1110 4444 %%%%1*?1??_ )=_ZW,Y3Z+[_P#+O_6X4445D9A1110
M4H4GZ=S3PGK^7_UZDH :% ^O<TZBB@ HHHJE%OR7< I0">!3E0GD\#^=2  <
M"J;4=%J^O_!_R7GL1*:6BU?Y#50#D\G^5/HHJ&V]69MMZL****0@HHHH ***
M* "BBB@ HI0">E2A0/<^M #%3N>/;U_P_G4H&.!110)M+5A11109RFWMHOQ"
MBBB@@**** "OT#_X*-_\E<^%G_9N'PE_]$:W7Y^5^@?_  4;_P"2N?"S_LW#
MX2_^B-;K\^SW_DXOA_\ ]BCCK_TWPV?I7#W_ ";'Q)_[''A]_P"GN)S\_***
MD">OY?\ UZ_0&TMS\U&!2?IW-2A0/KW-.HK*4F_)=@"BBBI ***D5.Y_+_&@
M3:6XP*3T_/M4H4#W/K_AZ4ZBKC!O5Z+\?Z_JQE*3?DOZW"BBBM4DMB0HHHI-
MI:L HHHK.4V]M%^(!1114 %* 3P*<J$\G@?SJ0 #@4 -5 .3R?Y4^BB@ HHH
MH ***4 GI_GZT )3PA/7@?K3U4#W/\OI3J#.4_Y?O_R_X(@ '2EHHH,PHHHH
M **** "BBB@ HHHH *4*3T_/M3U3N?R_QJ2HE.VBU\^G_!(E.VBU\^G_  1H
M4#W/K_AZ4ZBBL]6^[9DW?5A1115QAU?W?Y@%* 3TIRIW/'MZ_P"'\ZE QP*;
MFEHK?H T*![GUIU%%9MM[@%%%%( HHHH **** "BBB@ HIP4GV'K_AZU*% Z
M?GWH)E)+S?\ 6XQ4[G\O\:DHHH,FV]PHHHH$%%* 3P*D5 .3R?Y4 -5">3P/
MYU^A_P#P3" '[5.D ?\ 0E>,O_2*WK\]:_0O_@F'_P G4Z1_V)7C+_TBMZ_.
M?%[_ )-=Q]_V2N<_^H=4_5_ K_D\OAC_ -EKP_\ ^K"B?GI1117Z,?E 4444
M"<DM_N"BBB@R<F_3M_6X4444$A113U3N>/;U_P /YT-V_1=7_7_#@- )Z5*%
M ]SZTX#' HI6;WV[?Y]_3;U ****8!113PA/7@?K2;2W8FTMV- )Z?Y^M2JH
M'N?Y?2E  Z4M9RFWHM%^/S,I3;T6B_'YA1114$A1110 4444 %%%% !112A2
M?IW-4HWU>B[_ .7]?>#=M6)4@3U_+_Z]."@?7N:=3<K:1T\^K_K^K&4I]%IY
M]_\ +\PHHHJ" HHHH **** "BBB@ HHH SP* "G!2?8>M/5.YY]O3_'^5/H
M0 #I2T44";2U84444&<IMZ+1?F?J?^P__P DG\0_]E#U;_U&_"5?9-?&_P"P
M^"/A1X@SQ_Q</5O_ %&_"5?9%?\ !5^TK_Y3O^D[_P!G+QO_ *K<M/\ M>_9
M\_\ *%OT=?\ LWF"_P#4['A1117\.']CA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2T6K_(****#-MO5GXOT445^T'^BX4444 %%%% !1110 4444 %%%% !1110
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M[GU_P]*^L?V#/^3Y?V,?^SK_ -G7_P!6_P"#Z^4*^K_V#/\ D^7]C'_LZ_\
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M_D(J@>Y_E]*=1109MMZL****!!1110 4444 %%%% !12A2>GY]JE"@>Y]?\
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MN^K"BBBJ ****F4DO-_EZ@%%%%9-M[L HHIRJ3[#^?TI - )Z5*J8Y/)_2G
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MAZU* !TI:* "BBB@B4TM%J_R"BBGA">O _6@S;;U8T GI_GZU*J@>Y_E]*4
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MS>O[2&#C#DC5BZ4)IWC0I)6?:_\ "ROB+_T/WC7_ ,*K7?\ Y/H_X65\1?\
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M"W_HVO '_B'<._\ SN\E]P?\1.\2O^CA\<_^)9G_ /\ /#R7W'9_\+'^(?\
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MXY_\2W/_ /YX'9_\+'^(?_0^>,__  J-<_\ DZ@?$;XAG@>//&?_ (5&N?\
MR=7'!2?8>M2@ =*O_B%/A9';PVX!;_[([AW_ .=VFNMM_P  _P"(G^)?_1P^
M.?\ Q+<__P#G@=BOQ$^(74^//&9]O^$HUSC_ ,GN?Y4[_A8OQ!_Z'OQE_P"%
M/K?_ ,G5QM%0_"KPN;O_ ,0VX!_\0[AW_P"=P?\ $3_$O_HX?'/_ (EN?_\
MSP.R_P"%B_$'_H>_&7_A3ZW_ /)U'_"Q?B#_ -#WXR_\*?6__DZN-HI?\0I\
M+O\ HVW /_B'<.__ #N#_B)_B7_T</CG_P 2W/\ _P">!V7_  L7X@_]#WXR
M_P#"GUO_ .3J/^%B_$'_ *'OQE_X4^M__)U<< 3T_P _6I54#W/\OI1_Q"GP
MN_Z-MP#_ .(=P[_\[@_XB?XE_P#1P^.?_$MS_P#^>!UZ_$/XA'D^._&0'I_P
MD^MY_P#2[BI/^%B?$#_H>O&/_A3ZW_\ )U<=11_Q"GPN_P"C;< _^(=P[_\
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ME]QUX^(GQ / \<^,?_"GUO\ ^3JE7X@_$#J?'7C$^W_"3ZWQ_P"3W/\ *N0
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M^\<^)VNKGRO--KK%YIT!\F&.!/+L].EM;.']W$@;R8(_,?=+)NE=W;F/#_\
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MAW\7_P#A2ZS_ /)M'_"P?'O_ $._B_\ \*76?_DVN0HH_P"(4^%W_1MN ?\
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M+M/#XG&5:4UHM)0:T"BBBOKCY0**** "BBB@ HHHH(E-+;5_@%%."D^P]?\
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M@RE.^BT\^O\ P HHHH("BBE )X% "4]4)Y/ _G3E0#D\G^5/K.4^WW_\ !
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MO\P"E )Z4Y4[GCV]?\/YU*!C@4W-+16_0!H4#W/K3J**S;;W ****0!1110
M4444 %%%% !12A2?IW-2A0/KW-!,I)>;[#0GK^7_ ->I***#)MO<****!!10
M 3TJ54 Y/)_E0 U4)Y/ _G4@ ' I:* "BBB@ HHHH$Y);_=U"OT,_P""87_)
MU.D_]B3XR_\ 22VK\\Z]:^"?QH\8_ /QW:_$/P*ND2:]:Z=J6EI'KEC+J&G2
M6FJ0B&Y$EO!=64V]0J/$\=S&5=!N#H61OD./\DQO$G!/%609;['Z_G&1YCE^
M#^L5'2H_6,3AYTZ7M:BC-PAS27-+EE9:V/M?#'B3+^$_$7@KB?-_;K*\AXER
MG-,?]5I*MB%A,'BZ5:LZ-)SIJK44(MQ@YQYGHFKGDM%%%?7GP8444]4[GCV]
M?\/YT-V_1=7_ %_PX#0">E2A0/<^M. QP**5F]]NW^??TV]0"BBBF 444\(3
MUX'ZTFTMV)M+=C0">G^?K4JJ![G^7TI0 .E+6<IMZ+1?C\S*4V]%HOQ^8444
M5!(4444 %%%% !1110 444H4GI^?:J46]7HN[_K\=@$J14[G\O\ &G!0/<^O
M^'I3J?,E=15O/J_\OZV,I3Z+[^OR[?UL%%%%00%%%% !1110 4444 %%%% !
M3@I/L/6G*G<_E_C4E "  =*6BB@3:6K"BBB@SE-O1:+\PI0">G^?K3@A/7@?
MK4@ '2@@15 ]S_+Z4ZBB@ HHHH ****B4TM%J_R ****S;;U8!1112 **4*3
MT_/M4H4#W/K_ (>E!,I)>;[?Y]AJIW/Y?XU)115J#>^B_$R;;W"BBBM4DMA!
M12@$]*E"@>Y]:ER2\WV_S[ ,5.YX]O7_  _G4H&.!1163DWO]W0 HHHI %%%
M% FTMS[AU3_E'9X<_P"SKY__ %6>O5\/5Z=/\6?%%Q\(++X)/%I(\'6'CM_B
M)#*EI.-:;Q ^C7>A%9+TW;6YT_[#>2XMELDD\Y8Y#.0&5_,:^6X6RC&91'/U
MC%23S+BG.LWPWLI\_P#L>.K4YX=U/=7)5<8MSAKRO3F9]IQWQ%E_$-3A.67.
MORY-P-PUP_C57I^R_P"%'*L-4I8M4K2E[2@ISC[.J^7G5WR1ZE%%%?4GP@44
M5(J=S^7^/^'_ .J@!H4GV'K_ (>M2A0.GY]Z6B@ HHHH ***>J$\G@?SH :
M3P*D5 .3R?Y4X #@4M !1110 4444FTM6)M+5A1116<IM[:+\3.4V]M%^(44
M45! 444X*3[#UJU%)7D[>7]?DM0&@9X%2JG<\^WI_C_*G  =*6ASOHM%^/\
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M?\G6?%3_ +D?_P!5QX/KY.L[J2RN[6]B"-+:7,%U&L@8QM);RK*@<*R,4+(
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MA_K+B_\ H7<._P#B-Y)_\P_U=^5ON#_A)?\ @FU_T1;]N#_Q)[X#?_0BT?\
M"2_\$VO^B+?MP?\ B3WP&_\ H1:^'Z*/]5<%_P!#/B;_ ,2C/O+_ *C_ "_%
M]P_UEQ?_ $+N'?\ Q&\D_P#F'^KORM]P?\)+_P $VO\ HBW[<'_B3WP&_P#H
M1:/^$E_X)M?]$6_;@_\ $GO@-_\ 0BU\/T4?ZJX+_H9\3?\ B49]Y?\ 4?Y?
MB^X?ZRXO_H7<._\ B-Y)_P#,/]7?E;[@_P"$E_X)M?\ 1%OVX/\ Q)[X#?\
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M?U^"^WO^$E_X)N_]$6_;>_\ $GO@/_\ 0BT?\)+_ ,$W?^B+?MO?^)/? ?\
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M^!/_ -"77Q+13_U6P?\ T,^)O_$HSW_YO_J[\K2^*<6O^9;PVWV_U9R/\?\
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M7[:__B3'P+_^A,I?^$C_ ."<O_1&OVV/_$E_@5_]";7Q/12_U6P?_0SXE_\
M$GSWR_ZCO+\7W(?%>-?_ #+>&[?]DQD7X_[#_29]L?\ "1_\$Y?^B-?ML?\
MB2_P*_\ H3:/^$C_ ."<O_1&OVV/_$E_@5_]";7Q/11_JM@_^AGQ+_XD^>^7
M_4=Y?B^Y/^M.,_Z%G#7_ (C&1>7_ % ^7XON?;'_  D?_!.7_HC7[;'_ (DO
M\"O_ *$VC_A(_P#@G+_T1K]MC_Q)?X%?_0FU\3T\(3UX'ZT?ZK8/_H9\2_\
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ME/@;_P#0H4?\)'_P3M_Z(Y^VE_XDI\#?_H4*^+:*/]5\'_T,N)/_ !)L]_\
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MD_@=_P#0I4?\)'_P3N_Z([^VC_XDG\#O_H4J^+J*/]5\'_T,N)?_ !)L\_\
MF[^KORLO]:L;_P!"SAC_ ,1;(/\ YW_U=^5OM'_A(_\ @G=_T1W]M'_Q)/X'
M?_0I4?\ "1_\$[O^B._MH_\ B2?P._\ H4J^+P">E2A0/<^M'^J^#_Z&7$O_
M (DV>?\ S=_5WY63XLQB_P"99PPWV_U6R#RW_P"$_3_@Z>7V</$'_!.__HCG
M[:'T/[2?P._I^RC_ /7IX\1?\$\!P/@Y^V?_ .))_ __ .A2KXPHH_U7P?\
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MD7_!//\ Z(]^V;_XDC\$/_H5*^,J<JD^P_G]*M<+8)*\LRXDZ?\ -39YY?\
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MIXU__@GJ>OP?_;,'_=Q_P1S^7_#*U?&RJ![G^7TIU'^K&#_Z&7$G_B39Y_\
M-WE^?=A_K;C?^A7PM_XBG#__ ,[_ "_/NS[*'B'_ ()ZCI\'_P!LO_Q([X(_
M_0KTO_"0_P#!/;_HD'[9?_B1WP1_^A7KXTHH_P!6,'_T,N)/_$FSS_YN\OS[
MLF7%^-6V5\+-_P#9*</_ (_\)_E^?<^R_P#A(?\ @GM_T2#]LO\ \2.^"/\
M]"O1_P )#_P3V_Z)!^V7_P")'?!'_P"A7KXTHH_U8P?_ $,N)/\ Q)L\_P#F
M[R_/NS-\78Y[Y5PM_P"(IP_Y?]2_R_'T/LO_ (2'_@GM_P!$@_;+_P#$CO@C
M_P#0KT?\)#_P3V_Z)!^V7_XD=\$?_H5Z^-**/]6,'_T,N)/_ !)L\_\ F[R_
M/NQ?ZW8W_H5<*_\ B*</_P#SO_J[\K?9?_"0_P#!/;_HD'[9?_B1WP1_^A7H
M_P"$A_X)[?\ 1(/VR_\ Q([X(_\ T*]?&E%+_5C"?]#+B3_Q)L\\O^H[R_%]
MP_UNQO\ T*N%?_$4X?\ _G?_ %=^5OLO_A(?^">W_1(/VR__ !([X(__ $*]
M'_"0_P#!/;_HD'[9?_B1WP1_^A7KXTHH_P!6,)_T,N)/_$FSSR_ZCO+\7W#_
M %NQO_0JX5_\13A__P"=_P#5WY6^R_\ A(?^">W_ $2#]LO_ ,2.^"/_ -"O
M2CQ!_P $]ST^$'[9?U_X:.^"/_T*]?&X3U_+_P"O4E0^&L&M%F7$C\_]9L\\
MO^HW7;TU?</];L;_ -"KA7_Q%.'_ /YW_P!7?E;[('B#_@GN.GP@_;)^O_#1
MWP2_^A7I?^$A_P""?'_1(/VR?_$CO@E_]"O7QM16?^K.$_Z&7$?_ (DN>?\
MS<'^MV-_Z%7"O_B*</\ _P [_P"KORM]D_\ "0_\$^/^B0?MD_\ B1WP2_\
MH5Z/^$A_X)\?]$@_;)_\2.^"7_T*]?&U%'^K.$_Z&/$?_B2YY_\ -P?ZW8W_
M *%7"O\ XBG#_P#\[_ZN_*WV3_PD/_!/C_HD'[9/_B1WP2_^A7KZM_:Z\-_\
M$^_AKX]\$Z+_ ,*1_:0L(]3^$7@;Q)"O@+XU_"GPQI]Q%K*ZG*MUK%EK/[/G
MBJXNO$DS1,-4U"#4HK*Y"6RVNGV<<)0_D:J=S^7^-?H'_P %%_\ DK/PM_[-
MR^$W_HG6Z^*S?)8TN.>"L!3S;B2.%QN6\7U<32_UDSNU2I@Z>1/#R;^NW3I_
M6*UK/7G=T]+?=Y+Q!*OX?<>YA/)>%)XS+\UX(I86M_JID%Z5/'5.(5BH)+ <
MK57ZM1<KIV=.-FM4<,-?_P""?(_YI!^V1]3^T;\$O_H6*=_PD/\ P3Z_Z)#^
MV1_XD;\$_P#Z%BOC>BONEPM@UJ\RXCO_ -E+G?\ \W'Y[_K?CGJ\JX5?_=I\
M/>7_ %+_ "_%GV1_PD/_  3Z_P"B0_MD?^)&_!/_ .A8H_X2'_@GU_T2']LC
M_P 2-^"?_P!"Q7QO15?ZL83_ *&7$G_B39YY?]1WE^+[A_K=CO\ H5<*_P#B
M)\/>7_4O\OQ?<^R/^$A_X)]?]$A_;(_\2-^"?_T+%'_"0_\ !/K_ *)#^V1_
MXD;\$_\ Z%BOC>BI?#6#7_,RXD;_ .RFSORW_P!N\OQ>UP_UNQW_ $*N%?\
MQ$^'O+_J7^7XON?9/_"0_P#!/G_HD/[9/_B1GP2_^A:H_P"$A_X)\?\ 1(?V
MR?\ Q(SX)?\ T+5?&U%9OAG"/?,N(W_W<N>?_-P?ZW8[_H5<*_\ B)\/>7_4
MO\OQ?<^R?^$A_P""?'_1(?VR?_$C/@E_]"U1_P )#_P3X_Z)#^V3_P")&?!+
M_P"A:KXVIRJ3[#^?TI?ZLX3_ *&/$?\ XDN>?_-P?ZW8[_H5<*_^(GP]Y?\
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MS^7^-)\-8-;YEQ'_ .)+G?\ \W ^,,:M\JX4_P#$2X>UV_ZEW]7]+?88U_\
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MT_U8P45_R,>(K_\ 92YW=]-/]N#_ %OQW_0JX4_\1'AWR_ZEWE^+[GV&-?\
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MGA/_ ,1'AS_YV_U=^5OK\:_^P&.GPC_; _\ $B/@O^O_ !B]2_\ "0?L"?\
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M([[7?$F=_P#S:'^N.._Z%/"7_B(<.?\ SN\OS[L^O_\ A(/V!?\ HDO[7_\
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M]$F_:]_\2%^#/_T,5?(5%'^K6$_Z&/$7_B29W_\ -W]7?E8_URQ__0HX1_\
M$/X;_P#G;Y?GW9]>_P!O_L$?]$F_:]_\2%^#/_T,5']O_L$?]$F_:]_\2%^#
M/_T,5?(5%'^K6$_Z&/$7_B29W_\ -W]7?E8_URQ__0HX1_\ $/X;_P#G;Y?G
MW9]>_P!O_L$?]$F_:]_\2%^#/_T,5']O_L$?]$F_:]_\2%^#/_T,5?(5%'^K
M6$_Z&/$7_B29W_\ -W]7?E8_URQ__0HX1_\ $/X;_P#G;Y?GW9]>_P!O_L$?
M]$F_:]_\2%^#/_T,5']O_L$?]$F_:]_\2%^#/_T,5?(52*G<_E_C1_JUA/\
MH8\1?^))G?\ \W?U=^5C_7+'_P#0HX1_\0_AO_YV^7Y]V?78UW]@D_\ -)OV
MO?J?VA?@S_\ 0Q4\:]^P4.GPF_:[^O\ PT+\&L_^LQ5\BT4O]6L)_P!#'B+_
M ,23.O\ YM#_ %RQ_P#T*.$?_$/X;_\ G;Y?GW9]=_V_^P7_ -$F_:[_ /$A
M?@U_]#%1_;_[!?\ T2;]KO\ \2%^#7_T,5?(E%'^K6$_Z&/$7_B29U_\VDOC
M7'+191PBW_V1_#?EO_PF_P!:WW9]>?V_^P5_T2?]KS_Q(3X,_P#T,=']O_L$
M_P#1)_VO/_$A/@S_ /0R5\AT\(3UX'ZT_P#5K"?]#'B+_P 23.__ )N_J[\K
M9OC3,'OE'"+_ .[.X;\O^I;Y:^K\K?70U[]@H]/A/^UY_P")"?!G]?\ C&.G
MC7?V"Q_S2?\ :Z/U_:$^#7_T,=?(P '2EH_U:PG_ $,>(O\ Q),[_P#F[^KO
MRLO]<\?_ -"CA'_Q#N&__G:?77]O_L&?]$G_ &NO_$A/@U_]#)1_;_[!G_1)
M_P!KK_Q(3X-?_0R5\BT4?ZM83_H8\1?^))G?_P W?U=^5C_7/'_]"CA'_P 0
M[AK_ .=A]=?V_P#L&?\ 1)_VNO\ Q(3X-?\ T,E']O\ [!G_ $2?]KK_ ,2$
M^#7_ -#)7R+12?#>#6KS'B'_ ,23._\ YN_J[\K'^N>/_P"A1PC_ .(=PU_\
M[#ZZ_M_]@S_HD_[77_B0GP:_^ADI?[?_ &"_^B4?M=_^)!_!K_Z&6OD2BLGP
M[A'MF'$*7_929WKZ_P"W=>J\W\C_ %SQ_P#T*.$?_$.X:_\ G8?7?]O_ +!?
M_1*/VN__ !(/X-?_ $,M']O_ +!?_1*/VN__ !(/X-?_ $,M?(E%3_JWA/\
MH8<0_P#B1YUY?]1OE^+[A_KGC_\ H4<(_P#B'<-?_.P^N_[?_8+_ .B4?M=_
M^)!_!K_Z&6C^W_V"_P#HE'[7?_B0?P:_^AEKY$I0I/3\^U'^K>$_Z&'$/_B1
MYUY?]1OE^+[A_KGC_P#H4\(_^(=PU_\ .T^NO[?_ &"_^B4?M=_^)!?!K_Z&
M6GC7/V#.O_"J/VNOH?V@_@U^O_&,M?(X4#W/K_AZ4ZFN&L*]LPXA_P#$CSKR
MW_VWR_%]S-\;9ATRCA'U_P!3N&M?_,9_7D?7/]O?L&_]$G_:Y_\ $@O@W_\
M0RT?V_\ L&_]$H_:Y_\ $@_@W_\ 0RU\C45HN&,&K?\ "CQ#?_LH\Z\O^HWR
M^^_<C_73'_\ 0GX0_P#$.X:\O^I;Y?B^Y]<_V_\ L&_]$H_:Y_\ $@_@W_\
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MB4_M;_\ B0'P<_\ H:*^2**/]6\)_P!##B'_ ,2/.O+_ *C?+\7W#_73'_\
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M/_\ T-=']O?L,?\ 1*_VL?\ P_WP?_\ H:Z^3J*/]6\)_P!##B'_ ,2+.O\
MYM_J[\K#XVQZWR?@[_Q#.&-=O^I9_5_2WUC_ &]^PQ_T2O\ :Q_\/]\'_P#Z
M&NE_MW]A;_HEG[67_A_?@_\ _0V5\FT4?ZMX3_H8<0_^)%G7_P V_P!7?E;)
M\<9B_P#F3\'6_P"R+X8_'_A,Z]5MT/K+^W?V%O\ HEG[67_A_?@__P#0V4?V
M[^PM_P!$L_:R_P##^_!__P"ALKY-HH_U;PG_ $,.(?\ Q(LZ_P#FW^KORM/^
MNV8?]";@W_Q"^&/_ )V>7Y]V?67]N_L+?]$L_:R_\/[\'_\ Z&RC^W?V%O\
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M#'E_U*_+\7W/K'^W?V&/^B6?M8_^'\^#_P#]#;1_;O[#'_1+/VL?_#^?!_\
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M_P#P_GP@_P#H;:/[=_8:_P"B6?M7_P#A_/A!_P#0VU\H44?ZN83_ *#^(/\
MQ(LZ_P#FWR_/NP_UWS#_ *$W!O\ XA7#'_SK/J_^W?V&O^B6?M7_ /A_/A!_
M]#;1_;O[#7_1+/VK_P#P_GP@_P#H;:^4**/]7,)_T'\0?^)%G7_S;Y?GW8?Z
M[YA_T)N#?_$*X8_^=9]>Z7JO[#-WJ>G6C?"S]JPK=7UI;MYGQZ^$C1[9KB.,
M[UB_9SMY63#?,L<\,A7(2:-B'7VS]IW2?V'/A]\<?&_A!OA%^T-9'2/^$:S:
M^"_C+\,M"\,Q?;_"&@:G_P 2W2M7^!'B/4;7>+WS+S[1K-YY^H/=7,/V>":*
MU@_.WP__ ,A[1/\ L+Z;_P"EL-?4?[=W_)UGQ4_[D?\ ]5QX/KX[%91&''^0
MY?'->(5@\1P?Q9C:M'_6'..66)P>=<%4,/5_WR]X4L;B8=FJCOT/TK+^(Y5/
M![B[.I\/\%O,L'XE>'>5X?$_ZE\,\]/ YCPOXHXO&4$O[,LXU<1E6!J-M73H
MJSLV5/[=_8:_Z)9^U?\ ^'\^$'_T-M']N_L-?]$L_:O_ /#^?"#_ .AMKY0H
M )Z5]@N&\+_T,.(/_$BSGRW_ -L\M?5]S\U_UWS#_H3<&_\ B%<,?_.L^K_[
M=_8:_P"B6?M7_P#A_/A!_P#0VTX:W^PV?^:6?M7@?]E[^$'Z?\8VU\IA .O)
M_2GT_P#5S"+_ )F'$#?=\0YS;IM_MJUTZ]WZF<N.LP^SDW!OK_J5PQ^'_"7^
M9]6C7/V&QT^%O[5W_A^OA#^O_&-]+_;O[#G_ $2W]J[_ ,/U\(?_ *&^OE&B
ME_JYA7J\PX@?_=Q9SY?]1GE^+(_UXS%ZO)N#?_$*X7\O^I7Y?U=GU=_;O[#G
M_1+?VKO_  _7PA_^AOH_MW]AS_HEO[5W_A^OA#_]#?7RC11_JYA?^AAQ!_XD
M6<^7_49Y?B^XO]>,Q_Z$W!G_ (A7"_\ \Z_+\^[/J[^W?V'/^B6_M7?^'Z^$
M/_T-]*-<_8</3X6_M7?^'Z^$/_T-]?*:IW/'MZ_X?SJ4#' H_P!7,+_T,.(/
M_$BSGR_ZC/+\7W#_ %XS'_H3<&?^(5PO_P#.OR_/NSZK&M?L.#_FEW[5N??X
M\_"'_P"APIW]N?L._P#1+OVK?_#\_"'_ .APKY2HH_U<PO\ T,.(/_$BSGR_
MZC/+\7W#_7C,?^A-P9_XA7"__P Z_+\^[/JW^W/V'?\ HEW[5O\ X?GX0_\
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M^$9_E^SB*?\ VY^Q#_T2_P#:J_\ #\?"/_Z'&OE6BLWP]A7OF&?O_NX<Y_\
MFT/]>,Q_Z$W!G_B$\+?_ #J/JK^W/V(?^B7_ +57_A^/A'_]#C1_;G[$/_1+
M_P!JK_P_'PC_ /H<:^5:*7^KN%_Z#\__ /$ASG_YM#_7C,?^A-P9_P"(3PM_
M\ZCZJ_MS]B'_ *)?^U5_X?CX1_\ T.-']N?L0_\ 1+_VJO\ P_'PC_\ H<:^
M5:*/]7<+_P!!^?\ _B0YS_\ -HGQUF"WR;@ST_U)X6_^=9]5?VY^Q#_T2_\
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M (A'"WE_U*_+\7W/JG^W/V(O^B8?M4_^'W^$?_T.=']N?L1?]$P_:I_\/O\
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MASJ0:S^Q$.?^%8?M49_[+M\)./\ S705\L  <"EH_P!7<+_T'Y__ .)#G/\
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MM #0,\"I53N>?;T_Q_E3@ .E+0 4444 %%%% 'XKT445^T'^C 4444 %%%%
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M4 %%%."D^P]?\/6@!M2*G<_E_C3PH'3\^]+0 5]7?L'?\GQ_L9?]G7?L[?\
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MB_$****" HHHH **** "BBI%3N?R_P :3:6X# I/T]:E"@?7N:=164I-^2[
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M-I:L***4*3].YH,Y3;T6B_,2I GK^7_UZ<% ^O<TZ@@**** "BBE"D]/S[4
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M!1110)M+5A11109RFWHM%^844H!/2I0H'N?6@@8J=SQ[>O\ A_.I0,<"BB@
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M/ H 2GJA/)X'\Z<J <GD_P J?6<I]OO_ . 9RGV^_P#X @ ' I:**S,PHHH
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MGCV]?\/YU*!C@444&3DWO]W0****!!12@$]/\_6I54#W/\OI0 P(3UX'ZU(
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M/?\ AG?Q9_T&/#O_ '^U+_Y6T?\ #._BS_H,>'?^_P!J7_RMK["HH_MW,/\
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MVOKFBC^VL?\ ST__  7$/^(D<4_]!&$_\(Z7]?\ #ORM\C_\,_>*N^K^'_\
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M\CY,_P"% ^*/^@OH'_?W4?\ Y7U(/@'XF'35M!^OFZAG_P!-]?5]%']M8_\
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ML/7_  ]:E"@=/S[U?NP\W_7W?UY ,5.Y_+_&I***AMO< HHHI %%* 3P*D5
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M$2FEHM7^0444H!/2@S;;U8E/5.YX]O7_  _G3PH'N?6G4" #' HHHH ****
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MKTJE"O0J3I5J-:$J56C5IR<*E*K3FHSIU*<TXSA.*E&2<9)--!17]S'[*_\
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MXW?"SPKH'Q)LM<O=.T#Q!I?BVXUC3DT/Q3KOA6=+V;3M/FLG:>ZT*>ZB,$C
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M(\^5 .3R?Y4^O2/LEI_S[6__ 'YC_P#B:NQ65GQ_HEM][_GA%[?[%9_7H_\
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M.#I&F'CO86OMS_JJREQ!2BK_ %:ILG_$CUM_=\R_]7ZG_03#_P %R_\ DCY
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MS\/3U\">#>I_YE?1/3_KQJTOPW^'I(_XH+P81W_XI?0\=/\ KQJ'XI81*_\
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MA?:?[;_X2NZL[;[?_;W]L6_]F_8/M>_[+_8M_P#:O+V_:+;?N7YXK^L/P1X
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M #*\4_\ W:7G^'?3^'>BO[DT_9[^ >X?\6/^$'?_ )IIX,]#_P!06K"_L]_
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M_&/?P/ZC_FD_@+U_[ %6$_9C_9LR!_PSW\#L<\?\*F\!>G_8 K)_2XR5)O\
MU,S317_Y&N$_^9/7^GII'Z$^?2=O]?,H6E_^1-C?_FP_SOP">E2A0/<^M?Z(
M:_LQ?LU[A_QCU\#N_P#S2;P%Z'_J 5?C_9@_9J.,_L\? T_*/^:2^ ?;_J7Z
MC_B;O)?^B+S3_P .V$_^9"O^)(N()MI<?9.E_P!B7&Z[;_[;^!_G7T5_HL)^
MR_\ LT$G/[._P,/'_1)/ /J/^I?JRG[+_P"S0<Y_9W^!9Z=?A)X ]_\ J7Z%
M],'(UHN"<UM_V-\)_P#,GK]R^51^@YG\K_\ &?Y.K?\ 4DQO_P VG^<]17^C
M3'^R[^S.<9_9V^!1^8?\TC\ >W_4OU>3]ES]F4@Y_9U^!)Y_Z)'\/_;_ *EZ
ME+Z8F21M_P 83FNO_4WPG_S(:1^@QQ!+7_B(&3_^&3&^7_4<?YQ%%?Z0"?LM
M_LR8!_X9T^!&>>?^%1?#_/4_]2]4Z_LM?LR;1_QCG\"._P#S2+X?^I_ZEZL9
M_3'R1:+@C-5UO_:^$_\ F0TC]!3B&2O_ ,1!R;_PR8[R_P"HX_S>*]__ &B_
M@7_PH'Q;X6\+?\)3_P )9_PDOPX\)_$#[=_8G]@_8O\ A*$OG_LG[+_:^L_:
M?L/V/'V_[1!]I\S/V*WV8;_0*_X9:_9C_P"C<_@1_P"&A^'_ /\ ,]6QK7[/
M7P"\27%O>>(O@?\ !_7KNULK?3;6ZUKX:>"]4N+;3K,,+2PMY[[19Y8;*U#N
M+>UC98( ["*-=QSY&(^E]AIYIEF(P_"^94,KP]#,89EE[Q^7U)X^M76%67U8
M8F6!=7#K!.GBG.%.<(U_K$544O90MZ^%^@YBZ>3YMAL5QAE6(S?$U\KGE.91
MRW,Z=/+J&'EC'F=&IA8YBJ.)>/C5P:A.K"<L/]5DZ3A[6?-_FO4 9X%?Z1/_
M  RU^S'_ -&Y_ C_ ,-#\/\ _P"9ZC_AEK]F/_HW/X$?^&A^'_\ \SU>G_Q.
M+DG_ $1&:_\ AWPG_P R'D_\2)\0_P#1PLF_\,>._P#FX_S>U3N>?;T_Q_E3
MZ_T@?^&6OV8_^C<_@1_X:'X?_P#S/4?\,M?LQ_\ 1N?P(_\ #0_#_P#^9ZC_
M (G%R3_HB,U_\.^$_P#F0/\ B1/B'_HX.3?^&3'?_-I_F_45_I _\,M?LQ_]
M&Y_ C_PT/P__ /F>H_X9:_9C_P"C<_@1_P"&A^'_ /\ ,]1_Q.+DG_1$9K_X
M=\)_\R"_XD3XA_Z.#DO_ (9,=_\ -OK_ $]/\WZBO]('_AEK]F/_ *-S^!'_
M (:'X?\ _P SU'_#+7[,?_1N?P(_\-#\/_\ YGJ/^)Q<D_Z(C-?_  [X3_YD
M#_B1/B'_ *.#DO\ X9,=_P#-OK_3T_S?J>J$\G@?SK_1^_X9:_9C_P"C<_@1
M_P"&A^'_ /\ ,]1_PRU^S'_T;G\"/_#0_#__ .9ZC_B<7)/^B(S7_P .^$_^
M9 ?T$^(NGB%DJ_[H>.?_ +N^O]/3_.%  X%+7^CS_P ,M?LQ_P#1N?P(_P##
M0_#_ /\ F>H_X9:_9C_Z-S^!'_AH?A__ /,]1_Q.+DG_ $1&:_\ AWPG_P R
M$?\ $B'$7_1P\F_\,>._^;O7^GI_G#45_H\_\,M?LQ_]&Y_ C_PT/P__ /F>
MH_X9:_9C_P"C<_@1_P"&A^'_ /\ ,]1_Q.+DG_1$9K_X=\)_\R"_XD/XA_Z.
M'DO_ (8\=_\ -WK_ $]/\X:BO]'G_AEK]F/_ *-S^!'_ (:'X?\ _P SU+_P
MRW^S+_T;I\"?_#1?#_\ ^9ZC_B<7)/\ HB,U_P##OA/_ )D#_B0_B'_HX>2_
M^&/'?_-WK_3T_P X6BO]'K_AEO\ 9E_Z-T^!/_AHOA__ /,]1_PRW^S+_P!&
MZ? G_P -%\/_ /YGJ/\ B<7)/^B(S7_P[X3_ .9 _P")#^(?^CAY+_X8\=_\
MW>O]/3_.%HK_ $>O^&6_V9?^C=/@3_X:+X?_ /S/4?\ #+?[,O\ T;I\"?\
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MF?UIY?E&64?;XW%K!8/$9ABW1I77,L/@L+B,35;:4:5&<GL?+=%?J+_PZ/\
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M***@ HHI0">!0 E/5">3P/YTY4 Y/)_E3Z $  X%+110 4444 %%%%!G*?\
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M_+Z4X #I10 4444 ?B?1117[0?Z0!1110 4444 %%%% !1110 4444 %%%%
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MO;SXX>*@8_-CAM/AP;:^\,F>,@QRV]U\0KOP9IUS'+^[>WO9@RR\1/\ EF%
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MW'W!]O\ LH<K\O\ J*\_ZL:1\+/$Q67^H'&"UU?^KN:;:?\ 4*?E;#T'T/\
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MH?K_ $%6XOX?Q_K51.A^O]!5N+^'\?ZUSSV7K^C-X[+T7Y%M.I^G]15F/O\
MA_6JR=3]/ZBK,??\/ZUA/X7\OS1U4]X^GZ%B/O\ A_6M*+M_O#^E9ZKM[]:T
M(NW^\/Z5S3>EN_Z6.J#U:\K_ '?\.7$^\/Q_D:L)]X?C_(U73[P_'^1JPGWA
M^/\ (UA-77IK]R9T0W?I^J+*=3]/ZBK\7;_=']*H)U/T_J*OQ=O]T?TK$Z(;
MOT_5%J/O^']:NKU'U'\ZI1]_P_K5U>H^H_G7.=$-WZ?JBPO4?4?SJZGW1^/\
MS5)>H^H_G5U/NC\?YFN:6S]'^1U0V?K^B+</0?0_SJ\O0?0?RJC#T'T/\ZO+
MT'T'\JP.J.R]%^187H/H/Y5:7J/J/YU57H/H/Y5:7J/J/YUSF\/A7S_-EV+M
M_O#^E7$^\/Q_D:IQ=O\ >']*N)]X?C_(US2V?H_R.F.R]%^183[P_'^1JRG4
M_3^HJLGWA^/\C5E.I^G]16!T1V7HOR+B]!]!_*KL??\ #^M4EZ#Z#^578^_X
M?UKG.JGO'T_0NKU'U'\ZLI]X?C_(U67J/J/YU93[P_'^1K":M&_=-_@=4-WZ
M?JBPGWA^/\C6A%V_W1_2L]/O#\?Y&M"+M_NC^E<QT0W?I^J+*=3]/ZBK,??\
M/ZU63J?I_459C[_A_6N<Z:?7Y?J6HNW^\/Z5?3H?K_050B[?[P_I5].A^O\
M05G4Z?/]#IAL_7]$64^Z/Q_F:L)]T?C_ #-5T^Z/Q_F:L)]T?C_,US3W7I^K
M.B&S]?T0ZBBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\^OV
MW/\ @G%\"OVUM N[K7[&U\!?&"&UM+;P]\9M"T>.\U^SBLFQ!IWB72TO](@\
M::$(&D@33M3O[:]L596T?5M+/FB;^,+]JK]E#XN_L??%"]^&'Q:TF**X:)M0
M\,>*=*^TW'A7QMH1D\N/6O#FHW%O;//$DA%OJ%C<P6^I:3>!K6_M8BT+S?Z(
M5?(_[:G[(7@+]L_X)ZU\+/%R6NF:_;^;K'PZ\<-9R7=]X%\8Q6\D-IJT,,%U
M8RWVF7<3OI^O:-)<K:ZGI\Q;$6HV>F7UE_1'@QX[9OP%CL'D>?8JOF7!5>K&
MC4HUN:OB,A51QA]<RZ=I5OJE&RGB,M3E1E3]I4PE*GBI2]O_ "E](3Z-.0^)
MV6X_B/AC!8;*?$/#T9XBEB*'+AL)Q,Z493^H9O"\<.L=75Z>$S>2A7C5]C1Q
M]:K@H0^K?Y[]%>I?&GX,_$3]GWXF^*OA'\4]!E\.^-?!]^+/4[)G6>UN89HH
M[K3M6TJ]C BU#1]7L)K?4=+OX<)<6=Q$S)%*)(8_+0,\"O\ 2G"XK#8[#8?&
MX.O1Q6$Q="EB<+B</4C5H8C#UX1J4:U&K!RA4I5:<HSISBW&49*2;3/\A<;@
ML7EV,Q67X_#5\%CL#B*V$QF#Q5*=#$X7%8>I*C7P^(HU%&I2K4:L)4ZM.<5*
M$XN,DFF@IP4GV'K3U3N>?;T_Q_E3ZW.80 #I_GZTM%% !7H?PGM4O/B'X7B<
M9"7LUT!C/SV-C=7L9_X"]NISVQD=*\\KU#X,?\E*\-_]QC_TP:K7-C6XX/%M
M:-8:NT_-4IM'C<1SE3X>SV<7:4,FS2<7VE' UVG\FDS[PHHHK\X/Y "BBB@
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M':S:4\D*P*Y<S?RGX$U\TR>'$/$\Z6 EPMDF$QN+SF<J&%GFKQ6%RVO6PE/
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M#U:45^1/CS_E+/8_]ES^''_IG\+U^U/[8G_)K/Q]_P"R6^+?_37-7XK>//\
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MT#P$='TF+3@-%NO&MEIXN+J<237%])<Z?X;T8K)<2ML$3NJB2>9G_J#\6_\
M(J^)O^Q?UG_TW7-/QDGQ#5RGPLK<4UL-B,]KT<^KXVKA(1IT)0KYAE=;!*,(
M4:$8SA@)X6G6BJ44JT:BO/XY'T)J/ASA>,?I9X/PFP.:9;P#@,;X>9?DF#SB
MO4Q.84ZV7\.\58//)U,16QN85*U'$<04,UQ&#J2Q=3FP57#M1HJU"G_$E%%)
M/)'##&\TTSI%%%$C222R2,$CCCC0%G=V(5$4%F8@ $D"OU5^#7_!)SXQ>/\
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M%%%% !1110!^>]%%%?H!_5#=]6%%%% !2A2>GY]J>J=S^7^-24 -"@>Y]?\
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MCIX<\/WEB,MY4/B5--?Q9<PAF47^MW3 _-Q\C_\ !SM_R3C]D?\ [';XL?\
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MU1<  X%6EZCZC^=5JLKU'U'\ZYG\,?\ M[\S:/PKY_FRPO4?4?SJZGW1^/\
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ME@%7R]X'GC[&O.JU%PA[51G&DI/7EO;2Y_-Y_P 19W[&G_1MO[3?_?OX5_\
MSP*_?O\ 8>_:[\%?MV?LR_#S]J+X>>&?%/@_PC\1I_&5OI?A[QF-)'B.Q;P7
MXX\1^!+]K\:'J.JZ9MN]0\-75Y:?9[Z8_8KBW\X13^9$G^1#7^FU_P &Z_\
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MY77O+1Z'Y'?\19W[&G_1MO[3?_?OX5__ #P*/^(L[]C3_HVW]IO_ +]_"O\
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M;R:XACM=4&EWE_IXND:W8O\ 9+RXAPR[9"<@?Y[/_$-9_P %7?\ HDWPW_\
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M/@MXW:]U;X>:EJ\4>A:U'%#$[W,O@WQ!JMR+\D!H_#^NWNI74T=CX>(7^3T
M#I7^E5XV\'Z#\0O!GBWP#XJL_P"T?"_CCPQKW@_Q)I_F-%]NT'Q+I5WHNL6?
MFIAX_M.GWMQ#YB$,F_<O(%?YQ_Q/\ :S\*?B1X]^&7B(?\3SX?\ C#Q'X-U6
M06UU:1W%[X<U:[TF:[@M[Z&WO(K6\:U^U6HN88I6MIHF=%+8K_0GZ*?&]?.N
M&,SX0Q]7VF(X6JT:V6SFVYSR?,9UY+#W=W)8#&TZT5)M*%#%X6A"/)11_E;]
M-OPYPW#W&63\>9915+"\:T<10S>G!6IT\_RBGAH/%62C&#S/+ZU"3A%-U,5@
M,;B:DN?$._#4445_5Y_$(4444";2W"O4/@Q_R4KPW_W&/_3!JM>7UZA\&/\
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M)@1C4?$.F2IH5NQ)!#7^OVVEZ=$5R?.NX]V$+$?H3\8O^"I_[/GQ"^$?Q3\
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M5JVGZKJD^HZYHVM:IJ,>GS$7<-C8)X?LK:*[GBC@OGU"063SK:W#)C?L[_\
M!6C3=.\.Z;X8_:(\.:[?:OIEM#91?$#P?;V=\^LQ6\2QQW7B70;R^L'M]3<1
M[KS4='GNH;ZXE,BZ/8*'+>\>-_\ @K9^SQHFD3S>"M \>^.->:)_L.G2Z7:^
M&-*\\+E!J>KZC=W%U:0,>#)8Z-JLH/\ RQ ^8?G%#A[Q?X<X=S[PUPO"DL=E
M^=8[VO\ :V'A[:C&%3ZK"L\/CO;T\)2H8NG@Z%UCHTJN'C*MSPIU)_NOZ9Q_
MB1]#/Q,\2> /I09MXN4\AXCX&R!81<(9E76!QDZV'_M3$8&.99!]0Q.<XS,,
MGQ.<X]PED-7%X/,:M+!>RK8G#4&L5B?\%>O'&F:5\#_ O@$W$9UWQ=\0;?6H
M;/>OFC0O"NC:JFHW;1\N%74];T2"-B%5S)-AB8F4_4'_  3YGBN/V.O@C)"X
M=%T7Q# 6'02VWC;Q-;3I]8YHI(S[J:_FC^/GQZ\>_M%_$*_^(7CZ[A:\FB2P
MT?1K 2QZ-X:T2!Y)+71](MYI)9$@C>66XN)YI)+F]O9[B[N)&DEPOWW^PK_P
M4*\-_L_^!IOA)\6=&\1ZCX3LM4O]5\(^(/#4-IJ-WH8U>X6[U+1-0TF\O=.W
MZ4VHR7VL6]]8W-Q>17NH7<$EA/#+'-:_:<3^$N?X/P>R;AW+:']IYYEV>QS_
M #/"X249.I+%8?&X>O1P:DX^WE@X8C"TVHN]>-"O5IQ;E"!^'>%?TP?#O._I
MH\;>)/$N/?"O 7$G ,_#WA7-<XI3I1P]/*LRR+,<!C,Z=&-58"EG%7+LWQ$7
M57)@9X[ X7%58JG6KFQ\8?!7BOP?_P %2O WBCQ'H.IZ7X:\<_&OX=7/A#7[
MFSGCT?Q&D-CX,L+U-)U!D%M>3Z;?WMK8ZG!"[2V-S-$DZH)H6D_9[]IWPSKG
MC+]G?XT^%_#6GSZMK^M_#;Q98Z1I=JADN]2OY-(N6M["SB )FN[MU%O:PK\T
MUQ)'$""X-?BK^WC^VM\(_C9:?![4O@Q>^+8_'/PO\</XMT[6]3T"/2;+3D\F
MTN8S;RW%\]Y)J$6LZ3HMS'$MB;5H[:9WNE=(HYOLCX??\%:_@'K/AS3YOB'H
MGC7P;XL2S0:S8Z=HT/B#09+] 1*VB:C;:BM]):3D"2--3TZQFMC(;9Y+E8A>
M3_,\4\,>(&:Y+X9<0T>%,;+,N&<!3RC&95##U7B:,LCQT'E>)K8.4EBG1S#"
MTH3JRIJ2I58U%)TH3H\WZGX4>*GT=>$N-OI2>&^-\7,BAPSXH<0XKC')>+*V
M8X197BZ?'F0UJ?%668+.J=.64QQO#N:XNM0PM/%3A/$X6>'G%8JK0QOL_)/^
M"0_B-O#][\>?@SXC@NM$\8Z3JVD>(G\.ZI;2V6J6[:9)?>%_%=O=6=PL=S;7
M>AZDFAV>H6MQ''+!/>I&RAUE"^B_\%2_V;_B3\8-+^&7CGX9>&M3\8WW@UO$
M.A^(- T2W:]UHZ=KCZ5=Z;J=CI\9^T7L-G=Z?=VU]%:1SW*"_M)Q#]GANI8O
MR/\ 'G[1LVB?M9>,?VA_@->ZKH<.H>,KOQ+HR:[916TNH0:K# WB#3=?TJSO
M[F&XTG6KU]12>T^VB:2SGAN ]CJ*(UK^NOPT_P""N/P4UO1+4?%#PMXP\$>)
MXH8UU :)80>)O#5S.%Q)-IMU'>VVL0)*ZF06=[I;&U61(1J%\4><_1\5\+<>
M9-QQE?BIPOD4LSKYA@L'BLSR3DE4Q&7X^OE%/+\?@JV$A.&)J4JE*4I0KT'4
MJ4,5[3VL(1A3=7\S\(?%CZ/_ !MX#\5_1*\5^/Z?#&!X<SS.LIX6XY=:EALN
MXCX?R_C.OQ'P]GN!S>M0KY7AL70Q4*=.M@<?'#T,=E+P[PE:M4KXI83WO_@G
M9\#?%_P'_9YBT3QYI\FC>*O%_B_6/'6H:'.T;7FB0:CINAZ)IVGWWDO)''>M
MI_A^WU"XMMYELY;]K.Y6.Z@FB3\GO^"LWCC3/$W[2.D>&M,N([EO 'P^T?1=
M9,;JXM]=U74M6\136AV9 :+2-3T5Y%+;DEEDC959#GZT^-O_  5S\$VFA7VE
M_ ;PGKVL^)[N"2"V\4^-+*UTGP_HSRJ0M];:/#?7NIZY=0<^7:7RZ-9I,8YI
M9;Z%)+.;\(/$&OZUXJUS5_$OB/4[O6=?U[4;O5M8U6_E:>\U#4;^=[F[N[F5
MN6EFFD=VP HSM154*H]?PIX(XMK\:YQXC\98%91B<<L:\'ETDJ==U\?*$:E3
MZNZE6IAL+A<+&>&HT\3)8FJYQG)<M-SJ_&_2X\>/!_+_  -X,^C-X*9\^,<L
MR*621SKB6E*5? 4\OX?A4K8?#+,%0PN&S/-LVS6I2S3&8C*Z;RS"0HU,/3:J
M8A4,)_65^P]\0/\ A9/[*WP;UZ6?S[_3O"T7@_4RS;IQ?>";B?PJ9+D\DSWE
MKI-KJ+,Q+2)>)*W+FL'XUV6F?LY?L0_$C1=*E2"W\+_"O7O#>GSQ#RD36O&)
MFT*VN(00I&=?\2)- & 9B4##<2*_);]A']O?X>_LS?#3Q/\ #WXE:%X^UR&\
M\83>)_#DW@[3?#^I1VD.HZ5IUCJEE>'7/%/AU[=1<Z5!=VR6T=TCR7=X\C1,
M5$G5_MJ_\%$?A=^T+\$+OX7?#?P[\2-'U+6/$_A^^UJY\7Z5X9T[3)- T:2Y
MU-[>&71?%_B"ZEO6UJWT66*&6SBMS!#<2M=)+%#%/^?8CPJXLCXEU\-1R;&O
MA#$\:8/-JN+C&G]2_L^GC*N*A*_/S7PN$QV+PL?=OSRFFF?T9E_TN/"&K]%S
M!9GC>-LD7C+E?@?G7"&$R:K4Q']N?ZQXG)<'E-:GR>P<%'-<WR+*,WJ6JV=&
MG3G&2Y3]<O#EGI?[3'[*/A:VU>2.:W^)_P */#$^HR3 RI#KDNE:==W'G@9+
MFP\0VK+-MRQ:W<H<X-<3_P %!?'O_" ?LE_%FZBF\J_\4:79^ ]/3=M-P?&%
M_;Z1JL2GKE?#LVM7! !++ R\ EA^</[(G_!2;X3_  -^ WA#X5_$7PU\3M7U
MWPE<:_!;7_A;2/"VH:9+I&I:[J&M:?$;C6/&>A7@N+0:E+9M$;'RHX(+=8YI
M!D+Y1^WK^W9X _:?\!^"O WPWT/QYHMEH_BN?Q3XB;QEIV@::MU/::3<Z7HD
M=@-#\3^(C<"-=6U>2[%T+18F%HT7VAF<P9Y-X4\6TO$; 83$Y+C8<)99QCC<
MSH8R<:?U&6"I8JE7C53YW+EQ^&RW X=KEYF^2#LTVNCC3Z7/@]BOHSY_G&5\
M;Y'6\8N*/!;(^%\?DU"IB/[>IY[B\IQ&7U<)).@J;GP_F?$^?9C&7M'!)5ZJ
M<HNS_+.M#2=)U/7M5TW0]%L+K5-8UB_M-+TK3+&%[F]U#4;^>.UL[*TMXPTD
MUS<W$L<,,2*6>1U502:SZ]4^"GQ;U_X&?$WPM\4?#.GZ)JNL>%KN>>WL/$%@
MM_IMS%=VD]A=Q,H:.XM+A[2ZG6VU"QG@O;*8K-#+\K(_]HXV>+IX/%U,!0IX
MG'4\-7G@\-6J_5Z6(Q4:4I4*-6NH3]C3JU5&$ZO)+DC)RL['^'F14,HQ6=Y/
MAN(,?BLKR'$9G@*.=9G@L&LPQF7Y55Q5*&88W"X%U:"QF(PN$E5K4<+[:G[>
MI"-/GCS7/UB\"_$[_@H#^Q5;:+X)\?\ PFU3XT?##3].L4TIM)@U#Q"=!T]8
M8V&D:=XX\-V&I3Z5_9^Y[!=-\6:5?PPK:K%H6S2DMYI?V:\%>(+/XK_#;0O$
M&M>#M5T*P\<>&XY]4\$^.-+ACU&UM-5MGBO-'U[2IQ+#)'-"\D;PW$86ZLY4
M::WB\UX$_.?P+_P5Q^ &MZ9;MXZ\+^/? VM[/],M;6QL?%>BJX4'%EJUE=V&
MHW"LV1_I/A^Q*G&2P)8<#\9?^"NW@*V\.ZAIWP.\'>)]7\67<%S;6?B'QI9Z
M=HWA_19)862#5(--M=1U74==GMY2)%TV\AT6V8A'ENYD#VS_ ,0<1\&\>\7Y
MAA:?_$+Z/#W$/UMRS+/<LG4P.5XUMM.O5@\35RRE.-2^)JXO"5ZE>O/F<54E
M*$3_ 'A\-?&SZ/O@UP[FN)7TJ\;XC>'*R:%+AG@#BBCA\^XLR-4XPY,!@Z\,
MLP?%.)P]3#VRW"9/F^ PV R^BX1G4H4Z%:J8/[ GA+P_X#_;F_:Q\&>%-B^'
M/#-CXMT?1K=':5;&QLOB+I$4.EB1\O(=* .FL[EG9K4EW=B6/??\%A_^2*?"
M[_LJ1_\ 43\05^;O[$/[67A7]GGXL_$3XD_%BU\;>*I/'7AJ^LKB[\,VFCZK
MK-UX@U'Q+IVO7NHZG_;FO>'X62[:WNY9[B.ZFG:ZE3-N4=Y(_6/V]/VX?A/^
MU)\//!GA+X?^'OB'H^I>'?&?_"17L_C'2?#>GV4ME_8>J:9Y5K)HOBWQ#.]U
MY][$^R:V@A\E9&\_>%C?]+Q/!?%4?&KAO.YY?C<=E6 P>3T,;GEHO#U:V%R.
M6$Q-><I34^:>)OS7A?FGZG\N97XW^$M7Z#GB=P)1XCR3(>+>(<[XRS#(^ N>
M<,PPN!S7CRCF^6X##TJ=%X=0H98TJ2C54?94=-K'Z]_\$_\ _DSWX(?]@#6O
M_4O\15_/Q^W_ /\ )X/QP_[&#1__ %$?#U??7[+W_!2SX%_!3X#?#KX7>*_"
M?Q9O_$'A#3-1LM2O/#VA^#[O1IY+K7M6U.)K&XU+QWI-[(@MKZ%9#/IULRSK
M*BJ\:I+)^7G[3_Q2\/\ QK^//Q&^*/A6SUG3_#_B_5+"]TVS\06]E:ZQ!%:Z
M'I6F2+?6^G:AJME%(T]C*Z"WU"Y4PM&S.KEHT[/"_A+B3)_%/CO.<SRC%X+*
M\R_M_P"HXVM&"HXGZUQ%AL7A_9-3E)^UPT)58WBO=B[V>AXWTK/&#PSXU^B;
M]'_@GA7C+)\\XKX87A[_ &_D>"J5I8[*O[+\-<RRG,/K4)T80C]4S*M2P=7E
MG*U::2NKM?V&67_'G:?]>T'_ **2OY0?V(O#GC_Q-^UG\/K3X<^(CX5UFQUW
M5-9U/7&A^UV]OX7TN"ZN?$=G=V'FPC48-9TT2Z)]B:6-)9]1A9IK<(;F']:[
M?_@KU^S7%!!$W@CXXEHX8XV*^&O 14LB*I()^)8.,CC(!QU K\U/^";GA7XA
M>*/VK-!\1^ )]-L;'P?;:OK_ (UN];CN);-O!VJ9T+4-+BM[26-KC6]1&K(-
M&C-PD%K?6PU6X^T6NFS6T_R/AQPWQ'P7P?XKXKB'+/[$^M</X>.!J9S2I3P>
M(JT\-GE-TYTFZT*T74Q6&I.E.G.-2=>G!TZBDX/]A^DQXF>&OC?XS_1 RKPY
MXH_UY>3^(>8SS_#\$XS%4<YR["8G-. ,3&O1Q45@ZV#FL+E.9XI8O#XBC4PU
M' 8FO'$8:=*-:/\ 0-\>_P!H/P+\!+'P[<^/_#GCG6](\47&I6R7?A/P?/XI
MTW3)=)2QN-OB"2.:*/3VO3=H=*1UEEO'M+UXD"6,\B?G+\??^"JVF6GA/4]'
M^"/P[\=6?B'4;.ZL+?QIX]TBTT'3/#C3QF&+5-)TB&YUF36KZ#>7M(=3;2;2
MWN1!-<0ZC"DEE+^B?QC_ &KO@'\ =<TCPY\6?'B^%=9US2WUK3K)?#OBS7Y)
M-,2[EL5NYO\ A&M"U@6L<UW;W,-N+GRFF:UN-@(B8U>^$/[2?P)_:&;7-/\
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MOR>.2818;"RI9%F> S#(\DP>$A7P[K9GAL5@YYSF=7$+&8?$QH8.GA[U^@^
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MS\!]3_L[ZC@_[/\ 9^R^H_5J/U/V2?,J?U7D]A[-/7DY.6^MKA]>QWUOZ_\
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M:]_:R^&GAC2O!'PY_:@_:(\ >#-#2YCT3PCX)^-?Q*\*^&-'CO;VYU*\32M
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M_- 6(^_X?UJU%V_WA_2JT?)(]2/ZU<1>1@< _P OZUG4C=N^SM^%C6&S]?\
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MKG.FGU^7ZEJ+M_O#^E7TZ'Z_T%4(NW^\/Z5?3H?K_05G4Z?/]#IAL_7]$?Y
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M.\2_$OQUXM^('B&7>TGFZYXRU_4/$>K2>8X#R;[_ %*X;>P#-G<P!)K^WO\
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MOHOA_4/''BG[)%8_\)#XJN]*L[6?7=8:VB"-J&HO<7+O)<3M(9[JYDE3Q/\
M"7X6^-?&'@3X@^,?ASX(\5>._A=<:M=_#;QCXA\+Z+K/B;P%=:];P6FM7/A#
M6]0L[C4?#MQJEM:VT%]-I5Q:R7,<$*RLPC3'Z._%.K+&5%+*J4LGE@OJ\<N<
MX*I[;V;O.5?V3@Z,Y-T)4O9<BH<LU'VBE&?Y/'P9HPP%)PSJO'/H9@L4\U4*
MGLO8*JFH1P_MN>->$4L1&O[;G>)YH2G[)QE#*^!'Q!\1_%?X+?"KXE^,/A]X
MC^$_BSQWX \*^*?$WPS\76SV?B3P)K^M:/:7VK^%M7MI0EQ%=:/?S7%GMNX;
M6],<4;7ME8W;36<'J]%%?D]2495)RA!4X2G*4::<I*G%MN,%*3<I**:BG)N3
M2NVV?MM*,H4Z<)U'5G"$(SJR48RJRC%*5248)0BYM.344HINT4E9!1114%A7
M\-G_  6,\*6WA;_@H1\;GLK7['9^)[;X>^*XH5MI((FN=4^'?AB'5[J&21W%
MW]NURRU.^N+F,)&+VXNK8(&MF+?W)U_'+_P7QCL$_;6\+-9SRRW$O[/O@:35
M8Y 0EM?CQI\2HHX("88@T3:7%IMR2KW \ZXF7SE*FW@_IGZ*.+J8?Q.Q-"*D
MX8_A?-,/42ORQ]EC,LQ<9R5FM)8;DC)V:=1I2]YQE_'OTW<!2Q7@YA,5-P53
M+.,\EQ5)M+GE[; YQ@)TX.Z=I1QGM)17,G[%2<;P4X?B31117^CY_D;*?1??
M_EW_ *W"BBB@S"O4/@Q_R4KPW_W&/_3!JM>7UZA\&/\ DI7AO_N,?^F#5:Y<
M=_N6,_[!<1_Z9F>+Q)_R3N?_ /8ES7_U!KGWA1117YR?R2%%%% !1110 444
M4 %%%% !1110 45V7@CX=>/?B7J=SHOP\\&^)O&^KV5@^J7>F>%M%U#7;ZVT
MV*XMK22_GM=.@N)HK1+J\M;=IW01+-<0QEMTB [WC?X)?&'X::7;:W\0OA?X
M\\$:/>7\>E6FJ>*?"VLZ%87.I2V]S=Q6$%UJ-G;PRW<EK97=PENCF5H;:>0+
MMC<CBGF674\5' U,?@H8V?+R8.>*H1Q4^97CRX>515I<RUC:#NM5H>Y1X8XE
MQ.4U<_P_#V>5\BH>T]OG5'*<?5RFC[*2A5]KF4,/+!T_9SE&%3GK1Y)-1E9M
M(\OHHHKM/#"BBB@ HHHH **** "BBB@ HIRJSLJ(K.[L%1%!9F9B JJH!+,Q
M(  !))  S7U)HG[$G[5_B'2X=8TWX&>-Q8W$*SPG4K6RT.[DA< HZZ;K=[IV
MI8=2&0&T!9"'4%2"?.S#-\IRB%.IFN:9=ED*LG&E/,,;AL%"K*-N:-.6)JTE
M.2YHW46VKJZU1])PYP;Q?QA5Q-#A+A7B3BFO@X0JXNCPYD>9YW5PM.HY*G4Q
M-/+,+BIT(3<)J$ZJC&3A)1;Y7;Y9HKJO&G@;QC\.?$%WX4\>>&=:\)>([%89
M+K1M>T^XTZ^CAN$$MM<"&X1#+;7,1$EO<Q&2WG0[XI'7FN5KMHUJ6(I4Z]"K
M3KT*T(U*5:C.-2E5IS2E"I3J0<H3A.+4HSBW&2::;3/$QF"QF78O$X#,,)B<
M#CL'7J8;&8+&4*N%Q>%Q-&;IUL/B<-7A"M0KTIQE"I2JPC4A-.,HIIH****T
M.8**** "BBB@ HHHH **** "ONO]@7]J30/V8OBGK%_XUM+^X\"^.=$M]!U^
M[TN(7-]H5W97R7NDZ\+(*9=1M+3??VE]96SI=&WU!KRU6ZGLH["[^%**\C/\
MCR_B7)\PR/-:<ZN S*@Z&(C3FZ=6*4HU*=6E42?)5HUH4ZU*3C**J0CSPG&\
M7]EX>\><1>&'&G#O'O">(HX;B#AG'K'Y=4Q-!8G"SE*E5PV)PN+P[E!U<)C<
M'7Q&#Q4(5*55X>O4]C6HU>2K#^I_QG\2O^">O[2&G:/?_$+QU\#O%*Z?"SZ3
M<>,/$EEX0\0Z=;W#K)+:H^L7GASQ'8PRR(LEQILIBC>11)-;%@&KE=._:6_X
M)\_LM>&]5A^&FN^!H/M3QO=:/\*[*7Q7X@\17%NLIMHKG6H6N(;H0+),+6;7
MO$5O86WFR)%<1-/MD_F*HK\6I?1^RE4(Y;B.,>,,1D,*JJ1R1XZC3P=E4]JH
MRIJC+#7<[RE4IX6E/F;G%PF^9?W'B_VBW%T\=4XGR[P6\&,N\0:^$EAJW'7]
M@XW$YS[V'CA92I8F6-I9GR1HQ5.G0Q.;8NBJ484:L:U*+A+["_;*_:SUK]JW
MQ]I^L#2Y?#?@;PE;7NF^"?#EQ.ES>PQ7\T,NIZWK$T7[@ZSK)M+$7%O:E[.P
MM;&RL8);N2&XU&^^/:**_;<FR?+N'\KP>393AH83+L!15'#8>#E)0CS2G.4I
MS<IU*M6I.=6K5G*4ZM6<ZDY.4FW_  GQMQKQ+XB\59WQKQAFE7.>).(<8\;F
MF85H4Z;JU%3IT*-*E1HPIT,-A<+AJ-#"8/"T*=.AA<+0HX>C"%.G&*****],
M^6"BBB@ HHHH **** /Z5OV9_P#@H=^S]X]^&GAGPG\5?%&F^ ?'&E^&['P[
MXDT_QC#)'X:\0G3].ATV[U6RUQ[1M"%EK4:&>;2-5GL[NWEN+BQ2&_MH$OKF
M[)X=_P""6'A[58_%PO/V:FOH[DWT45IXNTC7K&.?*N"OA&SUK4M*1$8*8K8:
M((87!$4*,"*_F<HK\(K^ V44L?C\5D7%7%7#N&S.I.IC,ORS'1IT)*<IR]C"
M<8TZDL/#VDXTJ>)>*E",FN=IV/\ 0' _M!.,<5P]P_E/'WA+X2^)6:\+X:CA
MLEXCXIR*KB<?1E0IT*<<=5HU:N)H4\QK?5Z53%8G*_[*A6J4Z<_8PE!-_P!
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M  &_9>TGX#_!/XM_&S5?#WQ<\8:CK^E?"3X<>,/B1J>B:?>>#8K:UU#5M/\
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M7]HR>*Z_9M^.US _F07'P0^)\\+[67?%+X#UR2-]KA77<C [656&<, <BO\
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M..,R1[]X_IP_X.V]'TOP])_P3OT#0["UTK1=#\,?M&:/H^EV42P66FZ7IC?
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M!V_&;_@V6_Y2G>#?^R-_&/\ ],-I7]IG_!:#_E%G^VU_V1?4O_3SHU?RC?\
M!O%^QG^U_P#!;_@I'X6\=_&3]E7]H_X2>"+/X2_%:PNO&/Q/^"'Q,\ >%H+_
M %+2+.VTZP?7_%GAG2-*%_?3GR[.R%V;JY*R&&)UBD*?UQ?\%:_ _C3XE?\
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MR^MA9\Z6L%6Q>=X9TI2M[1X:LH<WLZG+YO1117]_'^6X444]4)Y/ _G0VEN
MT G@5ZE\&5 ^)'AP]3_Q./P_XD.J5YF !P*]/^#?_)2/#G_<8_\ 3#JE<F.N
M\%C.B^JXC3_N%/=_HOO:/%XD_P"2=S__ +$N:_\ J#7/NJBBBOSH_DD****
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MT **** "BBI%3N?R_P :3:6X# I/3\^U2A0/<^O^'I3J*RE)OR7];@%%%%2
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MS;$O'2R7&Y9C<)A,QJ?6;*M7PE".*=1J<IU9K"U)PDE6A1I>@_LR_P#! O\
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M/Q=C4!1CWY[]:NQ=O]T?TJFGW1^/\S5R+M_NC^E?Z+R3<FEY?EU/\W8;?/\
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MZBBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^/4=<OK.TBEUN?P]H2R)9H;9(M-DUB^MK&TDN[B+3%O+^::#386MODS_ (+
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M:A<[_P <?^"=?[.'QE@U+4-/\,I\,_&5X)[B'Q1X#2/3;62^E5G2;5O"V/\
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M^MPHI0I/3\^U2A0/<^O^'I09MM[LU/#Z?\3W12>/^)MII _[?(>M?47[<_\
MR=-\4?\ N2?_ %77A&OF'0/^0[HO_86T[_TLAKZ>_;G_ .3IOBC_ -R3_P"J
MZ\(U\+C?^3F<-_\ 9"\;?^M!X?GZWE?_ "8?CG_L[GA5_P"L;XR'R71117W1
M^1A12@$]*E"@>Y]:ER2\WV_S[ ,5.YX]O7_#^=2@8X%%%9.3>_W= "BBBD 4
M444";2W"BBBFDV[(RE)OR7;_ #[A1116L8I;ZO\ +T_S)"BBI GK^7_UZ;:6
MX# I/T[FI0H'U[FG45E*3?DNP!1114@%%%% FTM6%%%%!G*;>BT7XL****"
MHHIP4GV'K0 T#/ J54[GGV]/\?Y4X #I2T %%%% !112@$]* $IZIW/'MZ_X
M?SIX4#W/K3J"+N6D=%U?^7]=>@ 8X%%%%!2BEZ]7W"BBE )Z?Y^M Q*>$)Z\
M#]:>J@>Y_E]*=6<I_P OW_Y?\$SE/^7[_P#+_@B  =*6BBLS,****:BWM]_0
M HHHK512\WW_ ,NP!1115 %%%% !2A2>GY]J>J=S^7^-25$IVT6OGT_X(#0H
M'N?7_#TIU%%9-WU8!1110 4444$RDEYO\O4***4 G@4&3;>XE/"$]>!^M.5
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MUEGO[)[[3]&\17>C?OM:_P#!Q[\$/%VF:5??%O\ 8@GU?Q=I,?\ H\MKXO\
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M.S7D0M9=6U?5KB&'4?%GBB>R1;6?6K^.UM+:-[N+0=&T*VO[ZVN.K_X)D?\
M!1P_\$Y?''Q0\9?\*<'QC7XD^%-&\,G3/^%A'X>G1CH^KRZJM\+W_A"/' U
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M9W2QF/?UFEAZF$P_U?#QE4MB\10=6W)152=H'[I_%#P9XN\>_P#!N+X*\/\
M@CPSKGB[7A\(_@[K(T7PYI=YK&JOI7ASXR^&M>U[4(]/L(9[N6UT?1-.O]6U
M&6*)UM-.LKJ[FV002.O\B7PE^$OQ"^.7Q'\)_"?X7>&-3\6^._&FKV^C:'HF
MF6L]Q,\\S_O[R\:&.06.DZ7;+-J&LZI<B.RTG3+6[U"^FAM;:61?VR^$'_!>
MWXH_ ']F/X _L_?"?X&^'-.UGX,#P_I>N^./%7C:3Q/H_P 0_">F+K/]K>'Y
M?!5MX+T"_P#"L^L3ZC875MK6G>.;Z[TJ72E3RK^WO;B!?L;3/^#COX.:%I&J
M^)O#_P"PM#H/Q8UB"0:A<:9XZ\+6>D:E=O@_:-5\6V7P[LO$NH0&4+<26L^B
MM+)M$'VQ6(NU_+^%*'C-X;8?C? Y9X8X?B.GQ-QQQ/Q#DN-AQ9DN$E@IYG5H
MX?"5<UP4ZT^?!5:.%H8RFJ&+HUXQ=;#XOZI4E3E']'XHK^#_ (BXC@S&YEXD
MU^'Y\.<%\-9!G&#GPMG&*CC(9;3K5\53RS&0I1<,92K8FOA*CK82M0D_98C"
M?6J<*D9^W?\ !<?Q!X4_9L_X)H_L[_L?PZW9ZAXKOY?A)X%TFQA!MY[WP5\"
M?!]K;ZYXI%H3(T-BFMV7A"Q2&9P[S:V#$TQLKDI@?\&V?_)M?[6'_92=%_\
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M:OA<31P,)5Z<JM.G25.4N2%JE23FZE*%&O\ D/\ \$G?^4C'[)7_ &5.V_\
M3+K-?>O_  <:W$UG^WS\/KNVD:*XM?V:?AW<6\JXW130?$GXN2Q2+D$;DD56
M&01D<BOB?Q!^W[X9F_X*-:+^WGX/^ .F^$-&T+Q;X9\30_!73/&,-G8WA\-^
M#[3P<P3Q-:>#8[/1KC6H+*+5KS['X0N;:VOYK@+#>-(]U)R?_!1_]N;_ (>"
M?'C0OC;_ ,*N_P"%2?V+\,= ^''_  C/_";?\)[]I_L/Q'XOU_\ MG^VO^$1
M\%^3]J_X2O[)_9W]DR^1]@\_[=-]J\FV[?\ 5SBG-/&#@WCO%Y!++<JI>&V)
MRS.85,RRO%3RG/,;BZN+GE$U0Q/ML<Z'MO9O'83#5,%5Y>95(7Y5P+B+AC*_
M"/C'@?"9]',<UJ^(N&S+)YTLNS/"QS3)<%AJ&&AFT)5L-[+!*M['VBP6+Q%/
M&4^;E=.5N9_TQ?\ !8GX=ZM^WA_P3<^#'[27P*T^Z\9CPC+X9^-DNBZ)93ZC
MK%QX!\6^$KC3O&*6FGV?GW+:GX/U&ZTR]\06 CDFTZPT+Q"]QLDTV1&_D%_9
M]^ WQ&_:8^+_ ((^"WPLT*^UWQ;XVUNQTR+[+9W-U::'ILUU#%JOBC7I+:-_
M[/\ #GAVSEDU36]2G,<%I902,S[VC1_T(_X)Y?\ !7WXZ_L$Z5<?#P>'].^,
MGP/N]0O-7C^''B'6[S0-2\,ZK?\ [R^NO OBZ&QUO_A'[;4KH"\U71KW0-;T
M>ZO&N;^SL],U34-1U&Z_4+5/^#BKX1^%=!UW4_@?^Q!IOA;XF^)+:1K[5=5\
M1>&-*T(ZK)'F/4-=F\(^$K+Q!XQM[:Y6*22SGN?#MQ?1IM74]/?;(OPG#>6>
M+_A'EF<\"\,<#87C/)I9EF.*X,XDCQ!EF6TLMP^9U)58X?/<NQLH8FJ\!6F\
M15=%TJ>(G*K1I5Y0E"=/[?B/,O"3Q8S+)^-^)>-L3P=F\<NR[#<8\.RR#,\Q
MJYC7RVG&E.ODF88.,\/36.HQ6'I*JJM2A"-.M5H1E&<*GJ/_  <4?$3P;\/_
M -EW]FC]E+2=3@F\42>--"\:QZ6DBF^M/ /PR\"^)? EC?:A:J7-I;:UK/B:
M"/3)9747<_A_5XK4S?8;LQ6OV!AC_@WX_:='_5-OVP#_ .6KK-?RU_M$_M%?
M%O\ :H^*WB#XS?&OQ1)XI\;^(1;V[SI;0:?I>D:18*T6E>'_  _I-HB6FE:)
MI4+-':6D*M)++)<7]_<7NJ7M]?7/Z)? /_@J\WP/_P""?GQ0_84/P%'B@?$?
MPY\8/#R_%(?%$Z(=%7XKZ3=Z9]K;P2?AWK']IG06NVN/('B[3QJBH(?-TXDS
M"<?X-<2Y1X3\#<'Y73IY]GV7>(&2<5\1U:.+PF%H)O%8S$YI7P]3,*V"5:C@
MHUJ&'IQBEBL5&G[:&&4IRI0K+_&'AS-O%7C7B[-*E3(\BS#@/.>%N':57"XK
M%5^58;!X?+*&(IY?2QCI5L9*C7Q%24F\-A95/8SQ,HPC5G^/U?V!_P#!;C_E
M$C^QA_V47]G/_P!9I^*]?Q^5^P7[;G_!5W_AL?\ 9(^"_P"RS_PH3_A7/_"H
M?$?PYU__ (3K_A:7_"7_ /"0_P#" ?#3Q7\._LG_  C'_"N?"_\ 9/\ :W_"
M3_VQY_\ PD.I_8/L/]G^3>_:?MUO^E>)'"F?Y_QMX0YOE. ^MY=POQ)F6/SW
M$?6L%0^HX3$83"TJ-7V6)Q-&OB>>=.<?9X.EB*L>6\H133?YOX=\49%D7!GB
MSE.:X[ZKF'$W#F78#),/]5QE?Z[BZ&+Q-6K2]KAL/6H8;DIU(2]IBZF'IRO:
M,VTTOQ]HHHK]D/R$_L,_X(.?\HR_VOO^RH?&+_UG_P"&]?QYU^PG[!__  5A
MD_8D_9D^,7[.:? 5/B6WQ7\3>,?$D?C)_B@W@X>'I/%GP_\ #O@46C^'1\/?
M%!UA-//A]-5\U=>TIKL736.RV\H7DGX^!2>GY]J_&_#KA3/\AX[\8,ZS7 ?5
M<MXIS[)<;D6)^M8*O]>PV$P.,HXBK['#8BMB,+[.I5IQY,92P]2=[PA**;7[
M!XA<4Y%GG _A)D^5X[ZUF/#&19Q@\\P_U7&4/J6)Q>-PE7#TO;8C#TJ&)]I3
MI3ESX2KB*<;6G.,FD_VZ_P"#?7_E(CH7_9(OBA_Z1:77B7_!:A,_\%.?VHR>
MG]I_##C_ +HE\->M>)?\$^_VQ3^PG^T1I_Q[7X=#XI?8O"7BCPJWA0^+3X),
MR^)+>VA^W+KP\,^+O*-DULK_ &8Z-*+D,4\^ @/7%?MJ?M*_\-@?M.?%']HW
M_A"_^%>?\+)NO#%S_P (;_PD?_"6_P!B_P#"-^"?#7@[9_PD/]@^&?[1^V_\
M(]_:.[^P[#[/]L^Q[9_L_P!JG,+PIG]/QYS+C2> MPUB/#.CP_1S+ZU@GSYO
M#B#"8Z6#^IK$/'QMA:4ZOUB6%6%?+R*NZC4'.)XIR*IX&9=P=#'7XCP_B16S
M^KEWU;&+ERF>08K!1Q?UQX=8"5\55A2]A'%/$J_.Z*IIS7]+7_!LWQ\(_P!J
M;'_11OA[_P"HSKE?F!_P;_?%W0?AE^WU;^&_$.H)I\'QH^%7C+X8Z*\Y5+6;
MQ4-5\,>.M&MY9F*K#/?0^"]2TK3MQ)NM1U&UL(E>>\A%>?\ _!,W_@JW_P .
MZO"/Q3\*_P#"A?\ A</_  LSQ'X>\0?;_P#A:7_"OO[$_L'3+[3OLGV7_A77
MC?\ M+[7]M\[[1]HL/(\KR_)FW[T_)/1M:U?P[K&E^(?#^J:AH>O:'J5EK&B
MZSI-Y<:?JND:MIMS'>:=J6FW]I)%=65_8W<,-S:7=M+'/;W$4<T3I(BL/EZ7
MA?G.<\1?2%H9SAGEV2>(V"X6PG#V:K$8+$^VJ9=DN88:OBG@Z&)J8JC' 8^K
MA92I8REA98F*?U>4H\U2/TU;Q-R?)^'_   KY1B5F&<^'F+XHQ7$&6.AC,-[
M&GF.<Y=B*&%6+KX:GA:TL?@:6*C&K@ZN*CAY-.O&,N6G+^H'_@KA^UI_P5!_
M8S_:=\1#P=\;/%/A_P#9W^(1L-=^#^J6GP^^'&I>'[&.73((]=\$3Z[JG@&^
MD'B'0-9M-3F&FW^J7>IS>'KG1]7D=TO6\K\QM*_X*Z_\%5M>LM<U+0_VA/'.
MLZ=X8T]-6\2W^E?"GX7ZC9>'M*DN8K--3URZL_AK-!I.GO=SPVJ7E_);VS7,
MT4 D,LB*?OGX,?\ !PWK,GPYL_AQ^U_^S7X8^/WV:WMK.[\6Z5J.D:1_PD<%
MG L45UXJ\ ^(O#>O^&M0UN>0-->:EI5_H.FN\C?9_#]L=Q?C?V@O^"[7A_Q)
M\&?'OP)_9F_8V^&7P:\)?$70M9\*^)=0U]]#U6QN?#WB#2[G1M42T^'OA+PM
MX4T"WU=["Y>.VU'5-9\0V=OG#:1,41Q\CPOPMQ-E&"RCA;._HY<"9WF&7/!Y
M;BN,EB.#:659AE^'G3H3SFM2KY;6S:6-J86+J5:,J+Q.)Q3EB)4:*G*A'ZGB
M?BKAK-L9FW$V2_2'XXR7 9BL9F.&X/>'XQJYKE^/Q$:E>&3T*M#,*&50P5+$
MR5.E6C66'P^%4:$*U5TXUY>0_P#! G4+S5O^"C]AJFHSO=:AJ7PO^+.H7UU(
M%$ES>7D&GW%S.X150/-/(\C!%50S':H& /!/^"U'_*3?]J+_ +"?PQ_]4G\-
M:\1_X)^_MCM^PI^T3I_Q['PZ'Q2%CX2\4>%F\)GQ<?!)F7Q);V\/VY=>'AGQ
M=Y1LFME?[,=&E%RK%//MR ]<1^VI^TK_ ,-@?M.?%']HW_A"_P#A7G_"R;KP
MQ<_\(;_PD?\ PEO]B_\ "-^"?#7@[9_PD/\ 8/AG^T?MO_"/?VCN_L.P^S_;
M/L>V?[/]JG_5<)PGGM'QXS'C)Y>H<,5O#*AP[0S&.)P5GFU/B#"8UX)8*.(^
MOP4<)2G45>6$CA;1]FJWM&H/\KQ?%>1UO S+^#UF#GQ-1\2Z_$-?+Y8;&\RR
MJID&+P2QCQLL/]1FY8JK"FZ$<5+%7E[1T?9J4U^P?_!NC\ /AW\3_P!H7XO?
M%KQOHVE^(=9^!7A7PA<> +#58Q<PZ5XG\<ZCX@MF\76ME(#;S:CH6F^&KNST
M^YN$E&F76MQZA:)'J4%E=VOCG_!0'_@JY^W7\2/VC/BK\)/ WCWQW\"O!O@[
MXC^)?AQX8^'7PQ>]\*>-+M]!U^Z\-VUQKWB72(;;QQJ/B37Y+6.>;2[/5+?2
M;>:ZCLM+TPD/=7?PK^P9^W/\3/V!_C0?BMX!TW3_ !3H^MZ._A?Q_P" =9NI
M['2O&'AJ2[M[]($U&WAN9=%US3+ZUAO-#U^&SO7T^4W-M<65_I>H:EIUY^XO
MBC_@X<^"K/=_$'P3^PGHR?':\L4M(O&7BGQ%X3E>REBA$-J]YXJTGP1%XPUV
MPL0 $TY9M!:>%!#'?6 821_ \7<*<7X/Q=S;C)>&V#\4<IS'(LJR_AF.-SK*
M,'0X4Q6$ITXXV$\-G,:U.C'%8F-?&RQF'PLY4XXB4:-7VM7$4C[WA+BGA'%^
M$N5<'OQ'QGAAFN7YYFF8<32P639MBZ_%6%Q52<L'.&*R=TIU987#.A@XX/$8
MF$:DL.I5J7LJ6'JGUO\ &G0/C%X9_P"#?'Q+H_Q^B\:0?%R'X9Z-=^+X?B)J
M&H:IXVBDU7]HC2M6T5/$=UJUW>ZJFH+X=OM(#6.ISC4-+B\K3+VWL[FTEM(/
M@_\ X-GQ_P 7K_:=/K\+?!G_ *EEY7S'\9?^"WWQ8_:'_8U^*7[,/QC^%6D^
M(O&_Q/O9'G^,.D>++7PWI6@Z/'\0-(\:Z5H-A\,K/P+.;JUT33]*7PS8WMYX
M\?4I[=K?4M4NM0O()UO?J#_@VB_Y+7^TY_V2WP9_ZEEW7PN;<)\4\)> _CC3
MXLRW 97C\]XRQ?$.'HY7BJ&*RV>#S#,N&W&K@/95)U:.#6(I8BCAJ&-IX?&0
MHTHNMAX*47+[7*N+>%^+/'7P1GPGF6.S/ Y'P?A,@Q%?,\+7PN8T\9E^7<1\
MU+'>UIPI5\8Z%2A5Q-?!5,1@YU:LE1Q%3EDH_B[^W]X*\7>!OVU?VI;#QCX8
MUWPO>ZQ\??B]XITJVU[2[S2Y=4\->)?B%XCU?P]X@TY;R*+[=HVMZ7=6]_I>
MI6IEL[VVF26WF=237]-O_!"'X-:A^R?^R%\>_P!JCXYQR_#SPQ\33I7C.!_$
M5E<:==6WPE^$OA_Q'J-KXTN(;E8[D6&O7'BKQ'-HD MQ)J6G6%CJEBUW:ZU8
M,WD'CC_@O!X:\"_&SXS?"/\ :1_9.\+?%3_A3WQO^+?@[P3XW\,WVD17L.B>
M%/'>N:'X>BN?#'C/1-<CMM7BL-.M8]1U_2_%-DE[(HG30[>0-YOYI_\ !1#_
M (+.?%[]MGPM/\'_  5X3B^"7P*O&M'\1^&;?6D\1^*O'TNG7T%_IR>)_$*:
M7I$%CH-G=V=G>VWA?1;&.%KZ'S=6U?6XH[&&Q]_.,O\ %CQ2X4X>\.L=P3AN
M%.'<53X?J<1\7OB/+\SPV-R7+7A,71649?1IQQU/%8N>'P^(IT<33FZ%:G##
MXF5*C*>)7@9/F'A1X7\5<0>(F!XVQ/%?$.%J9_3X=X17#N899B<'G.8K%82L
M\WS"M.6!J87"0Q&(P]6MAIP5>C.>(PL:M6,,-+\T]%^/GBSPG^TG;?M+^$V.
MF^,-*^,<OQATF*25VC35&\72^*QIMZ\9!N+&Z:5].U*$@QWEE/<P2H\4SH?[
M5OC5^RQX-_;N_:&_X)F?MU>!K.WU'P)I26WBOQW<2"">Z?PC8^&[SXO_  AM
M]2@& PT/XDV=[X8UZTFW^3>>*&M;B)&MY()?X,Z_M@_X);?&3QI^S!_P1M\1
M?'+XT!8?#'PZ_P"%N>+_ (-V&J>=;7&J>#);N!/!^AR^>R2AO%WQ>O/$FF^'
MG)BAN-,UO1);5_L4UO,>_P"DAE>,RG+^#^*.%:L,+Q)0Q6,X P&&BVJV99?Q
MCE.,RM8.A%2YJ^)P-:$,3@8RO&C5G5Q+O*G&,O/^CCF>#S;,.+^&.*:=3$\-
MU\+@^/L=B6E['+<PX/S;!YF\77DURT,-CJ,IX;'2C:5:E"EAE:-24H_A3_P7
M+_:)_P"%Z_MX^-O#6EWWVOPE\ =*L/@YHRQ2[K9M?TB6XU;X@731 E([^'QE
MJNI^&[J0$O-;^&; /M\I43\=:V/$7B#6/%GB#7?%/B&_GU37_$NLZGX@US4[
MDAKG4=8UF]GU'4[^X8 !I[R]N9[B4@ &21B !Q6/7]"\&\-8?A+A;A_AG"V=
M#),JP> =2*M[>M1HQ6)Q35E[^+Q+K8FH[).=63LMC^>^,>)<1Q;Q3G_$N)YE
M6SK-<9CU"3YO84:U:3PN&B[N\,+AE2PU/5VA2BKO<*** ">E?4I**T^;/E]7
MYL*>J$\G@?SIP0#KR?TI]1*?\OW_ .7_  32,.K^[_/_ "_X80 #@4M%%9C<
MDM%O^"_KL%%%%!FVWJPKZL_80_Y/A_8U_P"SK/V>/_5N^#Z^4Z^K/V$/^3X?
MV-?^SK/V>/\ U;O@^O"XH_Y)GB+_ +$6;_\ JOQ![O"O_)3\.?\ 8^R?_P!6
M&'/E.@ GI3E4GV'\_I4H '3_ #]:]T\$:$ Z\G]*?110 4444 %%* 3TJ4*!
M[GUH)<DO-]O\^PQ4[GCV]?\ #^=2@8X%%%!DY-[_ '= HHHH$%%%% !5VWN=
MF$D^Z3PW=3[^HZ<]1[CI2HI-*2LU_P #J--IW1TT!!P0002<$'(/'8BKB?>'
MX_R-<I!<2V[9C(P3DJPRI[<CJ/JI!]ZUX-4B)'G*8R/XERZGMV&X'GIAN ><
MX%<E:E-W<5S*Z>F^UMMW\KG3"K%I)^Z[6UVT\_\ /;\]U.I^G]15^+M_NC^E
M9$-W;2'Y)XSD< L%;G'\+8;\,<'@\UJQ.F =RD;<9# CC Z@X[5QRO'XDT]K
M6=_Q.R,HM*S3T6S3[%Q._P"']:THNW^\/Z5G!T[.GX,/\:O121\?O$^]_?7V
M]ZXYIZ:=_P!#6$M;75DM/5M/[]2^GWA^/\C5Q/NC\?YFL])8L@^9'CGG>OI]
M:N)-%M'[V/O_ !KZGWK%P;>M[6MYW_IK^F;QFDK::M==+.W]?-%Q/NC\?YFK
MD7;_ '1_2L])8BHQ)&>O\:^OUJ]')$ "98^@&-Z^WO64E:^CMK;1[7_X8ZH2
M26K6KT_#7T\]C0J[%U_%?YFLWSH3TEB/_;1?\:NQ30@\RQ#E>LB^OUKEDGRO
M1].GFO\ -&D9*ZU5KJ^J[_\ !-%>H^H_G5U/NC\?YFLU9X,C]]%U'_+1/7ZU
M<6XM]H_?P]_^6J>I_P!JN:<96V>_9^9T1:NM5NNJ[FC#T'T/\ZM)U/T_J*SX
M;FW &;B$<'K+'Z_[U6XI[<GFX@ Q_P ]8^>G3YO\^]833Y7H^G1]SH4HIK5;
MKJB]&"<XYZ?UK1BZ_BO\S6='<6R@_P"D0#ISYL?/7_:YJU%=6V?^/B#JO_+:
M/U/^U7--2LE9V>^GIY'1&<4U[RLVKZKR_P _Q-=.A^O]!5J'J/J?Y5FI=VF#
M_I-OU_Y[1^@_VJM0W=ID?Z3;]3_RVC]/]ZN:<9::/KT?D;<T?YH_>OZZK[S3
M3[P_'^1JRG4_3^HK.6\M-P_TJW[_ /+>+T/^U5J*ZM"?^/NV QU\^+V_VZYY
MQE=>[+9='W?D="E&R]Y;+JO+_-?>:$8SD#V_K6A'W_#^M9L=W9J#_I5L,XY\
M^+GK_M592\M!G-U;#IUGB]_]JN>49MZ1E:/D^MO^ ;QG!I>]'9=5_F:Z@D@]
M@15V'J/J?Y5EI>V0!S=VHY_Y^(O;_;JU#?661_IEKU/_ "\1>G^_7/.$KW49
M:[Z/RMT.B,X67O1V7VE_F:J?>'X_R-64ZGZ?U%9BWUEN'^F6O?\ Y>(?0_[=
M68[ZR+<7EIR.OVB''4=]]8SA.R]V6_\ *_/R.B,X67O1V7VEV]367H/H/Y5=
MC[_A_6LJ._L,@&]M.!_S\P]1C_;JU'?V//\ IMIV_P"7F'W_ -NN6<9W2Y):
M=>5Z[;:&L)PLUS1[_$O\_P"KFPO4?4?SJ[%V_P!X?TK'74+ D8O;0\C_ )>8
M?7_?JY'J%@,9OK,?-WN81Z?[=<TX3YG[LNGV7V7D=,)PL_?CO_,O+S-A/O#\
M?Y&K*=3]/ZBLI-1T_(/V^RQSS]J@]#_TTJS'J.GD\7]ET/\ R]08ZCOYF*PG
M"=_@EM_*^_IYHZE.%E[\=E]I>7GYK[S87H/H/Y5<BZ?@O\C63'J.G9 -_9<#
M_GZ@ZC'_ $TJTFIZ:,YU"Q'3K=P>_P#TTKE]G/\ DG_X"_\ +S7WFL*D-5SQ
M[WYEY:;FTO4?4?SJ[%V_WA_2L1=3TW(_XF-CU'_+W;^O_72KD>J:8,9U&P'S
M#_E\M_;_ *:5A.$^9^Y+_P !?9>1M"I3O\<-OYH^7F;:?>'X_P C5A/O#\?Y
M&LE-4TPL,:C8]_\ E[M_0_\ 32K":GINX?\ $QL?_ NW]#_TTKF]G4_DG_X#
M+_(Z(5*=_CAM_-'R\S73J?I_45H1=/P7^1K%BU+2P>=2L"<'_E\M\=1_TTJY
M'JNE\_\ $RL.W_+Y;^__ $TKG=*HMZ<__ 7UVZ'5&M2=ESPT7\T?+S-H #I_
MGZU>3H?K_05A_P!K:6>FI:>?^WRW_P#CE7$U?2<?\A/3NO\ S^VWM_TUK&5.
MIS/]W/I]F79>1O3J4]?WD.GVX^?F;4/4?4_RJVGWA^/\C6)#J^E#KJ>G]3_R
M^VWI_P!=:M)K&D[A_P 333N__+[;>A_Z:USRIU.9^Y/_ ,!EV]#>%2G=_O(;
M?SQ[KS-I.I^G]15^+M_NC^E8*:MI(Y_M33N1_P _MM_\=J['K&D#&=4TX?*/
M^7ZV]O\ IK7/*G4YG[D__ 9=O0WA5II_Q(.^GQQZV\S;C[_A_6M%.A^O]!7.
MIK&D#.=5TT=.M]:^_P#TUK036M'Q_P A;3.O_/\ VOM_TUKF=.KNZ<]?[DO\
MCIIU:6O[RGT^W'S\SOK#Q=XAL/#&L>#K34/*\.:[>V=_JNG?9+&3[5=Z>T<E
MG+]KEMGOX/)>-#Y=M=0Q28Q*C@D'$3[H_'^9KVSPA)X<G_9O^*VKROHDUW8>
M+O",%OJDC6$ES91W5U8K-##>L3+;)<@ 21I*BS  ,K8%> )K6C%1C5M,[_\
M+_:^I_Z:UX>7UJ>)Q&=0H8+ZO+!YM+"XJ<*<4\5B5E^75WB:CA"+=1T<10H-
MU'*IRT8+FY%!+Z',:-3"X?)9XC'_ %F&-RF&+PD)U)-83#/,,PPZPM)3J22I
MJOAZ]=*FH4^>O-\BFYREO0]!]#_.M&+M_NC^E<W#K6C#KJVF=#_R_P!KZ_\
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MD.MK=3H4!SGMC_"KE<ZOB/P]@?\ $]T;H/\ F*6/I_UWJS_PD?AX]->T4_\
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M_P )MX,_Z&[PQ_X/]*_^2Z/^$V\&?]#=X8_\'^E?_)='U7$_] ]?_P $U/\
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M5<3_ - ]?_P34_\ D0^N83_H*PW_ (/I?_)>:^\Z>BN8_P"$V\&?]#=X8_\
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MD\-U:SS6US;RI-;W%O(\,\$T3!XYH9HV62*6-P'21&5T8!E((!KZ,TS]L/\
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M+10WVT7Y^O?\D92DWY+M_GW"BBBD2%%%/5">3P/YT - )X%2*@')Y/\ *G
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MJE"@>Y]?\/2G45E*3?DOZW ****D HHHH$VEN%%%%!G*;>VB_$**4 G@5(J
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MWU?X&;;>K"BBBK$%%%%3*27F^P!11163;>X!113@I/L/7_#UI -J14[G\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+_&I***AMO< HHHI %% !/2I0@'7D_I0 Q5)]A_/Z5* !T_S]:6B@#[8U/\
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M%%%1*;>BT7X_,RE-O1:+\?F%%%%02%%%.52?8?S^E #0">E2J@')Y/\ *G
M=/\ /UI: "BBB@ HHHH ***4 GI0 E2*G<_E_C3@H'N?6G4 %%%% !11109R
MGT7W_P"04444&84444 %."D^P]?\/6G*G<_E_C4E1*?1??\ Y=_ZW 0*!T_/
MO2T45D 4444 %%%%5&+?DOZV_P ]B)3Z+7S[?Y_D%%% !/2M4E%:?-F6K?=L
M*<JD^P_G]*>$ Z\G]*?42G_+]_\ E_P32,.K^[_,0 #I_GZTM%%9C<DM%O\
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M4UF'^S-*UZ^T^'5;7^RK?48M$O?M4<\J^?J&FW=S!OS;30LJD?'5?H/\*_\
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MDHZ+?^MP&A .O)_2GT45FVWNP"BBBD 4444 %%%% !1110 44H!/3_/UJ55
M]S_+Z4$N27KV_K88$)Z\#]:E QP***#)R;W^X****!!114BIW/Y?XT -"D^P
M]?\ #UJ4*!T_/O2T4 %%%% !1110)M+<****#*4F_)=@HHHH)"BBG*I/L/Y_
M2AM+<!H!/2I0@'7D_I3@ .G^?K2TM7Y+MU^;7Y+[^@!1113 ***<%)]AZT-I
M;B;2W&@9X%2JG<\^WI_C_*G  =*6LI3;VT7XF<IM[:+\0HHHJ" HHHH *Z3P
MAXB;PGXBT_Q EHM\UA]KQ:M,;<2_:K&YLCF813%-@N3)_JVW%-OR[MPYNBIG
M"-2$Z<US0G&4)*[5XR3C)7335TVKII]F8XC#T<7AZ^%Q$/:4,31JX>O3YI1Y
MZ-:$J=6'-!QG'FA*4>:,HR5[Q:=F?27_  T1<?\ 0IP_^#E__E91_P -$7'_
M $*</_@Y?_Y65\VT5P?V3E__ $#K_P &5O\ Y8?*_P"H/"7_ $*(_P#A9F/_
M ,UGTE_PT1<?]"G#_P"#E_\ Y64?\-$7'_0IP_\ @Y?_ .5E?-M* 3P*I9/@
M'_S#I+NZE;_Y8'^H/"7_ $*(_P#A9F/_ ,UGTC_PT1<?]"G#_P"#E_\ Y64X
M?M#7)_YE.$#M_P 3E_\ Y65\X*@')Y/\J?0\IRW989>KJ5OR]I_7XF<N!.$N
MF41]?KF8_E];/H[_ (:%N/\ H58?_!P__P K:/\ AH6X_P"A5A_\'#__ "MK
MYQHJ?[)R_P#Z!U_X,K?_ "PG_43A3_H4Q_\ "S,/_FL^CO\ AH6X_P"A5A_\
M'#__ "MH_P"&A;C_ *%6'_P</_\ *VOG&BC^R<O_ .@=?^#*W_RP/]1.%/\
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MZ(_9?OV_:*^*MI\-KB$>$XKG1-9U<ZQ"YUET.DPQ2BW%DZZ8K"<R;3)]J!C
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M_P#R8?ZE\,_]"R/_ (5X[_YJ\OS[L]Z_X7E<?]"W#_X-'_\ D"C_ (7E<?\
M0MP_^#1__D"O!:<%)]AZ_P"'K1_9F!_Z!U_X'5_^3#_4OAG_ *%D?_"O'?\
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MBAOHM%^?J_Z7D92DWY+L%%%%(D***>J$\G@?SH : 3P*D5 .3R?Y4X #@4M
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ME"D]/S[4]4[G\O\ &I*4IVT6OGT_X(#0H'N?7_#TIU%%9-WU8!1110 4444
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M'7D_I3@ .G^?K2U]%*;>VB_$^3"BBBH **** "BBB@ HHHH ***4 GI_GZT
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M3TOP[_PC_P!EOM6-L=0G_M?PMHFNS_:#9P6UO^ZN-3FAB\N!/W,<>_=)N=O
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M_1/_ /F5PGE_<\W]WF'U#)/^B@_\Q6+\O[_F_N\SY1HKZN_X:K_ZMN_91_\
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M #*X3R_N>;^[S%_9^1_]%#_YB<9_\F?*= &>!7U</VIR?^;</V4P/7_A3_\
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MI_\ JW+]E7_PT/\ ^$-'_#4__5N7[*O_ (:'_P#"&O;_ +0SS_HGO_,M@_\
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ML[>G^K]E_P!C7">6_N>OW>@O[/R/_HH?_,3C/_DSY7HKZH_X:E_ZMS_97_\
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M/^&I?^K<_P!E?_PT7_X0TX?M1D_\VY_LK@>O_"H?Y?\ %0\T?7\[_P"B?_\
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M /F5PGE_<\W]WF']G9%_T47_ )B,9Y?W_-_=YGRO17U1_P -2_\ 5N?[*_\
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M+IQ%\_[(QGETY_7[O,^6  .G^?K2U]3?\-1_]6Z_LL_^&C__  @H_P"&H_\
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MG_X04[_AJ/\ ZMU_99_\-'_^$-0\RSI;9!K_ -C7"-=.T->J(>!R%;<1:_\
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MV^GEYDRP&0K_ )J.[[?V1C/_ ),^60GK^7_UZDKZD_X:A_ZMW_9;_P##2?\
MX04?\-0_]6[_ ++?_AI/_P (*S>8YX]\@_\ ,KA--O[GF_N\T9/+\B>_$?\
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MG_X04?\ #4/_ %;O^RW_ .&D_P#P@H^OYW_T3_\ YE<)Y?W/-_=YA_9V0_\
M11_^8C&?_)GRW17U)_PU#_U;O^RW_P"&D_\ P@H_X:A_ZMW_ &6__#2?_A!1
M]?SO_HG_ /S*X3R_N>;^[S#^SLA_Z*/_ ,Q&,_\ DSY;HKZD'[4&>!^SM^RW
M_P"&D_\ P@J0?M/>O[._[+?X?"3I_P"7!1]?SO\ Z)__ ,RN$\O[GF_N\P_L
M[(?^BC_\Q&,_^3/ED*3[#UJ4 #I7U'_PT_\ ]6\?LN_^&E__  @H_P"&G_\
MJWC]EW_PTO\ ^$%'U_._^B?_ /,KA/+^YYO[O,/[.R'_ **/_P Q&,_^6'R[
M17U%_P -/_\ 5O'[+O\ X:7_ /""C_AI_P#ZMX_9=_\ #2__ (04_K^=?]"#
M_P RN$_^0,W@,A>BXDMY_P!CXWRV_>>OW>A\NT5]1?\ #3__ %;Q^R[_ .&E
M_P#P@H_X:?\ ^K>/V7?_  TO_P"$%'U_.O\ H0_^93"?_($?V;D'_12?^8?&
M^7_3SS?W>9\NT5]1?\-/_P#5O'[+O_AI?_P@H_X:?_ZMX_9=_P##2_\ X04?
M7\Z_Z$/_ )E,)_\ (!_9N0?]%)_YA\;Y?]//-_=YGR[17U%_PT__ -6\?LN_
M^&E__""C_AI__JWC]EW_ ,-+_P#A!1]?SK_H0_\ F4PG_P @']FY!_T4G_F'
MQOE_T\\W]WF?+M%?47_#3_\ U;Q^R[_X:7_\(*>/VG">O[/'[+H'_9)>?_3_
M $GF&<K?(?\ S*83_P"0#^S<@_Z*3_S#XWR_Z>>;^[S/EL GI_GZU*J@>Y_E
M]*^HQ^T\!T_9X_9=_P##2_\ X04O_#3_ /U;Q^R[_P"&E_\ P@K.68YV]%D-
ME_V-,)?Y^X']FY!_T4G_ )A\;Y?]//-_=YGR[17U%_PT_P#]6\?LN_\ AI?_
M ,(*/^&G_P#JWC]EW_PTO_X05'U_.O\ H0_^93"?_(!_9N0?]%)_YA\;Y?\
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MD'_12_\ F&QO_P L/F&BOI[_ (:;_P"K?/V8?_#3_P#W_H_X:;_ZM\_9A_\
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M_O\ T?\ #3?_ %;Y^S#_ .&G_P#O_5+&9UHWD.G;^U,*GZ?!_7ST7]F</_\
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MA?+^YYO[O,^#_LSA_P#Z*;_S#8WR_P"GGF_N\SYCHKZ<_P"&F?\ JWW]F/\
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M7]SS?W>8?V9P_P#]%-_YAL;Y?]//-_=YGS %)^G<U*% ^O<U].?\-+_]6_\
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M ._U'_#2O_5 ?V9__#5__?ZH^OYS_P!"+_S*87R_N>;^[S,_[+X=_P"BH_\
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M6-SA*W]@_P#F4POE_<]?N\T+^R^'/^BI_P#,'C__ )8?-=%?2@_:1)Z? /\
M9K_\-;_]_:D'[1P[_ 3]FO/M\+?_ +^4/,,X6^1?^93"^7]SU^X/[+X<_P"B
MI_\ ,'C_ /Y8?-*J3[#^?TJ4 #I_GZU])_\ #1__ %0;]FW_ ,-=_P#?VC_A
MH_\ ZH-^S;_X:[_[^UF\PSE_\R/3M_:>%_\ D-0_LOAS_HJ?_,'C_P#Y8?-M
M%?27_#1__5!OV;?_  UW_P!_:/\ AH__ *H-^S;_ .&N_P#O[4_7LX_Z$?\
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M@W[-O_AKO_O[1_PT?_U0;]FW_P -=_\ ?VH^O9Q_T(__ #)X7_Y C^RN&_\
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M9/"__($/+>&]4N*M>_\ 8>/?;7^)_5O2_P WT5](?\-&_P#5!_V;_P#PU_\
M]_*/^&C?^J#_ +-__AK_ /[^4?7LX_Z$?_F3PO\ \@9_V7PV]^*__,'C_+_I
MYZ_=YGS?17TA_P -&_\ 5!_V;_\ PU__ -_*/^&C?^J#_LW_ /AK_P#[^4?7
MLX_Z$?\ YD\+_P#(!_97#?\ T57_ )@\?Y?]//-_=YGI&I_\H]_#W_9U$_\
MZK;7*^* ">!7Z&W7[7_A:7]FK2OA^GPG^"TOC.#XNR>*Y?#;_"\KX/MO#K>&
M-2TP:E$HU6-'\0M?S11F5IIY!87#QAA&BQ0^#_\ #18'3X$?LXC_ +IA_P#?
MROD.$%G^ AQ(J_#]6G];XOS['T?:XVC1YZ&)K4Y4JE/VE-.K2FHMPK0_=U%=
MP;2N_P!%\17PAFM3@IX3C'#UEE_AUPEE6)^KY9BL3[+%X'"U85Z-9T:K5#$4
MW+][AJC56B[1J)2=E\W*@')Y/\J?7T=_PT7_ -4)_9Q_\-A_]_*/^&B_^J$_
MLX_^&P_^_E?7_7LX_P"A'_YD\+_\@?G7]E<-_P#15?\ F#Q_E_T\\W]WF?.-
M%?1W_#1?_5"?V<?_  V'_P!_*/\ AHO_ *H3^SC_ .&P_P#OY1]>SC_H1_\
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M. 4GZ=S4H4#Z]S7T=_PT3_U0K]G/_P -C_\ ?NC_ (:)_P"J%_LY_P#AL?\
M[]TGC\XZ9%9?]C/"W^;Y/PV\C*66<-O_ )JRR[?V%C__ )8?.=%?1G_#1/\
MU0O]G/\ \-C_ /?NC_AHG_JA?[.?_AL?_OW2^O9Q_P!"/_S)X7_Y G^RN&O^
MBL_\P6/_ /EA\YT5]&?\-$_]4+_9S_\ #8__ '[IR_M#D_\ -"OV<P/^R8]?
MI_Q.Z/KV<?\ 0C_\R>%_^0#^RN&O^BL_\P6/_P#EA\X@$]*E" =>3^E?1O\
MPT.!T^!G[.@_[IE_]^Z/^&A_^J&?LZ_^&R_^_='U[./^A'_YD\+_ /(!_97#
M7_16?^8+'_\ RP^=:*^BO^&A_P#JAG[.O_ALO_OW1_PT/_U0S]G7_P -E_\
M?NCZ]G'_ $(__,GA?_D _LKAK_HK/_,%C_\ Y8?.M%?17_#0_P#U0S]G7_PV
M7_W[H_X:'_ZH9^SK_P"&R_\ OW1]>SC_ *$?_F3PO_R ?V5PU_T5G_F"Q_\
M\L/G6BOHK_AH?_JAG[.O_ALO_OW1_P -#_\ 5#/V=?\ PV7_ -^Z/KV<?]"/
M_P R>%_^0#^RN&O^BL_\P6/_ /EA\ZT5]%?\-#_]4,_9U_\ #9?_ '[H_P"&
MA_\ JAG[.O\ X;+_ ._='U[./^A'_P"9/"__ " /*N&EJ^+/_,%C_P#Y8?.M
M%?18_:)Q_P T+_9T/U^&6?\ W-TX?M$$]/@5^SG_ .&Q_G_Q.Z?UW-_^A)_Y
MDL+Y?W/-_=YF;RSAI[<6V7_8AS"_3_IYYO[M]3YRIZIW/'MZ_P"'\Z^CA^T,
M!_S0S]G3/M\,<?\ N;I?^&A_^J&?LZ_^&R_^_='UW-_^A)_YDL+Y?W/-_=YD
M?V3PS_T5O_F!S#R_Z>>;^[S/G4#' HKZ*_X:'_ZH9^SK_P"&R_\ OW1_PT/_
M -4,_9U_\-E_]^Z/KN;_ /0D_P#,EA?+^YYO[O,/[)X9_P"BM_\ ,#F'E_T\
M\W]WF?.M%?17_#0__5#/V=?_  V7_P!^Z4?M#D\#X&?LZ_\ ALO_ +]T?7LW
M_P"A)_YDL+Y?W.FOW>8?V3PS_P!%;_Y@<P\O^GGF_N\SYTIX0GKP/UKZ,'[0
M@[_ W]G;/M\,O_OW2_\ #0O_ %0[]G?_ ,-G_P#?NLWF&;],D^?]I87RV]SU
M^X/[)X9_Z*W_ ,P.8>7_ $\\W]WF?.P '2EKZ(_X:%_ZH=^SO_X;/_[]T?\
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M/UJ0 #I7T,/V@L?\T1_9Z/U^&O\ ]^J7_AH/_JB'[//_ (;7_P"_5'UW-_\
MH2?^9+"^7]SS?W>9/]C\,RLY<7:;V609@OO_ 'OK_P  ^>:*^AO^&@_^J(?L
M\_\ AM?_ +]4?\-!_P#5$/V>?_#:_P#WZH^NYO\ ]"3_ ,R6%\O[GF_N\R_[
M(X8_Z*[_ ,P&8?\ RP^>:*^AQ^T&3T^!_P"SS_X;3_[]5(/V@/7X(?L\Y]OA
MK_\ ?JD\?FRWR37_ +&6%\O[GK]PGE7"ZWXN_P#,!F'_ ,L/G=4)Y/ _G4@
M' KZ%_X:"_ZHC^SW_P"&V_\ OU1_PT%_U1']GO\ \-M_]^JS>.S=_P#,ETZ+
M^T<-_P#(&3RKAB6_%^G;^P,PTV_Z>Z[O[O,^>Z*^A/\ AH+_ *HC^SW_ .&V
M_P#OU1_PT%_U1']GO_PVW_WZJ?KN;?\ 0E_\R.&_^0%_9'"__17_ /F S'R_
MZ>^;^[S/GNBOH3_AH+_JB/[/?_AMO_OU1_PT%_U1']GO_P -M_\ ?JK6*S?K
MDFG_ &,L+W6_N=K^>@?V1PO_ -%?_P"8#,?+_I[YO[O,^>Z*^A/^&@O^J(_L
M]_\ AMO_ +]4?\-!?]41_9[_ /#;?_?JM%C<W5E_8EO^ZEA?+^YYO[O,/[(X
M7_Z*_P#\P&8^7_3WS?W>9\]T5]"?\-!?]41_9[_\-M_]^J/^&@O^J(_L]_\
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MFW_0E_\ ,EAO_D _LCA;_HL/_-?S'_Y:?/M%?07_  T!_P!43_9]_P##;_\
MWYH_X: _ZHG^S[_X;?\ ^_-0\?FVT<EN^_\ :.&?W>X+^R.%_P#HK_\ S7\Q
M[K_I[ZOY'S[17T%_PT!_U1/]GW_PV_\ ]^:Y_P 5?&#_ (2G0;_0O^%7?!WP
MY]N^R_\ $Y\*^"?[(UZS^RWMO>?Z!J/]IW'V?[1]G^RW7[E_-LY[B#Y?-W+5
M+$YI*K357*/9PE.$9U/[0P\_9P<HJ4W!1YI\D6Y<B:<N7E6Z,<1E?#E.A6J4
M.*?K%>%&I.CA_P"Q,=2]O5C!RIT?:SJ.%+VD[0]I).,+\TE9'CM%%%>R?-!2
M@$]*<J=SQ[>O^'\ZE QP*")32VU?X#0H'N?6G444&3;>X4444 %* 3T_S]:<
M$)Z\#]:D  Z5$II;:O\  !%4#W/\OI3J**S;;U8!1112 ****"922\WV"BBB
M@R;;W"BBB@044H4GI^?:I0H'N?7_  ]* &JG<_E_C4E%% !1110 4444"<DM
M_NZA11109.3?IV_K<***<JD^P_G]*"1 ">E2! .O)_2G  =/\_6EH **** "
MBBB@ HHIX0GKP/UH : 3T_S]:E50/<_R^E.  Z44 %%%% !1112;2U8FTM6%
M%%%9RFWHM%^9G*;>BT7YA1111&#>KT7X_P!?U8@***4*3T_/M6FB71(!*D5.
MY_+_ !IP4#W/K_AZ4ZHE/HOOZ_+M_6P!11168!112@$]* $IZIW/'MZ_X?SI
MX4#W/K3J#.4^B^__ " #' HHHH,PHHHH **** /PWHHI0I/3\^U?N!_I@)4B
MIW/Y?XTX*![GU_P]*=092GT7W]?EV_K8****" HHHH **** "BBB@ HHHH *
M<%)]AZTY4[G\O\:DK.4^B^__ ",Y3Z+[_P#(0 #I2T45F9A1110 4H4GZ=S3
MPGK^7_UZDH 0*!T_/O2T44 %%%%:1AU?W?Y@%%%%-R2T6_X+^NQ$II:+5_D%
M%%%9MMZLS;;U84444A!0 3TIRJ3[#^?TJ4 #I_GZT -" =>3^E/HHH ****
M"BBB@ HI0">E2A0/<^M #%3N>/;U_P /YU*!C@444 %%%%!+DEZ]OZV"BBB@
MR<F]_N"BBB@0445($]?R_P#KTFTMP&A2WT]:E"@=/S[TM%92DWY+M_GW ***
M*D HHHH2OHA-I;A1116L8=7KY=O\_P C*4F_)?UN%% &>!4JIW//MZ?X_P J
MIR2W^[J)1;V^_H,"D^P]:E  Z4M%9.3?DNW^?<U2C%7?WO\ 0****DB4V]M%
M^(4444$!113@I/L/6@!H&>!4JIW//MZ?X_RIP '2EH **** "BBE )Z?Y^M
M"4\(3UX'ZT]5 ]S_ "^E.H,Y3_E^_P#R_P""( !TI:**#,**** "OJK]A/\
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M109-M[A1110(**** "BBB@ HHHH ** ">E2A .O)_2@3DEO]PQ5)]A_/Z5*
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MO;^O4@***<%)]AZUHHJ.KW_K;^K@- SP*E5.YY]O3_'^5.  Z4M3*;>VB_$
MHHHJ "O;?CO\$]2^!/B7PUX:U37+'7[CQ'X"\->/$N=/M9[6&TMO$OVUH-/9
M;AWDFGMDLP9IP(XV>3:B83>_B5?>W_!0W_DJ_P ,/^S=_A5_Z)UJODLTS;'8
M7C#A+**-6,<#FN XHKXVDZ=.4JM7+*>3RP;C5E%U*:IO&5W)4Y153F7.I*,;
M?<9-DN78S@7C?/,11E/,<ES+@_#9=656K&-&EF]7/8XY2I1DJ55U8X'#J,JL
M9NERR=/E<Y-_!-%%%?6GPX4444 %%%* 3T_S]: $IX0GKP/UIZJ![G^7TIU!
MG*?\OW_Y?\$0 #I2T44&84444 %*%)^G<T\)Z_E_]>I* &A0/KW-.HHH ***
M* "BBB@B4[:+7SZ?\$****#)N^K"BBB@ H SP*<%)]AZU* !TI7Z+7SZ+U\_
M+?TW :J8Y//MZ?XT^BBA+YO^MNR_IW ****8!13@I/L/7_#UJ4*!T_/O4RDE
MYO\ K<F4DO-_UN,5.Y_+_&I***R;;W,FV]PHHHI""BBB@ HHHH **** "BE
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M "E )Z?Y^M."$]>!^M2  =* $50/<_R^E.HHH **** "BE"D_3N:E"@?7N:
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M% FTMPHHHH,Y3;VT7XA11100%%%."D^P]?\ #UH ;4BIW/Y?XT\*!T_/O2T
M%%%% !112@$\"@!*>J$\G@?SIRH!R>3_ "I]!',WI'[WM^7]=NH@ ' I:**!
MJ*7F^["BB@ GI04%.52?8?S^E/" =>3^E/K.4_Y?O_R_X)G*?\OW_P"7_!$
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MGT&<I_R_?_E_P1  .G^?K2T44&8444 9X% !3@I/L/6GJG<\^WI_C_*GT (
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MY1_X+S#_ .8_/\^S%_Q+KXU_]&^SC_P=EO\ \W'Q;17VE_PQ#\0?^AK\&_\
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M_@W+?_F[S_/LSXOHK[0_X8D\?_\ 0V>#_P#OK6O_ )54?\,2>/\ _H;/!_\
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MGV9\8 $\"I%0#D\G^5?9P_8G\?#@>*O!_P#WWK7_ ,JJ7_ABCQ__ -#7X/\
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M7_4?Y]?T9\>!0.GY]Z6OL+_AC+QY_P!#1X1_[[UG_P"55'_#&7CS_H:/"/\
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M)QD8QKKFJ?5G['6%0\WHHHKZ,^4"BE )X%2*@')Y/\J"7)+UZ(:J9Y/ _6I
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MK2T5DY-^G;^MS)R;].W];A1114DA1115QAU>GEW_ ,OS ****U2MH@"BBB@
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M?Y'X;T445^X'^E84444 %%%% !1110 4X*3[#U_P]:<J=S^7^-25$I]%]_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110!\G?MBC/PRT(#_ *'O3/\
MU'_$]?FZJ=SS[>G^/\J_27]L+_DF>A_]CUIG_J/^)Z_-VO\ 3OZ*TG_Q"3!I
M:?\ "[G6O7^-2/\ (/Z9G_)[<?\ ]D[P_P#^HU4****_HT_E,**** "BBB@
MHHHH *^]O^"AO_)5_AA_V;O\*O\ T3K5?!-?>_\ P4,!/Q7^& '_ $;O\*O_
M $3K5? 9Y_R<+@'_ +%7&_\ Z:X=/TWAW_DUWB9_V.?#S_T]Q0?!%/5">3P/
MYTY4 Y/)_E3Z^_/RZ4^WW_\  $  X%+1109A1110 4H4GZ=S3PGK^7_UZDH
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MD  Z4M% @HHHH **4 G@5(J <GD_RI.27KT0#50GD\#^=2  <"EHK)R;].B
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ME-+1:O\ K<B4TM%J_P"MPHHHK+63[O\ KY(S;;W84445K&*6^K_+T_S$%%*
M3TJ55 ]SZ_X>E$I)>;[?Y]@&JG<_E_C4E%%9-M[@%%%%( HI0">G^?K4JJ![
MG^7TH)<DO7M_6PQ4[GCV]?\ #^=2@8X%%%!DY-[_ '= HHHH$%%%% !1110
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MIK-Y:WFBV%MJ-U+JL?BGX?\ @R""VD@NHUMWM+B^E>5762&) KM_2G_P0?\
MV$?"'P;_ &>O#_[5/C#0;/4?C1\<M.GU?PUJNH6T<]SX%^%=Q-+;:%IV@M-$
MS6-[XUMHF\2ZWJ5I()+_ $?4-!TEO*CL+P7G[IFOB9P#X3>$.49MPG6CQ#DF
M'4>'N%:%+&5)O-,PHO$*N\1C*M-SITJ-3#XO$8ZM"CR0E%X?#4H>TH4E^'Y5
MX:\=^*WBWF^4\5TI</YUB&\_XIKU<)3@LLP%:.&=!8?"4JBISJUJ>(PF'P5&
M5;GG&7M\15G[+$5'^"?@3_@A+_P4:\;:#;Z]<_"_PIX%2[@%S:Z3X[^(?AK3
M=>DB95:,7&E:1<:Y/I<\@.#9ZP=.O(&5DN[>W8!3\>_M.?L"_M9_L?FTN?CU
M\(-;\+>'=1NA9:;XVTV[TOQ5X(O;MT+Q6?\ PE'AF]U32]/U&X19'MM)UF;3
M=6N$@GEAL7BAD=?[,OVV?^"S/[-7[%/Q8C^"FO>&_'GQ/\?Z=::9J'C:P\!I
MH$=CX(MM8M8-1TZPU2_UW5].6Z\17FDW5GK$6CV<+01:=>V4M[J=G+<QP'[H
MT#6O@7^W9^S'9ZO!9V_CSX'?'[P+<))8:S8QQ7$NFWYGL;VSO+67[2-*\3>&
M-:L[BW,UO)+<:%XFT<76GW9N+&WNJ_#*/TD_&+((9%Q3QIP-EE+@;B*O!8.O
MA,#CL#7JX6I%UHSR_%5\SQ:5:>%4\5A88_#*GF-&G*>'G"BW7I_MM;Z.7A!G
MT\\X6X+XXS*KQQP_0F\70Q6.P6.H4L33DJ,H8_"T,MPG[F&*E##8J6 Q+J9?
M6J1AB(3JI4*G^;G\&_@W\1_C]\2?"_P@^$7AI_%_Q%\9SW]MX:\.IJFB:*^I
MSZ7I&H:]?H-3\1ZEI&BVGD:5I=_=EK[4K5)!;^3$TEQ)#%)]6?&[_@F%^W3^
MSE\-M<^+WQF^ ][X.^'?AJ?1K;7/$8\>?"SQ$FGS>(-9L/#VCK)IGA3QQKFL
MR+>ZUJFGZ>DD&G2Q13741G>*,EQ]9_\ !/CX,:E^SM_P6L^'7P-U6^75+OX7
M?%SXQ^$$U9(S"NL:?I7PQ^(\>DZP(" 8/[6THV6HF#GR#<F+<P3<?[H/$UEX
M8OM$O/\ A,K30;SPYISV?B"__P"$FM]/N-$L'\,7UMXCL-;O/[51["U?P]J6
MEV>NV>I3;#I-]IUMJD,UO<6<4\?WGC#](?._#SBWA7!9'EF2YWPWGG#N4\1U
MZF(I8^.:8K"X_,L?1E3R[$TL=2PV'=; X6E+"RQ&78KV5>HYU:=6%J*^#\(/
MH]Y+XA<)\4X[/,SSK).),DXBS?ARA3P]7+Y99A<5@,MR^M"IF.&JX*KB<0J.
M.Q=6.*AA\QPJJT*2A2J49WK/^ /X*?\ !&3_ (*"?''PO8^,]&^#D/@?PWJM
MM'>:/>?%+Q)I/@?4-3M9HA/#<P>&;Z6?Q7;6UQ$T3VMUJ6A6-M=QS1S6LTT.
M^1/FO]J+]A/]J;]C:XT8?M _"O4?"&D^([BXM?#OBJQU30_%/A'6;JV4R26<
M'B'PQJ6JV%EJ9A62YBT76)--UJ6TBEO$TYK6-Y5_N/\ A+_P5@_8F^./[0UI
M^S3\,OB7?^)/'6JRZU9^']<B\-:K;> O$VK>'[2\U#4-'\/^*;N.&+4+E[#3
MM0O-,OQ:1Z%K<5J$T75[^XO-.AO?:?V\/@MX>_: _8__ &A/AAXCL1>QZK\,
M?$^L:&RHCW&G^,/">G3>*?!VJ6I92RS6'B72-,F=8RC7-J+BR=Q#<R@_!8;Z
M3GB7DO&648#CS@S 9%DF<5L%4>7U<MS;+LWPV48_$2PU+,<-B,=BY+%2HN-2
M=55<'"GB9X>MAX+!3?/2^[Q/T9?#7.>#LWQ_ G&6/SW.\HHXVFL?1S+*<PRC
M$YO@</'$5<NQ-#!82+PT:RE"%)TL;.IAHXBE7F\;"/)5_P TVOL/]F3]@;]K
M/]K\SW7P'^#^N^)_#EE<FSU#QQJEQIOA3P+97*?Z^U'BKQ->:7I6I7]J"CW>
MDZ)-JFL6Z20O)IZI-$6Z'_@G-^R6?VT_VLOAQ\%=0FN[/P6[WOC#XF:A82&&
M]L_A]X52*\UN"SN%24VE_KUS+IWA;3KXQ2I8:CKMI>R1R1V[HW]__C[QO\"?
MV)?V=]4\6ZS;:1\,?@A\%_"UK#;:/X=TR.&UT^PCGM],T7P_X?TBV\O[9K&N
M:O>V>F:;;EUEU+6=1CDO;H//<78_8?&WQRQ?AYF&4\)<*911S[C/.H4*M'#X
MB&(KX7!TL7B)83 TWA,)4I8G'8_'XB%2&&PE.O0Y(QC5J.:JT:53\?\ !/P/
MPGB'E^:\6\59O5R+@S):E:C6Q&'GAZ&)QE7"8>&+QTUB\73JX;!8# 8>I3GB
M<74HUE.4I4J:@Z5:I3_BA\<_\$*/^"C'@O0I]=MOA?X4\<K:VYNKK2? WQ$\
M,ZCKL4: &1(-+U>YT.;4[A%R1::.=1NIRI2VAGD*HWY)^(?#OB#PCKFK>&/%
M>AZOX9\2:#?7&F:WX?U_3;S1]:T?4K20Q75AJ>EZA#;WMA>6\BF.>VNH(IHG
M!5T4\5_>[^Q%_P %C_V<_P!M[XMWWP4\+^$_B#\./'$VEZKK?@^V\<Q>'Y+/
MQGIVB1/=ZI:V-SH.L:G]BU^RTN.;6)M)N8WMWTVTOY[;4[A[.2,_G=_P<8?L
ME>&KOP+\/_VQ/"^G:?IGBW1O$6G_  O^)TEK:I!<>*]"UNSNY_!FNZC-#&HN
M=0\+WVE3^'Q=71>ZN=*U[3;,S_9-!LH$^8\/O';CVCX@8#PZ\6^&,%D.8YU"
MG_9>,PE"OA*D*^(A4G@H8FE+&YAAL7A<=4I5,'1Q&$JTGA\8O8UXS:K/#_2^
M('@7P'5X Q_B+X2\38W/<OR:<_[4PF+KT<7"I0P\Z4,;/#U8X/+\1A,3@:=:
MGC*V'Q5*JJ^#;K4)4[T8U_P.^!W_  3%_;E_:1^&NA_%_P""OP+N/&WPZ\23
MZO;:+XCC^(/PIT%;V?0=7O="U9!I?BCQUHFM6_V35=.O+0M=:; DQA\ZW::W
MDBF?D?#?[ '[7OBS]H+Q-^R[H7P5U^_^-7@D:=+XV\,VVI>&[G3/!UEJNGZ;
MJMAJ?B3QE::U/X*TS3+K3]7TZ>WOIO$'D7+W4=G:M/?G[)7]EG_!"X8_X)H?
M P'_ *#OQ@_]6]XVK[:^,'Q,_9E_8S\._$O]H/XIZMX9^%]IX_\ $&@W_CGQ
M5);7E[XB\?\ BO2/"FE^$/#&F66G6$5_K?B#5+3PMX9LK'2]#T:SD@L[.QU+
M5Y+6V637-3D^4SWZ4?'&4\<<:<'8/A7)LYK9?G&<</\ "='+\'FT\PQ&8X3.
MHX+!U,RIPS+$/'PE@:>*E4PV787"5L1C7AXTYX>@ZG+]9D7T7N!\UX(X+XPQ
MG%6<Y-1S#)\GX@XKJYAC,IA@,/EV+R5XW&4\NJ3RW#K 3CCJF&C3Q.88G%T<
M/@OK$JD,17C3YOX6OVH_^"4_[7/['OPMC^,'QDT+P+:>"CK.D>'[JY\/^/-'
MUK4;+5M;$_\ 9]I+IN+2YNV=K:82-I(U%(5CDN)"MK'+.GS#\!_V5/VC/VG-
M5FTCX"_!WQO\2YK29;?4-1T+2FB\-Z1.Z+)'#KGB[4Y+#PKH4LL;J\,>L:S8
MM,IW1!QFOVL_X+-?\%/O@#^V=\%_A!\+?V?-=\4:I::9\2]6\=>.X/$'A;5/
M##VCZ#X<N- \([&O0;?48=2'BOQ'<+%:SS/:MIL3W\-M))9[_P!#/^"9'_!5
M?]E'P'^P/X5TKX[>// WPB\7? 91\.+_ ,(Z9I\47B#QYIME:BY\*^+_  OX
M(\-64^L:]>:WIK)IWBO5[>PF!\7:=JNM>(;RPAUFUN)?T>IXE>,F3>%> XHS
M+@&.:<99EG^(RS^Q:.7YI@ZF5X*=6IA\OQ>+R6G+$YCC/K&)H2IQC1Q.#3IX
MO!55)PDY3_.*7AQX.9QXIX_A?+N/I97P=EN04,S6<ULPRO%T\SQD*=*OF&$P
MF=5(8;+L']7PU=5)2K8?%N-3"8RDXJ45"'XPVW_!!+_@HU/H[:G+X!^'EG>K
M"DH\/7/Q5\)OK#NPR;99[.YNM $T9^5V?7%MR0=D[KAC^?7[1O['G[2W[)6K
MZ;H_[0GPD\1_#N36A+_8>JW4FE:YX7UQX%5[BWT?Q?X8U'6O"^HWUK$\4UYI
MMKJ\FHV,4T,E[:6ZS1EO[-O@%_P7*_8W_:&^./A/X%^%]$^-'AK6O'>L6WAS
MPCXH\9^$?#5EX5U;Q%?2"#2])D?0O&WB'7=.DUB[>&RTRYO]$@M&O)DBOYM.
M1DDD^^OVQ?V</"G[5_[.'Q3^"'BG3+2^?Q5X7U-_"=]<Q1O/X;\>Z?9W%UX,
M\3:=,Y1[:[TG75M9)3%+"+W39+_2KIVT_4+R&7\MH?21\5.#^*,JRWQ4X/RS
M*\KS.="M6C2R_'9;F.&R^O6]A+&X.I5S+&X>O#"24ZE;"UJ4JU1TW1EB,-*2
MFOT_$?1O\+.,N&,US+PKXPS+-,TRR->C1E5S# 9EE^(S"A15>.!QE*EEN"Q&
M'GBXNG"CBJ-6-&"J*LJ&)C%P/\^G]FS]A[]J+]KJ#6[[]G[X5:AX_P!*\,:I
MIND>)=5@U[PEH=CHEYJD4EQ:)=R^)]?T0R;[6&:XQ:B<B.)@<.55O])O0M'M
M/#VB:/H&GKLL-#TK3]'LDP!LM-,M(;*V7 X&V&!!@<#&!Q7\;O\ P0S_ &\/
M@9^RN?'7P2^*R>-8/&7QW^,'PUT3P8^@^'(M5TBUO+WS/"2-XANGU2SN].AA
MU75[4SFVL+^9;59Y$ADD187_ +-Z^"^EEQ#Q3F/&.#R+-\II8#A[(Y8RKPOC
MX8?$TJF=4<QP>3RS'$5:]7$5:&)6$Q5#ZM2>%HX=4DZD:JJRDI+[SZ)W#O"N
M7<'8S/<GS:KC^(,\C@Z7%& GB,-5ADM;+L7F\<OP]*C2P]+$89XO"XCZS56)
MK8AU7&G*DZ<8.+_S[_VBO^"4W[??@6Y^-GQE\5? "XTOX:^&M1\?_$#6_$W_
M  LCX07L=EX0LK_5-;NM8_LO3OB!=ZW<I%I:F[^QVFFSZBX'E1VCSD15ZY_P
M2PO_ /@JYX3\)>/?%W[!7@RQ^('PMO/%@T3QOX<\5ZY\-!X0'CJPT72;[[;!
MHGC3QQX1UVQUH:#J.D176K^'YK:VU.R^Q66HSWSZ3:0V'Z\?MJ?\%J_V,_B1
M^SY^TW\ /#L'Q?7QYXM^&_Q0^%VE/J'@;3;;0QXGU#1]6\.6YN=13Q3/-#IO
M]HL#)=K9R.MOF7R"WR5N_P#!MR /V1?C4!_T<=JW_JLOAK7ZWGOB/X@Q\%N(
M<X\0O#[AJG7PF<9#E>79+GN29H\IS++,1&B_KM;"XC.)UZN(HUDI8>O0Q-"-
M*I",E3<DF?DF1>''A[+QHX>R?P\\0>)JN'Q>39]F>8YUD6>96LVRW,L.ZR6"
MHXO#9/"A2P]>BW'$8>OA:\JM.3BZBBVC\-_^"J%W_P %,O$>J_#+Q;_P4"\+
M6O@C1KQ_$NF?"?PMX>UCX=S^$+"ZM(M&N/%<NGZ3X'\7>++Y=1GCN=%-YJOB
MB]N;VXA%O9V5X;2T-K!^2EM;7%W<06EI!-=75U-%;6UM;1/-<7%Q,ZQ0P00Q
M*TDLTTC+'%%&K/([*B*6(!_K._X.8?\ D2_V1?\ L:/C'_Z:?AW6-_P;[_L*
M>#]1\+ZK^VS\2M!LM>UYO$>I>$O@99ZK:QW5GX=A\/LMMXI^(-I!<1/"^NW.
ML/-X9T&_0K/H::+X@EAS/J=O-:?9\)>+N5\,> .5<?YED63Y7'VN8Y=EO#?#
M.&GEF78C'QSK,L'A,)A*=>MC9X?V\,+4QV88BI4KSM#&8J-.K4<:,_C.+?"/
M,^)_'_-N ,MSW-\TE[/+<PS+B7B;$PS3,L/@)9)EF,QF+QE2A1P4,3[">*IX
M'+\-3IT(7E@L+*I2IJ5>'Y-_"+_@BS_P4,^+V@6?B>U^#,'P_P!%U*"*XT^3
MXJ>*-%\%:M<PRH75Y?"EQ/=>+]+PNP[-:T#37<2*8ED4.4\S_:)_X)8?MQ_L
MP>';[QK\2?@MJ%[X$TJ![K5O&O@35]'\=Z%HUK$VV:\UU/#UY=ZSH&GP@HTN
MIZWI.GZ8@D0&\WB14_MS_;5_;_\ V??V#?#'A;Q!\:[OQ/J&I>-[Z_LO"7@K
MP)I.GZWXPUR+2([:36M4@M-7UGP[H]KI.D&_TZ&]O=2UNR#7&HVEO9I=3/(D
M?K'[-/[2WPA_:^^#^C?&3X.ZO/K?@S7I;_2KNRU>Q6PUO0M:T_9'J_AGQ-I#
M2W,=EJMDL\#SP1W%Y97=E=VFH:?=WVFWUI=S_B\?I.>,6%PF$XRS#@?)WP/C
MLPE@J%>&7YMAL/7E3G44\-ALYGCZ\%BOW-:FL34PE;#2KT:\88;FI5*4/VB7
MT8O!W%8O%\&X#CC.(\<8'+X8VO0GF&4XG$4(U84Y0Q.)R:& H3>%_?4:KPU/
M%T<3&A7H2GB>6K3JS_S*:_1OX>_\$E/^"A/Q4\"^$/B5X"_9YNM?\$^//#FD
M>+/">MK\2_@WIJZMX?UZRAU'2=06PU?XAZ?JEF+NRN(9Q;:C8VEY"'V7%O%*
MK(/K+_@N5^PKX6_99^.OAGXL?"?0H] ^%'Q]CUW49O#VGQ1Q:+X/^)6C7,%Q
MXGTK1K:%$BTG0-=L=5TW7M%TK_46EY_PD=CI26VCZ?8V%E_6)_P3QX_81_8^
M'_5N'P@_]0?1J_7O$SZ0.,R+P\X*X\X'P>58VAQ7C*^'JX?/J&+KO!/#8>M]
M9PKCE^8X!QQ6%QM"KAJLG5JTIJFY4TXRA-_D'AG]'_!9[XA\:\!<<XS-<%7X
M4P5'$TJ^0XC!T%C%B,10^K8E2S#+L>I83%X+$4L31BJ5*K!U%&HU*,X+^#WX
M,?\ !/?]L'X^_$'QM\-?AG\%/$6L:_\ #3Q7K/@CXB7]Y=Z-H_A+P;XJ\/:A
M<Z7K6AZQXTU34K7PL^J:?=V=RIT[3=5U#4+N*+S].M;R%XY'^C_BW_P1:_X*
M#?!_PGJ7C74/A#IOC/0-$TN?6-=/PX\9>'?%6L:596L9EN6/AE;NR\2ZS+;Q
MJTDL7AO2=;=8U>7!BCDD7^O/]IW_ (*'?L8?L(ZC;>#/B3XFMM(\8>(KK4?%
MD_PZ^&OA=-:\2"3Q)J<VJZMXL\1Z=I*V>G://XBU2^O-7GOO$%_9:KXFNYK_
M %*UCU247DR_:WP\\?\ A'XK>!/!_P 2_ 6L0^(/!7CSPWH_BSPMK4$<\":C
MH>NV,.H:=<M;744%Y9S-;SH+FQO8+>]L;A9;2\MX+J&6)/R/.OI2>*^#CE/$
M4>!,MRKA+,I*G@*N9Y?G$X9Q*C"#Q<L+FWUK"T+S]^>&5##U848WC.>/]A5E
M+]:R;Z+7A/CI9MPY/CS,\UXNRR+J8^CE>89-">3QK3DL)'%93]4Q=>T/<AB7
M7Q%*=:34H1P'MZ<8_P"7 002"""#@@\$$=01V(HK]2O^"R_P8\/?!3_@H'\9
M-,\*6(TSP_X]7P_\5[73TC6.WM=1\=Z8FH>*?LBQJD:VESXPA\07L$,:)':I
M<BSC79;J3^6M?W)PQGV&XHX<R+B/"4Y4L-GF4X#-:5&;4JE".-PU/$.A4DDE
M*I0E-T9RBE&4X-QT:/X6XHR#$\+<29[PWC*D*V)R+-L?E56M3BXTZ\L%B:E!
M8BG&3<HTZ\8*M",FY*$TF[IA1117NGA!1110 4444 %%%2*G<_E_C2;2W$VE
MN,"D]/S[5*% ]SZ_X>E.HK*4F_)?UN92DWY+^MPKZI_84_Y/=_8X_P"SJ?V>
MO_5N>$*^5J^J?V%/^3W?V./^SJ?V>O\ U;GA"O#XG@WPSQ$WHO["S?U?_"?B
M#W>%/^2IX:_['^3_ /JQPQ\K444]4[GCV]?\/YU]#I%=OU_S/ &@$]*E"@>Y
M]:<!C@45E*3?DOS]0"BBBI **** "BBB@ HHHH ***4*3].YH!NVK$J0)Z_E
M_P#7IP4#Z]S5^SM/M$B[R5CSSC[S=3@>@XY//L.X3:BFWLB+N3Y8_?\ UM^?
MST([6RN;R01VT+2MQD@81!ZNYPJ#ZD9[9KO=)\#1S,K:C=O@@'R;3"D$X.&F
ME1\CL0L0)ZAQ5C2HXX@$C144(3A1@9[D^I/<G)/<UW&G_>'X?R%>1BL;55U2
M?LUWM>73J[I;]%?S/7P>!HMIU5[1ZNS;4%IV5F]];MI]D7M(\$^&8-@;2XKE
M@ #)=M)<%R0,LR2.803C^")%4Y*J,G/HFG>&?#:N&7P_H:DDJ2-)L 2O)VDB
MWR1D XZ9 /85BZ?]X?A_(5VVG_>7_>/\C7RF,Q&(DKRKU6VH[U)]=^OX'U^#
MPV'C91H48I+I3@NB_N[^>YKV7ACPTQ4-X>T-A@<-I-@>Y];>NRL?"/A0D;O#
M'AX@XZZ+II[#/6VK+L1PA]<?S/\ A7;V'\'^?2OE\7B*ZT5:JMMJDULTN_\
M5CZ?#8>@^7]S1:T?\.']W7X2_9>"O!S!=WA/PRWR _-H.EMZ^MJ:[*S\">!S
MU\&^%#TZ^'=(/7&>MG5.PZ)_N#^1KM[+_P")_I7S6*Q6)3TQ%?5PO^^J:_\
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MU-=?9?!OX0M][X5?#=N>_@;PP>X]=+K4T_JOU_HM=I8]/Q'\Q7S^)S',-?\
M;L9_X4U_[O\ ?/H<+EN7-J^ P3TZX6@^B_Z=F'9?!7X-L4W?"7X9M\X'S> _
M"QXSTYTJNNLO@=\%&*[O@_\ "UN!][X?^$SZ^ND5O6'5/]\?S-=I8=4^@_F:
M^=QF9YDK6S#'+?;%XA?R_P#3P^EPV599I_PFX#I_S!X?^[_T[.>L/@-\#6(W
M?!GX4-S_ !?#OP@>_OH]=A8? 'X$,/F^"GPD/"]?AOX./<YZZ-^==1IXP1[\
M_F:[6PZ#Z)_):^<Q6;9HE*V99@M.F,Q*[?\ 3P^FPV492[?\)F7.]O\ F"PW
M]W_IT<G9?L\_ $L ?@=\'VZ?>^&G@L]"?71*[*Q_9S_9[8@-\"/@TPXX;X8>
M"#V'KH9KK['[X_SW-=MI_P!X?A_(5\WBLXS97MFF8KWFM,=B5I[FG\4^FPV2
MY-I_PDY9T_Y@,+_=_P"G1Q%C^S9^SJQ3=\ O@JW#?>^%G@8]O?0C796/[,O[
M-S$;OV?/@@WRC[WPH\!G^(>N@&NGGU?2]!TVZUG6]0L])TG3K>2YO]1U"XBM
M+.TMT W2SW$S)'&N2%!9@6=E10690?@'XP_M^O"M]H'P4L@&VB%/'VM6@..5
M9I]#\.:C:D$_PQW.OPD??$FBGY):^4S/B3,L+%.IG691D_AA''XISDDD_=BJ
MM[7TN[13>K5SZ[+^&<JQ+7L\DRN2C;FF\OPBA'X=Y.C:_7E5Y-:I-(_0&#]F
M;]F"WA:>[_9]^ T$"*ADFN?A1\/8XD+E44O)+H"HNYV55R1N9@HR2!7#ZIX$
M_P"":TD$EKXH\"_L27L-K+!.=/U3PC\#=2DBG8&.*9-.ETVYF\T0W+8DCMRZ
M6\KN2L+.U?A/XQ^(GCKX@WK7_C7Q;KWB6<W$MU&NJZC<7%I:S3)''(UAIY<6
M&G(T<440BL+:WA6*..-45$51QE?)U>+\]<N:EFV;0L[QE_:>,4NFJY:RY7H]
MI/?<^JI\*9!&/+5R7)ZB:2E"65X*4'HKIJ5%J2TZI>A^[.L_L5_\$H/B_<7]
MI#\)_P!EG4+N]M;>RN;7X9ZYX<\&W$,)<10/:0?"_P 0>'I-+NYI,1_;]/6T
MOKESL>XD8X/PI\<?^#=O]G[Q/8O>? /XL^/OA5KT5K/LTOQG#8_$CPC?W442
M&RB!C'AGQ-HOVJ998]1U%M7\11PI-%<66AYM'M+[X1KW3X:?M+?''X1O;)X)
M^(FOV>F6TUM+_P (]J-S_;GAR1+6W^QK;'1=7%Y96T,ED$M)&L([2X$4%FT,
M\4^GV$UK])D'C#XD\-UH5<KXRS^G&#BUAL7CZN:8%J*Y4G@,T>+P;7+[K_<I
MV4;-.$7'Y;B+P;\+>*:,Z6<\"\.U)5%)/%8++Z64Y@N9J3<<QRI8+&IJ2YE>
MNU=RNFIS4OQ6_:K_ ."='[6'['/]H:I\7_AWYG@.TU6PTFT^*?@[48?$OP^U
M:XU3[:-.:#4(TM-9TC[9)I]W#%:>*]"\.ZFLHM1-81+J>EM>_#E?Z!7P%_;^
M^%GQATZS\"?&"ST_P=XRUZ.30KZVO-.>Z^''BHZH[V0T^WN+RXU5]-CU"VE:
M&\T[Q5LTTB3[+'K.H/<" ?EQ_P %&/\ @AEHOB*#Q#\:OV++'3_#6MV6GOJ.
MN_L\P6TL6B^(Y;9+FXO[_P"&FI27LD>A:U-&L$=OX%GLTT'496E.C:IH,L5M
MH^I?V3X6?2JRW/Z^'R7Q H8/(L=6=.EAL_PCJQR;$59<L(T\PH595JN5U)RU
M^M>VJX!N4G6^H4J:<_XD\6_HA9GP_AL1GWAMB<;Q#E]"-2MB^',;[*>>86C'
MFJ2J9;B*4*-+-J5.'N_4_84<Q2A%4?[1K5'&'\GE* 3P*N7NG7VF7UYINIV=
MWINHZ==7%CJ&GWUO-:7UC>VDSV]W9WEI<)'/:W5K/')!<6\\:30S(\<B*ZLH
MA  X%?V$FI)2BTXM)IIIIIJZ::T::U36C1_$[3BW&2<91;4HM---.S33U33T
M:>J8U4 Y/)_E3Z**8@HHHJE%OTZL HI0I/3\^U2A0/<^O^'I5^[#S?\ 7W?U
MZDRDEYOM_GV&JG<_E_C7[??!OP:G@+X:>$O#9ACAO;?2X;S5@D$L#/J^IYO]
M1\Y;C_27DAN;A[4-.L<@BMXHQ;VL21VL/XW^!-/.K>-_!NE!58ZGXJ\/:>%=
M4=&-YJ]G;!721DC=29,,KNJ,,AF522/W>K^%_IG\08B.&X*X8IU.7#8FMF>>
M8RFI?'5PD*&!R^3C;:$<7F-FY--S6BY$S^]_H.\/8>KBN.N+*U-2Q6%HY5D&
M!J..E*CC)U\PS*,9-OWJDL'EE[13C&%N9J;2****_@H_T+"BBB@ HHHH ***
M* "BBB@ KUWX)_!7Q=\>O&A\">"KC1+;61I%_K;3:_>75CIZV>G26T4X,]G8
M:E.9F>[A6)%M2K98LZ!<UY%7Z$?\$SO^3D)O^R=^*/\ TNT&G%7E%/9M)_-@
M>9_&K]BKXN? ?P4WCSQIJ7@>ZT5=5L-',7A_6-7OM0^U:B)S P@O?#^FP^2H
MMY/-?[3O7*[8WR<?(=?T(?\ !2K_ )-JE_['SPK_ .B]5K^>^JJ14965[66X
M!13XXY)I$BB1Y9976...-6>221V"HB(H+.[L0JJH+,Q  )-?I+\*/^"9WQ4\
M;:+::[X\\3:7\+X=0ACN+71KG2;CQ'XGBAE57C;5-+BO]&LM+D>-@WV275I;
M^W;=#?6=G.K1+,8N3M%7 _->BOTG^+G_  31^)_@/P_?>(_ GBBP^*,6F1/<
MWFAVNAW7A_Q/-;1_-))I.F'4=<M=5EAC#2/91ZE#?3JOEV%K>W+I;M^<$-I=
M7%W%8V]M<3WL]PEI#9Q0R274UU+((8[:.W13*]Q),RQ)"J&1I"$52Q HE&47
M:2M_7=: 5Z*_1/X7?\$U_C7XVLH=5\::CHOPNL;@*\-CJR2:WXF:)QN6:71=
M-FBM+,$8!M[_ %FTU"-B4GLH2M>H>)/^"5'BZRT^:?PI\7="U_4H[>22+3]:
M\*7OAJ&XN$1F2W2_M=<\2"/S6 19I;545F!D"H"PKV<[7Y7^%_NW_ #\G**Z
MCQIX,\3_  \\4:QX,\9:3<:'XET"Z%IJFF7+1/)!*T4=Q"Z36\DUO<V]S;30
MW5I=6TTMO=6TT5Q!+)%(CGZ,_9R_8[^)G[1:7&LZ5+9>%/!%E=-9W'B[7(KB
M6&[NX]OGV>A:;;[)]7N;8.IN7,]EI\#$P2:@MT/LYE1;=DKOL!XC\'_">F>/
M/BM\-_!.M27D.D>+?''A?PYJ<NGRQ07T=AK.LV>GW;V<T\%S#%<K!<.8));>
M>-) K/%(H*G];OB[_P $[?@5X$^%7Q)\;:-K/Q)EU?PCX%\5^)-+BU#7]!GL
M9-0T31+W4;1+R&#PK;32VK3V\:SQQ7$$CQ%E2:-B'&%X2_X)N>+_ (8?$KX9
M>/?#_P 2-%\9V?A/Q]X+U_6M-O= N?"M^=+TWQ#IUUJLNG.-7U^TNIK2TCFN
MHX+B>R:Y2)HHF^T-%%+^A_[2/_)O?QQ_[)+\0O\ U%-5K>%.T9<\=5JKZ]/+
M0#^5FBN]^&OPS\9_%SQ?IG@;P'I$FL>(-3\V1(O,CM[6SL[9/,N]1U&]F98+
M*PM(\--/,PW2-%;0)-=W%O;R_I?HG_!*3Q)<6$<OB+XS:+I.I-"C26>C>#+[
M7K..<J#)$NH7GB'P[-)&C959O[.1G #F%/NUC&$I?"K_ ')?>[ ?DG17VC\?
M/V&OBY\"=%N_%\\^C>-/!%BZB_U_P^]Q#=Z/%+/%;6T^MZ+?QQ7%K%<3S)$L
M^G7&KVL#LHN[FW,D0?XNI-.+LTT_,#]1O^">?[.'PE^+^D^._%_Q(TF/Q9=>
M']9T[1-+\.W-[>VUA8Q7%B;Z35[RWL+BU>]DO'9K.SCN97M(A97C-;R3/%)!
MR/\ P4)_9Z^&?P2UWX>ZO\-K#_A'K7QK;>)8]4\-+?WM]:6USX?DT1HM3T\:
MA-=W=M%>KK4D%S;F[^R)):0&R@BWW(KG/V)_@]\:OB!)XW\3?!OXMQ_"Z[T"
M31M*UCS$OIX]9BU--0NK59[.&&XL;E+-K&4Q_;;>1X7G+6Y3?+NYS]M/X5?%
M_P"'/B[PIJ7QA^)T?Q/UCQ5I.H-IVI1F^C&EVFC75NDVGQ6-S!!:6-JTNHK<
M10Z='%"\\EU++"LK&2;33V7P:_SZ=U\]=NW;R#XMKT;X/^$],\>?%;X;^"=:
MDO(=(\6^./"_AS4Y=/EB@OH[#6=9L]/NWLYIX+F&*Y6"X<P22V\\:2!6>*10
M5/MW[.7['?Q,_:+2XUG2I;+PIX(LKIK.X\7:Y%<2PW=W'M\^ST+3;?9/J]S;
M!U-RYGLM/@8F"34%NA]G/W'X2_X)N>+_ (8?$KX9>/?#_P 2-%\9V?A/Q]X+
MU_6M-O= N?"M^=+TWQ#IUUJLNG.-7U^TNIK2TCFNHX+B>R:Y2)HHF^T-%%+,
M82=I<MU==MK]MW]P&[\7?^"=OP*\"?"KXD^-M&UGXDRZOX1\"^*_$FEQ:AK^
M@SV,FH:)HE[J-HEY#!X5MII;5I[>-9XXKB"1XBRI-&Q#C\2Z_JF_:1_Y-[^.
M/_9)?B%_ZBFJU_+7H^CZKX@U73M#T/3KS5M8U:\M]/TS3-/MY+J]O[VZD6&W
MM;6WA5I)III&5$1%))/IDU=:*BXJ*M==/4#-HK]2O /_  2V^(>NZ3;ZAX_^
M(>A^ [ZYB27^P]-T27QE?68<9\C4;F/6= TV.Z0X#II]YJEN,_+=.00/+?CU
M_P $^_BC\&_#UWXQT+5['XE>%M+C>?6I='TR[TS7]'LHU9YM4N]!DN-22;2K
M9%W7ES8:G>36<>^YNK6*QAGNXH=.:5^5V_'[M_P ^!Z*]@^!7P?U3X[?$C2/
MAMH^KV&A7^KVFK7<6I:G#<3V<*Z1IMQJ4J21VH,Q:6.V:.,J,!V!;Y<U]8>.
MO^";7QJ\+W7A6R\-ZEH?CJ?Q+K$FE7,NF0:AIUAX:@CM7NVUC7[^_C\FUTP)
M%*F]!+<RSB.UM+:ZO+BWMY$HR:NDVKVT[Z=-^J_I,#\[Z*_6N'_@E)XE;2%F
MG^,VA1Z\8U+:;#X.U";2%E*_.BZT^O6]ZT:MPLIT!&9?F,*$[1^>GC_X'^.?
MAE\4X?A+XPMK73_$%WJ>E65A?1S/<:/J5EK5ZMEIFN6-TD7G3:7<N68EK>.\
M@>&XM;FUAO;>:VC'"4;-Q:O\_P MOF!UOP'_ &7?B9^T5;^)KKP!)X;@@\*3
M:3;ZE)XAU.ZTT22ZPFH26R6?V;3=0\XQ)ITK7._R?+$MOM\SS&V<=\:?@MXP
M^ WC&/P/XWET:76I-'L=<5M"O9[^R^Q:A->00 SW%G8R"</93>9'Y!55*$.Q
M8A?WS_8Y_9KUK]FSP?XKT3Q%KFC:_J_B;Q%!JS76AQWJ6D%C::9!9VUJ[7\%
MO-)*EP;V4L(E0),@'S;@/&OVK_V'_%_[0OQ1B\?:'XV\-^'[.+PMI.@?8-6L
MM4GN3/IUUJ=P\_F6:-$(I!?HJCEP8V)&"*U=%\B:3Y^JNK:_Y>O>_D'P;^P#
M\"?AS\;OB#XM7XCVIUK3O"/A^RU*Q\,_;;NQAU6[U"_:T-Y>R6$UM=S66EK$
MH>UCN(8YKF^M#<&6!)()O;_^"@O[,/P?^%/@/PO\0OASH<7@_4KOQ?;>%]2T
M:TO[^?3=6M;_ $?6=22]AL[^XO3:7FGR:.D9^PO:6DMO=RM<Q27"6['Y:_9+
M^$/Q2\<_%?Q)I?PO^(T7PW\7>"-(U"[N-?B?4&BN[:/5K71;NP5+6/-U;7$T
M\<S07UN]M*D*-)")4CV^K?MF_!+X_P#A33/ _B7XQ?&:V^)L.I^(#X5T:T1+
M^R@T:[N[1[MKN+3A:6VF(+F*R,=[=00K>S&&U64W"(ODROX;]R_][335?/\
MS]+@>,?LG?LN:M^TMXLU.VEU27P[X)\*QV-SXIUR&W%Q>R-?2R"ST71DE4VW
M]J7T5M=R_:;GS+;3K>!KF>WNG:VLKK];H?\ @G!^S%%8K:/HWBZXN!&$.J3>
M+M06^9@NWSFCMXX-,\PGYR%TY8MW B"?)7>?L>?LZZU^S?\ #_Q#X7\1ZSHV
MNZSKWBZ?7WOM#6]%G'8'1M'TZTLF-_;6L[SPW%E?SLXB$9CNHPOS!Q7!?MC?
M"7XX^,MWCWX=_&;4/AWX5^'G@/6M8O- T?5O$NBZAJNL:8NK:OJ%]]JT&XM8
MY7GTNWTZPL?MDC_9)8[IXQ&ES*9-(P487<.:6C:=M-?NT6_?KIL'F/[,7['G
M[-?B'1_'GB.\T2?X@VL'Q+\<^$M!?Q'JUU+_ &5H7A;5Y='LP\6C-I%G<7VJ
M)#_;!OIK4RK97VGI;I;.D[S_ )]?MS?!7P/\#OC-:^'OA^DEEX?U_P (Z9XI
M70YKZYU Z%=76IZUI<]E!<WCSWK64PTB.]MEO;NZN8VN9X_,%NEL*]K_ &-_
M@E^T7XN\ ZOX[^$/QTB^'.F:EXFO]*U31KN&^U&.^U+3+6QF?5)K26VO=.:>
M6+4(X?M7DB[=(MDLC1K&H^7/VK?AU\0?AI\7;[2/B=XW'Q"\6:MHVE^(;GQ-
MYU_,]Q;7INK2VMI!J*)) +,:>\$%K /L=O:+;QVRQ1CR(HE_#C[EM?B5K>O?
M7ST^X#YLHKZ<_9]_9.^*?[1,US=^%K:RT7PGIUS]DU+QEX@:>#2([L(LKZ?I
MT5O#/=ZOJ21.DDEO:1?9[420?VA>60N;<R_:VH_\$HM=BTUY=)^->DWNKB-B
MEEJ/@:\TO37EVY5'U2V\3ZO=1QEN&E&D2L%.X0L1M,*$Y*ZB[?=]U]_D!^1M
M%>C_ !3^%'CGX,^+KWP5X_T:72-8M!YUO*I,VFZOI[R21V^K:-?A5BO]-NC&
MXCF0++#*DMI>0VM];W-K#W_[/_[,_P 2/VB]:O+'P=;VFGZ)I!A&O^+-:::#
M1-*:<%HK16@BFN-0U2>-6>#3[.)W"!9;R6SMG6XJ;.]K._:VOW > 6L2S7-O
M"Y(66>&)BI 8+)(J,5)! ."<$@C/4&OWLG_X)B_L\Q032+KGQ3W1Q2.N?$?A
MTC*(S#('@\'&1S@CCO7S?K__  2P\9:3IHU+PI\5="\3:U:(+H:+JGAF[\-0
M7<\!$JV=KJT>N:\@DGV^5#+=V5K )60SR01%Y(_VEN_^/2Y[?Z/-_P"BV]*W
MIT_BYX]K7^=]OD!_'O17KWP1^"GC/X^>.K;P'X*2SCO6L[C5=3U/4Y98=+T3
M1K22"&YU*_D@AN+@QBXNK6T@AMX)9KB[NK>)51&DEC]R_:(_8B^)/[/?AJW\
M:W^LZ#XN\)M>6VG:CJ.BK>VMWHMY>82U.HZ??1+_ *#=W!-K;7MK<W(^T&..
MZAM&N+<2X<LFN:SLNH'Q?1112 **** "BBB@ HHHH **** "BBB@#Y1_;"_Y
M)GH?_8]:9_ZC_B>OS=K](OVPO^29Z'_V/6F?^H_XGK\W:_TY^BM_R:7"?]CW
M.O\ T]2/\@_IF?\ )[<?_P!D[P__ .HU4****_H\_E,**** "BBB@ HI0">!
M4BH!R>3_ "H)<DO7HAJH3R>!_.NM\6>"/%O@._L]+\8^'M4\-ZAJ&EV>N6-G
MJUJ]K-=Z/J!E%CJ=NK_ZZRO/(E-K<H6BG1"\;,A#'EZ^\_\ @H5_R57X8?\
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M\OW_ .7_  1  .G^?K2T45!F%%%% !1110 4444 %%%% !2@$]/\_6G!">O
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M\_R"BBB@R;OJPHHHH * ">E.52?8?S^E2@ =/\_6@!H0#KR?TI]%% !1110
M4444$RDEYO\ +U"BBB@R;;W"BBB@1T+>$_$R>%H_&[Z#JJ>$)M;/AN+Q(UE.
MNC2Z\+.34#I$=^4$#WXLHI;HVZN7$,<CD81L<]7VOJ0)_P""?7AX#_HZ:?\
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MTX5,+C>*L]SKA^%:6GUF&,E7S7 T6WS1J-PAF^%5/E]C5P^88A256<6?8?\
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M.UCX16OCFVDN-(T^ZTG^W8/$LBZVCRZ%/I<UA]N 9M+DLF@_T8PU+H'[<O\
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MP<]Y]JC\'17W@DWL$!F$ITU/%$_A*:=[%4S;1O)I3ZBMOM,FH2W(-RWY/_\
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M-\,:)9[Y2XAALML B\^Y,W[/?\$+_P#E&C\#/^P[\8/_ %;WC:OQ _X.2_\
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M^#D7^W/^&N?@K]H^T?\ "-_\,Y:5_9&[S?LG]M_\+,^)'_"0^3N_<?:?L/\
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M$68?^K")_I+]!S_DE..?^RAR[_U6L****_C _N,**** "BBB@ HHHH ****
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M7A[7?BK8:/ [,[PZ*NCZU+H\32-EI&CTR6T1I&YD(+G&[%?K=^T/\8H_@/\
M"?Q)\26T5_$$^D'3[.PTI;E;.*XU'5[^#3;)KNY*2/#90S7"S71ABEG>*-HX
ME5W$B?CG^QWX]U/XH?MRVWQ!UFUL[+4_%B>/-7N[.P$PLK62?PMJ*K;VWVB2
M:<PPQHD:&65Y"%RS$DU^C/\ P41_Y-9\9?\ 8<\&?^I/IU9P=J<VOYG;[ET
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M\6_]E@\0_P#J&> *^.O^"I/_ "7_ ,'?]D>T#_U-?B!52E+V2=]7:[ ^W?\
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M'G\IA112@$\"@!*>J$\G@?SIRH!R>3_*GT&<I]OO_P" ( !P*6BB@S"OO/\
MX*%?\E5^&'_9O'PJ_P#1.LU\&5TOBCQEXL\;7>GW_B_Q%K'B6^TO1[#P_I]Y
MK5]<:C=VNBZ8)1I^FQW%R\DWV6T$TH@C9VV!V /-?-YADE;&<3<-Y["M2A0R
M3!\08:M0DI^UK2SB&61I2I-)P2HO 3]HIM-JI'EO9GUV5<18? <'\6\-U,/6
MGB.(L=PQB\/B(.'L</'(:N;SKPK*34W*NLRIJDX*23ISY[)Q9S5*%)Z?GVIZ
MIW/Y?XU)7TA\B-"@>Y]?\/2G444 %%%% !11101*:6VK_ ****#)MO<****
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M$)Z\#]:E QP***AR;W^X HHHI %%%2*G<_E_C0 T*3[#U_P]:E"@=/S[TM%
M!1110 4444";2W"BBB@RE)OR78****"0HHIRJ3[#^?TH : 3TJ4(!UY/Z4X
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M.G&=JB2?,DPHHI0">!7T9\8)3U0GD\#^=.5 .3R?Y4^LY3[??_P#.4^WW_\
M $  X%+1169F%%%% !1110 4444 %%%% !2A2>GY]J>J=S^7^-24]%V;_#Y]
M_EIZ[$2G;1:^?3_@C0H'N?7_  ]*=112,F[ZL**** "@#/ IP4GV'K4H '2@
M!JIW//MZ?X_RI]%% !1110 4444 %%%% !11103*27F^P44H!/ J14 Y/)_E
M09-M[C50GD\#^=2  =*6B@04444 %% !/2I0@'7D_I2<DM_N 8JD^P_G]*E
M Z?Y^M+163DWZ=OZW ****D HHHH$VEN%%%%-)O8RE)OR7];A1116D8):O5_
MA_7]6)"BBGJG<\>WK_A_.J;2W : 3TJ4*![GUIP&.!164I-^2_/U ****D H
MHHH!NVK"BBB@RE.^BT\^O_ "BBB@@***4*3].YH U= _Y#NB_P#86T[_ -+(
M:^GOVX%!_:B^)Y/3_BBN/^Z>>$J^5(F>!TEB=XY8W62.6-F22.1&#(Z.I#(Z
M, RLI#*0"#D UM>(_$NO^+]9O/$7BC6-0U_7=1^S_;M6U6ZEO+^[^R6L%C;>
M?<S,TDGD6=M;VT6YCLAACC&%4"OGJ^35JO%>5<0*M36'P'#V?Y-4H-2]M.MF
M^9<-XVC6@TN3V=*&25X5%)J3E6I.*:4VOM\'Q3AL-X<<0\$RPM>6,SGC?@WB
MFCC(RI_5J.&X:R'CO*<3A:L6_:NOB*O%F$JT)0BZ:IX7$*HXR=-2Q****^A/
MB HHH )Z4 %.52?8?S^E/" =>3^E/H(<F](_?T_'^O(0  8%+110-12\WW84
M44 9X%!04X*3[#UIZIW//MZ?X_RI]9RGT7W_ .1G*?1??_D( !TI:**S,PHH
MHII-[ %%%%:J*7F^X!1115 %%%% !2@$]/\ /UIP0GKP/UJ0 #I42FEMJ_P
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M !_E3Z** "BBB@ HHHH *4 G@4Y4)Y/ _G4@ ' H :J <GD_RI]%% !1110
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M.HH ****:BWM]_0 HHHK5*,5=_>_T$VEJPHHHJ)3;VT7XF<IM[:+\0HHHJ"
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MB#.J&?U9SJ5LZIYGC%FM:=5*-5U\?[;ZS7]K%*-55:DU5BN6HI1T/V$^)/\
MP73_ ."AOQ(\.:OX6?X@>!O!NEZ[IUSI.JGP=\-/#,5Y<Z=>V[VM_;+>>)H/
M$\UJ+RWEDBEGLC;W4:N3:SV[[6'X]T45/#W"7"_"=&OA^&>'\HR&EBITZF*C
ME> P^#>*G24HTI8F=&G&==THSFJ3JRG[-3GR<O/*]\0<6<3<5UJ%?B7/\VSV
MKA83AA99ICL1C%AH57&56.&A6J2A055P@ZJI1A[1P@Y\SA&Q6IHNLZSX=U;3
M]>\.ZMJ>@ZYI%W#?Z5K6C7]UI>JZ9?6SB2WO=/U&QE@O+*[@D >&XMIHYHG
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MNHZE<2,SW5Y.Q!'B'QY_X*O?M[?M%Z!?>$/'WQ[UO3?!NI[TO_"WP^TCP_\
M#K3[^VE5DFT_5-0\(:7I?B+6M*G1ML^DZWK>HZ;, IEM78;C^=5%?&8/PP\.
M\%CUFF#X&X3PV/C55:GBZ60Y9"K1K*7,JV'MAK4*JE[RJ4(TY\UWS7;/L<9X
MG^(F-P#RK%\<<58G 2INC4PM7/LRG2K46N5T<1?$\V(I.-E[*M*I3M96TL>G
M?!KXR_$G]GWXF>%OC#\(?$A\(_$;P5<7]UX9\1#2-"UTZ;/J>D:AH5\_]D^)
MM+UG0KT7&E:I?VA34-,NXT%P9HD2XCBEC^Z?&/\ P6/_ ."D'C[PCXI\"^+/
MVC6U3PMXT\.:WX3\2Z8GPD^!6FOJ.@>(],NM'UFQ74-*^&-CJE@UWIUY<VXO
M--O;._M3)Y]G=6]PD<J?F117N9IP?PEGF-P^8YWPOP[G.8X2G3I87'YKDN6Y
MCC<-2HU9UZ5/#XK&8:M7HTZ5>I4K4X4ZD8PJU)U(I3G)OQ,KXOXLR/!XC+<D
MXGXBR?+\74J5<5@,JSK,LOP6)JUJ4*%6I7PN$Q-&A6J5:%.G1J3J4Y2G2IPI
MR;A",5W7PQ^)?C;X-_$'PA\4_AOKC>&O'G@/7++Q)X4UY;#2M5.E:UITGFVE
MV=-URQU/1[]8W^_::EI]Y93H6CN+>6-F4_HM?_\ !:O_ (*;:M87VF7_ .TM
MY]CJ-G<V%[#_ ,*:_9_B\ZTO(7M[F(2P_"J.:/S(9'3?%)'(F=R.C@,/RS5.
MY_+_ !J2ISKA/A+B+$4<5G_"_#N>XO"T_8X;%9SDF69G7P]+G=7V5"MC<-7J
M4J?M)2J<E.48>T;G:[;+R7BSBSA[#U\+D/$_$6187$U/;8C"Y/G>9990Q%7D
MC3]K7HX+$T*=6I[.,:?/4C*?)%0ORI(0*!T_/O7U]^S-^WE^UA^R%)<P_ ;X
MP:]X5T&_N!=:EX+U&#3/%7@:_G+!IKEO"?B>RU;1[#4+I56*YUC1[;3=:EA5
M(SJ(6- OR%17;FF4Y7GF"JY=G66X'-LOK\OML%F6$H8["5>5WBZF'Q-.K2DX
M/6$G%N$DI1::3//RS.,SR+&4LQR7,<=E684+^QQN6XNO@L52YE:2CB,-4IU8
MJ2NIQ4K35XR33/V;\0_\%[?^"C.M::MCIWC[X>>$[D*5;6/#WPK\*7&I.2 -
MS1^*+?Q+I2L,$CR],C +'@@*%_+GXP_'+XP?M >+KGQW\:?B/XM^)7BNY\Q1
MJOBK5[G438V\DAD-AH]DS+IVA:5&YS!I&BVEAIEM]VWM(E %>545XF0\"\&<
M+59XCASA7(,EQ-2,H3Q6795@\+BYTY.\J4L53HK$.DVK^R=3V:Z11ZV?\=<9
M\4TH8?B/BG/\ZPU.2G3PN8YKC,5A(5(JRJ1PM6M+#QJI:>U5/VCZR9]]? K_
M (*@?MS_ +-7PTT3X/\ P4^.)\%_#GPY<:Q=:+X=/PU^$'B064^O:M>:[JSC
M5O%O@#7M<G%WJNH7EWLN=3FC@,QAMDAMTCB3P[]I+]K#X_\ [7?B[1/'7[0_
MC]OB%XI\.>'(O">BZF?#'@SPHEEH$.IZCK"6*Z?X(\.^&M+F;^T=6O[AKRYL
MIK^03)!)=-;V]M%#\[45U87A'A3 YM6S_!<,</8//<14Q%7$9UA<ERW#YM7J
MXQREBZE;,:.&AC*M3%2E*6(G.M*5=RDZKDV[\N*XNXLQV4T<@QO$_$.,R+#T
M\-2P^2XK.LRQ&4T*6#48X2G1RZMB9X.E3PL81CAH0HQC048JDHI*Q7W7^RC_
M ,%(OVN_V,].N_#?P5^)1A\#W]W+J%Q\/?%VDV/B[P;'J,Q+3ZAI>G:FC7GA
MZ[NF)>_D\-ZAI U218Y-46]>"!HOA8*6^GK4H4#I^?>NW.<CR;B' 5,KS[*\
M!G&75I1E4P6982CC,-*<'>G4]E7A."JTV[TZL4JE.7O0E%ZG%D^=YSP]CZ>:
M9%FF/R?,:*E&GC<MQ=?!XF,)I*I3]K0G";I5$DJE*3=.I'W9QDM#])/VD?\
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M'FB';'YMS]MS]JGX>_M*6WPVA\"Z-XRTIO!T_BR74SXLT_1+%9UUZ/PXEF+
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MXO\ _2."O@.OO_\ X)JKC]I[2B>O_"&^+O\ TCMZ_.O%UI>&''E^O"V<)?\
MA)4/U[P!_P"3V>%G_9<</?CF%%'P$%)]AZU* !TI:*_0')OR7;_/N?D(4445
M(!1110)M+=A111092FWHM%^/S"BBB@D***>J$\G@?SH : 3P*D5 .3R?Y4X
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MMJPHHI0">!092GT6GGW_ ,OS$IZH3R>!_.G*@')Y/\J?00( !P*6BB@ HHH
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MW^?<****DD****N,'N]NW7_@?F 4445JE;1 %%%% !113U0GD\#^=)M+5@-
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M&U(J=S^7^-/"@=/S[TM !1110 4444 %%%.52?8?S^E " $\"I%0#D\G^5.
M Z?Y^M+0 4444 %%%%#:6XFTMPHHHK*4V]M%^)G*;>VB_$****(P;U>B_,@*
M**4 GI6EDEV0"4]4[GCV]?\ #^=/"@>Y]:=42GT7W_Y  &.!11168!112@$]
M/\_6@!*>$)Z\#]:>J@>Y_E]*=09RG_+]_P#E_P $  .E%%%!F%%%% !1110
M4444 %%%% !2A2>GY]J>J=S^7^-24$2G;1:^?3_@C0H'N?7_  ]*=1109-WU
M84444 %* 3TIRIW/'MZ_X?SJ4#' H :% ]SZTZBBIE)+S?;_ #[ %%%%9-N3
M_)( HIP4GV'K_AZU*% Z?GWJXPZO[O\ /^K@?AA1117[8?Z4!2A2>GY]J>J=
MS^7^-24 -"@>Y]?\/2G444 %%%%:1AU?W?Y@%%%%-R4=%OV6R]2922\W^7J%
M%%%9MM[F3;>X4444A!13@I/L/7_#UJ4*!T_/O0 Q4[G\O\:DHHH **** "BK
M%I:7>H7=K86%K<7M]>W$-I965I#)<W=W=W,BPV]K:V\*O-<7%Q,Z10PQ(\DL
MCK'&K,P![_\ X4Y\7?\ HE?Q'_\ "'\3?_*NL*N*PV':C7Q%"BY*\55K4Z;D
MD[-I3E%M)Z7770VI8;$5TW0P]:LHM*3I4JE11;V3<(NS?1/<\XHKT?\ X4Y\
M7?\ HEGQ'_\ "'\3?_*RI%^#?Q;')^%OQ&)_[$CQ-Q_Y3*R_M'+_ /H.P?\
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M^/KU:<HN24G%PFG&]G:UU<[73^B_3^JUV=E_\3_2N,T_HOT_JM=G9?\ Q/\
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M=\16"0S2V5R]O/'-;7"EK>]LKVSFN;'4+*<*PBN[*YG@,D<T)=9X9HX_TO\
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M ****H HHHH *4 G@4Y4)Y/ _G4@ ' J)32T6K_(!JH!R>3_ "I]%%9MMZL
MHHHI %%%%!,I)>;[!110!G@4&3;>X4X*3[#UIZIW//MZ?X_RI] A  .E+110
M 4444 %%%% !10!G@5*J=SS[>G^/\J!.26_W=1@4GV'K4H '2EHH,G)OR7;_
M #[A11102%%%%)M+< HHHK/WI^2_K[_Z]0"BBBM%%+UZL HHIZH3R>!_.F)M
M+5C0">!4BH!R>3_*G  <"EH,Y3;T6B_,****" HHIRJ3[#^?TI-I:L!H!/2I
M0@'7D_I3@ .G^?K2UG*;>VB_$ HHHJ "BBB@ HHHH,I3Z+[^OR[?UL%%%%!
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M6[TK6M/N]+U*U9U#HMS8WT,%U 61E=1+$I96##((-?Z7/P>^$?[./[%OPO\
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M]%%*%)Z?GVKW3P!*D5.Y_+_&G!0/<^O^'I3J#*4^B^_K\NW];!11100%%%%
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M$,:J56KA*DK1Q-I4FVDE6IZ<OK4@[+75PC%*\CXBHHHK\[/T(**** "BBB@
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MVF\%RVNX]0!-=WFP<@Y?[I7YG)J5.-2VL6G;TE9KT>X'ZV^#KCP==^&],N_
M$OAN?PC<QS3:/<>$6TQ_#T\37,PN)=-DT?.G2(UVMP)GMB5-P)=Y,@>OG3X[
M^+/V;X/#7Q2T;Q+XA^"T7CT^#_$MK<:9K>I>"5\6G5KCPU<_V;;RVE]*-7.H
M3++9_8HW3[2X>V\D'='5O]B?_DUKX/?]@'4?_4DUNOP^_;<_Y.G^,'_8;TG]
M?"^A8ISG:$79>\EIVTOI^@'Z<?\ !.#P=X1UW]GN[OM<\*^&]9O1\0_$D O-
M5T/3-1NA!'IOA]HX1<7EK-*(D9W9(P^Q2[E0"QS\*?\ !1S0]$\/_M#Q6>@Z
M/I>B6DO@#PU=2VND:?::;;27+WNN0O</!9PPQ/.\4$,32LAD:.*)"Q6-0/T.
M_P""9?\ R;C>?]E(\3_^FSPY7P+_ ,%,O^3C[;_LG/A?_P!./B"IFE[&.BVC
M^2 _8'X9_"WX=:[\%_A_;:CX(\*2MK/PP\*07UV/#NBB^D.H>%+".YN1=M8O
M+]K<S/*+ABTGG'S"6;.;GPN\#? ;X)/IOPK\#2>"]&\5FP-TVE7&JZ)+\1/$
M,44+37&L:G')*FOZINC\R=YEMQ86D'[JS@M+&**"/L?@W_R2'X5?]DW\#?\
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M#?\ P4_MX8?VAO#\D2!7N_A1X<N+AAUDF7Q-XTM%=O<6]K!'_NQBOVQ^$/\
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M;_=U&!2?8>M2@ =*6BJC%OR7];?Y[&3DWY+M_GW"BBBM4DMB0HHJ14[G\O\
M&AM+<!H4GV'K_AZU*% Z?GWI:*RE)OR7;_/N 4445(!7WU_P37_Y.>TK_L3?
M%W_I);U\"U[;^S]\;=4_9^^(MM\1='T/3_$-[;:3JFDKIVIW%S:VK1ZI$D4D
MQEM090\00%% VL2=U?'>(63X_B#@?BO),KI1K9CFN19C@<%2G5IT85,3B,/.
MG2A*K5E&G34I-)SG*,8[MI'Z%X3<0Y5PGXF\!\39Y7GALHR+BG)\TS+$4Z-7
M$U*.#P>,I5J]2%"A"I6K2C3C)JG2A*<FK1BV>)4445]B?G$IMZ+1?F%%%%!
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M27F_ZW"BBB@R;;W"BBB@044H!/3_ #]:E50/<_R^E)R2\WVZ@,"$]>!^M2
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MS]:6B@FSE\6BZ+_/^K^AK:!_R'=%_P"PMIW_ *60U]+?MN_\G/\ Q._[DO\
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M;[?Y]@HHHH,G)O?[N@4444""BE )Z?Y^M2JH'N?Y?2@!@0GKP/UJ4 #I110
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MYDVWN%%%%(044X*3[#U_P]:E"@=/S[T ,5.Y_+_&I*** "BBB@ HHHH **4
MG@5(J <GD_RH :J$\G@?SJ0 #@4M% !1110)R2W^X_TXOV.O^31?V6/^S<?@
M?_ZK+PQ7\-W_  6Q_P"4GG[4'_7W\)O_ %1'POK^Y']CK_DT7]EC_LW'X'_^
MJR\,5_#=_P %L?\ E)Y^U!_U]_";_P!41\+Z_P [?HK_ /)Z^._^R=XD_P#6
MLR _T"^E$[^"_ S[\0<.?^LIGK/S,\*_\C/X<_[#VC_^G"WK_52K_*M\*_\
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M\/WL%CJD,VF7T%_;/!-=V>HV3J9H%62*\L+N!D8L(UF2*:/*^"GPK^&OP/\
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M+.YT;5=#N;J=8;"?5-(EN;Y;>SN;IX+6WOK+5;T)>RQ07"6QEMGG_8W]E/\
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M9^RZ2IS(=9N-.^SC[2(2/%A^T/\ ']0%7XY?&%54 *H^)GC4  #   UO  '
M X K[)_X)C^&/"/B'XS>+-8\0P6FH^(O#'A%=6\*6U_#'<_9[JYUBTM-3U^V
M,N[9J.FQRVMG!.%:2)-8N)$9)51UMS52=.RM:77U3_0#]?/C+\+?%GQ+M] '
MA#XP^-?A'?:'/J,DMQX46WN+36X]0CM$6/6;":6U:Z;3S:%M.9;N.. WEZ9(
M)GDA>W^*?B%_P3R\<?$>*)_%?[5/CCQ9<69DET^'Q?H%YK6G6LT@PQM;1_&J
MPZ?YH^226T@W;2,QN%V'WO\ :<T3]L"\U;P[J7[-?BW0-+T:#3)K77]!O;3P
MJ=4N-6>\>1-32Z\6Z+J=A+9"R\FW6WBNK*>WEBFD\N\%T/LVW^S/I'[5=C;:
M_=_M*>*O#>L_:DM$\.:1I>G^'X]6TZ6-YC>W&H7WA?2M)T=K>>-H4@MD_M*9
MF5I6N+0(8KC1J,I-.$WYW:CLM?BMVV5P/P7_ &@_V<_'G[.7B>RT#QB;#4+#
M6K>XO/#GB32'F?2]:M;62..Z14N8H;FTU"Q:>V&H6$\9,!N8)(9[JVG@N9?
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MHHK)R;W^[H9.3>_W= HHHH2;V_KU$%%* 3P*D5 .3R?Y5=HPWU?];=O5_+L
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MN%%%% !13@I/L/7_  ]:E"@=/S[T ,5.Y_+_ !J2BB@ HHHH **** "BBB@
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MI %%%%!,I)>;[?Y]@HHHH,FV]PIP4GV'K_AZTY4[G\O\:DH$(% Z?GWI:**
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MMHOQ/]*Y3;VT7XA1114$!113@I/L/7_#UH ;4BIW/Y?XT\*!T_/O2T %%%%
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M+S-.3E)E%%%>R>*%%%% !113PA/7@?K2;2W8FTMV- )Z?Y^M2JH'N?Y?2E
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M^XOIHH [R):VHF=H[.SB>1S#96B0VD&]A#"@)%<I114@%%%% !1110 4444
M%=)X1\8>)_ 7B'3?%?@[6[_P[XBTB8S:?JNFS&&Y@9D:.5#D-%/;SQ.\%U:W
M$<MM=02207$,L,CHW-T4 ?H3HG_!3']H_2K.&UOK?X=>)9HHEC?4-;\,:A!>
M7##_ );3)X=\0:#8"1OXA#8PQ?W8U/-<?XU_X*"_M+^,M/N-,B\4:5X.MKH%
M9I/!6C1Z5J'ED$&.WU>]N-4U:QY(83V%[:W0*@"X"EU;XFHJN>;TYGVW M7U
M]>ZG>76HZE>76H:A?7$MU>WU]<2W=Y>74[M)/<W5U.\D]Q<32,TDLTKO)([,
MSL6)-5:**D HHHH ***\^^)GQ!TKX;^%K[7K^2)[WRI8-$TUG EU356C/V:W
M5 Z2?9HY"DU_.F3;6:RR*'E\J*7T,IRK,,\S/ Y/E6%JXW,LRQ-+!X/"T8N5
M2M7K24(172,5?FJ5)-0I4XRJ5)1A&4EY>=YUE?#F49EGV=8RCE^4Y3@ZV.Q^
M,KR4*5##T(.<Y.^LIRLH4J4%*I6JRA2I1G4G&+^)OVL/%<&M>.=-\/6DZSP>
M%=,>*YV.CI'J^JRI<7L2E'<;H[.WTQ)0VR1)UEA= 8@6^6:M7]]=ZG?7FI7\
M\EU?:A=W%]>W4I!EN;N[F>XN9Y"  9)II'D<@ %F. !Q56O]B^!.%:'!'!_#
M_"N'J*M')LOIX>M7BG&.(QE2<\3C\3&+2<8XC'5\17C%^]&-11;;3;_P:\2>
M-,3XA\=<3\9XJE*A//LSJ8FAAY24YX7 TH4\)EN$G--J<\+EV'PN'E.-HRE2
M<HI)I(HHHKZT^';2W84444&4IMZ+1?C\PHHHH)"BBE"D_3N: $KZ1_:8^,NB
M_''QCX0\2Z)I&J:-;^'OA?X,\#7=KJS6CS3:EX;BOEO+NW:SGF0V4SW8%L9#
M'.RH6EAB+;!\Z!0/KW-?0G[1WP5LO@9XN\+>&K#7KKQ##XC^'/A3QVUU=V,-
MA):2>)1?N=,6.&XN%F2S6T11=$Q-<,S.8(1A!\WF"R5\2\./&2J1SQ8//_[$
MC'V_)/#.&6?VPZG)%T$XQ^H^S]O*,]9>QU50^MRM\1+A#BU8"-)\-O'\,/B*
M4GAO:QQ:J9Q_8*I*I)8GEE-YE[7ZM&4+*'UAQ7LK_/M%%%?2)6T1\D%%%*%)
MZ?GVH 2I%3N?R_QIP4#W/K_AZ4ZLY3Z+[^OR[?UL92GT7W]?EV_K8****S("
MBBB@ HHHH **** "BB@#/ IJ+?IU?8 IP4GV'K3U3N>?;T_Q_E3ZJZCI'5]7
M_E_73J9RGT7W_P"0@ '2EHHJ#,**** "BBB@ HHHH **** "E )X%.5">3P/
MYU( !P* &J@')Y/\J?110 4444&<I]%]_P#D%%*%)Z?GVJ4*![GU_P /2@S&
MJG<_E_C4E%% !1110 4445+DEYOM_GV ****R<F]_NZ %%%%( HH SP*E5.Y
MY]O3_'^5 G)+?[NHP*3[#UJ4 #I2T52BWY+N9.3?DNW^?<****U22V)"BBI%
M3N?R_P :&TMP&A2?8>O^'K4H4#I^?>EHK*4F_)=O\^X!1114@%%%% FTM6%%
M%%!G*;>BT7YA11100%?2?[*/QKT+X ?%^P^(?B/2-6UK2[?0]<TF6RT0V?\
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M44$RDEYO^MPHHHH,FV]PHHHH$%%* 3P*D5 .3R?Y4G)+UZ+N U4)Y/ _G4@
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MBB@F4DO-]@HHHH,FV]PHHHH$%%*%)Z?GVJ4*![GU_P /2@!JIW/Y?XU)110
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M0H'3\^]+10 4444 %%%% !1110 4X*3[#U_P]:<J=S^7^-24&<I]%]_^7?\
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MH[G_ .5%'_$LGC/_ -$KA_\ Q(>'/_GK_5GY77_$V'@5_P!%AB?_ !&N)_\
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M\1GBG_YS'Z!T5^?G_#;.J?\ 1/;#_P **X_^5%'_  VSJG_1/;#_ ,**X_\
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M%?!/_#9VI]_ %C_X4%P/_<2:/^&SM2_Z$"Q_\*&X_P#E31_Q+/XS?]$K0_\
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M?_/47_$W7@%_T6>(_P#$7XJ_^<O]6]+_ 'E17P;_ ,-EZE_T(-C_ .%!<?\
MRIH_X;+U+_H0;'_PH+C_ .5-'_$L_C-_T2M#_P 2#AS_ .>HO^)NO +_ *+/
M$_\ B+\5_P#SE_JS\K_>5%?!O_#9>I?]"#8_^%!<?_*FC_ALO4O^A!L?_"@N
M/_E31_Q+/XS?]$K0_P#$@X<_^>H?\3=> 7_19XG_ ,1?BO\ ^<O]6?E?[RHK
MX0'[9&IGKX"L1_W,%Q_\JJ7_ (;'U+_H0['_ ,']Q_\ *JC_ (EG\9O^B5H?
M^)!PY_\ /4/^)NO +_HL\3_XB_%?_P Y?ZL_*_W=17P1=_MBZ\\)6Q\%:1;W
M&Y2);O5;V]A"@_,#!#;6#EB/NL+@!3R5;I7F'BC]I+XI^)"T<&L0>&K-MO\
MHOARV^QN3&^]';4;B2[U59",+*L%]!;RJ"&MPK%:]G)_HK>*V85X4\PPV39#
M0<G[3$8_-\/BN6"Y;NG2RC^T9U)R3?LX2=*+E%JI4I)J3\'/?IH>"N5X:=7*
M\9G_ !+B%%>RPN69'BL%S3DG95*^>?V5"G3BTO:S@JTXQE>E2K-.)]Z?$;XO
M^#OAM9S'5;^*\UORBUGX<L9XY-4N)&B9[<W4:ESIME,0 ;Z[14*;S;QW4JB%
MOS+^(/Q"\0?$C7I-<UZ9<(KP:;I\'RV>EV)E>1+6W7 +MELSW4NZXN7 :1MB
M11Q\9<W5S>W$UW>7$]W=7$C2W%S<RR3W$\KG+R332L\DLC'EG=F9CR2:@K^R
M/"?P-X9\+H/'0J2SOB>O1]EB,\Q5&%-8>G-)5</E6%4JBP-"IM5J2JUL57C>
M-2NJ+5"/\$^-GTC.+_&.HLNJ4X\/<(8:O[;"\.X*O.J\54A*]'%9UC'&D\QQ
M-+1T:4:-#!8:5ITL.ZZ>(F4445^W'\ZRFEMJ_P  HHHH,VV]6%%%% @HI0I/
MT[FI0H'U[FDWV5W^'S?Z;^0#0GK^7_UZDHHHMU>K_+T7]/S *^[_ /@H+_R5
M/X8_]F]?"S_T5K5?"%?6?[8GQ-\$?%3Q_P"!=;\!ZW_;NF:-\&_ /A34KG^S
M=7TO[-K^B1ZFNIV'DZS8:=<3?9C<0C[5;Q2V4V__ $>YE"OM^)SG"8JKQUP3
MC*6&Q%3"83+>,*>*Q5.C4GA\-/%4\B6&AB*\8NE1GB'1K*A&I*+JNE45-2Y)
M6_1L@QV"H^&WB+@*V,PM+'8[-^ JN"P=7$4J>+QE/!UN)7BZF%P\IJMB(855
MZ#Q,Z4)QH*M2=5Q52'-\F44H4GI^?:I0H'N?7_#TK[64DO-]O\^Q^;RDEYOM
M_GV&JG<_E_C4E%%9-M[F3;>X4444A!1110 4444 %%%% !114BIW/Y?XU?*D
MKR^[K_7]7N)M+<:%)]AZ_P"'K4H4#I^?>EHI.3?DNQE*3?DNW^?<****DD**
M** "BBB@ HHHH ***>J$\G@?SH : 3P*D5 .3R?Y4X #@4M !11102Y)>;[?
MY]@HHI0I/3\^U!DY-[_=T$J14[G\O\:<% ]SZ_X>E.H$%%%% !1110 4445G
M*?1??_D 4445F 4444 %."D^P]?\/6G*G<_E_C4E"5]$9RGT7W_Y=_ZW$  Z
M4M%%:QAU>OEV_P _R,PHHHJP"E"D_3N:>$]?R_\ KU)42GT6OGV_S_(!H4#Z
M]S3J**R;OJP"BBB@ HHHH(E-+1:O\@HHHH,VV]6%%%% @H )Z4Y5)]A_/Z5*
M !T_S]: &A .O)_2OOO_ ()M?\G.:7_V)OB[_P!)+>O@>OKK]B/XH>!OA#\=
M;#QE\1-<_P"$>\-P^&?$6GRZE_9FL:MMO+^WA2TA^QZ'I^IW[>:R,/,6U,4>
M,R.@()^$\4,'B\P\.N-,#@,+B<;C<5PYFE#"X/"4*N)Q6)KU,+4C3HX?#T8S
MJUJLY-1A3IPE.3:44V?J?@?F.7Y3XP>&N9YKCL'EF6X#C+(L5CLPS#$T<%@<
M'AJ..I3JXC%XO$SIT,/0I03E4K5JD*<(IRE))7/D6BBBONS\L"BE )Z5*% ]
MSZT ,5.YX]O7_#^=2@8X%%% !1110 4445+DEZ]OZV)<DO7M_6P4445DY-[_
M '&3DWO]P4444)-NR$%%* 3P*D5 .3R?Y5=E#?5]%_7Y_< U4)Y/ _G4@ '
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M=/\ L^?^K:\(U\L5]3_L+_\ )[7['7_9T_[/G_JVO"->%Q1_R3/$7_8BS?\
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M44 %%%% !113@I/L/6AM+<!H&>!4JIW//MZ?X_RIP '2EK*4V]M%^(!1114
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M4GZ=S4H4#Z]S5-J.B^[_ #?]= &A/7\O_KU)116;;>X!1112 **** "BBB@
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M3R?Y4G)+UZ+N U4)Y/ _G4@ ' I:*FSEK+1=%_G_ %UZ %%%%6 44 $]*E"
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MH$%%* 3TJ4*![GUH 8J=SQ[>O^'\ZEHHH **** "B@#/ J54[GGV]/\ '^5
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MH,VV]V%%%% @H SP*<%)]AZU* !TJ922\W^7J U4[GGV]/\ '^5/HHK)MO<
MHHHI %%%%!+DEZ]OZV"BBB@R<F]_NZ!1110(**4 G@5(J <GD_RH :J$\G@?
MSJ4 #I110 4444 %%%% FTMPHHHH,I2;\EV"BBG!2?IW-!(VI GK^7_UZ>%
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M!_X;3Q)_\A4?\.W_ -O?_HT+]H#_ ,-IXD_^0J/]<^#_ /HK.&O_  ^Y7_\
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M<-?^'W*__FH/]2^,?^B3XF_\,.:?_,OFOO/BJBOM7_AW#^WK_P!&A_'_ /\
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M;Q_Z-&^/O_AMO$G_ ,A4?\.YOV\?^C1OC[_X;;Q)_P#(5'^N7"'_ $5?#?\
MX?,K_P#FHR?!7&CWX1XG]/[ S6W_ *B'Q=17VC_P[F_;Q_Z-&^/O_AMO$G_R
M%1_P[F_;Q_Z-&^/O_AMO$G_R%1_KEPA_T57#?_A\RO\ ^:A?ZD\9_P#1(\3_
M /A@S7_YD/BZBOM'_AW-^WC_ -&C?'W_ ,-MXD_^0J/^'<W[>/\ T:-\??\
MPVWB3_Y"H_URX0_Z*OAO_P /N5__ #4'^I/&?_1(\3_^&#-?_F0^+J*^T?\
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M\#]:^SE_X)U_MU#_ )M*^/9/_9-O$G'T_P!!IW_#N[]NO_HTKX]_^&V\2?\
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MQY_\-SXB_P#D*C_AW=^W5_T:9\>?_#<^(O\ Y"H_URX0_P"BJX;_ /#YE?\
M\U!_J+QM_P!$=Q5_XCV;_P#S'YK[SXTHK[+_ .'=W[=7_1IGQY_\-SXB_P#D
M*C_AW=^W5_T:9\>?_#<^(O\ Y"H_URX0_P"BJX;_ /#YE?\ \U!_J+QM_P!$
M=Q5_XCV;_P#S'YK[SXTH SP*^S!_P3N_;I[_ +)GQY'_ '3CQ&?_ &RJ0?\
M!._]N<=/V3/CS_X;CQ'_ /(5)\9\(+;BGAQO_L>99;Y_[4'^HO&W_1'<5?\
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MCV;_ /S&?&]%?9'_  [R_;G_ .C3OCQ_X;GQ%_\ (5+_ ,.\?VY_^C3OCO\
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MU3=2G?"WY^=SA#XW  Z4M?8__#O/]N7_ *-/^.__ (;GQ%_\A4?\.\_VY?\
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M_1J'QV_\-UXA_P#D.C_7'A'_ **GAS_P^99_\U!_J)QQ_P!$;Q7_ .(]F_\
M\Q^:^\^.:*^QO^'>O[<G_1J'QV_\-UXA_P#D.C_AWK^W)_T:A\=O_#=>(?\
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M_P#1J7QU_P##=>(O_D.E+C+A/9<4<.KS_MO+=?\ RYT_,/\ 4/CC_HC.*_\
MQ'<W_P#F,^/**^P_^'?/[</_ $:E\=?_  W7B+_Y#H_X=\_MP_\ 1J7QU_\
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M/_R'1_KAPE_T5/#G_A[RS_YJ\U]Y$N!N.=EP9Q7Z_P"KN<?A_L?FO^#<^/
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M8?@-\,[&6\T74K+5+6*]MHM7%S9R7%C-/"EU;EU$]NSB6(LHD1=PSC_\._\
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M  W^O_\ R)1_PP)^VO\ ]&M?&_\ \-_K_P#\B5G_ *W<*?\ 13\/?^'K+?\
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MXVD^O_"O_$'_ ,AT?ZW<*?\ 13\/?^'K+?\ YI#_ (A[Q]_T0_&'_B-9U_\
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MY8^&\_C]?KX/$TZU/"<U#+ZE9.O)*FG3IU)IR3C"3LG\:45]:_\ #!?[:/\
MT:]\;?\ PW^O_P#R'1_PP7^VC_T:]\;?_#?Z_P#_ "'7T7^MW"G_ $4_#W_A
MZRW_ .:3Y#_B'O'W_1#\8?\ B-9U_P#,7FOO/DJBOK7_ (8+_;1_Z->^-O\
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M*H3R>!_.I  .!7UK_P ,&_MH?]&P?&S_ ,(#7_\ Y#H_X8-_;0_Z-@^-G_A
M:_\ _(=2^+^%9?\ -3</6Z+^VLM\O^HG7=??YA_Q#SC_ /Z(;C#_ ,1G.O\
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MO_#UEO\ \T^:^\/^(><?_P#1#<8?^(SG7_S$?)E%?6?_  P=^V=_T;#\:_\
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M&$?VS?\ HV+XU_\ A :__P#(='^MO"G_ $4W#W_AZRW_ .:?-?>+_B'G'_\
MT0W&/_B,YU_\Q>:^\^3J*^L?^&$?VS?^C8OC7_X0&O\ _P AT?\ #"/[9O\
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MT_\ A Z]_P#(E1+B_A;:/$O#_K_;.7>6W^T^:_IHB7AYX@[+@3C+U_U8SO\
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M\TB_XASXA?\ 1"<9_P#B+YW_ /,/FOO/E&BOJ\?L*?MDG_FV;XSCZ^ ]=_\
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M?]$)QG_XB^=__,/FOO/E*BOJW_AA;]L?_HV;XS_^$'KO_P B4?\ #"W[8_\
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M_MA?]&U_&3_PA=<_^1:/];.%O^BEX?\ _#SEW_S3YK[P_P"(;>(O_1 \:_\
MB+9Y_P#,'FOO/E<#' HKZH_X8=_;"_Z-K^,G_A"ZY_\ (M'_  P[^V%_T;7\
M9/\ PA=<_P#D6C_6SA;_ **7A_\ \/.7?_-/FOO#_B&WB+_T0/&O_B+9Y_\
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M_6KA?_HI,@_\/&7?_-'FOO#_ (AKXC?]$!QM_P"(KGO_ ,P>:^\^7**^H_\
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M^8#Y=HKZB_X8E_:Z_P"C</C!_P"$/K?_ ,BTH_8E_:Z[_LX_& #_ +$?6_\
MY%I_ZU\+_P#129!_X>,N_P#FD/\ B&GB-_T;_C;_ ,13/O\ Y@/EP GI4H0#
MKR?TKZB'[$_[7 Z?LX_&#_PA];_7_1:7_ABC]KG_ *-Q^,'_ (0^N?\ R+1_
MK7PM_P!%+D'_ (>,N_\ FDSEX:^)+V\/N-TO^R4SZ_\ Z@'R_17U!_PQ1^US
M_P!&X_&#_P (?7/_ )%H_P"&*/VN?^C<?C!_X0^N?_(M'^M?"W_12Y!_X>,N
M_P#FDC_B&?B1_P!&^XW_ /$4S[_Y@/E^BOJ#_ABC]KG_ *-Q^,'_ (0^N?\
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MQ3^UO_T;E\7_ /PB-;_^1:/]:N&/^BCR'_P\9?\ _-!G_P 0Q\2?^C>\<?\
MB)Y]_P#,!\P45]/_ /#%/[6__1N7Q?\ _"(UO_Y%H_X8I_:W_P"C<OB__P"$
M1K?_ ,BT?ZU<,?\ 11Y#_P"'C+__ )H#_B&/B3_T;WCC_P 1//O_ )WGS!3U
M0GD\#^=?4"_L4?M:CD_LZ?%XG_L2-;X_\E:?_P ,5_M;?]&Z?%[_ ,(C6O\
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ML%%%%9D!110!G@4 %."D^P]:>J=SS[>G^/\ *GT ( !TI:** "BBB@ HHHH
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M<JS_ #;+L)&K5:=2I'#8/%T:*J5&DYS4.:;2<FVC]6O^'W?_  5 _P"CG/\
MS"_[/?\ \Z>C_A]W_P %0/\ HYS_ ,PO^SW_ /.GK\I:*\]>%?AG+_FW7 EN
M_P#JCP__ /.\[Y>*?B6M%XB<=-_]E=Q!I_YD#]6O^'W?_!4#_HYS_P PO^SW
M_P#.GH_X?=_\%0/^CG/_ #"_[/?_ ,Z>OREHK1>%?ABE_P FYX#?F^$.'_\
MYWF?_$4O$W_HXO'?_B7<0?\ SP/U:_X?=_\ !4#_ *.<_P#,+_L]_P#SIZ4?
M\%NO^"H)Z?M.?C_PI?\ 9[Q_ZJ>ORH5.Y_+_ !J2IEX7^&"T7AQP&_/_ %0X
M>M_ZKM2X^)_B=N_$7CNW;_6_B"__ *L-/S/U7'_!;G_@I]W_ &G,_P#=%_V>
M_P#YT]+_ ,/N?^"GW_1S?_F&/V>__G3U^4]%9_\ $+?#+_HW7 G_ (B'#_\
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M:I0H'N?7_#TH_P"(6^&7_1NN!/\ Q$>'_P#YWA_Q%+Q-_P"CB\=_^)=Q!_\
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MXB/#_P#\[Q/Q4\3EJ_$?CS_Q+^(?_GB?JD/^"V?_  4[/ _:9_\ ,,_L^_\
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M_P!'(X]_\3#B'_YXGZHC_@MC_P %.3T_:8_\PS^S]_\ .IJ0?\%KO^"G'?\
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M<@_^=YG_ ,18\4O^CE<?_P#B8\1?_/$_4S_A]5_P4S_Z.5_\PW\ /_G54?\
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M -'*_P#F'/@#_P#.KH_X?3_\%,?^CE?_ ##GP!_^=77Y:T4?\0P\-/\ HWG
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M/B/_ .>1^HW_  ^B_P""EO\ T<G_ .8=^ 7_ ,ZRC_A]%_P4M_Z.3_\ ,._
M+_YUE?ES11_Q##PT_P"C><#?^(ED'_SO#_B+7BK_ -',\0?_ !,^(_\ YY'Z
MC?\ #Z+_ (*6_P#1R?\ YAWX!?\ SK*/^'T7_!2W_HY/_P P[\ O_G65^7-%
M'_$,/#3_ *-YP-_XB60?_.\/^(M>*O\ T<SQ!_\ $SXC_P#GD?J-_P /HO\
M@I;_ -')_P#F'?@%_P#.LH_X?1?\%+?^CD__ ##OP"_^=97Y<T4?\0P\-/\
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M11_Q##PT_P"C><#?^(ED'_SO#_B+GBM_T<[Q"_\ $TXD_P#GD?J)_P /G_\
M@I7_ -')?^8>^ ?_ ,ZRC_A\_P#\%*_^CDO_ ##WP#_^=97Y=T4?\0P\-/\
MHWG W_B)9!_\[P_XBYXK?]'.\0O_ !-.)/\ YY'ZB?\ #Y__ (*5_P#1R7_F
M'O@'_P#.LH_X?/\ _!2O_HY+_P P]\ __G65^7=."D^P]?\ #UH?AAX:+5^'
MG W_ (B60?\ SO#_ (BYXK?]'.\0O_$TXD_^>1^H7_#Y_P#X*6?]')?^8=^
M?_SK*D'_  6<_P""E??]I+\/^%/? /\ 7_BUG\J_+X*!T_/O2UE+PS\-7HO#
MS@9>?^J607_]5^@?\1<\5O\ HYWB%_XFG$G_ ,\C]0O^'SO_  4J_P"CD?\
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MW@?_ ,1/(?\ YWA_Q%WQ8_Z.?XA_^)KQ)_\ /,_4#_A\U_P4H_Z.0_\ ,/\
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M_P""DG_1QW_F(/@-_P#.NK\PZ*/^(8^&W_1O>!__ !$\A_\ G>9_\1?\6?\
MHZ'B)_XFO$O_ ,\S]//^'RO_  4D_P"CCO\ S$'P&_\ G74?\/E?^"DG_1QW
M_F(/@-_\ZZOS#HH_XACX;?\ 1O>!_P#Q$\A_^=X?\1>\6?\ HZ'B)_XFO$O_
M ,\S]//^'RO_  4D_P"CCO\ S$'P&_\ G74?\/E?^"DG_1QW_F(/@-_\ZZOS
M#HH_XACX;?\ 1O>!_P#Q$\A_^=X?\1>\6?\ HZ'B)_XFO$O_ ,\S]//^'RO_
M  4D_P"CCO\ S$'P&_\ G74?\/E?^"DG_1QW_F(/@-_\ZZOS#HH_XACX;?\
M1O>!_P#Q$\A_^=X?\1>\6?\ HZ'B)_XFO$O_ ,\S]//^'RO_  4D_P"CCO\
MS$'P&_\ G74?\/E?^"DG_1QW_F(/@-_\ZZOS#HH_XACX;?\ 1O>!_P#Q$\A_
M^=X?\1>\6?\ HZ'B)_XFO$O_ ,\S]//^'RO_  4D_P"CCO\ S$'P&_\ G74?
M\/E?^"DG_1QW_F(/@-_\ZZOS$"D_3N:E"@?7N:F7AGX:K_FWO [?;_5/(?\
MYWDR\8?%A?\ -T/$1OM_KMQ+_P#/,_3H?\%DO^"DG?\ :._#_A4'P&_G_P *
MOIW_  ^2_P""D7_1QO\ YB'X#_\ SKZ_,6BLWX9^&[_YM]P/\N$\A7_N@9/Q
M@\6G_P W1\1?EQMQ*O\ WIGZ=?\ #Y+_ (*1?]'&_P#F(?@/_P#.OH_X?)?\
M%(O^CC?_ #$/P'_^=?7YBT54?##PX>_A]P0E_P!DGD.OI_L'XA_Q&#Q:_P"C
MH^(O_B;<2_\ SS/TZ_X?)?\ !2+_ *.-_P#,0_ ?_P"=?1_P^2_X*1?]'&_^
M8@^ _P#\Z^OS&"D]/S[5*% ]SZ_X>E4_#/PUBK?\0]X';_[)3(;_ #_X3P_X
MC!XM?]'1\1?_ !-N)?\ YYGZ<+_P60_X*1=3^T;^'_"H?@/^O_%KZ=_P^0_X
M*0?]'&?^8A^!'_SKZ_,>BLWX9^&[_P";?<#KTX3R%?\ N@'_ !&#Q:_Z.CXB
M_P#B;<2__/,_3C_A\A_P4@_Z.,_\Q#\"/_G7T?\ #Y#_ (*0?]'&?^8A^!'_
M ,Z^OS'HI?\ $,_#?_HWW!'_ (BF0_\ S '_ !&#Q:_Z.CXB_P#B;<2__/,_
M3C_A\A_P4@_Z.,_\Q#\"/_G7T?\ #Y#_ (*0?]'&?^8A^!'_ ,Z^OS'HH_XA
MGX;_ /1ON"/_ !%,A_\ F /^(P>+7_1T?$7_ ,3;B7_YYGZ<?\/D/^"D'_1Q
MG_F(?@1_\Z^C_A\A_P %(/\ HXS_ ,Q#\"/_ )U]?F/11_Q#/PW_ .C?<$?^
M(ID/_P P!_Q&#Q:_Z.CXB_\ B;<2_P#SS/TX_P"'R'_!2#_HXS_S$/P(_P#G
M7T?\/D/^"D'_ $<9_P"8A^!'_P Z^OS'HH_XAGX;_P#1ON"/_$4R'_Y@#_B,
M'BU_T='Q%_\ $VXE_P#GF?IQ_P /D/\ @I!_T<9_YB'X$?\ SKZ/^'R'_!2#
M_HXS_P Q#\"/_G7U^8X&>!4JIW//MZ?X_P J/^(9^&__ $;[@C_Q%,A_^8!/
MQA\65OXH^(OI_KMQ+?\ ]69^FH_X+'?\%(3_ ,W&8'K_ ,*A^ __ ,["I/\
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M$C_Q.>)__GH?IA_P^&_X*,_]'$_^8D^!?_SL:/\ A\-_P49_Z.)_\Q)\"_\
MYV-?F?11_P 0T\./^C?\$_\ B*Y%_P#, ?\ $9/%[_HZOB1_XG/$_P#\]#],
M/^'PW_!1G_HXG_S$GP+_ /G8T?\ #X;_ (*,_P#1Q/\ YB3X%_\ SL:_,^BF
MO#+PY?\ S;_@FW?_ %4R+_Y@#_B,GB]_T=7Q(_\ $YXG_P#GH?IA_P /AO\
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MX*+=3^T/CV_X5+\#.?\ S&?'\Z?_ ,/?O^"B?_1PW_F)?@;_ /.SK\U:*/\
MB&GAQ_T;_@G_ ,17(O\ Y@#_ (C/XP_]'7\2O_$ZXH_^>A^E7_#W[_@HG_T<
M-_YB7X&__.SH_P"'OW_!1/\ Z.&_\Q+\#?\ YV=?FK11_P 0T\./^C?\$_\
MB*Y%_P#, ?\ $9_&'_HZ_B5_XG7%'_ST/TJ_X>_?\%$_^CAO_,2_ W_YV='_
M  ]^_P""B?\ T<-_YB7X&_\ SLZ_-6BI?AMX;K_F@.";]O\ 57(O_F#0/^(S
M^,/_ $=?Q*_\3KBC_P">A^E7_#W[_@HG_P!'#?\ F)?@;_\ .SH_X>_?\%$_
M^CAO_,2_ W_YV=?FK16;\-O#I_\ - <$KTX5R)?^Z ?\1G\8?^CK^)7_ (G7
M%'_ST/TJ_P"'OW_!1/\ Z.&_\Q+\#?\ YV='_#W[_@HG_P!'#?\ F)?@;_\
M.SK\U:*7_$-?#K_H@>"O_$5R+_Y@#_B,_C#_ -'7\2O_ !.N*/\ YZ'Z5?\
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M ,%$/^CA<_\ =)O@=_\ .TK\V:*R?AOX=/\ YH#@E+RX5R+\_J ?\1H\8O\
MH['B7_XG?%/_ ,]3])O^'O/_  40_P"CA/\ S$_P._\ G:4?\/>?^"B'_1PG
M_F)_@=_\[2OS9HI?\0U\.O\ H@>"O_$5R+_Y@#_B-'C%_P!'8\2__$[XI_\
MGJ?I-_P]Y_X*(?\ 1PG_ )B?X'?_ #M*/^'O/_!1#_HX3_S$_P #O_G:5^;-
M%'_$-?#K_H@>"O\ Q%<B_P#F 3\:?&%:OQ9\2_\ Q.^*?_GJ?I-_P]Y_X*(?
M]'"?^8G^!W_SM*/^'O/_  40_P"CA/\ S$_P._\ G:5^;-%'_$-?#K_H@>"O
M_$5R+_Y@,Y>-?C&]O%CQ+2_[+OBF_P#ZM3])O^'O/_!1#_HX3_S$_P #O_G:
M4?\ #WG_ (*(?]'"?^8G^!W_ ,[2OS9HH_XAKX=?]$#P5_XBN1?_ # 3_P 1
MI\8_^CL^)G_B><4__/4_2;_A[S_P40_Z.$_\Q/\  [_YVE'_  ]Y_P""B'_1
MPG_F)_@=_P#.TK\V:<%)]AZT?\0U\.O^B!X*_P#$5R+_ .8 _P"(T^,?_1V?
M$S_Q/.*?_GJ?I(/^"O'_  40/ _:$_\ ,3_ [_YVE2C_ (*[?\%#^_[0GX?\
M*G^!_'_F-*_-L #I2T?\0U\.O^B!X*_\17(O_F /^(T^,?\ T=GQ,_\ $\XI
M_P#GJ?I)_P /=O\ @H=_T<'_ .8G^!__ ,[6C_A[M_P4._Z.#_\ ,3_ _P#^
M=K7YMT4?\0U\.O\ H@>"O_$5R+_Y@#_B-/C'_P!'9\3/_$\XI_\ GJ?I)_P]
MV_X*'?\ 1P?_ )B?X'__ #M:/^'NW_!0[_HX/_S$_P #_P#YVM?FW2@$]/\
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M1\$?_G:T?\/<?^"A7_1P7_F*/@C_ /.VK\WZ*C_B&_AW_P!$%P7_ .(MD?\
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M_$6R/_YA(EXW>,BV\6_$UO\ [+WBJW_JV/T>_P"'M_\ P4(_Z.!_\Q3\$?\
MYVU'_#V__@H1_P!' _\ F*?@C_\ .VK\X:*/^(;^'?\ T07!?_B+9'_\PF?_
M !&SQF_Z.YXG?^)[Q5_\]3]'O^'M_P#P4(_Z.!_\Q3\$?_G;4?\ #V__ (*$
M?]' _P#F*?@C_P#.VK\X:*/^(;^'?_1!<%_^(MD?_P PA_Q&SQF_Z.YXG?\
MB>\5?_/8_1[_ (>W_P#!0C_HX'_S%/P1_P#G;4?\/;O^"A/_ $<!_P"8I^"7
M_P [:OSC"D^P]?\ #UJ4*!T_/O1_Q#?P[_Z(+@O_ ,1;(_\ YA#_ (C9XS?]
M'<\3O_$]XJ_^>Q^C8_X*U_\ !0CO^T#^'_"J?@E^O_%MOY4[_A[9_P %!O\
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M(_\ YA,GXW>,[_YN[XG_ "X^XJ7_ +UC]'/^'MG_  4&_P"C@/\ S%7P2_\
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M ."@?_1?O_,5_!3_ .=Q1_P]G_X*!_\ 1?O_ #%?P4_^=Q7YST4?\0X\//\
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MX,_\1?(__F$/^(X>-7_1W_%'_P 6!Q9_\]C]%/\ A[%^W_\ ]%\_\Q9\%?\
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MN_M]_P#1>O\ S%OP7_\ G=4?\/7?V^_^B]?^8M^"_P#\[JOSOHH_XAUX??\
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M/^"K7[?7?X]9_P"Z6_!?_P"=U2_\/6OV^?\ HO7_ )B[X,?_ #NJ_/&BL_\
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M/7_A5WP9_3_BW?-2?\/5?V]O^B\?^8O^#/\ \[NOSUHH_P"(=>'W_1"<&_\
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M\ A2?8>M2@ =*F7A[X?+_FA>#F_^R9R33U_V(/\ B/7CG_T>CQ8_\6+QA_\
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MW_SOJ/\ AZ-^W7_T7+_S&?P>_P#G?5\! $\"I%0#D\G^5'_$/. /^B&X/_\
M$9R7_P"8@_XCYXZ?]'I\6?\ Q8W&'_SY/OQ?^"H?[=9Y/QRP/^R9_![G_P Q
M]3_^'H?[=/\ T7'_ ,QG\'O_ )W]? =%'_$/. /^B&X/_P#$9R7_ .8@_P"(
M^>.G_1Z?%G_Q8W&'_P ^3[\_X>A_MT_]%Q_\QG\'O_G?T?\ #T/]NG_HN/\
MYC/X/?\ SOZ^ Z*/^(>< ?\ 1#<'_P#B,Y+_ /,0?\1\\=/^CT^+/_BQN,/_
M )\GWY_P]#_;I_Z+C_YC/X/?_._H_P"'H?[=/_1<?_,9_![_ .=_7P'11_Q#
MS@#_ *(;@_\ \1G)?_F(3\??'1;^-/BS_P"+&XP_^?)]^?\ #T/]NG_HN/\
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M]7BU_P"+'XQ_^?)]]?\ #T#]N?\ Z+C_ .8T^#__ ,[^C_AZ!^W/_P!%Q_\
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M4)Y/ _G3E0#D\G^5/J)3[??_ , !  .!2T45F 444H!/2@!*<JD^P_G]*>$
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M%%%%23*?1:>??_+\PHHHH("BBE )Z4 )4BIW/Y?XTX*![GUIU !1110 444
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M$]>!^M.5 .3R?Y4^FYVTCMW_ *_4SE/^7[_\O^"( !TI:**S,PHHHH ****
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MOZW"BBB@D**** "BBB@ HHHH ***>$)Z\#]:!-I;L: 3T_S]:E50/<_R^E.
M Z44&4IMZ+1?C\PHHHH)"BBGJA/)X'\Z &@$\"I%0#D\G^5.  X%+0 4445G
M*?;[_P#@ %%%*%)Z?GVJ$FW^O^8"5(J=S^7^-."@>Y]?\/2G5K&*7F_ZV_SW
M ****H HHHH ****SE/HOO\ \C.4^B^__(****S,PHHH SP* "G!2?8>M/5.
MYY]O3_'^5/H 0 #I2T44 %%%% !1110 4444 %%%% !2@$\"G*A/)X'\ZD
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M .7YA1116JBEM]_4@****8!1116<I_R_?_E_P0"BBBLP"BE )X%2*@')Y/\
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MH : 3T_S]:E50/<_R^E* !TI: "BBB@ HHHH$VEJPHHHH,Y3;T6B_,****"
MHHI0I/3\^U "5(J=S^7^-."@>Y]?\/2G4M7Y+\7_ )?GZ, HHHII6T0!112@
M$]* $IZIW/'MZ_X?SIX4#W/K3JSE/HOO_P C.4^B^_\ R #' HHHK,S"BBB@
M HHHH **** "BBBFHM[??T *4*3].YIX3U_+_P"O4E5=1VU??MZ?U]Y$I]%K
MY]O\_P AH4#Z]S3J**AN^K,F[ZL**** "BBB@ HHHH **** "@ GI3@I/L/6
MI0 .G^?K0 T(!UY/Z4^BB@ HHHH,Y3_E^_\ R_X(44H!/2I0H'N?6@S&*G<\
M>WK_ (?SJ4#' HHH **** "BBBI<DO7M_6P!11163DWO]P!1112 ***D">OY
M?_7H$VEN,"D_3N:E"@?7N:=15*+?DNYE*3?DNP4445JDELOGU)"BBI%3N?R_
MQH;2W 8%)Z?GVJ4*![GU_P /2G45E*3?DOZW ****D HHHH$VEN%%%%!G*;>
MVB_$****" HHIP4GV'K_ (>M #0,\"I53N>?;T_Q_E3@ .E+0 4444 %%%*
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MG)+?[NHG)+?[NHP*3[#UJ4 #I2T5DY-^2[?Y]S)R;\EV_P ^X4445)(4444
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MIW/Y?XT";2W&A2?8>O\ AZU*% Z?GWI:*";.6^B[=_7^O\PHHHH*22V"BBI
MGK^7_P!>DVEN#:6XP*3].YJ4*!]>YIU%92DWY+L92DWY+L%%%%22%%%%7&#>
MKT7X_P!?U8 HHHK5)+8 HHHH ***<%)]AZT-I;@- SP*E5.YY]O3_'^5.  Z
M4M92FWMHOQ ****@ HHHH ****#.4^B^_P#R"BBI GK^7_UZ#,8%)^G<U*%
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M(3UX'ZU* !TH(E-+;5_@-50/<_R^E.HHH,VV]6%%%% @I0">!3E0GD\#^=2
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M@$]/\_6I54#W/\OI02Y)>O;^MA@0GKP/UJ0 #I2T4&3DWO\ <%%%% @HHHH
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M"@!H4#W/K3J**!.26_W!11109.3?IV_K<****"0HHHH **** "BG!2?8>O\
MAZU*% Z?GWJ922\W_6X#%3N?R_QJ2BBLFV]P"BBBD 44H4GZ=S4H4#Z]S03*
M27F^PT)Z_E_]>I***TC#J_N_S,FV]PHHHK004444G)+?[@"BBBLG)OT[?UN
M444H!/ J0$IZH3R>!_.G*@')Y/\ *GT ( !P*6BB@ HHHH ***>$)Z\#]:!-
MI;L: 3T_S]:E50/<_P OI2@ =*6@RE-O1:+\?F%%%%!(4444 %%%% !1110
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M[?Y]B7)+S?;_ #[#%3N>/;U_P_G4H&.!1163DWO]W0R<F]_NZ!1112$%%%%
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M1110 4444 % &>!3@I/L/6I0 .E #53N>?;T_P ?Y4^BB@ HHHH,Y3[??_P
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MM_GW"BBBI)"BBB@ HHHH **** "BBGJA/)X'\Z:7R7?^MWY";2U8T G@5(J
M<GD_RIP ' I:+VVZ[]W_ )+R^]LSE-O1:+\PHHHI$!112A2>GY]J $J14[G\
MO\:<% ]SZ_X>E.H **** "BBB@ HHHH **** "BBB@SE/^7[_P#+_@A3@I/L
M/7_#UIRIW/Y?XU)09B  =*6BB@ HHHH *4*3].YIX3U_+_Z]25$I]%KY]O\
M/\@&A0/KW-.HHK)N^K **** "BBB@B4TM%J_R"BBBJ46_)=S-MO5A1116J26
MP@H )Z4Y5)]A_/Z5* !T_P _6E*:6BU?];@-" =>3^E/HHK)MO=@%%%%( HH
MHH)<DO-]O\^P4444&3DWO]W0****!!12@$]/\_6I54#W/\OI0 P(3UX'ZU(
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M'0M'T>TU:U*RK+%9@*4_$C_@HS_P3'^*7[ /B32-2NM7'Q'^"WC*]N++P?\
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MKXKUU?*^RVGC'2/A[X..H1Q)->Z7X6L;O3;SQGXL?3/-5+C5HY[)9H?+NIM
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MX<?\$Y?^"0?[2>KW?P^^!7[1'CS5?'&A0O<WEKX=^(6DG7=5M+(E;V^L]/\
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MA[\,+^WU'3=3_P"$IT>T\4:CI/AW7IM;TR.WT2>PN]&MH-;U'7[1+;1(]/\
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MDP-"CB*Z@X5*D80G!R_FRHK]T_\ @HK_ ,$FO"G[-_PJD^/W[/\ XL\4^)O
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M7 8F3E7Q]"K4P-&K!0JU)-\K_A[K^A#_ ()Y_$[_ ()G^%_V/M:T7]H^P^%
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M1A\72C-9EPM4A4H8K"5:V'KT:]&I3K4:M*I*,Z52$O=;<44445_1Y_$8444
M9X% !3@I/L/6GJG<\^WI_C_*GU#DWI'YOHOZ_39@( !TI:**:BEKN^[ ****
MH IP4GV'K_AZTY4[G\O\:DJ)3Z+[_P#+O_6YG*?1??\ Y=_ZW$"@=/S[TM%%
M9&84444 %%%% !1110 4444 % !/2G*I/L/Y_2I0 .G^?K3LEOOV_P W^BU\
MT1*:6BU?];C50#D\G^5/HHH;;W,VV]6%%%%(044H4GI^?:I0H'N?7_#TH :J
M=S^7^-2444 %%%% !1110 4444 %%%%!+DEZ]OZV"BBI%3N?R_QH,G)O?[AH
M4GV'K_AZU*% Z?GWI:*!!1110 445($]?R_^O2;2W 8%)^G<U*% ^O<TZBLI
M2;\EV ****D HHHH$VEJPHHHH2OHC.4V]%HOQ84445K&'5Z^7;_/\B HHIP4
MGV'K5MI;@- SP*E5 .3R?3M_]>G  =*6LI3;VT7X@%%%%0 4444 %%%%!G*?
M1??_ )!11109A112@$]/\_6@!*>$)Z\#]:>J@>Y_E]*=0 @ '2EHHH ****
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MV76T^)7Q;^''@"Z:-F21;?QEXQT;P[,8W3#(XCU%BK*0RM@CD"O)*]4^!?Q
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M/QQ\1I].NAX-\ Z#YL3ZEJFM:R8Q8G4(K)I)-)T".X.K:W=B.VLK9E,TT/\
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MK8.T@8/] 7_!M  /$'[88'_0&^!OU_X_OBOUK\#?VT_^3Q_VL_\ LYCX\?\
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M_B>X\0BY:TDT8:*(/M\>H07,<L5U;2P1R6C13&Y6)8I2O]FWQFL]+_X)P?\
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M!8KBC/L\Q>8U,XQ.&RS,)X+"XG+J.'I9+E^-HQG4QL(X:M5Q$82J)*-&3O\
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M=IVHWTT^G^&/#EII&ESQ:1H=DS"UTRR:ZGN+VXCM(HC>7UQ<7UVT]W<33/\
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MI5:SJK"XV-+%5J'Y^?\ !O-_R6;]H?\ [)CX8_\ 4J>ORE_X*!?\GO?M5_\
M9=/B)_ZD5[7ZF_\ !O5?VT?QW^/NEN^+R\^$FCW\$?&7MM-\8V%O=OUS^[EU
M6R4X!'[T9(XS^:?_  4G\+:YX2_;I_:;LM>TZZTZ?5?BGX@\4Z<+F%XA>Z'X
MKF7Q!HNHVS,-L]K=Z=J$#I-&63>)(B5EBD1/:X:E&'TC_$:G*2C.MP9P_4I0
M;2E4ITZ>40J3@GK*,)R49-746TGN?.<74YU/HE^$]6$)3I4/$'BJE7J1BW"E
M5K5,ZG2IU))6A*I"$I04FG)1;5['N/\ P1=_Y2&?![_L _%3_P!5AXKKMO\
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MI9VEND=K8:9IME!;:=I>FVD45II^GVMM9VT4<,**/ZS?V=KO5?V2O^"--O\
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MU_P]*=117Z:W?5GX>W?5A1110 4444 %%%% !1110 4 9X%."D^P]:E  Z4
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M1V'A[P];7/@WX=Z8$5B6L))1XJF-O*0B2Z'IDX61T1XON?\ 9L^"'Q"\,?\
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MKX3^(&C6VEZA)X4U.8;9_%^B2/?QR::L<U_'IZZ9J=C%?6UKJ::9\0_M(_\
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MEO\ 3_!L&IR7]W/8+J373:A'X)T+4;2#4$N4O1%>!D/[:?L)?\$L?B3^R/\
M'3PC\7_%?Q_\&S7B:5XFT'5OAYX5T/5;BW\9Z=J^@WL;:6FOZSJ.@W7DZ1J<
M>F>*0T?AB[=Y= A22&")WN(>M_X*T_&OXJ_LG?L^?"/P/^SA;3_#/PAXCO\
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MR H7HHK]%O\ @G=_RB1^,7_8M_M+_P#J*:E7Y_\ _!=G_D[_ ,!_]F[^#O\
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M";IU:F Q];)<-C<+*I&TE2Q>&G4PV)C%Q5:A4JT9WI5)PE^ E%*%)^G<U*%
M^O<U_0I_&Y_53_P09!'[-7Q<S_T7*\_]0'P17\K%?U4_\$&_^3:_BY_V7&\_
M]0+P37\M?]A:W_T!M5_\%UW_ /&:_ ?#*<(>*OCMS2C&^:<(6YI)7M@<ZO:[
M5[75_4_K[QUIU*G@!]$[DA.=L@\1K\D92M?-.%K7LG:_2^YE5_9!^S?\$OB#
MX8_X)=>"_ _[.%UX?\*_%[XI?"72/&-CXHUN[NM%MXM>^+(TW6M;\17FK:;I
MFLW\>KZ3X/U5['P[>QV$\T$NCZ# CVD5NDUO_'?-I&JV\3S7&F:A!#& 7EFL
MKF*) 2%!>1XE506( )(R2!U(K^MW]F+6/$O[5O\ P2JTOP1\&O'NM^"/BWX1
M\!Q?#'3];T#Q%J7AC6] \<?"Z\TR_P##NE-KVBWMG?Z78>*= L/#UM<W,5QY
M::%XCFCN89T2YM&\[Z1SQ+R3@FO3Q&&HY50XYRJ6:8C&498O+,._9UOJN(S7
M#4Y)U\OHOVSQ%%M*K&2IIJI.F>S]"F.!7%'BAA:V#QV*S_%>%.?PR'"9;B89
M=GF,7ML+]>P60XVM%K"9OBD\)'!XJ,92P\H2KN+I4ZMORH?_ ((;_MD.S._B
MGX$N[L6=W\;>,69F8DLS,?AV2S,22222222<U^G?[:_PE\?:%_P2/O/!WQLU
M/0?$7Q1^$6@_#26[U_3;RYU;3YK[P]\0=$\,6%[::KJ>F:7J%QJ-QX'U-].O
M+Z:Q@N[J^NKV.66Y6XEN+C^=KQA^T3^VY\/O$NK^#?''Q\_:?\)^*M NWL=9
M\/Z_\6_BCIFJZ==( WEW%I=>(HY562-DF@E :&YMY(KBWDE@ECD;%^(/Q3_:
M]UGX?Z9)\5/B3^T=JWPM^(IGBTC_ (6!XS^)>H>!/'(\/W6FZA<+IZ>(M3FT
M'Q(FCWTFE7CF!;Q+*\^QSYCN(XF7KQW _B'Q)FW!.9<1<:<&XK"9%Q)EG$&7
M/+,HKX7%8V.&:Q.(PN#Q+Q52-:EC,#3J2E3AS4ZD:=.M.].E=>9E?BMX-\$\
M/^*.2<&^&/B5@<PXLX)SSA#.HYYQ)A<PP&5SQL98+!X_,L%' 49X;$9;FM:C
M3IUJKA5I3KU<-32JXBQ_1?\ \$J=*\/_  &_X)T>-?V@$TRUGU;6H?BY\4O$
M%U*HAGU#3/A9#KNC:7H\]XH:4:;9CPIJMQ;Q@;;:YUK5)HTWW$C/_+A\0_'_
M (M^*GC?Q/\ $3QWK-WK_BWQ?K%YK>MZI>S2S237=Y*9/*A$KR?9[&SB\NST
MVQB(MM/T^WMK&TCBMK>*-?Z@O^"2.K^'OCC^P#\1?V?[G6(XM1T>\^)GP^UR
MS"":[TGPY\5M+U"^TS5OLS,BRVE[<ZUXDCMLNJS76DW\)*^66/\ ,I\6?A)X
M_P#@C\0O$/PP^)'AV_\ #OB[PWJ$EC=6-W;RHEY%YC+9ZII4S(J:EH^JPA+O
M2M1M3);7UK+'+"[!B!AX32PM/Q.\::68RI_ZRSXBA4H+$.V+EPXZF*E@5AE4
MM4>%IT98'VSI7ARO .?N_5V=/TB(YA6\"?HOU\EIU7P1#@NK1Q;P2<LNAQJJ
M.7PS5XYT;THX^KBJ>:O#*O\ O?:1S>-+WUBT?TS_ /!"[4]2O?V6/BI8WFH7
MUW9:1\9-8MM)L[F[GGM=+M[GP3X1O[FWTZWED>*R@N+ZYN+V>*V2*.6[N)[A
MU::61V_E/K^O'_@C;\&OB5\(OV6?%T_Q)\*ZEX/G^(7Q"U'QIX8TS6X6LM8N
M/#,GA/PWH]IJE[I4P2]TR._N]+O)+"&_BM[FYL5@U!(?L5Y9SS_R'5OX38C"
M8KQ-\=,1@:V'Q&&J9QPMR5L-.G4HSJ0P^>PKN-2DW"4E7C5C4:;?M5/F?-<X
M_I$X/,,O\"_HGX3-,+B\'C:7#/'GM,-CJ-:AB:5*IB^$ZN%4Z->,:M.$L).A
M.BI12]A*FX+D<0HH SP*E5.YY]O3_'^5?T&Y);_=U/XV&!2?8>M2@ =*6BIL
MY;Z+MW]?Z^X HHHJTK:( HHJ14[G\O\ &DVEN)M+<:%)]AZ_X>M2A0.GY]Z6
MBLI2;\EV_P ^YE*3?DNW^?<****DD**** "BBB@ HHHH ***<JD^P_G]*=OD
MN_03:6K&@$]*E" =>3^E.  Z?Y^M+1>VU_7K_P !?TWVSE-O;1?B%%%%(@**
M*4 GI0 E2*G<_E_C3@H'N?7_  ]*=0 4444 %%%% !1110 4444 %%%%!G*?
M\OW_ .7_  0IP4GV'K_AZTY4[G\O\:DH,Q H'3\^]+110 4444 %*%)^G<T\
M)Z_E_P#7J2HE/HM?/M_G^0#0H'U[FG445DW?5@%%%% !11101*:6BU?];A11
M15*+?DNYFVWNPHHHK5)+9?/J(* ,\"G!2?8>M2@ =*4I)>;_ "]0&JG<\^WI
M_C_*GT45DVWN 4444@"BBB@ER2\WV_S[!11109.3>_W= HHHH$%%* 3P*E50
M/<_R^E # A/7@?K4@ '2EHH **** "BBI GK^7_UZ!-I;C I/T[FI0H'U[FG
M44$V<M]%VZ_E_7;J%%%%!226P445(J=S^7^-)M+<&TMQ@4GI^?:I0H'N?7_#
MTIU%92DWY+^MS*4F_)?UN%%%%22%%%%7&#>KT7Y@%%%%:)):( HHHI@%%%."
MD^P]?\/6ANVK ;4BIW/Y?XT\*!T_/O2UE*=]%IY]?^  4445 !1110 4444&
M<I_R_?\ Y?\ !"BBI%3N?R_QH,Q@4GI^?:I0H'N?7_#TIU% !1110 4444 %
M%%% !2A2>GY]J>J=S^7^-24$2G;1:^?3_@C0H'N?7_#TIU%%!DW?5A1110 4
M445#G;1:O\/^" 4444E%O65_3^MEY?D 4445HE;1 %%."D^P]?\ #UJ4*!T_
M/O03*27F_P"MQBIW/Y?XU)1109-M[A1110(**4*3].YJ4*!]>YJ922\WV :$
M]?R_^O4E%%9-M[@%%%%( HHHH)<DO7H@HHHH,G)OTZ(****!!10!G@5*J8Y/
M/MZ?XT ,52?8?S^E2@ =/\_6EHH **** "BBB@3:6X4444&4I-^2_/U"BBE
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M/#^&%\%GXF^)Y?$8\++K)\0C1$>SM+-+(ZV=+T0ZFR):*[W7]DZ>)'=L6T8
M%> T5]S0X4X?PG$V/XQH8#V?$>99=1RG'9E]:QLO;Y?AYT9T</\ 5)XF6!I\
MDZ%)^UHX6G7ER6E4DG)/X#$\8<18KA7+^"\1F//PQE695\XP.6?5,##V&8XF
M%:G6Q/UR&&CF%7GA7JQ]C6Q52A'GO"E%J+7Z??\ !-?_ (*0?\.\]0^+]_\
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MY_+_ !J2BBM(PZO[O\S)MO<****T$%%%%)R2W^[J 4445DY-^2[?Y]P"BB@
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M^6C_ (B.?$?_ $:5HG_AZ+__ .=E1_Q$<^(_^C2M$_\ #T7_ /\ .RK^1O\
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M#\SZ*Y\TX/X<SGAC_4S,LN^L\-?4\OP']F_6\=1_V3*ZF&JX&C]<P^*I8_\
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M#QQI_B?XG7&G:/X;\,K?6_@7X>^&TN(?#7A2UU!X#>SHUU+/>ZMKNIK:6?\
M:VN7\IEN3;10V5MIFFPVVG0<[^Q5^TX?V/OVB?!OQ\'@D?$,>$K#Q78GPF?$
MA\)?VB/$_A;5_#?F#7O[!\2_8S8G5!>[3HUT+D6YMMUN9OM$7RG2@$]*^VI\
M(\.4>&JO"%+*L-A^&ZV78G*:F585U<+0> QE.I2Q5)5</4I8F-3$1K595<3"
MM'%3K5)UW6=>3J/X*IQOQ56XNH\>8C.L5B^+</FN$SNEG6,5'&8B.98"K2K8
M*NZ.*I5L).GA94*,*.$J8>6#IT*5/#1PZP\527V+^W3^UHW[:GQ[OOC>W@%?
MAJ+OPMX;\,IX7'BD^,#"OA^"XB-XVMGP[X6$K7CW+OY TB(6ZJL?FSG,A^K_
M  __ ,%3I-#_ ."?<_["O_"BTN3/X(\2>"_^%IGXF&$+'XB\7ZIXI;4/^$''
M@"0E[2/4SIPMO^$P F>$7IGB5_L:_D@% ]SZTZO,Q? /"&,RCAS(:^4>TRGA
M'&Y=F'#V%^OYG#^S\9E-.I2R^LJ]/&QQ.+]A3J3C[/'5L32K<W-7IU)*+7JX
M3Q0XZP&>\6<2X3/?99WQQE^:Y7Q1C?[-R>?]J8'.ZM*MF=#ZM4R^>$P7UFK1
MIR]KEU#"5J'+RX>I1C*28!C@5^N7Q4_X*G_\+,_8'T+]A[_A1/\ 8G]B>!?A
M-X*_X6?_ ,+/_M+[3_PJ[5_"FJ_VG_PA7_"O+#R?[<_X1CR/L?\ PELO]F?;
MO-^UZA]F\NX_(VBN[/.%<AXDQ&28O.L!]=Q'#F:T,[R:I]:QN'^IYGAI1G0Q
M7+A,10AB.24(OV.+C7P\K6G2DFT_)X<XTXFX2PO$6"X?S+^S\-Q9DN)X=X@I
M?4\OQ7U_)\9"<,3@^?&X7$U,+[2,Y+ZQ@IX;%0O>G7BTFOV+_P"")GP ^(/Q
M5_:VL?BCX3\77/@CPW\ K6U\1^,]3LK6SOKKQ#!XK34]"LOAZMM?)-;16WC'
M38/$<>IZE)!++INEZ9>S::]IKC:3>VWZB?&S_@NC^SOX?^)OC3P&/V<]9^*^
M@>"/$&H>'=,\9WNK^&8+?7+G2IFLM4O].T75]!U&6QTQ]1ANH],N'OGGU&P2
MWOY[6PDN#9P?DG_P2:_;U\)?L3?%3QK8?$ZPOY/A3\8K'PWIWBG7](MYM0U/
MP?JWA*?7)?#OB#^R;>.6ZU?2$C\2:S9:U8Z>AU18;JWU"PBOIM/_ ++O_P!#
M_BG^PS_P28_:/\6:Q\6OAG^W%X%^$*^,[V[\2ZWX3;XC_#BWTJUO]6G-W=W6
MG^$_'EWX=\7^%$NKV>:XN=*U&:6TLY9A:Z?8Z5:QQ6:?S1XC93D6*\5LTS#Q
M2X=XCQ?"L,@RK!<&9OP_@,TJX6E*"EB,UIYKB\@2S'ZZL?7Q5/!T*\ITJ>%E
M.;H15:E6?]?^$^=\28/P3R;+/!CBKA/ \:3XGSO,?$#(N*,RR:CCJT)N.%R6
MKDV"XG;RI9<\LP^"J8_$X>%.K5QD(4UB92H5Z"^COV8O^"A?[#_[=GQ6T;]G
MSQ1^R1HVA^*/&FGZ^OAH>,/ OPY\;>&M3.AZ%J?B'5M-N=0BTV*_T>Z.B:7J
M-Y93-I;V<LEK) ]_:7;V:77Y/?MC^%-'_P""8G_!3#P9XV_9Y\/VEQH]AI?A
M[XJ^&/A[J-Q?7MA8V_C)/%/@GQ/X*M[M9KC58[/4%L]=.BR.UQ=Z3#K%C%'%
M>QV,(N/O;X2^*?\ @DG_ ,$OXM3^)'@GXOW/[3?QPN-/O](TG4/"VHZ'X]UB
MUM[I-E[9>&9O#T.G?#_P;97T?DVVI:SJFN76O7%C)>VFG7EY97%YI4OY8^"O
M^"E=_)^W3KG[:/QK^$GAOXI276A:OHWA3X?S/9);?#^.QM(#\/I?".KZOI>J
MKIFK^'KS3[:&]\3)IC:C,FL^)]6M+6&^OTMEPX)X<Q4.(N+<RX)X8XNJ>&M3
M@O'97/AKBO'8W+X<7YYB93BZ.54<[J^WPV#J85N@\?B;3HR>)IJ<5BO80Z/$
M/BS!5.%>!LH\1.,>!J7B[2\0<NSF'%_!.79?FE3@/AS"1I35?.J_#M%8?&8^
MGC$L3'+,)S0KQ6$JRIRE@OK-3]<_^"V/Q3NO%7[ W[.#_$'P9'\._BA\3OB3
MX.\=2?#:]UI-7U;P6NG?#GQ=-XELY+UM.T>>_N=!G\5:)H>K/_9-G':WFK>3
M,J2I")OY1:^J_P!L#]L#XK?MH?%6;XG?$^>RLXK&R.B>#?!VBB:/P[X,\.+<
MRW2:9IRSN]Q>7MU<3/=ZQK=ZSWVJW94'[-IUIIFFZ?\ *E?N7A'P7B> ^"L%
MDF.CAZ6.JXO'YKC,)A*M:OA,OJYCB)5H9=AJ]>=2M7IX'#JCAG6G4J.M5IU*
MOM*BFIR_F_QT\0L)XE^(>8<19=+%5LMH8'+,EP&-QU"AAL=F=#*L+&A4S7&8
M;#4Z-##ULRQ3Q&,CAZ=*E'#T:M*C[*DZ;IQ^C/V2OC^?V6_VA_AI\>QX3'CD
M_#O4-8OO^$4.NGPR-8&K^&=;\-M#_;@T?7_[/,"ZR;P2?V/?"0VX@,:"7SH_
M7/\ @H)^VH_[=GQG\.?%UOALOPM'AWX9Z+\.4\/+XP/C8W2:1XH\9>)CJ[ZN
M?"_A(1-<OXO>S%B-+<0I8+-]LE-R8X?A>BOK*W"N0U^)L+QA5P'/Q'@LLJ9-
MA<Q^M8R/LLMJU:U>>&^J1Q"P,^:K7JR]M4PL\0N?E551C&*^(H<:\38;A#&\
M!4,SY.$\QSBEG^,RGZG@)>VS:C0H8>GB_KT\++,J?+1PM"'L*6,AAI>S4I47
M.4I2_6_]CG_@J>_[)7[,/C[]G%?@6GCYO&VM>.]8C\9M\3#X772F\:>%-'\,
MBW?PX/ 'B(Z@-,?2?MYD77[ WRW'V0)9F+[5+^2(4GZ=S3PGK^7_ ->I*>4<
M+9#D.8Y]FN4X#ZIC^)L92Q^=XCZSC*_UW%T8U8TZOLL3B*U'#<L:U1>SPE.A
M3ES7E!M1:SS_ (WXEXERKAK(\ZS/Z]EG!^!KY;P[AOJ> PRR[!8B5&=:BJV$
MPM#$8SGEAZ+]KCJN)JQY$HU$G)/];_A'_P %3/\ A5?[!GB/]B/_ (45_;O_
M  D'@7XN^"_^%F_\+._LO[)_PM6\\4W?]I?\(7_PKW4?M']@_P#"2^7]C_X2
MR'^U/L6_[7IWVG;!^2%%%&2<*Y#PYB,[Q>38#ZGB.(\UKYUG-3ZUC<1]<S/$
MRE.MB>3%XBO##\\IR?L<)&AAXWM"E%))1Q)QMQ/Q;A.',#Q#F?\ :&%X2R7#
M\/</TOJ67X3^S\GPL(0P^#Y\#A,-4Q?LXTX+ZQC9XG%3M>=>3;;_ %J_X)[?
M\%5=?_84^'WCCX:W?PD_X6]X;\3^++;QCHD#?$-O K^%]4FTJ'2?$"H6\$>-
M!J5OK4&FZ%+'$@TQ;"?3[J4B\?4G-M\@?MH?M4:_^V1\?_%'QQUO0?\ A$8-
M7T_0-$\/>#5UMO$4/A70- TJ"RATR'6GTK1&O_M6I?VGKMS-_95BIO\ 6+L1
MP)&$KY4HK@P' 7".6<4YEQK@<FI8?B;-Z$\/F&9K$XZ;KTJGU;VG+@ZN*G@,
M/4J/!T'5K8;"T:U1QFYU).M6=3TLS\3N.LXX*RCP\S+B"MBN#LBQ$,5E>3RP
MF74UAZU+ZY[+GQ]'!T\TQ5*BL?B51P^,QM?#TE*G&G2BL/AU2VO#?B/7_!^O
MZ+XJ\*ZQJ/A[Q+X=U.RUG0M=TB[FL-4TC5=.N$NK'4+"\MW2:VNK6XCCEAEC
M=61U!![5_0M\'/\ @OSKL?A"U\(?M,? +2?BA=)$EIJ7BWPAJUAH::Y:1HB"
M36? >MZ-J>B3ZE*5,UY<:?K6D:5-*^+71+"-0I_G152?8?S^E2@ =/\ /UK+
MC#P]X/X]HX:EQ1DU+,)X%RE@<7"MB<'CL&YN+FJ&-P5;#XF-.4H0G*C*I*A.
M<(3E2E*,6MN ?%3CSPRKXRMP9G]?*Z>8QA',<#4P^$S#+,<J:E&#Q.79A0Q6
M$E5A&4X0Q$:4,3"$YPA6C"<HO^B3XF_\%XH;3P?K'@W]FO\ 9=\(?#@ZG%+:
MQZYXNO\ 2]4TJWM;B&2WN&/P\\->']#TJYO&@D/D/J'B._TY&'EWFE:C;L\+
M?DE^R1^VE\9_V,_B)?\ CSX47ND26GB06=KXX\%ZWIT<_A?QAI=E<7-Q:V5Y
M#:FUO=+GT^2]NY=(U'1;NQNM/DGDB/VC3Y[O3[KY)HKBR7PKX!R#*,WR/ <.
MX:679_&E'.Z6/KXO,ZF:>PYG0>*KYAB,36;P\YRJX?V<Z<</6DZU!4ZOOGH\
M1>-?B=Q1GN1<29IQ5BX9MPO*M+ARMEF'P.34LF^L\BQ,<%ALJPN$P\5BJ=.%
M'%.K3JRQ6'BL/B95:%Z9_2_'_P %U_@)XOL+/6/BO^Q9;:SXZTXH]K<1ZMX,
M\56"W,"!8KJSUGQ)X2L]8TDLP^2&.SOI+1,*MW<E=Q_/7]O3_@JQ\5_VUM"@
M^&]AX5L/A+\'(-1LM7N_".G:U=>(-=\4ZGIV7L9/%OB0V>C6M]I=A=;=1TW0
M+'0[&SMM12WO;^?5[S3]+N;'\JJ*\O(?!3PVX;S;"YUE?#\EC\OG*IELL;F>
M:YE0RR<FI<^!PN/QN(P]&I&24J=9TYUJ,DI4JD)),]GB;Z1'BYQ=D>-X>SGB
MB+RW-*4:.;QR_)\DRG$YQ3BG'V>98W+,NPN*KTIQ<H5J"JPH5X2E"M2J0DXO
MZ-_93_:=^(/[(GQH\._&CX<K87FIZ5!>Z3K6@:O]H_L;Q5X8U98TU?P_JAM)
M8;F.*<PVU]974,A?3]8T_3=1\JY%H;:;]Z]2_P""^OP9U:ULO$NH_L?:AJ7Q
M&TJWECTE]2\8>%;VUTPLKLL5EXRG\&OKMI;O-))YHMO#T)VN[A&9V6OYAZ*]
M#B[PHX$XYS'#9MQ'DTL5F6&PZPD<9ALPS'+JU7!J4Y?5<3++\5AOK%).I447
M44JD(SE"%2,)2B_)X&\<?$KPVRK%Y'PGQ!#"93C,4\?+ 8S*\JS;#T,PY:</
MKN%CFF"Q;PM>U&DY*BXTJDZ<*E6E.I&,U]?_ +)W[5-E^RO^U)I'[1VE_#2#
MQ)INBW/CQK#X<6_BJ3PY!;6'C+0]=T2TTZW\2R>'_$$D<6@PZQ$8I)-"G:^C
MLA"RVK3^?"_]N7]K%OVT/CS??&UO 2_#<7?A?PYX93PP/%!\7F)?#\-Q&;Q]
M;/A[PN)6NWN7<0#2(A;JJQ^;.<R'X]I02"""00000<$$<@@CD$'D$=*^B7"?
M#ZXDH\7+ -\14,F604LQEB\=*4<I5>6)6%>&EB7@YOV\Y5'B9X>6+=^5UW"T
M3XZ7'7%,N$:_ CS-+A/$\0/BBME$,!EL(RSQX:&#>-CBXX..84XK#4X4E@Z>
M+A@8\JDL,IWD?V)>$OC#_P .A_\ @G[\&M&^/-WKGQ<\>^)M5N%\+?#?3CI>
MC1>&1XD2/Q3X@\%Q:])9WA;0O!*WU_/?ZOJ$.L7=]XBUE=*TR&U\/R6 TGY@
M'_!=']F*\D*ZK^Q?>-#<$B\<7?P^U"1UD_UN8;GP[:I<ELG*RS1!_P"(C)KT
M&V_:Y_X)^?\ !3W]GWPC\,OVN?'%K\#_ (M>&5@U":^U;78?!JZ1XIMK(:;J
M'BCP3X\US3KGP3<Z-XDA)DNO#'B4O=P>9]FDTZYETO3?$#_/-C_P38_X)6^"
M-3M->^(/_!0[POXJ\,P2I='PWH?Q,^$=K?ZI @\U;>6Y\/WOB36)K296B6>3
M2M.M+J2)F%K=VLTL4L7\:9/DG E.IGM7Q;X2XXH^(6,S[.,=F']C9;Q%3R_,
MGB,5.MAGD3X?=++:V&<7S0KUFG6Q$ZM:6)JTIP<?]!\^XC\3:M+AJCX%<=^&
MU?PIR_AG(,MRK_6'..%*N:90L)@J-#%+B5<4QK9OA\9&<>6>&PZE'#X:G1H1
MP=&M3G&?UI^U;\"?V./VT?\ @GEXJ_:]^#OPIT+X::]HOP]\6_$GPAXDTSPA
MHG@/Q.L_P[U'5[;Q7X2\8V'AUETK7X;J?P_KNBPRSW.JQ0WC6FJZ'?O&0MU^
M6/[ O_!7WQK^R!\/H?@QXY^'P^+/POTR]O[SPC]C\0+X;\4^"UU>^DU+5M-M
M;BXTS5M/UW0I]1N+W4K73;J+3;NSO]0O636)+%K>PMO9/V^_^"FWP7U3X#6W
M[%_[#VA3:+\((=.@\+>)_&+:/=:#IMWX1TZXAND\->"+#5)%\0SPZ_>H]QXL
M\3^);.PU75D:^A-OJ#ZW?:J/P,"@>Y]:_6O#/PWJ9[P)G61>(F4YI7X>S'B?
M%9KPGD/$>-Q4\^R+*(Q5/+WB,52JTL5EV,Y'44J%.I2=IXF4Z*AC:M.?X3XQ
M>+U+AKQ,X>XD\*,\R7#\695P;@<DXYXFX1R[!T^&.)<_G+VN:+#8.O0K8+-,
MOYX473Q-:C7O[/"0I5I5,NH5H?T1?%__ (+O&#PAJWAC]E/]GW2/A)K&M><\
MOC;Q++H%[)I=Q<9$NHZ?X*T'2+?1KW6@'>6WU'7=5U*RBG"F\T34HV:.OC7]
MM#_@J%KW[9G[.?PL^!WB;X5?\([XA\!>)/"'BWQ%\2G\>IKTGC;7O#G@7Q%X
M0U.]/A:'P/X>@T#_ (2"^\1W>OO%'K>JII[(NG1BY1OM:_E317Z)D?@SX<</
M8G+<?EO#E.GF>4XV68X/,ZN/S.OF"QDZ7L'.OB:N,E/%4HTFU3PN)]K@Z4G*
MI2P\*DI3?Y1Q'](/Q=XJP>;Y9G'%M6KE&>9;#*<?DU#+,FPN5/ 0KK$*EA<'
M1R^%/!5IUDI5<=A/8X^O!1HUL5.C"%./I7P=^+/C3X%?%#P1\7OAY?Q:=XR\
M Z[:Z]HL]S$\]E-)"'AN]-U*VCEMY+K2=8T^>[TG5[2.XMWNM,O;NW2>%I!*
MO]$=O_P7R^$WB;P_I4WQ._9'N=:\8:*(+FRCM_$_AK7/#\>L+%']IU'2KSQ!
MX975/#PFN(EE@BBM-4NK:(1Q2:A=O )Y?YDJ*]'C'PQX+X\Q&!QO$N4RQ6.R
MZG*AA,=AL=CLNQ<,-.;G/#3K8#$8>56A*4IN,*O/[)U:SHNG*K4<O)X \9?$
M/PQPF8Y?PAGD,%EN;588G'9;C,MRS-L#4Q=*$:=/&0P^9X3%0H8F,(4XRJ4/
M9^V5&A'$*K&A14/>OB]\==0\?_M&>-_VBO ND7'PDUSQ1\1[WXG:+I_A_7KB
M]O/"/B.^U,:W)>:?X@CLM(GFO?[::?5/MD=A8J+F=Q';11JJ5^W/P:_X+YZA
M'X+A\)_M-_ BS^)&I16RVUYXL\&ZCI6E6_B2./:J/KG@76],N='BOI-@FO+O
M3-7MM-GG8_9/#^FQ(L9_G- )Z?Y^M2JH'N?Y?2CB;PRX'XMR[*\LS[)(8NCD
ME"EALHKQQ6-H9C@*%&G3IPI4LRHXB&.G!PI4W4CB*]:-6<(UJL9UHJHHX0\9
M_$;@/-LYSCAGB.I@<3Q%B:^,SS"2P678G*LSQ.(JU:U2M7RC$82IEM*HIUZO
MLJF&PV'G0I5)T*$J="4J3_H$_:-_X+P>/?&?@Z^\"_LV_"V+X,1:A8/IDGCS
M6]9M==\5:782Q&%D\):)INF6&A^&M0BCQ';ZM<W7B![9':33[+3[Z&UOX?P!
MEEEGEEGGEDFGGD>:::9VDEFFE8O)++(Y9Y))')=Y'9G=B68DDFHZ*Z>$.!.%
M>!,'7P7"^44<MIXJI"KC*WM*^*QF,J4U)4Y8K&8NK7Q-94^>HZ5.57V-%U*G
ML:=/VD^;Q^/_ !/XY\3\PPV9<;9]7SBK@:4Z.7X?V.&P67Y?2JN#JPP67X&C
MAL'0E6]G25>M&C]8Q"HT?K%6K[*GR_K-^T5_P5&?X^_L;>"/V2?^%')X3_X0
M_1OA7I$GQ _X64==_M,?#/2++3/M">%/^$"T;[ =;>R6X\MO$M\--5V@WWY
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MA,=@Y>TIMQYY8>4X?%3E"23+NF7IT[4M/U 1B8V%[:7HB+;!*;6>.<1EPK%
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MU_\ A$_$.G:]_9?]H_9+_P"P?;_L'V3[;]@O?LOF^?\ 9+GR_)?[>_X*"_\
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MO^+:Z(/$A^&_CKPUXT_X1\ZB=(_MH>'M5MM2.F?VJ+'5/[.-X+<P"]_LV_\
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M>%RW OAK@_&?5J$JM2LZ?UK,.'\7C*UZM6I+FQ&(JS7-RJ7*HI?M_P#M._\
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M4M=WW9^>A1115 %."D^P]?\ #UIRIW/Y?XU)42GT7W_Y=_ZW,Y3Z+[_\N_\
M6X@4#I^?>EHHK(S"BBB@ HHHH **** "BBB@ H )Z4Y5)]A_/Z5* !T_S]:>
MBWW[?Y_Y+7O8B4TM%J_ZW&A .O)_2GT44-M_U^AFVWNPHHHI""BE )Z5*% ]
MSZT ,5.YX]O7_#^=2@8X%%% !1110 4444 %%%% !11102Y)>O;^M@HHJ14[
MG\O\:#)R;W^X:%)]AZ_X>M2A0.GY]Z6B@04444 %%%2!/7\O_KTFTMP&!2?I
MW-2A0/KW-.HK*4F_)=@"BBBI ****!-I:L****$KZ(SE-O;1?B%%%%:QAU?W
M?Y_U8@***<%)]AZU5TEV0#0,\"I53N>?;T_Q_E3@ .E+6<IM[:+\0"BBBH *
M*** "BBB@SE/^7[_ /+_ ((4444&8444H!/ H 2GJA/)X'\Z<J <GD_RI] "
M  <"EHHH **** "E"D_3N:>$]?R_^O4E!#E?2.OGT7]?U<:% ^O<TZBB@:C;
M5ZOO_E_7W!11104%*%)Z?GVIZIW/Y?XU)42G;1:^?3_@D2G;1:^?3_@C0H'N
M?7_#TIU%%9-WU9DW?5A11132;T0!1116D8):O5_D 44458!1110 44X*3[#U
M_P /6I0H'3\^]3*27F_ZW 8J=S^7^-2445DVWN 4444@"BBB@ER2]>B"BBB@
MR<F_3H@I0">E.5.YX]O7_#^=2@8X% AH4#W/K_AZ4ZBB@ HHHH **** "BBI
M%3N?R_QH$VEN,"D]/S[5*% ]SZ_X>E.HH,I2;\E_6X4444$A1112;2W ****
MAN4M%HOZW?Z+\0"BBBJ44O-]P"BBG!2?8>O^'K5 W;5C:D5.Y_+_ !IX4#I^
M?>EH,I3OHM//K_P HHHH("BBE"D_3N:&[:L!*D">OY?_ %Z<% ^O<TZLI3Z+
M3S[_ .7Y@%%%%0 4444 %%%%!G*?\OW_ .7_  0HHHH,PHHH SP* "G!2?8>
MM/5.YY]O3_'^5/H 0 #I2T44 %%%% !11101*:6VK_ ****#)MO<**4 GI4H
M4#W/K0 Q4[GCV]?\/YU*!C@444 %%%% !1110 44X*3].YJ4*!]>YH 8$]?R
M_P#KU)110 4444 %%%%3*27F^W^?8F4DO-]O\^P4445FVY/\D9-M[A1115QA
MU>OEV_S_ "$%% &>!4JIW//MZ?X_RJG)+?[NH# I/L/6I0 .E+163DWY+M_G
MW ****D HHJ14[G\O\:!-I;C0I/L/7_#UJ4*!T_/O2T4&4I-^2[?Y]PHHHH)
M"BBB@ HHHH **** "BBGJA/)X'\Z!-I:L: 3P*D5 .3R?Y4X #@4M!G*;>BT
M7YA11100%%%.52>>@_STH 0 GI4@0#KR?TIP '3_ #]:6@ HHHK.4_Y?O_R_
MX(!112@$]*A)R?=_UN E/5.YX]O7_#^=/"@>Y]:=6L8I;ZO\O3_,  QP****
MH HHHH ****SE/\ E^__ "_X)G*?\OW_ .7_  0HHHK,S"BBB@ IP4GZ=S3@
MGK^7_P!>I* $"@?7N:6BB@ HHHH **** "BBB@ HHHH *4 GI2JI/L/Y_2I0
M .G^?K01*:6BU?\ 6XT(!UY/Z4^BB@S;;W84444""@#/ IRJ3[#U_P /6I0
M.E3*26F[_K<!JIW//MZ?X_RI]%%9^])_U9 %%%%:**7F^_\ EV ****HER2]
M>W];!11109.3>_W!1110(**4 G@5(J <GD_RI.27KT0#50GD\#^=2  <"EHK
M)R;].B _#4*![GUIU%%?M[;>Y_I<W&.B^Y?K_5PHHHI&3DWO]W0****!!12@
M$]/\_6I54#W/\OI0 P(3UX'ZU( !TI:* "BBB@ HHJ0)Z_E_]>@3:6XP*3].
MYJ4*!]>YIU%!E*3?DNP4444$A1110 4444 %%%% !113E4GGH/\ /2DVEJQ-
MI:L: 3TJ4(!UY/Z4X #I_GZTM9RFWMHOQ,Y3;VT7XA111246_)=R HHIP4GV
M'K_AZUJDHKMW8#0,\"I53N>?;T_Q_E3@ .E+6<IM[:+\0"BBBH **** "BBB
M@ HHHH ***4 G@4 )3U0GD\#^=.5 .3R?Y4^@SE/M]__  !  .!2T44&8444
M4 %%%% !1110 4444 %* 3TIRIW/'MZ_X?SJ4#' H(E-+;5_@-"@>Y]:=110
M9-M[A1110 4H!/3_ #]:<$)Z\#]:D  Z4 (J@>Y_E]*=110 4444 %%%%3*2
M7F^Q,I)>;[!11163;>YDVWN%%%%(044H4GI^?:I0H'N?7_#TH :$]?R_^O4E
M%% !11132;V ** ">E2A .O)_2M+1AOJ_P"ON_X<3DEO]PQ5)]A_/Z5* !T_
MS]:6BH<F_3M_6YDY-^G;^MPHHHJ20HHHH **** "BBB@ HHIX0GKP/UH : 3
MT_S]:E50/<_R^E* !TI: "BBB@SE/HOO_P @HHHH,PHHHH **** "BBE"D]/
MS[4 )4@3U_+_ .O3@H7Z^M.K*4^BT\^_^7Y@%%%%0 444H!/2@!*D5.Y_+_&
MG!0/<^M.JE%OTZLSE/HOO_R"BBBM5%+U[F84444P"BBBLY3Z+[_\@"BBBLP"
MB@ GI4H0#KR?TH 8JD^P_G]*E  Z?Y^M+10 4444 %%%% !2@$\"G*A/)X'\
MZD  X%!$II:+5_D-5 .3R?Y4^BB@S;;U84444""BBB@ HHHH **** "BE )Z
M5*J@>Y]?\/2IE)+S?;_/L3*27F^W^?8:J=S^7^-2445DVWN9-M[A1113C%OR
M7];?Y[""BE )Z?Y^M2JH'N?Y?2M+QBK=?Q?K_7H Q4[GCV]?\/YU*!C@445D
MY-[_ '= "BBBD 4444 %%%% !1110 445($]?R_^O0)M+<8%)^G<U*% ^O<T
MZB@RE)OR78****"0HHIRJ3[#^?TH : 3TJ4(!UY/Z4X #I_GZTM !1110 44
M44";2W"BBB@SE-O;1?B%%%%! 444H!/3_/UH 2GJG<\>WK_A_.GJH'/4_P">
ME.I:OR7?K\NWSU_,  QP****=K %%%* 3P* $IZIGD\#]:<J <GD_P J?6<I
M]OO_ . 9RGV^_P#X @ '2EHHK,S"BBB@ HHHH **** "BBBFDWLOGT *4*3T
M_/M3U3N?R_QJ2JNH[:OOT^7]?,B4[:+7SZ?\$:% ]SZ_X>E.HHJ&[ZLR;OJP
MHHHH **** "BBB@ HHHH **<%)]AZ_X>M2A0.GY]Z &*G<_E_C4E%% !1110
M9RG_ "_?_E_P0HI0">!4BH!R>3_*@S&A">O _6I  .E+10 4444 %%%%)R2W
M^X HHHK)R;].B ****D HHJ14[G\O\:!-I;C I/3\^U2A0/<^O\ AZ4ZBJ46
M_)=_\NYE*3?DOZW"BBBM5%+;[^I(444]4[GCV]?\/YT-I;@- )Z5*% ]SZTX
M#' HK*4F_)?GZ@%%%%2 4444 W;5A111092G?1:>?7_@!11100%%%*%)^G<T
M )4@3U_+_P"O3@H'U[FG4 %%%% !110 3TH *>J$\G@?SIRICD\G]*?0 @ '
M I:** "BBB@ HHHK.4^B^_\ R,Y3Z+[_ /(****S,PHHHJXQ;WT7Y^G^8!3@
MI/L/7_#UIRIW/Y?XU)3<DE:/W_KY_P!= $  Z4M%%9@%%%% !2@$]/\ /UIP
M0GKP/UJ0 #I0 BJ![G^7TIU%% !1110 4444$2FEHM7^04444&;;>K"BBB@0
M44H4GI^?:I0H'N?7_#TH :J=S^7^-2444 %%%% !11102Y)>;[?Y]@HHHH,G
M)O?[N@4444""BBI%3N?R_P :3:6X#54GV'K_ (>M2@ =*6BILY;Z+MW]?Z_S
M ****M*VB ***D">OY?_ %Z3:6XFTMQ@4GZ=S4P4#Z^M+164I-^2[&4I-^2[
M!1114DA1110 4444 %%%% !113E4GV'\_I3M\EWZ";2U8T GI4H0#KR?TIP
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M3PH'3\^]+64IWT6GGU_X !1114 %%%% !11109RGV^__ ( 444]4[GCV]?\
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ML/6GJG<\^WI_C_*GU$I]%]_^0"  =*6BBLP"BBB@ IP4GV'K_AZTY4[G\O\
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M/7_#UJ4*!T_/O3E)+S?];@,5.Y_+_&I***R;;W ****0!1110 4444 %%%%
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M4444G)+?[NH!11163DWY+M_GW *** ,\"I *<JD^P_G]*>J <GD^G;_Z]/H
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M2 ****"922\W_6X4444&3;>X4444""BE"D_3N:E"@?7N: &A/7\O_KU)110
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M]O1:^A,I)>;_ "]1H0#KR?TI]%%#;?\ 7Z&3;>["BBBD(**4 GI4H4#W/K0
MQ4[GCV]?\/YU*!C@444 %%%% !1110 4444 %%%%!+DEZ]$%%%2!/7\O_KT&
M3DWZ=$,"D_3N:E"@?7N:=10(**** "BBI%3N?R_QI-I;@,"D]/S[5*% ]SZ_
MX>E.HK*4F_)?UN 4445(!1110)M+<****$KZ(SE-O;1?B%%%%:QAU?W?Y_U8
M@***<%)]AZ_X>M7HEV2 :!G@5*J=SS[>G^/\J< !TI:RE-O;1?B 4445 !11
M10 4444&<I_R_?\ Y?\ !"BBB@S"BBE )X% "4]4)Y/ _G3E0#D\G^5/H 0
M#@4M%% !1110 4H4GI^?:GJG<_E_C4E!+EK:.K[]%_7]=AH4#W/K_AZ4ZBB@
M%&VKU?Y>@4444%!2@$]*<J=SQ[>O^'\ZE QP*B4TMM7^!$II;:O\!H4#W/K3
MJ**S;;W,FV]PHHHH2;V ****TC!+5ZO\@"BBBK **** "BE"D_3N:E"@?7N:
MF4DO-]@&JG<_E_C4E%%9-M[@%%%%( HHHH)<DO7H@HHHH,G)OTZ(*4 GI3E3
MN>/;U_P_G4H&.!0(:% ]SZTZBB@ HHHH **** "BBGJG<\>WK_A_.@3:6XT
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MIW/'MZ_X?SIZJ![G^7TIU:QBEOJ_R]/\P #' HHHJ@"BBB@ HHHK.4^WW_\
M ,Y3[??_ , ****S,PHHHH *<%)^G<TX)Z_E_P#7J2@! H'U[FEHHH ****
M"BBB@ HHHH **** "@#/ IP4GV'K4H '2@F4DO-_EZC53N>?;T_Q_E3Z**#)
MMO<****!!13@I/L/7_#UJ4*!T_/O4RDEYO\ K<!BIW/Y?XU)116?O2?]60!1
M116BBEYOO_EV ****HER2]>B"BBB@R<F]_N"BBB@044H!/2I @'7D_I2<DM_
MN :JD]>!_/Z?XU( !P*6BLG)OTZ( HHHJ0"BBB@3:6X4X*3].YIP3U_+_P"O
M4E!E*3?DOZW/POHI0">!4BH!R>3_ "K]P/\ 2X:J$\G@?SJ0 #I2T4 %%%%
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M?S^E2@ =/\_6@B4TM%J_ZW&A .O)_2GT44&;;>["BBB@04 9X%."D^P]:E
MZ4 -5.YY]O3_ !_E3Z**3DEO]W4 HHHK)R;\EV_S[@%%* 3T_P _6I54#W/\
MOI3C!O5Z+\P&!">O _6I0 .E%%:I); %%%% !1112<DO7HB7)+UZ(****R<F
M_3HC)R;].B"BBBI$%%%2!/7\O_KT -"D_3N:E"@?7N:6B@ HHHH **** "BB
MB@ HHHH ***<%)]AZT";2W&@9X%2JG<\^WI_C_*G  =*6@SE-O;1?B%%%%!
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M ,U^?]69,O";Q2V7AUQIZ_ZM9OI_Y:?\#[F?C^% ^O<TZOU^_P"'%7_!2/\
MZ)!X5_\ #M_#3_YI:/\ AQ5_P4C_ .B0>%?_  [?PT_^:6C_ (BWX7?]'#X+
M_P#$DRG_ .:O/\^S,_\ B$?BF]7X=\:Z_P#5-9OY?]0GG_5F?D#17Z_?\.*O
M^"D?_1(/"O\ X=OX:?\ S2T?\.*O^"D?_1(/"O\ X=OX:?\ S2T?\1;\+O\
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M/_+O7\M^PO\ B$/BI_T;GC7_ ,1K-_\ YD/R"HK]??\ AQ9_P4A_Z)'X4_\
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M^:2C_AQE_P %'O\ HD?A7_P[/PV_^:2C_B+/A?\ ]'"X,_\ $DRG_P":R?\
MB$'BK_T;CC;_ ,1G-_\ YD/R'HK]>/\ AQE_P4>_Z)'X5_\ #L_#;_YI*/\
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M\(_"V/;XL_#;_P":2C_B+/A?_P!'"X,_\2/*?_FKS_/LP_XA!XJ_]&XXW_\
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M ,%'._PC\+#_ +JQ\-O_ )I*/^(L^%__ $<+@S_Q(\I_^:O/\^S#_B#WBO\
M]&WXW_\ $9SC_P"9#\B@"3@5*J@>Y_E]*_70?\$-_P#@HT.!\(_"W_AV/AM_
M\TE+_P ../\ @HW_ -$C\+?^'8^&W_S24?\ $6?"_P#Z.%P9_P")'E/_ ,U>
M?Y]F'_$'O%?_ *-OQO\ ^(SG'_S(?D917ZY_\../^"C?_1(_"W_AV/AM_P#-
M)1_PXX_X*-_]$C\+?^'8^&W_ ,TE'_$6?"__ *.%P9_XD>4__-7G^?9A_P 0
M>\5_^C;\;_\ B,YQ_P#,A^1E%?KG_P ../\ @HW_ -$C\+?^'8^&W_S24?\
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MX_\ $8SC_P"9#\BZ*_73_AQO_P %&O\ HDOA7_P['PX_^:.C_AQO_P %&O\
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M?PQ_Z.#P;_XD>4__ #4'_$&_%G_HVO'/_B+YS_\ ,9^2%%?K?_PX]_X*+_\
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M !%\Y_\ F,_)%5 ]S_+Z4ZOUM_X<@?\ !17_ *)-X6_\.M\./_FBH_X<@?\
M!17_ *)-X6_\.M\./_FBH_XBOX8_]'!X-_\ $CRG_P":@?@YXL_]&TXY?IPO
MG/\ \QGY)45^MO\ PY _X**_]$F\+?\ AUOAQ_\ -%1_PY _X**_]$F\+?\
MAUOAQ_\ -%1_Q%?PQ_Z.#P;_ .)'E/\ \U&3\&_%R7_-M..DNW^J^<^6_P#L
M?_#?)GY)45^MO_#D#_@HK_T2;PM_X=;X<?\ S14?\.0/^"BO_1)O"W_AUOAQ
M_P#-%1_Q%CPP_P"C@\&_^)'E7_S5Y_U9D_\ $&?%O_HVG'7_ (B^<_\ S'Y_
MGV9^25%?K;_PY _X**_]$F\+?^'6^''_ ,T5'_#D#_@HK_T2;PM_X=;X<?\
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M/S_/MI^2]%?K1_PY%_X*)?\ 1)O"_P#X=7X<_P#S1T?\.1?^"B7_ $2;PO\
M^'5^'/\ \T=7_P 18\,/^C@\&_\ B195Y?\ 45Y_U9D_\08\7/\ HV7'?_B+
M9S_\Q^?Y]F?DO17ZT?\ #D7_ (*)?]$F\+_^'5^'/_S1TO\ PY%_X*)?]$H\
M+?\ AU?AU_\ -%0_%CPP7_-P>#GZ<195_P#-0?\ $&/%S_HV7'?_ (BV<_\
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M /AU/AU_\T5'_$5O#+_HX'!W_B195_\ -0?\07\7?^C8\>?^(KG7_P Q^?\
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M^'3^'7_S14?\.4/^"A?_ $2GPQ_X=/X=?_-%6?\ Q%3PT_Z+_@__ ,2+*O\
MYJ\_S[,/^(*^+_\ T;#CW_Q%<Z_^8_/\^S/R@HK]7_\ ARA_P4+_ .B4^&/_
M  Z?PZ_^:*C_ (<H?\%"_P#HE/AC_P .G\.O_FBH_P"(J>&G_1?\'?\ B195
M_P#-7G^?9A_Q!7Q?_P"C8<>_^(KG7_S'Y_GV9^4%%?J__P .4/\ @H7_ -$I
M\,?^'3^'7_S14?\ #E#_ (*%_P#1*?#'_AT_AU_\T5'_ !%3PT_Z+_@[_P 2
M+*O_ )J\_P ^S#_B"OB__P!&PX]_\17.O_F/S_/LS\H**_5__ARA_P %"_\
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M /$BRK_YJ,WX)^,3W\+N/O\ Q%,[_P#F,_*2BOU;_P"'*W_!0?\ Z)5X8_\
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M )J#_B"7C%_T:[C[_P 13.__ )B/RGHK]6/^'+/_  4&_P"B5>&?_#I?#O\
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MX*"?]$K\,_\ AT?AY_\ -#1_Q%/PU_Z+[@__ ,2'*O\ YJ\_S[,/^((>,?\
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MA\/?_F@H_P"(I^&O_1?<'_\ B0Y5_P#-7G^?9A_Q _QD_P"C6>('_B)9Y_\
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M*?AK_P!%]P?_ .)#E7_S5Y_GV8?\0.\9O^C5>(/_ (B.>?\ S$?EA17ZG_\
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ME?E_U%?U\F'_ ! [QF_Z-5X@_P#B(YY_\Q'Y7T5^J'_#F/\ ;_\ ^B7>&?\
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M  Y_P]_^:&C_ (<U?M^?]$M\-_\ AS_A[_\ -#63\4O#=ZOCWA'_ ,2'*_\
MYI\_S[,/^(&>,_\ T:GQ"_\ $0SW_P"83\M:*_4K_AS5^WY_T2WPW_X<_P"'
MO_S0T?\ #FK]OS_HEOAO_P .?\/?_FAH_P"(H^&W_1>\(?\ B0Y7_P#-7G^?
M9A_Q SQG_P"C4^(7_B(9[_\ ,)^6M%?J5_PYJ_;\_P"B6^&__#G?#[_YH*7_
M (<T_M^?]$N\-?\ ASOA_P#_ "_H_P"(H^&W_1>\(?\ B0Y7_P#-7G^?9B?@
M;XSK;PH\0G_W:.>__,/]?>?EI17ZE_\ #FG]OS_HEWAK_P .=\/_ /Y?T?\
M#FG]OS_HEWAK_P .=\/_ /Y?T?\ $4?#;_HO>$/_ !(<K_\ FKS_ #[,R?@7
MXTO?PI\0_P#Q$,]TV_Z@OZZ[,_+2BOU+_P"'-/[?G_1+O#7_ (<[X?\ _P O
MZ/\ AS3^WY_T2[PU_P"'.^'_ /\ +^C_ (BCX;?]%[PA_P")#E?_ ,U>?Y]F
M+_B!7C1_T:CQ#_\ $0SW_P"8?/\ /LS\M**_4O\ X<T_M^?]$N\-?^'.^'__
M ,OZD'_!&K]OD?\ -+_#1/K_ ,+-^'_Z?\3_ (H_XBCX;?\ 1>\(?^)#E?\
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M>&__  YOP_\ _F@H_P"'-_[?'_1+_#8_[J;\/_Z:^:7_ !%#PX?_ #7?"/\
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M\S\OZ*_4#_ASO^WG_P!$Q\-_^'+\ _\ R^H_X<[_ +>?_1,?#?\ X<OP#_\
M+ZC_ (BAX;_]%WPC_P")!E?_ ,T^?Y]F9_\ $!O&W_HTOB+_ .(?GW_S"?E_
M17Z@?\.=_P!O/_HF/AO_ ,.7X!_^7U'_  YW_;S_ .B8^&__  Y?@'_Y?4?\
M10\-_P#HN^$?_$@RO_YI\_S[,/\ B WC;_T:7Q%_\0_/O_F$_+^G!2?8>O\
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MG_HNN$O_  _Y9_\ -/G^?9A_Q /QO_Z-%XC_ /B&Y_\ _,!^8JH3R>!Z=_\
MZU2@8X%?IO\ \.@OV[/^B9^'/_#D^ __ )>T?\.@OV[/^B9^'/\ PY/@/_Y>
MT?\ $3O#G_HNN$O_  _Y9_\ -/G^?9A_Q /QO_Z-%XC_ /B&Y_\ _,!^9%%?
MIO\ \.@OV[/^B9^'/_#D^ __ )>T?\.@OV[/^B9^'/\ PY/@/_Y>T?\ $3O#
MG_HNN$O_  _Y9_\ -/G^?9A_Q /QO_Z-%XC_ /B&Y_\ _,!^9%%?IO\ \.@O
MV[/^B9^'/_#D^ __ )>T?\.@OV[/^B9^'/\ PY/@/_Y>T?\ $3O#G_HNN$O_
M  _Y9_\ -/G^?9A_Q /QO_Z-%XC_ /B&Y_\ _,!^9%%?IO\ \.@OV[/^B9^'
M/_#D^ __ )>T?\.@OV[/^B9^'/\ PY/@/_Y>T?\ $3O#G_HNN$O_  _Y9_\
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MC_Q#,_\ _F _,VBOTR_X=$?MT_\ 1-/#O_AR/ ?_ ,O:/^'1'[=/_1-/#O\
MX<CP'_\ +VI_XB9X=?\ 1<\)_P#A_P L_P#FD/\ B /CC_T:'Q(_\0S/_P#Y
M@/S-HK],O^'1'[=/_1-/#O\ X<CP'_\ +VC_ (=$?MT_]$T\._\ AR/ ?_R]
MH_XB9X=?]%SPG_X?\L_^:0_X@#XX_P#1H?$C_P 0S/\ _P"8#\S:*_3+_AT1
M^W3_ -$T\._^'(\!_P#R]H_X=$?MT_\ 1-/#O_AR/ ?_ ,O:/^(F>'7_ $7/
M"?\ X?\ +/\ YI,WX!>.;V\(/$E+_LC,_O\ ^H.F_P"?F?F;17Z9_P##H?\
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M#S_/LS\SZ<JD^P_G]*_3$?\ !(K]N4=?AKX=)_[*/X%Q_P"GRG_\.C?VY?\
MHFOAW_PX_@7_ .7E'_$3?#K_ *+GA/\ \/V6?_-/G^?9A_Q+]XY_]&?\2O\
MQ"^(/_F#S_/LS\T  .G^?K2U^EW_  Z-_;E_Z)KX=_\ #C^!?_EY1_PZ-_;E
M_P"B:^'?_#C^!?\ Y>4?\1-\.O\ HN>$_P#P_99_\T^?Y]F'_$OWCG_T9_Q*
M_P#$+X@_^8//\^S/S1HK]+O^'1O[<O\ T37P[_X<?P+_ /+RC_AT;^W+_P!$
MU\._^''\"_\ R\H_XB;X=?\ 1<\)_P#A^RS_ .:?/\^S#_B7[QS_ .C/^)7_
M (A?$'_S!Y_GV9^:-*%)Z?GVK]+A_P $C?VY._PU\/?A\1_ G_R]J0?\$C_V
MX_\ HFWAT>W_  L?P+_37*/^(F^'7_1<\)_^'[+/_FGS_/LQ/Z/_ (Z7LO![
MQ*]7P7Q DO\ RP_KY,_-(*![GU_P]*=7Z6?\.C_VX_\ HFWAW_PX_@;_ .7E
M'_#H_P#;C_Z)MX=_\./X&_\ EY1_Q$WPZ_Z+GA/_ ,/V6?\ S3Y_GV8E]'SQ
MSW?@_P")+;_ZHOB#3;_J _KRLS\TZ*_2S_AT?^W'_P!$V\._^''\#?\ R\H_
MX='_ +<?_1-O#O\ X<?P-_\ +RC_ (B;X=?]%SPG_P"'[+/_ )I\_P ^S*_X
ME^\<_P#HS_B5_P"(7Q!_\P>?Y]F?FG2@$]*_2P?\$C_VXN_PV\/?A\1O O/_
M )7*D'_!)+]N(<#X;>'O_#C>!?\ Y>U+\3O#M;<<<*-_]C[++?\ J2)_1_\
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MX>_\.-X%_P#E[1_PZ3_;B_Z)MX>_\.-X%_\ E[1_Q$WPZ_Z+GA/_ ,/V6?\
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M? __ ,O*/^(E^'G_ $7'"G_A^RS_ .:0_P")>_';_HSOB9_XA7$/_P [_/\
M/LS\VJ*_27_ATQ^V]_T3CP]_X<7P/_\ +RC_ (=,?MO?]$X\/?\ AQ? _P#\
MO*/^(E^'G_1<<*?^'[+/_FD/^)>_';_HSOB9_P"(5Q#_ /._S_/LS\VJ*_27
M_ATQ^V]_T3CP]_X<7P/_ /+RC_ATQ^V]_P!$X\/?^'%\#_\ R\H_XB7X>?\
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MX=-_MN_]$X\/#_NHO@?^FMFC_B)?AY_T7'"G_A^RW_YI#_B7GQX_Z,YXF?\
MB%<0_P#S ?FY17Z1_P##IK]MW_HG/A[_ ,.+X'_^7='_  Z:_;=_Z)SX>_\
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MVS_T3GP__P"'$\$?_+NC_B)7A[_T6_"O_A]RW_YI,_\ B7;Q[?\ S9KQ._\
M$)XA\O\ J7_U\F?G#17Z/?\ #J#]MG_HG/A__P .)X(_^7='_#J#]MG_ *)S
MX?\ _#B>"/\ Y=T?\1*\/?\ HM^%?_#[EO\ \TB_XEV\>_\ HS/B=_XA/$/_
M ,[_ #_/LS\X:<%)]AZ_X>M?H\O_  2@_;7ZGX=>'_I_PL/P1^O_ !.ZD_X=
M1_MK_P#1.O#_ /X</P1_\NZ/^(E>'O\ T6_"O_A]RW_YI#_B7?QZ_P"C,^)W
M_B$<1?\ SO/SB"@=/S[TM?HY_P .H_VV/^B=>'__  X?@C_Y=T?\.H_VV/\
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M^'"\$_\ R[H_XB5X>_\ 1;\*_P#A]RW_ .:0_P")=?'S_HS'B?\ ^(/Q%_\
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MG_5F?G;17Z)?\.K_ -M'_HG>@_\ AP?!/_R[H_X=7_MH_P#1.]!_\.#X)_\
MEW1_Q$CP^_Z+;A;_ ,/N6_\ S03_ ,2Y>/W_ $9;Q1_\0?B/_P"=_G^?9GYV
MT5^B7_#J_P#;1_Z)WH/_ (<'P3_\NZ7_ (=7?MH_]$\T#_PX/@K_ .75'_$2
M/#[_ *+;A;_P^Y;_ /- ?\2Y>/W_ $9;Q1_\0?B/_P"=_G^?9GYV45^B?_#J
M[]M'_HGF@?\ AP?!7_RZH_X=7?MH_P#1/- _\.#X*_\ EU1_Q$CP^_Z+;A;_
M ,/N6_\ S3_7R8?\2Y>/W_1EO%'_ ,0?B/\ ^=_G^?9GYV45^B?_  ZN_;1_
MZ)YH'_AP?!7_ ,NJ/^'5W[:/_1/- _\ #@^"O_EU3_XB1X?_ /1;<*_^'W+?
M_FGS_/LP_P")<O'[_HRWBC_X@_$?_P [_/\ /LS\[**_1/\ X=7?MH_]$\T#
M_P .#X*_^75 _P""5W[:'?X>:!CV^(/@K_Y=4O\ B)'A]_T6W"W_ (?<M_\
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MT9'Q4_\ $$XD_P#G<?GY3@I/T[FOT"'_  3"_;#[_#_0_H/'O@W_ .7-2?\
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M ,[C^H^BBBO\R3_J;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[;ZK"C/V_-["A[/G]M;V5I\O+?VDKZ%%%%?/'U(4444 %%%% !17X%_M6?\
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M[?ZS^\]E["E]7Y?J_P /M*W-S_$N7WBBBBOGCZD**** "BBB@ HHHH ****
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M!BN&:=6JLUPE.52I3G1<:4U&G1JRC2JW:G-4Z\9\MD^6-1_9U_5^BBOY-O\
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MS7[^TO\ 0O$%CI5G%H\OA#XE^!+>WM)+>YD>XCO+74)GF"-'<0H#&WY;6/\
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M]?"5J-;#8JG#F47/V->$)3IQE*,)SI<\(3E&,W&4HI^U4445X)]*%%?ST?\
M!<__ (+$_$[_ ()FW7P#\#_ +PS\*/&7Q/\ BE!XO\5^*[+XJZ1XJUW2_#O@
M+09--TC0[JUT_P )>-_ U_'J'B;Q#=ZO%97EQJ%Y:);^%=6@:S\Z:">+U/\
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M3SPK*2H$;2HLA+8VC86#9;(VC'.1CK4U?YZ?_!4G_E9/\*_]G&?L"_\ J-?
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MW8)M%T_5[C4HIF[1/;*Y[+7JE?QW?L>?\&N-IX+U;]EWX]?%S]I>Y?QEX/\
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M^K_5??\ 9>PJ_6.?ZS\/M*'+R?%+F]W_ $'Z***^>/J0HHHH **** "BBB@
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M)6'HRFJ5**C*K6KU6G)4J-*"<YS:3;=E""7-4E".I_5'17\"VK?\%L/^"_\
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M>_\ @OTS)_P2*_;%*,RDZ'\)U)4E25?X^_"I'4D$':Z,R,.C*Q4@@D5^>/\
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M%P:_X2^$_A0,Y:&:W\%_#2T\5KIL@DFFT^Z\+>'ITS(8KE.>_P"#3'_D\_\
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MM&M2=#$QI55R\KE"2JTF[._+4BT]VF5_VB/^#EW]GSX-_LY? GXA^%?A3?\
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M1_''BN\\;^*M*\!:!9^'].U?Q-?6]O:3:A)9V21V]M%%:VD%M8Z;91VVE:9
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M(;3Q!XVUF^E_L_P-X:O;B&:"QO+R#4M:U5X;B30_#NK6UEJ,]G_/"W_!W/\
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M"M!>V=.*C&,5)^T5_P '8'A/2O'-[X2_9(_9>U+XJ>'K2]ELK#X@?$[Q3?\
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M4<0Y):\GU2%>,Y:*/.G)VT?]/W_!.S]G!/V2?V(/V9OV?9+-+#6O /PK\/\
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M:I9M7M_6S_P0B_Y1+_L:?]B7XV_]6[\0J_DW_P"#A_\ Y3+^$/\ L2?V;_\
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M'I55*G*T:M)63I3E-5[U80H\M3\&/VZ?^"_GPQ_X*)?\$Z/CM^SMX]^#VM?
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MLRX?EEN'HT*6%;BZM.CC*,8U95,-&5ZCBJ5E"I-5<1RJ-7^T"OPN^-7_  7
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MX:W7PBO/C)X*LO'UG\/[WQ$GBRZT7P[KT]S=>$KJ77X]#\-I?GQ#X5;1O$J
M:+9_8TUA;$_:#;&[G^DJQ_#WA_1O">@:'X6\.:=;:1X>\-:/IGA_0=)LT\NT
MTO1M&LH-.TO3K6/)V6UE8VT%M F3MBB5<G%;%?'XB=*=>M.A2]A1G5J3HT>:
M4_8TI3DZ=+GG*4Y^S@U#FG*4I6O*3;;?W>&A6IX?#T\16^L8BG1I0KU^2%/V
M]:,(QJUN2G&$(>TFI3Y(0C"/-:,8I)+^>/3?^#A[X :)^V[\?_V3/C;\.8_@
MAX(^ .N?&W0=8^/GB+XFP:OI^O7WP9O]1L6L]+^'MCX%MM6GU?QB^EW2>'=
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MQKXGL=1LO$WB[6]4O=)TK7+G2TNM)T;PR;C0;Y4\1Z@:[,BR7*JN7YGQ-F&
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M!+XE^#O%7@_3KI_,/A_1OC%I?B>74M-L"?FBTNX\2> =8UM;1?W46JZQJUV
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ME3.88N<.',LQ>2PCEV%H_P!E45@:3IX>;Y9QQKC"=*#JXB+<G2<FKS9^OO\
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M/\#FN&H5L.\TR6EEM'#X6A0KUH4>3"8JSQ56,*E2%-59NC5CS*I/VL8SB_\
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M&>CRWR76G1:C%!>7.CKJ-SHEU?6UM-J&GSW%I;M%1_;_ /\ DP[]MC_LT?\
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M[\0J_DF_:V_96?\ 9@_X-X_V-+_6-.-AXX_:._;'\/\ [0WB\31%;E=/\7_
M[XPV7PULC(X6<6T7PTT[PUJWV.146SU77M9"1[YII9OZV?\ @A%_RB7_ &-/
M^Q+\;?\ JW?B%7L<?8VCC>&:,L,HK"X7B6>7X90MRJE@,%BL-[K7Q0E4IU)0
M?\DHI723/"\-,!7R_B[$1Q;E+&XWA*EFF,E-OGE7S/'X/&>^GM.-*M3A47_/
MR,F]6?SE?\'<'_)>OV/?^R1?$7_U,M(K^Q+]C/\ Y,__ &4O^S;/@7_ZJ_PM
M7\=O_!W!_P EZ_8]_P"R1?$7_P!3+2*X#X2?\%@/^"\?@SX4_#+P?\/_ -BS
M4-<\!>%/A[X+\->"-:7]C?X^ZVNL>$="\.:;I?AO5%UG3M:CT_5UU#1K6RNQ
MJ=BB6=^)OM5LBP2H!S5\AQF>\%<)T\)6P=*6'>/G-XS$QPT9*IB:D8J#E&7.
MTXOF2V5NYV8?B3 \.>(7&U7&T,?7CBEE=.FL!A)XN473PE*4G44)1Y$^=*+?
MQ.Z6Q_?)7RG^VE^V3\&OV#O@#XH_:+^.=SKH\&^'+S2M'L]&\*:=;:MXL\5^
M)==N3;:/X:\-:??7^DZ=/J=Z8[FZ:34]6TO3K/3[&^OKV^M[>U=J_G?_ ."=
M?_!4G_@LO\>/VR_@G\(_VGOV1[OP#\"_&NI>*K+Q[XRF_98^-OP\3P_:Z?X#
M\4ZWHUW_ ,)AXEUB?0-&,WB/3-'L-^J6\T%V+LZ?$BW=U;RQ_N[_ ,%'?V$/
M!?\ P49_9>\2?LW^,?%NI^ );S7M \9>#_'6E:5;:_/X3\9>&GNETW4[C0+N
M\TR+7--GT_4M6TC4],35M(N+BPU.X^R:K8720W"?"5\DADN<9?A,]KT98.M*
MA7Q57+JZQ/)A)5I4ZEI4X.2J)4Y-QC"4U!J4%)M)_H^&X@J9_D69X[AS#5XX
M^A'$8?!T<UP[P?M,;##PJTKPJ3472DZL%&<JD*;FG&<HQ4I+B/\ @G#_ ,%2
MOV<O^"G'A'Q_X@^"%AX[\*>(/A9J>AZ?X\\!_$C2M(TWQ%I-OXHAU2;PSKME
M<^'M<\1Z'JNA:XVA:[:6T\&IQZE:WNC7L6J:5813:9<:C^DU?C1_P2'_ ."0
M'A?_ ()8Z!\6[E_BY>?&GXC_ !DN?"T&O^)1X03P-H.B>'/!G]NRZ+H6AZ"W
MB'Q5>27%Q>^(]2O=:UB\UG%_Y>E6UMI>GKITTVH?LO7%GD,IAFF+CD=2K6RM
M2I_5JE934VG2INK_ !(4ZC@JSJ1INI",W!1YKOWGZ'#L\[J9-@I\14J-#.'"
MI]<IT'3E3BU6J*B_W,ZE)3E05*554JDJ:J.7+9>['Y$_;Q_:PLOV'/V3/B_^
MU/J/@BZ^(]I\)[#PO>2>"K+7HO#%SKK^*/'7A?P/!"FO3Z3KD6G+:S^)HM0E
ME;2;XR0VDD"1!Y5D3\4X_P#@YY_9-L/V2]&^//B/X<ZU;_&[Q1XJ\7>&/#W[
M+7A?QSIOBKQ+!;^&)+$0^+?&GCF3PWH6G>"_"6KQZA;_ &&ZO/#E[K-_<"ZB
M\/Z'X@ATS5[K3OMW_@OY_P HB?VQ/^P+\)?_ %?_ ,**_GX_X-D?^"=/[-/[
M0'AKXI_M=?''P=8?%/Q7\,/BFGPU^'/@CQ?86>K> /#MY:>$_#?BN\\<7WA^
M[2>S\2^)&;Q)#8:)'K5O<:7X=^P2ZM:V5QK<^G:AHGUF0Y5P[+A3&Y[G6'Q-
M:>"SCV"CA:U2G4Q-+ZMA72P;7.J5.G4KXASJUU%5HPBU":?+%_%<29UQ3#C3
M+^',@Q6#H4\PR+ZS*6-P].K2PE58S&*MCXM0]O5JT\/AE3HX9U'AYU)*52FU
MS276^"/^#N7Q*WC*V_X6/^Q;H<7P^N+Z-+P^"/BY?S^,M(TQSMFN;9=>\&V^
MB>([ZW!\R.RE;PM;W97R6O[+?]H3]GOVK/\ @O[^PM^SC^S_ /"WXS>%/$%]
M\=/%/QR\'0^-?A9\(/!MQ;:7XIDT5[F]TRZU#XD7]^EW;?#33])\0:9JGAC4
M1J%IJNNS:_I>JVF@^']=ATC5[JP\ _X.6_V5/A'XR_X)V^*_V@(O OAK2_B?
M^S[XO^&6HZ!XSTC1=,T[7V\+>-/'/A_X7ZSX1O\ 4K:VBNKSPU<2>,-*U:/3
M)9'BMM5T/3+FV$*K<K/^9O\ P;&_\$Z/V:/CIX$^)?[9'QK\&:=\4_&WP]^,
M=[\*?ASX/\9:=9:QX"\*2Z-X*\$>,;KQS)X?O(Y['Q!XJN9O&L5AI#ZU;W-C
MX9&D_P!JZ9;-K=S:ZAI7J/ \%X[(8\3K+,9EU' XR>#Q65X7%U*ZQM?DIRHT
M7B:[YJ4&JU&I4KTXTIJG[6'+*I[.9XL<Q\0,NXEGP>\XP&:XC,<!#'X/.,9@
M:6&_L_#\]6.(Q"PF'CRUZD70KTJ>&JRK0=7V-3GA2]K3?0_#O_@[DU23QI:P
M_%?]B_3K3X>WNJ6D5W??#_XNW=YXP\.:/),BWM]#IOB'P5::/XQU&V@,DMMI
MK:EX(M[R0)%)J=FI,H_KO^%7QT\$_'SX%>%?C_\  N[3XB^#?B#X&_X37X?>
M7*="E\1":RGEL]$O&U2%7\/ZJ-4@DT'5H-3MUFT+58;RWOX%ELYHQ^"/_!S+
M^RG\)/%__!/K7/VAH/ WAS2OBE\!/''PWN=)\:Z1HNFZ?KUSX0\:>+-+^'&K
M^#]4U&VMH[F_\.RW?BG1M9M["9W%CJFBV4MD;>*:_CNM3_@UJ\;ZEXJ_X)HZ
M[H%_<W4]M\-/VF_BEX+T:*XFDEBL]+U#PI\-/B+);6*.S+;VKZSX]U>[>"((
MAO+J[N"IDN'=_+SC 9#C^&*/$F39=/*ZF'S)9?C<%+%5L52G>FIJ2J59<[:4
MZ#4H*E=5*BG%RC&9[.0YGQ+EG&%?A//\UIYS2Q.4O-,OQ\<'0P5:%JKIRA*E
M1CR*+=/$)QJ2K<KI4G"<8RE37<?\$VO^"^'@W]O[]J'5/V5O$/[..N?L\>.(
MO"/B_7-!FU_XF6WC.37/$G@>\LO^$@\#2:0O@'P==Z7K5IHC:[K[/)-=*EMX
M8U6WG@AE$3'^@FO\];_@J_X'U_\ X)4_\%LO O[77P\TNXM? OQ!\=^'?VHM
M!M-.06]OJ4NJZQ-H_P"T-X %P/)B$_B2^?Q5<7MO%Y266@?$;280X8^97]]3
M_%'P&OPL;XU#Q'8O\,5\ -\41XM1RVF/X#'AT^+/^$C20@$V+>'Q_::O@$VY
M#8!XK@XKR? 8:.2YGDM"5++<ZP$*E.@JM7$.EC:;BL30]I5G4J.474IQY7)W
MJ1JJ&D;+TN"L]S+%RX@RCB#$PK9MP_F52E5Q'LJ&&C6R^K%RPF)]G1A2IJ,E
M2JS<HP5J4Z+F[RU_#C]L[_@O%HG[+W[=ND_L%_#W]F/5_C_\1M2U3X4^$9-8
MTWXLV?@B"V^(?Q;;2YM!\'II+?#SQ?)</;Z;XC\+7ESJ/]HPGSM7FLFL86T]
MIKC]FOVA_P!HGX._LJ?"+Q=\<OCQXVTSP%\-_!=FMSJVM:@9)9[JZG;R=.T3
M0],MDEU#7?$.LW12RT?1-+M[G4-0NI%CAA*K(Z?PX?\ !#SP5KW_  40_P""
MRGQA_;=^(&FSW&@_#?6OB)^T/>07H%U9:=XU^(FL:GX;^$'@\N-_EGPOIFIZ
MKK/ATK)M@_X5M:J))!&%DZ__ (.C_P!I3Q7\4/VO_@S^Q?I'B&VT;X?_  M\
M)>&O%VNVVJZK'H?AZ?XK_%:]O+>WUSQ/>W<\6F1Z7X3\!IH']FZOJ#1IH,7B
M;QDYEBMKRX9_?K\'Y=7S_)N&\-%X>MA\JIXWB+&0JU*DY57"$ZD*<*LYTJ4K
M\BI<D(PBL5&4XU/9J)\WAN.\TP_#.?\ %F*E'%4,5G57+^%<#.C2HTXT54G3
MHSJ5*-.E6KQ_B2K*K4E4D\%.$)4G4<E]%_%K_@[1U&?QAJ.F_LY?L;'7?!FG
MRW,EIKWQ1\?7EKXHUK2[5W>74;GPAX,T'4;#PPHM5$DD9\6^)4MQF2:< &,?
MI%_P3._X.&_V?_VZ_'^E_ OXJ>!I?V:_CEXDN8-/\ Z;?>*1XQ\ ?$O5)=X3
M0M \5-H7AVZT+Q9=%,Z=X;U_3%M]5=H[#1O$.JZS/!I<OT%^PUX[_P""//[
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M?#CPM?KJOACX?^"?#FJ+%+ NI:%X5T+2+]8)@!-"MYI]A;W BE"J)8Q($D
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M$^ /"G@OQ/\ !/QC-IO@;5O$_P 0K'2+/3_$_B7PGJ.IM9Z1\2[OQWKEO?\
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M:P/_ *2CW_#/^+QM_P!E=F/_ *4PK\J_^"D'_!7O]F+_ ()DW7PZT'XRZ/\
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M):'3_$-AX1/C#7M*U> "ZB\36VG7S2&4&0?SG_\ !N;\.O\ @G)\,O"?B_\
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MF5Y;?2K/XA^#+1;VQTX.2+:UEU3P=>:G+:Q;81?:A>7@03WMQ))^6W_!V/\
M\GX_ 3_LT?PS_P"KD^-%<N4<+9>^-\9P]CHSQ6"P\<4Z=ZDZ51P]A"OAISG1
ME3;G"%6#E:T)33;AROE.S/.,LS7AW@.*<NG3P>/Q,L"JO+2IUJ2G]8EA\9"$
M,1"K%4YU*510OS5(0:2GSKG/T[_;&_X.I/@=\+/&>I^!/V2/@W<_M%0://)9
MW_Q7\5>)KWX>_#^\O8#(DW_"(:(GAW5?%/BG2TD"QC6=1;P?;W+QS2Z7!JFF
MR6>IW&;^QU_P=3_"?XI?$/0?A[^UE\#A\ ]+\2:A:Z59?%[PCXSF\8^!]$OK
MZ6*WMYO'&@ZKH6C:WX;\/1RLQO/$FG:GXF6P62.6_P!)M-.@O-4@_=3]@'_@
MGQ^RO^P_\&/"7A[X'?#/1;/Q#K/A72+CQI\4-?L=/UGXG>/+_4M-MKG4)_$G
MBV6SCO#I\L\LAM?#6EKIOA?2XW:/3=&MC+.\W\WO_!T7^P!\'?!'P\^%_P"V
MW\)O!'AOP%XNO_B/;?"7XQVOA738=%L?&T'B/PYK.M>#/%^H:581P:2FN>'[
MCPCJ>A:AJ\-M#J>N6OB'28M3FO$T.Q-MT92N!LTS"'#\,EQM+ZPYX?"YU5Q]
M5XNIB(Q?)4J86-L/1]JXM0C&-6GS2@IT(J4G#FSI^(V3994XHJ9_EV(^JJGB
ML9P_1RRE'!4L)*<>>E1QD[XJO[*,DZDI2HU>2-1T\1-QA&?]G]O<6]W;P75K
M/#<VMS#%<6US;RI-;W%O,BR0SP31LT<L,L;+)%+&S)(C*Z,5()_F7_;\_P"#
MEWX'_LM?%WQ+\!OV??@YJ7[37COP3K=[X5\:^*G\:P>!_AOH_BFQD%I>:%X;
MOK#P]XRUOQYJ&DZHMQI&M"WL/#>E0:A;O#I6MZSLE\O[,_X(9?'3Q[^T5_P2
M>^!^K:OK\=]\1_ V@>._@K!K]XIG9)/AQK&K>'?AU/J8E:5[JYT[P6/!L6H7
M$[23:C+;2WLY:6Z<5_'!_P $;_V@?@=_P3K_ ."C'BK4?V_/ VK>&=6T/0_&
M7PQ'BGQ+X6OO$6K_  *^+H\3Z(]YXJUG08[6^UR$S:?I>O\ ARZ\1:#I^IZW
MIT>N"XM()=(U#4[N+FX=X7PCQ7$\<QPM7-Z_#UZ5#*L-6J8>>8555Q%-U5*F
MU7]G%4(N,:?,Y>U2<)RY*=3JXIXPQRP?!\LJQM'(\/Q5RU<1G6+H4\3#*Z4J
M.%JQI.-9/#^TD\3.,YU>6,?8MQG3CSU:?[-?"7_@Z^OM-\<Z?X:_:K_8QU/P
M-X<N[BW&I>(OAQXRU&Y\3>'K"YD COS\/O''AW1_[>A6)O-<Q>,-&E:.)WM8
M+N1TMQ_7%\(OBMX'^.GPP\!?&/X9ZK<:Y\/OB9X6T?QGX-UFZTC5]!N-3\/:
M]9QWVF7TFD:]8Z;K%@;FVE258;^QMYMK*X0HR.WS_K/AK]AK_@I'\(]/GU2R
M^ O[7/PC_M""^TO4;:X\-?$'3=$UJ'R9R+/5=-GN-2\)Z^B*MMJEG%=:3JXM
MGN-+U6#[/-=6CV?VX?CO'^Q_^Q7^T-\=O#MAIUK>?!SX-^)-3\"Z4MC"FBP>
M*H=+&A_#S3)-/@6*"+1%\47N@VES:P(D<.F^9'#&%14KP,TGE.95L%A<IR/$
M9-F53$_5L1AIXRKB,/*524*=!1CB(*O3JNI)JHK4X4TDE&K*;E#Z;)J>=Y30
MQ^,SKB3"Y_E%/"?7,+BX8"CA<5"%*%2KB)2GA:LL-5H1I03IR3J3J2;?/1C!
M0J?FM_P4Q_X+[?LT?\$^_%FH?!GPSX9U']HG]H32X8G\0^!O#'B&R\-^$/A_
M)=0>?:V/C[QW)I^OO9>(9(I+>\7PKH?A[6M2@LW#:Y/X?:YT\WGY"^!/^#M?
MQK:>)]+;XP?L3Z1#X#U6:.5KWP)\3]6MO$]GH[S&*74=+M?%'A)M&\4S0%)5
MCM3J'AJUNYD,3:G9;6<?"?\ P01^'G[%'Q*^/_QG_:S_ ."BOQ[^ %IKO@G6
M-+O_ (=^$/VE_BQ\./#[?$3XI>-;_6/$7BSXJZUH_P 1?$6G7'BR;PDUG:&P
MFNK+4]+N?$GBN?5KADU?P[8L/ZYOVK?CE_P2'_;'^!?C3X!_&;]LC]A77?"W
MBG0M1T[1]0N/VC_@!=ZOX"U^;3KBST3QMX+N9_&OF:)XF\,W$T=[I=Y9R0!Q
M$^GW@GTR[O+2?[#&9;PUP_BJ>38CAO,L]J0A1699O"MC:*IU*L(3E]2H4(NE
M4C2C-24>>#3_ '4ZM2<9-?"8'-^+>)\'6S[#<695PY2J3KO*<CGA\OQ#JTJ,
MYTX?7\1B9JM2E7E!Q<O9U(V_?4Z5*$HQ?V]^RU^U1\#_ -LOX->&_CQ^S[XR
M@\9^ /$AGM#,;>;3]9\/Z]8I VK^%?%.C706[T3Q)HKW$*W^GW :.2&>TU+3
MKF_TB_T[4;O@_P!MS]NG]GO_ ()_?!J[^-/[0GB6YTW2I;S^QO"7A+0+>#5/
M'/Q"\2M ]S'X=\&Z'/=V,5[>+;QO<W]_?WNG:'HUHOVK6-4L8I(3+_)U_P &
MH?QB\1>'?C_^UI^RO-XFBU7P??\ @&W^+^E:=:7<-]HI\2^ _&>A?#S6_$>@
M7$,DMNR>(-)\9:!%>W5I))%JEEHVA2%Y([&!J^.O^"WOQ5^*'_!0/_@L#H?[
M'7A?6(X/#?P]^(WP]_9<^$>FW9N$T;3/&GQ#O?"=K\0O&6LP1F1EN)_&FK_V
M;JM_  &\)^"M S&DEK*TG#1X(H/B_%Y/5Q%193@<-_:=;$-J-:6 <*<X4^90
M455]I45*<U!+DIU:L8J24#TJ_B)B%P-@<]H86E+/,RQ:R>AA$I2H+,U4JTZE
M7DY^?V/LZ3K4Z;FWSU*-&<VFZA]M>*O^#N;QRWBF9_!'[%7A2+P3%=,MO;^*
MOC#J]QXIO[)" DTUYI'@BVTG2;J=0TC6R6.M16A<0B[O1$9YOS&_X+6_\%0O
M@[_P4_T/]D#QW\/?"GBKX<^._AOHOQDT+XJ?#?Q*\>KP>&[OQ!??#:]\.7WA
M[QG96ECIWBS0]9CTS6XH;HZ=H>LVEQI-PNJ^'M-@N-,N=2_ON_9+_87_ &:O
MV+_@SH?P6^"_PT\,Z;H]GH\6G^*O$=_HVGW_ (M^(^J2Q0_VQX@\=ZY=037V
MNWNLW<9N7LKF=])TNW%MI&BV.GZ-I]A86W\8?_!T9^RS\ /@!\=/V<?'?P5^
M%WA;X8:W\;/"WQ0U'XEVW@O3X] \/^(M8\(ZQX,BTO7?^$9T\0:%INM7$?B3
M41K-_I5A92ZY,8;W5?M5^LEU+[O">8\)8KB;"4,JR+$Y=B*/USZCC?KU6NL1
M!82O&HL9AJTIJFIT>><'3J5:D:JA%R4'-'S?&^5\;X/A#'8G.N),)FF&KO ?
MVCEW]FT,.\+4EC<-*D\#B\/&#JNGB%3IS52E1IRHRJ24'4Y&?VD_L$_\F,?L
M7_\ 9IW[.G_JG_!U>U_&#XG>&_@I\)OB;\8_&,WV?PG\*O 'C#XB^))0Z1LN
MB>"_#^H>(M3$3/\ +YSV>G2QP*02\S(BJS,%/BG[!/\ R8Q^Q?\ ]FG?LZ?^
MJ?\ !U?E)_P<L?M)?\*/_P"";OB'X=:5?_9?%?[3'CSPO\)[.."4)?1^$=.F
M?QYX[OXU)&ZPGTWPO9>$-3.'/E>,HHPH,OFQ?F^%R^6:\20RZ-_]KS:=&;6\
M:4L3)UIZ:_NZ2G-^43]8Q>:0R7A.>:SM_L.24Z\%+:=:.$@L/2]:M=TZ:\YH
M^ O^#7WX8^)/B[\1_P!N?_@HG\2(?MOB[XI>.[SX<Z7K;1N?M&O>+M='QF^-
M!CEFW.8Y]2U3X9&$HQVB.YBD9B %_83_ (*U?\%;-'_X)6Z7\"M0U3X&:E\;
M'^-U_P#$2SMK>P^(-KX 3PZGP]M_!<]Q-//<>#_%YU)M3/C.!(8HX+(6PL9G
M>64S(B>A_P#!&;]FW_AEK_@FU^R_\/K[3SI_BOQ)X%@^+GCN.6+RKX>+/BW-
M)XZGL=43  U#PWI&L:-X0E&/DC\/0QEI&0R/^"?_  =Y?\B[^P1_V&OVE/\
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M6^*FFZ'X;\.6GC3X;:5\1GUG4?"=WX-E$>EZ':ZM%8:A<W/C"SCVP7&HN]O
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MQ$]YX/\ !OAK4;'1BL(#2QQ>-];17<CS]L8:7[J_X)U?\')GP0_;%^+WACX
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MR+)XAT*T'AOQ5XD\66%W</#K>JR^'M/UFWU#1-3U:RN?F^&L@RZIA,WSS/\
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MZ#S9O#&D>-M"U8VT-O/JD::%<74[Q:#:P5^SO_!U7_RC>^'O_9W'PS_]5?\
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M#\9Z%\/-;\1Z!<0R2V[)X@TGQEH$5[=6DDD6J66C:%(7DCL8&KY:_P"#F?\
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MM>B\,7.NOXH\=>%_ \$*:]/I.N1:<MK/XFBU"65M)OC)#:20)$'E61/X5_\
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MYA0P49/%8K&5ZE.4*-:LJ5:I##4*7L%!0C:C-MKW_P#:L_X+^_L+?LX_L_\
MPM^,WA3Q!??'3Q3\<O!T/C7X6?"#P;<6VE^*9-%>YO=,NM0^)%_?I=VWPTT_
M2?$&F:IX8U$:A::KKLVOZ7JMIH/A_78=(U>ZL/QO^'?_  =R:I)XTM8?BO\
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M?DCFVL%QAEN84DVVH_VMDV8XQ4U=Z+_8FH16CE4Q"6_Q:'_!UU^T]=6?@?\
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M#NI:096L+VXN=,U*:W>_T;2[FT^;O^#7+7]5\;?\$[=;M_%NC6EXGPL_:/\
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MX@USQ];6UW T$FL6\/AWP]>C_3/#^LZ]ITD%Y-^7O_!V/_R?C\!/^S1_#/\
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M$.G6NHW7@3PEJM_:7$FD>"?#"S1Z/!;:4;2'Q'=V4WB+5(Y;J]BBM/TH\?\
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M6'TM_P $]?VM?B/^VY^SOHG[1/CG]G/5/V;=#\<7DMU\-?#>O^/8_&^N^,/
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M)6=*E&IB;%%%%?&'WX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVDZE;-9:A;W'BSQ?K'CVZ\&V=W!=K+J'B'1;OPM<Z; //CUG3;(W!?\ :_\
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MFN397GF'AA<VP5+'8>G6CB*=*MS\L:T85*<:BY)1?,H5:D=[6D[H_F]^ O\
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M&I3>(IXBC6_<0J.G[6$*=)1I.HX*FOK'LI+,_P"#O+_D7?V"/^PU^TI_Z0_
MRORB_8-_X(8?M'_M]_LK?&+]J?Q)XDU_PO=6?P^72?V2]!\12&XOOC-XA\ V
MVGZ996=]>:XTDFB_"ZS\.>'I/ACX)NK::UB777T^ZM9K3PGX+FT[Q#^XG_!T
MG^SA^T-^T'H'[%$?P$^!'QE^-\OA/6/V@'\4P_"'X8^-?B5-X;CUNR^#BZ-)
MKT/@S1-:DTB+56TG5%TZ2_2W2]?3KU;=I&MI@G[Z_P#!.+PEXI\!?L _L7^"
MO&_AS7/!_C#PM^S%\$]"\3^%/$VE7NA>(_#FNZ;\/M!M=3T77M$U."VU+2-8
MTV[CEM-1TS4+:WOK"[BFM;N"&XBDC7AH<38G(> \A66U<.L;6QN,A4<G"I5H
M488_%8B471NVHXCEA"4I)+V4I<OO2A.'H8CA'"<2^)7$SS:CBGE]'+\!4I*"
MJ4J.(Q%3+,%AHR5=)*4L-SU*D(P=U6C'GO",Z<_YF_\ @V8_X*-:EHVH:]_P
M3,^/.H7FDZUHM]XGU_\ 9V/B7SK+4=/O]/N+W4OB7\$KFWO1'<6E[8746K>-
M_#>G3PI/!)'X[TVXF1H="TZO[-J_B-_X+K_\$N?VB?A?^V-X _;[_P""?_PO
M^*GBW7/B#XOL/&'C/1?@1X$\2^./%OPV^/GA*X@UVT^)</A_P?I&KW]MH/CU
M;*+5=3U"73IM.B\<Z=KDNMW?F^,M*L9?ZQ?V)/CK\0_VC_V8OA5\5_B[\'?B
M!\!/BQK6A"P^)?PN^)/@CQ/X U[P_P"-]"GDTGQ!<:?H'B[3].UC_A%-=O;1
M]?\ "5Y+%*9M U.PBN)VO[>]2/Y_C##X''1P?%&5RHQHYO'_ (4,%&I!U<'F
M44U6YJ::GR5Y0F^?D495(2JMVQ%-'U' F*S++IX_@[.(5YXC(I?\)F82I5%0
MQ^42<?JZA5:<'4P\:E./LU-RA2G&C9RPM61]6U_GI_LM?\K1OB?_ +/D_;"_
M],_QNK_0LK^%S]F[]D+]K#1/^#CWQ%\;]:_9C_:"T;X*S?MB?M5^+(?C!JWP
M;^(FF_"R;PQX@T;XPG0/$,7Q#O?#L'A"31M=;4]-BT;4DUAK359]0L;>PEN)
M[RWCDTX(K4:6%XM56K3INIPWC84U4G&#J3=.I:$%)KFD[JT8W;[&7B%0KUL=
MP,Z-&K55+BS+ZE5TJ<ZBITU6HMSJ.*:A!).\I6BNK/[HZ_ST_P!AW_E:-\:_
M]GR?\%"O_3/^TO7^A97\+?[&_P"R'^UAX;_X.._&'QQ\2?LQ_M!^'?@I/^V+
M^W5XJM_C!K_P9^(NC?"VX\,>+=*_:$C\*>(;;X@:EX<M?"=QHOBB36]&C\.:
MG#J[V>N/JVF)I<UTU]:B4X+K4:6 XQ56K3INKPWC(4U4G&#J3=&NE""DTYR;
M:2C&[=UH'B!0KULRX"E1HU:L:/%F J573ISJ*E36(PS<ZCBFH023;E*T4D[O
M0_NDK_/3_P""?/\ RM!>*/\ L\C_ (*)_P#J&_M/5_H65_"W^PQ^R'^UAX4_
MX.,?$WQP\5?LQ_M!^&/@M)^U;^WAXFB^+WB/X,_$70OAA/X=\8>%OVB+3PEK
MMOX^U3PY:>%;C2/%%SKVB0>'=0@U:2UUN35]-73);HWMOYAP96HTLNXSC5JT
MZ;J\-XRG252<8.I-T,2E""DTYS;:2C&[;:26H<?T*];-> 94:-6K&CQ9@:E6
M5.G.:I4XXG"N52HXIJ$$DVYRM%)-MZ']O/CSP1X9^)G@?QE\./&NEP:WX.\?
M^%?$/@KQ9HUR,V^K>&_%.DW>AZYIL_?RK[3+ZZMI".0LI(Y K^$C_@BQXI\1
M?\$R_P#@LM\;OV%/BCJ[V'ACXCWGC#X+W.HZI(FG:;J7B+P0;WQ_\#O']P',
M:1Q>+O"#:E9:$DB*,?$VU+K#\Q3^^*OX;_\ @ZI_9H;X<?&[]G7]MWP%>OX=
MUCXB:=/\,/&5[HU^^DZW;^.OAHL6N^ O&%G<VLL6I-J=WX7OKO0YM2M)8O[*
M@\#^'D#1SW<;O/ U:GBZV9\,XJ?)A>(,%4I4Y-<RHX_#1E6PU91;2O%*I*UU
MSU(48MZ(KQ'H5<#A\HXOP=/GQ?"^8TJ]:*?*Z^6XR<,/C*#DDW:<I4HWLU3I
MU*\DM7?RS_@EOH5S_P %./\ @O5\8?VP=>@EUCX<?"KQIX[^/VF3WT320+8:
M%>P_#G]FS0))F4F/5-"T\^%_$>G_ "Q"5?A[>LHB51$?W>_X.9? &J>-/^"6
MWC#6M-M[RY3X8?&+X2^/]32SCEE$>ERZGJ7@":XNTB#$6=O/X[MIII)!Y4+)
M'-(5$>X>8?\ !K[^RQ_PIK]A+7_C]K>G?9?%W[5'CZ\UZSN)8C#=?\*P^&DV
MI>#/!5K-&X\U5N/$K?$/Q!:S92*\TO7M+N(D:+RYYOZ$/B[\*_!/QR^%OQ#^
M#?Q(TE=<\!?%#P=XA\"^+M*9A%)=Z#XFTNYTG4!:W&UWL[^&"Y:XTZ_A N-/
MOXK:]MF2XMXG7?B'/:6%XSP56A%RP'#57 Y?0I0:UHY?)+%0C]E3=1UJ49=5
M"FV[))<W"_#E;&\ 8^CB9*&8\6T<QS3$5IIZ8C,XRE@YRWDX*DL/6E'HYU+:
MMM_P;?\ !%G_ ((V?L/?\%,OV;_&7Q ^)7QA^/OA?XS_  X^)6H>$/&G@OX<
M>+OACI^E67AR_P!*T[6? _B=-(\2_"OQ7K=M:>(8I==TN.[GUB:VO=5\+:VE
MK' +62)/V)_XA//^"?\ _P!%Q_;$_P#"T^"O_P X:OQ@\=?\$_/^"LO_  1'
M_:8UKXR?L6Z/\0/C)\(KZ^GT[2_&'P[\(WGQ-TGQIX#%S_:5OX2^/GPF\.PW
M>L:3<6$2K;WGB!=-L-(@U$OJ/@GQAI6I7/DV?T-=?\%[/^"VWQGTT?#/X/\
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M9U,M>&G#$X"A4ACJE>->A><J=2.)Q2C43DXJK4TE9IG]5/\ P66\ :K\3/\
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MK!@\3>*;/6M$\%>!-!BU_3]'TNRTSP_JBS3+J>D:/8^%[/1;:XN_N7_@M/\
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M0A*G]=PTW[6'/)MPJ<B]G*%XMU.5'S[_ ,%&_P#@B1^T)_P2=T6;]M/]D?\
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MJ.@VJVWE@OYYGOXQ#L!?S"NT9Q7\BG_!S=^R9^U1\>_VT?@EXK^!?[-/Q_\
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M=E\'%T:37H?!FB:U)I$6JMI.J+ITE^ENEZ^G7JV[2-;3!/WK_P"":OA#Q7X
M_P""??[&/@KQUX:U[P;XQ\+_ +-GPAT7Q-X3\4:3?:#XD\.:U8>"])@U#1M>
MT/5(+74]'U?3[A7MM0TS4;:VOK&ZCEMKN"&>*2-?!S2M1EP!PQ1C5IRK4\QS
M*4Z2G%U(1>(QK4ITT^:*:DFFTDTU;='TF34*\?$_C#$2HU8T*F595&G6E3FJ
M524<+ERE&%1Q4)2BXR349-IQ:>S/PG_X.T/^3/OV:/\ LY27_P!5?XVK]//^
M"#'_ "B3_8V_[%/X@_\ JY_B37PU_P '.WP'^./Q]_96_9[\._ GX,_%?XU>
M(-%_:"DUK6=#^$OP[\7_ !'UC2='/PY\7V(U;4],\':/K-[8:8;VYMK,7]U!
M%:FZN(+?S?-EC1OT6_X(L?#OQ_\ "?\ X)A?LG?#[XH^"/%OPX\>>'?"WC:+
MQ#X*\=>'=6\)^+-!FO\ XK^/M6LH-:\.Z[:6&KZ5<7.F7]E?16]_9V\S6MU!
M-LV2H28VM1?AUD]!5:;K1S[$3E14XNK&#IX^TI4T^=1?-&TFDM5KJ@R^A7CX
MJY]B'1JK#SX9PU.%=TYJC*:JY9>$:KCR2FN65XJ3?NRTT9_&K_P2-UG0_P!F
MC_@OE%X!\<WUMID2?&S]I[]GY-1U4DM%XOO/^$_\*>%[,2N"ZZCXA\6Z;I7A
MFU8#=->:W'"Y5)G8?Z.-?Q1?\%V_^"+W[0UW^T/K'[?'[#_A/Q/XX;Q?J.E>
M,?BC\/\ X:"[/Q2\#?%#1/L83XF?#W2-(:+7O$-KXAN+&PUK4K7PLE[XNT/Q
MDNH^((+6ZTK4WF\/_/\ \+_^"X7_  7:NO"VG_ ;0/V8U^)/Q02PM_"VG^/=
M5_9>^+VI?%\7T$-O:#5]7TW2]<TSP+=:W BBYO;[5_ 2Z<)9)+[6+6:/S2??
MSW*?]=:659YE&.R_VL,MH8/,L-BL5##U,)6HRG.4YIQ;45*K4C*ZCS0A3J4E
M4C4=OFN&L[_XA[6SGAS/,MS/V4\UQ..RG&8+!SQ-+&T*\:5.%.FXRBG*4:-*
M4%%RY*E2K1K.G.FD_,/^#FEE;_@JS\.0&!*? 'X)JX!!*L?B#\1G"L!]TE65
ML'!VLIZ$$_Z%E?YG'[6W_!+#_@J_IOQ8^%OQJ^//PI^-_P"TC\7?CY':_$GX
MD:K\-/ OCOXT7_PXO[;Q##IEMX2^(WB+P)X<U;PGH.MVFBVUE<V7A[0KMO#F
M@:$MKI&C2BTTQK:T_P!,>O)XW6%I9/PA@\+CL-F"P6$S##U*^%J*=.4Z<L#"
M4HV;DH.<)JG*27M(QYXZ,]OP[>,K9[QUCL9EV+RQYACLLQ5+#8RFX58TZL,P
MJ0C)V4745.I3=6$6W2G+V<GS(_ST_P#@V&_Y2F?$C_LW/XR_^K&^%U?Z%E?P
MN?\ !NM^R%^UA\$?^"D?Q#\<_&?]F/\ :"^$7@F?X"?%C2+;QC\3_@W\1/ /
MA6\U?4?B#\-KC3]*L?$/BOP[I.D7NI7]K9WEW96%I>37=U9V5Y>0126UI<2Q
M_P!T=<WB16HU^(U.C5IUH?V=@X\]*<:D>9>UO'F@VKJZNKW5T=7A-0KX?A1T
M\11JT*G]JXZ7)6ISI3Y7[&TN6<8RY79V=K.SML?YQ/[06LZ;^R)_P<@ZMX]^
M)DW]A>$-(_;?\%_$S7]<UV*1;'2_ OQ8O]!\47GB@R2H=^F:%H?C*XU&.X@$
M@MTTQEAS-;;%_P!'565E5E8,K ,K*0592,AE(R"""""#@CD5_-__ ,%W_P#@
MC#XA_;_T_P ._M$_LX#2HOVGOAYX<C\):IX1U?4K/0M'^,'@&RNM2U33=*AU
MB]$.FZ5X\\.ZCJ=ZN@ZCK-W8Z1J^E:A/H^M:I8QZ;HD]K^%_PA_X*Z_\%Q?V
M&/ EA^S1XX_9MUCQQ=^!K(>&_"VI_M"_ 'XT:U\0=%TFU/V+2+&R\3>&?$_A
M&V\9Z-8*8H-!U/5H?$KW-BMC;VVM7FEQVD(]C'8&/&^4Y%B<KQF#AFF5X&&6
MYA@,7B(4*G+2C!0Q%+F3O3E)3G>SC*-514E4I3@_#R[,9>'>=<1X/.,!CYY-
MG&8U,VRK,\%AIXFES5VW4PM;E:Y:D(2ITVM)1G2E-P=*M3J+]$O^#MGXM^%K
M;X0?LH? A-0LIO&VL_$GQ3\6Y]+3$FI:;X6\->&+OP=::A<X!:TLM;U;Q9>V
M]CYA0:C/X?U'R1(=+G,?Z_\ _!!+P)KGP]_X)+?L@:/XA@GMM0UCPW\0/'<-
MO.6PNA_$7XO_ !!\<^%YX$;_ %<%_P"&/$&CZD@7Y7:\>8?ZTU_+G^S5_P $
MK_\ @HW_ ,%@?VJ(?VG_ /@H/8_$7X9?"*^U'3;OQ;XF^(VC7?@/Q1KW@O3+
MMK[3_A7\#/AMJ4%GJOAKPY<6]Y/!IOB.71K'PGI4&H:KXEBO?%GBJ:ZLM8_O
MQ\->&]!\&^'/#_A#PMI-EH/ACPKHFE>&_#FAZ;"MMIVBZ#H=A!IFCZ386Z?+
M!9:=I]K;V=K"ORQ00QHO"BO.XHK8/*N'<HX3P^+H8[%X7%5,PS*MAIJI0HXB
M4:\8T(5%I)KZS.+6DXQI1E4C!U.5>KP=A\?G/%6>\;8G XG+<#C,'2RO*</C
M(.EB:^&A+#2GB9TWK&,GA*<HRUA*5:<*<YQI<\O\^[_@V&_Y2F?$C_LW/XR_
M^K&^%U?Z%E?PN?\ !NM^R%^UA\$?^"D?Q#\<_&?]F/\ :"^$7@F?X"?%C2+;
MQC\3_@W\1/ /A6\U?4?B#\-KC3]*L?$/BOP[I.D7NI7]K9WEW96%I>37=U9V
M5Y>0126UI<2Q_P!T=8>)%:C7XC4Z-6G6A_9V#CSTIQJ1YE[6\>:#:NKJZO=7
M1OX34*^'X4=/$4:M"I_:N.ER5J<Z4^5^QM+EG&,N5V=G:SL[;'^>G_P:G?\
M*1SXF_\ 9G_Q)_\ 5M? BO\ 0>U3_D&ZC_UXW?\ Z3R5_#3_ ,&T?[(?[6'P
M)_;V^(WC3XX?LQ_M!_!GP?=?LK^/_#UIXI^+'P9^(OPY\/7FOW_Q0^"]]9:'
M9ZSXP\.:-I]WK%U8Z5JE];Z9;7$M[+9Z=?W20&"SN)(_[F-15GT^_1%9W>SN
ME1%!9F9H'"JJ@$LS$@  $DD #-/Q'K4:_$\YT*M.M#ZG@USTIQJ0NE.ZYH-J
MZNKJ]T+PFP]?#\'PIXBC5H5/[0QTO9UJ<Z4^5NG9\DXQE9V=G:SMH?Y]O_!J
M'_RD5^,/_9F/Q&_]7;^SQ7NO_!VWX U2R^/_ .R3\4FM[PZ+XF^#OC/P!'=^
M7*=/CU3P/XU'B*>W$N/)CO);3XAV\C1EA+-! K ,D!*Z/_!LU^R+^U;\!_V[
M_BOXS^.7[,O[0/P8\(7W[)GCKPS8>*/BQ\&_B)\.?#]_XCO_ (O? O5++0;'
M5_&/AS1K"\UBZTW1=7U"'3;:>6\>RTR_NEA,%K,Z?U!?\%0/^">G@G_@I+^R
M_K7P.\0ZNOA'QIHNJQ>.OA#X^^S"Z7PE\0M+T[4M/L3JT"(US>^%-=L=3O=%
M\3Z?;,L[65U'J=F&U72=,:/Z3.<]P>5^(^&S*=6%7!+"4,/B*M&2JQA3KT*E
M&52]-RO[&4HU)QBG)QC**7,T?*9!PYCLY\*,9E$*%2CF$L;B,3A:.(A*A*I5
MP^*HUXTVJJAR^WA"=*$Y6@IS4I244V?@7^R9_P &W?\ P3>_:G_9H^!W[0WA
MGX^_M77>G_%KX:^%?%]Y%HGCOX+7%AH_B._TR!?%WA@,_P #;F6&[\)^*HM9
M\,ZC:7$\US9:CI-U:7,CSP2,?H;_ (A//^"?_P#T7']L3_PM/@K_ /.&K\2?
M@;\0?^"XW_!#K6_%/PIL/@!XJ\>_!N?4)]7;P]KGP]\9_&C]GVXO;R9%F\6>
M _'WPVO]-F\*:IJMM;^9>Z./$NC2NUQ%=^+_  6=5CMS!]3/_P %3O\ @X&_
M;^U?2/AK^S#^S+/\#+:XU:UDO_&W@3X.^*-!LH(8)8KAK7QA\7/CKJ6M^!?#
MNF PB=HM+B\-ZWJ4*W&GP2ZHEPUA+OC,/QE+$UL1@.+L#/)9SG6H9A5S'#4Z
M5+#2?/&-9*E.7/3B^5N"G&3CS7C?ECS8'%<!1PE##9GP+F,,_ITX4<3EE'*<
M74K5L7!*%26';K0C[.I-.<54<)Q3<>6?*G+^O/\ 8R_9-^'?[#G[-OPY_9>^
M%.K^+=?\"?#/_A+#HVM>.[W1M1\6ZC)XR\<>)?'NJRZS>^']#\-:1/)%J_BB
M^M;/['HEBL6FP64$BS3127,WY\?MX?\ !!S]A?\ ;HU[7_B1J/A[6_@=\;_$
M$EQ?:M\4OA#+8::OB?69V,C:IX[\$:E:7GA;Q/>7$[R7&J:O9VOA_P 6:Q*Y
M;4/%$I2,I](?MP_";]M[]H#]@/7?AK\"/B+X'^!W[6/B_P !>$H_&NIZ+J?B
M#_A'CJC:3:S_ !.\"_#GX@0PV&N>$QKFI_;-$\->/KO0I;R+1B\4]CH%YJJ^
M(?#_ /+1X(_X*M_\%Y_^"?6E:5\'_P!IG]E+Q+\:-.T.=M)TCQI\8?A=\1]=
M\4ZI#;;8(-,TSXW?#76QX0\?"$HSG6-3C\9>(KSSD>[UVXB, 'QN0X#/,=5Q
M6:Y1GV$I9S]<K?6,-+'+#XO%1FU5GB%SI8?%4:M5R;A+FIWCS2LW&)][Q)F?
M#N6T<%DN><-8ZOD'U&A]5Q<,N>+P6#E2C[&EA&J<GBL'7HT(P49Q4:MI<D;I
M3D?#OQ_^"W[?7_!NE^T[\._$GPW^-B>(OAW\1+G5=>\'ZMH\NLZ?\,_C1I7A
M"XTNS\5>"_B[\)KC5IK>VUG3K'7M%-U&NH:K)IMKKVF:OX*\:0ZW9SS:-_H4
M?LW_ !ETW]HK]GSX'_'S2-/DTC3OC1\)OA]\4+;1IIEN9]%7QSX5TKQ))HMQ
M<(JI/<:/+J,FFW$R*$DFM9'0;2*_@_\ BA\-_P#@KI_P7^_:#^%LWQ.^ >K?
M GX,_#]9=/TG7]7^'_B[X>?"'X9^&?%>H:4WC3Q9I]]\0KI==^*'C;5K71=)
M-QI'AO4-0NKL:1H]O#IWAO2#>:DG]0'_  50_9U_:*\,_P#!)>^_9P_8+'CN
MZ\4?##P;\'?AY8Z'X#O);+XE^*O@U\/+?1_#NOZ%X>FT:33;Z[UK4-#TNQNM
M9TK0]E_XFT>VUSP_86%^^L#2[OWN+:=',5PS@LRQ>54^):]9T,WQN%E2="AA
MZE2,*$\;.ERT_:1A*$^5N$8R5;V?)0G"3^;X)JXC*O\ 6_,,HP.<U>$L-0CB
M<CR[&0K+$8G$TJ,JF)C@(5U*K[.4XSIJ24YS@Z"J*KB*<XK]J:*_B!_X-;_C
M?^T5I?[5?[3G[)7Q-U?XBGP?X?\ A+KOCC6? 7Q!E\0?;/AI\6/ 'Q.\%^ M
M3TLZ)XCD6\\':Y?V_B[7-.\5Z,;.RO;K4/#-C'JENMSHH$7]OU?"\19)/A_-
M*N6SQ%/%*%.C5IXBG'DC4IUJ:G%NFY3Y&KM-<\TTE)2:DC]'X6XAI\3Y/1S:
MGA:F"=2K7H5<-5FJDJ57#U'3G%5%"GSQ=E)2]G!J[BXIQ9Y%^T#_ ,D%^-O_
M &2+XD_^H;K5?P^_\&F444O[8'[2_FQ1R;?V;(MOF(KXS\4/!6<;@<9P,XZX
M'I7]Q_QOTW4-8^"WQ>TC2;*ZU/5=5^%_C_3=,TZQ@ENK[4-0OO"FK6ME96=K
M KS7-U=W,L<%O!"CRS32)'&K.P!_CR_X-B/V4?VH_@'^U+^T/XE^.O[-_P >
M?@KX>UCX V^AZ/K?Q;^$/Q ^&^E:OK+?$3PI?C2M*O\ QEX?T:VU+4%L;*ZN
MY+2RDGGBMH'FD18P&/T?#M:E3X/XSISJTX5*L,N]E3E4C&=1QJU+^SBVI3MI
M?E3MU/E.*L/7J<=< 5:=&K4I4:F;.K5A3G*G2YJ-'E=2<8N,+M>[S-7:T/JK
M_@YR_P""=:?%_P""6B?MR?"[P^LGQ%_9_P!-3P_\7[33+4?:O$OP1O+^6>V\
M0S10(TES=_"[Q!J$]]/(L:^7X/\ $7B34=1NA9^&;**/Z%_X-S?^"B__  UM
M^RL/V=OB1KOVWX\?LLZ7I'APS7]SYFJ>./@NP73O 7BLO,PGO[_PL(1X#\33
M(L\D2V/A76-5NY-1\5D5_0OX@T#1/%>@ZWX7\2Z58:[X<\2:1J6@>(-$U2VB
MO=,UG1-8LYM.U72M1LYU>&[L-0L+F>TO+:9&BGMYI(I%9'(/^?C)^Q5^WI_P
M1\_X*M-\2OV4_P!F;]I3X^_ KPGXM_M30=5^%/PE^(_Q&T+Q]^SS\0)-^O?"
MWQ%XA\+>']8TI?&6@:2UQH<HUF2.XM/&/AKP_P".UTQ;*;1WFZ<CKT.).&L7
MPUC:]&EF&5J6/R+$8BI"FI13?M,&ZM1Q23E-P47+2%:$E%QPJ1Q\18;$\)\7
M8'BW+L/7K99G#CEO$F%PM&=5QDTO98]4:49/F48*I*2BKU*$X.7-C6?WU_%#
MXA^&_A%\-/B'\5_&-U]B\)?#+P/XK^('BB\RH-MX>\&Z%?\ B+69P7*INBT[
M3KAU#, 6 !/-?R3?\&QOP\\2_'/XW_MX_P#!1WXD6OG^*/B/XTU'P!H^J,'F
MA?Q)\0_$A^,OQ@AMIIE'EBQDF^&4%H8L,MG?W%NPABVQR?H3_P '%/[5,/PG
M_P""7&N:/H<FJZ'XE_:NUSP/\+M$T[5]/O=!\4:;X6U:$_$#QT-7T#4HK;4M
M*E_X13PW/X,\1:=J-M%=Z9=^*DL+N"&[("?6/_!$W]FW_AE__@FC^S-X-O[#
M[!XL\<^$?^%V>.!)%Y-Y)XA^+LQ\8V=MJ46%,>H:!X2O_#'A2YC8"2,Z L<N
M9%<GS,(O[+X,S/%2O#$Y_F-#*Z*>DU@\!_M.+J1_N5*S6&J+=M)6MJ>QC6LY
MX_RC"1?/A>&LJQ&<5[:P>/S-K"8*G-?\_*5!2Q5)Z64F[WT/U9K_ #Q?B$B/
M_P '0MBCJKJ?V\/AIE64,IQ!X4(R""#@@'D=1FO]#JOX4O&W['_[65[_ ,'&
M]E\;K3]F']H.Y^"R?MG?#_Q<_P 8(/@U\1)/A8OA:PL_#<E[XB;XA)X=/A$:
M+:"WG2XU,ZQ]CBFAD@>43HT8ZN JU&C4XC=6K3I<_#F.A#VE2-/GFY4[1AS-
M<TGTBKM]$<?B70KUZ7"BH4:M9T^*\MJ5/94YU.2G&-:\Y\D7RP764K175G]0
MO_!5C]@?P]_P4'_8X^(?P5ALM,M?B=H\1\?_  /\0W"06W]B_%/PW9WC:-9W
M%\R@6NB^+[*YU#P9X@ED$L5II>O2ZLEO+?:78M'_ "V?\&U7[?&M_L[_ !_\
M9_\ !.?X[7%_X;\/?%'Q7K$GPUT_Q-YMC<^ /V@] #:5XF^']W;WOEMI7_"?
M66CM8+83,A@\>>&],TNRLFU/Q=?2M_=W7\/_ /P<!_\ !*KX\:)^U?X-_;:_
M8B^$GQ6\>7WQ8U>TUCXB:)\"/ _BSQEXN^'WQP\&M::CIOQ-MM*\#:7J.K:3
M8>-+2SLM3FUN&S6&S\>Z%JVIZEJ*:EXLTR*73@_'87,,%F/".;5H4L)F$)XC
M+<36DE'!YC2BIIJ<VE",^2,U'FBI2IU*6KQ+OGQWEV-RO,,KXXR2A.MC<JJ4
M\+FV$H1DYYAE5:?LW%P@I.<J3G*FY<DY0A4IUG:.#C;^X"BOB_\ X)]?'CXN
M?M&_LF?"?XD_'[X0?$7X'?'!]';PW\5_ ?Q,\ >)/AMK*^-O#+C2]6\3:3X<
M\4:7I%_'X6\9&*+Q3H+PVTEI:6VJMHOVJ>[TF[(^T*^#Q.'J83$5\-5Y?:X>
MK4HS<)QJ0<J<G%N$XMQG!M7C.+:E%IK1GZ3A,32QN%P^+H\_LL31IUZ:J0E3
MJ*%6"G%5*<DI4ZD4[3A)*4))Q:NF?PG_ /!V[_R<1^R+_P!D7\<?^IQ!7[E_
M\%M?V4_^&HO^"2&NW&D:;]O\=_L^^#/!/[0O@SRH=]TT'@+POY7Q L4:,&XD
MCNOAEJOB^ZBL80XO=8T[1MT3R00/%^5?_!T#^RU^TW\?_CK^RYK7P'_9U^.O
MQLTC0/A+XSTO7M4^$?PD\??$BPT/4KCQC;W=O8:Q=^#?#^M0:7>7-J?M%M;7
MSP2W$*O+"CHCE?Z^_!^AP7GPN\+>&_$>E+-;77@'1-#UW1-6M#LE@G\/6MAJ
MFE:G872 [9(VGM+VTN(P<&2&5!\RU^@X[-/[/R+P^QF&JPGB,NJYE7G2A4BY
MKEQE"7LZL8MRA&M!3@U)+FA*5KJY^7Y=D[S/B7Q0P&+HU:>%S6AE&&IUITIJ
M$G+ 8B"JT922C.5"HX5$XM\LXQN?YB7P-\2?%C_@J+\5?^"8O[ &O&^E\)_!
M>+5_A5%?PWD]Q??\('K7Q#U_XE_$GQ:B!$CL9/"GP9T71/#&FVJ9#6OP]T^2
M2[5KP);_ -1O_!U?I.F:!_P3W_9ST+1;&VTO1]%_:J\%:3I.F642P6>G:9IW
MP1^,UG86-I @"0VUI:PQ6\$2 +'%&B*  !7VY_P3S_X(3_LY_P#!.[]HGQ-^
MT9X"^(GQ ^(?B#4O"/B7P9X3T+QO8^'DT[P)I_B?6-+OKV^TF\TRUBU"]UB+
M2-,_X1J*_O) 6TG4M6$L;RWNZ+P?_@YL^!?QL^/G[%'P7\+_  *^#_Q0^-'B
M?1_VH_#7B#5?#?PG\!>*?B)XAT[08OA/\7M-FUR]T3PAI6L:G;:/#J.HZ=83
MZG+:K907FH6-M+.DUY;I)ZM;B/+<UXRX;CELE1RG UZU92JQ>'A]<Q]2OB<;
M5E&IRJ"<W36NG.IN+Y9(\2APIF^3< \6RS:#KYWF-##T7&C-8JI]1RVGAL)@
M**E2YG-PIQJNRO+V?LU-<\9,^RO^"$7_ "B7_8T_[$OQM_ZMWXA5_)O_ ,'#
M_P#RF7\(?]B3^S?_ .GJ]K^OC_@C!\//'OPI_P""8O[)GP_^)_@KQ9\.O'GA
MSP?XLA\0^"O'/A[5O"GBS09[WXG>.-4M+?6O#NNVECJ^E7,^G7UG>QV]_:6\
MYMKF&4QA9%)_F2_X+L_L?_M9?&'_ (*S^$?B)\)?V8?V@_B?\/D\(_ "TE\>
M_#WX-?$3QEX*M[G2-:O#J]O=^*_#OAW4= M)M)0K+JD=SJ$3:?"R3W@AA97/
M-PMB,/3X[X@K5*]&%*?]O<E6=6$:<^?'1E#EG*2C+F6L;-\RU5T=G&>%Q-7P
MWX8H4\/7J5Z?^K?M*,*-2=6')ETHSYZ<8N<>27NSYDN5Z.S/[K:***_*S]G"
MBOYI/^#G+0_VN==_91^#UO\ LYVGQ-U+X=1_$W5C\>M+^%4/B"ZUBZLI-"A3
MP!)XFM/"ROJUUX(M]4_MX:E%<I)H*^()O"T^HQ_;8=(EB]@_X-P;/]JVP_8
MO;;]J"V^(EI;+\8?$[? ^#XJIKD7BZ/X4/X<\([5M(/$6-6@\&GQF/%<GA=+
MR./>)-2ET\-H4FCL?HY</J/#=/B'^T<*W/%O"O+_ /F(C:<X<SESZU'R^U]E
M[-6H257VC^$^5AQ.Y\6U>%O[*QBC3P*QG]J/_=I-PIU.10]G94U[3V7MO:O_
M &F+H^R7QG[]U^.O_!?S_E$3^V)_V!?A+_ZO_P"%%?L57Y4?\%N_AS\0?BU_
MP2X_:L^'OPK\"^,/B5X^\1:/\,D\/^"/ /AK6?&'B[79--^-OPTUC4(]&\-^
M'[+4-8U26RTG3[_4KJ.QLYWAL;*ZNI%6""5UX^'I1AG^1SG*,(0S?+)3G)J,
M8QCC:#E*4FTHQBDVVVDDFV['=Q/"=3AKB&G3C*<YY'FT(0A%RG.<L!B(QC&,
M4W*4FTHQ2;;:25V?EI_P:9_\F3?M$_\ 9TVH_P#JI?AA7]'?[1_@>]^)O[//
MQY^&VFK.VH_$'X,?%'P/8+:EA<M>^+/ ^N:#:K;E/G$YGOXQ$5^;S"NWG%?@
MW_P;'? ?XW_ +]C[X[>'?CK\'/BE\%O$6M?M)ZCK6D>'OBSX \5_#K7M4T7_
M (5?\-[$:S8:-XPTG1]2N](>^M;NQBU."U>QEO+.]M8YWGL[F.+^DNO4XOQ$
M?];,UQ-"<*BCC:=2G.$E.$G"G1::E%M27-&SL^C1Y' V&E_J3DN%Q%.I2E++
MZE*K3J1E3J152K7BU*,DI1?+*^JZIG^7I_P1E_85_9E_;^_:>\8_LW_M,>/O
MBE\,M9/PZUCQ1\,H_AYKO@[PWJWB+Q5X4U;3U\3^$KN#QMX(\9+?:C!X8NM3
M\1P6%C;:?>6]CX9UZYN'FBMF2+^H?_B$\_X)_P#_ $7']L3_ ,+3X*__ #AJ
M^%_^"M'_  1)_:F^#W[3FL?M]_\ !-:R\6:Z=5\87_Q>\0^!?AK>):?%CX4?
M$RZU&75];U[X::):&WO?&/A3Q#J-U<W\7A;P[#J>OZ7<7VHZ)'H&I>&)(19\
M#X<_X.!?^"T7@K1;7X<>,OV)/#GBSXG6-O9:7#KWBO\ 9O\ V@- \5ZI=QQ"
MWDO?$?@OPYXG\.Z==ZS?SKYSQ^'=,\*Z:LS-';:1''MC7])S+&9]Q!]6S7A/
MB"C2PU?#TEB\LJ8NAAZV Q,4E4YHU87<'=<S;3<HNI2]I3J1:_),IP'#?"ZQ
M62\;\,5ZV+P^*K/ YQ1P.(Q6'S+"5)7I<LZ,U^\3NHI)J,6J57V=6E)2_<?]
MC'_@WL_8[_8>_:2^'/[4/PQ^*'[1_BGQW\,?^$M/A_1?B%XG^&.H^$KB3QCX
M'\2> M0EU.R\.?";POJ\\EII'BG4+K3_ +-K=HL.I16D\RW$,3VTOY:?\'>7
M_(N_L$?]AK]I3_TA^!E?IC_P1@\=_P#!87XJ>*_C5\5?^"BWA>;PK\'_ (B:
M)H^H_"CPWXTT/2/ASXX\'>*M(U,VS:5X7^%&FZ3:Z_H'@?5?#VH7K:S>_$>:
MT\33ZKX?\-W6GQ:VFKZ[JT?SO_P="_LA_&C]H?\ 9X_9]^*?P:\!^)?B3/\
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M$<)<OL\_H82E7A5E4PE/#X:E#%TJ;A4]C"M0Q2BU)*24Y4Y>TEAV_P"ER/\
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M6SO[2Y,7DW$3M_:WX-M;BQ\'^%+*\A>WN[/PWH5K=6\HVR07%OI=K#/#(O\
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M$?%VO^)]2T2/3?$OB&+39/$5OJ7AKP]H^IZA<:0+"Q_IN_X(T_&[XE?M$_\
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M6Q'!F8TJ%&K7J.OE[5.C3G4FTL;0;:A!2DTEJVEHM6?JI_P6U_93_P"&HO\
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MZTZ-6%&K3RGV56=.<:=7EPT%+V=1Q49\KT?*W9[GOU%%?C)_P7OTW]J+5O\
M@G!\3+3]E)/'DWBT^*_!<GQ!M/AB-6;QW??"%+R\/B^UT-/#W_%036[7Y\/R
M^)K?2,S7'@^+Q!!?I+HTFIQ2?&Y=@UF&/P>!=>GAEB\12P[Q%;^'2]K-1YY:
MJ]KZ1YH\SM'FC>Z^]S7'O*\MQV8K#UL6\%A:V)6&H*]6O[*#G[.&DK.5M9<L
MN57ERRM9_LW17\H?_!K9I/[8FC_#7]IVU^.NG?%;3/@<->^'8^#]K\5;?Q-9
M)'XSBB\8Q_$G_A K3Q,L=U'HQLO^$.C\2/:0C26UB&QCLG.I0Z\J_P!7E=.>
M96LFS3%Y:L52QJPLJ<5B:*M"I[2E3JVY>:?).'/R5(<\N6I&4>9V.3AW.'G^
M38+-W@ZV7O&0J2>$Q#YJE+V=>I1OS.%/GIU/9^UI3]G#GI3A+E5S\=?^"_G_
M "B)_;$_[ OPE_\ 5_\ PHK\Y_\ @TS_ .3)OVB?^SIM1_\ 52_#"OU+_P""
MW?PY^(/Q:_X)<?M6?#WX5^!?&'Q*\?>(M'^&2>'_  1X!\-:SXP\7:[)IOQM
M^&FL:A'HWAOP_9:AK&J2V6DZ??ZE=1V-G.\-C975U(JP02NOP7_P;'? ?XW_
M  "_8^^.WAWXZ_!SXI?!;Q%K7[2>HZUI'A[XL^ /%?PZU[5-%_X5?\-[$:S8
M:-XPTG1]2N](>^M;NQBU."U>QEO+.]M8YWGL[F.+ZG!UJ*\.<VH.K35:7$-*
M<:+J1564/89?[\:;?.X^[+WDK>Z]=&?'8^A7?BKDN(5&J\/'A>O3E75.;HQJ
M/$9DU"551Y%.THOE<E*THZ:H^I_^#AK_ )0]_M>_]T!_]:A^"E?#?_!IW_R8
M)\=/^SP/%_\ ZI?X&5^C/_!=?X;?$7XN_P#!*O\ :E^'GPG\ ^-?B?X_\0_\
M*0_L#P-\//"VN>-?&.N?V3^T;\(=<U7^Q_#/ANPU/6M3_LS1=,U+6-0^Q64_
MV/2]/O=0N?+M+2>:/XY_X-E/@9\:_@'^Q#\8_"WQT^$'Q/\ @OXHU?\ :H\5
M^(=+\,_%?P'XI^'?B+4- F^$OP:TR#7+/0_%VE:/JEQH\^HZ7J=A;ZG%:M93
MWFG7]M#.\UG<)&L+6I+PXS*@ZM-5I<24YQHN<55</JV7KG5._.XW37,E:Z:O
MHPQE"N_%?*<0J-5X>/"=6G*NJ<W1C4^N9F^255+D4[2B^5RYK23MJCZ#_P"#
MB7_E$%^U5_U_? 3_ -:/^$E?&_\ P:?_ /*/+XT_]GG?$#_U1_[/-??W_!>'
MX:?$?XO_ /!++]I3X>_"7X?^-OBCX^UV\^"C:'X'^'7A37?&WC#65TKX^_##
M6=4;2O#7AJPU/6M173=(T^_U6_-G93"STVRN[ZX,=K;32I\I_P#!LQ\#OC3\
M _V$OBSX2^.GPB^)OP8\5ZM^UGXY\3:9X7^*W@3Q1\//$=_X<NOA!\"])M=>
MM="\7:7I&J3:/=:IHVKZ?;:DEH;.XO-,O[>&9Y+2=4,-6HKPXS"@ZM-5I<20
MFJ+G%57#ZM@ESJG?G<;IKF2M=/71ABZ%=^*^68A4:KP\>$ZE.5=4YNC&I]<S
M!\DJJ7(IVE%\KES6DG;5&A_P<H_L@?\ #1G[ 6H?&#P]I?VWXA_LF:Z_Q2L9
M((?-OKCX9:O':Z'\6=+C;:1%96>F1Z'X_P!2E+(5M?A^RJ27\N3\9?#_ /P4
M[EF_X-J/%_PRN/$13XQ^'_&FF_L'VP>ZSJ5S\/\ Q2DWC73;MK4,9!HC? /3
M_%OPRM) 4C%SX;<RCE([C^Y7Q3X8T'QKX9\1^#?%6EVNM^%_%NA:OX8\2:+?
M(9++5]!U[3[C2M8TN\C!!DM=0T^[N+2X0$%HI77(SFO\H[XF?L6?$CPA_P %
M!?%G_!.+PIKE]JE[>_M0Z3\)/#K1WDMUI.JQZAXAFT7P%XZUW3K.5+ 7NF^"
MO%;ZQJDTR+/X=M=0\0V;SVL7V_=[O DL'G.6O*<QFH_ZOYEA^(,).:O'ZM3D
MWBJ,NU&-2\ZB=U*6(3:?*K?.>),,=D&;+.\JIN;XHRC%<,8V$':3Q=2$%@J\
M>^(E22ITI+6,<,TG'GN_[9_^#9K]EG_A17_!/>'XOZWIWV3QI^U3XUU/XBS2
MS1>5?1?#OPL]SX,^'.G3\?O+2?[%XH\::7)N;S+'QQ&_RYV+_.)_P<F_#^T\
M)_\ !62;Q-XV@U^/P/\ %3X9_!'Q?>W6EE(+Z;PWI%K+\.O$D?AN[O;2]L$U
M*VC\$7S0>9:7L%OJ,\4MU9S)*8I?]"GX8?#OPO\ "'X;?#_X4>"+$:;X-^&?
M@KPMX \*:>-I^Q^'/!^B6/A_1;9BBHKO#IVGVZ2.$7S'#.0"QK\E?^"TO_!*
M6P_X*9?!#0)?!.JZ;X5_:.^"_P#;VI_"36]7;[/X>\366O)I[>(OAWXOO(;:
MXNK33-<?2-/N]#UE(YSX=UVV29H&TS5-:27Q^'^*J-/C3%9SCYRI87-)8K#5
M*KO?"T*\H/"N5K^[05##TIR7P4U*>O+9^]Q/P97K< 8/(,LIPK8S)H8+%4J*
MLEC,3AH5%C%&[BN?$O$8FK"+LIU)1I^[S\R^ /"W_!K)_P $W?&_AGP[XS\(
M?M%_M:>(_"GBW0])\3>&?$.D>/?@C>:5KOA_7;"#5-'UC3;N+X$-%=6&I:==
M6]Y:7$9*36\T<BDAA6]_Q">?\$__ /HN/[8G_A:?!7_YPU?C-^SS^VY_P7#_
M ."0^B3_ +.GC3]F'QGX_P#A7X0OS8>'- ^+OPJ^(7CKPKX7MC++-/8_"?XQ
M?#75[/1[_P /7DTZR06,7B+QEX:TR19(M&TW2IY;])?LKX.?\%"?^#AG]OGX
MW_"F[^$/[/&F?!?X5>#/&V@>)/%L,OPR\2?"GX/^,M TO5K>?5-!^(?Q5^+D
MOBSQ#JME?:<;G3-0T3X63)KC6MVNHVWA:\OK.UN8?H<5AN-Z,JU>EQ?@997%
M3J4<RJYEAJ=*I2LY4TXJE)JK-<L>6/-3YW[M1QM)_+8/%^'E>&'P];@;,89Q
M.5.EB,JI93C*E:E6<E"JXRE5A&5&F^::E)QJ^S7O4HSO$_I+_:1^$WAOX"?\
M$I_C[\#/!USJM[X2^#7_  3[^*WPK\,7NNS6=SKM]H'P_P#V=-?\*:1>ZW<Z
M?9:;87.L7EAI,%SJEQ9:=86L]]+<2V]E:Q.D"?S)_P#!HE_R/7[=/_8I_ #_
M -/'Q:K^Q#]HKX:77QH_9]^.OP=L;FWLKWXL?!OXG?#2SO+MI$M;2Z\=^"=;
M\+6]S<O$DDJV]O-JJ2S-%&\BQHQ1&8!3_!'_ ,$5?&O[;G_!./\ ;^LOV?\
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M[X=UJT62&UO/AK\.;OQ?XQT77I6"+Y$6J>%?"VG3(L^W[1>:A!9,S3W*J_\
M1'_P=5_\HWOA[_V=Q\,__57_ !MJ_P#\$$/^"-OBK]@O2/$G[1_[2=GIMO\
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MP_\ BYX!.HZKX>\4Z%K>E:+K4EN);CQ!X5\1PZ+JT.O:%H$ESI^G7_U9X/\
MVW/^#@;_ ()26VH?"KXV_ GQ9^T;\-=#U:2RT;QI\5O!OQ"^-&AV]E'-(L:^
M$/CW\/=>M+V6PU6,Q7&F:3\0-3UN^TFS6.RM= T)H;JPB\:_:?\ B_\ \%C?
M^"[&J_#?X)6?[(VM_#7X1^&_$W_"66MI8^!?''@7X80^)8;*]T1?&?Q%^*_Q
M+D.F75UX=T;6=;M=(T;1Y[2[EMM1U1-,\-:[K$D.SZOA[ Y]E%:G2Q6=Y/F'
M"/)45>=?&X?$8.6%]FVHT85KU:,U[O[F,OJZ?-S<ZLW\9Q1C^&\\H5:V#X>S
M[*^.>>G+#4\-EV*PN/CC?:QBY5ZN'2HXB%E+]_./UEQY7#DEHO[-_P#@F?\
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MU"U2<VO=:_!7_@[S_P"0_P#L#_\ 8'_:7_\ 2WX$U_6%^Q)_R9A^R+_V;#\
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MQI?WDGA?Q#:Z-9:I>6-Y:VEJGBK089K;SKI)9/Z"O^(3S_@G_P#]%Q_;$_\
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M::/[I*_ST_\ @J3_ ,K)_A7_ +.,_8%_]1KX"U_H65_"Y_P4=_9"_:P\>?\
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M*AUB]$.FZ5X\\.ZCJ=ZN@ZCK-W8Z1J^E:A/H^M:I8QZ;HD]K^%_PA_X*Z_\
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MI#--I]Y:7L:-;7,$LC/V>/\ @KE_P78\#?"[PK^R!\.OV;-9\<^+_"NA:?\
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MHZ-6E24IRI<_G(_X-/?^"?Q (^.7[89! ((\:?!0@@\@@CX#X((Y!'6I(_\
M@T^_X)^HZ.WQN_;"D575FC?QK\%PD@4@E&*? E'"N!M8HZN 3M93@C\CO@?_
M ,%:O^"WW_!/_P (:;\ /C#^RKXM^*&D>"8Y/#?A:_\ C[\$OC$_C+3M.TN%
M;'3-&TCXC>%-3T/3O&_AO3Q;YTW4[^+Q5>7E@T4.G^*#I,5@D'Z(?L#?M?\
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MCCXPV$_[07C]7B,%RVK_ !1M['4/#-K>0N!-;WNC?#:R\#Z%?VTY\R'4=,O
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M0AM+N6RAOWMY+J.UN'@6189"O]/O[(WA+4-%_8X_9B\"^./#MUINK:3^S/\
M!;PEXP\)>)M+DMKW3]0L/A;X:T?Q!X=\0:+J,*RV]U:W,5WIFJZ7?VZR12QW
M%I=0AED0=..Q]/"<*\"UZ4Z56O@,?C,5*@JD7.+HXZ5:"J13<H*?*K.4=G=7
M.3+\MJXWC;Q'P]6G5I8;,LKP&#AB)4I^RDJ^6TZ$W3FTH5'#F?,HRT::=C^
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M@7_P2H^/OP2\-7^J:KX<^#O_  3Y^*?PKT#5-<>TDUO4M$^'O[..N^$M*O\
M6)+"TL+&35+RQTB"XU![*QL[1KN29K:TMX2D*?H-7R_^V]X>U_Q=^Q=^UYX3
M\*:)JWB7Q1XG_9?^/WA[PWX<T'3[O5]<U_7]:^%/BS3='T31=*L(I[[4]6U7
M4;FVL-.T^R@FN[V\GAMK:*2:5$;U99_F^;8S+89IF%7%4J&.H5*:K>S4:<G5
MIJ4KQC&WNK5MV21XU/AG(\DP6:SR;+*&"K8G+\12J.@JCE5BJ-1P@U*<[^\[
MI)7;?6Y_)7_P:)?\CU^W3_V*?P _]/'Q:K^W2OX_/^#6_P#9C_:2_9^\7_MF
MWOQZ_9^^-GP1M/$_AOX&VOAJX^+WPK\<_#6/Q'<:9JGQ2FU2'0&\9Z%HO]LO
MID5Y9/J0TW[3_9ZWUB;SR?MMKYO]@=>EX@U:5;BS,JE&I3JTY0P/+.G.-2#M
M@,,G:46XNS33L]&FGJ>1X7T:V'X)RFE7I5*-6-3,7*G6IRIU(J698MQ;A-1D
MKIIJZU336C/\]/\ X*D_\K)_A7_LXS]@7_U&O@+7^A60""" 00001D$'@@@\
M$$=17\+O_!1W]D+]K#QY_P ' _A;XR>"/V8_V@O&'P@7X]_L1ZO+\5_#'P;^
M(FN_#.#2/"N@_!6U\4:K=>/=+\.W7A2UTWPU<:3JL7B"_N-6BM-%;3;[^TI;
M46DYC_HU_P""R/P&_;V^/_[,%EX?_8%^++?#GQYX9\66GC3Q9X>T37]0\ ^/
M_B9I7AY8[_0?#7@?XFVFIZ?;>%KZRUV"'5[G2M2ETJR\4RVVGVMSXJT6TL+K
M3/$7K<20PN8X?@/!_7\)AHRR/"T*^)JU%*EA&Z&%3^L>SYI4VG%QM/D2E\<J
M<5*<?%X4J8S*L3XDX]99CL9./$>+Q&&PE"DXU\;'V^+:^K>UY(U4XR4[P<VX
M?PXU)N$)?+G[;/\ P;??L,_M3ZIK_COX6#7/V4_BGKDMS?W.H?#.RL=4^%VI
MZO<EWEO]8^$VHR65A9^9(RO);^ ]?\"6LLOFW-S!<W4TTK_S$>'OBA^WA_P;
MK_MO:3\(/%OCB3QK\)+V'1O&6N?#S2]>U;4_A%\9/A#XGUF^TRZ\7>&?#>J3
M6O\ PAGQ!M;K0==L+35A96&LZ/XHT.XL+^X\1^#+V5?$'WCX8_X+>_\ !;[]
ME:TTSX3?M*?L4S_$7Q+I%B^GV'BGXA_ SXM^$O'/B=K96CAU&ZUSP3?67@3Q
M?!"BI&^I>&_#-NVH>3)-=ZK=7LD]VWBWPZ_8A_X*6?\ !<3]M[PO^T;^VE\)
M_$GP0^!VAS^&M$\3:OXC\$:S\,M"T;X5^&K^^\16_P ,_@YX0\<RR>+O%-QX
MCO=3UF.7Q1*-?TG3-4\0:IJ^NZR[6]CX?NOI\II9MEN&QE#B[,\KS#AA8*JH
MRK8VEC:E64;*@L#-VQ4I-)JE">L7RJA&-7EM\?G=?),VQ> Q/!&3YQE?&+S"
M@Y*A@*^7TJ,).^(_M.";P<8)M2K3@K37.\3.5)M/^F[_ (+XW5O??\$?_P!K
MN^M)5GM+SP[\'[JUG3)2:WN/CW\)IH94) )62-U=<@'!'%?PU?\ !*#_ ()H
M_%W_ (*<_&"Q^&ZZUXH\)?LS?##5I/%OQ?\ '=O))+IGA9_$<&FVEUHG@:QU
M!+K06^*7Q"LO#.E:=#</97"66C>'X->U^WU.P\.:;HVH?WG?\%N?AOX_^*__
M  2V_:J^'7PH\!^+OB1X[U_1?AA%X=\#?#_PSK'B[Q9K;:7\;/AIJ]]#HGAG
MP[9:AJ^I/8Z1IU]J-Q#864[V]A97-TZK!;R.OPO_ ,&R/P)^-OP"_8Q^-OAK
MXZ_![XH?!;Q+K/[3NNZ[I/ASXL> ?%7PZ\0:EH3_  J^%6GQZU8Z+XOTK1]3
MNM'EU"QO[&'4X;5[&:\L;ZUBG>>SN8XO X=SR>2<"9O7P=2A''RSJ=/#QJ3A
M*K2C7PF I2Q,*3UG*G'VG))QY%-7DI1C*$OIN*N'*?$7B1D>'QU+$2RR.01J
MXJ5*%2-&M+#8W,:T<)4KI<L(U9NG[2*DJCINT'"4HU(_@1^P9\<OB5_P0:_X
M*E_$/]E_]H75+B/X!^.O$>E^ OB3K,L<]MX?O/">HW,MW\'?VC=&@+R(EMI5
MGJPF\1Q02W<NG^'=8\:Z%<17?B/0K2&U_P!#.">"Z@ANK6:*YMKF*.>WN()$
MF@G@F02130RQLT<L4L;*\<B,R.C!E8J0:_G3_P"#B#_@F+JO[:'[/NE?'[X)
M>#M0\3_M+_L]6DXM?#OAC2;G5O%/Q5^$M]=M<Z_X'TO2]-@FU+7?$?A?49W\
M8>"],MDNKNX#^+M"TC3[W6/%%E&OH?\ P0#^-/[6^O?LNS?LX?MB_L_?M"?"
M;QM^SG!HOA_X=>.OC/\ "3XA_#ZP^(GPFO([FW\,Z)::MXST#2+?4_$OPV^P
M-X;NK:WD,S^$7\(3[+FZ@UB[K@XDEA>(\FPG%%"="GFE!4\!GN$4X0J5:E-1
MA1QU.E=2E&2E!2<5)*G.G"]L-49Z?"D<9PIG^.X-Q%/$U<FQ#JYEPWC7"I4I
M4:55RJ5\NJUDG"$H.-24%-PYJM.K4:OBZ43][J***_/#]1"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **9)+%"N^62.)<@;I'5%R<D#+$#
M) .!G/!H22.50\3I(ASAT974X.#AE)!P00>>#Q0 ^BBB@ HHHH **** "BH5
MN;=W\I+B%Y,D>6LL;/E<[AL#%LK@Y&.,'/2IJ "BBB@ HHHH **** "BBB@
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MT(.?[U\G.Y?PXVU****\8]X**** "BBB@ HHHH **** "BBB@ HHHH ****
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M-*UV4445Y9[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<-2Q-3$X6M&>+G5IT>6C4YYIRHT:\U)KX;4VF]&UN?;?@+_D1O!?_8I^'?\
MTSV==9533[&UTNPLM,L8_)LM.M+:QLX2\DABM;2%+>WC,DK/+)Y<4:+OD=Y'
MQN=F8DFW7S,VI3E);2DVK[V;;U/KX1<80B]7&,8MK9M))[Z[A1114E!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HK\>O^"M7_!6S1_^"5NE_ K4-4^!FI?&Q_C=?_$2SMK>P^(-KX 3PZGP
M]M_!<]Q-//<>#_%YU)M3/C.!(8HX+(6PL9G>64S(B?!'[9'_  <\?LT_ G3O
M"N@?L^?#Z7]I'XF:YX0\+^)O%'V/QE!X?^%WPZO?$NAZ?K;>%;OQK:Z'K5YX
MU\4:&E\++6[#P[H]II.GWB26%YXBM=;L]3T2Q^@P/"V?YE2P=?!9=5KT,<Z_
MU>M&I05-K#5/95Y592JKZO&%3W%*O[-5):4N=M7^8S'C+AG*:V/PV89K1PV(
MRU8;ZW0G2Q#JQ>+I*MAXT81HR>*E4I-3<<-[9TXZU532=OZ?**_D8_8V_P"#
MJ/P+\5OBQX5^&?[5/P$L/@GX?\8ZO8Z#9_%[P9XXN_$WACPSJ>IW'V6QG\9^
M&M9T'3]1TWPVUQ+;QZAXCT[7=3;2(V:\N]':P2YN[3ZC_P""C/\ P<?_ +.O
M['7CO6O@K\"O!)_:@^+7A>\GTKQO?Z?XKB\+?"KP/K-K*T-[H$_BRWTGQ#>^
M+O$VERQF'6-*\/:=%I&EW+/IUWXIBUNQU/1[/IGP5Q-3Q]/+GE59XFK3=:#A
M.C/#NE&2C*I+%1J/#P492BI*I4C-.4%RWG!2Y*7B!PA5RVKFL<ZH1PE&K&A4
M4Z>(AB56G%RA3C@Y4EBJCG&,I1E3HS@XPG+FM3FX_P!(E%?R:_L1?\'2?PZ^
M-WQ<\'?"']J#X#0? JV\<ZM9>&]&^+?A'QU=^+_!^G^)=9OK>PT6T\7^&=3\
M,Z5JWAKP_=7$ZV]UXKM?$'B&'3)Y;>?5-*L-&74-9T[]^O\ @H%^UKJ_[#?[
M*WQ$_:>TSX0ZG\;;7X:3>&KCQ#X+TGQ3!X0O(O#VN>(M-\.W_B+^UIM \3'[
M)H$NJVM]J$,.CW#+8+<WDTEK9VES<Q<>/X:SK+<?A<MQF"='%XZ<*>#BZU!T
ML1.I4C2C&GB%5="_/*,9*=2+@Y1]HHJ46^_+>+>'\VRW&9M@,PC7P67PJ5,=
M)4,3&MA84Z<JLY5<+*BL3R^SA.490I3C44)^S<W"5OM"BORR_P""4_\ P5&\
M#_\ !4;X3_$7X@>'OAW=_"+Q1\,/'=OX0\3_  ]U#Q?;>-KN'2]7T.TUCPQX
MLCUFV\/>&%_L_P 0RIXATNWM9-*CEAO?"^IYFFB>)Z_4F66*"*2>>2.&&&-Y
M9II76.***-2\DDDCD(D:("SNQ"JH+,0 37FX[ XO+<76P.-HRH8K#R4*U&3A
M)PE*,9Q]ZG*<)*4)1E&4)2C)233:9ZV7YC@LUP6'S'+Z\<3@L5!U*%>,9P4X
MJ4H2?)5C"I!QG"491G",HRBU))HDHK^?W]@3_@N[I/\ P4&_;+US]EOX7?LO
M:UI7@[0-/^)/BF]^-MS\5K75+6/P#X*O/[)T#Q9-X(B^'=A) ?&6M:EX3TR+
M3#XK<Z._B02&]U/^SVCN_N__ (*'?\%.OV9_^";/P^TWQ7\;=6U+6_&GBU+U
M/AS\(?!JV5[X\\;3V*A;F^CM[RZM++0?"NG3R01:OXJUBXAL;9I5M-.AU?6)
M+;2;GNK\/YSALPH955P%7^T<33A5HX2G*E6JRIU.;EE)4:E2-+2$I3564)4X
M+GJ*,+2?G8;B?(<7E>(SJCF5%Y7A:E2C7QM6%;#T8U*7(IQB\12I2JWE4A"$
MJ49QJU)*G2<YWBOT3HK^(F^_X.V_BI)K=QJVC_L-^$5\ 6]^+<V]]\8?$<^M
M[)&9[>WN/%%K\/8=%M+^XMXW<1GP[<!6#&-9HXR7_HT_X)I_\%8/V<?^"F7@
MO5+SX:'4/ GQ<\'6,-]\1?@CXKN8+GQ-X;L9[E+*#Q#HFKVL%MI_C'P=<WDD
M5I'KVG06EU8W4]K:>(=%T*ZO].@O.W-.#^(<GPOUS'Y?*GAHN*J5:5;#XA47
M)I1]LL/5J.DFVHJ<DJ?-*,>?FE%/S\GXZX6S[&?4,MS2%7%R4I4J-;#XK"RK
MQBFY/#O%4:,:TE%.3IP;J\D93Y.6,FOSE_X.J_\ E&]\/?\ L[CX9_\ JK_C
M;7T9_P &X7_*)/\ 9_\ ^QL^.7_JY_&]?.?_  =5_P#*-[X>_P#9W'PS_P#5
M7_&VOHS_ (-PO^42?[/_ /V-GQR_]7/XWKW*W_)L\)_V4TO_ %%Q1\YAO^3N
MX_\ [)"'_J;@C]T**^1OVT?VX?V>/V!_@_=_&?\ :)\72:%H;71TGPQX:T:V
MBU;QQX_\1-"T\7AOP3X>:ZLSJFI&%&GN[FZN]/T31[0&^US5M,L0;BOY3/'O
M_!W)XP?Q+<+\+_V+_#</@Z"Y9;6;Q[\6M4NO$NI62L0MS<6_A[PA9Z7H5S,"
MI:SCN?$,5LV4%]=Y##Y[*.%<^SRE*OEN G6P\).#KU*E'#T7-;PA.O4IJI)7
M2DJ?-R-KGY;GU.><9\-\.5H8?-LRIT,3.*FL-3I5\37C"7PSJ4\-2JNC&6K@
MZO)SI/DYK,_MLHK\!/\ @FM_P<%?LR_MZ^,M%^"GC?PKJ?[-_P"T!XBF-IX3
M\)>(=?@\5^!?B!?1VS3G3/!_C^'2?#YB\27 @N)+;PQXET#19KUC:Z?X?U3Q
M)JDQM4_?NO.S+*\PRC$O"9EA:F$Q"BIJ%3E<9P;:4Z52#E2JP;3CSTYRCS1E
M&_-%I>KE.<Y7GN$CCLIQE+&X9R<'.GS*5.HDFZ=:E4C"K1J*,HR=.K"$^649
M6Y91;**_ ?\ X*:?\' /[.7[ 'C34O@EX+\(7_[1G[0.C1Q?\)3X4T+Q':>%
MO _P[N+JW$]OIOC3QL=-\07#>)A%+;7DGA30= U&XMK9S#KFJ^'KQ[>&;\K?
M@W_P=N3W7C;3K'X^_LAV6D_#V^OHX-2\1_"GXBW>J^*?#=C)*H:_B\+^*=!L
M=.\5R6\6[S+)?$OA9I1F6*X+(MM+[6#X*XFQ^"CC\-EE26'G#VE+GK8>C5K4
MVKJ=*C5JPJRC*/O0?(E433I\]U?Y_'^(/"&6X^66XO.*4,53J>RK*G0Q5>C0
MJ7Y73K8BA1J482C*\:B<VZ34E5Y&G;X>_P""5/\ RLA^+?\ LO\ ^WG_ .F#
MXXU_H5U_G7?\$=/&GA;XD?\ !PE_PL3P/J,NL>"O'OQ9_;5\:>#]6FLKS39M
M4\+>*?!?QFUSP_J,NG:A!:W]A+>Z3?6ES)97UM;WEJ\I@N8(IHWC7^EC_@I_
M_P %S1_P3*_:%\+_  4\7?LE^)/B7X>\7^ =$\?Z#\2M-^+&G^%;34[*]UG6
M-#US3;+09_A_X@634O#EYH[BYM[C7[66>.]TZ>2*RM+ZUN9OJ>-\IS#->(<J
MP& P[K8M<-X*;H2J4:$[4JV,]HO]HJ4H\T.L+\]E)\MHRM\7X=YWE>2<+9WF
M698N.'P+XMS"FL3&E7Q%/FK8? >R?^RTJTN2?V:G+[/6*<DY1O\ OS17-^#?
M%WA[Q_X0\*^//".I0:SX4\;>&]#\7>&-8M26MM5\/>)-,M=9T74K<G!,%]IM
M[;741/)CE4U\*_\ !3?_ (*%>#O^":?[-B_M >*?!=Q\2;_5/'OACX=^$?A_
M9^)H/"-UXDUW7XM4U2\QKL^B^(A86^C^&M U[6II!HMZ+B2QM]/)MFODNHOS
M7#8/%8S%T<#AJ,JN+KU50I4;QA*55OEY&YN,86=^:4Y1C%)N323:_6\9C\'@
M,%7S'%UX4<%AZ+Q%;$/FG"-%+FYTJ:G.=TUR1IQE*;:C",I-)_H=17YJ_L._
M\%&_#_[5G[$>J_MU?%7X=Q?LO_"G3;SXAWXE\4^.HO&5D_@#X;O_ &?K7CN;
M6H/"GA0PV[^(=.\4:'!I$&E7MU+/H :UN+NXU*&RA_!/XR?\'7D-YXXU;PG^
MR9^QMKGQ(T*SFD71_&'Q&\97^E:WX@MK8[;J^3X8^#/"^O76EV!*F6SGN?&\
M]Y):RPRZAI>E7(ELD]G!\*9_C\5C,'AL YU<OJRHXV3KX:%##U8MJ5.6(E65
M"52+3O"G4G-6;<;)L\+,.->&LLP> QV,S*-.AFE&.(R^,</BYXC%4)J,H588
M6%!XF%.2E%J=6E3@[I)W:1_8M17\MW["W_!SG\'_ -HCXJ^%?@?^T;\"/$GP
M#\9>./$6E>#?!_BKPAK&I?%+PCJGB_7-2M](T?0M=T.W\+Z-XR\*S:EJEU!I
MEG/:6/B^T2\E235[G1[(3W<'[K?MX_M867[#G[)GQ?\ VI]1\$77Q'M/A/8>
M%[R3P59:]%X8N==?Q1XZ\+^!X(4UZ?2=<BTY;6?Q-%J$LK:3?&2&TD@2(/*L
MB<^.X=SG+L?ALMQF!G1Q>-J4Z6$@YTI4\1.K4C2@J5>%25"5ZDX1E^\7LW)>
MTY+G3E_%.0YKEN+S; 9C3KX' 4ZM7&U%3KPJ86%"E*M5=;#3I1Q,;4X3E%*D
M_:J+]ESV/KNBOY?D_P"#I/\ 9+M/V8=-^+^L_"OQ2OQXUWQ)XDT'2?V8_#GB
MZWU^_L=/T.6U%GXM\8_$ZY\*:'HGACP[K45UBRCB\/:UXCENHI$LO#^H6$%W
MJ5K\&>'/^#N?QTOBF*3Q=^Q/X3D\$RW2+/9^'/C+K$'BFRLG)5Y8M1U/P'<:
M3JEU ")4MWTK2(;LH8#<V8E^TQ>K0X#XKQ"K.&4U(>PJ3I25:OA://.F[25'
MVM>*K0NFHU:;E1G9\E25CQ<1XE<%89X=3SNE/ZQ3IU8NAAL975.G52E!U_98
M>;H3LTY4:JC7A]NE$_MTK^-'_@[R_P"1=_8(_P"PU^TI_P"D/P,K^G+]B3]M
M[X#?M^_ [2OCO\ ==O+[0)[Z?0?$WAG7K>WT[QEX \6V4%M<W_A/QAI-M=WU
MO9ZI!:WEG?6UQ97U_I6JZ9>V>I:7?W=I<+(/YC?^#O+_ )%W]@C_ +#7[2G_
M *0_ RNG@?#U\)QMEF&Q-*="O0JXZG5I5(N,Z<XY=C$XRB]4U]S5FFTTSD\1
ML5A\;X>YOB\)6IXC#8BCEE6A7I24Z=6G/-< XRA):--?-.Z:331_1A_P2H_Y
M1J_L*?\ 9K/P7_\ 4'TBOOZO@'_@E1_RC5_84_[-9^"__J#Z17YF_MT_\')G
M[(/[)WC/Q5\)OA3X/\6_M.?%;P9JVJ>'?%,'A^_A\!?#3PYXDT:YFL-4T&_\
M?:UI>L:CJFIZ;J$+VUW_ ,(MX-U[1DDAN;<ZZEY ]N/)GE&99SGF:8;+,'5Q
M=6./QDIJFHJ%.+Q55*56K-PI4HMZ*52<4WHFV>Y2SS*<AX<R;%YOCZ&!H2RW
M 0A*JY2G5FL'1;C1HTXSK5I):RC2IS<5JTEJ?T845_$?X:_X.Y?'EOX@$GC;
M]B#PM=>%;CRS#;>&OC5K.E^(+2!G97NA?:M\.M5TW5]H!,=NNGZ.DKHR&]BW
M;X_ZN_V*?VU?@9^WQ\"M%^/OP"UJ_P!0\,7M_<^'_$.A:[9#3/%7@7QGIUI8
M7NL>#?%6G)+<VT&L:=;:II]T)].O=0TG4M/O['4]*U&]L;N&=EF_"N?9%2AB
M,RP$J.'J24%7A5H8BDIM74)RH5*GLY.SY?:**FTU!RL[/(N,^&^(ZU3#93F4
M:^)I0=26'J4<1AJSI)I.I3AB:5+VL$VN9TG-P3BYJ/,K_6M%?&W[<W[=?P$_
MX)\?!"]^.7Q\U?4H])?4[?P]X3\(^&;:SU'QMX_\57<,]S;^'O"FEWU_IEG-
M<1V=K=ZCJ5_J&H:?I6E:;:SW-[>QNUM!<_RTZ[_P=D?%O5KZ_P!:^'7[!6D?
M\(#HMRZZI>Z[\5O$VOWR6A;_ $:6_P!9T+X<Z3HOAVYN(MDKV]Q;ZM% S^5'
M=72H)Y#*>%<]SNC+$Y=@75PT9NFZ]2M0P]*516O"G+$5:?M))M)^S4E&32DX
MO06=\9\-\/8B&$S7,8T<5.FJJPU*AB<56C2=[5*L<-1J^QBTG*/M7"4XIR@I
M)-G]K]?G/_P5+_;MOO\ @G1^R=J_[2.E_#[3OB?J=CXX\%^#+'PAJGB*X\+6
M=[)XJO;F*>Y?5[72=:GB>QLK.ZNHX5L)!.T81GB7+CYF_P""7/\ P6^^ ?\
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M)4RV<]SXWGO)+66&74-+TJY$MDGT+^PM_P '.?P?_:(^*OA7X'_M&_ CQ)\
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M*5&"3:M3E455\T'&#4XW_4VBOYHO@I_P<Y?LD^-/V??BQ\;/C/X!U?X->)O
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M5-:OO$<^F&188;W47\.^#;?1O#DMS(R#[.7UVWMY'6!;^\;$C?MO_P $N_\
M@M]^SK_P4FO9_AM_8-[\#/VC+&QN]5_X5#XCUR+Q)8^+-&TVW%SJ>L?#OQG!
MI6AP>(UTN 27.KZ'?Z-H?B*PM(Y]0M].U/1[*^U6W]C,.#.),LP<L=C,ME'#
M4TI5I4JV'Q$J$6K\U:G0JU*D(Q3O.;BX07QRCH>#E?'_  EG&.AEV!S:$\55
MDX4(5L/B\+'$23MRT*N)H4J=2<GI"FI*I4>D(R/VNHHHKY<^Q/X?O@1XW_X+
ME#_@M1IVD>.9?VLY_A5/^TWJUA\0-"UJT\>M^RO:?LZCQ7=)J^H>';6^M_\
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M-K/PVNOBO<^,+>/QM<_&NR\60:'_ ,(E\/O%GCUY)/#\/PM\/2:@+V/PL^F
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MK2I8N*BYX6C2KXNO34HJ<?;0PM*M[#F@U.*K.FY0:E%---_VRT5^"G_!+O\
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M!9A1CB,#.<*_ML51G"%13HX14GBYI0J4W*U"]/GC[11<E?\ J6HK^*WX9?\
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M654.-,90Q.=J'#E#)G1C'ZEB)P_MR&-HJHKT\'+&.4</[:#=WA?=;3<^5O\
MJS_X+,ZE^U[I'_!/[XO7_P"Q'_PG:_&F&]\)>?/\*X+^Y^*-KX!;7[0>-;KX
M?1Z1'-KB^(8M-V&6XT",Z_9Z(=8O-&>'48+>>/X7_P"#<WQ)_P %#?$/P0^/
M:_MRR_'B_P##NG^.?"$/P/U?]HZ/Q<WQ&O'?2_$*_$NVMK_XA1CQKJ7A'3YX
M/!2:1/?S7.D0:M-XBLM'E6:VU2"']"_BW_P46TWX4?\ !,32O^"DUU\)K_6=
M-U3X*?!3XQ+\((?&-O97T*?&:_\  >GVGAYO&LGAJX@<Z%+XZADGU4>%U&H1
M:=(8M.M6N46+$_X)3_\ !2[3O^"H'P7^(7QATWX/7OP8B\!?%"X^&KZ!?>.8
M/'DFJ20>%/#/BC^V$U*#PIX16S1E\1K9?838W+*UHUQ]K(G$,7@4WF-#A3,\
M++)<'+"4\VC1Q.;RE0>+PN*IO#-X6"4W5DO=A'VE-2IJG6JQN^9R7TU197B.
M-<HQD>(,?#'5<DG7PN10CB5@<9@JJQ26,J/V:HP?O3FZ564:SJX>C.RY%&7Z
MB45\C?MH_MP_L\?L#_!^[^,_[1/BZ30M#:Z.D^&/#6C6T6K>./'_ (B:%IXO
M#?@GP\UU9G5-2,*-/=W-U=Z?HFCV@-]KFK:98@W%?RF>/?\ @[D\8/XEN%^%
M_P"Q?X;A\'07++:S>/?BUJEUXEU*R5B%N;BW\/>$+/2]"N9@5+6<=SXABMFR
M@OKO(8<.4<*Y]GE*5?+<!.MAX2<'7J5*.'HN:WA"=>I3522NE)4^;D;7/RW/
M2SSC/AOARM##YMF5.AB9Q4UAJ=*OB:\82^&=2GAJ55T8RU<'5Y.=)\G-9G]M
ME%?@)_P36_X."OV9?V]?&6B_!3QOX5U/]F_]H#Q%,;3PGX2\0Z_!XK\"_$"^
MCMFG.F>#_'\.D^'S%XDN!!<26WACQ+H&BS7K&UT_P_JGB35)C:I^_=>=F65Y
MAE&)>$S+"U,)B%%34*G*XS@VTITJD'*E5@VG'GISE'FC*-^:+2]7*<YRO/<)
M''93C*6-PSDX.=/F4J=1)-TZU*I&%6C4491DZ=6$)\LHRMRRBV45_-%^S9_P
M<U?LM?%5OCU??'?X=77[-?A[X,^&(=?T.>[^(EK\2/%/Q8U*?Q&/#T7A#P3X
M-T_P9X5O;GQ)(\UI>&&*^OK"QLY;K4=:O])T33+_ %B#X \??\'<NM)XRF7X
M7?L7:7<?#ZUOF6WG\??%R[M/&6MZ:H^6>:U\.^#KW1/"U]*2"UJEYXPM[<#
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MR32***_G/_;I_P"#DS]D']D[QGXJ^$WPI\'^+?VG/BMX,U;5/#OBF#P_?P^
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M9?\ @K)_P5U\+_\ !*V#X$MX@^".O_&:Z^.O_"T/[+AT;QKIW@NWT'_A6/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% '\:/_!WE_P B[^P1_P!AK]I3_P!(?@97Z<_\$*O^";O[+WP"
M_8Z^ W[1NG^!-(\:?'OX]_"_PG\3O$WQ1\9Z3I^KZ]X<M_&>CP:Q;>"O 8NH
M;B+PCX>TBTO4L[R;2?)U;Q1=I+?Z]?7%NFDZ7H_YC?\ !WE_R+O[!'_8:_:4
M_P#2'X&5_1A_P2H_Y1J_L*?]FL_!?_U!](K]*S#%8G#^&_#M*A7J4J>*Q^8T
M\1&G-P5:G#%XZ<:=1QLY0YDI.#?*Y*+DFXJWY)E>#PF)\6>*JV(P]*O5P>69
M75PLZL%-T*L\%ED)5:2E=1J<C<542YXQE)1:4I7_ )'/^#JC]E_X6_!W]H#]
MF[XW?#GP=H?@O4OC_P"#?B3I7CZT\-:78:-I>O\ B;X4:IX+>'Q7>6.GP00R
M>(M1TCXC6&EZMJ)027]KH>E/-ON8IYIOZ!O^"'O_  3>_9>_9T_8Z^ 'Q]T;
MP'H_C'X[?'_X/?#_ .+/B[XJ^,M(T[5_$NBI\1/"NG>*(O!/@F2ZAN$\)>%]
M#MM633)UT;[-?^)[BV.J>(;J[(TZQTK\DO\ @[Y_YQZ?]W9_^^SU_3)_P3&_
MY1Q_L&_]F?\ [.?_ *J7PG6F<9ACO^(=\,16*KI8G$XZAB+5))UJ.%Q.,IT*
M522?-*G3A3@E!OE]R%T^6-L<ARO+O^(J<7R>#P[>$PF7XG"\U*#6'Q&,PF J
MXBM2BURPJU)U:C=2*4USS2DN>5_X\O\ @Z@_9>^%WP8_:/\ V>OC1\-O!^A^
M";OX_P#@7QY9^/+#PUI=CHVD:YXM^%^L^&<^+;BPT^""'_A(-5T;Q]I>G:S>
MJB_VA'H>G7,RO?->W-S_ &+_ +.^FZ+^U?\ \$YO@1I7Q5M[CQ'H/[1G[&'P
MLM?B'!J$QGO=7L?BK\$]!7Q.UQ=7 G=]0N4UR\D^VOYDJWC"Z#-(H:OY@_\
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MMH_#7_@FM\)O@Z)=33XV?#C0_P!I_6?!FE3?;K@^-/B4H^&WP\\)%$;']O\
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M_;0^#5S?65OXQN;CX2_$W1M-;"ZCK'AFQC\7^%?$M[#@9ELO#FJ:AX4@N=S
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M:G=0ZA!HGP\U#P#X0BEANHHYK4OX=GDM3''Y<QD#RR?B5_P:6_\ )W?[3?\
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M7X2_^K_^%%>7.<Y>(7+*4FH\9^ZI2;45_;>EDW9*UMNA[5.G"/A>I1A",I<
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M9/?1-) MAH5[#\.?V;- DF928]4T+3SX7\1Z?\L0E7X>WK*(E41'^RO]O_\
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M=-\6_$#1/#>MZ1XDOM'2S;Q7I4UAK%Y-9VGB)=272M1;[?I36<\MTUQ^RO\
MP3M^)WAGXQ?L(?LA?$/PE?65]I&M?L\_"JSF.GX%MI^O^&_"&E^%_%N@[% 6
M.X\->*]%UKP]>0J-D-YID\2%E0,?SS_X.0V5?^"2_P =@6 +^,_@>J D LP^
M+WA!RJ@_>(56; R=JL>@)'PN S',<1QWA*^(Q&(CB*F?TL/6C[6I%QI/'*C+
M"V35J,:=Z/L6N3D7*XVN?HV9Y3E6&\-L;AL)A<-/"TN&:V*H2]E3FIUUE[KP
MQO-ROFQ$ZMJ_MT^?VCYU):'@/_!JU_RC;\<_]G8_$[_U7'P:K\5/^#L?_D_'
MX"?]FC^&?_5R?&BOVK_X-6O^4;?CG_L['XG?^JX^#5?BI_P=C_\ )^/P$_[-
M'\,_^KD^-%?79)_R=+-?\>9?^FHGQ/$/_)FLF_Z]91_Z>D?TV_\ !)7_ ()3
M_ ?]A[]FGP!<:[\/?!GC#]HWQ]X4T?Q1\7_B9KVBZ1XCUBWUKQ#IUKJ-UX$\
M):K?VEQ)I'@GPPLT>CP6VE&TA\1W=E-XBU2.6ZO8HK3Y"_X.8?VD-3_9N_X)
M^>%?@7\+WB\'2_M'^/(/AKJ<'A^!-&M[+X1>%-&N?$?C/1-*331;1V%OK6H#
MP?X;U"R@C6TOO"VK^(=*GC:WO'C?^B3P%_R(O@O_ +%/PY_Z9[.OY4_^#MCP
M!JNJ_LX_LG_$VUM[R;2?!'QE\:>#]5FACE>SM)OB)X-M-4TV6]**8X3(WP[N
MK>VEE*KYDKPHV^95;Y'AS$U,XXVRZOFE:6(E6S"I7E[63E#VU*G6JX:$8-N,
M80K0I0ITTN6$4H17+H?;\5X2ED7A[FE#)J$,*L/E='#P]C%1G["M5P]'%SG.
M*4I5)T)U9U:LGSSFY3D^;4Z7_@VM_P"";'P=\,?LOZ#^W%\3_ WAOQM\8_C-
MK/BH_#+4?$FG0ZRGPU^&OA?Q!=^$(FT/3=1BGL--\5^)_$?AS7M6N_$MO"VI
MKX8GT+2["ZL(9]<BU+]%/^"T'_!-;X.?MJ_LF?%KQ;;^!O#>F?M'_"CP1XE^
M(GPK^)>GZ=#IOB2[U#PIIQU[4O!'B#4K".*?Q!H/C'2=)NM @L];-];:)JU[
M8Z]8+;W%E(9S_@W[^+7A;XJ_\$JOV;;;0-0L;C5OA;;^,_A1XVTRTVK+H/B7
MPUXSUO4+2ROXU "W>J>#];\*^*-PW>=;^(+>5V\UY%7]%OVNOBWX6^ _[+G[
M07Q@\::A9:;X<^'_ ,(O'FOWDVH8:WNKF#P]?0Z1I"0D,;N\UW6)[#1-.L45
MY=0U#4+6RA1Y;A$,9KFN<1XTQ6)C6Q"QV'SB>'PU-3GI2IXITJ&%A!.SHU:2
MA"5-)PK1G)R4O:.^N29-D4_#_!8.=##/+L5D-+%8RHX4WS5ZV"5?$XR<[7CB
M*59SG&HY>TP\J<8QE'V45'^4'_@TV_:D\4W]U^T=^QOKM_<:CX7T71+#X_?#
MN"YNY9?^$;EDUG2O!/Q%TZRAF:3RM,UF[UCP1JL=K:FWM;/58M9OFAFN]>N9
MA\C?\'8__)^/P$_[-'\,_P#JY/C15K_@TY\":YJG[;OQ_P#B/!!/_P (UX-_
M9@U/PGJMY&66%->\??%'X<:EX=L;DCY76[T[P!XJNHHGZRZ:LJ\PU5_X.Q_^
M3\?@)_V:/X9_]7)\:*_1:-&A1\5*_L5&+JY=*M6C&UE7GA*?.VEM*<5"I+1.
M4IN3NY-O\IKU\17\%Z'UARDJ.:PH8>4]6\/3Q\U!)O5QIR<Z4/Y8TU!644E_
M6O\ \$[O^":O[*W[#?P,\*>'/AA\/-!UOQKXD\*Z3>?$?XN^+-$TO5/B!X_U
M35=.MKG4DO\ 5+F"XDTCPNDLK0Z1X+TB6#0=-M%5YH=0UBXU36=2_A[_ .#C
M7]FCX;?LT_\ !1[5K7X5>%M)\$^%_C-\(? _QMG\+>'K"TTKP]I?B+7-=\:^
M"/$DVBZ58Q0VNG6^M:Q\/[KQ#>VT$:1'6=7U.>&.*&:.*/\ T@? 7_(B^"_^
MQ3\.?^F>SK^!'_@Z_P#^4B7P9_[,M^'?_J\OVC*^6\/<PQV)XPKU,1BJ]>>+
MPN,>(E5J2G[5PE"<.9-V_=RBE3225.-X048NQ]EXHY7EV$X$PU/"X/#X>&!Q
MF7K"QHTH0]DJD9TZBBTN9^TC)NJVVZDTIU'*:3/["OV"?^":G[*O["/P:T/P
M+\*OAWH&L>*=5T&S'Q%^+7BK0]*U3XA?$C4[NTB;4I=:U>YM[B73_#SS-(-*
M\%Z7+#X=T>V;$=K<ZC<:EJFH?Q$?\%W/@[X*_8<_X*SZ+XU^!^@6GP]TK7]$
M^#O[3VD>'_"5O!H6E>'/%]KXMUK3M6N?"]GIJ6T6C)J/B?X<77B;R;411VNL
MZK?/9+;6OV:W@_T==&_Y ^E?]@VQ_P#26*O\^G_@ZT_Y2-?"S_LSOX;_ /JW
M_CY4^'F/QF-XKQ#Q>)K8AX[!8SZU[6I*:K6=.4>9-\ON-6A9)0BW""C%M%^*
M.6X#+^"L(L%A*&%66YAE[P7L:4(.A=5(2Y))<WOI\U1MMU)J,YN4TF?U>?\
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M&_\ LKLJ_P#4?''^AM7D7[0/_)!?C;_V2+XD_P#J&ZU7KM>1?M _\D%^-O\
MV2+XD_\ J&ZU7P6'_P!XH?\ 7ZE_Z7$_2\5_NV(_Z\5O_3<C^('_ (-+O^3P
M/VF/^S;(?_5H>"J_I_\ ^"LW_!++PC_P5(^$7@/P1J/Q*OOA%X[^%?BC4_$W
M@3QQ!X9@\9::D6OZ=;Z=XD\/:[X<?6?#MQ=Z=K4>GZ1.EY8:[87>FWVE6ESY
M6HVXN-/N?Y@/^#2[_D\#]IC_ +-LA_\ 5H>"J_O;K]"X\QV*RWC:ICL%6=#%
M8>A@IT:JC"3C)X50=XU(SA*,HRE&49QE&49---,_+O#;+L%FWAY2R[,:$<3@
M\5B,PIUZ,I3@IQ6,E.-ITI0J0E&<(SC.$XSC**E&2:N?FK_P2S_X)O>$/^"8
M_P"SKJ7P3T#Q]J/Q3\1^+?'6I?$7QYX]O]!A\+0:KK]]I&BZ!:V&B>&XM5UU
MM&T+2-'T"PAM[>ZUS5KNYU";5-2ENH8[Z'3[']*J**^ QF,Q.88JOC<95=;$
MXFHZM:K)1BYS?7EA&,(I))1C",8QBE&*221^FX# 83+,'ALOP-&.'PF$I1HX
M>C&4Y*%..RYZDIU)R;;E*<Y2G.3<I2<FV_SO_P""J7@KP;K/_!/K]N#Q+K'A
M+PSJOB/2?V1/CTNE:_J6@Z5?:UIBV7PV\67MF-/U6ZM);ZR%I>3S7=L+:>(0
M7,TL\6R61W/\TW_!I7X(\%^,K;]OH^+_  AX7\5'3I_V7!IY\2:!I.N&P%W'
M^T/]J%G_ &G:77V7[3]FMOM'D;/.^SP>9N\J/;_4#_P4]1W_ ."</[>(16<C
M]D/]H9R%4L0D?PJ\4N[$ $[416=VZ*BLQ( )K^:+_@T(EC\K_@H+!O7SB_[*
MLHC+#>8U7]HU&<+U*JS*K,,A2R@XW+G[S)ZDUX><5M3DG#'96HM2:<4\9@%:
M.MXIZZ*RW/S?/J=-^*'!2<(-3R[.G-.,;3:P./LY)KWFK*U[O0_IX_;0^,&B
M_L3_ +%/[27QS\#>'/#N@W7PL^%GC#Q5X4T?3-$L-/T.X\?W6GC2?!AU#3=/
M@MK>6UN_%U[H$&J/Y?FR6(D!+%%6OX@?^""/P\_8H^)7Q_\ C/\ M9_\%%?C
MW\ +37?!.L:7?_#OPA^TO\6/AQX?;XB?%+QK?ZQXB\6?%76M'^(OB+3KCQ9-
MX2:SM#8375EJ>EW/B3Q7/JUPR:OX=L6']C'_  65\ :I\3/^"7G[:GA?1K>\
MN]0@^#.I>,(K;3XY9;N>'X<:QH_Q$O(HXH0TLJO9>%;@2Q(K&2'S$*D,0?XI
M/^"'/_!,3]C[_@IK+\>?!OQU^*?QE\"?%3X7IX1\2^$_#OPP\3_#[1H_$W@#
M7#J>F:]K#Z=XO^'7C2_O)/"_B&UT:RU2\L;RUM+5/%6@PS6WG722R>CP@L'3
MX/XEQ6)Q>*P4JN,P^'Q>-P=+V^,I82V'Y%%74E"K.O7IU)7]V$YRNG'FCY''
M3Q]7COA+!83!8+,(4<#BL7@<OQ];ZO@:V.4L3[24Y6<7.C3P^'JTH6]ZI"$=
M5)QE_93^U;\<O^"0_P"V/\"_&GP#^,W[9'["NN^%O%.A:CIVCZA<?M'_   N
M]7\!:_-IUQ9Z)XV\%W,_C7S-$\3>&;B:.]TN\LY( XB?3[P3Z9=WEI/_ #N?
M\&H?QB\1>'?C_P#M:?LKS>)HM5\'W_@&W^+^E:=:7<-]HI\2^ _&>A?#S6_$
M>@7$,DMNR>(-)\9:!%>W5I))%JEEHVA2%Y([&!J_03_B$\_X)_\ _1<?VQ/_
M  M/@K_\X:OO+_@GE_P1$_9;_P"";/QG\3?'/X+?$+X[^,O%OBGX9ZQ\*[NR
M^*GB#X?:MH5GH&M^*/!_BN]O=/MO"7PU\&7\>L?;_!6EVT5Q/J-S:I8W&H1-
M9/+/%/!PO,N%\!P[G>48/-,RS!YA&A4PU#%X+V5*ABJ%53]K3DFU!U;0]I+2
MZI16YZ2RGC',N*N'L\Q^3Y1EBRN>(I8O$8+,'6K8G!XFDZ;I58N*=2-&\W1C
M=I.K-]K?S(_\'8__ "?C\!/^S1_#/_JY/C17]TY\9Z3\.?@6?B%KYE&A>!/A
M,?&>M&!0TPTGPOX/_MO4C"K$!I19V,WEJ2 7P"0*_A8_X.Q_^3\?@)_V:/X9
M_P#5R?&BO[;/BGX'OOB;^Q]\1_AMIBSMJ7Q!_9K\7^!]/6V+"Y:^\6?"_4=!
MM%MROS"<SW\8B*_,)"N.:.(XPEPOP!&H^6G*GCHU)7MRP=7!J;OTM%MW'PK*
MI#C+Q-G1CS58U<ME2B]5*I&ACG"+7G))?,_S\_\ @EM^S_>_\%DO^"J7C7XA
M_M1S2^*_"9'C/]I+XW:0^HZE:P^)-/M]:TC0/"/PRTN]MYTOM.\.0:UXC\,:
M/!IUK<6IM?AYX:U#1=,N+"2.REA_T-?$7[-O[/WBSX4W'P,\0_!7X8:C\';G
M2)]"/PU?P5X?@\'6NF7%F=/>#3=$M;""STF6*UVI:7NEQV=]8O'#/97-O<0Q
M2I_"W_P:M_%/P]X _;S^+7PI\57-OHNO?%OX$ZYI/A*VU*)K?4-2\7> /%6@
M^)[_ ,+VJ2HLT5\?"EOXMUVYM9!'F#PQ<>8/.AB0_P"@?1XD8G%T<_HX.G.I
MA\'@,%@WEU&E*5.E3BX.]:DHM)352,J2J1]Y1HQ@G:"2GPEP>"K\,XG'U:=+
M$X_,LQQRS6O6A"K6JS4XVH5Y24I.#IRC7=*?NN>(G4<;U+O_ #7?BCX6U;_@
MB)_P6STA?ACJE^GPQ\'?$GPEXET*RGU6\=];_9S^+Z6P\0>!-?O+AWDU*;0]
M U37/#$>IZHE[OU_PQI?BUHI+V"W,?\ 8Q_P7\_Y1$_MB?\ 8%^$O_J__A17
M\B/_  <'>*++]IK_ (*_7OPK^%LMIXB\0^'M"^"_[.,0TQ?-2\^(VH:A=7MQ
MHIFC&+K4-+USQ_!X<OU1G>TU'3KC2Y"L]C)&G]<__!?* 6O_  2 _:\M5DEE
M6V\/?!^!99W,DT@A^/?PFC$DTC?-)*X7=(YY9R6/)KVLYE+$8[PPS#%+_A1Q
MDLN6+G)6JU84\7ELZ-2IL[SE7KU-5\4YI;6/!R",,+E_C!EF#=LIP,<T>!IQ
M=Z-&=7 YM3Q%*ENK4XX;#T]&_=A!O5W?\_\ _P &R/\ P3I_9I_: \-?%/\
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M7OA_XOT^UDFD>TMKOQYX.U32-2DMH68QPRW$?P^T[[2T:*91% 7+%%V^;?\
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MVGB#X?>$M/@^%>JW2%O+!TWQ=X9\,ZO<DR M);2-YZNWG#^!#]E']C_XN?\
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M\^&W@ZP\0? CX0^(OBO\*_$&C^&]%TS6/ MW\*]-?Q9/8>'+RTLH9-,T76-
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M.AC7-RE.I.NJCE*3;_6C_@CV_P#P2>_8*_94^&3']KO]AZV_:/\ B+X&\/\
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M#7A6S\&Q7Z(0)_)M/&?BZYM8I=T8EB:?;YL,3I^P'_!#SX)?"3X._P#!,_\
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M2>-=3\4V]G=>.(@PGUG0O#R>%)+@>%FV:7X@O+Z"/7S>:+:7FBZO_=%^W_\
M\F'?ML?]FC_M(_\ JF_&=?RA_P#!HE_R/7[=/_8I_ #_ -/'Q:K7AO%8C!\#
M\78C"UJE"O&O@(QK4Y.-2*K5:-&IRS6L7*G4G'F34ES7BU))K+BW!X7'>(G
MN%QF'I8G#3P^9SG0K04Z4W0HUJ]+GIOW9QC5I0GR23A+EY91E%M/^GS]N?\
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M8FA3A2K5Y9IAJLZ<5!SHTJ%.-.$N5*\81Q-:,4]E-I::&G_P=.?M,>,OB/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MINM:)\2-;\,V/A^ZTO7=5U*UT[2;FXU"&:_U&XBLA$M_+]E'][%%?#'[:?\
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M+,QPCGC<JI2A4H2YJU2%6GAJDI0>&HUE&]2BX5J<ISFY1E&3@?BG_P $3O\
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MXZ^&BQ:[X"\86=S:RQ:DVIW?A>^N]#FU*TEB_LJ#P/X>0-'/=QN_]5/[:?\
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M(U,=1QDJU&I2JSI0;G0C/"U)QA*HH^UC74(/W^>/[\?\&OO[+'_"FOV$M?\
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MQ#IVCVMW>6.B^(;?QEJ]M::T8&TZWOM$ELM2N;.XOM'BU#]]?^"-O[6OQO\
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M>/O$6C_#)/#_ ((\ ^&M9\8>+M=DTWXV_#36-0CT;PWX?LM0UC5);+2=/O\
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MV##\-T,/PM+A:.)JRP\LKQ65_6G""K*GBJ56E*KR+W.>*JMQC\+:5^I_.O\
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MKXG2;3-)OI]*?6M \3^']<M9X(AJ/AR]9];_ -'ZBM^'^(ZF11QV'G@L/F.
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M5%.;AJG)VV1^5/\ P6Z^''Q"^+?_  2Y_:L^'OPJ\#>+_B5X^\0Z-\,U\/\
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M7EV"R[!*4)0=?.8S@ZTZ[I8FM2HNE0C[*G&,%-N,J-6\7*2?\Q]Y_P '/O\
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MZ2_2W2]?3KU;=I&MI@GZ=?#_ %G]I?\ 9D_X(??#&_\ A3\(O&VJ_M3?#/\
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MM4L8]-T2>U_"_P"$/_!77_@N+^PQX$L/V:/''[-NL>.+OP-9#PWX6U/]H7X
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M"WB:76O#W@^^T?XC_"LZCJNBWFHM?Z1J^F^!/$']K6MY?7-[XF>>VL?Z#_\
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MIJ4DM$VTM HHHKE.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7/.G@L-1PT)SM;GG&C""E*VG-)-VTO8****Y#M"BBB@ HHHH **** "BBB@
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M ':4'[^L%&+O&*2****XCT HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J.***"*.""*.&&)%CBAB18XHHT 5$CC0*
MB(J@!54!5    J2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH C$40E:<11B=XTB>8(HE>*)I'CB:3&]HXWFE=$)*HT
MLC* 78F2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img44536338_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44536338_1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +T!=4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBOWP_, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRQQSWE[=2+;65N\<.H7FG?0\<<4$4<,4<<,,,:QQ11JL<444:A4CC10$2-$
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M=?&T,/B9SHX#->)\'"J^>FX1JU:>'IRK>SC&+FFDK)6ZG_A:OQ0_Z*1X]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$'# X(..A!X(Z@]: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=(TBSA\3:AI'@BY\)2?V9JEZ9+*SFFO+*QDO4N+K3))UCA2=(6L]TS0L\(F
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M&&V,AD^%WQ3\ ^/S'&"S3P^$O%.EZY<VI0?ZV.[MK*6UEA(*S13/$P*N0?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7YP_\%,_C1_PKOX&+X TJ[\GQ+\7+R30V$3[;BW\'Z88+SQ1<##9"7YDT
MWP](DD;)/9:QJ.QED@!'Z/5^:7[4O["?C7]IGXHCQW??%G2_#NAZ=I&G^'_#
M_AC_ (1N^U-]-TNS>:YNY7U :O90/?:KJ-U>WLTJZ=_H\4MI8,]]'I\4\H!^
M8?[.'Q;_ &I?@%X:U6/X2_!N]U73/&]U8:[=>(M0^&'C77IM6M8++RM(CL]1
MTZXM+&;2+>.XO+NQ,$4A>74[R4W,T4D*0^:?"_XB^-/V>/VB_"OQ/\1^$=5\
M#RGQ!<:SK?A2?0]7\/PS>"_$]Y?Z?KUCI.DZP#=R:7%93:C#H1N'O4M]0TRT
MD\^>[L/,7^IWP]H.E>%M T/PQH5JECHGAS1]-T'1[&//EV>E:190:?I]K'GG
M9;VEO#"N>=J#-?%W[8W[&%O^U+<^"=8TWQ79^"?$7A.#5M-NM2N=$?64UC1=
M0DMKJUL9TBO]/EC;2KZ&[N+)Q,T:C5=1$D3M)$\0!]NZ??V6JV%EJFG7,-[I
M^I6EM?V%Y;N)(+NRO(4N+6Y@<</#/!)'+&XX9'4CK7\[OQ=_Y2@:3_V<+\$?
M_2SP#7[C?L_?#CQ/\(OA-X3^&OBKQ5:>,[SP?:S:/IWB"UT^XTLSZ##/))HU
ME<6<]Y?;)-'LI$T>!HIS&^GV-D643>:6^._%_P"P1K?BK]JFT_:/_P"%DZ78
M6=K\2?!'CK_A$_\ A'+NZN9+;P;<Z!)_9_\ ;']K6\2SZC%H>?._LYH[.2ZV
M;+I8/,F /TKHHHH _FP_:.M=;_9F_;JO_B'<Z9/=6#?$:Q^+^CJ#]FC\0:+K
MNJ?VQK5I:W!4HC?;I-<T*60AO+G@:1T9&7?^Y>H:W\'/VI_@SK6D:9XY@N_!
M7C[PZT.I7NA:KIEAXATFR>2*6X2YMM4MK_\ L74;.:'R+N#5=,<V[K(LD1^5
MZL_'W]F[X8_M&^&XM"\?Z7+]OTY+H^'?%&ERK:^(/#MQ=K&)9+&Y9)8;BVF:
M&%KK3K^"ZL;DQ(S0K-'%-'^5.N_\$C/&T-VP\,_&+PMJ%@TS;&UWP[JVCW<=
MN6.S<FGW6N0S3*F V)+>-V!(\L$* #XX_:0^%'PN^#/Q[\/^"OA+XPN_&GAR
M"V\*W]]J=_X@\/>([NSUZZUF[COM+GO/#6G:786[VUM;V,WV&:T%["+D23.T
M<T(7]/\ _@K7_P D8^&W_93T_P#44\0UR?PQ_P""3>B:/JMKJ_Q+^*VI:REC
M<VUW;:1X)T>WT13<6LJ3H;K6M;;6WFMGD14EMX-%LYC$&,=]&\BF+[+_ &PO
MV9M2_:A\%^%O"&G^++'P?_PC_BAO$DVH7FE3ZQ]HVZ5?:9'91VD%YI^S?_:#
MSO<-<GR_(6)8)/.,D(!^>O[*W[)G[)OQ-^ O@3QO\3/$'V'QOK?_  E']MVO
M_"Q;'0O*_LWQGXBTC3?^)5-(LEKOTBPL)/F \_?]I'RS U^AG[/'P/\ V<O@
M9K6N)\'O$]K=ZMXRM;.TO].F\<Z9XCN+R/1?MM[ UG:1R&Y5[:.XO99C""I@
MWR3*5A5T_/3_ (=#>(_^BY:)_P"$+?\ _P T]?1?[+7_  3\UO\ 9T^+5A\2
MKOXFZ7XKM[71=;T>32;;PS=Z1,?[6MEB2X2[EUG4$/DO&NZ%H%WH[,)5*!7
M/SF_:0\*Z9XZ_P""B&J^"-;:Z31O&/QA^%WA75VL94@O5TSQ#;^"](OVLYY(
MIXX;H6MY*;>5X9DCE".T4BJ4.#^UU^SGI'[*OQK\,K;:+<^+OA-K\6FZ_H.G
M^(-0O86UF#1Y;*W\7^$M5UK1FTF]2[6<QW,EYI7V.6TTSQ#I1A?[3'+C]1/%
M_P"P1K?BK]JFT_:/_P"%DZ786=K\2?!'CK_A$_\ A'+NZN9+;P;<Z!)_9_\
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MU#X7?'*V^-OCWXG6?Q$U2SN/$.N1VB^&)=,ENO%VOK<1OKM]<7&KZA%*UO\
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M &H^A7C5BO +A^@FG_9N=<38)KLZF<8C,;/SMCT_1H_SZ^D%AW1\3<TJ-/\
MVO 9/B%YJ. HX6Z\KX9KU3"O4OAQ,/+U:$G&UK289(QAEG1C^&Q<GIR*\MKK
M_"%Y]DFU<$X\S2+@H<X_>I)$L?'?_6,?7CCK7]L\%U?9<3Y3KI5K5,._-XC#
MU:,5_P"!SBUYI'\]<10Y\FQVGP4X5?E2JTZDO_)8R7S/QQ_X+[?$E_#'_!/[
MQ9X?69D'Q=^,GPO\&M&"1YL&E7FM_$L(ZC^!'\ 6[DM\HD2('YR@K^&:OZ^/
M^#CO7/L_[/O[/?AK?C^UOC)J^N>7G[W_  CW@G4[#?COL_X2?;GMYF.]?R#U
M_NU]%G+Z>"\*,+6IQY7F>>YQC:C_ )I4IT,KC+SM2RVG#_MP_P >/I+8Z>,\
M3\31G+F679+E.#@OY(U(5LR<?G4S"<_^WC_2G_X)B?&./X[_ + W[+GC]KK[
M9J4?PLT3P1XAG>027,OB7X8M/\.=>NKU<EHKG4M2\+SZLR.J;XK^*>)1!-"3
M]XU_-!_P;2?&V/Q%^S_\<_@)?WR2:E\,OB/I_CW1;60L)T\,?$G1TL+B&V!^
M22TL?$7@W4+N?RP7@N=?7SCMN;<5_2_7^>?B]PX^%/$SC3)%3=*A0SS%XK!P
M::4<OS-K,\OBM%=0P>,HPYEHW%VMLO[Q\*^(%Q/X=\(YPZBJ5JV2X7#8N=TW
M+'Y=%Y=CI2MLY8O"5I\KU2DM]WY5\7KHP^&[6W4X-WJL"L,]8H8+F5OKB583
MZ=_2O._A-J'V7Q.UHS834[&X@5<X!F@VW<;?410SJ/\ ?/>NF^,\YQX?M0>"
M=1G<>X%G'&?_ !Z7_.:\C\.W_P#9>NZ3J&<+;7]L\I)P/),BI.">V86D&>@S
MSQ7D9?A_:Y).FEK7CB)+_&I2C!_?3B>KCJ_L\XA.^E&6'B_\+C&4U]TY?,^S
MZ***^//JPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM6G^SZ?<N#AFC,2^
MNZ4B/CW 8M] :T:YCQ--B&VMP>7D:5A[1KM7/L3(<>Z^U>?FV(^JY=BZR=I*
MC*$'U4ZMJ4&O24T_D=6"I>VQ="%KIU%*2_NP]^2^:BT<=7\_7Q;U,ZS\4_B-
MJ9;<MYXX\42Q'.<6_P#;5XELN>X2W6) >X6OZ I9$ACDED8+'$CR2,>BHBEF
M8^P4$_A7\XVHWCZAJ%]?R9\R^O+J\DSUWW,[S-GWW.<U_C;^TJS-TLC\)\F4
MM,;FW%F9R@GURO!Y'A:<I+IIF]11;WO.U[.W]\?1'P:GF7&^8..N'P.28.,O
M+&5\QK2BN_\ N$&[;65]T4Z***_R9/[>/I?]DF\^R_&K18,X_M'2/$%GC^]L
MTR;4,'U_X\=WU7-?K37XS?L\:BNE_&GX?7+':)=9DTX'./FUC3KW2%'_  )K
MX+COG'>OV9K_ %V^@/F$<1X1\0X!SO5R[CW,FH7NX8;&9'P_5I.W12KPQ=NC
M<7UN?PU])C"NEQQE>*2M#%\-81.5MZN'S',X35^K5.5&_:Z\@JQ9W'V>[MQG
M N)#;M[[XW=1^+QKGV!%5ZS+ZX^SW6F.20J7B3-@X^6)X]P)Z8*NP/L37]^<
M.3]EGV45KV5#,,-B&V[)1H5(UI7\K0=^EM]#^8<Y7-E680M?VF%JTDO.K'V:
MMYWEIYG\VO\ P<HZK(MM^QWHB-^ZFG^.^JW"9ZR6T?PAM+-L=.%N[X9/KQWK
M^62OZ9O^#DJ]\SQY^RCIV?\ CU\(_%>]V^G]H:SX'@S_ ,"_LW'_  '\OYF:
M_P"@OZ.U)4O!S@Y)6<X9W5;[NKQ'G$TW_P!NN*]$C_%/Q\J^U\6N+7>ZA/)J
M2\O9\/Y3!I?]O*3]6S]H/^"#'QZ;X,?\% _!'AB^O7MO#?QY\-^(?A%JJ$H;
M<ZQ>PP^)O!DSI(1_I,OBCPYI^B6TL7[Y%UVXC ,4TRG^_BO\I?X>>-];^&?C
M[P1\1_#,YMO$?@#Q=X;\::#<!VC,.L>%]8L];TV3>A#J%O+&$L5YVYQ7^I9\
M+?B%H/Q;^&GP^^*?A>9)_#GQ'\%>&/'.AR),EP#I7BK1;+6[%&FC 1Y([>]2
M*4A5(E1U9$8%1_+'TRN%OJ?$_#/%U"E:EG>65LIQLXQ]WZ]D]55:%2K+_GYB
M,%CH4:=]Z>7NWPL_I7Z)/$OUOASB+A6M4O5R?,J6:82,GK]2S:DZ=:G37_/N
MAC,%.K.VT\<K_$CS/XR3;M;TJWS_ *K2S-C_ *[W<Z9_'[/^GY>/UZM\8/\
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M^6,:&9T\%5J5)?!1C6U2DV?VS?&#_D9[/WT2U_\ 2W417E5>L_&)<>(]/?\
MO:) OXK?:@?_ &<=_3IW\FK_ #2RMWR_"?\ 7I+[FU^A_H?F2MCL3_U\;^])
M_J=?X%U?^Q?$^FW+MMMYY/L-T3G @N\1;FP?NQ2^5,>O^KZ5]<U\+].E?8?A
M#5QKGAW3+\OOG:W6"Z/.1=6W[F<MGD&1D\T=<K(IR<UXO$6'UH8J*T:=&H^S
M5YTW\USI^B[GKY!B-*V&;V?MH>CM&:7I:#LN[?<Z6BBBOF#Z,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@N7 /&6=\.0IRA@*.+JXS)I-/EGD^/J3Q6 C"3^/ZK3J/ 59Z<V(PE;16/\
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M-!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX??&#P=+Y?B'X?>)]-\1643.(X;^&UEV:EH]T_ERXL=<TN6]T?4-L;,;*^N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '">(6W:B1_<@B7Z9W/_ .SY_&L*M76VWZG='L#&O_?,,:G]
M03657Y-FD_:9CCI=/K5=+S4:DH)_=%'V^#CRX3#+_IS3;]7!-_BSY5_;.7=\
M!?$)_N:QX:;\]9MD_P#9J_&&OVI_;%A,O[/_ (P<=+:]\+S-]&\3Z3;\_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \TU%M]_>
M'_IYF7\$D91Z]@/_ *W2J56;PYO+H^MS.?SE>JU?CN)ES8BO+^:M5E]\Y,^\
MHJU*DMK4X*WI%(^>_P!JNW^U? #XC1XSML=&N/\ P$\3:+=Y_#R<_A7X=U^\
M'[15O]J^!_Q-CQG;X5OKC_P$:*[S^'DY_"OP?K_&7]H]AN3Q9X)QEOX_AWAL
M-?O]4XEXBJV^7UV_S/[^^B=6YN".(:%_X?%56M;_ *_Y1E4+_/ZO^ 4445_G
MF?U,%%%% 'VK^Q3XI^P>,O$OA.:0B'Q!HT6I6J$C:=0T.<@H@)R'EL=0NI&*
MC#+:#=]U<?I60""#R",$>H-?B-\(?%)\&?$SP9XA:0Q6]GKEK!?N&V :;J);
M3=2+'H0MC=SOM;Y25 )'4?MS7^O_ -!/B_\ MOPFS#ABM5<L5P7Q%BJ%&FVV
MZ>4YZGFV#E=ZKGS*6=PC%:*-)6WLOX4^DCD7]G\;87.(0M1X@RNC4G*UE+&Y
M;;!5UV?+A%E\F][SU[O@I4,4DD9Y,;NAZ=48J>G';MQ7QE_P4%^##_'O]CKX
M[_#VSM%O-<?P9<^*O"\)WB:3Q-X&N+?QAH]M:M&K.MQJ=SHO]D+QLD34)(9B
M(9)#7VYJL7E7DA P)0LH_$;6_-U8_C6;7^F?"O$&,X?SCAWBC+I<N/R7,LKS
MO".[BOK>78JAC:49-:\KJT5&=KWC=6:=C^*^(\EPN=99GG#V.C?!YK@,PRG$
MJR;^K8[#U<+4<4].;V55RCV=G='^:/17U_\ M[? T_L[?M;_ !L^&5O9O9Z!
M:^+KKQ)X.0A/*_X0WQBB>)_#L,#Q!8Y$TVPU1-'E9%3;=Z;<Q/'')&Z+\@5_
MT/\ #^=X'B7(<EXBRV?M,OSW*L!F^"G=-RPN8X6EBZ',UIS*G5BIK>,DXM)I
MH_Q!SK*<7D.<9KDF/A[/'9/F.-RS%PLTEB,#B*F&K6ND^5SIR<7UBTUHPHHH
MKUSS#L/A]X\\3_"_QSX2^(O@O4I=(\5^"?$&E>)M U&%I%-OJ>D7<5Y;B58Y
M(FFM)FB\B]M6<17EG+/:S!H9I%/^@-^S'\>_#'[3?P,^'GQI\*O%':>,=#AG
MU72TFCEF\/>)K(M8^)?#MT$EE9)M(UFWN[:(RE9+FS%K?*ODW<3-_GDU^['_
M  1$_; ;X7?%N^_9F\9:D8_ WQGO5O/!,ES-)]GT/XIV]LD$%E"FUHXH?'&F
M6\>E2,63?K>E^'H(US>3O7\]?2)X!?%/"?\ K!E]#GSGA:%;%M0C>IB\FDE/
M,</HKSEA5"./HIM\L:6*ITHNIB-?WCP$XX7#7$[R/'5N3*.)94L*G.5J>&S:
M+<<!7UTC'$N<L%5:2YI5<-4J24*&G];%%%%?YZ']X'LWPF\2?9KN;P[=28@O
M2UQIY8\)=JO[Z $M@"XB7>J@<RQ$#YI>?H*OAR">:UGAN;>1HIX)4FAE0X:.
M6-@Z.I]58 C((XY!%?87A;78O$>B6>I(5$KIY-Y$I_U-Y$ )TZ#"L2)8^.8I
M$/>OD,^P7LZL<7!>Y6?+5LOAJI:2?_7R*_\  HMO62/J<CQ?M*<L+-^_27-2
MOUIMZQ]82?\ X#))*T6=#1117SQ[X4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >6W)S<3GUFE/YN
MU<9K/CGPMH/B+POX0U'6+6/Q3XSGO8?#7A])%?5-3CTNQN=3U:^CM@P:+3=+
MT^TN+B\O[@Q6RND5E%)-J-W96=S\>?M=_MR>#_V?HM1\)^%OL7C#XMS!ECT4
M2L^C^%1.I:._\47$#*WGA&6:UT&WD2^NE*27<NG6LD4\WQ'_ ,$[=6\9?&O]
MISX@_&7XB:S>>)-8T'P)=1MJ5XP$=CJ'B+5;*STVSL8$"VNFZ;;:/:>((+33
M[2.&WA1V,:#]Z7O)/!K.\5P1Q'XD\1JKDG#>697B<7E%.K#DQ^?8^M*.'RM4
M*-2-Z&55,;B,/[7&32GBJ7[K 1DJOUO#_@7&OTM>$,M\9^ _H_< O#<8^('$
M?$^ RSBFMAJWM<DX)R3"JIC^(_KF*H2:QO$U#)\%CEALIH2=++,0EB<ZJ0>&
M65X[]B?BY9?VC\*OB58XW-=> O%T48_Z:MH-_P"21[K*$8>XK^?JOZ!/&&J#
M4M'UC1K$AEOM-O[&6? 82+=6LL#1Q#!RK"0J9.IZ(!PQ_G[K_#?]IED6(P&>
M>$&<5Z?L_P"U<EXNP--2TGRY5C<BQ/OK[+_X64U%OF2E>25T?[%_0ZS[!YG@
M?$++,)5]M_9>8Y!B*M2-G2<\QPV:4DJ<K^^E_9LE*:7*VK1<DFPHHHK_ "\/
M[2"BBB@ K]K?@IXO'CGX8>$-?>42WKZ7'IVJ$;MW]J:26TZ]=PV2IN);8W2@
MD@QSHP)4@U^*5?H1^Q)XO+VWB_P+<2DF"2W\3:9&SY/ES"/3M65$/*HDD>ER
M83Y=\\K$!B2W]E_0?XW_ -6O%Z?#>(K>SP''63XG+%&4N6G_ &QE<9YKE=63
MO;G="CF>!HQ:O*KCX1B[M)_@?TBN'?[7X&CFU*'-B>&\?1QG,E>7U'&RC@L9
M!+>RJ5,'B*C7PPPTI/1-K[;UR+,<,P_A8QM]'&Y2?0 J1GU8>U<Y7:WT/GVL
MT8&6VED]=Z?,H'^\1M^A-<57^WF1UO:8-TV_>HU)1MUY)^_%_P#@3FEZ'^<.
M<473Q7M+>[6A&5^G-!*$EZV46_\ $?S.?\' /P'=;GX,?M):18$Q2PWOPC\;
M74%K@)+"]YXG\#7-W/$"&:=)?%]BTUP%*K;:;;)*X,44?\U5?Z!O[;?P#M_V
MF/V7?B]\(Q;I/K>L^%[G5?!KM'O>W\<>&BNO>%&B8/&T0N]7L+?3+J1&R;"_
MO(RDB2-$_P#G[SP3VL\UM<PRV]S;RR07%O/&\,\$\+F.6&:*0+)%+%(K))&Z
MJZ.I5@&!%?[-_0GX]7%'A3/A?%5N?,^ \QJ9;RR=ZDLDS.=;,,HK2?\ +3JO
M,<NIQ2]RCE])-ZH_RL^EEP8^'O$:/$.'I<F7\98&&.4HJT(YME\:6"S.DE_-
M.G]1QU25_>JXVIIHR*BBBO[&/Y<"KVF:EJ&BZEI^L:3>7&G:KI-]::EIFH6<
MKP7=CJ%C/'=6=Y:SQD/#<6MS%'/!*A#QRHKJ00#5&BE*,91<9)2C).,HR2<9
M1:LTT]&FM&GHUHQIN+4HMQE%IQDFTTT[IIK5-/5-:IG]ZG_!/O\ :OL/VOOV
M;O"7Q#N+BU7Q]HB+X/\ BEI<!AC>R\::/;P"YU*.SCED:VTWQ-9R6OB'3 0(
MXX[^:P1FET^X"_;E?Q%_\$IOVP9/V5_VD-+TSQ-JC6GPB^,$NG>"_'R3S.MA
MHU_+<.GA/QH\:I(%;0-3NY+34)L*(_#^KZQ*V^2"W"_VZ @C(.0>01T(]:_S
M,\:. )<!<8XJAA:3AD6<>TS/)))/V=.C4J?[3EZ>REEU>7LHQNY?59X2I-WJ
MV/\ 13PAXX7&_"6&K8FJIYUE/L\NSF+?OU*T(?[/CVMW''T8^UE*RC]:ABJ<
M%RT@KTOX9>)?[&UH:?<R;=/U<I Q9L)!> XM9LLP55<L8)3W#QLQQ%7FE*"0
M002"#D$<$$="#V(K\=Q%"&)H5*%3X:D7&]KN+WC)><9)27FC]9P]>>'K4ZT'
M:4))V_F6THORE&Z?J?<]%</X \2?\)%H433R!M1T_9:7P)R\A5?W%TW _P"/
MF-26(R/.24#@"NXK\ZKT9X>K4HU%:=.3C+L[;-=U)6E%]4TS[ZC5A7I4ZL'>
M%2*DO*^Z?G%W371IH****R- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/9+=H;-8O%=Q<2>)M-MB&>%1I/B^'7(([:)E-OITFFL888YX5/\ <E7XO?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$T:F5\1UYTL-A$JN'Q-:CEU"2I8=?#7PJT.3_@GM^T'\#O%'C.6ZL_"7Q?\
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M(X5%]6=B$4=V(JS7F/C/5C/<+I<+?NK8A[@@G$DY'RH<<%85.2#_ ,M&.1E
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M#_V_X:US1U4X^_J6F7-G&03]UE>961@048!E((!%OPX,:7&?[TLQ_P#']O\
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MMHGAE72UL-/MX[2SMD>7X(R2NL%O#'$K2R/(P4%W9B6/UK\9/^">GQ.^)/\
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MO[=0_9+_ &2O"?[4@U_XNV9\?GQ3H5]K?_"#'2_&/Q?_ .$6%B;+Q#H(MO\
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M;V^MC0=+^S6'[1OQ1N/L-[%)J+74G_"+E$:"+=J-IN"S=%_P5_N=2LOV1?\
M@BQ>:-I\>KZQ:?"W0KG2M*E0R1:GJ4'PR_9TEL=/E17C9X[VZ2*V=%D0LLI
M=2=P_H&_X*B_L:^.OVZOV7V^!GP\\4>$_"'B$_$3PEXQ&K^,VUA=&^P^'H-9
MBN;7.AZ9JU]]KG.I1&#_ $3R<1R>9*AV[OC;]N[_ ()6_'3]J#X#_L&_#/X;
M?$_X9^#_ !?^R/X'M/#^O:]XF/B<Z9J^N6'@WX7Z!::EX973O#>JSR6T.I^
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MK , S '."1S1_K!C_P#H'R3_ ,1GAS_YU!_Q#O(/^AAQU_XM'Q,_^BX^?O\
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MIJ__ -%-7VE11_K5F?\ T"\-_P#B'<(__./R_/NP_P!6<N_Z">(/_$LXJ_\
MGR?%O_"K/V[?^CP_@?\ ^(::O_\ 134?\*L_;M_Z/#^!_P#XAIJ__P!%-7VE
M11_K5F?_ $"\-_\ B'<(_P#SC\OS[L/]6<N_Z">(/_$LXJ_^?)\6_P#"K/V[
M?^CP_@?_ .(::O\ _134?\*L_;M_Z/#^!_\ XAIJ_P#]%-7VE11_K5F?_0+P
MW_XAW"/_ ,X_+\^[#_5G+O\ H)X@_P#$LXJ_^?)\6_\ "K/V[?\ H\/X'_\
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M%-7VE11_K5F?_0+PW_XAW"/_ ,X_+\^[#_5G+O\ H)X@_P#$LXJ_^?)\6_\
M"K/V[?\ H\/X'_\ B&FK_P#T4U'_  JS]NW_ */#^!__ (AIJ_\ ]%-7VE11
M_K5F?_0+PW_XAW"/_P X_+\^[#_5G+O^@GB#_P 2SBK_ .?)\6_\*L_;M_Z/
M#^!__B&FK_\ T4U'_"K/V[?^CP_@?_XAIJ__ -%-7VE11_K5F?\ T"\-_P#B
M'<(__./R_/NP_P!6<N_Z">(/_$LXJ_\ GR?%O_"K/V[?^CP_@?\ ^(::O_\
M134?\*L_;M_Z/#^!_P#XAIJ__P!%-7VE11_K5F?_ $"\-_\ B'<(_P#SC\OS
M[L/]6<N_Z">(/_$LXJ_^?)\6_P#"K/V[?^CP_@?_ .(::O\ _134?\*L_;M_
MZ/#^!_\ XAIJ_P#]%-7VE11_K5F?_0+PW_XAW"/_ ,X_+\^[#_5G+O\ H)X@
M_P#$LXJ_^?)\6_\ "K/V[?\ H\/X'_\ B&FK_P#T4U'_  JS]NW_ */#^!__
M (AIJ_\ ]%-7VE11_K5F?_0+PW_XAW"/_P X_+\^[#_5G+O^@GB#_P 2SBK_
M .?)\6_\*L_;M_Z/#^!__B&FK_\ T4U'_"K/V[?^CP_@?_XAIJ__ -%-7VE1
M1_K5F?\ T"\-_P#B'<(__./R_/NP_P!6<N_Z">(/_$LXJ_\ GR?%O_"K/V[?
M^CP_@?\ ^(::O_\ 134?\*L_;M_Z/#^!_P#XAIJ__P!%-7VE11_K5F?_ $"\
M-_\ B'<(_P#SC\OS[L/]6<N_Z">(/_$LXJ_^?)\6_P#"K/V[?^CP_@?_ .(:
M:O\ _134?\*L_;M_Z/#^!_\ XAIJ_P#]%-7VE11_K5F?_0+PW_XAW"/_ ,X_
M+\^[#_5G+O\ H)X@_P#$LXJ_^?)\6_\ "K/V[?\ H\/X'_\ B&FK_P#T4U'_
M  JS]NW_ */#^!__ (AIJ_\ ]%-7VE11_K5F?_0+PW_XAW"/_P X_+\^[#_5
MG+O^@GB#_P 2SBK_ .?)\6_\*L_;M_Z/#^!__B&FK_\ T4U'_"K/V[?^CP_@
M?_XAIJ__ -%-7VE11_K5F?\ T"\-_P#B'<(__./R_/NP_P!6<N_Z">(/_$LX
MJ_\ GR?%O_"K/V[?^CP_@?\ ^(::O_\ 134?\*L_;M_Z/#^!_P#XAIJ__P!%
M-7VE11_K5F?_ $"\-_\ B'<(_P#SC\OS[L/]6<N_Z">(/_$LXJ_^?)\6_P#"
MK/V[?^CP_@?_ .(::O\ _134?\*L_;M_Z/#^!_\ XAIJ_P#]%-7VE11_K5F?
M_0+PW_XAW"/_ ,X_+\^[#_5G+O\ H)X@_P#$LXJ_^?)\D^&/AO\ MFV'B/0;
M[Q9^U3\'_$GA>SUC3;KQ%X>TG]E#4_#.IZYHD%Y#+JFD:?XBE_:.\01Z%>:C
M9)-:6^KOH6L+ITLRW9TV]\K[/)];445Y6/S+$9E.G4Q%/ 4Y4X.$5@,JRO*H
M--WO4IY7@\'3JSOM4JPG-+W5)1T/2P.7X?+X3AAZF.J1J24Y/'9GF69S32LE
M"IF6+Q=2E&V\*4H0;]YQ<M0HHHK@.X**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KX-_P""B*:[)\&?A='X6N=)L_$T
MG[8O[$\?AR\U^RO-2T*UUUOVI/A8-(N=;T[3M0TG4+_28+_[/+J-E8ZIIMY=
M6:S06U_9S2)<1_>5<1X]^''@SXG:;HFD>.-&_MO3O#GC?P+\1]&M_P"T=5TW
M['XS^&GBS2?''@G6?.TB^L)[C^Q?%&AZ5JG]G74L^E:E]E^Q:M8W^G3W-I,
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M>3^)O!]G_;VG6$E[;ZK]Y:9\+? FCW7Q2O=.T+[/<_&G7(_$GQ,E_M/69O\
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MLEW=.ME+ &N)V!E;E_@/#\:_VD-'OOCS>?M'^/OAV/\ A<WQ0\.>&_@]X/\
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M_7,#42KY?C8K91QF"JT,1RJ_)*I*F_>@TBBBBON3Y$**** /TZ_X)-_M3?\
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M$_X2OS1J5R/#WV#_ (:D_P"%RD_;QI?VC[8?"^04_L_:=:/V4R^4?MM6M/\
M#WQR^$_QG_:2N?V?-,^!/QA\,?%;QSX>^(_B[PWXR^+^M?#OQK\%_BY?_"_P
M)X.O[7Q+#H/PY^)HUCP/XG\'^#/!OC/2[6X3PYXHTJ6]U2.PLM:T/5=)N=+
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M_#=O#&G:MX6\1_$6]\):7::@OBG6#IOPWLK_ %MM(U#QO>Z?HUS>@'<^*/\
M@H%\+O#-[\3BGPR^/WB7PK\#O''B#P/\</B+X6^'-KJ?@3X32^%[6WU+7/$7
MB;4YO$EEJ6K>'=+T.Z@\1ZJW@;1_%VN:%X?EAU;7]#TJUN;1I^_\??M<^$?!
M?Q%O?AOH?PT^-?Q<U#PUIW@W6OB1K?P>\$6/C/1/A=HGC^6_'A35/%$+>(=+
M\3:\-3L]+U#5SI/PR\.?$#Q#::-;C4KW1K>WNK)KGA9_V<O'LGP _;D^&8D\
M.?\ "1_M%^(_VE=5\".;^X&F);?%GP*OAKPL/$=S_9WFV$T=XBKJRV]MJ(M+
M50\+W9 CKP;]I3]E[XQ^.YHQ\.O@_P"#]/\ BG8?"[P/X7^%?[4G@CX^^,/A
M!XX^'GC+P_I-_91W?Q2T;P_H2R?$GP-X.UW4)=?\/>%Y5\8:7X@TZZUK1=2T
M#1I;XW5P >W^'OVPO%EQ^T9^T/\ "CQ+\#?B1IO@#X-^%_"_B"T\;V^C>$"E
MO:S:1\4-7UK7/$=R/BE>75UX?\7Q>!;"+X7IH_A:#5Y)KJZ3Q?9Z0LT,MGUW
MPZ_;4\ ?$I?A;J6F?#WXQZ#X/^.'BSPUX/\ @]X\\7>%=#T/PW\1=0\1_"OX
MF?%Y]0T"U?Q9<>+8_#VC>&?A9KEO>>(-8\,:7I>LW^K>&;KP5<>*_#>JR>(+
M/F=;^$WQGT_XX?';5M*\.^'/%?@G]HCX'> O U]XU?Q5%X<U#P-XO^'GACXO
M:9,^I>$)M)OIM7TGQ1>^,_#G]FW&BZH\FFA]9.HVT<6G63ZI2\3_  $^+FD?
M K]BBP\$Z?X.\1?$[]DC7/A3XHU+PCJ_B2\\.^'/&@\.? 7QS\"O&NA:/XLB
MT#5GTR\72_B+K&M^%[[4-"%A>ZCH^GV.J?V7:WT][9@'OGBS]I7X3^ ]6^,F
MF^--8OO#=M\"?!7P]\>^/];O-+NKS3(=$^)U]XRTSPK!HD&D#4M<U[6[O4/!
M&J6 T33M&EU&[O[W1K#28-3OM16WC^=OBG^VWXL\)_!OXZ^-M'_99_:0\,^,
M/AK\+_&OC[P?:_$OX?>%H_"7B2T\/:+J%Q;>)[[5_#/Q3NM-L/#FDZA'IE]X
MG\'Z]XD\'_%N7P[<7EYH7@RZ?3]3DTSS?7OV7/VC?C;>?M9>*?B$WPV^%FM_
M&'2/V2=4^">D:3K>J?$"W\&^(OV7/B1XN^*F@Z5\4;M=&\-PZW;ZQXM?P[/X
MD?PS')9V^DZWJ_A_29M8;P];>(O$7OGB73?VD_V@/A)\</A+\0?A+\/_ (-6
M_CWX%?$3X>Z=X@A^+EQ\17O/'WC7PW?^&;2YLM.TOP#H?V?P%IT-]=WUSK.J
MW-GXINW>QMHO!UN%NYE ,^R_:*AU>[^"GBSQ5X7_ &@O ?BS6_AC\;O&&G_!
MFUTKX?R6'Q$MO _ACP#K>N76IZ;9>(/%5U<ZC$VL6<7PCMK#QGHKW5YJVM0>
M*(]C6;0^Q0?M*?#'4-!_9V\1:'=:KXAL?VH[S1(?A-%HME;W-Y?Z=K/P^UGX
MH2^(M6MYKVW_ ++\/Z%X.T*]O_$&H%YVT^YDL=,6"XU#4+.VF\>\%?#?XS>)
M_B#^RO\ $CQ[X)\/?#R3X+^ ?C+X'\6^'K?QQ!XPNKF?Q?H7PITWP]JNCWVG
M:)86=Q9WEYX0UU[BWG:WNK&S&FRRJ]Q>3VECQ?P*_8]\6> _BW\0)O&^IZ%J
M'P1\$:'\2_!G[*6A:/>WS:]X2\)_M"^,9?B1\7X->AN+&&VTFY\,ZA;^'/AK
M\,WTZ\U.XT[X?Z#<QO=6B:S/IL0!Z!H7[='POU_5_#EU;^!OC+:?!SQIJ^D^
M'?!7[3.H>![6#X#^*O$'B'Q#8^$?#>GV6L1Z_-X[TK3O$WBG4+70O#'C/Q3\
M/] ^'OB6[N+&?0O%VH:?K&B7NI_:=?B[\,/V#_''@_3/A/\  WQ3\%/#7C7P
M?\.=7\$Z5K7QQU[]K#]H2X\+^*? 'PYOM'O] UFQ_9QMO$5MIVE?$K4;;1=/
MME\,/J:_#3P=XHMQXBTN\UW0K.R\*2_M%0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B%W^T?\%+
M/XG2_!D^.K2]^*-IJEII&K>#-&TKQ!K^K>';G4-!T3Q/87/BL:'I.H6OA'1K
M_1/$>C7EEXA\37&DZ#=M>BSM]2DOH+JV@]OK\^YO@!XP\8:G_P %.M&MK63P
M)JG[2<&C^#?A]\1I;=8I+JRF_9%\"?#JPUZVO+3=?SZ?X/\ &]SXE2*/Y7M=
M0@U1K2,/.TD@![QX#_:V_9T^)OC6W^'_ (&^*6BZ]XFU(:T?#T<=CKUEHGC0
M>'6E&O'X>^+=3TFR\)?$8:.D%Q<:C_P@NN>(?LEI:W=[-LM+6XGBH^+?VR/V
M9_ OBS5_!GBKXKZ-I>K>'-4M-"\57_\ 9GB2]\'^#M>OHX9;30/&WQ!T[1;O
MP%X+UZ=+FS*:+XI\2Z1JFZ_TY&M ^HV*W'P5\&OA'X_\4ZI^S9X.^)7A3]N?
M3-0^#OBKP9XJUK1?&>M_LSZ?\"?AMKWPR\/WMMIUUX;\4^"?"-EK'CSPEJ%Y
MM\)>'M&\%SP:M?\ A#Q#<OXDMO#T%KJE@G5^&/\ A/\ X$_LX?%']F#Q'^RY
M\1/B;K\S_M 0VWBZPM?!%W\&_B_I/Q+\2^/?%EMX[\>^,;_Q3#=>&EUG3/$2
M-\3].\1Z#/XGM=5BUBV\-:1XRBET)M6 /TB\*_%CX<^-[S0K#PGXNTG7;SQ-
M\/- ^+&@V]C)*\FJ?#GQ3*T/A_Q=;!XD#:3JLJLEK(Q65F!W1+7"^(/BEHVM
MZA\+9_ _Q;\&Z+IFH?'GQ/\ "OQ#9ZEH%UK\_CW7O!.@?%"P\6_"?PY=)J6D
MCPYXOT;Q-X,O]7N];EBU2W@L_ VNZ:MC<B_25?@#]GR3QS\*O#G['GQSL?A+
M\0_BMX!\1?\ !-_X%_"W4!\*[3P_KGBCPYXP\.:?X;\7Z-#J/AO6O$/AVYN-
M(\5Z9X@U.WM-:TV6[L](U+0S#X@.F6FI6=Z=7X5_"KXUW'A;]FS4?&'PNUGP
MCXCTS_@I?^T[\<O''AJ2[T_53X,\"_$*/]L>]T/6+O5=/N9+#4M*EF^(OA&P
MM]4TZ2:"^EUBSG@003$H ?<>F_M6?L]:OXA\6^&--^*.@WFH?#]?&O\ PL&^
MB@U?_A%_A_+\.M7U?0_&EGX\\:MIJ^#O!FI:#J&@ZL+C2_$VO:7J,]E9MJME
M:W.E2P7LLOPP_:C^ OQBO]:TKP!\0['4M5T#0HO%>HZ9K.D^(_!FI-X0G?RX
MO&6FV/C71O#UUKG@QY#''_PE^B1:AX;#SVJ-J@:ZMA+\.^(OV8OBCXM_8K_:
M>^&7AOP]<^&?B3XT_:Z^.WQLT72OM&A:#?\ Q!TK2_VS=1^+_ABR;5]8LM4T
M"%_B?\._#6B^'=&U7Q38W^AP6.KZ2/$ME/H-M>V+6_AO\,M:^(WQ.T3QMXS\
M'?MO>+F^'_PO^*]E%9?M+ZK^SWX4\,2ZE\1-#TOPYJWPJM['P'H>G:OXK?Q;
M902SWVO6>KR_#_1[SPUH=])J^HS7%EY !]M?"?\ :?\ @5\<-9N_#_PP\>V_
MB35[;08_%EO:2:'XHT :YX1FO8].B\8>$;CQ+HFC6OC7P?)?3VELOBOPC/K?
MA\R7^F_\3+;J5@US\S_MA_';PQH?QC_9L_9ZU?XK>+_AGIOQ,\2^*=4^(EUX
M ?Q)HGBZ^\,Z9X#\5-X/T6P\8Z#H]YJ&@V6M^.X=.FU.Y\-W^GZ^L6BPVMQ?
MV&B7^H"\Y7]CW2?C=X0^(_AGP/HVA?M*:%^S7H'P=U73]:\)?M2Q?"_4-2^%
M7CS2]1\$:=\/O OP?^('A+S?'/Q"\/PZ!!XXM?$EYXKU?QEX?M;71_"]WH?B
MR&:^&FWGTS\7_!OBC7?VB_V0_%6D:+>W_AWP-XA^--UXNU:!4-IH-OX@^$6L
M:'HLM\S.KHFHZO/#86Y1)"9Y%#!5^8 &AXJ_:[_9M\!>+K[P%XH^*ND:9K>@
MZAI6A>);N2Q\1ZCX7\&:SJZV_P#9>D?$#X@V.D7O@?P)K-]'=V,T>G^-?$NB
M:@\.H:?<R0B+4+.2?IO'G[1_P5^&GC#3/AYXP\<VMEX^UK3]$U?2?!&EZ3XA
M\3^+M2T;Q!J&NZ7INN6?ASPMI&M:Q<:']N\,ZY#J.M1V;:7HHL&FUJ[T^">U
MEG^$O#=A\2_@W\"OC+^RWJ'[+'Q(^+OBOQ9XD_:*?0/%>CP> KGX4_&JS^-_
MC7QWXLT?Q-\0?&&L^+K*;PE-+8>+[31/B9:^+]*;5;*?2M0;PQ:>*M+DT-;O
MUS]GWX!^+_A7\??#%SXFM9?$\'@']@#]F[X!K\5I[=7'B+Q?X&\:?$N3QQ:V
MM[<$Z@DNJHGA;Q)JEO(J+.+G2I;@R3P*(@#UKQ+^VO\ LM>#]?\ $OA[Q+\8
M= TF;P;?7^D>*]<GT_Q')X&\.^(-+M9+N_\ "NK_ !'M]%F^']CXQMUC:U;P
M=/XF3Q0VJ-%HT>DOJTT-E)T&J?%[P[X8\:_$#Q'XF^,/@JR^%_@[X ^%_BSJ
MWA270+N'7?"7AZ36/B'<ZK\7-8\7)J,L=UX-US1/#QTVPT2/0$N-/NO"&L:D
M;^1;X6H_,/XAS?&?X"_\$Z/C5^ROXE_9?\6>+=6\#?L^_&_PY?\ QA_M_P"%
MJ? 7Q3X2.E>+KN_^,VNZW>^-X_'=MXAO=(O9?&OB7P==_#Q?%^H>/&U&TTTW
M>ESIXQ7U#XT?!OXH^,/!O[6!\,>"=;UC_A8G_!)CPC\'O!(M88MWB/XG1V7[
M2KR>"]/666-FUI%\8^&"T,HBC']LV8,N6<( ?=_PZ_:J_9\^+/C!O ?P]^)^
MA^(_%4FEZCKNE:=#;ZQ80>*=!T>[M[#5O$'@75=5TVPT?Q_H&FWEW:V]]KG@
MG4-?TJUDN(1/>)YBD\[XE_;5_9<\'^(?$OAOQ+\8-!TJY\&W][H_BS6IM.\1
MR>!_#GB#3K5[N\\*ZU\1[?19OA_IWC"%5^RGP?=>)H_$[ZG)!H\>DOJUQ!92
M8GQ(^&NLR_&3]AK5O"OA1T\-?"KQ/\2[7Q%<Z7:P6]AX/\,:I^SQXX\+Z3:3
M1QM&MKI=UXB/AO2K>U@C:(7D>G+Y:K CI\">/9OC/\!/^">?QL_98\2?LO\
MBWQCJG@SX#_'70;OXP+K_P +(_@+XK\(W=CXPO\ 4/C'XCUR_P#'$/CJSUZZ
MT?4Y_&?B[P?=_#W_ (2W4O&XU6UT<ZAIES%XO !^T)\0Z*OAX^*SJ-O_ ,(Z
M-&/B$ZL"YM?[%%C_ &D=1!"F0V_V'_2<A"YCZ+NXKY_\ _MD?LR?%'Q7X?\
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M+IW[(_[.5]?3V]Q_PDOP;\.^/?%?C>#QS:.D]Q<E?$?@B[^!G@[5?M/D2?\
M"0_"G5P5N0$N6F^/GB6_\$_M]_L_>,+'X1:_\7$T3]EG]H9+ZV\&0:)J'CGP
M=9:G\3_V?M.D\6^&=$UW4M(36]LL\/A_6['1KY/$2:)KU[>:?;:A:6VIZ?=
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M+E\5^%_^$LT#0XO%WAJ'4+NQM)M>\+2:QI4,NHZ:);M%U*Q-QU7Q@B^)^B?
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M!A8WNZ53$TW_ .%%2HD_E47RL%?BO^V%X8_X1OXZ>(IXX_*MO$]CI/B>V7&
M?M=L=/OI ?XO-U;2]1E)[,Y7DKD_M17YQ?M_^%MUM\/O&L,>/*GU3PMJ$N,[
MOM$::MI$>[ML^S:XV#G=ORNW:V[^&/IX<(OB7P S7,Z5+VF*X+S[(^):7+&]
M1X>=>>08Y1:U]G3PN=SQE9-\O)A.=IRIQ/ZF^C7GBRCQ/P6#G/DH\099F.43
MN_<]K&G',\,VOYY5LNC0INU^:ORJRFS\U****_PK/](@HHHH **** "BBB@
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M345U;2--U)"#]LLX)V XVRM&/.3CC,<H=#CC*G'%?#<18=1JT<3%?Q(NG/\
MQ0U@_5Q;7I!'VF0U^:G5P[>M-JI#_#/227DI)/UF:E%%%?-GT 4444 %%%%
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MOQ.^/7Q2T_\ 9V_8X_;!_:>UCPDOA?7/BW\&/C?'\//@Y\-_%5U?> /#UQ\
M/C/XKU2T.JW/BOQ5J_CW4]4TR\TN\D6+1O#>G>%KF+4K2?4-6TF!O$,8!^W
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M_AWQ7I?Q9M/%/BO4=6U2\\7>)$\:_P!M^*Y]2OG\17^IF[G\ST7X2_!OX;_
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M:UEI6J3V? ZY^V5^S+X;\/>'_%>M?%O0[+P[XNU7QOH?@[53I_B&>V\:ZO\
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M16>E:7;-!I6AZ;I>C65AIUJE_P#$7X?:5X/_ .%AZGX[\&Z=X -K!?#QS?\
MB?1+/P?]BNI4M[6\_P"$FN+Z/1?LMS/)'#!<?;?)FED2.-V=E4_+7[3/[3&A
M^$O!'P?/PU^,'PTT*Y^.WQ6\&> ]#^),VL^%?$VDZ)X.U2;5;[Q9XX\/VMSJ
M\>@ZZ]CIN@7FAZ9J-Y-?>'=*\0:MIUYK%GJEO:2:/? 'H.D?LG_"72?C)\<_
MC:UOK>K>(?VA/"NC^$?'?A[5]0M;CP9;:;8^'=,\*:[<>'=&@TZVNM.U'Q[H
M'ASP;I_CJZNM3U%=9B\#^%3;PZ>UA<&\Y3PE^Q+\)/!W[.GA;]F[3M9^(EWH
MG@OQ2_Q \._$J_\ $UH?C%8?$P^-M1^(,?Q)_P"$QL-%L+.;Q='XDU2\:6:;
M0GTC4M&GN/#6LZ1J7AZ\O],NO:[KXF_#GX;VG@?PQ\1_C-X(M?%&N:5I=CH]
M_P"-/%/@OPEKOQ#OXH;2QGUG2]%2XT:QO;K6;]TN)+3PUIL>G175ZMKI]I!
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M4 *"5(920P((()!!!R"".00>01R#7[)?L_?$<?$GX<:3J-U.)==T@#0_$ +
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M$L/CQ\5(/VCD\2?%S]F[X"^'_B+:?L;O\%];U#P7\9/AMH_BF?QKX(UKP_\
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M8121PW.E6TD[6RQPRCZ1\(?$'PAX]F\86_A/5_[5F\ ^,]3^'WBU/L&IV/\
M9/B_1[#2M3U'2-VI65FM_P#9['6]+G^WZ8UYIDWVKRH+V6:&XCB[*@#\3/BK
MIOQ\U'_@G=XC_8<T/]C3QOK?Q@TK]GQ/@<LUK)X#M_@)<OX1\)VNBVWQ(\'^
M.]1\3VC7L>J)IEKXD\ >'9M M?&5IXTNM(TKQ-IN@0Z?K7B/3OU+_:+\+:;X
MV^!GQ3\):Q\-M6^,&EZ_X.U;3;[X9Z!K]CX6U_QC;SP@2:3H/B/4=6T&ST37
M& ^T:1J4NMZ2;348+:6'4+2=8YD]HHH _'&[\!?M0?$OX ?MI?"?3K3X]^-?
MA_XB^ :Z3\#S^U-:?#/PY\:-3^*FIP>.I_%/@33]7\+1Z/)K?@>WT_\ X0J#
M0_$WQ+@@U*/Q#JVI6$/B75]'L[F\T_ZU\+Z9XD^)?[5GPM^/S_##QGX-\):=
M^S)\9_ ,LGQ#TG2=#\4:!XIUWXO?![4=/TJ[T6'5]3O;.37=%\):WJ5K<0-)
M;RZ=9J;B:%[FWAF^IO"7Q!\(>.;[QSIOA;5_[4O?AOXSG^'WC2'[!J=C_8WB
M^V\.^'/%<VD>9J-E:1:CLT#Q;X>O_M^DR7VF-_:'V5+UKVTOK:V[.@#\'_\
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MCPD]_>7=S. ?E7^RO\*_"GCSP7_P3FTS7/A1>Q>"?!_QZ_X*(Z]!X#\9V/\
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M36^I:KI\?A6&&TUWQ#+IOAZ]M]5DX7P!#X:^&GBK]DSXF?M%>%]<O/A58?\
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MHYI\U66:Y;3HQI8^K=W;S/!U,%F,ZG*H*KB<32@W[&5O\R_&[@?_ %3XKS7
M8>C[/+L4_P"VLEY4U!8+%2J.IA8>6$KQQ&$C%MR<*-&I+^)%OD*_G;_X+Y?L
MYQ:UX%^&W[3VA6 .J>"[]/AKX]N(4C#S>%M?GGOO".H7;",.8M&\2-J&E*S2
ML3+XKMD$>V/<O]$E>/?M _"#1?C]\$_B=\&M?*)IWQ#\'ZOX>6ZD4L--U.>
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MX0\&Z1:^%=.@\!?$?P9X1T7Q9XD\?:'XMBT2SUZ1F^"_C#PYI.N^'(]0M_\
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ME<^'_#D1DM-'-[?BV<+=,H^3_'GP5N?B;_P4&\6>(])^(OQ5^#WB?PE^Q_\
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M+]AQ?L^^!(O!WQV\#K-K_P#8W[0^M>/->\?.=0MC>PWWQ%\)Z=X,U\>'Y_L
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M&WQB^%/Q4OM8B2R^&W@OXQ^#+SPE<:,M]!XHM?BZGP_BN)IM3;4H%TZ+2(O
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MW_P.\4_&7X@>(?$W@36_&/QLU/P=?>(M.^$OPF_X4E\,--/@G2=2TJQU#2O
MD_COXEZI+XLUY=6N;CQCXLUCQKJE]KWV30[..#3]/T2RM5 /G+5_B+\2/ G[
M?_QJ\:>-_!?PMTSX1_#S]CCPAXC\1>-$^+'BR_\ %?A_X4Z/X^^//B*Y\5V'
M@W_A1T.GW'B;6M3\.FR\3^"4\<6FE:9HN@:-K]IXW\4:C(OAG3>_'[6'QO\
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MCX>UO5?"_C+P98^,?AWK-Z+'7_"NBZSX<U?0O'7AW4]%NAJL'G7FGZUJ%G*
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MX*\'?$76A;WWB1+6VTBZ\,RP:I!JDNIP !\/?C!^USKW[9WB7X>^*?AO\)]
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M/_#/&N_LSZU_PF'_  BGD_\ "8?\,[>+_!WBO[-_PC__  DDO_"/_P#"8?\
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MLR-8^.M%?0M22V!)(MK*]\#VDTT:X2.XU<28WW+D_P!"E?QR?\$,OB"_A/\
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M"A\-Z?\ #;XC^-?%_BEH+>>RU^+2/$NB?#:#2=0UO3M5\$RW-WI^BV=L]W(
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M/]HCH#_=''8DU_/U_P % /AF? 7Q[OM;M8&BT?XD:/8>,;1QL\H:I(IT[Q#
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M]139<D]I%5_Q^Z?U7./<5\S_ +#'C;_A-_V9/AQ++)OO?#%I>^";U=V_RO\
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MI7^;7X8UZZ\+>)?#WB>Q)%]X<US2=>LR&*D76D7]OJ%N0PY4B:W3##D'FO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVZCGCGGBOZ8+.[M[^TM;ZTD6:UO;:"[MIE^[+;W,2S0R+_LO&ZL/8U_,!7]
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M?W'X.\1?V[P;@Z%6?-C,CE_9.(3?O.A1A&6 J-/7E>$E3H*3;YJF'JOI9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_$QF4XJG4HQMU:PF+S"5]THOHVU\@T445_C.?WZ%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=NIK_H5R>?)CZ*Z352#^<)-??*,3_+/-8<^"J]X.$U\II/[HN1\U?MC^&/\
MA,/V%OVN-!6/SIKCX%?%B^LXL;C+J.A^!]0US38P.NY[_3K95/\ "Q##I7^=
MQ7^F7XBT&#Q'\(?B%X>N4WVWB3PCXRT>X3:#YD.J>'[O395 Z-NCD9<'K]WI
M7^9I7^S?T&L3+_4GB3+G>V&Q628]+I_PI87'0NO-QP$;^21_EK],3#)<3\,8
M]6OB,%F^#;Z_[#B<'4L_1XY_-L****_N(_CHOZ3I=]K>J:;HNF0-=:EJ^H6>
MEZ?;)]^XOK^XCM+2!/\ :EGECC7W85_JM?#WPA8_#WP#X'\ Z9M_LWP/X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\[\9:64D35(E&R3
M;#= 8XD (BE( Z.H\MB3P50=6KT2H+FWBNX);:==T4R%''0X/0@]F4X93V8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9G4IKU4)13\S_77PWJNMX><"U7JY<'\-\S[R63X.,G\Y)L****_*S[0****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]@WPQ_ZC^GU\MU]1_MDD'X_>*@""5T[PP&'H?^$=TYL'WVL#]"*^7*_YL_I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "D95=61U5T92K*P#*RL,,K*<@J02"""
M"#@\4M% 'EOB+PX]@SWEDK/8L<O&,L]J2>AZEH"?N.<E/N2'[KOXQ\2/A[X>
M^*/@W6O!7B:W$NG:O;E([A4C:ZTV^CR]EJE@\@(BO+&?;+$PP)$\RWEW03S1
MO]<$!@58!E8$,I (((P00>""."#P17F?B+PT;+??6"%K3)::$9+6W<NO4M!Z
M]XN^4RR_0Y5FU;#UZ%2-:=#%X>K3JX;$PERSC5IRC*E)2Z5(S2<9?:=D]?B^
M?S3*J->A7A*C"MA:].I3Q.&G%2A*E4BXU(\KWIRBVI1^RFVK17N_S#_%+X:>
M(OA+XUU?P3XEB'VO3I=]I?1QNEIK&ES,QL=6L2XRUM=QJ25)9[>=)[28B>WE
M4>>5^_W[2'P#T?XY^#9+18[>S\:Z)%/<^$M;<!#'<, \ND7\@4L^DZF45)0=
MQM+@0WT0)BEBG_!;7-#U?PUK&I>']>T^YTK6=(O)K#4M/NT\NXM;JW<I)$XR
M589&Z.2-GBFC9)8G>)T=O[4X#XSH<6Y8G4<*6;X*,*>8X9-)3;5HXRA'?ZO7
M:=XVO0J\U*5X^SG4_C?CG@^OPKF35-3JY3C)3GE^(=WR).\L)7ETKT4U:3?[
MZE:K'WO:0IY5%%%?=GPX4444 >V?L]?%*?X0_%7PWXK:5TT:2X&C^)X5)VS^
M'M3DCAOF9!C>]@PAU2W3(W7-C"I(5FS_ $,V]Q'+'!=6LR2Q2I%<6]Q"ZO')
M&ZK)#-%(A*NCJ5>-U)5E(9200:_EZK]P?V)OBN?B%\)H/#NI7)F\1?#QX/#]
MWYDF^>YT-XW?P[>MND>1E2UBFTHL0N7TLL1^\!/X3XT<.^VPV#XEP].\\*XX
M#,7%:O#U9MX2M/I:E7E.A*3O*7UBC'X8:?M_@]Q![+$8OAS$5+0Q*ECLOYGM
M7IQ2Q5&/6]2C&->*5E'V%:7Q3U_331]074]/@NLCS"OESJ/X9XP!(,8  ;B1
M0.BNHK3KR[PAJ/V6^:RD;$-Z $ST6X0$QGH<>8NZ,],MLSTKU&OY/QE#V%>4
M4O<E[\/\+>W_ &Z[Q]$GU/ZGPE?V]",G\<?<G_BBEK_V\FI>K:Z'\Q__  5'
M^#*?#3]HF7QGIELL'A_XOZ8?%4?EAQ'%XGL7CT[Q7;C*A2\\YT_7)2KM^]UM
MQA H!_->OZ>O^"H?PC'Q&_9IU#Q78VPEU[X2ZM;>,;9U#&9] N-ND^*+9<!E
M$*65S;:W<%MN$T)<./NO_,+7^@?@EQ,^). ,L]M4=3&Y+*>1XMR=YM8*--X*
M;O[SY\OJX52G+XZL*NK:9_SE_3H\+H^&7TA>*OJ6&6'R+CF%'CO)HPARTH/.
MZM>.=X>'+^[A['B+"YK.G0@HJCA*V$CR1C*#91117ZV?QZ?1'[)7B/\ X1;]
MI3X,ZKYGE+-XXTO07DSM"Q>*_-\+2EVZ+&8M9<2,V%"%BY"@D?TS:BN+IC_>
M5&_\=V_A]W^O>OY*O#NL3^'?$&A>(+;/VG0M9TS6+?:=K>?IE[!>Q;6['S(%
MP>QYK^M.[N(;Q+.]MW$EO=V<-Q!(,@/#,#+$X!YPR2*W//-?R'])[ <M?AS,
MN7^-A<5A'*W_ $!8BG4BF^G_ ",IN-]_>MU/]<_V:>>^VX;\3>&7/_D6Y]DF
M=PIM_P#0\R[$X&K.*>__ "3E%3:6G[OF>L3T#15VZ79CUC9N?]J1V_KQZCFM
M2JMBGEV5HF,%;:!2/<1+N_7-6J_SRQ4U4Q6)J+:>(K37I*I*7ZG^X67TW2P&
M"I/>GA,-3?K"C"+_ "/Q(_:YG\_]H3X@$'*Q'PS OMY7@_P^KC_OYO/_ -?)
M/S=7O'[3D_VCX\_$F3.=NM009SG_ (]=*TZVQ_P'R<8[8QVKP>O^:3QIQ'UO
MQC\6,5>ZQ'B7QU63_NU>*,TG&WDDTEY'^OGA]2]AP%P11M;V7"/#=-][PR;!
M1=_-M._F%%%%?F9]>%%%% !1110 4JJSLJ(I9F(554%F9F. J@9)))   )).
M!25[S^S?X$/COXJ:%#<0-+I'AY_^$DU<E&:$QZ9)&]C;2L,)B\U-K2%HV;,E
MO]I(5U1Q7TG!_#&8<:<5</<)Y5'FS#B'-\#E.&;BY0HRQE>%*>)JI:JAA*4I
MXG$3T4*%*I-M*+9Y.?9QA>'\ES3.\;*V%RO XG&U5=*4U0IRG&E"^]2M-1HT
MH[RJ3C%:L_3?X,^"?^%??#;POX;EB$6H16*WVL#YMQU?4F-[?(Y;!)MI9A9H
M2%_=6T8P,5]%>!='-[J/]HRKFVT\@H3T>[93Y8'/_+$'S2>S>7_>KB[>WENI
MX;:!"\T\B11H.[NP49QG &<L>@ )/ -?0^D:;%I&GV]C%@^4N99 ,>;,W,LA
M[_,W"@\A J]J_P"E7PEX'P&687),IP%#V.0<(9;EN78*FTO?678:EAL!1DTD
MIRC"A&OB)6?/**4U^^N?Y(<<\1XG%U<PQN)J>TS//L7B\5B)J_NO%59U<5-7
M;<4W4=*E&_NI^Z_W=C3KC_&4P2SM8BP4/.\S$G "P1$$DG@*/.R<\# /:NPK
M\Y/^"HOQ_@_9R_8_^.'Q$2ZBM]<A\!WWA+P<',A>3QI\0'_X1/0'ACA9)9'T
MVXU%=<G17CQ9:9<RM(B1LX_JOAG*<5GV?Y1DN"@YXO-,PPN7X:*3=Z^,K0P]
M)M+[*J5(N3V44VVDFU^%\0YIALDR3-<WQDU#"Y;@<3CL1)NUJ.$HSQ%5)]W3
MIR459MR:23;L?P)?M@_%UOCS^U)\?/BZMR;JP\;_ !2\7:EH,I?S"OA2WU6?
M3/!]OY@.)/LGA:QTBT$BA4<0;D1%(1?Z%_\ @WH_80DU'5K_ /;4^(^B,MM:
M_P!J>%O@A:ZA;#;, )--\9?$"V+.6"Y:X\%Z',8UWE_%4HXBLIF_ ;]BC]E?
MQ1^V/^T5X$^"/AUKJRT[5[LZOXY\16T<4G_")^ =(DAF\2Z^1.1 ;F.WDBT[
M1X9<I=Z[J.EV;#;<,1_I,?!KX:>%?A)\.O"?@'P5HUKX?\+>%- TKP[X=T>T
MB6*'3]#T>SCLM.M\*B>9*T4?VBZN'!ENKF:2YG9YI'=O[_\ I->(6'X(X,R_
MPSX>KJEC\TRS#8/&>RDE4P'#6%IQPE/#OE:Y*F9J@Z#6J^I4<5"<(K$T9O\
MAGZ.G =?C+B['^(N?475P669CB,7A/:1O#'<18FH\54KI2OS4\N]NJ]]/]KK
M8:<)-X>K%>I4445_G(?W^%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLO\ %]4MZV/],/V9.(E6\2^.<A5VLTX=R?$M+:V!SCZKS/\ PQS:3OT5SZT
M   X   'L.E+14<TL<$4L\K!8H8WED8]%CC4N['V"@G\*_S)E)14I2:48IRE
M)NR22NVV]DEJVS_H12;:C%7;:226[>B27X)'X!_&+4O[7^+'Q*U$-O2Y\<^*
M3"V<YMH]9O(;7GOBWCB'''''&*\WJ[J5Z^I:CJ&HRY\R_O;J]DR<G?=3R3OD
M]SND.35*O^7CB+,WG?$&>YS)MRS?.<SS.3=[MX_&U\4V[ZW;JW=];G^R&58-
M9=E>6Y>DDL#@,'@TELEAL/3H)+R]S0****\<[PHHHH **** "OUD_96^&_\
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MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRO9O^"C_ ,#KZ.RNWLX_!NG"6Z6WF:VB;[+\1/DDG5#$C#S$!5G!RZ\?,,^
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MB,#C*,J&*PM6=&O2G\4*D'9JZNI1>DH3BW&<6IP;C)-E%%%=1S'Z _\ !/\
M^)7_  C_ ,0=9^'5_<!-.\<6!O=+21T5$\1Z'%+.(X]V,-?Z2UZKA6S++8V<
M81FQC]C[2Y>TN8+J,_/!*DJ^^U@2I]F&5;U!(K^9#PGXEU+P;XGT#Q7I$ABU
M+P[J]AK%FP8J&FL+F.X$4A&289PA@G4@AX9'1E96(/\ 2/X4\2:=XQ\,Z!XJ
MTB02:;XBTBPUBS(8.5AO[:.X6*0K@": R&&9< I-&Z,%92!_,OC/D*PF<87.
MZ5->PS>A[#$M+3Z[A(QA>71>VPKI**M[SH59-MW/Z1\'L\>*RG$Y-4G^_P I
MK>VPUWJ\'BI2G:*=V_8XI57)[15>E&Q]-P3)<0Q3QG,<T:2H>#E74,O3(S@\
M\]:_/+_@I_\ # ?$#]EO7M>M;=9M7^%^M:3XXM&4-YQTU9'T/Q#$I4$>2FE:
MM)JEPKX5AI,; [T0'[D\'7WVC3FM';,ED^U<GDP2EGC]SM<2)Z!0@]*M^,/#
M&F>-O"?B?P;K,:RZ1XK\/ZQX<U.-D60/8:WI]QIMV-C_ "L?(N7*@\;@.1UK
M\,X=S:IPOQ1D^<0<KY3FF%Q4XQO>KAJ=6+KTN]L1A95*4EUC4:/TKQ0X,PWB
M?X7\;<#XA4W'BSA;-LHH3J6<,-F6(P=19;B]4TI8#,X87%TVTTJE",NA_$51
M72>,?"^I^"/%OBCP9K,;1:OX3\0ZSX;U.-D:,K?Z)J-QIMT-C_,H,ULY4$GY
M2.2.3S=?Z@TJM.O2IUJ,XU*5:G"K2J1=XSIU(J<)Q?6,HM23ZIG_ "EXK"XC
M XK$X+%T9X?%X.O6PN*P]6/+4H8C#U)4JU&I'[,Z52$H3CTE%H*_J1_8;MS+
M^RK\(M18' T![&-B.ICU;5_. /MY<(_G7\MU?U5_L/P^5^QA\#"0 \NF:S*Q
MY.[?XH\2B,D]L0K$N.VT 9QFOYD^EC/D\-L+;>IGN'I^?*\#CJDOE^[2?J?Z
M6?LKZ*K>/?%/,O=H>'&/Q.VCJ1XDX;H4T_-/$.:\X'TK7GWQ9UL>&_AA\0-<
MW!7T[P?XAGMR3@&\.EW,=DF>WF7DD$>>HW< G@^@U\M_MD:Y_8WP'\1VROY<
MWB#4M T.%@<,=^J0ZK<(OKYMEI5U$XP?W;OC!P1_D9XM\0?ZJ>%WB)Q(I\E3
M)>"N)<?AG>SEC*&48N6"IQ>EI5<7["E#5>]-:H_Z-N!\K_MOC+A7*>7FAF'$
M.486JK7M0J8Z@L1-K^6%#VDY?W8L_%NBBBO^:$_UW"BBB@ HHHH *?%%)-)'
M##&\LTKI%%%$C222R2,%2.-%!9W=B%1%!9F( !) IE?:'[)GPA;Q!K"_$36;
M0RZ9HUT8/#5LZL1?ZXA >^"8Q)!I6X"$Y*MJ+*P^:R<'[WPS\/LY\4.-,FX-
MR2$E7S*NI8S%^SE4I99EE%QEC\RKJ-KPPU%OV=-R@\3B9X?"4Y*KB*:?S/%_
M%.7\&\/YAG^8R3I82DU0H<RC4QF,J)QPV$I-_:K5+<TDI*E1C5KR7)2FU]D?
MLU?"";P+X.L-': ?\)/XADBU7Q%+ACY$[1#R;)V/W8=(MW,#XPC79NY8\^>,
M_>VDZ9;Z190V5L/EC&9)"/GFE('F2OUY8]%SA%"H.%%8WA+P]'H6G1F0*U_<
MQH]U( #L!^=;>-NNR,GYR.)) 6/RA O5U_TW>#?ACE/AEP;D60Y=A(X:&6Y5
MA<!A:+2=3"X:$%.HJLTE[3&XRO*>+S&O9.MBJDV[OGG4_P ?^/N,<?QCGV8Y
MEBZ[K/%XRKB:U1-J-:M)\L7"+;Y,/AZ:C0PE*[5.C"*3MRJ)1117ZZ?"GQ+^
MVEX(UOX]^%-'_9DLAJFF^!?BA=P7?QY\6:?='3I]-^#VBW2WM_X*T2\\B62;
MQ-\6-9M+/P>1:F$:1X(_X3K79KZVU.S\/:;KWO7PV\%Z'X<TG1="\/:18Z'X
M5\):9I^B>']%TZW2VT[3K#2[6*TTW3K*WC 2&UT^TAA2*-1A52)>>36WJHEU
MO7/L=N<I!^XW?P(L9S<2G&>CDJ.[%47J17>VEK#96\5M H6.)0!ZLW\3L>[N
MV68^IXP, ?18G-L1'),!DT'[+#4)XG&.C"4K5<9C?9QKXZO=ZXB>&H87!TU%
M1A2P^%@HQ]K*O6K^%A\KH/-\=F\E[7$XBGA\(JTXQO3PF#YY4,%1LKJA'$5\
M5BZC;<ZF(Q,W*7LXT*5&Q1117SI[H4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'D'[0/_)#?B[_ -DZ\7?^F2\K\=O"_@O]G6[^ ^J^*/$?C[4]
M(^,5K9Z_/I7AZTO4DBN-1L[J9?#UJVF#2991%J2I;1W%PNHQ_9HII+W=&L)2
MOV.^/5O<7?P3^*]K:037-S<?#_Q7#!;V\3SSSRR:-=K'%##&K222.Q"HB*S,
MQ 4$XKY4_9,^ 'PTU_X.^'M=\>_#32;_ ,4MJNOBYG\1:7<?;'AM]7N8[);F
MRO"D<D2VZQK&LULT;QA20P.3_G7])KPLSGQ;^D1PGPQE.1<#YO.MX$\8/ZSX
MA83/<1DF45*G%>78..:Y9/(94\33XFP+QBK96ZE6%%4GBG-J7LY+^J?"'C/
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MS1;<HCDWNKZI<V]E:*P5&GE0.Z [@?6LG_Z%.(_\.DO_ )C_ *N_*Q]5S?\
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M<W_Z&N'_ /#8O_FSU_I:^'?\+VTO_HFWQQ_\-#XP_P#D&C_A>VE_]$V^./\
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M_0@?&'_PU_BG_P"0Z]AHK_0/^QN//^BXRS_Q#:?_ ,_C^8/K_#?_ $3N,_\
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MS$*JJHRS,QP H )))  &3Q1_8W'G_1<99_XAM/\ ^?P?7^&_^B=QG_A^G_\
M.W^KORMX_P#\+ET[_H0/C#_X:_Q3_P#(='_"Y=._Z$#XP_\ AK_%/_R'6SX/
M^,GPA^(6KZGH'@'XJ_#?QQKNB*[ZSHG@_P <^&/$VKZ2D<YM9'U/3=%U2]O+
M!8[E6MW:ZAB"SJ86(D!6O2*/[&X\_P"BXRS_ ,0VG_\ /X/K_#?_ $3N,_\
M#]/_ .=O]7?E;Q[_ (7+IW_0@?&'_P -?XI_^0Z/^%RZ=_T('QA_\-?XI_\
MD.O8:*/[&X\_Z+C+/_$-I_\ S^#Z_P -_P#1.XS_ ,/T_P#YV_U=^5O'O^%R
MZ=_T('QA_P##7^*?_D.C_A<NG?\ 0@?&'_PU_BG_ .0Z]AHH_L;CS_HN,L_\
M0VG_ //X/K_#?_1.XS_P_3_^=O\ 5WY6\>_X7+IW_0@?&'_PU_BG_P"0Z/\
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M_!]?X;_Z)W&?^'Z?_P [?ZN_*WD?_"Y=._Z$#XP_^&O\4_\ R'1_PN73O^A
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M/X%^)FB:Q\+/!^M_M$_"3XY_L[?!K4?"VD>*-1TWX<?$*T_:/\;^!O#'P_\
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M=7'@3XUZ%\:[2TFM,_9$AO\ 5-"BT2X="7BL)Y+B+-PJBO+OB3^PI<^.K?\
M:1\+:+^T!\0? GPN_:HNO$>M?%/P+HOAKP)?W\_B/Q1\/=)^'>LOH_CG5-$G
M\3V'A?5=+\/:'-JGAAY[F5UBU72])UO1=)U8V=H =+XE^/WQ@U#]HGQ=\)O
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MW0_!D/PY^#_B_P 3^(?BY\']6\:1SOX1N/%.IWZ'PQ\1],M-073_  WX[OM
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M\12ZQ%I>G^7\5OVQ[[4;B.;1"-3CU*UT];N31)8B$35H[)[HBV$U=_\ %/\
M87G^(7AO]H#X<Z'\?_B/X!^$?[24_CG6O'_P_P!(T3P7J+6/BGQ_X?ATKQ%>
M^%/%FH:/_P ))I'AW7=6M8?$GB7PK<7>I0:M=WFO:=9:CHVDZW-:0?07_"@O
M#\WQ'\=_$*_U?4;P_$/X"^!/@%KNA^7!;VJ^'_ NN_%36[?5[*\A(N8-1U3_
M (6QK=G>QL)((H]/TV6U,4@N?/ /FK]GGXY?&NQ\&?L.^&/BW%X+\2ZU^T)X
M2N+BX\5:%>^)IM2BT'PY\ =*^(.FZMKLFNEGO_&FN:U!J*>))HV.F&.XBGLR
M;@RYU_C+^UYXS^&^F?M477AOX>:/XNU7X ?$']F[P5X8T.;6Y](D\;O\<KOX
M7V][!>ZC+%+;:->V+^/KFWTFY\J6R$MK9S:@C0F=3JZ1^QUXBTWX;?!7PG)^
MT%XRE\=_LXZO;7'P8^*5MX,\!V6HZ-X9MOAO)\+)?!?B[PN=+N?#?C31M6\,
MW=_)K=W+;Z1K$^KR6&I:7?Z/)I=NC0V?[$=I+H/QKL?%?Q@\:>,_$?QX^)GP
M1^*OC3Q9JVD^'[2Z@\0?!36/ .JZ7IVB:3I5O9Z3IGAR^@^'VD:'::7#;^9I
M&CA?,O-6U876K7P!Y3\6?VQ_B5\'O&WAGX$>//'O[*W@3XNZCX'D^+7BGQWX
MV;QWI?PLT#P7JNO:IX7\'^$_"_A@^(XO%_C_ ,8ZMKGAWQ0NIZ[-X@\%Z)I&
MBZ"NK3:.U_K&G^'Z^H/V2_VB8OVD_AGJOBN2V\/1:[X.\=>)?AIXJN_!>K7>
MO^ ==USPRNGW2>)_ .NW]CIM_J7A'Q+HFL:-KFFKJ%C!J&DRWUUX?U![J]TB
MXO;FW\5_V?-1\:?$7PY\9/AQ\5/$WP9^*NA>%+[P!J.NZ+H?A?Q9X?\ &_@*
M\U5->M_#'C;PIXKTV\M[]/#VO"ZUGPGK&C:CH&MZ'>:MKL O[O2M;U+3;CU;
MX:>#]<\#>$K30?$OQ"\4_%'7OMNK:GJOC/Q?%H5KJFH7NLZE<ZG-;6NF^&M)
MT71='T+3&NO[.\/:-96.-+T:ULK.:[O[B*6]N #X1\??M'7GPAL?VPO%'P_^
M$W@C2-9\%?M6_"7X8^,/'*Z'X@O]):Q\;_!#]G37]5^.WQ>TWP98R>*=>M/
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M'IUYK_@3Q-K-SXCTL^ O$,MIJ6B^,+1=>D>UT*\\,W5C????QO\ @_I'QP\
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MXI_X1U%NFAO=0.E?:F,0OO* D .,L_C[^T=\4[SXE>)OV>OA5\+]=^&GPO\
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M?PK^+WPJD\40>#?&L?AS3?&6D7/AWQQ::9;>,_!'C'PCJ=SIHU_PAXDG\/\
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MM[5KR[D($=M:K/(AN+AR0$AA#R,2,*:_GW^*WA_X?:+\<?VF?!_[16M?L2^
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MY))+*[MKR.&XFM9GM9XKA(KJV<Q7%M(T3NJ7%O(#'-"Q$D3@HZJP(KC?AO\
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MBT SGS[2Q\-VT4CX&R'5-@)$S8_<?Q&V[4%']RVC7\WD?_V;]*^/_P#@FO\
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MU>*G5JQISG"$Y26SHND:?X>T;2=!TJ!;72]#TRPTC3;9<;;?3]-M8K*S@7
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M?9AY7:^)H****]\\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\7Z5=Q>;_9S0W[@'US'''#&D42)%%$BQQQQJJ1QQHH5$1% 5$10%55 55
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M:+P#XU^'/Q,\$>(+:PUGPAXHU#1]4L)-2T[6-,U*&70?%?A7Q)H^FWD$ME=
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M1>%&\0ZJFC0>R_!+XW1?%M?&NAZUX*\0?##XF?#'7;+P[\1OAOXGO-#U74-
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M:,NEWNI62:I?1ZMK&BVL6ES1W<T]L ?,'P\^ _Q?A\6_LV>-?BEXD^&\^K?
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MCQ/IUW>S:5K'A)H)=%U;2=9OK4_H-10!^>/B_P#9"^)OQ6T#X\>(_BEX_P#
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M32]/C-Y?SZR!IWT/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;CQQ\.KKPVD&LZOI6CZAI_CG0Y7U,W?ZMT4 ? 6D?LJ>-_A?+\!/B%\&;+X
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M+M=2^Q_:O(MOM/V;[3Y/VC[-;^=L\SR(MWEJ =+1110 4444 %%%% !1110
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M'Q$TLVC:9X]\4_#'P3X@\::<U@JI8M8>*=6T2[URS-FB(MH;>^C-NJ*L.P*
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M@'Y<ZX/B98?LE?M__M-W7Q[^.-_\0/ WB#_@HGX7^%.G1_$?7])\&?#3PYX
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M_B!=6/Q-\0Z#;?$GQ7\5/VSM&^*/P\^-WA'Q/X7UK7==O_A[\'Y[J7PGX/\
M%VG+ GCCPAIGP,T;P;;VFB>&]2T74=.U'0I-1V?K%X.^'?@3X>IXGC\"^#_#
MGA!/&GB_7?B!XN3P[I%EI*^)?''B=X)/$7BW6Q90PC4O$&MO:VS:GJMUYEY>
M&"'SY7\M,>?^#OV9?V>?A[XP_P"$_P# WP5^&GA/QE''J45EX@T'PAHNFWVC
MQZV\DNO)X>-M:1Q>&U\0SS2W/B(:!%IO_"074DEUK/VZX=I2 >4?L/\ _)-/
MBU_V>3^W'_ZUM\8:^'?BEHOQ'USX:?\ !2_X^?\ #07QZT/Q;^S5X[^+^N?
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MCXBWNO>$M-T?XP^(M2^-/AWQOINLZ/XQM;.TBL_"46G6R_8_[*'Q&\8_%_\
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M8^&7A74TLKW0=$\8:KKC:9JOPYL=;U'Q-X7O;'3-8T;1]4LKG5;[]03X(O\
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M,NOV;OV'_"/BC0_C#;OX[^"_P3^'&C_&+Q1X'UJ+X=>,/BYIWPITM=<\+_\
M"6:C<-KAUB\UG0=>L=/\2Z]HEAX5\8:S:2P>&/%&OSW5JUS]":IX ^*^@?M7
M?$'XB^'?!VD>*?AW\:/@5\(/AEK.OR>,+30M4^'VN?"3Q+^T'KDUW<>';K3+
MJ?Q+I_B.T^,&DP:>VF7MO-9WNE7R7\<5K+#=#SS1/V</B18?LE_L(?!Z>ST5
M?&G[/VI?L:7GQ#@35(&TZU7X*:?X5MO'SZ1?B+R]3DBETK4!IWDI&=3!5D*>
M;0!Z9XX_;/\ AKX)UWQI8IX.^,'C3PG\+M0;2OB[\5/ 'P^NO$WPV^%FHVMK
M'J.N6?B75X;ZWUC6)_"6E30:IXW3P#H'C/\ X0RTEV>)CI=Y#<VD%SQ3\;OA
MWX"^('Q@\;:O\1_&VIZ%\./V4_#GQO\ $/@C2K+2=6\ 67PZLM9^+>JCXB>$
M[BTT]=7U?QIXEM/"FLZ7>62:]+IEQHWA_P -O:V44]TUU)\/>(?V+/B'X6\8
M?'+1='^"5G\;/#?QB^*'Q+^)G@[QM>_M??&_X.>'_"<GQ>U:_P#%OBCPO\6O
MA?X6U-+.]T30O&&MZ_\ V;J7PXLM;OO%?A:ZL-/UK2]$U>WO-5O?<OBM^REX
MSU2T_:6T#X=Z-H&G>&O'7_!.'0_V4OA?IAUR=8+3QGH$?Q^LM.T:XFU-KK4+
M?0+.P\?^$K>#7-2N+F>5#=/=-)/:S/( ?8/P>^,.F?&K0)_%OA[PAX^\/^$Y
MVM+CPIX@\;Z#:^'+;Q]H&H6WVO3_ !9X4TU]4NO$">'K^W,<]E+XGT;PWJ5S
M;SV]U%IC6L\4[>9^.OVM_!?PW\7:AH?B_P"'7QOTCP;HOB7P_P"$-?\ C5=_
M#/4;3X0:'KWB>XTVQTA;O7KZ[M=?O- DU/6=*TN\\<Z+X7U7P#I=[>[=3\46
MD%GJ,]G]&^&-/FTGPUX>TJY5$N-,T/2=/N$B8-&DUG86]M*L;* K(KQL$8
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M$G[3VJ?#^$ZE#]BO+7XK>!?^$>\)'6;LQ[--DFO0L5^DRR&R@ >0NH"UXO\
M%/\ 9&\=6/Q?M/C!H_PTN_C9I/B_X,_"CX<>-O!&A?M)?$7]G_Q5X/\ %_PO
M_P"$AM]/\3^'[_PKK&B>$_&OA?6]+\42V6OZ7XCO;'6O#]UH-OJWA:351KVK
M:2H!]1:U^VU\$M,\/_"'7=,'CWQA<?'6^\9Z#\-/"_A'P%X@U3QEJ_C+X?\
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MF?1(_P!F7Q]XS^%O[0'QET*;4&BUF]^.GP%T75]"\$0Z?HPMFM[K1_%][8_
MOQ=KMZ\H:TU#X VUM(LK>*FDMP#V/Q[^U[X'\#^)O%/AFP^'_P :/B5)\.8-
M.F^+6L_"KX?2^,]#^%+ZEIEEKT6F^*KJWU.UNM6\1VWAS4;+Q+J7A'X?V7C;
MQ9IF@7NG:G?:)!!K&C'48O&?[8_PW\.:OH^C>#_"OQ1^-]SJGPJ\/_'*ZE^"
M'A&#QO;:+\(O%UYJEEX1\<W<DNLZ0^L6?BR70?$#^&M#\'Q>)_%NMP:%J4VG
M^'ITC@-Q\A>-_P!D/X@^%_C%\;_$7AOX.2_'#PO\;?'4WQ(\-:S:_M=_&+X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9^US\#[SX4^,?C#JVOZUX.\.?#OQ$/!?C_0_&GA'Q-X>\?\ A#QY+_8?]G^
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M)+X:\0>()-0O=?\ %WB1?"8UB^N4MK.+G-0_:DTKP[^V#=SW6C_'#5+#Q?\
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img44536338_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img44536338_2.jpg
M_]C_X  02D9)1@ ! @$!2@%*  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 1!".@# 2(  A$! Q$!_\0
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH
M\-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^%
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M-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\*
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
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M7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_ -!/Q-_X&:5_\IJ]RHH
M\-_X4!X-_P"@GXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^%
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M-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P# S2O_ )34?\*
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MGXF_\#-*_P#E-1_PH#P;_P!!/Q-_X&:5_P#*:O<J* /#?^% >#?^@GXF_P#
MS2O_ )34?\* \&_]!/Q-_P"!FE?_ "FKW*B@#PW_ (4!X-_Z"?B;_P #-*_^
M4U'_  H#P;_T$_$W_@9I7_RFKW*B@#PW_A0'@W_H)^)O_ S2O_E-1_PH#P;_
M -!/Q-_X&:5_\IJ]RHH ^2?B7\--$\!Z)8:WHFH:VU\^M6UD&N[NT98D>SU"
MZ\V$VEA9S).LEI%L<2D*I?Y"Q5E*]$^/_P#R)NF?]C-9_P#IJUFB@ ^ '_(F
MZG_V,UY_Z:M&KW*O#?@!_P B;J?_ &,UY_Z:M&KW*@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#PWX__ /(FZ9_V,UG_ .FK6:*/C_\ \B;IG_8S6?\ Z:M9
MHH /@!_R)NI_]C->?^FK1J]RKPWX ?\ (FZG_P!C->?^FK1J]RH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \-^/_P#R)NF?]C-9_P#IJUFBCX__ /(FZ9_V
M,UG_ .FK6:* #X ?\B;J?_8S7G_IJT:O<J\-^ '_ ")NI_\ 8S7G_IJT:O<J
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHU[K,$L.I0Z)%-877B1Y+6RDT>='M[1;>6Y,DQNHP#][:*** "BBB@ HHHH
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M/9VUUK]MK6OVZ:!#J&N*?$^C>);^.+5=2OM)E":( ?U74444 %%%% !1110
M4A( ))  !)).  .223P !U-+7Y\?\%5?BEK?P>_X)_?M*^,O#5]/IVNW'@_2
MO!6GWMK(8;RU'Q*\7>'?AYJ%S93JR26UY:Z3XGU"ZMKJ%TN+66!;FV83Q1T
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M>"?$.MP2>']-UE8/%6@R6>G6T'BC2&NS%J$UEIFEQW.GW>D3W-A]M>YO[_\
M6&@ HHHH **** "BBB@ HHHH **** /S4_:2_P""JG[-/[+7[0/A[]F_XBZ/
M\5M1\<:_!X7N)-5\)>%] U+PIH<?B^[-KHW]L7VJ>+]$U>1F^6XN1HFAZR((
M'4$M.'@7]*Z_BM_X+)_\I6/"_P#V"_@!_P"G"*O[4J "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /#?C_ /\ (FZ9_P!C-9_^FK6:*/C_ /\ (FZ9_P!C-9_^
MFK6:* #X ?\ (FZG_P!C->?^FK1J]RKPWX ?\B;J?_8S7G_IJT:O<J "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K^('_@MGX9\7_"G_@I5JOQ7U71WO-"\9:9\(OB#X';4
M8WFT75[7P/X9\->%-6T<R>4(3Y/B#PA>'5-/#S3PVVJVMW,J0ZE;*W]OU?'_
M .V?^Q-\&OVXOA@GP[^*]G>V>HZ+/>:IX"\=Z$\</B;P+KUW;I;S7VG-,KVN
MH:9J"0VT.O>']0CDL-7MK>W<&SU2QTK5=. .M_9:_:P^#'[7_P ,-(^)_P '
M/%%GJMK<VML/$?A:XNK1/%_@/6I4;[1X=\8:)%/+<:5J%O-%,MM.P;3M9M8T
MU71+S4-+N;:[E^DZ_AM^-O\ P3*_X*$?\$\O%MW\7/@KJWBOQ;X7\.BXGMOC
M!\ [[6+'Q!I^B1/]IF7QOX'LKF3Q+I>G-!:_:M>@\GQ5X(AMH_+U/7KB,E#]
M_P#[ G_!>O5=7U_PY\)?VU;32A'J]Q9:+H_Q\\/6$&CI;:A=3I;VTGQ/\-68
MBTFWL+B24+<^*_"UMI=II*I"^H^&GM'O];L@#]@?^"F/[07[3_[-WP&\.^./
MV5/A>OQ1\<ZE\3-$\->(+$^!_%7Q";0?"%YX?\4:C<ZVOA_PC?V&H1E];TK0
M]'.JWC7&F6@U0VLL'VZ_TZ>#^+'QK\?OVD/$'[<%G^T/XE\!?8/VF[?XI> ?
M&5M\/O\ A!/$MAYGCGPS%X<3PIH__" 7-T_BB3^TDTK1F_LA;L7VI?:LVDB"
MZAV_Z+R.DB+)&RNCJKHZ,&1T8!E964D,K @JP)!!!!P:_BN^//\ RL :%_V=
MW^SA_P"DOPNH ^SOV<_^"F'_  5F^('Q[^#?@;Q[^RVEMX%\8?$KP=X:\:W[
M_L\_%OPPND>$=:UVRT_Q+KI\1:AK1T_1?[!T6XO=9&I:BDNGVIL1+?07%HLT
M,G]$_P =_CK\,OV;?A9XJ^,?Q=\11>&O!'A*T2>^N_*>ZOK^\N94M=,T31=.
MB_?ZGK>L7TL-EIUC"!YDTOFW$MM9PW-U!Z]7\E/_  <:?'?6=0^)OP1_9ML+
MZ6+PUX:\'3?%_P 1V<+L+?4_$WBG5M:\*^'?MZ%BKW'AS1?#FM36&U$V1>+[
MPN\Q>-;< N^)/^"V_P"W3^TGX\U3PK^P_P#LV1?V-ITGVJ&WM_ WB7XP?$/^
MRE:2*#4?$LFC3P>%/#EG?F-Y7M3H]REG/BRA\2:AY1GN.0UC_@K3_P %:_V8
M+K0]7_:9^ UF/"FJW(LXW^)GP6\2?#RVUB7?/<2V6C>*] GT+2;?75MHI/+@
MEM-5,-I$MU/H\X;SY/Z*/^"?_P"S#X6_9._98^%GPST/3;"#Q%=>&M)\5?$G
M6[6W6.Z\3?$+Q%I]MJ/B+4+RZ:..ZNX-/N)AH6A_:OWEIH&EZ99A(_)*U]'_
M !4^%G@'XV?#[Q3\+OB?X:TWQ;X'\8Z7-I6N:)JEO'/#-#)AX+NV=U9[+5--
MNDAU#2=3M3'>Z7J5M:ZA930W5O%*H!\O?L)_MZ?"/]O+X9WGC/P!%=>&?%_A
M>:RL/B-\,]9O(;S7/!NI:A'/)831WT$-K%KOAO6!:WAT+Q%!9V27QLKVVN[#
M3=2LKS3[?[3U75-,T/3-2UO6M0L])T?1["\U35M5U&YALM/TS3-/MY+N_P!0
MO[RX>.WM+.SM89;FZN9Y$A@@C>65U1&8?Q$_\$Q-6\1_L@_\%9H_@?/J\EUI
MMS\0/BS^S3XTDA#0P>((=*N]=L_#^H1P.P1%D\:^%?#.K02,K2+8O<00D?:6
M)_>?_@N[\:]5^$_["VJ>&-!NY[+4_C?X]\._"Z[GMP5FC\,/9:QXN\3IYV-L
M<&I67A>+P_>)DR3V6MW,*KL:62, ^#?VC_\ @O1\4_&?Q(N?A-^P-\(+?QBC
MWUUI>C^-O$/A;Q-XU\7^.);6*22:^\"_#309-/N--LU%O-<V<VOKX@OK[2P;
MF]\/:'.'AA\CG_X*N_\ !7;]G.6R\8_M'_LY74_P[NKJ![U_B'\"/&/PUTT6
M^HW)>#2M.\::3#I.GZ-K*)_H=G#KEMK5Y AC;4=*O;AUD?[A_P"#??\ 9L\(
M>$?V;-;_ &D[W2=.OOB)\6O%GB+0-(U^>QADU'0/ '@Z]70SHFF7DT;7%HFL
M^*+'6M1UO['+%#J4=IH,5TDDFD1,/W\U32M,US3;_1M:TVPUC2-4M)[#4]*U
M2SM]0TW4;&ZC:&ZLK^QNXYK6\M+F%WBGMKB*2&:-F21&5B" ?,?[&'[67@W]
MM/X">&OCIX+T35O#%OJM[J>A:]X6UJ6&ZO?#GBC0I8X=7TM-2MHXK;5[$>=;
MW>F:M#!:-?:==VTMUI^F7WVK3;3^5C6/^5@&'_L[K0__ $DT^O[ /@_\%/A7
M\ O!Y\ ?!SP3I'@#P8=;UOQ$OAW0Q=+IT6K^(KZ34=6N;>*[N;IK:*:YDVV]
MC;O%8:=:1V^GZ;:VFGVMM;1?QN_$;Q=X8\ _\%V-<\;^--<TWPSX2\)_M16?
MB#Q'X@U>Y2TTS1]&TO2[.\O]0O;B0[8X+:WB>1L!G; 2-7D95(!_9;\7?BW\
M/O@5\./%GQ8^*7B.R\*^!?!6E3:MKNL7K<)$A6*VLK*W7,^H:MJEY)!INCZ5
M:)+>ZIJ=U:V%G#+<7$:-_/-^S9_P5>_;K_;@_:UA^'_[-_PB^%NB_ ZP\265
M_P")M0\9^'O$NIZEX0^%,.J^5=Z[XS\4Z=XNLM-B\7ZWIR7$>AZ'HU@(I]9,
M.GVD>H66G:MKA^,_C_\ &CX_?\%O/VJM*^ /P"AO?"O[./@'4)M8M+G6$N+;
M2M-T.UG32]1^,GQ'MHI$:]UR^CNGL?!/A*-OM5A!J"Z1:M!=7WB?6S_4A^R7
M^R7\(OV-?A%I'PD^$FD>1:P>7?\ BGQ3?QP/XF\=^)G@2*]\2^);V)$\^ZGV
M"*QL8@FGZ-IZ0:9ID$%K JL ?3E%%% 'S=^V3_R:#^U7_P!FW?'+_P!5AXHK
M^:7_ (-O/^2V_M)?]DL\)_\ J6RU_2U^V3_R:#^U7_V;=\<O_58>**_BY_X)
M3_M\?#C]@CX@?%?Q=\1_!OC;QE9>/O!VB^&]-MO!*Z$UU976F:V^IS3WW]NZ
MOI$0MY(F$<?D232>9G<BK\U ']Z]?PA_\%9XK31?^"J_Q3D^&EM%#XAA\6?!
MC55@LHB(7^(-UX$\ :I)+#' N7N;W5)[2ZU Q!I9=7N+YY";EY17ZE?&'_@X
MZ\%GP=?VWP#^ ?BUO'EW#)!IVJ_%C4=$M/"^B2MM\O4+C1_">K:GJ?B(H/,
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MU#3==U^VF1K2[TCPM::8UW9:7*)8]1UR[L;F[5;32)+34@#V_P#9I_X*L_\
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MFJ>-E\8Z?=7FF_#_ ,8^&?#\"S:ZMM8:O?:IJFD^+M-MRM['H-K?ZR?$EO\
M;)-$AM;BT&E2?O5%9VD-I'80VMM%816R6<5E%!%':16D<0A2UCME40I;)"!$
MD"H(EB C"A !7\ G[2W[,?A"/_@JKXG_ &6?#\S^$/!/CS]J/P-X'T^32[6V
MG_X1#0OC+XC\+7'EZ-88MK5K?PU;>,GATC3Y&CC6VL+6TFF.UY2 ?K9\6_\
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MQU32_P"V95U#1;N]T^/5;W4O#\6KZHD<HE;4-1FO;A//NI'< _N3K^=K7?\
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MBBB@ HHHH **** "BBB@#PWX_P#_ ")NF?\ 8S6?_IJUFBCX_P#_ ")NF?\
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MZT7QGX2\.>*](N;)@]G<:9XAT>SU>QFM'!(:VDM;N)X3DYC*UUU?QI_L'?\
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M;\<@3\$_C" "2?A;\00 !DDGPEJX  '))/05_*E_P;A?\G#_ +07_9&-+_\
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MXVOV!O$UY;:C-H-T ?9/_!Q5H%_?_L@?"G7K6.26T\/_ +0>AIJ6SE+>#6/
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M;:%I=_X[,&@^##-J]G>ZA-_PBD'AG^V-EO+?V^K366EW@N #]P**** /Y/\
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M5=U1II=GB67RH@Q!DD\J*238F6V1N^-J,1_:M7^=7X-^&/QU^*7[9?Q+T_\
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MZ9;Z<E]?.BJLVHZ@T#W^HW&T&YOKFXG;+2$T ?QY_P#!9/\ Y2L>%_\ L%_
M#_TX15_:E7\5W_!90$?\%6/"V01G2O@"1D=1_:$8R/49!&1W!'45_:C0!^.G
M_!=O_E'=X^_['_X6?^I;:5P7_!OI_P F'ZO_ -E\^(7_ *CG@*N]_P""[?\
MRCN\??\ 8_\ PL_]2VTK@O\ @WT_Y,/U?_LOGQ"_]1SP%0!^Y%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!X;\?_P#D3=,_[&:S_P#35K-%'Q__ .1-TS_L9K/_ --6
MLT4 'P _Y$W4_P#L9KS_ --6C5[E7AOP _Y$W4_^QFO/_35HU>Y4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB>!PDL:2+AU4C>HH \-\$?LP_LU?#/Q GBSX;_L\_ WX?^*8Q*L?B7P1\)?
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M=-\0:+>-;RI/;M=:7JUM=V-P8)XTFA,L#F*5$D3:Z@CH** /GOP7^R3^RO\
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ME>'M TBUCLM)T/0].L])TC2[*$8BM-.TVPAM[*RM8@2([>V@BB0<*@K5HHH
M^=_&W[(?[*?Q)UN3Q+\0/V:O@-XS\23W$-S=>(?$WPE\":SKE[)!(\T:ZAJ]
M]H4VH:A;F261Y;2]N)[6<R/Y\,@9@?5O _PZ^'WPQT6/PU\-? G@WX>^'8FW
MQ:!X'\,:)X3T6)P-H:/2M L=/L48+QN6 ''&<5V5% !7)>-/ '@/XD:-)X=^
M(G@GPCX]\/S$M-H7C3PWHWBG1I692C-)I>N65]9.2C,A+0$E6*G@D5UM% 'R
MUIO[#?[%ND:@^JZ9^R3^S79:@T\5S'=0? _X:K):3PQ+%')IX/AHKIA"J"RZ
M>MLLDI:>17F=Y&^E=*TG2]"T^TTC1--T_1]*L(A!8Z9I5G;:?I]E "6$-I96
MD<-M;1!F9A'#$B L2!DFM"B@ HHHH *:Z)(C1R*KHZLCHZAD=&!5E96!#*P)
M#*0002",&G44 ?-'BC]B_P#9 \:WMQJ?BS]EK]GKQ!JMW-'/=:OJ?P<^'UQK
M%S+'.;@&XU9O#_\ :,RO,6::.2Z:.X$DJ3I)'+(K>A?#[X$_!#X2N\GPJ^#?
MPJ^&<DJ2122?#[X>>$?!CR1S-OEC=O#FCZ:SI*_SR(Q*NWS,">:]5HH *Y#Q
MG\/? /Q'TV#1OB'X'\(>/-(M;M+^VTKQGX:T7Q1IMO?)%+"E[!8ZY97UK#=I
M#--$ES'$LRQ2RQAPDC ]?10!EZ)H>B^&M)T_0/#FCZ7X?T+2;6.RTK1=$T^T
MTK2=,LH1MAM-/TVPA@L[*UB7B.WMH8XHQPJ 5J444 <7XZ^&WPZ^*&D+X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \-^
M/_\ R)NF?]C-9_\ IJUFBCX__P#(FZ9_V,UG_P"FK6:* #X ?\B;J?\ V,UY
M_P"FK1J]RKPWX ?\B;J?_8S7G_IJT:O<J "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /#?C__ ,B;IG_8S6?_ *:M9HH^/_\ R)NF?]C-9_\ IJUFB@ ^ '_(
MFZG_ -C->?\ IJT:O<J\-^ '_(FZG_V,UY_Z:M&KW*@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /#?C_\ \B;IG_8S6?\ Z:M9HH^/_P#R
M)NF?]C-9_P#IJUFB@ ^ '_(FZG_V,UY_Z:M&KW*O#?@!_P B;J?_ &,UY_Z:
MM&KW*@ HHHH _EK\?^._AU\"O^"]GC'QU^U\MC8^ O$/@OP]'\&?&_C2R?\
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MM^P=^UM::<CR7$?P(^(.HNJ,ZM]CT?0KG5]2;*98A-.L;IV3[LBJR/\ (S4
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M\-_L'X\?]#KX9_\  2V_^9*C^P?CQ_T.OAG_ ,!+;_YDJ /<J*\-_L'X\?\
M0Z^&?_ 2V_\ F2H_L'X\?]#KX9_\!+;_ .9*@#W*BO#?[!^/'_0Z^&?_  $M
MO_F2H_L'X\?]#KX9_P# 2V_^9*@#W*BO#?[!^/'_ $.OAG_P$MO_ )DJ/[!^
M/'_0Z^&?_ 2V_P#F2H ]RHKPW^P?CQ_T.OAG_P !+;_YDJ/[!^/'_0Z^&?\
MP$MO_F2H ]RHKPW^P?CQ_P!#KX9_\!+;_P"9*C^P?CQ_T.OAG_P$MO\ YDJ
M/<J*\-_L'X\?]#KX9_\  2V_^9*C^P?CQ_T.OAG_ ,!+;_YDJ /<J*\-_L'X
M\?\ 0Z^&?_ 2V_\ F2H_L'X\?]#KX9_\!+;_ .9*@#W*BO#?[!^/'_0Z^&?_
M  $MO_F2H_L'X\?]#KX9_P# 2V_^9*@#W*BO#?[!^/'_ $.OAG_P$MO_ )DJ
M/[!^/'_0Z^&?_ 2V_P#F2H ]RHKPW^P?CQ_T.OAG_P !+;_YDJ/[!^/'_0Z^
M&?\ P$MO_F2H ]RHKPW^P?CQ_P!#KX9_\!+;_P"9*C^P?CQ_T.OAG_P$MO\
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M?]#KX9_\!+;_ .9*@#W*BO#?[!^/'_0Z^&?_  $MO_F2H_L'X\?]#KX9_P#
M2V_^9*@#W*BO#?[!^/'_ $.OAG_P$MO_ )DJ/[!^/'_0Z^&?_ 2V_P#F2H ]
MRHKPW^P?CQ_T.OAG_P !+;_YDJ/[!^/'_0Z^&?\ P$MO_F2H ]RHKPW^P?CQ
M_P!#KX9_\!+;_P"9*C^P?CQ_T.OAG_P$MO\ YDJ /<J*\-_L'X\?]#KX9_\
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M9_\  2V_^9*C^P?CQ_T.OAG_ ,!+;_YDJ /<J*\-_L'X\?\ 0Z^&?_ 2V_\
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M\-_L'X\?]#KX9_\  2V_^9*C^P?CQ_T.OAG_ ,!+;_YDJ /<J*\-_L'X\?\
M0Z^&?_ 2V_\ F2H_L'X\?]#KX9_\!+;_ .9*@#W*BO#?[!^/'_0Z^&?_  $M
MO_F2H_L'X\?]#KX9_P# 2V_^9*@#W*BO#?[!^/'_ $.OAG_P$MO_ )DJ/[!^
M/'_0Z^&?_ 2V_P#F2H ]RHKPW^P?CQ_T.OAG_P !+;_YDJ/[!^/'_0Z^&?\
MP$MO_F2H ]RHKPW^P?CQ_P!#KX9_\!+;_P"9*C^P?CQ_T.OAG_P$MO\ YDJ
M/<J*\-_L'X\?]#KX9_\  2V_^9*C^P?CQ_T.OAG_ ,!+;_YDJ /<J*\-_L'X
M\?\ 0Z^&?_ 2V_\ F2H_L'X\?]#KX9_\!+;_ .9*@#W*BO#?[!^/'_0Z^&?_
M  $MO_F2H_L'X\?]#KX9_P# 2V_^9*@#W*BO#?[!^/'_ $.OAG_P$MO_ )DJ
M/[!^/'_0Z^&?_ 2V_P#F2H ]RHKPW^P?CQ_T.OAG_P !+;_YDJ/[!^/'_0Z^
M&?\ P$MO_F2H ]RHKPW^P?CQ_P!#KX9_\!+;_P"9*C^P?CQ_T.OAG_P$MO\
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MZ[C3[S3-?\')K-Q-#:Z/+KEK<6>HV%]=/%:#7/#^C07MWI]C/=7]O\1^"O\
M@I=_P4L\+?#NR^&WC+_@F#\=O&_QRT32X?"R?$]/#_CZQ^'GB+7[>W-E;^+=
M?M=-^'%UHIA:5;>^UE-$\?6VAZQ.;V6PUCPU9S0QV?\ 0]10!^/_ /P2J_8C
M^*_P B^,7[1O[3EW!=_M,_M,:\_B'Q=IL-S9WI\'Z/=:I?>([K3+RZTMWTEM
M=U_7]4FU'6K/2I;K2-)MM-T'3-.G#6UZK?L!110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'AOQ__ .1-TS_L9K/_ --6LT4?'_\ Y$W3/^QFL_\
MTU:S10 ? #_D3=3_ .QFO/\ TU:-7N5>&_ #_D3=3_[&:\_]-6C5[E0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!X;\?_P#D3=,_[&:S_P#35K-%'Q__ .1-
MTS_L9K/_ --6LT4 'P _Y$W4_P#L9KS_ --6C5[E7AOP _Y$W4_^QFO/_35H
MU>Y4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >&_'_\ Y$W3/^QFL_\ TU:S
M11\?_P#D3=,_[&:S_P#35K-% !\ /^1-U/\ [&:\_P#35HU>Y5X;\ /^1-U/
M_L9KS_TU:-7N5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'AOQ__ .1-TS_L
M9K/_ --6LT4?'_\ Y$W3/^QFL_\ TU:S10 ? #_D3=3_ .QFO/\ TU:-7N5>
M&_ #_D3=3_[&:\_]-6C5[E0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?(?[8GQ#U'PC
MX$TWPSI,S6UWX[N-0L;RY0D2KH6FPVK:K;PL"-CWSZA8VDS'<&LI;N';F4.G
MT'X\^(_@[X;:2VK^+M8@TZ)@XL[-?W^IZE*HSY&G6$>;BY<DJKR!5MK?>KW4
M\$69!^4GQ[^-\_QGUG2I8M%BT71/#JZC%H\<DC3ZK<+J361N9]3F5_LJL_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK$LMM:Q11;BSE3(SNW;?"[X(^.OBQ=@:!8?9-$BE\N^\2ZFLD&D6NTCS(H9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG6Q6)IRY$@         &  .  !P !P .E+117^DB22LE9+1);)=C^?PHHHH
M**** "BBB@ HHHH **^?OC?^U=^S7^S98'4/CO\ ''X:?"X& W-MIOBOQ7I=
MEXBU*$*7)T;PLD\WB77'VJS"+1])OI64$A"!7X _MJ_\'(/P/\/>"/$_@_\
M8JTGQ3\0OB?J4%QI>B?%7Q=X8;PS\-_"J7$<D3>)]+T+Q$T7BWQ7K-E]_2]%
MUWPOX>T47,D%_J=WJ5K:3Z#J7O91PQGN>5*<,NRW$U:=248O%3I3I8.FF[.=
M3%3BJ245>3C&4JC2?)"<M'X>:\29)DM.I+,,QPU*I3BY+"QJPJ8RHTKJ-/#0
MDZK<G:*<HQ@FTYSC&\E]>?\ !7/_ (*]^%/V$_#5Q\)/A%<:+XQ_:K\3Z9'-
M9:7<"/4M"^$6BZA$'MO%WC:U1]ESKEY XG\)>#YG1[U6BU_74CT%;&S\1_,?
M_!(#_@M_+^TAK&G_ +-O[8FO:)IGQQU6\,'PR^*::?H_A;P_\5)[E\Q>#=>T
MW2+;3?#_ (>\?B1C'X<?2['3=$\7P&+1K>RL/%$%E%XK_BQ\8>,/%/Q!\4^(
M/''CCQ!J_BOQAXKU>^U[Q)XDUZ^GU+6-;UC4IWN;[4=1OKEY)[FZN9Y&>21V
M/4*H5%51@0S36\T5Q;RR07$$B303PR-%-#-$P>*6*5"KQR1NJNDB,&1@&4@@
M&OWZAX79##()976BJF8U$JL\Y4%]9IXI1T=%-^[@XOW7A7+EJPO*<E7Y:L/P
MJOXEYY//8YG1DZ>7TVZ4,H<W]7J85RO)5FEKBY)<RQ2CS4I^["/L>:E/_7,H
MK^<;_@A)_P %3O'O[6NFZK^RQ\=X=7\2_%SX5^!'\6>'?BUY<EW_ ,)OX T?
M5=#\.S6GC^X&6B\<:-=Z]I$,'B*3<GC+3I)9]6:+Q+I]U?\ B?\ HYK^><\R
M7&\/YEB,LQ\8JO0:<9TWS4JU&:O2KTI:-PJ1U2DHS@[PG&,XRBOWS)<XP>>Y
M=0S+ RDZ-9-2A-<M2C5AI5HU%MSTY:-Q;A)6G"4H2BV4445Y)ZH4444 %%%%
M !1110 4444 >&_'_P#Y$W3/^QFL_P#TU:S11\?_ /D3=,_[&:S_ /35K-%
M!\ /^1-U/_L9KS_TU:-7N5>&_ #_ )$W4_\ L9KS_P!-6C5[E0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445POCWXD^#OA
MKI)U?Q=K$&GQN'^QV28GU34Y4 )@T[3T/GW+Y**\N$M;<NCW=Q;Q'S!X^?\
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M>?\ IJT:O<J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#WU]IF>+GB\2HNU_9T:4JW)HE^[J5*%DDK*R1_G^? 7]BK]K#]I^XAB^ WP
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MDFFWSDJA"/)$-N0=QWY'H:Z&F21QRKLEC21,@[9$5UR.AVL",CL<<4 >-?\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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MYY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $4 >0_\
M"]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\G5Z]]ALO^?.U_P# >+_X
MBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P# "W_^3J/^%[^"/^>6N?\
M@!;_ /R=7KWV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !% 'D/_  O?P1_S
MRUS_ , +?_Y.H_X7OX(_YY:Y_P" %O\ _)U>O?8;+_GSM?\ P'B_^(H^PV7_
M #YVO_@/%_\ $4 >0_\ "]_!'_/+7/\ P M__DZC_A>_@C_GEKG_ ( 6_P#\
MG5Z]]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 10!Y#_P +W\$?\\M<_P#
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M?P1_SRUS_P  +?\ ^3J/^%[^"/\ GEKG_@!;_P#R=7KWV&R_Y\[7_P !XO\
MXBC[#9?\^=K_ . \7_Q% 'D/_"]_!'_/+7/_   M_P#Y.H_X7OX(_P">6N?^
M %O_ /)U>O?8;+_GSM?_  'B_P#B*/L-E_SYVO\ X#Q?_$4 >0_\+W\$?\\M
M<_\  "W_ /DZC_A>_@C_ )Y:Y_X 6_\ \G5Z]]ALO^?.U_\  >+_ .(H^PV7
M_/G:_P#@/%_\10!Y#_PO?P1_SRUS_P  +?\ ^3J]AMKA+NVM[J(,([F"*XC#
M@!PDT:R(& ) ;:PW $@'(!/6F?8;+_GSM?\ P'B_^(JR         !@ #@
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MFZM82K)%'+#>:;?V=[;31QS6]Q%*BN/SO_X<J_\ !,S_ *-J_P#,R?'_ /\
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M ]U?7<LUW>33W4TLK]A110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSB^THS2DOF@HHHKH,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOYLO^"P/_
M  6W_P"&8]1U#]F[]D77-$U;X^V-P(?B-\2GL-*\3^'_ (0M$P9O"^E:;JEO
MJ&@^(/B)(P5=8AU2SU'1/"-OOT_4+&_\0W%Q:>'O7R3(\QX@Q]/+\MH^TK33
ME.I-N-##TDTI5L1449>SI1NE=1E.4G&%.$ZDHQ?DYSG67Y#@:F/S&K[.E!J,
M(02E7KU7\-&A3<H^TJ2LW;FC&,5*=24(1E)?TFT5_/S_ ,$QO^"X_P '/VC?
MAG?>%_VN/'_P\^!_QU^'FD?;-<\2^+-;T7P+\/OBEH-L4A_X2?PY>:O=V6E:
M5XLB9XD\1>!X9P]Q,XUKPE;S:5-J&C^%^D_:!_X.(?V!?A&+W3?AM?>//VBO
M$EN9(8HOA]X<G\/^$4O(]^8[[QAX['A_S+,E JZCX8T3Q7;R&2-H1-'YCQ^A
M4X,XFAF-?+(Y/C*^(H34)SH49SPKC)7A5CBY*.'5*I&TH3G.'6,E&<91CPT^
M+^&YY?1S*6;82CAZ\.:,*U6$,2I+XZ4L*G*NZM-^[.,(3UM*+E"492_>*LS6
M=:T;P[I=]KGB#5M,T+1=,@:ZU+6-9O[72]+T^U0@/<WVH7LL%I:0(2 TT\T<
M:DC+#(K^&G]H+_@Y-_;+^(YOM-^!O@[X;_L[Z'.THL]2AL1\4OB!;1.2JK)K
MWB^R@\&2$1\[HOAQ!,LI+I. %"_B7\:OVG/VA_VC=5.L?'7XT_$GXJ72S_:+
M6W\9>+=8U?2-+DVLNW0] FNO["T&$!Y"+;1=-L+</+,XB#S2L_VF5^$.=XGE
MGFF,PF64W9RI0OCL5'JTXTY4\,K[*4<54L]>5I6?QV9^+&2X;FAEF$Q>935[
M5)VP6&?9J52-3$/NXRPT-++FNW;^_?\ :#_X+;_\$Z?V?#>V%U\;[;XN^)[,
M2_\ %+? G3_^%D3SO$2CPIXLM;FP^&\$ZRCRVM[WQO:W"MDF+:KLOX<_M!?\
M'//Q/UH7FE?LQ_L]^%? MHWFPP>,/B_K-[XWUV2*082[M/"7AF3PSHFB7T).
M4CO]?\8V3, TL$B$Q5_+=HVBZSXCU2QT/P]I.IZ[K6ISK:Z;H^C6%UJFJ:A<
MN"4M['3[&*>[NYV )6&"&21@"0IP:_53]G[_ ((C?\%&/V@?L5];? ^Y^$/A
MF\:,'Q1\=]0'PWAMTDY667PE=6U_\2983'F19K3P1<P,FW$NYXPWW%'@+@3A
MNG'$9SB*>(FES*IF^-IT:3DM_986DZ$*J>RIU(XEMNVKL?%U>.>-^(:DJ&3X
M>="+?*Z>58.=:K&+V=7$U57E2:ZU(/#I+5V5SYT_:!_X*/\ [<'[3XOK7XQ_
MM(?$?7/#^H,_VGP5H.J1^!O <D3 K'!<>"_!$'A[PYJ"V\3&&&?5-.OKPHTC
M374LTT\LOQ'7]EW[/W_!L-\+M%^Q:K^TW^T)XL\=7:^5/<>$/A#HUCX(T&.5
M-IDLKKQ9XEC\3ZYK=A*0P>6QT+P??>6P$4L+CS#^X_[/W_!.#]A_]F#[%=?!
MS]F_X<:'X@T\1FV\:Z]I3^.O'L4R_-)/;>-O'$_B'Q+IS7$O[Z:WTK4K"RWK
M$L5K%#;V\4.>*\3>$<EI/"Y'@IXN,/@IX#"T\NP*DDE9SJ4Z<UVYJ>%J)I73
M:LWIA?#?BO.*JQ&=8R&%<K<U3&XJ>88VSUTA3G4@]-7&IBJ;3T:3O;_/U_9]
M_P""9W[=7[3OV"Z^$O[-WQ#OO#NH^6]OXV\5Z=#\/? TMJV&DO+3Q9XZG\/:
M-J\,$9\V2'0KG5+Z08CMK2>XDBA?]QOV??\ @V#^(&JBQU;]I_\ :(\.^$;=
MC'-=^"_@SHEWXLUB2&3YFM9O&_BV'P_I.CW\*X64VGA#Q78F7<(;F>)%FE_K
MC\??$OP9\--*.J^+M9@L%=7^Q6$?^D:MJ<B#_4Z=I\9\^<[MJ/.PCL[=G1KN
MYMXVWU^9GQ?_ &H_&7Q&^U:-H)F\(^$9=\365G.?[8U6!LJ1J^I1%2L,J9WZ
M;8^5;;)'@NI=154D'\)_2?\ VCO GT?<%B,'FF8X3&<:5</[3+. .&9X?,.)
M:BJPYJ%;.L9BO:X+AS+JG-"2QN.PU+%UJ+J5<JP&95*4Z2_H?PO^BMB.,JU*
MO&CBJN5PJ<N)SO-'4PF51<&E..#PV&Y,1CZ\;-.A3Q%6C&7+#%5L/&2D_FOP
M[^P!_P $NOV.MEEX$^ ^B_M"?%+3V5'\3_&O4C\3].T^[MV'ES:GI=[%;_#U
M-1M9@95A\->#+&\2=&CN]0L)(;=4V_$_C'7O%T]L^K7,*6>G0_9-&T33;2VT
MKP_H-@N!'I^AZ)81P:=IEI&H5?+MH$>4J)+B2:8M(V'I^GW^JWMMINF65UJ.
MH7LJP6EC96\MU=W4[G"106\"O++(W9$1F/)Q@&OO/X0?L<2S_9=>^+$C00G9
M-!X-T^Y(GD4@D+KNIVSC[.#P6L=+F:;!7S=0MY%EMJ_PDXK\3/IB_M(^,ZF0
MY>LQ_P!2,%CJ=2>28;&X_+_#?A2FYJ6'QG%6<U_:/.,UITDJU&%>.-S"I*&(
MGPYD6%I3JX9?WCDO"GA!]';)HXI4<%0S:M1E%8M87#U,_P TDE:I2R["4E'Z
MMAY2]R<HRIT4G3688ZK-1J/Y.^&WPA\<?%34/LGA?2V:RAD6/4-=OM]MHFFY
MVDBYO?+?S9]K*ZV5I'<WKH?,6W\H/(OZ=_"+]F[P/\+5M]3EB7Q/XN0*S>(-
M2MXPEC+U/]AZ>S31:;CH+HR7&HL#(!>1PR&W7W;2=(TO0M/M=)T73[/2M,LH
MA#:6%A;Q6MK;QCG;'#"J(N22SMC<[EG<L[%CHU_J)]&;Z 7A3X"K <39_3H>
M(_B905.O'B/.,'!9-D&+24FN%<BJRK4<+5H325+.L>\7F[G!UL'4RJG7J8-?
MSOXA^-_$W&KKY?@93R#AZ?-!X#"5G];QU)NU\SQL5"=2,U?FPE!4L+:7)5CB
M90C591117]Z'XH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!X;\?_\ D3=,_P"QFL__ $U:S11\?_\ D3=,_P"QFL__
M $U:S10 ? #_ )$W4_\ L9KS_P!-6C5[E7AOP _Y$W4_^QFO/_35HU>Y4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !114<TT-O#+<7$L<%O!')-//-
M(L4,,,2EY9997*I''&BL\DCL%1068@ FC?8"2BOCWXI?\%!?V(/@M]JB^)/[
M57P-\/ZA9QO)<Z#!\0M \0>*8D0$DGPGX9N]9\3,7P5B5-)9IG5DA#NK*/S?
M^*/_  <7_P#!.KP(9H?!VI?&#XT7"JX@D\!?#:YT/37F'"K-=?%/4_A[>10%
MOO3V^F7C! 6CAF.U6]O!<-Y_F-G@LFS*O&6U2.$K1H_.O.$:*^<T>-C.(LBR
M^ZQF;Y=0E&]Z<L71=;3>U&$Y57;K:#L?O%17\?GQ1_X.CO$<XGM?@K^R9HFF
M%0_V;7/BC\2+_71*2,(9_"OA/P_X=-N(R,N(_&5SYH;:##LW/^;_ ,4_^#@7
M_@I5\2!=0Z+\2? WP?L;MF\VQ^%GPU\/0E(6#?Z/:ZOX_7Q_XCLE4E66XM-:
M@OP8U4W91IDE^LP7A7Q;BK.M0P>7Q?7%XR$FEWY<&L7).VT9<KZ/E/E<9XG<
M*X6ZHUL9CY+2V$PDXIO_ !8MX6+5]Y1YE;6/-I?_ $(Z^;?BG^V/^R=\$?M<
M?Q:_:1^"7@"^LE=I]%\1_$KPG9>(SL#%H[;PS_:C^(;V<!&Q;V6F7$[%2%C)
MXK_-/^*G[8/[5GQO^V1_%S]HWXU_$&RO\_:-&\3?$GQ9J/AT(QR8;?PU)JH\
M/V5N6RWV:STV"WWEF\O<Q)^<:^MP7@SM+,<\[<U+!8/TO;$5ZOJE?#=GY'RV
M,\7]XX#)?\-7&8O\Z%&EZ;8CR\S_ $'OBE_P<$_\$U?AR;B'0_B+X^^,-[:A
MQ+9?"WX9Z^X:5<_N;?5/B&?A[H%X6&"MQ9ZO/9G<!]JW!POYP?%#_@Z.T*'S
MK7X+?LEZOJ&XR_9]=^*'Q*L]'\H  0F;PIX3\.ZY]H,A):4)XSMO)$8C0SF;
MS(/Y-?!'PU^(OQ,U/^Q?AOX!\:_$'6,H/[)\$>%==\5ZGF0X0?8-!L+^ZRYX
M0>5\QX&37Z%?"S_@C-_P4K^+1M)='_99\:^$]/NE6634?BG?>'/A8+&%PI$E
MWHWCK6=#\3[@756M+30KJ_0EBUH$BF:/WUX?^'^2I2S7$QFXI.^;9M#"IO=-
M0H2P2DGTBU)/9J77PGQYQWG#<<LP[@I.ULKRJ>):3TUG7CC7'SDG&V]UT^H/
MBE_P<6_\%%O'HN(?!^J_"'X+VTC2+"_P_P#AM;:UJ*0-O5%FO/BEJ7Q#MY+@
M(RF2YM=/L094$D$%L#Y8_-_XI?\ !0']MSXT_:HOB5^U3\<O$6GWI<W6@Q_$
M/Q#H7A:;><MN\)>'+S2/#(')"A=)4(GR(%3Y:_9_X6_\&Q?[5'B%;2Y^+GQW
M^"OPRM+C#3VGA:U\6_$[Q!8)T*75E-I_@+09+D$%O+LO%%W;F,QG[6)&>*+]
M'_A;_P &R'[)GAS[-<_%CXV?&WXH7T#1M+:^'AX3^&OAR\VE3)'<Z>-)\9^(
M$BDPR@6?BRTF16.)BP#A_P"LWACD6F"I9=.M#9X#*Y8BL[;?[9.@HSU6E\4]
M==G</]7/$G._]\JYA"C+=8_,E0HJ]K_[)"LY1TWMAEM;5Z'\0TLLL\LD\\DD
MTTTCRS32NTDLLLC%Y)))')=Y'<EG=B69B68DDFM?P_X:\1^+=3AT7PKX?UOQ
M-K-P";?2?#^E7^LZG. R(3#8:;!<W4H#R1H2D3#<Z+U90?\ 2"^%W_!'+_@F
MK\)1"^A?LH_#[Q+>1F-Y;WXHRZ_\6C=2QA1YLVG?$;6/$NAQ!]H\RWLM*M+)
MCN_T8;GW?H-X/\ ^!/AYIO\ 8W@#P5X2\#:0?+SI7@_PYH_AG3?W*E(?]!T6
MSLK7]TC,L?[KY%8JN 2*\S&^,N70NLOR;&8CI&6+KT<(O7EHK&-KLN:+>FJZ
M>C@_"''SL\?G&$P_5QPE"MBWYKFK2P:3\^623Z.VO^;5\+?^"3O_  49^,'V
M9_"/[(_Q;T^UNECEAO\ XA:19_"6PDMI0K)=Q7?Q2O\ P?%<6SQ,)HI;4S_:
M(B'MA,&3=^C_ ,+/^#:/]MCQ9]EN_B9\1/@;\)=/E*_:K,Z[XB\>>*K0$$DC
M3/#_ (?M_#-P5.!A/&JY).#@ G^Z.BODL;XN\2XB\<)0RW 1=[2A0J8BLO6>
M(JRI.W3]PO.Y]5@_"GAVA:6*KYCCI+XHSK4Z%%[;0H4HU5?5/]^]'I9ZG\NG
MPX_X->/@-IMICXN?M/\ Q<\97YBD.[X=>%/!WPVLHIF1O*!B\2CXJSW$,,I3
MS2)[22ZC1@GV)Y 8OYI?V_?V OC)_P $_?C)=?#CXCVKZWX/UM[W4?A;\4M.
MLIK?PW\0_#=O,BF> ,\ZZ3XFTE9[:W\5>%;BYFO-%O)H)H9]1T/4=%UK5/\
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MO$W0:1GJ%TW?=Q-]S4V4E:^2=2U/4M9OKC4]7O[S5-1NY#+=7^H7,UY>7,A
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MYJN SB%6_?EP^(R^CRVU:3Q,K[76Y^$2.\3K)&[1R(P='1BCHZG*LK*0RLI
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MWL\7AJV'G=;KEK0A*Z]!]%%%>P<@4444 %%%% !1110 4444 %%%% !1110
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MJUI\E&E"\ZDX03DO7+BX@M()KJZGAMK:WB>:XN+B1(8((8E+R3332,L<44:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#?C_\
M\B;IG_8S6?\ Z:M9HH^/_P#R)NF?]C-9_P#IJUFB@ ^ '_(FZG_V,UY_Z:M&
MKW*O#?@!_P B;J?_ &,UY_Z:M&KW*@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN:\5^-/!W@329M>\
M<>+/#7@W0[<,9]:\5Z[I?AW28 HW,9M1U>ZL[.,*OS,7F7 Y/%5&,IR481E*
M4G:,8IRDV]DDKMM]DA2E&*<I248Q3;E)I));MMV22ZMG2T5^;OQ3_P""O/\
MP3=^$!N8O$W[6?PSUN\ME;-C\-)]7^+<\LX+*+59OAEI7BNPAN#(AB<7=Y;1
M6[D&[EMX\N/S?^*/_!S/^QUX8,UK\+OA+\<OBG?1%]E[J-CX5^'GAFY'2/R-
M0O\ 7M?\1@L0QD%SX/MA&IC*&5FD2+Z#!<)<39A9X7(\QG&5N6I4P\\-1=^U
M;$JC2:[OGLNIX&,XJX<P%UBLZR^$H_%3IXB&(JKUHX=U:J?ER79_2%17\3GQ
M1_X.>_VF->$\/P@_9Y^#7PV@F9PEQXTUCQ=\4M6M82/D-M<Z=<?#32C=(<9F
MN]#NK=E+#[$K%77\W_BG_P %J/\ @I=\6/M4&I_M.^)_!NF7$CM#I?PMT3PK
M\-?L*,<^3:Z]X2T33?%SQKT1K[Q'>3@<><:^MP7A+Q1B;/$RR_+XZ<RKXIUJ
MJ77ECA*>(IR:[.M%?WCY;&>*?#.'YEAEC\?)7Y70PRHTV^EY8NI0J13[JE)_
MW3_1RU;5])T'3[K5M<U33M&TJRC\V\U/5KVVT[3[2+('F75[>2PVT$>2!OEE
M1<D#.2*^'OBE_P %0?\ @GQ\&S<Q^.OVN/@NEW9+(UYI?A#Q0GQ,UNT:(,7@
MN="^&D'B[68+O"Y6REL4NY T9C@82Q[_ /-?\>_%?XI?%74#J_Q0^)7C_P")
M&JM(9FU/Q[XQ\1>,-0,S+L:4WOB'4=1N3(4^0N9=Q7Y2<<5P-?6X+P9PL;/,
M<[Q%7;FIX+"T\/;NE5KU,3S>4G1C_A/E<9XOXF5U@,FH4OY9XS$U*]_-TJ,,
M/R^BK2_Q']WWQ1_X.3?V#O!QFMOA]X9^./Q@O0)/L]WHO@_2?"'AR0H2%^T7
M_C?Q#H_B&W$IVM&8O"5T0A8RB)U6-_S>^*/_  =$_&'4A-#\%_V6OAOX.P9$
M@O\ XF^-O$WQ&>5?F$<[Z9X7L?A>EK(?E=K?^U+Y$(*>?*/F/\\?PL_9/_:>
M^-YMF^$'[/?QG^)%M=JLD6I^#_AMXMUO1%A?:%N;G7;+29=&L[0EXU%W>7T%
MMNDC7S=TB!OT?^%G_! ;_@I;\2C9S:K\*/"?PDTR] :+4_BG\1_#%B(HR,^9
M>:'X-N?&WBVQ(.5,%WX=AN@1DV^PJ[>Q_J?X;9%KF-;"3JP_Z&>;?O6TM5]6
MI5J$*CZN/U>3[)'D_P"MOB)G>F7T<5&G/_H6Y5>FD]G]9JTJ\Z:[2]O'?5LY
MSXI?\%V/^"F/Q/\ M-O%\>+7X;:3<M(QTGX6^!O!_ACR=Y;:MMXBN])UCQK
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MGP_\86D:$AIV\/:I+:94LIQ>06TMJWW2?EF.5VN,HRL>$G@GMI7@N89;>9"
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MUFBCX_\ _(FZ9_V,UG_Z:M9HH /@!_R)NI_]C->?^FK1J]RKPWX ?\B;J?\
MV,UY_P"FK1J]RH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_=6J/A*O!O''#%26(RBK6KTT^9U,HQ$W*:6RK8&?)4K/36$:.(@K;O0_5O\
M9L_X.1OV/?B@;#1OCYX1\=?LW^([@I'/JTT,OQ.^&ZRMMC3'B+PMIEKXOM6F
ME)9OMOP_CTZRA(>YU@HDDJ_NI\)OCC\&_CSX<3Q=\%OBEX"^*?AMEB\S5O G
MBG1O$UM9R3!REKJ0TJ[N9=*OU,<J3:?J4=I?6\L4T,]O'+%(B_Y=OQJ_9O\
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MBOV,^3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ)SCBBKAU*+>7\&X3*X.25G^\S/.,0I.$G[LZ=++:=103<,0IR7)_$5\*/\
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M?#O(Z5*]XTO[(P.*X%GFE.G%<L/[7IYGC:BYE.I6J3DY?W!P+1^B3PUAXX?
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M8'!VZX;"T*,GYN5.$9-]VVV^K"BBBO..\**** "BBB@ HHHH **** "BBB@
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MB#'%J_A/2+2:9T@-_%LN9+;^]CX,_LX? +]G;1O[!^!GP=^'/PJTYX$M[O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%E5.SQV:8[%-6;CAZ=#!P;TNFIK%SY7K\,XRMLTS^,3X6_\ !KQ\:M4%K/\
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M<W?SN?48; X+!1Y,'@\+A(6MRX;#TJ$;+9<M*$%;RL%%%%<AU!1110 4444
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MP\WYSI-ZO75GCYGD&39S%QS++L-BI6LJTJ?)B(K:T,32<,1!;:1J):*ZT/\
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MLD$\$\;Q3031.8Y89HI KQRQNK))&ZJZ.I5@""*^@_A%^UC^T-\#6MXOAO\
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MKXG\731?"WP'(S<17MG%=6VN^-]3ABYDDL=1\,>%)9L+$E[#O::+\(_VA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \-^/_\ R)NF?]C-9_\ IJUFBCX__P#(FZ9_
MV,UG_P"FK6:* #X ?\B;J?\ V,UY_P"FK1J]RKPWX ?\B;J?_8S7G_IJT:O<
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG[1WPI\#:M8&07?A:Y\4V>L^-XS$<2A? ?APZQXSF,;81Q!H4A5R$/SD*?\
M/!^.7_!2C]NS]HPW<'Q6_:>^*>J:/?>8MUX5\.:Y_P *_P#!=Q$Y)6&Z\'^
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M:W6MK?;9=X6<.83EEC)XS,ZBLVJU7ZO0;7:EAO9U4K[J>(FGL]+W_%3X&_\
M! 3_ ()S?!S[%>^(/A]XL^.NOV?ERC5?C%XPO-1L/M(^:5AX1\'P>#O"%W:.
MQ*Q6>N:)K8BA"+)-<3J]S)^M7PZ^$WPL^#^B+X:^$_PV\!_#+P\HC T3P!X1
MT#P?I1\E2D;/8>']/T^VDD120))(VD^9B6)9B?0:*^"S#.LWS63EF698W&ZW
M4,1B*M2E%_W*+E[*FNRA"*78^YP&3Y5E<>7+LNP>#TLY4,/3A4DO[]51]K4=
MM+SG)VTN?@=^W%_P0-^ O[7/Q^T7XZ>$/'5Y\!YO$6M1WWQV\,^%_"EEJUC\
M1 ;A;B_\1^&&EU73K+P1XZUF-9K36]5ETOQ#HVJWEU#XGN]#?6K?6/\ A*?V
MA^#'P8^&7[/?PR\)?!_X/^$M,\$_#WP3ID>EZ#H.EQL$C0,TMU?7]U*TEWJN
MLZK=R3ZCK6LZC/<ZGJ^IW-UJ&H7-Q=W$LK>H45ICL^S?,L%@LOQV/KXC!Y?%
MQPM";7+35K1<W%*5:5./[NE*M*I*E3O3IN,&XN,'DF4Y?C,9C\%@:&'Q>/DI
M8JM3B^:>S:BFW&E&<E[2K&C&G&K4_>5%*:4D4445Y!ZH4444 %%%% !1110
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M4LF^]O\ P]=KI/C'0+,(9/\ 1M+7QW=AHTPS"9O(_?7X!_M??LQ?M1:8NJ?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /#?C__ ,B;IG_8S6?_ *:M9HH^/_\
MR)NF?]C-9_\ IJUFB@ ^ '_(FZG_ -C->?\ IJT:O<J\-^ '_(FZG_V,UY_Z
M:M&KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_\ (-'_  N;X9?]#9:?^ >J?_(-']F9E_T+L=_X28C_ .5A_:67?]!^"_\
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M._\ "3$?_*P_M++O^@_!?^%5#_Y8>GT5YA_PN;X9?]#9:?\ @'JG_P @T?\
M"YOAE_T-EI_X!ZI_\@T?V9F7_0NQW_A)B/\ Y6']I9=_T'X+_P *J'_RP]/H
MKS#_ (7-\,O^ALM/_ /5/_D&C_A<WPR_Z&RT_P# /5/_ )!H_LS,O^A=CO\
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MO$4_OK*Y:*[@<-'/#'(C*/S'-,@SG)9\F:9;B\'K95*E)NA-]J>)I\^'J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /#?C_\ \B;IG_8S6?\ Z:M9HH^/_P#R
M)NF?]C-9_P#IJUFB@ ^ '_(FZG_V,UY_Z:M&KW*O#?@!_P B;J?_ &,UY_Z:
MM&KW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWL1+\7?[O+N .%<NY91RR&+JQM^]S"4L6Y6ZNC4_V5/K>-"/W6/%OA#^SA\
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MV^4X_=W.JWTL0QD +"TYB0<GA4 R6.,DD\[7J4>!GH\1F"7>-'#M_=.=5?\
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MC_SY6G_@-#_\11_KU#_H62_\*U_\S!_J3/\ Z&4?_"5__-!^45%?J[]@L?\
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M7_S,'^I,_P#H91_\)7_\T'Y145^KOV"Q_P"?*T_\!H?_ (BC[!8_\^5I_P"
MT/\ \11_KU#_ *%DO_"M?_,P?ZDS_P"AE'_PE?\ \T'Y145^KOV"Q_Y\K3_P
M&A_^(H^P6/\ SY6G_@-#_P#$4?Z]0_Z%DO\ PK7_ ,S!_J3/_H91_P#"5_\
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M -0DZ'_N&G;?^K!]6XPH_:Q[M_U%4Z_;_I]4O_P_F6K?]ISQ$I'VKPUHLPW
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MT!]G\7>&9B0&VIKNF&0!N!NC^U;T)/&&4'/&,URSP.-I_P 3!XJ'^/#U8_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<!R3DEP&/(!KF69F9F9BS,2S,Q)9F)R68G)))))).2>37Y1G'[7[ P<H</\
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MG_2]#QFW^//Q/A(\S7H+H J=MQH^C@87JI-O8V[D-_$2V_T8&MNW_:.^(,
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M()^RZE<G#'Y1@$Y^\%7YJ^4+CX7_ !#M@3)X.UYL!C_H]C+=G"]<"U$Q)/\
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M+(S8'0;F9L#EB<FOG_\ 6_)9?%0Q6FW-AZ#^ZU=GN_ZIYS'X:^%U_EQ%9?\
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M1@4U#Q3" ,;(M0TPJ3DG<3-HTK9.0#A@N ,*#DD_UGX>EHZ,[?WL'3:_!O\
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M]7_[^Q__ !JC_A;'Q'_Z&_5_^_L?_P :KZ'_ .&8M"_Z&C5O_ .S_P#BJ/\
MAF+0O^AHU;_P#L__ (JC^W.%/^?6'_\ #:__ )0']B\4_P#/[$?^''_[MY+[
MCYX_X6Q\1_\ H;]7_P"_L?\ \:H_X6Q\1_\ H;]7_P"_L?\ \:KZ'_X9BT+_
M *&C5O\ P#L__BJ/^&8M"_Z&C5O_  #L_P#XJC^W.%/^?6'_ /#:_P#Y0']B
M\4_\_L1_X<?_ +MY+[CYX_X6Q\1_^AOU?_O['_\ &J>GQ;^)$;JZ^+M5)4Y
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M1_:_"'_/K!_^&N7_ ,RA_9/%G_/W%_\ ASC_ /-)X?\ \+F^)O\ T-EW_P"
M>E__ "#2CXS_ !.!!'BNZR"",V6E,,@YY5K J1Z@@@C@@BO;_P#AE^Q_Z'&[
M_P#!-#_\L:0_LOV6#M\8W0;!P3HL) .."0-24D ]0&!(XR.M']K\(?\ /K!_
M^&N7_P RA_9/%G_/W%_^'./_ ,TGC?\ PO/XI_\ 0T_^43PY_P#*BC_A>?Q3
M_P"AI_\ *)X<_P#E17K7_#+G_4\_^6S_ /A#1_PRY_U//_EL_P#X0T?VGP9_
MS[R__P --3_YB#^S>+_^?F/_ /#K#_YL/)?^%Y_%/_H:?_*)X<_^5%'_  O/
MXI_]#3_Y1/#G_P J*]:_X9<_ZGG_ ,MG_P#"&C_AES_J>?\ RV?_ ,(:/[3X
M,_Y]Y?\ ^&FI_P#,0?V;Q?\ \_,?_P"'6'_S8>2_\+S^*?\ T-/_ )1/#G_R
MHH_X7G\4_P#H:?\ RB>'/_E17K7_  RY_P!3S_Y;/_X0T?\ #+G_ %//_EL_
M_A#1_:?!G_/O+_\ PTU/_F(/[-XO_P"?F/\ _#K#_P";#R\?'OXG  '6K4D
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M^)O_ $*=W_X&:7_\G5]S_:>6_P#0QP/_ (5X?_Y8?%?V;F/_ $ 8W_PEK_\
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M\NUP#V!MTB88['.>^<Y-9)DU#4I1&7O+^9LL$+3W4K;1EB%)D<X4$D@< 9/
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MPH4J:DUS3YI-R91117Z8?/!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*+T?_H9O$W_@3:__ "-1_P *+T?_ *&;Q-_X$VO_ ,C5[E10!X;_ ,*+T?\
MZ&;Q-_X$VO\ \C4?\*+T?_H9O$W_ ($VO_R-7N5% 'AO_"B]'_Z&;Q-_X$VO
M_P C4?\ "B]'_P"AF\3?^!-K_P#(U>Y44 >&_P#"B]'_ .AF\3?^!-K_ /(U
M'_"B]'_Z&;Q-_P"!-K_\C5[E10!X;_PHO1_^AF\3?^!-K_\ (U'_  HO1_\
MH9O$W_@3:_\ R-7N5% 'AO\ PHO1_P#H9O$W_@3:_P#R-1_PHO1_^AF\3?\
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M(X?'4>;RGB(12^TWH_T-_P"%%Z/_ -#-XF_\";7_ .1J/^%%Z/\ ]#-XF_\
M FU_^1J^2-'_ &YO%<&W^W_ WA[4L9W'2-1U+1"1VP+P:^ 0.N<@GIMKU;1_
MVWOA[=%$UOPQXKTAV.#):+IFKVL?&<R2&]T^YVYRH\NSD;)4E0"Q7^B^%_V@
MGT3.*/9TZ?BGA\BQ51Q3PG%&0<29'[+FV]IF&)REY,DG=2<,SFH6O)J+C)_
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M_P#(U'_"B]'_ .AF\3?^!-K_ /(U>Y45^VGQYX;_ ,*+T?\ Z&;Q-_X$VO\
M\C4?\*+T?_H9O$W_ ($VO_R-7N5% 'AO_"B]'_Z&;Q-_X$VO_P C4?\ "B]'
M_P"AF\3?^!-K_P#(U>Y44 >&_P#"B]'_ .AF\3?^!-K_ /(U'_"B]'_Z&;Q-
M_P"!-K_\C5[E10!X;_PHO1_^AF\3?^!-K_\ (U'_  HO1_\ H9O$W_@3:_\
MR-7N5% 'AO\ PHO1_P#H9O$W_@3:_P#R-1_PHO1_^AF\3?\ @3:__(U>Y44
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M10!X;_PHO1_^AF\3?^!-K_\ (U'_  HO1_\ H9O$W_@3:_\ R-7N5% 'AO\
MPHO1_P#H9O$W_@3:_P#R-1_PHO1_^AF\3?\ @3:__(U>Y44 >&_\*+T?_H9O
M$W_@3:__ "-1_P *+T?_ *&;Q-_X$VO_ ,C5[E10!X;_ ,*+T?\ Z&;Q-_X$
MVO\ \C4?\*+T?_H9O$W_ ($VO_R-7N5% 'AO_"B]'_Z&;Q-_X$VO_P C4?\
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M\3?^!-K_ /(U'_"B]'_Z&;Q-_P"!-K_\C5[E10!X;_PHO1_^AF\3?^!-K_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** /#?C_ /\ (FZ9_P!C-9_^FK6:*/C_ /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /#?C_P#\B;IG_8S6?_IJUFBCX_\ _(FZ9_V,UG_Z:M9HH /@!_R)NI_]
MC->?^FK1J]RKPWX ?\B;J?\ V,UY_P"FK1J]RH **** "BBB@ HHHH *_G"_
MX+H^,+S6/B]^PQ^SUX\\6ZIX&_9M^*'Q#34OBYK%C?PZ7:W=E9^-/!7AW5=1
MU"]N<VJQ>!/#'B#4M:@^VK+I]I<ZQ%JEU:W$MC9F'^CVODO]L;]C#X,_MN_"
M]/AI\7K'486TJ^DUKP;XQ\.SP67BKP7KSVSVCW^D75S;W=K<6=[;N+?5]%U*
MUNM,U2&.WDE@BU"PTO4+  \=_P"'4'_!.N^\'P^%H_V8_ ,NCR6$4$&L6FH>
M)T\330-;0Q17B>-[7Q"GBB:XDCBCG%Y_;+M+*\EP69KB9I/IW]GSX$?#O]DS
MX)Z!\'/A]=^(%^'G@$^+=2TN7Q7JW]MZII]CX@\3:]XUU&VEOXK.S\RPTRZU
MN\MM.06OVB/3;>V6[FOK[[3?7/X%>(_V</\ @K#_ ,$Q_"^H>+OV=/CM8_M1
M?L]>!;2?4M0^&/B[2[S4]4T+PII4!GN&@\#:S?WNJ:9HNF6RN\]O\*/B!;7[
MK#-?RZ##9I/Y7Z?_ +,G[;&C_MY_L1?%'XJ^$]!E\&^.]'\)?$?P3XP\(/=2
M:G!H/CFR\%3:A92Z1J3PZ=)JFAZM8ZKI.J:?<-%;2V\EQ=Z//+)=:7/=R@'Y
M2?\ !-GX'>#O^"F_Q_\ VG_VY?VJ/#B?$G0+3QY!X(^%7P\\3O-?>#]#@6$:
MW!IUUIC3B&_MO!7A*Y\*Z3IFDW(FT>[N==US6-6LKW5)X+J/:_X+)_L>?#3]
MEKPG\)/VU?V4/"&B_ OXA?#CXL>']+UV'X::?'X5\/7%OJD&HZEX?\0IX?T9
M+;1M,O-(UW2(=&N$TRTTZWUK3/$L]GJR7D=K9QI]"_\ !NT;+_AB3XBK;NIN
MA^TUXV;4$RV])F^&?P@6 D-C"-:I#L*9B+"0 ^:LP'M?_!=/[)_P[I^)OVAD
M6;_A-/A5]@#.RE[O_A.](WK&H($CBQ^VL48,H17DQN164 _37X+_ !&M/C!\
M'OA3\6;"$6UE\3OAQX(^(%M:J<_9(?&/AK3/$*6AR\A5[4:A]G=&D=T>-D=B
MRDU0^/GQ2MO@A\$/B]\8KNV2^A^%_P -O&OCQ=/D9U34[CPOX>U#6+32RT9#
MH=3N[2"P5E9=K7 8N@!8>,_\$^K"[TW]AG]D6VO01.W[.WPDNPK$EE@U'P5H
M^H6BMNY4K:74"E#CRR-F %Q7'?\ !3]+]_\ @G[^U<NFG%P/A)K3R'!/^@1W
M-E)JHP'C^]I:W@SN(&<E)0#&X!^4?_!(?]BKX9_M-_#[QO\ MQ?M;^$M)^//
MQ.^-'Q-\57.@I\2M/@\2^&;'2= U"33=4U9/#FI_:-&U*[U7Q,NL:4MOJMC>
MZ?HNC>'-(T[1+6PB-X)_)_\ @I'\'/ __!,S]K3]DK]L;]FK0(_ACX3\1>*[
M_0OBAX'\)?:;#PM=6^A76B3Z[966CPRI:65CXZ\$ZOK6FWVAV;VNDP7GAZTU
M6QL8=0EN+D_K!_P1?-D?^":?[-0L75D2#XJB?!8LEZ?C?\2GO$D#X=6%P[E0
M1M,9C:+,)C8_#_\ P<<K;-^S9\!%.&U!OCG.MK&&8RO;'P%XF%WY<0.' G-@
MK-M9D9XU4@2,& .W_P""Z?QC\<_\(+^SO^R)\,=3FT_6_P!K;XBC0=<O-/GF
MCEOO#.E:IX5T;3O#<TEO)&7TOQ1XH\9Z1<7L<4A^VV?AV?3I\V-_<17'VAX+
M_P""3?[!OA/X0VGPDO\ ]GWP)XO!T*TTK6_B%XBT>&X^)NMZG'8?9+WQ''XX
M1E\0^'=0O[AYM0^R^&=0TK2K*X>..RL88+:WCC_,S_@IC87FE?\ !1G_ ()$
MVGB"15TW3_&?PKL=SLY1=>T_XR^ X[]WE#MN1IQHV]GC1 H+3RO$6$7]*- '
M\WG_  1E\0>)_P!G_P#:N_;2_P"">VMZ]J>N>%OAKK7B+QM\.CJDKL+2S\+^
M,K+PEJM_:PLT4%I+XRT3Q3X(UV]LK2U2W^UV%U=PA3+<23_TAU_-]^RI8?:_
M^"_O[:%SI9#66E_"KQ#=ZBZ2.R!YHO@/I]U&S$MF0:S>X:$G:CQ2!%580%_I
M!H **** "BBO-/B)XTU3PL= T[0]/M]0UKQ)>O9Z>EX3]D$D4UC!Y4H6ZLB)
M+B2_B2*1KB.&(JS3';R #TNBO#?[>^/'_0E>&?\ P+MO_FMH_M[X\?\ 0E>&
M?_ NV_\ FMH ]RHKPW^WOCQ_T)7AG_P+MO\ YK:/[>^/'_0E>&?_  +MO_FM
MH ]RHKPW^WOCQ_T)7AG_ ,"[;_YK:/[>^/'_ $)7AG_P+MO_ )K: /<J*\-_
MM[X\?]"5X9_\"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\-_M[X\?]"5X9
M_P# NV_^:VC^WOCQ_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?_ NV_P#F
MMH_M[X\?]"5X9_\  NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH_M[X\?\
M0E>&?_ NV_\ FMH ]RHKPW^WOCQ_T)7AG_P+MO\ YK:/[>^/'_0E>&?_  +M
MO_FMH ]RHKPW^WOCQ_T)7AG_ ,"[;_YK:/[>^/'_ $)7AG_P+MO_ )K: /<J
M*\-_M[X\?]"5X9_\"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\-_M[X\?]
M"5X9_P# NV_^:VC^WOCQ_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?_ NV
M_P#FMH_M[X\?]"5X9_\  NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH_M[X
M\?\ 0E>&?_ NV_\ FMH ]RHKPW^WOCQ_T)7AG_P+MO\ YK:/[>^/'_0E>&?_
M  +MO_FMH ]RHKPW^WOCQ_T)7AG_ ,"[;_YK:/[>^/'_ $)7AG_P+MO_ )K:
M /<J*\-_M[X\?]"5X9_\"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\-_M[
MX\?]"5X9_P# NV_^:VC^WOCQ_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0E>&?
M_ NV_P#FMH_M[X\?]"5X9_\  NV_^:V@#W*BO#?[>^/'_0E>&?\ P+MO_FMH
M_M[X\?\ 0E>&?_ NV_\ FMH ]RHKPW^WOCQ_T)7AG_P+MO\ YK:/[>^/'_0E
M>&?_  +MO_FMH ]RHKPW^WOCQ_T)7AG_ ,"[;_YK:/[>^/'_ $)7AG_P+MO_
M )K: /<J*\-_M[X\?]"5X9_\"[;_ .:VC^WOCQ_T)7AG_P "[;_YK: /<J*\
M-_M[X\?]"5X9_P# NV_^:VC^WOCQ_P!"5X9_\"[;_P":V@#W*BO#?[>^/'_0
ME>&?_ NV_P#FMH_M[X\?]"5X9_\  NV_^:V@#W*BOG'5_B%\7M"N=*L]5\+^
M&;6XUNZ^QZ9'N:?[3<^9!%Y>^V\2S1P_O+J!=]PT4?SYW;5<KN?V]\>/^A*\
M,_\ @7;?_-;0![E17AO]O?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_
M ,UM 'N5%>&_V]\>/^A*\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6T >Y45X;
M_;WQX_Z$KPS_ .!=M_\ -;1_;WQX_P"A*\,_^!=M_P#-;0![E17AO]O?'C_H
M2O#/_@7;?_-;1_;WQX_Z$KPS_P"!=M_\UM 'N5%>&_V]\>/^A*\,_P#@7;?_
M #6T?V]\>/\ H2O#/_@7;?\ S6T >Y45X;_;WQX_Z$KPS_X%VW_S6T?V]\>/
M^A*\,_\ @7;?_-;0![E17AO]O?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X
M%VW_ ,UM 'N5%>&_V]\>/^A*\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6T >Y
M45X;_;WQX_Z$KPS_ .!=M_\ -;1_;WQX_P"A*\,_^!=M_P#-;0![E17AO]O?
M'C_H2O#/_@7;?_-;1_;WQX_Z$KPS_P"!=M_\UM 'N5%>&_V]\>/^A*\,_P#@
M7;?_ #6T?V]\>/\ H2O#/_@7;?\ S6T >Y45X;_;WQX_Z$KPS_X%VW_S6T?V
M]\>/^A*\,_\ @7;?_-;0![E17AO]O?'C_H2O#/\ X%VW_P UM']O?'C_ *$K
MPS_X%VW_ ,UM 'N5%>&_V]\>/^A*\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6
MT >Y45X;_;WQX_Z$KPS_ .!=M_\ -;1_;WQX_P"A*\,_^!=M_P#-;0![E17A
MO]O?'C_H2O#/_@7;?_-;1_;WQX_Z$KPS_P"!=M_\UM 'N5%>&_V]\>/^A*\,
M_P#@7;?_ #6T?V]\>/\ H2O#/_@7;?\ S6T >Y45X;_;WQX_Z$KPS_X%VW_S
M6T?V]\>/^A*\,_\ @7;?_-;0![E17AO]O?'C_H2O#/\ X%VW_P UM']O?'C_
M *$KPS_X%VW_ ,UM 'N5%>&_V]\>/^A*\,_^!=M_\UM']O?'C_H2O#/_ (%V
MW_S6T >Y45X;_;WQX_Z$KPS_ .!=M_\ -;1_;WQX_P"A*\,_^!=M_P#-;0![
ME17AO]O?'C_H2O#/_@7;?_-;1_;WQX_Z$KPS_P"!=M_\UM 'N5%>&_V]\>/^
MA*\,_P#@7;?_ #6T?V]\>/\ H2O#/_@7;?\ S6T >Y45X;_;WQX_Z$KPS_X%
MVW_S6UB:_P#$'XO^%[)-1UWPMX9L;.2X2T2;<USFXDCEE2/R[/Q-<2C<D,K;
MR@0;<%@64$ ^C:*\,7Q!\=V567P7X9*L P/VJW&01D'!\6 C(/?FE_M[X\?]
M"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_ )K:/[>^/'_0E>&?_ NV
M_P#FMH ]RHKPW^WOCQ_T)7AG_P "[;_YK:/[>^/'_0E>&?\ P+MO_FMH ]RH
MKPW^WOCQ_P!"5X9_\"[;_P":VC^WOCQ_T)7AG_P+MO\ YK: /<J*\-_M[X\?
M]"5X9_\  NV_^:VC^WOCQ_T)7AG_ ,"[;_YK: /<J*\-_M[X\?\ 0E>&?_ N
MV_\ FMH_M[X\?]"5X9_\"[;_ .:V@#W*BO#?[>^/'_0E>&?_  +MO_FMH_M[
MX\?]"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_ )K:/[>^/'_0E>&?
M_ NV_P#FMH ]RHKPW^WOCQ_T)7AG_P "[;_YK:/[>^/'_0E>&?\ P+MO_FMH
M ]RHKPW^WOCQ_P!"5X9_\"[;_P":VC^WOCQ_T)7AG_P+MO\ YK: /<J*\-_M
M[X\?]"5X9_\  NV_^:VC^WOCQ_T)7AG_ ,"[;_YK: /<J*\-_M[X\?\ 0E>&
M?_ NV_\ FMH_M[X\?]"5X9_\"[;_ .:V@#W*BO#?[>^/'_0E>&?_  +MO_FM
MH_M[X\?]"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_ )K:/[>^/'_0
ME>&?_ NV_P#FMH ]RHKPW^WOCQ_T)7AG_P "[;_YK:/[>^/'_0E>&?\ P+MO
M_FMH ]RHKPW^WOCQ_P!"5X9_\"[;_P":VC^WOCQ_T)7AG_P+MO\ YK: /<J*
M\-_M[X\?]"5X9_\  NV_^:VC^WOCQ_T)7AG_ ,"[;_YK: /<J*\-_M[X\?\
M0E>&?_ NV_\ FMH_M[X\?]"5X9_\"[;_ .:V@#W*BO#?[>^/'_0E>&?_  +M
MO_FMH_M[X\?]"5X9_P# NV_^:V@#W*BO#?[>^/'_ $)7AG_P+MO_ )K:/[>^
M/'_0E>&?_ NV_P#FMH ]RHKPW^WOCQ_T)7AG_P "[;_YK:/[>^/'_0E>&?\
MP+MO_FMH ]RHKPW^WOCQ_P!"5X9_\"[;_P":VC^WOCQ_T)7AG_P+MO\ YK:
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M&?\ P+MO_FMH_M[X\?\ 0E>&?_ NV_\ FMH ]RHKPW^WOCQ_T)7AG_P+MO\
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MW_;WQX_Z$KPS_P"!=M_\UM 'N5%>&_V]\>/^A*\,_P#@7;?_ #6T?V]\>/\
MH2O#/_@7;?\ S6T >Y45X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\ @7;?
M_-;0![E17AO]O?'C_H2O#/\ X%VW_P UM']O?'C_ *$KPS_X%VW_ ,UM 'N5
M%>&_V]\>/^A*\,_^!=M_\UM']O?'C_H2O#/_ (%VW_S6T >Y45X;_;WQX_Z$
MKPS_ .!=M_\ -;1_;WQX_P"A*\,_^!=M_P#-;0![E17AO]O?'C_H2O#/_@7;
M?_-;1_;WQX_Z$KPS_P"!=M_\UM 'N5%>&_V]\>/^A*\,_P#@7;?_ #6T?V]\
M>/\ H2O#/_@7;?\ S6T >Y45X;_;WQX_Z$KPS_X%VW_S6T?V]\>/^A*\,_\
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M^-^G6=WJ%YX/\,PV=C:W%Y=3?:(I/*MK6)YYY/+B\5/*^R)&;9&CR-C:BLQ
M/JW@_P 0KXJ\.:9KRP&V^WQS[X20=DMK=W%E,5PS8C>6V>2-2S,L;*K,S D@
M'2T444 %%%% !1110 4444 %%%% !1110!X;\?\ _D3=,_[&:S_]-6LT4?'_
M /Y$W3/^QFL__35K-% !\ /^1-U/_L9KS_TU:-7N5>&_ #_D3=3_ .QFO/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \-^/_\ R)NF?]C-9_\
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M=.^SSS>(O"'BEO#4OAS7+AVO;'3Y;W3UN&C734M/T_\ @Y^USX7U#]@WX?\
M[8?Q;U.+2-&3X'Z/X_\ B-?6EO%@Z_IVE1V7B>TT73TD19KK5?%EK>:=X>TE
M)$ENKN\T_3DVSR@  ^UZ*_!CP!^V)_P5B_:ZT2X^,O[*O[.O[/WP]^ MWJ5Z
MWP];XZZKK]QXV^(.F:7>+8RS[]*\4Z-9K9WL\5R?M%OI&BZ=%)%>6.G>*-8:
MS6_N/J7]@;_@H)XC_:6\8?%#]GCX_P#PQB^"/[5OP3W7'C?P/9W;7'A[7]%%
M]#93:]X56ZO]2O[>+2Y[_1XM1M9=3UNPN+/6]!US1/$.JV.KR0Z6 ?J%17YD
M_P#!0G_@H:/V/Y?AY\+/A?\ #RX^-/[37QIN#:?#3X:VDERUI;0RW\.D6>M^
M(K;3"VM7D&IZO*^G:!HNFBTGUVYL-8#:OI,.F2W#_)>J?M4?\%HO@99V_P 5
M?CI^R!\&OB/\*X7BN?&?@OX(ZC>7'Q&\*:8\JK-<:?'I_CWQY<W/V2-FFN9(
M-&\8V<$$9EU"^TNV6>^C /WJHJM97/VVSM+P07%L+NV@N1;7<8BNK?SXDE\B
MYB5Y%CN(M_ES1J[A)%90[ 9-F@#XX_:Z_;N_9U_8M\,+J_Q>\7+)XIU.UEF\
M)?"_PRL6L?$3QA,NY8ETS0DFB73].DF0P/XAU^XTG0(9A]E_M%[Z2WLY_*?^
M"<?_  4&@_X*"^"_B7XQ@^$\OPG7X>>+].\,)I\OCA/'#:S!J6DG5(=1:Y3P
MEX2&FRH%:"6P$&H("%D2_?<47VO2/V(_V;],_:,\;?M6WO@&V\4?'#QK>:%>
M?\)9XPG;Q$GA!O#WAO1_#%@/ >EWR-IWAB<V&BVTLNJVUO+KJSSW<-MJMMIL
MRZ?'^-G_  ;>?\D2_:2_[*GX3_\ 42EH _H-^)?Q)\#_  >\ ^+/B?\ $GQ#
M9^%/ O@C1KK7_$VOWXGD@T_3;11O9;>TBN+V]N[B5HK33].L+:ZU#4K^>VL-
M/M;F]N8()/Q5C_X+&_&GXH6VM>,/V5/^"<?QW^.WP@T#5;^T?XCR:IJF@KXA
MM]+8P7<&@Z-H'P\\;I-J0ED@N)+.RU;6M3L+;"7^C0SSM]CWO^#@?4/$ME^P
M;I]MH37"Z5J_QV^'NG^,Q!),D<GAN+0_&VJVB7B1?NY;;_A+],\*R*ER?)6\
MCM)%4W"0,OZ9?L<V'@73/V4/V<;+X:"P_P"$'C^"OPXD\/OIQB:">WN?"NF7
M-S=3/$SA]1N[^:ZNM7DE=KJ35IKU[QC=M,: /)/V%O\ @H!\(/V[O!NO:QX&
ML=9\&>.O ]S9V/Q"^&'BJ2T?7_#<]\DOV34+.YM'$6M>'+VXMKZSL]6%MIUV
MMW87-OJ>D:7.8(I_NVOYJ_ 5K;? W_@X:\8^$_!RKI/A_P"/_@#7=1\0:5;2
MF*TN-0U?X1Q_%#6[AK>.-(WGOO&G@2YUU_,WLD^H7<J3 2&&OZ5* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KQ/\ :0^-FE_LX_ KXH_'/6=%OO$>G?#+PEJ'B>?0
M-.N8;.\UA[7RXK73X;RX26&S%U=SP12W;PW M86DG%M<-&()/;*^!O\ @J1_
MRCY_:L_[)9?_ /ISTN@#X$\*?\%I?C1X[\)V7CWP/_P2]_:D\9>!M2M[V[T[
MQIX4C\5^(O">H6NFW5U9:C<V7B+2/A!>:/=6]A>V-[:7LT%Y)':W5G=6\[1R
MV\J)]&?LO_\ !8G]FC]H+Q[:?!OQGH_C?]G/XSWM];Z/9>"/B]80:=8:MK]R
MJF'0-)\2PR)%#K$[/'#8Z=XJTSPI>ZM=3VEEH]OJ%]=0VK=C_P $;O\ E&Q^
MS)_V"OB/_P"KD^(E>!?\%O/V1_ /Q8_98\7_ +0EAHUAH_QF^ \&D>)].\9:
M=8Q0:WK_ (-@U6WT[7/"6M:C ([FYTRPM=5E\3:-+.9YM)U32!%8/9VNK:M]
MH /VTHK\\?\ @GI^U$WQ?_X)^?"O]H+XL^(([6]\,^ _$]M\4?%>K/(%W?"7
M4-<T#7?%VKW+;_-GU31_#D?BG5KB+*FYO[K9%&RF"/XC\&_MU_\ !2+]M:X\
M4^-OV$_@!\'O"'[/>B:S>Z-X9^(7[1%SK4?B/Q]=Z4LR7?\ 95IHWB6QTZV1
MYXQ;W=M;:5J]CI5[-#I]QXN-U;:FEL ?O517Y*_L9?\ !0KXH?$7X_\ C']C
M3]L3X2Z)\$_VH/#&F7?B+0T\)7MQ/\/_ (AZ#:6UM?SGPTNHZSX@O8[X:1-)
MXAT]K77M>L=5T.SU>:2XTF_T2YT^?V7_ (*$_M\>&/V%OAWX:U)/"EY\2?BU
M\3]7NO#/PG^&FG7+6\^N:K;0P"[U?4WMX;O4!H6DW6H:1:36^E65WJNK:IJ^
MEZ18I;_;)]2T\ _06BOP/G_:5_X+C^#-#@^,?C+]C[X$>*? ,-DFM:_\(_!-
M]J47Q1L= \J&=A86L'Q(\4ZR/$7D8:6PL]'\7ZC;S/=Q3>$XI8EM[3]N?AGX
MS_X6/\-_A_\ $/\ L+5_"W_">>"/"GC/_A&?$$/V;7O#G_"4:#8:Y_86MV^%
M\C5](^W?V?J4.T>5>V\R8&W% ';U^2/[5W_!5[0O@7\9=:_9N^"7[.WQ=_:I
M^/'A>WTVY\5>$?A_I^J6FDZ -6TG3]<LK5]3TCPUXTU[5+]=)U.ROKM-*\)7
M&EVPN([.;64U".]M;+];JPM,\+>&=$U7Q#KNC>'="TC6_%UW97_BO6-,TC3[
M#5?$]]INGP:3IU[XAU"UMXKO6KNPTJUMM,LKG4IKF:UT^W@LH'CMH8XE /Q*
M^#/_  6LLKGXS^'/@-^V!^S#\1/V1?&7BJ[T_3-%U?Q;>ZG=:(U_K%ZECHUU
MKVG>)O"'@?6O#WA[4[IGM;?Q';1^(M(CE6.ZN[NUTQ[J^L?W)O;VSTVSN]1U
M&[MK#3["VGO;Z^O9XK6SLK.UB>>YN[NYG>."WMK>"-YIYYG2*&)'DD=44D?S
MB?\ !P]!H7BWPU^R1\+]"TVUUGXU^+_BIKD'@JQM(X9M?;0M0L-+\/7NFQ%,
MW=O:^(?%NK>$(;2-MD.H7ND2&'S)-.F\K[X_X*V>/O$OPB_X)J_&A[#6)?\
MA)]<\->!_AA=:OYK)/>P>,O$GAWPQXR?=$86:35O#-QXA@?8%'^EL[1F-60@
M'S;XH_X+0>*/'_CGQ+X2_8?_ &+?BY^UCX?\(:A)IVM_$K2&U[1O#$D\+\2:
M;9:)X'\73IIVI1K*^E7WB/4?#5_<HB2Q:%/'*N/I[]B3_@J#\/?VN/'7B?X(
M^+_AMXN_9U_:+\(Q7UUJ?P@\?W+75S?6VEE!J\>AZM=:/X9O[G6-$61+C6-
MU;PSH>K06#-J5C;:CI]GJMSIW7?\$HOA3X>^$W[ ?[.-AH>G6EI=>-_ FG_%
M3Q+?06\$5WK>O_$9!XF>_P!3GAR][=6>DWNDZ#:SW#O-%H^C:98XBBLXH8OR
MV_X*@6MO\!O^"J__  3W_:)\,1?V/JOCW7O"OA3QK<Z>&@FUS3M"\=Z5X/\
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M-3\("^54NIM"\7V.G7FD3Z=+,]E;:C>V6MK;M>:=$6XS_@BS^T/KWQU_8/\
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MZL[C4&FO)0#]$/V./VC5_:U_9L^&/[0R^#CX 'Q&L_$5T?"#>(!XI.C-X?\
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MPSX^TJP%PXEM-&3Q)H.G:W96*1B./4?$.N74@CGO'\P _HPHK\;/CU_P4/\
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MTP7=UJ^J+<R:AK4ZR2ZA?K.]S<S7 D- 'Y=?LM?\%@/#GQ=^.MC^R_\ M#_
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M_IJUFBCX_P#_ ")NF?\ 8S6?_IJUFB@ ^ '_ ")NI_\ 8S7G_IJT:O<J\-^
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M0Q R;M !7\W7_!MY_P D2_:2_P"RI^$__42EK[N_:0^-G_!6'PG\9O&'A_\
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M:.*-%CCCC\6>&$2-$ 5$1%_;#"JBJ JJH 4    5^J=KX"\9_M)_LDR_#?\
M:H\':1X%\=_%SX4ZAX6^+?A3PK?6>K:9X4U_7M-N;&\E\-WT.L>);-YM(NFM
M]8T>1->UN.ROH+<#4[XV_P!HD .<_P"">GB*Q\3_ +"O[(FI:>ZR6]M^SQ\*
M/#LC(VX"^\(^#M*\)ZFA.!AHM2T6[C=<?(Z,F6VY/Y&_\%?5M_'O_!0+_@EK
M\*-/C>\UN+XEZ?KFJVD.Z66W\.^*?BU\-+(:A-!"KSQ6=M;>!_$EW<7)4HMM
M874@XMI2,+X$^&O^"OG_  3BT#4?V>/ /[/G@7]J[X*Z9KVKWOPR\6V?B6ST
M^;2(->U*6^N+6.WD\6:/K>BZ7<ZA=SZUJ>C:[H$EOI^L:EJDFF^*;K3M\H^C
M/V,?V*OVI_'_ .UOJ/\ P4'_ &^AX9\/_$^PT.?P]\(O@YX9O++5K+P'87>E
MWNC)<W4EAJ.NZ3I=CI.C:MK$6BZ1;Z]KVKW>MZ_J_B+7[ZPU6WCBOP#]R***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#YN_;)_Y-!_:K_P"S;OCE_P"JP\45^;O_
M  0$_P"3!(/^RS_$?_TG\-5^J/[1'@C6_B9^S_\ '/X;^&5M6\2?$#X._$WP
M1X?6]G%K9-K?BOP5K>@Z4MW=%7%M:F_O[<7$Y1A#$7D*MMP?YY?V-O"7_!:3
M]BCX*GX)_#O]B#X4>*-&7Q/X@\5PZSXT^+OPOGU-=1U^*QCEADCT/X^:+:RV
M5N;"%HXUCAG<-(K7()5D /W5_;>^*7AKX-?LC?M$^/\ Q3J%KI]CIOPD\;Z=
MIPNY(XQJ?B;Q%H-[X>\)Z#;B5)$DO->\2:GI>DVT;12)YMV'E3R$E(_#?_@G
MMX-\7?#;_@AK^UYXRM+&:#4?B5X=_:;\=Z#-*LD$O_",V?POT[X>7FIVY,:L
M5L7\%^)-0LY!O1Y8@XD\M@$] \1_L*?\%+/^"AWB?PR_[?WQ&\$_ ?X#Z'J%
MAK-Y\#?@W?VVHWM_J%MY^YH+>QU3Q?H(U9K:XN;&'Q1XH\=>,V\/"X=]$\/7
M*7%Z)?WDTGX._#30_A';_ C2O".EV7PFMO LOPUC\%PK,-,;P5<:-)H%WHLS
MF4W=PE[I<\\%]>3W$E_>RW%Q=W5U+>3RSN ?S2_\$P;;_@J9!^Q]X&E_90A_
M9"C^#][XA\>7.GO\31XT'CNXUQ/%FIV>N3>(#I'_ !+V=;JT6#2S;_\ ,#@T
MM9?WRR5]!>+?V)/^"G_[1W[4O[)GQO\ VC=3_92T.P_9S^)GA?Q0^H_#+4O&
M=IJUSX8TWQIX:\6ZYI\EAJ&BZDNLWLL/AV6TT2TDO=+LEN=4NDOKJ&UN9KFW
MROA+\!O^"F?_  2[UKQ[X#_9O^%WA+]L/]EOQ)XGU#QGX>TJ[\5Z5X8\<>$K
MBZ^R6CP/:ZCK&DZE!K=YI5A9VNJ0Z#I'C#P[J%S90ZW:PZ+?WM_ITWVO\"?C
M!_P57^,/QF\$3_$[]F7X3?LS?L]Z=?W=YX\;7?&-GXT^(_B*P&EWZ6FD>'SI
M'B"\-E,=2ETV626_\)Z(FR&=EU=E233Y@#XL_P""TD:ZY^V+_P $LO"?BBWC
M?X?:E\9)H]3$\27%K?+JWQ1^".F^)K>ZM)2(+J.UT1+'$4_R&/4;B/*I-+G^
MC2OS,_X*B?L'7O[<OP6\/Z?X'UK3O"_QK^$_B"Y\7_"WQ!JDMU:64\E[:10:
M]X3N]3LEENM&MO$#6&AW\&KV]M<2V.M>'=&DD5;,W;CXL\/_ !__ ."[L'A>
MR^$MW^Q[\,9_B';Z?::+)\<]<\5>#CI A>W>V'BW4K+3/B4?"5]KL4<3:E=I
MIB26AO D;>"Y6N(M)G /TR_;+L?VZ[[2? B?L0:S\&-&U1-1UUOB)+\7H;^7
MSM/-MIH\.1^'OLVF:K;KMN?[8;5OM$,<Q_XEGV:78+I&\(_9CTC_ (*VVGQC
M\.3_ +5/BG]F35/@BMGKX\4V?P]MM1C\827;:'?CPXVD.WA[385\OQ$=,?4/
MM%T(CI8O0B/<&$#[9_9K\'_%SP%\#/ASX4^//CR#XF_&'2]&G;X@>-[0,+/6
M=?U'5-0U2=+$O9:8TEAI4-[!HMC-_9FFB>TTZ&9=.L%D%I#[E0!Y5\;/C7\-
M/V>/AGXH^+OQ<\36?A/P-X1L3>:GJ5T3)/<SN1%8Z1I%C'FYU77-6NFCL=)T
MJS22ZOKR:.*),%G7\)_V5_A7\3O^"I'[4>C_ /!0+]HKP[<>%OV:/A1J-S9?
MLJ?![5HXY$\12Z1J;S6GBC5[9@\-]8V6L6\6M^(=7^:'Q1XML--T"QFG\(^$
MVL).7_X*F_LN_P#!2G]IK]J32+CP!\$]#^,W[+'PNF\):Q\._ FM_$GP%X6\
M$^*];?0-,NO&%UX\T&X^*_P^\:ZA?R:]-K'AY+J*\TIK?PU!%;Z%>6HU/5[G
M4/4])^-G_!??0-*TW0]#_8'_ &2M&T71K"TTK2-(TKQ'X2T_3-+TS3[>.UL=
M.TZQM?VOXK6RL;*UBBM[6UMXHX+>"-(HHTC15 !_0%7P-_P5(_Y1\_M6?]DL
MO_\ TYZ77N_[+OB3]HCQ;\$_"6N_M5?#WPI\+OCC=2Z]'XO\&^"M5M=7\.:?
M%:Z_J5MH-S8W5EXI\;6R'4M BTV_N+:/Q9K9@GN)%DN+>4O86GXW?M5:Y_P6
M;_:"^&_QE^ K?L-?"&T^'?Q!@UOPI:>)]*^+_P .D\1?\(R=6$FEZI;C5OCE
M%;+?W-E:VLL@O=$M@&ED$FGVK_N8P#[<_P""-W_*-C]F3_L%?$?_ -7)\1*_
M3>OYZ/V&XO\ @K_^S/X$^!/[-VI?L6?"P?!WP;XE@T?Q+X[U7XM?#JZ\5Z=X
M.\5?$&_\1^+=<-OH/QJNH;F]T2S\0ZK-86^G^'+^:>.RMHDTW4+EC%/_ $+T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M11^)KCXPKXM/C63QQ;>$/ C7D#2Z*/LIT2'0+CP_+IL18M'<W6I2E5>X<O\
MU*_ [X&_#C]G?X2>#O@E\+]$72/ ?@G1SI&G6=RT=U=Z@]Q+-=ZOJ^MW(BA3
M4=9\0:G=7NK:W=^1#%=:A?7+Q6]O;F.WB_#CP_\ LI?\% _^":OQA^*FL_L-
M^ ?!/[1_[,7Q=U^Z\52_![7/$>F>%]<^'=[]HN&TVVL3KWB/0KF2YT>QN8O#
MUKK.@W_B'_A(]$L[1O$OARTOM+TV^M0#F?VF?V(O^"M?[:-Y\(['XX:I^QWH
M%C\+?&\?BO0M?\#:IX\TW5=+ENWT^/4I94N=&UK[? L6GVEU'90PV\DMW9VX
M^T(FZN@_X.+;VY/P1_9IT.[DDM_"FI_&[4;W7KJ/YFMKG3O"-Y9Z?(L195DD
M33=9\0R1[B,&,KN4.QKZ?^'/QX_X*Z_&CXC_  ^M+S]D;X4_LS_"!?%WA;4/
MB1XE^('C>U\7^++CP1;ZEI]WXHT;PYINF:Y#J%MKFJ:*NHVE@]YX'\JVO[BU
M@N-5TAX+B]7ZB_X*(?L7:3^W1^SGK'PD;5;+PUXVTC6+#QI\,O%6HQ7,VG:+
MXQTJ&[LUAUB.R5[Q]"UW1M2U70M3-O%=2V(OX-:@L-1N])M;*8 ^W=.L+#2M
M/L-+TNUM['3--L[6PTZRLXTAM+.PLX$M[.UM88P(XK>WMXXX8(XP$CB154!0
M!7S%^U[:?M>7OPUT>']B[5/A9I'Q0'C/3GUZZ^+45Y+H3>!1HVOC4HM,%II^
MI@:XVO'PVT7VFU\G^S5U/;,DXA63\A_AC\7/^"Y?P7\!:%\![O\ 8_\ AU\4
M]<\+:)!X6\'?&#6/&OA9[*?1M'\K2])U'Q3<:7\2M&TO59K73S91V\FHGPKK
M]_;6IO=;M+_4AJ=P_P"P'['O@W]HSP3\$=(L?VK/B#IGQ&^-NL:[XE\4>*-2
MT2.)-$T&+Q!JLU_IGA#1Y+>QTNVFL/#MD\=K']DTZTL;:1I;#3Q<V%I;7MT
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M21ZYX@\.>&X_I+_@LQ\#/V^?VD_#OPY^$7[*_A&3Q1\']1M]5UCXO6.F^.?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZUOQ?X/\/>%K^VFVHAM?$6A_#[Q-K5D),.]NL;)$=KO%\_\ [,S_ +<FI_\
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MLT=-$UE+SP_J,VF7XEM(;W4;5X3<0EH+BTO[J%T.QWCN8I[>'Z%HHH ****
M"BBB@#PWX_\ _(FZ9_V,UG_Z:M9HH^/_ /R)NF?]C-9_^FK6:* #X ?\B;J?
M_8S7G_IJT:O<J\-^ '_(FZG_ -C->?\ IJT:O<J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#PWX_\ _(FZ9_V,UG_Z:M9HH^/_ /R)NF?]
MC-9_^FK6:* #X ?\B;J?_8S7G_IJT:O<J\-^ '_(FZG_ -C->?\ IJT:O<J
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MN(@X!Z#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI4 '4T444 %%><>-/C%\(_AO=6MC\1/BG\./ 5[?1--96?C3QQX9\+75Y"A
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M **** "BBB@#PWX__P#(FZ9_V,UG_P"FK6:*/C__ ,B;IG_8S6?_ *:M9HH
M/@!_R)NI_P#8S7G_ *:M&KW*O#?@!_R)NI_]C->?^FK1J]RH **** "BBB@
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M3G&:]DH*-27[D45^&/\ PMSXK?\ 13OB%_X6GB3_ .65'_"W/BM_T4[XA?\
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M?ET:M^YU%?AC_P +<^*W_13OB%_X6GB3_P"65'_"W/BM_P!%.^(7_A:>)/\
MY95U?\5=?#G_ *-#QM_X?,B_^0]?Z>F?_$K>?_\ 14Y/_P"$>-_S]?Z>G[G5
MYG\9OBQX2^!7PI^(/QA\=W36?A+X<>%=7\5ZT\6PW5Q;Z7:O-#IMA'(R+/JF
MK7?V?2]*M2ZFZU*\M;92&E%?G9\!?CW\2[3XB>%?#^L^)=9\5:'XDUJPT&]L
MM>O9]6N(3JMTMI!?VE_>M/?6\EC/<)<2()S!-;))#)'Q#)!F?\%QK_5;+_@G
M)\7H].>5(-1\3?"JPUEHF*?\2IOB/X<NMDI4@F*34K33HG7D/O","K&O[I^C
M1])?@[Z3O!V:<5<*93G>0ULASC^Q,ZR?/(8:5?#8N>$HXW#U\+C,%6K8;&8+
M$T*UJ=3_ &?$PK4:\*V$I05"K7_&?$+P\S7PZS7#9;F>*P>-CC<)]<PF+P3J
M*%2FJLZ-2%2E6A"I2JTYP]Z/OTY0G"4*LGSQA^9O[.7[.?QP_P""T_B?Q!^T
M[^UW\1O%O@W]F'2/%>M:'\*/@QX&U!].M+BYTV/RI3X?;4+*YTFVT[1/MB:9
MKWCNYTG5/$OBW6;;5M'@FT6TTQ$L?T \3_\ !!3]@+6O#[Z5H6B?%'P3K*P*
MEOXMT+XD:IJ&KQW480QW<MCXHM]?\/REI$W3PQ:/;*RR2K;M:MY,D/U7_P $
MM[;0[3_@GS^RG%X>;?8/\++"YN#C&-<O=3U.\\3KS_<\23ZLF>^W(XKXM^,'
M[67_  62^&$?Q1\7G]AKX%/\*/AXGC;Q(?%MU\4/"]S<O\//"2ZGJG_"1W&E
MVGQR@UJXG;PWI_\ :<UA;:!#JDLA:WATB.[9;(?T<? 'Z/\ [&?P#^(?[,_P
M3L_A#\1?C-K7QVN_#WB7Q#)X7\;>(K>]@UJW\$7EQ%)X<\.7_P#:.JZU=22:
M+$L\4>=3NK>VAFBL+#R=/L[6WBZ/X]_M:_LW?LP6VF7'QZ^,'A#X<2:U%-<:
M/I>K75S>^(=5M;=C'<7FF^&=%M=3\17UE#*/(EO;72Y;5+@K;M,)F6,^&?\
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MPC6G12LH8GVB?M*E.UHUN;GJ1:51.<74J?ZC%%?Y=/\ P\"_;S_Z/;_:Z_\
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MX@ED\-8E,)\/6[V^OZ>D5\J[H_"M^]EXQ^$MUYC>7'%IUE91M%)<+YW]$/\
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MCCQ)-X'USXBW,WG21W%C=ZEJ":/IOA/2+S5+>==!BM=:DT*%=8U.5=0^P/\
M@A5^T*_QA_8ML?AQK5V\WC#]G7Q)??#F^BN&S>R>#]0:7Q#X$O)8^/)MK6RN
M]3\'V495'$7@YC(K,?-D[O\ X*._\$P-._;-U3PG\8_A;X]D^#7[3'PYM+2U
M\+>-XFU"VTC7[32K^75]!L]>O]"V^(?#^J^'M6FFO?#OC/05O=2TE;BYMI])
MU9%TI]' .%\?_P#!"C]BW5++2[[X,R?$_P#9Y^(/AZ:QU#P]X^\#_$'Q/X@O
M;76M/FBFMM6O+'QGJNLRBXCDC\^-O#>J>%I[>Z$4UK<P)&87L?\ !>>::+_@
MGOXI2*66-+GXG_#&&X2.1D6>%=8N+A8IE4@2Q"X@@G$;AE$T,4H&^-&7XH\&
M?\%+/VZ?^"??CKPU\'O^"EGPLOO&WP]U.[.FZ'\=?#T%C/KUQIUML1]5T_7=
M$$?A'XDPZ?;O9SZCHMY!X;^(=G:W37VNW%YJ3P:9<_7'_!<?Q'H7C#_@FQ+X
MM\+ZK9:[X:\3^.O@_P"(?#VMZ;,MSI^L:)K,T^HZ5JEC<)\L]G?V-S!=6TJ\
M20RHXX- 'FG[.7_!%S]A/XQ_LM?LY_$3Q)X.\=Z;XS^(GP&^$WCCQ3KF@?$?
MQ%;->>)?&/P[\/ZYK-]!IVIR:MH]DC:KJ-S>6UG:Z='9P%D@$#6J""OEKXBZ
M-^T9_P $,OB[\-_$'@SXG^+OC)^P=\3?&2Z+K?@KQ:BZCJ7A-XA!<:GI1$<-
MIHFC^.)O#RW^K^%/$'A9?#VG^,'\/:C9>(_#EO::3 )?Z _V&?\ DR;]CS_L
MUG]GS_U4OA&OA?\ X+NVVC3_ /!/#QU+JC$7UG\0OA;<^'  IW:RWBF"TG4Y
M(('_  CUUKK94%LJ!C:6( /UR\,>)-#\9^&_#WC#PQJ5OK/AKQ7H>D^)/#VK
MV;%[35=#UVPM]4TG4K5F"LUO?6%U;W4#,JDQ2J2 3BOPC_X+-:]JOQV^)7['
M7_!.WP9J%Q;:Q\=_B=I7CGXAS6(#W>B^ ](O+O0=,U.>'$@N=.MXV\=>*[F&
M2(JDW@*UEP^-H_1K_@FN=3/[!'[)9U8N;K_A2/@H1%WE=O[,73E710#+\X1=
M&%@L:#]U'&%2']RL=?E1^PKXG\/?M9?\%2?VNOVT?$&O:(O@/X.6A^#'P.GU
M35+*TMYX[DW/A6V\0^'FN9XV:"Y\)>'O$NKW\8XCD^)ZDG<Q1 #H?^"&OCGQ
M#\+M9_:M_8"^(=WN\7?L_?$W6_$?AJ.7>C7N@S:N?!_C%]+MY&W1Z#;:_IGA
M[Q%8R*'2Y;Q^URLKQS1$_NY\3?B#X=^$OPX\>_%'Q=.]MX7^'7@[Q)XW\031
M!6G71_"^D7FM:@MM&[()KN2VLY(K2 ,&N+EXH4R\B@_SH?MA>)-"_8V_X+!_
MLX_M8>']:TA_AK^T=IMGX$^+$NEZE97%E!>)%IWPW\57^JK932)!9:1HNH?#
M;QTI)BFU#5= U"4I<,D_G?JK_P %9M8U'0_^"=G[4M[I8+7,_@72]'E 8)_Q
M+O$/C3PQH&L')ZA=)U.^8KU< H.6% 'XQ?LI?LX_$S_@L_X^\9_M7_MB^.?%
M>G?L]^&?&&K>%?A;\%O">K7.EZ9]JM8;.^N--T>=[<6VF^'M"T[4=-TW7?%%
MC8-XJ\;ZW]KBGUG2SHDD;?<'QS_X(*_LD>)_ ]\/V>U\5? WXL:7;1WO@[Q3
M_P )MXM\5>'Y=?L/(EL_^$FT_P 0ZCK.I06EU/;G?J/AB\TN_P!(NKD:E:VU
M_%9QZ//]%?\ !&"TTNU_X)K_ +-[:7\R7<'Q0N[Z5D1))=4?XS?$.*_\W86W
M?9YH39P.QWFTMK?<%(VC]1: /PQ_X(Q?MD_%KXN:3\7?V5/VD+_5=6^-W[-6
MI?V<NOZ_-)=^)-:\+V>KWOA;5M)\37SAY=3U_P "^)-/CTRZUR^G>_UJPUG2
MS=/>7^GZCJ-W^YU?S3?L,W'V+_@NS^WA8>'U#Z-J'@WXHS:TOEF-8KY/'WPA
MO+ZY"QAU,R^(IKNW#R.@ECNYY6 F=8Z_I9H _(G_ (*^_MT>*_V0_@OX8\&_
M!YV/Q]^/6JZAX6\!W-M:C4K_ ,+Z)8)90^(_%6FZ:$G^U^(5N=9T70O"EM/
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M1RK#<6&M'P/H?B.'1KFSF;RK^/5);0V$B2I>^0T,P3Y:_P""J/[6GB7X<?\
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M -@;XE^,+?P'X0_::\!77B>]U*WT?3[/5X/$OA2RU34[ORA:66DZ[XLT'0]
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M%/8M-F_X)_?M7IJH!M5^$6NRQ9C63_B96\UG/HQVLR@$:Q'8D2 EHB/-569
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M/6-)M-?TO7K#PO:Z=87\MIH[R:OH>K36;ZOI>IZ1:6]GJ%KIU[J44X!][_\
M!0?]KGX:_LM_ 'XD1Z_\5;'X;?%WQU\'_C(GP$C-IJ%[K.K_ !$T+P7<KH$N
MD1V>E:I9VT]AXGUCPRL5UK:VVEBZN[=9Y6B$X3\]_P#@F=_P56^"^H_LY^ ?
M"O[5W[3MK>?M":IXU\2:/+#XNTOQ#-K%S9ZMXHD@\(PWFL:1X9;0EADM[N"*
M"YN]006EL8TO)X(( (_19=8\'_ME?\$;+W]H+XU>!/ 'Q*^)OAW]CG]H>[T3
MQIXN\&^'O$6O>&O'W@OP=XS\)ZYXP\+:GK.G7MYX6\1ZMXA^'VGZ[?ZAX?FT
MZ7^V+"RN8&B&GV M_//^"*7[-?[.?Q _8=^'OQ!\>? 'X*>-O'L7Q!^(+Q>-
M_%WPK\"^)/%\;Z-XMG_L=H_$NLZ#>ZRC:5Y,7]FLMZ#8^5']E,6Q< '[Q:WK
MFB^&M'U/Q#XCU?3- T'1;&YU/6-;UF^M=,TG2M.LXFGN[_4=1O98+2RL[6%'
MEN+FYFCAAC5GD=5!-?!-K_P5<_X)X7?B<>$8OVJ/AZFJL\48N[JV\567AC=-
M(T2$^-KWP];^#%164F61M?$<$96:=HX71V_-'_@M[\9M'U+XQ?LB_LD?$+Q\
MWPY^ 7CCQ#IWQ-^/^NVIU07<O@VR\4?V%917"Z3#=W5Q9VEGI_BN[L;);&^B
ME\1?V-J,MN9-'MF7T/Q1\9_^""/B;X0WOP4.J_L_Z)X1GT.;1M/OM"^$GB[3
M_%^B3M:QV\'B'3?&J> &\5?\)1#)!;7<WB"[U>ZU35;B$G6KG48[BZCG /WK
ML;ZRU.RL]2TV\M=0T[4+6WOK"_L;B*[LKZRNXDGM;RSNH'D@N;6Y@DCFM[B&
M1XIHG22-V1E8^%?'C]JC]GC]F/3=,U3X\_%KPC\-H=;-R-%M-;NYY]:UE;-
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MT9$51]SPPPVT,5O;PQ6]O;Q1PP00QI%###$@CBABBC"I'%&BJD<:*J(BA5
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MWH&F1F'3]'T;2[>.TL-/M(V9V6&VMXTC0N[R-C=([N68]-0!_)5\(_B#J_\
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M,J3PW.G>#[RZN/!^F&*9$FCCT[0K6%)1YBQAR6/V^         !@ #@  <
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MPZVEG+XHT2?2]?FM;59'6VMY=1>&!3MB15  ['X+?LT_ ']G2PU'3O@=\(O
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MK-[?4O&&L2:CJFKRZAJ\C2NDES-JFM:KJ%P\,</VB[OIYY@\A5E]AH ****
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M]"TZSTG1]*L;==D%EINF:?#;V5C:0I\L5M:P10QK\J(HXK5H **** "BBB@
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MQ'K>KK)XA\2^(]'N$ 672=?\1ZOJNL:8X+YL;VWS)*<R-](U^/\ ^Q%^P?\
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M8\2Z9,;C2_$EOX+TF^\0:7<;D<7&EZWJT%_JFFSHT:^7-8W4$D0WK&RK)(&
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MF)8T =K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'AOQ__ .1-TS_L9K/_ --6LT4?'_\
MY$W3/^QFL_\ TU:S10 ? #_D3=3_ .QFO/\ TU:-7N5>&_ #_D3=3_[&:\_]
M-6C5[E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7)W7@+P-?>+=-\?WW@OPG>>.]&L9=+TCQK=>'-'N/%NE:9,MVDVG:;XDF
MLWUFQL94O[Y9;2UO8K>1;R[5XR+B8/UE% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!R?A/P%X%\!0ZE;>!O!?A/P7;
MZSJ,NKZO!X3\.:/X<AU75IU"S:IJ46CV=FE]J,RJJRWMTLMS(J@/*0 *ZRBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \-^/_ /R)NF?]C-9_^FK6:*/C_P#\B;IG
M_8S6?_IJUFB@ ^ '_(FZG_V,UY_Z:M&KW*O#?@!_R)NI_P#8S7G_ *:M&KW*
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\
M*1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ]
M,HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\
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M\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\
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M "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K*
M/3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I&N__ "LH ],HKS/_
M (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\
MRD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RL
MH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\
MH8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\
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M_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\
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MPY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*RC_A</PY_P"AB_\
M*1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?^AB_\I&N_P#RLH ]
M,HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\ *R@#TRBO,_\
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M\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:[_\
M*R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K* /3**\S_X
M7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I&N__ "LH ],HKS/_ (7#\.?^
MAB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[_P#*
MRC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7#\.?
M^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_ "D:
M[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K* /3**
M\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I&N__ "LH ],HKS/_ (7#
M\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\ RD:[
M_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RLH_X7
M#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\ H8O_
M "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\ \K*
M/3**\S_X7#\.?^AB_P#*1KO_ ,K*/^%P_#G_ *&+_P I&N__ "LH ],HKS/_
M (7#\.?^AB_\I&N__*RC_A</PY_Z&+_RD:[_ /*R@#TRBO,_^%P_#G_H8O\
MRD:[_P#*RC_A</PY_P"AB_\ *1KO_P K* /3**\S_P"%P_#G_H8O_*1KO_RL
MH_X7#\.?^AB_\I&N_P#RLH ],HKS/_A</PY_Z&+_ ,I&N_\ RLH_X7#\.?\
MH8O_ "D:[_\ *R@#TRBO,_\ A</PY_Z&+_RD:[_\K*/^%P_#G_H8O_*1KO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH OZ5_P A
033?^O^S_ /2B.BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>gern-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-26T17:17:13.4476+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.geron.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:gern="http://www.geron.com/20241231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION" id="Role_DocumentDOCUMENTANDENTITYINFORMATION">
        <link:definition>100000 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" id="Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100040 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100080 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>995457 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton" id="DisclosureRevenueRecogniton">
        <link:definition>995467 - Disclosure - REVENUE RECOGNITON</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>995477 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" id="Role_DisclosureFAIRVALUEMEASUREMENTS">
        <link:definition>995487 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT" id="Role_DisclosurePROPERTYANDEQUIPMENT">
        <link:definition>995497 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureLicenseAgreement" id="DisclosureLicenseAgreement">
        <link:definition>995507 - Disclosure - LICENSE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES" id="Role_DisclosureACCRUEDLIABILITIES">
        <link:definition>995517 - Disclosure - ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" id="Role_DisclosureCOMMITMENTSANDCONTINGENCIES">
        <link:definition>995527 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES" id="Role_DisclosureOPERATINGLEASES">
        <link:definition>995537 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT" id="Role_DisclosureDEBT">
        <link:definition>995547 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY" id="Role_DisclosureSTOCKHOLDERSEQUITY">
        <link:definition>995557 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES" id="Role_DisclosureINCOMETAXES">
        <link:definition>995567 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1" id="DisclosureConsolidatedStatementsOfCashFlowsData1">
        <link:definition>995577 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting" id="DisclosureSegmentReporting">
        <link:definition>995587 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995597 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>995607 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonTables" id="DisclosureRevenueRecognitonTables">
        <link:definition>995617 - Disclosure - REVENUE RECOGNITON (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>995627 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" id="Role_DisclosureFAIRVALUEMEASUREMENTSTables">
        <link:definition>995637 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables" id="Role_DisclosurePROPERTYANDEQUIPMENTTables">
        <link:definition>995647 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables" id="Role_DisclosureACCRUEDLIABILITIESTables">
        <link:definition>995657 - Disclosure - ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables" id="Role_DisclosureOPERATINGLEASESTables">
        <link:definition>995667 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables" id="Role_DisclosureDEBTTables">
        <link:definition>995677 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables" id="Role_DisclosureSTOCKHOLDERSEQUITYTables">
        <link:definition>995687 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables" id="Role_DisclosureINCOMETAXESTables">
        <link:definition>995697 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables" id="DisclosureConsolidatedStatementsOfCashFlowsDataTables">
        <link:definition>995707 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995717 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail">
        <link:definition>995727 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1">
        <link:definition>995737 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" id="Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails">
        <link:definition>995747 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>995757 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SEGMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails" id="DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails">
        <link:definition>995767 - Disclosure - REVENUE RECOGNITON - Schedule of Reconciliation of Gross Product Sales to Net Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails" id="DisclosureInventoryScheduleOfInventoryDetails">
        <link:definition>995777 - Disclosure - INVENTORY - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails">
        <link:definition>995787 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2" id="Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2">
        <link:definition>995797 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails">
        <link:definition>995807 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails">
        <link:definition>995817 - Disclosure - FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails">
        <link:definition>995827 - Disclosure - FAIR VALUE MEASUREMENTS - EQUITY INVESTMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails" id="DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails">
        <link:definition>995837 - Disclosure - FAIR VALUE MEASUREMENTS - SALE OF FUTURE ROYALTIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" id="Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails">
        <link:definition>995847 - Disclosure - FAIR VALUE MEASUREMENTS - CREDIT RISK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails" id="Role_DisclosurePROPERTYANDEQUIPMENTDetails">
        <link:definition>995857 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails" id="Role_DisclosureLICENSEAGREEMENTSDetails">
        <link:definition>995867 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails" id="Role_DisclosureACCRUEDLIABILITIESDetails">
        <link:definition>995877 - Disclosure - ACCRUED LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" id="Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails">
        <link:definition>995887 - Disclosure - COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails" id="Role_DisclosureOPERATINGLEASESDetails">
        <link:definition>995897 - Disclosure - OPERATING LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" id="Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails">
        <link:definition>995907 - Disclosure - OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" id="Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails">
        <link:definition>995917 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails" id="Role_DisclosureDEBTAdditionalInformationDetails">
        <link:definition>995927 - Disclosure - DEBT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" id="Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails">
        <link:definition>995937 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails" id="DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails">
        <link:definition>995947 - Disclosure - DEBT - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails">
        <link:definition>995957 - Disclosure - STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails" id="DisclosureStockholdersEquityPublicOfferingsDetails">
        <link:definition>995967 - Disclosure - STOCKHOLDERS' EQUITY - PUBLIC OFFERINGS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails" id="DisclosureStockholdersEquityWarrantExercisesDetails">
        <link:definition>995977 - Disclosure - STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails">
        <link:definition>995987 - Disclosure - STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails">
        <link:definition>995997 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails">
        <link:definition>996007 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails">
        <link:definition>996017 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails">
        <link:definition>996027 - Disclosure - STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails">
        <link:definition>996037 - Disclosure - STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails">
        <link:definition>996047 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails">
        <link:definition>996057 - Disclosure - STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails">
        <link:definition>996067 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" id="Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails">
        <link:definition>996077 - Disclosure - STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails">
        <link:definition>996087 - Disclosure - INCOME TAXES - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>996097 - Disclosure - INCOME TAXES - SCHEDULE OF PROVISION FOR (BENEFIT FROM) INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" id="Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails">
        <link:definition>996107 - Disclosure - INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" id="Role_DisclosureINCOMETAXESDEFERREDTAXESDetails">
        <link:definition>996117 - Disclosure - INCOME TAXES - DEFERRED TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" id="Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails">
        <link:definition>996127 - Disclosure - INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" id="Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails">
        <link:definition>996137 - Disclosure - INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" id="Role_DisclosureINCOMETAXESCARESACTIMPACTDetails">
        <link:definition>996147 - Disclosure - INCOME TAXES - CARES ACT IMPACT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" id="Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails">
        <link:definition>996157 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" id="DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails">
        <link:definition>996167 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>996177 - Disclosure - SEGMENT REPORTING (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails" id="DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails">
        <link:definition>996187 - Disclosure - SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>996197 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION" xlink:href="gern-20241231.xsd#Role_DocumentDOCUMENTANDENTITYINFORMATION" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="gern-20241231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="gern-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="gern-20241231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" xlink:href="gern-20241231.xsd#Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="gern-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="gern-20241231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="gern-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="gern-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:href="gern-20241231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton" xlink:href="gern-20241231.xsd#DisclosureRevenueRecogniton" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureInventory" xlink:href="gern-20241231.xsd#DisclosureInventory" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT" xlink:href="gern-20241231.xsd#Role_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureLicenseAgreement" xlink:href="gern-20241231.xsd#DisclosureLicenseAgreement" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES" xlink:href="gern-20241231.xsd#Role_DisclosureACCRUEDLIABILITIES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:href="gern-20241231.xsd#Role_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES" xlink:href="gern-20241231.xsd#Role_DisclosureOPERATINGLEASES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT" xlink:href="gern-20241231.xsd#Role_DisclosureDEBT" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXES" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1" xlink:href="gern-20241231.xsd#DisclosureConsolidatedStatementsOfCashFlowsData1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:href="gern-20241231.xsd#DisclosureSegmentReporting" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="gern-20241231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:href="gern-20241231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonTables" xlink:href="gern-20241231.xsd#DisclosureRevenueRecognitonTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryTables" xlink:href="gern-20241231.xsd#DisclosureInventoryTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables" xlink:href="gern-20241231.xsd#Role_DisclosurePROPERTYANDEQUIPMENTTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables" xlink:href="gern-20241231.xsd#Role_DisclosureACCRUEDLIABILITIESTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables" xlink:href="gern-20241231.xsd#Role_DisclosureOPERATINGLEASESTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables" xlink:href="gern-20241231.xsd#Role_DisclosureDEBTTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables" xlink:href="gern-20241231.xsd#DisclosureConsolidatedStatementsOfCashFlowsDataTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="gern-20241231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" xlink:href="gern-20241231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" xlink:href="gern-20241231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:href="gern-20241231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails" xlink:href="gern-20241231.xsd#DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails" xlink:href="gern-20241231.xsd#DisclosureInventoryScheduleOfInventoryDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails" xlink:href="gern-20241231.xsd#DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" xlink:href="gern-20241231.xsd#Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails" xlink:href="gern-20241231.xsd#Role_DisclosurePROPERTYANDEQUIPMENTDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureLICENSEAGREEMENTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails" xlink:href="gern-20241231.xsd#Role_DisclosureACCRUEDLIABILITIESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" xlink:href="gern-20241231.xsd#Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails" xlink:href="gern-20241231.xsd#Role_DisclosureOPERATINGLEASESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails" xlink:href="gern-20241231.xsd#Role_DisclosureDEBTAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" xlink:href="gern-20241231.xsd#Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="gern-20241231.xsd#DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails" xlink:href="gern-20241231.xsd#DisclosureStockholdersEquityPublicOfferingsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails" xlink:href="gern-20241231.xsd#DisclosureStockholdersEquityWarrantExercisesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" xlink:href="gern-20241231.xsd#Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails" xlink:href="gern-20241231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:href="gern-20241231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" xlink:href="gern-20241231.xsd#Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" xlink:href="gern-20241231.xsd#DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="gern-20241231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails" xlink:href="gern-20241231.xsd#DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="gern-20241231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2" xlink:href="gern-20241231.xsd#Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScenarioOneMember" xlink:label="gern_ScenarioOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PaymentOnRoyaltyAgreement" xlink:label="gern_PaymentOnRoyaltyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingTable" xlink:label="gern_PublicOfferingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_BiopharmaCreditPlcMember" xlink:label="gern_BiopharmaCreditPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseInAllowanceForDoubtfulAccounts" xlink:label="gern_IncreaseInAllowanceForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TotalGrossToNetAdjustmentsMember" xlink:label="gern_TotalGrossToNetAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MenloParkOfficeSpaceLeaseMember" xlink:label="gern_MenloParkOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SiliconValleyBankMember" xlink:label="gern_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionTwoMinCashDebtCovenantMember" xlink:label="gern_OptionTwoMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinCashUponLicensingTransaction" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheBMember" xlink:label="gern_TrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DirectorsMarketValueStockPurchasePlanMember" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtTheMarketOfferingMember" xlink:label="gern_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingLineItems" xlink:label="gern_PublicOfferingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CostMethodInvestmentOwnershipPercentage" xlink:label="gern_CostMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLeaseRentAbatementPeriod" xlink:label="gern_OperatingLeaseRentAbatementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ProceedsFromSaleOfFutureRoyalties" xlink:label="gern_ProceedsFromSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DueToCounterParty" xlink:label="gern_DueToCounterParty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LicenseAgreementDisclosureAbstract" xlink:label="gern_LicenseAgreementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsFederalAndStateCredits" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheOneMember" xlink:label="gern_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheAMember" xlink:label="gern_TrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentFloorRate" xlink:label="gern_DebtInstrumentFloorRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:label="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedEndOfTermCharge" xlink:label="gern_AccruedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_JanssenBiotechIncMember" xlink:label="gern_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TotalInterestAndOtherIncomeExpense" xlink:label="gern_TotalInterestAndOtherIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:label="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CaliforniaOfficeSpaceLeaseMember" xlink:label="gern_CaliforniaOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesAndSiliconValleyBankMember" xlink:label="gern_HerculesAndSiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_BorrowingAvailableStartDate" xlink:label="gern_BorrowingAvailableStartDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommonStockAggregateOfferingPrice" xlink:label="gern_CommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PharmakonLoanAgreementMember" xlink:label="gern_PharmakonLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfSeverancePlan" xlink:label="gern_NumberOfSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LongTermDebtGross" xlink:label="gern_LongTermDebtGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceSalesAgreementsTable" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfInterestOnPastDueOutstanding" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialExpensesMember" xlink:label="gern_CommercialExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FacilityCosts" xlink:label="us-gaap_FacilityCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CardinalHealthIncMember" xlink:label="gern_CardinalHealthIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NewJerseyOfficeSpaceLeaseMember" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RevenuesBeforeAdjustmentsMember" xlink:label="gern_RevenuesBeforeAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MarketCapMinimumToUseOptionTwo" xlink:label="gern_MarketCapMinimumToUseOptionTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MaximumCommissionRate" xlink:label="gern_MaximumCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfFinancialInstitutions" xlink:label="gern_NumberOfFinancialInstitutions"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentMinimumPrepaymentAmount" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ConsultantsMember" xlink:label="gern_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsRevenueParticipation" xlink:label="gern_DeferredTaxAssetsRevenueParticipation"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ExpiryDateOfTranche" xlink:label="gern_ExpiryDateOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SeverancePlanLineItems" xlink:label="gern_SeverancePlanLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TermLoansMember" xlink:label="gern_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UpfrontPaymentReceived" xlink:label="gern_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DirectorsPlan2006Member" xlink:label="gern_DirectorsPlan2006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfCommitmentAmountToFundLoan" xlink:label="gern_PercentageOfCommitmentAmountToFundLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfPrepaymentCharge" xlink:label="gern_PercentageOfPrepaymentCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LicenseFeesAndRoyaltiesMember" xlink:label="gern_LicenseFeesAndRoyaltiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CostMethodInvestmentsCostBasis" xlink:label="gern_CostMethodInvestmentsCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CARESActImpactAbstract" xlink:label="gern_CARESActImpactAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAbstract" xlink:label="us-gaap_DepreciationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheFourMember" xlink:label="gern_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementNumberOfStudies" xlink:label="gern_CollaborativeArrangementNumberOfStudies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DepositsAndOtherAssetsNoncurrent" xlink:label="gern_DepositsAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClinicalSupplyAgreementMember" xlink:label="gern_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PurchaseWarrantsMember" xlink:label="gern_PurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SalesReturnsAndAllowanceMember" xlink:label="gern_SalesReturnsAndAllowanceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinimumCashBalance" xlink:label="gern_DebtCovenantMinimumCashBalance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" xlink:label="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedEndOfTermCharges" xlink:label="gern_AccruedEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SeverancePlanTable" xlink:label="gern_SeverancePlanTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ChargebackAndDistributorServiceFeesMember" xlink:label="gern_ChargebackAndDistributorServiceFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfAnnualNetSales" xlink:label="gern_PercentageOfAnnualNetSales"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_McKessonFinancialCenterMember" xlink:label="gern_McKessonFinancialCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FosterCityOfficeSpaceLeaseMember" xlink:label="gern_FosterCityOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_InterestOnlyPeriodPaymentTermDescription" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScenarioTwoMember" xlink:label="gern_ScenarioTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesLoanAgreementMember" xlink:label="gern_HerculesLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedManufacturingActivitiesCurrent" xlink:label="gern_AccruedManufacturingActivitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployerTaxReceivable" xlink:label="gern_EmployerTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentRebatesMember" xlink:label="gern_GovernmentRebatesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheSixMember" xlink:label="gern_TrancheSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionOneMinCashDebtCovenantMember" xlink:label="gern_OptionOneMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployeesAboveTheVicePresidentLevelMember" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncentiveAwardPlan2011Member" xlink:label="gern_IncentiveAwardPlan2011Member"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheFiveMember" xlink:label="gern_TrancheFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ASDSpecialtyHealthcareLLCMember" xlink:label="gern_ASDSpecialtyHealthcareLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesMember" xlink:label="gern_HerculesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedCapitalizedInterestCosts" xlink:label="us-gaap_AccumulatedCapitalizedInterestCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SinaDrugMember" xlink:label="gern_SinaDrugMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheTwoMember" xlink:label="gern_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheCMember" xlink:label="gern_TrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentFaceAmountExpired" xlink:label="gern_DebtInstrumentFaceAmountExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheThreeMember" xlink:label="gern_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionThreeMinCashDebtCovenantMember" xlink:label="gern_OptionThreeMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ChemistryManufacturingAndControlExpensesMember" xlink:label="gern_ChemistryManufacturingAndControlExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployeeRetentionCreditAmountOutstandingReceivables" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FormerCollaborativeArrangementMember" xlink:label="gern_FormerCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:label="gern_PrepaymentPremiumOnPercentageOfTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentEndOfTermChargePercentage" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="gern_LiabilityRelatedToSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FairValueMeasurementsInterTransfersBetweenLevels" xlink:label="gern_FairValueMeasurementsInterTransfersBetweenLevels"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SubsequentDirectorOptionMember" xlink:label="gern_SubsequentDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EquityInvestmentReverseStockSplit" xlink:label="gern_EquityInvestmentReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfSharesSoldFromEquityInvestment" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ResearchAndClinicalExpensesMember" xlink:label="gern_ResearchAndClinicalExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FirstDirectorOptionMember" xlink:label="gern_FirstDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of new offering period in a case where the fair market value of common stock on the purchase date is less than the fair market value at the beginning of the offering period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration Of New Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of the new offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to the treatment of research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScenarioOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Scenario One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of six-month product revenue forecast to satisfy minimum cash balance debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt covenant percentage of product revenue against forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum cash balance requirement to be met as a percentage of six-month product revenue against forecast</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PaymentOnRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment on Royalty Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PaymentOnRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment on royalty agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PaymentOnRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment on royalty agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of common stock reserved for future issuance, which may include but is not limited to outstanding options and outstanding warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BiopharmaCreditPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BioPharma Credit PLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BiopharmaCreditPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BioPharma credit PLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BiopharmaCreditPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BioPharma Credit PLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government sponsored enterprise securities due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Sponsored Enterprise Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Performance Obligation, Description of Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest payments description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At Market Issuance Sales Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Sales Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At Market Issuance Sales Agreements [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Amount Capitalized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseInAllowanceForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Allowance for Doubtful Accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseInAllowanceForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in allowance for doubtful accounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseInAllowanceForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase in allowance for doubtful accounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other segment expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TotalGrossToNetAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Gross To Net Adjustments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TotalGrossToNetAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total gross to net adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TotalGrossToNetAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total gross-to-net adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MenloParkOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Menlo park office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MenloParkOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Menlo Park Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MenloParkOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Menlo Park Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of loan amount outstanding to be held as minimum cash balance under debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt covenant minimum cash balance percentage of loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum cash balance as a percentage of loan amount outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Current Maturities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease term additional period extension.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term Additional Period Extension</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term, additional period extension</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to unsecured promissory note (generally negotiable) that provides institutions with short-term funds ), due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING LEASES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Municipal securities due in one to two years member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Investment Owned, Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Investment Owned, Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee stock purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Public Offering of Common Stock and Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Public Offering Of Common Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Public Offering of Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionTwoMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option two min cash debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionTwoMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Two Min Cash Debt Covenant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">REVENUE RECOGNITON</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount outstanding under term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum cash covenant required upon certain licensing transactions being executed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Covenant Min Cash Upon Licensing Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt covenant minimum cash balance upon licensing transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of cash equivalents and marketable securities with unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US Treasury securities due in one to two years member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that Geron must pay during certain phases of the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Cost Sharing Percentage Of Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of costs to be paid by Geron</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors&#8217; market value stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors Market Value Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors Market Value Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of options to be granted to purchase shares in each year during the optionee's service on the Board of Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options to be granted to purchase shares (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate range, minimum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Municipal securities due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities (due in less than a year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Municipal securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new shares issued during the period in connection with exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Warrant Exercise Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of warrants (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost method investment ownership percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Method Investment Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost method investments ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseRentAbatementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease rent abatement period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseRentAbatementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Rent Abatement Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLeaseRentAbatementPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent abatement period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares authorized (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total - Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Future Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of future royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of future royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Research Organizations And Clinical Trial Costs Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRO and clinical trial costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DueToCounterParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of obligations due to counterparty. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DueToCounterParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due To Counter Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DueToCounterParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due to Janssen Biotech, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseAgreementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseAgreementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets federal and state credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Federal And State Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of consecutive purchase periods in an offering period in the purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Consecutive Purchase Periods In Each Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive purchase periods in an offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unused Borrowing Capacity, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available remaining loan principal under second amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense included in operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with public offering (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new shares of common stock issued during the period in connection with public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Of Common Stock Issued During Period Shares New Issues Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of term loan, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit, maturity period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares under options that were cancelled or that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Forfeitures And Expirations In Period Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options cancelled/forfeited/expired (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Interest expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment on royalty agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, initial term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expire beginning 2028 through 2041</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four pre-funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Pre-funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateNoteSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of financial instruments measured at fair value on recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized loss (gain) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFloorRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Floor Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFloorRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument floor rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFloorRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Floor rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Reconciliation of Gross Product Sales to Net Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Gross To Net Sales Adjustments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of gross to net sales adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued end of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment charge assessed upon debt prepayment occurring 36 months after June 30, 2022 under second amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dollar prepayment charge 36 months after effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Charge for prepayment occurring 36 months after effective date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Awards granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae, due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the Janssen Biotech Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Biotech Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_JanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Biotech</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Remaining Contractual Life (In years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weight Average Remaining Contractual Life (in years) - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum borrowing capacity under term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TotalInterestAndOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total interest and other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TotalInterestAndOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Interest And Other Income Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TotalInterestAndOtherIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total interest and other income (expense).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Activity Within Liability Related To Sale Of Future Royalties Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of activity within liability related to sale of future royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Activity Within Liability Related to Sale of Future Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CaliforniaOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CaliforniaOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CaliforniaOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen inducement award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Inducement Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Inducement Award Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum expiration term of options granted to employees having more than 10 % outstanding common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Award Options Maximum Expiration Term For Options Granted To Optionees With Ownership Of More Than10 Percentage Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum expiration term of stock options granted to employees having more than 10 % outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the reporting period in the amount due for interest payments related to marketable securities and in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Interest Receivable Net And Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2022 pre-funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Pre Funded Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined public offering price per share of pre-funded warrants and accompanying stock purchase warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock options exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost of goods sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesAndSiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules and Silicon Valley Bank. member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesAndSiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules And Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesAndSiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules and Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BorrowingAvailableStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First date to available to drawdown any amount under a tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BorrowingAvailableStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowing Available Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_BorrowingAvailableStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Start date to borrow under a tranche for a debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration term of stock options from date of grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Roll Forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available For Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the aggregate offering price for which the entity may elect to issue and sell shares of its common stock under the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Aggregate Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommonStockAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from exercise of stock options (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt discount amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Percentage of Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying value of liabilities related to sale of future revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Carrying value of liability related to sale of future royalties at November 1, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Carrying value of liability related to sale of future royalties at December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate range, maximum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options cancelled/forfeited/expired (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PharmakonLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pharmakon Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PharmakonLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pharmakon loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PharmakonLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pharmakon Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the gross unrealized losses for cash and cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid on or after third anniversary but prior to fourth anniversary of funding date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">severance plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Severance Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE AGREEMENT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of provision for(benefit from) income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LongTermDebtGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate value of term loan, including accrued interest payable and end of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LongTermDebtGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LongTermDebtGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Municipal Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MunicipalBondsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Municipal securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At Market Issuance Sales Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Sales Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At Market Issuance Sales Agreements [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from public offering after deducting underwriting discount and other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Added percentage to current interest rate under debt instrument to past due amounts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Interest On Past Due Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional percentage of interest on past due amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product Revenue, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commercial Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Expenses Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CommercialExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FacilityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FacilityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facility Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of offering periods in which an employee can participate at a time in the purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Offering Periods In Which Employee May Participate At One Time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of offering periods in which an employee can participate at a time</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CardinalHealthIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cardinal Health Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CardinalHealthIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cardinal Health Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CardinalHealthIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cardinal Health Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New jersey office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Jersey Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Jersey Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of term loan payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RevenuesBeforeAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues Before Adjustments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RevenuesBeforeAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenues before adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RevenuesBeforeAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues Before Adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted future non-cancellable lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risks, Types, No Concentration Percentage [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and awards available for grant (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average estimated fair value of other than employee stock options granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period for recognition of compensation cost on weighted average basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MarketCapMinimumToUseOptionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum market capitalization required for this option to be available to meet the minimum cash balance debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MarketCapMinimumToUseOptionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market cap minimum to use option two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MarketCapMinimumToUseOptionTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum market capitalization requirement for option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MaximumCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum commission rate, based on gross proceeds of sale price per share of common stock sold through sales agent under the sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MaximumCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Commission Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MaximumCommissionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum commission rate (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Nature [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of financial institutions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institutions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_StockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity impact of the value of stock issued in connection with exercise of warrants during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock In Connection With Warrant Exercise Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Equity Securities, FV-NI</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in fair value of equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum amount allowed to be prepaid under debt instrument.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Minimum Prepayment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum amount of prepayment allowed under debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Payments Under Term Loan Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsRevenueParticipation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Revenue Participation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsRevenueParticipation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets revenue participation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsRevenueParticipation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Participation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty four underwritten public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principle amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing stock price (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of restricted stock that vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ExpiryDateOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date to borrow under a tranche for a debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ExpiryDateOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expiry Date Of Tranche</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ExpiryDateOfTranche_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Last date to drawdown any amounts under a tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of months following a change in control when an employee is terminated without cause to be classified as a triggering event for severance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within which employee is terminated by entity without cause following a change of control</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock authorized for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock under equity plans (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nontrade Receivables, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NontradeReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nontrade Receivables, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Plan [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TermLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of net product revenues maintenance period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum percentage of net product revenues maintenance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum percentage of net product revenues maintenance period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with at market offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Stock and Warrants for Services or Claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation for services by non-employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation for services by non-employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Notes Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Borrowing Capacity, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration date to borrow under a tranche for a debt instrument, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsPlan2006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the 2006 Directors Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsPlan2006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors Plan2006 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DirectorsPlan2006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Directors Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfCommitmentAmountToFundLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commitment Amount To Fund Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfCommitmentAmountToFundLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commitment amount to fund loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfCommitmentAmountToFundLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commitment amount to fund loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total pretax intrinsic value of stock options exercised (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncurrent portion of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock options granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of the purchase period under the employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration Of Purchase Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of the purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of aggregate stock option and award activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assumptions used to estimate the fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 Pre-funded warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Pre-Funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfPrepaymentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment amount to be paid upon prepayment under debt instrument.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfPrepaymentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayment Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfPrepaymentCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment charge (as a percentage)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_UnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseFeesAndRoyaltiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Fees And Royalties Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseFeesAndRoyaltiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License fees and royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LicenseFeesAndRoyaltiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">License Fees and Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">12 Months or Greater - Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase common stock, exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (loss) related to foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentsCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost method investments cost basis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentsCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Method Investments Cost Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CostMethodInvestmentsCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost method investments cost basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deposit Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposit and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deposit Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CARESActImpactAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES act impact.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CARESActImpactAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act Impact [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae) due in 1 to 2 years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Sponsored Enterprise Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net product revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the minimum percentage of ownership required for granting of options at a price not less than 110 percent of the fair market value of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Ownership Required For Granting Options At Minimum110 Percent Of Fair Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of ownership required for granting stock options at least 110% of fair market value of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAXES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule reconciles the federal statutory tax rate to the effective income tax rate from continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants exercised during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock exercised, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions used to estimate fair value of awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that the company must pay after the termination of the Collaboration Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement After Termination Cost Sharing Percentage Of Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of costs to be paid by Geron after termination of Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Basis for Effective Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan interest rate description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Amount Awarded to Other Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering of Common Stock and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Of Common Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering of Common Stock and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax Rate reconciliation net operating loss not benefitted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss not benefitted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation for equity-based awards to employees and directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Segment reporting, CODM, profit (loss) measure, how used, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for (benefit from) income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementNumberOfStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of agreed upon studies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementNumberOfStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Number Of Studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementNumberOfStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of agreed upon studies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant components of deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Investment Holdings [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum duration of the offering period under the employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Duration Of Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum duration of offering period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock outstanding warrants to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">State and Local Income Tax Expense (Benefit), Continuing Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits And Other Assets Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty Pharma Revenue Participation Right Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma Revenue Participation Right Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Pharma Revenue Participation Right Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities Related to Sale of Future Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost not yet recognized, net of estimated forfeitures (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of allocation of stock-based compensation expense related to share-based payment awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ClinicalSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Two Thousand And Twenty Three Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At market issuance two thousand and twenty three sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of remaining term commitments held under loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Remaining Term Commitments Held Under Loan Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of remaining term commitments held under loan agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from debt financing, net of paid debt issuance costs and debt discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Stock Issued During Period Value New Issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering stock issued during period value new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility range, minimum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SalesReturnsAndAllowanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Returns And Allowance [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SalesReturnsAndAllowanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales returns and allowance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SalesReturnsAndAllowanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales returns and allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Covenant Minimum Cash Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Covenant Minimum Cash Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinimumCashBalance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt covenant minimum cash balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation related to issuance of common stock and options in exchange for services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Nature [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-cash Interest Expense on Liabilities for Sales of Future Royalities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash interest expense on liabilities for sales of future royalities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash interest expense on liabilities for sales of future royalities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of base salary in connection with a non-change of control to be considered for severance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan Non Change of Control Triggering Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency period of current base salary to be paid under severance plan non change of control triggering event.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average estimated fair value of employee stock options granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued end of term charges.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued End Of Term Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedEndOfTermCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Holdings [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost related to unvested stock awards not yet recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss of extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating leases, right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental operating and investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SeverancePlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance Plan [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in less than one year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate notes (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ChargebackAndDistributorServiceFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chargeback And Distributor Service Fees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ChargebackAndDistributorServiceFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chargeback and distributor service fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ChargebackAndDistributorServiceFeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Chargebacks and distributor service fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains (Losses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized investment gains (losses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Realized Investment Gains (Losses), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting period of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, if recognized would impact effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfAnnualNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of annual net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PercentageOfAnnualNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of annual net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At market issuance two thousand and twenty sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Two Thousand And Twenty Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation for employees and directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_McKessonFinancialCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">McKesson Financial Center [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_McKessonFinancialCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">McKesson Financial Center.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_McKessonFinancialCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">McKesson Financial Center</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of maturity date terms for term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of options to be granted to purchase shares upon appointment to Board of Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares Upon Appointment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options to be granted to purchase shares upon appointment (shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information by type of sale of the entity's stock. = 2022 Underwritten Public Offering [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FosterCityOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foster City office space lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FosterCityOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foster City Office Space Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FosterCityOfficeSpaceLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foster City Office Space Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total - Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest only period payment term description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Only Period Payment Term Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest only period payment term description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario two .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ScenarioTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Scenario Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty purchase warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing basic net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the period following change of control within which an employee is not offered comparable employment (new or continuing) by the entity or its successor or acquired and to be considered as triggering event for severance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within which no comparable employment is offered by the entity following a change of control</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term, option to terminate lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Claims [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InsuranceClaimsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance Claims</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Liabilities, Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules Loan Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules loan agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesLoanAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hercules Loan Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility range, maximum (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Included in cash and cash equivalents:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of annual salary that can be withheld to purchase shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Of Annual Salary That Can Be Withheld Per Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award maximum amount of annual salary that can be withheld per year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum cash covenant required upon achievement of certain regulatory milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Covenant Min Cash Upon Regulatory Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt covenant minimum cash balance upon regulatory milestone achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedManufacturingActivitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedManufacturingActivitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Activities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AccruedManufacturingActivitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Issuance Costs and Debt Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployerTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount as of the balance sheet date of employer taxes paid to tax authorities representing refunds based on calculated eligible credits. Also called employer tax refund receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployerTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employer Tax Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployerTaxReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee retention credit, CARES Act</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities operating leases right of use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Operating Leases Right Of Use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating leases, right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentRebatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Rebates [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentRebatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Government rebates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_GovernmentRebatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Government rebates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionOneMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option one min cash debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionOneMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option one min cash debt covenant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock under equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees Above The Vice President Level</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees Above The Vice President Level [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees above the vice president level.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncentiveAwardPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the 2011 Incentive Award Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncentiveAwardPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Award Plan2011 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_IncentiveAwardPlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2011 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and cash equivalents gross unrealized losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion, and Amortization [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials and Supplies, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Raw Materials and Supplies, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PerformanceBasedStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ASDSpecialtyHealthcareLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ASD Specialty Healthcare LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ASDSpecialtyHealthcareLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ASD Specialty Healthcare LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ASDSpecialtyHealthcareLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASD Specialty Healthcare LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property and equipment, stated at cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hercules.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_HerculesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hercules [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share - Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid On Or After Fourth Anniversary Of Funding Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid on or after fourth anniversary of funding date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid On Or After Fourth Anniversary Of Funding Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expire beginning 2024 through 2037</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards subject to expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Subject To Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue interest payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SEGMENT REPORTING</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedCapitalizedInterestCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Capitalized Interest Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedCapitalizedInterestCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedCapitalizedInterestCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At market issuance, 2018 sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At Market Issuance Two Thousand And Eighteen Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offering price of common stock per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined public offering price per share of common stock and accompanying stock purchase warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional legal and accounting fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercisable at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PROPERTY AND EQUIPMENT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">INVENTORY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Prior To Third Anniversary Of Funding Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid prior to third anniversary of funding date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Prior To Third Anniversary Of Funding Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent liability related to sale of future royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Liability Related to Sale of Future Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncurrent liability related to sale of future royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the gross unrealized gains for cash and cash equivalents.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Certificates of Deposit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Certificate of deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock options cancelled/forfeited/expired (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at the beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Service [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Goods Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental schedule of non-cash operating and investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument unamortized end of term charge.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized End Of Term Charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized end of term charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and cash equivalents unrealized gains.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the aggregate number of share instruments issued under a share-based compensation plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Aggregate Shares Issued Under Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate shares issued under plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SinaDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sina Drug [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SinaDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sina Drug.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SinaDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sina Drug</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Purchase Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the period within which employee resigns following a change of control due to material change in terms of employment and to be considered as triggering event for severance payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period within which employee resigns following a change of control due to material change in terms of employment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less Than 12 Months - Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of components of Income/(loss) before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of significant components of the entity's deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, increase in option reserves (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, increase in shares reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tranche C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stated interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum interest rate (as a percentage)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFaceAmountExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument face amount expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFaceAmountExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentFaceAmountExpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument face amount expired.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs/debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage applied to common stock market value in calculating purchase price under purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the maximum percentage of annual salary that an employee can choose to have withheld to purchase common stock under the purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Annual Salary That Can Be Withheld</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of annual salary that can be withheld</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tranche three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tranche Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionThreeMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option three min cash debt covenant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_OptionThreeMinCashDebtCovenantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option three min cash debt covenant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ACCRUED LIABILITIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period (in dollars)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US Treasury Securities Due In less than one Year Member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities Due In Less Than One Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury securities (due in less than one year)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Pre-funded Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Pre Funded Warrant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three pre funded warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2023 Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2023 Underwritten Public Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Underwritten Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ChemistryManufacturingAndControlExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chemistry Manufacturing And Control Expenses Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ChemistryManufacturingAndControlExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chemistry, manufacturing, and control expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ChemistryManufacturingAndControlExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Chemistry, Manufacturing, and Control Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae), due in one to two years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government-sponsored enterprise securities (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Retention Credit, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Retention Credit Amount Outstanding Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee retention credit amount outstanding receivables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FormerCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Former collaborative arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FormerCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FormerCollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Former Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification between prepaid and other current assets and deposits and other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Between Prepaid And Other Current Assets And Deposits And Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification between prepaid and other current assets and deposits and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less Than 12 Months - Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplier [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplier</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting, expense information used by CODM, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 1,350,000,000 shares authorized; 606,387,666 and 544,912,215 shares issued and outstanding at December 31, 2024 and 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Employee Related Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaymentPremiumOnPercentageOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Premium on Percentage of Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaymentPremiumOnPercentageOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The prepayment premium on percentage of term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PrepaymentPremiumOnPercentageOfTermLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium on percentage of term loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from public offering issuance of common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Public Offering Issuance Of Common Stock And Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of costs that Janssen must pay during certain phases of the agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Cost Sharing Percentage Of Counterparty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of costs to be paid by Janssen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award minimum exercise price of options granted to employees with more than 10 percentage of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Exercise Price Of Options Granted To Employees With More Than10 Percentage Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum exercise price as a percentage of fair market value for employees having more than 10 % outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding loan amount payable upon maturity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument End Of Term Charge Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">End of term charge for loan, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LiabilityRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Related to Sale of Future Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LiabilityRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liability related to sale of future royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LiabilityRelatedToSaleOfFutureRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability related to sale of future royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) from effect of unrealized losses and exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">12 Months or Greater - Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FairValueMeasurementsInterTransfersBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements inter transfers between levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FairValueMeasurementsInterTransfersBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Inter Transfers Between Levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FairValueMeasurementsInterTransfersBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurements inter transfers between levels.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term, option to extend additional period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options fully vested and expected to vest at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency period of current base salary to be paid under severance plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of base salary to be considered for severance payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SubsequentDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the stock options to be granted by the entity subsequent to the grant upon first appointment to the Board of Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SubsequentDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Director Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_SubsequentDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Director Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2022 Stock Purchase Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Stock Purchase Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Stock Purchase Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in one to two years.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Note Securities Due In One To Two Years [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate notes (due in one to two years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Income Tax Expense (Benefit), Continuing Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Jersey lease and Foster city lease member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Jersey Lease And Foster City Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Jersey Lease And Foster City Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Variable interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage added to prime rate for debt instrument interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DEBT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplier [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplier</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of cash equivalents, restricted cash and marketable securities by security type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock from equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EquityInvestmentReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split ratio for equity investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EquityInvestmentReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investment Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_EquityInvestmentReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment reverse stock split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion and amortization on investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments, at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total number of shares from equity investment that have been sold during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Sold From Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number Of Shares Sold From Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease assets obtained in exchange for operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Funded Warrants Purchase [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ResearchAndClinicalExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Clinical Expenses Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ResearchAndClinicalExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and clinical expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ResearchAndClinicalExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Clinical Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FirstDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the stock options to be granted by the entity to a person who first becomes a non-employee director.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FirstDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Director Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_FirstDirectorOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Director Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Work-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease,remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and warrants excluded from diluted net loss per share calculation due to net loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Lines of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value - Options Outstanding</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ScenarioOneMember" xlink:to="gern_ScenarioOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:to="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PaymentOnRoyaltyAgreement" xlink:to="gern_PaymentOnRoyaltyAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingTable" xlink:to="gern_PublicOfferingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_BiopharmaCreditPlcMember" xlink:to="gern_BiopharmaCreditPlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_AtMarketIssuanceSalesAgreementsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncreaseInAllowanceForDoubtfulAccounts" xlink:to="gern_IncreaseInAllowanceForDoubtfulAccounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TotalGrossToNetAdjustmentsMember" xlink:to="gern_TotalGrossToNetAdjustmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MenloParkOfficeSpaceLeaseMember" xlink:to="gern_MenloParkOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:to="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:to="gern_OperatingLeaseTermAdditionalPeriodExtension_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CommercialPaperDueInLessThanOneYearMember" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SiliconValleyBankMember" xlink:to="gern_SiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:to="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OptionTwoMinCashDebtCovenantMember" xlink:to="gern_OptionTwoMinCashDebtCovenantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinCashUponLicensingTransaction" xlink:to="gern_DebtCovenantMinCashUponLicensingTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheBMember" xlink:to="gern_TrancheBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DirectorsMarketValueStockPurchasePlanMember" xlink:to="gern_DirectorsMarketValueStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtTheMarketOfferingMember" xlink:to="gern_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_PublicOfferingLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CostMethodInvestmentOwnershipPercentage" xlink:to="gern_CostMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OperatingLeaseRentAbatementPeriod" xlink:to="gern_OperatingLeaseRentAbatementPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ProceedsFromSaleOfFutureRoyalties" xlink:to="gern_ProceedsFromSaleOfFutureRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:to="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyTwoPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DueToCounterParty" xlink:to="gern_DueToCounterParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LicenseAgreementDisclosureAbstract" xlink:to="gern_LicenseAgreementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsFederalAndStateCredits" xlink:to="gern_DeferredTaxAssetsFederalAndStateCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheOneMember" xlink:to="gern_TrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheAMember" xlink:to="gern_TrancheAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" xlink:to="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyFourPreFundedWarrantMember" xlink:to="gern_TwoThousandTwentyFourPreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateNoteSecuritiesMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentFloorRate" xlink:to="gern_DebtInstrumentFloorRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:to="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedEndOfTermCharge" xlink:to="gern_AccruedEndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:to="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_JanssenBiotechIncMember" xlink:to="gern_JanssenBiotechIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TotalInterestAndOtherIncomeExpense" xlink:to="gern_TotalInterestAndOtherIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:to="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CaliforniaOfficeSpaceLeaseMember" xlink:to="gern_CaliforniaOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="gern_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:to="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:to="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:to="gern_TwoThousandTwentyTwoPreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_HerculesAndSiliconValleyBankMember" xlink:to="gern_HerculesAndSiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_BorrowingAvailableStartDate" xlink:to="gern_BorrowingAvailableStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CommonStockAggregateOfferingPrice" xlink:to="gern_CommonStockAggregateOfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PharmakonLoanAgreementMember" xlink:to="gern_PharmakonLoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CashAndCashEquivalentsUnrealizedLosses" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:to="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NumberOfSeverancePlan" xlink:to="gern_NumberOfSeverancePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LongTermDebtGross" xlink:to="gern_LongTermDebtGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MunicipalBondsMember" xlink:to="us-gaap_MunicipalBondsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="gern_AtMarketIssuanceSalesAgreementsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfInterestOnPastDueOutstanding" xlink:to="gern_PercentageOfInterestOnPastDueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CommercialExpensesMember" xlink:to="gern_CommercialExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FacilityCosts" xlink:to="us-gaap_FacilityCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CardinalHealthIncMember" xlink:to="gern_CardinalHealthIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NewJerseyOfficeSpaceLeaseMember" xlink:to="gern_NewJerseyOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_RevenuesBeforeAdjustmentsMember" xlink:to="gern_RevenuesBeforeAdjustmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MarketCapMinimumToUseOptionTwo" xlink:to="gern_MarketCapMinimumToUseOptionTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MaximumCommissionRate" xlink:to="gern_MaximumCommissionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NumberOfFinancialInstitutions" xlink:to="gern_NumberOfFinancialInstitutions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_StockPurchaseWarrantsMember" xlink:to="gern_StockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentMinimumPrepaymentAmount" xlink:to="gern_DebtInstrumentMinimumPrepaymentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ConsultantsMember" xlink:to="gern_ConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsRevenueParticipation" xlink:to="gern_DeferredTaxAssetsRevenueParticipation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" xlink:to="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ExpiryDateOfTranche" xlink:to="gern_ExpiryDateOfTranche_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:to="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivablesCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_SeverancePlanLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TermLoansMember" xlink:to="gern_TermLoansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_UpfrontPaymentReceived" xlink:to="gern_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:to="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DirectorsPlan2006Member" xlink:to="gern_DirectorsPlan2006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfCommitmentAmountToFundLoan" xlink:to="gern_PercentageOfCommitmentAmountToFundLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:to="gern_TwoThousandTwentyPreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfPrepaymentCharge" xlink:to="gern_PercentageOfPrepaymentCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_UnderwrittenPublicOfferingMember" xlink:to="gern_UnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LicenseFeesAndRoyaltiesMember" xlink:to="gern_LicenseFeesAndRoyaltiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="gern_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CostMethodInvestmentsCostBasis" xlink:to="gern_CostMethodInvestmentsCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CARESActImpactAbstract" xlink:to="gern_CARESActImpactAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:to="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_DepreciationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:to="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheFourMember" xlink:to="gern_TrancheFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementNumberOfStudies" xlink:to="gern_CollaborativeArrangementNumberOfStudies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="gern_TwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DepositsAndOtherAssetsNoncurrent" xlink:to="gern_DepositsAndOtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:to="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ClinicalSupplyAgreementMember" xlink:to="gern_ClinicalSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PurchaseWarrantsMember" xlink:to="gern_PurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:to="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SalesReturnsAndAllowanceMember" xlink:to="gern_SalesReturnsAndAllowanceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinimumCashBalance" xlink:to="gern_DebtCovenantMinimumCashBalance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" xlink:to="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedEndOfTermCharges" xlink:to="gern_AccruedEndOfTermCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SeverancePlanTable" xlink:to="gern_SeverancePlanTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ChargebackAndDistributorServiceFeesMember" xlink:to="gern_ChargebackAndDistributorServiceFeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PercentageOfAnnualNetSales" xlink:to="gern_PercentageOfAnnualNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_McKessonFinancialCenterMember" xlink:to="gern_McKessonFinancialCenterMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:to="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FosterCityOfficeSpaceLeaseMember" xlink:to="gern_FosterCityOfficeSpaceLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_InterestOnlyPeriodPaymentTermDescription" xlink:to="gern_InterestOnlyPeriodPaymentTermDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ScenarioTwoMember" xlink:to="gern_ScenarioTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceClaimsMember" xlink:to="us-gaap_InsuranceClaimsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_HerculesLoanAgreementMember" xlink:to="gern_HerculesLoanAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:to="gern_DebtCovenantMinCashUponRegulatoryMilestone_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AccruedManufacturingActivitiesCurrent" xlink:to="gern_AccruedManufacturingActivitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EmployerTaxReceivable" xlink:to="gern_EmployerTaxReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:to="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_GovernmentRebatesMember" xlink:to="gern_GovernmentRebatesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheSixMember" xlink:to="gern_TrancheSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OptionOneMinCashDebtCovenantMember" xlink:to="gern_OptionOneMinCashDebtCovenantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EmployeesAboveTheVicePresidentLevelMember" xlink:to="gern_EmployeesAboveTheVicePresidentLevelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_IncentiveAwardPlan2011Member" xlink:to="gern_IncentiveAwardPlan2011Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:to="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheFiveMember" xlink:to="gern_TrancheFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PerformanceBasedStockOptionsMember" xlink:to="gern_PerformanceBasedStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ASDSpecialtyHealthcareLLCMember" xlink:to="gern_ASDSpecialtyHealthcareLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_HerculesMember" xlink:to="gern_HerculesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:to="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="gern_OperatingLossCarryforwardsSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedCapitalizedInterestCosts" xlink:to="us-gaap_AccumulatedCapitalizedInterestCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:to="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CashAndCashEquivalentsUnrealizedGains" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:to="gern_DebtInstrumentUnamortizedEndOfTermCharge_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SinaDrugMember" xlink:to="gern_SinaDrugMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyStockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheTwoMember" xlink:to="gern_TrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:to="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheCMember" xlink:to="gern_TrancheCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentFaceAmountExpired" xlink:to="gern_DebtInstrumentFaceAmountExpired_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TrancheThreeMember" xlink:to="gern_TrancheThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_OptionThreeMinCashDebtCovenantMember" xlink:to="gern_OptionThreeMinCashDebtCovenantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ChemistryManufacturingAndControlExpensesMember" xlink:to="gern_ChemistryManufacturingAndControlExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EmployeeRetentionCreditAmountOutstandingReceivables" xlink:to="gern_EmployeeRetentionCreditAmountOutstandingReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FormerCollaborativeArrangementMember" xlink:to="gern_FormerCollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" xlink:to="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:to="gern_PrepaymentPremiumOnPercentageOfTermLoan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:to="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_DebtInstrumentEndOfTermChargePercentage" xlink:to="gern_DebtInstrumentEndOfTermChargePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LiabilityRelatedToSaleOfFutureRoyalties" xlink:to="gern_LiabilityRelatedToSaleOfFutureRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FairValueMeasurementsInterTransfersBetweenLevels" xlink:to="gern_FairValueMeasurementsInterTransfersBetweenLevels_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_SubsequentDirectorOptionMember" xlink:to="gern_SubsequentDirectorOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:to="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCustomer" xlink:to="us-gaap_ConcentrationRiskCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:to="gern_NewJerseyLeaseAndFosterCityLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_EquityInvestmentReverseStockSplit" xlink:to="gern_EquityInvestmentReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_NumberOfSharesSoldFromEquityInvestment" xlink:to="gern_NumberOfSharesSoldFromEquityInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_PreFundedWarrantsMember" xlink:to="gern_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ResearchAndClinicalExpensesMember" xlink:to="gern_ResearchAndClinicalExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_FirstDirectorOptionMember" xlink:to="gern_FirstDirectorOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="gern_LiabilityRelatedToSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DepositsAndOtherAssetsNoncurrent" xlink:label="gern_DepositsAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="gern_LiabilityRelatedToSaleOfFutureRoyalties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_NontradeReceivablesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="gern_DepositsAndOtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DebtCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LicenseFeesAndRoyaltiesMember" xlink:label="gern_LicenseFeesAndRoyaltiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_LicenseFeesAndRoyaltiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_4"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtTheMarketOfferingMember" xlink:label="gern_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PaymentOnRoyaltyAgreement" xlink:label="gern_PaymentOnRoyaltyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ProceedsFromSaleOfFutureRoyalties" xlink:label="gern_ProceedsFromSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" xlink:label="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseInAllowanceForDoubtfulAccounts" xlink:label="gern_IncreaseInAllowanceForDoubtfulAccounts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gern_PaymentOnRoyaltyAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="gern_ProceedsFromSaleOfFutureRoyalties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gern_IncreaseDecreaseInOperatingLeaseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gern_IncreaseInAllowanceForDoubtfulAccounts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureInventory" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureLicenseAgreement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LicenseAgreementDisclosureAbstract" xlink:label="gern_LicenseAgreementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" xlink:label="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:label="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" xlink:label="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyFourPreFundedWarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAbstract" xlink:label="us-gaap_DepreciationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DepreciationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RevenuesBeforeAdjustmentsMember" xlink:label="gern_RevenuesBeforeAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ChargebackAndDistributorServiceFeesMember" xlink:label="gern_ChargebackAndDistributorServiceFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentRebatesMember" xlink:label="gern_GovernmentRebatesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SalesReturnsAndAllowanceMember" xlink:label="gern_SalesReturnsAndAllowanceMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TotalGrossToNetAdjustmentsMember" xlink:label="gern_TotalGrossToNetAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_RevenuesBeforeAdjustmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_ChargebackAndDistributorServiceFeesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_GovernmentRebatesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_SalesReturnsAndAllowanceMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_TotalGrossToNetAdjustmentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CostMethodInvestmentsCostBasis" xlink:label="gern_CostMethodInvestmentsCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfSharesSoldFromEquityInvestment" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EquityInvestmentReverseStockSplit" xlink:label="gern_EquityInvestmentReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CostMethodInvestmentOwnershipPercentage" xlink:label="gern_CostMethodInvestmentOwnershipPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquitySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentsCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_SummaryOfInvestmentHoldingsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_NumberOfSharesSoldFromEquityInvestment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_EquityInvestmentReverseStockSplit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentOwnershipPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FairValueMeasurementsInterTransfersBetweenLevels" xlink:label="gern_FairValueMeasurementsInterTransfersBetweenLevels"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="gern_FairValueMeasurementsInterTransfersBetweenLevels" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_McKessonFinancialCenterMember" xlink:label="gern_McKessonFinancialCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfFinancialInstitutions" xlink:label="gern_NumberOfFinancialInstitutions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ASDSpecialtyHealthcareLLCMember" xlink:label="gern_ASDSpecialtyHealthcareLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CardinalHealthIncMember" xlink:label="gern_CardinalHealthIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SinaDrugMember" xlink:label="gern_SinaDrugMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_McKessonFinancialCenterMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="gern_NumberOfFinancialInstitutions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_ASDSpecialtyHealthcareLLCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_CardinalHealthIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRiskCustomer" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_SinaDrugMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FormerCollaborativeArrangementMember" xlink:label="gern_FormerCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LicenseAgreementDisclosureAbstract" xlink:label="gern_LicenseAgreementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_JanssenBiotechIncMember" xlink:label="gern_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementNumberOfStudies" xlink:label="gern_CollaborativeArrangementNumberOfStudies"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClinicalSupplyAgreementMember" xlink:label="gern_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DueToCounterParty" xlink:label="gern_DueToCounterParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_FormerCollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gern_JanssenBiotechIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementNumberOfStudies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_ClinicalSupplyAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfEntity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_DueToCounterParty" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedManufacturingActivitiesCurrent" xlink:label="gern_AccruedManufacturingActivitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="gern_AccruedManufacturingActivitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SeverancePlanLineItems" xlink:label="gern_SeverancePlanLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfSeverancePlan" xlink:label="gern_NumberOfSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SeverancePlanTable" xlink:label="gern_SeverancePlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployeesAboveTheVicePresidentLevelMember" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_InsuranceClaimsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_NumberOfSeverancePlan" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="gern_SeverancePlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gern_EmployeesAboveTheVicePresidentLevelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanTable" xlink:to="gern_SeverancePlanLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_SeverancePlanLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MenloParkOfficeSpaceLeaseMember" xlink:label="gern_MenloParkOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NewJerseyOfficeSpaceLeaseMember" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FosterCityOfficeSpaceLeaseMember" xlink:label="gern_FosterCityOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CaliforniaOfficeSpaceLeaseMember" xlink:label="gern_CaliforniaOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLeaseRentAbatementPeriod" xlink:label="gern_OperatingLeaseRentAbatementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseTermAdditionalPeriodExtension" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_MenloParkOfficeSpaceLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyOfficeSpaceLeaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_FosterCityOfficeSpaceLeaseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_CaliforniaOfficeSpaceLeaseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseRentAbatementPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyLeaseAndFosterCityLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesLoanAgreementMember" xlink:label="gern_HerculesLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesAndSiliconValleyBankMember" xlink:label="gern_HerculesAndSiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheOneMember" xlink:label="gern_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_BiopharmaCreditPlcMember" xlink:label="gern_BiopharmaCreditPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PharmakonLoanAgreementMember" xlink:label="gern_PharmakonLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesMember" xlink:label="gern_HerculesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheTwoMember" xlink:label="gern_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SiliconValleyBankMember" xlink:label="gern_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheThreeMember" xlink:label="gern_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheFourMember" xlink:label="gern_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheFiveMember" xlink:label="gern_TrancheFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScenarioOneMember" xlink:label="gern_ScenarioOneMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_BorrowingAvailableStartDate" xlink:label="gern_BorrowingAvailableStartDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheSixMember" xlink:label="gern_TrancheSixMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScenarioTwoMember" xlink:label="gern_ScenarioTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ExpiryDateOfTranche" xlink:label="gern_ExpiryDateOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionOneMinCashDebtCovenantMember" xlink:label="gern_OptionOneMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionTwoMinCashDebtCovenantMember" xlink:label="gern_OptionTwoMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionThreeMinCashDebtCovenantMember" xlink:label="gern_OptionThreeMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheAMember" xlink:label="gern_TrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheBMember" xlink:label="gern_TrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheCMember" xlink:label="gern_TrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentFloorRate" xlink:label="gern_DebtInstrumentFloorRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TermLoansMember" xlink:label="gern_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfCommitmentAmountToFundLoan" xlink:label="gern_PercentageOfCommitmentAmountToFundLoan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:label="gern_PrepaymentPremiumOnPercentageOfTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_17"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UpfrontPaymentReceived" xlink:label="gern_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfAnnualNetSales" xlink:label="gern_PercentageOfAnnualNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_InterestOnlyPeriodPaymentTermDescription" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentEndOfTermChargePercentage" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentMinimumPrepaymentAmount" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfPrepaymentCharge" xlink:label="gern_PercentageOfPrepaymentCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinimumCashBalance" xlink:label="gern_DebtCovenantMinimumCashBalance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MarketCapMinimumToUseOptionTwo" xlink:label="gern_MarketCapMinimumToUseOptionTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FacilityCosts" xlink:label="us-gaap_FacilityCosts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentFaceAmountExpired" xlink:label="gern_DebtInstrumentFaceAmountExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinCashUponLicensingTransaction" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfInterestOnPastDueOutstanding" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedEndOfTermCharge" xlink:label="gern_AccruedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedEndOfTermCharges" xlink:label="gern_AccruedEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_HerculesLoanAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesAndSiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gern_BiopharmaCreditPlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_PharmakonLoanAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_SiliconValleyBankMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_ScenarioOneMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_BorrowingAvailableStartDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_ScenarioTwoMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_ExpiryDateOfTranche" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionOneMinCashDebtCovenantMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionTwoMinCashDebtCovenantMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionThreeMinCashDebtCovenantMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheAMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheBMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheCMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentFloorRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TermLoansMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfCommitmentAmountToFundLoan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PrepaymentPremiumOnPercentageOfTermLoan" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_UpfrontPaymentReceived" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfAnnualNetSales" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RoyaltyExpense" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_InterestOnlyPeriodPaymentTermDescription" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentEndOfTermChargePercentage" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentMinimumPrepaymentAmount" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfPrepaymentCharge" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalance" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MarketCapMinimumToUseOptionTwo" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FacilityCosts" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentFaceAmountExpired" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponLicensingTransaction" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponRegulatoryMilestone" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfInterestOnPastDueOutstanding" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharge" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharges" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LongTermDebtGross" xlink:label="gern_LongTermDebtGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedCapitalizedInterestCosts" xlink:label="us-gaap_AccumulatedCapitalizedInterestCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="gern_LongTermDebtGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_AccumulatedCapitalizedInterestCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="gern_DebtInstrumentUnamortizedEndOfTermCharge" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtCurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingTable" xlink:label="gern_PublicOfferingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingLineItems" xlink:label="gern_PublicOfferingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoPreFundedWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_PublicOfferingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingTable" xlink:to="gern_PublicOfferingLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyFourPreFundedWarrantMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PurchaseWarrantsMember" xlink:label="gern_PurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyPreFundedWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyStockPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommonStockAggregateOfferingPrice" xlink:label="gern_CommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceSalesAgreementsTable" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MaximumCommissionRate" xlink:label="gern_MaximumCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_CommonStockAggregateOfferingPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_AtMarketIssuanceSalesAgreementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_MaximumCommissionRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="gern_AtMarketIssuanceSalesAgreementsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncentiveAwardPlan2011Member" xlink:label="gern_IncentiveAwardPlan2011Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DirectorsPlan2006Member" xlink:label="gern_DirectorsPlan2006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FirstDirectorOptionMember" xlink:label="gern_FirstDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DirectorsMarketValueStockPurchasePlanMember" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SubsequentDirectorOptionMember" xlink:label="gern_SubsequentDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_IncentiveAwardPlan2011Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsPlan2006Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_FirstDirectorOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsMarketValueStockPurchasePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_SubsequentDirectorOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" xlink:label="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ConsultantsMember" xlink:label="gern_ConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="gern_ConsultantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsFederalAndStateCredits" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsRevenueParticipation" xlink:label="gern_DeferredTaxAssetsRevenueParticipation"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsFederalAndStateCredits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsRevenueParticipation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxAssetsOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="gern_OperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CARESActImpactAbstract" xlink:label="gern_CARESActImpactAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployerTaxReceivable" xlink:label="gern_EmployerTaxReceivable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployeeRetentionCreditAmountOutstandingReceivables" xlink:label="gern_EmployeeRetentionCreditAmountOutstandingReceivables"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_CARESActImpactAbstract" xlink:to="gern_EmployerTaxReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gern_CARESActImpactAbstract" xlink:to="gern_EmployeeRetentionCreditAmountOutstandingReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" xlink:label="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ResearchAndClinicalExpensesMember" xlink:label="gern_ResearchAndClinicalExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ChemistryManufacturingAndControlExpensesMember" xlink:label="gern_ChemistryManufacturingAndControlExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialExpensesMember" xlink:label="gern_CommercialExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TotalInterestAndOtherIncomeExpense" xlink:label="gern_TotalInterestAndOtherIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_ResearchAndClinicalExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_ChemistryManufacturingAndControlExpensesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_CommercialExpensesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gern_TotalInterestAndOtherIncomeExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPurchaseWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LicenseFeesAndRoyaltiesMember" xlink:label="gern_LicenseFeesAndRoyaltiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_LicenseFeesAndRoyaltiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" xlink:label="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" xlink:label="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtTheMarketOfferingMember" xlink:label="gern_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_PublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PublicOfferingOfCommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyFourPreFundedWarrantMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RevenuesBeforeAdjustmentsMember" xlink:label="gern_RevenuesBeforeAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ChargebackAndDistributorServiceFeesMember" xlink:label="gern_ChargebackAndDistributorServiceFeesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentRebatesMember" xlink:label="gern_GovernmentRebatesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SalesReturnsAndAllowanceMember" xlink:label="gern_SalesReturnsAndAllowanceMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TotalGrossToNetAdjustmentsMember" xlink:label="gern_TotalGrossToNetAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_RevenuesBeforeAdjustmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_ChargebackAndDistributorServiceFeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_GovernmentRebatesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_SalesReturnsAndAllowanceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_TotalGrossToNetAdjustmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:label="us-gaap_RestrictedCashAndInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RestrictedCashAndInvestmentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInLessThanOneYearMember" xlink:label="gern_USTreasurySecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_USTreasurySecuritiesDueInOneToTwoYearsMember" xlink:label="gern_USTreasurySecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInLessThanOneYearMember" xlink:label="gern_MunicipalSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MunicipalSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_MunicipalSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialPaperDueInLessThanOneYearMember" xlink:label="gern_CommercialPaperDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" xlink:label="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" xlink:label="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CommercialPaperDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember" xlink:label="us-gaap_MunicipalBondsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="us-gaap_CorporateNoteSecuritiesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CertificatesOfDepositMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MunicipalBondsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateNoteSecuritiesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:label="us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable" xlink:label="us-gaap_SummaryOfInvestmentHoldingsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CostMethodInvestmentsCostBasis" xlink:label="gern_CostMethodInvestmentsCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" xlink:label="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfSharesSoldFromEquityInvestment" xlink:label="gern_NumberOfSharesSoldFromEquityInvestment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EquityInvestmentReverseStockSplit" xlink:label="gern_EquityInvestmentReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CostMethodInvestmentOwnershipPercentage" xlink:label="gern_CostMethodInvestmentOwnershipPercentage"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_SummaryOfInvestmentHoldingsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquitySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentsCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedBalanceShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="us-gaap_RealizedInvestmentGainsLosses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_NumberOfSharesSoldFromEquityInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_EquityInvestmentReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="gern_CostMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_McKessonFinancialCenterMember" xlink:label="gern_McKessonFinancialCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfFinancialInstitutions" xlink:label="gern_NumberOfFinancialInstitutions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ASDSpecialtyHealthcareLLCMember" xlink:label="gern_ASDSpecialtyHealthcareLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CardinalHealthIncMember" xlink:label="gern_CardinalHealthIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCustomer" xlink:label="us-gaap_ConcentrationRiskCustomer"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SinaDrugMember" xlink:label="gern_SinaDrugMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_McKessonFinancialCenterMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="gern_NumberOfFinancialInstitutions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_ASDSpecialtyHealthcareLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_CardinalHealthIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRiskCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_SinaDrugMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FormerCollaborativeArrangementMember" xlink:label="gern_FormerCollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_JanssenBiotechIncMember" xlink:label="gern_JanssenBiotechIncMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementNumberOfStudies" xlink:label="gern_CollaborativeArrangementNumberOfStudies"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClinicalSupplyAgreementMember" xlink:label="gern_ClinicalSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" xlink:label="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" xlink:label="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DueToCounterParty" xlink:label="gern_DueToCounterParty"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_FormerCollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gern_JanssenBiotechIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementNumberOfStudies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_ClinicalSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gern_DueToCounterParty" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SeverancePlanLineItems" xlink:label="gern_SeverancePlanLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SeverancePlanTable" xlink:label="gern_SeverancePlanTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceClaimsMember" xlink:label="us-gaap_InsuranceClaimsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NumberOfSeverancePlan" xlink:label="gern_NumberOfSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EmployeesAboveTheVicePresidentLevelMember" xlink:label="gern_EmployeesAboveTheVicePresidentLevelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" xlink:label="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" xlink:label="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" xlink:label="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_SeverancePlanTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_InsuranceClaimsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_NumberOfSeverancePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_SeverancePlanTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gern_EmployeesAboveTheVicePresidentLevelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_SeverancePlanTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_SeverancePlanTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_SeverancePlanLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLeaseTermAdditionalPeriodExtension" xlink:label="gern_OperatingLeaseTermAdditionalPeriodExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MenloParkOfficeSpaceLeaseMember" xlink:label="gern_MenloParkOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NewJerseyOfficeSpaceLeaseMember" xlink:label="gern_NewJerseyOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FosterCityOfficeSpaceLeaseMember" xlink:label="gern_FosterCityOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CaliforniaOfficeSpaceLeaseMember" xlink:label="gern_CaliforniaOfficeSpaceLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLeaseRentAbatementPeriod" xlink:label="gern_OperatingLeaseRentAbatementPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseTermAdditionalPeriodExtension" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_MenloParkOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_FosterCityOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_CaliforniaOfficeSpaceLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="gern_OperatingLeaseRentAbatementPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NewJerseyLeaseAndFosterCityLeaseMember" xlink:label="gern_NewJerseyLeaseAndFosterCityLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="gern_NewJerseyLeaseAndFosterCityLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesLoanAgreementMember" xlink:label="gern_HerculesLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesAndSiliconValleyBankMember" xlink:label="gern_HerculesAndSiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheOneMember" xlink:label="gern_TrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_BiopharmaCreditPlcMember" xlink:label="gern_BiopharmaCreditPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PharmakonLoanAgreementMember" xlink:label="gern_PharmakonLoanAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_HerculesMember" xlink:label="gern_HerculesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheTwoMember" xlink:label="gern_TrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SiliconValleyBankMember" xlink:label="gern_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheThreeMember" xlink:label="gern_TrancheThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheFourMember" xlink:label="gern_TrancheFourMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" xlink:label="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheFiveMember" xlink:label="gern_TrancheFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScenarioOneMember" xlink:label="gern_ScenarioOneMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_BorrowingAvailableStartDate" xlink:label="gern_BorrowingAvailableStartDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheSixMember" xlink:label="gern_TrancheSixMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ScenarioTwoMember" xlink:label="gern_ScenarioTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ExpiryDateOfTranche" xlink:label="gern_ExpiryDateOfTranche"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionOneMinCashDebtCovenantMember" xlink:label="gern_OptionOneMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionTwoMinCashDebtCovenantMember" xlink:label="gern_OptionTwoMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OptionThreeMinCashDebtCovenantMember" xlink:label="gern_OptionThreeMinCashDebtCovenantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheAMember" xlink:label="gern_TrancheAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheBMember" xlink:label="gern_TrancheBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TrancheCMember" xlink:label="gern_TrancheCMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentFloorRate" xlink:label="gern_DebtInstrumentFloorRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TermLoansMember" xlink:label="gern_TermLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfCommitmentAmountToFundLoan" xlink:label="gern_PercentageOfCommitmentAmountToFundLoan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PrepaymentPremiumOnPercentageOfTermLoan" xlink:label="gern_PrepaymentPremiumOnPercentageOfTermLoan"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UpfrontPaymentReceived" xlink:label="gern_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfAnnualNetSales" xlink:label="gern_PercentageOfAnnualNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_InterestOnlyPeriodPaymentTermDescription" xlink:label="gern_InterestOnlyPeriodPaymentTermDescription"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentEndOfTermChargePercentage" xlink:label="gern_DebtInstrumentEndOfTermChargePercentage"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentMinimumPrepaymentAmount" xlink:label="gern_DebtInstrumentMinimumPrepaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfPrepaymentCharge" xlink:label="gern_PercentageOfPrepaymentCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" xlink:label="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinimumCashBalance" xlink:label="gern_DebtCovenantMinimumCashBalance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MarketCapMinimumToUseOptionTwo" xlink:label="gern_MarketCapMinimumToUseOptionTwo"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" xlink:label="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" xlink:label="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FacilityCosts" xlink:label="us-gaap_FacilityCosts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentFaceAmountExpired" xlink:label="gern_DebtInstrumentFaceAmountExpired"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" xlink:label="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinCashUponLicensingTransaction" xlink:label="gern_DebtCovenantMinCashUponLicensingTransaction"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtCovenantMinCashUponRegulatoryMilestone" xlink:label="gern_DebtCovenantMinCashUponRegulatoryMilestone"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfInterestOnPastDueOutstanding" xlink:label="gern_PercentageOfInterestOnPastDueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedEndOfTermCharge" xlink:label="gern_AccruedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedEndOfTermCharges" xlink:label="gern_AccruedEndOfTermCharges"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" xlink:label="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_HerculesLoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesAndSiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gern_BiopharmaCreditPlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_PharmakonLoanAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_HerculesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gern_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_ScenarioOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_BorrowingAvailableStartDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gern_ScenarioTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_ExpiryDateOfTranche" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionOneMinCashDebtCovenantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionTwoMinCashDebtCovenantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_OptionThreeMinCashDebtCovenantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TrancheCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentFloorRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="gern_TermLoansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfCommitmentAmountToFundLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PrepaymentPremiumOnPercentageOfTermLoan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfAnnualNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_InterestOnlyPeriodPaymentTermDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentEndOfTermChargePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentMinimumPrepaymentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfPrepaymentCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinimumCashBalance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MarketCapMinimumToUseOptionTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FacilityCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtInstrumentFaceAmountExpired" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponLicensingTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_DebtCovenantMinCashUponRegulatoryMilestone" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfInterestOnPastDueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharge" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_AccruedEndOfTermCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" xlink:label="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingLineItems" xlink:label="gern_PublicOfferingLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PublicOfferingTable" xlink:label="gern_PublicOfferingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyTwoPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreePreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyThreePreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyFourPreFundedWarrantMember" xlink:label="gern_TwoThousandTwentyFourPreFundedWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_PublicOfferingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoPreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_PublicOfferingTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyThreePreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyFourPreFundedWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_PublicOfferingLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" xlink:label="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPreFundedWarrantsMember" xlink:label="gern_TwoThousandTwentyPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_UnderwrittenPublicOfferingMember" xlink:label="gern_UnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyStockPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyStockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PurchaseWarrantsMember" xlink:label="gern_PurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_StockPurchaseWarrantsMember" xlink:label="gern_StockPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PreFundedWarrantsMember" xlink:label="gern_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyPreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_UnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_TwoThousandTwentyStockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_PurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_StockPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gern_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails">
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:label="gern_AtMarketIssuanceSalesAgreementsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceSalesAgreementsTable" xlink:label="gern_AtMarketIssuanceSalesAgreementsTable"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommonStockAggregateOfferingPrice" xlink:label="gern_CommonStockAggregateOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_MaximumCommissionRate" xlink:label="gern_MaximumCommissionRate"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" xlink:label="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_AtMarketIssuanceSalesAgreementsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_CommonStockAggregateOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gern_AtMarketIssuanceSalesAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="gern_MaximumCommissionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_AtMarketIssuanceSalesAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncentiveAwardPlan2011Member" xlink:label="gern_IncentiveAwardPlan2011Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_FirstDirectorOptionMember" xlink:label="gern_FirstDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="gern_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_SubsequentDirectorOptionMember" xlink:label="gern_SubsequentDirectorOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DirectorsPlan2006Member" xlink:label="gern_DirectorsPlan2006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DirectorsMarketValueStockPurchasePlanMember" xlink:label="gern_DirectorsMarketValueStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" xlink:label="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_IncentiveAwardPlan2011Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_FirstDirectorOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_SubsequentDirectorOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsPlan2006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_DirectorsMarketValueStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandAndEighteenInducementAwardPlanMember" xlink:label="gern_TwoThousandAndEighteenInducementAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="gern_TwoThousandAndEighteenInducementAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" xlink:label="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PerformanceBasedStockOptionsMember" xlink:label="gern_PerformanceBasedStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gern_PerformanceBasedStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ConsultantsMember" xlink:label="gern_ConsultantsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="gern_ConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="gern_OperatingLossCarryforwardsSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="gern_OperatingLossCarryforwardsSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="us-gaap_TaxCreditCarryforwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="us-gaap_TaxCreditCarryforwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TaxCreditCarryforwardTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ResearchAndClinicalExpensesMember" xlink:label="gern_ResearchAndClinicalExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ChemistryManufacturingAndControlExpensesMember" xlink:label="gern_ChemistryManufacturingAndControlExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CommercialExpensesMember" xlink:label="gern_CommercialExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TotalInterestAndOtherIncomeExpense" xlink:label="gern_TotalInterestAndOtherIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_ResearchAndClinicalExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_ChemistryManufacturingAndControlExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="gern_CommercialExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="gern_TotalInterestAndOtherIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" xlink:label="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" xlink:label="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_TwoThousandTwentyTwoPurchaseWarrantsMember" xlink:label="gern_TwoThousandTwentyTwoPurchaseWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" xlink:label="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="gern_LiabilityRelatedToSaleOfFutureRoyalties" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="gern_DepositsAndOtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_NontradeReceivablesCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DebtCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="gern_LiabilityRelatedToSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DepositsAndOtherAssetsNoncurrent" xlink:label="gern_DepositsAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NontradeReceivablesCurrent" xlink:label="us-gaap_NontradeReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_IncreaseInAllowanceForDoubtfulAccounts" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="gern_ProceedsFromSaleOfFutureRoyalties" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_PaymentOnRoyaltyAgreement" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="6" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="7" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="11" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="12" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" order="16" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="17" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="18" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="19" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="20" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="21" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="22" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="24" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="gern_IncreaseDecreaseInOperatingLeaseLiabilities" order="25" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseInAllowanceForDoubtfulAccounts" xlink:label="gern_IncreaseInAllowanceForDoubtfulAccounts"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" xlink:label="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" xlink:label="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_ProceedsFromSaleOfFutureRoyalties" xlink:label="gern_ProceedsFromSaleOfFutureRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_PaymentOnRoyaltyAgreement" xlink:label="gern_PaymentOnRoyaltyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" xlink:label="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="gern_IncreaseDecreaseInOperatingLeaseLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="gern_CashAndCashEquivalentsUnrealizedGains" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="gern_CashAndCashEquivalentsUnrealizedLosses" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedInvestmentsAtFairValue" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedGains" xlink:label="gern_CashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsUnrealizedGains" xlink:label="gern_RestrictedCashAndCashEquivalentsUnrealizedGains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_CashAndCashEquivalentsUnrealizedLosses" xlink:label="gern_CashAndCashEquivalentsUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" xlink:label="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="us-gaap_RestrictedInvestmentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gern_AccruedManufacturingActivitiesCurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" xlink:label="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_AccruedManufacturingActivitiesCurrent" xlink:label="gern_AccruedManufacturingActivitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="gern_LongTermDebtGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_AccumulatedCapitalizedInterestCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="gern_LongTermDebtGross" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="gern_DebtInstrumentUnamortizedEndOfTermCharge" order="6" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtCurrent" order="7" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_LongTermDebtGross" xlink:label="gern_LongTermDebtGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedCapitalizedInterestCosts" xlink:label="us-gaap_AccumulatedCapitalizedInterestCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DebtInstrumentUnamortizedEndOfTermCharge" xlink:label="gern_DebtInstrumentUnamortizedEndOfTermCharge"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" xlink:label="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsFederalAndStateCredits" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsRevenueParticipation" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="gern_DeferredTaxAssetsOperatingLeaseLiabilities" order="5" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" xlink:label="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsFederalAndStateCredits" xlink:label="gern_DeferredTaxAssetsFederalAndStateCredits"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsRevenueParticipation" xlink:label="gern_DeferredTaxAssetsRevenueParticipation"/>
          <link:loc xlink:type="locator" xlink:href="gern-20241231.xsd#gern_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="gern_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="gern_ConsultantsMember" name="ConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_USTreasurySecuritiesDueInOneToTwoYearsMember" name="USTreasurySecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_IncentiveAwardPlan2011Member" name="IncentiveAwardPlan2011Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_GovernmentRebatesMember" name="GovernmentRebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyThreePreFundedWarrantMember" name="TwoThousandTwentyThreePreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TotalInterestAndOtherIncomeExpense" name="TotalInterestAndOtherIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_CommercialPaperDueInLessThanOneYearMember" name="CommercialPaperDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" name="TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" name="Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_CollaborativeArrangementCostSharingPercentageOfEntity" name="CollaborativeArrangementCostSharingPercentageOfEntity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ClinicalSupplyAgreementMember" name="ClinicalSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember" name="TwoThousandTwentyFourUnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EmployeeRetentionCreditAmountOutstandingReceivables" name="EmployeeRetentionCreditAmountOutstandingReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_StockPurchaseWarrantsMember" name="StockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheBMember" name="TrancheBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_SeverancePlanTable" name="SeverancePlanTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_JanssenBiotechIncMember" name="JanssenBiotechIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LicenseAgreementDisclosureAbstract" name="LicenseAgreementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_HerculesMember" name="HerculesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" name="LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_FairValueMeasurementsInterTransfersBetweenLevels" name="FairValueMeasurementsInterTransfersBetweenLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_AtMarketIssuanceSalesAgreementsTable" name="AtMarketIssuanceSalesAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtCovenantMinimumCashBalance" name="DebtCovenantMinimumCashBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember" name="TwoThousandTwentyTwoStockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_CollaborativeArrangementNumberOfStudies" name="CollaborativeArrangementNumberOfStudies" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" name="ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount" name="DebtCovenantMinimumCashBalancePercentageOfLoanAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_USTreasurySecuritiesDueInLessThanOneYearMember" name="USTreasurySecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" name="GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandTwentyStockPurchaseWarrantsMember" name="TwoThousandTwentyStockPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" name="GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtInstrumentFaceAmountExpired" name="DebtInstrumentFaceAmountExpired" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_DebtInstrumentMinimumPrepaymentAmount" name="DebtInstrumentMinimumPrepaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" name="ShareBasedCompensationForfeituresAndExpirationsInPeriodNet" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_NewJerseyOfficeSpaceLeaseMember" name="NewJerseyOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyFourPreFundedWarrantMember" name="TwoThousandTwentyFourPreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheTwoMember" name="TrancheTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtInstrumentEndOfTermChargePercentage" name="DebtInstrumentEndOfTermChargePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PercentageOfCommitmentAmountToFundLoan" name="PercentageOfCommitmentAmountToFundLoan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtCovenantMinCashUponRegulatoryMilestone" name="DebtCovenantMinCashUponRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TrancheFourMember" name="TrancheFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DeferredTaxAssetsFederalAndStateCredits" name="DeferredTaxAssetsFederalAndStateCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" name="LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" name="ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_McKessonFinancialCenterMember" name="McKessonFinancialCenterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CommercialExpensesMember" name="CommercialExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" name="ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_SinaDrugMember" name="SinaDrugMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandTwentyPreFundedWarrantsMember" name="TwoThousandTwentyPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CARESActImpactAbstract" name="CARESActImpactAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_OptionThreeMinCashDebtCovenantMember" name="OptionThreeMinCashDebtCovenantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TrancheOneMember" name="TrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" name="USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" name="ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_NumberOfFinancialInstitutions" name="NumberOfFinancialInstitutions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_PercentageOfPrepaymentCharge" name="PercentageOfPrepaymentCharge" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TermLoansMember" name="TermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate" name="DollarPrepaymentCharge36MonthsAfterEffectiveDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" name="PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PublicOfferingTable" name="PublicOfferingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" name="PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" name="LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_InterestOnlyPeriodPaymentTermDescription" name="InterestOnlyPeriodPaymentTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_OptionTwoMinCashDebtCovenantMember" name="OptionTwoMinCashDebtCovenantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PercentageOfAnnualNetSales" name="PercentageOfAnnualNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtInstrumentUnamortizedEndOfTermCharge" name="DebtInstrumentUnamortizedEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_NumberOfSeverancePlan" name="NumberOfSeverancePlan" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TwoThousandTwentyTwoPreFundedWarrantMember" name="TwoThousandTwentyTwoPreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AccruedManufacturingActivitiesCurrent" name="AccruedManufacturingActivitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" name="AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_LicenseFeesAndRoyaltiesMember" name="LicenseFeesAndRoyaltiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" name="RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CorporateNoteSecuritiesDueInLessThanOneYearMember" name="CorporateNoteSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EquityInvestmentReverseStockSplit" name="EquityInvestmentReverseStockSplit" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" name="LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DirectorsPlan2006Member" name="DirectorsPlan2006Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues" name="PublicOfferingStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PurchaseWarrantsMember" name="PurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_BiopharmaCreditPlcMember" name="BiopharmaCreditPlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" name="IssuanceOfCommonStockInConnectionWithWarrantExerciseValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_SalesReturnsAndAllowanceMember" name="SalesReturnsAndAllowanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyTwoPurchaseWarrantsMember" name="TwoThousandTwentyTwoPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CostMethodInvestmentOwnershipPercentage" name="CostMethodInvestmentOwnershipPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" name="DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_NumberOfSharesSoldFromEquityInvestment" name="NumberOfSharesSoldFromEquityInvestment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ChemistryManufacturingAndControlExpensesMember" name="ChemistryManufacturingAndControlExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PrepaymentPremiumOnPercentageOfTermLoan" name="PrepaymentPremiumOnPercentageOfTermLoan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ProceedsFromSaleOfFutureRoyalties" name="ProceedsFromSaleOfFutureRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_TwoThousandAndEighteenEquityIncentivePlanMember" name="TwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_FormerCollaborativeArrangementMember" name="FormerCollaborativeArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandAndEighteenInducementAwardPlanMember" name="TwoThousandAndEighteenInducementAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheFiveMember" name="TrancheFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_SeverancePlanLineItems" name="SeverancePlanLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" name="USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue" name="PublicOfferingStockIssuedDuringPeriodValueNewIssue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" name="AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" name="IssuanceOfCommonStockInConnectionWithWarrantExerciseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_MunicipalSecuritiesDueInLessThanOneYearMember" name="MunicipalSecuritiesDueInLessThanOneYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" name="NoncurrentLiabilityRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_PercentageOfInterestOnPastDueOutstanding" name="PercentageOfInterestOnPastDueOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_DebtInstrumentFloorRate" name="DebtInstrumentFloorRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_NewJerseyLeaseAndFosterCityLeaseMember" name="NewJerseyLeaseAndFosterCityLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TotalGrossToNetAdjustmentsMember" name="TotalGrossToNetAdjustmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_OperatingLeaseRentAbatementPeriod" name="OperatingLeaseRentAbatementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_HerculesLoanAgreementMember" name="HerculesLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheThreeMember" name="TrancheThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CollaborativeArrangementCostSharingPercentageOfCounterparty" name="CollaborativeArrangementCostSharingPercentageOfCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" name="EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_DueToCounterParty" name="DueToCounterParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_LongTermDebtGross" name="LongTermDebtGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_DeferredTaxAssetsRevenueParticipation" name="DeferredTaxAssetsRevenueParticipation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_AtMarketIssuanceSalesAgreementsLineItems" name="AtMarketIssuanceSalesAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" name="LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_MarketCapMinimumToUseOptionTwo" name="MarketCapMinimumToUseOptionTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" name="TwoThousandTwentyThreeUnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PharmakonLoanAgreementMember" name="PharmakonLoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EmployerTaxReceivable" name="EmployerTaxReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" name="IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" name="CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PublicOfferingLineItems" name="PublicOfferingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" name="AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" name="TwoThousandTwentyTwoUnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_MunicipalSecuritiesDueInOneToTwoYearsMember" name="MunicipalSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ScenarioOneMember" name="ScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_RestrictedCashAndCashEquivalentsUnrealizedGains" name="RestrictedCashAndCashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_ScenarioTwoMember" name="ScenarioTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CommonStockAggregateOfferingPrice" name="CommonStockAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_OptionOneMinCashDebtCovenantMember" name="OptionOneMinCashDebtCovenantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_HerculesAndSiliconValleyBankMember" name="HerculesAndSiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PublicOfferingOfCommonStockAndWarrantsMember" name="PublicOfferingOfCommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CardinalHealthIncMember" name="CardinalHealthIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_RevenuesBeforeAdjustmentsMember" name="RevenuesBeforeAdjustmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_MaximumCommissionRate" name="MaximumCommissionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_TrancheAMember" name="TrancheAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TwoThousandTwentyPurchaseWarrantsMember" name="TwoThousandTwentyPurchaseWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_BorrowingAvailableStartDate" name="BorrowingAvailableStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" name="RestrictedCashAndCashEquivalentsGrossUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ExpiryDateOfTranche" name="ExpiryDateOfTranche" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember" name="PrepaidPriorToThirdAnniversaryOfFundingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CashAndCashEquivalentsUnrealizedLosses" name="CashAndCashEquivalentsUnrealizedLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_OperatingLeaseTermAdditionalPeriodExtension" name="OperatingLeaseTermAdditionalPeriodExtension" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_PerformanceBasedStockOptionsMember" name="PerformanceBasedStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" name="AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" name="ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_IncreaseInAllowanceForDoubtfulAccounts" name="IncreaseInAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_LiabilityRelatedToSaleOfFutureRoyalties" name="LiabilityRelatedToSaleOfFutureRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_EmployeesAboveTheVicePresidentLevelMember" name="EmployeesAboveTheVicePresidentLevelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_MenloParkOfficeSpaceLeaseMember" name="MenloParkOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DebtCovenantMinCashUponLicensingTransaction" name="DebtCovenantMinCashUponLicensingTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_DebtCovenantPercentageOfProductRevenueAgainstForecast" name="DebtCovenantPercentageOfProductRevenueAgainstForecast" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" name="PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_ASDSpecialtyHealthcareLLCMember" name="ASDSpecialtyHealthcareLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CostMethodInvestmentsCostBasis" name="CostMethodInvestmentsCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_CashAndCashEquivalentsUnrealizedGains" name="CashAndCashEquivalentsUnrealizedGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_AccruedEndOfTermCharges" name="AccruedEndOfTermCharges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_TrancheCMember" name="TrancheCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_TrancheSixMember" name="TrancheSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_FirstDirectorOptionMember" name="FirstDirectorOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ResearchAndClinicalExpensesMember" name="ResearchAndClinicalExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_SubsequentDirectorOptionMember" name="SubsequentDirectorOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_DirectorsMarketValueStockPurchasePlanMember" name="DirectorsMarketValueStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_FosterCityOfficeSpaceLeaseMember" name="FosterCityOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod" name="MinimumPercentageOfNetProductRevenuesMaintenancePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="gern_CaliforniaOfficeSpaceLeaseMember" name="CaliforniaOfficeSpaceLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_AccruedEndOfTermCharge" name="AccruedEndOfTermCharge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="gern_ChargebackAndDistributorServiceFeesMember" name="ChargebackAndDistributorServiceFeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_PaymentOnRoyaltyAgreement" name="PaymentOnRoyaltyAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember" name="CorporateNoteSecuritiesDueInOneToTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" name="ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152425536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GERON CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,430,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">636,904,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GERN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-20859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-2287752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">919 East Hillsdale Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">473-7700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:90%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:9%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Document</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form 10&#8209;K<br/>Parts</span></p></td>
     </tr>
     <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Portions of the Registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2024.</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">III</span></p></td>
     </tr>
    </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Geron Corporation (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024 and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 26, 2025 expressed an unqualified opinion thereon.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152336784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 79,016<span></span>
</td>
<td class="nump">$ 70,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">327,550<span></span>
</td>
<td class="nump">263,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">35,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Interest and other receivables</a></td>
<td class="nump">2,853<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">38,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">490,992<span></span>
</td>
<td class="nump">341,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Noncurrent marketable securities</a></td>
<td class="nump">94,519<span></span>
</td>
<td class="nump">43,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases, right-of-use assets</a></td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">4,079<span></span>
</td>
<td class="nump">4,697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">593,781<span></span>
</td>
<td class="nump">394,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,595<span></span>
</td>
<td class="nump">6,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">22,808<span></span>
</td>
<td class="nump">13,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LiabilityRelatedToSaleOfFutureRoyalties', window );">Liability related to sale of future royalties</a></td>
<td class="nump">20,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">35,549<span></span>
</td>
<td class="nump">40,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">88,298<span></span>
</td>
<td class="nump">108,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">3,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties', window );">Noncurrent liability related to sale of future royalties</a></td>
<td class="nump">104,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent debt</a></td>
<td class="nump">118,476<span></span>
</td>
<td class="nump">35,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">313,461<span></span>
</td>
<td class="nump">146,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,350,000,000 shares authorized; 606,387,666 and 544,912,215 shares issued and outstanding at December 31, 2024 and 2023, respectively</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,051,794<span></span>
</td>
<td class="nump">1,844,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,772,341)<span></span>
</td>
<td class="num">(1,597,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">280,320<span></span>
</td>
<td class="nump">247,949<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 593,781<span></span>
</td>
<td class="nump">$ 394,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149581152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">606,387,666<span></span>
</td>
<td class="nump">544,912,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">606,387,666<span></span>
</td>
<td class="nump">544,912,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151394656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of goods sold</a></td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">103,738<span></span>
</td>
<td class="nump">$ 125,046<span></span>
</td>
<td class="nump">$ 95,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">145,732<span></span>
</td>
<td class="nump">69,135<span></span>
</td>
<td class="nump">43,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">250,726<span></span>
</td>
<td class="nump">194,181<span></span>
</td>
<td class="nump">139,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(173,732)<span></span>
</td>
<td class="num">(193,944)<span></span>
</td>
<td class="num">(138,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">19,607<span></span>
</td>
<td class="nump">18,152<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,504)<span></span>
</td>
<td class="num">(8,312)<span></span>
</td>
<td class="num">(6,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (174,572)<span></span>
</td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share</a></td>
<td class="nump">646,033,247<span></span>
</td>
<td class="nump">570,645,405<span></span>
</td>
<td class="nump">380,784,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net loss per share</a></td>
<td class="nump">646,033,247<span></span>
</td>
<td class="nump">570,645,405<span></span>
</td>
<td class="nump">380,784,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues:</a></td>
<td class="nump">$ 76,495<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_LicenseFeesAndRoyaltiesMember', window );">License Fees and Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues:</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_LicenseFeesAndRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_LicenseFeesAndRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932259485376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (174,572)<span></span>
</td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss (gain) on marketable securities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (174,496)<span></span>
</td>
<td class="num">$ (183,723)<span></span>
</td>
<td class="num">$ (141,947)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151717824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 126,416<span></span>
</td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">$ 1,398,006<span></span>
</td>
<td class="num">$ (1,271,741)<span></span>
</td>
<td class="num">$ (173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,731,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(141,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</a></td>
<td class="nump">69,916<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">69,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection with exercise of warrants</a></td>
<td class="nump">15,163<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">15,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares', window );">Issuance of common stock in connection with exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,663,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">2,185<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,518,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">79,998<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">1,493,469<span></span>
</td>
<td class="num">(1,413,642)<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,262,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(184,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(184,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</a></td>
<td class="nump">213,337<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">213,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection with exercise of warrants</a></td>
<td class="nump">105,912<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">105,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares', window );">Issuance of common stock in connection with exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,349,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">13,070<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">13,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,255,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">18,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 247,949<span></span>
</td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">1,844,988<span></span>
</td>
<td class="num">(1,597,769)<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2023</a></td>
<td class="nump">544,912,215<span></span>
</td>
<td class="nump">544,912,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (174,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs</a></td>
<td class="nump">140,729<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">140,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue', window );">Issuance of common stock in connection with exercise of warrants</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares', window );">Issuance of common stock in connection with exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,071,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuances of common stock under equity plans</a></td>
<td class="nump">32,683<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">32,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuances of common stock under equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,395,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation for equity-based awards to employees and directors</a></td>
<td class="nump">31,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 280,320<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 2,051,794<span></span>
</td>
<td class="num">$ (1,772,341)<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balances (in shares) at Dec. 31, 2024</a></td>
<td class="nump">606,387,666<span></span>
</td>
<td class="nump">606,387,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares issued during the period in connection with exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock issued in connection with exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering stock issued during period value new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932150348448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember', window );">Public Offering of Common Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9,271<span></span>
</td>
<td class="nump">$ 14,507<span></span>
</td>
<td class="nump">$ 5,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151364592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (174,572)<span></span>
</td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion and amortization on investments, net</a></td>
<td class="num">(9,683)<span></span>
</td>
<td class="num">(11,150)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs/debt discount</a></td>
<td class="num">(3,108)<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PaymentOnRoyaltyAgreement', window );">Payment on royalty agreement</a></td>
<td class="num">(2,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities', window );">Non-cash interest expense on liabilities for sales of future royalities</a></td>
<td class="nump">5,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss of extinguishment of debt</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation for services by non-employees</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation for employees and directors</a></td>
<td class="nump">31,185<span></span>
</td>
<td class="nump">18,526<span></span>
</td>
<td class="nump">8,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseInAllowanceForDoubtfulAccounts', window );">Increase in allowance for doubtful accounts</a></td>
<td class="num">(251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(37,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(35,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables', window );">Interest and other receivables</a></td>
<td class="num">(1,198)<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
<td class="num">(1,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other assets</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
<td class="num">(2,630)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposit and other assets</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">692<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,435<span></span>
</td>
<td class="num">(4,029)<span></span>
</td>
<td class="nump">3,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">9,049<span></span>
</td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(4,759)<span></span>
</td>
<td class="nump">7,208<span></span>
</td>
<td class="nump">3,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(715)<span></span>
</td>
<td class="num">(640)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(218,618)<span></span>
</td>
<td class="num">(167,743)<span></span>
</td>
<td class="num">(127,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(680)<span></span>
</td>
<td class="num">(830)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(476,932)<span></span>
</td>
<td class="num">(475,594)<span></span>
</td>
<td class="num">(258,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">371,608<span></span>
</td>
<td class="nump">296,102<span></span>
</td>
<td class="nump">320,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(106,004)<span></span>
</td>
<td class="num">(180,322)<span></span>
</td>
<td class="nump">62,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuances of common stock from equity plans</a></td>
<td class="nump">32,683<span></span>
</td>
<td class="nump">13,072<span></span>
</td>
<td class="nump">2,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs</a></td>
<td class="nump">140,729<span></span>
</td>
<td class="nump">213,337<span></span>
</td>
<td class="nump">69,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">105,912<span></span>
</td>
<td class="nump">15,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt financing, net of paid debt issuance costs and debt discounts</a></td>
<td class="nump">121,120<span></span>
</td>
<td class="nump">29,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">(86,554)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">334,372<span></span>
</td>
<td class="nump">362,021<span></span>
</td>
<td class="nump">87,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">9,738<span></span>
</td>
<td class="nump">13,929<span></span>
</td>
<td class="nump">21,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">71,138<span></span>
</td>
<td class="nump">57,209<span></span>
</td>
<td class="nump">35,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">$ 80,876<span></span>
</td>
<td class="nump">$ 71,138<span></span>
</td>
<td class="nump">$ 57,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of unrealized losses and exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due for interest payments related to marketable securities and in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_IncreaseInAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_IncreaseInAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense on liabilities for sales of future royalities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PaymentOnRoyaltyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment on royalty agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PaymentOnRoyaltyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from public offering issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152414160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in the biopharmaceutical sector, which is a highly regulated sector subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; disruption of our clinical trials, manufacturing or supply chain; violation of privacy laws and other litigation and legal risk; and reputational risk. We rely primarily on industry-leading third parties and a cloud-based infrastructure for our information technology systems, and accordingly are dependent on these third parties&#8217; own cybersecurity risk management practices and strategy. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including clinical trial data, intellectual property, confidential information that is proprietary, strategic, financial or competitive in nature, and personal data (&#8220;Information Systems and Data&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We take a risk-based approach to identify and assess the cybersecurity threats and risks that could affect our business and Information Systems and Data.  Our Information Technology personnel help identify, assess and manage our cybersecurity threats and risks, and support our efforts to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use various methods and tools to identify, assess and manage cybersecurity threats and risks, including, for example, automated tools, industry reports, third party threat assessments and penetration testing. In addition, we encrypt data at rest and maintain network security controls, such as firewalls and virtual private networks. We also conduct computerized system monitoring and access control, including asset management, tracking and disposal associated with onboarding and offboarding of personnel. We maintain cybersecurity insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. For example, we have implemented and maintain an incident response plan, and we utilize automated tools designed to maintain email security. We have also implemented a computerized system security and password policy that defines security for access to computer systems managed and controlled by us, and a procedure for computerized system incident management to address any unplanned issues in regulated computerized systems that could impact subject safety, product quality, and data integrity. We periodically conduct cybersecurity incident tabletop training exercises involving our personnel and plan to conduct similar training in 2025.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management processes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, our head of Information Technology evaluates material risks from cybersecurity threats and reports periodically to the Audit Committee of our Board, which evaluates our overall enterprise risk. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, cybersecurity software providers such as Crowdstrike, cybersecurity service providers such as Mimecast, penetration testing firms, auditors, and professional services firms, including legal counsel. These relationships enable us to leverage specialized knowledge and insights, enabling our cybersecurity strategies and processes to remain consistent with industry best practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party service providers to perform a variety of functions throughout our business, such as contract manufacturing organizations, contract research organizations, suppliers and consultants, and third party logistics organizations and distributors to distribute RYTELO. We conduct quality audits of regulated vendors, which typically include an assessment of such vendor&#8217;s information technology systems, and we impose appropriate contractual obligations on vendors pertaining to information security. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our efforts may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity threats that may materially affect us </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Report, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Information Technology Systems, Data Security and Data Privacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to hire information technology personnel with skills appropriate to help us prepare for cybersecurity incidents, approve cybersecurity processes, and review security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including executive management. When appropriate given the nature of any potential cybersecurity incident, our executive management works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, and to make any legally required notifications to individuals or regulatory agencies, including making any required disclosures under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management processes.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the risks from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity threats that may materially affect us </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Report, including &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Information Technology Systems, Data Security and Data Privacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Management Personnel</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to hire information technology personnel with skills appropriate to help us prepare for cybersecurity incidents, approve cybersecurity processes, and review security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including executive management. When appropriate given the nature of any potential cybersecurity incident, our executive management works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, and to make any legally required notifications to individuals or regulatory agencies, including making any required disclosures under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. For example, we have implemented and maintain an incident response plan, and we utilize automated tools designed to maintain email security. We have also implemented a computerized system security and password policy that defines security for access to computer systems managed and controlled by us, and a procedure for computerized system incident management to address any unplanned issues in regulated computerized systems that could impact subject safety, product quality, and data integrity. We periodically conduct cybersecurity incident tabletop training exercises involving our personnel and plan to conduct similar training in 2025.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249368704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (174,572)<span></span>
</td>
<td class="num">$ (184,127)<span></span>
</td>
<td class="num">$ (141,901)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149871408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249429696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249295568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="note_1_" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The terms &#8220;Geron&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; and &#8220;us&#8221; as used in this report refer to Geron Corporation, which was incorporated in the State of Delaware on November 28, 1990, and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. Geron UK was incorporated in September 2021, and its operations commenced in January 2022. Geron Netherlands was incorporated in February 2023, and its operations commenced in June 2023.  The Company's first-in-class telomerase inhibitor, RYTELO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imetelstat), was approved by the U.S. Food and Drug Administration, or FDA, on June 6, 2024 for the treatment of certain adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, and is under development for the treatment of other hematologic malignancies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. Foreign currency translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#8217; equity, on our consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,095,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,335,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. In January 2023, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,007,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2023 pre-funded warrant. In March 2024, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,999,998</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,002,668</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2024 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 10 on Stockholders' Equity for further discussion of our public offerings.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2024, 2023, and 2022, the diluted net loss per share calculation excludes potential dilutive securities of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,369,889</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,458,854</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,726,765</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. We recognize shipping and handling costs as an expense in cost of goods sold when we transfer control to a customer. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We distribute RYTELO in the U.S. through third party distributors and specialty pharmacies who are our customers. The third party distributors subsequently resell our product through their related specialty pharmacy providers to patients and health care providers. Separately, we have or may enter into payment arrangements with various third-party payors including pharmacy benefit managers, private healthcare insurers and government healthcare programs who provide coverage and reimbursement for our product that have been prescribed to a patient.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies. To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. See Note 2 on Revenue Recognition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Sales, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Items Deducted from Gross Product Sales</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. The most significant items deducted from gross product sales where we exercise judgment are rebates, sales returns and chargebacks.</span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Product Revenues</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net product revenues are recognized, net of variable consideration related to certain allowances and accruals, at the time our customers obtain control of our product, which is generally upon delivery to our customers. We use the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts to estimate variable consideration and consideration payable to parties other than our customers related to our product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record reserves, based on contractual terms, for components related to product sold during the reporting period, as well as our estimate of product that remains in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare providers. On a quarterly basis, we update our estimates and record any needed adjustments in the period we identify the adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell RYTELO to our customers at wholesale acquisition cost, and calculate product revenue from RYTELO sales, net of variable consideration and consideration payable to parties other than our customers. Variable consideration and consideration payable to parties other than our customers consists of estimates related to the following categories:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Allowances</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We pay fees for distribution services, such as fees for certain data that customers provide to us. We estimate our customers will earn these fees and deduct these fees from gross product revenues and accounts receivable at the time we recognize the related revenues.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discounts for Prompt Payment</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We provide for prompt payment discounts to our customers, which are recorded as a reduction in gross product revenue in the same period that the related product revenue is recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Returns</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer customers the right to return products if they are damaged, defective, or expired, as defined in customer agreements. We estimate product returns considering experience from similar products in the market, historical return patterns, sales data, and inventory levels in the distribution channel. These estimates are recorded as a reduction in gross product revenue at the time of sale. Once products are returned, they are destroyed; we do not record a right of return asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chargebacks</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks occur when our contracted customers, mainly federal agencies that can purchase off the Federal Supply Schedule and Public Health Service 340B covered entities, buy directly from our distributors and wholesalers at discounted prices. The distributors and wholesalers then charge us the difference between their purchase price and the discounted price. We estimate chargebacks considering the terms of the applicable arrangement and our visibility regarding utilization. These chargebacks are recorded in the same period as the related revenue, reducing our net product revenue and receivables. We typically issue credits for these amounts within a few weeks of notification.</span></p></div><div><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Rebates</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to discount obligations under government programs. Reserves for rebates payable under these government programs are recorded in the same period as gross product revenue, reducing our gross product revenue and creating a liability in accrued liabilities. Major rebates include those from the Medicare and Medicaid programs. Estimates for rebates are made considering statutory discount rates and expected utilization. These estimates are updated each period with actual claims and other current information, taking into account historical data, comparable products and other considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-payment Assistance</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer co-payment assistance to patients with commercial insurance that have coverage and reside in states that allow co-payment assistance. We estimate the average co-payment assistance amounts for our products based on expected customer demographics and record any such amounts within accrued expenses and a reduction to product revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of Intellectual Property</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability related to the Royalty Pharma Agreement and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assessed the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#8217;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations.  If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 4 on Fair Value Measurements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.</span></p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Accounts receivable are stated net of an allowance that reflects our current estimate of credit losses expected to occur over the life of the receivable. In developing our allowance for expected credit losses, we use assumptions to capture the risk of loss, even if remote, based on a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The payment terms on our trade receivables are relatively short. As a result, our collection risk is mitigated to a certain extent by the fact that sales are collected in a relatively short period of time, allowing for the ability to reduce exposure on defaults if collection issues are identified</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We update our allowance as necessary to reflect expected credit losses over the remaining lives of the accounts receivable for outstanding trade receivables that are past due, have known disputes or have experienced any negative credit events that may result in future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collectability issues. We do not currently expect our current or future exposures to credit losses to have a significant impact on us. The estimated allowance for expected credit losses was not material as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, nor were the changes to the allowance during any of the periods presented.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory is recorded at the lower of cost or net realized value, with cost determined under the weighted average method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, salaries, wages and stock-based compensation for personnel involved in the manufacturing process, and indirect overhead costs. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. Prior to regulatory approval, we expensed costs associated with the manufacture of a product candidate to research and development expense unless we are reasonably certain such costs have future commercial use and net realizable value. Since we consider attaining regulatory approval of a product candidate to be highly uncertain and difficult to predict, we expect only in rare instances that pre-launch inventory will be capitalized, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We began capitalizing inventory related to RYTELO in the quarter ended June 30, 2024, as we received approval of RYTELO on June 6, 2024, and the related costs were expected to be recoverable through the commercialization of RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs. Cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. For the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, other than packaging costs, substantially all of our RYTELO inventory sold had a zero-cost basis as it was recorded as research and development expenses prior to the FDA&#8217;s approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current RYTELO (imetelstat) clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and Amortization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record property and equipment at cost and calculate depreciation using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock or restricted stock unit awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 10 on Stockholders&#8217; Equity.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#8217; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_075bab03-7a15-4dd6-87b2-88c5d830351e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> represents our chief operating decision maker. We view our operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. For additional information, see Note 13 on Segment Reporting.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued and Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment.</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods.  We adopted the guidance in the annual period ended December 31, 2024. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13. We view our operations as a single segment. See Note 13 on Segment Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249348192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITON<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITON</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. REVENUE RECOGNITON</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Product Revenue</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.434%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.564999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross product revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,418</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross-to-net adjustments:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chargebacks and distributor service fees</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,772</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government rebates</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">926</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales returns and allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross-to-net adjustments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,923</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net product revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249387200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INVENTORY</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our inventories are related to the manufacturing of RYTELO. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our inventory as of December 31, 2024: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:43.120000000000005%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,904</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148224144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash Equivalents, Restricted Cash and Marketable Securities</span></p><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.337%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,215</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,215</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,978</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,193</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,937</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,620</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,741</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">284</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,618</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,909</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">421,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,069</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.337%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">843</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">843</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,752</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,894</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,598</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,270</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,268</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,409</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,360</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,628</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,734</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,784</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.76%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,076</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,076</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,724</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,622</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,622</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,567</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,567</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The gross unrealized losses related to U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of December 31, 2024 and 2023 were due to changes in interest rates and not credit risk. If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors.  Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflict between Ukraine and Russia, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We do not intend to sell the investments and it is not more likely that not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value on a Recurring Basis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We categorize financial instruments recorded at fair value on our consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:1.84%;box-sizing:content-box;"></td>
      <td style="width:7%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:90.16%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></p></td>
     </tr>
    </table>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:1.84%;box-sizing:content-box;"></td>
      <td style="width:7%;box-sizing:content-box;"></td>
      <td style="width:1%;box-sizing:content-box;"></td>
      <td style="width:90.16%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The embedded derivatives are classified within Level 3 of the fair value hierarchy. See Note 9 on Debt.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liability Related to the Sale of Future Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We determined the fair value of the liability related to the sale of future royalties based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3. See Note 9 on Debt.</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#212529;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Level 1, Level 2, and Level 3 during the periods presented.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 and indicates the fair value category assigned.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.008%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.482000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.142000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">427,046</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474,121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,658</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,658</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">324,904</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.074%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in restricted cash on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in current portion of marketable securities on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in noncurrent portion of marketable securities on our consolidated balance sheets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Risk</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple institutions in the United States. Generally, these deposits may be redeemed upon demand and therefore, bear minimal risk. Deposits with banks may exceed the amount of insurance provided on such deposits. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, government-sponsored enterprise securities, U.S. Treasury securities, municipal securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. However, we are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents to the extent recorded in our consolidated balance sheets. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk of our financial position at the depository institutions in which those deposits are held. As of  December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable: McKesson Financial Center, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable; ASD Specialty Healthcare LLC, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable; Cardinal Health Inc., which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable; and Sina Drug, which accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our gross accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249330256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. PROPERTY AND EQUIPMENT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, stated at cost, is comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.6%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and computer equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,878</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,007</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,408</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,697</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,231</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,310</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,177</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932147883296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. ACCRUED LIABILITIES</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued liabilities consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.6%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CRO and clinical trial costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,968</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,541</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing activities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,839</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional legal and accounting fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">556</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest payable</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,186</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,081</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,549</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,308</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249411056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purported Securities Lawsuits</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are not currently a party to any material pending legal proceedings. However, in 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed, and final judgment with respect to the other two lawsuits was entered in October 2023. In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  All seven of the shareholder derivative actions were dismissed with prejudice. There is no liability outstanding with respect to these lawsuits as of December 31, 2024, because they were fully settled during the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. We could be forced to expend</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant resources in the defense of any additional lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Expenses associated with any potential future lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. We have not established any reserve for any potential liability relating to any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnifications to Officers and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Plan</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> severance plans that apply to all of our employees who are not subject to performance improvement plans, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> plan covering employees above the Senior Vice President level, i.e., executives, and all other employees hired before January 1, 2022, and the other plan covering all non-executive employees hired on or after January 1, 2022.  The severance plans provide for, among other benefits: (i) a severance payment upon a Change of Control Triggering Event and Separation from Service and (ii) a severance payment for each non&#8209;executive employee upon a Non&#8209;Change of Control Triggering Event and Separation from Service. As defined in the severance plans, a Change of Control Triggering Event and Separation from Service requires a &#8220;double trigger&#8221; where: (i) an employee is terminated by us without cause in connection with a change of control or within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months following a change of control provided, however, that if an employee is terminated by us in connection with a change of control but immediately accepts employment with our successor or acquirer, the employee will not be eligible for the benefits outlined in the plans, (ii) an employee resigns because in connection with a change of control, the offered terms of employment (new or continuing) by us or our successor or acquirer within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days after the change of control results in a material change in the terms of employment, or (iii) after accepting (or continuing) employment with us after a change of control, an employee resigns within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months following a change of control due to a material change in the terms of employment. Under the severance plans, a Non&#8209;Change of Control Triggering Event and Separation from Service is defined as an event where an employee is terminated by us without cause. Severance payments range from</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_22c29184-2380-4a26-aec3-6f112ba2f86e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months of base salary in connection with a Change of Control Triggering Event or from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bdc4642e-5d95-4614-922b-411dcd56cbf5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six weeks</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months of base salary in connection with a Non-Change of Control Triggering Event, as well as a pro-rata portion of the employee&#8217;s annual target bonus, depending on the employee&#8217;s position with us, payable in a lump sum payment, and monthly COBRA payments for the severance period. The severance plans also provide that they shall not supersede the provisions of any individual employment agreements entered into between us and our employees, and that the employees with such agreements will be entitled to whichever benefits are greater under the severance plan or their employment agreement. A copy of the severance plan covering our executive officers is filed as an exhibit to this Report. As of December 31, 2024, all our executive officers have employment agreements with severance provisions and will receive the greater severance benefits of their agreements or those in the severance plan applicable to them.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148248016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. OPERATING LEASES</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Jersey Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-time option to terminate the New Jersey Lease without cause as of the 103</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month anniversary of the commencement date of the lease</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date. Based on the initial term of the New Jersey Lease of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, the right-of-use asset and corresponding operating lease liability was approxima</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tely</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represented the present value of lease pay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments over the initial lease term, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rent abatement period, using an incremental borrowing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n information available as of October 1, 2019. As of December 31, 2024, the New Jersey Lease makes up $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of our total right-of-use asset balance. Under the New Jersey Lease, we are also obligated to pay certain variable expenses separately from the base rent, including electricity and common area maintenance. Such costs are being expensed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the period they are incurred. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining lease term for the New Jersey Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ye</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ars.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">California Office Space Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months with an option to extend for an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Foster City Lease commenced on March 10, 2020, upon the substantial completion of all tenant improvements. As of the lease commencement date, the right-of-use asset and corresponding operating lease liability was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, which represented the present value of remaining lease payments using an incremental borro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">wing rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% over the initial lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, net of a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rent abatement period. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the Foster City Lease makes up $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of our total right-of-use asset balance. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Foster City Lease, we are also obligated to pay certain variable expenses separately from the base rent, including taxes and common area maintenance. Such costs are considered non-lease components and have been excluded from the calculation of the right-of-use asset and corresponding operating lease liability and are being expensed in the period they are incurred. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the remaining lease term for the Foster City Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, and the Foster City Lease were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:19.516%;box-sizing:content-box;"></td>
        <td style="width:22.555%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.296999999999997%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.639%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.077%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.657%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">962</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,248</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,306</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,254</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:10%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:60%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><div class="item-list-element-wrapper" style="margin-left:5.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.3875491341761395%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs represent non-lease components, such as common area maintenance charges.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:35.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.686%;box-sizing:content-box;"></td>
        <td style="width:2.857%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.457%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,014</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,040</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">376</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">383</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,821</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">581</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,240</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249438336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. DEBT</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hercules Loan Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On September 30, 2020, we, Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, or SVB, entered into a term loan facility, or the Term Loan, for up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was amended in August 2021, or the Original Loan Agreement. On June 30, 2022, we entered into a second amendment to the Original Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, with such principal being available in a series of tranches, subject to certain terms and conditions. Over the course of the Term Loan, we had drawn down a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All obligations outstanding under the Hercules Loan Agreement, amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, were repaid in full on November 1, 2024, upon which the Hercules Loan Agreement was terminated and all liens on our assets granted in connection with the Hercules Loan Agreement were released.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmakon Loan Agreement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-year senior secured term loan facility of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, may be requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed under the Hercules Loan Agreement, which was terminated effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The remaining proceeds will be used to fund our general corporate and working capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Term Loans mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 1, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Term Loans bear interest at a variable rate per annum equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% plus the three-month Secured Overnight Financing Rate, or SOFR, with a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_63389fc4-357d-477a-9d6b-0ecf16309618;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SOFR</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> floor of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Interest is due and payable quarterly on the last day of each quarter with the first payment due on December 31, 2024. The Pharmakon Loan Agreement requires we pay an amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the Lenders&#8217; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a make-whole amount equal to the sum of all interest that would have accrued through such 2nd anniversary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Pharmakon Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pharmakon Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We and our subsidiaries are bound by certain affirmative covenants setting forth actions that are required during the term of the Pharmakon Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we and our subsidiaries are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Pharmakon Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#8217; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified exceptions. The Pharmakon Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or the occurrence of a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgements, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Pharmakon Loan Agreement. Upon the occurrence and during the continuance of an event of default, the Lenders may, among other things, accelerate our obligations under the Pharmakon Loan Agreement (including all obligations for principal, interest and any applicable make-whole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future Minimum Payments</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.96%;box-sizing:content-box;"></td>
        <td style="width:46.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.939999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,475</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:  amount representing interest</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:  unamortized debt discount and issuance costs</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,525</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent portion of debt</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,476</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liabilities Related to Sale of Future Royalties</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, </span><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#2b333d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, or the Purchase Price, in exchange</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for which Royalty Pharma obtained the right, or the Revenue Participation Right, to receive certain amounts calculated as a percentage of future U.S. net sales of RYTELO for each calendar quarter, or Royalty Payments, during the term contemplated by the Royalty Pharma Agreement. Specifically, </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the revenue participation rate commences at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for annual U.S. net sales of up to and equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">500.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million declining to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for annual U.S. net sales exceeding $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031 or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we had the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Buy-Out Payment&#8221; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We accounted for the Royalty Pharma Agreement as a financing liability, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over the estimated term of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have determined the fair value of the liability related to the sale of future royalties is based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying value of the liabilities related to sale of future revenues as of December 31, 2024 is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in non-cash interest expense in the twelve months ended December 31, 2024 related to the Royalty Pharma Agreement.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the activity within the liability related to sale of future royalties during the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.8%;box-sizing:content-box;"></td>
        <td style="width:1.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:33.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liability Related to Sale of Future Royalties</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrying value of liability related to sale of future royalties at November 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,634</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,345</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrying value of liability related to sale of future royalties at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,793</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Embedded Derivatives and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.  The embedded derivatives are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148223328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Common Stock</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023 our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">675,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,350,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 1, 2022, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,333,334</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,095,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2022 pre-funded warrant, together with accompanying warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,714,286</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our common stock, also known as the 2022 stock purchase warrants. The shares of common stock and the 2022 pre-funded warrant were immediately separable from the 2022 stock purchase warrants. All of the securities were issued separately. The combined public offering</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of the common stock and accompanying 2022 stock purchase warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2022 stock purchase warrants have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and are exercisable immediately. The term of the 2022 stock purchase warrants expired in the third quarter of 2023, pursuant to the terms of the warrant agreement. The combined public offering price of the 2022 pre-funded warrant and accompanying 2022 stock purchase warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.049</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2022 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until the 2022 pre-funded warrant is exercised in full. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, none of the 2022 pre-funded warrant and all of the 2022 stock purchase warrants have been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2022 pre-funded warrant and 2022 stock purchase warrants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the issuance of the 2022 pre-funded warrant and 2022 stock purchase warrants, we evaluated the terms of each warrant to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and FASB Accounting Standards Codification Topic 815,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2022 pre-funded warrant and the 2022 stock purchase warrants include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2022 pre-funded warrant and the 2022 stock purchase warrants should be classified as equity with no subsequent remeasurement as long as such warrants continue to be classified as equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 10, 2023 we completed an underwritten public offering consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,007,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and the 2023 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.45</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The public offering price of the 2023 pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.449</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2023 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until the 2023 pre-funded warrant is exercised in full. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, none of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 pre-funded warrant has been exercised. The net cash proceeds from this offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">213.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2023 pre-funded warrant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the issuance of the 2023 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and FASB Accounting Standards Codification Topic 815, Derivatives and Hedging. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2023 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2023 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 21, 2024, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,999,998</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,002,668</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2024 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The public offering price of the 2024 pre-funded warrant was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. The 2024 pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and may be exercised at any time until the 2024 pre-funded warrant is exercised in full. As of December 31, 2024, none of the 2024 pre-funded warrant has been exercised. The net cash proceeds from the March 2024 offering were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, after deducting the underwriting discount and other offering expenses paid by us, and excluding any future proceeds from the exercise of the pre-funded warrant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon the issuance of the 2024 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and FASB Accounting Standards Codification Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2024 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2024 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Exercises</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, warrants to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,071,981</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants were issued in connection with underwritten public offerings of common stock and pre-funded warrants, together with accompanying stock purchase warrants in May 2020, April 2022, and January 2023. As of December 31, 2024, the following warrants remained outstanding:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pre-funded warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to purchas</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,433,145</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, which have no expiration date; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock purchase warrants with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402,522</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hares of our common stock related to the public offering of our common stock in May 2020, which expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2023, warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,349,859</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock were exercised for net cash proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million The warrants were issued in connection with an underwritten public offering of common stock and a pre-funded warrant, together with accompanying stock purchase warrants in May 2020. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,430,477</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock was outstanding and stock purchase warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,474,503</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock associated with the May 2020 public offering remained outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement with B. Riley, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from time to time through B. Riley as the sales agent. We have agreed to pay B. Riley an aggregate commission rate equal to up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2023 Sales Agreement.  The 2023 Sales Agreement will automatically terminate upon the earlier of (i) the sale of all common stock subject to the 2023 Sales Agreement, or (ii) termination of the 2023 Sales Agreement in accordance with its terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock were sold pursuant to the 2023 Sales Agreement during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Plans</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2011 Incentive Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2011, our stockholders approved the adoption of the 2011 Incentive Award Plan, or 2011 Plan. The 2011 Plan provided for grants of either incentive stock options or nonstatutory stock options and stock purchase rights to employees (including officers and employee directors) and consultants (including non&#8209;employee directors). Upon the adoption of the 2018 Equity Incentive Plan in May 2018 (see below), no further grants of stock options or stock purchase rights were made under the 2011 Plan. Stock options granted under the 2011 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. Stock option exercise prices were equal to the fair market value of the underlying common stock on the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service&#8209;based stock options under the 2011 Plan generally vested over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. Other stock awards (restricted stock awards and restricted stock units) had variable vesting schedules which were determined by our board of directors on the date of grant. All outstanding awards granted under the 2011 Plan remain subject to the terms of the 2011 Plan and the individual award agreements thereunder.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 15, 2018, our stockholders approved the adoption of the 2018 Equity Incentive Plan, or 2018 Plan, as the successor to the 2011 Plan. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. Eligible participants under the 2018 Plan include our employees, consultants and non-employee directors. The number of shares reserved for issuance under the 2018 Plan (subject to adjustment for certain changes in capitalization) is equal to the sum of (i) the unallocated shares of common stock remaining available for future grants under the 2011 Plan as of May 15, 2018, (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> newly </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reserved shares of common stock and (iii) the number of shares subject to awards granted under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2002 Equity Incentive Plan, and the 2011 Plan as such shares become available from time to time, referred to as the Prior Plans&#8217; Returning Shares. Such Prior Plans&#8217; Returning Shares become available for issuance under the 2018 Plan if outstanding stock awards granted under the 2002 Equity Incentive Plan and the 2011 Plan, after May 15, 2018, expire or terminate for any reason prior to exercise or settlement or are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or, subject to certain exceptions, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award. In May 2023, May 2022 and May 2021, our stockholders approved amendments to our 2018 Equity Incentive Plan to increase the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,360,000</span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,500,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, an aggregate total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,447,090</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock have been reserved under the 2018 Equity Incentive Plan, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,587,928</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> available for future grants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock options granted under the 2018 Plan expire no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of grant. Stock option exercise prices shall be equal to the fair market value of the underlying common stock on the date of grant. If, at the time we grant a stock option, the optionee directly or by attribution owns stock possessing more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total combined voting power of all classes of our stock, the stock option exercise price shall be at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the fair market value of the underlying common stock and shall not be exercisable more than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> after the date of grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We grant service-based and performance-based stock options to employees under the 2018 Plan. Service-based stock options generally vest over a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the date of the stock option grant. Performance-based stock options vest upon the achievement of specified milestones. Other stock awards (restricted stock awards and restricted stock units) have variable vesting schedules as determined by our board of directors on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under certain circumstances, stock options may be exercised prior to vesting, subject to our right to repurchase the shares underlying such stock option at the exercise price paid per share. Our repurchase rights would generally terminate on a vesting schedule identical to the vesting schedule of the exercised stock option. During 2024 and 2023, we did not repurchase any shares under the 2018 Plan. As of December 31, 2024, we have no shares outstanding subject to repurchase under the 2018 Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our Non&#8209;Employee Director Compensation Policy adopted by our board of directors in March 2014, as amended and restated in February 2024 and February and March 2022, provides for the automatic grant to non&#8209;employee directors of the following types of equity awards under the 2018 Plan:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">First Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each person who becomes a non&#8209;employee director, whether by election by our stockholders or by appointment by our board of directors to fill a vacancy, will automatically be granted a stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, or First Director Option, on the date such person first becomes a non&#8209;employee director. The First Director Option vests annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> upon each anniversary date of appointment to our board of directors.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Subsequent Director Option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Each non&#8209;employee director (other than any director receiving a First Director Option on the date of the annual meeting) will automatically be granted a subsequent stock option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, a Subsequent Director Option, on the date of the annual meeting of stockholders in each year during such director&#8217;s service on our board of directors. The Subsequent Director Option vests in full on the earlier of: (i) the date of the next annual meeting of our stockholders or (ii) the first anniversary of the date of grant.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2018 Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, our board of directors approved the adoption of the 2018 Inducement Award Plan, or the Inducement Plan, pursuant to which we reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock to be used exclusively for grants of inducement awards to individuals who were not previously Geron employees or non-employee directors, other than following a bona fide period of non-employment.  Since adoption of the Inducement Plan, t</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he compensation committee of our board of directors, or the compensation committee, has approved amendments to our Inducement Plan to increase the aggregate total number of shares issuable under such plan to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock.  The most recent amendment, approved by the compensation committee in December 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased the total number of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, effective as of January 1, 2025, to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, an aggregate total of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,959,342</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock have been reserved under the Inducement Plan, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">851,137</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> available for future grants.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards, and all awards under the Inducement Plan are intended to meet the standards under Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved 2018 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#8217; Market Value Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2018, our board of directors adopted a Directors&#8217; Market Value Stock Purchase Plan, or the Directors Market Plan. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock have been reserved for the Directors Market Plan. Under the Directors Market Plan, non-employee directors may purchase shares of our common stock at the prevailing market price on the purchase date with cash compensation payable to them for their services as a board member. As stated in Geron&#8217;s Non-Employee Director Compensation Policy, each non-employee director receives annual cash compensation, payable quarterly in arrears, for their services on the board and various committees of the board. As provided in the Non-Employee Director Compensation Policy, a non-employee director may elect to receive fully vested shares of common stock in lieu of cash and such shares shall be issuable from the Directors Market Plan.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, we issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,351</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,864</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,962</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, respectively, under the Directors Market Plan. The weighted average grant date fair value of stock granted during the years ended December 31, 2024 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.84</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. The total fair value of vested stock grants during 2024, 2023 and 2022 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,079</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85,400</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, Inducement Plan and Directors Market Plan is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Available</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For Grant</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,750,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,984,351</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,603,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,603,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,351</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,907,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.77</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options cancelled/forfeited/expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,171,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,309,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,967,367</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.35</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,204,849</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercisable at <br/>&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,943,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,488,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options fully vested and expected<br/>&#160;&#160;&#160;&#160;to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,159,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.30</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,613,420</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based stock options granted that have not achieved the specified performance milestone.</span></div></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on Geron&#8217;s closing stock price of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.54</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share as of December 31, 2024, which would have been received by the option holders had all the option holders exercised their stock options as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, 2023 and 2022, there were</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,943,520</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,995,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,085,389</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> exercisable stock options outstanding at weighted average exercise prices per share of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.06</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, all of which were granted at an exercise price equal to the fair market value of our common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total pretax intrinsic value of stock options exercised during 2024, 2023, and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million  and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Cash received from the exercise of stock options in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 totaled approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2014, our board of directors adopted the 2014 Employee Stock Purchase Plan, or 2014 Purchase Plan. The 2014 Purchase Plan was approved by our stockholders in May 2014. The 2014 Purchase Plan replaced the 1996 Employee Stock Purchase Plan, or 1996 Purchase Plan, which was terminated effective as of the date the 2014 Purchase Plan was approved by our stockholders. In May 2022, our stockholders approved an amendment to our 2014 Purchase Plan to increase the total num</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber of shares issuable under such plan by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, for an aggregate total reserve of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sh</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ares. As of December 31, 2024, an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,741,634</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock have been issued under the 2014 Purchase Plan since its adoption.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2014 Purchase Plan is comprised of a series of offering periods, each with a maximum duration (not to exceed </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months) with new offering periods commencing on January 1st and July 1st of each year. The date an employee enters the offering period will be designated as the entry date for purposes of that offering period. An employee may participate only in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> offering period at a time. Each offering period consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive purchase periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; duration, with the last day of such period designated a purchase date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the 2014 Purchase Plan, employees can choose to have up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their annual salary withheld to purchase our common stock, up to a limit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per year. An employee may not make additional payments into such account or increase the withholding percentage during the offering period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purchase price per share at which common stock is purchased by the employee on each purchase date within the offering period is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of (i) the fair market value per share of our common stock on the employee&#8217;s entry date into that offering period or (ii) the fair market value per share of our common stock on the purchase date. If the fair market value per share of our common stock on the purchase date is less than the fair market value at the beginning of the offering period, a new </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> month offering period will automatically begin on the first business day following the purchase date with a new fair market value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation for Employees and Directors</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure and recognize compensation expense for all share&#8209;based payment awards made to employees and directors, including employee stock options, restricted stock awards, restricted stock unit awards, and employee stock purchases, based on grant&#8209;date fair values for these instruments. We use the Black-Scholes option&#8209;pricing model to estimate the grant&#8209;date fair value of our service-based and performance-based stock options and employee stock purchases. The fair value for service&#8209;based restricted stock awards and restricted stock unit awards is determined using the fair value of our common stock on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As stock&#8209;based compensation expense recognized on the consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures, but at a minimum, reflects the grant&#8209;date fair value of those awards that actually vested in the period. Forfeitures have been estimated at the time of grant based on historical data and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, 2023, and 2022, our board of directors awarded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">832,790</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,741,750</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> perfo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rmance-based stock options, respectively, to certain employees. These performance-based stock options are included in the outstanding stock options table above. Performance-based stock options vest only upon achievement of discrete milestones. Stock-based compensation expense for performance-based stock options is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being achieved, if ever.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize stock&#8209;based compensation expense for service-based stock options on a straight&#8209;line basis over the requisite service period, which is generally the vesting period. We reco</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gnized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2023. We did not recognize any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended December 31, 2022 ,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as the achievement of the specified milestones was not considered probable during that time. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock&#8209;based compensation expense related to service-based stock options and employee stock purchases for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, which was allocated as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,280</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,647</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,099</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,927</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was capitalized to inventory for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 has been estimated at the date of grant using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.36%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.87</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.82</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.83</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.77</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.82</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.42</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.94</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.69</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of employee stock purchases in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 has been estimated using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.36%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">. to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.19</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.79</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.83</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.61</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.87</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.73</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.40</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.79</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend yield is based on historical cash dividend payments and we have paid no cash dividends to date. The expected volatility range is based on historical volatilities of our stock, since traded options on our common stock do not correspond to option terms and the trading volume of options is limited. The risk&#8209;free interest rate range is based on the U.S. Zero Coupon Treasury Strip Yields for the expected term in effect on the date of grant for an award. The expected term of stock options is derived from actual historical exercise and post&#8209;vesting cancellation data and represents the period of time that stock options granted are expected to be outstanding. The expected term of employees&#8217; purchase rights is equal to the purchase period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the Black-Scholes option&#8209;pricing model, the weighted-average estimated fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. The weighted average estimated fair value of employees&#8217; purchase rights for the years ended December 31, 2024, 2023 and 2022 w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.82</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.48</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. As of December 31, 2024, total compensation cost related to unvested share&#8209;based payment awards not yet recognized, net of estimated forfeitures and assuming no probability of achievement for outstanding performance-based stock options, was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over the next </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months on a weighted&#8209;average basis.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation to Service Providers</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We grant stock options to consultants from time to time in exchange for services performed for us. In general, the stock options vest over the contractual period of the consulting arrangement. The fair value of stock options held by consultants is recorded as operating expenses over the vesting term of the respective equity awards. With the adoption of Accounting Standards Update 2018-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Nonemployee Share-Based Payment Accounting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or ASU 2018-07, in the first quarter of 2019, the measurement date of stock options granted to consultants was fixed at the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded stock&#8209;based compensation expe</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nse of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">103,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">742,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the vested portion of the fair value of stock options held by consultants in 2024, 2023, and 2022, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common Stock Reserved for Future Issuance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.133%;box-sizing:content-box;"></td>
        <td style="width:1.667%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:23.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,967,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and awards available for grant</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,309,969</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,366</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,835,667</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,371,369</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249417904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. INCOME TAXES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of Income/(Loss) before income taxes are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,737</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,521</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,734</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provision for (benefit from) income taxes:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.224%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.164%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.104%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.104%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.889%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.122%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.281%;box-sizing:content-box;"></td>
        <td style="width:5.181%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.122%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.101%;box-sizing:content-box;"></td>
        <td style="width:4.081%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.281%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss not benefitted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of our deferred tax assets are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.413%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,353</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue Participation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">767</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,963</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">429,913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">395,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial performance. Forming a conclusion that a valuation allowance is not required is difficult when there is negative evidence such as cumulative losses in recent years. Because of our history of losses, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had domestic federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Of this, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">631.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will expire at various dates beginning in 2025 through 2037 and the remaining will carryforward indefinitely under the new tax laws, but is subject to an 80% taxable income limitation for tax years beginning after 2020. As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had state net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">844.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion expiring at various dates beginning in 2028 through 2044. We also had federal tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million expiring at various dates beginning in 2025 through 2044, if not utilized. Our state tax credit carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million carry forward indefinitely.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We adopted the provision of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, we recognized no material adjustment in the liability for unrecognized tax benefits. At December 31, 2024, we had approximat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ely $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milli</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">on of unrecognized tax benefits, none of which would currently affect our effective tax rate if recognized due to our net deferred tax assets being fully offset by a valuation allowance.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,331</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,310</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If applicable, we would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2024, there has been no interest expense or penalties related to unrecognized tax benefits.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently expect any significant changes to unrecognized tax benefits during the fiscal year ended December 31, 2025. In certain cases, our uncertain tax positions are related to tax years that remain subject to examination by the relevant tax authorities. Tax years for which we have carryforward net operating loss and credit attributes remain subject to examination by federal and most state tax authorities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249413808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.291%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.437000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.437000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.437000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental operating and investing activities:</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Reclassification between prepaid and other<br/>&#160;&#160;&#160;current assets and deposits and other assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest paid</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,364</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,017</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,154</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249446112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. SEGMENT REPORTING</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently developing therapies for the treatment of hematologic malignancies. To date, our only source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2024, we have identified </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment. We define our operating segments based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker or CODM to analyze financial performance, make decisions, and allocate resources. Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_48950aed-512d-4e10-b713-0562fb188089;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the CODM.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Further, the CODM reviews the segment's assets based on total assets reported on the consolidated balance sheet. All long-lived assets are held in the United States.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.22%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:23.7%;box-sizing:content-box;"></td>
        <td style="width:1.54%;box-sizing:content-box;"></td>
        <td style="width:21.2%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="5" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Product revenue, net</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.5</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Royalties</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.0</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Research and clinical expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.9</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.9</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Chemistry, manufacturing, and control expenses</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.2</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.5</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Commercial expenses</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.4</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses*</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.4</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.7</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194.2</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and other income (expense)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.</span></p></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, the Company consists of a single operating and reportable segment and the consolidated financial statements and notes thereto are presented as a single reportable segment.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932147961168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. Foreign currency translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#8217; equity, on our consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,095,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,335,239</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. In January 2023, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,007,741</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2023 pre-funded warrant. In March 2024, we completed an underwritten public offering of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,999,998</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock and a pre-funded warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,002,668</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock, or the 2024 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 10 on Stockholders' Equity for further discussion of our public offerings.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2024, 2023, and 2022, the diluted net loss per share calculation excludes potential dilutive securities of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,369,889</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,458,854</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145,726,765</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. We recognize shipping and handling costs as an expense in cost of goods sold when we transfer control to a customer. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We distribute RYTELO in the U.S. through third party distributors and specialty pharmacies who are our customers. The third party distributors subsequently resell our product through their related specialty pharmacy providers to patients and health care providers. Separately, we have or may enter into payment arrangements with various third-party payors including pharmacy benefit managers, private healthcare insurers and government healthcare programs who provide coverage and reimbursement for our product that have been prescribed to a patient.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies. To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. See Note 2 on Revenue Recognition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Sales, Net</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Items Deducted from Gross Product Sales</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. The most significant items deducted from gross product sales where we exercise judgment are rebates, sales returns and chargebacks.</span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Product Revenues</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net product revenues are recognized, net of variable consideration related to certain allowances and accruals, at the time our customers obtain control of our product, which is generally upon delivery to our customers. We use the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts to estimate variable consideration and consideration payable to parties other than our customers related to our product sales.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record reserves, based on contractual terms, for components related to product sold during the reporting period, as well as our estimate of product that remains in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare providers. On a quarterly basis, we update our estimates and record any needed adjustments in the period we identify the adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We sell RYTELO to our customers at wholesale acquisition cost, and calculate product revenue from RYTELO sales, net of variable consideration and consideration payable to parties other than our customers. Variable consideration and consideration payable to parties other than our customers consists of estimates related to the following categories:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Allowances</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We pay fees for distribution services, such as fees for certain data that customers provide to us. We estimate our customers will earn these fees and deduct these fees from gross product revenues and accounts receivable at the time we recognize the related revenues.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Discounts for Prompt Payment</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We provide for prompt payment discounts to our customers, which are recorded as a reduction in gross product revenue in the same period that the related product revenue is recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product Returns</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer customers the right to return products if they are damaged, defective, or expired, as defined in customer agreements. We estimate product returns considering experience from similar products in the market, historical return patterns, sales data, and inventory levels in the distribution channel. These estimates are recorded as a reduction in gross product revenue at the time of sale. Once products are returned, they are destroyed; we do not record a right of return asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Chargebacks</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks occur when our contracted customers, mainly federal agencies that can purchase off the Federal Supply Schedule and Public Health Service 340B covered entities, buy directly from our distributors and wholesalers at discounted prices. The distributors and wholesalers then charge us the difference between their purchase price and the discounted price. We estimate chargebacks considering the terms of the applicable arrangement and our visibility regarding utilization. These chargebacks are recorded in the same period as the related revenue, reducing our net product revenue and receivables. We typically issue credits for these amounts within a few weeks of notification.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Government Rebates</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to discount obligations under government programs. Reserves for rebates payable under these government programs are recorded in the same period as gross product revenue, reducing our gross product revenue and creating a liability in accrued liabilities. Major rebates include those from the Medicare and Medicaid programs. Estimates for rebates are made considering statutory discount rates and expected utilization. These estimates are updated each period with actual claims and other current information, taking into account historical data, comparable products and other considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Co-payment Assistance</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We offer co-payment assistance to patients with commercial insurance that have coverage and reside in states that allow co-payment assistance. We estimate the average co-payment assistance amounts for our products based on expected customer demographics and record any such amounts within accrued expenses and a reduction to product revenue.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Licenses of Intellectual Property</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Milestone Payments</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalties</span></p><p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The liability related to the Royalty Pharma Agreement and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assessed the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#8217;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Agreement</span><span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Equivalents and Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations.  If an available-for-sale security&#8217;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 4 on Fair Value Measurements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Accounts receivable are stated net of an allowance that reflects our current estimate of credit losses expected to occur over the life of the receivable. In developing our allowance for expected credit losses, we use assumptions to capture the risk of loss, even if remote, based on a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The payment terms on our trade receivables are relatively short. As a result, our collection risk is mitigated to a certain extent by the fact that sales are collected in a relatively short period of time, allowing for the ability to reduce exposure on defaults if collection issues are identified</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We update our allowance as necessary to reflect expected credit losses over the remaining lives of the accounts receivable for outstanding trade receivables that are past due, have known disputes or have experienced any negative credit events that may result in future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collectability issues. We do not currently expect our current or future exposures to credit losses to have a significant impact on us. The estimated allowance for expected credit losses was not material as of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, nor were the changes to the allowance during any of the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory is recorded at the lower of cost or net realized value, with cost determined under the weighted average method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, salaries, wages and stock-based compensation for personnel involved in the manufacturing process, and indirect overhead costs. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. Prior to regulatory approval, we expensed costs associated with the manufacture of a product candidate to research and development expense unless we are reasonably certain such costs have future commercial use and net realizable value. Since we consider attaining regulatory approval of a product candidate to be highly uncertain and difficult to predict, we expect only in rare instances that pre-launch inventory will be capitalized, if at all.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We began capitalizing inventory related to RYTELO in the quarter ended June 30, 2024, as we received approval of RYTELO on June 6, 2024, and the related costs were expected to be recoverable through the commercialization of RYTELO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of Goods Sold</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs. Cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. For the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, other than packaging costs, substantially all of our RYTELO inventory sold had a zero-cost basis as it was recorded as research and development expenses prior to the FDA&#8217;s approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current RYTELO (imetelstat) clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock', window );">Depreciation and Amortization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation and Amortization</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record property and equipment at cost and calculate depreciation using the straight&#8209;line method over the estimated useful lives of the assets, generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock or restricted stock unit awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 10 on Stockholders&#8217; Equity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Debt Discounts</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt Issuance Costs and Debt Discounts</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Accumulated Other Comprehensive Gain (Loss)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#8217; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_075bab03-7a15-4dd6-87b2-88c5d830351e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> represents our chief operating decision maker. We view our operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. For additional information, see Note 13 on Segment Reporting.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New Accounting Pronouncements &#8211; Issued and Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment.</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07 also permits the disclosure of more than one measure of a segment&#8217;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods.  We adopted the guidance in the annual period ended December 31, 2024. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13. We view our operations as a single segment. See Note 13 on Segment Reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249330256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITON (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock', window );">Schedule of Reconciliation of Gross Product Sales to Net Product Sales</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:71.434%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.564999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross product revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,418</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross-to-net adjustments:</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chargebacks and distributor service fees</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,772</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government rebates</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">926</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales returns and allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total gross-to-net adjustments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,923</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cceeff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net product revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of gross to net sales adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249310432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents our inventory as of December 31, 2024: </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.88%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:43.120000000000005%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,904</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,093</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,714</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148282480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of cash equivalents, restricted cash and marketable securities by security type</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.337%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,215</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,215</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,978</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,193</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,860</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,937</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,959</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,620</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,610</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,741</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,131</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">180,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">284</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,618</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,909</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">421,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">470</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">422,069</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents, restricted cash and marketable securities by security type at December 31, 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.337%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.301%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.864%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,815</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">843</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">843</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,115</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,752</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,877</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,894</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,598</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,270</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,268</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,409</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">48,360</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,628</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,734</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,784</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">402</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">212</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of cash equivalents and marketable securities with unrealized losses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:33.76%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less Than 12 Months</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 Months or Greater</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper<br/>&#160;&#160;&#160;(due in less than<br/>&#160;&#160;&#160;one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,076</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,076</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in <br/>&#160;&#160;&#160;one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169,724</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,993</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,717</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities <br/>&#160;&#160;&#160;(due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper (due in less than one year)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,622</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,622</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in less than one year)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,567</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,567</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes (due in one to two years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,952</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,518</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">211</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial instruments measured at fair value on recurring basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 and indicates the fair value category assigned.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.008%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.482000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.142000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.922%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2024:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,802</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">273</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,570</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,748</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185,201</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202,527</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">427,046</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474,121</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31, 2023:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,658</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,658</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Certificate of deposit</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Government-sponsored enterprise securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial paper</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,268</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate notes</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)(4)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,092</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306,974</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">324,904</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in cash and cash equivalents on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in restricted cash on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in current portion of marketable securities on our consolidated balance sheets.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included in noncurrent portion of marketable securities on our consolidated balance sheets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit Risk</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249418640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, stated at cost</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment, stated at cost, is comprised of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.6%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and computer equipment</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,878</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,273</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">129</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,007</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,408</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,697</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,231</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,310</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,177</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148240672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.6%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.34%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CRO and clinical trial costs</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,968</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,541</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Manufacturing activities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,839</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,629</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professional legal and accounting fees</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">556</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest payable</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,186</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,081</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">814</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,549</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,308</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249371072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease costs</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, and the Foster City Lease were as follows:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:19.516%;box-sizing:content-box;"></td>
        <td style="width:22.555%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.296999999999997%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:2.639%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.077%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.259%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.657%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">987</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">962</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">944</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">344</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease costs</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,248</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,306</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,254</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:5.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.3875491341761395%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Variable lease costs represent non-lease components, such as common area maintenance charges.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Undiscounted future non-cancellable lease payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:35.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.686%;box-sizing:content-box;"></td>
        <td style="width:2.857%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:26.457%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,014</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,040</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">716</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">376</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">383</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">292</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,821</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">581</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,240</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249427728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Minimum Payments Under Term Loan Facility</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:61.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:28.96%;box-sizing:content-box;"></td>
        <td style="width:46.1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:22.939999999999998%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,081</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">190,475</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:  amount representing interest</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:  unamortized debt discount and issuance costs</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,525</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent portion of debt</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,476</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock', window );">Schedule of Activity Within Liability Related to Sale of Future Royalties</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the activity within the liability related to sale of future royalties during the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.8%;box-sizing:content-box;"></td>
        <td style="width:1.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:33.24%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liability Related to Sale of Future Royalties</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrying value of liability related to sale of future royalties at November 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121,634</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense recognized</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,345</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,186</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carrying value of liability related to sale of future royalties at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124,793</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of activity within liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249264176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of aggregate stock option and award activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, Inducement Plan and Directors Market Plan is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.72%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding Stock Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Available</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For Grant</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Per Share</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58,750,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,984,351</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,603,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,603,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Awards granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,351</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,907,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.77</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options cancelled/forfeited/expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,171,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,713,075</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,309,969</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,967,367</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.35</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,204,849</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options exercisable at <br/>&#160;&#160;December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,943,520</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.84</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,488,305</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options fully vested and expected<br/>&#160;&#160;&#160;&#160;to vest at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,159,549</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.39</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.30</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,613,420</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> performance-based stock options granted that have not achieved the specified performance milestone.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of allocation of stock-based compensation expense related to share-based payment awards</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the stock&#8209;based compensation expense related to service-based stock options and employee stock purchases for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024, 2023 and 2022, which was allocated as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.863%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.281%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,280</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,426</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,720</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,647</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,099</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,281</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Stock-based compensation expense</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,927</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,525</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,001</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate the fair value of stock options granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options granted in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 has been estimated at the date of grant using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.36%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.87</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.82</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.83</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.77</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.82</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.42</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.94</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.69</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.57</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;yrs</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of employee stock purchases in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024, 2023, and 2022 has been estimated using the Black-Scholes option&#8209;pricing model with the following assumptions:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:18.36%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.72</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">. to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.19</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.79</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.83</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.61</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.87</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.73</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.40</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.79</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term range</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="font-size:9pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">&#160;mos</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of common stock reserved for future issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.133%;box-sizing:content-box;"></td>
        <td style="width:1.667%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:23.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding stock options</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,967,367</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options and awards available for grant</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,309,969</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee stock purchase plan</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">258,366</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants outstanding</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,835,667</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">171,371,369</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common stock reserved for future issuance, which may include but is not limited to outstanding options and outstanding warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249322752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of Income/(loss) before income taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of Income/(Loss) before income taxes are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.9%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.78%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.4%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:20.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,737</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,930</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">215</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,521</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">181,734</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of provision for(benefit from) income taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provision for (benefit from) income taxes:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.224%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.164%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.104%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:4.201%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:21.104%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">398</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule reconciles the federal statutory tax rate to the effective income tax rate from continuing operations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.889%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.122%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.281%;box-sizing:content-box;"></td>
        <td style="width:5.181%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.122%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.101%;box-sizing:content-box;"></td>
        <td style="width:4.081%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.942%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:3.281%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss not benefitted</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the entity's deferred tax assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of our deferred tax assets are as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.413%;box-sizing:content-box;"></td>
        <td style="width:1.5%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.36%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.863000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">272,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state tax credits</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,492</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,700</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,300</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,353</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue Participation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">767</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,100</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,963</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">430,595</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">396,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">429,913</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">395,200</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating leases, right-of-use assets</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.444%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.757%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,331</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">494</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,473</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,310</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249300240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental schedule of non-cash operating and investing activities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.291%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.437000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.437000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.8%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.437000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental operating and investing activities:</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net unrealized loss on <br/>&#160;&#160;&#160;marketable securities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">431</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Reclassification between prepaid and other<br/>&#160;&#160;&#160;current assets and deposits and other assets</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest paid</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,364</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,017</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,154</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249260400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023:</span><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.22%;box-sizing:content-box;"></td>
        <td style="width:1.34%;box-sizing:content-box;"></td>
        <td style="width:23.7%;box-sizing:content-box;"></td>
        <td style="width:1.54%;box-sizing:content-box;"></td>
        <td style="width:21.2%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="5" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenues:</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Product revenue, net</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.5</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Royalties</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenues</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.0</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of goods sold</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Research and clinical expenses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.9</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.9</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Chemistry, manufacturing, and control expenses</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.2</span></p></td>
        <td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.5</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Commercial expenses</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72.0</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.4</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment expenses*</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83.3</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.4</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250.7</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194.2</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0ff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and other income (expense)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">184.1</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152508080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>May 27, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember', window );">2024 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering</a></td>
<td class="nump">41,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants | Public Offering of Common Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,095,238<span></span>
</td>
<td class="nump">8,335,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember', window );">2023 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember', window );">2023 Pre-funded Warrant | 2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyFourPreFundedWarrantMember', window );">2024 Pre-funded Warrant | 2024 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="nump">8,002,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,002,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_PublicOfferingOfCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyFourPreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyFourPreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149949712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock options and warrants excluded from diluted net loss per share calculation due to net loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)</a></td>
<td class="nump">77,369,889<span></span>
</td>
<td class="nump">75,458,854<span></span>
</td>
<td class="nump">145,726,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932253230224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932146775712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SEGMENT INFORMATION (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151975056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITON - Schedule of Reconciliation of Gross Product Sales to Net Product Sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_RevenuesBeforeAdjustmentsMember', window );">Revenues Before Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 89,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_ChargebackAndDistributorServiceFeesMember', window );">Chargebacks and distributor service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(11,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_GovernmentRebatesMember', window );">Government rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_SalesReturnsAndAllowanceMember', window );">Sales returns and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_TotalGrossToNetAdjustmentsMember', window );">Total gross-to-net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="num">(12,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 76,495<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_RevenuesBeforeAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_RevenuesBeforeAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_ChargebackAndDistributorServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_ChargebackAndDistributorServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_GovernmentRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_GovernmentRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_SalesReturnsAndAllowanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_SalesReturnsAndAllowanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_TotalGrossToNetAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_TotalGrossToNetAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149844240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw materials</a></td>
<td class="nump">$ 4,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">30,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">3,717<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 38,714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932150230400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">$ 50,193<span></span>
</td>
<td class="nump">$ 16,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">50,192<span></span>
</td>
<td class="nump">16,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">421,790<span></span>
</td>
<td class="nump">306,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">470<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">422,069<span></span>
</td>
<td class="nump">306,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">45,215<span></span>
</td>
<td class="nump">16,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">45,215<span></span>
</td>
<td class="nump">16,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Included in cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">4,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CashAndCashEquivalentsUnrealizedLosses', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">4,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Amortized Cost</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember', window );">U.S. Treasury securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,937<span></span>
</td>
<td class="nump">26,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">7,959<span></span>
</td>
<td class="nump">26,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInOneToTwoYearsMember', window );">U.S. Treasury securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">22,620<span></span>
</td>
<td class="nump">2,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">22,610<span></span>
</td>
<td class="nump">2,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember', window );">Government-sponsored enterprise securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,741<span></span>
</td>
<td class="nump">86,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">8,748<span></span>
</td>
<td class="nump">86,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember', window );">Government-sponsored enterprise securities (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember', window );">Commercial paper (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">180,131<span></span>
</td>
<td class="nump">102,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">180,225<span></span>
</td>
<td class="nump">102,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember', window );">Corporate notes (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">130,361<span></span>
</td>
<td class="nump">48,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">130,618<span></span>
</td>
<td class="nump">48,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember', window );">Corporate notes (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">26,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 71,909<span></span>
</td>
<td class="nump">$ 26,734<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CashAndCashEquivalentsUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the gross unrealized losses for cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CashAndCashEquivalentsUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152428160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">$ 169,724<span></span>
</td>
<td class="nump">$ 166,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater - Estimated Fair Value</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater - Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">171,717<span></span>
</td>
<td class="nump">166,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(191)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember', window );">U.S. Treasury securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">18,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">18,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember', window );">Government-sponsored enterprise securities (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,377<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember', window );">Commercial paper (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">66,076<span></span>
</td>
<td class="nump">58,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">66,076<span></span>
</td>
<td class="nump">58,622<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember', window );">Corporate notes (due in less than one year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">31,549<span></span>
</td>
<td class="nump">34,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Greater - Estimated Fair Value</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Greater - Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">33,542<span></span>
</td>
<td class="nump">34,567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember', window );">Corporate notes (due in one to two years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months - Estimated Fair Value</a></td>
<td class="nump">53,506<span></span>
</td>
<td class="nump">3,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months - Gross Unrealized Losses</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total - Estimated Fair Value</a></td>
<td class="nump">53,506<span></span>
</td>
<td class="nump">3,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total - Gross Unrealized Losses</a></td>
<td class="num">$ (98)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_USTreasurySecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CommercialPaperDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInLessThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148535056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details) - Recurring basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 474,121<span></span>
</td>
<td class="nump">$ 324,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">46,802<span></span>
</td>
<td class="nump">17,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">30,570<span></span>
</td>
<td class="nump">29,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">8,748<span></span>
</td>
<td class="nump">99,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">185,201<span></span>
</td>
<td class="nump">102,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">202,527<span></span>
</td>
<td class="nump">75,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">47,075<span></span>
</td>
<td class="nump">17,930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">46,802<span></span>
</td>
<td class="nump">17,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">427,046<span></span>
</td>
<td class="nump">306,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">30,570<span></span>
</td>
<td class="nump">29,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Government-sponsored enterprise securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">8,748<span></span>
</td>
<td class="nump">99,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">185,201<span></span>
</td>
<td class="nump">102,268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value on a Recurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 202,527<span></span>
</td>
<td class="nump">$ 75,092<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151956736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - SALE OF FUTURE ROYALTIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_FairValueMeasurementsInterTransfersBetweenLevels', window );">Fair value measurements inter transfers between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_FairValueMeasurementsInterTransfersBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurements inter transfers between levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_FairValueMeasurementsInterTransfersBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152456432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - CREDIT RISK (Details) - Accounts Receivable - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCustomer', window );">Concentration risk, customer</a></td>
<td class="text">four<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">McKesson Financial Center</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">ASD Specialty Healthcare LLC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Cardinal Health Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Sina Drug</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_McKessonFinancialCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_McKessonFinancialCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_ASDSpecialtyHealthcareLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_ASDSpecialtyHealthcareLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_SinaDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_SinaDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932258275344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,007<span></span>
</td>
<td class="nump">$ 2,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(1,697)<span></span>
</td>
<td class="num">(1,231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,878<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932256001360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent', window );">CRO and clinical trial costs</a></td>
<td class="nump">$ 18,968<span></span>
</td>
<td class="nump">$ 23,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AccruedManufacturingActivitiesCurrent', window );">Manufacturing activities</a></td>
<td class="nump">11,839<span></span>
</td>
<td class="nump">14,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional legal and accounting fees</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 35,549<span></span>
</td>
<td class="nump">$ 40,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AccruedManufacturingActivitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AccruedManufacturingActivitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151690368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Plan</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NumberOfSeverancePlan', window );">severance plans</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod', window );">Period within which employee is terminated by entity without cause following a change of control</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity', window );">Period within which no comparable employment is offered by the entity following a change of control</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment', window );">Period within which employee resigns following a change of control due to material change in terms of employment</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=gern_EmployeesAboveTheVicePresidentLevelMember', window );">Employees Above The Vice President Level</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_NumberOfSeverancePlan', window );">severance plans</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan', window );">Period of base salary to be considered for severance payments</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent', window );">Period of base salary in connection with a non-change of control to be considered for severance payments</a></td>
<td class="text">42 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_SeverancePlanLineItems', window );"><strong>Severance Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan', window );">Period of base salary to be considered for severance payments</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent', window );">Period of base salary in connection with a non-change of control to be considered for severance payments</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency period of current base salary to be paid under severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency period of current base salary to be paid under severance plan non change of control triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of months following a change in control when an employee is terminated without cause to be classified as a triggering event for severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period following change of control within which an employee is not offered comparable employment (new or continuing) by the entity or its successor or acquired and to be considered as triggering event for severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period within which employee resigns following a change of control due to material change in terms of employment and to be considered as triggering event for severance payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_NumberOfSeverancePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_NumberOfSeverancePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_SeverancePlanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_SeverancePlanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=gern_EmployeesAboveTheVicePresidentLevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=gern_EmployeesAboveTheVicePresidentLevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932150211488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 10, 2020</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,881<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=gern_NewJerseyOfficeSpaceLeaseMember', window );">New Jersey Office Space Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating Lease, Percentage of Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term, option to extend additional period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Operating lease term, option to terminate lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-time option to terminate the New Jersey Lease without cause as of the 103rd month anniversary of the commencement date of the lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_OperatingLeaseRentAbatementPeriod', window );">Operating lease, rent abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease,remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=gern_FosterCityOfficeSpaceLeaseMember', window );">Foster City Office Space Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating Lease, Percentage of Discount Rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, initial term</a></td>
<td class="text">87 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">87 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease term, option to extend additional period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_OperatingLeaseRentAbatementPeriod', window );">Operating lease, rent abatement period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease,remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_OperatingLeaseRentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease rent abatement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_OperatingLeaseRentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gern_NewJerseyOfficeSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gern_NewJerseyOfficeSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gern_FosterCityOfficeSpaceLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gern_FosterCityOfficeSpaceLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152083456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 987<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,248<span></span>
</td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 1,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932146777280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details) - New Jersey Lease And Foster City Lease<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(581)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 3,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=gern_NewJerseyLeaseAndFosterCityLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=gern_NewJerseyLeaseAndFosterCityLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932150081728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_HerculesLoanAgreementMember', window );">Hercules Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 86,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember', window );">Pharmakon Loan Agreement [Member] | BioPharma Credit PLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Line of credit, maturity period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Liabilities Related to Sale of Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Revenue interest payments description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the revenue participation rate commences at 7.75% for annual U.S. net sales of up to and equal to $500.0 million declining to 1.0% for annual U.S. net sales exceeding $1.0 billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031 or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.In addition, we had the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option. &#8220;Buy-Out Payment&#8221; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Carrying value of liabilities related to sale of future revenues</a></td>
<td class="nump">$ 121,634,000<span></span>
</td>
<td class="nump">$ 124,793,000<span></span>
</td>
<td class="nump">$ 124,793,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Interest expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,345,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Liabilities Related to Sale of Future Royalties | Scenario One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Liabilities Related to Sale of Future Royalties | Scenario Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfAnnualNetSales', window );">Percentage of annual net sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Liabilities Related to Sale of Future Royalties | Minimum [Member] | Scenario Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue interest payments</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember', window );">Liabilities Related to Sale of Future Royalties | Maximum [Member] | Scenario One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue interest payments</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TrancheAMember', window );">Tranche A [Member] | Hercules Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Term loan maturity date</a></td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TrancheAMember', window );">Tranche A [Member] | Pharmakon Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">10.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TrancheBMember', window );">Tranche B [Member] | Pharmakon Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TrancheCMember', window );">Tranche C [Member] | Pharmakon Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TermLoansMember', window );">Term Loans [Member] | Pharmakon Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Term loan maturity date</a></td>
<td class="text">Nov.  01,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Percentage added to prime rate for debt instrument interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DebtInstrumentFloorRate', window );">Floor rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PercentageOfCommitmentAmountToFundLoan', window );">Percentage of commitment amount to fund loan</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TermLoansMember', window );">Term Loans [Member] | Pharmakon Loan Agreement [Member] | Prepaid Prior To Third Anniversary Of Funding Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PrepaymentPremiumOnPercentageOfTermLoan', window );">Prepayment premium on percentage of term loan</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TermLoansMember', window );">Term Loans [Member] | Pharmakon Loan Agreement [Member] | Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PrepaymentPremiumOnPercentageOfTermLoan', window );">Prepayment premium on percentage of term loan</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=gern_TermLoansMember', window );">Term Loans [Member] | Pharmakon Loan Agreement [Member] | Prepaid On Or After Fourth Anniversary Of Funding Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PrepaymentPremiumOnPercentageOfTermLoan', window );">Prepayment premium on percentage of term loan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember', window );">Hercules and Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity under term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding under term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument floor rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PercentageOfAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PercentageOfAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PercentageOfCommitmentAmountToFundLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commitment amount to fund loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PercentageOfCommitmentAmountToFundLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PrepaymentPremiumOnPercentageOfTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The prepayment premium on percentage of term loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PrepaymentPremiumOnPercentageOfTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_HerculesLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_HerculesLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_PharmakonLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=gern_BiopharmaCreditPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=gern_BiopharmaCreditPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gern_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gern_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gern_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gern_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TrancheCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TrancheCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=gern_TermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=gern_TermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gern_HerculesAndSiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148227984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">13,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">13,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">13,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">13,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">135,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_LongTermDebtGross', window );">Total</a></td>
<td class="nump">190,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedCapitalizedInterestCosts', window );">Less: amount representing interest</a></td>
<td class="num">(65,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(6,525)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Noncurrent portion of debt</a></td>
<td class="nump">$ 118,476<span></span>
</td>
<td class="nump">$ 35,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_LongTermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of term loan, including accrued interest payable and end of term charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_LongTermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedCapitalizedInterestCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedCapitalizedInterestCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149962736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details) - Liabilities Related to Sale of Future Royalties - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Interest expense recognized</a></td>
<td class="nump">$ 5,345<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payments</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Carrying value of liability related to sale of future royalties at December 31, 2024</a></td>
<td class="nump">$ 124,793<span></span>
</td>
<td class="nump">$ 124,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249310432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 12, 2021</div></th>
<th class="th"><div>May 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">1,350,000,000<span></span>
</td>
<td class="nump">675,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151308592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - PUBLIC OFFERINGS (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2024</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember', window );">2023 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Public Offering | 2023 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember', window );">2022 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember', window );">2022 Underwritten Public Offering | 2022 Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,095,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember', window );">2022 Underwritten Public Offering | 2022 Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember', window );">2024 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="nump">41,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="nump">$ 141.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember', window );">2024 Underwritten Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock per share</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember', window );">2024 Underwritten Public Offering | 2024 Pre-funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_PublicOfferingLineItems', window );"><strong>Public Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="nump">8,002,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,002,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_PublicOfferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_PublicOfferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyThreePreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoPreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoPreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyFourPreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyFourPreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932150429024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="nump">$ 105,912<span></span>
</td>
<td class="nump">$ 15,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock outstanding warrants to purchase</a></td>
<td class="nump">60,835,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock outstanding warrants to purchase</a></td>
<td class="nump">59,433,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember', window );">2020 Public Offering of Common Stock and Warrants | 2020 Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,430,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember', window );">2020 Public Offering of Common Stock and Warrants | Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock outstanding warrants to purchase</a></td>
<td class="nump">1,402,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiration date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | 2020 Stock Purchase Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,474,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised', window );">Warrants to purchase common stock exercised, shares</a></td>
<td class="nump">1,071,981<span></span>
</td>
<td class="nump">77,349,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 105,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_StockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_StockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyStockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gern_TwoThousandTwentyStockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932146825600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AtMarketIssuanceSalesAgreementsLineItems', window );"><strong>At Market Issuance Sales Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember', window );">2023 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_AtMarketIssuanceSalesAgreementsLineItems', window );"><strong>At Market Issuance Sales Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_CommonStockAggregateOfferingPrice', window );">Aggregate offering price of common stock</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_MaximumCommissionRate', window );">Maximum commission rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at market offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_AtMarketIssuanceSalesAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>At Market Issuance Sales Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_AtMarketIssuanceSalesAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_CommonStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate offering price for which the entity may elect to issue and sell shares of its common stock under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_CommonStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_MaximumCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum commission rate, based on gross proceeds of sale price per share of common stock sold through sales agent under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_MaximumCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932150237120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EQUITY PLANS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>May 15, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,371,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,309,969<span></span>
</td>
<td class="nump">58,750,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total pretax intrinsic value of stock options exercised (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercise of stock options (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,943,520<span></span>
</td>
<td class="nump">39,995,642<span></span>
</td>
<td class="nump">36,085,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member', window );">2011 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of stock options from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,447,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue', window );">Minimum percentage of ownership required for granting stock options at least 110% of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock', window );">Minimum exercise price as a percentage of fair market value for employees having more than 10 % outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock', window );">Maximum expiration term of stock options granted to employees having more than 10 % outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Common stock, increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,360,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,587,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan | First Director Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment', window );">Stock options to be granted to purchase shares upon appointment (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan | Subsequent Director Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares', window );">Stock options to be granted to purchase shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration term of stock options from date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember', window );">2018 Inducement Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,959,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Common stock, increase in shares reserved for future issuance (in shares)</a></td>
<td class="nump">40,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">851,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember', window );">2018 Inducement Award Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember', window );">Directors Market Value Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember', window );">Directors Market Value Stock Purchase Plan | Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,351<span></span>
</td>
<td class="nump">36,864<span></span>
</td>
<td class="nump">15,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.84<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock that vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,079<span></span>
</td>
<td class="nump">$ 85,400<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award minimum exercise price of options granted to employees with more than 10 percentage of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum percentage of ownership required for granting of options at a price not less than 110 percent of the fair market value of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of options to be granted to purchase shares in each year during the optionee's service on the Board of Directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of options to be granted to purchase shares upon appointment to Board of Directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum expiration term of options granted to employees having more than 10 % outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_IncentiveAwardPlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_FirstDirectorOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_FirstDirectorOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_SubsequentDirectorOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_SubsequentDirectorOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_TwoThousandAndEighteenInducementAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gern_DirectorsMarketValueStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149052016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward', window );"><strong>Shares Available For Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">58,750,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="num">(29,603,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted (in shares)</a></td>
<td class="num">(8,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet', window );">Stock options cancelled/forfeited/expired (in shares)</a></td>
<td class="nump">5,171,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">34,309,969<span></span>
</td>
<td class="nump">58,750,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">72,984,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">29,603,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="num">(17,907,649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock options cancelled/forfeited/expired (in shares)</a></td>
<td class="num">(8,713,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">75,967,367<span></span>
</td>
<td class="nump">72,984,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable at the end of the period (in shares)</a></td>
<td class="nump">37,943,520<span></span>
</td>
<td class="nump">39,995,642<span></span>
</td>
<td class="nump">36,085,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options fully vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">74,159,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options granted (in dollars per share)</a></td>
<td class="nump">2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Stock options exercised (in dollars per share)</a></td>
<td class="nump">1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Stock options cancelled/forfeited/expired (in dollars per share)</a></td>
<td class="nump">3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Stock options fully vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weight Average Remaining Contractual Life (in years) - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at the end of the period</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable at the end of the period</a></td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options fully vested and expected to vest at the end of the period</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value - Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance at the end of the period (in dollars)</a></td>
<td class="nump">$ 94,204,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options exercisable at the end of the period (in dollars)</a></td>
<td class="nump">57,488,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options fully vested and expected to vest at the end of the period (in dollars)</a></td>
<td class="nump">$ 92,613,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life (In years)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Available For Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled or that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932147845920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">75,967,367<span></span>
</td>
<td class="nump">72,984,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152330720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Item </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,371,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan', window );">Aggregate shares issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Common stock, increase in shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for future issuance (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod', window );">Maximum duration of offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime', window );">Number of offering periods in which an employee can participate at a time | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod', window );">Number of consecutive purchase periods in an offering period | Item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod', window );">Duration of the purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld', window );">Maximum percentage of annual salary that can be withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage applied to common stock market value in calculating purchase price under purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod', window );">Duration of the new offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear', window );">Maximum amount of annual salary that can be withheld to purchase shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate number of share instruments issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of new offering period in a case where the fair market value of common stock on the purchase date is less than the fair market value at the beginning of the offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of the purchase period under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum amount of annual salary that can be withheld per year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum duration of the offering period under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of offering periods in which an employee can participate at a time in the purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum percentage of annual salary that an employee can choose to have withheld to purchase common stock under the purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive purchase periods in an offering period in the purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151274800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">29,603,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 31,927<span></span>
</td>
<td class="nump">$ 18,525<span></span>
</td>
<td class="nump">$ 8,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember', window );">Performance-Based Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">208,100<span></span>
</td>
<td class="nump">832,790<span></span>
</td>
<td class="nump">2,741,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in operating expenses</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gern_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932152501712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 31,927<span></span>
</td>
<td class="nump">$ 18,525<span></span>
</td>
<td class="nump">$ 8,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,280<span></span>
</td>
<td class="nump">7,426<span></span>
</td>
<td class="nump">3,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 21,647<span></span>
</td>
<td class="nump">$ 11,099<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151268608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Compensation cost related to unvested stock awards not yet recognized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized, net of estimated forfeitures (in dollars)</a></td>
<td class="nump">$ 65.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition of compensation cost on weighted average basis</a></td>
<td class="text">32 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility range, minimum (as a percent)</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility range, maximum (as a percent)</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate range, minimum (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">1.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate range, maximum (as a percent)</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.94%<span></span>
</td>
<td class="nump">4.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term range</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of employee stock options granted (in dollars per share)</a></td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility range, minimum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility range, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate range, minimum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">4.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate range, maximum (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">2.79%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of other than employee stock options granted (in dollars per share)</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate fair value of awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932147846720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation for services by non-employees</a></td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="nump">$ 828,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=gern_ConsultantsMember', window );">Consultants | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Stock-based compensation for services by non-employees</a></td>
<td class="nump">$ 103,000<span></span>
</td>
<td class="nump">$ 742,000<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=gern_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=gern_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932258257808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">75,967,367<span></span>
</td>
<td class="nump">72,984,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock options and awards available for grant (in shares)</a></td>
<td class="nump">34,309,969<span></span>
</td>
<td class="nump">58,750,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">60,835,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">171,371,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">258,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249448944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (174,737)<span></span>
</td>
<td class="num">$ (181,884)<span></span>
</td>
<td class="num">$ (141,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (174,521)<span></span>
</td>
<td class="num">$ (181,734)<span></span>
</td>
<td class="num">$ (141,902)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932147891920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - SCHEDULE OF PROVISION FOR (BENEFIT FROM) INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Foreign</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932340074064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Federal and state tax credits</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted', window );">Net operating loss not benefitted</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.10%)<span></span>
</td>
<td class="num">(24.80%)<span></span>
</td>
<td class="num">(27.50%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax Rate reconciliation net operating loss not benefitted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148752112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - DEFERRED TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Significant components of deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 272,970<span></span>
</td>
<td class="nump">$ 272,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsFederalAndStateCredits', window );">Federal and state tax credits</a></td>
<td class="nump">70,492<span></span>
</td>
<td class="nump">64,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">39,503<span></span>
</td>
<td class="nump">43,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,353<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsRevenueParticipation', window );">Revenue Participation</a></td>
<td class="nump">29,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">8,963<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">430,595<span></span>
</td>
<td class="nump">396,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(429,913)<span></span>
</td>
<td class="num">(395,200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets', window );">Operating leases, right-of-use assets</a></td>
<td class="num">(682)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(682)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 45,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to the treatment of research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsFederalAndStateCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets federal and state credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsFederalAndStateCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxAssetsRevenueParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets revenue participation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxAssetsRevenueParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities operating leases right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932258187664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, expire beginning 2024 through 2037</a></td>
<td class="nump">631.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 844.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932249330256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 79.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 23.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932148329712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits, if recognized would impact effective tax rate</a></td>
<td class="nump">$ 28,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the period</a></td>
<td class="nump">26,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to prior year tax positions</a></td>
<td class="num">(494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">2,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the period</a></td>
<td class="nump">$ 28,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932151248624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental operating and investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Net unrealized loss on marketable securities</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="num">$ (431)<span></span>
</td>
<td class="num">$ (68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets', window );">Reclassification between prepaid and other current assets and deposits and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 10,364<span></span>
</td>
<td class="nump">$ 7,017<span></span>
</td>
<td class="nump">$ 5,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification between prepaid and other current assets and deposits and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932250093440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment reporting, CODM, profit (loss) measure, how used, description</a></td>
<td class="text">The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">Segment reporting, expense information used by CODM, description</a></td>
<td class="text">Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932145775264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of goods sold</a></td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">145,732<span></span>
</td>
<td class="nump">$ 69,135<span></span>
</td>
<td class="nump">$ 43,628<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">250,726<span></span>
</td>
<td class="nump">194,181<span></span>
</td>
<td class="nump">139,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(173,732)<span></span>
</td>
<td class="num">(193,944)<span></span>
</td>
<td class="num">(138,550)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(174,572)<span></span>
</td>
<td class="num">(184,127)<span></span>
</td>
<td class="num">(141,901)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of goods sold</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">83,300<span></span>
</td>
<td class="nump">49,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">250,700<span></span>
</td>
<td class="nump">194,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(173,700)<span></span>
</td>
<td class="num">(193,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_TotalInterestAndOtherIncomeExpense', window );">Total interest and other income (expense)</a></td>
<td class="num">(900)<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(174,600)<span></span>
</td>
<td class="num">(184,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">76,495<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue, Net | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">76,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_ResearchAndClinicalExpensesMember', window );">Research and Clinical Expenses | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">67,900<span></span>
</td>
<td class="nump">74,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_ChemistryManufacturingAndControlExpensesMember', window );">Chemistry, Manufacturing, and Control Expenses | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">26,200<span></span>
</td>
<td class="nump">42,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=gern_CommercialExpensesMember', window );">Commercial Expenses | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Selling, general and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="nump">$ 27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_TotalInterestAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total interest and other income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_TotalInterestAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_ResearchAndClinicalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_ResearchAndClinicalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_ChemistryManufacturingAndControlExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_ChemistryManufacturingAndControlExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=gern_CommercialExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=gern_CommercialExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45932149397808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="nump">$ 105,912<span></span>
</td>
<td class="nump">$ 15,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering', window );">Issuance of common stock in connection with public offering (in shares)</a></td>
<td class="nump">68,007,741<span></span>
</td>
<td class="nump">68,007,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from public offering after deducting underwriting discount and other offering expenses</a></td>
<td class="nump">$ 213,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period in connection with public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gern_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MWF/WZY?^PQBU'WH(/@?C9S1XN'L<?FF/!X\/Z!1]'?70T6_'UW4!V4FC>E!
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M8)'I23,C;G,QH]7!K%E"J[)6RGO7J(%7K"G'0ET8PV:4:377#IQ[S&8$M8,
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M74"A\9?Q0C;_@_N=+1R!K):*E[O!&D&95]N_]/LN$9T!*!@8@'<#\','D-T
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MC;;:SCR_@>0=R=+L$)\RJ:X$63-2MS;@.D ]GS$F7SKZ7E#> _T_4$L#!!0
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MN!-$SHN"BM<SR/FR9SG6V\)]-DV57K"C[HQ.803J<78G<&8W*DE6 ),99T3
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M=?U2!)]PHG=LXQW;N+-&#UA[E^1)D;+:2AH^Y/2U1= K"]L8Z>C;0#D=5+M
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MV<M53C1K':#:2RJ>DJRJMX-"(^@G45C25C5-F<-2/*"<0I"!CZ+6*$6Q!FO
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MWF2A7Z?H.E\W4;RVW6;/E>Y==ECJGP4($Z"?YYRKX\1L,/Q^DC=02P,$%
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M[/42(S,TTQ XW<8+O-?.MT.<-O[] 1,2_/Y!:W<,0H'I12M_ 5!+ P04
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ME[V<_CJ-EHB^PK7B)V6A:8!@[+379MW+J4[/S\*)0 TPJF@A$,LE/_]?13.
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MZ6):L.H6K MCYMQ[!R027%,96;:@>+_W*FK\W@0ZP+XBB\>(^>/C9&S$IF*
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MA82RX8#_3C%J\IKB\S"*M&\?S[*%2^JP3 E6?F5*'LJFLPZUM_T^AW4#,'%
M&L")6$I@"*G%A!DYVZM5- +V')1-RWT#4JS] ,\0B?MW;$.I#X#Y=DO:F,1]
M]#>)S+CV!F,I'4=*"JUZ\).>0&C3D QJJ96"&68CTC 5"(/.]J%N)4)U66#3
MA62=NZDVK6+QLJ]MN6JT\"\?K7V)X=3D3:6AH"C;+]5/H5ACY_+QS'%A<5JS
MD>\75EZ,%>(XPTSG2ZH3XDS;^ Y9L"D=QE8IES5XW5_;N3=Y Q#2F4OM/!IF
M3ODCI,7BG;CJC1NU0P,TT%>Q[K7?E!0L[,B,BCX7QKVPV!VM,&^;%]&X$:'+
MR'TTWRT/*HE+$36_)R6)6(,+<I)2IGIC28=U4@FC+VLIC!]?$ZZ_T-ICC0#3
M##B0!@WXG"6P[HUU;>,=$I1N8:B$6)-Q1E$L6@_<'@@R'"$^ELH4.'05WYCF
MWKDC#5W")<A5H# NND$QF8MPKW5$+MV$Q0A?CRZJ]L=H%L)\IZR1Q#SFA99?
MLN/(\3U:2[3TWNY1ZQ[':@O??"TR3RU7RHP KY!Y+Y,5&IVV2W55$=A4.B'J
M.D@_KM@-!9>!7(LN1%7C8NMQ$AYK1L0BX5"#,L*SG#X.4SWV;\?'N=8%:+D*
M2QY(AO,@,Q :ZZ'GV#)/./3.M%:)+J3%D6&5,G-:%;NY1!'"-2A1,;Z"9]@-
MHL<DOBA2 S/)7/4:BQ*:-:3N%MU'%ZD)011\0+"F,=1 YX/4%HUT;AP1(32H
M$P'$5QQR#H_/V%>)F%)UG)8EBRIU[,)>$LA -(9NW'1$#<H[K7,+_XH-!0T*
MX2Q.GOK1$9I01'N52R9.KF4.>,_1O"$_Y2'4A>O418U1^YW9VPL5*Z'[3N4=
MMM ,R)-TN#Q+._3*;\6"*E)\3>K<T:Y4X"?3-C?%0M+HAR9E<+X$9%^K-=78
MO>)CV@D(J.V0R;1LD$O3B)N6IF#K3N9P$O:E#DHEZN!\J:'E2_1%S^T,K%&#
MRJ'CR,<-G=A\Q^WP#L@GV* 7-#0HG'A$'+9(D)'ZP_=WW^(&SQG50?E(N80/
M,(M?HW1&.3-$!E:HE/2A!*HZQ.%K9E(AEZ,W[LF%MB."D0H\HZETC;R,/)KY
M.3>A=]WKQ+W)D"LD>=&=(9 >#3SQ016U5"H0>9B(TK\1AK3;. _!X,9K,#'<
M   .83!5!=VGR_%-=*6AT1Q@::%I@;CE.;2M8_$<8NHTKQ>M-BG.;SKQ$\9#
M(8$@#?L$NG&)<IE4 VT@V74NG@X]RQH8&1IR43;J2TEC^]9K1D(E@T$2T,M<
M[W=KXGK\OOU4JQ#VZ'O1-2/'/W*6F=%HR=#X]IF&I\38$E4"%1=A65OOL4CB
MN::Z.2<MN6P0L3[!@7EU >LMH^I?C2V!)6=[%G>4K^1R+!ZI0_V@_@&.)^K[
M440E[<>6O@EQ?.*:F0=2PZ)%$U6"$%EE9RYSOA=_XVLB+;$3G$4610G,R4#?
M@CW2GNZWPQHX]MO?4A__-;KLE_N#0'SR-';U^0(UL!D*J",\V=A2&.FAT11%
M$IO7(*(/K :10,(^(/^HK%?J)]6\6M?MUI@NR'QBLJ@6+#T#S7U2%7-4 8Q@
M"PT8FNJJ"H_O+#I_).M%F,<-/J&[CITKU$&S!A,P-2^5 W<4\*+#'O!4:U&U
M8P)B+M&]^"DJ].*A3&]TR/;& %XTW'C(;<_CQI2@EV6C= Z')(-0%7H6T3,2
MGG"B89'];EP[";$2Y!$PGC9%;*QT/Q1R:/R(P,73O'EU$>+:PF5<"^P7>14M
M\EH7^?3#;8*=&8U,]-_Z])--_$UB8L,>7E0\*"6AO&/,'E[3-#CU2%KRJ2QE
M9$9\Y\MN(RB0[K"F/B2C:Y[7#^MCB_#6M34/G CVD+R?9W4Q@[O$VG0C18L8
MI2*WLNN!$TEMZB<]&K5)+A1?17=ISNV^>.X%:H )%N[LO>>*C;>-9=A=T'KI
MTUGEA@5U*<3$S-S%U<S1[>V\ZK< ,O4!Y_!"+X0-1Z>(<R,II%R6)[@XUA./
M*? %2O%5^H2^,B)'T=70$&:(Q_GO8H5+G4R$3,YH>FLYJJ@+OTO!X\@N/WT0
MGN<3 <M5K72 2A+3$PI%>5(\18,A).TK@E9[W $,W$(B&[Z>*R2V\'=LHJF]
M*(HQ84;+3P.K);7U>ZV8)K294N:-^,*/+B, 6#.RGO.#WD-6CANV/+QT?GC,
M4K][."0:>=QUO'-(/!3MHYDU#A_X-E?=FH+.#?4>H>G/4P0EJK+76*JI"]1R
ML+'QT^H\B&)H^Z068W?&4>W0]QXR%%%[T33["_AS-S@6(II)&[_&<WLYKNY7
MH%8]B2^S\TU&N<R>5,L_:NB\A='91;Z[N*=3$+E@BZ&1JPKW(DXYAL,G!; (
M#"^-+4BH)](NSRI>-,IA8&40J&]4 Z=/GU&476OI]A.%8-_.AWHG,")5NJ''
M>HZTQW'M:?8+SFQ<MCP] '^&(Y0GA1R WXH"2*'8<F3G.550A"!-G+ND^9!3
M'J0L!WI)'',96SQ?39!16B'/\UC1/F_8IJ+A%.R\2^W&WL16%\+>,B][0Z,2
M9?R5UL>C':-V%6L)_5/ZN+3W2J1IX1.5:!MQJ*7Q2\A6H=\* /4S>(U,H X;
M[DZZ^Y$5Z 4,03\A?R.D<3I.75%P059)T4(!7"6I"1$36RM1=(V;D8T?[^;K
M O:;]:E23>R!N-XU*K09!8.;'^3%I+YHI_3)>W;XPR^&?B7%5^;E/\96.I#&
MGU'BG[Z KM+:F[A R'O-7-'D T;[M7\4NA?#/[@K?M&H.2Y9<\?M :;6R7D<
M<^4$9> P^&MNJ#*_VQE]KJ44A^&_=?4=]4/\0;QRP1XYWUP-W!T'YB@@*^R$
MC1S8JR#$#I;L'=Y-@H]Y7#BBE=,\-A$#ZIJ@\0.XH\.E3?_)NP<"1 <X4UN9
M4O84R_4HMY#V&!<O\4_?O*S!CYE<E]0A*B]3=(C02A/ET"VAHB,V#0@<7H^[
M0D-K2IPH"CV;<?*'+:/O[+QRN08*9NV]D2#S*#*X&B'!PYZL9C,X_8RF28H0
MMP>FQJ=3CO=^,D'$C Y\7OA?-]A+:Q?QS^?XZ'6$%DJ '=V,B@9"*@L\]J)G
MHF6C41I7[#Q$-<-XPKW5U/*GN?IAV'"T060AL9DHY>DT^5P0'2I\VT37[=1Y
MCM^;:GV>$"TW(?7@-,W_CZHS#=+N[R&],V0&AY*WE V4AQB./U8E0=6QH\8E
MZ)7#O_N@92NOI6R%K*?QZGTDH- ,G:>M/''Q1-PR;;M,YFMQ&8R,U$[N!MC@
MMX$S?V*8Q-E3S9Z L[8SM'NODN964[VY%&=WL/>M?MOIT\AJ8;0>ONY'-G!@
M-AZZ2<][ F$ R)8<AR==-^V H;'S_$I4?F])9H36);9-=Y"V-V2^IW;ZX/I0
M;'@,:Z-NH11#$YR>W*.$9@IC,/#55 AH\ /Z;[F6U/#C:F?G&AX+\U7(.1OY
MJ3+GJ]&DMU*]_SWL' !H!XRHG>"?!@4$P@^@2>MJ+782E);2L?R"GV.7SA7D
M:J*BPE&07KV3G771D9V3<_&$NFX(,8\:.'IX+JVE\1*<5RNY8@?$SPSHB4_O
MN.@UGF$53;;5] (]SM8\9I11,TBN,S+G"S]Q1/A&@QLXG:WV!;3I!5'%@+XW
M7D/1)>Y<IC\2R4-DJ!"./+AMW"DUQB+Q")[(+0\I,8OUSO3#'Q2RY@@6UVZ[
MX MJQI_3Q5ZHY_+S)!2YIB1SJ'NA& BMXOMDHP,);8XP'5?M6:E5V\L_::L0
MCP32T6Z^_YP!$)UQR$?YH8,V*@NHR9#^CCH^DE;T8HYNN_[,%L7!SYYF<4N9
M+M!P<;2_7)D=EFMZS0\30XY,?G)$JN'9NM,)MZ%(C_QE(Y4IR&,2E6%;X<<*
M1=48YQ5U_@CVJF L0TN+,3PSZ[.K#G^EK324V.@D4@Z?AP%)]*?5Q]+4?@TF
M;TT]@[XRC92%,4E,,B',.&8^UEH-!%$.:AQ0@S "(#\WTBP$[C"%*6BTB/ ]
MTS8\XVSL$!S*2M;B^MAX+"&Y,6!YL*Y-AD72NZ%\7>MKD_+UPU7K<;Q' \BT
MXM'&!ZVUN(AJBGG.UV524_P6^>S.+U11?/&#^N,%/:O5QY+Y4UZ-QFP>+DN.
MYEZE;7=[/S,Y_2$T]%M'MR#R0V4UOM)T]Q>,+(\6=C3'7 H4]NM-*6AZZ"=?
MHEGM!WX^%$4K'?<S_I!+$J+S(^?[XONAG]J)JR.]NL3GF11D?O@**^'=-IIB
MU,5CC';I]=CO ='/LOD&B"B<KEW&FH_6I>B'JCG3HS]8DSZ\TY: :3#?JTSI
M:N(63I&,H41%"Q6/!B,3J8+.!7N3'Y.'J56-.#"TC,XDXJBQS_8?C&"C;/CQ
MQ20-6,RAIN&\!;[%<W+B2!7;+XB XCN7YC"^1&ER5-F7>7,7Y_C-%@=3_T9^
M7J+'\0Q3/]%T'ZO1<&SJI&WG<_P4?S(O8W^>R-B7G,U,60Q=F&Q!KO-6JUZI
M3!F4=4A;ZH@8+Z8X7-,D[8H$/#*<5^((GXQ&Z-*@DJ:!(R(3 8K%W5PY=!7E
M.2C?MK1FKMKCAJ;ZV)+F4(M^D')C>BQ05F5*FKE+WH\C+>Q+NJ*?^*;I;WCO
M)!46[*JR%@C)$!;G.E$C#+R@F);,KMFI:26OWC-@G+N1G^DR.+;3&=O$@8WH
M3%$/YO@Z>X-2=29\P($<Z+;>_GWR]N4:/JG,F%+).@Y7"H; 1S"&VT&,WBY[
M#W@]_"WIE+-G9)( O"^''O?+_@:4>E&U]#-M8+=ZB<\_FD?9?W_N\#M/T38O
M6ZRQO_/FXOKE7?T%VM'?AOK"Y;=W+JZ_W*7E)Z=/\U2@XW?ZU5WQ/Y[?ZU\\
MOV<[^$\)_P./ _Y+6NI5T1<OGJ^,6Q@<VD*_@=7T/Y^<G42?HKS_^>3B[*>+
M\Y-[\&9X_,7S=;$P[PJWP!A';>;PZNGT\<,3=A/TC[Y=XY+@[?1]NZ)_8A;:
M.'P OI^W<&OR!VZ "5L"[\7_ 5!+ P04    "  QC%I::%3Y%V #  !,!P
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MZ7 PO?! -;V[F1A9NGX92D,%Z(89/7>H+(#V$RG-86(== _H\AM02P,$%
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M970Q-BYX;6S56DF3V[@5ONM7H'J<E%W%47.3*'EL5[6[;8\K]L35;<\<4CE
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M*5T50K-_7,UT6< [_GE*:$LR/DV2(N:YWO!4O+Q 2&A1W(N+5W_](1C[/SW
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MPZ:<J4VU=<XJ8*D1+X-39"3([]5\:<#@T/MDOJDPK])6,6L#W<()WJX]-#M
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M?8\K5S\VOSZGO&T+E6W-BE'U+X5_\ U9QR;"QGX5*=*6VTIAL)><>*9X,3=
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M&0U _T(!H=P++=!\(_WJWU!+ P04    "  QC%I:'VJJ.,0"  #N!0  &0
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M605",RF(@F+BSH+1/+;VC<$W!GM]<B<VDXV4OZRPS">N;PD!A\Q8!(J?9U@
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M>T%9 WPOI#1'P0;HMOGT#U!+ P04    "  QC%I:!V* K\4*  !!'0  &0
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M\7PB?/I@EQZB6_%'LL+%Z!K^62N<D3Q-P/C2N=@]T ;]5]/3_P)02P,$%
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MS6OX4N8%O^\_S\LR3_GC2DFH@Q;@^2+/R_"%#JC_ \C[_P=02P,$%     @
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M.0BG)+;K%)$%LT&6UCTF'8']4&B6>KZJ.5E;ZF9?H+;&$:OZD2BG99[(P>6
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M2E*;-(JRCY0FB4U5<8"#$HJD0$&1]=EAGE\6B<;"GJ:@/*?2P9]NXCE$(*M
M;5 S'$*=HSVE!BD\R #B*@YTQ^:%/H H;SL0:9$RVU):W+E[1O&9Y#]6*;_)
M=W6>GY="G!C5B5P^L,(6MC4+5S8VV+NKDFMF;MWG!H-,#0<W&8+O8ZYD;<-:
MD&!7G1DI\#<MF%0.YG"63X$W44"#0*TDNLS3_E[?F\,SW^;T7FXK$C^;$C!$
M0]Y.OFCJ"I-A,?O@U6>#4NSQB*,[VQ&F9W,)T<PXN&F0=IMQV%8;=1(='%6Q
MW>>YHIP$,2L?=''Z2Y+"Y 44^*;%7=UAYE:0NM+'@"*(HB'>UQ9Z;CP^S1'M
M;4%./$2?,0//"3@TH-$=I\'I2!.10Q\)1[784"5N+QM,@AEJ]!N<V+3#&!_<
MW$W[U XZ(:1BFYD!94=8/\RNPM0:N_D@[66V.<CMEUW-ZZZ>U/0-F?)4U_-H
M^#\=U6,J71HSZYDZLD,4[1.89EWKZR9N\>>;H6:EAP-#FM'Q;^Y'ZX6JLW8;
M>9UDF:[>]9"?$D>@X(S2Z]=![>KJ=6(KL[J(78'J1HQ0:)UN@O[$($_9P5DW
MSNDR,I\N;^2Z4-6]LK+;3!=\ @'BD^&ZH6*;7V?)7UME&'T[!%M&<TRO<0!$
M2YO)9M.AF$:G%IV6KTM:]6$?*P*MXL%7]N,WCALUC^TH)^HBSUVOH)6DLD4.
MN@@!YJI(CU#36J4UQG-PPSX_O@(=B%U4C+.&ALJ F_UB2=*)[4 'XTB-S&L+
MQ0]NB1M;,ZLJ9Y9=;J=H[."#V\O, TFCAZQ2AH.[*SNA$_-2MTTV4.OE1<NJ
ML0&%1C1/DY@/"6#JFPT S@XDC'0JXBO2J;A&RSJFU)26)G:QR0S=S@;L[=S\
M4N"-++H>87@A-HWC%75L;ZJ270:@(3I9U*2/V6=U"M.4>S3$[B$33K75&1>3
MJ=#&ZW4]MWNIJL7-;84U6U.O?P^.2UY0QQL@$VD&N4&/TL-._DSBV1ZP^)[@
MLTRFP\+X,_",S@4Z1 #E@"K4!):X(H,0AQ)]L>1P*(?$H#+8RO,I%[L*9MYR
MS2G:&;G@R[E.(HEAT6JG -QV>J/:2,+871N74JI ZNL]C%7OG'JP;:Z<;-M
MB'1BARGYH]2UU&HQQ7M_"I#01H<IV8S'(_)%#O(]\R:J(88WVI/4-K#90*N_
ML&FV^F!#4X%P(11BPPU1 (5WNZT*[8KQP><&4 @D4^!&?+@!TY7*#9HY#C((
MYWLEDH-;#==Z(8/XHP-*/GU,I^A=[#>2\E(Z[T@'3M5]M&_2E2^N(@^61%('
M,X/(G(@(B"&\*,BNU7;_1.WK6)%>SJ!>6?S= LS%:7!X\S^J$;P/TK *'6I1
M"19%=,>6<;#8@T[<EFVWN];H,HV\T+3Z1BPF<YLU,CFI7\KGNHOLX09F^/CX
MIX8%HRS^/SW: :%=MR4;GJ&NY'\HPD.&?";LF=.64FSF_VO-2'FM(7&V$2%:
M2(KN/S3;@#D[33\@ X31AUU/]6?L;3-C@C7FZWV5;^.F ^LSEF[=\,_($:\Z
MP,ZP/@>6NE( 2ETX95H$>_8>;"+E7,GS!\JG^9&(CY=S>+,5UGB67CA;(/-[
MR]GT[/<LZ%P1C=$50@5".9&9[RW")1W 6J\%_@"$?_:!LG+WVC%,+'OKV1+G
M77GS&1:Z\.9%?WAHSC<<+:U (FWL@57>HR3#F\*PZ<D0O;R5Z8TT:9I!P?_0
M<8W[ZU9#Z?/Z1L&VO]9PI1U'_.1@Q2:2G/9'!=S,F TS0FOG7V)3)JQ?W"68
M[L&4D/X[>V5L\DT.W([7U=V) L\$([FQ-( 5B"7^8]X$^,U2OP&N2M3GQ[M"
M<C,7QB5\X0H#"2:8"<&VQ,D"7@23<&;>KT-XY4\6:_/!?.GB0S\UP4 6DZFX
M _$Q_\\!*/[?W;A!.7S WOTK;M.$4GT3?XUOU\Y&+7RSA?=L5#A9\3[,)[@O
MX609N.^G6)2F]S.<8&"?Q&/.OZB!EZT%NC&<$\-0ETYL'K590]PS<VB&#@Z!
MW]9XE*^?I!S5!ZJ##9%L8%[[7%+7 '0*E//YH/MP"SNVT8FA]?6#V[S ,"7/
M2#.9/GW;EDC*"8 AH\"L%4=UC@]/J59S,VD!&Z?9;G#[W"4A](^3JXGX;UGD
MXD5.$<B'@I)*=Z!CB^0H_HP;4)LGV=A-C*6H]M2;$K#5&#X]_*$SO%MWQ'"B
MJ*N4.M9T2&]KEI1<R95Q4(UOJ?LP[&5T)L9MU/7K9G!]I514#FAR_IV;1C#2
MN*.K=TTVO#3Y_O8YM?:%":VR@7//Y$.4"Y\J-27TQ[:$7D=))YBN4YNZ^MNJ
M9OBS0QZW<LUM7?J^KJYNU7\ Y7L)^U4)HEM!N)/A8MS]J<4]7 WC/GR-HSD6
M[';#4P>]]1.KS.U%',O'HI:XDX[/CH&HY$);7P#,/A@:%;Z/2;O K-:P;.@X
MTT@O-X]QCY/OZ6U>S-UROXWV6H+2EUZ@0S:!*3=RJ&FV7Q/!, %%F_<FR&$J
M?698O.-64LZ,ZR/*[>/'[GTJW;OE^*8%NNC$C9*5H8O..U2<U=+!;?<PMW(.
M*.ODIFVA<U2/3GMB,A+=@(+T<WWIVYBT4BUN<]=8CDX\4.X,VP XVG+OA[8(
M&67I_DA7S=K-@Y 0-QJ?Q3TCTWLI\L<CZ7]L>'P\77KBS8'Z!.R1EI\@2K--
M#\CWCWE'WVF.=X!2 \3EU<<:6.)67QH_$.:O>0_<>W*-(1IH+&MR G+U+OE2
MN^-U!ZR-]HFN)\2#(E/F$M-IH)M)(5H*J>_ M"@%7!5U;P-!P<\+]PC2@QE@
M*-'::@9R?W7QO=MQ_YH/D]A;(U\TK^AQGM3'3NS%, ,M;6-=K,WUU+V-K>Y#
MVV*K6B=?>(OJ]LBS5_T>/3>0S.8K +XXLY=PNUIO,?56L",+F)P#4VK7Q#\(
M.?I^;/.)\Z.H!UE<TT^_8O(.F)=_']5^:G]=]I)_5+5^G'^:]L>HN$XR+&[N
M8"CXY/-';,S,FS(_TD^L;O*RS _T<B_!NRSP ?A^E^>E>8,3V-_<??9_4$L#
M!!0    ( #&,6EJ=)WL!9@D   L8   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;)U8VW(;-Q)]UU>@&"<E5XVIN?&F2*J2;*>BK3AVV<YFJ[;V 9P!
M1<3# 0-@1&F_?D\W9LB11$K9/$B<"[IQ^G:Z,6<;8[^YI5)>W*VJVIT/EMZO
M3T].7+%4*^F&9JUJO%D8NY(>M_;FQ*VMDB4+K:J3-([')RNIZ\'%&3_[9"_.
M3.,K7:M/5KAFM9+V_DI59G,^2 ;=@\_Z9NGIP<G%V5K>J"_*_[;^9'%WLM52
MZI6JG3:UL&IQ/KA,3J]R6L\+_JG5QO6N!5DR-^8;W5R7YX.8 *E*%9XT2/S<
MJK>JJD@18/S9ZAQLMR3!_G6G_2>V';;,I5-O3?6[+OWR?# =B%(M9%/YSV;S
MLVKM&9&^PE2._XM-6)ME U$TSIM5*PP$*UV'7WG7^J$G,(T/"*2M0,JXPT:,
M\IWT\N+,FHVPM!K:Z()-96F TS4%Y8NW>*LAYR^N?WW[\<-[\?7R7^^_G)UX
M:*3G)T4K?16DTP/222H^F-HOG7A?EZI\J. $4+9XT@[/5?JLQG>J&(HLB40:
MI_DS^K*M?1GKRP[95Q=FI<17>2?>:5=4QC56B7]?SIVWR(C_[+,Y:,SW:Z0J
M.75K6:CS <K *7NK!A<_?)>,XQ^?P9MO\>;/:7\Q'L]+)\E0]#6(KTLEX("U
MJ57MG3 +$1QR<OR+<>ZUF"O4M1(Z>,G+.^6$Q /IQ,)4J%AW>D21H'!D]"\]
M>H>5SNM"'(MDDD>3;")>T_4TB:;3/%SG233+8O'Z")6#NJA%FHQ$,HI%.CWZ
M:KRL6N%1FFR%)UE/.$YQ_<F:6\W5#Y#B>*YJM=!>+*Q9O7X ^0G&+UYZ);+9
M5/SPW31-TA^[WRV@42+2=/LT8,KS6>\A^RXX0=<WV&A>*=!08>I"5W"3I]>J
M5!:2#OLUWMA[PB,L;>X-KU"+A6+BZ0$."\@,Q*;VNFYH _ LGL/:I^90]DK?
MVX45I,DP%M\__&DMW^T5B1K,CKAW4#LOPM%#BMQX.,;?].BG]KVL2]XH("VL
M*C42)\7:?)C@;X8M3/'M#5%AR;D%AF;<4!D/0SSCX:3]G2()?B4$P3K8B1)T
MHC:^0^*AAE:.6&+42N;##)(?X4++4,>MOE'[BWV.WBYE?4/&BEM9-0&#I'C)
MNE!8E79PTIQPT,6$%!R]WP9E&PW2B1WAR)C=&?Z_4PMEX8*'!8*^04V%XTO>
M)24ASEQA7J'>+#J<*#6>6@4T#M;ZC5(U"Q72VGORA5R9IJU+Z9S"%;F_TG*N
M*^VU<ISY"UW#(HW@6 7-[,5U8]?&J2! .CM5#86%I'KYUBT>BB_(?;W0A:S]
M(UXPC:5N%LPEH0[0(S8 0:O5'%$!2>_R].CXFDPSC0,>MS?D;#2 ;:0MG7B%
M6*31;!*W5UD<OY""DSC*9ZD8@W*P]JU<:]2L_B_0$@M+6RQ9L%2WF#36F!L\
M"" :Q9G(,U9_,&^G43;*1))$F&2./D.^;I3X).'H0J_#DA2:\LF6+S[N3%/0
M]R!BD_%$)%$"52%[I]%LG(DL&N-)X)E];LZS.!K-1H \9AB_*.=.#^1U#C2S
M)..,SF8C6M]6V3[-XVD*/#'A>8C:1<+2S/+&+-X@:[KUQRS!3$Q2T+P'==_@
M0P+U 4"OM@R[N_H]4*LM#TIU?'KG*;(;A8*JM*(27JH=^(VN*K&BEE;I;ZH"
M'X,C6K;!#B%AT"-KS%#?R!.N0=Z4RBN+X8I='9%R\++3R$;RNY"W4E=,_Z@B
MS;Q!F5:K&\DWZA9+$9J(:JYJ2M:+Z;EL*L[.6V6=K+C*#CDQ$FMK_@"#4/$V
MGF84K. ]0QU'H9 K6=>LWA-KW>B6 . [\LJ.*!!I'MB!:BAH?&6V(;, D%LJ
M'./Q9%^&Z<#/5OW9:"8_QTRF"TRZ8K,,)&;#NL<^" X%813-JJG".RI_ -5U
MA_,>Y0HRNE*%I,1KV6>I'3<WW :):,NP^Q)B*6\I"8!FT505B2WP7,SO]ULU
MY'Z^U]P:%,.L -E7(AN!^E<"B<3+X-U7(A^A :W:1T2N!(RM$(H&7]%G11Y=
M69"8,2)Z6H=V4]T/Q27GP=/UG'9+"0+KYJNN8]<O<2EUCS7RYT[CE$))_TK0
M,# />(?B(WH2G!OA^3A+T $[2[A:U-U:$\=[.,=J,+@HH84:UHT.R8;  >((
M2JQI;I:XP<S7]1VKZ.A'RUA;'QD$$3B\9%!-3?44(KH)^2\W #5O/&62:^9_
M<%,U4"VF\?>/"@#5L@+C^VT$H"!$8 =4+E#'A#7^"WX.'>;O.'>:Y\-\ER+L
M0-[^)1=.>RZ$#F(]\()A.%VT=RWO92"3&:7J_PUC]  &6&O!]=YXW=+C1U3C
MXP;\,IHTPP35H>'58E\B#,5OO%$()?3L"0$GUZ&M5_*>V/QAPH 7&WBOER1E
MPT.XV=2@WZ5>BR*,B[LECDB7>(LKGS+SND8"U=#330%O31G(WD&JDIU;UMW)
M!"QV^7CG@!!53W2IV\#\;6O;$YJC$C"A'T%+8-EVY-LQX2Z$E%JE65,_(<.V
M@'E Q0/849<4&JHE612DB0#1;0-6M!Y5S>T=%CR8?J'C'Q(F([Q<4_$$$5T3
M5=)^70.E;HY1D\:SV@C*$4M]299_-,[S<*;#+-PUP?MVZYX@^:0]))"?_=-J
MWA;S+A=%FXS3+AE%,/J@9IR0, 73DLU2PZL;TU08$!OTF]I#E^3)GCN4>GIN
M0.WT]'8YA[6'VM9<L9O_6LNZW!XX]3:!R&D]RD/NH 4].DP<-):8=C?-BV/=
MG]I/CZYDQ2U1[B7/C/PZCK(LH5, ]TS@0Y.G30QR3"."Q,EA5N%9B<H!$^L,
M9_NCZ_JI4.OG?6)IE$^R%R#E'.HH2V)QS8Q4X6R#IL&)T4:R@N?UXAX)AR1$
M:V6?8?J7%>=W#\PV\1\A>5 "5,\X.O! $5AT3UJ& 6DI7:A+E,!V]U:<BOD
MB(,E@*(N#7/U+CU)74$VW8.C>H<[)COWK$*D*S<,_I*A78'ZY##L'VE&/#9W
M#BK" 8(R_9#7Z.38LVO7L'GT#'-#G\75G>QF\(Z/(:YNR1PNH :I:GE<'O('
MO:"-:*.M7!6H\,$,<H!O6ZZ5WEN-"81#\ *@1>]XNC+.]UID']J^CX GO0^T
M*V5O^#,T)@TJV/"M=OMT^Z7[,GS@W2T/G\D_2(O:=SC"+2 :#R>C03C&=3?>
MK/ES[]QX;U9\N502T&D!WB^,\=T-;;#]_G_Q/U!+ P04    "  QC%I:1*+$
M?\D"   /!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RE56UOVC 0
M_LZO.*55U4JH>2%0U (2I: B]4VE6S5-^V"2@UA-[,PVI=NOW]F!K)4HFK0O
M]IU]]]QS.=^EMY;J16>(!MZ*7.B^EQE3GON^3C(LF#Z5)0JZ64A5,$.J6OJZ
M5,A2YU3D?A0$';]@7'B#GCM[4(.>7)F<"WQ0H%=%P=2O2\SENN^%WO;@D2\S
M8P_\0:]D2YRA^5(^*-+\&B7E!0K-I0"%B[XW#,\O8VOO#+YR7.MW,MA,YE*^
M6&6:]KW $L(<$V,1&&VO.,(\MT!$X^<&TZM#6L?W\A9]XG*G7.9,XTCFSSPU
M6=_K>I#B@JUR\RC7U[C)IVWQ$IEKM\*ZLHU;'B0K;62Q<28&!1?5SMXVW^&=
M0S?XQ"':.$2.=Q7(L;QBA@UZ2JY!66M"LX)+U7D3.2YL469&T2TG/S,8W=_-
M[F^F5\.G\17,GFB['=\]S>!^ J/A[!HF-_?/,Z#K8<\W%,]Z^<D&^[+"CC[!
M#B.XE<)D&L8BQ?0C@$]$:[;1ENUEM!?Q"I-3:(5-B((HWH/7JK-O.;S6)WBS
M55GF2&_,L!Q&3&<PH5<*X^I,P_?A7!M%+^?'KNPK['@WMNVF<UVR!/L>M8M&
M]8K>X.@@[ 07>YC'-?-X'_I_UFTO]F[F870*_QZT\0V9JLH.5#0LYJALX1JV
M<+9Z+;M$C>.I )/)E68BU2>-#_6@P:.8X6()= E<O**N--O(W'#4YXT[&ELK
M0=,HY[\I5"ZU!NKU0^AV:3F&N!7"B9,Z73AI/&*2,ZWY@B?,#84YFC6B ,JS
M9#QUD:3)B.S103<*HXMZ/X8V 4R%0?HD!ISU(81!L]6)23AK!N$9[>UFV(YA
M5X']=TU:H%JZ4:0AD2MAJGZM3^MI-ZR:_*]Y-2IOF5IRH2''!;D&IV=M#U0U
M?BK%R-*U_%P:&B!.S&ABH[(&=+^0TFP5&Z#^!PS^ %!+ P04    "  QC%I:
MIHQB@6P&  !E#@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R-5V%O
MVS80_>Y?07C%EA:);,M.G&1)@#1-NPY-$R3IAF'8!UHZ2T1ITB4IN]ZOWSM*
MEITU2?O%EL2[X[N[=X_2R=*ZS[XD"N+K3!M_VBU#F!_W>CXK:29]8N=DL#*U
M;B8#;EW1\W-',H].,]U+^_V#WDPJTST[B<]NW-F)K8)6AFZ<\-5L)MWJ-6F[
M/.T.NNL'MZHH S_HG9W,94%W%#[-;QSN>FV47,W(>&6-<#0][9X/CE^/V#X:
M_*%HZ;>N!6<RL?8SW[S/3[M]!D2:LL 1)/X6=$%:<R# ^-+$[+9;LN/V]3KZ
MVY@[<IE(3Q=6_ZGR4)YV#[LBIZFL=+BUR]^HR6>?XV56^_@KEK5M>M056>6#
MG37.0#!3IOZ77YLZ;#D<]I]P2!N'-.*N-XHHW\@@STZ<70K'UHC&%S'5Z UP
MRG!3[H+#JH)?.+N[?'=U^?%>W%[>7-_>O__X[J07$)87>UD3XG4=(GTBQ" 5
M5]:$THM+DU/^,$ />%I0Z1K4Z_39B&\H2\1PL"O2?CIZ)MZP37(8XPV?2I(*
M\"B(6YI;%Y0IQ-_G$Q\<*/'/8_G6T4:/1^,Q.?9SF=%I%W/@R2VH>_;S3X.#
M_J_/8!VU6$?/1?^QACP?8C!,Q#=AQ)\DI"-PRCG40J_ W05F<L[E""4Y.5?D
M!<:<[T3 A(=8-#L5+ 3!:ENH#-S3JC#29+!.Q+T5N0RT*VSEA#6(ZG&5$7O-
MG<VK+&!T%V0J$J7T8D)DQ-39F?B4W"7"2XT]87O[U_WEA^M=L2Q55L*JD$;X
M4LUK=+:9!')>*"-^KPQ%:B3B/,\53[?4>@5OWF1!HB"#? +EL/9 JZ8JDTC%
MV974826DR856&:2%Q)2H15B!OT[(PA%QZAZ5D"A %?;6UH&RTG E5HQJ(9VR
ME1>9G<VEB05YV]1O1=()XGD08#/-)@B\9O0&J,JQ#=#!RB(G2"U@<\J,T$6V
MRHDFX6L")]Q$2(YB6RYX:]\8^*A0' R9!W*Q+DT@/(8C-TYJK-9ZSL(8DU0>
M9D6EI8L."Z@?'":KF,Q%J6@JKMO=D)&*JGPE/R,OI'QQ_>:**R*QX^I?VMH)
M3G$KDX$E,]@C@=K;[\8T =%F:!9VK;F#*EXCN7K3RZ^452S<XGJ*+F(WY6M,
MV!'\:ZX:R/524XQ?/%-PJ@(#U-9O%<?@M-OA1R]1"72/-C6*!<&8 )_5*H\L
M\@%_ZV%HBH[U")][[ZCD8PH@'P:MU[&2,W-1!LJD#WO![D%Y*JE]9!"7QO.^
M4GRI)$!P"P!5U=-(7^=,O8:,/,(YTQ.H-LP&[RK'0[S;UN:)BDCO:9LFP08T
MJ7GZ;!$F4C-2$<\:3)[6**HI,!H+K#81&%Y)F@<O1OAD%/O><0'7?65P-30_
M!Q60@>#^%]:Q "U5*!6?]QX3!"W@&C9*%3O0EH,7<+I#_(K=9N)U3:@<YZ1B
M>8^\V3CX[9*) HOK-"&)NAZ&"84E:Q0:!1VJG(DA:Q[)B=(JK&K632UXNXSR
M%$<4O;5@/.M96\9&5SQ/QK>4J]4FMF<+5@,76\),S36UDLR2XI_2E @3%\/C
MSH.U[9M.-&2CS@Y*/%,H'CK\LG/;X#SNW#S4[-T(>WR0[(N]SFU43^Y1'_?]
M).W<1_*T6;X0XW'2QQ^O;=1BW8#CSH7U<80*:W,TPX(G@V3(H9_H]L.%#+U&
MD?2FI0?CY$B,1\E1YP)G%/=\Q2)CJBD/F(O4:(8P.+OEF!XD*8".TF2_<_=]
M$@'Y#*=/%+0VQCA%LNDX&76N>?360]8:O!*'0V0W.H)%72G[34V (=WO)V/\
M#XY&*-L'UJEX0&[IS(X8C(<P>LE71T/D_+*)&%6>4%7&;".,AET[S1;LTV</
M<90<=CZBG5$*7\2@H^0 "_'Z<)0,</WJ\5PXJJYR7. <SC[OU?K!VH?E>G+6
MQ-T@^9&AQ(%34#QR/-ZCN30Q>>3NK3&DL8</M1 JDZN%RJ-N@K[_BSBM3+91
M98TW"-V.+GD?WQ'XL(<*G6>8^!Q[\3M#U,MX?J]JK>;MP%&)J83%]P_E^/@;
MM=P<@.WA42,S-D0M1]OXO'0\Z2"Y"5%$-]L^<OH_]G;9VWKU!T.+^('#;R25
M"?570/NT_88ZKS\=-N;U!]@56H'W)=1N"E>0<K\K7/U14]\$.X\?$A,;\#(6
M+TM\!Y)C ZQ/+7)K;GB#]LOR[#]02P,$%     @ ,8Q:6F-W%7/8+   [Y0
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M50D\0Q"5=>_:O%FMLWH;=L?WX4+K+B,AP:_"F==9RW".'@3./PU!,G1(-[A
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M+.Z\RLH5+RH=#M0DT5L_'X1B]HTBFS67D! T1O!K.&&% 6*\VB!;P[K6Z,(
M1W.D.ORB0Z.*<A1!288_9^'/-E)-IS!!'HH%\U,^9+L3YT4 \(*I5$<C:FB1
MC6\7RQ42&;+<.'3*;CLA9!.(\??F573A5D@<:S!5]JQY-OUV>%AHTU<.<65Q
MT(3&2=H+(E^$$# W%=U@C+?:QJ7XG;LAI:+!81,XCN+X39U3N!CS+-FB!A\
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M/DB9<I97<S%T0P?.*97X[/:"L$& Q6=E+[5\>,#EL,(*B]6LW38UF$%=[U9
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M6K[U&KK&:6<RBH/*T6!%$((9#9M:EK.2@W=2;F^@0(; 7II0A()?>^#U<33
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M5#ZK17D0*O,(E6<4N*)5_% #<R"AS1&FXSKB4JIG]Y*MVM?)\]MT#J<?%L(
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ML/OEPI+GZ+?TT0ZI9MKO(*!,P:'/K)D/DQSX>OD4[9R%-H&SZ2+_*T;9%_P
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M^6X0&"XYR.V06M?AV0>*$[B$1]["2BDJ^N8&#XR,T#!Z'#HGQL<23D+)[GU
M4W^,0YMELV;HC5QS8M7;8?WB6'398H&)"C*?_:=Z4?@&%%/6S=O2&LB[Y$\E
MBYD6^:-G3SEURT!KB80VJ4O*0*UTFUZ"C7#?,>-P[ O %";X@*4 0HKG0HI
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MT!] R>*2R:SI^V9%_\0:9-?B _#W>0.(E1]P RS7)?!>_1]02P,$%     @
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M;9WVS@+0U0RM#E8M_=R*E:7&]-N</CNHG0+=9TK9[<$YJ#]DHS]02P,$%
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M(Q&52[#Q)9'9&&Z#;L@F?P%02P,$%     @ ,8Q:6H8^#!I7!P  !AD  !D
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MT .P?\;1I9J*7F#SU\?5GU!+ P04    "  QC%I:8FAX8]("  #Y!0  &0
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M,\Y6;?\AHN\8M;:7_SMEC*IM<R4%R@Q/P/N%PM5WZ+" \6O0R7\ 4$L#!!0
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M]8O2KX;!1(L82->&L_T_D/I)G_K)B_N&PHIC!<LHU_]JI395,!7TX\_*'!A
M8N M.ZH4Z,&4/FAW.*5O]Q(0C1RR^ZR#XY8+U1(7!;?=IS0=3:XY^B :A>FC
M!E<\HU(^8O_:4)DK\AJ7PG?FB=N- M?]008FKA/.?1+C-H&R%[1FV*K8-V1K
MO*,R6UO%'.[Q$%GCD5!CWW,B-R!A8.'WIFWJ!%% /,_!0^KH"^KS!L@-E;@Q
ML;H5\1$I3/HV^?G)-4 \4C*Z9"73#-M"$B?$<SR$:I,W=>9Q0 (GQIFVO0Z%
M.0Q<)YI'2#FV-#Z 4L=[TCI$-G,OL D=S",CWQ79$'*<^LC'-7R^9ZT<(LUQ
M]*THWC8*MO(3JV%W3Z.%R .L=QW>I\#W$'K=;RRO7[+%I'V=I2^NLVV79FWP
MNOI:PHIQ;OPWB0(\M\-*-%T)--SH88%\ZPAW#6JP^ Z2&2Z^L_^:%V%JIS;)
MA.W6X/'HG)8V8ZA%V2W<=FO!RHN=(/!,34N;QQ)*:MHQ[EVU9'C6>,3"LB9K
MH9C=FTS^S?%T-<+#WS.EK,'%QL(;4/.=, E^0"DTE+ :/7<P(68[-Y@*Y,K>
MT["QF$"UEYE^MK\*GK4WH"?Q]A[YD4J,N<)"*% 5=RL\E<GV;M:^:%';^]!2
M:+Q=V>$:K[,@C0!^+X30VQ=CH+\@+_X!4$L#!!0    ( #&,6EJZJSE/V (
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M:&G9YV@Q%C2N"TKSH&A5K^U7^'7Y$O^93"=^!ORGVI,\6FWW0=(L4)H-2G-
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M^G<#A3'0^RNN,U-/S '-#\SX#U!+ P04    "  QC%I:9\DKR"X"  !>!
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M.PD)9E,+)/<&8L?GL?W&Q_:QQSM"7]D:@*,?69JSB;7F?'-MVRQ<0X;9)=E
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M>ZB*MJIS53$$4U09-*H,M*K,UIC&L,3A*T-B,D11PCA-E@4G8ET6=24AH!5
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MN1R*]M#J3J1*<+(I;PF6A'.2E8]KP!%064"\7Q'"]PE907,S-?T)4$L#!!0
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MV6YS4?+E^GVU!UZ6?+'^.&?QE.65@/A]QD6BVEY4K\#M7GD<_0]02P,$%
M  @ ,8Q:6M:;SK# !0  ,24  !D   !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&ULO9IQ;]HX%,"_BL5-ITVZE=@F 78M4D=IA]1N55,ZZ4[WAPMNB9;$S#:P
MW:<_)V0Q)(ZO@5!5*DEX?G[O.>_YQTM.UXQ_$W-*)?@1A;$X:\VE7'QHM\5T
M3B,B3MB"QNJ;)\8C(M4I?VZ+!:=DE@Z*PC9R'*\=D2!N#4[3:[=\<,J6,@QB
M>LN!6$81X3\_TI"MSUJP]>O"7? \E\F%]N!T09ZI3^5D<<O563O7,@LB&HN
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MU)0&[9A6NV8WRF.9MA<N'=*DA:S(LD_-MFNLW0AP7KY82),2LI/2D$41Y=-
M^;8@"_5+K&9EMJNO[>,QD IM=8!>K074; _H&!"&-(2A8[:!4!G)/,_I>@5V
M,8BY/0]5W>":M="1&T'(0%YNR7J#$,85MFN@0G:@JEM)4;GY8PQU6<P6:@TV
MR-[9V:=$&GHYY> :A"J#JWD#V7ECR/B"<155$#-9'TGMVFMG>$/:=F.AN03U
M7JOP-0HH36G;#8LF&60GF0,+7YE$,'0[_>+=;1#KN%X%L& -+-@.+ <7/FP
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M.9%LD;[B\LBD9%%Z.*=D1GDBH+Y_8JH69B?)6S/Y6U*#_P!02P,$%     @
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MP@ZFAO39\>FDGMY7(U,.#RZ'!^=XI&UX_$"@KWZX92C37(7X=4;<Q&\/2,V
MV:_R0YKX2W;94S^[E(D=ZTU__\T=.G^:V *!U;B3DCNQH4\?N?1#$\-]VB!/
MRVX3NRGUJ(O=27]7K;T91C =.[0,JU5%RZJHM:I['K-7]0L0W]4];KUM$9D5
MH^LD ('5Z Y*N@-H 0X@N0.!U;@/2^[#TP2X3QM6!3@<.?A ?\THUQL.1F;Y
M>65-GK6F&1,R6 =+7ZH)6:L'1L+30)J*M.)TG08@L!KE44EY!"W!$21W(+ :
M]W')?7R:!,<-<6&/' C0%(/-\G,=_;QVK!4]72PNT*-R;.E6O*(TFXM !LS\
MJ+5"=9T'*+0Z\8I1<:%E6"!"\0="J_/73L2U/NS;I5CD575&G('G'*C1$(;'
M'FT3I'8)KMTF?.([)F+E[.7[-.%QR@5;(77$1"*"E/U*HE;PSE,$A%8?"FU-
M7 HN45"G H56YZ^]BFNU Q:)#AK:&WET=*C09M1X/&J]96H;X=I]Q(Q'$1/+
MP ]1XB=,&"NT0G2>!R"T.F'M45P/7(>@=@4*K<Y?&Q;7Z@DL.APU/>%H@)W#
M5Q=3G(/QL,4\NMI.N'8_,>,BX2(SCS&7+7=$*T+GF0!"J[\]:[>"'?#W9U#3
M H56YZ]-"[::@G8E%GFUI[&#!]@[4*(ASALXXY9[(J[T->QNXC/;L1"YQM)@
M.QCG:&%@[4XP 1<@J"6!0JOSUY8$V]LE[0*DS9=HS_$&A_IKAKG>F#@M^M-6
M =NM0J$_]"\ZKJ%CA^L\*>=H:V!M2/ 07)2@_@0*K<Y?^Q-L;Z*TB]([JK-C
M"+.T=K#V#=CN&[0HCV_SV"$[3\PYFAU8VQ,\!A<FJ%V!0JLWO+5=(?;F2GO+
MVSFBWV,,:GE2$VTAB-U"[$6)C56!]C>@T.H\M2,AX$LM!-2I0*'5^5=66TY=
M;B'-FR+V'#H\E%\SCCC#L=>RX$*TAR!V#U$H4-T6NS0?[:"=)^<<G0VB[0H!
M7X8AH(X%"JW.7SL6<N)2#&FNLIB:CX8P2_.1:"=![$Y"2_/_M2'M7]-YLL[1
M_B#:QA#P!1L"ZF*@T.K\M8LA)R[:D.:*C*$-:8BRM"&I-A?4;BZT5H]I2-K!
M.B]AGZ,-0K6'H>!K-Q34VT"AU?EK;T-/7+NAS4498T/2%&=I2%+M.JC==51%
M^<O6I!VK\YR<HS-"*_M(P!=K*.RVDG-8&JHM#3UQL:;(JV[<,;8F#7&FUF2_
MLCDMVQEX[XOG($Y1R-8JS[GP%(#8;[;;'TB>Y/O5OG$I>91_W#!_Q406H*ZO
MN=)G<9!M@2NW/$[_ U!+ P04    "  QC%I:VF[J.UD"  #:!   &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-RYX;6Q]5&%OFS 0_2LG-DVMM!5"TF[J"!)I
MB!JI6:O0=)JF?7#@$JP:F]DF=/]^MDE8)K7Y@GWGN_?>F3M'K9#/JD34\%(Q
MKL9>J75][?LJ+[$BZD+4R,W)1LB*:&/*K:]JB:1P217SPR"X\BM"N1='SO<@
MXT@TFE&.#Q)44U5$_ID@$^W8&W@'QY)N2VT=?AS59(L9ZE7]((WE]R@%K9 K
M*CA(W(R]9' ]&=EX%_!$L55'>["5K(5XML:\&'N!%80,<VT1B%EV>(.,62 C
MX_<>T^LI;>+Q_H ^<[6;6M9$X8U@WVFAR['WQ8,"-Z1A>BG:6]S7<VGQ<L&4
M^T+;Q5X9QKQ16E3[9&-7E'<K>=G?PU%"&+Z1$.X30J>[(W(JIT23.)*B!6FC
M#9K=N%)=MA%'N?TIF9;FE)H\'<^2^1*>DKM5"HLTR5;+=)%^>\S@$V3)70KW
M,YBM'HT7EO<_DKO'>9K!V10UH4R=1[XV"BR.G^_9)AU;^ ;;((2%X+I4D/("
MB_\!?".]UQ\>]$_"DXA3S"]@./@(81".8)5-X>S]^0G<87\O0X<[?.M>")7P
M1%B#,*4J9T(U$A7\3-9*2]-*OUXKOH,<O0YIQ^M:U23'L6?F1Z'<H1=_>#>X
M"KZ>$#SJ!8].H7>"=TYPA<2J-:.C%5"N48+1S-4&I8(UZA:1 \,=,O5:%1W/
MI>.Q,[V+@\C?'4OSC_JM0KEU4Z4@%PW77>OUWGYPDZY?_X5W4[\@<DNY,G(V
M)C6X^&QX93=)G:%%[;IW+;29!;<MS>.#T@:8\XT0^F!8@OXYB_\"4$L#!!0
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M=^5]_!F)'^\S/_[HU(_?YGZOAEM'@KG/_[@Z9<]T)-%0K)>E:U;:GKI)^\\
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MUM)6(T?SMIG8[JHYY;"]&O<F3*\X7CT$+%$TNKC&@-?5!%4MK"K*J66A+,Y
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MB3Y*DHE_&JKYH<3VF[%Z"CX72QR3BXZ:8P7A3Z0S_?47=^C\UC3>D# ?$A9
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MO.\X.UJ S!A PD)(6 0$,[1PMM'"63LM7%'\0%,JGYLD8&6UE<#9,1* S!A
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MTCF_4"GQ:OQ4&\E*TY!G3*KV;I:9FMC -4"=SQF3FXV^H/D/$/T%4$L#!!0
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MS8<R7]8OF[W-RS)?U'_.!5<"ZP3J]UF>EZL/NH#U*Y1/_P=02P,$%     @
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MW@/)1QWYZ"7RL8M\Y""G]/ Y[_4>2#[NR,>]Y-=KP.*]-*!<_&,'?S*)@H,
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M7^A1>)1Q@LD9=#MO( S"7EM"_PQ_E$ZWV?=NR==]EF]!,)6&=&'O),'73S8
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MQ%F&.-V/KMX/W[YY?S8:7T9/R?C#]>G59_*"1(.S<40&KR_'X_/QNZN([(U
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M[0W2+,#YJ1!ZV3$;U-5\_P=02P,$%     @ ,8Q:6CRK/:PW#@  W;@  !D
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M6C6_CY.<+./\"R_;R\.F.WE5Q@]:T +57*A&H1IKM,G.QC$X,[K)@]:I0+4
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M[>,_X//AP_1N>#_CA[/1U['S=#<&DR]@>'/S,+X9/HY!TA9,IH^WDWLPO'?
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M&4WW'J8'+-PDN_&>0\;"=?)Q1;!+:'P!_WX1ANQP$'>0[P =_ =02P,$%
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MBX_7D]_.KR^GLYO%3S#[_?;BXR?X&697\\OK3[,9I,]A?GLS.1\M9C"_''V
MMU.J2!#*=WU;80C:D>WETXVSZ=P#TSEPQ9GR)<S8DBXK["<OV+L&!S9B+PAP
MMP2,7:/'*_($3><]N W7!>D306556&8G4^J=;+VTX'8QA;=OWL&%HE&ERV>!
M-HN5:J9S- ^ME'8$8TS9)4QXA'4L25H)(R$(6U.L+07C)]@=-R=/Z>W1AH@E
M_'6)+M.HY-]52Y?-WZJ>7_>3,QD3CPXL;!B2B@=J#7_\P>DT?JDBK"9GSZAJ
M%52U3-Z'2$^$Q&#Q>/?O\Q6 ?)HE8.^#5:(29"F0,B',H_ V8/FXRJ0V3G<L
M,YFS3NI,=]F'H7/J-/'7Z?7MAPK8[0)VVPA[%L4A?Z(4%AHXS!/A^9@&, \)
MJT)E]'8LJIJ</0/>*8!WOG-I=.JDJB9GSZ@Z+:@Z->;(:+T6=$T4W9:%+@&D
M(\%V*B ^D"E&G\?"/ZW(_Y;3:;:JL[];(.L>4?0!\U#58/(7A?VO&D!W/^9&
M^E?$G&$SAOB-2]LK".C]OUVOMP?:K01M#.L;03N-4L TC+"OR&,0)1$L$Y$5
M/5_A;T5%P-80XX%7Z8RQV>NQ.?U"C"A;HE2VF!#O2#;'Z.U#$MUAL>[CE#K;
M-W[@^4 8T.WKP,.+F @5>$&L*Y\H(*!0C,.7M.55TF,,X6AZG/WZJ:YVQRU9
M<%_)@L>9I%ZBOP<@WK[T=A@A[&NB3,"-LQX-W-VOH0/ 2QWH&+73<+J3Z,K?
M@UP)JE9I]T)\G5?D>JGD'+.4VU8W8O/P=8U?EAHV82PA(4@2XJ<GDH 9K9/\
MCN+7D_)]&E:S4*N,R[WU=I:V<7(HJTL)YY@UW+S$2>(X#+!S*XX97K9V_/H3
M]_A]_T#")'V]>23TDA!30J=WD0LBP :?O]6+FP=>[^:8CB:F74%,MWV F5+C
M.49=M)?VC&Y>U>=KE6XOQ/BJ/E]*-<>LU4QZ'CM87AJ5H&L5;'5Y>TY#J>N<
M[G=6]TY-LBVGZ[\0@4ZI AVS#-QV3!+Q!!EX5;?4/:;H$KER_ )O*KFJ2>WE
M7&7>VKOOQ_:NPLQ(L'<VN"(JUNF^G\2VB BSO:[B;K&W.$IWU.QR>+8Q>47$
M.F 20KI"T\;)*<XMLKV^[$+Q.-TNN^-*\2@]]2G!/JH'X/,5YVI[H2<H=ER'
M_P!02P,$%     @ ,8Q:6BH)81^A P  # X  !D   !X;"]W;W)K<VAE971S
M+W-H965T-C8N>&ULQ5=M;]LV$/XKA%9T";!$K[;LS!9@6RX:K*D].VDQ#/O
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M=.JZU,DE6. 2##D"J^ATMM;IS#IG KJ@$4DC\$Q)'($3S $&,Y*%)!7&=:6
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M$AR13 7([\>,B9<3U<!Z%W7_?U!+ P04    "  QC%I:#(L\K2(#  "S"@
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MD(#Q+9 'D_%3\C1-U:HNM,\?QFEZ 8;)[?@Y 7OH\Q@)B$M^(7E>TAB<GUV
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M16#H!4V6;2$(W3Z6PYKET,ARH?Q'MQ@\(BY)0HI>BL/6[FX<^%&#HW&SGTS
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M;]HP$,>_BI554R=UY)&'=2$2A79#:@M*VG73M!<F',2J$V>V(>VWG^W0*)N
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MZ49FIVO]<J P#GI_R;G:&Z:;U6]1^!M02P,$%     @ ,8Q:6E1>.2[9 @
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M#U(.1E?%-@CI]4",-@7-G^A@]O-/V+5^T0D$">8#@77$<UKQ'!/Z;,X*7M;
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M,,SK;;KU"6?;:N/J(^.<I=7AA@81S<L \?N*,;X_*6_0;I:>_0=02P,$%
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MJDJ[+HS_Q=1E^D?,-X0*E$.JD,[=2!G)Z]*W;DBVK4JU-9.J\*M.,\!JWN@
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MFZ@')^^A_P/.\'R3U)LL&%=,U+TY2U,JGAT,M;PB$_VGZ):^'I_2C"RX>FC
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( #&,6EK*94<<7 8  '<U   /
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MF>H2W.[SW);;_&)9IIOG_PT]_^?IPW]02P,$%     @ ,8Q:6JN<,4MN @
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M+GAM;%!+ 0(4 Q0    ( #&,6EH\QT<X[0   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #&,6EJ97)PC$ 8
M )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ ,8Q:6KW*?(SE"@  ISL  !@              ("!# @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #&,6EHWE /1Q08
M /<=   8              " @2<3  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  QC%I:9XLL=OT"   3"@  &               @($B
M&@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ,8Q:6A\R
M1C]'!0  <!@  !@              ("!51T  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( #&,6EHG9NA8*0,  " )   8
M  " @=(B  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  Q
MC%I:L[7IB@\*   "5@  &               @($Q)@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ ,8Q:6G#V)@>: @  L08  !@
M         ("!=C   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( #&,6EKK =(\10D  ,0M   8              " @48S  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  QC%I:$]YK+6 -   G/@
M&               @('!/   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ ,8Q:6M]L-0]E @  BP8  !D              ("!5TH  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  QC%I:+'5HOD,"
M  "*!@  &0              @('S3   >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( #&,6EH\I3,X$0(  -T$   9              "
M@6U/  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ,8Q:
M6A]&E8]N*@  3H4  !D              ("!M5$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  QC%I::%3Y%V #  !,!P  &0
M        @(%:?   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( #&,6EKI 2;OG@(  *L%   9              " @?%_  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ,8Q:6A9:C@YR#@  +RT
M !D              ("!QH(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  QC%I:'VJJ.,0"  #N!0  &0              @(%OD0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #&,6EI"KG*X
MR (  -D%   9              " @6J4  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ ,8Q:6@=B@*_%"@  01T  !D
M ("!:9<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  Q
MC%I:6>'&F&,&   2$@  &0              @(%EH@  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #&,6EH',&S&%!$   PR   9
M          " @?^H  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ ,8Q:6CWD"Z:3'@  ?W<  !D              ("!2KH  'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  QC%I:G2=[ 68)   +
M&   &0              @($4V0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    ( #&,6EI$HL1_R0(   \&   9              " @;'B
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ,8Q:6J:,
M8H%L!@  90X  !D              ("!L>4  'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    "  QC%I:8W<5<]@L  #OE   &0
M    @(%4[   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M #&,6EJ/%C@,(P,  -0&   9              " @6,9 0!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ ,8Q:6G\((SJ$ @  < 4  !D
M             ("!O1P! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  QC%I:ACX,&E<'   &&0  &0              @(%X'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #&,6EIB:'ACT@(
M /D%   9              " @08G 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ ,8Q:6H9DO\B_ @  IP4  !D              ("!
M#RH! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  QC%I:
M59PZ>H0#   Y"   &0              @($%+0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( #&,6EJ\O17HM@,  -T(   9
M      " @< P 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ ,8Q:6DFDT73*!@  &1(  !D              ("!K30! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  QC%I:-N]8U8<%   L#P
M&0              @(&N.P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( #&,6EJZJSE/V (   ,&   9              " @6Q! 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ,8Q:6N^OOWL2
M!   JP@  !D              ("!>T0! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  QC%I:OO;<T&D%  #_+   &0
M@('$2 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #&,
M6EK9/26;)0,  ,P(   9              " @61. 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ ,8Q:6F?)*\@N @  7@0  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( #&,6EK6F\ZPP 4  #$E   9
M  " @;YF 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M,8Q:6H&6@Y"M!0  _B@  !D              ("!M6P! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  QC%I:VF[J.UD"  #:!   &0
M            @(&9<@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( #&,6EJR*XTF, ,  (X,   9              " @2EU 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ ,8Q:6I0L6IL? P
MT@L  !D              ("!D'@! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  QC%I:B7K$(.L"   R"   &0              @('F
M>P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( #&,6EJH
MTY94NP,  -,.   9              " @0A_ 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ ,8Q:6HM_11XW!@  -C4  !D
M     ("!^H(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #&,6EI+N53RZ@(  .H'   9              "
M@;2? 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ,8Q:
M6KQY]%YW @  ] 8  !D              ("!U:(! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    "  QC%I:MX'7L,8(  !.8P  &0
M        @(&#I0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( #&,6EI&LU>E*04  /\?   9              " @8"N 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ ,8Q:6G*-7V1! P  V0L
M !D              ("!X+,! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    "  QC%I:/*L]K#<.  #=N   &0              @(%8MP$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( #&,6EIK:9B#
MB 8   TJ   9              " @<;% 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ ,8Q:6N*3_%77 @  DP@  !D
M ("!A<P! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  Q
MC%I:[:Q "-H$  !]%0  &0              @(&3SP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( #&,6EHJ"6$?H0,   P.   9
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M970W,"YX;6Q02P$"% ,4    "  QC%I:#?#G">$"   Q"   &0
M    @(&-Z0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M #&,6EHAQM;RKP(   X'   9              " @:7L 0!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ ,8Q:6C&919?! P  <0T  !D
M             ("!B^\! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    "  QC%I:\%,VPS $  #X#@  &0              @(&#\P$ >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( #&,6EJ46.=[FP(
M &8'   9              " @>KW 0!X;"]W;W)K<VAE971S+W-H965T-S4N
M>&UL4$L! A0#%     @ ,8Q:6OGV@(EA @  EP8  !D              ("!
MO/H! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    "  QC%I:
M5%XY+MD"   O!P  &0              @(%4_0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<W+GAM;%!+ 0(4 Q0    ( #&,6EIPR?E)+ ,   @)   9
M      " @60  @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%
M  @ ,8Q:6M.P0BW/ P  80D  !D              ("!QP," 'AL+W=O<FMS
M:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  QC%I:O]7CNYD&   X+0
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M+G)E;'-02P$"% ,4    "  QC%I:RF5''%P&  !W-0  #P
M@ 'V%@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,8Q:6JN<,4MN @
MVB\  !H              ( !?QT" 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ ,8Q:6D3DWU@> @  ERX  !,              ( !
M)2 " %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %D 60!F&   ="("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>245</ContextCount>
  <ElementCount>411</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>98</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995457 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995467 - Disclosure - REVENUE RECOGNITON</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton</Role>
      <ShortName>REVENUE RECOGNITON</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995477 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureInventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995487 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995497 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995517 - Disclosure - ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES</Role>
      <ShortName>ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995527 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995537 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995547 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995557 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995567 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995577 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995587 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995607 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995617 - Disclosure - REVENUE RECOGNITON (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonTables</Role>
      <ShortName>REVENUE RECOGNITON (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995627 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/DisclosureInventory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995637 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995647 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995657 - Disclosure - ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables</Role>
      <ShortName>ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995667 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995677 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995687 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995697 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995707 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995717 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995727 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995737 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995747 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995757 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SEGMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SEGMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995767 - Disclosure - REVENUE RECOGNITON - Schedule of Reconciliation of Gross Product Sales to Net Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails</Role>
      <ShortName>REVENUE RECOGNITON - Schedule of Reconciliation of Gross Product Sales to Net Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995777 - Disclosure - INVENTORY - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORY - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995787 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995807 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995817 - Disclosure - FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995837 - Disclosure - FAIR VALUE MEASUREMENTS - SALE OF FUTURE ROYALTIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - SALE OF FUTURE ROYALTIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995847 - Disclosure - FAIR VALUE MEASUREMENTS - CREDIT RISK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - CREDIT RISK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995857 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995877 - Disclosure - ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails</Role>
      <ShortName>ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995887 - Disclosure - COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995897 - Disclosure - OPERATING LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails</Role>
      <ShortName>OPERATING LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995907 - Disclosure - OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails</Role>
      <ShortName>OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995917 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails</Role>
      <ShortName>OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995927 - Disclosure - DEBT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails</Role>
      <ShortName>DEBT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995937 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails</Role>
      <ShortName>DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995947 - Disclosure - DEBT - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails</Role>
      <ShortName>DEBT - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995957 - Disclosure - STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995967 - Disclosure - STOCKHOLDERS' EQUITY - PUBLIC OFFERINGS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - PUBLIC OFFERINGS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995977 - Disclosure - STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995987 - Disclosure - STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995997 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996007 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996017 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996027 - Disclosure - STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996037 - Disclosure - STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996047 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996057 - Disclosure - STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996067 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996077 - Disclosure - STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996087 - Disclosure - INCOME TAXES - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996097 - Disclosure - INCOME TAXES - SCHEDULE OF PROVISION FOR (BENEFIT FROM) INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - SCHEDULE OF PROVISION FOR (BENEFIT FROM) INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996107 - Disclosure - INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails</Role>
      <ShortName>INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996117 - Disclosure - INCOME TAXES - DEFERRED TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails</Role>
      <ShortName>INCOME TAXES - DEFERRED TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996127 - Disclosure - INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails</Role>
      <ShortName>INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996137 - Disclosure - INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails</Role>
      <ShortName>INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996157 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails</Role>
      <ShortName>INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996167 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996177 - Disclosure - SEGMENT REPORTING (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>SEGMENT REPORTING (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996187 - Disclosure - SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails</Role>
      <ShortName>SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="gern-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996197 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="gern-20241231.htm">gern-20241231.htm</File>
    <File>gern-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img44536338_0.jpg</File>
    <File>img44536338_1.jpg</File>
    <File>img44536338_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="851">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "gern-20241231.htm": {
   "nsprefix": "gern",
   "nsuri": "http://www.geron.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "gern-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "gern-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 349,
   "keyCustom": 62,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 63,
   "hidden": {
    "total": 13,
    "http://fasb.org/us-gaap/2024": 8,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.geron.com/20241231": 2
   },
   "contextCount": 245,
   "entityCount": 1,
   "segmentCount": 98,
   "elementCount": 859,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 851,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION",
     "longName": "100000 - Document - DOCUMENT AND ENTITY INFORMATION",
     "shortName": "DOCUMENT AND ENTITY INFORMATION",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "100040 - Statement - STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_0b8accab-dfee-4fdd-a488-21c280ad6a1b",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0b8accab-dfee-4fdd-a488-21c280ad6a1b",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_90739fa8-e72e-4147-a181-ff8aba129f93",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_90739fa8-e72e-4147-a181-ff8aba129f93",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100080 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_e4021ad0-3e5e-48de-9cd9-3300958d415f",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e4021ad0-3e5e-48de-9cd9-3300958d415f",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "995457 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton",
     "longName": "995467 - Disclosure - REVENUE RECOGNITON",
     "shortName": "REVENUE RECOGNITON",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureInventory",
     "longName": "995477 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS",
     "longName": "995487 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT",
     "longName": "995497 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES",
     "longName": "995517 - Disclosure - ACCRUED LIABILITIES",
     "shortName": "ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES",
     "longName": "995527 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES",
     "longName": "995537 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT",
     "longName": "995547 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY",
     "longName": "995557 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES",
     "longName": "995567 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1",
     "longName": "995577 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting",
     "longName": "995587 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "995607 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonTables",
     "longName": "995617 - Disclosure - REVENUE RECOGNITON (Tables)",
     "shortName": "REVENUE RECOGNITON (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryTables",
     "longName": "995627 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables",
     "longName": "995637 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables",
     "longName": "995647 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables",
     "longName": "995657 - Disclosure - ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables",
     "longName": "995667 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables",
     "longName": "995677 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables",
     "longName": "995687 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables",
     "longName": "995697 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables",
     "longName": "995707 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995717 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
     "longName": "995727 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b",
      "name": "gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_59108335-739f-4e5e-b267-22b8c789f159",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1",
     "longName": "995737 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NET LOSS PER SHARE (Detail1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_f8d8f292-1d56-4204-b316-2a9290be7c09",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f8d8f292-1d56-4204-b316-2a9290be7c09",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails",
     "longName": "995747 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - USEFUL LIVES OF ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
     "longName": "995757 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SEGMENT INFORMATION (Details)",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - SEGMENT INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails",
     "longName": "995767 - Disclosure - REVENUE RECOGNITON - Schedule of Reconciliation of Gross Product Sales to Net Product Sales (Details)",
     "shortName": "REVENUE RECOGNITON - Schedule of Reconciliation of Gross Product Sales to Net Product Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_a57a8238-5f15-4041-aa47-381c050af69a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a57a8238-5f15-4041-aa47-381c050af69a",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails",
     "longName": "995777 - Disclosure - INVENTORY - Schedule of Inventory (Details)",
     "shortName": "INVENTORY - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:InventoryRawMaterialsAndSupplies",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails",
     "longName": "995787 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - SECURITY TYPE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
     "longName": "995807 - Disclosure - FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - SECURITIES WITH UNREALIZED LOSSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
     "longName": "995817 - Disclosure - FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - RECURRING BASIS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_b715e801-fcfb-431f-8bab-f2e143bebd19",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b715e801-fcfb-431f-8bab-f2e143bebd19",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails",
     "longName": "995837 - Disclosure - FAIR VALUE MEASUREMENTS - SALE OF FUTURE ROYALTIES (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - SALE OF FUTURE ROYALTIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "gern:FairValueMeasurementsInterTransfersBetweenLevels",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "gern:FairValueMeasurementsInterTransfersBetweenLevels",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails",
     "longName": "995847 - Disclosure - FAIR VALUE MEASUREMENTS - CREDIT RISK (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - CREDIT RISK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails",
     "longName": "995857 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails",
     "longName": "995877 - Disclosure - ACCRUED LIABILITIES (Details)",
     "shortName": "ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
     "longName": "995887 - Disclosure - COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Severance Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "gern:NumberOfSeverancePlan",
      "unitRef": "U_Plan",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "gern:NumberOfSeverancePlan",
      "unitRef": "U_Plan",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
     "longName": "995897 - Disclosure - OPERATING LEASES (Details)",
     "shortName": "OPERATING LEASES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails",
     "longName": "995907 - Disclosure - OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)",
     "shortName": "OPERATING LEASES - COMPONENTS OF LEASE COSTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails",
     "longName": "995917 - Disclosure - OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)",
     "shortName": "OPERATING LEASES - UNDISCOUNTED FUTURE NON-CANCELLABLE LEASE PAYMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
     "longName": "995927 - Disclosure - DEBT - Additional Information (Details)",
     "shortName": "DEBT - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_b78714b6-f9c0-495e-8c29-1ef95e3bcf60",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b78714b6-f9c0-495e-8c29-1ef95e3bcf60",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails",
     "longName": "995937 - Disclosure - DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)",
     "shortName": "DEBT - Schedule of Future Minimum Payments Under Term Loan Facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
     "longName": "995947 - Disclosure - DEBT - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)",
     "shortName": "DEBT - Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_e03f65aa-0f08-4125-91e7-89e207442e89",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e03f65aa-0f08-4125-91e7-89e207442e89",
      "name": "us-gaap:PaymentsForRoyalties",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails",
     "longName": "995957 - Disclosure - STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - AUTHORIZED COMMON STOCK (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ffad885e-eeb0-4c57-b284-7102190be086",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
     "longName": "995967 - Disclosure - STOCKHOLDERS' EQUITY - PUBLIC OFFERINGS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - PUBLIC OFFERINGS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_9accca2e-98a7-4feb-90e0-dd4c4473e5a3",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_432034fc-3319-4587-adae-2e7c9b692266",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
     "longName": "995977 - Disclosure - STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - WARRANT EXERCISES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_04ccb33e-9db2-4428-ab1f-e86203e71f68",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails",
     "longName": "995987 - Disclosure - STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - SALES AGREEMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_ece3b919-9c68-4419-b2c9-c5d7c4dcca3d",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ece3b919-9c68-4419-b2c9-c5d7c4dcca3d",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
     "longName": "995997 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EQUITY PLANS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails",
     "longName": "996007 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
     "longName": "996017 - Disclosure - STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EQUITY PLANS - SCHEDULE OF AGGREGATE STOCK OPTION AND AWARD ACTIVITY (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bdeda059-8b87-497a-b9cd-e4cf9530f303",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
     "longName": "996027 - Disclosure - STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - EMPLOYEE STOCK PURCHASE PLAN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5",
      "name": "gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
     "longName": "996037 - Disclosure - STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - PERFORMANCE BASED STOCK OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails",
     "longName": "996047 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION EXPENSE FOR EMPLOYEES AND DIRECTORS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e43f9ac5-e990-42e5-a162-14377ebe69a7",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
     "longName": "996057 - Disclosure - STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - PRICING MODEL ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
     "longName": "996067 - Disclosure - STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - STOCK-BASED COMPENSATION TO SERVICE PROVIDERS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dbe4854e-8234-4b3f-bb3b-8c19d5981bf6",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
     "longName": "996077 - Disclosure - STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - COMMON STOCK RESERVED FOR FUTURE ISSUANCE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1066105-def2-48bc-a08b-a1be59df1fe9",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails",
     "longName": "996087 - Disclosure - INCOME TAXES - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAXES (Details)",
     "shortName": "INCOME TAXES - SCHEDULE OF COMPONENTS OF INCOME/(LOSS) BEFORE INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails",
     "longName": "996097 - Disclosure - INCOME TAXES - SCHEDULE OF PROVISION FOR (BENEFIT FROM) INCOME TAXES (Details)",
     "shortName": "INCOME TAXES - SCHEDULE OF PROVISION FOR (BENEFIT FROM) INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails",
     "longName": "996107 - Disclosure - INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)",
     "shortName": "INCOME TAXES - EFFECTIVE INCOME TAX RATE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails",
     "longName": "996117 - Disclosure - INCOME TAXES - DEFERRED TAXES (Details)",
     "shortName": "INCOME TAXES - DEFERRED TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
     "longName": "996127 - Disclosure - INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)",
     "shortName": "INCOME TAXES - OPERATING LOSS CARRYFORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-8",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails",
     "longName": "996137 - Disclosure - INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)",
     "shortName": "INCOME TAXES - TAX CREDIT CARRYFORWARDS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails",
     "longName": "996157 - Disclosure - INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)",
     "shortName": "INCOME TAXES - UNRECOGNIZED TAX BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails",
     "longName": "996167 - Disclosure - CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA - Supplemental Investing Activities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "996177 - Disclosure - SEGMENT REPORTING (Additional Information) (Details)",
     "shortName": "SEGMENT REPORTING (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
     "longName": "996187 - Disclosure - SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details)",
     "shortName": "SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "996197 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Details)",
     "shortName": "SUBSEQUENT EVENTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_375cfc07-5431-4a75-8af6-40a50bbfc4d7",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "gern-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "gern_ASDSpecialtyHealthcareLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ASDSpecialtyHealthcareLLCMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASD Specialty Healthcare LLC [Member]",
        "documentation": "ASD Specialty Healthcare LLC.",
        "terseLabel": "ASD Specialty Healthcare LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED LIABILITIES",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r65",
      "r1072"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r835"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "terseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion and amortization on investments, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "gern_AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Research Organizations And Clinical Trial Costs Current",
        "terseLabel": "CRO and clinical trial costs"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AccruedEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AccruedEndOfTermCharge",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued end of term charge.",
        "label": "Accrued End Of Term Charge",
        "terseLabel": "Accrued end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AccruedEndOfTermCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AccruedEndOfTermCharges",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued end of term charges.",
        "label": "Accrued End Of Term Charges",
        "verboseLabel": "Accrued end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "gern_AccruedManufacturingActivitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AccruedManufacturingActivitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet of obligations incurred through the date and payable for manufacturing related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Manufacturing Activities Current",
        "terseLabel": "Manufacturing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional legal and accounting fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties",
        "verboseLabel": "Carrying value of liabilities related to sale of future revenues",
        "periodStartLabel": "Carrying value of liability related to sale of future royalties at November 1, 2024",
        "periodEndLabel": "Carrying value of liability related to sale of future royalties at December 31, 2024",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_AccumulatedCapitalizedInterestCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedCapitalizedInterestCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Capitalized Interest Costs",
        "terseLabel": "Less: amount representing interest",
        "negatedLabel": "Less: amount representing interest",
        "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r154",
      "r619"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive gain",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r78",
      "r160",
      "r616",
      "r646",
      "r647"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12",
      "r20",
      "r503",
      "r506",
      "r563",
      "r642",
      "r643",
      "r991",
      "r992",
      "r993",
      "r1001",
      "r1002",
      "r1003",
      "r1005"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r1001",
      "r1002",
      "r1003",
      "r1005",
      "r1083",
      "r1149"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation for equity-based awards to employees and directors",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r405"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r880",
      "r891",
      "r901",
      "r934"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r926",
      "r935",
      "r939",
      "r947"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense included in operating expenses",
        "verboseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r443"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs/debt discount",
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r801",
      "r802",
      "r996",
      "r1098"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential dilutive securities excluded from diluted earnings (loss) per share calculation (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r123",
      "r155",
      "r188",
      "r220",
      "r227",
      "r246",
      "r250",
      "r291",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r496",
      "r500",
      "r535",
      "r612",
      "r697",
      "r787",
      "r788",
      "r835",
      "r855",
      "r1038",
      "r1039",
      "r1104"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r163",
      "r188",
      "r291",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r496",
      "r500",
      "r535",
      "r835",
      "r1038",
      "r1039",
      "r1104"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r822"
     ]
    },
    "gern_AtMarketIssuanceSalesAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AtMarketIssuanceSalesAgreementsLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Issuance Sales Agreements.",
        "label": "At Market Issuance Sales Agreements [Line Items]",
        "terseLabel": "At Market Issuance Sales Agreements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceSalesAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AtMarketIssuanceSalesAgreementsTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Issuance Sales Agreements.",
        "label": "At Market Issuance Sales Agreements [Table]",
        "terseLabel": "At Market Issuance Sales Agreements [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AtMarketIssuanceTwoThousandAndEighteenSalesAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At market issuance, 2018 sales agreement.",
        "label": "At Market Issuance Two Thousand And Eighteen Sales Agreement [Member]",
        "terseLabel": "2018 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At market issuance two thousand and twenty sales agreement.",
        "label": "At Market Issuance Two Thousand And Twenty Sales Agreement [Member]",
        "terseLabel": "2020 Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Sales Agreement",
        "label": "At Market Issuance Two Thousand And Twenty Three Sales Agreement [Member]",
        "documentation": "At market issuance two thousand and twenty three sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "gern_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Member.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r884"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r884"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r884"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r299",
      "r611"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities:",
        "label": "Debt Securities, Available-for-Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r299",
      "r513",
      "r604",
      "r822",
      "r825",
      "r1018",
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r299"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Noncurrent marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r259",
      "r299"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "gern_BiopharmaCreditPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "BiopharmaCreditPlcMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioPharma Credit PLC [Member]",
        "documentation": "BioPharma credit PLC.",
        "terseLabel": "BioPharma Credit PLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_BorrowingAvailableStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "BorrowingAvailableStartDate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First date to available to drawdown any amount under a tranche.",
        "label": "Borrowing Available Start Date",
        "terseLabel": "Start date to borrow under a tranche for a debt instrument"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationCostOfAcquiredEntityEquityInterestsIssuedAndIssuableFairValueMethod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method",
        "terseLabel": "Business Combination Cost Of Acquired Entity Equity Interests Issued And Issuable Fair Value Method",
        "documentation": "The method of determining the fair value of the equity interests of the acquirer, including the number of instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "gern_CARESActImpactAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CARESActImpactAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES act impact.",
        "label": "C A R E S Act Impact [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CaliforniaOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CaliforniaOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California Office Space Lease",
        "label": "California Office Space Lease [Member]",
        "documentation": "California office space lease."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CardinalHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CardinalHealthIncMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cardinal Health Inc [Member]",
        "documentation": "Cardinal Health Inc.",
        "terseLabel": "Cardinal Health Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Included in cash and cash equivalents:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r151",
      "r770"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r110"
     ]
    },
    "gern_CashAndCashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CashAndCashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the gross unrealized gains for cash and cash equivalents.",
        "label": "Cash And Cash Equivalents Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CashAndCashEquivalentsUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CashAndCashEquivalentsUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the gross unrealized losses for cash and cash equivalents.",
        "label": "Cash And Cash Equivalents Unrealized Losses",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r87",
      "r186"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r87"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value",
        "totalLabel": "Amortized Cost",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r1115"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsData1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "CONSOLIDATED STATEMENTS OF CASH FLOWS DATA",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "gern_ChargebackAndDistributorServiceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ChargebackAndDistributorServiceFeesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chargeback And Distributor Service Fees [Member]",
        "documentation": "Chargeback and distributor service fees.",
        "verboseLabel": "Chargebacks and distributor service fees"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ChemistryManufacturingAndControlExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ChemistryManufacturingAndControlExpensesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chemistry Manufacturing And Control Expenses Member",
        "documentation": "Chemistry, manufacturing, and control expenses.",
        "verboseLabel": "Chemistry, Manufacturing, and Control Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "verboseLabel": "Warrants to purchase common stock, exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants to purchase common stock, shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase common stock, shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "gern_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the period",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised",
        "terseLabel": "Warrants to purchase common stock exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock outstanding warrants to purchase",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "gern_ClinicalSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ClinicalSupplyAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical supply agreement.",
        "label": "Clinical Supply Agreement [Member]",
        "terseLabel": "Clinical Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "gern_CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CollaborativeArrangementAfterTerminationCostSharingPercentageOfEntity",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that the company must pay after the termination of the Collaboration Agreement.",
        "label": "Collaborative Arrangement After Termination Cost Sharing Percentage Of Entity",
        "terseLabel": "Percentage of costs to be paid by Geron after termination of Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CollaborativeArrangementCostSharingPercentageOfCounterparty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CollaborativeArrangementCostSharingPercentageOfCounterparty",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that Janssen must pay during certain phases of the agreement.",
        "label": "Collaborative Arrangement Cost Sharing Percentage Of Counterparty",
        "terseLabel": "Percentage of costs to be paid by Janssen"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CollaborativeArrangementCostSharingPercentageOfEntity": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CollaborativeArrangementCostSharingPercentageOfEntity",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of costs that Geron must pay during certain phases of the agreement.",
        "label": "Collaborative Arrangement Cost Sharing Percentage Of Entity",
        "terseLabel": "Percentage of costs to be paid by Geron"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureLicenseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "LICENSE AGREEMENT",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r136",
      "r145"
     ]
    },
    "gern_CollaborativeArrangementNumberOfStudies": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CollaborativeArrangementNumberOfStudies",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of agreed upon studies.",
        "label": "Collaborative Arrangement Number Of Studies",
        "terseLabel": "Number of agreed upon studies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "gern_CommercialExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CommercialExpensesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial Expenses",
        "label": "Commercial Expenses Member",
        "documentation": "Commercial expenses."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CommercialPaperDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CommercialPaperDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to unsecured promissory note (generally negotiable) that provides institutions with short-term funds ), due in less than one year.",
        "label": "Commercial Paper Due In Less Than One Year [Member]",
        "terseLabel": "Commercial paper (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r327",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r115",
      "r613",
      "r684"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r318",
      "r319",
      "r764",
      "r1026",
      "r1031"
     ]
    },
    "gern_CommonStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CommonStockAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate offering price for which the entity may elect to issue and sell shares of its common stock under the sales agreement.",
        "label": "Common Stock Aggregate Offering Price",
        "terseLabel": "Aggregate offering price of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, shares reserved for future issuance (in shares)",
        "verboseLabel": "Common stock reserved for future issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r843",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849",
      "r1001",
      "r1002",
      "r1005",
      "r1083",
      "r1146",
      "r1149"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYAUTHORIZEDCOMMONSTOCKDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r685"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balances (in shares)",
        "periodStartLabel": "Balances (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r685",
      "r703",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 1,350,000,000 shares authorized; 606,387,666 and 544,912,215 shares issued and outstanding at December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r615",
      "r835"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Significant components of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r168",
      "r170",
      "r175",
      "r605",
      "r626",
      "r627"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r257",
      "r763"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r257",
      "r649",
      "r763"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r257",
      "r763",
      "r973"
     ]
    },
    "us-gaap_ConcentrationRiskCustomer": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCustomer",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Customer",
        "terseLabel": "Concentration risk, customer",
        "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures)."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r92"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r257"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r51",
      "r109",
      "r763"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r51",
      "r52",
      "r257",
      "r763"
     ]
    },
    "us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRisksTypesNoConcentrationPercentageAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risks, Types, No Concentration Percentage [Abstract]",
        "terseLabel": "Credit Risk"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r194",
      "r220",
      "r229",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r787",
      "r788",
      "r1038",
      "r1039"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r194",
      "r220",
      "r229",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r787",
      "r788",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r775"
     ]
    },
    "gern_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to consultants.",
        "label": "Consultants [Member]",
        "terseLabel": "Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CorporateNoteSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CorporateNoteSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in less than one year.",
        "label": "Corporate Note Securities Due In Less Than One Year [Member]",
        "terseLabel": "Corporate notes (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CorporateNoteSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CorporateNoteSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest), due in one to two years.",
        "label": "Corporate Note Securities Due In One To Two Years [Member]",
        "terseLabel": "Corporate notes (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNoteSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNoteSecuritiesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Note Securities [Member]",
        "terseLabel": "Corporate notes",
        "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest)."
       }
      }
     },
     "auth_ref": []
    },
    "gern_CostMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CostMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost method investment ownership percentage.",
        "label": "Cost Method Investment Ownership Percentage",
        "terseLabel": "Cost method investments ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "gern_CostMethodInvestmentsCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "CostMethodInvestmentsCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost method investments cost basis.",
        "label": "Cost Method Investments Cost Basis",
        "terseLabel": "Cost method investments cost basis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r343",
      "r371",
      "r564",
      "r584",
      "r610",
      "r772",
      "r774"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r1036"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r1036",
      "r1037"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r257"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r958"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r958"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r960"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r960"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r962"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871",
      "r960"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r864",
      "r953"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r954"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865",
      "r954"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r952"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r952"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r863",
      "r952"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r866",
      "r955"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r957"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868",
      "r957"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869",
      "r958"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872",
      "r961"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870",
      "r959"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867",
      "r956"
     ]
    },
    "gern_DebtCovenantMinCashUponLicensingTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtCovenantMinCashUponLicensingTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash covenant required upon certain licensing transactions being executed.",
        "label": "Debt Covenant Min Cash Upon Licensing Transaction",
        "terseLabel": "Debt covenant minimum cash balance upon licensing transaction"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinCashUponRegulatoryMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtCovenantMinCashUponRegulatoryMilestone",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash covenant required upon achievement of certain regulatory milestones.",
        "label": "Debt Covenant Min Cash Upon Regulatory Milestone",
        "terseLabel": "Debt covenant minimum cash balance upon regulatory milestone achievement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinimumCashBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtCovenantMinimumCashBalance",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant Minimum Cash Balance",
        "label": "Debt Covenant Minimum Cash Balance",
        "terseLabel": "Debt covenant minimum cash balance"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantMinimumCashBalancePercentageOfLoanAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtCovenantMinimumCashBalancePercentageOfLoanAmount",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of loan amount outstanding to be held as minimum cash balance under debt covenant.",
        "label": "Debt covenant minimum cash balance percentage of loan amount",
        "terseLabel": "Minimum cash balance as a percentage of loan amount outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtCovenantPercentageOfProductRevenueAgainstForecast": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtCovenantPercentageOfProductRevenueAgainstForecast",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of six-month product revenue forecast to satisfy minimum cash balance debt covenant.",
        "label": "Debt covenant percentage of product revenue against forecast",
        "verboseLabel": "Minimum cash balance requirement to be met as a percentage of six-month product revenue against forecast"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt, Current, Total",
        "label": "Debt, Current",
        "terseLabel": "Debt",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r187",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r326",
      "r327",
      "r339",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r355",
      "r362",
      "r363",
      "r365",
      "r545"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r58",
      "r59",
      "r112",
      "r114",
      "r194",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r832",
      "r997",
      "r1027",
      "r1028",
      "r1029",
      "r1097",
      "r1099"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Variable interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Percentage added to prime rate for debt instrument interest rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal amount outstanding under term loan",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r114",
      "r366"
     ]
    },
    "gern_DebtInstrumentEndOfTermChargePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtInstrumentEndOfTermChargePercentage",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding loan amount payable upon maturity.",
        "label": "Debt Instrument End Of Term Charge Percentage",
        "terseLabel": "End of term charge for loan, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principle amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r545",
      "r546",
      "r799",
      "r800",
      "r832"
     ]
    },
    "gern_DebtInstrumentFaceAmountExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtInstrumentFaceAmountExpired",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument face amount expired",
        "label": "Debt Instrument Face Amount Expired",
        "documentation": "Debt instrument face amount expired."
       }
      }
     },
     "auth_ref": []
    },
    "gern_DebtInstrumentFloorRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtInstrumentFloorRate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Floor Rate",
        "documentation": "Debt instrument floor rate.",
        "terseLabel": "Floor rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Term loan interest rate description",
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r1097"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r369",
      "r545",
      "r546",
      "r832"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Minimum interest rate (as a percentage)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r341"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r832",
      "r997",
      "r1097",
      "r1099"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Term loan maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r798",
      "r1088",
      "r1089"
     ]
    },
    "gern_DebtInstrumentMinimumPrepaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtInstrumentMinimumPrepaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount allowed to be prepaid under debt instrument.",
        "label": "Debt Instrument Minimum Prepayment Amount",
        "terseLabel": "Minimum amount of prepayment allowed under debt instrument"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r194",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r832",
      "r997",
      "r1027",
      "r1028",
      "r1029",
      "r1097",
      "r1099"
     ]
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Description of term loan payment terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r62"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r41",
      "r42",
      "r53",
      "r100",
      "r101",
      "r194",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r832",
      "r997",
      "r1097",
      "r1099"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt discount amount",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: unamortized debt discount and issuance costs",
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1096",
      "r1097",
      "r1099"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount and issuance costs",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r367",
      "r544",
      "r545",
      "r546",
      "r799",
      "r800",
      "r832"
     ]
    },
    "gern_DebtInstrumentUnamortizedEndOfTermCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DebtInstrumentUnamortizedEndOfTermCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument unamortized end of term charge.",
        "label": "Debt Instrument Unamortized End Of Term Charge",
        "negatedLabel": "Less: unamortized end of term charge"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "verboseLabel": "Available remaining loan principal under second amendment",
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r326"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs and Debt Discounts",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Greater - Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r303",
      "r796"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Greater - Gross Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r303"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months - Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r303",
      "r796"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months - Gross Unrealized Losses",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r303"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "totalLabel": "Total - Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r301",
      "r796"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total - Gross Unrealized Losses",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r302"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents and marketable securities with unrealized losses",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r796",
      "r1025"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Gross",
        "verboseLabel": "Debt issuance costs",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1099"
     ]
    },
    "gern_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to the treatment of research and development costs.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DeferredTaxAssetsFederalAndStateCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DeferredTaxAssetsFederalAndStateCredits",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets federal and state credits.",
        "label": "Deferred Tax Assets Federal And State Credits",
        "terseLabel": "Federal and state tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "gern_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "gern_DeferredTaxAssetsRevenueParticipation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DeferredTaxAssetsRevenueParticipation",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Revenue Participation",
        "documentation": "Deferred tax assets revenue participation.",
        "terseLabel": "Revenue Participation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "gern_DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities operating leases right of use assets.",
        "label": "Deferred Tax Liabilities Operating Leases Right Of Use Assets",
        "negatedLabel": "Operating leases, right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DepositsAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer; and amount of noncurrent assets classified as other.",
        "label": "Deposits And Other Assets Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Abstract]",
        "terseLabel": "Depreciation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion, and Amortization [Policy Text Block]",
        "terseLabel": "Depreciation and Amortization",
        "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "gern_DirectorsMarketValueStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DirectorsMarketValueStockPurchasePlanMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors\u2019 market value stock purchase plan.",
        "label": "Directors Market Value Stock Purchase Plan [Member]",
        "terseLabel": "Directors Market Value Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_DirectorsPlan2006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DirectorsPlan2006Member",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2006 Directors Plan.",
        "label": "Directors Plan2006 [Member]",
        "terseLabel": "2006 Directors Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r884"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r884",
      "r927"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "verboseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "gern_DollarPrepaymentCharge36MonthsAfterEffectiveDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DollarPrepaymentCharge36MonthsAfterEffectiveDate",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment charge assessed upon debt prepayment occurring 36 months after June 30, 2022 under second amendment.",
        "label": "Dollar prepayment charge 36 months after effective date",
        "verboseLabel": "Charge for prepayment occurring 36 months after effective date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "gern_DueToCounterParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "DueToCounterParty",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due to counterparty. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Counter Party",
        "terseLabel": "Amount due to Janssen Biotech, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r210",
      "r212",
      "r214",
      "r215",
      "r216",
      "r219",
      "r490",
      "r493",
      "r510",
      "r511",
      "r606",
      "r628",
      "r778"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r212",
      "r214",
      "r215",
      "r216",
      "r219",
      "r490",
      "r493",
      "r510",
      "r511",
      "r606",
      "r628",
      "r778"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r218"
     ]
    },
    "gern_EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of unrealized losses and exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Unrealized Losses And Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Net effect of unrealized gains and exchange rates on cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r819"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r454",
      "r481",
      "r819"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r819",
      "r1000",
      "r1075"
     ]
    },
    "gern_EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax Rate reconciliation net operating loss not benefitted.",
        "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Not Benefitted",
        "terseLabel": "Net operating loss not benefitted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r1000",
      "r1075",
      "r1077"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r819",
      "r1000",
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r819",
      "r1000",
      "r1075"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESEFFECTIVEINCOMETAXRATEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Federal and state tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total",
        "negatedLabel": "Federal and state tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r460",
      "r1000",
      "r1075"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "gern_EmployeeRetentionCreditAmountOutstandingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "EmployeeRetentionCreditAmountOutstandingReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Retention Credit, Outstanding",
        "label": "Employee Retention Credit Amount Outstanding Receivables",
        "documentation": "Employee retention credit amount outstanding receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation capitalized",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-Based Compensation Expense",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation cost not yet recognized, net of estimated forfeitures (in dollars)",
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]",
        "terseLabel": "Compensation cost related to unvested stock awards not yet recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition of compensation cost on weighted average basis",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "verboseLabel": "Employee stock purchase",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "gern_EmployeesAboveTheVicePresidentLevelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "EmployeesAboveTheVicePresidentLevelMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees Above The Vice President Level",
        "label": "Employees Above The Vice President Level [Member]",
        "documentation": "Employees above the vice president level."
       }
      }
     },
     "auth_ref": []
    },
    "gern_EmployerTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "EmployerTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESCARESACTIMPACTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of employer taxes paid to tax authorities representing refunds based on calculated eligible credits. Also called employer tax refund receivable.",
        "label": "Employer Tax Receivable",
        "terseLabel": "Employee retention credit, CARES Act"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r146",
      "r172",
      "r173",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r204",
      "r206",
      "r208",
      "r221",
      "r292",
      "r293",
      "r309",
      "r374",
      "r479",
      "r480",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r547",
      "r549",
      "r563",
      "r624",
      "r642",
      "r643",
      "r644",
      "r658",
      "r725"
     ]
    },
    "gern_EquityInvestmentReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "EquityInvestmentReverseStockSplit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse stock split ratio for equity investment.",
        "label": "Equity Investment Reverse Stock Split",
        "terseLabel": "Equity investment reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investment",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r836",
      "r850",
      "r851",
      "r852",
      "r1151"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r877",
      "r888",
      "r898",
      "r931"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r885",
      "r895",
      "r928"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "gern_ExpiryDateOfTranche": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ExpiryDateOfTranche",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date to borrow under a tranche for a debt instrument",
        "label": "Expiry Date Of Tranche",
        "documentation": "Last date to drawdown any amounts under a tranche."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FacilityCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FacilityCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility charge",
        "label": "Facility Costs",
        "documentation": "Facility expenses incurred related to gas and oil produced and sold during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value on a Recurring Basis",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r527",
      "r822"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r527",
      "r822"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r528",
      "r823"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r528",
      "r823"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of cash equivalents, restricted cash and marketable securities by security type",
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r526",
      "r527",
      "r529",
      "r571",
      "r572",
      "r573",
      "r799",
      "r800",
      "r811",
      "r812",
      "r813",
      "r822",
      "r825"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r517",
      "r822",
      "r1088",
      "r1091"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r524",
      "r525",
      "r526",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r603",
      "r822",
      "r826"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r395",
      "r400",
      "r514",
      "r527",
      "r571",
      "r811",
      "r812",
      "r813",
      "r822"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r395",
      "r400",
      "r514",
      "r515",
      "r527",
      "r572",
      "r799",
      "r800",
      "r811",
      "r812",
      "r813",
      "r822"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r514",
      "r515",
      "r516",
      "r517",
      "r527",
      "r573",
      "r799",
      "r800",
      "r811",
      "r812",
      "r813",
      "r822",
      "r825"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r517",
      "r822",
      "r1088",
      "r1091"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r512",
      "r514",
      "r515",
      "r516",
      "r517",
      "r526",
      "r527",
      "r529",
      "r571",
      "r572",
      "r573",
      "r799",
      "r800",
      "r811",
      "r812",
      "r813",
      "r822",
      "r825"
     ]
    },
    "gern_FairValueMeasurementsInterTransfersBetweenLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "FairValueMeasurementsInterTransfersBetweenLevels",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsSaleOfFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements inter transfers between levels",
        "label": "Fair Value Measurements Inter Transfers Between Levels",
        "documentation": "Fair value measurements inter transfers between levels."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1091"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r304",
      "r305",
      "r364",
      "r372",
      "r508",
      "r534",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r625",
      "r796",
      "r822",
      "r823",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r836",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1084",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "gern_FirstDirectorOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "FirstDirectorOptionMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the stock options to be granted by the entity to a person who first becomes a non-employee director.",
        "label": "First Director Option [Member]",
        "terseLabel": "First Director Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "terseLabel": "Gain (loss) related to foreign currency translation",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r705",
      "r853",
      "r1093",
      "r1094",
      "r1148"
     ]
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Foreign Income Tax Expense (Benefit), Continuing Operations, Total",
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r453"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r935"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r935"
     ]
    },
    "gern_FormerCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "FormerCollaborativeArrangementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former collaborative arrangement.",
        "label": "Former Collaborative Arrangement [Member]",
        "terseLabel": "Former Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_FosterCityOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "FosterCityOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foster City office space lease.",
        "label": "Foster City Office Space Lease [Member]",
        "terseLabel": "Foster City Office Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and computer equipment",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss of extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39",
      "r40"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "gern_GovernmentRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "GovernmentRebatesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Rebates [Member]",
        "documentation": "Government rebates.",
        "verboseLabel": "Government rebates"
       }
      }
     },
     "auth_ref": []
    },
    "gern_GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government sponsored enterprise securities due in less than one year.",
        "label": "Government Sponsored Enterprise Securities Due In Less Than One Year [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "GovernmentSponsoredEnterpriseSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae) due in 1 to 2 years.",
        "label": "Government Sponsored Enterprise Securities Due In One To Two Years [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_HerculesAndSiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "HerculesAndSiliconValleyBankMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules and Silicon Valley Bank. member.",
        "label": "Hercules And Silicon Valley Bank [Member]",
        "terseLabel": "Hercules and Silicon Valley Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_HerculesLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "HerculesLoanAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hercules Loan Agreement Member",
        "documentation": "Hercules loan agreement.",
        "terseLabel": "Hercules Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_HerculesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "HerculesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hercules.",
        "label": "Hercules [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r861",
      "r884"
     ]
    },
    "gern_IncentiveAwardPlan2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "IncentiveAwardPlan2011Member",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2011 Incentive Award Plan.",
        "label": "Incentive Award Plan2011 [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r452"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r117",
      "r122",
      "r607",
      "r621",
      "r780",
      "r787",
      "r1007",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomelossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r452"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r316",
      "r317",
      "r519",
      "r523",
      "r528",
      "r639",
      "r641",
      "r710",
      "r767",
      "r824",
      "r1117"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r519",
      "r523",
      "r528",
      "r639",
      "r641",
      "r710",
      "r767",
      "r824",
      "r1117"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r454",
      "r455",
      "r464",
      "r476",
      "r819",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r454",
      "r455",
      "r464",
      "r476",
      "r819",
      "r1079"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r447",
      "r454",
      "r461",
      "r462",
      "r463",
      "r469",
      "r475",
      "r482",
      "r484",
      "r485",
      "r486",
      "r655",
      "r819"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for (benefit from) income taxes",
        "verboseLabel": "Total",
        "totalLabel": "Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r143",
      "r207",
      "r208",
      "r220",
      "r232",
      "r250",
      "r451",
      "r454",
      "r483",
      "r630",
      "r819"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r449",
      "r450",
      "r469",
      "r470",
      "r474",
      "r478",
      "r651"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "gern_IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due for interest payments related to marketable securities and in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.",
        "label": "Increase Decrease In Accrued Interest Receivable Net And Other Receivables",
        "negatedLabel": "Interest and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposit and other assets",
        "totalLabel": "Increase (Decrease) in Deposit Assets, Total",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits",
        "totalLabel": "Increase (Decrease) in Employee Related Liabilities, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Increase (decrease) in fair value of equity investment",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r180"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "gern_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other assets",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "gern_IncreaseInAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "IncreaseInAllowanceForDoubtfulAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in Allowance for Doubtful Accounts",
        "documentation": "Increase in allowance for doubtful accounts.",
        "negatedLabel": "Increase in allowance for doubtful accounts"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r926",
      "r935",
      "r939",
      "r947"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r951"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r951"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r951"
     ]
    },
    "us-gaap_InsuranceClaimsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceClaimsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Claims [Member]",
        "terseLabel": "Insurance Claims",
        "documentation": "A demand for payment of a policy benefit because of the occurrence of an insured event, such as the death or disability of the insured; the maturity of an endowment; the incurrence of hospital or medical bills; the destruction or damage of property and related deaths or injuries; defects in, liens on, or challenges to the title to real estate; or the occurrence of a surety loss; and the costs to process claims."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Operating and Nonoperating",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r227",
      "r231",
      "r233",
      "r250",
      "r543",
      "r787",
      "r788"
     ]
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpensePolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense",
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1099"
     ]
    },
    "gern_InterestOnlyPeriodPaymentTermDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "InterestOnlyPeriodPaymentTermDescription",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest only period payment term description.",
        "label": "Interest Only Period Payment Term Description",
        "terseLabel": "Interest only period payment term description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r183",
      "r184"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "terseLabel": "Interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Gross",
        "verboseLabel": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r771",
      "r835"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r150",
      "r161",
      "r306",
      "r307",
      "r308",
      "r601",
      "r777"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsAndSupplies",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials and Supplies, Gross",
        "totalLabel": "Inventory, Raw Materials and Supplies, Gross, Total",
        "verboseLabel": "Raw materials",
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "verboseLabel": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r230",
      "r250",
      "r787",
      "r994"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Investment Owned, Fair Value, Ending Balance",
        "periodStartLabel": "Investment Owned, Fair Value, Beginning Balance",
        "label": "Investment Owned, Fair Value",
        "terseLabel": "Fair value of equity investment",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r660",
      "r661",
      "r662",
      "r664",
      "r666",
      "r667",
      "r668",
      "r671",
      "r676",
      "r677",
      "r688",
      "r689",
      "r729",
      "r732",
      "r733",
      "r735",
      "r740",
      "r741",
      "r744",
      "r745",
      "r746",
      "r748",
      "r749",
      "r752",
      "r754",
      "r755",
      "r844",
      "r855",
      "r1147"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r671",
      "r731",
      "r742",
      "r751",
      "r844"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r663",
      "r664",
      "r667",
      "r671",
      "r729",
      "r732",
      "r737",
      "r741",
      "r744",
      "r747",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r844"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r663",
      "r664",
      "r667",
      "r671",
      "r729",
      "r732",
      "r737",
      "r741",
      "r744",
      "r747",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r844"
     ]
    },
    "gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "IssuanceOfCommonStockInConnectionWithWarrantExerciseShares",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares issued during the period in connection with exercise of warrants.",
        "label": "Issuance Of Common Stock In Connection With Warrant Exercise Shares",
        "terseLabel": "Issuance of common stock in connection with exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_IssuanceOfCommonStockInConnectionWithWarrantExerciseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "IssuanceOfCommonStockInConnectionWithWarrantExerciseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock issued in connection with exercise of warrants during the period.",
        "label": "Issuance Of Common Stock In Connection With Warrant Exercise Value",
        "terseLabel": "Issuance of common stock in connection with exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Stock-based compensation for services by non-employees",
        "verboseLabel": "Stock-based compensation for services by non-employees",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "gern_JanssenBiotechIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "JanssenBiotechIncMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Janssen Biotech Inc.",
        "label": "Janssen Biotech Inc [Member]",
        "terseLabel": "Janssen Biotech"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r974"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r974"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r834"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r561"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r562"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r562"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Operating Lease, Percentage of Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Undiscounted future non-cancellable lease payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1102"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Operating lease term, option to terminate lease",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease term, option to extend additional period",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, initial term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r58",
      "r59",
      "r60",
      "r64",
      "r65",
      "r66",
      "r67",
      "r188",
      "r291",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r497",
      "r500",
      "r501",
      "r535",
      "r683",
      "r779",
      "r855",
      "r1038",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r116",
      "r618",
      "r835",
      "r998",
      "r1024",
      "r1092"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r149",
      "r188",
      "r291",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r497",
      "r500",
      "r501",
      "r535",
      "r835",
      "r1038",
      "r1104",
      "r1105"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related to Sale of Future Royalties",
        "documentation": "Liability related to sale of future royalties.",
        "terseLabel": "Liability related to sale of future royalties"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LicenseAgreementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LicenseAgreementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License Agreement Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LicenseFeesAndRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LicenseFeesAndRoyaltiesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Fees And Royalties Member",
        "documentation": "License fees and royalties.",
        "verboseLabel": "License Fees and Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityBorrowingCapacityDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityBorrowingCapacityDescription",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Borrowing Capacity, Description",
        "terseLabel": "Expiration date to borrow under a tranche for a debt instrument, description",
        "documentation": "Description of the credit facility's borrowing capacity including discussion of how the borrowing capacity is determined (for example, borrowing capacity based on the amount of current assets)."
       }
      }
     },
     "auth_ref": [
      "r984",
      "r985"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit, maturity period",
        "label": "Line of Credit Facility, Expiration Period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity under term loan",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r63"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "terseLabel": "Carrying value of term loan, net",
        "totalLabel": "Long-Term Debt, Total",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r114",
      "r352",
      "r368",
      "r799",
      "r800",
      "r832",
      "r1114"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less: current portion of debt",
        "totalLabel": "Long-Term Debt, Current Maturities, Total",
        "negatedLabel": "Less: current portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "us-gaap_LongTermDebtDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtDescription",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Description",
        "terseLabel": "Description of maturity date terms for term loan",
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r41"
     ]
    },
    "gern_LongTermDebtGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LongTermDebtGross",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of term loan, including accrued interest payable and end of term charge.",
        "label": "Long Term Debt Gross",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r1042"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r194",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTScheduleOfFutureMinimumPaymentsUnderTermLoanFacilityDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Noncurrent debt",
        "totalLabel": "Noncurrent portion of debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Nature [Axis]",
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r325",
      "r444",
      "r648",
      "r797",
      "r1032",
      "r1033"
     ]
    },
    "us-gaap_LossContingencyNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNatureDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Nature [Domain]",
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r325",
      "r444",
      "r648",
      "r797",
      "r1032",
      "r1033"
     ]
    },
    "gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency period of current base salary to be paid under severance plan.",
        "label": "Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan",
        "terseLabel": "Period of base salary to be considered for severance payments"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of base salary in connection with a non-change of control to be considered for severance payments",
        "label": "Loss Contingency Period Of Current Base Salary To Be Paid Under Severance Plan Non Change of Control Triggering Event",
        "documentation": "Loss contingency period of current base salary to be paid under severance plan non change of control triggering event."
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of months following a change in control when an employee is terminated without cause to be classified as a triggering event for severance payments.",
        "label": "Loss Contingency Triggering Event Employee Termination Without Cause Following Change Of Control Period",
        "terseLabel": "Period within which employee is terminated by entity without cause following a change of control"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period following change of control within which an employee is not offered comparable employment (new or continuing) by the entity or its successor or acquired and to be considered as triggering event for severance payments.",
        "label": "Loss Contingency Triggering Event Period Following Change Of Control During Which No Comparable Employment Is Offered By Entity",
        "terseLabel": "Period within which no comparable employment is offered by the entity following a change of control"
       }
      }
     },
     "auth_ref": []
    },
    "gern_LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period within which employee resigns following a change of control due to material change in terms of employment and to be considered as triggering event for severance payments.",
        "label": "Loss Contingency Triggering Event Period Following Change Of Control Within Which Employee Resigns Due To Material Change In Terms Of Employment",
        "terseLabel": "Period within which employee resigns following a change of control due to material change in terms of employment"
       }
      }
     },
     "auth_ref": []
    },
    "gern_MarketCapMinimumToUseOptionTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "MarketCapMinimumToUseOptionTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market capitalization required for this option to be available to meet the minimum cash balance debt covenant.",
        "label": "Market cap minimum to use option two",
        "verboseLabel": "Minimum market capitalization requirement for option"
       }
      }
     },
     "auth_ref": []
    },
    "gern_MaximumCommissionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "MaximumCommissionRate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of maximum commission rate, based on gross proceeds of sale price per share of common stock sold through sales agent under the sales agreement.",
        "label": "Maximum Commission Rate",
        "terseLabel": "Maximum commission rate (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r401",
      "r444",
      "r517",
      "r600",
      "r638",
      "r640",
      "r648",
      "r672",
      "r673",
      "r730",
      "r736",
      "r738",
      "r739",
      "r750",
      "r765",
      "r766",
      "r795",
      "r803",
      "r814",
      "r825",
      "r826",
      "r830",
      "r831",
      "r838",
      "r1040",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "gern_McKessonFinancialCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "McKessonFinancialCenterMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "McKesson Financial Center [Member]",
        "documentation": "McKesson Financial Center.",
        "terseLabel": "McKesson Financial Center"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "gern_MenloParkOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "MenloParkOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo park office space lease.",
        "label": "Menlo Park Office Space Lease [Member]",
        "terseLabel": "Menlo Park Office Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r401",
      "r444",
      "r517",
      "r600",
      "r638",
      "r640",
      "r648",
      "r672",
      "r673",
      "r730",
      "r736",
      "r738",
      "r739",
      "r750",
      "r765",
      "r766",
      "r795",
      "r803",
      "r814",
      "r825",
      "r826",
      "r830",
      "r838",
      "r1040",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "gern_MinimumPercentageOfNetProductRevenuesMaintenancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "MinimumPercentageOfNetProductRevenuesMaintenancePeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of net product revenues maintenance period.",
        "label": "Minimum percentage of net product revenues maintenance period",
        "verboseLabel": "Minimum percentage of net product revenues maintenance period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal securities",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "gern_MunicipalSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "MunicipalSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities due in less than one year.",
        "label": "Municipal Securities Due In Less Than One Year [Member]",
        "terseLabel": "Municipal securities (due in less than a year)",
        "verboseLabel": "Municipal securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_MunicipalSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "MunicipalSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Municipal Securities Due In One To Two Years [Member]",
        "documentation": "Municipal securities due in one to two years member.",
        "terseLabel": "Municipal securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r89",
      "r118",
      "r147",
      "r167",
      "r169",
      "r174",
      "r188",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r213",
      "r291",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r490",
      "r493",
      "r511",
      "r535",
      "r623",
      "r706",
      "r723",
      "r724",
      "r853",
      "r1038"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "gern_NewJerseyLeaseAndFosterCityLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "NewJerseyLeaseAndFosterCityLeaseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Jersey lease and Foster city lease member.",
        "label": "New Jersey Lease And Foster City Lease [Member]",
        "terseLabel": "New Jersey Lease And Foster City Lease"
       }
      }
     },
     "auth_ref": []
    },
    "gern_NewJerseyOfficeSpaceLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "NewJerseyOfficeSpaceLeaseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New jersey office space lease.",
        "label": "New Jersey Office Space Lease [Member]",
        "terseLabel": "New Jersey Office Space Lease"
       }
      }
     },
     "auth_ref": []
    },
    "gern_Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash Interest Expense on Liabilities for Sales of Future Royalities",
        "documentation": "Non-cash interest expense on liabilities for sales of future royalities.",
        "terseLabel": "Non-cash interest expense on liabilities for sales of future royalities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r881",
      "r892",
      "r902",
      "r926",
      "r935"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "gern_NoncurrentLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "NoncurrentLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liability related to sale of future royalties",
        "label": "Noncurrent Liability Related to Sale of Future Royalties",
        "documentation": "Noncurrent liability related to sale of future royalties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NontradeReceivablesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Interest and other receivables",
        "totalLabel": "Nontrade Receivables, Current, Total",
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "gern_NumberOfFinancialInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "NumberOfFinancialInstitutions",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institutions.",
        "label": "Number Of Financial Institutions",
        "terseLabel": "Number of financial institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1008"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r781",
      "r793",
      "r1008"
     ]
    },
    "gern_NumberOfSeverancePlan": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "NumberOfSeverancePlan",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "severance plans",
        "label": "Number Of Severance Plan",
        "documentation": "Number of severance plan."
       }
      }
     },
     "auth_ref": []
    },
    "gern_NumberOfSharesSoldFromEquityInvestment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "NumberOfSharesSoldFromEquityInvestment",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares from equity investment that have been sold during the period.",
        "label": "Number Of Shares Sold From Equity Investment",
        "terseLabel": "Number Of Shares Sold From Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of goods sold",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r780",
      "r1007",
      "r1009",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r834"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESUNDISCOUNTEDFUTURENONCANCELLABLELEASEPAYMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Noncurrent operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "gern_OperatingLeaseRentAbatementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "OperatingLeaseRentAbatementPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease rent abatement period.",
        "label": "Operating Lease Rent Abatement Period",
        "terseLabel": "Operating lease, rent abatement period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating leases, right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "gern_OperatingLeaseTermAdditionalPeriodExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "OperatingLeaseTermAdditionalPeriodExtension",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term additional period extension.",
        "label": "Operating Lease Term Additional Period Extension",
        "terseLabel": "Operating lease term, additional period extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease,remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r834"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expire beginning 2028 through 2041",
        "label": "Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "gern_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expire beginning 2024 through 2037",
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "verboseLabel": "Operating Segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r787",
      "r788"
     ]
    },
    "gern_OptionOneMinCashDebtCovenantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "OptionOneMinCashDebtCovenantMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option one min cash debt covenant.",
        "label": "Option one min cash debt covenant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_OptionThreeMinCashDebtCovenantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "OptionThreeMinCashDebtCovenantMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option three min cash debt covenant.",
        "label": "Option three min cash debt covenant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_OptionTwoMinCashDebtCovenantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "OptionTwoMinCashDebtCovenantMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option two min cash debt covenant.",
        "label": "Option Two Min Cash Debt Covenant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r90",
      "r91",
      "r108"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax, Total",
        "terseLabel": "Net unrealized loss on marketable securities",
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r624"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r624"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_StatementSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "verboseLabel": "Other comprehensive loss",
        "terseLabel": "Net unrealized loss (gain) on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166",
      "r290"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income (expense), net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r879",
      "r890",
      "r900",
      "r933"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r903",
      "r936"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r882",
      "r893",
      "r903",
      "r936"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PaymentOnRoyaltyAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PaymentOnRoyaltyAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment on Royalty Agreement",
        "documentation": "Payment on royalty agreement.",
        "negatedLabel": "Payment on royalty agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Royalties",
        "verboseLabel": "Royalty payments",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "gern_PercentageOfAnnualNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PercentageOfAnnualNetSales",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of annual net sales",
        "documentation": "Percentage of annual net sales."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfCommitmentAmountToFundLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PercentageOfCommitmentAmountToFundLoan",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Commitment Amount To Fund Loan",
        "documentation": "Percentage of commitment amount to fund loan.",
        "terseLabel": "Percentage of commitment amount to fund loan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfInterestOnPastDueOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PercentageOfInterestOnPastDueOutstanding",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Added percentage to current interest rate under debt instrument to past due amounts.",
        "label": "Percentage Of Interest On Past Due Outstanding",
        "terseLabel": "Additional percentage of interest on past due amounts"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfPrepaymentCharge": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PercentageOfPrepaymentCharge",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment amount to be paid upon prepayment under debt instrument.",
        "label": "Percentage Of Prepayment Charge",
        "terseLabel": "Prepayment charge (as a percentage)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PercentageOfRemainingTermCommitmentsHeldUnderLoanAgreement",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining term commitments held under loan agreement.",
        "label": "Percentage of Remaining Term Commitments Held Under Loan Agreement",
        "terseLabel": "Percentage of remaining term commitments held under loan agreement"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PerformanceBasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PerformanceBasedStockOptionsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based stock options.",
        "label": "Performance Based Stock Options [Member]",
        "terseLabel": "Performance-Based Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PharmakonLoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PharmakonLoanAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pharmakon Loan Agreement [Member]",
        "documentation": "Pharmakon loan agreement.",
        "terseLabel": "Pharmakon Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "gern_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants Purchase [Member]",
        "terseLabel": "Pre-Funded Warrants",
        "documentation": "Pre-funded warrants purchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r370"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r685"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r370"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r685",
      "r703",
      "r1149",
      "r1150"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r614",
      "r835"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "gern_PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid On Or After Fourth Anniversary Of Funding Date [Member]",
        "documentation": "Prepaid on or after fourth anniversary of funding date.",
        "terseLabel": "Prepaid On Or After Fourth Anniversary Of Funding Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]",
        "documentation": "Prepaid on or after third anniversary but prior to fourth anniversary of funding date.",
        "terseLabel": "Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PrepaidPriorToThirdAnniversaryOfFundingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PrepaidPriorToThirdAnniversaryOfFundingDateMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Prior To Third Anniversary Of Funding Date [Member]",
        "documentation": "Prepaid prior to third anniversary of funding date.",
        "terseLabel": "Prepaid Prior To Third Anniversary Of Funding Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PrepaymentPremiumOnPercentageOfTermLoan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PrepaymentPremiumOnPercentageOfTermLoan",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayment Premium on Percentage of Term Loan",
        "documentation": "The prepayment premium on percentage of term loan.",
        "terseLabel": "Prepayment premium on percentage of term loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from debt financing, net of paid debt issuance costs and debt discounts",
        "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r652"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuances of common stock from equity plans",
        "totalLabel": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Net proceeds from public offering after deducting underwriting discount and other offering expenses",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r652"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r178",
      "r1019"
     ]
    },
    "gern_ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from public offering issuance of common stock and warrants.",
        "label": "Proceeds From Public Offering Issuance Of Common Stock And Warrants",
        "terseLabel": "Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Future Royalties",
        "documentation": "Proceeds from sale of future royalties.",
        "terseLabel": "Proceeds from sale of future royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from exercise of stock options (in dollars)",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "verboseLabel": "Product Revenue, Net",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r602",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r769",
      "r804",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r1034",
      "r1035",
      "r1043",
      "r1116",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r254",
      "r602",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r769",
      "r804",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r1034",
      "r1035",
      "r1043",
      "r1116",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r167",
      "r169",
      "r181",
      "r188",
      "r198",
      "r204",
      "r207",
      "r208",
      "r291",
      "r328",
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r490",
      "r493",
      "r495",
      "r498",
      "r499",
      "r511",
      "r535",
      "r607",
      "r622",
      "r657",
      "r706",
      "r723",
      "r724",
      "r820",
      "r821",
      "r854",
      "r993",
      "r1038"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r561"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r138",
      "r141",
      "r142"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r153",
      "r620"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r561",
      "r608",
      "r620",
      "r835"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, stated at cost",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r561"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESUSEFULLIVESOFASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PublicOfferingLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Line Items]",
        "terseLabel": "Public Offering [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingOfCommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PublicOfferingOfCommonStockAndWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering of Common Stock and Warrants [Member]",
        "label": "Public Offering Of Common Stock And Warrants [Member]",
        "terseLabel": "Public Offering of Common Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PublicOfferingStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering stock issued during period shares new issues.",
        "label": "Public Offering Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingStockIssuedDuringPeriodValueNewIssue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PublicOfferingStockIssuedDuringPeriodValueNewIssue",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, pre-funded warrant and warrants to purchase common stock in public offering, net of issuance costs",
        "label": "Public Offering Stock Issued During Period Value New Issue",
        "documentation": "Public offering stock issued during period value new issues."
       }
      }
     },
     "auth_ref": []
    },
    "gern_PublicOfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PublicOfferingTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Table]",
        "terseLabel": "Public Offering [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_PurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "PurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase warrants.",
        "label": "Purchase Warrants [Member]",
        "terseLabel": "Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r394",
      "r401",
      "r432",
      "r433",
      "r434",
      "r444",
      "r517",
      "r574",
      "r583",
      "r600",
      "r638",
      "r640",
      "r648",
      "r672",
      "r673",
      "r730",
      "r736",
      "r738",
      "r739",
      "r750",
      "r765",
      "r766",
      "r795",
      "r803",
      "r814",
      "r825",
      "r826",
      "r830",
      "r831",
      "r838",
      "r844",
      "r1030",
      "r1040",
      "r1088",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r394",
      "r401",
      "r432",
      "r433",
      "r434",
      "r444",
      "r517",
      "r574",
      "r583",
      "r600",
      "r638",
      "r640",
      "r648",
      "r672",
      "r673",
      "r730",
      "r736",
      "r738",
      "r739",
      "r750",
      "r765",
      "r766",
      "r795",
      "r803",
      "r814",
      "r825",
      "r826",
      "r830",
      "r831",
      "r838",
      "r844",
      "r1030",
      "r1040",
      "r1088",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized investment gains (losses)",
        "totalLabel": "Realized Investment Gains (Losses), Total",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "gern_ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification between prepaid and other current assets and deposits and other assets.",
        "label": "Reclassification Between Prepaid And Other Current Assets And Deposits And Other Assets",
        "terseLabel": "Reclassification between prepaid and other current assets and deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "verboseLabel": "Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r885",
      "r895",
      "r928"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Long-Term Debt",
        "totalLabel": "Repayments of Long-Term Debt, Total",
        "negatedLabel": "Repayment of debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r653"
     ]
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of line of credit",
        "label": "Repayments of Long-Term Lines of Credit",
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r343",
      "r371",
      "r564",
      "r584",
      "r610",
      "r773",
      "r774"
     ]
    },
    "gern_ResearchAndClinicalExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ResearchAndClinicalExpensesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Clinical Expenses Member",
        "documentation": "Research and clinical expenses.",
        "verboseLabel": "Research and Clinical Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r767",
      "r787",
      "r1112"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r875",
      "r886",
      "r896",
      "r929"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r876",
      "r887",
      "r897",
      "r930"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r883",
      "r894",
      "r904",
      "r937"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "totalLabel": "Amortized Cost",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r151",
      "r186"
     ]
    },
    "gern_RestrictedCashAndCashEquivalentsGrossUnrealizedLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "RestrictedCashAndCashEquivalentsGrossUnrealizedLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents gross unrealized losses.",
        "label": "Restricted Cash And Cash Equivalents Gross Unrealized Losses",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "gern_RestrictedCashAndCashEquivalentsUnrealizedGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "RestrictedCashAndCashEquivalentsUnrealizedGains",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents unrealized gains.",
        "label": "Restricted Cash And Cash Equivalents Unrealized Gains",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Investments [Abstract]",
        "terseLabel": "Restricted cash:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedInvestmentsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Estimated Fair Value",
        "documentation": "The aggregate value of all restricted investments."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r743",
      "r753",
      "r761",
      "r762"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r102",
      "r617",
      "r645",
      "r647",
      "r654",
      "r686",
      "r835"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r195",
      "r196",
      "r197",
      "r199",
      "r204",
      "r206",
      "r208",
      "r292",
      "r293",
      "r309",
      "r479",
      "r480",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r502",
      "r504",
      "r505",
      "r507",
      "r509",
      "r547",
      "r549",
      "r642",
      "r644",
      "r658",
      "r1149"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenues",
        "terseLabel": "Revenues:",
        "netLabel": "Net product revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r220",
      "r228",
      "r229",
      "r244",
      "r250",
      "r254",
      "r256",
      "r257",
      "r391",
      "r392",
      "r602"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Revenue interest payments",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r220",
      "r228",
      "r229",
      "r244",
      "r250",
      "r254",
      "r256",
      "r257",
      "r391",
      "r392",
      "r602"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r768"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecogniton"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "REVENUE RECOGNITON",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r393"
     ]
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "verboseLabel": "Revenue interest payments description",
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "auth_ref": []
    },
    "gern_RevenuesBeforeAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "RevenuesBeforeAdjustmentsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues Before Adjustments [Member]",
        "documentation": "Revenues before adjustments.",
        "verboseLabel": "Revenues Before Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease assets obtained in exchange for operating lease liabilities",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r834"
     ]
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "verboseLabel": "Interest expense recognized",
        "terseLabel": "Payment on royalty agreement",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "verboseLabel": "Royalties",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "gern_RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalty Pharma Revenue Participation Right Purchase Agreement",
        "label": "Royalty Pharma Revenue Participation Right Purchase Agreement [Member]",
        "documentation": "Royalty Pharma Revenue Participation Right Purchase Agreement.",
        "terseLabel": "Liabilities Related to Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offering price per share",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Combined public offering price per share of pre-funded warrants and accompanying stock purchase warrants",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "gern_SalesReturnsAndAllowanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "SalesReturnsAndAllowanceMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Returns And Allowance [Member]",
        "documentation": "Sales returns and allowance.",
        "verboseLabel": "Sales returns and allowances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r972"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r1004"
     ]
    },
    "gern_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario One [Member]",
        "documentation": "Scenario one.",
        "verboseLabel": "Scenario One"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Two [Member]",
        "documentation": "Scenario two .",
        "verboseLabel": "Scenario Two"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r402",
      "r970",
      "r1004"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureACCRUEDLIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Activity Within Liability Related To Sale Of Future Royalties Table Text Block",
        "documentation": "Schedule of activity within liability related to sale of future royalties.",
        "verboseLabel": "Schedule of Activity Within Liability Related to Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental schedule of non-cash operating and investing activities",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "gern_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of common stock reserved for future issuance, which may include but is not limited to outstanding options and outstanding warrants.",
        "label": "Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of common stock reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of provision for(benefit from) income taxes",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the entity's deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule reconciles the federal statutory tax rate to the effective income tax rate from continuing operations",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r819",
      "r1075"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONEXPENSEFOREMPLOYEESANDDIRECTORSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of allocation of stock-based compensation expense related to share-based payment awards",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial instruments measured at fair value on recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1086"
     ]
    },
    "gern_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Reconciliation of Gross Product Sales to Net Product Sales",
        "label": "Schedule Of Gross To Net Sales Adjustments [Table Text Block]",
        "documentation": "Schedule of gross to net sales adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of components of Income/(loss) before income taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under Term Loan Facility",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosurePROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r561"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of aggregate stock option and award activity",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r104"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate the fair value of employee stock purchases under the purchase plan",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to estimate the fair value of stock options granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r818"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r786",
      "r794"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "verboseLabel": "Segment reporting, CODM, profit (loss) measure, how used, description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r783",
      "r791"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r234",
      "r235",
      "r236",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r257",
      "r781",
      "r784",
      "r785",
      "r787",
      "r789",
      "r792",
      "r793"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "terseLabel": "Segment reporting, expense information used by CODM, description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r236",
      "r250"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "verboseLabel": "Other segment expenses",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r235",
      "r236",
      "r250",
      "r787"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r253",
      "r256",
      "r782",
      "r783",
      "r790"
     ]
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense [Abstract]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "auth_ref": []
    },
    "gern_SeverancePlanLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "SeverancePlanLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance plan.",
        "label": "Severance Plan [Line Items]",
        "terseLabel": "Severance Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_SeverancePlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "SeverancePlanTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance plan.",
        "label": "Severance Plan [Table]",
        "terseLabel": "Severance Plan [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation for employees and directors",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate number of share instruments issued under a share-based compensation plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Shares Issued Under Plan",
        "terseLabel": "Aggregate shares issued under plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period of stock options",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of new offering period in a case where the fair market value of common stock on the purchase date is less than the fair market value at the beginning of the offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Of New Offering Period",
        "terseLabel": "Duration of the new offering period"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of the purchase period under the employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration Of Purchase Period",
        "terseLabel": "Duration of the purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "negatedLabel": "Awards granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of other than employee stock options granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of restricted stock that vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to estimate fair value of awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (as a percent)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility range, maximum (as a percent)",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility range, minimum (as a percent)",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate range, maximum (as a percent)",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate range, minimum (as a percent)",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount of annual salary that can be withheld to purchase shares",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Of Annual Salary That Can Be Withheld Per Year",
        "documentation": "Share based compensation arrangement by share based payment award maximum amount of annual salary that can be withheld per year."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum duration of the offering period under the employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Duration Of Offering Period",
        "terseLabel": "Maximum duration of offering period"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of offering periods in which an employee can participate at a time in the purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Offering Periods In Which Employee May Participate At One Time",
        "terseLabel": "Number of offering periods in which an employee can participate at a time"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum percentage of annual salary that an employee can choose to have withheld to purchase common stock under the purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Percentage Of Annual Salary That Can Be Withheld",
        "terseLabel": "Maximum percentage of annual salary that can be withheld"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award minimum exercise price of options granted to employees with more than 10 percentage of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Exercise Price Of Options Granted To Employees With More Than10 Percentage Of Common Stock",
        "terseLabel": "Minimum exercise price as a percentage of fair market value for employees having more than 10 % outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum percentage of ownership required for granting of options at a price not less than 110 percent of the fair market value of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Percentage Of Ownership Required For Granting Options At Minimum110 Percent Of Fair Market Value",
        "terseLabel": "Minimum percentage of ownership required for granting stock options at least 110% of fair market value of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of consecutive purchase periods in an offering period in the purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Consecutive Purchase Periods In Each Offering Period",
        "terseLabel": "Number of consecutive purchase periods in an offering period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Stock options and awards available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable at the end of the period (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercisable at the end of the period (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total pretax intrinsic value of stock options exercised (in dollars)",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock options cancelled/forfeited/expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)",
        "verboseLabel": "Stock options granted (in shares)",
        "negatedLabel": "Stock options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of employee stock options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value - Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "terseLabel": "Common stock, increase in option reserves (in shares)",
        "verboseLabel": "Common stock, increase in shares reserved for future issuance (in shares)",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance at the end of the period (in dollars)",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Stock options outstanding (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares - Options Outstanding",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share - Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of options to be granted to purchase shares in each year during the optionee's service on the Board of Directors.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares",
        "terseLabel": "Stock options to be granted to purchase shares (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of options to be granted to purchase shares upon appointment to Board of Directors.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options To Be Granted To Purchase Shares Upon Appointment",
        "terseLabel": "Stock options to be granted to purchase shares upon appointment (shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period (in dollars)",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Life (In years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Life [Abstract]",
        "terseLabel": "Weight Average Remaining Contractual Life (in years) - Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantRollForward",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Grant",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Roll Forward",
        "terseLabel": "Shares Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPERFORMANCEBASEDSTOCKOPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options cancelled/forfeited/expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Stock options granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "gern_ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum expiration term of options granted to employees having more than 10 % outstanding common stock.",
        "label": "Share Based Compensation By Share Based Payment Award Options Maximum Expiration Term For Options Granted To Optionees With Ownership Of More Than10 Percentage Of Common Stock",
        "terseLabel": "Maximum expiration term of stock options granted to employees having more than 10 % outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareBasedCompensationForfeituresAndExpirationsInPeriodNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareBasedCompensationForfeituresAndExpirationsInPeriodNet",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled or that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Forfeitures And Expirations In Period Net",
        "terseLabel": "Stock options cancelled/forfeited/expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r410",
      "r429",
      "r430",
      "r431",
      "r432",
      "r435",
      "r439",
      "r440",
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "terseLabel": "Supplier",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSTOCKBASEDCOMPENSATIONTOSERVICEPROVIDERSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "terseLabel": "Supplier",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "gern_ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with public offering",
        "terseLabel": "Issuance of common stock in connection with public offering (in shares)",
        "documentation": "Number of new shares of common stock issued during the period in connection with public offering.",
        "label": "Share Of Common Stock Issued During Period Shares New Issues Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Closing stock price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration term of stock options from date of grant",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term range",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Stock options exercisable at the end of the period (in dollars)",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options exercisable at the end of the period",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance at the end of the period",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock options fully vested and expected to vest at the end of the period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "verboseLabel": "Percentage applied to common stock market value in calculating purchase price under purchase plan",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r103"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Public offering price of common stock per share",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Combined public offering price per share of common stock and accompanying stock purchase warrants",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "gern_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank.",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_SinaDrugMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "SinaDrugMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sina Drug [Member]",
        "documentation": "Sina Drug.",
        "terseLabel": "Sina Drug"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "State and Local Income Tax Expense (Benefit), Continuing Operations, Total",
        "terseLabel": "State",
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r999",
      "r1074",
      "r1082"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESOPERATINGLOSSCARRYFORWARDSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r69",
      "r72",
      "r73",
      "r146",
      "r172",
      "r173",
      "r174",
      "r195",
      "r196",
      "r197",
      "r199",
      "r204",
      "r206",
      "r208",
      "r221",
      "r292",
      "r293",
      "r309",
      "r374",
      "r479",
      "r480",
      "r487",
      "r488",
      "r489",
      "r491",
      "r492",
      "r493",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r547",
      "r549",
      "r563",
      "r624",
      "r642",
      "r643",
      "r644",
      "r658",
      "r725"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r221",
      "r549",
      "r602",
      "r650",
      "r659",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r845"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r402",
      "r970",
      "r971",
      "r1004"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r221",
      "r258",
      "r549",
      "r602",
      "r650",
      "r659",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r685",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r704",
      "r708",
      "r709",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r725",
      "r845"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r889",
      "r899",
      "r932"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail1",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEMPLOYEESTOCKPURCHASEPLANDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYPRICINGMODELASSUMPTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock options and warrants excluded from diluted net loss per share calculation due to net loss position",
        "verboseLabel": "Employee Stock Purchase Plan",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Stock-based compensation related to issuance of common stock and options in exchange for services (in shares)",
        "verboseLabel": "Shares issued (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in connection with at market offering, net of issuance costs (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r69",
      "r102",
      "r652",
      "r725",
      "r760"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under equity plans (in shares)",
        "totalLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r69",
      "r102"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock options exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r69",
      "r102",
      "r416"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock-based compensation related to issuance of common stock and options in exchange for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with at market offering, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r68",
      "r69",
      "r102",
      "r658",
      "r725",
      "r760",
      "r854"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuances of common stock under equity plans",
        "totalLabel": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture, Total",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r69",
      "r102"
     ]
    },
    "gern_StockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "StockPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase warrants.",
        "label": "Stock Purchase Warrants [Member]",
        "terseLabel": "Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72",
      "r73",
      "r93",
      "r687",
      "r703",
      "r726",
      "r727",
      "r835",
      "r855",
      "r998",
      "r1024",
      "r1092",
      "r1149"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r728"
     ]
    },
    "gern_SubsequentDirectorOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "SubsequentDirectorOptionMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the stock options to be granted by the entity subsequent to the grant upon first appointment to the Board of Directors.",
        "label": "Subsequent Director Option [Member]",
        "terseLabel": "Subsequent Director Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r566"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r567"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYCOMMONSTOCKRESERVEDFORFUTUREISSUANCEDetails",
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Investment Holdings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r675",
      "r707",
      "r844"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfInvestmentHoldingsTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSEQUITYINVESTMENTDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Holdings [Table]",
        "documentation": "Disclosure of information about summary of investment holding, including, but not limited to, investment with value exceeding one percent of net asset value of registrant."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r674",
      "r675",
      "r707",
      "r844"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureConsolidatedStatementsOfCashFlowsDataSupplementalInvestingActivitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental operating and investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESTAXCREDITCARRYFORWARDSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "gern_TermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TermLoansMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loans [Member]",
        "documentation": "Term loans.",
        "terseLabel": "Term Loans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1103"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureCOMMITMENTSANDCONTINGENCIESSeverancePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TotalGrossToNetAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TotalGrossToNetAdjustmentsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureRevenueRecognitonScheduleOfReconciliationOfGrossProductSalesToNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Gross To Net Adjustments [Member]",
        "documentation": "Total gross to net adjustments.",
        "verboseLabel": "Total gross-to-net adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TotalInterestAndOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TotalInterestAndOtherIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationOfReportedRevenuesToNetLossIncomeUnderSignificantExpensePrincipleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total interest and other income (expense)",
        "label": "Total Interest And Other Income Expense",
        "documentation": "Total interest and other income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r1015",
      "r1016",
      "r1017"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DocumentDOCUMENTANDENTITYINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheAMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche A [Member]",
        "label": "Tranche A [Member]",
        "terseLabel": "Tranche A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheBMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche B [Member]",
        "label": "Tranche B [Member]",
        "terseLabel": "Tranche B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheCMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche C [Member]",
        "label": "Tranche C [Member]",
        "terseLabel": "Tranche C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheFiveMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Five [Member]",
        "documentation": "Tranche five."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheFourMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche four.",
        "label": "Tranche Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheOneMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche one.",
        "label": "Tranche One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheSixMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Six [Member]",
        "documentation": "Tranche six."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheThreeMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche three.",
        "label": "Tranche Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TrancheTwoMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tranche two.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r364",
      "r372",
      "r508",
      "r534",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r625",
      "r822",
      "r823",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r836",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1084",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "gern_TwoThousandAndEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 equity incentive plan.",
        "label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandAndEighteenInducementAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandAndEighteenInducementAwardPlanMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYEQUITYPLANSSCHEDULEOFAGGREGATESTOCKOPTIONANDAWARDACTIVITYParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen inducement award plan.",
        "label": "Two Thousand And Eighteen Inducement Award Plan [Member]",
        "terseLabel": "2018 Inducement Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyFourPreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyFourPreFundedWarrantMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four Pre Funded Warrant [Member]",
        "documentation": "Two thousand twenty four pre-funded warrant.",
        "terseLabel": "2024 Pre-funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyFourUnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyFourUnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four Underwritten Public Offering [Member]",
        "documentation": "Two thousand twenty four underwritten public offering.",
        "terseLabel": "2024 Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyPreFundedWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Pre-funded warrants.",
        "label": "Two Thousand Twenty Pre Funded Warrants [Member]",
        "terseLabel": "2020 Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Public Offering of Common Stock and Warrants.",
        "label": "Two Thousand Twenty Public Offering Of Common Stock And Warrants [Member]",
        "terseLabel": "2020 Public Offering of Common Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty purchase warrants.",
        "label": "Two Thousand Twenty Purchase Warrants [Member]",
        "terseLabel": "2020 Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyStockPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Stock Purchase Warrants [Member]",
        "label": "Two Thousand Twenty Stock Purchase Warrants [Member]",
        "terseLabel": "2020 Stock Purchase Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyThreePreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyThreePreFundedWarrantMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Pre-funded Warrant",
        "label": "Two Thousand Twenty Three Pre Funded Warrant Member",
        "documentation": "Two thousand twenty three pre funded warrant."
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyThreeUnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyThreeUnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNETLOSSPERSHAREDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2023 Public Offering",
        "documentation": "2023 Underwritten Public Offering.",
        "label": "Two Thousand Twenty Three Underwritten Public Offering [Member]",
        "terseLabel": "2023 Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoPreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyTwoPreFundedWarrantMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 pre-funded warrant.",
        "label": "Two Thousand Twenty Two Pre Funded Warrant [Member]",
        "terseLabel": "2022 Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyTwoPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Purchase Warrants",
        "documentation": "Two thousand twenty two purchase warrants.",
        "label": "Two Thousand Twenty Two Purchase Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoStockPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyTwoStockPurchaseWarrantsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Stock Purchase Warrants.",
        "label": "Two Thousand Twenty Two Stock Purchase Warrants [Member]",
        "terseLabel": "2022 Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "gern_TwoThousandTwentyTwoUnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "TwoThousandTwentyTwoUnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock. = 2022 Underwritten Public Offering [Member].",
        "label": "Two Thousand Twenty Two Underwritten Public Offering [Member]",
        "terseLabel": "2022 Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureDebtScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSCREDITRISKDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureLICENSEAGREEMENTSDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureSTOCKHOLDERSEQUITYSALESAGREEMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae, due in less than one year.",
        "label": "U S Government Sponsored Enterprises Debt Securities Due In Less Than One Year [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae), due in one to two years.",
        "label": "U S Government Sponsored Enterprises Debt Securities Due In One To Two Years [Member]",
        "terseLabel": "Government-sponsored enterprise securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprise securities",
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae)."
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1113"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSRECURRINGBASISDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury securities",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "gern_USTreasurySecuritiesDueInLessThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "USTreasurySecuritiesDueInLessThanOneYearMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Treasury Securities Due In less than one Year Member.",
        "label": "U S Treasury Securities Due In Less Than One Year [Member]",
        "terseLabel": "U.S. Treasury securities (due in less than one year)"
       }
      }
     },
     "auth_ref": []
    },
    "gern_USTreasurySecuritiesDueInOneToTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "USTreasurySecuritiesDueInOneToTwoYearsMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITIESWITHUNREALIZEDLOSSESDetails",
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureFAIRVALUEMEASUREMENTSSECURITYTYPEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Treasury securities due in one to two years member.",
        "label": "U S Treasury Securities Due In One To Two Years [Member]",
        "terseLabel": "U.S. Treasury securities (due in one to two years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt discount and issuance costs",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "gern_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityPublicOfferingsDetails",
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r465",
      "r818"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease related to prior year tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r818"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r818"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESUNRECOGNIZEDTAXBENEFITSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits, if recognized would impact effective tax rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r818"
     ]
    },
    "gern_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.geron.com/20241231",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureDEBTAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Upfront payment received",
        "label": "Upfront Payment Received",
        "documentation": "Upfront payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureORGANIZATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r135",
      "r137",
      "r139",
      "r140"
     ]
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceAbstract",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureINCOMETAXESDEFERREDTAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/Role_DisclosureOPERATINGLEASESCOMPONENTSOFLEASECOSTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r834"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/DisclosureStockholdersEquityWarrantExercisesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expiration date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1087",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r216"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.geron.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing basic net loss per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r216"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-9"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0000950170-25-027982-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-027982-xbrl.zip
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M<-"2;O%4@9VO1WBF,E'G9\3V]+N3_4NGEYXAX>R;NY'0^ )J'O0]-^ ZTTQ
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M%F-6E(B"T2"X.;$1L\TXU<Q+7[+L7#2H*P=;JZG^\2'('(%8,< ])=66!"W
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MG?5JN]S!;4XYL@4J1^&*\XX2':+!&(0D01>0+Z-S"HZK%#I[)M6AC.85B9H
M@.:T)Z:=+VRD(CYR3YB*)8BD@XV=+3#N\($B4%+=.#T=+ET4,0// @<"8Q81
M.%)8*.X,X3(EDS')6'7NY.B1XMSM7.,;1SS,VBFO\]&PZ2W!DUL2G!4Q #>
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M]RT6,H["1!DHDX'(@%*7LB+.94V,B4GPR(4NG<U/Z6*QZP++*@W &)\X-@@
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MQ14G26]F*SOM@?=$6<I&)@IV1HH6C(.7.%--$!6E82DQ;$'>69;JH-NX2'<
MYTU'/'F3"0=,>HO'2Y88;V2DT>? .FNW.YU<O*+@62E.1<<(*]@:0PM&K,N
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M\'>!/YCPFN6DB7=XX.>8(, 5G/#$"C=:.LON?9XPU<:3FJ1E,L>O;SZ^7[/
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MZZU3DK[M^T]G!SJ7WM><R*@>W[5GP1)2L\X>.]^L/=CW*?2E:DZK.8"=;]M
MZ4I#,:\W3N6U'8@QJ;X87JPF:SLL3BHZ)S^;UFR4?EO* 1_%85WGDU$-:+_J
M&JLXABB.GWO#<=,_GDGC94]=FD1**T.TV*VQ9$]DQ!$D@CD"6BVH9*E*^MY8
M['0J]F!W=#AZ@Z^^?;(A5TEF\?VF6Z)Y$^"V%LUK[#&BI5:$A@"V)E)P*APS
M49X3M]9FG50CH-&.P[;@ FQS_[CI-=/9)YBW]CF#84'\A0@M#YJ),<>*"/BJ
MK0X[>?J\ )\8]_,MF.MFOK2B!K3X&>7]9 E33#BO;Z:5&I)N,/J:,% Z&VO4
MMIB\^.8@]_LSH%_]<$DE_26)WZ#J@0*3RMRYVEPLBUJ21LW,&JY<)MF90*3V
MEEB:/'&:^T1%$9PNJ(7U+F[(94YM9S7H&MS<M$F-__0)^!\%Y'#2H:;M<85<
M_7G8 GIT64X+/Z8?QDF'+-26H^,*V*-5>G/U(06Q"=SU,AB#95_^"'S3KSU@
MI-P_ODQ 5E=J]#_O*Z_WBMV<?>\3T7_;EI#!ED\[KF5IDW&!F!+ OV%:$"=R
M(2HX[85Q3%P<H1-C"$XR2[2-$6&8)%YZ2524+NBBJ.3EHNQ_:#V\M_VA'ST#
M'[(WN=L?^W_LOGX&>C$""?O-S\_H6;TP&!^2-&QG@N,%SW[ASZ6@SPVESRGV
M)3[[4AVK->O4:B8X8WPTG$#^V!\V*(!'H,SR-Q#&5$";MO<4_./?QX-< 04J
M3KFLIC>;-JCZM3\,X 3LMD&J::.JC0J50_3].*L2G3YK!?HB?VW=G@8,,Z"V
M]HHSKS>[7=LC<@JHGE>IAUAO6+<+:B\\&/93:_(O5J+"?D]=JR_@V57SRQE,
M?I#@+]R4'J(!</^ 7B?[<G)YZTB-FUG;CP$ PJ;Q-7! Y:?/:!#UG;U#.1FU
M!P#O".!JLYC*L:=BIK9:DK_-H1Y[ ,.<M5RL.B6FSY&C@'-:]KFO 5GH4<#E
M!B3P) 0XY$10,9M:6+(C8#^H+<91YB^T=K'>69UY(<Q3B5-$+7%*<$)#3$X'
M[0J]K-5"*ZIM$[S=5GYWQJ,V0@TK/V-1)M(];U3>O7][C5G10C]W5#Z7INM&
MI3GHU'HN5:3#4\K<2 /)#?4=U:ZFWN=+A/F.T3!J>=:1@KPY\+Z"X\1A UUM
M3'0YFA+YO8=5S*)AS>E,WIQ>'</=0$<-8MZ#6[_J ]V?5;F)_@B).PE2?[\3
MXE_O;/_Q^YOW>[O5N_?;.Q\_['S<VGOSNGKU7]7'-V_??'SS?OO-F4;3#WWP
M?8T,\*5*P.K'F-^TA/N2NF-W_2CSRZJ5[_*CZZNB3_,B%S!X]K)WOF9BV]49
M'E.2S#Y!G5HUPWXO79'F<8\1S Q^NB#(><<!X%,%>6G&S (&X%VYE]5?2OL_
M*B[;@*7N\FT[_-XWZ6W97-F-_5OVF-+ZL&)TZBK_K9V8]\'7H^;R'?^F;KE;
MUG6WQE@O:I[%TG/Q/F#JQ;2=#08<+AFC-VMZ\QD[:@V_'I\>Q9YTWT-?M_*#
MP=CWJ\.<VW@*W' NI-&<Z4UXIN/7:9<O)K?:-*(>GE%/>OE]8UVE!Y"P7QUG
M7U>3%*77.6:<>5:)B?\M-Y:E-V\FT\N=:M)UC=B%/5JHK+Q[]^XZ=39+3;QX
MI@.NV5DO]=R.L3/ZXWX(_:PM8JTM2L,Q+.R>X/U4RRW/?VV'0>'V?,KD+%J'
MM<XYN/_=:N.OFT2\+/W\E4R"J:!&$&J/#P<O4Z\Y ER_B=^VRYC:%[#-P)W_
M&#>C7CF>K:B]BH :>7DTG&0Y;M89U=)G1.P3\IT2\: ^YV#T!OW> #9N!#9O
MX@V<_0)N//EX\EJM]?(%&';3][^ FIO"[OGW.YL$C4N>>^.YU\'\YHMKGD/W
M)]SP=15YT"ODJ$N$[I%$"Q:X*WM;KWY[4^V\K;9WWN]AV. !1VM.^*&-)P$2
MV$?>/R730KNMW=5;OV.[-48WQ!WZD5FQ(>WM?Z8WV+6_6N6\PQLC@LO5CWNT
MGN-Z3Y:S)[>-\-P#0W; =_X :O&6A<FMAGZPZ;5GO><-M@C_N;W+.0]ZX]L8
M6-_JK%A?15A?'=1X6O$7, VC_=[5I"[EAJ1N'Y-RQ.,+!&%M&0/"OBG3WH(5
MMC[N5:=.AE\:0UROU!\\9-*)\5@W\P-'^;!BE\<6[AU9>""(?B(%L!.'^^SV
M4K XII]UC;B*[1<=C%AA ]2%LJ%>LM%8ZXA[ZXBM)Z4D_'[=:_[<+QYSUKXQ
MB63Y*N,CK*-Z.UG'6FW<CC.Y7>N-KNN-5T]*;X3]\:#.(..?<]IO1KZ4?<SI
MPKR?52J1/TX65>WBHJKMZ:+6&N5V/&OD6J-T7:-L/RF-$O?C<<CUM.SY>)5:
M9'M^(6O-L=8<3TQS\*>D./C^43T\PO7EE4*/#R>K6&N,6VH,M=88'=<8XBEI
M#+'?SY]\'_5&S.TPR94JCM]P,=6'T\6L]<=:?SPQ_7%%UN;CU!]R']XU[S>^
MY-'Q?NHU6!T]KE<+/W[''^VV2ZI>GRYIK4LZIDO6Q_97'MMW\=Q^?7#_&,R+
MNK5Y.;.C?(.K&V_J9>KHBEV>WO?L1D\_7,)>3].?+QHLM3]IFK%?AO7^:?N)
M9G]2AKV?_SE>J>F:=/28%9Y<4A8R*>:OWK1]/)[#%?UV<-3N7'N-W[&_:=VT
M;3?>8:/!NOHPKN.!;V#[VMJE89G> )LF3ELKKLWC+<WC.D&AZ[I0/R6HK4%=
M-;G^G-,J%=3_]W&ZB/]_K2_6^N*)Z0OS1/3%8?*K!3$7>JFC&SYNFMZT ?O6
M7$/7MR<]D+>'@S3IP(_7@*(9]R=-F'>.\F11:Y!R6Z5CUDJGZTKG2651&K__
M3RQ][XW:0DW\HS_[]S0\N$K5]'_FUM9JF?]SNK[Y6&&U%8;C62?&"O,QUYKG
M=KSMZ%KS=%SSV*>D>.S^R3"%_=.>\OO-^.BHW_[;UZM4/*<H9_>TX3TJH-VY
M!1Y7K_W(KS7-+34-6VN:CFL:]Y0TC=N?#.IJ]GL#Q#3^4YVGV@:[^^S[&%>:
ML3E9'$Y*0/WR>GZ!DREF6Y-94;X=<3.8_=F;=HX^U52G>&BMDF[']$RLT4_G
M==*3\KN<WY_.GVLFR5QIU5D8V]/EM$KEP\F2UJIDK4J>G"IY4@5M+NP/:\ V
MD[;OH 16J45VVJD,[TX7L]8?M]4?:_>H\_KC296ON3B7"(HY-K[&=6'&#3#8
M2K7)J4>#J363=55O)^NJ_GU<]YK4FTXG;$?.?*CS9_@EZ)_F:#JV<*U_NJ9_
MUFFD5Z>1=C*/=)U(^AB,$K#L$S)*C.[/QI$U^R?#7_<GHU_WV^DLJS5,T[4]
MK]Z<3*;=F4VF10]Z>S9 IOH5)])BC&X=ENN<+5JKG7NKG:?5>8[-*9OY4=6K
M5#:G&F9[;D5K97);9<+7RJ3KRN3V[1WN7@W3F>*7*U01WY_U<=D??AD KCCH
M'>T#OACYWF _Y$$NJU1*TT*4XVIGMC;,_-R>+*]ZA<OKM:>2D^];3'2::#K-
M&+U8"].6NTP+8M8:;JWAGIR&>U+M*)@X44B341_# 6J"9O)73ONCE29QS;31
MQ_FUG5$]>[4'.#6)%#Z?YE],AV"_@\<>X2"GM>.VUD1/41,]J<863.X?U;U!
M[!WY/F9T33.D]DO.S3Y6P/56FN3U8;:VN62NZBVL;9)3VJYOG6O1/36S/JNX
M\JSB<P>/*OZ^/JEX#);G]CTONFQYU'[^>M +O5%S64G#?A,/5AL\G*SM7*[P
M255#M1L/<AKWU]:G>]9GK6KNK6J>5$L)IE=:$G5VJ':U.SZ$-U@WF;ZUVECW
M?%RLVNC"],".J(D&/O6C59<2[+[[]?W6WA\?W^RNE<-ME<,WN\[,YGGC/[^C
MR<FK>-V;DG71+__QO_;>_+8S>_E;KNB<Z#3C(Q"*TV7J#;-((AGYLKKC0I>R
M=:V+,VP+$$:U3QD[!S;5$,SI)+Y633\HU:^Y'@Y.4K3:#C9'1]G7F%[<&U2C
M@UY3;0T&8W"4/F:X9H1UEU/\0_Y6_=!>\&SRU;,?*U_GMOW?M)O_\:6/V*CV
M\%?3^^&J?6\ ;EF:]-"!1[6+K@8>WO_Y_!O@:UUXA?8]X3K8WGAPZ0K@[UY=
M@2EH4Z$_YVIRBKQ1_4>NTK :#$?PKK!UL&?CNAHW&;=J.J7^Y D5)L'X02\W
MT]Y 5Z[RPCZ/AE7O\*A_7/EJ_G"HK6E]CI?#HX=U,_%"\=='<,'PY"AYW%3A
M^#F^!:[L[%HV[LUV=G%<MV)%M=;+#_+R[Z9J82*_SZOQH)^;9L*87WK HH"%
M0?7BH>*T&6C[VZ^CN4OJ_,]QKT:Y06'B]&6K))ZW?["7LP_QMZ>=3L]_^R6?
M_V3<G'R"FF+Z*<CT[%. AJ@2AQ=UTG.0S=<@FU]0?\0SG\.=,&KTY6#8!Q%&
MU0%*:!R:7NJ!GL1WF-SMC[]5O_4.@0H);_;' /]5_0VV,PT/IP)[/+G=Y/KW
M&;>C#Q_ +5YM_'VC7<-X!$IL>O7&=\IA;>I+E^SII?*>>I^KV/=-@\#]4R;3
MX>BX'K@AO 5>,%WX?[<.XM=-(EZ6?OY*)AG=Z%O *XT/!R^GUF83O[V \#<4
M8'Q<V\P-AC^G?8)GBVQ_2,".O#P:-JT9W9R8FL_Y91A^Q1W!MSP9X/[UAAX"
MX[<Z,J&7NR)=H.'9!&J@S?3_(RD/3@(-T]?I#=#=(\W(UZ--/QX-7Y[] C9Z
M\O&$\FW$P1=XVTW?_^*/FY?/7ISPR&7.74O1.:8X1]S%TO"I&-E3>G55$<Z?
MZ"UE3P!Y@X5*T\CC;\/AGPC43QLSK1'8A9"<W%!"_&O7 O>+WH^]>436&\3^
MN*T0G4*@V23W&0X"S^X#:+;JW?-J<C@P\9).G;(Y^+3$GJ@7EC-;CSFWGN>G
M7F(Y(P']J02<]DV;E+_V!I]Q@&R%<[$G;N-X,,W/&[60S0.@R_T^_A<L^/CP
MZ+1V%O:O=1F/JT'^#'#Q$&Y=PQL!Q1#0@F/Y&3$N@$2TX;BT<3]5T:/?.$&L
M)Z]Z"<R$.TP^G6+C[1DP!%2:>J7,/1#09JD!.XX.AG#K_!4XJ&DFJ!K=R1[\
M,QP#% 7 >-VN;%1;\+)SNS0-#ARTG'OZ::E@TT?#&D,G%<X3;_WI\[L[>>,
MSC-V9THW>#KX#,WP$) U=O)_?CT1(ZP+[M]#">Z5Z9OB=K7..9 GUR )(&N?
MIAL =)SRZZ$_/N\7P-8!I9KS'P/@&ESX<!((N/#QEUZ_?_ZSY@#WX?RG\;(/
M@6G^<=D20@8R?LX7EU9GK.>^\#GV ,7LJ='%GV3 @X>7?7$T1!T!_'1A_3G_
M>?(9,-7)"V#"V#C/?8,[/\B?)LU&D7,R1D7J^6!$C>'8>;I@E.=* 9QX8O"2
MR/8^3"4*E%9^WD9%L(5I'YVIJ=1<?9M)]NIHN%G]X'\$)ZUUJD"V)XP[CA%D
MIHS[J&/:V=9U;$49^6T28*Q^ *4[RGWDOA]/YE>, -*-)O&84DV?6,&^]TZ;
MD?6'7P"&X<JJP^/<'Z9CA/! A5@UQX,$DHNL#O>;N_#WU[N3%\1XT0 6UBK1
M67HMZMW_R]Z;-K>-)=NB?P71+^I<.2XD2_)<BON!EB=56;:>Y>H^]WTY 8*;
M)$H@P,8@F?7K7Z[,W - 4I)=Y;9<QHDXU99$ GO,<>5*L\B2HVAG[.>"X;QL
M$<Y*"FZBD;'HY4>_/(X1L(-(JNU\-DYAZ]!I1#</B%<^',^K%R/^W<OC"#?#
MCB'R2\G#D/.A\0 6L&4A8Z,/PI"N([F;\)GI\_0U$GLT_?0>A^+XAN*(A%MG
M[$2SHKLVY'+;9?F-GC'I' >4GJ800>XZT"S)XZJ#6&DRN43+8$A7$GVUR'06
M/::HR/O'8I*\IX%#/L:1- ^+(X-RUR2%$#?IW/XQS41XI3%'%_.<YHDXJHU,
MQB3HBQ9"MN5P*\91F5E+)[JL5E$ZIZ4PEA"/;7ZLQ#R1*Q@YA T4#BT6'71>
M<SQF84SC5C98;/P-:XH0!AD<)#+(IJAIK8Q?JV (Y.',2^FQ$BUQLQMY<UOQ
M)R<DN?)R:8]8L/=0^O+:531.R#0(=M=?<%)[;C$C5+U@)%,_DDWWDZ2[; L_
MD1<C:9HJ&[<B!J*,=LCN(U-@='06;[EH<>''D/ 4VLNGKASG?BDR+3=LOD
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MOJ3-F3!+>IV2I<9"6NN> YY;Q!Q%;-<1SIMMRFRB]U52S$STO"PO+.27=$"
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MKS%RB?7M4K4EY2GX]9MV@6EITN[XS>E9K+8OAD9&1+F491-Q@BS4,L,BH,,
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MK SK'/=-J:;@O@<[$UJI^;VH8CR*BGX>0QRH#OR2MRQ;*+%2)L]\?X[ON/,
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M+>G-*E@*"VG&.T@V"ZJY)UFY4#6Y$"7 XEUIH]BN (VA5-@FG9)767?IQ!K
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M15L&#Y,9\YO(%9LFJ7")&HT6+NG6-\9V0'%(3QTY^Y_1.YJ*5)^B.FT#/TZ
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M?22SA%Q8"+03%Z-^@<(R.)V#1+E[*_ -0T!*TI,QJ!=P\8D]*!;\P'D7;2V
MW@W"75.V8-/A (^'&!<XB3-_$DM4-C7^. ;-N$XD5('G 3JDX_"%@S":N9^$
M=/2X,I8SB*$QZ!!MC7P!ZR^\O<T]F0'+D^&-$\M;=TU]B70FV//7!*:#R%MI
M-^()Y:3X2<M:&%BIA4),Z8=*&TT >5:F0AHF:\5+KW 7++CNK68Z98,$Q/\9
MBGZ1SY*NU28E_X07[LHO37]#-CU3][%#[5<ZW#CFMIP =Z14@C*$6J)AB9#7
M#7;(H'^VIZ^"R_AVM5C.X12_"1#.IP'">;!:?E!=,TJ3B5EP-QH5K(S)TP)?
M%=U6QN;V&&T#RHN^D.!,J&$2R[>C)8M5X_]N4.S$)3V^YE?08?2:)&_F*VEI
MWTDHD"2MTTS44LK!&M1E9O4Z_4!P"]P4E<1.V\*_B$:(Y:+8ODL%H$SGW.:E
M5[5#7F-N"W76R@AN7*:]*))N#SH,4HB6>&XBH:PE*CGIO4FU"KUE=9Y[LT!5
MP+(=YUD]EVC<W>8N>IZ7Y>1.H?!HR=ZA,DQC;8>T/R\_+?/2=152>M0OV&JT
MRJ"KP\8*G>Z$'X'3A?)Y6#]M?:<1B7_3JH9;QJ]HIY'F:Z4%,AFT*L(^>'SW
M2V&_@'0;X,C;%F^IBQ=6Y2Z31K'<C>!6N0<"F\;9 O$_!?["^!TC<L>V_+\0
M.,^-_78@AUU%P&][YWM!@?[O;9757.O.9?H,-];\>B6<PE'#54"U22L3#D@K
M/$%R)=-(JBHI9HKE5W)E;H3!954LH;NC'161*>B6IU+JI8,6 #/BCDNF:) V
M]1'[!<E,Z$\#/R"9H"8#?^"VAM 4ILF4@:%4O\I<,-47*9%RY7I0!10HK,L8
M0:]P =.B#XZ2""@ML[I?Y8+4<BHUL-+&CB;VX?\BQAKM>/EWS_4QTYYHW#I,
MGJ%?C%TE M<VDPOE2X[5K\DVG9.(20O,;/5]R,8?\H*_OW'S+,V'(";(:*';
M%I9Q<"]*ND#S0B$<E@HHK'J>EGG.)?-CLH3$FV85"L85A/-SX#72EEOE%45Y
MJ5%]_BC;?Z54[;A"JHX0LJ&--'$7GHF+,FO9<1.7E*U,^RBZGI-L8NN9VEKF
M5YER&J.NLP4]2EL%5"7(6=HOTT59M+E_&W*,I<PIZ("(H2O77J7<(Q]=WD0,
M09!OR>.EYV+2V'>P(.Q45W&0@[;-"BQ93<MQPR<A$RX8E5 D8AF<XQ*ED+F3
M3>SYD]:W7NQ6Z/#01()><B-U^\5 6FI*$Z/>BXYMR2GW@L=QR<#'A3?'T9@$
MV20X+#I2[0S0UBUS$)E/RPS@J3G"+VXZM0P!XV3>^'"D=4! M;Y%]>?L42QR
M-&GNLLP:*DR^KPJ3P[5:A:'"Y/L*,'T6??7?Q3A0/<+R6"4I%)Z3L6RT\CA5
M":&KA_3=QO><*<RT93#5+Q$)$4834)\)2,?^<QPB3>N4S!!6W8Y0;<W5"/L[
M\N.[==;P.FS[ 9I#8P3.Z?6C&Y_@:NRL0%.GH3(96N;;+M ]JLDZ9NH"C?9\
MTE8)HCPET.1"2OHFE#$/=:Z=DGG.I=#7>>GH?UT:"HY%<EERX&Y1%IQ@91K,
M*WA2/=.&FY*BJS$71)LN*$RJX-><SVX 4E]!3W,C",.%#"*)DM260(<.7^ [
MAF]PD:$:/7QP:+2\'\^V75T+,RN1%@Q\:'*!Z8A*(+4RX9MBG2\?<)'.-)(9
M(E+ U\CWW8<2KE:WD2DPMTKQEZW-[W\1L)B-7Y4337:&[UQDL7!L!*;&-K1?
M]^.ELJMNA8,/$+OA^/=8<#+$%!8=J@BE4LRX'3S_P=,)RNYYMD5^V*?&X=+U
M"_"$&ICY8!4]W#\"#!.-=QW-UIG*3]IN.'\;PV/\W8,C5 BF53:6EP8/C%X)
M>:3]G(7_G\3126,6T<'(N3<?F.AFH%FY%GZT'I7Y46[+%Z[8>;M B^T?994^
MYQ1)XP!VC?G><KMNN-6D*UL?.IW3^8YF>3EFFB@7*ZQP^-EVRAJ.TX*&MB/(
MI897A8F^,XC9VK;90>S665%[T2@'6]5,*%95E4%4D!B$2V_?(# 7#-I&4)D\
MMF2H]8*6<0YC[M)X$TZB4#XFZJPY&Q>0D<8!>W??EA#'6-O625M#'^/0B3I+
MUD5V?5%IWZIDW2BA"F]!(S%K^DVWLL;V.*0U$7HQ;[SJ8V&2>"N6QU27"^.6
MC#[)/[O%9A7.,>D@<J+38*"\8N+=+OH8RL90"4_'?E*LX91UDS6'>7 32Q%L
MQSSH_8V@L.Z-NN7]<0'"R\ 4=N>-2:4/]Q\\B'; U^+#HT(8M.$4W8N6XNCH
M.5@K^0<%#,:!4GZ__4,X_\Z>KY/P(,$ID:O<O<EZ%E34,WNHWV<-OH+NE?$)
MGW>@6&6P@&3]DO1T1R>YYX226+.;],'FC)5< QEHW2^Q>;07O2NOY",6^JBD
M6Q-/K85);])=]AOLR?CVPYL$,)<.VMCW9>:D,G[SHFIG9$RC8<>Q)OILJD!C
M(Q_QM _D:6DE(II9<8>!9T\?1CN^+.A>'*DG]@;4Z;O_2C[1B<"G50@SY9N2
M>\1*)KM%%(=-*Z\_&KTS4<H7KM/9;%TL&4T)O2R!H$%.W&$YL5W-B.18EQ)M
M+7)AD[ (D#>?)R_>WW2PG'Z3E[$K&I+<'#[LM$J6N]XAU@LNNZO;>WG<+59"
MZGWC$/6>)_0.D@F,&D 0\\SC"XY)ATKRT?!E/3\[9L[&)8)(#0Q*>80L.+WO
MF!8ZS?)HY^7Q/0M"P8/>E7O1P\?/[A_N[S]SU]Y]BQX;?#AFF$)A+%H!>Z/6
MA+?C@FWL[E]LI9Y[^DLZ&R40A".2!?[E+T==6V^+8/DQ+O_?)9=Q1U;@3MA(
M<@'BS6+P*L@M+-NJ;CD&*ST+.M)QW9GJ06RN]:S4T(8'YU *VK>$O%7/<%6#
M^YE+F-%]" U%?%N5C8 %'\4E>R2<X]9<^$76J,\8NR0(?4B3'PPK0LQO_]E1
M>578LF)Y)@<>X>0/%W^X^-])&#$TQE]:C3\8BF%E@0W8J2RT+><5&<1LS>8B
MR&+UK"=(((Y+J9W2"WST E,<"LN$M/FVH3!;^64?&3B'$VT9@"=4,GQYO<#1
MA 7;]YM7>]%UB'*/Q"1<WPX\QLXYV3PDETG4ADZ6>Q'#9$VP>2(D@._KFS63
MQM-'DA15>.*K7?/]U*:*F)R:Z?2M/ZM5!NAL<%I6IF3:[+6088BI\RIR^QMK
MZ3E2K&+AQ$:;-=O+!1Q*&GV4I3,%UX;4=8@7ZYC^CJ]"F[LXCCZN-;2-3SCE
M&^1WI;PDE9ROW\R6A@!F]+TH>N'1;4C$!WW,-FW=W+**9TWM80@!GIBQ:DP/
MQ5.U&5UL;A -#H??Z1CI)F*5LUT*1MEAQ?PD-74:=;LE\*;U -&;-B[!(5>6
M$DD?3[>=O!" 33\OVKS)EGG@4J"#'7Z)?FQY.#@D"+A14-THG1:[)?8]I>X^
M8T?=^R21C@C+G;86!IC=]P6S>S# [+YS"W4@<M[@HQ:?&\^VGEN7!+)+[>]L
ME+#[:Q#>L0'C&P._84A?@'2+Y%.V:/G;/AX4D8V1Y6&H_L$^9V-MX(X?H 8Y
M5.%'E/.@34;T'K7Z$EO[[?SL(UF)WE0C^Q3Y;=<-Z=9SVA3]MF%OM5O"F<GH
M'4?6@R?=L6-8X:CJP/)R'<?!&H#^MY,>6P!4X98 :3>ZKU"V[8%[&E0&6-:D
M9-XPEZ8&58-V[@A3L[Z#2L;$!]KIP?8HV6+=\C)A'+PP-V<1V*BW1M-:;FDO
M>L\=]6XZ9D&ZIY.N8</#EH#=D-;P 1!KV4O+&F<U&E\&N"5%-#B'(0I'*M1R
M+L9QH;3Z^F"\C\!_J=3J!.T!PKSYMO<2[2]?CISYC:BXSS-J?N,:01;+%+H)
M#Q$/X>^>=A;"Q=E5P(E("R3&>69O@?OH]1"9K=F0S;>B[;0[#H[_9^Q7?/NK
M0@M\IRW['_O>GH327CJEMSB062 KV5.^1CP&X.=U*<E??/F;)!*G&5?1^Q[3
ML8=*<[M>^P,]3P!7$JK6(M1>K6%0N>_B'7!**[G_4M"%+HTX_-(KG14N>Z$+
MF-]HO5WCWG/Q 7>F .I5^\,/0-7KJD6K):)*#&\(F@%*.I@[FFVJI+\+1_Z'
M$0!?N+._%1RZ.T>'OZT\0G^WM;I=I0J; LB@05[\NZ413D7EE7(;^$]A+QT-
MWKUZ,2))5S9SEX)S[;-M1QP@-&U#0]'9(+SWY4>V@:/F!3WX/[R(C 6B)[W'
M^_ &>C&2= =/CKCMN8 6@F"W=$]\OV7T6>WBU7XB[GEJN) @#H=P%M0L<^@B
M)(#M"7#N_PB!SVM8"1L;+T?=60]7<^7!P EW541D60IS6+I'4W/%0"P:S.'^
M?DRG(UJ:$M'+4".5XN5L77UY6!VTHK4/0R27G*@6/2*E+4&^ZKHA\EQ.+Z!'
M(FK:RX*#]^+DV08/V@,A!8Z95D(7QA+9+9(+5X2-1;WRE1^<)D'(&,98G>1=
M/VCK5LIAS;1TG[O.EY4-?_.GL05H!8]VF^$^P1HMX%2'.#<^8#[0;$]IDWRB
MDXIVH+*E]JV3-0K /ZT0GO[U^N NB!AMJ6H62^FJ@5TF$X5,)\.@>=DKET4*
M@SY)X<20;CP+"9M[""Z/>O4U%VL6&I1AOX+U=F#;Q98/0$/W7*5GVXBYY]G\
MEN8S./^AL/F@#,QZ676R,&%MOO\E352Z6'N",LTCT9#,4D4!8__I=72K5L(T
MQND<1M>[PLT:Y5)7[!N./0%ECJ0;)] J"W*VW^#7!C/O7J70W'6]9!'/X9B(
M+HA0Q/,:2$;04R2X&^;FNDGR.+"5?,)^I_.@#5]3]C$, 4PS-*KRPO@J5B>P
MRRT3DFOM-$U6I>T";3K3;AK0+;6KIU IDD$R))J?36KM>&MLO:YCV@H\"Q(,
MBA'IL49PJ2<4GX6]<&_@P8&\LS;1J-N_N'/;F:T/98,BS/C@N7V&"I0V@!K!
MWF9#*0@@B$UL>JX5DG04->=M.N-QU#5<MSKI#G.C&2 2C/4_9YD#\Z3[08\)
M\ H[\:;3EGD) PQ_2!.RVQ; -Z_.&]6_N)Z3I.JXY-W&U,PY*,@,-E#'MKAC
MO=VTC*1.ID;9T P;0!GH\@78D73WCLW3,=H_00@+2V$SKQ@<DDQH&)9+![W*
M%23&M%O2C$+:C-1_B80-AX57Z"1#D<E<E2@9XR93MQ/"VY_LOKO^V)OD=*1=
M38 A!",:S%PK=3N;!P_ P?A,%<!X-XE5'BDL; V^.JL;/(4"V]N\SD,$NY=G
M^Z4M#'JE/N)]"O)3!X_6NZ=NNZVW:)]Z^DK") ABDR!;RF7#]G&PRR&2?#_X
M,"BMH[0=9# FNH-B[#%2961A)5V'3+I\!W61+^G(T=.Y>O^E=J9C"PM%H&5!
MQM)% 1M*S]U[YLJ+GI?E12SB6\<$*;[EB 7=T<3_$4R0K5O;;I$@AJX3?7#0
M"4Q+>@A"DS&XS+R1)8Z!0 !!P64*+P)?H^$V?%ZK%\',;=E>[Q*N%R4!$!9:
MY(GE#2AH0.D<+,7@E8<AZ&@&Z+J\.WX9A\Z%253PJL_<%;PX? 4REZ20F+1P
M;$SAD55,^;)2U+/SS), 11?DI0/U(I>N<6V= I.AZQ'I#70N4 I'A:^])=(
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MB.O&U92=8.8T =N!L,92M,@[9;?#,0%^ZM>=BU<<,R#&(=UR-V1<G,*P7 )
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MA3$*\-F#N'"SU$PXDN>0^B\7@I#FGX$<JZH$2Y)UT=M;1J#OV'5Y2W=.Z!7
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MS'\7U>43_P?G-9^DR9P.'RB&&>UWJH%R%#:=L@ES3L/)[K1*'( YWQ<PY\D
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MICFXBO$5)-59":>BA%E]\R]8G?,Q$,W;E7W3SO/Z>EP@N;!3YB1@<A "7DD
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M(U$;;J_2P-J[?@C$(1P4*;''(>(6&O94!NX:ZZ8$:5-I5+GTR03]]KKD_IA
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M\B3^G<04O3@\$R_OV1#K\,J@N:',R-][69>;3M#'/B;<E5<3B'[0.!#8KTZ
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M2Q3E) [SL-%Y3=J8WR0MQP5!3VN.U,]M!QIXHQPAT*%?]##+!0!=4ZPL%Z*
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M WN6[DNT$X-0P?,TR73DIB^ZE%PV]-#P@$ =Q,9/'V^PY(YDF&!ERMC-ROS
M95P2?A'$ 6Z1SHW6:VK[L/A<]'QRTROO)-^A5[D.*&+%C\NT/\A=T66N6O&V
MK=]V+4=,&*?PFG<3C.S#Z4PF/L*[P4=XW7370%U4=1S RWD*&][&0G:EJQU-
M2L39@?$T1)03:,>3 M<YA=M?3)T*MB9&QY<JEUT8<9.&+#AQH.H8/'RU<A#:
M.#CL,?'8 ^RH@(C)_GQ7R^A*N:V-PX+8ZVJ3XJA+6F->)\*N@&'DN!.FFLK
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M([06X5%8;I'ICX5P;N[$=7Q,K@5R%VA@S+> :^\Z+>\P>09<$(FIK^%=\>;
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M,O;,_7\LBS)BSH,LA1^M::OKJI^7INY02YTOS0H8W\U).#1;A]P;/##74<&
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M,F>J5#=*]<1#Z[D73QH*ZQEFQX"=*Q[,RC,]MNR:P:#5B.$(%;P8Q*ES2NU
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MF,E2*U=O^NU!9T;LP?#/0RT9F<H $.%?+_7&8SW)$3Y:4DK<TY<RTNL!V.N
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M$? 7Q!FDA9X6^CDL]#[_-9/J%4_FE+M=N6F#=$F5+TELX$I [*'05:I8'>P
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M7I:-G(0$JYL"+AQ#*/S2RZ;;.3@:RE43J<I*P0962<#HIZ[*R[+*$$:THRD
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MU=;51%4OA7^$VG#[AE8M\QKY,%&K;L'"QD&E;Q[<E'FFM9_6_MVL?6H-EM2
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M+J-Q?<-G23/[-UM)&H1Y (,PS](@S ,'C:0=*NU0?WC]6- N4J*M>3I&-I"
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M6*5MZ DOB9(&JS95U5RA,I'+\>6OAXK#M3U6EC10,NQ53)X"?T56@3IO#S9
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M89[O62-4&DMRBATMNM =8(/$.N4NOGF&=8$3ZUP]>@9XX=R2&)Q?E%-CAP7
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MB<A^CS823?7TR%8 3S!O"R+*Q<M%C/"(O!7)R6Q]1=Y@9&'QZV0B6ZK4J.O
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M=+3DCUS5)Q"-S4GF")%AI>BFTIO@7X%#-&\!G]]A<7 Y*@_1Q,]@1X%@M]_
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M-U.\TD+D7R77F];UB=?U;6<LF+N#IUJ9VV!< Z>9))U/;=E5*VK:']</JI+
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M@@S[YLC;;P=X7 &\$@<0Y^64)B BQ*;.D>LW.GZT=[C.Y>UJ*Z6\T%930;B
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M4UMPQV<!JV.# ]BC \DFSL<T3'M,>!YB;C/:,XC!:;U*/=$!\! *FRL\=4/
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M4T2E;>\\<1'<NTZ<,X:Y///>4Q"D0A8TC'8*FRWY'48GOXODY0?R8ZFNXXF
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M1W-'$INTAN ]I#D7A$!@>+BA"&Y.]#@4IJQF<[?.<5=S@<9>:;X/2 T]DH6
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MG(8 61F@RB2:7LFM18[._D@0/TXVE&A?!/J?4^0,FW3+I=!I3=]3U_.?1#]
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M5E8ES>V\/C!-B68_E_)UJ1E+K_#4[W6AK";VQ10$,N%S;%/-\6HZ.$;:+9B
MC< >(P;5SV'#1,785XOYK<"#M:"#XXX 1*94Q?US[%X)>U=-+!KA]*,MI8>
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MR->O;JISS44]H7@E3X1J?<:0P1C+10Y>([4]+@1W?@3$]R[DHC20C6O5M1>
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MR.T5+9U!?\3OGP$?R,0[,!82;G60K"P2HT"PSKC )#TG2&#OZ!=2+59E.R(
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MC/K&.(P[]<-,E&]Y@?T#N^5C).S0?"-U-4WDP_PA'( $7S /(^S0A Y ?04
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M94+E.; W:- (-=;?>Z!ZP[GV/I$WB!CBWPBA,Q&;V6XREWU.=<33! -<IAX
M)AHWRA>IQ$YN@)?EV ",>N88>6)D+Z9B@I4!F8I:43-]-M",-G=D10DU^(^B
M0M7\UWR69&)]17;:2BW1[NG!339,5GG)GT1N.>% L4VQ B<GJS*",-N*<]B
M807&")PDC"E31"6(<O_FJB:I"IKRY0*U9LZ@P]$(U"-[Y8$.-C55$U[E$*F%
M:OBMG6IF:1C"Y#3F"E6C#)AV47ER*N8)IG*KZ2FZ]E<^0K Q%%.66I3(?N5D
MV\U"3C'@O*>(5NVI;K$65P\45]]3F?T;ZL,A9$'TKVD"EF<%<2U['"C8GE>Z
M#,AZ$ /.E'Y)/@,L&8$_3K%+,Z-9*L;:AZ[^S;$Z50'M4YO[R-.!NK*_A;>D
M& >WC\?.$M(E'_#X0(IC,K9)20!V.Y:?&N_G^H^QYW]E)])\419GJ0XS^!=&
M0707+'AR]S3UYM*[1$6JE-RC^U5@=37/)8 7P\N5U^G,BWPU3TS5^^H)@B$=
M-8#G)$((KP88RO"JC@=+8J=T"U98!%[NN9H@5),A4ERE$34N\E!G<Z6<:8Q#
M%<W>&CS5A99(^C8Y/8RN&4:S#%K:M)R@Q+%FG@HPQ[2S%<\8_:0BMV-^/4HG
M5OOE,\OW2T_+VIJ9$V!QL8@,>8;[E]TL:+@'O2W ZA1_J1QE5 &?Z5;<3$/9
M9BCAYI\>#D%+<QP!R6'NMG,J@_G*.[;QUHK;BT4S^CO9/C%B5M3O.U/S0F0
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M3\JWP!=J&NNL6$EHV2H4YW<5D5ACR.WD PN9VIQ06P:P;749N6IF9MJ%FWM
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MU\8(O5HAJGQR!67P?#&,5(4'$@PO;X%(2 IY"2^^BXW ?U37TT24129>J<F
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MSEX=MD%$<8\54,1E,NI591UN!B]O@01+"GD)OZG;Z;0[/ZKK@6,B;Y&)5YD
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MNTHJMB4] E7VB!M.\A-1W%T)XB,9MBH%\&T-)D@8;U.=**B$^I4L20.BHI&
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MJ&TD "RBV;? _1?JNP.]_]8G2F,[F8YG)P;K-'ZA+T4X5&Y\RB/ K"5@63[
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M)3*;**Z=SQ4_9B'!UO&>T1Z1X)?M^5G8 9!(RSF5HTLW^ZN05.G;+5]>N%]
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M+6*I6FGYO"U&^06+G>>?/C72V/79)[1TWK2E<[&FVP68!6 6=!%EP"S8H5F
M.5.Q3A2*<^=CLAS'2%F"D?,SC6/<S)ATI;K+)HYFL_W.ZP!';?F2(NY1LJY
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M_?,U7\-'G#W:MS;X"CW",HWG_]OD&3"_PY[?#<=MXL8,SG4X\X CN-:#>^(
M8WNP2/=?I"U=9&]KY=:&W+:[=$Z1_6_^^@S'SQXL; ]/@ZEE9XN+W+*K<*=-
M^)=5X^BU\QS-0HN5K6G]QGDB7=B*K0D\T-O^(C<L$M#;0^B- +MMC=U\HS"@
MLD>E,@!/0(!N(0 %!  $  3HKB1N'0$(( "XLT\;:F"1P)W=FVAM9Q%SNTSU
M_.TPFGP930LU-$4OLM\SZ^G$-\P.W:XO[;CZEU$3M4G1YCU?_ET0UBVW^;;+
M6/?$F9WGMS]P@S[:KW8XM<6++M#805Z[.(3RV?OCDX&TP2K!*H'V@5S!*NW#
M*H'V@5SMW+."OH.[=L,^C$=FFDVB<>F.]:*AA<:#G2M7 [Y;JQ>4.RZ)7:LC
ML&'H\, +!!A)21*G2&EE$8NQ1 )3@3@VF>&&I#I=:7?!"<E5;C2*4\L0HU0B
MC6.*,DJH,C')J$U7>V(%8'XS'EV<N(?Y0?RS/_ER,BW<4MCQZ^_98.JWX;@H
MK/L_TU[+BS3I,?E(!<P[KI$=H8&.KQ( /@#^X0)^K(3"G'&4^+:ZC!J"5&PY
MRG66"9'9S.!D&?"5Q%EF>8QHSA/$2$R0R+1&EL0)5DSEEIF= 7[>_VX-^J\=
MCY[]@@#F >8!Y@'FGSS,)PD6*DXS9)CBB&6*.AO=_8&))CJ1A*>)789Y*7T]
M,.NL>:4<-3@V0#K/*"(I3KG2L<Y- C#?&3W<;1;)(\<Z'Y!6<H#ASG=]AUZ%
MC7+KAN3SK,:C*S7PU?<Z@+%/E,LAZ+GC&JM=$4:0NTY;1D88:[7FB%+LG%GF
M?%^9ISEB.B9*BXPKLV(9<6;RU!")E&+N.Y3E2&MBD:5)GNLXRW'6H8@GDSOO
MK0&Z"/0)$@9HOWNT9UK3/,8H$](ZY-8:J9QA1*1.%$D$3XE:1OLTIX(Q;!'1
ML?.=#4N1R'6&L,IY'C,:)RGK#MH3F@+:=TH7 >U!P@#M=X'VG$C#C6;.K$_=
M'VF6(RD=Y-.$D-AA.!%ZI:>J='8]H00CDZ8*,9E3)+#DB,M<<*,RF7+2';3G
M<N?=#PY)%S?/]81;="UJ\VE9/GOX.;+?+WUD$^[3P7VZ_;I/!^L(,@BW-$!3
M#UO:8.U 4T%3]T':8.WV,L\%[O3-=O-D5$RB41Y]'HU,X4O4&8C70G)+EU$&
M@FX@=[L^[E22QS%'.,TQ8BK/D!"6(:5UJF))E)#Q<@"<ICS+LSA%G%'_G90C
MH?($L5CQ6.L\8V8EN646L/,@[5O^OJ[B=BV%N7&/< AT=TOG@"8AC[PCXG6
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MGLY1_#A2+8_P-EYT0T)>VE*3GEN2](YBO-HMY)JSF/I')?Q77UW/N.E!G<_
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M4OX[5"&1I JE-C>2:(OS6( ]?2CV-!0'VGUFR.GDBQT[+6ST@H-,$3 )P"0
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M<I$*Q'SFOLJT0%H*D3&<.I2W#T[HV3D%\![FT">^8RH*-  RMJ<T $?=((@
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M+".(I=9@F:8B%N0A.2^W6+DA\'6SD7MCA3*20 7*CFD>H#O(V)ZB.YBR((@
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MY.F*^=]VOLU6T9_TL(#87L>T$Q@ 9&Q/&0".J4$0 >P [+HE8P!V ':=$$0
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M?3+C*9@$8!* 20#^#P@B@!V W7!E#, .P&X0@@A@!S(&8 =@]UT((H =R!B
M'8#==R&( '8@8P<*=L]N@[7VVN'(%,(,!\1U+9%RQ"',-</$:\MSP=GEI!J-
MF!I.'8J$>\29TLAHGWMNF$!,#$%K<S6I5M("QYM9@76.[>BS&4^,G837L^:#
MF80/P2V:\7P<VO4I'[^$.&O"^^ FIFW',:UT?HF-4T#>AOE)_&C^O'M'6,[V
M?C(':"TP \@8,,,0F4$&IXR0''&'#>*<))2G%B,I:Q]HK(,-6\QPGW(+8(9G
MK[70L6/_=1E)@]*,3ZND0$V8NHMJWIAI.RG*4IF5M@"Q [$#L4-\"P01P [
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M-1Y3X[5GLA9[(8'B MZ]: = ?F *"" /,@8@/PR0QZ%6HA3B4Q<0E]$CBZ-
M3K!(M%?:;>_=_.::G<<'^:^9^TPS8(%A:2BP ,C8@;( Y+)!$ 'L .R&)6,
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M#$P[@0% QH !AL$ M;",,.D0CB$Q $\_+$[^6^1!!($#K<W6'H0=,D!QW>Y
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MZ6'H58=")]-?UQCT>M9\R AT$E\7_"F>?OG+KIJNC1B'*N-!J2A0 ,C7 5+
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M,32:&)1" N"#? '@[QOP*>7!$QM1LN.3S5]3BY2R.N$_4819X@W&CQ,P?%S
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M2:N<(C6J<3X(,&B)K! J$;/UP6M.J;&/$B+]^PK:/JR0;5>VA*Q'FNU]E_Y
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MB 1M"2="14-W4?CZ(-OA76C&,_^F![67H?OORJ+8M%(Z8V9'UH,>2:;V;4"
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ML.3L5@&-)MA5B=GR]\Z;[>(COH_63$R_R6(=K.QB+*MD<3(-UZ'@'&7^4LJ
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MQ_63OLRPN\N3I0>'#"#7*,7W"" OEZ'"(NKONCCBNRZ."&!R.YCTNI\G[J8
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MZ(?W>DW.6[EIJU>\%1,J-68]R>I>4)SFU!ZW?=A7M1;[K%MD_,N*?ZP'#\>
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M$L/F_C3UW-Q&9:UFH]W:/1E"!%]_,6N[[FM'W4[KGMEPU#R.[^O7U-6IE4
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MAZC>3X=J0"F@%$CB$*@&E )*@20.@6I *: 42.(0J :4&OCT\/[@I'BA?>[
MZ,\FBA?K7SU]JHE-.XT0_.;_>-W,VDJ<?SV[6),QTMTCAU0GH]^?,\0I[ ^L
M[SON\>H%MXKEN$"I<!@Q)E)4I"E!5NHT%T5N!,DW1BIJF3-N-,*Y\L<4KD"*
M,XP(,RI+,592ZILC%<.4O]YDR!>+EW(^O_8W'8/SNUJ,F)T1G!U\9\A0A/
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M"7).@IXPLZ57EX.#_(<:H?]]:.S_!K*>#/IS[JA.B\([G=8[G84W :20VIL
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M9I4*PQTQ"&?4("9PCJ3-<^3RW%B;IUG!U<VIS&$ZWZM5I/+%XJ6<SZ_]3<<
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MS\?+;' 7HAV,K4-F3&@M%O-\H;.;"94C#,63:J:GC8N[_@60NOZX7ONHO'6
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MZ3M=)V_5D+>I%9VVY%WJFVA<-/6I+?96.V_QWR9@Q=?/-AY43AE_K)?L,OD
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MT9-6)KS7)??)XM=OEGQ\WN[""O1F9H\,7>3+AT"&JS;3]<C0(T./#%WERX=
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MO#]^ @E^UC#;O[9+<3*_\-/2PN^N_+(RQ0WB,9CFOF:]O@BLS>"UU]54S^6
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M)X5S*0E&,*YL0;5S6QBF\BQS)B4", XTK"A(D<.-JA!Y;KFQN0F/P6+BZE;
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MPK*@X)[,$%,X24* AZ14">?]HZA1<43IU?MO>X%Z]@+5 W3/3P<&T,9+G08
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M4@1K<K^GCFVH1%>1XC>_;^TI\\<_FN(9BU,/Q#WG]$!\2R#V)J5.I06A:<H
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M\(*\5(%(83PI/,]);H1DWA7,IMD^'*D'@7S%9 _X772ZGEU2J!/:I"=3?UA
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M]> =^%A\*4CGT4)9^ 9XCI8B<H2 @9^L"D=\?'RDOHAGSC<.) 8BX2LPDRN
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M>Y.E+V%F<#/.>L6K6ZD%6*L5,7X&F#5JM["MY9/:T'P]AM4\$Q(E5L.M593
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M KPA9Q7AQAAK@Q!6;/4*8T*GX$3!/8KA-@%9$*,D(T)*FV>!F8P]&P$N#D:
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MQMOQ1712YWY%'>Q0?6O[^,N+"P\K!?!]61="_]PTM '8GL:M]$">7YJ&-NT
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M!CF?(-= Q_E[.[O6\^G7>RC::&T# W]M(+61C.M"O[OH]5-1ZTE1$1(&)R.
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MJ"7%+"J29,>4#67^8Y3Y-W%,GV[P%/I.36#14H41IEYE/@=OS0:-=$J"1)K
M"G8V,!V-S]]MC.3#EWJ9,6=L3/H^6']=9VF]=[Q (L[F-?!PG5(*(-P_9/=D
M;;TW2=G!B@]6_$C,>7 IP"E;\J2"DA9T%'<X(AXXSM#M#@GFN8N8!"SV=(9J
M[HRDB 2B\R[S" J1"N0U2912$T-DO;'D-T.WLYZW)^TSY$-"\HZ&7'MC".-(
M8YM;[N$GPY1'BA "[)H\#O;1V/R8AIR,.:9C06F_>;97GN;AO.=60\1RSPC
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M @Y&.:/ 5''VI_\!%.VW);[*X;G]>+2$\YV-?LER<O7W\-5J4BVKT_ %G2/
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M'-EI[50SKB^SDU%=763_'1:@"?HK7NZN15ZK0>:\AR^F3PM$#2/\ B\;Q9N
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MTPGOA16<<D<-"QV8(M3;->]FTGO3/+T2ZB7KTD?3MV,^0[$ZO3GUEJ*S=,.
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M%C@_6$)V>!%R=8'=9FP4EC1\ =PUL$%S!+](&1/6-[!)^#@>&%>/P$,+6;_
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M5S+TX&<*Z;PH4!&.7!*<N4+(UY!_1I^PYRC%DCIED)T\?+C &_;,-M>SW6;
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M/!J^O_X#D+K]NEW[&/U0'N;[3O6_J<OF_0]_G7')K29@6-,YMKBQO,M=Q:U
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M@4W"*VIWU55\J/_1\M%,*":C#/&'<P>L?Q!"3+9JN7WZB"]1/4PB(_%!D]M
M9MJ8&$AL4"?9^ *D!IA]I$*L"D9T?C$)3^F@H\(#^]6?KE^=#8=1&OUX% @=
M#E@?-2!YSJAQXR:CNQ97JP8A5@+$[E?GU:C=CS%'W<F0FITVIA+)J!V0:$Y
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M,R9:+:BT!:QAAP/16V==031I:G$)2JE:JM1575&T6JF^3S5-U?5J]6_V6,@
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M%P#D!LDJ><M,;A!1Y,HQ^J+,5<#C H8&&I>=68PS)-"X?(,,&@<:!QJW]0*
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M=-A I^/>]UIQ8%\=5U15)>T-]5P5E*7G%#'4K'OM>,,T7S+-5SIT ?4T0K.
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MSA:=GM [_N>?OLN7H_&D][)A@5F#PY'M&O+.#C.I6)BXT!X%^N+UI_)[7%-
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MC<9KV"FVB<X.E2BJQ67UGZWXG@Z/>"5Z+K.CJ0T&Y76ZUDS'DFN2AX$G%DJ
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M1 %F0D9'"Q'*.H0C<WD'NM:5X[6ZHF'D,P]JE%]?<*^I;Y.*&MTN@L /4PL
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M7)%DLE-'@L:-C^"1VE)=7R]E2B>-]*3$AD+5Z-KI4KVD;>$--$_<4E%OO&J
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M[AX>1P)KM#"%2'4E?=(U"RJ[,4RFDBFQ2!<4U*F.]2E3M66P)6,H29Y9![T
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MP+1C6KN #861--O;6PI1YV<@5(?'B65!F4#\<VN[9^=+Y_2(H'0A/Q"DB7D
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M[L@6D(D"Q+3?([I[+ITT>S$B*XK%7+\M$"%[AI?MB;D\Q$+=.>P9$CKV 1)
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MBY7^+=^\E3@<%G=%'G?J<GN)LL,(/SGK'$!++>6E"TA8R'CQ R\@^=B,>W!
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M4XO-HRBGQ96042^LCX ]"P%QH:FGVVHKC_'CG(W%%07&P7 @S%+'Q% 8C@5
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M][O-]FR6&Z%_X:'YQQ/N=KD(>*78_R;1+B<->8O8!MA\HX P9<'ZNI=NGIT
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M0L6I+%CJNR*/.W7GN=#;\&+'69-@$$H69!A$[-,PS&'[U5(PA'0B!KA=><H
M;$&#[K)9$%NZKJY?,'.OEM8O95'M74#:X[Y%H[(W+1S9#^#,34IBM?/,0;C<
M=T*U8!_>'UL*0GY4C_PK>23G<T#O.1:/Z/Y5*K^]Q0(/GHSS"81/H%I:^"*M
MON;%(U3L0!SJ.E\UM8L_<[[&7[\ ^*S+ BKK]ZW/ #$,Y;#?25*X%MX#N\"I
MZS!^\&W^?5E 2F0-P79 PH,($1ZXNNPF2N@ 8_C4PJ\%!]H.^C7,!1DFR6@6
M-V;-3] LZQCTEH<6Z/3=KY'4WO-01V7]7::>\WF:8Z;P/,I"="#X,'N4)]]E
MM/A^0(N![*/(TH1@-XL^2&P=D8<DK>W3MJT8YYC#<;3X!278]_1TV5 9PGAV
M+V0OQ,<^X$$3J441O:^D+MG=)XL>X!,-J"B!O_47_8-3'-J%]FV/O7+;.Y>W
M/;;EML?4@"#WHH84 K?SX!YT8N O3SGOUYE&G$C_IX&XVY,L'.UT^C;R)(PK
M2 QV#N_-&N<2OLVD<$1W.V8KX'FF];H?PK_7(,Z4MH,R_OETA/.\+?K#:#XO
M\;;M) 'PV!/A&A9)]0%[+ZM^SCA.4VEUB,--CS9M-,/YCQ1NF9?V7H%A&<76
MH!J1Q9V\6:XD66_/3)TO1%4I1&0H,4Q?M!G/D;S:X5RX\Y6W?-)4Q.G+JSI=
M8OTK5+HZ[!C5MO!;6!JO^Y)#R037;7B]U+Y^_OCY(U#[GLU0-GN6P@-SE/5D
MG'QAMI'4"0V,5)B^TL/0TO5D:ZM>DIZB:V&PZAY#S'PAWO%Y5V(0MZS'YF76
M93W OXWDVRNHU#;?.  9=Y^.4%%1IV+-8MXFJ2=CCAN,T%;$*(Q]0.H,@\#C
M/8>ABY<EDFBW5<94:"MQP3I$>S+$3;IMVN,7U\PO,^?A^4@],;"^/\.<]O$#
M\(@2S4L:0]'0%>?5,$\FQ3K*.O?Z2YD,A#(AE6FQC.2>CD5MZBYIV0PL@U-6
MJ<1[ICCJTR9W^7,>5F0_K)!U2J:\:Z*VRPKV80SD1]D04.B[=ABU:LRDRK7"
MN _7413(;O<Y3Q>\Y&AI",I7 ZTQ?(K2#.ZR )\299PXI1IQ,_B:BP%EP,@!
M7%,*M_S3YULD+QN7X*?]F_[@*&Q&,6!Z'&>SHCR#D0R8&0LS@V'(WJ6&,V"?
M/C,:$4#PT)C>MP?M?<DQ_HO0!F_*&1O)D$$2D&\4BSW&,WG'&Y<3( =4U=-(
M=:L_K.2GU:=]4Z188",N85(@6(\23<TY\?A:WZGTE_SWQ8=PA3T-M(FJ/IS(
M@-^%G>XRJ2T5EVV=K;(A- >!?0"<HY4X",+&3_!3XD@XGEVET)*70J> YM&%
MU$VU_:-.:2\MT.$C#I7V.J0#['=@JQ>\U]X5)4_G.57! PNC\$6$X*U?A#FP
MZIL]8.^+E=[Y0";[ %)_&C"IFBG=S%(^8(]<;*-(&GC*+K"?+QF?@?&LY!GN
M;M!()]T0*S< )D25^:\FV<"1W=Z#GGX_4G#K4G.YB9'+"AT4H19H"P_3,_2#
M-ZOUP7 #4[<-.L L+2=JK#VQQ[N?I5?KH#'_EM>+(KG.@5 =%TSX(98+=YRT
MB#BP1.DL->*Q5Y\]@@*_\[1?X]2Q$P9/4IDEEN 54/ )V>2B*KSVM YRE+SI
MBJ.PZYH0%BFA>:S2)(W*-=P.%6[I_@#"(,4@TH;!#>[-!B?Q;1OBG0^/UP B
M=E\63VG"D_/UUXJ+]XC>)+'XRE*>M#/]&>"_(UR94@5=9Q] FWBU?F):(3,:
M \)R^W?#!C+=+"N>*S8KBZ5<6Y#:6^OQCM]M%DNX?UP = H0S>)&U2F.;F\!
MH6Y;_1OC4E9JB_P;$I<$YD]_7N>7? 41LC$P9=)Q:^_G0B+9!R7\)^CEE/+E
MH?*D[-O:>Z?L,?2B80@T?#PYNXWG38_/<Q\/G;>&D]&#6!"OERNQ7.V['K8/
MQB 4EC^6HEC/Q^!>3%#'*39D$S9B#[!U,1(9"HF)4*X0<0LHZ<6E/QD!O^ZJ
M3"MN8O&7C9B.XYQ/B^ES 8F9?O**E_Q1_ -H3 ?LL<B3RGKIL*C' (HC*0]M
M^E\?V%P/FU5JW(P#:QY\]<.7AQ&$<@"^DG^+EBM(>CPV-<L+H+A8IA3C&+ K
MGH@[8L9^*98<\:#8;5'6<RC$N2C*52&K^#]<_7)S>P&GW"NA)TDYNXWBG\RO
MW^'7Q%_T;XN7J8A3]=MWMT/\Y2C/\7?Y3P0Q!H6'FT,XC_(_4.7Y3S]+1 AA
M$]4X:1_ KYIG]]H(OL@1?$GU"%C2<'C]/T&PYS-;PS/U^\X$GFKRY;*<I-4R
MH]>&XQ>:Q3&2"=V $095A:@^3)5%8.\X$4"M^LQYF92+K)?P@YPU18ZPL;7P
M$<Z< % Y2,]V)4Z[BA'EM[1>7#15+5Z<4@.GP"XF_@>AI;T!=% 3':R5+J(,
M4]ILH!:E,$1(.( 36LES!%%2U'COP#Q[VBNJ0>\7)9]VZ1.LZF"^V^0T/,Z^
MNRTTD./G7#R?1;J:0/.\6(6NBA*A-2#S1<7XPUK^WJ=/'^6OCF>0C+]%+K^]
M8,->;A]=;J6.+-10A9-IK'C:F,O1XE=D^T!40]DK9LWQ_"&>L1 L-GIA@I*J
M&@6Q#4'2$NIN!#L->Z1MJ,?S,%4PKW,CJZ(,=8NSM55,F04)0Z8,4_TX;%@S
M8YN2 0*P<(3L\UL_\EX>J+UD;Z=Q?>U==+MYHAKS036\?O\7?OW5=RX@Y*^X
MHXLM ;@?Q.,J^4(\L?2)RY_V"/[KB&<D/V"TE!2*?>XRK>*L %R=KEUST@;(
M;AJA[/> G6]]&N4$#^\NQK<C-AW^_Z,'[TQA><GC8IY#48&PY)SG?);6E0H8
M51->-1F\5'"8N2_3HI3@G=$W58:W;W315HV/42D''@X9N=+JZ72. U  L_ K
M>@SORD\[HI32)U;-Q@K] 1<RK&E8A?*&Z?D<S6; L:R6+&'N1 S.1<3JO4E6
M*V76(@!ZF:OXH-VP_CVSM?>UE HX'69G,MI4B<V@J8MRC1.EE"PPB(&BG9F2
M,_47\)6+J0@7C[A47^%Q?NW#$= U%KLO14"PO1-R?U=9\?S0K%89#BO*S(Y3
M=49)@M0BR!?&6AJL3;4*NJOZ,M=)IX[O'L8WUY?#Z>B2/4S%'[>CN^D#&U^Q
MB^'#+^SJ9OS; Q,?#[VO%SP3/YY_$?N)>$W%Q!XF</^$J07OY)XPRBVT3=(Q
M8'/20L 7CI[3-#-KV??%LL]5$ H,VX^==E+O.XP-!-'G<IAU*L!ND;0%*P;H
MPP1G?7'M.&P;#1XR_'47R4.6]V?DP4@'P<NUU!B*X9Z0AFZ6!6SR DV*+!/C
M@L!-O[4=VTF"0!V3^D[=?K=,Y\U.\#^]5^+H3M<"V#>6@#]/Y4A[O[M&(ERI
MQ6E*PU[9X@?LKLAE!B$ \66/AKKOKQ%+!QQ+\"G99.WU>S[!("4]V\J,[QK(
M3(]G9AF]B+(,BB/;S6NJMZTK\B=IA)C <[MS+P$<4"3W7/B&83RH1]31"4NT
MQZ9$>ZQ*M*6/Q$?6]D;#@(2(;@14OU#IUL_WZ;"M_9Z[NB#-=!I()'[OV"]8
M_!?'9<,3JS'FHA/O# IE4JK=]C-0Q#.G99;3]@.2PQ]*A"T 5E7=1^L.!^P=
M)Q EG$GI)V>>PV&@C%F=JC&O%]6V'YCG/1C(_$90_;@>)HGX3B7_N$ES_GG/
MJ4CRF)0T4']A(!.*XT["%H?V_$ &=2:9L8E(%(JE.%92RUJ1%?/.O+#=.9X,
M'H:#/PI'4VN< </D1^CM%I'+;D!2%XP4,8G]HQ*931@ !_JF'K;$:WZ)('S#
MONUS0(JOA^?7-]?3Z]$#&]Y!*F%\\1^_C&\N1Y.'?V"C__QZ/?V;YT[63/RS
MH+BO-=<13PFPE](<7P/H2X79+^Y#=H4/K9#]EL^YI3I(*0[5;S5^*([6JRA?
MLV53U7 <D)!4\%%M1JN*XRSK8&V:EYS[A_L\B$O5)<[6[2S&J)U9ZJE76@Z@
M5;-&8WA_7GJ)&KJB2YS"C16;UQ=>0JR$)I@[N79,K!#4R_>*B^=2+/Q=Z:-E
M)<P("%*%N*,?_U;:Z$!&O-*X*U%O[,9=/WW+6I'5MWRZ-COLJ<+P& Q?68;/
MM+E1,',AEV.PBZZAL44<M:#\!@$>KHI2%^=,.KR%D#$R:I"0&Q5A*=* <"RP
M,-74*TT"3'#/UCN<VX RF4$/6ZILQ\JAA%=QF:Y\AMYA3;J.9^6P2=*Z*(=U
MS2LZD5QET7S?:,S%U81)B<P2R4#F:5CBI+<.88Z:AMOKWRYT.=E85Y/M&Z]X
M8Q7@0)V.3M=B>Y4U9JM"/?\WJ3J=X\ ?>%U33=80D?KQ_LR3:8$QV/NHW/OD
M:W0PHV3 2 V3>N" 1Y%L5'72=CO72&-\91E/; C^FQ':-^.[HN[>>["EC #D
MAFIS=W'+Q[,+S.D0VD[>+\5*&Z.=NBT@@T3 0A#]"$M)XM-X^8#;1H];1@_?
ME='.Q?,['K?O=W<HMI8DS1K8#DS&5$(()-1_NEPUM>0['$4ED-A68C_$4"@M
M9OLR=%NZ[<RRTJ[ZJ;5^K-R7(X MF:++:HU_EZYRYHU8_<08HHQIKUE]]MSQ
M&GX#>O*5NR1<ISA 4!9:W+.RN,DDVD,XEGBGT*7;%N$4[(0+"_=AP<ZZHT";
MVUM:2\1EW(!LBLDC-E_9M%1WKKH9;6L9P9-WZ?;?Y+RV$58!;QXZHA_U0/R&
M<H/[Z3MO)@PB)A8F*_A'Z&=F ._+/?9[<_?:U/"^(23_W4B(MFDQ3)*4 '7N
MHS2YSB^B52JN7+CT/[9SBM@.7:4U)Y1N21\\H?Y ^$*7/O;A_?7%8'OBU>9R
MU64($%_"5("E_T=SG=,(!X>P,U2,V2:=VD9L*+R(R$\IS8IY6$D#3IG*)!6K
M6%V4_D]OQ^9&*\K0QS0,U'_2=ZW<(:ODO!3(*8,"X&'W;X<])\/;0>3&V]'*
MU_*- (BN7GB;))5S"Z1]H"?B>B SG+!"A&=S"N$*)[D0C,A)\B%.^ IJZO/Y
M19$L[\M"G$/@R',K+&U*_DOQ#%FS2Y/:V+M=$;4QK4ZL+N/+VP$CE9*7@DFU
M R84LZ]8@'SI/ZT2V"7M1E7R3-GVS$IZAF[!2^69A?!,@YX)D'#:0/V079;R
M.-P=Q43*8Q^D1.^7^9XL<4E@BR=Q,)''K0_R-(]!C9^LRZ+_A;LGV[:@XYW(
MR.V-TW\[$)#5Q M^);[02TQ=RA.SJ"D]4Y5W';E\D=6(05 PGN!V%ZS5']M#
M:(LPO+ 'UD0JO8,G]F^3#CB^H9<Y3 !O5_6<[GZJFZ0[WU&K,#/7O7(1%+Q)
M;O6*5!VFIK*CO?+![JZ:M%K?2,,I6NE$S5YZAMY1$HJET,:1N76#T:DK#(^6
M#<9MXZX*"+CCPTXG1I7.\W26QM"F&3N&)YL493[+CL2F!3BT#^OE8Y'MO_$A
M+C().=K1.C?+($/>76"Q;UH!?WD E5QE^MC0SEP74 P3(#35W8R5*AV6C^$\
MR@!*RS]:74\C?ZBCLCZYL6]<!*BQ61?G\"#P%@_-<AF5:P \5<PXOX@10'+[
MIB,YF10-RZ<1SI3T( QE=)-X+J:+HJFB/!GFR0B:U#G/Z:&)2QTD_Y_XO1#=
MRPWI\\=/_R*?'5RL23I;"?&>[TM^K52;RG/!E!JL)5**5"V95L5 5Y@*(\^F
MVSL4/ET0=:1@T=$W@&6^;$I9+J.JH2@1U3,>.RD#. ^G.ZQ0%5BT.K,F3V0K
MF<KG20@'#>S@_^TX%H^JI;$[*+ITOAH80J(KQ]_[1U4Y%H>Z<9'-"=F:C/ZK
MF%K7DB]E4?7(%#Q@*/ TS-@\X02\1BE3[DNH9JG7L&C7L#V(;6%%$Q0(!CO0
ME-X4^?SL1FPM\(#R>0JG?O16(,I2#Y8YQ>^[S#L(4^ZXJ:M:;/#B5>Z6*[BP
M080*(]4 55F00Z=FJ@K:[*(%'C!+^*D9MQ4?RGZ" >MMMV]_1+XA7D7GU%G=
M%UD:[QM<>*74A_U.TH-BJ?LW?K-R;/.P%(0-1-AS4\11MB/[UV/;'*K#0C=4
MR%[*0 ^84<R,YO?B$0=7N;M; M6[!?..\VYX[#/$@[YDI06L%HO^]J[(X_T*
MQ]ILL6(A7\/C,B@[2P+LJL4:5ZGC(E BI.+:LXI*;,N *@9-#B!V:S%&+N%,
MX,;$A=-CR<7Q"-7O=5/FXI_BMZ+5*DOQ$RHS7<DUE:JV@$X1:3O$-Q_YNI#<
MH*8@.E[' "*6SE@FSD>\_*O"-&V(SR?7CI'G6Q;#-IC.0&=4$:6JW[MNWT],
MWT9(+(9])&XA66A$GY1=K6X1,BXTU_2O49E"O@#+]J!0=\^GH^2HVD00=?1C
MMY^ -B#CA/59^7>^(879>9?J M*NA XP8EAKN*T5'=S"H);[LG$KR<UXQI06
M:?,PI,W[T-1T><![<]3X=0.NEI-B'67B88NS^C*2Q*?0$)_&Z8IZ%> Z=B\O
MNAIJ:;\0N7O%EJH9Z6:*Q]?1+C&0E7[_6$_AG9+UX(TP"92@;FDG%;JXQ^]!
M*JA;7-P)@]$X,:QR6 DGSIA730V4BC2\ /5%(YFVD4U-VZ__XAP&.5Z>8)2_
MPAN7_3F<#^Z*^F^\GFC"/C\A$43=I[$H4%3L@((.SC77G5#_"_7I87K<C\:!
M#A>.G7>"XQ;V>8*#2LM!V"D\TXBH2.@ZXVF-]&,0<$N@N"X [_SQ^- .3O0]
M$SV'*EXY($&L0BQOE3@LFA].>+4J\BKM@2ORQ?,2T]IAPED_MP80E/#.HHQ\
MR]P;9F)4,J=I'BQE->&I=R8$?'6RR5!3@L=-V:=J3Z[#TFX>UH?.=<44)D5:
M(?RKVM6CS&6DT:)XQ42#_*Z.(7D%B);D'&F>QE&&+(SK?H]B2C:K4#B5,@<
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M/:!@@+K[EO_:+;;-D@ISH7L,H'1^+3(A!A830&RYC;ZERV9YN)8+JPG7&NR
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M,J44&]^56H9ZF58<J.PJF$M:  __TK8W6$-&CYV84N)A&C$1M[A5#'!90)'
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MKPSR/*S+:R$-U.Q=LT%K@H)&-;7#)/54K-FRS(4VR92NO0P4-JP5C39.I)Z
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M&P2DS%0>SX9YWD390Y1%Y7JZB.J+*#_GT/"[X%G78$.K87Y)VJW0%RPR$0X
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M>D"^O%_9BZ8;[,:Q,CU(+-^O[?:;\?7GAY^-!RKC@0\)E;.X3W\ME ;N5Y]
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MN_;OR!=6QG+MI\3(^E+4S87#?<L(JJG9;(3)1_R1A@"1V5F*#>)%CBS.4"/
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M@-8Y((8QQES08@\6+2;%0F5H'<',:=AK,$[+;YNGBB<--1[\8.YAZV>TD/@
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M_YQUC* (%/H?7/]C%1^/+MVSY19R->4>;\6Y1@"Z(B[\=?<%[FY@N7 @$_L
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M971Q^K5HK!& B+/%J"7.[IIK5IVM_Z:6]_I@;0B+L:"19>4:7RKCC3B])8F
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MNZ[ 2 =J!V'M1.R9M9UWQXXMFDA*2UJB+6_O'-<^XU5\P%I.-X*,"R5RUK[
MK$-Y,LN_*'G@^):A[NL9@9!JN\1$R9A[M-\\0O,*-_0.GBO[<$_"3> <J_U
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MLQD%D0[R& D",$:!T)Z?I$%P9^Y]'NI5ZA2Y<KG&L5?_2HE#8T:!Q/-MG:(
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M]9[\[ !B0:!Q;-@0[5XK#N56GWS9M\WZ*G_;2K_WG9!59O;KP-G!W^&_9N^
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MHE6!"N1&'W(D6)>HP&U*#8 M>E3 ,WH' 6^II0*PT8O^U*I/!4J3+X!:BZJ
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M*J!X!^%K8!@8=8=J R450'@&(#!%EPS"O3S*Z!*I]XE:4^THPE.44'B-1:L
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MLN-:J,YBN1_1E^\5.WMTQ5"=8<QN>FOYEI,W/WN.C[6#\O0P;%^XJ>KN$S\
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M\=*'&Y&@;6FHFS63#*FU-HM2=4(T7RZNI2'3IGAO,0T-F72SK"QUZJ7FMB]
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M/5B_>GE)MY)DN3[F,TX+*Q*MP&W&TKWTAS X%\_P4)7)>1+% >0Z2W_O)<@
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M92!5@I,--G5FBE(ER!AH=.1-?*H$#P-M,MR)594 8I;R2<W;JF3]9NI;+1/
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M1'\4)_=59S2.TQMAF^,^>@B$'<9;DRY/@FVP9#T]/ZZ_+S*;U?/+9O[;;+M
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MA*YF50^X9N<%>\AS8A=$<\?SP.'NLYAVWI"T-5U'57[M? 0=]I#<6^<K@ST
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ML(I'FG-%Y3X&+87H5N9<%JF_\BN-XO[EN;S(W0U+S8'$5R^(H$I[+4JPW9_
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M-CN_(BJK]S0DB9,MH_YDV4Q=;-(;FIR*6C J1NEZS3*+2M0!TXN*WQ=E@@;
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M%R)F!IV5Y'[*7BB9^&+CHPZ"]KW"B?/KU6>M1[RB_0W'PYF@B=IH^J<U1Y%
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MQ,ZO,)TS#N6<O(D/MC^Q7QV;@2SG.P> >\;HXRP':3& ),-X8=P5&V""H$[
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MAT=A/_![8)&2^N#$[+#A$2@M1ZO.J8R3>DG!\B(+L&14=5'# 8U;[[;1<:P
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MWE!=!0R<46?X+^]Z5UM)#(Z>HR-AH,/\.U-"XEN^^[=16@8_1.5[50?_21>
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M?M^3GW*ZZG$-@QX\V<HI.D-PUS/%,U/Z2Y1+NZ9$NAICFQ/KX#^B%=X925M
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M/V8'+\Q/&=5%Z&6)3,/JL.4WV5H/D4"EBM-(<Z_0XXS3M!AWR9\Z'Q<D']Z
M;<U=,<S+7=^2D7&,F7?;O90I4^RB''^O_Z8>/U2UCX?-HQ[[(2K?JSKX3WI9
M?:U<HIZ,Q5([VYH%#60_T<]D,"GM'XL7@$:FMPWU-1PK-U0: IYPV#6^Q,($
M/_7091DB1)FM.F(&8-106;I-F: M-'=\NE@OEYULRB:ZX79;XI=O=QGX[4'4
MU)NB1(H3>+B?<6'J8NE,+@R-=I%T9WA8.9=_J",ZC/:4%>&!'>V(+H9_V^S7
M)VTI^1:]S+NF1-84V^"^9R#$48*0:J9W&$*O]%\]\Y*,A9?D+]/F)7E5W*@\
M0ER4WQAJMAFG:3-.A'GDZB9*,Z<9$]?:C<QN?.<4Z9!:PA<>1#QTU(PU*0A6
M;'=24]PE 2[>6WXQ5$%@OU1KBG3E9T53&^SX@ZN4^42/[D1/!'[MM$O]1W1+
MYX89\\9^J"NEWA-_X8J@U$Q#'G%WTB:+ZJ*DC!?!6:0$[QI<PCV:R'A&?X5I
M5PE'L0/0QJ4UP<D#-!:S>^(YJMZQ-^N"^/S8Z ;C+1NL[>EK(>G>[G+D=#(Z
M5!<&F^)6P:J-:9>$@32:285(L8[>4Y-/S2LMK](KXX1WQ_UL80<,=1$V6X,3
MJ6Z]CI!2>V^9]D)B6!ZIJ:GCN1#=8XL;T>MF8M2-"M0:B['$JZE-PQ[Z+BZJ
MVB])I7EKR)=[,,PCCQT.?^O3<L9%D\.>)DR;^S!.%.4J!H<\8M(J^CZ+;M=-
M9@DNZ4Q(<]6!0C=>VKI]Q%?8\3E+U8UN,X#?@'02^P,?N :E+M7XK1-X^-RU
MU[_2W8/Q>B;3HI_8M4!>TA5GN<\Q?=]IBR"U#3#@ZU3SE;<R<:V-HP'+V%L(
M?N)2@I)#C*T?W%FXFZ@E. SYL#S-(1@US;G;_6AQ-9U0>V6W_-V0?G,=QER'
M<0_I_%!U&+,M/#I;>"(9D1^+X*<5O&T#]?ZQP#5 :?I#FJ=;>%SP+OJ@Q@;_
MZ-C&% 7.BR!I:AI]X<T*?^9J+_PHN3&=]W3YL &0ZDBP4#DBOMZV^XE:5LRW
M38E1U6U1JAZ-?GA@<(O<S];TC$LZS4N1MIN#+3L-Z=N&&O:69W"[-+0SM/IM
M=8HY :W0-0_[N>^%</IX8"I;O5]H :,/!*@C/1^S6^ /3E;:3K%C'\Z!Z9$$
MIK^:=F#ZA[2*P7R.<E4T<^QJHOIZ(M'H?[(O]W-9Q$J!"T<^XB_@:G8"+R-3
MV/Z(R0T4!WD@;B01!=<![&9?4<5PIY< G'E51N"S@X\]IYC^'(=Z(@%IV__H
MBF.SK_2V1H/O.QU,&3%NR<Y FC?%[@PB"=%($85AINTQ"=N&N@Z*8>1-671'
MTD,$1_9CW!I(J(-<UL >J.H(,5 (_^5?K\%(EO9+3#K/H$N/%QXL8!@+1B^%
M/5Y#J;P@5451QR:GBQ*-SH+1-7!8#)T>&^M4OTKCZK0^Q6BI=+R^46Y_<3MC
MN%6!DG'&:MT3J\5@(G)7\KK"C5 566/P6W E*)AJ&21%3/M O^?V9O-WO0V$
M:NX;1N;,K^>>K\='QX5=BEEX1^U\MM!58R4ZTFZT.V 4E:'6&.R.3(%+.(S\
M#O6[9]8XW")-)B'N. //.@;30Y4E@^<8Z\9L00X\^[Z/"@<.N"%4*HMLN&>Q
M#CQ0U3Q(FE7* 01FXA3WFSA)2H+HT>;\R$5QC,W9Q)J4B361..<O#DL@TU*.
MS(+ZL3AD]S FU(N7D1D!G],Q%W,*?R#08I),\F,2>B"Q=@S%#0_U%/:*SUPQ
MT$D68B,?LKG<<6.$D#%"J6)0JB2@678228C-288Z)>CF 0]QA(8=Z>3ZAUC!
M3V*,F3VHL4_[[AV M#/A3O<^G,T*VW#"X%5)X'N1F]BYB!=#"^79X_PSB,-D
M&N(0I,T;V\(5#J'@PH4Q>Z02LL-%V\6F>,:*K?&W/AR*G[@A3PP!]PS(8*LM
M;C4R;=^["\G'.V 21S.^(9Z&&@VWO%AJ4J;-+IP3]BHFB0,+[F-S6@U]]6SC
M"-$&-35=4.LU"BRWLJ,M%6\C6ZA1E-+CE"\S.J(EL3I/1DFG>>!)V)/SZ>P:
M:F_[1G>"I24K2L/.FQ=U*E"8]E=QU'"G7)+0D6G_ZR S;$'S ):DVA#& W]A
MAH#U-;M4N16+TK[&KI^P?];2^I?NB^$6L.8%1?*:(!O81WEQ(0Q[<I/VC]O@
M%,._3(K$_M .)W)8 OU6?'V=G(/%TYX!Z/%U'L\]_(Z\5E:-+1Q,MR['.AUP
M3U/*7LN.M E$YRGXI[-O*Z]7KJ',CK$9 +_O64=.4T>J:>A(VRL>[T%&8UJ/
MD%;'"PL.]/C0W;$S^!6WWL IQ69*)FBA2BP^U<:RTYE<]P'K8")%SWHG'TSE
M!GMI+MC>CS!H&QI5@"J ROLLXV$[@)%6GFYIB30=\C#?;R@F$YL7AH*JD513
M%*R;+#NC"9L+R+O!TEG_\Z6C=[S>\AH[V -@<(;MEB9N1-ZQJNVG%R-VV ]8
MC?E>X?@Q$E/M"@G3X!KJ8MS^D@WA#HFV18,;T?'<8*@.-4#'KR'5!VNL(V@T
M&0RKX3U7BEJ_ZW9RW17A0+M9[-96$M]KO\3OLE0U@>%<<MF82/\QWM1.->2>
MM8G/9$*M[6B7FHB?H[MZ_+9VK%SWFV<TL'G6P:@9O[>6Y]Q>V+;99=:U,$>
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M?@WW:E4>^+6;ABQ=+,4'4[&SQ?<0%M_%M"V^-R:(_5H@%X?VWQRZ,ZRR0GI
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M3LN*FWE1.(RTMW#-5XKD",A'7=&8]]#!8T?M:YC0IIK)VJ<F8$Z=K/W*9Y[
M/<QA5&%.=P.IQ$!0<%ODP1"::P/T$+EP& ])TN"A>(068A.MT'[;1NRUN3<I
MZ+N58GIEBN*1B0=W&1S, #LS6N7U?NG0BCS_^G-]#<=8X=9RUQV8RJ7^\OBT
MQ<(X^.3!Q>%P.-U@8/4O'Z0D>18=XQ0=IRD[$LX74',"\+4*RCJ#]YK7^[-U
MT? .AA-#V9TXRA0&_8,M7+^I6)H@G.\F3<#YJY!A4:-\5@IV%PL"7;S/][>>
MIDO>AEXBM5N#.20FZ0WWPQ8SF9#Q:.]#TN/(/&=<"W0%O!^Z;1C0&R+FMQNF
MRXI0&+#75(,DB= VN"W.ZDTJ7>(YW(5-0RT!JH"%8(H@5)3V ^U@B]S]7=\R
MD*\EJURV)W=@.C!Z9TVBRNT55A5F9J'QA]BA#F(5<==Q9\W-A"/P3W]EH%-K
MPD*$<Q=Q-8/J9U#]'P"JGW7@2'7@:2I!;D2BU5AH++T20Z'-+E@XN$R=! &9
MJ;M/7SQ;),O%LR5></$<__UTJ67J&YW>OXKK)2;X;?TCJX=<K5-*NQ>W.9(=
M]C^*<*L7SY*S9XA=V#;9=>2S+?C/@2NV3 \.]O'3)\8^AO_E=VDBZQO&L]TZ
MY3-[FE3&E":),K;ALDR@2KBO:V8QH \EAU=5JFY[>Y0AF??U9/?U:6YK"6)P
M3PBOL7CI]_R]$QKXSU6[? 13EJY[&?+<Q*=A79;0< <RT$) <OF',.)5)IV6
MJ+4J,>%.H,<MTK#P2Z32Y\K%5&H3XOF3KZ_L2TUTCQR':;8H!P;5H>O;-NC=
M997O]IE:%!=<R$M ]PU-4!V]35LQ\PY]R:;<!V_5=2/);S3C_W)Y<8ZC/GNV
M2)?8]<9GB)>&)^1MNY-L%VC_N;;H.T'=(D1&B35(&0OL.LX8E)0X('4-DF[9
MH@U'AV=?$LDNT[U7L(35^%E3@:<)VO!VHRA:T7<"6E'0#1+MZ 1*N_E>M"IN
ME%.1%!I,@]O8R(?%</>8+C6E1'S2/$:$; W3WB+NI*P"=I'Y"&.H>7#3_%D)
M58Z(NKZWS#M(<+$V7\;Y,$0C9!B@CPD7P*X"R!B,G_7&TCL4VEW/PH;9$6IL
M726U1"@4P5,0@@/R4)JKDJQ >OH(!!^LMU(6T;X&SRS&^CGBT&[=G[T@MYNS
M @U:[)7VK^H 5'V.2/D4]IG+F=]B)H79$3A#E^M1DL RT+M-).E<AOT\]T),
M:EK*A#A+].\2B>-E>VY#8_Z2X1SJ'2M.(5%=(WZ=*:.E!T9:LO]8;=(=G3E-
M9>[=X2YCG<]:#RT^B;Z; HPQD6E)T:QJ4=*(,SQTWKC-,'4FU@X+.22ADR>2
M.@1'WRM-@Z8^6#'> NR0@8%/UC(@*;9IG&9JT#Z<W^EQ^>F3\[?:R7OP3ZL'
M*8+2V0.Z!"("G5Y<(UX+-\N2@09.Q.D!Z9-EWU7-#NM2$C582WRPL;UKHOK@
MVLN@TWQ/&MY13\*C2]*[(F04NS ,?N;A)0J'I\9K0#04G\0B-H/ 1N/8:Q#8
M^B3=^E,%@8$G.DK<EZV4_AZ9Q-!E>HM>;,/>,XJ>BZ^_^I)*W\!>RDE<L1[6
MV6[;+16)QL2S9;3R=2.*GMP/LBYG3.DTQ<GU+$X>4YQ(Y&/$,B7BBA>*SR :
MWG$J+1<#6$6WFV+K4,5@T&2%]EH"AY]S<UY7-K3X8G ?6:Z0Z:5=XJ>+>#F+
MEVF*E\TL7AY7O.@,]H@EC*1X<*A53[)]%@73% 6GB8PY75& 9VG$4N [51:Y
M:2K)F13+L>P$FF=Y,$UY\.LL#QY3'N18'1.-GMH)H[927VUB%4&4W*1548:$
M/4\KHA)0^75T/9#'<FOKL4R'TF,Q+X&.;_,M]T'%!<25QB88O()*;#- _:-0
MTG9+_H2H(!!'3KAQ;<>L-'==XG+7>:.ZR[/.@^#O.KXLG^DT)3U4>V-,EF ;
M $?!6JG.[4)+"\0I3GL#7*.5,NQ4R!9DL!)VWYAWU4<2X37_.)$C,2J>D:/Y
M;#X7U";,HW0R[\?M'\W<93FV,L+]\"TV3O_E["M$L("2E/RM);^R(-I?;$[Y
M*B9NM>@F2C,*$M))PNN17RT5VC",$:PY@\>YV4[JS6;(G82USJKPK&"GVWDP
M8RWN4P4Z-)4G.PW6O#1->](]_8;3TAP?G5B)(ZS4J._B:LSU'7-]Q[TTVL/7
M=\SVZBCLU?>SO?JH]FJ+X65,VKH3T)):QUX2':U\3-N_0?(C@U%$8S1X(Q"N
MT!IJR+AC%"5AJAA> R*\;(BMRFU@FB"GCD.E67,S"M)\^#<#*]OP";:6[; /
MTRS=<:QT66LH;[C&:$V%H ='XIFQIOVV7O52\4+8=3C0\O$37Y VH6V3V.BN
MS$F7CV5O?N2)ZZ):QG3BZ&V/>P%'Y4^DZ_XSYG-DI94<,L:3BB-,1=-DH__6
MP!JL]W+(G8,0>4T;W$3?$+]7>("'K8?.2_/:.$ZIYK9Q2+V$VX:0UW1[F>_1
M&8!D1%2C^A!AI4GHR2;I2[$N,;]I15L;C4H$BJZ$:[GX[%<[7K;UOYVBA+PE
MM=8]BX&M.KS2 MO[%58^BVY#)\\JCEB\2=4:L?)"7 !>&MRIC5X6*DF0HTAJ
MZ+IJ[9>'3:XMLEXKJKN].%<_&37$V$T,Y.!B9HI8B]:&T]+E*O F-S Q-V!4
MI> ?TAUAW/ V:D1-RQ,\8",YGU&F?ZM#.P1"7:/FZ<$@AEW"0O$Q-<MS=9S=
M.>I.6*^;X]WWK&X[]G*#G0>1A@59*-T2&'+^M9<MVR8RO<J-#O7QT?;]PV/,
M'.VGG4'O"A"1>T-(JA&*W'A&B'BZK]9 /'$R= <7BZ3IUZV@"#O-C]W:&MC_
MYP]>QCB[7*-PN;+9Y7I,ETLS[;^S*/PQV32], +0O]NMX63%$@.X3]:I'.2O
M5"FD5Q2B0IO"_@IC^VM+?R>0IR$VX[EN>F(BY]0I\+BV)B1J(Z=L# <K<=F/
M)PJ8-_MT-_LI[_;A;:XION!.JJ:D<HP&Y^+K)Y\;8IJ!6LV9^>5/M/E/=??W
M-HDBR2X]D5SSQPOUFE)8CAW[/*,.Z@K98>:M/]VM?YKL,)'I-_8@)V!P]P<K
MZ=XV1 \VR ^L8F4B/O<:(Z,>-3/P:A_<I&7=& _DGO-%8@-=O4N-WFQVR;;7
MW5*AO%%](3=ZTTH5(RU'>77F^NF^^FFW!OBNI=1<1=_G@]O(\?@*Z><(VVEJ
M AUAVYZD&CC1")M.!8TXJ-;&LE+>Y=RI_+L/..]^8+PVEF_&_4]3Y.2SR'E,
MD5-%*\R!CK@4Z$AGPC 0EGV9B&%4<Y$,<!$7!.@>-DZ(,\ 6?.LFP^Y\8.G7
M>V[3003QIEM(DL84##7MNE"V[3;["C^G=( BAK84S*"TI/0EMXV+<F:EV[&-
M12AI:D228BUTQ%W'Z*=8(@UR2V!:/1?BE\Q@3\R$DONU70E0[MJN'Q=/31<"
M(L2W*5TIK*Z"IT^1;.S9DNH-D'QP$2$U\R)F!C*7;1%_89L)]4([--QB%56I
M;0H@2Q<H:O,<*^'CDDN09PT9^TO1#Q9J'J=EW&SQ'6&MPRSK)RGKBUG6/YZL
M]YO0CU?>,Y3)#-;R9NHBCJ0 R:!0\G/4!CY_K6*V2R^>AP'<ZZO0(K]T 5*G
MR8ECP,Z=/.9*C[G28]9:=]):NUEK/:+6$GSMB/65K4O6O+K'RHX?MG:WNE_Q
M;FZJ=_7:WKUV=[:_)R7)?ILEV2-*,BH^&+,<<U.<(6'^A3$[#+)TFZ*##N)+
MPBRQ%6T"LBFV"#>/\1/,=<'IDT91L_B8IO@H9_'QB.+#:6 V8B'2HHEP1\VL
ML\^>^ZRSFJ.[;#)A67'I9MUF;C/;[-0%2C4+E,<3*-]&:1G\$)7O51W\9Y0U
M(W:Q2&)(+B:ANCJ4&#<X: > 8O%73H8BJJ0Z8R[*F)S8./6BC.][MFY:!;@!
MN7H9]SO8U-$*/MK 1\R'JK1.+0C(E?3_=DLGFT]*YZAS,('0BQWPHJ3YPJ#)
M*9MHZRH':[HI89<5%6'E(]3CNU+7HW*D@NX,9_&WII"Y2>FIG0H/F'J"<#%S
MYRO#P'!-5;!5'=Q@9)UE "R$E+JVUW3I%8(C\9IRN!](MI0*VP5Q>A36I6C*
M6'72E*5"[R<;1#W.@F0"@N0T)<D_VT?5Y/M;Y MKCQ)EZ,QVI-+A T2]S?KE
MC*E;=R6$RC)JF$;/DUL3N,'BH^E)EI>"A 7*#L8UJP]PM!X>%3"?PQ&=P],\
MB-_S;M9D!@8%0V>BZCU<0RKZ&-P&5-5U423!.D*U2)2AJ+Q@O+D22!%URD4W
MW&VH4'$S5<+\/'WJPGQFMWI:QTF[U?5)'J43=:M_+/(S0PHT9DCW'[6NI\>6
MI=,CEJMI4VB.VP6W:,7<:Q1P5]_:ME?%Y$@OM5*7/"XI%-\&;2 $/KF=L4/]
MN/[VJ"'341TBXB-73%-X,:N7)@F./1X^ <@:V+T4#"&DU,M-!POPT-1.$*GP
MY;9HF$6(NO^@U88,46#S-6!OWA9-ENCNNH:?A^&>WX-. 9WT?!$1Z-3IH_W+
MV?_U(L#M;LLM/N+%B8H,?\9CVOE:5BR7S@;=%56%WH9F)T-'7'9-M[K,VO"=
MW7#/G1!J6G2J+Q%Z=S)Y5@WX%3@B!IS!=L8NOW=\LKNGS/-7/<^_- Q@J>MI
M]?*BPZ*>&2&@>=X'819OFTP%%U^NSI[-%M@T+;!FML >U0(CDL8:^S=P_.*G
MW<C9JDAX,LFCKI5S!9/NA?>"_3HCBGW^2OV^TASI3-"&D 9:=&/S1'0&)4R*
M#Z>.%VOSB-DG_%-(I-,D>#A1B?03^P!CEC\:P2HM=+!!2+_C<EAZ7'RI?^\B
M/V8A,DTA<CL+D4<4(J.W88)!RPMM&+!G0")4@Z0Y?7;/#$"?M@#Y, N0QQ8@
MP94FV!ZU*-%DX98.O(=MG2)"8*KPS#:PEMA\C"O--5,1LXWC#^%I2<H9,&;C
M_\EQN,Z#X$T4;X+V(IDT7-6L?K5$)8.WG276M"76?I98CRVQ^%R/6EJ)\T29
M#^X+(G($7*E#=DV -7[8A-$T.)!&*&X+"O+)<!'8+7.X!?DA<YO"N7A]+EZ?
M]=>=]->_9OWUB/J+I+A#>C=F)0:V-O4&6H&/GC G;L$DZO!O+ 9E7JRU*@G:
M9AO_.=!QS<<RI/.&K&8=/OQR$2]GRWF:DB>*9M'SB*+G-A]5A\8_&G7VD<LX
M*AS:Z6Y%E<R;<=Z,8UA#W(SCZET[;\8_]V9$L.+XUG+L^/!1;;]6&!!<IC?<
M:=C6\(";0B2^>J>B?68\,-V[V/D2-*;[M930N3^P>-)B'4H_8;I+% NTU?LU
M;C/G"K>G52I52NWAAX-P\WI3%LWUAI'BL QE%-=A0#2^UXJY.0G1JR.5H0_-
M=7N(A$1\C.AT3@O?%-2R=E?<(CN:>)3<V(+91>@;G"S\4O=1YI$Q*P!=WR6-
M%L8T/>G9RYRFE[E:S5[FXRDPAV-]3/+X:'[&:X;]^^9HG"?-,F>:,B>.9YGS
MB#('SN2(A0WQE'^G2I )KYR.<4A*'GR?)TW,L!(6/3-29+I2(4EFJ?"8-915
M7:9QJ\G4B.6$R;>A+]:/B'V =%HTI],F*EZ4FL7+'RU>IH>E#01$2_QP Y.^
M*\!VZ'H/;WML86?\[2SV7+&W7L]B[P\4>__,TWJ\IM6)K>XH<Q@E+@/W*60>
MFM_/.%W-QNE$I?3U]2RE1R&EQVVAGM@ZCU)>/YAQ[VR:C[?PG9L<-O/[MNAL
MZ\]:Q-4BF\VL11Y1BQ@6LC&)N58PPP[2(P:T?:/]AC.E-/N.8U55#!6Q=R#F
M]S277K-"H0@#);$#_YW%RC3%RHE22Y^R6'G^Y,78A0H,<4"D^"RC=VH6/<N%
M$Y0+O_XZRX7'DPO^J1JQ=.@A&N9&=L_<1G:SL3!-H?#^_2P4'E$H< IPAXU@
M4@9.O<5!C%(\@#]QJLM\]7:,*WIBJSC*<& G?4/M:-P#1<!$)Y%#C,*?D,=Y
M,:N^::J^+)M5WZ.KOK&FUAV>\HZ(Z:7QM/XSANA#J>'"E,(!GM#0EF9T;(!P
M$%'4^XV38) P8(>-919<TQ1<V^TLN/X0P37N;/-'X2&="K>[IT4'T8XSQ'$6
M7T?%5Y[/XNL1Q5>SJM(DC<K]>&56MYK=$50A]:#C2GQ;;P9R@A%ZVZ)4W+[M
MQ9//M?AP"U3C:(>+%G"OF$UT0RT=2O@.UL0KQ\<'@QR):VHS^FM14G\XON.J
MD%H6W>VJ,LU/W6$MTE)F@88C#5*A608F')?O8^(UE+$02[-N*D82#4TY^H?J
MOSU)4B)!P*[A9*?27]XLB,8NJGB1\)D;%(FZDX6F-( _0=;OJ=N7-[8A3@0B
M;= M6LV[0?%-3</POLBB)U0,89"EVQ3-56PJGF:XE+'MW3=3NLZ4KJ.D='U<
MX^"4]!^+*<7$+T2?B>+7M2@WU$!3N$H<Z6';*"Y$' ;286==E%L42B*_L&^@
MMD>97CK'G#6,@R6C2')B9$E7S2%RZ ?>Z5_"I>/=ZW]VT?G-%ZLBV?_UW[[Y
M8E-OL[_^?U!+ P04    "  QC%I:]6=BV50L  !8D@$ $    &=E<FXM97@Q
M,%\Q-RYH=&WM7>MSVT:2_WSW5^"RE2VJBF(D^1%;\J5*L;-95]TF.=NYN_TX
M!(;DK$$,%P-(XO[UUX^9P0P(4E),V:",K;J+18*#>?3T\]?=KQ;5,O_AWY-7
M"RDR^&_RJE)5+G_XZ?^.3T\FI]^_^H[_AB>^LX^\FNILG9AJG<O__&8ELDP5
M\_,7JYN+I2CGJC@7=:7_0RU7NJQ$45U\0Z-FZJKUD^-*K\Y/)L]4<?&O8U5D
M\N;\^,G%4A7'"ZGFB^K\%+Y9::,JI8OS4N:B4E?R8JIOCHWZ%[YSJLM,EL?P
M";SDU<J-/]-%A8_(\].3565GQ6^[H.]F8JGR]?D'M90F^45>)^_T4A3NP:FN
M*KV$9RMY4QV+7,WA[3@A? G^WKTGU;DNS_]T0O^[N%ZH2AZ;E4CE^:J4Q]>E
M6/'KKGDY4YUG%\W<7L+4=LV&OOLHRP)76NA"TM9<JZQ:G,]4=9S"]Y*V]Z?_
M^^O;']]^2.QYX0]_>/7=ZBO>D;^)(A.5+M?)>YGG2:63U_I*EFYO^CCE)#RX
M[^"VT*UYR!/,Y6SC +>OOWGW?M;[YS^=/C^Y"!;]T,M-X;VR;"^8!KL2I0).
M=6Z6(L^/4[$R%Y]&%J=/][9//\M2%T"^);!3@9SP8;?L#&=^^+OV[OWOR>6U
M*+/DYQ+FF/RB*Y7*5]/RA]'9R>F+Y&V1U:E<PL/VL=]R472Q!]J*"L8P,UTN
MS^O52I:I,+(_2SUZ6((X/8L)XA^UJ=1L_4<Y/\_G].&N1S*J%C+Y\Y]NX)S3
MB_US_+O-G5YUKBK8L_0>JWFMERM1K#]EUOO>8-[)[.)HG*SJTM1XFT">JLHD
MVV_2.!$F$?!A)K.#/I!M;*$'I[&0I9RN$X&;;O!(?A,E,#FUPA,:P?YG<J8*
MV/^IS/4U_ "/H:B74UDF>I:4TE2E2BMXP%0Z_9C4!9ZI6<E4S11\"BI4 M<)
M?P428 E?R2H!)E@M>,2#/E<O'WIYN)/D VQM(\,4;'X]_8=,Z>J!M,4#; X&
M3PI&R<A0"L\)2405]+WBDT1ZIK_Q#Q[\<EY*OK^'?*!^%;T\T'$"TG2!IP8O
M3Q>)*&4BJDJD"[AH>$IXK'1*J95D]G,X-CXY528PIH(GUY/DM5C1!OT+GF(2
M*'25R)L5[!D8ZVM_]>T0T[KR'X6$H$NF T\!9H'$M1!7DKY82H&+#$EJU\\G
M+4VD$M-<NC.PMCIN.^X;J.;X[7$NUKJNR&5PP5OX\OO)R;<7]G$XN1P42WEN
MY$K@MK W <8NW<!7RJBIRE6U/G=/VX?@J<P;-C3VLY>39R^^#5T(]K"<#^&[
M*MORTZ<GDZ=G=_DI_*-LS]$Y-)"TKF%EQ]-2BH_G]/^/\8-NHMQ<1N0Z0?>(
M_1MMN?.3R<GWZ$T!2Q<$@<BMQ@;/^N><813\E QY_]LM?I33![0Y[WH[[R:P
M&R%X'EG4'0>[Q\WTGBC^9/)L!<O3N<KZL\V?N+$;]OI \+T@^#? %%&PD)T[
MD/Q \H^?Y/\'3!=X"*S^):@=UOC$>S"0_T#^CY_\?_$V_+O&AG]/-OSO:,,/
MM^#SW@+X+YHRO8S7[-.6[8C7],_">W(Z.7WZQRR\YR\F+YX/%MZGAP@^A0-N
MN([NI1&\1X=*G3>*P(,QX>0S,ME#/,<[;>+9LV^=)W.;.YH<4E?PI?-%SU0)
M?XBB4+!Y1I1K-T)F#:$Y!?S0FX;#PX,U#+'&1^ NSBI9CD-G:N-%M<-P^*):
M*!.%#ANGJ?=VX3?7JEJ8"KY#ZJ/IZ5+.-?PUIEGCQ[P&?(DJ<([U"I82^"G8
M2_CRPOAG,(P%TWD-&Z6*6M<F>2_+*YC%9-#&#H$=O348)P.BV>!' [?XX]SB
MUT+B72HEWXWE$FX)J[W7"B[85"8*]AT8"-S!1(ITT<U4K L>;Z=)1,4< %8:
M.[G? W_ :_C<\85.+_?GU 7W'(C_E!C-?3VQR67ZL=#7N<SFM(7FD^3SOB>:
M_+A.0$4%W@G;*JH:"(P#G$!&TW4B<R"%4A<J342:RE5%-QN^ XUV@3&9E!DV
M!MJ0?I;TA2XI.C,EP9/8N/X8WP-$"'HO"0T2*@()"YX2D??.02;37!CSG]_
M7BR/<V6J8Y@.;B'MQTJ6W[C=L\1"#.,4U.M,F16HWN>S7-[$)&<)Q^T /7$,
M\RFK"Z*L8WR9.9\*(W.%^[9)ALU6/ID\>?+DVUX!1)Y,OC]Y$OX/E/I !GZ4
M<@53S?T.J0*7>4P;M6-O;#CO[,P;00&DE=]\>A)L/ _;%YS,1D!YCH#(PI$H
M?- -F3KHH'"$_>H1QPGBPDZM7)4:S5R,WP>*Z*;6.7;A_R:0O!09J*<)6,\5
M_Q8.,]-IS4KJ[T4N#0R*^N^U,O9-61P)OI/""Z2@YQ+'82S)@1)%0^?]Q@S
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MNZG.UC_\^ZOO%M4R_^'_ 5!+ P04    "  QC%I:)[=R(Y X  ![X0$ $
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M] >>G-,*[D85O9.$OL>)OX UK&?PPK<^QXS=H"B7C$A!F#_=)ER;@/ F#D@
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M6[0DP21C5Y,,!X>K]'*PALB6,@>8CAU/'#_DBY#Q6V3!L1MGVM3R0S!0AMT
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M9=1VX$UP)[]Y.[XHDNBC#TQV Q+.K)YV>6J*#1, 5A>9Z1PY($ W P'Z;$"
M#@C0 0&ZPJ:B3/&&UXVH=-*:F$(H/X$:! SI7-855E[;3Z(\MQS<J=<71S,8
M02+R*-"VZ''0!_'?R+I1:$R:O2 H$HX?S/5<B6:KII8 #T.CJR:[,7@M0L#!
M09V(MQH2/E,JH[.B/VM,+!6$9%J.HI^9)S5>51RNT1(V7PCFY6$$'CPU1_QL
MJ!)CBDPS3"+H&U4VC>X)4<.U^C2-* H2.!G$XP.KYPA-6Z-Q^(<K94>9_L54
MCKC'$FFIWV173 :2)Y<M&L'!!;@'+L"S#7(!X&S *5YZ0_*5]+VE>B.501*V
MH54&%C$N*1[*R7&Z]?!+$^_H</N#W)(*JBO-5]W51DD*AC^1))$@0DFPR)$[
ML[5<+7$!!GI=<M)]I?5!\*9!3-P#,;&WNT%RP@-/>MGM^)*NEOYOR!J'_'X(
MB4:]7<SG15G5.:*3L$ %'.]::[9L#);)]"U)HV),H &1(G,;UT4VR6OK7,ML
M36 !Q4<R+93)K4^)ODWRTS0;8%0=L\)+C%QU^.E$E')2FWI4#OORCR3:"!J@
MR9?O:K_9S+ 3;5ZRC>%D7"FT9]D .@?_.X?S##O"\"&TG0@_=$$348<;6EUL
M1>^@+5:B#*NHP'I3B3'?SC&S#M_6D@!CU=160G]RRU":F#)OI<41A(A8LR6N
MIBI$EPVR^3[(Y@WB#WK!4@7.^"]BT<= [A$(I;]JN/)TT^ O"7_/TA]@!8PI
MFK'5.2:KY4DT+JQB.@,14N:>TYUJ@=AQ.ZV(IWT2NM7#!;\'%WR#>'C>6A*L
M0 ?V[IHW3(+0)%EIR8U96VP=0P3,:% YDB\5ZO@Q)FFFBDA&I@W^BVZJV651
MEU$N9A(;_&#/ 6;EBHDN;#Y%7&9>S\;45\_(A+$"8P.;W2#1A^V.LW0?TR(C
M7A;.PIA*011,?Q;CB+J)@Q559!G'W+"/W]UAU7%GZJ6H1.\.4TBK\\*<DL:(
MF4TFTPW4DEW]4YECP@"K#,+OV(>2&6HL3 MDPNAA4$M:8),)T"+P^E,*F^(K
M^?Q) PD&J[)] ILCM*4'C)IU=0=QP!(5$L>X2T"&O>VZR&_FNP 'W$"(S4WR
MEBP,%=.+8Z'1\+7E_9IRG:NC6K,^=H)H.4] LY+M#V9Y62#QC0Z:>)2QH_VQ
MU%E4_XL/S^09/!M[XOJ6)+9Q9$-&F "VH4S0MKS H3!:5'U$K$.3XD#*U:=E
M6/R8R]44#G_B(TSXFJD&+8"[,#W9V8H!OZE<^O[$L%ET1ER[&0(]<]4$![?G
M=3DOM&G%%42T#8GB3.2"@-LDUZZ:EFZL,-R1.#+L3[ EU!GT7,E%A%842]7F
M/&.BMX"-HJ]XCJ.D*$N+-,3N,]RX!=^=EJ+Q.+MY 2/DV-2+<'?81M>XJ4TP
MV$<)\IYIQO9)=-$9>=A>B97)#X;=/3#L-HA9XIB(^)EM .[5'T7YH7>J>$1
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MJ%3YP[&MY@V<;R[>A%E@E&5"^)\BAU&\JLMJ:M%( PIU,U"H/D<^P% '&.H
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M'QM1-*";'@0?DN1;1NG8D9S CO<BR(N@5RN"?O4BJ+&961)=^3:']Q0-OO'
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M9SI'ZJ6$EQ*O5TIX).9=9 "NY_%;(9 $(/'$AEYHO&*AX>&8S:9%DLX$9T/
MOIC\JU!<[X(N2;7SRZ',8$0@54(O4AXF4CR3V<L2*1[)V9QA3;)\:Q E&0*V
M1A)$2LIE(5Y8K#^)[SR#V<L2%A[:>7?7>R\@O(!XM0+"PSI7U(5<270U%@=@
M2^1%BNU=:IPC&K?E:0[O)T \S>'+$B >\'E7ZX:3,3Q2Z!Y1-2'2T.&ATN#A
MH/R3V9EU. 1N=E!E=^_!/]-ODNI5Z$J5Y:D:%Y[$V0NH5RV@/*AT!8,:'%=%
M69LX3T&*8)MMF\ I:5G! *HQMIH?>*ER#ZFR(30;GJ^U8?&>U4=J\\0<#W_S
M9*VO0"IX6V,M,>')6ILG!EP10VCH8R5>/+Q:\> 19"MPIG$H.!43#"Y%?(&X
MCT_)1!A$2.F6>.GAI<=KE1X>2M8<QY#IA4RSG@LC@W]]4O"O4'>E2E(,AV9)
M5'@;Y+Y2I'';>2FRJ5+$H\=6Y'M#.<YE&,O,BX?[B(?&_>3%PZ:*!X\76X$7
MFQ2SL2^"\^+A=8L'CQ9KSH,D@2F6/987U+ E.(UD2)&,VB=>?'CQ\5K%A\>*
MK=/,SD%A>.)A+S1>N]#P^*U5256+[P0K P'K6>X+WKRP>-7"PK,#KG)01A+E
MQ40G1.*RS'Y1@8I[Z7$?Z>%['+PHZ>') IMG!F0%[$3%-!R'<IP?!*<RG:D<
M_SU(8IH%[,CJIE$\<-R+&"]BED2,QX@VTXB!ZQ*2^X)HC:]"P6MG& TY22]$
MK/X6FF/,UJ5X(7(/(>+[)+PL(>*1I'<T8_+2P4N'5RL=/%)TK59M9_ GAT.P
M7KX?YVKK,_Q^$7P2L*LE%M7[=F[WE26^?<++DB4>+[IF];R7$B]/2OAJ^(;%
M>U801YLG9OC'\/C\+#CY&!P./_:_?#IOG4AH=S&\YSY_0:;#S[X8?@5/L5A@
M_#(XE%-11#X7XB7$JY40/HJY(DYQA6!0+R*\B'CU(L*',ALGYJO*+\-47(LH
M&")1,7*!ZH!$/\3,J=1,&@=>>'CA\5J%AX]=-D,M\EQ,+F<D-C[)*Z(XS_(4
MBU 0&/JAR)0O@_>2XS5+#E\&OX(E(TLBL#<F"R\<[B$<? >V%R4<?!%\X\2<
M<+/HBU3ZOFM>1+QN$>$+W1LGYG\6X867#?=M8>%;KKTHV>#KV9L152I+)?PN
M@W\*7XGJA<2K%A*^CKUQ8CXE(G9;$WEF<"\LO+#P9>LK )FCH[,^)TB]>/#B
MX=6*!X_$7)'-@.,Z266H\L0)7'I1\?)$A2_D:%B\9PU$M'EB1D>__7Y^%O2/
M#X/1\//P\&AX%GPY/3F&3P(J\O U'@^5%[ZY\@LR+7[Q-1XK! CN72XK'X%-
M$2K?-<!+B=<K)7R=1W,E6'(M4Z2XZL/#TUAZ4-5]9(3O;OBB9(0O]&C&:L_G
MD2H[H>KB438M3M-D(F68!5_F\*TO%O,RY)7+$%_OL:*>M.PG<@$?_=L_;O9V
M=G\]R()/2HQ5I/)%,$U2GTQ]F!#Q#5)?E!#QI1^K.@@P*>^!#6D$@V)61-3;
MS L,+S!>J\#PY2#-_8GD#)T4(S0^BV_R^C*)9-"?84NS W!?Y%QSX<"?,U7,
MO!1Y>5+$9UX;%N]9T9UMGICCD_.CP?"L=8*@W4G56T4!_%>,(TE_ANHJF$0B
MRW *+^06=G61*3T9G@)CQ OT$/^FXW>SO_7V8!K)FZU0I9+HDO=A\,4L/@A5
M-H_$8A^_79KK[9]@MG' 1OK /_\JLEQ-%V;D],,M&8<'\R13=.=4LCEY,$YN
M<"'PU?48X9.G%MKECGC(4I5CN>WQZZ_JEEG4-@Q&J3:-9JNRWV'/ZO_%+7Z9
MU@Q1%4<JAG'E(LWW19$G!]4O8 /RQWPB2/F)*6R$?1%=BT7&^LX]&17I0QO=
M.2NU/=^2K=TDN'_<>OW;/W;?[QPL+1I.*\DF,Z*J.,(WP&^W0,@DA5X[OOWN
MSL[VSC\/]/43C%O-,[F?@4&9BEQJ$\6Q@:Y4ICC2M6^N;K!C],W?;?_Z[I_N
M.NDW,0O5I)'XI[_L;>^^?]A/][9_7>>'WL#;"#OF>1'Y;9Z9P>\G8.$A@.Y3
M_VLO^&-X_&78(ZC=__PR^C,X'QWU/P5?^T=_#$?>"KR7%;@AC>*\O&B2%\\*
MI&OSS/PV/!Z.0"2<CD[^.#H[.CGVSN']Q()O[O2"HLV[NQYRNZI%[60BLRQ)
M=3>G+(/'>M2MEQ2O5U)XV.V*LK]0SF(UU; Z+R+N(2(VI&^3%Q%KB@B/NFTV
M)B2\IX'&(>PV33""Z#F)O+1XS=+"XVM7X&M3G1I%65&E*/+RXA[RPI.HORQY
MX:&TS34](!E"+N-1<? U53G\Y"! .I*+U/LD7FJ\;JGA\;0KK(P"#^Q<I-ZJ
M\/+A%<L'SZV^(@&27JDK7[OG9<,KE@V>6WV%[1!/%:ZY$AC2]"+"BXA7*R(\
ML_JJII#$0909=H#@HY19+Q@DF:8;&=[,99QY)K-[20_?U^EE20]/M7X+XR&F
M/\YDOG4RG7HAX87$ZQ42'J/9W.))I-FEB")*=U@J,Y 803\#]\3+C/6G\OV&
M$*][F;&NS/!HS>8>+I&<Y&D2JPDX(')2&)B%1UAXJ>&EQJX'<#8'/,7<MY#T
MPN&5"P>/UUR5#<GRM+"(3=_YR4L++RUV/5JS<6K.+U4:!J<"WM7G/KR$>,T2
MPB,S5U$C]\,KE27I(DC2X*,*BXD2\(_#PF,MO,1XS1+#8S6;/1!J.FN,"HNX
MH.X,7F#<0V!L2*,XSWG5)!^>->/1YID9G'SZU#\GVJO^;\-CWV/V10H%;T6L
M)R4\X]7*UG")BG-JH$"45T5^F:0>WNV%Q6L6%AY&<6M':OC_P2<)JY]Z*>&E
MQ*N5$AXVT0RVNID4T5SD&,GTG%=>4GA)X3FO5M@3,E(BGLA@O'#ZQOH(YKWE
MA6]!_;+DA4=1K.@&&<D+V\;^L/!@"B\G7K6<\%B*%78%\O9;0>%-"R\RO,C0
M(L.#*5; K^(MZXZ V*C+#$J.G.27,M613V]XW$>*;$B?:2]%UI0BGB)K15&(
ME1HH+WXK1"KB?!%\%GGN1887&:]99'C*K!6^BIJ-BS2CVC$,A'KSXOZRHC&^
M[F7%QLH*3Y"URDN!EY3,I'>4RUD6Y(D7&"]78'C(=Y-\>%;<19MGYG#X\>CX
MZ-SW-WZI\L ;$.L)"(_V7I5 G:I8>5*;1Q4/\%\QCB3]^<CON8OG_8X-LOK=
MRL??]L3UI^'?_K'[?N? F8HG>./WU1?^J\AR-5T\8'7I)J&<)-P,:[] (SE2
ML0RR)%+AT\S0\.92C54>],TD/61+/O:@]M^\H7:"_?"*LALC^:]"9GGP,4EG
M?C'O7LP/6[LM6TY<.4QLGZ>PH)<RZ ?G$CZA50874?I576=5]UJ^JA_\JCY@
M5=^V?%4'?E7OO:J#EJ[IF9P46"O92/[F5W/%:AZV;#4'R6RFJ (V.P@XP@JV
M4IC*K-JGQ"_HB@4=MFQ!S?&$A9UK1,\ O=<I^*_M$+C/[+.%ZBJ81"++T,V_
MD##V%+8+C0=N"&/%"_10_Z8HT<W^UMN#:21OMD*EVY3OPPH7L_@@5-D\$HM]
M_'8I'K#]DXII;"9N!O_4<V(&23_<DG%X,$\RBDWLIS*";7PE#\;)#<X(OJ4>
M(WSRU/&$,FK1AOV\U:;#I91JTW"V*F$9V+3Z?W&/7]J0K5YJ%:,\W,IRD>;[
MHLB3@^H7L /Y8SX2%+<54]@)^R*Z%HN,0[7NT:B$R&BG.X>EMNE;LK=;%D J
ME^N) V?-9YHNR,$PSZ:@,O:+^5RF$Y')@W4W]#4O\#B)GDC%?CKI'P?]WT;#
MX><JA4]ESMQ@_J/&[>O3^' #Y<=,U_GO1V=!\YRU05X%G?Q290%3M4T.OF=H
M3SZ52RY-&R:09RX\Z/:"$$RY$*DHP- [3J[D;"S38+<7[.WLO<-YEILQS</I
M%,VI*QD<.K9IJ^8:06D(.!&S)+X(?AN.3HZ#P<GH]&34QU1S+Q#!(2BU:Y'*
M !R0N?9!@H[8D*W^(4G3Y+HD,VG3[//,!P[7XP(V/VYO#2Y.TBS@:B?D6[B4
MJ<P3))!-L%;A6F4RF../S#?3-)D%.0P+D4/XWQ[1N8 A@VLFHJ#**MD+/AR=
MG/[>'WWN!X/1\/#H/#C]-, EGQ?C2$V"2('O# =Q KZ6B!>!BLT6@ _)"Z7!
MPO:@DSJ,+R)Z(_B_KR*"R;E6^:7]=5SP,=YY]^[M[J\[M(4VYBBO*C-KTW:"
MO?/A=# */AU]/CH?'@:G_='Y\7!T]OO1*2ZJ64W<,K%,LTLU#V2&Z4V57=YG
M05-YH;)<"P*]JI].=_9V?GWWCE95;,::5EF.6K62-.5+I_/H^(_AV3D:/F?!
M'T'G<__L?#CJPMSC\@[$ AX6'&6X9%D@;^1LCLO=M.P"M!*(>Y#]*L\"V,^T
ML?45L(M4<GHITID534?Q%>P4;L;W1_#;:?#IT\"O]".=V3G2Z(22A2&(F%F&
M-6HPE,EE( 7\#X\^H,:(P4Q\0[&.VT-K-OU%*N=BP=I#K]KP!AY&_#RT5J@D
M5$Q>;Q B5D2&W>UG]SIN@\7L/O>^V7WS6-OZ66*X_<'@Y,OQ^='Q;T'_^# X
M.?]]. I 9'P^>_9E;[NSN;N]^Z8_F21%C)*R39)C.X"#/9'SG/PC:PC*FSDF
M-:*%D2>A/O @+$ Z"/LN6L3$2>[\6LL#L/ "\F*M@ZB%RZ4 )P9%RTP*'"+R
M!*)A"C]!4_-2SO"G,$B,M6#2C R%W_K]4QCN0$23(J)]S^CV4.(85*P_FL%>
M",9P;Q'*8 J&5G*-X]2_/IH& BMT%VS9XA^32Q%?2'PB7A-<)T4$1@HY6S1(
MM#B+W%($X$_@]40\40+EY+\*E>J7DSD\,(6APKWP,LK<FL:100<,WJC ,"!>
M!58Q&+^9)-,(YB$K4OQF4B8BZ*7Q-G/#C(:7/G#S/(O$../P?_"^33N^R_I.
M*JK0MFHO86-UJ9B;=VR6T$J#V=)KOJQ!A<;R(LD57(7;X2))PF J<$EABPO8
M$&&0%9/+R@:";_#8R50?CR15(/3@&8H&CY^E$O8 W"\R_<_I)M4M?+!1F\0(
MF#;MD=Y&S6!^*5KE0?8"U UT:&BCR[ 7=&ZZR_N=SPG^4,4%A1G&1MRR]D ]
MDX:E-"0!/4\5'M:DLO5S5D]T#CN++FFI4DJ#7YK3([/>BE0OJY(,O)M(@$%K
MFOU:]=<#-1.I*WA(B*(B*\:@F'*M%@O'HH8WN/,W>7(A2?JPB(<Y@3F8*!@5
MB<NQS*^EC%GYU+6=F*'FS1QE8UY]+.'?DB\BL_Q"7:%*D5J5)4VR E3B<9+C
M.&".8E).J')(ESN*!]=(D$YWS0#M7J!.=$T">-=RZD$M%S"J(K._+2=JPHT1
M<:9HU+09K++E.^O73>54IBD;"&8(I3Z%FV[2@35Z\:<VG5I:@DV<Q599%^7F
M1ONS1R<\*?+ELXBG3$;Z%5B ],\&P2][/VWM[@0=.$/E.?QH3U/I1 1G>%Y%
M&F9@=\!_FK\:)"$+.(JR;T1T!6:A30M:!M&2.Q8"+^C/0;=,L,:C\0K'!3CZ
M.#H+?NVB+T1"U^H>, "+*,>;\6;IXFZY$E'!WLH1;)4Q*)$8W#,;O =S4(Q!
M?V <WO@H;AX@T-OIK!AG*J1><4U7@6=DM@B8JBD_U4S \P=WVN_E[[TYU*XO
M(G>S[39M9'"<YRJ'F?P;M>BC>.T5AW<35<=NJR#@8(OU89[Y1/,*E7;7TJJ@
ME1V1$+ K"(>0C%FPIYJ7K(SFC!?:CPVECKD$\H:<3#(2^>F8IC6[0EN9>HQD
MCLD8"0;@UQNA5P[192^Y#]JPX#9S"^)Y(^;P_VGE[.$V_1)36NHL)U].KW7#
M$0&1)T.ORNY696_?#(H4C_BB36L.XN=C+7:Z@7HG\Y[?=PVX71Z?#LI2_"B)
M9+0PN(9LKGT]U*X<R#!FMVO%]YR$>&G1$]94L)E"J0SX!N,EQ6PF3'0LF.@C
M:GYS2?D&+?OB) !K5&AG8G@E^?'F,^NHAFA/<& %S85D0G<U021*(V.JA.R"
M^XT;S!5P>.ANO<:7Z&1)$"%43&0/N'\/'18[OEN?!(XX/&*.>:)JU*YKUHS@
M!\;WFNHH&8X_2$FEX&=FMN6-#J+Q7%',ZPK'!N/PNN5NW?+NS=G)QU&;#C'H
ME?.FM$Z82':3KD6*$#IRI">4+\7S#1M,D=^]0#^(HY@Z^0._H>.$I]UXY\N2
MH2.Z.L=(,7"39(0[A3#4$A>%'U'\.,O,/YW(,&[.2L!H1B2B 140V*0J5Y/B
MS <C8[X'(\Q/P6_M=SUS)XS$PI3A)%@J$)N!@FOX6+AQ6<4AZ^7+[3U%!,.*
MJ:@!WP<F,LL2RKVE<A[!,M-9QSOS3W&&RI )WN$#C/H2]O\W> ?[BZX;"[Z^
ME%H8<BY!5U.00+@4*8@.F<+$JHF-E)#DN<?0UAH2+#6+5Q/7R1.:!O# PF+"
M7EDF0&YQ: ?#/; )DIF:!)@A@4]I??3D64>.?X+E5/2;2,&U(>XLD?5N7>2>
M\TUEKY3#MXD5A'&%*C.;DL:1@BTMK@2\"F]E&E9GS-N7(U6P"K-Y1*\O[)2[
M*Z!#3CJO#],W8"F[ZO3A<<*QB.F4DB/2B7B9O0W7<=AK)D PQQ>"<QN.FD H
M%.;\G8Q^]>BL.6V]^V[A]?:)7@QX'WF%$D:$*, Y^Z0/ 6YO!F]AR4F/=3\(
MN!CF082@>3)RXDW^>=5TX@QE%'.&.^ 2\ QD29%.>&HQ]4RL@? $15D7D24Q
MA3-Q/\!8Z%0GL-LF,L7(Q'?NN>J;H5V?%2*V1I--,-5"'VU2'4%-X?N*R8VK
M*O.E@!NX:#^@%/ [+>G'GHC2NB1S /R[TK!TQ#_K*0WSK8C=4] 4(+\1?1:*
MF;@HDT7?8 >Z1A0+(OPUQI134NYHM"H1]4!*HWEW18IHHM"A 16C_2T$28%&
MA@_T$\!033+$741)EK&6D3=S&>/?'6.KH1Y)TKQ'=C"::-6R%'QQ<REH\DA<
M\\C(4J(JEZE^3[!%61G75+PU\U@Q&\,D=E!5W4IPW/Y@65,ZBO+YG;U6 Y[W
M-AOPC-6A9X1U)I1S</(Q..W_Z:MKUUGY[=TWIREX,VR9GHIV19$W??V>JJR1
MXF(@_8H8OC-U?@P"QZ6D9-\<_2RGD(2 JD5NX6/@18)6F&-?$QORM$X"(J*Q
MAI#H!4-7:Z'0)8&K;TN L,D$T6'T=Q'/A0H)"9LB)2%+;0;\E1K.P,5"<*E+
M9)[(C J)Z9L&9&'5P=CX#?(##OC>FW)%-^YP[[[=?OOV[3,MWEUZ^;%GI".Z
M#U7$SU-HY(296K6S @10_>4D=31,(L:B9BTO&\(5;B!HD];!9"O;M 8;-8$.
MN7@;YFZSJAK>;K>*=773)J]5R+9-F[QW?O(>/GFMPK;T-@[<\G:[5?"6[OXJ
M>_J.5B&[[[;W?GG_6DQL]6 3^VD=>H%&*/GMNGZUR?G=I.-AH-LM.R:ZJ-@E
MV)!7F'M%:)%= Z3;" 2Y#4&$Q>%N "31R53+U#^(D@Q]AD-=0RSBLB)X*<H"
MJPO_,$5^/ 9&R/YZD+EU*:<R18I#S).;R(Q](C=_X!OJ_<+A\#*W,"YR#K<3
MJ.TJ4;R/X%9A4HSS'B%?X(5%;@!IC0-RWM)R*@<=6+V(.<XB33ZR$;#HZ@2V
M:5O:ZJ7OFL"G3IE[E=*H4EJF4_JY%0/E.;8EC"YTP^N3[S\BCZE*/OQP5?+A
M&53)AY>D2CZT6)6@J>,E^%H2W(MP+\(?180/?K@('SR#"!^\)!$^:+$(;].H
M5GH#K4G8_G Q/>7JC;E8F.*G>?FOCD(^SR22&@2'1*M=*O<JVX49_I!YDKJ%
M&%W"@(\EW!MQR7B(URN&?5WY\O%FY<M'9FNTZ52OW%;>0FQOV/B\@M-R <&(
M.M80K-+8R$N(54<@@/@V2T#SAJX"=/$%82'=+[7Q-#2 80/V,FQA#/IRT6<&
M  8G@NR;DH:\0L:9(0LDLEOHYYG+09Q."[QQ7,6L!9^1Q@R!UFA^M8O7Q1^T
M#0RF54^:4<NDY6'?)W&T>"F)FKWMO<ZDVZ:Y[V$!MZ8\MIC_#64P^J5=$"-O
M3"Y)GLEF&9.GCMLQ#38,XNM57GMMRQH[MJUH3^:6RZ.D9;?4(\W9\)ZFRJ8>
M%=H%)K]X5D2YFD=<V(:Q)Z)_HL#3__[W?__W_]/5/C/YS[U;ZQ8RQW9LJET8
MFQJ[\D(7].M)N+_;L*6R_4Z_6P9%;7.3ZQ1Y7&)<8NS!K.'82Q7OR)6>.Q'N
MQ]DU\*A6S9,O0+]'+;-OV;NZIJ=-@_$->U]>E7Z#>?8LIM@/=_8=\P&5B\CR
M8(J-/#L_@7(KP*Q!?7,(&['6W,"-^G,++ZWPV(;B\)RL\<L]H""3.R_HZ(-N
MD-+YP-P^\XI#H(=5NZ/EDL. !?9G5&45O8G5K5/,F5^F27%QR312Q$PU=9[?
MJ]ZO%NGCCD&QUO04+JG/X:8GN#&4(EL52MDX=+T[E=-V325U0+29>6K:V#.<
M:L2.A#P6[G:V>4!<!#1;M4W;:XB1UT\+\]C9 XF_7D@X(7@LF]P9NHHD"]VN
M&DQW"QPW_XRUJOBGNXK,B^CEL"Y_GD<+4@O3:EV^]GW GI=J7LIN5B ]NYZE
M3K@?5*0F6V&8UDO#8#:(=? V.%NC=59%EKN;;#.W"4:U.ZI=(D0MK8MN9T?1
M%F8WA1-/G9V1[52WZ4'^TB6;P#+M,0T@;;H*^2H;))6;5.E?2R9,W>O'T+XF
M)@A44OP0#RTXFC+4^ 9EV>Z:C0&3,B'6>@S@:QH'?I(LS9RED]/!$;'%4\26
MX8ZY.2]E%/;*8FXDCD6R)!X9<_4%,:Q,Q0PC/ 5UM0KU?3,MGNL&";,*C35+
MDO,V79]2W+SX:KL#K$8WL*C7'2DEL4 C<UB)R,,X6F=WI]D302"1FLUDB/2;
MF)2<!M_BY#H.IO)ZG1MT36S.GG_-R$5R:F![D0W@-=(DZAE-UGAR43"D*G?D
ME2:KQ@0I0Y[@6()C0D+&?M5ERZGA8;?X5"[UI<R%BC!;J-^%>YKU,%;-Y)ZA
M$94J!9,(/:\)!Q.;WS+H5%7Q9N :EU_CF%Z@36? (AQ=>\2<!Q2V%N%!ZF<U
M,]$=T?U>Y5 4<^RNI6E >-?E)/"[]]KZ#.JM(WB)];>8X0\Q%MX(Q*GC8K[?
MU]9;M/P5]V;4K'HX00([^L%]2HI7@_XY,C\"BU$E81!R:UL^;"M.A,I<"\$)
M0=SF\C?Q[+\\$[-E-N;F.W@^B/)J@BB]>J]5'QCQ@9&EP @9FRNLF\>/E'CG
M:A-+YTY-8H;**IR<!/Q9I)-+"E6D,I2SN>E]8#H_F(")WFFGM@L-[+0K;$&-
M>Z;2U[,!^HE;ENGF.AM3";7R_49VGMJTQ&6K5T*>D /I9.1N 83WEIV--9UO
MFP8,*]F_U6[#W5-Z7Q\:Z;@G58_Y?H_[05[TW4/94+]ZC1=[O9YV[;R4#K;I
ML[;^/KVO?TT[LCF1?@]_N\E)=6ML*HYN:4.\4E_7.[O>V6WO5+;;V?6>K?=L
MFSS;M>V+IT %P)U1=5DEBG>?)JF\2.!?:*K&EGEB"B^<7.-%#;U)$5RVSJOL
M!YUK&W;'UF@:]SVD5C$V-IUQO-Y!MDU$1GWL(R4+_/<T9;\-IA^& [_IHJER
M"68@FBIPP1I^7*T#'#W":FQ,&I1C['(+.9U&=L:%/UQI3."7=X^CJ7_<4O^#
M2K<UZB4/ P #O00"A/KPLT=R@2U/J:D\+?K=HS@(.C==S*6#RY,N\#E+:T(I
ME+O608/QS2S@%-V6[N!)XG5;<]FHER5U::17T[^%3WFY\@>Z\+?,\4,F<]%]
M<"SB'J&(@HIN>.>FR43*T#:-4EE6F"+O=0Z#L9JK-R-I=85[OM;\3]Z :%'X
M*E*DF&6+KQ%1A XR/BRN-'<JGZ\WU:%,U16AL;,UH*&W31U/6?> &E[^K1M>
MV@[ 4_@;VXG")*TQ!Y@BZ^RVRXKPY2.^?.0Q!M,JQGE?/N++1YXJ&?*C]W)%
M@V!4.%=Y01H'H8CK:-Z-R1B,'#2I^SJ'\#)M$B]EJJ"C02]5HX80MF3B.382
MV1RWO6&W-'WP.7?_ &$S<[O^["7A$V7H%"^O:J(<=/:Z2R8X?/JVN_Q"/03^
M@9W5^Q'F&JE8HN3@IO*-MML]K"YN5?ZN:UV+-5V')#:/8F,OO)>IU[$M1%U,
M="BS2:K&FT<XDA7C+3 +"^[;VBX+UD#9-FD^P9-HU1R*<7*U.3FS\OR=EX>K
M3?-I%(1N#K>11*:-D]PJ(I@R">EYA^KR)=Q8WB$=76[;D=X.@GXEWM:0U=[\
M5$C;R-HH I=1M1I6KYDY![M-1C(5;C1S9B Y+V]=?MG>[8AVK4NGBJS5BT+5
M_PLTD3^+;Y++DS6%.&I"YY3#GS-5S!AKI<HTY:8OE4^YO^"4>R^HI=QMII)<
M1]BR!LO4G/]1J7$^$??7F$;E)($H=:!QL$_&8&<([C&L:0'*C"F%"?>#H*.Z
MP52ER*<+/[N=3O<@P.*2()-8[TK7W^8-"RH= D=]*E .C[@- 8&QPA=P:-]V
MQBW;:1QQH452&))1*2P2;J2DR&%ER_V!80R+]5";NQAEB"%H7=63=H_7.R,E
M2AA/":[@%9S*I$CSRU6WZ(=<<2XBC"AE*M2VC;,-\!YJJF]!V=LE98I7X8E6
M-\YE=47,M[2BAWY#8@#AR>7/[DDA-)9\(1,88PT_Q;Y(+A'HMY&?CR.4(P-[
M,,(3:_LYE\C=AFB(,$;R>/4<QD@R,1.*LN9F_\/=XB52[WN#F[PWN>1-RLWR
M)NM[ODVRI%U4#Y[K80.Y=%?$(:I]7)U&381LWU2SH-VQ"8+N^_A$Z^(35<RC
MKFW2MDQ98_50RE-*^4U$I,555LQEZKS'^^V?'^U%XE:1,F\M)*((XQA!G)E(
M%\O"I]*HCOSCGJF (Y.0,:C+9)$5S&MCF4[YC+I^]T6UF\A8=+L:^^#5V(\2
ME5Z/>3WF]5A-^CR]'OO@]=C+((>X79$-O"+SBLPK,J_(GD61#7Z (ANLK\A>
M;PA]NEDA].7L4INVO0^B;]X!V"BCS0?1?YA=L,)BJ])1W<->8VJ<Y$IEB0'*
MA%A$HXSMMY+%"\W'@3<?VVD^/E$H>5G/>2?<!Y,WY)RV49Q['_RU"=$/7HCZ
M2.8&'U0O15N\.*]&B@[6D**>G,>3\SQH,*UB./3D/"^/G.?UQO4OVF?!+=5>
M@C714'II"B1J1H;P5<X_/(/@JYS;;.KI[NA949+1XM1'ZE^%"JD=6BAF5+N9
M@7 2,%UD^U&VV^%TU_67NAJJNM1,FN0P3V*!TG+K]3)T?9SDDAE3K2\FL+HI
MTQ755%3M]%\H":&J_15*.GW#;H2,_B>CT<G7X2@8_O?I:'AV]NG/X&O_Z(_A
M6= Y/PG.?Q\&'[]\^C0\.X<+SH?'Y\'1>?"Y_V?PJ?\5O_@S.#P)SDZZ=.7I
MZ.2/H[.CD^.SX.1CT#_^,\!;XH].1G";\R^C83 :_G]?CD;#S_ I707W@=_V
MS_''OQ]].,)/1_0$\P'=>G "@QB<P[W-K3_W_]?PZ^\GGX9!__/)%WX&/.ZT
M_R?>&__\?/3E<W!T#+\]/M:__7IT_CO]^NS+X'?W<OAQ?S 8?AJ.^OR047 "
MSQU]/3H;NGT/Y WNC@SFT%V"CC;PL0L"5@=J5B_%O6LC<8U?+((P@;/%/4?V
MJ7Z7MLVZY?/51:9N(YG)@(3%Q#H>Z<S2-V]%,K[(J[Q4X)@@^6PRO\0],.$6
M?Z:=YUPF\PC)@<:T1?%=T=*F/3Z!P64RTK7$]QJZ4SO->BANX(K&BKXM>.*5
M4!%^!K;!-YD'()YP]W.]90[GVSI:W-]PBM,P$Z$LZV?AX^!28*6BA/?%@:?<
M5!W+GW&F> Y,#6+E9%VH*R+GG<N)FJH)L?#9&DU.,N&T.Q.*1=QT8H4M.83M
M@'TQ[C-'NOH1ZT=K33:P]7$&IM0<E@%?C4Q>YIT#!Y%;JH1J.I7Z<%/W#%0Q
M.)R0*8XWNU_$1:LTQ<:2+/RR_;Y-\[A"K$ZPZW DPXM2OV7+1ZNIW'G%R>H9
M-4QH-&XFSH7%=7V=X95XQ%2%O@^M-6Q6FBH1:;IP,Q2',Y_(Q&<P)+*J!Z#?
M0?P/41$@Z3N\[%==T"_@J$Z(6Q OU%9XG7<_1;\T8Z9X;#\K>6"LVJNTZ"P%
MJ=;;SN<49&CFSI7SKFNZ#->ZP+K'I=9.KP C=UD\Y:5,&B- S9;(PZ4J"G39
MO&X0M,PLL19\K,T<L$].SK:W_?;-:6D<VIZ["2]*?:>UBK;-@P.7@@ABL\"!
M=KOA8=V(K>73CNU%XIT5X[]T0Y--.@3M)0\"G1LEUSWM!]:Y6QQB%[8<R",I
M(PNLP9FDIL)M(QZZ//=]2;KSOLKA]$SN\=IS24CX=B&5R54M,WXTS6<G'T?D
M(>("65EZ"K9D$K+IA%^V?+*CHE5&!<UEWS5H42)O$/=]E36J35-K:79-KU<K
M%)9".+#-4_@NHO:?(@4?8!47WL9&'EK5Y\3;.YN(53VJGA^M:I.XKHDGR0P<
M/&K]@%1PW$M:=Y1C[1Z")X]]$>A8UC($.@+*OZL_J7HMX8TH[Y>DS#EIX@>&
M6[_R[#L?;8*?YG:*J0G];MU(4*#=KK",=7*]4N";[6NOYIH*D043$4V*2.B,
M02,38(>WD;F22$[K72!!X"."*1!C3#_ WH[5E/(J:9JDO8W2)E2>$LI659)R
M7+5Q=6Q3>QQT(/%_W9XVSJIQ6TL3<2PCE]AS'IY#'2YAS<"2J,BVX%!.Y&P,
M]OO;W5ZPM[/W[L"OYW?GKC=I!B]AOUS)M%T3R)F&:8GR#(GU.*/FR2+X8!*D
MAT+W]7 "ZLLV<EUTZE"MFF$H'VX<$>QF(DG#NO?V\=(E'3G>K'BIF]MHTQ;?
M#D!=,_X$V7]7I(IT1JI.0FYR04&'$STZ22XIDV4X>IT3<9&*";43GF#+VSE%
M.[ID>9+2X)[-I!1*BMZP2(V]B:-6L>VF!E;F40Q+!N.>+()3;E1&VJ3,>%5O
M[A24WG7KA>8%'E[I_(I>P%[EM%)'6\/('5,+;7Q@*&?XQ7CAY/ ,U?&2:L5
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M!W2IH9M:9O7;J.6Q'45:Q6U@L$&;.96M"H\\N(7>,T]BN]BZ?*>@QYG'SA(
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MBT%65^00CBJ"]8D%IQI!\'^ G=$:+H]E?W!CJ0%^O#11S4K!5^-[TZ%*W-8
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M-H9_O=WM!7L[>S_Y@_BZ#J(N4&_7!-Y]$ ?M/(B#^QU$DU2@H[AL5=T'7&J
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MR6TDVQ+\K'\!F[89(\N@>%)(*666;#Y$:JE25RX:2=G58VUM8R !,I ! DR
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MY59?1Y6-!F+GJ'BJ@O(KV+]<8&A4I16#=RWD2<^@'21\$FX="5W0DM+CNIK
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MJTLI<V+AT1G7'TXCP="?11[2*K:AK;"_$+#[*VY5^_<H?./]@WF'N]6XYW3
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M.P? =# V:&82\2'F;&]XR+=KADB[C,]VP!D<+UB>8@4N)441</$Y$N.<G,0
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M\C'?)"("$JF_3ZNKX/5UE-4BO0EV_]=4J[3(_P3/O-Q2O5P)DEQ-;HS225:
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M^@Z-S&GT_<82PM<,4!^?3@GAL !5?1#/KS5P>,?MHF)#55,')AK=OQ!0R]X
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MFKCYQS4)BS,\/NY9L$$%=O'@=#[GTK8I:D9$JP+[,"7W"Q]1SA2Y;"^F)YR
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ML2E.P,'/G#W/VP]B\)*R8LTYQH@$L 8U'F,CT-@(=!<W\^3)D.YF; 2Z?XU
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M5B-G,1.4'T]$,QE#0I2"P%DFFLGP3)AZUMY;LP1,$RZE<Y4KL$,^&#T HK3
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M^]NTND$E-M^+=$51Q!R3NEMD.&CUW/PHRJOJ)JQ6291+AOQ]LJPE??@Q#/[
M*_Y/G23*^_0>(IWR&B7AHS)&K>X%S;BDDI)1=\S412"?R 1&GA2RRL%;;81;
M4U32O.0;B'V"?SQ\ A=<)/J2X2F<V_XC<-2! VD?6YL.@Y9J[6CU]UO]QP_>
ML-9C<%&)VN;0#/\[K091$,R[O@F$M:8DT[1/P=B!]T7SJ[RXR9)XF;3GDPA?
M.C _.D3(^55H4WN4+ZD"0_@#VBD*D2NIB4Q5[1*6QU982.,O6874,2^6,M7?
M5C9&.IHLQ"M[2XP?->A0)X5M\A%]?, ,IJ2G@46]K@B462:!1VY$$A(6\$/
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M.G4]!W)$8&Z04H3/<GQ*+>P?--,'&]R3(1G'DR,#@ %\.J@!I'QMW$D X'2
M24SFA6&]ICP*_BQ2<NB19EGB-YCWL3+;X,\^J)&VH=1$K"2B$"8(D=]L8%_2
M9-RFF(:?/W+G=U_?',)KM$,NPTLFD[--\!+<,5YX-->F/T4\A*XXR62\;*QM
M8IB./D7\1R-$HQ:R[HT-FSB=D%:R VZHC%T)'?:9?!:977#5G;M+*#DH>\R$
M/!>79;JBK. :_:8JE'\1@$5P5RMY#,R328C8:)/D#9.:'&-P\^$^:-?6<_1M
M[1BTU_@K7F/41C++HORJ@;IS1JD"BU4A+*TH>Y-JMN]A_^#MVYPIT-0N#(Y
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M75;,?.;%"CLF:Q<9XPB+)9JX,"GR]"&DN45(\Z<]$Q ^RI$4=K8J#UK;AAW
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M53981=P?CD5B=TUH&)BC=9[$&B44Y]5TQ;V^)_^N4&">X'ZFDN"NFTHH2PA
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MA"B]35>O@DZ"WN_W%/0L"]!R"MHX*9R^V\1W@?RM&4(LEU$2F\O&Y*Y%Y6W
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M=U=#ZV Y%/9.YW(2A'[=E&&-'D(;5%BC-%?46VCG:C-T)K5G,7.J*AA:;.T
MY_6CC)DP^*#4DKFDIMQ(TS)=8(E3:$O-B":1$7MAA^\B!5)\ZNK,8")'O0(W
MU W4=@')R)C"2D:F8AS;<N4,+68E]X45VQV,:Q.,7@ZZ;=!M@V[[ KJM[)UR
MRS^5J..KS&+O4%9^Q6$OAC2D]A],[;_:PU[*<0$J*&5HVT%W:]4^+2[A+;'$
MJ#Y^;BE:-GJ'NB0%IGRDDU-+[C+LYQW;SZ_W#E>K:':[H)U\JM:; S3'5D6$
MW-M@!VBH9Y\6=D"P]!W!@G8]NE328\*0&R/L5ZD/FDJ%MEY(AG8!$ZH8X9O
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M*VIO@[ZCRK 7FU"M8FB(.39A&M:4CS0I,]T0WFN]Q%V,N'&FWJ/VW:2A$C?
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MQ#.CK 01\MXCB[2MA6> [:U0K*T&]\Y6><.Q] .OEI@TJ9D!J/J7!1R\9(D
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M+UBS%XQ!8$!Z[OG756X,JWD YZIM-ST9J%7)C(###G<3+GZPL)9I5=HN-73
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MAJ8;@Q2YK\'^TIV@2H>A"+D(JDR#_,7P<0J7MTV.+K D;TJF'!9%<YXDMJ'
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M]Q\#^?Z[YY"MJ ^@\ [C=5+FR 5_>H$'<G__!4?YW_P,T\SJ, S^Q\N?7KS
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M@GNQ"LB]K445E#"(-")Y'",H@O[BEB(H5 ML9( S14@)).W ']?T"+VDYK+
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M^$C;JSK/'_S88*W,?V.\YP-8.+9+WEMD4:6P3I UK#OQ7S0/B+\046I9U-M
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M(51>)@'SB#@]5SWF_P/BDK!8]0A)!S9=0@:4WDD&X-Z)7GAT,AATQOG,'1Z
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M=PDT2K7Q"_[U&0'CV[#Y(3- *<T53S:GB7CX&"\.UZV5A6,UZI:.,D^L=<-
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M%4G[?X/PY8VY,N4B'L60)<4.!YWBV7EI,JX@?(T["DX[.!.QVK"O7)WQD2L
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M=N7_[4%/V@;^.H79!^\AH+N85A76W$-GKB&YE\$\_WY*HYEK2+Z]&I*_1!P
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M.$ZS=)Q>.^[_E.;@:19-=*5@ZX$C00,^X$7>BA"F?2-4#%>NS-:2R3<UC&.
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M,/UG.OW'1%,FO :TX(1?BD8X*-B_?<&JY 1/Z3@89HQA6\<MZHR*7O"C%0&
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M':*0@C=)$P+U$"TM7T7UIM D\!7IA8._/J)Q(^!@F5+<S6T+4]IX[+]UV5H
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M3%M-@ +-=]YYB+EBI21MU ^^ET3Z(+>Q"8*SZOI&K@J(^("(?Y#&?#<I3:F
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M2::>Q\;\^/)*#HI_P[_^_>SIM]]^^UUL9/>:+DU5TU2U:::(==A+#%,=?4W
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ME]O+Z,*P+U]3Y2D\8D$$G(SE/VE9XG*ZW6GI6=_LP3 K3BNL.F<N)"XZCGZ
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MJRW2K3"+U4?IU8?S1)W[46JAS;38?9,D70,&\EB/P$^XRU1[M\],-?;$G1K
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M-_U@./O\MT]OKB9C[_/_ 5!+ P04    "  QC%I:-:T;'5:J  "T'0< $
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MN%R<O'M_M?4,\IT,W"YP3O^XY4&.Q0-GX=Z6CC/D7!S,01GE.;RZD9"SG:+
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M\0WV)Z\#J9+TI,:4G,C8!I&11'C<9!T]R>]<K.^(KY?$5Z%M*?VD!U1(,MI
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M68%]HT@94X>1U;AL)7?='$,[NBH*5L6XR8';N#@DDS#-P;J"$5,\IJM9\#G
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M3H:*R//$#REE_+-MLX3:9K'$G^.0_G.(56378?:P>N1TNM<-=:UIM+K)L?N
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MF/^[!(4-7K/TCJ0(\&V=I-6P%IZ\5/4B+_<.X'1Q=+A5='@A$4724:&CPL?
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M%&TWP0T3="G:/60[EZ*]'<KNLN-P.^A )2>/:>JD,JXLM0W=,3?S))(6?O$
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M=8DEZ=X"'DC-[E1[B'HC63L-ITD'DO+F]3-P?.92;NK,?:!363#8#P.(BIE
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MB$/3YS_4O2SX NOSG2S\-J-^A1QW0)1&',W11E ?X5 .,6^J0)':)9-*;\<
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MKGGG%R>'8Q?\_;K@[[.]_2>'48)A]2YMNDI UCD+? ZP>_Y67[X*%(C/B&H
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M5)N'G6+RD(+N.OR>)C?*9:5J6@KR*"C%>F@T<;P""SE0Q\8JE[9"IQH4+X^
MG\-"BI^TM!]5Y4>M5EH1F\/CRT4]TVL]MA$7YPPM+Q )+JN@%TMW$*W'5*M4
M"Z%!BF*3-5ROBG",\M6,\NS)6&/5$$)=YSBE5O&#W%(1C[$P*:^<25@14FQ3
M5C*%(X)S@1NNX KFB!/2Z7"F7R8AR_YU:'W#NV#\-,J'D#<)E-"<3R*GI'<X
M/ZB[[@J@4 -$2O6*UQ7X8+;'?IBJ_LTH0$! [&B 0)Q;&$C5*$K8H$)XXO/5
M6!%6H(ZQDB_FLDYZE'7RHL.)"B[KQ$UPPP1=UDD/V:Z7G7(>6=-ZCO#,ATD\
MA<.]8UDG=[<'ZM'T]5U*OL8XT)U*R,P.%7 GQIH9]?E:<@&^KY:P*LE6WA6A
MH&2J4.X*OC(%E#<]CK^HH"\#.178Z[7"]23TS9_+8&::=59 MTIGI$*8)&OI
M*ZU&HK2_J:Z4-"-2>-UZ3*3PJ2'D"O+F=G_"75T4=W \=($Z/=<WZ:MESHLG
M('#RSF6Y>=ZXX@!D*I5C4?7+57)&Q_]41A5Z#2-E!^5%XG^N:I0S[E$:$QAN
MSHX*A+H BVZH?7T(I$Q=687M&\)6Y+,P+XS#5H+9DPD-BZSP?[5T0,0;&/"[
M!/B%*LI@=&/@6X7MSDEBP$K<U+71_S=0&"+)I!"$;]00I[P86+):QX'G1K^Q
MVE8:RH[*C#%"VS:"E[?)Z6&56K-1NM_%FZ3DJGI<3?"O/$]-;_-IL )+W"UQ
MY*31UTJC'U$#.@4VGG7<*:M[.)"K$7VN[/74<0"#3D6]T#)$@HY-@_>IPESS
M69J + D70SCF0SJ[L=F*\2=EMD^&>BO#OZJ?\SHA ^,PJ-3_%2<WD0QF*Q@Q
ML0(3NO<@C'^MF%-+'911J[ZMH5)%[ASAP,?.!85:6#G9#L7$28*OE00O02\!
M<1_BJ=.E+>US(.%!%@3S[T=@BBE31MDG>3E9A'G.'\*8](=*!Q&%, G U&)>
M0S^&L>YD0<![,LM"RI*EQQ&</OP$RDRD>EIPM%GD((ZUHJA0LQB=<NE=R%D)
M+\*'C$R(3'5G0/U#SD4T;9B!-Q02QDXN' '(T%=-+G*8YT++'95<EEMY'81<
M@X@#*%JK)<!W&3 O#?-FGE.F 3>W93V5C+LL,VT^$4\NJ"+8&@7NCLN-UB&O
MME(S6SL;\ !IH>BE50BN6GB-@U+=V;:T3OQVFE<G@R>-R'*%SF?G*VU(]]2'
M]Q&2U462+'+3_8/YA'F&.X%@_4S(P:<:[VB5"*Y;E+&F8P+%8UI4ZE,>HM'!
MF(&K91KMIA",&F4(PS:V"H!0LJM$R2"\(V1/"KP@S,#T3*,DK-K4*NFTYXWL
M.5R*J019<D9:'>,H9G(:L9ZBL?^,)I58P'X34*?FF&H2D 0<E3,@$V__^= [
M>'KPW LX ZUZBEEJ1'N654;V.YDE\>[;HUV\S21F;]@[=WBUE+.L:<W43EQS
M0C]8*)FHU/@A-QK'3Q8 =D891<Q9F)W4^+V.OET=@428M^G &HA36(<?CO_X
M:$34'%\G\$(<>PK*FK]<28?6)'2<B1+,A4\Q'7>7%N[YM-*PCV&.<*Z\S<*)
MQ-0IY+V3B$$BWH%Z6!)+:0(<&B\%+6N;B5(-,0]A!T7&PPSQ\*NUWZ,%WGA6
M.9)NDG0P>')IB<V=D>IV99WJ8/W5I=?0VWD[N-5HY,<08&P"B@20$[8C"BJ1
MF"H:)O$/-F$+A*TA=---Z192AWO1O4X)"FML/J;(G<-[S@!+L(";2SBV5KLD
M5FQX%X?Z78:_LS^ *;0?'YN6"9UG!W!KES4KEPK2HU20'SN</>!20=P$-TS0
MI8+TD.W^I.V4S$FOXH]*:XC$1%;]0HUIV3#+,8B :D06HC;"E@8B5)(C".:F
MBA5R_=0/(BY1GRFSYJ/)-O#AC0BB[Y6Y2FE8+&1&C5CQ&U)V2#WD3JA4]<[*
MW9#-XOLH0_2@.SKSC7H$#U9^,UV'D?BDFJGPPI8603R,"2!7W#RTIQ0DUDYU
M5CE%Y;DU!I8(X,&H!V?L;PWSO*PBT6AB*@-/&V]MCL!F?Y1C%:<_3A(@HJ.L
MG+'6?ICD"PDJL#?R%8S*>3F!X7COI8A@@)<RNT8%F7ZV1JH<FFRLPL1P6)99
M6/E92>SFUB34!#8,GNQ0W1*)K5A:&"3PC'.^;V)XZ#Q,,1G@6D8(E0@3PA:[
M] >JL$F.B06'AM/H&!A6[C&TCV!OXB!2I4I"436WK\ID"E8P_F1:ZC!#YRMI
MYIPIH6P?U8"66+;&3]0%&-ZKG &V%]EL_5T2@^Y@D/69(Q\Y[O73DU-.1>E6
M/DZ/-_3!HEY]@C$]B7<[25>45%&Y9*QA-APS)%=4\J5)!(+;R<GEJ',USM,G
MZOQ8%KT@3WN<=Z-/5,-^%G&>@_JE[O1N1&ZWLF(]3#\"0S4VMI0.*5_"$2\7
M$U!%#G[".-'^3RLV P%<@<Z5A]>4XYM% 4P*O9/)$G2IY>XTD_")$>X086NW
M!/T%;(Q48D<5G0.I%0E$3Z/NB?C;.1=E+U6S1JWUL$;5#*7K";\-DT+Z\R$\
MRM\C3;(>3*E*V)M+A$I25>8) U(A.580E6'37VCXYG3?(61$EPA_%2.^"Z-R
M>=Y?KU>^>M+*SUW:7J=D]ES)-'@Y0&XP]B[1EK:9V]!]HC O<KLM;'6R&PB6
M<TQU)4\#.C74J:U<7_R;.AGWO#780FXC'WHC:[!,H>J"GBB@4*,9J5H.=FZA
M&T<G)ZD'-[;<;*O;OP=G1-U;C;=.1<-QRU+>"LQ$Y[^L[$<O+E$MIC1,A#X1
MA "4HV9]ONDVBX'7;;G;\^^YY^BL5751B4K($G9C7.16Y2F=BVO&Q:KZTZMD
MH=:M;/JB*[ J<H+J9SA=M]O:T&3PY(S*XVK)VNMS]0AI3=?GT#6J@F9XMQH9
M3A:B2A^[VB4RY4E#)ITI7$:=G,&\_B*TY3[TDE0'A GF+/PLN9 F(.++ZG K
MUTFD:'JY^22JB@@W&>A.EV[)]!Q5I[P*!VFU[M;#@/'GFCG(L(\6QL^0H+]+
M> E]Q6J'E:!F JR12 G.7'Y)0Q5CHQV]"7-I>89,9$>-+,'8$\->E1FW_=9
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MLD04@!E?6G'G=C*UJR*=+4&ZCY%F2INN"&T/0B'"#:5E*V>,F)Q2Q5;'P9O
M"Z6"4;WQ'N!"F]/> GOI39*&^^JWB&=_N_2&JK7P\^8W5.R6EM3N-3,?[,;
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M!!,!U*LD5\+.5.M/$4?('@UQD-Y&W@1^$L:AU.CS9^*IP<5B2F $()+9U1/
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M%]\ELR#K2",_P=5R1/L<QW)^.89Q'U/O]'MQ#_&K^5?OA\?'(WKQW^.#ICG
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MM8]*/:#L-,K7'0R7-=$?K(_P UMTZ:YHCPO&"FTD__O?GO];HY9"321_TR+
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ME[^W!@]][TYO[8L>7MKST>]4/@4S GT_O&:=,:6N*%<8**J51R?2!<@T4TC
M7:YS-&%1'""1.EXMXZYLK;&W87&*-=S*K;FCPS2<I1NLUM/1[TH,]2'.D?5
M7<8SC!IBG#9B9F02Y9/MQVIK7G-8\BZ2J='OP%N+LT*K?1H.KIH)_6$<V8:+
M05'"C_]1C'60%)0A0= 2"'3<PCG^;!8MU498G8+O6+0&GJJGZ8MFE#$$_1S/
M4$3P!,-@4J9P/."#<:TQJ TJ6NLB3F'P)EZ]!+\9G.\01$BF-)L4,LL:A@7B
M8AXE++#B&/P1<HQ=DM*=*K(%,+[I.^!P+,NBDL)4M"WJ:E:4L!L)"#0*A&7^
MVV!J33O!/(G>A1F\04P=F:%Z,?H=G+E4HTVZQMP1:T";*HG&!1QXU(%+$DE#
MT-L&O1=>56LTC=)<HU#@:%4ET2JTNL>ZR.I*C0)P"BC+!),]BB@EAKZ#=-*#
M.TU2#XPI+<*;$G,FB3V.L/\")OM0O.Z6_*. =B'3A=V*=NZ0A#NGZH)<Q2!T
MHY),>SYX:62BG7C8%XI./(C"B+3)B1'Q..)<<1BSC- :G,,,U_1#\OY4.54Y
M.(;J$SXCK4"^<G:*!@>_6BIX+36Z:(P/9G"%?^)15A5F;E-MT[68^D4OS_IZ
M/73=>@$[N;D3''$:J )I96+AWL:,>C"E038;V?S?H^M1,%$@BF&#O71_%JT\
MTRXNICF\DNSP.7QARCL>IV5<SW6%MA3)AY94!TD.IP',!+;]2$R2KEPL##T.
M&?=!.@<=L> ?FG,2S+%-#,B6:%FD"0L(6 6M2M"S+9NM5(NZXN-(<B.!&RY'
MDGQ)N)U@'@8XT@0L,4K1P#H@KH_&B'B0YFP<1L@()WCP%(1AL,BB/,<_>4,5
M!<!X$OD\Q<'#CQ1#&7 X5M;@H/;)W^LB;#P7W-M4,8:%QJ7KR42QC(2IP OB
M *Q/S6Y37"(EHZ)$;5Z!/;N@4!FL\@3'M0Y646HN+>D(F2\N.7[4ATNZ/2CS
MN*XIATA)V]F.<;AO<#7%P\+C1!?66EIH4;4L+#QZ>)NS=)Z:M*%\),E^\XLH
MP^' +<*60/"QP)ZL.5'P+09S(M4'1$GA2VF6$1H U;;^K8:A9&L[6(,VL''8
M4? 7,!ZHLAVM:[(4,(BOX?_FY&_!8V#'9N9^FQA1E8)@428@Q/][\8J\-XX
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ME7[H\CYT; \.Y]<D^[8;&$D!FD?=I7!\=B3"\<WUNW>C'M"9[!>"MI>@M4K
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M^,EO-2P)ETNRZ6%*EN!T:H,$"4X\4P9;QWY*YS5!%,Z?R@(P6* ]<7S0:>B
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M2WY+,Q&KCB>""1D];]N?>#,,LVH:)X*EWP>7X8=?1J]'EZCBZ2TZ_P,N"1A
MY*,%YNAT?#$<7Z+3$S0:'P_/AO ';L^';T87E\/SX3$Z>__Z[>@(O3HZ.GT_
MOAR-WZ"3T?F[[POBOT;4?\7O6\/U!T%PH^ &:8'TE"#*$R$A@6&3>]!DCB3)
MB"0\,4U6(A.,B1FH1N?DBBJ]$+W06),<-*GH@<%\P/14Y_N$8:5>[H$=N<,
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M!?"HU6JU^E$_K;$Z0YO*XY]89P@\QM^L8X65<-S[$APT]IJ=??\1!?9+B<Y
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M?C@:U<B?]9/Z,ER;NCUG[C.#GL*OZ31@(L4LMVMDD#"(L93 LL*^2R 713/
MIEN#!-,VC+[,L-Y(JJ*GU(V?-H_8R'SK2TVB=?77OZIU]6-(L^;\<Y0P7;:
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MK#<:SN#C^_Y?I-L;:X-FO=Y\"#VS:OT C)1]5&VW6OOEF+=T;G'PO_HAMFT
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MYO,"J"" 6>*1"W AG&""M!H53*'FT7I2#(WO^YSP4\XQ)= ?QXP@,Z8"XU'
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M-: (3@WLT)5KHF)(E0@DF/N9A%!-U+MP-2F/6YV($GH:\;< ^ZD<=6?> AM
M_AB..R"_E39BK(U*.0(D')@TC&,P!D2=:&KM0\S8TY[R(6K@_N_,40#PG$ B
M(I>)1J:7P6/$C1(1H^G<%D4L(ENF8*. K<#QJF%T?5H95-$9)6);9B*W6N1^
MROZ.O^'("3CJ>P99*>!P7HNR%,B#XT.P\RY<? M>]"<< JDI!7IH485\M DK
M DWE[&C9JB+&JJB4 _@<.^QS1LEQ3<Z)5!*%PR-O=\YYMDZ0-KP@;21I&D@;
M ;'0 6G[3O3E FN(NP!6CP6)#Z".);Y:9+2A[9P<C:D4<!SHKX)0?S&C*# 4
M:T.)_;O8%%1E'IT/K058\8 ]#!'LF=#19>@L:!X$=(^'R*AWW\8PA?.HLE'^
M]#,$P&&$UB5929Y$7L(YLX#3)\0"Q-97!KW\ZW^\\#MC1<ZQO)85TTEHY8'(
MCX0N\4IXZVO.)>;\IJAUKT_X;CG^A0_9?;+\9M8)"]"T^QN:LF:B@L1K"V6+
M,N2AS]_A.$SF4_B0+DZ"F(SEDJ#-#:[=/W1\$GM^J5F>LF\:8&&6?KL ER*>
M%I&S?"TBE_H=]HJ2%QH*8_A[93IHY Q:2RIHV4=034'+IH $ZPVGF>Y#UK'8
M0!XDBKUS\UV7?.=#MW%+/0'5YY?.S0H8NH@&VB4=/U#XK#-O_WL>Z#4A)7"Q
M.>C9G<C?T/DYZMUG 1JJB(1>I%\P7O0LO^]B#>A1*>MI-MS([Z[X-!J+ PPS
M@;>  +1BK"CQHH)D3VS"B<(1.DZWT!#3AP1T-V ;@2V#; +L'HH@L-6K"$)N
MDQ#C^:B4#8#7YF^8_QPD7MLVL/&X(:[]YZ7!\&3&QJ'AGW2!3*4; K[WJ@SA
MT_:BTV<"S5,UQ#4F8-6-Z( _698*.@SPBFOA1DJ9._J%<)Z"<?L&=$@=&QU\
M&>T\Z9U@"@E]9 :.8BP83=!%H+.>+*=P8MLIR,?/A:W]5!0/#*6$"K 2M]A$
M=#9E)F$X+$54D/K:0NW_HW5M4_N1$4S^6DNJN OSM<?D+Q#KK+,--Q'[W-C
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M@!FLFLHYZ8_(.:"1?F7XL3*+%1XB/;U'GQF%J!0JD6GL+<[MZ\:^AG!P6Q!
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M704I3,6SY0U!AE.B*FB<*[X 0D,PL)-#HSB:JHC<.F#;)VX.C"S;:2TW 8]
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MF-/"/-[,R0.@:*H+S!/&\'^;%QS,G\E,,*?VU::><U4RZ]$MN[$W%&7^8VX
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MN2%SV60R*"S[AD;?0]36YH/*P<'/MZ MV6&> T9*GE^C(\+5X-SD3%C@<>T
MY*'R4/Y$VQ3E5, YCN/1!7(5R3E2,+!G[M8$:IE-^P-\AN%!LM^"K@[B#],#
M9_\E@VL]>L\4#:8E%?TJ8][^R',U-DUP$P>SEED4&1M<2\C*+5-,R*JUIKXO
MWS7 A0;E/\^\O*)4G7ZO2(_%TDUPMM#>/P$?';@Z44JOUB_1JTL@Y!"&=]9)
M/%&MAKAYJ\6;)-_H("PC-./EH5,BX8:0R8@RU,50_% WIW1N=D$[0\]T^19:
M\3U_9((&#0"&S(+WP>2SA_8P;AK@(T@@7,!32^%];L_.E-[4N^JZ^!ZMB\TM
M,6\F-7D(R;5]9;#'%HVI]]?V'QTE$7MDZNUO:(,S"$.^/SJ./H#<6-BHW7EU
MO5V0IZ%[\T,H9_S<P!/S#B>QIGI[;0+VU/J7>!J "4J]^X H,C;;LIHU;C4L
M4E\<$SCHTLDKX/,8^!U[#@[O@]N6QO<79XQ_4DNE0QYLWFV O5ST:_K*Z6U>
M8,WUM/N07^G;]XER?1?Y^I);1>*3Q9)!"O*6'H:_?G33 *=_)#-*X*_=<5?Z
ML2#0ZQ)>#)9'\MEH&K/P2@94@IF3.L,>W+Y:;EYDB2<I08=RK'4+O;595 VX
M0(CPB\?/]@?(Q79QN!#9EB2[OO^65/4B@,2!'X[0#/ OG*,H?ZEZ,R9&\D4&
M#H;[:%PNU;1DRE2PU2]1KGO,P@16O%VCY/G9(OP&HL,4="^1GGIAFY3]$<&H
M"2(!K<FOH(M I$H>J^BD<AZ++>P1H8>PTNTD3L2/N=35C._=68ER)5(>W\*_
M2QSXVJI[I;J\\6?>X7%OUU=&_8S=]T6?0^PYD!^B4UG(ZC;)9"@V0DA(:/_A
M:!_O-SK2=8+)F:0W[(5T6'H!YO#+.$1\[E5_2$(0S"-&+:/=]46/YIW)TS#^
MLN<<'WMJ.ZF'C$_S8X\&$GP.MT,7: "5XLW<:S!S_$\FF!XX9D>6OR!SQ0RN
MD:MQ:6.T#COE=M,%'1#;:X6A[AE8'PVW/.[K1VAP6D;5MD ]VNSMD;5)-YDR
MH6?>S8@XI\>N,+C87GK$]EJ!_UD<"K*05!ADZE6WL;&5:A4<O.Y>!T(NB5WV
MW)J8&-,OKG4<^SZ9O<\@_C:_8<_=J+&<07)N&J('%=C-L/:?,>AV:0WSRIC4
M%;"ZCKS)\7Z+JV^_+%VBU&GPNDI.5C T<',BZ,^QI$2E62/1K.;08I1N/;CD
MOWM,S%DG?GNLP.6B0YL^*7N5#ZV&]#P+6N0-9')OXPOT^W_=70O?D<H0^%@V
MGFJ\[S53M['MW@@>#'(\-V;5[+VJ' 0MKG4"%ZQQFOYYYB^ <.I3>N'4+Z>^
M9AUGZ8GYQ,W("NO)QU9FFE!)O<>^,BVM1CDUDG=C!B_?V_1C>,W/$5>NKRS\
MVLYK+<OK7<N[.M>3\QOE9N_!T'?_V&Z+_B6I<OG;H&IG%YY9ZCV6;21EW#Z^
M==M'HF%L4U9.C.T/DYU+/@4I-_DR388;O3-,[DA?.]P\KO0>'X=P:PK=47,X
M/^5/,HI4VPUD]R$0@5V%1+?,YYH<9=]#N3,K[,60=3>>;"E7&O_\<S(H(J6O
M7/_!O5'9P-CT/_39R=<4I_;Z#J]3^["UZ(TB/))8_!$8I<5##G'VY_<J\[9[
M4M>X($ZBN_U83RX6#BD?1! 0K)J^'W".UI;-R#'_I'XIS^ >T"NX\0'8KS'Z
MUSM7S$OIO&N$BT(#4IU(N8M+3"BI?'7S8MO29>4_XE!FWNDV!@J8I3VOO@5%
ME/$48M2)[X@/5I#\Z#,ZQO]5N_U??OMNMX*(35&\RR$Y,-TB WV,7+&F,H-?
MD,1Q#2 $-"AD-TMDB%VENH=&(^'ZA7-'* OB_H=WL]LVU+$2+]7]8*KKROWP
MH,%6_^TGQ=X/OTZKT9][OWY800-$/@<M"4ZA]^VT>&F [X)747ACM!X1T?6*
M7-II1HA[I?E(74^E9RG/#*F^+%$A(BVC8[_.WGDO9^V)R\+P]&%KYDJF<N9*
MN"PY!-RY)97,A%'-#2Y*O_=#K@I\NN:76%QI;/'&DXCN1:[\O;!#L$](P-R+
M1_-IICKA[\(M_E-*^U_RV5/Y)UCZ$[/%VYI'?^ME<9S'?S_+:6HDNO^W-<;K
MDLS"43.B@Y+PCQ'Y1+LJ:?(TZ!LU_<1'?D$';;S(]1]^AM_7&FO<^U!F($D#
M)/\ZD7G>?K<0K_/K'VOQTF]!M<EO#=R_W,<GPM=_R9P!N6F M/\RVQ)_^UK^
M)=(\E71BOWKY'U7(J7VMXT;TS.[1AZ!!.:/)W>09T&)/?N$Z-W?HNTR$#W&Q
MR]<WK-B;FS0_XWA<<;A<SO_0D"7Q]@'SIS6_:]8T 'Z.!FAL/.(#]FY35!:$
M:(!OQPGI%N09:.>VUHF.3?*$WE22E&P&FUN,[H @0^MSGY& !!J@<SOZ8"O?
ME;O8^2UYCD#_G")1#O&J=?@ZHUUBNSJ[7^D<$N"JO)0S7VCMUTG4#X &G+[C
M%F$!^;&/,!Q2RP5Q/.OPL]*)S^$CQ_D5WUS>6S?(84B)S([BVPG554TU-;5N
MCT?L\N6-T#W+S\3[D[=4AM\'KG_!6.08K(OEZRI+C3T?YS(8%Q)P$WWS^G7N
M;"UEL=7_4#!\$L+\0'2B%7%XC1)"#$_V;1F>I-PD9O?:/8SEGO@ZMY>=R*S4
M/8N^YKX=]2N9?VK(V?#)#>C1W59U0C(S#&,0[4#,C*F3X_R>R2(<?- ;K0QE
M]C7((?C4%&H@7_D'>4EU8:7C4A5T\4^53_K_LVXG 0 N0?Y)3.Y%"&@QD8&&
M1(]-%IP,CS7I]2IN_NK W7IR1_'J7SF&#B.:AD4VVF<TDN.7QC:WMC25"9=<
MJ--M$^S,/.89!T,[LT;7-M5X5GVC!W]\%M7I@:N"KQSL2^8R\+8S\EI57::/
MK50V>!W Q"V;((4G4B=ZE/WENR;V>9;+;YHE&OQ%SKUQ<)6PDQ#-F^>GQSX<
M(TA_P?RR9H% 9)$A5P+&]-W:>(9]8J=5#I.QT(RN>4%4+E\*ZJ&!Y9*523%H
MR7X?<)0>F#>GNO^:^'B#!J@@8TR(HGF$1&"/QNMVD3&E;)^'^R.M"OA$<!>;
MMF#>XQ#G,^6/12+F[@P^0@K_]:EL(Q^\"Z0!6"?@2C1 01EIF'I9AHX&R&JF
MO#E>(2X:H/]..#MBNI@$I0$LT3'KA_THNE4APG", UOOM'1!5%-*@WFF)3X!
M#31G!M.ENUA4!]4RS2;:#;U3I8NM>%WJ7**=;F$Q6@SK5M<?F#VX!M/#8P7(
M3Y*&8+7($@_>'%F)SX\.8&5-&U/,XKCO;C/*H19/<AF!R+?CD@3HH/Y8$+#.
MV\S?U)!2HQS&-:;L8VYDRS10O*;:("4EKION(^OV]$X_XUE9(28+=L[7I_VS
MABJWN5B/PRZOV265M@JN*]]8@Q@C3D[<O[%-UCSTD:WXQCH_YV#WV?0^FP-&
MF)W3/\TOI:Q:C[_<E4G]S-1/968OTX#'I1HFJ6VIOAFR1GH3Y7/0W0\4$3L&
M9:AX^2TN#RYH7:92FN7>][J6EEJIT=_9*/=O2()52DZ=W:_=XW6[K_1;G ^.
MDQ!]<16IFF%[2=J_*U$XJ??M6W'ISV%GS^09I!!FEX?<&UL:<R<#\?BFN#NB
MMT+/)5E:0[IU[G_+KH6^*O_[$,EIH/'FS%S6<,9^6PYJ]A#R*>*WITZ=[5O0
M;:O'P1:W=:2W-OZTM 1DN N?-;D@_/2<MV$\-%O?:6%K(<SVR^]+NVE_)WTJ
M6PLODW!TFK*N#6YOL#*:"Q.=P&8)Y* \H+/[HUN;4IO!J6-]?XV<'"I99MM+
M#:SR24D99O=9\NDF35YX*&PS=;GP?I1 A*SN\A7Q3WW+Y:PWKR2P=="7:"'3
MQWQ$JRJ#GECN-Z^&77_\_G=KWFP\-%CN*%9;/[%9/_&3 3#\MP_VQ!U_W^"W
M3>O?PY=7->7P0"XRUCH:0V4D]L; (2@'X13[[[D\(T$R".M<M?=N*0*J^@TM
MK>E"3.VNA=*E+YH2X@Z/J\3%0V%/;$/>I@(>$4$5(D<74JX3=QMXJ*)3#Q_*
MR>!(>K&!B1<V[X]K2A&/OZ2Z3!#PTII*K;[_^2;;>Z-*]C+0+K.9M=@" <G#
M0SR9XU #SG24T7K6!^<;*7B:N(+99O)J*#M(G"]4H &@4!:?RYJSO?%PH]!1
M[P/J&PO-5&^-B:.!FZRL'WTV\,CSZ+Q69])/,6(M5W2?N)M:PF&L@HVG*S?+
M[,"I9QUXR:$B#662VM2MUG*+<K/71QD\C+H%:5[#<U.=C8:SQZ$;IK ;.M1J
MUTD(^*KK&XVG\G:Z%$? L*[\&&!"CVFB1CJ1[,#D?PDV4FR08Q<^Q1-?:21A
M$9&OS9GNZT9]W+RRD7EH0?8P\ GKRJL%;=+A-YEE%C;W<@)PPUT^8@:&-FEU
MF3(E6/+#A4&?11/;Y6OG1VY*?Z2#@/Y](]'COG^2])!P:ZC(SRB*3CXLI9]W
M818Z2&<]MA=O4^5ZN+_CX#7%(]^K@>"_2]#9>HOF.VXI3XC AE@DHJZX$\5/
M\29;XYFO=6+K,B,"'0V[^TI@OL;VNN0/SOG3#DYK6NPDE;S[5QO&*88EMA_[
M\'EL P\//D[([!X)'NP;">+B08,PL54?Y&# AJQ^C\.UB\""I*[13O/!][#9
M^N^X\LG77J.V22Q<T456N;Q#II;^@>M]7YPHQ-'B8;.\54K0[HUN-WY0_+":
M5)Q8ER7QDEU3_RM=53J#J ?!@L]%S&H'_)L<C.PL%2194PN>ET;'=8$>72J9
M^!8%QA/BQ%$;M>27_QMKXT1A'_.?@OD3:VC@B;?QRMNG%U;-?AL?WYS[[_;1
M?_D*1$>_&A6=>'/3"A>RY=8#)/3;5" G5KW?F)G?)H,_F?\%0Q@VIX;^!DC\
M(]KYER_D;83=0#'XQ_;JK\C@B<12KA-[MQ?^Q!935+CRA/N$D?GT/YSK_S8V
M/,8RAW-1],E]A'($'46"J!JG]0>Y?6UTAXK%Y+*-; <-.AD*:,AI'1!MI[N5
MRGV@W'PA\U;"TG'V\)C*703E.FK_.*T4&))_T #(E2X0)1IRG#H[Z!%+5[0$
M:8 :>Y(<#6#48'GTT7HG,Q%X1YH&P,C*%V-"W'52E]5"ODU+]Q$4)A2J*\H(
MY8L2!EDVH>.KAVJ]S#R7N_MWTN<K,O?EG@%UA_A)KA%0?UUHE_J"=5QQ[N).
M$7)@]9[8S=%.9Z)ROF6K$5_ZC<*E^*P4,],Z5[>P1FK0%) (!LV]G17- L^(
M+1Y>?:2#QK!P.?8CYB.FC+,>'P@_@*Z@@'!A<B7Q'4EI.P[$U'Z%HCHN', ?
M['2#Z!M#^>.Q4)2LV74$JU<SO$:E6^ZY;G\$9HD7M>LS0@-X 6?FNC02['2?
MD;9Q#1_*C13MM=]YT@"<K<RE:XI?]:_$J5VMJ9GR^)#B)7)5*=9%=H<UKJ@)
M=9.4%Z')2[J,R<J,I"#PX(NPN<ZL+E&L)1$;M^MX'?)E[SSX=LOHGF%8N?H^
M,$LEA7VDB877^E3T2I-O$9;CGD*@<Q><[GDQLF3LM?QT!4:V^U!E--U "JC-
M85P>\=C$^[7[)H]5SJ_,51@JWYK!W4;R!]Z7C93N;S%FDBMU(6/YI1S4'6_0
M,E!]R2[-8K:V),?6W#JKP.IK,@6S_E./>F'BN.)\3DS>[#X$S<,]I[148*GX
MO<W&+B ;6=Q3PSHR<#!X O>E;O/TP?4?3T*JO$9C'UZV@RV<>FBF<+KF4_<G
M)R$JX]GC:Y"(/S>\2%(8"*L6NQVD@WB=L-=3U?PP^='.@@[Q9T]6F,P2#?#\
MRKB(EZSHESUF%7P0F 'A:2C[IF'?;C)':0I:4+G9NP6DL#)2[YJ;'S]'VR>X
M2%,:@,YZ75":7!F7&1GR&$@.R9X<6'JU/!/$9Y.)[+3H^O)\027C.ETLAK#J
M\MV\RZ3+>9[O:QDT*U.9K[9(;3QO,9R)?/UY<I)M,9(J>C_MVJ4E=14OIP8V
ME^JZ]TUQ?]DPS(0[1W7AUN^1N.3WB-/I3M%*;WY)[E@7,'S)40M70W3H@G O
MPMF.D.&G5B&\2G*)3D+DR) 2^!WBSV>06Q.MP'>>*B,=E=_;Q2<@ICP-H0L%
M4D8/J< DSD85O,!#Q\]QKI:^F"SJ\0.$PT70;ZCB_[ISAOJE_32 (R&/K!TN
MPL]B_M28_A[X3R@9W5C?W!)L:.^UY2@4XBB#3_&XDWIVR2W1IL+S_,*WLPX)
M+R#ZNV&$H2N+<A?Q.20M-\UAQ9!)CRA8<YU?D\=>*-!Z7^F7?)K\K@^]^JS3
M\"OL0FI-8]^1J-IU9!-/U]HK^@M+)OV/ZE^XJ37A2JU[7#(G%4"V^Q.6=Q\*
M<3G]V/=O?5(0U]C"%7P<Q:RW/'Y@3E %5F^JVYJ3O'PJMJI<&AVGV#M\E48^
MHA=>+>K:9,[W)X<:%5;-&NH$CUJ'BJ >OQ?O-QXQ!EO?SPZV:W2;\>[_YZ W
M1D9VR\JCH:&IR3"0W4&3M4^R@U>-_>Y(^?F_<NG4+<42EE.]I!I2QJPVZH/M
MVK=UEI6R@_4;JV(=OU?M.F:@/J'^=F&]9LUM99DL!%Q,5\RR]Z8!3ITOHY^:
MHDB,6Z;5M*;,&H[7?0A3LQ&>\CI3Z<-1?<I,O_/2BY<U3RMP*;KT5VL>K8NF
MSQIL3?E\S\P.$]GA,UKH:Q&=3PW6=VQ\&.N]T/?0ZJ2C_/>>Q_K).,,(8/BG
MO.KB'C0++)N0W*5<0T:1,!\/R,A%O%Y"A4]V9^ZYD<+4Q]&MMC[X/O>F!M+T
M)*4E9LYRZH],PY$@1B^E+N)1VUYE1DL9W -(:H#@MYE<87F*'<N7*"KL@9X5
M6O8W)\LEIU\=2@K.%K[VQ!&'"A(D"22.1'$#D^*SUFQ6B0SHQW@4P-U)S#^8
M[KEB0K!UI@OI?9=UAI1R5QFG%Y[XUWY3LK.!I"5INE[?(/"]C8UQI0Y#NJ2&
MFK=:@@[P(_H4=9@&$&@7FY7-)X[ABKO1,0UR0EV9"V?)_HM [IFZ:H&:GD:-
M<XDEMT9UOVK02T<C 1,@?C@7N8_8P_F!G$[,)/ABYD)$N?M 29KTA+P+G3_I
MA?],69^URDU4 +Q@=5FA7T+M)D]0M'$TP.G5C&34>BX?,3@!*:/5L?<$;$C<
M?QG%*LVMDAAVHZ@L+?%6M\^%RZ9_WF90&\W%ZI)$_R(ZWGP'/;A8>__,7\,"
M[\H+O9N#OCJ/:SZ2WG\\:2U?\_YK38?2@_-?"SDHZ<!W@E"FN_Y<:G2,1YD:
M5?)Q0]4*76K=A_UJ?6[)+&85+F->SBE@/6BIW*;MDW.*7GBWZ&*"D\**TJJN
MI? .D_#[ZM>9+1+W7+.E+37,4[P583VS$P%*8S2 @J34@>CQS9Y =*BU"\ O
MC.Y"9B-Q8M$R<"!N'M'50.4BO\(Q<Y^BCU9B#K".V]_6)ODB-RPIE2SZ$V+U
MV3H3@8:7\*/20;R!MDK9AG>V45?!*^YH%)DE<<>7E0P]VS5SN9)?5M+2<PKC
MXGJ)\%[MZW73KGLDA>?%+%Y&34,<SY<8CEN:2OH!4Q&*-@$4/;.-U+1]Z9?)
M*LG1<V_1H!W($Y6V$OE9_M++#WC_:5N+YY)A&J4&'%%W= /].<M-LAX5SAW7
M!@>_].54I\DF;^.D1.>^_H,O0N/7[YS[[SB;?]L2 1[/S,H>:QZ&(I)WWIQL
M@ 3]!ZY*\=%_N8Y-[OSWHY(;OU'UHSXR-MF&5K]-WB4"(:"!5:K2B0-S\M&)
M)WS9XS?KPOFX\BA<Z#K+^0\GPDZ\I+SMD ;(W/N;.W:R]Y*&^VUSK%?\;4(^
MH86Q&)#MB;Z$QI[-\!^=V/-:@N1&@E[,[I'HD]!#'6)P;%C5FDJH3/U\^O.#
MHL'Z!+,^Y@3KYHP\SY_L9Q,<G.R[6^ E+&W'94<;^J'<@3(H"4'V#:(!J+=1
M6!!9%8.+WA?KQ";0 '47BST:?O;F2HRU\Y.=0@JZ2O';9^T2[9U::N'PR=">
M-@*C(>].KVHXNR279LTH0H>+$D* C'JHX+:4AYI<A3_MP ?H4\?SHTH3>JQZ
M).L5\JP*K'F-=*-L;BE@K$LUI8PU%T83YGR4$*%D[5U0G]I/S )P\>)5PMU#
M\=Z5\6JU61NFLTSM%A+']9,]2N^4Y0#'K2)],$]4$9.+MT-9[M4L?;5^&F Y
M>Q$-($_A$?'*B--P'6)#"P[%^YT%*EB/3V9?G=(P;BQJVXNJ*KW?V/QD5L^?
M?G9W;OWZ^J/O9R8S3<"\GDNZFHF(/X\K<C^Y#A:R#O4Z7(J\_6[F5^CC;M^S
M7\G@+@X=0<M61^(6@2MB:^=/+=L].8;U69FHMPI'W[1XFR3R).\B0%Q'0OB?
MW.:+N<R?U-YQKH[D0B/,NYU7#<R*HWOQ:^.=[IP2'QI!'H:\MUHE AI5]6_V
M-6S1 "EP,UQH.[\_#<!!=#.H]^?<<>@>ZW"!]LA7Q@TH6'BYUGPVLCQ3>F@W
MS60L&-2693'A8:9@:IA^7*8^>4$\I0/>MT?5'M5NC!VE?MX)G_C6MX]0Y=UI
M/6JW?I44_' ^R3_N^>E0,Z/K,\4>'AYA6L.U.^=>^YRX= X<;V2A]49B_SVH
M$_P;OF=^+>U #DUYRN1W7,RG $X,B4PI8 ! 73@WHJBIH:DN_4US8]:L&Z!.
ME4V?J>S2.;.13V4X^2L1?WZZDB3>W':B_0_RLMN:3Y\X='Q\=;!82B55O^6Z
MZ/;]A:G@X&UW[9,&H/BLV'0H#1!=J?X;5E0Y-_MUOD7/R^?&0*&/E)XO4ZI&
MUTNLD+1WM^O=Q*$_+3_U\7)FZZO,ZC^<JW&J3!0333/W^9YBU' H7._F]_<K
M>_-,Q/DKN,B.,T%G@J^>'&L'0 ,;UH,GQ^+U_NK*U.4]V]+_)B/176JI[NEI
M@W/2 .&XB-]J496<G(W)U5]5)3[*T'=5J=96S6'*WPZT\G4X3Q9"!GZ(R/MV
MXCTVPEK][@X 8(,,\?NO1M5&OJ7H6MQ9M H1=E>SO&UB^RH6 +@@C#L-*^>8
M'?:0FINW'_31A+%K^W-@%-GIF$^V$NY<2>Q7/"\4:?X9U9^U7!O<W):>&CQ?
M.&L\IY+JO5C;J)PGLQEVW?'=:/N4EZK/QBM'<_Y<\"KX;9R7O2,6L>[[5T3;
M\+X'6=N+]&/Q9Z=OI.K!_#!RHUT8-FQ K!QJ\?#@S@\JTBEI$7*ZZ::T/^+0
MQ^I08>9PNS+7P3H&<V9*L9";.*"YTS"-/]E<N5PUGDAWO>&4F@F8:S^9PE%J
M!YPKWW=,LO3,T9(GNZOJG]+3.[P=6YW^5/*PW;&0KB7!(X[85,P;,T"&QI"F
M-=I[>9]]"H"[<Y>9O"YUD9]FTO'FLI#4]<L4L='5-V9_GE57(!)(S8NHH<AZ
M]6B*9"QS:E5G+CN _UHBSRJF&_BAHKJ77QI<RKI8)'&K\$810TUDNL9?I5RR
MG@:*=9E;+!3M;N(/:I)O#X+\,!!$]9;ZU4T^?D'[YW"]O7+QV/,5]5Y[ZV D
MA!WN@3-T]%Z;O'XYQXZ%$19! ^C$F^8.251=K<\B24^&R"SFWH]Z_?;36G[R
M@?+4KUWJ_!66.;W]JE[$+ ]A%41VA 91ZG=]2'*)9*P605.,RV.B%J["*(8A
M^*65.2MN*!8XP:;-TG6DN5F8U56-275+XGOZJ@&'>JO/\"S1@GS$QO/+_!P8
M3D5I=[<\ A'6/U[]JT%F"F,^4.S$6<34*]]C'I%H\:[(F#7;>\BAJK??X-\\
M&LA48N,'"F N[/\%]><_.*7&?]-U3CSR)P"LWSBNR..,Z,F+LRA[^>WD8%_I
MMQG]7]B?%N\3=D&_>7L\6 M-/&FS_]ZZ/R&B_D_/?Y;1]X0ET-)Q!ALX 8:,
M9OR#GMJY]OLC9VTN_(.)7?K[L*SB-RP#P I0XZPSM7WZ3PYEDYC30>6!R7_\
M)_KG?["PWIP[&8@Q5O(O2-@_V=SL-Y#KZ:5_05C_M:=PMS S>^/W+\[?2,57
M*@LGF3LU[/P_L!6#OYEIZ>$;FMB]G^&(*__%<=7VV:)?N<%I"BG(FSKU/[D%
M_]L/9*&7<GF.!A!?(F*/TE%QB(/ ]RA<+KHMF:S:2#4=P*,/I2"<-,#NJC/D
M.'_=!?Y2(OL>2M4@CFX.#J]"WA937F_H':7,H*COW/2R:(".OKP=9S0+8F-5
MDXX&*!M85 [70W1\$*0CJB:?C$=."O5-HO#BP7RKDY!33@=#F.YV@5%-?3>O
M,!J D;'C_9.:V2G;VK8(1M15+^?#VZ:%[18U>FC7FKPI(%G]&O6N*G[[*$?L
M*6+/%NZ.&L@CJT"IQHV+*T?9Q]]A[1/1*-SVXX3WEP,@*=U.6=*TG,G] =XL
M;<FX$+A?98'B[2C5F:D/'*OU/!)+6#6OW"W#:UB6=E:JXQ_5:P3]P=MI>*BJ
M&)PF_/I^56HMV#+@P/BH$H'+QM;F;9H3'_W <\#D.O(N1-$ <:U<**-%2#2"
M!2Y0!*L9,R:NQ"H=@1U&ZUK6GZB,;=3"XC&DM>8SUHU G_HQCW'G"5FE2EMI
MX^R@K;Q:]$;BH1JU/Y>[AICW$?&\G94H4%]?8365-9^1Z1NT"&35-+C92M)+
M0*4L=K7_T?;BU=S@A++4\V?V&_O^=K-ZS*U/IGHA0"Q%G"Q$2B9DI+MZE'GG
MG>P#W2)1L]^M,2O:>*M2+Q*34 2IZY=7&F!;W$-;B\9)"TMO7HC:W _@*(]R
MIB*H L=%<GWX_&SCICIN.Y$J?/0V_*JF NSPUK@R")EE'5/O(X:C4"_YN&,/
M#3LP^/3*%<K54<],#>W!=[S;TG+*A#,:%<V?FX]:-6K"E?%Y %CZ(CV3QP<G
MQVX4(\;A>DQI4H;]*]?JVH*7'C8;THX:3IW/W==Z+/Q8XU )KU?O+:E*R_""
MV>)\]U!L:E@,EJ$I6>1S-46V6E,[SZ0X,LDY$T=\4?ZL7Q[V2C+]1KW737/O
M*I5'^VIW;E7)W-3CL)//1QH>?CHJ MVG 9[FU3<^5?:-SN-O%_1TDAVK9]9:
M'KX[5?2^-KY'B[4E2YV;&=K1+J8RZAT.G*AP1]3=E*EX-_H-63^^L<>L0=CJ
M7Z1,TP!>OL]R18Y>4;7@MF1FPN@H%,)(@9:3W5 )3@90#0<.QCP66-P"N^W;
M6I)<=%5@6WB_JI:+G;>)]#,'Q>0]<=2/X[ ?L>^9T0RF< XLBFR^[\H5)A9W
M"CPD @ \IG %XM"S%TD7UWT89J9Q[!M=W[[EC6DA6VVSM>-JMRY6)J#L1;K]
MCAZL,$>66Q49J-WM/?7RGOP6S.Y1*E+ Y?U,E&]EF#+01UJ+=V@KS8ZRO>J!
MX;U/A@H3^FWLE&KA6B&&$ETNI6-1&DT5YU3I$JOR8TLOE4[!'NB>RYQH*RS:
M<(6PYKN9%N_Q4-C U L2>-_9W%'?V>C]U-&'0: (#=G&H *X.AD^]G5Z#FY.
MNIAX[6;E>NC1_.O]GVAB)!EJJEVD5VQKQ$92C:FLORQS:UE [!9Z[+@0W_C9
ML4!/A&#0+--D\$=!-F+O,XK<.]T_QN"J>&9Z0^)"E#,KX/S&;H[@Y%#GC#S]
M ',S'59Y$5NCVEDIAD-LM!V"*&(C/F_KZXBJG>#3WZ<$[TKY[@^ZP4%N 009
M)]A?9WFRL#&RRC=<CMXS94Y-L0-?#88#CN,,!MVHV@.,M*8!SJ/=09%.:B0Y
MC#NI^/EVNQA<GP1\KAR?0]<5VAXEVQ:"1Y\G>P\[C"XU3 962AII8Q;$6TEG
MK*RM%NUO%DT/"TUKE]@YA3_.=8=#=O\B/8*#H@;=HOK+%G_PA<CR<%C5]M<X
M),LD>K4&$M-RREVKU4(52IW*DANZ%J7&,(?>:G?,;!!M?354+B)=Y[1'T^MJ
MEVN2,.GV=[XQF+&"H^+L%=Z$$LR:?[>%=5$$9JH,KYN=68/!BUM4E5IU&Q2@
MCIC)B/U'9!$\,,%NJG?X ER#N!+5+@7+[N31HB>!X^#J[LW"N1)?'BI77H,
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M]N#-92_\OKB8T5]_EYN%/K*KH^RE;Z5UYZ)'/$K7I.N128%!CLUHN9,R2/Y
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M!ZPA:HZ#.;;4&T+7SK+&EY1/Y,$=[1T=_<2 SLXO8)WF*3>(&S^M,S/-OZ>
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M=?I+5<+CT">?P^['^>Z6DA&+QY_W>-K*01+J;&0)PB-B!-F(V$2*:M#5,OV
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MS0TMN>MDN\-WUQ B9NJIC$&CE/[/X(,='#Q)]-H+CV L!Q"B/GQ)V^?>9^?
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M8YH%[1Z8(43)GX]R=7CY,W\\0M=# 2G++3BUEM9[E(FRIEJNC"6H+_$"0V;
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MA(\D=KX6%>*G%KC*UX_&'RTBN*C32[W :"1KUQ5([VGA)5Y](;H^=7I=8W
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MZTFL9NT]N,^75AWHH>YL^K/Z.\LMHU#O<0N!Q 8#^3O)0S^6FG/7?[R+FH$
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MN^_!A1GLXH>&<XX+O3"OFE]=(M2JDR(3EPN18C1AO*3TC#+[A5,CN9"I$,]
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M+])01 OQGP=V]1@_)5(\JGMK3?A?_W.+<VJ2$C.PIDU>?/F\J$?AD#G_Y[%
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MM"=C1_:D,?[5P&. M#!SA'.M*LP9KLLQZM3I;,CN#^"ME[!$R)YY%S]R[6(
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ME1NPU.G_5)OR\C\?BF.XJK^(:OT=ZA]WG)F([<7%"EZ/!S-RRA5*MR0+E-?
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M$Z0H8&@MVYKK@9PH9G$'TXT *,V3V04)@#YE'>^@\S^-X#^[X?8[0?/31VK
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M>,@-FH ,@"2Y":<3L+QX4LC=N0E^E)'8E'+%% ,22Z0OWW!QHX\4Q96'!-<
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MG_Y/T04.:"A_(=G3P\3- A.FN8'ANQ5I[AAYM:C^1L+RB<EZA;!Z51*:Q4<
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M<3CLHK/VE"5,TPY[ &-]A+1']>TNTHGY650S A+5AA4,=)YSLMN*/H%I@8K
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M9*A]%A<M"6K4L>&RE'T?=I;"^*^1VZY&'&@PL;0N*8Z\5QST(:[_5S%5!@5
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MG#T.I79C&OJB-P-I(%9HBK;X+VT)(#ES%.M1Z@2DX I2J,(P&VTEC/D@A[?
MPBN"T0WC1^YWWK=H"SOI_3+XX+S.:P.=?*!Y)T[4MU;_2F5Q\7E]O5,9H^D9
M[NZ7*D_?.LMV1XVB@>RD9QF?E#-A4R[UO)%M$%*!;0-9'0MY^0(:BX"6 2U=
MN@4&9)M$B@6R=(AXTP9[Z'G:!7BZ +D(!.B-!TE^RVRI[LVB/SP/I^UU?Q<$
M^Q\;T,-X&/TN"NG!9Y94UXFL\^M%<JTYLP,;I V]T39^_(T1#F^2W1S%E;20
M]3C']]6UI- /1FR?R2MY;GX^9; 6EKJA<M@CR39]E!JY=4IVSW2*8DA:3/+/
M9X8[=+_=Y+G!G4WJL,B^O_M#:&VB_"VN5C;,5<M:Q[F=]Q@8'WP*N)*:6TQR
MRR.BO'WKI<:Q#R3 ?0@E\HU7)&<- (W5$'IVAC'#W]HO@_B4Y:'T>%DFL8Z"
MD2N+)+#<9!H\R;<*N-L+3[2^6)&#2LH3Z.@-DG[P9&*UZ?@)LM.]S>:8C?)\
MNH,%CCG0GD3HH^A]L>',!$300,RQ0+ A^3!&35#P>:[-6)488%PEU^K54NSB
M*5"=L]XTXE'AE24YKJ7L,*C0SU- >HH(/K0^N :ML2X+"0E6?7;0^*Q 9&IE
M?87PB)&+YX!$X7K^*,?F_IL> 956MHJ2US)':D##WT*IOJ33"LR41X ;+B6N
MA;M^*\B]#!C!MOBVM/C,G[5I&_-H;TK=,&@+U$TV:K\6XA 3R^=L'9<-9B9%
M'/QSDA4&6F>MH@@!S"0,_J#M>_]CA,%[P-0HI9LP=:_+P8JL]DU=<V=N@"_.
M)\N,S?!TW-7[E2DC3YT52.JL6+B]W6ID=K)[C\9C64F"$I^O_,B3Y\[NL:AS
M#$GEDBL?/YZ&9[97/[X&.6.?I)GZSE-C;"D2JCNBH=Y79</Y8..AL^+R9Q=&
M@K^5#/[3S,>+>(HO+--U?6CHOE>OW;]>;OAHT]E[W02E/9G),CXC-I1-?@!5
MEDXRI5"212E]0$7/(H3'JZFLF"X9TRAU9\WV/#'R$;!%T0D@7F@3.]<J(Q&A
M):**&KM"^OG=7>9#+K'BM, WNS=!?W1<BA=)5HM1F/,=W&'S$*X]&NA5F"HI
M)9["3ZB,I?C3 P74K&%2-DP8CNWF#5[M%0&U?!Z?W9OQ#?SY;&K;NG&LZJ'4
M^S6!A>SW/_195[+].:A/IH^,\!W,,4^TP-A P%2F^^'L>0F%:/>7@TI!2@W^
MMM M^PP565TAW;M=U8\=U_NXXZN'I#,\Z))+7FP?^1#YEBKAUIP%Z7MG;)&P
MZZ@=W*WQN-?ND6L.;@WGY>J/F55=6W[K/?/"SD>:3S,0%=EU;SE)TW*EX:@[
MK';#R<INUHRK3HFIXGV=BM(7JS.BJ7= ( .)TY@*-"!:0&$?(!I])O5MZ1X[
MP>_KAIZJFZ9R4CBFJ\&Y;IKI+>-:,+*,<?-=_1!&=B< V6GCGU67U3^!,&()
M?J-?/$_Y:[_$!3C]73P<O#4(IT))'],(/<!S$JP'RDZ!^%5]\=W<0PJNB:@!
M 45K(E>,)/QJG5S6KCE?F10=9]U45[+UYG#PGJKIJ? Z"EUN.N1W^08U&.&O
M:XO@ML#F"UDIS[UM:XF6T!S&6V1Q6S F6W$]W?S<N>M:;)X.F5;RJ=A-/(DZ
M9RB-LE^<A.BFG'TJ?Z7+G"P3YR0[G ]604=]W9$:7^FRZ+TOK*XUJ&SAV%P^
M7JFVKR5@"F;4V>#^Z=42^($R<FQ+G8)>P+@A(^U'>A836D9F'_L$SP >V&L*
M+/GBY.FXDFB#QP@5?"[_0]/ZA1^;RDX_OYIC[WPR2C*U:&ZJ;4K]*\U'YC8.
MT$#AL3O"B\S;ZQ+/.^_K-[.VP$UJ0'6/_7(^2TJJWS4H@=O<2K[7W%1G5Y)/
M_5,43[2;_*C0$-+#JYY<27U]%!U3Y#UN[^C=HIU5/G)?@D?%6R 4M3GU8+7_
M^$Y]Z@J_R _'T'PPM/_A+B(6,;1@[Y/N97\?Q*KY!00"V<V_!.% 9^&@BR!A
MF3\;76 >(+@K(X%.01\:-!+BE"H"Q=Y-$YC@%^Z3+AI4B;A$4K%]FMJSO2H]
M!+'8#,/?BF7<)NE"WDA]^"!NFP/>0LH.(:XCU+$:_+?;E.V%;E@HYJLKFGD1
M X0<1FJ!J0-I\V@P6$C+RW6BPM*WVOO=! TT:!__U^<K_. 6%Y1T3\[W!MPM
M"HJWH*A>OO)OTJEK.?DF$TSO\U>%IHE,[X7R37?0>_,1S3$GC_'.$()[Y%'X
MR-,J$8]]A:I0V#K&H5B@ [NAW0?>.BE05Z@_X/I<C?003MD93VH./C$A+%S!
M>R121Y^?]TD:H+9\HH$LCQ8G90RSFHZ:FKJ/P5Z#0YO4&H<T/Z\;CMZ%6OD,
MN^6@,Z^,=$,O[Y@8'P7>HC/[I:*7*E_^<S[@WAEN@P/(R)KY2P;3W7W4_Q!Z
MFI>O^-A?:_H!<[_^L+#2O],(N_M_IQE>%\7#_\,*'^1YEAX>H/89EN  2D?Z
M^U-CF?_U;A23Z?CG:BZYJA9Z/H;NG-^JY"AAW/B#W%_K_.?H4'7=)/1JT?:)
MS\EC=ZD]^^>'-)#"-_HWA9_^OWL.@_+30189_W%UIA<8G$W73-^#9TV!2\"9
MO_7-OZ&_LOX"W+A/ECUU40:(I#<^&W+@'ZV_Y3:M!!=J[N/*XQ#TKND:'1 E
M3&).4C_K4U$K,4>5>\ITG-*)IX%J^S1IH FAMU2M?2B@@3QHB(8-PA3H":JN
MRES'7U5Q,*B(8O3YGZMOWMQ]HTM6'BH1E1R>+>(?5M1 )T ]H8!,P5;/L:[G
M7$I4PW9<(P;<)ER)O=E8CO>+S/F'9%5:[/64R=@]Y&-NNT5OEB;BN\J\XUH=
MO'#O>/ZY:/S1W++C],H"'38O"]) 1R<M--#HCI4TE=A/N40:%.O^WK?\@_/U
M6*_9DW)]=H?S-6G%UM?\*_4W:KOU,FSK44SU$QZ,(:.I+PI6.X*)P0EV!SP=
M3CG^-!#[5*>-19D+JXX0275C+(,HK48M%%*M-'L7.CM6*37^+O"=/1-U$HE[
MZ;+S(*?@) L9"SU* 00P\17_KU>5CVQHH/[RK)/T;"@UM[>@ZH05N41&'XL%
MC)Q<STK'X'#(/TH85N1L%YR9!KJW':<&7*8'15,:*/TU@HD&^F33,W)BL:")
M7J"!  T(]:X?UN7@2?YI>K/?(!B'74!V<M) RZ*0TYA-;G( ?20?)E?BM<3I
M;W<@;A_SP%_1L=X 4@B,TD!2(?B^DR2**@TT20'_7L ,'^+Z.F$*<Q(')-)(
MIY,Y@3#]+_#J^!_O.?W8LOH [G7X S"7]XN"."I6TN"L^C;^F-5 UB,0CF_U
M=']CKWH?.<J$&<;B37L#3_*AOE P!=;<D'-H"@0=_[.N26UP?WRGI8VT#F^Z
M5T\6J\[^4;R5)7!N"L5:NO/@V*A;S";AA7IW*+?UPQT:B&?J[MS0(NORAK1_
M;>JW/*&3^X[/V^>K;&IAN4;;A?31?=<F0U^-9&ZW;M[/R_4H1<.\-6$@4R):
MY'Y)\;8J*7_V!LRG ?J]LK.#E83&CC#]$F$@06/V,$R 3E>+4VD"?OOBK\8W
MMFLO]++<^>+GQL;F+G&S<_D&^XP-R1AH[1BHIMY9'$K9<J>!SBT!">\I]F3]
MSI%9(]QA3(.=ECIA2^?+&_@@X5PCAF!LTY-#+2COB%$DE;W24D,6&CQ,6R<-
M^A4)&UE-;0?!'S;F^'":-+^=D=A+PID* U!"<$2;.OG,%Y'+XP@KW"*OU[6<
MU1C$K1(3>5FUF]<.E$15_L4QQ.L.Z@3!GKQQFG725\M;8G.ZI2JU])TZ#*G=
M?MD61 "G#)("<(M16F%CWMKB9'"/0PHCW,%P2E9>A']EBF($C?.MOD+M;6V)
M-FI-"G:*)@RL_'%O:9[T757^M@68GEY])X']T^N?2%Q@Z_./ALY:EF4NS[QS
M?RRG^7QZ2K2&8UC*9)+,^2ZW3,Q:(\8071^D&%1IPBV)U(7'8"E>W;,BNN%T
M1;SSFV$PM%KS<ZE7]!>S7JO*UZ'V8%:AU'KH+.E[&;-51+&6*LS\0#I?,^J"
M95GL$1-/<+S$FV>M>HD;X:U.Z3Q.U:F*!GRB;Q)%8$ R/=+\1O;30/ 8:G\P
MUO3DVL+T01K.11C0(?A%!BJ(  S= L'Q;<*$$(4M"!A(,,@H'0^"<<I^8FZ5
MRF8;/&/$4I'JPW3,+&\9CDQ* >2"FJ(5H#C4/7OXO,6DJLOYGW H;K(I(2@/
M;!IC/55?P#+\,,%Y8B])FK RS&IJ^6DLY_<ZUC3G]Y3,8'-14RJ!Z_57S(<3
MGJL6#(1\5Q9=@;T*/-Q!*PEQH]AB0W7]7N]R?#5OS/)!QP)'XOM?.R&FGI^O
M/Z^'BAP],,R\T;E9"W^L)](@Y,+W9.\3@'+.FO0>Z[X?X&'$5J-%Q:[O1A+-
M;%8/G(>.3<*,35,P#[?GZ@YZ3F(#TX%V4OQB][7%\VVN!"]5XP?C/1T\DPW(
M\+^%^ FPL]/VEEE5C9F-^9(-GW).R6U'-[1?[4:Z)?F@6G-Z%QS<J=E0-R@@
MU_?%;\ZA)XP#L" +=N4L=IK&4Q4F K?!\%!Y>2(9BMWFA&>99]Z0@]X9HQCY
M^?TM4\FL"UL[GUNV,2?$ _7\W#CN1CZWO_<IC@;Z!^DAQWQ@0J:!-K&X@M,4
MYD8@A'SUP"^AZZ!#>&Q/HFZ\S:AP8?;?L].-^8JC00D&8MKBGS&IH3K=!_GB
MX^^G%IV:VUHFJ]TPF1:.Z' ,[IT+/;EB,;$O;'I<SH<-:Y_^WA;P?OW)AKU(
MI:]::X(PITU#NJE[A9>(4/OD;X1*J<N,H[3CVO0S32W.M6DSW8 '![M8KKA1
M D/< I__D//E%![ /V_IG55,93+6_7JOF0,X\MNJM-#$)W;"77DI_(/*L7O%
M1OPF#2S#U0)/,H3D#*5TY9&L6E?)P=@!+05Y)K)%#! 1X6_Y=-,YZ(U'H)+&
MC])W_DQYCP<04HF=50^7HZO6;2I?ENNPIYNAS9^@$U%. \8G-L3M4W H(26<
M8DS:[3LZ7T H. _OTV_[CM!_[_WF^91]9G8H>[QGP3GWZ(=B'O5MC:F"@X+-
M[]MK\YF;+V=#4TT!T;!<MV,-&JC3MD,1P9AE:4>(, 7H&5C%L*T#?J5YRN5+
MOMKX_L;UT5N6L/F?-_#?IGLE]7#13RJX;<'K9PX*3CYH<X;UNS U+,9C>! Z
M'J5VMO9.Z!B$9M,3B5A* .$"?M$-CV1:&^XEFDV@'WF:/W\0MZ6:H)YE,[E2
M-[8E_[&(+B(&H7.<A(M9Q_K]QV9>ZD_6:"".10*UD%SX*/'.8].X?2CW#Z#Q
M: S^!A^2)'[P^_=*+W4HCV/W;G/^F-GRW?509#'Z@C\#%\DC/MMTF_2'@6WI
MTZ#RT4R46GAYMU*TU%CW/>.G@^L),_H036M$'?:VKWG9.3#SFGZ?D$HGY3EN
MX6DFA+>[3:5@Y-J0I*N[\0H7W-E*T;L1PD'X@]^?WH]S3]\XK@@D!TE]Z$7I
M6YQ<0I>TQ0_L.&G/"<X#U;ZB-77-+3#!D-;NJ+FYN9#)QC:8AL=;4?.?<JAQ
MA^+ZHKFG^1;(:W_-HB,B&PIBJ%)DAG MV#%XHX.?[!<5!/O)W.T,F:1>1Y6B
M2M;G K?]GKL'GRTX_\K@2@;?>:?1@2CWJ*6XT?G][0/IDQ8J,W6.!KH8B.&$
M0QS&59&QU^8"_8C;D4US#27Y\B3?,G9;!5&>?SN#*@%GPE*<J@N7O3VSX(9=
M8?26ZM8#F1/QP;$.A;"OR#IP7[L]F WA"O"2%OL6+C?&WX!3=*L!WZ] 5+7K
M[)*](ZPQ#E;I-/N%398GV";-X39J2O*-^VLHT5$>, T/V"2*D?VPE,'K>;Q,
M3%&R(\H#*K)EW#$9NNHFF;R05UTK?(Z//?BEZZJ(@X9)"#&OL4HUB\-D!4<O
M L/%AW;T()LOYF[')=,+CW'N,,M8M;,.B.SN2BRO:*C)]G5+'%1ZRWC;/T,@
MD.M/I0V6Z&F!UN-  ?0\+N0CW&UC,4_M??&.--.5Q5NG0YYTCQ]>,(KUN9J_
M_B^@W._'_//'_%Q)'9=><W,TMYMH3648"QUVZS<QC9"MRT1,RA;^#$X2X0K#
MR]PPO9 73.7P&-VB*.!9P=AS+DX">N%-6\B DA_>V4Y7OCHPXST: WQ]RZ@;
M;6;'JM2!!7;@#%D?;TD#@:F\B*N #($&8MP0".[F5PV5P6J?'<6-^U8M15%T
M*S><=3/J[?,3MT0*RV!'U=U9 N[[U:@?P1<.R&^H+[2U2-0,/%0(WM<UQQNW
MAQ'TS!<DFV */:E*HV<KB^%HH[$@AU9F,(>7D6;)8!GLV2?=<KNJ"E&>0Z7H
M_K,%FY#B_*M=F]O7"(\7P^&\PEUVR7:W,^UK--HVK@]?3AY081SM-C8@*JF1
M^.XZ^L.9?#^*7$3!1P]44+%YFF]C]0&_-8-H,C)FQY>C7^L?,J\\\2[Z6K?U
MD'MDY\/K//I:F!L#:U-=G3WWG[Q]W"<8GLFL7/&!X"UM^_R!=@W3C'V0E*N'
MMDE'Q<E;Y ,::.[, 2:7P (Y@[C*&YN"]6.!<,#&7=;9?AT$<PY=[2N!.QAA
M6LW<H E:.DLN!D5K638\UH=L:SF1T[Q3;[[P4ZW06YS4"\7DU0-#S$D.18*D
MCW]6Z(I;3+*WF=OWB]=F)M\\B<(D:@43&0MC-T0TOXM"/;0E24N-G^QGUZ8.
M&.4.(_="M0?UI^2FOT983]) MN3B%)41,%RY\3EV5G87@9Q6!(*M Z4)RI3*
MBS\JIOM6 G]9ECFYYFGZ,9N8Y6GZ=S^0,JFV_?#!BN+VQ>5B<W#W;ZU"[#O3
M@O%^Y>T/A!JE8A9C(7F/=X2B8GUPYC*WDFH%?D'*LJHFZ+*&5:66O$"]Y/=W
M*.ET9-(BV]\)S]-D\6+\")=GRV%$FQ-^<+5N,M XP!3S'7&KR-MZB:>I?7S[
M0<.$ZG%SG/6LJIGA^\I7X8S4,@Q=GPMB/)&Q1\&]V^<1M\D2B8@ 4EKGLS#.
MK,ZYU01T$*N7E@HA=VU?; (A5;@QEVL:)):WD)S9@AI^V51G[_EH;NSWU-B7
MC;IV&FA;H=OO)?1TF**CO3/"#E @E1&"EL,O5"EH(4F'76&*;;6QBDCQL8UN
M 9-"?Q]&UZQX?@[ULY65,FPA*8S C2YZ-JQJ4\#Y,<,#.O/YQZW23$C;D7LW
M5; MW.'7?VRXEW@>-+X(K:A#?/ODT,NW<TN-$D+P&%.7)G.^(@M==PEWBQY6
M0EHBY_@2W5F<(3*5,=VCW5;=RZEP0S@&YJSJ'F,P"-[\-5W.E*'$9A[E\AO*
MV)' /Q)%O>+:7!$3J]*S!.=.,I+IPBGQR9KXZ7-&HJ-1D4/%^W/-"FXQ>9X/
M'-/]M<<Z!-+7S+N&>E&0;!K(;^0</*2/!JK1WS+&TT"<\W,CI5B2.D$][GU(
MS\]ST9]Q!:PNP"#6OM5MQ7J4HOM^[461\FL=^U-?12&[+>B-12HSG6W.70%<
M\0H1VLHGF1T7 :P^&=VC$)?Y%.Y"8*6!HO9O^-@8 ,&X[%(E(,MP,LB(L:P6
MR0UDSO$CKE$%[41;QE5#3NSIXT\@<%4OQIQZ^W;:WF_8H4)1P<75SY S*\W?
M%L%QG:X!WU8T-LL8XR/7+/,%,B\FBY2Z"J@86JZY>?"-HZ3TE*M-&9E&32)_
M313LHL=OQ#<'Q")T^I]<%Y%A?/L "+F<Z9+G]B2@S#Y=*:AFDJQ:V_] ZO/M
M:L=SUP=0GK?-DT4^7@L4)<:6Q9892_^3C\FB@9S?<8'1 2;H]:O WO_8&K]G
M(4E;_?=.>8S]<M3?Q:?3-F]ZWP.M&>F>-S'^([^X^E][U_WOW_;+*CC[<4A-
M8U0EIY=W[TO3TR669]+ZJ98X$,Y\ZFGN"SG>%0^IIJ+1O\O@+4L6NL]Q_1?C
MVTM^J&P_IH&R]I\(G+HI?>]ET!(U'0=:HX;5-RC_QV*$_]J8[C\/3"D24"_
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MR4^4+XQ7S@0MF3M0!(%;,&)YF*0]11KP\R'+(Q5-R1R+7Q;X8OHL&(O@XAQ
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MIH?4P5]3MPM_+T^R^NK9AA<8[!&UZA'7W[JR2E"9=-HFM& LG^UB6\%8@=T
M<I#>/5D4-C:0)K*@6H[+^CZ7F2Z(?IPU?#8*6QVG7C#3Y>)7#[7]:WYB_M+4
M\&GI<ZV08"C>_%7R.9"JI,CJ5-Y_6Z.8_-^B-U#/?]R_0.K_F*U(NXNV+3[X
M^^<^O;'%YW_T-QXR219%YL[<TI7\WTU4>>BZ0@.A6W?_@";_^T.D!?V>T$]^
M?8[K5/XYP_^V7GG)][?YS%\R&-I+GMD-BY=$CX$W7OY?CY?_]X%^ 3P_MJ32
MD]:%-HU\,&!Z? ?Q G#%2V[+-_!1Y$B[1(9NA7/PIS=O \7.B^)Q> R[5\X#
M9V=5_]Q*5 /G#[[OWWY;^>/J;>15SKSZYEFE[1K11?P@U5M4F(@=[1ZUNI*3
M.*E)>G>=@!+C?[HK.F?LE*=QUU?EE-7T%P)90WKX8FYU)-H&;-5E?/W61+&&
M::J)DJ]ZG=>U>OUFA-%)*0WDI9!X)%P6K:U(_8X4TI:%>V.M8AQK2(?=F 21
MF^2%&(_J>?N%&8<-GAS3>+43ZZY%JZ::B2!FC: +/F._91R.YP.S75OR1)>I
M_)2'0#O)Q@9#9NC$Q&,XM#DVYDISYK3+JBDJY)$X"D/ENJ:.D\-"8P:R'.Y@
M.8964)UJJZ]OA0G&E32H6S<>GE>XQO<3L1#?RV]B9<2@U9)OES4^N'YM_;YK
M!%:'P:R_W&"$6< [\AV*KW_WUL\>]0J]NF^[TF^;W=8?\:T1RW=VW#P2NHUX
M+UH21>[>K= <74[P3RJMRC72&RG;'YD/.!@A:R=4P6'=F(;%+2@!<A&(,<*,
MJIV<<02.R0[6HT%#O%;UF5C+,;4D:1JH)XM',S.KW';D9AZU(.3L059FFI&?
M/\OKK[\6E624E5M4KA:?US>WRDA?MK-ELTI_>>LLF]ZMH6OQ53QVF<LUY2RM
M"E^6295BTI\Z714!VXET&UEW<U6I<8MTMZ*GQJBB[^\>N;U]Q!%)!C8?:0:F
M)5TG*EF1E<MX?A,9K=_]X/2Z5C3FX[0>^A#JAYPO 3%LH8[M0" 0>$Z%> %T
M$02"]X%.?;=Y":>!"-!N:#Q5O)5<UJ,@ A\AV"3ZX>H:.\@>*12SC_"^[NG&
MN=#Z9\]X#E\<QJ(;A,U7F 7O%#74Q</*DN?F-'!1YJ)60N[<F6#1_J?K:/:L
M97[G\VV%TN;5$5]<%1N<KFL,6/XTY"I49S1D2W^_//#CRER;54//*G^'=FIA
M\I"*D ^WFIE9#[%&(\>PQ+*8OR*H8IC)/[$D/77%T-Q@MG6NIJ-]7,%'3>[:
MSH;I1.#Q!X7'"IN^8O7MM6U_C>1;ZUN:X*N-+8WYJCG,L0\-7#,X[OQTN@5!
MPMVH3)_IDH"'%/V*-[H>.3=/:,MQO#;HP;DQ?623$ 3'F3:7$Q2XU^RG8ZV^
MNW*X5CP?Y+.=NB50D3+R0D9K/F:'Y4BU,/_A<[T@)HZGA2SS<IV/E(HE8 /I
M_NDRTD^?V3PQ:)4+5!U4^;$MFF&W-#L,2S>I-:N6K5/LP8E92Q\DV;G*F =Q
MM-;F>CG-!\P&%<S)$ ]CM>ED[#,5=@UAC0%ZRKZ.>15PN0.O"!GD@S<M@I6N
M(DF$YH8[^^T""S<<Y@<UY );YXU@(3?*MR[%W_!ROOIC8[%Q<2N/D,=I2QJ)
MHX%@!7,AW6&"9)ZL#YYAETC4=O(NX2.Z"-8B7PF32RXOWA P*20,)K":&DU4
M>>2/W!O?]EFM;VO(<0B)?1BMK_<G.C[@J[(TFF7]X6=C_7"4233KB'SG$%YR
M-"U/6L/76V'&''5MV21/_LYMXP$I]:>N>:NJ4Y<MAG8U8;SFJ,?VT5!>[OA*
M:VDU;\)U;[2/>8EYDL'$2CHA-<U+..MEQQ7*+<"*$*(@B% @3R=V" (C=^-W
M6-5[%DZ3M9OH,IYSC;1^+<W6FVT6MB#2,=[@< ==Y2M1VY;,W#RV/O:\N@S,
M\C%I#TQ1[]N:>$&=<VDHH(KZ]4*HCV%+ ]+D;'&CMY-6NRS%,GW3B=R24[WW
M%=]6U)3Q&YJ55MB@KG_0,T]/Y_ILB1+/F/=]DMWK][+D%R[@;M\Y/8L@,7W&
MY&Y\N6:J66*%9J!WUT5?Q43'G!5O)>-9F>L_EX-3];U$WV0OO9EI;?TL^WNS
MNTY%2?9;=Z9HJH%:@-&DVDU.\YHI52>]XSN3>ZVM(2<J5F._?\NJR6D>35GE
M3!WT'HW=^>@COU7Z;^;"RH+M2K2EW=6@H+-F1>T2? /R'(GNC+J]9EX:S0T>
MO+S%"?:JDSGC;B/FZ0]1_!H#<H;*QN52$D&B4^5E%5X_;YI^7V1"=MIB<,7.
M+&.%H_5^<T1"PU ZVTF^.OGF2@HQ](Y^(NO<2))J"AN,XTYQ9([183;HU$,0
MTQ\BT6_+Z_@N=8SU K!&_O]8>Z^PIM:VWY<Y+2A%E-Y1Z;WW"-,"&!"0&@A-
M0$I .DB0DJGT/J5*EQ)""Y$2>I$2D"Z$HG02 0'!!"4&"&'']_V^;^UW7?M@
MK>O:!R-'@3$RQC/N^_=_[H;%>0SN2=NEHS][%DL0K1$A&T4ZWWT'0BNAUI)O
M":L%P2.'=S!QV7[*50P'HV]9BCU1Q7W^L*MN;6O[,IVQ;4%_O/FA&0F[E.'V
MQMY/!34ACWS<CT5-2'?V0D)#@U8P1!"[.[?I-PJ,U8.\?"DK"IX\J<QOPI:C
MUAR%M+NAI69M;9]C;?U)^J D=HU@8;JTM#X5*]/%0OA!*B.75) MC)J-=1].
MAQC?-R6&U"<C[K/>]4-XIN(%U)U*]+#[MQXDC0X;Y<_,C'#Y5"BD))'!20<3
M@8#<.Z5,:F&9FV&3O(5G2(".=^Z&,N_U:N_PA^9#9D@3Y99"8E)V<SLFQX.G
MQPALDU*B.MY8^&#CV[:3S+#+.PZ$R:\OV?:R8(LL>91T9NI1P[X0%\QS*EU7
M"&#JAI=/.:?CHMZ*H,%^SI8QGP71(TG5P:Q+YU&#B<7 \\;EL_B!?XX)]W4_
M_]3VT6'142D9^Z%_\K.7[)>^5$M--R4UG=,-II('SNDF4B/R]#QT!#9.WD3(
ML58:9$XQOHRI7G^''5,P'UC?F1BRB.-,J=*"0DW,DK,@^C<R4^R,X3[")1[_
MH!(Q]S4G2A.'3%05H0E;&A\6,"97JTS9K*RMI"<9S,VR;8$8M4Q@XVIIE=/N
MPJ^.^MKPT.K=%T4KDZ757N#8\87<D]BS+U-!8>'A88&']@XK*\M D5_JRB,B
MV GA,>G.3L4%0DDRQ79=_@;D=WU1(N7^^A2G)^CVKP=$W5A5I-' ZJWI[QRV
MG'M&\\')!7?T^]>%.ZXB?5TR794.%@<%GR<=B>MG&YJ7FF=K?BQ2-PSVN#*:
MM6,(R$!(!9JP(B34N2X7VCM)6W_\X6I=)S74+&49ZVEL%6LS:5;+^SI7J9HW
ML5K?"P@T5A65M>A!?-TLH7!@J0P&KA5BB?3[/D3);QD2.#9'O8U( Y T[S-S
MZLU9P)T@%*"":41YUU@%E2?Z>CD']4^/0M1'(7Z8IX#[PJ 0'U66<H^,K(7L
M!>9;#:=1;.O(:7<XI;&^?K(_I>\8'H0+7)O?0?H4XQ8>MC2VY*TG?DDL5G7^
MP@Z*SR'D,GSYE)LR0O:(/ZQ[VG[<$.9KG+,>(+\HSK/:P\5L6+N='%"T_5T,
MVW&G<"!)(U=MH$[0>]#VP",F75Z.2V&B@3RN]24TMLHE@$-23C\SM?P '>(>
M>;^<NBS44A(?G"H]0!4Z0_5ZR3+>_=B\)"#T8%H%ED[3&S\GA UF5,9LZII7
MI VQS[KL+A675.Z0_.]#7%TA3&HM.>\P?G[L ?H)@'2<TQ!+,HPWI%:7E>)*
M+B=RX:82FO?E9-E,%ZBBY*7!5>WY.A4;WX/O&S,R1T[LNR^01_6Y'*126!AG
MR<4=B,#*_DK_/;'VO+7)JOIQ-6#&>@,+5_2H4I>8[(\UCK@Q0I8BRR*,]:C:
M+-9@7V>M^WMD;>&;%+PZYJ.-O37D#<Y_+./3,WUM-O K$FP S9OM9AQH&QC>
M\_WS.] L[.(YG0]J<8D4]$Y+M\]TD0V7/G!V ?:FAWNFRS0\9$-C2^XI9(-0
M6;<8'W^K[?6GO/K;,S.0E](R:;VR$>UZ/F\V\WS]XG(8U<;>:19?\S&$/AJ^
M&C^T 9=8G<EF,M9JKIA;*8CV.ABRX1]6&"7>P&R^^>;ND/PJ($[\0A(J9E!?
M"3WK[;QM4F'1V$%C!OO33%PHA;V3=$0>*+,G^PVOH4TQW??_ZDG</V(6UEO
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M.1*F..S:G5Q0?C3N*,SVS?XX;$7>QSQJ8BJ#GY*S]27U^RCRJ.1W3''NG,X
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M,>D+5*G%X[(P1&=;\<%!&$WG5^;@MK:V0,4X',X#XEX,@;MGV,)?YP/=:(=
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MKM!_2>")B[$Q>%'%N24??[Q\^IB+?)?ILL$.^NBIN-OAP\H;.GY18(&;WQR
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M'/9IZOR72["7C'9]1D7#SV#7F3Y=\I8\_U!I2]-R@XD?%-BUQU&1+42%0/G
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MF+2W*"U) K[!?G;R#[VV&/'J"PV7)*:C#NR+5;\5(GF0',1!,LF_; /!N:_
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M(_?AIO&"67U]!EZ_WO?PW*%4G.<F_Y"U>35Z@:S?3IE7I'Z*'3[DWI729)V
MHO;KYR[,YK)N?/V@%:.42?XX5&A"G=@I9$-4L)1148=0M$(H9B(4BY4H6GK;
MLS+6$BT;IM?O@[]'9.&LC@5)9Z?U%R:#$#4]2GQ#C6L?2>$?9>RG,9KR6>!7
M.O(K#_FU3H+\&@M^U4-^?8/\2E?ZM0P*]UC0Q>(C**SSJ]G4%GVYG3"58@7
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M3U"CV0,(\5S';F>!;/-G& L]T T#TJ:H+U$_;@^PP>(+&XH@+FB2 $X64[:
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M2D;?_YH<3!4Y0DD;=A^\?OQO/'+%'P1DF$Q47+V+XU[B2@+H61R9G5J.<:?
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M/@@!%$#D'W,+BV2WZ.73Z2T-,.F%B9IO65C#A$-M;Z81C5ST35AM9AFWMJU
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M2MC[*=Y%(*2TB)!Z4^]0MWEHK]#776.^@*/!E*T8*$THW&>E$!EL.$(*.<S
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M(-ETA.W2*?3IV" #M[=E",IP$_"9)R50RA-"!VIT@8_WS?V@PLWA8.EP5Q$
MSDUOS#D H!*(LBF,51F*E%XP.;4!$B2@FQDA@$E=N[8 +Z.;5L!<70&\OL:+
M1A6/$UI*O;F(6.U/291)0H7MK&FX7V+[+L *\\NKY0=/A]R##NA%CCT8^*28
M,_P1,-WJ3!IZ@$(9%GJ'(;W9'B.DG[H[T=+P!-%3"L!(@/S5,9Q)/LKYU=W
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M?;#WPH6\@!*6I+><@[T%W+ TA0YJ3JT5,2PUA#@KXL;S:[S$B*^!=TE(SQO
M<P;5J#<@H2*V!6CL+-,8QC[0MUK3'H;A$X3"5\GD"R.DB4@OH@KW&]KH8=,;
M^:'S*,0U6'X- ,ITY]*"3CS7K;LF7A66;N740SPE%'QDRU- *,;O R%[#XLD
MI5Q;LG,].YM>2$87LBJGDE"&@/D^& >PTG:,X'HGT%80O!#77(H)0<>A;Y=<
MZ" 0@?"V/F.)S7H9 C>%%RX6JO24@$S"9H-"TA;?-R=*&DQ,)<1 0J;>$3!
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M@7,YTIG(?_2\^B\]J1VM?)@ZM9]%\TKPS \.8 RZ>[</R-X@RY.2Y"+ 5ME
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M'F9<62W/29\["+6G&2-!A!5Z"?4,@7JR^X-$A8$1P@@<8(->8 , [0L9,AO
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M0X"EL\:PF8_&:/2&@,-[&.?+HYP?(4T+GBY<N"&GOJW6VX ]*I"U41@>Y_G
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M:*SO6(AU&+K0%/Z$Y+#D0.]#_XW+6)_\:6&(YZ+5)^[D#0R5GI_L HZ?(9J
M 3'7R H%XZ "I#E)&<@FKA9D^7OAL6'3%]/QBCG;&%6!11.B8O6LLG TPS.?
MEY%1EVQ[MH !/I,.WW$6X%G'\X<]10P1Q8[NCBEJW\SRHS[<>W-#V:&NT!)L
M)/L!ZS\5^X,0S-4]XJM^WE<[QLXTLECE.?.9W/#"B)MV'XLUF#+PEQ'WZ]!2
MO T>UD6>C=[&7A>SHBEC>]6V,6IOGH$[V"G<=C3@X^JR#6&R!P@KW=33,4J4
MM_+$J([G>:2*9\X8XI5)-SJ;!F+7=U9I>=6G$]GYKCY//'=P>XN5>;!8%\QV
MLW$>4M+=]"C/,@H3J7Q9N_9$7^P,8@Y/^.,/Q?=J?<T#'59?D^QTS@^7$2R2
MY!G ZR'PL1:^Q9D5D>-$JJO8!D$]GU% H?YATQV':086Y?*1TOZH,5:44XW-
M8#X9UC8MN)<7$0R1U>XCV\_3TX??S15\62!->*8=8U.)1?0TWU#M*/@9X:;K
M]M%8D^,GW4S$W\[?-OX-XH,\1P,E!>+7R+&HI0U3K!Y6 ;A* UU<:Y_YR4D#
M#2]@'%+A^;=0GU^CMAGV$N;P)1A!=<E1F)J"UM4<1.S.<>$)(BQ[;VNO/7M$
MDWW>)"AJ8^?FL=]$"O7.,#>AAUX<GD+[KS-Q0Q33\)KL-P^/6H8I?,N+V3U'
M[?S[H;G_<%&?PQQ1P+GQ=I_)E6T30).LZ8FN$4F \I10](>;M(,"\=D2K8^8
MBS%+7KG >$<+1X*J)[G/9G(![WW^HW.3G^0I$]NHZ*O7+7P6@G&#VM13U320
M:.=N*NK[D?V.[);@#A6JU\Y-7QP[$7+L:P:6_L[6_;OM')T(.QQ+=&%4*T'(
ME,Y4M-]7[B4^OIW@_JJGA3-"6[1-KED^Y8U="NYE<((=I!WIV?6PQ;J3QQXZ
M=2P2'V>AGB!0CC0_-=PYW'<?"940PTO@EZ_P*F42YU,^\[Z:BDV*A7>E4S@@
MVZP?4;,Y-% -)$*=$? C"&!)$@8D[38P&'F3=[H^U]J-:TQN1?T2:2U\?K"O
M-H*:Z^/'#B-&2%$"0\J_X&IL)LIIH$'-SNZ%+R@-&/%^-P5MV99(EA\XNE<Y
MXX$U^(!"< :>,S#3%Q+9Q)_C:O7&N=JN5Z0PNMM9Q#!>S$FBL=9I62]'(%M<
MUELVQB-;25M_<K7^UV*,M;IM._6\[QV#%$?GT-[+E+$B"%U$O-ZH\[48C)X>
M2[%#H<V0GDFR8<#%K=KO27!/5*L:RL6 :WMDMS08$MS?<HX47#QK+]&5&1B_
M5@$UR%^JRVS)=9IF(UHT$UY=B&S;)HQ-NC1E:2?TFVSDQHA-FS%^*T'EKP&1
M$GCP+C^\(Y%R)9B;!II?#59"M=+!YD7@1_<7+)$&,OL9OT+.V\6H"WG.G(3=
M&9CDF@-'E/MGS;!11 %^DBO!,DJR=N7QVW+F-0>BS)-:&HC=G;.QKSQB.R/(
MK^"S!Z]YDTU\<UHAYDO?G0UMKR!W.:$.5.^,SM[]>G@XVWUU[MD6H?(41S]#
M@??+[?1GA2UM4C8D@_VR9IMK5ISO*66^-HUG5% 6@KER#R_<-.CKW5%]!V%&
MJA-\F#<J! D_((693O<_DQ4*)<TJE>/%?^\E6FN9QFW?+ SK<ESJ:S.O9(N]
M%R D_J+"2_05#:3:F$CA8R(.V3ZP%]FN)_6E#EI,*.832W\;E1I]^DO?UA;1
MJ_-L1,!:<Y+S[$F-OF"SX"DX44-F,GW[.C&XGF3:;M,50J*!\+#(\HLC4(,*
M0,9@Q!_.@[#5#TF<#&A&O;.L]M@KU1UMKIL0:" 3XH]F@FRA3>%T;EE[T9*%
MJ0?'EE&[#* <M?V\BN3P^PPW]222F202DKGS16$%%;D=K$H,C'4>=K :^S&G
MTT*226SRRAMX['4DS=-3M>_R-,.$N90+[K4N[P^9[^E:H_YH;H2/WMCW5!]_
M&7:W!RKE>?;O"J4WL[W;)!HX%\9N+EL0^I>.?]3AT7D0W\X8MMYTE1 XI-&*
M'!?"$D[*R0S<?S%4Z*K/8)&F:\F4@ E+!6-O%B;VO$;<:#\6B]%GT1W*=A&'
MCEXPOMFIE6WCN50%8PY.I$J[9#0+T+4Y5]D-2$4(6;+I5?CJLX3EB"NT8&R*
M&.0ZG5XK?9#2>_ZHI$QTLK:XA[F.UUS,##5/IQED2_9'"@VJGPC^A*O!ML$9
M)BJR\?#C%"=22Q9>3>&VNZ4!L;"KVK<8X6S 6BES;GB3[XOZP./D"[]4"U1[
M+7O,J2$N#Q,@5WHO?Y^B[]NR&SX2]N'>YR6Q73A?%"8ZOS\YR60[P/E#LKMJ
MP>0(E??#:X[ULNY+O;)0G'6O;T/9R0O/ZL$^85A3L&5J359B#4;:8LC+9DGM
M**X(_ E./:5 G-INW$UI80D>M%E<I9]+/.F!8]U<8YFQ!USUB YA)>X[MF[!
M"B29".>$2>J&1=V;!MNG_MQK9WN/LJ?A"3>-.;)^H;&;QOM-36F@'EF4"YP,
M0E[=/[:3Q(Q#JZ><]>F$TKW[)>S99MULEW6IT]>!2Z;#R=V1B(@V:QWID7MQ
MXYN2\ST@T^,R-B+7N.=2W)J!D+2ED,P7]?_#B->;2.'0I](?\=HK) # ESA
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M()\M+%;\.X/R1-)8DZ/_0&GYS]ID;;,#8:RVR8%Z_0#6>G:@_A3Y"ULU0G_
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M[/X+S#K?@*R.O)S);><O=U;MQE#S(T3)O9OA(]]>*7#PIIH:IRJ^2-D*M+"
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M%5P/!N\E9%<::+:4!JI"K8J0(?\/>^\=U.3Z]7M'19$F"M(%5$2DBX!4B8J
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MFW/P8\,Y?N+,O^:S3P@"LR*)&HH'0IMNU?%B1&_A!%'0T!2NNMT6!<BQN$.
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M*!!94^(6Z)3+M;J)T,2%[DT%(]:0 =;T@:#=/LK.S ;E'%G'CX*?_EZ1(CE
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M%,$^W?L!2J"BS;)8SS?31@>QZG4CJ]1?6G&QZI5H\T.7)$$#&I4QK6NH7*^
MZ^8#^<0*$:-IS]<>!3IN#U8#FU +>%FU9-&I]6RWWHR,0Z8P@V%NJ7U7Y=]
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MYLX_L%6;[>TIV $ V8$A.#LMY&]P2=/Y6[*_TQW?_69JO7]LX9]GW=D,XO
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M%6@L)P,(22SM2#P_EQ 9,%C>!M73(^221LF -1<0!W0Y UQ*!FB.,A&-9LD
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MR^F7OH[K^$NQV?[42%\5Q8DJ^.<L[O[HSO[E-#1V-N68Q@XRX-A2S5!QBZN
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M;_H-'V#D7KD)409*2(? 3&>O8F;YNZ[5-5[-Y)_;*#T>,_CA:9W?"4E7L9R
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M=>JSV;$]='%.H4FV@E%/1_ZFF(@'YUOT]7%(.]H'(N>,'EY3Q\M0N\,+6OC
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M[5T5VR259BV$?TPSC1FB0JM,\_=D+EQZ;)&\^XPD3:K[C(I:79A20^&7PI%
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MX6?KY[]%5+7/L#A;T8ET>!/BMH(($,;(@<>1MRWDH'9^5RG3>+PMKRR@;GN
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M25-VN8K*GP4@V(H:;SOL,AE0Q,U8<?2XVI^X!O2Y2&%H8(TQ9S*M:E%RW%/
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MTM+HOD\-2LB;C*X=4SM'IG>\O:];A"JE'FW:V;KQY8Z6UXJN7&'1$JG(?R\
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M]1UU:KZ*\99KQR\_&=23[4L+RA['KU0TEV4A0D/Z!S*M0DP&$[+1"INKK;]
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MP'R? 0E+'*_671ZXIUUZ6=C?85*-&S#&O$C<6(X,0:QA%\<$7<9 I6 /8#_
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M@=2;I4N&,7>*)X^T7@LK<2T5@,Y!F.<%($!)6.L RG@*:@M:L]U#<8 K2D>
MD$NWENYP;]*F9<5ME\P,W[RIR8PCA7]5.^_GV4=ROS7<89TQ-2P[JSME;'FV
M>\[KC98KW/>FD5UR,Y. O]KU,B7=+.V]\X5 U1])9</1YZ*]25KV):<M'*37
M:Q6IJ[0Y>!W6SM.O3Q"=:%V.V16%O7^/;J)<Y/+'BPP)R)G7CP^?KES4O^:-
MQKB#M6S3SWY;+E)QMTLJ;78VMR\2=3@/IPD'0<9MH ;_6:)E8*616!IPSP]"
M\L63K+:(FYU_W1A[NMON+5D,JM.C\_"'3[K.K#I4'6[;)P.O=@Z47CK?^'I[
M_(\?!QY\$S;_F=$A,#"N"8N[*"_2<FVDL[#N#E9T>J?;U_G X)LT0L*O[W*L
MBEP_$&Y<KN\G):H%H_;Z/3\7*7J??K^/_X/?3*WRI1 _:X\9$]Y28\&#<49P
MI%X\% 4&"*TF!U,W]@ES^^SU7HM>XN*!WMEUG_T&=DQF*^"??O9W/-$CAMP\
M7O^*W/=<,U2,.*[-%R.RD"Z <"5L1/ >-D(![+#:K!<-WM05Z6%2U?M<_DEM
M_P$FN8V<>*LAVZHO3JP=64I!:A!"OHN5RQR57+Y-A-VM2D,7M'H<:;ULE^L_
MX0*3.ORBG+9X\Q6],B%YRT>-CP_R7%03"1G7K R>=65IZD5ID?1?MRGHM5U=
MF "[L,U;6>]+/T(<<_(UUSWSG'YI7GSZ(RG=H:M#OT3%/DFI4XH7SG4&@I]B
M$( _ Q\]/%!')VSS&S5ACI;0W!&N3.M*'0DI%W_7SNJA*:53 \DUM%Z44G4&
M$E%31$HUD_RYN_:LXVE B6TH[$2M^!\0E=06GB6]_2T/Q0"C8YV93PO&OCI9
MLQ I5Z#X;0&NN@413P/.:9)R(%N_CX]/]2R9DUY69KMENKEL*+^?<>_^HF9T
M@SL3QI[B95&=F<_K,5Y,)(-X)U1=87S^5-_SD.2 G@[7%SE6 SKO-,I]\+;,
MKB0C W3OL/LI!7G+DX-7S'=G?-W-WT+DRF;1(8!UX2O4R#S](>"CR05"O)FA
M\^A)4K4&[D4A2PNXUPAQ6XC]@T]%B!HWI.*U^3M>WELV'4,C/]N\G1B2#FW[
M_$.LR+:L*.6][WW&_!:7M))BBPI55K/#W<E+RM;;<@KBBS:WUB@[C+,3('E7
MRRB?.@!\;/6HR0?]G>D6+PH>7JZFS5"T"[*M4T,"NEO,1%RE5"Y5+JK4VSY.
M*+ ^4I^F%ASN3('PMV&Z2>_X>[#O3/:FIR$-?5/X*M\'E$_.!6I?8 HK:LU0
M1Y%CM46#L:2+;]>]NG_]Q CANR7;7-CKV_.R<#-4DZVXJ9?,K[B-5*8C\3.Y
MA5HE,@L1H;SD>C*(\IB]+$1LH)$W,ZH%:S3HYC&0 P]-M&19)Y9]H:"\A+4N
MRB]_+RE+PPW>6Y[*.-7(G%VX=_H@+49SSNQ_WB*"$.?B(Z/*[*#D:HCHN+1M
M03?,[8EN/ZS='&S7;KV[SL+9WY&H"CVRJ&:=[&=17@3^]"P[\4+9#\RY]Y4W
M]>[R96A'N5]]'XHRM+E!NXXX.T5.%#VTC]'JSI!V8!U]["1N6V,A-?F>5 1F
MEA8^Z4W@K\.-"3]A+:1=8EB3W01T7J-3P4!"!P4B;J($]+[%B6-V/)W.CJZ+
M-=KS"*W6<BLV]HIO[Q7UPMI:/K4_YB'4'8= 7BL),$RF[,LV-NRRJGK!'4DU
M/W3_6_JHB_>-5/,#/L(]ZW/UZ]<[/_YHJ=;>^:$EU1PZ1ZTA<//@L\+-TW<]
M*U, <M2+5YN8XC?19K9):+X[FJLA)FXF%EN0>9%FG0Z^=O?2FVC=N?</THH.
M31B\>V5]/6W\FXJN %2'1OX6V7%]:X[([>9/S9[/O-&[;0M.YOHW:ZV\,3#>
M+WR]DLK'ZT&AJA8.2BK6M@\XF7S1+&%%MXF7@IL9XPO;YZG3_HCOGAP/#&*@
M$83M($#X4'1 6Y<-"T*!W!W58^%C9Q;748=^3F?K1M\,+LQ9..Z!5 [=6)?]
MX^M65#!*+F-:1UTY"]8%^T\7'BWF2H[P;5@<+]P0&6,F /5N[,?IHB=.IJCA
M7\J(QT66F>Z BYQ\HX+(* (/#5:7B+H4^S?;)E9;=YW!?T,5*BBD:+;@)8X\
MS+Y6$=MJ^Y8VW9.^'-!=00@W)'WS(1RFJ9P>*O:9Z85]A-/UVO")"!F,&QTA
MCSD')#,DP$!UFXS,+N"!ZV#--*<C^?R%CQK@CV>SO6NB+.X,Z%1U5UR,,N\-
MI-61>F<J*@(?Q< 6AGD91FJ/ 5FV#R^_ 4)[-LOX9*3'A--NX(LB,A_Z5+]@
M.B9N#;.8&,^:T\UY]?R NOJ'7G.CCS]_G\%U7")_&N%O[N=X"[?X4EXR'XSV
MA[XQPK@#$C3(-JX&D$4[H=OI.#S2S$9\5A!GH>O2R@==?9.,] H_4RU+CL>\
MA^UH)_JK-EOIQ[#Y]_><4>2YT;B.Z[<^SOCFO-)W+:2R+TV95I! Z2F*+%$-
MH3^V2-8[B?:S3#^YBVB1ZM]W%_$I0NGH!3M:D&R;]V>/<V5*'Y#=;=W-/><?
M1Z=HBI])65<^:9L0K2KY593FJ5M@G<N2]'N:YWQZHHZ[PXD-?\".QK.?O&+5
MS<J$L1)@"=("D R.IO@**"A^A9-QG68!,>*MF+V9945FP9(WM":[$6?N^WW/
MOGS4+"A.IA<W5@76S7K^Z]< 85^KINZ2KGZ1>2BQO/FC)'X6)H&>;W;E)Q5<
M ^ED-^9X@;>'!7F2=MW&BO)*<6.1J1A_H)=.3L")P)!="ERI3PWA=''3EM%]
MS$TECZ;S#7L6K'Q=Z\-Y/C@1JBOW%#-IX)9Q/W=0YD:C;&,DFD2YRJX%EQM>
M<;P50?RFQ)5ZP!<U?\YOP8$:93$.0#BKF#[1.K>EJYRP$7/]03OX?:*:>[#C
MT,TQZO;O^9#*#[<0T7-!Y<0%Y+2\F^W@CRNA\4:&7OU!;K:A==RYV*M9L)W7
M9#;8MZ()\1^"SVGH:>:O/]QV]8=A$O-H4W]1LHOO8 ##I-B\+Q\R]?GF^?S]
MN66&%^X%^$.RKK9)'*#G*XUM>4F6T7)YBHIJ]TX_^J5,GK(G6O3;S[<.!7@7
MI\$I1L:FQ!*[+94O_3TGXHL-?Q;-T Y".Y<FN+*FG%,"4/,)9C$#/]-43D7U
MF<@#V10Z,;)BXD%(%PTA2U%(I)?)*L__=/8S.=0=\M4"\ZQS+D4^RN1GE; ?
MC8S#MMI@SOVR(L V*QR,M=@)(!C>M9ETN-RFJ(C:XIL<S:]P>I>,&4Y75RP"
M_O8\&D+QODSYD:%<D/;NVCJE,2)W!_67_5%,D/ :M[G;6!MY2Y\Q2BQ9Q\PQ
M8G+6'S\#J:>!#/;PF?O&,RUW8]K-6"W8'2SQ/UY$R=T8-DH:AVZR%X!,Y1$T
M 2@:2I5%:].ERXI:P^CDV!5<8@A5=,KV8N,#% --<L/M>+CI:[/;=."FYJ&<
MJS82V46[ZU_<RC\PT +<I#OZYH]Y*GL"9;':4!'X5YLVQE6I2JC\#Z*J0<56
M!5\7]]K2[S_ZWZ DI^D-VBPG*%VN,9<6P]@FTYDFKWGC2#OCY]1RA%E8D/_Y
MCT> K</U ZP*OYI#KW": M!8G0!$4N(J:P)*=:TY$2:<&:P*,*2;P]2FA!\8
M.7P/^*JIQ"+^7FCY38^2I]C*;KSNZ?GZ]8MME ^G'LS#^>*W!:!4' <A 'UF
M,''">CC?A)@)&_N&&M[%WTG%4T5P/KS]G \]_.WH_7/M)JJ1>[0@W$/DG1/1
M5PZCGHB,O^IND*?QU&Q?W%C?4<=*?GL2,]C>AV->$>$^$("&A3U7.R1* %JY
MS%H,E(OBR'QG9=%+33.E"%[7OXQ6##8\@QMV5 *[J>4'HQ]O/2?]CN[;7XUF
M3K ENC.AK?W%[Q+IA[%.>8[7/58H?5W7/^@B9(=_Y%:B;Z%+D9=9=D@7[3;A
M"$S,+2OC7LCPX@DRN(7E,0O^$[(W?LMW["9>%MF7* ($'$,O2(AS=P'N!9,(
M[_$]Y3,-4D\H\CVOEI^&=S[]@8P7LPS6Z8%K-[PX!ODVR-^&%0Y)+&<?[G,6
M*TP @N=O( X1 $6GV<PQZG 96P_PIQ4.++!886.PNYACS-=TW^@-(U W)$IL
M"'<1K==*'[6M=O?//\(<?> 5H5&T3E:9:Z;PIK!,5(<N^Y:>2Y:/8SI1&IKO
MJMHW>7_^,*[_X]0W,'Q/EM>^:**#VL]>NP+;R!*UT_8M=L6AJE6VRXV:'=I;
MG6XW[AYW#@@-N'CTP__#WGM&-;E^_9^Q(B @TFM4I#>1CI%8CB @A-XA(B)-
MFH!$"41%>CLB16JDA(#T$II A% .(+T)*)!0%!!(I'@+(4S$\W]^QV>>,_-?
MLV;-JWF1%["2W/NZ][7WM7>2_?EZ/A+LG"C45;*_I-QITD*2EL!V&2A+C!#>
M5%8[6G 89/XHN@'9IF]W*5K7M^"!"MJ(A:;*7LX:34&;<FV&M$X]'P#E]/LN
M3UJQ"X:>:JDK>WYZRZ]@[4Y<QV4-Z2]#LD(<M\)NK@X>WO&B<HMH#2O/ &+H
M52>GHHN88N&C@_ZOK%I?[&&)Z\((/?A@HN>9XR\MAN\[7F-=?:_RS)NM!8J#
M44\9PV*A_$@+"FSV\^JCN9EG#3SQR*L%B/0V3="HDI!OI[5]9/&*!0Q5W#^[
MNP*/R&)/Z]=NP*>1UL8) 0,P[E>>PF,$LW#]J'X8CII'7TDEJD52>>9#_"P/
MP2L*SQ:L1+4%FHA66R]GR^*,$7-61D[NI6Y3\A !DA '89LO7H_<M#J:1(L-
M<BQRL][KC:L0#[_UN*3'S:!FA[S&(4XR.#<;]:J,@Z(>YQK:L;#QSNE5GU"G
M4=9Q2XWJBB*9G55;YY$EC9>$/1LV*8XVDR1GO006?9%@WI;Y#),VZB$+'M*B
MM%(O&?&U,M\FR;'.\4(VI-F2J=IG16IGS_;!NT%_*0=S'A89"$7IL[UI4\;Y
M_'J\'FIV$AJ#)[^D]<(%:"?L/_T8WP<Q-DM^0+R]%:;]8Y6J0(%=_S9;71N3
MY3%+D7]*U0^2/G-)?$Q!$GY1:.;>9/![[DX:LW])\" +=FUH=B]2*<C?B_KZ
M,%)O%.)>@!2/X;MP59H\1?AN^/*%"'/HU0B2QSZH+X J4$%)H7&MK\[YDB>_
MK?0,T2XAI2D!H;*K=MO7Q:.0PC7[H%.;[C7G0UV)@Q!5TA2S__UU#ZO!0R_^
M!*^]4(J]>-E^Q5Y/@L>J<;C8+SKS#_&=6PWW4GT+IC],*";X'&L:*RGH*\@.
MT/%;Z%F-=Y:/FK$DRI]"E"+,I/SJRLY5+B#?6"+'E"3F/J8!B917)VW<)NO/
M;S]0HSHBLI@ITC'B(3&%@W/"0JX/FLUD-'T$+PNV=^T5C'0L?.A22FD7Y:EZ
M\3F+ 2A[C9CK1/,'@UV_:2G//&N6(^-#J=</_R5$(<V$-;,"T7GV-W-?(7?A
MG#UN%1GSEGR^NQ_E%]FHIU6W;6KWTK;0@(0@(Q;EK%U$F\Q2(^/#[ESXH04/
MRV(?K$:S4S43;X,<N:&G_4\D67QWH_PU2$U@^D&O O5WZ9F_=?SG%X;T>L"H
M45HL3UYI/4)30E.1' AYFV#', N+D==D^V W>?CAV@A2GB3/V*/D9O></ZC.
MMO/^*GQ0=<*/[22!=-FWNW+H3'-=>ENSV CKV2CW:"%^@C[:'/_@85C(C4$9
MV844IF--,???E=_SBNTG VLLR3ZMC3@NF5T)(L3^G&HP[1RO+;<SU']Y#@:V
M$-"2]IM-,-<4B"#7T8XG![1\Q'$)G^U24^6+C)W!1V*?O[LWRB,]9H1]-=8Y
M\*S*)_&T[G@MF=Z<' , PCZ(69O&)#T7SSIE%X35 21G48>14A4N,RJ+JTI=
M2'K!$L%ZK+TV N);L*0:UWW>U2^;79;SU!S%NBED^SF ?43IG.OL@,>D]"K4
M ;F4ZYV:$/8^@UUW%"<BQ7A,YNNU!&1=L<S:;.4S]F^$8XW>KT]$,<2/?T<S
M.TF?(S9&BR\8)=LEW?;&E3CU1F##G[7U3NF-M 5:)]1:*>YQ$D^F>G]G]M[6
MZ<Z%5(GWD).*2WHC,6'Y%6;\UKYF;0TX40_U_-:?0DH[BFNP_S[SM8AB0,UG
M  $T$OVT"1I9&9;>O,^VF\Q&:_&F_^,> _6/()F[^R"2:W!"H>L^2& ?U''Y
M\3ZHZW_-@@4S26! 6<= HI"SEQ'@DLNF;+[4YL3EN'N?<FLMO'IV]D$73H$T
MC =O&$?9>ZR]D\AYPKATZW!6 4S\*76I^]7\-Y1ND+/D]B[]..+K#FK>!P$,
MBY<YC>#YX(FG_SO<;7CA#!D6#YSO7&6@^PH41K=/6&C$#QXZ<VS3SMJ#S03
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MEP#E1,0;Q9;FQ%WZI'A]I#IRV!3L^((R=J/5GL-;_#0E_W&Y7P7D;*MGJ:H
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MJ.=V)/R8.6Y8=/VYVMLSA,5Z?0T<A3?2@6(J+B/G'))TW\QZ:\$\U'*@Q,H
M=\,@7W(XQ)3(FQ.U5[CW!#H;3;_Y^/OPL!1P-5L;.C(-_'5I%YKWN'$'%KVU
MQ[N2M@^*DJEF%+[L:#N\F?[)L75')7YVBL\#)V 3S[UB?S;6?!W6H)*FDNW$
M65NQ1Z]$9@#5^.V'P!16IX36.T,V\F(!-OX8\HQ+);' ",VL9-7V58UQTV_)
M5YW%L+/0Z,>7\U_Z@1*N.P1NIX=P2)[,47&]I+@N1)4E-O:#D^XUZJC=N?AF
M'V3:ZWZ[\OZ&TKN%NIZZ8F%%<+)37:,L! YQTK5$C&9:FSEHF.4:Y#EQ=24
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M( @=8+*A['624.T3I,[L^G-\U3[H:Q<)]J1!/M)_]3@+LS;P8@X5/7T9T*>
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M>V/ ?T^JQW1<UF/-HT2YC,.=?D9=-FE+&3.RL]?&6K>F>8;>36 D#1KD\HV
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M=-MAZ'AHB^D]5\O3;^84] &1C7T&)4T)>XW<ZZYD1#)&R6@>W).O1-5=J_%
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M&OBRUEK0_@1</K->1CO-*,@ANG]PAHZ$A7ZHXYUTVQ16D1F/\A#"ZYJ.OE_
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ME=+E!3+:5/"RI(Q+'O='6^R@T+&]L?J2*&4RA$<HPG_I48GO?\DBI!  ,A+
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M0M]^!/#6'^9>ZXPH!AE?M]J(?ORQ2T9C>B;W'PY-COFX5_7V$;M-./7&_O.
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M5)3!(,P]T]C]BWK(VZ7DK,$XK,^I 9*["1JQF@?M@!R-)M0=R[=!RT]L%?Q
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MNW_<<>^ ;<;>N%?FGO.9<ZVYU[/FXFQA)"H13N-6C7 ![7 @- G37)&_\'&
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MO)]](.],37&^I2;A*FH\C56FRQ@O7'Y$7) DQ'TMV\ZZ&YY20P'<A'D""2+
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M^4D<M)2L'<]' 52>\Z8 2H@WUW$#Q.1@$ 7PH*F4 C#&+?4D&VH$=;]D,=0
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MR;ADJXBT7"BJ2XT=-Q"-+$?<3@3*WAJI%?[EJQO%NE^%EW5.>Y_"BYWE+J(
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M+P_O6&B 2/;)QCJR%5XWR %RI=]W,<GMU_=.++6>U'S]M*3D..]35A/ \7B
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MW!5TAH4L^37CB@C_%WOO'=7T\OU[1SV*@(HTZ<1&;R(=@:@<1$"(]$Y$1+J
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M-SO%3XC(R@D_CG@IN\\KIEF?W:2T$/="O53;SJ9XG<?#>5;(,M/6C='BO/I
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M_Y\&G$&&H8R':E>D [RFR++PO9BUE3SKN:J[;1$T$"FC:0K0(!G:8U6G&A&
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M6=("_2 O''T/J<EOTY_(5B Z$GQ+0AID=>?90A70;?5<V[?GW$3]1'6@6D_
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MI,]*91(WQ".UK@S9G2+RKN^+5G/V]4B\UX6ZB$]BU\?*BV'F$"2(T06S_'1
MU1=J*NC!U-;MWI)O=@W<#XBUG4ZN>#$M*QG.&-2]F;H1V0,R@UDVN%->$>I@
MGA>UKAH&IMA2$QEN1S-4QUZK-[:%WTR,J2B^*X1:!Y;=%ECG0N?YA.EB]<YK
MG_LB-*Z6@V.@&0>(*A-<@5[U.D(<>H-9<PN]R'V;SCRQDKD-RZ07?R\?^O-U
MF77Z\F[S0=9/!%"6QN5#8(E-\\]*.S/Z-\"AO7)_JT+YX\6D/'YJ#C-!CYAM
MSH,KW=Z3#MBUS<\L2I:.^P;L*#J=W8DD'HT_*V.>W;]SNKDSM2U;19RR'7^J
M"4W\U\)XVCN5,@'N.WI$9G]MU9]U5 %_U[+<=M+MTU<F,R$A3DGS_;;*/$"-
MX#%O8@JI]?G(C1S</ON'>(1. %FT=A&L\9![,!#ABT%M[UH2)XR3%#"3<*%O
MQGP@T)L4UNSOF53<\]L6LNOC@-77JE+Q,[X:N5$>G/?XYV=. 18@>0B"N>^F
M+((5M#S2< B^H/,:LB=KAIA<^_T^0=G?)M9&]H9U:Z BU,:J2%A'&FH(TR%4
M-)O&IVA68.L&LUA-Y/HV!H,$-QYA)JZ-:(G=^&T&YN.@PO:D4]2M<8#PI*@O
MO)S?_>JB6V_+^0@W/K-D1;8$7J=3R2[6H^;S9I\2,!I,KBI@NP*M,;*$\<R5
M\9J8UY3.;=*D\Y<*CX_8%ORAE-J+M\Q2G!:_2F^^3,[X"AF:BY66_A(X3,&4
M, FI2_^B;+<[^/+N'?Q >?H'A_%SXC!B)F!'M#KXEUI9R+Z;"+WO=, ?]YB4
MS5_1AY_50%FGS5.V7? B8-N=CJ"_'C<WTBNA1/[48^:Q"G[_'3X\P:S'R_ +
MO=]J!FF[V1C+C,;?1!!O,IFB]=J#.VM-;BS#>:[\8([^_+@=R;2!;4_E^I26
ML4(+B93^R8P5G6UC^,OIF[[PU\^VUXR_5KY>09,DOC<BHC"B&/>[P"@,]ZV[
M";Y-WYTXB3I%8EG/2XH^?RO;2#M8.A2 G'L<Z'%3]<A#0?&'N(<G?7K3..M@
M1A D8UX9M)S8J.]]3P?D<+3. #=FO2 (4EEBZVRVD'^K<]I5(K]P*'MD@+<)
MMT!XF3E'#/:JE+.G28HG[X*ABI0EZB12H,G0H*0@- *GRK+G*2GC;=!MUW"L
M"X%_5?(]8:3^R.D$+1,^WJB2>!1;I2*/=.NMXKZB?3/J)J?C'U?HST7_XAY,
M<C%G06K_TQIUE[=9.D;_O=P6IWO:[K.22SF_ [[]6(<K 6,[-K*WZ[/:_>BW
MY-U07D\1UUQ:S<KFO60"LQQLY8]4HNC5^,65J2WJI5G0+)D1 VC[MUUD.X7X
M>Z1"LH'!/57:V^;SG^W[$ZN1%'NOX!0MN:U&N/:9^2A_E@[^F_3<P$Y0^6NE
MV!W%P^WRSD7G[Z^ONHN;&75M_*FZ:7=!!/*1=GT[>^!]QK"=_RD-_3N3"#0Q
MWKIUELEH:;']H5,S$,H#/<XQ C]'&C[R5!.F^X::=YT4&% "=Y^JJFS@!>]:
MLOLZ"G=5P7H4J0^4R7TB>]]^?\LEJ?TTSYV#7R]O<T6,I[?D9Y8/A#J(^I.O
M.@#;:+S6T?">)<CNX6:_"TI\\5&\]4[B#6(XZ%0T >KF5+I8QW]).]@P4C!-
M"[G\V=3,,T5RC*??4_$BE:59^!#['O.P5';6J"992-2$5&*+K+;@+:L30C%-
M@XRTU]8\/N3Y\?I'*9[];PP?&70;1S-KC.<V3%!(.T/V2U+^OFKJS%D)I.&V
MLCPS[6.*&D(0A?^.R&V77M:]/1AV>S#F;T7!7:76[((8LU^AL]W\<^6W+S3(
M$T9O2JF5[_I1@+:,QR+0EY*V3CWZ V1![?TYNLFHWA!JJ".FC*E+V?EOB<>V
MWYG\H':4DK<4,)1PP*'D2M-S3WYP0>!OZZA?R!#@>*'H_&:(U, O.=5SOQC$
M?3XU)?^A6/?CD"IX&MJWZT_21[+&NH3RAF^-9L<$:][^J9%I],C)MV9S@^&.
M3#&T [_$^LSN)^YE.LR7[[>VHTH.*M<>&U3F<22-=<[^HV?JD6]MK_IA2A];
M>(H:5*T=WW6^?I@RK&'UVVZ=<.J+!B&2$8YO18#(C9N_[RW1KR6#^T+Z'?YR
M^88"6D7J&6V(H!"ITK'RO>8;^([:T\+%.X\5,F0V/8ZWB([,Z$%V$Z8H\78L
MU,A*-%7^04,MP[\B&=D6#@:A U[M87C<G0=>^/(GG19:>KCEW_Q59NXW^UGS
MS\C@>&U+5;RMN+6F[=0=C VER!K#V-[6&2G3$LE7_:A8]'X5P0KPFO<^R'U$
M.,PR'<P2F>H:003>.TW1T;&0JG<]<.A,),RPV<7O5KF\SE"V$&]TQPO><IX3
M*B9E#J*"^0Q#!3-$'R;]%^KW%W!NYTLK3RDOA4>+C-5]^)9XWX3[#I?#"-8+
MF]^1N8\?AQJ5,TO:,V(V8X$K.OEW@;D?!>?_<[T$II0EINS!-@>UCSD>K'\J
M*H*WI10O'_V7G0T=D/:%X;FDHSN5K?^M%'D2";Y5;,C5$!T#SAWNJ=FDG=^[
M#?''RMA@2\B8GJWR/QB^?H7A4UMWE-=_N%"N>343<9S;PPPY3"Y6+<3F;_ZX
M7KNC>;B\3;0R5M3M_2N2*9(X^',KN/4G(+U "ZV2WO9LR5U_*3_^<VY*G'P3
M?)S)3C/B%U/6^W/\CT"9_SCXV%_DA!WS1-9#0.A!RKU?NZ)M-MGBE=K"^!:3
M;BMB1.+@GYP=P)T)ZQ9?_K'^,U4H?P)YK)4U3(E'5RFU3QC094;T/OD_6B)B
M=[WV9.8K?XD0/(<97?+;&F.2[XPI]*SF5[AAB.[C8/TO"XRLPNGLKVL+!;FI
MKQN6&0W<H\7V;.=2B/8O)=**[; 0O\/-'OOO"J R OG-7W<[3-[[EJR,#]+B
MOGS>KA._^6?&.G[WZ8X8Y7DVJ?._2K<#**\82<GZ'O*5?RM:_I?7&B@2P1<J
M"^,;OD$Q)]S!PYM!X31Q3)_;!X5Z/4)_:\-)@OCKNSF.3C:>:G9RDVB<#]AP
M0/Y61I:N8=\75/_UVKL::.5Q]J)C'LLKDR _.B"21*W#?&;L)KU E(M3\2#*
MR/#[9.N4N'<O+S55-+M\]2X1BO:/%X$Y0<*;A_R2L'Q650)=K:#K6D..7-JR
M\H&95SRD^67'E1H_F"6G",N#>*/RD0JQAEG2+QXDE[Y"R$U9A;C1 0>)Y$!X
M[P)M"$YZB.&';Y;GT81F-A@S-*^?6<>3>"+T%!WPS04B;NHPM8AFIP-ZU?Z
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M&%9!M\B/P**B5%/A':"!,Z(G0QKX]U;\L#Y"%+<O+]*B'WU=@A)XV/[!.J>
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MGS/[1?V"C7+<IWK2DA\-%46;&H!=/*>?KN;)<C&P$L_WL:7+$!YP5QL?R08
M"/&PO(T@02/)IN?R3(' G4,"SP'L9@$^^!.U^2H-)W52M6"%I<B8I6Z)_5 =
MDA!$T90<K(DQ7T8>MC[,,D*C6<++P 3]0]:_D*R8!#>R<IN+V KE$HPQ9[VD
MV.DARFOV S9*8$30&%+GH-]EV?#^:_5"<*I2.>X^6)80#C[N780[F)HBV\Q!
MQ'H]D'1I$X3=O'R&Y@F"99H60/KP%Y78_:J;""<;V4\3KR U>@/\5A9!2E=]
M+;L/M_-@3X84@C0P^#$N[?M_>[GGY%U%&:Y%6_XW+5?L%R5ZPBNR6),@HQH#
M5NQP":\A\1O9.439= 8/Q*CP-BY-Z4#>E :H[V_D03U*H$7 F ,]^,&!N%"]
M[D+@I1EG(/[@,-/]!P)ZKL:X;CV0,AL$!W0-\BGN2(\<=PL8^G?@FR&/T8@[
MLP$P6H=]\])(ZZ1I"6MD]P_1&NN%B6+X^:"(#IBSR)ED_+G54P* /:#I+@5-
M+Q2",X0MVW;HH*<23<X!>DHT8:Y:*5U&YX%DPL93\A? OD@$4%[A#+!/R[&1
M3:?S #F&-RMTY-QK DY?%ZV#Q:9AA\+WET0B[>E<HM1R+U#:AX+FCS21#Y$U
M"XVN$0+IF0(!2' 2TR%.-K2?*EY!; 1;PY=@.LIH]=HXYB/FH=X@HIR%WQF.
M KG]1E S_H$^##@ CLHX72^K-Q[R?LN+0!>ULOM0.P_RI$DA J:+=#J#ER+9
M'01ETWE+5B(<,MFQ38Y;> =*(E<K&C&! N^*Z7V.- :[$"6B-)?"3^]=R:N)
M%&YQ+DQ&6)=H'+3N ]*T2;P+U2$*0:&=DB6["?&E9 ?@?^G 72$6 8VN%(*3
M,[L%Z[&M#":#^LXC'&JGE4+\.LQ/#T#U"XV&89$(]]KWE4B7T;"'#6T\)'_!
MG %1ZI!2X1Q(-IW&6PR4RN8F*)2Z$N.3Y1B?K ,;O*W,EEJ*Y+@A.Q&!UZ?6
MP#ZT1C'+_FY>OBP#]HR,7'^8M?D.J'9.?A18DLP;]9M#N3VI K<BO4N3[H<>
M6%(LR7DX=AV#* *,.'JL[ 8Z2^HL($:ANM(PV75T>@BT&66B__!]DP09)8]\
MDJFR)$[%+-M:B\L+U M='FV!&K53SW[*T&O83GT1/]AR.:@P9@79](:;#9S^
M,=[8^+;IHY-Q-S(G.I_?]?!AA-:^<L-;_G=L)]ML?#KI]A)\#EI+&'.0=)0V
M31K SV(VQJ=EM*.@"#SAT74H^K[/A-0 62Z(1'A11#-O;G%C=?V JUL^WZK%
MO02E:K@/E#YAM75^F#8A+\.06??/_;JD6HY4F#/VRH&WYL_*#5(O\C\8KZNC
M:QNJS?]K<=#]TYPVETF,L8Z%Q2=2[&[.(7;<?>O,=<HC+"^RY^[G\-\M-.3<
MMMSEMKE8O_6WEX*I-I.=2M->91IT3QT__:]?="SC#9+&GF<Z,8ACYCOIN<1/
MV AJ\E,ULGN AKM +*%*+>4X#60P/>4;=$BD"G04>%PO. Y\N1(P#E%JLAU2
M7-DO!\G?D$/0I+5AP-1J=,DN$,8;T!J"* S5AWN=;4:"![G2VH0YS5RH *NA
MBI_,!O]O+68+^1!8T\ *X+,IGV#.X2'IO!3#53ML&?W>IU*N<Z3G"[KUG^Z3
M(@URW)VN,P$,K:Z\C#,$FK#5DXYN]1XDK,>S;(1%A-Z_20^>B:7!2J&,I,L2
M>$ (FST2 /[/HE99VXBSF30066DB+RRII(G;B@E]S@(CE!!(5#(+,N*AP E(
M.4:RZ0D\HZ^<P/I')XB4!3;CQ08B\ 7\0_I02D5"==8+@6^DW)=A_0&'# '<
MU(BEA4:7"Q.^<M/K6$XU#<NI,$IU4>;G_[];\ZAD'_JFA,[;]8U]:I6=H&)Q
MYC MD]!1.0&N@B[ G QEG?]0$"[3)(/OA[\%I6MB?L+;, -HOQS'T@B2W48\
M#\!=CZ4.)6CJTFZ1#YZECD8SA?% -)X 1.7$Q,&;(PK,!16J"6F2D>1.:S*I
M7_-#P8<P4!6H79/LA*O>4*K9HK"">2!B.@+LA_/. %CLD*R'.4)1"A!X [G&
M^CLI6_W.YC&[!*1)A^0XW[W)[G!VJ-%'PGJ8N8_RAM;W-^%!+DKPBX"DM54C
MG81D@C7KPJ9:_DC5EHN Z%EG8+Y$0=6): .2H^<HV42I9K)0K=PB7;BGHWFP
MEL8'CI)#D$V'>89 4_5<X*\F)KW.(]$UAGV7@"'L6\:!/U3*[@+/[00<0I):
M(AKP8!J@$$C(!.9CR%)AOE@*RL#6FP5>U[\3$%2W6T1,-.+E'*#;3]A]"9MJ
M9"11EL),#_0-W!<DQSU@H 02IHOZ"B>G AUE<K&.PF[8A$<]7OVP8X9T&<P+
M!Q8@26P!9OJ5)B#\B_UJ7N843(=[?R^UW(R9.E;UO[7;! 5M_([M]J@<UZ*+
M72"NC(+:;W/!D:T8QX&3J]$D.P#'U:/5B"B,,HR:$60FUPWU3X0SM@";K!X?
M P[>1$#M/Q1P+$V:1R.3/XMY@9#CQSL-MV)";@F&^$^4ZSI06:;"9X1>3(MI
M8FG0T+H-"BH&,O]Q80X;D'%+[B>+A'<?=HM8421IW15;D$X&$BL[;:H!2I <
MO&QZ, _4W^$UW'"E9?:B;Z"^(/8#.DH@1A PPQQTR3@5XN/#'-1#M>]"TJNT
M_IHH&&S;3PH!:E<D3D31?C9+%8U^+(P%MO\HL,*\#>)DP?L)8O/N1E KX.E%
M>-3+N_61\H9(.).\+/>?)<K8LPJ^<P5$!FL/=5!Q+1TJ:=>"6E/X?"7D!0X'
M.Q]7PST%]>NGV? 2)-OQ@X^Z&S?**.;DC0KC^%R_3U[.9"BK>\WM\. 5J-YN
ML0(Y"%\&D(,ENS> \K.@_7BQ.;N1."P0]L3_"]E=J+T3]H2DEC0-:#"-<7E>
M*IKIWR;[52$?/&B#5<D'FPEB0S-0^^ ;AFF-B.H8"Y\"I&3*P.)\L5(:JFA_
M)4L%C<X5QGS1Q>!]P#QW /-<^T7A?'@Y;EX/R1^S= ;W_1S2P-8*""N2W]M4
MP_P&6HZJ;+H?3^\;NU#>$/J"D >TSW:)M?]>RJC48NGNOBV;"TOA-P-+$2*6
M?0;TT:3+/'@ LC;N$G!N3I_HVI#3_' :D]X]&C_BD0O7;UL"E)FK4"9VO?<_
M6U+1V)#:[PVXX@^,(X$KEEE@EP@84^$J]T*VB%(!#]X6_TEI@'/&-%'JONRQ
M-D.R&WTSG<@#IZ'YB;;1-,SDN'(ZK85DBE.U=1M)H_"=_#T 2GX8E$"1U)KU
MT4BT'P'E,!J=);P #-(F@(!!(B#.?3D.%#UB\\I&$$[PM$+P%2_#UD;@6RYY
M@>B)J4JTIV!UXB-!@DPS'Q38X5WUX.#*&\B(1V.W ,IE#(Q/($\CJ26LCM73
MC,N>BE;$53]B*JC92&P8HL 4=L6+MA;(MP<%I^@+HCU(0 D0"#;26L<2WGD)
M*1G)]N#-5I4E0&<&Y;C:ZP7^SBIOY3BC5//_M6IM4!T]X1, U S9#9@_2 ;P
M;[T.<$IKE*#1#"&HH9@M2K4,/AH1IS]JE3#2T:U2DF0]6L7^C;SB5HA5"?)
MM9BM(R*Z2O2$C%,6)(%["64._Q-=.*[3QZY$8F7].JCSW;*!+K>XN.1KGL++
MGI2*,$^?X GEIV>>M["->$2&SFU,L\N>%C,OQ26*XQ+G%NH[-LG66;_43E._
M]JSF/+M)47O&%*6ML=^PM'JOL^AQA&"I]PZ!!;'0+,IR9IRM681F[^VR3.U:
MKV<U&6NR#2Y><DRSO3%GGA/=K$S]Q)7=B3ZC->RW7:&SNN6X(^1:Y?^Q'J![
M%4TI,^S]7*^C!=T;QQY0M,K4YRAF"O2]O>!"90.3B8\<4;8>OYZE;%Z,2XYM
ML6NC^I'X:-"\*4T;5;#VLI[?]*'%FJ<K!H/[/-FDZ#M-'[V@[]N!Y6E?6I,>
MVS,[G[T=?'V)SY/GBI['./7J5$77ZW6E1MO.^*IH*H8N.!Q13)F_?O,E:7+D
M=3D.ZD"Q?;BY5.'L5TUM<DH??F]E^1SD7>UW(ZH-AWJE[_[PK_JM)M\BZAV5
M?E1.-V"?N[S>9>E/(9HSAP?<_Q0?R?)]/ !_R"\0?FX_'O&G8G#UQ[>O?G(Z
MJGA&RVP>85MKDD(7A/@^>VO*57C_\-3K_[$_81X2X%*E_90BFO!O."L!O4/X
MI;XTKI_6!1Q#KTXR&6YH0%^2Q'EDG6UX3;AT<2$LG/$2ZB>=7EDP58Z[0 44
MV!4<!W=0I@TNB9C'"!'\GY[C@*^F'9?C>J+@Q@&TG/#,3[9B7]U@)LF3;"ZJ
M:2+@*86D!S;/ICMNS _GX@L)I]GCR38<G^5+RTMO,PXR)GA--M4NS/(ZO^:U
MBX-;T=X/5L'S';9,G3FY7'])*#RY_KG_7M6IQU_D_YD6^;R>Z?C"[-.=%2KF
MM70[LWP=CJ7Z\]LNNH[K7*X*S+9L&.TR8:.PUM 1,5D^1WAE:]3SG?QI8\8O
MFQL],T1W7.KQXM5Q:VOCM;1TYW#W6S%=H]P/9AA,B5KIY[$TM2O#(<W7[?S^
MZQ&&GRHCOW3RO?K3H8VCAIZ@;E*,"!"/_ZKC^-/4ZQ'CGW^OD=B?#CG&K4A>
M^01F#M9>W7747C\UA\'_9K2\YF6?3[M9AT]JV*_]23FIWDPQQ7TM;OJ\49JK
M!J#RCW9*7\EC9M24(X,4K!F]^X7H2#JQ$YUV:9V1Z9MYBB;U2C>^\=V8^8TJ
MSLIQY%^+AJO\*=7I4ZBP3XXCM*P:CSU,D+8*:VL[U'H7&W*@OPZ9PY)*@&!_
MS+#64+9<O[S^;Q5EX_OTJX=I+7U8/^'L*S??1UJ+I-A4%4Q71Y?%WS;L\T/'
M^LAQ<V(X>DA7$3\0E 7>V8.EI-THBS;58HS@,=>(63F);%EK9#+=:)5H*I_U
MS/Q&PB.?UH0%R.G\E;^DR3+WWGU?HE,Q/>.]U93')]9YK_!;UE.N'0ZI7]DC
M*LL__/1-1XA;O_^F^8RHC\V+-Z8NW\'/7GRP9_2)DX?2S!R3Y[RZ<ZO8QSSZ
MK+5.3QG;,Z:9'YNG'KW()&"I_J[%EVBJ3L]W>+A,+-R9QC%HJ]0TU[CLF#'>
MG/'':W\'ISHW7Y_ -7*<CKVU\@H\Z5#C>J"H61P'OQU'OV[LG62M:$^<6:'A
M%/0W$EPC[L9ZO,\N"]-BU[>PQ)A9?AV+-?>.Q<7V#U'W03[V.DH0#K?K\W02
MQ;,<=(-@*$%4&SL5.QI=C>4?\ZZ^^+[[K_XJO:-V"@P&_8[S-YBS]($;\H]R
MUH'V+56]&&E:G_WF3KUW<APIX+)/!X!#YJR?LP\5O(.:3L_# LC70RW*//=E
MPZ^;EBHZ-UMB<S+>*9O9?WW25,5,"X=TQ9/.Q[9<Z.?)]B\:!JC^OJNEI4_0
M)A!#?AOJVSSTH]3<JLOK X8UAK6I5K9SSL3<Y!RCFB$"5;(TJ1644SL)9T%6
M$O$:,?'F^;W!-YL>*?B)\DI,*L2?.73V?0PGA+R >W:N=^?*)1+7>,,*NY=S
MLM3VT*T"_JXJG;UFIL!*+_YEYN^;!LREJA%YXWT].;G3]C3\K3XQNJ0YQ&,9
MD[,HQ-:1<::0:\ Q6).DK>&9YI3A<B,Q2O_YDM@;U1$^-RAG.'-W'"W+MVNR
M*%]2Q.%/I8R+.$"V,]:)S!QOJ34N/#6*;I MT.PH6_K1@:[18AX3N^/7FQ^J
M-] TAXOI*[^8:;BR:4DGE=1NY>D[MQH;7%+FZ.>CQ?70S\V)% #?N'KD>H2_
MLAOY*Q4O:V4S[Q!L\M#'?5^&J3C?"HJ/%+-S6[\;JO+Q(6NM#%0"A%8YKNE2
M65B!'"?Z"8N0(PX[&#%?4*!68TSI H71EASPJ\E5= K_THC?\5A,UTJ8^3IU
MK"JQ\@DV_0C-_3P5R65#;MYHC*FP02HK$F.QH*M((W9<4SXI;:UY8T>=C-VJ
M9#0W;/(%EA  1&C&Q%"2D,RGRED.O\]9N3&9J#)8$Z=HRV!YY#><F<8#95@D
M4+S8/5'(>+B!NP7N2!>HD55)[EZ09KXZU&5UC:P9Z9B$SMB,5L60_WQ8#6<Q
M7C="8Y$C_4FC_:!LM[>>C.6U=WC-$HU@HX.S8BH6G[ Q[-FN&(\@BO[U&9?O
MS\V.9+HR+5QU!+K&XS.JD_1(8TXSUKTJK&Z+"DL=6[:@.D/G^?4-Q1L(5T-.
M4I\V>_D'@J/>I)[@2TXN,J.'9]KEU@GR]B_8Q%T4]^1*:I= 8W:MMWU2NJ./
M?M%BQ90:+^>-E@4(QQ;XAS>O\N4>D "U=2AGQ7P=_Y7YR[OL[>^R=WZ3Q&RV
M#9N<'(9-LUD2*UZ O?"5@ USLMW0M<K>>A[6,3W#6G.Z.V!7&;SVYS1-C-X]
MGPW-7DG5[R/!I 2_SNU8\_D?AO701^N]P4:49"X?FH+QTK$=P*BG6^;[NQ*&
MUX\O&H+/Z.4*$]6"X';UE_2C]3'2 EHS\0LY_!I;70423H4[5^0,8/W0OXL]
M#GXYC)Y^WN!=[>&!&9,[^N&$ZRBM?!40[^)H; Q0*M8V/^W ^@JA'&=9^'!.
MJP2F[0" TWV/<*0=&Q<_!<$-D,RG4XKQ!\HQ/LHXIL90D^/^*;H*O_&VE>.J
MVPT[J:)Y?M)DK2(Y3G(.ZG<-F5NPJFKAC*S7#R(?A_?P>$'KQYWYT-A]?\I"
M;KQK@W963JV+SZW;O"B#"ZN@U90WI$D6<P3!PBC1&0'^:6YO!T53@)?.A!J"
MZR>;)NZOD>-VB[28VM.%$D/1]L?AY;4'R_]QK3AC47AV#_7@@5FF13OY(0]%
M9YEO1#LRRE6LCN4Q5=VUM!U#O#;E;SO\M.YNGE=<;-@50^Z\IGMQ^ZIC8SL<
MF:Y79C;;^E#.'BEIVL'1TVP)+-YQ[=+._#5-XRDZHPQJ7R\I4%5A6L[A"/+*
M-@4;>3NJG2C<:S;6+*+J.'W-'6,UNP-1&8X.@]<C#%8E(PERW+8"CO6"/3U;
M2?WB3]27.ACYBH--YBD>9HNPV_#Q?E=4*D CR/D-UGT[0$>!BU<JJ[[."^RP
M,1@8GT_")I9@@TI6*ACC^J3/HSV2%;>2KJX"[/=ED(>'/J@;V2B)O^KSP(U8
M?<BN-7EX)LJ<L(F3:-8,FE^O]-1)E<ZW-;>N9RO&"\EQ&5--PS8-C3L <8.>
MKHB*<9.2'K@- J&.?2$QS9C@NB-# 4==?PZ@1*.-7]<RW\QM>:6B^6T2]']N
MX@$V50(KW)Z"!&#X9#_Y+'B#C6NP]6E_0*)B47_,6.5(F:L_I_UT""7)#ODK
MC/CUR*/C^L3K$K'T,>R.%7\@DP RX?3+;DCP;7WT$RH,O3YZ[7+3&Q241NW_
M ,*$HH:+\-+W?OP)D/ 1XZ?I2C:HJ5N1'/8$*AET[%P.5@0>-<0)O^',':H4
MY>H/L[N>T@W42YM@\W. M?O<.R1_]P,V&KBI''2@YJ024XI-E[B6,S!4B9[
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M]#84W+WX,I&2=LOM2$_^MJVU)XHW&1KU>\AQ$T L/.8#,KE4,LBSGU(UL;;
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M092A,,JL:@_(86PQ;$G<BFR'KQGK2Q6/8^<?8DMX^@"][%]R?0-)4MZLXQ5
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M>_BXTM(I N>/.6[%U'#^O\Y@4D=.!M7U%UT<"%!M@5@>3!)Z]D0B+Y;H\O(
M<<TL!9&&DUI1NE]:N3-C.+.^Z#%MO$. A%0 ($LHEV5NC$>;/P#'R/DY-9I!
M:9*5X*V#Z+)!#:19$W#]9JR(1]+565X,Y!*?ABBWW(0^V5?W\7%SF_,I=\MU
MTC/.ID,#::))/&-LL4;E,LP=+6!2OZ5)T7. S(XB/RQ)S59H;7_1/AE$J05
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MY=7XN.$D["'9@(#$Q_F&TIOF<T4$]!JE'NC5@C AR97_@6<[SSJ "V7888^
M6)'YA D)KKQ84Z6G: YO=?E9L(W6(@J#"VNV0Q,9(.!72H&@<0PDO!%!S";.
MYLL+J.@GVF(7I*)A-W>:4D"<"/>EW"[#>R]&P[1^](DRA.S2F@ YT6%K TP=
M=XF+F2#:1_S!L."(LT71W^JAQ6^:LX',VDG><SH-)N[!S-05,U/K$>I86]![
MRDO!%:AJ1MAGZ)-O+1YI;@V;$.#^'D=D?A@)-$;J]+ V.[+&R#$%08#96-UY
M(^!_37MH3 >X" U%@%<%SX UXS]B]7MHSYJYN*"Z;W_P<6LL,(&&[T*+67EU
M$\NX>*K%[=.2@R_(@ H3UW]&_TQ3:%5DJBQ^!A(.:<[>8'9F-L!7IMX%-/%Q
MZ93.^\/3M]:M+:>T4$@=:]#W^,)%&63#YS(@@V^M7/_<[C:0@*WD\6)_6XFL
M_TQC71_$D[B;QJ4"MVA;S5^W6*\+M=X%Y#SC BV+*OEN!BN+6+E(2>*9\''/
M031*;29U6""Z"_-Z $NV/((&9FJ)2'-["+"5P*"ZP[>"!$9(\'YV4@[O;D)2
MR^8[\A[?$*/>&T&#JB46G!3H[!^!LMKO7M%>:WN3.%#R(M1&Q8Q_>]NRC%70
M:4RR!5Z,X/# M9!6-+A/';/'^_G&8'B.%[T(Z++L(RQG68C>#RB$\Q/TWIFM
M+VB%<,PXFN8,:$C[(Q)[IQX &(,,:4SL'" V%@.A;?^J=33'\X+H[VA.@!YI
M: $+KYRZVS3#WFY"8UE8='7=LGC_%22@ A7J<\#G[A=!1V(VW/R.?09Z>T\3
M>F-C1?27\RU0KYXFE7?8)8,TIXQ%_;_F)'@^L; "9<(=8_12#^?P,[)L"KA!
M,0'1K9L'%"Y3ZB% 76XM!6GI@-B[ X"Y'L*.M%4% %C+""89]>WV)$QF2'6B
MF>H6!$[B4EKXS2$2+8M'!1E<J3A?%N$@</O]@Q:HF_M5((Y_4"U@5!(/,R@S
M<FPJC7>LC=*B?F<#;9ZX 6+H@Y2_R8K&/%U:CX:=V<W'A4B!^^@$ MB>EC6$
M2 "35T[PHOX:'C#_ _A]GR:FYY1T/F[M."^*-G)G! _KL\$5&NU$]NXO@!H>
M\MK^C[# %S>TUY)F=1BQB&(#M-B*\8D_352XR_$L\]BN L!(-\H?&",.$0>]
M4;>G?E@406N 8:P LQXG][>BM3>29O\<@'L6M3:,]X3:?0=^3"*-CIJ.--=Z
MDK@>H416EB;F:Q:8K^W/I4YHH;)U7/'8Q8<] JBXG!:QJ7I.&:H$'//\[3U!
MRV$(T#V@WNAWM#%7D(U$Q V,]W(W1WC3N!5_3SXV#[%5$9!'&[P 4%1UMQ<X
MBAS(ZV#6;Q8. N-6. $3M+H3%:1SQ?X4A(4>0@R#0<"GI)4@QA=\(9&W[BQ@
M4VOP,M",I14:5RZ=3BLDIUIPPC[2%B>QER$0\Y1VCU=_;YI:/V]P;PGZ5'3P
M921:2V. &Q5J\=99 %;,.#@(H>Y*(/-?V<>+.#H\@ _C0)\K!V.].2E*Q,<E
MJ[?[Q[&)J-AWP-GW K.*#I2$NU_12K3M29SP!MKB9TCFJMV\$85E1NNZ.TS$
ME1-[41>\#*#Q;<W6.8B8Z_R6WX<'1,-BB;.[X.%>]$D*!4Z. <G\(X(XL(@3
MP"*\@98AMDHY"',&C2"WK4KKY^/2AMG/#"%G&FN2TA6&AHN&T5@/V5A_)@G
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M+%&2N/3V/9$'?)">S<<-9*S(F6A@_+$$/]X_$?H85*E''.G&0GS(/X,1%2R
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M9V6,5I]TUS[CM>:U7*C]H73IZ1A"2OH9^V@3<5Z"TS[E5\!%H8%!$0'#=N(
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M;*QL-!4R,,COJ&:?1G:,"P/ W\1!W>GL%?#0;*<#1K9BG$@7RZK8T*=6E!@
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M_SFOV9LOCZ_E/M 68K=AO)&KK%?ET<"6X*)B30/(^FZ>'?K8ZM@'+9'M&NK
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MC:-#'^=Q^7?=S;U7KMT@9F(TN25"H6?O#D>P8Q>E@5XT/YSN;#%Q(#\@JBJ
M8A",EZ/.[D<A_3Q=@7%44.=['R@YX/7492[%#ER2$9>[ V?SVPQ)+S=6*C0I
MF:_>7URH0%95-2,P2-C:VNJWRL*S_;]?"#_] ;G-AD>2N8.IC"^JH,[HEMX8
M3; #5,UA+%!2Q&2<+%0*$R(N5T"($,NV-TUO1V$:(>7W02P* D"3EB$?X9>&
MS:BA!N8-J9^VKLUOWC4WI(I"B-OT.YJ["J_UB0=[2O.2]2F)[1>FB0M8MVZK
M!<(NTMEK?HX?*@8Z";LQ[N/3FP #NY= %]""W.^:1X*8B>S=C>SNC?[NC>(X
ME4"U (['>A=)F->-XLE$?YZF:+)CI[IUAHM9$43A0X#ZR,7!-V\?<I_;$&+!
MB.]38!*^<7E2ALIDH*2+=E!!LF^NWO-R/0CG=B;:5^>LOOA"$@<N[_S'+;&4
M@LSE1P_M<Q>?YX2) -=G:M=[5^7]9+M5GUN5W:W)&<VU,LYDU./ 1I5/+#?\
MHV-/+U(ZKL'G*^%O&-:W2(QD #W'QR],TM,RXH2[IDP] 1R%Z<0D"EZ@#B+,
MB&D+&B%&QI502^SXVU>S\;E"YB.;Q]WWBX:[I-3CGW&.FG9PCU DE4/ .$/
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M58NE^)PQ9?^?4V:K]FK%;UMO$?ADL+ )YHQ%CC><Y:&F:\J3SJ(657UB(YY
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MCV1PMT2<;A?^OML2'1.TUKP>.&V;:&J*_]J(<.288'NM,;;8I8@/=[#FO*Y
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MI]#OT4D#2A-]56Y.J>T&XC>?4%E@AO1>8Z#[(8B+K(0+:1.GGD7%A G^K-<
M=\XJC51OMG_%H1B_/_;<LVQISP5.%K2&]&D.+6EY$VZJISBB)WN,;W:R;$E4
M92_6!XC-33D,2%<D=8[TFN]F7%4.4;^\6KZUK-OL/P+K4W/XN$%P1O_0^!B&
M:.?SRX1T\$.2L2PGFN769LS#L97+G&@HN!R[=1K7WI1WI\.LGWYG+=+G*T@/
MS#3B<\P-+87A;^#S<98/?X%J9DM89,7[' DO>QJ;]%31:M\=6-JLIF>F9FW[
MP9,9GEL@*K,+%G+6ACK6SDY@R38G#,$,\&EHB\=2A9DC&D6[^05K5-%HTQ&O
M93.9@5*K^ J>'U[GLN]7[? QYOYF?\LV[:#>")MSX*.D-< Y8>K$ZNP2LA@$
MM)JI.K7VV+RR)7V6@6#05K[2]'BP)\6=;Y4W,Z7*_<^5QJGFD=1-TWI5J5PI
M1(D#]]M85"B"RJ1/8H6[%-?/U4M'\(X*&::P2G<G5UPU>[!P4U! ]5L QTS%
MN9%QMZ\U=[( I+=>8;P+1JRU[0+=?E>.7^IQ&6!FN=%CCM:NXGW.^(G)!QC3
M[2C@<3Z.?3G2)LCLHDIIO]WVJ@E8$4=^UR-=T#0"3"1;]ZD+XA#L_F<D\_QL
MQ1^=8E:J"._%-B. $5V&$0$/2H0QSEE+UJYNT8'B=_V@C)9([8AEO6PT[LV7
MB3UZ#W7B(L'UI4@$ZK[T;_6[0ZN[#I?P;O$7&UW-6UM&@C3D+(9^B"0R A4:
M(L?3//D_OJIJ;<EH]B]>U9BC[[M&GXW@ZK /#B#\<D+R>QJ  V:"=ZA2V,EK
MPQF=66O<=T$^DYXGR:U\7L/W%7BD7G>O[);$?&E0NO\@<ZE?7_1;TA*N3PJ>
M@:&WH?7=<^LU) LH$K?\WK-T!W5<)%'=N=AJ136R83S#9<$G8JHDMNA=[5 #
ML^?+(-30XKL1R<"7)!6'B0T;Q1HW%S_)JDY; Q<_BBCYX#2>*FH/G+U5P^L1
MO6L ,S>L>+T?@PD1&'1'-PKK,J+Z4EF#C6I&U17*)S]@J9C+JNG!J;;KJ5L&
M;U)O>K\CPKO?!AERP"2(\0SHR5E+=4,0XW,<UYEJWC;NA+*8HAATY;U,=DYN
MWE3T:,&&L_5(<F/1U2WM0MA<D>43LFT$H5]0Z6;G'Z3N9-;F:=8TU\E-1I=4
M',L9OTSG!33QCPJ^#-=A[%0 YJ?-]BJV=.FY7>]J!IZ#8"X(22PR'BZ+JOJY
M](R^<0O2NE7!,:TWL<C)X[BL&'G@:2O%,EQ;@#9!;/6Q3E3]-S%>DL-H)9E'
M(2_-X]V$',3@!%3EZY/;Y%=$+8('F-[XX$WA47/<\T.+>+(@F%*@+HJ<OI_V
MM8B\[U(_U9:@.)[FH'.R/EA.Z\2Y6%=]J/&<GYGQ4\@[$"]JO@SRIND9^1P.
M=&:EA4CLHY05>ZAR8M!S)Z 0,P-IRS=C52*U;?6C"H,^!D.MXES)P2S#TZM
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MZ WW2OD/5 J">!E,1NB@(21NS<OP5<9JRTV&./A\.>B-=P$6<<Y]%R+0NC9
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MG?LZT8&8,QZ:DBC]=Z([GM/)_X>T]X!J:MT>?6/;*(C8Z,U&;R(= ]F*@("
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M<^2A"L@+KI3VW3V."2Q%4BI&50"H?=RO8:BC299/>M?AG?<7XZ4BD[JVY/(
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M4ELYI!PJ(W:7C6),^E*)C0[4%\(5VP18!@3I-V-/5S M9<@KG70M;W/ .._
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MJYY<&.86^512P7C/Z2F[%.UA'P'_U?N!A8W/&D)-N8OF,SAYL0KT=C<'23*
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M2 -=XY, T.^=H15QT:HR% G\?$5C)?")B.$'N%M-2%;C]>H*T7*\;NJ- 6*
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MFQ?^&=%<.KT>Y<F,&/, FFD@%*\@EIW>C*_T_53$CO%3_\+$8+>48K$"?]%
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M\*CLZG_J-!;F@3_J47N;X .1+4_@>CV$=K$A%:"K?=G\*"\6__EW4<WQEZ[
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M"[CSQPG\S%#*#!I+,QA!#TCR6VA;C]9@(XK'D:\2Y?$!G0B@%2RF(TN1,),
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M%9?1JYDR!RD>9=BE+MO/$B:)OJX&2BYZ3+T_5%0-%/)7WZAIBHO0.N9+IJ0
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M-Y-+"17SF#^QNW;6?*A%K@1\+F?L@:AMIX^[+!7P7(E1)S<JX\/H@_55\<D
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M=93.77H*HAV10IN7QY91/\T2 0<)<^F*J<JC+0H_XF]::'6OKA,]XWI:"]L
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MI*-UGT[!']%T(-G\)6L4!GPFT(YX)T)Y(M"5>./WD683Y>*@V%[1R$@_W]'
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MP.&P+^\W^VE,.Z#4Q>UXR/+R#LA#<=M1FQW+%(?[DDF";)W\*KJ))8C,L.V
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MZ=^5G<U?]\$N^7,'3#H+Q;VN*2\/+:_^%R4Q*U01.I#=\5ER^]Y!>JBSRCC
M?KG57X)<A9EB>WX(_4,Z8_F'47;C< ZMXW*E4Q9Z%)^*(3-XJC#0*<\Z^;Z:
MRU+Z?SGI5(\16RV2$+.C;OX,WH:FEF%RU/S9++$CRV9MLJ_^FD"(/9YX236/
MD+;.O?9]*$$P1QDY8/;:.N1B=;+^\ I>+T#V8Z)TJ&9JV5'FS]4&JE6R5?XA
MWQ)8ZO>C&+$_^#X:M8\G.@!&I3_?[[+1@7H5_$>&/ONECX-^^!>,[ GMUPXH
M$[R_Q$UO[(/2,)5)#Q?^4QRM?R,">5!P&?-Q^^C%LP?[],9!S:PTCE?^LJ]
MLTT.4%9&'M]V1^99UO^4LF?D13]ZQ6';/4S802+W'![>)T3E_H.1ZY'=5YX&
M^\6EXC_W1;#]BN"U/\>65OOR]1^69=?PORKVP9S_;U)0YB#ZI*41E-L^1*NH
ME+R7U5-J_L$W[2]A_Y%]I%_&?\X+TC]^H8HVS'3=[^P_2/K_T\5#A^R VCY#
MU\W1M\!;' SU'=#"%K$*[<,##!UX&C_2!,08+*E8Y*DQN@WU=0?T>+7V"4\1
ME8'E6<K/"/]D;GRU#EEVYH1SCWP_+1U;U.TF'PX$<T*DJSG]F[U[."+XM3'A
M2EHBI@1U.91V16%D(9NCEV6B9IJCDZ.XUXV?TGI^03FDW.<KH6^X/+I\:6;)
M_0B'\ST7WIMA$PFF1Q;,T^S]+=.$ D7>& U725DDRVOZ9;P1#[5SJL^G,N^
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M8WZ$Z[FZ/Y2J\$X_^J1T]?X?VUG"#WU)6OYE]N6IFRBE" K[8<]GO=L7@0?
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MIUD\<V'3,'UFW#[XU]67"<RT/=!C"S0)?W(/Y#,3T24IP))7667Q \[5<)V
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M AP==&RK2[BFJ+3MC.#P>W!=)[F_0J6/J^UGO-IKH_-/2"LI;^E!L='AL3R
M:A;2W5"]DUP#*&1%U;9\S? 9S^<)U0K;59T:31:"W"V,WTEB/G7^&EN?:O#A
M*QG*\UI/GS(&(?E.>"ES/^[VFH8^-U'$.B4%W8A!;8$]S&R]VM,S)5=KZ&EF
M0U^RE+[M:+*.9_A3$[;HOYC/*M$ZQ)<N*+4"RDTKW[^166O>Q.'5_J*5A;=!
M?O 2E>7-96OD'HC%'8)_O <*3>ZJ21-]M]B8YE"PT\]\@][?QTYX W12N<M
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M<LX4N8LHAI3SG 1/2U*#LM8/[[?%,O1N:G6GHLK/P8\8[]381KL'T;7OOYJ
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M&U4]KQ\/4MSE:E6.=@A5K+PN"U2J') \$>4P'2WGZ+"1$[J:]FJ2_%DI1Z'
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MP6']L.WH8P:"MIB[4AU*@?H%)1F(MYDA# 1I(Y&!6-';F*)IK3_$K]ZL.L%
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M5?)4B+50;Y4VT?6R%OTR9F'<5$+B^(]2EF,7:G]P#.ETS1\OZ?:>,]1RX;?
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MZ(<J'*>!-Y]--IAD\$GH!W"%5/E'>EH6U+XV!>\!)FGH GS!&;7"0#P ^QB
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MYT<NCQ&I>Z]F,0G%T+(V@YC@AR0L51>T3<\!P83QD2!"A@&@]6VK1@X0]3-
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M9#D@>NX;.-]%L,EK 23,"=CKS]U;ZF?!6YH[S V.,Y&JM:B,A'F1#:.;HEA
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MH+^#:.+GLJ(-^JL&3&*>;I$#>?X%>IJHC$(5\LE&DD'^M<+M07#B_IQ*+_W
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MH]IQ@GJ'!<! .:7KKBGWU;GS\GR7%Y?4^7_^NU=VX\>5O>T:;G01S._L&!"
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MIR99!F@UM]M!A7CU)K/=L#\QWEV(?4QN^%[G*V!2EE AI0+R4"M5@F5$NRV
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M"G>ERJMX-4<&=J4%W&>3VT](UNMF)^?!()9"G+#9#)FW5WW\WKSAXR R,TS
MRT8*^PYB&%$G1X>J8T3C3ENU.V]!%O\_,%C:]\LW0]PBJ%/T>9@L')C $.T*
MBTD!1R4S$N5E)Y@J9'G\)R'PLA;E538!,-2K"Z18K]3R1213QP0<\@LXQ)81
M]GX@H,\;,774W4H6$[H3$?7-GAL%Y*A,BE@M"!CV@$NNM614W[Y+B3I&84L:
M-"B6 PJAX@QR.+X;)1JK*5G)5\"O">A5P[CE4%LM[\CN_*SX(;G@5^SYWD-
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M_(^_)HTP1KW\_V!&BSRN$VL5NX>XUT2D'(C"=?]NR)E3,QUI](G@(54OB;.
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MW-'96<([,-!U*SZK-)B"<1;]/J3UY<V()I\%DLQXUW"$:_@:YN^DBW6.5Y"
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M9ZN(H A:B CZZA>%= 3-Y&F'+F+X<__'R?U/EA4Y6:/?B3<(XH:_OS5>TS[
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MMR;D><:$>ES(? #DZ;F5D&>K6)X(0,K-ZON$/$L)>?ZS U*'E!9^U@#!)@,
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MS(<Y$?YA>#"_1C('Z>>/LFK)U5FDZ/G,4CXV/DC5=39#5R*6:X,#2EP%XH)
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MME+^##:3$\<@(J]W)L2;NQ/4SS';X/M(0[E@F#B_#53_8@4B*$+AERG*?^R
MCEK@BMZ3@4GG +?>4$W<<8I8!/CG1C[2O\P30?4 +7X)!08*HDD^ C8E3M6X
M<H_H_7IY"'LU!?BE)Z'_>V;)(LZ2)4+R41PW;#X^'UA>R X@V0QBLODV0%#P
M>:1M=PW,\4* '4U%=@/?20=9-^ >\1W=1A57N.V;QL1$6!Z*DG%%1!&L*^\!
MTE#[?5GT?&;_LDXZNF*D97W3&R(6NIC9^^.)E^U^_1E;G4L6RAFVXA/!]WCS
M /:8?3B=</]$2HNM7^PFG'B0B5H[#L=5QVQ<3#G[<,$6SDNL9BC:KV(ITU>Q
M.,!'[VVJ8GNM\SW/^27=:O+=.:-D5#Z>*%8,/)2UV&'E%H9M<$1T6K261_OJ
M*2_IR;QJKU-QVZ\V]O(J+VS?[?'<-GELDTIZ@M;=)[5.7P7CIMKL:*=L"/A^
M>'M_?#QCB0!QQBE7Y?YY@A1KLODV*P+/'#Z</7P*!MK_[3"FW8DQ@+/+WW][
MKKVPO)YXS-^\8K L:.[W\PK$,QK(7'+$Y/N#%_%1J$4CG]4.A336$0__K"7G
MTS5W9*3[!O+)G?RO8]:='.AVK[19=R'C&+/X/?A^"I0(Q44V6[72O"D<W'?1
M] 9[<W>O5&Q\9'F=(SI1?!S*QF1?W?%K*SZSAQ]U__,7\]/QK]HZ(:NUKJ__
M_34SLK[PP'+Q$;';\:&JS+87"(738IGY5/QDE3@\=-M^S.77N#U4]?V8XI5?
M3M_'AX[]<D4$^6V)#_U^JDTNYD;O3F;I[P=4AX],2X1DF?ABU+=S."L[D%+S
M+<2CS#=>;>D4VO<C[E)=J3*+XH,UK/A+C, \KXA3T>&&S!?8WS+$0\"*9_=U
M+1ZO6;!)\IRYXA0AN*K(I#+W5A;&7/;C$9,2.YS"Q)@-Q)/5JR,?V%PSGCB<
M(3G4!"]HBP\5[L(YOYQT^K_\>W CQT6!JYP/J_A;O)H]J:+P?B-K)GIC+0<Y
MTY_@MW>7'CS9_X9#>MD12R.6A^.*8[Y_954RO.Y?^'S+SW.O5TM C>.R-1'F
MCVP3#74[MMZWG9IL>[K#(=76YXSA$;:R1F7R2KWIZR9;V<5<#]]SPVO^QR/M
ME?=M8S6WQ#IEN,TXDEP1%FL>I;Y@^KI)H8<B6Q<F3"_0U]"-\(IYI\2O$T'R
M9. 4$D106?I:HG;E(""4UB3*U<]*:$ 3696Z5ESG7J;-S["&EF77V*7_ZKIT
MR.+/GRWN6Q0<RV;(GTEJ7V;9*FNMW60?I[7[8(WL_A=9K;&[MOY%Q6T*C=3R
M)Q56_>V?%'+X>8#7HJUO/?:N_.Q\-6_4QOA435^?QSF-GJ:R5CZW7+;$^HU_
M;9-2X1'3U;TO1J-@Y4S.D;X'JJ6/CUT[8U;^:KWN&QVYL=PJ]^<VL4;S??R/
M64^Q56286$VU;U9VBG WO,14-D$V&/9@JEX"5W=$?A]W8S17OX%VCAK@>;LX
MQ8)34FS'-8FI\9N\_0;CZT2U@N>TD/OI%K%'W4\^S#2,V%\[QD7)/0-=?/4S
MN:_J;GM-[<9;R.V.*Y<_>#CM;*Z.O?OAT\:R'1]9VZT&:XY&3UXV<>;@T&0S
MN4</Y2+4-%2DGJ)V-%3_XK35'/JD9EY3L:9=(NVBO*_29IW[74HJ);$>1U(,
M]6)GI%R<-SE*IB36Q.IVS((#V0L;+BYNJ#FUP_J2ZV/OKAF^FKL20R\8;UZ7
M^/73MMQ$S:@Y*64.[H:5ZHNJ;Z>LK4R:O?]S[%0;B@OU[L]G>?YG?X[5R$,8
MHSM^!9&PFYM@)=+!YGA1KU&VXZ] F!!(>>0FC*5_;19!J2$Y&0U<1^SR3%,1
MM&=FDPAR0(/KV'3>(A3!BP(<\21VZ65 !T.T2;^]HO/37]REK M/=-V\36R+
M9M^&#JXNG0J]T3)?LG!PQ^09-]7F_-T!+WMQE;3GYD4TU9TM>&*@XWPR_(MN
M4L6C\TCLOHX*YQ)8'7DC@FIN><0TISOSG/L&EMU]<,[_0'M:6%C0:FHI/B^)
M(N.R BGW.@MW E^DFLPO4.#Q2$58%MB%=I3,_8_K*"$@0W8:=%MBXIO*EJUN
M]_6LF<EC8@>2K,>RF!8OUI; S9EWD-98ZVH _KY!F,93Z  .MK6>J=#7APET
MPN)?7&JP7!,3^+A4!*F!1";%GR-UVVI<5S0.I-/D ._,)>Y:"<M%T+SLU'-(
M;P>X8LPLI38U]N<[:^ ##UL_ P&&5Z9RZNQW7T*2+HYJ[9HE@KHND!D-X#*8
M<3O2:XQ47:U64!Q,(.=A6.G*^)?SJ=I5-PPJ=;M7!U6(H$+-7$RSJNY.XIV!
M(M@#7%0)KC4@\\>'?"+C&QAW05+9"K*,7DJ?T?/0@=V<Z.WJI%HG-]P2Z5V]
MF2X]<*<(V]R??;CP@."8"$JHS*J ,O,K!"#Q_YL0C"M>6OCR81^(+!R$Y 6X
M:<3WHVAZG4T-W4_7J-F5^PP >7YQB@J2\WQ785]NZ'8%Y(E?S&E=U$S\5/M@
M;2#<53[;^:J%=:I5:9(N;.Q:M)^QCW+JF, -7_C<H.@ER"'GV17E*$Q:X9.Z
MO_[8#1:^X79?S"/O,+"($\3MW5%[5<+J)MCU@%1YOG^&4K<L1SW?4@0M#U3N
MRX8%[O3R1,J)H/E_(OE-&U0&]$40=M;=J$?3N<F='&6-KT$^\**%H^T%;+")
M."63XXUX:?:"/UV=WA<>!IGG$Z2]Y#8IK>C\^5?5_>32+>!RAM%QS5I4+S(F
M!18P1^_R/N\_9UEGDS#ZM3ZA4K\A7N*RZ,#U[N"*U;X*^/HDVL<7!4MB/+-)
M394=,';&M@^+]:8E#!%W!:0>[RCK"DX=RB-N5OC&9_\E@L[NYSH*I3%8!$61
M\'7)CH-[N*ZNN*:"?'C,(5\ROO8V&K+0N8EX_*L'\Q0ZO]C^G>;W1(K!L@93
MX-F;>7=_?!C77XX7?UY2-'L.I[71UT@$M4_<!.\M5;Y$1S=1]7D="'9R6_%Y
M;:\KNTVH*6 KM_=;_)V6%/]J*\703P15Q"'526\C'2LZ!5IH =\_)(\2YA'W
M%"1^ <DA7Q.:U$JQ^4'3O[CU>#"Q!TIT_NM+(%XL#/ED!Y9.(.,/8$//:H2R
MG8$@XN'M[JU2&K#%7\?I[K[4:"UWM*.6@0A"[#L%\U#BL9P2^<Q9N+:*R=MI
MB]Z8Z]QBKY25 C#Y",P1 /!_S=<;DP')P>(^_!XU5G(BJJ8Z53 '_;!+01%U
M5 ^/K@)I0+UV(@G\Y.*$(FS^YZG2PBX*6$L4W&D%W-5Z0Q(ZD8)O=>2GQ3%Y
M5VH$P'#ROES7ZGPDF.7_!22LN=9L6-"Y300U[S6G/V)<I">%&BTT'/!RK2'U
MRR7B&0>'A!.7B2!B$D>AY\<+!PN#!HNUA/U,WFZN4&EPCC"<>M1*.I2Z0 0%
M>L+8O>2:04UNIQQ-"5US4&')/9#H/-UIVU@RXR+OR6P1Q&8DX;:8"!KU8%HI
M"RO6:A=V6&0>BW,KC'2L)7'RXP  ;J7EB*"A:A#(OTFYANSN.3>QHB!;OO.B
M%3'RW+9IMJI5\8H\?F_U  CH*?0VA3,&E]IGID[N?&=:_))BS+S%M50:_" \
M&S1W"@VUR%(EUH5@*<G27S6XDX@-4QJ8@DZ0*S1;NN)/.<5 S-FJK3-8]^?!
M5?(+O'$3@S!F#T@@FI/RISK6NPY.1L]M1-C+.-M(/9YT+!E@4Q8-_V3DVO#@
M6G,&"[>WS]9A^V;[G-V*=WGC]O# JO/,-IOS(!2[B_2RX-(T8^6DE"FO&Q!#
MP2-D%W*NGH1NIBI:CZ76]I!XFY*+OD[@+DBCJ?B3:(XU3)ZU'?Z<DU+5:D#!
MI)C10D.@^#<[5/-['"XW(AQ-$I:.KB$>^PT!E.3 00L>EF(+XZ1F-O5T NN^
MD^R(3^!RE_/]*UXQPSKQ:P"SRV^CK#/3>-7*0.2 ZM^$X(D^UL()CRBHD@+N
MW,H;="M8<1#-MI;KZ-FM?'X^Q^ME<V1MW\<[=W&5X"UNFW3;?8^>GJ6Y*F\^
M-^^/H3-N9&W349_F);=T#J6RH[\Z-'U:-3A>F$B5)8=FS>'3SANK8XLK[WNK
M>;E]W6*2V&'X1YJISPN+[=CKL1M,F_,[(_2U+WJR3XJ@L=UHS!JUPL]C6H6,
M24CO]>S#:ES]LX=G.BJ6W0_/V>4:R97KS=+;9-@7$#7N\A=T@';WRFSCDD/W
M:?=/#WJ]Z]VM9NQIN1%>&XMZY5\+4@W1LLEI\GG\[I!,0.RQ0_:['O/+WQW^
M4[ERSN=Y.S@7%BLM=C3<LN-#LFD$]U!T:[,2?Q*38T4/!8F^3M&)$!7!9Y ^
M-R_9!#?$,*>J&G!+3_@/>$\"1GCEY5!1S)S,TH-T5!YXL,@XQ88@K>-_7 6,
MX0WHL/DSHM97(CZX6\5?R.18]H2JXVX,B(O7G O!V9968(@5ZE511%$H,A#@
M\TC%&X82<>9!1*CP;<8+!\G37CXVHN#CUHN@Z !Z[-KA8[^,,D J8VO0>QM-
M+Q*MQEBEBDAOZ&T*NC"ZX&BA40"'XP;W5N3' @;9HAG=*"U51!5(,;OJ@6O5
MT#BHK/SR\6(P*7 +S46M2DK\34S.YM*PL6[X%%9(<$4K%VRX?A;8\#72M$W2
M^)2>$*H(RFRDX#: G//7-[R$F^;D=&8^ QANGKT+E0T_>G%]F#>V[3C2/B \
MIM/G$BI<#)9"*GBB,AM&?>M2T1M,X2L/"NH[5% B@B89ST1800MAP<FI]'-9
M4S.H:X.!,2R'L9LA[*$9JWOEW'!ID'8WXPA]7Y";#>4.T>KQ*9KUR7@N5;_S
M(@4X9>QFLBFF6-S(,Q!!9T(X'TA#&"#Z-S)T]!PV6029R"N((*@ Z050RE_5
M1.&K<^GH;&#HT?2K1QP[QH-HW9&Z"^[;@JL&6J @<(]4V@.C"RB%HPW0$$[E
M[&/,T-4^-?AD?DBCXYA$$;1@&C%?/D/X"D9#C(@6A(,Z(FA,7@ "P@BXXRWV
M7)*!:@U,1W(TC9=?/LE59B<)AQKIN%N'";B:+=75FW>7)8<":!3 6&FU-E?K
MY!#5]!2Q<4.D>32S495;))SRE(4I -P5EQ8[:0VL07+4@[2?^'!);-IL1B,#
M=TLANHY<14LVD3B/C:<?%D&61HXBZ&W7>B[YY%;,[!1EL$4+L!56F*77%)W"
M?NN-2Y\!@FQM=E#B/Z%SS,@7EB)?;F-+QP"Q;6\LW0P<T.G#_,H\?((J]W8,
MDEM,%*X/] <\<*V#PIWBKX"';I8!JE].P4I@]&R67\59[KM!.Q"9]:WEK38)
M>JR SK<NC#]HO !;*H*RL>W$8LSAAK_HJN.E\6ENN25('=<;V%&49X&"0A-S
M2H/WISQE% &PW FBI'.N12"\N^XY$WO&N4[-?H32(RHA:W/A 6L4H+^PNA6?
MYIW[Z+U0!$T#7N+9@7L*J%IK(;NBT3N7(> U]M3@&BG6!=8*Y4Q^Z0E"DD'.
M(BB-%T62-1#VY!E\81:=KA%!2V%2[U'LHJ0S(J/& :AC%>;CS4MFR1QK$KJ%
M 2=\':!I<G'3)0)-=$X"COLS@0A2"ETT463P:<(H$$[MP9@=TZO\G8O:CV<M
MIP7M0"V8E,'@WFFAPB 29V//Q0T :K*F;&-K01!(!EL\^?;!^/@*[OMP6B@\
M@=G#G([TZ=EB#IP![X+I"M@80+=O\YDRV/K+(BB"0LH.HT\00>_4F[J4!'),
MSD;*Q7?A5%O4HN38ZZ;9K*'%E6"R'&Y]C$(H,@'N:0UG\JXF _DQV)_IW*B]
M_+:7;X'B=!#*0ME<9/+L>BT:8/^K,.X.S]K/^*@$=KR$&G" KF0\N;^47ZJ"
M]"VW8V"3'9M*1L%*09-G@IC&6L55!-D<BVZL"=$*T@(NC^,"$'XMU$41#1]D
M[P"!F-0N(*@D/D^'FR@^P!RU2'*J5AA-XIC M#^(_3NR%>#^BD($*R86?(O+
M^0MF>U+G? %B!GZ5=P68TN3#>30^T44*4P9#+=[+&>,QT^,'XW:+H.!E"%8>
MI%U&29<%,#='^4)C+8R$_<%-NH.T;=4#,<:I>53$ .8\"9)O(-8\HQ6LF=)I
MBU$X'[T+GOGALH5(GP:%.YYHH!IOO5PL!#+_//"1I077M0:3$:(F=?J8?C2#
MX\>]7)@-@K9;]I6IX&JKA#?-6AMK<DHI W$KP+JV)J(Y['A'JG.T,_ZR">%%
M(EQIS+P]=R4-E\M!^FS0^&\]*(0/*>C<FJZQ_J1IV1/#D0IK5; &.P5T+J-K
MO!7,/D"=T8I?]Z\70=UW-2GA02I+4.92RI "(*.WV7\PI:G65\).ZV@A-6^5
M6 R!(QLW;=RI)#C$)%HYU"H]I^Y$=6IFOFY"\+WB!FJ:PENOB[ E/<&DH:$B
M$O8:R O=D]F(98J@<<0R*5PIJC729]I"077& 429-DY4$IR&&TXST\U4Q"6>
MG'$<!7*[IGD-C)+2+<"7=J&+#=2%;A>MU]/X4\]8<.FY ZE-,[]-R4!/X8M$
M4-FL:TA#/>!!/?K9?L=N@(93\D%E&QJHN]$E(@@Q FST-A;XC&!2NK,;:7JV
MC$^G^D4F+R(Y2!=URFQ:G('4&X'H67NBOU8C /UU?1U"/23<$Y9M8WS:"Z8;
MCY>] ]/3&NBD_IHB!/N[$MCFV(G"A!M)A=:G=OJ\C5L%-+,Q&MO(E(7;'A<C
MG*T@&KPFXS+!/V6P(:N4P"C"NX<MB&?Z%6&3U ;_4B=QGA&5PUFELY&^N;8*
MZ!Q2U_PU,.=9MC0!( H8)=EB!SC)WH77W'#9(O E"G>LT5: 'K*N>'ED?AB!
MGIPW?ZDS0 I?P_@,PO=3$%YN4(HM]3XU<ZC/*""..;C(!QB4JD!@EFD-4#V&
M[W;-Z#A13<Z-/--(J[WPVIZ=0F+QUW2QU]$G\<5?GZKKN@35C&+@+NX\^JE*
MQQZB;5@V*SU5CG:!-.:X;W31)P 8JV1I3+598 %<0%(#9?9CE+CA?+6V%%?S
M.[/:OT;+XD42K=.;?QIDF=I(XSC_)X,-X344_O$38#"<6/:K-UI#GY"&SSVU
MNYDM&539F4U";YJ0V6$Y! A/M4*P^3(-W8F,9O;TY"O@KA[1%UT4"Y#77E'\
MYR#<QUTU_!4:.^M.IE$P%4"O+7D<><D+4XRV46!22JV;"FD&/E:XF3E)IUT$
MK?-6T@2[R$+2F_K1CQPU[HU&A0=PVV8];6Y=KI=7X4=;( 2X&+_9SZHINV/+
M42X8RAS=PD3U";ZLX.'QS)N 0Z2Z\8K;8P"79#; :G!GT!S@:U2L29P#I5U&
M0',OLL<0;D\\K+R-.8LZWYE;:,_LG@V0</6-RRCTU6##CCHP#5 65B>D7L/X
M-I3W!P&Y^"(>H]< "_C$4:;SO;B 8JZF1"$-GQ1JSS^G>J/2-:3.;!#W]"F9
MH3UL1=;%0PQ,Z2K21U2F@5# ?QL6 K\?? C(Q0N.>Z/%5Z6@^NJ#\;OIJ L,
M%0DS4$ M;W<:(3E/F1DJA*DU<V1Q'-L -J>9B ZP95@7']/%4Y(&>K5PD T5
MPOPY?0BF&AV 5'K3!_8A1GIE_E?(TXH"]N/+P_)M.I1G[(UYHM!H7UG=ZZ6R
MX2_WWMH5=\?VNI]8OWB%]P3/+?,B#.35=L%($:9Z1F [&2P$@1"@2FM\CV<'
M7%N$C_<4K,7?SU[)H812];B'&SZ'N;'II[.ET4 _[P=F3;L/^R2C3JM-R&2O
M@I SY'F"B3E9X74J\RW"U7@/BPJI?U+*E7,[ DJLS]S*YVU4'Q6:UY)6M.^^
M:WSOFZO^#7'RI^YPEA[>'IY28V43Z0"G''^SHSCZ8V[@+*.MR1&MTU,PK9C=
MC] =&QWDI.SC1EOH))V[HN>J]3QL=H*UP%#WKIZ*R3.A]R>?YFC]7C\39 .%
M*Z_0!=C(I+1!02A$06SYUI(TPMAQ$G<V1@(6VJD!T+8=2'UY !YX#23#^4S_
MUT!/T[P)/?4 -<76BCN,(QO6XQ-SA'>+*!<I$ UHZCQ-N([H^Y5O0%0#5R:?
MH P--:J#B>R1_.,<! ^[!_YQW#X25@#RGS^8"4/AGPRD]0<&G_FQ\4\\>@D*
M'4EDM"'XW'QQ2?9GU-$BB,F<#/-"$T8<4V.=)O7OW NC9.##6G1@-)JIPFP[
M"<B.<W0GX-^BOAP3XH055UZ]"T3H)L4-RL.[=2"-.#8;F_--  &$ $(P"U8X
MJW]-"TC#]4$DUM+$:XAGW@*?0J809=[C?\ B;<0Q6M DI,PW4@0UW -8OQJ,
M+^@I].;/.4S $^ESQSC BH!%K3\O %ZH[! *? L2- _I4S(=<<R4*0V$\/P-
MH&C@V-^Z@$B>C$:7$KLN@3D'B$UG@S'$:*IC/[#<28U!E4C_CNQ1"(MUCHX5
MV(PX-+D'Y/W\I<-6I$QO_0CVW4KLNY4DV3:13<-Q,ELF-#CVK_Y]#CM@*32!
MS47I(A)0N4"L<MT15+X',2U5X1^4 K31O70'<\BOM.\K8F0N>?N;\IZ%K;\D
MWK*/>,O98,M33$<<&T$,^W":B^YJ"N0&E@S\9DN/>,GF@$] /'>(**"_%(:8
M/4.$%>\?>6@(^"ZA\G9K7.8MS L#:RL008I]3:;"22I%^,1BA/<"C)6V1IR8
MT$YY_X$P!MC#6 3-#!KE6NL-Y) /@K.);X1W3:TODH!# 8P!U^"+4N#&U<0K
M7B;5=L##I2G@>_HP <#K^0!N GY.KHG@5";VB;@CT/=FDGP6O1R(H@A;'RVP
M0<"NI8E=B_G3=,2Q$41!XI*-=9&R43$@K@#!QHTL$63\%@]H8[2YXG.+A7>9
M;4\QX F8+)!LBTUKA#$U%L@=Q;:E1=@6&4A3 8VFSX#;3A!  _G N\]BH/4[
M]H-X<%(S7DGIWQ$$(GI6SSD$*[ E#O @&0I"9=()^E!?(R"6Y4?HM+A)1YKN
M@0B[?G%.D#_<^25'.#MK/Z7/NP]8F\\A%GX S]Z,!]QEM+F)5X6 58T%JZ(3
MJPI+&&'L'HOF,GDUVJG1/QAPACF@4-K7=<>ZK:_)CI6'-574-C\1095-O!9@
MM'0TA#P(3#>^B3,%QZF %EJ6TD88B\9,Z>.1MF??)!HDL3%D!M+&:AT&UW\]
M8PS<4%]:>P)Y=Q =;RWT1<_PD0)ETQ&F)'&7XB 4*F-^$V=17\GW @5"621_
M)8N0G@*0WI!$>B,.!7!"\+"881LK B "\ROV-%D+5;%A9-4CJ^T=NXD[X%)#
M0?77C>-JGON%P6X4I1WW'FW4C94NRM;/K)PU?[Y1)SG4>+J_M_GD-9!V:H?G
MRK$!R]X>DBY@ D_=< 4DJR&O1%"7!5T)+\%U:HZL7EC9H6R\ /69E90?.T6P
M/*A\7^5M;ZEZ#_X5NJ?'%3\=U@57RXH#NG4;+@JVG*I^TU+=B!S7X-KE47O3
M#WYT4^5\5IMLTUN15ZJ7MSNU,JKQF;M-@=49I_O/YD<9F+UF11EO=VX]3!MO
M9//W_N(IUSG*4]D/W]/T-F_6#M^JI6"^(C(FU3'7CF$>:7LZ)M:LP-3*\_!&
MXIB!?5I=J9=1=>:R8N_#WHO_VN%<JEI@-"6W:^;#=W*ACTT6VVK-O_0\-2%5
M"WH5.GS03CCA4('&3O-!]_MVSI_\>I!VW$>]V'=^A=4[O?O5':6>OD_?WQ8H
M4#@#R>M.5O3U6(B?R7?A@6\3%V+1WGW$>Z-F<[^]7+Z#<5Y/!'W]&R_V6)L=
M=?C%J24)*T>ODU][Z5EOY2DIV8=S-)GKC_O.BDHLJ*<?&G]]G<ZI?(6H40-'
M-<.Z<[.,6QJ=7YQ_X.95_O9K]_$_^FUJ9!)D$AZ?D#;OS"US^*-Y@?^ZVB.1
MS]6_9"(+TE;7TY9>U$Y/W7JA;8OGI^/V*0,V@4U*[I:^67MZII5->?%WU_R+
M)=T%L9_"=):O7/S6;/[EU_._5.R/?VG7'6$V/\),:WZZV9*(G8K$N_UG_L=O
M>CM6?R81)=.\2I7:#-5#C70$"X+*9HB@LYC9;??G(BADH(O$5KZH-U'=^?U
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MV_N T;]/N6_/J(HT:^WQ5_[[N1C@/V1+_XO-ZV%NRGOL*6/6_V*%_&],D$F
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MF]<<KE2^-[CAY??=MX-CYMI I9A8GMNK8@7#^CCSI7B_NP@-(-$'NSY^#&
M[ED0]3>8/KI0 R*P3EC.6ZD10F'@F6H<(M)W98H]YV;[G:<UU&Y27FG0CRJ+
ML^H.+FBWU/O9%D)W?9!$C_AU6I:Z&-X$B097]%7:+:S.<E)LF%[7\_G((A2)
M0KA@I=7J,9;'3Z:M257H0I?4P85J:ZC :-SW8'#V(U(*A"3FKQ@ZST/0YN3
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MB%<R7W@HS:X9_AF/_C:E_W$9Z3Q2O^U$X:&.SE8= S8D#EV@M10CTAI!HYC
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M5^$BB$%B@6=WIFD];L5NIK)6_1 L8"Z:)\67;S.&(@/<BWM_^[7SAA>JF]#
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M9KI?ZM@'ZH=5'EV"%4Q9<%WE>(+0I- =LL)I:%$&::6!;Z5\0PY,BHB-!-V
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M"_5'&OIDO/>E<C@WWVL2.BLT\?0R\GX"W<CK&6P.EBP03KEFUH2L-(TN@(\
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MZEM)U/..^P\%:)XJM9=C.)LJ"]"V/2_1D/T;WA#)/$\I.:^YV[\JPX*G"C+
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M]DXV+4^,(H2:7CAG-!T1:"7ZOYXY=Y@VK!24(V,O$ARS(,P,IST+H1)CW)0
M6.3K!Q@1PM&I\=3PH:_G?7WN!TX,V('Q_;/LS(A/6]S4VX8WCPQ?$O][<A<.
MPI(7Z(&X3D0<6HL5HZ7DW8TXPP8CF^T1&;!S&Y.V#)T8R'6"KYGWJ6<4[_@Q
MA&]+P+>AIKBE5[2G9C^,1SY_?OI1\ \N2>IJT':BU!D/C3;-(Z!*>=0O<R+E
M)[,RPJ5>_+J%=DZ@:?S50>%<K_,%;1_)5IT&6)2(_/FYO-0HO&]6*3C Z&ON
M"AH,1!4'Z:2\="F-12['_;I@IQ-7^R%+X^I3_"O*FF>8GWM6T!3S+%C2Z$Y%
M4L$U&GVDTVL<48^U>(O;J"P?8X?#* 38471("[.DO;)W0"Z]ZN\)S6(.))C:
MED3O^>MH$WD&X/S8BJX*9*@\0VD[<6L'D&G)O%U;=-!E/;4R$S8^-^F'FS(J
M=S/$N:V%.[GF_BA$4X[<0_L\+SW\&3'0SU6V RI(GXS9J2I^5GQV5R%-HW-&
M))?*@D89NR*Z']<M#'B^G9EQ-HM0:BS$MN;"!2WH3K/DKU;GQS%8#" KRQ0H
MWHMD91PQ@R%YX5PK)V5;$CVT7YSP>I)]B6G$*,OTJ#[DZ)3%E,^81$50,5R&
M^*AZ<_K7#"K2L:&J,! >/VK'./D.X>M4^/VQ_9%=?+6GP4B(@<C2(TES@[R9
M7E8EA3^$Y((F^10#](#5SC3QL-ILM0]84]6W%4-%ES/)-!^JY_7);LNT,SPX
M.7F8+)@'^9&\(/Q^79F\-(WRN_\'ZUM@2 9QZYW7M6AT'.D<[?C1L-9;6N$D
M)%\-E2J344N[H.1HWZV7K-S\YQ<E]3[_\^=;ZL8FY9^EUTYO&F&P]NVPF4..
MO0NL5@+$CP**;;M,]^[F;A/Y<K)E(;[5A"(QY;_9L*JRU?!1$D/:<].@;V+3
MZTO,0[Q_=%4^\ OC>S.WVOE[(Z!\ZNTA!Q33<3L,,Q5. 6T0&'TD*?UAZ F4
M'I#!@.]% K]*41=&K]!!\?Y,<QI<U(3./N2X.6I-DC6C[S3G[,<U)Z*,J"L!
MV\P^HX:6UOCOKO_DC YP#1S9#=."$:+ 7:29&CTA\6?_(8=82N=0CCVD]Y-+
M%,_Y\E'\!1>Z+3*2.S6T)#J_!_Z;/YID-+Y7U+LK.N31EG8]3 K<'0P]T06)
M4?NB^M[%R/-ECTHIG-.I2<JZ5%%3+:M^SD[8ID@99IVQ73!_V303MPF^Q(X4
MLM_GQ71<1O.@Q!DZ3,',/9=)U"UZ+C4W4>N322?T:NZ=B;#!8X"]W7C@VPR:
M;.K==+,!@Z-;??_Q0VCTM1*3(F_/9-U%*WXAT"/@^L%_H[>@&'>00$UV248,
M#(268[HS<@A5*S,]Y$,.(:3X*"TC91<AN#XI*E(D0E<LNIA[>ZP[ ><R1WJ#
MC.PLXJUMKN?U>_A0*7#W0Z"6Q">-#&R-;;87T_I?PV?U!22=SQK^:-OHDMA^
M.1ML'J1>+)7D$1RV1CJA]R&,QX9>V7*'Y"7H2U#,NF2!M2VRW4'T_X)4Q==_
M8>18/^O]U4\X\8JV?N^=EKN]DF.Z('=BI_N#T1QUH=K=-9LN/96\ME.\TR'&
M5H4WK6 #<_]SJAK[7R+=$C8E2]G>S#R ,6\.[P8>![S *?O><;LL##60'!F@
M/-_3):Z2KOE-?FG=J+EU8N-2AM482K_Z6\?97,+*[Q&$PYS#G,1G_"F\.W;>
M"7.RN-9[ [L8.&NREPI@Z*".JQNSY-R!\J--'P^"SG84G1@15\@0!FHVN6_.
MK>[Q[44ICSC>-;='?!K1]"P2"SM?@,ZE8M);K]-T>(-! O=4ZZG%NQ;0V<2@
MJ7X7M2Q5Y'7W=5KYHH^'SQ )8L330']?7M[':UR'3Z@PM\H+Q5G_6N!GB@X"
M7$GJRN"2I 1^J"RZ[S+97;6NTZZ+MNB6+E5SMD8 ZV]0XI1]VT+<PDS0*07K
M)BSIT&BE^L?FN 7'%PB'7N;JWR<%3E^,B0:=Y!_CGTH^Y+A%Y$#QLF*.>. E
MAK,G46F'D  ^U0JF?E;TUSJ"7K2.J]YBCYO\.,[V9KXC(ZJK%$@AZRT1@L\T
M:Z,O#$N+/+_IG4!J ]?6)3J1K'L..4YAW,& /*:]ZIN5+AK,1-#1+9/[%BF,
MP':&S\0\C Y/W#AI+OV +9-I@>!'^B%&G9P5/A)!?CF=@Y9U10-:WT!6PX01
MB>)>T9%##F4DL89P]GTFR]0QN0_;E2$HT5W5\,>-TW/[V"[!X^"0HP+SD.4^
M.JZP@L[__YSWP7'EZ;$K!1S7KQ0]/?M]<@:JRTJ *@,>>[1QC+NY\D!81E(%
MPVF6.IE0\TU\IL]V1(M0[SM_@=$U];?&ZC[?]K/M#4A@^<U.DY$=1^4KA6;.
M-QM9>^S/Q>]P&Z,'O$SU412,OM I=:%I4K-0S)O1TZW"[^"3MI@A/#_KS+V;
M%N+&,)J12%.Y^>MRT=:L0=W'AB-?ZI?5V&0L*JK!+J;A,N;4J#7V_WJH J8%
MEB^#C<\6^;SX 5QP4<VJ\M1RMP@-4;10#U6S)E%KY:O=8[YWT.3O>8OWJJ8^
ML"W 7*=/MK,O,[C4O](;&9I R G2RY97CP/3N]UQR15F&EB]?ZMRJ?1_\?%I
M*&/P=*]#C;^K.!)IFIDU5V6=2LS9!K13V'##11@KGROQ*)A^*&G"& *X'LB^
MG4_YS2K4B8/M6C$]"9/$:+8<*Q6M@3*81*N@!^>O EP,$,TKKL2WZ!0#GL86
M6G<[.]%JR940QO(PF@C4Q BZ 6YKSGT#&G<F("IOU\0#NNN:SXEM>.::?+#Y
M0-0!_UM,?[3 ?*73L7V@%\B#6<,"?8C/T^$2<#+H[>3)8&'_%# )F?>R%<>=
M_.67V'6::B/] UH&]#N31)6WP=H55(SC]%ZZ0&8*/Q7+IRZS3%X&H70E5C:[
MQ?@4USG)YY\@_?N$$P:"^.^4))4F]5#+/GV>)'<*RPU8%"S"!=UTTEC8V5A,
MX@SKOWS_JZA3=- F[\$3 -:)$4()'VVK1+?C0Y!C#-FN^8OTXN2&CP%^I/T7
M,T $$X9M*RV;-U'"]TZMHZ5'538A*U.&F "_H)<YUZ;0M^S_RXKO$&\<G$98
MLEZT'5\%\X7!GN86@W<"8W($4#:C3,%@.CLPI>6^QOHIA1[&CKB$3JJ21][!
M@9*R,YDGY>KDE(C52$HP8A)QLT:W.PB><#V_W?-/O((@63/X%2<$?1QO"I)&
MSIVZA/&UPYL6+%MHXC=6335*KKIA=<2'LPG,9HH*E[LN,>/GC[2>NT%3J.0:
M04@1KX2I<&F!HHP.Z)"#NZ'"IN*TA6W$)^S-7N$W*Z/E6%/+3T1E#(42.*V_
MY\TJ)GJ#HXND 6FZ A73B8]T!F9"S1'V=)58S8RS:^(YSX\<I6PRX<C>!2J'
MKC_P+!K<;,J9=/LGU>,7)?GVP[],?@8@UDP8Z]V(>GATJWXI@CW:)@-(4S'<
MW]81]^FLA9X;SNTS%L^":>!WWP;VHJ00DH.GBI5K6?G"&_'Z,GX=]W,53?Z]
MHL7\"]-A I4 0'M'WQ5=842OW]-J!:R/-"^M%R5-;X[7@L<VMXFU <B\UGF!
M426F6?7<FA37@=WSO4"^V1FW-;3\AT;'K8V-G:K)/-D\T#6V^<Y=AK-$VF=<
MYS0;46 &ROPQ_=_$L/>+6MTT-;&HVU )"8,PU4Q"4HFR?5Q)4L7U6XME)7!>
MZ]^6]M]9L%4Q:HX@=T%/TJ/;:&OQ/S4PZ<_OYB1R*"ONC"$\@LM.B*&*3<!+
M>2;B$V)M[,Y>^$4V_(V?S6<\_(^I*%)(2FK,SL7H&W\/8$H)&Y'_S7)F/2?>
MQ20LWAF!:%#QX=TM=JEA@6!F)/#*KW0.>#9K7AM9Z&==-];H&:5/78C%"^CG
M/\>NU$W-S/H,&>HD:BGYLF=<W0)#4ME="\VXIUH'9MX _\$=Y*F9+<Q9OQ<.
M7ZAP\,R1QYFNN^AJ,%RSS=2I[O'3<_-QBLO^6EA!$LK9+\I\_+0CQ,D+?-N_
M*,<]N<BRW7$IL!-0-%?4EDV<U].5ZYGYTEUHE-NG1+Z#VTTW?=%IV>WUTG1W
M47C0(O;/*@D"&C;4KGA&,M%<],]7H-WVDBJ3!OVK>*$V&/U5WO8BHP]LT,!*
M@$@G5\7V!=L\^-)FFEWRY?HAQ\M/P@>\AQR<,?_]&.J(;B>>1^E7,;6++8G
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MX&':^F!F:=:LF"P%G@S[=.O2"ZTQ0DV ",/+%6RN^F1A<_/H0%4"7 ?BJ)M
MP@'$!6E&RTAN4UL!@[Z6^E4"WL;T!O99^B%'&L2::EV#%#6;?!BV(/*@I:!I
M2<G08'QW%J]Q<^Q%C]F8N\B_:[GK(>Y<ZUP=+ \*^Q-]F?2DN?V&&;4;3\]9
MU?J;*FE(O3H83X!*?<V9F<#ZX4%GYY!_+Y!JWB&3^=P6K,5#^*7J14J%)U2L
MOH-Z8("2"3EP:FMVSY15P10L1Y+V'B-FTLVYJ*P&J'"^'1 AVY/1Y +@J.Q2
MG,J>;C8S2H(8[3;/GC=^9HN2'W;E<KU8G<U$O%A"@@0A@3T>[_OB=6/T2 SP
M.44E2"E?&CZA*V@78A'RK.^=^H"\(9?=VY_,A!.PRGMT]B 7]W@:]$G#/:P%
M9E*LS36-_KMC[BPH]GV*]!>&V"GC6HV!X/.F6O3I#?JTA08X+=V9FU;1>7YC
M6XPKN7-R[^4'@X+*1]:5?WP-O[*Y,!V=L-H;S>WP4^:,OZ%7D0A:<7PKZ*T/
M^@I=)(WBT_AY-Y#_P1,7$5'#SB>;^&_$!&>+"66EM(FLL$U#TM)7WMCF,9'I
MUSY@@,8J@<J#TC%24$V4CZN("A^NJS@9#072P G4%]<SC5*ZT=?&(88B.9/\
MA@]S'TWUE"LU=JU$"T9"'KFV/OBEGK'CRLIF'V/RC&&\P-,]=\:@O"@9(K$-
MX*-'_]S?_T4=C-DBJ*@HMTD!3R+SJZI>[7CGT99HWA&X(N\(K^SY6Y*%23"R
M?;O*&:0O E"$QS#!*@D-UR%7B,U>A->$N.\C_F!2J6$,;0OO>2I5TZY9[\%(
M27VZ_LV&[?JH%_KW;XKP"\2!1Z#'O-W /Z:;4R)P/$$UX=FTG[<_\F?TF*@/
MKBS9*%"#D*F]'_M^?K;N"WK1,9+MHC1^VZ6>9PWZ5;FQ1,OZST'W1FEZ\!]$
MW(= P6!E^$MJ?4'4&9&SCF@3>Q6\B6!R2:[E_I[[]:7SY;2U[B+YK^<=* ^:
M<%=-?V74,YM+CY"E_:+@E&#!F?V""T\H^_;[+O^A AV.F$[8RZ&+Y-*7R8<<
M9Y@2U(#CLSW0<PPT'O:L5?K(*?&NYXTGQ.U>PH13O28;S)3T;4=#B0*SKT(+
MG98ZU_3'WKTOF+X5^$1I:Y/Y<:\:^'%PE?WY"&["-_GHZ^UN5UG%*%Y:X#'4
M6<:8FP@@3&6%4+?2:OB>;'=.-DD)U@4FB(0'K8W@MYHQ93?(+Q[\,H=8FT7(
MO7KUC77AXVIXS.#5+,HC,"@$U0?I#[E&88@]&O X ^7BMFL2!25T]TF:R'69
M5N&=^75[4SJ&L0::I?(OJ\93I4D9^XJTG\@E9/]Z^L]JHFS[CVUA0ZF?7RS:
M-(0M<F3:I+DN"/N/\HF;9LOS9RDHVCIE8RV[SSM;9Q7_Z;><Q&)>-S,%9"FX
M#H(@IN,ZS',@G%S,C19#QCB/H:1ICF%\WBYT<%Q8@-W^3?9E9/?I[ZUC*CM5
M*1]S;UY.%HI8>NQ0FJYUB?^O?4%*[L:W TXT"2K;3"?$9E*Y2$>H"A9CNM?X
M.5V=S&B]1?D8F(+6'X<8X>?F250B)]\]<WWG#T.A29[FLB2V(#TLU2FL6OOY
MY[UPI_[]^-+(T0*6TL]JG ZM(+[XA+=8? #I3Y-[-F6%&B*N7OI*D2":2EJL
MS5XC';.J<35(@URNR0J:^J-EGX/Z%VM5M]0+39G.\<D.F@B'JO>^N^X5F4T)
M4;1UL4#8:=7]?N4>]#)51"!-SL-GI&>RREIH)7(J5<CZ+58J8CQ.FCG]).SU
M\2?'@]2#IYZP%%A*AQS^1P*P>&/@(!AIJ@)"(>C^VE*7:L<:OAF: ,6465=I
M(R#W38]WE/  ^Y4/S;'AXV)XZ?IC@W7SL=#">Y,VHVJ/M<S\=+6J^#0LZS<Q
MWH<<I]@]8"[1.ZP\F/=;0/*U'YIS^+*4(N!,^>;=*9Y YE52917#,QV I+?.
M"V[(7O82V[LYQ7*2>3=7]$GVW'!4W4\?[%_SUOM>]QO539']X&/+NM5;A:9U
M_7785R/IKKD4GQ:U>#W';Y"6AK7.1M.UK$N0*E"?G6":XVCJNY^$594W;H%P
MW8K8+D:-=?R798N\OE^RN6,Y,,G4O,KE&$<(8\?=(K3DUG@!]=7D$DY7+RC?
M=M&$25XAK&>RSPJS8J#\ ((:& _S!\5)\=)_/V4ZNB\&*'2 A3>8:KBN-ZMN
MRL.MMSS#P0FM9F%O5QE=6!,:'Z_#:,!.59K!_,C$+\=WDUEKS?8!I3Z?BS]_
MPY@BO6DB]K1P;@I0)4^:[#!H]#<&B3TE]PHKW%4#;AG9DWKQFA63,;&K]B5.
M:C$5"7A36SG+RF7CXE_;B07<KY!A9*!-O+]JN-LB6_Q\JXP^2&RT-*WCGH>L
M<:N/S<-0+QQ/@X)55EG%9*F=:H537IPC"W]D6A<!^]=,/U8+[$@ Q+?)#VU
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M8F]M4ZM541WE8$3]A!<V?-4W;5T!IIFP>98/.3A1@/T!"G4>"*1C*(,Q:#E
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MI%*HG:0%,VQF/%1@I"7D_)@DU^ E++XK8W<]#-31"8A5+IHC<U0)#F%>M;!
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M]H%=>[9@8%-A8@JJ@TT%J@!;VII,QQ0QCC// ;3/!$XZ#QD*";Q'%8LF00X
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M)_>X(9!W#H Y>:DMSC[5CH0 QVJ9MO087Z:VK!=69&GDO ;8=22'('/ ]@!
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MHP6_9\K#2[ZE;^_97KG?74 N59LX&8Q,KX.:R!][]Q.ASW7DD[)*9Y)JQ5)
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M:_&Q%#H^^0$1*W%RR^3EQ!7::*-85UG OC^AB<TC)]4^=;9KTCTXF_=S@#"
MN)&\R8B[-.PPT; =I2B5U#JD11_C@ XS.:"\1',#]-R#@W?HO0VZ)?X"S:W?
MS'@O)0E<KPJF\_\H..9SMQ'UUNU1Q<__!C[O3WHKUH9_K>E,,]']9N:UEA^W
MHK=9IUO/QJ_*?.]9),=4J'=-NEK;+B$#;53&NQL*$QZ4[?-RASC*@M-_]4
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MKG6,B,I5M33;>Y:+V%'Y@2[F%UUB.=,$JFA5E!0B.FE^UKN.94A?3V<=J45
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M*%E8AT@1@[LCTT3BV[,)+A76D]4V&<57+)W6];<GO,;#WUE.H(DA:!L([>X
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M$EUY\\E =(A"UQ<A6]$1?OZIEG_]DJ^N9933KDK>'Q:NU;LK>;_S%.\*!6^
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MWE-=945CP3[X\5[/XY(NVK;JOLG'K64CDD]S0)AZ]"L$2[R,?>,I_3V['YZ
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MQ,F9N:[EY.,BZ 9LS6/#,NW?%A#O0[[-K8!IB"/)CP/_=,)HZIC(%T+7H(*
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M[6B<;.FZU,O@83;/>[G;(<+XT,WR.B:&S5*LQ8-J_$HNOLE_QY?.Q4)XR\"
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M9*/,@]?.@PBNMP"> BS.,B?X=XIC\#_S>V%+2HC=FX>?JW[&'I7^%CST_M!
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M>=,FU5YQ^[016'5;Z'H;@WQ\OV0TFU)VS"G5^'OKK*SL514,'^+/N+JGGFU
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MO]+(007 !E'K0-J@?%GM?1/*-' ;BJR)(Z?7=7F2K=3%RS<D*,RW:0<2)G]
MK:\J@,DF*(8U8@VY&O03#W(''BI[QLX?5,-,(??@+4"<Z>#T;PI]3Z;P,!Q
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M2P?R3*.>8F0S&Y$.#0F#\: SW&Q8(+B%T3WWX@U(A[I8,^4;7BLEQSUYN*7
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M*,C&%Y!7N*Z8$0R("QK>VM5FV-)UE3)>"ZUZ86M1OO[EG;_;_@N"(X?V3$
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M0$R/8BV#3DB^_0H_WV>G_:SO+4^>;.$YQS<QR_M^M/P]$]X+/(^R!\W0=2$
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M<J%;:NC8R\;A$HAY36W%J !%_^GXQ#ZZW+NM^>H M"KXAO05#%-D';/3?K)
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ML?W_',1#^ <$7.&@7^329>!J0P>F#+=3WH\&FDSVZ(RL;QZPL ,^)LTI?Q
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MU.$!S^FM%G.L>>U+ +C6 Y;3S6!]"AL'A\<!RRD\5Z']-[X9^='*DH@Z$PZ
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M7".XU\ 3=-4 7@R986\X[)S=4FQ2NBSH$%&7_M*MQ%YRF$J(5U;,O=[J"[M
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M-QX.T4,#648.6OMM,P(T9(*PXJS'FQ9$AMW):7VW*TN/M^M/R;PB<$ IW!R
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MJJ=8!->XPJH4MQ%2I7ET_*8TOP_>I:VY8'JE9O-+>"Z?@/JIP?CSZ:[H3"[
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M:)Z8%_2HQ47[T[9@O)9ZGF($-/J/@R51GW$1 G**,PH7@ 9L8A9W67F370K
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MWCGB-W<W]O=UV$</<MC*E2@(*QJ(^)>MSZ@EUD*3B,':EULGMWPF(V;JZB?
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MYZ\HY:_DVHMUV/_[ G$WV[:]./*!*Z</V],U#TDD(@&5K:>:.RW4%X<@\I)
MUX4@KS/;SXR5D^#7XJYEVZ#?J'^C=?I3KAF>=(;JE L2<YCR71D'+[ (V%G,
M?]A&*!D\+]HCSEPW:B9OAG]>"M"7@/DBZ#C!P(>11OHI:$AD^+//,=D:T>3=
MO02\V.Z<YH)->^["K83IH%25FX>@(G;,,S^3J[1#D!ACT</]=VD0V;# Y6F5
M0]D[)V8$0TQE(C[P7;!C64KYE.K$R]PTU>'WC:_9?_5(+O+(+Q=(CFZ?T!MZ
M-R(_U"#C9'!UWLC _>Q\1*5=ED')J(F.:)7UI90'^2KEQ?/0QBT ,M /22<=
M(WD?:#L":G3(&< ()L:^R\#'<?Y&-??,N">\KD'(\74QUM*(RDV>D=;9 @='
M1CV8>IFT8:4M^UCZYQ!Z*Z<[^T[N7'/+MC"@7\9Z">PR%UB/@ 8:,FTO)ZTC
MJ BMS"0D<I,]$2N*]C$KJ?(*DHI,;NRT^^[., +PCMG1^5%LP;#BV77I$.6V
MCG'NGI+\EAN>(U!F63SO$:/!F.$(*'"]Q,3!OQRY)\NP5(PX \::?O4,U4R+
M[.="K.?L^WOC/3(SC^P*69L0!P8R>5/\QEN;XO7<$N+[],B!DP/_P8M(=X47
MH*P'!^4=5YF6W?!W?3@6GBS\Q-E+L*Z3.9).*V-$DC>O4N0NYE#&(?%LP:+/
MB#;;E0UW07SB^?;I"/,)=9W.^:9LG88*#T^!^4.03OWXZ$]AONV1OT9-%#Z\
M8S_T+!@;"46'OJ(&_5.48U$*Y4EXF^7^&ZV01+D3Q97Y=9RA2_FJ@/JMRK$2
M>\<'T(\=9QZ8;/7=SDO_B3WS@/U0X.+[P!4#+Z%N'X2/(B[+1%Q;Q*GM5NA$
MMER"K.6^'8G8?:5$QDO2L<9!Z&TRNPG;\Q_\6#B.!S,+%393_]IT?PZ<3N+?
M5&)>2/Y?C&4_6#C"JD,WK'+H\;%O:(4P:K[^V?/Y%XK]-"[P_*81UI4Y0@]G
MJFO-U#&#<F<SKML5%;%-@$R"9V]QS%MCB B027Z$P9\OVCKNB^]MRUW(['DA
M_<Q0$#Y$Q&)BY)BH#F2<"9^'](611JT..W&AHA#XK6Z_5VRA(ZI[/Z_R)))[
M\>9VEVQLP&2.$:VN!2;>,ITM=#%=TL\5?6/RM/W>M+Y&]_*E=P\G"E#S0/*M
MZ-9!V^_W"9OM',&]@S@H[3I;HOV@FJ,00/('\,RMZPE+W>(SK'VDB1KCGU'!
MG?0OWI,F$MC3A,U-$_,+!W12@L[2\:&CSSI9)2%+'[!L40$6G+&T&;,?R)8#
MM)>#&I#4Z+Q-EWXY'2)N6$)J*X$M6.*)XFHG\BDK$<MF+C._;@3"C:OZLB7O
MZ>SO#RVX!+5'HXH/05<(.(P@4$@7?MP%9?!M;-'! FQ=(*L:9<I69.Q3]H9K
M?LF!&?H+YDV9F@1?1*&';2@RFG9PQ.8[7L \.("5O;=2^T+SW/[1L'*VXS<?
MNCJC\0'VQ$_V/:WUCNL,%.?\AZI]5V_&Z_/,=V3JUUL5UF*J1F),5.!L!WFV
MW\D[OKL7I^CJH^H(A>]=NG_FDFX8_'0]8+7\C4MYTW6&Q^"6<Z,BR2/GXM+1
M3H'AZW:GG,IIH6?NSX*#5":RE:6-.GZMQ3^=AG%IX@H0Q$K(68[9BLM=W")C
M^3'&J#)J?'9S$"1?.$D7S -X].AC5"?O^/K'UVR:^!)0B?][5S"WN+A'-B=.
MWKD#N0A-@@$0'+N83-\Z2%XZCMWQ0#TDU<(!Q9D-CV7D+)05,F5V C@$]6.D
MF(ND<K0#TP67T4X+(*(:EQ%T687>/;3SB_3 ^>F=K3MY5UIRHTR:DK/I\K6C
M'<(]?]I)X=BB$W0^MA)8@D3]]Q#$*$ 9<T[]A60D]I(8L3%X#^X:D3?A=QE;
M7(E,C"G:P,Z2_/>Q>P_-YE9C<"L+:^BLW\ICNSK4$7'FLGX/5;O2Z8%ZB&,R
MK4#J@S_L-*FI?O;-T-\EL2MQQ>L.-:]APE[M3C[6Z8:&YH-OSMCOX3+<(L69
MRK&O_2"R+V^5Y7MKJT-/,86.B)*)+_]A "=_U&KG!KZ-MS9$JXT5/7I0X5Q\
MRQ<Q_!X_)(N%0QE7"=SGOW)01+KS^2I=8D#X\>()X/GR]2X=X#MY#$BD\%<2
M]P+:0E*I"ZFR!M*FUN-@^?F8*S^O#V21(BAY;]+^8L>Y[')]S+$U[* 9$;IO
M $D&[^%0QTBEG"S#)D0FRI7YVLSWE:_KZ Y.N62GNEDRJ9L>DV6-FC'"+ DX
M9,']]<^VDO.R;U=^FP./+%F\:= 8[K#:*PW*X1HAR!XI=VJOR?LI>?D^9UKL
MHK68:892OC5F_(3#"AZB$Y6?VV[:0+-DBTBS1(!0IC_=I<\627N8RI2'2*#B
M(X1YV$;,AP4S)$$SL:_@.=8SVW^_<D3;.KOJF+K#TV]SFB?6.6J>5L&;*^_J
MQ\.'-3:1R BO,E;YGP:O& JTT9_LB>WE2 (7&,M4*&[)KA7)R[8"KE)K)'HD
MS&1GIM5G/8.\9!G51N+)]$V1U>NTJ5\Q7I_+"GIM"!OY-N93[@O.1$X4E+H,
M3L6*XC9SJ$L)EX M"HN+^1T7&+@>.2UN+CQ5)P95R0K8,D.J" !ALTLIHW^8
MFA$<-6,U413GW+:]5?VV,4'ZPB:=5Y@EN*\/9+HP<1M,AD3?WL&GMH1..B&6
MJ\(ZK&J6/AF^B/X,O\TPBZ]8=PF[_C^(QO#*Y,3U+T=&-BAA\ &9?]@W:6;2
MC)F^D[#DUZM0<)]!I"-O?%GJ@(.;^<FF!"%7*>VP/AO^5Y:B"3EL%8>*)R76
M-;Y.=["-7DI$!-;U?N6?R]SB*&"ABQRY+[/J$H(S-_OO*,?W3$;5W.MMNN 3
M=/FJH(S=,:[&<YFL)$L[U!C999*K3Y#'B\!Q)%\2H."_H<NU%@)6C-TD,T&4
MQ/)21OH;RSZ\2)<VRN8ZLZ:_O?(ELG&X"'"A(&I00;U&-V!JY-)O;:;/.U+&
M-$A$8DR00X:M'?*#,*!AR3[MP8IA(#<VZ>#Y/!8"B"EAJS(M>UM_Y9' @'XO
M"+%XD@E[LN/I):MT"'(F,I;%&\;8YK2J36>RO=LOYXGJ$+:I$(%W-3\Z^EB6
M1O.J!!F.X_(VVIRK^C\RFI--+)G2?;D_JO@VJPCH\XUY-Z=#OB20:7U;E$Z/
M;D'JL-E[SWOW3 S!">?%!8K=/:[>7=5M1>4RB#V<3BRU9#I[E\2 +2U(2;_*
M#IA@10'Y#\L_\_8E)B )-8K@S<L1R)/O.9^"WLQ,KQ+1UHSF/K!@F,D,168F
M^9()0AVG-UQAW:67?21<VV3D[ V,K8G8;<\;F@K\,&'G6>LZ\C^T*PYQY'\8
M.$%KRZ&5EVPH4YF,/?5@H_G)@T4PF?%BY$%';74 =7W9!ZXQ5)+2O?JQWY'L
M2/G89]=I3*\8Z=*,>'F7ZYT<*$XIG+^QU"SN5#U& 17]@:%1_N^Y784T?-R2
MX*\AR!FV.U,HXV-IQ][#P@C3@C@:3- J A'C&TP7/K/H[E6MO\MJ<$<\LLBI
M"<28[WPN*7@=<Q ?^.<HVFDUE@%C]&GX*!=MN=9+^"ABC[U)(PE]QS?J-L>R
M;:I198Y-S1(2?;I;J0Z!NY'-E1D-2Z-(';TFI1_SGYU'I%/5_-BR7'T>R#%C
M0QG"_4@<GL?$J7+VZZ(:L%:(-IWBR+Y'?PMI8U4P.CNB-1MHT59+*SG.;>,F
M?GO3^7<_U)C6QE>]BOQ0(<JIXUIGKMNBYN EL=1_<T>[X:)H*2;IR2_I0U "
M V@@8\Z/=9U;-_KQN@3K@WJ[=6U2@2F4'%KXU>O<"UOKD6!Y&T\;N]R13^OB
MXXA1WHU@[_..,<ATM'G>:I>A S5#??G>\F,3L\(<6I7WI=\QM^TD!)/2;V>X
MSN"JRP<O]DW6Y%?^OA8TXX3P+DH,K^C/AP49HDE/)85<LE&ZCFDH_[B?!0;+
ME;-L<QEG 5D;X63*S2P3NH%N[-OO%HZ]$T4OC0RKR\?"U^\H>CI57)BX523\
MCH"EOEQBV)GZK0<[P.; 5,YWUKZ5D5=.=,DWBC6/FMMLP%Y^P>N@D,&KEK)9
MC7JTZY?^/49Z!@$TMGIQ<SCJUJ8'%7R",Y@+(0_S=+N 029JU4 <# BN6?C>
M=I%9LT2!I.@U-P1*B._55C?M4;KDZADS>0A%BH.@:?@"[IQ/2X8;M@E\%LCA
M<E\]82,LK!*U3V&Y%$@"?S&4;3XBB5Q;_%]3*KV*< PP&B4_<NI@6ND0]*J6
M;;W&!^P:)NYDT]</04Y3U+JF?7,*,_$0I WC!1R=F6MI:&5J\!%P8U"7-E,O
MCF8K?E([:KXYB6CC";9+/"$ UOKY\TQO[,!#D%(;)B7<(--XI 6?JHW1H=_&
M"C,ZG%WBR'ZN&P.B67Y8SZ*T_'NWEM/Z1PJD2MT2R/\PY09F;[U1P"7J?'M0
MB\$6]X6 W__,D*&E$9ZBHGD+0L\7^*00<JB,L^@AC;V2V^=5:,OJ2D*B%,</
MH6+,<%-"4YEDQYG?WHZO?V(CP74F]IP^/,-< TS/FD3XU"*60)P+F+$P&_GJ
MX(H@+T@34R*-S7?6&22Y%>[&%BMRWU+TBWB<?0L-V8[D&H'3+ZQ(U%(\OV_6
MHILO ]?/K_C"PO^%%9@VD#3W^7.R?^0=M]?)?G>LSN=RDK@;MZ5+;1SK#P,4
M*]G2# K)NX&97<^(IDHDT-.J(T6 R-[0/GI[TK@.5+&C0 X(W+.E\0R*!,I_
M>C8C$L?^\S*5A[2B!#Y.VK #.@]!E0L4IPG:BM'K@3CX==*I>I&7H3*A\/1+
M.I^FBAD&)@3IY,+!O2L%ROH#WLN\Q::)JN^L-$-,*DY6]>% P.FG1:HRTC9Q
M7V_98];[Z=LFXG*=XXL1%W]["764[N";;)L6H*58 !*3OUC(?= E(-G;.R@T
M)B:&*4K=S,_*>G/ZT^?/G_]T%KV>,#\]/2\65:NIJ12><ES>,MO-TR?=[17/
M]AI;-(QS',M0INUV:QA3H$VPWG0^NC_7*"6E^M!-7<@%BCDW,V& 8[%N>U,F
MM=T@_/O^=3_FZ:L/9C!:DV>'SDX5F)[N*VGX..$P!<5T6-&$3Z+Z->2$SWQU
M#R$A_T6E6C!#<,A*#\7/G8G):.-P2*-@B'14Y)4(08F;KCNRFE$B\P/VL3,W
MFWYN:6B4I5))@.IJR;Y5P%(=H7_3@W6[?5\8%[YYTA/(WH)EK'1X!C/:=/,X
MXK(SC_V:GIOUT1=,3W9NN"S<[6SZN+DS\%$<>@;K_>DR^W-/U]_,\RUP!49F
MPG9B;ZK9LDOZ!R#S^U2=H'J_H3/\"=E&(OYE$.VB06 +@LZ<>/J2J85ZY%)F
MD>6;Q'E"'^&E[5!>CZ;(7,[25(I2/JXNY\D5DPY%Z;94Q=<^]:]>T>I5;X6Z
M?C(WN7:_Q<!.\VQXE1/1>@IA!/ZOF2TNT0^M&\ED.B^P, >I9GQL4\8;L(!N
MWB10R(SL?;>^;46'2Y!/[L6,/C$QV@Z2>!0\D,"^I/XB/=(Y**ITR@1V9![A
M,(]H.S^#D3^8^'.V%-LC< CR)X&X3@+>)SP_T<W5-.(<'6#H6B-3;"D6;1,1
MJ<R=7Z*X^W"'2RXR$9>P.?Q23IYIGO_TOP+%+J9 8*YG;=5YEI0<7@KQOGH=
M2VF[[G#M9?RSHNIX7\^O*ZYZYQW)52*)CKM/_MXA[ @"VDPL;6L3R]4/T70D
M&2:2C%9@(KMS;EIBB^U(\YBSDT1;O1@UK[':6\%!8!' TCEZ6(LU?S,=63ZK
M?0'E?@&^E_A-+)5.$F";437%:;5_TPU67GUR]HFG>ZG5X 9F1D)1;3IU$>4.
M%#^[#J;!HZB7]9*E:NNWU";BBAYGG$YU#72Z,/I[H/LVY"2 &S )IKRY_/SN
MZ0_W4?>.*2>VW,D6X+6\T$NKG.RSKW%.\"H?$'8OA4M)ADA_CR@?L:]*SU:M
MW.MS#TM\WR5RD$6B/E]J?&,FSQ@E0V*7ZA,I;ABYP$O?,.K-@ UM-/'4]P(I
MTK[Y3K$XY]PD!JR8T'K:\S8B-\7#JGS1M.DM*Q)V-$?>4 :]LG^?F]PF)&HN
M]AC6%S*OW>=,.H(Y@39C;B9V"Z<_&B6;7CD$N;6,[;Q&!W$Y<[JVPU0_06,'
M+J(0F-N7D^0_9C: "$)&*JQ+N,>TQEIITE*\]#G\_-S$S0=&]T%L+V"!"::/
M4L!'@(R!/B\Q'&TM-IQTQ"MH)JCRVP5ZM.<CN!B0*^AO,48?(_(F6D[4_!I6
M&@\.+90J?9>Y+E)]2G=W%<*6(3&C>Q;5@;5]$_;?'XFR:O9,:"_L*+#DP7SG
M:I<CD:LQ0UDX!!T?*OQJ]#[MW3S<LAAEJ#M[3U$M0@Y/ES9>2P_>D7;)_.DE
M-'CI]TRZF__1^_!4&7C!_:SC$R/UDILG,0%?6_[Y.>OG6FF0ICQS_Y>B=9>/
ME*&3];CUQ6Q-G;431,2@]L'5E.T;0O8T(9]^&4\:[L273_;N3EJYDAIH(??*
M;?HVOR_PJ/$2U)'@I1M E;T]>";SP<O[[][X6K]95L%J.^TW<(,B<I#;Q8N9
MP#?"^N$GT-$ @K:5S)%E_)$7=%EI*Z;4(K$67X/M#:,%Z^];_.4;Z:^,9TDO
M5-UK;XL*([UO/XH1=?F5Q75*P]CW4VC,(:@A!KI7WR$)7R@P]@EMC7SZ!ID^
MQ$15'],7SAHK $O$4IQZZ>6VJV<-6L<H-_.-&HN7+Y@/BJ:&9KHT!'!,&'"^
MIP- 4<^LR4,)X?1>EP^55[HD)*YD*PNZ"_"DODAW%RLR<I(O.?O>(C3HM7)0
M\:,EM@29=?X@"^H'F]NE$M(P1]AG&'BR\.D@TME5QG1])2J8&)YI_W&% 4LB
M6M2U)6P[MA.?BQ^";C2TI#CRX04LOIVID-DN[JK@!L/H(.X0=!<R;\S2F#0[
MA[X/"%()R7(ZJ<NPC Y3<!+Z?[E5\-+4TJ]=@BWU$T\:)FO._=0HFX2<3XOR
MV+UMU?I?MUS9(8A/&_N^&@WB1N(Q\L#%ZQ+A+E?RA9%6P.[X@S<2%-R!90</
M_+_9D0MTU,&9!V^^A<JA&Y*9G3=TMGWS5@6TLF5]PLZ7V\C5@]VSSA2);>2[
M"%BH9;_WV,OD(Z.-.)ENI3=_GLQ:N4E=1R7YXE2[.[IT.14Y4*2,:.%.P'1'
M\<';XK(H_>$JTT0:DGUJFW4:P#*Q=,L^["FTW@1&81X@4 3* 6%:3O*F'S8!
M+J #W=@W\!L+7Q+H*HP,I@]5U9A#"(J3':[S\26=U2QG=[_4LE'_B/+ F+5-
M0VZ,H@\2#D$!T 2. J/K"4.--M #D_Z$<(#$<<ZAY1G9J50NA@H'-7VL'_]!
M%%0CB[MC4NFRBFO\QXBEZVW!'W+:T#E@G[:)'?-WDUP:SR< !C/T 4KK(>@>
M=_^I(&50S\VD49'4W5BV4S%*?NE62R-CA9!,K(GL2RT'8FVUIFC-'=/^MFJP
M%%/KG9"0S7\:4P2L_GFJ!?YNR3K/M&M=QLY.L.R8N.0=@1HXI4#E(*_K^/>N
MOZ>V2J-3/WMX3'%'#]QVFH(H/\O)W;+ORHX>>BV3'57ZT._\"PQ/FC<]4> ^
M/E%.E=YA.WH)6%2,5XSM<>SS^5I=)AQ+MJ]Z7&;8X=&[/*T@;,6-PEC!D70C
MXN]%I:BT>MTJ:#/-"@BEO+$?6)3R[C!^7^=J)I=OY7,IZ^*L*D&'D$9Q*LFH
M.*NN2J'FGY@ZW3V5H%?];>S++84GZ2=T7'YGH89Z'ZT][H#3"4> @DE7(+,'
M<W[&1)DN+2)_0WUG5"@PTMVL)E#QBH,]$NL?>OPYOR5_J]51YZ.G8!$F>M,?
MAT+#0M7O>RST2 ^;;'^@&Q0FJ)"MU-_]-_B\/V7D1\\M\;]=9N",FT$>T9"%
M=M90,S'9^PDT$)PQ\OSOWG-Y=/]DO_NI8RX?GJ>\I=T\57GD,9\'=['[& 7Q
MRW! !;R!HQV"3ELBS9X=@J38BE7#R,AAXM1,0LAYIEX.0@N<'?!CQU9^\-/"
M?U)J>/V-GU5]"MR$LBZAP%VHS7TMN3(<<OR2B O9(<2$,W2!,U%U)0_]P^33
MN[)CO^?;2/KP[<]WS992<T[>K'F_V?+\KDZHV+W?,:7^!W@[XK56QY4.?^,'
M9?[-L&\V''[N1([R I>I>#[ AX[?+"D98FK3,>TE[NO+U,]]PR-XJG"B;8S4
MJ% ._7*IY^689:28:_=8:66.?C9'=&*KI'-"85QWJ][]^S;G'2KS_XY'8YJ6
MS,1&P.9@K+O$/-A$P1YKE+S(PXB,8SOYEEXOE+9OFV(K(]^B:N<7>!^NBP8>
M+_^B94=(('@=-&!44$74LHV<_>MH=X8US[)P(IZ7(X^J(I_N$(@0R^XL!OSM
M6\=W;%+]>V^[?Y-(%2J+X,E_L>!NG?ZSGK"MT0H\66X?/1-4H-_&+$OY8>)+
M]Y\N9H)3%9E"U9SS,WC*\]N7Z:+507Y;^S8.G,^Q/]8%__&Z_4%71=,_@6$K
M,ZZ&Y45%DKN4#N1#3:SZYG#)<X23 ZH##KTKP+W6Y9*$HN0:_CO.8+XG/:NO
M@]7;^9^2!U^*RVMVJ8D:9424.%2K3E4<$ =:=Q,Q/-X -KY.3F;ES95M$]G;
M%E 1G*MN4DUBD0'M,]I+6RS'3^P24.WDZQSR-.NDGMRI+T52X65V^= .D^!]
M-?;%@[=0:J%[\P97(1W]W3:#-F<L4,ST<L@<8:9R&E%G*KS3&#967; ]4*"&
M\VALM&D?3>#(!&D$;I';TM<7O[=-/_$IJ\,[31%MG%HYW5R#/0K(#VQ<V-<!
M-*<7^K$GV1K[EU%T8Y\P.BZ))!TN"Z$\E' \'Z3XW[B)<)7LU9ZNLQ\W7RN^
M&!=OF"2B-C^55M%-7?LS(30\6UJ7%BQZ\Z"$F[$0B45+I&8G#1^;^Q#W]C=)
MA^$&E/6WW=H;'JZ4J6PY!#T-LR5F4_]2#_5L/-&K5C%U"+(E49=)*6;:#.B&
M-Q5Z#( [DL9U\"E+DHTD(6 QFG^MB3/-6$REP451*5!!K_<GDU<1>]G-OB6!
M+GKC?#;X#9V,_WEK%>.=Z#]B^KDXER*C3+6XVM?:!,O^V/,%=7+4.%N>P"I%
MIA$>NWZR0^3>N3_1Z]S?ACK>6WS_8DTBF5[_H_&[E:%]MO0J6N,]ZJH"8SF9
M'3@"P-6&PT[,=BQ+YMQE%L+VC55[[0=B8,(YOK/H:Y=NW<=,2%^XO.QKT8DV
MXW=(5PR8SE#8P/[?B["4\9M@:GN[&O@)YB_ IR)0S^$];32)])?.,)CVH[#X
MT\B_/97N<RCGQ:6>+H7'8F1W5.*5:?6[R2MZWX/#[[0G GX'S8<@GZ4D>-W:
M)A\=_P1Z2BG12?QB#UWX*- VPA/DO8S_*W!&XME7.15B8Y3_BU[$8N_^C6F=
M5N46(^?.TL"V<)=(UO3'0 GL.(DMK<BT[,?\#?CNV[,5IW6-]P]!O&P]IG[O
MUAF4ULB/J!\:C6I+R>*D4U2F;<(;I:SQP<&?V*,(=\*LQFEC[PK/];:XLGFB
M=+(?#4I=&SW^E3[!@C(W0MVO$HBC_=#CBS?J_^V:; Q/I?UH*#57;T>_U]"Q
MF=/UC]5:.)='D5"O:GNH6_:TP[P?(X/ZELZ F]+O(<6^O$KTRI 6P55X-=81
M%__7D@GII_UY9_3]G\ZNT[.W_8X5*)6*N1!49UY^4WTW2F''/6W9[TD#I[[6
M%Z("_@;D2MWZ,Q=UOCID*.%82WNDC-X[)5<2Q+.U9^F$Y%Z?P)L)BF-O*]PO
M57ZS_$6B(MFG,UF\0.J^.EMN*@(YUTQCFUUDSG0+)\XGE"R?I4T73]&9$*XJ
M0TCH%RB:2TW>-'N;6_(K]VVY*SWHV3$1(;XBS@<LPQ(VZ\@*9\AET89=J/@G
M9D9 7[""F0J0SJSJ-5+.V &?"JRN8>7E0\E="G&NC*6GORB1 8V;:E?K,US5
MEYNE"DJJUZW,JL)8\(V<0Y!2U;XV=JZ++7D(F@JCM7'4S 396. ]'0YHNCQ%
MP^C(I$7UF1T<< ]VFJV:L&P_'5*<PG7@6QD[!!XPG^M<54TZ+E&>L5SR\I%I
M2:/XWV39@4Q6X=K,%[3B4Z8R)0I5\I@,9.)7HN "M&VY<Q1OM57) BVW]'N"
M-T;7)2.,4J4M2D7Y%2T:@W3=PR\,>U=V'%,MD;+#K=^&I7#5Z6,?6I,6*7%.
MR?=UJ,8]TKG"E*(G0W7/N^W[KVJZ?HJY;B+K>J?>/B*@S6HL_M'SO3[%#/*5
M&G.//=&#:A(U#EZ_M2E,A_*@<FBU.7P;HU$EP(MI6-)#^(E?QL;!//T<?I'K
MR/!T[=YQF'"B"9A>DJ^18\VTRRSM3.\078<N8*29,@-V,= -PG&N4-:$4@L6
M3S+NFO%.D.YB8]UK<P2+'SX([-)D..<L0R4_;4@&Y>%D46\U7/KH/UW\GJ_%
MN3\N])81.,E_QNKK(:@9F\YV8\RP( <5)C%4VP>[9#,M1F(W(=EH-P%]M;01
M4?XU=QI/B[&(%K3KM?+).M?1D.\<C6!)Q-ZU*E*35Q!>U>8(U@'/E_.1K,*#
MDD;!R#YW3JLW?33N([!+47";VB):12 E KI,&-.9"+K@E:!O/Y3:IX834W2#
MHHC\Q=$5=/S=\>OBIF\,Y9G&:6P5NI<J@>X5=56%L4@\@9)Y36?^I"ROT[][
M5SIGH0<S(,)NEKR6(I+_**9&I54\&.5/2#CVM'4I)!0BU&))692CY9K)?=EI
M@)^ZX%R@K>=Z[\Q]0!7E[IH2[F,)J4H@6 -MC>?KZWNKCP:&68HE96LU1BG\
M/ 2Q)7@X_.^Y*\M2 ?*IPDE+/.'[G1+4I?X^YIFKO2X2/]>=%WF82XG%[]HF
MP]/%5YEX>_C)[X^<:Q#E =DN,T;I_?A(;X)[S<:C!]^<G0]!DUBV2#O''K^O
M@IW-I^,.W,QT"2-;@.&+\<]__KM]G#-\.J\*.R^E=MT/BC&.7DK@&.:N*AZ"
M_!#J&K*=5)CU@<@A*%8?.ZC]Y^?[HAWVAZ JY7[BCIQ\J 6R#V\!%6I0WY;P
MN/B!P8Y('E);9FIGW;#3+.#AH=RJ(X:*W?WTW25#;*S(H7&APOU6OON[?+>1
M![\+>&@?" EFS]'1.5]FW5UENIIY/WY _%/'2#<Q$R_5ER;OA.HP?M%?(NRS
ME>>GRBSX'8ND4K(,^M^<.[NG5\0EUK6#I AXFI<),,<$4\N>F%U WP):Z4XS
M$9Z.])V"_.54YY9W8^$'JC.6W 1G7SZS>)8X\6M3WR;%_'JX3;J#,R)$5]!B
MX[R<93>684\ Y%TV:,P&&CBEPW]?FZW-V.J!9W $/Q+3L60C*#E8:N(R(Y)2
M$3[$#U%@Z!&HF]"-7*'\\B"->_<:A4\%9+=Y3A741 H$@>?;'@;3.$@H]1W^
M-.?<*!?!#8'-:.5TMA.+E&"FPO#%D5-?SA!52AFRM7G4+?[OTQ<!L^NU]AT&
M&L2%]IH0I7';HO0[J\N.ZLBR[(><'<P1%.$V<ZF;%,LQ8!IM,B%I7:)H0R8\
MZ=:U9\$S)N;4 VF7J9=7Y102)79S> 8OOX.VD%3$OC#-^"A(OG>X$^PK/4!R
M[FHFW:2*-Z4HRZDJ(T% H_?CT(-/SJ**%0DU. JM0:9^!2CW5K:EW7_YM4V\
MQ-S0H0(V3?N ! $UN:C,[I9:GB&MV;N2V1!A%ZTR&SX3/^\D N[#Q9;JQ;,I
M!NIF"G^].H@65+^AJFZG5.+KOA-D?.LI%Y=(@$).#S0!+@=%$A+! F:Z*+ -
M<R96%R+(MFN9YLKYLS^F!Z,W1;OG5PO+.C\\W)Z_73PME5ZM_?9WN7/ X^?7
M>8-VJS@"&G^:1!VDF1W!])!$S%30,@=XM"AC?V!>(A4CM?#-2^FCM$<"9WK)
MC5F:5;3^<,5_JE:C+';;KK,U]GKMW]D7W93-;9*\LZ&C.$!I]\\Q#WXN4*$Y
M*@#<.CS3AK'6#UZ 7IW(O?1T7SQ+F9(G[02ZKW?UR+F%EX/Y:>^)N!\XML0H
MQ[Z0B>0,0)]R#?VO$P>1E%K-T<"8<^QS13G^;B/PS#64)JC_CM8;/?_TPL>$
MDZ-)ET8:+[D:.570OK<URJBXL!KAQ++CO8@^%<(@VY2&SI7C 2I<P"]7##9F
ME/N97:+"N7>T-F31P9*^O^5XYFP$4ZNL2QZIYD>H3L9D.6VL6XT(6K5"^_&
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M^7S9("]Q]^_CS[&'"PH'-.H_U+VZ^"X?>8BH[VGQJSL_@K>$I0$CU4%J3-K
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M :+H.X62VNZ7=<-\MO)-N'AOJ'-EN8^=,A9<M T.N/52P?6;[!CYL'E'ZUG
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M.W\W^##[\WLX[,V@%,?K/-C;! F&*_"8?A@2<Q;0;W/A_;KE>SV$M!;A,?8
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M>KA5"GWJR: B7:LHUK.50#?.^S-DYRO>$[O2HJD)_08>5N[,61-X[MZB96M
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ME+JD))5OOPR^Y_H45@QT9^QFDPSKR[K4>8562^%*_;_Q0]II>U,/3>9=!&!
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MB9+S7*_<'A6 2T@:NJF%"<22 ;/CMQ1N%/I[=W6H&0Q?=V*>FH"1,B$TLS5
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MB5\>W3B-@I?^FLQQD=?ION-[JU6M7CI)[VS^TX*X(I="$Y%50CQRRE*!Q"3
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MM @AH""]"2@AB4J7'4K<0$AN]-QO?.^]W_US?R1C,[('<ZTUY_/,9^ZQ]II
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MJ_[@!/4^%-1$\<A$KC#+O<X"J *(TR(M9QES!P4X$W[WS-L >EI((OA=/+P
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MGZR/0PTG2[].KS_R<-VAXO4]]V/\EOBCYNB1W^_WC\ZY;I;^;CD?CX!4(V1
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M D7%S"X1&I>%RO2R:#7^65(<6'=Y_]5T_OI7EZ!3"7?N@\3V"6G.U3/I-"V
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MD([$1N\"4@1B^8 /$9 N-2+2I0E(@)"H]/Y)500B(D0($)&F$(@0RJ<(2%=
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M*;0@!#.!NN#E6'!$RN'.5N.:[@WQ$[](!C5WA.N>1IRNEV/W^^'&6)_$,"+
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M,OLG<T.8,LOG2#V7E$#K\ E(5HA1O7_O[3?^U<A5H'3Q0<#)>KF,R$ZB-[X
M3\\*G<1L9('AQSYF#U+V5E81;&5WWI2-STK)8U:A.QYR( ORT 8=UA,V#P>R
M_ \0Z7Z:JL0^4<F(9O?#N DZ5/@<IA<-7&N70!CO5!H8DHD *.@HTI15PCX[
MT0@36N%EU5%FDZ+IQ$AZ?]CM47Q=;-5T&KJ!53AZU8='A(:LI,W.#W:C)STI
M2<DH3680#<Z4)0H2'$72^(@4JU48+Q"\1D/$7!\AZ)3AZ;#XAEBN*XT,Z;37
M2W27ZH96[_<,V*1J^NZ#08,T$OJH;ED<TVM^5D#3 '45?H%2T W[#KCR*6G@
M"JW9TQ17OK#X_04>$\>$3ELZPE7[!B++([/KP5VI\^93M@]P0EE,%W*[(K7@
MR7M^U0Z?\+!,25>=G55+'=Y'V/PQ=B]YU=LV=;_<7SS_O+#MY-W0D\7\@7&E
M_5=OV!OF_579]V_ ?A'HUGOM%UE)O<0&XBH'$A.12Y-+,%"@A9&:,AD.DEG'
MEM\!U[NS#F8?SH%WS/,?>V[GU:5_)>*(R#5BW^D8].HNXV^D'RL/=7Z2Z0QP
MS?L1#M .#IJ-A<M'_-Z&\0 9?#DUG?\L/]21T$G;=D-?;4TDWTT9_;$4UD:@
M=D3<ITZ33E7N$U,)HK9=JA"*D2!IM'.HQ_N9LYH:/CWOML<;;S%E=^CIN.+H
M7'F*TLBK%7*I9</OKSAKZ^*_*D=;XXD7J8-IE50UJ7M2UNXELDU"JEUCMY?%
MC"T1J=^DW$7:N45/:*W8EYJ4VYL**.:6.C3*Z[^-BSCKI<N!O.'#JB42!"J
MWIZ".A>_AT\GW8#Z[LE7+P6MN)*VQ51^$5L>//C5=WVH9L[X\ZMN?_5#6IFS
M@QP(4[*?8>(/ET!)L[_I0Y.#;LZ<3:-GCAKI3'=K59B]3)H?*_\Q-BT@<J:-
M$,V!/-[!-7L=3BLV<?PGRT@#/H#.0,_5HZDV^&04+RWXD8$;XX9Y)6#5:R0^
M08!28B_QQV,.AJ<T\O,C7IBW#$7@Q!H#1<F)Q=5+V3^6FILOT98E+$L]*[]K
M/?G5N3FYK%MA5<"!>*M-Z=#S61F-&.$ #J0^N.L#2G*Y_=*(%@O:+91U B'9
M_75Y$I47H;U>?"H?A :#*:LJY0T?WK]'U*[6!.(/6FG)AO&\,YG]O,<UY)(:
M8@2E[?+_^H#GN:M;D(RC-MZ,$[\N^<*A[^VI31XO_V_)GDKCGWPI2[$!W"FX
MQ/@0X.;-NY5?6^/MGK*4BEDR[X/%>PT$2KP^! M\)3,3LP1M!ZAY;Y^[*:,N
M1<T(9B@*=@Z5OQ@CV>VWR_&;"^@Y=GLLJ$:/V^18<""O^7N#I7_#ZY-6-VAX
M2F-Q>4DQEGD1B*+!*'>=7AUI;IE0"6=%=F]VU6DH[NKOIOB$G!-SPD?PJPA?
MK\K:$J4:+HR7TM0Z=G<G!'_,S  KI-V" MM6,\/^L0&BGW9WU["&RH7Z&QL7
M,KOJ6S4%S;1W^7M@@)(C\Q1T?I=D)8*$ O6,JWV4K"247EWS"-*6#*#$D&+4
MD>4FD9:,DDIA7("[$!!1BG@R(-OVMC$@863'Q:KQXSLG-_'J6M7 !29U9&-]
MNY6A8MGI&1R+=9N"?W<]8JKN-GFS0&3D<)Z[CH:%A*Z3P% J>2SW'[0KE;NC
M>J.34):F0./3D>M==#5+(VDG?PX56W60UE46$2&$T/#PTP4+.RQ"'6+U_G*/
MEN+UG.]6DP,/<L_N!6?,J-QCRW@3-&S/=?QZKUR61/V6]K5?_@YU;"&]F^)[
MH[7,_$AFKS5=@W3G;0A6P2'^ ZLZMNA.F1X'4C71A=Z3*P&Q?YUF-W3?LQV_
M-0PB4[T_#*/#"I#O75V@8$270WZSQ28BB(+(RZ,[DAFXX, (FF1'^QDJ.M']
M5^2YR^8PX*9V,#_WU/?G9^K?Z8CJ")H>?J"_K5_ %%EAGT#CEB;V'4H9%JQ7
M)-MW+2,;-1P(V9P]&!I%CWQK%AC&_X*K$U&1UI_H:'51_'R>3E#&T$>//<OC
MAT_^?>;),=TSF5<//SAF\$3?\?'<[*,_3QRIS2D&:MW?\\V22WNC@J!*Y? S
M79ZTL,ZA_<2()UWC5?4\]<K6./XU??N0SYC&]')+U-!(0U3;H @RY),N*<7
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MV&?[,NO1C+^6WKSYC!YV9$IJ<R!R]C0&NQ_,P>4>JA?J,?K_>,]H[R_6<V(
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M.F^%XFU5G"*<AVJ+]<'*55_Y:T.U1+%8?ZL69^R0M?QT_R^$N:-Z::]8"?=
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MX[-FZ<$@$W?0B5/:YF;S>7,@.;>! QR(#V1VOY;@"?\LM]K/<&-_Y4#J9M-
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ME<#2N.=-JF,B4J_LAV1@@-,HWGB,C@F+.ON!83 AZ$P*/GS[9\D)FJ7+/%8
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M\:7\:M_#5$7C_]#-$E16Y?"*FCQ;;9]="XH]<B%_=N*-M;&>'<:#R<Y]8>[
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M>JMAP"J\#_N1.*5$?\UZOAT822(>:-=%;) 3X_XLMVYLDR3I%X4L->^7?>_
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M4H,7??8J(LPI*:?N.&&#ZG6"&3ZVZ$XWM1@Q#F2#P<]Z'9#UJFRY ;8XR[:
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MZ;/X@64EV(Y0@O3>7S J'KH IJP[?.S;Q&F:\YCWUA\=P6YY$5-VB'U"J/K
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MKF__0,^52_R>0\H,9Z*7@PA@-O(Z60$*#DUEF/A":[U!9L8N$KW0'@9_]NC
M<'Y=01)29-OI@@H'XO$A#U1<<W^O'@$D]80Z+X:!;E:/"BQ@.V'>@.7IB,:$
M**A@M#64KNL.IJ4-/Z!0^UX=1KZUI O=T9WQ^;.;VA*\P,X.W:4[1]P7M 5#
M91JLP"]@-3%O"U(,?!N<IEFH\GPV=!6$1:2-AZAR<-HKKI88KFU\;X\C"L0
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MY_G6ZE'CS<5[0,[U$:]O$YK2R1H/2 T#XI2#OGML<MF[=SM ]G@,ER/Z@A+
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M)E%&JA@3R[B46Z$W +^^H_QZE/]YF^]=V1ABU,$TU2M!,C_W4RSB^;\;SA2
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M^?#%!U]?750M:>L*S&GZ6*XG!68:@/DL>1$JY.%RD-5WN-X^LH+X=7+DJP_
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M7G2PUXWJXV5;?2?ZU>6]-)F4PIJ^)'Z$T[R@98WW97T!^>>P[ W4A9C;WHI
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M"=71*XH8](-44[51,;7%]Q.A(>=;J@XY?XNTF1'56"T#V65%+>L'1GNCW<-
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MYL'GP.Q5&1C1JDB.=WJU=+$YBTJ.RG2,2@X^),<H]%<KM\N1=8UR!+(#A^3
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M,8S&2;5-_\AJ60"M2UWCK8[#;W$UF-@"!= TI0W#*,Q@DGPJ<,94X ZD"ZC
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M4MP!%JB-[)4CJ)T4N(WW"),:X&"<"T;9UHRE^XO5 )Y!BAE=E3,"Y7?K+$X
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M-7\#@N4C(S[,82,]S4/F6P,_OOBO1IS6-; +WKFE.W-X(D*7EAQEZIZ97!V
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MR[HJ=!"@Y-4X0$&\2 PGCOBP@4?LYR2"G&I5,2IH%Y\Z63\D\2<R*8*MOFL
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MT)X[OWKC(/G_V:R*>58K23T*],E]H+[+717@]^^&\AMAJ%]LT/U&P9_ !C=
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ME!TWZ8&IN9VC];_Y-1J(U:P U Q^*00!+@ND=#U9J;)GB>-D$79-XQ0/$>%
M<W.NB/#!V7P )>1<3]0:>#0$G Q@?%H#^>*(]9HPXUF://X9G_]<@VGD67-E
MZW/@ZB@1C8).-91I(0!22L[D>8) V-*< P*AR>M=&\Z<4)_]DM1GYC&%UA^F
M$P>4;1C&]*)]R6W*1WL,R"V&_L ARD0VE0KGN=$I@C7(/%I_O<6OCZS1H]!C
M>0Y:])W(WDVKH6H B(J;H6JP?S^8A? I#FD&MBAA$X0TB,\Z;B ^HP(S72U\
MM5ZVE13V;6P26EDK6 N@YLEI %))(8[TK.%O,?S6%B."#DEZ][]E.%6>(?L
M5Y@1,!<D^X]Y(/5X715$V4,2Y+Y&.7-9\X# TD@@19X-4V0:IC(7"*]R5$_,
M^L&F=$"S4P6SB#W>E"GG8;7ER0$)36(F0)%*(86OQP@A\8X& ##U9*<"KV"_
M[;5;H] >C-N 31<1%*@I5Q)R35>?6$J:R!<1J'/E>>CS#:D"@UJGUZ?VGS;T
M!V^3N=3$$,YSHE.A)M#^^LI?'U5A'_#4%OCB::\7P T9D-I>Q%(_-W(5BH"S
M2G"W%1%^5X)G<6W_.&;D3X^$^8,^#%<X/'93X%/BT0K21)3E44@23L6W]\6]
M)PLB2&>1<2<H]0^9==68/*.45(=I4D4$.\H(+QMA9-E>!(?F3!R:-/Y\N W1
MLIS09DH"#K3H)F3)--K)!@N<#,;&CF>A(SW[-8+1A>;E-.#9:!S=)BIV3GQN
M4!7*U_I5/<DC/!HX*0D-1KHA0*L!^-Y&@"OT&2 ].%\JA7(WP(+^=;1M)<I.
M,P"1K;(64O#0)3 @COAP!+A:]4"XN@&X:H@(-V3A&:?7C0+@5H*,V4Y8!! K
M=!LT0>>A$1Z-I/Z0D70ESR4)U,T#$2Y *XW]3@!DU>)B-,*COCX8<1!>A(<L
MB#@OR(OBO9Z[4ZG\GD(]UT8HQHQUY#;8[I&_G+R0MQ($YN ,GG?D@ IIGC36
M8^?+,V8?<D<.4Z L,3WTNR@I$E$>- _L.=[[W#T'4]$'Q72EM$"[Y\:UN4GF
MW:EUE0@[+0!$_,H:7&H^G&HH-<^"I3P?=O5&MA#+8(H(D=A$SB.J2Q_I@>]^
M((\2?Y5M;P0##2XND0_;E939!I$W[(6AM<[9$P(:;C?TW[,SELI)]%D\U=2K
MY\X\N^BVS1%'4FS<4Q5LYS,.55LF1%NEV3VR-XM155G<8GF':9;@IO9:^\+5
MES29S[XGY._+:^]:H^ZE9IVI6]&\;&J);;3:AM<F$7,F)]D4L]1S2]*]EG/3
MZS+76:68>2O/HLVZ$:I1:W#DYVZ^AQU79MG1.MP5IT[)HU11#.4ON7X=I"4?
M^W@8JT).8\5@JW&;=#6_ A'AT]^PZRH77H2.$=<K:Y4[&OA_CQO: -:4OW3I
MI! R%\R7^:'?M+@7-&PX?1-O1'QMG)1*V[LWDL:RA.%=+U7%M-\_=KT<VZ%Y
M-[DQ@XO1_@)SE3'6/!.*-Y#-6AW;5&\?/D9?)F:0@1G\A66M9?S)0[09:[?F
M9Y'.61C*CX6-06\T1GV%/;G3E!_T]T(BB5.0-IRM.DJM_6RW+_%U@K@/9V]"
M:@.HSD^-)DB/C@W56"YI"'E&>=TAR&2QUU#<QW)2?,&=0\.H8M-@2V&\<R0R
MK_5&J/"4B/#;S^T__X_[*7@H/'T:R;']8A_1F#W(O%#3[8NWC^<W]$D3 MX3
M[Q]'6K_0G!#A+J4I5.E0VL?++&1@:@N13RU68DPV1N\DZ,?F,%;$?,) LF*P
M9?N8C@Y,KEV5ZMO_>3BEMN0';^F=MO%T[]?#CHOS&O?!_^R]+NXRBH/Q0,/)
M(#F+/_YC<^GMLW(^TI#?8)OK;_MH&??7*M/>OP'#E[^@*3<(!KYW'_^98>%7
MKOEA?/.CK@UE2KH$73F<'WQ"5C9LUB_FG5\*?GT\WI7<G)%-^(4Q!6=1(,6Y
M=>P!$WLH ;5Z\[C>$\O>HTU#36TEW=DS5X9^N3C3]=O^'UOENZPUXVOJ@S#\
M;.6%F5T![Y$F^#?6,E:MP *[NX0X7PF<DK21<S-1P1E3K,F;O9=%G?;6%R'E
M/7RSJG%"O<O5Q)S@[ SAVJJM!@,V%=>?;-6RS+OGVWQR77S9SEO9OI77O-1O
M>EX7$U*SP]%F>V+VG^LQ+?*\9HSU!.'9MNPF,V2=5CX\XC1S;YLCE[WBK]RK
MM[;:9>I=O-VC?O^O;OVR@8WIX3++8HS,=5(#^SQC%^ZZK&O>D/MZ99J_UM2/
MO0_NJ,C495RV+C5:QTSW*U'<KO9RHF;RTJYU9;$DXY?YCI8)AQVSM0_?7!02
M:;#,O4]F6XQ=IJ3!K+]V#VS\.^JWL5P)'5X*WAYXP_2K=IJDWMRA%KZ3&MQL
MQ/W$AS5M5?M-TBK)\F-<?"?F?_Z8:3DH: WH\NN2UN>C]/XWUT!"(W_I*.GC
MA<&.Y+OVU@@;/\^7],PU29=^C)%,4I6)W=BC4:<'>P[#YK(?1 1W +X_?C2C
MP4[38^OM+^# P-^/*46WJZZ(CN\FU3)'IE. A/3C.C/F2)@ZQ)U+-D2G^L],
M\D>;8-=KX*SP1MR$F/GFI#*0F)GA,AI.GF)SC.)&PT9)7!98S,&#\A6\2R4?
M-#@QGVY=9X%"EQ=2XM.GZ)H4MM^?M=7%LLYM:9:_ONZ]*M=EWJ;Q:9G<AFE+
MS[PN4C"UW[OHW+[?.I-.T#:B33?G4\(:98 /2Q[\X*C_#ETWY2PK8,Z+E%.I
M#H_<SK F;5U:M'V1XN7QGRQ>OK>S;GLR(\8PG/]%WDB1*V= 53ID\]F!T;[B
M7>PCG2#=9/W@_;:R1LJE[I\5']DK'HM9^GQG7L^AJDR;&\4;Y3Z=\IW]Y/ .
M\J:TWBO'7H=H>"/KTWX@3*BKHBR;+_X$QPZ7>\8%^T;#?CYZ64H5XL1'_R2\
M*=>3]EOIZ/BHT"QO :V)UI%R+KJJP98W&1HH0-:F(=_R3YPOI[Y3O?P6;WH<
M;U\=?T)3H;E'S PT^!<$ #(\?%Z*LA<^T_[A$R$[#94EPG6HO9CBX,?6T&+*
M)XO30U0O=Y>W<[N[,-*52T,$1-DF]0O!FV[6V\.^Z@^C&RH/T8B7 1RVC3(9
MM5[M92)#Z0.-*6C?IOWLVCB\4_5PMH01_=(O/;C%RWB"3/2EEQ2,J[GDP#8/
M)1LU"8_K+LF.M&,_RDGCH3:F+C$3/8Y>C;CD[>Q[;Y=Z>KG,JT4QOTW7(&@D
M4"O=>,HY@L2 2R+"/N2"B,"-J"\@A3]\HK^F2-^(LF]%NU_VI&25TOWMGV+2
M-X<O)2]_XVBYPR[&*:1D8X*&\@LUT\F[%W]M,W?J4R)^E.=EA/-L@]EO4W9=
MFI;D]/CX3J,UUTV\.X"#\#UG&;PB1M$W86Z[66!4VJQ-"B'15Q]D2G=IO;ZJ
M"J],M,M&BOLZKQ^,_@8/H_E:-,$%<4_L!3 GD;,Y05L-&XD[S_)&??I/#5XV
M2L#%9+GM<VQ85ULW5L">JCH/,>!F?>^*/?2S#4H>!V3:;Y!DLP+G=!$>78GG
M* :AJCJN^7^#7QP/V5AB5"'#$.%'ZI9AE B_MK*7%W>]6M+9\I%&+1X7],.]
M3SO5[&\#3\@#-'J/)&F1T+%6N6H6XSY'$D^=W]A 'JO[T3<;H[Z Y1HO^)%H
M"4];4I0RWP8$4.I>G,_*4?P!G.X D-?+;GJ1(GN%?D.D+FE#E&'O43G>5?/)
M)4UUG)E/L*DAM@;S0XJH&>V3F;G9S2[*YVM9%>6%U8MJRJ,?O$TT=C5D9L>:
M>JZ)_A(B4]!1@WZ:"Z_M/,S.%1%J'%DR/,L"SQ"=$SOS/'-,QYB/$<87^SVR
ML+!*4Z389YQ*,YM1:AX;-,7D<IRR6G5<=K1=;?[6NCJ/XYM("RA3-A<XV>KX
MT<9_7-NK8A/=YK\QV'ECBIV?HP'93*7>LE U=^.=W>.WKBN=;'CH)52'E/_L
M[H568A+WM=NFF*OT6[6.PMN%?V\1GK\:N&D32/=E/J&C'^UM-YF@*":9&$H3
MSIO5:Y+Y:"$D,5G2E2&F+)O$QK-0:,S71FAG7K6\'>OJP>Z*W8Z=LNO4,X,,
M.2#U;>O_EA8=U8/6-FGC7#PW\?[G@PQGTS_&47^''LAL*]]K \X7=&I"FR7N
M#Z^-&QX930>;[8LC2<68T9 ""N]B#U"4HC>TA*TIN?&F[D,D+%=,MO9K,6#:
M%+4Q5(T)(YV+H5SVI7[47G#JT ]Y_C60VZ:\R)\9QL6>$G#'9H%+Z[<I$<8+
MHM;N]0G=D7@@](^W47]\W#PI<D[:I(@+8S34)MT9-7:JAI-#G6 #*]^NJUA)
MO<X[<GI'#F;4D)V)6N77KG)I?-"PR=&E+]]T6]+G[I8OM<=K^_[TJT8NN8Z=
M:O1(]:+\A[G;GF A'<+[MSQ%!#?\# /XG;C!,PR]@A,%KB9Q\I]VSGE6G7C$
M1]:I/TM'13<]]_!.!T?Z#KW<6=5>NSZ9S]%GQ2Z\6;LP8>]2*=V7X4Z6JU3]
M(Q1".NK8(#5@W?X<X\Q\\%J;:4!,BTJW\M*.Z7D7%ZZCN/9FQYTMSD5W[<U#
M/&:96*<$9NK=*\\PFY6@[VP6J]',5[U1<);7)&%46@'=#K4LI_<>T-U48.NS
MF[:-,I,QO]>;.LB6@]/^F-A]#SVO?\GIH(M'&+4)>$N)FX0I,<MV+\H03!TO
MSDF\Y;8E9S8\%2CT"C5@>/E-#B2LJ>HX_]^?!%UY/$/Z^!/=U!V0)AUL.'$/
MP&K\CXGXH*=:![PBB3?AFV"VA*YE7ZIG:0Z5A^I%3W)7O1'<]?&I)H@X'VZ9
M;>WZYB6F3!BBUS@T',XIO[31%Y> O1O]]&5;-N".:>5H7_F%XA(;%EB2J J\
M:T\%FA0=;VHSYK?!Z)H@)EL$,;#!D <7/$0J(2&\ 8]NXLD;\.YBR655'C?]
M.DH,9N=V,4$$R)&ZA:!Z%1'&CH6$5=_]^S0UKET_2 \16%3"@D[">P#,QUS"
MES,*?OM*8[:9_1,YCG+9C1IL8AU_(%B<JE0:CK8H>%#3UTJ[FP^5?&^XD\#M
M/2YM192#6W>OXA"-S["ZQUBC]2Q8H0L>JD0$&UA!/!O4UR!5!"B[*PDUN% M
M\2KUQ0N:V3GPMK2?. WY[\1$.-^CR819XJCWG:&#$+"NTE!^8!1V2NH7(JG_
M4WZLBF;4G>97+*EZ'SZ<[2P:E/H5CGAIABRGWJ'MB>PWH/S]%'M=U@?<14UA
M4WO_ZH('PC/(1SZZKVM@G=9;AHA@*QV84<BB]B_1C<2*UY9B&1SI;#JQVY+]
M31BY@B(TIU.6 'ET*<WZG@#@E>CM48-M.1/PT' GQ2#,W  GNS*!.;N(4 ;3
M1,B"MFU"VP\,?,YOX$!5;K NS-IF:BLBC$))L)0P$7L '3QG ;G G5<X)6$"
M_/(%4\KZ)"%$/C68F7P7B>I8MMI+?-L"N DIPBI)8)-L58BW>&[\E)= (E%0
M=:@[BAE-QFP7=XX;SK2S=4D?J,./F=;ACDS^SKZX>$&^A+L)IWH1;]F8 $=!
MMW![X?,C-V+2%X5>'Z%_H:&<I0XD9Z(Q($'*=!"9QO8*:'PNX=E0JIT(<!<F
M4!81HET#:DE]M@%3T+:Z/ZBO0[GO9S1+1^HC[*?/:>.XY38?D! 18>HJ?VD'
MSK*+2ZZD;EW_/)/Y]-Q=KZ=/_2TZ(U*=[S<%'3PS)^71E46CKK][7?YY>W>"
MSL7F%62WV?NTK>BO*5,]'+?TC+YMYAF]W).)*;U\HRWCE9;N&W3^)4>S*#Y#
M]D";\?9CT==ETUF[NB8D[,E%9(."?*W_\K5),@[W9H[?[)OKU(\=; EQS[!X
M'4C_['L@U<*2DAV^XXF)]H7/%H9KQ=E_K]/+U;%W#@U^OV%U"N=BKQ"SM?R0
M=HO]W6\J,(T<;54CJ4NK:WYK21,1UJO5)*16 BQ]%%,R$F8U 36HK47*183=
M6XK@WYVV4[V-98H(=O.G)Z4EF8_I31VD^=XRM'%E,A*OUX^.;:'5HS"2 86]
M^7N>H+KB*/_>C9\Y7"5@S,9OT+<N$1,U71CDE M<@N_QC!V.#D*%A#GJ^\LA
M4=R$%YH8")>P/M);I #^,Q_XMM]_9L_9EX:8D]C4"@9/E5=:TAB$]KG2QI=^
M&I=#HJQJ0V9@FKXMS3.I-UP^(#7S:WK=9'GFO[,=*#[CXE/;?"O(^CD3;VU:
MJ>B:GYGUL#C'\OPR<DS4D< %RANHL:\>;''0"=.UUT_1FR@=U:0;-S'L;,NJ
M<XE;6+,W%CV9:OW)S#WPF4W?5V_G7$^KC^%FSL?\CV]/:F+O(I:\E3JT3VG-
M^E)V@8:TGGOJTI5J'[-USN]K/I>0_ORFRJK+%GTR<NG/R=E^G\QCYV*NAG*V
M-8L_E/X5)#>DWIK;M]L_T&K?@X0]?##NZH+HF@9W""AI,#(*A##=7ORCUJ+5
M$+//IZ;?Q+/2MD)\NQ3^TWB\LH7UQ! 7&Y[CCTJ2(LA]LO1K11@F)X:$ZB\!
MTRG\L^M#DKVIH<BP5IQ^WKIT\CL-4#$>*>V>JYT @7;1<J"I4S )WJJ9C<(X
ML?/1ASL Q>V2:K2-4#'(FW2J=/2/NWW#=D0DK+U[T\5]$.6VB6/>;S]0,-$,
M:4VQC=W>?'/A.4Q'1*A:=UC01K7@&7$\2REC!(ZNS8TA>EF*R'G7(V[<O[_>
M]2I?9W/Z3K;J[VO<7SBGV[VW3V1:Q/YN&*.TJF%)42NH 4O[E73.YVJ$ZI[4
M2E)*6J?W0F?2TPGZN]JMZ)L+-&3UO-Z?B$ZS39,QL=S5':0>9;I=X7Y?P1S.
MDC&!O(' W.25J:$9<0?T-\5\OESOJ^[5SFH)+F2EU6;.7:]><X^;:ANE%;5*
MHRKLN-GAELOJXL(24J!EV;YYN;5_66/+.YZQ,;XI"1:Z,2P@<><"D#Z+MW/L
M[)8[H&$8[673<JCF6S+2YHQ\3?D$ (9.S!_:[Y\_D=J)T_[3_W>>!NZ"$92'
M#@?U595::A-_PWW),(XMM RH-DXP%88)?'QWRT9S.W?QW"PM\_L::/T^O0UU
M>P:CST;C@$S\K&"/''[I+56\)1LS/3'+KA^4"V=^3W6=6>"/-(5+]O(.O.\]
MN+719A@=&/Q9&5])&$X'M=V9N#9@(A^[L^4FC#:;A_+E2D/38=O!WVM9Z?<G
MJ(+D$#K2=SR'R+^3MX$D8WO=E+/IN0]Q8F?!%./;S[#1#SG)Y-\>58&2\XO-
M9V3&ZHL>U[,;^ZX^>Q+XS&L@K7E@;MSD(XLOE4_KLM8HE/C/_@"%%_?]5GKV
MAB5.R*L.U4EHD?VBLO8V4T<FJV6CO%];]2>J_,ST(GUV6(ZF<:9Y5K/#PF<<
M>3.%V'&SKKHH-Q7,8[XCU3I7WVJ)>.G>J[;/:=/;VDQ&</2M1,5+?=[*<QY7
MWN(J#K'"6E:2MI%WX#EHRB,J>VB7>H5K_G,IE;:.'VFGX7803("C;WZ(U^J
MP?KF:,D!R(21ZGA@REJ434/''^FA#FZ/1PWM/*<?K;_WX[;C3A.?2N>6.HR
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M6FM/+OVR[TPM4<N\.G.AF[IRSVQ%V_>+GA*O%!_@I>?MO]3"B9$Z\\R=,?U
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M)'F]'@G@W8.\L9]?8B6^AH? >T>&HJ_6:#RT+F?W],7/'RL9<#TW8F:Q6^]
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MZ*JC(Z6Y6%C9?_J4I7"DKC^B$;Z;CVEQ0F_[=/Z+T;8T2>Q)*+CQ[LI,9"-
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M-VJW#(4:WK+M053E#;&G< ,$-&[TFC%] UZ*IY=%Z@F/D)[B^;2&XCA[\5=
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MUD;@GKN0J)'A]]> MAHG*,X?9+^IPK?=!HWYXY=6@EQ:#;< V^RG# +;0#&
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M619M>G+%=\>![X)!O_FW\X:A^@28( @*8T%0@*ZQO4\0%*R=4*T4??CQZNN
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MU:AU5N_WTZ2T274GM3US.QT-O?+>LM?5IS(V]>@<I<&3<,_86Y^FQ^F+XV,
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MQ?UD;$J <L?(QA%CG=7F+J013?_[E3+1YKY3!@KKF"Y=TG<]0VRE=XX=RCR
M?^OE^%'U5/:ZT<V^9V<+1%[0Q72MCDBABM2I\15+D?()1;0?=#:)Y5_["-N
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MH<;&XE ?[B:.BXN<FATMXORJ2X<567U;8-+Z11<+!>E4T]1@]5+/38U\S(6
M06*]>/5KCSF]&&Y5J]M&J-Q^\7EL.6^H=/'4%,-8E[*=;7JL4;O%[N1<='IY
MFKISDSJA6^<"Q1&=9W_:9]__0KH<Z)?;/&U$I3>W[;BE0FM*K%*Z)9)[YI6)
M^H>UK$+3V3TNUY,V;%I[5 9_]KIE:N\H1C8LA&EG8)<JH[AFQ$"H>U7@1V$#
M6CL55L8A]_@8T"]\BN5CJB02W3B T<GS,4GNP\1E'.&76Z_:LERL\:W-Q: ;
M'HV8_S,\V$;$1@GM+A?6E$T@GX&*@_IE5&LB>&_,3T44O> 09G?E__@2D4:'
MSM.%6\-],AU'%)R9ALR*WCON"P38#>V[_-UB*L3O. ,]0OU<;+-(:?L,T1D/
MT*ZOY8I(,, M^!MO^+]?1_WO/]6QQ:N@-3?>1X7%]_$Q&X\7\3&)+43N$FAD
M3+,AJWTXS@R!%YC&Q_SA@S9QE7F2$Q'**IP%IXQ@FTAZ=UQ YVUWAA4+-TU8
MB,$?W#60&I$409RD?KIJYT#U7\A'QS[UTX91/;B/L$Z9L2=1O.DFH5?I8=GW
MA]6T2>BSOYIYL^?]V/)%/J;?DMNQ2&E"W<*(04OAG?-OB,[=&KJ/Y(AO>DI/
M'+I<5MAU><!QQI^FN7/Y3Z=^YYW);6JG609WTX<S3LM.5;NSBUD$!JRA6>T[
M3-T$G^M<JK=+>U"3<L77$S^JG_:C8Q /G=MW2,E;MON]II34_2>B3Q,=>4DU
M.V +9FQCA%Q]INZ5THYS77I^6R=;_97>CZ>%9NS>5O.4\[;(\A7ZTT+N_ID[
MIC']7&_']3[?(H:626@[=6VU!=O>E1T<"TH S*@W5GK=L3;-+^O T*[[O$<%
M#C[!AH^FNWU>?5JZ6A;DU"#V7O/GKJJC#26I5-\D+1T&816B,H+#X$TY)C>1
M,RUDTIT*F^6+CLJK^^J_S3\_IZ7V_M6G'S1Q9Z';]5T?]_:0J7).(7:NSNJY
M/P+@F[DM=_*)&V-R^QH&%0-?FK#\10,HMF_3JT=BYN@_OJ=SI P=)ACK"M/[
M*RYX.M@_-B?+X[7#\8H)#3:-Q'[;I_-DLF6*(VID?^0IF=!0\_OUGY=Q8G"\
M<]GMHC>-=Y_XA-Y;U]R2W^+EJ^MSZM+;5VI#4M-#16EU;]188XTGI!E<!#K/
M_IGB&<:*N-JBK=)]X7).^2T-HV]Q=T<BYZS?O(J93NEH?>BR\V)2]05"(-YS
MA 0R0:A:;DLQZT"^EBC9PMQ78T?=(,/R'D,^*>9.T_$NW0+5_F-;EP*/-@N5
MTM/$JW5.**>MT3;D01VYXX$6C1_7LK0V5_35JV-COOSVI\?>"J'[9_:D7SCA
M<AA0')ST@U&##W:$O2W:2);R6YL&ZQQ.RB1+R:UZ[Y[+K^;9DZ7^8@UT!2_F
MKXW?7>08B-9-UD?E#^/N',*I;+?2K=9WM$N=MJIKB!I<V*4E=:?IC)?II5.[
M#V5X=Z7([.YY9&])G6OX*UP7CF8].C?"&%1@V\>5^EWLW&[T\[YO%DGOZ^WU
M UO"X,'-RYLU^9@=%I?=$ZCK7CA<=S169J?=PDL_-XYCS6"G%.1ZDG9F3'![
MJ4&YKGK5T;UJZ5FO[^CHE13(W7RY8VA-MOS.A)*115H=M<SL+2^(A;WUXQSG
M1$[RTY?)S(IYK*1/F6%JBD>!^L9):<-'&;1G_<Y$C\"<P4G_]19A0B7VOF/-
MONKO'E-9,P-5K%\,:MR#H>NZ;:M\4C-W4.MZ:W[W\W#KZC5]11C8Y+VVY7AI
MM6>"5FOYXI76[MFWNTIO?&V0EQ8_X-:P!57ER5:O&Z:MU0$LSN# A%029VSS
M=_EC^*S?[KJKLGFJCM.RX>9%YA7A$JY1K4'R70/M+2D7T$P_RQIE]0^7OAC6
M,\\SA&X]3G!D>\53=@8*X[YG[*62[=,#!D_<>;_]3OVH+?/^1T>_8]]Q_7OR
M;C:<V>/@@BO.NQ7P_GMDBJ'#!TU-6E'!_C,JM@SJ*D"?$57(;*6@.3N+C=E>
M+JKR/"WCZ#?JZ>G^Y_M#&PZNV7#P]ZB[MFI<2WCO_Z+M/:.:ZMIWW]@%1)0J
M15 !05JD(RTJ @)"I'>B(!U$!"34J$AOCU2I$>DUTCL10I$FTGM)4#J24&*
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MYU^?&$KZ_SBB^C]YK7^R*P'V;_Z3LYC[)V3QKM/_#G\/8#;2KJT[\V]DYQ\
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M;@[DD/7EP*DAIEV*_'&/C9$">"N0& J#AAU>*7$IS4U/]<V;QV\>NJ[(+T?
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MOHA'!MBKU]6.W C_;#?DY:?A$?X&L<A#IH%3)X(XHBA)+5_1N($V"H#%M#<
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MG! CO1-&>N=MKUVZ=]H..2J)AG3$AE  G$2:C_XZ!*U%);HN\DF<4N7,2J
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M/Z[,/'/_L,4 S?R4WQN*W]3+L.+LNT.J86(M&$2-9(/*[L<PL83V?W:G #+
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M]AI4F=<'E\3UU22SZH=9*3AN;GZ<)L52 ,\VZ3 A\<!V>/CEF5FH 43;!CW
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M2UM>H"@$H\1QFB.M^8N'2>EKPH>F7VKLN1$_MJ:P8@L42<_BJ.LD.\] (0E
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MW4?PHG\LB"=KA8!5<<%*(YX(EH3!+P&)="O>[?D1=8"=<F':JK-)]_?!LH$
M-YNP+B6=A$N<-1 ]0XDOW;@O*/4W1)-8A>S-Q=[#FK^]MLVQX=YY[)W/L829
M,L 2>S-C]3>BRE"Y)@X]DNOROEG53J*!2.7RB9]F*\AQSO@\CWP=&S\2!A3R
M;\G2,2_!O;JAU_FRB^>=K"FB%L6BW4L?\I'')AN>YND?AUHB"WDKPU)D0_#;
M%LUBUJ:,TVN0^3,0&D)+HK<G+*L0_-^2[N+B+0R;IWVU'^^@\[C&#BP^C?ML
M^IP(:P66C+M6QF/DY>6G;_'G\-S3NN@O.+*O=VXX0Q'Z1/>P _>K<"[TZ[2I
M6#O\CZEJTJ/ DH5^6%"@<W%'_I6.9/ZPHB\SNKP'== B+\'VFX_<^8_EY^XU
MDV*RUM=7U,3$^'.>5-10%B?KW:ICLH^[+Z'JR#LC=L'6-"X9]HONDV,,F0X>
M0$??D9#'#LB_LS<[<HX>D!;C61U0 )=?,1 ?KGOFI]<SD\-H%$KNKXZM#$_7
M,T\W>UPL@A7I7O/ 3';;SU"HT%&E*6]T*E.MC@AF7#O7,8C S%6O70YV/WI!
M7%D:L3D*[Z$ EI/G+HSJG3[>4[J](^*JB-]^#']F]>KEYW&,;8WR5$7!->&C
MMA6F73L"%JU\8]2W.NKUE9(XDF/Y5F-K1"%CW;JE4Y9D^Y-6;;$^#7>Q*6=1
M6_B']O:)>ZU9L,\;,#L83'QVAZB&*LA_"^$$TQ/1W4J(*:7X,&7!1)T$.GI
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M*HL 2(T)R,H'Z^N-+3<UKA>6 Y>,43'/ MR#BK<8]YUIWKR$Y,@$/7CF)C?
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M2_:=/+E_(H'L\D;!H+/R*[IO((ZH2"0=TM'5O2O_NJAL]@,Z0V)36 >OB[)
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MIE%V$I,2UHM&/=XF7?WR@EIT\5TZC:SMA67A9N9C=9 )QZ,/IWF(FR=&I"M
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MP49Y<CWU"-F/0&OB\^.5N:JPP75&%89^DG6+]777F8+C7M#E4T5LL8U<1?3
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M\3BI7G?@P(,ZE;\-035D4%Z"XL$'2* F^"L#]L[I7BJ/: JELY J0+S6C%S
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M"-K]O/F"^ X5>A)$BW5G@=$YW8?"^Y-#[.OU*.D.!$,D#N8"M@N1,E-%5KM
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M19C'BZ-FD.>I?5VR)$=\R$TX-FB SQM-Y>-N;%PJ>&NW9JCX\\DC!:%AQ+J
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M*]2S')?CN[3&6=-:9)/2#[$9+:V.,L:AZ*YO&8UNYC2WU-^81M$W:;Y(6OR
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M:9ZHMN:Y/KY@W!B.,GS]XNCC1E;R]N:3\C9/+FU>L$J*RS79V-OO:]?4JBF
MTP3<S'/?$$G_\W@:.UQBQ*X;U\-1GZ0KL>01\-BUVTYC$M=J6T=*=\\O)LUH
M2DB5? J>NAKFGNPE-TH!Q%3O>KZ"N_'%\#$471F6A7/-K')J%&BQU*1A]51
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MWJG;K_8VH:/_P;N[=3G9VI4" 'RBPXFTZ1!XJX4!3S]U-ZYVO3U5*K2+&-(
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M#WAW)_DK!4#0\'>G /+[?!8>4_^8A")WV:A3 #D.#/!P:JLVX @G"&,\CX4
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M_[<!_S%X6R>!JU)(R7!V"F"VD0(HR RV+AK?US]4AW4[X>%'O:B#\.^&Y/G
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MG%W,Y.\F#OC7V"6_,A=WD:KAWJA_Y7)DHZ5[-'[!TFR> K@U#V\DU.N,35,
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MC[I2W=8'F8VR0]5>W6NX+HR$"6T[7=@).^)NK86;G GG4M.9+FN+-Q91%N\
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MPM=>)# _NJ%R_YQ_Z7J[/1G@!/XCOQ1-!IP(6R(WSIW( # IE@Q0UZ5'6."
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M,Y),:FWB/-1?U;H!VO4O9JL6FJO>1<;:D.T5%$AW)N$ DBNQ%*?;\4EY LY
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MG>KW$L8W]]75[>^AFFM1.UL!J'EUF-1Q-FH^8NYZTVGY=5EJ3$+DS1RU\ D
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M6-WKH\QD@G]#42G<@V9<78;N(:C7?H%NDT!0ERUAX44QX72,.=^=X':G'O6
M3/77/W.&/HP?PT_'97CJP9_D:C<I?7%^Y%\$0]Q*-X*"]%<-7B/'0AA/$7XE
MR T30[L:N^:IBFF/A5)VEMV;;DGRY<BW'0JP$SIT:'@7/*(WLI(,7XC9>0;7
M2(&R8[RI;[;;':CUE$]->+0EPUW^QD26AA'S15J?Y(D91=KR?).++_OP9;)_
M*<@IB05/SS?MFB,+![W>C61P223V8!^Z\G4L)J<.E!DKZW?6;5:R=A@G4;O/
MRK/?M]2GXF%O,N.W*HO-2A)4@WT#(T<+H(6>RZ0?9SB-TZNQ5! A3T(X# E_
M'5=(0$). +0D<7SE([QM$J;8'$B?O>9Q0_<9CER /:V0KA(;']6$$NTL<*6A
M,-G<=<*#L+WXE@A]=5;3@FI*%V5=.R+Z" P?9!$Y7VI-KX'(CK&6)MV993O.
M@M-N9%"J!B96XI*B]T6N0#<>#[\=D>_Q.?VO/Y)"1]%@OZUE"XWL/L^[.;%B
M(NL*Z2< "F[C-<9WZW+@34K<AOJ8$&FH<LYACOY315/@0-A\4D]]#5'^-MZW
M3/V>F+/WW.T85AOVUZ2/Q+DCBSGX]TR<%BHXLXHG:UX=%$)'#,0RMJ9?@_'9
ME/9@H4587$LYIIG=E=4D2?GKBZ;8_8_^GSB?O9T1#'/DL FR<:N>5Z##;L9$
MU97*Q03OP23FFU9>>Q@YOU(-Q#K'R/1M>"A0WF)^OBLH1<F?#BK0S#/6O16<
M+F?T5&LYRF2<_\AD..* 6N(L]T,5@\7^*_>/W@AM6V%JX1A\F>;-P=ZEM=2Y
M1(RTL+MV[/J@WP&#OU6@2\]/2)#3RM]<K>><\"'19Q+6B*<&NK0/HH$+K((N
MDR3Q-(0B8BH&04^DQ-A%D,!6 SE$^38.1M2(-^2V5&G!C)GIAIUFD@'>-;X/
MDTG]PWZ4F&C,H6%H7E$S7'PW<S&3R+5"HC\!G/9PR?B53DCEY!9S-I'V,,"P
M=7HELHD&"[Y*A$-HU.DG0[8E%B> 0L4.%8X^!+G@=-]L1T/&Z8!-C\?^#CQQ
M#XOQ8Z,ZT2Z@%011CH:L""F''+\Y =AS'@L0)2$9*)S;'"DGKM7B!'"#+'C:
M?5Y3C=DM[9.!H!6H^A4BIF*8K'="K:$9,-F.Y 2V%7J39ICMA3S%E.6QEYL*
MYK)C'JWS!:.M;7KMF(7K^DL&34C^Z/S&0S M-*RSCB8'?C'(W;@(ER9/=0((
MJ3BLUV1)8)%YY@+<%NQ=7]A86+CN:/3=;-W:=@WKU.M]OU#/6JE-$4)]W"!1
M +($$?D1G5&*\]7!R5E@G,^"6Y"",$Q^1*3(NNFKA'\40@V'ZAQ@52;W1Q4G
MD.0MI4/C-*I&%Q*9[PYC@L>%=8PZ6\G%"O3DN4QVV-G71#WQO%OCR!GH+;C4
MFL(-8D&)29L=YH@(HYV<I2;F8D6N.G"\"N2IE]QH]XH2F]SRR*MD3EE5%:M2
M(QN1S5'S]9D[\:73_L=S;S(/ASBO(0EH@K]!$OE&(;[W+ZK(S-/KLV?P?ER?
M8$W<6I#-$63D?O*$JD13JDLZ341R'W[?QMCN)A2RYS>T6W2%\<' +G"[O:B2
M\X-506%=FJ9IV@OO<M^,*]4.TK*8\@_Q2,-\GK%U8=OM5V0W=&2?Z)<F%?P,
M5Z]'722U?M(+,K>M#-L5#M<,5IH/-L8#5%+FD=EJ"INB3,_DO>S'PC5OS_&/
M]"! 9ZO4D^@I"8G'34V<\]N78![51">W3T3.CEH%_F'35C+#6!7EQ+AP5?U>
MF-+FKUFNB5A_2(794X-[P0RT6YY\@"S2RJ=P<L.7.L0]3&1#HC;ZP);N?M_]
MP6(U([8;W"HTFKE^L4@3CWSVVX5Z\?G2$QJ5!]9R0^+PN_W\MO7+UN$#XBQ?
M<S5+Q)FUQTMU;O-U)=SO=3,H&(VTY!A6O7Q;VZ)MZ9^;W(\NW[^$X]-7W6@E
M(\#X@D<77S^F33$1@BQ*:E&#>0]T5S\%2LV,!YT^\<U_O]E];4WGC.XW5L^]
M?(3(M#*+W0U #95U:J[$N$%P9._[3//:2B\69T\ /HJ\/+^.&D[/]?3Q&2#P
M!  R2="C\22UQ -:S\A_U7^>W=L^6_RM0 G%_?U"2]E9C"P>H*QICN1IIB9/
M  :G72=R\? 033A5U[CEXTC0YB;(#G)L2J8N90ROMVPGJ9P K-@6QD\ [:^X
M#C?]86(C6 MVE-DNWVD_3XE;Z=G35O(_>V>B?'?D]&>9MA+]O?^Z@0YHS=DC
M'>EE/?JE@,*L:?Y>AN[W=OX6RM?+=:;N$"UW>#VYVK5R=/'/Z XX"+*[A^QM
M"WY\&#U_R-*K78-TZUN6^=ELN!PP>KY(>>PVRH5F&H4I;:L7^CGTYFXC@A5F
M,N;"8F^J3C3'F*:JQ]#^X>/:O@!NQ'-W#B;-!S!JA_$P<-S%&\1X S6<;F^B
M5G]86EKG&DTYI-@DY*7GK4TD$EC@F99N-]*C@J+2^-P<;&P<7-_/3$^;S'2S
M,1!P*FP/%%F4:/GY/Y\ A!$78&K$*%PO84.7Z+9P!GA7&*MFU;;\[,AQ%6_0
MB)'?V+@E9T8IT-=\A=R.7?]JIL2&G?;EN"7A<%]CM>BAWFEU4?WX!)":>/P1
ML']:0??@64\G+CPFA6R-KVPE<^.=Y/I$XXF5(KTOG5,O"BI<%"Q.PI:+1PO0
M:>MU+Q3JY8?F4QC2%F#L[W=)1;%Q"_CO?I[;0P4J2.)6@F2E;((*VNM(DS(#
M^/(.ZTI^&9(4BPAE<-[:O+O>VA"-CF,&^UC'Y,OX4OYOA2@KB3'$J%SX"4"\
M^AB)<M3*)HL9+AS,OX2+P?[B/0'HR"6 '+>GWZV JO*[%T9+NT"A&2> ?=%)
M+ 3/X[MRS"@+)C/C,TE3&\<N1R(D36'5$\!?RDZGB@@[?;48YQI""9&B=8P$
M.0K2$'M$8M(I2!,BH0C2L%[/D0%\S B$CX5PRIT ABV)(:N@=:NBN:]S\JJH
M_07^47(.$45VY@<] [Y'G@ *9$L()X#W+71]Y"R:O=+2(4XBO\AF,6C+Z8B#
MI(Q3":GZ4 T.@]\,YPR#7/]JVO3K%X<@+K;/TQNS)6IM/[5-<L D>V]3K.'[
M^(V%BXO7:FN3HSN-0<$Q1$?4= @Y6F5ACLS!^<_(],AC@A2D%XCN[.U3_SY-
MV@4;)P!Z>K]ZFF'=\#H[8&\EJ39Z)P5*2N4,ZG]0X:LL':OO/FZIKU.8*"K[
MM>C3ZF3>G)")>+HL+[.$K^_V2&9071SWP$NVOM>5QO/BL"N\?X2K2[?M=F7P
MQ!?(Q>?@7)Y4,ZOJ9^E,YI^A&D;":T/_C55T+V[(V^/A0/_(=[/OJO=^,=)]
MV04#=V5CC?,2GXRH"U:( V/EQ1LKQ6D[4L[!2I.$CM17&O?&4RL;FFLT>S?,
MIPTW8[ S4XV@>],3DUNOX@XJOI]#A0SIB(AYT$C!.:O,XS<A[OH974?KQR'\
M<_EOZL_'@C%: $?@@8%MW[^ ;DM/?($T*_J?'ET!\X*2+I0:T$V8N.0OHA26
MT];7A(N=#DX D-'8!Q?>/41\+!@] PMIG0.:\C3SU\CT\8>P$X#BTY_-VBX*
MJR> AP/&8;(]>VO$:-3*3B'^#(>%#/M-4SI#)45_5GIHT;#Y[)R!57N.1E(Z
MN\SQ<W!3_6^<4@#E^_N7P2_%#_7#W_S&F5GIP;F/O?Z=8!;D1_.1K/^;<ICV
M+?D<@G0Z !(BN1#/HPEF\]I?.T" <DTNLEWO.D<Q_I @C-6<P\22_6(^D[VO
MG^.+;,YM?,Y C+KS+T84\AP36/C^#(QD!L&0^#54?X,-L^\\.C,C\AQL5<12
M69[S(C9\_0307TG[_,7N$%@S,W/G</SM.<;JT[^!#R?HB)G[PRQT^N>0)GVU
MWR/IR@=GKKJQ)WTBA9T3I S.*8WZ\;2/-Z\.&)^SJ%[\B N(RJK</[[U\K^C
MX&@,YE[V_6]\+<]S M5_@*,,WE$WMV$K,C9&]VTZIVH7-<^1M>LC@-M_;),&
ME/YAOD42+%#+#HQ><\G\YQ9J+[C'T7H"X"_Y-P[<A(J:P];JJQ2WUT## J*\
M!?XX.F&%J(XV"4[/W?"KG:GZ1NY$%#:H6%)\XVF*T:W?G37J3G6P XJZ]H\H
M7[PUF'^V9#LB-\!TGN9 ?"AZC@ BG9I]Y(="BPX8<P+X^P2@=O ]7[ST@U5=
M<)2]]ENQM!UC6^:1R 6^K]'Z"=;Q&YYC*0EN+M'%C/R.:0_3'$KM^G-ECZ^X
M)%KN? ?1&&3+C22ZO5<4[^"O>)M-]5>E\^3%GL=/TMCLC]@N,[\<\^;=XM8^
M4F%^<K,*V;@J-_Y_L>DFBW7SA_: ;\XA7/QZ__=DZIRQVD8R(4GK&@;\S:9Z
M/Z&$4]VG63%B*68)2.$.I65DCP:O&)S'BO:?[7^?X2(+=/\-?>A="*[_[:T%
MV6=^%?1O^[W_Y101Y6=36K!^]0Q7IY]KMCNS_SN*(B)4-V9(87HO[I_&LM[Z
M U%B2IB,)=F?):5<RB3G*/'\Q#ICJN=4+J<K1=-;9"6TS]KAI^E_.?T8W[]@
M:L9#-AN'XO9G&=GT-\*/EQ_\^4]$E,'Y(^PYM-) >2D\_3SJ+FO^__ ]W[$%
M?K,[^ <9]G5CYUC]_#C26_N<'.9:D3HL?$0JLO\'D5:IGWT&AS1PNCO9)@+9
MX?W-\BL</A</R;>U\-)=B>B^8;C2AW\,L>.G;W2^VW%.'U-7[SV<G@LKX@1G
MGOD\(J,K[_-OPF)*N73P]NB^4GCRN8$_._[FD-4/J/]&]SF<8P'USB/M'WPH
M[QG5L^'4O<]A@>/5JPJ!!_I/S]2I^%_@M""5,_DT.CN:]QO8QO2O?2?QEXY5
MO\UQ]>../T?F@F[^.<<O\ARUVO3*(F+G/VB/O:;HR7V5O\[^\A]7'S_^/2ES
MW4R!>Y>4+/:_\O@"AZNG*JTV?_,,_]',O\B,.Z3A(O;)P;DW@O_@8_]!:/)\
M_9T3?D<\2V0:G"?WXL6+U9XI<84+IQ5!KO'Y(![K=I]I37EF!QD2*V=]QL%[
M]9N:9WCF-=HJ_\)B:O2L]Y^?O>[2'O+^ ST_*GC"@%!F-BGJ^7CL1NFRAL%O
MT![RG]^M(_*E^@=Q!LM9.>LL0+SINM0)P#;%_ZF;%5CJ6NV,V0LTS^J]!$.H
MP0%SHE)W?\3[-+E]FC#.'>81Q*;A,&J/&1ERR\*]$W.?FT-M#Z^;ZK#+J_+M
MY4[5B.J1JJ>Y_)1QL=O:,+H]CY(U+"XE@R./]J9JB3*RH1>VUEDS61DCE,MJ
M_N.A4/MO/NAOA*76OS\P 6,0(@-,BO\#X-"%!CS,?G/JD!SZ&^!8=YZ/\O]M
M?P5RJ1GQ9?4,2/A7P?_"]N.GY#GW.G7M<U)I;HGGQ_\E.XV!SX+S-^'V/UF2
M1OJKX#&:I1/ J:CL&PCEUA>Q@,=-5[R,SI_XXERYLOYMOTSN[N:Q%^E_!ATN
M_+^"#@W>74P[+=\VQE1_J1S\_ W<K5_"H38*JLPG\S+?<)]7.K\'^^G<:K]+
M%*,412P$U!/WFVKI<GXF[7/0+M+A3!^*\AOVCHW+^?\_SB'?N>TTM'Z+X6_X
MH^.]WU#(0:_?*O</X_#\<GY7%4'XOE%2]!N__ZY5B;C]8^TJ!?I=TM1O7K'A
M.793[UQR&\\G+^R</6KD>@S2 Y_*NE&)[_F!<UE4.Y_8WV7&]?/Y^PVG3$WB
M.I<NQZH QHUCQP%+H3DD:6"A8@_R_G^/U@3-3-#7:5809)CVM+=*MOP?%MK^
M7S=()YC$'C</82768CDW=3TQ8 HHLF."8$%%G+F\U!W2]!"YH36M(5R/FWV:
M59^D45D??<WF+Y]H66/V8>/XFSDQ6R;A!**_;.+C5,M*(\P$'V;!0J%=WYP>
MY/8D]\KQIR 5#GW=U'F?ZJKFR2&\IB('3X^HKR!>IZV;7E BXZY$@@\-$FN/
MU=%+5U,S^YG$]6N\OKZZ.O,@%M%V'<X$4_^*F$?.55PI+H$!\8,1N<;$5"R7
MA:-?[=OJ8WEPM;$")>GI&ZGZYJ913,WK%RE&&$7!0@YC6DGN'Z<-E$;#_9)!
M?JPJ7D$N6 KZ=/X'U;T'A6E.<NMJDDB#E16O I.?E3$B K5"!^F;=3(B;S%M
M!ZZ\PL%R1ONAW6"6#77JLD%J*$R2QNX+TK !8KB\O&RXLK3TR[7W_J>6YX>X
M3^'W ?\/VT5<-Z&5^(</+J[K%P??R)U0(F4W2^[^; S!FU_BH8$E86;K A;H
M',[MP%LWG$S=X[4'!>PZ\_(N3).3@1[SF3=(2KB6XOEM!H>U GN_@;K@]0M=
MLE9>WHG3.R/>!UNESC]IY5--WR[S9>LHYBVZH46F*0@O\/FM SI.7>$+'1R
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M:OQU>O5B 3[;?O_-F/"X2F&C=6EW?*7IVYYMLT:^K-AF@-\!ZGU';K90-*L
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M/,&'9/%4Z[3QB]U%Y]0U8G^&<L2]QT@-'8/6J[_ !58QC9P T+5 [S%MT-5
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M0I:/N/43)F#='XMAXV_?"7K5P"6T2HLI'RKXC^46[@X_U(IL(N:G60(\H1?
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M5NI;.AG"7<J'!,.9:0@,'<<QAK>0H+VQKX/Q8'ASL@\5;.,A'B-AZHQMV\_
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MA\'=P]F^#07:X"2!A=$H0\SLU:)^2,B)N<<$0[_$<368Y.*B,&LOBN#,:L;
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M=WXER(3X[O6?4_:;>^&GSFG@9_49%M7HDK1H7.SQ(47 QL#A5*%;7_S;46N
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M.Y[T%$/URW14#@V@($_,\4M.V8^,(K\> ?EO<G+LNEYKU;R;1; (#0!.,G)
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MF+I\2<(B =)@24.[W0FL)"U9M.P/-AV3.@_2"_FJN4+6(_[#F'_2OS6<>"5
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MU'O=4'79+E5W8?S*YL-GL@.3U!8'&U(Z43&>4FS>@L/;0#S"+)X-3CT7J4W
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M^<W(D'L&O_$>OZH-Z^K!GNSX:?]:?*0).8[<7CSF\:LE/S]^=?1>@X<O3UZ
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MV.2@G,"O*"^G:7# OI:,*Y[>$HC5DCDAQ(DH5[Q%R%L@D=AFWP_RCMR;' G
M6Q%D\3(2?Q?(RH9S#G20#O*+Y S%/-I@.*O6G5YQ.X@M0/9U8T]*4^FXYYQ
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MATS8D,$O-H01-A3$_1$AL8!;("(R(2,VE!%P%).6$C(JDP&*(6#K9?PC"-,
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M"3-]"LST'WR ].&1 ALBOMY( *Q*N61QBVS1&%AT&0!6U' "VK6B>)!9F&$
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MVJO2 ;.+ +,#Y7O,07+Q1A<D%[!4S8(&D%P8$,G%8+Q%TY$];.$\=JH[3F8
M3HY71 _[YF)=%I@+6XP@HU"AFG:]UG_/T$3\DR00;00,Q02^<'^F:Z7E?\_/
MUQ'3#XPQ#CVR#^5OX+)N 1S=A:WNQLJP/U>)_$ZX4L<_LIK(I5&P%G<<_F@/
MTH@0HX/ #"SV#5OMFRXMPH\LJ30@Z&UN%=YUI2;]H ILV*E.[\4G!<9"*>G5
M2I@ ( !\X>A4.#H5CAZKB/W&59BR45M>[8,P/1;(3ST ZRGUL0/+G8""U3X
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MD7@NT-1CS/#&APR%/0SQFY5G/V/E"QIX4I);A7L64G$;2"E+!4C)=$Q?,/8
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MRH*+3?.#:U/ [2K*2OO5 :F75;?]32!@Q?(J\(GR>[3]>Q1</\)9+P"+K5(
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MOZ,02]:#4>9J1$=.B,Q2*#^M^DN-% W2\=B!M\J)MIM#^K[+ )$Y\]@6XM]
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M6.SWC5>&)8MCZT52'Z4\HO@*"B:*TELRB#,*G2_)":R_SQN!PK?1L!2E-7!
MF:K\. 8Y[81?1BU>Q2F#3K!^MD]5)@IP&G50_(>??D*,T-6)Y-R# &BEWP0E
M$#1XB,V.,M/1OH^MVGD(LVP@9C9B;-.F6_M($[MTQ#@'CK92(E;)).)0M%F
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M5IW/>/$MWH)NS'S0:6=>M"WQW'1@W1879CPA!1A, .AFLP$HNLDEH;HI&D8
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M(5A<=(AHU>OH42SP?*1%-9K8H_91B=QGXJ= N]65>V2<:6W9?L.&AU#WD:<
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M^$Y1+5&_J0"G@MQ(:,\8[0@[KR&HXJI[FX<X#ZVA8X(JI'Q05501SMZK)=@
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ML8* ]$Y41*0K'42BL@$! >E2([+I)8 B 4*B(EU D2(MD2Y=>A$('1'I38I
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M*$PA/@J<9+<?"5-A2.5\AO/=!4HB58QORSB/!/.$E!+%<GCME 4M9DIDG,@
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MBU''T[+)[">F;]O[,RP8']3+*K/>Q(BV'3E'NM[54O!CT8^ZAKS&/R"L\?/
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MTPI@1P:0 5U;4K$'XLJ'9$#"/&54]_]O)>]/(<^R5Y\][G,$F3NYM;9$ OU
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M4Z2^@1H+Z+NX9/#VF#67 Z!63_W?BJ>4<=Z[^(\^OSDI=I%ZG\.K-BH"O8\
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MG]6+0O+BCN9"NWP?$^)D1O%V/Z\FJI&J7C02)V'1_Y6"18E7SC4@.G+6:L@
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MV3;BPR!542ZHV*R-;N:'?P;X?R >&K\XMCIO.S_&SR3CUW5\H]DH+[7J5U>
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M"#=K-QL%SDBC\G%3X+#6.;11&LA)6QCZ7?FO+,/QC@E_Q</.FT)TA[E3/_9
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M<AY+<6[7-EC).K8O]]@Q13@$<%+Y(RD,MC;JEZ)4?P\>;^)O22I\M=N/6V#
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MGL:#5F<0SEC*$1%U!LBY($CB\-MT/@-HS%!TSP +V' $E2A^S'P:A5C,S,5
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MKZXT-(W=KR49A9$4+? _V6/*U7@WJ<DT!A:"//%TIR<W5/5.R,934D)RN;/
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MM0[7UI,_(9YM3POBW10;?R#"-C):S,<;H--5,#^BB_]X"VL<%7"&<KB]1)5
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M?ML)YDR*;2F2CBHM0-#IUDBU?6VP.M:54K.2>B3L<S\?2G=%2G6  /[MLL)
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MT4EY2K'[*9.-52K@$.UW7Z/(,"J@HH+(3"E8#AG:68X$KJC*$*?@::S3,L=
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M_79NH -!MQ451CEW=^IAK"L/F;F(?+<_WBGD8#H,*TKR?7_ A+GSZ:G\G\^
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MFCY[EV/&W: E-97 N;_4=_^WAS^R*>XY%<"%<H(!YX!'&UD@1VE);:!OR7*
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M;IGS4BA].'+^S8)IU]UY& ?%O*V?1U@W !F45834?%^0DX'DGGB=U.WL+^(
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M!6(*-Q@6%K\'OW9LTC[QO]&.3&9]A!979C=U_TT]8N[X\HP./R5B>RZL%C3
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M-ZZ&.5H_)%&%'6;45"".-N["*+OZLWEG<PVJBZ3,- HG$]Q$S=(O: [GO#O
MS,FL;E.3:;E 8@'](B V9^35S5 ;?9Z#V+.XD_'$*EM\H"VH HBW:4*JXKE^
M"9HY7,_,&JL)\2@BRM-H/Q\W-=6_\/UN[_MG3FE-)I$U%-H-GJ"-=_:S&1Z"
M3LY/TV]FZL;IF?7Y0N/.4.RG6>_OFLYP<TY_=)U=Z#WOF?)YIY_.>[1]YOA!
M'#.6T^&"A(=3WX](>'5KJU,V.@Y!,<$;*O+!F:T2@&$ID-_&.$&1:"'*>\"&
MM^'\#[(*L9 J%?U I=@S>0N+1E#C%^.[453TV@93[DR1U_J[)>QI"0 >0>4R
M<EU1M]X#)VSW<=\9^-281)8X=X,REOV4)7H+S]GV@PBBK+7FJ,9G/_BB,99Y
MWRM<8WXC'F5,%8MO[+U(65'[A#2/1G)?SKL1VQ>(*K7M4H&21<5[)2(2A:!N
MX;V4]!+CA!5SN,V/7%%*T/?@6RQ[S4A[8A*(Y,3;I[DO_Q7 0.>]FT1^@N5[
M:M32G2]#H@AR;62LE3*ML3E,-OV.9:1H\O*Z/T[7X,4;W/UJJ!?WMWY:^$$<
M/52(N)&<QX;FFO'T=YQ!VG=D^8P\Z0Y'>17:&HEKB&(B4;<>XCA7_51I73O&
M'Z*(CD,ZW[-6M(QSI49X/O]"5_;3^3;F871^]D[MJY3,-O0INBJ%AJ7\OCY$
MUROOH\K94]7CW0)=<)Z7$1F#2RF 1QOC4M[3@L;8K ?KY:MDFQC7+#UIY8/K
M*&?JB=Q#T'%=IL26\(**T=$%W[CCT9P,260#&;+7DH=Q347,\K;^U8=32@BZ
M=O:D@,NP=]@9I/W-T8+&H;7;?K:V /9TG%#HY2_X-C3%.YF>L3$9S?@,?T'8
M5FS&JX>I^-^EGZ9R7^NXM[F*ZP!SU2#\U@-UTR_>KRY]'056_>@LE=0^6'Y%
MG^1OH2Q 8@LHUQ =\;2(:$DK.3<0'8%2XQ9 <DN]C>_^B6+MWG4-I!?6V;TD
MNOM]M.[U;\2^Z!C#GNR\[S=:;)JV?#.-+]^.?P'L)5H&[--LF1?$'?;M$%0;
M]CQH'GK* 8#.P<.CWJ*+?C5@>,8[6#K"9)-A'U+ZZEJ.MC]YF+)30OKPVCE]
MZ\"Z0\B.?;F^<-9DR'MCJ[?8%Y86-@ZGZ'%/<=.,J=S$ P4ZM CE/=AZ$9DW
MU:;-.LXXI5.^XALX+]>+V)!O5BI_8!>56N0YJ8X+=7,KGIVX>[]ET+UJV'=1
MJ_U:[O2E1VB*>3)P(7/-F>I!JP,^DWBH7EUP[F86BCUY,;E5$LG2!N5L-JH
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MJOB7#!(.009,\<W1K$T]H;;I'?T<I==365<];70WOP.UW-R:'_/EPF#0A=#
MHX:<XH6:#G?)Y/P(O%U9VEM]+0%9W7+H#SR#-?4?^FO?/H*N Q-':8YJ@Q&M
MO( (%4RR*J%R((<=QA[UW5RY.U*':W%M(TU=DR':;7IJ^!8A[2V3>ULP=Y\Y
M?$:(3<L'&JJ"AWSI@GP,UL#]&XS90Q!/&#//S/7'M9X"GAH!3^<(IX!@NV@R
M+ 8%?S<S/>LY^4,TMS;+U4F4 HZ?RQM5(+ME&>+BKUB9"9QYR>I/QS+:6]6
M6,HPK?\@CWZ1!)4$".V381^8T76*,IO@#9$C^P3>&(98.WM0[6\-NU:-K];V
M3AF&>ADC%;=/6O6;Q_WDKIEU['"9"+Q,6.^FBSM3D\D;1*4$=$U0,A$=A^%A
M@&T],9P0Y^"2">!<MZ0,);<B/X@[SN=,U,^]V1NC\F<_-,:=O1_G%9%R9UZ*
MYT6*W""5CZ7[%0'<>"1)KR-$^@0R)S[6'Z)D+91BV3G<0\'+%HG/9+@8W2<=
MO+46,XO4)Y6VD<9$^8I8;S[D[(TFTF%'22BV^=+WX]R+FM^<?[=*$*D*\HK^
M,'9(/V^-5DI/J=OOO3+&6T,6XQ9-,L+(&AG;7I!&$BGNIN!N'"2':2/U:,M#
M!!<\%[*?*"EP\*86&FO5>FJ 'O06P'=JP:)4D_FGEGKQ2Y.T=/*:S/7DSLF@
M)OL0#<$GD?CH>Z/E1:Z<;L>*%Q30;3</01ZP23C-#=A!S,$G/Y CP$*,"UYA
M?U$.00EOJ662UZA%'8%!I$0]"RI78J$MC*P$1MA!8YI7Y#:XEP>S1<HZZYI]
MQ#.&/J6F7)T%I)B2GGZ+O %<S%RM(\,$O2;'8^DZ.)1MW?O1H$/0J>7,R;&Z
MDFE.%LL(6+%G5MJ.QGC-R?RD,PI?-C635*]/F5[?]V!P78G3)_C"041>U93>
M?164=MR% =Z-\\S;I/CN[///[O<%KO](.1Z6;1ZGLLJ=X'"F[=6$FV83$L])
MO<*LI[ 9[4FR%3Y17<919PO9>2Y^;>53PIM%U]E(AK1K. RED0O"?"4E/E'S
M>/Q]A>9<7I.629";[0LA3B<*G<WJ13.L8]N'\#?SE+A/MB<I2>CFHMVI<:>R
M$9M=RJBB1;U5.#-(5@X*#T$/^P)HPW/=D=ZKS>!WTV(P7KH%M:YS/9*R>+V9
M1P=*<\CJK,@MA7N)KMRZUEQTDS*36>:9,>!H-[.L3M-ZU/L$:HP*918PTXSQ
M5DD*?;+A>9@LG1M@)DM;HT"-R*]OR0163^L=GG.0)X_#T3C@\?S-]TWO[U41
M%5M*D9Z?'6O\@X]Y.A&L#D&^L)A,..5./R"MU(Y_<0BJ*2@A)<?D27T8;!5"
MS*A6)XWY&!#M"4-J8 &Z-?"JVJ&]UY\LX4X;HO4;-:DOU-HG\WS[CL A)*.+
M;@AMKNW_82[I0CVA$_GSZ&AM!3LZ'$B?OZ:T']:S2-8(AS#+LZ<=>TH=4,[>
M8-]#$.N);-P$,MYD1$',IGG8)4M!IL-=&?>KH4NL]^JG=D-Q GNJ/_I_4/;F
M\5#V;___M I)MNRF+-E)]G6N<B'$A.S+7)*$A)"QS139MZN$LDVR3-;).I)F
MLH>0/4N8$;)E1NC$++_!YW-_KON^O]_?[_'[8\8Y9LXYW\MQ'._C>,S[?#V3
M<%*NRCCE6:&>F <B?!_G?IUF9[W]KMY:!Z&<X)IAW '/Z11>^VOCDYL,8B&R
MI5NDN]##L/RF9T0PQ[9F/PO\"J%248)P1J>G(4V/>._AL2/)Q/!%V=X+CUK\
MFFJD2O39,F?3->4Z[+20N'*R4F8=6LJF>*HLPB3V$Y)33Q#^B\"4HF-,&B,&
M1P>E'@?66P02EUS$2!T?O$:S\C)#JSJUY*KF"[*F%R;N*MY3K+B=UVGQMJ$>
M_[;A7<V[R!"]26 ?']U.+<1=1GR:F%E[2MKV/0;$?LQ2JPIYU3G+IO6KPR&U
MG1I\LYI\,9UPIY:T'JV".3:S)%#X:UG@0VU]_0H17EDI[Y93"/:TJ[A#_4@'
M1:7J,0.*C.($Z:$X>:Q5S4^_PBMK"]_R(>!F?6V,9K@I <,#.-J1?S^N5#6>
MVYEV!L&#VV[8:[]DO4)DPH8\=)@XOPNF,2N3K6P!04;C[(!<<O8?0[54F#-@
M[;%G2KDZ$/C!;HI-]L9(N!C:9:4QHKAHV_BO]VI<W[ZV"A,GH2=:)VOC3Y,^
MV=RT[TSA_ZG<XG)F;EJ@AQ08\'DRZ4&E8.^#>^[S,;MCV$Y"S6DVK2W=554=
M=R=Y?D*5Y7:Z7T/X=5VTKMUU>Z/(ER)<[?<59LU%.^=DO[^S/;608Y2^R&=J
MQ+'EZ_:X[2^E$2FKW_Y<+99MHS%B;& /*$]<:\_XAF4.>_=!.4VZ'[P6/X<_
M80]'=[KH L:D1(>1>V*X:I("/H2H>!9(A'KF&[O6DO^D"0W\K#4375^4]3_S
ML@2(-+VJ9I[H)XY-W1C;[J'&XG00+3.<]VA"X?<' Y,G%E *F-EU?KC5#90M
MR2,Y,-M3-')W_<JPHES@!Q/-VIZ2@MH1E0\>QH-UWOSN]7F.7.B9)2RV$2%&
M!T7&("9P<D G4Z>/XW8*4)BG6S/Z>K2VM1@HLQYL4BPLY[WU4Y[=E&2#"O(E
M.$)8GYWFU1,R$U]RB*Y-ZRQQ=*D;&>JEBB&;FSW,@:=[QQ%=,X(_Y>1F1[<4
M$Q LWNK7 E13<LG0V?XD'<>RKPY0A;VX\OGWI(PDCR?=X0M5-2%-G5A#F*&0
M%1%_$GC\,<1(Z,Z44MYWW/FQSQN_H[L>E'YE:AW/X&*%<IED</$X^'*DM&K5
MO1E(ON>A:S*,JY(>S+=404/TPI4),#X_7J&%*:YT_XO&.22VTUB1*OL^3U.A
MABB%]EOHV#);GN@BGMCF6SQ:JJ7=*1Q7N4N;M)(=-A=MSM*T>0YH&A'"C$5@
M&T\MPW'#;:$DQ5;V":LY;&O_"4].EYXBN&DSC(?B3T"Q+3WSLAT3R'N]BX@O
M6'D8&I0-\[(-=H@F8.M3U]2QMKQ6OGDAMWUSI3 _[MUWSEP(+(C][*>AT_+$
MR[#\[IS?L']@@8W2<S<;E9660IYK'0%)=UX7%FB*KUU$_:*Q7NJ<KW,14^AT
MN\0S;S:8?N_<Q?ISY24F%CDEC<\ES>]G/[\@R:1@*V5HYB*-68NEG?I 'INS
M;<?L2SL:S:4FP,XAQ,(-R>@8G%BX337I=V*X[YSB67A!6Y9$1BY)_Z, #N51
MY!TZ0OU9Y.KM6CKMO/SPX?:84JLW,C@H^*A$>]L@9.,='<1^G/H>^6,#[\5.
MT<-STD$[19@E;=HI33I(JH>*P:^^";]%!XTB 5]89RY2'6[5.GY2K TC3 *2
M4B4Q^DQM31 HLV&]?629*:MY"$+/*D8@YX<)]P5-P\O//0V5TA)\U)Y2^8D9
M2)1KDR9)FR.V[U<H#SE''07E=4AQ3RJRY=&"4XX^(?-<<%#&2%T<EK"Q]#<K
M'+Q'_<RPUY/+NY@XR&SA]L3V^Q*8M]8TEM1/_(DI7]XMFOJ]FU=6NFR,GE[6
MRBB(>+ Q-0V#.?>JCGS[UO8,ZN\OEV:R+E8#KF DURA ?&;-:B\0V6R$]T()
MP\7,OR"$PZ5BV\#L<O(T"8I9MLU@+9+#Q2Y<$ CSB/"=_:!^?;#.#-9&!]UZ
MCWTVL6X1.3K62G(6W[[L[691UU"=.H<$U,=HEF+YR'%1()\.*G1P#@-3>(]M
M4ZG%Q=1RFABM9YH32,10U  C4C;M[)Y=+3)VMP--R-7OR,J,:V(E( 5<EJ=5
M1P-[RGQ,;4V]46>I469?: ,BCSU.YGJ'47,5*G\M<X;H&.@G>5'%JKXJG&B[
M_>Z.:QP)=4*?)\N#+_1%N9Y%NG[<F[Y*2:9,BW2-.7_<=!X7:TRK]?-+ ]&A
MZ5YU L80:&R97[1B00>K8,>F<E*/8CXQ3PTG*->MQ$UJ2)I4R60?B9;34[Y4
M(?"L>7:$Y463N1B'R>4VDT#/P>)WI?6X"&H59#9VI@ZVFD;J<0*Z&^F@1WJ7
M*-JD0M'?[;_UCJ.<:\A&T8&W+;91',LX@;':;(V?.A W,5'8M[M9'9@P5];Z
M B3:8<EF#+N-3RHM7WV3T/>SV8+[W)T[&M;6H(P[XB"0>-HC9=A$/^4L:DXR
ME0[R0GWMGUMO[D_&28W@Q!T J[;0S$>U5-N.3*R+Z CX(XQ3AY/414B&WAB1
M>/]NI+:'M:%NR(.'DLEYQ;4$Z5Y&!]V9L'.81)Q#-I_!WUEG00R L;XQ>(+&
M$&&$HDRR;=[M[UC:#*MC=RU;R>,=TU%Z!9B,;E\T,DT, W,!9:9DUO%K?ZKW
MY-=53/1[2+37SIBVZ$F3SYD](@><(*I>/^/]$H#*712M='_N:G-4<YI)Y2.Q
M*L0'4KIB&"/31"I%J8BQW-@=T3!7_-I7!\LA]I_60*IWPJ%)I.T\==F>IILI
MBNRF"KU5BL)RF8(9;GXOKG>@1^^5V;;<2)$>]GJ0:U\N;]QB;!,MX!*U=YF1
MJAQE6"\L->_4$.("O-^2Y/&1C<OIL<*F&1-1!W$AD\@VGU0J,F.!(\6D%QG3
M0:>H1=U"K=Z8Y8G[32!.L]?ZON)<9K/X>A2%4VR[FAJOHT@'L?)VJ+GP *FD
M:NVZNF%*!*GQM\-(>;C4F'*K3S$V.;#"X^J7+5_VYI(I\XSZW9R'$QF/,M=/
MYOI7&" CT([3B.9]C#2.&]ELRY@LQ8EC,-+^#: PKE?4ESHL63;9LV%@)F"N
MI?',T[D/!K7OO7N].T5$L:D=6D$_T6$*Z+"0PA_;6;57A06O#570>EW=2V96
MK*:I48QUOA"0W[LS1>N'U$JN8NB@$TQ &'%'CW=Y0C<CD;3]BPB.KX5R+__.
M$R!WI!/-!#M=SF"'[X7K5WHE%OVX.F0P$JXSQFDX(3%: <^*:%/J1#=[[ZQ!
M^8$YJ4\/&%5:@)XF:4CEXRWO^8:F_E:ATOJC]@O.S^[ $[B?7[(#[EA]]M=<
M8$FYF'[O#B]';*#?1G3(S85H_D&]7534%$^V1P,C3CZ89B:#Y3I=WRQH.+UO
M:QK,T--4<,V9;PBMRZEJ8)[_TD,:5[A<+U(A=%$F.LBF2>;&#?]<KR#;#?F]
M\X@N""?2!YF4@3J&XUZFL0[H.(80O@6W#<" /:O16A2[?&SLZTCOKX5-7W2T
MB<E_.'_"GI)W<Y9^_?"T1-[9(Y!7X*.0V>B9>G '2B0<2NK=^OT((0*8$FQ3
MPJ^0?ED +XFL> XG>$!'W@52[][21&NXRA"11*W_0/2Y.#C/8ERQ[(",5<%H
M*JALO?=QZ;PQ5*'5#YSO2 XF] /27O!0BA3^"TZ(XCJ N9KSYOU@>WKR)ZMO
M?W[18!KBV52G\)K26*3)H^ )(R=J&HT+/M>.9PT_0LHV(PV0*_JCMAA>Q^:-
M/*OC2D2=6=)38G^S$JH[7U](._=ETSG Z.W;+QF.WM[)[JK)IE9F!H9Q*OU?
M&C#).J:=  ;"!G!Q/?V+U%!YYJ,_]Z^FH9-DY-=:$;VZTRY:Z:>ZY%HJ+S2=
MXV*.*?V0)'-+PN;U=_,B<#\ BZ)H?(3;LW-HS+'GW2+;W5?L]*-<OH?A>XO1
M+'^KXDVXI"IKHKC,_7998\I%E@OZ>PA]Q;)X9\ISA/(*8*QXQ]> K5G(Q.\V
M?!6R-8P/?Q><,"U0]455ED#JZ+34"LI-P>??#=UU]AX36!7P0<?<J^V!<?P8
M6-ZMKPGSS??\M:QVH[=,#BLMC,B B]'8FJ@56[TGY:$=J',T)H#+KJ%>N9W0
ML*[C3"Q[K_GRB*FNF\50D[9G8;-6USO)-*/W8Q5N-T0$$W.>PSH5(R%UF+5C
M)*ZY7/0:!R,C(9ZL"R('^03I7O[5EB>7M]AA*R):/1J8NJJ=".;LQ)B%3HMB
M':VKG_6QF?VT&=TS'51X99UM7JM$>PK7WV:X9.17Q-<\Z;= ^\.96I[<GT4J
MH:-I<_BX&:Z+  2]=&D*K#6XTI(G.!PT<P;V8_?/QT\F(O"1X9+G7KS]A#V7
ML>(KE?X!H=(!?_J,L/'&ABS;.LW6<VG\(HMF*N=B PML0G.&TPHMM7"VU;UA
MREQ0MF5^1.*4;<%IG>4Y::K;N$P0-Q="G<DU7*NO;*&F@- 9)^3VDJA<?KN:
M)OBI:@194^TB5&)YN6<Q_K.?W3USSX3/KOS#^0[P.,L6Z#)M9!C=-XQ0H=8C
M9W-1M<A5WLH?#R'\M;FLUB1L0I9=N"Q9\F-6-*UN-N(^;5K,/^@U%6,U6*L+
M,QFK8%1U2(7,BKL3X9F7Y,:TKC?FYM:U#S-J<M?UKTQSZFL[Q%1A.'1V+ XA
M"$=: A&OEO)$1XN!M IXID%U0]5($+/*Y-W-KG!5 CMOK^X@E$MEX)OC>%O5
MV2Z5%!/VY1X:BR>CPHK!,DP'-N:#],PDC>+)>P18+.XL/+'-171@D38TM$#N
MB":SMKIPCNB8N86/"MREC9*9HNH^>,G;.)JR:EL@*Y<S1I_*1YV'9(%)]^@@
M2@9^(IC6Y<NH:K?DFC )/>&>Q'L]'W&J<W8WN^;;G02S1S^YIWX<"-JXUU<)
M!J=U\!<+LEN&$L@OA 8>%&FT6+O*;"X-H#4L8L?OZ+'Y33O/Q9X@W5Y:/$NX
M?ZG[KD?51[<R&?X^1RC'X]YY*]DVHG3+"D=4QWRR<4.W/UICH,2RXIIY+<V!
MFDL'S3Y&UF,Z*BZOM.FI(YG"CWPIP'VH>AM+-%W!S+%YRE6Z#"]GZ)T9K'V)
M4:&*$H@O*R3(!HNQ0;(-QWDS&IVV>6\X8Y,0DRB2T<Q$P;8$J91B3&:BB$%X
M$-SM*@]W^U,0 O5U@3K"XNO<:JES/JR,;(NJ_^=;_+NTU=&LD0*O"4ZG[#!=
M?:NA]?7-/6U&-"%98@ I]C4W,FR[%!B??;^>)'*)%/N(QDEQ!J))Z\UZ)X!@
M(EM ,X*_=I#"-&<&:]UUJ2H=O[N;<QD>U<[KO^2_S#OQLTYW[3-O6O^9E$;S
MY_43/OAU&(5#<3N1#%WKVI-$?('5Q*[)EWG!>+@^<BQ-GQI6[>=V42NH!*((
MT/;U,_ TLYHO0;T.WWM*O"8RG@814-R=OIAEY2DOPX[?IECU,[LW']22>?F!
ML68A2 8<U<8?RWQ'1UEKW.S>[Z@'3=5U,N/W+7*L\V/S'9ES1M^0-<HC-(EO
M-Y=_-1#<$M[D2(^U2O(XZ39/L_I7(E_"W?^>U< H$.]:]+[Y'N[Z<B'0:^!S
MS;W7Z>$&H79-6<F0,H(?SX7HMIM%JW-R-]_63N2:\&6>0VK#:C 43LQV'+4$
M>8<1?(;!IRCVI& ;$B:R,\5U-)PUF CATR=KK(@<&[1U;B*M%<=[SC)*:G;C
M2N^LF[L^B['RQ63K#Q]60W%9B@J;VQGN4;^<0%JVF_N_,YX%UOU)DMM-P-">
M %!SX^XF,CX B)EI]?O65><*%)%B5FP3EB?XLF^K;<!3F]_"HS'?^9XMK+<*
M\&09?N[";J316!3W%&<0O7@L;P<D$B<R@*:UC31Y@N,1YSQ';59[0@CL<1M&
ME8"MT:";-5L -5D!+1E5'7>Z,2,V2"#J$?3'E'*G9B^,"][SN"&FGA-^S=W>
M]QS)1B;]%,%%-E;)9Z#3"J-WWV'K$M_$\[?D,G>MIP7Q9:H]@IA> !7Y(!3!
M3PH6)%&%G)0L>P,4N.:N2SALM)6K<[A:5CPNN:J#S8>"H]"V'#(.+3EEKDM7
MWIGT%^ZSI8XW4U_1%&F?\E2I=;48#HHD"=.\?GP) 1E%8\G8N":+(@ +&T((
M3?1>K L@5$#,2.8UKUVH>*NZ#Z2%6)[UN-HE#.6*F[^;^,.J%PJ2E'G,"HK&
M,E;^E=8&(9G"QK';@J1O4^=H$F1J:C1%D?C43?35L HL]L823@THJ/C3]<(7
M>"JQ&$U8RD78W5^M<W9@"KEA*H3ZU!X(&+6/+PK/\__F6E!D%\H4;-?LX(U:
M&FC=X^^)V5C5;W$EVV4U]8YAXMJLVJX^\)*YW(ISEKR[ =2UV(./+HRSGW;O
M.?NK',SZ':B\5.+(L98O(OK9;X4WKH6P]*#H:@J8W?()0;"K6W6NMSRDT,*
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M"JF?\3_6AZSU7 C)4(!9]!3$YZ_Z![EJV9225;(S9<('OO]^^!Y2URT+E,
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MG*6#1?4P2D4<#-?5P[X,'1B-_?#2+^J9%_\=";<?@:P/F65O#^9I3&6?Y7@
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M4(0E2?N[.'<@=/Q&P](MVX<^VK3- Z'L@B;<WM:[]6<^R*3S:-PLXV&R-N=
M#& _33UW)N*OM /&;7G,B/X9;@VFQ"I[/=FX2_8>9Q?X@._PQH;5<[Q[5MH?
M;Y&^>MZ2=7V;+AEG9_REPCKL5(?>M QGR1F'- "YS45]- _L$"93$V <X<:5
M<&]"^M9\7V+Q#Q?!7/D@)/A*L<OC4BK6XF&6O'IK?59[TD,SCJKW'X9]RRLG
M3@XF1Q=M]2]O1Y&BMKFI.12/V=RC0W\ S@1,?%9>38$#7&;,91C<-JW7,!:D
M_360*O#++-6I:;3N/?_/.F9BRI!5@K;VM?N"@<H?13^'KU.XU(E,,>'.>]*
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MI*79]UFWXLU@K^_[9Q/O_N5GRI[ZT;:#*,ERT]-4^;/2N WKY%CV#;2!6X"
ME[6,B<J28>&R^8U8E<P?1I1S8-HU5,OZG@QLKP2(HK A."@*@ \1F4@'G0V7
M)8TUUP\XP]/:)UY[9H5.F7YWF"QME_^VG1^FQE]0-;BYXOW!9&<NQ3YC<-#M
MN+)9M20-B[P+&Y_["*[%/QHBT$%M8N63GJ.-O:@XE0^VK=B,>JW1M++Q*\%W
M,]4"8';+#Q72[&'3XTZ3TW;.^N*\<LM/I]I]_=GGV&-Q0L"Q;3##@5,HZE\N
MCJAR P$E/\[BXHGLO,YV4*0K'<2,CZ[K/U5!*W@S8;<D$/APKD/M]VC M'QN
MSCDMZ[;B!S;3]K 5':$YB@CKHQH7@1Y/6TS[2T/;MO$%)F8=[3Q!?IFSNWT"
MW(O,OZQ+9.H*^%V?)=MWI+L8E0OA17:](H1KRM>76%L0DF0]V2./2;%)0$W+
M]+'^FE#^)*D[+^64M@K2[UA7J7@/;,.OZ^HHG*FX=B<MUTF>Y46Y8EWB? 5?
M1#]IG<:,W5.A7")MP*/FA.<[V]E@1D.O(F#M"-TQC H[LZ>:0U"3GV%&HRZN
MPL?5[;6=0\O?[;QQJO+N\@0GN2\MHC'@M[3C7K"CBDV"83Y[.NJ/^Q_7^G+
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MDW!'@!*WTUAC@K./Q,B]"^,+RRXBPSZ+@^%&:/V%ZA:L>I;P%D7M07=X@Z+
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M?2@YM6!":3RZNM@I=KDFY^+HVLVV3$E'[SOP"<A3,,UE.AX*0M^%_@6MWNY
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MW2=OB4DSSSTD2[^Y[OF;AEIV)DIZTO%3PS>A+TAC9J.2I<H5R1?7;,1_O?-
MD8(^@9IN$\_B'-5XPYE"\3,/OF,:&'YI<21C! UHMC?HB9<>:<804/PUM*!?
MZ1K82/?J@7*-0J4W(SC];O*Q+%_?G?(#!,2@WG VAB6$9LQQ03%/D(@O;9<
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MU681#:QIW<DUOJ%WW4IXM[\P(9:#-2N=665&%K45<2[A'ZZ%<D$L04W.T7H
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M@0M_#V[A[6'JW3V.-#/J;&(9P"'IDI*?JXI?'X;\6IDBJ00=OCL;7W+T_M-
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M=\''M*V23UODVXZ/=%KJ;S]MP#X-1)V<=9)A&74A7#-G=^:\7P6J5]A?\DO
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MYJ ,>O:Z8?M6LR46/ZL2V!R&@$03#?+8T[O'[,+10T2'GXMAF(4/]:<W1"J
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M_8>1EP;GD]$2B*G%R1W5*^^\%\_X2JOBCCI.,5.L'",D83*WP^/*TQ6U >F
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M.$2[V)7'#?&@6\"&U-S&+7 4']P-SI8Z( 3F=)-(8$J Y&"NQ/91IA][ 46
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MYL+F, P_9S<-@\&,X<N&(,G="74HJ=%@F(1N6G5/'L9THZ2J.@ "YM*Q[77
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M1V.@O.B4,YA^;P^)*W5LH7*0#?Q+YH9UEV_;@)CE3/3)TO# C' '2Y8#X1G
M_1SL8L%QB>C$C:X?O;W]\*L&F_E[%K#-(_#4'LS/BAW.'@/9$X-$\<V,BF@,
MRZ$O?"%_-#(;$ $+PC+#$=##!&LX#6Q2JC7==FS0;P0$16W62=SJ)0 #.P;
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M2\&,[URW%X#Z_P;54Q58TDC?_.N]8'41[*R_HWSIWPQ-:8'[ >(W6\YLXI8
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M5*V/ +O]K6I&E<&7JL0_ZD^*9<YW!H[G]<,'MAG:Q/\MM0EC^2B[PC92O9<
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M^%<S&SL:$1=R$B?O,#QDV\L5&Q :QY_^B1S\NZ4IH+;/$,[3(>\ UJ7QK)G
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M]>.UVP,647\111W4*@!>CP%,NM"G+M9?P%&B<(T(U61^F0J,[<V&\J!$('Q
M"I(P*="N2B.SYL/-IL+\(/4V]VX>M1^0LEE\.09$=ULICX$$PFT^:#&6;0$2
MQ-4>/RR+ =S''9AU]!2$J>.XV&]9OIH15L#Y(E)]A^LM9L^#3E4@$X1TH*,%
MO4P:"LD=$CC0XZ;B0'F,C%>&"0*@\08 S9=K&"B2AM-B_U$L'S+"I"ZPB<-,
MU#]\*H["F!OYP_%RIB&^8SU^*H*C;=GW">D/NNE3&$=+,G/_@5E)[)U;]FG_
M,915/H-JV 5;U%K?ZNU:_NO=HCXTOP [UD]Z_8F@B)6&9]^9R!\"O0P9T(2/
MPEB]$@KT;2RE%8D=V6!&,0#X-MSI5F!Y8']K/B?W"P@SB?6 F$9$)1 ! ,CQ
M(#,A!J!]GN4_$"J5>18-".3D'LX2H.U_Q?V-0%.ZN6*$H<L%,'#:_MO)C.':
MOQ-F@LUGN%4+@S2%\$$L+B7P59\(5)\*8H.HD,GG+,MW,H*D*#G@(_B[; L(
M8.M,^2F;M@O>GXCX&MGCM<*?82\"EP),N+/_+.:0V^.%P)9E5'H9/*")'"5S
ME,E<+A!&0S1>O -XC'X IY!TK_'V3"W-WX)R=40O/BG]CX>X&U'TPJWU1<QW
M*F/M-MQNJ(O<<^X71F>"P%)**Q;^)FCE(D9(!Z$U&/B6.DPSQP0Q.X0;2G0A
M3/=49&;8-\#+.:N9BK1 D7?1SF=,VK*G,TFKG(O</*8ZNDQ6.E=Q@V%U=^]^
MGSLUXFLL\YFWYZ[ZQ!2ZOJE8:N[7E( ".FKOFU>:=]CAD'-%DO6<+3M$C_='
M=\J9A40^-%C17Y-:^;"?)!27:R42X$UHV8LJY-D^M2(M.O*BP]SSJ/75M[8.
M7_(:'2H23.=?HQ@;YY5=-[O?;C;XAVB3O,@G7X,6LJMA#VK&8EF/IP6,)34K
M)W/OP?2O\" CNW:\5_<)V)3Q(GS/@1*+_&:O,Q%PEZ-$YAHI5 /5GP,D$':8
MB%]%-"I+EM@W\^:(<^@8DQW&S[ E3F,#?XR6#"2NDS"&>PD>?L>19BV*:R<F
M@.K>__5 R3^(6\__A(>"<['Z)FYX'M)O!C<O7#Z2;RG7\I+G;P28"3- -)=G
M!;2HACAVG7KMU07<&4#:I'QQCT/!'VX%6E,L$!S@<#P.8.WW+ON3KC%I^!D3
MD1K-LTPAMK)]+4U &ZSY I'SD08/3;:QSKOF+5V%YN-8TSY(4!PY="S63^$H
M!7*-#*LI8&*NV*-@E;?!*F>RE<$J4[!5;FE4C,O6LHOC?-J0;7T>VX;VL)^+
M#"6>;D6>]H#H_.G0DP"6*2JAC<9+=52!YS/Y?-\-^#Z5"TPV_2N09$;&WCJ:
M''P0\\&%<1_\DS!8'+$5^#7%*XA8O*M<2M(5J?DSB@P!4X%PE!' '*'.9=LX
M8)2^3CHV;(A:WA;KGP)S4]4ETI&]#  ID(D-6$.4O9YEH\]T>DGQ=[O,EC)<
M +4/\*D-4+?MDO<GA.F,L-E667E;X;[5Y9F,*'$>=*L"H.FI_X^Y-X&'^FO_
MAZ=5):DD6YDV(5M*EI(I?1&*["&FDFR)%B'#IPT1^9:MB,F6+4V%J# QM&=?
M0AE#=C*3;<SZG,_,\$7][OO[/,___W^>U^OG=[_N[IDSYYSK.N]K.=>YWJQ0
M+*.TDXT ".8N/!K+4(&81SR:P:\+>/,V"/B^60)T5;!!3^ -,F[*C:#!V7AC
M?DYJ [T"J@'P=$\3@F''/;GD[N_?0<)7*F/[H=-$QBXB@)!94E_XJU+"EF+%
M.DZ! ?#%O]G=V#G@=]]0@00^O>MP+/,FA49CD?^=D")P3JC137 N4X2;=);^
M@XQ^^U8BRKGC,BRE-^ LVU:QL'\\G%6T;= (7P0'0S? ET.N%ISB::M:++FF
M_2*5GZX:04\C,AD 3U&L#+7!5C#-UW^$9,B1W,,41DU>?\=),;3(]2E1@6!H
M#XFY'BSQ81:KYG?)_]%T_A=ANQ#&PZ59SDJ#+?!5^C XR4*5_W5M7MS6JO[;
M4,[MNS&+F/$!>'+V2S:BKDMIKB[]MZ'RK."><+"BX*<4Y7_/WN ?Y-CK>-"S
MIN;ABQ;(00M#W8)(V'.*=\:EXF<?'+TY2W%3N]>C=":4.&$&HQ^RZ4[\)Q_W
MWL(L8/(D43R3]R^&<052@JK!XG?XH%G[(@:?@, Z.9M[O*<<I=]75!O1HIZ(
MG3=UF+*/%G7ZGKJ$'M\)ST4\X 0SF@"-6L"KF<;B9FY;Z*9:A_&P!2QGM<'O
M6(_ KVS$-UA('LPC4#,>3 D<8$C&-^A<WGDY13:B!<SI@'%5M])<U"'J^&\$
MGP9S-4>. Q0E %>'^!% #=1_G07L&]4-^">3P%7N9-V881^PH^8 -'A;W(M+
MG?N%?<R4"V^H@G0U !H GX>[@*N$Z@5!]WU-)4Z>#0-$KV,,8(*#PB7<>W%]
MP1:YIG:]02(5HP0GS3YZ,U30S"/89J / L'P@F9:!\1LC:M$S*N-*;G-K4+(
M$J*K@Y]^ROEI<@TTI@TY(1FJ2'!"?S-2,S%"O0:M!\&5(@U+F0\@\E=HXE<$
MU1E/2T+E1K D!%FL_[@3#YQQ*<%#8A&3X.,A-,9V^-?WL,356!FH01!#!.%A
M,^#O!V:6A&2=(N,95P452,6F'3E^;,2)3J([%,*T!4&*6@WZ($30!9/@8\8#
MH *8QYD&D?801"\02QQ(;O9$%D/-&-6)#CS  P8O)_3O!*LW!_^M!-B(&@N.
M >#=U_2)8QDI1 )QW$L(:/^+)KF.*TO;K7K=FX8@D@MT.D>.1,-(4Q64PMJI
MKZ5#N\BM#"6Y=KK'BH*@70K;74UD&AST*/SH+VM.6\;Y+@HDO!75O;5&2Q#,
M;"V?\55D[DTVXM4)>&:3*U9:L^:O.YA-9MI MAT,.E*OI=.YIB<I),?(/,ML
M/*HNV\!5H2P/Y6UB5YH'#)$.19@<Y&9V+5$HS',L!DUJ6NIX%)O==>^Q\?.*
M=L_\$_;A3KK9YLIKON']@C(:;!1K,J(28K_P'@G]%RE;-3%G2FFRZ0\;,Q(N
M//J;?OY!^^8H_C%P)'1@^\CB)5 J5:QJB+-4-%VP10TYLA]X$FS$.Q(T5^_G
M2]H2#(W'LM'T59VCK:S$BTT_M3R22_X&OQT.?GOFH2/7X,>XXS" 3S17^9>W
M61$B N0XRL^[[/DR:E7[^[?^DPI?P3\O]&"%XGBJ![O ,"#H#8D:&U_Y1UW-
MKX^' K#2&R0!L*+"8"4=\:41^_7R.*NN#$!H*F2W@"X7Q$;T9DW-A^,QON12
MU>%2\'!14O\-5B6*>@8%%'?.SLOZ7] X^^L]"]WB8POUH<ALQ!7(T9/(%$8#
M:S*5/_FOI]MBULK^/$!$BTPB=CY75E4LZ>@-S&3@],4)TS6 "PNF$M"G25"S
MG7*F%Q;E!L4R&L R">\F/>B<4=2R9KZ;+ D#VPIBM"P1.L!$TC,@N.] !*@Q
M;3;""<5013'ICQ-1ZGX_L$I#\KM><5(5SE^ZX/->%3N^]H0'4QW3H^,O!C8"
MG%!S)=@N$QS D7J%(B5#_8&L2HAZ!J)/& Z\Q#.7HD:D>-%+!3 MZ%%+J)N?
MBUV]N)397P!;;,P\@F^N B,#A WHI?T$.*)MS/@P;?(_DG T.=3((BX 7[2J
MP<Z>.- <:58&>A"$O4% 4OB+_MY .9.D6:>>3IM\SR:F,';R&L?D]^R6ZZVB
M.F-I25 NEB6!9#%K?E^6UFL BM5P!\*CT]Y0H1LKM(I1ZL#QAA*$1YTX<\=-
MS[U_/_W 908_\P$+2WX,X<:[4$]ZUN+'X8F\&O+S2\S.;[J7:$60"Y 'VK>6
M:PIFI&R]YPS7^[O(I",J=Y^RA TWL7L2)5 4EA;C"3R=N.>?"L:Y VK4H'4A
MPE] ^\ \ *P#DSWQ,V+6:FMGG7/H?UC6/R+I^T0_ #9"16[\P@+6APAT.L.H
M=[:)G"VA#=/935VX..]J7;O38"_JYWV(,Q&(EH3-Q;$DE,"VSS9SLS0EP1F7
MC(<+P/N# BKQU#-XCJJ@F$>JFH&E$HCEJ,I_F$2>50T:+J,>.X!R0C-4T1PU
M0;(RG 8'P+9^XJC)G&,X4T5LY'IQL^?*K8<VWSGN!1;ER%&1F:[8'.W($1ZU
MFCM=;FUOEAA]-Q#G<\X)G 7;@MM(:=D=,X<XRDP&*U11&K^(0@>!8/C;=_6
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M'YG&> %NC4_$(-SF/!E$V]O%(F*9>SG^V,<9G<7R1Y$,%3ZF":H93$T ?"X
MSNZ#@#M+FJX%?ALL>?@+ZDDW<50*3.ZV!*>\]P]C#@F/BC(?PJZLX3@&N++
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MA'36']U[\]#W'SQJNZ4#T]']=;P-IT-E(] --Z<805V2[5;_U@,H2TKKUO#
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MSS@LK8./V2D[W_JNNDA/M.OV(OV_N\6V%,;R/>@J+$$&20B')5X(?GLD.X;
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M[+;^RJ66?^EB+ '0+& C2O>7B/<V76X+?LC83JT0OOM!A>9=AE]?I?K"/?G
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M3";;X+\>&(]L5&1HN'7F>+07W#R>5UB27Q>@94WU>W/I57[. U-CGQ:/$'#
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M<O6Y'&^J@?!>"#:2_H:J%9/(']9P/\O$04FLSCW;1:($'NC[(N=9WU>"5XZ
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M7*$!O0.5EM%/" ]-<;2S/PCZPKJ;]79U6*I'QF38^MBV4QQ-G-)X=+J,@EH
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M@N1?Y[PR=E49(=3>R1=CNR[$AB<:=#QP6YBY?$<G'J0B@9E-0):-[!NY# 0
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MZ' :5@.Z5&\A'R[)'> #'6$E0M;B[M82A6))7M/O<B+T'7959=Z49U?KBO_
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M+L<NZHVN2ZC<_D'=NA,]M6BR&8N;JX/*3 C*%NCIR,=G3P6JCCJ.@^N+L>^
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ML8Y,&HH'*/U))OX;P_HR_/<%.DO!&MO^Y@TTW]K?DUD^\1_'<OH7WH/6#A6
MS'" 4 Z ;?[WM1BW'!N/VS=>RI[I^!\@$?3>!IG5G*K_BA8#E<O35&-?ZV0
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MIAT_HZ 8AHA];)(&XO]AG:Z2("W:T%>+M3R6DJ&_6<A_K-SPC'JJH+16BM=
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M&ZJ+-'ATV>Y9"F"@V[L=ME-,Y 4+]_4 <TN("3.+3A2 E>ZN(@4P/X0+@5(
M++#FZ_7@S8NM%, &^)TBF84""$?XH19A$=1+FABAR#W]^G\,=^S)/="][ G0
M.T2#(*^/[]%@']&#*R/@L-4]R8A7M&9B]HC"V70*P!H^0Y;T-3_LCX/!U;\7
M%'K!,"A]=3 7N<1Z1W73E2"-U1ZDGQ!'@]^,GK;^TN?-ZX;0P(U4D>K<BP<5
MXW^DF5O6L^=F?5!3#/,OM'8Y\6+G*'!)?]!F#6T=_J!2%[3##[U&<,)H^X!.
M$IEQ%36]P(&$TSAZ/V?8<3?OCD UN;ERT4@I'6VOYQ\:-D>TUKY+Q^8D7CRV
M<4X=.T^>K&JHSQG[-D,\Q80)B0F"47, XNUNMMX[!$U<G&E5QX=Z;4^F@$JK
M=)M1UI+*$I/UW0_GLKS9R_"^J5,-V<MQ7R^5;!K-;IFZ]*;;C_5/P3[#-'B$
MZBT):!&,G(MIS6-.%Q&(AUHA(G8ZO=OI:W%L<@SZZ%=I5TWL5751H7S4#GC]
M!D9!"5QK F?O267_B#_YQ)CN5H%:N;N688NF?MIHKLL:YP3?.]W\K[G]JL+E
MNGG4M5A]3?*@-5E8\=I+,SAV,GM,3?Q?<U)@&SP*W04*)O).J9;/KRT:+9%0
M7VZ_>@Q;RK[ MZN8;[G$U1H:5KH46MV;5*40)]GPV#V'3KI6(X8U!FOSR,:\
MB'-58RQ5;[#<<*ZL(Q-8I.44IM_2MAI\V2MRFE-*Z2SA01.#\0GC.U,G77;+
MNU>2,F]E^-I>VY6TJ3-GFA#6FE6"=U;8G0S8 '[K,\2C:Z50)[VEB 8X%?B9
MFVD$UR:>"_F=7P+458^\[UM[,'=%)=OIY?S[N:[!^C=FGYX.OFT3%ENW,$(G
MD517)4EKC)HB]LPG@I.&DH/0/^L['%3FC!%:V5*=D,L824]II#YQS<VT]*P%
M_V%S/C!](-(W*Z+<\/E&/%> HECD^.)2WN!]9^TM^E7)P3D*P-D;^,.8$Q'*
M#!JA ]ZBW\CI;:$  LA1:P1X.[&3Q.3 )'K&G *00HV?RWZ%YM\=ZV::,X^/
MH0"82<(AN;MSY*T-U@$3&![460W;@\S./4=935$ Q?&^8:/:6S';QC8/B<"9
MSM(*8"5\17PUIQ-- +6G0I?%'5 4@)H2_%BA(N_VG:5%.<1/V'7S5/^;Z]J3
M10W]+MI?:"KN8B#\V!SX:N"@1=AJP :'9N(<\/OET>P<4X+5K=Y*50\#4VM3
MK<3,!T=>WL#;;':92SP,%_PLD20N>NAYZX67AJ&<#S*DL:KO7)8T&KB6D5C1
M1[!"V]C11)=TL/H! VEV)X6V]XE/5[.QPQ>+7VM].W\7$WPHY ;I-@E1%% (
M?RM'U)%KW&E=#DLNB.DGWQOT<745/ 5:X++S%/SK VAFU.2SY5/5*3YO4./'
M3QJ<MX_#R]0CLODZVK)2#WLO7T4@[%USLDAOW^9VA)ZL%DQM-\I(9>_13SW:
M/)0?.;U<OBKV32 ID(!>O/5/5:<<T$/J G1!KY&2%1A$2IQN)A+:ULBG1+TY
MOK_+N8B_SI<0Q-?TL>6L3K\;?/<,V3/"SZ]M=%;X</2-L1NP6ECUH08\]^9M
MW%;# @,SZ!WY &&G22=\[F%5:33H(/36KK@OU-"*Y>7[%D8+AW<8W)%L1T_H
MP^+B_)_+R<S'<BZ&@EL9A%NRY5:[=/(^+2&?V?]565@:_/H2NU%^RN::RMWS
M"GI)<N%'AY//]ZTG[NK/]0(Y4 ]183K<VL4W)Y #<4T[U9^.YL>Z\W8[5)^U
M-9WQ7_[2U?M0H<2(*[=K)5M488W7W*SAV(> 2^37&-@I8XRW(D9AV6>*_55[
M_I99M):8FXCAD[<_!-9$HZ G>4^KF.68ALYE(G 6@L^G3HK@%H()WI6\DF$8
M8M,\$3\=?)6@?JWI25'6EAL4?<(/R9-AT*4I#YR1V"^ZZBK#"D1+RLA<Q;2)
M'+U3NLHL!V9!QV"3&<1K%$#^V_%VTMWU05(3$AWF@UHU].:$#=S$69%3/"#>
M$WW;2^MM5$\?]X8"6%3^")NOX]_16*>&C'#]4-AB8@MJPY3JR)$3=+O!_^A:
M[[V$Y\$#]!,P7Y 5!1#D,-'.,3=ZH7O=%9=3D.@5AY8JATRG4,]D(5+6?*LN
MFL8J15+S(BEG2H8.!9I(*9\7+9G*$$0\C1V1((^#/%"8.6 !!4 Z1@%PH'!P
MG#$%H, %^C_](Y$UJ7"S:W7WU18\<(QC"L^^=  +#P&?%"L:8VSUQ)82-3!Q
MF?6%!7T2 Q?>#,J$=$NY>D2]>_'S6\000V:+69 [U['ZW!81U0TZC#:1E;Z6
M?5"Y**81>'S!@^G=EQ#>TEXHG]T1)(:D]L% L>O^@S'3^?([^7G\B[IB>4<'
MV\0M&7/YL9*L5S\G#6F[OBP'+;3H@#P4J!OYL!*!-^6^.:P.B$&==4,9GV:V
M/-$0XN\O87*YILYBWMAURR,JGW&U=^?$W*/4&SJW^[!; =Y\MK%]#9H:V+80
MA$TU4Y\8\2\%"&+ 6EAN;D>J@">9)Y.QU\Y59)6-R^?1JOF/W"KT]X=O1H>;
M(.R?=>\@!$U7(%G97X$5>]-:XP@P_8;YP6_$.S^)QA@P2X/U6\,P]4Y,+Q'D
MXA;(IN8<]+7H4'=RX-3K3Q 7AJ,A"?AG#D@HJDBCK83(*H[!$I8U+,=![$"_
MG]9;MK%9;#OWR-=0>/;!Q>J&2QZ*3>]$)+Q -S3XNGU&[3/=TX>'-1X*-3QZ
M/SS42O!5!MG)\[D@S&Q)-W9;-D=(7RL/[*JKX5J)#,D$M!H/HS9'#C7\'WL*
M3^K_U/[.K&ZZ91'83S[?YY-T(<G<*W/I2)_5)X<I]]W)U2J-32WJZ?*5"500
MYQ>':\$VAF79DKE_1BT1KV*]#D!6),W%M<.-HA5Y#;L<[+,:EGPC6L[G5156
M[!K&?_2KL=G2O<W0L.VJ+.;N) LVKHXUTX*?![WTYJ4F]5ID%ALNQAE,]&NL
M.+M;DO7W_K0R1 @=NE?KN0))R\GU,N(%;]MZ?FZAKDM>DI=*TXO6!^ &)$%@
MI1;$0Q0B!(V'\-;!6;*+X!QNW/5DSJ[I[D*'8\II9F,+L:+3<8=*8MBJ)2O*
MS62>EAG'WA6Q^EB?DEHA>PP<9&#H:5.="3ZO-$L*ASW;A0_4M>OA$@K&%[29
MW81->[3R7!Q3N2'7&SR\$R^Q]>:WQ;Q0@12U@ M,&S_8E ='Y]^\( [),*M[
M7!*S'@ ;3Z4 "ASS=DVTWVDXTJB+2GRSE48^6SE\+)^P^;1$ 5PX5T;_^2_X
M3&^@;J9,YN7LSH6_E,BD; K _L3MS=>=737>)SO$*_EQ\\($Y$ICNN.A6 H@
M,*W )4:+*[LJHO5)VOW[PTQ%8C$.GND!R$=%E='K186G&G G6 S4M31+,O_R
M?D.N1Q7!T*B!$G6"K^5$/'MC;%:U2+>"O&L:RF>==')'QK(34F1M;T18X+GX
M,Y;_9?6KFO-F42XFT,9W&<=D5X:L-C_B@$M\F400"B<5@5T2 AZWJ3Y?T&W<
M$,TE&5R@D3%BXV16%#Z[LUD>KA+P1.!CV^:/K X?DP./X"<Z#-O%+#1%YW)"
MQ[V3O)O'<#H,XKY*I[J\.:'W.S9"P&B/,U4H/P7M+Z)5TYFI<ZOJG4TIMN60
MI9Z/5;GY[H_9I(MC8+8%!:?Z3RC-"SQTJXXBA%$-5YZ@FV)]'>YG2O^NTAP;
MD"S\*'8Z08*)R42V9FU#MG4X-OY;F'SG][H.Y=[&@ WN<RV2WLRZFH:Q1MK*
M21TV)/?7NQIX._)Q>9QV$^IX]44"[UT<HD$88M7(<P0/\G/>+A+EKM.UB=[:
MF0YR3ZL5G6I AM@O1[=QYAA.AS-P3E\5%+1ONV4\V806#_ 6(RA/:'(W)1SM
MCM/J<[;92L-UFMBRO7CH(!&OUZ_P:.U>]X4CW)DO9@G"BI7%6\^'AI5K.O0%
MOVM*EP]D TB#!%J-'410S9R3FL#R^U4:4D^PIR[9BJM\L*%_1P0IO)VZUC_"
M-Y*3>>I]V)7!$9O'9O3W?3<P1A]_$H*H[[Q!T'^2,F8*5<(9!RH\S&P]&XT'
M,IO=M^;AL)Y6#9DL>US=(VGWK094F2MG&#ZB8LKK97\_ERB1A!S2ZBW?R$=M
M>P.\A'>O$:UP3;7(T!UP@SCS;'D8D7<SSRU%,XF@U#LXC>W:==7H%ED2=6Z!
M.-S/"QXPT71EN6$^W_H\^L/RM>$?I1&+\$'DYCQ!%=\R7HW"S=19G".$(.P\
M<E(QNRV>R-,V/)R%G>&B_/<+N\78;-;;V>>W['C1=%D71!X;169\ZT@4 PE8
M?]6W%1/J]:0 J':'([U#V0(!WJU.1/6()E/58,DG^$B+TYI7W+2U.QR"Z6_
MSA1A4.1^_!&?BV="GO8MCEE)*_]PY;'V?^8-:1]RVDPG>.ZJFT&E_&O*I8,+
MTW#.9)$8?261KG4-UGB76:),]*.:6?+%OGMIUU,>D%(>,.B\'E\-'DHY#:57
M/KLZ-=D5TV6^LOUZ4WHQ8/<^F-QJ2D9"TN>D+7AQ3(&CS1LDH>_.809=R&=W
M\FJSK>V<+KV\-D)*<"VIRBL+[U14YUAB75DR;6,'?O4G'P?O2@4=<&/&,CQ@
M$25%*HA:BZ,!=X._N>2EKCRZ<K3[GCNOT^MP$-Q4*%E/U\BH1",;A>QFJD0]
M#1MTP,34,H6"V<@7YKV!^,B$D_A"BPO%N,:HQ/Y9U]BV3S9?">5C#[H@13(.
M14N7:P_GQ#$-(#PU%CX_R!!QK+SW1 NUV4G*]>8D=U0?P<']H*<3"0OJJ)^5
M]UV&RBH-TZS9I,)-89;S<K 8R.4/6*\75F5K.1.0\"$T>V3.Z$O<U[&X;H.U
MEJ@F#6FORI6= SM6NYSD@3$&Z@G4P7=GY0T4\H6P9= C">*Q31 H*<45?\(L
M+!S.K?ZI<#55F;'3=E3@Y_(9O)B$!B)<HBCZ-./[:\/7"S\TC,.+'9K:Z<D=
M8.9U(!>!7Q,O%I-JXWVP2T'4T0$;IRC6HN-UJZ5>2: G-9:C,-[*K-A.JKAW
MZ8PLS[+L#_RPL%F*S=EP8IBRM*S,U[DGU-ORW05Z#P&/4V]KQ:>/APX/]R>?
MMS6MK!;KE9PLPS7&8%I&I!<]?*,C'!@A4IG8;+99\TO1US]9LD'.)-]IEB^0
M4UT#+L'PJ#I8(7W#5ZC[^ BH7N[I!Z#/.N3HD%MLEV9^=\AHO$N&ML*;<\)&
MO=G>/YJ]3@6TCD=]>LQT')!*-DGRI]Y*A8D9 O**Q$2*!CF8NXZ'AMB,,_',
M;HU*$F!/J*',<OC^@_IJ 5Q5H4]%_]R"EXB17'5X_K*GN=3RBE9X0UJDV3SH
M\5T1R]W5"?)Q\UTI]".Q"? [:?TH^MUK8W6]F=!CG$*/RWNS"T=JB"DA-W*T
M&57NDKT$$%P%@?DVJ44]2R28.6!7>Q-%RI(8&S33P6U4AXW+0*53W%2\U KC
M'0S*=XV#)+F]U""]GI[U!8YI-IMBO;UK\;) HW#YCT;W7>ZH6?E9H#9!I.(T
M$KQP 7Z ,*32#57#+:_HQ!GDQ:BZ<5O@&C;Z;T)%( Z(XH)NYXH!7HT YZW*
M7$^[DK*J-^X)TW;N,)!U^DR,M"1I>=,\NW@(9DRWU=* PNG#7IM:^#JY8!2%
M&RV$\'2W)K0[Q22^.@N+%[%<!BUIZLTO6T)LSQZ.UF!0U(*^/S,2^8D]KA,V
M_I4"H)_&C7Y.N(0#UW^MU!4+LBV?-.4)P[@7'NKC:6;7-;\\30$TG9H73R&5
MMFP*BHN>65M,,$D0E[D"\I,PW+49W3(S[>WJZ]NYX07<%??^Z5&R.(7G))I;
M)B(#UD>L[L+1L9NO[$<;/8>XXRKD^_F[<GJY4][J%53GE[AQV6E\G"X)7_V6
M(OJRQ(@"J 05@@(A*[#'\ !O?OR1#^Z8M#[RF='FR[[9A8)?9P>; M8_9JVW
M7J8 OKE?)/\L['41EE>Y8V\?J6+($0EN O?K8U5K* "_:EG\TR(\7+N#UT[Q
M2)<)SBK0!2*T8EKV<R/[XGIV0VB0)<3!HSG3MG<+/SPXVO#8?FE(Y6JMZS.Q
M2V>6R/WPXL(QX%)VY;%Q+WE=' 6 MN.>W6#HZV'4M;,0Z8:8WGPB2JI*V6+;
M-%7^X% X,)>&G59;.62\%1IA9FHV**,1?:8RHJHSS&"S8K%\<_OU-DF9Q>C\
M_PR?4U_0Y-V'L.;K/ZD'#(\NT 80K^AMWS?'ON1+ 5QJOTT!Y"W<HP"Z8?4;
MVQ7@N?8.,[*F&#.YJ:R/G) ">P^[U[ZM6$H![/*[48.;;H8O"T!;/6I/;-!X
MW9V8-!F#O/-GWKPF->DM_V62W/D],;Q_Z^!ZK5 CW!$Z,AL"S3Q&YIS!&)/?
M]=J-[^RBR<=/4 !\^I@P4EQ['9)T.JNOQ@J^^KR4GMSPP($"2"MU)H'\*(#)
M7K=XJO7!3Z+6*0 6.'V',NO6S/2^5.HP;9(W]3(Q9F;^U]CP+TVY5]S[0ZE=
M=:^[UE8T-(Q'Q)MFAJ:0:35[2!R!/2&Y?27=^O2#>Q)VSW64JEKE\B-W1!5V
M*8"8Z2>"ZZ;N6Q2 .$UF\,U_Q)'I%([;BNZX>+T2_+XW4X_(L(R@J?=VS><D
MI[CN0QS:]&>K*8#54[\FI TX?5G^B*3>^#_.:^L<%-I#YL3O#Q1STA3Q^FAT
M1/OWNS>":WW>>E_G5>_OI?X%X*'I9#87;P&2 @4!M&ER ]IXLE(\:F?]6+,H
M>3GYWWJ/&5=I8_ZPA$:M?^C5!AS?72,?RZ0 ^&^F4 #]<5CJ.9#W334=$D4]
MZL1FA@UZJO,CB1>JQ2B 3GD/XD)#;XS?67?O2M'/?!2 3Q137^4!"B!B &-%
MBCFK2)AFT<6=^J-TB_QY=D_\L&R;I@9*V[('(:+]>]]S7S.2)O-Y7 "1P=P\
M#I,#6/_!-FC1-$5_?==]M!9 _8-^&1'5^/FWR/(_#\B_GOOU/97#-X$"63_J
M O=Q,CU?73S$RRB FO]*FTY!>)-62-Y?SM.4*'_-E=,&DI$$CZXH&A(*AJ8
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ML8?0Z$WX?=,T[.D>.F;?;!GK]M?XJ]-L$>US41LT#(K:[:SJE37:[[8^H'Y
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M6F]TC+%SX$%5);X5\CPU>^49\MET65ZW".)XG7"%\*?Q:ZH2?+UN3T-!G11
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M]\R?& 0LEB;Y5]/#YE#85)CZ&+.2.%2 (/IET TQP53?#H *X5K)R".O+;'
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M6XH;:GH7R+ I-_K[\Q2?+MKB&+,B[LELHM^T? $A7? &6VH%!T@K>A.'#+J
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M?C0@.NW-3\NWP2<>9.0BH7G><:(YYOY\R2RZ9R3PU<11&B QG]1  ]AWR=
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MP^D?Z LUWW7OW!Q]PZJ\P/SY6O@MW=SH;]>G4C#5$2N.6 -&OT<[,Q:-;L)
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M;WHB(]:KTENBQC_'UC;T&AO76;^9?+.<>'G)_'RE4Y_QK'Z[+,IG%=$,')Q
M-$PQ4R5(>EX4F :^+18N4 9]9G7GXH>!$FG9L1\A#;[92SYA79\>/LQL,^IS
MSTX181D?O2L8?2YD-XJTB9\(.D.V)SW'+XEEXGJ:K,G?H9XZN@;"T8BC/%7A
MPU*5ZK:(!U,C3/EF)X8/&[^YF8\)H 'NV;Q9P]#'+ZS40Z#C.^KLF&9WR^L;
ML)EU=JVC_O?U_[K/>$KG$JO@+4..Z^B_Z#[#^HXZ!&+M*#0F3C(XGC_T&8,]
MA&]<<_56-M,T4 #X%!4[GN@><I^*PF#= *0.S%/, WISB?A*9<071*A=A!M]
MEZHS(K#=?5\])+45Z#.IW,76,%1-$&J)13KML%163D5>K$Y0E.-=O:D<O[+?
MZ.;U5^GDD.[R5%//T1L/O&? )T:7GI]^XXD+/,Q\ZW96SK6KSE6O?KF*07E%
M6A+>XCS>96]H*+^VLK?2)58-?&5OZ@X&V7H^JWJBR44RI3>T@;G&08.I(B3]
MWE:>IEBUB*,;:^ ^#?#RG"#_91(85^II2K)BB%0Y@F-&: =[#=8=EY%5U=GH
M/N'3XL\\%&Q]GW/@KU=3U]W:*ZY<M!6TNW^<7$FI S\ G_33;9+'\-2S02_Y
M!77>^?R,--_( W=%WO)!A@U<\SG8I7<EYYAL165=)K>WGO2@B9Z-]A"UC_?H
MAUH;S'/PHR\PNPAB$DFQ>&1B0K?$&<2A(L5,Z?4)2*MU"["K>D]@_/1R[1%7
MC0,U.S7AFG84-*.\"Z$UQ>>ZLDYE)$/*!RY)EJEQ^VTHIYX'B0M@W0PK.H!:
M(8<M?]PKSGY__IESHIF]1"YRA%R&L060V^D%B2T)TJ1V 4\#M'(-DY6S7.)=
M2OP4W5"6?;(4O=(4&YDS9\V/?ZE.;_S(KGX^IO!)E"5K#@CN@J 7^(XR)_R&
M]F<<HRO 1Q=2BPN@R#L6DV*!#-IXG^ A84\^(NH!@B\S%EIJ5WQ1M^CNFW4.
M*0$;1JDC$Y0<G %)"$2.QO" 5^2FT90+!+XG8+Q9;>V'4CC/>R[YPRT5&.Z)
MRM=(@X^5H[8+AGGMU1,_T\+")H5>%[S^4'O^7LD-Y][<O(Z,!*C:*KW.B@05
MTRNBD'I>L@4>N;@W&8V-YR%IW>T'?'RM\:#(\BZT^@-#\+K&P"I3VN._VE7C
M<G(G-"3U!3Y7?-+F5&38-"!H39?NA(*= @.F?2+.UWZ&\4,GN?#-J=*^>BZX
MM#1&%2GBR&'@5!KS SV;$9:3NU1/S9-N/6NI*TR>JL,K*'QEF:"_-=N,LM/(
MC_(34N1 7.1TO*3VR*D;%UYH'KX5&76XD&/781]"RB4Q$-<'53PX"FL0)TBI
M6%!45W:R^M-1AG#XV2+>)_//W%F_W:BC?/]*+'J7&",\F.:\ZN.\/C3T'3BT
M'C95/O65!AA)_7K5.1&JQ%B#)X9)%\V (_>H*.;)4A_9Y4>U@W*'Y!KM#/*@
M[;-_$6NN)9G+QBF<R5NE[K_9!T: 6=5.!/4I"0W58F56P+R6"Q:=^9-M97Y.
M>6O)OD(U=S7C[=&+O>,M[/C/EVS5>:W'N0OBQ#)U_?M4;:V'&\$5L ;=?3UY
MDUI^5E+Q='OVAT'[9RV!4+<2:Y9CO16H0S#9Y8Q2N?0V^\Q177_N+$DXFFA$
M25VA 1Z!3OM];(5PHCB=ZR4&2F#;4G>@B!\IUZJL52N_*0667(,5.AO4" 0@
M5+O&4^_ISK?Q-/",^2<Z5W@8Z;XJKJK=J@Y8W)VZKB)#W!FL/^YG,9T:5W?,
MC>'9%OC%7DM\2*4,< $9%%9@[1?N<FCF"X]+<2VTI&([P-+&H,\;=?GGIV?:
M1]EN^3+.:%L0P90(,G :==+/$R?2PG=XK 7$(M?)%'A_2FO8;::N5X7/!<%Z
MUW(D/]Z#U\:6%"SA+Y!H5#\@\(G:4R<\?"=J8O5A_1>2!/$+Z0T6% .J+(N5
M3D:X%/NI-_FJG<*?&LT53[!TOK:'B)2&R2V6_IR5<<VI'ZJ4N%TV4,'URF9W
MJ$<J]Z6NR!9+J9ZO2X[S, \\R&&[_@U"+N:&.JPV?,A**H<QF->K(XH+RJ#0
ML&C$7J"HG3L0.%C@7E_\D(&1(28(2"J^.ZC&>0,'!)!"('WW,N1@AZ*[@,9U
MY<%\'^S4O=^FO ZKO"+H^YWWB=NIR%1MKM?/,5((&/!'3V,F*[YKO14=.GJ'
M'_2Q7_J>FB(^',4K_(HO/\N;.:,>@]T7;="3DH*)A/.9Z%::]IOW>6,JPALD
MW8?6IPU&T#;#690\M=/.1%]?XV6>B!8#)G6$EVWFW-J8W7!IB<I-=T'E-V%K
M;Q"%>3]C$^XC'5TW(;T[;3;*RO0(@^!:V3[%)!$?SJ\2-_L70T<DR<94ZDI(
M[_37E&O<X@LE)\[S:/^?I_ X&>K)""R*F>3;C#EA$$$&9SM!7+^3;8B8%3?Q
MICO[%B/K6P;EE((5PQOSN_QPJD%:;>=FWDCU-_A>_'_-W9]0)/%Y<@SF.'B%
M809,D<%3A%/?C[ABSDH\)T;\[S:R4R01K./*U+Z:<W!W$_4,C)E4W5HSNSH;
MNQZU[788Q+EL\;0J2_(EE!_DIK'J'HYRDRRRSU_8XZ@SO,_][>4XI&[GJL-_
M:W,M<+ZKGPN7F/?-R"89Z+))-WFKWHO]LP%O,E;N5^'7HE7KS&.Z]2H,[ZQ+
M7FXT$G@UTJM^6>BSZ,WTSR8^YA@]CJFR%X?V7^SK4GOX&4D3^/EFHD4FJ"^Q
M-:5&/Z>0I-M,L-: %5LN$ZL2.A^P[Q 7JBV4'+9ZVZ!%EN.RQ(T;(IDOHSM=
MM+%D+DI2_7&M_1MP^SXX2Z"O7'Q$B:L[V0!7&VU\#(NG)GLXP%3S$D$I$ADZ
M^X;]6\V?+[0@)U47HCS=SZ?N^3__]EY=8+KB9>OJ\U;;(^> =Q+;\A"*J/?S
M+:5,6(95CF-MD;XV"T&R_=LR$?V36FRW:VQ;RTNA7#4:XZ\TF2AI^R:W/W[X
M['74QL9.UZNC_<A)<='-AOJRGNZA2NK^TT/[MFAG4'G;RJOI6+!)75^=,GZ]
M2=VPJM<5I/.]H'YPFT]S2?'AR3XKZRF7FLKOE569<QM[&RYOPK[4RNZ<FC0&
MOUWP 9^L%UE :L7+EC(T\DOTU>D5C"U9N]=Z8B>NS;F,:2<E7:FD1(S=1PH#
M3Q&K=?FZ2IN?C(UKL/>V\^Q"5HWVY:V#^B9/])*OP'5%0K<-@,N$9:1=*26#
M@G96'[UK.65E!\5M&O@+?*I.UV7OM6T3E.<D/%21D74;]KNJCH>M-.#EM7KE
M,*R"=APD-^SBF F!,[_8=?C)EY:A@L*[&H\2]'&!ZB9UGWC<$V%"$_TJQ-'
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MA;=I!C^L8UVRXQZ83:Y3Q,E&ELB_SY)T1=\,3JGY\HZ%F';_YIW7-9521UA
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M>8T9%V/].SX.5(E9.]:EG \5J'&.'N"7%JL_UG<:TCHEB7.*\;Y0C.]N)5W
M/2JM[K\38]$ZCH;"7:\-''TS4\4^7M(SV5<=NI"8\UQ_7FO@\^?W]6>AQDK"
M=W[$HW*.[,/PBF0 ?_BLQ4$"Y AD61HZLHG#KI.,8)K4<\M&,F!H>:/!KGMN
MNL- X>N@X2!2+N#.X-:!.GJJJ[FY&Z,8+?%PM7C-7D?"74+B+OI2\#AZ_-@
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M>O\II%HQAA]]*=[]@A#^R7[>Y?B/W3"IEZJB(_VMM\/.JI4EWBJDE:9E<EN
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ML4\(A$?-4_+V*!9"=1!_0@O79,[/^.-I[LC\1_=L>MP\Q.X=O8\([>TY^2"
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M^(K$@S?M</?V<3@5DA0/?@NJ'613>B3)=K_"^H;QTYL&C[]\O1MRC[YGX81
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ME.K/LGX?Y_1CK?CL*R&W&=2RJ)7)92JJ.;QBN?I[#/*/'TLV0,EXWNB?Q9:
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MY2/IQSU9!G[A6I4\=NL!*SE2C$RKFL+XN)@-\-G]^>Y=6G;HDJ?690U:;VV
MYC$S$#RT1@ )ULW>#ZB\YF<%C+3N30KYS54"R1RHZKUS:Z**3W3W(V;W+B_
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MD4(?%""W3AG=*>OS(.NWDEF?14['S:G*E8[U?0S8EPQI[4^  NXQ>[\#2L;
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MZ,@#!!G8KY.$?J2$U[MI$P!$K(4W$T'AYD#H.9#]:L9]6&O6@.&_LFAI4,)
M@2H9?YC 6[Y7O05XOQ #4M\^-,)E<^HE<V-A$[OQ3J)(R7#3ZCY@(]U6@7R*
ML6K 4((,(N"OO\^B:=_Y0^BT[&0;0(DM@/I0?AQH7$S91" CB!8J;%!5'$%H
M%J_E)[$/,6X?F=:88Y>SU\.0NC_MT.-K_D6'ZD^)4AZSWVE)"NK1K1A0-!;N
M7#Y:@;ZN9^&_<DJ=B1 .J8TFVC8^_5$PC8 RS;7CGEJC/CT<=T*!%MRI!35L
M*I*6M>M0WQC$M^;*IU@W1H-4B914:L_LTJ/;J$DDK?%L^ *5X!ZH!&/0<0@>
M6 9@_I,#8'"EY144E&FI^R_[8W>J?@&%P"YE!SJZH@UC27T+Y;<'@6>=L$^/
MQ!@PX?ZR="3WTUYC^1168Q2\Y!'UDB:2=-P 8Q\ 8]?6*N+/PT_#9A+S0)E^
M65C+3UXH,6X-J4R@I.W#J>^8V(!5:=\3);R6G3S21N54)4WFB7Z*>*2NR,Z:
MRA,D;A2R3CQ<7H_S C$:A7]&T^VJ!-*Q-O#N(7?4N/&'O1^$U4!MV0XT[RZ7
MH\8-P&!C23Y@L LNH#"8*F;>I_( @]MH#.X^>A+A3IOP[R+"PX@[@*+5(_%C
M2ID:S0^@PW&J#M]#ATH&F\X4GW6H3*&6D<?PJB\]A#_!9!,>1).;GBPL[W^9
MK=N:)9_BT'B+4MUCM1<"KG_O3VL"HYVUJXA3_9E>,L%AFV=0O\5?@?I-+ZJ"
M&VKO!_ X< @]8J"L:2B?K@B?,1.B%/JUF4UR:RFY=8Q$2L\H( >SU;$-!?S@
MME"L+K!*2[[@ 9].$K,9KH?8+J'O#"3Y2/-.S&!.&T[V:!&[(E+25Q$7R"KV
MJ>(0@_7)+L<N[]KE?&),$Q/-T\IDXB&N;#K1;NWXA$8J( WQ%O2V'@>.=?0'
M592#"Z M\"Y4=)#"C-#6Q\<0@. F"H+?  #YRH@@_RGD*9!0'-186+;QQB]7
M>\^WC^*_\DI91,A_5<A@LP94]>@!>)1&--.Y,NB_-^%^H,J-9.QR.@'W !<'
ML@0M\\6!X.%%*@\W5!\QX@< _GV[6"\PV4*VP&TM[_C>]P9I21SYV'#3!/V
M1[>*W88AV\^_&J?#W)EOG'CDU=EQ?U8VVV;UK5[1:%,#S@?%&%-JV12"X1S(
MJL3\&'<]HE^US*.A3?PQ 7E@G.%K;K1PRQI+OB86\.F[U "'H3M2QH8M>B/<
M_5=0Y'GQ^"OBD1/''YW87CXYQ\8B"-]L][<7US6MV%_/ZH7XS_YX4^/E6PK'
M\V-/WGKUY':E<(EL?/O%RU7#SL<N7MDJ[_4[?NZ9W#TUV2D,YV2T)U@'-I<E
M6J96AP8TXPK_%"WMI?&VQI8#4ZYO:7ANZO8VRM'MN4WJTN=R-WL_2"P#]63;
M(;WPN>Z=W1)-"%7HMV4*U&Y9E-=5H6<^()6CQ&V*P?*-H-K"O4K&2RC<[19%
MI$!R"1B@B$/KBE*LU!F&1#:LU*&3W7[_:&<A!.>V1+2L\U!W*HMKI7VV8S?/
M]SK2Z#'B53)6/R"':;2<O18$ZT.4("T[!>!!JJB33V$W1D)P/A$GJH-S[YE*
M0O>\G)56SBN=01=3V,OG^('*[Q,K/*9 PE_ES;>0'FYFHQ>^K-1MY??0Q1Y,
M-70E(S-7/MH23/G3M8>)Q]8E2G/420*XP&60_R?KX>2AGX#F% 9MY\=@PL.8
MNX44'@KAX7-V"N3'6>QW9I+<D;SB(U4;$<GHG;B2\69F?$:RL2%;6]0,A:_K
M9"A1;H8WH0]!F0 1BL%EI#9?D=IT>&[:<4@Q92@#V78T[QYWEY*1VIN&,N$1
MU%U+:J5%O8]4BR..'=L*.K766A=!E%"E*KD "[$)Y(X(\B"#TW4FQ0Z2S!H@
M'PJ@U TY4N6J"D.*;W1[#[N! UERB4H!*@+3' H<(H $)6\ );O%$2EQ8/=!
MBCBD[IV=%2KL1;G2;!3,CMQ2_.EOJ4"$O8HP=LLBI+"<1.!+:@0FN3HQII8)
M7C@(HOUD+5N>SCW=^4 >LP8V_FM3Z2Q25#:(VD8"!DAJ*',%2<EE_%0-J/\^
M_+NN+]C[N?;XL/ (MJM):L4,0?$Y#6 ^!VDI">V>;5\K@'1;J ^D8QX"7 RY
M#)[X9^@9$_X=\/*NC\JG^#0"O5R0)@8]]#4\0%.O=;Y.1+#'J$X5@(:PB<EO
MO_HPK3IM!HE*S G+V<">TC3\BP4MNQ"PBNA0$49!)J6 0%(!,RD%$ DB0,RR
MV9U8X%8++>Y<M'F>.)@M^:5V/\3N_?]2AYY\Z!"!#B]#RKNX$%S1IU)#,3AY
M,_PK$PCQ2^/G9YT+4=$S08*/PD K$Y./WMM$_'2=>0]&*Y!LQ N1SW-4V2'Q
M&%IW SQ%;ELM(-.#IGP.F$;O)"H>\0I^<;3=_!HU8<*/T?C$E&W3Y#V _OCR
MT?H$VG(JC!CN(,F!'+0)+U+G(,#T9!*"K-40Q+-L.]%A782R+I4FZLT:F/A&
M9JDU$7*"\I<.UQXGVP8_OL_=^36&_B./^4_[A/(ZK:]_<13A#HU5%89<=-9_
M[(-TCVGD7O=+]GX0J@/'J$3:T<D/CR*[!%(KBQ#V/_CAOJ&BMG2]B(H-4R'9
MK)KV!/V2M42QU^%YG',A6Y3*3. H#/0R^;1M@ 7-5VFR #2I^80FT]TT>0&@
M8:98@PC:,)4\LA%JBQHF9/ )>>PU*#E&K&476Q_K\!TE@U:%\W_@C6#SY+DJ
MFP\G;1Z8XU?[/(X^%XF]A@]FWWJ*]2E+?(TG&QS_&?GBR*-MA.;=)[=.I0Y8
M3^HC,*-L4DNH-I0_T:]V-Q4-J4E1) 7*YV.#D;IC54SY@FD8L=%N"7GZO]_F
MGIX'?:*[<J562 B"S]V)R8\O\6+WMVB_]9 \FZ&4*O%:L<K.#CJ<=M"9P=(L
MT@]?@O8VX\"(C@Y[3'.AOD0QKV47JH^*#A>A[4.C%>Y"EG3BPP.=2D:DTA _
M!&G"@DP3/P(4-/?[LI<^G>5<ZVDB%4E8]H%XR=-G)<I'SVQCMD_,08CA3I(7
M\*XMU+LH2YT;6DD,*[%=G$9@I3-\S@L:[79*MQ_WW5>IF7W()KM(L1HDU9)H
M?Q#1%_NTHO(I48WG '>>BZ,ZX4Z CB(6JRNVFPY(U9N/?C%RA5@GIT?#1J-M
M:[*3Z2G-7&),41"[99Y7&#%N!'#P*3R3Y6QG</'^_L7LEET\&*[*_!M9I69$
MR)DJ5B?H2%3H)'= 1R?K:Y_$U J=%RS%>A@D*+3+&\*DQ:D8>#PDK5&[FRCB
MOV$TA$F_3#9^TA65IW*OVOM!_ Z<*-N*YL5RW3H%SS%D%U]JQ0)CJX+G?[,K
M^JC\E'O,>V&-I_<3+S%]@(G[ S;D$J>!FH,5-%C%854.Q."UI-J<("/8K$1S
MEJ0U2HCB[)CFG=JX!79UJJ@IW2BB8NE4#O&<VYQ-_ 7:Y*H/V_<#GQYH)ML"
M[XV5;R>=7"TLNHLGM6*',,')0=CYE>7##HBMH2P3UE)\S5A8%,1Q?GH9X.9S
MD2H:"=<7TYT+!*)4+(&E,+#(#)6/CJ<QPUGR'(RT%<\CO9XR$E;X2I?"-<@@
MS6%H\\]8Y4C\&'BX\0CP< O2P[6 "9W=SH_.^C11MH77GL Y6=50,=N').G+
M9?V)=U6$^Z4JNP/ 5EH%\!;%+B$;H@;(E-8,'W*)4SZ?-QBK.UJ%R.V;(:@!
MZ';(UN:Q)0:OY3.34LY+Y4C<V9)K2?KUPT+NV-]@!DHS'N9O>3ML\_[S$_9M
M/KH^;FQ9SGBO]DOO5\C/L']-E&LK&9(W2T;-]B1R>#HY9Q.SEJ[62WLE??IP
M<#*Q)7S4PG7LX*PMNR)7A/VR9,I+Q[+U%ZI/66=#L Q3W =N4TR>!BW4N LT
MQLAWS3#.L^)?O/<&5FDR,R9ES7[9O"-7YFK&=D[??'O>7L^4&G-GB::I==BD
MUK:("ZUEZ]/\C;UT\-VK<P?BN1;[+/I^L)T5P*[/&HS<K?AR4?MZX$OD0-@\
MP;J3[3&L\//A'SY<^').MY4CGY+8"+1J08X8@+ OI3B3'N4Y@#6X]@</6 (\
M!-^7C;5?:V?B@79C4/!%%#]1BY(IIKG:U*Q>@&_DE#*)D$M5"#%X?Y.*.$V6
M 5+F/> "#TK5HD&RJW71]!GB 430TFGD^;;J;#!Q.7L5X,$ _W=*1LLN 1A>
M=(0$P-#N;^E*)J">RZ7 A4>,;2?!A5S:610L322&KY-D@:]MPW/!UT:I$+;[
M*UH?',/JKJL)Q=N:H_*9XGYHCD8FY^VQYES*6_Y)B1,;9-!?Y!G9-+FK\5MB
M\.0#3.G"'&97'3['O2O'[1<Q*7\.1P&P@SL=&!7?ZBJ?DMMX KK.I;J>K ;7
M$8K[:%TQ09JG#PFNW3IFBS5MYX-VM4XJ&6*]7 2@T#%8RB>&NTHR8.2NU,B'
MJ:!P(/$.<JV208[\, 6W,/(N5.K?]M9*7DFR:VF49#N> P704:WU"C1OHMUD
MX4HH$LSG**9=?@1H\#>:;B/6(H+L*%O;@JVUJZ>HKMES+D!%:>P$8X6!0R9'
M/IJ*6V+X3DDZO DZ55OLW*7*<CVTV?%#O]\ R#"FY K8.RL(;9DK)NU=2R83
MTSSV2C1MD/\[7HL[<P36X3G\4FTB)++*6N4Y*Y2,&"X@EKTY9(_ DRK?^>_U
MM9R(%T%>>J1!C)I* _:H,6 9#2I(> #8T?9^H(J!EK)-:%X<=UM'.+#)K@8#
M18^3;Y-S^]T-K=WI("U*!9=T_,"DC?IBPT@\N,6E3^9QM'AR.+N62.7>LO>#
M=#EPFFP3O"1.#O0N5<\%NEN+" /076RI%>\DAL]KX,E/K'4(?NCLDUZ&^ M*
M9^S%6HW9?_/P &(LFM<GDX>?<"5E^\?>ELO 1P!OM_%/1A(?EGB#&P)[+"SO
M&L#68FTBR!QR?OHZVJAS.DZ[2XEFWA,T'K5A/F!ELN5C+,&LY+S]2,4]0)J2
M%*" PGX4TKB:FPM](BI_.60A&UE=HF14_]U#OSO,ZGGXQMQ2+2(DNLJ"&'Q1
MC3,S9%#.YL5S2=FU*<6&MO+),/X;$8G_0<C_0F=(8<HP&',8).&T3&C) >,.
M%J2SI*,? KD8LJL9"C36N9O\VZ@P$-F%2*WXI/Y)"@CU66TCJ&I!@3@,0GF)
M"FK7XNN(8)<CD)!&D GI J;)M=]OWJN*S6Y=-QM;@KV;+A [O,AW+D!$:;P$
MIL+ 6:T]" IO\H*'R!TXI)"C$V@8Z^K(OP"R&)"?3_RD!05$Y60 &0W(F3V*
MN C9B)4.A$'!B.7< 7>U%/&1BIU"CG3B;BVY[58*" :1^WLB-$)0\3# @2-
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M>/[)AK5Q]6MH'O Z(Q= URB 08<&J*.5"7$=?BJ^YSLB?[$YN<)!G?I]MW5
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M9J(?E8W_@;X[Z2+6P6?4582@I>C(R#2I@/IZ Y<. ._T,\.K7BL^T5^@TZ7
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M#4(K92"'JQPH0?1>X?(.W+,;F2M[440FR!SI+ZC9#( 4=OAMGIPD2)LZK:6
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MR>V?*#,^'0;_-]HA4T)OV:Q.:FXN%V>+-8,#1^CAHS.U4K'+3T8<$)#1_L"
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MA^'CKO]HN*<=#H=8A5^91-OK>POTQCWDJ@?@$;W%MP6:R<(OX G;<P4 &=^
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M2&L5WA=3+$6G6#IS": U%A_?U2GR$9R!3.%4WE.8LU^)F Z-I)=A>R0P9^F
M$=9E=1Q,??8Z]B9[(MJ[:*R;LBJ0F?)!3"W?H06GFZ']$SZ]@5>,):> UVD
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M7_Z\V<@QJJ:WT\CQ1S67T%ZO(T_7TCL.Z%I4K5>#@"AMU[YB\DX5VVILZNK
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M+2KD@#CZ8M1OM+Q0PAPB8&*>KW@L(=I=AL=(K,'='%.7KF!H1!(=+[#-NW7
MD9OKWR4ZS,%4\>R:6;I(@699)]B473'E3:+81E;@>EWE+G:/4^A>_>JQ&FZZ
MCU8*'4]5F53IO/KO*YB.TE]'9\F>Q)D]>NR& =.W"W^L _(%/C>OP?0;?S97
M^3W'3,YH3%E:6[<IKLV@[,R2F?JUD0?/3=NO?^W5&!*^JJ<_N6?]IK:FE4W0
M4 6E_5D";MMP,*P(K-]> 8=@9E4^IMOA.0M"Z%TL3HJ[8^+>Z>&@8E" (B5*
MKF$.M6CF6O[1,AP74O$FT9T]PNX?8?S5% ,%M8T7_6-9\H VPW/C6K4C1;B=
M?L AXHS1'=5T*AW!WP9$_OY9I4H5^[QM=>RR@6\UF.IX:6WDFZM&/L\8]-XO
MA?OL /A#U=FF;G*C\<8Y)H2A'1?":VEV],ZD?P,Y9EYJ7$62!H12DO6_H=N4
M7\TZ<OHZ71F,&31UT8J7"&6?)T^0M*V4Y[+9KD/J2'6F$[7C_")2E)[4&PEJ
M/Y5WE0^4"GKV?6SHQX/U,X2+=P.:YWJ*3^:)F H9ZEHN)=789S?'W8NHQ97$
ML@OZOE?S 'B*OCBC6H[VX$TR>CA5@;X&+)OE_[!^]STWB_-BF5NMO8K#:,]X
ME5BSR:"-\VC*58@I!*8]P0Q1/. PU46P^'?8)Y;V/+T>S^?L2;,0"%XTV;0N
M\TL3!9NPNY.D^>3LPX2+FJJG6/I@5=DZ^VPS +8\U[F?_?&+?/"WR<G=3^T]
MHO <U%S0]GGPS=Y)EA,V!B50V#C14(6<?>)&VZ%*BG&_8&DSAOFZ=9YN/C!\
M=WEU=NCEA7^<T&F4K,N#H:^19@\' DN]M7?U:\M8.T .O2E5GY-E#,1V8V.0
M9]N!WA08I,K1-YN/Z*91>]G9";Y9N2F=<K/[6UK9;,/NP]IB<\<QZ]%OU3_W
MWBV16C*UV+WDQ9)Y$2#T=Q#('\7 PH;IJU6$*QU^#+S:M=  B2Z\[[#9D"AI
MOH 8Z[B(UOWVA8>4G)\55/IQON_$]V];_L>_[(@*,S.KO1DZ YU('1K/&QV&
MQ$HR2X^1U+O'N0XSTTP::L9>K:3Q\"R];-KPI3&%%*Y;/@I\55/3T^):-DD9
M(:**S^CS,.N?@I1+?<W:,HO84Z"X"GMAMXFG<['._-R[+V7#DL<R#<,5SB3I
MZ89(2]DH; K!3J8H5$D8/A:$Q\\J;FFSN:[L\;!4]]OUM5@&H#?3CLK6 QH3
M:5!<%O+*V&8$%(5^3+%NGCC'],<U'".U95$CQ)F:A=/B9H_6;%.X=51XJ;9?
M56Z87K!DOP35V2?L '':\4(F-UUUHW?/>!:C"*J[,<6[=R%=>9)M@8NI7.MB
MARSZ%690/H.6<V'VIH;LR7XHG&)9O'+RWNT$8G'!AN/G30E[9M^R2L7;.<WW
M3>-9'HOFIX>"^*2&+DU/KZ!/GCD)] ,O'RJ*)[U'NHO E'GJ4J0$,E7(YQ]5
M9LGH<O7.3L1JA)$5:=CC.C\2OS\@QSUZP'?200I^.K4 -B;ZTC7 'M;B7I=T
MR>:'R71\EXZ)Q'>+UP<<8;9O++<U2OH4L:H_[;9*F%GL$X@]698+*%G!LMJ/
MUK_D^W@G[O7HYA;T> E+KD,$Q --O:&Z2G;_^D&YX_M8ZZ4PH6B]:><?27UE
M,\RU4@=OQQ>^>L;7;<)D:]FWJY6_*:O(D5HC?7TKO E-+8W-\;3FIF;<[)57
M^:)"]Q.\BFQ3[(MLT)\<) W^Q5GU%BD#D..F,?U$B&T/12"-[HH;?/1^C-/J
MR,NE+9_RE 2J:_%RND^K)HUKK,PBW$2H;" S>$GH,W,G!F-%ZY%6)E"M ZPH
MGCH^+RI+U/N9#3]XZB\5WAJSR1<7,+O68FE3:AY09IZ;I_O3Q]!$2/J\V*'!
MP=XXX*@ELD[[TH::]N"S[ ER4TGW)]1B"472CE*#;KH)%*>5?D&>'F]8X)X?
M./V!=8V!%P8K;D]N:##IOMY^Q2-M,D5?2AQ;HZQ'KTULD!*+/[S>_4$[+/P@
M-A?G'K*W#/YU>,^ 93%1C9%UD[HP!H,RCU[+LHOD2GUVO* ,#*=#*$YY$=S<
MB='W#WE*^>ZHBN>/5S$.+VW.@Q]75CEIVXB$]U_FXNIO"YLF9A[5&J[#1(FG
MTEAD*-=%F*RT9JH,I]VLIKE*0H5)T:SUFHGRS3T)_)<=NG @KG^MA!*&A%_M
M,E;K^\ZS'A=@SW?V?8! *BSP!:;<>6L"ZI%W2Z&COTI';D.^RZ3W^_7_;/9
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M)=\*+D5M3TNI%QIK3,E0)VBP'D'U=U[MU7>^KC'D]SY,:A2J1NA_*UD-V-4
M<98Z"VZIB]E;WZO4VY155 8\X]Z5^^QG!E27W2T/KQL-<8<^0F['?A<UC(CR
MPM<V1>EK_$[-O[^?"O=$)/RE?Q8,JT;O.7Y@B3/]+<:#L:).+FAM2H10!S.F
MA8YJ1-OJ06\P928ZD@M]9;L63'5=\@E87M+3UEK^OE"1>FRG.7PQ2X0,('*P
M,?HRH_KRT 0D%_@LJ/)+S-H!!T6>YN)/8<M\V'BPF3])'^5U<VH8U_ADV[/F
ME,/][J%R26-F_[>A;Q]PI+:V?7'V>3DN8SW:T)FJEP/<5 F;=,K5OKI*<XBX
MZ6F[HY;)CP%T?"L$$D6\Z!IH88^Q\;')NZWI8\+G<PF_3&;RZ72$<?('FO'4
MZ51+T6#S85(A.:ZUS0K-CW5V0VI^RDG A,_=N]0@#4/R(P1P!;9)WO=*)](G
MM.6-OYL3(KF^E<3,SHH^5'DHD\(=CI8.*\D/RS465.L^XRV3Z2!JJ3/B\&E:
M(9)Z,H'L#E^,@=9/IC)[MQ='6*;T9'V]0T-_A"53QG+84QZW&'0+H:^;&9L
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M4IPJ_8ITQ44%8[44^]HK^/:3:)@$\Q%)M[YT1<%T3@$Y=">]8U/@YU],J.I
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M>](?(?MUE(Y748*E?+&.\[BTI_BF<HMWI)9A>9?#NL.RH4)*..E%85OXP4M
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M2;J!<##^^CT&B]A5;?"&GUQW!J[&Z+-Q9@-D'6SF#;7T<Y9Q-:[B?'>G/$1
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M*K6=N2/?=&N-.\2>ZR.!\E'^UAV%\9_<VHG/"??.U5:_NO(CDQA,N<A^?!Y
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MKR=3@YPC10DAJS7?BP!,*-=<C]"=)#4L GH"LM=L([],<?X(G@PKIWP(M=A
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M]=/*@Q ;O,A%;TT)\4ZBHJ-DPRJ;KQZ@^KO@/Y&-PFED S/]K\C&X9_(9EX
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M&9[6$ 2@!YH3]= 932SN-I!RA(G/Q)_C5R:XDFYHRD_NS7Y<\6)H"D>?3_P
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M;=POAL8QV%I_.>3VW$\H'+*OKVO[]&K4,&MDU[ >L.<B!D<H%RET_FSVVDI
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M=I=VP]_R+E[BOI4&AI?N#C!O?O0X%G!6]<U7BL;H8)BID=@FA&/9M%8],Y(
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M;>JGB\7'3%#"?MGYK7+N\W!V<93O4!,*. &)>_^KF+OL/QM 7>0=:N<"W:,
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M\-S<Y$I[4]L^> ZNK'QGU,=O[O%:LU5'![)_<6F[N7DV8\9ZXCMU1U.2AS"
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ME -)D,!G4;'BG@Y/=UC>^W?@A:6N:NGDI_:>\!6/YIKS,1+!>EH>GIBQ29S
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ML]<K=\KE6A?4(O<@+L0O]_[*M'L]VU13+*!G/6TP.[^YUU3(,] 7@#L-\>$
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MH)U^[AM^Y81E<U,H^%HC-$"RT#H@2G(^3<[S'?QG/ZL<+'!LB7*F.6.I%?2
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M$D=D^!:^>E%@1)2Q3T3T_;[1@A:/P.*<,E^UI9V@(HF0SKG.7%VN6]E"OUU
M<=6G_7_D_QIV?D)::132/L4\OS5B(LQZJ5$[RPRJ8T_ A9F7(FJ1.=\3ZFJ]
MD"R4:PWJ#^JUY2G5"5%LE0NR:,A+U%/7LL2BYY5$H/FYLK'_<$S)%R\2YBHD
MXM&D\L.S%<?U(&#C-S5]X?#3\>L663%>\:7HIHFD=K ?T+?4ODB?OGJ2/VLH
M3N4;=A+2;/46EJ(8I3)?GS)"F@OL] .%.-"SX+QA:^=8EP8$)WOB%#Q4&%,J
M0^&*0</Z&S&G?3+>4%ZWR!@DN*C)NS_ 3PG8%JCHT%S UM5660I? IB_1B^"
MMI#%##A.2/@@@<Y@0IMVEZ(?@YW+A:D/RUZNV9A4D'+/N05(>- ")*3SKW3.
MJA7OQ&4NI^W)IJW"/3S@GAT_HH5N<P"NZ"& B1:C>AC4)5-'S1"PVF:*T2)(
M6^G+#A_*8]Z7ERM0/3L2Y*91UT7:>A[I2H9<G?6< =-OO_5MM)8L]-][A[Z"
M'O(R$66:437W%FC+!+8FU2\M$BB ,J4]HH$>#9B]#)@=JT1B+8HL9JKT8V5>
M-1S%'[M/"O\#=QMZL%",^GP7U]U5]!]V&L[0WZ5;T3;&1C2%V/.K*A^BKO&3
MZ*GK>^Y#<(']0U7%SMS107F:PL;KP=<-GZ$&%U8^#XK/1"ZO:!S?25%H[YOK
M[/G2M.]7<6N^.80#L"!_B18@#6;1CN8\>M=;P;_EK[<=16ZE1C;Z15UER@XY
MX&^441S$+'0R"$[9\COV!7R'#=]4G/Q $PQ-37(I?*8![HAYS@'X>X/-W[?^
M++#Z0&@@7N5S+5>G-)"WG)0=AA;&E0X#[1OF5%H)I)?V6U$OA^'7N.I@QS[Y
MF?T'-[('/\.!ESHR;6:X/X(694_QQLN49OX6,! 70^( 4I<VCN3-3JS!=R1"
MV-41EU451ECO%AYH%<?((V:Q#,WN44_W]8HO$U0'>C0C='M]7X#I.A=5IN34
M2CTV*;K -&! JQD/5C5_=UM>?%:5B%^ #5ZFKO>U_=EJZ5<U5-N!\(F(XF?K
MHH?,<8$K/",55$=/"PKBL49*/RGW$?Q\@EB "0@WB_$(<F!*$'4R6;$A)J32
MY0F$?E8SV!11LV9ZJ6/P5<[$G0Q3D7\#67CNY<RPIXZF]C*/Y9@@UHO!DVXK
M*%.0 (H#2'-[6$8Z-B?J L^CE!@EI#V)[["%R" 7\,3$<IGFL=CP4<=12,=5
MVZ4_YUJL+D9NI$"G:)&-OKUKTVXHOUA#/;%+A3(-8ZOBP8IH5N;C'/O6%FRO
MA0A4B/5//G:<Y !T754I@X%FPIS\[S\'SM"E^.90/\0(=H3IF*BZ]-&P+?I7
M(U?"*[[<?55O%9)SY!*^WAP#MCD58/34$9<+_9VQ, (_!_8D3<D@)3V)**U?
M'4D"Z6[[J5$LQ4UK&U/K.9V?A7%!)3'5?V1=_5*HN")"T%08V):_^E82[0VA
M.I6$R-&KN)=_BR%'S\--[\G2% NX\_=WA50DMC54O>H3TUI&C+J6H1,7 X\B
M% ??07X+CPJ2*XCI")+L[9[TYM?\9DF%K5<0<$M"9%C*H!!*B3I83<9*(*O8
MJL;&_)<5D,'J P3WE2"W/D?_R#*>6\F3J]A&+QWG0M'6@?9;Y^80NYIL_I/D
M_5/L"1R5NV)3<6WJM=VG*\D0D<_H,X-"C/L+=[N)6*82U8YYJ6F7K5XX)SWR
MNK*72[4'R\/?#..FA,PNQ*Q[6(NM,B;5U*%" V?QOK8BR)8BT3$A-P,_E*^&
MF!/UP:1OIB,N1DJ8>M#ZH&[/+:E^YIVTZL@]]9];CSZ,>#.5COZ\]SW9" 6"
M)2JD5(/M-X:<R0NFDE+EXH9.7N,NG^\%KE,</J[6!,Y/Q#?74,>VX$S)*B!3
MUV\T?YE]<?_79G NE;$PND:%[6>@SR=<2ECA$L0 A (2"5Q:?42=(B0.RYSX
M\-5ON9H!^S/3<J8%TSZC\_GFP\*9-2]KA<VZ6%G]I;*WEIHM?M_4YS7;T>LK
MT)]&N&P('5&<RFY"IQ[^W."*HC4'\/0QF\@!T.VY=#PKD^UIJ,XG,IA?ZN?5
MS.>DZCU@,NZ7TF@45G8;O.,\_IE8</&MH?W3;=O(NLL&O0ZE+Y:SBA/0Y^^U
MZ@QF2/&;%\027Y*95N^],ZIMFTA0(3Y'[5ABI9=@7K:_0_,9IZ1 97-=;[XG
M5N&9\ X(-60MLS/] +LT]B9:K/L" VU--!%$]EO.+GX/\FD*ZEH[KX,^[V4&
MHG[Z_UB<OLZ:AF?3.0 AE/ZQUB_Y0-G0M&$S7W4A/$QY5BM;UBNP.+[FRE0"
M6+N&:4<3+4&;E""T+<X>U59@=+J7/(#J?=8OW9;-0T,28VCL=O10%P?P[0I[
MH8)^FJ'  6#6A'=IF13<,#H-)P5!["]ID]##N;P["7JT_0Q<P%2N7I]8:N23
MT&[]7 1-<N1'=X1E1-RUYN3D@H*"SI$-=O7+E247EZ7KNI,;[ZZ8?P-"9/&^
MG6 $;9?G&1&3])8VH(P/TJLW^C!\IRZ9$$8_)_[%QNU;6%VJ57:PF5M/^KC*
M.2=56]CFD\_AYS1UZ];%IJ>D"QV:L]Y3I;Q'H(IU?$*C9)5[U$_66>7PY.K4
M+#^'"QM>*1(%:CIR2G8WRL3-6EPJ9BN8PCQT7FHW4\1A&,W/55/<8AVE+FEK
MO@/.8_."$7.HFOG:@K20<:#:^#/JWV L(A*IJ8O]'=EHA2,B[LY1^CYT&J_O
MG<YMVI9P6BWT!8WO[RD=2R;,0MHT:G00.7"!**XF;$N4,3IF4$Z!M%TO $UW
MI2-:R+TEG]PLZ]Y\88?IRJKZ>DWQ:YQGPONYC;C7&N^>W[F/="!#]QR.A5&6
M<P>XL\@*<MT7#H F9OHZ!W0!&8"90QG+?[^>VIU)&!0F5AM!TCI^GL>,U,3.
M%]5O1_^CH_]PV-_K(O1PZM@$Y3Z/7G^!IEJ#,DS46<U,P:K%=)0J#6XY0#O;
M)[M]!$D/'N EM3?X<^T]^%K=N]QS3U[Z'[WIS4;H%+H;HX614/O^&4IK!_)@
M&7[)QV#AC53_'W6LYJ?A"\G(TF7>@HUQ1U(B&=60$N36HG26ZA3VU06\E"74
M['9A$PLVM=*IWV#X7;3[(</S-_O)SSI!(GOT/1-,2^3/]]%&O;=K!"-XM\2S
MRI//RBC[?";[2(5:NX7J^-N">Y#>LP^:':Z.*)OCQBNX[GBX[,0"27-L*L?>
MQ7V"G!U!5L@=+O&T=[%KZ6"='!Z4^(""OW1Q]>CZZ_$:C CVK?4(_&>L5:-F
M6B==\;O$>Z#FSRZN=X<@V^FEK!<)2BA?VL/ZJ)=39*QP8)N_:+LG-"* *[P\
MRW /4Q)<((#?6'^QHUG20G3^@YG$J&+)GMALHY>7QX32@>DO#D3Y?\A-28 D
M3.D75:T1_F&D6C%&2,>\?UUGU=? MV,1B2BG</^2[N<Z0<U*P]9Q3[Y;-"WI
MQ"4Y!'/36Q_7%@-E$OY%=UCDFD@CZVX0@YFJ,63U"%<&G!P3O*H.&I4YV4_T
M[9E&'/1W"/BIKR07C'158+>I-O)])MBS](B7T/8)_>XWVL,D]C\)FM/O-\YL
M,09 0&BJC +&N<7TK)1O=MW?$8SM457EJ$JS;M0U5RM]C.O8%M,B15/P((AJ
M.WB=+X\T(*.?'D"[,5S[>9IL2"D-T]46.?75L73UP4O;/JN/Q5I9N#@S*-V"
M+;#,X #(!$8V+9%^GWAH7;)_"HZ\ ,\L%YW=UZ@K! *1B7_20*E,?;*XCGMT
MA$!'@E(;S3>;7B^ATCA%ZH]+F_,MWMMD5G+37#5*;7KPW*].61VYCYF&=6.8
MSU>1X_A1-]\L@#JF RW(U'S!O-[7W9I]HT94;RDW'1L2$G+/*>6]N.B,@LOZ
M'<A]W/H:>M%AE'UAD%%R[('<-1^DXI('+-;A#!A$0&&^V2:-9O($C0WP4J"A
M,X/9"QNWBD4K(,DZTMJV<X5Z;7/RO?,SJY3[S_5+&.E<09=DK)'VES3I'[F7
M2/,;%FO=\;HP/^#J4\F ._S=VSG7 3R!##*EBCYO=D7@,Z\]6,-;-RV'NJQ4
MX6!(RL._'!*54@@L>; EX2^I_'%E:J%G*IGO(S3NE,9EE])FNZP-Z _-BU*Z
M:L-EGINMPJT[=?NO>\*)6B[PJK5D9*C<5EW9' 4\*X)WU,HL LE<0'HLSI<9
MS+&.WDP(N:O76P0B!-PU(CF L,\@XM8>C/9C#-)>Q!1<)N%R3"17K6N04ZX,
MWF-C!H\%3:03OPQ'^J)\UZ?X XK+7]=:GK\PUN06 $+D6O1FN"C,=EIGVC@K
M2UB+I,#)5UU]RUT5BRT5BP-D7'T+EBQ]"\TUY?-N_=?_[U=KXU:U=]9:\OGP
MCV),X1+VG0JJ!9N 6%3E .R@P 7:T?_KD-%]I'TW["G2/;/U@'I0F34:S@&<
MMQ^YYPCK:K;FE5*:J[>M(VS?B=H=+S#^=B.JT49!)1\!Q"1X9S>/,,6*G CS
MY3PG23B!^6%OJ;57^/G1"<G#/N(V4Z7KDC>5UNS\/B)%)DE!B<^1B.Z%+/JM
MBQ%PO-P$)HOBH7+3K_L =2UQ4)?IQ="J8FQ!:0]Q<3$OEO!D2-;:HAL=1P[:
M\[.>B9HT5P\RIYJW':%3-,FS+4K=):;4O8$';J9!4O2UU#&VP"&K9V7)$@P_
M!EO*M1O_R[Y&PQOW7W!]7D)*5WMGJ4;(LY0O#Z(KT:WGF0['][A_+Q.9"T"=
M961B&2<ID,>#TB/4$IL%;N3'.PR[<0 I[#]0<H,SG<"S_OOD:Z?98W8S.OMB
M2(0M=;)YY9.^K YU/T,QYRM_DG6C'ML=A3BV35A#"Z!@S0Q),L^>]+$[4G]4
M1NIU/,2#NI;&UD%YSG1F7]T#(#1VQO<)M-N9\L'YR^]$7O1U%:J6!"AT%RO#
MOV/YKPS*+I UA:D>QB-2JOE^'8Q=?6SY>CNS<-"[E!Q@U9_#+\U')<P\;:M3
M2DL1+?51B50RZA1^JA6).(K.9$R=O?))BW0:DLZPR-)^+U-/VK1.)7U!G]OZ
M&-PM.^R4(Z,]MJ[BO>/=:'YQ."ML3JO U\ 1:RM<W].[WFC  =C"N[N'<M/8
MOSJ J:\R0)359M*:$-.3H4I:2];V0N9;#?;/1RX> L\RK3Z E>K67(,DN@IJ
M F%NF"D\R\WF*IU-@78/#!!#]ZN*@S"]A3L4??:9PQHD@LY-FX_O(G_0\VP4
M9^+]/!,IL)%]P=7;@V:CF!KF'XD$-]$G51Y>+P)P;5\L$CLS2_S?J 9$M>S,
MWBSW?<>%LV>@=+@8!Q 2'TWJRM<<!6:@.T4[J9GDF)[,FQQ <CX%F[%4A)]*
MD\/#BIWK'NA\9$(;IDAKPF.5.Q<^+[SG<J9T\H^/&K]E;!IXHFLY (8LO9M4
ML<3#YNVG0>C!_0NRJ8X?]A-4F;HT@;3KU[YFDQ!9;K:8EP%N"XL7G_BVX?H7
M4$[2M7^9E7\W(U;>*W=]2*;Q/]:VY:%&2"=.:I>>"R^ZGZ!.0B9"RDU3FU,G
MJ+WF>IH".1,D,\?Z+P'>WYMT9:Q4/)ZJ]CG:TW?&HE-0Z'P:!Y#CFJ!]^=_O
M9W.UQU&B(]0U 7P:34?+L%#3Z(W-O3;F>-2&;=&\"OF!E&="[+=<$[ESC; 0
MTD;$3SG&<YK<*%J,&4]>2\>=/UQ>NX"<&EU:H>.P.S^^3X"[Q;IGGH.?_=YF
M2?<T&=74&+.>)?EVSNHL!]F8O#=H5J],AS3G,O2[G><0N+^ F4?Q= PZQKL*
M]6!!/3)(M7$B,]-&<7[_C0D?,;2Y8R*@ANLZOD;Q-Y9LDSIO51=_VR3OF 5L
MYIFS[R1<98HQGE#YR?#TP0M,>^IH-2E7@N%N7P0=F,6JU]X<3)WT;9T[B"G7
MM7&X.7^7-ZXZL+#<MZ7:3\?AS1?Q1ZPD]-!9]FF4(T/U^!)RAD(N2CR$_SY%
MTR1[U5%PO-M&!P+>+9Y(>_AII/O-]KG]CO1A>(!6H'ZQV4%QI$26WD)T;.SR
M3O@0G7]9-3-W>C#OX[LG2.,;A3Q"A4UZVEJDGW_IO)H+VRE4XC</K^?U_:?V
M9^ =S"/46U)^,MAXY885!U 8+T0U/*:]?QV,YRT>\.)1(]^BB7@X25DW)X\L
M)-6_-^RT>K*)\>JZV^LVHFOT#-/18 $EYV5<QF[/_OSC<E4&X'+54V6([6;*
M7N-O*G^6XXHX *]282 VPK8)8Y()->$ -G[^;TVJE7!Y144@P.K)_RW4Y!X4
ML<N6>;J#$=.TW;2O,/MQ^//AKS+:JDX[ZX7>W\R$'0!5&:J&_[?4]]]?%7IO
M+K\X$0O;03,OR-$MN.I4PVH:,(XA7]/>6^,?Y&.EDN&Y PS4),2^_]5K$#6)
M844)\^>NG*1,@O-N5)ROT3,L4[\2F7=.2ME$3(AV#CY<"BFAR028W#X'?83-
M;LJWBO(T6,J1*-++&=08J/=^14.+Q!(IQ".3\R345+9!A1S)H[S"Q*=\TP!U
MZC1Y@T^E"0L7<[5P2AWRIKB+I>?-B\>**-"AV\=LWFO'\AP 7HG]=E"DG7;N
M.1V4 1=A3]*TR; *8!&ZSBM(U X]K$N2S*9,IK(%(>=*K-V7%:,SU@C=Y?+E
M9]5)4]MEPC#&/N$YVWO$D!Y"<,5  W+?:\W1/J:4A-7N3/9%*GM]U;E"+ ";
MR(#N):N$N9F!OF+YPN9=AS[IYX4-0J&+OKVBGBD3K][6U-G=>>RDI5MJ;T^X
MMVOTK,G&.N&[H%NS1=-SAB<7&699>3A2>,*4,ZA#+%EGJH,K4:ACI]5^NG^T
MYPX7]3L#N(8^*<_P(6 6/0QZV5R7\2+F&;[.'S\R4_4\]#TZ.X,KF_'P6[.Z
M+"7'#YW]_)X.YO,'NRMRL%G-2NM,=8O;Q&9,.^[5P.,_[>/<)UPQW3W)0Y:R
M3Z8?G35#E]?MS1U?"42W@?8,::#U.4(TE-2O;L&^H)GJ5C;_(\2/M)!64_P=
M+W8_>G-G%YKL1_W:&G:B>O=(IJDU.ZV& T"PA ;^/&([/$/&/X,-JBK2G[>8
M36G&UCJE-PWBDI)7<79CSCFR@O/V=<]LS%20(9 I:&U="GJQ=Q5&#H6E=@%-
MZ*[Z@L<&QQWMI0H\K)+L>M\Z>HKG#1?7\7'!QD*'!Z$MZA&H5#-A&%V+*2_"
M*N0F387*"G>NF-]!%EE0B8]!YZU!>P+5(VHN,7*T4P<23<5_965$\]I+LM0+
MSEW\QQR?8H_.OI-TN)[0R=+CGCV(ZQA-K86,0!:-"7W)KPLKR=*.3!=&@  Q
MH]IUT$9FXB;C4:5[1]/)53S&OUQR(5CG\\D!NG.YTN#E>E]MW#K$\G:C]#.D
M+USR4;7:34:$\3@R5?"&5D3$\-T-N$!:_F-H<=D9GX1VSP[B9;M&>^<L2?@,
M[N:G??4)L"?>=[%0UB 0Y83_N<!/:KV0EQ1 ::7BR:]>99O/9 ??IH(<\?+$
MAGOAPOYC:_7"',!SISO7IKX=.30>\K#Y_(Y_8UYGY9OH(Y<)Y2#J_3K(%QI%
M\SR<D4G:SXP,DLR< B+OS[KUQ8U29?HC$/QF+P)-I/K*0S1OI=HC%URG0[X@
MOH1JA$(Z0KXD!+.><  ^V*R*+A!A1>@-3@"EVZ#W^*BL)D&'D6A2\0 LMQX"
MG$SOE+9VF5O2NH<@MP7(SQQ<WC*J;8^4ZVKO]KTZ"=QQ14M21WV&GR)GRA&/
M,?C#*X)C\V/.!/MLL%1\7CT,F!&(6/2Y\CTT.5B5Q0P7C'24-N?&LO@D^!KE
M;'NV*E4@./=*,^'@N[+OTZL[XFXSC3D5704JXDT28;F=;^Z]*%1,T7('JJD5
M7B(Z$FMP==C$Z4_^<.KU$$^4%3LRG_V6 Y"JZ0I(N.W.R/A./KLJ?+T?^R2H
M_O,TG@.X!NY8_O$W=A+(T"]BVY90-%G_<+TXRV7P-^P'"$,-.PI*Y0#:@5\L
MU]<^[I.6E[:7N@G2FL,R_--@X]^'L ? 1 [@G-^L!K:SI"OM1'/CCI%H-BFI
MD'9^-Q--=D_S<CV8F 5M;3$E)S@ )1M:$?O?4[\*T." A6]Z4 NA+*K2Z-<K
MC:GU2<.T[@M;%U=AYDV&4J\NO*.6=E8+?W+T4JQ5%?BZ$N'M>Y\R/O7U[ _!
MI#?Q<NQ<,+^%B(5D-O4XZ9N&S'O5Z9)Z\<VP<:V!CS&VEC:3=[?OTA*.[#=&
MQYXK?Z^FY#)4BT9 (.:?K%ZV[F<939IM8_-GB," .7?R;"YLQO=9)'>(=S2K
M;%K;*-FF600A% X_M7GN1%?)Q==[/,VCD]&*IS(/W=D"D[305I."8R>&:-Q$
M>J2 ]AV&-7E2%>HWV9R#;7%G'%LL[,OF=AQA*KBF[.Q7DX/8FX!?]X'05$?@
M3\C:4B9[_";NZ*_IW<-VM@!W4O[A /9".("[Z,>X(W>:.>XF39,G"7/@B;$J
ME$A6B43"_J8)5UH]51XNBWV>"K1M]C<7M-)5&>_T<PY0=HQJZ.W:L>4 "A@6
MN6/.1]YSS7"Q="Q,<-1+CM1(;';#N,[C9\895<+^CD\WE&T+Q+T_FV<;ZO/9
M59HYV#F^J&9</W;8+I00VW,XMO"GCG( B\60O9,T].V,RQEC2A]U.("TU4N=
MMRCWFM(X +\DE0M-#1\5;HECN5F#/[6:D<H]XU7%,%P$!3JVQ5(3S6G=7.]-
M_HV$5RL.HRIBUB>=I]ZP_^AS 5U@A+[?MY_U%E"Q_EV_N.7)0Y+)>\7,GSFL
M5O1_7W&!Z&.#_1S043L*"I]3[*;E[+)Y;3B WS=9I7=Q5$0Z)" H/OY 77)$
M<%?B!QV=,G#-A[(B9$_+Z<:8-F%3498A :0XP[HBO,FYZ4-^96]<]W-,\7_R
M%M!\B+!?-OX>$_"^+4/P/3+_U#.C&#^!A49K?FNCNJRW;3O/DV'/R'52BOQ"
MB2YN@GAG@M=<:T.3C_[UV?+5<Z::(^N#^6!(^3W??\(*O0O-6Q CSP)%6CL9
M"2T\D$GN0G2&)271>G.$I&C/GI,_>_>BP_^.]#,*.M^ I\'99P)(B+0EW-X:
M"2[(,%]SA/,@H4,))B7DVLI@Q5PKN$"0B2CQX/5)JSDE6,YJ ((9H9FB>;!G
M9)X7@YG&$"N[\M1E-X,20&Q^"S2ID0O!EZ-'$0R+0NUPOQJF[BL:F-H'UC=1
MZ&)$D2K#_IUF5EE[:AV4&>WQ:DH?%A ?D)VBX*_ 0=RDN5:$'^2?1\D=*[/'
M04"3$VN!7WZ J'D3Z.K KD*CY/'?^^9"F(*DJ5,,:[/^>5FOX/W#,@NGC@!G
M?=R,YA_.G>@W"$%&IB<M.DT7)X*L<!Y<0%F2;=SO+$3M(1QZXIHMG.=UW>L1
MG>KF1YLW_BK_2O\:TZ)4\%93/FNL.;[BEV44]Y-1O.^E0#,WM4BZK"%4/1SC
M?*,=+!/P[-[VP/#%@N );<+&3.$%<'O6R^D76RH#+1FEWH<N[W%#X0M"5 TS
MDHP#2>DT32'!D&"='10^&$7(&]=:U(,];F85@&M3')YZ:[N82FL$/LB.9>3<
MFMYR6C%T//I23\*UP1F7U]+W(=X(AL):<H(H4[Y@0"&NX3KU>/U42G/-6\7G
M]1\5&U_L2G#A7C?3LFG)4&X!;.-'RKV0;<6\I>&V3Y!(J6F/[_^KD_G7XLK*
M]H^'W70QF"AL'G;><]%K<5*]<P6STM&HVSG73%#+=__D_BY=3>CFMII]U5M)
MU9=RQS=836 1-'<*?G6K@"&51BK.%$(O,.9TH"=1;A]TSJ">[Q]")9&:MD24
M-F6?1S7F&7NUT]-T--;SJ9U8B*E;6T=[Y@\8V8EMA()PA_%7/W!,*CX7B+0F
MN(WE'EY#L 7[0:<_;HO-(@OCD1ZZ3<5_3A,@H3ELR:0\U9(8;TOUVPZ23RZ,
M7((6'NF2KXB'"I.9>C[.R2:7A\-3HAVR1#7"4J[JYM56IXWV3=H:F'VAV67M
M0.XUSHX%-L0]C$?,+.7XI%%L3X_X.FKI]D! ;P:N63\2Y1-1^KM0QK:Z4$S3
MT0&C%D3OX4J+R-Y&:GU17$L)?OF( R >_N0 0B$,6=M."B)M6K&78JSYR$N;
MIOL5(]>^ Y.YQBKOA)R7EY$/^'A1;HYIQ3ZIOU21WQI:33M=^5=EB*:$$5.=
M.V0JZ/&;"><X@(\GR=WL!@Y %/:U8I3?1IO-N\65A] >QC5*B/VHIDP0[LR
M-;5AS2;#?S7$FNPWID^3P9!7M"T+5Q81U=2L!!6:V;<=JUWA)5A*\OA>3/->
M!;6=?::> U 69!ASU1>8L7;4R'2% X=DWB>(L&15-^S"26#;@+%.I/=U*P/7
MNZM.Z;9(@WX++F0ZNYPQ&WJP6I(8&KE9M,;(V,&/5E352AH55TAZ7T6??4E+
M!5>K>6@#]YJ$>[5F;"9VX>XQ!98-N<]':P+EZXF)\=V_R@>@LRX<0)L3E<(!
M6'9:L3)8%4PTF>N-<=0;_: TF1/S+6!#"N@L2H11$4]BQ4[^$3>IR(:FLZ]V
M6!]#.LQT[%;=QR+D"]N?+>Y]_3U:,*10QYNQRXVT.0X@_V >\J4 9?#K<6)[
MG',"B ,8Q^ES /0;; 4.8&>1YJFA4FDMN/YCFIPB6V#T$64A%B; 1PRZH:OL
M7 W3&!O&J#S=Q/ ]W;EAGT0RZ'E_-3R@=MI#) V;1-O?AF8,SS>F$$@]DH1/
MYB#!&S7;L$JOG) "8K5;MENH-L:YX-9HY,X-NU(ED<L=,W[?+%_NN.5@7WKM
M''6ROM8W[$072:14U^_H.ZSN2"2S/DV%1\?'Q47(=^M'%\$N6%X;>??MK<ZL
M\81<>[L6>X ;0Z_O'Y-AS//'0R9@FAGQJ"(]=% X8=Q+E:BK6G?!8XV1;S^7
M(!T0.UH'3O+%X.)]''J>#-*"'O,:&K+_!"AAT)[H3H,QYGGC-XFSZ[ OSR#?
M]AA.< QRQ;9 0X&JUVQP0]>?499/VA[7LKI3"1=\[%1OAODZ^[+>WCZCPRTI
MLL,)IW!D/-_HD#3XI$/%L73;F1H'&7&J,S0TKU4")H_UB6R6H.8"C.8\_@]C
M[QW4U!:^^^?8$!&0WHF*@'2E2#&0HQQ%0(B ]!(5D1(A(B!!0J+TSA$$I$:D
M20U*E9)(ER8"@= A04":)$K90LK-^=[YS>_>_^Y,)I-)]IYDK_6L]_D\26:]
M"ML7F].\#[]R.!1+^WO.N&,/VC#1YHL?0/+55Z)YZ 3<XBO_\Q4N"#HJY?-!
M=8'OHTB_T"6*A6Z7_=GHOU35@F2^=*>G=6,7/\R+ 0EO,0M@L5V8S,PZ;HJ@
M N-!0/F#KGZX/!8$/F9,<94R_YA@_&J*(CIM6>A>YFT0>28$X_8!\1YVX5IU
MZU33-B /:T>D)+%!#=L=AJ)@,83LJ9AV>]T%80T=')^;?$JL?,SGD>[W[47>
M]H*JL3%.I(<?QG0L1FY#:_R"'OTJ4C[#6L',X&AVL!CL<:(73 9]%*@]%/?F
M+, Z?/28%]E-F,Z5I.,K*$K:Y87],[;KO5NE<9VNVSE\9F9R30L6().!J_)N
M3AIL-"VIGTK,LIX8ZZ'>]@OX%V#::%(>)[MX9KDSKI9*K\HE7SW^FOJTE1<R
MGZ1JI'4T9;!\K&,\:&.D8.O)G;8;W.0J-7F+SCD*A'B6BBP442U-TDLV B_K
M(^/K/?^E2W^<[81T>.JGNR2W/;;CTAS0C-?QKQ,%\\,%-@-.)6N[WN+$X@D1
M.0,PS9(IU25[@E-1=%G?G&)Z!ERO+WS.WH[&>N&%4%=O3T@LIL*C#O"=H:$"
MHIG(9^;.3D!*C^B\.F%$SD%.,KT'+UKVL/&R3\/8,*.>H0[@EE(BP&?02G1S
M2G6;/P4GC5*Q37"D_:Q'BK1U.KD6/6U7MD"$B'3G;:4O%^V+&D1%?1>:ACO,
MSD[-&:L*?4DZ4#OTQ[8[8+184VZB*92@S*@=> 3N1%)/7NA[ -PY7=S35@XD
M;YB]AI5T4N'"0Z4_XD(+O1LOS[@Y>#WWBRB<5&/6UV\=K&M-K>'=_[31MBFK
M24:JJ(5.,"]+!O5\O]OM"CVY OD.%?#W&"/J$RE(*J_;_7=U26-M76/TA8R5
M/=;!RG0GK#::NG>P,C\Z[UUX".,%8-I]-;-A79"@J/Y?S;/^N0]^YPZ<.Y@
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MOC&0OL46>Z:0&P5K!\?VZ5Z-9*OCS09WR1[RA)IXKZU= >$G"R;^?B5RC!+
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M(L;<D.;H^]VY^HGXF"J=BXMSDI\RI,[D^3DH?4ORL=FSS54Z-%//G3TWU$_
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M"(ICF_+-0;>XXNKA?Z'PMVFYODWHW[- QK9Y_8<;RKU6^=^^O[ BM'"F= -
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M+BEM>R0>\D+MFL0UXFK8[JUQN-F^'0O2)E]+.HP1I6TTS*4D1O("XBBN>XS
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M(B'G71BE\O_U2ED('I)_1/=&/O+0;[;]?7CUU%Q)D/A3]/4QF51ZZ;;EI9R
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MS"2WGA7];SII.L%XXM__>"2@@?'&A7-T7_?)_!)RJFB^G#F"JH5U8E.0E%#
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MQ@?_/\;>.ZK)K&W[SHRC2#/2.XP%D=Z1$LF((D.-TGL$I'<$B1#(2.]8*()
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M3[+\>*8#7K.B)^)UQ5424(1^>Q$TH_-)VSME_5XHR# 5DS&D\JS+<[*H4IU
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MR.9NF](4=+1R;*;C Y?+V7K)+?'72&;;"F10O- ^U^H5XDBO9\N06R(QQDG
M&&N!&:,VA@H[SF)CEZ,$?/NW;B!'V.BW("< VY@3P,M3)P#R[6Q:"I)9=7P"
MT&([ 1 R$>I[=E\7J$H=W"> +Q*L1D#^$\ NA;' O+*ZQGD",&*UTK0X>P+X
MYK-YB=KQO@Q&H=^B-)>^I=D1\CID\XG3@N@W?GQ.ZX5G*C2-Q@*" C3E(YH+
ME!J/X\5N1H@:$)?.73+;E.K L<ZS^/YHUI6GB9*_I4@1,J85AS^5+BLE#YU=
M'Q>]Z)_W]/7?^?:4*]C2]2B%HR*4V<2#M:-/SU%#\D\#7_M2WUK1M^Y"@XDE
M$A2$N!L%%BO]L=QC'AJ13W9S$DCHO3>RW.[C41OQUCU71]O LE2NH50'SU>L
M8Z'JO^OZ&]6?(,4=:D^W8POEAE=[58-&3EMQQPVH#72AY4WY\E:$ RPX;-S1
MVC=Y+#)!AKH/BG4CW-C[E(_$:2RE?WHN::3KJ#<>Y[4]A<!#SV6AN<;K-F*5
M1C7>6YE@FUO33*.3P$"0)HG!9]+:[G-?WW1=\F+'R-.D_CGYNUCO1!S25!%J
M.:(9;1YM^NZER=@>@R78+7 C8IM\:].YJ#Y71Y>U;?_EF#1_O;=+A5^JVW$-
MH- 7#P.<O:W3_C%\Q;+#8O#.P.2>SZ39"NVK*V$H4$]U@*VZ5%IO7X;?[><$
MLBHMP]RAAZ?:QN!9CN_-Z=%0M.0CJ-)UJEU6NS'1LZ5#=4CZ17NA0/E7&ER?
M4[F/\NB^*E^I;O_IA#Y*BR[_JJWU5=U<%/L$LNXUVJ8B9)F9P3Q] NB*T0Q4
M[\IS%6"4,CFP!&Z_3_CK^KL]3/9QC;G+M!+^E#]&_.>YQO9^#+\>K?& 7KO;
M.KR?'JBT0W:([?][+>1T4BLX%4IQE1)SACWOU$+\IL^Y)L7-%(8Y$:/TL>0M
MCFW[$260,2MQ "?7S\^ONYYO[,!2!MJD_M)@!"DW.<ZOBS[,)BNZW'\F]BYZ
M\J)05,SJ[J$A/!Q^FO):)!/> Y))#B.85"W'Y>FIY=EQ-+W2MJ@6;R(SRTWN
M9AH?G\7G^)+NCU)J2W7#EX%MY7MEU/$RJZ0^\$2[M2S)PZ!(_:QG*^A!16/(
M+MJR6/QV* .Y3[\EK6L]?\5&WJ1&2\Z:.J:JL6Z3P9QC=" "RA@M'>H^8,$9
M4A]=152JNUB(M .#P1IIGV>5GI*5!6%_K0]6(KEH=VY/*)/SFP1OFKIQ3"G@
M_',^64JEO'V-,_L8%H!-KJ\Z9_R<U('.\VR\E-CE%M,$-ZI[=6;6;:O.QI\L
MYX#=MJVT##KZB$RG2O%X@YQ*5N"F!.VA+:X-'2)$K, C%I.(9WCS:0KWH<<H
MUBJ3)M?NIGU]99"K&?A[$\?5U^]O$O[7$A=]6F;RY]_NJP%:_S(81O_+:/KG
MX<<ZTKC9_SBFQ@M=8>A>D"6Q;W0R?-=9R\/E/?2="X!3*,5_.3BS';$S>Z1V
MO)'UR8R7=IT8ALV\( ;E3Z?L(:>A!UF?P]]?N_GY!. #S&S32BWU/8BRR"Y=
M PO (]&^/XU G'J]T6MM04AOS$U?#_3D]$WNZN+B*E6GZ1FB^/G;3R^^97TV
MJ8KQ%O?M:X<^@D2BL831H #BG!?.D&M;95!= :[=+8?F>@@6R<C4\6S!RH6R
MRJ;=G><VPT$<\.HWS_W6+@_M]5\ZB@KY=/?9_4,;"/#!]$B_6A5.N=C'6P?N
M9@M3D!;7J+BMAL<*#PZ'93@%7GD>B/SF8(@H0=(UO;<,61E.FKK+&H1  ICI
M\_;_=3<A",+K5=R>@R>8%M"#V+VQ?@(@WM!V8F9^0K!ZN/W=":  LJ> V;7#
MP/]?'X=)Q&XL8A+LMSE. ./0FE5MLX7CZ&.QJ1@[3B?N?<0F;LL5X;OE9[UZ
M@)M665[&*M?G;@]4T[%[.4<W/&/U$.6(J7:=%R$G@*-J9MTQ N,10ANJ/@$$
M(=RBP9[[4=;OD6,L32WW8'?WP;%/V$R>G:S!\Y'=K7_Y%Y?+_[ Z]+)J3H?J
M(RF0!H2;\O0&4[ATR?P'D4JAP4V/(Q]'#)V^EIR==@(@G5/-]+?ZK*F\)3W6
MFT2W^5FN+K+*56^1DBFCXM)9!VW(].Y!4O TYB"%EDRETB]V_*9_/9CC*<EP
M I*:]*Q#B ))H@O_M9%L])G[V%4FV>[.0^:'^O.:4\V<5Q,@RH.-=JE&"3MR
M(%-HQH7'RV20A8WXLPZW_:K[K3LM$Z5I]G8)>1<6/?QH4>H'G[N-SA_JN'BS
MFRBORX=."+AK*W.2E@/&AN(I#GLM2.[G#%.E[/HAF03"/<^L(WK(TT$9N)(R
MC^GZF&I#%\;W4^WZ&S?MG+N&,2([1EO8S9]0\.#A$X 7\/$3YM )0$"?SP_,
M Y?^>XZ6!.'P<SQ7B9J9);Z!E=[%C>\CN#?:M)I\QATS7_H[EJ$CN'<6Y&/R
M+9_A _7MJ]T>@74TLJ=-76G!QS;^4HT3G5NZX%]=T$2@,&P#[RK<L1,AH6="
M.0&D-06Z^K;S51AY2R*YOV<J)^]'9Y]S[?5JMA03D:CR:FS-XGS1X?T_UL>6
MC[-.P[78NK^?[]O5EQD,>63MD;HD;(LFA/NYJVI21-((?55U066_-OF2W!2L
M*VWS+HR@@#[KHU,6?E#42H<R++[X?A'?DZ7=M2%VTICS=5<@X0O^7FUKC04E
M]!47E\]*2\!UA9@_[[DE=?>>K;1[^>;MW<B@W&M2:ZX+3,Y>"A;Z);Q_* 5<
MGSA?OG3]O'1/H2+=AC3G81AOK7IQ=L&WL 1+2AB#ZRM)9SKP<DJ8D,\V&THO
MCQA(/\?3]5B=2Z8-^5(C"9(:5"B^F,^5YA9)*@@'<\)__TRW+Q&6E!I#6H\$
M6Q&CL%E![2+D0#O"-'8R,#B\//!V_NLU??/-2$%;+;X;#QBO:#J&\(=BG6 .
ME2_$KI J^1'B<#'0.WU@-\,LI-'/0E/.2#G7&8Y^7(06:[\M&DXUUNFRLU[5
M-MVFXDQ^DL :.FW@D5:<3K^XYLG/W%/3E^@RE4HI-;'VA6AE<I5I-)C<05_)
MXQ.S:#[=I['>S[4^C+*41%'5R1YT0]H$]=22F,_'-\9+N#17>=J+>4FA%88&
M2SRE*],MP]TJQ/2TWIM>Z3@^B],2+%LT/,BNZX1^A';@%O^6HEBN,-I 8JRX
MXZ4HJ'R2'TR,,)V=*GH"8 K*4M_Y52-0""_%OYM9TE,(?['+C6M78R5Z1%9>
M..UWU,+.I[3C60@;945=A=0^P9<O]X+)@TY!=8\QL5G)!S$@5\DLWO:87)"9
M#_F0LB=K!9& \)(^#IGWO$')'-IR$BQ4^^NSU#^$/.HNS87%.[%#TRFX.WWK
M"/^Q3@]58;H"X[TS/U4;Z)E.M*M8RK/MNHT&-U2@3502HK<3)75. (EN5%,2
MAH!AI:(AFET)F!*9A:B+G6$4,# G@+/Y*8U;B&/E8Z/-PN0#Q 'K-:4_<\"Y
M4/]H'C&E!,=),TDL+9^ Z+H!)K4K=?#-LOK@S<\-FQ, !WZAYW, ZYE_,/FR
M6><VNT]Y\Q*+P LMG@ VAS:W:;=5L4&O#G!8;RV<%[%W];1 LWKBCD(L2TO?
M5CZU]6 V*>L:,&>IHR$#O6^BDRCZ GY?O]J4ATL"$7B[^L\'[B'[*,C+PIQ7
MTB)*SKAL;?15DM+%16><QH&X(A%6A!5"+D,M^RL8")X<=Y\EM:-L"2B;G2J>
M >5)+K5Z?CJ]&X^1D8:-HF5O0RNA]3)T_JT3@"=TJK(7VM!'YX5(8#/VD6+K
M5%I7QR4D5TT>W(,4>*G;G8U"H<BD<--&G$R.0Y]&S/!%-3!RI%^E;UDR+;\8
MBD XOSH(NI6LM-JRK;<PI8G#O=XVS']VR&R$QS+E_FN'[ IO,4=PX4Z\GZ('
M 11!=+;)">DP1'HAH7TMRLJ87,HGOG6'AT+'ZK^DYK*/O]JBP,ST942&%#2%
MMAYP3%9\^6JB>1$EK3RVD BF6 W1;,&U0RDX]Q, S5)J!C$S?Y;6L+A <P!3
MZG$-L1]/ )P&NX0?B&DH)1F!_^7MHQ/ )(+R]!#AP8I.A=06N&[[V!9YD%D;
M:TE4>&(L_OD#99#S39TI7V.8X>4 29U+3\_>#[\G(O&GY[VSO__EFV/Y$>9T
MD31[.S+M(T7*"D-P*(:OZB#'0U]DUWC9IUK8U(%>5!G"W Z7=< >B9E<H&"?
MX31C&<)L)!'N%D_*8./QPJC@*4%&B:1/8F]J'1YR+[=JG>-?(]7ZE9UB2ZQ,
M#W]E4GCT21=6Y=P:K+L3B#UN/=;^Z9/"E*:#*1')?^%\@$G-2+&JQGXQERM#
M/0]C?Y>4H":.%P2?Q<J2^V-NFDR$(X46VN6>-J.*?_V^X6%>:5P!A5S?.$*F
M(1;;8CDI'<\K'9A#R/J'J:08?\O$P8Y6LHOWG\-[_=&K>LR1<II35]3IZIYW
MPD\:A)/3PPLD/CQ%LX5)K=[Z'Y8$)HX(XR-YJ:M4OQ@CI1C "OMY4KI(#0HS
M;'FV-6_0(D.*^*6WBTL"T@@/BQR5G?;6;_T%"_L9;,.5O?!W5[N_[FF348XP
MD![^WJ[X0_,G7CKS0MQ7HW6LT,4>]0.W/73Z1&.\FJ):6J:5A%-:;N974!<R
M-!$I'5K4R&SZ3<F7@N^6H+S^KG+C[E\:-P(OF;A8N8X&:;)2\29#;=!RNN?S
MG'.?6W/BPYZ$7P=F7C"GF7U(BA-&''Z%<B65LK"$Z2Z/5?1EBHQ4-P8">T65
MW@NF+@$WHX4MYWMZ"7FZB8G?"\A.+_T]3?_<3VC_HNS9C$UMNC76Q!X4(8(X
M^Q930\[ZE:2OUD>9NG;^ZYYJBSAG>N=MONK$ZK]"T*)WCTIDV"TSHW@.0A-D
M3 2NY]KC>2HM_'A,=^=/4Z'9]&M#H>U&772CM'YULR\6.E7K5MT>E*DJ/]O<
M1PB?Q;J]4&TS:T;CNC7:%255=:?8L;Y[#"7W/(Q!H_UT[_E 96F39!2E=[.;
M$@FA_3$Q43?G%ZLZL?(E(@;:KR;OPBKCWA;#%S\K:(I]>)TU'QALU3;QQO21
MM%.@_O2.GHN!5"HK89\ *'=L&>]6:>:R-!,<QP@IW%4[\PYLDT9JZJ&6THR+
M!Y"4)-H?OI5H(,?OUCP+8J51 ZZS?PA"/W'(][#R'3M(GP1_:%?X=18,X2[\
MNM,[Q%;0+_9BO*=UQ1Y:[B&=5NDDI)EEU:UC50H1$=VKC1VNHEA3=BLMK8[T
ME8X,8.][=5RCGU!EA&QZOH(,(7*H@OM/^M4"M!S+O[[8+UC^TOFY>WEO.;>O
M1%=C@^SO.8*?&'"1X]^5:^FSOHJ7:E^@W%*>-B)[)S$O^2$;9)*9XMU+RK_"
MMNT[:,ED98'>M[-K=E)<N ;X]7,OWVY,+(=OF8S8C43$HV@/;C0,K\1<1&RE
MO_1*OAM1\B<;$4>Q.0'P?7.59W3$7E^ Q6QY-XT$TR5(E3/O')[=;YT *?\L
M:]/GVNM?]%]T7IMN2IS/#!4D4_O+Z@=X@]4T-D\ WAB:;-;[8^78?L?L+F@\
MC@,N_8KN/-[T/M8%LI3PQ%[KU97,MZ8'Q9+K/TQ<]#Y19=(T!'%C&EN\&ZZC
M95_"771G3&V&-56EY]J8'O,N\WYVV*@\5.2#MWZZB6/$?<;^UYW9N7G7N;[=
M.9<YYX$A3>+@P(ZQQN[ MD+]NS\W75+UI;@H%FKY:>W07EK12^ 3M[I'#TB;
MW**P[1IW6)RI2!(FE>SLHAOA?5,Y,\J>2U*,,R[#S38DT^RV7(XJ]QAF7SR8
M'.0$[0P&@BYWA5Y13E=MX2*%QOJF8'*KWK'A5?)<,O&++?+*U;:)(-M@D")\
M0K7'HT'G$XHC0L:4[3'&BB.72U'3X!$(N JM7*B%T/G73@!N+#7@JDH+1_[V
MG.Q+A6;)4%_[*U(EVD4U5E]V'UU)9)0<A5!DTC+7R[_D;6P9, =J6WQ B3N$
MH4-SP]A4PJSBT] L*[M+9!#P(,O.L9IC7P7GT..F4T$JJ[B;W]Q)5FE)_*B!
MZA>M4)OV,[U)G6=?JI&CK()+"72QPA. A_<+N+X\IY$X*[NZ?;PI8OR%,'+4
M[)O0>V]Y2Q8K^<AM61MNO<Q^N;_-<^VGV<8=GM3,Q"W4MY3F+MFF$AV")[[N
MCY7KJ.;FV57?'N#:PM;/?2.YX)GG71T 2C9=-H+F6L)&U2HE:_VT3$^!!TQ7
M0GVA4^D^BCC2&4I*K?U-T*!JR5Z?2<_%%-E(.O9UB2?^4#"XZ+X#T^/Q44]@
MMV7/T&4BPUO$=-UR0-:J-",6GW0Q3XQOJWP8+>;^;<+Z\%'Y5>/F@?RLELKD
ME@=I,%.9P5AT-]V?JQG)YWD"L.RO/ 'X=LM@[/CRC39@5=(!0<#U_<JQEX]B
M9<YN/ ASE["_K>JRC<>((_#UM%>4!3+D 'JP0)=?D(*!>Z4F<8',0>8$J_I!
M"+H/WS/R&:4'IB> VAC<IM3]X^!)UE!>83TQ2YK0\X^CF1R<K*<'L *ZV4:S
M>L!:V>0S!;SI\F((T:X&)M\0S0*,!9-4GN/K@^982R;O!' #H@%'$NF9:TN>
M9LX433->"DD5Y5@OP;PO]'H?@OD]5/1GKG_P60HYM-#;T/X08YOE=KM,2@18
M,4RXR0:=N5MI*3Y9=-W7:F4%==5<5CJ?NLK_E7Z)X,SYUV L!M]NE]H?6L"T
MV1=OPTQ016Y?25)7+M]?I^D69 FMTXJNBQ:]4/ 2+0ZR,*%6LEOP/I/UC+-?
MC3.^4"C":^^5.JWCGJ<%%'_Z(0$4=GM13?=)7Z?:DS\TCR?(V30E7";<B&+E
M2 L5ZGRQAY/:0'#7M(M<(VK'RC7&31#:DI.=##NH1&1"/NE]:QH":ZK?Y%:*
MY&USF-40W/&S"\4/F],N&#YJM^JDR_;DJK6UFS\?'I1Y-E&>VB]A=OL:<-^O
MR=/ YE$>D"_9/LW&,^GO]3N$BE&933+*N!+]+>1:&O-WF+^1_JLN<2/HA5+"
MI(F]PG?^$ <O]8T74>>)!LD*#>+GU& F>QZ91#G[=O[:R8K8Z2"!UX<!=N-2
M]="M?&K^P35J]6H:4\A/\%J4ZSON)G0Z'4B^^AT#DB6_U',PRQN*]O6/\ [U
MKIQ\]#Q3WJFV)>F(X#S;V;,*>==1VW:HG_9#W0RM-*1&M[5Z>:_V,,LE$[U9
M9P^RT;3-]'D@J^3S'L7>HRD[FIZQ9ITA9Y7C+?P1GG<#N>JL6'1/G2DQ0"W0
M?Y!G:Y]QSN.O:CGAHNNN#@86?%G/$DT>%,N-EJ%,WHN,ECKRH73PT&%G',5Y
M(6Y>IA8[VAY]? %2 6NPN*4;9DJ&LM.>X44Z]:87G,?A%[S+?5/LZR"7C%LC
MN/[Y![ .. A'DPW./ $$N@@94!20W'!IR@*I-RGB'8)G3==:"$C&"#8W!*(7
M?$TU>]-K-!BB8H&@J85/E2B?HS,OJAQ.,^;?*&Z9214L>C^VK(@$'4<ALG<P
M<:RR=@:N0PH8X2Y:=N GO;CGK;.\KZI3%IB-SN]['?H<[T9M6=^[('_-KP&M
M6Q>X8W$-?(]\ GB#R6A_\&0)%IP"JREV1FN@+?)"C4X]#6':0*]ERLI:9;EE
M](>U*RE5\658O\4W*5PW%*[(0=V/;6=^0%#L%C*D&O+CPK,3)4$4KTPJFH1,
MWJQN1' [0OUNXN=E*?./?X-ZF9^;<(HW'MO4+)8<%N<44_2^77@@/#I9TR#Q
M5S.V\9CC!Y/S$<4*K[+>AL$#IWY=^).:5^>KP,J9W\M)8(YNQ?Y$V)NQ(+@J
MJ7+.SKDQ:?E2H9.QDL:ATBV3R@C_2PI?$-I[=OK!B^BDUG'/U,'0(MUR<NB8
M2P"^A$UU4&WSBGY5685)F?SIQSTDRG#1NBO*V IE8>-G8B/7^LG"R C(N H*
M(A7EGWZR/'M_?;&^C:?;4^"!<_Z%3PWB90FRQ\*6G5X.-4[I/?AB75"C#[XZ
MZDOWEP19MS&YT+NN,\<&S,]07ISO0IKN*A&75E@DQ+P\;CG]:;[?(LW?G+-[
M6C&NWG=>BO(=J3DXLW9DF/+,EU>HM:6EM;VU?13S/6A??J._E5G->(Q;?%VB
MQ4@);H>4 CF<X+=I'DNFE3%6CI2$:4+;&509+6YX=+*;##RW<;'?IKFII:5!
M\*!M,'?E>81D=2!ZK:[W05F_#Y;[L-\P)LL;#[KVDK)! L7>3:SL7K!]E9CD
M8 X!&B2*R\=W&W$K:*S9=$. <B&Y<HUR5N5L8N7KVX=E1F1EL9!5$2.".#JE
M;D^[=^-%>XSS06/Y4JA]E<5UZRQ=^TD/7[(*;1K6,EXI;BCN(CKJU_,P]_JE
M8)9DG.YE<A IWDL379!4! ==^EC%^)4_6*!Q3G\"2LVJJX8][/G>?V<D(AUX
M?M+O4YODXU $V;08;#^BJ!1HR$25)3\U&WZ:% <YQ7@&7BS#'"O$#G;H,)!"
MBZ]I:^V>5; 9NVSB%E68YAO>0TU.W,L^=U:JN[NS[1 GZN^+"%)3:G4/%D34
M)S2JQI1!^OI@_Y@I'E8I)[2S)9".BI3%7[\/R*OQOZE;GDCP.APT[E?##Z-N
M E/LLS&]/*=-,CDT<D4C+B3GR!*M45HU,1W@-6[R)S?B'NP[W"BQ.U1+Z@(Q
MA"C^$)BL[9>H^^B*[GNXK?H92K9L"6\I)I5 EN\7<,PT<Y:S??MM BWXNF/F
M)VB:SD%=[5V8QI)Z'B\"^6=A?'<H-IM0?DVHN,.,XP(49G>;XEI:-EML!!G9
M?N8DSS#8MFL;UG"2=_JF%+[2.N:>;]78-N+^+@[R#7A0_9/5#A>@7:*F$Z5^
M4^[@\EL0,GK\!EM+E6P^*DEV*W."5?;M8O;2N:_9?ME7;E;*Y6\^F"@LR!M
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MMPIRL2BU[ZU-]Z)C]SC&-E%D!.W:4&F9*&>C&E$Q2G!?3B%8V$ '0H?2YB_
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M^_:],0K.WIALB;U)9.;\],U! WDWB[XA@*;,)>G=!@77*3^87@83W3!O4&P
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M8""$TW$;!#BA/SA5P5T$!_F&W)4#,>8#^HX[^8UA2\,,7)S ^^5 N^,7YM0
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M_$F@XB;KD<LF3BF_R\:F</M7D9',7)@?&K6TSU'Q 2X_HY4D.W_^QT8_-!S
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M'I\H &!#=$7LCMP(DMJ"3Y5'J>Z#]-YL?8)5U67)7&+A9Z>XFS*K-VX;^1R
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MQSIYU2X"S(WD,$<T1CCY(@*!-C*E-TEJ/2\QYM)KS=,[XDRKJ C';__37S1
MTV,;SUPBBH^'8*M%)JNCJOX "U=S5LL^8C5*OT950LR"TLOISX=OYV+F9/]_
M:D8O>>7WSOI@7=F2_(R(^T;!GVW39QD%.:B2'%>Q*Y+!%];XLGDB_;04''0A
M'W3PZ&+TGQR*2>">/#,W(^,,P N^GK>5DP++,R7Q<FT)D?<M&Y&+"Y.&Z@&%
M:14L:Y.?[(F27?!@@YC93S1>K@<TU;=X#& A%+J,^,\*D"E8)BS<-#^HF9R
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M!$3-V1!)4<Q+\F=G0XT-[1WVJ!&[0V'!EDK5B7]]%F,KH7HIR@X1KV+F \Y
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M<=SJ<5CL&4U=Y&J0BP@A +$^W:%HF&\#!(K:*Z-;+RV*WD7BI[V%53\7AOA
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M/N[HCVJP\1;8\9!I'_LIM#.NA@JVRS0X$@GS7L"ESRSB743G)K_9M!_X\1/
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M8JQ]M=?DC"NAN>E\#5<MQ$O$QB^3I$R_[(5=2%1YZN"2[LD1BX (/?64\85
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M .LW>^602F0%0;8],6EM4-1/P_0_FRE=1>1!_03?<"T5U=9L+/6G,G;Y:-[
MYP_JK<0C9^5!!FN<41[>\(;^VJ,SD2//LDDQO@1V,%YVZT-Z<^^%#F</E6.
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M^Z0_%7^'LXUG2AC:TH[(Y1<-3UZL3OJ(+9+COQ2E&\F"EN[28\#.PV, \!A
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M'E/7E 657-T0CQ^]-56N[=@"=C"3PM'<?@:#YKDNA2D4_+?X<:7^1$!5R3V
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MYX$>P>ZCMUG)\P%-:\=B<1C*\G,Z !^9Q0G$'*'D_<!.<3T0R4F<:"KH1+F
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M36RC7E1JGK)B.M0AZ/@3H[GI;H'B:+2WE-CS4?4+<@)UMDDZ/J';6ET%3?'
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MG;:6=W+A>WI/**M-E#$)^XU4K-I'."G/S<).][-)RK"[P3G+X6A_54)*5<*
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MJ1=/HN0PMF#3&7PT1\SO.V-7Z'&$4CCY0Z/-H\/_KJIH3$6@(&#@YC&ML++
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MQ8.ZRU0H>"J?)UW*:EG?8"T^ID\):GI&05X-4.H!W'AH]D8CDP]%KT+%,#>
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MIJN/,45Z"_%?!IFD_'O[/PNMWZL&/6X=C%*,NI=3R98>,QFCN621C[EGAQZ
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MQ,&AEVCK%Q<#7_I.S8G=[/IF)JKP;WZ7;6Q!W,4M6R:\LTZ8+] $^_E2/"%
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MM$>U4=M$M[ +V>D:X?VITL@L<[C8:>GO?%VZE<R"=IC1HXJ;3]_;=<2X?^"
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MWB,SV]XVX1(KR/:TEFZX=)#)!>\59.B P8?YD+&0<B]L'YI,7T[B1@!,"OS
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M)CP'<UF.59T=.FH?CR320YZ0WVCO"H7W2)LL2X%6W,,K0.8 O'EY@\XYBUV
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M[UT:?C__HP!J[RSU2<P7H430R@)%P6)M,6:)M+$#Z.9!EA=Z (VC+_4OD.3
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M_]<J] +:@G^@FW,%H\HKZW$%U!S 1#\6_!5?@<6N9TGII=_U$7\.W,QD2$#
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M1]8M4__US!SA3?/NX6AXR O2.ASPZ_=1%3SEV*5FEG@SW?L8<Q O ^6HP#W
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M()^JTCJ+;*ID>IC!6W('1@U*?:X.O6]7G,HQ1^*:4?]?+"S.R??K92P*@RL
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M!+LM$S67*UYY6)TJ#!]N.[#J.-R8!7G;^-[.YS'=,%UWY#5CT,34^%,)5.I
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MD0NAO2!U2?M14?;Z? W:OX,QU%<LG&;6+XD07V<?#JUR7U749F 3:&.DIF^
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MQJ@!,8$<-5+2[(NBN1&VS1(KMG6+'CQ_W><LIY/D3\DF\9."M./+#H$[@,W
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MSP]VSP=7LJY=<S?&%:- PST^KL X16=IDUG+4&QDO!@]%D[!?=VD<B1&%,\
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M$O#)V^"A2AM*W*.G2B6AY%2#V_M2SELPE0'I0PA@^&D\0)+%32TKT+!>[WT
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MU(K:>L0P9/[@M$:BV1X JH\DJE5OZE]J2M7"*J,WIL;@LQ@=P.7*U,&W/[Y
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M;R>'HGT "98O'1[7977GR1Y?;0^(I.B(%IW]=L\O?>B\E?Y@8QW.!@%<U%E
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MO>=D<XY-O<-O"=YPO7!]?[J]$,C #<B'3JK_EFPU!L4I;]GC@P;IT'2$,8X
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M$7HA'%.,._'K#YK+ "R9+,,6HB&2>/E+ECJ1 H-T^58:Y-)P_&"S5<M<R['
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M+P>=-6)=#[6,#*HL3'EB6689U#'7W<P]S,L7!ZHY=5JDH M17$$?UKT ,V4
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M^9RIH0Z>W,^<!!UL&5E%!J757\37B^5?SWQ5 IAXZF;A&+7>*W#N/NX-GJW
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MK"<ZI7(8!@&G;3CQ6_$?_>U?@SC:X\+ACN E]Z1SPF(]?ZUSM4 _Y'$UF=?
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M5@^*F)_,XU$XL&?=\4![SYP22S6WT=</+?3[QZTOTIY-%FJ).*C/I[!"3W)
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M83PF0/"3C: =0[T'.9W&3@*)P+^6)X']HTA5CI4 Y:7[_45:WXP:5].J9[^
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M>Q%A)/?<.V"C8+J:ED*JM_'2/78SQWFTONA>HUO/9@]7:'=&3TDMSW%?8(X
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MG4L.VGF,X)4<?K$M[<2XS;P;3L.);*3%(X KB"_$]N:-^H;[Q82]%$/&1'6
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M+.4$0\BJ(-'O,[+ =O:KJJ#T":1!++<D4AZ?ORZ,SQH;37YS28W4A@-N1WW
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MZID;Z6-<U[CSJ=1VM_SB>0M'U[NI7OKOP^_V9F:9'QPC7C@4C+'<%]807,@
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MND@H61<$#I.1CL#ZE!E7V!V29Z*\<%T[?+5Z7<*A<[,IQS1)]>N[@X-#C5!
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MR_.;FJY)G>JP_LR[B2Y-]/UF7R49Q3V!D5?^W_O#<JJL2,\X.KCN3Z"??N2
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M+TRO3''$&0LSL>S'38 JXRE8$_,[:Z0OBG<48]\,V&G[R9,[IC'"K)-S_9E
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MA5B.U@8WH<279MD/GR/:#Q6]QCV'UWO.>"*,VR]F]W[P]H;23]7Z*+ZN(>5
MJ,\)3'L"H)W1IPRA9:P%[$(!=?KVFA0+SPA<3%K5ZSJ.T64:)W=I /G4H+@.
M2' Q0D5NG&-#6XC?.5Q%$\>;P1(#IXU:Q\U5:8#3^-57X[J+4W<4^Q3*28$!
M.UW>W-=X.CK )#;QI0M3JDCWN%)7CK^,M9S@:,VJK[FJNM"ULLMYKLH8VT77
M$T?G734U"$G?%I;GM>(TKYL$Q!LHM&5I7$?<-"V[70>5C"G0HLV?FF74:&97
MN_6ZWLFCT$"-[-"J"Y?3C*5V_N4V=1RIVF_.&HOC>-.()X5?YZ_@/FK1CJ0Z
M"4OG>#^[#H102?@%23W'4_%>-A(? :_%$4OG=G$CCV UL@J..B:>JB+5BIJ3
MHNJPB_V#& \<>?(8=^94OMK$1/.>@.B2Y+YE[-FV5LQ-)$H$H5 1*WOK6:L5
M3\/3W\HY;'1/P /7*![_HQ;W]\+,8C?6D+G5E[U6L;K.S.WA:3,KDIJJ@N^L
MZ1)Y"@#.9AISD2XJ[A)CNO;CCVS=IL_>MA/!3SP"[5+L7LE,71E@">X&X;J5
M]P10)$!-;NVB^IHC/U(9#< S!BG^_OE62!+F"(FCU0+6 @J9@]-N1:A6CAEK
MD3)G0MHB**$=YF?*QN^$(W%B0&S/['J"")QQ(=AL[8=.&? #U'L]U+PQR<1=
M*K7X(>EI0-$%G=[IO 25\I.%"-3'P9+M@/?,"2>[/.=XV_0"']KQH?57!.&G
M7^5;!4/*Q7]+?'?WUTV?AM4YP?CRY1M5_EK7*K/13GZ;;;):DAJ0",-EY]+J
M0<-EVVM[ G^::0$7]@U85W#=]W@Z  (6"Q(G_QU]48K>0I)NM^:HD<7V!&Z"
MTA1R>[VE-&U0;*XQ!7MJ&N-,T]%S>Y@#OV.D;-<SW>[:FK6AEG_CCRCG'>__
MB#93_N\8C#XW$_(21RV>5\_MQ1TS$E=8P:HQ_U)18_W-,P-J: N'T8D#5</%
M' ?6]<Z)S5VNC?DE<%7E=Z_P.F*M+SK28B)X4W%WQ;%B%HV[_*MC+H[U3$V0
M7@]\:C#RO>5<$E.2DH9QO7_/:9%T]/)YE^>_=.<<QN[X$*T,=CHRT^XJ63RU
M/I3S]5=O9>U%V\D-$:O#:(R*2JV2Z=E)=2?W\&KU"V?*2=(E(W*FSCR'/8'@
M<F\88*;7_=/G\>]Z:]V[OU\9,?XQ&9#Y%[= ^?2-C[^?MW9W-W%*!5UP0'*%
MD<#^$X7X_R![<S!A+:5X_ZT <F#&;\ N7;>0+BR>,#VOTP[XOY@':@8@(F!M
MCF93_2C&@!Y"2Q-ZO^N+$_F$#NWA2;YN8LET$7"!I<@=M[+#K\'YHM\26A?^
MY'5#F%YD0'-D[=0NGX@O',:>XO6=+Z'UES%TU'OV!)2QI]'65%A_FI[+N*&R
MU?"F,\,7YC+)L0RGCOSV\7L[\0>!CI(:":W(UTI!PE>;*@U?_?BC$54S<FZP
MP(+",7WZ]6F!C&V4@Z62KK]#G6:VYH0F[8S3(O[T[!VG;--^R8@L<N3I-K72
M+BV\P7T?G=Y/[MDW@:O]V3XK2>II0UI.W6XD"REKY:2JU6_5SO9G>F3@[TNG
M#6]D>[14.]_%91":9!O+>?\2F/?$B(R%I$R</]KB"K>5(\<R@$T;?2SU5M9[
M0Y;5VP1)^Z&?O]54WKD97PP,,AS3Z;_]T6JOGZ,T'%R/&YWT]'3-CM42&!R\
MY.9T3O[*OW_$'/V#FF[YGU[AOGL"P"GQ1!R*"Z&0FZ"K5,-*,GP=7Z24T>-5
M$1?^P';D\BCO+/KPX(K3I.%G3>4;FQ;E2W[FS!\E5?-UL94KQA%F5J0RA-3W
MG:FJ )7\%U D &/B>4(K_/+=QTTP%_3?-40SV,%3YB&15.0)&ED8@6O2>\//
MA.E>93F;9LB-,>W;'?8T@A1@-==_WRCFZ?,/X1>]0,<ZAY,_SLTAW?-\(AXE
M#UP/Z/_E8)DTR'IJ<O.9WV'Y._[_]-%/7*[0.=-M(6GW[,)X5M9BM,F@D8M+
MMJUS;,%K_5Q\U+0D=2/U,#CJ?,C3B>&&VI%#"45JN481GZ_JW'%K0UP^5F%/
M5)4?R_JDK#FQK#>J!UP(HB_$$[LDL(.@WZ6N->3WSX[T$J0YW@2[JS95\"Y9
MYG2"+D<97NE#E6UJF-I"R?K-??P5?[@$@M\"G;X2UO8.1^+?T$MZOR,)XCCJ
MDX6&PQGTX^HM$T89HIP_69_.;^3T?,=)8O4XEU@C\8L/%;D^<KSCK,,957_
MLF=9WT K]CA=7*,[YQB9)\2?FD,/N=4GN!7[&U/8$$FL/.9DUT38'%D6R*>?
M3XND0J21\\+CNK-\#'-G&M!:R@X5U=!(8C[>\]##^733,"1(<.D:0H&4=*.3
M%91<WMXP!2&#1-&H2TP4WAQ"$Q>&G_<23S#7>@'W4V1^PY?WM,Q&I#S_'B$!
MSP-G^M\A:,MZ11"0J""D$*?^DLBMCC.D"\E:UW_6*0^:0,53BM/[:"&N!B*#
M+0J(,B&3)*N.@,LRLD^0*P8I7@[Z9?(NJ<H.KLO,"!"H@.46W?^Q0$Q=YPWC
M;%A#1X5X:FQ9$BDA[N58D5K8?'UJT;&"$AU_#;<"C?<A92-Z&_M[>?W)7S4(
MQR"KGWCG]@26^P'?_T$Y%8G[SEZ@@SAJ*4Z"$\HB[)O6=4FBU7#_$&0-4U#'
M]YD-2^H-6*9C<@N4"!&M,^1J#O2"M9@_,DO]EMW9+9&Y$6ZRN9F^GSUG_/PN
M2>=,Y1X;X(Y.J9QV*X$E3GR?K/ "S7PTV1@K0%@_B_8>R!.MX?]\]E4$["]W
M@>*5S2T5FC1Q"$;96Z^")6CVKJ)=3DAJFV]A8>WJ6CUG@U^]!B$-1SB&0:N'
M*C'7F>Q<]D(BKN%F^YZ =.W?,:#S.PQ:#DFY#L\*LDMK>2R37?1,!<_@VCK]
MZS9-V]5\ AO*9.52^%'DW'9SGZKQ*>,@H]<2K _@^O-0JZ#;*BMFV2/\?Y N
MG3<:OS,[H?_H5AI3',I"4;1L?KO2-Y+P:=#TR@](&TP:"+C$(B5@K*D+,O"(
M]H5XCG<Q@A]N:BF8!#L=V*7IIMTT+8^Q]5,'Y77"1<$_Z&.TWPZ]R)X^94KZ
MF0X\VY7%7&'B.=)R?02F@YX0,G>V;&U]S:*4<YJY8AVE,Y59/5")3@B6>^-G
M-AVV8NKTQF^I2XCEO:)0.GYRA#;G:]%['G6Q%H;Z_(-Y^F74>Z^?!?T(R#(O
M$$\7.?V-!*IQSD17GUNS,M(S2_ILZQ$WBZE>N$"_JC]S^'9C1W5^/CVU1(9R
M_..E6:B<DX2')FL],?MTU=B3*7V*84$4/T!:<,!Y)-MS3R">KTL.;N/IO-:*
M!YG]A&9H6C@DL='.T,]U$R;&T=X&BP"A%="!=1WU7;ED<WC9V[:.(9"2U9Z
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M?H\,OF UT4S&%^DSC7X\"R(NF7U1\,O)/>4PP8>+3ALB<4M9"&FSCD(9B7]
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M>S5%^,0#>@W1*2"\TG@0TJK.D1SG"050YT!Q"TJ\,X X [=FO7N9-S8-D<3
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M^8]6<L.\"(J0F3S?4K^8Y<A) ).T[<U]"#EXMEL".+0U"?R@!R2ORJ1YKS>
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M[DQ"S)_DY2V7T6'J<1!U97:KLFTF6E[JZ@S<-]0?HSNBP*(M#,*VX^+--G#
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M@)R:[C=^*)GE(:":<S\O]D;[$1_T%^3$&GGGV=]!WG$4D?IOT0X)1Z_73/W
MVK8.YTH8<#ZELBQT%W+R@(#V%_MGT-ULOJCK=G-^2MJ6\38$*-&5+&K7P#,F
MW<B:ZD,,4QU9QB3ED@A35Z-S\YP1CLTK#"EC([8W:I_NX=Y[?WG@\,*'=[>*
M[L?B4"YA_CDAYB$"#L"\:R(G?P]FE:,$&/+T&/19/:IXF.(/"ZKZ(>CYSCZ4
M5R/A$3!.X@F61X5PI:P6=JZJGZY?X;(/J7 LZ*IV(S:5Z)$LKYWMD^\_X:";
MII3%;=\NB3__2.A:JZ08@J)@&:\ "RY8C%E$W!Q']1EH&0H^8IIT?HU7V^[[
M\ODJ4YUC:@_,BR5](3U0@!RU93II*2EK6Y09?ZA0/R^K[:MLG@16U+VENS [
MSX?IT$/I 7K4:=;L!R:2 &SD4?-.ZP&Z-@>%A?0@E$%KZ CS#H&/5E7#NF@
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MNEL/REL6W=!7!^M,=\\5B;D=:D8>6_G)^?[K&[/#Q^RL'D&_Y=LIH8*%$ J
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MH<.:)^+F=,-Z:X=';-VXX<&)P+J A21,^9;XDXHHYEM4WS+DNP:K#\00/\*
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M61=VU+$94U72L%GX!%^QX@XK-,?Y0&NA,24)],]N6X:11]U13_1F7>\T#T1
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M38DDXOW=&UKI4NXH]PJS&<\?"8+0"*?U8MF1Z$'P8JHJD(=G W=GMUOOY<+
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M !0%VOM*]H-N3-%DO#+O..B&O<C4BRT(2?4=XQH L4L_B#6)F?/$E"F8U-E
ML_:FFLCF-I<$KM*K62N?TP_\N.=^?MXA0@6.?N.3,).B0UXN$I?%O#&!$0$?
M,_6:",H!5443)[[W:-UORC5S"=0,1JB_]._]8II](U3VZK!1:1R%\7J<%7%[
M(B$FTJ(F1Z/-,Z?\C92J>H6@2&V$E$9;H%A.WJ:4.4YR%R)$HO]0<N.B_$-8
M!+;Q6!!7(.+^DV5Y EDE>2L2ICWR:RO7>);Z/483F&U^PDQMQT0R>[QP/79>
M5QSYT7*ORL&MM+#O[91VB<=,H YQ15DK],B4-:P?,,,4>1JA(^H<:]S<%GM;
M5_4-O\[\;8MT)I\PA04<F]M'C8;4UIR99/N&MP^WJLHS?F;(?=R0'2WQC\T5
M=*IX;]NH:4\T__C1>VB\U.Q)@HW:N/J@QND!._LT#SZ3X_V?3.X,9;)4^?[;
MJ%%B$E$>.P";-'PCN61=H:IA;LUG<CWV>TS.'(Y^0=I'"L"#>OX]J&D^5)P,
MXQSE.H&6N@GT'7'.NVL8$CMCG*=ZT><Y!H5D]9/7)/I),S+>!U/?M27L3+S,
M5&Y'5PQ+PM1LJM_;VZ3>OFSHG!43RALE ?>0L5CC>80#&5]/6/T4RM+K,?/Z
MTCRY"Y& :8)MG&XQ\(E/1-K<[3G(:+CP9=<WHW76[W7QD40PR792K3GKT#C6
MJ/Q+<JU$]9'N(IN,[8[7O[VL''I] GQO3^5Z0D_;"'MYY\P&.%^+7^Q<N(2X
M8?K@FY6E0Z92/_=DWH- DQIFCB:=E5O/M5 V/.M Z9=)PC:5RHL]7W8DV")S
MF<?E?(J(4FZ#ESEB+TCYF:"Z/U>1 ,#9;T$" _?O+D0E1MJ&8XPU9TU6!C#6
M(> +6I\8.,A(2NFP>37$?J!'+LBHB'H!AKD"SDVULX-!+S$QYV>"(BW'-S7$
M1^>]QW1_K&K_(+V\O]'@6:C__JR04#[#/Z'V],]NZVN5@H\[6Y><*C1&7V4[
M8QN"]68+TAHOU.3!!C!)@JQ\V+D2_7C_U663O@JSG"HWFZPF^1&">T[-F"=@
MC9Z+RXF #R-YPHF[D)R7>^X/#6'@(!]5%!@1.$\5P*W8AMTY"J?C:3+$7<@-
M.&@[-7_5N$O\YS?0Y>#.<*\""M),N@U%1P#;%TZ8-O6RCKH'DW7Z'LI-K?ZZ
M7.-]>UBD[& 'GY&<W/.V-N96&# M=PKQ?:@=5YI0-2=TIP.'%M+[',:^"I(X
M#LNPPVU@9@!00N[9RL)H#GJGDF7,5L"R?F\9 'KL92<LN\Z<H%/#4TN]]M1Y
M-"3M,=5JW]_*3D]@NY#T"F?%L*<#B?)/S[41<C1-K+]T#4HX3641+A'.7[.K
M/O?\"S5EL:,X&WX&^"'IS_@8I&BAWXQ*BFAH02DEA3D!.;Y)\57,@&B3@>#P
MZQ5VI\V'-JA:^64;"CSAH;V3!6,*_ #L G%M4*\_=1<BLL0S!>+A^S=Q5#.X
MC#$%W?] CZ+%TJ52=R%,2=^^MKSX\-]TP#Y @C845GZQ&L'4TE%V*IAQC%7Y
M/DK:NS25PX^'_=IYGN!# ,64Z5,RIF^N=S_J.,BZ-,^H_BXS9QK7GQ68=9&!
M/ J6<7R,3D,U&%(-%BBQVKS/B/1!+7>C?NI_19=E1G<AS7IKE9P+,3VHPWH\
MHYA/,0:HHYA;6D\J;LOKXO<ME^BSIAY]C?5(#1'BT\'J"QW4R:;0H_K#QZ-6
M?W7J?M1HNA#I,-I8'5WX/>;\!4)F?ZBT?MK&V^L_!<&4\%U(/:!IY&M+K"?(
M]A0\_W;DXPOK6JN+5"=U4R.%QB[._S88^7]H,"+U>Y/S ->-P/GA0'71>$/X
M,=Y(R:FIFRR5M-*)FR .&.N6/PG&]7L;F^E-NSAF(V*9\U='#&MA/38KI^LV
M<1)HJEI!_9?>D)#0,,Q2X"[DPRXD@]]1X-*#=7P)(TAFJX^4 K6U'Z*#.R)8
M<0Z=4WHUV'<OW=:P%^AH'>-+K6\%!C../R"20]2.E*S#7+\-O+5Y9% %=QO<
M6,X],_3>4LRY0O&"W-L6N6@-IJ8#NSDK-#BK("VG3*W(W<MT2@$@B4YA^!VO
MPD9&2@:J(^_$BEBJ-+>%467=G3J3#.6+G/P1 \+6&B\+>=.WB=U(4)7&E2'1
M]?A:K3^)'OFH2R40WT#K7YFQV;'L418<[[A6<AX@41!PB]'%B8@W#*3<1<:P
MD)7HH_!J(1U+YTZ@K^&YVY5PM'_GJ)%74&W$E<9UOUU(;#VNVPNKQY=^M7%T
M&TP</8/$*EB9)W)U1%??AH?(+\T)M8S@&*Z[D)X.CC\[86@]J<-2=8I="2:@
MV2$-[GK3?87_^/V$@CUAPXD_VZ)JH5D8P2<?EOL<*A)SOA/1A\<JG9TTIB*D
ME<,GS)Q4H(%OYR02?C.9$9=3P/LO;1P>!2R&$[(_Y?AXR,ECDJ/ELZNMTP*<
MR%5(*=OJ2N\4=MB+EV7V$J&.7\LQF5P)%YZ0%5-TAL.> K<X&MY8@1&8\FV4
M %:&9= GC\HT7%<)5#Y%8FG'[ <;Z/A$MO.6F=)PPJ_4(%.C:+C,N0;#U\N1
MB9-HPX9T]8Q;;S.W1DF#2-Z1@#V7RV9^+,)X$S@I7$!Z&$/J6Y\E6 R0^G"B
M+X'.O(SC )0:L9[*.PD*]6^@TVN&&2BIBJ_W"-W9 4/7#0=O%3>=:I,)%7)N
M><N;YP-2%@YP%=;B"1*B6(MC5\&#K[CB*OMKN^0]D3I;E-201_LI>.!-!>MK
MJ*7X#'BR>Q<R;<F7]/'*%G?77CUH#-24"HKYKV]^&9R*>V/J=/_S:KLNVU17
M12C."5V#,.V]H6DM&0CW]Q"#.H01[<6VKC-;ZVHEJ2!)].U/H6*?[W[3+]&;
M&7_V^I[]D:CL:IVSH*US>EC,*MI=UAUC6)I$L+<I>?'JMWONXB@N#@?8J2CP
MJ>3=1ARHE=C@!XB@J!^X)IE,XW]?@*+/N;!&UBJIP>(-W:KFEWHJ3WP%H3;+
MDPE\ZN!E66U,:=^%*-7V]N4;NE=.Z&K_2H?;<N!;^U'_JC0)[ T,V"G@QZ+L
M/IPK,1<RC7=A991682^"8G0YF*8ERWOX8GTS?CXAZ>'F8:-30#06-JG^-I7\
M!$,]\'2ZPRIXN_RI>'Q!M[]%YA:OP_MD=4;E0\9$ZGL@RL]DX0G&&O0W'__P
MRKI$)4_"R[ZH0N!V7VB"XTN">TWQ[X),4D_.W6VW3"FH](/,CYJ#QCFAG^_<
MJ*M<<'WF2/GI\\^/QN-'J@<<%^SCPF?-)$\TQMX]35RLY@D*\#FP)F\(7X_+
M[+@,A-#U_M6#!\*38>*DMD]85-UGL'ZFFW8$:E#G;O75^S:[2R?I"@M6,8]
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MT:;D;$Z.NWWN+N3),&A6QD:!'D D^]^=PBYCK"EP+XG>:</G#'$QIY:\88W
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MB4:NAFJMQP\4B-0>M<V:O8/_5<T[S,?0@Z?YL<!@?K+M=TKX3'X7DE1B!.(
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M%'4_^RPX#" ]0"?Z%<-"O?@Y_6Q&"]LE_I?PN9 DF/8(]VRE%W@>!5@UOD[
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M\R#'$9>C AK.L,M9B)VI-26.PDK+EGQFPB\O<?+\%OFM;O!"'D^L]>9D./$
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M4.?[A&Z@33Y3[2&1T$OW2>OFG/:IZNE4?11>7GC-Z0QO<LG-U-3#/8O4\'#
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M^5%%T?#]:"Y8)+E*P>*N4<'7<F<K@[OYI?8?6I:T/[D\^SI?I:DQQ]GZOXL
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M?M)%)M)^>@@\TD7@;LF"S"W7!4,/4HY"]W#.<U^@CZ!LF%64>Y"+6.&M+A4
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M[G,^R!HV$\9SSV'"N%C-S10^J!J3,\F]A"%A8$N'82V:W'MH 7"O\4' )<3
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MKIA!"<WD8YVJ\GVZ;^S!513&F6% (V_C-0/,^@<08]O/(<7LF"O]E#SP092
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MXV^X91!IET@-FF->Q@/*:;I]^!?ALJ/U77*K798=A'?_"K5.7'O]]WG/,1O
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ML_RDWYI>ZF$I/VVN[5RY_C+7Y5'D3@5/6(!D#/NMS[JLR\#U?E8[-ZV!&"P
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M+<$S;"9TW#?@Y)^M#ZI#Z \?_.D%?5=DBD4A*^;\6\].<<'=4.3&A"AP9O"
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MS>@R12X#&1@L1,KVU?LDHQ^IS25M SAX-F+]'0#9N<+E$R+F$FC",F##&L$
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M[:G8 FBE&,EP369@WY4)"M]V.O\:B=^(OX9"93LQ35E(O3>_//9YGAJA*N?
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M OZ@P!?Y!20,DEN%!V%)?#40!P0LMJ5B_(%A#OH]7!%D]>EAK-FF/^]L1Q8
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M VA*&P_7LR:5V<2'_<%&I/P8]EQ,#84K]@1/[PJ-;:?34\#L:@O%.TIH+7C
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MNZ"V>O7*NDR%DC&$O9(:HP3]%JUDZ]79.&D8KWVES':VQ5[VZ_OC<;"?P_+
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M7;QVM+W81R0-5^"(KZEHZ#[9K=7,EL7,1$BM=8?DXZ=+O%M4K[?CG,-<<E]
MOH3.JXYG&BF()98['DVB3/32:P8+"D!B$,F;DUF+RSA(<:"@S6:GC:9?:V>
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M7KPX">X)U@ A67[[W[L[L_^],W?N?W9W]LX]Y[QGCCQ'WH^<S^LS\V#_8#<
MC]55U%0 . ]P %;W*P"[#% "X/P'EW\]Y#_Z#!SL3P %P8,+O#E<'#;  PH<
M7 H<;#\ " #@X/U; <!_67 >X#[$>X1/0$A$?%^@Z3'@ 0XN[H.'N'AX#Q_>
M7PVZOPYX2('WA%7DY2-*'6M\-D\JT2])!03LK^IZJ76G$!QB-A]#"8EH:.GH
M&3BYN'F>\8I+2$I)R\@JO59647VCIJZG;V!H9&QB:OO>SM[!T<G9R]O'UP_L
M_^EK6'A$9%1T3')**B0M/2,SZWMA47%)Z8^R\OJ&QJ;FEM:V]CYH_\#@T*_A
MD>F9V;GYA3^+2S#XYM;VSN[>_@'R[/SB\NHOZOKF7[YP +C_U?K_T!?%O:\'
M#Q_B/L3_ER^<!W[_*D#Q$(]5Y-&3ESKXUIZ4;*)?"*A>)174]1*RB^DBJ&T^
M3A'1<(C#.)'_LO:?G?T_,Q;Z_\K9?S7VWWPM 4AP<>X;#Y<"H C 8'B^QP#^
MSU!K(A6X9%EK00X((WBO,A]H5[;*(=RHX5&[9TJ:VCX9Y2Y88&='TV!F!OU'
ME8_Z[)+9=U!Y=;M](3_+'BQ72(#,6*HKUC+.(7L4DUI(&S6TD[&B8))F528C
M/;2\><YD28L7J9=J=;A04BJM<F9A+,<<Z!-B'?DU9XY?A:U0K4F#]"MT;F!3
MA%)-Z@CQQY2ZCMI42SU7YF/9<^[EA2STRSG) =>BUXM.46UM@*VHJ:A049S)
MR:=.PBHAOF$>+E/%D*<Q:L56=5#&47:6F*0R>]N+=YI@47.U&E068?'#V'$5
MG-JMHR8U_8>XF,SE$O(7;S@V.19&D1-VO'1$]%HLA@.[$H7AAFO2P6"5"M^%
MO_6YLI(A5-PZ0N%Y"Z36U&\-WOH8?*(/DC%T/3HX&^YU0=?%'8"*"EEV6_?G
M^R;Z1F9)@O+F"=[LGZL^J: \,7X2I,95K:,<5,SK6:B>2\?W"B*M%WI,IZS"
MMY6LX/LQ=??9\)I>:C'WFJYKR]_:[S%\KU[%\/SSX/_7_W01;*?QL"7[;R70
M6<=O9SE9V,;P%.J>J7$DO%)E<B1^7D=43BP"H 018"8PXMF;^<=X2#]XGW@5
MS)W T1!(+D=,51"F]':V2<V'N.J5].+6ZZX>5SSW:@OU8>;N"KQ"FM< 'U#S
MZ<!7Q.[&W5IXR2J=G"J28@>Q^B5^9-*]T-\9P]&MFY!0>"3*E59=E)IM$/."
M#!H7@N+& L*Q@#H%W'BW-TBIN$"3ZD/"9^9B)DZ#R]!OK\GI8YY7,6#T)Y$K
MZA]? D)8D*7,D_$8"(8>Q9>ZX/,QG^RC^?K ^F,G'<BFD7B"!7]AZ,<QO5C=
MF!%DYA5^E/-4%H1WKJY-P,ZYU<Y]%14240CM)D1&1AD?!&:<\(T)RY'VG6<U
M1)#"-Q/A3'94)T7(5-$5%0.BI,;]&>B.^"K,9/T@A,4Y__T,S:!D_])7UP\L
MADML#'J_[_XN C]4*)!3]Z'8R)_W2U:J*'<:B>5KL8)3\PM'B@*^7 B#.W0P
M4_,GF6;>DD4FT FCQ\D<=L>1&;]>,JNLN03 9EEK+HGC0LH;$QX'R5U_Q?0X
MW&":;KH^N$RVWN([><$0K3?>'J/@=I. 7/]A;^<J4P/G4E=;Z5+O)*0W @M8
MS!&)<OTX5Q,!4:^Q+XW5*:;KGGB<P^J6K%TA_S&&IV9I<O)_=X?[7Z,$IX*6
M^)(\8UCT(TN37-MX_(KG$ .6K2]:AD8&WG;>5O0F;^SLY$(K"1]2_'JZ,7NN
MF@G-DCO@U:(U'Q%H+-H,.&O.TIIWE0@H>?[<R^2L>1J2FZTF6=,T[=34KNG'
MK$QE0/!_&SA^[&0Q@I><MA/HOMEM9\Y+__[4T&:@<_*&JFZ8Z0='S.LT27JC
M>,A4Y \[SC<W#'E@KUL%Q_.S\S,OP6"-L_./:^@632_3A>F_0/XV_S:0P+5_
MY;5_5;#9<8#X<<"RSH6.\KO0&%Y63YR,Y>CO4D0%2SAL]*$L"3:KG<^.!CP"
M&#+51;9W4FW'.>G.Q=N*9IQ%.N8UN:9-&_.R2+E.WZ]"5E-\-7R/Z^><+V;3
M8GC*'^LH4P'^P](9$M=[)#S*5,!<Z,58$9;DV2[)J[5@'O_+ \K^U+ZHF%Y%
M35U 33['U.E&HI!1\[GXC%E))6:'2D=9!(]*Y\6_R2@V^'?/DQ288I\0':I/
M)DU EUFF<9(<M\,+]=5(T7J&_L'9^OLTPUD[>M!%P+.$C1<U^#&M*;P;:_1P
M,H%)ODI)3:B)I%W>#F2U1AL7 N.S]10DTN+UL> 5C>=U.M<OAVE)I28'YVFD
M;GH=K?,-BQYH-2M*#<%$5Y@Y0T(HXVM(Y*FY4K9#<U_O\ID^UDVIU\Q/Z&G6
M'J!!I2-K+&*F-S1A6,##$T1$%+L'XM>-]S2S\R71#R.I3U"+[^K$UVF^\^"/
MY?\$0]&<TWJPOS_= 4[6K[WV\_!^K_G \*\&2VU)CY& \W/GE@7R7RLO.>(7
M:W8+H4L60]&=F@5[!5MIA_T,)YG%T?19:D6M<TT$ KAIKF-G<NF,L4],,K:V
MLC )G4%>S"6YI4Z2,-OX#.GH1P]]YY.B"N+(AML&I[" MUT5Z']N'B%IG(;,
M/2]RD9N*/5?S7OS9N.$_M@[XQ5'IHA-BA-NM3B/CUA_+32Q?AA=H:YD+D,@]
M4<_+7U94,Z_ AP8^WSB-:'- QYY=)O8OA)I7EX\(9Y#P>T*^9ULN,\K9.Y@6
MM<^7&:R=R14EJW'\:_NH)I>LMI7LSW%98XCRHA'P44-BZ@/ #>M_17ZAT')8
MP'SG]ZY"&#I 7 ;(-!KR?'>6WQ"9^*O@SN4.9X/(<B9:^/Q3.UV@A?ZMC(ZW
M^U]#EYT0$<_7UZ(Q=5A /L11[[:<-_\V[N1^7-TAT#__]S/A_UQ5!00XE"RN
M'LB&S](8TM#,K%FN6:A_,S,U-7L]8VZ^HLEJ# LET-E.,[)[LVEH__2!RQGC
MYM#Q(CR18MT2'+!QM,!"@QA3,7- OJUE0Z68+3]]=*AM L$"8,#:;ZRW/ 0^
MF:P^>?[>B[E' G?G&")2) ,6 ,W#02Q\ONAH<.5.N"3>;\KGS'5(?X5 U2<=
M+4XMC+9TS[H?C97_O"OA>_;/#KMLR^[ZT2@"A*%U[U\6>( >!89?Q/HN!!J)
M4Q)PN_(N&<,3^I:T+!QF3[E")\>B_+^9R8]/4X.I%JZ5+T9O7H*+\U!-*4$T
M:/(A6U'S4[&RE WI;.D1I%BO_9^QR:A:5" 4/]7ZW%P>*<.EF;:%RJ(O\<^
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MZ=/WQHBZE4;ZT*NG#P:"\,8\3Z-MD[  2RS !A0M%?)8@=C$V+E%Y= $P57
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M9Z=46<'3]>==&4DUHY,N'9.7A4,8%N TF;!&-BMP6JG "2[4?R-:50K.U^]
M*J3+J9XJ">0U26PHLW_A;%A>49ZGA\LMG C]7+]FR\?O.4I#*V !L]IO:B;7
M43PYP0]BM'&)"1K#4%\%YHL%R^<)G=M3P '#>K@NEB\HD[B^'RW96GR\]6&G
M8'T_M(/A#*)!80&]BO@\J--O01RH+.D5,B,H_<I'YU@IV(J!\^*V>;-XK;^]
M9R3\R*M_4[AAZ-D,5'^TD,F"E_K]MC(WY:&TQJ 6/9(XD1O6[0 3U$*@<NS=
MTSL#+?$E"K7H?>3,<@,M'U2K1NK_,$Q@3#.PC74+.]!3T_=-NDP_&KI570P,
M0%RB/X7G-L=OAI!E1'04+38>V_HX>*@ON<B:Y SSFFJS#;O+%S6L:-MYT3W1
MX)"BF5:[I X6O?]H.9H+M .2_879D0MBUY!VT8:=LU,)%M(0V.-3<HY+-TQO
MC$8_)GYTEU5SX;=G!R^E!O=N")%Y&C$8&$^P]^W0]Y!O-ABHT/GE#''WEQM_
MF*CBU0FGCJF(*%-/D"RF>P7YX :D,!7?;T_(44SM#-H82_\BISY>;PG\6@ Q
MA%IYR4D2SD(,TCN#6#ZU2FNY&<C'\:GX""/+GFGEL53QNNEMZT$".CK,B#6R
M#P\S^(\JJW8Z.CO:($^;FYKN\ZG6UM8L%6/8_<#<2C.AUQ4WM&=]*7%-B-R\
M.D0:15T28P'D@< \$#'*DC9M!O,D+8S\B4L!9V]7+2UA/OF?MQ68J%#VRD;^
M%EK*_7/UFZ":[OL*>8EA=V9A0M!&=.(7KV8[(%?OT#?#X;D.*?<04I=4F3FU
M8-=U51CB:&>(?TRQJ($SIOE?(,3V/T.($/EZIBVB.\EMZ31F)]0:#^ID.#U
MXDLS'729K]>9M?9O%-(U/O(O"CESF!';QX.G!<'G-2[,$,^9XX>]QD:J=;[
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M;_JT'11*\2HE&;RW&J331M4;Z\VBS!Q#KS1^]3U:F\2HW5&+@!,9,+F!/IM
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MO)BX2>?@<G[1<O(0FP;G"X2T['53L/QHPU$+.;\6ES[B(LT5LN&R,.IL4$$
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M6S4AT$O15TN\D]&6;_2,*".]QT$!/$-94 #=9;$:_X* 76_S<YRJMV;.M:M
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M:,4(P1QM%%YB+MMV8>MTV37A<%DK92JOB:;CF?_CO?7;=0TM^W^^45TCAU
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MN:#326C,-R^@\T0CBM>&R(.K?%Z_8.,)NE'#FH[E\?.V7K\:*C0U8S)YP"E
M>V0]-VLCRU#7.WS!XGNA3!Z$-HRBU73,9R*XP,+&-& K/45U0;Q_$E+ >W7Y
MKH-MK.X^HDG\2Z,OT*+#^\L:@Q LW84E6JO74MFMIL3DR1WJ5.*-RT%/(TH3
M!E=YV+XKCT8CM588&,%II\O/?SN&54$9/4/:\WX$T$6W9V0TQ>Q]:A@2B)P#
M';]W'WV@J*@0!T_]#6RBWI,N(O]49\:=)<HOTVSGBS;BJ>.,8UV:QOUK)&I]
M:XUR0BN$T#D_ED3O/;(>X;H>_-'5$U=;W:>N0@C'FY%O9:P8)TQ GN/XXB7D
M_%FWFS]LM@<G9[V+$-'\"F)C\_/=]Y>CNT]D;%:6))<Q];D%JS5H^O-\RY#$
M-K%E[05=CCN"K#N ]K\0W:( RLOB/*F8R+QKN -R/$.R!BZLD + MY_;G;XD
MM:C*7AB#T4!<2M2*;TC/X28O%_3N@N/V>7Y!*#>^MJ(,E.A-JQ!P@WXDPAWD
MJ&5N_>9:D/ F!:"*<O=/6/XF NNZ21#1(LQ@-&B]H$P^*,RE/49G7Y@0W"K
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M+$.P'C=-<A]CN+=AC_JJR@R$HX^RMZW&>@*Z'ZCLYQ9/$E%%">)D$,/)'Q*
M%$,!K)=3  OI%$!'<,0[JXV!71E"&^$+W]D*[A)HE]M4]5$7IJ@G.Z3OY[R#
M!IM[F'.['GL[MFW"<KS(/T.^#8^4+02+TF5VDAGD/+97^31PE'C[E *XVG7
MT(,Z^K6^I?XE_2<%,+O3*_Z'S#O<H=,6=Y+XXD/JF6OD0BH1K 8%@4---./,
M[5J:OF-!"(4\L>:+"L5#C0)P+;V-F3?9 >LY<BZO%!&D8XS8>1L">RWIW9O=
MBYW1Q9'3RW?>P@?[)8_WQ'YY7VS]TD_2]/67B)6XP9:F/(,3N#3 6,))Y>"E
M!'@1_/%<O5E^+1H\2! ^S COFBH:TC$5(>K)*SGMLQIJQ^MMN!HOI^B\*G-'
M]^K3$J@3!8 SXXL?P&3MWKUX2<BF2:UWL"6RXJ6CJ_?1OF'A9EC#(@*U83;;
M-=]6V$4?:XT/%(9Q4?+O &Z$7*@3C0I6R@:@47SLODDPXYAE9B+5ZA'WRP9C
MAFBD&7PG2P%.??YG?Z\:WI3)>'N$>93I:NT3"L"<G*3*0;J4C229#"%EI%[6
M<,RK-.^5"NXLOC@OQN:T#/M5*I/M/3$YN)LO]-=R20AK=58J442_*D:=;V @
MOL[$<,Y\+?>E9]^(Y"1H36G.&^DU:;M  9AEBW7"%VM(\!K2)[R#C>-\=P@H
MF*KZ@_W<0F^#W2AM@OX@\YBR'E>%V(_N]]U5+$3M"</2;%#CA"6HAA.TG1U6
M?,$A-PXJS3:4V\]^6YH]5MKL8I/!DO?#7$OBYUNQ<J'X4P"C=RP!6J705+SL
MV,$(=)C2I=;@-Q9SU&$?_>_C0F7Y[M?;EXQX=AH2$SS\8=ZFVK4I*0K&")29
M+;0/:K-]M9*2$\)[!:%&D UIG[#_)D(R'('/2;TE%8DZ?7B?O^R6]&@ +RW2
M4JQ#-Y+IC%<@B/].>CTK*7)VX0G\O5(5M_;S56O8?'YRJ/QBAQ)P8M9HJ:QI
M3(ME/?_=_RW'D?]_L*PV&(C,HZLZ1''4^\05.K&#0;QTW_"@G,)=]?E$*/46
MC&:4V9Y6X2GPB]PR@VZ:]J!:9EWYKEL:0&?S) (4,8GZ5I ,!14D" R$++.^
M1M%OOGWSL8P 19/9+_W%[\(L7-&@(;36;RW\/Z_3%VJG5>6+CDLC8EO+FW@#
MT,O1<-X"YL-W$4[D7WRLE_0,?.?(.>5",,#YG5E,J/H'.]4N@A-?$)Q6'=[Z
MVD[32(OKIHR:3-1*2KB/2ZZV(COJ'FK=#PU6&33\.:9W6W.]@(;,3Y@X!9.*
MB.)XC=Z(NU,0!E'\]?Z&&H)I.(,5CB@+ENX]RSJ/Z'0IV5+^KA@("K Q+$<7
M<L5V&H1K/F],'\W?1_\$;H>@Y^@S,+Y4FKC^&*],99%8N7#%)V.[+J-9'G 0
MZPO0>7AUZ(9;)QSYL#9T+DH>'[*7?,%N1YYL4;\U+;?,,DL0Z75DBK*<\&L2
MS[M[\FE:SN&I@7>5'<>X.$G=>EZ_"[:/'>P=X4RV,F%\MB=H?(=ZOCV<E%GE
MY%8)FGFXM'6> 6\BQ:QUQ-_KJ$?&2$GZO0Q HU49=23\E%R#!6J@*B@VZ-H#
M3F-2KG0W'TD"1Q>Q&C&Z3*]JC$O$*$:3.0E5?9;YLDA<>/6<>AZ6QD%]U4!V
M\^&H8+9\1E_N6=:\X-ANB2'OC80@KJU3!:U/ANN9A(,^"N";=@L6,5<Z<9I*
M <2DP__8S!'U<#HI* S3Y4P&[F^O&_C?6-ADA'I0 #Y0;[O>ANU'GJ%'J(9L
ME<=2S3[MUJJ#[S3T-XL2 &0?#<\=!_]3=U([@GQ_82M]T5JQUYLO\5PYZM23
M^*1HI[WLM+\)Y/W*O$AQOF1&3M3U/K)M!<3#P1%"7MOF7.X>G2M8^=54 LI_
M''G0[:B.V]&L<-RTK?WBA.41'OR;8!?=UCPEB;B,U<%<CPL/I5:F7@\H[-=+
M?.3+V!X=6)[MP*3N<6%:&Z7YM@))*".#8LPR,RBP!A&GJA+PIB[>M:[--9,K
M$93-;KMCA(K<[O_;F_2[>JQ/#IJA?$!DE.W_O?@--]HO3>/%2B?KXQN";F].
M#>%I<VD(!)W9_I5]7O'N3]J2XDO=P^[; '4E4HDZ,T2*((L_0)-O$PQ6:5"<
MX$ :_]O+RUXAY'NXL[C]W9.=&O=]E3VIL%$ZT)Q#3,?\_\;>=S8U 77=QHJ(
MB(A(!Y7>I4D1B(TN(""]1)H0$) F+1!%Z4VZ=.E2(S7T(%6Z= @EA"H]H81
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M44-*%$ =CU<H:A 1N8AZ-Y?@]KC/\- N)A5G@'M*2H0$$D11OBG]*\NQB2O
M*[Z%]YM:,,0@UN;1C9_3Y>/]]5/E8JN3QW=02K"SJ[E.HZKP5X4%/=:\7_0&
M#F0C@$N)B]Q8NO Z$I3,I!/A0&JL<$KOG06BKR,:".*XK*,3A,,A!8!^\'GD
M0)$"$!X^L#Y\M'^0O_ 3$*!+?!BVPTL!/ >1[5NE*(#8Z3D$,ZR-V@EZ_3B#
M HA.S;X]H<RPH (6RP\HG^>=BGJO/6&KD]"QW+W:F/%*-D^B6#EV]T?&URMI
MAU>"="F SMP6-0I 9> %!=!Q]Y_J3O<G)"Z#=B"HVU![Z,6@D=1L">W'9G@_
M%W1CK=L=\YF79Y9D&#I&6&_T?J+^6$R'!2U0?_SX,>+1M;W"5)WF!)KP5<3=
M(,L_5'] EX!H[7\=??\@T,^A'?+G,S[GC<+I$KF5'6;(X[@P\A^" Q*Z;$LJ
MPV6AW,CGP1F134* R=>/D:>).!U2UGU26M!=^,>1\)QNUJ*29;9]1N>FO#F9
MY#A<(2DTM2C#4FAH+5W]G4MY;91<5^+O:28?+L>F^#<:-K7P,]?_69<MX %H
MR %N:_P%K"8>?;\IVY5Z9>]^/=5:B&(/U]&8SD<*H"GR&@4 F5Z![J(K2,W+
M19_R\O>BGF&\\]4;":E-E<4E%H,2?UQKPG3>'<MO?!0^'COP]/16)+U(D!)W
M^\I^;R/[E@!1&#.'JYP$UK4IX\FOYO)KFL:D&T(]& BR3\9V^?4V,QKVV&,'
M5XU/?0BJ#2FO%9E#;V>>RY+BE?E$T22&*1-VQ)6,]2UM[VCA-1,VV$8F*(T4
M?_2JG]N@B]HX";JJVRD?*ZJ)%-'AI__47A<4^QK;D-)TT)V_X2^0A^BL(3$K
M;Y+"7 UE]KEF<UJ5X_,LXBSK4^&CLMO^:43A(RO$0Z!-\PC_<E"K8R^-WU+&
M0;[2V_JI6OZGL?B(#47/WI=V<>-GYPI-.<1W,A)#$_:7+P?GZMTUP]>LD-;#
M+5%S6*\$5(T[W-Z\$N8%T1X2DCYG40R+\GV_'TL":-<66*CSY$.8/M[]X<&Q
MHT;/5.TWNVCK%"];_#N+[,S( ^0V\;X?3J/NO8[BT(.EW&&@?\*+*BR*9,ME
M);<-FE-D,IYU5S:H3'9^W8F0#>^<S&>D #X-B_H50)7<[\@?O/N0<T7.\%2_
M3*< <6#2!QGIY<*+P[M2,;U$!D)W-I=I&E4W*CJ'AL@Z&JR6<379KX*H=6T+
M^(FK_>Z>%B3O13A7YG<8.AT!B\/+[5L0@#L$@A+>.>A\JB2=SC92<UHI@&LG
MP=Z/:?'[->3;@8V[Z[:MT'O'Y-W NQYGON+7']:5]":O^^VYQ_PX#X[7Q<^%
MHUMVM42+Z0CO*0!.Y829S15%W:[1S,84RX0U.3GQU1AUH\',(&\IZA'R(G L
MATP=@8T%QIZ[0-F=QA5<$^%M(5?'$,,OSOM9J[<M!I9!H:+ SBS_K6,/,^$L
M+7U,RUD-=ZE;)%EP6>_RG\23&*@T%\:%OV>&J$( $CWQU%!(@A/H1AOW)EEI
MU,5.A%_W!D1C=*QCF>U-D(:H"$1E:>'9'E2$*7@#!)+;;80SDL2G3S>63VXJ
MW\%*Q4BJ:(_E/E?L7O[Y'ES(CI!REAI8KC5^]6M%H#/-<=ZRHIJ,Q<#"F1CP
M/AWRG3]*C2H2T.]G&A=D18(LF5)M"X7?K45U&.4(3PJ*G@098OW_=J*;S;WE
M9/W+KW<JV832I)EO1Q@Q;*+&6O;1CW)Q((:Z_$<,!E4-GXSEKCH^6NA!Z=V1
M.A]%R$EEQHKB!B=7'56P-\M\P"<']G/KRYE*7&^)ZSR7(;/^>XD_'&A<H.\.
M$MXK)CXH6,J>#2E@^2LUPKAJCX<Z)^BDFTW'/M B.NE'<Z%T^,MB83N'X3IG
M>BF<XD0QB:3I!7G(2,W?O$C\X59'I,#WB__!?R]JZL#DD>+Y!KFWT5UMS84/
ME)7:;5!/G%4;XQBTPUTJ?JVM@DT"5)N-E;M^N^^U36ZLS\25KLTT]2$UHW.I
M)G4J2I["-+2!\9/!A;M57O>=B_4TM0@_3U;;G$39O:% T-UCJ7*B 3ZF)&4>
MGBV'?5'%OG&>FN:,(]XU[MU>L'D2$ +[>]WT-O-JBBH-N_J!>F]>GN!;VYT[
M#'CCPY@?B\JY/T"@OAS)LX.M@Y?'*,_'@[,G\QLRY$?DL?*AL=]$_KZDVI[U
M>=.T?NKC?HP?Y]W,@B9PQH2>6\#P= W\I'>4ZVIQFGO;FY5*KDL);U;$1>PA
M/;5YS11 P]-F%_O 49U( =B!'7E1.964X*8\@"U3^2Q''AU3?.H0M_]NG&_B
M82!TI==GTA-4(8,?(B@Z"1<2P?A CU['5--$'2JYT[H8A1-U/0K@HO-2PWZF
M#VPVG0*P;/MX^L6=DQY[\\+PL<>>TF!ZR!XZM,<. C1*A*L(8;KG\MT#7:&T
M@7P/*U/9[7T+*FZ :*T9DN%E88.><MJ@LM=KJJ3*EN!RT_G [+UYAXO+SUT7
M"2L^>O@6YYPW*L;E ]MQ-0O@6(WKJ1%2;U;6(E;FJ3>#*]L)#"!4ICS0/L>>
M$6;__&&G#9MKGVJ(^E0RL8(J* 7U_#1,WF+6R)H&A+1V&M,:+@],AV>M%:<1
MD>?&NE^A/,J%P/$W'-64#HT]J^AP*$\9)=ZOK7GGA7;=#]6%<6R?VL$V,\@W
M-5L/%?T( INS%$ <Z!K1N'5NDY1;CN>\00&T(VK<*8 +1$3:^2A\1^37\6K]
M&KZI83K,LF!$:&I1R]26I0!<&V OXK"ZO?UMT]V5HCY-7PZ<M 9F,62#JZFD
ME@*2.= 1N/29BS-CJ9=XA^X7)W-;:X ;+=$/@PH/HG?ZH<GF66[521?1PB)5
M\ 5:,+ <=Q-\QEM;%73*9-D0?>G.N""9+$PL)'/ZHLSQ#BO[ER%JF,'UN:X@
M -8GE C^/D_E.*C0&W(<I>2FG>A_:^ON0<_M;K^Y3..S%(@H/N0[T1P/QA"6
M<T+6-8CR6*Y?5LS8X; '+U,!FU9"H^_JFN^ \R]PJN_NZPNJ&SYX[6VG>D7M
MH'=<.*2MN(LHU3TA:);BDV+4[UX3'8B"V1T;FC$*#9"#;!Z:_-4K#MQ<VT/1
M  N#(A2UCMO8E\48*_2//2#]*> OT=D(_:$2!>^2<=#A7JC4%86:^O%>8:+Z
M(3 ZT77JJ Q" 92.#<[\NY7A603EJB'GI,9-ET'>4 #QV0/D]@^(,U")<=+T
M8>SKA %,"72DF3A?@%H>^7MC",45 3TZ0'G9()[OZ%[;^FR*64^$F$C#G+[.
MV\*0+C5N\MSUF]QB5">6ZK_O36M8\6,\#5$NI7_')/BHN2=$)U9(%NU//:C>
MWW[QJ2K:-3GN\N%N,M8OA*[,5N).0NWK^>]- KJHX%-5#?^BP*"K\*F'24)6
M!^_U<O#HO8%],$+UCIZ*>Y;U_P4M!_^_@@57.-^A]]4G'O=BY4CP6W9NO1L
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MKG"PT92^-[];=7PJ)CQG38K.V7^(B]S;!'ZB .::NG&:2@.O]51\':K_5P.
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M DQBH*1;W",6I"%;"NP?*4R]JLR)955\'E;8EXI-N<J\)E#V3+X>Q&HB,IP
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M7S=\?AB5Y+%I.3'P5W#=HG9K0"SKG1:!L*M_=F@PL2]VS*&EU]R F)"A(43
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M)3436DM79TZ$9H0UMN6M$7X?*Q[SBNC<KDLN/Z?QH*:@M__8'&H,Q#S/05(
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MNQ%::EVP?J1GA$8RI/_C1P8[;7S-#W8*B>C%"%:!DT>E"0O3<%U6[.JV*S@
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MCZHZ&JND(41U B+OE0JW!Y?D3X6'#-5;%92*(K_(D/<SK?,MM;Y_/@BI%8*
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M&/"L%CUV#*B']6+F!]:$")AS*._93G4ZC&;.X@,!OM!D\5WGIIN^2M\^,=[
M'I;\/L3=KX9A3%[&NF.8V+4 !:"BT0SD>B!U^,D-:%,DK[.+*X,%ZQ%WQ.(5
MBBQ>>#1<\'JU@W;.'.86#?"HFW_ O4UC@+E\7WRXK<+-?%.1HV![:/&!.Q2\
M)BG\:2,7KSGV'BGRC081=,\S[BPKXCC[BI1]_FQ"]3";4Y&LX Q[@&O;CTDG
M+$X#3LSI2:=I<U,U:1N4T/].V% :S++&/7Z4/64EM@N(?'P,(+AQTAQ]7CMN
MNZG,^A_H:VX[M4\9J/L>I7;EG/VZ8XVP\"CUU0I>K$H_FS52[(ZF4T^<^=D*
M>@A:MS%0*\8Z&1@^ R#Z<_M>*NHT,.[*+!CV%]*&V(4C^F6=I#$-H*@/WN(#
MY7P?]J+OE'!8+:_C]<<JC>:J$@RXU3\/ UZ*E3/_(/5)_J%)D6=:U74<1_V;
MFP/-06'E3^Y%/@#R&9YW%LYI7J=J4!SR^*_\J<'9*\QVN(FC[,@_'>UN[T.<
M,SO+LMW-%<O3[13H%QX(D _KPH)2Z2J!?C:<-YJ\:YQ#;#("]&3I0".T-ZL/
M0;8'S<M2=RC&I:O F"-L:J<\10@V^1#\!76:8HX_\HI'7:_RGE5[^SB6&AW\
MFA;?AY:822NX^BSJJ\&B6X"3F(X3G:Y?51V(:V*JU#X?IT7H$_V':F $1WL]
MF9$?O86FJY0#V1LM]17YI4[LYMG5HHD&9M.ENB'!+U/R4UX>5:5#!Y$Y(%S>
M-Y$B;LWABK$P8G*/?:ROVVR^6:E\:Y=ON,_7T,ER8=ND3)<WF?_SGV72X__/
MGV5'G" EV784;O.Y2Q/]27<YL624I.QG/ <.@-\B,SMN-6RW%V%)*Z>^;AY!
MSLGALAY,_R0F#6DFL;WE5LM,,C[%O1N+NDJW0P\5J=(.*8'4"%HT<9P7Z6<\
M9<!%>P&N#AEVUGW=-:,\1U@6G!UQNE4W]7-W9,7K<XT4T#]O'K)9_(<:F88M
MICD6>.8*B:R&*BTW*0BSZZ"C+*LJVRLR-Q(__;H(9N<+LZD42*BV+SPKY]@W
M#<O3_(X8/0:82W*2T@S()@9$-&>/ARKC>BH)R$W1-G,X&YNM$BO>D(X,5!_P
M^($7DR,^V%_B.O'[H.IQM@$NTN9T=T-.;Y$6&;$+H_LS'M%D:Y&UU) .&B_Q
MA+3:JS_T=Y"J WY>[LPQ<PV\/5LSOP=VM@#>F7G;E&Y.A\8=/-&S:!5L+RK%
MA$9$GBU<)U!= _'YHX:PDV8I1L]H'=U&>,_XH_F0;W[=CO;*W_ 57.#&ZU21
M]C_*P-36I2W^E: WK^4Q*VNC#2190\LZY/3=!HHY]=4T>(5M":DUX";6.1'V
M]=+8A@.&SPFFWQ)]-\WYA^S$ZF0VS[)8.XCZQ#[BKZ@G%81/TD>,!H*+I'M.
M\#E$2H^GXSGXOZM*<S+$)2P')-PWG.+ V%,<"1:.O!?<1'E5,5-G&>L(\K'7
MV)S"#9]Y^VV#-L#/%&WH$B?!N+3C9<9H+01+A7'6\P+I?M;5X"(_\\L]]X)T
M8-Q!4#[R[&E57/:W5Q?S%7ON[K=Z!$VOS)";@AU2+&47[ MOR1FG#V+)M\;9
M3]PQ#]K/G>QT8.]VF58'2KLW]3/\@^/E:?!7=;-I#<+LE>F FH=G<C1#D24.
M7;/0QD IU>%W7<_KAJ\D^]L"R7 H.](<_QC:>_(5%Q^A)6EU0FE7I@*:JJ_>
MFSK\:F,V=3 (3CA43,YWEQA=6A::50K#[&P/BJQ/81V0:R_.]E8_,M!A/NW2
M9"C2RJL9CLQ$EL(FAMNY[])7TVJD(L'_WI1_["%^:<EQ<U@SFN1ZWGE"JBVK
M1N.K+$%4*<3[.O1S.$?Y&8Y+2"#U'&V18D,J2Z1X4+_0*DM1-PR$LA<LQ'K<
MQ#U4\E%*..<$I4.!^!ODV>@WWB^7"#FBV5FOO2>':^*DCEB3AM=RMC$MK1Y,
M]#$@H9S5N3H+.X3ZL"KW/8X!LY:!.]WEF$H_E:.6:73Q;N/1^&P7;GAOWYGY
MCH%A73X&)'530!B*/()R2KWV<(KNM[5"$6 V7S^!H^$3GJQ&+'93^+IG$;N@
MW6/ R5$>M3*/G<<L&DS]EES$LB[!3C&K6,!%5#BSG05 02DE+IOQ)*&/Z9R.
MVWQ.\DG;MV9!_BP9A$GDQ;,OG"QD'=/$FAHR$V0U5SQ;[>-,^?^4G4@YX1AP
M$?/@&+!00OV;-@#ZPG!=E=#YR9(8#I;6<(K+*U+X?*CO<6/JP2NCJWTILQFX
M5)3*LM7+[9O3X B/,X*:CPZ/2BFR5%M*>BHT@#OF&-#8%)_0"?8CP@#(AWBC
MZ4:Q_IGS"8%>C8$B.=D$0]QPV2L'9/:4UP*H&',0E?*.N<Q2I'YG1N=3WTQW
M*J[!3I^$''(.@5-2Z//AXM='>@=3*$/B:YFVJ;[AS4<1<\"%!>5?@P*998M"
MHNCBX+.CGURAEHENYB1N]NGTOX*^1Z26B,=SO/B6&T/1(-HCML8%OSF.Z5W#
M#RV/CD[VK1:$+ 76IUKZ@G^ M>7L7A9I'>G06N*PZ5U7R2HFJ94D+I^!SG!\
MIMJ(I32'*1*W^EN2?-(4/STM3U@T52!Y\->[69+_"U(%D5FD=2K=NCBA',YF
MRN"EM+"LM.C@8\"\Q4F@,V.IH3'?YKI0TK09NK]^#EZ"M]L#<ZX[6G2NY[$S
MLKI3'SVG3(R+MV@TN.R3GL!HT/,QH=\:"J"*L'F<6_DZ5\NXSHSKNHSLIBK2
M8'3U+[2.GN9E)?+YY!(*5VGM5\V6$W@[W*VW6&N[+2BCK&!A/B[=]^AN)/7:
M0+Y?+582GCNTB6F ,OBQ-Z<T=L7,F=6=;%YE/H*"CQ\4>N<9'#2]?]^2-COY
M51(1KV8V?+;3BE MW9G"+_3HGFDY18CM09N!5W2V5T]X)2Q->T[]3>L;W"4K
M6[).LP'XFL/2Z4%OTR&[S8$%,^U2[W>3C7RAQAH0,"4^IG4N]E>>B_):'/=I
M\X^8T]H(488"GN:3FBUM0!1_9JN^E)Z0(_:=?\VR")& G2%"2LLM2V_#P#XV
MMF6=)BQVL4IDRPUF&\8KP.-CD6 3I24E;.\4,F0;W\7WX>G/ ##3$BJ._-&#
M<[DN3JTW%__V_%,.3T::./P+I@'6!UMHZ(?R51^DIR#JCP&Q+'X:Q#OOPSSE
M4<Z;94<WPXI_GE>G/G-Q\<M[IN!6U? V2?FW6O&=+;;S6&;%,<"C-O48((+6
M0*G2ALD=)%ATIQ )&(]FFV@T?V+BG&Z;<0=VR2=O(P'L-5.UVO(9[*J_6QB>
M,*O1GBYS,U/__3^Q[8'1V'/00.!%AAFYIH/B1<TD8U.[)'U^PU\B<WH7T-G/
MW7RIDYL1L]3G/7)D@TRKU]-E]1WWP!S^I1V<XUAEACA>DU@U@%^*/R6.?[;U
M(!+!?H\,[F[RI8BK+VFJ:!<\E.)7:[TK!ZEYNV4<%&;0_L=-"J?L:)Q=>: B
M2>3FUP[<! [,,]TD*-V<O4MVI.\61:LK%X@H,"'HG%>F[7#(Q?8N][[PAAT4
MLB)6'&PF,.O.C!6PUT$+8=G87W64HSV06FNU?=!Y.O4-LZ4SF+Q&3 %>4@I
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M0'R[!:OIW2<']-8PK.4EIL$Y7D'2YR_E#U5_Q[>V96M/BUP%' /D,'RLO_V
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MU,OFHOD]KTR;6U3^VN,O?<BNR8F-H,A!>^H$V]:SZ:^G_[F(G"2"M02^7MB
M4R]"RG?K)C<Z23MID31\#5L[VD#Y)K"$M:D$_%Z=]YLU_F9W$VC3D9M\+O>0
M5TGX9A&L'*?&35#I/ZRMF3.I2MCXZ?T4E'(_7$=E2U_3X:Q<A<-G6@RJ[&.R
M_O*V.-X4_ ,;NZ2ML4??!W#^43T[E)VI_8?66ZO)/4.Y=\ SR_46=_5+E.^&
MC_729_7N[OMF<M"9^D,U2>WOU_[^1+=2^R-1L<;?]5W/&+R\_[VD_..^86L3
MB%&.VTP4ROR$8DIP&T#W-(%[*819S@2$>>"FR;Y\&T)*AQ,)=ZZS#42D=CB2
MT%/F;B^Y!@B'%]OR)^['<%KU3>;] H //PA1\;A5*O/)^7@XWT@X3 9<U>%)
MK(:5I XK$6S#&\B?ZY2TG+ .<GD:A-]:*U"MHN/KL)(L"E.VL S[\<<W[,1>
MG?812\N_0[//ZC]/MR,%;ZS<^<MV.$%7!+NC,VMN)E#TQ%\B)*&5<$81()R*
M5(M$9+*V=NV"F S/0<'!2BB9?EI-\R?Q67"^%3'5Q-'"X<6@?J2CA7UZN-&$
M0W!YR HAP+3L:M@?Y&;A:Q;@#1?;0M&2 /($2BB.; ;':1,VS@8@)4=B+0__
MII1 <92VL.;[SZ=??(@!G+D_@ZJ-QRQ"/;ZWM19Q3Z9:_G;8%XCIJNG3T@P\
MHA-SNYBJH9AOWY)FZ5?$J83N&^KU7-I_,2(6*Q?P^&*>-+OB[=FN7=L)@=(!
M^[U;0R)C7BQ61G3CK R5>%])1]Z&-]4;(OJ+'2A"I;?A2M!?ED;ISZ2ON+JH
MSM\0>+=FJ)Z_,?#,7&L0Z]44\U)9[P:CRNX49@$.Z;LG"RQ$,-GO:]4F=7.:
M*OS+6#W*+QD4WY#&/V,._>[^I"?&A?;\,2KLN/J'-ZF;NS\?](0#IUB;(6<1
M3+BE@J_/8F']*8P6AI8*V-K:V3X0.5;PJALJYO7?T'F5_^7'P^VPNRDW-^W\
M3LS^7E>,#&5]H7%5YA%\>=R)M8(:@2=G#).68 7%<Y R$UB:#PKJ.&*69ISI
M3O&J;:KR,<PI<\1KEA6'%[/L_F).'\OYZ><2)NUW-U8$>^$^M\#%?[%8MH6,
M^%90/^H3SI:+26ZS336>=T<!W<.R27C#.AY2 9NK,O2Q*H TL^EP352YP7>^
MXQ.9Y=2RSS5:-,SD6U#6QZG;Z\E!#:81?2>W;KGQ^H7)5%?=!Y2[DWG55_?L
M/05WQ5(K3BD\#-EG/+Z["=UFNXMV 8PERCOH/3P4# 6OY>G[G#X7R2F@IW&R
ML$=Z[9U7W_5,5)<5[[U1EG-J$2F#QY!EL;%TH119G,,S@V'&FFH,ATXH#IA>
M,!Z+-^R3L9[_!A6"/6:A!8>?HF*^\-)WW\PUT[_?5Y)CLWX8R?Z6";<;P/LM
MW#5M,\TC!9O6)XP4*;<^&#M3W_SB]B3F+GI[<?"$NL?SS!]!W'33AQ4W[C_?
MMK]2XC.KD2%09' #^T0P:)_97 T_&,+W=6T<Q&T$5'HFE#]UV')\_)I [OR5
MR:-@"A4M_]7QN4$N(:IXNTX3F'EOZQKY0F,VO:G]M[S_UHY.M$"Y8%D)2A'3
M_E]KQ XI((-3ER%087=B>LC;%]&I*_G$+)2WCR'/8<A2F4>7[O>_&BFCZ]$N
M_/1@H?>FNWQ:6'&SZ3+#AN1Y\OS;U5.V-&^3%.Y"\:B%8M% LE02]D:N2EJH
M(S? 2;^7=NCC3!NVI.+(V>>E:11Z_L.04K7[*[7YZ/5/ /16=PY&\[K'U=QJ
M\(D#<81Z?6FOOF7@(TY WN7AAP"=N4?R6JU61YCSA;69&VTC9G_Z^18)_Q02
M35M/2(7C$R?<<A^@.4!H?(7@$"!L K=8JE9ES%N\=G?WTBDLA]Y>NPQVO)!J
M=Y*S9#(_+CL?U[EW>K3V<:I )&ZX-AX'6;V89#R JOM214.O%ZJ)%0(;JN(L
MW.Y2>@5$4S#6H1C(OJY6%^+X1P=.HMYJO%T.,YP1P9S?7RM9(P2_V0VO-29^
MCA9*E3Z;CKV648KOMA4J>$['6A,#2Z>;TS@YD4TOAN9YC0W-MGGL>P_:NC'2
MX7H.VF^ZCT5?V4,8):LBV45$Q:[=XJ;'&1FX,-9R!FRY?;5+2Z -&#[FA$7T
MF">&\OKR2^=S\JACP=<B&YL'RCY]:"3PXJVRYV.;&MO#$$;;=ZU#="9SBS9Q
MA 9]D\Z]4+#[N@PV8NN-R5L<>T&@N]1C_Y?8,]JO _Y\:VB[<%"I,E"APF7+
M<4^?V.#CVTG.M5KV=UEIZ&2HWY*#TW%^,;'3N8_3.G8[?%:3.GS8/E<7T>T7
M[I&41;L,OIUQ>^:LZGSWH&OQHX'R/Z3D<R0?<P"=0:S/>@;RA9(,L4NMH1C^
M!6PV9X52=T<-,7<[G!UDO7>:J56^$[R05Z3 P/G48#&GAA<-W.:P%!0C2@3;
M:B""I2":'&I,*4>!E>1&S\7I!76W^L:A*,*<Z:]W]//-^?WG&IN[&EK/93-]
MCRF/-$YM/^#YM%!KG]*AJHV1%U6/]1TU@=[\<YZ6< \OB627Y2%;X'.]//%A
MK96@,/#@3C@\00'[3.!(^HHM[3AQB$2]\NECRK,0)N[!#*-9S98:IC-YOKWQ
M 3*U(F:YQ$?V2CJ&:2_(Z[NV]RV4=X C*3B(1A138O"; [!GJG9UGU#6<)<:
M/5N*Z]=]7\6==&XV4K:%.]?8'V:Z:FG5*GA@!].K[#OMB23(CO*X3NXBMC)%
M?H#FQI6.5K[B44TW[W.0T3=3.!].LD5\N*YT_07)02JYYG;28=?N8=+\]*7B
MU!R[./.'P4-"7V0H1EQJ6$)9Q;74Q;AXB5.)I]L@.TZ%861K9/OVQMDT=:&:
M1 3]TM\&C1\GSG@&[[IB?2$&N8M+$&B8[[#>OW8[08HUKGN[:Q,TR77*;")H
M?BBA84J"YLN9(60I@9$..?:^C>8=%N304[0/E!YU=^GSVF[2_B,;=W'CVFZ(
M):YO2]!C\(10,H-OF3#N99N)DR()+"$K=KQVS^KD71,=$ 86D6)(^![Z[VO&
MI4T#I$\?&L08BB#]N?+;K3EO36$ETG]K#/D$OONH"':1+(;:.<2=1$YTEHD>
M?0N41VE[6+0'"@7E'!JS1+!S ":-^0ZEJC7IF!MWDF%YI IUV@!W@K/2^9*/
M.\?T\6)-K]86E,UL(T;G8+-[_B!5()4GW-^JW'JA&EOY ;CQC(%Y:_H?P^",
M/$4_[?0<R;_7A-IZ,46*!Q+ZE'],4U8DHX9WX7P#Q1V=_(\./9ZI2U(_)YD6
M+J?A8/:F@AOB3!GX\.NK/C9:"1BHVR*<E'N,#[ST0H_Y[I[2)']%TO"&=?:
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M"IN$E&\J\S0.80Y_;]OJ8OA\8N^$VA"BY*&TQ+!QL6%:N"J2.O#Y2_ UVF"
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M?T<"5<AKK%5+Y&TQ6R3GD\5\9@+_-V/QI3:XZ-41L2K\A) 1P;B:/4@![Y>
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M[DHW&!'&]\ NO!8:#2_Y:/,>LAHE_MG)GB #:5-&%;%FU-6)3!XKR06G >X
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M5=4S(I@T/:-+#^<%I46POS0M;$)2QM:0MIU0$H^@Y-O+$9/X[GS#^YPCUW0
M<@KO@4.GA.U0E$1<_3J01'%BVO+06<_6BD2PP,<"%VED8VXB2*%-;%XK[W *
MY"S(WF*)>Y$KJI'SMGU",\*Q/#OBR4_LM6=7Q7IOOXP>W\QV2.7D8,*1K[Z0
MSR)J7K('A28VTIF*R^^@&C9>'A</^3Q-&,X3FCJI8.=P%I#C,ZS9,AI>O_8S
MC8U6#Q4J-D/A/#V6 K89D6FF]K%"-BDB@(?6TDWM,*O&XOL&O_878WW[CPYD
M4]Q%L-I\B=?DNQ,J4#N/13"7N[.X9L&=I*Y)47S50$:F=MOP]RY&(WKS48-(
M=;/ZUJZ"TT/,B5$+A]#^3CVGEYVC!HN="IHAO'.$XP.YM/=-_T 3,RI U4 ]
M_->K3&]L<>\Y:+*W2&G(6E?@,6"MA*7UG9LX5@%7A.CLH@Q>(9*]D+'47V,_
MRG(9CD(H0"H7VD9,#OL/F^PSK%-R.JJ*;.E_C+^X,&9X*I,3C+PL%ML;F:HW
M_]Q7@>RXS0??OBPT>V:!]F_[*1%ZH-M:@K<$@7P+@2&$YQ\E,"-ZD2HF^P1A
M ,(&I%,,T!26M")'+LM8+H.L(-@BIDN7 :$""HOI]D)FX0Y63IMV&? Q%*E9
M@B94&>:&T@M%;N_E5D391:EC!N0TL @*7,%2A;N04F0ZZ,<0J/+(TK-=LN"U
MI'"3D0XU>G*'8^EX$/-'CDGOO>66%S;EP7DM;@\< R,P46KVOENX.<XV %XZ
MH8_50+MKZ2CN#::ZMH**#NSQ\U%UZR$4"JH"Q09+"=97V:P?\YQ!RG7)0D1:
M+*T'O\YG^OII<*H!>Z([5F\JQ';Y6/W^$ACN EG>,IY=0"0D;(<PM4S(C(I7
M1[++U:*[;T))T24>H62@+I*@B-L,N=>&:NT>:JSQT_E4*["+\.?$X!#L8<;<
MDI4,SI]KM6[)"N[9[#Y89V7;IV4)-?!U!.<'+8TB0 L:L9%P1Q .J"QG0(42
M*0F[IH4;D/(X ZX(=BM?)=&$OR_2()K#N".0V?2,7:>&FEW1TAR)_!!Q=!@1
M253QA4)\5+SN]+L0;>"^,^0&>G=G-(6H@-M3#>VBNXC]WTM7LP75:<SXGZ6U
M3FLUO*HXM!3S,U39,[]T(IY3&&@O9A^]GI;\/:RDVDCW3TMA"G34@)!2O051
M4@RT+X=!8H_ZC'2XLM>T>\V$AJ.+J996>!X\5013LMXGN +F";1S&5NB59*K
M<3Y@2E^1.:B5S2$WV\I\Z](:C+(P4(OKCT-5S)6T-K4\V"&7;,*2%WXB2R.O
MU,&$GUO0C>0T:VULL>L+:!\/KBK0*: @I?T@%>ZX%+<N52!3%B*4@ +\BK&'
M^KE:B?B-*>E># X^51<B< W<G1G<(:=T=VHSL^E#?BSA#ANB\\]@VWE"LLJ\
M(BC%SKH/%/-2,KID!!: &45F/>?J:',:VP!)>=#/74B;!R5>^YJ-"-S+(9HK
M.1OU\M/<$EPZZ!P.2?[$;6X,<W)^Q2!^L;3@;TOXJ*4,;DOD:JITF\^=QSKY
MI%"%6P&??^[;S8AE]" V8=,'V3[33,8=X>;0!//A!%GLB?,#"W]-3)GYJ@.&
M>8:)<1KNL48>7WLU*NIX]"\(-IJ*5YD1'@'E4@0H$D2@WI]^B>W!_(7S@2A
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M*B[^QKH_*VS"/:0*/@2]5?A!N+D1RJO!20Y:8OB*.*.U*D%\I<!X$+=']Y[
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M(>I1M&@07PC(Q1BC"-%:FL6)!D O7JF(NEX\7C?\J+!=Z>H4'EFNE%:6,UH
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M(D5PC>\U+MP"^8+2YJ]#M(ZSH$,T;O1G*%6Y45<H$.W*_24V,ASA?-"E103
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M]9%N W<@SED^Z,-5=J#&?5XK8YV/ LT9#Q45;D>$L@]]$8N(HFE7#^5E'>?
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M^<V<I=P$P2Z<^W5-SJ=WGE;*G1-MU/"G*1YGD 9#?UAS]32%A(OJ>XS]67N
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M*IH:;AG ZOO'US_Z>>]G4<C3R!C1G=Q=H.]WM<8N@:K\H2"POL6<V9@=8*N
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MH(<*XB#G> _>2.?(N3O[JLD;)YE5> Y@HZAIT)6YN9J!2%D"[#W"6=E/0>.
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M@/K!7Q%&V*W]H1WDC&!ATWR5[V>NDMS/;,ZUZQ48+N!A*O!Q$=&"F5I$Q)<
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M!?LN:2Y!$!P5:WEJIW\J_IM/7?=,Z*:;@<&BE^[?,I0^OR(+!><7SFG?XI>
M_\J-Z/Z@MUL7[!U4$A+M5,,.KARF,9NB.Y(.>2JF+%KQ#M+I,I$>#7FV3_62
MQ_'HAB]RQWSG:F0U**=9-949O$4S7 '6*YSB"N"SLD@N.L0\,!VP]_L!JK\9
M>VWV]<@.TZ8L][2EDR6[/!P.,E=3YIWXESK=7>0#84[*UY4V02;:PV0Z JI5
M>#K/WH.LE5/6LS(P-QTD*MFMS+4A9G(]1T)_+7X-_2Q ;NW80,MNWBR5:+>#
M'?'?H6C!IWMZ$6'F.2+'O%9EM^X6/S$DO_HZ4>?ZEIUW-D8FX?37*]=SI_8
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M+.'F6B!3Q\/7@Q1(Y*3.)N[BG)7^'JDH;S"M,#Q8$4)5?3U2^?$/_JA-"],
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M32/I)JH+4-5#DKT2-=ZKU"!5 V!&@;(]$VE17$N38UAS;F%D(ZA<1LW%8,"
M;*Q\?3?ZM$*Z=(!4)E=5.K-,VY""H^J(%+>L2K)764PH,]467.9&L<ZZ@KTP
M[7_8O\.YS2>T)\'0P=:G<VO<M'](4->W^\_$\6VNS8-^C1.>!U\UW+0G[+2W
M/UKRLK'AQ9T=#K(\W](;-M['93P#7LP\K&\>IHS*^J:V 'H5J]QGLATX.P9_
MS_'F ),YG&V)E21OC]U&CCA3"*<U;M/SS!$.6M(.-CYC%T0"[/R6V\L:\O(W
M-GIU5?J+@L!45-:L[6MFU@KRBKKG(++%R%Y.S5X+A<4JQ@J..;CP$'VD,]]1
M2T6L")SOZ>-_\'J*G\^='#4WLTP1/'_!;7C.ODG(I.[0&I#@BO>U<T&4=IQ)
M0HJAZD4/&BL/H.&LIH@(2*FZ]P)**='06S!HL7H1=?%=.>HW:$G81U+B_OPA
M?GU@#"/8,I(A]SV3P\_'95@=L[Q4=KX4EJ*S<'^4*@2ZI4 :D*)>ZYP+C5(X
M^(B(1O6IK*VR'C&?LK5[DP[ER]?.PZXE\@>W-716J6TJH#JC-2[3,VGC"6_5
MA\N\;_I0'X7YK[I1W2Y 2:2J2U"(HO#7N0[H;NGPK"J=6!H!53E,T4T(^2%7
M*J?_?HY/Y!F3?>03)D' $-_/OO],Q&[#=L3HX)JZV,WS,(*%][]&'Z%^W7 6
MJ%/N:W6?3VWY.[0(')[B#D4H>1\3!9%N -OL3MTLX]H0P!"P%HSA3*=C=^\X
M??0AT_\YT10'W225W G[I^!(HIO1^<VWZJ&$1*6TK_X@- \#?AS3%'#MR.$%
M"JIH'I9#-2/;* -H=8A%/6A[T,8+:JHJ;7PT3''MUKFTQHAC7@XM[SU(DU,>
MD0DG"0_A2T@[O;J=4_P.B[]HVY_!9N@?F2U:&X@^YZC>"-;G),S15Y'2!):1
M+Q.IK($V(\%LOE A71%Z[).S:O3IN]3FP9[-IZZ?C3YY/37IWW%>]#PL0[I,
M#?]U *"%1\?!6;(>RC;U<2A9SELY,FL]F3[NF,#2AZ2B2^?46VHZT[^]2JB"
MQII"J>DN\,4X0]NYQ!RUG[S_6?'(A5'+]*I"(?RCV^M(.^CXW'HR'(#GJK<@
MKY*#Y'3#P9%949H\5C5H?0_*"7V1XU=SZ]09/T/",5G8TM =17[8]3[9;F>\
M?A:_YNE1UGFQM/]MA]+DVOL]F*6Z,G%=*\6MYOR98!B&O_^!8ZZ<X_6?F9%3
M<ZL#OR3X>5R8$7%_XP":=_:?O!*KHV?VW?FQ]N8*.$^[2AT#X4">3W=M>[K6
ML0;T8M*FRSENBIV!^"?1DJ$,LB<1CZ<ZIBOHRZ!4T3X0F5&;\+1K*ZJEH!H?
MFJ+\."B)]#$,"_>TG[U-?@;4-&$V?*#&8"6\%C>)Z2!33D3@D37]4.*Q^#W/
MP.5E<J8!B><#KKDC#&<SW$_%/O@8Z;LA>C"T;X]%YX:ETQ[_WQN#[TCO<:@]
M\>_1<P4D[@L'5^SWY52#T3$:*$:.S[F,$]V03YK6(F<MJBM777X6;QZ3C8.,
MOLPB@A/= K:(WB;PWR'M<@]3K]%1+!$<LE.5K7L)V11O6;]9!JK*-K>W;KCY
M5FY_="GB::7;#LRM? V=)0R [+KN@HE-PS4S.J!>OFWDZVC2H2'P.S4@1C/7
MU!!#6?<YMF+._7*5%R7W](Z/9=^_BMO_FX=Y: M<AGR&^T4WKMVC/,N2VYG4
MY1TD'[\1] _Q%?-Y2"W+JJP8K_4/]#+5O*:F7?W?6DWZX^UJXXR?2%]HH#1J
MYHZ$?H65:9O*Z!G<6O\N;RXL8-V;]VYK=[QI'SV2\VP ^^(_SCSL^5[M;6AH
M'K:PO!O-S$2:LOTA[0?@4LZ3L^V#6E'/H)BR<US[J27Y<I%:^PZWJ;4\934-
M"6Q<J$N>?2P9%@GD,1!?NV_.Q*#K*E/LOJS>[*L>E7^9^3@/(VO3+F>+4M:\
ML+PM+K]2(5QM64>-89@-'<W>-V#)/S$LK1B(?G^KF=[V/2DG46]D:+&6$)%[
MCFM^KKZFA9KW\<:TKXWV>H",T,#Z'+>.YDB(F(>A-[=19?]Z_DC[R1Q!Z1]1
MW5ULYM98<MC$7Y>]O/9E86][?7\:HN!-I,OID+?6G91-4GZOX@2<? 05]9V_
M0ND]&S\WLD"+<@ONG+;P'7\?<O,EMM;TIW"."H4EU/,G+?D(=/ET@&&,L7(G
MM\,R1K(GN?'LG.N+CW\,\.SK"7':U;.D<SD*',PI_/UM%#Y;QIFS482&/WOE
M0RN\_'GU%[-:53SP\A-X^Q:9\^^!2_?*!=K269>AG,T@=E':O9^;P<7'_OUB
MTCCC48D7.?%=>45!SX<_E$Y08M1/WIU5=SW,ME?;8SO7_I^W>ED? _I$"A_U
M5ES&;#RCYN?@6N!KFW[X8-\=O,-#W-,8^/?2R0E#I)WO!EA%I!?I_BT+EJAA
MUDH5#=V8AQG,*;RNN]7\C$2"N%OWQZSRUJ?B2^9A60?NS\-L5JIV#JW<^_F)
M*.KRI7%*($Z,]4*:4A6KH7*&Y^^".82%$GZ2?WD&_3/Z^%!6)>_9CU!&S$KM
M^_]L5P=7N<7\<<EIV\WNXN](2PBE.2?[+_PI.Z7T_(V+7_NBMA(/5>(]-;Q%
M5K:VTY5;3]O%*ZOV1RQ;WX=\,MM=U^OW: W&.'QYGOX;D1[T3^R&>T:/]3<]
MK6@L,BVR6!>7]RC*0O(_"EQ+9DSY;W*M.'&_OQ$>34Y+FT;07GSE#8XS3">>
M?KO&G/Q=E?UMY)<(1'\#_^WFZ:B?607R5W=L^KU"3;\--!P)'N)!;$;!A7'R
M^;G+VK9@7FWB>!-H)3]R"7BK>'9<EXM#^!7EYTI;18.6><EM2[:699[L6<E"
MNZ5L,_HRTC"@3'=\X@-L23Z=6#H8,2))9ZM"5.9.?9%] WN B- (R3L@O#^\
M:7WEW^T+.SB'O=97B-9O=\]8&#(;T@OJ3+_HGN8.5;Z'(NY%FJ#_*$UAR"<G
M8(S!;6S7#Y<ON4?1JTK2T<F/TDPY!_?,]#*"*?:YR_*^NV6B5NHSSC11.W'W
MF5G2P+8:GL$/M-?3G\T5 O3V)P%[O_Z[;T7&^2N/"F);+1@=)?2R)=^;D7W_
MOAT[Q.4U,?>CX-SZ.U\P-J>G4#C[^._[-<WNK2A!SS_/.:?]-E2EMW27IY;_
MX?:'AFIHM,XG0#2Z^2%/S%?/&6Q^>,5 DZ:K (Z4SG8@1/6X#CI=)64CEFCN
MQSIP+"ZNN?E<(B%]:_KFJ%Y4OMWBYC:7@4^SC/2#F8\NW1(\W2;Y^PY.].Y#
M9T*$S^YNYP&B#X=YH)N=LKL]J'/:,.3[M[,)UIBO.QOM6R\OWA= N+CLL #Z
M><HKKOL')XS_XH"#G#-$VU9WQ"G<*'S[8V7;--GK]OY-=MO&T)L<5YW_/2+*
MU[:D8_(<-R5;3EG[[J+:AE'7NHW];/E*!JK^ 65_L.6AD67!E@E/?U!;@Z:Q
MG:G9/YDJM.9^_#Q,0E6=@\+ .]T3C,,@BG:_'HR]7;/%W[Y%8N]Z2]&&;3V2
MR3<F!#-"S.Q [U-BQ[-QINB72ML1'>VTK=G*,__GZ^IQ%M+W0\N7CQQO?7/O
M,+'@>,S[W&B<W^.N:S<)OO8NQ3ZS*0SETY>E^OIW_WIB]Q%-,<MP,@R*/0S/
M*K'L*HO+.W@O+.#(MZ+'4_",?)$J)-OAX0U5?TRVA-RW%G5WG5&,R ,N"=[1
MM'#%\_IPF2809^1CP]]P02#<D-6S=^" A?7J[=N+A$=_@S]FL>/]O1)B;?R[
M_DY3M>ZP_6M'O[TW^K/RNFAS_ ZEW7DAV6WE\:Z8#H&0:NQX;QXF-/I+$QX6
M^;>/Y)3+S_)N?GV5ZQ-/M5.G[^4M&S1G8G1UXT?4AT6K O_\OY[+3 $UFXN
M<!>!01V%[B%N@!Z 3KNAH/O6B,$6^58=8C*RC^P>9[FD)3\>F2 6>\7*^[L:
M7CR/V/W3]D[W"7%I[M<[<)3F&<8.8LE$XS^5\#408LRW4WUD=I(?L'!8:],[
MGE%R'W(D9N-6<<R!9AR2D)0<'NJ3_ A:W-]B K7,]B@4]G_(.A#V,WYF+Q.@
M5F5B,Q9!MH%RYU;[56J[F,9<QQ&,G8:%AA,K(3_E'N1R1U:<VL_\BM9VE* (
MH+EQ%P,^5XEHM,,=JS>U1'UV*"_=IN/;.N9>]@?'J;J4<+UIO6:$DXYUYK''
M-"'\BS%.?7CN!M#GVC?IX0_H7?*WO>% '.\QZ:1@A>=IA3_*]U7C\[H>=N-8
MLL.9SL$4\]#Z; ^_/5TNUHY?>[['E?+6<[R4[1*&B+<DKUX>ZZ<TSU+;W]=^
MQ-8Q4KD.PCD//Z#83_,0*P\A_P')07H3;JDS,8,'U*P7DVTOED 78O6:9Q.S
M;S9_ZQ=),M++^JWMQ@[E1\18#5#UU*$@;L*PDJP'Z<D#)'H*4;K:HU)M!K4K
MJ9E2DP2X 81]C62SLL@G@63=CUQC'!G5=1:%=DJ4,V&DBM?NVI)*(4A),6FV
M/<3CBMG.'9LZG:M.:+^-ZTTG9:N5X*6[8*8Z&'*86U,V@0)M]W1,T]-YJRE;
MH0+E'G==DD3E(3PZR(9*'"UR-5#&]S<7&).\B4OQ,Q(7&CVO6*EC%"-%2P/,
M"*[N9V@;;PWW)G%KG_0RH&(EJH5X[9#Z#+1E'F9(/ ;^A+:!]=JEK<3[ZJ/@
M\@+Y>66-#"G!J6X!C%3R1:!5X?$MMWBDR*(G0>/4'!K\Y!3HP,M@6Y]1_NKL
MMO/R8_:L&@?<D,(H=8&XA=H/5'/.17E ;M'O0%0&.L+U5MD(]:G/A F8Y+!I
MT,CQ\E;R13G5#-+;!Q!S,E_6O'AI@@=PI%3)NZ41[,92-UQTS<N; _LC%[$@
MJJJN#M(#0A280C!,E0F]LA7NA"^&>E4Y8HI!.Q# GX>M(F/O1Y =NET<[+TU
M^1RLLLID-\"]=;\L-\%A&?3><(!Z"+I='1UZ)"0IKCZEW*]R%V7![) 79>LH
ME<T3(*TEVC;I(BZ25*\J!2-O**0T'K)V,DOK E"O4E:0W%2L%R"\"9F%60D1
MW/@I%+Z(H5T%N%TA^\IR"8)Z,Z990JP^OR'O964X/G_9H#6[,YYE/.K^"7M.
M*Z+80/WEPUACM!-(\X%NYB=>)<>615,-.3@P#YE1AS-#GY016 M)84&WM38?
MU5NZI[%+W++C4:LBH#0_R^[<NG3;3+4[>F>%-/KI*,,R]PN@_Y$=HH1/W !/
M*HH*'U/$.#/N0K6OAD6TU3#(#E4QYL](FZ2J8V+JJ<E%I-;7N&7C&!L"P@#*
M+5'[=^N&<5'QCWL/,^6T6RZ+;,RUYP'/"6\?D6((R!4C2TO@EU\\A=KF=FD[
MF6O4"_!SWN2#D /0VL33GX>=F32/=L<V$U T5^U&G 79&Y?M%EKX2;L9K+^B
MCG).,JJ,-!8C8HT[W^M5#;RM"7P5L<DPU_803+.1Y=S!M2,EAT,O03V9L*2H
M!IF-L8+,Y8D"ZPM:Q:#0V?"5E:*G!O3S!+[4W4HP*W8MQI2=3@3H@IN$<X/X
M2ZYW>F8:K#Y&CA[Z).67:F/).R$A6*.Z5Z?YA[MBE&=>RTN;H: U1=P-ZF/0
M,]!<7LJ0^]N*>";H74"] IZ&,4?"2<O'!/FHS"GLPJ,X'"&$ZP9^GMUT-:%2
M$B8E)>X!)@;3RCY)!Y '- RTAX*XA-*/JPNXQ@D$8W10>F,[C;*((JQSC\HB
M>YZ6-P:L&<EW:,^B$@9"^?PB;$&S.XXV97184&=[*%_5?Y0-?$W#/)!'^/$/
MQUQ*S*_OKZTZHC>5G0W9MQR"YI23$TY@B,R!U4)%JHT GZ9?_=WT.?C?R!N8
MS;,H 14!W5+D58&.%M-CD\90!9_B$$:%06=:7ZL:'/+H#X=5]">DHJ&P@LCN
M.(>MSFV_?^_-Q[4@<Y@(M.><TQA2Y]$L6#16C[*8O 8L>J5@933@^.V+R4'0
MD$*'+O.'!!J$4MAPISQ%CEJ)QUCIXG,==#Z6Z)@K\]#SI!\!+]67;RI/69YS
MLG28\2<RBKP/JGA(_OT5A#M9B9^M4DM-N9NCI09L5[%Q1_'3GNDJ/8%V/>U@
M=V[W0(U/B<X\?E!)LC.GT>UPW\-09Y0S@#30V@TSS2K148^'0RD594TR9C9R
M)<8T9FG%QH=^B55J%]!A*+VV<'?;V6^3*T9"&M*O_\#3=PH3-][-]JOP\^V;
M4*J["A3(//+QQ^3U0 !=':!/GZ9>80)'/&QEM4S!"_8KE'<#E%8\@JOIS>(0
M3E82&BZEFY;1Y&!<)CG!+15]2HL0.\<:#PD1J[KCSL9'K/;;Q(@ZP!?6X)D&
ME'4DD]T@741<#BD5=/4J<U6%KO)<FT+V58OE)]4X\-TP%PUE*5@KHMTQ]>#M
M$P \E>WGC_1AA('PZ],I87S1@3KQ_<XJE]:PMKC!P7&]J4D%38B#DS>*U3;E
MI+SV8Z_26I@F& 39KE.\I_[9RSM2 =98'7!<[F'PXV"8QL=_+YO@[W,P(S94
M,>A7,;SUSK&M4V,_NQV88GO@I!#A ;VM4IN"5#[6 IH12N Y& -JDP_V%)%6
MM!!*F_NSGVS;J[6!#N\!Z6JG&4&*<4#6D$S[B@K4MR#6 7>J0)-#]6(6>^#2
M9O2NTK!A,^V6F^U![F^1)Z&,.05C_"X8)<NX0]E!/JPI)KN!TE"((>>9D P5
M_V#ATT@+O*3]JM: - ]3=+/RN)92R*JI:$&$N>^='Z^#!U> /NG?QEUPRYK<
MKNN"^#>Q9Y=9=.U]>*>!/5BM;$$B.*BY-<-2X.!/:DR .8G5(J$U\_3)L5W:
M948H^3Q,[917^Y!4+?7L^0S9R%&&H5"DM*7.DK^K7"3C+8'ZM.LB2(K)%NG)
MAIZRKDH4"[U9.UU"T+KW4+#:OD@GB#:W&Q*_GH?I44_SUI .S,-V XFTK>HM
M9<.7DO;SGK.:>9D4-QZH+4^0QQ($F U RXW$ZE'*Q@X.]B2UU&=Y50HKG(!2
M&!(A[W%G&+SCB8+L]:NKBOD'<Z'EG0J'GLQ!VTZTE:I].=Z]_?H&G/$8!54#
MF);>W<BX%J^)TVZJ V.G=%Z1X/#D&"EN[V0<Q_-BR4=\0VXWZW-[$].2?+&3
MZT9>"FB+E>W]NXDP2E>1)?3LD724QV[2_./PF7&PDVLY2/8&Z@72U$$$Y$DM
MA_CRO)(3#M65GP&J +Y$,AR(SR\M,*N10[5MZS]&GB&OI8ET$^:=(EI 8WRD
M)<:6X%[WZ^CSHFZNM6& *?8J<>H5UJ>7*JOLY1FJ$ZAE_2-%BSN^F1R#<N4I
M%W$(QY<-C0TU$9YAO :@C49;N?6O&IB&]9"W@_Q'B3I4\YB[GO(A5$'I_-5*
M7G\$IT=Q)6"74!!D+!2(![X.MK00ET GFR3C@TX0F[L=P.5,(ZW#2>T'>[U9
MI:28Y#9XLXH+8_ID#+;XAQWI<A&![1D\4RV&TH/9I/DW7@^LB( \Y).9S.<B
M$6X-^5 7=SD>89PZ\TN0C0@RY/5\(W,A<ODTSFHX<B=./YKBF!/:Q3E<*MV%
M8#WNAW!'ZL53K9"+50YUY3$8Y74'SE8KTCJ +:]DQ,PB$RA-,>&C6-X($)4,
M(3*M9]"C=^L4 6X,Z?*T<7?5-[)#!?0$OAS?X'@5E?40T#XK&W'OUM(?CI@E
MU7XKV%2E*21XC(_@F/.P6FD+-;O(FJLIINQ4PZ&<N4B"&:XF_$?.O^R]U-.%
M*-7N#I=)VNSBG">D7CDSAXVUCHE< PV JV.>1TH_0L6"P94UX/)R^2M"('TO
M4%2&J) _*-N_8.YXI#EHJ#JI*=+:0S?0)T$KF90O-8<J\:T//T$Y1X&>0LRS
M)\.;GS\A)>)X>T^^ )$970%_X):/=<:XK\67'#_>X&/[&6X^@K7&H-3)FFJT
MRT.M&&>"@4,^LKIT@!H*X8O).SJYUOHY+:$S_,(07+<C&9>L1.I!#=25I%V3
M6RM/49<TQP\3'[WJP1U\]6++ R.K5,A+B:2'7DJ;TZ=T4E#03V6 583V8Q*/
M/^"D8#0;3M@VN6+UT;\<!((KB=F6!F3'3N=YF$$_B=\L85QU8<))B?[^?H?
M4JYVBQB>N1%<YA::5Q:56'*%\APON<0L'E&Y'[AQ_'3)2&A$85UA*3X_H=+,
MG5)8UK?[3L\E5]?@#F$L/@I/7',N+"Q,N&:%IZ67\?KUCU_B;E&L.3I0GB,3
M"7C]!EA)38L.KJ(]Y1&'E1/25*[IR&P4OQXR!.9V04Y*% (*;FVFFI/_> (=
MFA12G+J^5:K7SV!-:L>8:R!JL-C%OI\-'"DR3O,1/R(,ZO=JW;0]\S"SZ0DW
MK3E3B.R;E ^(QI/GK,EXZF(UZAF4@E=:VRC<6OJ9>989)7%<.U!TE1-[_F3Q
MR"7MTN>U/>SHLS>5QWCBJ<PO7553I 2-E>!/Y).ND,_,5.UV\CE(\X#RAKIX
M&I7CSFJ>\%/PKE*CVQ(5K!;DPNA!RTYU@C+"4W462I?#,VZ0</(IR?O;U:2P
MIL'U4&J"QE,T:/>R!A!VO__5Z!\^9E8$IWO_,-+>FL36?'L&[N1+:VD31@!*
M. ^SFJ9?'S2"+@)852P8D%8@:$B\YL Y+J_RU,6&YF'L]!C6:A2SX@-GY\DJ
M4OYD ,#(*++>$RT)8,I7HVTW?DGO>3';FZG^<\%,H>E/.;B6? 2JF".0F+)-
MM^:\H$;9)-_#7A4"X<#=,WS<<@>R"0&T$B!L>BA;R7B@M/A)-&(+B,O@''9-
MDP]OC<<:2: &?Z=]L0?"V$ N]V[%\.\#A, QWD[RGYI2"D:]N0YDCL^5D1J%
M4E/R+MW<)"*9=!PL)I\%)M,QUCAU&.TUTX2K'Z$^]>H9M[.V0+J4O+&+ZS9,
M\V0TY5,SI_UW[@>^-('UJ1S/<L@FJ"?]/;T*1ODO$)=KHKZH*9V'15%I\S#V
M@5+G 'I2[Q6T-1"()LBH:R@?<X X'?O&Z$,/GI D_<W2T]TLKA%TPU%]&'C2
MOK>G0)1H*[ACEM1R(U9&7X7_&ZI+-IQP;=\S0UTY0C6;AYUFF:D7@LY2=J]
M2C=C6E+<2/:R>9@@8!$YY#ET<1.C@I?'GEQY@(N"O/ RJC[D/O3:G+ORU7.B
M,0ZB#$X*$%:-$+64X-H;>KG;>0RYXL\%L[LB<7!AA#$UUY+Q>DH\'?A+ I"2
M!08K@TZQ+6V&\V>RU;OD5AX8BT5]O-C@G?.PY;CP3\4?1=%W;DJ<0R[N_^&I
M/Q309 17MHNPUR)1D+)2VU^T$Z!FHFU 3U5N)QKY"+JX%PK2;V;IXW'+*-O5
M>X'!6\?!')]NCLGCL<@_@CK8.S>"6UZ"J QLC=K.N1OXV)'0C^=$5?R,;9\(
M4>[TL&K!U>U'P-EIHADDL)=^C;>F&/@'B/!]B-=N[M9A9'LA+.+/WK]Q;^4>
MJ$".MJ,QI,N!]0@88)=,.L0=;5NM/R$T_;D+2!-0V3,TKJ-Z0V,853(CPECJ
MD"YVG)[;.N>)E]:XW@+:?3HW -B<A'_1"4"<5$[+<>0$R0W'L*LEPP=9J0J&
M<!91+ MKVQNQK8=-"%B)%>M66;>>'E198BXV"I[%&+2+A<ON25>2=P'MRI1_
M@#[JZ:8R]2X@N%IGMU^]*SQJ!B1,.-D?Z,W@H"S[!L.V?B#OXC@UD0')HS^1
M?X68/%![Z6RWMB?N;,*QV-@II!6.[-ZUL7>J,*HY4_N[>-HJ99._O1]FLWB*
M.O&1Y;*SD>!@%?Q!-X[X6(KBE#_\8)<O2Q?RVDX>FUOU (_5YT0H6@=,E/2)
M;6"QB@05 I>^>ICOJ>WAKJ'\Q[-NS\1L@:1-OG_%C^48'0Z#G( Y6:(NQ2V1
MQM1W1$0<^Q03:<0\RDEN'#.<\!:)0L"A%GK&CT]C/'/*>E(\9*4U* ;&Y'GI
MYM?"FBYML\V@3_@!R9[ RP9+7IJ+B!D(42S]#S?-[%+F)AR+#%C9#^6UG[X)
MHU21=%F(QO$'L0I<<[*AQQGD2K5]AQ8Q1EGWJK'^&=V+PX9NZV=]<]X\1?@W
MP2IG+"=G#U#ZT.445QP_+,-7IM^K5_A*^L7VWV]Y04C04#?BVK()K-S:5O4O
MU HH?8'VILD^]\X97:S1Y-EJ7Y"7I7@&-6Q-D)J3<@3,Y>A=#T519<(SO>:6
MJ'2UD[S?GS)WI,$_J-^W-F=?P;BT#ZX(R-:B*&W(Q;J)?E.\FVDI6@]$Y)!8
M@>+*8O'9!-R*D8N?AO.Y-;&ES?LMSX8*5068Q\YS%U4$DTNQL:\S-K^&S;K_
M_U'-K7&I<K2^Z-W-#LO:F"$]*D9-O?Q"(Q:N<D^OK+OYUFPZ_D?@IC/TI.V3
M>A>>OG&//ZA/H[17 +K\"!_G+E%[@!MU9*M*QYIW8O4I[47K7W9O=1R?WNEQ
ML8FZC*S_Y&CHJ)-_*3[I4ADU0=9N#/F%<;K0'M8MF7$NE[<^*++OMQ\S1)UG
MO?$W#-*4HW<JL= 6;*[6$,J1<:_*B30L>_D#Y68V-I.R&$S,=:%G(;9T\$XQ
M^WJ#NM5.YY\,8U>@C6*!.7Y6,;[!H[J U?^1U'ZDH=>EH+6UT+'7'QC%:VUG
M33%8=00TI.3IJ9VAE;IA9"")FGO<U91.W@KRK_OI$H8@*SX7J;2>R8KGT;@P
M@''-N=U4C4V="VEL  )R)M6^BH& "$9 !UMC&R"N5'M0J0ID?30,F1R(*W!%
MUK):L,L@FC> $Z08RJ=FF7RB1/J:5^.F0[ FT,7]H%$1K0JZJ$SD>V %2#V,
M'1G+YH".#VRO#O6BDY6\]"(3D)I&]D]6TL<K"@]'/!<GC&7J<KU_2[AVD&FR
M 0B86/1X9- 8L%5O["31F^Y(GU65"+D\5P:(;=:5=:XKE*:*@2*J2 T2!XIA
MVX4P7J;6Y 6H;2@RY0'#=5"(DJCW$\2[WQJ,J8<A*YQ#WC-KW83$U6H#R$3!
MO!YI(9[R.*^U_$3R$Q9Y/.^.GSB4?)F[:B32_H-4N:FX6%@6HTITI[Q\2';!
MV('FM.KJTN[QV 0/NVX7![<C;'PQL4#M,W=Q@&2C8$W\A@XIAF(Q,/7O.ISK
M&0+8YFZ-U"1(S=1[-$RUB0R+4.. J9E.W*?HWDOF^8F"Q@C]IDOY<0QB^3R,
MJ-X*E:CZIJW./_)9HC\\8/K36A'0;ZNDJ3?H0.>N:M*M)NI"K2W)4T9LQB'5
M<:!UV;@0G%.E=3I2[,@'.VK#9J!D6?MBLD=O,685P+K&]'[QHIOCJ0-,,>Y?
M&WI[0KUIC_KK"BO'5J8,S*'(.-!<A$H+U:>3<?*=[8M)Y;5$<U(4KG/H R=$
MWFBT>Q[65&3?0]Z*#I-7V8@L(^F*?JP^]%7L6P<RTATXN\KXE<>&W2=R,QYW
MCIK5'WJA;X(=]P5<OT8$!#1@35 8Q%CH9^[&;JXACOP7=)L*!,_#CK[H00K,
MUQ-IYMR-+SZ(^8RD_V[&N W"4G=0K&/,C?_@ K??/3L\W48Y1**K *A<3J51
MUKQL!)A7)K6;=:#4392R4W6OTZ$2[4-\ (6I2)J[Z/ >'?.P)3DV<;P2GH2-
MS@PN!*.:YF&FI&#KBX>[G3_K:+[6*7E1I\\R^"#$5[V"RGYM/ DFEZG_ *17
MIO>RYF%X*0W[W/:U1V)D6J3_)EPF@VEP&BH!&2*NQXMG/1UJ3YF4)DF*D432
MY5(C3WF*7R2(3:UE&O*R8C_W3"3D+M.;2N*N GGCK7,H$F9N=P>94*'>S_X?
MU);5,VMV&]CWZVW!0)2,E4VQ(;170U_BL[3686.6#-J4=/FH.#K_6TTYM'LB
MGG=M]AKHKR."/[]R,@PSD#D\A':9.D#,744^V4M9HPZD*7R:F=E:C ZF&39Q
M]7JX5FW%I!KY(AIM&KZ29"N*-.2 ,WF*;N>4D_[@QNIZN=0TNLBFX^M5=EL(
M/[_N[UX3?-)$>PO/A.M!/O2K3R[QHU+5I"FKI2]%I4^WYU 78]Q$P _9$)]J
M&H$CZ?%[D3",$\0ZPG:O:L]6!U5 ,SJCMK8Y?O?*\08&"^6$?VOM?:>-PGRO
M<CQU&. U;-F"*SM@\7J=+UEF4&MST6\=]$P.06%MVRQ9TNULM+(V]X+*>J>_
M?YC0_5NAG+X<_STR?/LNZ_>U"H>3?AWQPY\3W$+O/,#C$6>*7(B_:YCHX[KR
MA;HRH;4A^]1#*8^.D:8G.$' 9+/V-Q[5!)NA18RJS'HCK>O *(&A/S48X.6I
M@QZ'OFG@ECV!D &='&29R_?AI(U#.953P^J3U9YSA\CKJ71<#:N%>,VU4\,(
M!GOYDROQ&(NNA0_U.]11UM?S::DN'TLW[G$:QJ!J.EP*+B>B&![7B2\O?8,A
MZ(IY6&:1'D1UNU:E/J_[LAPZ0$5 /#] /_5A[W28AV. *4D:EJH:\@%*KS$N
M""1W7I4WE>'\3I=*LARKC7M.KHI]VCT1TA*YZH/:2TY<,JI=U^DL-8'DM8^
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M0N":KB] 4K6T!+,-BL%M(",%>"VNB<(#<I,W:C1GEJW^P==1.$,!<I0&M+C
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MHY]CD9Q8F3SBBAJT1^/=%'P^>KGX&E>?$AZ E3&2J#"%%VX5)';IH/C#XZ]
MF?F0PR5.=P1^G>)R/? )<I7AMQ,&RA\D4E#/H%8O\?/><K/NX"ZEA&3SBOJ0
M7"U4@:1Y4N3/78RB@"[%02EVXQA\<2%9<;)\V*EXS-XJO7#0]?;+,+_T*?YN
MV[XG3SI=K;O^?K>OI,55[0[UNK*=^9K5;!DBO9K_DA(($>1:YD*,)50.SOA
M=T>^0G20]'->]X/+T4O'*!X]Z)TO%1<A5RD+$8K54NXY5D(VHVF;%K8*D.NA
M/\*X>@%PCS?$7,1P2Q^*ER.UXQ>#@05R7_3>8C?6SVPTB=$+PQT.<'\1H+#O
MCK3T]ZH&7G"W/9$J;)9SC:8;7CW=%I%8_Z:VP3ZN73! .>LG_.XMX$%[ZMYA
MUU,V0&RPN*G.V!3\(FY."Y7S *T95>I/HZX&T0,MA05$Q+>DH+X(D8[B,$F/
M[-F,V5O=89-0H'#KI>Q3KFF(PTP;!H2-?S6(;W3"+[-Y5R6:A+SM/91C\O1;
M;F_ I*PR(D87$+8VSZ31@->4<T'/B#<@F@_&" I!WKT"T<L#/HWKWNXBU).2
MK"+-.V7UX':OA^28CQ,7[JU>4>,S/_V8OPUYRBU-6O,T@4 6+)ESL&@\QB[>
M)5FYFW(.E-"5AF/V']X;%!<I]@&D# 5!AM.@[*MLJ,D./SA%-0K%;$V,($Q;
MG^JT?OJUBN8%L8 <J:@515?N@'S!D.884@8&22ZQ'E4<D\;Y#%DF%=5[E%^N
M&./>ZK_D-V3B2T0$,E\>!2Z=&+M!U+O^;A]%Y+-<L:(6HJ7>\I"LZ0V5/.^?
MZ%/N3&M&I,L_$;^3L2? 1^W;;T"'!4R='5VF$$W*W+;M&YN-T04U4F8E.J9?
MIIE7%L.&Q@W.BM) \_F!Y3\Q.A!#&+@9_"9<7R/1(QLLN%6#+2F%9)=6[GX>
M<,E/3)^EZ1.RQ6F7 7HB6RYE;?@\FJU\K)+FAJ*::QR336+=L07$9[_'N7.%
MKS5>CS,UE-LF\+H4.$CS!*(>1(,64@E=X2+%KR6S'Y+GD#"()GPNC%P^]/%(
M2,;[?*X[9GAW;([OMZK$F9W=7]AIYWK.3^2!,!7>1PN--4$&?PK?]!_ 8Z!_
ME^BA74E%Y 0A8EVIN0 +G:KA&0Q"@\X@)J%\+&\/P$JUGM$;K?=H+""J2"/"
M?UGO8O<4*>+VY-642YY0X=(9A39D]X+LY@-*&.$[&:WC#R%-5Z"((<,E*_>#
M[?EUM9RL\P I'K,]=-@"9*1&Q!I:M#E,>?IUU%@L6YQZW: R )2EI=7.IPJD
MK%6ACQK1N(O1(LME,W?G9B#_2LC$&Y#0V5J:S3'X="M,NPREZQ(2IYTFT\(Y
M ]XIALW1?8@3"Y[C#R:RKVB<[BO#-_N]Z::X[>C^0WV<IJXP U#\TBF<%\#-
M*2FJJPC%; ;Z&F5&-&&@)<A,B5PV?Q<U4,Y*S,*#YO?GVFD!8ALM>R.2U^&)
MF(K\V^7CU1)<9%D8(O&];Q;IW? ZH)B/WS#*70=@TC7HBKW2B=OA$>'&P\2&
MY&OA7^OSOOO(LQ=EX]-'%^P.?S@CUGU-6+])?Q_CKHUHT%\JOL<C')E#ZBF.
M@EY/ ;H 7ZW-D+$V0LXD.DVW"/0JETW@TX8Q@))7-L;<:$F!8X5N.0V.AD<U
M2SSR](BQ[KI=$F_FAVXKRYGBQ2#\<@4VA*&M<GVLL(&5W!'&70\]F8'S^Q5(
MJ6@K>4&09_U&M?0-/=<4-B,H=2A6@,'TSFEME'CT7 %MF<'2IR2*E?74,8H3
MJ<@QO4NP:C9NR]]DC58N#"H8D< H1X%UO& 938-<BF-<Z(AL@_WR:V---/DO
M-/R<_[!OH-]GH>.3@B+)H-^X_=5\4F3QN&UM7:W8 )R;_?_NROG_7A?FM([S
M75\W]MKX3S@>/M,=?AW%-G(Y^S;I0W/SASZSO/'O\]^_R.O8[-I$8V):RK\9
M6W]S?NARX;P+7,I,PVY4$*5#WBW&6E 6L*(FY.IV7*E/NP2Z)%&"I>VQ_'KK
M6MM*26#KJXD8K\+H(D*7GZ^[UI>NP(#C??-5K3?VG,J]=.=FMO<[QGJ" 18Y
MNQ3N(F# IHQD[2$MF".$&>N6K-,]<Z)$U3*[1&LD(AR-=U>^9O"IJSMGPF6]
MW9?>N%__=O[MDW'BAO*(0:Q#+^T*0VL]=6L@I"&C"WD)2COH(M!P"CK\@G(*
MBHL%OD\(C7=!-YX+B^+H?*Y=)W<7Y0BXP&?HN9!BB[3\<8T- "(,H5U<0GP(
MA4V<3+C4&S[=^$-5PG6XQE"UOYAC(R49DP\+N"9 V52X+$Z=K]S3:9-+XF?M
MW9$X-3=EX<%]R^O\YGHJY7G/CKH'5W9N3#K",H:6EXZ3D5+>7>H!PB)2(*+;
M,A&4G0!#ADSGV(Q8.@DQVW.$K!)R]+MZ26I$3A9PH?XA,:OV*.$];9\F<E_L
M^B^/WB1$W%'7_C9O#Q%H@)V,]F[918#7B=P""<L"H#H93!@KTB&(0)H?1-^=
MK3^ $R0KG+,WQ:Q[*A-M<)7BUJ,2],X Y<5)G(-$*4I[K-Z;_FNW]=]EJ8'4
M%NRZZPJ7)0MRQA&%VZ^T*UJKY<VJ$&?MCKU0F7"TSQH+.4?@M$/[,.C*<#-7
MRC%DHADP3)?1-K)S^S(6<:DUHW-;".7%G-=OYF?60BT6O$2J-BA)FW-'G0YP
M>I>' .V2(XD3:>'FIZISSG6416H='[\]'9S:U=P>\N;!W2=74O5WNHU<?2.Z
M1ZMA-O'2L=JSM)1A+; VGFO8VVWFB \ EO.*7_QSI=? PO%FG\2[,>U,XQNZ
M<P\IO/SJVT/NEXDV ^KZA[>^<R0)AK=W<BY+19O);@*O<V%4).B1\@JZ%= =
MLHU^MI/=H)E^V+/J3^W*@/X W)J$^E-$V7_8D3R>NA577;%EF6ECA)<YETJQ
M\4@]2ZX%P7AG#]KEA;N<@2 _B0L2^O'2RKF[5'Y[W0*W.92GZY*N\"R$%IO;
M3G>^Z+,N#PQ5$6!#<OCU9XO8<\O/,.ICQDA@)LV&E,Y</\O;"#7-F !9*6QD
MBK%6U<^!]$C<&Z+;+#!=?:M,6$PD!44QB.3ZX/;.VC?.\;\^+#DG)A?(-.XH
M=$*L"N0X0[)+,X*"H&37B)5[0+/T9[[\0J?HH,NVQ99]Y;&$-3$4[X&BI\&F
M$V]JW1J=6_H+]0(&7]PQ/@Q:S(=U<TB@ 3(M3QMB@<01G. MQ2)DA+898DE-
M)?Q^EW2*Z8MQ1$6I=-FP!;,5*@<F9%GQ-DG QWP6.?X;/Z8#$-:E6%]FA?7U
MQ?P3%<VX[LAX9[RI%HH;6=9KFE<Q>QKGHG'ZFC'S9,5MF8.*F,D-_@V<QK<]
MI#G+6P$]/NV1D9%QMV_L\Q\\&5)(B&I?]SA_K#XP/?ARL5_ABIH 3Q_P3EA1
MDUX>ISH UW-'U(EK ;!=E=)GW; :RZGC%^K8G!6U>]FR14?X9-WA]]L/7(JK
M>Y_MJWMD*/<QK@U?(YHZF ^Y-2$U1'S\?:26M04S0[*%LVW$$28[,R!*I+B_
M&,W3[C7K)7%\Y0S8P.=Q<-1^XM-8_=JO]*(PNTP\.?HTN*Z\.)!H$%/8^"+;
M$=!X-H:LHC4'F,O-6['IY:3R\>&=R_EHBP+(I95JW#NGZ<]8YT^HQ1AUH_=6
M?"9'.R=XU-9WLY'&H\;;@>M,>6EI.>Y<P%55Z;\PR"]F)S9QOJ!-EW05NX'H
MR3$IJ;_!0\7] :-YFJ";XB@P(RA=4=/S0][W0NK!TMG(Y(,*UY\;E_DG7U?G
M"#NAS L<PM6<XW$FYSN+WP!]U2_" HTYO&ZKQHH)&8G/3)K/TP!:!;3[P^O9
MH/-;U0+;.ZZHI:,]1W@;B+S-,[*DKI:X$+?.\W+GRL;Z/M*0U>X:H"_'.'=+
M[_C V/P?1\-' DN%>8X ZLYD40_GEARW 3KL45N9X_F&!X8DS]*T^_W':A<&
MKC_%Y-OT5=X.6>-U8-SO(Z/8/7IWVIKH@8J<T.^6PKFRFW?(N'NTX')S9]"L
M6DXS5OA"C6!K:S;]KLU,4HS=?<S> (IM72/@$J_P-,N](8NS:(J!-<\D,3<I
M= HOD3-F3G9<9P_=_-9<3T^V">FPCHV=\HHU/!@Z^%K9'KB&_@Y9S>3??46N
M<-><#^KA&H]3U^3Y#VV;LPPC)0VOZE4:A3X@?\!/ZH2\'!P>C6GO_5AIG![T
MS+&EZ ]W@FEB]OL@5%R)XC?(Y3E^=,"K&L1)6QZ\(C,N,)R ^9P22,ZWA2].
MLZT1P3WVF/20R%<G;[P*>SA(C+$1Q,3=OS7$07"?'FH.XK$)41'89./5H.U;
M&6P3F=2BU%'E4(KY[^'HB](IF*#>MKR"?'7T@%.X3,NL>5ZVHN;\1OOXUDC#
M6(+ZYH:;-XXBL9#_O N0Q9_1A,3OF)NXNU4/%3R"W:(X#BP(PO6:\M:#F+M%
MH4Q-4HU(EZ#<!]HE*K>P1?=8;)RFPA%Z\.K39U4U,I"?[Z4XK,U[*]/$KO$E
M'S+R&_'N[7U'D!A@#(C&AWLPVPE8725RG+EY]M';K N <:X<I3T,B=PS1!^6
M+F73$Z?8>R/;K-D_\I?</ONTO+[=>;N0(A Q^I4]&#7H+G'I*#EZY%L:>E4%
MQ1W:LSB=H)TEF]DZ9F]W;XZYQ8^" HH%Z7;G<WP[*]A#'EBZ5ZD\#N8"XM(L
M9U.0)WJN4=Q"]U_-<?5ZH]:QG$<+YB7AJZTE6\VA6^;)WVCI6 ...Q@K"!)D
MIV<\KS<KE!%T;TF1&RR?/"Y,-W_GI]46!L<8=ERGU5R/>,_.]8XJN64D.-?T
M@;)C.5FYAF(('0;]1XP?%!(#]T($D"D(/"*F1!9 8L^ZGN+&:K OK1CRHVWL
M#QSSBZ);,I+0AT>6#4\ ](3P(*V24?MU*85'L\L6GJ3$Q,D%2#TT'%AH'K!+
MH>XGRZ4+_(8 9TO,0)RG(/!0ES56\WU%@&]<43C61<QQL4W3+C"TCD;]VKX=
M[AWU^_*+@9,_GD?  P\ CS,>%$/Q2T)CH^J.R-"U?8_+AX@QP=P')8.VCR,K
MTM*QY[/']K-^M3=-GWYM6IM]ZN/CD,B7ZY9,.=T[-.XI#BW_%8FB4W< \Y6E
M/W?QU#"$X:BFQ4AECA2IH7 %27=S^#$GHN=#/(BYOY%648X R%2,*7Z \,]\
M?>2,\.?/3\??='^]53K B0'<+T9S,4J1\>;EYQ$2>@PM3<6-S$UM0(/L^E/P
M5K,]C[],A6E-1%%M.A26*G5JAF8]'-<=J\]\'U)8?)]E\^>DR:E?N;W60X<D
M/H@L.M.G@TTZ#]#3%7!0PYDA"%P-TA(5).E_5Y\,6$8W(Y29L@"$6_+Q;<\8
M%SHK9J[EA9Y(#DX)06V-L"KX_9_ P^#"7>KVT!4UX '%"63=XVA(5]383D'+
M#7*LSJ@2WJD<O+F;&(N=<KSYO:5MREM3O\B0AOWXR&7GB5_3[\"T ._)NOQ0
MK@4'% MX*4Q];"@+WC92'BUM>5RJ",-J&7?S,1K@E?H+PP< Y5TI/I&G1863
MS=:"":-^"#+3APOTY<LL \6N5=W3D0G%^VL?_DLYM/RP7&D0")F)3BT_6U$C
M6!*E=7S?!$AC1)Q,(8XL %AZN67-8+F)<^=UQ<E\A6,']R!9S \T[JX8&'16
M%5I2*O5@ATF&! =7+?_\U=QY_#,;U<-IHP]++?!(<J9,(QZ-'?'_5&9>!5;4
MR1HU7(''GQ&O]F=?ZN.:\'AUG=.[>A[T3NY.!;O ;7Y#+];HY1/E. U\*,([
M=9+C*\T1:4X4"4+S=K/%-0WIZC[V+]I(15H6/JECLU-'Q^VT__!)<WO*%1\N
M\U(&O3Z_2MI)_2"!78[_,!3)W*;_>KEP#C]0I#N0E.S+W1FVF%%9\GFT2T?:
M 4LX+_>O/V4]=Z&O;^M4'T[G]-CNA]_K19/1!2JL0X91UT-C2\<5.X Z(7ZS
MA%PMP_)QB<,6@,<#*4P'RO([E248F'Y<2N1I<UQ!E+2B5/9^%W%&9QRY'K-#
MX<CA]5F1;&;SM&*FY><S^Z70$K!/SO<D?X2EXS>$ '&U#?#$:;0W3$#3<).6
MTO3<$6TP^E6QIV^XE6643ZYIVJF'8Y$;3"(CZO:]RY/@0?H]CH6TC;F57*"*
MQ8#D7EGYLT8.Z,$K'\O&TBWW3V?OKFUXVS=G6!IW2)-(SUL3?_OZP[W9H4_L
M@G:M_CF6PW!%+1B7R*O12*5NA!I:PV57>I3KR%R),,\H[62OM*8*M#989"7]
M]-GU-,9OW-<]1:!Y? 4:/\)8!7WXX;QT\KZ8NAMP29K^QHLE$AL<Q KWY9R(
M&6/*\2J(+46ET@PPZR@>:<VO(;@/R&CV%]&_N_T<N^<S;I_!*@@U1@$B(8[.
MU*=H5IR4MGOZB5D<FU?N4I^YY74!-']W.^^ZA'-O$ANCL,DK:C SX!R4"6.@
MMZ'X^9?-7E'BD*G6=L#9[IV/GV6=Q^SUE^=KKB]V27+CT^8C'B-L_[#_PYIB
MH;K;!FC&J1K$QJ//227;R,2S/Q+IR12+\C'NSHZ9=(Z(]/O^N?!=7[\W?_O[
M3<8IL^_7D1^R[5+FZP_=V31#']:L@VZK"F.S@7(72$_S=G5KR1%P,:#13*HB
MH'QXW"]QN/3EN'U?71R[,%NF7/PR-7DM?-+:W>#OP5"N<5=-NB:NNZ8-]Q'5
M/SA_JT_AQZNA)5NC&+0:5-,1Q<6E &7WE(RG3;'MI1J?S(?8)E#!*\*\?0\-
MJ.+"%<?%E)TOV_,_]1,D@UC-.9[ZI>&!)JW)ZO:2%S&IRRXRQD"=]-$"K0;.
MGUD#B8XR9:PFVBK\Q%21Z%4H_*QDPI/L),PSJ:GNG,SO_<KKN\Y!4RQB*+[%
M.8:WK1,0P@C;&@;<%U"7TQ,Q^\B:TN9+Y*5W]2)A $Z*OT,)DC/6CU)W=A2"
MV@]>DM.:ZZW*2RY)R%X?E7'>SM6Q0R?^/#_>MT?FFG__EP^ZJ]Z/2ZI@_+^M
M68FV/$VTNWQ%[8[]0A-IW27%$0"6CM'#0WXX'7\*ML?P!/,"0$N^IC2#7&2X
M>^CP%^,Q#+IU^/6OI&V0=V#O;^*IJ^+]D1:.N/.]UUGIV/DS'=:,M5#.\4ZE
ME>)6%W<'6=0:@Q+P#"BQK\%H^C.H48;="D7CNF8##+[Y8@&Z'=_2C1]#H]>$
M._#[5M2TK90(-T!H71K' Y+BJGQ)R&$9E [,T_3\R%8P(\B6M%725!K@ WF@
M]$8?DK/G!X]RWW;-#::YKT5EE-Q8EU;B&T@8J.E0N4;D7&%[H=SIQIK*0KP&
MY0)T&328\*V"XD#DNT#[1F"RC233Q&F0^?QA\_J."F/7WT[9Y,3IG>-FG7GZ
MI2[/)G5N1]3#;6?WAG[>HW&7'#U_!+#*F*^O8,M%J1@'L%H1"TBF#&6D9*IE
M#T4_;P]8)X"MAQ#(I.'M;/$D9^\(3E.5-X&*QR,-EJB3[ X*7(K:X+(])J"\
MX\W2M<7'PF6&'O7O83AH5;QTRD$51U@%9*?Y$H"GTELJ3RLBEDE7K8XKBYPI
M]:9S-P4J?G9P90&#7F!?BGP/9ZTT0 ,7/T0AW!I)85E#<XXN35D+Z;M9LZV*
MW51CY0?$S/Q\^G)RMV75!';@";;?63K3\NBUEI-H:>=3]G'KWF1WCN3!5?W/
M.D:WAJV@ D D79ZF%T$+,M1=BLY+*'ND'[K.%PY;J8 N:8;B%&4:KT[,'YBP
M3WRTR'Z7]W5 ;^V]:-V4ZSL8U_\+VK3JYRE^WA7<O14U8_%(##2.T]\+:<F6
M-86!B#B]BU7=HI2RB*M=UZTX&^3LG-,<1B!$DX7C^'D&O8J+TD&?V>HR/.1_
MPKLQJ<6PU**1E(JOSL@"8:WUYD+:)H4[5 BXR?+2I6D,]38Y[]Y"WAI5B2;O
M"S_M?E72/+P?^":$J2G< 7CR[)")S]L>&QSL<UB@3HXW,#==7N;V?#P*.U W
M@<6"(?)_J&N@AB4'@@ZYNMF>Q$<9#5%^3Y/!DVW<IO8Y6@DQ",C>'U*',KY.
M6VCICV%,ZNJK^C9U%V?=(&&8D?^V;TKFN4!$H?$V,"\M6(;3@-*.@WAZY.[;
MUE.Q?#\NLV*T#FPU.3$3_(H0#?>R._6PH&5JS?=]?]^_EW1>;9TYGZE^$OC6
MC BY5P"JZ#1L_M"X=S1U'T27.3#TH0;_GLCT\S]\>DAL=P^?\O#+KBC6]-HD
MQO.Q11>ZM=8OX1$XK=%Z#/WRY6)_LC9[R62L&LIL&:B+Q_Q"B86.25DI7),&
MD"0@):VH;9J;H==BM$'OY#GR_BF%:YE?F+$J5<I$R7A8)&Q+ZY5J*/6'%)6A
M1 X%CHOMZ<FR[$%!?>+72KL.8SOH*2"7/LY]4@":J$P?@R0LYO:_[F8I2"K3
M;XZ*203N?[@V6<&>6%IO-2TX^G?XR&TSG?@OMO>[R#P5N-'H Z99*9184*/)
M>#WPM=#:8""*I]*'02@&T8F:MGH6F^.SGQUP5?FA99R8$SHL6_\LSR5[S>T@
MKW0W-9@F%+V$I*"@H"+%ABZT32DT=0T;PDI"ZBIUH2WFXLGPZ>MH%.@A;ZI#
M?&EAEX0N6CTN65&[/A;R;O$$U:@W0K-]U:S49K9;&!O5EV5+J6 NZ9)O^@[3
MD(H;R\^H!VV90($,V<13KQ,TTJ2-O:U\UGK*N6[K1G@+W-Z@4(I*Y.JH)"G+
M638_T;7?6\@TB(0E+XZW7NEJNVWS,?^5B#:7*TE3F!:/V5-Y-!E#NS_4KP9)
MZ)HK;22=J>V*M"!-YC3&3B&HA38??(>/+=.+)1.8<$Z7RW)F</3+Z26CFF[S
M/#)C/A[Z12JY-[P7^LS;S#&1J8J&;B>[\>J2(&\+B*7;#-E"HWX1BX\_/G@1
MYC7PNHLT-_%2:C! ?6*S]5M#8][ 9WW"HXYU&AG8JRJCAP:EXF:)&DP7^M:<
MQ5QK@UM/IDM#!*@-XS&FK S%3AEI+40\!US/80V^+R-'^P,9I3=HTG!B8(?-
MLKG 6/6^!RL(]M/EEVG/VH@W=S%DR(&$>7= PJ?U%\R_!?6@09E8%<>W4>*Z
M,)O&D+ISK.3%CPDOQV,6R8=E^EY><$0P_2[%="07Q3\YBS,(('@C0A(C&I'\
M/ONH]!>NST/K'?^-*?]:LI"1 -[$)GMCU[-G$@?J^ Q=BCTHB/G2FCIGR-LF
MX%IV>Z'6"UFA]K1$:T=CB7=WY-!UBZ52'\7E(@D1<2W/N,MW1F;7%7YOW@N_
M16DP'FA:#5S-!2W>P94'>JYAV3^;=?J2V_AU@::\;ML/*VH#MC'ZB/O9A;U)
M?U^EL9O"YI=^>\SYQ_E?-?+UQ"5SGT&(U40U 6=:40PL(H*5E+?#V (BC>!3
M_<3\'-8&LHN@=MZ^*.L%L<I]1)2$V0@R,N9(VF.+PDF_=06@MY"+X72SJ.VL
MLB[RDP\BWP0'P8I:)?,>VI.PY ;%?/O9\@@KG9DZ5TA^+I%I\!UM9Z1UBEWU
MR!1*D/2G-^#!F7@;=Q=I7H%\RD(@CD$EAD>-U?/2(U?45CO17HXOWJ-N@GL?
M<"7,W8]IR3S0>\:O*'=/1P6B^]+!X<$CG15=S=T78\,OE!4OV4NM&Y:,7/,;
MOE_QUQQT:WX^_'4;\B_01<"@4]<#0W7W*02Y9"WDTFR7]%X%]#*&_FB,1M)T
MSOED4;%E[=M7$C]"9@ZT*OOODQ$MXSNN)/QSU%WMMH8 VU\E$BHQ7*A@A)'&
MA&/4H:4 X"M#BMI&5,ENFFK8#L^H@6E?(L(QB%H01^=:*&R@0JGK'%*;EVSS
MIH:F1X@Q>"QK\'=T=C\R\9 P/V];6PGAY\]#P=)5@.\L401?KAYA"O#)6 /K
M9<]S?5-SX4&MS,W<O:JH ;]'B9314OQJ"XHN2:"$<V(]64B*3?_N[@KK@\2R
MHLRU?]8!TSD&=X9_$&7,37B"GVU#L,QQW8\3H*$/BLY."\#CWG2QO_9>L'U2
M;YNOQ1\(2R_9J_7K_JM_#>]=]_F45D".3Y?E=,6UD%[K4=2UFB]]J/U?N;49
MX]VG"%8[ \Y_'?KB^VMWMK_;RR>+%]R"3-G-&Z*==IS5AO/Q&Q6.4GP*7D^Y
ME["0_<_P#JB2..*&T_$=_NSSOL#7!5APZXW(W5+C3[:>B!T,J:_MG<9?L!M(
M>E'M\8?-\W[G*A=4H7C+"",%J\TU\PD,8VHIXD98R?97F>2(I667)N-]'1SO
MRT%4$]_T]"]?$V@T4CAY5\2C0?==9TPBXW)\] 8Z5OW/M*7_YW6)D?[;H="F
M5D4E)]YI<F,;K+BLH+NN8ZXW7;:5VOE\_*#<-#S[5\>I#Q\/SBSQ6@M)B5EF
M9O?R/I2A1O_-I.WN;\H^/]\?99L][./WF2>[O_TY]V:J2[+WUV^*+>I.]O1W
M>"WBP8HKJE@@R-WEZK]-,[AD-'!795;>(,O?8QLZTN@4J\O^/_C\9 >M3D4K
MS-1SNV.GK1L"U /KCKQG+"&%")LO_]X)4MXMB;D')MYT?;>+AQ_9'M)#%B>"
M6M];EXBKCM^,=<ZSXOS^>+?BD<5[WFZ1G/7"UGV9-T)*[0]CH"7JWZ#% Z>G
MR?>9ZMYV_.,6_Q7BU3T.*G_X7Z?96)\[27OFHAA+_)]A(L9O 4T!$DBC_*Z2
MU#J:E9&=S"[A"X<B5YI^)_8="+/(4Y-<MFR^\J]6_X[["<L^9_*NG#<[Y+L5
M5J*!?-#$DG\=EA'=DJW*/PMOA%M[;S[%B_DE/_*A^27P4:27L8S'0FI/;(;H
M_$4#'JGN;[%U^&&?!,*'_^QS'\$KP\U_"<BLT/9PMO@O=DSO+DZ'[S/M_PJZ
MUJU^<?Y"R+UR#\L5M=N_$0<5^U?4O+!7OT9]>4(NYE?EYND=D%)F8.N4Y@S^
M5VC[)5E]+';RGXTY$U,[V+5/=_SAI!Z_?@?CW-^[&L.VG>@0'EKN_RWC7,:?
M#]09'>+'E\RST"_7J46]FSU_DP>-;1F-T>=&95US;7,V-IGZTK"/L;3P6HEY
MK- 1_AF-N+#/9N8LZ_P]SMO>N>_G"TAF"M&\]YV#MD+Y[^(NKD'>KKW<FGTW
MQ[JFCR1)(I$F@:E[6'2L)U:'1T1JTII18'>+Q79J0'&R<9O0EK[U![8V_*'[
M<9Q3;ICEF2LA#C>IX>\H4GP!3R6#Q-K/"@Q8=C"D/>$"4)MOBYEYL"ML .U?
M^7&F9H(1[SST]&RTK>3COA6U7%:AQGI:"<:1_#3S>%95L^Q(*F_SKT%;!QXV
M@8[[T$[.N5JZ\SXA3W'K'];?>_V]2&*]3?F*_$O>BEI9X#8@Z?+>'WV%CST_
M@)8-HHEMZ&^/>QY[O(KTTK494IIZ'3[==>RDOO<(?>SN__'!K(Z_D'3>:?7Z
M'7\<T]@1_\L:XV/;$_!5^.H%P0W07-J2^7+(PU0<<<<:NWGUNP\+?>>>I?[7
MXA9TOB;4JNT/_<^._Q"8N^5@%??I\A/,SU/.,-! <HKWYGL-<EMRA+_HX#R?
M].KV_0BWKY_'$%OJ'TSN?E"EJ_G?E1W_!2%[\">86[ R0W+)G::O6YE!_$OA
MDT=N'?F69;D)8\4F04[_?(MUQGK^LR_.KYSP_GB2^H'6BX\_7^09@OSX%;6^
M84V![$!-8Q&)/]QM\^YFR]R^CGM8J9N&T79F73-_\/A?GH_/>,"UUKY=I)7Y
M_W>K;/Q )BS':$U:T^+U2\B;6Q?['*/$M2MJA-J'.],_#1G'VG_GG?G^8O%@
MQ>[X#6M^S5CO>&S61CE[!6*2$L]F-I[6\HS[;+GTEC:"^1;;/'-+T=K^^S!?
M]]N6L,@9FWZ/%34.8[B'-S5AR?A[!MK/FQ2MJ&F*Y\_V**+S/QFRC"BKW]9#
M=PMK=. -#<"M)B.>0&MOE)-UTM;9Y'".Q]]%CEU0X.[A-1F&T!O6;%E/Q)(1
M'L?M8COXH&:'/#Y.X'KV7P_R#6?M)_T:2VSP3_YSRT/-M-M7DGP^;2$//;JO
MA_\VM11*%7E+JKY-68)N(_]VBI89SR:^CV,V-?QUT)YQESV'X"5:W2O?/TSI
M)-C]3ECX?KO"^T(E+W'^O=[S%;57S&,P74QCY@U8XG]))CDZ#WNR=(#9?:>_
MW_:RK=GS;>MIUX9]Y/T?*Y!;GV<^*L[YS13HCEI1^X7Z)V?#W!GQ;E!S[?&>
MPZ$NNT3FZ_OWMVXX??$FQ]TYDP.2UWLWO[5]=/G)V=2&I]^_Z)_#CYY3G/[?
MDP"7V;2F'52,2C+ \GW*EL*PZ)89(7.=53&$8VT(?NCVI#MBC^4T!Q[5?.GM
M78Y)7"&!8+7@>KTF]HN75XJ< 3UF?9Z!=LRT% .DJ;UR7(+W L.8 6:^^S%,
MB&+][F4.,OE?F;Y5W\L'%Z[Z<BQNR^3['SQ^RGU_[?[ND\;>,N0IS%:&#OG&
MT]]*NK^U %_\;D]O*YR)W63_>/\';?]71%0Y7F?/U+X_P]P5>UG]Z(TRNS^@
MNUG25[@L#8'^^)4WR7732]><TL]P3SO8,P,+G>\%<RXGO\H2="O?E(;PQ9+^
M[.D'M-S2\)=^[_=^/ S[J]3^6^VHWTD1SZFK\B7KQ\T;GO?R44DW'N%?9.*
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M5<ZR1<) ]&U&*'L1C:0DW-#CCUV@7NWBT),644KO2(-VNB-,5FS"AZKLW(+
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M.JE7!-%N7+J$X_NH6"M$3G&WRQ^'QUV^^;I"YMC7F)7.K$6FA+ ]!?+VAAW
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M%I.7C@XO'VAGCLRB6$=N.&7N&*R!/__::R,%.YR>!=G?\C<\I<W]9LBU1M9
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M0VK@,N \&Y$(/QCH1E%F'*(< ^=H;-OT4')T4,B+<=.@,;T$LB[00XN:W%?
MPVDJ6]0/+-R P%98FQ"^XNT^NI8A>&[R4+/@^2&8)+>G<U(=L$TPPT.$@\]5
MP0=<3KO:<K:>/3*YCN\(^I9A;G7;W#5?/!TKK4+_,(76P+3SQ8G!(\K18G0U
MF"<QY?>W;#51DUV(<)! I@@M@05$PW0Q@&?II?+]6$SY(-P!01G,E&4RANAR
M(TA'9J)HFY"_03TX1:=H#IG-_VP4./\[)(+Z'<!Z.BR<E2V+=6AX;7G;NRE]
M=QVK>21NF26ST,R-994NTVHDW<"5*;02UA3TU:V^;=-&76"Q:B0YB/2(0G5[
MPGE@.IL+94\PLF VK!IO,V#$O26W>:HO 2%#=J\)5G,M')]?<^JM-!=J4A="
MN9+M&WF9$<@$@AI?<HJ:(#S.[4OE1XV)I>(#D#)8&[ 0X%WDSJ2@R5Z<. 0+
M1:]Q[_9$)4;4Z#EQX<2:>37=;#HB :&X#Z %/PQ:LX,_"O+UO;'E>Q.S$9<\
M93+&6<L=@$F^=."&L+N[$!*X3\V$G3B5G_G//,T9&8>,R#O8\XOVG1M":DQ0
M#'H*G813K1_ZS5M6 6=<!VL'SZ>MB81O(UX.I'H ZXDD@A/XUU<RM_+1/#?L
M^5;0I"08I8B3Q-%0DG +D.8U"(NM^/>YY9=%+))GWUN&U2>UM +)>65!DRHC
M6'%V^B*B:[$(7E2KERE_TIJF+%[DV0[?A'3*? VG$>3YL5P3]D,,QPE TVMN
M(I/4&.WX%"W%+S4W^"@ VH67(A\7.:/.ZEFUQV,9(\^-@.7T17-:.8;QSK.V
MH!Q$TRE[LF9H8W3+JK" BJ"'?*0@FV_-C3XK*%+I)"C]?D-VY%D+NWVD!#G\
M4]4_"=)+AR+B%"[]S?5N(WM',*\,@UMF[RX--\]JB.2^<@Z=LN/_4S][!!/I
MAU<+3G8U*;L3 B+6DL#A4&X(*YK&S!0)5[X1P#D+SKS$]#F!D:\P7FP2(QMV
MBC41WG[;G)AVDR_#19Y^"\:Q3NJ=99C ]#>2RO++XV&.'.^=X^[]JP@90>W<
MA-FR[!SE9#5NC*I9 LIQ$&,S[Z@-^$0^BG<L$"[+16?S#P9$<N^MBV)6G1P#
MK- \HXKC KC[^SI00 T)O3-P4I,Q5:>UKZ[?F!P9S:Z;.HA@[76PX'2B0X"U
MF06"%E9;!!-,-N$=(94 W,=?QW<\'B''5>.OXJ\)FH7R*/ ";$L5J"Y"U#'4
MF!OA*W,4/T8=>Q[]U1S5] =Z]5<-C$GJ!ENY;C,=O;PC_&N"7&I WQB3'EKT
M#;1D!]#02<PZ/D$,=5Y017#G*HVTE6+P+&,"GCV>:=@YAF_W'Q$I-)9R"]>X
M%'CN82:36&]WLKO3W@C^T2CJL,RW-ENV<KP(%I(LF4I\Y\-?^$=>8G;/LU52
M9JZNIQ?_M$(G,^GYY,[BI./&281RVG_?NV]F'TL^*-&P':HA,];#02=AH5/4
MK$V(HG +)J2=V4#,,D?N.&4T6< 5!1<*' 7Z:'AY4J;V:0"1"=?%B.1\*6AS
MPV:MM=B>(U#H$!EMZU?@[AZGA],39,]\BU=^/$VR>,D\7DJ&9J(ZZC5OI4R<
M,IU"*LY^^B5XY#J YI\4:4IA\S7O\^%QSS<^>U5(5MF:Y!B?LFV'[K?FZ?"O
MC/ /3E'C$0KXP$7M;GP#XUZDS-8>T6](U/8D8*:S3RL0+[4:IW 9P"<*#V ]
MH8HD@G3(;9>6[*3?:/"\'D 4B=9M<\^-Z^\M=;"%7=(7-B&?(76^O#/" ;P\
M3AL;"02THT=76!.?[P(R; VJC#E2C>\&#M:"<!I;JXFR&TC.X QB5<HQ7BQH
MELEO7KJ7B9)-*#'8ZE?MH](^XT>"/$2JWMN119CEIQ[>+4QW%YH' _%3V>_L
M"8J8><X$=7%+V=R8+1VJ.0ZJ.(#J'.@HM?.Y*H"@%QJR0Z?3643U;SY!GI9I
MD:'A-L(!@-14'%D9G.]V-[1DEA&E923\^N4-]1YNA^"%.3)-1+<CK4 TAYB
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M6NE<RTRRN6%HM/,74CS>_\M7X1>4!E:<@TR\;;*H"82_\Q$#FKOZ%&A3)KO
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MY^H[EW%[!<\CH"HB@"[DBG5Z9MQF),$-A'UP+<%SK.V4>..'?6FA8O9<$[H
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M)W.QC0MEC63S/&VX7FM8T@ 9Q3O /P@BN?"UO@ZH0@'=1PU\Z\>U=@8)_MM
M25<JH)5>-=L2FH"0_I[HSU6.5ZY$I-Y<S9:QR-E->/$5+*9/D&86I7G6GF!Z
M.W67^Q21YBYX =\W^]P S/1EH4$OG[WX9(*44!)S%24>% XFLPG9OJ#O@7)$
MUDV^,_L)W[ 4@WCW7(:KE5,=K-SLF8 S;/BR@%XUQ#_&*?&EN":+NM5"IO,D
M'ST,WP^Z<Y@TU.@\RR>5NPJ3]"OGGQS"6@,;^ Q/1IHO:,(ZB;A$:AR!JV*N
M=K/%$LW&0YT87?!]S<-\/\N,0GZ Z!]:[C0+MH)M *(3;L3=A-S#'<7J@JFE
M?!.P]>_ZVH1WQ6XB@/ '<Z;0RN"VSHWL9%*;>X?P*."?G8'3G+=\V8T":M.K
MP7#W+^1(U@32ID6M6BMRFE 3K'SK#B9#I+W+4_C[Q_J2A >QVG7 3#9% QL
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M &$3HEHYM7C*?5I+G_OP_<2G6_-Y<@?A/;JO';^I_(;%F?@H_=UNX1H#X>^
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M]1\N,\:WWY[1@SYVR5E:/$,=><V->WL8\\G<C)I[</7D\A3]:1.#U2<.)QQ
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M3C:O-FP3LFVM.EL!@SK/[;N[RA0+.5*=[YX&LZP(5)GKKVX-)9T0OU&2(P?
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M@#U&?^Q3[9C>I\DUA]ES^E3).YV+=!^LGE]DGR[X<-&21C-?1ST@ #K##?_
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ML)2@=03&#=T*H7%H+ $^"M:-<B,W34NHI,9S-/E_0VM\8A5[?F(V[%3U8_G
MU-B'B,\?. U15A"\P9D!5"-/A3H-3?+/<M!E0L]4@O#;N'T^37*RJ@FN,*B+
M+20%7 _M&MY<ED>.Z4:TUSI^1F#QQ<\<C\T&GLBT*+%"59]-#9UDS: D788@
M2U]>XQ9-@A\I4AJ>E>,5_HU\@&KX7Z G((1QZ 3PD<_E7X71XCWZ17]#4]_Q
M=%PZ,EV&+V79FFNPIK6M?GK^@UI#W(]'B:57KM,4(="\'?V!=7<(AZTX%C+
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M(P#V^MW+K'D\_UP6E4_T>TD.1E;FEEGK[)2WR/A'-7V75BU72Q>#LZ!I(@B
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ML2B6O-C^%"D(W1"6DXTI=S1:=;:X_14KU?H6;%3(0 ",8^6H].K5C!PX O1
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MW*3=,WSTV=CCTL9N2R>W0_=I'C!<_MGP&8@4XK@$J0O]#7QBW2]I89])2P#
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M70(I"Y#MU$WOO/1]@,,X*B/7#F\8G^.B#W3^"#6 +[P*"6X":^,7V(')JSR
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M;ET#2#_9.K+LKAKE#/2R\8VY/.6;D)LN3Q@VK7XPL5F)<HC-9>>JW\R7'I9
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MUSC0TL_;*5Q=+?Y!5AUZG.053A$#76+L-S7*)5'7#+5W!8>N7 .,X-0+8]>
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M]<H3)WVT8EE##DAY)]5(G#]=Y.BI$O#< R0\>.-IZJB?9./>AX:1BBQZS1E
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MA;WLP"8A@X/W&F,)ME"U+]F_8WY]3;&*R_&"*!,S(=(]LE\AEA9OUL*_KTQ
M)/EUHD=VX*@@5_@OW=Y_W5DMQ-T4DH\6:MSRN;#$B.(":O?LW>0B%YUSRHO)
MQHIEUT!K9^.NMJ894ZN#/[5'14&7*V,ZBE(IZD$YW=5!+B9[V7(K3I\%Y.*;
MZ%&L2Q"W.<,6C*:8;[&\O_$\(RQN+-O&;WG=SUK%42 UG7TH04!WG7[GO8GC
M@_WB"MRKW:"#,8[Y;'?4!O9S2]\%[P8['/L-C[@&?'2Y*<N.2J\!WV7P6]>
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M,.L$:SF^084 HA9^JA9@'=E," 1VEU\KW"$=G'HJJ#GXZ>"[9-01P?M@.Y>
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MNAXK!\^#?LZ#9C"6N.OS>-+<!$57?K_)2Z4->9>MH=BIZ,%MHNS#P:OT]]8
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ME0I?WT!>@=X#1;>):L=3K++42"J<942U8,KO^0=,)NRX1P [@MJ2XSDJ4S^
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M<%AP98"8P4]5#G].*T4W[@8GPKJT!+IQ='#>(.[IQT#A7L1<EC!-E@SPI]A
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MV(D7$M ;*7V^]:U\U<,E>,SFJ,X;$MI=*V1:W5[MN^0+<<$V=VN6$>L)@5M
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MI3)R6&PI/0.S#7.%F29PUJ>M?@/(^5.?*\@[!J9JC&^&G3:?7FOO*5H7-M;
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M7YI&D0<)96(9@2K3AC=WQ8C1_&(?10WF1(B]#/WFOJ;7PFGH.+Y_]HSC$_?
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M>49LG[OZKK8*\A3]WYU>U$>YWO68:Z)D+9]@%54S0^HFYN+]C+P?EIZZ]S2
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M8+;R"4E:UITL78@G(6>PX<SCII5[EMA;'=9@F4U!!/]>Y'X=8Z]DG.U1TMX
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MM%X8*@L8:1!3N,\C&X,)!96@;J_K\:<SJP6T9+86E-S-UK8CF>"*_)W#Y\.
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M;2STNR<[+]\'AM;4!2L'G/$<@48PI'9*\2#.;:\X/+6Y_.# \3':\AS6=1^
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MRY(^ /SE>F,\<A-3Y2HD74A#B@,3.*@L 8,R7]= / FV9A"UA),Q(E16L_4
MA;VN'GEPMBTAQ[8YF0J#PR?E5DW*?J@G4:0Y'IM'T1H78%77L8AEL%/WP_EO
MK#OME#N)>E"_S&%V#;:)J69X9T)HSQW(<%Z\S3R,W#'Q!0'<X0GQV[X8\O4[
M!E)W Q\IG*K3K4U,IZ"=?#-OU\3X%6?B7ZG[<*"DFVWD>MTIRP$U(1 33<TR
MR1\OD;,0+Q9[%G[>OLCWOOJU[^2P7$\6 >6^Z?8XXZAE.B%&4Y"&A(K@0LTK
MGD[S<P[Q+\Z_$+@3U\EH?\TJ#S# FG2'*.NNEK;6U.44IYX$Y'ZPGF75,M3
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M.NI)A);9F'G(3L*Y0$_1147A3S;DP\I/JX)N=C9B)]*)Z R^RY+M(ICWA!I
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M\Y$O53$-^W\.^GUV- W-"T+-UX#XBU!BHGC2*;CU!?!RU!$#XZ78WXTE9_E
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M!;[GO CV+IN(?Z3YZ63 V^(M2V6<0SS$+/Y6Z K(\Z;"E*>E)K\*(78SY<
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MUS?W$IB53(T BKD'^+63.TLHGB"^C;9NF$Q@7CY:5?Z1$@[U225W%L(^#7Q
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M4W"E9OK[NLKBC65>7WXO=S^_&O/?3]A7D.MI[?N Z^HLC%V'^9VLZ,";4*)
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MZ)FHU.I+JM[7G(>JP27KOJBG*8,3D_^@$&)CQ=&GBY>5[I!V-! L0 #5E'T
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MA7;:<_8Y9>"2>W\1KP9#'G@]VL6:]Z"9&.7X$KKNBS/0OO)%2[@J_MPBY>]
M"_]-AE7/(PH<F?8,3-4S0L%?8E_YA,E)<7)RS51SV$*I!UM,R=]]>"X@PY1#
MC+Y\_I%%O>8Z >)_,P;D=A\&M*.\%2M@WOX90C:6(:8Z2\C9[E".O#5<1BU3
MRW&*V$?I#K[CR1$9XE/),VE7*&XE_)J/9%-^LQV?$(^F[FIZ!41E/:6=(Y:.
M#(?R:L9Y3:WM8ZKU4*$"?HMF@-98=%$>&D0CGT$!"@RODHSQK&.!<V458Q(X
M)4"Q#*,[F@QT9J(UI!*3B8+:'.*Y%Q/^[" &G<=&!2H3GD('U\8&HL["7PE;
M7[TBUJW:-B[SB7NMM^45D3SJ;7&[?.0K:O=;V_KM[NDV;RU>I-RP9-^XD3_7
M.RP)&AD5'WUJS6JY8U-(N+_K;'W;'LZ)'6'^ZR8\I#I[-"@/:JG]H]M:P0H!
M5DNY"5JI'DJ624#;ITO8]4H<&$"GN$EQZ\8'J;M";'R'9K$KR48C'<VJ3*=L
M)?Y)1%!345QM\ @F6S9BYG:\#@! 5/./B69JS@35%%(\(>=-SMUJ8/?$=NWC
MA6<;CD">0IOXIG7BUJ7.-@8=;W)7O./.W+G/GD\I7KV_TC1 UGVB,[7$,.CO
MX)!W*Z;RU3, '%BS-:U?&M!['%H_ZIW9WQO<;2;0Z3G"W$2VWY9./ET949ZU
M[UA5R<N,XWTQT^<[9GP&JFU9OGM4FDW</I;I:>1EDEV9Z45V2^/KK."$U.VA
MYCM+R1^O_N-.\;ZV&.5>TPV,N$,XP*\3OX%" +7F;@"TZ8/HK5%R/#U4E]N'
MV0C]_5;G\;GP:#EOPP=W.<[<];.Q?\:3B'&KM"M1G$\D8?SF^)2,I:I/T,C<
MGZ!&?F8M=Y-R.V2JP-]CZ*+WR>!PLD1NE1$F5R\<X@@45TY^[6 %E-^NA7*$
MS;--#Q(5/+TB4_\<'-"1;%^FD9M2O,!.G2W2].WGN$;7W$KT)1*C+D1I%.5R
MC/+R7G:2B$3B^AMS@^\/WMYV9\VVD^D;S[N?S/ICX+BNQBG8BM/BK#192&1@
MXU*P%Z"JV5W #WQ5UW\9-?DO9?'ZW,*E*@?6_T[PBE:P'FII??,%3</31T_]
M" SXLH\7!5\[R36'CDBTT!J*[#2\OFHO.[L4X+5[!;@#[%0EBJH[627#W<M'
M&+"*:'X9_%#-EU"@PCB[+=3RM7->G6.I0JO5Y1"07)'VC)M^[0L>QK50.ZVN
MVF6Q8AC4(LM/YQJ0V>V,^LZI;[+6A':N=7./0ZIUCLI(-(VL&5]8AB53<+*6
M);=#("Z9%;7W-&O1OC+*LNQ+>654U5A01WXYT<1U]J^SB-(X(R#D@$--O^Y'
M\4>A9:N0)2"@#-KV;/R2$G'1/^MT6>;C[9D##WK2ZW.W^T?QZ(U:ON8(>-!8
MO&O3;=*&J\%C-Q;"_G1&ZPJW%.PXUV=Q^W))^L[<L"S4[>/;CTVLA!';,;]3
MWP>8KX>2GB@W0W& 1(#?2+6?+#9J!F>'DF-"@@\ 31DR!'VNX,G[?"$7!=+3
MOD_'=%N-G![R5X=T$X\B4@V9+C#)S*JR;,HQ?U!"C&\J^N+,GAZ6BN 4;"OH
MT0ITR3,961PGD-]&:^!E<=<%CJOE'V,!79#3LM5&N!W(37XQ0E3P,5;O.7[A
M<J1.I&H#^'\H>_.PI-+WCY]6,U,T4PL3*BO;E"FW,H0VL\:,RG)-F6I*D91I
MTB0]0N6".U--.NDHE:F9"YD+I0@IJ)_&#'<21Q"8R3W/*<4S"OBC_W[_?'_7
M]?.ZCG_H!3SG//=]O]\OGG.>^WBZTC#*G>(IN<[9UM!35-M?$?4;DMLME1TH
M>9LE6__%X=B1SU%I3KG#A\I?&?Y[ ;DC*3A[L^T/F0'W?EIK;.-ZM"LJ5/#P
M1-=,XRYO7[6WY_F'WCU3>TCG>K<AO!CT_E<B2<[K%4N]RA*V?D$8;T;XW04V
M:Y]$8S&:(Q"W&8O6[(!(3>)4_FI0D(2+TR9Q*'2S[_L-4)?2Q.<@A]3G-'U,
M; =O5;T,$&_+>JNPIWA"EJR706.!68]H=8Z'T87%X;ZYB>P3G2MH%?8_Y7Y6
M6E-HD=B0 UB[M/6JW"\G+GG10CZ?/_.-=\9SHUE-^>1OSXX_W_(RC?)TM*SL
MO7)%MU.MI.BUMTMP1-3"X;+W)9Z;<P\:.F]>U1BW]5'N^5IRAM%FAZKDK?U%
M__=]+?_9EC*:W/&VP8.T0N%9O;]=TX\23UE?6C@DAIAGX>#2(5T7>J\7)DL:
MVDI!KH#;6V/<*H8J.&J;HGSNG4D>\;FAKD\_B60TID9O!RJ<C1X[R3F#ZI]Z
M<![(J6J%'!U^=IQOJ'T%''HM'Y.>R6V_T,FSCUMP G;!RRK\3\;M>V^EKJFF
M&9SOGUF8"),>]*^U<0] ?99>U)(\$/1?-*;:#%X0.-U",OZ"NZ!@?7H9C%7\
MV:PD80"<-L=)8*@)AE-O%(]9Q88R:XT&QV;CAC"*RFJ+F7Z\G626NOIDA7?I
MA-M/M5W/P/Y'+RX&MLU2VQB)\\R6(3L%/[\DO#_P((Q1Y31-IUN="VG"3<27
M:)R@RCQEWM3VOP\=SIKSX5;%!9W\YX/IA_%O2^](WG0=PK#9&Q<15TYJR-#'
M181*?H_GO+ ?EER 8NY^7VU#P[;J^[ 71F1CJ=!8W>8$TXBM>$/(O7PD +S%
M7<%)X401S,>6G>YS(EF,^=(QCY)9I:-><?%W5:1/)2VQV>D++AW/[":'*L,9
MRSBZ[>%Z&R[$F +K\!;: B! B4S=?6D;.\,)RZ2O[YO=H<'J7?AK<D<)O-NO
M-Z?%KX<<J_?07YR-/M5.>4?3&"=>/$%^)"W7M?!=P)*$*+'Q$$WPSB^G2C>(
MWJA]&;T!<%4$<5;0PB7'7@6OGKL ,I)Y]N3ME;FD^Z7D'-\0=-V;WB_=-AO*
M2;[]M<;G#K:7B2MU!(U=-3P!$I4YS4;MG[N)(LSR"9E-3^VGK@*&\83DUCG7
M9)[/M9<7,O7EBW<4_5AI@[NW6C96-_5Q;XC@XBV6<JR6NAYN;\8J,.O']M*.
M2)KG?H ;_'OV5/!L5,N4E. ?/WM15X[_$I[C5Y\O23[]9QU_1];"J6X)L;[7
MJ;<V_K#= _]#!'? >P%!8[:PC1FAQ#7A<K.:F\I%Q"I8?E$B(%/-CCX=*LII
MY1AJ N"G3S2WM$\T%D5!1O=O%([I"S!_-TQH9E^BS+UEG0*CBV0/?FMQ#'06
M=/'MM'F1O"#EM+3=MQ?G3;WZC-XM7PH8@-=DN[UV7NO#_2#;T*5S#)NOY.[/
M]:^@9G_&IOE6?PILVWH,_^B7G+6[Q.;8OKXV&K>EA^8[TE371?-LQ>]"8Z',
MG,2K;\#LO"LO!FE'K#OL ON"6F3['LR=[PG2#^!A6'N1;-SWY$N29QD%95\>
M>+%KJ,/]E<$'#!*_3$-BM@BJ0S/I.VD/%;QY[COJ4LUYT+B/?2=*;CY(EJKS
M5!%(Q;6'3\=-75,BOU3^Q*_)>Q=;)"O;F%&G\RV]1+FVE>*57L8FP3Y@X5GX
M]O<.ML16U_K&@L((J%UEP-1M(_O>ZB2NF[?(R@2MA]N:-SAU'#EY,NOS>(2G
M(E['V=C_*>EZM-?^];?!#\3O\9_/L!)<SFN,4Y5D\??3K)O9U0997_"[1_EK
M:R!QDH!,2KC2-E5$*VQ"'0 _LE2897 #L=[;S[NV%["G/@OC;P4OJ-GX?(8K
M,ZKCBE=_C=?[V;!9E,Q1FXX+N,%8.$"1;<14YZ1?@[<-8S;27,_!-Z%EPTU=
M=,,.)1433E\O<2:FLTWH&)J7[YL>8(DJZ."0D5^W@OO AO8WS&A%#;VDU,?_
MD\/-%8Q.T21M\G0V6,A?/XXQ$R@PBXC$PDG\3IBLX$Q2IZB31%>=I9U(;J!Q
M6Z"J6>I(3O4"1K=6,,6JCD]:1-3@F[3LD4_:LJG^=YA--%>U+7P7G%-,"Z?A
M8[IM-'2/BM2,9<DWTEUH6%$W0&BHA4,KR(N(C;.,C6(5DED_+=3:DGHJ-01%
M_M$3$"];>AF.$9D'PT?/=0('XJ[>K SX1")+!55RO:I.0$@?>)N2E![B" =*
MN<U4Z19".CBZB$#JDSS3\4<N^"=F!7T'@"49M;R$$T2H6G5CY<4)AJF5Z"O%
M#Q7#+)\J?Z#R8'GG3SWIC>0W/;N#<VV6&\YBD+I.^0:ZDW=9P$4RVYR/ HQ
M^^3T=>85NIP8,"<0'GP9[CH78T(7._,YF!9O_.X=BJ7^F!]YY/<!3]J,(>RP
MI&4]WE$(+2*&B6F 01&MW1>F%&NVP0D*0JK4I/$ES:=%9PE*4F?%EK#UA9Y9
MEM$$ZEJU@K$6/G@!8F1M#@@4BE"A*4X"B[\#9 /^0^38D$)D7]09@W>Q;9,)
M*I;I][,O^>Z,-/:E&@">AEP5<ZWNC%87V;H^)Q8SD)J*-PMG&V/Q*)KM*5"@
MV8HJ;D3>C0JV5?@Q>812>0?G(ISN_[87\%1FNT@"'_%95R;E2)TY<+@*EI<#
MO\()%32W>*J(O82OU^R^&L+*@8E?R+[U\@3\%HTOE#%?D._"Q<W]2HYQ"V7-
M=+@YO[W:$#>U;WY,R>6^X7+3Q\+?]?$N*!H-+H!US I*[K6<<IK<M[&3M[DX
M9$A(C5-ZAWJ#NBIE@];Q^+WC =CIZQIGQ=3-BV^X=W#WR;G>VL$EQC493S %
MZ!W:NY718B;!9 ^A1F=!2U=BFPDL>8VD%;/& R(JZC6>\%DEPYC>);#2[= <
MZN=C:&W-?G/2^$EO=*:*C2P2I,W$M?368*S@XVU^KVO[G%*I-<&>L81/@R*_
M180!?0=MB\I;F\>WIK&4V R=V41=G6 IW\0#G!.BMM\%N6U\"^C!F-OGTA5"
M.*$MMZ#$(;-"3"X==ZGW*$AU>>.T8+/CL/'GIR]T*6</;71Y3(90A!3\[L:^
M68'A1<T/;T!]3;\$AB1<>AJ>+=O7HZ^1-SC<#"KO*$=<<9'L5G#_Q:"W0M19
M/AD59)2WTSX:4RMV@?]ACQ &T]4_0U93/F @82G-NNT7S0\P\RG\4BCB&T&:
MNGWC!L+7I%&]UMW!7>MLBH3$ZHH@!2L+N/GTT_\R7]L</5>3&_V#YW9\>D[;
MV4"X)P3,U\,G+J!XC(X!\3FJ/$&*9#X^$6,2N;DWFF@Z)@FQ?BTY_4+R%2X[
MS 6_46)U;!>6GB.8Y6%^Z:473]+5:EV\$LD*M&=F$*XU+A/>NH7_ 9R>VO8"
MSK9?UAI[K0$U5H=R2 <+122+*([I&"@L(7DH#V),/XW^$A!X.S Y9^,/>F.3
M>O/6J_3==Y#+M1S&Y11"&#619*BS!/"0AZ#Y$WT#Q91&/PA7.#CP>\"C(K8)
M<!*D*$N$7M'<!ZZI.!]0W.*:[6ME<BM@(C D]85EZF3W^>H%#UW;;\!IF#VL
MG[XU^NO]+C-.)#,#T4]!CC]HUR9/RM8GB@Y-2W_7,V$IV]3)/AYW>[A78Z!D
M&X2WE^;;^?7LF8T_>*Y+<[@\K+XR8V3![EPW?TI?#7:K;\/>T6#<.T=:W+D>
M_%HRZF.%TCU4)&UD-1&2W1C-K"72CE+>#Y_(ZL 5^?]J/Y;=+!SM#[R6>4.9
M?WET7#H_!@6+*<7-]C7MA"2Z*Z.)0-\,>-=K*YV&=HLP2R++!>%>WHR_X!((
MJ8@L5(JS2"9[:DE,-^J]ZWP;.(Z4XQN!U9EFHB>\WO# OMEGY!CZV@31_%!'
M-K.44@>-2YGCVG5+O@D2^8;!HP)KO(.&V.]L[^C3A=\!6,*&8"G/?9W5;O?R
M181A-#5+,O_OOT.BI,L%PA NW' EXNJZPW9WQOPJ;HC *RI2$@8D9OHH_#2;
M9$M>@Y+)B$K &8Y3VJ_UME:Z-"SL);OE3!F4 NZ@K(0:7P@?)/65](J3L3RR
M-H="561ZJ4R:7I("C^NVZ@7C",;BM/0!O=1/;_=,='JKHB2U"-(+UG<!-HI!
M3)+  /!=1*R996T81]OW6K?2-\,LJP2>L2KN4Q1Q>1#-UWM[3].\;[Z*$KP]
MGNH#/8]M?5HQ(#<BF1PM&I2.N_UFD+.(:/*PC^0(K@C2?7W=\OM3X^*BP>[N
M]H"J+&G0U)8O(\J1.\-U?7N4O+2X PXU_^4[3'6/&U84^)\-33[1;FO%7LX(
M8Z71[>"KR#8Y1H-IT",:6^F2 /UH[*J(N:LA/=-7 []TWIJYN1#$&\BF+0UW
MJ7),9M3E%$SWWMT:FY7TU"ZE<M8]QJ.G9E3C&?ILVPR*+<'O #G)FHBG0S"E
M1:JW<42D_/T5^R^9Y8%'XTN"O8K#+>LKV5O5U64MM@/COBXQ_9-_G?+S[?SP
M!ZTW<QZA>5"]B+@7"WC6,$]W(E/X2XCDI[H>W6IM82C,Q38/G29)EREO@^(I
MLZ= &-5$XPD5R2IHK\)_&,V-HYW$>16V_SJ?SV<J!E?-B$W@V*"I7=@@N'1A
MD^8H7 6U-2TBS)SSY /?3C#?R=?CK" [(6$]SQ&LOMBYB" W.C;I3/MGIB*I
MB525-6/=]X<,L6E[:OX#C)3!U^:/=T<3EH?GU,VAESP\GR:;91R>_L(77HF+
M^_<_P96:M_5?N=>_X<5&[?].2Q=<)P?UP?7Q5MT/]%.PT8)^IING!?"V*WJK
M::6QQ8!O%A$_8Q"ZO@*J9AMAD 1F,9IO$)A/]&&##-78UA/5 C5)K9Z&?W0=
M8T0L.,AASPB<IGG)O^3O9R(AD$E,P4;>A;@%?)B^?!MKHI7L=0*1('$18>0L
M7@[\ A<JO$,/0?B[18 ]S"KGIF%GX@1&@VW*@];39A>'WBL])-&8U6-S]<=9
MBH/YYV[73!2@M;_QMP!XD/7.F*20L#36H5#AL"'<\SQ #A<*8_NKP+DV_!)8
MH10JV9:TW4&O>YSSS45N3A,O1OE+^VM8YF.2F&IR8%MBKJ$>[$_V4RN(H\YZ
M4%3I[?6 D9+:$K%,U9:BVTG3ER8)9CU]'TQ0L(01&S2;%8TQ/\+QH$HA;M9[
MH' T[E7GGBM]T?E!(ORV_FA]U:(EB'(Y*0 1D/J_)=?8[&H[VE->LSWO[+RC
MTK,IWZ^-L &_#CCU&MK;N4>'UKC#4\-E;R8?7) 4?%/^@S'Y23_0M=\H4JE8
M\1GT[FMRW?N_D+@RE]03:6=B.2S&.H+B!& $=T$E"TC=6@9\GF#(MP7.Z&>"
MLD!<L-*MQ<"'<)AR&F<!N1"Z0/#5O=?UZ]XO&*C9:M\2-;(FOFP!/_?7@E/!
MXY+@140866VE(SU4#^X.$NQF//XWOGC5YZ^:CE+!-6V#>OMD:/@(8ME7@<)@
MT@ R4&@7$9-O34I*Z1^ED3D+^VB?">LNPDS]9:CP$\K-Z*Y_8Y(+<'!,G%*<
M(MO9YYSO^W6PQ:V7_T->2\&V5VD3%^L@NS1.Y6R<]K;UJ5?<AEGB.ETK?Q?T
MF;G@K]D$$=,TEO+E@C".Q;A@'>#.B% ,'5E$* GW=';!'N#'A:-O^J*T(5]4
M[V1V^H0%_(9W\@ZC']VX:C31_XU<O[UX2QWS[!N!=M6S.WA3?0C;PR6*.9&[
M42L?"V(G28J[BF"#@)X*[/>6N+_1,"VZ+9)9VJ8>5BI&-%]7]H($6S8;;PI7
MWZ3Y'<FYZ)9+2QZ7+8@XH9<V6@WE3 4L'*2Q5!7RIOR;PCF,B7,R[*'*]&NU
M(JS1.<*4LU!H,PO]OA0..@]^SH_AC,5&_+-O$&8U6=4GTK>"UZKP[(K!,>GO
M?KN<1B._1#A'.$Y(=RS[.B]76\!%%/";DL!T8J0QD+@-*HPU_=,B8O4B@F)L
M% )2A==Z<)N''P,&"N2]7&=QXG7<\NB]U%+RJW"VD8.J.BW^<G\$XY@@92+P
M44'5;48<YDT08 B+(4^EJY"Z0=<MVP$37\#4X1D^MA_ #&.2T.NA2/95)7(C
MW-:$D@N#V.MI@HL0(V7VX!^34=1E-&[K_/'48>WNT](<V8Z' ;V ]POOY^2Z
M]^I,?6J\D;_VG%H2 [H-JG&]? ? \:WV\3#8R&S.8ZWU'":9MT#B<[!121$_
MB[WFBYT^(GGP%LQ:&6WU$!TS3EIWY?6#DY,A*M$O-)0D)!\E[^5Y@]:J6TQH
MMPJ3CE\%'(-O*_*7J69S$FRAZ^A]8&1#N=Y[?Q$H""OMA*T0]<[V+HUG,1DU
M.$0+(H*J0-H54;:+KR_J<^)<]_B<VJVF/I@M=;[KFL9S-4B+6D0L]ZXDWZ<)
M+WRWK!6N0F+,Z@E7F36H^[X]NNQMQ$]!XKQ3W;7$M3"]>7[*5$B-+A_K_-]?
M<V=7(F#24>WO_#T 'B8OF) )2-Y5\,N$$C.9"<IZ%-EEA(PHUMJ.8?%ZLJO
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M42/-5I;U?5I=9H6*-8!5"EHZ;-5I$%.DYV<#+[@6:F\2&.!1<(Q09_U&,DM
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M\LKJLK% _-,2>.3HHUG'F'FN!P)8\9S^5X$K3,*^(Z:05E[G(^!0I6<S=AE
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MAO A+?M;$TJ64(&+W8C>W5<Y1?+JG6D?*PZ;C)PNZ8QTCL#X:)>5DW$'%&/
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M 6OXK")N$9%*7PHGRBRU3W4.@8/ QE?:USB_0AI'Y=?,6A-6L+F[ALUTU1,
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MD0U-!?OIWIRQN#;<"J!>E(ES'O6MJ2>#Z&, *L][FM4_@'RP+U&P437I)K[
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M-G"Q=X7I?YM\P;P2V3+6P7&=(A6;O0+W(TP$^5>Q'B!5+9.6!6M0A5A734:
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M4=HTA"?7A?70DS!Y7N[$E;0\@FW$GV\C7HY'NSQMZ$K9]#+<8J2,:O'PY;W
M(XL :4$%3:0JGERDVQ94#1^'1* %P]=H)2VH-CP2-JY.C3$>DR0&;X"=*<!H
M,U!2G!WP*8<[#>,!SA'* >\"C,%Z.KN180=XI1U^WE\I)NO+8K<0'>AK0.ID
M.(A68UJ1BL)#I;(+"PA;F*)A+B*7?,N#PW2_CC81)Q8026YYV-A[\2.;(:<4
MG=<8*E,]G5W9P&OJ-:RFI1*> L.%TB@?Z6M.U/<N9?!I_MFOW_9,MQCLA7TP
MACM"8QYXT0_;.W"05U/"'U;<U(EOD$.M26D-:?[BS3?;O)U]5SWD.BS;[=]
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MQM&-AY_I?H5_%T$]:OG5<D\HBPK^J-6&72L4$U;0BE]9C9^5J8V:(#1MX\H
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MITFAJ(+[HR6)U?Y]#6Q%O^/AJH[:^/Z2>R.[*\<.*;+_+"JNDN]"E_H&9=5
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M3U'\!8^&YK_0C*.XQE!V5)H/1XRUJ/@8<VS1 ZK\&?ZV\+/F/;-1Q-^)TR6
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M&ZA#7%\GDRUH%QGZ3:EXH5,O@UZXD7/RS? "8[T58[B$B&J@G!T1?!C_]=2
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MU8(R._? _^MY_?_V7]Z02P/_!E!+ P04    "  QC%I:IL?]XHU9 P#=:@0
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M@885.')'LP8P79\_.B7WUH9_I:M=BY"\65SJ)V#<G:^^)C#)+C-79P2QGO_
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MNX:1],T.6VYU79M?"7@8R/U>>G+"B@X1(V@5O7P5Z$J)X*02J>ZIYD(=?S?
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M%#C9"Q\)#/-\$IZW;\YI*'Q!+4AC?^TTEG"MOP!'_GQ_8H,Y<C*>4X.X0]#
MPX 5OG>U5V"S'M@D*.URK>^S2 X6+8#N$EC<A>;^@CZ*4_V1X"6B<G<9^@4N
M^\+=JQE89XIX_7KU.JO:65+3T!K1+.$3!O!&)DVH@G-3IB/IRU:@C&D'(FE"
M7N#V9M+.OUU7;\ 6S:,-X3'<;F$:HMW+/:Y9&Z>+-8YV2W4<-@ZY,>C5Q-KI
MW=T8E8*[[6*WO;'Y7_=V! TCTHAKT7)@M:/5\#"6$1Y1^JGG1=!#C.1C9I[5
MZ4'*B^;^\EFMCN9\]PXMER>T&%JV.^M6EB"P#Q4E,_JOAE6%V!F'YB);.8GL
M;_?Q[I/DQ.8-0&*R+;%B')?:E:\/V;R$Q1B$M^!6;>3>-XW#MJB*$:^C,17C
M+C;.$4:LE<W7>9[52KMSW/$<9?PM< ?WH$8'1M->#1>0E083R+4CY:?;Z?_\
M./8\R+JC9GR?DUYGDX_>K;/':F"(OQ$ B@$:_HVH6TFB8N*(ZK9Z7$XB1]N\
M9_U4>XZ11(/>F-X"F57S/ O^%+.@/[SI+ZCP/?I%1XMWM08=G"YS8\5_3U,O
M>-D2&:KT.'H3L>ZQR$YDF=N"V03IQ#?YND@Y"SA\5E>F6?S2CP+T<.*6#(W1
M;9A/F"W\[T940Q<E*<PE_QLZ&_4ZL6/U0=XF2U<[BO)H[J%;^J=2Q:UGY7[Z
M"'_U>(BM2Z3P&&&P <['1 )=+2399A7<<9[C&ZX>%ZZ$/0LN7!*8)MCO!5$M
M^>K ]?LTR;ZAG0++VNKIU>42_:S R_Z21V5Y(="<. %(<BM[-1+ 7,G&!:@+
M#HI+J';1/N)4HA^?B 8O%KI$JU57/!?M%#AUZA"NT?SV-:PDZ[U^ Z3,G>]0
MR8(K!MRV&BTPNS2ZZV-]\!0=T],[ E^^ OCSPZ#%C)@2)=&)YJ%@6Y6; M,I
M>(K();#$[&@,.3!?A6G!]Q-9Z:RZ;&)?L!Y[Y7 U^H575A.U)N/SIR>F7@J-
MQ 5XJRX<(-^Q/5  &KZ5Z/33=W$1FV:8J^A$D157;#]ZJI\28SE\J\6_;&;Y
M9D=H\,9--1Y3ZS[[/^X^^?W#&E$+X9T4!OBFIU@C.U#(>PP:^@[%%#X3:<T&
MHR\()(G<\:LM]KO!R)=C/D:ZH>DB[1=CXT?#BCQ0.[M>.I>R ZSKTJYE^+Z[
M6M6SV9NQ='A+S26'+0!J6Y^+%FI3O_6[+34G"Z:R]BJ_=MZ6U-+?]]AOQ]\/
MCY*_9$N43,1Y>,.2%L![^7F?>:JB:7OS#M82/!ZA8EIU67D,5WBB#^,+Z!80
MOSQ^$,W7. .5<_+B"],O:0LFYC/FT1L,+'/L_CY ^.62=Q%VS3+4&)/YI%K_
M).K<5#G6&AE/)<-\SWRF\$:YM%31\4F?=28^^4X94Q*5/!F'#,_B,'V^ 6FW
M[C&8W,]?MNEY$V60,?DB1[V &+8N+RTA'MBYO/SCZXD$-G. R?=_\Z;^Z?OB
MLT<WA1J]/BS_J,A,>8W%2F]7+VCLWT5*):E&I-\C BZA=[W('2<I>_-M(*R;
M0;D.@OWP4FZ Z;I:K/TVX$R"<1' BO^<=_&R )Y&&(*T_KIO_>$;!@YC?S(D
M"G<+2)M_2>GLMF.?/1'*H.DD,\%T$S) /='-\\:Z=S35M_[*VNGFK;L3>T9J
M>])O"<1_2MYS7I-;33\)N2;)$ FJQZLED/RV:-CK"70^G+5*QD?PT+5=:O_Q
M++/<,66EX?'<BQ]_^-1I.3R,.S5@7+DXZAT=#I/X$1#0YT*>*@1^![-Y'H\0
M^HET*</F?RP'\XA*01RE)<P]A#HESR3*+T[H?[RNR3KD41C-KWWF<@4NV#CB
MJ5''XVI:04+.O\C*]$2DLJVA //6?A/X=#+8Q8(DAQ.V69NFTBU>%#[IF4@C
MSP!!;JHN,I(?S)D_ZD\N&'U3N.D7GNEUJ3BL;:<I#RG:I@'XMQ*,Q(_P2,&#
M&'NFZ3;\;C"9.ZIC=NGD%>\9D?%49'U_!!GN<O.+9DE-]D5KW9HMQCNKFCX^
M65#G4"]53I @";=5$%+&"P4-OB6:]SC.1I?3X8+C/.0]2HT-G71]4+]ID.Z5
M]:JV4476G;"/?J"0?[+M2?_:<GV9Y;_^9Q]@^WTN\/^=,/S745P 44LA SB'
M! W*^%&"ZC:>?T*U_2Y)K^0@^(+'C^1>SQ9L=FZ*:\O R5U@AD8@%#[AS<!'
MA>UII1.!A&W6A.SRZ<@!W(-!Y_K:QHRI-C<:2]7GGS7B2RS!B!0F)R/Y@-A@
M#\>? X\*<KD?'Y?AT!AP#I%>*%A(,$_%W0C/<_(&G$0[%A!I1I0Y/U2TG9-'
M:@?23V#HW26K%2\N*:T6H%Y"A/^%Q50AMKPC*CU(^=DCW <RD2JRKKK9&NWB
MC3YJQ?:^BS%1]!V*/W9^#7YMFO#Y^HCN%;0%G=1=]5?HJ*%$(49X)J ACWR/
M!\W+.-M#61+M!Q!74H89W OXS4 XZ]C*>?K04L7,5JR]R7"V%<M-T*/;Q.L>
MQ:)<;%P&PXTMV8K;9%9?0B;($VQKEUA#?Q (W1,[!#'CP\OU!$1O0=.7Q2J[
M\8_97-/-<Y+-P")K,SWCG6T&+OK$P),>HS3S$554LN8=2:#$_N2C7^YW<?>C
M 0LD=65^=*O_'\_IKT1&*?KKDM9]?CQPB%7QS_L4A?UR0A70 6AK0ZRS5Q?9
M@0Z3]7YQK0Q%.N(YSNR8AE%ZE$5BXN)HC+7A^#&/ ?/Z(:J,#";(?:>YE?N*
MAL:F@A(+T1WH@P+MMXK.B_,8DP6W_?G^OVRCKP.7I!&$W$#8B3/L1(P,CN&N
M<'BF;8J&;:NG)[8-A?!&9:U;+^'TT +9!OSKT1YB65#LUZ'W5YL"8$B*M60/
M<G(26F76&L/OX8JO?-V[+C%9(@-J"5V>379L'Z0[3:5I?9?UN][^\))'5$9G
MBX[;U[T;H\(<%U;3 8C?U@+P#@8"KP2Z%Q)Z\JU2.QEJA!V0R8[F;0@180O;
MN N;QG"][=;NB>2(/"7>H,.P1>B6XR6H\G<QZW.C2W"7%Y[3E+O+/6HI_4*&
M2!V[#!.8\I.!N#9?).A4TO$2?P/<$Y&;9MHF^'>_+RALT1I@NY!!K_=16OJY
M/H,ABW,^H:W+-#/YTH=S.1<+4\6W5(\@+TD0( TE6+DC4INJ4N(QYQP$I'OT
MP[RFG5_?Q8V,!>;OZ)]?BM:LVJ:JQ49YU^=OSGSRGN6#Z23-ZT D^4RP,']Y
M<EH*N\YA>W,QJ;;^7&1BFGT:U[/RGJX6F <L3XQ_B01\:<]Q&1QTG/?@C>_7
M#$L53T'RB8FWD7M:UCC+OCU3YX6F288XP)_K:P3HM^ZD3<AKQ'L3YH!_FFV8
MADCO-6ZN4W7&*SV9DD0-/=B*,EV+<VUSQ1ZXA,N1PGH3%$V]Z$.E,=:>^D+U
MN)OE%H_%3^0@RR!C@-!B3#;*>0/XK(:L[ @A!G]1$$(JG_F>Z8'!8=XV)-Z/
M8#&?U]_;6DP;HB"5J(MFL6Y1)KRVVO<E#"_DY)3=>LG/90_0F*>-^Y+1=AP4
MA%XNWSID_F=SXZ3I5KMG/Z>^GOAIGAP\<,R68<G5NPXW.M5';/EU5S.78"G.
MW\XB!G+2"3IO $9[KR8813\ S+W-H:\U#FLA* U=IS0SJ0NJGWH0>45@67N&
MYZ=/(S.FGX.\U..5"M:_3(XDCP6R_>?0_#:AZ0RI3F/^G<!LTF7\2W5F!9A^
MACHDTB1/'!MH>8Z;:J,]G-/5&C+X,?SM06?T*&8^SX__Z/N9N!>SCXZD&Z44
MRWR&@SNZ4BC(7V=.#A'@ :L7/YC-ZJX3F':0%' Y6R=V9W1[T<$\'DG;>W3,
MZ$;OMG1N[]8 C:!:V8=M89M?/LG9'<K:)U&#W/PH8OEOJ/F/X*^ D+C@T5I]
MT.> CV^(F_*MP8L\FS<BJUOLNB?9EEKH=((N6.PQR[[1A_%>HS)\HY*:K@1V
MG8A]=^6-\XW%)K>VQ4Q>KVA;8/!+7" E=.3;<AASD*=4LT7=.J1*8'JIMGG
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M%/QBAMT!6:]L/-NDJJQX>3N"1A3 R^8A=W*4F$X"_Z0?EL(^J$6[S_^$=C1
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M):4-0K-^9DGNXEI %KN-!5HG@:"JB4'55V2_[ -20-<UJ\'<#'T**+C8H%*
M5WQH";9]E*KUI:E8.SKTP+8U0\+A&83(? L\CEAS_IQ-8/6U1JFXW.P/M@M<
MWF^ O/#:S67Q^\>:F[:W ^:<$X.\;>QU1P; E*LC-!GB.H9^ _W.@)LV1.5Q
MH#4 T^O^3"SBHM7S'$<2# F:;A'#'+W-[TH&@LH]D-8.KQNS&.IWGHT$/_)\
MZYOKUVJ4IK"4BGF!95DXZ"@8AIT9(/N]\;B[J:)J+?*-^H[4@79V740&];NJ
M3(@-Q&I-)9TQ*\753]74.MDW19F6=HXM3X1N91V9.\LT_C.':!:[S:K:41HH
M-VI1]T@JY)B6I 5I)VDK=H)AM%AK%9&J*FF[8QE-UP F0(XQ_!]Z^+OF.S5A
MO)HFEM/F[ BX9'UQ+M7?C1YNUF;K%\$L64$&6G\$,Z-8/1=,(2%9.>^)XC9V
MYBOSV!A=G#D,$49)4['=)Q@VTR#O15CRT'>N*TO6(BNS3?'>51[.[BOOJCH+
MRI PPXCJ.1'5KYGX#1W;V;EYD<WAAD]N<^^$W]IBNOM9L;\XYET(?$ $0GJ-
M=3E;W1\R]).-S&*.O##=VJ(V3H\;[YQ/,G/#AVC:\ >_'#Y)5]_JHLEA&8+B
M2]B-KW0C6C(^&])0]Y2RLQTZBN*H6\WQ//NS_1HYTG>@;SNW,!'^'!K&U#_K
M;\!Y+F [K#6&2$FZ1"K:2,W^09Q;);A PZ(6#^W\8RSV\Q^)?YXF7.U&(RR"
M-V3+5PB6SP,*1;MHY\@%YK)GB)93FI;6CM2<Z&=MZPVP;+WO*>CADVRWD?><
MO_C,!6+IAUAR-W&O(I1GUFY;E>;EGYMOAZ0O-CUX@3I%BR]Y=SMSU;%9BI]0
M/-ZN@'57.$UV@P@A7?'6$\43,@DF(=5]6&>9:?X5I]O3LYA&ZS<\\9!&5OXG
MBC'X:<5EDB8]A><(8I.;)T^H5CY;G5I7U83P^^MH#"C.K.4>+9802RO2-Y'A
M,^-PA5Q"E'MXNEHS_)!KVVA6//P9<Q-G:JZ"^9D2[VI6(3R95[QX^JRYO^7<
M^]Z#D:)Y0G,M+/G)F/AQBR?MNNC>A[/6";X-;80MYSHUE"A9?"**Z/[P$+T
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M-\<I140@B^..G4H]'2=RXY*$39^ E^WY8B/[-$T'0Z/CSP!'+%A=FVL8A]O
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MWHM9%Y?(*I)7K%_+#]2*HWQO6K< =UF2_*%#O0L"E.;44%@7-W(([\J6C+J
M%@QJ5./WW[W;4>RIF%\UOW*O%C>?^L;6[)HF]P%=P9]3!71N9M^N<856[;D_
MB6U=2S/"Y7H;C@:D3 DWY+Y].[4C=ELN+L85/MB8,N[N+-OXL[Z7\$[I"GOZ
MJKG\P8[2@K(B6)"W%RS(QP?*>7<[^^Y#(S@,%L07D\01@71@!>_#PVGR8]<$
MCC@ #CC*O[@/^F$= V9?IKY F>:P(O$=^K1,97#AA4?=GF(8,1FJ:[+(LK5
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MM(!Z5VM."X';T$6:?]V3RQ7*K??FE#.S"XW""SX'E8;6REF,-M(MI0T)H7M
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MR5K9O9Q.W6_'W^T5EZ%0.8YMR<$_;0FNM/#%-B4A)$7TVE<*\T5%[\-AB2J
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M5PH)R,406L)P_TC3[EEL=UF2P!YZ[./"[>2*3%EC>^3K4N9AG1#R]%'/G7V
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M.&G1?;.XSGA2P6FZZV1@^F;-NA?TYK%C/)HCO8Y38X%'(ZJ?GFYZP/V[-/6
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M!:$E>YUW\C_D*TU[$G)KE;FESKM7L^E.[,8=8F=O 0[D0P9 %@,BW^NH1[U
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M<"O/J1$<%R98S<?.<:'"1#:N5=>/:G9F!L&A4]3R47WPH)R']&)-0XS^"7Q
M"N#>'9BFN$*1<T]V]UQ3/5Z6N5:X%E90?L<JD:R.M##Y]J4.156%\VDA($NA
MBM;_]-7ZMF4?3"KE^L4&>95]=_WL.&=59H5$]<TFL0"8+-,#T*6974,+,.\
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MQM:;+P9=:V$H$76!F E[^O]4+_\_=0.&P@)ZVGB[F\ZS!F;<P)%)G,I,_GP
MWPFO[NTRX\$<ND%7#RL-#L)39P:O_^S5?EQ)SB)TM]K4/T3NP+CG)&L27B!+
MI%2.B1P>_AW(, )Z%\W6]B4'AP8=_./0&^Q].OX=Y&G.$>89<$2K]]R!3^X?
M]QT7WRX/#X!PFC#($AWRT?M*9"(+O=)MTDI,\)0U3?T1=8AP95+)G('/EU\M
M;!!P'OR")?::Z<R0PTW.U\Z_'XZ6@Z9]!,H1=(W(2CMO6YWN=_7CEN^RP8![
MQ2NB[%S#I*9H-I&_8&#LNV:?5$/FH9V>DMF5=(\<I4SAW=C8Y-T75'+'F9:6
M("2ZTCY!:&[H<H%^4U:VW4==SD N@RAAY3<T,-\C2,3N\/OYLQ@493ZZ JI)
M1UD!#ZE7^-^[7/YT[_GW=$@7U_!)YZEOXA=:JXR=K]F,]B(2)RW3!<>VI*(N
M3.$]Y\N"$]'=01#@7$ '7OS[)$QJKXB$Q),AB\(]6;Z3N);%?C3?-QL'K.:F
MRN>JL0JF*V58;'7RI:/3E:Z#)I9=$.[9BC #M3:) '/.HQL$029YWVLJ8I%T
MXK;[7BO<"P+(3':919 ;NMB@<-P1VE(Y%1)NN]L]N/8I_7#ZW6S!R5K;$:4-
MY0VS\$<D 4"VQ^T6G2>,4%E9.ZO957\KZ]+.8.F<M\O._E(%[Q7#U)'92GLY
M>%?$='&7*@"GDM9T*^P=@.<]&IJ3VB[EE'TW@1(_'][AH$Z((Q3_3D^-=">L
MY#NWTL5;7 6>A(:%4J++@T2D1$.I70<83YHGXG:3TU6\R2@4[[E$9SGTFJ-%
M[ G#BX&*-XN^G^J4>A#F]?220:*GFYRV-9,)Y+.X?^_EY *.^^*-4[@;'B.$
MK]4-2_$K_T82J$/SVW$K6 %/7W*55*K['!_3-2; K[6-CYH0BKP7N[2=-*^O
M^* =&NL4 GX@:+IFY)]4Q!H_S98*Z2#&B1:RFNA!V[YTERS*%83S1)$J$&U+
MJVP2*A4.CX^L+$@T](?S?B,WA+5:YGJ+UJ2F[_9U&N3<2MVP3MQE_3JTC=N7
M%B&H\M*\^OKZ*,-U9=F$\R&<Y_42[8M2]>RH41?&LPW/IO *OGYU0:;\^VYJ
M5KEC]* RJ]^BUA/3/9'CS_&UZ9'6(_Z9#U*Z'U^>O>%N^/X@*6W?Z6!L>Q T
M1P1Y;)$PV943P5*E%?\P9D!1;P'T>]8!&JPJW9 >EONP9&4B6^13(3_9.UV]
MIY3@  3=HMM&;LWT.QN;C]S;J(6? + SCB[<%OT9>_4DM[:'K&." ;29[=Z]
M"-AY[-4QJ )Z,4NU R'0?@9H0; ^?ZP[K:ZUOO&KQ%^]IG847P\5(<BD^5/V
M''KM'?<<C<:)CYP=KX\3B**7:]_QK/1$46#"V*LC.$6F*A!(-^[,Z UG26$D
M.]IU1FQL]=.O*'0WGXUK<Q48R#F?K8 "J)D7#KCK.QV\J Y%4_>$*3LA3,3B
M/-\_$W/B-/W0+39(>'62\U1;>S2%(+]A/RYC+MDMXE5QKSCA9J+>BY+/WYIN
M'V@)QKL5.?0'E;HX(+=OW?M9N5%YOK8N?"#A?/Q@8]9B%%S%7C)2LW%>,D_9
M/EG8898\[]@=Z/80'8B\'V*@3/"(H\[=E7I*-^."6IP_]_3? 17.84%F/>L#
MOL8LB@U:J(%) 1D,!]RT.)0^V_"^3;97._PYCAM[FH:(R-$?42L:(Q#4N0"J
M(P&V.S>F._*KS<UXM'#\48D24Y<Z?RK+XZ?5.$%R=&+R5B<P2YOI(M%NPLGA
M"YI=Q&=LT"EF ('U 2&J/OD1)HO5H<<1Q(D<+T?7?]72;VHJN*,*D6G:,0Y'
MJK#Z-#8(8:+![=W!!NF//R+8K+!!AJB2K?L\*^0:SXG:($=&L/RRS9A/G7&M
MO9+:],::*ZE)'\DK/C=D:$.]&Q!F91.G<6+$X$UBS-$O\TPAR>U!^N0/ @.&
M<>QD@XY I&J #_O)3-=/S)GW#K,1<<'Z5T>4%!<:Z9H16%AAIB%Q8U_:Y'K5
M1!0XGHD_%>L@(ME:56V/0],"F*>$%WQ)M)XYQB*QVRPF6WJO &I8V%V!Z:>Z
MO%X\8SP(-Z9WC^>F4M1:E#QOM+;2CR04S;?>&@XBKJB@M#>GVSYKDH_.6$S\
M>VCW2!X)!%^(!]>">W).,AWW\O$+V?A:S2@BUH<Z/#VQ;-D.!%-]'-;W_W?+
MC([L,W1ITHNZ/3EUI>M(]!;/2?1XJR01D-?I2628CJIG,$2D1?WK7[L5X]B@
MCP=T!6[]'?\[#L&?X=T;9,1[\ F.H21/"4QQ-STLGL%OEJ5;F:%Q<HRP(E^M
MZV6U.7&1*_8F,\].*2]%^6@'$$GU/ "8=-JU*]/Y(S?;!?^]F!;=XV']V_O.
M6['JS(OVOL>3O1=KG#HJ7.7,^S=_:"B(V%S*S-7MX4\.K@@/?U@I.X!TMS_I
M'#GP=MS?JHK6BKS^77LJ:M0O/RSWR&@65M?H41[9%%F;TX[2GDB@S&ILV$WZ
M*UR1-7X;T^^/Q_N=K:N]H'6F("%9^/%YB<@ 0[68MS?C)>5SAG.BV:!Z]=D-
M<BTXE/>#JW= )SP&0GC7WNA4?6E$[?MX:+)OXZ7Y^7R7M0=WJJNRU;+;;P&Q
M=$3/O$ =I $@6@<2J GS9B,$S1FO9KO;MD(VL+O/!Z8>7YD=2!,>+1)"O1:T
M.NYR /!9!$<^J1J%2N8/XB5.#Z[]7.*&_!.E]R['G.3W9:;H4/7-$VD!!S4=
MC8,BA=WQD>)76",\@M![0WBJ\)YHM:DDI8)XN<M,H6,IT$.T'M(UI)ABZK7I
M;O5@OL(X[.+X[4)UL>HB66VKTHJ;/^^U9[X]?0%_FV;VE*G^'C#;BN\2\SAT
ML8LB5V'R#TRF 'E_V[[?<S R6W*ZHJ? .1][O?CY4E)(QV1BL3U]LJ$A/66V
MFY4?\! ?'*!@YA\8"&W0M%6]W-]_I6M@<U RV_[+8X\KAL02V"E6W]PEX-FV
M,ZIKWHN&?_%E6M[8_X#H>OD!\KOOZ8]68(.'_\4'E'H??RN(6:ZK_20AQ5/%
M.H7K=^$&'BOYYYRJ$(?0'P5).[8TJN8C54%G1$TS-+ZF>N6L>P>L2@]],23<
M'GO5ZKFBO0?Y-LFXZ.E0R1\'2YSZ0/437-&_6$BIM'TU5+!B70I!R?D5\U+D
MFR;*+7P?$%/NVA4/RAY_%;/M:Q=S\/?\*5Q"P@OY+W/BHU;?.Y1?-(;S7]/5
MN^14ZBX2;"?-V2V5&]DS-N)L^5[!LL)/_##@O\ &A>T:?6/QCJS]FCI]OJ59
M<NA3G=S+4\KJ"K\/-#:_%'H0,7"NX>0(N?.P5LSCK6%,>?<</TTY-)@:?P;(
MZ9P[29M($\FPI M'U1$T.\E"69R'7Z/K@EV6ALUJ8T"&B52J.H@_FQNGQ_H(
MI[E  %FS=T5M8[6D*.WB7@2_@V(^@V?!]\6<0A72JOJJ?IR_(XD'>Z6I/M7Z
M]N9W<?GQXC!!U0Q]/D>E7L:-#BA_>+]**RD,D V[X#XM8WG]-+3E H59F<TC
MWW__XX2:%X7V".EZ,3DI*6DTTZE@6>:KQOSFD<"N1Y(N[>Y=EP?$(8*:#NT*
M*CT/J6_5Q>-\K8OEMY8+$Z,R#.T5]/JW35]+)72>Z5<H,+\9*Y5HT)?0*RKG
M&?#XO#GO-0^/\];7I)XJ "5[;_ +2QODH]UZ&\9[F;!CF*,4\5=+!G?HFO$;
M&SA9S+O>&-U -S>T<"A6-O]STL\K1?E%0/OLT7]E7K)HN+-,W%X+_!X/.7(]
M:;%AC9L.Z4VW_D* SO%G. <??8=2T(&_1M,8'?1OV9QU"<8^ADJUG%EN5A$7
M8WEMMRJ(':;GNS>'+Q%?])7J/-2SW%V2DR6GBAL]'WM$]T-..P;A?%X#Y2]=
M+^>FC70OI0C^=C\=;'F"O&'3&MP\67&_VD1FHVX_%(&WG^]+Z;?[B3F<#?(@
MKG%!P+B1=JX)IGGQ[P3#A?@PU7XZO/O.-E1H#.T#%18G%&.>,)#S7X$:JX_G
MK6?:_55N2C&U_CPB^W9&BS5;R.I'U#R:5*JWKJ(3>V/]?"CV1W[%%@)^"PK?
MW;.%=&1XV" NC2'G-QW;_PXNR6Z>%WM@(J'+!ZWN6Q7SZZG8-)2LLKJIRY$U
M&V%MS?$Z L2'^F6V';Q_A:;[5W@5CC1W#5[@F>[M:=8,@W08@V/;9:[Q=/(<
MKTM:]LUW"UBT5]OW:*>FUL41KRG.FB[)[0M557%NX#G75JV%UK!DO\MSD%5H
M<W-3MDHV%^>71.#"6)8X6MY?P;;E<6VM?B<5>GWQQ&9%U;2&\,IGLGS@8S[,
M@*UB[<ZJ5:P[>/>W:<I)*Z(_*IU4>Y0IN,HZ+LC0#Z[N[P'7(J*QTI0,TB4X
MY21@<!NP?2-=T/A34;F8]@0Y)S%9D?F\&2R VOU^^Q_W@6OF> W/[*#2I::F
M=,?HC,B[V51JH#AR.=M3Q5AM]%\'0_=4/<]$?8^ QXI=;V5(A/CI'18WKNVE
MW4I.G>::)$?9>BR1*4@#WT2]=I PG[T#Q"_.<$J$W&^A>/5V*OR;>EW:N-3\
MH"$CE@';G[%S^REC]GQ-^-0&]#Q#!V/9S9*IW2P05P&:JYF6D^3U4X<#MJLP
MC?/ PVMM3K[\&,35CR'MSN:(I>((.G\(!I=<-:TL>,=A;-K=3A[SCVHB&Y23
MLM(3DK.'+3;C?;SQ>,8K=U]6B7B.2T8.^9GQ! <7>49G0_CRUO">>LGE#[S2
MUE>L<N\F5E?K_V9A.?:B2"@>,HYZNOT0%@2\IHOV!4)S $,UTLG/4QB9.;3F
MATTB,ZCR+.2]P]VPJPOZ):O;%3<M&SF4EKW8H/O[>A30\-Q.HR=4C<.]_H0N
M'MAQ)#_G4A-MXP5AO5T>LW1. )JJF>/92)L/J?V=F71P'LF2IZM=O(AD?7A0
MDF"R5W?ML%#5#9\_YX1,T/4YVEIY"RY>.WQ!,NKTG1A%/UT![U(QK[*(*,&K
MMSB,$4?3,4U=I]N]W!NQ,M8F:^K@2FH^&^2'ZM'",VM- F#SBK1BB8[].[#K
M3HU1U.>/#W:S1=B@S_(J*<$,:CHJ%R#^QQ(<W%^"+#;HT&!8/A4.PD0O;D3^
M2+],JH>I8<),' T81EF;+VB0L#6F^D)YR]$[?#H07J_L\QB*E:%R\<M^-1)Q
M[@0-$@(3\Q+*%@ "%^:/ SP=VR(,GC"F"&5-LF.7(]5":WA:+?CD4*]IPX"?
MKLBF3]*7.'5&R1M_*]OEP+B'Z4MCRP,U8A[JQ9@*W2<I<N_9H+%F4Y>^Q'FC
M^U'CWTMW@!/Y"GV4#VFW+[Y21QE^S.4T1;&RK8W)5D^4O$W-="N?Z0K8IC\Y
M_]_(DXZ&,?%_:B7_^5,K.?RG5G)0 /L__ 6$_1\+*C'H_U)V^9\\*L^?!S*'
MQX&9Q7@RC^%>(]Z5#8JLQW/#D5?D^XW#N]*5WSXFXUXO&JHIB<-YIKP='I?[
M(<N1EU8T741JQY@*!(QC%]D1T.E*U\VJ0<PB1WM+N#V[H6?9(([0O7RX!T+8
M"\Q%6BC"5R^UT,@F1OYO&X#N!1.87[Z+[B%.977$C].56QO<0 >71^*96%\V
MB+(<4Q!TX47.;5K6P)BCW>3WH:1]UL6]R'66%%8/,*2:Q67S ^Z+&Z%SZG3(
M,ZQ9 =:V)9ZR%KV2+32N_"AC=5"RBW4^<;+C27;&0W_4Y;=>ZN]+H/+$A\7[
M:L:&.;[O\H9PT_-O=[J(TSS.@/0"/!)_$J:#=:+/1S*Y_&BKIH!SY;<<OC,=
M3^+BJ8,:;) 576FHB1(4Z_C/Q_5UZ!5T!6 Z:>;X:W++@WZ=/(.L^?Y@)4#C
M#?CC_N+HOP$Z.W?!T5"E?<F_'_-;C0N^[VZ$;PW*+^D,JMJ-U*'LB+6S1AWK
M0EZ5BAL^LF'4.:^IB@2#"A[U=]B'P QM=?L18+L(CL$+JD]!X0LD#J3%BG9H
M?PJJA9'$(.C<&%FS']DZ&^#8CE$;E#2+B%0F5DI<'^E=,LJYA/NWO@;W+YQF
M9O9\>3MJ'$\YB=Z/0$?.3\(DARL2%%G\==>"B+!G#P6CAG8<XL-_;!"PZB=S
M;C<$V*:'9MH(7=]<L6O=Z)0&?M-F6,<_,'1Y!%AC;) X2P WA*^:?\<&\4;'
M'\2>HF_TP,-9A^GS/=PXJ;TY M498DV_$E8J$+"M\HR JKJ^^SBTP,5D@7AH
MWFG5-EN![M-X=))$TV>#7I!X<2I,][T\^$(Q_/2C0.B5$M9'A[@6RO"+;/$F
M0[(!E,>/@$Q[$D=$2G?HC7Y+%9H3HTT^:U4J4>%JTYOLW-W[')4:\-ARW@]<
M:S6&0M#NA_](<"V5,S81ID@G:[N9U(T:^$#/TQ>[7M8:RU@?W1Z<'3"L/6(_
M4A"_4R"Z5P+X,\Q8O<UKRZ&LTTR9_<OP&$2;HU ('D!UW]=V;D233OB;7#<V
M47Y'R(ZF$+DP 5V:PA;7BK^GWG3\ONL>+4U(*0_TDSJ510IG@VBVE]6)T\]9
MQX\R>'!S?,CFV/E.PFDO$@_4)Z"8//A(T;(3)DL7+R;:UX2>ZBX'TB@[\<RK
MV6=K Y/6-@&$.8;:73A6=?17.6+ D\G7SK"F3:[E[!MZ0-+5NH1[M0@^IGY[
M;<ATMM;B^"-$U+R@8^?$VU"X8AAD[7"#S_L1M^#B5'4&8C%^9F<;3H-T<-]8
M])GO98-"=^>?K_TZYC\H/].9K4IC$:D(O@'%T96QSEV>,)^M0X193.JF(>''
M4+1Z2MM2QL-+H@-/[ME,)LZP//9=ZO%V04R:#1#(,,%-N,#&?!4A)!0\JJ&!
M[!PZ\+!;<#ZL%5X"E%N,J[<<R]17K!<=CH;Z4Z^<]9ASN$%Q57.WT0T$7<0O
M?"XWX-^V *9QA;"QAXSK" >C@V_\.-(ZXT$FOO;A&\=%(.OU"F>C;H9>')3!
M_6FM/C]S#<[D1R]B:VXF&GI68B6;ZAZ+7#2=%V(*>XWV!%VN;VY\D8TSS P@
M#N(!R3_E/L=QG?NFB4>!IQ#;472/!-JD91T0*DY<4$+W[$S,G?[H/VMV-6[G
MYJ?P[:'*;>U'D$7XL>(0IOG"9+:QE_K@)67NY,3/3M^W)\7G]^>\8J^4!69:
M <8+\5,U"[)1O\#1>!&<)O,6S9JP$\8\5#Z%*7P4>\9@'#=>9+<RV:PT^)40
MUT0 WF.UTQ\G0<.^/YJY8FO1&C4ZIR/G^PYNAE](5YD?9!QD?2"6*A1V,(5H
M,>:1QQ3OG:OU4BOB:)K:=7J,/O7M;;4\\XU-,5, 8=XVR@:Y\I"I2^_%#;\"
M''19TP2W.Q6*=7CN>:1V="*GCN38AF]!PA,U[Y5WI>>V4K6+.^%3EMMZM-=
M/-5C#":&&R(=PQZE* 5UT;\WQQ6JCV("C#^VGO$)/)E62';V%M9L/S>1/GX^
MA L!,#\E#6Z>XS,4EM:,@^W'U??7\7>&(W? AUMU98@4>!R8"R;/U/JXY6QF
M\NG1F39(ET-<>"5PW6#+1,>R(61]-!CLE"#ULM;2P:E3(,"F>F[*Z8;B._#%
M?=#)M7/U^ZN)9HJD2X09[_L+K&-+,[F$,PLF!]2_OQF*\\#7V#N^''7O$#!G
MU%V%W6:#GL<JO4%/*RP,SMP,6^(A0PSKP^[ , O- )(NXQB1O&U84%,7</K+
M>W Q-)YY:F:[;E]*@9^[:.V]9&D"I&N .=V6 NF:%QS, ]!4\5*WA>];W,(.
M+4]7'<YFK$X*F9M1\=P8,IA/G^"%DEBY19Z?&A8L&+E68NS3MW_!UBPYC.3V
MSMX;-N@N<4IVX6AT[7!$C1E=#:BA#D=!>8)\J%<.=0BID/4+U3X0D!9SR+2T
M; &:3V\L4Y=Z82'1ZU<7JZ\ZT;+$R=E^YJD[_OVM]2UG]/9^O I1]W*1B#+(
MRW"A2<^]F90=N%8&A/>2#OY@7A,HU?QW]'JS>VZC"F3CT)LT>1!X;!P/!=,0
M9N$N2K3]]Y+<P>3P=P[W:G09ZEB3YKI/$^1CRPTC%+K2Y'/_>$[OW;34"B6U
M(# O$U;[,7UM3EH[/K*V10,ITUS/M?MV 3'#V+Y.GWP_"%G$PL$X82\87S-M
MJ[VE?!H([YD#CV$-*4&I-:B,^9.K[6?2?_OWX_GL!KD'7XXLCGUM^[0<BM /
MOQ6R,N3XE*=W^%FDGQL;=)0'-V:SZW1$1X<8I@DICPB05VJ;[-AXKIU<TW?D
MQK&ML;L;+5\U^<OC7UT@?I<G92$ J:\I.VLZC >XF7U/>>MML7<Z_BG4I&2.
M*0\X*I=Z2M>@M'VVBRF,X=I3,Q-7S#JS_Z1B2EO&F*5$A: <(9-[L><;9.#?
MROZSB&>YU8SJK-/QQ'%5-.]S79X9=PN772*R8<@HEW/SIL:7L[TX_=S*L-=2
M?GTMTK%2_SROOVGK%!>..JBB(^9W55Q]7QC-OP?_['=B@]YQX5FF^2QA4@A\
M.;6)#7HJQ 8QLUS:ML] ?O_<5VWO,"0@"M;IS@;!'I, 'N%]([XJ?N,OX"_@
M+^ OX"_@+^ OX"_@+^ OX"_@+^ OX"_@+^ OX"_@+^ OX"_@+^ OX"_@+^ O
MX"_@?PL RGY*HJ:-D"XAY_DX1-#:^G"-JN !ZZM2B5=!?*9R&HD^M8DF];.)
MQC8S3Z12?VA.;<(!%Q8G&Y3ML,P".;)!F_X>WJ3:\$X?OG&B^N6Z:"^KL[D_
M? 9JM$0V%R(0Z/0;T[R&AY9\RKAXY  2PQK0[(![?V0><"L$:KH,EVXHE]R)
M9:H7#A2FD/ G>R<J)<^!Y7OL?N!N.YI[QJ[%+\M&89VI<-&5,11.9EQ9W>3Z
MO:>;/^*X,)L&#=6USR1JJ^LM#!V#[.Y$7/*4=WX=__OMK_2]_#DQC/Y>;D>V
ML.+1R+ES(]N-WE.9,!G+!9Q8MQX]<>"GD[3!\)6>6UG)FQ5QS?DB>G5BO@_3
MJ"6M:FS0FU8=VE$X-=[U-5V2V-DD\-O[>N;WPDP/@:STW7;1"H?W%IGH_LB>
M:Q^*CXUTV!;#O=K3@3:&(Z:\)V3Y)DUE%H!W6OA&&7>G6':1"V1%?E:NS8X9
MA-+#ZL<\ J=\[?U%<E/>(!($[Z9?C2 J5FL=+Q/YDO!Y 73$?O85#225]#F=
MS@:)L$;@-3D=J]$1+$6F/Q! VU(T]-$;98.L,A#T?RY4?EOU7( ?<T2UJW]:
MAHB]S"-[F?B<?<<[-SNMYW#W-ZF;1$. IQT7;@H_P?]XSX "PXN>,1.7E<RZ
MX3$!S9Z=:X=-;\77 T&=HG<PI"X^)$];OH:F"D;5]K5(XC;+/4PF#3#N8(/R
MPL<4ME_X^8*[3*^4=XD@#MN4[,6+T7V/5#HGN&[VU4E>7H!>IJ17]]]_M7)<
M#HY*:Q4RMR'(IZB>H+9[#I[07Q5S7!0.F==G5A9=2[WSH'EZ5HOU4Z+O+6_W
MDF67GI(\\UI,OIB-1*A^M5W$>%>/2HR7JVN8TR<VR!EVFBE+6_OZV2&G:V;0
MI=,HIB+AF[92*[IT?B'L6'"0XDAOT<S%=Y@%PXT"O4?SQ7WETL%^5!)Y9_N?
MO0PH! 6.A;I3T"]@HB%R4E4-])/Y;S"8N92.OFV-!G*70U@#7N$"7X87L8ZK
M5 \QF"1#"D?\V4(>R@9Q' =^;Z^>P4>E![P'GYBK2&"#.B[3P->BWU5W5(H<
MZEX,BHY%49U4(UZ5JQ-C?0C]K-]*>0EN<K_UJ3R\0'AW<]MR!-2:B(+)3-:)
M_$,.:Z!R6S#LQS>6KGBT?JH364<K%U[YDNWY\/,D@_[K_EY.^^D]\0<8"L:3
M*RPWZTX5+3^+[J&<!5V,4:W-E-:VRYPCB$F?:#@JUZ%J[V(>FI_2\XAB8^<]
ME8W]APT:9H/X<,F7Y\6H7[5KWYZ.4;K<9P=MMQ8_)/N^S2)+4? R5>%.V8/Z
M]IKHBK<FAMVF:J-%I*;Y.!+M@?X/$]KZF7[(<Y8@4$AG=%U,<T0JJI7CPUV.
M)AJ,/]?WIZ*%1*#Z0A[38@^_SQT87W./,=%V$K#CF*3*_L?N=!'<+$(PE/6:
MECY)6?ZQ3%D-2U!:HJ6&@V.Q#^H357U#?G9G:T=;C@S,F?,26*$+PR?G;LX4
M-:0>:VV(IF<LL$$_MN@SV\\F3CZGW: <[4)'D0L>]')_@AVFA351M=0FDGT-
MU:/W-(:"N$7GT4.3#H3QK KDSP\J1'6&_7]4?3;"ZW>Z#[F78MTG6&*L(1=P
MIMZ.4/,2 =R%$.\],2 B74]K"%$NIHT)AC]*<O0FG5)SG)+R\OE:9V_R;RVK
M-OX$\+##T$PE^V21Q#&=I:G0F"X3J:S%M&M!EW\%%(?X.*-0X)AV23I7E&.8
M\PEW;7Y?C;ZJC6/AT4\<['ZW8] HL].IZS,U]#-44J]9+/ALW01=LR<^:OY4
MNSRJ)2OO4VLP=2V@6Y6L0/^"7*U .'<7D26>B6DX8!]/O+Q9>N)4+Y_\2?[.
M.5$Z.+HNR(P'L+PZP30C>O-Q5JB9\2!MR1/$(+ESG&MJLQI<&?VOCYT['"9\
MQ^#T$JF%./V3Q3VX%]HN&/S<$J@+H'-MQ](%&PV5)>@>#9 0[/$=\Z<6*+-C
M@*B/IAWOL:.OMK678Z&Z[EI<@ETJ[^[&F9%Y0O$@W!$F]PB<(@9HTIY3B!U[
M @4H]?!G6&'*QHG>)R/+]W:3TTU"*\A9,WS#2DNY2N.?1U7[U88E:\#PBW2T
MQ+O.E=\RCHC3I94.ON9ASL^C&+ A:(J"%N&WN'CLMHG+*ND Q28@-J=AZ*'H
M:7W-07,]RX%+#X*MOGPUC4J:-K$E^'QVKM@W7_A"#I.7L4T&.K;3'(J?_II_
MC@,W75)%(83]]6E[Y)O=#K>@DH4.J&R-J!6M#+F3A90UE6/2$D(M$16#/&OH
M_]R<S;F7")6_5X<@ZRPBNHG13V)<93(ZQ4$?U7+"8*=4<K92;7=VM-.BF/;E
MY M2TA,9I1C8BO[Q):V7:I ][[VP?A9V#4\3A[ DXJNF\<-91-:A;C:HRW8Y
ML#B2:?WJY_4XF3A;/5N784A!KL4L)+)BU38FS=X\ZPRI.B61P:SI]#W=_]O3
MD=M6E7 &A@VVU0Y8O7=%4.]%/EG=U;HP/^DS<QTX1)/=/KJ7EE^'?H:H*7X!
M/58VW?.RD]K8*HTD8NCYNK?X\!$PN4]UI#.S,K<N&V?AK%12DXFO?O2N_@]Q
M]LG.U#W2\M D&W2 R@91+S"XTYB_R6S0 A3!U,6*2PI&]EBG8%TDVN5KV^6G
MHL85QM. ,NOD(I9/#CJ\T[4J.45,63Q,- 8G:O?$ZMMH?*&V7XQ-_]U 'B8$
M?Q@_K/20#0(IL4&_M>/_6Y]\V_?_*P'T%_"_)J MC$Q17B.LYYV0; I1B.A\
M*B8U4A%Q^N!5GPI-D,'1<_P3K_\ON63U_WE.]FG021#H/N@L!TCI_Z:AU/_$
MOF3@>#:(9DV<"J+H=Q.G28OZ71L'< .[\'B2]Z%BX Z<<Q5WA+;V&7QJ*]B(
MT=,N/.I_UF@->DDIAJ74/(I5]R^=,]IE:K?<*)PR* C.GN:]DK$-9H-"<+C!
MG)KA3G!(NW(U<)1REF>QNW@_*SHXO&@F@B('S[4M&D,BA''\(S,]#?5I<S(M
MXT6T]EP_(AZIN#UW5M2D+L3D8;'=#'E*AYPS4G;AT',@E];[;EZ$!09J*)Y=
M@T<@ AB>7M&;N\)1:L?0_E?4_:^H4!*^//765EK/*+<SJM85JYI#-FP'U(_I
MBTWL\!I%+?XDL<3*]]W> !N4[\T&#?S9QKN_O 1<T?XL9,.Y\ O)I"K9]_@(
M%P&@E#:Y(. B3I\/4;?;(G&M)F'_ 7J)16EEG0)O;SQ1B^=C7I]0T_EPVSYK
M07C79_2&5MR2E'&$:PIL!,B@-5#F>] <JXB3[?* YE7Z1@CTVO'.<@RZ*QVK
M'9;U\&M5XAQ5_65@_9/0Y/?*C]9,^QQ]]$U;XA1:N,J#7N6G!)$O'-JLV5<B
M(0K[T5KK%X1W!HCC>3JVPHT,DMZJCZS$Z@))%8"?E(I:PC6_ F]QA>RS1GV?
M7T:ZE[5MM8[D%?X(N%V_\8E;6'>D]7(!LOEH>&V6ZK6/M:@S/JKZ(VJ.7,X0
M@]%',Q=2N:[ 3<;NW0D9ZND9/6S@0U!RC>*4T(V[,")P82SO*0RZ5TBZC9_6
MV6YJJ1IOUV9*CF)-J#[*9)VS\!YMEWP"8-9-M].%9(AG/20"CN:CZ+I@#8DQ
M0GT6H;W0W6V[I:GB7%U3UG(%9+J7=:R7<8;5ASN?U ,_PN)&.MC&&IEQDV):
M=<M1<^ITF32. =P_M&_:\='J5Q L7@J48VU=YF/>6*7O6E$V>3UP(641?G_?
M[(/HCA2SSHTX, _4G%9,+0Y;:T70V*">QY>^MTO3UF8G\MU.%B(YOM;G^^8Q
M#%K'MHSEUH@_"! EWU^,5>-^5#G&,P3S)=;.%7L<X*&5;Z, 9"[V/'")XL4$
M+T!.?BCYC"1?7W%HK]%Q\=X96WE2N+=.J)SW?E*?&Q@<_%!MTS@@Z$+DB<>I
MY6@W'Q\?'N+(5?!1W,?]&^B?C:GR[5SZW6P84$=S,VVECP\GJ\.%,0@GNFR(
M>I:_ZXOW(G1^P-)FM&*+D1)QC<_;H:UPB2 FE%J?@.CUY&R /6.HXSISJB=_
MQ(J_V7<P[?Q>[;P3ZAC8AW),Y?J&-5TSQI]+]4+FE"$UGA^Q0AZL3]VLL/A0
M@-RQ>6)5<PT-K3>#\OY+LANY>CI;FC8<CG5_@Q(7H#\.+<#D=(J?&UM_1 CH
M)+.RD.7?FGM>!XI$K9I]^M4/%->TUS3&1IF@'YY(,"@^442ZN+[OSZ(0-%,N
M$J\A50C@#0 E_H;,7Z\%TNC:,YWM=U("GJE]8SJ)GA$IM$GX<;LQ:OQP/!HM
MIA&B\VC/-N^IUK[S8\)H\(YASF_M!P$TY<JA]^(G:&MOJD>@ZI0LE4F#437@
MD%K\E^GI7@&/H,ALXXS^TD.S".=^]=DO8[,FBL2I_]^/TOX[_AO'CJ/C6))8
M&.#\Q@D@4CWC6L_2?G9LW\X@\6&6N\B0%[\4?,J<?N^VMP6YNO(>YW)=%UC@
MX[ ZKYT8<U[$]('WI1<27^4,?^0+9/C\,M3XD)S/V?<PV96SZ*N<^NENI<\%
M9$-E0HMD=1Z)%^\%!K1X6,=6:59SR'9>>G@TW O"-W,L3S2@ \S]0?F9(/7N
MS0:<!AW+$J9][8YY<7"2)=Q$-TL3^9SZ4VLSGE*\QKVOOI19XRY7C-=DMX,
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MZ7-VF>HR>>'9GZQ1@J! <R.>ESLQ(,8.^YH"!;"%IXE-HXU-:0M<J <0>W*
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MI>2:Z.[GQZC/T-5HA]*)NI4:#Z;76ZD\*NWS-ENKR W73I5#QCCTSI1>MD_
MDG.NYPO:,,+]_0N-*Y#=UH)DWQ!YB(4PRN@]%M(O90DXE?6[B\0)#))3.-*E
M0LB]G;9LEEWOQ(:MRVN=^,[HR+ZQ:SI$Z3KO\>_MKK4V9#-FF'Y^T]S8TI3,
MT=3<E$:K:A=D/Y^?0F]ED\!M9:M&D3P1^0F* 7::A(9X+DC[[T1VZL^.]XR7
M*@T(?/6,U(TMFPQ.,G$HFH*\[K25(AU,J$Y=%_HY:&(!=YS^6])T8IO+@1;
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MM)*J/N==<L$3]-7"8F6!8_P[:].KWK1,4::X_)+JO1W#B:D.N4#=]P/"!%+
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M$%P6Q,T<!%D4GMDR0=:\E] @;:HR7T9D.OA*N1ICSZA?<=,/%# P_TW4U@6
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M$YQ6H41TO8@'J"_7/[AC/KJ^9J-=(<=07>$P=@$0NSFG?Y)[>M\"9TSG9M^
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MJ!OK;LHWX@,JX@:M5^Y_K68ROVY!,>^!2,#QT'4IX?8\SUOPP.O^:BVHE@N
M-=3JWGAWV9_C8HPUK;'*Z8$CV1A,@68[MQHEYQ:YG82(M8>7Y+KX%;0NY&P=
M;6(6Q;QYA+90'Q&]"^1E%VZAK\-GJ/D.C%&U7]OG6=$@2]>1@N25-]L4$I_-
MQH[ W^UTWDA^4^7=LHQZ6OJR/M*[,@;;D"Q;7E*V/2Q$&T$E]PK][\ K<'<E
MH@\:^^O1H2D.[G' <UW!^.:6XUYL13Z^6"3,<RCZ %1TNVE&ZZ')+]QL+.8)
MR)D@+8YLP)'&JU,-7O:MYX"77F3SL BN+Z#LELT.*,S)<>'W%G9]^-#GMZ>_
M<C-O.=@9M#FU76F5G8*LC%.Y 0-?7>?5_P@X::TY$R;Y35$H$;54C 2NY0;6
M0?YM!]%B?<I0$4?#/^FRZSX/F7:BG(40?Y-Q;,-8#U)>N%K -+&*G1W^P] *
MFN02RF]ZG/H9[C,5AD&IL[QR]5G6G;IAY12;?+C[=[*<7=ZLQ\.,6;*G2^0Z
MFO=)CM34#L5-GFJ-QVHT1^!HGCN!ZLN88B#)R9.=@3T8?UPE5F[>6.#XR$>L
M)FPRW";%RCNI1(2; 2K8FK72'F/WXLTK_ 3'@###E2NK:1;3;QZQ4=R-_#IW
MR&(.:1Z3-T_2J-H\5DKB4T@XG5S:E6RK>J;MSYD@SV0*_5F]\6X(:Z]YQBO%
MWC,)$UP-AKQJ6125I_=S!,IO[%"__8%4&U;)"3%5#'.HVVY9![N_.C5S<7'-
MQ8<S=Y\+OZ5=JF?)&3-!/_E8L(P-PG:?-#>=P[V-C69;"KE(8WR6TX?MTIU?
MIA"[M>#@Q[N+/J*&!8.QBN,F:AV29S;5) :B=NVN_/*M+H'V@QX[,>XYO<)A
M6AJ94UN;+^,A&5WML&B?^7]%UD\KMI/Q^B:B/LUB5IINBH+Z<T=R@&Q:O?(:
MN2KVR,^82GKS-PEM#JBX#9[&G"%2"FH.JH'FN=7D^=777!@T$4^$R/H\^S6H
MR*Q,8V2$.7!KG@QN+JH+2[FS*?F)^#F4<XYOHJ':\\'0UDFP4_2!&81#JS3'
MVZDL]%FKFH(,*@7%&ACV80(GGU!HQF%E,KTV>PG'ZE$SYS]>_Z-@/CC3MW*U
M)E5W$O4,F&S[PKAEZR5S9W.$5@WV3.'?5W+!J&/>;Y^OP2J<M!:^QIS4_!HS
M.V;'!_:B/H(@. ?0FV"XEXWGRT]FR(B^216@']TPH-QJ[;.:[(N>FC-:8BO7
M!>![D2)^_7W$9</O7B_EL-F]\$:Z$*>[#^Z^>"L0H_-X8E6B9'E'$C_AR#5&
M,D"O/+P T"JX#&S?]\D9S<"N?9:T-V.?"73<DS,4XX@I&)>H(;\\!1%NO25)
M ,T09B%O\77V8D%A>RD5V6T:#CN)=F#S>OVR\!_G0E&"Q\NO#KG^>06:V*XS
M>_RM7^Y;>L0N5\@3L;97@^J,T:(ZHDMIERW#J?(]9KLX<,D*1:R;2';+^JK"
M'^OKJUIN)OL,ZKZ],!'&QQ< 62]4(\_@F'+(?* /ASVUL9)5G,RO/U>0ZQ:S
M/+K/55U>-RM^_R2N!SGPL5J!#^RP*H-A2@2;?Z]U9;,;#M8Q"-'J-W>8+@U6
MOM=U%Z?7DG_XHQU.D"QN[NQ7"XE_#F>05*!5&Q 7QH?2O'7=7]//[;H 4/5-
MB\Q9ZA<.*>8EGW3/ZXYHGT8>OL1Q/2>!@5,(,]=L@H,>T\SQ!<"I)M?H=LA+
M\,W\EUY9J9-A(L>M1+XJ)KO4VUM*TJ@KL@X4EI^<'U_W#%SPT;LVOIKSPE+V
MYEH!73Y94(\X@<^WQ<A< .**;H?X9\9LV'^<V@7'.#,OF&3/8A.JFZ3B$N\E
M-5#DD?2G90JM=#.&9V3&- QS!&!UZN/KXX:C?W)<T?ZMVOY)*4?%CK.&9U9=
M+X:]PXP322#\;_DB;CTFK#X%^H=LGH-=GNRBP9YTOUGE[(]V5P&.FMZ25)9#
MUY5:>Y5ZBZ*-[Q8FCK<L&K?[Z>K'J15 *KK:<W?N7P#>GK]^MK<=Q-I%5CV>
M/.5<'6]JCUD7/1C*I>APCQP,Y=%#@B=:6F9F"D;]W0-4:G\]SU@PY+_#>^VV
MI4XNE\Y=;M;G5[:NAV"L!I83;.]:3*GR0ON6^ $"G=ZG66,?7EU-;@VQNH-)
M$JZ.X/UL0?/U"AB)W]MYB1U9&N>T6<D.RK$=J>>+A8Y2% ;LO)CJ<[/AUM@^
MQ11\;/%Q?5E_"@M7^]64&BL]JM!/&7=N[;*?]UT_V+0F=M#E!0I=.402W'5@
M(IZ5A<]< #AEQFHD$GR"/#)V!ZI_V8IVN<;3^7NZNK^XCUM\VN[VN+K2XI'9
MWZ2UWM6SL)I:HEG?R[SZ*]X2.S["[A3NHOM@+[_8NZIZ=A]<W\1]4N<G+\3"
MO;2_12H>>\N$\_IEEKF:VNQ1FPR:5H@QYN70NI$T+ .G.I.R6,=-K )+!#_W
M2/ <0@@<5&-'D&W1;R)M9&/IP@>Z@99?_-I8JU1K"@>4S\:\+@!&E8C(0-1"
MB7J.Q^PYC]>L-FOPY%&GBAD_Q8&PP[P'D;8WW(P7PTK:?0PY+)0X'B1*PI$[
M.8[\7U\/KL\$"F9J24=,D!,#:CF%3E(^;7@H7&\ [OY0/L2<"OMK-YV/$9"1
M^/H2/9&XBER_')$<W1[AT7U7H[F9L4&1FM:*@542#T%"?/UTB'*]Y04$7JD-
MS'-<O@1J,//:SW2?8]6J#R@956EX[Q.UE<)EBF>^903P#@>VV]L.&5T(XEA1
MD;XD:8EN;10B3JKY'S8#%GY9U2M:$ R/(Z_2LOGRW<K_>X]$*E'QI E>>CX"
M;WH+8-'GX8)!9X9%.X,I(3%+UZ99/'\8-(P*HBNNJXL> YH^7 ">^ T!UPM<
M7O>Y=<EK97MFK&YJT$>,^Q$+0/L%CNP?3&/XJ-X*IP*3W@LUKYI1*6WI+LFK
ML8P3B_FQF)F&]E8YA6?!W*85=A*/J\RX]&I]"X6_>_EE&:CHU\C&F=?-E)QN
M(A(N !YPHA!BV^1,-*QU;A6\PX0_Z"_B;3BP7.UE5RV32 Z_.R0#%];P7P%?
M?X0@EA@=K)'1\K;U.4Y.ZZ+E=FTER/9TGA7IX[@+0$15^-)R,Z&GB9AQIDE<
MZN_[,V@.OTI2ZDC%%D>RC]A? - =%P!=O*G'/C%E'+1&F0@!/0IH$U$9;>0%
M3WB1783QSXVSRT/RA>HX&^9=5=T7$76X)^G>;MD,>J=5-MXGY9ZX;2L9J6=U
MHT&<6BYF62_)5L#[F*W\ 4W,7()/&3GU_)L:/F#N52"B=9.G<6+[!$'LV;&T
MKNOR(518(/'UL4Q]S.9M2+Q\5'U+G;OM5+DR?](2%-7'@@/5SOI]]BN. C=K
MDYBUSZG9SG3(/4-H.(_L1&P14P\_SW424^(Y4W@BXRU)L8*.GLB'A$&$BX*R
M>S.!);'EK8"ZRU/))MY]X/SR.573F=_Y]/*33J+BF1+LGYDN^<KM4#@7-,,X
M\1,<^+,5DF=78\Q&Q(11_C.3OJ2V-.KS?FDK+_)!BG+H@XVB)39X",H=3I0#
M#G3$?@^"8TJ.XR9ABKZCC,@B2B)/J3[":XPSW^%=!HXR:;MY4<*@&VDP(&4'
MO8-N-526C#BU=K)J/X740#U[40/GX]E2V>?S70N2%LQC)OJW\5,^-GHR>+QM
MZ^2Z^QC9!>TKCFP\_YK"4+XT((H K/QQG.F@N7,]M$7X;?S.TT/M_<2@H*"P
MH(#0T "5M;6?!PX.BXN& @,S,S/H9)D_\O)WI$=!!R-[HE-_LY6DE9ND&<*K
MR,4H)SCFX+@L[SN,DES<PT?\8]"1>Q?,U/M!+G9%H>P%J"$G7(T@DR<?4<=E
M+2T3HG1H*NH_>G\L35GBS\(9"-[+ U\IN@ T/?G8C<_9/L,B.*#EPRYJ^#R2
M\R)!&\U@/X <G1:K)1GEJ#)^17RMM]SH6V+_:L/:=-<473Q)_/]W<M'J=1YQ
M2)US>M^@/,BV(X5/*J_LVFQ\[7UVTP+<40O!_&D6@G'!Y,]SU,W?^MGE 7GJ
M>;[[_6OXH/M3,Q4):"W)I.SQ[U[5?YKSK. #<]M[%X ;0R0?@OQWV52,]VI.
M9#B+9_V_<ZI HF?%#Y(&(4#S5?G('\?IU%C8@_>.$-$+@.>4U>!LA(PF]:3!
MI:P@+Y$++P K<<5XHXGYG];@?KPM3U*1<*-.)!2Q.K!/^C?[A8OK&P,8KTIY
M,1ZSY)KU;YJQ]TJE+ZZOLOUNP.F<9KAW'F&9<9WT#>W6TG H #]^1GG&)&[5
MQ?]K?[:&1_C(J_C#&HR^7]%8M-(UTWLV&8617-[)>I%5IU#]8[I*W_#79(6/
M3Z?T89V@WM? !3$>C2D9,H?.U#M]!S6]R=JZYAVYOEG)N)W:VF>K,;.S-X>H
M:.FUV5.8-&'^9_[AGY8!:I#EF& 44%5VTS:K_/V[)=6*%7A<SYT,HRE2Z(J/
M%D3(\0+@O/4R);\:8USJ;?*(#A$G0V<T>* _PYN ^:GA7;O9H5I73D9HPL99
MV!(^X:I<_-XFM,$<V,[T+#;'!DL%ZY;E'9]B\K)6%=JUO$PRC'\1% S$Y>G,
M*!/>Z_4P-ZL4ZC'=+3-Z/#F:XSHRZ><USJ!GXJ4K>V"\77@F0&(B)_;<^@6^
MKDH)#6J&TVT^@[0D>YN$ADXP7:K:''I-YA+<,MOOA[;SR7;@Z7\EM2:X6LH+
M*VP>>9;\R@O/_?#=VG-V6=]$4XN/'LSB6"]XQ[(,IOEBI,YKYNF&:9ENYXA9
M1J</:M_VWJ_')=$E^G0Q94;1U+>3E<P]-=4+E?PMDYQ82]/U27^H1V9;QGCZ
M\UQGFQ!>P;9:.:YLZ>MGC]M2,$L"YTQ2.B/LNK<8A,P"FW0L%=)^NIJM@%E0
MGL772)(LMH:1%0E=8&YB2G+%^(<)@P):BKHM8?Z4F3<_6Y([?GA=?Z7[H3E%
MLPW\!1Z'8KH,=MIFYU\)CG7\>$T^E9A4[XX%S<D9)*#5\LK\M=>L@W]RZ/SA
M4D[N'5D6ZA> XF+=8@PE%OP:C.&4[)OJ)V;@'(#>L47:62Y\YPC\L;A\Y 7
MY@##/5L@R?HRP7&.;U2U*?=,S[3?92WCS!::\0<,!-'A'&6.V5*>5OM= (#&
MV1\&G:O4$"Z;RFI$HU[C;*-"G84,COACJ*^-<":S1+;Y1$V/Q/GWN9P+@-?7
M<,:A^\5N(?WRB7M/%BKMWW-8_^J _4Y6E6.;#X6EPBPB-3TK)MA'PAF[NKNF
M?7<ECFAJ\G__;G<,K1D=7FOO:"_2$N.?8[D,13+UZ*9AOJ:/BOQYVR0*_-0@
M_(ZL21E46SN/G):Q@]QW6]:=XG,Y[S29YH*]O;$X_N9!^NX*7UU=\SY=UJD[
M/O+8'N_>7]SX6PD?.W NGOBT*NR%KUJC3%5F+'@[6<YARRWZTWR5XPG2[IM;
M2ZJQ**%X?S46I'AJ$_YU7+QLP-XD%_<01!,],%.A'W?@Q5K0U+_+_F'K.<Z/
MDZW_L+PH*->L@L?)TEH^?L"R2B]*(56M?\3\(_!4X^$$21(O*))MDXW=G!WW
M,DTJR\&Z&]\I6K^SUJUTTJJD]]T E+^14%TUF>2JZ$ID*Q/V7EV.XFFL2"3!
MCQV\!]0\\/!H_GEA%;1R$-GVQO774X$G<\QO=  +E5Y"E:8Z&\W-J+B"\!PH
M!W8C2I734Z0$JJV%G!(;'^QH XQ5>DG?'<+(<IR$V#N,Z#J_7QY^)9F"$>*E
M83]NMCI3.0P^Y84^.O3[9%K3=V)\O/'7;(IS*I48D45K?-O90<>.7D-43P+8
M/^^@JRA1Z>H?K3=M(>0&_3+>PHH#_BP"$8P3H.==);G.X169ZA6J''R?1@+Q
M,B?@=I &!./R4;(Q?)EAC=5P&%OEA)4W$/J0<%ZN)O>_QPOQ?UQ \JL7 %)\
MASLY:19^ZC7K4?+_J;^C6*&\K!>3D^:*3[V^U?RHZ0\'P#_G5UU*RK$7%X#R
M.O;ND?\C7?W?9 _)1LP_TPJ?6+[ND@=.XN%4I2>)W]9<[W)4(R9B>:CL&S.7
MV?L]Z[>.Y:VD#<HTN[N[I":>;Z<M#/&G)&!,2RR[9I1DJBVKQ*HFHZH-3[6H
MADEIA;;-E;W3=::%PMXO9@H\>U^.^&C"YK>GK5;W_GJ/;_S'>[P(PY.2L\QP
M9!<4["."A;PB.>$>W77 7N/FO=1TP-Z,YOJDN(_0W!%2NL&]".LR^%\/<#5\
MH%6?@]I8[ IR&T&X,S#0-1W[UST\E8X$LE;6]+^?@;4#QM<%4ZWM:#4]\?_4
M>:,G_WHOIU5J4_]/ZU^#=OI,1@JLLHOZ'*)*WDU6*/UBY:15599/BU;C>%/_
M)07/40[^,X6558>*19FZV:$C34TX93$C:N4G8F%NT#D4''O.3>3%OQS.':M;
MCUX9,QY8XHOG@&JVHPAS<;++0/OF)R4B UB1AY/W'=A8T6KRYP\N +W&:BOO
MBMDTI\.5R77G,J/N,/!.AW$4R4J^W^?&#N?:NP[\!: ?VB7XP=YVMU^LM"-T
M@4]8ZM\Z=J;3+RQ1($W'R4'GQA^TCH0@+YRWQ-GS+ '-"P!6ZP+P8K]M@EDA
M/%;&[^VS(0Z!YBQAZY=2%P#DUDQ0SOF="T#:>>;E$"+Q-5C-US/A#V"&Q##\
MG+ZU[<J6HQJA.!;$]43L6T+7^@':-KO0EU?KNJW9_8$GCYX\0HS_-?&Q72;>
MC^W+\(=4GD\Y<A&*JJB5!\IA8E]!=@1.1T9^UIVC"P#-KY"EV\G#K,:MQ)1O
MG+='UL*=SI^SE]=4>^=%S];5>5F=#E:%WLW^8SHC(2Y+I[[[.)$U?6M_5[?>
ME_]FW.NUM._WJC>H :XQQ?#J);M-C$/R>EFEHPYO<T-#:][^_I;;L'7=CL^D
M[D;:*WYM!FE.SELBO_W"Z=8")[-="ES\Y:S2^[Z]CXS):UX$U^OGA#;C,'.+
MJE8LN%UWD[:U$R,@,.P>0=9[50"S:7J:U_DK+]WXY%)H>($9X2L;R_--&@?O
MB2IG2B078K+_[333U2'VY:APYLV $<FUEJY3\PO G1;I9R>*H87WQK'!J]O+
M<MB3;H+^^2U7<B/LL;B8*@OL 9$#7SWH/"BRL*@\P'.[R\1+D3ZNA<O8\1M,
M9N7&EV(/_--!;>L1UL>ZG,69*!KX2AX/<F,0W(AZ!7^*2$8&A[QGG[ F"$9"
MPGF(+W?X ;6M2_S$2UR]V?-:YAI][NIT'M.O<;KP5)+(!2 2H@;9XPA+V1@Z
M+>XUCI0S=4+4@0Q7\Q%,Q(1)*3_+I7[L>CPN%;AD+Z[Q H(;5:".N;<'-8=H
MGU'T;2?:.QC4EWG ]#ER]=ELYH]Z!YMQ1\LYM(BF;3^X+S'GDF=V3'W!:L%I
M>M<(O=^L=A*S6$?=ZF#ZC3-![OUPQK\;W\5X4V 2CW?J $]+!9K,/DYX*QO;
M[UTG@A5HMMRV\\E3Z^>2[@M)7Q#U^:G0V=&>M\N;N%E?^#.$>&= ]2$!DB+K
MV7(!8"=6H,,?SOG"5U=M"4;(*F*D93%GJK+)3'W]GD#O.6D,//>G;X(H.X4M
M>]-2O.J^8[5:?$=:JGLW"]_TZ27EZRBJ:*"/-X*(-"7&^.;SSD-<\3-OK\S0
MO=Y/'#M]A.\\OREV ;@V0?2XF_=GI0=)T#9'WN2;"1<BJ1/"&^T\3I).@;%'
M$C1$]9\C_[B?:<>L46OQTHLH-8^B'2F&/V"SG%Q-1[.TA4>JL'=/;48Z>D,[
M1%K8'$3*Q"AY@,15^?0BS_ADY1YWT0GIJL2\ [W(P=#9>45M!XZ4BI/EZJ;&
M#P_<G)DL'KFYN;RJOJ'+_P8 2#>Z'N:"1QX#R<VJLF'9QC$\C1M#$DS6CEKI
M"[^_PA0)XH58=UV QW<BTJ9AJDN:-<N(&-71R/98>I#-XE(\ZUT 8GB:Y+<W
M\(__#0>2;A!5\'W6;[3$253XY3YNYFE^"C79P9(23^:</Z:MNNFA^;EN:8DR
MZ=(,QLBYB5686_[?I"')<]NV'W:%9(_'932PC^+GVJA(? 3UY!?IJM&3JB?X
M!.9#A&/M7EA(?PVD?@A/@6\ZI_MQJ=M32/^<\2^)X#?Z$!''2( ^'TR+F%/A
M9?5F(=W(,+;OMT3<)$W5O2O8YO;T;]G:.I#2C_YJ:9>C@#RG\V\"-SF0O,EU
MXA6CVL<30)(8T9NI?OJZP8>%06XQ M/Z<9H^OQN8XEU<=%94;Y((&6("%D@F
MZ"=^##'_:&U_S9'0^V339]Z8Y:@Z[2AI:OO;D8(:+=&,QMV*+F%(UZLL:6!Z
M>9P57#V5OI_)OIM+A.-1YW1;EWU^1E*YK8M3NP;3)0Z%4&C?^T$R(!;6+;S/
M IP4&Q/=6?H+I:")R>M+N^/KE#S\5?POS$XU\)W'@N0WX=2LKD2K,VG8+;SA
M4;L&=TL)21;_@9B6Y"Z92S(.*+>'QOQ$/W>69R_HL9-N]!%'D]4T8=GR<=(_
M!G]SY:\KO!U]&>2?M<@5HI>05\9X6ME[/\P2R#LL=09B-LO!EM9Y9>(S+1SD
MNJTH+0T#G^<[:3):I;SL_9\TZ[OV?("1H'N-,"0CK44PI*ULU!0U?:#+ERY_
MG5M>W>+;:TM3B]?7$DC]Y%+42@H8;XS ^"U[.0H164IA($+T2;8N* 1OJM/#
M!HW<D6Y2&3A:SR^Q'5XI##4ITCJXCR*H106-(OW;Q@YT>(ZN)NQ\6E<@M58C
M<E;]%80QCN7L+7I2Z6 W6+J>_QY;E6;YE*&<_^ISTBT7W:]#*_CO(\;G#CB/
MJ;K+J)$'(O@R?),5:N&?]"Q/(SF$3X+QSW(&(;1AG;;D[!Y9HATN^VU^>62O
MVITZCD_<4CJ#*ZV6W/Q3J!82'V*)@3YYL(+EM8]<5^25#V9J*\9#EPQKX[B$
MG(T8B[W\_AI.K\HVZ*LZ#*GW?LF(5 5.^S[73BLA;FC[Z/=V_'B7FBN3''R4
MR>AVQ8$&7K5H,B/3+6TWA0A,]C9JF#DLU,/8J6CKSXB)[1W^/KOLNDK=3M:/
MYPL.=@91I0W&C&DZ4355UQ+(@D($B&KO\ZDOOYR:7@H/CY5%#LQ[EMD^#!0H
M)Q'=%67K#.W40&,PD<\?"V:D,-^3JFMFU,5P^)R#,EN]CLYS>[TD2*EHNMJP
M7?_Y/0)EU%$^D!YJY3 +D\;1"0=U3!XM [=".N2:RG]4\OJ*RJHHA7HO*$XS
M,'N_6'US]9\G5(CO$_--YS3S%X#KUXD4QW0BZ!Z5290'G!)S+;[9.!D#P^S%
M,?]HS/W92DPN7?0X5VJ;=F!Y)N\H. LS<:=@V##,%ZTC6_W]XS4@1,&*'6;(
MD8XJHSY>?I"E7!>8$$ZQM$!D!X+>?W?'R[0J(?ICX\O1<Q!/+ >7WE[@NRU_
MW;M9\&($QNR<KH)<V<.3K&%+SN_AA_(=O_KZGL'0!YL<,$JT(G#UWM#9WG&:
M#:+3_V2;KTZA(4!>3H8IS$F],!TH^Z>QRW(9KIW<!DRHZJ<K,'D?6STGZKFA
MX.7U$((+E,0?9_ZJV5&T[#<L)\]4JS(@;A"&:,VS^81J;+ME3@H-2NCE'Y0U
MUKTN%M";,'1B5X@3\3U4L_PO+R..8Q7BNV<RD-0B>L+<]C)..2)MHL:0%G6G
MAZ.VKE5F**Y+K-R6V#-3GID-:26II1HU1L6VSU+SIR-V*_H@*6HWSD%$?Y #
MW@Z7\ZKG =$G6T+:$B^8$ BY8V<S_/!Y=L>;R?I=UTG$])"P8<66"09L-\KX
M=0+"^5$G\=P!Q8YRNP"D%C=E=\#D"7,K%P"T1+1MS80H<^*J,<U6GDI,[=<
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MO<SH&$:C[Y.A@?6VHJIW+ \1WLJA>.Z!5\!P8R3DS5S=4S3*QE^GSJ&H5:]
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M#D70C0O!/LGF.TU$\L"#UB5+#U',80U$-W3\JY,I":S@.EET)$\@,W7+YR3
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MLB0SZ$ F_N^;]4$<Y;_"*\%>+6X,(0O3RMW?3U^U@JO1H671NS-3?R;U$/>
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MKE+&#P:(M5QRB1W/@R=8B4FRM]_/?1G7.]139S'>UR)8_X]WIUY%,9&E$:*
M+&Z5Z-"Y$V%% <!P'Z5R9N8A1/M0'*^8ENVS+8_+V\V!MI?[AR\_>IV\(_FS
M]$_\H^T_93YK8R6W1PNHQXH4\VA\ED0'O ,T9".]$P.9=..5/Q10/R^Z;8"^
M[/_4^UF(_EROOK.LE5O^&T%6@/?DX1FHM1/R-:5--K" ),JG<II'TG47B@0#
M#ZI-$8*+OLTAC+]A0%\782VES'47%/$%<&C+%JN*]]-A[GU'2V8D#X,)7IBM
M=B)LZQC6NG7W.[C*+VQ;+9::)%>@OC0(%J"'9M -1C6Y.+W*W883>?S>"+^K
MICU!-'VUU%1*$H!X),%?=?IC),Y 5>>_/]H+V)^K?\V%)]=)59U;Q2CC99<M
MY[B8?A4U'*(J'0([/G5<.+SC@ZQYW1C@*V+-UBA/Y.FSE(<T0CB!C58PO3QM
M"ROI(3$E%$&)"[@:^*TC6XY('X\+O-@G*A"\]::KP=\6;;YRN^"#_Z3HKB9_
MX)@-A*?%$05('Y*8EQ;#9WP&J8"^CH5JZ4@WQ*^P%$+  Q<,@Z9/ R-M"R_P
M&44/6*VT/>R#P<UV.G6Y=B5?>B2T!'M$MG C91&OB)> DB6E3C 8H4^D;2I/
MKXM#F)8!A>M3]F)6M%<FI-U'GU8]B^]FC0DR-VV]JJ=&P=C.XEC/=P7P7SH#
M1?)=KR'DM,,N 2UX]DB/]VQ(;H)F6$T.Z\:D>=9-L,.(O+CXZ8,7+Q/D?[[>
M5&HLNO."88W3(833BDUUX6Z_N$T#N\J:]4=/$\=\C*!^C:91]6+-(9XP6)X\
MN=?4W1D]R"RL*=3GB&M8$!##\U2DIBD1&GV<BGURE>H$D@7?+$#_B/_+90].
M@KC$O4>YC[0XG(% ")73[/T['173&W[Q#)$+UQ8'?L?":Z!,)D[S5X*]P0IE
M!4  DM!7HT]^_F"$S(-P.45#'%'3$"/R-+!%S,-#.G4ZTM#5P5VJ8N.^EOPZ
MK^<^#NU32UT)_J26XBWI8ZG8-F6FQ6ES>;9N/6=SZPQTY?A<&.^K*M2$H9<P
M=(#!P6M"05]IPCJ8U??7*E%GZMJWY0J"<$B*U81-\]6?16B@W(.JZLC[[B"+
M/67&X:L#O_,%N+;8MH3AVY\#>TOG=*;:J 6D\6TD9A0A"?BK1,Z0+1G:4@ZM
MY-WRJ?:D.PP\5*RCD\577*&FJV0>SR#/OJ5W11%!-96-XC*=O;T#MWX*BVIL
M.'#5CXUZS %ERZ51':H2SB9'MDZXPE&L@^FB3'QSF<CB#8[>?N<"G2NC6@$S
M,. UX3",I([?LN]NQS(/*6"8@>#GJ>9KZ>SAU=^V7$S'W*D$U&P+G;Y:S,_]
MO"^@[D$1>U_8_0)F$CJU1*;2/ -=9@:.#B0?&@"FM@3NMDFD0<XUA-]X1NOA
M!F/[0/!WL\#L;T2^^=W;[V4[2P#HX^ITA\=T)'.IE[7D ]6KY $PJ,7!C?N$
M<M&A=2$<0E.]^DYR^PR$HR9DQ^4NK,=WZ27][;<9&5<(?/.[VJMJ;L-X\M!;
MWG'D22=+G#,FKA]ATVVX@DZT^RAS_H4SQF9T3-1I:81"[#0^IC@-,H+Y-VZU
M4,L\;W"V/TIR?5[M'D9#2Z>N6I'D'%EF5O%F@\IZ>:4,LZ=P<O?\(*L@5:A@
MNEC,R6,$C+C3U6_&'NE/DE[<@"/9X$Q/BM.J3XX^-1(98OZ:Z!U*O(E-P7M0
M0<5(6W87[K(?ZBPJ;?J=2"%_*NJ9DB@ 1L(,+G/X^T&E2R-[N*0@,?1O4[!+
M9PE\R8"=+#OQ#-,78V[9W):01_,8D_\'T__*2GAP#RV89E_?I'[G;I-RT:9G
MBX3D92B#3W5+E7?M5L[GY4RE^)?KTE)],O5OXJ>_H;<J(("!Y1C&O?8@&=MS
MF47/BGK[_U9%[^6Z&7UH:?F<K?J(K^%W;E])Y8$C3_K[G6.WHB_]X+VP9C9F
MK"A-&=(]E,W.&]INZSEN6&Q-]!&U<7QNB=:H=GCJ8IS_^5"^P*B,NJN JT9D
M++:B2-L;?1M+S.1*.)+[40-]B[I2$_.O\]PK7&I=$,?::\U'*F]OH=43H2*>
MGY9I,I-=M^V%^VM@OW86L7DMF\E6-X?J',!39OM[KLMQ/:=U]%69[I=6%]JD
MO'52CM,C2:CWR%@^D!>L.N4:7!H7:VM5=D1,6"P'MZ]('39720A=#%-5:CZ=
MU9ZT''$8?W'[#!1[:\#P'7[^9B[5]%BR1VR1FKG'P9L:M-K!1,:H;ERO]#3E
M@0LTY-@H!^]Q=9VKL XW)97>;>RF)9F^\SC;)OAILI;$I[I(<YWNO;+IUT&,
M=$,U(3LN]=^/;K5\DH3JC-:4J>YHC6^Z^4K>(E/6-E<TA]V-,D\5X( 7AJF_
M]%5AC$]ZP?G8C@*ALP3^%=5^G)RGL!.L8NJ%^W9G6<K'30<:Z#P_IJBE(XY#
M.<&_YGZ/%6_U5YRX6SXPQ$WZ=&R&['<73F%!E8,ULGG[O#*5TJP)7W\VW8U]
M%=KGU<!GIY%3@8G]0;30C&U?K/#74&;!16"",>G=O$'=8QT2O%<UKM2(W698
MPUQ5_>#OW8>J;'K0C1>UY_ ?@R..<&(V(DLR>RGR(DNBBR(#-1*&[*(&H8[6
MEEQC_)1FGF6<3^M6FI'9Y,[YBV,J$!R=7Y=9)IT[PL'K1?HC_:#*VKB\TQJC
M$^L+"9(/M@^\Z+?M@P:X/_(](:I$$]@WS7'W*)\%&Q +FR'1R(&5Q]5PUZ=Q
M^2J1[;TG7NQU*2G$+]S3EY-[V6UN9DE=-];"#OTKH%<7-#)"Y>;F9ATY/ST]
M+Q V/S_/8H(+HK(UC!6QCC&Z_3G&D%_]N3H-"/PY\!(VB >%@X%QI)?$1-J@
M'Z]<HRZE6<,A(3)3V92*/T66]J+I7#&<60XF3>6U2J)Y&LEZ,=W6,K>O*MYE
MC<P69I<PDEZ7OJ21+-=&+.G*C(OP5LX4;O,5M_6LG_[UIJ'<Q8#!G/:!CTQ2
M;D1!2)M^1UNLV*MDL1BNFI*Q/.U,IY'G:P&^9OH%"BQZL,T;I"\L>NJ@_]T#
M[M%]!CIB]AD\X2P] ^V/EPYK_K</[E-^9SAB]H6<<&(@^^-YQ@W&8230&2A>
MR> ,5)&^=P;2-5,(2/K?/O/_[C TW]B0O#6P^FP,(^ES0GO;"K][?(SGUKEK
M#F]U$FYHJ(?C@CC&V/SM?!^!DE^([V4LI9!8)\G4<R>0J!D/#N2H%051J-E>
M  JHDUG[_(DPLX1=R9GJJ9SO1M,K,7FPB[&QV?SC^R8O/E!M"X=IQIA74:8L
M[7%E]UT(ZK1UMA2^*L57YB^^^;OH@47)@)&6\USL$RO(I;?H+:]?/Z7HLS)6
M.XT+'DC-96EIINU7?G/+3YJ&//Z#698^GP;OY44ZR%8Z:A-W(@^@._;L\-5$
M:!>$:0W+6!$QE,0.)H3#58#R0_W:U+?# EB9(?='3[@<\2D^M, ,<9!,VWP.
MCM>!"?<M":S4&NJR#^U7W#XXB(^CDI#8Q1WB@F+?8 (R\)*E\45V5P:[C(8;
M;':XE1_9GI36M<V+=^_V-E]5--4V0OS:?!2(EC9_UBZA;B@U7%SD7.-EY-"Q
MHBKDB:5,EW?!RXE%/;5@I?:&%6S86/%EQ/D;^+H-*^62@ZSN HF$'9Q[N'0$
M60@X:471(Y2NG($@':IWB4_#<;ST8,FK<2OK\]=;1C?YISBD3K:OC%V.9;%O
M^7 & B30)#;\(%XRK.5$#-DY+^M$HOYB/IA/L@)6<1L1BV>@D-YI'T>/ILN$
M53T]EC[<'5N'.J)F5)GV&:C-@%LK[X\!^*K"=BX>ND+9M7 -$4"4MLCI6&!L
M\OCGFP825OVF$0^7/)@V5,4FI93N/IY'EI7/+RST-4QE-?6%]57)_DXT5!%=
MW&&'[Y@&MV,I"9CW)#L\;8%#[5"3:.XZ\L:$.R.->!.75;R+?\"M/&5Q>4\9
M_3_4E\-03W"#M)4_$UEU;OTDELB5A9UNB1GD\JC2Q)A,%8]&KQLF.6@5KC4F
MA"J(ZXZN1%N@;N,9F/8D-N@,I/H\/23SWI_.:7\H$P-ZQ[+.[9,'62+#,<^W
M]![(9<0L%HOT:ELL![(2F ]J3PL@=H. #N7F"3&E:X'&H%O1Z#6?>%1;8Z2Y
M^0:CTZC*<6#'Q*',;.L5](N164W;4M-NCQ(S<RO8U,Q\MQ,J@.(,I*+%\^$'
M43N.I>*NIH"WN$#\CVC#X>&W+WU>&":]M7NA!HH\O7\&"G) M4IA_P6UJJL$
MOI$_^88)1UTD<7O'(QX!+;[YM7D>ET\>I"B2KQ+<0B;99.!17<9#?12',E$_
M]L] 5YWDNDLW$M*DJB7!'>#/]D FACK%1I:SXVN?%)ICH&6BJ*N&TTPOZ?:)
MJ 9R(N]+[F91%W-FL?<7]=[N[W8FKH/LJ=:$HT=>##)%PEQ@P\PBPQC\TIT
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M9Z"I%-UC9%3XN>15)!XTQ%H'?5HF:OM6<,SJ'N\)/I5?;CFEN(?<(XVK<B%
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M--[I-WKEM]?PE\.5GO8RWQ,^!MJ0T+*^L/:17&[)%$D1-?/>5G46XQMC_Z>
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M7IX]QB>Q3WZ10BTR!0]#G)PBWY"X022;J'\(C:K34 ?=!,@5]<5?(__ZB5R
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M,L'AA;S4BHJ$3&M[ +C&DPH0W:^03@BZ6S'\AQ^)J @?'JEQ#--_/&!W?QL
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M66;(";"LT<8TC^X8L\_D75YNX@U2&O8U'BBI$B[J[X*+'J2HM@D/)'UQ%2G
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M8WV]*&,*>W"J<&--3("!TJ9:S^_CJRAE@Z(-V=:7S2(/BQ93&UZ9N(XJ_ET
M57W_E?I5@ZXJY5<\CR<WF:KJM93Q] Q;VSL985SA-WA8@_VD.T$L!!PHP;7W
M!09\=_.9CZI)SX;&BIZS7<GIIF5>B:H),C^X*[/:9"]?RG*>C7D)BB@/[9WM
MUD=OO_+8;$Q?Q>YZ,V4\EQGQT1I[>?:"6CA?GER)20->K:E6N=SMK#;IUGZ_
MF&RSIN'?UEOJ;_^11D<$"R%HH5\Y)9"Y$0(<2ZKMXA3_LP!0!""_<@C@G!OQ
M_U?"^G.P77J5#!/;5H!-F"VX=!JO7"K[WRL\'KL99(JV7*ME0.]U=E 1 OC(
M=MTUD6CI3%9(#YC2P>1O0?E>"$7'- E\\D!!M71A3*@OP\/+ZVH]3J H<3C3
M5^P63_@S'1JE_^<I@?VS&*7/?B^?_YS%Z-8XX-A^-\PE7"8UUN[ZF"BF6 %<
M++7>0BJ!SO)&85PLO-D/B<.R'64EF4O6%]1X%EU^\*1.-YVH.<WEZ&KI.?+4
M+#KR9!XT?]7X(?6@=G L"8(T24;STG0F-YDX01JD8E$"/8SAFOEL:#ZK8)0B
MX@!^SS9:A';[=C/LRC$%!<HH1_=K^UC[D!IM$#0J6P>! KM^HXC\K:XD<<.T
M,L,%\SA!]!HB(V%-YOV?($4D?6I"RO$O+G1.%/B'WLJ>P*[GGQN(W-D,>-U;
M,[[!$8/>WM?EGM!F%NL\7CVY0W5)MFF>!8>+W/X$M+W@IE'N"H5<2IN7>YW?
M8/O0_J",ON$\(7Z9G"5N:TC>2VV'(F+Z#B,LB;V2#_!  H0!QXX1&%>7Z"\/
M>HHJC0D".7O4<P_5IUE,O55<E/]V!&]JH#/3%C.RBE,SUL$#^6/]8+00!$,/
M66M>%"3$D0X<AO#DF)J>B@YV]+V2.8Q$]+0=[_!S!=U";LRS3"G-E!N'&$>_
M]^^#&E6SX9N8[EF,,L*-9<]0;BM.<MFW-^3N]'TJ_RKGR_PO-7LFB; FAAIO
M*I7 RKW6O!Q@Z&'2\!S+_[[/E.-EIG^32PQ,B+ULU5&;00J:,5-]ZO=4HS)1
M;KQCUJ2 XB.Z-3SFH7A5Y>WWF>.5B964#^EPMBK),[PR';%3A<)G : 5RWX0
M6D8#1PY'IO^9\Y/OY51 G]<L?+K#6$ 1Q.;K]E5H 5D.C@L*!$=XY<1+=+DH
MP?I[=%W K6K+)F+H%=08CMH+^QGS0L3K</Y\503F%B4E?O%!J1;][RO5BGQ^
M7V7"W(0O^Q9Z%2C@U>)G+U1&G,L=0_CKPUY\<VU[QS$! ?^YB<T".XJ\[U!"
M@U:E>U?H3,W\0RP*BS&*J!=M<K&O&K2E&A:L':7&?WVNT_ (I'>5-9 \YX71
MH+G!![5K>\GH\G;PJEO$I<^B8YH..F9-@VU>^'/..W4A+VB,#OKX5?1?XL>L
ML\:-X\T:/+J?4A1VK*X4> &DU(MTE(?1[K?ZS6&/D!G-DMJW]T%S$V4ULS\$
M'ZD4_CQU6T.9>??-_W#O;@XO?B3KB1&IB]-V1NQ=.36LG!=:9+N]R4A%CB59
M(E_2+,+.XIDR\0!AR7$\C).+3@PR,T,;=E\.!BD@O9#?73+/+>C1$#=X'IE.
M'(-+2E.QC;\4Z<[]5+T):1AQZK^=!CQIJ6KKJ=H\:0.\U1!"B$@&7HTHN.8E
M4N\$XE24Q&BCD[U^W,^!65*>6%('B8RG.IREV8)CVPG2C=8[V*+;WH#6;-&!
MD[Y#5/%7YA];.M"T6\3*]]G]1TABDS$D].P)^HEPH^-W!,JP5][%=$TZMO"'
M\DUO"B&E_MF%C([XH![&E<]&.U*HOU[1"SP^!J?W>CZI&&K"C]Y^+7XN$BWS
M0I%)J&L9(MV8P3K@-)$NFL&(E53XA3QS_O1*_SAAX58.NCBN-G;8PP RN,/?
M8'K(@MAIK*_76NF9[;*<!YWE8PM=[\2LNG5JQQ70N6SF_'*Q[\91S;ABQ!RY
M?!(2M7OK3&#PQ'O$<>.?O#4M1N_<K6.BO%$[!PV#(%W&#GI13/L$O<+4KHRL
M/0L9+SY*7$[Z7@ONT69_7 =O-MU6)&'*IVLY2H/D<<SV",G9IO>RJNQ.JKEA
M]9<PSNCXA[<73/9$'1EUE-D9SP)4LDJ,G[A1BKW_&KV<.;T5S5QXC3M.-O.A
MSI=7).;M!E\0>(!A=QXW@;K_(Z@4]*-UVJWXO0T7252I&-<ZLHQ4@_U-:D@@
M2R^[87R[>_R#0;XAQ[+9$3&=DSP'*]&1<VVJ>\&?#N$RSE'(IDR^S=;&YX=D
M_"RNC&[:]>I^N>J&$WNWF5RS%*^C'^$!T@U<MR4%X\35VF&OVWL0J[>S!VBQ
M :O4$V#9+4)LP3"*;>.-KBE!%==F=R:6HSB?5DCQB1/=P1J@E9"&9T38+)O0
M(#K"[XC.[+PB9_H 0L@41$-=O280J9U!>]C?+!=2B@A^S#O\RUODMA9]0U)B
MFX'(:GID*#D/0*K&"]#H:0.&@S:>^T,2>OZSM'8M@P:>Y>H,=R*ZC9WO(W]O
MP7I-SIUNCD^<J4ZN'K/_$/(P5J7>\%./+;Y97ZI@<?^2)_-N4,;Z%:_N7G5M
M(/;G_XU#%"S8=+&EC<;25+S=;<&U?VY<)GUY!TG!"(XO*I6L<6<^$;"1H?9H
M[5!MF3D)-(M/U.J3XM!9?OIFI^#4:>,24K\4$-=3T*_('G/'=:.%NX%QLJ#S
M8?E-4)FU[%[N&BJ$%^6V/0\_;S"S1VQ%RU+?C4_-I%- $7'![,330QZ\'/SC
M2&D;D%*_6:I!KN?(ZS<O<7"TG]SKRKWA+W(3)265/N%48PG[N/#1*W\B4PC.
MJYYK/EW,C]+6U"[Q!B43O,RM^88D!UC=8.GFSH)Y>:=5@L NMTZ&NT1CYN/5
MW.A?Q.X+R3T@=J<?4>?QDCNZ]6WT4S4N!XO<9%(S$TK7F'\1#762A/9MCH6;
M!:G56:)/)X5+3JZ>_5X,ADS'5X6TGE7%=O#L*A^[E1JI%"RU2$N300WCG+5R
MO71_G<C4;H7<QQ:#GU)3ORN-0C&RJR44+?BYTJ[F\PX738S+V'VLRKJ6-J,U
M^F=,,F?BX-Z#UN!-\Q,/U)I"0^6Z?MVEQ$*)1X%MBT.U')S/IA(!+YQ!/Z^>
MJ7[X,U7MS:<%XR+_-^^R4E4=.=X#UT=[ZMD!<;75:R]J:=S>Y]^G_>2R^;V1
M^'5/FVWBDJ7?AZ>['U:^<7&TRY \7B(?>*#(@_Y[EW6LE[4FO;.<ZNN+-CI;
MW]>9XZF]\4'[Y#R9S)3/]8F0%ES8^A75)8IR[>@@*92S8I[T@[X2FTBX,*C+
M0'="HE"/73,7,2TK]+/I>M3STZ+@4?,38=1UJ&"]UGVXPD\UW@?P"KOY1 =+
M;YDAX<YQ3W-_,;KX0,V_P6RE?C8]V1V3Q0ZL,U]K&RKG'7V;^:)'9\25B+Y^
MZ9*?#P<(2'^^0P8#,?6GE9OLM%$Z2?!T<,TV:((&S<.?3B@%0A@FPFX?&\6_
M:U(0Z[0=ZVO^PX]2++LQA5&M=;K38A5<Y<3T.K%85+FWY],%2UH!_%X K0 I
ME'8,ZE)SYW@27E"XS&P.M8\;4WB6NV2H]9:1*/)NT9]S(W2QLXEAVU45=%LM
MRJQN).AQK;QI=CX15ZGFHUJGN8310@UO#./RH;=+R $G);(X2^Z\#Q2UX"/M
M_\'(+XG#\XPV2DFPJ>G)]0YF<:Y/\4=,?SL&(@OJD[)2JH*LH--%>IV]A$"1
M<O>[FP"7TL;H@EVMT_7$'HEA1GTV!(^5Z>I@D,> 1)6NRM&O+2=55HD?S5^_
MA@\'A]Z',HV!WY9.,(FFER// 3^;M+["]6)*5Z98B8IQSP9#0>3\IL:8WN$2
M=D4@S6QJ,TO@*@&Z_0[>P:!BA%E\CQJ5&]2M#>_N+:YLYXWL559>M&CZ6=2L
M>&H9!ZDK2?#,YDUJUQI*K/DM=]V787ECK-I!M)G(G_:9H7.",%+_GN5"+9PT
MX1KRO*O$G^GO2$ V548_5S3ICLMI8 *E\+4/$:VCUT#@WAG.ZZB9ROHKD:X0
MP:GVSIO!$;#LWDVDSN#-X/Q1S<X^RM"$\-"6"Q7GQN_8 IS$+A<;),:".X$0
MFO:?-I@8P_5;67-G(MT[*<,R*2.$$PK7*K"*4 <PIS.,1<IQR& W&PXBKV?_
MRWE:5:XJWH5BMVUSE)1?>76B&)X5IGC]C=3EP0M*=L$-P:'WR#D^1\P1;*I3
M8WK9W^A2Y?AL:^;F_D0(^XX4?P6C9/OLWT:2Q[="I18= W3X0937][NOYVE_
ME"$$Y(NFB)\S&_43[0PE7Y9NPR=.37.BECY?'_.M'B&JDS)^WJB\S6%&[6\*
MFN=>B]I4P /4CFU&LIM7/2;<)_S7N#7;IVCNQ!*Q7&,6I6J0=K2ZNHW1+'"V
M1,=T&=P(J/)M&SGHAI^E_FKC$64O,9=:EO*L6"2W;K?<4SW07<O! _5^B^%G
ML[YXX)5X 8W0R#P>L'8?^[[R9C6S2>V^#\0^F/7([<*_Z[3U(1Y(*1%XM#BT
M]RD9C-,,3B+3P59VR%JZWD8WK6@E-ML] L-P("WF\FMVK9.N-2_M;ABH3?^R
MHQ[KD_F!!Y*@S(U"*P[H%,3<>:KVG*1SH@"+!^^@%\Q.QY7YFE3HIX1K+ ]"
M2@CQN)7&S,)":4^\D>BK=A-(M&W;DC3'8/W2GD\@]>]BL\6!8UI*/QW3QF_8
M: P-Y\J!-@NZYIC-%QO.P:VY'.KK<J5<4EDO%-ZZTG"]U.-..AZ(M<$6+[D<
M>E '(R0I'WG;M63U*PA^&X]LMIQO$18?YK>"5VX6G[*Z8L;FF_Z.H=]#5:L*
M7I!2<.6I^SAN8%AT7WF:@JOT!QU4/!=7SB9V#AUMCCNN^A2%I\GE"N*"5,O2
M$G(.WKW\P4LY*NXJ7,1+O0\;_Y13SG.<<3EF=<4>Q%)/<18/H=W]\9AX9:^:
MQ9/.U?1*?%8+R,3"YVZYK5X##9@7)^^/(^6UF2,Z&6GS/=T:.7SU>+[I:&->
M2&I\4-SF>J"O9_39?"0/N5*WLO.H)\,F'A$BB5PC?VGAN(DQ[#6>L>)TEO7$
MFD:ATN\%"CNOP7T9VNIU7^[<@8]:,FD(#TI<?I\8HLBT_:A.O6BY8/>JI#I8
MZ,GI'.9-Z5V%I+*XT;^#[]\7YRV_OUGQF7:X)[3B&L\'8"1DRRB(%VU5<FL&
M1(UA<.,:O6])Z3#B$3YX%3)^+V?4T%. 1-Q%K^(Q\<W]_881:2WS[) "F]<?
MN6TSBA@KPWM_+1)[)##968N%]S3K:88DI^%^:3VH6L-]\UOY8%LQ,/(&P_!Q
M2^O20BQ3^KTG%6>Y9K\FB'ON F,X42 4A2OLFEM2=:NVIQ?-]G5*(N(XOW^X
M#(ILXB1#U50V$WP=QS?5?#!_1D.S.YO3S$C1O'^6ZKJD'[XFR]]I3\91'-,)
M3FC+7*G'R*(4 CNY#\[ \T:4Q7WPBD>?E$*?T#14PIG)[F@?Y#%<UFA>W6V7
M^3) Z-?/OOF\Z@/P][H7\7>W#@=.YSV8ZML6<Q9,?8.3LWNQ?!(7Q\&J475!
MTD=8-Y;$/H*?!,Y5D4E_W3@%<PF"WXPE27]Y\8>I;E(_6HG@>T]&;Y*2I/;A
MSE[QY.5P,$P?<=!3SCK;7-%B]%HN:KW'B'=V?BUX4UGONJM,4/_R$B.=S&2Y
MTEHU_/LZNG:J0N#4K.#,.)BY;M2RUEI!'<%8/8*M[?6CE,ORFE&"70BHG>FU
M:2,Z2D>L<:D6=Q$B^U:P.8J#4[.Z]@4\T+WD(R:]6[W1")5["[;25/LE5] 3
MR/9:7'W.SPEQTL1LI;3D+!>R/-"2]>"*^=KW+AZ?)M"WV0CN16SIFAO=G]<U
M>.";B:.)SP:U!LG5,[F:;ION<OGN%F']] N;OZS_JVO!V-N>%L9ZR&2*Y&KZ
M6E,91)+DB/^!BVUTGP?'BYL!S@-1X0$EU5^.C:#L[7J]RQIQ3CH1"\POFA_
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M;OEGIH% %I&V'TJ56&;U'H+D:W;-KB+2#H*)4;Q$ \MN=@AD&T=&9]W,?"=
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M4$=$\M*E&AA9^:K\QC3U@>X$*4UWP=M!,'.PA&1M8Z.?E+/<SZ^$ X3N!ZT
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MV;R\+: 1[^SPA>A#?!KOGEV>H[3"H^EX4V$;Z_0&5AF6Q:G*1*Q77)+PT?G
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MMOPXO%R9^:Z_+(&UUDW;/+<P;' /N%[!?1-[>PA,5/<:-7"]I*M>+E2%$2>
M<B^YRD5VQ0')?-E'DJC>8JK[<W/'RK\5=\KCTLM<,A1?SGM:0V('ED$305J%
M?\]>[<1]W9%OA,\HY./DNG1S!E1(KZJN 6^3Z']<P/I L2#V]6EE;=A*;[7,
M3'9(8I#'-V5FRM;G8T75^&>=[3.O$](?OGTWG_-37'4SF/<F0#?0LJFH?)S
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M]?T'?$=F\Y81&754<JHTXFN[MUDDFS+>76JP.X1>;$G!"9JH/XFK##CVE&N
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M[6@4!S>^MZGG;&AH+*NR@H3UA_!DJH5NJ$ZO3[ ;-L_>!USI7(4I<_JO<R_
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MQ[5L$'K>EC6WU-:U-\V(V-?.;$SR),,3E/I;Y6*D0?1KV_6:=E7@:9'"';I
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M+JFN5Z4MC3*,=AT];0 O;:\2:;6OLUGQ.+0)-4)I^YLL_=H\X0_&%C6=3S]
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MWAE_+=$7>;/RB>S7!8W8<A67YN'UCVX2"[]\5J0 B1M >0PUB8Y@T&:Z@CB
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MB!A6U ZJE?#.-J:%%2=_;2?R!:;-/BB3<R!\44H6"Q[_)WY'^%]89]7A_(P
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MU^2_F@X<?7/Q[N;C;,N"5(7B+DT9YQ/XMXQ<^F4:49)D%LF\3=9=#ON:JJ]
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M=OQ<.^P7I/HX6/_ B+JYA:40)OYC4+YWRUDQ._;^^H'$W".XJN%U5[A)7?)
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M4=*G[':TGL46P>T45?Q1D(^:M+K?<7.X79\*TR#(YWBEA,HO8A][>0SA3-!
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M6& PSY]=FV^<+<3JHH%_>?BJV=[+_I>GE_]4&5GZ[B9Z*;V)WR>/5^CYRCS
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M7O4_KGW]+P1J#;'I//P;#$X+E#]7&D[Y[]-A/SOQ6=+[^'UB2AML:(WD,8@
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M4LOQUCUN^G&2GP)$',-7 (OAJS/VC?.UX2F.80(2!'1H&;46ER?MA"?)?//
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M-2]-&YQX&O&^/ZS3;SJ_2ND/K9_/+'\/$B8<].4"9(D/Z"-V4&Q,E9Z;6H$
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M\?X,<A\SR3FRKWBKZ0HC2HT?57-L=A$T(,UKKQT!M87: HM>XT?LS3A-K)Z
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MQ2D&8+5!?.E$F!"^,])0Y?M%(+TVFS<(P3C6\.?)F0H]93/,&5N22E;-I\D
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MS$GDT-_-++NX?1B>PBRX#,:'M]EQOS47FH<8876YBXJS*X(,[2S>O:?11\]
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M/$E-G2CY=QTB/"G16(?,G@@Z"=/ =_Q-M0@K_$O\]"9.%K08; $SU]PQTV=
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MCU14*4M5#5'CRE\51@F%;Z;#8G/!\'Q^)TSD#ELW[:5S14.=Z,3LF;KG.A^
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M(W6J ?;K)F$JG<!Q-O(20 JDF^@;J9O5S?B=A$J[B>%<P' J4@CB"_K52\A
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MA2_J/P6+I58:IV2% *E3VL\#'O.5>3>K!GS)H;!6?S#(C!T;FU?867@!';S
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MT63CZ_U(<U;IUL[;-\( A\4MW(,\HT%-/8P(OA.V74,/)2(7(F;[NTE.JK[
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M2P$"% ,4    "  QC%I:X&S(3N?2! "7/CP $0              @ $
M9V5R;BTR,#(T,3(S,2YH=&U02P$"% ,4    "  QC%I:^:"P1QGZ 0#W&!P
M$0              @ $6TP0 9V5R;BTR,#(T,3(S,2YX<V102P$"% ,4
M"  QC%I:N5+6U'8L   FE $ $               @ %>S08 9V5R;BUE>#$P
M7S$R+FAT;5!+ 0(4 Q0    ( #&,6EKAE1J2?E<  (-I P 0
M  "  0+Z!@!G97)N+65X,3!?,3,N:'1M4$L! A0#%     @ ,8Q:6O5G8ME4
M+   6)(! !               ( !KE$' &=E<FXM97@Q,%\Q-RYH=&U02P$"
M% ,4    "  QC%I:)[=R(Y X  ![X0$ $               @ $P?@< 9V5R
M;BUE>#$P7S(Y+FAT;5!+ 0(4 Q0    ( #&,6EH9!GJ"PV " 'Z3%P 0
M          "  >ZV!P!G97)N+65X,3!?,S,N:'1M4$L! A0#%     @ ,8Q:
M6C6M&QU6J@  M!T' !               ( !WQ<* &=E<FXM97@Q,%\S-"YH
M=&U02P$"% ,4    "  QC%I:Y>4,F=I7  #Z$P, #P              @ %C
MP@H 9V5R;BUE>#$Y7S$N:'1M4$L! A0#%     @ ,8Q:6C4@Z3P/ @  V0L
M  \              ( !:AH+ &=E<FXM97@R,5\Q+FAT;5!+ 0(4 Q0    (
M #&,6EI6TM>N(P4  %4I   /              "  :8<"P!G97)N+65X,C-?
M,2YH=&U02P$"% ,4    "  QC%I:!W8=<Q$)   L.0  #P
M@ 'V(0L 9V5R;BUE>#,Q7S$N:'1M4$L! A0#%     @ ,8Q:6M&?11(3"0
ME3H   \              ( !-"L+ &=E<FXM97@S,5\R+FAT;5!+ 0(4 Q0
M   ( #&,6EHXTE,5;P8  "0?   /              "  70T"P!G97)N+65X
M,S)?,2YH=&U02P$"% ,4    "  QC%I:JQ#6/X0&   L(   #P
M    @ $0.PL 9V5R;BUE>#,R7S(N:'1M4$L! A0#%     @ ,8Q:6F,T3^W3
M:Q@ 3E<< !$              ( !P4$+ &EM9S0T-3,V,S,X7S N:G!G4$L!
M A0#%     @ ,8Q:6M4W,2!3< 0 .\,$ !$              ( !PZTC &EM
M9S0T-3,V,S,X7S$N:G!G4$L! A0#%     @ ,8Q:6J;'_>*-60, W6H$ !$
M             ( !11XH &EM9S0T-3,V,S,X7S(N:G!G4$L%!@     2 !(
*6@0   %X*P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>gern-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:gern="http://www.geron.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gern-20241231.xsd" xlink:type="simple"/>
    <context id="C_81b5227f-c6cc-4463-87df-b07ef92efeea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_833a88bd-1656-4796-b8aa-0fb692b42fdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="C_8348b52f-8813-4f32-97db-ccc55a82dd58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_84180ddc-e18d-4b81-bb38-f3d15f581d85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_850e68a3-343d-4aa2-b753-44e2d3e644c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_85175ee7-1c57-4e09-a0fa-9cca0710633c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_867aa2fc-a030-470c-984d-778ea052f5b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87979f69-8b59-4913-a42e-83306a925036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_87998687-0289-453c-ace1-aaa39dc47de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8a986e2f-1a04-4888-9532-0bcd96b69f07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2025-02-21</instant>
        </period>
    </context>
    <context id="C_8b21a8eb-d5f2-4432-a5df-39b506f65c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8eb77d4c-4335-48c8-9562-05e492af76dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_90739fa8-e72e-4147-a181-ff8aba129f93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_912929c3-b7b6-4d47-ab01-1fc308ac8161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91c5c5f0-c7f2-42ce-8dcb-ed6118918880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:SinaDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_92e38419-310b-4d37-89de-c52fbe362d53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9378206f-1b63-4c2e-84ae-c7c453b28fb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9553826f-3f43-4285-8839-dca64833f51a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_95741265-2348-4239-94c8-9bc131f6f43a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_95b33fbb-e8c1-4fd0-a15d-92e7aa65e86a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9660272a-a38b-4587-990c-81de73711c8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9706dd18-9926-47e0-b3e8-d29b8905bbab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_97cc69ce-fec1-4d91-ac38-fcc58be903e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_9814d90e-77b9-4d3a-907e-2bf9844e66cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:SalesReturnsAndAllowanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9979f2e9-baa0-488c-bfc3-27175ab0bfd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9accca2e-98a7-4feb-90e0-dd4c4473e5a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="C_9bd8d342-06ae-415c-868d-cf0b5f73cacf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_9d292321-d77a-49f3-8195-59f85dac9752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:LicenseFeesAndRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9e25d180-78c3-41f5-b9e4-3eedf3398835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9f924c06-9556-4a79-8ba5-be2f6840286d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9feb8ba3-51fd-46c5-a45b-f7d80b5c6b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a0f038aa-10fb-4ef4-a320-6fa3bd5a6a6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a177d587-0918-4df7-8a99-cd04f1e5d2b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a4269ae4-d56a-4edf-a592-a2ea8119922f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-21</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="C_a450a2dc-f974-4416-9511-c7302a719fa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a57a8238-5f15-4041-aa47-381c050af69a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:RevenuesBeforeAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a5c5ddc7-dfaa-4256-a811-8005fe000d01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a8af3954-eaf3-42b5-9e3a-4922b0dd6706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a91cce50-3f56-4202-8cbb-e2061a4afe4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-10</instant>
        </period>
    </context>
    <context id="C_aebd100b-45b2-4709-8a8b-13cb1b274d38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_af40aa95-e806-4f0d-9a2b-c4155550c1c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_afd8ecd1-ed86-4a5a-81e0-ee569ecd5bc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_b09d7f2d-153d-4916-ae66-f66dee60587b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1066105-def2-48bc-a08b-a1be59df1fe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b3d1f256-a05e-41ae-82ba-3a0ca866b306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b494d8bd-5ad3-4784-83cb-b49455558821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b54b04e2-e7b3-40e7-b38b-61e399b5089e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChargebackAndDistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b715e801-fcfb-431f-8bab-f2e143bebd19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b78714b6-f9c0-495e-8c29-1ef95e3bcf60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_ba48a767-b0d9-4ebe-9ba8-df6962a5903f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bd2577b2-9506-4398-a405-ba1b3a537279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bd7cb667-7647-4a87-b629-ce1a51b824be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_bdeda059-8b87-497a-b9cd-e4cf9530f303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_becb8b88-64b7-49ab-8230-4c474b6aaf48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_beffeaec-493f-452e-bd41-2df765eaa06a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CommercialPaperDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf2a2f52-c8bd-498e-90a9-db80650a3434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c155be43-9cca-497f-9c0d-dff7e4f971aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_c2ddaf0c-c480-4121-89b7-e270b06ea351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_c38d97f7-08a0-4702-99f8-8f86ab3205f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c3e030b6-7508-4442-bbe2-6485ef87fd91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:SubsequentDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c553e0ac-d5c1-4b9f-adf7-7df417d4ceff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="C_c57b8848-5a92-444a-b366-673e8854e689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ChemistryManufacturingAndControlExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c65b60ba-872b-41db-a6e2-d82180268abc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_c72d7d41-863d-4713-921b-5709d77691bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ca99313c-81e1-4fdc-aa00-501a9a8750eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cba66e27-c320-4315-b06d-66eeb091ebf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cc4a2b91-0d00-4a37-ad88-ee5bbfe05947">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:CommercialExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ccbb9418-68cc-4fe4-a4a4-5c49b6f5042f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_cf181ee0-e9ee-474a-9747-6fe8c5a5fe77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d081fa8e-07f3-4c84-807f-535a7bef49f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d0c523ca-eeda-4f55-8129-78a974c61e15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:ResearchAndClinicalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d17eed81-8c6b-456e-9079-f7df0f14e619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d1fd165f-236b-4ae7-b110-10c3c05b8919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d3392540-02f2-4e5b-8f42-37beb9ba9e45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d6e09048-ab65-4a10-a9a5-9d240f0d04d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d755aa78-f964-4edb-8019-908621c662cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d8b9e1c3-d9eb-45ec-948d-6b383d0103b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:McKessonFinancialCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d99633b0-a319-42ee-a07d-8348a36501df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dba11232-95dc-4b7a-a0b2-f0bc6076e0cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dbe4854e-8234-4b3f-bb3b-8c19d5981bf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e0278ce3-6fc4-403a-a17d-ddee1151eca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e03f65aa-0f08-4125-91e7-89e207442e89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e0933482-a77f-4d10-a7bc-f05210a15513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e0d5fa89-8410-4f47-ab1c-e5b7ef68f3cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">gern:EmployeesAboveTheVicePresidentLevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e14d38b0-ffbb-44d6-87e8-09d3acf16873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e1976851-cb4c-4762-8274-5ea9e52c9f8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e3a7796a-70fb-4745-ac2a-15cfb3d6b8c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_e3b2e318-43ca-4428-8f97-24dd7e3a155c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e3cb3a12-8449-4080-9d04-c09977c81469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e3f5c2dc-7c9d-424d-9590-a69e1018f7df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_e4021ad0-3e5e-48de-9cd9-3300958d415f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e43f9ac5-e990-42e5-a162-14377ebe69a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e4b1ab6e-2114-4b83-8ccc-b3e864bf5c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e6cc2f93-1577-4be8-9efd-57f44ff9b16c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e92973db-cfa0-4226-992e-ba00f3710cd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="C_eb68352e-6df9-4716-b022-e07659784349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:IncentiveAwardPlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ebc02be3-4e6f-4b78-bff8-d2cfc26bed45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ebd06010-cba9-4fe3-8531-00bccfe44019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ece3b919-9c68-4419-b2c9-c5d7c4dcca3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentySalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f086f31f-ebe6-4d2c-8914-9edaca62d90f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f0e977cf-938a-4204-9bd8-6c42bf0b34b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-01</endDate>
        </period>
    </context>
    <context id="C_f15e23b8-0e8e-4dda-a5e3-a439fd53eafa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f18cad10-57aa-4265-bcc3-f8c0b2fe427f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:FirstDirectorOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f38cb9df-eb50-49af-95e3-99de5b6c1109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f41156cc-9535-49b9-8050-64099a0eb8b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f5b3d0b0-b24e-4a9c-9342-027dfaa89069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:TotalGrossToNetAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f748ab50-900a-4fdc-8839-e5051a63beb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f784b962-1d18-4a7e-8f25-c81f2229ede3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyPublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f79ee241-9a76-41d9-93df-733bd1f3b85d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyFourPreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="C_f836de54-c5fa-4e2c-bc3b-676b8b48b141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f8d8f292-1d56-4204-b316-2a9290be7c09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_faf26aae-a2ff-481b-b390-795807f43711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="C_fb2e1524-ef21-4d37-878b-0564d9d43f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:GovernmentSponsoredEnterpriseSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fc579693-1a73-41bc-8a82-5c04df25f0f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ffad885e-eeb0-4c57-b284-7102190be086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_03b38bc3-3391-4183-82aa-61b99babb682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_04908c45-edaa-4013-80e1-3425b2d3f4a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_04ccb33e-9db2-4428-ab1f-e86203e71f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_05b9bc29-068c-441c-b91d-5eaab4b6ab0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-30</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_06fd0fff-364c-40d2-aea0-8957283902a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="C_08593508-3737-4150-83da-4b9da613a6e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_08984eb3-5203-4824-90b9-9a8e53b3fb49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0b8accab-dfee-4fdd-a488-21c280ad6a1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_10d09233-7a55-4348-a7b7-3be6db7ca118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:PrepaidOnOrAfterThirdAnniversaryButPriorToFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_13450eff-f3fb-4504-9420-67b321adf1b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_13a5e7dc-1814-4249-b841-344c76f1b61e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_15852a6c-ac98-4815-b64c-948a1a3c90a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_17031fc2-3062-43d6-85c0-79a5d605b251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_17d0f4ad-e466-499f-a3c7-32b9663b6681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_18c60a52-303b-412b-986a-7e6145b28956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1be1e923-b173-4348-90d9-a245cf7eecd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1d985ed6-a26a-4250-9a37-ac2116b89df0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-10</startDate>
            <endDate>2020-03-10</endDate>
        </period>
    </context>
    <context id="C_1d9cd387-5d68-43ac-8286-4091e49b513a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:CardinalHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1e35341b-2d2c-4a8f-916a-1bacddb10f79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:PrepaidPriorToThirdAnniversaryOfFundingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_1e3660ee-c4ab-4b1a-a885-f4768cde0fc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenInducementAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1e5e1688-ab30-4578-81a0-c6560b774866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:PrepaidOnOrAfterFourthAnniversaryOfFundingDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_21447006-602d-46aa-a917-f6697b7e69d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_23479e27-d886-45ff-8c25-d7ca04bd3cee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoPreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_24fe1187-bbca-4f70-b50e-1470d3032743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_275fb7a4-efea-4c31-83c8-55c94f697b31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2d097eb2-6e57-4299-a3e5-9151a4df0198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:AtMarketIssuanceTwoThousandAndTwentyThreeSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2f02a42c-f14d-4389-a9d0-40ae1afee99a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2f48563d-cfb2-405d-b3c5-32ab5e666ff0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2021-05-11</instant>
        </period>
    </context>
    <context id="C_2fc64b5e-3892-4a81-a7e8-b127182a99ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="C_3111e83f-2076-4782-b9bc-ed01f0ea1874">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:DirectorsMarketValueStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_335cdb98-b657-42f3-973a-6dc964cba271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3360e8d8-eaad-4e88-a960-8e7053699623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_344637f9-35dd-4606-aaa8-39e3e4eed402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3462f4ba-71e7-4d47-bf58-841e2d8028a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyFourPreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-01</instant>
        </period>
    </context>
    <context id="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3776fecd-f521-4873-82e1-b99ba90cc41d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_38766db5-3955-4239-979e-89377c2bc7bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:ASDSpecialtyHealthcareLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_38ee5de3-7306-4f4b-8d58-eb882cf9590d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyFourUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_39107341-c344-46be-aec9-e2e8aba0d53f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3b922920-9a03-448f-bb58-c0e801fa437e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:HerculesLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_3c58eba1-098b-4137-bffd-fc83f6d66c00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3ca647dc-16b1-48f8-b741-24db5011baac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_407442e0-3cce-4289-80e2-39b67a1f061b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4318e20a-42cf-473e-af78-4bb847a7d856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_432034fc-3319-4587-adae-2e7c9b692266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyThreePreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyThreeUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_442d47d2-f480-4e09-a7ea-6656c80440a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4599e5dd-ea25-4616-91b6-01afed02aaca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USGovernmentSponsoredEnterprisesDebtSecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_46ea59e0-e969-4c87-9aa0-1688daa1c9f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gern:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="C_478aad18-c78e-45d2-87ec-89af59700049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_48142c5b-ce3f-4966-921e-0b74263697ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:TwoThousandTwentyTwoStockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_49f4818c-2720-4101-a534-f0f765371106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4c42d843-dd04-4e25-a34a-b1f703d11e39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4cbc89b0-e52f-4d52-bc4b-5e66f232255a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4d32eb3b-1b07-4090-88b7-029d9a631b5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gern:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="C_4dcad59e-1e3b-43e6-a526-804130f682d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ed65fc6-0752-419b-9c26-e718bbbc446a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4f241416-b409-4908-b332-b7b4d33cd845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_501b1eb2-a39a-4305-ada7-ee277b99376c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_50c8ecec-b2ba-4651-95b8-c5c262b21836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_50fa79d0-89b9-452b-b91e-8b9da8f97576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_522fafdb-07e4-4339-b103-c323ad02c3e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_53975bd8-a789-4655-ac7f-6b97e0b87f47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gern:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_53d31f32-ae1d-49da-94b2-102d0fe79050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54df7d29-aa46-434f-bb2e-e36ffb0cf1c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:LicenseFeesAndRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_54e7473e-71f1-4f3c-b458-f1ccbff39749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_552c454b-a9ab-449e-b749-65c139a3cf3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_57c67b07-3a75-4f83-a90b-a0845eba9d49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_59108335-739f-4e5e-b267-22b8c789f159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="C_5cdbb065-c4af-42c3-8862-71fcb82d98f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5d81f491-dae6-42b2-9a9d-49bae561bc54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:TwoThousandTwentyTwoUnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="C_60b6c4c4-4c33-4d69-a53f-c3b0700c6a65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">gern:BiopharmaCreditPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_61e2613d-481e-46a9-a123-9bcad10f9439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_634d30a6-a512-472f-83d8-6f6a44496fa1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:USTreasurySecuritiesDueInLessThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6363eeb0-8a4f-484c-b027-c3513703d5d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyLeaseAndFosterCityLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_63aba9ed-ce8e-4616-9977-5edb1c01930b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_6535ff7f-99fc-4830-9136-f45d3598ba88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_66ae5200-0971-4718-bfb2-d5a1adbf70ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6787832d-92fa-4613-99b8-8a61345db4cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_68fdfe38-0960-431a-a3e9-7b0ac25ccc4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6a2d0968-c085-4357-bd45-6a8affcd8162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:RoyaltyPharmaRevenueParticipationRightPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6da2f1f4-f5f1-49c8-b49b-064df08d4b0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6dee5fa2-b2df-4b03-9654-001c5bf49a8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:PublicOfferingOfCommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-27</instant>
        </period>
    </context>
    <context id="C_6ec90163-a65e-40c3-a187-132ae7c4e62a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">gern:CorporateNoteSecuritiesDueInOneToTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6fcf6750-e138-4d4c-96d6-c8e04e8003f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:FosterCityOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7040d2ec-efa9-4e10-8449-1b261c220739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gern:HerculesAndSiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_70ca9604-7e05-4828-abc7-17e9195e5429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">gern:TrancheAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gern:PharmakonLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="C_710a5831-6f23-4a2b-a4c5-44b55c5ee9c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_710c0d17-5aa1-473a-867a-7efd92be1f08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_71d1f837-aa40-49d4-bd3f-4a76ced03892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_747285d8-621a-48db-811f-49f35ea38d3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_78978391-737a-40c3-9d68-851dcc4702f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_799b9a49-462d-486f-9022-ce4831f01775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7b831c0a-b680-4a42-bf82-33530e797307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">gern:NewJerseyOfficeSpaceLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_7c4b014b-4b49-4de5-99e6-77cd32c236fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7d3dad2f-bb11-4150-964c-bc94e9c01233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7d57e1e2-e7e9-4439-be29-506043e9a42a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7e54cf5e-d7b0-4905-96d8-e3ba1772cfd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gern:StockPurchaseWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">gern:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7ec87361-5500-473b-846d-d51e7d5b6cdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7f38441e-2b05-4d47-8fbc-1af5f0430674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">gern:LicenseFeesAndRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7f4d8a67-ca97-43b2-8f25-f36157f4f6b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">gern:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7f8c13fe-b7c8-47a4-9aa3-5c471dd1c446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7ff95c91-1f33-4631-89e1-565d8329dc34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886744</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="U_Item">
        <measure>gern:Item</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Plan">
        <measure>gern:Plan</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>gern:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_26d73443-b530-404b-a728-97e8ba301d05">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b8a40b0d-57b8-4eb8-bb53-891b5f563592">0000886744</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_cabef66c-bc33-408a-9fb3-4eae52d00f42">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      id="F_1e7bd566-1752-45f9-87e1-a254ef8b2f87"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      id="F_43d919e9-8f34-4532-901b-4bc0e74ccfa9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      id="F_57e68bf4-b075-47ff-94cb-4fffa7fbe456"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      id="F_a7f284af-766e-40ff-94ba-04d6489d905a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_075bab03-7a15-4dd6-87b2-88c5d830351e">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan
      contextRef="C_e4b1ab6e-2114-4b83-8ccc-b3e864bf5c71"
      id="F_22c29184-2380-4a26-aec3-6f112ba2f86e">P3M</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent
      contextRef="C_e4b1ab6e-2114-4b83-8ccc-b3e864bf5c71"
      id="F_bdc4642e-5d95-4614-922b-411dcd56cbf5">P42D</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="C_13a5e7dc-1814-4249-b841-344c76f1b61e"
      id="F_63389fc4-357d-477a-9d6b-0ecf16309618">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_48950aed-512d-4e10-b713-0562fb188089">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b594768e-a825-40e0-997a-23655ecd9aeb">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_ee50eca2-e555-49bc-b703-3ff5ac445b1d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_a9a5138a-1aa5-46d8-9bef-8bcad6f7a41c">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b03b6ade-16e8-4476-aa1a-3add5f3d7d50">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_709161c1-8393-4d9f-b956-78388f2c01be">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b86f3797-610b-4ab0-b668-66c38f626e87">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_58f1f8ec-1836-4cff-8011-d350045ed197">000-20859</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b1074c17-9cd7-4be3-b535-38a8620fd97e">GERON CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_19065c60-8f59-4880-bbac-ee0d02ce7f0e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_4aaeaf82-59b5-4f4b-a6c9-8cde5dfcf2a4">75-2287752</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_41800749-02e8-4e93-be69-d8bf5adfe6ef">919 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_cb024a79-2b93-4cda-85d7-ad7c9ae1ba3e">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_540cc183-e155-4851-92eb-e11337ba0a27">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_a0c8dfc5-010a-4543-98e5-06a64532cf72">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_3a62eb84-6bd2-4419-8e3e-7179f34f8b7c">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_963b9701-d5b2-47eb-9354-e0972ef3191d">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_eec82bd0-7d10-493d-b809-b2451a192840">473-7700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_63064263-b6e5-4dbe-b94f-1e39cad8bc79">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_13a61ed6-a9e8-4913-ad82-2d1f27649817">GERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_da62c10f-b7e7-4389-b377-b2a33cf1517c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_45850bd9-591c-40a4-abd2-39dd6ce899fd">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_de1aa834-6bfd-4826-9c61-6ce1ad59e026">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_3843e50e-1c34-47f4-b58b-7a5a71b501aa">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_df7a2e15-9c02-4edb-a8a2-04ad1f457cc2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_45b8d0d9-99e0-4c9a-ab88-2d7f2c8402dd">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_dbd02901-7902-4e12-bdb5-e010f59abfe7">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_a4f07cfb-9465-4e79-8f28-4e841cd48dd1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_3c986f20-ba1c-48e6-8dd4-342cf9b3004d">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_484bc8b2-4fea-4c80-b319-effb5d805d61">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_e187259e-e97b-46a8-80da-962ad03f320c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_ccbb9418-68cc-4fe4-a4a4-5c49b6f5042f"
      decimals="0"
      id="F_6e48d79b-7fbc-4163-93ef-5b96a37913ef"
      unitRef="U_USD">2430700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_8a986e2f-1a04-4888-9532-0bcd96b69f07"
      decimals="INF"
      id="F_b2d33bc8-3035-4f4b-afe9-b9608f7901a6"
      unitRef="U_shares">636904470</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_4082e6c0-b996-4b92-9263-677c9ec7fc20">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:90%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:9%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:7pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Document&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Form 10&#x2011;K&lt;br/&gt;Parts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="text-indent:-10pt;padding-left:10pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;III&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_9d4db841-4040-49af-8130-b75213b7c7ed">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ITEM 1C. CYBERSECURITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We operate in the biopharmaceutical sector, which is a highly regulated sector subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; disruption of our clinical trials, manufacturing or supply chain; violation of privacy laws and other litigation and legal risk; and reputational risk. We rely primarily on industry-leading third parties and a cloud-based infrastructure for our information technology systems, and accordingly are dependent on these third parties&#x2019; own cybersecurity risk management practices and strategy. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including clinical trial data, intellectual property, confidential information that is proprietary, strategic, financial or competitive in nature, and personal data (&#x201c;Information Systems and Data&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We take a risk-based approach to identify and assess the cybersecurity threats and risks that could affect our business and Information Systems and Data.  Our Information Technology personnel help identify, assess and manage our cybersecurity threats and risks, and support our efforts to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use various methods and tools to identify, assess and manage cybersecurity threats and risks, including, for example, automated tools, industry reports, third party threat assessments and penetration testing. In addition, we encrypt data at rest and maintain network security controls, such as firewalls and virtual private networks. We also conduct computerized system monitoring and access control, including asset management, tracking and disposal associated with onboarding and offboarding of personnel. We maintain cybersecurity insurance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. For example, we have implemented and maintain an incident response plan, and we utilize automated tools designed to maintain email security. We have also implemented a computerized system security and password policy that defines security for access to computer systems managed and controlled by us, and a procedure for computerized system incident management to address any unplanned issues in regulated computerized systems that could impact subject safety, product quality, and data integrity. We periodically conduct cybersecurity incident tabletop training exercises involving our personnel and plan to conduct similar training in 2025.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our assessment and management of material risks from cybersecurity threats are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management processes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For example, our head of Information Technology evaluates material risks from cybersecurity threats and reports periodically to the Audit Committee of our Board, which evaluates our overall enterprise risk. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including, for example, cybersecurity software providers such as Crowdstrike, cybersecurity service providers such as Mimecast, penetration testing firms, auditors, and professional services firms, including legal counsel. These relationships enable us to leverage specialized knowledge and insights, enabling our cybersecurity strategies and processes to remain consistent with industry best practices.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We rely on third-party service providers to perform a variety of functions throughout our business, such as contract manufacturing organizations, contract research organizations, suppliers and consultants, and third party logistics organizations and distributors to distribute RYTELO. We conduct quality audits of regulated vendors, which typically include an assessment of such vendor&#x2019;s information technology systems, and we impose appropriate contractual obligations on vendors pertaining to information security. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our efforts may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the risks from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity threats that may materially affect us &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Report, including &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks Related to Information Technology Systems, Data Security and Data Privacy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management Personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We seek to hire information technology personnel with skills appropriate to help us prepare for cybersecurity incidents, approve cybersecurity processes, and review security assessments and other security-related reports.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including executive management. When appropriate given the nature of any potential cybersecurity incident, our executive management works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, and to make any legally required notifications to individuals or regulatory agencies, including making any required disclosures under the Exchange Act.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_e9365d51-f92d-462d-a65a-e9d7fd331738">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_90bdaef6-ceec-4029-8744-390a20f65019">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data. For example, we have implemented and maintain an incident response plan, and we utilize automated tools designed to maintain email security. We have also implemented a computerized system security and password policy that defines security for access to computer systems managed and controlled by us, and a procedure for computerized system incident management to address any unplanned issues in regulated computerized systems that could impact subject safety, product quality, and data integrity. We periodically conduct cybersecurity incident tabletop training exercises involving our personnel and plan to conduct similar training in 2025.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_0246080b-20b7-4edb-8206-ae894cec5ae2">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our assessment and management of material risks from cybersecurity threats are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management processes.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_d9fb0844-88b1-449c-ad94-e91dcaa4a750">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_eaee845d-97b4-4832-8a26-c62d1f8aed4e">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_7b1c2ed4-86f8-431c-9b0b-b9a08941c47d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the risks from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity threats that may materially affect us &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Report, including &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risks Related to Information Technology Systems, Data Security and Data Privacy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_2abeb59a-11a9-4d53-9a85-b262a95612bb">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_d9d60646-4433-4ac2-a640-6088b0475c9f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Board of Directors addresses our cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_be3bb9df-7855-44d7-88e4-2d91afd5cb40">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee of our Board is responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_234925f5-d938-4907-96c3-8700f5a65e39">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Audit Committee, as well as our Chief Financial Officer, Chief Legal Officer, and other members of our executive management as appropriate, receives periodic reports from our head of Information Technology concerning our significant cybersecurity threats and risk and the processes we have implemented to address them.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_e9da2177-def8-4aa4-a687-7dc441e57773">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Audit Committee also receives various periodic presentations related to cybersecurity threats, risk and mitigation. &lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_cc874063-203b-421b-ab90-3c115a2c5bdd">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk Management Personnel&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We seek to hire information technology personnel with skills appropriate to help us prepare for cybersecurity incidents, approve cybersecurity processes, and review security assessments and other security-related reports.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including executive management. When appropriate given the nature of any potential cybersecurity incident, our executive management works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, and to make any legally required notifications to individuals or regulatory agencies, including making any required disclosures under the Exchange Act.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_2729f3c0-08e3-4ecc-93fc-ee69873ccf5c">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Information Technology personnel responsible for cybersecurity risk assessment and management processes are managed by certain members of our executive management, including our Chief Financial Officer.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Together with our executive management, our Information Technology personnel are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. &lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_33dd99d3-c213-4a5e-844a-0a84e199b3ae">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <dei:AuditorFirmId
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_ddf7e96f-b19e-45f1-a8bc-1465a1489444">42</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_fe11bf57-e3d9-468d-a6a4-cfaab74c6da7">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Geron Corporation (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024 and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 26, 2025 expressed an unqualified opinion thereon.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_589284f5-eb08-4dd6-aa87-69929f518824">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_219e0fc2-6b5f-49ad-8878-abec1ab12e57">San Jose, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_812b0185-8fe9-4bcf-bc23-f00e3c3fbd08"
      unitRef="U_USD">79016000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_de933eaa-9a97-4859-af60-73fb21ba3331"
      unitRef="U_USD">70023000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_aa8f6022-ae17-41da-94fa-1a576589b19f"
      unitRef="U_USD">1860000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_bb29fd94-a540-4516-b86f-0af37696a1d8"
      unitRef="U_USD">1115000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_8895f688-af1f-48fe-ab9d-b2a60d56129a"
      unitRef="U_USD">327550000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_75d9a0f4-3cf5-4742-8acd-334b8646849e"
      unitRef="U_USD">263676000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_9e7b5015-af42-4a14-a716-e89307704c3b"
      unitRef="U_USD">35946000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_bc0d0bea-e76c-45a4-977f-be294c6ad0b9"
      unitRef="U_USD">2853000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_cfa33b03-c3a0-4bfd-ba65-1d35d8f2832b"
      unitRef="U_USD">1655000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:InventoryNet
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_ab8f4498-aea9-4464-ae32-a6936d3f6a3c"
      unitRef="U_USD">38714000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_5b7b1649-3bcd-41dc-b033-1ccb9f671514"
      unitRef="U_USD">5053000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_c8d903fe-4e81-4fd5-9525-f192ab622ab8"
      unitRef="U_USD">4879000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_fce85f4c-45b2-4622-aa80-b562783a9bce"
      unitRef="U_USD">490992000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_b96a95cd-34d3-42e1-b22c-3b2006e5b152"
      unitRef="U_USD">341348000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_bdf751b5-73e6-4e0a-9dd1-85d54fe8ac0a"
      unitRef="U_USD">94519000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_90593b22-8a5c-43bc-bf47-a8ce6a5bb150"
      unitRef="U_USD">43298000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_e80e749a-b907-4385-bf82-01ee21e481c0"
      unitRef="U_USD">1310000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_9eb64496-b934-4554-bd28-f027c74ab1ed"
      unitRef="U_USD">1177000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_6ce29e59-263e-4d5a-b40f-0d52e270d9b0"
      unitRef="U_USD">2881000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_74caa8ce-2e83-41cd-b669-91ca36789789"
      unitRef="U_USD">3556000</us-gaap:OperatingLeaseRightOfUseAsset>
    <gern:DepositsAndOtherAssetsNoncurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_f5a3aa4f-c0cf-4216-a6bb-d82054d9766d"
      unitRef="U_USD">4079000</gern:DepositsAndOtherAssetsNoncurrent>
    <gern:DepositsAndOtherAssetsNoncurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_464468e0-e1b0-4f5b-bcd1-28a8d60c87c6"
      unitRef="U_USD">4697000</gern:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_23342465-6ed0-4d10-a3c8-5a80aba55293"
      unitRef="U_USD">593781000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_29cfaaf7-0f4d-4e72-a71a-a964ee6dddfd"
      unitRef="U_USD">394076000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_9b44b725-cc74-4bad-a332-d97e12a9c10d"
      unitRef="U_USD">8595000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_82139d85-d0d7-4c9b-a91a-b42c25f1a223"
      unitRef="U_USD">6161000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_7e8d64d5-0445-49b3-b4d0-e38f9301a4dc"
      unitRef="U_USD">22808000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_7614c751-3166-40b4-8250-e6135319603c"
      unitRef="U_USD">13759000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_89b9c8ef-0e47-46ad-95e1-0fe9c3064bd7"
      unitRef="U_USD">974000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_8bb8ddcd-56ff-45bf-a91e-583aea7b0db6"
      unitRef="U_USD">949000</us-gaap:OperatingLeaseLiabilityCurrent>
    <gern:LiabilityRelatedToSaleOfFutureRoyalties
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_5fa0683a-f6dc-43ce-87b8-409a704461f7"
      unitRef="U_USD">20372000</gern:LiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_e8f08164-d5d0-4ced-b125-0ea8af599246"
      unitRef="U_USD">35549000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_98063a31-9af4-4e77-98d0-0106e9e0693b"
      unitRef="U_USD">40308000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_ef47f803-b47c-4204-a738-aaf6f9e67336"
      unitRef="U_USD">46893000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_ed6264b6-d94b-4aac-8917-6f7ed7d3e766"
      unitRef="U_USD">88298000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_20685f1b-1db3-4e7b-9b2a-dc81a8c6f4e4"
      unitRef="U_USD">108070000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_1b3d4a56-0b50-4283-850d-f93e0af18685"
      unitRef="U_USD">2266000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_6fcee147-d483-44be-bec8-d6b22bb13a54"
      unitRef="U_USD">3006000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <gern:NoncurrentLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_e7d04c25-d371-40fd-ad75-3b8486eccf68"
      unitRef="U_USD">104421000</gern:NoncurrentLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_93f4554c-3947-4128-8377-3c620117eddf"
      unitRef="U_USD">118476000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_81685c33-791b-4928-9e50-1fd3fc23b9c3"
      unitRef="U_USD">35051000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_ca96dfc5-976f-412e-85ac-49e1e538c6f4"
      unitRef="U_USD">313461000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_7764ccde-1ec6-4742-8d73-c38e1fec2ea5"
      unitRef="U_USD">146127000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_2d39d09d-5ce3-42ae-988d-a2935a761c22"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_aa2355f5-3f1c-4480-8842-2280d841a76c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_0050eff5-6556-4196-9f85-598b2bdf24b0"
      unitRef="U_shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_95c08f86-9a57-46b6-b64b-0418f1068397"
      unitRef="U_shares">3000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_93191638-c4c6-463b-ae5c-0d95105f68a0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_d5c895ad-36a3-452d-8380-12e332271ba5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_0802e70a-29d6-4244-b1a4-721fc6874726"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_5bfb4060-68aa-49ae-a91a-1fc6e9515b04"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_61fcc0c9-e194-447b-86db-7c210b6cfeea"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_7e15d54e-808d-4382-b8f4-4f6f7d487568"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_19ac7154-748c-4ff3-ab66-8a716e35cfa2"
      unitRef="U_shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_4317bdf9-cd75-41c2-9a7f-2b6688377422"
      unitRef="U_shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_ba668ac2-8b92-4c32-a232-ac7c2cf1bb5e"
      unitRef="U_shares">606387666</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_e8baf14d-58bf-4205-a249-32424a4844fc"
      unitRef="U_shares">606387666</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_3bc4669c-1d31-418d-93ec-ce138995f850"
      unitRef="U_shares">544912215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_fee11e69-affa-484d-af6f-f96d4a29c01f"
      unitRef="U_shares">544912215</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_2cacec14-5ccf-4eb8-92ee-578277d8f219"
      unitRef="U_USD">606000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_09334395-e678-4370-888f-ab0442de1754"
      unitRef="U_USD">545000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_508c9d71-e7be-4537-94d4-a8757f4eafb3"
      unitRef="U_USD">2051794000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_ca9fe6f5-224b-480f-847b-06c875cbe170"
      unitRef="U_USD">1844988000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_44d3c4a0-b7f4-4460-a47d-89b3c37e1612"
      unitRef="U_USD">-1772341000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_74462f0c-a920-4b76-8df9-655db4797ada"
      unitRef="U_USD">-1597769000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_8b4c5879-b85d-4709-99b7-f6142c05470d"
      unitRef="U_USD">261000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_f1eed248-98fd-455d-8ab9-36ba79b809a3"
      unitRef="U_USD">185000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_154a0b6a-0f09-4f10-ae21-614d185cdd78"
      unitRef="U_USD">280320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_f4308541-ae59-4dc3-b880-3e12eb6da142"
      unitRef="U_USD">247949000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_b72dfec3-705b-4da4-9633-9ab45260ff81"
      unitRef="U_USD">593781000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_4e390f3b-9fed-4fb3-a504-f511bad79f21"
      unitRef="U_USD">394076000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_522fafdb-07e4-4339-b103-c323ad02c3e7"
      decimals="-3"
      id="F_4d932607-abae-4019-8138-51dcd5d27b7d"
      unitRef="U_USD">76495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a91cce50-3f56-4202-8cbb-e2061a4afe4d"
      decimals="-3"
      id="F_0a8a1545-6460-43d2-a0e5-fbcc88cecd16"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9979f2e9-baa0-488c-bfc3-27175ab0bfd6"
      decimals="-3"
      id="F_6618a07c-d4a5-4ca3-b1a3-12b2b692576e"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_54df7d29-aa46-434f-bb2e-e36ffb0cf1c7"
      decimals="-3"
      id="F_d8deebb5-3316-44e5-9f7f-4b02ab8c5ade"
      unitRef="U_USD">499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7f38441e-2b05-4d47-8fbc-1af5f0430674"
      decimals="-3"
      id="F_d4bb3f01-c89e-43bb-af41-29b6a268572a"
      unitRef="U_USD">237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9d292321-d77a-49f3-8195-59f85dac9752"
      decimals="-3"
      id="F_529d5db4-4474-47cf-99bb-362208fb28b8"
      unitRef="U_USD">596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_d4a95005-17f1-4afc-88e4-abb7a092a890"
      unitRef="U_USD">1256000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9262e17d-8d35-474a-a820-adef83a29095"
      unitRef="U_USD">103738000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_f3be454a-a8e5-4d6f-b0c3-8b32c7f611a0"
      unitRef="U_USD">125046000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_b237b2b2-4459-49eb-a75e-e6bf3904960b"
      unitRef="U_USD">95518000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_4f55a90f-29f8-4ca3-84a3-f33be89653ef"
      unitRef="U_USD">145732000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_e0221685-0357-42ec-904b-d9495254f9a3"
      unitRef="U_USD">69135000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_a9755eaa-fa6c-4a86-82d7-337451b63a01"
      unitRef="U_USD">43628000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9cb6e45d-9de8-4e53-afad-9b909461957e"
      unitRef="U_USD">250726000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_30157bdb-59fd-4569-bd83-5eaa8c456cd5"
      unitRef="U_USD">194181000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_73ac5f0c-14c4-4f49-a774-5c62de584bff"
      unitRef="U_USD">139146000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_72a754ca-f0f2-4f1a-90c2-d26d34f4ca72"
      unitRef="U_USD">-173732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_82a617df-25c3-4796-9a9a-a5f86fc50562"
      unitRef="U_USD">-193944000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_e0426b26-f0a1-4ad2-bc64-fb59750cf8b1"
      unitRef="U_USD">-138550000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_1c781a37-1588-4460-b608-6b263fb3077d"
      unitRef="U_USD">19607000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_f3350d50-c62a-4c46-8618-ce5ea9603945"
      unitRef="U_USD">18152000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_88198c9c-9cc6-4f1a-9317-c469cfeedf2a"
      unitRef="U_USD">2529000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_5c54b32c-9aaf-4325-bb52-8976fcb31cde"
      unitRef="U_USD">18504000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_844209a9-8fce-4b47-9205-8717ac6c1ee2"
      unitRef="U_USD">8312000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_ed78a984-5a36-4262-bae9-2973c6b7e168"
      unitRef="U_USD">6882000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_52ff9f42-cf65-4103-be22-76ab6c0eb5d6"
      unitRef="U_USD">-236000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_ef7bc292-d953-4e5d-905b-a6977fa5a752"
      unitRef="U_USD">-23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_d2c6db8c-473c-4eac-aab1-cd1dba052d07"
      unitRef="U_USD">1002000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_4d397d94-1ba0-476a-9eea-b34ef503cc7a"
      unitRef="U_USD">-1707000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_49539888-b6f2-424f-ad6d-d25b05566cc3"
      unitRef="U_USD">-174572000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_b63e9a93-afce-48d5-8658-ee43495af3f5"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_75d3689d-f154-48a1-9196-ce9adc4104ef"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="2"
      id="F_e3725e44-f40e-478f-bd27-00c8d6451a65"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="2"
      id="F_8bb2ac66-d8b1-4e40-95c1-1e4ca1acd499"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="2"
      id="F_9667dbdf-63a2-4c65-8e2a-d4040e122fdd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="2"
      id="F_27849bee-dd81-4f9b-befd-e0f344c1fe7b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="2"
      id="F_c03f4010-f907-4e85-aa29-a3964d7fb2ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="2"
      id="F_0b09dd1a-b350-41a8-83ea-b84a52118770"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="0"
      id="F_df748b26-0556-49f0-b56b-b1a12e4d6c2e"
      unitRef="U_shares">646033247</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="0"
      id="F_7f6de24c-185a-4708-ae03-205f7449a1a8"
      unitRef="U_shares">646033247</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="0"
      id="F_afbf85e0-ec48-4ef6-9094-09e8dddf923d"
      unitRef="U_shares">570645405</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="0"
      id="F_f3710073-b82e-43f2-8680-4247fe781f80"
      unitRef="U_shares">570645405</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="0"
      id="F_d616b9c6-fb7a-4580-b934-5b4f32052295"
      unitRef="U_shares">380784846</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="0"
      id="F_3e8dd9f3-7079-4856-ad9c-1c64c0a3dbf2"
      unitRef="U_shares">380784846</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_3fd6c14c-f553-4b6b-b7b3-ec5a46bf3962"
      unitRef="U_USD">-174572000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_6376558b-e041-4b98-89be-2e5dec5aad8c"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_dc0d9307-ef26-4486-a18e-4d6dfc004d2a"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_c57c6812-edf9-433a-95e6-8699d2194635"
      unitRef="U_USD">88000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_4abdf747-d9fd-467b-9171-0e41b6556eb1"
      unitRef="U_USD">431000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_15a119db-ca60-4969-948e-d38b11a1d692"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_215039e0-856f-446f-a8d5-ce7cd9b1f0b7"
      unitRef="U_USD">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_5a20dc78-4e86-4019-ba64-c5d525c1bb94"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_a345a3ea-a8f8-4136-9067-bcafed027c14"
      unitRef="U_USD">22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_67b6a06a-d158-420d-b9e6-3d12c500fbdb"
      unitRef="U_USD">-174496000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_fe6ac07e-00e1-4666-aec1-6c2212e6521a"
      unitRef="U_USD">-183723000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_eaeb4413-e060-431b-9c76-c7a56643dcb0"
      unitRef="U_USD">-141947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_87979f69-8b59-4913-a42e-83306a925036"
      decimals="INF"
      id="F_44f16411-c14e-4d28-aab3-92ab7adf4814"
      unitRef="U_shares">323731591</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_87979f69-8b59-4913-a42e-83306a925036"
      decimals="-3"
      id="F_058e0fc5-d23b-4c2d-89f9-ab6b0e0b9b33"
      unitRef="U_USD">324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_08984eb3-5203-4824-90b9-9a8e53b3fb49"
      decimals="-3"
      id="F_46d94c8e-3299-42f9-9ce4-0308e1db38aa"
      unitRef="U_USD">1398006000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_17d0f4ad-e466-499f-a3c7-32b9663b6681"
      decimals="-3"
      id="F_7092ff20-fe67-4a5b-97cd-863eebfc9c41"
      unitRef="U_USD">-1271741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1976851-cb4c-4762-8274-5ea9e52c9f8b"
      decimals="-3"
      id="F_fee57700-bd22-46cb-8122-c105c65b469f"
      unitRef="U_USD">-173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0b8accab-dfee-4fdd-a488-21c280ad6a1b"
      decimals="-3"
      id="F_4ac52faa-b2ed-4a27-ba53-53c191887280"
      unitRef="U_USD">126416000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_4c42d843-dd04-4e25-a34a-b1f703d11e39"
      decimals="-3"
      id="F_1da30298-8fd4-4607-8107-7b1ffd4d9f84"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_3672568f-3ad1-47a6-bc71-3bb0e17ba4ad"
      unitRef="U_USD">-141901000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_39107341-c344-46be-aec9-e2e8aba0d53f"
      decimals="-3"
      id="F_6ee37a67-124c-4df6-9067-860b4a519439"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_ef679a5e-a67b-46ce-b844-953d787086b3"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_39107341-c344-46be-aec9-e2e8aba0d53f"
      decimals="-3"
      id="F_4e8b0609-9fbf-4414-852b-79c5eaed3d80"
      unitRef="U_USD">22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_6c967d11-5302-41f5-89e9-b57321517b5b"
      unitRef="U_USD">22000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_f15e23b8-0e8e-4dda-a5e3-a439fd53eafa"
      decimals="-3"
      id="F_4ee24207-1c02-4ff7-9ed8-5ce391ab4c49"
      unitRef="U_USD">5066000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="INF"
      id="F_fd29d91d-d700-436b-8638-9b387d894745"
      unitRef="U_shares">53333334</gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="-3"
      id="F_59133ce0-14ad-45b0-bca3-4641e90356f3"
      unitRef="U_USD">53000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b"
      decimals="-3"
      id="F_9b062a03-f9a5-4b22-ad9c-73d72c578eb8"
      unitRef="U_USD">69863000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_e2dfc793-d5f7-4487-932f-da180a428216"
      unitRef="U_USD">69916000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="INF"
      id="F_fa2dee53-f6d2-4e53-86a2-697c7f89e42a"
      unitRef="U_shares">11663387</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="-3"
      id="F_6ad8483b-aaaf-4f6e-8a4c-e4a158876e9b"
      unitRef="U_USD">12000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b"
      decimals="-3"
      id="F_eca1f661-4878-491d-acb8-b988c417fc5e"
      unitRef="U_USD">15151000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_7e014323-f555-4522-a695-a4690b5f7985"
      unitRef="U_USD">15163000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="INF"
      id="F_ff17f34f-c4b9-44f4-8a77-d2d9e5eebca1"
      unitRef="U_shares">15962</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b"
      decimals="-3"
      id="F_c3336420-770d-4a77-ae42-47ed19778082"
      unitRef="U_USD">264000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_f204a165-a6db-4daf-b6a3-19aab4898725"
      unitRef="U_USD">264000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="INF"
      id="F_36d674d9-5c75-498d-9a1b-5bab76daa907"
      unitRef="U_shares">1518250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_b3315e20-fc51-4a6d-a7f9-64625bdf5415"
      decimals="-3"
      id="F_6e9b1900-e7e4-470c-a1b8-f037cb8f495f"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b"
      decimals="-3"
      id="F_b2f34486-945a-4f35-a048-9b9a9a729577"
      unitRef="U_USD">2184000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_d5e06ffd-f33b-497e-93d8-acc58b7c45f6"
      unitRef="U_USD">2185000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6bfd42fc-e577-4a10-9f88-ca0ab52d078b"
      decimals="-3"
      id="F_bee341ba-266c-4740-8f7c-b03353863d08"
      unitRef="U_USD">8001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_7abc6bc8-baca-459e-be5a-b792ef2f0f77"
      unitRef="U_USD">8001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_57c67b07-3a75-4f83-a90b-a0845eba9d49"
      decimals="INF"
      id="F_93914976-3dcf-44c7-a223-30d4249efaa9"
      unitRef="U_shares">390262524</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_57c67b07-3a75-4f83-a90b-a0845eba9d49"
      decimals="-3"
      id="F_012feda0-cf77-423a-badd-f96f40d732ed"
      unitRef="U_USD">390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f38cb9df-eb50-49af-95e3-99de5b6c1109"
      decimals="-3"
      id="F_84a3ee51-67d1-4d09-848e-335a63c77039"
      unitRef="U_USD">1493469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7c4b014b-4b49-4de5-99e6-77cd32c236fc"
      decimals="-3"
      id="F_a7729e67-4a8b-4f3a-95e8-c2967502b46a"
      unitRef="U_USD">-1413642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_442d47d2-f480-4e09-a7ea-6656c80440a8"
      decimals="-3"
      id="F_8f323869-3750-406d-a670-236dcf4e0deb"
      unitRef="U_USD">-219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402"
      decimals="-3"
      id="F_0f0bf244-027b-4c54-866b-a3a949de1fa9"
      unitRef="U_USD">79998000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_3360e8d8-eaad-4e88-a960-8e7053699623"
      decimals="-3"
      id="F_49f620e7-3754-4621-a87c-7d80515b04e0"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_dbb3b687-ab84-45bd-a535-8cbf64112aed"
      unitRef="U_USD">-184127000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_2f02a42c-f14d-4389-a9d0-40ae1afee99a"
      decimals="-3"
      id="F_9d9c0f38-030e-4967-8c1c-049301d9b423"
      unitRef="U_USD">431000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_7ec8a574-4c0a-4419-a2b0-776de2f6ebe3"
      unitRef="U_USD">431000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_2f02a42c-f14d-4389-a9d0-40ae1afee99a"
      decimals="-3"
      id="F_ee082f77-cec7-44bb-9190-62359c6f2098"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_8658b480-bbad-47ed-a1fa-0f48b22360e9"
      unitRef="U_USD">-27000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_4dcad59e-1e3b-43e6-a526-804130f682d4"
      decimals="-3"
      id="F_9b038ee2-ba38-499f-b7a6-f239bbc071a1"
      unitRef="U_USD">14507000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="INF"
      id="F_0439cd37-f048-4b67-894e-9708de23acf6"
      unitRef="U_shares">68007741</gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="-3"
      id="F_41f2683a-e099-4fe0-92fa-205882ec6fbf"
      unitRef="U_USD">68000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d"
      decimals="-3"
      id="F_9534fd71-818d-4623-be9c-36ec8ba561cf"
      unitRef="U_USD">213269000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_a7b00710-4f3d-48b6-a4a1-80193c9fead7"
      unitRef="U_USD">213337000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="INF"
      id="F_78f40225-b770-4f28-8350-c93b57f3a0db"
      unitRef="U_shares">77349858</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="-3"
      id="F_15a727a4-85b1-46e9-9116-795d2f459ef4"
      unitRef="U_USD">78000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d"
      decimals="-3"
      id="F_d1c030b3-b5f7-4cce-9038-093d5de17cc1"
      unitRef="U_USD">105834000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_b6a3da67-d0cd-42ee-b84b-340c3922d9d4"
      unitRef="U_USD">105912000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="INF"
      id="F_a6da2683-01e0-4b31-a1ca-18a80e4d6c15"
      unitRef="U_shares">36864</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="-3"
      id="F_57c4b745-eb7f-4028-b82c-f4fb79292020"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d"
      decimals="-3"
      id="F_13ae2b89-1db1-4ede-beaa-c8ef037b8402"
      unitRef="U_USD">828000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_adebf9f4-42db-4e5e-a8c7-02e816c4c97f"
      unitRef="U_USD">829000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="INF"
      id="F_5874e2cd-edf6-43f1-b71e-82896980ae07"
      unitRef="U_shares">9255228</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_4ed65fc6-0752-419b-9c26-e718bbbc446a"
      decimals="-3"
      id="F_d3cedfe3-67dc-49f5-90b3-49b8e8554517"
      unitRef="U_USD">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d"
      decimals="-3"
      id="F_235db96b-22c2-4f21-9d8a-a6f28a1baf01"
      unitRef="U_USD">13062000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_94de86a8-283f-4946-8c5f-89037b1f1902"
      unitRef="U_USD">13070000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3eb5fb7d-a0c7-41db-b035-e52acb2e0c4d"
      decimals="-3"
      id="F_99ba0b77-5680-4680-a27d-6c7e95f3b092"
      unitRef="U_USD">18526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_242282de-69a5-4f98-a5f5-ddc61fadd6f0"
      unitRef="U_USD">18526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8eb77d4c-4335-48c8-9562-05e492af76dc"
      decimals="INF"
      id="F_760823e3-0973-4707-be49-5b9d6e90cd79"
      unitRef="U_shares">544912215</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8eb77d4c-4335-48c8-9562-05e492af76dc"
      decimals="-3"
      id="F_8c6096a7-5e0b-486d-9a2a-48a7a48459c1"
      unitRef="U_USD">545000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cf181ee0-e9ee-474a-9747-6fe8c5a5fe77"
      decimals="-3"
      id="F_7535fb2c-4c36-407c-9160-82c769a0b62b"
      unitRef="U_USD">1844988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7f8c13fe-b7c8-47a4-9aa3-5c471dd1c446"
      decimals="-3"
      id="F_823ce54e-9508-48e5-ba9c-081c44b6e0a0"
      unitRef="U_USD">-1597769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_71d1f837-aa40-49d4-bd3f-4a76ced03892"
      decimals="-3"
      id="F_f4c34e56-12ed-40bf-95f1-411546f31812"
      unitRef="U_USD">185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_ec73b497-8141-43fc-9111-44c7f7004864"
      unitRef="U_USD">247949000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_9e25d180-78c3-41f5-b9e4-3eedf3398835"
      decimals="-3"
      id="F_7aceb52a-8887-41a0-91b4-20c9970456e9"
      unitRef="U_USD">-174572000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_77389319-7d1d-4e92-b706-f55854a90e0a"
      unitRef="U_USD">-174572000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_ba48a767-b0d9-4ebe-9ba8-df6962a5903f"
      decimals="-3"
      id="F_78f1350c-2220-424f-974a-876e20d8b749"
      unitRef="U_USD">-88000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_8955b3fc-a4b2-45b8-95d6-f54a1d660ec0"
      unitRef="U_USD">-88000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_ba48a767-b0d9-4ebe-9ba8-df6962a5903f"
      decimals="-3"
      id="F_0b153788-4bf5-4c55-8ca4-c82059ac0733"
      unitRef="U_USD">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_44090d8a-83df-4f30-8f56-c5450f82fe97"
      unitRef="U_USD">-12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_90739fa8-e72e-4147-a181-ff8aba129f93"
      decimals="-3"
      id="F_401433a8-11ea-4921-8a01-184e5cccc2d7"
      unitRef="U_USD">9271000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="INF"
      id="F_d7202d94-d3d4-4269-8aef-8ca3a04b5c92"
      unitRef="U_shares">41999998</gern:PublicOfferingStockIssuedDuringPeriodSharesNewIssues>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="-3"
      id="F_7ad967b3-f657-4635-a84b-9d5a73ea111a"
      unitRef="U_USD">42000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c"
      decimals="-3"
      id="F_5db575f9-6ecf-42a5-8259-3a58a68562d6"
      unitRef="U_USD">140687000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_8181308b-4980-43cd-bcef-2d1b6bf0f151"
      unitRef="U_USD">140729000</gern:PublicOfferingStockIssuedDuringPeriodValueNewIssue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="INF"
      id="F_036bce50-2d71-4f35-ba47-e199c4952029"
      unitRef="U_shares">1071981</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseShares>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="-3"
      id="F_df4af869-b193-4d73-becf-ad02ad9d3765"
      unitRef="U_USD">1000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c"
      decimals="-3"
      id="F_0e685269-82ce-47fd-b0f5-c53f19d89c97"
      unitRef="U_USD">1393000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_e2531462-1362-48a3-84e6-a16a1dd84738"
      unitRef="U_USD">1394000</gern:IssuanceOfCommonStockInConnectionWithWarrantExerciseValue>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="INF"
      id="F_3799f6f4-9bb4-45d3-8434-2c46deece504"
      unitRef="U_shares">8351</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c"
      decimals="-3"
      id="F_0a800cd0-ff04-48fd-b01e-2d0c2eec7264"
      unitRef="U_USD">134000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_4cfb65eb-5e91-4b9e-b33e-8b7093ea6304"
      unitRef="U_USD">134000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="INF"
      id="F_5a65ef10-38f0-473c-933d-d4261b14aea7"
      unitRef="U_shares">18395121</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_84180ddc-e18d-4b81-bb38-f3d15f581d85"
      decimals="-3"
      id="F_65b3137c-0fe0-44e0-b09e-f4e5e50e26a8"
      unitRef="U_USD">18000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c"
      decimals="-3"
      id="F_61901433-caf9-48ef-aebc-4cff533674de"
      unitRef="U_USD">32665000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_b8af13dc-1eeb-4b5f-95f3-4800ba4e161f"
      unitRef="U_USD">32683000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7fb7dc7a-74d0-4ea8-bd38-7a74c0caeb1c"
      decimals="-3"
      id="F_8d4ffdfd-f252-4260-9298-0a33f155002e"
      unitRef="U_USD">31927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_1026960b-2f20-4993-87b6-26eb2847831f"
      unitRef="U_USD">31927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a5c5ddc7-dfaa-4256-a811-8005fe000d01"
      decimals="INF"
      id="F_943c9266-ca8c-4423-802d-d2b2075e320e"
      unitRef="U_shares">606387666</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a5c5ddc7-dfaa-4256-a811-8005fe000d01"
      decimals="-3"
      id="F_9b020498-8595-48da-b6f3-9ed94d57760b"
      unitRef="U_USD">606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9feb8ba3-51fd-46c5-a45b-f7d80b5c6b95"
      decimals="-3"
      id="F_00992095-1501-4327-ab87-db00a2133167"
      unitRef="U_USD">2051794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_552c454b-a9ab-449e-b749-65c139a3cf3c"
      decimals="-3"
      id="F_4c610e7d-4ead-4d36-a3b2-3ae291199975"
      unitRef="U_USD">-1772341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc579693-1a73-41bc-8a82-5c04df25f0f9"
      decimals="-3"
      id="F_9d5be308-44a4-4680-9d4d-ac9c845d0e41"
      unitRef="U_USD">261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_8d64ede8-20f1-4bcb-8a22-4eb9b3c8674c"
      unitRef="U_USD">280320000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_33ad62d5-ea09-4732-ad6f-0f8a0e909a51"
      unitRef="U_USD">-174572000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_7216fbf0-adaf-4e99-a7a6-a1d8f568f674"
      unitRef="U_USD">-184127000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_03e4e39a-a48a-4266-a5ea-7c011d47da0d"
      unitRef="U_USD">-141901000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_2e9630b3-79d7-4774-9141-f10f250f418c"
      unitRef="U_USD">546000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_d0693592-24d3-4713-bbab-bc52d419c5e2"
      unitRef="U_USD">442000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_a4f3fbc5-c6a1-4bfe-8496-2b981984cbe7"
      unitRef="U_USD">288000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_e5cbba39-ea0a-444e-a898-07b94bd55b0e"
      unitRef="U_USD">9683000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_fd55c20a-4de7-429c-b561-c4aa0bf1681f"
      unitRef="U_USD">11150000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_0028ac57-9adf-4d70-a27a-27762bd9b15d"
      unitRef="U_USD">965000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_72282d4a-4d9f-4708-89c7-efc922867b03"
      unitRef="U_USD">-3108000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_dbc7e26f-b020-4a53-8d2d-34a8374326db"
      unitRef="U_USD">1088000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_99bfa767-63c7-4151-a26c-22f5c2809f9f"
      unitRef="U_USD">1327000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <gern:PaymentOnRoyaltyAgreement
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_2fc2943f-79a2-433f-803c-33f1d825fd09"
      unitRef="U_USD">2186000</gern:PaymentOnRoyaltyAgreement>
    <gern:Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9e583434-6b76-49c5-97b7-1315a66211d2"
      unitRef="U_USD">5345000</gern:Non-CashInterestExpenseOnLiabilitiesForSalesOfFutureRoyalities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_1d02b4cd-6715-4d68-a627-68300efbb573"
      unitRef="U_USD">-1707000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9a11231d-984e-4250-81db-d518dd6f65e3"
      unitRef="U_USD">135000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_28b1b870-c659-4d05-8a62-dc93dc55b28a"
      unitRef="U_USD">828000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_4c94e1de-2a35-453d-a77f-aa50d2e1c777"
      unitRef="U_USD">264000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_e8cb0b5c-5ee1-4da1-b583-75616385c1f6"
      unitRef="U_USD">31185000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_60ceb1f1-b8d3-42fa-a879-a1c4d757635d"
      unitRef="U_USD">18526000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_38bff75c-3708-4dc8-9eef-c73c7093ee95"
      unitRef="U_USD">8001000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_dadd2c38-9732-4ed9-927f-5bfaf972d974"
      unitRef="U_USD">675000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_313f52a4-9b3a-4963-bd7e-bf3966aeee54"
      unitRef="U_USD">591000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_bf2f194f-091b-4b17-a276-2d0d875b528c"
      unitRef="U_USD">580000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <gern:IncreaseInAllowanceForDoubtfulAccounts
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_3e5299bb-bd9c-4515-b2ba-a3027808b486"
      unitRef="U_USD">251000</gern:IncreaseInAllowanceForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_09b04647-5ab8-4760-949d-6d5e13e67aa9"
      unitRef="U_USD">37971000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_50a8168c-e47f-4e7f-a1d4-dfb87f4b02dd"
      unitRef="U_USD">35695000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_cae4ef4c-e596-49df-aa2f-a9c0aa781f6f"
      unitRef="U_USD">1198000</gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables>
    <gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_41bbf653-5179-4a4b-8ff3-f71d95416bbe"
      unitRef="U_USD">-1490000</gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables>
    <gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_af2ead2e-2197-4773-bec0-c7317ad72481"
      unitRef="U_USD">1381000</gern:IncreaseDecreaseInAccruedInterestReceivableNetAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_7ce3a1b4-32a5-4273-95a6-f470c055870a"
      unitRef="U_USD">175000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_e9ba6774-e019-482e-9a00-24e5073181ed"
      unitRef="U_USD">886000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_479416f7-9abd-4274-b0ca-80a8b22f5f1a"
      unitRef="U_USD">2630000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_cd7518de-ab14-4851-920a-381258e326bd"
      unitRef="U_USD">-618000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_ef2a6a20-e271-48ce-9e8f-028eb0f6c86f"
      unitRef="U_USD">-692000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_79f1ea9e-0e45-4531-935c-7c710bdfdd44"
      unitRef="U_USD">594000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_1e339ac2-b7a8-46e8-85d1-595492a4d593"
      unitRef="U_USD">2435000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_dd3b7133-8b09-40fb-a66e-1137485b84c5"
      unitRef="U_USD">-4029000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_4d8d0b61-6838-43a7-8e53-46113400d119"
      unitRef="U_USD">3503000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_987748f9-c3d3-40e4-a622-81efb148e8d4"
      unitRef="U_USD">9049000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_805bf7bc-2e1a-468f-864c-037808970d83"
      unitRef="U_USD">2224000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_d6355c41-d560-405a-9ed2-83f97671fc54"
      unitRef="U_USD">3435000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_71b1f931-d045-4fa2-bf34-9cef89c12e9c"
      unitRef="U_USD">-4759000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_470203fe-914d-4953-b794-de1e9c7e9f3f"
      unitRef="U_USD">7208000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_224ed1bf-75c5-462b-88b9-911813b1da00"
      unitRef="U_USD">3266000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9a2354b2-a439-4b58-a8d3-f5711bfd7f1e"
      unitRef="U_USD">-715000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_b9e007ad-0937-4b49-ba15-a62f087ef704"
      unitRef="U_USD">-640000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <gern:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_08ff0e10-0635-4dcd-9824-76f85c69a539"
      unitRef="U_USD">-572000</gern:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9c46a5f0-b293-4ae6-8a11-40df2fb93fb3"
      unitRef="U_USD">-218618000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_87cee3df-a3e1-436f-a366-d01705a38b70"
      unitRef="U_USD">-167743000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_2d2e02b1-cb10-48b9-8e5d-9f9d5813bb01"
      unitRef="U_USD">-127379000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_0bee8173-ec7d-4fc5-9edd-052687c88330"
      unitRef="U_USD">680000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_a70e0bab-61da-4651-8913-04dc66562c92"
      unitRef="U_USD">830000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_89d6ced3-ef75-4374-96e1-34fe8b6ba893"
      unitRef="U_USD">431000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_d7b8c816-601a-4e97-b558-debded9422ab"
      unitRef="U_USD">476932000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_213f5548-0c50-421f-aacc-10fb250d11dc"
      unitRef="U_USD">475594000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_8b1a7d4b-4b2d-4ff6-808c-ce1180b083c2"
      unitRef="U_USD">258007000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_a20f6298-21fe-4fbb-8725-956cba29e774"
      unitRef="U_USD">371608000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_7d8d8ae5-5748-4ec4-b52e-7cd3d035fd18"
      unitRef="U_USD">296102000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_7861066c-abef-4bc5-8e21-8b1638fd4d91"
      unitRef="U_USD">320505000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_c4aa65fb-9e34-470a-8cea-6171d927f1c1"
      unitRef="U_USD">-106004000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_27c6f550-90ed-4b19-96ad-1e7568df8813"
      unitRef="U_USD">-180322000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_b0a9ed18-e1e1-463c-806d-2cb3c88e9af4"
      unitRef="U_USD">62067000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_3f751bab-0500-4380-8e17-f2da22e28009"
      unitRef="U_USD">32683000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_606aa39a-17aa-429b-a411-1ed1c9af79f2"
      unitRef="U_USD">13072000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_b1815b45-1e31-4d32-b149-39b5a6134534"
      unitRef="U_USD">2185000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_cecac0ea-0b30-4462-acdb-52d904afe22b"
      unitRef="U_USD">140729000</gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants>
    <gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_8a35237a-3f2c-4338-87ad-00bf300b0e27"
      unitRef="U_USD">213337000</gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants>
    <gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_96498626-4554-4322-80ea-c40ea503e877"
      unitRef="U_USD">69916000</gern:ProceedsFromPublicOfferingIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_ce4b1264-8307-408c-a595-d5c12548a975"
      unitRef="U_USD">1394000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_2cb3a636-8629-4a3c-84dc-a51c53dc74bf"
      unitRef="U_USD">105912000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_bc62a797-405d-45bf-a72e-6677aded5b3d"
      unitRef="U_USD">15163000</us-gaap:ProceedsFromWarrantExercises>
    <gern:ProceedsFromSaleOfFutureRoyalties
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_0a71a93d-e8bb-4421-8485-e7b4d57eadd8"
      unitRef="U_USD">125000000</gern:ProceedsFromSaleOfFutureRoyalties>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_18eb4811-6e58-4e40-bc2d-87978ef41703"
      unitRef="U_USD">121120000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_fc9ce04e-5c13-4b75-80f3-c79fe355591b"
      unitRef="U_USD">29700000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_8cccca09-5de4-4297-9946-946fff452329"
      unitRef="U_USD">86554000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_22ca60d5-1113-49b6-9c45-069a7f1d5417"
      unitRef="U_USD">334372000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_ffe8764f-6cdb-4c71-90af-2216de8cb956"
      unitRef="U_USD">362021000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_5c232f9d-9f49-43b8-91ab-adb8f297db2e"
      unitRef="U_USD">87264000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_d014a4c1-8d85-47d1-b348-1516076fde1c"
      unitRef="U_USD">-12000</gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_2c12ce3d-87a3-4499-a943-885540c4006d"
      unitRef="U_USD">-27000</gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_ca35dc36-bc26-4f77-80b0-b93139d77bf4"
      unitRef="U_USD">22000</gern:EffectOfUnrealizedLossesAndExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_b49b890c-ece8-4140-b507-1e9b14158fa2"
      unitRef="U_USD">9738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_ae7a8236-2312-456f-83c4-580970e57fd9"
      unitRef="U_USD">13929000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_922ab298-8e9d-44d9-81f6-3b3bcbd5fb42"
      unitRef="U_USD">21974000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_61262f9b-0935-472e-8bc3-0dd41fc341b8"
      unitRef="U_USD">71138000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402"
      decimals="-3"
      id="F_a819b22a-398a-4aac-b502-c9501d519fd2"
      unitRef="U_USD">57209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0b8accab-dfee-4fdd-a488-21c280ad6a1b"
      decimals="-3"
      id="F_44519b0a-c7da-48e7-8781-76f120333ab8"
      unitRef="U_USD">35235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_50c03b10-980c-493d-b546-63aef5381ea8"
      unitRef="U_USD">80876000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_932dd683-db53-4ebc-9956-fa4d837b9cd3"
      unitRef="U_USD">71138000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402"
      decimals="-3"
      id="F_51982665-5e06-4534-a684-c1b857fe7833"
      unitRef="U_USD">57209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_f9cf17f0-f995-4bd5-beb4-097010dee656">&lt;p id="note_1_" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The terms &#x201c;Geron&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d; and &#x201c;us&#x201d; as used in this report refer to Geron Corporation, which was incorporated in the State of Delaware on November 28, 1990, and its wholly-owned subsidiaries, Geron UK Limited, or Geron UK, a United Kingdom company, and Geron Netherlands B.V., or Geron Netherlands, a Netherlands company. Geron UK was incorporated in September 2021, and its operations commenced in January 2022. Geron Netherlands was incorporated in February 2023, and its operations commenced in June 2023.  The Company's first-in-class telomerase inhibitor, RYTELO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (imetelstat), was approved by the U.S. Food and Drug Administration, or FDA, on June 6, 2024 for the treatment of certain adult patients with low- to intermediate-1 risk myelodysplastic syndromes, or lower-risk MDS, and is under development for the treatment of other hematologic malignancies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. Foreign currency translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#x2019; equity, on our consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,095,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,335,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. In January 2023, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,007,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2023 pre-funded warrant. In March 2024, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,999,998&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,002,668&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2024 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 10 on Stockholders' Equity for further discussion of our public offerings.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2024, 2023, and 2022, the diluted net loss per share calculation excludes potential dilutive securities of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,369,889&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,458,854&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,726,765&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. We recognize shipping and handling costs as an expense in cost of goods sold when we transfer control to a customer. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We distribute RYTELO in the U.S. through third party distributors and specialty pharmacies who are our customers. The third party distributors subsequently resell our product through their related specialty pharmacy providers to patients and health care providers. Separately, we have or may enter into payment arrangements with various third-party payors including pharmacy benefit managers, private healthcare insurers and government healthcare programs who provide coverage and reimbursement for our product that have been prescribed to a patient.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies. To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. See Note 2 on Revenue Recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Sales, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Items Deducted from Gross Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. The most significant items deducted from gross product sales where we exercise judgment are rebates, sales returns and chargebacks.&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Product Revenues&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our net product revenues are recognized, net of variable consideration related to certain allowances and accruals, at the time our customers obtain control of our product, which is generally upon delivery to our customers. We use the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts to estimate variable consideration and consideration payable to parties other than our customers related to our product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We record reserves, based on contractual terms, for components related to product sold during the reporting period, as well as our estimate of product that remains in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare providers. On a quarterly basis, we update our estimates and record any needed adjustments in the period we identify the adjustments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We sell RYTELO to our customers at wholesale acquisition cost, and calculate product revenue from RYTELO sales, net of variable consideration and consideration payable to parties other than our customers. Variable consideration and consideration payable to parties other than our customers consists of estimates related to the following categories:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Allowances&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We pay fees for distribution services, such as fees for certain data that customers provide to us. We estimate our customers will earn these fees and deduct these fees from gross product revenues and accounts receivable at the time we recognize the related revenues.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Discounts for Prompt Payment&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We provide for prompt payment discounts to our customers, which are recorded as a reduction in gross product revenue in the same period that the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We offer customers the right to return products if they are damaged, defective, or expired, as defined in customer agreements. We estimate product returns considering experience from similar products in the market, historical return patterns, sales data, and inventory levels in the distribution channel. These estimates are recorded as a reduction in gross product revenue at the time of sale. Once products are returned, they are destroyed; we do not record a right of return asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chargebacks occur when our contracted customers, mainly federal agencies that can purchase off the Federal Supply Schedule and Public Health Service 340B covered entities, buy directly from our distributors and wholesalers at discounted prices. The distributors and wholesalers then charge us the difference between their purchase price and the discounted price. We estimate chargebacks considering the terms of the applicable arrangement and our visibility regarding utilization. These chargebacks are recorded in the same period as the related revenue, reducing our net product revenue and receivables. We typically issue credits for these amounts within a few weeks of notification.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Rebates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to discount obligations under government programs. Reserves for rebates payable under these government programs are recorded in the same period as gross product revenue, reducing our gross product revenue and creating a liability in accrued liabilities. Major rebates include those from the Medicare and Medicaid programs. Estimates for rebates are made considering statutory discount rates and expected utilization. These estimates are updated each period with actual claims and other current information, taking into account historical data, comparable products and other considerations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Co-payment Assistance&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We offer co-payment assistance to patients with commercial insurance that have coverage and reside in states that allow co-payment assistance. We estimate the average co-payment assistance amounts for our products based on expected customer demographics and record any such amounts within accrued expenses and a reduction to product revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The liability related to the Royalty Pharma Agreement and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement&lt;/span&gt;&lt;span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assessed the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#x2019;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Agreement&lt;/span&gt;&lt;span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations.  If an available-for-sale security&#x2019;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 4 on Fair Value Measurements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Accounts receivable are stated net of an allowance that reflects our current estimate of credit losses expected to occur over the life of the receivable. In developing our allowance for expected credit losses, we use assumptions to capture the risk of loss, even if remote, based on a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The payment terms on our trade receivables are relatively short. As a result, our collection risk is mitigated to a certain extent by the fact that sales are collected in a relatively short period of time, allowing for the ability to reduce exposure on defaults if collection issues are identified&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We update our allowance as necessary to reflect expected credit losses over the remaining lives of the accounts receivable for outstanding trade receivables that are past due, have known disputes or have experienced any negative credit events that may result in future&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;collectability issues. We do not currently expect our current or future exposures to credit losses to have a significant impact on us. The estimated allowance for expected credit losses was not material as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, nor were the changes to the allowance during any of the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory is recorded at the lower of cost or net realized value, with cost determined under the weighted average method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, salaries, wages and stock-based compensation for personnel involved in the manufacturing process, and indirect overhead costs. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. Prior to regulatory approval, we expensed costs associated with the manufacture of a product candidate to research and development expense unless we are reasonably certain such costs have future commercial use and net realizable value. Since we consider attaining regulatory approval of a product candidate to be highly uncertain and difficult to predict, we expect only in rare instances that pre-launch inventory will be capitalized, if at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We began capitalizing inventory related to RYTELO in the quarter ended June 30, 2024, as we received approval of RYTELO on June 6, 2024, and the related costs were expected to be recoverable through the commercialization of RYTELO.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs. Cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. For the twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, other than packaging costs, substantially all of our RYTELO inventory sold had a zero-cost basis as it was recorded as research and development expenses prior to the FDA&#x2019;s approval.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our current RYTELO (imetelstat) clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We record property and equipment at cost and calculate depreciation using the straight&#x2011;line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock or restricted stock unit awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 10 on Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Debt Issuance Costs and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated Other Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#x2019; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_075bab03-7a15-4dd6-87b2-88c5d830351e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; represents our chief operating decision maker. We view our operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. For additional information, see Note 13 on Segment Reporting.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued and Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods.  We adopted the guidance in the annual period ended December 31, 2024. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13. We view our operations as a single segment. See Note 13 on Segment Reporting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_dc0ffe87-e45e-40ad-80b8-f49754cafa20">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts Geron Corporation and its wholly-owned subsidiaries, Geron UK and Geron Netherlands. We have eliminated intercompany accounts and transactions. We prepare the financial statements of Geron UK and Geron Netherlands using the local currency as the functional currency. We translate the assets and liabilities of Geron UK and Geron Netherlands at rates of exchange at the balance sheet date and translate income and expense items at average monthly rates of exchange. Foreign currency translation adjustments are included in accumulated other comprehensive income (loss), a separate component of stockholders&#x2019; equity, on our consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_d1b3f941-46c6-45e4-8eca-b983befdea85">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding for the periods presented without consideration of potential common shares. In April 2022, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,095,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, also known as the 2022 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. In May 2020, we entered into an underwriting agreement in connection with a public offering of our common stock, pursuant to which we issued a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,335,239&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2020 pre-funded warrant, together with accompanying warrants to purchase shares of our common stock. The 2022 pre-funded warrant and 2020 pre-funded warrant each are exercisable immediately at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. In January 2023, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,007,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2023 pre-funded warrant. In March 2024, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,999,998&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,002,668&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2024 pre-funded warrant. We included the 2023 pre-funded warrant, the 2022 pre-funded warrant and the 2020 pre-funded warrant in the computation of basic net loss per share, as applicable, since their exercise price is negligible, and they may be exercised at any time. See Note 10 on Stockholders' Equity for further discussion of our public offerings.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net income per share would be calculated by adjusting the weighted-average number of shares of common stock outstanding for the dilutive effect of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued, as determined using the treasury-stock method. Potential dilutive securities consist of outstanding stock options and warrants to purchase our common stock. Diluted net loss per share excludes potential dilutive securities for all periods presented as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented in the accompanying consolidated statements of operations. Since we incurred a net loss for 2024, 2023, and 2022, the diluted net loss per share calculation excludes potential dilutive securities of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,369,889&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,458,854&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;145,726,765&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares, respectively, related to outstanding stock options and warrants, as their effect would have been anti-dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_59108335-739f-4e5e-b267-22b8c789f159"
      decimals="INF"
      id="F_4d46f569-08f1-409f-81ae-c291ef0ab720"
      unitRef="U_shares">18095238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_6dee5fa2-b2df-4b03-9654-001c5bf49a8a"
      decimals="INF"
      id="F_486c75f4-9676-4940-aa52-f81d30bbfb22"
      unitRef="U_shares">8335239</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_59108335-739f-4e5e-b267-22b8c789f159"
      decimals="INF"
      id="F_7459775d-24b0-4b26-bc9d-ccae4841845a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6dee5fa2-b2df-4b03-9654-001c5bf49a8a"
      decimals="INF"
      id="F_b90234e5-c34a-4511-9d5d-4e5a53630092"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_08593508-3737-4150-83da-4b9da613a6e2"
      decimals="INF"
      id="F_56b6f06a-bbb9-4ccd-bf37-8243c5d4351c"
      unitRef="U_shares">68007741</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_9accca2e-98a7-4feb-90e0-dd4c4473e5a3"
      decimals="INF"
      id="F_9e57488d-cea9-4432-acb8-7f9bdbaf5017"
      unitRef="U_shares">25000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_38ee5de3-7306-4f4b-8d58-eb882cf9590d"
      decimals="INF"
      id="F_574ffa5e-2190-4e7d-9f7b-f0297aec328d"
      unitRef="U_shares">41999998</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_3462f4ba-71e7-4d47-bf58-841e2d8028a7"
      decimals="INF"
      id="F_cd45bb7f-2ee8-4718-8e5c-4dc7bd475262"
      unitRef="U_shares">8002668</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f8d8f292-1d56-4204-b316-2a9290be7c09"
      decimals="INF"
      id="F_dca45a7e-e715-4520-8b3b-00a7178e6188"
      unitRef="U_shares">77369889</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7d57e1e2-e7e9-4439-be29-506043e9a42a"
      decimals="INF"
      id="F_83e2c7f0-161a-462d-bea2-c1233ce05952"
      unitRef="U_shares">75458854</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7ec87361-5500-473b-846d-d51e7d5b6cdc"
      decimals="INF"
      id="F_f6c38662-c430-4bd8-b1be-8ca85ac133e3"
      unitRef="U_shares">145726765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_20b39356-7994-4094-9c5b-42646cdaff10">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to accrued liabilities, revenue recognition, fair value of marketable securities and equity investments, operating leases, right-of-use assets, lease liabilities, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other market specific and relevant assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_1410e17b-8fcf-47c3-a460-0076a1321bfd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, we perform the following five steps: (i) identify the contract(s) with our customer; (ii) identify the promised goods or services in the agreement and determine whether they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations based on stand-alone selling prices; and (v) recognize revenue when (or as) we satisfy each performance obligation. We recognize shipping and handling costs as an expense in cost of goods sold when we transfer control to a customer. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We allocate the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised goods or services underlying each performance obligation. Estimated selling prices for license rights are calculated using an income approach model and include the following key assumptions, judgments and estimates: the development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We distribute RYTELO in the U.S. through third party distributors and specialty pharmacies who are our customers. The third party distributors subsequently resell our product through their related specialty pharmacy providers to patients and health care providers. Separately, we have or may enter into payment arrangements with various third-party payors including pharmacy benefit managers, private healthcare insurers and government healthcare programs who provide coverage and reimbursement for our product that have been prescribed to a patient.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following is a description of the principal activities from which we generate revenue. License fees and royalty revenue primarily represent amounts earned under agreements that out-license our technology to various companies. To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. See Note 2 on Revenue Recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Sales, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product from our consigned inventory location for shipment directly to a patient.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Items Deducted from Gross Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenues from sales of products are recorded net of government rebates and rebates under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience. The most significant items deducted from gross product sales where we exercise judgment are rebates, sales returns and chargebacks.&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Product Revenues&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our net product revenues are recognized, net of variable consideration related to certain allowances and accruals, at the time our customers obtain control of our product, which is generally upon delivery to our customers. We use the expected value method, which is the sum of probability-weighted amounts in a range of possible consideration amounts to estimate variable consideration and consideration payable to parties other than our customers related to our product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We record reserves, based on contractual terms, for components related to product sold during the reporting period, as well as our estimate of product that remains in the distribution channel inventory at the end of the reporting period that we expect will be sold to qualified healthcare providers. On a quarterly basis, we update our estimates and record any needed adjustments in the period we identify the adjustments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We sell RYTELO to our customers at wholesale acquisition cost, and calculate product revenue from RYTELO sales, net of variable consideration and consideration payable to parties other than our customers. Variable consideration and consideration payable to parties other than our customers consists of estimates related to the following categories:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Allowances&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We pay fees for distribution services, such as fees for certain data that customers provide to us. We estimate our customers will earn these fees and deduct these fees from gross product revenues and accounts receivable at the time we recognize the related revenues.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Discounts for Prompt Payment&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We provide for prompt payment discounts to our customers, which are recorded as a reduction in gross product revenue in the same period that the related product revenue is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Product Returns&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We offer customers the right to return products if they are damaged, defective, or expired, as defined in customer agreements. We estimate product returns considering experience from similar products in the market, historical return patterns, sales data, and inventory levels in the distribution channel. These estimates are recorded as a reduction in gross product revenue at the time of sale. Once products are returned, they are destroyed; we do not record a right of return asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Chargebacks&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chargebacks occur when our contracted customers, mainly federal agencies that can purchase off the Federal Supply Schedule and Public Health Service 340B covered entities, buy directly from our distributors and wholesalers at discounted prices. The distributors and wholesalers then charge us the difference between their purchase price and the discounted price. We estimate chargebacks considering the terms of the applicable arrangement and our visibility regarding utilization. These chargebacks are recorded in the same period as the related revenue, reducing our net product revenue and receivables. We typically issue credits for these amounts within a few weeks of notification.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Government Rebates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to discount obligations under government programs. Reserves for rebates payable under these government programs are recorded in the same period as gross product revenue, reducing our gross product revenue and creating a liability in accrued liabilities. Major rebates include those from the Medicare and Medicaid programs. Estimates for rebates are made considering statutory discount rates and expected utilization. These estimates are updated each period with actual claims and other current information, taking into account historical data, comparable products and other considerations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Co-payment Assistance&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We offer co-payment assistance to patients with commercial insurance that have coverage and reside in states that allow co-payment assistance. We estimate the average co-payment assistance amounts for our products based on expected customer demographics and record any such amounts within accrued expenses and a reduction to product revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We previously entered into several license agreements with various oncology, diagnostics, research tools and biologics production companies, whereby we granted certain rights to our non-imetelstat related technologies. Under these agreements, non-refundable upfront fees and annual license maintenance fees were considered fixed consideration, while milestone payments and royalties were identified as variable consideration. Since June 30, 2021, no active license agreements remain. The license related to our specialized oligonucleotide backbone chemistry, as well as patent rights covering the synthesis of monomers, the building blocks of oligonucleotides, terminated effective April 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the divestiture of our human embryonic stem cell assets, including intellectual property and proprietary technology, to Lineage Cell Therapeutics, Inc. (formerly BioTime, Inc. which acquired Asterias Biotherapeutics, Inc.) in 2013, we are entitled to receive royalties on sales of certain research or commercial products utilizing our divested intellectual property.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Licenses of Intellectual Property&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If we determine the license to intellectual property is distinct from the other performance obligations identified in the agreement and the licensee can use and benefit from the license, we recognize revenue from non-refundable upfront fees allocated to the license upon the completion of the transfer of the license to the licensee. For such licenses, we recognize revenue from annual license maintenance fees upon the start of the new license period. For licenses that are bundled with other performance obligations, we assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable upfront fees or annual license maintenance fees. At each reporting date, we reassess the progress and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Milestone Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of each agreement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that we do not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory authority. Once the assessment of probability of achievement becomes probable, we recognize revenue for the milestone payment. At each reporting date, we assess the probability of achievement of each milestone under any current agreements.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;text-indent:4.857%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, we estimate the sales incurred by each licensee during the reporting period based on historical experience and accrue the associated royalty amount.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_df2b125d-9e59-4f32-b324-35107e108566">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The liability related to the Royalty Pharma Agreement and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Agreement&lt;/span&gt;&lt;span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of non-cash interest expense over the estimated term of the agreement. Each reporting period, we assessed the estimated timing and amount of future expected Royalty Payments over the estimated term. If there are changes to the estimate, we recognize the impact to the liability&#x2019;s amortization schedule and the related non-cash interest expense prospectively. Additionally, the transaction costs associated with the liability will be amortized to non-cash interest expense over the estimated term of the Royalty Pharma&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Agreement&lt;/span&gt;&lt;span style="color:#060606;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_9c0482ae-369c-4445-80f5-da8b5a641f29">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. We are subject to credit risk related to our cash equivalents and marketable securities. Our marketable debt securities include U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We classify our marketable debt securities as available for sale. We record available for sale debt securities at fair value with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses are included in interest income and are derived using the specific identification method for determining the cost of securities sold and have been insignificant to date. Dividend and interest income are recognized when earned and included in interest income on our consolidated statements of operations.  If an available-for-sale security&#x2019;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;See Note 4 on Fair Value Measurements.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_fbc50aa9-041d-4d51-a735-7bb3f1844223">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash consists of funds maintained in separate money market or certificate of deposit accounts for credit card purchases.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_10a84c55-8bb9-4b06-81cd-1f8e34e9b470">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In general, accounts receivable consists of amounts due from customers, net of customer allowances for cash discounts, product returns, and chargebacks. Accounts receivable are stated net of an allowance that reflects our current estimate of credit losses expected to occur over the life of the receivable. In developing our allowance for expected credit losses, we use assumptions to capture the risk of loss, even if remote, based on a number of factors including existing contractual payment terms, individual customer circumstances, historical payment patterns of our customers, a review of the local economic environment and its potential impact on expected future customer payment patterns&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The payment terms on our trade receivables are relatively short. As a result, our collection risk is mitigated to a certain extent by the fact that sales are collected in a relatively short period of time, allowing for the ability to reduce exposure on defaults if collection issues are identified&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We update our allowance as necessary to reflect expected credit losses over the remaining lives of the accounts receivable for outstanding trade receivables that are past due, have known disputes or have experienced any negative credit events that may result in future&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;collectability issues. We do not currently expect our current or future exposures to credit losses to have a significant impact on us. The estimated allowance for expected credit losses was not material as of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, nor were the changes to the allowance during any of the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_79b81e55-2e26-491a-9bf9-d165a0ef2eda">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory is recorded at the lower of cost or net realized value, with cost determined under the weighted average method. Inventory costs include third-party contract manufacturing, third-party packaging services, freight, salaries, wages and stock-based compensation for personnel involved in the manufacturing process, and indirect overhead costs. We periodically review our inventories to identify obsolete, slow moving, excess or otherwise unsaleable items. If obsolete, slow moving, excess or unsaleable items are observed and there are no alternate uses for the inventory, we record a write-down to net realizable value. The determination of net realizable value requires judgment including consideration of many factors, such as estimates of future product demand, product net selling prices, current and future market conditions and potential product obsolescence, among others. Prior to regulatory approval, we expensed costs associated with the manufacture of a product candidate to research and development expense unless we are reasonably certain such costs have future commercial use and net realizable value. Since we consider attaining regulatory approval of a product candidate to be highly uncertain and difficult to predict, we expect only in rare instances that pre-launch inventory will be capitalized, if at all.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We began capitalizing inventory related to RYTELO in the quarter ended June 30, 2024, as we received approval of RYTELO on June 6, 2024, and the related costs were expected to be recoverable through the commercialization of RYTELO.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_d104f9ee-c443-4ec8-afa1-97a1308474b3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of Goods Sold&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including salary related and stock-based compensation expense for employees involved with production and distribution, freight, and indirect overhead costs. Cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. For the twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, other than packaging costs, substantially all of our RYTELO inventory sold had a zero-cost basis as it was recorded as research and development expenses prior to the FDA&#x2019;s approval.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_a8cab4cd-ac97-4e21-984c-b3dfc45a67b5">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses currently consist of expenses incurred in developing and testing imetelstat and research related to potential next generation telomerase inhibitors. These expenses include, but are not limited to, payroll and personnel expense, lab supplies, non-clinical studies, clinical trials, including support for investigator-led clinical trials, raw materials to manufacture clinical trial drugs, manufacturing costs for research and clinical trial materials, sponsored research at other labs, consulting, costs to maintain technology licenses and research-related overhead.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our current RYTELO (imetelstat) clinical trials are being supported by contract research organizations, or CROs, and other vendors. We accrue expenses for clinical trial activities performed and managed by CROs based upon the amount of work completed on each trial. Expenses are recorded based on contracted amounts agreed to with our CROs and through monthly reporting provided by CROs. We monitor activities conducted and managed by the CROs to the extent possible through internal reviews, review of contractual terms and correspondence with CROs. We record expense on the best information available at the time. However, additional information may become available to us which may require us to record adjustments to research and development expenses in future periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_59c9641c-9e90-4791-a7dd-0511951124d8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We record property and equipment at cost and calculate depreciation using the straight&#x2011;line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the estimated useful life or remaining term of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:DepreciationDepletionAndAmortizationPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      id="F_1616b450-2530-4369-a96a-0edc2d31e843">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_2387a91b-b859-4a73-8b32-8fa2b0349569">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain various stock incentive plans under which stock options and restricted stock awards can be granted to employees, non-employee directors and consultants. We also have an employee stock purchase plan for all eligible employees. We recognize stock-based compensation expense based on grant-date fair values of service-based stock options on a straight-line basis over the requisite service period, which is generally the vesting period. For performance-based stock options with vesting based on the achievement of certain strategic milestones, stock-based compensation expense is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being met, if at all. If the assessment of probability of the performance condition changes, the impact of the change in estimate would be recognized in the period of the change. The determination of grant-date fair values for our service-based and performance-based stock options and employee stock purchases using the Black-Scholes option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. The grant-date fair value for service-based restricted stock or restricted stock unit awards is determined using the fair value of our common stock on the date of grant. We evaluate whether an adjustment to the assumptions of fair value of our common stock and historical volatility are required if observed prices of our common stock materially differ from historical information.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We measure share-based payments to non-employees based on the grant-date fair value of the equity awards to be issued. We recognize stock-based compensation expense for the fair value of the vested portion of non-employee stock-based awards on our consolidated statements of operations. For additional information, see Note 10 on Stockholders&#x2019; Equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_dffff53e-92bc-4e23-bf16-cb29b70842ff">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating leases are included in operating leases, right-of-use assets and lease liabilities on our consolidated balance sheets. Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of remaining lease payments over the expected lease term. The present value of remaining lease payments within the 12 months following the balance sheet date are classified as current lease liabilities. The present value of lease payments not within the 12 months following the balance sheet date are classified as noncurrent lease liabilities. The interest rate implicit in lease contracts is typically not readily determinable. As such, to calculate the net present value of lease payments, we apply our incremental borrowing rate, which is the estimated rate to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment as of the lease commencement date. We may adjust the right-of-use assets for certain adjustments, such as initial direct costs paid or incentives received. In addition, we include any options to extend or terminate the lease in the expected lease term when it is reasonably certain that we will exercise any such option. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For lease agreements entered into after January 1, 2019 that include lease and non-lease components, such components are generally accounted for separately. We have also elected not to recognize on our consolidated balance sheets leases with terms of one year or less.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_45ec2dd9-4817-4a92-a372-a3f6fa7f62de">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Debt Issuance Costs and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Debt issuance costs include legal fees, accounting fees, and other direct costs incurred in connection with the execution of our debt financing. Debt discounts represent costs paid to the lenders. Debt issuance costs and debt discounts are deducted from the carrying amount of the debt liability and are amortized to interest expense over the term of the related debt using the effective interest method.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_70682e9b-1a2b-4d09-bdb3-c3767c43277f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated Other Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated other comprehensive gain (loss) includes certain changes in stockholders&#x2019; equity which are excluded from net income (loss). Accumulated other comprehensive loss on our consolidated balance sheets as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, is comprised of net unrealized losses on marketable securities and cumulative translation adjustments.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_2599758c-9551-4025-bd53-e89ba766228d">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We maintain deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and are subject to tests of recoverability. Our deferred tax assets include net operating loss carryforwards, federal and state tax credits and capitalized research and development. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Our net deferred tax asset has been fully offset by a valuation allowance because of our history of losses. Any potential accrued interest and penalties related to unrecognized tax benefits would be recorded as income tax expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_51f66d73-2bbc-42d1-94e8-7765ecca9758">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_075bab03-7a15-4dd6-87b2-88c5d830351e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; represents our chief operating decision maker. We view our operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_72fea7cf-c9c5-44bc-98b4-73a0c18edffe;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; segment, the development of therapeutic products for oncology. As a result, the financial information disclosed herein materially represents all of the financial information related to our principal operating segment. For additional information, see Note 13 on Segment Reporting.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_f20747ad-193b-4a35-a27d-3579319404c2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Standards Accounting Board (FASB) issued Accounting Standards Update (ASU) 2023-09, Income Taxes (ASU 2023-09), which requires issuers to make additional discloses on an annual basis related to specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis, disclose additional information about income taxes paid as well as other disaggregated disclosures. ASU 2023-09 is effective for the Company as of January 1, 2025 for annual periods. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 address investor requests for more detailed expense information and require additional disaggregated disclosures in the notes to financial statements for certain categories of expenses that are included on the face of the income statement. This guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are evaluating the impact of this ASU on our consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New Accounting Pronouncements &#x2013; Issued and Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (ASU 2023-07), which requires issuers to make additional disclosures with respect to segment expenses, including required disclosure on an annual and interim basis for significant segment expenses and other segment items. The improved disclosure requirements apply to all public entities that are required to report segment information, including those with only &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07 also permits the disclosure of more than one measure of a segment&#x2019;s profit or loss. ASU 2023-07 is effective for the Company as of January 1, 2024 for annual periods and as of January 1, 2025 for interim periods.  We adopted the guidance in the annual period ended December 31, 2024. There was no impact on our reportable segments identified and additional required disclosures have been included in Note 13. We view our operations as a single segment. See Note 13 on Segment Reporting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_b1a01b63-fcbf-464f-8b0d-6e1beebe8bde"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_7aaa359a-617d-45fc-903c-9207360b3e82">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. REVENUE RECOGNITON&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net Product Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, our only source of product revenue has been from the U.S. sales of RYTELO, which we began shipping to our customers in June 2024. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.434%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.564999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Twelve Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross product revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross-to-net adjustments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chargebacks and distributor service fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government rebates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales returns and allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross-to-net adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net product revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_9db2a7fc-5cae-4a44-ad2b-5f8dfc2d7478">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:71.434%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.564999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Twelve Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross product revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross-to-net adjustments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chargebacks and distributor service fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government rebates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Sales returns and allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total gross-to-net adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cceeff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net product revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gern:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a57a8238-5f15-4041-aa47-381c050af69a"
      decimals="-3"
      id="F_a39aaa23-fbe9-42eb-8b37-6600025f017a"
      unitRef="U_USD">89418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b54b04e2-e7b3-40e7-b38b-61e399b5089e"
      decimals="-3"
      id="F_b10dadee-7dfb-40fe-ab84-7d6c5d3cec75"
      unitRef="U_USD">-11772000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d755aa78-f964-4edb-8019-908621c662cc"
      decimals="-3"
      id="F_9b8b8e74-d377-4c68-8035-119ce9be76b6"
      unitRef="U_USD">-926000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9814d90e-77b9-4d3a-907e-2bf9844e66cc"
      decimals="-3"
      id="F_7f1113d2-379f-4375-a0bf-30f8bb1c33fd"
      unitRef="U_USD">-225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f5b3d0b0-b24e-4a9c-9342-027dfaa89069"
      decimals="-3"
      id="F_d2d6fd0d-15ca-473f-b7a9-6a1011e8a8c4"
      unitRef="U_USD">-12923000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_522fafdb-07e4-4339-b103-c323ad02c3e7"
      decimals="-3"
      id="F_a2ad3dbc-9b7e-4f9d-9c72-e40468f4ad69"
      unitRef="U_USD">76495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_909d6628-6d94-4b4e-afe9-6b6b75ff1057">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;INVENTORY&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All of our inventories are related to the manufacturing of RYTELO. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents our inventory as of December 31, 2024: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:43.120000000000005%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_d2e4ffa4-aec9-471a-a748-7e165e11b342">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents our inventory as of December 31, 2024: &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:43.120000000000005%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSupplies
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_6977c68f-b1c9-420d-a855-5f91b5cbbd04"
      unitRef="U_USD">4904000</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryWorkInProcess
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_2e259f9c-c9d3-4ff4-9291-af3ef4aedf7a"
      unitRef="U_USD">30093000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_b91560b2-625e-41d6-98da-04454c6c0d61"
      unitRef="U_USD">3717000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_37809950-8f9f-42e7-9cb3-51213db9efc4"
      unitRef="U_USD">38714000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_7a3765fd-f8ac-4d61-bc8a-22705f864a3a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash Equivalents, Restricted Cash and Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.337%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;421,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;422,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.337%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;br/&gt;&#160;&#160;&#160;(due in less than&lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The gross unrealized losses related to U.S. Treasury securities, municipal securities, government-sponsored enterprise securities, commercial paper and corporate notes as of December 31, 2024 and 2023 were due to changes in interest rates and not credit risk. If an available-for-sale security&#x2019;s fair value is less than its amortized cost basis, we evaluate whether the decline is the result of a credit loss, in which case an impairment is recorded through an allowance for credit losses. We have not recorded any allowances for credit losses on our available-for-sale securities for the years ended December 31, 2024 and 2023 as we have not identified any unrealized losses for these securities attributable to credit factors.  Our exposure to unrealized losses may increase in the future due to the economic pressures or uncertainties associated with local or global economic recessions as a result of ongoing geopolitical events, such as the current military conflict between Ukraine and Russia, as well as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failure. We do not intend to sell the investments and it is not more likely that not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value on a Recurring Basis&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We categorize financial instruments recorded at fair value on our consolidated balance sheets based upon the level of judgment associated with inputs used to measure their fair value. The categories are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:7%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:90.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:1.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:7%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:90.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Below is a description of the valuation methodologies used for financial instruments measured at fair value on our consolidated balance sheets, including the category for such financial instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds and certificates of deposit are categorized as Level 1 within the fair value hierarchy as their fair values are based on quoted prices available in active markets. Commercial paper, U.S. Treasury securities, municipal securities, government-sponsored enterprise securities and corporate notes are categorized as Level 2 within the fair value hierarchy as their fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The embedded derivatives are classified within Level 3 of the fair value hierarchy. See Note 9 on Debt.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liability Related to the Sale of Future Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We determined the fair value of the liability related to the sale of future royalties based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3. See Note 9 on Debt.&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#212529;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers between Level 1, Level 2, and Level 3 during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 and indicates the fair value category assigned.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.008%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.482000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;427,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;324,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.074%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in restricted cash on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in current portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(4)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in noncurrent portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We currently place our cash, restricted cash, cash equivalents and marketable securities with multiple institutions in the United States. Generally, these deposits may be redeemed upon demand and therefore, bear minimal risk. Deposits with banks may exceed the amount of insurance provided on such deposits. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents and marketable securities. Cash equivalents and marketable securities currently consist of money market funds, government-sponsored enterprise securities, U.S. Treasury securities, municipal securities, commercial paper and corporate notes. Our investment policy, approved by the audit committee of our board of directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. However, we are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents to the extent recorded in our consolidated balance sheets. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk of our financial position at the depository institutions in which those deposits are held. As of  December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; customers accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our gross accounts receivable: McKesson Financial Center, which accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our gross accounts receivable; ASD Specialty Healthcare LLC, which accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our gross accounts receivable; Cardinal Health Inc., which accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our gross accounts receivable; and Sina Drug, which accounted for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our gross accounts receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_63559f1a-ab9d-4fb5-b402-9e0677c28f1c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.337%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,620&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;421,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;422,069&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents, restricted cash and marketable securities by security type at December 31, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.337%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.301%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.864%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted cash:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;48,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,628&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac"
      decimals="-3"
      id="F_87eb4618-09f1-4490-8002-eac06986d926"
      unitRef="U_USD">45215000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac"
      decimals="-3"
      id="F_095e5a54-0125-4e53-908f-efd68b1b52a0"
      unitRef="U_USD">45215000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b"
      decimals="-3"
      id="F_0bb4d2f3-d74c-41e4-8a2e-4380c3c35a4a"
      unitRef="U_USD">4978000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b"
      decimals="-3"
      id="F_d40cbb7c-55cf-41c0-87f7-28e55e8a17c1"
      unitRef="U_USD">1000</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_cbe12500-3a15-45d9-ae4b-e2b5b6c5629b"
      decimals="-3"
      id="F_35eae2f3-3f62-4c7b-911f-d1d3724a703b"
      unitRef="U_USD">4977000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_ac75c302-82ca-4059-9ef3-c879d44097ae"
      unitRef="U_USD">50193000</us-gaap:CashEquivalentsAtCarryingValue>
    <gern:CashAndCashEquivalentsUnrealizedLosses
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_635d1a08-aa59-4b71-8f04-f9b9d628cd48"
      unitRef="U_USD">1000</gern:CashAndCashEquivalentsUnrealizedLosses>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_2128ca22-a5a3-4903-be91-379223cd2f32"
      unitRef="U_USD">50192000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac"
      decimals="-3"
      id="F_f6aa2671-3819-4590-8372-0e2ed5b4f6fe"
      unitRef="U_USD">1587000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_3ca647dc-16b1-48f8-b741-24db5011baac"
      decimals="-3"
      id="F_16a2187c-a521-4e52-99bd-2e06314d22bb"
      unitRef="U_USD">1587000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_50fa79d0-89b9-452b-b91e-8b9da8f97576"
      decimals="-3"
      id="F_6a1bae39-b0cf-406f-9dfb-bb6dfc9d5fe7"
      unitRef="U_USD">273000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_50fa79d0-89b9-452b-b91e-8b9da8f97576"
      decimals="-3"
      id="F_bd214dc0-b4d5-4f71-8ab0-84324c2227c9"
      unitRef="U_USD">273000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_68198153-2144-4fdb-b4a5-23eb0ec339d6"
      unitRef="U_USD">1860000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_41975bca-23be-404c-b82f-511796a9c77b"
      unitRef="U_USD">1860000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_377efc67-17d1-4c2f-b1ba-a630aaf4fd5d"
      unitRef="U_USD">7937000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_0cd99a46-d251-4b33-8a11-7920a582bed8"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_87e61c79-3b46-4e84-9a4e-74a2e8c51c0a"
      unitRef="U_USD">7959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c"
      decimals="-3"
      id="F_a44fcce1-eac9-4f32-9edb-7616db92a24b"
      unitRef="U_USD">22620000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c"
      decimals="-3"
      id="F_1731833a-b386-4c28-ab55-05dcce98ba55"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c"
      decimals="-3"
      id="F_972827ce-0805-4c9e-a703-df0927303f31"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_25936ce9-b5e7-4f52-81fd-3eed441c5f3c"
      decimals="-3"
      id="F_8b4acd2c-d598-4cfa-9dfa-0cd9d43a4f99"
      unitRef="U_USD">22610000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4599e5dd-ea25-4616-91b6-01afed02aaca"
      decimals="-3"
      id="F_aa2b59cd-a306-4b0c-b39f-3fbb9c65917a"
      unitRef="U_USD">8741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4599e5dd-ea25-4616-91b6-01afed02aaca"
      decimals="-3"
      id="F_13f294e7-88d2-4abf-87bc-f70469c6570d"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4599e5dd-ea25-4616-91b6-01afed02aaca"
      decimals="-3"
      id="F_cbf659f4-5d3c-477c-ae30-059c3c007731"
      unitRef="U_USD">8748000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_17721376-21ba-4213-97cc-ba4ef44f9a96"
      unitRef="U_USD">180131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_97ade9ee-9557-42ab-9bd1-2a2247bb67b7"
      unitRef="U_USD">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_9f64e876-0e91-4289-b37f-feb63351cc59"
      unitRef="U_USD">56000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_8f1ca466-351f-4950-9e1b-3a2401a0a5dd"
      unitRef="U_USD">180225000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_fb9db193-29c6-4666-a1f5-d02bc41aea4d"
      unitRef="U_USD">130361000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_7a9ed543-b391-42ce-9c72-380a2f1a9fd5"
      unitRef="U_USD">284000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_6efa5a8c-a1d8-4c2f-a0f3-a668c7cb07b6"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_6d9a235d-d6fc-4bd2-a2b3-3a81592c936a"
      unitRef="U_USD">130618000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_3cf480bb-1dcf-4e9f-aa02-e451b160c9c7"
      unitRef="U_USD">72000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_55a269c6-ac7b-441a-b63a-4efd1717c521"
      unitRef="U_USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_66f85f91-032e-4748-a293-9f363f51b5b2"
      unitRef="U_USD">97000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_f6a79685-cc70-4176-b41a-a2f013f7ec0f"
      unitRef="U_USD">71909000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_77f3c088-03ee-4870-a9ac-b4224034ed80"
      unitRef="U_USD">421790000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_948e21f4-1130-4524-b988-88dac7c0ea9b"
      unitRef="U_USD">470000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_f9ea9fbd-2410-4aa8-8b94-5f267dec4f3a"
      unitRef="U_USD">191000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_23f4137e-3709-4331-9957-e2f5f30a89c5"
      unitRef="U_USD">422069000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b"
      decimals="-3"
      id="F_4dfb5297-aa2e-4dab-8162-1a462b2cfed4"
      unitRef="U_USD">16815000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b"
      decimals="-3"
      id="F_5ae60958-702c-4719-b6b2-666e334e8b82"
      unitRef="U_USD">16815000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_4eb74d6c-8ea5-496b-8701-0ce1a3018d42"
      unitRef="U_USD">16815000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_f21598e3-406f-494a-acbb-2e2536e6dc76"
      unitRef="U_USD">16815000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b"
      decimals="-3"
      id="F_dd3458ac-9f43-4cb4-b8ff-9c64fcfb1a97"
      unitRef="U_USD">843000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_b09d7f2d-153d-4916-ae66-f66dee60587b"
      decimals="-3"
      id="F_0c956c86-c7b3-4089-99a6-7c2e39f28034"
      unitRef="U_USD">843000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_78978391-737a-40c3-9d68-851dcc4702f4"
      decimals="-3"
      id="F_12a71e67-e375-4201-89ee-9d831c2eb728"
      unitRef="U_USD">272000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_78978391-737a-40c3-9d68-851dcc4702f4"
      decimals="-3"
      id="F_fb6cc6d4-0edd-4ee5-8ba0-dad85f2e7a8c"
      unitRef="U_USD">272000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_44aa6ca8-be52-4bd8-a809-bc93222a617d"
      unitRef="U_USD">1115000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_352e9f33-9d20-4fe7-ac6a-d36ecfafc936"
      unitRef="U_USD">1115000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_634d30a6-a512-472f-83d8-6f6a44496fa1"
      decimals="-3"
      id="F_1e7bae57-cc56-4bf8-a363-d050bc1c651c"
      unitRef="U_USD">26752000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_634d30a6-a512-472f-83d8-6f6a44496fa1"
      decimals="-3"
      id="F_479eff1c-dbaf-4d81-a7a0-39e2c76636fa"
      unitRef="U_USD">95000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_634d30a6-a512-472f-83d8-6f6a44496fa1"
      decimals="-3"
      id="F_9d69e8bb-f716-4378-b3d7-8207c67bddae"
      unitRef="U_USD">26847000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_335cdb98-b657-42f3-973a-6dc964cba271"
      decimals="-3"
      id="F_11173291-3cd5-457f-a3d2-e63e409ba587"
      unitRef="U_USD">2877000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_335cdb98-b657-42f3-973a-6dc964cba271"
      decimals="-3"
      id="F_3385a966-e8b9-4427-8121-cd7cb472e1ae"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_335cdb98-b657-42f3-973a-6dc964cba271"
      decimals="-3"
      id="F_a9ad8be0-33da-4097-bc3a-6382c05eb6ed"
      unitRef="U_USD">2894000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d"
      decimals="-3"
      id="F_d1cd7a98-7152-4e22-8e7b-af32002f79d8"
      unitRef="U_USD">86250000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d"
      decimals="-3"
      id="F_84eb8233-7fa6-4f0f-8793-c4afd2dabae4"
      unitRef="U_USD">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d"
      decimals="-3"
      id="F_e2813aed-5592-47c8-936e-9062054681a1"
      unitRef="U_USD">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f6a4e7d0-90ee-49d6-aea0-7f336081815d"
      decimals="-3"
      id="F_264ab2f4-0d45-4427-bd57-bcce025e7135"
      unitRef="U_USD">86201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f"
      decimals="-3"
      id="F_7de1cf12-836c-479e-8e65-dbbb0f9feece"
      unitRef="U_USD">13598000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f"
      decimals="-3"
      id="F_399aeb7e-b6d2-4a57-a399-cc0eff26a10c"
      unitRef="U_USD">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a66fda4f-4e3c-4112-a056-63dc2e81ad8f"
      decimals="-3"
      id="F_afa96b49-6ff8-4a77-8d2d-1fdef64e948d"
      unitRef="U_USD">13670000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_7cb2efea-c085-4dab-9ff4-0f7da922a5b2"
      unitRef="U_USD">102270000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_330f22a3-f74f-4307-8c4e-1b8a536c7ea7"
      unitRef="U_USD">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_9d2eb039-ae94-4778-9f73-c8715c46f459"
      unitRef="U_USD">33000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_1b3b1f9e-ed16-4f2f-9871-98ec950a70bd"
      unitRef="U_USD">102268000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_82ad382c-84e1-4bea-9874-b9953081885a"
      unitRef="U_USD">48409000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_413033af-303a-4ef8-adb1-d9dbf2e286ea"
      unitRef="U_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_936b1d2a-3d39-4ce7-a01f-b6459df48f95"
      unitRef="U_USD">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_869c0f9a-7085-4036-94b4-d8dfe7735a4e"
      unitRef="U_USD">48360000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_de2275a5-dc71-4d42-8b9c-4d34a4c061fa"
      unitRef="U_USD">26628000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_a28f7e79-8c5f-4f10-80c6-070e58caf924"
      unitRef="U_USD">130000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_e1aeb9f8-50fe-4193-8e2a-857c579df7c8"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_c109d090-e2f3-4739-ab7c-1b80450b82e5"
      unitRef="U_USD">26734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_8f7698d1-6893-49d5-bd91-654b185a45b9"
      unitRef="U_USD">306784000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_8723f6bb-1266-489a-a92f-64166f5d012e"
      unitRef="U_USD">402000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_a0411d34-1128-4e0f-a6d8-848f473cba10"
      unitRef="U_USD">212000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_0a096ba0-c7e2-4b46-92da-0da07f076845"
      unitRef="U_USD">306974000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_7ffdbdb7-56a7-455f-9fb7-b55426252eca">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents and marketable securities with unrealized losses that have been in a continuous unrealized loss position for less than 12 months and 12 months or longer at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less Than 12 Months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 Months or Greater&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;br/&gt;&#160;&#160;&#160;(due in less than&lt;br/&gt;&#160;&#160;&#160;one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in &lt;br/&gt;&#160;&#160;&#160;one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities &lt;br/&gt;&#160;&#160;&#160;(due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in less than one year)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes (due in one to two years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;211&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_882ff649-1c77-4675-88fa-641eeaf95ec4"
      unitRef="U_USD">18593000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_6b894488-7927-4fee-aa0c-3ef8fd45bb26"
      unitRef="U_USD">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_4373d2a3-4606-4897-bbc2-47a335e751e7"
      unitRef="U_USD">18593000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_d17eed81-8c6b-456e-9079-f7df0f14e619"
      decimals="-3"
      id="F_864bf9d3-c69b-40c2-936f-71cd686f31d2"
      unitRef="U_USD">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_990c2e50-4517-412e-980e-3de56cbeb0a5"
      unitRef="U_USD">66076000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_a1209979-03eb-47ad-9be0-07bb77904e34"
      unitRef="U_USD">56000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_3635a0f3-f358-454d-aeab-21b8b958afda"
      unitRef="U_USD">66076000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_b5e55ab0-3380-41b2-b5f6-dd0b7c86f73f"
      decimals="-3"
      id="F_2b15e1ff-6c3c-44f2-94bd-89b6a14e3a1f"
      unitRef="U_USD">56000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_2aa6b2fd-8237-44b0-b66b-a225ee27ed71"
      unitRef="U_USD">31549000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_4e256966-0030-4dad-b098-b7ace84078b2"
      unitRef="U_USD">26000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_e1f8c7a8-f4b9-4b76-b6c4-028492eb283a"
      unitRef="U_USD">1993000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_ee3f06f0-407d-4fc2-9ec3-813add0cab9b"
      unitRef="U_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_a17255e1-9685-499b-9f1b-46fc954357d5"
      unitRef="U_USD">33542000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_d081fa8e-07f3-4c84-807f-535a7bef49f7"
      decimals="-3"
      id="F_4a1f1333-29e3-4b02-a775-a01a51a41a55"
      unitRef="U_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_3c368dae-dfb6-43ec-bc72-238024dfd874"
      unitRef="U_USD">53506000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_0522581f-1a66-49ab-89fa-0e26de76a06d"
      unitRef="U_USD">98000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_c4105b1a-754b-4d8e-a698-592433c78509"
      unitRef="U_USD">53506000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_1be1e923-b173-4348-90d9-a245cf7eecd9"
      decimals="-3"
      id="F_4fe42b2c-efc6-4a1e-8a80-0c55b7bf699e"
      unitRef="U_USD">98000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_1fd99e7d-a96b-4223-b077-f2233786a742"
      unitRef="U_USD">169724000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_f0aaa168-2a47-400a-b787-5b381f3d0695"
      unitRef="U_USD">190000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_756fcd5f-98a1-45e0-8adb-829775d65408"
      unitRef="U_USD">1993000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_412398bc-07ee-4cac-8628-b6f6ddb40567"
      unitRef="U_USD">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_a4608c58-c01c-4629-9d94-120f998398d3"
      unitRef="U_USD">171717000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_161ac69d-cf6a-452d-b7d5-1b2c8cbdfc74"
      unitRef="U_USD">191000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79"
      decimals="-3"
      id="F_6c61db07-f6b7-467f-8b68-f74e8b5b1f03"
      unitRef="U_USD">69377000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79"
      decimals="-3"
      id="F_28af4b16-452f-4925-aa46-1cacd9ea10d7"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79"
      decimals="-3"
      id="F_997cb6ad-b529-4e8a-941e-677dc458e595"
      unitRef="U_USD">69377000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_fb2e1524-ef21-4d37-878b-0564d9d43f79"
      decimals="-3"
      id="F_ce0fbfc3-1756-43da-a2f9-be23744f5a0a"
      unitRef="U_USD">92000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_2702367b-64a3-4129-870e-651ea9cdf529"
      unitRef="U_USD">58622000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_f0e2f7d3-2946-4e59-a9e1-5e7f790b70fd"
      unitRef="U_USD">33000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_a0a5d31b-fae5-434f-97dc-7123cdaa389b"
      unitRef="U_USD">58622000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_beffeaec-493f-452e-bd41-2df765eaa06a"
      decimals="-3"
      id="F_31ba9081-d6b8-4a3b-bbf8-fc3c6d07149f"
      unitRef="U_USD">33000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_e8c4e810-0caf-40ea-9de4-01da3fe165db"
      unitRef="U_USD">34567000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_b4b000df-8477-437e-bac1-ab6d0903f2ba"
      unitRef="U_USD">63000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_efc4806e-60a0-46ed-8e08-066959546f79"
      unitRef="U_USD">34567000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_88b634eb-d4b2-4f97-ad12-a3e66feccf11"
      decimals="-3"
      id="F_4181f318-a687-414e-aebd-5be179250cf1"
      unitRef="U_USD">63000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_33890984-6907-4fe6-81fd-b47fa89854ff"
      unitRef="U_USD">3952000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_052c0e4f-3eea-40a1-981c-fd7f8ba074b4"
      unitRef="U_USD">23000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_90e33335-9926-4889-b2e2-29c3a16a59f0"
      unitRef="U_USD">3952000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_6f182ab9-879d-41e1-bcf7-1da96f1c3ac7"
      decimals="-3"
      id="F_2be9d355-d8d3-43cd-a2da-55fd564f044b"
      unitRef="U_USD">23000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_5a0d8d13-9e78-42f7-8317-bf5545a1d9ea"
      unitRef="U_USD">166518000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_ac5b4032-b346-40e1-95d5-c00f09ddcdf0"
      unitRef="U_USD">211000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_a3a559f0-0ed3-4da2-be63-6b7fe65b240e"
      unitRef="U_USD">166518000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_ea88ad00-53fb-43ec-a3aa-0ffdf5cee9d4"
      unitRef="U_USD">211000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <gern:FairValueMeasurementsInterTransfersBetweenLevels
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_73c85e3e-f761-4436-ba68-cd5bcf9ae86b"
      unitRef="U_USD">0</gern:FairValueMeasurementsInterTransfersBetweenLevels>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_20cdfba5-408e-40bc-8d91-e813ab6c49aa">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 and indicates the fair value category assigned.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.008%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.482000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.142000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.922%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;427,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2023:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Certificate of deposit&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Government-sponsored enterprise securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;99,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate notes&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;324,904&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in cash and cash equivalents on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in restricted cash on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in current portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(4)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included in noncurrent portion of marketable securities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Credit Risk&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_95741265-2348-4239-94c8-9bc131f6f43a"
      decimals="-3"
      id="F_e6ea2a23-5def-408f-84ec-747b99c40dbf"
      unitRef="U_USD">46802000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_92e38419-310b-4d37-89de-c52fbe362d53"
      decimals="-3"
      id="F_fef454f8-459d-43ee-b094-c0e87ec6599f"
      unitRef="U_USD">46802000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9378206f-1b63-4c2e-84ae-c7c453b28fb4"
      decimals="-3"
      id="F_306acfdc-5676-42ee-b6c3-9d4baca724b7"
      unitRef="U_USD">273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e3b2e318-43ca-4428-8f97-24dd7e3a155c"
      decimals="-3"
      id="F_c8dfb500-4183-4913-9094-59b265b02bf9"
      unitRef="U_USD">273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_81b5227f-c6cc-4463-87df-b07ef92efeea"
      decimals="-3"
      id="F_bf743e7c-7177-4e01-b454-5a5af6c87369"
      unitRef="U_USD">30570000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8b21a8eb-d5f2-4432-a5df-39b506f65c7b"
      decimals="-3"
      id="F_111727e5-94ba-4c3a-a9bc-4dc4f4c2b0eb"
      unitRef="U_USD">30570000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e0933482-a77f-4d10-a7bc-f05210a15513"
      decimals="-3"
      id="F_e6fb5385-2316-4738-8ee4-e00579d6767a"
      unitRef="U_USD">8748000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_747285d8-621a-48db-811f-49f35ea38d3d"
      decimals="-3"
      id="F_e0333e75-0041-4d72-bafa-6fc4ab2d2059"
      unitRef="U_USD">8748000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_68fdfe38-0960-431a-a3e9-7b0ac25ccc4d"
      decimals="-3"
      id="F_ec31dbbf-4c9d-40de-85c1-614b62ecec0a"
      unitRef="U_USD">185201000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_17031fc2-3062-43d6-85c0-79a5d605b251"
      decimals="-3"
      id="F_e3f3d8cc-f4cc-4c90-85ce-92af072b748a"
      unitRef="U_USD">185201000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f748ab50-900a-4fdc-8839-e5051a63beb9"
      decimals="-3"
      id="F_cdcd57f8-acf3-4aae-be07-dce10cb41ba1"
      unitRef="U_USD">202527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_24fe1187-bbca-4f70-b50e-1470d3032743"
      decimals="-3"
      id="F_851d45fe-9605-4bea-90ae-2c02036168c9"
      unitRef="U_USD">202527000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_53d31f32-ae1d-49da-94b2-102d0fe79050"
      decimals="-3"
      id="F_6b38db7d-66a9-4c3c-b4d1-b0b4102ee9b5"
      unitRef="U_USD">47075000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5cdbb065-c4af-42c3-8862-71fcb82d98f6"
      decimals="-3"
      id="F_50345e39-644e-4768-b278-259ef4b3852c"
      unitRef="U_USD">427046000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b715e801-fcfb-431f-8bab-f2e143bebd19"
      decimals="-3"
      id="F_21c6a09a-14da-448f-88ad-f737bba0b25a"
      unitRef="U_USD">474121000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7ff95c91-1f33-4631-89e1-565d8329dc34"
      decimals="-3"
      id="F_48b46f28-0233-4605-ada3-485e6a0e7078"
      unitRef="U_USD">17658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4cbc89b0-e52f-4d52-bc4b-5e66f232255a"
      decimals="-3"
      id="F_1a77a563-308b-443d-8390-be317e36f3f1"
      unitRef="U_USD">17658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4f241416-b409-4908-b332-b7b4d33cd845"
      decimals="-3"
      id="F_72086aca-081a-4802-af4e-9988250c785e"
      unitRef="U_USD">272000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7d3dad2f-bb11-4150-964c-bc94e9c01233"
      decimals="-3"
      id="F_5df5fb7b-520f-4bca-b8cc-7dded2c26cb6"
      unitRef="U_USD">272000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9706dd18-9926-47e0-b3e8-d29b8905bbab"
      decimals="-3"
      id="F_b7655c78-8c5e-4d0f-bb85-a2c2544b6b6c"
      unitRef="U_USD">29742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_66ae5200-0971-4718-bfb2-d5a1adbf70ec"
      decimals="-3"
      id="F_67c13420-9b2f-41b7-94ea-07c2c3e6c21f"
      unitRef="U_USD">29742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_becb8b88-64b7-49ab-8230-4c474b6aaf48"
      decimals="-3"
      id="F_dffeeb5b-6cc4-4d24-ab3f-d0d77fe4fe08"
      unitRef="U_USD">99872000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d1fd165f-236b-4ae7-b110-10c3c05b8919"
      decimals="-3"
      id="F_e174155c-7ea1-4687-b092-be11f9255495"
      unitRef="U_USD">99872000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ebd06010-cba9-4fe3-8531-00bccfe44019"
      decimals="-3"
      id="F_b59f29ab-95a3-4136-b49e-e86a726edc10"
      unitRef="U_USD">102268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b494d8bd-5ad3-4784-83cb-b49455558821"
      decimals="-3"
      id="F_70ba9f94-8c71-49b4-8e01-8870155c6787"
      unitRef="U_USD">102268000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_867aa2fc-a030-470c-984d-778ea052f5b5"
      decimals="-3"
      id="F_f1bca93b-a2a6-4f01-81e8-1e04357040f4"
      unitRef="U_USD">75092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6da2f1f4-f5f1-49c8-b49b-064df08d4b0b"
      decimals="-3"
      id="F_50411d2f-5cda-42e9-aec2-883661a22180"
      unitRef="U_USD">75092000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4318e20a-42cf-473e-af78-4bb847a7d856"
      decimals="-3"
      id="F_a82e7f93-1887-41aa-bf18-ac9b10e9f160"
      unitRef="U_USD">17930000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_49f4818c-2720-4101-a534-f0f765371106"
      decimals="-3"
      id="F_a8d169f3-f212-48c1-b495-1b5d89c1451c"
      unitRef="U_USD">306974000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6787832d-92fa-4613-99b8-8a61345db4cc"
      decimals="-3"
      id="F_0fa895d9-2077-44b5-b10a-7fbbbb385d6e"
      unitRef="U_USD">324904000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConcentrationRiskCustomer
      contextRef="C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408"
      id="F_a870bced-a433-42b6-b64b-75400fd81ddb">four</us-gaap:ConcentrationRiskCustomer>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_3a3d67c9-70c8-4dcd-9fc9-f076cbb5a408"
      decimals="2"
      id="F_819efcbc-dd4c-462a-93d6-29dcda955d22"
      unitRef="U_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d8b9e1c3-d9eb-45ec-948d-6b383d0103b4"
      decimals="2"
      id="F_d26a8431-3a1e-49aa-bd71-2ce4558749f0"
      unitRef="U_pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_38766db5-3955-4239-979e-89377c2bc7bf"
      decimals="2"
      id="F_2eed7789-5d88-4a9e-9dd5-fb3128c90add"
      unitRef="U_pure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1d9cd387-5d68-43ac-8286-4091e49b513a"
      decimals="2"
      id="F_e2a7a3a7-3000-42ed-bcaf-ff9276a34660"
      unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_91c5c5f0-c7f2-42ce-8dcb-ed6118918880"
      decimals="2"
      id="F_6c5fd900-e6f4-497a-99d3-0724b0a21aab"
      unitRef="U_pure">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_0e3c3b3e-4c18-4424-a32c-b546efffe3e8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, stated at cost, is comprised of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b71d06dd-d1ae-43db-b5df-d1ff62bea2d7">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment, stated at cost, is comprised of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,273&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bd2577b2-9506-4398-a405-ba1b3a537279"
      decimals="-3"
      id="F_f07cc260-1650-4829-b6be-bc42e539eccf"
      unitRef="U_USD">2878000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d99633b0-a319-42ee-a07d-8348a36501df"
      decimals="-3"
      id="F_fdf31f3e-dff2-464b-b8b0-3a5244234256"
      unitRef="U_USD">2273000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9553826f-3f43-4285-8839-dca64833f51a"
      decimals="-3"
      id="F_ef8f1d1a-8414-420f-ab50-c80d78cea1eb"
      unitRef="U_USD">129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f836de54-c5fa-4e2c-bc3b-676b8b48b141"
      decimals="-3"
      id="F_6c05e058-3283-4103-8ebb-404b880ccd68"
      unitRef="U_USD">135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_d39855fe-545e-4f33-9e69-2fcf17094331"
      unitRef="U_USD">3007000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_be4a5fb1-3c3c-4697-91d5-445cc8ded2b4"
      unitRef="U_USD">2408000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_9969a23e-c2d9-478b-bdc8-cac843b011e9"
      unitRef="U_USD">1697000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_1a7778bf-ec06-444b-b069-faf86e0a62ba"
      unitRef="U_USD">1231000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_e0cfb7eb-a287-4922-a7b7-7e7308396244"
      unitRef="U_USD">1310000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_d5bed175-feec-4c33-814e-2bca4ef18f6f"
      unitRef="U_USD">1177000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_60ac4847-6287-40c7-945a-4cb3f415bbfb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. ACCRUED LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;CRO and clinical trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_0256451a-c37d-48d0-b987-41307602a675">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;CRO and clinical trial costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,968&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Manufacturing activities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Professional legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_473fd94b-51f5-4346-9c04-adf249175cb1"
      unitRef="U_USD">18968000</gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent>
    <gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_16e7c4db-2fbc-4996-b36b-16d6b206e4b3"
      unitRef="U_USD">23541000</gern:AccruedClinicalResearchOrganizationsAndClinicalTrialCostsCurrent>
    <gern:AccruedManufacturingActivitiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_6994dda4-d96f-4bcd-ac16-dcc14b924354"
      unitRef="U_USD">11839000</gern:AccruedManufacturingActivitiesCurrent>
    <gern:AccruedManufacturingActivitiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_0ec26ef3-ef4c-4b30-afe4-81fc077489b1"
      unitRef="U_USD">14629000</gern:AccruedManufacturingActivitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_01082603-f118-4982-a863-38cccd6fcb7e"
      unitRef="U_USD">475000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_eb50d859-0551-4f83-b8d2-33438be75398"
      unitRef="U_USD">556000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_de6969f0-d95a-4de6-90b2-7f547ec99a0e"
      unitRef="U_USD">2186000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_b155b438-76ed-4793-a9c1-9b2df9eeb2d1"
      unitRef="U_USD">768000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_389e57bb-5332-40f2-8505-b15ed6fd88cb"
      unitRef="U_USD">2081000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_05f54997-e48f-43be-9e27-7b341ed91c56"
      unitRef="U_USD">814000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_2a274347-bc80-4ef1-8d94-b094a7a5711c"
      unitRef="U_USD">35549000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_f77764f5-f525-414c-85da-fe8a70245d7c"
      unitRef="U_USD">40308000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_03891902-74cf-43cf-9a0c-41d83383144d">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Purported Securities Lawsuits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We are not currently a party to any material pending legal proceedings. However, in 2020, three securities class action lawsuits were filed against us and certain of our officers. One of the lawsuits was voluntarily dismissed, and final judgment with respect to the other two lawsuits was entered in October 2023. In 2020 and 2021, seven shareholder derivative actions were filed in a number of courts, naming as defendants certain of our then current officers and certain of our then current and former members of our board.  All seven of the shareholder derivative actions were dismissed with prejudice. There is no liability outstanding with respect to these lawsuits as of December 31, 2024, because they were fully settled during the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;While we have settled these lawsuits, it is possible that additional lawsuits might be filed, or allegations might be received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. We could be forced to expend&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;significant resources in the defense of any additional lawsuits, and we may not prevail. Monitoring, initiating and defending against legal actions is time-consuming for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. We could be forced to expend significant resources in any potential future lawsuits, and we may not prevail in such lawsuits. Additionally, we may not be successful in having any such lawsuits dismissed or settled within the limits of our insurance coverage. Expenses associated with any potential future lawsuits could be material to our consolidated financial statements if we do not prevail in the defense of such lawsuits, or even if we do prevail. We have not established any reserve for any potential liability relating to any potential future lawsuits. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Indemnifications to Officers and Directors&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our corporate bylaws require that we indemnify our directors, as well as those who act as directors and officers of other entities at our request, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with any proceedings arising out of their services to Geron. In addition, we have entered into separate indemnification agreements with each of our directors and officers which provide for indemnification of these directors and officers under similar circumstances and under additional circumstances. The indemnification obligations are more fully described in our bylaws and the indemnification agreements. We purchase standard insurance to cover claims or a portion of the claims made against our directors and officers. Since a maximum obligation is not explicitly stated in our bylaws or in our indemnification agreements and will depend on the facts and circumstances that arise out of any future claims, the overall maximum amount of the obligations cannot be reasonably estimated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Severance Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have adopted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; severance plans that apply to all of our employees who are not subject to performance improvement plans, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; plan covering employees above the Senior Vice President level, i.e., executives, and all other employees hired before January 1, 2022, and the other plan covering all non-executive employees hired on or after January 1, 2022.  The severance plans provide for, among other benefits: (i) a severance payment upon a Change of Control Triggering Event and Separation from Service and (ii) a severance payment for each non&#x2011;executive employee upon a Non&#x2011;Change of Control Triggering Event and Separation from Service. As defined in the severance plans, a Change of Control Triggering Event and Separation from Service requires a &#x201c;double trigger&#x201d; where: (i) an employee is terminated by us without cause in connection with a change of control or within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months following a change of control provided, however, that if an employee is terminated by us in connection with a change of control but immediately accepts employment with our successor or acquirer, the employee will not be eligible for the benefits outlined in the plans, (ii) an employee resigns because in connection with a change of control, the offered terms of employment (new or continuing) by us or our successor or acquirer within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days after the change of control results in a material change in the terms of employment, or (iii) after accepting (or continuing) employment with us after a change of control, an employee resigns within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months following a change of control due to a material change in the terms of employment. Under the severance plans, a Non&#x2011;Change of Control Triggering Event and Separation from Service is defined as an event where an employee is terminated by us without cause. Severance payments range from&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_22c29184-2380-4a26-aec3-6f112ba2f86e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months of base salary in connection with a Change of Control Triggering Event or from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_bdc4642e-5d95-4614-922b-411dcd56cbf5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six weeks&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months of base salary in connection with a Non-Change of Control Triggering Event, as well as a pro-rata portion of the employee&#x2019;s annual target bonus, depending on the employee&#x2019;s position with us, payable in a lump sum payment, and monthly COBRA payments for the severance period. The severance plans also provide that they shall not supersede the provisions of any individual employment agreements entered into between us and our employees, and that the employees with such agreements will be entitled to whichever benefits are greater under the severance plan or their employment agreement. A copy of the severance plan covering our executive officers is filed as an exhibit to this Report. As of December 31, 2024, all our executive officers have employment agreements with severance provisions and will receive the greater severance benefits of their agreements or those in the severance plan applicable to them.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <gern:NumberOfSeverancePlan
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="0"
      id="F_21859aa3-b9e2-4f46-a51a-33ec743a5434"
      unitRef="U_Plan">2</gern:NumberOfSeverancePlan>
    <gern:NumberOfSeverancePlan
      contextRef="C_e0d5fa89-8410-4f47-ab1c-e5b7ef68f3cf"
      decimals="0"
      id="F_12a69d4d-c45a-4228-88de-8766de6822b6"
      unitRef="U_Plan">1</gern:NumberOfSeverancePlan>
    <gern:LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_90f4246b-5d49-4a91-b146-a3f5449b7568">P12M</gern:LossContingencyTriggeringEventEmployeeTerminationWithoutCauseFollowingChangeOfControlPeriod>
    <gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_109e94c4-7c72-4c91-8b44-d2c22870826c">P30D</gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlDuringWhichNoComparableEmploymentIsOfferedByEntity>
    <gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_20ebaed1-ecd8-445b-bce1-ff0885690c95">P12M</gern:LossContingencyTriggeringEventPeriodFollowingChangeOfControlWithinWhichEmployeeResignsDueToMaterialChangeInTermsOfEmployment>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan
      contextRef="C_e14d38b0-ffbb-44d6-87e8-09d3acf16873"
      id="F_5c474040-3f74-4eec-a7b2-a36944b8967d">P18M</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlan>
    <gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent
      contextRef="C_e14d38b0-ffbb-44d6-87e8-09d3acf16873"
      id="F_3c692317-06b4-4fed-bc45-6581386b35bd">P12M</gern:LossContingencyPeriodOfCurrentBaseSalaryToBePaidUnderSeverancePlanNonChangeOfControlTriggeringEvent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_114ae0c2-e091-4840-913f-479caf2a793f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. OPERATING LEASES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;New Jersey Office Space Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2019, we entered into an operating lease agreement for office space located at 3 Sylvan Way, Parsippany, New Jersey, or the New Jersey Lease. The initial term of the New Jersey Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with an&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;to extend for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-time option to terminate the New Jersey Lease without cause as of the 103&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rd&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; month anniversary of the commencement date of the lease&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The New Jersey Lease commenced on October 1, 2019, upon our control of the office space on that date. Based on the initial term of the New Jersey Lease of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, the right-of-use asset and corresponding operating lease liability was approxima&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;tely&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represented the present value of lease pay&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ments over the initial lease term, net of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rent abatement period, using an incremental borrowing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% based o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;n information available as of October 1, 2019. As of December 31, 2024, the New Jersey Lease makes up $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of our total right-of-use asset balance. Under the New Jersey Lease, we are also obligated to pay certain variable expenses separately from the base rent, including electricity and common area maintenance. Such costs are being expensed&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the period they are incurred. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the remaining lease term for the New Jersey Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ye&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;California Office Space Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2019, we entered into an operating lease agreement for office space located at 919 East Hillsdale Boulevard, Foster City, California, or the Foster City Lease. The initial term of the Foster City Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months with an option to extend for an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Foster City Lease commenced on March 10, 2020, upon the substantial completion of all tenant improvements. As of the lease commencement date, the right-of-use asset and corresponding operating lease liability was approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, which represented the present value of remaining lease payments using an incremental borro&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;wing rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% over the initial lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;87&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months, net of a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rent abatement period. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the Foster City Lease makes up $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of our total right-of-use asset balance. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Foster City Lease, we are also obligated to pay certain variable expenses separately from the base rent, including taxes and common area maintenance. Such costs are considered non-lease components and have been excluded from the calculation of the right-of-use asset and corresponding operating lease liability and are being expensed in the period they are incurred. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the remaining lease term for the Foster City Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, and the Foster City Lease were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.516%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.555%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.296999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.639%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.657%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:10%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:60%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:5.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.3875491341761395%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs represent non-lease components, such as common area maintenance charges.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:35.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.686%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.857%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.457%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6"
      id="F_91da9249-33ec-4a08-b47a-9e822ac3a70a">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_7b831c0a-b680-4a42-bf82-33530e797307"
      id="F_5b6735f4-22cb-4f45-99cc-2416017a6d75">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_7b831c0a-b680-4a42-bf82-33530e797307"
      id="F_44f26f98-f7cf-4131-ad99-b445e966b869">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_05b9bc29-068c-441c-b91d-5eaab4b6ab0c"
      id="F_aca00b71-f6bf-4352-b860-21d9b1462d65">one-time option to terminate the New Jersey Lease without cause as of the 103rd month anniversary of the commencement date of the lease</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6"
      id="F_5c47a5cd-6650-4581-83f2-dbfea2a1fb8e">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6"
      decimals="-5"
      id="F_79ff40fe-137f-4d8f-821f-822606ade7fe"
      unitRef="U_USD">2400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6"
      decimals="-5"
      id="F_ed770cd4-990e-452e-a6b9-d7cf0885d37d"
      unitRef="U_USD">2400000</us-gaap:OperatingLeaseLiability>
    <gern:OperatingLeaseRentAbatementPeriod
      contextRef="C_c553e0ac-d5c1-4b9f-adf7-7df417d4ceff"
      id="F_8dd61fde-97ef-4a30-a1b9-883d710338d2">P7M</gern:OperatingLeaseRentAbatementPeriod>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_3545b8a9-169e-472a-94c6-e4d45cfbfaf6"
      decimals="INF"
      id="F_9984cdf9-c65a-4901-9e5b-06eff40a9683"
      unitRef="U_pure">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_87998687-0289-453c-ace1-aaa39dc47de9"
      decimals="-5"
      id="F_74b1eb36-c3fb-48d7-910d-3c2e9b8cfdac"
      unitRef="U_USD">1400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_aebd100b-45b2-4709-8a8b-13cb1b274d38"
      id="F_1989ce0d-2947-4a57-9dad-1c2350516d55">P5Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_63aba9ed-ce8e-4616-9977-5edb1c01930b"
      id="F_8d691dd1-2782-46ed-a5ce-f1eb993bd83c">P87M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_63aba9ed-ce8e-4616-9977-5edb1c01930b"
      id="F_842cabde-297f-4ee3-895c-090d126f3b67">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107"
      decimals="-5"
      id="F_5d1c8e00-cf9a-44cc-8a1d-ac6a8b4467f4"
      unitRef="U_USD">3400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107"
      decimals="INF"
      id="F_a859a870-e267-46d8-8c3e-f2d9ad023d95"
      unitRef="U_pure">0.07</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_abb4ec56-cb12-4068-b63f-a3a9c80c8107"
      id="F_baef92d4-b523-450e-9f60-5d63e5b0cc7b">P87M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <gern:OperatingLeaseRentAbatementPeriod
      contextRef="C_1d985ed6-a26a-4250-9a37-ac2116b89df0"
      id="F_dbc037db-28d3-4039-acd2-8b40ae896f50">P3M</gern:OperatingLeaseRentAbatementPeriod>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_a8af3954-eaf3-42b5-9e3a-4922b0dd6706"
      decimals="-5"
      id="F_735c1ed7-fa79-458d-8767-1ec0b2a43ac4"
      unitRef="U_USD">1400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_6fcf6750-e138-4d4c-96d6-c8e04e8003f1"
      id="F_ded8bb3a-433e-4116-b0a9-d65f52ad7027">P2Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_822e9d8f-c5f5-4142-954c-dde729234e78">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease costs included in operating expenses on our consolidated statements of operations for the New Jersey Lease, and the Foster City Lease were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:19.516%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.555%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.296999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.639%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.259%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.657%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;962&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:5.87%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.3875491341761395%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs represent non-lease components, such as common area maintenance charges.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_0423a5c3-b82b-4d35-b664-f0a44e92202d"
      unitRef="U_USD">987000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_10315d1f-a3db-41ad-8088-20c6293d7a84"
      unitRef="U_USD">962000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_a7b7cd93-6d60-46ca-b6e7-ccc1260f0eb3"
      unitRef="U_USD">944000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_f9516251-5ca6-4b3f-b958-e291a6b82a73"
      unitRef="U_USD">261000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_5aa5f16e-5495-4595-a689-0897f84e6e7a"
      unitRef="U_USD">344000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_73d7647e-0cd1-4569-835e-b7d8342bf7cf"
      unitRef="U_USD">310000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_4ce2de9b-5fa9-4725-901b-a0bfca313e9b"
      unitRef="U_USD">1248000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_40397594-a2ec-4303-86cb-b06ad35ff3e8"
      unitRef="U_USD">1306000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_ffe1ddd6-225b-40d6-9594-3f0895f77657"
      unitRef="U_USD">1254000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_eb9759c0-efb8-43d2-862b-5c9b8f83af5e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The undiscounted future non-cancellable lease payments under the New Jersey Lease and the Foster City Lease as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:35.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.686%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2.857%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:26.457%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;292&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_eea94f30-4c31-48b6-92ec-d02c18d8e95f"
      unitRef="U_USD">1014000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_1e6b2328-54d1-4a44-bb45-b9d65deb4809"
      unitRef="U_USD">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_c143c1f8-a9e9-45b5-a020-9fb0737123ae"
      unitRef="U_USD">716000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_dd6ebd5f-0bc3-4aa9-ad49-6156b306290e"
      unitRef="U_USD">376000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_4ba97847-b1e4-4a52-95da-72b0673721f5"
      unitRef="U_USD">383000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_aed5141e-c549-4b3d-bd4c-a8b24d1c6b69"
      unitRef="U_USD">292000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_a1387fa7-c968-40e6-baf0-1a058b3a5a2d"
      unitRef="U_USD">3821000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_0bff9db2-c8ee-4428-91b5-ed7a77228313"
      unitRef="U_USD">581000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_63a1e0a3-b395-431f-86cb-4dc647c8c8f1"
      decimals="-3"
      id="F_77e53283-f654-42b5-b051-e6139c1806eb"
      unitRef="U_USD">3240000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_5c1fdfe9-ce4b-4173-ab4d-89d8cd31db6e">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. DEBT&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Hercules Loan Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On September 30, 2020, we, Hercules Capital, Inc., or Hercules, and Silicon Valley Bank, or SVB, entered into a term loan facility, or the Term Loan, for up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which was amended in August 2021, or the Original Loan Agreement. On June 30, 2022, we entered into a second amendment to the Original Loan Agreement. Under the second amendment, the aggregate principal amount available to us increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, with such principal being available in a series of tranches, subject to certain terms and conditions. Over the course of the Term Loan, we had drawn down a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All obligations outstanding under the Hercules Loan Agreement, amounting to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, were repaid in full on November 1, 2024, upon which the Hercules Loan Agreement was terminated and all liens on our assets granted in connection with the Hercules Loan Agreement were released.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pharmakon Loan Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 1, 2024, we entered into a loan agreement, or the Pharmakon Loan Agreement, with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership, each, a Lender, which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent, that provides for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-year senior secured term loan facility of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, divided into three committed tranches: (i) a Tranche A Loan in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or the Tranche A Loan, which was funded on November 1, 2024, or the Tranche A Closing Date; (ii) a Tranche B Loan in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or the Tranche B Loan, which is available, subject to certain limited conditions, at our option; and (iii) a Tranche C Loan in an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or the Tranche C Loan, and together with the Tranche A Loan and the Tranche B Loan, collectively, the Term Loans, which is available to us upon reaching a specified trailing twelve-month RYTELO revenue milestone. The Tranche B Loan and the Tranche C Loan, once available, may be requested on or prior to December 31, 2025. A portion of the proceeds from the Tranche A Loan were used to repay, in full, all amounts owed under the Hercules Loan Agreement, which was terminated effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The remaining proceeds will be used to fund our general corporate and working capital requirements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Term Loans mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 1, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Term Loans bear interest at a variable rate per annum equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% plus the three-month Secured Overnight Financing Rate, or SOFR, with a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_63389fc4-357d-477a-9d6b-0ecf16309618;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; floor of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. As of inception of the Tranche A Loan, the interest rate applicable to the Tranche A Loan was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. Interest is due and payable quarterly on the last day of each quarter with the first payment due on December 31, 2024. The Pharmakon Loan Agreement requires we pay an amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the Lenders&#x2019; total committed amount to fund the Term Loans, payable with respect to each Term Loan on the funding date of such Term Loan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We may elect to prepay the Term Loans in part or in whole prior to the Maturity Date with such prepayments being subject to a prepayment premium equal to the principal amount so prepaid multiplied by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% if made prior to the 3rd anniversary of the funding date of the applicable Term Loan, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% if made on or after the 3rd anniversary of the funding date of the applicable Term Loan but prior to the 4th anniversary of the funding date of the applicable Term Loan, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% if made on or after the 4th anniversary of the funding date of the applicable Term Loan but prior to the Maturity Date. In addition to the prepayment premium, prepayments of any Term Loan prior to the 2nd anniversary of the funding date of such Term Loan are subject to a make-whole amount equal to the sum of all interest that would have accrued through such 2nd anniversary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our obligations under the Pharmakon Loan Agreement are secured by substantially all of our assets, including our intellectual property. Certain of our subsidiaries may, from time to time after the Tranche A Closing Date, be required to guarantee our obligations under the Pharmakon Loan Agreement and, in connection with such guarantee, pledge substantially all of their assets, including intellectual property, to secure such guarantee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Pharmakon Loan Agreement contains customary affirmative and restrictive covenants and representations and warranties. We and our subsidiaries are bound by certain affirmative covenants setting forth actions that are required during the term of the Pharmakon Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. There are no financial covenants. Additionally, we and our subsidiaries are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the Pharmakon Loan Agreement, including, without limitation, (i) selling or disposing of assets, (ii) amending, modifying or waiving our rights under material agreements, (iii) consummating change in control transactions unless all amounts becoming due under the Loan Agreement are paid in full immediately upon (and concurrent with) the consummation of any such change in control transaction, (iv) incurring additional indebtedness, (v) incurring non-permitted liens or encumbrance on our or our subsidiaries&#x2019; assets, (vi) paying dividends or making any distribution or payment on or redeeming, retiring or purchasing any equity interests, and (vii) making payments on subordinated indebtedness, in each case, subject to specified exceptions. The Pharmakon Loan Agreement also contains the following events of default: (i) failure to pay principal, interest and other amounts when due, (ii) the breach of the covenants under the Loan Agreement, (iii) the occurrence of a material adverse change or the occurrence of a withdrawal event in respect of RYTELO, (iv) certain attachments of the credit parties assets and restraints on their business, (v) certain insolvency, liquidation, bankruptcy or similar events, (vi) certain cross-default of third-party indebtedness and royalty revenue contracts, (vii) the failure to pay certain judgements, (viii) material misrepresentations, (ix) the loan documents ceasing to create a valid security interest in a material portion of the collateral, (x) the occurrence of certain ERISA events and (xi) the occurrence of a default under any subordination or intercreditor agreement, in each case subject to the grace periods, cure period and thresholds as specified in the Pharmakon Loan Agreement. Upon the occurrence and during the continuance of an event of default, the Lenders may, among other things, accelerate our obligations under the Pharmakon Loan Agreement (including all obligations for principal, interest and any applicable make-whole and prepayment premiums); provided that upon an event of default relating to certain insolvency, liquidation, bankruptcy or similar events, all outstanding obligations will be immediately accelerated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future Minimum Payments&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:46.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:  amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:  unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent portion of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Liabilities Related to Sale of Future Royalties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 1, 2024, we entered into a revenue participation right purchase and sale agreement, or the Royalty Pharma Agreement, with Royalty Pharma Development Funding, LLC, or Royalty Pharma. Pursuant to the Royalty Pharma Agreement, &lt;/span&gt;&lt;span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#2b333d;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#2b333d;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, or the Purchase Price, in exchange&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for which Royalty Pharma obtained the right, or the Revenue Participation Right, to receive certain amounts calculated as a percentage of future U.S. net sales of RYTELO for each calendar quarter, or Royalty Payments, during the term contemplated by the Royalty Pharma Agreement. Specifically, &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the revenue participation rate commences at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for annual U.S. net sales of up to and equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;500.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million declining to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for annual U.S. net sales exceeding $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031 or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, we had the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Buy-Out Payment&#x201d; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We accounted for the Royalty Pharma Agreement as a financing liability, primarily because it has significant continuing involvement in generating the future revenue on which the Royalty Payments are based. The liability related to Revenue Participation Right and the related interest expense are measured based on our current estimate of the timing and amount of expected future Royalty Payments expected to be paid over the estimated term of the Royalty Pharma Agreement using a discounted cash flow model. The liability is amortized using the effective interest rate method, resulting in recognition of interest expense over the estimated term of the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have determined the fair value of the liability related to the sale of future royalties is based on our current estimates of future royalties expected to be paid to Royalty Pharma over the life of the arrangement, which are considered Level 3.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying value of the liabilities related to sale of future revenues as of December 31, 2024 is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in non-cash interest expense in the twelve months ended December 31, 2024 related to the Royalty Pharma Agreement.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the activity within the liability related to sale of future royalties during the year ended December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:33.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liability Related to Sale of Future Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Carrying value of liability related to sale of future royalties at November 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Carrying value of liability related to sale of future royalties at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Embedded Derivatives and Debt Discounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The conditional exercisable call option related to the event of default is considered to be an embedded derivative which is required to be bifurcated and accounted for as a separate financial instrument. In the periods presented, the value of the embedded derivative is not material and therefore, no amount has been recognized. If an event of default becomes more probable than is currently estimated, then the embedded derivative could become material in future periods and would be recognized as a separate financial instrument at that time.  The embedded derivatives are classified within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_afd8ecd1-ed86-4a5a-81e0-ee569ecd5bc3"
      decimals="INF"
      id="F_76bdfd09-72a3-4b8a-a8dd-ae37425a78a8"
      unitRef="U_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_afd8ecd1-ed86-4a5a-81e0-ee569ecd5bc3"
      decimals="INF"
      id="F_c68839c2-660d-4ec4-9c15-a52a50030c39"
      unitRef="U_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_c65b60ba-872b-41db-a6e2-d82180268abc"
      decimals="INF"
      id="F_27e4423f-43f9-42b6-a9bd-871f050a20b1"
      unitRef="U_USD">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_7040d2ec-efa9-4e10-8449-1b261c220739"
      decimals="INF"
      id="F_99bbfef3-95e4-4570-bcf6-3761decb9cfa"
      unitRef="U_USD">80000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_b78714b6-f9c0-495e-8c29-1ef95e3bcf60"
      decimals="-5"
      id="F_4177ba3e-bae2-4733-b75d-6bb8b6efe8c7"
      unitRef="U_USD">86500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="C_bf2a2f52-c8bd-498e-90a9-db80650a3434"
      id="F_fa5247f9-a31f-48af-a89a-6490d26c9658">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_60b6c4c4-4c33-4d69-a53f-c3b0700c6a65"
      decimals="INF"
      id="F_02696b3b-77ae-4b19-9800-c2b821af7d6f"
      unitRef="U_USD">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_70ca9604-7e05-4828-abc7-17e9195e5429"
      decimals="INF"
      id="F_fe7d4bee-d856-4a67-8ac5-2134785c6fbf"
      unitRef="U_USD">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_6535ff7f-99fc-4830-9136-f45d3598ba88"
      decimals="INF"
      id="F_15cec262-b985-4dcd-8d75-1bd6d849eca9"
      unitRef="U_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_e6cc2f93-1577-4be8-9efd-57f44ff9b16c"
      decimals="INF"
      id="F_80d1e5ed-b1f7-4f26-8136-770692d5d2f6"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_3b922920-9a03-448f-bb58-c0e801fa437e"
      id="F_8bc719cf-ae64-4464-89b7-d4b439007b06">2024-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_13a5e7dc-1814-4249-b841-344c76f1b61e"
      id="F_da29e78c-1a5c-4d97-8dc8-2bbbccf33c35">2029-11-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_13a5e7dc-1814-4249-b841-344c76f1b61e"
      decimals="4"
      id="F_eae93062-8c1b-4c0e-bac9-6118c294bfdb"
      unitRef="U_pure">0.0575</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <gern:DebtInstrumentFloorRate
      contextRef="C_61e2613d-481e-46a9-a123-9bcad10f9439"
      decimals="4"
      id="F_33446183-d741-40b1-911e-c1c10c460dce"
      unitRef="U_pure">0.03</gern:DebtInstrumentFloorRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_70ca9604-7e05-4828-abc7-17e9195e5429"
      decimals="4"
      id="F_d3dd16ee-6910-48c9-8f8d-8df2db843929"
      unitRef="U_pure">0.1032</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <gern:PercentageOfCommitmentAmountToFundLoan
      contextRef="C_61e2613d-481e-46a9-a123-9bcad10f9439"
      decimals="4"
      id="F_9f062065-1237-4e1e-a24d-ed769cf0051f"
      unitRef="U_pure">0.025</gern:PercentageOfCommitmentAmountToFundLoan>
    <gern:PrepaymentPremiumOnPercentageOfTermLoan
      contextRef="C_1e35341b-2d2c-4a8f-916a-1bacddb10f79"
      decimals="2"
      id="F_1d8a2103-3fa5-429c-a86e-2c61ef692960"
      unitRef="U_pure">0.03</gern:PrepaymentPremiumOnPercentageOfTermLoan>
    <gern:PrepaymentPremiumOnPercentageOfTermLoan
      contextRef="C_10d09233-7a55-4348-a7b7-3be6db7ca118"
      decimals="2"
      id="F_fddd206a-84bd-4ec7-9ae8-c2c5d208f6d5"
      unitRef="U_pure">0.02</gern:PrepaymentPremiumOnPercentageOfTermLoan>
    <gern:PrepaymentPremiumOnPercentageOfTermLoan
      contextRef="C_1e5e1688-ab30-4578-81a0-c6560b774866"
      decimals="2"
      id="F_26aaaa2e-5ddc-4015-ae69-bae3e5c1ab0b"
      unitRef="U_pure">0.01</gern:PrepaymentPremiumOnPercentageOfTermLoan>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_794f4bb0-37a3-4057-9438-cfa7407db859">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents future minimum payments, including interest and the end of term charge, under the Term Loan as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:61.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:28.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:46.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:22.939999999999998%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;135,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;190,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:  amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:  unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent portion of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_d38a7ff6-e913-466f-922b-48ac43ea3d9e"
      unitRef="U_USD">2186000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_c4ea4e9e-0c35-4743-a354-7cd678305911"
      unitRef="U_USD">13081000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_010012e2-13d3-47a7-a8a5-fc58def85351"
      unitRef="U_USD">13081000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_11ad6189-586b-45fa-8dcb-af1c1b0a7e75"
      unitRef="U_USD">13081000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_9d7be102-e675-4943-b388-e6e258d0a9bd"
      unitRef="U_USD">13116000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_341f750b-37ad-46f3-88c1-1f7d5e54f69d"
      unitRef="U_USD">135930000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <gern:LongTermDebtGross
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_7ba5929f-7f13-4571-b274-771c8dabb74a"
      unitRef="U_USD">190475000</gern:LongTermDebtGross>
    <us-gaap:AccumulatedCapitalizedInterestCosts
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_f931d163-2940-4404-a5ac-f1486b1e6c8d"
      unitRef="U_USD">65474000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_6ac48523-4275-421f-bc46-2e264ff39033"
      unitRef="U_USD">6525000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_9e7870e8-e27d-480b-9a49-661f9debf37d"
      unitRef="U_USD">118476000</us-gaap:LongTermDebtNoncurrent>
    <gern:UpfrontPaymentReceived
      contextRef="C_9bd8d342-06ae-415c-868d-cf0b5f73cacf"
      decimals="-5"
      id="F_8be2c395-bacf-4bd3-9574-dc5ded19e6d0"
      unitRef="U_USD">125000000</gern:UpfrontPaymentReceived>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="C_54e7473e-71f1-4f3c-b458-f1ccbff39749"
      id="F_7b048f02-cf35-40a7-a192-f0d4971bc451">the revenue participation rate commences at 7.75% for annual U.S. net sales of up to and equal to $500.0 million declining to 1.0% for annual U.S. net sales exceeding $1.0 billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031 or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.In addition, we had the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option. &#x201c;Buy-Out Payment&#x201d; means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027. </us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <gern:PercentageOfAnnualNetSales
      contextRef="C_cba66e27-c320-4315-b06d-66eeb091ebf4"
      decimals="INF"
      id="F_35e97a9d-8a7b-46ec-9232-24b02fdce884"
      unitRef="U_pure">0.0775</gern:PercentageOfAnnualNetSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_4d32eb3b-1b07-4090-88b7-029d9a631b5c"
      decimals="INF"
      id="F_0ebbb937-cf7e-4183-ad96-7afcd2e250e2"
      unitRef="U_USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <gern:PercentageOfAnnualNetSales
      contextRef="C_04908c45-edaa-4013-80e1-3425b2d3f4a4"
      decimals="3"
      id="F_56f555b1-6250-471c-897f-62b4912ba4c0"
      unitRef="U_pure">0.01</gern:PercentageOfAnnualNetSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_97cc69ce-fec1-4d91-ac38-fcc58be903e6"
      decimals="INF"
      id="F_a29ca48e-8e17-4d49-8bc3-a2ba16b01e9c"
      unitRef="U_USD">1000000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_85175ee7-1c57-4e09-a0fa-9cca0710633c"
      decimals="-5"
      id="F_ec063344-2353-4416-8a35-96fb1fdf6f11"
      unitRef="U_USD">124800000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:RoyaltyExpense
      contextRef="C_54e7473e-71f1-4f3c-b458-f1ccbff39749"
      decimals="-5"
      id="F_5ab0878c-a6c2-4d06-ba96-2b0352d6ebe3"
      unitRef="U_USD">5300000</us-gaap:RoyaltyExpense>
    <gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_eefd9704-a69d-4515-882e-b0edcc67eaae">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the activity within the liability related to sale of future royalties during the year ended December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:33.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Liability Related to Sale of Future Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Carrying value of liability related to sale of future royalties at November 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense recognized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Carrying value of liability related to sale of future royalties at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;124,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gern:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_6a2d0968-c085-4357-bd45-6a8affcd8162"
      decimals="-3"
      id="F_d72dd40a-3c2a-45a0-8519-16ba9a624278"
      unitRef="U_USD">121634000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:RoyaltyExpense
      contextRef="C_e03f65aa-0f08-4125-91e7-89e207442e89"
      decimals="-3"
      id="F_a5a18c7c-ebfe-43c4-b2c9-383da735613b"
      unitRef="U_USD">5345000</us-gaap:RoyaltyExpense>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_e03f65aa-0f08-4125-91e7-89e207442e89"
      decimals="-3"
      id="F_0f26d212-9661-4e91-9132-f1e710408d4c"
      unitRef="U_USD">2186000</us-gaap:PaymentsForRoyalties>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="C_85175ee7-1c57-4e09-a0fa-9cca0710633c"
      decimals="-3"
      id="F_dc3f064f-6e69-4be3-bea3-46da67435b2e"
      unitRef="U_USD">124793000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_4266a16a-f049-4f53-8b58-ae5faf7fdc81">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Authorized Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2023 our stockholders approved an amendment to our Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;675,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,350,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Public Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 1, 2022, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,333,334&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,095,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2022 pre-funded warrant, together with accompanying warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,714,286&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of our common stock, also known as the 2022 stock purchase warrants. The shares of common stock and the 2022 pre-funded warrant were immediately separable from the 2022 stock purchase warrants. All of the securities were issued separately. The combined public offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;price &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of the common stock and accompanying 2022 stock purchase warrants was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The 2022 stock purchase warrants have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and are exercisable immediately. The term of the 2022 stock purchase warrants expired in the third quarter of 2023, pursuant to the terms of the warrant agreement. The combined public offering price of the 2022 pre-funded warrant and accompanying 2022 stock purchase warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.049&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The 2022 pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and may be exercised at any time until the 2022 pre-funded warrant is exercised in full. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, none of the 2022 pre-funded warrant and all of the 2022 stock purchase warrants have been exercised. The net cash proceeds from this offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2022 pre-funded warrant and 2022 stock purchase warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the issuance of the 2022 pre-funded warrant and 2022 stock purchase warrants, we evaluated the terms of each warrant to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and FASB Accounting Standards Codification Topic 815,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2022 pre-funded warrant and the 2022 stock purchase warrants include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2022 pre-funded warrant and the 2022 stock purchase warrants should be classified as equity with no subsequent remeasurement as long as such warrants continue to be classified as equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 10, 2023 we completed an underwritten public offering consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,007,741&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and the 2023 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.45&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The public offering price of the 2023 pre-funded warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.449&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The 2023 pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and may be exercised at any time until the 2023 pre-funded warrant is exercised in full. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, none of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023 pre-funded warrant has been exercised. The net cash proceeds from this offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;213.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting the underwriting discount and other offering expenses paid by us, and exclude any future proceeds from the exercise of the 2023 pre-funded warrant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the issuance of the 2023 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and FASB Accounting Standards Codification Topic 815, Derivatives and Hedging. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2023 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2023 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 21, 2024, we completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,999,998&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock and a pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,002,668&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, or the 2024 pre-funded warrant. All of the securities were issued separately. The public offering price of the common stock was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The public offering price of the 2024 pre-funded warrant was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. The 2024 pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and may be exercised at any time until the 2024 pre-funded warrant is exercised in full. As of December 31, 2024, none of the 2024 pre-funded warrant has been exercised. The net cash proceeds from the March 2024 offering were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, after deducting the underwriting discount and other offering expenses paid by us, and excluding any future proceeds from the exercise of the pre-funded warrant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upon the issuance of the 2024 pre-funded warrant, we evaluated the warrant terms to determine the appropriate accounting and classification pursuant to FASB Accounting Standards Codification Topic 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and FASB Accounting Standards Codification Topic 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Warrants are classified as liabilities when the warrant terms allow settlement of the warrant exercise in cash and classified as equity when the warrant terms only allow settlement in shares of common stock. The terms of the 2024 pre-funded warrant include certain provisions related to fundamental transactions and a cashless exercise provision in the event registered shares are not available, and do not include any mandatory redemption provisions. Based on our evaluation, we concluded the 2024 pre-funded warrant should be classified as equity with no subsequent remeasurement as long as such warrant continue to be classified as equity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant Exercises&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, warrants to purchase&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,071,981&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock were exercised for net cash proceeds of approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The warrants were issued in connection with underwritten public offerings of common stock and pre-funded warrants, together with accompanying stock purchase warrants in May 2020, April 2022, and January 2023. As of December 31, 2024, the following warrants remained outstanding:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;pre-funded warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share to purchas&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,433,145&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, which have no expiration date; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;stock purchase warrants with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share to purchase&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,402,522&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; s&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;hares of our common stock related to the public offering of our common stock in May 2020, which expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2023, warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,349,859&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock were exercised for net cash proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;105.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million The warrants were issued in connection with an underwritten public offering of common stock and a pre-funded warrant, together with accompanying stock purchase warrants in May 2020. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the pre-funded warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,430,477&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock was outstanding and stock purchase warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,474,503&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock associated with the May 2020 public offering remained outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sales Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 1, 2023, we entered into an At Market Issuance Sales Agreement, or the 2023 Sales Agreement with B. Riley, pursuant to which we may issue and sell shares of our common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from time to time through B. Riley as the sales agent. We have agreed to pay B. Riley an aggregate commission rate equal to up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds of the sales price per share for common stock sold through B. Riley under the 2023 Sales Agreement.  The 2023 Sales Agreement will automatically terminate upon the earlier of (i) the sale of all common stock subject to the 2023 Sales Agreement, or (ii) termination of the 2023 Sales Agreement in accordance with its terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock were sold pursuant to the 2023 Sales Agreement during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2011 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2011, our stockholders approved the adoption of the 2011 Incentive Award Plan, or 2011 Plan. The 2011 Plan provided for grants of either incentive stock options or nonstatutory stock options and stock purchase rights to employees (including officers and employee directors) and consultants (including non&#x2011;employee directors). Upon the adoption of the 2018 Equity Incentive Plan in May 2018 (see below), no further grants of stock options or stock purchase rights were made under the 2011 Plan. Stock options granted under the 2011 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant. Stock option exercise prices were equal to the fair market value of the underlying common stock on the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Service&#x2011;based stock options under the 2011 Plan generally vested over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant. Other stock awards (restricted stock awards and restricted stock units) had variable vesting schedules which were determined by our board of directors on the date of grant. All outstanding awards granted under the 2011 Plan remain subject to the terms of the 2011 Plan and the individual award agreements thereunder.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 15, 2018, our stockholders approved the adoption of the 2018 Equity Incentive Plan, or 2018 Plan, as the successor to the 2011 Plan. The 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. Eligible participants under the 2018 Plan include our employees, consultants and non-employee directors. The number of shares reserved for issuance under the 2018 Plan (subject to adjustment for certain changes in capitalization) is equal to the sum of (i) the unallocated shares of common stock remaining available for future grants under the 2011 Plan as of May 15, 2018, (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; newly &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;reserved shares of common stock and (iii) the number of shares subject to awards granted under&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2002 Equity Incentive Plan, and the 2011 Plan as such shares become available from time to time, referred to as the Prior Plans&#x2019; Returning Shares. Such Prior Plans&#x2019; Returning Shares become available for issuance under the 2018 Plan if outstanding stock awards granted under the 2002 Equity Incentive Plan and the 2011 Plan, after May 15, 2018, expire or terminate for any reason prior to exercise or settlement or are forfeited, cancelled or otherwise returned to us because of the failure to meet a contingency or condition required for the vesting of such shares, or, subject to certain exceptions, are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award. In May 2023, May 2022 and May 2021, our stockholders approved amendments to our 2018 Equity Incentive Plan to increase the total number of shares issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-variant:small-caps;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,360,000&lt;/span&gt;&lt;span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,500,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, an aggregate total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,447,090&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock have been reserved under the 2018 Equity Incentive Plan, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,587,928&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; available for future grants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock options granted under the 2018 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of grant. Stock option exercise prices shall be equal to the fair market value of the underlying common stock on the date of grant. If, at the time we grant a stock option, the optionee directly or by attribution owns stock possessing more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total combined voting power of all classes of our stock, the stock option exercise price shall be at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the fair market value of the underlying common stock and shall not be exercisable more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; after the date of grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We grant service-based and performance-based stock options to employees under the 2018 Plan. Service-based stock options generally vest over a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the date of the stock option grant. Performance-based stock options vest upon the achievement of specified milestones. Other stock awards (restricted stock awards and restricted stock units) have variable vesting schedules as determined by our board of directors on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under certain circumstances, stock options may be exercised prior to vesting, subject to our right to repurchase the shares underlying such stock option at the exercise price paid per share. Our repurchase rights would generally terminate on a vesting schedule identical to the vesting schedule of the exercised stock option. During 2024 and 2023, we did not repurchase any shares under the 2018 Plan. As of December 31, 2024, we have no shares outstanding subject to repurchase under the 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, our Non&#x2011;Employee Director Compensation Policy adopted by our board of directors in March 2014, as amended and restated in February 2024 and February and March 2022, provides for the automatic grant to non&#x2011;employee directors of the following types of equity awards under the 2018 Plan:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;First Director Option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  Each person who becomes a non&#x2011;employee director, whether by election by our stockholders or by appointment by our board of directors to fill a vacancy, will automatically be granted a stock option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, or First Director Option, on the date such person first becomes a non&#x2011;employee director. The First Director Option vests annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; upon each anniversary date of appointment to our board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Subsequent Director Option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  Each non&#x2011;employee director (other than any director receiving a First Director Option on the date of the annual meeting) will automatically be granted a subsequent stock option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;180,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, a Subsequent Director Option, on the date of the annual meeting of stockholders in each year during such director&#x2019;s service on our board of directors. The Subsequent Director Option vests in full on the earlier of: (i) the date of the next annual meeting of our stockholders or (ii) the first anniversary of the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2018 Inducement Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2018, our board of directors approved the adoption of the 2018 Inducement Award Plan, or the Inducement Plan, pursuant to which we reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock to be used exclusively for grants of inducement awards to individuals who were not previously Geron employees or non-employee directors, other than following a bona fide period of non-employment.  Since adoption of the Inducement Plan, t&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he compensation committee of our board of directors, or the compensation committee, has approved amendments to our Inducement Plan to increase the aggregate total number of shares issuable under such plan to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock.  The most recent amendment, approved by the compensation committee in December 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;increased the total number of shares issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, effective as of January 1, 2025, to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, an aggregate total of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,959,342&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock have been reserved under the Inducement Plan, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;851,137&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; available for future grants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards, and all awards under the Inducement Plan are intended to meet the standards under Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the Inducement Plan and the inducement awards to be granted thereunder are substantially similar to our stockholder-approved 2018 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Directors&#x2019; Market Value Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2018, our board of directors adopted a Directors&#x2019; Market Value Stock Purchase Plan, or the Directors Market Plan. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock have been reserved for the Directors Market Plan. Under the Directors Market Plan, non-employee directors may purchase shares of our common stock at the prevailing market price on the purchase date with cash compensation payable to them for their services as a board member. As stated in Geron&#x2019;s Non-Employee Director Compensation Policy, each non-employee director receives annual cash compensation, payable quarterly in arrears, for their services on the board and various committees of the board. As provided in the Non-Employee Director Compensation Policy, a non-employee director may elect to receive fully vested shares of common stock in lieu of cash and such shares shall be issuable from the Directors Market Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2024, 2023 and 2022, we issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,351&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,864&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,962&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, respectively, under the Directors Market Plan. The weighted average grant date fair value of stock granted during the years ended December 31, 2024 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.84&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. The total fair value of vested stock grants during 2024, 2023 and 2022 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,079&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85,400&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, Inducement Plan and Directors Market Plan is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Available&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,750,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,984,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,603,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,603,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awards granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,907,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options cancelled/forfeited/expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,171,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,713,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,309,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,967,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.35&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,204,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercisable at &lt;br/&gt;&#160;&#160;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,943,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,488,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options fully vested and expected&lt;br/&gt;&#160;&#160;&#160;&#160;to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,159,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,613,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance-based stock options granted that have not achieved the specified performance milestone.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value in the preceding table represents the total intrinsic value, based on Geron&#x2019;s closing stock price of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.54&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share as of December 31, 2024, which would have been received by the option holders had all the option holders exercised their stock options as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, 2023 and 2022, there were&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,943,520&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,995,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,085,389&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; exercisable stock options outstanding at weighted average exercise prices per share of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.17&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, all of which were granted at an exercise price equal to the fair market value of our common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total pretax intrinsic value of stock options exercised during 2024, 2023, and 2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million  and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Cash received from the exercise of stock options in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023, and 2022 totaled approximately&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2014, our board of directors adopted the 2014 Employee Stock Purchase Plan, or 2014 Purchase Plan. The 2014 Purchase Plan was approved by our stockholders in May 2014. The 2014 Purchase Plan replaced the 1996 Employee Stock Purchase Plan, or 1996 Purchase Plan, which was terminated effective as of the date the 2014 Purchase Plan was approved by our stockholders. In May 2022, our stockholders approved an amendment to our 2014 Purchase Plan to increase the total num&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ber of shares issuable under such plan by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock, for an aggregate total reserve of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sh&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ares. As of December 31, 2024, an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,741,634&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock have been issued under the 2014 Purchase Plan since its adoption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2014 Purchase Plan is comprised of a series of offering periods, each with a maximum duration (not to exceed &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months) with new offering periods commencing on January 1st and July 1st of each year. The date an employee enters the offering period will be designated as the entry date for purposes of that offering period. An employee may participate only in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; offering period at a time. Each offering period consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive purchase periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019; duration, with the last day of such period designated a purchase date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the 2014 Purchase Plan, employees can choose to have up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their annual salary withheld to purchase our common stock, up to a limit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per year. An employee may not make additional payments into such account or increase the withholding percentage during the offering period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The purchase price per share at which common stock is purchased by the employee on each purchase date within the offering period is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of (i) the fair market value per share of our common stock on the employee&#x2019;s entry date into that offering period or (ii) the fair market value per share of our common stock on the purchase date. If the fair market value per share of our common stock on the purchase date is less than the fair market value at the beginning of the offering period, a new &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; month offering period will automatically begin on the first business day following the purchase date with a new fair market value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation for Employees and Directors&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We measure and recognize compensation expense for all share&#x2011;based payment awards made to employees and directors, including employee stock options, restricted stock awards, restricted stock unit awards, and employee stock purchases, based on grant&#x2011;date fair values for these instruments. We use the Black-Scholes option&#x2011;pricing model to estimate the grant&#x2011;date fair value of our service-based and performance-based stock options and employee stock purchases. The fair value for service&#x2011;based restricted stock awards and restricted stock unit awards is determined using the fair value of our common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As stock&#x2011;based compensation expense recognized on the consolidated statements of operations for the years ended December 31, 2024, 2023 and 2022 is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures, but at a minimum, reflects the grant&#x2011;date fair value of those awards that actually vested in the period. Forfeitures have been estimated at the time of grant based on historical data and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2024, 2023, and 2022, our board of directors awarded&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;832,790&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,741,750&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; perfo&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rmance-based stock options, respectively, to certain employees. These performance-based stock options are included in the outstanding stock options table above. Performance-based stock options vest only upon achievement of discrete milestones. Stock-based compensation expense for performance-based stock options is recognized over the period from the date the performance condition is determined to be probable of occurring through the date the applicable condition is expected to be met and is reduced for estimated forfeitures, as applicable. If the performance condition is not considered probable of being achieved, no stock-based compensation expense is recognized until such time as the performance condition is considered probable of being achieved, if ever.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize stock&#x2011;based compensation expense for service-based stock options on a straight&#x2011;line basis over the requisite service period, which is generally the vesting period. We reco&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;gnized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the year ended December 31, 2023. We did not recognize any stock-based compensation expense for performance-based stock options on our consolidated statements of operations for the years ended December 31, 2022 ,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as the achievement of the specified milestones was not considered probable during that time. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the stock&#x2011;based compensation expense related to service-based stock options and employee stock purchases for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022, which was allocated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was capitalized to inventory for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options granted in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023, and 2022 has been estimated at the date of grant using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of employee stock purchases in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023, and 2022 has been estimated using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;. to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Dividend yield is based on historical cash dividend payments and we have paid no cash dividends to date. The expected volatility range is based on historical volatilities of our stock, since traded options on our common stock do not correspond to option terms and the trading volume of options is limited. The risk&#x2011;free interest rate range is based on the U.S. Zero Coupon Treasury Strip Yields for the expected term in effect on the date of grant for an award. The expected term of stock options is derived from actual historical exercise and post&#x2011;vesting cancellation data and represents the period of time that stock options granted are expected to be outstanding. The expected term of employees&#x2019; purchase rights is equal to the purchase period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on the Black-Scholes option&#x2011;pricing model, the weighted-average estimated fair value of stock options granted during the years ended December 31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. The weighted average estimated fair value of employees&#x2019; purchase rights for the years ended December 31, 2024, 2023 and 2022 w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. As of December 31, 2024, total compensation cost related to unvested share&#x2011;based payment awards not yet recognized, net of estimated forfeitures and assuming no probability of achievement for outstanding performance-based stock options, was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over the next &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;32&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months on a weighted&#x2011;average basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation to Service Providers&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We grant stock options to consultants from time to time in exchange for services performed for us. In general, the stock options vest over the contractual period of the consulting arrangement. The fair value of stock options held by consultants is recorded as operating expenses over the vesting term of the respective equity awards. With the adoption of Accounting Standards Update 2018-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Nonemployee Share-Based Payment Accounting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or ASU 2018-07, in the first quarter of 2019, the measurement date of stock options granted to consultants was fixed at the grant date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recorded stock&#x2011;based compensation expe&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nse of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;103,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;742,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the vested portion of the fair value of stock options held by consultants in 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.133%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.667%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,967,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options and awards available for grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,309,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,835,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,371,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_2f48563d-cfb2-405d-b3c5-32ab5e666ff0"
      decimals="INF"
      id="F_c014d901-a55e-49db-9583-80e3ebec9445"
      unitRef="U_shares">675000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ffad885e-eeb0-4c57-b284-7102190be086"
      decimals="INF"
      id="F_7c70bce0-764e-4a57-81fa-7b6c188c756f"
      unitRef="U_shares">1350000000</us-gaap:CommonStockSharesAuthorized>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_5d81f491-dae6-42b2-9a9d-49bae561bc54"
      decimals="INF"
      id="F_5a104fbc-561d-46e9-8891-f4d3c4eb77ec"
      unitRef="U_shares">53333334</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4"
      decimals="INF"
      id="F_7b232a02-f42f-4cbb-80bb-8c65dc4fed9d"
      unitRef="U_shares">18095238</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_48142c5b-ce3f-4966-921e-0b74263697ba"
      decimals="INF"
      id="F_c61191f2-3d3f-4fe4-9123-56d1d0118067"
      unitRef="U_shares">35714286</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_bd7cb667-7647-4a87-b629-ce1a51b824be"
      decimals="2"
      id="F_6c4b6126-4b64-4ddf-9bbc-7e74de0486e8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_48142c5b-ce3f-4966-921e-0b74263697ba"
      decimals="2"
      id="F_62127ad7-9e6b-471a-8187-707249fb6119"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4"
      decimals="3"
      id="F_f725df0a-fd87-4784-86d6-ca87f3e98e95"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.049</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_23f93018-af22-4a35-bebe-6d9e8b2bdbf4"
      decimals="3"
      id="F_3baf58cf-5353-41c2-a510-43cb3f391888"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_5d81f491-dae6-42b2-9a9d-49bae561bc54"
      decimals="-5"
      id="F_458d86c8-2ddc-4375-ba7b-e10fc8cfdde8"
      unitRef="U_USD">69900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b"
      decimals="INF"
      id="F_723049e2-3322-41b2-a2aa-32f55d5fc666"
      unitRef="U_shares">68007741</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_e3f5c2dc-7c9d-424d-9590-a69e1018f7df"
      decimals="2"
      id="F_c07e95e5-4d91-4418-8749-39c7b5292ff2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.45</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_432034fc-3319-4587-adae-2e7c9b692266"
      decimals="3"
      id="F_b8e78a05-2c34-48b2-b012-233768dd2d38"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.449</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_432034fc-3319-4587-adae-2e7c9b692266"
      decimals="3"
      id="F_1b55bbbf-bc04-4cf5-8efd-cb3133feada7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_ea5e4e47-d150-43f1-90d2-00a3ad0ca77b"
      decimals="-5"
      id="F_bfe68040-bd73-49a7-998c-9ed2e9d09091"
      unitRef="U_USD">213300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering
      contextRef="C_a4269ae4-d56a-4edf-a592-a2ea8119922f"
      decimals="INF"
      id="F_29552e16-556c-45c9-a94f-642d4261c2a7"
      unitRef="U_shares">41999998</gern:ShareOfCommonStockIssuedDuringPeriodSharesNewIssuesPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f79ee241-9a76-41d9-93df-733bd1f3b85d"
      decimals="INF"
      id="F_764c762f-bb68-49e8-9f30-a1794d07cdc8"
      unitRef="U_shares">8002668</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_faf26aae-a2ff-481b-b390-795807f43711"
      decimals="2"
      id="F_d8f6e1f1-41d6-446a-8ec3-494a94483a86"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_f79ee241-9a76-41d9-93df-733bd1f3b85d"
      decimals="2"
      id="F_7209635b-1585-437a-b031-0b2266fce8af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.99</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f79ee241-9a76-41d9-93df-733bd1f3b85d"
      decimals="3"
      id="F_371673e8-9a3a-431a-9fb2-0c5990fb6c36"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_a4269ae4-d56a-4edf-a592-a2ea8119922f"
      decimals="-5"
      id="F_6e96fcd6-0c3d-4f9c-aeda-8d95e3a0f1df"
      unitRef="U_USD">141000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised
      contextRef="C_9660272a-a38b-4587-990c-81de73711c8d"
      decimals="INF"
      id="F_c12ab290-2ddb-48be-bd7d-99e354b62529"
      unitRef="U_shares">1071981</gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_e92973db-cfa0-4226-992e-ba00f3710cd8"
      decimals="-5"
      id="F_819b3bbc-e42f-4342-b85f-86afa1e992f5"
      unitRef="U_USD">1400000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_04ccb33e-9db2-4428-ab1f-e86203e71f68"
      decimals="3"
      id="F_85f6c159-24f2-4011-a39b-6566570193d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_04ccb33e-9db2-4428-ab1f-e86203e71f68"
      decimals="INF"
      id="F_9d3ea270-02c7-401f-8ad8-8ff51e2f023d"
      unitRef="U_shares">59433145</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_f784b962-1d18-4a7e-8f25-c81f2229ede3"
      decimals="2"
      id="F_f7d76a28-4b0e-4d40-818b-53c4be01d05f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_f784b962-1d18-4a7e-8f25-c81f2229ede3"
      decimals="INF"
      id="F_98c99134-80a6-4434-937c-7111edefc0da"
      unitRef="U_shares">1402522</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_f784b962-1d18-4a7e-8f25-c81f2229ede3"
      id="F_13efd343-b34e-48fc-8bc5-3964de0a143d">2025-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised
      contextRef="C_8348b52f-8813-4f32-97db-ccc55a82dd58"
      decimals="INF"
      id="F_0dfa8a73-0946-40b2-8186-ccab75d428d3"
      unitRef="U_shares">77349859</gern:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_7e54cf5e-d7b0-4905-96d8-e3ba1772cfd6"
      decimals="-5"
      id="F_ae767d76-9962-4f25-85f2-0f08cef5e160"
      unitRef="U_USD">105900000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_ebc02be3-4e6f-4b78-bff8-d2cfc26bed45"
      decimals="INF"
      id="F_32799005-a514-4411-922b-5d10baa833cb"
      unitRef="U_shares">51430477</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_f086f31f-ebe6-4d2c-8914-9edaca62d90f"
      decimals="INF"
      id="F_d2c898d6-bd2e-4d6b-955a-601ee94459a6"
      unitRef="U_shares">2474503</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <gern:CommonStockAggregateOfferingPrice
      contextRef="C_f0e977cf-938a-4204-9bd8-6c42bf0b34b1"
      decimals="INF"
      id="F_7b723e34-8b5d-4f83-b8bb-52d2804ea4fe"
      unitRef="U_USD">100000000</gern:CommonStockAggregateOfferingPrice>
    <gern:MaximumCommissionRate
      contextRef="C_f0e977cf-938a-4204-9bd8-6c42bf0b34b1"
      decimals="INF"
      id="F_50ab5eb7-a0dd-4d72-876a-d8d1ef6232d8"
      unitRef="U_pure">0.030</gern:MaximumCommissionRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ece3b919-9c68-4419-b2c9-c5d7c4dcca3d"
      decimals="INF"
      id="F_4e47e178-0cf9-4fb0-a6bb-bdfe86d8efe5"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2d097eb2-6e57-4299-a3e5-9151a4df0198"
      decimals="INF"
      id="F_f8cf00b7-24b3-49c3-b920-8caafa98a730"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_a450a2dc-f974-4416-9511-c7302a719fa4"
      id="F_97147fad-d359-41d4-9a40-cefffd973ca1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_eb68352e-6df9-4716-b022-e07659784349"
      id="F_d9c90039-2003-4b2d-b191-180e4bf4abb2">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2fc64b5e-3892-4a81-a7e8-b127182a99ad"
      decimals="INF"
      id="F_79b71a2b-6c6f-440c-969f-22aa98de0b76"
      unitRef="U_shares">10000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_46ea59e0-e969-4c87-9aa0-1688daa1c9f0"
      decimals="INF"
      id="F_5e4dcb7a-9778-4d04-a91c-956e73dd4b19"
      unitRef="U_shares">43360000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_21447006-602d-46aa-a917-f6697b7e69d8"
      decimals="INF"
      id="F_3ae08904-49ee-4657-b765-c6649be071f3"
      unitRef="U_shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_e3a7796a-70fb-4745-ac2a-15cfb3d6b8c8"
      decimals="INF"
      id="F_58a2ad36-2004-4426-975b-94e5231d839b"
      unitRef="U_shares">12500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00"
      decimals="INF"
      id="F_5352b55e-34dc-4626-afd9-73910cf7df24"
      unitRef="U_shares">81447090</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00"
      decimals="INF"
      id="F_a65134a1-110f-4148-8467-f36ef5536ed6"
      unitRef="U_shares">32587928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_18c60a52-303b-412b-986a-7e6145b28956"
      id="F_75a9de43-de59-4e19-94c9-2883b71681c0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue
      contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00"
      decimals="INF"
      id="F_31b10bbd-f5ca-453d-b895-df6fa8097c59"
      unitRef="U_pure">0.10</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumPercentageOfOwnershipRequiredForGrantingOptionsAtMinimum110PercentOfFairMarketValue>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock
      contextRef="C_3c58eba1-098b-4137-bffd-fc83f6d66c00"
      decimals="INF"
      id="F_7030c30d-afd9-44f7-aa79-739aaedea49b"
      unitRef="U_pure">1.10</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumExercisePriceOfOptionsGrantedToEmployeesWithMoreThan10PercentageOfCommonStock>
    <gern:ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock
      contextRef="C_d3392540-02f2-4e5b-8f42-37beb9ba9e45"
      id="F_2c1071ac-0239-400a-9aa3-4d1bcf5e035b">P5Y</gern:ShareBasedCompensationByShareBasedPaymentAwardOptionsMaximumExpirationTermForOptionsGrantedToOptioneesWithOwnershipOfMoreThan10PercentageOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_d3392540-02f2-4e5b-8f42-37beb9ba9e45"
      id="F_f8c096ae-3637-4c50-8712-b6054189a795">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment
      contextRef="C_dba11232-95dc-4b7a-a0b2-f0bc6076e0cb"
      decimals="INF"
      id="F_38a9c6ba-04b2-46f6-9a25-7dff361929c1"
      unitRef="U_shares">270000</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseSharesUponAppointment>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f18cad10-57aa-4265-bcc3-f8c0b2fe427f"
      id="F_d679e5ae-55e5-4d01-8549-f749fa07c0f1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares
      contextRef="C_c3e030b6-7508-4442-bbe2-6485ef87fd91"
      decimals="INF"
      id="F_89510334-1c74-4a57-bf71-39b3b1e811e0"
      unitRef="U_shares">180000</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsToBeGrantedToPurchaseShares>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c155be43-9cca-497f-9c0d-dff7e4f971aa"
      decimals="INF"
      id="F_c2c440e3-9337-48c6-b6e8-4b970922545c"
      unitRef="U_shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_c2ddaf0c-c480-4121-89b7-e270b06ea351"
      decimals="INF"
      id="F_1d2759f6-840f-47f7-9a39-989d04e516f7"
      unitRef="U_shares">40300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_e3cb3a12-8449-4080-9d04-c09977c81469"
      decimals="INF"
      id="F_b69b6421-0aa8-43f1-a94a-12eb2f6a3c28"
      unitRef="U_shares">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_833a88bd-1656-4796-b8aa-0fb692b42fdd"
      decimals="INF"
      id="F_dc7492b1-5495-4fff-bd63-ec595ebefb31"
      unitRef="U_shares">40300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1e3660ee-c4ab-4b1a-a885-f4768cde0fc5"
      decimals="INF"
      id="F_9c42239d-43f6-4787-90e3-8357bd7e538a"
      unitRef="U_shares">27959342</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_1e3660ee-c4ab-4b1a-a885-f4768cde0fc5"
      decimals="INF"
      id="F_111bf922-474d-4e2d-a6d4-1e43d8910483"
      unitRef="U_shares">851137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_06fd0fff-364c-40d2-aea0-8957283902a3"
      decimals="INF"
      id="F_7206442e-75c5-4a3b-a767-d2e6b89689e7"
      unitRef="U_shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_13450eff-f3fb-4504-9420-67b321adf1b9"
      decimals="INF"
      id="F_7095e372-1834-4031-b0c0-0be25fc01c15"
      unitRef="U_shares">8351</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4"
      decimals="INF"
      id="F_38bd2ffb-039e-45de-a882-f139de827b8a"
      unitRef="U_shares">36864</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_3111e83f-2076-4782-b9bc-ed01f0ea1874"
      decimals="INF"
      id="F_ec65d2d9-076b-46fd-a4f0-d99e39ec7fc4"
      unitRef="U_shares">15962</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_13450eff-f3fb-4504-9420-67b321adf1b9"
      decimals="2"
      id="F_228f093b-1ee9-4d9f-9461-4333ca16ab07"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4"
      decimals="2"
      id="F_102bacf3-07da-4286-99ae-17a1cfb47d20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_3111e83f-2076-4782-b9bc-ed01f0ea1874"
      decimals="2"
      id="F_fa3261cb-7824-4138-a1cb-a634eaf542a4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_13450eff-f3fb-4504-9420-67b321adf1b9"
      decimals="INF"
      id="F_78aa6370-2a7c-4d5a-b52b-5496668656ec"
      unitRef="U_USD">32079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_c076e2a3-ce27-4e69-ab7a-2f2e0ca92ab4"
      decimals="INF"
      id="F_b4e9eb29-fbe4-4823-9e52-e9686a8ef5e4"
      unitRef="U_USD">85400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_3111e83f-2076-4782-b9bc-ed01f0ea1874"
      decimals="INF"
      id="F_8414026b-c487-426c-be46-c5cc5f26b268"
      unitRef="U_USD">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_5a032cf3-eca9-4ee7-9e1d-2fd152932be4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Aggregate stock option and award activity for the 2011 Plan, 2018 Plan, Inducement Plan and Directors Market Plan is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Available&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;For Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;58,750,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,984,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,603,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,603,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Awards granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,907,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options cancelled/forfeited/expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,171,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,713,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,309,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,967,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.35&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,204,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options exercisable at &lt;br/&gt;&#160;&#160;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,943,520&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.84&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,488,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options fully vested and expected&lt;br/&gt;&#160;&#160;&#160;&#160;to vest at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,159,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.30&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,613,420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:76.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.13%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.13%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; performance-based stock options granted that have not achieved the specified performance milestone.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_87aa576e-a59b-42a6-a9bb-2686c5775867"
      unitRef="U_shares">58750670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_a0a10bac-9ff2-4312-9835-4deb56f4b110"
      unitRef="U_shares">72984351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="2"
      id="F_5c8239f2-a012-4f43-9792-81b252dbd5aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_dbad5f20-1212-499f-8f24-7d439ecbcd9d"
      unitRef="U_shares">29603740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_7456b955-062c-4d2e-a23c-f00fcc322aff"
      unitRef="U_shares">29603740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="2"
      id="F_334d4b75-2dc8-4c40-a2cb-084e12730670"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_1c3d9541-ca88-4bb7-a00a-b12f0c4e5f73"
      unitRef="U_shares">8351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_010e80d9-6bc7-4dab-9ec0-d5e23da2061b"
      unitRef="U_shares">17907649</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="2"
      id="F_44963a4e-4959-4bba-935e-31e9798732e6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gern:ShareBasedCompensationForfeituresAndExpirationsInPeriodNet
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_33613232-dc0d-4f0b-874b-66035d6c778b"
      unitRef="U_shares">5171390</gern:ShareBasedCompensationForfeituresAndExpirationsInPeriodNet>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_3edaafd9-b963-4db1-93e4-f949b95372e5"
      unitRef="U_shares">8713075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="2"
      id="F_8ff0094a-4eb4-4407-ad9c-76d117b9c72e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_e81efcfd-c962-4e21-8c2a-b19bde45c996"
      unitRef="U_shares">34309969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_d36a7fb7-46ca-4bee-b979-c294b906104c"
      unitRef="U_shares">75967367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="2"
      id="F_b38a9d76-ef8e-4a4b-b9fc-4ce8d426cf86"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_4ffef491-959a-494e-85f7-cbd45140615c">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="0"
      id="F_6fc12cc9-9a06-4754-b2ec-acf3f252f0f6"
      unitRef="U_USD">94204849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_1faf68a5-0fac-4e45-9b19-dbb9cd66cc08"
      unitRef="U_shares">37943520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="2"
      id="F_112bf966-7183-4397-a8f1-7a236f24ca3c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_8775a655-6d98-463d-a52a-a61fb69fe49d">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="0"
      id="F_d911dea9-c35e-4747-9cbc-d44cf72120ea"
      unitRef="U_USD">57488305</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_f9ede76c-7c8e-415f-b3d1-8dcf5c535246"
      unitRef="U_shares">74159549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="2"
      id="F_bb241461-5069-4082-b526-e458f5874866"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_e94da6c0-333e-48d3-a3ba-2c39bd04e50e">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="0"
      id="F_bec5b6b1-8480-42ec-8c31-79df5efde3d8"
      unitRef="U_USD">92613420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bdeda059-8b87-497a-b9cd-e4cf9530f303"
      decimals="INF"
      id="F_d8a3c649-8e36-40e2-9457-22bc2071526a"
      unitRef="U_shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="2"
      id="F_d533cca2-4a6c-440b-9d27-2566338393fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.54</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_c1ab4fcc-8673-4362-abb7-3877cae0ff40"
      unitRef="U_shares">37943520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="INF"
      id="F_6b36ba45-d79b-4541-b50f-0dfa5acd8a8e"
      unitRef="U_shares">39995642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402"
      decimals="INF"
      id="F_02f94de1-0a5d-4e4f-891b-357e42db3ea2"
      unitRef="U_shares">36085389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="2"
      id="F_4642928b-cd89-4245-95cc-14c331376fe7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="2"
      id="F_cad2f14e-fec9-40d0-89fd-6af3a9b28350"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_344637f9-35dd-4606-aaa8-39e3e4eed402"
      decimals="2"
      id="F_6520349b-0b78-4c21-a3d6-9e28174d4884"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-5"
      id="F_0f3b4513-5f10-4c19-b7d4-6d8e1d131cb4"
      unitRef="U_USD">41200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-5"
      id="F_e2248f6a-0017-41cc-a998-56a9b892ad24"
      unitRef="U_USD">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-5"
      id="F_b87916bb-5607-42cb-8758-21fb898043a8"
      unitRef="U_USD">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="1"
      id="F_851138b4-0dcb-4e30-9993-3fa01bad9d97"
      unitRef="U_USD">31.6</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="1"
      id="F_a575bfb0-ad62-4ba2-9fc1-383b4377b688"
      unitRef="U_USD">12.4</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="1"
      id="F_a6ecad68-ffe4-4478-a6e0-d8a2a480554a"
      unitRef="U_USD">1.8</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="C_6ec90163-a65e-40c3-a187-132ae7c4e62a"
      decimals="INF"
      id="F_b72fa4ad-1ae3-466b-be20-8bc5e4e9384a"
      unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_15852a6c-ac98-4815-b64c-948a1a3c90a1"
      decimals="INF"
      id="F_6ab1d658-7b60-42a9-ab4b-b593757ce91f"
      unitRef="U_shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      decimals="INF"
      id="F_46941953-ee56-4cf8-9ac5-8db0a31ca8f3"
      unitRef="U_shares">1741634</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateSharesIssuedUnderPlan>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      id="F_ca20c405-9648-4791-8abe-035c43e229b3">P12M</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumDurationOfOfferingPeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      decimals="INF"
      id="F_ff264806-ec98-43b8-8aab-3a3a7c5f3fcb"
      unitRef="U_Item">1</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfOfferingPeriodsInWhichEmployeeMayParticipateAtOneTime>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      decimals="INF"
      id="F_bb17c524-23b1-4c2b-8fb8-b79af58c71d8"
      unitRef="U_Item">2</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfConsecutivePurchasePeriodsInEachOfferingPeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      id="F_3185bc27-2c8d-4b34-8366-84cba140bd65">P6M</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfPurchasePeriod>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      decimals="INF"
      id="F_e2d13071-25b2-48fa-bfee-6a6e271f37ef"
      unitRef="U_pure">0.10</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumPercentageOfAnnualSalaryThatCanBeWithheld>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear
      contextRef="C_275fb7a4-efea-4c31-83c8-55c94f697b31"
      decimals="INF"
      id="F_f4f96dd0-c53a-47a4-bd4c-45b6bd27bd39"
      unitRef="U_USD">25000</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountOfAnnualSalaryThatCanBeWithheldPerYear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      decimals="INF"
      id="F_9af08305-b4cd-4ef1-bb39-cd7cd6cff14b"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      id="F_cb1da935-4dec-4539-beb8-73e563b2c2cb">P12M</gern:ShareBasedCompensationArrangementByShareBasedPaymentAwardDurationOfNewOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_407442e0-3cce-4289-80e2-39b67a1f061b"
      decimals="INF"
      id="F_daa27c9d-c749-442c-bea1-c3ac9a63a794"
      unitRef="U_shares">208100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_53975bd8-a789-4655-ac7f-6b97e0b87f47"
      decimals="INF"
      id="F_4c848d2b-e871-4b46-aab6-f0e78c844f19"
      unitRef="U_shares">832790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a177d587-0918-4df7-8a99-cd04f1e5d2b8"
      decimals="INF"
      id="F_a84183dc-c704-494e-87c9-d28f05e5fed6"
      unitRef="U_shares">2741750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_407442e0-3cce-4289-80e2-39b67a1f061b"
      decimals="-5"
      id="F_292cd253-dee7-4712-80b5-59cdcf07a91d"
      unitRef="U_USD">6500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_53975bd8-a789-4655-ac7f-6b97e0b87f47"
      decimals="-5"
      id="F_a796f5be-ab58-4f7c-9615-1d06dbf2d25b"
      unitRef="U_USD">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_e29fa5db-e1d1-4bd8-aa10-7d236dff595f">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the stock&#x2011;based compensation expense related to service-based stock options and employee stock purchases for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024, 2023 and 2022, which was allocated as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,426&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e43f9ac5-e990-42e5-a162-14377ebe69a7"
      decimals="-3"
      id="F_a8bcecef-21f2-443f-b2ab-fe5ec729cc42"
      unitRef="U_USD">10280000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c38d97f7-08a0-4702-99f8-8f86ab3205f8"
      decimals="-3"
      id="F_4619605e-2e8d-4be1-aeeb-ed9deff1404a"
      unitRef="U_USD">7426000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_501b1eb2-a39a-4305-ada7-ee277b99376c"
      decimals="-3"
      id="F_74fbd64f-f763-4eb0-936f-c336cb290b66"
      unitRef="U_USD">3720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_799b9a49-462d-486f-9022-ce4831f01775"
      decimals="-3"
      id="F_f96d4a38-d64c-4133-b318-c8d745bdc462"
      unitRef="U_USD">21647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_03b38bc3-3391-4183-82aa-61b99babb682"
      decimals="-3"
      id="F_42746394-4723-4fb8-943c-1a8976a05ecc"
      unitRef="U_USD">11099000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_23479e27-d886-45ff-8c25-d7ca04bd3cee"
      decimals="-3"
      id="F_8e64e89e-a90a-4a58-82f7-3bebbea4ddcd"
      unitRef="U_USD">4281000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_2a0bd475-5871-4827-9198-173eb6d4fc22"
      unitRef="U_USD">31927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_3b797ce7-4ed7-4067-89c9-6078bf9340ef"
      unitRef="U_USD">18525000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_ea5c42ca-8066-41c0-b396-f639244c316b"
      unitRef="U_USD">8001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-5"
      id="F_67d1e2d2-6d9b-4b5d-8de2-cf18dd54cc07"
      unitRef="U_USD">700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_0072c981-b561-4dbb-b0c9-515bf89feccc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options granted in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023, and 2022 has been estimated at the date of grant using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;yrs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      decimals="2"
      id="F_89b3d1fa-d931-44a3-8c53-e4cfaa867e16"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      decimals="2"
      id="F_f6da028b-5e51-4dc1-abc4-f96dacd4d008"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      decimals="2"
      id="F_4b055a5a-b312-493d-836d-6841ba40ebe0"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      decimals="2"
      id="F_9273b2b1-d2c2-4086-b8f7-5ea9170716e3"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      decimals="2"
      id="F_5f67b0d0-0d01-44c2-94b5-9255eaeb2935"
      unitRef="U_pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      decimals="2"
      id="F_b1fbdab7-0291-456f-baec-a70b61acad9a"
      unitRef="U_pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      decimals="2"
      id="F_8738b1f7-c9bd-4ab4-9134-4c1bfb024ca8"
      unitRef="U_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      decimals="2"
      id="F_803a4958-6f9f-4733-9aa2-426ca744445d"
      unitRef="U_pure">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      decimals="2"
      id="F_2b6809a3-4874-4fe4-a04c-37986c066c05"
      unitRef="U_pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      decimals="3"
      id="F_d3fa08fa-242f-4363-b449-58b32103e748"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      decimals="3"
      id="F_149272c7-93ca-4072-8596-79ffe399a50b"
      unitRef="U_pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      decimals="4"
      id="F_fb89a32a-af04-4f1e-9db4-d85d54101049"
      unitRef="U_pure">0.0342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      decimals="4"
      id="F_71cdf7ea-1198-44a0-9721-b51c46aaffb0"
      unitRef="U_pure">0.0494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      decimals="4"
      id="F_b0efacec-e537-4a54-9639-8e67f86993ba"
      unitRef="U_pure">0.0169</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      decimals="4"
      id="F_6ec4b954-3250-46af-9ab8-1e711e1ff135"
      unitRef="U_pure">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      id="F_04bc8b7a-d51b-45f0-828f-46c8920d56c3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      id="F_71730464-1137-4c60-b926-c18ff90479dc">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      id="F_ec7ab7b5-48ac-4594-9ca6-247731a994d2">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_d2ac6b6c-0e25-424f-8a13-22a7ca5eb0d4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of employee stock purchases in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2024, 2023, and 2022 has been estimated using the Black-Scholes option&#x2011;pricing model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:18.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;. to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.61&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:9pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;"&gt;&#160;mos&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"
      decimals="2"
      id="F_d8990397-5472-4ee6-b7c6-330ce5f8eb54"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d"
      decimals="2"
      id="F_d2823e92-db1f-46b7-bc9c-d78682c6cced"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d"
      decimals="2"
      id="F_dc1535ea-b119-4729-a581-7cb2fa09aece"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"
      decimals="2"
      id="F_e2e0adbd-b511-41bd-9060-9900c00733c4"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"
      decimals="2"
      id="F_4e0cfa73-a7d1-40fa-b79b-153404379f2a"
      unitRef="U_pure">1.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d"
      decimals="2"
      id="F_6de2ef5f-2ae7-47fe-aded-6714858136c1"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d"
      decimals="2"
      id="F_c4f2e8d8-e9f4-4f9b-ada4-b92147472d90"
      unitRef="U_pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d"
      decimals="2"
      id="F_b8133eb3-edce-4ce0-b470-75a1f0d56af3"
      unitRef="U_pure">0.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d"
      decimals="2"
      id="F_21873e23-e898-474a-8058-90dceb51873f"
      unitRef="U_pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"
      decimals="3"
      id="F_cd2c1918-bbdb-4d07-9bb9-262d291602c7"
      unitRef="U_pure">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"
      decimals="3"
      id="F_85b0299f-2495-4102-a33c-19a51c94136e"
      unitRef="U_pure">0.054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d"
      decimals="4"
      id="F_505d1d20-406f-45f5-bbb9-7833032be38c"
      unitRef="U_pure">0.0473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_1cf6f9af-5127-4f9f-b3aa-9fc836babb9d"
      decimals="3"
      id="F_1c1ab24a-5f41-4ff8-b1e9-9c1aa04b4e11"
      unitRef="U_pure">0.054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d"
      decimals="4"
      id="F_2c1615bc-702e-4334-be9b-9702530e06ea"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d"
      decimals="4"
      id="F_fda18233-3858-496d-b1bd-643610f443d6"
      unitRef="U_pure">0.0279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_478aad18-c78e-45d2-87ec-89af59700049"
      id="F_dd861fee-bb87-4d8b-9fe3-b3ce158ed8c2">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d6e09048-ab65-4a10-a9a5-9d240f0d04d7"
      id="F_097a7de3-966d-4305-ae9e-ef69cbf2e4b9">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ca99313c-81e1-4fdc-aa00-501a9a8750eb"
      id="F_67498a68-c59d-4f03-a575-60029250bbc9">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a0f038aa-10fb-4ef4-a320-6fa3bd5a6a6a"
      id="F_99d2815d-eb8d-44d1-8f64-53ebbf21dfc0">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_af40aa95-e806-4f0d-9a2b-c4155550c1c5"
      id="F_fc5037f4-5f80-4ac4-9749-6833eee3da5a">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_710a5831-6f23-4a2b-a4c5-44b55c5ee9c6"
      id="F_eeeca4ad-e554-4806-9d91-3854743cd511">P12M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bac4749c-9c53-43aa-bbe5-75a550f11bb8"
      decimals="2"
      id="F_c6be0cd7-8b1c-4efb-b3ba-93189571f53e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c4a69c5c-4f98-4e0c-a822-ef0162b12003"
      decimals="2"
      id="F_8dff05cb-9693-47ef-a6bd-be4584139e68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_847af0fb-b827-4d0e-8139-d0b1e4298eaa"
      decimals="2"
      id="F_c5cedbd5-ff2b-40e0-92cc-be4ca7c3c6db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e39f9a90-6bc7-4b74-b6f0-f76edb925db5"
      decimals="2"
      id="F_538d214a-2df7-47e3-a52e-b39a81f166ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_850e68a3-343d-4aa2-b753-44e2d3e644c1"
      decimals="2"
      id="F_bd58051f-3eee-4ce1-9144-8cde0be35c78"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9f924c06-9556-4a79-8ba5-be2f6840286d"
      decimals="2"
      id="F_f9a14e17-177e-4b4c-b171-25f19ae35cd4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-5"
      id="F_87188bbd-57b4-4bc0-a1f2-452859f8a3ab"
      unitRef="U_USD">65600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_1f658223-c795-4118-898d-363b73e0b4a7">P32M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_dbe4854e-8234-4b3f-bb3b-8c19d5981bf6"
      decimals="0"
      id="F_7a8bb30f-56c5-44a7-8bbe-dd0a21b0f65f"
      unitRef="U_USD">103000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_7f4d8a67-ca97-43b2-8f25-f36157f4f6b9"
      decimals="0"
      id="F_6b9eef0c-cb7d-45c9-b11b-c2789438a21a"
      unitRef="U_USD">742000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_e0278ce3-6fc4-403a-a17d-ddee1151eca7"
      decimals="0"
      id="F_a8b1cfb8-3b21-4e1f-b48e-9dc7afb6a654"
      unitRef="U_USD">235000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_b0832cbd-a429-4d47-99aa-429b7b39acd0">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.133%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.667%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,967,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options and awards available for grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34,309,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;258,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,835,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;171,371,369&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</gern:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_1c9f6487-eeaa-48fd-9d0e-c7887bfc9bae"
      unitRef="U_shares">75967367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_c39a25e6-f2f4-4f89-b509-63c85050427e"
      unitRef="U_shares">34309969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b1066105-def2-48bc-a08b-a1be59df1fe9"
      decimals="INF"
      id="F_9428bc9c-3cf6-4a9f-be79-488adc1b84d1"
      unitRef="U_shares">258366</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_6ebc2ed8-9262-4a56-9588-7fb891241405"
      unitRef="U_shares">60835667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="INF"
      id="F_16c03763-1d49-4890-b54b-378e8f588eaa"
      unitRef="U_shares">171371369</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_c278426e-2e11-405d-a84e-14e8a6db247c">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of Income/(Loss) before income taxes are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provision for (benefit from) income taxes:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.104%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.104%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.889%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.101%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.081%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss not benefitted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of our deferred tax assets are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.413%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue Participation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;430,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;429,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;395,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating leases, right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial performance. Forming a conclusion that a valuation allowance is not required is difficult when there is negative evidence such as cumulative losses in recent years. Because of our history of losses, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we had domestic federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion. Of this, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;631.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will expire at various dates beginning in 2025 through 2037 and the remaining will carryforward indefinitely under the new tax laws, but is subject to an 80% taxable income limitation for tax years beginning after 2020. As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we had state net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;844.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion expiring at various dates beginning in 2028 through 2044. We also had federal tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million expiring at various dates beginning in 2025 through 2044, if not utilized. Our state tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million carry forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Utilization of net operating loss and tax credit carryforwards may be subject to an annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We adopted the provision of the standard for accounting for uncertainties in income taxes on January 1, 2007. Upon adoption, we recognized no material adjustment in the liability for unrecognized tax benefits. At December 31, 2024, we had approximat&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ely $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milli&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;on of unrecognized tax benefits, none of which would currently affect our effective tax rate if recognized due to our net deferred tax assets being fully offset by a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If applicable, we would classify interest and penalties related to uncertain tax positions in income tax expense. Through December 31, 2024, there has been no interest expense or penalties related to unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We do not currently expect any significant changes to unrecognized tax benefits during the fiscal year ended December 31, 2025. In certain cases, our uncertain tax positions are related to tax years that remain subject to examination by the relevant tax authorities. Tax years for which we have carryforward net operating loss and credit attributes remain subject to examination by federal and most state tax authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_5b017453-31f6-4092-8682-5f5e8785e6e9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of Income/(Loss) before income taxes are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:20.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;181,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_50557ddf-515b-44fd-b2c9-c3c745cc5d35"
      unitRef="U_USD">-174737000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_5b01fd18-9a23-43e2-8344-044121307003"
      unitRef="U_USD">-181884000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_6dc00069-39ac-4c39-acff-9b56318f3ab7"
      unitRef="U_USD">-141930000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_2b9b339a-15ba-4880-8bc0-0fcbd023e2a8"
      unitRef="U_USD">215000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_9bff284d-e457-4128-96d5-592306a07fce"
      unitRef="U_USD">150000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_be5187eb-1c39-45a9-93ee-d24ae555bfbc"
      unitRef="U_USD">28000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_4238943b-6083-4ee6-bbcc-aaba7f21907d"
      unitRef="U_USD">-174521000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_71eaeb9e-cbd6-49b1-8ac0-6ca3b8ccf3a1"
      unitRef="U_USD">-181734000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_4df10418-d3b9-4262-a6ce-95e51685640d"
      unitRef="U_USD">-141902000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_344d87d8-665c-4e55-a78b-8551ac42f5e5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Provision for (benefit from) income taxes:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.224%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.104%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.201%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.104%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;449&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_9feeb256-25c3-40df-98b1-8388fc7cbd51"
      unitRef="U_USD">398000</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_bb5fbd20-acbf-4532-b80f-f7e6f7651752"
      unitRef="U_USD">51000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_9b6df448-453b-4e2c-9723-af8a606d4d0f"
      unitRef="U_USD">22000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_593b3d9a-6977-4a33-8bba-eb621befddd5"
      unitRef="U_USD">449000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_e2b18bde-16f2-42c4-ab42-e5b77eddd447"
      unitRef="U_USD">22000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_be0ae519-3c8f-4723-90fb-09b7a7ae4298">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the federal statutory tax rate to the effective income tax rate from continuing operations:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.889%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.181%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.101%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:4.081%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.942%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:3.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss not benefitted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_0c96094f-ae99-42ef-a0fb-4b83f622a016"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_32b54690-9a4c-4dd9-bb92-3c792ad2f8d5"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_5f05cb2b-1a3b-41ea-b3ea-5c55c3e8798f"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_79a49445-54df-4828-8330-8b63cf43941d"
      unitRef="U_pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_b90fb593-7b42-424a-a83a-cd700d682dd4"
      unitRef="U_pure">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_f56a4d52-f9e4-47c3-9964-09d60fe69390"
      unitRef="U_pure">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_db5554d7-ef1f-4348-815c-f5fab04c6552"
      unitRef="U_pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_7a2baacf-bda6-4ec0-9914-b1e1936cc496"
      unitRef="U_pure">-0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_f43bc94c-617c-48dc-bad4-528024dd8a0f"
      unitRef="U_pure">-0.049</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_cb9543c5-901b-4946-abeb-e87148cf2ef4"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_a42e3bc4-3511-49e4-8bf9-1342263af187"
      unitRef="U_pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_f1ef9afe-5764-46ac-92e8-8412a72ec72e"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_fc40da67-4412-4b49-814a-e0f4265aaf22"
      unitRef="U_pure">-0.005</gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted>
    <gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_0ba00e22-ff1c-4a40-ac88-f681ab18dd6a"
      unitRef="U_pure">-0.057</gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted>
    <gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_412daa98-93d4-40cf-bcb2-097614cb028b"
      unitRef="U_pure">-0.043</gern:EffectiveIncomeTaxRateReconciliationNetOperatingLossNotBenefitted>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_21b85213-5ab0-4763-8ab3-7846173583cc"
      unitRef="U_pure">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_5de68629-d8a5-4e96-b3dc-f916341ca694"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_85385ef7-7e55-4759-8727-e9c9706d538f"
      unitRef="U_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_ba23980a-21b4-4a02-b264-672665d98509"
      unitRef="U_pure">-0.201</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_9bee23b7-a7f9-4ed9-9d8a-97d28afcfb52"
      unitRef="U_pure">-0.248</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_24aa90ec-eff7-4079-9ea1-2a0f21e5d31d"
      unitRef="U_pure">-0.275</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="3"
      id="F_2f95e797-d979-48a1-b23c-6e70ab0f2d2c"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="3"
      id="F_6f71be06-5b0b-4ec9-93e9-697f84c794bb"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="3"
      id="F_e6d8a9df-33b3-44b3-a3b7-e05578a164f7"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_a6a2d675-1b16-4197-a27c-33ef09e6ce02">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of our deferred tax assets are as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.413%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.36%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.863000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;272,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue Participation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;430,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;396,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;429,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;395,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating leases, right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_22aa7ab5-9fec-48f5-bcec-d565a3d6150b"
      unitRef="U_USD">272970000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_7e28bb15-4a68-4ce5-840d-3fe50872a4ff"
      unitRef="U_USD">272300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <gern:DeferredTaxAssetsFederalAndStateCredits
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_248ba70e-362b-46f2-aadd-75edd00f086c"
      unitRef="U_USD">70492000</gern:DeferredTaxAssetsFederalAndStateCredits>
    <gern:DeferredTaxAssetsFederalAndStateCredits
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_5f39763d-9b3d-4aad-9cff-53954b6aa769"
      unitRef="U_USD">64700000</gern:DeferredTaxAssetsFederalAndStateCredits>
    <gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_f288367a-06e8-4214-8c70-d94933c49dfa"
      unitRef="U_USD">39503000</gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_802c8d41-0e29-4ef5-a7b0-5fad9b76d3df"
      unitRef="U_USD">43300000</gern:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_2695cbf0-8ab0-4c4e-8e76-6c2d9c803214"
      unitRef="U_USD">8353000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_a28e1244-9c75-4ba5-9bce-ac8518918ebb"
      unitRef="U_USD">11200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <gern:DeferredTaxAssetsRevenueParticipation
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_9aedc9b3-e0a7-492e-b745-7a058591441c"
      unitRef="U_USD">29547000</gern:DeferredTaxAssetsRevenueParticipation>
    <gern:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_c14c18c5-8484-4d9e-80f0-9e9a571244e8"
      unitRef="U_USD">767000</gern:DeferredTaxAssetsOperatingLeaseLiabilities>
    <gern:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_0fa433c2-01fe-41d0-93f9-4b9c0d31c8e4"
      unitRef="U_USD">1100000</gern:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_a2d76017-d274-4f52-896a-85f7f95bd070"
      unitRef="U_USD">8963000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_a3a5aed4-8521-444d-8bee-d8e9c9a18b98"
      unitRef="U_USD">3600000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_629e99ba-e0c2-406a-acf4-b7a32234a2ee"
      unitRef="U_USD">430595000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_4262e037-1cd2-4bbd-8213-3bb977975746"
      unitRef="U_USD">396200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_7a1b2557-c0f8-4736-ae53-3c1c3092131b"
      unitRef="U_USD">429913000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_8b5e4b13-af52-4eee-9b8a-9cc5588354c5"
      unitRef="U_USD">395200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_1b05030f-9a9b-41ec-a943-50e5eb38c4c2"
      unitRef="U_USD">682000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_c3bc2a6e-76db-4595-bfbc-171a5fb792cd"
      unitRef="U_USD">1000000</us-gaap:DeferredTaxAssetsNet>
    <gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_71bf048c-27fb-4708-8474-1cec6421ed78"
      unitRef="U_USD">682000</gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets>
    <gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_a449bea5-ca91-47b3-8594-cec2084d151e"
      unitRef="U_USD">1000000</gern:DeferredTaxLiabilitiesOperatingLeasesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_a8c7bb82-392c-43e3-b7dd-39d480340b71"
      unitRef="U_USD">682000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_c18aa806-f5a8-48cf-a18c-f9a3a1bb584b"
      unitRef="U_USD">1000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-5"
      id="F_e6e827f8-f06e-4ce6-ad5e-b3725cc9def1"
      unitRef="U_USD">35000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-5"
      id="F_08a57297-c357-4716-ab25-a9020d01e1da"
      unitRef="U_USD">45600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d"
      decimals="-8"
      id="F_bec6b6fb-9e7b-4f04-9d7a-39e56b5d48bc"
      unitRef="U_USD">1000000000</us-gaap:OperatingLossCarryforwards>
    <gern:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d"
      decimals="-5"
      id="F_2fa734ba-3117-4c53-bbb5-1cf3012df2b5"
      unitRef="U_USD">631500000</gern:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f41156cc-9535-49b9-8050-64099a0eb8b5"
      decimals="-5"
      id="F_cdbec5e8-472a-4532-a9c4-5c2fe5abbaee"
      unitRef="U_USD">844400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_7438569d-d3c0-4514-9d9c-b3fb0c35fa3d"
      decimals="-5"
      id="F_99e318da-e0ea-4967-855c-ba48a1ec32d9"
      unitRef="U_USD">79000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_f41156cc-9535-49b9-8050-64099a0eb8b5"
      decimals="-5"
      id="F_92fb4ff2-2ece-4f06-a9c4-c622dfba21bb"
      unitRef="U_USD">23300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-5"
      id="F_ce50be07-a955-4cbd-8530-c4d0de68bf17"
      unitRef="U_USD">28300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_a95789f9-59f9-436a-9d7a-45d513a8ca3f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,331&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:15pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e878acb0-c1d3-4a1d-9497-65b76e2ddff9"
      decimals="-3"
      id="F_6685758f-99ae-4cfb-9628-fcc87fcdc6d5"
      unitRef="U_USD">26331000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_37b54052-83f0-4681-aca9-7b605183f8d4"
      unitRef="U_USD">494000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_6d00eab1-8f17-4f73-995d-d1a9aced1933"
      unitRef="U_USD">2473000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_1a5d2cb1-16f8-4f6b-b9d4-ff5455083dee"
      decimals="-3"
      id="F_5cd695da-01b0-4d56-be0e-259b0bbfff44"
      unitRef="U_USD">28310000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_bf6f0552-13cb-47d4-a6e4-f08885463ba8">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. CONSOLIDATED STATEMENTS OF CASH FLOWS DATA&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.291%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Supplemental operating and investing activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net unrealized loss on &lt;br/&gt;&#160;&#160;&#160;marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Reclassification between prepaid and other&lt;br/&gt;&#160;&#160;&#160;current assets and deposits and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_6c511785-4766-47db-9e01-ed22138694e6">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.291%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.437000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Supplemental operating and investing activities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net unrealized loss on &lt;br/&gt;&#160;&#160;&#160;marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Reclassification between prepaid and other&lt;br/&gt;&#160;&#160;&#160;current assets and deposits and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_2fb1ea8c-fa06-4264-bcd7-3bde3026dd6d"
      unitRef="U_USD">88000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_e1c2e20c-7283-40bc-a828-d0523acbcb6c"
      unitRef="U_USD">-431000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_6e7267bc-dfe8-48d8-9916-557a0a6163ad"
      unitRef="U_USD">-68000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <gern:ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_cb843d14-0cdf-43ed-a8f3-59b1eef7fc7e"
      unitRef="U_USD">-5000</gern:ReclassificationBetweenPrepaidAndOtherCurrentAssetsAndDepositsAndOtherAssets>
    <us-gaap:InterestPaidNet
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="-3"
      id="F_e3bec6d6-5986-4bb0-b5d9-4f95d7d66c60"
      unitRef="U_USD">10364000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_01b0f8a9-30a3-4602-8a60-84cfe779fc64"
      decimals="-3"
      id="F_5b15287d-064c-4318-a7c8-dc82ce255e13"
      unitRef="U_USD">7017000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_710c0d17-5aa1-473a-867a-7efd92be1f08"
      decimals="-3"
      id="F_ad87b9e7-319d-4e7d-80a4-e79b0afba167"
      unitRef="U_USD">5154000</us-gaap:InterestPaidNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_f54e0200-00ca-49c0-8a9f-55169136964a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. SEGMENT REPORTING&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are currently developing therapies for the treatment of hematologic malignancies. To date, our only source of product revenue has been from U.S. sales of RYTELO, which began shipping to customers in June 2024. Additionally, we have generated insignificant royalty and license fee revenue under agreements that out-license technology to various companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2024, we have identified &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment. We define our operating segments based on internally reported financial information that is regularly reviewed by the Chief Operating Decision Maker or CODM to analyze financial performance, make decisions, and allocate resources. Our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_48950aed-512d-4e10-b713-0562fb188089;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is the CODM.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Further, the CODM reviews the segment's assets based on total assets reported on the consolidated balance sheet. All long-lived assets are held in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Research and clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Chemistry, manufacturing, and control expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Commercial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and other income (expense)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;184.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accordingly, the Company consists of a single operating and reportable segment and the consolidated financial statements and notes thereto are presented as a single reportable segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_6a053beb-ea5a-4e72-8ea4-a985727ae767"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      decimals="INF"
      id="F_8351dcaf-de65-4b9f-9b6a-7412ad73e8d9"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_def9db1e-67ba-44fc-aa0f-849a8e72ba4b">The CODM reviews the segment's profit or loss based on net (loss) income reported on the consolidated statement of operations and comprehensive (loss) income and considers forecast-to-actuals variances on a quarterly basis for expenses that are deemed significant.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_2e943352-4435-4b34-963b-bad0d8f6f45a">Our CODM views specific categories within research and development expenses and selling, general and administrative expenses as significant given the correlation between cash burn and profitability.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_00ab337d-b01d-4a36-a8d7-35a482bf0fd4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:23.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:21.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenues:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Product revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of goods sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Research and clinical expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Chemistry, manufacturing, and control expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cceeff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Commercial expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment expenses*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0ff;padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0ff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and other income (expense)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;184.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*Other segment expenses includes stock-based compensation expense and other general and administrative expenses largely resulting from personnel costs for individuals in administrative functions and legal and professional fees.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_50c8ecec-b2ba-4651-95b8-c5c262b21836"
      decimals="-5"
      id="F_d715795b-7e05-4c20-9fca-ae92364b4f58"
      unitRef="U_USD">76500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3776fecd-f521-4873-82e1-b99ba90cc41d"
      decimals="-5"
      id="F_0a977d92-ae9d-4035-96c4-0bfa2a4cf478"
      unitRef="U_USD">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b3d1f256-a05e-41ae-82ba-3a0ca866b306"
      decimals="-5"
      id="F_a3305e6e-3f6e-4d3f-ad57-593dfc8e2deb"
      unitRef="U_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_b3e2d800-b451-4d0c-8217-ba0d27aaed1d"
      unitRef="U_USD">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"
      decimals="-5"
      id="F_cdb86014-38a9-4fc6-bf91-a172e06a05e5"
      unitRef="U_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_a5cb804e-7489-4b5f-9a04-f554a87ae28c"
      unitRef="U_USD">1300000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d0c523ca-eeda-4f55-8129-78a974c61e15"
      decimals="-5"
      id="F_bc1f27a8-1c04-485d-a974-bd48244341d8"
      unitRef="U_USD">67900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_912929c3-b7b6-4d47-ab01-1fc308ac8161"
      decimals="-5"
      id="F_f2fd225c-13af-41b1-9091-4102a6c2a4fa"
      unitRef="U_USD">74900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_95b33fbb-e8c1-4fd0-a15d-92e7aa65e86a"
      decimals="-5"
      id="F_b5d040de-6c94-4952-9f93-9d109862f597"
      unitRef="U_USD">26200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_c57b8848-5a92-444a-b366-673e8854e689"
      decimals="-5"
      id="F_5809ec53-7970-4c08-9e63-d7458efe52f7"
      unitRef="U_USD">42500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_c72d7d41-863d-4713-921b-5709d77691bf"
      decimals="-5"
      id="F_7296b9c6-cef8-4e0d-b856-a9d3100166b3"
      unitRef="U_USD">72000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_cc4a2b91-0d00-4a37-ad88-ee5bbfe05947"
      decimals="-5"
      id="F_3cb10ff5-acab-44cd-add0-6b99610d2aad"
      unitRef="U_USD">27400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_138d24fe-66d4-4838-b1b9-1328b58dd5f8"
      unitRef="U_USD">83300000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"
      decimals="-5"
      id="F_a8c82fbe-7476-4389-bb62-b894d69b33f0"
      unitRef="U_USD">49400000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingExpenses
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_e7a1efd1-0d89-452d-8c6c-9f5e60f78697"
      unitRef="U_USD">250700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"
      decimals="-5"
      id="F_03acafaf-5499-407c-896c-4136828ece59"
      unitRef="U_USD">194200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_062446a5-8ff8-4498-8226-e0f5935ad5cf"
      unitRef="U_USD">-173700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"
      decimals="-5"
      id="F_957d2082-ca36-4e85-9e62-c0b18e111bb2"
      unitRef="U_USD">-193900000</us-gaap:OperatingIncomeLoss>
    <gern:TotalInterestAndOtherIncomeExpense
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_6bda81fa-1057-4c6e-a578-25ac4686f50c"
      unitRef="U_USD">-900000</gern:TotalInterestAndOtherIncomeExpense>
    <gern:TotalInterestAndOtherIncomeExpense
      contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"
      decimals="-5"
      id="F_2bc262d0-219f-4701-b573-997b210af84d"
      unitRef="U_USD">9800000</gern:TotalInterestAndOtherIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_e7446e83-84fa-4d17-9ab9-b9b2cf8b1744"
      decimals="-5"
      id="F_61c4e5cc-237f-4de1-914d-950e4be1ec24"
      unitRef="U_USD">-174600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6363eeb0-8a4f-484c-b027-c3513703d5d3"
      decimals="-5"
      id="F_52c4579d-dded-4600-ac3f-a45b9075dc1e"
      unitRef="U_USD">-184100000</us-gaap:NetIncomeLoss>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f"
      id="F_8c55ddab-a213-4ac5-81f9-ef36eba0666c">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f"
      id="F_f9cf7e9c-fb0f-43e9-90ce-0b4bff0c3bf1">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f"
      id="F_a8a6e871-8d3f-4945-84f8-bde2c7635390">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_e4021ad0-3e5e-48de-9cd9-3300958d415f"
      id="F_aae82a06-82fd-4efc-9df8-a54d7784ffc1">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_375cfc07-5431-4a75-8af6-40a50bbfc4d7"
      id="F_082c05ad-5a5b-4b79-998a-30deffc0b416">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
